vmod||important-26/JJ||considering-1/VBG	det||health-5/NN||the-2/DT	amod||health-5/NN||great-3/JJ	nn||health-5/NN||animal-4/NN	dobj||considering-1/VBG||health-5/NN	amod||impact-8/NN||economic-7/JJ	dobj||considering-1/VBG||impact-8/NN	conj_and||health-5/NN||impact-8/NN	prep_of||health-5/NN||ibv-10/NN	det||emergence-16/NN||the-14/DT	amod||emergence-16/NN||recent-15/JJ	dobj||considering-1/VBG||emergence-16/NN	conj_and||health-5/NN||emergence-16/NN	nn||coronaviruses-19/NNS||novel-18/NN	prep_of||emergence-16/NN||coronaviruses-19/NNS	prep_such_as||coronaviruses-19/NNS||sars-coronavirus-22/NNS	nsubj||important-26/JJ||it-24/PRP	nsubj||investigate-28/VB||it-24/PRP	cop||important-26/JJ||is-25/VBZ	root||ROOT-0/null||important-26/JJ	aux||investigate-28/VB||to-27/TO	xcomp||important-26/JJ||investigate-28/VB	det||role-30/NN||the-29/DT	dobj||investigate-28/VB||role-30/NN	nn||reservoirs-33/NNS||wildlife-32/NN	prep_of||role-30/NN||reservoirs-33/NNS	nn||biology-37/NN||cov-35/NN	nn||biology-37/NN||infection-36/NN	prep_in||investigate-28/VB||biology-37/NN	prep_in||investigate-28/VB||epidemiology-39/NN	conj_and||biology-37/NN||epidemiology-39/NN	sars--1||coronaviruses-19||no||considering the great animal health and economic impact of ibv as well as the recent emergence of novel coronaviruses such as sars-coronavirus, it is important to investigate the role of wildlife reservoirs in cov infection biology and epidemiology.
prepc_compared_with||increased-10/VBD||with-2/IN	amod||subjects-4/NNS||healthy-3/JJ	pobj||increased-10/VBD||subjects-4/NNS	amod||levels-8/NNS||serum-6/JJ	amod||levels-8/NNS||non-vldl-tg-7/JJ	nsubj||increased-10/VBD||levels-8/NNS	advmod||increased-10/VBD||significantly-9/RB	root||ROOT-0/null||increased-10/VBD	prep_in||increased-10/VBD||patients-12/NNS	nn||f2-15/NNS||stages-14/NNS	prep_with||increased-10/VBD||f2-15/NNS	amod||ch-c-18/NN||f3-17/JJ	prep_with||increased-10/VBD||ch-c-18/NN	conj_and||f2-15/NNS||ch-c-18/NN	advmod||observed-23/VBD||however-20/RB	nsubj||observed-23/VBD||we-22/PRP	parataxis||increased-10/VBD||observed-23/VBD	neg||difference-26/NN||no-24/DT	amod||difference-26/NN||significant-25/JJ	dobj||observed-23/VBD||difference-26/NN	prep_in||observed-23/VBD||patients-28/NNS	prep_with||observed-23/VBD||livercirrhosis-30/NNS	f3-17||livercirrhosis-30||no_rel||compared with healthy subjects, serum non-vldl-tg levels significantly increased in patients with stages f2 and f3 ch-c; however, we observed no significant difference in patients with livercirrhosis.
det||hormone-4/NN||the-1/DT	amod||hormone-4/NN||pineal-2/JJ	nn||hormone-4/NN||gland-3/NN	nsubjpass||shown-10/VBN||hormone-4/NN	nsubj||inhibit-15/VB||hormone-4/NN	appos||hormone-4/NN||melatonin-6/NN	aux||shown-10/VBN||has-8/VBZ	auxpass||shown-10/VBN||been-9/VBN	root||ROOT-0/null||shown-10/VBN	amod||studies-13/NNS||numerous-12/JJ	agent||shown-10/VBN||studies-13/NNS	aux||inhibit-15/VB||to-14/TO	xcomp||shown-10/VBN||inhibit-15/VB	det||proliferation-17/NN||the-16/DT	dobj||inhibit-15/VB||proliferation-17/NN	amod||±-22/NNS||estrogen-19/JJ	nn||±-22/NNS||receptor-20/NN	nn||±-22/NNS||î-21/NN	prep_of||proliferation-17/NN||±-22/NNS	nn||±-25/NNP||erî-24/NNP	appos||±-22/NNS||±-25/NNP	amod||lines-32/NNS||positive-28/JJ	nn||lines-32/NNS||breast-29/NN	nn||lines-32/NNS||cancer-30/NN	nn||lines-32/NNS||cell-31/NN	dep||±-22/NNS||lines-32/NNS	cancer-30||estrogen-19||no_rel||the pineal gland hormone, melatonin, has been shown by numerous studies to inhibit the proliferation of estrogen receptor î± (erî±)-positive breast cancer cell lines.
num||weeks-3/NNS||40-2/CD	prep_at||showed-11/VBD||weeks-3/NNS	nsubj||showed-11/VBD||rats-5/NNS	vmod||rats-5/NNS||treated-6/VBN	num||sulindac-10/NN||1000-8/CD	nn||sulindac-10/NN||ppm-9/NN	prep_with||treated-6/VBN||sulindac-10/NN	root||ROOT-0/null||showed-11/VBD	amod||diameter-14/NN||narrower-12/JJR	amod||diameter-14/NN||esophageal-13/JJ	dobj||showed-11/VBD||diameter-14/NN	nn||inflammation-17/NNS||milder-16/NN	dobj||showed-11/VBD||inflammation-17/NNS	conj_and||diameter-14/NN||inflammation-17/NNS	det||rats-21/NNS||the-19/DT	nn||rats-21/NNS||control-20/NN	prep_than||diameter-14/NN||rats-21/NNS	inflammation-17||sulindac-10||yes||at 40 weeks, rats treated with 1000 ppm sulindac showed narrower esophageal diameter and milder inflammation than the control rats.
prep_in||examined-7/VBN||addition-2/NN	amod||research-5/NN||limited-4/JJ	nsubj||examined-7/VBN||research-5/NN	aux||examined-7/VBN||has-6/VBZ	root||ROOT-0/null||examined-7/VBN	poss||role-9/NN||their-8/PRP$	dobj||examined-7/VBN||role-9/NN	prepc_in||examined-7/VBN||providing-11/VBG	amod||support-15/NN||emotional-12/JJ	dobj||providing-11/VBG||material-14/NN	conj_and||support-15/NN||material-14/NN	dobj||providing-11/VBG||support-15/NN	dobj||providing-11/VBG||protection-17/NN	conj_and||support-15/NN||protection-17/NN	amod||children-23/NNS||hiv-19/JJ	conj_and||hiv-19/JJ||aids-affected-22/JJ	amod||children-23/NNS||aids-affected-22/JJ	prep_for||support-15/NN||children-23/NNS	prep_for||support-15/NN||families-25/NNS	conj_and||children-23/NNS||families-25/NNS	aids--1||hiv-19||no||in addition, limited research has examined their role in providing emotional, material support and protection for hiv- and aids-affected children and families.
nsubj||has-2/VBZ||bortezomib-1/NN	root||ROOT-0/null||has-2/VBZ	amod||activity-4/NN||significant-3/JJ	dobj||has-2/VBZ||activity-4/NN	prepc_in||activity-4/NN||treating-6/VBG	dobj||treating-6/VBG||multiplemyeloma-7/NN	appos||multiplemyeloma-7/NN||mm-9/NN	multiplemyeloma-7||bortezomib-1||yes||bortezomib has significant activity in treating multiplemyeloma (mm).
aux||understand-3/VB||to-1/TO	advmod||understand-3/VB||better-2/RBR	advcl||measured-14/VBD||understand-3/VB	det||potential-5/NN||the-4/DT	dobj||understand-3/VB||potential-5/NN	det||spread-9/NN||the-7/DT	amod||spread-9/NN||airborne-8/JJ	prep_for||potential-5/NN||spread-9/NN	prep_of||spread-9/NN||influenza-11/NN	nsubj||measured-14/VBD||we-13/PRP	root||ROOT-0/null||measured-14/VBD	det||amount-16/NN||the-15/DT	dobj||measured-14/VBD||amount-16/NN	dobj||measured-14/VBD||size-18/NN	conj_and||amount-16/NN||size-18/NN	amod||particles-21/NNS||aerosol-20/JJ	prep_of||amount-16/NN||particles-21/NNS	vmod||particles-21/NNS||containing-22/VBG	dobj||containing-22/VBG||influenzavirus-23/NNS	nsubjpass||produced-26/VBN||influenzavirus-23/NNS	auxpass||produced-26/VBN||were-25/VBD	rcmod||influenzavirus-23/NNS||produced-26/VBN	agent||produced-26/VBN||coughing-28/VBG	influenza-11||influenzavirus-23||no||to better understand the potential for the airborne spread of influenza, we measured the amount and size of aerosol particles containing influenzavirus that were produced by coughing.
nsubj||anticoagulant-7/NN||warfarin-1/NN	cop||anticoagulant-7/NN||is-2/VBZ	det||anticoagulant-7/NN||a-3/DT	advmod||prescribed-5/JJ||commonly-4/RB	amod||anticoagulant-7/NN||prescribed-5/JJ	amod||anticoagulant-7/NN||oral-6/JJ	root||ROOT-0/null||anticoagulant-7/NN	prep_in||anticoagulant-7/NN||patients-9/NNS	amod||thromboembolism-16/NN||prosthetic-11/JJ	nn||thromboembolism-16/NN||valve-12/NN	nn||thromboembolism-16/NN||disease-13/NN	prep_with||patients-9/NNS||venous-15/NNS	conj_and||thromboembolism-16/NN||venous-15/NNS	prep_with||patients-9/NNS||thromboembolism-16/NN	prep_with||patients-9/NNS||stroke-18/NN	conj_and||thromboembolism-16/NN||stroke-18/NN	stroke-18||warfarin-1||yes||warfarin is a commonly prescribed oral anticoagulant in patients with prosthetic valve disease, venous thromboembolism and stroke.
amod||feeding-2/NN||infant-1/JJ	nsubj||challenge-16/NN||feeding-2/NN	prep_in||feeding-2/NN||communities-4/NNS	det||prevalence-8/NN||a-6/DT	amod||prevalence-8/NN||high-7/JJ	prep_with||communities-4/NNS||prevalence-8/NN	prep_of||prevalence-8/NN||hiv-10/NN	prep_of||prevalence-8/NN||aids-12/NNS	conj_and||hiv-10/NN||aids-12/NNS	cop||challenge-16/NN||is-13/VBZ	det||challenge-16/NN||a-14/DT	amod||challenge-16/NN||potential-15/JJ	root||ROOT-0/null||challenge-16/NN	prep_for||challenge-16/NN||mothers-18/NNS	nsubj||decide-22/VB||mothers-18/NNS	nsubj||feed-25/VB||mothers-18/NNS	aux||decide-22/VB||must-20/MD	advmod||decide-22/VB||ultimately-21/RB	rcmod||mothers-18/NNS||decide-22/VB	advmod||feed-25/VB||how-23/WRB	aux||feed-25/VB||to-24/TO	ccomp||decide-22/VB||feed-25/VB	xcomp||decide-22/VB||feed-25/VB	poss||infants-27/NNS||their-26/PRP$	dobj||feed-25/VB||infants-27/NNS	prep_within||feed-25/VB||contexts-29/NNS	nsubj||constrain-31/VB||contexts-29/NNS	rcmod||contexts-29/NNS||constrain-31/VB	poss||choices-33/NNS||their-32/PRP$	dobj||constrain-31/VB||choices-33/NNS	aids-12||hiv-10||no||infant feeding in communities with a high prevalence of hiv and aids is a potential challenge for mothers who must ultimately decide how to feed their infants within contexts that constrain their choices.
nsubjpass||found-3/VBN||bmscs-1/NNS	nsubj||reach-6/VB||bmscs-1/NNS	auxpass||found-3/VBN||were-2/VBD	root||ROOT-0/null||found-3/VBN	aux||reach-6/VB||to-4/TO	advmod||reach-6/VB||preferably-5/RB	xcomp||found-3/VBN||reach-6/VB	nsubj||undergoing-8/VBG||sites-7/NNS	dep||reach-6/VB||undergoing-8/VBG	det||process-10/NN||the-9/DT	dobj||undergoing-8/VBG||process-10/NN	nn||proliferation-13/NN||cell-12/NN	prep_of||process-10/NN||proliferation-13/NN	prep_such_as||undergoing-8/VBG||wound-17/NN	prep_such_as||undergoing-8/VBG||tumor-19/NN	conj_and||wound-17/NN||tumor-19/NN	vmod||undergoing-8/VBG||suggesting-21/VBG	mark||used-26/VBN||that-22/IN	nsubjpass||used-26/VBN||bmscs-23/NNS	aux||used-26/VBN||may-24/MD	auxpass||used-26/VBN||be-25/VB	ccomp||suggesting-21/VBG||used-26/VBN	det||vehicle-29/NN||a-28/DT	prep_as||used-26/VBN||vehicle-29/NN	nn||therapy-32/NN||gene-31/NN	prep_for||vehicle-29/NN||therapy-32/NN	prep_of||therapy-32/NN||tumor-34/NN	vehicle-29||tumor-34||no_rel||bmscs were found to preferably reach sites undergoing the process of cell proliferation, such as wound and tumor, suggesting that bmscs may be used as a vehicle for gene therapy of tumor.
nsubj||developed-2/VBD||we-1/PRP	nsubj||avianinfluenzaviruses-10/VBZ||we-1/PRP	root||ROOT-0/null||developed-2/VBD	det||technique-4/NN||a-3/DT	dobj||developed-2/VBD||technique-4/NN	aux||measure-6/VB||to-5/TO	vmod||developed-2/VBD||measure-6/VB	amod||influenza-8/NN||ambient-7/JJ	dobj||measure-6/VB||influenza-8/NN	conj_and||developed-2/VBD||avianinfluenzaviruses-10/VBZ	influenza-8||influenzaviruses--1||no||we developed a technique to measure ambient influenza and avianinfluenzaviruses.
nsubjpass||used-4/VBN||nitrofurantoin-1/NN	aux||used-4/VBN||could-2/MD	auxpass||used-4/VBN||be-3/VB	root||ROOT-0/null||used-4/VBN	amod||cystitis-7/NNS||simple-6/JJ	prep_for||used-4/VBN||cystitis-7/NNS	dep||cystitis-7/NNS||aminoglycosides-9/NNS	amod||uti-12/NN||uncomplicated-11/JJ	prep_for||aminoglycosides-9/NNS||uti-12/NN	prep_in||uti-12/NN||inpatients-14/NNS	uti-12||nitrofurantoin-1||yes||nitrofurantoin could be used for simple cystitis; aminoglycosides for uncomplicated uti in inpatients.
nn||glucose-2/NN||plasma-1/NN	nsubjpass||measured-12/VBN||glucose-2/NN	nsubjpass||measured-12/VBN||glucose-2/NN	nsubjpass||measured-12/VBN||glucose-2/NN	conj_and||glucose-2/NN||insulin-4/NN	nsubjpass||measured-12/VBN||insulin-4/NN	conj_and||glucose-2/NN||c-peptide-6/NN	nsubjpass||measured-12/VBN||c-peptide-6/NN	nn||concentrations-10/NNS||glucagon-9/NN	conj_and||glucose-2/NN||concentrations-10/NNS	nsubjpass||measured-12/VBN||concentrations-10/NNS	auxpass||measured-12/VBN||were-11/VBD	root||ROOT-0/null||measured-12/VBN	conj_and||measured-12/VBN||measured-12/VBN	conj_and||measured-12/VBN||measured-12/VBN	det||min-15/NN||every-13/DT	num||min-15/NN||30-14/CD	dobj||measured-12/VBN||min-15/NN	amod||ingestion-42/NN||â-17/JJ	dep||â-17/JJ||60-18/CD	num||min-21/NN||180-20/CD	prep_through||â-17/JJ||min-21/NN	amod||administration-26/NN||random-sequence-23/JJ	amod||administration-26/NN||double-blind-25/JJ	prep_with||min-21/NN||administration-26/NN	prep_of||administration-26/NN||diazoxide-28/NN	num||mg/kg-31/NN||6.0-30/CD	appos||diazoxide-28/NN||mg/kg-31/NN	prep_of||administration-26/NN||placebo-34/NN	conj_or||diazoxide-28/NN||placebo-34/NN	amod||min-40/NN||â-36/JJ	dep||â-36/JJ||30-37/CD	dep||â-36/JJ||1-39/CD	conj_and||30-37/CD||1-39/CD	prep_at||placebo-34/NN||min-40/NN	prep_from||measured-12/VBN||ingestion-42/NN	det||meal-47/NN||a-44/DT	nn||meal-47/NN||formula-45/NN	amod||meal-47/NN||mixed-46/JJ	prep_of||ingestion-42/NN||meal-47/NN	parataxis||measured-12/VBN||ensure-49/VB	advmod||ensure-49/VB||plus-50/CC	prep_at||measured-12/VBN||0-53/CD	vmod||0-53/CD||min-54/VBN	prep_after||min-54/VBN||diazoxide-56/NN	prep_after||min-54/VBN||placebo-59/NN	conj_and||diazoxide-56/NN||placebo-59/NN	cc||measured-12/VBN||and-60/CC	det||occasion-65/NN||a-63/DT	amod||occasion-65/NN||separate-64/JJ	prep_on||measured-12/VBN||occasion-65/NN	npadvmod||measured-12/VBN||ingestion-67/NN	prep_of||ingestion-67/NN||glimepiride-69/NN	number||mg-72/CD||4.0-71/CD	dep||glimepiride-69/NN||mg-72/CD	num||min-76/NN||0-75/CD	prep_at||glimepiride-69/NN||min-76/NN	prep_with||glimepiride-69/NN||glucose-79/NN	vmod||glucose-79/NN||infused-80/VBN	aux||prevent-82/VB||to-81/TO	xcomp||infused-80/VBN||prevent-82/VB	dobj||prevent-82/VB||hypoglycemia-83/NN	prep_after||measured-12/VBN||diazoxide-86/NN	prep_after||measured-12/VBN||placebo-89/NN	num||adults-94/NNS||11-91/CD	amod||adults-94/NNS||healthy-92/JJ	amod||adults-94/NNS||young-93/JJ	prep_in||placebo-89/NN||adults-94/NNS	hypoglycemia-83||diazoxide-86||yes||plasma glucose, insulin, c-peptide, and glucagon concentrations were measured every 30 min from â60 through 180 min with random-sequence, double-blind administration of diazoxide (6.0 mg/kg) or placebo at â30 and 1 min, ingestion of a formula mixed meal (ensure plus) at 0 min after diazoxide and after placebo and, on a separate occasion, ingestion of glimepiride (4.0 mg) at 0 min (with glucose infused to prevent hypoglycemia) after diazoxide and after placebo in 11 healthy young adults.
nn||options-2/NNS||treatment-1/NN	nsubj||include-11/VBP||options-2/NNS	amod||pd-9/NN||advanced-4/JJ	nn||pd-9/NN||parkinson-5/NN	amod||pd-9/NN||sdisease-7/JJ	prep_in||options-2/NNS||pd-9/NN	root||ROOT-0/null||include-11/VBP	nsubj||nucleus-18/VBG||subcutaneous-12/NNS	dep||nucleus-18/VBG||apomorphine-13/JJ	conj_or||apomorphine-13/JJ||pallidal-15/JJ	dep||nucleus-18/VBG||pallidal-15/JJ	conj_or||apomorphine-13/JJ||subthalamic-17/JJ	dep||nucleus-18/VBG||subthalamic-17/JJ	xcomp||include-11/VBP||nucleus-18/VBG	amod||stimulation-21/NN||deep-19/JJ	nn||stimulation-21/NN||brain-20/NN	dobj||nucleus-18/VBG||stimulation-21/NN	appos||stimulation-21/NN||dbs-23/NN	amod||gel-29/NN||levodopa/carbidopa-27/JJ	amod||gel-29/NN||intestinal-28/JJ	dobj||nucleus-18/VBG||gel-29/NN	conj_or||stimulation-21/NN||gel-29/NN	appos||gel-29/NN||lcig/duodopa-31/NNP	parkinson'sdisease--1||carbidopa--1||yes||treatment options in advanced parkinson'sdisease (pd) include subcutaneous apomorphine, pallidal or subthalamic nucleus deep brain stimulation (dbs), or levodopa/carbidopa intestinal gel (lcig/duodopa).
amod||asthma-2/NN||aspirin-intolerant-1/JJ	nsubj||condition-9/NN||asthma-2/NN	appos||asthma-2/NN||aia-4/NN	cop||condition-9/NN||is-6/VBZ	det||condition-9/NN||a-7/DT	amod||condition-9/NN||rare-8/JJ	root||ROOT-0/null||condition-9/NN	nsubjpass||characterized-12/VBN||condition-9/NN	auxpass||characterized-12/VBN||is-11/VBZ	rcmod||condition-9/NN||characterized-12/VBN	det||development-15/NN||the-14/DT	agent||characterized-12/VBN||development-15/NN	prep_of||development-15/NN||bronchoconstriction-17/NN	amod||patients-20/NNS||asthmatic-19/JJ	prep_in||bronchoconstriction-17/NN||patients-20/NNS	prep_after||characterized-12/VBN||ingestion-22/NN	amod||anti-inflammatorydrugs-25/NNS||non-steroidal-24/JJ	prep_of||ingestion-22/NN||anti-inflammatorydrugs-25/NNS	prep_including||anti-inflammatorydrugs-25/NNS||aspirin-27/NN	asthmatic-19||aspirin-27||no||aspirin-intolerant asthma (aia) is a rare condition that is characterized by the development of bronchoconstriction in asthmatic patients after ingestion of non-steroidal anti-inflammatorydrugs including aspirin.
nsubj||have-11/VBP||adults-1/NNS	amod||origin-5/NN||south-3/JJ	nn||origin-5/NN||asian-4/NN	prep_of||adults-1/NNS||origin-5/NN	vmod||origin-5/NN||living-6/VBG	det||kingdom-10/NN||the-8/DT	amod||kingdom-10/NN||united-9/VBN	prep_in||living-6/VBG||kingdom-10/NN	root||ROOT-0/null||have-11/VBP	amod||risks-13/NNS||high-12/JJ	nsubj||raised-20/VBD||risks-13/NNS	amod||obesity-18/NN||type2diabetes-15/JJ	conj_and||type2diabetes-15/JJ||central-17/JJ	amod||obesity-18/NN||central-17/JJ	prep_of||risks-13/NNS||obesity-18/NN	ccomp||have-11/VBP||raised-20/VBD	xcomp||raised-20/VBD||circulating-21/VBG	dobj||circulating-21/VBG||insulin-22/NN	dobj||circulating-21/VBG||triglyceride-24/NN	conj_and||insulin-22/NN||triglyceride-24/NN	amod||concentrations-29/NNS||c-reactive-27/JJ	nn||concentrations-29/NNS||protein-28/NN	dobj||circulating-21/VBG||concentrations-29/NNS	conj_and||insulin-22/NN||concentrations-29/NNS	amod||hdl-cholesterol-33/NN||low-32/JJ	dobj||circulating-21/VBG||hdl-cholesterol-33/NN	conj_and||insulin-22/NN||hdl-cholesterol-33/NN	dep||circulating-21/VBG||when-34/WRB	prepc_compared_with||raised-20/VBD||with-36/IN	amod||europeans-38/NNS||white-37/JJ	pobj||raised-20/VBD||europeans-38/NNS	obesity-18||triglyceride-24||no_rel||adults of south asian origin living in the united kingdom have high risks of type2diabetes and central obesity; raised circulating insulin, triglyceride, and c-reactive protein concentrations; and low hdl-cholesterol when compared with white europeans.
poss||history-5/NN||his-2/PRP$	amod||history-5/NN||past-3/JJ	amod||history-5/NN||medical-4/JJ	prep_in||undergone-10/VBN||history-5/NN	det||patient-8/NN||the-7/DT	nsubj||undergone-10/VBN||patient-8/NN	aux||undergone-10/VBN||had-9/VBD	root||ROOT-0/null||undergone-10/VBN	num||resections-13/NNS||three-11/CD	amod||resections-13/NNS||transurethral-12/JJ	dobj||undergone-10/VBN||resections-13/NNS	prep_of||resections-13/NNS||bladdertumors-15/NNS	amod||carcinoma-20/NN||urothelial-18/JJ	nn||carcinoma-20/NN||cell-19/NN	prep_due_to||bladdertumors-15/NNS||carcinoma-20/NN	prep_since||carcinoma-20/NN||2000-22/CD	amod||gastrectomy-25/NN||total-24/JJ	dobj||undergone-10/VBN||gastrectomy-25/NN	conj_and||resections-13/NNS||gastrectomy-25/NN	advmod||gastrectomy-25/NN||splenectomy-27/RB	amod||chemotherapy-32/NN||adjuvant-30/JJ	nn||chemotherapy-32/NN||fluorouracil/cisplatin-31/NN	dobj||undergone-10/VBN||chemotherapy-32/NN	conj_and||resections-13/NNS||chemotherapy-32/NN	num||months-35/NNS||7-34/CD	prep_for||chemotherapy-32/NN||months-35/NNS	amod||carcinoma-40/NN||advanced-38/VBN	amod||carcinoma-40/NN||gastric-39/JJ	prep_due_to||undergone-10/VBN||carcinoma-40/NN	prep_in||carcinoma-40/NN||2005-42/CD	bladdertumors-15||cisplatin--1||yes||in his past medical history, the patient had undergone three transurethral resections of bladdertumors due to urothelial cell carcinoma since 2000 and total gastrectomy, splenectomy, and adjuvant fluorouracil/cisplatin chemotherapy for 7 months due to advanced gastric carcinoma in 2005.
mark||suggested-6/VBN||although-1/IN	det||studies-4/NNS||some-2/DT	amod||studies-4/NNS||previous-3/JJ	nsubj||suggested-6/VBN||studies-4/NNS	aux||suggested-6/VBN||have-5/VBP	advcl||examined-24/VBN||suggested-6/VBN	mark||comprised-14/VBN||that-7/IN	amod||growth-9/NN||posttraumatic-8/JJ	nsubjpass||comprised-14/VBN||growth-9/NN	appos||growth-9/NN||ptg-11/NN	auxpass||comprised-14/VBN||is-13/VBZ	ccomp||suggested-6/VBN||comprised-14/VBN	amod||factors-17/NNS||several-16/JJ	prep_of||comprised-14/VBN||factors-17/NNS	amod||properties-20/NNS||different-19/JJ	prep_with||comprised-14/VBN||properties-20/NNS	nsubj||examined-24/VBN||few-22/JJ	aux||examined-24/VBN||have-23/VBP	root||ROOT-0/null||examined-24/VBN	predet||association-27/NN||both-25/PDT	det||association-27/NN||the-26/DT	dobj||examined-24/VBN||association-27/NN	prep_between||examined-24/VBN||ptg-29/NN	prep_between||examined-24/VBN||posttraumaticstressdisorder-31/NN	conj_and||ptg-29/NN||posttraumaticstressdisorder-31/NN	dep||examined-24/VBN||ptsd-33/VBN	prep_between||examined-24/VBN||ptg-37/NN	conj_and||ptg-29/NN||ptg-37/NN	conj_and||ptg-29/NN||resilience-39/NN	conj_and||ptg-37/NN||resilience-39/NN	vmod||ptg-37/NN||focusing-41/VBG	prep_on||focusing-41/VBG||each-43/DT	det||factors-46/NNS||the-45/DT	prep_of||each-43/DT||factors-46/NNS	prep_of||factors-46/NNS||ptg-48/NN	ptg-48||posttraumaticstressdisorder-31||no_rel||although some previous studies have suggested that posttraumatic growth (ptg) is comprised of several factors with different properties, few have examined both the association between ptg and posttraumaticstressdisorder (ptsd) and between ptg and resilience, focusing on each of the factors of ptg.
advmod||show-3/VBP||here-1/RB	nsubj||show-3/VBP||we-2/PRP	root||ROOT-0/null||show-3/VBP	mark||interacts-7/VBZ||that-4/IN	det||ar-6/NN||the-5/DT	nsubj||interacts-7/VBZ||ar-6/NN	nsubjpass||methylated-12/VBN||ar-6/NN	ccomp||show-3/VBP||interacts-7/VBZ	prep||interacts-7/VBZ||with-8/IN	auxpass||methylated-12/VBN||is-10/VBZ	advmod||methylated-12/VBN||directly-11/RB	ccomp||show-3/VBP||methylated-12/VBN	conj_and||interacts-7/VBZ||methylated-12/VBN	det||set9-18/NNS||the-14/DT	amod||set9-18/NNS||histone-15/JJ	amod||set9-18/NNS||methyltransferase-16/JJ	nn||set9-18/NNS||enzyme-17/NN	agent||methylated-12/VBN||set9-18/NNS	enzyme-17||ar-6||no_rel||here we show that the ar interacts with and is directly methylated by the histone methyltransferase enzyme set9.
det||beginning-4/NN||the-3/DT	prep_as_of||includes-16/VBZ||beginning-4/NN	prep_of||beginning-4/NN||2013-6/CD	poss||â-9/NN||our-8/PRP$	appos||2013-6/CD||â-9/NN	amod||â-9/NN||$-10/$	dep||$-10/$||antibodies-11/JJ	aux||watchâ-13/VB||to-12/TO	vmod||beginning-4/NN||watchâ-13/VB	dobj||watchâ-13/VB||$-14/$	num||$-14/$||list-15/CD	root||ROOT-0/null||includes-16/VBZ	num||mabs-19/NNS||28-17/CD	amod||mabs-19/NNS||single-18/JJ	dobj||includes-16/VBZ||mabs-19/NNS	num||mixture-23/NN||one-21/CD	nn||mixture-23/NN||mab-22/NN	dobj||includes-16/VBZ||mixture-23/NN	conj_and||mabs-19/NNS||mixture-23/NN	nsubj||undergoing-26/VBG||mixture-23/NN	aux||undergoing-26/VBG||are-25/VBP	rcmod||mixture-23/NN||undergoing-26/VBG	dobj||undergoing-26/VBG||evaluation-27/NN	prep_in||evaluation-27/NN||phase-29/NN	num||studies-31/NNS||3-30/CD	nsubj||includes-16/VBZ||studies-31/NNS	amod||disorders-36/NNS||inflammatory-33/JJ	conj_or||inflammatory-33/JJ||immunological-35/JJ	amod||disorders-36/NNS||immunological-35/JJ	prep_for||studies-31/NNS||disorders-36/NNS	prep_for||studies-31/NNS||cancers-38/NNS	conj_and||disorders-36/NNS||cancers-38/NNS	amod||cholesterol-41/NN||high-40/JJ	prep_for||studies-31/NNS||cholesterol-41/NN	conj_and||disorders-36/NNS||cholesterol-41/NN	prep_for||studies-31/NNS||osteoporosis-43/NNS	conj_and||disorders-36/NNS||osteoporosis-43/NNS	prep_for||studies-31/NNS||alzheimerdisease-45/NN	conj_and||disorders-36/NNS||alzheimerdisease-45/NN	amod||disease-48/NN||infectious-47/JJ	prep_for||studies-31/NNS||disease-48/NN	conj_and||disorders-36/NNS||disease-48/NN	osteoporosis-43||antibodies--1||no_rel||as of the beginning of 2013, our âantibodies to watchâ? list includes 28 single mabs and one mab mixture that are undergoing evaluation in phase 3 studies for inflammatory or immunological disorders, cancers, high cholesterol, osteoporosis, alzheimerdisease and infectious disease.
nsubjpass||described-8/VBN||3-octadecylglycerol-1/JJ	amod||alcohol-4/NN||batyl-3/JJ	appos||3-octadecylglycerol-1/JJ||alcohol-4/NN	aux||described-8/VBN||has-6/VBZ	auxpass||described-8/VBN||been-7/VBN	root||ROOT-0/null||described-8/VBN	det||agent-12/NN||an-10/DT	amod||agent-12/NN||inflammatory-11/JJ	prep_as||described-8/VBN||agent-12/NN	mark||considered-22/VBN||whereas-14/IN	amod||acid-17/NN||conjugated-15/JJ	amod||acid-17/NN||linoleic-16/JJ	nsubjpass||considered-22/VBN||acid-17/NN	appos||acid-17/NN||cla-19/NN	auxpass||considered-22/VBN||is-21/VBZ	advcl||described-8/VBN||considered-22/VBN	acomp||considered-22/VBN||effective-23/JJ	prep_against||considered-22/VBN||obesity-25/NN	alcohol-4||obesity-25||no_rel||3-octadecylglycerol (batyl alcohol) has been described as an inflammatory agent, whereas conjugated linoleic acid (cla) is considered effective against obesity.
det||dengueviruses-3/NNS||the-1/DT	num||dengueviruses-3/NNS||four-2/CD	nsubjpass||transmitted-15/VBN||dengueviruses-3/NNS	det||agents-6/NNS||the-5/DT	appos||dengueviruses-3/NNS||agents-6/NNS	prep_of||agents-6/NNS||denguefever-8/NN	prep_of||agents-6/NNS||denguehemorrhagicfever-10/NN	conj_and||denguefever-8/NN||denguehemorrhagicfever-10/NN	prep_in||agents-6/NNS||humans-12/NNS	auxpass||transmitted-15/VBN||are-14/VBP	root||ROOT-0/null||transmitted-15/VBN	advmod||transmitted-15/VBN||predominantly-16/RB	det||aegypti-21/NN||the-18/DT	nn||aegypti-21/NN||mosquito-19/NN	nn||aegypti-21/NN||aedes-20/NNS	agent||transmitted-15/VBN||aegypti-21/NN	denguehemorrhagicfever-10||dengueviruses-3||no||the four dengueviruses, the agents of denguefever and denguehemorrhagicfever in humans, are transmitted predominantly by the mosquito aedes aegypti .
nsubj||medication-6/NN||ranolazine-1/NN	nsubjpass||considered-16/VBN||ranolazine-1/NN	cop||medication-6/NN||is-2/VBZ	det||medication-6/NN||a-3/DT	amod||medication-6/NN||proven-4/JJ	amod||medication-6/NN||antianginal-5/JJ	root||ROOT-0/null||medication-6/NN	prep_in||medication-6/NN||patients-8/NNS	amod||coronaryheartdisease-11/NN||symptomatic-10/JJ	prep_with||patients-8/NNS||coronaryheartdisease-11/NN	aux||considered-16/VBN||should-14/MD	auxpass||considered-16/VBN||be-15/VB	conj_and||medication-6/NN||considered-16/VBN	det||agent-21/NN||an-18/DT	amod||agent-21/NN||initial-19/JJ	amod||agent-21/NN||antianginal-20/JJ	prep_as||considered-16/VBN||agent-21/NN	prep_for||agent-21/NN||those-23/DT	prep_with||those-23/DT||hypotension-25/NN	prep_with||those-23/DT||bradycardia-27/NN	conj_or||hypotension-25/NN||bradycardia-27/NN	antianginal-20||bradycardia-27||no_rel||ranolazine is a proven antianginal medication in patients with symptomatic coronaryheartdisease, and should be considered as an initial antianginal agent for those with hypotension or bradycardia.
det||study-2/NN||the-1/DT	nsubj||included-3/VBD||study-2/NN	root||ROOT-0/null||included-3/VBD	num||patients-7/NNS||one-4/CD	num||patients-7/NNS||hundred-5/CD	amod||patients-7/NNS||eighty-6/JJ	dobj||included-3/VBD||patients-7/NNS	dep||patients-7/NNS||divided-8/VBN	det||diabetic-13/NN||the-10/DT	amod||diabetic-13/NN||following-11/JJ	nn||diabetic-13/NN||groups-12/NNS	prep_in||divided-8/VBN||diabetic-13/NN	amod||disorders-17/NNS||ischemic-15/JJ	amod||disorders-17/NNS||cardiopathy-related-16/JJ	prep_without||diabetic-13/NN||disorders-17/NNS	appos||diabetic-13/NN||dm-19/NN	amod||disorders-35/NNS||diabetic-22/JJ	prep_with||diabetic-22/JJ||clinical-24/JJ	prep_with||diabetic-22/JJ||off-clinical-26/JJ	conj_or||clinical-24/JJ||off-clinical-26/JJ	dep||diabetic-22/JJ||electrocardiogram-28/NN	amod||ultrasound-31/NN||cardiac-30/JJ	appos||electrocardiogram-28/NN||ultrasound-31/NN	amod||disorders-35/NNS||ischemic-33/JJ	amod||disorders-35/NNS||cardiopathy-related-34/JJ	appos||diabetic-13/NN||disorders-35/NNS	amod||ic-39/NN||dm-37/JJ	amod||ic-39/NN||+-38/JJ	appos||disorders-35/NNS||ic-39/NN	dep||patients-7/NNS||nondiabetic-43/JJ	conj_and||divided-8/VBN||nondiabetic-43/JJ	amod||disorders-47/NNS||ischemic-45/JJ	amod||disorders-47/NNS||cardiopathy-related-46/JJ	prep_with||nondiabetic-43/JJ||disorders-47/NNS	appos||disorders-47/NNS||ic-49/NN	cardiopathy--1||dm-37||no_rel||the study included one hundred eighty patients divided in the following groups diabetic without ischemic cardiopathy-related disorders (dm), diabetic with clinical or off-clinical (electrocardiogram, cardiac ultrasound) ischemic cardiopathy-related disorders (dm + ic), and nondiabetic with ischemic cardiopathy-related disorders (ic).
expl||remains-2/VBZ||there-1/EX	root||ROOT-0/null||remains-2/VBZ	nsubj||remains-2/VBZ||controversy-3/NN	xcomp||remains-2/VBZ||controversy-3/NN	mark||impact-8/VB||whether-5/IN	nsubj||impact-8/VB||furosemide-6/NN	aux||impact-8/VB||can-7/MD	prepc_on||remains-2/VBZ||impact-8/VB	amod||outcomes-10/NNS||clinical-9/JJ	dobj||impact-8/VB||outcomes-10/NNS	advmod||ill-13/JJ||critically-12/RB	amod||patients-14/NNS||ill-13/JJ	prep_in||outcomes-10/NNS||patients-14/NNS	prep_with||impact-8/VB||aki-16/NN	advmod||showed-26/VBD||however-18/RB	det||survey-21/NN||a-20/DT	nsubj||showed-26/VBD||survey-21/NN	prep_of||survey-21/NN||intensivists-23/NNS	prep_of||survey-21/NN||nephrologists-25/NNS	conj_and||intensivists-23/NNS||nephrologists-25/NNS	parataxis||remains-2/VBZ||showed-26/VBD	dobj||showed-26/VBD||equipoise-27/NN	amod||evidence-30/NN||high-quality-29/JJ	prep_for||showed-26/VBD||evidence-30/NN	det||issue-34/NN||this-32/DT	amod||issue-34/NN||important-33/JJ	prep_on||showed-26/VBD||issue-34/NN	aki-16||furosemide-6||yes||there remains controversy on whether furosemide can impact clinical outcomes in critically ill patients with aki; however, a survey of intensivists and nephrologists showed equipoise for high-quality evidence on this important issue.
det||drugs-3/NNS||the-1/DT	amod||drugs-3/NNS||adjuvant-2/JJ	nsubj||effective-16/JJ||drugs-3/NNS	dep||drugs-3/NNS||ketamine-5/JJ	dep||drugs-3/NNS||ntg-7/JJ	conj_or||ketamine-5/JJ||ntg-7/JJ	advmod||added-10/VBD||when-9/WRB	rcmod||drugs-3/NNS||added-10/VBD	aux||lidocaine-12/VB||to-11/TO	xcomp||added-10/VBD||lidocaine-12/VB	prep_in||lidocaine-12/VB||ivra-14/NN	cop||effective-16/JJ||were-15/VBD	root||ROOT-0/null||effective-16/JJ	prepc_in||effective-16/JJ||improving-18/VBG	det||quality-21/NN||the-19/DT	amod||quality-21/NN||overall-20/JJ	dobj||improving-18/VBG||quality-21/NN	prep_of||quality-21/NN||anesthesia-23/NN	prepc_in||effective-16/JJ||reducing-25/VBG	conj_and||improving-18/VBG||reducing-25/VBG	amod||pain-27/NN||tourniquet-26/JJ	dobj||reducing-25/VBG||pain-27/NN	prepc_in||effective-16/JJ||increasing-29/VBG	conj_and||improving-18/VBG||increasing-29/VBG	amod||tolerance-31/NN||tourniquet-30/JJ	dobj||increasing-29/VBG||tolerance-31/NN	prepc_in||effective-16/JJ||improving-33/VBG	conj_and||improving-18/VBG||improving-33/VBG	det||analgesia-36/NN||the-34/DT	amod||analgesia-36/NN||postoperative-35/JJ	dobj||improving-33/VBG||analgesia-36/NN	prep_in||analgesia-36/NN||comparison-38/NN	det||group-42/NN||the-40/DT	nn||group-42/NN||control-41/NN	prep_to||improving-33/VBG||group-42/NN	pain-27||lidocaine-12||yes||the adjuvant drugs (ketamine or ntg) when added to lidocaine in ivra were effective in improving the overall quality of anesthesia, reducing tourniquet pain, increasing tourniquet tolerance and improving the postoperative analgesia in comparison to the control group.
aux||determine-2/VB||to-1/TO	csubj||mean-13/VBP||determine-2/VB	mark||improves-12/VBZ||whether-3/IN	det||template-7/NN||an-4/DT	amod||template-7/NN||electronic-5/JJ	nn||template-7/NN||order-6/NN	nsubj||improves-12/VBZ||template-7/NN	amod||insulin-10/NN||basal-bolus-9/JJ	prep_for||template-7/NN||insulin-10/NN	vmod||insulin-10/NN||ordering-11/VBG	ccomp||determine-2/VB||improves-12/VBZ	root||ROOT-0/null||mean-13/VBP	acomp||mean-13/VBP||bloodglucose-14/JJ	prepc_in||bloodglucose-14/JJ||hospitalized-16/VBG	amod||patients-19/NNS||general-17/JJ	amod||patients-19/NNS||medical-18/JJ	dobj||hospitalized-16/VBG||patients-19/NNS	prep_with||hospitalized-16/VBG||hyperglycemia-21/NN	prep_with||hospitalized-16/VBG||type2diabetes-23/NNS	conj_and||hyperglycemia-21/NN||type2diabetes-23/NNS	type2diabetes-23||insulin-10||yes||to determine whether an electronic order template for basal-bolus insulin ordering improves mean bloodglucose in hospitalized general medical patients with hyperglycemia and type2diabetes.
nsubjpass||employed-3/VBN||autodock-1/NN	nsubj||dock-5/VB||autodock-1/NN	auxpass||employed-3/VBN||was-2/VBD	root||ROOT-0/null||employed-3/VBN	aux||dock-5/VB||to-4/TO	xcomp||employed-3/VBN||dock-5/VB	det||polymerase/rt-8/NN||the-6/DT	nn||polymerase/rt-8/NN||hbv-7/NN	dobj||dock-5/VB||polymerase/rt-8/NN	dobj||dock-5/VB||adefovir-10/NN	conj_and||polymerase/rt-8/NN||adefovir-10/NN	hbv-7||adefovir-10||yes||autodock was employed to dock the hbv polymerase/rt and adefovir.
det||findings-2/NNS||these-1/DT	nsubj||relevant-4/JJ||findings-2/NNS	nsubj||smallpox-14/VB||findings-2/NNS	nsubj||emergent-16/VB||findings-2/NNS	cop||relevant-4/JJ||are-3/VBP	root||ROOT-0/null||relevant-4/JJ	det||design-7/NN||the-6/DT	prep_for||relevant-4/JJ||design-7/NN	amod||vaccines-10/NNS||new-9/JJ	prep_of||design-7/NN||vaccines-10/NNS	prep_of||design-7/NN||therapeutics-12/NNS	conj_and||vaccines-10/NNS||therapeutics-12/NNS	aux||smallpox-14/VB||to-13/TO	xcomp||relevant-4/JJ||smallpox-14/VB	xcomp||relevant-4/JJ||emergent-16/VB	conj_and||smallpox-14/VB||emergent-16/VB	amod||orthopoxviruses-18/NNS||virulent-17/JJ	dobj||smallpox-14/VB||orthopoxviruses-18/NNS	mark||i-22/VBD||because-19/IN	det||type-21/NN||the-20/DT	nsubj||i-22/VBD||type-21/NN	advcl||smallpox-14/VB||i-22/VBD	amod||protein-24/NN||interferon-binding-23/JJ	nsubj||factor-29/NN||protein-24/NN	cop||factor-29/NN||is-25/VBZ	det||factor-29/NN||a-26/DT	amod||factor-29/NN||major-27/JJ	nn||factor-29/NN||virulence-28/NN	ccomp||i-22/VBD||factor-29/NN	nn||models-32/NNS||animal-31/NN	prep_in||factor-29/NN||models-32/NNS	nsubj||induces-38/VBZ||vaccination-34/NN	det||protein-37/NN||this-36/DT	prep_with||vaccination-34/NN||protein-37/NN	ccomp||relevant-4/JJ||induces-38/VBZ	conj_and||relevant-4/JJ||induces-38/VBZ	amod||immunity-40/NN||protective-39/JJ	dobj||induces-38/VBZ||immunity-40/NN	poss||neutralization-44/NN||its-43/PRP$	nsubj||prevents-45/VBZ||neutralization-44/NN	conj_and||relevant-4/JJ||prevents-45/VBZ	nn||progression-47/NN||disease-46/NN	dobj||prevents-45/VBZ||progression-47/NN	smallpox-14||vaccines-10||no_rel||these findings are relevant for the design of new vaccines and therapeutics to smallpox and emergent virulent orthopoxviruses because the type i interferon-binding protein is a major virulence factor in animal models, vaccination with this protein induces protective immunity, and its neutralization prevents disease progression.
mark||reduces-19/VBZ||although-1/IN	det||minimization-3/NN||the-2/DT	nsubj||reduces-19/VBZ||minimization-3/NN	det||volume-8/NN||the-5/DT	amod||volume-8/NN||applied-6/JJ	amod||volume-8/NN||tidal-7/JJ	prep_of||minimization-3/NN||volume-8/NN	appos||volume-8/NN||vt-10/NN	amod||ventilation-15/NN||high-frequency-13/JJ	nn||ventilation-15/NN||oscillatory-14/NN	prep_during||volume-8/NN||ventilation-15/NN	appos||ventilation-15/NN||hfov-17/NNP	advcl||result-30/VB||reduces-19/VBZ	det||risk-21/NN||the-20/DT	dobj||reduces-19/VBZ||risk-21/NN	nn||stress-25/NN||alveolar-23/NN	nn||stress-25/NN||shear-24/NN	prep_of||risk-21/NN||stress-25/NN	nsubj||result-30/VB||it-27/PRP	aux||result-30/VB||can-28/MD	advmod||result-30/VB||also-29/RB	root||ROOT-0/null||result-30/VB	amod||co2-elimination-33/NN||insufficient-32/JJ	prep_in||result-30/VB||co2-elimination-33/NN	amod||respiratoryacidosis-36/NNS||severe-35/JJ	prep_with||result-30/VB||respiratoryacidosis-36/NNS	respiratoryacidosis-36||co2--1||no||although the minimization of the applied tidal volume (vt) during high-frequency oscillatory ventilation (hfov) reduces the risk of alveolar shear stress, it can also result in insufficient co2-elimination with severe respiratoryacidosis.
mark||clear-4/JJ||although-1/IN	nsubj||clear-4/JJ||it-2/PRP	cop||clear-4/JJ||is-3/VBZ	advcl||cause-47/VB||clear-4/JJ	mark||have-16/VBP||that-5/IN	det||patients-7/NNS||some-6/DT	nsubj||have-16/VBP||patients-7/NNS	prep_with||patients-7/NNS||acetylsalicylicacid-9/NN	appos||acetylsalicylicacid-9/NN||asa-11/NN	amod||asthma-15/NN||sensitive-14/JJ	dep||acetylsalicylicacid-9/NN||asthma-15/NN	ccomp||clear-4/JJ||have-16/VBP	poss||onset-19/NN||their-17/PRP$	amod||onset-19/NN||clinical-18/JJ	dobj||have-16/VBP||onset-19/NN	prep_of||onset-19/NN||disease-21/NN	prep_in||disease-21/NN||childhood-23/NN	prep_in||disease-21/NN||bronchoconstriction-25/NN	conj_and||childhood-23/NN||bronchoconstriction-25/NN	mark||seen-30/VBN||after-26/IN	nn||challenge-28/NN||asa-27/NN	nsubjpass||seen-30/VBN||challenge-28/NN	auxpass||seen-30/VBN||is-29/VBZ	advcl||have-16/VBP||seen-30/VBN	prep_in||seen-30/VBN||0-32/CD	num||%-35/NN||22-34/CD	prep_to||seen-30/VBN||%-35/NN	amod||children-38/NNS||asthmatic-37/JJ	prep_of||%-35/NN||children-38/NNS	advmod||challenged-40/VBN||so-39/RB	vmod||children-38/NNS||challenged-40/VBN	nsubj||cause-47/VB||ibuprofen-42/NN	amod||doses-45/NNS||antipyretic-44/JJ	prep_at||ibuprofen-42/NN||doses-45/NNS	aux||cause-47/VB||may-46/MD	root||ROOT-0/null||cause-47/VB	amod||problems-50/NNS||acute-48/JJ	nn||problems-50/NNS||respiratory-49/NN	dobj||cause-47/VB||problems-50/NNS	advmod||cause-47/VB||only-51/RB	det||number-56/NN||a-53/DT	advmod||small-55/JJ||very-54/RB	amod||number-56/NN||small-55/JJ	prep_in||cause-47/VB||number-56/NN	amod||moderate-60/JJ||mild-58/JJ	dep||moderate-60/JJ||to-59/TO	amod||asthmatics-61/NNS||moderate-60/JJ	prep_of||number-56/NN||asthmatics-61/NNS	asthmatics-61||asa-27||no||although it is clear that some patients with acetylsalicylicacid (asa)-sensitive asthma have their clinical onset of disease in childhood and bronchoconstriction after asa challenge is seen in 0 to 22% of asthmatic children so challenged, ibuprofen at antipyretic doses may cause acute respiratory problems only in a very small number of mild to moderate asthmatics.
amod||studies-3/NNS||cross-sectional-1/JJ	amod||studies-3/NNS||epidemiological-2/JJ	nsubj||reported-5/VBN||studies-3/NNS	aux||reported-5/VBN||have-4/VBP	root||ROOT-0/null||reported-5/VBN	det||correlation-8/NN||a-6/DT	amod||correlation-8/NN||direct-7/JJ	dobj||reported-5/VBN||correlation-8/NN	amod||testosterone-11/NN||plasma-10/JJ	prep_between||correlation-8/NN||testosterone-11/NN	nn||sensitivity-14/NN||insulin-13/NN	prep_between||correlation-8/NN||sensitivity-14/NN	conj_and||testosterone-11/NN||sensitivity-14/NN	amod||levels-19/NNS||low-17/JJ	nn||levels-19/NNS||testosterone-18/NN	nsubjpass||associated-21/VBN||levels-19/NNS	auxpass||associated-21/VBN||are-20/VBP	conj_and||reported-5/VBN||associated-21/VBN	det||risk-25/NN||an-23/DT	amod||risk-25/NN||increased-24/VBN	prep_with||associated-21/VBN||risk-25/NN	prep_of||risk-25/NN||type2diabetesmellitus-27/CD	advmod||illustrated-30/VBN||dramatically-29/RB	vmod||risk-25/NN||illustrated-30/VBN	nn||deprivation-33/NN||androgen-32/NN	agent||illustrated-30/VBN||deprivation-33/NN	prep_in||deprivation-33/NN||men-35/NNS	nn||carcinoma-38/NN||prostate-37/NN	prep_with||men-35/NNS||carcinoma-38/NN	type2diabetesmellitus-27||insulin-13||yes||cross-sectional epidemiological studies have reported a direct correlation between plasma testosterone and insulin sensitivity, and low testosterone levels are associated with an increased risk of type2diabetesmellitus, dramatically illustrated by androgen deprivation in men with prostate carcinoma.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||efficacy-4/NN||the-3/DT	dobj||evaluated-2/VBN||efficacy-4/NN	prep_of||efficacy-4/NN||glimepiride-6/NN	prep_of||efficacy-4/NN||metformin-8/NN	conj_and||glimepiride-6/NN||metformin-8/NN	prep_of||efficacy-4/NN||rosiglitazone-11/NN	conj_and||glimepiride-6/NN||rosiglitazone-11/NN	amod||treatment-14/NN||initial-13/JJ	prep_as||glimepiride-6/NN||treatment-14/NN	amod||patients-20/NNS||drug-naã-16/JJ	nn||patients-20/NNS||¯-17/NN	nn||patients-20/NNS||ve-18/NN	amod||patients-20/NNS||type2diabetesmellitus-19/JJ	prep_for||treatment-14/NN||patients-20/NNS	det||study-29/NN||a-22/DT	amod||study-29/NN||48-week-23/JJ	amod||study-29/NN||double-blind-25/JJ	amod||study-29/NN||randomized-27/JJ	amod||study-29/NN||controlled-28/JJ	prep_in||evaluated-2/VBN||study-29/NN	nsubj||included-31/VBD||study-29/NN	rcmod||study-29/NN||included-31/VBD	num||patients-34/NNS||349-32/CD	nn||patients-34/NNS||korean-33/NN	dobj||included-31/VBD||patients-34/NNS	type2diabetesmellitus-19||rosiglitazone-11||yes||we evaluated the efficacy of glimepiride, metformin, and rosiglitazone as initial treatment for drug-naã¯ve type2diabetesmellitus patients in a 48-week, double-blind, randomized controlled study that included 349 korean patients.
nsubj||propose-2/VBP||we-1/PRP	root||ROOT-0/null||propose-2/VBP	advmod||propose-2/VBP||thus-3/RB	mark||glucocorticoid-8/VBD||that-4/IN	nn||compromises-7/NNS||gr-5/NN	nn||compromises-7/NNS||haploinsufficiency-6/NN	nsubj||glucocorticoid-8/VBD||compromises-7/NNS	dep||revealed-22/VBD||glucocorticoid-8/VBD	dobj||glucocorticoid-8/VBD||sensitivity-9/NN	aux||represent-12/VB||may-11/MD	ccomp||propose-2/VBP||represent-12/VB	conj_and||revealed-22/VBD||represent-12/VB	det||cause-16/NN||a-13/DT	amod||cause-16/NN||novel-14/JJ	amod||cause-16/NN||genetic-15/JJ	dobj||represent-12/VB||cause-16/NN	amod||hypercortisolism-19/NN||subclinical-18/JJ	prep_of||cause-16/NN||hypercortisolism-19/NN	advmod||revealed-22/VBD||incidentally-21/RB	ccomp||propose-2/VBP||revealed-22/VBD	amod||adrenalhyperplasia-24/NN||bilateral-23/JJ	dobj||revealed-22/VBD||adrenalhyperplasia-24/NN	amod||hypertension-27/NN||mineralocorticoid-independent-26/JJ	dobj||revealed-22/VBD||hypertension-27/NN	conj_and||adrenalhyperplasia-24/NN||hypertension-27/NN	glucocorticoid-8||hypercortisolism-19||no_rel||we propose thus that gr haploinsufficiency compromises glucocorticoid sensitivity and may represent a novel genetic cause of subclinical hypercortisolism, incidentally revealed bilateral adrenalhyperplasia and mineralocorticoid-independent hypertension.
det||impact-2/NN||the-1/DT	nsubjpass||evaluated-54/VBN||impact-2/NN	amod||treatment-8/NN||praziquantel-4/JJ	appos||treatment-8/NN||pzq-6/NN	prep_of||impact-2/NN||treatment-8/NN	amod||interactions-14/NNS||such-10/JJ	amod||interactions-14/NNS||potential-11/JJ	amod||interactions-14/NNS||inter-specific-12/JJ	nn||interactions-14/NNS||schistosome-13/NN	prep_on||treatment-8/NN||interactions-14/NNS	amod||morbidity-17/NN||resulting-16/VBG	prep_on||treatment-8/NN||morbidity-17/NN	conj_and||interactions-14/NNS||morbidity-17/NN	vmod||morbidity-17/NN||using-18/VBG	advmod||detailed-20/JJ||uniquely-19/RB	amod||data-22/NNS||detailed-20/JJ	amod||data-22/NNS||longitudinal-21/JJ	dobj||using-18/VBG||data-22/NNS	nn||--25/NNS||pre-24/NN	num||treatment-30/NN||one-27/CD	nn||treatment-30/NN||year-28/NN	nn||treatment-30/NN||post-pzq-29/NN	conj_and||--25/NNS||treatment-30/NN	vmod||using-18/VBG||arising-32/VBG	det||program-38/NN||the-34/DT	amod||program-38/NN||national-35/JJ	nn||program-38/NN||schistosomiasis-36/NNS	nn||program-38/NN||control-37/NN	prep_from||arising-32/VBG||program-38/NN	num||areas-41/NNS||three-40/CD	prep_in||program-38/NN||areas-41/NNS	amod||gou-46/NN||mali-43/JJ	nn||gou-46/NN||sã-44/NN	nn||gou-46/NN||©-45/NN	prep_of||areas-41/NNS||gou-46/NN	prep_of||areas-41/NNS||koulikoro-48/NN	conj_and||gou-46/NN||koulikoro-48/NN	prep_of||areas-41/NNS||bamako-50/NN	conj_and||gou-46/NN||bamako-50/NN	auxpass||evaluated-54/VBN||is-52/VBZ	advmod||evaluated-54/VBN||also-53/RB	root||ROOT-0/null||evaluated-54/VBN	schistosomiasis-36||praziquantel-4||yes||the impact of praziquantel (pzq) treatment on such potential inter-specific schistosome interactions and resulting morbidity using uniquely detailed longitudinal data (pre- and one year post-pzq treatment) arising from the national schistosomiasis control program in three areas of mali sã©gou, koulikoro and bamako, is also evaluated.
amod||fluid-2/NN||cerebrospinal-1/JJ	nsubj||revealed-3/VBD||fluid-2/NN	root||ROOT-0/null||revealed-3/VBD	amod||dissociation-5/NN||albuminocytologic-4/JJ	dobj||revealed-3/VBD||dissociation-5/NN	amod||protein-8/NN||increased-7/VBN	dep||dissociation-5/NN||protein-8/NN	prep||protein-8/NN||but-9/CC	amod||count-14/NN||normal-10/JJ	amod||count-14/NN||white-11/JJ	nn||count-14/NN||blood-12/NN	nn||count-14/NN||cell-13/NN	pobj||but-9/CC||count-14/NN	amod||dissociation-5/NN||suggestive-16/JJ	prepc_of||suggestive-16/JJ||guillain-barrã-18/VBG	amod||syndrome-20/NN||©-19/JJ	dobj||guillain-barrã-18/VBG||syndrome-20/NN	advmod||started-28/VBN||hence-22/RB	det||infusion-26/NN||an-23/DT	nn||infusion-26/NN||intravenousimmunoglobulin-24/NN	nn||infusion-26/NN||g-25/NN	nsubjpass||started-28/VBN||infusion-26/NN	auxpass||started-28/VBN||was-27/VBD	conj_and||revealed-3/VBD||started-28/VBN	guillain-barrã©syndrome--1||intravenousimmunoglobulin-24||yes||cerebrospinal fluid revealed albuminocytologic dissociation (increased protein but normal white blood cell count) suggestive of guillain-barrã©syndrome and hence an intravenousimmunoglobulin g infusion was started.
nsubj||performed-3/VBD||we-1/PRP	advmod||performed-3/VBD||thus-2/RB	root||ROOT-0/null||performed-3/VBD	amod||analyses-6/NNS||full-4/JJ	nn||analyses-6/NNS||genome-5/NN	dobj||performed-3/VBD||analyses-6/NNS	num||listeriamonocytogenes-9/NNS||four-8/CD	prep_on||performed-3/VBD||listeriamonocytogenes-9/NNS	nn||isolates-15/NNS||human-12/NN	conj_and||human-12/NN||food-14/NN	nn||isolates-15/NNS||food-14/NN	prep_including||performed-3/VBD||isolates-15/NNS	preconj||case-20/NN||both-17/PDT	det||case-20/NN||a-18/DT	num||case-20/NN||1988-19/CD	prep_from||isolates-15/NNS||case-20/NN	amod||listeriosis-23/NNS||sporadic-22/JJ	prep_of||case-20/NN||listeriosis-23/NNS	det||outbreak-28/NN||a-25/DT	num||outbreak-28/NN||2000-26/CD	nn||outbreak-28/NN||listeriosis-27/NNS	prep_from||isolates-15/NNS||outbreak-28/NN	conj_and||case-20/NN||outbreak-28/NN	nsubjpass||linked-33/VBN||outbreak-28/NN	nsubj||contaminated-35/VB||outbreak-28/NN	aux||linked-33/VBN||had-31/VBD	auxpass||linked-33/VBN||been-32/VBN	rcmod||outbreak-28/NN||linked-33/VBN	aux||contaminated-35/VB||to-34/TO	xcomp||linked-33/VBN||contaminated-35/VB	dobj||contaminated-35/VB||food-36/NN	det||facility-41/NN||a-38/DT	amod||facility-41/NN||single-39/JJ	nn||facility-41/NN||processing-40/NN	prep_from||contaminated-35/VB||facility-41/NN	listeriosis-27||listeriamonocytogenes-9||no||we thus performed full genome analyses on four listeriamonocytogenes , including human and food isolates from both a 1988 case of sporadic listeriosis and a 2000 listeriosis outbreak, which had been linked to contaminated food from a single processing facility.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubjpass||undertaken-5/VBN||study-3/NN	nsubj||investigate-7/VB||study-3/NN	auxpass||undertaken-5/VBN||was-4/VBD	root||ROOT-0/null||undertaken-5/VBN	aux||investigate-7/VB||to-6/TO	xcomp||undertaken-5/VBN||investigate-7/VB	det||effect-9/NN||the-8/DT	dobj||investigate-7/VB||effect-9/NN	amod||amygdalus-12/JJ||prunus-11/JJ	amod||nuts-16/NNS||amygdalus-12/JJ	appos||nuts-16/NNS||pa-14/NN	prep_of||effect-9/NN||nuts-16/NNS	amod||functions-19/NNS||cognitive-18/JJ	prep_on||investigate-7/VB||functions-19/NNS	amod||levels-23/NNS||total-21/JJ	nn||levels-23/NNS||cholesterol-22/NN	prep_on||investigate-7/VB||levels-23/NNS	conj_and||functions-19/NNS||levels-23/NNS	amod||activity-29/NN||cholinesterase-25/JJ	appos||activity-29/NN||che-27/NN	prep_on||investigate-7/VB||activity-29/NN	conj_and||functions-19/NNS||activity-29/NN	amod||amnesia-32/NN||scopolamine-induced-31/JJ	prep_in||activity-29/NN||amnesia-32/NN	prep_in||investigate-7/VB||rats-34/NNS	amnesia-32||scopolamine--1||no||the present study was undertaken to investigate the effect of prunus amygdalus (pa) nuts on cognitive functions, total cholesterol levels and cholinesterase (che) activity in scopolamine-induced amnesia in rats.
root||ROOT-0/null||objective-1/NN	aux||determine-3/VB||to-2/TO	dep||objective-1/NN||determine-3/VB	det||efficacy-5/NN||the-4/DT	dobj||determine-3/VB||efficacy-5/NN	nn||treatment-8/NN||statin-7/NN	prep_of||efficacy-5/NN||treatment-8/NN	prep_on||determine-3/VB||risk-10/NN	prep_of||risk-10/NN||coronaryheartdisease-12/NN	prep_in||determine-3/VB||patients-14/NNS	prep_with||patients-14/NNS||familialhypercholesterolaemia-16/NN	statin-7||familialhypercholesterolaemia-16||no_rel||objective to determine the efficacy of statin treatment on risk of coronaryheartdisease in patients with familialhypercholesterolaemia.
mark||establish-4/VB||in-1/IN	dep||establish-4/VB||order-2/NN	aux||establish-4/VB||to-3/TO	advcl||examined-15/VBD||establish-4/VB	det||effect-6/NN||the-5/DT	dobj||establish-4/VB||effect-6/NN	amod||o2-9/NNS||low-8/JJ	prep_of||effect-6/NN||o2-9/NNS	amod||properties-12/NNS||cellular-11/JJ	prep_on||establish-4/VB||properties-12/NNS	nsubj||examined-15/VBD||we-14/PRP	root||ROOT-0/null||examined-15/VBD	amod||cultured-17/NN||bsmc-16/JJ	dobj||examined-15/VBD||cultured-17/NN	amod||conditions-25/NNS||hypoxic-19/JJ	num||%-22/NN||3-21/CD	npadvmod||o2-23/JJ||%-22/NN	dep||conditions-25/NNS||o2-23/JJ	prep_under||examined-15/VBD||conditions-25/NNS	o2-23||hypoxic-19||no_rel||in order to establish the effect of low o2 on cellular properties, we examined bsmc cultured under hypoxic (3% o2) conditions.
nsubj||required-7/VBD||patients-1/NNS	prep_in||patients-1/NNS||groupb-3/NN	appos||patients-1/NNS||dyspnea-5/NNP	root||ROOT-0/null||required-7/VBD	det||dose-10/NN||a-8/DT	amod||dose-10/NN||lower-9/JJR	dobj||required-7/VBD||dose-10/NN	prep_of||dose-10/NN||morphine-12/NN	prep_for||morphine-12/NN||alleviation-14/NN	prepc_compared_with||required-7/VBD||with-16/IN	pobj||required-7/VBD||those-17/DT	prep_in||those-17/DT||groups-19/NNS	dep||those-17/DT||a-20/SYM	amod||pain-23/NN||uncontrolled-22/JJ	appos||those-17/DT||pain-23/NN	pobj||required-7/VBD||c-26/SYM	conj_and||those-17/DT||c-26/SYM	det||dyspnea-29/NN||both-28/DT	dep||c-26/SYM||dyspnea-29/NN	dep||c-26/SYM||pain-31/NN	conj_and||dyspnea-29/NN||pain-31/NN	dyspnea-29||morphine-12||yes||patients in groupb (dyspnea) required a lower dose of morphine for alleviation compared with those in groups a (uncontrolled pain) and c (both dyspnea and pain).
nsubj||been-3/VBN||he-1/PRP	aux||been-3/VBN||has-2/VBZ	root||ROOT-0/null||been-3/VBN	amod||drugs-6/NNS||anti-tuberculous-5/JJ	prep_on||been-3/VBN||drugs-6/NNS	dep||drugs-6/NNS||isoniazid-8/NN	appos||isoniazid-8/NN||rifampin-10/NN	num||year-14/NN||1-13/CD	prep_for||been-3/VBN||year-14/NN	poss||encephalitis-18/NN||his-16/PRP$	amod||encephalitis-18/NN||tuberculous-17/JJ	prep_for||year-14/NN||encephalitis-18/NN	tuberculous-17||rifampin-10||yes||he has been on anti-tuberculous drugs (isoniazid, rifampin) for 1 year for his tuberculous encephalitis.
nn||depletion-2/NN||iron-1/NN	nsubjpass||evaluated-15/VBN||depletion-2/NN	appos||depletion-2/NN||lack-4/NN	nn||stores-7/NNS||iron-6/NN	prep_of||lack-4/NN||stores-7/NNS	advmod||evaluated-15/VBN||irondeficiency-9/RB	nsubjpass||evaluated-15/VBN||irondeficiencyanemia-11/NN	conj_and||irondeficiencyanemia-11/NN||anemia-13/NN	nsubjpass||evaluated-15/VBN||anemia-13/NN	auxpass||evaluated-15/VBN||were-14/VBD	root||ROOT-0/null||evaluated-15/VBN	prep_among||evaluated-15/VBN||them-17/PRP	irondeficiencyanemia-11||iron-6||yes||iron depletion, lack of iron stores, irondeficiency, irondeficiencyanemia and anemia were evaluated among them.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||effects-4/NNS||the-3/DT	iobj||evaluated-2/VBN||effects-4/NNS	det||therapy-8/NN||a-6/DT	amod||therapy-8/NN||combined-7/JJ	prep_of||effects-4/NNS||therapy-8/NN	amod||âµg-18/NN||budesonide-10/JJ	dep||budesonide-10/JJ||200-11/CD	nn||âµg-18/NN||âµg-12/NN	advmod||daily-14/RB||twice-13/RB	advmod||âµg-18/NN||daily-14/RB	conj_and||daily-14/RB||formoterol-16/JJ	advmod||âµg-18/NN||formoterol-16/JJ	dep||formoterol-16/JJ||6-17/CD	prep_of||therapy-8/NN||âµg-18/NN	advmod||daily-20/RB||twice-19/RB	dobj||evaluated-2/VBN||daily-20/RB	prepc_compared_with||evaluated-2/VBN||with-22/IN	amod||âµg-25/NN||budesonide-23/JJ	dep||budesonide-23/JJ||200-24/CD	pobj||evaluated-2/VBN||âµg-25/NN	advmod||âµg-25/NN||twice-26/RB	advmod||alone-28/RB||daily-27/RB	pobj||twice-26/RB||alone-28/RB	nn||questionnaire-32/NN||asthma-30/NN	nn||questionnaire-32/NN||control-31/NN	prep_on||twice-26/RB||questionnaire-32/NN	appos||questionnaire-32/NN||acq-34/NN	nn||quality-38/NN||asthma-37/NN	appos||questionnaire-32/NN||quality-38/NN	nn||questionnaire-41/NN||life-40/NN	prep_of||quality-38/NN||questionnaire-41/NN	appos||quality-38/NN||aqlq-43/NNP	dep||aqlq-43/NNP||juniper-45/NN	amod||function-49/NN||pulmonary-48/JJ	appos||questionnaire-32/NN||function-49/NN	conj_and||quality-38/NN||function-49/NN	amod||inflammation-52/NN||airway-51/JJ	appos||questionnaire-32/NN||inflammation-52/NN	conj_and||quality-38/NN||inflammation-52/NN	det||study-59/NN||a-55/DT	amod||study-59/NN||cross-over-56/JJ	amod||study-59/NN||randomized-57/JJ	amod||study-59/NN||double-blind-58/JJ	prep_in||evaluated-2/VBN||study-59/NN	nn||periods-62/NNS||treatment-61/NN	prep_with||study-59/NN||periods-62/NNS	num||months-65/NNS||two-64/CD	prep_of||periods-62/NNS||months-65/NNS	vmod||months-65/NNS||separated-66/VBN	det||period-71/NN||a-68/DT	amod||period-71/NN||one-month-69/JJ	amod||period-71/NN||wash-out-70/JJ	agent||separated-66/VBN||period-71/NN	asthma-37||budesonide-23||yes||we evaluated the effects of a combined therapy of budesonide 200 âµg twice daily and formoterol 6 âµg twice daily compared with budesonide 200 âµg twice daily alone on asthma control questionnaire (acq), asthma quality of life questionnaire (aqlq- juniper), pulmonary function and airway inflammation, in a cross-over randomized double-blind study with treatment periods of two months separated by a one-month wash-out period.
amod||hyperglycemia-2/NN||postprandial-1/JJ	nsubj||showed-8/VBD||hyperglycemia-2/NN	advmod||levels-7/NNS||especially-4/RB	amod||levels-7/NNS||30-minute-5/JJ	nn||levels-7/NNS||glucose-6/NN	nsubj||showed-8/VBD||levels-7/NNS	root||ROOT-0/null||showed-8/VBD	amod||correlation-10/NN||significant-9/JJ	dobj||showed-8/VBD||correlation-10/NN	prep_with||showed-8/VBD||bapwv-12/NNP	prep_in||showed-8/VBD||subjects-14/NNS	amod||hyperglycemia-17/NN||fasting-16/JJ	prep_with||subjects-14/NNS||hyperglycemia-17/NN	hyperglycemia-17||glucose-6||no||postprandial hyperglycemia, especially 30-minute glucose levels showed significant correlation with bapwv in subjects with fasting hyperglycemia.
amod||concentration-3/NN||endogenous-1/JJ	nn||concentration-3/NN||formaldehyde-2/NN	nsubj||increased-4/VBD||concentration-3/NN	root||ROOT-0/null||increased-4/VBD	advmod||increased-4/VBD||significantly-5/RB	det||lines-12/NNS||the-7/DT	amod||lines-12/NNS||cultured-8/JJ	nn||lines-12/NNS||breast-9/NN	nn||lines-12/NNS||cancer-10/NN	nn||lines-12/NNS||cell-11/NN	prep_in||increased-4/VBD||lines-12/NNS	prep_in||lines-12/NNS||vitro-14/NNP	det||marrow-19/NN||the-17/DT	nn||marrow-19/NN||bone-18/NN	prep_in||increased-4/VBD||marrow-19/NN	prepc_of||marrow-19/NN||breast-21/VBG	amod||model-26/NN||mrmt-1-22/JJ	nn||model-26/NN||bone-23/NN	nn||model-26/NN||cancer-24/NN	nn||model-26/NN||pain-25/NN	dobj||breast-21/VBG||model-26/NN	prep_in||breast-21/VBG||rats-28/NNS	prep_in||breast-21/VBG||tissues-31/NNS	conj_and||rats-28/NNS||tissues-31/NNS	nn||cancer-34/NN||breast-33/NN	prep_from||tissues-31/NNS||cancer-34/NN	nn||patients-38/NNS||lung-36/NN	nn||patients-38/NNS||cancer-37/NN	prep_from||tissues-31/NNS||patients-38/NNS	conj_and||cancer-34/NN||patients-38/NNS	prep_in||breast-21/VBG||vivo-40/NN	cancer-37||formaldehyde-2||no_rel||endogenous formaldehyde concentration increased significantly in the cultured breast cancer cell lines in vitro , in the bone marrow of breast mrmt-1 bone cancer pain model in rats and in tissues from breast cancer and lung cancer patients in vivo .
prep_by||created-14/VBN||mutagenesis-2/NNS	det||domain-7/NN||the-4/DT	amod||domain-7/NN||vitamink-dependent-5/JJ	nn||domain-7/NN||gla-6/NN	prep_of||mutagenesis-2/NNS||domain-7/NN	prep_of||domain-7/NN||apc-9/NN	nsubj||created-14/VBN||we-11/PRP	aux||created-14/VBN||have-12/VBP	advmod||created-14/VBN||recently-13/RB	root||ROOT-0/null||created-14/VBN	det||variant-17/NN||an-15/DT	nn||variant-17/NN||apc-16/NN	dobj||created-14/VBN||variant-17/NN	xcomp||created-14/VBN||having-18/VBG	amod||activity-21/NN||enhanced-19/JJ	nn||activity-21/NN||anticoagulant-20/NN	nsubj||due-22/JJ||activity-21/NN	xcomp||having-18/VBG||due-22/JJ	amod||affinity-25/NN||increased-24/VBN	prep_to||due-22/JJ||affinity-25/NN	advmod||charged-28/VBN||negatively-27/RB	amod||membranes-30/NNS||charged-28/VBN	amod||membranes-30/NNS||phospholipid-29/JJ	prep_for||affinity-25/NN||membranes-30/NNS	vitamink--1||gla-6||no_rel||by mutagenesis of the vitamink-dependent gla domain of apc, we have recently created an apc variant having enhanced anticoagulant activity due to increased affinity for negatively charged phospholipid membranes.
amod||aes-2/NN||placebo-adjusted-1/JJ	nsubj||insomnia-9/JJ||aes-2/NN	advmod||common-4/JJ||more-3/RBR	amod||aes-2/NN||common-4/JJ	amod||er-7/NN||paliperidone-6/JJ	prep_with||common-4/JJ||er-7/NN	cop||insomnia-9/JJ||were-8/VBD	ccomp||congestion-36/NN||insomnia-9/JJ	nn||tachycardia-12/NN||sinus-11/NNS	nsubj||congestion-36/NN||tachycardia-12/NN	conj_and||tachycardia-12/NN||tachycardia-14/NN	nsubj||congestion-36/NN||tachycardia-14/NN	advmod||common-17/JJ||more-16/RBR	amod||tachycardia-12/NN||common-17/JJ	prep_with||tachycardia-12/NN||risperidone-19/NN	cop||congestion-36/NN||were-20/VBD	nn||congestion-36/NN||somnolence-21/NN	conj_and||somnolence-21/NN||restlessness-23/NNS	nn||congestion-36/NN||restlessness-23/NNS	conj_and||somnolence-21/NN||nausea-25/NN	nn||congestion-36/NN||nausea-25/NN	conj_and||somnolence-21/NN||anxiety-27/NN	nn||congestion-36/NN||anxiety-27/NN	conj_and||somnolence-21/NN||salivaryhypersecretion-29/NN	nn||congestion-36/NN||salivaryhypersecretion-29/NN	conj_and||somnolence-21/NN||akathisia-31/NN	nn||congestion-36/NN||akathisia-31/NN	conj_and||somnolence-21/NN||dizziness-33/NN	nn||congestion-36/NN||dizziness-33/NN	conj_and||somnolence-21/NN||nasal-35/NN	nn||congestion-36/NN||nasal-35/NN	root||ROOT-0/null||congestion-36/NN	salivaryhypersecretion-29||risperidone-19||no_rel||placebo-adjusted aes more common with paliperidone er were insomnia, sinus tachycardia and tachycardia; more common with risperidone were somnolence, restlessness, nausea, anxiety, salivaryhypersecretion, akathisia, dizziness and nasal congestion.
num||rct-3/NN||one-2/CD	prep_in||responded-19/VBD||rct-3/NN	dep||rct-3/NN||shankland-5/NN	num||shankland-5/NN||2002-6/CD	amod||score-9/NN||jadad-8/JJ	appos||shankland-5/NN||score-9/NN	num||score-9/NN||1-10/CD	nsubj||responded-19/VBD||patients-13/NNS	amod||headache-16/NN||tension-type-15/JJ	prep_with||patients-13/NNS||headache-16/NN	prep_with||patients-13/NNS||migraine-18/NN	conj_or||headache-16/NN||migraine-18/NN	root||ROOT-0/null||responded-19/VBD	advmod||favorably-21/RB||more-20/RBR	advmod||responded-19/VBD||favorably-21/RB	det||splint-25/NN||the-23/DT	amod||splint-25/NN||nti-tss-24/JJ	prep_to||favorably-21/RB||splint-25/NN	prep||responded-19/VBD||than-26/IN	pcomp||than-26/IN||to-27/TO	det||tray-30/NN||a-28/DT	amod||tray-30/NN||bleaching-29/JJ	pobj||to-27/TO||tray-30/NN	headache-16||bleaching-29||no_rel||in one rct (shankland 2002, jadad score 1), patients with tension-type headache or migraine responded more favorably to the nti-tss splint than to a bleaching tray.
det||administration-2/NN||the-1/DT	nsubj||stay-34/VBP||administration-2/NN	prep_of||administration-2/NN||cr-4/NN	prep_to||cr-4/NN||children-6/NNS	prep_to||cr-4/NN||adolescents-8/NNS	conj_and||children-6/NNS||adolescents-8/NNS	amod||results-12/NNS||tbi-10/JJ	amod||results-12/NNS||improved-11/JJ	prep_with||children-6/NNS||results-12/NNS	amod||parameters-15/NNS||several-14/JJ	prep_in||results-12/NNS||parameters-15/NNS	prep_including||stay-34/VBP||duration-18/NN	nn||amnesia-22/NN||post-20/NN	amod||amnesia-22/NN||traumatic-21/JJ	prep_of||duration-18/NN||amnesia-22/NN	appos||amnesia-22/NN||pta-24/NN	nsubj||stay-34/VBP||duration-27/NN	amod||unit-33/NN||intubation-29/JJ	amod||unit-33/NN||intensive-31/JJ	nn||unit-33/NN||care-32/NN	prep_of||duration-27/NN||unit-33/NN	root||ROOT-0/null||stay-34/VBP	cr-4||amnesia-22||no_rel||the administration of cr to children and adolescents with tbi improved results in several parameters, including duration of post traumatic amnesia (pta), duration of intubation, intensive care unit stay.
num||weeks-3/NNS||24-2/CD	prep_within||experienced-16/VBD||weeks-3/NNS	prepc_of||weeks-3/NNS||initiating-5/VBG	amod||treatment-7/NN||antituberculosis-6/JJ	dobj||initiating-5/VBG||treatment-7/NN	num||%-10/NN||40-9/CD	nsubj||experienced-16/VBD||%-10/NN	appos||%-10/NN||117/292-12/CD	prep_of||%-10/NN||patients-15/NNS	root||ROOT-0/null||experienced-16/VBD	amod||deterioration-18/NN||clinical-17/JJ	dobj||experienced-16/VBD||deterioration-18/NN	amod||illness-22/NN||co-morbid-21/JJ	prep_due_to||experienced-16/VBD||illness-22/NN	dep||illness-22/NN||n-24/VBN	dep||70-26/CD||=-25/SYM	ccomp||n-24/VBN||70-26/CD	amod||illness-31/NN||tuberculosis-29/JJ	amod||illness-31/NN||related-30/VBN	prep_due_to||experienced-16/VBD||illness-31/NN	conj_and||illness-22/NN||illness-31/NN	dep||illness-31/NN||n-33/VBN	dep||47-35/CD||=-34/SYM	ccomp||n-33/VBN||47-35/CD	nn||infection-42/NN||non-38/NN	amod||infection-42/NN||aids-defining-39/JJ	amod||infection-42/NN||hiv-1-40/JJ	amod||infection-42/NN||related-41/JJ	prep_due_to||experienced-16/VBD||infection-42/NN	conj_and||illness-22/NN||infection-42/NN	dep||infection-42/NN||n-44/VBN	dep||25-46/CD||=-45/SYM	ccomp||n-44/VBN||25-46/CD	amod||illness-50/NN||aids-defining-49/JJ	prep_due_to||experienced-16/VBD||illness-50/NN	conj_and||illness-22/NN||illness-50/NN	dep||illness-50/NN||n-52/VBN	dep||21-54/CD||=-53/SYM	ccomp||n-52/VBN||21-54/CD	antituberculosis-6||aids--1||no_rel||within 24 weeks of initiating antituberculosis treatment, 40% (117/292) of patients experienced clinical deterioration due to co-morbid illness (n = 70), tuberculosis related illness (n = 47), non aids-defining hiv-1 related infection (n = 25) and aids-defining illness (n = 21).
advmod||reversed-10/VBD||moreover-1/RB	amod||hc-030031-4/NN||oral-3/JJ	nsubj||reversed-10/VBD||hc-030031-4/NN	num||mg/kg-7/NN||100-6/CD	appos||hc-030031-4/NN||mg/kg-7/NN	advmod||reversed-10/VBD||significantly-9/RB	root||ROOT-0/null||reversed-10/VBD	amod||hypersensitivity-12/NN||mechanical-11/JJ	dobj||reversed-10/VBD||hypersensitivity-12/NN	det||models-17/NNS||the-14/DT	amod||models-17/NNS||more-15/JJR	amod||models-17/NNS||chronic-16/JJ	prep_in||reversed-10/VBD||models-17/NNS	amod||adjuvant-21/NN||complete-19/JJ	nn||adjuvant-21/NN||freunds-20/NNS	prep_of||models-17/NNS||adjuvant-21/NN	appos||adjuvant-21/NN||cfa-23/NN	advmod||inflammatory-27/JJ||induced-26/RB	amod||pain-28/NN||inflammatory-27/JJ	prep_of||models-17/NNS||pain-28/NN	conj_and||adjuvant-21/NN||pain-28/NN	det||model-34/NN||the-30/DT	amod||model-34/NN||spinal-31/JJ	nn||model-34/NN||nerve-32/NN	nn||model-34/NN||ligation-33/NN	prep_of||models-17/NNS||model-34/NN	conj_and||adjuvant-21/NN||model-34/NN	prep_of||model-34/NN||neuropathicpain-36/NN	neuropathicpain-36||adjuvant-21||no_rel||moreover, oral hc-030031 (100 mg/kg) significantly reversed mechanical hypersensitivity in the more chronic models of complete freunds adjuvant (cfa)-induced inflammatory pain and the spinal nerve ligation model of neuropathicpain.
amod||rate-2/NN||goitre-1/JJ	nsubjpass||measured-37/VBN||rate-2/NN	nsubjpass||compared-39/VBN||rate-2/NN	nn||hormone-6/NN||serum-4/NN	amod||hormone-6/NN||thyroid-stimulating-5/JJ	appos||rate-2/NN||hormone-6/NN	appos||hormone-6/NN||tsh-8/NN	appos||rate-2/NN||thyroxine-11/NN	conj_and||hormone-6/NN||thyroxine-11/NN	appos||thyroxine-11/NN||t4-13/NNP	nn||antibody-18/NN||thyroid-16/NN	nn||antibody-18/NN||peroxidase-17/NN	appos||rate-2/NN||antibody-18/NN	conj_and||hormone-6/NN||antibody-18/NN	appos||antibody-18/NN||tpoab-20/NN	nn||antibody-24/NN||thyroglobulin-23/NN	appos||rate-2/NN||antibody-24/NN	conj_and||hormone-6/NN||antibody-24/NN	appos||antibody-24/NN||tgab-26/NN	advmod||iodine-31/JJ||urinary-30/RB	amod||concentration-32/NN||iodine-31/JJ	appos||rate-2/NN||concentration-32/NN	conj_and||hormone-6/NN||concentration-32/NN	appos||concentration-32/NN||uic-34/NN	auxpass||measured-37/VBN||were-36/VBD	root||ROOT-0/null||measured-37/VBN	conj_and||measured-37/VBN||compared-39/VBN	det||goitrous-42/NNS||the-41/DT	prep_between||measured-37/VBN||goitrous-42/NNS	dep||goitrous-42/NNS||n-44/VBN	dep||478-46/CD||=-45/SYM	ccomp||n-44/VBN||478-46/CD	det||participants-56/NNS||the-49/DT	amod||participants-56/NNS||non-goitrous-50/JJ	dep||non-goitrous-50/JJ||n-52/VBN	dep||2,045-54/CD||=-53/SYM	ccomp||n-52/VBN||2,045-54/CD	prep_between||measured-37/VBN||participants-56/NNS	conj_and||goitrous-42/NNS||participants-56/NNS	goitre-1||thyroglobulin-23||yes||goitre rate, serum thyroid-stimulating hormone (tsh), thyroxine (t4), thyroid peroxidase antibody (tpoab), thyroglobulin antibody (tgab), and urinary iodine concentration (uic) were measured and compared between the goitrous (n=478) and the non-goitrous (n=2,045) participants.
det||activity-2/NN||the-1/DT	nsubjpass||thought-18/VBN||activity-2/NN	nsubj||determinant-23/NN||activity-2/NN	amod||dehydrogenase-5/NN||dihydropyrimidine-4/JJ	prep_of||activity-2/NN||dehydrogenase-5/NN	appos||dehydrogenase-5/NN||dpd-7/NN	det||enzyme-12/NN||the-10/DT	amod||enzyme-12/NN||key-11/JJ	appos||activity-2/NN||enzyme-12/NN	amod||catabolism-15/NN||pyrimidine-14/JJ	prep_of||enzyme-12/NN||catabolism-15/NN	auxpass||thought-18/VBN||is-17/VBZ	root||ROOT-0/null||thought-18/VBN	aux||determinant-23/NN||to-19/TO	cop||determinant-23/NN||be-20/VB	det||determinant-23/NN||an-21/DT	amod||determinant-23/NN||important-22/JJ	xcomp||thought-18/VBN||determinant-23/NN	det||occurrence-26/NN||the-25/DT	prep_for||determinant-23/NN||occurrence-26/NN	amod||reactions-30/NNS||severe-28/JJ	amod||reactions-30/NNS||toxic-29/JJ	prep_of||occurrence-26/NN||reactions-30/NNS	prep_to||reactions-30/NNS||5-fluorouracil-32/NN	nsubj||one-39/CD||5-fluorouracil-32/NN	dep||5-fluorouracil-32/NN||5-fu-34/JJ	cop||one-39/CD||is-38/VBZ	rcmod||5-fluorouracil-32/NN||one-39/CD	det||chemotherapeuticagents-45/NNS||the-41/DT	advmod||prescribed-44/VBN||most-42/RBS	advmod||prescribed-44/VBN||commonly-43/RB	amod||chemotherapeuticagents-45/NNS||prescribed-44/VBN	prep_of||one-39/CD||chemotherapeuticagents-45/NNS	det||treatment-48/NN||the-47/DT	prep_for||chemotherapeuticagents-45/NNS||treatment-48/NN	amod||cancers-51/NNS||solid-50/JJ	prep_of||treatment-48/NN||cancers-51/NNS	5-fu-34||cancers-51||no_rel||the activity of dihydropyrimidine dehydrogenase (dpd), the key enzyme of pyrimidine catabolism, is thought to be an important determinant for the occurrence of severe toxic reactions to 5-fluorouracil (5-fu), which is one of the most commonly prescribed chemotherapeuticagents for the treatment of solid cancers.
prep_conclusionsâ||demonstrated-7/VBN||$-2/$	det||study-5/NN||this-4/DT	nsubj||demonstrated-7/VBN||study-5/NN	aux||demonstrated-7/VBN||has-6/VBZ	root||ROOT-0/null||demonstrated-7/VBN	mark||amplify-16/VB||that-8/IN	amod||administration-10/NN||6-week-9/JJ	nsubj||amplify-16/VB||administration-10/NN	det||fluoxetine-14/NN||the-12/DT	amod||fluoxetine-14/NN||ssri-13/JJ	prep_of||administration-10/NN||fluoxetine-14/NN	aux||amplify-16/VB||can-15/MD	ccomp||demonstrated-7/VBN||amplify-16/VB	nn||mechanisms-21/NNS||ans-17/NN	conj_and||ans-17/NN||metabolic-19/JJ	nn||mechanisms-21/NNS||metabolic-19/JJ	nn||mechanisms-21/NNS||counterregulatory-20/NN	dobj||amplify-16/VB||mechanisms-21/NNS	amod||hypoglycemia-24/NN||moderate-23/JJ	prep_during||amplify-16/VB||hypoglycemia-24/NN	prep_in||hypoglycemia-24/NN||patients-26/NNS	prep_with||patients-26/NNS||type1diabetes-28/CD	ssri-13||type1diabetes-28||no_rel||conclusionsâ this study has demonstrated that 6-week administration of the ssri fluoxetine can amplify ans and metabolic counterregulatory mechanisms during moderate hypoglycemia in patients with type1diabetes.
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	det||approach-5/NN||a-3/DT	amod||approach-5/NN||criteria-based-4/JJ	dobj||used-2/VBD||approach-5/NN	aux||determine-7/VB||to-6/TO	vmod||used-2/VBD||determine-7/VB	nsubj||hiv/aids-9/VBZ||which-8/WDT	nsubj||purposive-27/JJ||which-8/WDT	dobj||determine-7/VB||hiv/aids-9/VBZ	nsubj||conduct-30/VB||hiv/aids-9/VBZ	nsubj||have-11/VBP||stakeholders-10/NNS	ccomp||hiv/aids-9/VBZ||have-11/VBP	det||impact-15/NN||the-12/DT	advmod||significant-14/JJ||most-13/RBS	amod||impact-15/NN||significant-14/JJ	dobj||have-11/VBP||impact-15/NN	amod||research-18/NN||hiv/aids-17/JJ	prep_on||impact-15/NN||research-18/NN	prep_on||impact-15/NN||programs-20/NNS	conj_and||research-18/NN||programs-20/NNS	prep_on||impact-15/NN||funding-22/NN	conj_and||research-18/NN||funding-22/NN	prep_on||impact-15/NN||policy-24/NN	conj_and||research-18/NN||policy-24/NN	amod||purposive-27/JJ||stratified-26/JJ	dobj||determine-7/VB||purposive-27/JJ	conj_and||hiv/aids-9/VBZ||purposive-27/JJ	nsubj||conduct-30/VB||purposive-27/JJ	amod||purposive-27/JJ||sampling-28/VBG	aux||conduct-30/VB||to-29/TO	xcomp||determine-7/VB||conduct-30/VB	dobj||conduct-30/VB||interviews-31/NNS	det||subset-34/NN||a-33/DT	prep_with||conduct-30/VB||subset-34/NN	det||individuals-37/NNS||these-36/DT	prep_of||subset-34/NN||individuals-37/NNS	aids--1||hiv--1||no||we used a criteria-based approach to determine which hiv/aids stakeholders have the most significant impact on hiv/aids research, programs, funding and policy and stratified purposive sampling to conduct interviews with a subset of these individuals.
advmod||go-5/VBP||finally-1/RB	nsubj||go-5/VBP||we-3/PRP	advmod||go-5/VBP||also-4/RB	root||ROOT-0/null||go-5/VBP	det||insights-8/NNS||the-7/DT	prep_into||go-5/VBP||insights-8/NNS	det||design-12/NN||the-10/DT	amod||design-12/NN||future-11/JJ	prep_about||insights-8/NNS||design-12/NN	prep_of||design-12/NN||drugs-14/NNS	vmod||drugs-14/NNS||targeted-15/VBN	nn||utilization-18/NN||sugar-17/NN	prep_against||targeted-15/VBN||utilization-18/NN	nn||cells-21/NNS||cancer-20/NN	prep_in||utilization-18/NN||cells-21/NNS	cancer-20||sugar-17||no_rel||finally, we also go into the insights about the future design of drugs targeted against sugar utilization in cancer cells.
nn||fabric-2/NN||cotton-1/NN	nsubj||ca-5/MD||fabric-2/NN	nsubj||showed-8/VBD||fabric-2/NN	vmod||fabric-2/NN||treated-3/VBN	prep||treated-3/VBN||with-4/IN	root||ROOT-0/null||ca-5/MD	advmod||showed-8/VBD||shp-7/RB	conj_and||ca-5/MD||showed-8/VBD	amod||activity-11/NN||significant-9/JJ	amod||activity-11/NN||antibacterial-10/JJ	dobj||showed-8/VBD||activity-11/NN	prep_against||activity-11/NN||mrsa-13/NN	num||log10-16/NNS||6.38-15/CD	dep||mrsa-13/NN||log10-16/NNS	vmod||log10-16/NNS||treated-17/VBN	amod||drying-20/NNS||conventional-19/JJ	agent||treated-17/VBN||drying-20/NNS	num||log10-23/NNS||6.46-22/CD	agent||treated-17/VBN||log10-23/NNS	conj_and||drying-20/NNS||log10-23/NNS	vmod||log10-23/NNS||treated-24/VBN	agent||treated-24/VBN||microwave-26/NN	vmod||microwave-26/NN||drying-27/VBG	prepc_before||drying-27/VBG||washing-29/VBG	num||log10-33/NNS||6.90-32/CD	conj_and||drying-20/NNS||log10-33/NNS	conj_and||log10-23/NNS||log10-33/NNS	num||log10-36/NNS||7.86-35/CD	conj_and||log10-23/NNS||log10-36/NNS	conj_and||log10-33/NNS||log10-36/NNS	advmod||treated-17/VBN||respectively-38/RB	num||cycle-42/NN||1-41/CD	prep_after||treated-17/VBN||cycle-42/NN	nn||laundering-46/NN||home-44/NN	amod||laundering-46/NN||domestic-45/JJ	prep_of||cycle-42/NN||laundering-46/NN	vmod||laundering-46/NN||washing-47/VBG	amod||-RSB--50/NNS||-LSB--48/JJ	nn||-RSB--50/NNS||hdlw-49/NN	dobj||washing-47/VBG||-RSB--50/NNS	mrsa-13||ca-5||no_rel||cotton fabric treated with ca and shp showed significant antibacterial activity against mrsa (6.38 log10 treated by conventional drying and 6.46 log10 treated by microwave drying before washing, and 6.90 log10 and 7.86 log10, respectively, after 1 cycle of home domestic laundering washing [hdlw]).
amod||antagonists-2/NNS||trpv1-1/JJ	nsubj||attenuated-6/VBD||antagonists-2/NNS	nn||scavengers-5/NNS||formaldehyde-4/NN	conj_and||antagonists-2/NNS||scavengers-5/NNS	nsubj||attenuated-6/VBD||scavengers-5/NNS	root||ROOT-0/null||attenuated-6/VBD	nn||responses-10/NNS||bone-7/NN	nn||responses-10/NNS||cancer-8/NN	nn||responses-10/NNS||pain-9/NN	dobj||attenuated-6/VBD||responses-10/NNS	pain-9||formaldehyde-4||no_rel||trpv1 antagonists and formaldehyde scavengers attenuated bone cancer pain responses.
det||china-2/NN||each-1/DT	nsubj||cares-3/VBZ||china-2/NN	root||ROOT-0/null||cares-3/VBZ	nsubjpass||required-6/VBN||site-4/NN	nsubj||carry-8/VB||site-4/NN	auxpass||required-6/VBN||was-5/VBD	ccomp||cares-3/VBZ||required-6/VBN	aux||carry-8/VB||to-7/TO	xcomp||required-6/VBN||carry-8/VB	prt||carry-8/VB||out-9/RP	dobj||carry-8/VB||surveillance-10/NN	dobj||carry-8/VB||surveys-12/NNS	conj_and||surveillance-10/NN||surveys-12/NNS	aux||understand-14/VB||to-13/TO	vmod||carry-8/VB||understand-14/VB	det||epidemic-18/NN||the-15/DT	amod||epidemic-18/NN||local-16/JJ	nn||epidemic-18/NN||hiv/aids-17/NN	dobj||understand-14/VB||epidemic-18/NN	aux||deliver-21/VB||to-20/TO	vmod||carry-8/VB||deliver-21/VB	amod||interventions-23/NNS||primary-22/JJ	dobj||deliver-21/VB||interventions-23/NNS	aux||reduce-25/VB||to-24/TO	vmod||deliver-21/VB||reduce-25/VB	vmod||deliver-21/VB||reduce-25/VB	conj_and||reduce-25/VB||reduce-25/VB	amod||hivinfections-27/NNS||new-26/JJ	dobj||reduce-25/VB||hivinfections-27/NNS	amod||groups-32/NNS||high-risk-31/JJ	prep_among||reduce-25/VB||groups-32/NNS	prep_from||reduce-25/VB||groups-32/NNS	aux||prevent-35/VB||to-34/TO	dep||reduce-25/VB||prevent-35/VB	amod||transmission-37/NN||mother-to-child-36/JJ	dobj||prevent-35/VB||transmission-37/NN	aux||treat-40/VB||to-39/TO	dep||reduce-25/VB||treat-40/VB	conj_and||prevent-35/VB||treat-40/VB	nn||patients-42/NNS||aids-41/NNS	dobj||treat-40/VB||patients-42/NNS	amod||medicines-45/NNS||antiretroviral-44/JJ	prep_with||treat-40/VB||medicines-45/NNS	aux||provide-48/VB||to-47/TO	dep||reduce-25/VB||provide-48/VB	conj_and||prevent-35/VB||provide-48/VB	nn||services-50/NNS||support-49/NN	dobj||provide-48/VB||services-50/NNS	prep_to||provide-48/VB||families-52/NNS	vmod||families-52/NNS||affected-53/VBN	agent||affected-53/VBN||hiv/aids-55/NNS	aids-41||hiv--1||no||each china cares site was required to carry out surveillance and surveys to understand the local hiv/aids epidemic, to deliver primary interventions to reduce new hivinfections among and from high-risk groups, to prevent mother-to-child transmission, to treat aids patients with antiretroviral medicines and to provide support services to families affected by hiv/aids.
nsubj||show-3/VBP||we-1/PRP	advmod||show-3/VBP||now-2/RB	root||ROOT-0/null||show-3/VBP	det||treatment-5/NN||that-4/DT	dobj||show-3/VBP||treatment-5/NN	amod||mice-8/NNS||tumor-bearing-7/JJ	prep_of||treatment-5/NN||mice-8/NNS	amod||cd40-24/NNS||il-2-10/JJ	punct||±-13/NNP||/-11/:	nn||±-13/NNP||î-12/NNP	dep||cd40-24/NNS||±-13/NNP	amod||cd40-24/NNS||cd40-15/JJ	neg||il-2-19/JJ||not-18/RB	dep||cd40-24/NNS||il-2-19/JJ	advmod||±-22/JJ||î-21/RB	conj_or||il-2-19/JJ||±-22/JJ	dep||cd40-24/NNS||±-22/JJ	prep_with||treatment-5/NN||cd40-24/NNS	vmod||treatment-5/NN||induced-26/VBN	amod||synthase-29/NN||significant-27/JJ	nn||synthase-29/NN||nitricoxide-28/NN	nsubj||expression-34/NN||synthase-29/NN	appos||synthase-29/NN||nos-31/NN	num||expression-34/NN||2-33/CD	xcomp||induced-26/VBN||expression-34/NN	amod||macrophages-37/NNS||tumor-associated-36/JJ	prep_in||expression-34/NN||macrophages-37/NNS	nitricoxide-28||tumor--1||no_rel||we now show that treatment of tumor-bearing mice with il-2/î±-cd40, but not il-2 or î±-cd40, induced significant nitricoxide synthase (nos) 2 expression in tumor-associated macrophages.
amod||enzymes-2/NNS||deubiquitylating-1/JJ	nsubj||hydrolyze-7/VB||enzymes-2/NNS	appos||enzymes-2/NNS||dubs-4/NNP	aux||hydrolyze-7/VB||can-6/MD	root||ROOT-0/null||hydrolyze-7/VB	det||bond-16/NN||a-8/DT	amod||bond-16/NN||peptide-9/JJ	conj_or||peptide-9/JJ||amide-11/JJ	amod||bond-16/NN||amide-11/JJ	conj_or||peptide-9/JJ||ester-13/JJ	amod||bond-16/NN||ester-13/JJ	conj_or||peptide-9/JJ||thiolester-15/JJ	amod||bond-16/NN||thiolester-15/JJ	dobj||hydrolyze-7/VB||bond-16/NN	det||c-terminus-19/NNS||the-18/DT	prep_at||hydrolyze-7/VB||c-terminus-19/NNS	prep_of||c-terminus-19/NNS||ubiq-21/NNP	appos||ubiq-21/NNP||ubiquitin-23/NN	det||post-translationally-28/NN||the-27/DT	prep_including||hydrolyze-7/VB||post-translationally-28/NN	vmod||post-translationally-28/NN||formed-29/VBN	amod||bonds-32/NNS||branched-30/JJ	nn||bonds-32/NNS||peptide-31/NN	dobj||formed-29/VBN||bonds-32/NNS	prep_in||formed-29/VBN||mono-34/NN	amod||conjugates-38/NNS||multi-ubiquitylated-37/JJ	prep_in||formed-29/VBN||conjugates-38/NNS	conj_or||mono-34/NN||conjugates-38/NNS	mono-34||enzymes-2||no_rel||deubiquitylating enzymes (dubs) can hydrolyze a peptide, amide, ester or thiolester bond at the c-terminus of ubiq (ubiquitin), including the post-translationally formed branched peptide bonds in mono- or multi-ubiquitylated conjugates.
poss||results-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||associated-20/VBN||that-4/IN	amod||inflammation-6/NN||colonic-5/JJ	nsubjpass||associated-20/VBN||inflammation-6/NN	amod||mice-12/NNS||il10-8/JJ	dep||mice-12/NNS||/-10/NNP	prep_in||inflammation-6/NN||mice-12/NNS	vmod||inflammation-6/NN||inoculated-13/VBN	prep_with||inoculated-13/VBN||solutions-15/NNS	vmod||solutions-15/NNS||containing-16/VBG	amod||strains-18/NNS||enterococcus-17/JJ	dobj||containing-16/VBG||strains-18/NNS	auxpass||associated-20/VBN||is-19/VBZ	ccomp||suggest-3/VBP||associated-20/VBN	nn||changes-24/NNS||gene-22/NN	nn||changes-24/NNS||expression-23/NN	prep_with||associated-20/VBN||changes-24/NNS	amod||changes-24/NNS||similar-25/JJ	prep_to||similar-25/JJ||those-27/DT	amod||ibd-30/NN||human-29/JJ	prep_of||those-27/DT||ibd-30/NN	advmod||cd-33/VBN||specifically-32/RB	vmod||changes-24/NNS||cd-33/VBN	mark||model-49/NN||that-36/IN	det||inoculum-42/NN||the-38/DT	amod||inoculum-42/NN||efâ-39/JJ	amod||inoculum-42/NN||·-40/JJ	nn||inoculum-42/NN||cif-41/NN	prep_with||model-49/NN||inoculum-42/NN	prep_in||inoculum-42/NN||particular-44/NN	nsubj||model-49/NN||this-45/DT	cop||model-49/NN||is-46/VBZ	det||model-49/NN||an-47/DT	amod||model-49/NN||appropriate-48/JJ	ccomp||suggest-3/VBP||model-49/NN	conj_and||associated-20/VBN||model-49/NN	aux||investigate-51/VB||to-50/TO	vmod||model-49/NN||investigate-51/VB	amod||interactions-53/NNS||food-gene-52/JJ	nsubj||relevant-54/JJ||interactions-53/NNS	xcomp||investigate-51/VB||relevant-54/JJ	amod||cd-57/NN||human-56/JJ	prep_to||relevant-54/JJ||cd-57/NN	inflammation-6||cd-57||no_rel||our results suggest that colonic inflammation in il10 -/- mice inoculated with solutions containing enterococcus strains is associated with gene expression changes similar to those of human ibd, specifically cd, and that with the efâ·cif inoculum in particular this is an appropriate model to investigate food-gene interactions relevant to human cd.
amod||anesthesia-3/NN||ketamine/xylazine-1/JJ	nn||anesthesia-3/NN||cocktail-2/NN	nsubj||caused-4/VBD||anesthesia-3/NN	root||ROOT-0/null||caused-4/VBD	det||hypertension-7/NN||a-5/DT	amod||hypertension-7/NN||transient-6/JJ	dobj||caused-4/VBD||hypertension-7/NN	det||cats-10/NNS||the-9/DT	prep_in||caused-4/VBD||cats-10/NNS	nsubj||inhibited-13/VBD||ea-12/NN	nsubj||shortened-18/VBN||ea-12/NN	parataxis||caused-4/VBD||inhibited-13/VBD	det||hypertension-16/NN||this-14/DT	amod||hypertension-16/NN||anesthetic-induced-15/JJ	dobj||inhibited-13/VBD||hypertension-16/NN	parataxis||caused-4/VBD||shortened-18/VBN	conj_and||inhibited-13/VBD||shortened-18/VBN	det||time-22/NN||the-19/DT	amod||time-22/NN||post-anesthesia-20/JJ	nn||time-22/NN||recovery-21/NN	dobj||shortened-18/VBN||time-22/NN	hypertension-16||ketamine--1||no||ketamine/xylazine cocktail anesthesia caused a transient hypertension in the cats; ea inhibited this anesthetic-induced hypertension and shortened the post-anesthesia recovery time.
amod||cytotoxicity-2/NN||cellular-1/JJ	nsubjpass||investigated-11/VBN||cytotoxicity-2/NN	conj_and||cytotoxicity-2/NN||proliferation-4/NN	nsubjpass||investigated-11/VBN||proliferation-4/NN	conj_and||cytotoxicity-2/NN||apoptosis-6/NNS	nsubjpass||investigated-11/VBN||apoptosis-6/NNS	conj_and||cytotoxicity-2/NN||differentiation-8/NNS	nsubjpass||investigated-11/VBN||differentiation-8/NNS	auxpass||investigated-11/VBN||were-9/VBD	advmod||investigated-11/VBN||comprehensively-10/RB	root||ROOT-0/null||investigated-11/VBN	amod||lines-15/NNS||realgar-treated-13/JJ	nn||lines-15/NNS||cell-14/NN	prep_in||investigated-11/VBN||lines-15/NNS	vmod||lines-15/NNS||derived-16/VBN	nn||patient-22/NN||pml-rarî-18/NNP	nn||patient-22/NN||±-19/NNP	nn||patient-22/NN||+-20/NNP	nn||patient-22/NN||apl-21/NN	prep_from||derived-16/VBN||patient-22/NN	det||atra-28/NN||the-25/DT	amod||atra-28/NN||all-transretinoicacid-26/JJ	prep_including||derived-16/VBN||atra-28/NN	amod||nb4-32/JJ||sensitive-31/JJ	dobj||derived-16/VBN||nb4-32/JJ	parataxis||derived-16/VBN||nb4-32/JJ	amod||lines-37/NNS||atra-resistant-34/JJ	amod||lines-37/NNS||mr2-35/JJ	nn||lines-37/NNS||cell-36/NN	dobj||derived-16/VBN||lines-37/NNS	parataxis||derived-16/VBN||lines-37/NNS	conj_and||nb4-32/JJ||lines-37/NNS	apl-21||atra-28||yes||cellular cytotoxicity, proliferation, apoptosis and differentiation were comprehensively investigated in realgar-treated cell lines derived from pml-rarî±+ apl patient, including the all-transretinoicacid (atra)-sensitive nb4 and atra-resistant mr2 cell lines.
poss||results-2/NNS||our-1/PRP$	nsubj||provide-3/VBP||results-2/NNS	root||ROOT-0/null||provide-3/VBP	det||view-6/NN||an-4/DT	amod||view-6/NN||enhanced-5/VBN	dobj||provide-3/VBP||view-6/NN	det||structure-9/NN||the-8/DT	prep_into||provide-3/VBP||structure-9/NN	prep_into||provide-3/VBP||function-11/NN	conj_and||structure-9/NN||function-11/NN	det||protein-15/NN||the-13/DT	amod||protein-15/NN||p2-14/JJ	prep_of||structure-9/NN||protein-15/NN	amod||myelin-18/NN||human-17/JJ	prep_from||protein-15/NN||myelin-18/NN	nsubj||able-22/JJ||myelin-18/NN	nsubj||bind-24/VB||myelin-18/NN	cop||able-22/JJ||is-21/VBZ	rcmod||myelin-18/NN||able-22/JJ	aux||bind-24/VB||to-23/TO	xcomp||able-22/JJ||bind-24/VB	det||lipids-27/NNS||both-25/DT	amod||lipids-27/NNS||monomeric-26/JJ	dobj||bind-24/VB||lipids-27/NNS	poss||cavity-30/NN||its-29/PRP$	prep_inside||lipids-27/NNS||cavity-30/NN	nn||surfaces-33/NNS||membrane-32/NN	prep_inside||lipids-27/NNS||surfaces-33/NNS	conj_and||cavity-30/NN||surfaces-33/NNS	lipids-27||cavity-30||no_rel||our results provide an enhanced view into the structure and function of the p2 protein from human myelin, which is able to bind both monomeric lipids inside its cavity and membrane surfaces.
det||mycobacteria-3/NN||the-1/DT	amod||mycobacteria-3/NN||recombinant-2/JJ	nsubj||grew-4/VBD||mycobacteria-3/NN	nsubj||sensitive-10/JJ||mycobacteria-3/NN	root||ROOT-0/null||grew-4/VBD	prep_in||grew-4/VBD||length-6/NN	cop||sensitive-10/JJ||were-8/VBD	advmod||sensitive-10/JJ||more-9/RBR	conj_and||grew-4/VBD||sensitive-10/JJ	num||drugs-14/NNS||two-12/CD	amod||drugs-14/NNS||anti-tuberculosis-13/JJ	prep_to||sensitive-10/JJ||drugs-14/NNS	vmod||drugs-14/NNS||isoniazid-16/VBN	vmod||drugs-14/NNS||streptomycin-18/VBN	conj_and||isoniazid-16/VBN||streptomycin-18/VBN	tuberculosis--1||isoniazid-16||yes||the recombinant mycobacteria grew in length and were more sensitive to two anti-tuberculosis drugs, isoniazid and streptomycin.
amod||searches-2/NNS||pubmed-1/JJ	nsubjpass||conducted-4/VBN||searches-2/NNS	auxpass||conducted-4/VBN||were-3/VBD	root||ROOT-0/null||conducted-4/VBN	prep_for||conducted-4/VBN||olanzapine-6/NN	prep||conducted-4/VBN||combined-7/VBN	pcomp||combined-7/VBN||with-8/IN	pobj||with-8/IN||pharmacology-9/NN	pobj||with-8/IN||schizophrenia-11/NN	conj_or||pharmacology-9/NN||schizophrenia-11/NN	pobj||with-8/IN||bipolardisorder-14/NN	conj_or||pharmacology-9/NN||bipolardisorder-14/NN	schizophrenia-11||olanzapine-6||yes||pubmed searches were conducted for olanzapine combined with pharmacology, schizophrenia, or bipolardisorder.
nsubj||found-3/VBD||we-1/PRP	advmod||found-3/VBD||also-2/RB	root||ROOT-0/null||found-3/VBD	det||infection-6/NN||that-4/DT	amod||infection-6/NN||subcutaneous-5/JJ	dobj||found-3/VBD||infection-6/NN	prep_of||infection-6/NN||animals-8/NNS	amod||results-11/NNS||y.pestis-10/JJ	prep_with||found-3/VBD||results-11/NNS	prep_in||results-11/NNS||bubonicplague-13/NN	prepc_followed_by||found-3/VBD||by-16/IN	pobj||found-3/VBD||pneumonic-17/NN	pobj||found-3/VBD||septicemicplagues-19/NNS	conj_and||pneumonic-17/NN||septicemicplagues-19/NNS	septicemicplagues-19||y.pestis-10||no||we also found that subcutaneous infection of animals with y.pestis results in bubonicplague , followed by pneumonic and septicemicplagues .
aux||review-2/VB||to-1/TO	root||ROOT-0/null||review-2/VB	det||literature-4/NN||the-3/DT	dobj||review-2/VB||literature-4/NN	det||treatment-7/NN||the-6/DT	prep_on||literature-4/NN||treatment-7/NN	prep_of||treatment-7/NN||gastroesophagealrefluxdisease-9/NN	dep||treatment-7/NN||gerd-11/VBN	prep_with||review-2/VB||emphasis-14/NN	prep_on||emphasis-14/NN||protonpumpinhibitors-16/NNS	appos||protonpumpinhibitors-16/NNS||ppis-18/NNS	advmod||review-2/VB||particularly-21/RB	amod||esomeprazole-24/NN||delayed-release-23/JJ	prep_on||review-2/VB||esomeprazole-24/NN	aux||identify-28/VB||to-27/TO	conj_and||review-2/VB||identify-28/VB	dobj||identify-28/VB||properties-29/NNS	amod||effects-32/NNS||adverse-31/JJ	nsubj||observed-35/VBD||effects-32/NNS	prep_of||effects-32/NNS||ppis-34/NNS	conj_and||review-2/VB||observed-35/VBD	det||treatment-38/NN||the-37/DT	prep_in||observed-35/VBD||treatment-38/NN	prep_of||treatment-38/NN||gerd-40/NN	prep_in||observed-35/VBD||children-42/NNS	prep_in||observed-35/VBD||adolescents-44/NNS	conj_and||children-42/NNS||adolescents-44/NNS	gastroesophagealrefluxdisease-9||esomeprazole-24||yes||to review the literature on the treatment of gastroesophagealrefluxdisease (gerd) with emphasis on protonpumpinhibitors (ppis), particularly on delayed-release esomeprazole, and to identify properties and adverse effects of ppis observed in the treatment of gerd in children and adolescents.
nsubj||medication-6/NN||ranolazine-1/NN	nsubjpass||considered-16/VBN||ranolazine-1/NN	cop||medication-6/NN||is-2/VBZ	det||medication-6/NN||a-3/DT	amod||medication-6/NN||proven-4/JJ	amod||medication-6/NN||antianginal-5/JJ	root||ROOT-0/null||medication-6/NN	prep_in||medication-6/NN||patients-8/NNS	amod||coronaryheartdisease-11/NN||symptomatic-10/JJ	prep_with||patients-8/NNS||coronaryheartdisease-11/NN	aux||considered-16/VBN||should-14/MD	auxpass||considered-16/VBN||be-15/VB	conj_and||medication-6/NN||considered-16/VBN	det||agent-21/NN||an-18/DT	amod||agent-21/NN||initial-19/JJ	amod||agent-21/NN||antianginal-20/JJ	prep_as||considered-16/VBN||agent-21/NN	prep_for||agent-21/NN||those-23/DT	prep_with||those-23/DT||hypotension-25/NN	prep_with||those-23/DT||bradycardia-27/NN	conj_or||hypotension-25/NN||bradycardia-27/NN	bradycardia-27||ranolazine-1||no_rel||ranolazine is a proven antianginal medication in patients with symptomatic coronaryheartdisease, and should be considered as an initial antianginal agent for those with hypotension or bradycardia.
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	det||mechanisms-6/NNS||the-3/DT	amod||mechanisms-6/NNS||possible-4/JJ	amod||mechanisms-6/NNS||anti-inflammatory-5/JJ	dobj||examined-2/VBD||mechanisms-6/NNS	prep_of||mechanisms-6/NNS||gabapentin-8/NN	det||attenuation-11/NN||the-10/DT	prep_in||examined-2/VBD||attenuation-11/NN	prep_of||attenuation-11/NN||neuropathicpain-13/NN	det||interaction-16/NN||the-15/DT	prep_in||examined-2/VBD||interaction-16/NN	conj_and||attenuation-11/NN||interaction-16/NN	det||effects-20/NNS||the-18/DT	amod||effects-20/NNS||anti-allodynic-19/JJ	prep_between||interaction-16/NN||effects-20/NNS	prep_of||effects-20/NNS||gabapentin-22/NN	amod||expression-28/NN||interleukin-10-24/JJ	dep||expression-28/NN||il-10-26/JJ	prep_between||interaction-16/NN||expression-28/NN	conj_and||effects-20/NNS||expression-28/NN	det||model-32/NN||a-30/DT	nn||model-32/NN||rat-31/NN	prep_in||expression-28/NN||model-32/NN	prep_of||model-32/NN||neuropathicpain-34/NN	gabapentin-22||neuropathicpain-34||no_rel||we examined the possible anti-inflammatory mechanisms of gabapentin in the attenuation of neuropathicpain and the interaction between the anti-allodynic effects of gabapentin and interleukin-10 (il-10) expression in a rat model of neuropathicpain.
poss||results-2/NNS||our-1/PRP$	nsubj||showed-3/VBD||results-2/NNS	root||ROOT-0/null||showed-3/VBD	mark||accurate-18/JJ||that-4/IN	nn||protocol-6/NN||pcr-5/NN	nsubj||accurate-18/JJ||protocol-6/NN	nsubj||rapid-20/JJ||protocol-6/NN	nsubj||sensitive-22/JJ||protocol-6/NN	nsubj||superior-24/JJ||protocol-6/NN	vmod||protocol-6/NN||used-7/VBN	det||study-10/NN||this-9/DT	prep_in||used-7/VBN||study-10/NN	nsubj||depends-12/VBZ||study-10/NN	rcmod||study-10/NN||depends-12/VBZ	amod||features-15/NNS||genotypic-14/JJ	prep_on||depends-12/VBZ||features-15/NNS	cop||accurate-18/JJ||was-16/VBD	advmod||accurate-18/JJ||relatively-17/RB	ccomp||showed-3/VBD||accurate-18/JJ	ccomp||showed-3/VBD||rapid-20/JJ	conj_and||accurate-18/JJ||rapid-20/JJ	ccomp||showed-3/VBD||sensitive-22/JJ	conj_and||accurate-18/JJ||sensitive-22/JJ	ccomp||showed-3/VBD||superior-24/JJ	conj_and||accurate-18/JJ||superior-24/JJ	det||identification-27/NN||the-26/DT	prep_in||superior-24/JJ||identification-27/NN	quantmod||7-31/CD||at-29/IN	mwe||at-29/IN||least-30/JJS	pobj||at-29/IN||least-30/JJS	num||species-32/NNS||7-31/CD	prep_of||identification-27/NN||species-32/NNS	prep_of||species-32/NNS||staphylococcus-34/NN	nn||staph-37/NN||api-36/NN	prep_than||accurate-18/JJ||staph-37/NN	nsubj||depends-39/VBZ||staph-37/NN	rcmod||staph-37/NN||depends-39/VBZ	amod||features-42/NNS||phenotypic-41/JJ	prep_on||depends-39/VBZ||features-42/NNS	staph-37||staphylococcus-34||no||our results showed that pcr protocol used in this study which depends on genotypic features was relatively accurate, rapid, sensitive and superior in the identification of at least 7 species of staphylococcus than api staph which depends on phenotypic features.
det||dose-3/NN||a-1/DT	amod||dose-3/NN||standard-2/JJ	nsubj||effective-9/JJ||dose-3/NN	prep_of||dose-3/NN||ivig-5/NN	cop||effective-9/JJ||is-6/VBZ	neg||effective-9/JJ||not-7/RB	advmod||effective-9/JJ||sufficiently-8/RB	root||ROOT-0/null||effective-9/JJ	amod||patients-13/NNS||many-11/JJ	nn||patients-13/NNS||gbs-12/NN	prep_in||effective-9/JJ||patients-13/NNS	gbs-12||ivig-5||yes||a standard dose of ivig is not sufficiently effective in many gbs patients.
nsubjpass||associated-4/VBN||perniciousanaemia-1/NN	auxpass||associated-4/VBN||is-2/VBZ	advmod||associated-4/VBN||undeniably-3/RB	root||ROOT-0/null||associated-4/VBN	prep_with||associated-4/VBN||vitaminb12deficiency-6/CD	det||association-10/NN||the-9/DT	nsubj||unclear-21/JJ||association-10/NN	amod||concentrations-14/NNS||subnormal-12/JJ	amod||concentrations-14/NNS||vitaminb12-13/JJ	prep_between||association-10/NN||concentrations-14/NNS	conj_and||association-10/NN||anaemia-16/NN	nsubj||unclear-21/JJ||anaemia-16/NN	amod||people-19/NNS||older-18/JJR	prep_in||anaemia-16/NN||people-19/NNS	cop||unclear-21/JJ||is-20/VBZ	conj_but||associated-4/VBN||unclear-21/JJ	vitaminb12deficiency-6||vitaminb12-13||yes||perniciousanaemia is undeniably associated with vitaminb12deficiency, but the association between subnormal vitaminb12 concentrations and anaemia in older people is unclear.
amod||loads-3/NNS||hbv-1/JJ	amod||loads-3/NNS||viral-2/JJ	root||ROOT-0/null||loads-3/NNS	amod||mutations-12/NNS||genotypes-5/JJ	conj_and||genotypes-5/JJ||precore-7/JJ	amod||mutations-12/NNS||precore-7/JJ	conj_and||genotypes-5/JJ||basal-9/JJ	amod||mutations-12/NNS||basal-9/JJ	nn||mutations-12/NNS||core-10/NN	nn||mutations-12/NNS||promotor-11/NN	appos||loads-3/NNS||mutations-12/NNS	amod||antigen-16/NN||serumhepatitisb-14/JJ	nn||antigen-16/NN||surface-15/NN	appos||loads-3/NNS||antigen-16/NN	conj_and||mutations-12/NNS||antigen-16/NN	dep||antigen-16/NN||hbsag-18/VBG	amod||protein-23/NN||interferon-gamma-21/JJ	nn||protein-23/NN||inducible-22/NN	appos||loads-3/NNS||protein-23/NN	conj_and||mutations-12/NNS||protein-23/NN	dobj||determined-37/VBN||10-24/CD	dep||10-24/CD||ip-10-26/JJ	nsubjpass||determined-37/VBN||levels-28/NNS	num||snps-33/NNS||four-32/CD	conj_and||levels-28/NNS||snps-33/NNS	nsubjpass||determined-37/VBN||snps-33/NNS	prep_of||snps-33/NNS||il28b-35/CD	auxpass||determined-37/VBN||were-36/VBD	rcmod||protein-23/NN||determined-37/VBN	serumhepatitis--1||hbsag-18||yes||hbv viral loads, genotypes, precore and basal core promotor mutations, serumhepatitisb surface antigen (hbsag) and interferon-gamma inducible protein 10 (ip-10) levels as well as four snps of il28b were determined.
nsubj||efficacious-8/JJ||incb13739-1/NNS	nsubj||tolerated-11/JJ||incb13739-1/NNS	vmod||incb13739-1/NNS||added-2/VBN	amod||therapy-6/NN||ongoing-4/JJ	nn||therapy-6/NN||metformin-5/NN	prep_to||added-2/VBN||therapy-6/NN	cop||efficacious-8/JJ||was-7/VBD	root||ROOT-0/null||efficacious-8/JJ	advmod||tolerated-11/JJ||well-10/RB	conj_and||efficacious-8/JJ||tolerated-11/JJ	prep_in||efficacious-8/JJ||patients-13/NNS	prep_with||patients-13/NNS||type2diabetes-15/NNS	nsubj||had-17/VBD||type2diabetes-15/NNS	rcmod||type2diabetes-15/NNS||had-17/VBD	amod||glycemic-19/JJ||inadequate-18/JJ	amod||control-20/NN||glycemic-19/JJ	dobj||had-17/VBD||control-20/NN	prep_with||had-17/VBD||metformin-22/NN	advmod||had-17/VBD||alone-23/RB	type2diabetes-15||metformin-22||yes||incb13739 added to ongoing metformin therapy was efficacious and well tolerated in patients with type2diabetes who had inadequate glycemic control with metformin alone.
aux||report-2/VB||to-1/TO	conj_or||report-2/VB||report-2/VB	csubj||caused-23/VBN||report-2/VB	csubj||caused-23/VBN||report-2/VB	det||occurrence-4/NN||the-3/DT	dobj||report-2/VB||occurrence-4/NN	amod||atrophy-7/NN||foveal-6/JJ	prep_of||occurrence-4/NN||atrophy-7/NN	nn||formation-11/NN||macular-9/NN	nn||formation-11/NN||hole-10/NN	prep_of||occurrence-4/NN||formation-11/NN	conj_and||atrophy-7/NN||formation-11/NN	amod||ranibizumab-14/NN||intravitreal-13/JJ	prep_following||atrophy-7/NN||ranibizumab-14/NN	amod||therapy-19/NN||photodynamic-18/JJ	prep_with||report-2/VB||therapy-19/NN	prep_without||report-2/VB||therapy-19/NN	amod||neovascularization-22/NN||choroidal-21/JJ	prep_for||report-2/VB||neovascularization-22/NN	root||ROOT-0/null||caused-23/VBN	prep_by||caused-23/VBN||age-relatedmaculardegeneration-25/NN	ranibizumab-14||age-relatedmaculardegeneration-25||no_rel||to report the occurrence of foveal atrophy and macular hole formation following intravitreal ranibizumab with or without photodynamic therapy for choroidal neovascularization caused by age-relatedmaculardegeneration.
advmod||used-4/VBD||here-1/RB	nsubj||used-4/VBD||we-3/PRP	nsubj||looked-20/VBD||we-3/PRP	root||ROOT-0/null||used-4/VBD	det||virus-6/NN||a-5/DT	dobj||used-4/VBD||virus-6/NN	xcomp||used-4/VBD||lacking-7/VBG	dobj||lacking-7/VBG||b5-8/NNS	dobj||lacking-7/VBG||viruses-10/NNS	conj_and||b5-8/NNS||viruses-10/NNS	prep_with||lacking-7/VBG||mutations-12/NNS	det||region-18/NN||the-14/DT	amod||region-18/NN||b5-15/JJ	amod||region-18/NN||membrane-proximal-16/JJ	nn||region-18/NN||stalk-17/NN	prep_in||mutations-12/NNS||region-18/NN	conj_and||used-4/VBD||looked-20/VBD	det||effect-23/NN||the-22/DT	prep_at||looked-20/VBD||effect-23/NN	det||modifications-26/NNS||those-25/DT	prep_of||effect-23/NN||modifications-26/NNS	prep_on||looked-20/VBD||a34-28/CD	virus-6||viruses-10||no||here, we used a virus lacking b5 and viruses with mutations in the b5 membrane-proximal stalk region and looked at the effect of those modifications on a34.
nn||predictors-2/NNS||baseline-1/NN	nsubjpass||identified-56/VBN||predictors-2/NNS	prep_of||predictors-2/NNS||level-4/NN	amod||acuity-7/NN||visual-6/JJ	prep_of||level-4/NN||acuity-7/NN	dep||acuity-7/NN||age-9/NN	amod||amd-13/NN||age-relatedmaculardegeneration-11/JJ	dep||acuity-7/NN||amd-13/NN	conj_and||age-9/NN||amd-13/NN	dep||acuity-7/NN||cataract-16/NN	conj_and||age-9/NN||cataract-16/NN	dep||acuity-7/NN||living-18/NN	conj_and||age-9/NN||living-18/NN	advmod||living-18/NN||alone-19/RB	amod||health-23/NN||low-21/JJ	amod||health-23/NN||self-rated-22/JJ	dep||acuity-7/NN||health-23/NN	conj_and||age-9/NN||health-23/NN	amod||life-style-27/NN||sedentary-26/JJ	dep||acuity-7/NN||life-style-27/NN	conj_and||age-9/NN||life-style-27/NN	prep_of||predictors-2/NNS||speed-30/NN	conj_and||level-4/NN||speed-30/NN	amod||loss-34/NN||continued-32/VBN	amod||loss-34/NN||visual-33/JJ	prep_of||speed-30/NN||loss-34/NN	nn||dr-42/NN||age-36/NN	dep||dr-42/NN||amd-38/NN	dep||dr-42/NN||diabeticretinopathy-40/NN	dep||loss-34/NN||dr-42/NN	appos||dr-42/NN||cataract-45/NN	appos||dr-42/NN||living-47/NN	conj_and||cataract-45/NN||living-47/NN	advmod||living-47/NN||alone-48/RB	amod||triglycerides-53/NNPS||high-51/JJ	amod||triglycerides-53/NNPS||fasting-52/VBG	appos||dr-42/NN||triglycerides-53/NNPS	conj_and||cataract-45/NN||triglycerides-53/NNPS	auxpass||identified-56/VBN||were-55/VBD	root||ROOT-0/null||identified-56/VBN	speed-30||dr-42||no_rel||baseline predictors of level of visual acuity (age, age-relatedmaculardegeneration (amd), cataract, living alone, low self-rated health, and sedentary life-style) and speed of continued visual loss (age, amd, diabeticretinopathy (dr), cataract, living alone, and high fasting triglycerides) were identified.
amod||knowledge-2/NN||adequate-1/JJ	nsubjpass||associated-7/VBN||knowledge-2/NN	prep_of||knowledge-2/NN||hiv/aids-4/NNS	auxpass||associated-7/VBN||was-5/VBD	advmod||associated-7/VBN||negatively-6/RB	root||ROOT-0/null||associated-7/VBN	auxpass||married-10/VBN||being-9/VBG	prepc_with||associated-7/VBN||married-10/VBN	acomp||married-10/VBN||poor-12/JJ	xcomp||married-10/VBN||having-14/VBG	amod||education-16/NN||low-15/JJ	dobj||having-14/VBG||education-16/NN	prepc_with||associated-7/VBN||residing-19/VBG	conj_and||married-10/VBN||residing-19/VBG	amod||areas-22/NNS||rural-21/JJ	prep_in||residing-19/VBG||areas-22/NNS	aids--1||hiv--1||no||adequate knowledge of hiv/aids was negatively associated with being married, poor, having low education, and residing in rural areas.
root||ROOT-0/null||conclusions-1/NNS	vmod||conclusions-1/NNS||â-2/VBN	dobj||â-2/VBN||$-3/$	mark||linked-19/VBN||$-3/$	poss||conclusions-6/NNS||our-5/PRP$	nsubj||are-7/VBP||conclusions-6/NNS	rcmod||$-3/$||are-7/VBP	dep||need-12/NN||1-9/LS	det||need-12/NN||the-11/DT	nsubjpass||linked-19/VBN||need-12/NN	nn||treatment-15/NN||insulin-14/NN	prep_for||need-12/NN||treatment-15/NN	prep_in||need-12/NN||lada-17/NN	auxpass||linked-19/VBN||is-18/VBZ	ccomp||are-7/VBP||linked-19/VBN	det||degree-22/NN||the-21/DT	prep_to||linked-19/VBN||degree-22/NN	prep_of||degree-22/NN||autoimmunity-24/NN	prep_of||degree-22/NN||î-26/NN	conj_and||autoimmunity-24/NN||î-26/NN	punct||autoimmunity-24/NN||²-27/''	nn||failure-30/NN||cell-29/NN	prep_of||degree-22/NN||failure-30/NN	conj_and||autoimmunity-24/NN||failure-30/NN	dep||subjects-34/NNS||2-32/LS	appos||failure-30/NN||subjects-34/NNS	nsubj||similar-47/JJ||lada-36/NN	conj_and||lada-36/NN||type2diabetes-38/NNS	nsubj||similar-47/JJ||type2diabetes-38/NNS	det||need-41/NN||the-40/DT	prep_without||lada-36/NN||need-41/NN	nn||treatment-44/NN||insulin-43/NN	prep_for||need-41/NN||treatment-44/NN	cop||similar-47/JJ||are-45/VBP	advmod||similar-47/JJ||phenotypically-46/RB	prepc_with||subjects-34/NNS||similar-47/JJ	dep||treatment-53/NN||3-50/LS	nn||treatment-53/NN||insulin-52/NN	prep_of||degree-22/NN||treatment-53/NN	conj_and||autoimmunity-24/NN||treatment-53/NN	prep_in||treatment-53/NN||type-55/NN	num||patients-58/NNS||2-56/CD	amod||patients-58/NNS||diabetic-57/JJ	nsubjpass||associated-60/VBN||patients-58/NNS	auxpass||associated-60/VBN||is-59/VBZ	rcmod||type-55/NN||associated-60/VBN	preconj||insulinresistance-63/NN||both-62/DT	prep_with||associated-60/VBN||insulinresistance-63/NN	prep_with||associated-60/VBN||î-65/NN	conj_and||insulinresistance-63/NN||î-65/NN	dep||insufficiency-69/NN||²-66/SYM	nn||insufficiency-69/NN||cell-68/NN	dep||conclusions-1/NNS||insufficiency-69/NN	type2diabetes-38||insulin-52||yes||conclusions âour conclusions are that 1 ) the need for insulin treatment in lada is linked to the degree of autoimmunity and î²-cell failure, 2 ) subjects with lada and type2diabetes without the need for insulin treatment are phenotypically similar, and 3 ) insulin treatment in type 2 diabetic patients is associated with both insulinresistance and î²-cell insufficiency.
det||steps-2/NNS||some-1/DT	nsubjpass||taken-5/VBN||steps-2/NNS	aux||taken-5/VBN||have-3/VBP	auxpass||taken-5/VBN||been-4/VBN	root||ROOT-0/null||taken-5/VBN	amod||studies-8/NNS||earlier-7/JJR	prep_in||taken-5/VBN||studies-8/NNS	nsubj||used-10/VBD||studies-8/NNS	rcmod||studies-8/NNS||used-10/VBD	amod||formulation-12/NN||nasal-11/JJ	dobj||used-10/VBD||formulation-12/NN	prep_of||formulation-12/NN||fentanyl-14/NN	mark||found-18/VBN||as-15/IN	nsubjpass||found-18/VBN||it-16/PRP	nsubj||achieve-20/VB||it-16/PRP	auxpass||found-18/VBN||was-17/VBD	advcl||used-10/VBD||found-18/VBN	aux||achieve-20/VB||to-19/TO	xcomp||found-18/VBN||achieve-20/VB	amod||relief-25/NN||adequate-21/JJ	conj_and||adequate-21/JJ||quick-23/JJ	amod||relief-25/NN||quick-23/JJ	nn||relief-25/NN||pain-24/NN	dobj||achieve-20/VB||relief-25/NN	pain-24||fentanyl-14||yes||some steps have been taken in earlier studies which used nasal formulation of fentanyl as it was found to achieve adequate and quick pain relief.
nsubjpass||documented-34/VBN||viruses-1/NNS	nsubj||develop-36/VB||viruses-1/NNS	dep||viruses-1/NNS||other-2/JJ	det||viruses-6/NNS||the-4/DT	nn||viruses-6/NNS||hepatitis-5/NN	prep_than||viruses-1/NNS||viruses-6/NNS	amod||virus-15/NN||parvovirusb19-9/JJ	amod||epstein-13/JJ||cytomegalovirus-11/JJ	amod||virus-15/NN||epstein-13/JJ	nn||virus-15/NN||bar-14/NN	prep_such_as||viruses-6/NNS||virus-15/NN	nn||virus-19/NN||transfusion-17/NN	amod||virus-19/NN||transmitted-18/JJ	prep_such_as||viruses-6/NNS||virus-19/NN	conj_and||virus-15/NN||virus-19/NN	appos||virus-19/NN||ttv-21/NN	amod||virus-26/NN||non-a-e-24/JJ	nn||virus-26/NN||hepatitis-25/NN	prep_such_as||viruses-6/NNS||virus-26/NN	conj_and||virus-15/NN||virus-26/NN	amod||viruses-29/NNS||unknown-28/JJ	appos||virus-26/NN||viruses-29/NNS	aux||documented-34/VBN||has-31/VBZ	advmod||documented-34/VBN||also-32/RB	auxpass||documented-34/VBN||been-33/VBN	root||ROOT-0/null||documented-34/VBN	aux||develop-36/VB||to-35/TO	xcomp||documented-34/VBN||develop-36/VB	det||syndrome-38/NN||the-37/DT	dobj||develop-36/VB||syndrome-38/NN	virus-26||viruses-29||no||viruses other than the hepatitis viruses such as parvovirusb19, cytomegalovirus, epstein bar virus, transfusion transmitted virus (ttv) and non-a-e hepatitis virus (unknown viruses) has also been documented to develop the syndrome.
nn||samples-2/NNS||blood-1/NN	nsubjpass||tested-4/VBN||samples-2/NNS	auxpass||tested-4/VBN||were-3/VBD	root||ROOT-0/null||tested-4/VBN	amod||antigen-8/NN||hepatitisb-6/JJ	nn||antigen-8/NN||surface-7/NN	prep_for||tested-4/VBN||antigen-8/NN	appos||antigen-8/NN||hbsag-10/NN	amod||hbeag-17/NN||hepatitisb-13/JJ	nn||hbeag-17/NN||e-14/NN	nn||hbeag-17/NN||antigen-15/NN	prep_for||tested-4/VBN||hbeag-17/NN	conj_and||antigen-8/NN||hbeag-17/NN	amod||antibody-25/NN||hepatitisc-20/JJ	nn||antibody-25/NN||virus-21/NN	nn||antibody-25/NN||hcv-23/NN	prep_for||tested-4/VBN||antibody-25/NN	conj_and||antigen-8/NN||antibody-25/NN	nn||rna-28/NN||hcv-27/NN	prep_for||tested-4/VBN||rna-28/NN	conj_and||antigen-8/NN||rna-28/NN	det||mutation-35/NN||the-31/DT	amod||mutation-35/NN||aflatoxin-associated-32/JJ	amod||mutation-35/NN||249ser-33/JJ	amod||mutation-35/NN||tp53-34/JJ	prep_for||tested-4/VBN||mutation-35/NN	conj_and||antigen-8/NN||mutation-35/NN	hepatitisb-13||hepatitisbsurfaceantigen--1||yes||blood samples were tested for hepatitisb surface antigen (hbsag), hepatitisb e antigen (hbeag), hepatitisc virus (hcv) antibody, hcv rna, and the aflatoxin-associated 249ser tp53 mutation.
amod||management-2/NN||obstetric-1/JJ	nsubj||focuses-6/VBZ||management-2/NN	amod||pre-eclampsia-5/NN||severe-4/JJ	prep_of||management-2/NN||pre-eclampsia-5/NN	root||ROOT-0/null||focuses-6/VBZ	amod||management-9/NN||medical-8/JJ	prep_on||focuses-6/VBZ||management-9/NN	nn||pressure-12/NN||blood-11/NN	prep_of||management-9/NN||pressure-12/NN	prep_of||management-9/NN||prevention-14/NN	conj_and||pressure-12/NN||prevention-14/NN	prep_of||management-9/NN||seizures-16/NNS	vmod||seizures-16/NNS||using-17/VBG	dobj||using-17/VBG||magnesiumsulfate-18/NN	det||cure-23/NN||the-21/DT	amod||cure-23/NN||ultimate-22/JJ	nsubj||remains-24/VBZ||cure-23/NN	conj_but||focuses-6/VBZ||remains-24/VBZ	xcomp||remains-24/VBZ||delivery-25/NN	det||fetus-28/NN||the-27/DT	prep_of||delivery-25/NN||fetus-28/NN	prep_of||delivery-25/NN||placenta-30/NN	conj_and||fetus-28/NN||placenta-30/NN	seizures-16||magnesiumsulfate-18||yes||obstetric management of severe pre-eclampsia focuses on medical management of blood pressure and prevention of seizures using magnesiumsulfate, but the ultimate cure remains delivery of the fetus and placenta.
det||risk-3/NN||a-1/DT	amod||risk-3/NN||decreased-2/VBN	nsubjpass||observed-8/VBN||risk-3/NN	nn||cancer-6/NN||breast-5/NN	prep_of||risk-3/NN||cancer-6/NN	auxpass||observed-8/VBN||was-7/VBD	root||ROOT-0/null||observed-8/VBN	amod||patients-11/NNS||female-10/JJ	prep_in||observed-8/VBN||patients-11/NNS	prep_with||observed-8/VBN||type2diabetes-13/NNS	vmod||type2diabetes-13/NNS||using-14/VBG	dobj||using-14/VBG||metformin-15/NN	det||basis-19/NN||a-17/DT	amod||basis-19/NN||long-term-18/JJ	prep_on||using-14/VBG||basis-19/NN	type2diabetes-13||metformin-15||yes||a decreased risk of breast cancer was observed in female patients with type2diabetes using metformin on a long-term basis.
nsubjpass||shown-7/VBN||hydrogensulfide-1/NN	nsubj||have-9/VB||hydrogensulfide-1/NN	appos||hydrogensulfide-1/NN||h2s-3/NNP	aux||shown-7/VBN||has-5/VBZ	auxpass||shown-7/VBN||been-6/VBN	root||ROOT-0/null||shown-7/VBN	aux||have-9/VB||to-8/TO	xcomp||shown-7/VBN||have-9/VB	amod||effects-11/NNS||cytoprotective-10/JJ	dep||sdisease-21/JJ||effects-11/NNS	prep_in||effects-11/NNS||models-13/NNS	prep_of||models-13/NNS||hypertension-15/NN	prep_of||models-13/NNS||ischemia/reperfusion-17/NN	conj_and||hypertension-15/NN||ischemia/reperfusion-17/NN	prep_of||models-13/NNS||alzheimer-19/NN	conj_and||hypertension-15/NN||alzheimer-19/NN	dep||have-9/VB||sdisease-21/JJ	hydrogensulfide-1||hypertension-15||no_rel||hydrogensulfide (h2s) has been shown to have cytoprotective effects in models of hypertension, ischemia/reperfusion and alzheimer'sdisease.
nsubjpass||approved-9/VBN||bevacizumab-1/NN	prep_in||bevacizumab-1/NN||combination-3/NN	nn||alfa-6/NN||interferon-5/NN	prep_with||combination-3/NN||alfa-6/NN	auxpass||approved-9/VBN||is-7/VBZ	advmod||approved-9/VBN||now-8/RB	root||ROOT-0/null||approved-9/VBN	mark||ve-13/VBP||for-10/IN	nn||¯-12/NNP||treatment-naã-11/NNP	nsubj||ve-13/VBP||¯-12/NNP	advcl||approved-9/VBN||ve-13/VBP	amod||renalcellcarcinoma-15/NN||advanced-14/VBN	dobj||ve-13/VBP||renalcellcarcinoma-15/NN	appos||renalcellcarcinoma-15/NN||rcc-17/NN	preconj||us-22/PRP||both-20/PDT	det||us-22/PRP||the-21/DT	prep_in||renalcellcarcinoma-15/NN||us-22/PRP	prep_in||renalcellcarcinoma-15/NN||europe-24/NN	conj_and||us-22/PRP||europe-24/NN	renalcellcarcinoma-15||interferon-5||yes||bevacizumab in combination with interferon alfa is now approved for treatment-naã¯ve advanced renalcellcarcinoma (rcc) in both the us and europe.
nsubj||disease-15/NN||trachoma-1/NN	vmod||trachoma-1/NN||caused-3/VBN	agent||caused-3/VBN||chlamydiatrachomatis-5/NNS	appos||chlamydiatrachomatis-5/NNS||ct-7/NN	cop||disease-15/NN||is-10/VBZ	det||disease-15/NN||the-11/DT	amod||disease-15/NN||leading-12/VBG	amod||disease-15/NN||infectious-13/JJ	nn||disease-15/NN||blinding-14/NN	root||ROOT-0/null||disease-15/NN	advmod||disease-15/NN||worldwide-16/RB	trachoma-1||chlamydiatrachomatis-5||no||trachoma, caused by chlamydiatrachomatis ( ct ), is the leading infectious blinding disease worldwide.
amod||expression-2/NN||gsta4-1/JJ	nsubjpass||downregulated-5/VBN||expression-2/NN	auxpass||downregulated-5/VBN||is-3/VBZ	advmod||downregulated-5/VBN||selectively-4/RB	root||ROOT-0/null||downregulated-5/VBN	amod||tissue-8/NN||adipose-7/JJ	prep_in||downregulated-5/VBN||tissue-8/NN	amod||mice-13/NNS||obese-10/JJ	amod||mice-13/NNS||insulin-resistant-11/JJ	amod||mice-13/NNS||c57bl/6j-12/JJ	prep_of||tissue-8/NN||mice-13/NNS	amod||insulinresistance-18/NN||human-16/JJ	amod||insulinresistance-18/NN||obesity-linked-17/JJ	prep_in||downregulated-5/VBN||insulinresistance-18/NN	conj_and||tissue-8/NN||insulinresistance-18/NN	insulin--1||obese-10||no_rel||gsta4 expression is selectively downregulated in adipose tissue of obese insulin-resistant c57bl/6j mice and in human obesity-linked insulinresistance.
nsubjpass||measured-19/VBN||markers-1/NNS	nn||control-4/NN||glucose-3/NN	prep_of||markers-1/NNS||control-4/NN	amod||test-10/NN||oral-7/JJ	nn||test-10/NN||glucose-8/NN	nn||test-10/NN||tolerance-9/NN	prep_including||markers-1/NNS||test-10/NN	amod||hemoglobin-13/NN||glycated-12/JJ	prep_including||markers-1/NNS||hemoglobin-13/NN	conj_and||test-10/NN||hemoglobin-13/NN	amod||glucose-16/NN||urinary-15/JJ	prep_including||markers-1/NNS||glucose-16/NN	conj_and||test-10/NN||glucose-16/NN	auxpass||measured-19/VBN||were-18/VBD	root||ROOT-0/null||measured-19/VBN	dobj||measured-19/VBN||adiposity-23/NN	det||accumulation-26/NN||the-25/DT	dobj||measured-19/VBN||accumulation-26/NN	conj_and||adiposity-23/NN||accumulation-26/NN	nn||lipids-29/NNS||liver-28/NN	prep_of||accumulation-26/NN||lipids-29/NNS	adiposity-23||glucose-16||no_rel||markers of glucose control, including oral glucose tolerance test, glycated hemoglobin and urinary glucose, were measured as well as adiposity and the accumulation of liver lipids.
nsubj||mitigated-3/VBD||oliveoil-1/NN	advmod||mitigated-3/VBD||effectively-2/RB	root||ROOT-0/null||mitigated-3/VBD	amod||osteoporosis-5/NNS||ovariectomy-induced-4/JJ	dobj||mitigated-3/VBD||osteoporosis-5/NNS	prep_in||mitigated-3/VBD||rats-7/NNS	cop||candidate-13/NN||is-10/VBZ	det||candidate-13/NN||a-11/DT	amod||candidate-13/NN||promising-12/JJ	conj_and||mitigated-3/VBD||candidate-13/NN	det||treatment-16/NN||the-15/DT	prep_for||candidate-13/NN||treatment-16/NN	prep_of||treatment-16/NN||postmenopausalosteoporosis-18/NNS	oliveoil-1||osteoporosis-5||no_rel||oliveoil effectively mitigated ovariectomy-induced osteoporosis in rats, and is a promising candidate for the treatment of postmenopausalosteoporosis.
nn||abnormalities-2/NNS||glucose-1/NN	nsubjpass||documented-4/VBN||abnormalities-2/NNS	auxpass||documented-4/VBN||were-3/VBD	root||ROOT-0/null||documented-4/VBN	num||%-7/NN||71-6/CD	prep_in||documented-4/VBN||%-7/NN	nn||type2diabetes-10/NNS||patients-9/NNS	prep_of||%-7/NN||type2diabetes-10/NNS	num||%-13/NN||29-12/CD	prep_in||documented-4/VBN||%-13/NN	amod||glucose-17/NN||impaired-15/VBN	amod||glucose-17/NN||fasting-16/JJ	appos||%-13/NN||glucose-17/NN	appos||glucose-17/NN||ifg-19/NN	num||%-23/NN||58-22/CD	prep_in||glucose-17/NN||%-23/NN	prep_in||glucose-17/NN||impairedglucosetolerance-26/NN	conj_and||%-23/NN||impairedglucosetolerance-26/NN	appos||%-23/NN||igt-28/NN	num||%-32/NN||37.5-31/CD	prep_in||glucose-17/NN||%-32/NN	type2diabetes-10||glucose-17||no_rel||glucose abnormalities were documented in 71% of patients type2diabetes in 29%, impaired fasting glucose (ifg) in 58%, and impairedglucosetolerance (igt) in 37.5%.
det||agents-2/NNS||the-1/DT	nsubj||comprise-5/VBP||agents-2/NNS	prep_of||agents-2/NNS||leptospirosis-4/NNS	root||ROOT-0/null||comprise-5/VBP	amod||members-7/NNS||several-6/JJ	dobj||comprise-5/VBP||members-7/NNS	det||genusleptospira-10/NN||the-9/DT	prep_of||members-7/NNS||genusleptospira-10/NN	nsubj||includes-14/VBZ||genusleptospira-10/NN	advmod||includes-14/VBZ||also-13/RB	rcmod||genusleptospira-10/NN||includes-14/VBZ	amod||species-18/NNS||non-pathogenic-15/JJ	amod||species-18/NNS||saprophytic-17/JJ	dobj||includes-14/VBZ||species-18/NNS	leptospirosis-4||genusleptospira-10||no||the agents of leptospirosis comprise several members of the genusleptospira , which also includes non-pathogenic, saprophytic species.
nn||cancer-5/NN||stage-2/NN	nn||cancer-5/NN||iv-3/NN	amod||cancer-5/NN||colorectal-4/JJ	prep_in||supported-9/VBN||cancer-5/NN	nsubj||supported-9/VBN||data-7/NNS	aux||supported-9/VBN||have-8/VBP	root||ROOT-0/null||supported-9/VBN	det||use-12/NN||the-10/DT	amod||use-12/NN||routine-11/JJ	dobj||supported-9/VBN||use-12/NN	amod||treatment-16/NN||prophylactic-14/JJ	nn||treatment-16/NN||skin-15/NN	prep_of||use-12/NN||treatment-16/NN	prep_in||supported-9/VBN||patients-18/NNS	dep||patients-18/NNS||receiving-19/VBG	dobj||receiving-19/VBG||antibody-20/NN	amod||receptor-25/NN||epidermal-22/JJ	nn||receptor-25/NN||growth-23/NN	nn||receptor-25/NN||factor-24/NN	prep_against||antibody-20/NN||receptor-25/NN	det||use-29/NN||the-28/DT	dobj||receiving-19/VBG||use-29/NN	conj_and||antibody-20/NN||use-29/NN	amod||chemotherapy-32/NN||upfront-31/JJ	prep_of||use-29/NN||chemotherapy-32/NN	amod||management-35/NN||initial-34/JJ	prep_as||receiving-19/VBG||management-35/NN	prep_in||receiving-19/VBG||patients-37/NNS	amod||metastasis-40/NNS||synchronous-39/JJ	prep_with||patients-37/NNS||metastasis-40/NNS	prep_without||receiving-19/VBG||obstruction-42/NN	dep||patients-18/NNS||bleeding-44/VBG	conj_or||receiving-19/VBG||bleeding-44/VBG	det||site-48/NN||the-46/DT	amod||site-48/NN||primary-47/JJ	prep_from||bleeding-44/VBG||site-48/NN	metastasis-40||antibody-20||no_rel||in stage iv colorectal cancer, data have supported the routine use of prophylactic skin treatment in patients receiving antibody against epidermal growth factor receptor, and the use of upfront chemotherapy as initial management in patients with synchronous metastasis without obstruction or bleeding from the primary site.
amod||options-2/NNS||several-1/JJ	nsubjpass||licensed-10/VBN||options-2/NNS	det||treatment-5/NN||the-4/DT	prep_for||options-2/NNS||treatment-5/NN	prep_of||treatment-5/NN||hepatitisb-7/NN	aux||licensed-10/VBN||have-8/VBP	auxpass||licensed-10/VBN||been-9/VBN	root||ROOT-0/null||licensed-10/VBN	det||interferon-15/NN||the-12/DT	amod||interferon-15/NN||last-13/JJ	nn||interferon-15/NN||years-14/NNS	prep_in||licensed-10/VBN||interferon-15/NN	amod||interferon-18/NN||pegylated-17/JJ	prep_in||licensed-10/VBN||interferon-18/NN	conj_and||interferon-15/NN||interferon-18/NN	prep_in||licensed-10/VBN||lamivudine-20/NN	conj_and||interferon-15/NN||lamivudine-20/NN	prep_in||licensed-10/VBN||adefovir-22/NN	conj_and||interferon-15/NN||adefovir-22/NN	prep_in||licensed-10/VBN||entecavir-24/NN	conj_and||interferon-15/NN||entecavir-24/NN	prep_in||licensed-10/VBN||telbivudine-27/NN	conj_and||interferon-15/NN||telbivudine-27/NN	hepatitisb-7||adefovir-22||yes||several options for the treatment of hepatitisb have been licensed in the last years interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine.
det||anticoagulant-4/NN||the-1/DT	amod||anticoagulant-4/NN||newer-2/JJR	nn||anticoagulant-4/NN||parenteral-3/NN	nsubjpass||licensed-11/VBN||anticoagulant-4/NN	appos||anticoagulant-4/NN||fondaparinux-6/NN	auxpass||licensed-11/VBN||is-8/VBZ	advmod||licensed-11/VBN||now-9/RB	advmod||licensed-11/VBN||also-10/RB	root||ROOT-0/null||licensed-11/VBN	amod||prophylaxis-15/NNS||venous-13/JJ	nn||prophylaxis-15/NNS||thromboembolism-14/NN	prep_for||licensed-11/VBN||prophylaxis-15/NNS	amod||patients-18/NNS||surgical-17/JJ	prep_in||prophylaxis-15/NNS||patients-18/NNS	det||treatment-21/NN||the-20/DT	prep_for||licensed-11/VBN||treatment-21/NN	conj_and||prophylaxis-15/NNS||treatment-21/NN	amod||deep-veinthrombosis-24/NNS||acute-23/JJ	prep_of||treatment-21/NN||deep-veinthrombosis-24/NNS	amod||experience-27/NN||clinical-26/JJ	nsubj||expanding-32/VBG||experience-27/NN	det||anticoagulant-30/NN||this-29/DT	prep_with||experience-27/NN||anticoagulant-30/NN	aux||expanding-32/VBG||is-31/VBZ	parataxis||licensed-11/VBN||expanding-32/VBG	veinthrombosis--1||fondaparinux-6||yes||the newer parenteral anticoagulant, fondaparinux, is now also licensed for venous thromboembolism prophylaxis in surgical patients and the treatment of acute deep-veinthrombosis; clinical experience with this anticoagulant is expanding.
amod||administration-2/NN||oral-1/JJ	nsubj||led-14/VBD||administration-2/NN	prep_of||administration-2/NN||pde5inhibitor-4/NNS	appos||pde5inhibitor-4/NNS||vardenafil-6/NN	prep_to||pde5inhibitor-4/NNS||mice-9/NNS	amod||lungtumors-13/NNS||her2-positive-11/JJ	amod||lungtumors-13/NNS||intracranial-12/JJ	prep_with||mice-9/NNS||lungtumors-13/NNS	root||ROOT-0/null||led-14/VBD	det||permeability-19/NN||an-16/DT	amod||permeability-19/NN||increased-17/VBN	nn||permeability-19/NN||tumor-18/NN	prep_to||led-14/VBD||permeability-19/NN	amod||dextran-27/NNS||high-21/JJ	amod||dextran-27/NNS||molecular-22/JJ	nn||dextran-27/NNS||weight-23/NN	amod||dextran-27/NNS||-LSB--24/JJ	amod||dextran-27/NNS||14c-25/JJ	nn||dextran-27/NNS||-RSB--26/NN	prep_to||permeability-19/NN||dextran-27/NNS	amod||increase-30/NN||2.6-fold-29/JJ	appos||dextran-27/NNS||increase-30/NN	prep_to||permeability-19/NN||herceptin-34/NN	conj_and||dextran-27/NNS||herceptin-34/NN	amod||increase-37/NN||2-fold-36/JJ	appos||herceptin-34/NN||increase-37/NN	pde5inhibitor-4||tumor-18||no_rel||oral administration of pde5inhibitor, vardenafil, to mice with her2-positive intracranial lungtumors led to an increased tumor permeability to high molecular weight [14c]dextran (2.6-fold increase) and to herceptin (2-fold increase).
nsubjpass||defined-5/VBN||uncontrolled-2/NNP	auxpass||defined-5/VBN||was-4/VBD	ccomp||¥-18/VBZ||defined-5/VBN	nn||¥-11/NNP||hemoglobin-7/NN	nn||¥-11/NNP||a1c-8/NNS	nn||¥-11/NNP||â-9/NN	nn||¥-11/NNP||-10/NNP	prep_as||defined-5/VBN||¥-11/NNP	prep_for||¥-11/NNP||diabetes-13/NN	nn||-17/NNS||bp-15/NN	nn||-17/NNS||â-16/NN	nsubj||¥-18/VBZ||-17/NNS	root||ROOT-0/null||¥-18/VBZ	num||mmhg-20/NN||140/90-19/CD	dobj||¥-18/VBZ||mmhg-20/NN	dep||mmhg-20/NN||â-22/NN	vmod||â-22/NN||-23/VBN	number||130/80-25/CD||¥-24/CD	dobj||-23/VBN||130/80-25/CD	xcomp||-23/VBN||mmhg-26/VBG	mark||present-29/VBP||if-27/IN	nsubj||present-29/VBP||diabetes-28/NNP	advcl||mmhg-26/VBG||present-29/VBP	prep_for||¥-18/VBZ||hypertension-32/NN	amod||cholesterol-38/NN||low-35/JJ	nn||cholesterol-38/NN||density-36/NN	nn||cholesterol-38/NN||lipoprotein-37/NN	prep_for||¥-18/VBZ||cholesterol-38/NN	conj_and||hypertension-32/NN||cholesterol-38/NN	dep||hypertension-32/NN||ldl-c-40/JJ	nn||¥-44/NNP||â-42/NNP	nn||¥-44/NNP||-43/NNP	dobj||¥-18/VBZ||¥-44/NNP	iobj||¥-18/VBZ||¥-44/NNP	num||mg/dl-46/NN||130-45/CD	dep||¥-44/NNP||mg/dl-46/NN	parataxis||¥-18/VBZ||â-48/VB	nn||¥-50/NNP||-49/NNP	nsubj||present-55/VBP||¥-50/NNP	number||mg/dl-52/JJ||100-51/CD	dep||present-55/VBP||mg/dl-52/JJ	mark||present-55/VBP||if-53/IN	nsubj||present-55/VBP||diabetes-54/NNP	xcomp||â-48/VB||present-55/VBP	prep_for||¥-18/VBZ||hyperlipidemia-58/NN	cholesterol-38||hypertension-32||no_rel||'uncontrolled' was defined as hemoglobin a1c â¥ for diabetes, bp â¥ 140/90 mmhg (â¥ 130/80 mmhg if diabetes present) for hypertension, and low density lipoprotein cholesterol (ldl-c) â¥ 130 mg/dl (â¥ 100 mg/dl if diabetes present) for hyperlipidemia.
det||study-2/NN||this-1/DT	nsubj||indicates-3/VBZ||study-2/NN	root||ROOT-0/null||indicates-3/VBZ	det||turnover-7/NN||that-4/DT	amod||turnover-7/NN||increased-5/VBN	nn||turnover-7/NN||bone-6/NN	dobj||indicates-3/VBZ||turnover-7/NN	appos||turnover-7/NN||inflammation-9/NN	amod||levels-14/NNS||low-12/JJ	amod||levels-14/NNS||vitamind-13/JJ	nsubj||important-16/JJ||levels-14/NNS	cop||important-16/JJ||are-15/VBP	conj_and||indicates-3/VBZ||important-16/JJ	det||pathophysiology-19/NN||the-18/DT	prep_in||important-16/JJ||pathophysiology-19/NN	amod||osteoporosis-22/NNS||as-related-21/JJ	prep_of||pathophysiology-19/NN||osteoporosis-22/NNS	osteoporosis-22||vitamind-13||yes||this study indicates that increased bone turnover, inflammation, and low vitamind levels are important in the pathophysiology of as-related osteoporosis.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||effect-10/NN||the-9/DT	dobj||evaluate-8/VB||effect-10/NN	amod||therapy-14/NN||hyperbaric-12/JJ	nn||therapy-14/NN||oxygen-13/NN	prep_of||effect-10/NN||therapy-14/NN	appos||therapy-14/NN||hbot-16/NN	det||management-20/NN||the-19/DT	prep_in||evaluate-8/VB||management-20/NN	amod||diabeticfootulcers-23/NNS||chronic-22/JJ	prep_of||management-20/NN||diabeticfootulcers-23/NNS	diabeticfootulcers-23||oxygen-13||no_rel||the aim of this study was to evaluate the effect of hyperbaric oxygen therapy (hbot) in the management of chronic diabeticfootulcers.
advmod||available-2/JJ||currently-1/RB	amod||information-3/NN||available-2/JJ	nsubj||suggest-10/VBP||information-3/NN	amod||trials-6/NNS||clinical-5/JJ	prep_from||information-3/NN||trials-6/NNS	amod||extensions-9/NNS||open-label-8/JJ	prep_from||information-3/NN||extensions-9/NNS	conj_and||trials-6/NNS||extensions-9/NNS	root||ROOT-0/null||suggest-10/VBP	mark||alternative-16/NN||that-11/IN	nsubj||alternative-16/NN||abatacept-12/NN	cop||alternative-16/NN||is-13/VBZ	det||alternative-16/NN||a-14/DT	amod||alternative-16/NN||good-15/JJ	ccomp||suggest-10/VBP||alternative-16/NN	amod||biologicals-19/NNS||other-18/JJ	prep_to||alternative-16/NN||biologicals-19/NNS	prep_in||biologicals-19/NNS||rheumatoidarthritis-21/NNS	rheumatoidarthritis-21||biologicals-19||no_rel||currently available information from clinical trials and open-label extensions suggest that abatacept is a good alternative to other biologicals in rheumatoidarthritis.
nsubj||drug-6/NN||alminoprofen-1/NN	cop||drug-6/NN||is-2/VBZ	det||drug-6/NN||a-3/DT	amod||drug-6/NN||non-steroid-4/JJ	amod||drug-6/NN||anti-inflammatory-5/JJ	root||ROOT-0/null||drug-6/NN	dep||drug-6/NN||nsaid-8/VBN	vmod||drug-6/NN||used-10/VBN	det||analgesic-13/JJ||an-12/DT	prep_as||used-10/VBN||analgesic-13/JJ	prep_for||analgesic-13/JJ||rheumatism-15/NN	nsaid-8||rheumatism-15||no_rel||alminoprofen is a non-steroid anti-inflammatory drug (nsaid) used as an analgesic for rheumatism.
amod||values-2/NNS||t1-1/JJ	nsubj||increased-6/VBD||values-2/NNS	nsubjpass||accompanied-33/VBN||values-2/NNS	amod||myocardium-5/NN||non-infarcted-4/JJ	prep_of||values-2/NNS||myocardium-5/NN	root||ROOT-0/null||increased-6/VBD	advmod||increased-6/VBD||significantly-7/RB	prep_from||increased-6/VBD||apex-9/NN	prep_to||increased-6/VBD||base-11/NN	dep||increased-6/VBD||from-13/IN	num||±-16/NNS||523.1-14/CD	nn||±-16/NNS||â-15/NN	pobj||from-13/IN||±-16/NNS	number||81.1-23/CD||99.5-17/CD	number||81.1-23/CD||ms-18/CD	dep||81.1-23/CD||to-19/TO	number||81.1-23/CD||561.1-20/CD	number||81.1-23/CD||â-21/CD	number||81.1-23/CD||±-22/CD	num||ms-24/NN||81.1-23/CD	dep||±-16/NNS||ms-24/NN	appos||±-16/NNS||p-26/NN	dep||0.001-28/CD||=-27/SYM	rcmod||p-26/NN||0.001-28/CD	auxpass||accompanied-33/VBN||were-32/VBD	conj_and||increased-6/VBD||accompanied-33/VBN	det||increase-37/NN||a-35/DT	amod||increase-37/NN||similar-36/JJ	agent||accompanied-33/VBN||increase-37/NN	nn||value-41/NN||blood-39/NN	amod||value-41/NN||t1-40/JJ	prep_in||accompanied-33/VBN||value-41/NN	nn||cavity-44/NN||lv-43/NN	prep_in||value-41/NN||cavity-44/NN	dep||accompanied-33/VBN||from-46/IN	num||â-48/NN||442.1-47/CD	pobj||from-46/IN||â-48/NN	vmod||â-48/NN||±-49/VBG	number||ms-57/CD||120.7-50/CD	number||ms-57/CD||ms-51/CD	dep||ms-57/CD||to-52/TO	number||ms-57/CD||456.8-53/CD	number||ms-57/CD||â-54/CD	number||ms-57/CD||±-55/CD	number||ms-57/CD||97.5-56/CD	dobj||±-49/VBG||ms-57/CD	appos||ms-57/CD||p-59/NN	number||0.001-61/CD||<-60/CD	dep||p-59/NN||0.001-61/CD	prep_over||accompanied-33/VBN||time-64/NN	base-11||cavity-44||no_rel||t1 values of non-infarcted myocardium increased significantly from apex to base (from 523.1â±99.5 ms to 561.1â±81.1 ms, p=0.001), and were accompanied by a similar increase in blood t1 value in lv cavity (from 442.1â±120.7 ms to 456.8â±97.5 ms, p<0.001) over time.
amod||artesunate-2/NN||monthly-1/JJ	nsubj||reduced-5/VBD||artesunate-2/NN	prep||artesunate-2/NN||plus-3/CC	pobj||plus-3/CC||amodiaquine-4/NN	root||ROOT-0/null||reduced-5/VBD	det||incidence-7/NN||the-6/DT	dobj||reduced-5/VBD||incidence-7/NN	prep_of||incidence-7/NN||malaria-9/NN	num||%-12/NN||69-11/CD	prep_by||reduced-5/VBD||%-12/NN	number||%-15/NN||95-14/CD	amod||ci-16/NN||%-15/NN	dep||%-12/NN||ci-16/NN	number||%-18/NN||63-17/CD	amod||ci-16/NN||%-18/NN	num||%-21/NN||74-20/CD	appos||ci-16/NN||%-21/NN	prep_by||reduced-5/VBD||anaemia-24/NN	conj_and||%-12/NN||anaemia-24/NN	num||%-27/NN||45-26/CD	prep_by||reduced-5/VBD||%-27/NN	number||%-30/NN||95-29/CD	amod||ci-31/NN||%-30/NN	dep||%-27/NN||ci-31/NN	number||%-33/NN||25-32/CD	amod||ci-31/NN||%-33/NN	num||%-35/NN||,60-34/CD	dep||ci-31/NN||%-35/NN	amod||sulphadoxine-pyrimethamine-39/NN||bimonthly-38/JJ	nsubj||reduced-40/VBD||sulphadoxine-pyrimethamine-39/NN	conj_and||reduced-5/VBD||reduced-40/VBD	det||incidence-42/NN||the-41/DT	dobj||reduced-40/VBD||incidence-42/NN	prep_of||incidence-42/NN||malaria-44/NN	num||%-47/NN||24-46/CD	prep_by||reduced-40/VBD||%-47/NN	number||%-50/NN||95-49/CD	amod||ci-51/NN||%-50/NN	dep||%-47/NN||ci-51/NN	number||%-53/NN||14-52/CD	amod||ci-51/NN||%-53/NN	num||%-55/NN||,33-54/CD	dep||ci-51/NN||%-55/NN	prep_by||reduced-40/VBD||anaemia-58/NN	conj_and||%-47/NN||anaemia-58/NN	num||%-61/NN||30-60/CD	prep_by||reduced-40/VBD||%-61/NN	number||%-64/NN||95-63/CD	amod||ci-65/NN||%-64/NN	dep||%-61/NN||ci-65/NN	number||%-67/NN||6-66/CD	amod||ci-65/NN||%-67/NN	num||%-70/NN||49-69/CD	appos||ci-65/NN||%-70/NN	amod||artesunate-74/NN||bimonthly-73/JJ	nsubj||reduced-77/VBD||artesunate-74/NN	prep||artesunate-74/NN||plus-75/CC	pobj||plus-75/CC||amodiaquine-76/NN	conj_and||reduced-5/VBD||reduced-77/VBD	det||incidence-79/NN||the-78/DT	dobj||reduced-77/VBD||incidence-79/NN	prep_of||incidence-79/NN||malaria-81/NN	num||%-84/NN||17-83/CD	prep_by||reduced-77/VBD||%-84/NN	number||%-87/NN||95-86/CD	amod||ci-88/NN||%-87/NN	dep||%-84/NN||ci-88/NN	number||%-90/NN||6-89/CD	amod||ci-88/NN||%-90/NN	num||%-93/NN||27-92/CD	appos||ci-88/NN||%-93/NN	prep_by||reduced-77/VBD||anaemia-96/NN	conj_and||%-84/NN||anaemia-96/NN	num||%-99/NN||32-98/CD	prep_by||reduced-77/VBD||%-99/NN	number||%-102/NN||95-101/CD	amod||ci-103/NN||%-102/NN	dep||%-99/NN||ci-103/NN	number||%-105/NN||7-104/CD	amod||ci-103/NN||%-105/NN	num||%-108/NN||50-107/CD	appos||ci-103/NN||%-108/NN	prepc_compared_to||reduced-77/VBD||to-111/TO	pobj||reduced-77/VBD||placebo-112/NN	malaria-81||pyrimethamine--1||yes||monthly artesunate plus amodiaquine reduced the incidence of malaria by 69% (95% ci 63%, 74%) and anaemia by 45% (95% ci 25%,60%), bimonthly sulphadoxine-pyrimethamine reduced the incidence of malaria by 24% (95% ci 14%,33%) and anaemia by 30% (95% ci 6%, 49%) and bimonthly artesunate plus amodiaquine reduced the incidence of malaria by 17% (95% ci 6%, 27%) and anaemia by 32% (95% ci 7%, 50%) compared to placebo.
det||female-5/NN||an-1/DT	advmod||healthy-3/JJ||otherwise-2/RB	amod||female-5/NN||healthy-3/JJ	amod||female-5/NN||27-year-old-4/JJ	nsubj||had-19/VBD||female-5/NN	det||history-8/NN||a-7/DT	prep_with||female-5/NN||history-8/NN	nn||hyperactivitydisorder-12/NN||attention-10/NN	nn||hyperactivitydisorder-12/NN||deficit-11/NN	prep_of||history-8/NN||hyperactivitydisorder-12/NN	dep||history-8/NN||adhd-14/VBN	vmod||history-8/NN||treated-16/VBN	prep_with||treated-16/VBN||atomoxetine-18/NN	root||ROOT-0/null||had-19/VBD	det||seizure-24/NN||an-20/DT	amod||onset-22/JJ||acute-21/JJ	amod||seizure-24/NN||onset-22/JJ	amod||seizure-24/NN||tonic-clonic-23/JJ	dobj||had-19/VBD||seizure-24/NN	adhd-14||atomoxetine-18||yes||an otherwise healthy 27-year-old female with a history of attention deficit hyperactivitydisorder (adhd) treated with atomoxetine had an acute onset tonic-clonic seizure.
det||study-2/NN||this-1/DT	nsubj||examined-3/VBD||study-2/NN	root||ROOT-0/null||examined-3/VBD	det||effect-5/NN||the-4/DT	dobj||examined-3/VBD||effect-5/NN	amod||consumption-8/NN||chronic-7/JJ	prep_of||effect-5/NN||consumption-8/NN	det||viscous-11/NNS||the-10/DT	prep_of||consumption-8/NN||viscous-11/NNS	amod||fiber-15/NN||non-fermentable-13/JJ	nn||fiber-15/NN||dietary-14/NN	appos||consumption-8/NN||fiber-15/NN	appos||consumption-8/NN||hydroxypropylmethylcellulose-17/NN	dep||hydroxypropylmethylcellulose-17/NN||hpmc-19/JJ	nn||lipids-29/NNS||glucose-23/NN	nn||lipids-29/NNS||control-24/NN	conj_and||control-24/NN||insulinresistance-26/NN	nn||lipids-29/NNS||insulinresistance-26/NN	conj_and||control-24/NN||liver-28/NN	nn||lipids-29/NNS||liver-28/NN	prep_on||examined-3/VBD||lipids-29/NNS	det||model-35/NN||an-31/DT	amod||model-35/NN||obese-32/JJ	amod||model-35/NN||diabetic-33/JJ	nn||model-35/NN||rat-34/NN	prep_in||lipids-29/NNS||model-35/NN	hydroxypropylmethylcellulose-17||insulinresistance-26||no_rel||this study examined the effect of chronic consumption of the viscous, non-fermentable dietary fiber, hydroxypropylmethylcellulose (hpmc), on glucose control, insulinresistance and liver lipids in an obese diabetic rat model.
advmod||induce-7/VB||however-1/RB	det||vaccines-4/NNS||these-3/DT	nsubj||induce-7/VB||vaccines-4/NNS	aux||induce-7/VB||did-5/VBD	neg||induce-7/VB||not-6/RB	root||ROOT-0/null||induce-7/VB	det||response-10/NN||an-8/DT	nn||response-10/NN||hai-9/NN	dobj||induce-7/VB||response-10/NN	det||virus-15/NN||the-12/DT	amod||virus-15/NN||clade-13/JJ	dep||clade-13/JJ||2.2-14/CD	prep_against||induce-7/VB||virus-15/NN	appos||virus-15/NN||ws/05-17/NNS	virus-15||vaccines-4||no_rel||however, these vaccines did not induce an hai response against the clade 2.2 virus, ws/05.
nsubj||higher-3/JJR||mortality-1/NN	cop||higher-3/JJR||was-2/VBD	root||ROOT-0/null||higher-3/JJR	amod||infants-7/NNS||very-5/JJ	nn||infants-7/NNS||preterm-6/NN	prep_in||higher-3/JJR||infants-7/NNS	prep_with||higher-3/JJR||hyperglycemia-9/NN	vmod||hyperglycemia-9/NN||treated-10/VBN	prep_with||treated-10/VBN||insulin-12/NN	det||period-16/NN||the-14/DT	amod||period-16/NN||neonatal-15/JJ	prep_during||treated-10/VBN||period-16/NN	hyperglycemia-9||insulin-12||yes||mortality was higher in very preterm infants with hyperglycemia treated with insulin during the neonatal period.
aux||determine-2/VB||to-1/TO	csubj||mean-13/VBP||determine-2/VB	mark||improves-12/VBZ||whether-3/IN	det||template-7/NN||an-4/DT	amod||template-7/NN||electronic-5/JJ	nn||template-7/NN||order-6/NN	nsubj||improves-12/VBZ||template-7/NN	amod||insulin-10/NN||basal-bolus-9/JJ	prep_for||template-7/NN||insulin-10/NN	vmod||insulin-10/NN||ordering-11/VBG	ccomp||determine-2/VB||improves-12/VBZ	root||ROOT-0/null||mean-13/VBP	acomp||mean-13/VBP||bloodglucose-14/JJ	prepc_in||bloodglucose-14/JJ||hospitalized-16/VBG	amod||patients-19/NNS||general-17/JJ	amod||patients-19/NNS||medical-18/JJ	dobj||hospitalized-16/VBG||patients-19/NNS	prep_with||hospitalized-16/VBG||hyperglycemia-21/NN	prep_with||hospitalized-16/VBG||type2diabetes-23/NNS	conj_and||hyperglycemia-21/NN||type2diabetes-23/NNS	hyperglycemia-21||insulin-10||yes||to determine whether an electronic order template for basal-bolus insulin ordering improves mean bloodglucose in hospitalized general medical patients with hyperglycemia and type2diabetes.
det||mechanism-4/NN||the-1/DT	amod||mechanism-4/NN||possible-2/JJ	amod||mechanism-4/NN||molecular-3/JJ	nsubjpass||explored-12/VBN||mechanism-4/NN	nsubj||indoleamine-18/VB||mechanism-4/NN	vmod||mechanism-4/NN||mediating-5/VBG	det||effect-8/NN||this-6/DT	amod||effect-8/NN||immunosuppressive-7/JJ	dobj||mediating-5/VBG||effect-8/NN	prep_of||effect-8/NN||uc-mscs-10/NNS	auxpass||explored-12/VBN||was-11/VBD	root||ROOT-0/null||explored-12/VBN	agent||explored-12/VBN||addition-14/NN	prep_of||addition-14/NN||inhibitors-16/NNS	aux||indoleamine-18/VB||to-17/TO	xcomp||explored-12/VBN||indoleamine-18/VB	amod||ido-21/NN||2,3-dioxygenase-19/JJ	dobj||indoleamine-18/VB||ido-21/NN	appos||ido-21/NN||nitricoxide-24/NN	discourse||nitricoxide-24/NN||no-26/UH	appos||ido-21/NN||prostaglandine2-29/NNS	conj_and||nitricoxide-24/NN||prostaglandine2-29/NNS	appos||prostaglandine2-29/NNS||pge2-31/NNP	amod||î-37/NN||transforming-34/JJ	nn||î-37/NN||growth-35/NN	nn||î-37/NN||factor-36/NN	appos||ido-21/NN||î-37/NN	conj_and||nitricoxide-24/NN||î-37/NN	number||1-39/CD||²-38/CD	amod||î-37/NN||1-39/CD	dep||1-39/CD||tgf-î-41/NNP	number||1-43/CD||²-42/CD	num||tgf-î-41/NNP||1-43/CD	appos||ido-21/NN||interleukin-46/NN	conj_and||nitricoxide-24/NN||interleukin-46/NN	num||interleukin-46/NN||10-47/CD	dep||interleukin-46/NN||il-10-49/JJ	uc--1||nitricoxide-24||no_rel||the possible molecular mechanism mediating this immunosuppressive effect of uc-mscs was explored by addition of inhibitors to indoleamine 2,3-dioxygenase (ido), nitricoxide (no), prostaglandine2 (pge2), transforming growth factor î²1 (tgf-î²1) and interleukin 10 (il-10).
advmod||administered-2/VBN||intrathecally-1/RB	amod||baclofen-3/NN||administered-2/VBN	nsubjpass||used-14/VBN||baclofen-3/NN	vmod||baclofen-3/NN||delivered-5/VBN	det||system-10/NN||an-7/DT	amod||system-10/NN||implantable-8/JJ	nn||system-10/NN||pump-9/NN	agent||delivered-5/VBN||system-10/NN	auxpass||used-14/VBN||is-12/VBZ	advmod||used-14/VBN||widely-13/RB	root||ROOT-0/null||used-14/VBN	det||treatment-17/NN||the-16/DT	prep_for||used-14/VBN||treatment-17/NN	amod||spasticity-20/NN||refractory-19/JJ	prep_of||treatment-17/NN||spasticity-20/NN	spasticity-20||baclofen-3||yes||intrathecally administered baclofen, delivered by an implantable pump system, is widely used for the treatment of refractory spasticity.
det||study-3/NN||this-2/DT	prep_in||examined-40/VBN||study-3/NN	prep_of||study-3/NN||rats-5/NNS	amod||models-12/NNS||oxygen-induced-7/JJ	nn||models-12/NNS||retinopathy-8/NN	appos||models-12/NNS||oir-10/NN	prep_with||rats-5/NNS||models-12/NNS	prep_of||models-12/NNS||rop-14/NN	nn||expression-17/NN||mrna-16/NN	nsubjpass||examined-40/VBN||expression-17/NN	nsubj||evaluate-47/VB||expression-17/NN	amod||factor-22/NN||vascular-19/JJ	amod||factor-22/NN||endothelial-20/JJ	nn||factor-22/NN||growth-21/NN	prep_of||expression-17/NN||factor-22/NN	appos||factor-22/NN||vegf-24/NN	prep_of||expression-17/NN||semaphorin-27/NN	conj_and||factor-22/NN||semaphorin-27/NN	appos||semaphorin-27/NN||sema-29/NNP	poss||receptor-35/NN||their-33/PRP$	nn||receptor-35/NN||neuropilin-34/NN	prep_of||expression-17/NN||receptor-35/NN	conj_and||factor-22/NN||receptor-35/NN	appos||receptor-35/NN||nrp-37/NN	auxpass||examined-40/VBN||were-39/VBD	root||ROOT-0/null||examined-40/VBN	det||course-43/NN||the-42/DT	prep_during||examined-40/VBN||course-43/NN	prep_of||course-43/NN||retinopathy-45/NN	aux||evaluate-47/VB||to-46/TO	xcomp||examined-40/VBN||evaluate-47/VB	poss||roles-49/NNS||their-48/PRP$	dobj||evaluate-47/VB||roles-49/NNS	det||congruency-54/NN||the-51/DT	amod||congruency-54/NN||observed-52/JJ	nn||congruency-54/NN||neurovascular-53/NN	prep_in||evaluate-47/VB||congruency-54/NN	rop-14||oxygen--1||no||in this study of rats with oxygen-induced retinopathy (oir) models of rop, mrna expression of vascular endothelial growth factor ( vegf ), semaphorin ( sema ), and their neuropilin receptor ( nrp ) were examined during the course of retinopathy to evaluate their roles in the observed neurovascular congruency.
det||effects-2/NNS||the-1/DT	nsubjpass||investigated-28/VBN||effects-2/NNS	det||treatment-6/NN||an-4/DT	amod||treatment-6/NN||analgesic-5/JJ	prep_of||effects-2/NNS||treatment-6/NN	prep_of||effects-2/NNS||treatment-6/NN	conj_and||treatment-6/NN||treatment-6/NN	amod||patches-9/NNS||lidocaine-8/JJ	appos||treatment-6/NN||patches-9/NNS	nn||activity-13/NN||brain-12/NN	prep_on||treatment-6/NN||activity-13/NN	amod||lowbackpain-16/NN||chronic-15/JJ	prep_in||activity-13/NN||lowbackpain-16/NN	appos||lowbackpain-16/NN||cbp-18/NN	nn||osteoarthritis-23/NNS||knee-22/NN	prep_in||treatment-6/NN||osteoarthritis-23/NNS	appos||effects-2/NNS||oa-25/NN	auxpass||investigated-28/VBN||were-27/VBD	root||ROOT-0/null||investigated-28/VBN	xcomp||investigated-28/VBN||using-29/VBG	amod||fmri-31/NNS||serial-30/JJ	dobj||using-29/VBG||fmri-31/NNS	dep||fmri-31/NNS||contrasting-33/VBG	dobj||contrasting-33/VBG||fmri-34/NNS	advmod||weeks-40/NNS||before-36/RB	conj_and||before-36/RB||after-38/IN	advmod||weeks-40/NNS||after-38/IN	pobj||after-38/IN||two-39/CD	prep_between||fmri-34/NNS||weeks-40/NNS	prep_of||fmri-34/NNS||treatment-42/NN	oa-25||analgesic-5||no_rel||the effects of an analgesic treatment (lidocaine patches) on brain activity in chronic lowbackpain (cbp) and in knee osteoarthritis (oa) were investigated using serial fmri (contrasting fmri between before and after two weeks of treatment).
aux||compare-2/VB||to-1/TO	csubj||pars-15/VBZ||compare-2/VB	amod||functional-5/JJ||anatomical-3/NNP	amod||outcomes-6/NNS||functional-5/JJ	dobj||compare-2/VB||outcomes-6/NNS	dobj||compare-2/VB||complications-8/NNS	conj_and||outcomes-6/NNS||complications-8/NNS	amod||g-13/NN||high-speed-10/JJ	amod||g-13/NN||25-gauge-11/JJ	prep_of||outcomes-6/NNS||g-13/NN	root||ROOT-0/null||pars-15/VBZ	nn||vitrectomy-17/NN||plana-16/NN	dobj||pars-15/VBZ||vitrectomy-17/NN	appos||vitrectomy-17/NN||ppv-19/NN	amod||ppv-23/NN||20-g-22/JJ	prep_versus||vitrectomy-17/NN||ppv-23/NN	det||management-26/NN||the-25/DT	prep_for||ppv-23/NN||management-26/NN	amod||retinaldetachment-31/NN||primary-28/JJ	amod||retinaldetachment-31/NN||inferior-29/JJ	nn||retinaldetachment-31/NN||rhegmatogenous-30/NNS	prep_of||management-26/NN||retinaldetachment-31/NN	appos||retinaldetachment-31/NN||rrd-33/NN	vmod||retinaldetachment-31/NN||associated-35/VBN	amod||breaks/holes-38/NNS||inferior-37/JJ	prep_to||associated-35/VBN||breaks/holes-38/NNS	speed--1||retinaldetachment-31||no_rel||to compare anatomical, functional outcomes and complications of high-speed 25-gauge (g) pars plana vitrectomy (ppv) versus 20-g ppv for the management of primary inferior rhegmatogenous retinaldetachment (rrd) associated to inferior breaks/holes.
mark||applied-7/VBN||after-1/IN	number||%-3/NN||5-2/CD	amod||patches-5/NNS||%-3/NN	nn||patches-5/NNS||lidocaine-4/NN	nsubjpass||applied-7/VBN||patches-5/NNS	auxpass||applied-7/VBN||were-6/VBD	advcl||exhibited-19/VBD||applied-7/VBN	det||part-12/NN||the-9/DT	amod||part-12/NN||painful-10/JJ	nn||part-12/NN||body-11/NN	prep_to||applied-7/VBN||part-12/NN	num||weeks-15/NNS||two-14/CD	prep_for||part-12/NN||weeks-15/NNS	nn||patients-18/NNS||cbp-17/NN	nsubj||exhibited-19/VBD||patients-18/NNS	root||ROOT-0/null||exhibited-19/VBD	det||decrease-22/NN||a-20/DT	amod||decrease-22/NN||significant-21/JJ	dobj||exhibited-19/VBD||decrease-22/NN	amod||measures-26/NNS||clinical-24/JJ	nn||measures-26/NNS||pain-25/NN	prep_in||exhibited-19/VBD||measures-26/NNS	mark||showed-35/VBD||while-28/IN	nn||questionnaire-32/NN||oa-30/NN	amod||questionnaire-32/NN||clinical-31/JJ	prep_in||showed-35/VBD||questionnaire-32/NN	vmod||questionnaire-32/NN||based-33/VBN	nsubj||showed-35/VBD||outcomes-34/NNS	advcl||exhibited-19/VBD||showed-35/VBD	neg||effect-38/NN||no-36/DT	nn||effect-38/NN||treatment-37/NN	nsubj||evoked-41/VBD||effect-38/NN	prep||effect-38/NN||but-39/CC	pobj||but-39/CC||stimulus-40/NN	ccomp||showed-35/VBD||evoked-41/VBD	nsubj||showed-43/VBD||pain-42/NN	ccomp||evoked-41/VBD||showed-43/VBD	det||decrease-46/NN||a-44/DT	amod||decrease-46/NN||borderline-45/JJ	dobj||showed-43/VBD||decrease-46/NN	pain-42||lidocaine-4||yes||after 5% lidocaine patches were applied to the painful body part for two weeks, cbp patients exhibited a significant decrease in clinical pain measures, while in oa clinical questionnaire based outcomes showed no treatment effect but stimulus evoked pain showed a borderline decrease.
mark||introduced-4/VBN||since-1/IN	nsubjpass||introduced-4/VBN||terbinafine-2/NN	auxpass||introduced-4/VBN||was-3/VBD	advcl||become-15/VBN||introduced-4/VBN	det||market-8/NN||the-6/DT	nn||market-8/NN||world-7/NN	prep_on||introduced-4/VBN||market-8/NN	num||years-10/NNS||17-9/CD	npadvmod||ago-11/RB||years-10/NNS	advmod||introduced-4/VBN||ago-11/RB	nsubj||become-15/VBN||it-13/PRP	aux||become-15/VBN||has-14/VBZ	root||ROOT-0/null||become-15/VBN	det||antifungal-18/NN||the-16/DT	amod||antifungal-18/NN||leading-17/VBG	xcomp||become-15/VBN||antifungal-18/NN	det||treatment-21/NN||the-20/DT	prep_for||antifungal-18/NN||treatment-21/NN	amod||fungalinfections-24/NNS||superficial-23/JJ	prep_of||treatment-21/NN||fungalinfections-24/NNS	vmod||treatment-21/NN||aided-26/VBN	amod||profiles-32/NNS||unique-28/JJ	amod||profiles-32/NNS||pharmacologic-29/JJ	conj_and||pharmacologic-29/JJ||microbiologic-31/JJ	amod||profiles-32/NNS||microbiologic-31/JJ	agent||aided-26/VBN||profiles-32/NNS	fungalinfections-24||terbinafine-2||yes||since terbinafine was introduced on the world market 17 years ago, it has become the leading antifungal for the treatment of superficial fungalinfections, aided by unique pharmacologic and microbiologic profiles.
det||pathophysiology-2/NN||the-1/DT	nsubj||multifactorial-6/JJ||pathophysiology-2/NN	nsubj||related-8/VBN||pathophysiology-2/NN	prep_of||pathophysiology-2/NN||anemia-4/NN	cop||multifactorial-6/JJ||is-5/VBZ	root||ROOT-0/null||multifactorial-6/JJ	conj_and||multifactorial-6/JJ||related-8/VBN	amod||factors-11/NNS||various-10/JJ	prep_to||related-8/VBN||factors-11/NNS	prep_including||factors-11/NNS||hemodilution-14/NN	nn||losses-17/NNS||iron-16/NN	appos||hemodilution-14/NN||losses-17/NNS	amod||drugs-20/NNS||anti-platelet-19/JJ	prep_from||losses-17/NNS||drugs-20/NNS	appos||hemodilution-14/NN||activation-22/NN	det||cascade-26/NN||the-24/DT	amod||cascade-26/NN||inflammatory-25/JJ	prep_of||activation-22/NN||cascade-26/NN	amod||losses-29/NNS||urinary-28/JJ	appos||hemodilution-14/NN||losses-29/NNS	prep_of||losses-29/NNS||erythropoietin-31/NN	conj_and||multifactorial-6/JJ||associated-33/VBN	conj_and||related-8/VBN||associated-33/VBN	advmod||associated-33/VBN||renalinsufficiency-34/RB	erythropoietin-31||renalinsufficiency-34||no_rel||the pathophysiology of anemia is multifactorial and related to various factors including; hemodilution, iron losses from anti-platelet drugs, activation of the inflammatory cascade, urinary losses of erythropoietin and associated renalinsufficiency.
amod||arthroplasty-4/NN||metal-on-metal-1/JJ	nn||arthroplasty-4/NN||hip-2/NN	amod||arthroplasty-4/NN||resurfacing-3/VBG	nsubj||offer-10/VB||arthroplasty-4/NN	nn||hra-7/NN||mom-6/NN	appos||arthroplasty-4/NN||hra-7/NN	aux||offer-10/VB||may-9/MD	root||ROOT-0/null||offer-10/VB	amod||advantages-12/NNS||potential-11/JJ	dobj||offer-10/VB||advantages-12/NNS	amod||arthroplasty-16/NN||total-14/JJ	nn||arthroplasty-16/NN||hip-15/NN	prep_over||offer-10/VB||arthroplasty-16/NN	appos||arthroplasty-16/NN||tha-18/NN	amod||patients-22/NNS||certain-21/JJ	prep_for||arthroplasty-16/NN||patients-22/NNS	amod||osteoarthritis-25/NNS||advanced-24/VBN	prep_with||offer-10/VB||osteoarthritis-25/NNS	det||hip-28/NN||the-27/DT	prep_of||osteoarthritis-25/NNS||hip-28/NN	metal--1||osteoarthritis-25||no_rel||metal-on-metal hip resurfacing arthroplasty (mom hra) may offer potential advantages over total hip arthroplasty (tha) for certain patients with advanced osteoarthritis of the hip.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||measure-8/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||measure-8/VB||to-7/TO	xcomp||was-6/VBD||measure-8/VB	det||impact-10/NN||the-9/DT	dobj||measure-8/VB||impact-10/NN	det||intervention-14/NN||an-12/DT	amod||intervention-14/NN||educational-13/JJ	prep_of||impact-10/NN||intervention-14/NN	prep_on||measure-8/VB||parents-16/NNS	prep_of||parents-16/NNS||children-18/NNS	vmod||children-18/NNS||taking-19/VBG	dobj||taking-19/VBG||methotrexate-20/NN	appos||methotrexate-20/NN||mtx-22/NN	prep_for||methotrexate-20/NN||juvenileidiopathicarthritis-25/NNS	appos||juvenileidiopathicarthritis-25/NNS||jia-27/NN	jia-27||methotrexate-20||yes||the purpose of this study was to measure the impact of an educational intervention on parents of children taking methotrexate (mtx) for juvenileidiopathicarthritis (jia).
aux||investigate-2/VB||to-1/TO	advcl||compared-14/VBD||investigate-2/VB	det||impact-4/NN||the-3/DT	dobj||investigate-2/VB||impact-4/NN	prep_of||impact-4/NN||irondeficiency-6/NN	amod||pathways-9/NNS||bioenergetic-8/JJ	prep_on||investigate-2/VB||pathways-9/NNS	prep_in||pathways-9/NNS||chlamydomonas-11/NNS	nsubj||compared-14/VBD||we-13/PRP	root||ROOT-0/null||compared-14/VBD	nn||rates-16/NNS||growth-15/NN	dobj||compared-14/VBD||rates-16/NNS	nn||content-19/NN||iron-18/NN	dobj||compared-14/VBD||content-19/NN	conj_and||rates-16/NNS||content-19/NN	amod||parameters-23/NNS||photosynthetic-22/JJ	dobj||compared-14/VBD||parameters-23/NNS	conj_and||rates-16/NNS||parameters-23/NNS	advmod||compared-14/VBD||systematically-24/RB	prep_in||compared-14/VBD||acetate-26/NN	amod||cells-29/NNS||co2-grown-28/JJ	prep_versus||acetate-26/NN||cells-29/NNS	irondeficiency-6||iron-18||yes||to investigate the impact of irondeficiency on bioenergetic pathways in chlamydomonas, we compared growth rates, iron content, and photosynthetic parameters systematically in acetate versus co2-grown cells.
det||advance-2/NN||an-1/DT	nsubj||development-10/NN||advance-2/NN	det||treatment-5/NN||the-4/DT	prep_in||advance-2/NN||treatment-5/NN	prep_of||treatment-5/NN||schizophrenia-7/NN	cop||development-10/NN||is-8/VBZ	det||development-10/NN||the-9/DT	root||ROOT-0/null||development-10/NN	amod||formulations-14/NNS||long-acting-12/JJ	nn||formulations-14/NNS||intramuscular-13/NN	prep_of||development-10/NN||formulations-14/NNS	prep_of||formulations-14/NNS||antipsychotics-16/NNS	amod||injection-22/NN||olanzapine-20/JJ	amod||injection-22/NN||long-acting-21/JJ	prep_such_as||development-10/NN||injection-22/NN	dep||injection-22/NN||lai-24/VBN	schizophrenia-7||olanzapine-20||yes||an advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (lai).
mark||analyze-4/VB||in-1/IN	dep||analyze-4/VB||order-2/NN	aux||analyze-4/VB||to-3/TO	advcl||studied-19/VBD||analyze-4/VB	amod||cells-6/NNS||dendritic-5/JJ	dobj||analyze-4/VB||cells-6/NNS	appos||cells-6/NNS||dcs-8/NN	vmod||cells-6/NNS||activation-10/VBN	prep_following||activation-10/VBN||infection-12/NN	amod||strains-16/NNS||different-14/JJ	amod||strains-16/NNS||mycobacterial-15/JJ	prep_with||infection-12/NN||strains-16/NNS	nsubj||studied-19/VBD||we-18/PRP	ccomp||mycobacteriumtuberculosis-36/VBZ||studied-19/VBD	det||profiles-22/NNS||the-20/DT	nn||profiles-22/NNS||expression-21/NN	dobj||studied-19/VBD||profiles-22/NNS	num||genes-25/NNS||165-24/CD	prep_of||profiles-22/NNS||genes-25/NNS	amod||dcs-29/NN||human-27/JJ	amod||dcs-29/NN||monocyte-derived-28/JJ	prep_of||genes-25/NNS||dcs-29/NN	vmod||dcs-29/NN||infected-30/VBN	prep_with||infected-30/VBN||h37rv-32/CD	det||virulent-35/NN||a-34/DT	nsubj||mycobacteriumtuberculosis-36/VBZ||virulent-35/NN	root||ROOT-0/null||mycobacteriumtuberculosis-36/VBZ	dep||mycobacteriumtuberculosis-36/VBZ||mtb-38/NN	nn||strain-41/NN||laboratory-40/NN	dobj||mycobacteriumtuberculosis-36/VBZ||strain-41/NN	dobj||mycobacteriumtuberculosis-36/VBZ||cmt97-43/NNS	conj_and||strain-41/NN||cmt97-43/NNS	det||isolate-48/NN||a-45/DT	amod||isolate-48/NN||clinical-46/JJ	nn||isolate-48/NN||mtb-47/NN	dobj||mycobacteriumtuberculosis-36/VBZ||isolate-48/NN	conj_and||strain-41/NN||isolate-48/NN	amod||bacillus-51/NNS||mycobacteriumbovis-50/JJ	dobj||mycobacteriumtuberculosis-36/VBZ||bacillus-51/NNS	conj_and||strain-41/NN||bacillus-51/NNS	nn||rin-54/NNP||calmette-guã-52/NNP	nn||rin-54/NNP||©-53/NNP	dep||bacillus-51/NNS||rin-54/NNP	appos||rin-54/NNP||bcg-56/NN	amod||pasteur-60/NN||aventis-59/JJ	dobj||mycobacteriumtuberculosis-36/VBZ||pasteur-60/NN	conj_and||strain-41/NN||pasteur-60/NN	nn||japan-64/NN||bcg-63/NN	dobj||mycobacteriumtuberculosis-36/VBZ||japan-64/NN	conj_and||strain-41/NN||japan-64/NN	nsubj||employed-67/VBN||both-66/DT	rcmod||japan-64/NN||employed-67/VBN	prep_as||employed-67/VBN||vaccine-69/NN	prep_against||vaccine-69/NN||tuberculosis-71/NNP	tuberculosis-71||bcg-63||no||in order to analyze dendritic cells (dcs) activation following infection with different mycobacterial strains, we studied the expression profiles of 165 genes of human monocyte-derived dcs infected with h37rv, a virulent mycobacteriumtuberculosis (mtb) laboratory strain, cmt97, a clinical mtb isolate, mycobacteriumbovis bacillus calmette-guã©rin (bcg), aventis pasteur, and bcg japan, both employed as vaccine against tuberculosis.
det||suspects-4/NNS||the-2/DT	nn||suspects-4/NNS||tb-3/NN	prep_of||tested-14/VBN||suspects-4/NNS	nsubjpass||tested-14/VBN||298-6/NNP	number||%-9/NN||58.9-8/CD	dep||298-6/NNP||%-9/NN	prep_of||298-6/NNP||them-12/PRP	auxpass||tested-14/VBN||were-13/VBD	root||ROOT-0/null||tested-14/VBN	prep_for||tested-14/VBN||hiv-16/NN	num||%-19/NN||27.2-18/CD	nsubj||hivseropositive-24/JJ||%-19/NN	appos||%-19/NN||81/298-21/CD	cop||hivseropositive-24/JJ||were-23/VBD	conj_and||tested-14/VBN||hivseropositive-24/JJ	hivseropositive-24||hiv-16||no||of the tb suspects, 298 (58.9%) of them were tested for hiv and 27.2% (81/298) were hivseropositive.
nsubj||disease-5/NN||malaria-1/NN	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||the-3/DT	amod||disease-5/NN||infectious-4/JJ	ccomp||changed-28/VBN||disease-5/NN	vmod||disease-5/NN||causing-6/VBG	det||morbidity-9/NN||the-7/DT	amod||morbidity-9/NN||highest-8/JJS	dobj||causing-6/VBG||morbidity-9/NN	dobj||causing-6/VBG||mortality-11/NN	conj_and||morbidity-9/NN||mortality-11/NN	prep_in||mortality-11/NN||angola-13/NN	amod||widespread-17/JJ||due-15/JJ	dep||widespread-17/JJ||to-16/TO	amod||resistance-22/NN||widespread-17/JJ	amod||resistance-22/NN||chloroquine-18/JJ	dep||resistance-22/NN||cq-20/VBN	dobj||causing-6/VBG||resistance-22/NN	conj_and||morbidity-9/NN||resistance-22/NN	det||country-25/NN||the-24/DT	nsubj||changed-28/VBN||country-25/NN	aux||changed-28/VBN||has-26/VBZ	advmod||changed-28/VBN||recently-27/RB	root||ROOT-0/null||changed-28/VBN	poss||recommendations-32/NNS||its-29/PRP$	amod||recommendations-32/NNS||first-line-30/JJ	nn||recommendations-32/NNS||treatment-31/NN	dobj||changed-28/VBN||recommendations-32/NNS	amod||malaria-35/NN||uncomplicated-34/JJ	prep_for||changed-28/VBN||malaria-35/NN	prep_from||changed-28/VBN||cq-38/NN	aux||artemisinin-40/VB||to-39/TO	vmod||cq-38/NN||artemisinin-40/VB	nn||therapies-42/NNS||combination-41/NN	dobj||artemisinin-40/VB||therapies-42/NNS	appos||therapies-42/NNS||act-44/NN	prep_in||therapies-42/NNS||adults-47/NNS	prep_in||therapies-42/NNS||sulphadoxine/pyrimethamine-50/NN	conj_and||adults-47/NNS||sulphadoxine/pyrimethamine-50/NN	appos||adults-47/NNS||s/p-52/NN	amod||women-56/NNS||pregnant-55/JJ	prep_in||artemisinin-40/VB||women-56/NNS	malaria-35||pyrimethamine--1||yes||malaria is the infectious disease causing the highest morbidity and mortality in angola and due to widespread chloroquine (cq) resistance, the country has recently changed its first-line treatment recommendations for uncomplicated malaria, from cq to artemisinin combination therapies (act) in adults, and sulphadoxine/pyrimethamine (s/p) in pregnant women.
amod||trends-3/NNS||google-1/JJ	nn||trends-3/NNS||flu-2/NN	nsubjpass||developed-5/VBN||trends-3/NNS	nsubj||estimate-7/VB||trends-3/NNS	auxpass||developed-5/VBN||was-4/VBD	root||ROOT-0/null||developed-5/VBN	aux||estimate-7/VB||to-6/TO	xcomp||developed-5/VBN||estimate-7/VB	nsubj||rates-14/NNS||us-8/PRP	amod||rates-14/NNS||influenza-like-9/JJ	nn||rates-14/NNS||illness-10/NN	appos||rates-14/NNS||ili-12/NN	xcomp||estimate-7/VB||rates-14/NNS	nn||searches-17/NNS||internet-16/NN	prep_from||rates-14/NNS||searches-17/NNS	advmod||correlate-24/VB||however-19/RB	nsubj||correlate-24/VB||ili-20/NN	aux||correlate-24/VB||does-21/VBZ	neg||correlate-24/VB||not-22/RB	advmod||correlate-24/VB||necessarily-23/RB	parataxis||developed-5/VBN||correlate-24/VB	amod||influenzavirusinfections-27/NNS||actual-26/JJ	prep_with||correlate-24/VB||influenzavirusinfections-27/NNS	flu-2||influenzavirus--1||no||google flu trends was developed to estimate us influenza-like illness (ili) rates from internet searches; however ili does not necessarily correlate with actual influenzavirusinfections.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||measure-8/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||measure-8/VB||to-7/TO	xcomp||was-6/VBD||measure-8/VB	det||impact-10/NN||the-9/DT	dobj||measure-8/VB||impact-10/NN	det||intervention-14/NN||an-12/DT	amod||intervention-14/NN||educational-13/JJ	prep_of||impact-10/NN||intervention-14/NN	prep_on||measure-8/VB||parents-16/NNS	prep_of||parents-16/NNS||children-18/NNS	vmod||children-18/NNS||taking-19/VBG	dobj||taking-19/VBG||methotrexate-20/NN	appos||methotrexate-20/NN||mtx-22/NN	prep_for||methotrexate-20/NN||juvenileidiopathicarthritis-25/NNS	appos||juvenileidiopathicarthritis-25/NNS||jia-27/NN	juvenileidiopathicarthritis-25||methotrexate-20||yes||the purpose of this study was to measure the impact of an educational intervention on parents of children taking methotrexate (mtx) for juvenileidiopathicarthritis (jia).
amod||feâ-2/NN||defective-1/JJ	poss||synthesis-5/NN||feâ-2/NN	nn||synthesis-5/NN||cluster-4/NN	nsubj||affects-8/VBZ||synthesis-5/NN	nsubj||alters-26/VBZ||synthesis-5/NN	neg||only-7/JJ||not-6/RB	preconj||affects-8/VBZ||only-7/JJ	root||ROOT-0/null||affects-8/VBZ	dobj||affects-8/VBZ||activities-9/NNS	amod||ironâ-12/NN||many-11/JJ	poss||enzymes-15/NNS||ironâ-12/NN	nn||enzymes-15/NNS||ulfur-14/NN	prep_of||activities-9/NNS||enzymes-15/NNS	amod||dehydrogenase-22/NN||aconitase-19/JJ	conj_and||aconitase-19/JJ||succinate-21/JJ	amod||dehydrogenase-22/NN||succinate-21/JJ	prep_such_as||activities-9/NNS||dehydrogenase-22/NN	advmod||alters-26/VBZ||also-25/RB	conj_but||affects-8/VBZ||alters-26/VBZ	det||regulation-28/NN||the-27/DT	dobj||alters-26/VBZ||regulation-28/NN	amod||homeostasis-32/NNS||cellular-30/JJ	nn||homeostasis-32/NNS||iron-31/NN	prep_of||regulation-28/NN||homeostasis-32/NNS	vmod||regulation-28/NN||causing-34/VBG	det||irondeficiency-40/NN||both-35/DT	amod||irondeficiency-40/NN||mitochondrial-36/JJ	amod||irondeficiency-40/NN||ironoverload-37/JJ	conj_and||ironoverload-37/JJ||cytosolic-39/JJ	amod||irondeficiency-40/NN||cytosolic-39/JJ	dobj||causing-34/VBG||irondeficiency-40/NN	irondeficiency-40||fe--1||yes||defective feâs cluster synthesis not only affects activities of many ironâsulfur enzymes, such as aconitase and succinate dehydrogenase, but also alters the regulation of cellular iron homeostasis, causing both mitochondrial ironoverload and cytosolic irondeficiency.
det||1980s-3/NNS||the-2/DT	prep_since||examined-13/VBN||1980s-3/NNS	det||study-8/NN||the-4/DT	amod||study-8/NN||majengo-5/JJ	amod||study-8/NN||observational-6/JJ	nn||study-8/NN||cohort-7/NN	nsubj||examined-13/VBN||study-8/NN	appos||study-8/NN||mocs-10/NNS	aux||examined-13/VBN||has-12/VBZ	root||ROOT-0/null||examined-13/VBN	dobj||examined-13/VBN||sexuallytransmittedinfections-14/NNS	amod||hiv/aids-18/NNS||particular-17/JJ	prep_in||sexuallytransmittedinfections-14/NNS||hiv/aids-18/NNS	det||cohort-22/NN||a-21/DT	prep_in||examined-13/VBN||cohort-22/NN	nn||workers-25/NNS||sex-24/NN	prep_of||cohort-22/NN||workers-25/NNS	prep_in||examined-13/VBN||majengo-27/NN	det||village-32/NN||an-29/DT	amod||village-32/NN||impoverished-30/JJ	amod||village-32/NN||urban-31/JJ	appos||majengo-27/NN||village-32/NN	prep_in||village-32/NN||nairobi-34/NNS	appos||nairobi-34/NNS||kenya-36/NN	aids--1||hiv--1||no||since the 1980s the majengo observational cohort study (mocs) has examined sexuallytransmittedinfections, in particular hiv/aids, in a cohort of sex workers in majengo, an impoverished urban village in nairobi, kenya.
prep_in||remained-9/VBD||contrast-2/NN	amod||cytokines-5/NNS||th1/th2-4/JJ	nsubj||remained-9/VBD||cytokines-5/NNS	vmod||cytokines-5/NNS||producing-6/VBG	nn||cells-8/NNS||t-7/NN	dobj||producing-6/VBG||cells-8/NNS	root||ROOT-0/null||remained-9/VBD	advmod||remained-9/VBD||lower-10/RBR	num||patient-13/NN||one-12/CD	prep_in||remained-9/VBD||patient-13/NN	vmod||patient-13/NN||detected-14/VBN	amod||resistant-17/JJ||adefovirdipivoxil-16/JJ	amod||mutation-20/NN||resistant-17/JJ	amod||mutation-20/NN||hbv-18/JJ	amod||mutation-20/NN||a181t/v-19/JJ	prep_with||detected-14/VBN||mutation-20/NN	hbv-18||adefovirdipivoxil-16||yes||in contrast, th1/th2 cytokines producing t cells remained lower in one patient detected with adefovirdipivoxil resistant hbv a181t/v mutation.
det||possibility-2/NN||the-1/DT	nsubj||allow-14/VB||possibility-2/NN	nsubj||help-27/VB||possibility-2/NN	prepc_of||possibility-2/NN||extracting-4/VBG	dobj||extracting-4/VBG||rna-5/NN	prepc_of||possibility-2/NN||measuring-7/VBG	conj_and||extracting-4/VBG||measuring-7/VBG	nn||expression-9/NN||rna-8/NN	dobj||measuring-7/VBG||expression-9/NN	nn||sections-12/NNS||paraffin-11/NN	prep_from||measuring-7/VBG||sections-12/NNS	aux||allow-14/VB||can-13/MD	root||ROOT-0/null||allow-14/VB	amod||investigations-16/NNS||extensive-15/JJ	dobj||allow-14/VB||investigations-16/NNS	amod||samples-20/NNS||stored-18/JJ	nn||samples-20/NNS||paraffin-19/NN	prep_on||allow-14/VB||samples-20/NNS	vmod||samples-20/NNS||obtained-21/VBN	amod||livers-24/NNS||diseased-23/JJ	prep_from||obtained-21/VBN||livers-24/NNS	aux||help-27/VB||could-26/MD	conj_and||allow-14/VB||help-27/VB	conj_and||allow-14/VB||help-27/VB	conj_and||help-27/VB||help-27/VB	prep_with||help-27/VB||studies-29/NNS	det||history-33/NN||the-31/DT	amod||history-33/NN||natural-32/JJ	prep_of||studies-29/NNS||history-33/NN	nn||fibrosis-36/NN||liver-35/NN	prep_of||history-33/NN||fibrosis-36/NN	prep_of||history-33/NN||inflammation-38/NN	conj_and||fibrosis-36/NN||inflammation-38/NN	amod||mechanisms-46/NNS||particular-42/JJ	amod||mechanisms-46/NNS||correlate-44/JJ	amod||mechanisms-46/NNS||basic-45/JJ	prep_in||help-27/VB||mechanisms-46/NNS	amod||outcomes-49/NNS||clinical-48/JJ	prep_to||help-27/VB||outcomes-49/NNS	basic-45||fibrosis-36||no_rel||the possibility of extracting rna and measuring rna expression from paraffin sections can allow extensive investigations on stored paraffin samples obtained from diseased livers and could help with studies of the natural history of liver fibrosis and inflammation, and in particular, correlate basic mechanisms to clinical outcomes.
nn||design-2/NN||research-1/NN	nsubj||$-6/VB||design-2/NN	nsubj||abdominal-59/VB||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||$-6/VB||methods-4/NNS	aux||$-6/VB||â-5/MD	root||ROOT-0/null||$-6/VB	det||total-9/NN||a-8/DT	dobj||$-6/VB||total-9/NN	num||adolescents-13/NNS||12-11/CD	amod||adolescents-13/NNS||obese-12/JJ	prep_of||total-9/NN||adolescents-13/NNS	prep_with||adolescents-13/NNS||ngt-15/NN	dobj||$-6/VB||19-17/CD	conj_and||total-9/NN||19-17/CD	prep_with||19-17/CD||igt-19/NN	dobj||$-6/VB||17-22/CD	conj_and||total-9/NN||17-22/CD	amod||evaluation-26/NN||type2diabetes-24/VBD	amod||evaluation-26/NN||underwent-25/JJ	prep_with||17-22/CD||evaluation-26/NN	nn||sensitivity-29/NN||insulin-28/NN	prep_of||evaluation-26/NN||sensitivity-29/NN	amod||-RSB--35/NNS||3-h-31/JJ	amod||-RSB--35/NNS||hyperinsulinemic-32/JJ	amod||-RSB--35/NNS||-LSB--33/JJ	amod||-RSB--35/NNS||80mu/m2/min-34/JJ	dep||evaluation-26/NN||-RSB--35/NNS	dep||clamp-40/NN||$-37/$	amod||clamp-40/NN||euglycemic-39/JJ	dep||evaluation-26/NN||clamp-40/NN	conj_â||-RSB--35/NNS||clamp-40/NN	amod||insulin-44/NN||first-phase-43/JJ	prep_with||17-22/CD||insulin-44/NN	conj_and||evaluation-26/NN||insulin-44/NN	amod||secretion-48/NN||second-phase-46/JJ	nn||secretion-48/NN||insulin-47/NN	prep_with||17-22/CD||secretion-48/NN	conj_and||evaluation-26/NN||secretion-48/NN	amod||clamp-52/NN||2-h-50/JJ	amod||clamp-52/NN||hyperglycemic-51/JJ	appos||secretion-48/NN||clamp-52/NN	nn||composition-56/NN||body-55/NN	appos||secretion-48/NN||composition-56/NN	conj_and||$-6/VB||abdominal-59/VB	dobj||$-6/VB||adiposity-60/NN	type2diabetes-24||insulin-47||yes||research design and methods âa total of 12 obese adolescents with ngt, 19 with igt, and 17 with type2diabetes underwent evaluation of insulin sensitivity (3-h hyperinsulinemic [80mu/m2/min]âeuglycemic clamp), first-phase insulin and second-phase insulin secretion (2-h hyperglycemic clamp), body composition, and abdominal adiposity.
nsubj||provide-14/VB||lapatinib-1/NN	prep_in||lapatinib-1/NN||combination-4/NN	prep_with||combination-4/NN||non-chemotherapeuticagents-6/NNS	prep_such_as||combination-4/NN||letrozole-10/NN	aux||provide-14/VB||may-12/MD	advmod||provide-14/VB||also-13/RB	root||ROOT-0/null||provide-14/VB	det||option-18/NN||a-15/DT	amod||option-18/NN||chemotherapy-free-16/JJ	nn||option-18/NN||treatment-17/NN	dobj||provide-14/VB||option-18/NN	amod||patients-21/NNS||postmenopausal-20/JJ	prep_for||option-18/NN||patients-21/NNS	nn||cancer-28/NN||estrogen-23/NN	amod||cancer-28/NN||receptor-positive/erbb2-24/JJ	amod||cancer-28/NN||+-25/JJ	amod||cancer-28/NN||metastatic-26/JJ	nn||cancer-28/NN||breast-27/NN	prep_with||provide-14/VB||cancer-28/NN	cancer-28||letrozole-10||no_rel||lapatinib, in combination with non-chemotherapeuticagents, such as letrozole, may also provide a chemotherapy-free treatment option for postmenopausal patients with estrogen receptor-positive/erbb2+ metastatic breast cancer.
det||use-3/NN||the-2/DT	prep_through||compared-15/VBD||use-3/NN	amod||gold-6/NN||quantiferon-tb-5/JJ	prep_of||use-3/NN||gold-6/NN	det||assay-12/NN||a-8/DT	amod||assay-12/NN||commercial-9/JJ	nn||assay-12/NN||ifn-î-10/NNP	nn||assay-12/NN||³-11/NNP	appos||gold-6/NN||assay-12/NN	nsubj||compared-15/VBD||we-14/PRP	root||ROOT-0/null||compared-15/VBD	dobj||compared-15/VBD||differences-16/NNS	amod||responses-20/NNS||quantitative-18/JJ	amod||responses-20/NNS||t-cell-19/JJ	prep_in||compared-15/VBD||responses-20/NNS	prep_to||compared-15/VBD||mycobacteriumtuberculosis-22/NNS	appos||mycobacteriumtuberculosis-22/NNS||mtb-24/NN	amod||antigens-28/NNS||specific-27/JJ	nsubj||quantiferon-30/VB||antigens-28/NNS	advmod||quantiferon-30/VB||-LSB--29/RB	parataxis||compared-15/VBD||quantiferon-30/VB	amod||disease-44/NN||tb-2g-31/JJ	dep||disease-44/NN||qft-2g-33/JJ	amod||disease-44/NN||-RSB--35/JJ	prep_between||-RSB--35/JJ||patients-37/NNS	amod||tuberculosis-40/NNP||active-39/JJ	prep_with||patients-37/NNS||tuberculosis-40/NNP	dep||patients-37/NNS||tb-42/VBN	dobj||quantiferon-30/VB||disease-44/NN	dobj||quantiferon-30/VB||those-46/DT	conj_and||disease-44/NN||those-46/DT	nn||infection-50/NN||latent-48/NN	nn||infection-50/NN||tb-49/NN	prep_with||those-46/DT||infection-50/NN	appos||infection-50/NN||ltbi-52/NNP	tb-49||mtb-24||no||through the use of quantiferon-tb gold, a commercial ifn-î³ assay, we compared differences in quantitative t-cell responses to mycobacteriumtuberculosis (mtb)-specific antigens [quantiferon tb-2g (qft-2g)] between patients with active tuberculosis (tb) disease and those with latent tb infection (ltbi).
nsubj||reviewed-3/VBN||we-1/PRP	nsubj||reviewed-3/VBN||we-1/PRP	nsubj||reviewed-3/VBN||we-1/PRP	advmod||reviewed-3/VBN||systematically-2/RB	root||ROOT-0/null||reviewed-3/VBN	conj_and||reviewed-3/VBN||reviewed-3/VBN	conj_and||reviewed-3/VBN||reviewed-3/VBN	amod||studies-5/NNS||published-4/VBN	dobj||reviewed-3/VBN||studies-5/NNS	det||databases-14/NNS||the-8/DT	amod||databases-14/NNS||medline-9/JJ	conj_and||medline-9/JJ||chinese-11/JJ	amod||databases-14/NNS||chinese-11/JJ	amod||databases-14/NNS||biomedical-12/JJ	nn||databases-14/NNS||literature-13/NN	prep_from||reviewed-3/VBN||databases-14/NNS	det||prevalence-18/NN||the-17/DT	prep_on||reviewed-3/VBN||prevalence-18/NN	prep_of||prevalence-18/NN||hivinfection-20/NN	nn||patients-23/NNS||tb-22/NN	prep_among||hivinfection-20/NN||patients-23/NNS	det||prevalence-27/NN||the-26/DT	prep_on||reviewed-3/VBN||prevalence-27/NN	prep_of||prevalence-27/NN||tb-29/NN	amod||population-32/NN||hiv/aids-31/JJ	prep_among||tb-29/NN||population-32/NN	prep_until||reviewed-3/VBN||15-34/CD	tmod||reviewed-3/VBN||april-35/NNP	num||april-35/NNP||2010-36/CD	nsubj||summarized-40/VBD||quantitatively-39/NN	conj_and||reviewed-3/VBN||summarized-40/VBD	det||estimates-42/NNS||the-41/DT	dobj||summarized-40/VBD||estimates-42/NNS	xcomp||summarized-40/VBD||using-43/VBG	dobj||using-43/VBG||meta-analysis-44/NNS	hivinfection-20||hiv--1||no||we systematically reviewed published studies, from the medline and chinese biomedical literature databases, on the prevalence of hivinfection among tb patients and on the prevalence of tb among hiv/aids population until 15 april 2010, and quantitatively summarized the estimates using meta-analysis.
amod||inflammation-2/NN||modulating-1/VBG	nsubjpass||identified-5/VBN||inflammation-2/NN	aux||identified-5/VBN||has-3/VBZ	auxpass||identified-5/VBN||been-4/VBN	root||ROOT-0/null||identified-5/VBN	det||avenue-10/NN||a-7/DT	amod||avenue-10/NN||promising-8/JJ	amod||avenue-10/NN||therapeutic-9/JJ	prep_as||identified-5/VBN||avenue-10/NN	amod||avenue-10/NN||consistent-11/JJ	amod||success-14/NN||preliminary-13/JJ	prep_with||consistent-11/JJ||success-14/NN	amod||trials-18/NNS||ongoing-16/JJ	amod||trials-18/NNS||clinical-17/JJ	prep_of||success-14/NN||trials-18/NNS	amod||compounds-21/NNS||anti-inflammatory-20/JJ	prep_for||identified-5/VBN||compounds-21/NNS	prep_such_as||compounds-21/NNS||minocycline-24/NN	minocycline-24||inflammation-2||no_rel||modulating inflammation has been identified as a promising therapeutic avenue consistent with preliminary success of ongoing clinical trials for anti-inflammatory compounds such as minocycline.
nsubj||effective-4/JJ||bcg-1/NN	cop||effective-4/JJ||is-2/VBZ	advmod||effective-4/JJ||also-3/RB	root||ROOT-0/null||effective-4/JJ	det||treatment-7/NN||the-6/DT	prep_in||effective-4/JJ||treatment-7/NN	prep_of||treatment-7/NN||condylomataacuminata-9/NN	vmod||condylomataacuminata-9/NN||caused-10/VBN	amod||humanpapillomavirus-13/NNS||low-risk-12/JJ	agent||caused-10/VBN||humanpapillomavirus-13/NNS	appos||humanpapillomavirus-13/NNS||hpv-15/NN	condylomataacuminata-9||humanpapillomavirus-13||no||bcg is also effective in the treatment of condylomataacuminata caused by low-risk humanpapillomavirus (hpv).
det||med-5/NN||the-1/DT	amod||med-5/NN||electronic-2/JJ	nn||med-5/NN||database-3/NN	nn||med-5/NN||pub-4/NN	nsubjpass||searched-7/VBN||med-5/NN	auxpass||searched-7/VBN||was-6/VBD	root||ROOT-0/null||searched-7/VBN	predet||articles-11/NNS||all-9/PDT	det||articles-11/NNS||the-10/DT	prep_for||searched-7/VBN||articles-11/NNS	prep_on||articles-11/NNS||â-13/NN	amod||â-13/NN||$-14/$	dep||$-14/$||establishment-15/JJ	prep_of||â-13/NN||mrsa-17/NN	det||emergence-20/NN||the-19/DT	prep_for||searched-7/VBN||emergence-20/NN	conj_and||articles-11/NNS||emergence-20/NN	amod||-rrb--26/NNS||vancomycin-resistant-22/JJ	nn||-rrb--26/NNS||s.aureus-23/NNS	nn||-rrb--26/NNS||-lrb--24/NN	nn||-rrb--26/NNS||vrsa-25/NN	prep_of||emergence-20/NN||-rrb--26/NNS	mrsa-17||s.aureus-23||no||the electronic database pub med was searched for all the articles on â $ establishment of mrsa and the emergence of vancomycin-resistant s.aureus -lrb- vrsa -rrb- .
det||pain-2/NN||the-1/DT	nsubjpass||refractory-4/VBN||pain-2/NN	auxpass||refractory-4/VBN||was-3/VBD	root||ROOT-0/null||refractory-4/VBN	amod||treatment-7/NN||medical-6/JJ	prep_to||refractory-4/VBN||treatment-7/NN	det||block-13/NN||a-10/DT	amod||block-13/NN||bilateral-11/JJ	amod||block-13/NN||sympathetic-12/JJ	nsubj||resulted-18/VBD||block-13/NN	prep_with||block-13/NN||lidocaine-15/NN	prep_with||block-13/NN||triamcinolone-17/NN	conj_and||lidocaine-15/NN||triamcinolone-17/NN	conj_but||refractory-4/VBN||resulted-18/VBD	prep_in||resulted-18/VBD||relief-20/NN	det||pain-23/NN||the-22/DT	prep_from||resulted-18/VBD||pain-23/NN	pain-23||lidocaine-15||yes||the pain was refractory to medical treatment, but a bilateral sympathetic block with lidocaine and triamcinolone resulted in relief from the pain.
advmod||+-10/VBD||however-1/RB	amod||p465l-4/NNS||pparg-3/JJ	nsubj||+-10/VBD||p465l-4/NNS	punct||akita-8/NN||/-5/:	amod||akita-8/NN||+-6/JJ	amod||akita-8/NN||ins2-7/JJ	dep||p465l-4/NNS||akita-8/NN	punct||akita-8/NN||/-9/:	root||ROOT-0/null||+-10/VBD	nsubj||aggravated-13/VBN||females-11/NNS	aux||aggravated-13/VBN||have-12/VBP	ccomp||+-10/VBD||aggravated-13/VBN	dobj||aggravated-13/VBN||hyperglycemia-14/NN	amod||islets-17/NNS||smaller-16/JJR	dobj||aggravated-13/VBN||islets-17/NNS	conj_and||hyperglycemia-14/NN||islets-17/NNS	amod||insulin-22/NN||reduced-20/VBN	nn||insulin-22/NN||plasma-21/NN	dobj||aggravated-13/VBN||insulin-22/NN	conj_and||hyperglycemia-14/NN||insulin-22/NN	hyperglycemia-14||insulin-22||yes||however, pparg p465l /+ ins2 akita /+ females have aggravated hyperglycemia, smaller islets, and reduced plasma insulin.
amod||mice-2/NNS||dba/2j-1/JJ	nsubjpass||treated-7/VBN||mice-2/NNS	amod||hyperglycemia-5/NN||stz-induced-4/JJ	prep_with||mice-2/NNS||hyperglycemia-5/NN	auxpass||treated-7/VBN||were-6/VBD	root||ROOT-0/null||treated-7/VBN	det||int-747-13/NN||the-9/DT	amod||int-747-13/NN||selective-10/JJ	nn||int-747-13/NN||fxr-11/NN	nn||int-747-13/NN||agonist-12/NN	prep_with||treated-7/VBN||int-747-13/NN	num||weeks-16/NNS||12-15/CD	prep_for||int-747-13/NN||weeks-16/NNS	stz--1||hyperglycemia-5||no_rel||dba/2j mice with stz-induced hyperglycemia were treated with the selective fxr agonist int-747 for 12 weeks.
amod||factor-2/NN||regulatory-1/JJ	nsubj||interact-9/VB||factor-2/NN	nsubj||histone-18/VB||factor-2/NN	number||1-4/CD||x-box-3/CD	dep||factor-2/NN||1-4/CD	appos||factor-2/NN||rfx1-6/NNP	aux||interact-9/VB||can-8/MD	root||ROOT-0/null||interact-9/VB	prep_with||interact-9/VB||dna-11/NN	amod||dna-11/NN||methyltransferase-12/JJ	dep||methyltransferase-12/JJ||1-13/CD	appos||dna-11/NN||dnmt1-15/NNP	conj_and||interact-9/VB||histone-18/VB	dobj||histone-18/VB||deacetylase-19/NN	num||deacetylase-19/NN||1-20/CD	appos||deacetylase-19/NN||hdac1-22/NNP	amod||down-regulation-27/NN||rfx1-26/JJ	nsubj||contributes-28/VBZ||down-regulation-27/NN	nsubj||dna-30/VB||down-regulation-27/NN	conj_and||interact-9/VB||contributes-28/VBZ	aux||dna-30/VB||to-29/TO	xcomp||contributes-28/VBZ||dna-30/VB	amod||hyperacetylation-35/NN||hypomethylation-31/JJ	conj_and||hypomethylation-31/JJ||histone-33/JJ	amod||hyperacetylation-35/NN||histone-33/JJ	amod||hyperacetylation-35/NN||h3-34/JJ	dobj||dna-30/VB||hyperacetylation-35/NN	det||cluster-38/NN||the-37/DT	prep_at||dna-30/VB||cluster-38/NN	amod||11a-44/NNS||differentiation-40/JJ	appos||11a-44/NNS||cd-42/NN	prep_of||cluster-38/NN||11a-44/NNS	amod||promoters-47/NNS||cd70-46/JJ	prep_at||dna-30/VB||promoters-47/NNS	conj_and||cluster-38/NN||promoters-47/NNS	amod||cells-52/NNS||cd4-49/JJ	amod||cells-52/NNS||+-50/JJ	nn||cells-52/NNS||t-51/NN	prep_in||promoters-47/NNS||cells-52/NNS	prep_of||cells-52/NNS||patients-54/NNS	amod||lupuserythematosus-57/NNS||systemic-56/JJ	prep_with||dna-30/VB||lupuserythematosus-57/NNS	appos||lupuserythematosus-57/NNS||sle-59/NN	cd-42||sle-59||no_rel||regulatory factor x-box 1 (rfx1) can interact with dna methyltransferase 1 (dnmt1) and histone deacetylase 1 (hdac1), and rfx1 down-regulation contributes to dna hypomethylation and histone h3 hyperacetylation at the cluster of differentiation (cd) 11a and cd70 promoters in cd4+ t cells of patients with systemic lupuserythematosus (sle).
amod||tests-2/NNS||serological-1/JJ	nsubj||most-12/JJS||tests-2/NNS	amod||igm-5/NN||dengue-4/JJ	prep_of||tests-2/NNS||igm-5/NN	nn||antibodies-8/NNS||igg-7/NN	prep_of||tests-2/NNS||antibodies-8/NNS	conj_and||igm-5/NN||antibodies-8/NNS	cop||most-12/JJS||are-9/VBP	advmod||most-12/JJS||still-10/RB	det||most-12/JJS||the-11/DT	root||ROOT-0/null||most-12/JJS	advmod||used-14/VBN||widely-13/RB	vmod||most-12/JJS||used-14/VBN	prep_for||used-14/VBN||diagnosis-16/NN	prep_of||diagnosis-16/NN||dengue-18/NN	antibodies-8||dengue-18||no_rel||serological tests of dengue igm and igg antibodies are still the most widely used for diagnosis of dengue.
amod||values-2/NNS||cortisol-1/JJ	nsubj||<-3/VBD||values-2/NNS	root||ROOT-0/null||<-3/VBD	num||nmol/l-5/NN||550-4/CD	nsubjpass||considered-10/VBN||nmol/l-5/NN	amod||test-8/NN||acth-stimulation-7/JJ	prep_upon||nmol/l-5/NN||test-8/NN	auxpass||considered-10/VBN||were-9/VBD	ccomp||<-3/VBD||considered-10/VBN	dobj||considered-10/VBN||diagnostic-11/JJ	prep_for||diagnostic-11/JJ||adrenalinsufficiency-13/NN	adrenalinsufficiency-13||cortisol-1||yes||cortisol values <550 nmol/l upon acth-stimulation test were considered diagnostic for adrenalinsufficiency.
nsubj||performed-2/VBD||we-1/PRP	root||ROOT-0/null||performed-2/VBD	amod||pyrosequencing-4/NN||ultra-deep-3/JJ	dobj||performed-2/VBD||pyrosequencing-4/NN	appos||pyrosequencing-4/NN||udps-6/NNS	amod||sequencing-11/NN||clonal-9/JJ	nn||sequencing-11/NN||dideoxynucleotide-10/NN	dobj||performed-2/VBD||sequencing-11/NN	conj_and||pyrosequencing-4/NN||sequencing-11/NN	nn||samples-15/NNS||plasma-13/NN	nn||samples-15/NNS||virus-14/NN	prep_of||sequencing-11/NN||samples-15/NNS	aux||assess-17/VB||to-16/TO	vmod||performed-2/VBD||assess-17/VB	det||prevalence-19/NN||the-18/DT	dobj||assess-17/VB||prevalence-19/NN	nn||variants-23/NNS||minority-21/NN	amod||variants-23/NNS||k65r-22/JJ	prep_of||prevalence-19/NN||variants-23/NNS	amod||viruses-29/NNS||subtype-25/JJ	num||viruses-29/NNS||b-26/SYM	conj_and||b-26/SYM||c-28/SYM	num||viruses-29/NNS||c-28/SYM	prep_in||variants-23/NNS||viruses-29/NNS	amod||individuals-32/NNS||untreated-31/JJ	prep_from||assess-17/VB||individuals-32/NNS	virus-14||viruses-29||no||we performed ultra-deep pyrosequencing (udps) and clonal dideoxynucleotide sequencing of plasma virus samples to assess the prevalence of minority k65r variants in subtype b and c viruses from untreated individuals.
det||associations-2/NNS||the-1/DT	nsubj||vary-46/VB||associations-2/NNS	prep_with||associations-2/NNS||age-4/NN	conj_and||associations-2/NNS||nulliparity-6/NN	nsubj||vary-46/VB||nulliparity-6/NN	appos||nulliparity-6/NN||parity-8/NN	conj_and||associations-2/NNS||age-10/NN	nsubj||vary-46/VB||age-10/NN	prep_at||age-10/NN||menopause-12/NN	conj_and||associations-2/NNS||type-14/NN	nsubj||vary-46/VB||type-14/NN	prep_of||type-14/NN||menopause-16/NN	nn||intake-19/NN||alcohol-18/NN	conj_and||associations-2/NNS||intake-19/NN	nsubj||vary-46/VB||intake-19/NN	amod||index-24/NN||adult-21/JJ	nn||index-24/NN||body-22/NN	nn||index-24/NN||mass-23/NN	appos||intake-19/NN||index-24/NN	appos||index-24/NN||bmi-26/NN	conj_and||associations-2/NNS||bmi-29/NN	nsubj||vary-46/VB||bmi-29/NN	prep_at||bmi-29/NN||age-31/NN	num||age-31/NN||18-32/CD	nn||history-35/NN||family-34/NN	conj_and||associations-2/NNS||history-35/NN	nsubj||vary-46/VB||history-35/NN	nn||cancer-38/NN||breast-37/NN	prep_of||history-35/NN||cancer-38/NN	amod||history-41/NN||personal-40/JJ	conj_and||associations-2/NNS||history-41/NN	nsubj||vary-46/VB||history-41/NN	prep_of||history-41/NN||benignbreastdisease-43/NN	aux||vary-46/VB||did-44/VBD	neg||vary-46/VB||not-45/RB	root||ROOT-0/null||vary-46/VB	prep_by||vary-46/VB||subtype-48/NN	dep||subtype-48/NN||p-50/NN	nn||¥-55/NNP||het-52/NN	nn||¥-55/NNP||â-53/NN	nn||¥-55/NNP||-54/NNP	dep||p-50/NN||¥-55/NNP	num||¥-55/NNP||0.08-56/CD	alcohol-18||cancer-38||no_rel||the associations with age, nulliparity, parity, age at menopause, type of menopause, alcohol intake, adult body mass index (bmi), bmi at age 18, family history of breast cancer and personal history of benignbreastdisease did not vary by subtype ( p -het â¥ 0.08).
det||observations-2/NNS||these-1/DT	nsubj||suggest-3/VBP||observations-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||have-10/VB||that-4/IN	amod||administration-6/NN||oral-5/JJ	nsubj||have-10/VB||administration-6/NN	prep_of||administration-6/NN||egcg-8/NN	aux||have-10/VB||may-9/MD	ccomp||suggest-3/VBP||have-10/VB	amod||effects-13/NNS||significant-11/JJ	amod||effects-13/NNS||beneficial-12/JJ	dobj||have-10/VB||effects-13/NNS	poss||patients-17/NNS||parkinson-15/NN	prep_in||effects-13/NNS||patients-17/NNS	vmod||patients-17/NNS||treated-18/VBN	prep_with||treated-18/VBN||l-dopa-20/NN	prep_with||treated-18/VBN||carbidopa-22/NN	conj_and||l-dopa-20/NN||carbidopa-22/NN	agent||treated-18/VBN||exerting-24/VBG	det||inhibition-27/NN||a-25/DT	amod||inhibition-27/NN||modest-26/JJ	dobj||exerting-24/VBG||inhibition-27/NN	amod||methylation-30/NN||l-dopa-29/JJ	prep_of||inhibition-27/NN||methylation-30/NN	det||neuroprotection-34/NN||a-32/DT	amod||neuroprotection-34/NN||strong-33/JJ	dobj||exerting-24/VBG||neuroprotection-34/NN	conj_plus||inhibition-27/NN||neuroprotection-34/NN	amod||damage-37/NN||oxidative-36/JJ	prep_against||neuroprotection-34/NN||damage-37/NN	prep_against||neuroprotection-34/NN||degeneration-39/NN	conj_and||damage-37/NN||degeneration-39/NN	parkinson's--1||carbidopa-22||yes||these observations suggest that oral administration of egcg may have significant beneficial effects in parkinson's patients treated with l-dopa and carbidopa by exerting a modest inhibition of l-dopa methylation plus a strong neuroprotection against oxidative damage and degeneration.
nsubj||searched-2/VBD||we-1/PRP	root||ROOT-0/null||searched-2/VBD	ccomp||searched-2/VBD||medline-3/VB	ccomp||searched-2/VBD||pubmed-5/VB	conj_and||medline-3/VB||pubmed-5/VB	dobj||medline-3/VB||terms-6/NNS	nn||stage-9/NN||labour-8/NN	dep||terms-6/NNS||stage-9/NN	dep||stage-9/NN||third-11/JJ	dep||ergonovine-17/NN||ergonovine-15/JJ	dep||medline-3/VB||ergonovine-17/NN	amod||ergonovine-17/NN||tartrate-18/JJ	amod||ergonovine-17/NN||methylergonovine-20/JJ	conj_or||tartrate-18/JJ||methylergonovine-20/JJ	amod||ergonovine-17/NN||oxytocin-22/JJ	conj_or||tartrate-18/JJ||oxytocin-22/JJ	amod||ergonovine-17/NN||oxytocics-24/JJ	conj_or||tartrate-18/JJ||oxytocics-24/JJ	amod||ergonovine-17/NN||misoprostol-26/JJ	conj_or||tartrate-18/JJ||misoprostol-26/JJ	ccomp||searched-2/VBD||and-28/VB	conj_and||medline-3/VB||and-28/VB	parataxis||and-28/VB||postpartumhaemorrhage-30/VB	parataxis||and-28/VB||haemorrhage-32/VB	conj_or||postpartumhaemorrhage-30/VB||haemorrhage-32/VB	conj_and||medline-3/VB||cochrane-35/VB	conj_and||and-28/VB||cochrane-35/VB	dobj||and-28/VB||reviews-36/NNS	det||restriction-40/NN||any-38/DT	nn||restriction-40/NN||language-39/NN	prep_without||and-28/VB||restriction-40/NN	postpartumhaemorrhage-30||oxytocin-22||yes||we searched medline and pubmed terms (labour stage, third) and (ergonovine, ergonovine tartrate, methylergonovine, oxytocin, oxytocics or misoprostol) and (postpartumhaemorrhage or haemorrhage) and cochrane reviews without any language restriction.
nsubj||believe-2/VBP||we-1/PRP	root||ROOT-0/null||believe-2/VBP	mark||have-20/VB||that-3/IN	poss||results-5/NNS||our-4/PRP$	nsubj||have-20/VB||results-5/NNS	nsubj||demonstrate-33/VB||results-5/NNS	prepc_besides||results-5/NNS||shedding-8/VBG	dobj||shedding-8/VBG||light-9/NN	det||mechanism-12/NN||the-11/DT	prep_on||shedding-8/VBG||mechanism-12/NN	amod||resistance-15/NN||chloroquine-14/JJ	prep_of||mechanism-12/NN||resistance-15/NN	nn||falciparum-18/NN||p.-17/NN	prep_in||resistance-15/NN||falciparum-18/NN	ccomp||believe-2/VBP||have-20/VB	dobj||have-20/VB||implications-21/NNS	det||development-24/NN||the-23/DT	prep_for||implications-21/NNS||development-24/NN	nn||therapies-27/NNS||novel-26/NN	prep_of||development-24/NN||therapies-27/NNS	amod||strains-31/NNS||resistant-29/JJ	nn||strains-31/NNS||malaria-30/NN	prep_against||therapies-27/NNS||strains-31/NNS	ccomp||believe-2/VBP||demonstrate-33/VB	conj_and||have-20/VB||demonstrate-33/VB	det||usefulness-35/NN||the-34/DT	dobj||demonstrate-33/VB||usefulness-35/NN	det||approach-38/NN||an-37/DT	prep_of||usefulness-35/NN||approach-38/NN	vmod||approach-38/NN||combining-39/VBG	dobj||combining-39/VBG||systems-40/NNS	nn||strategies-42/NNS||biology-41/NN	dobj||have-20/VB||strategies-42/NNS	amod||bioinformatics-45/NNS||structural-44/JJ	prep_with||have-20/VB||bioinformatics-45/NNS	amod||data-48/NNS||experimental-47/JJ	prep_with||have-20/VB||data-48/NNS	conj_and||bioinformatics-45/NNS||data-48/NNS	malaria-30||chloroquine-14||yes||we believe that our results , besides shedding light on the mechanism of chloroquine resistance in p. falciparum , have implications for the development of novel therapies against resistant malaria strains and demonstrate the usefulness of an approach combining systems biology strategies with structural bioinformatics and experimental data .
nn||transfection-3/NN||vivo-2/NN	prep_in||gave-29/VBD||transfection-3/NN	det||lipid-8/NN||the-5/DT	amod||lipid-8/NN||folate-modified-6/JJ	amod||lipid-8/NN||mm18-7/JJ	prep_with||transfection-3/NN||lipid-8/NN	dep||gave-29/VBD||containing-10/VBG	det||amount-13/NN||the-11/DT	amod||amount-13/NN||highest-12/JJS	dobj||containing-10/VBG||amount-13/NN	amod||co-lipid-16/NN||fa-peg570-diether-15/JJ	prep_of||amount-13/NN||co-lipid-16/NN	dep||co-lipid-16/NN||ww-18/NN	dep||ww-18/NN||9010-20/CD	det||ratio-27/NN||a-24/DT	amod||ratio-27/NN||neutral-25/JJ	nn||ratio-27/NN||charge-26/NN	prep_at||co-lipid-16/NN||ratio-27/NN	root||ROOT-0/null||gave-29/VBD	amod||expression-32/NN||luciferase-30/JJ	nn||expression-32/NN||transgene-31/NN	dobj||gave-29/VBD||expression-32/NN	lipid-8||fa--1||no_rel||in vivo transfection with the folate-modified mm18 lipid, containing the highest amount of fa-peg570-diether co-lipid ( ww ; 9010), at a neutral charge ratio, gave luciferase transgene expression.
nsubj||present-7/JJ||staphylococcusaureus-1/NNS	appos||staphylococcusaureus-1/NNS||sa-3/NN	cop||present-7/JJ||is-5/VBZ	advmod||present-7/JJ||usually-6/RB	root||ROOT-0/null||present-7/JJ	neg||only-9/JJ||not-8/RB	preconj||present-7/JJ||only-9/JJ	det||lesions-13/NNS||the-11/DT	nn||lesions-13/NNS||skin-12/NN	prep_in||present-7/JJ||lesions-13/NNS	prep_of||lesions-13/NNS||atopicdermatitis-15/NNS	appos||atopicdermatitis-15/NNS||ad-17/NN	det||skin-25/NN||the-22/DT	amod||skin-25/NN||atopic-23/JJ	amod||skin-25/NN||dry-24/JJ	prep_in||present-7/JJ||skin-25/NN	conj_and||lesions-13/NNS||skin-25/NN	atopicdermatitis-15||atopic-23||no||staphylococcusaureus (sa) is usually present not only in the skin lesions of atopicdermatitis (ad) but also in the atopic dry skin.
mark||indicated-8/VBN||while-1/IN	nn||studies-6/NNS||human-2/NN	conj_and||human-2/NN||animal-4/NN	nn||studies-6/NNS||animal-4/NN	nn||studies-6/NNS||model-5/NN	nsubj||indicated-8/VBN||studies-6/NNS	aux||indicated-8/VBN||have-7/VBP	advcl||shown-29/VBN||indicated-8/VBN	det||role-11/NN||a-9/DT	amod||role-11/NN||protective-10/JJ	dobj||indicated-8/VBN||role-11/NN	prep_for||role-11/NN||estrogen-13/NN	prep_against||indicated-8/VBN||cardiovasculardisease-15/NN	prep_against||indicated-8/VBN||glomerulosclerosis-17/NNS	conj_and||cardiovasculardisease-15/NN||glomerulosclerosis-17/NNS	amod||studies-20/NNS||clinical-19/JJ	nsubj||shown-29/VBN||studies-20/NNS	nn||therapy-24/NN||hormone-22/NN	nn||therapy-24/NN||replacement-23/NN	prep_of||studies-20/NNS||therapy-24/NN	amod||women-27/NNS||postmenopausal-26/JJ	prep_in||therapy-24/NN||women-27/NNS	aux||shown-29/VBN||have-28/VBP	root||ROOT-0/null||shown-29/VBN	amod||results-31/NNS||polar-30/JJ	dobj||shown-29/VBN||results-31/NNS	det||improvement-34/NN||some-33/DT	prep_with||shown-29/VBN||improvement-34/NN	prep_in||improvement-34/NN||hypertension-36/NN	prep_with||shown-29/VBN||worsening-38/VBG	conj_but||improvement-34/NN||worsening-38/VBG	amod||kidneydisease-41/NN||hypertensive-40/JJ	prep_of||worsening-38/VBG||kidneydisease-41/NN	neg||effect-45/NN||no-44/DT	prep_with||shown-29/VBN||effect-45/NN	conj_or||improvement-34/NN||effect-45/NN	prep_at||effect-45/NN||all-47/DT	kidneydisease-41||estrogen-13||no_rel||while human and animal model studies have indicated a protective role for estrogen against cardiovasculardisease and glomerulosclerosis, clinical studies of hormone replacement therapy in postmenopausal women have shown polar results with some improvement in hypertension but worsening of hypertensive kidneydisease, or no effect at all.
nn||tissue-2/NN||lymphoreticular-1/NN	nsubj||showed-3/VBD||tissue-2/NN	root||ROOT-0/null||showed-3/VBD	neg||evidence-5/NN||no-4/DT	dobj||showed-3/VBD||evidence-5/NN	nn||colonization-8/NN||prion-7/NN	prep_of||evidence-5/NN||colonization-8/NN	vmod||showed-3/VBD||suggesting-10/VBG	mark||similar-18/JJ||that-11/IN	det||pathogenesis-14/NNS||the-12/DT	amod||pathogenesis-14/NNS||peripheral-13/JJ	nsubj||similar-18/JJ||pathogenesis-14/NNS	prep_of||pathogenesis-14/NNS||kuru-16/NN	cop||similar-18/JJ||is-17/VBZ	ccomp||suggesting-10/VBG||similar-18/JJ	prep_to||similar-18/JJ||that-20/DT	vmod||that-20/DT||seen-21/VBN	amod||cjd-24/NN||classical-23/JJ	prep_in||seen-21/VBN||cjd-24/NN	prep_in||seen-21/VBN||vcjd-27/NN	conj_negcc||cjd-24/NN||vcjd-27/NN	kuru-16||prion-7||no_rel||lymphoreticular tissue showed no evidence of prion colonization, suggesting that the peripheral pathogenesis of kuru is similar to that seen in classical cjd rather than vcjd.
aux||determine-2/VB||to-1/TO	root||ROOT-0/null||determine-2/VB	det||effects-4/NNS||the-3/DT	dobj||determine-2/VB||effects-4/NNS	amod||supplementation-7/NN||combined-6/JJ	prep_of||determine-2/VB||supplementation-7/NN	prep_with||determine-2/VB||chromium-9/NN	appos||chromium-9/NN||cr-11/NN	prep_with||determine-2/VB||vitamins-14/NNS	conj_and||chromium-9/NN||vitamins-14/NNS	dep||determine-2/VB||c-15/SYM	dep||>-28/VBZ||e-17/SYM	amod||stress-20/NN||oxidative-19/JJ	prep_on||>-28/VBZ||stress-20/NN	prep_in||stress-20/NN||type2diabetes-22/CD	amod||subjects-25/NNS||adult-24/JJ	nsubj||>-28/VBZ||subjects-25/NNS	prep_with||subjects-25/NNS||hba1c-27/CD	conj_and||determine-2/VB||>-28/VBZ	num||%-30/NN||8.5-29/CD	dobj||>-28/VBZ||%-30/NN	vitamins-14||type2diabetes-22||no_rel||to determine the effects of combined supplementation with chromium (cr) and vitamins c and e on oxidative stress in type2diabetes, adult subjects with hba1c >8.5%.
num||nef-2/NN||one-1/CD	dep||deleted-4/VBN||nef-2/NN	root||ROOT-0/null||deleted-4/VBN	dobj||deleted-4/VBN||virus-5/NN	nsubjpass||isolated-8/VBN||virus-5/NN	auxpass||isolated-8/VBN||was-7/VBD	rcmod||virus-5/NN||isolated-8/VBN	det||development-11/NN||the-10/DT	prep_on||isolated-8/VBN||development-11/NN	prep_of||development-11/NN||aids-13/NNS	vmod||aids-13/NNS||caused-14/VBN	amod||levels-16/NNS||high-15/JJ	dobj||caused-14/VBN||levels-16/NNS	prep_of||levels-16/NNS||syncytia-18/NN	prep_in||caused-14/VBN||mdm-20/NN	amod||mdm-20/NN||similar-21/JJ	nn||viruses-24/NNS||control-23/NN	prep_to||similar-21/JJ||viruses-24/NNS	num||viruses-28/NNS||five-27/CD	npadvmod||isolated-29/JJ||viruses-28/NNS	amod||mdm-20/NN||isolated-29/JJ	conj_but||similar-21/JJ||isolated-29/JJ	amod||times-32/NNS||earlier-31/JJR	prep_from||mdm-20/NN||times-32/NNS	nn||onset-36/NN||aids-35/NNS	prep_prior_to||mdm-20/NN||onset-36/NN	vmod||onset-36/NN||caused-37/VBN	advmod||minimal-39/JJ||only-38/RB	acomp||caused-37/VBN||minimal-39/JJ	advmod||caused-37/VBN||cytopathicity-40/RB	virus-5||viruses-28||no||one nef -deleted virus that was isolated on the development of aids caused high levels of syncytia in mdm similar to control viruses, but five viruses isolated from earlier times prior to aids onset caused only minimal cytopathicity.
nn||none-2/NN||results-1/NNS	nsubj||provided-11/VBD||none-2/NN	det||organizations-5/NNS||the-4/DT	prep_of||none-2/NN||organizations-5/NNS	amod||institutions-9/NNS||governmental-8/JJ	prep_including||none-2/NN||institutions-9/NNS	root||ROOT-0/null||provided-11/VBD	amod||services-13/NNS||social-12/JJ	dobj||provided-11/VBD||services-13/NNS	dobj||provided-11/VBD||assistance-15/NN	conj_or||services-13/NNS||assistance-15/NN	prep_in||provided-11/VBD||prevention-17/NN	prep_of||prevention-17/NN||hiv/aids-19/NNS	aux||displaced-22/VB||to-20/TO	advmod||displaced-22/VB||internally-21/RB	vmod||provided-11/VBD||displaced-22/VB	dobj||displaced-22/VB||persons-23/NNS	aids--1||hiv--1||no||results none of the organizations, including governmental institutions, provided social services or assistance in prevention of hiv/aids to internally displaced persons.
nsubj||increased-3/VBD||honey-1/NN	advmod||increased-3/VBD||significantly-2/RB	root||ROOT-0/null||increased-3/VBD	dobj||increased-3/VBD||insulin-4/NN	num||±-8/NNS||0.41-6/CD	nn||±-8/NNS||â-7/NN	dep||insulin-4/NN||±-8/NNS	num||ng/ml-10/NN||0.06-9/CD	dep||±-8/NNS||ng/ml-10/NN	amod||hyperglycemia-14/NN||decreased-13/VBN	dobj||increased-3/VBD||hyperglycemia-14/NN	conj_and||insulin-4/NN||hyperglycemia-14/NN	number||â-17/CD||12.3-16/CD	num||3.1-19/CD||â-17/CD	number||3.1-19/CD||±-18/CD	npadvmod||mmol/l-20/JJ||3.1-19/CD	dep||hyperglycemia-14/NN||mmol/l-20/JJ	dobj||increased-3/VBD||fructosamine-23/NN	conj_and||insulin-4/NN||fructosamine-23/NN	num||â-26/NN||304.5-25/CD	dep||insulin-4/NN||â-26/NN	number||10.1-28/CD||±-27/CD	num||/-30/NNS||10.1-28/CD	amod||/-30/NNS||âµmol-29/JJ	dep||â-26/NN||/-30/NNS	dep||/-30/NNS||l-31/NN	hyperglycemia-14||insulin-4||yes||honey significantly increased insulin (0.41 â± 0.06 ng/ml), decreased hyperglycemia (12.3 â± 3.1 mmol/l) and fructosamine (304.5 â± 10.1 âµmol/l).
aux||understand-3/VB||to-1/TO	advmod||understand-3/VB||better-2/RBR	advcl||examined-13/VBD||understand-3/VB	det||changes-7/NNS||the-4/DT	nn||changes-7/NNS||gene-5/NN	nn||changes-7/NNS||expression-6/NN	dobj||understand-3/VB||changes-7/NNS	amod||diseases-10/NNS||htlv-1-associated-9/JJ	prep_in||changes-7/NNS||diseases-10/NNS	nsubj||examined-13/VBD||we-12/PRP	root||ROOT-0/null||examined-13/VBD	det||profiles-16/NNS||the-14/DT	nn||profiles-16/NNS||mrna-15/NN	dobj||examined-13/VBD||profiles-16/NNS	amod||cells-21/NNS||cd4-18/JJ	amod||cells-21/NNS||+-19/JJ	nn||cells-21/NNS||t-20/NN	prep_of||profiles-16/NNS||cells-21/NNS	vmod||cells-21/NNS||isolated-22/VBN	num||atl-25/NN||7-24/CD	prep_from||isolated-22/VBN||atl-25/NN	num||ham/tsp-28/NN||12-27/CD	prep_from||isolated-22/VBN||ham/tsp-28/NN	conj_and||atl-25/NN||ham/tsp-28/NN	num||ac-31/NN||11-30/CD	prep_from||isolated-22/VBN||ac-31/NN	conj_and||atl-25/NN||ac-31/NN	num||controls-35/NNS||8-33/CD	amod||controls-35/NNS||non-infected-34/JJ	prep_from||isolated-22/VBN||controls-35/NNS	conj_and||atl-25/NN||controls-35/NNS	ham--1||htlv-1--1||no||to better understand the gene expression changes in htlv-1-associated diseases, we examined the mrna profiles of cd4+ t cells isolated from 7 atl, 12 ham/tsp, 11 ac and 8 non-infected controls.
prep_in||increases-9/VBZ||addition-2/NN	nsubj||increases-9/VBZ||association-4/NN	prep_of||association-4/NN||quercetin-6/NN	prep_with||quercetin-6/NN||fludarabine-8/NN	root||ROOT-0/null||increases-9/VBZ	det||response-12/NN||the-10/DT	amod||response-12/NN||apoptotic-11/JJ	dobj||increases-9/VBZ||response-12/NN	nn||cells-15/NNS||cll-14/NN	prep_in||response-12/NN||cells-15/NNS	advmod||two-fold-18/JJ||about-17/RB	prep_of||cells-15/NNS||two-fold-18/JJ	prepc_compared_with||two-fold-18/JJ||with-20/IN	nn||monotreatment-22/NN||quercetin-21/NN	pobj||two-fold-18/JJ||monotreatment-22/NN	cll-14||fludarabine-8||yes||in addition, association of quercetin with fludarabine increases the apoptotic response in cll cells of about two-fold compared with quercetin monotreatment.
nsubj||compensated-10/VBN||patients-1/NNS	nsubj||overt-12/VB||patients-1/NNS	det||syndrome-4/NN||the-3/DT	prep_with||patients-1/NNS||syndrome-4/NN	nn||unresponsiveness-7/NNS||tsh-6/NN	prep_of||syndrome-4/NN||unresponsiveness-7/NNS	aux||compensated-10/VBN||may-8/MD	aux||compensated-10/VBN||have-9/VB	root||ROOT-0/null||compensated-10/VBN	conj_or||compensated-10/VBN||overt-12/VB	dobj||overt-12/VB||hypothyroidism-13/NN	det||spectrum-17/NN||a-15/DT	amod||spectrum-17/NN||wide-16/JJ	prep_with||overt-12/VB||spectrum-17/NN	amod||alterations-22/NNS||clinical-19/JJ	conj_and||clinical-19/JJ||morphological-21/JJ	amod||alterations-22/NNS||morphological-21/JJ	prep_of||spectrum-17/NN||alterations-22/NNS	prepc_depending_on||overt-12/VB||on-24/IN	det||degree-26/NN||the-25/DT	pobj||overt-12/VB||degree-26/NN	prep_of||degree-26/NN||impairment-28/NN	nn||function-34/NN||tsh-receptor-30/NNP	appos||function-34/NN||tsh-r-32/NN	prep_of||impairment-28/NN||function-34/NN	hypothyroidism-13||tsh-6||no_rel||patients with the syndrome of tsh unresponsiveness may have compensated or overt hypothyroidism with a wide spectrum of clinical and morphological alterations depending on the degree of impairment of tsh-receptor (tsh-r) function.
amod||experiments-2/NNS||previous-1/JJ	nsubj||showed-3/VBD||experiments-2/NNS	root||ROOT-0/null||showed-3/VBD	mark||reduced-10/VBD||that-4/IN	amod||heparin-6/NN||ultra-low-molecular-weight-5/JJ	nsubj||reduced-10/VBD||heparin-6/NN	appos||heparin-6/NN||ulmwh-8/NN	ccomp||showed-3/VBD||reduced-10/VBD	det||deficit-15/NN||the-11/DT	amod||deficit-15/NN||infarct-12/JJ	conj_and||infarct-12/JJ||neurologic-14/JJ	amod||deficit-15/NN||neurologic-14/JJ	dobj||reduced-10/VBD||deficit-15/NN	prep_in||reduced-10/VBD||rats-17/NNS	vmod||rats-17/NNS||followed-18/VBN	agent||followed-18/VBN||transientcerebralischemia-20/NN	det||mechanisms-24/NNS||the-23/DT	nsubj||unclear-30/JJ||mechanisms-24/NNS	poss||effect-28/NN||its-26/PRP$	amod||effect-28/NN||neuroprotective-27/JJ	prep_of||mechanisms-24/NNS||effect-28/NN	cop||unclear-30/JJ||are-29/VBP	conj_but||showed-3/VBD||unclear-30/JJ	heparin-6||transientcerebralischemia-20||no_rel||previous experiments showed that ultra-low-molecular-weight heparin (ulmwh) reduced the infarct and neurologic deficit in rats followed by transientcerebralischemia, but the mechanisms of its neuroprotective effect are unclear.
det||combination-2/NN||the-1/DT	nsubj||premixed-6/VBD||combination-2/NN	nn||propofol-5/NN||microemulsion-4/NN	prep_of||combination-2/NN||propofol-5/NN	root||ROOT-0/null||premixed-6/VBD	prep_with||premixed-6/VBD||lidocaine-8/NN	mark||effective-16/JJ||after-9/IN	det||pretreatment-11/NN||a-10/DT	nsubj||effective-16/JJ||pretreatment-11/NN	prep_with||pretreatment-11/NN||remifentanil-13/NN	cop||effective-16/JJ||was-14/VBD	advmod||effective-16/JJ||more-15/RBR	advcl||premixed-6/VBD||effective-16/JJ	prepc_in||effective-16/JJ||reducing-18/VBG	det||incidence-20/NN||the-19/DT	dobj||reducing-18/VBG||incidence-20/NN	prep_of||incidence-20/NN||pain-22/NN	det||injection-25/NN||the-24/DT	prep_upon||reducing-18/VBG||injection-25/NN	nn||propofol-28/NN||microemulsion-27/NN	prep_of||injection-25/NN||propofol-28/NN	det||treatment-31/NN||either-30/DT	prep_than||reducing-18/VBG||treatment-31/NN	advmod||effective-16/JJ||alone-32/RB	pain-22||propofol-28||yes||the combination of microemulsion propofol premixed with lidocaine after a pretreatment with remifentanil was more effective in reducing the incidence of pain upon the injection of microemulsion propofol than either treatment alone.
nsubj||antipsychoticdrug-5/NN||aripiprazole-1/NN	cop||antipsychoticdrug-5/NN||is-2/VBZ	det||antipsychoticdrug-5/NN||an-3/DT	amod||antipsychoticdrug-5/NN||atypical-4/JJ	root||ROOT-0/null||antipsychoticdrug-5/NN	vmod||antipsychoticdrug-5/NN||approved-6/VBN	det||treatment-9/NN||the-8/DT	prep_for||approved-6/VBN||treatment-9/NN	amod||disorders-12/NNS||psychiatric-11/JJ	prep_of||treatment-9/NN||disorders-12/NNS	nn||depressivedisorder-20/NN||schizophrenia-15/NN	prep_such_as||disorders-12/NNS||bipolardisorder-17/NN	conj_and||depressivedisorder-20/NN||bipolardisorder-17/NN	prep_such_as||disorders-12/NNS||major-19/JJ	amod||depressivedisorder-20/NN||major-19/JJ	conj_and||depressivedisorder-20/NN||major-19/JJ	prep_such_as||disorders-12/NNS||depressivedisorder-20/NN	prep_such_as||disorders-12/NNS||autism-22/NN	conj_and||depressivedisorder-20/NN||autism-22/NN	bipolardisorder-17||antipsychoticdrug-5||no_rel||aripiprazole is an atypical antipsychoticdrug approved for the treatment of psychiatric disorders such as schizophrenia, bipolardisorder, major depressivedisorder and autism.
root||ROOT-0/null||increasing-1/VBG	det||dose-4/NN||the-2/DT	amod||dose-4/NN||lidocaine-3/JJ	dobj||increasing-1/VBG||dose-4/NN	advmod||increasing-1/VBG||significantly-5/RB	dep||increasing-1/VBG||reduced-6/VBD	nsubj||increasing-1/VBG||pain-7/NN	nn||0.05-11/NNP||p-9/NNP	nn||0.05-11/NNP||<-10/NNP	appos||pain-7/NN||0.05-11/NNP	pain-7||lidocaine-3||yes||increasing the lidocaine dose significantly reduced pain (p < 0.05).
det||serosurvey-3/NN||a-1/DT	nn||serosurvey-3/NN||retrospective-2/NN	nsubj||showed-7/VBD||serosurvey-3/NN	amod||patients-6/NNS||febrile-5/JJ	prep_of||serosurvey-3/NN||patients-6/NNS	root||ROOT-0/null||showed-7/VBD	mark||had-16/VBD||that-8/IN	number||21-10/CD||>-9/CD	num||%-11/NN||21-10/CD	nsubj||had-16/VBD||%-11/NN	det||samples-15/NNS||the-13/DT	nn||samples-15/NNS||serum-14/NN	prep_of||%-11/NN||samples-15/NNS	ccomp||showed-7/VBD||had-16/VBD	dobj||had-16/VBD||antibodies-17/NNS	nn||rickettsiae-21/NN||spottedfever-19/NN	nn||rickettsiae-21/NN||group-20/NN	prep_against||antibodies-17/NNS||rickettsiae-21/NN	spottedfever-19||rickettsiae-21||no||a retrospective serosurvey of febrile patients showed that >21% of the serum samples had antibodies against spottedfever group rickettsiae.
nsubjpass||found-6/VBN||parasites-1/NNS	vmod||parasites-1/NNS||carrying-2/VBG	amod||mutations-4/NNS||pfcyt-b-3/JJ	dobj||carrying-2/VBG||mutations-4/NNS	auxpass||found-6/VBN||were-5/VBD	root||ROOT-0/null||found-6/VBN	num||patients-10/NNS||five-8/CD	nn||patients-10/NNS||falciparummalaria-9/NN	prep_in||found-6/VBN||patients-10/NNS	amod||parasitaemia-13/NN||recrudescent-12/JJ	prep_with||patients-10/NNS||parasitaemia-13/NN	xcomp||found-6/VBN||occurring-14/VBG	tmod||occurring-14/VBG||weeks-15/NNS	advmod||successful-18/JJ||apparently-17/RB	amod||treatment-19/NN||successful-18/JJ	prep_after||occurring-14/VBG||treatment-19/NN	det||infection-23/NN||a-21/DT	amod||infection-23/NN||primary-22/JJ	prep_of||treatment-19/NN||infection-23/NN	prep_with||infection-23/NN||atovaquone-proguanil-25/NN	falciparummalaria-9||proguanil--1||yes||parasites carrying pfcyt-b mutations were found in five falciparummalaria patients with recrudescent parasitaemia occurring weeks after apparently successful treatment of a primary infection with atovaquone-proguanil.
num||others-2/NNS||ten-1/CD	nsubjpass||infused-4/VBN||others-2/NNS	nsubj||maintain-29/VB||others-2/NNS	auxpass||infused-4/VBN||were-3/VBD	root||ROOT-0/null||infused-4/VBN	prep_with||infused-4/VBN||insulin-6/NN	num||units/h-9/NN||2-8/CD	appos||insulin-6/NN||units/h-9/NN	num||h-13/NN||6-12/CD	prep_for||insulin-6/NN||h-13/NN	prep_in||h-13/NN||addition-15/NN	det||injection-19/NN||the-17/DT	nn||injection-19/NN||lps-18/NN	prep_to||infused-4/VBN||injection-19/NN	num||ml/h-23/NN||100-22/CD	prep_along_with||injection-19/NN||ml/h-23/NN	number||%-26/NN||5-25/CD	amod||dextrose-27/NN||%-26/NN	prep_of||ml/h-23/NN||dextrose-27/NN	aux||maintain-29/VB||to-28/TO	xcomp||infused-4/VBN||maintain-29/VB	dobj||maintain-29/VB||normoglycemia-30/NN	insulin-6||ten-1||no_rel||ten others were infused with insulin (2 units/h) for 6 h in addition to the lps injection along with 100 ml/h of 5% dextrose to maintain normoglycemia.
mark||immunization-3/NN||upon-1/IN	nn||immunization-3/NN||rabbit-2/NN	advcl||elicited-8/VBD||immunization-3/NN	det||proteins-7/NNS||both-5/DT	nn||proteins-7/NNS||ha-6/NN	nsubj||elicited-8/VBD||proteins-7/NNS	root||ROOT-0/null||elicited-8/VBD	amod||antibodies-10/NNS||neutralizing-9/VBG	dobj||elicited-8/VBD||antibodies-10/NNS	det||virus-14/NN||the-12/DT	amod||virus-14/NN||homologous-13/JJ	prep_against||antibodies-10/NNS||virus-14/NN	dep||virus-14/NN||a/vietnam/1203-16/NNP	punct||a/vietnam/1203-16/NNP||/-17/:	dep||a/vietnam/1203-16/NNP||2004-18/CD	appos||2004-18/CD||clade-20/NN	num||clade-20/NN||1-21/CD	amod||antibodies-27/NNS||cross-neutralizing-26/JJ	dobj||elicited-8/VBD||antibodies-27/NNS	conj_and||antibodies-10/NNS||antibodies-27/NNS	amod||h5n1-30/NNS||heterologous-29/JJ	prep_against||antibodies-27/NNS||h5n1-30/NNS	amod||h5n1-30/NNS||clade-31/JJ	num||strains-33/NNS||2-32/CD	dep||clade-31/JJ||strains-33/NNS	amod||/-37/NNP||a/indonesia/5-36/JJ	prep_including||h5n1-30/NNS||/-37/NNP	num||/-37/NNP||2005-38/CD	h5n1-30||antibodies-27||no_rel||upon rabbit immunization, both ha proteins elicited neutralizing antibodies against the homologous virus (a/vietnam/1203/2004, clade 1) as well as cross-neutralizing antibodies against heterologous h5n1 clade 2 strains, including a/indonesia/5/2005.
amod||restriction-3/NN||light-1/JJ	nn||restriction-3/NN||chain-2/NN	nsubjpass||detected-8/VBN||restriction-3/NN	appos||restriction-3/NN||lcr-5/NN	auxpass||detected-8/VBN||was-7/VBD	root||ROOT-0/null||detected-8/VBN	det||b-nhl-14/NN||the-10/DT	num||b-nhl-14/NN||32-11/CD	nn||b-nhl-14/NN||fci-12/NN	nn||b-nhl-14/NN||diagnosed-13/NN	prep_in||detected-8/VBN||b-nhl-14/NN	nhl--1||lcr-5||yes||light chain restriction (lcr) was detected in the 32 fci diagnosed b-nhl.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	nsubj||tested-21/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effects-8/NNS||the-7/DT	dobj||investigated-6/VBD||effects-8/NNS	prep_of||effects-8/NNS||vigabatrin-10/NN	prep_on||investigated-6/VBD||epilepsy-12/NN	det||model-17/NN||a-14/DT	amod||model-17/NN||knock-out-15/JJ	nn||model-17/NN||mouse-16/NN	prep_in||investigated-6/VBD||model-17/NN	prep_of||model-17/NN||tsc-19/NN	conj_and||investigated-6/VBD||tested-21/VBD	det||novel-23/NN||the-22/DT	nsubj||hypothesis-24/VBZ||novel-23/NN	ccomp||tested-21/VBD||hypothesis-24/VBZ	mark||inhibits-27/VBZ||that-25/IN	nsubj||inhibits-27/VBZ||vigabatrin-26/NN	ccomp||hypothesis-24/VBZ||inhibits-27/VBZ	det||target-30/NN||the-28/DT	amod||target-30/NN||mammalian-29/JJ	dobj||inhibits-27/VBZ||target-30/NN	amod||pathway-36/NN||rapamycin-32/JJ	appos||pathway-36/NN||mtor-34/NN	prep_of||target-30/NN||pathway-36/NN	det||pathway-41/NN||a-38/DT	amod||pathway-41/NN||key-39/JJ	amod||pathway-41/NN||signaling-40/JJ	appos||pathway-36/NN||pathway-41/NN	nsubjpass||dysregulated-44/VBN||pathway-41/NN	auxpass||dysregulated-44/VBN||is-43/VBZ	rcmod||pathway-41/NN||dysregulated-44/VBN	prep_in||dysregulated-44/VBN||tsc-46/NN	epilepsy-12||vigabatrin-26||yes||in this study, we investigated the effects of vigabatrin on epilepsy in a knock-out mouse model of tsc and tested the novel hypothesis that vigabatrin inhibits the mammalian target of rapamycin (mtor) pathway, a key signaling pathway that is dysregulated in tsc.
nsubjpass||expressed-3/VBN||jmjd2b-1/NNS	auxpass||expressed-3/VBN||is-2/VBZ	root||ROOT-0/null||expressed-3/VBN	det||proportion-7/NN||a-5/DT	amod||proportion-7/NN||high-6/JJ	prep_in||expressed-3/VBN||proportion-7/NN	amod||breasttumors-10/NNS||human-9/JJ	prep_of||proportion-7/NN||breasttumors-10/NNS	det||levels-15/NNS||that-13/DT	nn||levels-15/NNS||expression-14/NN	nsubj||correlate-17/VBP||levels-15/NNS	advmod||correlate-17/VBP||significantly-16/RB	conj_and||expressed-3/VBN||correlate-17/VBP	nn||receptor-20/NN||estrogen-19/NN	prep_with||correlate-17/VBP||receptor-20/NN	appos||receptor-20/NN||er-22/NN	advmod||correlate-17/VBP||positivity-24/RB	breasttumors-10||estrogen-19||yes||jmjd2b is expressed in a high proportion of human breasttumors, and that expression levels significantly correlate with estrogen receptor (er) positivity.
prep_by||affects-5/VBZ||mechanisms-1/NNS	nsubj||understood-26/VBD||mechanisms-1/NNS	nsubj||affects-5/VBZ||hiv-4/NN	rcmod||mechanisms-1/NNS||affects-5/VBZ	det||thymus-7/NNS||the-6/DT	nsubjpass||multiple-9/JJ||thymus-7/NNS	auxpass||multiple-9/JJ||are-8/VBP	cop||multiple-9/JJ||are-8/VBP	dep||affects-5/VBZ||multiple-9/JJ	dep||affects-5/VBZ||only-11/RB	advmod||multiple-9/JJ||only-11/RB	conj_and||multiple-9/JJ||only-11/RB	advmod||known-13/VBN||partially-12/RB	dep||multiple-9/JJ||known-13/VBN	det||role-17/NN||the-16/DT	nsubj||remains-24/VBZ||role-17/NN	amod||dysfunction-20/NN||thymic-19/JJ	prep_of||role-17/NN||dysfunction-20/NN	amod||immunopathogenesis-23/NNS||hiv/aids-22/JJ	prep_in||dysfunction-20/NN||immunopathogenesis-23/NNS	dep||affects-5/VBZ||remains-24/VBZ	conj_and||multiple-9/JJ||remains-24/VBZ	advmod||understood-26/VBD||poorly-25/RB	root||ROOT-0/null||understood-26/VBD	aids--1||hiv-4||no||mechanisms by which hiv affects the thymus are multiple and only partially known, and the role of thymic dysfunction in hiv/aids immunopathogenesis remains poorly understood.
mwe||than-3/IN||more-2/JJR	quantmod||a-4/DT||than-3/IN	num||decade-5/NN||a-4/DT	prep_after||increasing-29/VBG||decade-5/NN	det||epidemic-9/NN||the-7/DT	nn||epidemic-9/NN||aids-8/NNS	prep_of||decade-5/NN||epidemic-9/NN	prep_in||epidemic-9/NN||thailand-11/NN	det||number-14/NN||the-13/DT	nsubj||increasing-29/VBG||number-14/NN	prep_of||number-14/NN||children-16/NNS	poss||parents-18/NNS||children-16/NNS	nsubj||living-20/VBG||parents-18/NNS	nsubj||died-25/VBN||parents-18/NNS	aux||living-20/VBG||are-19/VBP	rcmod||children-16/NNS||living-20/VBG	prep_with||living-20/VBG||hiv-22/NN	aux||died-25/VBN||have-24/VBP	rcmod||children-16/NNS||died-25/VBN	conj_or||living-20/VBG||died-25/VBN	prep_from||died-25/VBN||aids-27/NNS	aux||increasing-29/VBG||is-28/VBZ	root||ROOT-0/null||increasing-29/VBG	advmod||increasing-29/VBG||significantly-30/RB	nsubjpass||reported-35/VBN||it-32/PRP	aux||reported-35/VBN||has-33/VBZ	auxpass||reported-35/VBN||been-34/VBN	conj_and||increasing-29/VBG||reported-35/VBN	mark||discriminated-41/VBN||that-36/IN	det||children-38/NNS||these-37/DT	nsubjpass||discriminated-41/VBN||children-38/NNS	auxpass||discriminated-41/VBN||are-39/VBP	advmod||discriminated-41/VBN||often-40/RB	ccomp||reported-35/VBN||discriminated-41/VBN	prep||discriminated-41/VBN||against-42/IN	pcomp||against-42/IN||by-43/IN	poss||peers-45/NNS||their-44/PRP$	pobj||by-43/IN||peers-45/NNS	aids-27||hiv-22||no||after more than a decade of the aids epidemic in thailand, the number of children whose parents are living with hiv or have died from aids is increasing significantly and it has been reported that these children are often discriminated against by their peers.
det||1-year-3/NN||the-2/DT	prep_within||reported-10/VBD||1-year-3/NN	nn||diagnosis-7/NN||disease-6/NN	prep_prior_to||1-year-3/NN||diagnosis-7/NN	nsubj||reported-10/VBD||controls-9/NNS	root||ROOT-0/null||reported-10/VBD	advmod||more-12/JJR||slightly-11/RB	amod||infections-14/NNS||more-12/JJR	amod||infections-14/NNS||strep-tococcal-13/JJ	dobj||reported-10/VBD||infections-14/NNS	appos||infections-14/NNS||p-16/NNP	number||0.2-18/CD||<-17/CD	num||p-16/NNP||0.2-18/CD	dobj||reported-10/VBD||infections-21/NNS	conj_and||infections-14/NNS||infections-21/NNS	prep_with||infections-21/NNS||diarrhea-23/NN	prep_with||infections-21/NNS||vomiting-25/NN	conj_and||diarrhea-23/NN||vomiting-25/NN	dep||infections-14/NNS||p-27/VBN	num||0.3-29/CD||<-28/CD	dobj||p-27/VBN||0.3-29/CD	amod||use-34/NN||antibiotic-33/JJ	dobj||reported-10/VBD||use-34/NN	conj_and||infections-14/NNS||use-34/NN	appos||use-34/NN||p-36/NNP	number||0.09-38/CD||<-37/CD	num||p-36/NNP||0.09-38/CD	mark||significant-48/JJ||although-41/IN	nsubj||significant-48/JJ||none-42/NN	det||results-45/NNS||these-44/DT	prep_of||none-42/NN||results-45/NNS	cop||significant-48/JJ||were-46/VBD	advmod||significant-48/JJ||statistically-47/RB	dep||use-34/NN||significant-48/JJ	antibiotic-33||vomiting-25||no_rel||within the 1-year prior to disease diagnosis, controls reported slightly more strep-tococcal infections (p<0.2), infections with diarrhea and vomiting (p<0.3), and antibiotic use (p<0.09), although none of these results were statistically significant.
amod||countries-4/NNS||many-2/JJ	amod||countries-4/NNS||malaria-endemic-3/JJ	prep_in||compromise-10/VB||countries-4/NNS	amod||resistance-7/NN||increasing-6/VBG	nsubj||compromise-10/VB||resistance-7/NN	aux||compromise-10/VB||may-8/MD	advmod||compromise-10/VB||soon-9/RB	root||ROOT-0/null||compromise-10/VB	det||efficacy-12/NN||the-11/DT	dobj||compromise-10/VB||efficacy-12/NN	amod||sp-16/NN||sulphadoxine-pyrimethamine-14/JJ	prep_of||efficacy-12/NN||sp-16/NN	amod||treatment-21/NN||intermittent-19/JJ	amod||treatment-21/NN||preventative-20/JJ	prep_for||sp-16/NN||treatment-21/NN	appos||treatment-21/NN||ipt-23/NN	prep_of||treatment-21/NN||malaria-26/NN	prep_in||compromise-10/VB||pregnancy-28/NN	malaria-26||pyrimethamine--1||yes||in many malaria-endemic countries, increasing resistance may soon compromise the efficacy of sulphadoxine-pyrimethamine (sp) for intermittent preventative treatment (ipt) of malaria in pregnancy.
amod||antimalarialdrugs-3/NNS||fixed-dose-1/JJ	nn||antimalarialdrugs-3/NNS||combination-2/NN	nsubj||played-5/VBN||antimalarialdrugs-3/NNS	aux||played-5/VBN||have-4/VBP	root||ROOT-0/null||played-5/VBN	det||role-9/NN||an-6/DT	advmod||important-8/JJ||increasingly-7/RB	amod||role-9/NN||important-8/JJ	dobj||played-5/VBN||role-9/NN	det||treatment-12/NN||the-11/DT	prep_in||role-9/NN||treatment-12/NN	dobj||played-5/VBN||chemoprophylaxis-14/NNS	conj_and||role-9/NN||chemoprophylaxis-14/NNS	prep_of||chemoprophylaxis-14/NNS||falciparummalaria-16/NN	det||failure-20/NN||the-18/DT	amod||failure-20/NN||worldwide-19/JJ	prep_since||played-5/VBN||failure-20/NN	prep_of||failure-20/NN||monotherapy-22/NN	prep_with||played-5/VBN||chloroquine-24/NN	falciparummalaria-16||chloroquine-24||yes||fixed-dose combination antimalarialdrugs have played an increasingly important role in the treatment and chemoprophylaxis of falciparummalaria since the worldwide failure of monotherapy with chloroquine.
nsubj||sought-2/VBD||we-1/PRP	nsubj||determine-4/VB||we-1/PRP	root||ROOT-0/null||sought-2/VBD	aux||determine-4/VB||to-3/TO	xcomp||sought-2/VBD||determine-4/VB	mark||altered-36/VBN||if-5/IN	nsubjpass||altered-36/VBN||upa-6/NN	nn||inhibitor-9/NN||pa-8/NN	appos||upa-6/NN||inhibitor-9/NN	appos||inhibitor-9/NN||pai-11/NN	dep||inhibitor-9/NN||-1-13/CD	num||expression-20/NN||prostaglandin-15/CD	nn||expression-20/NN||pg-17/NN	amod||expression-20/NN||e2-19/JJ	appos||upa-6/NN||expression-20/NN	conj_and||inhibitor-9/NN||expression-20/NN	amod||fluid-24/NN||nipple-22/JJ	nn||fluid-24/NN||aspirate-23/NN	prep_in||expression-20/NN||fluid-24/NN	appos||fluid-24/NN||naf-26/NN	nn||expression-32/NN||upa-29/NN	conj_and||upa-29/NN||pge2-31/JJ	nn||expression-32/NN||pge2-31/JJ	prep_in||expression-20/NN||expression-32/NN	conj_and||fluid-24/NN||expression-32/NN	prep_in||expression-32/NN||plasma-34/NN	auxpass||altered-36/VBN||were-35/VBD	advcl||determine-4/VB||altered-36/VBN	nn||dose-39/NN||celecoxib-38/NN	agent||altered-36/VBN||dose-39/NN	agent||altered-36/VBN||concentration-41/NN	conj_and||dose-39/NN||concentration-41/NN	prep_in||altered-36/VBN||women-43/NNS	amod||risk-48/NN||increased-45/VBN	nn||risk-48/NN||breast-46/NN	nn||risk-48/NN||cancer-47/NN	prep_at||women-43/NNS||risk-48/NN	cancer-47||naf-26||no_rel||we sought to determine if upa, pa inhibitor (pai)-1 and prostaglandin (pg)e2 expression in nipple aspirate fluid (naf) and upa and pge2 expression in plasma were altered by celecoxib dose and concentration in women at increased breast cancer risk.
det||amount-8/NN||the-1/DT	amod||amount-8/NN||median-2/JJ	amod||range-5/NN||interquartile-4/JJ	appos||amount-8/NN||range-5/NN	amod||amount-8/NN||total-7/JJ	nsubj||lower-16/JJR||amount-8/NN	prep_of||amount-8/NN||norepinephrine-10/NN	vmod||norepinephrine-10/NN||infused-11/VBN	prep_during||infused-11/VBN||shock-13/NN	cop||lower-16/JJR||was-14/VBD	advmod||lower-16/JJR||significantly-15/RB	root||ROOT-0/null||lower-16/JJR	det||group-20/NN||the-18/DT	amod||group-20/NN||fuzzy-19/JJ	prep_in||lower-16/JJR||group-20/NN	prep||lower-16/JJR||than-21/IN	pcomp||than-21/IN||in-22/IN	det||group-25/NN||the-23/DT	nn||group-25/NN||control-24/NN	pobj||in-22/IN||group-25/NN	num||-LSB--28/NNS||0.6-27/CD	dep||group-25/NN||-LSB--28/NNS	number||1.0-31/CD||0.2-29/CD	dep||1.0-31/CD||to-30/TO	num||g/kg-35/NN||1.0-31/CD	nn||g/kg-35/NN||-RSB--32/NN	nn||g/kg-35/NN||î-33/NN	num||g/kg-35/NN||1/4-34/CD	dep||-LSB--28/NNS||g/kg-35/NN	number||-LSB--38/CD||1.4-37/CD	num||0.6-39/CD||-LSB--38/CD	prep_versus||g/kg-35/NN||0.6-39/CD	dep||0.6-39/CD||to-40/TO	number||-RSB--42/CD||2.7-41/CD	num||g/kg-45/NN||-RSB--42/CD	nn||g/kg-45/NN||î-43/NNP	num||g/kg-45/NN||1/4-44/CD	dep||0.6-39/CD||g/kg-45/NN	amod||0.6-39/CD||p-47/JJ	dep||0.6-39/CD||<-48/NNP	num||<-48/NNP||0.01-49/CD	shock-13||norepinephrine-10||yes||the median (interquartile range) total amount of norepinephrine infused during shock was significantly lower in the fuzzy group than in the control group (0.6 [0.2 to 1.0] î¼g/kg versus 1.4 [0.6 to 2.7] î¼g/kg; p < 0.01).
nsubj||agent-20/NN||rapamycin-1/NN	appos||rapamycin-1/NN||rapa-3/NNP	det||inhibitor-7/NN||an-6/DT	appos||rapamycin-1/NN||inhibitor-7/NN	amod||target-10/NN||mammalian-9/JJ	prep_of||inhibitor-7/NN||target-10/NN	prep_of||target-10/NN||rapamycin-12/NN	appos||rapamycin-12/NN||mtor-14/NN	cop||agent-20/NN||is-17/VBZ	det||agent-20/NN||an-18/DT	amod||agent-20/NN||immunosuppressive-19/JJ	root||ROOT-0/null||agent-20/NN	nsubj||has-22/VBZ||agent-20/NN	rcmod||agent-20/NN||has-22/VBZ	amod||effects-24/NNS||anti-proliferative-23/JJ	dobj||has-22/VBZ||effects-24/NNS	det||tumors-27/NNS||some-26/DT	prep_on||effects-24/NNS||tumors-27/NNS	rapamycin-12||tumors-27||no_rel||rapamycin (rapa), an inhibitor of mammalian target of rapamycin (mtor), is an immunosuppressive agent that has anti-proliferative effects on some tumors.
amod||hepatitisbvirus-2/NNS||occult-1/JJ	nsubj||transmit-8/VB||hepatitisbvirus-2/NNS	appos||hepatitisbvirus-2/NNS||hbv-4/NN	advmod||transmit-8/VB||infection-6/RB	aux||transmit-8/VB||might-7/MD	root||ROOT-0/null||transmit-8/VB	amod||units-10/NNS||viremic-9/JJ	dobj||transmit-8/VB||units-10/NNS	det||supply-15/NN||the-12/DT	amod||supply-15/NN||public-13/JJ	nn||supply-15/NN||blood-14/NN	prep_into||transmit-8/VB||supply-15/NN	mark||used-26/VBN||if-16/IN	advmod||antigen-20/NN||only-17/RB	nn||antigen-20/NN||hepatitisb-18/NN	nn||antigen-20/NN||surface-19/NN	nsubjpass||used-26/VBN||antigen-20/NN	appos||antigen-20/NN||hbsag-22/NN	vmod||antigen-20/NN||testing-24/VBG	auxpass||used-26/VBN||is-25/VBZ	advcl||transmit-8/VB||used-26/VBN	nn||screening-29/NN||donor-28/NN	prep_for||used-26/VBN||screening-29/NN	hbv-4||hepatitisbvirus-2||no||occult hepatitisbvirus (hbv) infection might transmit viremic units into the public blood supply if only hepatitisb surface antigen (hbsag) testing is used for donor screening.
nsubj||continues-4/VBZ||background-1/NN	nsubj||commit-6/VB||background-1/NN	prep_as||background-1/NN||china-3/NN	ccomp||become-23/VBN||continues-4/VBZ	aux||commit-6/VB||to-5/TO	xcomp||continues-4/VBZ||commit-6/VB	amod||access-9/NN||universal-8/JJ	prep_to||commit-6/VB||access-9/NN	amod||services-17/NNS||hiv/aids-11/JJ	nn||services-17/NNS||prevention-12/NN	conj_and||prevention-12/NN||treatment-14/NN	nn||services-17/NNS||treatment-14/NN	conj_and||prevention-12/NN||care-16/NN	nn||services-17/NNS||care-16/NN	prep_to||commit-6/VB||services-17/NNS	poss||policies-21/NNS||its-19/PRP$	amod||policies-21/NNS||hiv/aids-20/JJ	nsubj||become-23/VBN||policies-21/NNS	aux||become-23/VBN||have-22/VBP	root||ROOT-0/null||become-23/VBN	advmod||information-25/NN||increasingly-24/RB	xcomp||become-23/VBN||information-25/NN	vmod||information-25/NN||driven-26/VBN	aids--1||hiv--1||no||background as china continues to commit to universal access to hiv/aids prevention, treatment and care services, its hiv/aids policies have become increasingly information driven.
nsubj||binding-6/VBD||redistribution-1/NN	nsubj||ubiquitinated-16/VBD||redistribution-1/NN	amod||dna-5/NN||nuclear-3/JJ	nn||dna-5/NN||tar-4/NN	prep_of||redistribution-1/NN||dna-5/NN	root||ROOT-0/null||binding-6/VBD	dobj||binding-6/VBD||protein-7/NN	advmod||binding-6/VBD||43-8/CD	dep||binding-6/VBD||tdp-43-10/JJ	det||cytoplasm-14/NN||the-13/DT	prep_to||binding-6/VBD||cytoplasm-14/NN	conj_and||binding-6/VBD||ubiquitinated-16/VBD	dobj||ubiquitinated-16/VBD||inclusions-17/NNS	amod||neurons-21/NNS||spinal-19/JJ	nn||neurons-21/NNS||motor-20/NN	prep_of||inclusions-17/NNS||neurons-21/NNS	amod||cells-24/NNS||glial-23/JJ	nsubj||characteristic-26/JJ||cells-24/NNS	cop||characteristic-26/JJ||is-25/VBZ	conj_and||binding-6/VBD||characteristic-26/JJ	prep_of||characteristic-26/JJ||amyotrophiclateralsclerosis-28/NNS	appos||amyotrophiclateralsclerosis-28/NNS||als-30/NN	advmod||characteristic-26/JJ||pathology-32/RB	amyotrophiclateralsclerosis-28||tar-4||no_rel||redistribution of nuclear tar dna binding protein 43 (tdp-43) to the cytoplasm and ubiquitinated inclusions of spinal motor neurons and glial cells is characteristic of amyotrophiclateralsclerosis (als) pathology.
amod||hctz-3/NN||aml/val-1/JJ	amod||hctz-3/NN||+-2/JJ	nsubj||provided-4/VBD||hctz-3/NN	root||ROOT-0/null||provided-4/VBD	advmod||greater-6/JJR||significantly-5/RB	amod||reductions-8/NNS||greater-6/JJR	nn||reductions-8/NNS||bp-7/NN	dobj||provided-4/VBD||reductions-8/NNS	nn||hctz-12/NN||aml-10/NN	nn||hctz-12/NN||+-11/NN	prep_than||provided-4/VBD||hctz-12/NN	prep_in||hctz-12/NN||patients-14/NNS	nn||hypertension-18/NN||stage-16/NN	num||hypertension-18/NN||2-17/CD	prep_with||provided-4/VBD||hypertension-18/NN	hypertension-18||hctz-12||yes||aml/val+hctz provided significantly greater bp reductions than aml+hctz in patients with stage 2 hypertension.
amod||studies-2/NNS||recent-1/JJ	nsubj||suggest-3/VBP||studies-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||plays-10/VBZ||that-4/IN	det||induction-6/NN||the-5/DT	nsubj||plays-10/VBZ||induction-6/NN	amod||expression-9/NN||ho-1-8/JJ	prep_of||induction-6/NN||expression-9/NN	ccomp||suggest-3/VBP||plays-10/VBZ	det||role-14/NN||a-11/DT	amod||role-14/NN||critical-12/JJ	amod||role-14/NN||protective-13/JJ	dobj||plays-10/VBZ||role-14/NN	amod||models-18/NNS||intestinal-16/JJ	nn||models-18/NNS||damage-17/NN	prep_in||plays-10/VBZ||models-18/NNS	vmod||models-18/NNS||induced-19/VBN	agent||induced-19/VBN||ischemia-reperfusion-21/NN	agent||induced-19/VBN||indomethacin-23/NN	conj_and||ischemia-reperfusion-21/NN||indomethacin-23/NN	amod||sepsis-26/NN||lipopolysaccharide-associated-25/JJ	agent||induced-19/VBN||sepsis-26/NN	conj_and||ischemia-reperfusion-21/NN||sepsis-26/NN	amod||acid-30/NN||trinitrobenzene-28/JJ	amod||acid-30/NN||sulfonic-29/JJ	agent||induced-19/VBN||acid-30/NN	conj_and||ischemia-reperfusion-21/NN||acid-30/NN	nn||sodium-35/NN||dextran-33/NN	nn||sodium-35/NN||sulfate-34/NN	agent||induced-19/VBN||sodium-35/NN	conj_and||ischemia-reperfusion-21/NN||sodium-35/NN	vmod||plays-10/VBZ||indicating-37/VBG	mark||act-43/VB||that-38/IN	nsubj||act-43/VB||activation-39/NN	nsubj||reduce-50/VB||activation-39/NN	prep_of||activation-39/NN||ho-1-41/CD	aux||act-43/VB||may-42/MD	ccomp||indicating-37/VBG||act-43/VB	det||mechanism-48/NN||an-45/DT	amod||mechanism-48/NN||endogenous-46/JJ	amod||mechanism-48/NN||defensive-47/JJ	prep_as||act-43/VB||mechanism-48/NN	aux||reduce-50/VB||to-49/TO	xcomp||act-43/VB||reduce-50/VB	nn||injury-54/NN||inflammation-51/NN	conj_and||inflammation-51/NN||tissue-53/NN	nn||injury-54/NN||tissue-53/NN	dobj||reduce-50/VB||injury-54/NN	det||tract-58/NN||the-56/DT	amod||tract-58/NN||gastrointestinal-57/JJ	prep_in||reduce-50/VB||tract-58/NN	inflammation-51||indomethacin-23||yes||recent studies suggest that the induction of ho-1 expression plays a critical protective role in intestinal damage models induced by ischemia-reperfusion, indomethacin, lipopolysaccharide-associated sepsis, trinitrobenzene sulfonic acid, and dextran sulfate sodium, indicating that activation of ho-1 may act as an endogenous defensive mechanism to reduce inflammation and tissue injury in the gastrointestinal tract.
nn||glucose-2/NN||plasma-1/NN	nsubjpass||measured-12/VBN||glucose-2/NN	nsubjpass||measured-12/VBN||glucose-2/NN	nsubjpass||measured-12/VBN||glucose-2/NN	conj_and||glucose-2/NN||insulin-4/NN	nsubjpass||measured-12/VBN||insulin-4/NN	conj_and||glucose-2/NN||c-peptide-6/NN	nsubjpass||measured-12/VBN||c-peptide-6/NN	nn||concentrations-10/NNS||glucagon-9/NN	conj_and||glucose-2/NN||concentrations-10/NNS	nsubjpass||measured-12/VBN||concentrations-10/NNS	auxpass||measured-12/VBN||were-11/VBD	root||ROOT-0/null||measured-12/VBN	conj_and||measured-12/VBN||measured-12/VBN	conj_and||measured-12/VBN||measured-12/VBN	det||min-15/NN||every-13/DT	num||min-15/NN||30-14/CD	dobj||measured-12/VBN||min-15/NN	amod||ingestion-42/NN||â-17/JJ	dep||â-17/JJ||60-18/CD	num||min-21/NN||180-20/CD	prep_through||â-17/JJ||min-21/NN	amod||administration-26/NN||random-sequence-23/JJ	amod||administration-26/NN||double-blind-25/JJ	prep_with||min-21/NN||administration-26/NN	prep_of||administration-26/NN||diazoxide-28/NN	num||mg/kg-31/NN||6.0-30/CD	appos||diazoxide-28/NN||mg/kg-31/NN	prep_of||administration-26/NN||placebo-34/NN	conj_or||diazoxide-28/NN||placebo-34/NN	amod||min-40/NN||â-36/JJ	dep||â-36/JJ||30-37/CD	dep||â-36/JJ||1-39/CD	conj_and||30-37/CD||1-39/CD	prep_at||placebo-34/NN||min-40/NN	prep_from||measured-12/VBN||ingestion-42/NN	det||meal-47/NN||a-44/DT	nn||meal-47/NN||formula-45/NN	amod||meal-47/NN||mixed-46/JJ	prep_of||ingestion-42/NN||meal-47/NN	parataxis||measured-12/VBN||ensure-49/VB	advmod||ensure-49/VB||plus-50/CC	prep_at||measured-12/VBN||0-53/CD	vmod||0-53/CD||min-54/VBN	prep_after||min-54/VBN||diazoxide-56/NN	prep_after||min-54/VBN||placebo-59/NN	conj_and||diazoxide-56/NN||placebo-59/NN	cc||measured-12/VBN||and-60/CC	det||occasion-65/NN||a-63/DT	amod||occasion-65/NN||separate-64/JJ	prep_on||measured-12/VBN||occasion-65/NN	npadvmod||measured-12/VBN||ingestion-67/NN	prep_of||ingestion-67/NN||glimepiride-69/NN	number||mg-72/CD||4.0-71/CD	dep||glimepiride-69/NN||mg-72/CD	num||min-76/NN||0-75/CD	prep_at||glimepiride-69/NN||min-76/NN	prep_with||glimepiride-69/NN||glucose-79/NN	vmod||glucose-79/NN||infused-80/VBN	aux||prevent-82/VB||to-81/TO	xcomp||infused-80/VBN||prevent-82/VB	dobj||prevent-82/VB||hypoglycemia-83/NN	prep_after||measured-12/VBN||diazoxide-86/NN	prep_after||measured-12/VBN||placebo-89/NN	num||adults-94/NNS||11-91/CD	amod||adults-94/NNS||healthy-92/JJ	amod||adults-94/NNS||young-93/JJ	prep_in||placebo-89/NN||adults-94/NNS	hypoglycemia-83||glucose-79||yes||plasma glucose, insulin, c-peptide, and glucagon concentrations were measured every 30 min from â60 through 180 min with random-sequence, double-blind administration of diazoxide (6.0 mg/kg) or placebo at â30 and 1 min, ingestion of a formula mixed meal (ensure plus) at 0 min after diazoxide and after placebo and, on a separate occasion, ingestion of glimepiride (4.0 mg) at 0 min (with glucose infused to prevent hypoglycemia) after diazoxide and after placebo in 11 healthy young adults.
nsubj||leads-8/VBZ||conclusions-1/NNS	prepc_compared_with||conclusions-1/NNS||with-3/IN	pobj||conclusions-1/NNS||insulinglargine-4/NN	nn||degludec-7/NN||insulin-6/NN	appos||insulinglargine-4/NN||degludec-7/NN	root||ROOT-0/null||leads-8/VBZ	prep_to||leads-8/VBZ||improvements-10/NNS	det||status-17/NN||both-12/DT	amod||status-17/NN||mental-13/JJ	conj_and||mental-13/JJ||physical-15/JJ	amod||status-17/NN||physical-15/JJ	nn||status-17/NN||health-16/NN	prep_in||improvements-10/NNS||status-17/NN	prep_for||status-17/NN||patients-19/NNS	amod||therapy-24/NN||type2diabetes-21/JJ	amod||therapy-24/NN||initiating-22/JJ	nn||therapy-24/NN||insulin-23/NN	prep_with||patients-19/NNS||therapy-24/NN	type2diabetes-21||insulinglargine-4||yes||conclusions compared with insulinglargine, insulin degludec leads to improvements in both mental and physical health status for patients with type2diabetes initiating insulin therapy.
nsubj||superior-3/JJ||entecavir-1/NN	nsubj||adefovir-5/VB||entecavir-1/NN	cop||superior-3/JJ||is-2/VBZ	root||ROOT-0/null||superior-3/JJ	aux||adefovir-5/VB||to-4/TO	xcomp||superior-3/JJ||adefovir-5/VB	amod||dna-10/NN||decreasing-7/VBG	nn||dna-10/NN||serum-8/NN	nn||dna-10/NN||hbv-9/NN	prep_in||adefovir-5/VB||dna-10/NN	amod||alt-13/NN||normalizing-12/VBG	prep_in||adefovir-5/VB||alt-13/NN	conj_and||dna-10/NN||alt-13/NN	amod||adefovir-38/NN||similar-15/JJ	prep_with||similar-15/JJ||adefovir-17/NN	prepc_in||adefovir-17/NN||clearing-19/VBG	vmod||clearing-19/VBG||hbeag-20/VBG	prepc_in||adefovir-17/NN||encouraging-22/VBG	conj_and||clearing-19/VBG||encouraging-22/VBG	amod||seroconversion-24/NN||hbeag-23/VBG	dobj||encouraging-22/VBG||seroconversion-24/NN	det||nucleos-28/NNS||the-26/DT	amod||nucleos-28/NNS||hbeag-positive-27/JJ	prep_for||seroconversion-24/NN||nucleos-28/NNS	amod||t-30/NN||-lrb--29/JJ	dep||encouraging-22/VBG||t-30/NN	dep||t-30/NN||-rrb--31/VBG	amod||patients-34/NNS||ide-naive-32/JJ	nn||patients-34/NNS||asian-33/NN	dobj||-rrb--31/VBG||patients-34/NNS	prep_with||-rrb--31/VBG||chronichepatitisb-36/NN	nsubjpass||used-42/VBN||adefovir-38/NN	aux||used-42/VBN||can-39/MD	auxpass||used-42/VBN||be-40/VB	advmod||used-42/VBN||still-41/RB	conj_but||superior-3/JJ||used-42/VBN	amod||therapy-45/NN||first-line-44/JJ	prep_for||used-42/VBN||therapy-45/NN	det||patients-48/NNS||these-47/DT	prep_in||therapy-45/NN||patients-48/NNS	hbv-9||adefovir-38||yes||entecavir is superior to adefovir in decreasing serum hbv dna and normalizing alt but similar with adefovir in clearing hbeag and encouraging hbeag seroconversion for the hbeag-positive nucleos -lrb- t -rrb- ide-naive asian patients with chronichepatitisb. adefovir can be still used for first-line therapy in these patients .
prepc_based_on||be-23/VB||on-2/IN	det||parameters-5/NNS||the-3/DT	amod||parameters-5/NNS||pharmacokinetic-4/JJ	pobj||be-23/VB||parameters-5/NNS	nsubj||obtained-7/VBD||we-6/PRP	rcmod||parameters-5/NNS||obtained-7/VBD	det||regimen-14/NN||an-9/DT	amod||regimen-14/NN||appropriate-10/JJ	amod||regimen-14/NN||intravenous-11/JJ	nn||regimen-14/NN||cefpirome-12/NN	nn||regimen-14/NN||dosage-13/NN	nsubj||be-23/VB||regimen-14/NN	prepc_for||regimen-14/NN||treating-16/VBG	amod||bacteria-18/NNS||cefpiromesensitive-17/JJ	dobj||treating-16/VBG||bacteria-18/NNS	amod||calves-21/NNS||buffalo-20/JJ	prep_in||treating-16/VBG||calves-21/NNS	aux||be-23/VB||would-22/MD	root||ROOT-0/null||be-23/VB	num||mg/kg-25/NN||8.0-24/CD	nsubj||repeated-26/VBD||mg/kg-25/NN	advcl||be-23/VB||repeated-26/VBD	num||intervals-30/NNS||12-28/CD	nn||intervals-30/NNS||h-29/NN	prep_at||repeated-26/VBD||intervals-30/NNS	num||days-33/NNS||5-32/CD	prep_for||repeated-26/VBD||days-33/NNS	mark||occurred-41/VBD||until-36/IN	nsubj||occurred-41/VBD||persistence-37/NN	det||bacterialinfection-40/NN||the-39/DT	prep_of||persistence-37/NN||bacterialinfection-40/NN	advcl||be-23/VB||occurred-41/VBD	conj_or||repeated-26/VBD||occurred-41/VBD	bacterialinfection-40||bacteria-18||no||based on the pharmacokinetic parameters we obtained, an appropriate intravenous cefpirome dosage regimen for treating cefpiromesensitive bacteria in buffalo calves would be 8.0 mg/kg repeated at 12 h intervals for 5 days, or until persistence of the bacterialinfection occurred.
det||mycobacteriumtuberculosiscomplex-2/NN||the-1/DT	nsubjpass||regarded-8/VBN||mycobacteriumtuberculosiscomplex-2/NN	appos||mycobacteriumtuberculosiscomplex-2/NN||mtc-4/NN	auxpass||regarded-8/VBN||was-6/VBD	advmod||regarded-8/VBN||initially-7/RB	root||ROOT-0/null||regarded-8/VBN	det||population-13/NN||a-10/DT	advmod||homogeneous-12/JJ||highly-11/RB	amod||population-13/NN||homogeneous-12/JJ	prep_as||regarded-8/VBN||population-13/NN	advmod||suggest-19/VBP||however-15/RB	amod||data-18/NNS||recent-17/JJ	nsubj||suggest-19/VBP||data-18/NNS	parataxis||regarded-8/VBN||suggest-19/VBP	det||agents-22/NNS||the-20/DT	amod||agents-22/NNS||causative-21/JJ	nsubj||genetically-27/JJ||agents-22/NNS	nsubj||diverse-30/JJ||agents-22/NNS	prep_of||agents-22/NNS||tuberculosis-24/NNP	cop||genetically-27/JJ||are-25/VBP	advmod||genetically-27/JJ||more-26/RBR	ccomp||suggest-19/VBP||genetically-27/JJ	advmod||diverse-30/JJ||functionally-29/RB	ccomp||suggest-19/VBP||diverse-30/JJ	conj_and||genetically-27/JJ||diverse-30/JJ	mark||appreciated-32/VBD||than-31/IN	advcl||genetically-27/JJ||appreciated-32/VBD	advmod||appreciated-32/VBD||previously-33/RB	tuberculosis-24||mycobacteriumtuberculosiscomplex-2||no||the mycobacteriumtuberculosiscomplex (mtc) was initially regarded as a highly homogeneous population; however, recent data suggest the causative agents of tuberculosis are more genetically and functionally diverse than appreciated previously.
nsubj||diagnosed-4/VBN||patients-1/NNS	nsubjpass||recruited-20/VBN||patients-1/NNS	nsubjpass||randomized-22/VBN||patients-1/NNS	nsubj||receive-24/VB||patients-1/NNS	aux||diagnosed-4/VBN||have-3/VBP	rcmod||patients-1/NNS||diagnosed-4/VBN	prep_with||diagnosed-4/VBN||rheumatoidarthritis-6/NNS	nn||college-10/NN||american-9/NN	prep_as_per||diagnosed-4/VBN||college-10/NN	advmod||aged-13/VBN||rheumatology-12/RB	amod||years-18/NNS||aged-13/VBN	prep_between||aged-13/VBN||18-15/CD	prep_between||aged-13/VBN||60-17/CD	conj_and||18-15/CD||60-17/CD	prep_of||college-10/NN||years-18/NNS	auxpass||recruited-20/VBN||were-19/VBD	root||ROOT-0/null||recruited-20/VBN	conj_and||recruited-20/VBN||randomized-22/VBN	aux||receive-24/VB||to-23/TO	xcomp||randomized-22/VBN||receive-24/VB	amod||-lrb--26/NNS||leflunomide-25/JJ	dobj||receive-24/VB||-lrb--26/NNS	num||-rrb--30/NNS||10-27/CD	amod||-rrb--30/NNS||mg/day-28/JJ	nn||-rrb--30/NNS||p.o.-29/NN	dep||-lrb--26/NNS||-rrb--30/NNS	det||combination-33/NN||a-32/DT	dobj||receive-24/VB||combination-33/NN	conj_or||-lrb--26/NNS||combination-33/NN	amod||p.o.-41/NN||methotrexate-35/JJ	conj_and||methotrexate-35/JJ||hydroxychloroquine-37/JJ	amod||p.o.-41/NN||hydroxychloroquine-37/JJ	amod||p.o.-41/NN||-lrb--38/JJ	num||p.o.-41/NN||7.5-39/CD	nn||p.o.-41/NN||mg/week-40/NN	prep_of||combination-33/NN||p.o.-41/NN	num||p.o.-45/NN||200-43/CD	amod||p.o.-45/NN||mg/day-44/JJ	prep_of||combination-33/NN||p.o.-45/NN	conj_and||p.o.-41/NN||p.o.-45/NN	advmod||-rrb--48/VBG||respectively-47/RB	vmod||recruited-20/VBN||-rrb--48/VBG	amod||supplementation-52/NN||folate-51/JJ	prep_along_with||-rrb--48/VBG||supplementation-52/NN	num||weeks-55/NNS||12-54/CD	prep_for||supplementation-52/NN||weeks-55/NNS	rheumatoidarthritis-6||hydroxychloroquine-37||yes||patients who have diagnosed with rheumatoidarthritis as per american college of rheumatology aged between 18 and 60 years were recruited and randomized to receive leflunomide -lrb- 10 mg/day p.o. -rrb- or a combination of methotrexate and hydroxychloroquine -lrb- 7.5 mg/week p.o. and 200 mg/day p.o. , respectively -rrb- along with folate supplementation for 12 weeks .
det||proportion-4/NN||a-1/DT	advmod||higher-3/JJR||much-2/RB	amod||proportion-4/NN||higher-3/JJR	nsubjpass||attributed-12/VBN||proportion-4/NN	prep_of||proportion-4/NN||variance-6/NN	nn||levels-9/NNS||mrna-8/NN	prep_in||variance-6/NN||levels-9/NNS	aux||attributed-12/VBN||may-10/MD	auxpass||attributed-12/VBN||be-11/VB	root||ROOT-0/null||attributed-12/VBN	amod||factors-15/NNS||non-genetic-14/JJ	prep_to||attributed-12/VBN||factors-15/NNS	amod||i.e.-21/NNP||intra-individual-17/JJ	nn||i.e.-21/NNP||varianceâ-18/NNP	nn||i.e.-21/NNP||$-19/NNP	dep||factors-15/NNS||i.e.-21/NNP	amod||noise-24/NN||biological-23/JJ	appos||i.e.-21/NNP||noise-24/NN	appos||i.e.-21/NNP||levels-26/NNS	det||virus-30/NN||the-28/DT	nn||virus-30/NN||ebv-29/NN	prep_of||levels-26/NNS||virus-30/NN	vmod||virus-30/NN||used-31/VBN	aux||transform-33/VB||to-32/TO	xcomp||used-31/VBN||transform-33/VB	det||cells-35/NNS||the-34/DT	dobj||transform-33/VB||cells-35/NNS	advmod||i.e.-21/NNP||atp-37/RB	dep||i.e.-21/NNP||levels-38/NNS	prep||attributed-12/VBN||than-40/IN	pcomp||than-40/IN||to-41/TO	amod||eqtls-43/NNS||detectable-42/JJ	pobj||to-41/TO||eqtls-43/NNS	atp-37||virus-30||no_rel||a much higher proportion of variance in mrna levels may be attributed to non-genetic factors (intra-individual varianceâi.e., biological noise, levels of the ebv virus used to transform the cells, atp levels) than to detectable eqtls.
nsubj||similar-6/JJ||risk-1/NN	amod||pancreatitis-4/NNS||acute-3/JJ	prep_of||risk-1/NN||pancreatitis-4/NNS	cop||similar-6/JJ||was-5/VBD	root||ROOT-0/null||similar-6/JJ	det||exenatide-9/NN||the-8/DT	prep_in||similar-6/JJ||exenatide-9/NN	prep||exenatide-9/NN||versus-10/FW	amod||group-13/NN||diabetic-11/JJ	nn||group-13/NN||control-12/NN	pobj||versus-10/FW||group-13/NN	num||-LSB--16/NNS||0.9-15/CD	dep||exenatide-9/NN||-LSB--16/NNS	num||â-18/NN||0.6-17/CD	dep||-LSB--16/NNS||â-18/NN	num||-RSB--22/NNS||$-19/$	num||$-19/$||1.5-21/CD	dep||â-18/NN||-RSB--22/NNS	prep_in||similar-6/JJ||sitagliptin-25/NNS	conj_and||exenatide-9/NN||sitagliptin-25/NNS	prep||sitagliptin-25/NNS||versus-26/FW	amod||group-29/NN||diabetic-27/JJ	nn||group-29/NN||control-28/NN	pobj||versus-26/FW||group-29/NN	num||-LSB--32/NNS||1.0-31/CD	dep||exenatide-9/NN||-LSB--32/NNS	num||â-34/NN||0.7-33/CD	dep||-LSB--32/NNS||â-34/NN	num||-RSB--38/NNS||$-35/$	num||$-35/$||1.3-37/CD	dep||â-34/NN||-RSB--38/NNS	pancreatitis-4||sitagliptin-25||no_rel||risk of acute pancreatitis was similar in the exenatide versus diabetic control group (0.9 [0.6â1.5]) and sitagliptin versus diabetic control group (1.0 [0.7â1.3]).
det||ability-2/NN||the-1/DT	nsubj||important-10/JJ||ability-2/NN	aux||give-4/VB||to-3/TO	vmod||ability-2/NN||give-4/VB	amod||doses-6/NNS||high-5/JJ	dobj||give-4/VB||doses-6/NNS	prep_of||doses-6/NNS||iron-8/NN	cop||important-10/JJ||is-9/VBZ	root||ROOT-0/null||important-10/JJ	det||context-13/NN||the-12/DT	prep_in||important-10/JJ||context-13/NN	amod||irondeficiencyanemia-16/NN||managing-15/VBG	prep_of||context-13/NN||irondeficiencyanemia-16/NN	det||number-19/NN||a-18/DT	prep_in||irondeficiencyanemia-16/NN||number-19/NN	amod||conditions-22/NNS||clinical-21/JJ	prep_of||number-19/NN||conditions-22/NNS	advmod||high-28/JJ||where-23/WRB	nsubj||high-28/JJ||demands-24/NNS	prep_for||demands-24/NNS||iron-26/NN	cop||high-28/JJ||are-27/VBP	rcmod||irondeficiencyanemia-16/NN||high-28/JJ	dep||important-10/JJ||including-30/VBG	amod||bloodloss-32/NNS||chronic-31/JJ	pobj||including-30/VBG||bloodloss-32/NNS	vmod||bloodloss-32/NNS||associated-33/VBN	nn||menorrhagia-37/NN||inflammatoryboweldisease-35/NN	prep_with||associated-33/VBN||menorrhagia-37/NN	nn||kidneydisease-41/NN||chronic-40/NN	prep_with||associated-33/VBN||kidneydisease-41/NN	conj_and||menorrhagia-37/NN||kidneydisease-41/NN	irondeficiencyanemia-16||iron-26||yes||the ability to give high doses of iron is important in the context of managing irondeficiencyanemia in a number of clinical conditions where demands for iron are high (including chronic bloodloss associated with inflammatoryboweldisease, menorrhagia, and chronic kidneydisease).
mwe||than-2/IN||more-1/JJR	quantmod||50-3/CD||than-2/IN	num||%-4/NN||50-3/CD	nsubj||ribavirin-25/VBZ||%-4/NN	amod||viruses-7/NNS||hepatitisc-6/JJ	prep_of||%-4/NN||viruses-7/NNS	appos||viruses-7/NNS||hcv-9/NN	amod||patients-13/NNS||infected-12/JJ	nsubj||respond-16/VB||patients-13/NNS	aux||respond-16/VB||do-14/VBP	neg||respond-16/VB||not-15/RB	parataxis||ribavirin-25/VBZ||respond-16/VB	det||interferon-20/NN||the-18/DT	amod||interferon-20/NN||classical-19/JJ	prep_to||respond-16/VB||interferon-20/NN	appos||interferon-20/NN||ifn-22/NN	punct||respond-16/VB||/-24/:	root||ROOT-0/null||ribavirin-25/VBZ	dep||ribavirin-25/VBZ||rbv-27/NN	nn||therapy-30/NN||combination-29/NN	dobj||ribavirin-25/VBZ||therapy-30/NN	hepatitisc-6||hcv-9||no||more than 50% of hepatitisc viruses (hcv)-infected patients do not respond to the classical interferon (ifn)/ribavirin (rbv) combination therapy.
det||group-4/NN||the-2/DT	amod||group-4/NN||met-anov-3/JJ	prep_in||observed-10/VBN||group-4/NN	neg||correlation-8/NN||no-6/DT	amod||correlation-8/NN||significant-7/JJ	nsubjpass||observed-10/VBN||correlation-8/NN	auxpass||observed-10/VBN||was-9/VBD	root||ROOT-0/null||observed-10/VBN	nn||concentrations-13/NNS||amh-12/NN	prep_between||observed-10/VBN||concentrations-13/NNS	det||fluid-17/NN||the-15/DT	nn||fluid-17/NN||follicular-16/NN	prep_in||concentrations-13/NNS||fluid-17/NN	prep_in||concentrations-13/NNS||variation-19/NN	conj_and||fluid-17/NN||variation-19/NN	nn||androgens-22/NNS||serum-21/NN	prep_in||fluid-17/NN||androgens-22/NNS	amod||indexes-27/NNS||amh-24/JJ	conj_and||amh-24/JJ||insulinresistance-26/JJ	amod||indexes-27/NNS||insulinresistance-26/JJ	appos||fluid-17/NN||indexes-27/NNS	mark||detected-36/VBN||whereas-29/IN	amod||group-32/NN||met-ov-31/JJ	prep_in||detected-36/VBN||group-32/NN	amod||correlations-34/NNS||significant-33/JJ	nsubjpass||detected-36/VBN||correlations-34/NNS	auxpass||detected-36/VBN||were-35/VBD	advcl||observed-10/VBN||detected-36/VBN	nn||levels-39/NNS||amh-38/NN	prep_between||detected-36/VBN||levels-39/NNS	det||fluid-43/NN||the-41/DT	nn||fluid-43/NN||follicular-42/NN	prep_in||levels-39/NNS||fluid-43/NN	prep_in||levels-39/NNS||variation-45/NN	conj_and||fluid-43/NN||variation-45/NN	amod||indexes-53/NNS||serum-47/JJ	nn||indexes-53/NNS||androgens-48/NNS	conj_and||androgens-48/NNS||amh-50/NN	nn||indexes-53/NNS||amh-50/NN	conj_and||androgens-48/NNS||insulinresistance-52/NN	nn||indexes-53/NNS||insulinresistance-52/NN	prep_in||fluid-43/NN||indexes-53/NNS	androgens-48||insulinresistance-52||no_rel||in the met-anov group, no significant correlation was observed between amh concentrations in the follicular fluid and variation in serum androgens, amh and insulinresistance indexes; whereas in met-ov group significant correlations were detected between amh levels in the follicular fluid and variation in serum androgens, amh and insulinresistance indexes.
amod||conjugates-4/NNS||vivo-2/JJ	nn||conjugates-4/NNS||antibody-3/NN	prep_in||caused-5/VBD||conjugates-4/NNS	root||ROOT-0/null||caused-5/VBD	dobj||caused-5/VBD||suppression-6/NN	amod||growth-11/NN||human-8/JJ	nn||growth-11/NN||lovo-9/NN	nn||growth-11/NN||tumour-10/NN	prep_of||suppression-6/NN||growth-11/NN	amod||nih-14/NN||immunodeficient-13/JJ	prep_in||caused-5/VBD||nih-14/NN	nn||mice-16/NNS||iii-15/NN	nsubj||caused-5/VBD||mice-16/NNS	amod||doses-35/NNS||similar-18/JJ	det||therapy-23/NN||the-20/DT	amod||therapy-23/NN||commercial-21/JJ	amod||therapy-23/NN||photodynamic-22/JJ	prep_to||similar-18/JJ||therapy-23/NN	appos||therapy-23/NN||pdt-25/NN	nn||doses-35/NNS||agent-27/NN	amod||doses-35/NNS||photofrinâ-28/JJ	amod||doses-35/NNS||®-29/JJ	conj_but||®-29/JJ||at-32/IN	amod||doses-35/NNS||at-32/IN	amod||doses-35/NNS||administered-33/JJ	nn||doses-35/NNS||photosensitizer-34/NN	appos||mice-16/NNS||doses-35/NNS	nsubj||lower-44/JJR||doses-35/NNS	cop||lower-44/JJR||were-37/VBD	mwe||than-39/IN||more-38/JJR	quantmod||two-40/CD||than-39/IN	num||orders-41/NNS||two-40/CD	npadvmod||lower-44/JJR||orders-41/NNS	prep_of||orders-41/NNS||magnitude-43/NN	rcmod||doses-35/NNS||lower-44/JJR	antibody-3||tumour-10||no_rel||in vivo antibody conjugates caused suppression of human lovo tumour growth in immunodeficient nih iii mice, similar to the commercial photodynamic therapy (pdt) agent photofrinâ®, but at administered photosensitizer doses that were more than two orders of magnitude lower.
amod||viruses-3/NNS||many-1/JJ	amod||viruses-3/NNS||enveloped-2/JJ	nsubj||invade-4/VBP||viruses-3/NNS	nsubj||use-9/VBP||viruses-3/NNS	root||ROOT-0/null||invade-4/VBP	dobj||invade-4/VBP||cells-5/NNS	prep_via||cells-5/NNS||endocytosis-7/NNS	conj_and||invade-4/VBP||use-9/VBP	amod||factors-12/NNS||different-10/JJ	amod||factors-12/NNS||environmental-11/JJ	dobj||use-9/VBP||factors-12/NNS	mark||triggers-14/VBZ||as-13/IN	advcl||use-9/VBP||triggers-14/VBZ	amod||fusion-17/NN||virus-endosome-16/JJ	prep_for||triggers-14/VBZ||fusion-17/NN	nsubj||delivers-19/VBZ||fusion-17/NN	rcmod||fusion-17/NN||delivers-19/VBZ	amod||genome-21/NN||viral-20/JJ	dobj||delivers-19/VBZ||genome-21/NN	prep_into||delivers-19/VBZ||cytosol-23/NN	virus--1||viruses-3||no||many enveloped viruses invade cells via endocytosis and use different environmental factors as triggers for virus-endosome fusion that delivers viral genome into cytosol.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||review-8/VB||aim-2/NN	det||research-5/NN||this-4/DT	prep_of||aim-2/NN||research-5/NN	root||ROOT-0/null||was-6/VBD	aux||review-8/VB||to-7/TO	xcomp||was-6/VBD||review-8/VB	det||evidence-10/NN||the-9/DT	dobj||review-8/VB||evidence-10/NN	det||use-13/NN||the-12/DT	prep_for||review-8/VB||use-13/NN	amod||malignantmelanoma-19/NN||pegylatedinterferonalpha-2b-15/JJ	nn||iii-18/NN||stage-17/NN	prep_in||pegylatedinterferonalpha-2b-15/JJ||iii-18/NN	prep_of||use-13/NN||malignantmelanoma-19/NN	malignantmelanoma-19||pegylatedinterferonalpha-2b-15||yes||the aim of this research was to review the evidence for the use of pegylatedinterferonalpha-2b in stage iii malignantmelanoma.
num||cycles-3/NNS||twelve-2/CD	prep_after||revealed-11/VBD||cycles-3/NNS	amod||chemotherapy-6/NN||oxaliplatin-capecitabine-5/JJ	prep_of||cycles-3/NNS||chemotherapy-6/NN	amod||tomography-10/NN||abdominopelvic-8/JJ	amod||tomography-10/NN||computed-9/JJ	nsubj||revealed-11/VBD||tomography-10/NN	root||ROOT-0/null||revealed-11/VBD	amod||shrinkage-13/NN||marked-12/JJ	nsubj||showed-22/VBD||shrinkage-13/NN	det||metastases-17/NNS||the-15/DT	nn||metastases-17/NNS||liver-16/NN	prep_of||shrinkage-13/NN||metastases-17/NNS	nn||tomography-21/NN||positron-19/NN	nn||tomography-21/NN||emission-20/NN	prep_of||shrinkage-13/NN||tomography-21/NN	conj_and||metastases-17/NNS||tomography-21/NN	ccomp||revealed-11/VBD||showed-22/VBD	neg||uptake-24/NN||no-23/DT	dobj||showed-22/VBD||uptake-24/NN	amod||fdg-28/NN||18f-fluoro-deoxy-glucose-26/JJ	prep_of||uptake-24/NN||fdg-28/NN	advmod||fdg-28/NN||either-30/RB	det||liver-33/NN||the-32/DT	prep_in||showed-22/VBD||liver-33/NN	prep_in||showed-22/VBD||peritoneum-35/NN	conj_or||liver-33/NN||peritoneum-35/NN	amod||uptake-38/NN||localized-37/VBN	prep_except||liver-33/NN||uptake-38/NN	det||colon-42/NN||the-40/DT	amod||colon-42/NN||sigmoid-41/JJ	prep_in||uptake-38/NN||colon-42/NN	metastases-17||glucose--1||no_rel||after twelve cycles of oxaliplatin-capecitabine chemotherapy, abdominopelvic computed tomography revealed marked shrinkage of the liver metastases and positron emission tomography showed no uptake of 18f-fluoro-deoxy-glucose (fdg) either in the liver or peritoneum except localized uptake in the sigmoid colon.
poss||experiments-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||experiments-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||protect-7/VB||that-4/IN	nsubj||protect-7/VB||uti-5/NN	aux||protect-7/VB||can-6/MD	ccomp||suggest-3/VBP||protect-7/VB	amod||response-11/NN||systemic-9/JJ	amod||response-11/NN||inflammatory-10/JJ	prep_against||protect-7/VB||response-11/NN	amod||injury-15/NN||subsequent-13/JJ	nn||injury-15/NN||organ-14/NN	prep_against||protect-7/VB||injury-15/NN	conj_and||response-11/NN||injury-15/NN	vmod||injury-15/NN||induced-16/VBN	agent||induced-16/VBN||bacterialendotoxin-18/NN	advmod||bacterialendotoxin-18/NN||at-20/IN	pobj||at-20/IN||least-21/JJS	advmod||protect-7/VB||partly-22/RB	det||inhibition-26/NN||the-25/DT	prep_through||protect-7/VB||inhibition-26/NN	advmod||cytokine-29/JJ||proinflammatory-28/RB	amod||expression-32/NN||cytokine-29/JJ	conj_and||cytokine-29/JJ||chemokine-31/JJ	amod||expression-32/NN||chemokine-31/JJ	prep_of||inhibition-26/NN||expression-32/NN	uti-5||bacterialendotoxin-18||no_rel||our experiments suggest that uti can protect against systemic inflammatory response and subsequent organ injury induced by bacterialendotoxin, at least partly, through the inhibition of proinflammatory cytokine and chemokine expression.
nn||mulilo-2/NN||katima-1/NN	nsubj||has-3/VBZ||mulilo-2/NN	root||ROOT-0/null||has-3/VBZ	det||burden-6/NN||the-4/DT	amod||burden-6/NN||highest-5/JJS	dobj||has-3/VBZ||burden-6/NN	prep_of||burden-6/NN||hiv/aids-8/NNS	prep_in||hiv/aids-8/NNS||namibia-10/NN	aids--1||hiv--1||no||katima mulilo has the highest burden of hiv/aids in namibia.
aux||treat-2/VB||to-1/TO	ccomp||tested-29/VBD||treat-2/VB	dobj||treat-2/VB||hypogonadism-3/NN	aux||evaluate-6/VB||to-5/TO	conj_and||treat-2/VB||evaluate-6/VB	ccomp||tested-29/VBD||evaluate-6/VB	det||changes-14/NNS||the-7/DT	amod||changes-14/NNS||consequent-8/JJ	amod||changes-14/NNS||endocrine-9/JJ	conj_and||endocrine-9/JJ||physical-11/JJ	amod||changes-14/NNS||physical-11/JJ	conj_and||endocrine-9/JJ||psychological-13/JJ	amod||changes-14/NNS||psychological-13/JJ	dobj||evaluate-6/VB||changes-14/NNS	amod||patients-19/NNS||male-16/JJ	amod||patients-19/NNS||chronic-17/JJ	nn||patients-19/NNS||pain-18/NN	prep_in||evaluate-6/VB||patients-19/NNS	vmod||patients-19/NNS||treated-20/VBN	prep_with||treated-20/VBN||morphine-22/NN	amod||route-25/NN||epidural-24/JJ	appos||morphine-22/NN||route-25/NN	nsubj||tested-29/VBD||we-28/PRP	root||ROOT-0/null||tested-29/VBD	det||administration-31/NN||the-30/DT	dobj||tested-29/VBD||administration-31/NN	prep_of||administration-31/NN||testosterone-33/NN	det||formulation-37/NN||a-35/DT	nn||formulation-37/NN||gel-36/NN	prep_via||testosterone-33/NN||formulation-37/NN	prep_for||tested-29/VBD||one-39/CD	tmod||tested-29/VBD||year-40/NN	hypogonadism-3||testosterone-33||yes||to treat hypogonadism and to evaluate the consequent endocrine, physical and psychological changes in male chronic pain patients treated with morphine (epidural route), we tested the administration of testosterone via a gel formulation for one year.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	det||efficacy-4/NN||the-3/DT	dobj||assess-2/VB||efficacy-4/NN	dobj||assess-2/VB||tolerability-6/NN	conj_and||efficacy-4/NN||tolerability-6/NN	prep_of||efficacy-4/NN||lacosamide-8/NN	prep_in||assess-2/VB||children-10/NNS	amod||epilepsy-13/NN||refractory-12/JJ	prep_with||children-10/NNS||epilepsy-13/NN	epilepsy-13||lacosamide-8||yes||to assess the efficacy and tolerability of lacosamide in children with refractory epilepsy.
det||data-2/NNS||these-1/DT	nsubj||provide-3/VBP||data-2/NNS	root||ROOT-0/null||provide-3/VBP	amod||evidence-5/NN||further-4/JJ	dobj||provide-3/VBP||evidence-5/NN	amod||rsvinfection-8/NN||serious-7/JJ	prep_of||evidence-5/NN||rsvinfection-8/NN	prep_in||provide-3/VBP||children-10/NNS	det||federation-14/NN||the-12/DT	nn||federation-14/NN||russian-13/NN	prep_in||children-10/NNS||federation-14/NN	prep_in||provide-3/VBP||guidance-19/NN	conj_and||children-10/NNS||guidance-19/NN	prep_for||guidance-19/NN||timing-21/NN	amod||prophylaxis-25/NNS||seasonal-23/JJ	nn||prophylaxis-25/NNS||rsv-24/NN	prep_of||timing-21/NN||prophylaxis-25/NNS	dep||provide-3/VBP||especially-27/RB	prep_among||provide-3/VBP||individuals-29/NNS	amod||risk-32/NN||high-31/JJ	prep_at||individuals-29/NNS||risk-32/NN	amod||rsvinfection-35/NN||serious-34/JJ	prep_for||risk-32/NN||rsvinfection-35/NN	rsvinfection-35||rsv-24||no||these data provide further evidence of serious rsvinfection in children in the russian federation, as well as guidance for timing of seasonal rsv prophylaxis, especially among individuals at high risk for serious rsvinfection.
nsubj||observed-2/VBD||we-1/PRP	root||ROOT-0/null||observed-2/VBD	neg||modification-5/NN||no-3/DT	nn||modification-5/NN||effect-4/NN	dobj||observed-2/VBD||modification-5/NN	prep_by||observed-2/VBD||snp-7/NN	prep_for||snp-7/NN||association-9/NN	prep_with||association-9/NN||age-11/NN	prep_at||observed-2/VBD||diagnosis-13/NN	nn||history-16/NN||family-15/NN	appos||diagnosis-13/NN||history-16/NN	nn||cancer-19/NN||prostate-18/NN	prep_of||history-16/NN||cancer-19/NN	nn||intake-30/NN||diabetes-21/NN	conj_or||diabetes-21/NN||bmi-23/NN	nn||intake-30/NN||bmi-23/NN	conj_or||diabetes-21/NN||height-25/NN	nn||intake-30/NN||height-25/NN	conj_or||diabetes-21/NN||smoking-27/NN	nn||intake-30/NN||smoking-27/NN	conj_or||diabetes-21/NN||alcohol-29/NN	nn||intake-30/NN||alcohol-29/NN	appos||cancer-19/NN||intake-30/NN	alcohol-29||cancer-19||no_rel||we observed no effect modification by snp for association with age at diagnosis, family history of prostate cancer, diabetes, bmi, height, smoking or alcohol intake.
det||mixture-5/NN||the-1/DT	amod||mixture-5/NN||lidocaine-2/JJ	conj_and||lidocaine-2/JJ||propofol-4/JJ	amod||mixture-5/NN||propofol-4/JJ	nsubj||effective-7/JJ||mixture-5/NN	cop||effective-7/JJ||is-6/VBZ	root||ROOT-0/null||effective-7/JJ	prepc_in||effective-7/JJ||alleviating-9/VBG	dobj||alleviating-9/VBG||pain-10/NN	vmod||pain-10/NN||associated-11/VBN	amod||injection-15/NN||microemulsion-13/JJ	amod||injection-15/NN||propofol-14/JJ	prep_with||associated-11/VBN||injection-15/NN	pain-10||propofol-14||yes||the lidocaine and propofol mixture is effective in alleviating pain associated with microemulsion propofol injection.
nsubjpass||diagnosed-4/VBN||calciphylaxis-1/NNS	aux||diagnosed-4/VBN||has-2/VBZ	auxpass||diagnosed-4/VBN||been-3/VBN	root||ROOT-0/null||diagnosed-4/VBN	prepc_after||diagnosed-4/VBN||receiving-6/VBG	dobj||receiving-6/VBG||anticoagulation-7/NN	prep_with||receiving-6/VBG||phenprocoumon-9/NN	det||event-13/NN||a-11/DT	amod||event-13/NN||single-12/JJ	prep_after||receiving-6/VBG||event-13/NN	prep_of||event-13/NN||pulmonaryembolism-15/NN	pulmonaryembolism-15||phenprocoumon-9||yes||calciphylaxis has been diagnosed after receiving anticoagulation with phenprocoumon after a single event of pulmonaryembolism.
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	det||case-6/NN||the-3/DT	amod||case-6/NN||first-4/JJ	amod||case-6/NN||known-5/JJ	dobj||present-2/VBP||case-6/NN	det||patient-9/NN||a-8/DT	prep_of||case-6/NN||patient-9/NN	amod||squamouscellcarcinoma-12/NN||cervical-11/JJ	prep_with||present-2/VBP||squamouscellcarcinoma-12/NN	vmod||squamouscellcarcinoma-12/NN||complicated-13/VBN	agent||complicated-13/VBN||paraneoplasticsyndromes-15/NNS	det||secretion-21/NN||both-17/DT	amod||secretion-21/NN||dermatomyositis-18/JJ	conj_and||dermatomyositis-18/JJ||inappropriate-20/JJ	amod||secretion-21/NN||inappropriate-20/JJ	prep_of||paraneoplasticsyndromes-15/NNS||secretion-21/NN	amod||hormone-24/NN||antidiuretic-23/JJ	prep_of||secretion-21/NN||hormone-24/NN	appos||hormone-24/NN||siadh-26/NN	paraneoplasticsyndromes-15||hormone-24||no_rel||we present the first known case of a patient with cervical squamouscellcarcinoma complicated by paraneoplasticsyndromes of both dermatomyositis and inappropriate secretion of antidiuretic hormone (siadh).
det||nature-6/NN||the-1/DT	amod||nature-6/NN||strong-2/JJ	amod||nature-6/NN||invasive-3/JJ	conj_and||invasive-3/JJ||metastatic-5/JJ	amod||nature-6/NN||metastatic-5/JJ	nsubj||implies-9/VBZ||nature-6/NN	prep_of||nature-6/NN||cutaneousmelanoma-8/NN	root||ROOT-0/null||implies-9/VBZ	det||interplay-12/NN||a-10/DT	amod||interplay-12/NN||deregulated-11/VBN	dobj||implies-9/VBZ||interplay-12/NN	nn||adhesion-15/NN||intercellular-14/NN	prep_between||interplay-12/NN||adhesion-15/NN	amod||molecules-18/NNS||migration-related-17/JJ	dobj||implies-9/VBZ||molecules-18/NNS	conj_and||interplay-12/NN||molecules-18/NNS	det||study-21/NN||this-20/DT	prep_in||molecules-18/NNS||study-21/NN	nsubj||performed-23/VBD||we-22/PRP	rcmod||study-21/NN||performed-23/VBD	det||analysis-26/NN||a-24/DT	amod||analysis-26/NN||microarray-25/JJ	dobj||performed-23/VBD||analysis-26/NN	aux||compare-28/VB||to-27/TO	vmod||performed-23/VBD||compare-28/VB	det||profile-32/NN||the-29/DT	nn||profile-32/NN||mrna-30/NN	nn||profile-32/NN||expression-31/NN	dobj||compare-28/VB||profile-32/NN	det||line-39/NN||an-34/DT	amod||line-39/NN||invasive-35/JJ	nn||line-39/NN||blm-36/NN	nn||line-39/NN||melanoma-37/NN	nn||line-39/NN||cell-38/NN	prep_of||profile-32/NN||line-39/NN	nn||lie-42/NN||blm-41/NN	appos||line-39/NN||lie-42/NN	det||variant-49/NN||the-45/DT	amod||p-cadherin-47/JJ||non-invasive-46/JJ	amod||variant-49/NN||p-cadherin-47/JJ	amod||variant-49/NN||over-expression-48/JJ	prep_of||profile-32/NN||variant-49/NN	conj_and||line-39/NN||variant-49/NN	nn||p-cad-52/NN||blm-51/NN	appos||variant-49/NN||p-cad-52/NN	cutaneousmelanoma-8||blm-51||yes||the strong invasive and metastatic nature of cutaneousmelanoma implies a deregulated interplay between intercellular adhesion and migration-related molecules in this study we performed a microarray analysis to compare the mrna expression profile of an invasive blm melanoma cell line (blm lie) and the non-invasive p-cadherin over-expression variant (blm p-cad).
nsubjpass||studied-14/VBN||modafinil-1/NN	det||agent-5/NN||a-3/DT	amod||agent-5/NN||wakefulness-promoting-4/JJ	appos||modafinil-1/NN||agent-5/NN	amod||agent-5/NN||unrelated-6/JJ	amod||stimulants-10/NNS||classical-8/JJ	amod||stimulants-10/NNS||sympathomimetic-9/JJ	prep_to||unrelated-6/JJ||stimulants-10/NNS	aux||studied-14/VBN||has-12/VBZ	auxpass||studied-14/VBN||been-13/VBN	root||ROOT-0/null||studied-14/VBN	det||total-17/NN||a-16/DT	prep_in||studied-14/VBN||total-17/NN	num||children-20/NNS||933-19/CD	prep_of||total-17/NN||children-20/NNS	prep_of||total-17/NN||adolescents-22/NNS	conj_and||children-20/NNS||adolescents-22/NNS	det||treatment-25/NN||a-24/DT	prep_as||studied-14/VBN||treatment-25/NN	prep_for||treatment-25/NN||attention-deficit/hyperactivitydisorder-27/NN	dep||treatment-25/NN||adhd-29/VBN	hyperactivitydisorder--1||modafinil-1||yes||modafinil, a wakefulness-promoting agent unrelated to classical sympathomimetic stimulants, has been studied in a total of 933 children and adolescents as a treatment for attention-deficit/hyperactivitydisorder (adhd).
nsubj||had-11/VBD||patients-1/NNS	vmod||patients-1/NNS||using-2/VBG	amod||n-7/NN||insulinglargine-3/JJ	conj_or||insulinglargine-3/JJ||detemir-5/JJ	amod||n-7/NN||detemir-5/JJ	amod||n-7/NN||-lrb--6/JJ	dobj||using-2/VBG||n-7/NN	dep||-rrb--10/NNS||=-8/SYM	num||-rrb--10/NNS||5,317-9/CD	dep||using-2/VBG||-rrb--10/NNS	ccomp||±-27/VBZ||had-11/VBD	det||incidence-15/NN||a-12/DT	amod||incidence-15/NN||higher-13/JJR	nn||incidence-15/NN||dka-14/NN	dobj||had-11/VBD||incidence-15/NN	mark||5,365-23/CD||than-16/IN	nsubj||5,365-23/CD||individuals-17/NNS	vmod||individuals-17/NNS||using-18/VBG	amod||n-21/NN||nphinsulin-19/JJ	amod||n-21/NN||-lrb--20/JJ	dobj||using-18/VBG||n-21/NN	dep||5,365-23/CD||=-22/SYM	advcl||had-11/VBD||5,365-23/CD	num||â-26/NN||6.6-25/CD	nsubj||±-27/VBZ||â-26/NN	root||ROOT-0/null||±-27/VBZ	dobj||±-27/VBZ||0.4-28/CD	num||-rrb--38/NNS||3.6-30/CD	nn||-rrb--38/NNS||â-31/NNP	nn||-rrb--38/NNS||±-32/NNP	num||-rrb--38/NNS||0.3-33/CD	dep||-rrb--38/NNS||p-35/NNP	nn||-rrb--38/NNS||<-36/NNP	num||-rrb--38/NNS||0.001-37/CD	prep_vs.||0.4-28/CD||-rrb--38/NNS	nphinsulin-19||dka-14||no_rel||patients using insulinglargine or detemir -lrb- n = 5,317 -rrb- had a higher dka incidence than individuals using nphinsulin -lrb- n = 5,365 , 6.6 â ± 0.4 vs. 3.6 â ± 0.3 , p < 0.001 -rrb- .
root||ROOT-0/null||objective-1/NN	aux||assess-3/VB||to-2/TO	dep||objective-1/NN||assess-3/VB	det||risk-5/NN||the-4/DT	dobj||assess-3/VB||risk-5/NN	amod||suicide-8/NN||attempted-7/VBN	prep_of||risk-5/NN||suicide-8/NN	prep||assess-3/VB||before-9/IN	prep||assess-3/VB||during-11/IN	conj_and||before-9/IN||during-11/IN	prep||assess-3/VB||after-14/IN	conj_and||before-9/IN||after-14/IN	pobj||after-14/IN||treatment-15/NN	prep_with||assess-3/VB||isotretinoin-17/NN	amod||acne-20/NN||severe-19/JJ	prep_for||isotretinoin-17/NN||acne-20/NN	acne-20||isotretinoin-17||yes||objective to assess the risk of attempted suicide before, during, and after treatment with isotretinoin for severe acne.
poss||effect-6/NN||its-4/PRP$	amod||effect-6/NN||well-established-5/JJ	prep_in_addition_to||prove-13/VB||effect-6/NN	amod||bone-9/NN||subchondral-8/JJ	prep_on||effect-6/NN||bone-9/NN	nsubj||prove-13/VB||calcitonin-11/NN	aux||prove-13/VB||may-12/MD	root||ROOT-0/null||prove-13/VB	acomp||prove-13/VB||beneficial-14/JJ	det||management-17/NN||the-16/DT	prep_to||beneficial-14/JJ||management-17/NN	prep_of||management-17/NN||jointdiseases-19/NNS	amod||effects-22/NNS||direct-21/JJ	prep_through||prove-13/VB||effects-22/NNS	prep_on||effects-22/NNS||chondrocytes-24/NNS	jointdiseases-19||calcitonin-11||no_rel||in addition to its well-established effect on subchondral bone, calcitonin may prove beneficial to the management of jointdiseases through direct effects on chondrocytes.
amod||detection-2/NN||prompt-1/JJ	nsubj||essential-8/JJ||detection-2/NN	amod||resistance-6/NN||mycobacteriumtuberculosis-4/JJ	nn||resistance-6/NN||drug-5/NN	prep_of||detection-2/NN||resistance-6/NN	cop||essential-8/JJ||is-7/VBZ	root||ROOT-0/null||essential-8/JJ	amod||control-11/NN||effective-10/JJ	prep_for||essential-8/JJ||control-11/NN	prep_of||control-11/NN||tb-13/NN	tb-13||mycobacteriumtuberculosis-4||no||prompt detection of mycobacteriumtuberculosis drug resistance is essential for effective control of tb.
amod||aim-3/NN||objective-1/JJ	det||aim-3/NN||the-2/DT	nsubj||was-7/VBD||aim-3/NN	nsubj||assess-9/VB||aim-3/NN	det||analysis-6/NN||this-5/DT	prep_of||aim-3/NN||analysis-6/NN	root||ROOT-0/null||was-7/VBD	aux||assess-9/VB||to-8/TO	xcomp||was-7/VBD||assess-9/VB	det||effect-11/NN||the-10/DT	dobj||assess-9/VB||effect-11/NN	amod||pressurized-14/JJ||budesonide/formoterol-13/JJ	amod||inhaler-16/NN||pressurized-14/JJ	amod||inhaler-16/NN||metered-dose-15/JJ	prep_of||effect-11/NN||inhaler-16/NN	nn||pmdi-19/NNS||bud/fm-18/NN	appos||inhaler-16/NN||pmdi-19/NNS	dobj||assess-9/VB||bud-22/NN	conj_and||effect-11/NN||bud-22/NN	amod||criteria-25/NNS||predefined-24/JJ	prep_on||bud-22/NN||criteria-25/NNS	prep_for||criteria-25/NNS||asthma-27/NN	amod||asthma-27/NN||worsening-28/VBG	det||metric-33/NN||an-30/DT	nn||metric-33/NN||asthma-31/NN	nn||metric-33/NN||control-32/NN	appos||bud-22/NN||metric-33/NN	advmod||aligned-35/VBN||generally-34/RB	vmod||metric-33/NN||aligned-35/VBN	prep_with||aligned-35/VBN||definitions-37/NNS	amod||exacerbations-41/NNS||moderate-39/JJ	nn||exacerbations-41/NNS||asthma-40/NN	prep_of||definitions-37/NNS||exacerbations-41/NNS	num||populations-46/NNS||four-44/CD	amod||populations-46/NNS||different-45/JJ	prep_across||bud-22/NN||populations-46/NNS	asthma-40||budesonide--1||no||objective the aim of this analysis was to assess the effect of budesonide/formoterol pressurized metered-dose inhaler (bud/fm pmdi) and bud on predefined criteria for asthma worsening, an asthma control metric generally aligned with definitions of moderate asthma exacerbations, across four different populations.
aux||examine-2/VB||to-1/TO	dep||determined-10/VBD||examine-2/VB	det||association-4/NN||the-3/DT	dobj||examine-2/VB||association-4/NN	prep_between||association-4/NN||levels-6/NNS	prep_of||levels-6/NNS||hyperglycemia-8/NN	root||ROOT-0/null||determined-10/VBD	det||test-17/NN||each-12/DT	amod||test-17/NN||prenatal-13/JJ	amod||test-17/NN||oral-14/JJ	nn||test-17/NN||glucose-15/NN	nn||test-17/NN||tolerance-16/NN	prep_by||determined-10/VBD||test-17/NN	appos||test-17/NN||ogtt-19/NN	nsubj||determined-10/VBD||value-21/NN	dep||value-21/NN||fasting-23/NN	dep||value-21/NN||1-25/CD	conj_and||fasting-23/NN||1-25/CD	num||h-28/NN||2-27/CD	dep||value-21/NN||h-28/NN	conj_and||fasting-23/NN||h-28/NN	amod||outcomes-35/NNS||maternal-32/JJ	conj_and||maternal-32/JJ||perinatal-34/JJ	amod||outcomes-35/NNS||perinatal-34/JJ	nsubj||determined-10/VBD||outcomes-35/NNS	conj_and||value-21/NN||outcomes-35/NNS	aux||determine-38/VB||to-37/TO	conj_and||value-21/NN||determine-38/VB	conj_and||outcomes-35/NNS||determine-38/VB	vmod||outcomes-35/NNS||determine-38/VB	mark||differs-45/VBZ||whether-39/IN	det||risk-41/NN||the-40/DT	nsubj||differs-45/VBZ||risk-41/NN	det||outcomes-44/NNS||these-43/DT	prep_for||risk-41/NN||outcomes-44/NNS	ccomp||determine-38/VB||differs-45/VBZ	prep_for||differs-45/VBZ||women-47/NNS	dep||established-64/VBD||women-47/NNS	nsubj||established-64/VBD||value-49/NN	dep||value-49/NN||s-51/PRP	vmod||value-49/NN||equaled-53/VBN	vmod||value-49/NN||exceeded-55/VBN	conj_or||equaled-53/VBN||exceeded-55/VBN	det||thresholds-57/NNS||the-56/DT	dobj||equaled-53/VBN||thresholds-57/NNS	amod||diabetesmellitus-60/NNS||gestational-59/JJ	prep_for||equaled-53/VBN||diabetesmellitus-60/NNS	appos||diabetesmellitus-60/NNS||gdm-62/NN	rcmod||women-47/NNS||established-64/VBD	det||association-68/NN||the-66/DT	amod||association-68/NN||international-67/JJ	prep_by||established-64/VBD||association-68/NN	prep_of||association-68/NN||diabetes-70/NN	nn||groups-74/NNS||pregnancy-72/NN	nn||groups-74/NNS||study-73/NN	prep_in||established-64/VBD||groups-74/NNS	dep||outcomes-35/NNS||iadpsg-76/VBG	hyperglycemia-8||glucose-15||no||to examine the association between levels of hyperglycemia, determined by each prenatal oral glucose tolerance test (ogtt) value (fasting, 1 and 2 h), and maternal and perinatal outcomes and to determine whether the risk for these outcomes differs for women whose value(s) equaled or exceeded the thresholds for gestational diabetesmellitus (gdm) established by the international association of diabetes in pregnancy study groups (iadpsg).
prep_among||used-6/VBN||them-2/PRP	nsubjpass||used-6/VBN||doxycycline-4/NN	nsubjpass||used-6/VBN||doxycycline-4/NN	auxpass||used-6/VBN||is-5/VBZ	root||ROOT-0/null||used-6/VBN	conj_or||used-6/VBN||used-6/VBN	advmod||used-6/VBN||alone-7/RB	nn||chemoprophylaxis-10/NNS||malaria-9/NN	prep_for||used-6/VBN||chemoprophylaxis-10/NNS	prep_in||used-6/VBN||combination-13/NN	nn||derivatives-18/NNS||quinine-15/NN	conj_or||quinine-15/NN||artemisinin-17/NN	nn||derivatives-18/NNS||artemisinin-17/NN	prep_with||used-6/VBN||derivatives-18/NNS	nn||treatment-21/NN||malaria-20/NN	prep_for||derivatives-18/NNS||treatment-21/NN	malaria-20||doxycycline-4||yes||among them, doxycycline is used alone for malaria chemoprophylaxis or in combination with quinine or artemisinin derivatives for malaria treatment.
det||majority-2/NN||the-1/DT	nsubjpass||estrogen-17/VBN||majority-2/NN	nn||cancers-5/NNS||breast-4/NN	prep_of||majority-2/NN||cancers-5/NNS	nsubj||occur-7/VBP||cancers-5/NNS	rcmod||cancers-5/NNS||occur-7/VBP	amod||carriers-11/NNS||brca1-9/JJ	nn||carriers-11/NNS||mutation-10/NN	prep_in||occur-7/VBP||carriers-11/NNS	num||carriers-14/NNS||brca1-13/CD	appos||cancers-5/NNS||carriers-14/NNS	auxpass||estrogen-17/VBN||are-16/VBP	root||ROOT-0/null||estrogen-17/VBN	advmod||estrogen-17/VBN||receptor-negative-18/RB	dep||estrogen-17/VBN||er-20/RB	estrogen-17||cancers-5||no_rel||the majority of breast cancers that occur in brca1 mutation carriers ( brca1 carriers) are estrogen receptor-negative (er-).
nsubj||agent-20/NN||rapamycin-1/NN	appos||rapamycin-1/NN||rapa-3/NNP	det||inhibitor-7/NN||an-6/DT	appos||rapamycin-1/NN||inhibitor-7/NN	amod||target-10/NN||mammalian-9/JJ	prep_of||inhibitor-7/NN||target-10/NN	prep_of||target-10/NN||rapamycin-12/NN	appos||rapamycin-12/NN||mtor-14/NN	cop||agent-20/NN||is-17/VBZ	det||agent-20/NN||an-18/DT	amod||agent-20/NN||immunosuppressive-19/JJ	root||ROOT-0/null||agent-20/NN	nsubj||has-22/VBZ||agent-20/NN	rcmod||agent-20/NN||has-22/VBZ	amod||effects-24/NNS||anti-proliferative-23/JJ	dobj||has-22/VBZ||effects-24/NNS	det||tumors-27/NNS||some-26/DT	prep_on||effects-24/NNS||tumors-27/NNS	rapamycin-12||tumors-27||no_rel||rapamycin (rapa), an inhibitor of mammalian target of rapamycin (mtor), is an immunosuppressive agent that has anti-proliferative effects on some tumors.
nn||patients-4/NNS||uc-1/NN	conj_and||uc-1/NN||cd-3/NN	nn||patients-4/NNS||cd-3/NN	nsubj||had-5/VBD||patients-4/NNS	root||ROOT-0/null||had-5/VBD	advmod||higher-7/JJR||significantly-6/RB	amod||levels-10/NNS||higher-7/JJR	amod||levels-10/NNS||serum-8/JJ	amod||levels-10/NNS||s100a12-9/JJ	dobj||had-5/VBD||levels-10/NNS	prepc_compared_to||levels-10/NNS||to-12/TO	nn||patients-14/NNS||ibs-13/NN	pobj||levels-10/NNS||patients-14/NNS	dep||patients-14/NNS||p-16/VBN	dep||0.001-18/CD||=-17/SYM	ccomp||p-16/VBN||0.001-18/CD	det||comparisons-21/NNS||both-20/DT	prep_for||p-16/VBN||comparisons-21/NNS	cd-3||ibs-13||no_rel||uc and cd patients had significantly higher serum s100a12 levels compared to ibs patients ( p = 0.001 for both comparisons).
nsubj||drug-4/NN||magnesiumsulfate-1/NN	cop||drug-4/NN||is-2/VBZ	det||drug-4/NN||the-3/DT	root||ROOT-0/null||drug-4/NN	prep_of||drug-4/NN||choice-6/NN	prep_for||choice-6/NN||prevention-8/NN	prep_of||prevention-8/NN||seizures-10/NNS	prep_as||seizures-10/NNS||part-12/NN	amod||management-15/NN||comprehensive-14/JJ	prep_of||part-12/NN||management-15/NN	det||disease-18/NN||the-17/DT	prep_of||management-15/NN||disease-18/NN	seizures-10||magnesiumsulfate-1||yes||magnesiumsulfate is the drug of choice for prevention of seizures as part of comprehensive management of the disease.
det||data-2/NNS||these-1/DT	nsubj||established-4/VBN||data-2/NNS	aux||established-4/VBN||have-3/VBP	root||ROOT-0/null||established-4/VBN	mark||prion-9/VBN||that-5/IN	amod||prions-7/NNS||kuru-6/JJ	nsubj||prion-9/VBN||prions-7/NNS	aux||prion-9/VBN||have-8/VBP	ccomp||established-4/VBN||prion-9/VBN	nn||properties-11/NNS||strain-10/NN	nsubj||equivalent-12/JJ||properties-11/NNS	xcomp||prion-9/VBN||equivalent-12/JJ	prep_to||equivalent-12/JJ||those-14/DT	amod||prions-29/NNS||classical-16/JJ	dep||prions-29/NNS||sporadic-18/JJ	conj_and||sporadic-18/JJ||iatrogenic-20/JJ	dep||prions-29/NNS||iatrogenic-20/JJ	amod||prions-29/NNS||cjd-22/JJ	nn||prions-29/NNS||prions-23/NNS	conj_but||prions-23/NNS||distinct-25/JJ	nn||prions-29/NNS||distinct-25/JJ	amod||cjd-28/NN||variant-27/JJ	prep_from||distinct-25/JJ||cjd-28/NN	prep_of||those-14/DT||prions-29/NNS	prions-29||cjd-28||no_rel||these data have established that kuru prions have prion strain properties equivalent to those of classical (sporadic and iatrogenic) cjd prions but distinct from variant cjd prions.
nsubjpass||used-4/VBN||tegaserod-1/NN	aux||used-4/VBN||has-2/VBZ	auxpass||used-4/VBN||been-3/VBN	root||ROOT-0/null||used-4/VBN	prep_for||used-4/VBN||treatment-6/NN	prep_of||treatment-6/NN||irritablebowelsyndrome-8/NN	appos||irritablebowelsyndrome-8/NN||ibs-10/NN	expl||is-14/VBZ||there-13/EX	conj_but||used-4/VBN||is-14/VBZ	neg||data-16/NNS||no-15/DT	nsubj||is-14/VBZ||data-16/NNS	poss||effect-19/NN||its-18/PRP$	prep_regarding||data-16/NNS||effect-19/NN	nn||patients-22/NNS||korean-21/NN	prep_on||effect-19/NN||patients-22/NNS	ibs-10||tegaserod-1||yes||tegaserod has been used for treatment of irritablebowelsyndrome (ibs) but there is no data regarding its effect on korean patients.
advmod||av-6/VBP||furthermore-1/RB	det||e/e-4/NN||the-3/DT	nsubj||av-6/VBP||e/e-4/NN	root||ROOT-0/null||av-6/VBP	nn||increases-8/NNS||ratio-7/NN	dobj||av-6/VBP||increases-8/NNS	det||status-13/NN||the-10/DT	nn||status-13/NN||glucose-11/NN	nn||status-13/NN||metabolism-12/NN	prep_along||increases-8/NNS||status-13/NN	amod||metabolism-17/NN||normal-15/JJ	nn||metabolism-17/NN||glucose-16/NN	prep_from||av-6/VBP||metabolism-17/NN	number||-LSB--20/CD||7.6-19/CD	num||.1-22/CD||-LSB--20/CD	number||.1-22/CD||6.2-10-21/CD	npadvmod||-RSB--23/JJ||.1-22/CD	dep||metabolism-17/NN||-RSB--23/JJ	prep_to||metabolism-17/NN||impairedglucosetolerance-26/NN	number||-LSB--29/CD||8.8-28/CD	num||.0-31/CD||-LSB--29/CD	number||.0-31/CD||7.4-11-30/CD	npadvmod||-RSB--32/JJ||.0-31/CD	dep||impairedglucosetolerance-26/NN||-RSB--32/JJ	prep_to||metabolism-17/NN||t2dm-35/NNS	conj_and||impairedglucosetolerance-26/NN||t2dm-35/NNS	number||-LSB--38/CD||10.5-37/CD	num||.2-40/CD||-LSB--38/CD	number||.2-40/CD||8.1-13-39/CD	npadvmod||-RSB--41/JJ||.2-40/CD	dep||impairedglucosetolerance-26/NN||-RSB--41/JJ	advmod||metabolism-17/NN||respectively-44/RB	appos||metabolism-17/NN||p-46/NNP	number||0.001-48/CD||<-47/CD	num||p-46/NNP||0.001-48/CD	impairedglucosetolerance-26||glucose-16||no_rel||furthermore, the e/e'av ratio increases along the glucose metabolism status from normal glucose metabolism (7.6 [6.2-10.1]) to impairedglucosetolerance (8.8 [7.4-11.0]) and t2dm (10.5 [8.1-13.2]), respectively (p < 0.001).
det||analysis-4/NN||the-2/DT	amod||analysis-4/NN||case-control-3/JJ	prep_in||2.3-26/CD||analysis-4/NN	det||ratio-9/NN||the-6/DT	amod||ratio-9/NN||conditional-7/JJ	nn||ratio-9/NN||odds-8/NNS	nsubj||2.3-26/CD||ratio-9/NN	amod||thromboembolism-12/NN||venous-11/JJ	prep_for||ratio-9/NN||thromboembolism-12/NN	vmod||thromboembolism-12/NN||comparing-13/VBG	dobj||comparing-13/VBG||use-14/NN	prep_of||use-14/NN||oralcontraceptives-16/NNS	vmod||oralcontraceptives-16/NNS||containing-17/VBG	dobj||containing-17/VBG||drospirenone-18/NN	prep_with||containing-17/VBG||use-20/NN	prep_of||use-20/NN||those-22/DT	vmod||those-22/DT||containing-23/VBG	acomp||containing-23/VBG||levonorgestrel-24/JJ	cop||2.3-26/CD||was-25/VBD	root||ROOT-0/null||2.3-26/CD	num||%-29/NN||95-28/CD	dep||2.3-26/CD||%-29/NN	nn||interval-31/NN||confidence-30/NN	dep||%-29/NN||interval-31/NN	number||3.2-34/CD||1.6-32/CD	dep||3.2-34/CD||to-33/TO	dep||interval-31/NN||3.2-34/CD	thromboembolism-12||levonorgestrel-24||no||in the case-control analysis, the conditional odds ratio for venous thromboembolism comparing use of oralcontraceptives containing drospirenone with use of those containing levonorgestrel was 2.3 (95% confidence interval 1.6 to 3.2).
nn||heterozygous-2/NNS||patients-1/NNS	nsubj||constitute-10/VBP||heterozygous-2/NNS	prep_for||heterozygous-2/NNS||hbs-4/NN	prep_for||heterozygous-2/NNS||hbc-6/NN	conj_and||hbs-4/NN||hbc-6/NN	dep||heterozygous-2/NNS||hbsc-8/JJ	root||ROOT-0/null||constitute-10/VBP	quantmod||third-13/JJ||about-11/RB	quantmod||third-13/JJ||a-12/DT	dobj||constitute-10/VBP||third-13/JJ	nn||cases-16/NNS||scd-15/NN	prep_of||third-13/JJ||cases-16/NNS	vmod||constitute-10/VBP||making-18/VBG	nsubj||form-24/NN||this-19/DT	det||form-24/NN||the-20/DT	amod||form-24/NN||second-21/JJ	advmod||common-23/JJ||most-22/RBS	amod||form-24/NN||common-23/JJ	xcomp||making-18/VBG||form-24/NN	prep_of||form-24/NN||scd-26/NN	quantmod||80,000-30/CD||approximately-29/RB	num||births-31/NNS||80,000-30/CD	prep_with||making-18/VBG||births-31/NNS	nn||worldwide-34/NNS||year-33/NN	prep_per||births-31/NNS||worldwide-34/NNS	scd-26||hbs-4||no||patients heterozygous for hbs and hbc (hbsc) constitute about a third of scd cases, making this the second most common form of scd, with approximately 80,000 births per year worldwide.
nsubj||factor-6/NN||hypoglycaemia-1/NN	cop||factor-6/NN||is-2/VBZ	det||factor-6/NN||an-3/DT	amod||factor-6/NN||independent-4/JJ	nn||factor-6/NN||risk-5/NN	root||ROOT-0/null||factor-6/NN	prep_for||factor-6/NN||death-8/NN	amod||malaria-11/NN||severe-10/JJ	prep_in||death-8/NN||malaria-11/NN	det||effect-17/NN||a-13/DT	amod||effect-17/NN||recognized-14/VBN	amod||effect-17/NN||adverse-15/JJ	nn||effect-17/NN||treatment-16/NN	prep_for||factor-6/NN||effect-17/NN	conj_and||death-8/NN||effect-17/NN	amod||quinine-20/NN||parenteral-19/JJ	prep_of||effect-17/NN||quinine-20/NN	malaria-11||quinine-20||yes||hypoglycaemia is an independent risk factor for death in severe malaria and a recognized adverse treatment effect of parenteral quinine.
nsubj||indicate-2/VBP||results-1/NNS	root||ROOT-0/null||indicate-2/VBP	mark||associated-9/JJ||that-3/IN	amod||stigma-6/NN||shame-related-4/JJ	nn||stigma-6/NN||hiv-5/NN	nsubj||associated-9/JJ||stigma-6/NN	aux||associated-9/JJ||is-7/VBZ	advmod||associated-9/JJ||strongly-8/RB	ccomp||indicate-2/VBP||associated-9/JJ	amod||beliefs-12/NNS||religious-11/JJ	prep_with||associated-9/JJ||beliefs-12/NNS	det||belief-16/NN||the-15/DT	prep_such_as||beliefs-12/NNS||belief-16/NN	mark||punishment-21/NN||that-17/IN	nsubj||punishment-21/NN||hiv-18/NN	cop||punishment-21/NN||is-19/VBZ	det||punishment-21/NN||a-20/DT	ccomp||associated-9/JJ||punishment-21/NN	prep_from||punishment-21/NN||god-23/NN	nn||0.01-27/NNP||p-25/NNP	nn||0.01-27/NNP||<-26/NNP	appos||god-23/NN||0.01-27/NNP	mark||followed-40/VBN||that-30/IN	nsubj||followed-40/VBN||people-31/NNS	vmod||people-31/NNS||living-32/VBG	prep_with||living-32/VBG||hiv/aids-34/NNS	appos||hiv/aids-34/NNS||plwha-36/NNP	aux||followed-40/VBN||have-38/VBP	neg||followed-40/VBN||not-39/RB	ccomp||associated-9/JJ||followed-40/VBN	conj_or||punishment-21/NN||followed-40/VBN	det||word-42/NN||the-41/DT	dobj||followed-40/VBN||word-42/NN	prep_of||word-42/NN||god-44/NN	appos||god-44/NN||p-46/NNP	number||0.001-48/CD||<-47/CD	num||p-46/NNP||0.001-48/CD	aids--1||hiv-18||no||results indicate that shame-related hiv stigma is strongly associated with religious beliefs such as the belief that hiv is a punishment from god (p < 0.01) or that people living with hiv/aids (plwha) have not followed the word of god (p < 0.001).
amod||studies-3/NNS||previous-2/JJ	prep_in||demonstrated-6/VBD||studies-3/NNS	nsubj||demonstrated-6/VBD||we-5/PRP	root||ROOT-0/null||demonstrated-6/VBD	mark||reduce-10/VB||that-7/IN	nsubj||reduce-10/VB||bne-8/NN	aux||reduce-10/VB||could-9/MD	ccomp||demonstrated-6/VBD||reduce-10/VB	det||dna-17/NN||the-11/DT	amod||hepatitisbvirus-13/JJ||supernatant-12/JJ	amod||dna-17/NN||hepatitisbvirus-13/JJ	appos||dna-17/NN||hbv-15/NN	dobj||reduce-10/VB||dna-17/NN	amod||cells-22/NNS||hbv-producing-19/JJ	amod||cells-22/NNS||hepg2-20/JJ	num||cells-22/NNS||2.2.15-21/CD	prep_in||dna-17/NN||cells-22/NNS	hbv-15||hepatitisbvirus-13||no||in previous studies, we demonstrated that bne could reduce the supernatant hepatitisbvirus (hbv) dna in hbv-producing hepg2 2.2.15 cells.
advmod||twofold-10/VBD||conversely-1/RB	amod||blockade-5/NN||local-3/JJ	nn||blockade-5/NN||vmh-4/NN	nsubj||twofold-10/VBD||blockade-5/NN	nsubj||threefold-12/VB||blockade-5/NN	nn||glucagon-9/NN||insulin-7/NN	nn||glucagon-9/NN||amplified-8/NN	prep_of||blockade-5/NN||glucagon-9/NN	root||ROOT-0/null||twofold-10/VBD	aux||threefold-12/VB||to-11/TO	xcomp||twofold-10/VBD||threefold-12/VB	amod||hypoglycemia-15/NN||insulin-induced-14/JJ	prep_during||threefold-12/VB||hypoglycemia-15/NN	hypoglycemia-15||glucagon-9||yes||conversely, local vmh blockade of insulin amplified glucagon twofold to threefold during insulin-induced hypoglycemia.
nsubjpass||mentioned-4/VBN||it-1/PRP	nsubjpass||divided-23/VBN||it-1/PRP	auxpass||mentioned-4/VBN||was-2/VBD	advmod||mentioned-4/VBN||first-3/RB	root||ROOT-0/null||mentioned-4/VBN	agent||mentioned-4/VBN||maurice-6/NN	vmod||maurice-6/NN||raynaud-7/VBN	prep_in||raynaud-7/VBN||1862-9/CD	xcomp||raynaud-7/VBN||describing-10/VBG	quantmod||$-12/$||â-11/RB	num||asphyxia-15/FW||$-12/$	num||$-12/$||a-13/CD	amod||asphyxia-15/FW||local-14/JJ	dobj||describing-10/VBG||asphyxia-15/FW	det||$-19/NN||the-17/DT	amod||$-19/NN||extremitiesâ-18/JJ	prep_of||asphyxia-15/FW||$-19/NN	auxpass||divided-23/VBN||was-21/VBD	advmod||divided-23/VBN||further-22/RBR	conj_and||mentioned-4/VBN||divided-23/VBN	amod||raynaudâ-26/NNS||primary-25/JJ	prep_into||divided-23/VBN||raynaudâ-26/NNS	nsubjpass||related-42/VBN||raynaudâ-26/NNS	num||disease-30/NN||$-27/$	number||s-29/CD||-28/CD	num||$-27/$||s-29/CD	nsubj||phenomenon-37/NN||disease-30/NN	amod||raynaudâ-33/NNS||secondary-32/JJ	conj_and||disease-30/NN||raynaudâ-33/NNS	nsubj||phenomenon-37/NN||raynaudâ-33/NNS	amod||disease-30/NN||$-34/$	number||$-34/$||-35/CD	cop||phenomenon-37/NN||s-36/VBZ	rcmod||raynaudâ-26/NNS||phenomenon-37/NN	auxpass||related-42/VBN||is-40/VBZ	advmod||related-42/VBN||often-41/RB	rcmod||phenomenon-37/NN||related-42/VBN	prep_to||related-42/VBN||connectivetissuediseases-44/NNS	amod||strain-51/NN||physical-48/NN	conj_or||physical-48/NN||chemical-50/NN	amod||strain-51/NN||chemical-50/NN	rcmod||raynaudâ-26/NNS||strain-51/NN	conj_and||phenomenon-37/NN||strain-51/NN	chemical-50||raynaud-7||no_rel||it was first mentioned by maurice raynaud in 1862 describing âa local asphyxia of the extremitiesâ? and was further divided into primary raynaudâs disease and secondary raynaudâs phenomenon, which is often related to connectivetissuediseases, but also physical or chemical strain.
mark||contained-8/VBD||while-1/IN	det||diet-4/NN||the-2/DT	amod||diet-4/NN||high-fat-3/JJ	nsubj||contained-8/VBD||diet-4/NN	appos||diet-4/NN||hfd-6/NN	advcl||found-33/VBD||contained-8/VBD	nn||levels-10/NNS||equivalent-9/NN	nsubj||'s-23/VBZ||levels-10/NNS	prep_of||levels-10/NNS||n-3fattyacids-12/JJ	appos||n-3fattyacids-12/JJ||fa-14/NN	possessive||fa-14/NN||'s-15/POS	amod||levels-19/NNS||higher-18/JJR	prep_of||levels-10/NNS||levels-19/NNS	conj_and||n-3fattyacids-12/JJ||levels-19/NNS	amod||fa-22/NN||n-6-21/JJ	prep_of||levels-19/NNS||fa-22/NN	ccomp||contained-8/VBD||'s-23/VBZ	det||diet-27/NN||the-25/DT	nn||diet-27/NN||control-26/NN	prep_than||'s-23/VBZ||diet-27/NN	appos||diet-27/NN||ctr-29/NN	nsubj||found-33/VBD||we-32/PRP	root||ROOT-0/null||found-33/VBD	amod||decreases-35/NNS||significant-34/JJ	nsubj||'s-46/VBZ||decreases-35/NNS	amod||acid-38/NN||docosahexaenoic-37/JJ	prep_in||decreases-35/NNS||acid-38/NN	appos||acid-38/NN||dha-40/NN	amod||fa-45/NN||total-43/JJ	amod||fa-45/NN||n-3-44/JJ	prep_in||decreases-35/NNS||fa-45/NN	conj_and||acid-38/NN||fa-45/NN	ccomp||found-33/VBD||'s-46/VBZ	nn||maternal-49/NN||hfd-48/NN	prep_in||'s-46/VBZ||maternal-49/NN	amod||plasma-52/NN||fetal-51/JJ	prep_in||'s-46/VBZ||plasma-52/NN	conj_and||maternal-49/NN||plasma-52/NN	fat--1||fa-45||no_rel||while the high-fat diet (hfd) contained equivalent levels of n-3fattyacids (fa's) and higher levels of n-6 fa's than the control diet (ctr), we found significant decreases in docosahexaenoic acid (dha) and total n-3 fa's in hfd maternal and fetal plasma.
det||nested-3/NN||a-1/DT	amod||nested-3/NN||matched-2/VBN	nsubj||caseâ-4/VBD||nested-3/NN	root||ROOT-0/null||caseâ-4/VBD	dobj||caseâ-4/VBD||$-5/$	amod||study-8/NN||control-7/JJ	npadvmod||33-10/RB||study-8/NN	advmod||study-8/NN||of-9/IN	dep||paired-11/CD||33-10/RB	num||$-5/$||paired-11/CD	nsubjpass||conducted-16/VBN||cases-12/NNS	conj_and||cases-12/NNS||controls-14/NNS	nsubjpass||conducted-16/VBN||controls-14/NNS	auxpass||conducted-16/VBN||was-15/VBD	rcmod||$-5/$||conducted-16/VBN	prepc_based_on||caseâ-4/VBD||on-19/IN	det||cohort-22/NN||a-20/DT	nn||cohort-22/NN||study-21/NN	pobj||caseâ-4/VBD||cohort-22/NN	amod||mutations-69/NNS||long-24/JJ	det||china-30/NN||an-25/DT	nn||china-30/NN||county-26/NN	dep||china-30/NN||guangxi-28/NN	dep||long-24/JJ||china-30/NN	aux||determine-33/VB||to-32/TO	vmod||china-30/NN||determine-33/VB	mark||associated-46/VBN||whether-34/IN	nsubjpass||associated-46/VBN||infection-35/NN	prep_with||infection-35/NN||hepatitisbvirus-37/NNS	appos||hepatitisbvirus-37/NNS||hbv-39/NN	amod||deletions-43/NNS||pre-s-42/JJ	prep_with||hepatitisbvirus-37/NNS||deletions-43/NNS	auxpass||associated-46/VBN||is-44/VBZ	advmod||associated-46/VBN||independently-45/RB	ccomp||determine-33/VB||associated-46/VBN	det||development-49/NN||the-48/DT	prep_with||associated-46/VBN||development-49/NN	nn||carcinoma-52/NN||hepatocellular-51/NN	prep_of||development-49/NN||carcinoma-52/NN	appos||carcinoma-52/NN||hcc-54/NN	det||effects-60/NNS||the-58/DT	amod||effects-60/NNS||confounding-59/VBG	prep_without||associated-46/VBN||effects-60/NNS	amod||promoter-64/NN||basal-62/JJ	nn||promoter-64/NN||core-63/NN	prep_of||effects-60/NNS||promoter-64/NN	appos||promoter-64/NN||bcp-66/NN	amod||mutations-69/NNS||double-68/JJ	prep_in||cohort-22/NN||mutations-69/NNS	hbv-39||hepatitisbvirus-37||no||a matched nested caseâcontrol study of 33 paired cases and controls was conducted, based on a study cohort in long an county, guangxi, china, to determine whether infection with hepatitisbvirus (hbv) with pre-s deletions is independently associated with the development of hepatocellular carcinoma (hcc), without the confounding effects of basal core promoter (bcp) double mutations.
det||man-4/NN||a-1/DT	amod||man-4/NN||41-year-old-2/JJ	nn||man-4/NN||japanese-3/NN	nsubj||received-6/VBN||man-4/NN	aux||received-6/VBN||had-5/VBD	root||ROOT-0/null||received-6/VBN	amod||therapy-12/NN||successful-7/JJ	nn||therapy-12/NN||interferon-8/NN	nn||therapy-12/NN||ifn-10/NN	dobj||received-6/VBN||therapy-12/NN	prep_against||therapy-12/NN||chronichepatitisc-14/NN	prep_in||received-6/VBN||1994-16/CD	chronichepatitisc-14||interferon-8||yes||a 41-year-old japanese man had received successful interferon (ifn) therapy against chronichepatitisc in 1994.
det||results-2/NNS||these-1/DT	nsubj||indicate-3/VBP||results-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||drug-10/NN||that-4/IN	nsubj||drug-10/NN||aripiprazole-5/NN	aux||drug-10/NN||may-6/MD	cop||drug-10/NN||be-7/VB	det||drug-10/NN||a-8/DT	amod||drug-10/NN||promising-9/JJ	ccomp||indicate-3/VBP||drug-10/NN	det||treatment-13/NN||the-12/DT	prep_in||drug-10/NN||treatment-13/NN	prep_of||treatment-13/NN||children-15/NNS	prep_of||treatment-13/NN||adolescents-17/NNS	conj_and||children-15/NNS||adolescents-17/NNS	prep_with||drug-10/NN||ticdisorders-19/NNS	ticdisorders-19||aripiprazole-5||no_rel||these results indicate that aripiprazole may be a promising drug in the treatment of children and adolescents with ticdisorders.
nsubj||occurs-7/VBZ||scrubtyphus-1/NNS	vmod||scrubtyphus-1/NNS||caused-3/VBN	agent||caused-3/VBN||orientiatsutsugamushi-5/NNS	root||ROOT-0/null||occurs-7/VBZ	nn||asia-10/NN||southeast-9/NN	prep_throughout||occurs-7/VBZ||asia-10/NN	scrubtyphus-1||orientiatsutsugamushi-5||no||scrubtyphus, caused by orientiatsutsugamushi , occurs throughout southeast asia.
amod||time-2/NN||median-1/JJ	nsubj||different-13/JJ||time-2/NN	nn||progression-5/NN||tumor-4/NN	prep_to||time-2/NN||progression-5/NN	amod||endpoint-8/NN||primary-7/JJ	appos||time-2/NN||endpoint-8/NN	cop||different-13/JJ||was-10/VBD	neg||different-13/JJ||not-11/RB	advmod||different-13/JJ||significantly-12/RB	root||ROOT-0/null||different-13/JJ	det||groups-17/NNS||the-15/DT	num||groups-17/NNS||two-16/CD	prep_between||different-13/JJ||groups-17/NNS	nn||months-22/NNS||placebo-19/NN	num||months-22/NNS||2.8-21/CD	dep||groups-17/NNS||months-22/NNS	dep||months-22/NNS||bosentan-24/NN	num||months-27/NNS||1.6-26/CD	appos||bosentan-24/NN||months-27/NNS	nn||ratio-31/NN||bosentan/placebo-29/NN	nn||ratio-31/NN||hazard-30/NN	dep||bosentan-24/NN||ratio-31/NN	amod||ratio-31/NN||1.144-33/CD	number||%-36/NN||95-35/CD	amod||ci-37/NN||%-36/NN	dep||bosentan-24/NN||ci-37/NN	num||.827-40/CD||0.717-1-39/CD	appos||ci-37/NN||.827-40/CD	dep||bosentan-24/NN||p-42/NN	dep||0.5683-44/CD||=-43/SYM	rcmod||p-42/NN||0.5683-44/CD	bosentan-24||tumor-4||no_rel||median time to tumor progression (primary endpoint) was not significantly different between the two groups (placebo, 2.8 months; bosentan, 1.6 months; bosentan/placebo hazard ratio, 1.144; 95% ci, 0.717-1.827; p = 0.5683).
amod||aes-2/NN||placebo-adjusted-1/JJ	nsubj||insomnia-9/JJ||aes-2/NN	advmod||common-4/JJ||more-3/RBR	amod||aes-2/NN||common-4/JJ	amod||er-7/NN||paliperidone-6/JJ	prep_with||common-4/JJ||er-7/NN	cop||insomnia-9/JJ||were-8/VBD	ccomp||congestion-36/NN||insomnia-9/JJ	nn||tachycardia-12/NN||sinus-11/NNS	nsubj||congestion-36/NN||tachycardia-12/NN	conj_and||tachycardia-12/NN||tachycardia-14/NN	nsubj||congestion-36/NN||tachycardia-14/NN	advmod||common-17/JJ||more-16/RBR	amod||tachycardia-12/NN||common-17/JJ	prep_with||tachycardia-12/NN||risperidone-19/NN	cop||congestion-36/NN||were-20/VBD	nn||congestion-36/NN||somnolence-21/NN	conj_and||somnolence-21/NN||restlessness-23/NNS	nn||congestion-36/NN||restlessness-23/NNS	conj_and||somnolence-21/NN||nausea-25/NN	nn||congestion-36/NN||nausea-25/NN	conj_and||somnolence-21/NN||anxiety-27/NN	nn||congestion-36/NN||anxiety-27/NN	conj_and||somnolence-21/NN||salivaryhypersecretion-29/NN	nn||congestion-36/NN||salivaryhypersecretion-29/NN	conj_and||somnolence-21/NN||akathisia-31/NN	nn||congestion-36/NN||akathisia-31/NN	conj_and||somnolence-21/NN||dizziness-33/NN	nn||congestion-36/NN||dizziness-33/NN	conj_and||somnolence-21/NN||nasal-35/NN	nn||congestion-36/NN||nasal-35/NN	root||ROOT-0/null||congestion-36/NN	nausea-25||paliperidone-6||no_rel||placebo-adjusted aes more common with paliperidone er were insomnia, sinus tachycardia and tachycardia; more common with risperidone were somnolence, restlessness, nausea, anxiety, salivaryhypersecretion, akathisia, dizziness and nasal congestion.
amod||crf02_ag-2/NNS||hiv-1-1/JJ	nsubj||account-9/VBP||crf02_ag-2/NNS	amod||g-5/NN||subtype-4/JJ	conj_and||crf02_ag-2/NNS||g-5/NN	nsubj||account-9/VBP||g-5/NN	dep||g-5/NN||hiv-1g-7/JJ	root||ROOT-0/null||account-9/VBP	amod||hivinfections-12/NNS||most-11/JJS	prep_for||account-9/VBP||hivinfections-12/NNS	prep_in||account-9/VBP||nigeria-14/NN	poss||trends-19/NNS||their-17/PRP$	amod||trends-19/NNS||evolutionary-18/JJ	nsubjpass||documented-24/VBN||trends-19/NNS	aux||documented-24/VBN||have-20/VBP	neg||documented-24/VBN||not-21/RB	auxpass||documented-24/VBN||been-22/VBN	advmod||documented-24/VBN||well-23/RB	conj_but||account-9/VBP||documented-24/VBN	hivinfections-12||hiv--1||no||hiv-1 crf02_ag and subtype g (hiv-1g) account for most hivinfections in nigeria, but their evolutionary trends have not been well documented.
det||surveillance-3/NN||this-1/DT	amod||surveillance-3/NN||post-marketing-2/JJ	nsubj||confirms-12/VBZ||surveillance-3/NN	nsubj||highlights-24/VBZ||surveillance-3/NN	prep_of||surveillance-3/NN||levofloxacin-5/NN	vmod||surveillance-3/NN||conducted-7/VBN	num||years-10/NNS||4-9/CD	prep_over||conducted-7/VBN||years-10/NNS	root||ROOT-0/null||confirms-12/VBZ	det||safety-14/NN||the-13/DT	dobj||confirms-12/VBZ||safety-14/NN	dobj||confirms-12/VBZ||efficacy-16/NN	conj_and||safety-14/NN||efficacy-16/NN	prep_of||safety-14/NN||levofloxacin-18/NN	amod||use-22/NN||regular-20/JJ	amod||use-22/NN||clinical-21/JJ	prep_in||confirms-12/VBZ||use-22/NN	conj_and||confirms-12/VBZ||highlights-24/VBZ	mark||treatment-30/NN||that-25/IN	nsubj||treatment-30/NN||levofloxacin-26/NN	cop||treatment-30/NN||is-27/VBZ	det||treatment-30/NN||a-28/DT	amod||treatment-30/NN||promising-29/JJ	ccomp||highlights-24/VBZ||treatment-30/NN	det||variety-33/NN||a-32/DT	prep_for||treatment-30/NN||variety-33/NN	amod||ocularbacterialinfections-36/NNS||external-35/JJ	prep_of||variety-33/NN||ocularbacterialinfections-36/NNS	ocularbacterialinfections-36||levofloxacin-26||yes||this post-marketing surveillance of levofloxacin, conducted over 4 years, confirms the safety and efficacy of levofloxacin in regular clinical use and highlights that levofloxacin is a promising treatment for a variety of external ocularbacterialinfections.
aux||study-2/VB||to-1/TO	advcl||generated-9/VBD||study-2/VB	det||development-4/NN||the-3/DT	dobj||study-2/VB||development-4/NN	prep_of||development-4/NN||hamartomas-6/NNS	nsubj||generated-9/VBD||we-8/PRP	root||ROOT-0/null||generated-9/VBD	det||model-12/NN||a-10/DT	amod||model-12/NN||zebrafish-11/JJ	dobj||generated-9/VBD||model-12/NN	prep_of||model-12/NN||tsc-14/NN	vmod||tsc-14/NN||featuring-15/VBG	det||mutation-18/NN||a-16/DT	amod||mutation-18/NN||nonsense-17/JJ	dobj||featuring-15/VBG||mutation-18/NN	appos||mutation-18/NN||vu242-20/NNP	det||gene-25/NN||the-23/DT	amod||gene-25/NN||tsc2-24/JJ	prep_in||mutation-18/NN||gene-25/NN	tsc-14||hamartomas-6||no||to study the development of hamartomas, we generated a zebrafish model of tsc featuring a nonsense mutation ( vu242 ) in the tsc2 gene.
nsubj||concluded-2/VBD||we-1/PRP	root||ROOT-0/null||concluded-2/VBD	mark||alerted-7/JJ||that-3/IN	nsubj||alerted-7/JJ||anaesthetists-4/NNS	aux||alerted-7/JJ||should-5/MD	cop||alerted-7/JJ||be-6/VB	ccomp||concluded-2/VBD||alerted-7/JJ	advmod||using-9/VBG||when-8/WRB	advcl||alerted-7/JJ||using-9/VBG	dobj||using-9/VBG||propofol-10/NN	prep_in||using-9/VBG||patients-12/NNS	prep_with||patients-12/NNS||history-14/NN	amod||drugallergies-19/NNS||atopy-16/JJ	conj_or||atopy-16/JJ||several-18/JJ	amod||drugallergies-19/NNS||several-18/JJ	prep_of||history-14/NN||drugallergies-19/NNS	drugallergies-19||propofol-10||no||we concluded that anaesthetists should be alerted when using propofol in patients with history of atopy or several drugallergies.
nsubj||describe-2/VB||we-1/PRP	nsubj||assess-28/VB||we-1/PRP	root||ROOT-0/null||describe-2/VB	det||series-4/NN||a-3/DT	dobj||describe-2/VB||series-4/NN	prep_of||series-4/NN||exercises-6/NNS	vmod||exercises-6/NNS||involved-7/VBN	prepc_in||involved-7/VBN||adapting-9/VBG	det||model-13/NN||a-10/DT	amod||model-13/NN||computer-based-11/JJ	nn||model-13/NN||simulation-12/NN	dobj||adapting-9/VBG||model-13/NN	amod||cohort-26/NN||hivdisease-15/JJ	det||women-18/NNS||the-17/DT	poss||study-22/NN||women-18/NNS	nn||study-22/NN||interagency-20/NN	nn||study-22/NN||hiv-21/NN	prep_to||hivdisease-15/JJ||study-22/NN	num||wihs-24/NNS||-lrb--23/CD	npadvmod||-rrb--25/JJ||wihs-24/NNS	amod||cohort-26/NN||-rrb--25/JJ	prep_of||model-13/NN||cohort-26/NN	conj_and||describe-2/VB||assess-28/VB	nn||performance-30/NN||model-29/NN	dobj||assess-28/VB||performance-30/NN	mark||re-parameterized-33/VBD||as-31/IN	nsubj||re-parameterized-33/VBD||we-32/PRP	advcl||assess-28/VB||re-parameterized-33/VBD	det||model-35/NN||the-34/DT	dobj||re-parameterized-33/VBD||model-35/NN	aux||address-37/VB||to-36/TO	vmod||model-35/NN||address-37/VB	nn||questions-39/NNS||policy-38/NN	dobj||address-37/VB||questions-39/NNS	det||u.s.-42/NN||the-41/DT	prep_in||address-37/VB||u.s.-42/NN	amod||u.s.-42/NN||relevant-43/JJ	amod||women-46/NNS||hiv-infected-45/JJ	prep_to||relevant-43/JJ||women-46/NNS	vmod||women-46/NNS||using-47/VBG	dobj||using-47/VBG||data-48/NNS	det||wihs-51/NNS||the-50/DT	prep_from||using-47/VBG||wihs-51/NNS	hivdisease-15||hiv-21||no||we describe a series of exercises involved in adapting a computer-based simulation model of hivdisease to the women 's interagency hiv study -lrb- wihs -rrb- cohort and assess model performance as we re-parameterized the model to address policy questions in the u.s. relevant to hiv-infected women using data from the wihs .
amod||analysis-4/NN||multivariate-1/JJ	amod||analysis-4/NN||logistic-2/JJ	nn||analysis-4/NN||regression-3/NN	nsubjpass||performed-6/VBN||analysis-4/NN	nsubj||assess-8/VB||analysis-4/NN	auxpass||performed-6/VBN||was-5/VBD	root||ROOT-0/null||performed-6/VBN	aux||assess-8/VB||to-7/TO	xcomp||performed-6/VBN||assess-8/VB	advmod||associated-12/VBN||how-9/WRB	nsubjpass||associated-12/VBN||religion-10/NN	auxpass||associated-12/VBN||was-11/VBD	ccomp||assess-8/VB||associated-12/VBN	prep_with||associated-12/VBN||perceptions-14/NNS	prep_about||perceptions-14/NNS||hiv-16/NN	nn||treatment-19/NN||hiv-18/NN	prep_about||perceptions-14/NNS||treatment-19/NN	conj_and||hiv-16/NN||treatment-19/NN	prep_about||perceptions-14/NNS||people-22/NNS	conj_and||hiv-16/NN||people-22/NNS	xcomp||associated-12/VBN||living-23/VBG	prep_with||living-23/VBG||hiv/aids-25/NNS	aids--1||hiv-18||no||multivariate logistic regression analysis was performed to assess how religion was associated with perceptions about hiv, hiv treatment, and people living with hiv/aids.
nsubj||assessed-2/VBD||we-1/PRP	root||ROOT-0/null||assessed-2/VBD	nsubj||enrolled-7/VBD||nvp-resistance-3/NN	nn||infants-6/NNS||indian-5/NN	prep_in||nvp-resistance-3/NN||infants-6/NNS	dep||assessed-2/VBD||enrolled-7/VBD	det||transmission-34/NN||the-9/DT	amod||transmission-34/NN||â-10/JJ	amod||transmission-34/NN||$-11/$	dep||$-11/$||six-week-12/JJ	nn||transmission-34/NN||extended-dose-13/NN	dep||$-15/$||nevirapineâ-14/RB	dep||transmission-34/NN||$-15/$	amod||trial-19/NN||swen-17/JJ	npadvmod||of-31/RB||trial-19/NN	npadvmod||nvp-23/JJ||who-20/WP	npadvmod||single-dose-22/JJ||received-21/JJ	amod||who-20/WP||single-dose-22/JJ	advmod||trial-19/NN||nvp-23/JJ	dep||nvp-23/JJ||sd-nvp-25/NN	advmod||trial-19/NN||swen-28/JJ	conj_or||nvp-23/JJ||swen-28/JJ	prep_for||nvp-23/JJ||prevention-30/NN	dep||breast-milk-32/CD||of-31/RB	num||$-15/$||breast-milk-32/CD	amod||transmission-34/NN||hiv-33/JJ	prep_in||enrolled-7/VBD||transmission-34/NN	nsubj||acquired-38/VBD||who-36/WP	advmod||acquired-38/VBD||also-37/RB	dep||assessed-2/VBD||acquired-38/VBD	conj_but||enrolled-7/VBD||acquired-38/VBD	amod||hivinfection-41/NN||subtype-39/JJ	nn||hivinfection-41/NN||c-40/NN	dobj||acquired-38/VBD||hivinfection-41/NN	det||year-45/NN||the-43/DT	amod||year-45/NN||first-44/JJ	prep_during||acquired-38/VBD||year-45/NN	prep_of||year-45/NN||life-47/NN	hivinfection-41||hiv-33||no||we assessed nvp-resistance in indian infants enrolled in the âsix-week extended-dose nevirapineâ? (swen) trial who received single-dose nvp (sd-nvp) or swen for prevention of breast-milk hiv transmission but who also acquired subtype c hivinfection during the first year of life.
nn||adults-2/NNS||eighteen-1/NN	nsubj||participated-11/VBD||adults-2/NNS	prep_with||adults-2/NNS||adhd-4/NN	nsubj||responders-8/NNS||adhd-4/NN	cop||responders-8/NNS||were-6/VBD	amod||responders-8/NNS||clinical-7/JJ	rcmod||adhd-4/NN||responders-8/NNS	aux||methylphenidate-10/VB||to-9/TO	vmod||responders-8/NNS||methylphenidate-10/VB	root||ROOT-0/null||participated-11/VBD	det||trial-16/NN||this-13/DT	amod||trial-16/NN||randomized-14/JJ	nn||trial-16/NN||crossover-15/NN	prep_in||participated-11/VBD||trial-16/NN	adhd-4||methylphenidate-10||yes||eighteen adults with adhd who were clinical responders to methylphenidate participated in this randomized crossover trial.
det||response-3/NN||the-1/DT	nn||response-3/NN||bronchodilator-2/NN	nsubjpass||reduced-8/VBN||response-3/NN	aux||terbutaline-5/VB||to-4/TO	vmod||response-3/NN||terbutaline-5/VB	auxpass||reduced-8/VBN||was-6/VBD	advmod||reduced-8/VBN||significantly-7/RB	root||ROOT-0/null||reduced-8/VBN	amod||subjects-11/NNS||asthmatic-10/JJ	prep_in||reduced-8/VBN||subjects-11/NNS	xcomp||reduced-8/VBN||using-12/VBG	amod||laba-14/NN||daily-13/JJ	dobj||using-12/VBG||laba-14/NN	asthmatic-10||terbutaline-5||yes||the bronchodilator response to terbutaline was significantly reduced in asthmatic subjects using daily laba.
nsubj||induced-5/VBN||subjects-1/NNS	vmod||subjects-1/NNS||judged-2/VBN	det||pain-4/NN||the-3/DT	dobj||judged-2/VBN||pain-4/NN	root||ROOT-0/null||induced-5/VBN	prep_by||induced-5/VBN||capsaicin-7/NN	det||0â-10/NN||a-9/DT	prep_through||induced-5/VBN||0â-10/NN	dep||0â-10/NN||$-11/$	num||vas-14/NN||100-13/CD	npadvmod||before-16/IN||vas-14/NN	advmod||vas-14/NN||scale-15/RB	dep||10-28/CD||before-16/IN	conj_and||before-16/IN||after-18/IN	dep||10-28/CD||after-18/IN	amod||rtms-21/NNS||5â-19/JJ	nn||rtms-21/NNS||hz-20/NN	pobj||after-18/IN||rtms-21/NNS	amod||dlpfc-26/NN||left-23/NN	conj_and||left-23/NN||right-25/JJ	amod||dlpfc-26/NN||right-25/JJ	prep_over||after-18/IN||dlpfc-26/NN	advmod||after-18/IN||at-27/IN	num||$-11/$||10-28/CD	amod||min-31/NN||20â-30/JJ	prep_through||induced-5/VBN||min-31/NN	conj_or||0â-10/NN||min-31/NN	nn||application-34/NN||capsaicin-33/NN	prep_after||min-31/NN||application-34/NN	num||groups-38/NNS||two-36/CD	amod||groups-38/NNS||separate-37/JJ	prep_in||induced-5/VBN||groups-38/NNS	num||subjects-41/NNS||8-40/CD	dep||groups-38/NNS||subjects-41/NNS	dep||subjects-41/NNS||each-42/DT	pain-4||capsaicin-33||yes||subjects judged the pain induced by capsaicin through a 0â100 vas scale before and after 5â hz rtms over left and right dlpfc at 10 or 20â min after capsaicin application in two separate groups (8 subjects each).
nsubj||%-6/NN||prevalence-1/NN	prep_of||prevalence-1/NN||hivinfection-3/NN	cop||%-6/NN||was-4/VBD	num||%-6/NN||3.6-5/CD	root||ROOT-0/null||%-6/NN	nn||prevalence-9/NN||malaria-8/NN	nsubj||higher-12/JJR||prevalence-9/NN	cop||higher-12/JJR||was-10/VBD	advmod||higher-12/JJR||significantly-11/RB	conj_and||%-6/NN||higher-12/JJR	prep_among||higher-12/JJR||hiv-positive-14/NN	amod||women-17/NNS||hiv-negative-16/JJ	prep_than||higher-12/JJR||women-17/NNS	num||%-20/NN||37.5-19/CD	dep||women-17/NNS||%-20/NN	number||%-23/NN||95-22/CD	amod||ci-24/NN||%-23/NN	appos||%-20/NN||ci-24/NN	num||%-28/NN||4.0-71-26/CD	num||%-28/NN||.0-27/CD	appos||%-20/NN||%-28/NN	num||%-31/NN||14.3-30/CD	prep_versus||%-28/NN||%-31/NN	number||%-34/NN||95-33/CD	amod||ci.-35/NN||%-34/NN	appos||%-20/NN||ci.-35/NN	num||%-39/NN||9.6-19-37/CD	num||%-39/NN||.0-38/CD	appos||ci.-35/NN||%-39/NN	dep||women-17/NNS||ï-43/VB	number||2-45/CD||-44/CD	nsubj||<-50/NN||2-45/CD	dep||<-50/NN||=-46/SYM	amod||<-50/NN||13.3-47/JJ	amod||<-50/NN||p-49/JJ	ccomp||ï-43/VB||<-50/NN	num||<-50/NN||0.05-51/CD	hivinfection-3||hiv--1||no||prevalence of hivinfection was 3.6% and malaria prevalence was significantly higher among hiv-positive than hiv-negative women (37.5%, 95% ci, 4.0-71.0% versus 14.3%, 95% ci., 9.6-19.0%), (ï2 =13.3, p<0.05).
ccomp||receive-27/VBP||despite-1/IN	det||recommendations-3/NNS||who-2/WP	pobj||despite-1/IN||recommendations-3/NNS	conj_and||despite-1/IN||iap-5/NN	ccomp||receive-27/VBP||iap-5/NN	nn||academy-8/NN||indian-7/NN	dep||iap-5/NN||academy-8/NN	prep_of||academy-8/NN||paediatrics-10/NNS	conj_and||despite-1/IN||government-13/NN	conj_and||iap-5/NN||government-13/NN	nn||guidelines-17/NNS||india-15/NN	nn||guidelines-17/NNS||treatment-16/NN	prep_of||government-13/NN||guidelines-17/NNS	amod||children-20/NNS||few-19/JJ	nsubj||receive-27/VBP||children-20/NNS	vmod||children-20/NNS||suffering-21/VBG	amod||diarrhoea-24/NN||acute-23/JJ	prep_from||suffering-21/VBG||diarrhoea-24/NN	prep_in||diarrhoea-24/NN||india-26/NN	root||ROOT-0/null||receive-27/VBP	amod||solution-32/NN||low-28/JJ	amod||solution-32/NN||osmolarity-29/JJ	amod||solution-32/NN||oral-30/JJ	nn||solution-32/NN||rehydration-31/NN	dobj||receive-27/VBP||solution-32/NN	appos||solution-32/NN||ors-34/NN	dobj||receive-27/VBP||zinc-37/NN	conj_and||solution-32/NN||zinc-37/NN	nn||providers-41/NNS||health-39/NN	nn||providers-41/NNS||care-40/NN	prep_from||zinc-37/NN||providers-41/NNS	zinc-37||diarrhoea-24||no_rel||despite who recommendations and iap (indian academy of paediatrics) and government of india treatment guidelines, few children suffering from acute diarrhoea in india receive low osmolarity oral rehydration solution (ors) and zinc from health care providers.
aux||determine-2/VB||to-1/TO	advcl||analyzed-14/VBD||determine-2/VB	det||structure-5/NN||the-3/DT	nn||structure-5/NN||population-4/NN	dobj||determine-2/VB||structure-5/NN	det||agents-9/NNS||the-7/DT	amod||agents-9/NNS||cryptococcosis-8/JJ	prep_of||structure-5/NN||agents-9/NNS	prep_in||agents-9/NNS||china-11/NN	nsubj||analyzed-14/VBD||we-13/PRP	root||ROOT-0/null||analyzed-14/VBD	det||genotype-16/NN||the-15/DT	nsubj||isolated-25/VBD||genotype-16/NN	num||cryptococcusneoformans-19/NNS||120-18/CD	prep_of||genotype-16/NN||cryptococcusneoformans-19/NNS	num||strains-24/NNS||9-21/CD	amod||strains-24/NNS||cryptococcus-22/JJ	nn||strains-24/NNS||gattii-23/NN	prep_of||genotype-16/NN||strains-24/NNS	conj_and||cryptococcusneoformans-19/NNS||strains-24/NNS	ccomp||analyzed-14/VBD||isolated-25/VBD	prep_from||isolated-25/VBD||1980-27/CD	prep_through||isolated-25/VBD||2006-29/CD	amod||patients-32/NNS||cryptococcosis-31/JJ	prep_from||isolated-25/VBD||patients-32/NNS	vmod||patients-32/NNS||residing-33/VBG	num||provinces-36/NNS||16-35/CD	prep_in||residing-33/VBG||provinces-36/NNS	amod||china-39/NN||mainland-38/JJ	prep_of||provinces-36/NNS||china-39/NN	cryptococcusneoformans-19||cryptococcus-22||no||to determine the population structure of the cryptococcosis agents in china, we analyzed the genotype of 120 cryptococcusneoformans and 9 cryptococcus gattii strains isolated from 1980 through 2006 from cryptococcosis patients residing in 16 provinces of mainland china.
det||induction-2/NN||the-1/DT	nsubjpass||prevented-17/VBN||induction-2/NN	prep_of||induction-2/NN||obesity-4/NN	prep_of||induction-2/NN||dyslipidemia-6/NN	conj_and||obesity-4/NN||dyslipidemia-6/NN	prep_of||induction-2/NN||insulinresistance-9/NN	conj_and||obesity-4/NN||insulinresistance-9/NN	amod||diet-12/NN||high-fat-11/JJ	prep_by||obesity-4/NN||diet-12/NN	prep_in||diet-12/NN||rodents-14/NNS	aux||prevented-17/VBN||can-15/MD	auxpass||prevented-17/VBN||be-16/VB	root||ROOT-0/null||prevented-17/VBN	amod||fattyacids-22/NNS||n-3-19/JJ	amod||fattyacids-22/NNS||long-chain-20/JJ	amod||fattyacids-22/NNS||polyunsaturated-21/JJ	agent||prevented-17/VBN||fattyacids-22/NNS	appos||fattyacids-22/NNS||lc-pufas-24/NNS	obesity-4||fattyacids-22||no_rel||the induction of obesity, dyslipidemia, and insulinresistance by high-fat diet in rodents can be prevented by n-3 long-chain polyunsaturated fattyacids (lc-pufas).
amod||therapy-3/NN||antibiotic-2/JJ	prep_in||considered-12/VBN||therapy-3/NN	det||use-6/NN||the-5/DT	nsubjpass||considered-12/VBN||use-6/NN	prep_of||use-6/NN||thirdgenerationcephalosporins-8/NNS	aux||considered-12/VBN||should-9/MD	advmod||considered-12/VBN||only-10/RB	auxpass||considered-12/VBN||be-11/VB	root||ROOT-0/null||considered-12/VBN	prep_in||considered-12/VBN||cases-14/NNS	prep_of||cases-14/NNS||lymedisease-16/NN	lymedisease-16||antibiotic-2||no_rel||in antibiotic therapy, the use of thirdgenerationcephalosporins should only be considered in cases of lymedisease.
nsubj||contribute-3/VB||this-1/DT	aux||contribute-3/VB||could-2/MD	root||ROOT-0/null||contribute-3/VB	amod||chain-7/NN||reduced-5/VBN	amod||chain-7/NN||short-6/JJ	prep_to||contribute-3/VB||chain-7/NN	vmod||chain-7/NN||fattyacid-8/VBN	dobj||fattyacid-8/VBN||production-9/NN	prep_in||production-9/NN||ibd-11/NN	fattyacid-8||ibd-11||no_rel||this could contribute to reduced short chain fattyacid production in ibd.
nsubj||demonstration-5/NN||this-1/DT	cop||demonstration-5/NN||is-2/VBZ	det||demonstration-5/NN||the-3/DT	amod||demonstration-5/NN||first-4/JJ	root||ROOT-0/null||demonstration-5/NN	mark||induces-8/VBZ||that-6/IN	nsubj||induces-8/VBZ||stroke-7/NN	ccomp||demonstration-5/NN||induces-8/VBZ	amod||changes-10/NNS||immediate-9/JJ	dobj||induces-8/VBZ||changes-10/NNS	det||timing-13/NN||the-12/DT	prep_in||induces-8/VBZ||timing-13/NN	amod||secretion-17/NN||pineal-15/JJ	nn||secretion-17/NN||melatonin-16/NN	prep_of||timing-13/NN||secretion-17/NN	vmod||induces-8/VBZ||indicating-19/VBG	mark||impacts-26/VBZ||that-20/IN	amod||infarction-25/NNS||cortical-21/JJ	conj_and||cortical-21/JJ||basal-23/JJ	amod||infarction-25/NNS||basal-23/JJ	nn||infarction-25/NNS||ganglia-24/NN	nsubj||impacts-26/VBZ||infarction-25/NNS	ccomp||indicating-19/VBG||impacts-26/VBZ	det||timing-28/NN||the-27/DT	dobj||impacts-26/VBZ||timing-28/NN	nn||rhythms-31/NNS||melatonin-30/NN	prep_of||timing-28/NN||rhythms-31/NNS	infarction-25||melatonin-30||no_rel||this is the first demonstration that stroke induces immediate changes in the timing of pineal melatonin secretion, indicating that cortical and basal ganglia infarction impacts the timing of melatonin rhythms.
det||youth-2/NN||these-1/DT	nsubj||growing-4/VBG||youth-2/NN	aux||growing-4/VBG||are-3/VBP	root||ROOT-0/null||growing-4/VBG	prt||growing-4/VBG||up-5/RP	det||context-8/NN||a-7/DT	prep_in||growing-4/VBG||context-8/NN	vmod||context-8/NN||marked-9/VBN	amod||poverty-12/NN||pervasive-11/JJ	agent||marked-9/VBN||poverty-12/NN	amod||opportunities-16/NNS||limited-14/JJ	amod||opportunities-16/NNS||educational-15/JJ	agent||marked-9/VBN||opportunities-16/NNS	conj_and||poverty-12/NN||opportunities-16/NNS	amod||prevalence-20/NN||high-18/JJ	nn||prevalence-20/NN||hiv/aids-19/NNS	agent||marked-9/VBN||prevalence-20/NN	conj_and||poverty-12/NN||prevalence-20/NN	amod||conflict-23/NN||widespread-22/JJ	agent||marked-9/VBN||conflict-23/NN	conj_and||poverty-12/NN||conflict-23/NN	amod||controls-28/NNS||weak-26/JJ	amod||controls-28/NNS||social-27/JJ	agent||marked-9/VBN||controls-28/NNS	conj_and||poverty-12/NN||controls-28/NNS	aids--1||hiv--1||no||these youth are growing up in a context marked by pervasive poverty, limited educational opportunities, high hiv/aids prevalence, widespread conflict, and weak social controls.
aux||address-2/VB||to-1/TO	advcl||show-14/VBP||address-2/VB	det||mechanisms-4/NNS||the-3/DT	nsubj||responsible-5/JJ||mechanisms-4/NNS	xcomp||address-2/VB||responsible-5/JJ	det||composition-9/NN||the-7/DT	amod||composition-9/NN||inflammatory-8/JJ	prep_for||responsible-5/JJ||composition-9/NN	prep_of||composition-9/NN||reotcm-11/NN	nsubj||show-14/VBP||we-13/PRP	root||ROOT-0/null||show-14/VBP	mark||associated-26/VBN||that-15/IN	amod||secretion-20/NN||il-8-16/JJ	conj_and||il-8-16/JJ||ifn-î-18/JJ	amod||secretion-20/NN||ifn-î-18/JJ	amod||secretion-20/NN||²-19/JJ	nsubjpass||associated-26/VBN||secretion-20/NN	nsubjpass||decreased-32/VBN||secretion-20/NN	amod||cells-24/NNS||reovirus-infected-22/JJ	nn||cells-24/NNS||melanoma-23/NN	prep_by||secretion-20/NN||cells-24/NNS	auxpass||associated-26/VBN||was-25/VBD	ccomp||show-14/VBP||associated-26/VBN	prep_with||associated-26/VBN||activation-28/NN	prep_of||activation-28/NN||nf-îºb-30/NN	ccomp||show-14/VBP||decreased-32/VBN	conj_and||associated-26/VBN||decreased-32/VBN	prep_by||decreased-32/VBN||pre-treatment-34/NN	amod||inhibitors-38/NNS||small-36/JJ	nn||inhibitors-38/NNS||molecule-37/NN	prep_with||decreased-32/VBN||inhibitors-38/NNS	prep_of||inhibitors-38/NNS||nf-îºb-40/NN	prep_of||inhibitors-38/NNS||pkr-42/NN	conj_and||nf-îºb-40/NN||pkr-42/NN	amod||knockdown-46/NN||specific-44/JJ	amod||knockdown-46/NN||sirna-mediated-45/JJ	nsubj||confirmed-48/VBD||knockdown-46/NN	advmod||confirmed-48/VBD||further-47/RB	parataxis||show-14/VBP||confirmed-48/VBD	det||role-50/NN||a-49/DT	dobj||confirmed-48/VBD||role-50/NN	prep_for||confirmed-48/VBD||pkr-52/NN	melanoma-23||ifn--1||yes||to address the mechanisms responsible for the inflammatory composition of reotcm, we show that il-8 and ifn-î² secretion by reovirus-infected melanoma cells was associated with activation of nf-îºb and decreased by pre-treatment with small molecule inhibitors of nf-îºb and pkr; specific sirna-mediated knockdown further confirmed a role for pkr.
det||majority-2/NN||the-1/DT	nsubj||experience-6/VBP||majority-2/NN	nn||patients-5/NNS||cancer-4/NN	prep_of||majority-2/NN||patients-5/NNS	root||ROOT-0/null||experience-6/VBP	amod||loss-9/NN||dramatic-7/JJ	nn||loss-9/NN||weight-8/NN	dobj||experience-6/VBP||loss-9/NN	prep_due_to||loss-9/NN||cachexia-13/NN	dobj||experience-6/VBP||consisting-15/VBG	conj_and||loss-9/NN||consisting-15/VBG	amod||muscle-18/NN||skeletal-17/JJ	prep_of||consisting-15/VBG||muscle-18/NN	amod||wasting-22/NN||fat-20/JJ	nn||wasting-22/NN||tissue-21/NN	prep_of||consisting-15/VBG||wasting-22/NN	conj_and||muscle-18/NN||wasting-22/NN	cachexia-13||fat-20||no_rel||the majority of cancer patients experience dramatic weight loss, due to cachexia and consisting of skeletal muscle and fat tissue wasting.
nsubj||propose-2/VBP||we-1/PRP	root||ROOT-0/null||propose-2/VBP	det||model-7/NN||an-3/DT	amod||model-7/NN||influenza-specific-4/JJ	amod||model-7/NN||aminoacid-5/JJ	nn||model-7/NN||substitution-6/NN	dobj||propose-2/VBP||model-7/NN	nsubj||enhance-9/VB||model-7/NN	aux||enhance-9/VB||to-8/TO	xcomp||propose-2/VBP||enhance-9/VB	det||understanding-11/NN||the-10/DT	dobj||enhance-9/VB||understanding-11/NN	det||evolution-14/NN||the-13/DT	prep_of||understanding-11/NN||evolution-14/NN	prep_of||evolution-14/NN||influenzaviruses-16/NNS	influenza--1||influenzaviruses-16||no||we propose an influenza-specific aminoacid substitution model to enhance the understanding of the evolution of influenzaviruses.
mark||applied-7/VBN||after-1/IN	number||%-3/NN||5-2/CD	amod||patches-5/NNS||%-3/NN	nn||patches-5/NNS||lidocaine-4/NN	nsubjpass||applied-7/VBN||patches-5/NNS	auxpass||applied-7/VBN||were-6/VBD	advcl||exhibited-19/VBD||applied-7/VBN	det||part-12/NN||the-9/DT	amod||part-12/NN||painful-10/JJ	nn||part-12/NN||body-11/NN	prep_to||applied-7/VBN||part-12/NN	num||weeks-15/NNS||two-14/CD	prep_for||part-12/NN||weeks-15/NNS	nn||patients-18/NNS||cbp-17/NN	nsubj||exhibited-19/VBD||patients-18/NNS	root||ROOT-0/null||exhibited-19/VBD	det||decrease-22/NN||a-20/DT	amod||decrease-22/NN||significant-21/JJ	dobj||exhibited-19/VBD||decrease-22/NN	amod||measures-26/NNS||clinical-24/JJ	nn||measures-26/NNS||pain-25/NN	prep_in||exhibited-19/VBD||measures-26/NNS	mark||showed-35/VBD||while-28/IN	nn||questionnaire-32/NN||oa-30/NN	amod||questionnaire-32/NN||clinical-31/JJ	prep_in||showed-35/VBD||questionnaire-32/NN	vmod||questionnaire-32/NN||based-33/VBN	nsubj||showed-35/VBD||outcomes-34/NNS	advcl||exhibited-19/VBD||showed-35/VBD	neg||effect-38/NN||no-36/DT	nn||effect-38/NN||treatment-37/NN	nsubj||evoked-41/VBD||effect-38/NN	prep||effect-38/NN||but-39/CC	pobj||but-39/CC||stimulus-40/NN	ccomp||showed-35/VBD||evoked-41/VBD	nsubj||showed-43/VBD||pain-42/NN	ccomp||evoked-41/VBD||showed-43/VBD	det||decrease-46/NN||a-44/DT	amod||decrease-46/NN||borderline-45/JJ	dobj||showed-43/VBD||decrease-46/NN	lidocaine-4||painful-10||no_rel||after 5% lidocaine patches were applied to the painful body part for two weeks, cbp patients exhibited a significant decrease in clinical pain measures, while in oa clinical questionnaire based outcomes showed no treatment effect but stimulus evoked pain showed a borderline decrease.
nsubj||result-6/VBP||deficiencies-1/NNS	prep_in||deficiencies-1/NNS||gla-3/FW	prep_in||deficiencies-1/NNS||sda-5/FW	conj_and||gla-3/FW||sda-5/FW	root||ROOT-0/null||result-6/VBP	amod||susceptibility-9/NN||increased-8/VBN	prep_in||result-6/VBP||susceptibility-9/NN	prep_to||susceptibility-9/NN||bacterialinfection-11/NN	nsubjpass||associated-15/VBN||bacterialinfection-11/NN	auxpass||associated-15/VBN||is-14/VBZ	rcmod||bacterialinfection-11/NN||associated-15/VBN	amod||expression-19/NN||reduced-17/VBN	amod||expression-19/NN||basal-18/JJ	prep_with||associated-15/VBN||expression-19/NN	det||number-22/NN||a-21/DT	prep_of||expression-19/NN||number-22/NN	amod||$-26/NNS||immune-specific-24/JJ	amod||$-26/NNS||genesâ-25/JJ	prep_of||number-22/NN||$-26/NNS	dep||â-35/JJ||spp-1-29/JJ	conj_and||â-35/JJ||lys-7-31/JJ	amod||$-36/NNS||lys-7-31/JJ	conj_and||â-35/JJ||lys-2-34/JJ	amod||$-36/NNS||lys-2-34/JJ	amod||$-36/NNS||â-35/JJ	prep_including||$-26/NNS||$-36/NNS	nsubj||encode-39/VBP||$-36/NNS	rcmod||$-36/NNS||encode-39/VBP	amod||peptides-41/NNS||antimicrobial-40/JJ	dobj||encode-39/VBP||peptides-41/NNS	lys--1||gla-3||no_rel||deficiencies in gla and sda result in increased susceptibility to bacterialinfection, which is associated with reduced basal expression of a number of immune-specific genesâincluding spp-1 , lys-7 , and lys-2 âthat encode antimicrobial peptides.
aux||compare-2/VB||to-1/TO	advcl||ifnî-38/VBZ||compare-2/VB	dobj||compare-2/VB||adherence-3/NN	dobj||compare-2/VB||persistence-5/NN	conj_and||adherence-3/NN||persistence-5/NN	prep_among||adherence-3/NN||patients-7/NNS	prep_with||patients-7/NNS||multiplesclerosis-9/NNS	appos||multiplesclerosis-9/NNS||ms-11/NN	vmod||adherence-3/NN||initiated-13/VBN	amod||therapy-16/NN||disease-modifying-15/JJ	prep_on||initiated-13/VBN||therapy-16/NN	appos||therapy-16/NN||dmts-18/NNS	prep_including||therapy-16/NN||intramuscular-22/NN	appos||intramuscular-22/NN||im-24/NN	amod||intramuscular-22/NN||interferonbeta-1a-26/JJ	dep||adherence-3/NN||ifnî-28/VBN	xcomp||ifnî-28/VBN||²-29/VBG	dobj||²-29/VBG||-1-30/CD	dep||-1-30/CD||a-31/DT	nsubj||ifnî-38/VBZ||subcutaneous-34/NNS	appos||subcutaneous-34/NNS||sc-36/NN	root||ROOT-0/null||ifnî-38/VBZ	number||-1-40/CD||²-39/CD	num||a-41/DT||-1-40/CD	dobj||ifnî-38/VBZ||a-41/DT	dep||a-41/DT||ifnî-43/VBG	vmod||ifnî-43/VBG||²-44/VBG	dobj||²-44/VBG||-1-45/CD	dep||²-44/VBG||b-46/SYM	dep||a-41/DT||glatirameracetate-49/JJ	conj_or||ifnî-43/VBG||glatirameracetate-49/JJ	parataxis||ifnî-38/VBZ||ga-51/VB	multiplesclerosis-9||interferonbeta-1a-26||yes||to compare adherence and persistence among patients with multiplesclerosis (ms) initiated on disease-modifying therapy (dmts), including intramuscular (im) interferonbeta-1a (ifnî²-1a), subcutaneous (sc) ifnî²-1a, ifnî²-1b, or glatirameracetate (ga).
amod||prophylaxis-3/NNS||post-transplant-1/JJ	nn||prophylaxis-3/NNS||hbv-2/NN	nsubj||effective-31/JJ||prophylaxis-3/NNS	prep_with||prophylaxis-3/NNS||lamivudine-5/NN	prep_with||prophylaxis-3/NNS||intramuscular-7/NN	conj_and||lamivudine-5/NN||intramuscular-7/NN	vmod||prophylaxis-3/NNS||hbig-8/VBG	amod||dosage-11/NN||appropriate-10/JJ	prep_with||hbig-8/VBG||dosage-11/NN	aux||keep-13/VB||to-12/TO	xcomp||hbig-8/VBG||keep-13/VB	amod||titer-16/NN||anti-hbs-14/JJ	nn||titer-16/NN||antibody-15/NN	dobj||keep-13/VB||titer-16/NN	num||iu/l-19/NN||300-18/CD	prep_above||keep-13/VB||iu/l-19/NN	det||months-24/NNS||the-21/DT	amod||months-24/NNS||first-22/JJ	num||months-24/NNS||six-23/CD	prep_in||iu/l-19/NN||months-24/NNS	num||iu/l-28/NN||100-27/CD	prep_above||keep-13/VB||iu/l-28/NN	conj_and||iu/l-19/NN||iu/l-28/NN	dep||keep-13/VB||afterwards-29/RB	cop||effective-31/JJ||is-30/VBZ	root||ROOT-0/null||effective-31/JJ	prep_for||effective-31/JJ||prevention-33/NN	nn||recurrence-36/NN||hbv-35/NN	prep_of||prevention-33/NN||recurrence-36/NN	prep_after||effective-31/JJ||lt.-38/NN	hbv-35||lamivudine-5||yes||post-transplant hbv prophylaxis with lamivudine and intramuscular hbig with appropriate dosage to keep anti-hbs antibody titer above 300 iu/l in the first six months and above 100 iu/l afterwards is effective for prevention of hbv recurrence after lt.
amod||rats-4/NNS||forty-two-1/JJ	amod||rats-4/NNS||male-2/JJ	amod||rats-4/NNS||sprague-dawley-3/JJ	nsubjpass||divided-7/VBN||rats-4/NNS	auxpass||divided-7/VBN||were-5/VBD	advmod||divided-7/VBN||equally-6/RB	root||ROOT-0/null||divided-7/VBN	num||groups-10/NNS||six-9/CD	prep_into||divided-7/VBN||groups-10/NNS	nn||i-12/NNS||group-11/NN	dep||groups-10/NNS||i-12/NNS	appos||i-12/NNS||control-14/NN	amod||chow-19/NN||normal-17/JJ	nn||chow-19/NN||rat-18/NN	dep||groups-10/NNS||chow-19/NN	nn||ii-22/NN||group-21/NN	appos||chow-19/NN||ii-22/NN	amod||oil-26/NN||fresh-24/JJ	nn||oil-26/NN||soy-25/NN	dep||groups-10/NNS||oil-26/NN	nn||iii-29/NN||group-28/NN	appos||oil-26/NN||iii-29/NN	nn||oil-32/NN||soy-31/NN	dep||groups-10/NNS||oil-32/NN	amod||oil-32/NN||heated-33/JJ	dep||heated-33/JJ||once-34/RB	nn||iv-37/NN||group-36/NN	appos||once-34/RB||iv-37/NN	nn||oil-40/NN||soy-39/NN	dep||groups-10/NNS||oil-40/NN	amod||twice-42/JJ||heated-41/JJ	amod||oil-40/NN||twice-42/JJ	nn||v-45/NN||group-44/NN	appos||oil-40/NN||v-45/NN	nn||oil-48/NN||soy-47/NN	dep||groups-10/NNS||oil-48/NN	amod||oil-48/NN||heated-49/JJ	num||times-51/NNS||five-50/CD	dep||heated-49/JJ||times-51/NNS	nn||vi-54/NN||group-53/NN	appos||times-51/NNS||vi-54/NN	nn||oil-57/NN||soy-56/NN	dep||groups-10/NNS||oil-57/NN	amod||oil-57/NN||heated-58/JJ	num||times-60/NNS||ten-59/CD	dep||groups-10/NNS||times-60/NNS	oil-57||ten-59||no_rel||forty-two male sprague-dawley rats were equally divided into six groups group i (control) - normal rat chow, group ii - fresh soy oil, group iii - soy oil heated once, group iv - soy oil heated twice, group v - soy oil heated five times, group vi - soy oil heated ten times.
nsubjpass||obscured-8/VBN||relapsingfever-1/NN	nsubjpass||treated-13/VBN||relapsingfever-1/NN	vmod||relapsingfever-1/NN||caused-2/VBN	nn||bacteria-5/NNS||borrelia-4/NN	agent||caused-2/VBN||bacteria-5/NNS	auxpass||obscured-8/VBN||is-6/VBZ	advmod||obscured-8/VBN||often-7/RB	root||ROOT-0/null||obscured-8/VBN	agent||obscured-8/VBN||malaria-10/NN	advmod||treated-13/VBN||incorrectly-12/RB	conj_and||obscured-8/VBN||treated-13/VBN	relapsingfever-1||borrelia-4||no||relapsingfever caused by borrelia bacteria is often obscured by malaria and incorrectly treated.
det||regions-3/NNS||both-2/DT	prep_in||infected-11/VBN||regions-3/NNS	det||majority-6/NN||the-5/DT	nsubjpass||infected-11/VBN||majority-6/NN	prep_of||majority-6/NN||subjects-8/NNS	aux||infected-11/VBN||had-9/VBD	auxpass||infected-11/VBN||been-10/VBN	root||ROOT-0/null||infected-11/VBN	prep_with||infected-11/VBN||varicella-13/NN	advmod||165-17/CD||only-16/RB	nn||subjects-22/NNS||165-17/CD	num||%-20/NN||5.2-19/CD	appos||subjects-22/NNS||%-20/NN	nsubj||reported-23/VBD||subjects-22/NNS	conj_and||infected-11/VBN||reported-23/VBD	xcomp||reported-23/VBD||receiving-24/VBG	det||vaccination-27/NN||the-25/DT	nn||vaccination-27/NN||vzv-26/NN	dobj||receiving-24/VBG||vaccination-27/NN	varicella-13||vzv-26||yes||in both regions, the majority of subjects had been infected with varicella, and only 165 (5.2%) subjects reported receiving the vzv vaccination.
nn||propofol-2/NN||microemulsion-1/NN	nsubj||produces-3/VBZ||propofol-2/NN	root||ROOT-0/null||produces-3/VBZ	advmod||frequent-5/JJ||more-4/RBR	amod||pain-8/NN||frequent-5/JJ	conj_and||frequent-5/JJ||severe-7/JJ	amod||pain-8/NN||severe-7/JJ	dobj||produces-3/VBZ||pain-8/NN	prep_upon||produces-3/VBZ||injection-10/NN	nn||propofol-14/NN||lipid-12/NN	nn||propofol-14/NN||emulsion-13/NN	prep_than||injection-10/NN||propofol-14/NN	pain-8||propofol-14||yes||microemulsion propofol produces more frequent and severe pain upon injection than lipid emulsion propofol.
det||increase-3/NN||a-1/DT	amod||increase-3/NN||significant-2/JJ	nsubjpass||reported-10/VBN||increase-3/NN	prep_in||increase-3/NN||congestiveheartfailure-5/NN	appos||increase-3/NN||chf-7/NN	auxpass||reported-10/VBN||was-9/VBD	root||ROOT-0/null||reported-10/VBN	advmod||used-17/VBN||when-11/WRB	det||trastuzumab-15/NN||the-12/DT	amod||trastuzumab-15/NN||anti-erbb2-13/JJ	nn||trastuzumab-15/NN||antibody-14/NN	nsubjpass||used-17/VBN||trastuzumab-15/NN	auxpass||used-17/VBN||was-16/VBD	advcl||reported-10/VBN||used-17/VBN	prep_in||used-17/VBN||combination-19/NN	det||doxorubicin-24/NN||the-21/DT	amod||doxorubicin-24/NN||chemotherapy-22/JJ	nn||doxorubicin-24/NN||drug-23/NN	prep_with||used-17/VBN||doxorubicin-24/NN	appos||doxorubicin-24/NN||dox-26/NN	chf-7||dox-26||no||a significant increase in congestiveheartfailure (chf) was reported when the anti-erbb2 antibody trastuzumab was used in combination with the chemotherapy drug doxorubicin (dox).
det||cases-3/NNS||a-1/DT	amod||cases-3/NNS||few-2/JJ	nsubjpass||published-11/VBN||cases-3/NNS	amod||patients-6/NNS||celiac-5/JJ	prep_of||cases-3/NNS||patients-6/NNS	prep_with||patients-6/NNS||macroamylasemia-8/NN	aux||published-11/VBN||have-9/VBP	auxpass||published-11/VBN||been-10/VBN	root||ROOT-0/null||published-11/VBN	dobj||disappeared-17/VBD||whom-13/WP	det||disorder-16/NN||the-14/DT	amod||disorder-16/NN||biochemical-15/JJ	nsubj||disappeared-17/VBD||disorder-16/NN	prepc_in||published-11/VBN||disappeared-17/VBD	prep_after||disappeared-17/VBD||treatment-19/NN	det||diet-23/NN||a-21/DT	amod||diet-23/NN||gluten-free-22/JJ	prep_with||disappeared-17/VBD||diet-23/NN	celiac-5||gluten--1||no||a few cases of celiac patients with macroamylasemia have been published in whom the biochemical disorder disappeared after treatment with a gluten-free diet.
nsubj||underscores-34/VBZ||emergence-1/NN	amod||strains-4/NNS||drug-resistant-3/JJ	prep_of||emergence-1/NN||strains-4/NNS	prep_of||strains-4/NNS||influenzaviruses-6/NNS	nn||h5n1-10/NNS||avian-9/NN	prep_including||emergence-1/NN||h5n1-10/NNS	amod||potential-13/NN||pandemic-12/JJ	prep_with||h5n1-10/NNS||potential-13/NN	prep_with||h5n1-10/NNS||1918-15/CD	conj_and||potential-13/NN||1918-15/CD	num||viruses-20/NNS||2009-17/CD	amod||viruses-20/NNS||a/h1n1-18/JJ	amod||viruses-20/NNS||pandemic-19/JJ	prep_with||h5n1-10/NNS||viruses-20/NNS	conj_and||potential-13/NN||viruses-20/NNS	advmod||antiviralagents-24/NNS||currently-22/RB	amod||antiviralagents-24/NNS||used-23/JJ	prep_to||viruses-20/NNS||antiviralagents-24/NNS	amod||inhibitors-27/NNS||neuraminidase-26/JJ	prep_to||viruses-20/NNS||inhibitors-27/NNS	conj_and||antiviralagents-24/NNS||inhibitors-27/NNS	amod||blockers-32/NNS||m2-29/JJ	nn||blockers-32/NNS||ion-30/NN	nn||blockers-32/NNS||channel-31/NN	prep_to||viruses-20/NNS||blockers-32/NNS	conj_and||antiviralagents-24/NNS||blockers-32/NNS	root||ROOT-0/null||underscores-34/VBZ	det||importance-36/NN||the-35/DT	dobj||underscores-34/VBZ||importance-36/NN	prepc_of||importance-36/NN||developing-38/VBG	amod||strategies-41/NNS||novel-39/JJ	amod||strategies-41/NNS||antiviral-40/JJ	dobj||developing-38/VBG||strategies-41/NNS	h5n1-10||influenzaviruses-6||no||emergence of drug-resistant strains of influenzaviruses, including avian h5n1 with pandemic potential, 1918 and 2009 a/h1n1 pandemic viruses to currently used antiviralagents, neuraminidase inhibitors and m2 ion channel blockers, underscores the importance of developing novel antiviral strategies.
det||results-2/NNS||the-1/DT	nsubj||showed-3/VBD||results-2/NNS	root||ROOT-0/null||showed-3/VBD	mark||viruses-14/NNS||that-4/IN	npadvmod||viruses-14/NNS||9-5/CD	num||thai-9/NNS||10-8/CD	prep_out_of||viruses-14/NNS||thai-9/NNS	nn||isolates-11/NNP||prrsv-10/NNP	nsubj||viruses-14/NNS||isolates-11/NNP	cop||viruses-14/NNS||were-12/VBD	amod||viruses-14/NNS||nsp2-truncated-13/JJ	ccomp||showed-3/VBD||viruses-14/NNS	nsubj||evolved-18/VBN||viruses-14/NNS	aux||evolved-18/VBN||might-16/MD	aux||evolved-18/VBN||have-17/VB	rcmod||viruses-14/NNS||evolved-18/VBN	det||virus-21/NN||a-20/DT	prep_from||evolved-18/VBN||virus-21/NN	advmod||introduced-23/VBN||previously-22/RB	vmod||virus-21/NN||introduced-23/VBN	det||past-26/NN||the-25/DT	prep_in||introduced-23/VBN||past-26/NN	prep_from||evolved-18/VBN||one-31/CD	conj_negcc||virus-21/NN||one-31/CD	advmod||introduced-33/VBN||recently-32/RB	amod||one-31/CD||introduced-33/VBN	virus-21||viruses-14||no||the results showed that 9 out of 10 thai prrsv isolates were nsp2-truncated viruses that might have evolved from a virus previously introduced in the past, but not from one recently introduced.
advmod||associated-8/VBN||however-1/RB	det||haplotype-4/NN||this-3/DT	nsubjpass||associated-8/VBN||haplotype-4/NN	auxpass||associated-8/VBN||was-5/VBD	neg||associated-8/VBN||not-6/RB	advmod||associated-8/VBN||significantly-7/RB	root||ROOT-0/null||associated-8/VBN	amod||phenotypes-11/NNS||obesity-10/JJ	nsubj||suggesting-25/VBG||phenotypes-11/NNS	amod||mass-17/NN||bmi-14/JJ	conj_or||bmi-14/JJ||fat-16/JJ	amod||mass-17/NN||fat-16/JJ	prep_including||suggesting-25/VBG||mass-17/NN	dep||mass-17/NN||p-19/VBN	num||0.05-21/CD||>-20/CD	dobj||p-19/VBN||0.05-21/CD	advmod||suggesting-25/VBG||thereby-24/RB	prepc_with||associated-8/VBN||suggesting-25/VBG	mark||independent-33/JJ||that-26/IN	poss||association-28/NN||its-27/PRP$	nsubj||independent-33/JJ||association-28/NN	nn||pressure-31/NN||blood-30/NN	prep_with||association-28/NN||pressure-31/NN	cop||independent-33/JJ||was-32/VBD	ccomp||suggesting-25/VBG||independent-33/JJ	amod||phenotypes-36/NNS||obesity-35/JJ	prep_of||independent-33/JJ||phenotypes-36/NNS	fat-16||obesity-35||no_rel||however, this haplotype was not significantly associated with obesity phenotypes, including bmi or fat mass ( p >0.05), thereby suggesting that its association with blood pressure was independent of obesity phenotypes.
prep_in||induce-18/VB||contrast-2/NN	det||deletion-5/NN||the-4/DT	nsubj||induce-18/VB||deletion-5/NN	det||domain-9/NN||the-7/DT	amod||domain-9/NN||wd40-8/JJ	prep_of||deletion-5/NN||domain-9/NN	prep_of||domain-9/NN||zlrrk2-11/NNS	prep_by||zlrrk2-11/NNS||morpholinos-13/NNS	vmod||morpholinos-13/NNS||targeting-14/VBG	vmod||targeting-14/VBG||splicing-15/VBG	aux||induce-18/VB||did-16/VBD	neg||induce-18/VB||not-17/RB	root||ROOT-0/null||induce-18/VB	amod||defects-22/NNS||severe-19/JJ	amod||defects-22/NNS||embryonic-20/JJ	amod||defects-22/NNS||developmental-21/JJ	dobj||induce-18/VB||defects-22/NNS	advmod||caused-26/VBD||rather-24/RB	nsubj||caused-26/VBD||it-25/PRP	parataxis||induce-18/VB||caused-26/VBD	amod||phenotypes-28/NNS||parkinsonism-like-27/JJ	dobj||caused-26/VBD||phenotypes-28/NNS	prep_including||caused-26/VBD||loss-31/NN	amod||neurons-34/NNS||dopaminergic-33/JJ	prep_of||loss-31/NN||neurons-34/NNS	nn||defects-39/NNS||diencephalon-36/NN	conj_and||diencephalon-36/NN||locomotion-38/NN	nn||defects-39/NNS||locomotion-38/NN	prep_in||neurons-34/NNS||defects-39/NNS	dopaminergic-33||parkinsonism--1||no_rel||in contrast, the deletion of the wd40 domain of zlrrk2 by morpholinos targeting splicing did not induce severe embryonic developmental defects; rather it caused parkinsonism-like phenotypes, including loss of dopaminergic neurons in diencephalon and locomotion defects.
det||inhaler-3/NN||the-1/DT	nn||inhaler-3/NN||combination-2/NN	nsubj||product-11/NN||inhaler-3/NN	vmod||inhaler-3/NN||containing-4/VBG	acomp||containing-4/VBG||salmeterol-5/JJ	acomp||containing-4/VBG||fluticasone-7/JJ	conj_and||salmeterol-5/JJ||fluticasone-7/JJ	cop||product-11/NN||is-8/VBZ	num||product-11/NN||one-9/CD	amod||product-11/NN||such-10/JJ	root||ROOT-0/null||product-11/NN	nsubjpass||proven-15/VBN||product-11/NN	aux||proven-15/VBN||has-13/VBZ	auxpass||proven-15/VBN||been-14/VBN	rcmod||product-11/NN||proven-15/VBN	acomp||proven-15/VBN||safe-16/JJ	acomp||proven-15/VBN||effective-18/JJ	conj_and||safe-16/JJ||effective-18/JJ	nn||therapy-21/NN||asthma-20/NN	prep_for||proven-15/VBN||therapy-21/NN	asthma-20||salmeterol-5||yes||the combination inhaler containing salmeterol and fluticasone is one such product that has been proven safe and effective for asthma therapy.
nn||-lrb--2/NNP||ehrlichia-1/NNP	nsubj||e.-3/VBP||-lrb--2/NNP	root||ROOT-0/null||e.-3/VBP	amod||canis-5/NNS||-rrb--4/JJ	nsubj||bacterium-11/NN||canis-5/NNS	cop||bacterium-11/NN||is-6/VBZ	det||bacterium-11/NN||a-7/DT	amod||bacterium-11/NN||gram-negative-8/JJ	amod||bacterium-11/NN||obligate-9/JJ	nn||bacterium-11/NN||intracellular-10/NN	ccomp||e.-3/VBP||bacterium-11/NN	amod||bacterium-11/NN||responsible-12/JJ	amod||ehrlichiosis-16/NNS||canine-14/JJ	amod||ehrlichiosis-16/NNS||monocytic-15/JJ	prep_for||responsible-12/JJ||ehrlichiosis-16/NNS	ehrlichiosis-16||ehrlichia-1||no||ehrlichia -lrb- e. -rrb- canis is a gram-negative obligate intracellular bacterium responsible for canine monocytic ehrlichiosis .
nsubj||compared-3/VBD||we-1/PRP	advmod||compared-3/VBD||retrospectively-2/RB	root||ROOT-0/null||compared-3/VBD	dobj||compared-3/VBD||outcomes-4/NNS	det||series-8/NN||a-6/DT	amod||series-8/NN||consecutive-7/JJ	prep_of||outcomes-4/NNS||series-8/NN	num||patients-12/NNS||51-10/CD	nn||patients-12/NNS||aml-11/NN	prep_of||series-8/NN||patients-12/NNS	vmod||patients-12/NNS||treated-13/VBN	amod||busulfan-16/NN||oral-15/JJ	prep_with||treated-13/VBN||busulfan-16/NN	num||hours-22/NNS||1-18/CD	amod||hours-22/NNS||mg/kg-19/JJ	quantmod||6-21/CD||every-20/DT	num||hours-22/NNS||6-21/CD	dep||busulfan-16/NN||hours-22/NNS	num||days-25/NNS||4-24/CD	prep_for||hours-22/NNS||days-25/NNS	prep_with||treated-13/VBN||cyclophosphamide-28/NN	conj_and||busulfan-16/NN||cyclophosphamide-28/NN	num||ã-33/NN||60-30/CD	amod||ã-33/NN||mg/kg-31/JJ	nn||ã-33/NN||iv-32/NN	dep||busulfan-16/NN||ã-33/NN	num||days-36/NNS||2-35/CD	dep||ã-33/NN||days-36/NNS	dep||series-8/NN||bu/cy-40/NN	num||patients-46/NNS||100-43/CD	amod||patients-46/NNS||consecutive-44/JJ	nn||patients-46/NNS||aml-45/NN	prep_with||bu/cy-40/NN||patients-46/NNS	vmod||bu/cy-40/NN||treated-47/VBN	amod||busulfan-52/NN||pharmacokinetic-49/JJ	amod||busulfan-52/NN||targeted-50/JJ	nn||busulfan-52/NN||iv-51/NN	prep_with||treated-47/VBN||busulfan-52/NN	nn||min-61/NNP||auc-54/NN	num||min-61/NNP||<-55/CD	num||min-61/NNP||6000-56/CD	num||min-61/NNP||î-57/CD	num||min-61/NNP||1/4-58/CD	nn||min-61/NNP||m/l-59/NNP	nn||min-61/NNP||*-60/NNP	dep||busulfan-52/NN||min-61/NNP	nn||ã-64/NN||day-63/NN	prep_per||min-61/NNP||ã-64/NN	num||days-67/NNS||4-66/CD	dep||ã-64/NN||days-67/NNS	prep_with||treated-47/VBN||fludarabine-70/NN	conj_and||busulfan-52/NN||fludarabine-70/NN	num||ã-74/NN||40-72/CD	amod||ã-74/NN||mg/m2-73/JJ	dep||busulfan-52/NN||ã-74/NN	num||days-77/NNS||4-76/CD	dep||ã-74/NN||days-77/NNS	amod||bu/flu-82/JJ||t-iv-81/JJ	dep||series-8/NN||bu/flu-82/JJ	aml-45||cyclophosphamide-28||yes||we retrospectively compared outcomes of a consecutive series of 51 aml patients treated with oral busulfan (1 mg/kg every 6 hours for 4 days) and cyclophosphamide (60 mg/kg iv ã 2 days) - (bu/cy) with 100 consecutive aml patients treated with pharmacokinetic targeted iv busulfan (auc < 6000 î¼m/l*min per day ã 4 days) and fludarabine (40 mg/m2 ã 4 days) - (t-iv bu/flu).
amod||forms-2/NNS||several-1/JJ	nsubjpass||associated-7/VBN||forms-2/NNS	amod||suppression-5/NN||immune-4/JJ	prep_of||forms-2/NNS||suppression-5/NN	auxpass||associated-7/VBN||are-6/VBP	root||ROOT-0/null||associated-7/VBN	amod||incidence-11/NN||increased-9/VBN	nn||incidence-11/NN||mcc-10/NN	prep_with||associated-7/VBN||incidence-11/NN	amod||malignancies-15/NNS||hematologic-14/JJ	prep_including||incidence-11/NN||malignancies-15/NNS	prep_including||incidence-11/NN||hiv/aids-17/NNS	conj_and||malignancies-15/NNS||hiv/aids-17/NNS	amod||medications-21/NNS||immunosuppressive-20/JJ	prep_including||incidence-11/NN||medications-21/NNS	conj_and||malignancies-15/NNS||medications-21/NNS	prep_for||medications-21/NNS||autoimmunedisease-23/NN	prep_for||medications-21/NNS||transplant-25/NN	conj_or||autoimmunedisease-23/NN||transplant-25/NN	aids--1||hiv--1||no||several forms of immune suppression are associated with increased mcc incidence, including hematologic malignancies, hiv/aids, and immunosuppressive medications for autoimmunedisease or transplant.
aux||update-2/VB||to-1/TO	root||ROOT-0/null||update-2/VB	det||programme-7/NN||the-3/DT	amod||programme-7/NN||national-4/JJ	nn||programme-7/NN||malaria-5/NN	nn||programme-7/NN||control-6/NN	dobj||update-2/VB||programme-7/NN	prep_of||programme-7/NN||mali-9/NNS	det||efficacy-12/NN||the-11/DT	prep_on||mali-9/NNS||efficacy-12/NN	prep_of||efficacy-12/NN||chloroquine-14/NN	prep_of||efficacy-12/NN||amodiaquine-16/NN	conj_and||chloroquine-14/NN||amodiaquine-16/NN	prep_of||efficacy-12/NN||sulphadoxine-pyrimethamine-18/NN	conj_and||chloroquine-14/NN||sulphadoxine-pyrimethamine-18/NN	det||treatment-21/NN||the-20/DT	prep_in||update-2/VB||treatment-21/NN	amod||falciparummalaria-24/NN||uncomplicated-23/JJ	prep_of||treatment-21/NN||falciparummalaria-24/NN	malaria-5||pyrimethamine--1||yes||to update the national malaria control programme of mali on the efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine in the treatment of uncomplicated falciparummalaria.
det||drivers-3/NNS||the-1/DT	amod||drivers-3/NNS||cultural-2/JJ	root||ROOT-0/null||drivers-3/NNS	prep_of||drivers-3/NNS||hiv-5/NN	prep_of||drivers-3/NNS||aids-7/NNS	conj_and||hiv-5/NN||aids-7/NNS	vmod||drivers-3/NNS||were-8/VBD	nn||inheritance-11/NN||widow-10/NN	dep||drivers-3/NNS||inheritance-11/NN	dep||drivers-3/NNS||polygamy-13/NN	conj_and||inheritance-11/NN||polygamy-13/NN	amod||marriages-16/NNS||early-15/JJ	dep||drivers-3/NNS||marriages-16/NNS	conj_and||inheritance-11/NN||marriages-16/NNS	nn||expectations-19/NNS||family-18/NN	dep||drivers-3/NNS||expectations-19/NNS	conj_and||inheritance-11/NN||expectations-19/NNS	dep||drivers-3/NNS||silence-21/NN	conj_and||inheritance-11/NN||silence-21/NN	prep_about||silence-21/NN||sex-23/NN	dep||drivers-3/NNS||alcoholism-25/NN	conj_and||inheritance-11/NN||alcoholism-25/NN	aids-7||hiv-5||no||the cultural drivers of hiv and aids were; widow inheritance, polygamy, early marriages, family expectations, silence about sex and alcoholism.
mark||likely-14/JJ||since-1/IN	det||part-4/NN||a-2/DT	amod||part-4/NN||significant-3/JJ	nsubj||likely-14/JJ||part-4/NN	nsubj||relate-16/VB||part-4/NN	det||diversity-8/NN||the-6/DT	amod||diversity-8/NN||clinicopathological-7/JJ	prep_of||part-4/NN||diversity-8/NN	vmod||diversity-8/NN||seen-9/VBN	amod||priondisease-12/NN||human-11/JJ	prep_in||seen-9/VBN||priondisease-12/NN	cop||likely-14/JJ||is-13/VBZ	advcl||compared-28/VBN||likely-14/JJ	aux||relate-16/VB||to-15/TO	xcomp||likely-14/JJ||relate-16/VB	det||propagation-19/NN||the-18/DT	prep_to||relate-16/VB||propagation-19/NN	amod||strains-24/NNS||distinct-21/JJ	amod||strains-24/NNS||human-22/JJ	nn||strains-24/NNS||prion-23/NN	prep_of||propagation-19/NN||strains-24/NNS	nsubj||compared-28/VBN||we-26/PRP	aux||compared-28/VBN||have-27/VBP	root||ROOT-0/null||compared-28/VBN	det||properties-31/NNS||the-29/DT	nn||properties-31/NNS||transmission-30/NN	dobj||compared-28/VBN||properties-31/NNS	amod||prions-34/NNS||kuru-33/JJ	prep_of||properties-31/NNS||prions-34/NNS	prep_with||compared-28/VBN||those-36/DT	vmod||those-36/DT||isolated-37/VBN	prep_from||isolated-37/VBN||patients-39/NNS	amod||cjd-46/NN||sporadic-41/JJ	conj_and||sporadic-41/JJ||iatrogenic-43/JJ	amod||cjd-46/NN||iatrogenic-43/JJ	conj_and||sporadic-41/JJ||variant-45/JJ	amod||cjd-46/NN||variant-45/JJ	prep_with||patients-39/NNS||cjd-46/NN	preconj||transgenic-49/JJ||both-48/DT	amod||mice-52/NNS||transgenic-49/JJ	conj_and||transgenic-49/JJ||wild-type-51/JJ	amod||mice-52/NNS||wild-type-51/JJ	prep_in||cjd-46/NN||mice-52/NNS	prions-34||kuru-33||no_rel||since a significant part of the clinicopathological diversity seen in human priondisease is likely to relate to the propagation of distinct human prion strains, we have compared the transmission properties of kuru prions with those isolated from patients with sporadic, iatrogenic and variant cjd in both transgenic and wild-type mice.
det||anticoagulant-4/NN||the-1/DT	amod||anticoagulant-4/NN||newer-2/JJR	nn||anticoagulant-4/NN||parenteral-3/NN	nsubjpass||licensed-11/VBN||anticoagulant-4/NN	appos||anticoagulant-4/NN||fondaparinux-6/NN	auxpass||licensed-11/VBN||is-8/VBZ	advmod||licensed-11/VBN||now-9/RB	advmod||licensed-11/VBN||also-10/RB	root||ROOT-0/null||licensed-11/VBN	amod||prophylaxis-15/NNS||venous-13/JJ	nn||prophylaxis-15/NNS||thromboembolism-14/NN	prep_for||licensed-11/VBN||prophylaxis-15/NNS	amod||patients-18/NNS||surgical-17/JJ	prep_in||prophylaxis-15/NNS||patients-18/NNS	det||treatment-21/NN||the-20/DT	prep_for||licensed-11/VBN||treatment-21/NN	conj_and||prophylaxis-15/NNS||treatment-21/NN	amod||deep-veinthrombosis-24/NNS||acute-23/JJ	prep_of||treatment-21/NN||deep-veinthrombosis-24/NNS	amod||experience-27/NN||clinical-26/JJ	nsubj||expanding-32/VBG||experience-27/NN	det||anticoagulant-30/NN||this-29/DT	prep_with||experience-27/NN||anticoagulant-30/NN	aux||expanding-32/VBG||is-31/VBZ	parataxis||licensed-11/VBN||expanding-32/VBG	thromboembolism-14||fondaparinux-6||yes||the newer parenteral anticoagulant, fondaparinux, is now also licensed for venous thromboembolism prophylaxis in surgical patients and the treatment of acute deep-veinthrombosis; clinical experience with this anticoagulant is expanding.
nsubj||drug-6/NN||atovaquone-proguanil-1/NN	cop||drug-6/NN||is-2/VBZ	num||drug-6/NN||one-3/CD	amod||drug-6/NN||such-4/JJ	nn||drug-6/NN||combination-5/NN	root||ROOT-0/null||drug-6/NN	vmod||drug-6/NN||used-7/VBN	dep||used-7/VBN||both-8/DT	prep_for||used-7/VBN||prophylaxis-10/NNS	prep_for||used-7/VBN||prophylaxis-10/NNS	conj_and||prophylaxis-10/NNS||prophylaxis-10/NNS	prep_in||prophylaxis-10/NNS||travellers-12/NNS	prep_for||prophylaxis-10/NNS||treatment-16/NN	amod||cases-20/NNS||acute-18/JJ	nn||cases-20/NNS||malaria-19/NN	prep_of||treatment-16/NN||cases-20/NNS	nn||hospitals-23/NNS||european-22/NN	prep_in||used-7/VBN||hospitals-23/NNS	prep_in||used-7/VBN||clinics-25/NNS	conj_and||hospitals-23/NNS||clinics-25/NNS	malaria-19||atovaquone--1||yes||atovaquone-proguanil is one such combination drug used both for prophylaxis in travellers, and for treatment of acute malaria cases in european hospitals and clinics.
mark||involved-7/VBN||although-1/IN	det||variety-3/NN||a-2/DT	nsubjpass||involved-7/VBN||variety-3/NN	prep_of||variety-3/NN||bacteria-5/NNS	auxpass||involved-7/VBN||are-6/VBP	csubj||responsible-24/JJ||involved-7/VBN	amod||bacterialdisease-10/NN||invasive-9/JJ	prep_in||involved-7/VBN||bacterialdisease-10/NN	prep_in||bacterialdisease-10/NN||greenland-12/NN	prep_in||bacterialdisease-10/NN||streptococcuspneumoniae-14/NN	conj_and||greenland-12/NN||streptococcuspneumoniae-14/NN	prep_in||bacterialdisease-10/NN||escherichiacoli-16/NNS	conj_and||greenland-12/NN||escherichiacoli-16/NNS	prep_in||bacterialdisease-10/NN||staphylococcusaureus-18/NNS	conj_and||greenland-12/NN||staphylococcusaureus-18/NNS	amod||staphylococci-22/NNS||other-21/JJ	prep_in||bacterialdisease-10/NN||staphylococci-22/NNS	conj_and||greenland-12/NN||staphylococci-22/NNS	cop||responsible-24/JJ||are-23/VBP	root||ROOT-0/null||responsible-24/JJ	amod||cases-27/NNS||most-26/JJS	prep_for||responsible-24/JJ||cases-27/NNS	num||%-30/NN||69-29/CD	appos||cases-27/NNS||%-30/NN	nsubj||varies-34/VBZ||incidence-33/NN	parataxis||responsible-24/JJ||varies-34/VBZ	prepc_according_to||varies-34/VBZ||to-36/TO	pobj||varies-34/VBZ||region-37/NN	pobj||varies-34/VBZ||ethnicity-39/NN	conj_and||region-37/NN||ethnicity-39/NN	bacterialdisease-10||bacteria-5||no||although a variety of bacteria are involved in invasive bacterialdisease in greenland, streptococcuspneumoniae , escherichiacoli , staphylococcusaureus , and other staphylococci are responsible for most cases (69%); incidence varies according to region and ethnicity.
nsubj||useful-4/JJ||doxycycline-1/NN	cop||useful-4/JJ||is-2/VBZ	advmod||useful-4/JJ||especially-3/RB	root||ROOT-0/null||useful-4/JJ	det||prophylaxis-7/NNS||a-6/DT	prep_as||useful-4/JJ||prophylaxis-7/NNS	prep_in||prophylaxis-7/NNS||areas-9/NNS	amod||plasmodiumfalciparummalaria-14/NN||chloroquine-11/JJ	conj_and||chloroquine-11/JJ||multidrug-resistant-13/JJ	amod||plasmodiumfalciparummalaria-14/NN||multidrug-resistant-13/JJ	prep_with||areas-9/NNS||plasmodiumfalciparummalaria-14/NN	plasmodiumfalciparummalaria-14||chloroquine-11||yes||doxycycline is especially useful as a prophylaxis in areas with chloroquine and multidrug-resistant plasmodiumfalciparummalaria.
amod||concordance-2/NN||inter-laboratory-1/JJ	nsubj||better-5/JJR||concordance-2/NN	cop||better-5/JJR||was-3/VBD	advmod||better-5/JJR||slightly-4/RB	root||ROOT-0/null||better-5/JJR	prep_for||better-5/JJR||psv-7/NN	dep||better-5/JJR||than-8/IN	nn||assays-11/NNS||vi-10/NN	prep_for||better-5/JJR||assays-11/NNS	det||viruses-14/NNS||some-13/DT	prep_with||assays-11/NNS||viruses-14/NNS	amod||viruses-19/NNS||other-18/JJ	prep_for||limited-24/VBN||viruses-19/NNS	nsubjpass||limited-24/VBN||agreement-20/NN	nsubjpass||depended-26/VBN||agreement-20/NN	prep_between||agreement-20/NN||laboratories-22/NNS	auxpass||limited-24/VBN||was-23/VBD	conj_but||better-5/JJR||limited-24/VBN	conj_but||better-5/JJR||depended-26/VBN	conj_and||limited-24/VBN||depended-26/VBN	predet||virus-30/NN||both-28/PDT	det||virus-30/NN||the-29/DT	prep_on||limited-24/VBN||virus-30/NN	det||reagent-34/NN||the-32/DT	amod||reagent-34/NN||neutralizing-33/VBG	prep_on||limited-24/VBN||reagent-34/NN	conj_and||virus-30/NN||reagent-34/NN	virus-30||viruses-19||no||inter-laboratory concordance was slightly better for psv than for vi assays with some viruses, but for other viruses agreement between laboratories was limited and depended on both the virus and the neutralizing reagent.
nsubjpass||optimized-32/VBN||proportions-1/NNS	num||enzymes-6/NNS||six-3/CD	amod||enzymes-6/NNS||core-4/JJ	amod||enzymes-6/NNS||fungal-5/JJ	prep_of||proportions-1/NNS||enzymes-6/NNS	nn||²-15/NNPS||cbh1-8/NNPS	dep||²-15/NNPS||cbh2-10/NNPS	dep||²-15/NNPS||eg1-12/NNPS	dep||²-15/NNPS||î-14/NNP	dep||enzymes-6/NNS||²-15/NNPS	dep||²-15/NNPS||glucosidase-17/NN	det||xylosidase-29/NN||a-19/DT	amod||xylosidase-29/NN||gh10-20/JJ	advmod||1,4-xylanase-23/JJ||endo-î-21/RB	advmod||1,4-xylanase-23/JJ||²-22/RB	amod||xylosidase-29/NN||1,4-xylanase-23/JJ	advmod||²-27/JJ||î-26/RB	conj_and||1,4-xylanase-23/JJ||²-27/JJ	amod||xylosidase-29/NN||²-27/JJ	appos||glucosidase-17/NN||xylosidase-29/NN	auxpass||optimized-32/VBN||were-31/VBD	root||ROOT-0/null||optimized-32/VBN	det||loading-37/NN||a-34/DT	amod||loading-37/NN||fixed-35/VBN	nn||loading-37/NN||enzyme-36/NN	prep_at||optimized-32/VBN||loading-37/NN	num||glucan-41/NN||15-39/CD	amod||glucan-41/NN||mg/g-40/VBG	prep_of||loading-37/NN||glucan-41/NN	prep_for||glucan-41/NN||release-43/NN	prep_of||release-43/NN||glc-45/NN	prep_of||release-43/NN||xyl-47/NN	conj_and||glc-45/NN||xyl-47/NN	det||combinations-50/NNS||all-49/DT	prep_from||glucan-41/NN||combinations-50/NNS	num||feedstocks-54/NNS||five-52/CD	amod||feedstocks-54/NNS||biomass-53/JJ	prep_of||combinations-50/NNS||feedstocks-54/NNS	nn||stover-57/NN||corn-56/NN	nsubj||dried-63/VBD||stover-57/NN	appos||stover-57/NN||switchgrass-59/NNS	appos||switchgrass-59/NNS||miscanthus-61/NNS	dep||glucan-41/NN||dried-63/VBD	poss||grains-66/NNS||distillers-64/NNS	dobj||dried-63/VBD||grains-66/NNS	prep||grains-66/NNS||plus-67/CC	amod||-RSB--71/NNP||solubles-68/JJ	amod||-RSB--71/NNP||-LSB--69/VBG	nn||-RSB--71/NNP||ddgs-70/NNS	pobj||plus-67/CC||-RSB--71/NNP	pobj||plus-67/CC||poplar-73/NNP	conj_and||-RSB--71/NNP||poplar-73/NNP	vmod||glucan-41/NN||subjected-75/VBN	num||pretreatments-79/NNS||three-77/CD	amod||pretreatments-79/NNS||alkaline-78/JJ	prep_to||subjected-75/VBN||pretreatments-79/NNS	dep||pretreatments-79/NNS||afex-81/VB	dep||pretreatments-79/NNS||dilute-83/VB	conj_and||afex-81/VB||dilute-83/VB	amod||-RSB--89/NN||base-84/JJ	amod||-RSB--89/NN||-LSB--85/JJ	number||%-87/NN||0.25-86/CD	amod||-RSB--89/NN||%-87/NN	nn||-RSB--89/NN||naoh-88/NN	dobj||dilute-83/VB||-RSB--89/NN	dep||pretreatments-79/NNS||alkaline-91/VB	conj_and||afex-81/VB||alkaline-91/VB	amod||-RSB--95/NNS||peroxide-92/JJ	amod||-RSB--95/NNS||-LSB--93/JJ	nn||-RSB--95/NNS||ap-94/NN	dobj||alkaline-91/VB||-RSB--95/NNS	enzymes-6||endo--1||no_rel||proportions of six core fungal enzymes (cbh1, cbh2, eg1, î²-glucosidase, a gh10 endo-î²1,4-xylanase, and î²-xylosidase) were optimized at a fixed enzyme loading of 15 mg/g glucan for release of glc and xyl from all combinations of five biomass feedstocks (corn stover, switchgrass, miscanthus , dried distillers' grains plus solubles [ddgs] and poplar) subjected to three alkaline pretreatments (afex, dilute base [0.25% naoh] and alkaline peroxide [ap]).
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||determine-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||determine-8/VB||to-7/TO	xcomp||was-6/VBD||determine-8/VB	det||rate-10/NN||the-9/DT	dobj||determine-8/VB||rate-10/NN	amod||response-14/NN||sustained-12/VBN	amod||response-14/NN||virological-13/JJ	prep_of||rate-10/NN||response-14/NN	appos||response-14/NN||svr-16/NN	amod||factors-20/NNS||various-19/JJ	prep_of||rate-10/NN||factors-20/NNS	conj_and||response-14/NN||factors-20/NNS	vmod||factors-20/NNS||associated-21/VBN	nn||rates-24/NNS||response-23/NN	prep_with||associated-21/VBN||rates-24/NNS	amod||patients-28/NNS||chronichepatitisc-26/JJ	amod||patients-28/NNS||infected-27/JJ	prep_in||associated-21/VBN||patients-28/NNS	vmod||patients-28/NNS||treated-29/VBN	nn||therapy-36/NN||interferon-31/NN	amod||therapy-36/NN||alpha-32/NN	conj_and||alpha-32/NN||ribavirin-34/NN	amod||therapy-36/NN||ribavirin-34/NN	nn||therapy-36/NN||combination-35/NN	prep_with||treated-29/VBN||therapy-36/NN	chronichepatitisc-26||interferon-31||yes||the aim of this study was to determine the rate of sustained virological response (svr) and various factors associated with response rates in chronichepatitisc infected patients treated with interferon alpha and ribavirin combination therapy.
nsubjpass||treated-4/VBN||diarrhea-1/NN	aux||treated-4/VBN||can-2/MD	auxpass||treated-4/VBN||be-3/VB	root||ROOT-0/null||treated-4/VBN	prep_with||treated-4/VBN||loperamide-6/NN	prep_with||treated-4/VBN||diphenoxylate-8/NN	conj_or||loperamide-6/NN||diphenoxylate-8/NN	diarrhea-1||loperamide-6||yes||diarrhea can be treated with loperamide or diphenoxylate.
advmod||have-12/VBP||however-1/RB	prepc_compared_with||have-12/VBP||with-4/IN	pobj||have-12/VBP||youth-5/NN	prep_with||youth-5/NN||ngt-7/NN	nsubj||have-12/VBP||youth-9/NN	prep_with||youth-9/NN||igt-11/NN	root||ROOT-0/null||have-12/VBP	advmod||lower-14/JJR||significantly-13/RB	amod||insulin-16/NN||lower-14/JJR	amod||insulin-16/NN||first-phase-15/JJ	dobj||have-12/VBP||insulin-16/NN	amod||levels-19/NNS||c-peptide-18/JJ	dobj||have-12/VBP||levels-19/NNS	conj_and||insulin-16/NN||levels-19/NNS	conj_and||insulin-16/NN||gdi-21/NN	conj_and||levels-19/NNS||gdi-21/NN	dep||levels-19/NNS||p-23/VBN	dep||0.012-25/CD||=-24/SYM	ccomp||p-23/VBN||0.012-25/CD	mark||have-32/VBP||whereas-28/IN	nsubj||have-32/VBP||youth-29/NN	prep_with||youth-29/NN||type2diabetes-31/CD	advcl||have-12/VBP||have-32/VBP	det||defect-35/NN||an-33/DT	amod||defect-35/NN||additional-34/JJ	dobj||have-32/VBP||defect-35/NN	amod||insulin-38/NN||second-phase-37/JJ	prep_in||defect-35/NN||insulin-38/NN	type2diabetes-31||insulin-38||yes||however, compared with youth with ngt, youth with igt have significantly lower first-phase insulin and c-peptide levels and gdi ( p = 0.012), whereas youth with type2diabetes have an additional defect in second-phase insulin.
nsubj||clear-3/JJ||what-1/WP	cop||clear-3/JJ||is-2/VBZ	csubj||is-4/VBZ||clear-3/JJ	root||ROOT-0/null||is-4/VBZ	mark||is-7/VBZ||that-5/IN	expl||is-7/VBZ||there-6/EX	ccomp||is-4/VBZ||is-7/VBZ	acomp||is-7/VBZ||much-8/JJ	mark||unknown-12/JJ||that-9/IN	cop||unknown-12/JJ||is-10/VBZ	advmod||unknown-12/JJ||currently-11/RB	ccomp||is-7/VBZ||unknown-12/JJ	aux||able-15/JJ||to-13/TO	cop||able-15/JJ||be-14/VB	xcomp||unknown-12/JJ||able-15/JJ	aux||demonstrate-18/VB||to-16/TO	advmod||demonstrate-18/VB||convincingly-17/RB	xcomp||able-15/JJ||demonstrate-18/VB	det||risk-21/NN||a-19/DT	amod||risk-21/NN||substantial-20/JJ	dobj||demonstrate-18/VB||risk-21/NN	prep_of||risk-21/NN||cancer-23/NN	prep_in||demonstrate-18/VB||children-25/NNS	prep_with||demonstrate-18/VB||juvenileidiopathicarthritis-27/NNS	vmod||juvenileidiopathicarthritis-27/NNS||treated-28/VBN	prep_with||treated-28/VBN||etanercept-30/NN	juvenileidiopathicarthritis-27||etanercept-30||yes||what is clear is that there is much that is currently unknown to be able to convincingly demonstrate a substantial risk of cancer in children with juvenileidiopathicarthritis treated with etanercept.
prep_in_addition_to||secreted-17/VBD||rantes-4/NNS	amod||±-9/NNS||il-8-6/JJ	amod||±-9/NNS||mip-1î-8/JJ	conj_and||rantes-4/NNS||±-9/NNS	prep_in_addition_to||secreted-17/VBD||±-9/NNS	amod||²-12/NNS||mip-1î-11/JJ	conj_and||rantes-4/NNS||²-12/NNS	prep_in_addition_to||secreted-17/VBD||²-12/NNS	amod||cells-16/NNS||reovirus-infected-14/JJ	nn||cells-16/NNS||melanoma-15/NN	nsubj||secreted-17/VBD||cells-16/NNS	root||ROOT-0/null||secreted-17/VBD	dobj||secreted-17/VBD||eotaxin-18/NN	dobj||secreted-17/VBD||ip-10-20/JJ	conj_and||eotaxin-18/NN||ip-10-20/JJ	det||²-27/NN||the-22/DT	nn||²-27/NN||type-23/NN	num||²-27/NN||1-24/CD	nn||²-27/NN||interferon-25/NN	nn||²-27/NN||ifn-î-26/NN	dobj||secreted-17/VBD||²-27/NN	conj_and||eotaxin-18/NN||²-27/NN	melanoma-15||interferon-25||yes||in addition to rantes, il-8, mip-1î± and mip-1î², reovirus-infected melanoma cells secreted eotaxin, ip-10 and the type 1 interferon ifn-î².
nsubjpass||identified-3/VBN||irs-1/NN	nsubjpass||hospitalization-20/VBN||irs-1/NN	auxpass||identified-3/VBN||were-2/VBD	root||ROOT-0/null||identified-3/VBN	prepc_based_on||identified-3/VBN||on-5/IN	det||occurrence-7/NN||the-6/DT	pobj||identified-3/VBN||occurrence-7/NN	nn||treatment-10/NN||outpatient-9/NN	prep_of||occurrence-7/NN||treatment-10/NN	nn||room-13/NN||emergency-12/NN	appos||treatment-10/NN||room-13/NN	appos||treatment-10/NN||er-15/NN	dep||treatment-10/NN||visit-17/NN	conj_and/or||identified-3/VBN||hospitalization-20/VBN	prep_for||hospitalization-20/VBN||hypersensitivity-22/NN	prep_for||hospitalization-20/VBN||allergicreactions-24/NNS	conj_and||hypersensitivity-22/NN||allergicreactions-24/NNS	allergicreactions-24||hypersensitivity-22||no||irs were identified based on the occurrence of outpatient treatment, emergency room (er) visit, and/or hospitalization for hypersensitivity and allergicreactions.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	advmod||significant-4/JJ||statistically-3/RB	amod||association-5/NN||significant-4/JJ	nsubj||was-2/VBD||association-5/NN	prep_of||association-5/NN||hypomagnesemia-7/NN	amod||asthma-12/NN||tachypnoea-9/JJ	amod||asthma-12/NN||severe-11/JJ	prep_with||was-2/VBD||asthma-12/NN	appos||asthma-12/NN||use-14/NN	amod||²-18/NNS||long-acting-16/JJ	nn||²-18/NNS||î-17/NN	prep_of||use-14/NN||²-18/NNS	nn||²-48/NNS||agonist-20/NN	amod||corticosteroids-23/NNS||inhaled-22/JJ	appos||agonist-20/NN||corticosteroids-23/NNS	appos||agonist-20/NN||theophylline-25/NN	appos||agonist-20/NN||use-27/NN	nn||medications-33/NNS||â-29/NNP	nn||medications-33/NNS||-30/NNP	nn||medications-33/NNS||¥-31/NNP	num||medications-33/NNS||3-32/CD	prep_of||use-27/NN||medications-33/NNS	amod||exacerbations-38/NNS||previous-35/JJ	conj_and||previous-35/JJ||future-37/JJ	amod||exacerbations-38/NNS||future-37/JJ	appos||agonist-20/NN||exacerbations-38/NNS	neg||with-41/IN||not-40/RB	conj_but||agonist-20/NN||with-41/IN	nn||²-48/NNS||with-41/IN	pobj||with-41/IN||tachycardia-42/NN	pobj||with-41/IN||use-44/NN	conj_or||tachycardia-42/NN||use-44/NN	amod||î-47/NN||short-acting-46/JJ	prep_of||tachycardia-42/NN||î-47/NN	dep||use-14/NN||²-48/NNS	dep||²-48/NNS||2-49/CD	dep||use-14/NN||agonist-51/NN	dep||use-14/NN||montelukast-53/NN	conj_or||agonist-51/NN||montelukast-53/NN	asthma-12||theophylline-25||yes||there was statistically significant association of hypomagnesemia with tachypnoea, severe asthma, use of long-acting î²-agonist, inhaled corticosteroids, theophylline, use of â¥ 3 medications, previous and future exacerbations but not with tachycardia or use of short-acting î²2 -agonist or montelukast.
det||size-3/NN||a-1/DT	nn||size-3/NN||sample-2/NN	nsubjpass||required-16/VBN||size-3/NN	nsubj||detect-18/VB||size-3/NN	num||women-6/NNS||3,208-5/CD	prep_of||size-3/NN||women-6/NNS	nn||colonisation-9/NN||candida-8/NN	prep_with||women-6/NNS||colonisation-9/NN	dep||size-3/NN||1,604-11/CD	prep_per||1,604-11/CD||arm-13/NN	auxpass||required-16/VBN||is-15/VBZ	root||ROOT-0/null||required-16/VBN	aux||detect-18/VB||to-17/TO	xcomp||required-16/VBN||detect-18/VB	det||reduction-22/NN||a-19/DT	number||%-21/NN||40-20/CD	amod||reduction-22/NN||%-21/NN	dobj||detect-18/VB||reduction-22/NN	det||rate-28/NN||the-24/DT	amod||rate-28/NN||spontaneous-25/JJ	nn||rate-28/NN||preterm-26/NN	nn||rate-28/NN||birth-27/NN	prep_in||reduction-22/NN||rate-28/NN	prep_among||detect-18/VB||women-30/NNS	amod||candidiasis-33/NNS||asymptomatic-32/JJ	prep_with||women-30/NNS||candidiasis-33/NNS	num||%-36/NN||5.0-35/CD	prep_from||detect-18/VB||%-36/NN	det||group-40/NN||the-38/DT	nn||group-40/NN||control-39/NN	prep_in||%-36/NN||group-40/NN	num||%-43/NN||3.0-42/CD	prep_to||detect-18/VB||%-43/NN	prep_in||%-43/NN||women-45/NNS	vmod||women-45/NNS||treated-46/VBN	prep_with||treated-46/VBN||clotrimazole-48/NN	appos||clotrimazole-48/NN||significance-50/NN	num||significance-50/NN||0.05-51/CD	dep||significance-50/NN||power-53/NN	num||power-53/NN||0.8-54/CD	candidiasis-33||candida-8||no||a sample size of 3,208 women with candida colonisation (1,604 per arm) is required to detect a 40% reduction in the spontaneous preterm birth rate among women with asymptomatic candidiasis from 5.0% in the control group to 3.0% in women treated with clotrimazole (significance 0.05, power 0.8).
det||activity-3/NN||the-1/DT	amod||activity-3/NN||antimicrobial-2/JJ	nsubjpass||evaluated-9/VBN||activity-3/NN	det||pigment-7/NN||the-5/DT	amod||pigment-7/NN||crude-6/JJ	prep_of||activity-3/NN||pigment-7/NN	auxpass||evaluated-9/VBN||was-8/VBD	root||ROOT-0/null||evaluated-9/VBN	nn||pathogens-13/NNS||drug-11/NN	nn||pathogens-13/NNS||resistant-12/NN	prep_against||evaluated-9/VBN||pathogens-13/NNS	prep_such_as||pathogens-13/NNS||methicillin-resistantstaphylococcusaureus-16/NNS	amod||staphylococcusaureus-19/NNS||vancomycin-resistant-18/JJ	appos||methicillin-resistantstaphylococcusaureus-16/NNS||staphylococcusaureus-19/NNS	amod||²-24/NNS||extended-21/JJ	nn||²-24/NNS||spectrum-22/NN	nn||²-24/NNS||î-23/NN	appos||staphylococcusaureus-19/NNS||²-24/NNS	amod||cultures-28/NNS||lactamase-26/JJ	amod||cultures-28/NNS||producing-27/VBG	dep||staphylococcusaureus-19/NNS||cultures-28/NNS	nn||sp-35/NNS||escherichiacoli-30/NN	conj_and||escherichiacoli-30/NN||pseudomonasaeruginosa-32/NN	nn||sp-35/NNS||pseudomonasaeruginosa-32/NN	conj_and||escherichiacoli-30/NN||klebsiella-34/NN	nn||sp-35/NNS||klebsiella-34/NN	prep_of||cultures-28/NNS||sp-35/NNS	methicillin-resistantstaphylococcusaureus-16||staphylococcusaureus-19||no||the antimicrobial activity of the crude pigment was evaluated against drug resistant pathogens such as methicillin-resistantstaphylococcusaureus, vancomycin-resistant staphylococcusaureus, extended spectrum î²-lactamase producing cultures of escherichiacoli, pseudomonasaeruginosa and klebsiella sp.
det||phenomenon-5/NN||a-2/DT	amod||phenomenon-5/NN||well-recognized-3/JJ	amod||phenomenon-5/NN||clinical-4/JJ	prep_as||called-30/VBN||phenomenon-5/NN	amod||detectable-8/JJ||persistent-7/JJ	amod||replication-28/NN||detectable-8/JJ	amod||replication-28/NN||viral-9/JJ	amod||replication-28/NN||genome-10/JJ	prep_in||genome-10/JJ||liver-12/NN	prep_in||genome-10/JJ||sera-14/NN	conj_or||liver-12/NN||sera-14/NN	det||absence-17/NN||the-16/DT	prep_in||liver-12/NN||absence-17/NN	amod||markers-21/NNS||other-19/JJ	amod||markers-21/NNS||serological-20/JJ	prep_of||absence-17/NN||markers-21/NNS	amod||hepatitisbvirus-24/NNS||active-23/JJ	prep_for||markers-21/NNS||hepatitisbvirus-24/NNS	appos||hepatitisbvirus-24/NNS||hbv-26/NN	nsubjpass||called-30/VBN||replication-28/NN	auxpass||called-30/VBN||is-29/VBZ	root||ROOT-0/null||called-30/VBN	amod||infection-33/NN||occult-31/JJ	nn||infection-33/NN||hbv-32/NN	dobj||called-30/VBN||infection-33/NN	hbv-32||hepatitisbvirus-24||no||as a well-recognized clinical phenomenon, persistent detectable viral genome in liver or sera in the absence of other serological markers for active hepatitisbvirus (hbv) replication is called occult hbv infection.
nsubj||emphasizes-24/VBZ||background-1/NN	conj_and||background-1/NN||aim-3/NN	nsubj||emphasizes-24/VBZ||aim-3/NN	det||number-6/NN||the-4/DT	amod||number-6/NN||increasing-5/VBG	nsubj||performed-10/VBN||number-6/NN	amod||procedures-9/NNS||surgical-8/JJ	prep_of||number-6/NN||procedures-9/NNS	rcmod||background-1/NN||performed-10/VBN	amod||anesthesia-13/NN||local-12/JJ	prep_with||performed-10/VBN||anesthesia-13/NN	vmod||background-1/NN||followed-15/VBN	amod||discharge-19/NN||immediate-17/JJ	nn||discharge-19/NN||patient-18/NN	agent||followed-15/VBN||discharge-19/NN	det||hospital-22/NN||the-21/DT	prep_from||followed-15/VBN||hospital-22/NN	root||ROOT-0/null||emphasizes-24/VBZ	det||need-26/NN||the-25/DT	dobj||emphasizes-24/VBZ||need-26/NN	det||suture-31/NN||a-28/DT	amod||suture-31/NN||tight-29/JJ	nn||suture-31/NN||waterproof-30/NN	prep_for||need-26/NN||suture-31/NN	nsubj||capable-34/JJ||suture-31/NN	cop||capable-34/JJ||is-33/VBZ	rcmod||suture-31/NN||capable-34/JJ	prepc_of||capable-34/JJ||maintaining-36/VBG	poss||strength-39/NN||its-37/PRP$	amod||strength-39/NN||tensile-38/JJ	dobj||maintaining-36/VBG||strength-39/NN	det||phase-43/NN||the-41/DT	amod||phase-43/NN||postoperative-42/JJ	prep_in||maintaining-36/VBG||phase-43/NN	tmod||tumescence-47/VBP||phase-43/NN	advmod||tumescence-47/VBP||when-44/WRB	det||wound-46/NN||the-45/DT	nsubj||tumescence-47/VBP||wound-46/NN	rcmod||phase-43/NN||tumescence-47/VBP	nsubj||due-50/JJ||edema-49/NN	xcomp||tumescence-47/VBP||due-50/JJ	det||anestheticdrug-53/NN||the-52/DT	prep_to||due-50/JJ||anestheticdrug-53/NN	amod||trauma-57/NN||surgical-56/JJ	nsubj||disappear-58/VBP||trauma-57/NN	conj_and||emphasizes-24/VBZ||disappear-58/VBP	edema-49||anestheticdrug-53||no_rel||background and aim the increasing number of surgical procedures performed with local anesthesia, followed by immediate patient discharge from the hospital, emphasizes the need for a tight waterproof suture that is capable of maintaining its tensile strength in the postoperative phase when the wound tumescence, edema due to the anestheticdrug, and surgical trauma disappear.
det||virus-2/NN||the-1/DT	nsubj||pathogenicity-5/JJ||virus-2/NN	cop||pathogenicity-5/JJ||was-3/VBD	advmod||pathogenicity-5/JJ||low-4/RB	root||ROOT-0/null||pathogenicity-5/JJ	amod||analysis-8/NN||phylogenetic-7/JJ	nsubj||revealed-9/VBD||analysis-8/NN	conj_and||pathogenicity-5/JJ||revealed-9/VBD	mark||distinct-13/JJ||that-10/IN	nsubj||distinct-13/JJ||it-11/PRP	cop||distinct-13/JJ||was-12/VBD	ccomp||revealed-9/VBD||distinct-13/JJ	amod||viruses-17/NNS||reported-15/VBN	amod||viruses-17/NNS||h11n1-16/JJ	prep_from||distinct-13/JJ||viruses-17/NNS	virus-2||viruses-17||no||the virus was low pathogenicity and phylogenetic analysis revealed that it was distinct from reported h11n1 viruses.
nsubj||have-15/VBP||variolavirus-1/NNS	appos||variolavirus-1/NNS||varv-3/NNP	det||agent-7/NN||the-5/DT	amod||agent-7/NN||causative-6/JJ	dep||variolavirus-1/NNS||agent-7/NN	prep_of||agent-7/NN||smallpox-9/NN	vmod||variolavirus-1/NNS||eradicated-11/VBN	prep_in||eradicated-11/VBN||1980-13/CD	root||ROOT-0/null||have-15/VBP	amod||spectrum-17/NN||wide-16/JJ	dobj||have-15/VBP||spectrum-17/NN	amod||proteins-20/NNS||immunomodulatory-19/JJ	prep_of||spectrum-17/NN||proteins-20/NNS	aux||evade-22/VB||to-21/TO	vmod||have-15/VBP||evade-22/VB	nn||immunity-24/NN||host-23/NN	dobj||evade-22/VB||immunity-24/NN	smallpox-9||variolavirus-1||no||variolavirus (varv) the causative agent of smallpox, eradicated in 1980, have wide spectrum of immunomodulatory proteins to evade host immunity.
prep_in||produced-11/VBD||particular-2/JJ	nsubj||produced-11/VBD||combinations-4/NNS	vmod||combinations-4/NNS||targeting-5/VBG	det||enzymes-10/NNS||the-6/DT	amod||enzymes-10/NNS||downstream-7/JJ	amod||enzymes-10/NNS||sterol-8/JJ	nn||enzymes-10/NNS||pathway-9/NN	dobj||targeting-5/VBG||enzymes-10/NNS	root||ROOT-0/null||produced-11/VBD	amod||inhibition-16/NN||robust-12/JJ	conj_and||robust-12/JJ||selective-14/JJ	amod||inhibition-16/NN||selective-14/JJ	amod||inhibition-16/NN||synergistic-15/JJ	dobj||produced-11/VBD||inhibition-16/NN	amod||replication-19/NN||hepatitisc-18/JJ	prep_of||inhibition-16/NN||replication-19/NN	enzymes-10||hepatitisc-18||no_rel||in particular, combinations targeting the downstream sterol pathway enzymes produced robust and selective synergistic inhibition of hepatitisc replication.
ccomp||induces-6/VBZ||shigella-1/JJ	det||bacteria-5/NNS||an-3/DT	amod||bacteria-5/NNS||enteroinvasive-4/JJ	nsubj||induces-6/VBZ||bacteria-5/NNS	root||ROOT-0/null||induces-6/VBZ	det||response-10/NN||a-7/DT	amod||response-10/NN||major-8/JJ	amod||response-10/NN||inflammatory-9/JJ	nsubj||responsible-11/JJ||response-10/NN	xcomp||induces-6/VBZ||responsible-11/JJ	amod||rectocolitis-14/NNS||acute-13/JJ	prep_for||responsible-11/JJ||rectocolitis-14/NNS	prep_in||rectocolitis-14/NNS||humans-16/NNS	shigella-1||bacteria-5||no||shigella , an enteroinvasive bacteria induces a major inflammatory response responsible for acute rectocolitis in humans.
nsubj||accounted-23/VBD||questions-1/NNS	vmod||questions-1/NNS||related-2/VBN	prep_to||related-2/VBN||co-morbidities-4/NNS	prep_in||co-morbidities-4/NNS||hiv/aids-6/NNS	amod||cancers-10/NNS||non-aids-8/JJ	amod||cancers-10/NNS||related-9/JJ	dep||hiv/aids-6/NNS||cancers-10/NNS	amod||diseases-13/NNS||systemic-12/JJ	dep||hiv/aids-6/NNS||diseases-13/NNS	conj_and||cancers-10/NNS||diseases-13/NNS	amod||toxicities-19/NNS||chronic-16/JJ	amod||toxicities-19/NNS||antiretroviral-17/JJ	nn||toxicities-19/NNS||treatment-18/NN	prep_in||co-morbidities-4/NNS||toxicities-19/NNS	conj_and||hiv/aids-6/NNS||toxicities-19/NNS	dep||hiv/aids-6/NNS||metabolicdisorders-21/NNS	root||ROOT-0/null||accounted-23/VBD	advmod||lower-26/JJR||significantly-25/RB	amod||scores-27/NNS||lower-26/JJR	prep_for||accounted-23/VBD||scores-27/NNS	dep||scores-27/NNS||mean-29/NN	num||%-32/NN||41.7-31/CD	appos||mean-29/NN||%-32/NN	num||%-35/NN||95-34/CD	npadvmod||ci-36/RB||%-35/NN	advmod||mean-29/NN||ci-36/RB	num||%-38/NN||39.3-37/CD	dep||mean-29/NN||%-38/NN	quantmod||$-40/$||â-39/RB	num||%-43/NN||$-40/$	num||$-40/$||44-42/CD	dep||%-38/NN||%-43/NN	prepc_compared_to||accounted-23/VBD||to-46/TO	nn||epidemiology-48/NN||hiv/aids-47/NNS	pobj||accounted-23/VBD||epidemiology-48/NN	pobj||accounted-23/VBD||prevention-50/NN	conj_and||epidemiology-48/NN||prevention-50/NN	dep||epidemiology-48/NN||mean-52/VB	num||%-55/NN||65.7-54/CD	nsubj||$-63/VBG||%-55/NN	number||%-58/NN||95-57/CD	amod||ci-59/NN||%-58/NN	appos||%-55/NN||ci-59/NN	num||%-61/NN||63.7-60/CD	npadvmod||â-62/RB||%-61/NN	advmod||$-63/VBG||â-62/RB	ccomp||mean-52/VB||$-63/VBG	num||%-66/NN||67.7-65/CD	dobj||$-63/VBG||%-66/NN	aids--1||hiv--1||no||questions related to co-morbidities in hiv/aids (non-aids related cancers and systemic diseases) and chronic antiretroviral treatment toxicities (metabolicdisorders) accounted for significantly lower scores (mean, 41.7%, 95% ci 39.3%â44%) compared to hiv/aids epidemiology and prevention (mean, 65.7%, 95% ci 63.7%â67.7%).
mark||determined-7/VBN||once-1/IN	amod||infection-4/NN||acute-2/JJ	nn||infection-4/NN||dengue-3/NN	nsubjpass||determined-7/VBN||infection-4/NN	aux||determined-7/VBN||has-5/VBZ	auxpass||determined-7/VBN||been-6/VBN	advcl||distinguish-20/VB||determined-7/VBN	det||classifier-11/NN||a-9/DT	amod||classifier-11/NN||2-d-10/JJ	nsubj||distinguish-20/VB||classifier-11/NN	prepc_based_on||classifier-11/NN||on-13/IN	amod||kits-17/NNS||common-14/JJ	amod||kits-17/NNS||denguevirus-15/JJ	nn||kits-17/NNS||igg-16/NN	pobj||classifier-11/NN||kits-17/NNS	aux||distinguish-20/VB||can-18/MD	advmod||distinguish-20/VB||reliably-19/RB	root||ROOT-0/null||distinguish-20/VB	nn||infections-25/NNS||primary-21/NN	conj_and||primary-21/NN||secondary-23/JJ	nn||infections-25/NNS||secondary-23/JJ	nn||infections-25/NNS||dengue-24/NN	dobj||distinguish-20/VB||infections-25/NNS	dengue-24||denguevirus-15||no||once acute dengue infection has been determined, a 2-d classifier based on common denguevirus igg kits can reliably distinguish primary and secondary dengue infections.
agent||reported-56/VBN||employing-2/VBG	det||approach-6/NN||an-3/DT	amod||approach-6/NN||unbiased-4/JJ	amod||approach-6/NN||metagenomic-5/JJ	dobj||employing-2/VBG||approach-6/NN	nsubj||allows-9/VBZ||approach-6/NN	rcmod||approach-6/NN||allows-9/VBZ	det||detection-11/NN||the-10/DT	dobj||allows-9/VBZ||detection-11/NN	preconj||unexpected-14/JJ||both-13/DT	amod||agents-19/NNS||unexpected-14/JJ	advmod||unknown-17/JJ||previously-16/RB	conj_and||unexpected-14/JJ||unknown-17/JJ	amod||agents-19/NNS||unknown-17/JJ	amod||agents-19/NNS||infectious-18/JJ	prep_of||detection-11/NN||agents-19/NNS	det||detection-22/NN||the-21/DT	nsubjpass||reported-56/VBN||detection-22/NN	num||viruses-25/NNS||three-24/CD	prep_of||detection-22/NN||viruses-25/NNS	amod||virus-30/NN||aphid-27/JJ	amod||virus-30/NN||lethal-28/JJ	nn||virus-30/NN||paralysis-29/NN	appos||viruses-25/NNS||virus-30/NN	appos||virus-30/NN||alpv-32/NNP	amod||virus-38/NN||israel-35/JJ	amod||virus-38/NN||acute-36/JJ	nn||virus-38/NN||paralysis-37/NN	appos||viruses-25/NNS||virus-38/NN	conj_and||virus-30/NN||virus-38/NN	appos||virus-38/NN||iapv-40/NNP	nn||virus-46/NN||lake-44/NN	nn||virus-46/NN||sinai-45/NN	appos||viruses-25/NNS||virus-46/NN	conj_and||virus-30/NN||virus-46/NN	appos||virus-46/NN||lsv-48/NN	prep_in||viruses-25/NNS||honeybees-52/NNS	prep_from||honeybees-52/NNS||spain-54/NN	auxpass||reported-56/VBN||is-55/VBZ	root||ROOT-0/null||reported-56/VBN	det||article-59/NN||this-58/DT	prep_in||reported-56/VBN||article-59/NN	virus-46||viruses-25||no||by employing an unbiased metagenomic approach, which allows the detection of both unexpected and previously unknown infectious agents, the detection of three viruses, aphid lethal paralysis virus (alpv), israel acute paralysis virus (iapv), and lake sinai virus (lsv), in honeybees from spain is reported in this article.
nn||diagnosis-2/NN||laboratory-1/NN	nsubj||relies-9/VBZ||diagnosis-2/NN	prep_of||diagnosis-2/NN||tuberculosis-4/NNP	appos||diagnosis-2/NN||tb-6/NN	advmod||relies-9/VBZ||traditionally-8/RB	root||ROOT-0/null||relies-9/VBZ	nn||microscopy-12/NN||smear-11/NN	prep_on||relies-9/VBZ||microscopy-12/NN	prep_on||relies-9/VBZ||culture-14/NN	conj_and||microscopy-12/NN||culture-14/NN	prep_of||microscopy-12/NN||mycobacteriumtuberculosis-16/NNS	amod||samples-19/NNS||clinical-18/JJ	prep_from||relies-9/VBZ||samples-19/NNS	tb-6||mycobacteriumtuberculosis-16||no||laboratory diagnosis of tuberculosis (tb) traditionally relies on smear microscopy and culture of mycobacteriumtuberculosis from clinical samples.
nn||concentrations-2/NNS||serum-1/NN	nsubjpass||measured-50/VBN||concentrations-2/NNS	amod||cytokines-5/NNS||proinflammatory-4/JJ	prep_of||concentrations-2/NNS||cytokines-5/NNS	amod||interleukin-6-8/JJ||interleukin-1alpha-6/JJ	amod||cytokines-5/NNS||interleukin-6-8/JJ	nn||necrosis-11/NNS||tumor-10/NN	prep_of||concentrations-2/NNS||necrosis-11/NNS	conj_and||cytokines-5/NNS||necrosis-11/NNS	amod||colonystimulatingfactor-15/NN||factor-alpha-12/JJ	amod||colonystimulatingfactor-15/NN||granulocyte-macrophage-14/JJ	dep||necrosis-11/NNS||colonystimulatingfactor-15/NN	dep||colonystimulatingfactor-15/NN||gm-csf-17/JJ	det||markers-22/NNS||some-20/DT	amod||markers-22/NNS||biochemical-21/JJ	prep_of||concentrations-2/NNS||markers-22/NNS	conj_and||cytokines-5/NNS||markers-22/NNS	prep_of||markers-22/NNS||osteoporosis-24/NN	nn||alkaline-31/NN||osteocalcin-26/NN	conj_and||osteocalcin-26/NN||total-28/NN	nn||alkaline-31/NN||total-28/NN	conj_and||osteocalcin-26/NN||bone-30/NN	nn||alkaline-31/NN||bone-30/NN	dep||concentrations-2/NNS||alkaline-31/NN	amod||telopeptides-41/NNS||phosphatase-32/JJ	amod||telopeptides-41/NNS||procollagen-34/JJ	nn||telopeptides-41/NNS||type-35/NN	amod||telopeptides-41/NNS||i-36/JJ	amod||telopeptides-41/NNS||carboxyterminal-37/JJ	amod||telopeptides-41/NNS||propeptide-38/JJ	amod||telopeptides-41/NNS||carboxyterminal-40/JJ	dep||alkaline-31/NN||telopeptides-41/NNS	nn||collagen-45/NN||type-43/FW	nn||collagen-45/NN||i-44/FW	prep_of||telopeptides-41/NNS||collagen-45/NN	dep||collagen-45/NN||ctx-47/NN	auxpass||measured-50/VBN||were-49/VBD	root||ROOT-0/null||measured-50/VBN	osteoporosis-24||collagen-45||no_rel||serum concentrations of proinflammatory cytokines interleukin-1alpha, interleukin-6, tumor necrosis factor-alpha, granulocyte-macrophage colonystimulatingfactor (gm-csf) and some biochemical markers of osteoporosis (osteocalcin, total and bone alkaline phosphatase, procollagen type i carboxyterminal propeptide, carboxyterminal telopeptides of type i collagen--ctx) were measured.
det||retrospective-2/NN||this-1/DT	root||ROOT-0/null||retrospective-2/NN	nn||study-5/NN||multicenter-4/NN	appos||retrospective-2/NN||study-5/NN	vmod||study-5/NN||evaluated-6/VBN	det||feasibility-8/NN||the-7/DT	dobj||evaluated-6/VBN||feasibility-8/NN	dobj||evaluated-6/VBN||safety-10/NN	conj_and||feasibility-8/NN||safety-10/NN	dep||rate-13/NN||high-dose-12/JJ	amod||brachytherapy-15/NN||rate-13/NN	amod||brachytherapy-15/NN||electronic-14/JJ	prep_of||feasibility-8/NN||brachytherapy-15/NN	appos||brachytherapy-15/NN||ebt-17/NN	det||therapy-24/NN||a-20/DT	amod||therapy-24/NN||postsurgical-21/JJ	amod||therapy-24/NN||adjuvant-22/JJ	nn||therapy-24/NN||radiation-23/NN	prep_as||evaluated-6/VBN||therapy-24/NN	amod||cancer-27/NN||endometrial-26/JJ	prep_for||therapy-24/NN||cancer-27/NN	cancer-27||adjuvant-22||no_rel||this retrospective, multicenter study evaluated the feasibility and safety of high-dose rate electronic brachytherapy (ebt) as a postsurgical adjuvant radiation therapy for endometrial cancer.
nsubj||disease-9/NN||severeacuterespiratorysyndrome-1/NN	appos||severeacuterespiratorysyndrome-1/NN||sars-3/NNS	cop||disease-9/NN||is-5/VBZ	det||disease-9/NN||an-6/DT	amod||disease-9/NN||emerging-7/VBG	amod||disease-9/NN||infectious-8/JJ	root||ROOT-0/null||disease-9/NN	vmod||disease-9/NN||caused-10/VBN	det||coronavirussars-cov-14/NN||the-12/DT	nn||coronavirussars-cov-14/NN||novel-13/NN	agent||caused-10/VBN||coronavirussars-cov-14/NN	sars-3||coronavirussars--1||no||severeacuterespiratorysyndrome (sars) is an emerging infectious disease caused by the novel coronavirussars-cov.
nsubj||one-6/CD||isoniazid-1/NN	appos||isoniazid-1/NN||inh-3/NN	cop||one-6/CD||is-5/VBZ	root||ROOT-0/null||one-6/CD	det||drugs-12/NNS||the-8/DT	amod||drugs-12/NNS||main-9/JJ	amod||drugs-12/NNS||first-10/JJ	nn||drugs-12/NNS||line-11/NN	prep_of||one-6/CD||drugs-12/NNS	vmod||drugs-12/NNS||used-13/VBN	prep_in||used-13/VBN||treatment-15/NN	prep_of||treatment-15/NN||tuberculosis-17/NNP	nsubj||result-26/VB||development-19/NN	prep_of||development-19/NN||resistance-21/NN	det||compound-24/NN||this-23/DT	prep_against||resistance-21/NN||compound-24/NN	aux||result-26/VB||can-25/MD	conj_and||one-6/CD||result-26/VB	amod||problems-29/NNS||serious-28/JJ	prep_in||result-26/VB||problems-29/NNS	nn||procedures-32/NNS||treatment-31/NN	prep_in||problems-29/NNS||procedures-32/NNS	tuberculosis-17||inh-3||yes||isoniazid (inh) is one of the main first line drugs used in treatment of tuberculosis and development of resistance against this compound can result in serious problems in treatment procedures.
amod||lato-3/NN||borreliaburgdorferi-1/JJ	amod||lato-3/NN||sensu-2/JJ	nsubj||agent-10/NN||lato-3/NN	appos||lato-3/NN||s.l.-5/NNP	cop||agent-10/NN||are-7/VBP	det||agent-10/NN||the-8/DT	amod||agent-10/NN||causative-9/JJ	root||ROOT-0/null||agent-10/NN	prep_for||agent-10/NN||lymeborreliosis-12/NNS	appos||lymeborreliosis-12/NNS||lb-14/NN	det||disease-21/NN||the-17/DT	advmod||common-19/JJ||most-18/RBS	amod||disease-21/NN||common-19/JJ	amod||disease-21/NN||tick-borne-20/JJ	appos||lymeborreliosis-12/NNS||disease-21/NN	det||hemisphere-25/NN||the-23/DT	amod||hemisphere-25/NN||northern-24/JJ	prep_in||disease-21/NN||hemisphere-25/NN	lymeborreliosis-12||borreliaburgdorferi-1||no||borreliaburgdorferi sensu lato (s.l.) are the causative agent for lymeborreliosis (lb), the most common tick-borne disease in the northern hemisphere.
nsubj||has-2/VBZ||mtb-1/NN	root||ROOT-0/null||has-2/VBZ	amod||glycolipids-6/NNS||several-3/JJ	nn||glycolipids-6/NNS||cell-4/NN	nn||glycolipids-6/NNS||wall-5/NN	dobj||has-2/VBZ||glycolipids-6/NNS	amod||models-36/NNS||common-8/JJ	prep_with||common-8/JJ||ms-10/NN	nsubj||play-13/VBP||ms-10/NN	rcmod||ms-10/NN||play-13/VBP	det||role-16/NN||an-14/DT	amod||role-16/NN||important-15/JJ	dobj||play-13/VBP||role-16/NN	det||pathogenesis-19/NNS||the-18/DT	prep_in||role-16/NN||pathogenesis-19/NNS	prep_of||pathogenesis-19/NNS||tuberculosis-21/NNP	det||induction-24/NN||the-23/DT	prep_in||role-16/NN||induction-24/NN	conj_and||pathogenesis-19/NNS||induction-24/NN	det||response-29/NN||a-26/DT	amod||response-29/NN||protective-27/JJ	amod||response-29/NN||immune-28/JJ	prep_of||induction-24/NN||response-29/NN	nn||infection-32/NN||mtb-31/NN	prep_against||response-29/NN||infection-32/NN	det||animal-35/NN||some-34/DT	prep_in||infection-32/NN||animal-35/NN	prep_in||glycolipids-6/NNS||models-36/NNS	tuberculosis-21||mtb-31||no||mtb has several cell wall glycolipids in common with ms, which play an important role in the pathogenesis of tuberculosis and the induction of a protective immune response against mtb infection in some animal models.
expl||is-2/VBZ||there-1/EX	root||ROOT-0/null||is-2/VBZ	amod||concern-4/NN||worldwide-3/JJ	nsubj||is-2/VBZ||concern-4/NN	det||possibility-7/NN||the-6/DT	prep_over||concern-4/NN||possibility-7/NN	det||pandemic-12/NN||a-9/DT	amod||pandemic-12/NN||new-10/JJ	nn||pandemic-12/NN||influenza-11/NN	prep_of||possibility-7/NN||pandemic-12/NN	vmod||pandemic-12/NN||originating-13/VBG	det||influenzaviruses-20/NNS||the-15/DT	advmod||pathogenic-17/JJ||highly-16/RB	amod||influenzaviruses-20/NNS||pathogenic-17/JJ	amod||influenzaviruses-20/NNS||avian-18/JJ	amod||influenzaviruses-20/NNS||h5n1-19/JJ	prep_from||originating-13/VBG||influenzaviruses-20/NNS	influenza-11||influenzaviruses-20||no||there is worldwide concern over the possibility of a new influenza pandemic originating from the highly pathogenic avian h5n1 influenzaviruses.
det||pandemic-11/NN||the-1/DT	nn||pandemic-11/NN||humanimmunodeficiencyvirus-2/NNS	appos||humanimmunodeficiencyvirus-2/NNS||hiv-4/NN	amod||pandemic-11/NN||/-6/JJ	nn||pandemic-11/NN||acquiredimmunedeficiencysyndrome-7/NN	appos||pandemic-11/NN||aids-9/NNS	nsubj||has-12/VBZ||pandemic-11/NN	root||ROOT-0/null||has-12/VBZ	amod||effects-14/NNS||pervasive-13/JJ	dobj||has-12/VBZ||effects-14/NNS	prep_on||effects-14/NNS||culture-16/NN	prep_on||effects-14/NNS||economics-18/NNS	conj_and||culture-16/NN||economics-18/NNS	prep_on||effects-14/NNS||policy-20/NN	conj_and||culture-16/NN||policy-20/NN	amod||development-24/NN||human-23/JJ	prep_on||effects-14/NNS||development-24/NN	conj_and||culture-16/NN||development-24/NN	acquiredimmunedeficiencysyndrome-7||hiv-4||no||the humanimmunodeficiencyvirus (hiv)/ acquiredimmunedeficiencysyndrome (aids) pandemic has pervasive effects on culture, economics, policy, and human development.
det||success-2/NN||the-1/DT	nsubj||depends-8/VBZ||success-2/NN	amod||programs-7/NNS||large-scale-4/JJ	amod||programs-7/NNS||antiretroviral-5/JJ	nn||programs-7/NNS||therapy-6/NN	prep_of||success-2/NN||programs-7/NNS	root||ROOT-0/null||depends-8/VBZ	amod||initiation-11/NN||early-10/JJ	prep_on||depends-8/VBZ||initiation-11/NN	amod||care-14/NN||hiv/aids-13/JJ	prep_of||initiation-11/NN||care-14/NN	aids--1||hiv--1||no||the success of large-scale antiretroviral therapy programs depends on early initiation of hiv/aids care.
aux||determine-2/VB||to-1/TO	csubj||use-21/VBP||determine-2/VB	mark||decrease-17/VB||whether-3/IN	amod||administration-8/NN||pre-4/JJ	conj_and||pre-4/JJ||post-operative-7/JJ	amod||administration-8/NN||post-operative-7/JJ	nsubj||decrease-17/VB||administration-8/NN	amod||ibuprofen-11/NN||intravenous-10/JJ	prep_of||administration-8/NN||ibuprofen-11/NN	appos||ibuprofen-11/NN||iv-ibuprofen-13/NN	aux||decrease-17/VB||can-15/MD	advmod||decrease-17/VB||significantly-16/RB	ccomp||determine-2/VB||decrease-17/VB	dobj||decrease-17/VB||pain-18/NN	dobj||decrease-17/VB||morphine-20/NN	conj_and||pain-18/NN||morphine-20/NN	root||ROOT-0/null||use-21/VBP	advmod||compared-23/VBN||when-22/WRB	advcl||use-21/VBP||compared-23/VBN	prep_with||compared-23/VBN||placebo-25/NN	amod||patients-30/NNS||adult-27/JJ	amod||patients-30/NNS||orthopedic-28/JJ	amod||patients-30/NNS||surgical-29/JJ	prep_in||placebo-25/NN||patients-30/NNS	pain-18||ibuprofen-11||yes||to determine whether pre- and post-operative administration of intravenous ibuprofen (iv-ibuprofen) can significantly decrease pain and morphine use when compared with placebo in adult orthopedic surgical patients.
amod||subjects-2/NNS||obese-1/JJ	nsubj||candidates-5/NNS||subjects-2/NNS	nsubj||characterized-11/JJ||subjects-2/NNS	cop||candidates-5/NNS||were-4/VBD	rcmod||subjects-2/NNS||candidates-5/NNS	amod||surgery-8/NN||bariatric-7/JJ	prep_for||candidates-5/NNS||surgery-8/NN	cop||characterized-11/JJ||were-9/VBD	advmod||characterized-11/JJ||clinically-10/RB	root||ROOT-0/null||characterized-11/JJ	advmod||characterized-11/JJ||before-12/RB	dep||characterized-11/JJ||3-14/CD	dep||characterized-11/JJ||6-16/CD	conj_and||3-14/CD||6-16/CD	num||months-20/NNS||12-19/CD	dep||characterized-11/JJ||months-20/NNS	conj_and||3-14/CD||months-20/NNS	prep_after||months-20/NNS||surgery-22/NN	amod||evaluation-27/NN||fat-25/JJ	amod||evaluation-27/NN||mass-26/JJ	prep_including||months-20/NNS||evaluation-27/NN	amod||absorptiometry-32/NN||dual-29/JJ	nn||absorptiometry-32/NN||energy-30/NN	nn||absorptiometry-32/NN||x-ray-31/NN	prep_by||evaluation-27/NN||absorptiometry-32/NN	obese-1||fat-25||no_rel||obese subjects who were candidates for bariatric surgery were clinically characterized before, 3, 6, and 12 months after surgery, including fat mass evaluation by dual energy x-ray absorptiometry.
nn||culture-3/NN||tissue-2/NN	prep_in||inhibited-10/VBD||culture-3/NN	amod||acid-5/NN||phosphonoacetic-4/JJ	nsubj||inhibited-10/VBD||acid-5/NN	appos||acid-5/NN||paa-7/NN	advmod||inhibited-10/VBD||specifically-9/RB	root||ROOT-0/null||inhibited-10/VBD	nn||synthesis-12/NN||dna-11/NN	dobj||inhibited-10/VBD||synthesis-12/NN	prep_of||synthesis-12/NN||humancytomegalovirus-14/NNS	appos||humancytomegalovirus-14/NNS||cmv-16/NN	amod||cmv-20/NN||murine-19/JJ	prep_of||synthesis-12/NN||cmv-20/NN	conj_and||humancytomegalovirus-14/NNS||cmv-20/NN	nn||cmv-23/NN||simian-22/NN	prep_of||synthesis-12/NN||cmv-23/NN	conj_and||humancytomegalovirus-14/NNS||cmv-23/NN	prep_of||synthesis-12/NN||epstein-barrvirus-25/NNS	conj_and||humancytomegalovirus-14/NNS||epstein-barrvirus-25/NNS	amod||saimiri-29/NNS||herpesvirus-28/JJ	prep_of||synthesis-12/NN||saimiri-29/NNS	conj_and||humancytomegalovirus-14/NNS||saimiri-29/NNS	cmv-23||humancytomegalovirus-14||no||in tissue culture phosphonoacetic acid (paa) specifically inhibited dna synthesis of humancytomegalovirus (cmv), murine cmv, simian cmv, epstein-barrvirus, and herpesvirus saimiri.
expl||are-2/VBP||there-1/EX	root||ROOT-0/null||are-2/VBP	det||number-4/NN||a-3/DT	nsubj||are-2/VBP||number-4/NN	amod||issues-8/NNS||potential-6/JJ	nn||issues-8/NNS||safety-7/NN	prep_of||number-4/NN||issues-8/NNS	vmod||issues-8/NNS||associated-9/VBN	amod||glucose-12/NN||various-11/JJ	prep_with||associated-9/VBN||glucose-12/NN	amod||therapies-16/NNS||lipid-lowering-15/JJ	prep_of||number-4/NN||therapies-16/NNS	conj_and||issues-8/NNS||therapies-16/NNS	nsubj||relevant-19/JJ||therapies-16/NNS	cop||relevant-19/JJ||are-18/VBP	rcmod||therapies-16/NNS||relevant-19/JJ	amod||patients-22/NNS||elderly-21/JJ	prep_to||relevant-19/JJ||patients-22/NNS	xcomp||relevant-19/JJ||including-24/VBG	amod||risk-26/NN||increased-25/VBN	dobj||including-24/VBG||risk-26/NN	nn||exacerbations-30/NNS||heart-28/NN	nn||exacerbations-30/NNS||failure-29/NN	prep_of||risk-26/NN||exacerbations-30/NNS	nn||loss-33/NN||weight-32/NN	dobj||including-24/VBG||loss-33/NN	conj_and||risk-26/NN||loss-33/NN	amod||risk-36/NN||increased-35/VBN	dobj||including-24/VBG||risk-36/NN	conj_and||risk-26/NN||risk-36/NN	prep_of||risk-36/NN||hypoglycaemia-38/NN	amod||risk-41/NN||increased-40/VBN	dobj||including-24/VBG||risk-41/NN	conj_and||risk-26/NN||risk-41/NN	prep_of||risk-41/NN||myopathy-43/NN	dobj||including-24/VBG||contraindications-46/NNS	conj_and||risk-26/NN||contraindications-46/NNS	det||agents-49/NNS||some-48/DT	prep_of||contraindications-46/NNS||agents-49/NNS	prep_in||agents-49/NNS||patients-51/NNS	amod||impairment-56/NN||hepatic-53/JJ	conj_or||hepatic-53/JJ||renal-55/JJ	amod||impairment-56/NN||renal-55/JJ	prep_with||patients-51/NNS||impairment-56/NN	hypoglycaemia-38||glucose-12||yes||there are a number of potential safety issues associated with various glucose- and lipid-lowering therapies that are relevant to elderly patients, including increased risk of heart failure exacerbations, weight loss, increased risk of hypoglycaemia, increased risk of myopathy, and contraindications of some agents in patients with hepatic or renal impairment.
root||ROOT-0/null||mtb-1/NN	amod||vivo-7/NNP||specific-3/JJ	nn||vivo-7/NNP||antigen-4/NN	nn||vivo-7/NNP||stimulation-5/NNP	nn||vivo-7/NNP||ex-6/FW	dep||mtb-1/NN||vivo-7/NNP	vmod||vivo-7/NNP||altered-8/VBN	nn||expression-10/NN||clusterin-9/NN	dobj||altered-8/VBN||expression-10/NN	amod||samples-14/NNS||whole-12/JJ	nn||samples-14/NNS||blood-13/NN	prep_in||altered-8/VBN||samples-14/NNS	vmod||samples-14/NNS||collected-15/VBN	prep_from||collected-15/VBN||patients-17/NNS	amod||tb-20/NN||active-19/JJ	prep_with||patients-17/NNS||tb-20/NN	tb-20||mtb-1||no||mtb -specific antigen stimulation ex vivo altered clusterin expression in whole blood samples collected from patients with active tb.
amod||achievements-2/NNS||major-1/JJ	nsubjpass||reached-5/VBN||achievements-2/NNS	aux||reached-5/VBN||have-3/VBP	auxpass||reached-5/VBN||been-4/VBN	root||ROOT-0/null||reached-5/VBN	det||treatment-8/NN||the-7/DT	prep_in||reached-5/VBN||treatment-8/NN	prep_of||treatment-8/NN||rheumatoidarthritis-10/NNS	amod||decades-13/NNS||past-12/JJ	prep_during||rheumatoidarthritis-10/NNS||decades-13/NNS	det||recognition-17/NN||the-16/DT	prep_due_to||reached-5/VBN||recognition-17/NN	prep_of||recognition-17/NN||methotrexate-19/NN	det||drug-23/NN||an-21/DT	amod||drug-23/NN||anchor-22/JJ	prep_as||methotrexate-19/NN||drug-23/NN	prep_for||drug-23/NN||treatment-25/NN	prep_of||treatment-25/NN||rheumatoidarthritis-27/NNS	det||notion-32/NN||the-31/DT	prep_due_to||reached-5/VBN||notion-32/NN	det||window-36/NN||a-34/DT	nn||window-36/NN||treatment-35/NN	prep_of||notion-32/NN||window-36/NN	prep_of||window-36/NN||opportunity-38/NN	prep_in||opportunity-38/NN||patients-40/NNS	amod||rheumatoidarthritis-43/NNS||recent-onset-42/JJ	prep_with||patients-40/NNS||rheumatoidarthritis-43/NNS	vmod||rheumatoidarthritis-43/NNS||necessitating-44/VBG	amod||therapy-47/NN||early-45/JJ	amod||therapy-47/NN||aggressive-46/JJ	dobj||necessitating-44/VBG||therapy-47/NN	det||development-52/NN||the-51/DT	prep_due_to||therapy-47/NN||development-52/NN	prep_of||development-52/NN||biologics-54/NNS	dobj||necessitating-44/VBG||due-56/JJ	conj_and||therapy-47/NN||due-56/JJ	aux||remission-58/VB||to-57/TO	vmod||therapy-47/NN||remission-58/VB	det||target-62/NN||a-60/DT	nn||target-62/NN||treatment-61/NN	prep_as||remission-58/VB||target-62/NN	rheumatoidarthritis-43||methotrexate-19||yes||major achievements have been reached in the treatment of rheumatoidarthritis during past decades due to the recognition of methotrexate as an anchor drug for treatment of rheumatoidarthritis, due to the notion of a treatment window of opportunity in patients with recent-onset rheumatoidarthritis necessitating early aggressive therapy, due to the development of biologics and due to remission as a treatment target.
det||use-2/NN||the-1/DT	nsubjpass||associated-11/VBN||use-2/NN	prep_of||use-2/NN||warfarin-4/NN	advmod||associated-11/VBN||up-5/RB	num||days-8/NNS||90-7/CD	prep_to||up-5/RB||days-8/NNS	auxpass||associated-11/VBN||was-9/VBD	neg||associated-11/VBN||not-10/RB	root||ROOT-0/null||associated-11/VBN	nn||protection-14/NN||stroke-13/NN	prep_with||associated-11/VBN||protection-14/NN	nn||mi-17/NN||anterior-16/NN	prep_after||associated-11/VBN||mi-17/NN	nn||-RSB--23/NNP||hazard-19/NN	nn||-RSB--23/NNP||ratio-20/NN	nn||-RSB--23/NNP||-LSB--21/NNP	nn||-RSB--23/NNP||hr-22/FW	dep||mi-17/NN||-RSB--23/NNP	amod||-RSB--23/NNP||0.68-25/CD	number||%-28/NN||95-27/CD	amod||interval-30/NN||%-28/NN	nn||interval-30/NN||confidence-29/NN	dep||-RSB--23/NNP||interval-30/NN	nn||â-36/FW||-LSB--31/FW	nn||â-36/FW||ci-32/FW	nn||â-36/FW||-RSB--33/FW	dep||â-36/FW||0.37-35/FW	dep||interval-30/NN||â-36/FW	dep||-RSB--23/NNP||$-37/$	num||$-37/$||1.26-39/CD	stroke-13||warfarin-4||yes||the use of warfarin up to 90 days was not associated with stroke protection after anterior mi (hazard ratio [hr], 0.68; 95% confidence interval [ci], 0.37â1.26).
poss||efficacy-4/NN||its-2/PRP$	amod||efficacy-4/NN||well-established-3/JJ	prep_despite||is-22/VBZ||efficacy-4/NN	prepc_in||efficacy-4/NN||reducing-6/VBG	amod||death-8/NN||cardiac-related-7/JJ	dobj||reducing-6/VBG||death-8/NN	dobj||reducing-6/VBG||myocardialinfarction-10/NN	conj_and||death-8/NN||myocardialinfarction-10/NN	dobj||reducing-6/VBG||stroke-13/NN	conj_and||death-8/NN||stroke-13/NN	amod||therapy-17/NN||dual-15/JJ	nn||therapy-17/NN||antiplatelet-16/NN	nsubj||is-22/VBZ||therapy-17/NN	prep_with||therapy-17/NN||aspirin-19/NN	prep_with||therapy-17/NN||clopidogrel-21/NN	conj_and||aspirin-19/NN||clopidogrel-21/NN	root||ROOT-0/null||is-22/VBZ	neg||is-22/VBZ||not-23/RB	prep_without||is-22/VBZ||shortcomings-25/NNS	myocardialinfarction-10||clopidogrel-21||yes||despite its well-established efficacy in reducing cardiac-related death, myocardialinfarction, and stroke, dual antiplatelet therapy with aspirin and clopidogrel is not without shortcomings.
poss||data-2/NNS||our-1/PRP$	nsubj||suggests-3/VBZ||data-2/NNS	root||ROOT-0/null||suggests-3/VBZ	mark||provide-14/VB||that-4/IN	amod||screening-6/NN||genetic-5/JJ	nsubj||provide-14/VB||screening-6/NN	nsubj||provide-14/VB||screening-6/NN	det||mutation-12/NN||the-8/DT	amod||mutation-12/NN||s315t-9/JJ	nn||mutation-12/NN||kat-10/NN	nn||mutation-12/NN||g-11/NN	prep_for||screening-6/NN||mutation-12/NN	aux||provide-14/VB||may-13/MD	ccomp||suggests-3/VBZ||provide-14/VB	ccomp||suggests-3/VBZ||provide-14/VB	conj_and||provide-14/VB||provide-14/VB	amod||information-16/NN||rapid-15/JJ	dobj||provide-14/VB||information-16/NN	amod||selection-20/NN||anti-tb-18/JJ	nn||selection-20/NN||regimen-19/NN	prep_for||provide-14/VB||selection-20/NN	amod||monitoring-23/NN||epidemiological-22/JJ	appos||selection-20/NN||monitoring-23/NN	nn||resistance-26/NN||inh-25/NN	prep_of||monitoring-23/NN||resistance-26/NN	dep||provide-14/VB||possibly-29/RB	nn||transmission-33/NN||track-32/NN	prep_to||provide-14/VB||transmission-33/NN	advmod||resistant-36/JJ||inh-35/RB	amod||strains-37/NNS||resistant-36/JJ	prep_of||transmission-33/NN||strains-37/NNS	tb--1||inh-35||yes||our data suggests that genetic screening for the s315t kat g mutation may provide rapid information for anti-tb regimen selection, epidemiological monitoring of inh resistance and, possibly, to track transmission of inh resistant strains.
poss||objective-2/NN||our-1/PRP$	nsubj||was-3/VBD||objective-2/NN	root||ROOT-0/null||was-3/VBD	aux||examine-5/VB||to-4/TO	ccomp||was-3/VBD||examine-5/VB	det||relationship-7/NN||the-6/DT	dobj||examine-5/VB||relationship-7/NN	amod||indexes-10/NNS||common-9/JJ	nsubj||using-23/VBG||indexes-10/NNS	amod||glycemia-13/NN||postprandial-12/JJ	prep_of||indexes-10/NNS||glycemia-13/NN	amod||hyperglycemia-16/NN||overall-15/JJ	prep_of||indexes-10/NNS||hyperglycemia-16/NN	conj_and||glycemia-13/NN||hyperglycemia-16/NN	nn||variability-19/NN||glucose-18/NN	prep_of||indexes-10/NNS||variability-19/NN	conj_and||glycemia-13/NN||variability-19/NN	prep_of||indexes-10/NNS||a1c-22/NNS	conj_and||glycemia-13/NN||a1c-22/NNS	prepc_among||examine-5/VB||using-23/VBG	amod||measures-26/NNS||detailed-24/JJ	nn||measures-26/NNS||glucose-25/NN	dobj||using-23/VBG||measures-26/NNS	vmod||measures-26/NNS||obtained-27/VBN	amod||life-30/NN||everyday-29/JJ	prep_during||obtained-27/VBN||life-30/NN	aux||study-33/VB||to-32/TO	ccomp||was-3/VBD||study-33/VB	conj_and||examine-5/VB||study-33/VB	dobj||provide-40/VBP||which-34/WDT	amod||values-36/NNS||bloodglucose-35/JJ	nsubj||provide-40/VBP||values-36/NNS	det||day-39/NN||the-38/DT	prep_of||values-36/NNS||day-39/NN	ccomp||study-33/VB||provide-40/VBP	det||prediction-43/NN||the-41/DT	amod||prediction-43/NN||strongest-42/JJS	dobj||provide-40/VBP||prediction-43/NN	prep_of||prediction-43/NN||a1c-45/CD	hyperglycemia-16||glucose-25||no||our objective was to examine the relationship among common indexes of postprandial glycemia, overall hyperglycemia, glucose variability, and a1c using detailed glucose measures obtained during everyday life and to study which bloodglucose values of the day provide the strongest prediction of a1c.
mark||suggested-6/VBN||although-1/IN	det||studies-4/NNS||some-2/DT	amod||studies-4/NNS||previous-3/JJ	nsubj||suggested-6/VBN||studies-4/NNS	aux||suggested-6/VBN||have-5/VBP	advcl||examined-24/VBN||suggested-6/VBN	mark||comprised-14/VBN||that-7/IN	amod||growth-9/NN||posttraumatic-8/JJ	nsubjpass||comprised-14/VBN||growth-9/NN	appos||growth-9/NN||ptg-11/NN	auxpass||comprised-14/VBN||is-13/VBZ	ccomp||suggested-6/VBN||comprised-14/VBN	amod||factors-17/NNS||several-16/JJ	prep_of||comprised-14/VBN||factors-17/NNS	amod||properties-20/NNS||different-19/JJ	prep_with||comprised-14/VBN||properties-20/NNS	nsubj||examined-24/VBN||few-22/JJ	aux||examined-24/VBN||have-23/VBP	root||ROOT-0/null||examined-24/VBN	predet||association-27/NN||both-25/PDT	det||association-27/NN||the-26/DT	dobj||examined-24/VBN||association-27/NN	prep_between||examined-24/VBN||ptg-29/NN	prep_between||examined-24/VBN||posttraumaticstressdisorder-31/NN	conj_and||ptg-29/NN||posttraumaticstressdisorder-31/NN	dep||examined-24/VBN||ptsd-33/VBN	prep_between||examined-24/VBN||ptg-37/NN	conj_and||ptg-29/NN||ptg-37/NN	conj_and||ptg-29/NN||resilience-39/NN	conj_and||ptg-37/NN||resilience-39/NN	vmod||ptg-37/NN||focusing-41/VBG	prep_on||focusing-41/VBG||each-43/DT	det||factors-46/NNS||the-45/DT	prep_of||each-43/DT||factors-46/NNS	prep_of||factors-46/NNS||ptg-48/NN	ptg-48||posttraumaticstressdisorder-31||no_rel||although some previous studies have suggested that posttraumatic growth (ptg) is comprised of several factors with different properties, few have examined both the association between ptg and posttraumaticstressdisorder (ptsd) and between ptg and resilience, focusing on each of the factors of ptg.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||compare-8/VB||purpose-2/NN	nsubj||ketamine-21/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	det||combination-10/NN||a-9/DT	dobj||compare-8/VB||combination-10/NN	prep_of||combination-10/NN||lidocaine-12/NN	prep_of||combination-10/NN||ketamine-14/NN	conj_and||lidocaine-12/NN||ketamine-14/NN	amod||pain-17/NN||aquafol-induced-16/JJ	prep_on||compare-8/VB||pain-17/NN	prep_with||compare-8/VB||lidocaine-19/NN	xcomp||was-6/VBD||ketamine-21/VB	conj_or||compare-8/VB||ketamine-21/VB	advmod||ketamine-21/VB||alone-22/RB	det||induction-25/NN||the-24/DT	prep_during||ketamine-21/VB||induction-25/NN	prep_of||induction-25/NN||anesthesia-27/NN	pain-17||lidocaine-19||yes||the purpose of this study was to compare a combination of lidocaine and ketamine on aquafol-induced pain with lidocaine or ketamine alone during the induction of anesthesia.
amod||lupuserythematosus-2/NNS||systemic-1/JJ	nsubj||autoimmunedisease-9/NN||lupuserythematosus-2/NNS	appos||lupuserythematosus-2/NNS||sle-4/NN	cop||autoimmunedisease-9/NN||is-6/VBZ	det||autoimmunedisease-9/NN||a-7/DT	amod||autoimmunedisease-9/NN||systemic-8/JJ	root||ROOT-0/null||autoimmunedisease-9/NN	vmod||autoimmunedisease-9/NN||characterized-10/VBN	amod||interferons-15/NNS||increased-12/VBN	nn||interferons-15/NNS||type-13/NN	amod||interferons-15/NNS||i-14/VBG	agent||characterized-10/VBN||interferons-15/NNS	dep||autoimmunedisease-9/NN||ifns-17/NNS	nn||inflammation-21/NN||multiorgan-20/NN	conj_and||autoimmunedisease-9/NN||inflammation-21/NN	advmod||targeting-23/VBG||frequently-22/RB	vmod||inflammation-21/NN||targeting-23/VBG	det||skin-25/NN||the-24/DT	dobj||targeting-23/VBG||skin-25/NN	interferons-15||inflammation-21||no_rel||systemic lupuserythematosus (sle) is a systemic autoimmunedisease characterized by increased type i interferons (ifns) and multiorgan inflammation frequently targeting the skin.
root||ROOT-0/null||using-1/VBG	dobj||using-1/VBG||data-2/NNS	prep_on||using-1/VBG||mammals-4/NNS	dep||using-1/VBG||imported-5/VBD	prep_during||imported-5/VBD||2000â-7/CD	nsubj||using-1/VBG||$-8/$	npadvmod||host-17/RB||2005-10/NNS	dep||2005-10/NNS||we-12/PRP	poss||potential-15/NN||their-14/PRP$	prep_assessed||2005-10/NNS||potential-15/NN	vmod||potential-15/NN||to-16/TO	dep||27-18/CD||host-17/RB	num||$-8/$||27-18/CD	dep||$-8/$||selected-19/VBN	nn||zoonoses-21/NNS||risk-20/NN	dobj||selected-19/VBN||zoonoses-21/NNS	dep||$-8/$||created-23/VBN	conj_and||selected-19/VBN||created-23/VBN	det||assessment-26/NN||a-24/DT	nn||assessment-26/NN||risk-25/NN	dobj||created-23/VBN||assessment-26/NN	nsubj||inform-29/VB||assessment-26/NN	aux||inform-29/VB||could-28/MD	rcmod||assessment-26/NN||inform-29/VB	dobj||inform-29/VB||policy-30/NN	vmod||policy-30/NN||making-31/VBG	nn||importation-34/NN||wildlife-33/NN	prep_for||making-31/VBG||importation-34/NN	amod||surveillance-38/NN||zoonotic-36/JJ	nn||surveillance-38/NN||disease-37/NN	nsubj||using-1/VBG||surveillance-38/NN	conj_and||$-8/$||surveillance-38/NN	inform-29||zoonoses-21||no_rel||using data on mammals imported during 2000â2005, we assessed their potential to host 27 selected risk zoonoses and created a risk assessment that could inform policy making for wildlife importation and zoonotic disease surveillance.
nsubj||compared-2/VBD||we-1/PRP	dep||-lrb--10/VBZ||compared-2/VBD	dobj||compared-2/VBD||colony-3/NN	vmod||colony-3/NN||spreading-4/VBG	advmod||isolated-7/VBN||clinically-6/RB	amod||s.aureus-9/NNS||isolated-7/VBN	amod||s.aureus-9/NNS||methicillin-sensitive-8/JJ	prep_of||spreading-4/VBG||s.aureus-9/NNS	root||ROOT-0/null||-lrb--10/VBZ	npadvmod||-rrb--12/JJ||mssa-11/NN	dobj||-lrb--10/VBZ||-rrb--12/JJ	amod||s.aureus-15/NNS||methicillin-resistant-14/JJ	dobj||-lrb--10/VBZ||s.aureus-15/NNS	conj_and||-rrb--12/JJ||s.aureus-15/NNS	num||-rrb--18/NN||-lrb--16/CD	nn||-rrb--18/NN||mrsa-17/NN	nsubj||-lrb--10/VBZ||-rrb--18/NN	mrsa-17||s.aureus-15||no||we compared colony spreading of clinically isolated methicillin-sensitive s.aureus -lrb- mssa -rrb- and methicillin-resistant s.aureus -lrb- mrsa -rrb- .
det||rats-4/NNS||the-1/DT	nn||rats-4/NNS||asthma-2/NN	nn||rats-4/NNS||model-3/NN	nsubjpass||treated-6/VBN||rats-4/NNS	auxpass||treated-6/VBN||were-5/VBD	root||ROOT-0/null||treated-6/VBN	prep_with||treated-6/VBN||rn-8/NN	amod||rn-8/NN||saline-10/JJ	amod||rn-8/NN||dexamethasone-13/JJ	conj_and||saline-10/JJ||dexamethasone-13/JJ	dep||rn-8/NN||dxm-16/RB	vmod||rn-8/NN||treated-19/VBN	dobj||treated-19/VBN||rats-20/NNS	vmod||rats-20/NNS||served-21/VBN	amod||controls-26/NNS||normal-23/JJ	conj_and||normal-23/JJ||model-25/JJ	amod||controls-26/NNS||model-25/JJ	prep_as||served-21/VBN||controls-26/NNS	asthma-2||dxm-16||yes||the asthma model rats were treated with rn; saline- and dexamethasone- (dxm-) treated rats served as normal and model controls.
det||sensitivity-2/NN||the-1/DT	nsubjpass||evaluated-12/VBN||sensitivity-2/NN	conj_and||sensitivity-2/NN||specificity-4/NN	nsubjpass||evaluated-12/VBN||specificity-4/NN	det||elisa-8/NN||the-6/DT	amod||elisa-8/NN||epitope-blocking-7/JJ	prep_of||sensitivity-2/NN||elisa-8/NN	prep_for||elisa-8/NN||h5n1-10/CD	auxpass||evaluated-12/VBN||were-11/VBD	root||ROOT-0/null||evaluated-12/VBN	xcomp||evaluated-12/VBN||using-13/VBG	nn||antisera-15/NN||chicken-14/NN	dobj||using-13/VBG||antisera-15/NN	amod||clades-19/NNS||multiple-17/JJ	nn||clades-19/NNS||virus-18/NN	prep_to||using-13/VBG||clades-19/NNS	amod||subtypes-23/NNS||other-21/JJ	nn||subtypes-23/NNS||influenza-22/NN	prep_to||using-13/VBG||subtypes-23/NNS	conj_and||clades-19/NNS||subtypes-23/NNS	nn||samples-28/NNS||serum-27/NN	prep_to||using-13/VBG||samples-28/NNS	conj_and||clades-19/NNS||samples-28/NNS	prep_from||samples-28/NNS||individuals-30/NNS	advmod||infected-32/VBN||naturally-31/RB	vmod||individuals-30/NNS||infected-32/VBN	amod||influenzaviruses-37/NNS||h5n1-34/JJ	conj_or||h5n1-34/JJ||seasonal-36/JJ	amod||influenzaviruses-37/NNS||seasonal-36/JJ	prep_with||infected-32/VBN||influenzaviruses-37/NNS	h5n1-34||influenzaviruses-37||no||the sensitivity and specificity of the epitope-blocking elisa for h5n1 were evaluated using chicken antisera to multiple virus clades and other influenza subtypes as well as serum samples from individuals naturally infected with h5n1 or seasonal influenzaviruses.
mark||occur-10/VB||although-1/IN	amod||deposits-5/NNS||renal-2/JJ	nn||deposits-5/NNS||calcium-3/NN	nn||deposits-5/NNS||crystal-4/NN	nsubj||occur-10/VB||deposits-5/NNS	appos||deposits-5/NNS||nephrocalcinosis-7/NNS	aux||occur-10/VB||may-9/MD	advcl||common-28/JJ||occur-10/VB	amod||poisoning-14/NN||acute-12/JJ	nn||poisoning-14/NN||phosphate-13/NN	prep_in||occur-10/VB||poisoning-14/NN	prep_in||occur-10/VB||type-18/NN	conj_and||poisoning-14/NN||type-18/NN	num||renaltubularacidosis-20/NNS||1-19/CD	dep||type-18/NN||renaltubularacidosis-20/NNS	appos||renaltubularacidosis-20/NNS||rta-22/NN	amod||hypocalcemia-26/NN||hyperphosphatemic-25/JJ	nsubj||common-28/JJ||hypocalcemia-26/NN	cop||common-28/JJ||is-27/VBZ	root||ROOT-0/null||common-28/JJ	det||former-31/JJ||the-30/DT	prep_in||common-28/JJ||former-31/JJ	mark||typical-36/JJ||while-32/IN	amod||hypokalemia-34/NN||normocalcemic-33/JJ	nsubj||typical-36/JJ||hypokalemia-34/NN	cop||typical-36/JJ||is-35/VBZ	advcl||common-28/JJ||typical-36/JJ	det||latter-39/NN||the-38/DT	prep_in||typical-36/JJ||latter-39/NN	renaltubularacidosis-20||crystal-4||no_rel||although renal calcium crystal deposits (nephrocalcinosis) may occur in acute phosphate poisoning as well as type 1 renaltubularacidosis (rta), hyperphosphatemic hypocalcemia is common in the former while normocalcemic hypokalemia is typical in the latter.
nsubj||aware-4/JJ||clinicians-1/NNS	aux||aware-4/JJ||must-2/MD	cop||aware-4/JJ||be-3/VB	root||ROOT-0/null||aware-4/JJ	det||spectrum-8/NN||the-6/DT	amod||spectrum-8/NN||wide-7/JJ	prep_of||aware-4/JJ||spectrum-8/NN	prep_of||spectrum-8/NN||disease-10/NN	vmod||disease-10/NN||caused-11/VBN	agent||caused-11/VBN||ca-mrsa-13/NN	mrsa--1||ca--1||no_rel||clinicians must be aware of the wide spectrum of disease caused by ca-mrsa.
det||mechanism-2/NN||this-1/DT	nsubj||has-9/VBZ||mechanism-2/NN	mark||finds-6/VBZ||if-4/IN	nsubj||finds-6/VBZ||it-5/PRP	dep||mechanism-2/NN||finds-6/VBZ	dobj||finds-6/VBZ||support-7/NN	root||ROOT-0/null||has-9/VBZ	amod||implications-11/NNS||important-10/JJ	dobj||has-9/VBZ||implications-11/NNS	amod||research-14/NN||future-13/JJ	prep_for||implications-11/NNS||research-14/NN	det||hazard-18/NN||the-16/DT	nn||hazard-18/NN||mesothelioma-17/NN	prep_into||has-9/VBZ||hazard-18/NN	prep_into||has-9/VBZ||hazard-18/NN	conj_and||hazard-18/NN||hazard-18/NN	prep_from||hazard-18/NN||harn-20/NN	advmod||hazard-18/NN||also-22/RB	poss||view-26/NN||our-24/PRP$	amod||view-26/NN||current-25/JJ	prep_for||hazard-18/NN||view-26/NN	det||origins-29/NNS||the-28/DT	prep_of||view-26/NN||origins-29/NNS	amod||mesothelioma-33/NN||asbestos-initiated-31/JJ	amod||mesothelioma-33/NN||pleural-32/JJ	prep_of||origins-29/NNS||mesothelioma-33/NN	det||use-37/NN||the-35/DT	amod||use-37/NN||common-36/JJ	prep_of||view-26/NN||use-37/NN	conj_and||origins-29/NNS||use-37/NN	prep_of||use-37/NN||lung-39/NN	amod||burden-43/NN||parenchymal-40/JJ	nn||burden-43/NN||asbestos-41/NN	nn||burden-43/NN||fibre-42/NN	pobj||hazard-18/NN||burden-43/NN	det||correlate-46/NN||a-45/DT	prep_as||has-9/VBZ||correlate-46/NN	det||tumour-49/NN||this-48/DT	prep_of||correlate-46/NN||tumour-49/NN	nsubj||arises-53/VBZ||tumour-49/NN	advmod||arises-53/VBZ||actually-52/RB	rcmod||tumour-49/NN||arises-53/VBZ	det||pleura-57/NN||the-55/DT	amod||pleura-57/NN||parietal-56/JJ	prep_in||arises-53/VBZ||pleura-57/NN	asbestos-41||mesothelioma-33||no_rel||this mechanism, if it finds support, has important implications for future research into the mesothelioma hazard from harn and also for our current view of the origins of asbestos-initiated pleural mesothelioma and the common use of lung parenchymal asbestos fibre burden as a correlate of this tumour, which actually arises in the parietal pleura.
mark||demonstrated-9/VBD||although-1/IN	det||randomized-4/NN||a-3/DT	prep_in||demonstrated-9/VBD||randomized-4/NN	amod||prasugrel-8/NN||double-blind-6/JJ	nn||prasugrel-8/NN||trial-7/NN	nsubj||demonstrated-9/VBD||prasugrel-8/NN	advcl||associated-23/VBN||demonstrated-9/VBD	dobj||demonstrated-9/VBD||superiority-10/NN	amod||endpoints-14/NNS||multiple-12/JJ	amod||endpoints-14/NNS||cardiovascular-13/JJ	prep_for||demonstrated-9/VBD||endpoints-14/NNS	prepc_compared_with||demonstrated-9/VBD||with-16/IN	amod||clopidogrel-18/NN||standard-dose-17/JJ	pobj||demonstrated-9/VBD||clopidogrel-18/NN	nsubjpass||associated-23/VBN||it-20/PRP	auxpass||associated-23/VBN||was-21/VBD	advmod||associated-23/VBN||also-22/RB	root||ROOT-0/null||associated-23/VBN	det||risk-28/NN||an-25/DT	amod||risk-28/NN||increased-26/VBN	nn||risk-28/NN||bleeding-27/NN	prep_with||associated-23/VBN||risk-28/NN	amod||bleeding-32/NN||fatal-31/JJ	prep_including||risk-28/NN||bleeding-32/NN	bleeding-32||clopidogrel-18||no||although in a randomized, double-blind trial prasugrel demonstrated superiority for multiple cardiovascular endpoints compared with standard-dose clopidogrel, it was also associated with an increased bleeding risk, including fatal bleeding.
nn||arthropods-2/NNS||haematophagous-1/NNS	nsubj||vectors-6/NNS||arthropods-2/NNS	cop||vectors-6/NNS||are-3/VBP	det||vectors-6/NNS||the-4/DT	amod||vectors-6/NNS||primary-5/JJ	root||ROOT-0/null||vectors-6/NNS	det||transmission-9/NN||the-8/DT	prep_in||vectors-6/NNS||transmission-9/NN	prep_of||transmission-9/NN||rickettsia-11/NN	det||mechanisms-16/NNS||the-14/DT	amod||mechanisms-16/NNS||molecular-15/JJ	nsubj||remain-22/VBP||mechanisms-16/NNS	vmod||mechanisms-16/NNS||mediating-17/VBG	det||rickettsialinfection-19/NN||the-18/DT	dobj||mediating-17/VBG||rickettsialinfection-19/NN	prep_of||rickettsialinfection-19/NN||arthropods-21/NNS	conj_yet||vectors-6/NNS||remain-22/VBP	acomp||remain-22/VBP||elusive-23/JJ	rickettsialinfection-19||rickettsia-11||no||haematophagous arthropods are the primary vectors in the transmission of rickettsia , yet the molecular mechanisms mediating the rickettsialinfection of arthropods remain elusive.
expl||observations-6/NNS||there-1/EX	aux||observations-6/NNS||have-2/VBP	cop||observations-6/NNS||been-3/VBN	neg||observations-6/NNS||no-4/DT	amod||observations-6/NNS||systematic-5/JJ	root||ROOT-0/null||observations-6/NNS	prep_regarding||observations-6/NNS||changes-8/NNS	amod||secretion-13/NN||early-10/JJ	nn||secretion-13/NN||phase-11/NN	nn||secretion-13/NN||insulin-12/NN	prep_in||changes-8/NNS||secretion-13/NN	nn||prediabetes-16/NNS||korean-15/NN	prep_among||secretion-13/NN||prediabetes-16/NNS	amod||type2diabetesmellitus-20/NNS||early-18/JJ	nn||type2diabetesmellitus-20/NNS||stage-19/NN	prep_in||changes-8/NNS||type2diabetesmellitus-20/NNS	conj_and||secretion-13/NN||type2diabetesmellitus-20/NNS	appos||type2diabetesmellitus-20/NNS||t2dm-22/NNP	dep||type2diabetesmellitus-20/NNS||patients-24/NNS	type2diabetesmellitus-20||insulin-12||yes||there have been no systematic observations regarding changes in early phase insulin secretion among korean prediabetes and early stage type2diabetesmellitus (t2dm) patients.
nn||inhalation-2/NN||prostacyclin-1/NN	nsubjpass||used-5/VBN||inhalation-2/NN	nsubj||treat-7/VB||inhalation-2/NN	auxpass||used-5/VBN||is-3/VBZ	advmod||used-5/VBN||increasingly-4/RB	root||ROOT-0/null||used-5/VBN	aux||treat-7/VB||to-6/TO	xcomp||used-5/VBN||treat-7/VB	amod||pulmonaryhypertension-9/NN||acute-8/JJ	dobj||treat-7/VB||pulmonaryhypertension-9/NN	amod||failure-13/NN||right-11/JJ	nn||failure-13/NN||ventricular-12/NN	dobj||treat-7/VB||failure-13/NN	conj_and||pulmonaryhypertension-9/NN||failure-13/NN	mark||remain-19/VBP||although-15/IN	poss||properties-18/NNS||its-16/PRP$	amod||properties-18/NNS||pharmacodynamic-17/JJ	nsubj||remain-19/VBP||properties-18/NNS	advcl||used-5/VBN||remain-19/VBP	acomp||remain-19/VBP||controversial-20/JJ	pulmonaryhypertension-9||prostacyclin-1||yes||prostacyclin inhalation is increasingly used to treat acute pulmonaryhypertension and right ventricular failure, although its pharmacodynamic properties remain controversial.
nsubj||reduced-2/VBD||riluzole-1/NN	root||ROOT-0/null||reduced-2/VBD	det||number-5/NN||the-3/DT	amod||number-5/NN||average-4/JJ	dobj||reduced-2/VBD||number-5/NN	det||arrhythmias-8/NNS||all-7/DT	prep_of||number-5/NN||arrhythmias-8/NNS	prep_in||arrhythmias-8/NNS||phase-10/NN	num||phase-10/NN||2-11/CD	dep||arrhythmias-8/NNS||pvcs-13/NNS	number||+-16/CD||484-15/CD	prep_from||pvcs-13/NNS||+-16/CD	punct||+-58/JJ||/-17/:	poss||â-53/NN||â-18/NNP	number||32-22/CD||119-20/CD	dep||32-22/CD||to-21/TO	num||â-53/NN||32-22/CD	amod||â-53/NN||+-23/JJ	punct||â-25/NNP||/-24/:	dep||â-53/NN||â-25/NNP	dep||â-25/NNP||13-27/CD	amod||arrhythmias-31/NNS||non-29/JJ	amod||arrhythmias-31/NNS||sustained-30/JJ	dep||â-25/NNP||arrhythmias-31/NNS	number||+-34/CD||8.9-33/CD	num||0.5-45/NNS||+-34/CD	punct||4.4-38/NN||/-35/:	poss||4.4-38/NN||â-36/NNP	dep||0.5-45/NNS||4.4-38/NN	num||+-41/NNS||0.7-40/CD	prep_to||4.4-38/NN||+-41/NNS	punct||4.4-38/NN||/-42/:	nn||0.5-45/NNS||â-43/NN	prep_from||arrhythmias-31/NNS||0.5-45/NNS	amod||arrhythmias-48/NNS||sustained-47/JJ	dep||0.5-45/NNS||arrhythmias-48/NNS	num||+-51/NNS||3.9-50/CD	prep_from||â-25/NNP||+-51/NNS	punct||â-25/NNP||/-52/:	npadvmod||+-58/JJ||â-53/NN	number||0.5-57/CD||2.2-55/CD	dep||0.5-57/CD||to-56/TO	num||â-53/NN||0.5-57/CD	dep||+-16/CD||+-58/JJ	punct||+-58/JJ||/-59/:	vmod||pvcs-13/NNS||â-60/VBN	dobj||â-60/VBN||0.4-62/CD	nsubj||reduced-66/VBD||lidocaine-65/NN	parataxis||reduced-2/VBD||reduced-66/VBD	det||number-69/NN||the-67/DT	amod||number-69/NN||average-68/JJ	dobj||reduced-66/VBD||number-69/NN	amod||arrhythmias-74/NNS||non-sustained-71/JJ	conj_and||non-sustained-71/JJ||sustained-73/JJ	amod||arrhythmias-74/NNS||sustained-73/JJ	prep_of||number-69/NN||arrhythmias-74/NNS	num||+-78/NNS||0.4-77/CD	prep_to||number-69/NN||+-78/NNS	punct||0.3-82/NN||/-79/:	nn||0.3-82/NN||â-80/NN	dep||+-78/NNS||0.3-82/NN	num||+-85/NNS||0.4-84/CD	dep||+-78/NNS||+-85/NNS	conj_and||0.3-82/NN||+-85/NNS	punct||0.3-82/NN||/-86/:	rcmod||+-78/NNS||â-87/VBP	dobj||â-87/VBP||0.3-89/CD	advmod||â-87/VBP||respectively-90/RB	dobj||reduced-66/VBD||pvcs-94/NNS	conj_negcc||number-69/NN||pvcs-94/NNS	aux||390-97/VB||to-96/TO	dep||pvcs-94/NNS||390-97/VB	nn||â-100/NNP||+-98/NNP	nn||â-100/NNP||/-99/NNP	poss||234-102/NN||â-100/NNP	dobj||390-97/VB||234-102/NN	pvcs-94||lidocaine-65||yes||riluzole reduced the average number of all arrhythmias in phase 2 (pvcs from 484+/â119 to 32+/â13; non sustained arrhythmias from 8.9+/â4.4 to 0.7+/â0.5; sustained arrhythmias from 3.9+/â2.2 to 0.5+/â0.4); lidocaine reduced the average number of non-sustained and sustained arrhythmias (to 0.4+/â0.3 and 0.4+/â0.3 respectively) but not pvcs (to 390+/â234).
poss||data-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||data-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||likely-8/JJ||that-4/IN	amod||pathogenesis-6/NNS||hereditaryferritinopathy-5/JJ	nsubj||likely-8/JJ||pathogenesis-6/NNS	nsubj||result-10/VB||pathogenesis-6/NNS	cop||likely-8/JJ||is-7/VBZ	ccomp||suggest-3/VBP||likely-8/JJ	aux||result-10/VB||to-9/TO	xcomp||likely-8/JJ||result-10/VB	det||combination-13/NN||a-12/DT	prep_from||result-10/VB||combination-13/NN	prep_of||combination-13/NN||reduction-15/NN	nn||function-19/NN||iron-17/NN	nn||function-19/NN||storage-18/NN	prep_in||result-10/VB||function-19/NN	amod||toxicity-22/NN||enhanced-21/JJ	prep_in||result-10/VB||toxicity-22/NN	conj_and||function-19/NN||toxicity-22/NN	vmod||function-19/NN||associated-23/VBN	amod||aggregates-27/NNS||iron-induced-25/JJ	nn||aggregates-27/NNS||ferritin-26/NN	prep_with||associated-23/VBN||aggregates-27/NNS	iron-17||hereditaryferritinopathy-5||no_rel||our data suggest that hereditaryferritinopathy pathogenesis is likely to result from a combination of reduction in iron storage function and enhanced toxicity associated with iron-induced ferritin aggregates.
nsubj||symptom-7/NN||pain-1/NN	cop||symptom-7/NN||is-2/VBZ	det||symptom-7/NN||a-3/DT	amod||symptom-7/NN||common-4/JJ	conj_and||common-4/JJ||debilitating-6/JJ	amod||symptom-7/NN||debilitating-6/JJ	root||ROOT-0/null||symptom-7/NN	prep_of||symptom-7/NN||hiv/aids-9/NNS	aids--1||hiv--1||no||pain is a common and debilitating symptom of hiv/aids.
nsubj||forecast-11/VB||positivity-1/NN	det||antibodies-4/NNS||both-3/DT	prep_for||positivity-1/NN||antibodies-4/NNS	dep||antibodies-4/NNS||anti-ccp-6/JJ	dep||antibodies-4/NNS||rf-8/JJ	conj_and||anti-ccp-6/JJ||rf-8/JJ	aux||forecast-11/VB||can-10/MD	root||ROOT-0/null||forecast-11/VB	det||severity-13/NN||the-12/DT	dobj||forecast-11/VB||severity-13/NN	prep_of||severity-13/NN||jia-15/NN	amod||destruction-19/NN||radiographic-17/JJ	nn||destruction-19/NN||bone-18/NN	appos||jia-15/NN||destruction-19/NN	jia-15||antibodies-4||no_rel||positivity for both antibodies (anti-ccp and rf) can forecast the severity of jia (radiographic bone destruction).
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||association-7/NN||the-3/DT	amod||association-7/NN||independent-4/JJ	conj_and||independent-4/JJ||joint-6/JJ	amod||association-7/NN||joint-6/JJ	dobj||investigated-2/VBD||association-7/NN	amod||activity-12/NN||adiposity-9/JJ	conj_and||adiposity-9/JJ||physical-11/JJ	amod||activity-12/NN||physical-11/JJ	prep_of||association-7/NN||activity-12/NN	amod||glucose-16/NN||fasting-14/VBG	nn||glucose-16/NN||plasma-15/NN	prep_with||investigated-2/VBD||glucose-16/NN	amod||glucose-20/NN||impaired-18/VBN	amod||glucose-20/NN||fasting-19/JJ	prep_with||investigated-2/VBD||glucose-20/NN	conj_and||glucose-16/NN||glucose-20/NN	prep_with||investigated-2/VBD||type2diabetes-23/NNS	conj_and||glucose-16/NN||type2diabetes-23/NNS	det||population-27/NN||a-25/DT	amod||population-27/NN||chinese-26/JJ	prep_in||type2diabetes-23/NNS||population-27/NN	glucose-20||adiposity-9||no_rel||we investigated the independent and joint association of adiposity and physical activity with fasting plasma glucose, impaired fasting glucose, and type2diabetes in a chinese population.
det||review-3/NN||this-2/DT	prep_in||describe-5/VBP||review-3/NN	nsubj||describe-5/VBP||we-4/PRP	root||ROOT-0/null||describe-5/VBP	poss||experience-7/NN||our-6/PRP$	dobj||describe-5/VBP||experience-7/NN	nn||measurements-11/NNS||csf-9/NN	nn||measurements-11/NNS||neopterin-10/NN	prep_with||describe-5/VBP||measurements-11/NNS	advmod||untreated-14/VBG||382-13/CD	prepc_in||measurements-11/NNS||untreated-14/VBG	amod||patients-16/NNS||hiv-infected-15/JJ	dobj||untreated-14/VBG||patients-16/NNS	det||spectrum-19/NN||the-18/DT	prep_across||untreated-14/VBG||spectrum-19/NN	nn||diseases-25/NNS||immunosuppression-21/NN	conj_and||immunosuppression-21/NN||hiv-related-23/JJ	nn||diseases-25/NNS||hiv-related-23/JJ	amod||diseases-25/NNS||neurological-24/JJ	prep_of||spectrum-19/NN||diseases-25/NNS	num||patients-31/NNS||73-28/CD	amod||patients-31/NNS||untreated-29/JJ	nn||patients-31/NNS||aids-30/NNS	prep_in||untreated-14/VBG||patients-31/NNS	amod||infections-35/NNS||opportunistic-33/JJ	nn||infections-35/NNS||cns-34/NN	prep_with||untreated-14/VBG||infections-35/NNS	number||treated-40/CD||233-39/CD	num||patients-41/NNS||treated-40/CD	prepc_in||measurements-11/NNS||patients-41/NNS	conj_and||untreated-14/VBG||patients-41/NNS	aids-30||hiv--1||no||in this review we describe our experience with csf neopterin measurements in 382 untreated hiv-infected patients across the spectrum of immunosuppression and hiv-related neurological diseases, in 73 untreated aids patients with opportunistic cns infections, and in 233 treated patients.
nsubjpass||approved-9/VBN||bevacizumab-1/NN	prep_in||bevacizumab-1/NN||combination-3/NN	nn||alfa-6/NN||interferon-5/NN	prep_with||combination-3/NN||alfa-6/NN	auxpass||approved-9/VBN||is-7/VBZ	advmod||approved-9/VBN||now-8/RB	root||ROOT-0/null||approved-9/VBN	mark||ve-13/VBP||for-10/IN	nn||¯-12/NNP||treatment-naã-11/NNP	nsubj||ve-13/VBP||¯-12/NNP	advcl||approved-9/VBN||ve-13/VBP	amod||renalcellcarcinoma-15/NN||advanced-14/VBN	dobj||ve-13/VBP||renalcellcarcinoma-15/NN	appos||renalcellcarcinoma-15/NN||rcc-17/NN	preconj||us-22/PRP||both-20/PDT	det||us-22/PRP||the-21/DT	prep_in||renalcellcarcinoma-15/NN||us-22/PRP	prep_in||renalcellcarcinoma-15/NN||europe-24/NN	conj_and||us-22/PRP||europe-24/NN	interferon-5||renalcellcarcinoma-15||no_rel||bevacizumab in combination with interferon alfa is now approved for treatment-naã¯ve advanced renalcellcarcinoma (rcc) in both the us and europe.
det||increase-3/NN||the-1/DT	amod||increase-3/NN||life-long-2/JJ	nsubj||strain-dependent-14/JJ||increase-3/NN	amod||reactivity-6/NN||startle-5/JJ	prep_in||increase-3/NN||reactivity-6/NN	nn||deficit-9/NN||ppi-8/NN	prep_in||increase-3/NN||deficit-9/NN	conj_and||reactivity-6/NN||deficit-9/NN	vmod||reactivity-6/NN||induced-10/VBN	agent||induced-10/VBN||ms-12/NN	cop||strain-dependent-14/JJ||are-13/VBP	root||ROOT-0/null||strain-dependent-14/JJ	ppi-8||deficit-9||no_rel||the life-long increase in startle reactivity and ppi deficit induced by ms are strain-dependent.
nsubjpass||associated-7/VBN||treatment-1/NN	amod||drugs-5/NNS||standard-3/JJ	nn||drugs-5/NNS||antituberculosis-4/NNS	prep_with||treatment-1/NN||drugs-5/NNS	auxpass||associated-7/VBN||was-6/VBD	root||ROOT-0/null||associated-7/VBN	amod||resolution-10/NN||complete-9/JJ	prep_with||associated-7/VBN||resolution-10/NN	det||breastabscess-13/NNS||the-12/DT	prep_of||resolution-10/NN||breastabscess-13/NNS	breastabscess-13||antituberculosis-4||no_rel||treatment with standard antituberculosis drugs was associated with complete resolution of the breastabscess.
amod||studies-2/NNS||recent-1/JJ	nsubj||reported-4/VBN||studies-2/NNS	aux||reported-4/VBN||have-3/VBP	root||ROOT-0/null||reported-4/VBN	mark||involves-13/VBZ||that-5/IN	det||mechanism-7/NN||the-6/DT	nsubj||involves-13/VBZ||mechanism-7/NN	vmod||mechanism-7/NN||underlying-8/VBG	det||priming-10/NN||the-9/DT	dobj||underlying-8/VBG||priming-10/NN	prep_of||priming-10/NN||pulmonaryinflammation-12/NN	ccomp||reported-4/VBN||involves-13/VBZ	det||cross-talk-16/NN||the-14/DT	amod||cross-talk-16/NN||complicated-15/VBN	dobj||involves-13/VBZ||cross-talk-16/NN	amod||receptors-19/NNS||toll-like-18/JJ	prep_between||cross-talk-16/NN||receptors-19/NNS	dep||cross-talk-16/NN||tlrs-21/VBZ	dobj||involves-13/VBZ||interactions-24/NNS	conj_and||cross-talk-16/NN||interactions-24/NNS	prep_between||interactions-24/NNS||neutrophils-26/NNS	appos||neutrophils-26/NNS||pmns-28/NNS	nn||macrophages-32/NNS||alveolar-31/NN	prep_between||interactions-24/NNS||macrophages-32/NNS	conj_and||neutrophils-26/NNS||macrophages-32/NNS	advmod||-36/NN||am-34/RB	amod||-36/NN||ï-35/JJ	appos||neutrophils-26/NNS||-36/NN	amod||cells-42/NNS||endothelial-41/JJ	conj_and||cross-talk-16/NN||cells-42/NNS	conj_and||interactions-24/NNS||cells-42/NNS	prep_in||mediator-58/NN||cells-42/NNS	appos||cells-42/NNS||ecs-44/NN	amod||species-51/NNS||reactive-49/JJ	nn||species-51/NNS||oxygen-50/NN	nsubj||mediator-58/NN||species-51/NNS	appos||species-51/NNS||ros-53/NN	cop||mediator-58/NN||are-55/VBP	det||mediator-58/NN||the-56/DT	amod||mediator-58/NN||key-57/JJ	rcmod||cells-42/NNS||mediator-58/NN	cross--1||oxygen-50||no_rel||recent studies have reported that the mechanism underlying the priming of pulmonaryinflammation involves the complicated cross-talk between toll-like receptors (tlrs) and interactions between neutrophils (pmns) and alveolar macrophages (am ï ) as well as endothelial cells (ecs), in which reactive oxygen species (ros) are the key mediator.
det||gas-19/NN||the-1/DT	nn||gas-19/NN||impacts-2/NNS	amod||treatments-5/NNS||post-metallisation-4/JJ	prep_of||impacts-2/NNS||treatments-5/NNS	amod||acid-9/NN||phosphoric-8/JJ	prep_such_as||treatments-5/NNS||acid-9/NN	appos||impacts-2/NNS||h3po4-11/NNP	amod||gas-19/NN||etching-13/JJ	dep||gas-19/NN||nitrogen-15/NN	appos||gas-19/NN||n2-17/NNP	nsubj||anneal-20/VBP||gas-19/NN	root||ROOT-0/null||anneal-20/VBP	dep||investigated-39/VBN||forming-22/VBG	dobj||forming-22/VBG||gas-23/NN	appos||gas-23/NN||ar-25/NN	num||ar-25/NN||h2-26/CD	amod||gas-23/NN||anneal-28/JJ	det||$-32/$||the-30/DT	amod||$-32/$||cellsâ-31/JJ	prep_on||anneal-28/JJ||$-32/$	num||$-32/$||-33/CD	amod||properties-37/NNS||electrical-34/JJ	conj_and||electrical-34/JJ||photovoltaic-36/JJ	amod||properties-37/NNS||photovoltaic-36/JJ	nsubjpass||investigated-39/VBN||properties-37/NNS	auxpass||investigated-39/VBN||are-38/VBP	conj_and||anneal-20/VBP||investigated-39/VBN	phosphoric-8||ar-25||no_rel||the impacts of post-metallisation treatments such as phosphoric acid (h3po4) etching, nitrogen (n2) gas anneal and forming gas (ar h2) anneal on the cellsâ electrical and photovoltaic properties are investigated.
det||study-3/NN||this-1/DT	nn||study-3/NN||case-2/NN	nsubj||examined-4/VBD||study-3/NN	root||ROOT-0/null||examined-4/VBD	det||experience-6/NN||the-5/DT	dobj||examined-4/VBD||experience-6/NN	det||women-10/NNS||the-8/DT	nn||women-10/NNS||tanzanian-9/NN	poss||ngo-12/NN||women-10/NNS	prep_of||experience-6/NN||ngo-12/NN	appos||ngo-12/NN||kiwakkuki-14/NNS	prepc_based_on||ngo-12/NN||on-17/IN	poss||history-20/NN||its-18/PRP$	amod||history-20/NN||long-19/JJ	pobj||ngo-12/NN||history-20/NN	prep_of||history-20/NN||partnerships-22/NNS	amod||organizations-25/NNS||northern-24/JJ	prep_with||partnerships-22/NNS||organizations-25/NNS	advmod||addressing-28/VBG||all-27/RB	dep||ngo-12/NN||addressing-28/VBG	dobj||addressing-28/VBG||hiv/aids-29/NNS	det||region-33/NN||the-31/DT	nn||region-33/NN||kilimanjaro-32/NN	prep_in||ngo-12/NN||region-33/NN	aids--1||hiv--1||no||this case study examined the experience of the tanzanian women's ngo, kiwakkuki, based on its long history of partnerships with northern organizations, all addressing hiv/aids in the kilimanjaro region.
det||samples-2/NNS||the-1/DT	nsubjpass||analyzed-4/VBN||samples-2/NNS	auxpass||analyzed-4/VBN||were-3/VBD	root||ROOT-0/null||analyzed-4/VBN	num||months-6/NNS||2-5/CD	tmod||analyzed-4/VBN||months-6/NNS	conj_and||analyzed-4/VBN||then-8/RB	advmod||then-8/RB||again-9/RB	num||months-11/NNS||11-10/CD	pobj||again-9/RB||months-11/NNS	det||earthquake-14/NN||the-13/DT	prep_after||then-8/RB||earthquake-14/NN	aux||estimate-16/VB||to-15/TO	dep||earthquake-14/NN||estimate-16/VB	det||burden-18/NN||the-17/DT	dobj||estimate-16/VB||burden-18/NN	prep_of||burden-18/NN||hiv-20/NN	prep_of||burden-18/NN||hcv-22/NN	conj_and||hiv-20/NN||hcv-22/NN	det||areas-25/NNS||these-24/DT	prep_in||estimate-16/VB||areas-25/NNS	aux||determine-29/VB||to-28/TO	dep||earthquake-14/NN||determine-29/VB	conj_and||estimate-16/VB||determine-29/VB	det||rise-31/NN||any-30/DT	dobj||determine-29/VB||rise-31/NN	det||prevalence-34/NN||the-33/DT	prep_in||rise-31/NN||prevalence-34/NN	det||viralinfections-37/NNS||these-36/DT	prep_of||prevalence-34/NN||viralinfections-37/NNS	det||result-40/NN||a-39/DT	prep_as||determine-29/VB||result-40/NN	det||earthquake-43/NN||the-42/DT	prep_of||result-40/NN||earthquake-43/NN	rise-31||viralinfections-37||no_rel||the samples were analyzed 2 months and then again 11 months after the earthquake to estimate the burden of hiv and hcv in these areas, and to determine any rise in the prevalence of these viralinfections as a result of the earthquake.
det||combination-2/NN||a-1/DT	nsubj||reduced-9/VBD||combination-2/NN	nn||exercise-7/NN||cr-4/NN	conj_and||cr-4/NN||endurance-6/JJ	nn||exercise-7/NN||endurance-6/JJ	prep_of||combination-2/NN||exercise-7/NN	advmod||reduced-9/VBD||further-8/RB	root||ROOT-0/null||reduced-9/VBD	acomp||reduced-9/VBD||obesity-10/JJ	acomp||reduced-9/VBD||insulinresistance-12/JJ	conj_and||obesity-10/JJ||insulinresistance-12/JJ	det||condition-15/NN||the-14/DT	prep_under||reduced-9/VBD||condition-15/NN	amod||diet-18/NN||high-fat-17/JJ	prep_of||condition-15/NN||diet-18/NN	fat--1||obesity-10||no_rel||a combination of cr and endurance exercise further reduced obesity and insulinresistance under the condition of high-fat diet.
poss||findings-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||gene-11/NN||that-4/IN	amod||gene-6/NN||fsip1-5/JJ	nsubj||gene-11/NN||gene-6/NN	aux||gene-11/NN||might-7/MD	cop||gene-11/NN||be-8/VB	det||gene-11/NN||a-9/DT	amod||gene-11/NN||susceptibility-10/JJ	ccomp||suggest-3/VBP||gene-11/NN	nn||intolerance-14/NN||aspirin-13/NN	prep_for||gene-11/NN||intolerance-14/NN	prep_in||intolerance-14/NN||asthmatics-16/NNS	asthmatics-16||aspirin-13||no||our findings suggest that fsip1 gene might be a susceptibility gene for aspirin intolerance in asthmatics.
det||concentrations-2/NNS||the-1/DT	nsubj||compounds-5/VBZ||concentrations-2/NNS	prep_of||concentrations-2/NNS||antioxidant-4/NN	root||ROOT-0/null||compounds-5/VBZ	advmod||phenolics-7/NNS||namely-6/RB	dobj||compounds-5/VBZ||phenolics-7/NNS	nsubjpass||correlated-31/VBN||phenolics-7/NNS	dobj||compounds-5/VBZ||carotenoids-9/NNS	conj_and||phenolics-7/NNS||carotenoids-9/NNS	nsubjpass||correlated-31/VBN||carotenoids-9/NNS	dobj||compounds-5/VBZ||flavonoids-11/NNS	conj_and||phenolics-7/NNS||flavonoids-11/NNS	nsubjpass||correlated-31/VBN||flavonoids-11/NNS	dobj||compounds-5/VBZ||tocopherols-13/NNS	conj_and||phenolics-7/NNS||tocopherols-13/NNS	nsubjpass||correlated-31/VBN||tocopherols-13/NNS	vmod||phenolics-7/NNS||estimated-14/VBN	det||oil-18/NN||the-16/DT	nn||oil-18/NN||seed-17/NN	prep_in||estimated-14/VBN||oil-18/NN	vmod||oil-18/NN||increased-19/VBN	acomp||increased-19/VBN||due-20/JJ	amod||proline-23/NN||foliar-applied-22/JJ	prep_to||due-20/JJ||proline-23/NN	nn||conditions-27/NNS||water-25/NN	nn||conditions-27/NNS||deficit-26/NN	prep_under||increased-19/VBN||conditions-27/NNS	auxpass||correlated-31/VBN||was-29/VBD	advmod||correlated-31/VBN||positively-30/RB	rcmod||phenolics-7/NNS||correlated-31/VBN	det||dpph-36/NN||the-33/DT	amod||dpph-36/NN||enhanced-34/JJ	nn||dpph-36/NN||oil-35/NN	nn||activity-40/NN||dpph-36/NN	amod||radical-38/JJ||free-37/JJ	amod||activity-40/NN||radical-38/JJ	nn||activity-40/NN||scavenging-39/NN	prep_with||correlated-31/VBN||activity-40/NN	deficit-26||oil-35||no_rel||the concentrations of antioxidant compounds namely phenolics, carotenoids, flavonoids and tocopherols estimated in the seed oil increased due to foliar-applied proline under water deficit conditions that was positively correlated with the enhanced oil dpph free radical scavenging activity.
nsubj||cause-10/VB||feeding-1/NN	amod||oil-7/NN||fresh-3/JJ	conj_and||fresh-3/JJ||once-heated-5/JJ	amod||oil-7/NN||once-heated-5/JJ	nn||oil-7/NN||palm-6/NN	prep_with||feeding-1/NN||oil-7/NN	aux||cause-10/VB||does-8/VBZ	neg||cause-10/VB||not-9/RB	root||ROOT-0/null||cause-10/VB	det||effect-13/NN||any-11/DT	amod||effect-13/NN||deleterious-12/JJ	dobj||cause-10/VB||effect-13/NN	advmod||harmful-20/JJ||repeatedly-15/RB	amod||oil-17/NN||heated-16/VBN	nsubj||harmful-20/JJ||oil-17/NN	aux||harmful-20/JJ||may-18/MD	cop||harmful-20/JJ||be-19/VB	conj_but||cause-10/VB||harmful-20/JJ	mark||causes-23/VBZ||because-21/IN	nsubj||causes-23/VBZ||it-22/PRP	advcl||harmful-20/JJ||causes-23/VBZ	amod||damage-25/NN||oxidative-24/JJ	dobj||causes-23/VBZ||damage-25/NN	advmod||predisposing-27/VBG||thereby-26/RB	vmod||damage-25/NN||predisposing-27/VBG	prep_to||predisposing-27/VBG||atherosclerosis-29/NNS	atherosclerosis-29||oil-17||no_rel||feeding with fresh and once-heated palm oil does not cause any deleterious effect but repeatedly heated oil may be harmful because it causes oxidative damage thereby predisposing to atherosclerosis.
nsubj||assessed-2/VBD||we-1/PRP	root||ROOT-0/null||assessed-2/VBD	dobj||assessed-2/VBD||effects-3/NNS	amod||therapy-7/NN||high-dose-5/JJ	nn||therapy-7/NN||simvastatin-6/NN	prep_of||effects-3/NNS||therapy-7/NN	amod||sensitivity-13/NNS||peripheral-9/JJ	conj_and||peripheral-9/JJ||hepatic-11/JJ	amod||sensitivity-13/NNS||hepatic-11/JJ	nn||sensitivity-13/NNS||insulin-12/NN	prep_on||assessed-2/VBD||sensitivity-13/NNS	amod||deposition-21/NN||ectopic-19/JJ	nn||deposition-21/NN||lipid-20/NN	prep_on||assessed-2/VBD||deposition-21/NN	conj_and||sensitivity-13/NNS||deposition-21/NN	prep_in||deposition-21/NN||patients-23/NNS	prep_with||assessed-2/VBD||hypercholesterolemia-25/NN	prep_with||assessed-2/VBD||type2diabetes-27/NNS	conj_and||hypercholesterolemia-25/NN||type2diabetes-27/NNS	type2diabetes-27||insulin-12||yes||we assessed effects of high-dose simvastatin therapy on peripheral and hepatic insulin sensitivity, as well as on ectopic lipid deposition in patients with hypercholesterolemia and type2diabetes.
prepc_after||have-11/VBP||failing-2/VBG	det||blocker-8/NN||a-3/DT	amod||blocker-8/NN||first-4/JJ	nn||blocker-8/NN||tumor-5/NN	nn||blocker-8/NN||necrosis-6/NN	nn||blocker-8/NN||factor-7/NN	dobj||failing-2/VBG||blocker-8/NN	nsubj||have-11/VBP||patients-10/NNS	root||ROOT-0/null||have-11/VBP	amod||options-14/NNS||several-12/JJ	nn||options-14/NNS||treatment-13/NN	dobj||have-11/VBP||options-14/NNS	csubj||necrosis-20/VBZ||starting-16/VBG	det||tumor-19/NN||a-17/DT	amod||tumor-19/NN||second-18/JJ	dobj||starting-16/VBG||tumor-19/NN	conj_but||have-11/VBP||necrosis-20/VBZ	nn||blocker-22/NN||factor-21/NN	dobj||necrosis-20/VBZ||blocker-22/NN	dobj||necrosis-20/VBZ||rituximab-25/JJ	conj_or||blocker-22/NN||rituximab-25/JJ	conj_or||blocker-22/NN||abatacept-27/JJ	conj_or||rituximab-25/JJ||abatacept-27/JJ	neg||studies-33/NNS||no-30/DT	amod||studies-33/NNS||formal-31/JJ	amod||studies-33/NNS||randomized-32/JJ	nsubj||available-35/JJ||studies-33/NNS	nsubj||indicate-37/VB||studies-33/NNS	cop||available-35/JJ||are-34/VBP	conj_but||have-11/VBP||available-35/JJ	aux||indicate-37/VB||to-36/TO	xcomp||available-35/JJ||indicate-37/VB	nsubj||strategy-42/NN||what-38/WP	cop||strategy-42/NN||is-39/VBZ	det||strategy-42/NN||the-40/DT	amod||strategy-42/NN||optimal-41/JJ	ccomp||indicate-37/VB||strategy-42/NN	tumor-19||rituximab-25||no_rel||after failing a first tumor necrosis factor blocker, patients have several treatment options - starting a second tumor necrosis factor blocker, or rituximab or abatacept - but no formal randomized studies are available to indicate what is the optimal strategy.
aux||describe-2/VB||to-1/TO	csubj||associated-21/VBN||describe-2/VB	nn||persistence-4/NN||insulin-3/NN	dobj||describe-2/VB||persistence-4/NN	prep_among||describe-2/VB||patients-6/NNS	amod||therapy-11/NN||type2diabetes-8/JJ	amod||therapy-11/NN||initiating-9/JJ	nn||therapy-11/NN||insulin-10/NN	prep_with||patients-6/NNS||therapy-11/NN	amod||insulin-14/NN||basal-13/JJ	prep_with||therapy-11/NN||insulin-14/NN	nn||mixtures-17/NNS||insulin-16/NN	prep_with||therapy-11/NN||mixtures-17/NNS	conj_or||insulin-14/NN||mixtures-17/NNS	conj_and||describe-2/VB||determine-19/VB	csubj||associated-21/VBN||determine-19/VB	dobj||determine-19/VB||factors-20/NNS	root||ROOT-0/null||associated-21/VBN	prep_with||associated-21/VBN||nonpersistence-23/NN	type2diabetes-8||insulin-16||yes||to describe insulin persistence among patients with type2diabetes initiating insulin therapy with basal insulin or insulin mixtures and determine factors associated with nonpersistence.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	det||impact-4/NN||the-3/DT	dobj||assess-2/VB||impact-4/NN	amod||monitoring-8/NN||continuous-6/JJ	nn||monitoring-8/NN||glucose-7/NN	prep_of||impact-4/NN||monitoring-8/NN	prep_on||monitoring-8/NN||hypoglycemia-10/NN	prep_in||assess-2/VB||people-12/NNS	prep_with||people-12/NNS||type1diabetes-14/CD	hypoglycemia-10||glucose-7||yes||to assess the impact of continuous glucose monitoring on hypoglycemia in people with type1diabetes.
nsubjpass||associated-4/VBN||hivinfection-1/NN	auxpass||associated-4/VBN||was-2/VBD	advmod||associated-4/VBN||significantly-3/RB	ccomp||<-33/VBP||associated-4/VBN	prep_with||associated-4/VBN||tb-6/NN	vmod||tb-6/NN||caused-7/VBN	det||-lrb--11/NN||an-9/DT	dep||-lrb--11/NN||allopatric-10/JJ	agent||caused-7/VBN||-lrb--11/NN	amod||â-27/NNP||opposed-13/VBN	dep||-rrb--16/NN||sympatric-15/JJ	amod||m.tuberculosis-17/NNS||-rrb--16/NN	prep_to||opposed-13/VBN||m.tuberculosis-17/NNS	amod||m.tuberculosis-17/NNS||lineage-18/JJ	dep||lineage-18/JJ||-lrb--19/CD	dep||lineage-18/JJ||7.0-21/CD	conj_or||-lrb--19/CD||7.0-21/CD	number||%-24/NN||95-23/CD	amod||â-27/NNP||%-24/NN	amod||â-27/NNP||ci-25/NN	number||ci-25/NN||2.5-26/CD	prep_as||-lrb--11/NN||â-27/NNP	num||-lrb--11/NN||$-28/$	num||$-28/$||19.1-30/CD	nsubj||<-33/VBP||p-32/PRP	root||ROOT-0/null||<-33/VBP	num||-rrb--35/NNS||0.0001-34/CD	dobj||<-33/VBP||-rrb--35/NNS	tb-6||m.tuberculosis-17||no||hivinfection was significantly associated with tb caused by an allopatric -lrb- as opposed to sympatric -rrb- m.tuberculosis lineage -lrb- or 7.0 , 95 % ci 2.5 â $ `` 19.1 , p < 0.0001 -rrb- .
det||data-2/NNS||these-1/DT	nsubj||demonstrate-3/VB||data-2/NNS	nsubj||confirm-25/VB||data-2/NNS	root||ROOT-0/null||demonstrate-3/VB	det||efficacy-8/NN||a-4/DT	amod||efficacy-8/NN||significant-5/JJ	amod||efficacy-8/NN||vertebral-6/JJ	nn||efficacy-8/NN||antifracture-7/NN	dobj||demonstrate-3/VB||efficacy-8/NN	prep_of||efficacy-8/NN||strontiumranelate-10/NN	amod||women-14/NNS||young-12/JJ	amod||women-14/NNS||postmenopausal-13/JJ	prep_in||demonstrate-3/VB||women-14/NNS	vmod||women-14/NNS||aged-15/VBN	xcomp||aged-15/VBN||50â-16/VBG	dobj||50â-16/VBG||$-17/$	advmod||years-20/NNS||65-19/RB	dep||osteoporosis-23/CD||years-20/NNS	prep_with||years-20/NNS||severe-22/JJ	num||$-17/$||osteoporosis-23/CD	conj_and||demonstrate-3/VB||confirm-25/VB	det||efficacy-27/NN||the-26/DT	dobj||confirm-25/VB||efficacy-27/NN	det||treatment-31/NN||this-29/DT	amod||treatment-31/NN||antiosteoporotic-30/JJ	prep_of||efficacy-27/NN||treatment-31/NN	aux||prevent-33/VB||to-32/TO	vmod||confirm-25/VB||prevent-33/VB	amod||fractures-35/NNS||vertebral-34/JJ	dobj||prevent-33/VB||fractures-35/NNS	dep||age-39/NN||whatever-37/WDT	det||age-39/NN||the-38/DT	parataxis||demonstrate-3/VB||age-39/NN	det||patient-42/NN||the-41/DT	prep_of||age-39/NN||patient-42/NN	osteoporosis-23||strontiumranelate-10||no_rel||these data demonstrate a significant vertebral antifracture efficacy of strontiumranelate in young postmenopausal women aged 50â65 years with severe osteoporosis and confirm the efficacy of this antiosteoporotic treatment to prevent vertebral fractures, whatever the age of the patient.
nsubj||injected-25/VBN||adults-1/NNS	amod||type1diabetes-4/NNS||recent-onset-3/JJ	prep_with||adults-1/NNS||type1diabetes-4/NNS	prep_in||subacute-11/JJ||type1diabetes-4/NNS	det||process-9/NN||the-7/DT	nn||process-9/NN||disease-8/NN	nsubj||subacute-11/JJ||process-9/NN	cop||subacute-11/JJ||is-10/VBZ	rcmod||type1diabetes-4/NNS||subacute-11/JJ	ccomp||subacute-11/JJ||afford-12/VB	det||opportunity-14/NN||an-13/DT	dobj||afford-12/VB||opportunity-14/NN	aux||determine-16/VB||to-15/TO	vmod||opportunity-14/NN||determine-16/VB	mark||induces-20/VBZ||whether-17/IN	amod||insulin-19/NN||mucosal-18/JJ	nsubj||induces-20/VBZ||insulin-19/NN	ccomp||determine-16/VB||induces-20/VBZ	dobj||induces-20/VBZ||tolerance-21/NN	prep_to||induces-20/VBZ||insulin-23/NN	advmod||injected-25/VBN||subsequently-24/RB	root||ROOT-0/null||injected-25/VBN	prep_for||injected-25/VBN||treatment-27/NN	type1diabetes-4||insulin-23||yes||adults with recent-onset type1diabetes in whom the disease process is subacute afford an opportunity to determine whether mucosal insulin induces tolerance to insulin subsequently injected for treatment.
amod||tuberculosis-2/NNS||multidrug-resistant-1/JJ	nsubj||problem-18/NN||tuberculosis-2/NNS	appos||tuberculosis-2/NNS||mdr-tb-4/NNP	appos||tuberculosis-2/NNS||resistance-7/NN	aux||isoniazid-11/VB||to-8/TO	advmod||isoniazid-11/VB||at-9/IN	pobj||at-9/IN||least-10/JJS	vmod||resistance-7/NN||isoniazid-11/VB	vmod||resistance-7/NN||rifampin-13/VB	conj_and||isoniazid-11/VB||rifampin-13/VB	cop||problem-18/NN||is-15/VBZ	det||problem-18/NN||a-16/DT	amod||problem-18/NN||worldwide-17/JJ	root||ROOT-0/null||problem-18/NN	tb--1||isoniazid-11||yes||multidrug-resistant tuberculosis (mdr-tb), resistance to at least isoniazid and rifampin, is a worldwide problem.
det||plus-5/NN||the-1/DT	nn||plus-5/NN||genotypeâ-2/NNP	nn||plus-5/NN||®-3/NNP	nn||plus-5/NN||mtbdr-4/NN	nsubjpass||validated-9/VBN||plus-5/NN	nsubj||mdr-tb-32/JJ||plus-5/NN	advmod||validated-9/VBN||assay-6/RB	aux||validated-9/VBN||has-7/VBZ	auxpass||validated-9/VBN||been-8/VBN	root||ROOT-0/null||validated-9/VBN	mark||isolates-23/VBZ||as-10/IN	det||test-17/NN||a-11/DT	amod||test-17/NN||rapid-12/JJ	conj_and||rapid-12/JJ||reliable-14/JJ	amod||test-17/NN||reliable-14/JJ	amod||test-17/NN||first-line-15/JJ	amod||test-17/NN||diagnostic-16/JJ	nsubj||isolates-23/VBZ||test-17/NN	amod||sputum-20/NN||afb-positive-19/JJ	prep_on||test-17/NN||sputum-20/NN	prep_on||test-17/NN||mtb-22/NN	conj_or||sputum-20/NN||mtb-22/NN	advcl||validated-9/VBN||isolates-23/VBZ	nn||resistance-26/NN||inh-25/NN	prep_for||isolates-23/VBZ||resistance-26/NN	nn||resistance-29/NN||rif-28/NN	appos||resistance-26/NN||resistance-29/NN	conj_and||validated-9/VBN||mdr-tb-32/JJ	prep_in||mdr-tb-32/JJ||bangkok-34/NN	dep||validated-9/VBN||thailand-36/VBN	tb--1||inh-25||yes||the genotypeâ® mtbdr plus assay has been validated as a rapid and reliable first-line diagnostic test on afb-positive sputum or mtb isolates for inh resistance, rif resistance, and mdr-tb in bangkok, thailand.
amod||monitoring-4/NN||continuous-1/JJ	amod||monitoring-4/NN||subcutaneous-2/JJ	nn||monitoring-4/NN||glucose-3/NN	nn||systems-8/NNS||monitoring-4/NN	appos||systems-8/NNS||cgm-6/NN	nsubj||provide-9/VBP||systems-8/NNS	nsubj||hyperglycemias-20/VBZ||systems-8/NNS	root||ROOT-0/null||provide-9/VBP	dobj||provide-9/VBP||information-10/NN	amod||excursions-14/NNS||postprandial-12/JJ	nn||excursions-14/NNS||glucose-13/NN	prep_on||provide-9/VBP||excursions-14/NNS	amod||hypo-17/NN||nocturnal-16/JJ	prep_on||provide-9/VBP||hypo-17/NN	conj_and||excursions-14/NNS||hypo-17/NN	conj_and/or||provide-9/VBP||hyperglycemias-20/VBZ	hyperglycemias-20||glucose-13||no||continuous subcutaneous glucose monitoring (cgm) systems provide information on postprandial glucose excursions and nocturnal hypo- and/or hyperglycemias.
amod||women-2/NNS||pregnant-1/JJ	nsubjpass||assigned-7/VBN||women-2/NNS	vmod||women-2/NNS||attending-3/VBG	amod||clinics-5/NNS||antenatal-4/JJ	dobj||attending-3/VBG||clinics-5/NNS	auxpass||assigned-7/VBN||were-6/VBD	root||ROOT-0/null||assigned-7/VBN	prep_to||assigned-7/VBN||groups-9/NNS	vmod||groups-9/NNS||based-10/VBN	det||drug-13/NN||the-12/DT	prep_on||based-10/VBN||drug-13/NN	vmod||drug-13/NN||used-14/VBN	aux||treat-16/VB||to-15/TO	xcomp||used-14/VBN||treat-16/VB	poss||malaria-20/NN||their-17/PRP$	advmod||recent-19/JJ||most-18/RBS	amod||malaria-20/NN||recent-19/JJ	nn||al-23/NNP||malaria-20/NN	nn||al-23/NNP||episode-21/NN	nn||al-23/NNP||-lrb--22/NNP	dobj||treat-16/VB||al-23/NNP	amod||-rrb--28/NNS||sulphadoxine-pyrimethamine-25/JJ	amod||-rrb--28/NNS||sp-27/JJ	prep_vs.||al-23/NNP||-rrb--28/NNS	malaria-20||pyrimethamine--1||yes||pregnant women attending antenatal clinics were assigned to groups based on the drug used to treat their most recent malaria episode -lrb- al vs. sulphadoxine-pyrimethamine , sp -rrb- .
mark||respond-6/NN||while-1/IN	amod||patients-3/NNS||many-2/JJ	nsubj||respond-6/NN||patients-3/NNS	prep_with||patients-3/NNS||ocd-5/NN	advcl||remains-19/VBZ||respond-6/NN	prep_to||respond-6/NN||ssris-8/NNS	prep_to||respond-6/NN||clomipramine-10/NN	conj_or||ssris-8/NNS||clomipramine-10/NN	det||treatment-13/NN||the-12/DT	nsubj||remains-19/VBZ||treatment-13/NN	prep_of||treatment-13/NN||those-15/DT	amod||ocd-18/NN||refractory-17/JJ	prep_with||those-15/DT||ocd-18/NN	root||ROOT-0/null||remains-19/VBZ	acomp||remains-19/VBZ||challenging-20/JJ	ocd-18||clomipramine-10||yes||while many patients with ocd respond to ssris or clomipramine, the treatment of those with refractory ocd remains challenging.
amod||inhibitors-3/NNS||serine-1/JJ	nn||inhibitors-3/NNS||protease-2/NN	nsubjpass||involved-22/VBN||inhibitors-3/NNS	appos||inhibitors-3/NNS||serpins-5/NNS	nn||c-inhibitor-17/NN||antithrombin-8/NN	dep||c-inhibitor-17/NN||antitrypsin-10/NN	dep||c-inhibitor-17/NN||neuroserpin-12/NN	dep||c-inhibitor-17/NN||antichymotrypsin-14/NN	dep||c-inhibitor-17/NN||protein-16/NN	prep_like||inhibitors-3/NNS||c-inhibitor-17/NN	nn||inhibitor-20/NNS||plasminogenactivator-19/NN	prep_like||inhibitors-3/NNS||inhibitor-20/NNS	conj_and||c-inhibitor-17/NN||inhibitor-20/NNS	auxpass||involved-22/VBN||is-21/VBZ	root||ROOT-0/null||involved-22/VBN	amod||functions-26/NNS||important-24/JJ	amod||functions-26/NNS||biological-25/JJ	prep_in||involved-22/VBN||functions-26/NNS	nn||coagulation-29/NN||blood-28/NN	prep_like||functions-26/NNS||coagulation-29/NN	prep_like||functions-26/NNS||fibrinolysis-31/NNS	conj_and||coagulation-29/NN||fibrinolysis-31/NNS	prep_like||functions-26/NNS||inflammation-33/NN	conj_and||coagulation-29/NN||inflammation-33/NN	nn||migration-36/NN||cell-35/NN	prep_like||functions-26/NNS||migration-36/NN	conj_and||coagulation-29/NN||migration-36/NN	amod||activation-39/NN||complement-38/JJ	prep_like||functions-26/NNS||activation-39/NN	conj_and||coagulation-29/NN||activation-39/NN	antithrombin-8||inflammation-33||no_rel||serine protease inhibitors (serpins) like antithrombin, antitrypsin, neuroserpin, antichymotrypsin, protein c-inhibitor and plasminogenactivator inhibitor is involved in important biological functions like blood coagulation, fibrinolysis, inflammation, cell migration and complement activation.
nsubj||chemotherapeuticagent-7/NN||5-fluorouracil-1/NN	dep||5-fluorouracil-1/NN||5-fu-3/JJ	cop||chemotherapeuticagent-7/NN||is-5/VBZ	det||chemotherapeuticagent-7/NN||the-6/DT	root||ROOT-0/null||chemotherapeuticagent-7/NN	amod||choice-10/NN||first-9/JJ	prep_of||chemotherapeuticagent-7/NN||choice-10/NN	amod||cancer-13/NN||colorectal-12/JJ	prep_in||choice-10/NN||cancer-13/NN	amod||cases-18/NNS||most-17/JJS	prep_in||develops-23/VBZ||cases-18/NNS	nsubj||develops-23/VBZ||resistance-20/NN	prep_to||resistance-20/NN||5-fu-22/CD	conj_but||chemotherapeuticagent-7/NN||develops-23/VBZ	amod||mechanisms-26/NNS||various-25/JJ	prep_through||develops-23/VBZ||mechanisms-26/NNS	cancer-13||chemotherapeuticagent-7||no_rel||5-fluorouracil (5-fu) is the chemotherapeuticagent of first choice in colorectal cancer, but in most cases, resistance to 5-fu develops through various mechanisms.
nsubj||drug-6/NN||alminoprofen-1/NN	cop||drug-6/NN||is-2/VBZ	det||drug-6/NN||a-3/DT	amod||drug-6/NN||non-steroid-4/JJ	amod||drug-6/NN||anti-inflammatory-5/JJ	root||ROOT-0/null||drug-6/NN	dep||drug-6/NN||nsaid-8/VBN	vmod||drug-6/NN||used-10/VBN	det||analgesic-13/JJ||an-12/DT	prep_as||used-10/VBN||analgesic-13/JJ	prep_for||analgesic-13/JJ||rheumatism-15/NN	steroid--1||rheumatism-15||no_rel||alminoprofen is a non-steroid anti-inflammatory drug (nsaid) used as an analgesic for rheumatism.
amod||aspergilloma-2/NN||sinus-1/JJ	nsubj||occurs-3/VBZ||aspergilloma-2/NN	nsubj||progress-10/VB||aspergilloma-2/NN	nsubj||invasive-12/VB||aspergilloma-2/NN	root||ROOT-0/null||occurs-3/VBZ	advmod||occurs-3/VBZ||occasionally-4/RB	nn||patients-7/NNS||ra-6/NN	prep_in||occurs-3/VBZ||patients-7/NNS	aux||progress-10/VB||can-9/MD	conj_and||occurs-3/VBZ||progress-10/VB	aux||invasive-12/VB||to-11/TO	xcomp||progress-10/VB||invasive-12/VB	amod||disease-14/NN||aspergillus-13/JJ	dobj||invasive-12/VB||disease-14/NN	aspergilloma-2||aspergillus-13||no||sinus aspergilloma occurs occasionally in ra patients and can progress to invasive aspergillus disease.
nn||inhibition-2/NN||renin-1/NN	nsubj||has-3/VBZ||inhibition-2/NN	nsubj||efficacious-20/JJ||inhibition-2/NN	root||ROOT-0/null||has-3/VBZ	det||effect-7/NN||a-4/DT	advmod||pronounced-6/JJ||more-5/RBR	amod||effect-7/NN||pronounced-6/JJ	dobj||has-3/VBZ||effect-7/NN	prep_than||effect-7/NN||arbs-9/NNS	prep_than||effect-7/NN||aceinhibitors-11/NNS	conj_and||arbs-9/NNS||aceinhibitors-11/NNS	det||diabetescomplications-14/NNS||these-13/DT	prep_on||arbs-9/NNS||diabetescomplications-14/NNS	aux||efficacious-20/JJ||may-16/MD	cop||efficacious-20/JJ||be-17/VB	advmod||efficacious-20/JJ||clinically-18/RB	advmod||efficacious-20/JJ||more-19/RBR	conj_and||has-3/VBZ||efficacious-20/JJ	aceinhibitors-11||diabetescomplications-14||no_rel||renin inhibition has a more pronounced effect than arbs and aceinhibitors on these diabetescomplications and may be clinically more efficacious.
mark||multifold-10/VBN||since-1/IN	det||cause-4/NN||the-2/DT	amod||cause-4/NN||underlying-3/VBG	nsubjpass||multifold-10/VBN||cause-4/NN	prep_for||cause-4/NN||obesity-6/NN	prep_for||cause-4/NN||type2diabetes-8/NNS	conj_and||obesity-6/NN||type2diabetes-8/NNS	auxpass||multifold-10/VBN||is-9/VBZ	advcl||investigated-14/VBD||multifold-10/VBN	nsubj||investigated-14/VBD||we-12/PRP	nsubj||explored-29/VBD||we-12/PRP	advmod||investigated-14/VBD||further-13/RBR	root||ROOT-0/null||investigated-14/VBD	amod||effects-16/NNS||metabolic-15/JJ	dobj||investigated-14/VBD||effects-16/NNS	amod||supplementation-19/NN||leucine-18/JJ	prep_of||effects-16/NNS||supplementation-19/NN	amod||models-23/NNS||obese/diabetes-21/JJ	nn||models-23/NNS||mouse-22/NN	prep_in||supplementation-19/NN||models-23/NNS	amod||etiologies-26/NNS||different-25/JJ	prep_with||investigated-14/VBD||etiologies-26/NNS	conj_and||investigated-14/VBD||explored-29/VBD	det||mechanisms-33/NNS||the-30/DT	amod||mechanisms-33/NNS||underlying-31/JJ	amod||mechanisms-33/NNS||molecular-32/JJ	dobj||explored-29/VBD||mechanisms-33/NNS	leucine-18||obesity-6||no_rel||since the underlying cause for obesity and type2diabetes is multifold, we further investigated metabolic effects of leucine supplementation in obese/diabetes mouse models with different etiologies, and explored the underlying molecular mechanisms.
amod||deficiencies-4/NNS||immunoglobulin-1/JJ	amod||deficiencies-4/NNS||class-switch-2/JJ	nn||deficiencies-4/NNS||recombination-3/NN	nsubj||immunodeficiencies-11/NNS||deficiencies-4/NNS	appos||deficiencies-4/NNS||ig-csr-ds-6/NNS	cop||immunodeficiencies-11/NNS||are-8/VBP	amod||immunodeficiencies-11/NNS||rare-9/JJ	amod||immunodeficiencies-11/NNS||primary-10/JJ	root||ROOT-0/null||immunodeficiencies-11/NNS	vmod||immunodeficiencies-11/NNS||characterized-12/VBN	amod||production-20/NN||defective-14/JJ	nn||production-20/NN||switched-15/NNS	nn||production-20/NN||isotype-16/NN	appos||production-20/NN||igg/iga/ige-18/NN	agent||characterized-12/VBN||production-20/NN	immunodeficiencies-11||ig--1||yes||immunoglobulin class-switch recombination deficiencies (ig-csr-ds) are rare primary immunodeficiencies characterized by defective switched isotype (igg/iga/ige) production.
det||results-2/NNS||the-1/DT	nsubj||revealed-8/VBN||results-2/NNS	vmod||results-2/NNS||achieved-3/VBN	poss||study-6/NN||our-5/PRP$	prep_in||achieved-3/VBN||study-6/NN	aux||revealed-8/VBN||have-7/VBP	root||ROOT-0/null||revealed-8/VBN	det||risk-12/NN||the-9/DT	amod||risk-12/NN||highest-10/JJS	amod||risk-12/NN||thrombotic-11/JJ	dobj||revealed-8/VBN||risk-12/NN	det||groups-15/NNS||the-14/DT	prep_among||risk-12/NN||groups-15/NNS	amod||patients-18/NNS||diabetic-17/JJ	prep_of||groups-15/NNS||patients-18/NNS	nsubj||is-21/VBZ||patients-18/NNS	rcmod||patients-18/NNS||is-21/VBZ	amod||correlation-24/NN||direct-23/JJ	prep_in||is-21/VBZ||correlation-24/NN	det||values-28/NNS||the-26/DT	amod||values-28/NNS||high-27/JJ	prep_with||is-21/VBZ||values-28/NNS	nsubj||explain-67/VB||values-28/NNS	prep_of||values-28/NNS||interleukin-1-beta-30/JJ	det||modifications-33/NNS||the-32/DT	prep_of||values-28/NNS||modifications-33/NNS	conj_and||interleukin-1-beta-30/JJ||modifications-33/NNS	nn||parameters-36/NNS||lipid-35/NN	prep_of||values-28/NNS||parameters-36/NNS	vmod||values-28/NNS||acknowledging-38/VBG	det||data-40/NNS||the-39/DT	dobj||acknowledging-38/VBG||data-40/NNS	det||literature-43/NN||the-42/DT	prep_in||data-40/NNS||literature-43/NN	prepc_according_to||acknowledging-38/VBG||to-46/TO	dobj||alters-49/VBZ||which-47/WDT	nsubj||alters-49/VBZ||hyperglycemia-48/NN	nsubj||generates-63/VBZ||hyperglycemia-48/NN	pcomp||acknowledging-38/VBG||alters-49/VBZ	amod||functions-51/NNS||endothelial-50/JJ	dobj||alters-49/VBZ||functions-51/NNS	advmod||alters-49/VBZ||directly-52/RB	advmod||alters-49/VBZ||indirectly-54/RB	conj_and||directly-52/RB||indirectly-54/RB	prep_by||alters-49/VBZ||synthesis-56/NN	nn||factors-59/NNS||growth-58/NN	prep_of||synthesis-56/NN||factors-59/NNS	prep_of||synthesis-56/NN||cytokines-61/NNS	conj_and||factors-59/NNS||cytokines-61/NNS	pcomp||acknowledging-38/VBG||generates-63/VBZ	conj_and||alters-49/VBZ||generates-63/VBZ	dobj||generates-63/VBZ||metabolicdisorders-64/NNS	aux||explain-67/VB||would-66/MD	rcmod||values-28/NNS||explain-67/VB	det||risk-70/NN||the-68/DT	amod||risk-70/NN||high-69/JJ	dobj||explain-67/VB||risk-70/NN	amod||events-73/NNS||thrombotic-72/JJ	prep_for||risk-70/NN||events-73/NNS	lipid-35||metabolicdisorders-64||no_rel||the results achieved in our study have revealed the highest thrombotic risk among the groups of diabetic patients, which is in direct correlation with the high values of interleukin-1-beta and the modifications of lipid parameters, acknowledging the data in the literature, according to which hyperglycemia alters endothelial functions directly and indirectly by synthesis of growth factors and cytokines and generates metabolicdisorders which would explain the high risk for thrombotic events.
num||substituent-4/NN||one-1/CD	amod||substituent-4/NN||phenyl-2/JJ	nn||substituent-4/NN||ring-3/NN	nsubj||coplanar-15/JJ||substituent-4/NN	vmod||substituent-4/NN||attached-6/VBN	det||carbon-11/NN||an-8/DT	nn||carbon-11/NN||sp-9/NN	num||carbon-11/NN||2-10/CD	prep_to||attached-6/VBN||carbon-11/NN	cop||coplanar-15/JJ||is-13/VBZ	advmod||coplanar-15/JJ||approximately-14/RB	root||ROOT-0/null||coplanar-15/JJ	det||ring-19/NN||the-17/DT	amod||ring-19/NN||c3pse-18/JJ	prep_with||coplanar-15/JJ||ring-19/NN	mark||lie-36/VBP||whilst-20/IN	det||substituents-24/NNS||the-21/DT	amod||substituents-24/NNS||other-22/JJ	amod||substituents-24/NNS||organic-23/JJ	nsubj||lie-36/VBP||substituents-24/NNS	vmod||substituents-24/NNS||attached-26/VBN	det||3-carbon-30/NN||an-28/DT	nn||3-carbon-30/NN||sp-29/NN	prep_to||attached-26/VBN||3-carbon-30/NN	det||atom-34/NN||a-32/DT	nn||atom-34/NN||pv-33/NN	prep_to||attached-26/VBN||atom-34/NN	conj_and||3-carbon-30/NN||atom-34/NN	ccomp||coplanar-15/JJ||lie-36/VBP	det||side-40/NN||the-38/DT	amod||side-40/NN||same-39/JJ	prep_on||lie-36/VBP||side-40/NN	det||ring-43/NN||the-42/DT	prep_of||side-40/NN||ring-43/NN	pv-33||carbon-11||no_rel||one phenyl ring substituent, attached to an sp 2 carbon, is approximately coplanar with the c3pse ring whilst the other organic substituents, attached to an sp 3-carbon and a pv atom, lie on the same side of the ring.
det||case-2/NN||this-1/DT	nsubj||highlights-3/VBZ||case-2/NN	root||ROOT-0/null||highlights-3/VBZ	det||fact-5/NN||the-4/DT	dobj||highlights-3/VBZ||fact-5/NN	mark||has-8/VBZ||that-6/IN	nsubj||has-8/VBZ||one-7/PRP	nsubj||exercise-10/VB||one-7/PRP	ccomp||highlights-3/VBZ||has-8/VBZ	aux||exercise-10/VB||to-9/TO	xcomp||has-8/VBZ||exercise-10/VB	dobj||exercise-10/VB||caution-11/NN	prepc_while||exercise-10/VB||prescribing-13/VBG	dobj||prescribing-13/VBG||methylphenidate-14/NN	prep_in||prescribing-13/VBG||patients-16/NNS	amod||retardation-22/NNS||comorbid-18/JJ	amod||retardation-22/NNS||adhd-19/JJ	conj_and||adhd-19/JJ||mental-21/JJ	amod||retardation-22/NNS||mental-21/JJ	prep_with||patients-16/NNS||retardation-22/NNS	adhd-19||methylphenidate-14||yes||this case highlights the fact that one has to exercise caution while prescribing methylphenidate in patients with comorbid adhd and mental retardation.
advmod||describe-4/VBP||here-1/RB	nsubj||describe-4/VBP||we-3/PRP	root||ROOT-0/null||describe-4/VBP	det||construction-6/NN||the-5/DT	dobj||describe-4/VBP||construction-6/NN	det||influenzavirus-10/NNS||a-8/DT	amod||influenzavirus-10/NNS||recombinant-9/JJ	prep_of||construction-6/NN||influenzavirus-10/NNS	vmod||influenzavirus-10/NNS||expressing-11/VBG	nn||iii-13/NN||domain-12/NN	dobj||expressing-11/VBG||iii-13/NN	det||glycoprotein-17/NN||the-15/DT	nn||glycoprotein-17/NN||wnv-16/NN	prep_of||iii-13/NN||glycoprotein-17/NN	dep||iii-13/NN||e-18/SYM	appos||iii-13/NN||flu-na-diii-20/NNP	poss||evaluation-24/NN||its-23/PRP$	prep_of||construction-6/NN||evaluation-24/NN	conj_and||influenzavirus-10/NNS||evaluation-24/NN	det||candidate-29/NN||a-26/DT	nn||candidate-29/NN||wnv-27/NN	nn||candidate-29/NN||vaccine-28/NN	prep_as||evaluation-24/NN||candidate-29/NN	det||model-33/NN||a-31/DT	nn||model-33/NN||mouse-32/NN	prep_in||candidate-29/NN||model-33/NN	flu--1||influenzavirus-10||no||here, we describe the construction of a recombinant influenzavirus expressing domain iii of the wnv glycoprotein e (flu-na-diii) and its evaluation as a wnv vaccine candidate in a mouse model.
amod||stimulation-5/NN||atrial-1/JJ	conj_and||atrial-1/JJ||ventricular-3/JJ	amod||stimulation-5/NN||ventricular-3/JJ	amod||stimulation-5/NN||programmed-4/JJ	conj_or||stimulation-5/NN||stimulation-5/NN	nsubjpass||performed-15/VBN||stimulation-5/NN	nsubjpass||performed-15/VBN||stimulation-5/NN	appos||stimulation-5/NN||ps-7/NN	amod||infusion-13/NN||isoproterenol-12/JJ	prep_with||stimulation-5/NN||infusion-13/NN	prep_without||stimulation-5/NN||infusion-13/NN	auxpass||performed-15/VBN||were-14/VBD	root||ROOT-0/null||performed-15/VBN	advmod||analyzed-22/VBN||spontaneously-18/RB	amod||tachycardias-20/NNS||developed-19/JJ	nsubjpass||analyzed-22/VBN||tachycardias-20/NNS	auxpass||analyzed-22/VBN||were-21/VBD	conj_and||performed-15/VBN||analyzed-22/VBN	tachycardias-20||isoproterenol-12||no||atrial and ventricular programmed stimulation (ps) with or without isoproterenol infusion were performed, and spontaneously developed tachycardias were analyzed.
prep_in||carried-23/VBN||tunisia-2/NN	nsubjpass||carried-23/VBN||country-4/NN	amod||endemicity-7/NN||intermediate-6/JJ	prep_of||country-4/NN||endemicity-7/NN	amod||infection-13/NN||hepatitisbvirus-9/JJ	appos||infection-13/NN||hbv-11/NN	prep_for||endemicity-7/NN||infection-13/NN	advmod||studies-17/NNS||most-15/RBS	amod||studies-17/NNS||molecular-16/JJ	appos||infection-13/NN||studies-17/NNS	det||virus-20/NN||the-19/DT	prep_on||studies-17/NNS||virus-20/NN	aux||carried-23/VBN||have-21/VBP	auxpass||carried-23/VBN||been-22/VBN	root||ROOT-0/null||carried-23/VBN	prt||carried-23/VBN||out-24/RP	det||north-27/NN||the-26/DT	prep_in||carried-23/VBN||north-27/NN	det||country-30/NN||the-29/DT	prep_of||north-27/NN||country-30/NN	nsubjpass||known-34/VBN||little-32/RB	auxpass||known-34/VBN||is-33/VBZ	conj_and||carried-23/VBN||known-34/VBN	amod||regions-37/NNS||other-36/JJ	prep_about||known-34/VBN||regions-37/NNS	hbv-11||hepatitisbvirus-9||no||in tunisia, country of intermediate endemicity for hepatitisbvirus (hbv) infection, most molecular studies on the virus have been carried out in the north of the country and little is known about other regions.
nsubj||result-6/VBP||mutations-1/NNS	nsubj||produce-11/VB||mutations-1/NNS	det||gene-5/NN||the-3/DT	nn||gene-5/NN||hfe-4/NN	prep_in||mutations-1/NNS||gene-5/NN	ccomp||characterized-22/VBD||result-6/VBP	prep_in||result-6/VBP||ironoverload-8/NN	aux||produce-11/VB||can-10/MD	conj_and||result-6/VBP||produce-11/VB	ccomp||characterized-22/VBD||produce-11/VB	dobj||produce-11/VB||hereditaryhemochromatosis-12/NNS	appos||hereditaryhemochromatosis-12/NNS||hh-14/NN	det||disorder-18/NN||a-17/DT	nsubj||characterized-22/VBD||disorder-18/NN	nn||metabolism-21/NN||iron-20/NN	prep_of||disorder-18/NN||metabolism-21/NN	root||ROOT-0/null||characterized-22/VBD	amod||absorption-27/NN||increased-24/VBN	amod||absorption-27/NN||intestinal-25/JJ	nn||absorption-27/NN||iron-26/NN	prep_by||characterized-22/VBD||absorption-27/NN	hereditaryhemochromatosis-12||iron-26||no||mutations in the hfe gene result in ironoverload and can produce hereditaryhemochromatosis (hh), a disorder of iron metabolism characterized by increased intestinal iron absorption.
nn||activity-2/NN||disease-1/NN	nsubj||influence-5/VB||activity-2/NN	aux||influence-5/VB||did-3/VBD	neg||influence-5/VB||not-4/RB	root||ROOT-0/null||influence-5/VB	dobj||influence-5/VB||numbers-6/NNS	nn||leptum-9/NN||c.-8/NN	prep_of||numbers-6/NNS||leptum-9/NN	nn||prausnitzii-12/NNS||f.-11/NN	prep_of||numbers-6/NNS||prausnitzii-12/NNS	conj_or||leptum-9/NN||prausnitzii-12/NNS	prep_in||influence-5/VB||patients-14/NNS	prep_with||patients-14/NNS||cd-16/NN	prep_with||patients-14/NNS||uc-18/NN	conj_or||cd-16/NN||uc-18/NN	uc-18||cd-16||no_rel||disease activity did not influence numbers of c. leptum or f. prausnitzii in patients with cd or uc .
det||clients-3/NNS||the-1/DT	amod||clients-3/NNS||simulated-2/JJ	nsubj||wanted-4/VBD||clients-3/NNS	nsubj||know-6/VB||clients-3/NNS	root||ROOT-0/null||wanted-4/VBD	aux||know-6/VB||to-5/TO	xcomp||wanted-4/VBD||know-6/VB	det||antibiotics-8/NNS||the-7/DT	dobj||know-6/VB||antibiotics-8/NNS	nsubj||available-11/JJ||antibiotics-8/NNS	cop||available-11/JJ||were-10/VBD	rcmod||antibiotics-8/NNS||available-11/JJ	det||shop-14/NN||the-13/DT	prep_at||available-11/JJ||shop-14/NN	antibiotics-8||shop-14||no_rel||the simulated clients wanted to know the antibiotics that were available at the shop.
nsubjpass||approved-3/VBN||interferon-1/NN	auxpass||approved-3/VBN||is-2/VBZ	root||ROOT-0/null||approved-3/VBN	amod||treatment-6/NN||adjuvant-5/JJ	prep_for||approved-3/VBN||treatment-6/NN	prep_of||treatment-6/NN||patients-8/NNS	nn||melanoma-12/NN||stage-10/NN	nn||melanoma-12/NN||iib/iii-11/NN	prep_with||patients-8/NNS||melanoma-12/NN	melanoma-12||interferon-1||yes||interferon is approved for adjuvant treatment of patients with stage iib/iii melanoma.
amod||sepsis-2/NN||severe-1/JJ	nsubj||emerged-4/VBN||sepsis-2/NN	aux||emerged-4/VBN||has-3/VBZ	root||ROOT-0/null||emerged-4/VBN	det||cause-8/NN||a-6/DT	amod||cause-8/NN||major-7/JJ	prep_as||emerged-4/VBN||cause-8/NN	prep_of||cause-8/NN||admission-10/NN	prep_of||cause-8/NN||mortality-12/NN	conj_and||admission-10/NN||mortality-12/NN	amod||patients-16/NNS||hospitalized-14/JJ	nn||patients-16/NNS||hiv/aids-15/NNS	prep_for||admission-10/NN||patients-16/NNS	advmod||affecting-19/VBG||significantly-18/RB	xcomp||emerged-4/VBN||affecting-19/VBG	amod||survival-24/NN||short-20/JJ	conj_and||short-20/JJ||longer-term-23/JJ	amod||survival-24/NN||longer-term-23/JJ	dobj||affecting-19/VBG||survival-24/NN	advmod||ill-27/JJ||critically-26/RB	amod||patients-29/NNS||ill-27/JJ	nn||patients-29/NNS||hiv/aids-28/NN	prep_of||survival-24/NN||patients-29/NNS	aids--1||hiv--1||no||severe sepsis has emerged as a major cause of admission and mortality for hospitalized hiv/aids patients, significantly affecting short- and longer-term survival of critically ill hiv/aids patients.
det||assay-5/NN||the-1/DT	amod||assay-5/NN||adenosinetriphosphate-based-2/JJ	amod||assay-5/NN||chemotherapy-3/JJ	nn||assay-5/NN||response-4/NN	nsubj||test-12/NN||assay-5/NN	appos||assay-5/NN||atp-cra-7/NNP	cop||test-12/NN||is-9/VBZ	det||test-12/NN||a-10/DT	amod||test-12/NN||chemosensitivity-11/JJ	root||ROOT-0/null||test-12/NN	nsubj||offers-14/VBZ||test-12/NN	rcmod||test-12/NN||offers-14/VBZ	det||potential-16/NN||the-15/DT	dobj||offers-14/VBZ||potential-16/NN	prepc_of||potential-16/NN||selecting-18/VBG	nn||treatments-20/NNS||cancer-19/NN	dobj||selecting-18/VBG||treatments-20/NNS	prepc_based_on||selecting-18/VBG||on-22/IN	det||responsiveness-24/NNS||the-23/DT	pobj||selecting-18/VBG||responsiveness-24/NNS	amod||tumors-27/NNS||individual-26/JJ	prep_of||responsiveness-24/NNS||tumors-27/NNS	atp--1||tumors-27||no_rel||the adenosinetriphosphate-based chemotherapy response assay (atp-cra) is a chemosensitivity test that offers the potential of selecting cancer treatments based on the responsiveness of individual tumors.
det||man-4/NN||a-1/DT	amod||man-4/NN||42-year-old-2/JJ	nn||man-4/NN||indian-3/NN	nsubj||received-5/VBD||man-4/NN	root||ROOT-0/null||received-5/VBD	num||rifampicin-8/NN||450-6/CD	nn||rifampicin-8/NN||mg-7/NN	dobj||received-5/VBD||rifampicin-8/NN	appos||rifampicin-8/NN||rif-10/NN	num||mg-14/NN||150-13/CD	dobj||received-5/VBD||mg-14/NN	conj_and||rifampicin-8/NN||mg-14/NN	vmod||mg-14/NN||isoniazid-15/VBN	dep||isoniazid-15/VBN||inh-17/NN	advmod||inh-17/NN||daily-19/RB	auxpass||diagnosed-22/VBN||being-21/VBG	prepc_after||received-5/VBD||diagnosed-22/VBN	det||tuberculosisinfection-26/NN||a-24/DT	nn||tuberculosisinfection-26/NN||latent-25/NN	prep_of||diagnosed-22/VBN||tuberculosisinfection-26/NN	tuberculosisinfection-26||inh-17||yes||a 42-year-old indian man received 450 mg rifampicin (rif) and 150 mg isoniazid (inh) daily after being diagnosed of a latent tuberculosisinfection.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||effect-4/NN||the-3/DT	dobj||investigated-2/VBD||effect-4/NN	amod||mice-36/NNS||varying-6/VBG	det||rates-10/NNS||the-7/DT	amod||rates-10/NNS||intraperitoneal-8/JJ	nn||rates-10/NNS||infusion-9/NN	nn||mice-36/NNS||rates-10/NNS	amod||dose50-19/NNS||bupropionhcl-12/JJ	num||mg/kg-14/NN||120-13/CD	dep||bupropionhcl-12/JJ||mg/kg-14/NN	det||convulsive-18/NN||a-16/DT	amod||convulsive-18/NN||known-17/JJ	appos||mg/kg-14/NN||convulsive-18/NN	prep_of||rates-10/NNS||dose50-19/NNS	appos||dose50-19/NNS||cd50-21/NNP	conj_and||rates-10/NNS||on-24/IN	nn||mice-36/NNS||on-24/IN	det||incidence-26/NN||the-25/DT	prep_on||rates-10/NNS||incidence-26/NN	conj_and||rates-10/NNS||severity-28/NN	nn||mice-36/NNS||severity-28/NN	amod||convulsions-31/NNS||bupropion-induced-30/JJ	prep_of||severity-28/NN||convulsions-31/NNS	det||albino-35/NN||the-33/DT	amod||albino-35/NN||swiss-34/JJ	prep_in||convulsions-31/NNS||albino-35/NN	prep_of||effect-4/NN||mice-36/NNS	convulsions-31||bupropion--1||no||we investigated the effect of varying the intraperitoneal infusion rates of bupropionhcl 120 mg/kg, a known convulsive dose50 (cd50), on the incidence and severity of bupropion-induced convulsions in the swiss albino mice.
num||patients-2/NNS||nine-1/CD	npadvmod||seropositive-3/JJ||patients-2/NNS	root||ROOT-0/null||seropositive-3/JJ	prep_for||seropositive-3/JJ||hepatitisb-5/NN	dep||received-8/VBD||e-6/SYM	nsubj||received-8/VBD||antigen-7/NN	dep||seropositive-3/JJ||received-8/VBD	nn||monotherapy-10/NN||entecavir-9/NN	nsubjpass||analyzed-34/VBN||monotherapy-10/NN	num||months-13/NNS||12-12/CD	prep_for||monotherapy-10/NN||months-13/NNS	det||percentages-16/NNS||the-15/DT	prep_for||monotherapy-10/NN||percentages-16/NNS	conj_and||months-13/NNS||percentages-16/NNS	prep_of||percentages-16/NNS||tregs-18/NNS	amod||cells-21/NNS||th17-20/JJ	prep_of||percentages-16/NNS||cells-21/NNS	conj_and||tregs-18/NNS||cells-21/NNS	det||productions-28/NNS||the-25/DT	amod||productions-28/NNS||hbv-specific-26/JJ	amod||productions-28/NNS||il-17-27/JJ	prep_of||percentages-16/NNS||productions-28/NNS	conj_and||tregs-18/NNS||productions-28/NNS	det||patients-31/NNS||these-30/DT	prep_in||productions-28/NNS||patients-31/NNS	auxpass||analyzed-34/VBN||were-32/VBD	advmod||analyzed-34/VBN||longitudinally-33/RB	ccomp||received-8/VBD||analyzed-34/VBN	hbv--1||entecavir-9||yes||nine patients seropositive for hepatitisb e antigen received entecavir monotherapy for 12 months and the percentages of tregs and th17 cells as well as the hbv-specific il-17 productions in these patients were longitudinally analyzed.
amod||results-3/NNS||exenatide-1/JJ	nn||results-3/NNS||qw-2/NN	nsubj||tolerated-20/VBD||results-3/NNS	amod||coverage-6/NN||24-hour-5/JJ	prep_in||results-3/NNS||coverage-6/NN	nsubjpass||known-12/VBN||coverage-6/NN	nsubj||improve-14/VB||coverage-6/NN	nsubj||remain-18/VB||coverage-6/NN	amod||concentrations-9/NNS||exenatide-8/JJ	prep_with||coverage-6/NN||concentrations-9/NNS	auxpass||known-12/VBN||are-11/VBP	rcmod||coverage-6/NN||known-12/VBN	aux||improve-14/VB||to-13/TO	xcomp||known-12/VBN||improve-14/VB	amod||control-16/NN||glycemic-15/JJ	dobj||improve-14/VB||control-16/NN	xcomp||known-12/VBN||remain-18/VB	conj_and||improve-14/VB||remain-18/VB	advmod||remain-18/VB||well-19/RB	root||ROOT-0/null||tolerated-20/VBD	prep_in||tolerated-20/VBD||patients-22/NNS	prep_with||tolerated-20/VBD||type2diabetesmellitus-24/CD	type2diabetesmellitus-24||exenatide-8||yes||exenatide qw results in 24-hour coverage with exenatide concentrations that are known to improve glycemic control and remain well tolerated in patients with type2diabetesmellitus.
advmod||reported-26/VBN||besides-1/RB	amod||hemangioma-4/NN||unilateral-3/JJ	nsubjpass||reported-26/VBN||hemangioma-4/NN	det||case-9/NN||a-6/DT	amod||case-9/NN||unique-7/JJ	amod||case-9/NN||concurrent-8/JJ	appos||hemangioma-4/NN||case-9/NN	prep_of||case-9/NN||tetracycline-11/NN	vmod||tetracycline-11/NN||induced-12/VBN	amod||toxicity-14/NN||gastric-13/JJ	dobj||induced-12/VBN||toxicity-14/NN	det||dog-17/NN||a-16/DT	prep_in||induced-12/VBN||dog-17/NN	vmod||dog-17/NN||characterized-19/VBN	agent||characterized-19/VBN||gastritis-21/NNS	agent||characterized-19/VBN||ulceration-23/NN	conj_and||gastritis-21/NNS||ulceration-23/NN	aux||reported-26/VBN||is-24/VBZ	auxpass||reported-26/VBN||being-25/VBG	root||ROOT-0/null||reported-26/VBN	advmod||reported-26/VBN||here-27/RB	gastritis-21||tetracycline-11||no_rel||besides, unilateral hemangioma, a unique concurrent case of tetracycline induced gastric toxicity in a dog, characterized by gastritis and ulceration is being reported here.
num||measurements-4/NNS||77-1/CD	amod||measurements-4/NNS||different-2/JJ	nn||measurements-4/NNS||alp-3/NN	nsubjpass||included-28/VBN||measurements-4/NNS	number||nutritional-7/JJ||38-6/CD	amod||rickets-8/NNS||nutritional-7/JJ	prep_from||measurements-4/NNS||rickets-8/NNS	appos||rickets-8/NNS||nr-10/NN	num||rickets-15/NNS||7-13/CD	amod||rickets-15/NNS||vitamind-dependent-14/JJ	prep_from||measurements-4/NNS||rickets-15/NNS	conj_and||rickets-8/NNS||rickets-15/NNS	appos||rickets-15/NNS||vddr-17/NN	num||patients-26/NNS||8-20/CD	amod||patients-26/NNS||hypophosphatemic-21/JJ	nn||patients-26/NNS||rickets-22/NN	appos||patients-26/NNS||hr-24/NN	prep_from||measurements-4/NNS||patients-26/NNS	conj_and||rickets-8/NNS||patients-26/NNS	auxpass||included-28/VBN||were-27/VBD	root||ROOT-0/null||included-28/VBN	rickets-22||vitamind--1||yes||77 different alp measurements from 38 nutritional rickets (nr), 7 vitamind-dependent rickets (vddr) and 8 hypophosphatemic rickets (hr) patients were included.
nsubj||transporter-6/NN||frpb-1/NN	cop||transporter-6/NN||is-2/VBZ	det||transporter-6/NN||an-3/DT	amod||transporter-6/NN||outer-4/JJ	amod||transporter-6/NN||membrane-5/JJ	root||ROOT-0/null||transporter-6/NN	prep_from||transporter-6/NN||neisseriameningitidis-8/NNS	det||agent-12/NN||the-10/DT	amod||agent-12/NN||causative-11/JJ	appos||neisseriameningitidis-8/NNS||agent-12/NN	prep_of||agent-12/NN||meningococcalmeningitis-14/NNS	meningococcalmeningitis-14||neisseriameningitidis-8||no||frpb is an outer membrane transporter from neisseriameningitidis , the causative agent of meningococcalmeningitis.
mark||established-11/VBN||although-1/IN	amod||countries-5/NNS||western-4/JJ	prep_in||established-11/VBN||countries-5/NNS	amod||regimens-8/NNS||oxaliplatin-based-7/JJ	nsubjpass||established-11/VBN||regimens-8/NNS	aux||established-11/VBN||have-9/VBP	auxpass||established-11/VBN||been-10/VBN	advcl||accepted-40/VBN||established-11/VBN	det||treatment-16/NN||a-13/DT	amod||treatment-16/NN||gold-14/JJ	amod||treatment-16/NN||standard-15/JJ	prep_as||established-11/VBN||treatment-16/NN	prep_for||treatment-16/NN||patients-18/NNS	nn||iii-21/NN||stage-20/NN	prep_with||patients-18/NNS||iii-21/NN	amod||cancer-28/NN||high-23/JJ	nn||cancer-28/NN||risk-24/NN	nn||cancer-28/NN||stage-25/NN	nn||cancer-28/NN||ii-26/NN	nn||cancer-28/NN||colon-27/NN	prep_with||patients-18/NNS||cancer-28/NN	conj_or||iii-21/NN||cancer-28/NN	amod||resection-31/NN||curative-30/JJ	prep_after||established-11/VBN||resection-31/NN	prep_in||established-11/VBN||japan-34/NN	amod||regimens-36/NNS||fluorouracil-based-35/JJ	nsubjpass||accepted-40/VBN||regimens-36/NNS	nsubjpass||recommended-42/VBN||regimens-36/NNS	aux||accepted-40/VBN||have-37/VBP	auxpass||accepted-40/VBN||been-38/VBN	advmod||accepted-40/VBN||widely-39/RB	root||ROOT-0/null||accepted-40/VBN	conj_and||accepted-40/VBN||recommended-42/VBN	det||guidelines-45/NNS||the-44/DT	prep_in||accepted-40/VBN||guidelines-45/NNS	amod||settings-48/NNS||adjuvant-47/JJ	prep_for||guidelines-45/NNS||settings-48/NNS	prep_in||accepted-40/VBN||patients-50/NNS	nn||cancer-55/NN||stage-52/NN	nn||cancer-55/NN||iii-53/NN	nn||cancer-55/NN||colon-54/NN	prep_with||patients-50/NNS||cancer-55/NN	oxaliplatin--1||cancer-55||no_rel||although, in western countries, oxaliplatin-based regimens have been established as a gold standard treatment for patients with stage iii or high risk stage ii colon cancer after curative resection, in japan fluorouracil-based regimens have been widely accepted and recommended in the guidelines for adjuvant settings in patients with stage iii colon cancer.
amod||administration-2/NN||oral-1/JJ	nsubj||led-14/VBD||administration-2/NN	prep_of||administration-2/NN||pde5inhibitor-4/NNS	appos||pde5inhibitor-4/NNS||vardenafil-6/NN	prep_to||pde5inhibitor-4/NNS||mice-9/NNS	amod||lungtumors-13/NNS||her2-positive-11/JJ	amod||lungtumors-13/NNS||intracranial-12/JJ	prep_with||mice-9/NNS||lungtumors-13/NNS	root||ROOT-0/null||led-14/VBD	det||permeability-19/NN||an-16/DT	amod||permeability-19/NN||increased-17/VBN	nn||permeability-19/NN||tumor-18/NN	prep_to||led-14/VBD||permeability-19/NN	amod||dextran-27/NNS||high-21/JJ	amod||dextran-27/NNS||molecular-22/JJ	nn||dextran-27/NNS||weight-23/NN	amod||dextran-27/NNS||-LSB--24/JJ	amod||dextran-27/NNS||14c-25/JJ	nn||dextran-27/NNS||-RSB--26/NN	prep_to||permeability-19/NN||dextran-27/NNS	amod||increase-30/NN||2.6-fold-29/JJ	appos||dextran-27/NNS||increase-30/NN	prep_to||permeability-19/NN||herceptin-34/NN	conj_and||dextran-27/NNS||herceptin-34/NN	amod||increase-37/NN||2-fold-36/JJ	appos||herceptin-34/NN||increase-37/NN	lungtumors-13||dextran-27||no_rel||oral administration of pde5inhibitor, vardenafil, to mice with her2-positive intracranial lungtumors led to an increased tumor permeability to high molecular weight [14c]dextran (2.6-fold increase) and to herceptin (2-fold increase).
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||lidocaine-29||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
aux||identify-2/VB||to-1/TO	advcl||undertaken-29/VBN||identify-2/VB	det||variations-5/NNS||the-3/DT	amod||variations-5/NNS||genetic-4/JJ	dobj||identify-2/VB||variations-5/NNS	vmod||variations-5/NNS||associated-6/VBN	nn||intolerance-9/NN||aspirin-8/NN	prep_with||associated-6/VBN||intolerance-9/NN	prep_in||intolerance-9/NN||asthmatics-11/NNS	det||stage-15/NN||the-13/DT	amod||stage-15/NN||first-14/JJ	nsubjpass||undertaken-29/VBN||stage-15/NN	amod||study-19/NN||genome-wide-17/JJ	nn||study-19/NN||association-18/NN	prep_of||stage-15/NN||study-19/NN	num||polymorphisms-24/NNS||109,365-21/CD	amod||polymorphisms-24/NNS||single-22/JJ	nn||polymorphisms-24/NNS||nucleotide-23/NN	prep_with||study-19/NN||polymorphisms-24/NNS	appos||polymorphisms-24/NNS||snps-26/NNS	auxpass||undertaken-29/VBN||was-28/VBD	root||ROOT-0/null||undertaken-29/VBN	det||cohort-43/NN||a-31/DT	amod||cohort-43/NN||korean-32/JJ	amod||cohort-43/NN||aia-33/JJ	dep||cohort-43/NN||nâ-35/NN	num||â-39/NN||$-36/$	number||=-38/CD||-37/CD	num||$-36/$||=-38/CD	dep||nâ-35/NN||â-39/NN	dep||â-39/NN||$-40/$	num||$-40/$||80-41/CD	prep_in||undertaken-29/VBN||cohort-43/NN	nn||subjects-58/NNS||aspirin-tolerant-45/NN	nn||subjects-58/NNS||asthma-46/NN	dep||subjects-58/NNS||ata-48/NN	appos||ata-48/NN||nâ-50/NN	num||â-54/NN||$-51/$	number||=-53/CD||-52/CD	num||$-51/$||=-53/CD	dep||nâ-50/NN||â-54/NN	dep||ata-48/NN||$-55/$	num||$-55/$||100-56/CD	prep_in||undertaken-29/VBN||subjects-58/NNS	conj_and||cohort-43/NN||subjects-58/NNS	prep_as||cohort-43/NN||controls-60/NNS	asthmatics-11||aspirin-8||no||to identify the genetic variations associated with aspirin intolerance in asthmatics, the first stage of genome-wide association study with 109,365 single nucleotide polymorphisms (snps) was undertaken in a korean aia (nâ=â80) cohort and aspirin-tolerant asthma (ata, nâ=â100) subjects as controls.
amod||infusion-3/NN||continuous-1/JJ	amod||infusion-3/NN||remifentanil-2/JJ	nsubj||had-15/VBD||infusion-3/NN	num||kg/min-8/NNS||0.05-5/CD	nn||kg/min-8/NNS||âµg-6/NNP	nn||kg/min-8/NNS||/-7/NN	appos||infusion-3/NN||kg/min-8/NNS	advmod||postoperatively-11/RB||immediately-10/RB	amod||infusion-3/NN||postoperatively-11/RB	amod||pca-14/NN||alfentanil-based-13/JJ	prep_with||postoperatively-11/RB||pca-14/NN	root||ROOT-0/null||had-15/VBD	det||effect-18/NN||a-16/DT	amod||effect-18/NN||similar-17/JJ	dobj||had-15/VBD||effect-18/NN	det||infusion-25/NN||a-20/DT	number||/-23/NN||0.1-21/CD	dep||/-23/NN||âµg-22/JJ	amod||infusion-25/NN||/-23/NN	nn||infusion-25/NN||kg/min-24/NN	prep_as||effect-18/NN||infusion-25/NN	prep_with||had-15/VBD||respect-27/NN	nn||control-30/NN||pain-29/NN	prep_to||had-15/VBD||control-30/NN	nn||effects-33/NNS||side-32/NN	prep_without||had-15/VBD||effects-33/NNS	pain-29||remifentanil-2||yes||continuous remifentanil infusion (0.05 âµg/kg/min) immediately postoperatively with alfentanil-based pca had a similar effect as a 0.1 âµg/kg/min infusion with respect to pain control without side effects.
amod||challenges-2/NNS||current-1/JJ	nsubj||include-10/VBP||challenges-2/NNS	det||eradication-6/NN||the-4/DT	amod||eradication-6/NN||final-5/JJ	prep_to||challenges-2/NNS||eradication-6/NN	amod||poliomyelitis-9/NNP||paralytic-8/JJ	prep_of||eradication-6/NN||poliomyelitis-9/NNP	root||ROOT-0/null||include-10/VBP	det||transmission-13/NN||the-11/DT	amod||transmission-13/NN||continued-12/VBN	dobj||include-10/VBP||transmission-13/NN	amod||polioviruses-16/NNS||wild-15/JJ	prep_of||transmission-13/NN||polioviruses-16/NNS	amod||reservoirs-19/NNS||endemic-18/JJ	prep_in||polioviruses-16/NNS||reservoirs-19/NNS	dobj||include-10/VBP||reinfection-21/NN	conj_and||transmission-13/NN||reinfection-21/NN	amod||areas-24/NNS||polio-free-23/JJ	prep_of||reinfection-21/NN||areas-24/NNS	appos||areas-24/NNS||outbreaks-26/NNS	prepc_due_to||outbreaks-26/NNS||circulating-29/VBG	amod||polioviruses-31/NNS||vaccine-derived-30/JJ	dobj||circulating-29/VBG||polioviruses-31/NNS	amod||excretion-35/NN||persistent-34/JJ	dobj||include-10/VBP||excretion-35/NN	conj_and||transmission-13/NN||excretion-35/NN	amod||poliovirus-38/NNS||vaccine-derived-37/JJ	prep_of||excretion-35/NN||poliovirus-38/NNS	det||vaccinees-42/NNS||a-40/DT	amod||vaccinees-42/NNS||few-41/JJ	prep_by||poliovirus-38/NNS||vaccinees-42/NNS	amod||immunodeficiencies-45/NNS||b-cell-44/JJ	prep_with||vaccinees-42/NNS||immunodeficiencies-45/NNS	poliomyelitis-9||polioviruses-31||no||current challenges to the final eradication of paralytic poliomyelitis include the continued transmission of wild polioviruses in endemic reservoirs, reinfection of polio-free areas, outbreaks due to circulating vaccine-derived polioviruses, and persistent excretion of vaccine-derived poliovirus by a few vaccinees with b-cell immunodeficiencies.
csubjpass||undertaken-30/VBN||considering-1/VBG	det||number-4/NN||a-2/DT	amod||number-4/NN||large-3/JJ	dobj||considering-1/VBG||number-4/NN	amod||cases-7/NNS||clinical-6/JJ	prep_of||number-4/NN||cases-7/NNS	nn||genome-11/NN||infection-9/NN	amod||genome-11/NN||complete-10/JJ	prep_of||cases-7/NNS||genome-11/NN	vmod||genome-11/NN||based-12/VBN	nn||characterization-14/NN||sequence-13/NN	dobj||based-12/VBN||characterization-14/NN	amod||virus-18/NN||indian-16/JJ	amod||virus-18/NN||h1n1pdm-17/JJ	prep_of||characterization-14/NN||virus-18/NN	poss||analysis-22/NN||their-20/PRP$	amod||analysis-22/NN||phylogenetic-21/JJ	prep_of||characterization-14/NN||analysis-22/NN	conj_and||virus-18/NN||analysis-22/NN	prep_with||based-12/VBN||respect-24/NN	prepc_to||based-12/VBN||circulating-26/VBG	amod||viruses-28/NNS||global-27/JJ	dobj||circulating-26/VBG||viruses-28/NNS	auxpass||undertaken-30/VBN||was-29/VBD	root||ROOT-0/null||undertaken-30/VBN	aux||reveal-33/VB||to-32/TO	xcomp||undertaken-30/VBN||reveal-33/VB	det||pattern-36/NN||the-34/DT	amod||pattern-36/NN||phylodynamic-35/JJ	dobj||reveal-33/VB||pattern-36/NN	amod||virus-39/NN||h1n1pdm-38/JJ	prep_of||pattern-36/NN||virus-39/NN	prep_in||reveal-33/VB||india-41/NN	amod||$-44/NNS||2009â-43/JJ	prep_from||reveal-33/VB||$-44/NNS	dep||$-44/NNS||2011-46/CD	virus-39||viruses-28||no||considering a large number of clinical cases of infection complete genome based sequence characterization of indian h1n1pdm virus and their phylogenetic analysis with respect to circulating global viruses was undertaken, to reveal the phylodynamic pattern of h1n1pdm virus in india from 2009â2011.
amod||control-2/NN||efficient-1/JJ	nsubj||requires-8/VBZ||control-2/NN	prep_of||control-2/NN||tuberculosis-4/NNP	appos||tuberculosis-4/NNP||tb-6/NN	dep||mycobacteriumbovis-20/VBZ||requires-8/VBZ	dobj||requires-8/VBZ||development-9/NN	prep_of||development-9/NN||strategies-11/NNS	nsubj||enhance-14/VB||strategies-11/NNS	aux||enhance-14/VB||can-13/MD	rcmod||strategies-11/NNS||enhance-14/VB	dobj||enhance-14/VB||efficacy-15/NN	det||vaccine-19/NN||the-17/DT	amod||vaccine-19/NN||existing-18/VBG	prep_of||efficacy-15/NN||vaccine-19/NN	root||ROOT-0/null||mycobacteriumbovis-20/VBZ	amod||guerin-23/NN||bacille-21/JJ	nn||guerin-23/NN||calmette-22/NN	nsubj||mycobacteriumbovis-20/VBZ||guerin-23/NN	appos||guerin-23/NN||bcg-25/NN	tuberculosis-4||bcg-25||no||efficient control of tuberculosis (tb) requires development of strategies that can enhance efficacy of the existing vaccine mycobacteriumbovis bacille calmette guerin (bcg).
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||level-4/NN||the-3/DT	dobj||evaluate-2/VB||level-4/NN	prep_of||level-4/NN||pain-6/NN	prep_during||evaluate-2/VB||phacoemulsification-8/NN	amod||implantation-13/NN||foldable-10/JJ	amod||implantation-13/NN||intraocular-11/JJ	nn||implantation-13/NN||lens-12/NN	prep_during||evaluate-2/VB||implantation-13/NN	conj_and||phacoemulsification-8/NN||implantation-13/NN	prep_under||evaluate-2/VB||instillation-15/NN	amod||eyedrops-20/NNS||tetracaine-17/JJ	number||%-19/NN||0.5-18/CD	amod||eyedrops-20/NNS||%-19/NN	prep_of||instillation-15/NN||eyedrops-20/NNS	det||combination-23/NN||a-22/DT	prep_versus||eyedrops-20/NNS||combination-23/NN	dep||%-27/NN||lidocaine-25/JJ	number||%-27/NN||2-26/CD	amod||gel-28/NN||%-27/NN	prep_of||combination-23/NN||gel-28/NN	prep_of||combination-23/NN||instillation-30/NN	conj_and||gel-28/NN||instillation-30/NN	amod||eyedrops-33/NNS||tetracaine-32/JJ	prep_of||eyedrops-20/NNS||eyedrops-33/NNS	pain-6||lidocaine-25||yes||to evaluate the level of pain during phacoemulsification and foldable intraocular lens implantation under instillation of tetracaine 0.5% eyedrops versus a combination of lidocaine 2% gel and instillation of tetracaine eyedrops.
number||hundred-2/CD||two-1/CD	num||s.aureus-4/NNS||hundred-2/CD	amod||s.aureus-4/NNS||thirty-nine-3/JJ	nsubj||isolates-5/VBZ||s.aureus-4/NNS	root||ROOT-0/null||isolates-5/VBZ	number||121-7/CD||-lrb--6/CD	num||s.aureus-9/NNS||121-7/CD	amod||s.aureus-9/NNS||methicillin-resistant-8/JJ	dobj||isolates-5/VBZ||s.aureus-9/NNS	nn||-rsb--12/NNP||-lsb--10/NNP	nn||-rsb--12/NNP||mrsa-11/NNP	dep||s.aureus-9/NNS||-rsb--12/NNP	num||s.aureus-16/NNS||118-14/CD	amod||s.aureus-16/NNS||methicillin-susceptible-15/JJ	dobj||isolates-5/VBZ||s.aureus-16/NNS	conj_and||s.aureus-9/NNS||s.aureus-16/NNS	nn||-rrb--20/NNP||-lsb--17/NNP	nn||-rrb--20/NNP||mssa-18/NNP	nn||-rrb--20/NNP||-rsb--19/NNP	nsubjpass||screened-22/VBN||-rrb--20/NNP	auxpass||screened-22/VBN||were-21/VBD	rcmod||s.aureus-16/NNS||screened-22/VBN	nn||acgh-29/NN||array-24/NN	amod||acgh-29/NN||comparative-25/JJ	amod||acgh-29/NN||genomic-26/JJ	nn||acgh-29/NN||hybridization-27/NN	nn||acgh-29/NN||-lrb--28/NN	agent||screened-22/VBN||acgh-29/NN	vmod||acgh-29/NN||-rrb--30/VBN	aux||identify-32/VB||to-31/TO	xcomp||-rrb--30/VBN||identify-32/VB	dobj||identify-32/VB||genes-33/NNS	vmod||genes-33/NNS||implicated-34/VBN	amod||infections-37/NNS||complicated-36/JJ	prep_in||implicated-34/VBN||infections-37/NNS	mrsa-11||s.aureus-16||no||two hundred thirty-nine s.aureus isolates -lrb- 121 methicillin-resistant s.aureus -lsb- mrsa -rsb- and 118 methicillin-susceptible s.aureus -lsb- mssa -rsb- -rrb- were screened by array comparative genomic hybridization -lrb- acgh -rrb- to identify genes implicated in complicated infections .
amod||vaccination-5/NN||proper-4/JJ	prep_in_spite_of||developed-22/VBD||vaccination-5/NN	prep_with||vaccination-5/NN||mono-7/NN	nn||vaccines-11/NNS||bivalent-10/NN	prep_with||vaccination-5/NN||vaccines-11/NNS	conj_or||mono-7/NN||vaccines-11/NNS	prep_against||vaccination-5/NN||marek-13/NN	dep||marek-13/NN||sdisease-15/NN	appos||marek-13/NN||md-17/NN	det||chickens-21/NNS||the-20/DT	nsubj||developed-22/VBD||chickens-21/NNS	root||ROOT-0/null||developed-22/VBD	dobj||developed-22/VBD||symptoms-23/NNS	prep_of||symptoms-23/NNS||md-25/NN	prep_with||developed-22/VBD||paralysis-27/NN	mono-7||vaccines-11||no_rel||in spite of proper vaccination with mono- or bivalent vaccines against marek'sdisease (md), the chickens developed symptoms of md with paralysis.
det||data-2/NNS||these-1/DT	nsubj||established-4/VBN||data-2/NNS	aux||established-4/VBN||have-3/VBP	root||ROOT-0/null||established-4/VBN	mark||prion-9/VBN||that-5/IN	amod||prions-7/NNS||kuru-6/JJ	nsubj||prion-9/VBN||prions-7/NNS	aux||prion-9/VBN||have-8/VBP	ccomp||established-4/VBN||prion-9/VBN	nn||properties-11/NNS||strain-10/NN	nsubj||equivalent-12/JJ||properties-11/NNS	xcomp||prion-9/VBN||equivalent-12/JJ	prep_to||equivalent-12/JJ||those-14/DT	amod||prions-29/NNS||classical-16/JJ	dep||prions-29/NNS||sporadic-18/JJ	conj_and||sporadic-18/JJ||iatrogenic-20/JJ	dep||prions-29/NNS||iatrogenic-20/JJ	amod||prions-29/NNS||cjd-22/JJ	nn||prions-29/NNS||prions-23/NNS	conj_but||prions-23/NNS||distinct-25/JJ	nn||prions-29/NNS||distinct-25/JJ	amod||cjd-28/NN||variant-27/JJ	prep_from||distinct-25/JJ||cjd-28/NN	prep_of||those-14/DT||prions-29/NNS	cjd-28||prion-9||no_rel||these data have established that kuru prions have prion strain properties equivalent to those of classical (sporadic and iatrogenic) cjd prions but distinct from variant cjd prions.
nsubj||play-3/VB||vitamind-1/NN	aux||play-3/VB||may-2/MD	root||ROOT-0/null||play-3/VB	det||role-5/NN||a-4/DT	dobj||play-3/VB||role-5/NN	det||pathogenesis-8/NNS||the-7/DT	prep_in||play-3/VB||pathogenesis-8/NNS	prep_of||pathogenesis-8/NNS||type2diabetes-10/CD	mark||d-17/VBD||as-12/IN	nsubj||d-17/VBD||25-13/CD	discourse||25-13/CD||oh-15/UH	advcl||play-3/VB||d-17/VBD	nsubjpass||associated-21/VBN||concentration-18/NN	auxpass||associated-21/VBN||was-19/VBD	advmod||associated-21/VBN||independently-20/RB	ccomp||d-17/VBD||associated-21/VBN	preconj||sensitivity-25/NN||both-23/DT	nn||sensitivity-25/NN||insulin-24/NN	prep_with||associated-21/VBN||sensitivity-25/NN	nn||²-28/NN||î-27/NN	prep_with||associated-21/VBN||²-28/NN	conj_and||sensitivity-25/NN||²-28/NN	nsubj||function-31/VBP||cell-30/NN	parataxis||play-3/VB||function-31/VBP	prep_among||function-31/VBP||individuals-33/NNS	prep_at||individuals-33/NNS||risk-35/NN	prep_of||risk-35/NN||type2diabetes-37/CD	type2diabetes-37||insulin-24||yes||vitamind may play a role in the pathogenesis of type2diabetes, as 25(oh)d concentration was independently associated with both insulin sensitivity and î²-cell function among individuals at risk of type2diabetes.
det||combination-2/NN||the-1/DT	nsubj||reduced-12/VBD||combination-2/NN	amod||propofol-5/NN||cold-4/JJ	prep_of||combination-2/NN||propofol-5/NN	prep_of||combination-2/NN||pretreatment-7/NN	conj_and||propofol-5/NN||pretreatment-7/NN	prep_with||propofol-5/NN||remifentanil-9/NN	advmod||effectively-11/RB||more-10/RBR	advmod||reduced-12/VBD||effectively-11/RB	root||ROOT-0/null||reduced-12/VBD	det||incidence-14/NN||the-13/DT	dobj||reduced-12/VBD||incidence-14/NN	prep_of||incidence-14/NN||pain-16/NN	det||injection-19/NN||the-18/DT	prep_upon||reduced-12/VBD||injection-19/NN	prep_of||injection-19/NN||propofol-21/NN	det||treatment-24/NN||either-23/DT	prep_than||reduced-12/VBD||treatment-24/NN	advmod||reduced-12/VBD||alone-25/RB	pain-16||propofol-21||yes||the combination of cold propofol and pretreatment with remifentanil more effectively reduced the incidence of pain upon the injection of propofol than either treatment alone.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubjpass||recommended-12/VBN||treatment-3/NN	prep_of||treatment-3/NN||malaria-5/NN	prep_with||malaria-5/NN||sulphadoxine-pyrimethamine-7/NN	appos||treatment-3/NN||sp-9/NN	auxpass||recommended-12/VBN||is-11/VBZ	root||ROOT-0/null||recommended-12/VBN	det||prevention-15/NN||the-14/DT	prep_for||recommended-12/VBN||prevention-15/NN	prep_of||prevention-15/NN||malaria-17/NN	prep_in||recommended-12/VBN||pregnancy-19/NN	amod||africa-22/NN||sub-saharan-21/JJ	prep_in||pregnancy-19/NN||africa-22/NN	malaria-17||pyrimethamine--1||no||intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine (sp) is recommended for the prevention of malaria in pregnancy in sub-saharan africa.
nsubjpass||caused-13/VBN||paracoccidioidomycosis-1/NNS	appos||paracoccidioidomycosis-1/NNS||pcm-3/NN	det||systemicmycosis-7/NNS||the-5/DT	amod||systemicmycosis-7/NNS||major-6/JJ	appos||paracoccidioidomycosis-1/NNS||systemicmycosis-7/NNS	nn||america-10/NN||latin-9/NN	prep_in||systemicmycosis-7/NNS||america-10/NN	auxpass||caused-13/VBN||is-12/VBZ	root||ROOT-0/null||caused-13/VBN	det||fungus-18/NN||the-15/DT	advmod||dimorphic-17/JJ||termally-16/RB	amod||fungus-18/NN||dimorphic-17/JJ	agent||caused-13/VBN||fungus-18/NN	nsubj||brasiliensis-20/VBZ||paracoccidioides-19/NNS	nsubj||requires-22/VBZ||paracoccidioides-19/NNS	rcmod||fungus-18/NN||brasiliensis-20/VBZ	rcmod||fungus-18/NN||requires-22/VBZ	conj_and||brasiliensis-20/VBZ||requires-22/VBZ	amod||periods-24/NNS||extended-23/JJ	dobj||requires-22/VBZ||periods-24/NNS	prep_of||periods-24/NNS||chemotherapy-26/NN	det||frequency-30/NN||a-28/DT	amod||frequency-30/NN||significant-29/JJ	prep_with||requires-22/VBZ||frequency-30/NN	amod||disease-33/NN||relapsing-32/JJ	prep_of||frequency-30/NN||disease-33/NN	systemicmycosis-7||fungus-18||no||paracoccidioidomycosis, pcm, the major systemicmycosis in latin america, is caused by the termally dimorphic fungus paracoccidioides brasiliensis and requires extended periods of chemotherapy with a significant frequency of relapsing disease.
advmod||report-4/VBP||here-1/RB	nsubj||report-4/VBP||we-3/PRP	root||ROOT-0/null||report-4/VBP	dep||beta-amyloid-39/VBD||on-5/IN	nn||studies-8/NNS||vivo-7/NN	prep_in||beta-amyloid-39/VBD||studies-8/NNS	prep_with||studies-8/NNS||mq-10/NN	amod||treatments-15/NNS||acute-12/JJ	conj_and||acute-12/JJ||sub-chronic-14/JJ	amod||treatments-15/NNS||sub-chronic-14/JJ	dep||mq-10/NN||treatments-15/NNS	amod||$-18/$||7â-17/JJ	dep||treatments-15/NNS||$-18/$	num||$-18/$||15-20/CD	nn||os-23/FW||mg/kg-21/FW	nn||os-23/FW||per-22/FW	dep||treatments-15/NNS||os-23/FW	vmod||mq-10/NN||carried-25/VBN	prepc_out||carried-25/VBN||using-27/VBG	num||models-31/NNS||two-28/CD	amod||models-31/NNS||different-29/JJ	nn||models-31/NNS||mouse-30/NN	dobj||using-27/VBG||models-31/NNS	nn||-RRB--33/FW||i-32/FW	amod||-RRB--33/FW||scopolamine-34/JJ	amod||-RRB--33/FW||ii-37/NN	conj_and||scopolamine-34/JJ||ii-37/NN	ccomp||report-4/VBP||beta-amyloid-39/VBD	dobj||beta-amyloid-39/VBD||peptide-40/NN	advmod||²-44/RB||aî-43/RB	dep||amnesia-48/NN||²-44/RB	amod||amnesia-48/NN||induced-47/JJ	dep||peptide-40/NN||amnesia-48/NN	amnesia-48||scopolamine-34||no||here, we report on in vivo studies with mq (acute and sub-chronic treatments; 7â15 mg/kg per os ) carried out using two different mouse models i) scopolamine- and ii) beta-amyloid peptide- (aî²-) induced amnesia.
nsubj||resulted-4/VBD||induction-1/NN	prep_of||induction-1/NN||ir-3/NN	root||ROOT-0/null||resulted-4/VBD	amod||injury-8/NN||increased-6/JJ	amod||injury-8/NN||ischemic-7/JJ	prep_in||resulted-4/VBD||injury-8/NN	amod||levels-12/NNS||reduced-10/JJ	nn||levels-12/NNS||atp-11/NN	prep_in||resulted-4/VBD||levels-12/NNS	conj_and||injury-8/NN||levels-12/NNS	prep_in||resulted-4/VBD||increases-14/NNS	conj_and||injury-8/NN||increases-14/NNS	nn||ratio-17/NN||l/p-16/NN	prep_in||increases-14/NNS||ratio-17/NN	amod||function-22/NN||poor-20/JJ	amod||function-22/NN||cardiac-21/JJ	prep_in||resulted-4/VBD||function-22/NN	conj_and||injury-8/NN||function-22/NN	nn||hearts-26/NNS||bbz-24/NN	nn||hearts-26/NNS||rat-25/NN	prep_in||resulted-4/VBD||hearts-26/NNS	mark||attenuated-34/VBD||while-28/IN	nsubj||attenuated-34/VBD||inhibition-29/NN	nsubj||protected-38/VBD||inhibition-29/NN	prep_of||inhibition-29/NN||ar-31/NN	prep_of||inhibition-29/NN||sdh-33/NN	conj_or||ar-31/NN||sdh-33/NN	advcl||resulted-4/VBD||attenuated-34/VBD	det||changes-36/NNS||these-35/DT	dobj||attenuated-34/VBD||changes-36/NNS	advcl||resulted-4/VBD||protected-38/VBD	conj_and||attenuated-34/VBD||protected-38/VBD	dobj||protected-38/VBD||hearts-39/NNS	nn||injury-42/NN||ir-41/NN	prep_from||protected-38/VBD||injury-42/NN	atp-11||ar-31||no_rel||induction of ir resulted in increased ischemic injury, reduced atp levels, increases in l/p ratio, and poor cardiac function in bbz rat hearts, while inhibition of ar or sdh attenuated these changes and protected hearts from ir injury.
expl||is-2/VBZ||there-1/EX	root||ROOT-0/null||is-2/VBZ	amod||enrichment-4/NN||natural-3/JJ	nsubj||is-2/VBZ||enrichment-4/NN	nn||cells-7/NNS||nk-6/NN	prep_of||enrichment-4/NN||cells-7/NNS	det||liver-11/NN||the-9/DT	amod||liver-11/NN||human-10/JJ	prep_in||cells-7/NNS||liver-11/NN	det||predominance-15/NN||this-13/DT	amod||predominance-15/NN||intrahepatic-14/JJ	nsubj||underscores-16/VBZ||predominance-15/NN	conj_and||is-2/VBZ||underscores-16/VBZ	poss||importance-19/NN||their-17/PRP$	amod||importance-19/NN||potential-18/JJ	dobj||underscores-16/VBZ||importance-19/NN	det||control-22/NN||the-21/DT	prep_in||underscores-16/VBZ||control-22/NN	prep_of||control-22/NN||infections-24/NNS	amod||viruses-27/NNS||hepatotropic-26/JJ	prep_with||infections-24/NNS||viruses-27/NNS	prep_such_as||viruses-27/NNS||hepatitisbvirus-30/NNS	appos||hepatitisbvirus-30/NNS||hbv-32/NN	hbv-32||hepatitisbvirus-30||no||there is natural enrichment of nk cells in the human liver and this intrahepatic predominance underscores their potential importance in the control of infections with hepatotropic viruses such as hepatitisbvirus (hbv).
nsubjpass||concluded-3/VBN||it-1/PRP	auxpass||concluded-3/VBN||was-2/VBD	root||ROOT-0/null||concluded-3/VBN	mark||favor-7/VBP||that-4/IN	amod||nitrates-6/NNS||organic-5/JJ	nsubj||favor-7/VBP||nitrates-6/NNS	ccomp||concluded-3/VBN||favor-7/VBP	dobj||favor-7/VBP||regression-8/NN	prep_of||regression-8/NN||lvh-10/NN	amod||patients-13/NNS||hypertensive-12/JJ	prep_in||favor-7/VBP||patients-13/NNS	amod||dialysis-17/NN||chronic-15/JJ	amod||dialysis-17/NN||peritoneal-16/JJ	prep_on||patients-13/NNS||dialysis-17/NN	nsubjpass||considered-23/VBN||nitrates-20/NNS	aux||considered-23/VBN||may-21/MD	auxpass||considered-23/VBN||be-22/VB	conj_and||concluded-3/VBN||considered-23/VBN	prep_for||considered-23/VBN||use-25/NN	prepc_before||considered-23/VBN||employing-27/VBG	det||antihypertensiveagents-31/NNS||the-28/DT	num||antihypertensiveagents-31/NNS||five-29/CD	amod||antihypertensiveagents-31/NNS||other-30/JJ	dobj||employing-27/VBG||antihypertensiveagents-31/NNS	amod||antihypertensiveagents-31/NNS||other-32/JJ	prep_than||employing-27/VBG||nitrates-34/NNS	lvh-10||nitrates-34||no_rel||it was concluded that organic nitrates favor regression of lvh in hypertensive patients on chronic peritoneal dialysis, and nitrates may be considered for use before employing the five other antihypertensiveagents other than nitrates.
nsubj||correspond-2/VBZ||savings-1/NNS	root||ROOT-0/null||correspond-2/VBZ	det||costs-6/NNS||the-4/DT	nn||costs-6/NNS||lifetime-5/NN	prep_to||correspond-2/VBZ||costs-6/NNS	nn||treatment-9/NN||hiv-8/NN	prep_of||costs-6/NNS||treatment-9/NN	prep_of||costs-6/NNS||care-11/NN	conj_and||treatment-9/NN||care-11/NN	vmod||costs-6/NNS||avoided-12/VBN	det||result-15/NN||a-14/DT	prep_as||avoided-12/VBN||result-15/NN	det||hivinfections-19/NNS||all-17/DT	amod||hivinfections-19/NNS||vertical-18/JJ	prep_of||result-15/NN||hivinfections-19/NNS	vmod||hivinfections-19/NNS||averted-20/VBN	hivinfections-19||hiv-8||no||savings correspond to the lifetime costs of hiv treatment and care avoided as a result of all vertical hivinfections averted.
nsubj||mimetic-12/NN||exenatide-1/NN	advmod||known-4/VBN||also-3/RB	dep||exenatide-1/NN||known-4/VBN	advmod||exendin-4-6/JJ||as-5/RB	acomp||known-4/VBN||exendin-4-6/JJ	cop||mimetic-12/NN||is-8/VBZ	det||mimetic-12/NN||a-9/DT	amod||mimetic-12/NN||glucagon-like-10/JJ	amod||mimetic-12/NN||peptide-1-11/JJ	root||ROOT-0/null||mimetic-12/NN	nsubjpass||indicated-16/VBN||mimetic-12/NN	auxpass||indicated-16/VBN||is-15/VBZ	rcmod||mimetic-12/NN||indicated-16/VBN	det||treatment-19/NN||the-18/DT	prep_for||indicated-16/VBN||treatment-19/NN	prep_of||treatment-19/NN||type2diabetesmellitus-21/CD	type2diabetesmellitus-21||exendin-4-6||yes||exenatide (also known as exendin-4) is a glucagon-like peptide-1 mimetic, which is indicated for the treatment of type2diabetesmellitus.
prep_in||encompass-12/VB||addition-2/NN	det||standard-6/NN||the-4/DT	amod||standard-6/NN||optimal-5/JJ	nsubj||encompass-12/VB||standard-6/NN	prep_of||standard-6/NN||care-8/NN	prep_for||care-8/NN||osteoporosis-10/NN	aux||encompass-12/VB||should-11/MD	root||ROOT-0/null||encompass-12/VB	amod||calcium-14/NN||adequate-13/JJ	dobj||encompass-12/VB||calcium-14/NN	amod||intake-17/NN||vitamind-16/JJ	dobj||encompass-12/VB||intake-17/NN	conj_and||calcium-14/NN||intake-17/NN	osteoporosis-10||vitamind-16||yes||in addition, the optimal standard of care for osteoporosis should encompass adequate calcium and vitamind intake.
nsubj||investigated-2/VBD||we-1/PRP	nsubj||investigated-2/VBD||we-1/PRP	nsubj||compared-33/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	conj_and||investigated-2/VBD||investigated-2/VBD	det||heterogeneity-4/NN||this-3/DT	dobj||investigated-2/VBD||heterogeneity-4/NN	prepc_by||investigated-2/VBD||comparing-6/VBG	dobj||comparing-6/VBG||phenotypes-7/NNS	prep_of||phenotypes-7/NNS||lada-9/NN	prep||comparing-6/VBG||with-10/IN	amod||need-14/NN||perceived-13/VBN	prep_without||investigated-2/VBD||need-14/NN	nn||treatment-17/NN||insulin-16/NN	prep_for||need-14/NN||treatment-17/NN	dep||need-14/NN||data-19/NNS	vmod||data-19/NNS||obtained-20/VBN	prep_at||obtained-20/VBN||times-22/NNS	advmod||investigated-29/VBN||when-23/WRB	nsubjpass||investigated-29/VBN||diagnosis-24/NN	prep_of||diagnosis-24/NN||lada-26/NN	auxpass||investigated-29/VBN||was-27/VBD	neg||investigated-29/VBN||not-28/RB	rcmod||times-22/NNS||investigated-29/VBN	advmod||compared-33/VBD||also-32/RB	conj_and||investigated-2/VBD||compared-33/VBD	amod||phenotypes-37/NNS||lada-34/JJ	conj_and||lada-34/JJ||type2diabetes-36/JJ	amod||phenotypes-37/NNS||type2diabetes-36/JJ	dobj||compared-33/VBD||phenotypes-37/NNS	type2diabetes-36||insulin-16||yes||we investigated this heterogeneity by comparing phenotypes of lada with and without perceived need for insulin treatment (data obtained at times when diagnosis of lada was not investigated) and also compared lada and type2diabetes phenotypes.
det||time-4/NN||the-1/DT	amod||time-4/NN||shortest-2/JJS	amod||time-4/NN||mean-3/JJ	nsubjpass||obtained-31/VBN||time-4/NN	aux||hcv-6/VB||to-5/TO	vmod||time-4/NN||hcv-6/VB	nn||diagnosis-8/NN||infection-7/NN	dobj||hcv-6/VB||diagnosis-8/NN	num||month-11/NN||1-10/CD	appos||time-4/NN||month-11/NN	det||number-16/NN||the-14/DT	amod||number-16/NN||lowest-15/JJS	conj_and||time-4/NN||number-16/NN	nsubjpass||obtained-31/VBN||number-16/NN	amod||patients-22/NNS||chronichepatitisc-18/JJ	appos||patients-22/NNS||chc-20/NN	prep_of||number-16/NN||patients-22/NNS	num||hcws-27/NNS||1.9-24/CD	amod||hcws-27/NNS||/-25/JJ	num||hcws-27/NNS||7300-26/CD	dep||number-16/NN||hcws-27/NNS	vmod||hcws-27/NNS||exposed-28/VBN	auxpass||obtained-31/VBN||was-30/VBD	root||ROOT-0/null||obtained-31/VBN	det||strategy-35/NN||the-33/DT	amod||strategy-35/NN||alternative-us-34/JJ	prep_with||obtained-31/VBN||strategy-35/NN	dep||months-39/NNS||vs-37/RB	num||months-39/NNS||6-38/CD	dep||strategy-35/NN||months-39/NNS	num||chc-42/NN||7.9-41/CD	dep||strategy-35/NN||chc-42/NN	conj_and||months-39/NNS||chc-42/NN	advmod||months-39/NNS||respectively-44/RB	prep_with||months-39/NNS||baseline-us-46/NNS	chronichepatitisc-18||hcv-6||no||the shortest mean time to hcv infection diagnosis (1 month) and the lowest number of chronichepatitisc (chc) patients (1.9/7300 hcws exposed) was obtained with the alternative-us strategy (vs 6 months and 7.9 chc, respectively with baseline-us).
nsubj||included-2/VBD||these-1/DT	root||ROOT-0/null||included-2/VBD	det||role-4/NN||the-3/DT	dobj||included-2/VBD||role-4/NN	prep_of||role-4/NN||statins-6/NNS	det||agent-10/NN||an-8/DT	amod||agent-10/NN||anti-lipid-9/JJ	appos||statins-6/NNS||agent-10/NN	prepc_in||included-2/VBD||reducing-13/VBG	amod||morbidity-15/NN||post-stroke-14/JJ	dobj||reducing-13/VBG||morbidity-15/NN	dobj||reducing-13/VBG||mortality-17/NN	conj_and||morbidity-15/NN||mortality-17/NN	prepc_in||included-2/VBD||decreasing-20/VBG	conj_and||reducing-13/VBG||decreasing-20/VBG	det||plaque-24/NN||the-21/DT	amod||plaque-24/NN||carotid-22/JJ	amod||plaque-24/NN||atherosclerotic-23/JJ	dobj||decreasing-20/VBG||plaque-24/NN	prep_in||plaque-24/NN||middle-26/NN	vmod||middle-26/NN||aged-27/VBN	dobj||aged-27/VBN||patients-28/NNS	amod||risk-31/NN||increased-30/VBN	prep_at||aged-27/VBN||risk-31/NN	prep_of||risk-31/NN||cardiovasculardisease-33/NN	amod||infusion-36/NN||glucose-potassium-insulin-35/JJ	dobj||decreasing-20/VBG||infusion-36/NN	conj_and||plaque-24/NN||infusion-36/NN	amod||acute-39/JJ||hyperglyceamic-38/JJ	amod||patients-41/NNS||acute-39/JJ	nn||patients-41/NNS||stroke-40/NN	prep_in||infusion-36/NN||patients-41/NNS	dep||infusion-36/NN||pioglitazone-43/VB	det||medication-47/NN||an-45/DT	amod||medication-47/NN||anti-diabetic-46/JJ	dobj||pioglitazone-43/VB||medication-47/NN	nsubj||reduce-50/VB||medication-47/NN	aux||reduce-50/VB||to-49/TO	xcomp||pioglitazone-43/VB||reduce-50/VB	dobj||reduce-50/VB||recurrence-51/NN	prep_of||recurrence-51/NN||stroke-53/NN	nn||patients-58/NNS||type-55/NN	num||patients-58/NNS||2-56/CD	nn||patients-58/NNS||diabetic-57/NN	prep_in||reduce-50/VB||patients-58/NNS	parataxis||pioglitazone-43/VB||administration-60/NN	amod||urokinase-63/NN||intra-arterial-62/JJ	prep_of||administration-60/NN||urokinase-63/NN	det||agent-67/NN||a-65/DT	amod||agent-67/NN||thrombolytic-66/JJ	appos||urokinase-63/NN||agent-67/NN	det||role-71/NN||the-70/DT	prep_of||administration-60/NN||role-71/NN	conj_and||urokinase-63/NN||role-71/NN	nn||therapy-74/NN||laser-73/NN	prep_of||role-71/NN||therapy-74/NN	amod||dissolution-77/NN||clot-76/JJ	prep_in||therapy-74/NN||dissolution-77/NN	dep||administration-60/NN||given-78/VBN	mark||is-83/VBZ||that-79/IN	prep_at||is-83/VBZ||present-81/JJ	expl||is-83/VBZ||there-82/EX	pcomp||given-78/VBN||is-83/VBZ	advmod||fda-86/NN||only-84/RB	num||fda-86/NN||one-85/CD	nsubj||is-83/VBZ||fda-86/NN	vmod||fda-86/NN||approved-87/VBN	amod||agent-89/NN||thrombolytic-88/JJ	dobj||approved-87/VBN||agent-89/NN	nn||tpa-92/NN||r-91/NN	dep||administration-60/NN||tpa-92/NN	parataxis||pioglitazone-43/VB||benefit-95/VB	prep_of||benefit-95/VB||warfarin-97/NN	det||anticoagulant-100/NN||an-99/DT	appos||warfarin-97/NN||anticoagulant-100/NN	amod||patients-104/NNS||elderly-103/JJ	prep_in||warfarin-97/NN||patients-104/NNS	prep_with||benefit-95/VB||atrialfibrillation-106/NN	det||community-109/NN||the-108/DT	prep_in||atrialfibrillation-106/NN||community-109/NN	parataxis||pioglitazone-43/VB||nxy-111/VB	det||agent-117/NN||a-113/DT	amod||radical-115/JJ||free-114/JJ	amod||agent-117/NN||radical-115/JJ	amod||agent-117/NN||trapping-116/JJ	dep||nxy-111/VB||agent-117/NN	parataxis||pioglitazone-43/VB||minocycline-120/VB	conj_and||nxy-111/VB||minocycline-120/VB	det||tested-122/NN||both-121/DT	dobj||nxy-111/VB||tested-122/NN	prep_as||nxy-111/VB||neuroprotectants-124/NNS	dobj||decreasing-20/VBG||zoledronate-127/NN	conj_and||plaque-24/NN||zoledronate-127/NN	det||bisphosphonate-131/NN||an-129/DT	amod||bisphosphonate-131/NN||intravenous-130/JJ	appos||zoledronate-127/NN||bisphosphonate-131/NN	aux||prevent-134/VB||to-133/TO	vmod||zoledronate-127/NN||prevent-134/VB	dobj||prevent-134/VB||loss-135/NN	nn||density-139/NN||bone-137/NN	nn||density-139/NN||mineral-138/NN	prep_of||loss-135/NN||density-139/NN	det||extremity-143/NN||the-141/DT	amod||extremity-143/NN||affected-142/VBN	prep_of||density-139/NN||extremity-143/NN	advmod||role-148/NN||finally-146/RB	det||role-148/NN||the-147/DT	prep_of||density-139/NN||role-148/NN	conj_and||extremity-143/NN||role-148/NN	prep_of||role-148/NN||nicardipine-150/NN	det||calciumchannelblocker-153/NN||a-152/DT	appos||nicardipine-150/NN||calciumchannelblocker-153/NN	det||prevention-157/NN||the-156/DT	prep_in||nicardipine-150/NN||prevention-157/NN	prep_of||prevention-157/NN||vasospasm-159/NN	vmod||zoledronate-127/NN||hydrocortisone-162/VB	conj_and||prevent-134/VB||hydrocortisone-162/VB	aux||prevent-164/VB||to-163/TO	xcomp||hydrocortisone-162/VB||prevent-164/VB	dobj||prevent-164/VB||hyponatraemia-165/NN	amod||hemorrhage-168/NN||sub-arachnoid-167/JJ	prep_after||prevent-164/VB||hemorrhage-168/NN	stroke-53||warfarin-97||yes||these included the role of statins (an anti-lipid agent) in reducing post-stroke morbidity and mortality, and decreasing the carotid atherosclerotic plaque in middle aged patients at increased risk of cardiovasculardisease; glucose-potassium-insulin infusion in hyperglyceamic acute stroke patients; pioglitazone (an anti-diabetic medication) to reduce recurrence of stroke in type 2 diabetic patients; administration of intra-arterial urokinase (a thrombolytic agent) and the role of laser therapy in clot dissolution given that at present there is only one fda approved thrombolytic agent (r tpa); benefit of warfarin (an anticoagulant) in elderly patients with atrialfibrillation in the community; nxy (a free radical trapping agent) and minocycline both tested as neuroprotectants; and zoledronate (an intravenous bisphosphonate) to prevent loss of bone mineral density of the affected extremity, and finally the role of nicardipine (a calciumchannelblocker) in the prevention of vasospasm, and hydrocortisone to prevent hyponatraemia after sub-arachnoid hemorrhage.
prep_in||estimated-31/VBN||india-2/NN	amod||prevalence-5/NN||hbsag-4/VBG	nsubjpass||estimated-31/VBN||prevalence-5/NN	nsubj||million-35/CD||prevalence-5/NN	amod||ranges-9/NNS||general-7/JJ	nn||ranges-9/NNS||population-8/NN	prep_among||prevalence-5/NN||ranges-9/NNS	number||%-15/NN||2-11/CD	dep||%-15/NN||%-12/NN	dep||%-15/NN||to-13/TO	number||%-15/NN||8-14/CD	prep_from||ranges-9/NNS||%-15/NN	nn||india-18/NN||placing-17/NN	prep_among||prevalence-5/NN||india-18/NN	conj_and||ranges-9/NNS||india-18/NN	amod||zone-23/NN||intermediate-20/JJ	nn||zone-23/NN||hbv-21/NN	nn||zone-23/NN||endemicity-22/NN	prep_in||india-18/NN||zone-23/NN	det||number-26/NN||the-25/DT	prep_among||prevalence-5/NN||number-26/NN	conj_and||ranges-9/NNS||number-26/NN	nn||carriers-29/NNS||hbv-28/NN	prep_of||number-26/NN||carriers-29/NNS	auxpass||estimated-31/VBN||is-30/VBZ	root||ROOT-0/null||estimated-31/VBN	aux||million-35/CD||to-32/TO	cop||million-35/CD||be-33/VB	number||million-35/CD||50-34/CD	xcomp||estimated-31/VBN||million-35/CD	vmod||million-35/CD||forming-37/VBG	det||pool-42/NN||the-38/DT	amod||pool-42/NN||second-39/JJ	amod||pool-42/NN||largest-40/JJS	amod||pool-42/NN||global-41/JJ	dobj||forming-37/VBG||pool-42/NN	amod||infections-46/NNS||chronic-44/JJ	nn||infections-46/NNS||hbv-45/NN	prep_of||pool-42/NN||infections-46/NNS	hbv-45||hbsag-4||yes||in india, hbsag prevalence among general population ranges from 2% to 8%, placing india in intermediate hbv endemicity zone and the number of hbv carriers is estimated to be 50 million, forming the second largest global pool of chronic hbv infections.
det||study-3/NN||this-1/DT	nn||study-3/NN||cohort-2/NN	nsubj||consisted-4/VBD||study-3/NN	root||ROOT-0/null||consisted-4/VBD	num||patients-12/NNS||250-6/CD	amod||patients-12/NNS||adalimumab-treated-7/JJ	nn||patients-12/NNS||rheumatoidarthritis-8/NN	nn||patients-12/NNS||ra-10/NN	prep_of||consisted-4/VBD||patients-12/NNS	rheumatoidarthritis-8||adalimumab--1||yes||this cohort study consisted of 250 adalimumab-treated rheumatoidarthritis (ra) patients.
amod||infections-2/NNS||mixed-1/JJ	nsubj||result-14/VB||infections-2/NNS	prep_with||infections-2/NNS||chlamydia-4/NN	amod||virus-9/NN||porcine-6/JJ	nn||virus-9/NN||epidemic-7/NN	nn||virus-9/NN||diarrhea-8/NN	prep_with||infections-2/NNS||virus-9/NN	conj_and||chlamydia-4/NN||virus-9/NN	appos||infections-2/NNS||pedv-11/NNP	aux||result-14/VB||may-13/MD	root||ROOT-0/null||result-14/VB	prep_in||result-14/VB||generation-16/NN	amod||chlamydialinfections-19/NNS||persistent-18/JJ	prep_of||generation-16/NN||chlamydialinfections-19/NNS	chlamydialinfections-19||chlamydia-4||no||mixed infections with chlamydia and porcine epidemic diarrhea virus (pedv) may result in generation of persistent chlamydialinfections.
prep_in_addition_to||produces-7/VBZ||ct-4/NN	nsubj||produces-7/VBZ||v.cholerae-6/NN	root||ROOT-0/null||produces-7/VBZ	amod||toxins-10/NNS||other-8/JJ	nn||toxins-10/NNS||putative-9/NN	dobj||produces-7/VBZ||toxins-10/NNS	det||-rrb--20/NNP||the-14/DT	nn||-rrb--20/NNP||zonula-15/NN	nn||-rrb--20/NNP||occludens-16/NNS	nn||-rrb--20/NNP||toxin-17/NN	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||zot-19/NNP	prep_such_as||toxins-10/NNS||-rrb--20/NNP	amod||-rrb--27/NNP||accessory-22/JJ	nn||-rrb--27/NNP||cholera-23/NN	nn||-rrb--27/NNP||enterotoxin-24/NN	nn||-rrb--27/NNP||-lrb--25/NNP	nn||-rrb--27/NNP||ace-26/NNP	prep_such_as||toxins-10/NNS||-rrb--27/NNP	conj_and||-rrb--20/NNP||-rrb--27/NNP	cholera-23||v.cholerae-6||no||in addition to ct , v.cholerae produces other putative toxins , such as the zonula occludens toxin -lrb- zot -rrb- and accessory cholera enterotoxin -lrb- ace -rrb- .
amod||history-2/NN||careful-1/JJ	nsubj||revealed-3/VBD||history-2/NN	root||ROOT-0/null||revealed-3/VBD	mark||taking-9/VBG||that-4/IN	nsubj||taking-9/VBG||he-5/PRP	aux||taking-9/VBG||has-6/VBZ	aux||taking-9/VBG||been-7/VBN	advmod||taking-9/VBG||erroneously-8/RB	ccomp||revealed-3/VBD||taking-9/VBG	num||ml-11/NN||2.5-10/CD	dobj||taking-9/VBG||ml-11/NN	prep_of||ml-11/NN||dihydrotachysterol-13/NN	prep_per||dihydrotachysterol-13/NN||day-15/NN	quantmod||6-19/CD||at-17/IN	mwe||at-17/IN||least-18/JJS	pobj||at-17/IN||least-18/JJS	prep_for||day-15/NN||6-19/CD	num||weeks-22/NNS||8-21/CD	prep_to||taking-9/VBG||weeks-22/NNS	nsubj||caused-24/VBD||weeks-22/NNS	rcmod||weeks-22/NNS||caused-24/VBD	amod||intoxication-26/NN||vitamind-25/JJ	dobj||caused-24/VBD||intoxication-26/NN	amod||hypercalcemia-29/NN||symptomatic-28/JJ	dobj||caused-24/VBD||hypercalcemia-29/NN	conj_and||intoxication-26/NN||hypercalcemia-29/NN	hypercalcemia-29||vitamind-25||no||careful history revealed that he has been erroneously taking 2.5 ml of dihydrotachysterol per day for at least 6 to 8 weeks that caused vitamind intoxication and symptomatic hypercalcemia.
aux||determine-2/VB||to-1/TO	advcl||fed-25/VBN||determine-2/VB	dobj||determine-2/VB||effects-3/NNS	prep_of||effects-3/NNS||irondeficiency-5/NN	nn||activation-8/NN||ampk-7/NN	prep_on||irondeficiency-5/NN||activation-8/NN	prep_on||irondeficiency-5/NN||signaling-10/NN	conj_and||activation-8/NN||signaling-10/NN	det||composition-18/NN||the-15/DT	nn||composition-18/NN||ampk-16/NN	nn||composition-18/NN||subunit-17/NN	prep_of||effects-3/NNS||composition-18/NN	conj_and||irondeficiency-5/NN||composition-18/NN	amod||muscle-21/NN||skeletal-20/JJ	prep_in||composition-18/NN||muscle-21/NN	nsubjpass||fed-25/VBN||rats-23/NNS	auxpass||fed-25/VBN||were-24/VBD	root||ROOT-0/null||fed-25/VBN	det||control-27/NN||a-26/DT	dobj||fed-25/VBN||control-27/NN	iobj||fed-25/VBN||control-27/NN	dep||control-27/NN||c-29/SYM	dep||fe-33/FW||=-30/SYM	amod||fe-33/FW||50-58-31/JJ	nn||fe-33/FW||mg/kg-32/FW	rcmod||c-29/SYM||fe-33/FW	nn||deficient-37/NN||iron-36/NN	dobj||fed-25/VBN||deficient-37/NN	iobj||fed-25/VBN||deficient-37/NN	conj_or||control-27/NN||deficient-37/NN	dep||control-27/NN||id-39/VBN	dep||fe-43/FW||=-40/SYM	amod||fe-43/FW||2-6-41/JJ	nn||fe-43/FW||mg/kg-42/FW	ccomp||id-39/VBN||fe-43/FW	dep||control-27/NN||diet-45/NN	amod||wks-51/NN||6â-47/JJ	amod||wks-51/NN||$-48/$	num||$-48/$||8-50/CD	prep_for||diet-45/NN||wks-51/NN	irondeficiency-5||fe-43||yes||to determine effects of irondeficiency on ampk activation and signaling, as well as the ampk subunit composition in skeletal muscle, rats were fed a control (c=50-58 mg/kg fe) or iron deficient (id=2-6 mg/kg fe) diet for 6â8 wks.
root||ROOT-0/null||type-1/NN	dep||manifestation-7/NN||b-2/SYM	amod||syndrome-4/NN||insulinresistance-3/JJ	nsubj||manifestation-7/NN||syndrome-4/NN	cop||manifestation-7/NN||is-5/VBZ	det||manifestation-7/NN||a-6/DT	dep||type-1/NN||manifestation-7/NN	prep_of||manifestation-7/NN||autoantibodies-9/NNS	det||receptor-13/NN||the-11/DT	nn||receptor-13/NN||insulin-12/NN	prep_to||autoantibodies-9/NNS||receptor-13/NN	mark||nigricans-21/VBZ||that-14/IN	nsubj||nigricans-21/VBZ||results-15/NNS	amod||hyperglycemia-18/NN||severe-17/JJ	prep_in||results-15/NNS||hyperglycemia-18/NN	prep_in||results-15/NNS||acanthosis-20/NNS	conj_and||hyperglycemia-18/NN||acanthosis-20/NNS	ccomp||manifestation-7/NN||nigricans-21/VBZ	hyperglycemia-18||insulin-12||yes||type b insulinresistance syndrome is a manifestation of autoantibodies to the insulin receptor that results in severe hyperglycemia and acanthosis nigricans.
det||range-5/NN||the-2/DT	nn||range-5/NN||molar-3/NN	nn||range-5/NN||ratio-4/NN	prep_in||increased-28/VBD||range-5/NN	prep_of||range-5/NN||nhs-7/NN	aux||edc-9/VB||to-8/TO	vmod||range-5/NN||edc-9/VB	num||0.5-13/CD||0-11/CD	dep||0.5-13/CD||to-12/TO	prep_from||edc-9/VB||0.5-13/CD	det||ratio-18/NN||the-15/DT	nn||ratio-18/NN||cell-16/NN	nn||ratio-18/NN||adhesion-17/NN	nsubj||increased-28/VBD||ratio-18/NN	nn||activity-21/NN||proliferation-20/NN	conj_and||ratio-18/NN||activity-21/NN	nsubj||increased-28/VBD||activity-21/NN	det||samples-26/NNS||the-23/DT	amod||samples-26/NNS||chemically-24/JJ	amod||samples-26/NNS||modified-25/VBN	prep_on||ratio-18/NN||samples-26/NNS	advmod||increased-28/VBD||significantly-27/RB	root||ROOT-0/null||increased-28/VBD	nsubjpass||attributed-32/VBN||which-30/WDT	auxpass||attributed-32/VBN||is-31/VBZ	ccomp||increased-28/VBD||attributed-32/VBN	det||content-37/NN||the-34/DT	amod||content-37/NN||increasing-35/VBG	nn||content-37/NN||cs-36/NN	prep_to||attributed-32/VBN||content-37/NN	chemically-24||adhesion-17||no_rel||in the molar ratio range of nhs to edc from 0 to 0.5, the cell adhesion ratio and proliferation activity on the chemically modified samples significantly increased, which is attributed to the increasing cs content.
nsubj||represents-9/VBZ||pulmonarytuberculosis-1/NNS	vmod||pulmonarytuberculosis-1/NNS||caused-3/VBN	agent||caused-3/VBN||mycobacteriumtuberculosis-5/NNS	appos||mycobacteriumtuberculosis-5/NNS||m.tb-7/NN	root||ROOT-0/null||represents-9/VBZ	det||concern-14/NN||a-10/DT	amod||concern-14/NN||leading-11/VBG	amod||concern-14/NN||global-12/JJ	nn||concern-14/NN||health-13/NN	dobj||represents-9/VBZ||concern-14/NN	number||million-18/CD||8.7-17/CD	num||cases-21/NNS||million-18/CD	advmod||emerging-20/JJ||newly-19/RB	amod||cases-21/NNS||emerging-20/JJ	prep_with||concern-14/NN||cases-21/NNS	number||million-25/CD||1.4-24/CD	num||deaths-27/NNS||million-25/CD	amod||deaths-27/NNS||reported-26/VBN	dobj||represents-9/VBZ||deaths-27/NNS	conj_and||concern-14/NN||deaths-27/NNS	advmod||deaths-27/NNS||annually-28/RB	pulmonarytuberculosis-1||mycobacteriumtuberculosis-5||no||pulmonarytuberculosis, caused by mycobacteriumtuberculosis (m.tb) represents a leading global health concern, with 8.7 million newly emerging cases, and 1.4 million reported deaths annually.
advmod||named-5/VBD||recently-1/RB	det||polerovirus-4/NNS||a-3/DT	nsubj||named-5/VBD||polerovirus-4/NNS	root||ROOT-0/null||named-5/VBD	nn||leafroll-7/NN||cotton-6/NN	nsubj||dwarf-8/VBP||leafroll-7/NN	ccomp||named-5/VBD||dwarf-8/VBP	nsubjpass||shown-14/VBN||virus-9/NN	nsubjpass||associated-17/VBN||virus-9/NN	appos||virus-9/NN||clrdv-11/NNP	auxpass||shown-14/VBN||was-13/VBD	ccomp||dwarf-8/VBP||shown-14/VBN	aux||associated-17/VBN||to-15/TO	auxpass||associated-17/VBN||be-16/VB	xcomp||shown-14/VBN||associated-17/VBN	prep_with||associated-17/VBN||cbd-19/NN	virus-9||cbd-19||no_rel||recently, a polerovirus named cotton leafroll dwarf virus (clrdv) was shown to be associated with cbd.
advmod||determines-4/VBZ||therefore-1/RB	det||study-3/NN||this-2/DT	nsubj||determines-4/VBZ||study-3/NN	root||ROOT-0/null||determines-4/VBZ	det||magnitude-6/NN||the-5/DT	dobj||determines-4/VBZ||magnitude-6/NN	nsubj||antiretroviral-12/VB||magnitude-6/NN	dobj||determines-4/VBZ||predictors-8/NNS	conj_and||magnitude-6/NN||predictors-8/NNS	nsubj||antiretroviral-12/VB||predictors-8/NNS	prep_of||magnitude-6/NN||adherence-10/NN	aux||antiretroviral-12/VB||to-11/TO	xcomp||determines-4/VBZ||antiretroviral-12/VB	dobj||antiretroviral-12/VB||therapy-13/NN	prep_among||antiretroviral-12/VB||people-15/NNS	vmod||people-15/NNS||living-16/VBG	prep_with||living-16/VBG||hiv/aids-18/NNS	amod||ethiopia-21/NN||southwest-20/JJ	prep_in||hiv/aids-18/NNS||ethiopia-21/NN	aids--1||hiv--1||no||therefore this study determines the magnitude and predictors of adherence to antiretroviral therapy among people living with hiv/aids in southwest ethiopia.
nsubj||disease-10/NN||progressivemultifocalleukoencephalopathy-1/NN	appos||progressivemultifocalleukoencephalopathy-1/NN||pml-3/NN	cop||disease-10/NN||is-5/VBZ	det||disease-10/NN||an-6/DT	advmod||fatal-8/JJ||often-7/RB	amod||disease-10/NN||fatal-8/JJ	nn||disease-10/NN||demyelinating-9/NN	root||ROOT-0/null||disease-10/NN	vmod||disease-10/NN||caused-11/VBN	amod||infection-14/NN||lytic-13/JJ	agent||caused-11/VBN||infection-14/NN	prep_of||infection-14/NN||oligodendrocytes-16/NNS	prep_with||oligodendrocytes-16/NNS||jcvirus-18/NNS	appos||jcvirus-18/NNS||jcv-20/NN	pml-3||jcvirus-18||no||progressivemultifocalleukoencephalopathy (pml) is an often fatal demyelinating disease caused by lytic infection of oligodendrocytes with jcvirus (jcv).
vmod||undertook-23/VBD||theorizing-1/VBG	mark||related-8/VBN||that-2/IN	det||phenomenon-4/NN||this-3/DT	nsubjpass||related-8/VBN||phenomenon-4/NN	aux||related-8/VBN||may-5/MD	auxpass||related-8/VBN||be-6/VB	advmod||related-8/VBN||somehow-7/RB	ccomp||theorizing-1/VBG||related-8/VBN	det||eradication-11/NN||the-10/DT	prep_to||related-8/VBN||eradication-11/NN	prep_of||eradication-11/NN||smallpox-13/NN	vmod||smallpox-13/NN||followed-14/VBN	det||cessation-17/NN||the-16/DT	agent||followed-14/VBN||cessation-17/NN	nn||immunization-20/NN||vaccinia-19/NN	prep_of||cessation-17/NN||immunization-20/NN	nsubj||undertook-23/VBD||we-22/PRP	root||ROOT-0/null||undertook-23/VBD	det||comparison-25/NN||a-24/DT	dobj||undertook-23/VBD||comparison-25/NN	amod||cells-34/NNS||hiv-1-27/JJ	amod||cells-34/NNS||susceptibility-28/JJ	det||mononuclear-33/NN||the-30/DT	amod||mononuclear-33/NN||peripheral-31/JJ	nn||mononuclear-33/NN||blood-32/NN	prep_in||susceptibility-28/JJ||mononuclear-33/NN	prep_of||comparison-25/NN||cells-34/NNS	prep_from||undertook-23/VBD||subjects-36/NNS	vmod||subjects-36/NNS||immunized-37/VBN	det||vacciniavirus-40/NNS||the-39/DT	prep_with||immunized-37/VBN||vacciniavirus-40/NNS	prep_to||immunized-37/VBN||those-42/DT	amod||naive-45/JJ||vaccinia-44/JJ	amod||donors-46/NNS||naive-45/JJ	prep_from||those-42/DT||donors-46/NNS	vaccinia-44||vacciniavirus-40||no||theorizing that this phenomenon may be somehow related to the eradication of smallpox followed by the cessation of vaccinia immunization, we undertook a comparison of hiv-1 susceptibility in the peripheral blood mononuclear cells from subjects immunized with the vacciniavirus to those from vaccinia naive donors.
det||goals-2/NNS||the-1/DT	nsubj||were-6/VBD||goals-2/NNS	det||study-5/NN||this-4/DT	prep_of||goals-2/NNS||study-5/NN	root||ROOT-0/null||were-6/VBD	aux||examine-8/VB||to-7/TO	ccomp||were-6/VBD||examine-8/VB	det||influence-10/NN||the-9/DT	dobj||examine-8/VB||influence-10/NN	amod||type1diabetes-13/NNS||maternal-12/JJ	prep_of||influence-10/NN||type1diabetes-13/NNS	prep_during||examine-8/VB||pregnancy-15/NN	nn||adiposity-18/NN||offspring-17/NN	prep_on||examine-8/VB||adiposity-18/NN	nn||tolerance-21/NN||glucose-20/NN	prep_on||examine-8/VB||tolerance-21/NN	conj_and||adiposity-18/NN||tolerance-21/NN	prep_at||adiposity-18/NN||age-23/NN	num||years-25/NNS||7-24/CD	dep||adiposity-18/NN||years-25/NNS	aux||assess-28/VB||to-27/TO	ccomp||were-6/VBD||assess-28/VB	conj_and||examine-8/VB||assess-28/VB	mark||predict-40/VBP||whether-29/IN	amod||factors-31/NNS||metabolic-30/JJ	nsubj||predict-40/VBP||factors-31/NNS	prep_at||factors-31/NNS||birth-33/NN	amod||leptin-36/NNS||neonatal-35/JJ	appos||birth-33/NN||leptin-36/NNS	appos||birth-33/NN||insulin-38/NN	conj_and||leptin-36/NNS||insulin-38/NN	ccomp||assess-28/VB||predict-40/VBP	amod||outcomes-42/NNS||adverse-41/JJ	dobj||predict-40/VBP||outcomes-42/NNS	insulin-38||adiposity-18||no_rel||the goals of this study were to examine the influence of maternal type1diabetes during pregnancy on offspring adiposity and glucose tolerance at age 7 years and to assess whether metabolic factors at birth (neonatal leptin and insulin) predict adverse outcomes.
nsubj||require-4/VBP||patients-2/NNS	prep_for||preferable-21/JJ||patients-2/NNS	rcmod||patients-2/NNS||require-4/VBP	nn||therapy-6/NN||replacement-5/NN	dobj||require-4/VBP||therapy-6/NN	amod||immunodeficiency-9/NN||primary-8/JJ	prep_for||therapy-6/NN||immunodeficiency-9/NN	amod||infusions-12/NNS||subcutaneous-11/JJ	nsubj||preferable-21/JJ||infusions-12/NNS	nn||g-15/NN||immunoglobulin-14/NN	prep_of||infusions-12/NNS||g-15/NN	appos||infusions-12/NNS||igg-17/NN	aux||preferable-21/JJ||may-19/MD	cop||preferable-21/JJ||be-20/VB	root||ROOT-0/null||preferable-21/JJ	amod||infusions-24/NNS||intravenous-23/JJ	prep_to||preferable-21/JJ||infusions-24/NNS	amod||reasons-27/NNS||several-26/JJ	prep_for||infusions-24/NNS||reasons-27/NNS	immunodeficiency-9||immunoglobulin-14||yes||for patients who require replacement therapy for primary immunodeficiency, subcutaneous infusions of immunoglobulin g (igg) may be preferable to intravenous infusions for several reasons.
det||study-4/NN||an-1/DT	amod||study-4/NN||observational-2/JJ	nn||study-4/NN||retrospective-3/NN	root||ROOT-0/null||study-4/NN	amod||follow-up-7/NN||1-year-6/JJ	appos||study-4/NN||follow-up-7/NN	num||patients-11/NNS||104-10/CD	prep_on||study-4/NN||patients-11/NNS	prep_with||patients-11/NNS||oa-13/NN	nsubjpass||treated-38/VBN||oa-13/NN	nn||osteoarthritis-16/NNS||nodular-15/NN	dep||oa-13/NN||osteoarthritis-16/NNS	det||hand-19/NN||the-18/DT	prep_of||osteoarthritis-16/NNS||hand-19/NN	amod||osteoarthritis-22/NNS||erosive-21/JJ	appos||osteoarthritis-16/NNS||osteoarthritis-22/NNS	det||hand-25/NN||the-24/DT	prep_of||osteoarthritis-22/NNS||hand-25/NN	appos||osteoarthritis-16/NNS||eoa-27/NN	appos||osteoarthritis-16/NNS||osteoarthritis-29/NNS	det||knee-32/NN||the-31/DT	prep_of||osteoarthritis-29/NNS||knee-32/NN	prep_of||osteoarthritis-29/NNS||hip-34/NN	conj_or||knee-32/NN||hip-34/NN	auxpass||treated-38/VBN||were-37/VBD	rcmod||oa-13/NN||treated-38/VBN	nn||chondroitinsulfate-44/NN||gc-40/NN	conj_or||gc-40/NN||glucosamine-42/NN	nn||chondroitinsulfate-44/NN||glucosamine-42/NN	prep_with||treated-38/VBN||chondroitinsulfate-44/NN	nn||ii-48/NNS||collagen-46/NN	nn||ii-48/NNS||type-47/NN	prep_with||treated-38/VBN||ii-48/NNS	conj_and||chondroitinsulfate-44/NN||ii-48/NNS	appos||patients-11/NNS||gcc-50/NN	osteoarthritis-29||chondroitinsulfate-44||yes||an observational retrospective study, 1-year follow-up, on 104 patients with oa (nodular osteoarthritis of the hand, erosive osteoarthritis of the hand, eoa, osteoarthritis of the knee or hip) who were treated with gc or glucosamine, chondroitinsulfate and collagen type ii (gcc).
mark||expected-2/VBN||as-1/IN	advcl||reduced-6/VBD||expected-2/VBN	nn||therapy-5/NN||ribavirin-4/NNP	nsubj||reduced-6/VBD||therapy-5/NN	root||ROOT-0/null||reduced-6/VBD	dobj||reduced-6/VBD||levels-7/NNS	amod||virus-10/NN||infectious-9/JJ	prep_of||levels-7/NNS||virus-10/NN	nn||rna-13/NN||ri-12/NN	prep_of||levels-7/NNS||rna-13/NN	conj_and||virus-10/NN||rna-13/NN	det||lung-17/NN||the-15/DT	nn||lung-17/NN||mouse-16/NN	prep_in||reduced-6/VBD||lung-17/NN	virus-10||ribavirin-4||yes||as expected, ribavirin therapy reduced levels of infectious virus and ri rna in the mouse lung.
det||technique-6/NN||the-1/DT	advmod||used-4/VBN||most-2/RBS	advmod||used-4/VBN||commonly-3/RB	amod||technique-6/NN||used-4/VBN	amod||technique-6/NN||current-5/JJ	nsubj||dependent-15/JJ||technique-6/NN	nn||immunoprecipitation-9/NN||chromatin-8/NN	appos||technique-6/NN||immunoprecipitation-9/NN	appos||immunoprecipitation-9/NN||chip-11/NN	cop||dependent-15/JJ||is-14/VBZ	root||ROOT-0/null||dependent-15/JJ	det||antibody-20/NN||a-17/DT	amod||antibody-20/NN||high-18/JJ	nn||antibody-20/NN||quality-19/NN	prep_on||dependent-15/JJ||antibody-20/NN	det||protein-23/NN||each-22/DT	prep_for||antibody-20/NN||protein-23/NN	prep_of||protein-23/NN||interest-25/NN	nsubj||available-31/JJ||interest-25/NN	nsubj||cumbersome-36/JJ||interest-25/NN	nsubj||involving-38/VBG||interest-25/NN	cop||available-31/JJ||is-28/VBZ	neg||available-31/JJ||not-29/RB	advmod||available-31/JJ||always-30/RB	rcmod||interest-25/NN||available-31/JJ	cop||cumbersome-36/JJ||is-34/VBZ	advmod||cumbersome-36/JJ||also-35/RB	rcmod||interest-25/NN||cumbersome-36/JJ	conj_and||available-31/JJ||cumbersome-36/JJ	rcmod||interest-25/NN||involving-38/VBG	conj_and||available-31/JJ||involving-38/VBG	amod||cross-linking-40/NN||sequential-39/JJ	prep_involving||available-31/JJ||cross-linking-40/NN	prep_involving||available-31/JJ||reversal-42/NN	conj_and||cross-linking-40/NN||reversal-42/NN	prep_of||cross-linking-40/NN||cross-linking-44/NN	cross--1||antibody-20||no_rel||the most commonly used current technique, chromatin immunoprecipitation (chip), is dependent on a high quality antibody for each protein of interest, which is not always available, and is also cumbersome, involving sequential cross-linking and reversal of cross-linking.
advmod||components-8/NNS||indeed-1/RB	nsubj||components-8/NNS||isoniazid-3/NN	conj_and||isoniazid-3/NN||rifampicin-5/NN	nsubj||components-8/NNS||rifampicin-5/NN	cop||components-8/NNS||are-6/VBP	amod||components-8/NNS||important-7/JJ	root||ROOT-0/null||components-8/NNS	det||regimen-11/NN||any-10/DT	prep_of||components-8/NNS||regimen-11/NN	det||treatment-14/NN||the-13/DT	prep_for||regimen-11/NN||treatment-14/NN	prep_of||treatment-14/NN||drug-16/NN	amod||tb-18/JJ||susceptible-17/JJ	amod||drug-16/NN||tb-18/JJ	tb-18||isoniazid-3||yes||indeed, isoniazid and rifampicin are important components of any regimen for the treatment of drug susceptible tb.
amod||expression-2/NN||gsta4-1/JJ	nsubjpass||downregulated-5/VBN||expression-2/NN	auxpass||downregulated-5/VBN||is-3/VBZ	advmod||downregulated-5/VBN||selectively-4/RB	root||ROOT-0/null||downregulated-5/VBN	amod||tissue-8/NN||adipose-7/JJ	prep_in||downregulated-5/VBN||tissue-8/NN	amod||mice-13/NNS||obese-10/JJ	amod||mice-13/NNS||insulin-resistant-11/JJ	amod||mice-13/NNS||c57bl/6j-12/JJ	prep_of||tissue-8/NN||mice-13/NNS	amod||insulinresistance-18/NN||human-16/JJ	amod||insulinresistance-18/NN||obesity-linked-17/JJ	prep_in||downregulated-5/VBN||insulinresistance-18/NN	conj_and||tissue-8/NN||insulinresistance-18/NN	insulin--1||obesity--1||no_rel||gsta4 expression is selectively downregulated in adipose tissue of obese insulin-resistant c57bl/6j mice and in human obesity-linked insulinresistance.
amod||samples-3/NNS||cryopreserved-1/JJ	nn||samples-3/NNS||serum-2/NN	nsubjpass||tested-43/VBN||samples-3/NNS	det||subjects-6/NNS||all-5/DT	prep_of||samples-3/NNS||subjects-6/NNS	vmod||subjects-6/NNS||aged-7/VBN	number||60-10/CD||5-8/CD	dep||60-10/CD||to-9/TO	num||years-11/NNS||60-10/CD	dobj||aged-7/VBN||years-11/NNS	num||villages-17/NNS||two-13/CD	advmod||selected-15/VBN||randomly-14/RB	amod||villages-17/NNS||selected-15/VBN	amod||villages-17/NNS||rural-16/JJ	prep_from||years-11/NNS||villages-17/NNS	prepc_in||aged-7/VBN||zhejiang-19/VBG	dobj||zhejiang-19/VBG||province-20/NN	nsubj||participated-26/VBN||province-20/NN	amod||china-23/NN||eastern-22/JJ	prep_in||province-20/NN||china-23/NN	aux||participated-26/VBN||had-25/VBD	rcmod||province-20/NN||participated-26/VBN	det||survey-32/NN||the-28/DT	amod||survey-32/NN||china-29/JJ	amod||survey-32/NN||national-30/JJ	nn||survey-32/NN||seroepidemiological-31/NN	prep_in||participated-26/VBN||survey-32/NN	amod||infection-38/NN||hepatitisbvirus-34/JJ	appos||infection-38/NN||hbv-36/NN	prep_of||survey-32/NN||infection-38/NN	vmod||infection-38/NN||conducted-39/VBN	prep_in||conducted-39/VBN||2006-41/CD	auxpass||tested-43/VBN||were-42/VBD	root||ROOT-0/null||tested-43/VBN	hbv-36||hepatitisbvirus-34||no||cryopreserved serum samples of all subjects aged 5 to 60 years from two randomly selected rural villages in zhejiang province in eastern china who had participated in the china national seroepidemiological survey of hepatitisbvirus (hbv) infection conducted in 2006 were tested.
nsubj||state-8/NN||toxicity-1/NN	prep_to||toxicity-1/NN||glucose-3/NN	cop||state-8/NN||is-4/VBZ	neg||state-8/NN||not-5/RB	det||state-8/NN||a-6/DT	amod||state-8/NN||normal-7/JJ	ccomp||reported-15/VBN||state-8/NN	advmod||state-8/NN||however-10/RB	nsubjpass||reported-15/VBN||it-12/PRP	aux||reported-15/VBN||has-13/VBZ	auxpass||reported-15/VBN||been-14/VBN	root||ROOT-0/null||reported-15/VBN	mark||produce-24/VBP||that-16/IN	mark||ingest-20/VB||after-17/IN	amod||individuals-19/NNS||certain-18/JJ	nsubj||ingest-20/VB||individuals-19/NNS	advcl||produce-24/VBP||ingest-20/VB	dobj||ingest-20/VB||sugar-21/NN	nsubj||produce-24/VBP||they-23/PRP	ccomp||reported-15/VBN||produce-24/VBP	amod||tumor-26/NN||excess-25/JJ	nsubj||necrosis-27/VBZ||tumor-26/NN	ccomp||produce-24/VBP||necrosis-27/VBZ	dobj||necrosis-27/VBZ||factor-28/NN	sugar-21||tumor-26||no_rel||toxicity to glucose is not a normal state, however, it has been reported that after certain individuals ingest sugar, they produce excess tumor necrosis factor.
amod||â-2/NN||objective-1/JJ	nsubj||$-3/VBD||â-2/NN	nsubj||characterize-6/VB||â-2/NN	root||ROOT-0/null||$-3/VBD	aux||characterize-6/VB||to-5/TO	xcomp||$-3/VBD||characterize-6/VB	nn||action-8/NN||insulin-7/NN	dobj||characterize-6/VB||action-8/NN	prep_in||characterize-6/VB||africans-10/NNS	amod||diabetes-13/NN||ketosis-prone-12/JJ	prep_with||africans-10/NNS||diabetes-13/NN	discourse||diabetes-13/NN||kpd-15/UH	prep_during||$-3/VBD||remission-18/NN	kpd-15||insulin-7||yes||objective âto characterize insulin action in africans with ketosis-prone diabetes (kpd) during remission.
nsubj||agent-5/NN||burkholderiapseudomallei-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	ccomp||worldwide-17/VBZ||agent-5/NN	prep_of||agent-5/NN||melioidosis-7/NNS	det||endemic-13/NN||a-9/DT	amod||endemic-13/NN||fatal-10/JJ	amod||endemic-13/NN||infectious-11/JJ	nn||endemic-13/NN||disease-12/NN	nsubj||worldwide-17/VBZ||endemic-13/NN	nsubj||prevalent-21/JJ||endemic-13/NN	amod||regions-16/NNS||tropical-15/JJ	prep_in||endemic-13/NN||regions-16/NNS	root||ROOT-0/null||worldwide-17/VBZ	advmod||prevalent-21/JJ||especially-20/RB	conj_and||worldwide-17/VBZ||prevalent-21/JJ	nn||asia-24/NN||southeast-23/NN	prep_in||prevalent-21/JJ||asia-24/NN	amod||australia-27/NN||northern-26/JJ	prep_in||prevalent-21/JJ||australia-27/NN	conj_and||asia-24/NN||australia-27/NN	melioidosis-7||burkholderiapseudomallei-1||no||burkholderiapseudomallei is the causative agent of melioidosis, a fatal infectious disease endemic in tropical regions worldwide, and especially prevalent in southeast asia and northern australia.
nsubj||gave-14/VBD||treatment-1/NN	amod||ketamine-7/NN||intravenous-3/JJ	appos||ketamine-7/NN||iv-5/NN	prep_with||treatment-1/NN||ketamine-7/NN	det||infusion-12/NN||an-9/DT	amod||infusion-12/NN||alternate-10/JJ	nn||infusion-12/NN||day-11/NN	prep_as||ketamine-7/NN||infusion-12/NN	root||ROOT-0/null||gave-14/VBD	amod||remission-16/NN||complete-15/JJ	dobj||gave-14/VBD||remission-16/NN	amod||pain-20/NN||phantom-18/JJ	nn||pain-20/NN||limb-19/NN	prep_of||remission-16/NN||pain-20/NN	pain-20||ketamine-7||yes||treatment with intravenous (iv) ketamine as an alternate day infusion, gave complete remission of phantom limb pain.
amod||sensitivity-3/NN||mtb/rif-1/JJ	nn||sensitivity-3/NN||test-2/NN	nsubj||·-6/NNS||sensitivity-3/NN	cop||·-6/NNS||was-4/VBD	amod||·-6/NNS||76â-5/JJ	root||ROOT-0/null||·-6/NNS	number||%-8/NN||9-7/CD	amod||·-6/NNS||%-8/NN	amod||patients-13/NNS||smear-negative-10/JJ	amod||patients-13/NNS||culture-positive-12/JJ	prep_in||·-6/NNS||patients-13/NNS	number||385-17/CD||296-15/CD	quantmod||385-17/CD||of-16/IN	num||samples-18/NNS||385-17/CD	appos||patients-13/NNS||samples-18/NNS	amod||·-23/NNS||99â-22/JJ	prep_in||·-6/NNS||·-23/NNS	conj_and||patients-13/NNS||·-23/NNS	num||%-25/NN||0-24/CD	npadvmod||specific-26/JJ||%-25/NN	amod||·-23/NNS||specific-26/JJ	dep||specific-26/JJ||2846-28/CD	num||samples-32/NNS||2876-30/CD	amod||samples-32/NNS||non-tuberculosis-31/JJ	prep_of||2846-28/CD||samples-32/NNS	tuberculosis--1||mtb--1||no||mtb/rif test sensitivity was 76â·9% in smear-negative, culture-positive patients (296 of 385 samples), and 99â·0% specific (2846 of 2876 non-tuberculosis samples).
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	nsubj||compare-10/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	xcomp||was-6/VBD||compare-10/VB	conj_and||evaluate-8/VB||compare-10/VB	det||effects-12/NNS||the-11/DT	dobj||evaluate-8/VB||effects-12/NNS	det||combination-18/NN||a-14/DT	amod||combination-18/NN||long-term-15/JJ	amod||combination-18/NN||fixed-dose-17/JJ	prep_of||effects-12/NNS||combination-18/NN	prep_of||combination-18/NN||sitagliptin-20/NN	prep_of||combination-18/NN||metformin-22/NN	conj_and||sitagliptin-20/NN||metformin-22/NN	prep_as||evaluate-8/VB||add-on-24/JJ	prep_to||add-on-24/JJ||insulin-26/NN	nn||index-30/NN||body-28/NN	nn||index-30/NN||mass-29/NN	prep_on||insulin-26/NN||index-30/NN	amod||glucose-34/NN||fasting-32/JJ	nn||glucose-34/NN||plasma-33/NN	prep_on||insulin-26/NN||glucose-34/NN	conj_and||index-30/NN||glucose-34/NN	prep_on||insulin-26/NN||fructosamine-36/NN	conj_and||index-30/NN||fructosamine-36/NN	prep_on||insulin-26/NN||hba1c-38/NNS	conj_and||index-30/NN||hba1c-38/NNS	prep_on||insulin-26/NN||lipids-40/NNS	conj_and||index-30/NN||lipids-40/NNS	amod||dose-44/NN||daily-43/JJ	prep_on||insulin-26/NN||dose-44/NN	conj_and||index-30/NN||dose-44/NN	prep_of||dose-44/NN||insulin-46/NN	det||type2diabetes-52/NNS||both-48/DT	amod||type2diabetes-52/NNS||type1diabetes-49/JJ	conj_and||type1diabetes-49/JJ||insulin-treated-51/JJ	amod||type2diabetes-52/NNS||insulin-treated-51/JJ	prep_in||insulin-46/NN||type2diabetes-52/NNS	type2diabetes-52||insulin-46||yes||the aim of this study was to evaluate and compare the effects of a long-term, fixed-dose combination of sitagliptin and metformin as add-on to insulin on body mass index, fasting plasma glucose, fructosamine, hba1c, lipids, and daily dose of insulin in both type1diabetes and insulin-treated type2diabetes.
nsubj||disorders-13/NNS||irondeficiency-1/NN	conj_and||irondeficiency-1/NN||excess-5/NN	nsubj||disorders-13/NNS||excess-5/NN	prep_of||excess-5/NN||iron-7/NN	cop||disorders-13/NNS||are-8/VBP	amod||disorders-13/NNS||frequent-9/JJ	conj_and||frequent-9/JJ||serious-11/JJ	amod||disorders-13/NNS||serious-11/JJ	amod||disorders-13/NNS||human-12/JJ	root||ROOT-0/null||disorders-13/NNS	irondeficiency-1||iron-7||yes||irondeficiency as well as excess of iron are frequent and serious human disorders.
amod||cultures-2/NNS||overnight-1/JJ	nsubj||-lrb--21/VBD||cultures-2/NNS	nn||strains-5/NNS||reference-4/NN	prep_of||cultures-2/NNS||strains-5/NNS	prep_of||strains-5/NNS||candidaalbicans-7/NNS	prep_of||strains-5/NNS||escherichiacoli-9/NNS	conj_and||candidaalbicans-7/NNS||escherichiacoli-9/NNS	prep_of||strains-5/NNS||pseudomonasaeruginosa-11/NNS	conj_and||candidaalbicans-7/NNS||pseudomonasaeruginosa-11/NNS	prep_of||strains-5/NNS||staphylococcusaureus-14/NNS	conj_and||candidaalbicans-7/NNS||staphylococcusaureus-14/NNS	amod||strains-17/NNS||clinical-16/JJ	prep_of||cultures-2/NNS||strains-17/NNS	conj_and||strains-5/NNS||strains-17/NNS	amod||s.aureus-20/NNS||methicillin-resistant-19/JJ	prep_of||strains-17/NNS||s.aureus-20/NNS	root||ROOT-0/null||-lrb--21/VBD	nn||-rrb--23/NNP||mrsa-22/NNP	nsubjpass||used-25/VBN||-rrb--23/NNP	auxpass||used-25/VBN||were-24/VBD	ccomp||-lrb--21/VBD||used-25/VBN	nn||microorganisms-28/NNS||test-27/NN	prep_as||used-25/VBN||microorganisms-28/NNS	mrsa-22||s.aureus-20||no||overnight cultures of reference strains of candidaalbicans , escherichiacoli , pseudomonasaeruginosa , and staphylococcusaureus and clinical strains of methicillin-resistant s.aureus -lrb- mrsa -rrb- were used as test microorganisms .
det||aim-2/NN||the-1/DT	nsubj||was-7/VBD||aim-2/NN	nsubj||investigate-9/VB||aim-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||present-5/JJ	prep_of||aim-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||investigate-9/VB||to-8/TO	xcomp||was-7/VBD||investigate-9/VB	det||effects-11/NNS||the-10/DT	dobj||investigate-9/VB||effects-11/NNS	amod||antipsychotic-14/NN||selected-13/VBN	prep_of||effects-11/NNS||antipsychotic-14/NN	prep_of||effects-11/NNS||cognition-16/NN	conj_and||antipsychotic-14/NN||cognition-16/NN	vmod||antipsychotic-14/NN||enhancing-17/VBG	dobj||enhancing-17/VBG||drugs-18/NNS	advmod||drugs-18/NNS||namely-20/RB	dep||namely-20/RB||haloperidol-21/JJ	advmod||drugs-18/NNS||risperidone-23/JJ	conj_and||namely-20/RB||risperidone-23/JJ	advmod||drugs-18/NNS||donepezil-25/JJ	conj_and||namely-20/RB||donepezil-25/JJ	advmod||in-29/IN||modafinil-28/RB	advmod||drugs-18/NNS||in-29/IN	conj_and||namely-20/RB||in-29/IN	det||model-32/NN||an-30/DT	nn||model-32/NN||animal-31/NN	pobj||in-29/IN||model-32/NN	advmod||used-34/VBN||widely-33/RB	vmod||model-32/NN||used-34/VBN	amod||research-38/NN||preclinical-36/JJ	nn||research-38/NN||schizophrenia-37/NN	prep_in||used-34/VBN||research-38/NN	schizophrenia-37||haloperidol-21||yes||the aim of the present study was to investigate the effects of selected antipsychotic and cognition enhancing drugs, namely haloperidol, risperidone, donepezil, and modafinil in an animal model widely used in preclinical schizophrenia research.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||explore-8/VB||purpose-2/NN	nsubj||describe-10/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||explore-8/VB||to-7/TO	xcomp||was-6/VBD||explore-8/VB	xcomp||was-6/VBD||describe-10/VB	conj_and||explore-8/VB||describe-10/VB	det||challenges-12/NNS||the-11/DT	dobj||explore-8/VB||challenges-12/NNS	vmod||challenges-12/NNS||faced-13/VBN	agent||faced-13/VBN||people-15/NNS	nsubj||living-18/VBG||people-15/NNS	nsubj||living-18/VBG||people-15/NNS	aux||living-18/VBG||are-17/VBP	rcmod||people-15/NNS||living-18/VBG	rcmod||people-15/NNS||living-18/VBG	conj_and||living-18/VBG||living-18/VBG	prep_with||living-18/VBG||hiv/aids-20/NNS	poss||caregivers-24/NNS||their-23/PRP$	prep_by||living-18/VBG||caregivers-24/NNS	amod||villages-31/NNS||resource-poor-26/JJ	amod||villages-31/NNS||remote-28/JJ	nn||villages-31/NNS||south-29/NN	nn||villages-31/NNS||african-30/NN	prep_in||living-18/VBG||villages-31/NNS	aids--1||hiv--1||no||the purpose of this study was to explore and describe the challenges faced by people who are living with hiv/aids and by their caregivers in resource-poor, remote south african villages.
advmod||diagnosed-4/VBN||when-1/WRB	nsubjpass||diagnosed-4/VBN||retinitis-2/NNS	auxpass||diagnosed-4/VBN||is-3/VBZ	advcl||started-10/VBN||diagnosed-4/VBN	nn||therapy-7/NN||haart-6/NN	nsubjpass||started-10/VBN||therapy-7/NN	nsubjpass||improved-12/VBN||therapy-7/NN	aux||started-10/VBN||should-8/MD	auxpass||started-10/VBN||be-9/VB	root||ROOT-0/null||started-10/VBN	conj_or||started-10/VBN||improved-12/VBN	amod||therapy-16/NN||anti-cmv-15/JJ	nsubjpass||administered-30/VBN||therapy-16/NN	amod||valganciclovir-19/NN||oral-18/JJ	prep_with||therapy-16/NN||valganciclovir-19/NN	amod||ganciclovir-22/NN||intravenous-21/JJ	prep_with||therapy-16/NN||ganciclovir-22/NN	conj_or||valganciclovir-19/NN||ganciclovir-22/NN	prep_with||therapy-16/NN||foscarnet-24/NN	conj_or||valganciclovir-19/NN||foscarnet-24/NN	prep_with||therapy-16/NN||cidofovir-27/NN	conj_or||valganciclovir-19/NN||cidofovir-27/NN	aux||administered-30/VBN||should-28/MD	auxpass||administered-30/VBN||be-29/VB	conj_and||started-10/VBN||administered-30/VBN	cmv--1||valganciclovir-19||yes||when retinitis is diagnosed, haart therapy should be started or improved, and anti-cmv therapy with oral valganciclovir, intravenous ganciclovir, foscarnet, or cidofovir should be administered.
advmod||paid-7/VBN||however-1/RB	amod||attention-4/NN||little-3/JJ	nsubjpass||paid-7/VBN||attention-4/NN	nsubj||quantifying-9/VB||attention-4/NN	aux||paid-7/VBN||has-5/VBZ	auxpass||paid-7/VBN||been-6/VBN	root||ROOT-0/null||paid-7/VBN	aux||quantifying-9/VB||to-8/TO	xcomp||paid-7/VBN||quantifying-9/VB	nn||trends-12/NNS||health-10/NN	amod||trends-12/NNS||facility-level-11/JJ	dobj||quantifying-9/VB||trends-12/NNS	nn||numbers-16/NNS||health-14/NN	nn||numbers-16/NNS||worker-15/NN	prep_in||quantifying-9/VB||numbers-16/NNS	prep_in||quantifying-9/VB||distribution-18/NN	conj_and||numbers-16/NNS||distribution-18/NN	prep_in||quantifying-9/VB||workload-20/NN	conj_and||numbers-16/NNS||workload-20/NN	amod||demands-24/NNS||growing-23/VBG	prep_despite||paid-7/VBN||demands-24/NNS	nn||workers-27/NNS||health-26/NN	nn||scale-up-38/NN||workers-27/NNS	det||availability-31/NN||the-30/DT	prep_due_to||scale-up-38/NN||availability-31/NN	amod||funds-34/NNS||new-33/JJ	prep_of||availability-31/NN||funds-34/NNS	prep_for||funds-34/NNS||hiv/aids-36/NNS	nn||scale-up-38/NN||control-37/NN	prep_on||demands-24/NNS||scale-up-38/NN	aids--1||hiv--1||no||however, little attention has been paid to quantifying health facility-level trends in health worker numbers, distribution and workload, despite growing demands on health workers due to the availability of new funds for hiv/aids control scale-up.
nsubj||had-11/VBD||mice-1/NNS	vmod||mice-1/NNS||vaccinated-2/VBN	prep||vaccinated-2/VBN||with-3/IN	det||vlp-5/NN||each-4/DT	npadvmod||individually-6/RB||vlp-5/NN	pcomp||with-3/IN||individually-6/RB	prep||vaccinated-2/VBN||in-8/IN	conj_or||with-3/IN||in-8/IN	det||mixture-10/NN||a-9/DT	pobj||in-8/IN||mixture-10/NN	root||ROOT-0/null||had-11/VBD	amod||responses-14/NNS||robust-12/JJ	nn||responses-14/NNS||hai-13/NN	dobj||had-11/VBD||responses-14/NNS	advmod||viruses-17/NNS||homologous-16/RB	prep_against||responses-14/NNS||viruses-17/NNS	nn||responses-20/NNS||hai-19/NN	prep_against||responses-14/NNS||responses-20/NNS	conj_and||viruses-17/NNS||responses-20/NNS	det||virus-25/NN||the-22/DT	amod||virus-25/NN||clade-23/JJ	dep||clade-23/JJ||2.3-24/CD	prep_against||had-11/VBD||virus-25/NN	appos||virus-25/NN||anh/05-27/NNS	virus-25||viruses-17||no||mice vaccinated with each vlp individually or in a mixture had robust hai responses against homologous viruses and hai responses against the clade 2.3 virus, anh/05.
advmod||useful-11/JJ||therefore-1/RB	nsubj||useful-11/JJ||measurement-2/NN	amod||levels-8/NNS||urinary-4/JJ	nn||levels-8/NNS||î-5/NN	nn||levels-8/NNS||±-6/NN	amod||levels-8/NNS||1-act-7/JJ	prep_of||measurement-2/NN||levels-8/NNS	aux||useful-11/JJ||may-9/MD	cop||useful-11/JJ||be-10/VB	root||ROOT-0/null||useful-11/JJ	prepc_for||useful-11/JJ||monitoring-13/VBG	det||efficacy-15/NN||the-14/DT	dobj||monitoring-13/VBG||efficacy-15/NN	amod||regimens-18/NNS||therapeutic-17/JJ	prep_of||efficacy-15/NN||regimens-18/NNS	prep_for||regimens-18/NNS||priondisease-20/NN	conj_and||useful-11/JJ||possibly-23/RB	advmod||possibly-23/RB||also-24/RB	prepc_for||possibly-23/RB||deferring-26/VBG	nn||donors-30/NNS||blood-27/NN	conj_and||blood-27/NN||organ-29/NN	nn||donors-30/NNS||organ-29/NN	dobj||deferring-26/VBG||donors-30/NNS	nsubj||be-33/VB||donors-30/NNS	aux||be-33/VB||may-32/MD	rcmod||donors-30/NNS||be-33/VB	prep_at||be-33/VB||risk-35/NN	prepc_of||risk-35/NN||transmitting-37/VBG	nn||infections-39/NNS||prion-38/NN	dobj||transmitting-37/VBG||infections-39/NNS	priondisease-20||prion-38||no||therefore measurement of urinary î±1-act levels may be useful for monitoring the efficacy of therapeutic regimens for priondisease, and possibly also for deferring blood and organ donors that may be at risk of transmitting prion infections.
nsubj||relied-11/VBN||treatment-1/NN	prep_of||treatment-1/NN||attention-deficit/hyperactivitydisorder-3/NN	dep||treatment-1/NN||adhd-5/VBN	aux||relied-11/VBN||has-7/VBZ	amod||years-10/NNS||many-9/JJ	prep_for||relied-11/VBN||years-10/NNS	root||ROOT-0/null||relied-11/VBN	nn||formulations-17/NNS||psychostimulants-13/NNS	advmod||formulations-17/NNS||particularly-15/RB	amod||formulations-17/NNS||various-16/JJ	prep_on||relied-11/VBN||formulations-17/NNS	prep_of||formulations-17/NNS||amphetamines-19/NNS	prep_of||formulations-17/NNS||methylphenidate-21/NN	conj_and||amphetamines-19/NNS||methylphenidate-21/NN	adhd-5||methylphenidate-21||yes||treatment of attention-deficit/hyperactivitydisorder (adhd) has for many years relied on psychostimulants, particularly various formulations of amphetamines and methylphenidate.
poss||goal-2/NN||our-1/PRP$	nsubj||was-3/VBD||goal-2/NN	nsubj||investigate-5/VB||goal-2/NN	root||ROOT-0/null||was-3/VBD	aux||investigate-5/VB||to-4/TO	xcomp||was-3/VBD||investigate-5/VB	det||effects-7/NNS||the-6/DT	dobj||investigate-5/VB||effects-7/NNS	amod||training-12/NN||low-9/JJ	nn||training-12/NN||intensity-10/NN	nn||training-12/NN||resistance-11/NN	prep_of||effects-7/NNS||training-12/NN	nn||fat-15/NN||body-14/NN	prep_on||investigate-5/VB||fat-15/NN	nn||mass-18/NN||muscle-17/NN	prep_on||investigate-5/VB||mass-18/NN	conj_and||fat-15/NN||mass-18/NN	conj_and||fat-15/NN||strength-20/NN	conj_and||mass-18/NN||strength-20/NN	amod||fitness-23/NN||cardiovascular-22/JJ	prep_on||investigate-5/VB||fitness-23/NN	conj_and||fat-15/NN||fitness-23/NN	nn||sensitivity-27/NN||insulin-26/NN	prep_on||investigate-5/VB||sensitivity-27/NN	conj_and||fat-15/NN||sensitivity-27/NN	prep_in||investigate-5/VB||type2diabetes-29/CD	type2diabetes-29||insulin-26||yes||our goal was to investigate the effects of low intensity resistance training on body fat, muscle mass and strength, cardiovascular fitness, and insulin sensitivity in type2diabetes.
poss||case-2/NN||our-1/PRP$	nsubj||has-4/VBZ||case-2/NN	nsubjpass||treated-12/VBN||case-2/NN	rcmod||case-2/NN||has-4/VBZ	dobj||has-4/VBZ||rheumatoidarthritis-5/NNS	appos||rheumatoidarthritis-5/NNS||ra-7/NN	dobj||has-4/VBZ||bronchialasthma-10/NN	conj_and||rheumatoidarthritis-5/NNS||bronchialasthma-10/NN	auxpass||treated-12/VBN||was-11/VBD	root||ROOT-0/null||treated-12/VBN	amod||steroids-16/NNS||low-14/JJ	nn||steroids-16/NNS||dose-15/NN	prep_with||treated-12/VBN||steroids-16/NNS	prep_with||treated-12/VBN||methotrexate-18/NN	conj_and||steroids-16/NNS||methotrexate-18/NN	rheumatoidarthritis-5||methotrexate-18||yes||our case who has rheumatoidarthritis (ra) and bronchialasthma was treated with low dose steroids and methotrexate.
det||effect-3/NN||a-1/DT	amod||effect-3/NN||dual-2/JJ	nsubjpass||observed-8/VBN||effect-3/NN	nn||action-6/NN||insulin-5/NN	prep_on||effect-3/NN||action-6/NN	auxpass||observed-8/VBN||was-7/VBD	root||ROOT-0/null||observed-8/VBN	advmod||exposed-14/VBN||when-9/WRB	nsubjpass||exposed-14/VBN||myotubes-10/NNS	conj_and||myotubes-10/NNS||mice-12/NNS	nsubjpass||exposed-14/VBN||mice-12/NNS	auxpass||exposed-14/VBN||were-13/VBD	advcl||observed-8/VBN||exposed-14/VBN	det||additive-18/NN||this-16/DT	amod||additive-18/NN||cytokine-17/JJ	prep_to||exposed-14/VBN||additive-18/NN	amod||insulin-21/NN||short-term-20/JJ	prep_with||additive-18/NN||insulin-21/NN	amod||uptake-25/NN||increased-23/JJ	nn||uptake-25/NN||glucose-24/NN	dep||insulin-21/NN||uptake-25/NN	amod||sensitivity-29/NN||systemic-27/JJ	nn||sensitivity-29/NN||insulin-28/NN	dep||insulin-21/NN||sensitivity-29/NN	conj_and||uptake-25/NN||sensitivity-29/NN	amod||exposure-33/NN||chronic-32/JJ	nsubj||produced-34/VBD||exposure-33/NN	conj_but||observed-8/VBN||produced-34/VBD	dobj||produced-34/VBD||insulinresistance-35/NN	dep||insulinresistance-35/NN||impaired-37/VBN	amod||translocation-39/NN||glut4-38/JJ	dobj||impaired-37/VBN||translocation-39/NN	nn||membrane-42/NNS||plasma-41/NN	prep_to||impaired-37/VBN||membrane-42/NNS	prep_to||impaired-37/VBN||defects-44/NNS	conj_and||membrane-42/NNS||defects-44/NNS	prep_in||impaired-37/VBN||insulin-46/NN	xcomp||impaired-37/VBN||signaling-47/VBG	det||substrate-52/NN||the-49/DT	nn||substrate-52/NN||insulin-50/NN	nn||substrate-52/NN||receptor-51/NN	nn||level-57/NN||substrate-52/NN	num||-LSB--54/NNS||1-53/CD	npadvmod||irs-1-55/JJ||-LSB--54/NNS	amod||level-57/NN||irs-1-55/JJ	nn||level-57/NN||-RSB--56/NN	prep_at||signaling-47/VBG||level-57/NN	insulin-50||insulinresistance-35||no_rel||a dual effect on insulin action was observed when myotubes and mice were exposed to this cytokine additive with short-term insulin (increased glucose uptake and systemic insulin sensitivity) but chronic exposure produced insulinresistance (impaired glut4 translocation to plasma membrane and defects in insulin signaling at the insulin receptor substrate 1 [irs-1] level).
det||segregation-2/NN||the-1/DT	nsubj||cluster-11/VB||segregation-2/NN	nn||+-5/NNS||tb-4/NN	prep_between||segregation-2/NN||+-5/NNS	prep_between||segregation-2/NN||tbâ-7/NNS	conj_and||+-5/NNS||tbâ-7/NNS	aux||cluster-11/VB||does-9/VBZ	neg||cluster-11/VB||not-10/RB	root||ROOT-0/null||cluster-11/VB	amod||recognition-14/NN||specific-13/JJ	prep_into||cluster-11/VB||recognition-14/NN	amod||proteins-18/NNS||distinct-16/JJ	nn||proteins-18/NNS||mtb-17/NN	prep_of||recognition-14/NN||proteins-18/NNS	amod||peptide-23/NN||specific-22/JJ	nn||â-25/NN||peptide-23/NN	amod||â-25/NN||epitope-24/JJ	prep_into||cluster-11/VB||â-25/NN	conj_but||recognition-14/NN||â-25/NN	dep||â-25/NN||$-26/$	num||$-26/$||hotspotsâ-27/CD	dobj||$-26/$||$-28/$	num||$-28/$||-29/CD	amod||locations-32/NNS||different-31/JJ	prep_at||$-28/$||locations-32/NNS	det||protein-36/NN||the-34/DT	amod||protein-36/NN||same-35/JJ	prep_within||$-26/$||protein-36/NN	tb-4||mtb-17||no||the segregation between tb+ and tbâ does not cluster into specific recognition of distinct mtb proteins, but into specific peptide epitope âhotspotsâ at different locations within the same protein.
amod||prevalence-2/NN||increasing-1/VBG	nsubj||worsening-17/VBG||prevalence-2/NN	nn||resistance-5/NN||inh-4/NN	prep_of||prevalence-2/NN||resistance-5/NN	advmod||resistance-5/NN||especially-7/RB	amod||tb-12/NN||high-9/JJ	nn||tb-12/NN||tuberculosis-10/NNP	nn||tb-12/NN||-lrb--11/NNP	prep_in||especially-7/RB||tb-12/NN	advmod||prevalent-14/JJ||-rrb--13/RB	amod||countries-15/NNS||prevalent-14/JJ	dep||resistance-5/NN||countries-15/NNS	aux||worsening-17/VBG||is-16/VBZ	root||ROOT-0/null||worsening-17/VBG	det||burden-19/NN||the-18/DT	dobj||worsening-17/VBG||burden-19/NN	nn||programs-23/NNS||tb-21/NN	nn||programs-23/NNS||control-22/NN	prep_of||burden-19/NN||programs-23/NNS	mark||noted-30/VBN||since-25/IN	amod||rates-28/NNS||similar-26/JJ	nn||rates-28/NNS||transmission-27/NN	nsubjpass||noted-30/VBN||rates-28/NNS	auxpass||noted-30/VBN||are-29/VBP	advcl||worsening-17/VBG||noted-30/VBN	nn||strains-37/NNS||inh-32/NN	amod||strains-37/NNS||susceptible-33/JJ	conj_and||susceptible-33/JJ||resistant-35/JJ	amod||strains-37/NNS||resistant-35/JJ	nn||strains-37/NNS||m.tuberculosis-36/NN	prep_for||noted-30/VBN||strains-37/NNS	tuberculosis-10||inh-32||yes||increasing prevalence of inh resistance , especially in high tuberculosis -lrb- tb -rrb- prevalent countries is worsening the burden of tb control programs , since similar transmission rates are noted for inh susceptible and resistant m.tuberculosis strains .
prep_in||associated-21/VBN||addition-2/NN	prep_for||associated-21/VBN||three-5/CD	poss||genes-9/NNS||our-7/PRP$	amod||genes-9/NNS||selected-8/VBN	prep_of||three-5/CD||genes-9/NNS	nsubjpass||associated-21/VBN||hypomethylation-11/NN	det||tss-14/NN||the-13/DT	prep_at||hypomethylation-11/NN||tss-14/NN	det||gene-19/NN||an-16/DT	amod||gene-19/NN||epigenetically-17/JJ	amod||gene-19/NN||silenced-18/JJ	prep_of||tss-14/NN||gene-19/NN	auxpass||associated-21/VBN||is-20/VBZ	root||ROOT-0/null||associated-21/VBN	det||reversion-26/NN||the-23/DT	amod||reversion-26/NN||long-24/JJ	nn||reversion-26/NN||term-25/NN	prep_with||associated-21/VBN||reversion-26/NN	nn||level-30/NN||gene-28/NN	nn||level-30/NN||expression-29/NN	prep_of||reversion-26/NN||level-30/NN	vmod||level-30/NN||brought-31/VBN	dep||brought-31/VBN||about-32/IN	agent||brought-31/VBN||alterations-34/NNS	det||status-38/NN||the-36/DT	amod||status-38/NN||epigenetic-37/JJ	prep_in||alterations-34/NNS||status-38/NN	amod||treatment-41/NN||5-aza-dc-40/JJ	prep_following||status-38/NN||treatment-41/NN	aza--1||tss-14||no_rel||in addition, for three of our selected genes, hypomethylation at the tss of an epigenetically silenced gene is associated with the long term reversion of gene expression level brought about by alterations in the epigenetic status following 5-aza-dc treatment.
det||administration-2/NN||the-1/DT	nsubj||result-11/VB||administration-2/NN	amod||immunoglobulin-5/NN||hepatitisb-4/JJ	prep_of||administration-2/NN||immunoglobulin-5/NN	vmod||immunoglobulin-5/NN||followed-6/VBN	amod||vaccine-9/NN||hepatitisb-8/JJ	agent||followed-6/VBN||vaccine-9/NN	aux||result-11/VB||can-10/MD	root||ROOT-0/null||result-11/VB	det||efficacy-15/NN||a-13/DT	amod||efficacy-15/NN||protective-14/JJ	prep_in||result-11/VB||efficacy-15/NN	quantmod||90-18/CD||almost-17/RB	num||%-19/NN||90-18/CD	prep_of||efficacy-15/NN||%-19/NN	amod||transmission-22/NN||mother-to-child-21/JJ	prep_in||%-19/NN||transmission-22/NN	prep_of||transmission-22/NN||hepatitisbvirus-24/NNS	appos||hepatitisbvirus-24/NNS||hbv-26/NN	hbv-26||hepatitisbvirus-24||no||the administration of hepatitisb immunoglobulin followed by hepatitisb vaccine can result in a protective efficacy of almost 90% in mother-to-child transmission of hepatitisbvirus (hbv).
det||guidelines-3/NNS||the-1/DT	amod||guidelines-3/NNS||changing-2/VBG	nsubjpass||discussed-30/VBN||guidelines-3/NNS	vmod||guidelines-3/NNS||developed-4/VBN	vmod||guidelines-3/NNS||developed-4/VBN	vmod||guidelines-3/NNS||developed-4/VBN	vmod||guidelines-3/NNS||developed-4/VBN	conj_and||developed-4/VBN||developed-4/VBN	conj_and||developed-4/VBN||developed-4/VBN	conj_and||developed-4/VBN||developed-4/VBN	prep_for||developed-4/VBN||viraldiseases-6/NNS	prep_for||developed-4/VBN||viruses-9/NNS	prep_in||viruses-9/NNS||relation-11/NN	prep_to||relation-11/NN||cancer-13/NN	cc||developed-4/VBN||and-14/CC	amod||infection-20/NN||chronic-16/JJ	amod||infection-20/NN||central-17/JJ	amod||infection-20/NN||nervous-18/JJ	nn||infection-20/NN||system-19/NN	prep_to||developed-4/VBN||infection-20/NN	amod||agents-25/NNS||causative-24/JJ	prep_for||developed-4/VBN||agents-25/NNS	amod||diseases-28/NNS||chronic-27/JJ	prep_in||agents-25/NNS||diseases-28/NNS	auxpass||discussed-30/VBN||are-29/VBP	root||ROOT-0/null||discussed-30/VBN	advmod||discussed-30/VBN||chronologically-31/RB	viraldiseases-6||viruses-9||no||the changing guidelines developed for viraldiseases, for viruses in relation to cancer and to chronic central nervous system infection, and for causative agents in chronic diseases are discussed chronologically.
nn||condom-3/NN||contacturticaria-1/NN	dep||condom-3/NN||to-2/TO	nsubjpass||seen-8/VBN||condom-3/NN	appos||condom-3/NN||latex-5/NN	auxpass||seen-8/VBN||was-7/VBD	root||ROOT-0/null||seen-8/VBN	num||patient-11/NN||one-10/CD	prep_in||seen-8/VBN||patient-11/NN	latex-5||contacturticaria-1||no_rel||contacturticaria to condom (latex) was seen in one patient.
poss||data-2/NNS||our-1/PRP$	nsubj||suggests-3/VBZ||data-2/NNS	root||ROOT-0/null||suggests-3/VBZ	mark||provide-14/VB||that-4/IN	amod||screening-6/NN||genetic-5/JJ	nsubj||provide-14/VB||screening-6/NN	nsubj||provide-14/VB||screening-6/NN	det||mutation-12/NN||the-8/DT	amod||mutation-12/NN||s315t-9/JJ	nn||mutation-12/NN||kat-10/NN	nn||mutation-12/NN||g-11/NN	prep_for||screening-6/NN||mutation-12/NN	aux||provide-14/VB||may-13/MD	ccomp||suggests-3/VBZ||provide-14/VB	ccomp||suggests-3/VBZ||provide-14/VB	conj_and||provide-14/VB||provide-14/VB	amod||information-16/NN||rapid-15/JJ	dobj||provide-14/VB||information-16/NN	amod||selection-20/NN||anti-tb-18/JJ	nn||selection-20/NN||regimen-19/NN	prep_for||provide-14/VB||selection-20/NN	amod||monitoring-23/NN||epidemiological-22/JJ	appos||selection-20/NN||monitoring-23/NN	nn||resistance-26/NN||inh-25/NN	prep_of||monitoring-23/NN||resistance-26/NN	dep||provide-14/VB||possibly-29/RB	nn||transmission-33/NN||track-32/NN	prep_to||provide-14/VB||transmission-33/NN	advmod||resistant-36/JJ||inh-35/RB	amod||strains-37/NNS||resistant-36/JJ	prep_of||transmission-33/NN||strains-37/NNS	tb--1||inh-35||yes||our data suggests that genetic screening for the s315t kat g mutation may provide rapid information for anti-tb regimen selection, epidemiological monitoring of inh resistance and, possibly, to track transmission of inh resistant strains.
nsubjpass||randomized-3/VBN||patients-1/NNS	auxpass||randomized-3/VBN||were-2/VBD	root||ROOT-0/null||randomized-3/VBN	num||groups-6/NNS||2-5/CD	prep_into||randomized-3/VBN||groups-6/NNS	nsubj||received-14/VBD||group-7/NN	dep||group-7/NN||a-8/DT	dep||group-7/NN||n-10/VBN	dep||8-12/CD||=-11/SYM	ccomp||n-10/VBN||8-12/CD	rcmod||groups-6/NNS||received-14/VBD	det||emulsion-17/NN||the-15/DT	nn||emulsion-17/NN||study-16/NN	nsubj||lipoplusâ-18/VBZ||emulsion-17/NN	ccomp||received-14/VBD||lipoplusâ-18/VBZ	number||20-20/CD||®-19/CD	num||%-21/NN||20-20/CD	dobj||lipoplusâ-18/VBZ||%-21/NN	amod||medical-24/JJ||b.braun-23/JJ	amod||%-21/NN||medical-24/JJ	number||%-27/NN||50-26/CD	amod||ï-36/NN||%-27/NN	amod||ï-36/NN||mct-28/JJ	number||%-31/NN||40-30/CD	amod||ï-36/NN||%-31/NN	nn||ï-36/NN||lct-32/NN	number||%-35/NN||10-34/CD	amod||ï-36/NN||%-35/NN	nsubj||-37/VBZ||ï-36/NN	dep||groups-6/NNS||-37/VBZ	dobj||-37/VBZ||-3-38/CD	nsubj||received-47/VBD||groupb-41/NN	dep||groupb-41/NN||n-43/VBN	dep||8-45/CD||=-44/SYM	ccomp||n-43/VBN||8-45/CD	parataxis||randomized-3/VBN||received-47/VBD	det||emulsion-50/NN||the-48/DT	nn||emulsion-50/NN||control-49/NN	iobj||received-47/VBD||emulsion-50/NN	number||®-52/CD||intralipidâ-51/CD	num||kabi-54/NNS||®-52/CD	amod||kabi-54/NNS||fresenius-53/JJ	dobj||received-47/VBD||kabi-54/NNS	num||%-57/NN||100-56/CD	npadvmod||lct-58/JJ||%-57/NN	dep||kabi-54/NNS||lct-58/JJ	groupb-41||mct-28||no_rel||patients were randomized into 2 groups group a (n = 8) received the study emulsion lipoplusâ® 20%, b.braun medical (50% mct, 40% lct, 10% ï-3); groupb (n = 8) received the control emulsion intralipidâ® fresenius kabi (100% lct).
det||finding-3/NN||the-1/DT	amod||finding-3/NN||qualitative-2/JJ	nsubj||revealed-4/VBD||finding-3/NN	root||ROOT-0/null||revealed-4/VBD	amod||awareness-6/NN||low-5/JJ	nsubj||barriers-20/NNS||awareness-6/NN	amod||effects-13/NNS||non-disclosure-8/JJ	amod||effects-13/NNS||perceived-10/JJ	nn||effects-13/NNS||art-11/NN	nn||effects-13/NNS||side-12/NN	conj_and||awareness-6/NN||effects-13/NNS	nsubj||barriers-20/NNS||effects-13/NNS	nn||stigma-16/NN||hiv-15/NN	conj_and||awareness-6/NN||stigma-16/NN	nsubj||barriers-20/NNS||stigma-16/NN	cop||barriers-20/NNS||were-17/VBD	det||barriers-20/NNS||the-18/DT	amod||barriers-20/NNS||major-19/JJ	ccomp||revealed-4/VBD||barriers-20/NNS	amod||presentation-23/NN||late-22/JJ	prep_for||barriers-20/NNS||presentation-23/NN	amod||care-26/NN||hiv/aids-25/JJ	prep_to||barriers-20/NNS||care-26/NN	aids--1||hiv-15||no||the qualitative finding revealed low awareness, non-disclosure, perceived art side effects and hiv stigma were the major barriers for late presentation to hiv/aids care.
amod||ifn-gamma-responses-2/NNS||increased-1/VBN	nsubj||represents-15/VBZ||ifn-gamma-responses-2/NNS	amod||proliferation-7/NN||antigen-specific-4/JJ	nn||proliferation-7/NN||t-5/NN	nn||proliferation-7/NN||cell-6/NN	conj_and||ifn-gamma-responses-2/NNS||proliferation-7/NN	nsubj||represents-15/VBZ||proliferation-7/NN	det||subset-14/NN||the-9/DT	amod||subset-14/NN||cd8alpha/alpha-10/JJ	amod||subset-14/NN||+-11/JJ	nn||subset-14/NN||t-12/NN	nn||subset-14/NN||cell-13/NN	prep_in||proliferation-7/NN||subset-14/NN	root||ROOT-0/null||represents-15/VBZ	det||marker-18/NN||a-16/DT	amod||marker-18/NN||valuable-17/JJ	dobj||represents-15/VBZ||marker-18/NN	prep_for||marker-18/NN||vaccine-take-20/NN	amod||trials-25/NNS||bcg-based-22/JJ	nn||trials-25/NNS||tb-23/NN	nn||trials-25/NNS||vaccine-24/NN	prep_in||vaccine-take-20/NN||trials-25/NNS	bcg--1||tb-23||no_rel||increased ifn-gamma-responses and antigen-specific t cell proliferation in the cd8alpha/alpha+ t cell subset represents a valuable marker for vaccine-take in bcg-based tb vaccine trials
amod||testing-3/NN||one-off-1/JJ	nn||testing-3/NN||mtb/rif-2/NN	nsubj||detected-4/VBD||testing-3/NN	root||ROOT-0/null||detected-4/VBD	dobj||detected-4/VBD||933-5/CD	amod||·-8/NNS||90â-7/JJ	dep||933-5/CD||·-8/NNS	num||%-10/NN||3-9/CD	dep||·-8/NNS||%-10/NN	num||cases-15/NNS||1033-13/CD	amod||cases-15/NNS||culture-confirmed-14/JJ	prep_of||933-5/CD||cases-15/NNS	prep_of||cases-15/NNS||tuberculosis-17/NNP	prepc_compared_with||detected-4/VBD||with-20/IN	pobj||detected-4/VBD||699-21/NNP	amod||·-24/NNS||67â-23/JJ	dep||699-21/NNP||·-24/NNS	num||%-26/NN||1-25/CD	dep||·-24/NNS||%-26/NN	prep_of||699-21/NNP||1041-29/CD	prep_for||699-21/NNP||microscopy-31/NN	tuberculosis-17||rif--1||yes||one-off mtb/rif testing detected 933 (90â·3%) of 1033 culture-confirmed cases of tuberculosis, compared with 699 (67â·1%) of 1041 for microscopy.
det||prevention-3/NN||the-1/DT	nn||prevention-3/NN||stroke-2/NN	nsubj||reduced-33/VBD||prevention-3/NN	amod||reduction-6/NN||aggressive-5/JJ	prep_by||prevention-3/NN||reduction-6/NN	nn||levels-9/NNS||cholesterol-8/NN	prep_of||reduction-6/NN||levels-9/NNS	dep||levels-9/NNS||sparcl-11/JJ	nsubj||showed-14/VBD||trial-13/NN	rcmod||levels-9/NNS||showed-14/VBD	amod||treatment-16/NN||daily-15/JJ	dobj||showed-14/VBD||treatment-16/NN	num||mg-19/NN||80-18/CD	prep_with||showed-14/VBD||mg-19/NN	prep_of||mg-19/NN||atorvastatin-21/NN	prep_in||showed-14/VBD||patients-23/NNS	det||stroke-27/NN||a-25/DT	amod||stroke-27/NN||recent-26/JJ	prep_with||patients-23/NNS||stroke-27/NN	prep_with||patients-23/NNS||transientischemicattack-29/NN	conj_or||stroke-27/NN||transientischemicattack-29/NN	appos||stroke-27/NN||tia-31/NN	root||ROOT-0/null||reduced-33/VBD	det||incidence-35/NN||the-34/DT	dobj||reduced-33/VBD||incidence-35/NN	amod||stroke-40/NN||fatal-37/JJ	conj_or||fatal-37/JJ||nonfatal-39/JJ	amod||stroke-40/NN||nonfatal-39/JJ	prep_of||incidence-35/NN||stroke-40/NN	num||%-43/NN||16-42/CD	prep_by||reduced-33/VBD||%-43/NN	cholesterol-8||transientischemicattack-29||no_rel||the stroke prevention by aggressive reduction of cholesterol levels (sparcl) trial showed daily treatment with 80 mg of atorvastatin in patients with a recent stroke or transientischemicattack (tia) reduced the incidence of fatal or nonfatal stroke by 16%.
csubj||epithelial-6/VBP||using-2/VBG	det||alveolar-5/NN||a-3/DT	amod||alveolar-5/NN||human-4/JJ	dobj||using-2/VBG||alveolar-5/NN	ccomp||found-14/VBD||epithelial-6/VBP	nn||a549-9/NNS||cell-7/NN	nn||a549-9/NNS||line-8/NN	dobj||epithelial-6/VBP||a549-9/NNS	prep_as||epithelial-6/VBP||host-11/NN	nsubj||found-14/VBD||we-13/PRP	root||ROOT-0/null||found-14/VBD	mark||replicates-42/VBZ||that-15/IN	amod||kong/g1/97-17/NNS||a/quail/hong-16/VBG	nsubj||shares-23/VBZ||kong/g1/97-17/NNS	nsubj||replicates-42/VBZ||kong/g1/97-17/NNS	appos||kong/g1/97-17/NNS||h9n2/g1-19/NNP	rcmod||kong/g1/97-17/NNS||shares-23/VBZ	dobj||shares-23/VBZ||6-24/CD	xcomp||shares-23/VBZ||viral-25/VBG	amod||genes-29/NNS||internal-28/JJ	dobj||viral-25/VBG||genes-29/NNS	det||virus-40/NN||the-33/DT	amod||a/hong-35/JJ||lethal-34/JJ	amod||virus-40/NN||a/hong-35/JJ	nn||virus-40/NN||kong/156/97-36/NN	appos||virus-40/NN||h5n1/97-38/NNP	prep_with||viral-25/VBG||virus-40/NN	ccomp||found-14/VBD||replicates-42/VBZ	advmod||replicates-42/VBZ||efficiently-43/RB	mark||replicate-61/VBZ||whereas-44/IN	amod||viruses-47/NNS||other-45/JJ	amod||viruses-47/NNS||h9n2-46/JJ	nsubj||replicate-61/VBZ||viruses-47/NNS	amod||kong/y280/97-50/NNS||a/duck/hong-49/VBG	appos||viruses-47/NNS||kong/y280/97-50/NNS	appos||kong/y280/97-50/NNS||h9n2/y280-52/NNP	amod||kong/g9/97-56/NNS||a/chicken/hong-55/VBG	appos||viruses-47/NNS||kong/g9/97-56/NNS	conj_and||kong/y280/97-50/NNS||kong/g9/97-56/NNS	appos||kong/g9/97-56/NNS||h9n2/g9-58/NNP	dep||efficiently-43/RB||replicate-61/VBZ	advmod||replicate-61/VBZ||poorly-62/RB	virus-40||viruses-47||no||" using a human alveolar epithelial cell line a549 as host, we found that a/quail/hong kong/g1/97 (h9n2/g1), which shares 6 viral ""internal genes"" with the lethal a/hong kong/156/97 (h5n1/97) virus, replicates efficiently whereas other h9n2 viruses, a/duck/hong kong/y280/97 (h9n2/y280) and a/chicken/hong kong/g9/97 (h9n2/g9), replicate poorly."
nsubj||increased-8/VBD||animals-1/NNS	vmod||animals-1/NNS||primed-2/VBN	prep||primed-2/VBN||with-3/IN	nsubj||showed-5/VBD||afro-1-4/JJ	parataxis||primed-2/VBN||showed-5/VBD	dobj||showed-5/VBD||i-6/FW	root||ROOT-0/null||increased-8/VBD	amod||production-11/NN||ag85b-specific-9/JJ	amod||production-11/NN||ifn-gamma-10/JJ	dobj||increased-8/VBD||production-11/NN	det||assay-15/NN||the-13/DT	nn||assay-15/NN||wba-14/NN	prep_in||production-11/NN||assay-15/NN	amod||pg/ml-20/NN||median-17/JJ	amod||pg/ml-20/NN||>-18/JJ	num||pg/ml-20/NN||400-19/CD	dep||assay-15/NN||pg/ml-20/NN	num||animals-23/NNS||6-22/CD	prep_for||pg/ml-20/NN||animals-23/NNS	num||week-26/NN||one-25/CD	dep||assay-15/NN||week-26/NN	det||boost-30/NN||the-28/DT	amod||boost-30/NN||first-29/JJ	prep_after||increased-8/VBD||boost-30/NN	amod||tb-antigens-33/NNS||adenoviral-delivered-32/JJ	prep_with||boost-30/NN||tb-antigens-33/NNS	prep||increased-8/VBD||as-34/IN	prep||increased-8/VBD||compared-35/VBN	pcomp||compared-35/VBN||to-36/TO	pobj||to-36/TO||animals-37/NNS	vmod||animals-37/NNS||primed-38/VBN	prep_with||primed-38/VBN||bcg-40/NN	number||200-43/CD||<-42/CD	num||pg/ml-44/NNS||200-43/CD	appos||bcg-40/NN||pg/ml-44/NNS	dobj||primed-38/VBN||ii-47/NN	amod||proliferation-52/NN||stronger-49/JJR	nn||proliferation-52/NN||t-50/NN	nn||proliferation-52/NN||cell-51/NN	npadvmod||primed-38/VBN||proliferation-52/NN	det||subset-59/NN||the-54/DT	amod||subset-59/NN||cd8alpha/alpha-55/JJ	amod||subset-59/NN||+-56/JJ	nn||subset-59/NN||t-57/NN	nn||subset-59/NN||cell-58/NN	prep_in||primed-38/VBN||subset-59/NN	amod||index-62/NN||proliferative-61/JJ	dep||subset-59/NN||index-62/NN	num||%-64/NN||17-63/CD	dep||index-62/NN||%-64/NN	prepc_as||subset-59/NN||compared-67/VBN	pcomp||compared-67/VBN||to-68/TO	amod||animals-70/NNS||bcg-primed-69/JJ	pobj||to-68/TO||animals-70/NNS	amod||index-73/NN||proliferative-72/JJ	dep||subset-59/NN||index-73/NN	number||%-75/NN||5-74/CD	amod||index-73/NN||%-75/NN	amod||cells-80/NNS||cd8alpha/alpha-77/JJ	amod||cells-80/NNS||+-78/JJ	nn||cells-80/NNS||t-79/NN	prep_in||index-73/NN||cells-80/NNS	tb--1||bcg-40||yes||animals primed with afro-1 showed i) increased ag85b-specific ifn-gamma production in the wba assay (median >400 pg/ml for 6 animals) one week after the first boost with adenoviral-delivered tb-antigens as compared to animals primed with bcg (<200 pg/ml), ii) stronger t cell proliferation in the cd8alpha/alpha+ t cell subset (proliferative index 17%) as compared to bcg-primed animals (proliferative index 5% in cd8alpha/alpha+ t cells).
nn||infections-2/NNS||skin-1/NN	nsubj||likely-5/JJ||infections-2/NNS	nsubj||likely-5/JJ||infections-2/NNS	nsubj||develop-7/VB||infections-2/NNS	cop||likely-5/JJ||were-3/VBD	advmod||likely-5/JJ||more-4/RBR	root||ROOT-0/null||likely-5/JJ	conj_but||likely-5/JJ||likely-5/JJ	aux||develop-7/VB||to-6/TO	xcomp||likely-5/JJ||develop-7/VB	nn||carriers-10/NNS||mrsa-9/NN	prep_in||develop-7/VB||carriers-10/NNS	prep||likely-5/JJ||than-11/IN	pcomp||than-11/IN||in-12/IN	amod||carriers-15/NNS||methicillin-susceptible-13/JJ	nn||carriers-15/NNS||s.aureus-14/NN	pobj||in-12/IN||carriers-15/NNS	pobj||in-12/IN||noncarriers-17/NNS	conj_or||carriers-15/NNS||noncarriers-17/NNS	prep_of||carriers-15/NNS||s.aureus-19/NNS	det||year-24/NN||the-21/DT	amod||year-24/NN||first-22/JJ	nn||year-24/NN||follow-up-23/NN	prep_during||likely-5/JJ||year-24/NN	neg||likely-5/JJ||not-27/RB	amod||years-30/NNS||subsequent-29/JJ	prep_in||likely-5/JJ||years-30/NNS	mrsa-9||s.aureus-19||no||skin infections were more likely to develop in mrsa carriers than in methicillin-susceptible s.aureus carriers or noncarriers of s.aureus during the first follow-up year , but not in subsequent years .
det||study-3/NN||the-1/DT	nn||study-3/NN||simulation-2/NN	nsubj||shows-4/VBZ||study-3/NN	root||ROOT-0/null||shows-4/VBZ	mark||predicted-51/VBN||that-5/IN	det||used-11/VBN||the-8/DT	advmod||used-11/VBN||most-9/RBS	advmod||used-11/VBN||commonly-10/RB	prep_under||predicted-51/VBN||used-11/VBN	advmod||approaches-16/NNS||generally-13/RB	amod||approaches-16/NNS||accepted-14/VBN	nn||approaches-16/NNS||therapy-15/NN	conj_and||used-11/VBN||approaches-16/NNS	prep_under||predicted-51/VBN||approaches-16/NNS	nn||infection-19/NN||hdv-18/NN	prep_for||approaches-16/NNS||infection-19/NN	prep_such_as||approaches-16/NNS||lamivudine-23/NN	appos||lamivudine-23/NN||lmv-25/NN	amod||alpha-interferon-31/NN||ribavirine-28/JJ	amod||alpha-interferon-31/NN||peggylated-30/JJ	prep_such_as||approaches-16/NNS||alpha-interferon-31/NN	conj_or||lamivudine-23/NN||alpha-interferon-31/NN	appos||lamivudine-23/NN||ifn-33/NN	det||combination-37/NN||a-36/DT	conj_or||used-11/VBN||combination-37/NN	prep_under||predicted-51/VBN||combination-37/NN	prep_of||combination-37/NN||both-39/DT	nn||monotherapy-42/NN||lmv-41/NN	nsubjpass||predicted-51/VBN||monotherapy-42/NN	nsubj||reduce-55/VB||monotherapy-42/NN	nsubj||hdv-59/VB||monotherapy-42/NN	nn||therapy-45/NN||combination-44/NN	conj_and||monotherapy-42/NN||therapy-45/NN	nsubjpass||predicted-51/VBN||therapy-45/NN	nsubj||reduce-55/VB||therapy-45/NN	prep_of||monotherapy-42/NN||lmv-47/NN	prep_of||monotherapy-42/NN||ifn-49/NN	conj_and||lmv-47/NN||ifn-49/NN	auxpass||predicted-51/VBN||were-50/VBD	ccomp||shows-4/VBZ||predicted-51/VBN	aux||reduce-55/VB||to-52/TO	advmod||effectively-54/RB||more-53/RBR	advmod||reduce-55/VB||effectively-54/RB	xcomp||predicted-51/VBN||reduce-55/VB	det||hbv-57/NN||the-56/DT	dobj||reduce-55/VB||hbv-57/NN	xcomp||predicted-51/VBN||hdv-59/VB	conj_and||reduce-55/VB||hdv-59/VB	amod||loads-61/NNS||viral-60/JJ	dobj||hdv-59/VB||loads-61/NNS	det||case-64/NN||the-63/DT	prep_in||hdv-59/VB||case-64/NN	amod||scenarios-67/NNS||super-infection-66/JJ	prep_of||case-64/NN||scenarios-67/NNS	advmod||compared-69/VBN||when-68/WRB	advcl||hdv-59/VB||compared-69/VBN	det||co-infection-72/NN||the-71/DT	prep_with||compared-69/VBN||co-infection-72/NN	hbv-57||lamivudine-23||yes||the simulation study shows that, under the most commonly used and generally accepted therapy approaches for hdv infection, such as lamivudine (lmv) or ribavirine, peggylated alpha-interferon (ifn) or a combination of both, lmv monotherapy and combination therapy of lmv and ifn were predicted to more effectively reduce the hbv and hdv viral loads in the case of super-infection scenarios when compared with the co-infection.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	det||association-4/NN||an-3/DT	nsubj||was-2/VBD||association-4/NN	prep_between||association-4/NN||strength-6/NN	prep_of||strength-6/NN||analgesic-8/NN	prep_of||strength-6/NN||intensity-10/NN	conj_and||analgesic-8/NN||intensity-10/NN	prep_of||association-4/NN||pain-12/NN	advmod||intense-14/JJ||more-13/RBR	dep||resulted-16/VBD||intense-14/JJ	nsubj||resulted-16/VBD||pain-15/NN	dep||was-2/VBD||resulted-16/VBD	det||drug-20/NN||a-18/DT	amod||drug-20/NN||stronger-19/JJR	prep_in||resulted-16/VBD||drug-20/NN	analgesic-8||pain-15||no_rel||there was an association between strength of analgesic and intensity of pain more intense pain resulted in a stronger drug.
amod||fibers-3/NNS||viscous-1/JJ	nn||fibers-3/NNS||dietary-2/NN	nsubj||blunt-4/VB||fibers-3/NNS	root||ROOT-0/null||blunt-4/VB	det||rise-7/NN||the-5/DT	amod||rise-7/NN||postprandial-6/JJ	dobj||blunt-4/VB||rise-7/NN	prep_in||blunt-4/VB||bloodglucose-9/NN	advmod||known-21/VBN||however-11/RB	poss||effect-13/NN||their-12/PRP$	nsubjpass||known-21/VBN||effect-13/NN	prep_on||effect-13/NN||type2diabetes-15/NN	prep_on||effect-13/NN||obesity-17/NN	conj_and||type2diabetes-15/NN||obesity-17/NN	auxpass||known-21/VBN||are-18/VBP	neg||known-21/VBN||not-19/RB	advmod||known-21/VBN||entirely-20/RB	parataxis||blunt-4/VB||known-21/VBN	obesity-17||rise-7||no_rel||viscous dietary fibers blunt the postprandial rise in bloodglucose, however their effect on type2diabetes and obesity are not entirely known.
det||requirement-2/NN||this-1/DT	nsubjpass||demonstrated-10/VBN||requirement-2/NN	nn||ii-5/NN||nm-4/NN	prep_for||requirement-2/NN||ii-5/NN	prep_in||ii-5/NN||karyokinesis-7/NNS	auxpass||demonstrated-10/VBN||is-8/VBZ	advmod||demonstrated-10/VBN||further-9/RBR	root||ROOT-0/null||demonstrated-10/VBN	det||line-15/NN||the-12/DT	amod||line-15/NN||hl-1-13/JJ	nn||line-15/NN||cell-14/NN	prep_in||demonstrated-10/VBN||line-15/NN	vmod||line-15/NN||derived-16/VBN	nn||myocytes-20/NNS||mouse-18/NN	nn||myocytes-20/NNS||atrial-19/NN	prep_from||derived-16/VBN||myocytes-20/NNS	agent||demonstrated-10/VBN||using-23/VBG	amod||knockdown-27/NN||small-24/JJ	amod||knockdown-27/NN||interfering-25/JJ	nn||knockdown-27/NN||rna-26/NN	dobj||using-23/VBG||knockdown-27/NN	nn||ii-30/NN||nm-29/NN	prep_of||knockdown-27/NN||ii-30/NN	prep_of||knockdown-27/NN||treatment-32/NN	conj_or||ii-30/NN||treatment-32/NN	det||blebbistatin-37/NN||the-34/DT	nn||blebbistatin-37/NN||myosin-35/NN	nn||blebbistatin-37/NN||inhibitor-36/NN	prep_with||using-23/VBG||blebbistatin-37/NN	hl--1||nm-29||yes||this requirement for nm ii in karyokinesis is further demonstrated in the hl-1 cell line derived from mouse atrial myocytes, by using small interfering rna knockdown of nm ii or treatment with the myosin inhibitor blebbistatin.
amod||ovalbumin-2/NN||aerosolized-1/JJ	nsubjpass||used-4/VBN||ovalbumin-2/NN	nsubj||generate-6/VB||ovalbumin-2/NN	auxpass||used-4/VBN||was-3/VBD	root||ROOT-0/null||used-4/VBN	aux||generate-6/VB||to-5/TO	xcomp||used-4/VBN||generate-6/VB	det||model-10/NN||the-7/DT	amod||model-10/NN||asthmatic-8/JJ	nn||model-10/NN||rat-9/NN	dobj||generate-6/VB||model-10/NN	nsubjpass||administered-15/VBN||budesonide-13/NN	auxpass||administered-15/VBN||was-14/VBD	conj_and||used-4/VBN||administered-15/VBN	nn||inhalation-18/NN||ovalbumin-17/NN	prep_after||administered-15/VBN||inhalation-18/NN	asthmatic-8||budesonide-13||yes||aerosolized ovalbumin was used to generate the asthmatic rat model, and budesonide was administered after ovalbumin inhalation.
amod||levels-3/NNS||s100a12-1/JJ	nn||levels-3/NNS||serum-2/NN	nsubjpass||determined-5/VBN||levels-3/NNS	auxpass||determined-5/VBN||were-4/VBD	root||ROOT-0/null||determined-5/VBN	num||patients-8/NNS||64-7/CD	prep_in||determined-5/VBN||patients-8/NNS	prep_with||patients-8/NNS||ulcerativecolitis-10/NNS	appos||ulcerativecolitis-10/NNS||uc-12/NN	prep_in||determined-5/VBN||64-15/CD	conj_and||patients-8/NNS||64-15/CD	prep_with||64-15/CD||crohn-17/NN	dep||crohn-17/NN||sdisease-19/NN	appos||crohn-17/NN||cd-21/NN	prep_in||determined-5/VBN||73-24/CD	conj_and||patients-8/NNS||73-24/CD	prep_with||73-24/CD||ibs-26/NN	det||assay-34/NN||an-31/DT	amod||assay-34/NN||enzyme-linked-32/JJ	nn||assay-34/NN||immunosorbent-33/NN	prep_by_means_of||determined-5/VBN||assay-34/NN	cd-21||ibs-26||no_rel||s100a12 serum levels were determined in 64 patients with ulcerativecolitis (uc), 64 with crohn'sdisease (cd) and 73 with ibs, by means of an enzyme-linked immunosorbent assay.
nsubj||describe-2/VBP||we-1/PRP	root||ROOT-0/null||describe-2/VBP	det||device-5/NN||a-3/DT	nn||device-5/NN||novel-4/NN	dobj||describe-2/VBP||device-5/NN	nsubj||utilizes-7/VBZ||device-5/NN	rcmod||device-5/NN||utilizes-7/VBZ	dobj||utilizes-7/VBZ||immunosensor-8/NN	nsubj||detect-13/VB||immunosensor-8/NN	nsubj||demonstrate-22/VB||immunosensor-8/NN	amod||technology-11/NN||bio-optical-10/JJ	dobj||utilizes-7/VBZ||technology-11/NN	conj_and||immunosensor-8/NN||technology-11/NN	nsubj||detect-13/VB||technology-11/NN	aux||detect-13/VB||to-12/TO	xcomp||utilizes-7/VBZ||detect-13/VB	nn||-rrb--18/NNP||m.tuberculosis-14/NNS	nn||-rrb--18/NNP||antigen-15/NN	nn||-rrb--18/NNP||-lrb--16/NNP	nn||-rrb--18/NNP||ag85b-17/NNPS	dobj||detect-13/VB||-rrb--18/NNP	prep_in||-rrb--18/NNP||cough-20/NN	xcomp||utilizes-7/VBZ||demonstrate-22/VB	conj_and||detect-13/VB||demonstrate-22/VB	poss||use-24/NN||its-23/PRP$	dobj||demonstrate-22/VB||use-24/NN	nn||conditions-27/NNS||field-26/NN	prep_under||demonstrate-22/VB||conditions-27/NNS	det||study-31/NN||a-29/DT	nn||study-31/NN||pilot-30/NN	prep_during||demonstrate-22/VB||study-31/NN	det||area-34/NN||an-33/DT	prep_in||study-31/NN||area-34/NN	amod||incidence-38/NN||high-36/JJ	nn||incidence-38/NN||tb-37/NN	prep_of||area-34/NN||incidence-38/NN	tb-37||m.tuberculosis-14||no||we describe a novel device that utilizes immunosensor and bio-optical technology to detect m.tuberculosis antigen -lrb- ag85b -rrb- in cough and demonstrate its use under field conditions during a pilot study in an area of high tb incidence .
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effect-8/NN||the-7/DT	dobj||investigated-6/VBD||effect-8/NN	det||mixture-12/NN||a-10/DT	amod||mixture-12/NN||lidocaine-11/JJ	prep_of||effect-8/NN||mixture-12/NN	prep_on||investigated-6/VBD||pain-14/NN	dep||pain-14/NN||induced-15/VBN	amod||injection-19/NN||microemulsion-17/JJ	amod||injection-19/NN||propofol-18/JJ	prep_by||induced-15/VBN||injection-19/NN	dep||pain-14/NN||sought-22/VBN	conj_and||induced-15/VBN||sought-22/VBN	aux||determine-24/VB||to-23/TO	xcomp||sought-22/VBN||determine-24/VB	det||dose-27/NN||the-25/DT	amod||dose-27/NN||optimal-26/JJ	dobj||determine-24/VB||dose-27/NN	nsubj||reduce-32/VB||dose-27/NN	prep_of||dose-27/NN||lidocaine-29/NN	aux||reduce-32/VB||could-31/MD	rcmod||dose-27/NN||reduce-32/VB	dobj||reduce-32/VB||pain-33/NN	prepc_on||reduce-32/VB||injecting-35/VBG	det||mixture-38/NN||a-36/DT	amod||mixture-38/NN||propofol-lidocaine-37/JJ	dobj||injecting-35/VBG||mixture-38/NN	pain-33||propofol-18||yes||in this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture.
det||assay-5/NN||the-1/DT	amod||assay-5/NN||adenosinetriphosphate-based-2/JJ	amod||assay-5/NN||chemotherapy-3/JJ	nn||assay-5/NN||response-4/NN	nsubj||test-12/NN||assay-5/NN	appos||assay-5/NN||atp-cra-7/NNP	cop||test-12/NN||is-9/VBZ	det||test-12/NN||a-10/DT	amod||test-12/NN||chemosensitivity-11/JJ	root||ROOT-0/null||test-12/NN	nsubj||offers-14/VBZ||test-12/NN	rcmod||test-12/NN||offers-14/VBZ	det||potential-16/NN||the-15/DT	dobj||offers-14/VBZ||potential-16/NN	prepc_of||potential-16/NN||selecting-18/VBG	nn||treatments-20/NNS||cancer-19/NN	dobj||selecting-18/VBG||treatments-20/NNS	prepc_based_on||selecting-18/VBG||on-22/IN	det||responsiveness-24/NNS||the-23/DT	pobj||selecting-18/VBG||responsiveness-24/NNS	amod||tumors-27/NNS||individual-26/JJ	prep_of||responsiveness-24/NNS||tumors-27/NNS	adenosinetriphosphate--1||tumors-27||no_rel||the adenosinetriphosphate-based chemotherapy response assay (atp-cra) is a chemosensitivity test that offers the potential of selecting cancer treatments based on the responsiveness of individual tumors.
prepc_after||3.077-57/CD||adjusting-2/VBG	prep_for||adjusting-2/VBG||covariates-4/NNS	nn||type-16/NN||gender-7/NN	dep||type-16/NN||age-9/NN	dep||type-16/NN||hypertension-11/NN	dep||type-16/NN||diabetes-13/NN	amod||type-16/NN||va-15/JJ	prep_such_as||covariates-4/NNS||type-16/NN	nn||levels-19/NNS||hemoglobin-18/NN	prep_such_as||covariates-4/NNS||levels-19/NNS	conj_and||type-16/NN||levels-19/NNS	nn||index-23/NN||body-21/NN	nn||index-23/NN||mass-22/NN	prep_such_as||covariates-4/NNS||index-23/NN	conj_and||type-16/NN||index-23/NN	amod||hormone-26/NN||parathyroid-25/JJ	prep_such_as||covariates-4/NNS||hormone-26/NN	conj_and||type-16/NN||hormone-26/NN	amod||levels-31/NNS||calcium-phosphorus-29/JJ	nn||levels-31/NNS||product-30/NN	prep_such_as||covariates-4/NNS||levels-31/NNS	conj_and||type-16/NN||levels-31/NNS	det||ratio-35/NN||the-33/DT	nn||ratio-35/NN||hazard-34/NN	nsubj||3.077-57/CD||ratio-35/NN	prep_of||ratio-35/NN||vabf-37/NN	dep||ratio-35/NN||defined-39/VBN	prepc_as||defined-39/VBN||<-41/VBG	num||ml/min-43/NN||853-42/CD	dobj||<-41/VBG||ml/min-43/NN	prep_in||ml/min-43/NN||avf-45/NN	prepc_as||defined-39/VBN||<-47/VBG	conj_or||<-41/VBG||<-47/VBG	num||ml/min-49/NN||830-48/CD	dobj||<-47/VBG||ml/min-49/NN	prep_in||ml/min-49/NN||avg-51/NN	nn||va-55/NN||incident-54/NN	prep_to||ratio-35/NN||va-55/NN	cop||3.077-57/CD||was-56/VBD	root||ROOT-0/null||3.077-57/CD	num||%-60/NN||95-59/CD	dep||3.077-57/CD||%-60/NN	nn||interval-62/NN||confidence-61/NN	dep||%-60/NN||interval-62/NN	num||.395-65/CD||1.127-8-64/CD	appos||interval-62/NN||.395-65/CD	dep||interval-62/NN||p-67/NN	dep||0.028-69/CD||=-68/SYM	rcmod||p-67/NN||0.028-69/CD	hypertension-11||hormone-26||no_rel||after adjusting for covariates such as gender, age, hypertension, diabetes, va type, hemoglobin levels, body mass index, parathyroid hormone, and calcium-phosphorus product levels, the hazard ratio of vabf (defined as <853 ml/min in avf or <830 ml/min in avg) to incident va was 3.077 (95% confidence interval, 1.127-8.395; p =0.028).
expl||is-2/VBZ||there-1/EX	root||ROOT-0/null||is-2/VBZ	amod||knowledge-4/NN||limited-3/VBN	nsubj||is-2/VBZ||knowledge-4/NN	det||routes-8/NNS||the-6/DT	amod||routes-8/NNS||potential-7/JJ	prep_about||knowledge-4/NN||routes-8/NNS	amod||transmission-12/NN||h5n1-10/JJ	nn||transmission-12/NN||influenzavirus-11/NNS	prep_for||routes-8/NNS||transmission-12/NN	prep_for||routes-8/NNS||transmission-12/NN	conj_and||transmission-12/NN||transmission-12/NN	prep_between||transmission-12/NN||humans-16/NNS	prep_to||transmission-12/NN||humans-16/NNS	nsubj||clear-22/JJ||it-19/PRP	cop||clear-22/JJ||is-20/VBZ	neg||clear-22/JJ||not-21/RB	conj_and||is-2/VBZ||clear-22/JJ	mark||infected-27/VBN||whether-23/IN	nsubjpass||infected-27/VBN||humans-24/NNS	aux||infected-27/VBN||can-25/MD	auxpass||infected-27/VBN||be-26/VB	ccomp||clear-22/JJ||infected-27/VBN	prep_through||infected-27/VBN||inhalation-29/NN	amod||particles-34/NNS||aerosolized-31/JJ	amod||particles-34/NNS||h5n1-32/JJ	nn||particles-34/NNS||virus-33/NN	prep_of||inhalation-29/NN||particles-34/NNS	h5n1-32||influenzavirus-11||no||there is limited knowledge about the potential routes for h5n1 influenzavirus transmission to and between humans, and it is not clear whether humans can be infected through inhalation of aerosolized h5n1 virus particles.
det||steroid-3/NN||a-1/DT	amod||steroid-3/NN||high-dose-2/JJ	nsubjpass||administered-5/VBN||steroid-3/NN	auxpass||administered-5/VBN||was-4/VBD	root||ROOT-0/null||administered-5/VBN	advmod||administered-5/VBN||immediately-6/RB	xcomp||administered-5/VBN||resulting-7/VBG	prep_in||resulting-7/VBG||improvements-9/NNS	prep_of||improvements-9/NNS||periorbital-11/JJ	amod||periorbital-11/JJ||swelling-12/VBG	det||patient-16/NN||the-15/DT	poss||vision-18/NN||patient-16/NN	nsubj||recovered-21/VBN||vision-18/NN	aux||recovered-21/VBN||had-19/VBD	neg||recovered-21/VBN||not-20/RB	conj_but||administered-5/VBN||recovered-21/VBN	swelling-12||steroid-3||no_rel||a high-dose steroid was administered immediately resulting in improvements of periorbital swelling, but the patient's vision had not recovered.
nn||t3-2/NNS||serum-1/NN	nsubjpass||decreased-6/VBN||t3-2/NNS	conj_and||t3-2/NNS||t4-4/NNS	nsubjpass||decreased-6/VBN||t4-4/NNS	auxpass||decreased-6/VBN||were-5/VBD	root||ROOT-0/null||decreased-6/VBN	num||children-9/NNS||34/78-8/CD	prep_in||decreased-6/VBN||children-9/NNS	nn||infections-12/NNS||cns-11/NN	prep_with||children-9/NNS||infections-12/NNS	nsubj||lower-19/JJR||t3-14/NNS	nsubj||higher-33/JJR||t3-14/NNS	conj_and||t3-14/NNS||t4-16/NNS	nsubj||lower-19/JJR||t4-16/NNS	cop||lower-19/JJR||were-17/VBD	advmod||lower-19/JJR||much-18/RB	dep||decreased-6/VBN||lower-19/JJR	prep_than||lower-19/JJR||those-21/DT	amod||adult-24/NN||healthy-23/JJ	prep_of||those-21/DT||adult-24/NN	dep||<-27/JJ||p-26/RB	dep||lower-19/JJR||<-27/JJ	dep||<-27/JJ||0.05-28/CD	advmod||higher-33/JJR||still-32/RB	dep||decreased-6/VBN||higher-33/JJR	conj_but||lower-19/JJR||higher-33/JJR	prep_than||higher-33/JJR||that-35/DT	det||hypothyroidism-39/NN||the-37/DT	amod||hypothyroidism-39/NN||primary-38/JJ	prep_of||that-35/DT||hypothyroidism-39/NN	dep||<-42/JJ||p-41/RB	dep||higher-33/JJR||<-42/JJ	dep||<-42/JJ||0.05-43/CD	nn||levels-48/NNS||tsh-47/NN	nsubj||differences-52/NNS||levels-48/NNS	cop||differences-52/NNS||were-49/VBD	neg||differences-52/NNS||not-50/RB	amod||differences-52/NNS||significant-51/JJ	conj_and||decreased-6/VBN||differences-52/NNS	prep_among||differences-52/NNS||children-54/NNS	nn||infections-57/NNS||cns-56/NN	prep_with||children-54/NNS||infections-57/NNS	prep_with||children-54/NNS||children-59/NNS	conj_and||infections-57/NNS||children-59/NNS	amod||infections-62/NNS||non-cns-61/JJ	prep_with||children-54/NNS||infections-62/NNS	dep||children-54/NNS||p-64/VBN	num||0.05-66/CD||>-65/CD	dobj||p-64/VBN||0.05-66/CD	hypothyroidism-39||t4-16||yes||serum t3 and t4 were decreased in 34/78 children with cns infections, t3 and t4 were much lower than those of healthy adult (p < 0.05), but still higher than that of the primary hypothyroidism (p < 0.05), and tsh levels were not significant differences among children with cns infections and children with non-cns infections (p > 0.05).
amod||yields-12/NNS||interferon-1/JJ	amod||therapy-4/NN||ribavirin-3/JJ	conj_and||interferon-1/JJ||therapy-4/NN	amod||yields-12/NNS||therapy-4/NN	amod||virus-7/NN||chronichepatitisc-6/JJ	prep_for||therapy-4/NN||virus-7/NN	discourse||virus-7/NN||hcv-9/UH	nn||yields-12/NNS||infection-11/NN	nsubj||sustained-13/VBD||yields-12/NNS	root||ROOT-0/null||sustained-13/VBD	amod||rates-19/NNS||virological-14/JJ	nn||rates-19/NNS||response-15/NN	discourse||rates-19/NNS||svr-17/UH	dobj||sustained-13/VBD||rates-19/NNS	prep_of||rates-19/NNS||50â-21/NNS	dep||%-25/NN||$-22/$	num||$-22/$||80-24/CD	amod||50â-21/NNS||%-25/NN	chronichepatitisc-6||hcv-9||no||interferon and ribavirin therapy for chronichepatitisc virus (hcv) infection yields sustained virological response (svr) rates of 50â80%.
det||data-2/NNS||these-1/DT	nsubj||show-3/VBP||data-2/NNS	root||ROOT-0/null||show-3/VBP	mark||induces-7/VBZ||that-4/IN	nn||acutely-6/NN||ozone-5/NN	nsubj||induces-7/VBZ||acutely-6/NN	nsubj||insensitive-16/JJ||acutely-6/NN	ccomp||show-3/VBP||induces-7/VBZ	dobj||induces-7/VBZ||ahr-8/NN	aux||cch-10/VB||to-9/TO	vmod||induces-7/VBZ||cch-10/VB	dobj||cch-10/VB||independent-11/JJ	prep_of||independent-11/JJ||inflammation-13/NN	cop||insensitive-16/JJ||is-15/VBZ	ccomp||show-3/VBP||insensitive-16/JJ	conj_and||induces-7/VBZ||insensitive-16/JJ	amod||treatment-19/NN||steroid-18/JJ	prep_to||insensitive-16/JJ||treatment-19/NN	amod||inhibition-25/NN||cyclooxygenase-21/JJ	appos||inhibition-25/NN||cox-23/NN	prep_to||insensitive-16/JJ||inhibition-25/NN	conj_or||treatment-19/NN||inhibition-25/NN	ozone-5||inflammation-13||no_rel||these data show that ozone acutely induces ahr to cch independent of inflammation and is insensitive to steroid treatment or cyclooxygenase (cox) inhibition.
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	nsubj||drawn-4/VBN||data-3/NNS	dep||present-2/VBP||drawn-4/VBN	num||irondeficiency-11/NN||four-6/CD	amod||irondeficiency-11/NN||different-7/JJ	amod||irondeficiency-11/NN||conditionsâ-8/JJ	nn||irondeficiency-11/NN||$-9/NN	prep_from||drawn-4/VBN||irondeficiency-11/NN	amod||hypotransferrinemia-14/NN||congenital-13/JJ	prep_from||drawn-4/VBN||hypotransferrinemia-14/NN	conj_and||irondeficiency-11/NN||hypotransferrinemia-14/NN	prep_from||drawn-4/VBN||beta-thalassemia-16/NN	conj_and||irondeficiency-11/NN||beta-thalassemia-16/NN	nn||$-20/NNP||hereditaryhemochromatosisâ-19/NNP	prep_from||drawn-4/VBN||$-20/NNP	conj_and||irondeficiency-11/NN||$-20/NNP	dep||irondeficiency-11/NN||both-22/DT	prep_from||drawn-4/VBN||in-23/IN	conj_and||irondeficiency-11/NN||in-23/IN	amod||models-27/NNS||human-24/JJ	conj_and||human-24/JJ||non-human-26/JJ	amod||models-27/NNS||non-human-26/JJ	prep_in||irondeficiency-11/NN||models-27/NNS	prep_of||models-27/NNS||disease-29/NN	advmod||suggesting-32/VBG||together-31/RB	xcomp||present-2/VBP||suggesting-32/VBG	mark||exerts-37/VBZ||that-33/IN	amod||demand-36/NN||erythroid-34/VBN	nn||demand-36/NN||iron-35/NN	nsubj||exerts-37/VBZ||demand-36/NN	ccomp||suggesting-32/VBG||exerts-37/VBZ	det||influence-40/NN||a-38/DT	amod||influence-40/NN||stronger-39/JJR	dobj||exerts-37/VBZ||influence-40/NN	prepc_on||exerts-37/VBZ||circulating-42/VBG	nn||supply-44/NN||iron-43/NN	dobj||circulating-42/VBG||supply-44/NN	amod||stores-48/NNS||systemic-46/JJ	nn||stores-48/NNS||iron-47/NN	prep_than||circulating-42/VBG||stores-48/NNS	irondeficiency-11||iron-47||yes||we present data drawn from four different conditionsâirondeficiency, congenital hypotransferrinemia, beta-thalassemia, and hereditaryhemochromatosisâboth in human and non-human models of disease, together suggesting that erythroid iron demand exerts a stronger influence on circulating iron supply than systemic iron stores.
nsubj||ppp-rna-3/VBZ||5-1/CD	dep||inhibited-10/VBD||ppp-rna-3/VBZ	dobj||ppp-rna-3/VBZ||treatment-4/NN	amod||cells-9/NNS||human-6/JJ	nn||cells-9/NNS||lung-7/NN	nn||cells-9/NNS||epithelial-8/NN	prep_of||treatment-4/NN||cells-9/NNS	root||ROOT-0/null||inhibited-10/VBD	dobj||inhibited-10/VBD||replication-11/NN	amod||h5n1-15/NNS||drug-resistant-13/JJ	nn||h5n1-15/NNS||avian-14/NN	prep_of||replication-11/NN||h5n1-15/NNS	dobj||inhibited-10/VBD||1918-19/CD	conj_and||replication-11/NN||1918-19/CD	num||influenzaviruses-23/NNS||2009-21/CD	amod||influenzaviruses-23/NNS||pandemic-22/JJ	conj_and||replication-11/NN||influenzaviruses-23/NNS	conj_and||1918-19/CD||influenzaviruses-23/NNS	det||rig-i-26/NN||a-25/DT	prep_in||inhibited-10/VBD||rig-i-26/NN	prep_in||inhibited-10/VBD||type-28/NN	conj_and||rig-i-26/NN||type-28/NN	num||manner-32/NN||1-29/CD	nn||manner-32/NN||interferon-30/NN	nn||manner-32/NN||dependant-31/NN	nsubj||inhibited-10/VBD||manner-32/NN	h5n1-15||influenzaviruses-23||no||5'ppp-rna treatment of human lung epithelial cells inhibited replication of drug-resistant avian h5n1 as well as 1918 and 2009 pandemic influenzaviruses in a rig-i and type 1 interferon dependant manner.
nn||patients-2/NNS||results-1/NNS	nsubj||referred-3/VBD||patients-2/NNS	root||ROOT-0/null||referred-3/VBD	det||programme-7/NN||the-5/DT	amod||programme-7/NN||hiv/aids-6/JJ	prep_to||referred-3/VBD||programme-7/NN	amod||care-11/NN||general-9/JJ	amod||care-11/NN||primary-10/JJ	prep_through||referred-3/VBD||care-11/NN	nn||clinics-14/NNS||intervention-13/NN	prep_at||referred-3/VBD||clinics-14/NNS	cop||likely-17/JJ||were-15/VBD	advmod||likely-17/JJ||more-16/RBR	rcmod||clinics-14/NNS||likely-17/JJ	prep_than||likely-17/JJ||those-19/DT	nn||clinics-22/NNS||control-21/NN	prep_at||those-19/DT||clinics-22/NNS	aux||receive-24/VB||to-23/TO	xcomp||likely-17/JJ||receive-24/VB	amod||prophylaxis-26/NNS||co-trimoxazole-25/JJ	dobj||receive-24/VB||prophylaxis-26/NNS	num||%-29/NN||41-28/CD	nsubj||v-34/VBP||%-29/NN	appos||%-29/NN||2253/5523-32/CD	dep||clinics-14/NNS||v-34/VBP	num||%-36/NN||32-35/CD	dobj||v-34/VBP||%-36/NN	appos||%-36/NN||1340/4210-38/CD	dep||%-36/NN||odds-41/NNS	nsubj||interval-48/VBP||ratio-42/NN	num||ratio-42/NN||1.95-43/CD	number||%-46/NN||95-45/CD	amod||confidence-47/NN||%-46/NN	appos||ratio-42/NN||confidence-47/NN	rcmod||odds-41/NNS||interval-48/VBP	number||3.40-51/CD||1.11-49/CD	dep||3.40-51/CD||to-50/TO	dobj||interval-48/VBP||3.40-51/CD	nsubj||likely-58/JJ||tuberculosis-55/NNP	nsubjpass||diagnosed-61/VBN||tuberculosis-55/NNP	cop||likely-58/JJ||was-56/VBD	advmod||likely-58/JJ||more-57/RBR	conj_and||referred-3/VBD||likely-58/JJ	aux||diagnosed-61/VBN||to-59/TO	auxpass||diagnosed-61/VBN||be-60/VB	xcomp||likely-58/JJ||diagnosed-61/VBN	prep_among||diagnosed-61/VBN||patients-63/NNS	prep_with||patients-63/NNS||hiv/aids/art-65/NN	num||%-68/NN||7-67/CD	nsubj||v-72/VBP||%-68/NN	appos||%-68/NN||417/5793-70/CD	dep||patients-63/NNS||v-72/VBP	num||%-74/NN||6-73/CD	dobj||v-72/VBP||%-74/NN	appos||%-74/NN||245/4343-76/CD	dep||%-74/NN||1.25-79/CD	number||1.55-83/CD||1.01-81/CD	dep||1.55-83/CD||to-82/TO	appos||1.25-79/CD||1.55-83/CD	aids--1||hiv--1||no||results patients referred to the hiv/aids programme through general primary care at intervention clinics were more likely than those at control clinics to receive co-trimoxazole prophylaxis (41%, (2253/5523) v 32% (1340/4210); odds ratio 1.95, 95% confidence interval 1.11 to 3.40), and tuberculosis was more likely to be diagnosed among patients with hiv/aids/art (7% (417/5793) v 6% (245/4343); 1.25, 1.01 to 1.55).
det||purpose-2/NN||the-1/DT	nsubj||is-6/VBZ||purpose-2/NN	nsubj||compare-8/VB||purpose-2/NN	det||meta-analysis-5/NNS||this-4/DT	prep_of||purpose-2/NN||meta-analysis-5/NNS	root||ROOT-0/null||is-6/VBZ	aux||compare-8/VB||to-7/TO	xcomp||is-6/VBZ||compare-8/VB	det||efficacy-10/NN||the-9/DT	dobj||compare-8/VB||efficacy-10/NN	amod||terbinafine-13/NN||continuous-12/JJ	prep_of||efficacy-10/NN||terbinafine-13/NN	amod||itraconazole-16/NN||intermittent-15/JJ	prep_with||compare-8/VB||itraconazole-16/NN	det||treatment-19/NN||the-18/DT	prep_in||compare-8/VB||treatment-19/NN	amod||onychomycosis-22/NNS||toenail-21/JJ	prep_of||treatment-19/NN||onychomycosis-22/NNS	onychomycosis-22||itraconazole-16||yes||the purpose of this meta-analysis is to compare the efficacy of continuous terbinafine with intermittent itraconazole in the treatment of toenail onychomycosis.
nsubjpass||defined-6/VBN||irondeficiency-1/NN	appos||irondeficiency-1/NN||id-3/NN	auxpass||defined-6/VBN||was-5/VBD	root||ROOT-0/null||defined-6/VBN	amod||receptor-10/NN||high-soluble-8/JJ	nn||receptor-10/NN||transferrin-9/NN	prep_as||defined-6/VBN||receptor-10/NN	dep||receptor-10/NN||stfr-12/NN	number||8.5-14/CD||>-13/CD	num||â-15/NN||8.5-14/CD	dep||stfr-12/NN||â-15/NN	npadvmod||mg/l-18/JJ||$-16/$	num||$-16/$||-17/CD	amod||â-15/NN||mg/l-18/JJ	prep||receptor-10/NN||plus-20/CC	nn||depletion-22/NN||iron-21/NN	pobj||plus-20/CC||depletion-22/NN	irondeficiency-1||iron-21||yes||irondeficiency (id) was defined as high-soluble transferrin receptor (stfr>8.5âmg/l) plus iron depletion.
det||beginning-3/NN||the-2/DT	prep_since||provided-16/VBN||beginning-3/NN	det||century-7/NN||the-5/DT	amod||century-7/NN||21st-6/JJ	prep_of||beginning-3/NN||century-7/NN	nn||assistance-10/NN||development-9/NN	nsubjpass||provided-16/VBN||assistance-10/NN	prep_for||assistance-10/NN||hiv/aids-12/NNS	aux||provided-16/VBN||has-13/VBZ	advmod||provided-16/VBN||increasingly-14/RB	auxpass||provided-16/VBN||been-15/VBN	root||ROOT-0/null||provided-16/VBN	amod||initiatives-20/NNS||global-18/JJ	nn||initiatives-20/NNS||health-19/NN	prep_through||provided-16/VBN||initiatives-20/NNS	advmod||plan-28/VBP||specifically-22/RB	det||emergency-27/NN||the-23/DT	amod||emergency-27/NN||united-24/VBN	nn||emergency-27/NN||states-25/NNS	amod||emergency-27/NN||presidential-26/JJ	nsubj||plan-28/VBP||emergency-27/NN	nsubj||fight-37/VB||emergency-27/NN	parataxis||provided-16/VBN||plan-28/VBP	nn||relief-31/NN||aids-30/NNS	prep_for||plan-28/VBP||relief-31/NN	det||fund-35/NN||the-33/DT	amod||fund-35/NN||global-34/JJ	appos||relief-31/NN||fund-35/NN	aux||fight-37/VB||to-36/TO	xcomp||plan-28/VBP||fight-37/VB	dobj||fight-37/VB||hiv-38/NN	dobj||fight-37/VB||tb-40/NN	conj_and||hiv-38/NN||tb-40/NN	dobj||fight-37/VB||malaria-42/NN	conj_and||hiv-38/NN||malaria-42/NN	det||multi-country-47/NN||the-44/DT	nn||multi-country-47/NN||world-45/NN	nn||multi-country-47/NN||bank-46/NN	nsubj||aids-48/VBZ||multi-country-47/NN	conj_and||provided-16/VBN||aids-48/VBZ	dobj||aids-48/VBZ||programme-49/NN	aids-48||hiv-38||no||since the beginning of the 21st century, development assistance for hiv/aids has increasingly been provided through global health initiatives, specifically the united states presidential emergency plan for aids relief, the global fund to fight hiv, tb and malaria and the world bank multi-country aids programme.
amod||workers-3/NNS||exposed-2/VBN	prep_among||lowered-13/VBD||workers-3/NNS	det||presence-6/NN||the-5/DT	nsubj||lowered-13/VBD||presence-6/NN	amod||evidence-9/NN||radiographic-8/JJ	prep_of||presence-6/NN||evidence-9/NN	prep_of||evidence-9/NN||asbestosis-11/NNS	advmod||lowered-13/VBD||further-12/RB	root||ROOT-0/null||lowered-13/VBD	dobj||lowered-13/VBD||fvc-14/NN	dobj||lowered-13/VBD||dlco-16/NN	conj_and||fvc-14/NN||dlco-16/NN	dobj||lowered-13/VBD||fev1/fvc-19/NNS	conj_negcc||fvc-14/NN||fev1/fvc-19/NNS	prepc_compared_to||lowered-13/VBD||to-21/TO	nn||exposure-23/NN||asbestos-22/NN	pobj||lowered-13/VBD||exposure-23/NN	amod||asbestosis-26/NNS||radiographic-25/JJ	prep_without||exposure-23/NN||asbestosis-26/NNS	asbestosis-26||asbestos-22||no||among exposed workers, the presence of radiographic evidence of asbestosis further lowered fvc and dlco but not fev1/fvc compared to asbestos exposure without radiographic asbestosis.
nsubj||cause-4/VBP||burkholderiapseudomallei-1/NNS	conj_and||burkholderiapseudomallei-1/NNS||burkholderiamallei-3/NNS	nsubj||cause-4/VBP||burkholderiamallei-3/NNS	root||ROOT-0/null||cause-4/VBP	det||diseases-6/NNS||the-5/DT	nsubj||melioidosis-7/VBZ||diseases-6/NNS	nsubj||glanders-9/VBZ||diseases-6/NNS	ccomp||cause-4/VBP||melioidosis-7/VBZ	ccomp||cause-4/VBP||glanders-9/VBZ	conj_and||melioidosis-7/VBZ||glanders-9/VBZ	advmod||cause-4/VBP||respectively-11/RB	melioidosis-7||burkholderiapseudomallei-1||no||burkholderiapseudomallei and burkholderiamallei cause the diseases melioidosis and glanders, respectively.
nsubj||evolved-14/VBN||resistance-1/NN	det||falciparum-7/NN||the-3/DT	nn||falciparum-7/NN||malaria-4/NN	nn||falciparum-7/NN||parasite-5/NN	nn||falciparum-7/NN||plasmodium-6/NN	prep_of||resistance-1/NN||falciparum-7/NN	prep_to||falciparum-7/NN||sulfadoxine-pyrimethamine-9/NN	appos||resistance-1/NN||sp-11/NN	aux||evolved-14/VBN||has-13/VBZ	root||ROOT-0/null||evolved-14/VBN	advmod||evolved-14/VBN||worldwide-15/RB	malaria-4||pyrimethamine--1||no||resistance of the malaria parasite plasmodium falciparum to sulfadoxine-pyrimethamine (sp) has evolved worldwide.
nsubj||conclude-2/VBP||we-1/PRP	root||ROOT-0/null||conclude-2/VBP	mark||based-10/VBN||that-3/IN	det||plasticity-7/NN||the-4/DT	amod||plasticity-7/NN||experience-dependent-5/JJ	amod||plasticity-7/NN||behavioral-6/JJ	nsubjpass||based-10/VBN||plasticity-7/NN	auxpass||based-10/VBN||was-8/VBD	advmod||based-10/VBN||partly-9/RB	ccomp||conclude-2/VBP||based-10/VBN	det||sensitivity-14/NN||the-12/DT	amod||sensitivity-14/NN||reduced-13/VBN	prep_on||based-10/VBN||sensitivity-14/NN	nn||neurons-18/NNS||taste-16/NN	nn||neurons-18/NNS||receptor-17/NN	prep_of||sensitivity-14/NN||neurons-18/NNS	mark||contributed-27/VBD||that-20/IN	det||desensitization-22/NN||the-21/DT	nsubj||contributed-27/VBD||desensitization-22/NN	nn||neurons-26/NNS||taste-24/NN	nn||neurons-26/NNS||receptor-25/NN	prep_of||desensitization-22/NN||neurons-26/NNS	ccomp||conclude-2/VBP||contributed-27/VBD	conj_and||based-10/VBN||contributed-27/VBD	det||cross-habituation-30/NN||the-29/DT	prep_to||contributed-27/VBD||cross-habituation-30/NN	det||chemicals-34/NNS||the-32/DT	num||chemicals-34/NNS||two-33/CD	prep_to||contributed-27/VBD||chemicals-34/NNS	habituation--1||chemicals-34||no_rel||we conclude that the experience-dependent behavioral plasticity was partly based on the reduced sensitivity of taste receptor neurons and that the desensitization of taste receptor neurons contributed to the cross-habituation to the two chemicals.
det||arginine-3/NN||the-1/DT	amod||arginine-3/NN||semi-essential-2/JJ	nsubj||provided-14/VBN||arginine-3/NN	appos||arginine-3/NN||proline-5/NN	predet||aminoacids-10/NNS||all-7/PDT	det||aminoacids-10/NNS||the-8/DT	amod||aminoacids-10/NNS||essential-9/JJ	appos||arginine-3/NN||aminoacids-10/NNS	conj_and||proline-5/NN||aminoacids-10/NNS	aux||provided-14/VBN||would-12/MD	aux||provided-14/VBN||have-13/VB	root||ROOT-0/null||provided-14/VBN	amod||benefits-17/NNS||additional-15/JJ	amod||benefits-17/NNS||nutritional-16/JJ	dobj||provided-14/VBN||benefits-17/NNS	det||recovery-21/NN||the-19/DT	amod||recovery-21/NN||rapid-20/JJ	prep_for||benefits-17/NNS||recovery-21/NN	prep_from||recovery-21/NN||scurvy-23/NN	prep_by||provided-14/VBN||vitaminc-25/NN	advmod||limited-30/VBN||when-26/WRB	nn||supply-28/NN||food-27/NN	nsubjpass||limited-30/VBN||supply-28/NN	auxpass||limited-30/VBN||was-29/VBD	advcl||provided-14/VBN||limited-30/VBN	scurvy-23||vitaminc-25||yes||the semi-essential arginine, proline and all the essential aminoacids, would have provided additional nutritional benefits for the rapid recovery from scurvy by vitaminc when food supply was limited.
num||enrichment-3/NN||three-1/CD	nn||enrichment-3/NN||hour-2/NN	nsubj||increase-16/VB||enrichment-3/NN	prep_of||enrichment-3/NN||salmonellatyphi-5/NNS	amod||broth-9/NN||tryptone-7/JJ	nn||broth-9/NN||soya-8/NN	prep_in||salmonellatyphi-5/NNS||broth-9/NN	vmod||broth-9/NN||containing-10/VBG	number||%-12/NN||2.4-11/CD	amod||bile-14/NN||%-12/NN	nn||bile-14/NN||ox-13/NN	dobj||containing-10/VBG||bile-14/NN	aux||increase-16/VB||could-15/MD	root||ROOT-0/null||increase-16/VB	det||number-19/NN||the-17/DT	amod||number-19/NN||bacterial-18/JJ	dobj||increase-16/VB||number-19/NN	num||cfu-22/NN||0.75-21/CD	prep_from||increase-16/VB||cfu-22/NN	nsubj||similar-29/JJ||cfu-22/NN	prep_per||cfu-22/NN||millilitre-24/NN	prep_of||millilitre-24/NN||blood-26/NN	cop||similar-29/JJ||is-28/VBZ	rcmod||cfu-22/NN||similar-29/JJ	amod||samples-33/NNS||clinical-31/JJ	amod||samples-33/NNS||typhoid-32/JJ	prep_to||similar-29/JJ||samples-33/NNS	det||level-36/NN||the-35/DT	prep_to||samples-33/NNS||level-36/NN	dobj||detect-41/VB||which-37/WDT	amod||pcr-39/NN||regular-38/JJ	nsubj||detect-41/VB||pcr-39/NN	aux||detect-41/VB||can-40/MD	ccomp||similar-29/JJ||detect-41/VB	typhoid-32||salmonellatyphi-5||no||three hour enrichment of salmonellatyphi in tryptone soya broth containing 2.4% ox bile could increase the bacterial number from 0.75 cfu per millilitre of blood which is similar to clinical typhoid samples to the level which regular pcr can detect.
amod||years-3/NNS||recent-2/JJ	prep_in||discussed-21/VBN||years-3/NNS	det||ways-6/NNS||the-5/DT	prep_in||interact-11/VBP||ways-6/NNS	nsubjpass||discussed-21/VBN||ways-6/NNS	amod||programs-10/NNS||hiv/aids-focused-9/JJ	nsubj||interact-11/VBP||programs-10/NNS	rcmod||ways-6/NNS||interact-11/VBP	det||delivery-14/NN||the-13/DT	prep_with||interact-11/VBP||delivery-14/NN	amod||services-18/NNS||other-16/JJ	nn||services-18/NNS||health-17/NN	prep_of||delivery-14/NN||services-18/NNS	auxpass||discussed-21/VBN||is-19/VBZ	advmod||discussed-21/VBN||often-20/RB	root||ROOT-0/null||discussed-21/VBN	det||evidence-25/NN||the-24/DT	nsubj||limited-38/JJ||evidence-25/NN	mark||strengthen-31/VBP||whether-28/IN	nn||programs-30/NNS||hiv/aids-29/NNS	nsubj||strengthen-31/VBP||programs-30/NNS	nsubj||distort-33/VBP||programs-30/NNS	prepc_as_to||evidence-25/NN||strengthen-31/VBP	prepc_as_to||evidence-25/NN||distort-33/VBP	conj_or||strengthen-31/VBP||distort-33/VBP	amod||services-36/NNS||overall-34/JJ	nn||services-36/NNS||health-35/NN	dobj||strengthen-31/VBP||services-36/NNS	cop||limited-38/JJ||is-37/VBZ	conj_but||discussed-21/VBN||limited-38/JJ	aids--1||hiv--1||no||in recent years, the ways in which hiv/aids-focused programs interact with the delivery of other health services is often discussed, but the evidence as to whether hiv/aids programs strengthen or distort overall health services is limited.
nsubj||seems-2/VBZ||it-1/PRP	root||ROOT-0/null||seems-2/VBZ	mark||prominent-19/JJ||that-3/IN	det||impact-5/NN||the-4/DT	nsubj||prominent-19/JJ||impact-5/NN	amod||polymorphism-8/NN||il28b-7/JJ	prep_of||impact-5/NN||polymorphism-8/NN	det||clearance-12/NN||the-10/DT	amod||clearance-12/NN||spontaneous-11/JJ	prep_on||polymorphism-8/NN||clearance-12/NN	nn||genotype-15/NN||hcv-14/NN	prep_of||clearance-12/NN||genotype-15/NN	num||genotype-15/NN||1-16/CD	cop||prominent-19/JJ||is-17/VBZ	advmod||prominent-19/JJ||more-18/RBR	ccomp||seems-2/VBZ||prominent-19/JJ	prep_than||prominent-19/JJ||hcv-21/NN	nsubj||results-25/VBZ||hcv-21/NN	amod||hcv-21/NN||genotype-22/JJ	dep||genotype-22/JJ||3-23/CD	rcmod||hcv-21/NN||results-25/VBZ	det||observation-28/NN||the-27/DT	prep_in||results-25/VBZ||observation-28/NN	amod||rs12979860-31/NNS||higher-30/JJR	prep_of||observation-28/NN||rs12979860-31/NNS	dep||genotype-40/VBP||c-32/SYM	amod||frequency-34/NN||allele-33/JJ	nsubj||genotype-40/VBP||frequency-34/NN	amod||patients-37/NNS||chronichepatitisc-36/JJ	prep_in||frequency-34/NN||patients-37/NNS	prep_with||patients-37/NNS||hcv-39/NN	ccomp||prominent-19/JJ||genotype-40/VBP	dobj||genotype-40/VBP||3-41/CD	nn||genotype-44/NN||hcv-43/NN	prep_than||genotype-40/VBP||genotype-44/NN	num||genotype-44/NN||1-45/CD	chronichepatitisc-36||hcv-43||no||it seems that the impact of il28b polymorphism on the spontaneous clearance of hcv genotype 1 is more prominent than hcv genotype 3 which results in the observation of higher rs12979860 c allele frequency in chronichepatitisc patients with hcv genotype 3 than hcv genotype 1.
aux||elucidate-2/VB||to-1/TO	advcl||analyzed-8/VBN||elucidate-2/VB	dobj||elucidate-2/VB||measles-3/NNS	advmod||elucidate-2/VB||immunopathology-4/RB	nsubj||analyzed-8/VBN||we-6/PRP	aux||analyzed-8/VBN||have-7/VBP	root||ROOT-0/null||analyzed-8/VBN	det||response-11/NN||the-9/DT	amod||response-11/NN||immune-10/JJ	dobj||analyzed-8/VBN||response-11/NN	prep_to||analyzed-8/VBN||measlesvirus-13/NNS	prep_in||measlesvirus-13/NNS||mice-15/NNS	amod||mice-15/NNS||transgenic-16/JJ	det||receptor-20/NN||the-18/DT	amod||receptor-20/NN||measlesvirus-19/JJ	prep_for||transgenic-16/JJ||receptor-20/NN	amod||cd150-23/NNS||human-22/JJ	appos||receptor-20/NN||cd150-23/NNS	measles-3||measlesvirus-19||no||to elucidate measles immunopathology, we have analyzed the immune response to measlesvirus in mice transgenic for the measlesvirus receptor, human cd150.
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	det||mechanisms-6/NNS||the-3/DT	amod||mechanisms-6/NNS||possible-4/JJ	amod||mechanisms-6/NNS||anti-inflammatory-5/JJ	dobj||examined-2/VBD||mechanisms-6/NNS	prep_of||mechanisms-6/NNS||gabapentin-8/NN	det||attenuation-11/NN||the-10/DT	prep_in||examined-2/VBD||attenuation-11/NN	prep_of||attenuation-11/NN||neuropathicpain-13/NN	det||interaction-16/NN||the-15/DT	prep_in||examined-2/VBD||interaction-16/NN	conj_and||attenuation-11/NN||interaction-16/NN	det||effects-20/NNS||the-18/DT	amod||effects-20/NNS||anti-allodynic-19/JJ	prep_between||interaction-16/NN||effects-20/NNS	prep_of||effects-20/NNS||gabapentin-22/NN	amod||expression-28/NN||interleukin-10-24/JJ	dep||expression-28/NN||il-10-26/JJ	prep_between||interaction-16/NN||expression-28/NN	conj_and||effects-20/NNS||expression-28/NN	det||model-32/NN||a-30/DT	nn||model-32/NN||rat-31/NN	prep_in||expression-28/NN||model-32/NN	prep_of||model-32/NN||neuropathicpain-34/NN	anti-inflammatory-5||neuropathicpain-34||no_rel||we examined the possible anti-inflammatory mechanisms of gabapentin in the attenuation of neuropathicpain and the interaction between the anti-allodynic effects of gabapentin and interleukin-10 (il-10) expression in a rat model of neuropathicpain.
aux||assess-2/VB||to-1/TO	advcl||administered-13/VBN||assess-2/VB	det||effect-4/NN||the-3/DT	dobj||assess-2/VB||effect-4/NN	det||scd-7/NN||the-6/DT	prep_of||effect-4/NN||scd-7/NN	prep_in||scd-7/NN||septicshock-9/NN	nsubjpass||administered-13/VBN||pigs-11/NNS	auxpass||administered-13/VBN||were-12/VBD	root||ROOT-0/null||administered-13/VBN	dobj||administered-13/VBN||30ã-14/NNS	num||weight-19/NN||1010-16/CD	amod||weight-19/NN||bacteria/kg-17/JJ	nn||weight-19/NN||body-18/NN	nsubjpass||placed-32/VBN||weight-19/NN	prep_of||weight-19/NN||escherichiacoli-21/NNS	prep_of||weight-19/NN||escherichiacoli-21/NNS	conj_and||escherichiacoli-21/NNS||escherichiacoli-21/NNS	det||cavity-25/NN||the-23/DT	amod||cavity-25/NN||peritoneal-24/JJ	prep_into||escherichiacoli-21/NNS||cavity-25/NN	num||hr-29/NN||1-28/CD	prep_within||escherichiacoli-21/NNS||hr-29/NN	auxpass||placed-32/VBN||were-30/VBD	advmod||placed-32/VBN||immediately-31/RB	parataxis||administered-13/VBN||placed-32/VBN	det||circuit-36/NN||an-34/DT	amod||circuit-36/NN||extracorporeal-35/JJ	prep_in||placed-32/VBN||circuit-36/NN	vmod||circuit-36/NN||containing-37/VBG	dobj||containing-37/VBG||scd-38/NN	cavity-25||bacteria--1||no||to assess the effect of the scd in septicshock, pigs were administered 30ã1010 bacteria/kg body weight of escherichiacoli into the peritoneal cavity and within 1 hr were immediately placed in an extracorporeal circuit containing scd.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubjpass||implemented-11/VBN||treatment-3/NN	prep_with||treatment-3/NN||sulphadoxine-pyrimethamine-5/NN	appos||treatment-3/NN||iptp-sp-7/NN	aux||implemented-11/VBN||is-9/VBZ	auxpass||implemented-11/VBN||being-10/VBG	root||ROOT-0/null||implemented-11/VBN	advmod||malaria-14/JJ||most-13/RBS	amod||countries-16/NNS||malaria-14/JJ	amod||countries-16/NNS||endemic-15/JJ	prep_in||implemented-11/VBN||countries-16/NNS	det||regimen-21/NN||a-18/DT	amod||regimen-21/NN||standard-19/JJ	amod||regimen-21/NN||two-doses-20/JJ	prep_as||countries-16/NNS||regimen-21/NN	mark||reduces-24/VBZ||as-22/IN	nsubj||reduces-24/VBZ||it-23/PRP	advcl||implemented-11/VBN||reduces-24/VBZ	det||risk-26/NN||the-25/DT	dobj||reduces-24/VBZ||risk-26/NN	amod||weight-30/NN||low-28/JJ	nn||weight-30/NN||birth-29/NN	prep_of||risk-26/NN||weight-30/NN	appos||weight-30/NN||lbw-32/NN	det||prevalence-36/NN||the-35/DT	dobj||reduces-24/VBZ||prevalence-36/NN	conj_and||risk-26/NN||prevalence-36/NN	amod||anaemia-39/NN||maternal-38/JJ	prep_of||prevalence-36/NN||anaemia-39/NN	malaria-14||pyrimethamine--1||yes||intermittent preventive treatment with sulphadoxine-pyrimethamine (iptp-sp) is being implemented in most malaria endemic countries as a standard two-doses regimen as it reduces the risk of low birth weight (lbw) and the prevalence of maternal anaemia.
nsubj||afflicts-7/VBZ||bovinetuberculosis-1/NNS	nsubjpass||detected-15/VBN||bovinetuberculosis-1/NNS	vmod||bovinetuberculosis-1/NNS||caused-3/VBN	agent||caused-3/VBN||mycobacteriumbovis-5/NNS	root||ROOT-0/null||afflicts-7/VBZ	quantmod||million-10/CD||approximately-8/RB	number||million-10/CD||50-9/CD	num||cattle-11/NNS||million-10/CD	dobj||afflicts-7/VBZ||cattle-11/NNS	advmod||afflicts-7/VBZ||worldwide-12/RB	auxpass||detected-15/VBN||is-14/VBZ	conj_and||afflicts-7/VBZ||detected-15/VBN	det||test-20/NN||the-17/DT	amod||test-20/NN||tuberculin-18/JJ	nn||test-20/NN||skin-19/NN	agent||detected-15/VBN||test-20/NN	appos||test-20/NN||tst-22/NN	bovinetuberculosis-1||mycobacteriumbovis-5||no||bovinetuberculosis, caused by mycobacteriumbovis , afflicts approximately 50 million cattle worldwide and is detected by the tuberculin skin test (tst).
det||findings-2/NNS||the-1/DT	nsubj||show-3/VBP||findings-2/NNS	root||ROOT-0/null||show-3/VBP	dep||exposed-13/VBN||1-4/LS	neg||facility-8/NN||no-6/DT	nn||facility-8/NN||health-7/NN	nsubjpass||exposed-13/VBN||facility-8/NN	nn||worker-11/NN||health-10/NN	conj_or||facility-8/NN||worker-11/NN	nsubjpass||exposed-13/VBN||worker-11/NN	auxpass||exposed-13/VBN||was-12/VBD	dep||show-3/VBP||exposed-13/VBN	det||components-16/NNS||all-15/DT	prep_to||exposed-13/VBN||components-16/NNS	det||intervention-19/NN||the-18/DT	prep_of||components-16/NNS||intervention-19/NN	dep||proportion-24/NN||2-21/LS	det||proportion-24/NN||the-23/DT	dep||intervention-19/NN||proportion-24/NN	nn||workers-27/NNS||health-26/NN	prep_of||proportion-24/NN||workers-27/NNS	nsubj||received-29/VBD||workers-27/NNS	rcmod||workers-27/NNS||received-29/VBD	det||training-33/NN||the-30/DT	amod||training-33/NN||enhanced-31/JJ	amod||training-33/NN||in-service-32/JJ	nsubj||%-36/NN||training-33/NN	cop||%-36/NN||was-34/VBD	num||%-36/NN||67-35/CD	ccomp||received-29/VBD||%-36/NN	dep||proportion-41/NN||3-38/LS	det||proportion-41/NN||the-40/DT	prep_of||proportion-24/NN||proportion-41/NN	conj_and||workers-27/NNS||proportion-41/NN	nsubj||received-29/VBD||proportion-41/NN	amod||children-44/NNS||febrile-43/JJ	prep_of||proportion-41/NN||children-44/NNS	amod||malaria-47/NN||uncomplicated-46/JJ	prep_with||children-44/NNS||malaria-47/NN	vmod||malaria-47/NN||treated-48/VBN	det||drug-53/NN||the-50/DT	amod||drug-53/NN||first-line-51/JJ	amod||drug-53/NN||anti-malarial-52/JJ	prep_with||treated-48/VBN||drug-53/NN	appos||drug-53/NN||artemether-lumefantrine-55/NN	appos||artemether-lumefantrine-55/NN||al-57/NNP	nn||facilities-62/NNS||health-61/NN	prep_at||treated-48/VBN||facilities-62/NNS	advmod||was-65/VBD||where-63/WRB	nsubj||was-65/VBD||al-64/NNP	advcl||treated-48/VBN||was-65/VBD	prep_in||was-65/VBD||stock-67/NN	vmod||stock-67/NN||increased-68/VBN	num||%-71/NN||76.9-70/CD	prep_from||increased-68/VBN||%-71/NN	num||%-74/NN||95-73/CD	dep||%-71/NN||%-74/NN	dep||%-74/NN||ci-75/NNP	num||ci-75/NNP||69.4-76/CD	num||ci-75/NNP||83.1-78/CD	num||%-82/NN||87.6-81/CD	prep_to||increased-68/VBN||%-82/NN	num||%-85/NN||95-84/CD	dep||%-82/NN||%-85/NN	number||82.5-87/CD||ci-86/CD	num||%-85/NN||82.5-87/CD	amod||%-85/NN||91.5-89/CD	dep||were-95/VBD||4-92/LS	expl||were-95/VBD||there-94/EX	parataxis||was-65/VBD||were-95/VBD	amod||improvements-99/NNS||modest-96/JJ	conj_but||modest-96/JJ||non-significant-98/JJ	amod||improvements-99/NNS||non-significant-98/JJ	nsubj||were-95/VBD||improvements-99/NNS	prepc_in||were-95/VBD||dispensing-101/VBG	prepc_in||were-95/VBD||counseling-103/VBG	conj_and||dispensing-101/VBG||counseling-103/VBG	dobj||dispensing-101/VBG||practices-104/NNS	prep_of||proportion-24/NN||5-107/CD	conj_and||workers-27/NNS||5-107/CD	nsubj||received-29/VBD||5-107/CD	advmod||restricted-113/VBN||when-109/WRB	det||analyses-111/NNS||the-110/DT	nsubjpass||restricted-113/VBN||analyses-111/NNS	auxpass||restricted-113/VBN||were-112/VBD	advcl||exposed-13/VBN||restricted-113/VBN	nn||workers-116/NNS||health-115/NN	prep_to||restricted-113/VBN||workers-116/NNS	nsubj||received-118/VBD||workers-116/NNS	nsubj||received-125/VBN||workers-116/NNS	rcmod||workers-116/NNS||received-118/VBD	det||training-122/NN||the-119/DT	amod||training-122/NN||enhanced-120/JJ	amod||training-122/NN||in-service-121/JJ	dobj||received-118/VBD||training-122/NN	aux||received-125/VBN||had-124/VBD	rcmod||workers-116/NNS||received-125/VBN	conj_and/or||received-118/VBD||received-125/VBN	amod||guidelines-127/NNS||new-126/JJ	dobj||received-125/VBN||guidelines-127/NNS	nn||aids-130/NNS||job-129/NN	nsubjpass||observed-140/VBN||aids-130/NNS	neg||improvements-134/NNS||no-132/DT	amod||improvements-134/NNS||significant-133/JJ	appos||aids-130/NNS||improvements-134/NNS	amod||tasks-138/NNS||reported-136/JJ	amod||tasks-138/NNS||case-management-137/JJ	prep_in||improvements-134/NNS||tasks-138/NNS	auxpass||observed-140/VBN||were-139/VBD	dep||show-3/VBP||observed-140/VBN	conj_and||exposed-13/VBN||observed-140/VBN	prepc_compared_to||observed-140/VBN||to-142/TO	pobj||observed-140/VBN||baseline-143/NN	malaria-47||lumefantrine--1||yes||the findings show 1) no health facility or health worker was exposed to all components of the intervention; 2) the proportion of health workers who received the enhanced in-service training was 67%; 3) the proportion of febrile children with uncomplicated malaria treated with the first-line anti-malarial drug, artemether-lumefantrine (al), at health facilities where al was in stock increased from 76.9% (95%ci 69.4, 83.1) to 87.6% (95% ci 82.5, 91.5); 4) there were modest but non-significant improvements in dispensing and counseling practices; and 5) when the analyses were restricted to health workers who received the enhanced in-service training and/or had received new guidelines and job aids, no significant improvements in reported case-management tasks were observed compared to baseline.
nn||design-2/NN||research-1/NN	nsubj||â-5/VBP||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||â-5/VBP||methods-4/NNS	root||ROOT-0/null||â-5/VBP	dobj||â-5/VBP||$-6/$	nsubj||study-15/NN||this-8/DT	cop||study-15/NN||was-9/VBD	det||study-15/NN||a-10/DT	amod||study-15/NN||randomized-11/VBN	amod||study-15/NN||double-blind-12/JJ	nn||study-15/NN||crossover-13/NN	nn||study-15/NN||pilot-14/NN	rcmod||$-6/$||study-15/NN	dep||study-15/NN||placebo-17/NN	num||terbutaline-21/NN||2.5-19/CD	nn||terbutaline-21/NN||mg-20/NN	dep||study-15/NN||terbutaline-21/NN	conj_and||placebo-17/NN||terbutaline-21/NN	num||terbutaline-26/NN||5.0-24/CD	nn||terbutaline-26/NN||mg-25/NN	dep||study-15/NN||terbutaline-26/NN	conj_and||placebo-17/NN||terbutaline-26/NN	num||patients-30/NNS||15-29/CD	prep_in||study-15/NN||patients-30/NNS	prep_with||patients-30/NNS||type1diabetes-32/CD	terbutaline-26||type1diabetes-32||no_rel||research design and methods âthis was a randomized double-blind crossover pilot study (placebo, 2.5 mg terbutaline, and 5.0 mg terbutaline) in 15 patients with type1diabetes.
nn||models-3/NNS||animal-2/NN	prep_in||attenuated-25/VBN||models-3/NNS	det||number-7/NN||a-5/DT	amod||number-7/NN||limited-6/JJ	conj_and||models-3/NNS||number-7/NN	prep_in||attenuated-25/VBN||number-7/NN	amod||studies-10/NNS||human-9/JJ	prep_of||number-7/NN||studies-10/NNS	vmod||studies-10/NNS||carried-11/VBN	prt||carried-11/VBN||out-12/RP	advmod||far-14/RB||so-13/RB	advmod||carried-11/VBN||far-14/RB	nsubj||attenuated-25/VBN||polyphenols-16/NNS	conj_and||polyphenols-16/NNS||foods-18/NNS	nsubj||attenuated-25/VBN||foods-18/NNS	conj_and||polyphenols-16/NNS||beverages-20/NNS	conj_or||foods-18/NNS||beverages-20/NNS	amod||foods-18/NNS||rich-21/JJ	prep_in||rich-21/JJ||polyphenols-23/NNS	aux||attenuated-25/VBN||have-24/VBP	root||ROOT-0/null||attenuated-25/VBN	amod||responses-28/NNS||postprandial-26/JJ	amod||responses-28/NNS||glycemic-27/JJ	dobj||attenuated-25/VBN||responses-28/NNS	amod||hyperglycemia-31/NN||fasting-30/VBG	dobj||attenuated-25/VBN||hyperglycemia-31/NN	conj_and||responses-28/NNS||hyperglycemia-31/NN	amod||secretion-37/NN||improved-34/VBN	amod||secretion-37/NN||acute-35/JJ	nn||secretion-37/NN||insulin-36/NN	dobj||attenuated-25/VBN||secretion-37/NN	conj_and||responses-28/NNS||secretion-37/NN	nn||sensitivity-40/NN||insulin-39/NN	conj_and||responses-28/NNS||sensitivity-40/NN	conj_and||secretion-37/NN||sensitivity-40/NN	hyperglycemia-31||insulin-39||yes||in animal models and a limited number of human studies carried out so far, polyphenols and foods or beverages rich in polyphenols have attenuated postprandial glycemic responses and fasting hyperglycemia, and improved acute insulin secretion and insulin sensitivity.
root||ROOT-0/null||delayed-1/VBN	nn||results-4/NNS||insulin-2/NN	nn||results-4/NNS||secretion-3/NN	dobj||delayed-1/VBN||results-4/NNS	amod||concentrations-9/NNS||higher-6/JJR	nn||concentrations-9/NNS||peak-7/NN	nn||concentrations-9/NNS||glucose-8/NN	prep_in||results-4/NNS||concentrations-9/NNS	advmod||delayed-1/VBN||particularly-10/RB	advmod||impaired-16/JJ||when-11/WRB	nsubj||impaired-16/JJ||suppression-12/NN	prep_of||suppression-12/NN||glucagon-14/NN	cop||impaired-16/JJ||is-15/VBZ	advcl||delayed-1/VBN||impaired-16/JJ	mark||insulinresistance-19/JJ||whereas-18/IN	advcl||impaired-16/JJ||insulinresistance-19/JJ	dep||delayed-1/VBN||prolongs-20/VBZ	det||duration-22/NN||the-21/DT	nsubj||delayed-1/VBN||duration-22/NN	nsubjpass||marked-29/VBN||duration-22/NN	prep_of||duration-22/NN||hyperglycemia-24/NN	aux||marked-29/VBN||can-27/MD	auxpass||marked-29/VBN||be-28/VB	rcmod||duration-22/NN||marked-29/VBN	advmod||present-37/JJ||when-30/WRB	det||insulinresistance-35/NN||both-31/DT	amod||insulinresistance-35/NN||hepatic-32/JJ	conj_and||hepatic-32/JJ||extra-hepatic-34/JJ	amod||insulinresistance-35/NN||extra-hepatic-34/JJ	nsubj||present-37/JJ||insulinresistance-35/NN	cop||present-37/JJ||are-36/VBP	advcl||marked-29/VBN||present-37/JJ	hyperglycemia-24||glucose-8||no||delayed insulin secretion results in higher peak glucose concentrations particularly when suppression of glucagon is impaired, whereas insulinresistance prolongs the duration of hyperglycemia, which can be marked when both hepatic and extra-hepatic insulinresistance are present.
nsubj||heparin-6/NN||enoxaparin-1/NN	cop||heparin-6/NN||is-2/VBZ	det||heparin-6/NN||the-3/DT	advmod||heparin-6/NN||only-4/RB	amod||heparin-6/NN||low-molecular-weight-5/JJ	root||ROOT-0/null||heparin-6/NN	nsubjpass||licensed-9/VBN||heparin-6/NN	auxpass||licensed-9/VBN||is-8/VBZ	rcmod||heparin-6/NN||licensed-9/VBN	det||prophylaxis-14/NNS||both-11/DT	amod||prophylaxis-14/NNS||venous-12/JJ	nn||prophylaxis-14/NNS||thromboembolism-13/NN	prep_for||licensed-9/VBN||prophylaxis-14/NNS	prep_for||licensed-9/VBN||treatment-16/NN	conj_and||prophylaxis-14/NNS||treatment-16/NN	thromboembolism-13||heparin-6||yes||enoxaparin is the only low-molecular-weight heparin that is licensed for both venous thromboembolism prophylaxis and treatment.
det||efficacy-3/NN||the-1/DT	amod||efficacy-3/NN||variable-2/JJ	nsubj||necessitates-28/VBZ||efficacy-3/NN	quantmod||$-6/$||0â-5/RB	num||%-9/NN||$-6/$	num||$-6/$||80-8/CD	appos||efficacy-3/NN||%-9/NN	nn||©-16/FW||mycobacteriumbovis-12/FW	nn||©-16/FW||bacille-13/FW	nn||©-16/FW||calmette-14/FW	nn||©-16/FW||gurã-15/FW	prep_of||efficacy-3/NN||©-16/FW	discourse||vaccine-21/NN||bcg-19/UH	prep_in||©-16/FW||vaccine-21/NN	amod||tuberculosis-24/NNP||adult-23/JJ	prep_against||efficacy-3/NN||tuberculosis-24/NNP	discourse||efficacy-3/NN||tb-26/UH	root||ROOT-0/null||necessitates-28/VBZ	dobj||necessitates-28/VBZ||development-29/NN	amod||candidates-33/NNS||alternative-31/JJ	nn||candidates-33/NNS||vaccine-32/NN	prep_of||development-29/NN||candidates-33/NNS	tuberculosis-24||bcg-19||yes||the variable efficacy (0â80%) of mycobacteriumbovis bacille calmette gurã©in (bcg) vaccine against adult tuberculosis (tb) necessitates development of alternative vaccine candidates.
det||study-8/NN||a-2/DT	amod||study-8/NN||prospective-3/JJ	amod||study-8/NN||multicenter-5/JJ	amod||study-8/NN||epidemiological-7/JJ	prep_in||screened-50/VBN||study-8/NN	det||prevalence-11/NN||the-10/DT	prep_of||study-8/NN||prevalence-11/NN	nsubjpass||screened-50/VBN||seasonality-13/NN	nsubjpass||tested-52/VBN||seasonality-13/NN	amod||occurrence-17/NN||peak-16/JJ	conj_and||seasonality-13/NN||occurrence-17/NN	nsubjpass||screened-50/VBN||occurrence-17/NN	prep_of||occurrence-17/NN||rsvinfection-19/NN	appos||rsvinfection-19/NN||children-21/NNS	vmod||children-21/NNS||aged-22/VBN	nn||years-27/NNS||â-23/NNP	nn||years-27/NNS||-24/NNP	amod||years-27/NNS||$-25/$	number||$-25/$||2-26/CD	nsubj||hospitalized-28/VBN||years-27/NNS	dep||aged-22/VBN||hospitalized-28/VBN	amod||infections-33/NNS||lower-30/JJR	amod||infections-33/NNS||respiratory-31/JJ	nn||infections-33/NNS||tract-32/NN	prep_for||hospitalized-28/VBN||infections-33/NNS	num||regions-36/NNS||three-35/CD	prep_in||infections-33/NNS||regions-36/NNS	det||federation-40/NN||the-38/DT	nn||federation-40/NN||russian-39/NN	prep_of||regions-36/NNS||federation-40/NN	prep_from||hospitalized-28/VBN||september-43/NNP	num||september-43/NNP||2008-44/CD	prep_through||aged-22/VBN||april-46/NNP	num||april-46/NNP||2009-47/CD	auxpass||screened-50/VBN||were-49/VBD	root||ROOT-0/null||screened-50/VBN	conj_and||screened-50/VBN||tested-52/VBN	prep_for||screened-50/VBN||rsv-54/NN	vmod||rsv-54/NN||using-55/VBG	amod||immunochromatography-57/NN||rapid-56/JJ	dobj||using-55/VBG||immunochromatography-57/NN	amod||lavage-60/NN||nasopharyngeal-59/JJ	prep_of||immunochromatography-57/NN||lavage-60/NN	rsvinfection-19||rsv-54||no||in a prospective, multicenter, epidemiological study of the prevalence, seasonality, and peak occurrence of rsvinfection, children aged â¤2 years hospitalized for lower respiratory tract infections in three regions of the russian federation, from september 2008 through april 2009, were screened and tested for rsv using rapid immunochromatography of nasopharyngeal lavage.
det||study-2/NN||this-1/DT	nsubj||assessed-3/VBD||study-2/NN	root||ROOT-0/null||assessed-3/VBD	det||effect-5/NN||the-4/DT	dobj||assessed-3/VBD||effect-5/NN	amod||polymorphisms-8/NNS||glp1r-7/JJ	prep_of||effect-5/NN||polymorphisms-8/NNS	nn||secretion-11/NN||insulin-10/NN	prep_on||assessed-3/VBD||secretion-11/NN	prep_in||secretion-11/NN||response-13/NN	prep_to||assessed-3/VBD||hyperglycemia-15/NN	prep_to||assessed-3/VBD||infused-18/NNP	conj_and||hyperglycemia-15/NN||infused-18/NNP	num||infused-18/NNP||glp-1-19/CD	amod||subjects-22/NNS||nondiabetic-21/JJ	prep_in||assessed-3/VBD||subjects-22/NNS	hyperglycemia-15||insulin-10||yes||this study assessed the effect of glp1r polymorphisms on insulin secretion in response to hyperglycemia and to infused glp-1 in nondiabetic subjects.
nsubjpass||allocated-17/VBN||patients-1/NNS	nsubj||receive-19/VB||patients-1/NNS	conj_and||patients-1/NNS||methods-3/NNS	nsubjpass||allocated-17/VBN||methods-3/NNS	nsubj||receive-19/VB||methods-3/NNS	number||hundred-5/CD||two-4/CD	dep||patients-1/NNS||hundred-5/CD	amod||patients-9/NNS||thirty-six-7/JJ	amod||patients-9/NNS||chemotherapy-naive-8/JJ	conj_and||patients-1/NNS||patients-9/NNS	nsubjpass||allocated-17/VBN||patients-9/NNS	nsubj||receive-19/VB||patients-9/NNS	amod||cancer-14/NN||inoperable-11/JJ	amod||cancer-14/NN||non-small-cell-12/JJ	nn||cancer-14/NN||lung-13/NN	prep_with||patients-9/NNS||cancer-14/NN	auxpass||allocated-17/VBN||were-15/VBD	advmod||allocated-17/VBN||randomly-16/RB	root||ROOT-0/null||allocated-17/VBN	aux||receive-19/VB||to-18/TO	xcomp||allocated-17/VBN||receive-19/VB	preconj||mg/m2-22/NNS||either-20/CC	num||mg/m2-22/NNS||200-21/CD	dobj||receive-19/VB||mg/m2-22/NNS	amod||cisplatin-25/NN||liposomal-24/JJ	prep_of||mg/m2-22/NNS||cisplatin-25/NN	num||paclitaxel-29/NN||135-27/CD	amod||paclitaxel-29/NN||mg/m2-28/JJ	prep_of||mg/m2-22/NNS||paclitaxel-29/NN	conj_and||cisplatin-25/NN||paclitaxel-29/NN	dep||paclitaxel-29/NN||arm-31/NN	dep||arm-31/NN||a-32/DT	num||cisplatin-37/NN||75-35/CD	amod||cisplatin-37/NN||mg/m2-36/JJ	dobj||receive-19/VB||cisplatin-37/NN	conj_or||mg/m2-22/NNS||cisplatin-37/NN	num||paclitaxel-41/NN||135-39/CD	amod||paclitaxel-41/NN||mg/m2-40/JJ	conj_or||mg/m2-22/NNS||paclitaxel-41/NN	conj_and||cisplatin-37/NN||paclitaxel-41/NN	appos||paclitaxel-41/NN||arm-43/NN	num||arm-43/NN||b-44/CD	advmod||mg/m2-22/NNS||once-47/RB	det||weeks-50/NNS||every-48/DT	num||weeks-50/NNS||2-49/CD	tmod||receive-19/VB||weeks-50/NNS	det||basis-54/NN||an-52/DT	nn||basis-54/NN||outpatient-53/NN	prep_on||receive-19/VB||basis-54/NN	cancer-14||paclitaxel-41||no_rel||patients and methods two hundred and thirty-six chemotherapy-naive patients with inoperable non-small-cell lung cancer were randomly allocated to receive either 200 mg/m2 of liposomal cisplatin and 135 mg/m2 paclitaxel (arm a) or 75 mg/m2 cisplatin and 135 mg/m2 paclitaxel (arm b), once every 2 weeks on an outpatient basis.
nn||detemir-2/NN||insulin-1/NN	nsubj||has-3/VBZ||detemir-2/NN	root||ROOT-0/null||has-3/VBZ	amod||variability-6/NN||lower-4/JJR	amod||variability-6/NN||glycemic-5/JJ	dobj||has-3/VBZ||variability-6/NN	amod||variability-11/NN||less-9/JJR	amod||variability-11/NN||intra-subject-10/JJ	prep_with||variability-6/NN||variability-11/NN	amod||levels-14/NNS||bloodglucose-13/JJ	prep_in||variability-11/NN||levels-14/NNS	prep_in||has-3/VBZ||patients-16/NNS	prep_with||patients-16/NNS||type-18/NN	num||type-18/NN||1-19/CD	prep_with||patients-16/NNS||type2diabetes-21/NNS	conj_and||type-18/NN||type2diabetes-21/NNS	prepc_without||has-3/VBZ||increasing-24/VBG	det||risk-26/NN||the-25/DT	dobj||increasing-24/VBG||risk-26/NN	prep_of||risk-26/NN||hypoglycemia-28/NN	type2diabetes-21||insulin-1||yes||insulin detemir has lower glycemic variability, with less intra-subject variability in bloodglucose levels in patients with type 1 and type2diabetes, without increasing the risk of hypoglycemia.
det||use-3/NN||the-2/DT	prep_through||compared-15/VBD||use-3/NN	amod||gold-6/NN||quantiferon-tb-5/JJ	prep_of||use-3/NN||gold-6/NN	det||assay-12/NN||a-8/DT	amod||assay-12/NN||commercial-9/JJ	nn||assay-12/NN||ifn-î-10/NNP	nn||assay-12/NN||³-11/NNP	appos||gold-6/NN||assay-12/NN	nsubj||compared-15/VBD||we-14/PRP	root||ROOT-0/null||compared-15/VBD	dobj||compared-15/VBD||differences-16/NNS	amod||responses-20/NNS||quantitative-18/JJ	amod||responses-20/NNS||t-cell-19/JJ	prep_in||compared-15/VBD||responses-20/NNS	prep_to||compared-15/VBD||mycobacteriumtuberculosis-22/NNS	appos||mycobacteriumtuberculosis-22/NNS||mtb-24/NN	amod||antigens-28/NNS||specific-27/JJ	nsubj||quantiferon-30/VB||antigens-28/NNS	advmod||quantiferon-30/VB||-LSB--29/RB	parataxis||compared-15/VBD||quantiferon-30/VB	amod||disease-44/NN||tb-2g-31/JJ	dep||disease-44/NN||qft-2g-33/JJ	amod||disease-44/NN||-RSB--35/JJ	prep_between||-RSB--35/JJ||patients-37/NNS	amod||tuberculosis-40/NNP||active-39/JJ	prep_with||patients-37/NNS||tuberculosis-40/NNP	dep||patients-37/NNS||tb-42/VBN	dobj||quantiferon-30/VB||disease-44/NN	dobj||quantiferon-30/VB||those-46/DT	conj_and||disease-44/NN||those-46/DT	nn||infection-50/NN||latent-48/NN	nn||infection-50/NN||tb-49/NN	prep_with||those-46/DT||infection-50/NN	appos||infection-50/NN||ltbi-52/NNP	tb-49||mtb-24||no||through the use of quantiferon-tb gold, a commercial ifn-î³ assay, we compared differences in quantitative t-cell responses to mycobacteriumtuberculosis (mtb)-specific antigens [quantiferon tb-2g (qft-2g)] between patients with active tuberculosis (tb) disease and those with latent tb infection (ltbi).
nn||concentration-2/NN||muscle-1/NN	nsubj||different-18/JJ||concentration-2/NN	prep_of||concentration-2/NN||acylcarnitines-4/NNS	det||oxidation-14/NN||a-6/DT	dep||oxidation-14/NN||lipid-7/NNP	dep||lipid-7/NNP||intermediate-8/NNP	amod||²-12/NNS||fattyacid-10/JJ	nn||²-12/NNS||î-11/NN	prep_in||lipid-7/NNP||²-12/NNS	appos||concentration-2/NN||oxidation-14/NN	cop||different-18/JJ||was-16/VBD	neg||different-18/JJ||not-17/RB	root||ROOT-0/null||different-18/JJ	det||groups-22/NNS||the-20/DT	amod||groups-22/NNS||hpmc-21/JJ	prep_between||different-18/JJ||groups-22/NNS	nn||control-25/NN||obese-24/NN	prep_between||different-18/JJ||control-25/NN	conj_and||groups-22/NNS||control-25/NN	xcomp||different-18/JJ||suggesting-27/VBG	neg||oxidation-33/NN||no-28/DT	dep||oxidation-33/NN||change-29/NN	prep_in||change-29/NN||muscle-31/NN	amod||oxidation-33/NN||fattyacid-32/JJ	dobj||suggesting-27/VBG||oxidation-33/NN	prep_by||oxidation-33/NN||hpmc-35/NN	fattyacid-32||obese-24||no_rel||muscle concentration of acylcarnitines, a lipid intermediate in fattyacid î²-oxidation, was not different between the hpmc groups and obese control, suggesting no change in muscle fattyacid oxidation by hpmc.
amod||nanotube-4/NN||single-1/JJ	nn||nanotube-4/NN||wall-2/NN	nn||nanotube-4/NN||carbon-3/NN	nn||constructs-8/NNS||nanotube-4/NN	appos||constructs-8/NNS||swcnt-6/NN	nsubjpass||appended-11/VBN||constructs-8/NNS	auxpass||appended-11/VBN||were-9/VBD	advmod||appended-11/VBN||covalently-10/RB	root||ROOT-0/null||appended-11/VBN	amod||chelates-14/NNS||radiometal-ion-13/JJ	prep_with||appended-11/VBN||chelates-14/NNS	amod||,4,7,10-17/CD||1,4,7,10-tetraazacyclododecane-1-16/JJ	dep||chelates-14/NNS||,4,7,10-17/CD	amod||-RSB--23/NNP||tetraacetic-19/JJ	amod||-RSB--23/NNP||acid-20/JJ	nn||-RSB--23/NNP||-LSB--21/NNP	nn||-RSB--23/NNP||dota-22/NNP	dep||,4,7,10-17/CD||-RSB--23/NNP	amod||-RSB--28/NNS||desferrioxamineb-25/JJ	amod||-RSB--28/NNS||-LSB--26/JJ	nn||-RSB--28/NNS||dfo-27/NN	dep||,4,7,10-17/CD||-RSB--28/NNS	conj_or||-RSB--23/NNP||-RSB--28/NNS	det||tumor-32/NN||the-31/DT	prep_with||appended-11/VBN||tumor-32/NN	conj_and||chelates-14/NNS||tumor-32/NN	amod||e4g10-35/NNS||neovascular-targeting-33/JJ	nn||e4g10-35/NNS||antibody-34/NN	dep||tumor-32/NN||e4g10-35/NNS	desferrioxamineb-25||tumor-32||no_rel||single wall carbon nanotube (swcnt) constructs were covalently appended with radiometal-ion chelates (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [dota] or desferrioxamineb [dfo]) and the tumor neovascular-targeting antibody e4g10.
det||involvement-9/NN||a-1/DT	amod||involvement-9/NN||patient-2/JJ	amod||chest-7/NN||extensive-4/JJ	conj_and||extensive-4/JJ||painful-6/JJ	amod||chest-7/NN||painful-6/JJ	prep_with||patient-2/JJ||chest-7/NN	nn||involvement-9/NN||wall-8/NN	nsubjpass||treated-19/VBN||involvement-9/NN	det||cancer-14/NN||a-11/DT	amod||cancer-14/NN||metastatic-12/JJ	nn||cancer-14/NN||borderline-13/NN	prep_from||involvement-9/NN||cancer-14/NN	det||ovary-17/NN||the-16/DT	prep_of||cancer-14/NN||ovary-17/NN	auxpass||treated-19/VBN||was-18/VBD	root||ROOT-0/null||treated-19/VBN	det||carboplatin-22/JJ||a-21/DT	prep_with||treated-19/VBN||carboplatin-22/JJ	amod||regimen-26/NN||paclitaxel-24/JJ	amod||regimen-26/NN||chemotherapy-25/JJ	prep_with||treated-19/VBN||regimen-26/NN	conj_plus||carboplatin-22/JJ||regimen-26/NN	cancer-14||paclitaxel-24||no_rel||a patient with extensive and painful chest wall involvement from a metastatic borderline cancer of the ovary was treated with a carboplatin plus paclitaxel chemotherapy regimen.
amod||necrosis-4/NNS||interleukin-12p70-1/JJ	conj_and||interleukin-12p70-1/JJ||tumor-3/NN	amod||necrosis-4/NNS||tumor-3/NN	nsubj||factor-î-5/VBD||necrosis-4/NNS	root||ROOT-0/null||factor-î-5/VBD	amod||expression-7/NN||±-6/JJ	nsubj||lower-10/JJR||expression-7/NN	cop||lower-10/JJR||was-8/VBD	advmod||lower-10/JJR||significantly-9/RB	ccomp||factor-î-5/VBD||lower-10/JJR	prep_in||lower-10/JJR||patients-12/NNS	nn||â-15/NN||p-14/NN	dep||patients-12/NNS||â-15/NN	dep||â-17/NN||=-16/SYM	rcmod||â-15/NN||â-17/NN	num||â-17/NN||0.0039-18/CD	dep||patients-12/NNS||p-20/NN	conj_and||â-15/NN||p-20/NN	number||0.001-22/CD||<-21/CD	dep||p-20/NN||0.001-22/CD	prepc_compared_to||lower-10/JJR||to-25/TO	amod||controls-27/NNS||healthy-26/JJ	pobj||lower-10/JJR||controls-27/NNS	mark||higher-35/JJR||while-29/IN	amod||production-32/NN||granulocyte-30/JJ	amod||production-32/NN||colony-stimulatingfactor-31/JJ	nsubj||higher-35/JJR||production-32/NN	cop||higher-35/JJR||was-33/VBD	advmod||higher-35/JJR||markedly-34/RB	advcl||lower-10/JJR||higher-35/JJR	prep_in||higher-35/JJR||patients-37/NNS	dep||higher-35/JJR||p-39/NNP	number||0.001-41/CD||<-40/CD	num||p-39/NNP||0.001-41/CD	colony-stimulatingfactor-31||tumor-3||no_rel||interleukin-12p70 and tumor necrosis factor-î± expression was significantly lower in patients ( p â =â 0.0039 and p <0.001) compared to healthy controls, while granulocyte colony-stimulatingfactor production was markedly higher in patients ( p <0.001).
nn||chemotherapy-3/NN||conclusion-1/NN	amod||chemotherapy-3/NN||topical-2/JJ	nsubj||alternatives-11/NNS||chemotherapy-3/NN	prep_with||chemotherapy-3/NN||imiquimod-5/NN	prep_with||chemotherapy-3/NN||5-fluorouracil-7/NN	conj_or||imiquimod-5/NN||5-fluorouracil-7/NN	aux||alternatives-11/NNS||may-8/MD	cop||alternatives-11/NNS||be-9/VB	amod||alternatives-11/NNS||valuable-10/JJ	root||ROOT-0/null||alternatives-11/NNS	conj_or||alternatives-11/NNS||adjuncts-13/NNS	prep||alternatives-11/NNS||given-15/VBN	det||likelihood-18/NN||the-16/DT	amod||likelihood-18/NN||increased-17/VBN	pobj||given-15/VBN||likelihood-18/NN	prep_of||likelihood-18/NN||recurrence-20/NN	amod||excision-23/NN||surgical-22/JJ	prep_after||recurrence-20/NN||excision-23/NN	amod||basalcellcarcinoma-27/NN||superficial-25/JJ	amod||basalcellcarcinoma-27/NN||spreading-26/JJ	prep_of||excision-23/NN||basalcellcarcinoma-27/NN	basalcellcarcinoma-27||5-fluorouracil-7||yes||conclusion topical chemotherapy with imiquimod or 5-fluorouracil may be valuable alternatives or adjuncts, given the increased likelihood of recurrence after surgical excision of superficial spreading basalcellcarcinoma.
nsubjpass||piloted-16/VBN||the-1/DT	amod||the-1/DT||triggering-2/VBG	prep_of||the-1/DT||pain-4/NN	preconj||pain-4/NN||either-5/CC	prep_by||pain-4/NN||c-7/NN	prep_by||pain-4/NN||aî-11/NN	conj_or||c-7/NN||aî-11/NN	dep||pain-4/NN||´-12/NNP	dep||´-12/NNP||fibers-14/NNS	auxpass||piloted-16/VBN||was-15/VBD	root||ROOT-0/null||piloted-16/VBN	amod||factors-19/NNS||several-18/JJ	agent||piloted-16/VBN||factors-19/NNS	det||rate-23/NN||the-21/DT	amod||rate-23/NN||low/high-22/JJ	prep_including||factors-19/NNS||rate-23/NN	prep_of||rate-23/NN||stimulation-25/NN	det||temperature-30/NN||the-27/DT	amod||temperature-30/NN||low/high-28/JJ	nn||temperature-30/NN||base-29/NN	appos||stimulation-25/NN||temperature-30/NN	det||skin-33/NN||the-32/DT	prep_of||temperature-30/NN||skin-33/NN	det||path-39/NN||the-35/DT	amod||path-39/NN||short/long-36/VBG	amod||path-39/NN||peripheral-37/JJ	nn||path-39/NN||nerve-38/NN	prep_of||temperature-30/NN||path-39/NN	conj_and||skin-33/NN||path-39/NN	det||-rrb--47/NN||some-41/DT	amod||-rrb--47/NN||pharmacological-42/JJ	nn||-rrb--47/NN||manipulations-43/NNP	nn||-rrb--47/NN||-lrb--44/NNP	nn||-rrb--47/NN||e.g.-45/NNP	nn||-rrb--47/NN||capsaicin-46/NN	prep_of||temperature-30/NN||-rrb--47/NN	conj_and||skin-33/NN||-rrb--47/NN	pain-4||capsaicin-46||yes||the triggering of pain either by c - or by aî ´ - fibers was piloted by several factors including the low/high rate of stimulation , the low/high base temperature of the skin , the short/long peripheral nerve path and some pharmacological manipulations -lrb- e.g. capsaicin -rrb- .
det||report-3/NN||this-1/DT	nn||report-3/NN||case-2/NN	nsubj||describes-4/VBZ||report-3/NN	root||ROOT-0/null||describes-4/VBZ	det||male-7/NN||a-5/DT	amod||male-7/NN||25-year-old-6/JJ	dobj||describes-4/VBZ||male-7/NN	nsubj||developed-9/VBD||male-7/NN	rcmod||male-7/NN||developed-9/VBD	dobj||developed-9/VBD||obsessive-compulsivedisorder-10/NN	det||age-13/NN||the-12/DT	prep_at||developed-9/VBD||age-13/NN	num||years-16/NNS||23-15/CD	prep_of||age-13/NN||years-16/NNS	nn||treatment-19/NN||isotretinoin-18/NN	prep_following||years-16/NNS||treatment-19/NN	prep_for||treatment-19/NN||acne-21/NN	dep||acne-21/NN||10â-23/NNS	dep||10â-23/NNS||$-24/$	nn||mg/day-27/NNP||20-26/NNP	npadvmod||of-32/RB||mg/day-27/NNP	advmod||mg/day-27/NNP||since-29/IN	det||age-31/NN||the-30/DT	pobj||since-29/IN||age-31/NN	dep||16-33/CD||of-32/RB	num||$-24/$||16-33/CD	dep||acne-21/NN||years-34/NNS	acne-21||isotretinoin-18||yes||this case report describes a 25-year-old male who developed obsessive-compulsivedisorder at the age of 23 years following isotretinoin treatment for acne (10â20 mg/day) since the age of 16 years.
poss||data-2/NNS||our-1/PRP$	nsubj||suggests-3/VBZ||data-2/NNS	root||ROOT-0/null||suggests-3/VBZ	mark||provide-14/VB||that-4/IN	amod||screening-6/NN||genetic-5/JJ	nsubj||provide-14/VB||screening-6/NN	nsubj||provide-14/VB||screening-6/NN	det||mutation-12/NN||the-8/DT	amod||mutation-12/NN||s315t-9/JJ	nn||mutation-12/NN||kat-10/NN	nn||mutation-12/NN||g-11/NN	prep_for||screening-6/NN||mutation-12/NN	aux||provide-14/VB||may-13/MD	ccomp||suggests-3/VBZ||provide-14/VB	ccomp||suggests-3/VBZ||provide-14/VB	conj_and||provide-14/VB||provide-14/VB	amod||information-16/NN||rapid-15/JJ	dobj||provide-14/VB||information-16/NN	amod||selection-20/NN||anti-tb-18/JJ	nn||selection-20/NN||regimen-19/NN	prep_for||provide-14/VB||selection-20/NN	amod||monitoring-23/NN||epidemiological-22/JJ	appos||selection-20/NN||monitoring-23/NN	nn||resistance-26/NN||inh-25/NN	prep_of||monitoring-23/NN||resistance-26/NN	dep||provide-14/VB||possibly-29/RB	nn||transmission-33/NN||track-32/NN	prep_to||provide-14/VB||transmission-33/NN	advmod||resistant-36/JJ||inh-35/RB	amod||strains-37/NNS||resistant-36/JJ	prep_of||transmission-33/NN||strains-37/NNS	tb--1||inh-35||yes||our data suggests that genetic screening for the s315t kat g mutation may provide rapid information for anti-tb regimen selection, epidemiological monitoring of inh resistance and, possibly, to track transmission of inh resistant strains.
det||survey-5/NN||a-1/DT	amod||survey-5/NN||descriptive-2/JJ	amod||survey-5/NN||cross-sectional-4/JJ	nsubjpass||conducted-18/VBN||survey-5/NN	prep_of||survey-5/NN||knowledge-7/NN	prep_about||knowledge-7/NN||hiv/aids-9/NNS	prep_about||knowledge-7/NN||attitudes-11/NNS	conj_and||hiv/aids-9/NNS||attitudes-11/NNS	advmod||selected-14/VBN||consecutively-13/RB	amod||women-16/NNS||selected-14/VBN	amod||women-16/NNS||pregnant-15/JJ	prep_among||hiv/aids-9/NNS||women-16/NNS	auxpass||conducted-18/VBN||was-17/VBD	root||ROOT-0/null||conducted-18/VBN	tmod||conducted-18/VBN||november-19/NNP	num||november-19/NNP||2005-20/CD	amod||prefecture-23/NN||aksu-22/JJ	prep_in||conducted-18/VBN||prefecture-23/NN	amod||china-26/NN||north-western-25/JJ	appos||prefecture-23/NN||china-26/NN	det||population-30/NN||a-29/DT	prep_with||conducted-18/VBN||population-30/NN	number||million-33/CD||2-32/CD	prep_on||population-30/NN||million-33/CD	quantmod||000-37/CD||about-35/RB	number||000-37/CD||25â-36/CD	num||pregnancies-38/NNS||000-37/CD	prep_with||conducted-18/VBN||pregnancies-38/NNS	prep_per||pregnancies-38/NNS||year-40/NN	aids--1||hiv--1||no||a descriptive, cross-sectional survey of knowledge about hiv/aids and attitudes among consecutively selected pregnant women was conducted november 2005 in aksu prefecture, north-western china, with a population on 2 million with about 25â 000 pregnancies per year.
poss||role-5/NN||its-3/PRP$	amod||role-5/NN||principal-4/JJ	prep_apart_from||attributed-16/VBN||role-5/NN	nn||metabolism-8/NN||bone-7/NN	prep_in||role-5/NN||metabolism-8/NN	nn||homeostasis-11/NNS||calcium-10/NN	prep_in||role-5/NN||homeostasis-11/NNS	conj_and||metabolism-8/NN||homeostasis-11/NNS	nsubjpass||attributed-16/VBN||vitamind-13/NN	aux||attributed-16/VBN||has-14/VBZ	auxpass||attributed-16/VBN||been-15/VBN	root||ROOT-0/null||attributed-16/VBN	amod||effects-18/NNS||additional-17/JJ	dobj||attributed-16/VBN||effects-18/NNS	det||capacity-29/NN||an-20/DT	amod||capacity-29/NN||immunomodulatory-21/JJ	amod||capacity-29/NN||anti-inflammatory-23/JJ	advmod||neuroprotective-28/JJ||possibly-26/RB	advmod||neuroprotective-28/JJ||even-27/RB	conj_and||anti-inflammatory-23/JJ||neuroprotective-28/JJ	amod||capacity-29/NN||neuroprotective-28/JJ	prep_including||effects-18/NNS||capacity-29/NN	nsubj||implicates-31/VBZ||which-30/WDT	ccomp||capacity-29/NN||implicates-31/VBZ	det||role-34/NN||a-32/DT	amod||role-34/NN||possible-33/JJ	dobj||implicates-31/VBZ||role-34/NN	prep_of||role-34/NN||vitamind-36/NN	prep_in||implicates-31/VBZ||autoimmunediseases-38/NNS	prep_like||autoimmunediseases-38/NNS||multiplesclerosis-40/NNS	appos||multiplesclerosis-40/NNS||ms-42/NN	autoimmunediseases-38||vitamind-36||no_rel||apart from its principal role in bone metabolism and calcium homeostasis, vitamind has been attributed additional effects including an immunomodulatory, anti-inflammatory, and possibly even neuroprotective capacity which implicates a possible role of vitamind in autoimmunediseases like multiplesclerosis (ms).
amod||promyelocyticleukemia-3/NN||acute-2/JJ	prep_in||fused-15/VBN||promyelocyticleukemia-3/NN	appos||promyelocyticleukemia-3/NN||apl-5/NN	det||protein-13/NN||the-8/DT	amod||protein-13/NN||promyelocyticleukemia-9/JJ	nn||protein-13/NN||pml-11/NN	nsubjpass||fused-15/VBN||protein-13/NN	auxpass||fused-15/VBN||is-14/VBZ	root||ROOT-0/null||fused-15/VBN	det||alpha-20/NN||the-17/DT	amod||alpha-20/NN||retinoicacid-18/JJ	nn||alpha-20/NN||receptor-19/NN	prep_to||fused-15/VBN||alpha-20/NN	appos||alpha-20/NN||rar-22/NN	promyelocyticleukemia-9||retinoicacid-18||yes||in acute promyelocyticleukemia (apl), the promyelocyticleukemia (pml) protein is fused to the retinoicacid receptor alpha (rar).
nsubj||interviewed-2/VBD||we-1/PRP	root||ROOT-0/null||interviewed-2/VBD	num||parents-5/NNS||33-3/CD	amod||parents-5/NNS||hiv-infected-4/JJ	dobj||interviewed-2/VBD||parents-5/NNS	det||cost-9/NN||the-7/DT	nn||cost-9/NN||hiv-8/NN	prep_from||interviewed-2/VBD||cost-9/NN	nn||study-13/NN||services-11/NNS	nn||study-13/NN||utilization-12/NN	prep_from||interviewed-2/VBD||study-13/NN	conj_and||cost-9/NN||study-13/NN	appos||cost-9/NN||hcsus-15/NNS	prep_from||interviewed-2/VBD||27-18/CD	conj_and||cost-9/NN||27-18/CD	poss||children-22/NNS||their-20/PRP$	amod||children-22/NNS||minor-21/JJ	prep_of||27-18/CD||children-22/NNS	num||children-26/NNS||19-24/CD	amod||children-26/NNS||adult-25/JJ	prep_from||interviewed-2/VBD||children-26/NNS	conj_and||cost-9/NN||children-26/NNS	num||caregivers-30/NNS||15-29/CD	prep_from||interviewed-2/VBD||caregivers-30/NNS	conj_and||cost-9/NN||caregivers-30/NNS	det||process-33/NN||the-32/DT	prep_about||interviewed-2/VBD||process-33/NN	prep_of||process-33/NN||children-35/NNS	vmod||children-35/NNS||learning-36/VBG	mark||hivpositive-41/JJ||that-37/IN	poss||parents-39/NNS||their-38/PRP$	nsubj||hivpositive-41/JJ||parents-39/NNS	cop||hivpositive-41/JJ||were-40/VBD	ccomp||learning-36/VBG||hivpositive-41/JJ	hivpositive-41||hiv-8||no||we interviewed 33 hiv-infected parents from the hiv cost and services utilization study (hcsus), 27 of their minor children, 19 adult children, and 15 caregivers about the process of children learning that their parents were hivpositive.
nsubjpass||shown-4/VBN||it-1/PRP	aux||shown-4/VBN||has-2/VBZ	auxpass||shown-4/VBN||been-3/VBN	root||ROOT-0/null||shown-4/VBN	nsubj||containing-9/VBG||that-5/DT	dep||containing-9/VBG||2,4-diamino-6-arylmethylpteridines-6/JJ	conj_and||2,4-diamino-6-arylmethylpteridines-6/JJ||2,4-diamino-5-arylmethylpyrimidines-8/JJ	dep||containing-9/VBG||2,4-diamino-5-arylmethylpyrimidines-8/JJ	xcomp||shown-4/VBN||containing-9/VBG	det||o-11/NN||an-10/DT	dobj||containing-9/VBG||o-11/NN	amod||group-14/NN||carboxylalkyloxy-13/JJ	nsubj||inhibitors-23/NNS||group-14/NN	det||moiety-18/NN||the-16/DT	amod||moiety-18/NN||aryl-17/JJ	prep_in||group-14/NN||moiety-18/NN	cop||inhibitors-23/NNS||are-19/VBP	amod||inhibitors-23/NNS||potent-20/JJ	conj_and||potent-20/JJ||selective-22/JJ	amod||inhibitors-23/NNS||selective-22/JJ	parataxis||shown-4/VBN||inhibitors-23/NNS	det||reductase-27/NN||the-25/DT	amod||reductase-27/NN||dihydrofolate-26/JJ	prep_of||inhibitors-23/NNS||reductase-27/NN	appos||reductase-27/NN||dhfr-29/NN	amod||pathogens-33/NNS||opportunistic-32/JJ	prep_from||reductase-27/NN||pathogens-33/NNS	prep_such_as||pathogens-33/NNS||pneumocystiscarinii-36/NNS	det||agent-40/NN||the-38/DT	amod||agent-40/NN||causative-39/JJ	appos||pneumocystiscarinii-36/NNS||agent-40/NN	prep_of||agent-40/NN||pneumocystispneumonia-42/NN	amod||patients-45/NNS||hiv/aids-44/JJ	prep_in||pneumocystispneumonia-42/NN||patients-45/NNS	pneumocystispneumonia-42||pneumocystiscarinii-36||no||it has been shown that 2,4-diamino-6-arylmethylpteridines and 2,4-diamino-5-arylmethylpyrimidines containing an o -carboxylalkyloxy group in the aryl moiety are potent and selective inhibitors of the dihydrofolate reductase (dhfr) from opportunistic pathogens such as pneumocystiscarinii , the causative agent of pneumocystispneumonia in hiv/aids patients.
aux||estimate-2/VB||to-1/TO	advcl||conducted-13/VBD||estimate-2/VB	det||dynamics-5/NNS||the-3/DT	nn||dynamics-5/NNS||transmission-4/NN	dobj||estimate-2/VB||dynamics-5/NNS	nn||tb-10/NN||mdr-7/NN	conj_and||mdr-7/NN||xdr-9/NN	nn||tb-10/NN||xdr-9/NN	prep_of||dynamics-5/NNS||tb-10/NN	nsubj||conducted-13/VBD||we-12/PRP	root||ROOT-0/null||conducted-13/VBD	det||analysis-17/NN||a-14/DT	nn||analysis-17/NN||dna-15/NN	amod||analysis-17/NN||fingerprinting-16/VBG	dobj||conducted-13/VBD||analysis-17/NN	num||strains-22/NNS||55-19/CD	nn||strains-22/NNS||mdr/xdr-20/NN	nn||strains-22/NNS||mycobacteriumtuberculosis-21/NN	prep_of||analysis-17/NN||strains-22/NNS	vmod||strains-22/NNS||isolated-23/VBN	nn||patients-26/NNS||tb-25/NN	prep_from||isolated-23/VBN||patients-26/NNS	prep_throughout||isolated-23/VBN||japan-28/NN	prep_in||japan-28/NN||2002-30/CD	tb-25||mycobacteriumtuberculosis-21||no||to estimate the transmission dynamics of mdr and xdr tb, we conducted a dna fingerprinting analysis of 55 mdr/xdr mycobacteriumtuberculosis strains isolated from tb patients throughout japan in 2002.
amod||evidence-3/NN||current-1/JJ	amod||evidence-3/NN||clinical-2/JJ	nsubj||limited-14/JJ||evidence-3/NN	det||use-6/NN||the-5/DT	prep_for||evidence-3/NN||use-6/NN	amod||delivery-9/NN||aerosolized-8/JJ	prep_of||use-6/NN||delivery-9/NN	prepc_in||delivery-9/NN||preventing-11/VBG	dobj||preventing-11/VBG||fungalinfections-12/NNS	cop||limited-14/JJ||is-13/VBZ	root||ROOT-0/null||limited-14/JJ	amod||products-17/NNS||amphotericinb-16/JJ	prep_to||limited-14/JJ||products-17/NNS	mark||voriconazole-22/JJ||although-19/IN	amod||voriconazole-22/JJ||itraconazole-20/JJ	advcl||limited-14/JJ||voriconazole-22/JJ	nsubj||are-26/VBP||caspofungin-25/NN	conj_and||limited-14/JJ||are-26/VBP	prep_under||are-26/VBP||investigation-28/NN	fungalinfections-12||itraconazole-20||yes||current clinical evidence for the use of aerosolized delivery in preventing fungalinfections is limited to amphotericinb products, although itraconazole, voriconazole, and caspofungin are under investigation.
num||specimens-3/NNS||33-2/CD	prep_of||%-27/NN||specimens-3/NNS	amod||results-7/NNS||concurrent-5/JJ	nn||results-7/NNS||dst-6/NN	prep_with||specimens-3/NNS||results-7/NNS	nsubj||%-27/NN||sensitivity-9/NN	det||assay-13/NN||the-11/DT	amod||assay-13/NN||mods-12/JJ	prep_of||sensitivity-9/NN||assay-13/NN	prep_for||assay-13/NN||detection-15/NN	prep_of||detection-15/NN||resistance-17/NN	prep_to||resistance-17/NN||isoniazid-19/NN	prep_to||resistance-17/NN||rifampin-21/NN	conj_and||isoniazid-19/NN||rifampin-21/NN	prep_to||resistance-17/NN||mdr-tb-24/NN	conj_and||isoniazid-19/NN||mdr-tb-24/NN	cop||%-27/NN||was-25/VBD	num||%-27/NN||88-26/CD	root||ROOT-0/null||%-27/NN	num||%-30/NN||95-29/CD	npadvmod||ci-31/JJ||%-30/NN	dep||68â-33/NNS||ci-31/JJ	dep||%-27/NN||68â-33/NNS	dep||%-37/NN||$-34/$	num||$-34/$||97-36/CD	amod||68â-33/NNS||%-37/NN	num||%-41/NN||96-40/CD	conj_and||%-27/NN||%-41/NN	num||%-44/NN||95-43/CD	npadvmod||ci-45/JJ||%-44/NN	dep||79â-47/NNS||ci-45/JJ	dep||%-41/NN||79â-47/NNS	dep||%-51/NN||$-48/$	num||$-48/$||100-50/CD	amod||79â-47/NNS||%-51/NN	num||%-56/NN||91-55/CD	conj_and||%-27/NN||%-56/NN	num||%-59/NN||95-58/CD	npadvmod||ci-60/JJ||%-59/NN	dep||72â-62/NNS||ci-60/JJ	dep||%-56/NN||72â-62/NNS	dep||%-66/NN||$-63/$	num||$-63/$||99-65/CD	amod||72â-62/NNS||%-66/NN	advmod||%-27/NN||respectively-69/RB	nsubj||%-74/NN||specificity-71/NN	cop||%-74/NN||was-72/VBD	num||%-74/NN||89-73/CD	parataxis||%-27/NN||%-74/NN	num||%-77/NN||95-76/CD	npadvmod||ci-78/JJ||%-77/NN	dep||52â-80/NNS||ci-78/JJ	dep||%-74/NN||52â-80/NNS	dep||%-84/NN||$-81/$	num||$-81/$||100-83/CD	amod||52â-80/NNS||%-84/NN	num||%-88/NN||89-87/CD	parataxis||%-27/NN||%-88/NN	conj_and||%-74/NN||%-88/NN	num||%-91/NN||95-90/CD	npadvmod||ci-92/JJ||%-91/NN	dep||52â-94/NNS||ci-92/JJ	dep||%-88/NN||52â-94/NNS	dep||%-98/NN||$-95/$	num||$-95/$||100-97/CD	amod||52â-94/NNS||%-98/NN	num||%-103/NN||90-102/CD	parataxis||%-27/NN||%-103/NN	conj_and||%-74/NN||%-103/NN	num||%-106/NN||95-105/CD	npadvmod||ci-107/JJ||%-106/NN	dep||56â-109/NNS||ci-107/JJ	dep||%-103/NN||56â-109/NNS	dep||%-113/NN||$-110/$	num||$-110/$||100-112/CD	amod||56â-109/NNS||%-113/NN	advmod||%-74/NN||respectively-116/RB	tb--1||rifampin-21||yes||of 33 specimens with concurrent dst results, sensitivity of the mods assay for detection of resistance to isoniazid, rifampin, and mdr-tb was 88% (95% ci, 68â97%), 96% (95% ci, 79â100%), and 91% (95% ci, 72â99%), respectively; specificity was 89% (95% ci, 52â100%), 89% (95% ci, 52â100%), and 90% (95% ci, 56â100%), respectively.
nsubj||antispasmodics-9/VBZ||objective-1/NN	nsubj||peppermintoil-12/JJ||objective-1/NN	aux||determine-3/VB||to-2/TO	vmod||objective-1/NN||determine-3/VB	det||effect-5/NN||the-4/DT	dobj||determine-3/VB||effect-5/NN	prep_of||effect-5/NN||fibre-7/NN	root||ROOT-0/null||antispasmodics-9/VBZ	conj_and||antispasmodics-9/VBZ||peppermintoil-12/JJ	det||treatment-15/NN||the-14/DT	prep_in||peppermintoil-12/JJ||treatment-15/NN	prep_of||treatment-15/NN||irritablebowelsyndrome-17/NN	antispasmodics-9||irritablebowelsyndrome-17||no_rel||objective to determine the effect of fibre, antispasmodics, and peppermintoil in the treatment of irritablebowelsyndrome.
nsubj||conducted-2/VBD||we-1/PRP	root||ROOT-0/null||conducted-2/VBD	det||study-5/NN||a-3/DT	amod||study-5/NN||cross-sectional-4/JJ	dobj||conducted-2/VBD||study-5/NN	amod||patients-8/NNS||hiv-infected-7/JJ	prep_among||conducted-2/VBD||patients-8/NNS	amod||patients-8/NNS||negative-9/JJ	amod||antigen-13/NN||hepatitisb-11/JJ	nn||antigen-13/NN||surface-12/NN	prep_for||negative-9/JJ||antigen-13/NN	amod||antibody-16/NN||hepatitisc-15/JJ	prep_for||negative-9/JJ||antibody-16/NN	conj_and||antigen-13/NN||antibody-16/NN	det||center-20/NN||the-18/DT	nn||center-20/NN||penn-19/NN	prep_in||conducted-2/VBD||center-20/NN	amod||database-25/NN||aids-22/JJ	nn||database-25/NN||research-23/NN	nn||database-25/NN||adult/adolescent-24/NN	prep_for||center-20/NN||database-25/NN	aids-22||hiv--1||no||we conducted a cross-sectional study among hiv-infected patients negative for hepatitisb surface antigen and hepatitisc antibody in the penn center for aids research adult/adolescent database.
amod||combinations-4/NNS||docetaxel-1/JJ	conj_and||docetaxel-1/JJ||gemcitabine-3/JJ	amod||combinations-4/NNS||gemcitabine-3/JJ	nsubj||proven-6/VBN||combinations-4/NNS	aux||proven-6/VBN||have-5/VBP	root||ROOT-0/null||proven-6/VBN	acomp||proven-6/VBN||active-7/JJ	det||treatment-10/NN||the-9/DT	prep_for||proven-6/VBN||treatment-10/NN	prep_of||treatment-10/NN||non-smallcelllungcancer-12/NN	dep||non-smallcelllungcancer-12/NN||nsclc-14/JJ	nsclc-14||docetaxel-1||yes||docetaxel and gemcitabine combinations have proven active for the treatment of non-smallcelllungcancer (nsclc).
poss||adiponectin-5/NN||results-1/NNS	amod||adiponectin-5/NN||$-3/JJ	nsubj||showed-6/VBD||adiponectin-5/NN	root||ROOT-0/null||showed-6/VBD	det||dimorphism-9/NN||a-7/DT	nn||dimorphism-9/NN||sex-8/NN	dobj||showed-6/VBD||dimorphism-9/NN	prep_with||showed-6/VBD||girls-12/NNS	vmod||girls-12/NNS||having-13/VBG	amod||values-15/NNS||higher-14/JJR	dobj||having-13/VBG||values-15/NNS	nn||g/ml-20/NN||î-18/NN	num||g/ml-20/NN||1/4-19/CD	prep_in||values-15/NNS||g/ml-20/NN	num||5.0-26/NNS||10.3-23/CD	nn||5.0-26/NNS||â-24/NNP	nn||5.0-26/NNS||±-25/NN	appos||values-15/NNS||5.0-26/NNS	prep_than||values-15/NNS||boys-29/NNS	dep||boys-29/NNS||8.4-31/CD	vmod||8.4-31/CD||â-32/VBN	dep||3.5-34/CD||±-33/SYM	ccomp||â-32/VBN||3.5-34/CD	dep||girls-12/NNS||p-37/VBN	dep||0.0001-39/CD||<-38/SYM	ccomp||p-37/VBN||0.0001-39/CD	nsubj||showed-44/VBD||it-43/PRP	conj_and||showed-6/VBD||showed-44/VBD	det||correlation-47/NN||a-45/DT	amod||correlation-47/NN||positive-46/JJ	dobj||showed-44/VBD||correlation-47/NN	nn||cholesterol-50/NN||hdl-49/NN	prep_with||showed-44/VBD||cholesterol-50/NN	prep_in||showed-44/VBD||boys-52/NNS	advmod||boys-52/NNS||only-53/RB	advmod||boys-52/NNS||not-55/RB	conj_and||only-53/RB||not-55/RB	amod||anthropometry-65/NN||other-57/JJ	nn||anthropometry-65/NN||lipid-58/NN	nn||anthropometry-65/NN||parameters-59/NNS	dep||anthropometry-65/NN||insulinresistance-61/NN	dep||anthropometry-65/NN||proinsulin-63/NN	prep_with||boys-52/NNS||anthropometry-65/NN	nn||history-69/NN||family-68/NN	prep_with||boys-52/NNS||history-69/NN	conj_and||anthropometry-65/NN||history-69/NN	prep_of||boys-52/NNS||diabetes-71/NN	cholesterol-50||insulinresistance-61||no_rel||results âadiponectin showed a sex dimorphism, with girls having higher values (in î¼g/ml) (10.3 â± 5.0) than boys (8.4 â± 3.5) ( p < 0.0001), and it showed a positive correlation with hdl cholesterol in boys only and not with other lipid parameters, insulinresistance, proinsulin, anthropometry, and family history of diabetes.
det||study-4/NN||a-1/DT	amod||observational-3/JJ||retrospective-2/JJ	amod||study-4/NN||observational-3/JJ	nsubj||1998â-8/VBD||study-4/NN	prep_in||study-4/NN||taiwan-6/NN	root||ROOT-0/null||1998â-8/VBD	dobj||1998â-8/VBD||$-9/$	npadvmod||92-14/RB||2004-11/NNS	prep||2004-11/NNS||identified-13/IN	dep||patients-15/CD||92-14/RB	num||$-9/$||patients-15/CD	nn||streptococcalbacteremia-19/NN||group-17/NN	nn||streptococcalbacteremia-19/NN||g-18/NN	prep_with||1998â-8/VBD||streptococcalbacteremia-19/NN	nsubj||had-22/VBD||86-21/CD	parataxis||1998â-8/VBD||had-22/VBD	amod||equisimilis-26/NNS||streptococcus-23/JJ	nn||equisimilis-26/NNS||dysgalactiae-24/NN	nn||equisimilis-26/NNS||subspecies-25/NNS	dobj||had-22/VBD||equisimilis-26/NNS	streptococcalbacteremia-19||streptococcus-23||no||a retrospective observational study in taiwan, 1998â2004, identified 92 patients with group g streptococcalbacteremia; 86 had streptococcus dysgalactiae subspecies equisimilis .
prepc_besides||vanilloid-18/VBD||functioning-2/VBG	prep_as||functioning-2/VBG||chemosensors-4/NNS	det||range-8/NN||a-6/DT	amod||range-8/NN||broad-7/JJ	prep_for||chemosensors-4/NNS||range-8/NN	prep_of||range-8/NN||endogenous-10/NNS	amod||ligands-13/NNS||synthetic-12/JJ	prep_of||range-8/NN||ligands-13/NNS	conj_and||endogenous-10/NNS||ligands-13/NNS	amod||potential-17/NN||transient-15/JJ	nn||potential-17/NN||receptor-16/NN	nsubj||vanilloid-18/VBD||potential-17/NN	root||ROOT-0/null||vanilloid-18/VBD	appos||1â-22/NNS||trpv-20/NNP	dobj||vanilloid-18/VBD||1â-22/NNS	num||channels-26/NNS||$-23/$	num||$-23/$||4-25/CD	nsubjpass||related-30/VBN||channels-26/NNS	aux||related-30/VBN||have-27/VBP	advmod||related-30/VBN||also-28/RB	auxpass||related-30/VBN||been-29/VBN	rcmod||1â-22/NNS||related-30/VBN	prep_to||related-30/VBN||capsaicin-32/NN	appos||capsaicin-32/NN||trpv1-34/NNP	prep_to||related-30/VBN||pain-37/NN	conj_and||capsaicin-32/NN||pain-37/NN	amod||perception-42/NN||thermal-40/JJ	nn||perception-42/NN||stimuli-41/NNS	prep_to||related-30/VBN||perception-42/NN	conj_and||capsaicin-32/NN||perception-42/NN	amod||sensation-46/NN||itching-45/VBG	dobj||vanilloid-18/VBD||sensation-46/NN	conj_and||1â-22/NNS||sensation-46/NN	appos||sensation-46/NN||trpv1â-48/NNP	num||trpv1â-48/NNP||$-49/$	num||$-49/$||4-51/CD	pain-37||capsaicin-32||yes||besides functioning as chemosensors for a broad range of endogenous and synthetic ligands, transient receptor potential vanilloid (trpv) 1â4 channels have also been related to capsaicin (trpv1), pain, and thermal stimuli perception, and itching sensation (trpv1â4).
nsubj||included-2/VBD||we-1/PRP	root||ROOT-0/null||included-2/VBD	num||men-4/NNS||78-3/CD	dobj||included-2/VBD||men-4/NNS	prep_with||included-2/VBD||type2diabetes-6/NNS	nsubjpass||assigned-25/VBN||type2diabetes-6/NNS	dep||type2diabetes-6/NNS||aged-8/VBN	num||years-13/NNS||56.5-9/CD	nn||years-13/NNS||â-10/NN	amod||years-13/NNS||±-11/VBG	num||years-13/NNS||0.6-12/CD	dobj||aged-8/VBN||years-13/NNS	num||±-18/NNS||hba1c-15/CD	num||±-18/NNS||7.1-16/CD	amod||±-18/NNS||â-17/JJ	dep||years-13/NNS||±-18/NNS	number||%-20/NN||0.1-19/CD	amod||±-18/NNS||%-20/NN	auxpass||assigned-25/VBN||were-23/VBD	advmod||assigned-25/VBN||randomly-24/RB	rcmod||type2diabetes-6/NNS||assigned-25/VBN	prep_to||assigned-25/VBN||treatment-27/NN	prep_with||treatment-27/NN||pioglitazone-29/NN	num||mg/day-32/NN||30-31/CD	appos||pioglitazone-29/NN||mg/day-32/NN	prep_with||treatment-27/NN||metformin-35/NN	conj_or||pioglitazone-29/NN||metformin-35/NN	num||mg/day-38/NN||2000-37/CD	appos||pioglitazone-29/NN||mg/day-38/NN	amod||placebo-42/NN||matching-41/VBG	prep_to||assigned-25/VBN||placebo-42/NN	conj_and||treatment-27/NN||placebo-42/NN	prep_in||included-2/VBD||addition-45/NN	aux||glimepiride-47/VB||to-46/TO	vmod||addition-45/NN||glimepiride-47/VB	type2diabetes-6||glimepiride-47||yes||we included 78 men with type2diabetes (aged 56.5 â± 0.6 years; hba1c 7.1 â± 0.1%) who were randomly assigned to treatment with pioglitazone (30 mg/day) or metformin (2000 mg/day) and matching placebo, in addition to glimepiride.
det||unit-14/NN||the-2/DT	dep||unit-14/NN||patients-3/NNS	nn||scores-6/NNS||agitation-5/NN	prep_with||patients-3/NNS||scores-6/NNS	npadvmod||patients-3/NNS||4-7/CD	npadvmod||patients-3/NNS||5-9/CD	conj_or||4-7/CD||5-9/CD	det||peostanesthesia-12/NN||the-11/DT	prep_in||patients-3/NNS||peostanesthesia-12/NN	nn||unit-14/NN||care-13/NN	prep_among||given-24/VBN||unit-14/NN	appos||unit-14/NN||pacu-16/NNP	nn||patients-21/NNS||group-19/NN	nn||patients-21/NNS||iv-20/NN	nsubjpass||given-24/VBN||patients-21/NNS	auxpass||given-24/VBN||were-22/VBD	advmod||given-24/VBN||intravenously-23/RB	root||ROOT-0/null||given-24/VBN	det||mixture-27/NN||a-25/DT	amod||mixture-27/NN||1-ml-26/JJ	nn||saline-34/NN||mixture-27/NN	prep_of||mixture-27/NN||midazolam-29/NNP	num||midazolam-29/NNP||0.025-30/CD	amod||saline-34/NN||mg/kg-31/JJ	conj_and||mg/kg-31/JJ||normal-33/JJ	amod||saline-34/NN||normal-33/JJ	iobj||given-24/VBN||saline-34/NN	quantmod||3-37/CD||up-35/IN	dep||3-37/CD||to-36/TO	num||times-38/NNS||3-37/CD	dobj||given-24/VBN||times-38/NNS	agitation-5||midazolam-29||yes||among the patients with agitation scores 4 or 5 in the peostanesthesia care unit (pacu), group iv patients were intravenously given a 1-ml mixture of midazolam 0.025 mg/kg and normal saline up to 3 times.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||studied-8/VBN||study-4/NN	nsubj||studied-8/VBN||we-6/PRP	aux||studied-8/VBN||have-7/VBP	root||ROOT-0/null||studied-8/VBN	ccomp||studied-8/VBN||total-9/VB	num||patients-12/NNS||177-10/CD	amod||patients-12/NNS||eligible-11/JJ	dobj||total-9/VB||patients-12/NNS	dobj||total-9/VB||subjects-14/NNS	conj_and||patients-12/NNS||subjects-14/NNS	num||epstein-barr-virus-19/NNS||128-16/CD	amod||epstein-barr-virus-19/NNS||healthy-17/JJ	nn||epstein-barr-virus-19/NNS||latent-18/NN	prep_including||patients-12/NNS||epstein-barr-virus-19/NNS	appos||epstein-barr-virus-19/NNS||ebv-21/NN	amod||subjects-25/NNS||infected-24/JJ	dep||epstein-barr-virus-19/NNS||subjects-25/NNS	num||patients-31/NNS||17-27/CD	amod||patients-31/NNS||newly-onset-28/JJ	amod||patients-31/NNS||acute-29/JJ	nn||patients-31/NNS||infectiousmononucleosis-30/NN	dep||epstein-barr-virus-19/NNS||patients-31/NNS	conj_and||subjects-25/NNS||patients-31/NNS	num||patients-37/NNS||16-33/CD	amod||patients-37/NNS||newly-diagnosed-34/JJ	amod||patients-37/NNS||ebv-associated-35/JJ	nn||patients-37/NNS||hodgkinlymphoma-36/NN	dep||epstein-barr-virus-19/NNS||patients-37/NNS	conj_and||subjects-25/NNS||patients-37/NNS	num||subjects-44/NNS||16-40/CD	amod||subjects-44/NNS||ebv-negative-41/JJ	amod||subjects-44/NNS||normal-42/JJ	nn||subjects-44/NNS||control-43/NN	dep||epstein-barr-virus-19/NNS||subjects-44/NNS	conj_and||subjects-25/NNS||subjects-44/NNS	infectiousmononucleosis-30||ebv-21||no||in the present study, we have studied total 177 eligible patients and subjects including 128 healthy latent epstein-barr-virus(ebv)-infected subjects, 17 newly-onset acute infectiousmononucleosis patients, 16 newly-diagnosed ebv-associated hodgkinlymphoma patients, and 16 ebv-negative normal control subjects.
amod||citations-2/NNS||relevant-1/JJ	nsubjpass||selected-4/VBN||citations-2/NNS	auxpass||selected-4/VBN||were-3/VBD	root||ROOT-0/null||selected-4/VBN	agent||selected-4/VBN||agreement-6/NN	det||authors-9/NNS||the-8/DT	prep_between||agreement-6/NN||authors-9/NNS	det||search-12/NN||a-11/DT	nsubj||using-15/VBG||search-12/NN	prep_of||search-12/NN||medline-14/NN	prepc_after||selected-4/VBN||using-15/VBG	det||terms-17/NNS||the-16/DT	nsubj||hiv/aids-18/JJ||terms-17/NNS	nsubj||contraception-20/JJ||terms-17/NNS	xcomp||using-15/VBG||hiv/aids-18/JJ	xcomp||using-15/VBG||contraception-20/JJ	conj_and||hiv/aids-18/JJ||contraception-20/JJ	aids--1||hiv--1||no||relevant citations were selected by agreement between the authors after a search of medline using the terms hiv/aids and contraception.
det||data-2/NNS||these-1/DT	nsubj||established-4/VBN||data-2/NNS	aux||established-4/VBN||have-3/VBP	root||ROOT-0/null||established-4/VBN	mark||prion-9/VBN||that-5/IN	amod||prions-7/NNS||kuru-6/JJ	nsubj||prion-9/VBN||prions-7/NNS	aux||prion-9/VBN||have-8/VBP	ccomp||established-4/VBN||prion-9/VBN	nn||properties-11/NNS||strain-10/NN	nsubj||equivalent-12/JJ||properties-11/NNS	xcomp||prion-9/VBN||equivalent-12/JJ	prep_to||equivalent-12/JJ||those-14/DT	amod||prions-29/NNS||classical-16/JJ	dep||prions-29/NNS||sporadic-18/JJ	conj_and||sporadic-18/JJ||iatrogenic-20/JJ	dep||prions-29/NNS||iatrogenic-20/JJ	amod||prions-29/NNS||cjd-22/JJ	nn||prions-29/NNS||prions-23/NNS	conj_but||prions-23/NNS||distinct-25/JJ	nn||prions-29/NNS||distinct-25/JJ	amod||cjd-28/NN||variant-27/JJ	prep_from||distinct-25/JJ||cjd-28/NN	prep_of||those-14/DT||prions-29/NNS	cjd-28||prions-29||no_rel||these data have established that kuru prions have prion strain properties equivalent to those of classical (sporadic and iatrogenic) cjd prions but distinct from variant cjd prions.
amod||immunity-2/NN||innate-1/JJ	nsubjpass||thought-4/VBN||immunity-2/NN	nsubj||relevant-7/JJ||immunity-2/NN	auxpass||thought-4/VBN||is-3/VBZ	root||ROOT-0/null||thought-4/VBN	aux||relevant-7/JJ||to-5/TO	cop||relevant-7/JJ||be-6/VB	xcomp||thought-4/VBN||relevant-7/JJ	det||control-10/NN||the-9/DT	prep_in||relevant-7/JJ||control-10/NN	nn||virusinfections-13/NNS||hepatitis-12/NN	prep_of||control-10/NN||virusinfections-13/NNS	prep_such_as||virusinfections-13/NNS||hepatitisbvirus-16/NNS	appos||hepatitisbvirus-16/NNS||hbv-18/NN	amod||virus-22/NN||hepatitisc-21/JJ	prep_such_as||virusinfections-13/NNS||virus-22/NN	conj_and||hepatitisbvirus-16/NNS||virus-22/NN	appos||hepatitisbvirus-16/NNS||hcv-24/NN	amod||findings-29/NNS||recent-28/JJ	nsubj||indicate-31/VBP||findings-29/NNS	advmod||indicate-31/VBP||reproducibly-30/RB	conj_and||thought-4/VBN||indicate-31/VBP	mark||characterized-40/VBN||that-32/IN	nn||cells-34/NNS||nk-33/NN	nsubjpass||characterized-40/VBN||cells-34/NNS	amod||hepatitis-38/NN||chronic-36/JJ	amod||hepatitis-38/NN||viral-37/JJ	prep_in||cells-34/NNS||hepatitis-38/NN	auxpass||characterized-40/VBN||are-39/VBP	ccomp||indicate-31/VBP||characterized-40/VBN	det||dichotomy-44/NN||a-42/DT	amod||dichotomy-44/NN||functional-43/JJ	agent||characterized-40/VBN||dichotomy-44/NN	xcomp||characterized-40/VBN||featuring-46/VBG	det||cytotoxicity-51/NN||a-47/DT	amod||cytotoxicity-51/NN||conserved-48/JJ	conj_or||conserved-48/JJ||enhanced-50/VBN	amod||cytotoxicity-51/NN||enhanced-50/VBN	dobj||featuring-46/VBG||cytotoxicity-51/NN	det||production-55/NN||a-53/DT	amod||production-55/NN||reduced-54/VBN	dobj||featuring-46/VBG||production-55/NN	conj_and||cytotoxicity-51/NN||production-55/NN	prep_of||production-55/NN||interferon-57/NN	dep||production-55/NN||ifn-59/VBN	amod||³-63/NN||î-62/JJ	dep||production-55/NN||³-63/NN	nn||necrosis-66/NNS||tumor-65/NN	dep||production-55/NN||necrosis-66/NNS	conj_and||³-63/NN||necrosis-66/NNS	nn||±-68/NNP||factor-î-67/NNP	dep||³-63/NN||±-68/NNP	hbv-18||hepatitisbvirus-16||no||innate immunity is thought to be relevant in the control of hepatitis virusinfections such as hepatitisbvirus (hbv) and hepatitisc virus (hcv), and recent findings reproducibly indicate that nk cells in chronic viral hepatitis are characterized by a functional dichotomy, featuring a conserved or enhanced cytotoxicity and a reduced production of interferon (ifn)-î³ and tumor necrosis factor-î±.
advmod||show-9/VBP||here-1/RB	vmod||show-9/VBP||using-3/VBG	amod||analysis-6/NN||novel-4/JJ	amod||analysis-6/NN||statistical-5/JJ	dobj||using-3/VBG||analysis-6/NN	nsubj||show-9/VBP||we-8/PRP	root||ROOT-0/null||show-9/VBP	mark||exist-15/VBP||that-10/IN	amod||abnormalities-14/NNS||subtle-11/JJ	conj_but||subtle-11/JJ||significant-13/JJ	amod||abnormalities-14/NNS||significant-13/JJ	nsubj||exist-15/VBP||abnormalities-14/NNS	ccomp||show-9/VBP||exist-15/VBP	det||composition-18/NN||the-17/DT	prep_in||exist-15/VBP||composition-18/NN	prep_of||composition-18/NN||fattyacids-20/NNS	appos||fattyacids-20/NNS||fas-22/NN	amod||acid-27/NN||docosapentaenoic-26/JJ	prep_including||exist-15/VBP||acid-27/NN	num||-3-31/NN||225-29/CD	nn||-3-31/NN||n-30/NN	appos||acid-27/NN||-3-31/NN	appos||acid-27/NN||one-34/CD	det||fas-39/NN||the-36/DT	amod||fas-39/NN||omega-3-37/JJ	amod||fas-39/NN||polyunsaturated-38/JJ	prep_of||one-34/CD||fas-39/NN	vmod||fas-39/NN||found-41/VBN	det||cortex-46/NN||the-43/DT	amod||cortex-46/NN||post-mortem-44/JJ	nn||cortex-46/NN||frontopolar-45/NN	prep_in||found-41/VBN||cortex-46/NN	appos||cortex-46/NN||fpc-48/NN	prep_of||cortex-46/NN||subjects-51/NNS	prep_with||found-41/VBN||bipolar-53/NNP	amod||depressivedisorders-56/NNS||major-55/JJ	prep_with||found-41/VBN||depressivedisorders-56/NNS	conj_or||bipolar-53/NNP||depressivedisorders-56/NNS	mark||in-60/IN||although-58/IN	dep||in-60/IN||not-59/RB	advcl||exist-15/VBP||in-60/IN	pobj||in-60/IN||those-61/DT	prep_with||those-61/DT||schizophrenia-63/NN	fattyacids-20||depressivedisorders-56||no_rel||here, using novel statistical analysis, we show that subtle but significant abnormalities exist in the composition of fattyacids (fas), including docosapentaenoic acid (225 n -3), one of the omega-3 polyunsaturated fas, found in the post-mortem frontopolar cortex (fpc) of subjects with bipolar or major depressivedisorders, although not in those with schizophrenia.
nsubj||undergoing-3/VBG||patients-2/NNS	prepc_among||safe-21/JJ||undergoing-3/VBG	amod||stenting-5/NN||primary-4/JJ	dobj||undergoing-3/VBG||stenting-5/NN	amod||administration-8/NN||abciximab-7/JJ	prep_with||undergoing-3/VBG||administration-8/NN	amod||reversal-12/NN||immediate-10/JJ	nn||reversal-12/NN||post-pci-11/NN	nsubjpass||safe-21/JJ||reversal-12/NN	nsubjpass||associated-23/VBN||reversal-12/NN	vmod||reversal-12/NN||anticoagulation-13/VBN	agent||anticoagulation-13/VBN||protamine-15/NN	amod||infusion-19/NN||associated-17/VBN	nn||infusion-19/NN||heparin-18/NN	prep_without||anticoagulation-13/VBN||infusion-19/NN	auxpass||safe-21/JJ||is-20/VBZ	cop||safe-21/JJ||is-20/VBZ	root||ROOT-0/null||safe-21/JJ	conj_and||safe-21/JJ||associated-23/VBN	det||reduction-27/NN||a-25/DT	amod||reduction-27/NN||significant-26/JJ	prep_with||associated-23/VBN||reduction-27/NN	amod||complications-31/NNS||major-29/JJ	amod||complications-31/NNS||bleeding-30/VBG	prep_in||reduction-27/NN||complications-31/NNS	bleeding-30||abciximab-7||no||among patients undergoing primary stenting with abciximab administration, immediate post-pci reversal anticoagulation by protamine without associated heparin infusion is safe and associated with a significant reduction in major bleeding complications.
advmod||used-20/VBN||recently-1/RB	det||ns1-9/NN||the-3/DT	amod||ns1-9/NN||denguevirus-4/JJ	amod||ns1-9/NN||non-structural-5/JJ	nn||ns1-9/NN||antigen-6/NN	num||ns1-9/NN||1-7/CD	nsubjpass||used-20/VBN||ns1-9/NN	det||glycoprotein-16/NN||a-12/DT	amod||glycoprotein-16/NN||conserved-13/JJ	conj_and||conserved-13/JJ||secreted-15/JJ	amod||glycoprotein-16/NN||secreted-15/JJ	appos||ns1-9/NN||glycoprotein-16/NN	aux||used-20/VBN||has-18/VBZ	auxpass||used-20/VBN||been-19/VBN	root||ROOT-0/null||used-20/VBN	det||marker-23/NN||a-22/DT	prep_as||used-20/VBN||marker-23/NN	amod||diagnosis-26/NN||early-25/JJ	prep_for||marker-23/NN||diagnosis-26/NN	prep_of||diagnosis-26/NN||dengue-28/NN	prep_with||used-20/VBN||convenience-30/NN	prep_with||used-20/VBN||cost-effectiveness-32/NNS	conj_and||convenience-30/NN||cost-effectiveness-32/NNS	dengue-28||denguevirus-4||no||recently, the denguevirus non-structural antigen 1 (ns1), a conserved and secreted glycoprotein, has been used as a marker for early diagnosis of dengue with convenience and cost-effectiveness.
nn||options-2/NNS||treatment-1/NN	nsubj||better-12/JJR||options-2/NNS	prep_for||options-2/NNS||women-4/NNS	amod||cancer-8/NN||early-stage-6/JJ	nn||cancer-8/NN||breast-7/NN	prep_with||women-4/NNS||cancer-8/NN	aux||better-12/JJR||have-9/VBP	neg||better-12/JJR||never-10/RB	cop||better-12/JJR||been-11/VBN	root||ROOT-0/null||better-12/JJR	det||addition-16/NN||the-15/DT	nsubj||tool-26/NN||addition-16/NN	prep_of||addition-16/NN||bisphosphonates-18/NNS	amod||therapy-21/NN||adjuvant-20/JJ	prep_to||bisphosphonates-18/NNS||therapy-21/NN	cop||tool-26/NN||is-22/VBZ	det||tool-26/NN||a-23/DT	amod||tool-26/NN||valuable-24/JJ	amod||tool-26/NN||new-25/JJ	conj_and||better-12/JJR||tool-26/NN	amod||tool-26/NN||capable-27/JJ	advmod||improving-30/VBG||substantially-29/RB	amod||outcomes-32/NNS||improving-30/VBG	amod||outcomes-32/NNS||clinical-31/JJ	prep_of||capable-27/JJ||outcomes-32/NNS	det||women-35/NNS||these-34/DT	prep_for||outcomes-32/NNS||women-35/NNS	cancer-8||bisphosphonates-18||no_rel||treatment options for women with early-stage breast cancer have never been better, and the addition of bisphosphonates to adjuvant therapy is a valuable new tool capable of substantially improving clinical outcomes for these women.
det||receptor-8/NN||the-1/DT	amod||receptor-8/NN||insulin-like-2/JJ	nn||receptor-8/NN||growth-3/NN	nn||receptor-8/NN||factor-4/NN	num||receptor-8/NN||1-5/CD	nn||receptor-8/NN||tyrosine-6/NN	nn||receptor-8/NN||kinase-7/NN	nsubjpass||shown-22/VBN||receptor-8/NN	nsubj||play-24/VB||receptor-8/NN	dep||receptor-8/NN||igf-1r-10/JJ	det||receptor-17/NN||the-13/DT	amod||receptor-17/NN||chemokine-14/JJ	amod||receptor-17/NN||g-protein-15/JJ	nn||receptor-17/NN||coupled-16/NN	conj_and||receptor-8/NN||receptor-17/NN	nsubjpass||shown-22/VBN||receptor-17/NN	nsubj||play-24/VB||receptor-17/NN	appos||receptor-17/NN||cxcr4-19/NNS	aux||shown-22/VBN||have-20/VBP	auxpass||shown-22/VBN||been-21/VBN	root||ROOT-0/null||shown-22/VBN	aux||play-24/VB||to-23/TO	xcomp||shown-22/VBN||play-24/VB	det||role-27/NN||an-25/DT	amod||role-27/NN||important-26/JJ	dobj||play-24/VB||role-27/NN	nn||metastasis-31/NNS||breast-29/NN	nn||metastasis-31/NNS||cancer-30/NN	prep_in||play-24/VB||metastasis-31/NNS	insulin--1||metastasis-31||no_rel||the insulin-like growth factor 1 tyrosine kinase receptor (igf-1r) and the chemokine g-protein coupled receptor, cxcr4 have been shown to play an important role in breast cancer metastasis.
det||experience-2/NN||this-1/DT	nsubj||emphasizes-3/VBZ||experience-2/NN	root||ROOT-0/null||emphasizes-3/VBZ	det||utility-7/NN||the-4/DT	amod||utility-7/NN||potential-5/JJ	amod||utility-7/NN||clinical-6/JJ	dobj||emphasizes-3/VBZ||utility-7/NN	amod||chemotherapy-11/NN||platinum-based-9/JJ	amod||chemotherapy-11/NN||cytotoxic-10/JJ	prep_of||utility-7/NN||chemotherapy-11/NN	det||setting-14/NN||the-13/DT	prep_in||chemotherapy-11/NN||setting-14/NN	amod||cancer-20/NN||symptomatic-16/JJ	amod||cancer-20/NN||advanced-17/JJ	amod||cancer-20/NN||borderline-18/JJ	nn||cancer-20/NN||ovarian-19/NN	prep_of||setting-14/NN||cancer-20/NN	cancer-20||platinum--1||no_rel||this experience emphasizes the potential clinical utility of platinum-based cytotoxic chemotherapy in the setting of symptomatic advanced borderline ovarian cancer.
nsubjpass||characterized-3/VBN||type2diabetes-1/NNS	auxpass||characterized-3/VBN||is-2/VBZ	root||ROOT-0/null||characterized-3/VBN	agent||characterized-3/VBN||insulinresistance-5/NN	det||deficiency-9/NN||a-7/DT	amod||deficiency-9/NN||relative-8/JJ	prep_with||characterized-3/VBN||deficiency-9/NN	nn||secretion-12/NN||insulin-11/NN	prep_in||deficiency-9/NN||secretion-12/NN	type2diabetes-1||insulin-11||yes||type2diabetes is characterized by insulinresistance with a relative deficiency in insulin secretion.
nsubj||quantified-2/VBD||we-1/PRP	root||ROOT-0/null||quantified-2/VBD	dobj||quantified-2/VBD||reversion-3/NN	prep_to||quantified-2/VBD||wt-5/NN	det||series-8/NN||a-7/DT	prep_of||wt-5/NN||series-8/NN	nn||viruses-13/NNS||siv-10/NN	conj_and||siv-10/NN||shiv-12/NN	nn||viruses-13/NNS||shiv-12/NN	prep_of||series-8/NN||viruses-13/NNS	xcomp||quantified-2/VBD||containing-14/VBG	amod||amounts-16/NNS||minor-15/JJ	dobj||containing-14/VBG||amounts-16/NNS	nn||virus-19/NN||wt-18/NN	prep_of||amounts-16/NNS||virus-19/NN	amod||macaques-22/NNS||pigtail-21/JJ	prep_in||containing-14/VBG||macaques-22/NNS	vmod||macaques-22/NNS||using-23/VBG	det||pcr-26/NN||a-24/DT	amod||pcr-26/NN||sensitive-25/JJ	dobj||using-23/VBG||pcr-26/NN	advmod||using-23/VBG||assay-27/RB	virus-19||viruses-13||no||we quantified reversion to wt of a series of siv and shiv viruses containing minor amounts of wt virus in pigtail macaques using a sensitive pcr assay.
vmod||indicate-6/VBP||taken-1/VBN	advmod||taken-1/VBN||together-2/RB	poss||data-5/NNS||our-4/PRP$	nsubj||indicate-6/VBP||data-5/NNS	root||ROOT-0/null||indicate-6/VBP	mark||alter-13/VB||that-7/IN	nsubj||alter-13/VB||expression-8/NN	prep_of||expression-8/NN||htert-10/NN	aux||alter-13/VB||does-11/VBZ	neg||alter-13/VB||not-12/RB	ccomp||indicate-6/VBP||alter-13/VB	nn||ifn-16/NN||type-14/NN	num||ifn-16/NN||1-15/CD	dobj||alter-13/VB||ifn-16/NN	dep||ifn-16/NN||signaling-17/VBG	vmod||signaling-17/VBG||and/or-18/VBG	det||growth-20/NN||the-19/DT	dobj||and/or-18/VBG||growth-20/NN	num||viruses-23/NNS||two-22/CD	prep_of||growth-20/NN||viruses-23/NNS	dep||signaling-17/VBG||making-25/VBG	det||line-28/NN||this-26/DT	nn||line-28/NN||cell-27/NN	dobj||making-25/VBG||line-28/NN	det||reagent-31/NN||a-29/DT	amod||reagent-31/NN||useful-30/JJ	dobj||signaling-17/VBG||reagent-31/NN	prepc_for||reagent-31/NN||studying-33/VBG	amod||replication-35/JJ||viral-34/JJ	dobj||studying-33/VBG||replication-35/JJ	amod||interactions-38/NNS||virus-cell-37/JJ	dobj||studying-33/VBG||interactions-38/NNS	conj_and||replication-35/JJ||interactions-38/NNS	virus--1||viruses-23||no||taken together, our data indicate that expression of htert does not alter type 1 ifn signaling and/or the growth of two viruses, making this cell line a useful reagent for studying viral replication and virus-cell interactions.
aux||investigate-2/VB||to-1/TO	advcl||tested-41/VBD||investigate-2/VB	det||occurrence-5/NN||the-3/DT	amod||occurrence-5/NN||possible-4/JJ	dobj||investigate-2/VB||occurrence-5/NN	iobj||investigate-2/VB||occurrence-5/NN	prep_of||occurrence-5/NN||humanimmunodeficiencyvirus-7/NNS	appos||humanimmunodeficiencyvirus-7/NNS||hiv-9/NN	amod||virus-15/NN||human-12/JJ	amod||virus-15/NN||t-cell-13/JJ	amod||virus-15/NN||lymphotropic-14/JJ	prep_of||occurrence-5/NN||virus-15/NN	conj_or||humanimmunodeficiencyvirus-7/NNS||virus-15/NN	nn||i-18/NNS||type-17/NN	appos||virus-15/NN||i-18/NNS	appos||occurrence-5/NN||htlv-i-20/NNP	dep||occurrence-5/NN||infections-22/NNS	det||states-26/NNS||the-24/DT	amod||states-26/NNS||united-25/VBN	prep_in||infections-22/NNS||states-26/NNS	prep_prior_to||investigate-2/VB||1979-1981-29/CD	advmod||recognized-38/VBN||when-31/WRB	nsubjpass||recognized-38/VBN||acquiredimmunedeficiencysyndrome-32/NN	appos||acquiredimmunedeficiencysyndrome-32/NN||aids-34/NNS	auxpass||recognized-38/VBN||was-36/VBD	advmod||recognized-38/VBN||first-37/RB	advcl||investigate-2/VB||recognized-38/VBN	nsubj||tested-41/VBD||we-40/PRP	root||ROOT-0/null||tested-41/VBD	dobj||tested-41/VBD||sera-42/NN	amod||women-46/NNS||310-44/JJ	amod||women-46/NNS||pregnant-45/JJ	prep_from||tested-41/VBD||women-46/NNS	nsubj||participated-48/VBD||women-46/NNS	rcmod||women-46/NNS||participated-48/VBD	det||project-53/NN||the-50/DT	amod||project-53/NN||collaborative-51/JJ	amod||project-53/NN||perinatal-52/JJ	prep_in||participated-48/VBD||project-53/NN	det||1959-1964-57/NN||the-55/DT	nn||1959-1964-57/NN||period-56/NN	prep_during||participated-48/VBD||1959-1964-57/NN	prep_for||1959-1964-57/NN||hiv-59/NN	prep_for||1959-1964-57/NN||htlv-iantibody-61/NN	conj_and||hiv-59/NN||htlv-iantibody-61/NN	acquiredimmunedeficiencysyndrome-32||hiv-59||no||to investigate the possible occurrence of humanimmunodeficiencyvirus (hiv) or human t-cell lymphotropic virus, type i (htlv-i) infections in the united states prior to 1979-1981, when acquiredimmunedeficiencysyndrome (aids) was first recognized, we tested sera from 310 pregnant women who participated in the collaborative perinatal project during the period 1959-1964 for hiv and htlv-iantibody.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||compare-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	ccomp||added-27/VBD||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	det||efficacy-10/NN||the-9/DT	dobj||compare-8/VB||efficacy-10/NN	dobj||compare-8/VB||safety-12/NN	conj_and||efficacy-10/NN||safety-12/NN	amod||liraglutide-19/NN||once-daily-14/JJ	amod||liraglutide-19/NN||human-15/JJ	amod||liraglutide-19/NN||glucagon-like-16/JJ	amod||liraglutide-19/NN||peptide-1-17/JJ	nn||liraglutide-19/NN||analogue-18/NN	prep_of||efficacy-10/NN||liraglutide-19/NN	amod||sitagliptin-24/NN||dipeptidyl-21/JJ	amod||sitagliptin-24/NN||peptidase-4-22/JJ	nn||sitagliptin-24/NN||inhibitor-23/NN	prep_with||liraglutide-19/NN||sitagliptin-24/NN	nsubj||added-27/VBD||each-26/DT	root||ROOT-0/null||added-27/VBD	prep_to||added-27/VBD||metformin-29/NN	num||weeks-33/NNS||52-32/CD	prep_over||added-27/VBD||weeks-33/NNS	prep_in||weeks-33/NNS||individuals-35/NNS	prep_with||individuals-35/NNS||type2diabetes-37/CD	type2diabetes-37||metformin-29||yes||the aim of this study was to compare the efficacy and safety of once-daily human glucagon-like peptide-1 analogue liraglutide with dipeptidyl peptidase-4 inhibitor sitagliptin, each added to metformin, over 52 weeks in individuals with type2diabetes.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubj||reduces-14/VBZ||treatment-3/NN	prep_in||treatment-3/NN||infants-5/NNS	appos||infants-5/NNS||ipti-7/NNP	prep_with||infants-5/NNS||sulphadoxine-pyrimethamine-10/NN	appos||treatment-3/NN||sp-12/NN	root||ROOT-0/null||reduces-14/VBZ	det||incidence-16/NN||the-15/DT	dobj||reduces-14/VBZ||incidence-16/NN	nn||episodes-19/NNS||malaria-18/NN	prep_of||incidence-16/NN||episodes-19/NNS	amod||children-22/NNS||young-21/JJ	prep_in||episodes-19/NNS||children-22/NNS	malaria-18||pyrimethamine--1||yes||intermittent preventive treatment in infants (ipti) with sulphadoxine-pyrimethamine (sp) reduces the incidence of malaria episodes in young children.
aux||strengthen-2/VB||to-1/TO	advcl||identified-13/VBD||strengthen-2/VB	dobj||strengthen-2/VB||support-3/NN	nn||planning-6/NN||family-5/NN	prep_for||support-3/NN||planning-6/NN	nn||prevention-9/NN||hiv-8/NN	prep_as||strengthen-2/VB||prevention-9/NN	nsubj||identified-13/VBD||we-11/PRP	nsubj||sought-35/VBD||we-11/PRP	nsubj||determine-37/VB||we-11/PRP	advmod||identified-13/VBD||systematically-12/RB	root||ROOT-0/null||identified-13/VBD	amod||individuals-15/NNS||key-14/JJ	dobj||identified-13/VBD||individuals-15/NNS	det||field-18/NN||the-17/DT	prep_in||identified-13/VBD||field-18/NN	amod||hiv/aids-21/NNS||international-20/JJ	prep_of||field-18/NN||hiv/aids-21/NNS	advmod||field-18/NN||â-22/RB	pobj||â-22/RB||$-23/$	dep||field-18/NN||those-25/DT	nsubj||influence-29/VB||those-25/DT	aux||influence-29/VB||could-27/MD	advmod||influence-29/VB||potentially-28/RB	rcmod||those-25/DT||influence-29/VB	det||$-32/$||the-30/DT	amod||$-32/$||issueâ-31/JJ	dobj||influence-29/VB||$-32/$	conj_and||identified-13/VBD||sought-35/VBD	aux||determine-37/VB||to-36/TO	xcomp||sought-35/VBD||determine-37/VB	poss||perceptions-39/NNS||their-38/PRP$	dobj||determine-37/VB||perceptions-39/NNS	prep_of||perceptions-39/NNS||barriers-41/NNS	aux||facilitators-44/NNS||to-42/TO	cc||facilitators-44/NNS||and-43/CC	vmod||determine-37/VB||facilitators-44/NNS	prepc_for||facilitators-44/NNS||implementing-46/VBG	det||strategy-49/NN||this-47/DT	amod||strategy-49/NN||pmtct-48/JJ	dobj||implementing-46/VBG||strategy-49/NN	aids--1||hiv-8||no||to strengthen support for family planning as hiv prevention, we systematically identified key individuals in the field of international hiv/aidsâthose who could potentially influence the issueâand sought to determine their perceptions of barriers to and facilitators for implementing this pmtct strategy.
nsubjpass||excluded-14/VBN||subjects-1/NNS	amod||infections-6/NNS||hepatitisb-3/JJ	conj_and||hepatitisb-3/JJ||c-5/SYM	amod||infections-6/NNS||c-5/SYM	prep_with||subjects-1/NNS||infections-6/NNS	det||consumption-12/NN||those-8/DT	amod||consumption-12/NN||reporting-9/VBG	amod||consumption-12/NN||moderate-10/JJ	nn||consumption-12/NN||alcohol-11/NN	conj_and||subjects-1/NNS||consumption-12/NN	nsubjpass||excluded-14/VBN||consumption-12/NN	auxpass||excluded-14/VBN||were-13/VBD	root||ROOT-0/null||excluded-14/VBN	det||study-17/NN||the-16/DT	prep_from||excluded-14/VBN||study-17/NN	alcohol-11||hepatitisb-3||no_rel||subjects with hepatitisb and c infections and those reporting moderate alcohol consumption were excluded from the study.
amod||children-2/NNS||thirty-four-1/JJ	nsubjpass||screened-25/VBN||children-2/NNS	num||males-5/NNS||25-4/CD	dep||children-2/NNS||males-5/NNS	amod||age-8/NN||median-7/JJ	dep||males-5/NNS||age-8/NN	number||â-10/CD||10.8-9/CD	num||yrs-13/NN||â-10/CD	nn||yrs-13/NN||±-11/NNP	num||yrs-13/NN||3.4-12/CD	dep||age-8/NN||yrs-13/NN	amod||obesity-17/NN||severe-16/JJ	prep_with||children-2/NNS||obesity-17/NN	dep||children-2/NNS||bmi-19/VBN	xcomp||bmi-19/VBN||>-20/VBG	num||%-22/NN||95-21/CD	dobj||>-20/VBG||%-22/NN	auxpass||screened-25/VBN||were-24/VBD	root||ROOT-0/null||screened-25/VBN	prep_for||screened-25/VBN||diabetes-27/NN	amod||test-32/NN||oral-29/JJ	nn||test-32/NN||glucose-30/NN	nn||test-32/NN||tolerance-31/NN	prep_with||diabetes-27/NN||test-32/NN	appos||test-32/NN||ogtt-34/NN	amod||inflammation-38/NN||systemic-37/JJ	prep_for||screened-25/VBN||inflammation-38/NN	conj_and||diabetes-27/NN||inflammation-38/NN	amod||protein-41/NN||c-reactive-40/JJ	prep_with||inflammation-38/NN||protein-41/NN	appos||protein-41/NN||crp-43/NN	nn||inflammation-47/NN||gut-46/NN	prep_for||screened-25/VBN||inflammation-47/NN	conj_and||diabetes-27/NN||inflammation-47/NN	amod||nitricoxide-50/NN||rectal-49/JJ	prep_with||inflammation-47/NN||nitricoxide-50/NN	discourse||nitricoxide-50/NN||no-52/UH	amod||calprotectin-56/NN||faecal-55/JJ	prep_with||inflammation-47/NN||calprotectin-56/NN	conj_and||nitricoxide-50/NN||calprotectin-56/NN	inflammation-47||glucose-30||no_rel||thirty-four children (25 males; median age 10.8 â± 3.4 yrs) with severe obesity (bmi >95%) were screened for diabetes with oral glucose tolerance test (ogtt), systemic inflammation with c-reactive protein (crp) and gut inflammation with rectal nitricoxide (no) and faecal calprotectin.
det||incidence-3/NN||the-1/DT	nn||incidence-3/NN||cancer-2/NN	nsubj||higher-9/JJR||incidence-3/NN	nn||nonusers-6/NNS||insulin-5/NN	prep_in||incidence-3/NN||nonusers-6/NNS	cop||higher-9/JJR||was-7/VBD	advmod||higher-9/JJR||much-8/RB	root||ROOT-0/null||higher-9/JJR	prep_than||higher-9/JJR||that-11/DT	nn||users-14/NNS||insulin-13/NN	prep_in||-lrb--15/NN||users-14/NNS	rcmod||that-11/DT||-lrb--15/NN	num||-lrb--15/NN||49.2-16/CD	prep||-lrb--15/NN||vs.-17/FW	pobj||vs.-17/FW||10.2-18/CD	num||person-years-22/NNS||1,000-21/CD	prep_per||-lrb--15/NN||person-years-22/NNS	advmod||<-25/JJ||p-24/RB	dep||higher-9/JJR||<-25/JJ	num||-rrb--27/NNS||0.0001-26/CD	dep||higher-9/JJR||-rrb--27/NNS	cancer-2||insulin-13||no_rel||the cancer incidence in insulin nonusers was much higher than that in insulin users -lrb- 49.2 vs. 10.2 , per 1,000 person-years , p < 0.0001 -rrb- .
nsubj||superior-3/JJ||entecavir-1/NN	nsubj||adefovir-5/VB||entecavir-1/NN	cop||superior-3/JJ||is-2/VBZ	root||ROOT-0/null||superior-3/JJ	aux||adefovir-5/VB||to-4/TO	xcomp||superior-3/JJ||adefovir-5/VB	amod||dna-10/NN||decreasing-7/VBG	nn||dna-10/NN||serum-8/NN	nn||dna-10/NN||hbv-9/NN	prep_in||adefovir-5/VB||dna-10/NN	amod||alt-13/NN||normalizing-12/VBG	prep_in||adefovir-5/VB||alt-13/NN	conj_and||dna-10/NN||alt-13/NN	amod||adefovir-38/NN||similar-15/JJ	prep_with||similar-15/JJ||adefovir-17/NN	prepc_in||adefovir-17/NN||clearing-19/VBG	vmod||clearing-19/VBG||hbeag-20/VBG	prepc_in||adefovir-17/NN||encouraging-22/VBG	conj_and||clearing-19/VBG||encouraging-22/VBG	amod||seroconversion-24/NN||hbeag-23/VBG	dobj||encouraging-22/VBG||seroconversion-24/NN	det||nucleos-28/NNS||the-26/DT	amod||nucleos-28/NNS||hbeag-positive-27/JJ	prep_for||seroconversion-24/NN||nucleos-28/NNS	amod||t-30/NN||-lrb--29/JJ	dep||encouraging-22/VBG||t-30/NN	dep||t-30/NN||-rrb--31/VBG	amod||patients-34/NNS||ide-naive-32/JJ	nn||patients-34/NNS||asian-33/NN	dobj||-rrb--31/VBG||patients-34/NNS	prep_with||-rrb--31/VBG||chronichepatitisb-36/NN	nsubjpass||used-42/VBN||adefovir-38/NN	aux||used-42/VBN||can-39/MD	auxpass||used-42/VBN||be-40/VB	advmod||used-42/VBN||still-41/RB	conj_but||superior-3/JJ||used-42/VBN	amod||therapy-45/NN||first-line-44/JJ	prep_for||used-42/VBN||therapy-45/NN	det||patients-48/NNS||these-47/DT	prep_in||therapy-45/NN||patients-48/NNS	hbv-9||adefovir-38||yes||entecavir is superior to adefovir in decreasing serum hbv dna and normalizing alt but similar with adefovir in clearing hbeag and encouraging hbeag seroconversion for the hbeag-positive nucleos -lrb- t -rrb- ide-naive asian patients with chronichepatitisb. adefovir can be still used for first-line therapy in these patients .
nsubj||drug-8/NN||topiramate-1/NN	appos||topiramate-1/NN||tpm-3/NN	cop||drug-8/NN||is-5/VBZ	det||drug-8/NN||a-6/DT	amod||drug-8/NN||widely-used-7/JJ	root||ROOT-0/null||drug-8/NN	det||treatment-11/NN||the-10/DT	prep_for||drug-8/NN||treatment-11/NN	prep_of||treatment-11/NN||epilepsy-13/NN	epilepsy-13||topiramate-1||yes||topiramate (tpm) is a widely-used drug for the treatment of epilepsy.
nsubj||emerging-12/VBG||il2ra/cd25-1/NNS	det||gene-4/NN||the-3/DT	appos||il2ra/cd25-1/NNS||gene-4/NN	nn||±-9/NNS||interleukin-2-6/NN	nn||±-9/NNS||receptor-7/NN	nn||±-9/NNS||î-8/NN	prep_for||gene-4/NN||±-9/NNS	aux||emerging-12/VBG||is-11/VBZ	root||ROOT-0/null||emerging-12/VBG	det||gene-17/NN||a-14/DT	amod||gene-17/NN||general-15/JJ	nn||gene-17/NN||susceptibility-16/NN	prep_as||emerging-12/VBG||gene-17/NN	prep_for||gene-17/NN||autoimmunediseases-19/NNS	poss||role-23/NN||its-22/PRP$	prep_because_of||autoimmunediseases-19/NNS||role-23/NN	det||development-26/NN||the-25/DT	prep_in||emerging-12/VBG||development-26/NN	prep_in||emerging-12/VBG||function-28/NN	conj_and||development-26/NN||function-28/NN	amod||cells-32/NNS||regulatory-30/JJ	nn||cells-32/NNS||t-31/NN	prep_of||development-26/NN||cells-32/NNS	det||association-35/NN||the-34/DT	prep_in||emerging-12/VBG||association-35/NN	conj_and||development-26/NN||association-35/NN	amod||polymorphisms-38/NNS||single-nucleotide-37/JJ	prep_of||association-35/NN||polymorphisms-38/NNS	parataxis||emerging-12/VBG||snps-40/VBZ	det||gene-44/NN||this-43/DT	prep_within||emerging-12/VBG||gene-44/NN	prep_with||gene-44/NN||type1diabetesmellitus-46/NNS	appos||type1diabetesmellitus-46/NNS||dm-48/NN	poss||disease-53/NN||graves-51/NNS	prep_with||gene-44/NN||disease-53/NN	conj_and||type1diabetesmellitus-46/NNS||disease-53/NN	prep_with||gene-44/NN||rheumatoidarthritis-55/NNS	conj_and||type1diabetesmellitus-46/NNS||rheumatoidarthritis-55/NNS	appos||rheumatoidarthritis-55/NNS||ra-57/NN	prep_with||gene-44/NN||multiplesclerosis-61/NNS	conj_and||type1diabetesmellitus-46/NNS||multiplesclerosis-61/NNS	appos||multiplesclerosis-61/NNS||ms-63/NN	interleukin-2-6||type1diabetesmellitus-46||no_rel||il2ra/cd25 , the gene for interleukin-2 receptor î±, is emerging as a general susceptibility gene for autoimmunediseases because of its role in the development and function of regulatory t cells and the association of single-nucleotide polymorphisms (snps) within this gene with type1diabetesmellitus (dm), graves' disease, rheumatoidarthritis (ra), and multiplesclerosis (ms).
nsubj||inhibited-12/VBD||inhibition-1/NN	nsubj||prevented-23/VBD||inhibition-1/NN	nn||synthesis-4/NN||cholesterol-3/NN	prep_of||inhibition-1/NN||synthesis-4/NN	prep_of||inhibition-1/NN||accumulation-6/NN	conj_and||synthesis-4/NN||accumulation-6/NN	prep_of||synthesis-4/NN||lanosterol-8/NN	amod||treatment-11/NN||ketoconazole-10/JJ	prep_after||lanosterol-8/NN||treatment-11/NN	root||ROOT-0/null||inhibited-12/VBD	dobj||inhibited-12/VBD||uptake-13/NN	nn||integrin-20/NNS||collagen-15/NN	conj_and||collagen-15/NN||virus-17/NN	nn||integrin-20/NNS||virus-17/NN	conj_and||collagen-15/NN||clustered-19/NN	nn||integrin-20/NNS||clustered-19/NN	prep_of||uptake-13/NN||integrin-20/NNS	conj_and||inhibited-12/VBD||prevented-23/VBD	dobj||prevented-23/VBD||formation-24/NN	nn||bodies-27/NNS||multivesicular-26/NN	prep_of||formation-24/NN||bodies-27/NNS	prep_of||formation-24/NN||virusinfection-29/NNS	conj_and||bodies-27/NNS||virusinfection-29/NNS	cholesterol-3||virusinfection-29||no_rel||inhibition of cholesterol synthesis and accumulation of lanosterol after ketoconazole treatment inhibited uptake of collagen, virus and clustered integrin, and prevented formation of multivesicular bodies and virusinfection.
det||paper-2/NN||this-1/DT	nsubj||explores-3/VBZ||paper-2/NN	root||ROOT-0/null||explores-3/VBZ	advmod||informed-19/VBD||how-4/WRB	nn||information-6/NN||research-5/NN	nsubj||informed-19/VBD||information-6/NN	amod||findings-10/NNS||particular-9/JJ	prep_in||information-6/NN||findings-10/NNS	amod||trials-14/NNS||randomised-12/JJ	amod||trials-14/NNS||controlled-13/JJ	prep_from||findings-10/NNS||trials-14/NNS	amod||reviews-17/NNS||systematic-16/JJ	prep_from||findings-10/NNS||reviews-17/NNS	conj_and||trials-14/NNS||reviews-17/NNS	ccomp||explores-3/VBZ||informed-19/VBD	nn||making-21/NN||policy-20/NN	dobj||informed-19/VBD||making-21/NN	amod||development-25/NN||clinical-23/JJ	nn||development-25/NN||guideline-24/NN	dobj||informed-19/VBD||development-25/NN	conj_and||making-21/NN||development-25/NN	det||use-28/NN||the-27/DT	prep_for||making-21/NN||use-28/NN	prep_of||use-28/NN||magnesiumsulphate-30/NN	det||treatment-33/NN||the-32/DT	prep_in||informed-19/VBD||treatment-33/NN	prep_of||treatment-33/NN||eclampsia-35/NN	prep_of||treatment-33/NN||pre-eclampsia-37/NN	conj_and||eclampsia-35/NN||pre-eclampsia-37/NN	amod||africa-40/NN||south-39/JJ	prep_in||informed-19/VBD||africa-40/NN	eclampsia-35||magnesiumsulphate-30||yes||this paper explores how research information, in particular findings from randomised controlled trials and systematic reviews, informed policy making and clinical guideline development for the use of magnesiumsulphate in the treatment of eclampsia and pre-eclampsia in south africa.
det||purpose-2/NN||the-1/DT	nsubj||is-6/VBZ||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||is-6/VBZ	aux||investigate-8/VB||to-7/TO	ccomp||is-6/VBZ||investigate-8/VB	det||prevalence-10/NN||the-9/DT	dobj||investigate-8/VB||prevalence-10/NN	prep_of||prevalence-10/NN||hiv-12/NN	prep_among||hiv-12/NN||msm-14/NN	prepc_in||investigate-8/VB||heilongjiang-16/VBG	dobj||heilongjiang-16/VBG||province-17/NN	aux||assess-20/VB||to-19/TO	ccomp||is-6/VBZ||assess-20/VB	conj_and||investigate-8/VB||assess-20/VB	poss||levels-23/NNS||their-21/PRP$	nn||levels-23/NNS||knowledge-22/NN	dobj||assess-20/VB||levels-23/NNS	nn||behaviors-26/NNS||risk-25/NN	dobj||assess-20/VB||behaviors-26/NNS	conj_and||levels-23/NNS||behaviors-26/NNS	advmod||assess-20/VB||related-27/VBN	prep_to||related-27/VBN||hiv/aids-29/NNS	aux||explore-33/VB||to-32/TO	ccomp||is-6/VBZ||explore-33/VB	conj_and||investigate-8/VB||explore-33/VB	poss||associations-35/NNS||their-34/PRP$	dobj||explore-33/VB||associations-35/NNS	nn||resources-38/NNS||information-37/NN	prep_with||explore-33/VB||resources-38/NNS	aids--1||hiv-12||no||the purpose of this study is to investigate the prevalence of hiv among msm in heilongjiang province, to assess their knowledge levels and risk behaviors related to hiv/aids, and to explore their associations with information resources.
det||survey-2/NN||this-1/DT	nsubj||inh-4/VBP||survey-2/NN	vmod||survey-2/NN||evaluated-3/VBN	root||ROOT-0/null||inh-4/VBP	amod||mutations-6/NNS||resistant-associated-5/JJ	dobj||inh-4/VBP||mutations-6/NNS	mark||determine-10/VB||in-7/IN	dep||determine-10/VB||order-8/NN	aux||determine-10/VB||to-9/TO	advcl||inh-4/VBP||determine-10/VB	amod||detection-12/NN||rapid-11/JJ	dobj||determine-10/VB||detection-12/NN	nn||resistance-15/NN||tb-14/NN	prep_of||detection-12/NN||resistance-15/NN	tb-14||inh-4||yes||this survey evaluated inh resistant-associated mutations in order to determine rapid detection of tb resistance.
det||viruses-2/NNS||these-1/DT	nsubj||show-3/VBP||viruses-2/NNS	root||ROOT-0/null||show-3/VBP	dobj||show-3/VBP||persistence-4/NN	prep_in||show-3/VBP||oysters-6/NNS	nsubj||suggests-9/VBZ||oysters-6/NNS	rcmod||oysters-6/NNS||suggests-9/VBZ	det||mechanism-12/NN||an-10/DT	amod||mechanism-12/NN||active-11/JJ	dobj||suggests-9/VBZ||mechanism-12/NN	nn||concentration-15/NN||virus-14/NN	prep_of||mechanism-12/NN||concentration-15/NN	virus-14||viruses-2||no||these viruses show persistence in oysters, which suggests an active mechanism of virus concentration.
det||findings-2/NNS||these-1/DT	nsubj||point-3/VBP||findings-2/NNS	root||ROOT-0/null||point-3/VBP	det||immunological-7/NN||the-5/DT	amod||immunological-7/NN||relevant-6/JJ	prep_to||point-3/VBP||immunological-7/NN	advmod||involved-9/VBN||pathway-8/RB	vmod||immunological-7/NN||involved-9/VBN	prep_in||involved-9/VBN||resistance-11/NN	aux||invasive-13/VB||to-12/TO	xcomp||involved-9/VBN||invasive-13/VB	dobj||invasive-13/VB||aspergillosis-14/NNS	xcomp||involved-9/VBN||warrant-16/VB	conj_and||invasive-13/VB||warrant-16/VB	amod||study-18/NN||further-17/JJ	dobj||warrant-16/VB||study-18/NN	det||effects-21/NNS||the-20/DT	prep_of||study-18/NN||effects-21/NNS	nn||polymorphisms-26/NNS||tlr-23/NN	conj_and||tlr-23/NN||cytokine-25/NN	nn||polymorphisms-26/NNS||cytokine-25/NN	prep_of||effects-21/NNS||polymorphisms-26/NNS	poss||interaction-29/NN||their-28/PRP$	prep_of||study-18/NN||interaction-29/NN	conj_and||effects-21/NNS||interaction-29/NN	nsubj||occur-33/VB||interaction-29/NN	aux||occur-33/VB||may-32/MD	rcmod||interaction-29/NN||occur-33/VB	amod||levels-36/NNS||different-35/JJ	prep_on||occur-33/VB||levels-36/NNS	det||interplay-41/NN||the-38/DT	amod||interplay-41/NN||complex-39/JJ	amod||interplay-41/NN||biological-40/JJ	prep_of||levels-36/NNS||interplay-41/NN	det||host-45/NN||the-43/DT	amod||host-45/NN||immunocompromised-44/JJ	prep_between||interplay-41/NN||host-45/NN	nn||sp-48/NN||aspergillus-47/NNS	prep_between||interplay-41/NN||sp-48/NN	conj_and||host-45/NN||sp-48/NN	aspergillosis-14||aspergillus-47||no||these findings point to the relevant immunological pathway involved in resistance to invasive aspergillosis and warrant further study of the effects of tlr and cytokine polymorphisms and their interaction, which may occur on different levels of the complex biological interplay between the immunocompromised host and aspergillus sp .
amod||hypoglycemia-3/NN||progressive-2/JJ	prep_during||demonstrated-7/VBD||hypoglycemia-3/NN	det||subjects-6/NNS||these-5/DT	nsubj||demonstrated-7/VBD||subjects-6/NNS	root||ROOT-0/null||demonstrated-7/VBD	amod||release-10/NN||less-8/JJR	nn||release-10/NN||epinephrine-9/NN	dobj||demonstrated-7/VBD||release-10/NN	dep||release-10/NN||p-12/VBN	dep||0.02-14/CD||=-13/SYM	ccomp||p-12/VBN||0.02-14/CD	amod||impairments-19/NNS||greater-17/JJR	amod||impairments-19/NNS||driving-18/VBG	dobj||demonstrated-7/VBD||impairments-19/NNS	conj_and||release-10/NN||impairments-19/NNS	dep||impairments-19/NNS||p-21/VBN	dep||0.03-23/CD||=-22/SYM	ccomp||p-21/VBN||0.03-23/CD	hypoglycemia-3||epinephrine-9||no_rel||during progressive hypoglycemia, these subjects demonstrated less epinephrine release ( p = 0.02) and greater driving impairments ( p = 0.03).
det||profile-4/NN||the-1/DT	amod||profile-4/NN||largest-2/JJS	nn||profile-4/NN||mar-3/NN	nsubj||contained-5/VBD||profile-4/NN	nsubjpass||observed-23/VBN||profile-4/NN	root||ROOT-0/null||contained-5/VBD	num||antibiotics-7/NNS||six-6/CD	dobj||contained-5/VBD||antibiotics-7/NNS	dep||antibiotics-7/NNS||penicilling-9/NN	appos||penicilling-9/NN||methicillin-11/NN	appos||penicilling-9/NN||erythromycin-13/NN	conj_and||methicillin-11/NN||erythromycin-13/NN	appos||penicilling-9/NN||ciprofloxacin-15/NN	conj_and||methicillin-11/NN||ciprofloxacin-15/NN	appos||penicilling-9/NN||clindamycin-17/NN	conj_and||methicillin-11/NN||clindamycin-17/NN	appos||penicilling-9/NN||clarithromycin-19/NN	conj_and||methicillin-11/NN||clarithromycin-19/NN	auxpass||observed-23/VBN||was-22/VBD	conj_and||contained-5/VBD||observed-23/VBN	det||isolates-27/NN||the-25/DT	nn||isolates-27/NN||mrsa-26/NN	prep_in||observed-23/VBN||isolates-27/NN	predet||uk-31/NN||both-29/PDT	det||uk-31/NN||the-30/DT	prep_in||isolates-27/NN||uk-31/NN	amod||cohorts-34/NNS||maltese-33/JJ	prep_in||isolates-27/NN||cohorts-34/NNS	conj_and||uk-31/NN||cohorts-34/NNS	mrsa-26||methicillin-11||no_rel||the largest mar profile contained six antibiotics (penicilling, methicillin, erythromycin, ciprofloxacin, clindamycin and clarithromycin) and was observed in the mrsa isolates in both the uk and maltese cohorts.
amod||lymphohistiocytosis-2/NNS||hemophagocytic-1/JJ	nsubjpass||described-8/VBN||lymphohistiocytosis-2/NNS	nsubj||occurs-23/VBZ||lymphohistiocytosis-2/NNS	appos||lymphohistiocytosis-2/NNS||hlh-4/NN	aux||described-8/VBN||has-6/VBZ	auxpass||described-8/VBN||been-7/VBN	root||ROOT-0/null||described-8/VBN	prep_in||described-8/VBN||patients-10/NNS	amod||stages-13/NNS||advanced-12/JJ	prep_with||patients-10/NNS||stages-13/NNS	nn||infection-19/NN||humanimmunodeficiencyvirus-15/NNP	appos||infection-19/NN||hiv-17/NN	prep_of||stages-13/NNS||infection-19/NN	advmod||occurs-23/VBZ||rarely-22/RB	conj_but||described-8/VBN||occurs-23/VBZ	det||stage-27/NN||the-25/DT	nn||stage-27/NN||seroconversion-26/NN	prep_during||occurs-23/VBZ||stage-27/NN	prep_of||stage-27/NN||acutehivinfection-29/NN	acutehivinfection-29||hiv-17||no||hemophagocytic lymphohistiocytosis (hlh) has been described in patients with advanced stages of humanimmunodeficiencyvirus (hiv) infection, but rarely occurs during the seroconversion stage of acutehivinfection.
det||5-fluorouracil-4/NN||the-1/DT	amod||5-fluorouracil-4/NN||fluorinated-2/JJ	nn||5-fluorouracil-4/NN||pyrimidine-3/NN	nsubj||agent-13/NN||5-fluorouracil-4/NN	dep||5-fluorouracil-4/NN||5-6/CD	dep||5-6/CD||fu-8/NN	cop||agent-13/NN||is-10/VBZ	det||agent-13/NN||an-11/DT	amod||agent-13/NN||anticancer-12/JJ	root||ROOT-0/null||agent-13/NN	vmod||agent-13/NN||used-14/VBN	advmod||adjuvant-17/JJ||most-16/RBS	amod||regimens-21/NNS||adjuvant-17/JJ	conj_and||adjuvant-17/JJ||palliative-19/JJ	amod||regimens-21/NNS||palliative-19/JJ	nn||regimens-21/NNS||treatment-20/NN	prep_in||used-14/VBN||regimens-21/NNS	amod||cancer-24/NN||colorectal-23/JJ	prep_for||regimens-21/NNS||cancer-24/NN	cancer-24||adjuvant-17||no_rel||the fluorinated pyrimidine 5-fluorouracil (5- fu ) is an anticancer agent used in most adjuvant and palliative treatment regimens for colorectal cancer.
det||markers-3/NNS||these-1/DT	amod||markers-3/NNS||molecular-2/JJ	nsubj||indicate-4/VBP||markers-3/NNS	nsubj||high-14/JJ||markers-3/NNS	nsubj||rely-16/VB||markers-3/NNS	root||ROOT-0/null||indicate-4/VBP	mark||increasing-9/VBG||that-5/IN	amod||resistance-7/NN||pyrimethamine/sulfadoxine-6/JJ	nsubj||increasing-9/VBG||resistance-7/NN	aux||increasing-9/VBG||is-8/VBZ	ccomp||indicate-4/VBP||increasing-9/VBG	cop||high-14/JJ||is-11/VBZ	advmod||high-14/JJ||now-12/RB	advmod||high-14/JJ||too-13/RB	conj_and||indicate-4/VBP||high-14/JJ	aux||rely-16/VB||to-15/TO	xcomp||high-14/JJ||rely-16/VB	det||drug-19/NN||this-18/DT	prep_on||rely-16/VB||drug-19/NN	det||agent-24/NN||a-21/DT	amod||agent-24/NN||routine-22/JJ	amod||agent-24/NN||therapeutic-23/JJ	prep_as||drug-19/NN||agent-24/NN	aux||treat-26/VB||to-25/TO	xcomp||rely-16/VB||treat-26/VB	dobj||treat-26/VB||malaria-27/NN	prep_in||treat-26/VB||travelers-29/NNS	malaria-27||pyrimethamine--1||yes||these molecular markers indicate that pyrimethamine/sulfadoxine resistance is increasing and is now too high to rely on this drug as a routine therapeutic agent to treat malaria in travelers.
amod||reports-2/NNS||several-1/JJ	nsubj||indicate-3/VBP||reports-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||affects-7/VBZ||that-4/IN	nsubj||affects-7/VBZ||retinoicacid-5/NN	nsubj||alleviates-13/VBZ||retinoicacid-5/NN	advmod||affects-7/VBZ||positively-6/RB	advcl||indicate-3/VBP||affects-7/VBZ	det||progression-9/NN||the-8/DT	dobj||affects-7/VBZ||progression-9/NN	prep_of||progression-9/NN||fibrosis-11/NN	advcl||indicate-3/VBP||alleviates-13/VBZ	conj_and||affects-7/VBZ||alleviates-13/VBZ	det||accumulation-15/NN||the-14/DT	dobj||alleviates-13/VBZ||accumulation-15/NN	det||matrix-19/NN||the-17/DT	nn||matrix-19/NN||extracellular-18/NN	prep_of||accumulation-15/NN||matrix-19/NN	mark||report-24/VBP||whereas-21/IN	amod||studies-23/NNS||other-22/JJ	nsubj||report-24/VBP||studies-23/NNS	dep||affects-7/VBZ||report-24/VBP	det||opposite-26/NN||the-25/DT	dobj||report-24/VBP||opposite-26/NN	mark||exacerbates-30/VBZ||that-28/IN	nsubj||exacerbates-30/VBZ||retinoicacid-29/NN	nsubj||induces-33/VBZ||retinoicacid-29/NN	dep||affects-7/VBZ||exacerbates-30/VBZ	dobj||exacerbates-30/VBZ||fibrosis-31/NN	dep||affects-7/VBZ||induces-33/VBZ	conj_and||exacerbates-30/VBZ||induces-33/VBZ	nn||accumulation-36/NN||extracellular-34/NN	nn||accumulation-36/NN||matrix-35/NN	dobj||induces-33/VBZ||accumulation-36/NN	fibrosis-31||retinoicacid-29||no_rel||several reports indicate that retinoicacid positively affects the progression of fibrosis and alleviates the accumulation of the extracellular matrix, whereas other studies report the opposite; that retinoicacid exacerbates fibrosis and induces extracellular matrix accumulation.
advmod||started-10/VBD||then-1/RB	det||team-6/NN||the-3/DT	nn||team-6/NN||nutrition-4/NN	nn||team-6/NN||support-5/NN	nsubj||started-10/VBD||team-6/NN	nsubj||estimated-13/VBD||team-6/NN	appos||team-6/NN||nst-8/NN	root||ROOT-0/null||started-10/VBD	dobj||started-10/VBD||intervention-11/NN	conj_and||started-10/VBD||estimated-13/VBD	det||patient-15/NN||the-14/DT	poss||malnutrition-17/NN||patient-15/NN	dobj||estimated-13/VBD||malnutrition-17/NN	poss||weight-21/NN||her-19/PRP$	nn||weight-21/NN||body-20/NN	prep_from||estimated-13/VBD||weight-21/NN	number||kg-24/CD||30.1-23/CD	dep||weight-21/NN||kg-24/CD	nn||index-29/NN||body-27/NN	nn||index-29/NN||mass-28/NN	prep_from||estimated-13/VBD||index-29/NN	conj_and||weight-21/NN||index-29/NN	appos||index-29/NN||bmi-31/NN	appos||index-29/NN||13.9-34/NNP	amod||thickness-39/NN||triceps-37/JJ	amod||thickness-39/NN||skinfold-38/JJ	prep_from||estimated-13/VBD||thickness-39/NN	conj_and||weight-21/NN||thickness-39/NN	appos||thickness-39/NN||tsf-41/NN	number||mm-45/CD||3.5-44/CD	dep||thickness-39/NN||mm-45/CD	nn||circumference-49/NN||arm-48/NN	prep_from||estimated-13/VBD||circumference-49/NN	conj_and||weight-21/NN||circumference-49/NN	appos||circumference-49/NN||ac-51/NN	number||cm-55/CD||17.2-54/CD	dep||circumference-49/NN||cm-55/CD	nn||albumin-59/NN||serum-58/NN	prep_from||estimated-13/VBD||albumin-59/NN	conj_and||weight-21/NN||albumin-59/NN	num||g/dl-62/NN||2.6-61/CD	appos||albumin-59/NN||g/dl-62/NN	malnutrition-17||albumin-59||no_rel||then, the nutrition support team (nst) started intervention and estimated the patient's malnutrition from her body weight (30.1 kg), body mass index (bmi) (13.9), triceps skinfold thickness (tsf) (3.5 mm), arm circumference (ac) (17.2 cm) and serum albumin (2.6 g/dl).
nsubjpass||demonstrated-3/VBN||it-1/PRP	auxpass||demonstrated-3/VBN||was-2/VBD	root||ROOT-0/null||demonstrated-3/VBN	mark||effective-10/JJ||that-4/IN	amod||extract-8/NNS||persian-5/JJ	amod||extract-8/NNS||shallot-6/JJ	amod||extract-8/NNS||hydromethanolic-7/JJ	nsubj||effective-10/JJ||extract-8/NNS	cop||effective-10/JJ||was-9/VBD	ccomp||demonstrated-3/VBN||effective-10/JJ	num||species-14/NNS||10-12/CD	amod||species-14/NNS||different-13/JJ	prep_against||effective-10/JJ||species-14/NNS	amod||bacteria-17/NNS||pathogenic-16/JJ	prep_of||species-14/NNS||bacteria-17/NNS	prep_including||bacteria-17/NNS||methicillinresistantstaphylococcusaureus-19/NNS	appos||methicillinresistantstaphylococcusaureus-19/NNS||mrsa-21/NNP	amod||staphylococcusaureus-26/NNS||methicillin-24/JJ	amod||staphylococcusaureus-26/NNS||sensitive-25/JJ	appos||methicillinresistantstaphylococcusaureus-19/NNS||staphylococcusaureus-26/NNS	appos||staphylococcusaureus-26/NNS||mssa-28/NNP	appos||methicillinresistantstaphylococcusaureus-19/NNS||staphylococcusaureus-31/NNS	nn||epidermidis-34/NNS||staphylococcus-33/NN	appos||methicillinresistantstaphylococcusaureus-19/NNS||epidermidis-34/NNS	conj_and||staphylococcusaureus-31/NNS||epidermidis-34/NNS	appos||methicillinresistantstaphylococcusaureus-19/NNS||streptococcuspneumoniae-36/NN	conj_and||staphylococcusaureus-31/NNS||streptococcuspneumoniae-36/NN	appos||methicillinresistantstaphylococcusaureus-19/NNS||escherichiacoli-38/NNS	conj_and||staphylococcusaureus-31/NNS||escherichiacoli-38/NNS	amod||o157h7-41/NNS||escherichiacoli-40/JJ	appos||methicillinresistantstaphylococcusaureus-19/NNS||o157h7-41/NNS	conj_and||staphylococcusaureus-31/NNS||o157h7-41/NNS	appos||methicillinresistantstaphylococcusaureus-19/NNS||salmonellatyphimurium-43/NN	conj_and||staphylococcusaureus-31/NNS||salmonellatyphimurium-43/NN	amod||mirabilis-46/NNS||proteus-45/JJ	appos||methicillinresistantstaphylococcusaureus-19/NNS||mirabilis-46/NNS	conj_and||staphylococcusaureus-31/NNS||mirabilis-46/NNS	nn||pneumoniae-50/NN||klebsiella-49/NN	appos||methicillinresistantstaphylococcusaureus-19/NNS||pneumoniae-50/NN	conj_and||staphylococcusaureus-31/NNS||pneumoniae-50/NN	methicillinresistantstaphylococcusaureus-19||staphylococcusaureus-31||no||it was demonstrated that persian shallot hydromethanolic extract was effective against 10 different species of pathogenic bacteria including methicillinresistantstaphylococcusaureus (mrsa), methicillin sensitive staphylococcusaureus (mssa), staphylococcusaureus , staphylococcus epidermidis , streptococcuspneumoniae , escherichiacoli, escherichiacoli o157h7, salmonellatyphimurium, proteus mirabilis , and klebsiella pneumoniae .
det||bortezomib-4/NN||the-1/DT	amod||bortezomib-4/NN||fda-approved-2/JJ	nn||bortezomib-4/NN||drug-3/NN	nsubj||inhibitor-13/NN||bortezomib-4/NN	nn||®-7/NNP||velcadeâ-6/NNP	appos||bortezomib-4/NN||®-7/NNP	cop||inhibitor-13/NN||is-9/VBZ	det||inhibitor-13/NN||a-10/DT	amod||inhibitor-13/NN||peptide-11/JJ	nn||inhibitor-13/NN||boronate-12/NN	root||ROOT-0/null||inhibitor-13/NN	det||proteasome-17/NN||the-15/DT	amod||proteasome-17/NN||26s-16/JJ	prep_of||inhibitor-13/NN||proteasome-17/NN	nsubj||efficient-21/JJ||proteasome-17/NN	cop||efficient-21/JJ||is-19/VBZ	advmod||efficient-21/JJ||very-20/RB	rcmod||proteasome-17/NN||efficient-21/JJ	det||treatment-24/NN||the-23/DT	prep_for||efficient-21/JJ||treatment-24/NN	prep_of||treatment-24/NN||myelomas-26/NNS	amod||tumors-30/NNS||other-28/JJ	amod||tumors-30/NNS||hematological-29/JJ	prep_of||treatment-24/NN||tumors-30/NNS	conj_and||myelomas-26/NNS||tumors-30/NNS	myelomas-26||bortezomib-4||yes||the fda-approved drug bortezomib (velcadeâ®) is a peptide boronate inhibitor of the 26s proteasome that is very efficient for the treatment of myelomas and other hematological tumors.
det||deletion-4/NN||an-1/DT	amod||deletion-4/NN||in-frame-2/JJ	amod||deletion-4/NN||ae1-3/JJ	nsubj||aminoacids-7/VBZ||deletion-4/NN	prep_of||deletion-4/NN||nine-6/CD	root||ROOT-0/null||aminoacids-7/VBZ	det||domain-11/NN||the-9/DT	amod||domain-11/NN||cytoplasmic-10/JJ	prep_in||aminoacids-7/VBZ||domain-11/NN	det||ovalocytosis-36/NNS||a-13/DT	amod||ovalocytosis-36/NNS||proximity-14/JJ	det||results-19/NNS||the-16/DT	amod||results-19/NNS||membrane-17/JJ	nn||results-19/NNS||domain-18/NN	prep_to||proximity-14/JJ||results-19/NNS	det||increase-23/NN||a-21/DT	amod||increase-23/NN||marked-22/JJ	prep_in||results-19/NNS||increase-23/NN	amod||rigidity-26/NN||membrane-25/JJ	prep_in||increase-23/NN||rigidity-26/NN	amod||cells-30/NNS||ovalocytic-28/JJ	amod||cells-30/NNS||red-29/JJ	prep_in||results-19/NNS||cells-30/NNS	conj_and||increase-23/NN||cells-30/NNS	det||southeast-34/NN||the-32/DT	nn||southeast-34/NN||disease-33/NN	prep_in||cells-30/NNS||southeast-34/NN	nn||ovalocytosis-36/NNS||asian-35/NN	prep_in||domain-11/NN||ovalocytosis-36/NNS	appos||ovalocytosis-36/NNS||sao-38/NN	aminoacids-7||rigidity-26||no_rel||an in-frame ae1 deletion of nine aminoacids in the cytoplasmic domain in a proximity to the membrane domain results in a marked increase in membrane rigidity and ovalocytic red cells in the disease southeast asian ovalocytosis (sao).
neg||differences-3/NNS||no-1/DT	amod||differences-3/NNS||significant-2/JJ	nsubjpass||found-5/VBN||differences-3/NNS	auxpass||found-5/VBN||were-4/VBD	root||ROOT-0/null||found-5/VBN	nn||subjects-10/NNS||smoking-7/NN	conj_and||smoking-7/NN||non-smoking-9/NN	nn||subjects-10/NNS||non-smoking-9/NN	prep_between||found-5/VBN||subjects-10/NNS	amod||asthma-13/NN||mild-12/JJ	prep_with||subjects-10/NNS||asthma-13/NN	prep_in||asthma-13/NN||regard-15/NN	amod||changes-18/NNS||clinical-17/JJ	prep_to||found-5/VBN||changes-18/NNS	nn||control-21/NN||asthma-20/NN	prep_in||changes-18/NNS||control-21/NN	amod||function-24/NN||pulmonary-23/JJ	appos||control-21/NN||function-24/NN	nn||inflammation-27/NN||airway-26/NN	appos||control-21/NN||inflammation-27/NN	conj_and||function-24/NN||inflammation-27/NN	det||period-32/NN||a-29/DT	amod||period-32/NN||2-month-30/JJ	nn||period-32/NN||treatment-31/NN	prep_following||function-24/NN||period-32/NN	prep_with||period-32/NN||budesonide-34/NN	det||association-37/NN||the-36/DT	prep_following||function-24/NN||association-37/NN	conj_or||period-32/NN||association-37/NN	prep_of||association-37/NN||budesonide-39/NN	prep_of||association-37/NN||formoterol-41/NN	conj_and||budesonide-39/NN||formoterol-41/NN	det||period-44/NN||a-43/DT	prep_for||association-37/NN||period-44/NN	num||months-47/NNS||2-46/CD	prep_of||period-44/NN||months-47/NNS	asthma-20||budesonide-39||yes||no significant differences were found between smoking and non-smoking subjects with mild asthma in regard to clinical changes in asthma control, pulmonary function and airway inflammation following a 2-month treatment period with budesonide or the association of budesonide and formoterol for a period of 2 months.
det||mismatch-3/NN||an-1/DT	amod||mismatch-3/NN||allotype-2/JJ	nsubj||lead-13/VB||mismatch-3/NN	prep_between||mismatch-3/NN||adalimumab-5/NN	prep_between||mismatch-3/NN||igg-7/NN	conj_and||adalimumab-5/NN||igg-7/NN	amod||patients-10/NNS||adalimumab-treated-9/JJ	prep_in||adalimumab-5/NN||patients-10/NNS	aux||lead-13/VB||did-11/VBD	neg||lead-13/VB||not-12/RB	root||ROOT-0/null||lead-13/VB	det||frequency-17/NN||a-15/DT	amod||frequency-17/NN||higher-16/JJR	prep_to||lead-13/VB||frequency-17/NN	prep_of||frequency-17/NN||aaa-19/NN	aaa-19||adalimumab-5||no_rel||an allotype mismatch between adalimumab and igg in adalimumab-treated patients did not lead to a higher frequency of aaa.
det||trial-6/NN||a-2/DT	amod||trial-6/NN||prospective-3/JJ	amod||trial-6/NN||randomized-5/JJ	prep_in||non-inferior-10/JJ||trial-6/NN	nsubj||non-inferior-10/JJ||daptomycin-8/NN	cop||non-inferior-10/JJ||was-9/VBD	root||ROOT-0/null||non-inferior-10/JJ	amod||therapy-13/NN||standard-12/JJ	prep_to||non-inferior-10/JJ||therapy-13/NN	nn||endocarditis-18/NNS||staphylococcusaureusbacteraemia-15/NN	conj_and||staphylococcusaureusbacteraemia-15/NN||right-sided-17/JJ	nn||endocarditis-18/NNS||right-sided-17/JJ	prep_for||therapy-13/NN||endocarditis-18/NNS	staphylococcusaureusbacteraemia-15||daptomycin-8||no_rel||in a prospective, randomized trial, daptomycin was non-inferior to standard therapy for staphylococcusaureusbacteraemia and right-sided endocarditis.
amod||cancer-2/NN||colorectal-1/JJ	nsubjpass||associated-9/VBN||cancer-2/NN	nsubj||endocarditis-13/VBZ||cancer-2/NN	appos||cancer-2/NN||crc-4/NN	aux||associated-9/VBN||has-6/VBZ	advmod||associated-9/VBN||long-7/RB	auxpass||associated-9/VBN||been-8/VBN	root||ROOT-0/null||associated-9/VBN	prep_with||associated-9/VBN||bacteremia-11/NN	conj_and/or||associated-9/VBN||endocarditis-13/VBZ	amod||gallolyticus-16/JJ||streptococcus-15/JJ	amod||bacteria-18/NNS||gallolyticus-16/JJ	nn||bacteria-18/NNS||member-17/NN	prep_by||endocarditis-13/VBZ||bacteria-18/NNS	appos||bacteria-18/NNS||sgmb-20/NN	det||colonization-25/NN||the-23/DT	amod||colonization-25/NN||direct-24/JJ	nsubjpass||investigated-41/VBN||colonization-25/NN	prep_of||colonization-25/NN||sgmb-27/NN	poss||role-33/NN||its-30/PRP$	amod||role-33/NN||molecular-31/JJ	amod||role-33/NN||carcinogenic-32/JJ	prep_along_with||investigated-41/VBN||role-33/NN	dep||role-33/NN||if-35/IN	dep||if-35/IN||any-36/DT	aux||investigated-41/VBN||has-38/VBZ	neg||investigated-41/VBN||not-39/RB	auxpass||investigated-41/VBN||been-40/VBN	conj_but||associated-9/VBN||investigated-41/VBN	bacteremia-11||bacteria-18||no||colorectal cancer (crc) has long been associated with bacteremia and/or endocarditis by streptococcus gallolyticus member bacteria (sgmb) but the direct colonization of sgmb along with its molecular carcinogenic role, if any, has not been investigated.
amod||children-2/NNS||thirty-four-1/JJ	nsubjpass||screened-25/VBN||children-2/NNS	num||males-5/NNS||25-4/CD	dep||children-2/NNS||males-5/NNS	amod||age-8/NN||median-7/JJ	dep||males-5/NNS||age-8/NN	number||â-10/CD||10.8-9/CD	num||yrs-13/NN||â-10/CD	nn||yrs-13/NN||±-11/NNP	num||yrs-13/NN||3.4-12/CD	dep||age-8/NN||yrs-13/NN	amod||obesity-17/NN||severe-16/JJ	prep_with||children-2/NNS||obesity-17/NN	dep||children-2/NNS||bmi-19/VBN	xcomp||bmi-19/VBN||>-20/VBG	num||%-22/NN||95-21/CD	dobj||>-20/VBG||%-22/NN	auxpass||screened-25/VBN||were-24/VBD	root||ROOT-0/null||screened-25/VBN	prep_for||screened-25/VBN||diabetes-27/NN	amod||test-32/NN||oral-29/JJ	nn||test-32/NN||glucose-30/NN	nn||test-32/NN||tolerance-31/NN	prep_with||diabetes-27/NN||test-32/NN	appos||test-32/NN||ogtt-34/NN	amod||inflammation-38/NN||systemic-37/JJ	prep_for||screened-25/VBN||inflammation-38/NN	conj_and||diabetes-27/NN||inflammation-38/NN	amod||protein-41/NN||c-reactive-40/JJ	prep_with||inflammation-38/NN||protein-41/NN	appos||protein-41/NN||crp-43/NN	nn||inflammation-47/NN||gut-46/NN	prep_for||screened-25/VBN||inflammation-47/NN	conj_and||diabetes-27/NN||inflammation-47/NN	amod||nitricoxide-50/NN||rectal-49/JJ	prep_with||inflammation-47/NN||nitricoxide-50/NN	discourse||nitricoxide-50/NN||no-52/UH	amod||calprotectin-56/NN||faecal-55/JJ	prep_with||inflammation-47/NN||calprotectin-56/NN	conj_and||nitricoxide-50/NN||calprotectin-56/NN	obesity-17||glucose-30||no_rel||thirty-four children (25 males; median age 10.8 â± 3.4 yrs) with severe obesity (bmi >95%) were screened for diabetes with oral glucose tolerance test (ogtt), systemic inflammation with c-reactive protein (crp) and gut inflammation with rectal nitricoxide (no) and faecal calprotectin.
nsubj||have-9/VBP||adults-1/NNS	amod||living-5/NN||african-caribbean-3/JJ	nn||living-5/NN||origin-4/NN	prep_of||adults-1/NNS||living-5/NN	det||uk-8/NN||the-7/DT	prep_in||living-5/NN||uk-8/NN	root||ROOT-0/null||have-9/VBP	amod||increases-11/NNS||smaller-10/JJR	dobj||have-9/VBP||increases-11/NNS	amod||risk-14/NN||type2diabetes-13/JJ	prep_in||increases-11/NNS||risk-14/NN	vmod||increases-11/NNS||raised-16/VBN	xcomp||raised-16/VBN||circulating-17/VBG	dobj||circulating-17/VBG||insulin-18/NN	dobj||circulating-17/VBG||hdl-cholesterol-20/NN	conj_and||insulin-18/NN||hdl-cholesterol-20/NN	amod||triglyceride-24/NN||low-23/JJ	dobj||have-9/VBP||triglyceride-24/NN	conj_and||increases-11/NNS||triglyceride-24/NN	amod||concentrations-28/NNS||c-reactive-26/JJ	nn||concentrations-28/NNS||protein-27/NN	conj_and||increases-11/NNS||concentrations-28/NNS	conj_and||triglyceride-24/NN||concentrations-28/NNS	insulin-18||type2diabetes-13||no_rel||adults of african-caribbean origin living in the uk have smaller increases in type2diabetes risk, raised circulating insulin and hdl-cholesterol, and low triglyceride and c-reactive protein concentrations.
poss||laboratory-3/NN||our-2/PRP$	prep_in||address-6/VBP||laboratory-3/NN	nsubj||address-6/VBP||we-5/PRP	root||ROOT-0/null||address-6/VBP	advmod||unsettled-8/VBN||still-7/RB	amod||questions-9/NNS||unsettled-8/VBN	nsubj||ellipticine-47/VBP||questions-9/NNS	nsubj||mechanism-51/NN||questions-9/NNS	prep_of||ellipticine-47/VBP||mechanisms-13/NNS	prep_of||mechanisms-13/NNS||action-15/NN	amod||drugs-18/NNS||dna-damaging-17/JJ	prep_of||action-15/NN||drugs-18/NNS	nsubj||use-21/VBP||both-19/DT	advmod||use-21/VBP||currently-20/RB	rcmod||mechanisms-13/NNS||use-21/VBP	prep_for||use-21/VBP||treatment-23/NN	amod||neuroblastomas-26/NNS||human-25/JJ	prep_of||treatment-23/NN||neuroblastomas-26/NNS	dep||mechanisms-13/NNS||doxorubicin-28/NN	dep||mechanisms-13/NNS||cis-platin-30/NN	conj_and||doxorubicin-28/NN||cis-platin-30/NN	dep||mechanisms-13/NNS||cyclophosphamide-32/NN	conj_and||doxorubicin-28/NN||cyclophosphamide-32/NN	dep||mechanisms-13/NNS||etoposide-34/NN	conj_and||doxorubicin-28/NN||etoposide-34/NN	det||growth-41/NN||another-37/DT	amod||growth-41/NN||anticancer-38/JJ	nn||growth-41/NN||agent-39/NN	amod||growth-41/NN||decreasing-40/VBG	conj_and||mechanisms-13/NNS||growth-41/NN	prep_of||ellipticine-47/VBP||growth-41/NN	prep_of||growth-41/NN||neuroblastomas-43/NNS	prep_in||neuroblastomas-43/NNS||vitro-45/NNP	rcmod||questions-9/NNS||ellipticine-47/VBP	cop||mechanism-51/NN||are-49/VBP	amod||mechanism-51/NN||predominant-50/JJ	ccomp||address-6/VBP||mechanism-51/NN	dep||mechanism-51/NN||s-53/PRP	amod||mechanism-51/NN||responsible-55/JJ	poss||action-59/NN||their-57/PRP$	nn||action-59/NN||antitumor-58/NN	prep_for||responsible-55/JJ||action-59/NN	nn||lines-63/NNS||neuroblastoma-61/NN	nn||lines-63/NNS||cell-62/NN	prep_in||mechanism-51/NN||lines-63/NNS	prep_in||mechanism-51/NN||vitro-65/NN	neuroblastoma-61||etoposide-34||yes||in our laboratory, we address still unsettled questions, which of mechanisms of action of dna-damaging drugs both currently use for treatment of human neuroblastomas (doxorubicin, cis-platin, cyclophosphamide and etoposide) and another anticancer agent decreasing growth of neuroblastomas in vitro , ellipticine, are predominant mechanism(s) responsible for their antitumor action in neuroblastoma cell lines in vitro .
advmod||occurring-3/VBG||naturally-2/RB	prepc_with||undertook-13/VBD||occurring-3/VBG	amod||sub-populations-7/NNS||susceptible-4/JJ	conj_and||susceptible-4/JJ||resistant-6/JJ	amod||sub-populations-7/NNS||resistant-6/JJ	dobj||occurring-3/VBG||sub-populations-7/NNS	amod||westnileencephalitis-10/NNS||lethal-9/JJ	prep_to||occurring-3/VBG||westnileencephalitis-10/NNS	nsubj||undertook-13/VBD||we-12/PRP	root||ROOT-0/null||undertook-13/VBD	det||study-17/NN||a-14/DT	amod||study-17/NN||case-control-15/JJ	nn||study-17/NN||association-16/NN	dobj||undertook-13/VBD||study-17/NN	aux||investigate-19/VB||to-18/TO	vmod||undertook-13/VBD||investigate-19/VB	mark||plays-36/VBZ||whether-20/IN	ccomp||plays-36/VBZ||similar-22/JJ	prep_to||similar-22/JJ||humans-24/NNS	appos||humans-24/NNS||oas1-26/NNP	prep_to||similar-22/JJ||mice-29/NNS	conj_and||humans-24/NNS||mice-29/NNS	appos||humans-24/NNS||oas1b-31/NNP	amod||oas1-35/NNS||equine-34/JJ	nsubj||plays-36/VBZ||oas1-35/NNS	ccomp||investigate-19/VB||plays-36/VBZ	det||role-38/NN||a-37/DT	dobj||plays-36/VBZ||role-38/NN	prep_in||role-38/NN||resistance-40/NN	amod||infection-44/NN||severe-42/JJ	nn||infection-44/NN||wnv-43/NN	prep_to||plays-36/VBZ||infection-44/NN	westnileencephalitis-10||wnv-43||no||with naturally occurring susceptible and resistant sub-populations to lethal westnileencephalitis, we undertook a case-control association study to investigate whether, similar to humans ( oas1 ) and mice ( oas1b ), equine oas1 plays a role in resistance to severe wnv infection.
nsubj||causes-2/VBZ||chlamydiatrachomatis-1/NNS	root||ROOT-0/null||causes-2/VBZ	dobj||causes-2/VBZ||diseases-3/NNS	prep_such_as||diseases-3/NNS||trachoma-6/NN	amod||infection-9/NN||urogenital-8/JJ	prep_such_as||diseases-3/NNS||infection-9/NN	conj_and||trachoma-6/NN||infection-9/NN	nn||venereum-12/NN||lymphogranuloma-11/NN	prep_such_as||diseases-3/NNS||venereum-12/NN	conj_and||trachoma-6/NN||venereum-12/NN	amod||morbidity-15/NN||severe-14/JJ	prep_with||causes-2/VBZ||morbidity-15/NN	trachoma-6||chlamydiatrachomatis-1||no||chlamydiatrachomatis causes diseases such as trachoma, urogenital infection and lymphogranuloma venereum with severe morbidity.
advmod||is-8/VBZ||however-1/RB	prepc_as_of||is-8/VBZ||yet-5/RB	expl||is-8/VBZ||there-7/EX	root||ROOT-0/null||is-8/VBZ	neg||evidence-10/NN||no-9/DT	nsubj||is-8/VBZ||evidence-10/NN	det||criteria-13/NNS||the-12/DT	prep_on||evidence-10/NN||criteria-13/NNS	nsubj||guide-16/VB||criteria-13/NNS	aux||guide-16/VB||should-15/MD	rcmod||criteria-13/NNS||guide-16/VB	det||setting-19/NN||the-17/DT	nn||setting-19/NN||priority-18/NN	dobj||guide-16/VB||setting-19/NN	amod||programmes-22/NNS||hiv/aids-21/JJ	prep_of||setting-19/NN||programmes-22/NNS	prep_in||guide-16/VB||thailand-24/NN	poss||importance-29/NN||their-27/PRP$	amod||importance-29/NN||relative-28/JJ	prep_including||guide-16/VB||importance-29/NN	aids--1||hiv--1||no||however, as of yet, there is no evidence on the criteria that should guide the priority setting of hiv/aids programmes in thailand, including their relative importance.
amod||outcomes-2/NNS||secondary-1/JJ	nsubj||include-3/VBP||outcomes-2/NNS	root||ROOT-0/null||include-3/VBP	det||proportion-5/NN||the-4/DT	dobj||include-3/VBP||proportion-5/NN	dobj||-14/VBZ||proportion-5/NN	amod||users-9/NNS||new-7/JJ	nn||users-9/NNS||statin-8/NN	prep_of||proportion-5/NN||users-9/NNS	nn||â-13/NN||exhibit-11/NN	nn||â-13/NN||adherence-12/NN	nsubj||-14/VBZ||â-13/NN	rcmod||proportion-5/NN||-14/VBZ	number||80-16/CD||¥-15/CD	num||%-17/NN||80-16/CD	dobj||-14/VBZ||%-17/NN	dobj||-14/VBZ||persistence-20/NN	conj_and||%-17/NN||persistence-20/NN	nn||use-23/NN||statin-22/NN	prep_with||persistence-20/NN||use-23/NN	statin-22||secondary-1||no_rel||secondary outcomes include the proportion of new statin users who exhibit adherence â¥80%, and persistence with statin use.
cc||describe-22/VBP||in-1/IN	advmod||described-5/VBD||previously-4/RB	dep||describe-22/VBP||described-5/VBD	dobj||described-5/VBD||cases-6/NNS	amod||â-15/NN||flinders-8/JJ	nn||â-15/NN||island-9/NN	nn||â-15/NN||spottedfever-10/NN	nn||â-15/NN||-lrb--11/NN	nn||â-15/NN||rickettsia-12/NN	nn||â-15/NN||honei-13/NN	nn||â-15/NN||strain-14/NN	prep_of||cases-6/NNS||â-15/NN	nsubj||described-5/VBD||$-16/$	num||$-16/$||marmioniiâ-17/CD	amod||$-16/$||$-18/$	dep||$-18/$||-rrb--19/JJ	nsubj||describe-22/VBP||we-21/PRP	root||ROOT-0/null||describe-22/VBP	num||case-24/NN||1-23/CD	nsubj||typhus-28/VBZ||case-24/NN	amod||tick-27/NN||queensland-26/JJ	prep_of||case-24/NN||tick-27/NN	dep||describe-22/VBP||typhus-28/VBZ	amod||australis-31/NNS||-lrb--29/JJ	nn||australis-31/NNS||r.-30/NN	dobj||typhus-28/VBZ||australis-31/NNS	advmod||typhus-28/VBZ||-rrb--32/RB	num||cases-35/NNS||2-34/CD	nsubj||caused-38/VBD||cases-35/NNS	prep_of||cases-35/NNS||scrubtyphus-37/NNS	dep||describe-22/VBP||caused-38/VBD	conj_and||typhus-28/VBZ||caused-38/VBD	det||strain-42/NN||a-40/DT	amod||strain-42/NN||unique-41/JJ	prep_by||caused-38/VBD||strain-42/NN	num||orientiatsutsugamushi-44/NNS||-lrb--43/CD	npadvmod||-rrb--45/JJ||orientiatsutsugamushi-44/NNS	amod||strain-42/NN||-rrb--45/JJ	spottedfever-10||rickettsia-12||no||in addition to previously described cases of flinders island spottedfever -lrb- rickettsia honei strain â $ marmioniiâ $ -rrb- , we describe 1 case of queensland tick typhus -lrb- r. australis -rrb- and 2 cases of scrubtyphus caused by a unique strain -lrb- orientiatsutsugamushi -rrb- .
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	neg||correlation-4/NN||no-3/DT	nsubj||was-2/VBD||correlation-4/NN	amod||size-7/NN||infarct-6/JJ	prep_between||correlation-4/NN||size-7/NN	det||direction-10/NN||the-9/DT	nsubj||was-2/VBD||direction-10/NN	conj_and||correlation-4/NN||direction-10/NN	conj_and||correlation-4/NN||amplitude-12/NN	conj_or||direction-10/NN||amplitude-12/NN	amod||phase-15/NN||melatonin-14/JJ	prep_of||direction-10/NN||phase-15/NN	amod||phase-15/NN||shifting-16/VBG	infarct-6||melatonin-14||no_rel||there was no correlation between infarct size and the direction or amplitude of melatonin phase shifting.
amod||interventions-2/NNS||family-based-1/JJ	nsubjpass||established-15/VBN||interventions-2/NNS	prep_with||interventions-2/NNS||children-4/NNS	nsubjpass||affected-7/VBN||children-4/NNS	auxpass||affected-7/VBN||are-6/VBP	rcmod||children-4/NNS||affected-7/VBN	agent||affected-7/VBN||hiv-9/NN	agent||affected-7/VBN||aids-11/NNS	conj_and||hiv-9/NN||aids-11/NNS	auxpass||established-15/VBN||are-12/VBP	neg||established-15/VBN||not-13/RB	advmod||established-15/VBN||well-14/RB	root||ROOT-0/null||established-15/VBN	aids-11||hiv-9||no||family-based interventions with children who are affected by hiv and aids are not well established.
nsubjpass||evaluated-10/VBN||herein-1/NN	det||response-6/NN||the-3/DT	amod||response-6/NN||immune-mediated-4/JJ	nn||response-6/NN||cell-5/NN	appos||herein-1/NN||response-6/NN	prep_to||response-6/NN||hepatitiscantigens-8/NNS	auxpass||evaluated-10/VBN||was-9/VBD	root||ROOT-0/null||evaluated-10/VBN	amod||transfers-13/NNS||adoptive-12/JJ	agent||evaluated-10/VBN||transfers-13/NNS	amod||ester-17/NN||carboxyfluorescein-15/JJ	amod||ester-17/NN||succinimidyl-16/JJ	prep_of||transfers-13/NNS||ester-17/NN	appos||ester-17/NN||cfse-19/NN	vmod||ester-17/NN||labelled-21/VBN	dobj||labelled-21/VBN||splenocytes-22/NNS	amod||mice-26/NNS||hcv-24/JJ	amod||mice-26/NNS||immunized-25/JJ	prep_from||labelled-21/VBN||mice-26/NNS	amod||mice-30/NNS||hcv-28/JJ	amod||mice-30/NNS||transgenic-29/JJ	prep_into||labelled-21/VBN||mice-30/NNS	hepatitiscantigens-8||hcv-28||no||herein, the immune-mediated cell response to hepatitiscantigens was evaluated by adoptive transfers of carboxyfluorescein succinimidyl ester (cfse) labelled splenocytes from hcv immunized mice into hcv transgenic mice.
amod||effects-3/NNS||peripheral-1/JJ	nn||effects-3/NNS||vasodilatory-2/NN	root||ROOT-0/null||effects-3/NNS	det||monomer-7/NN||the-5/DT	nn||monomer-7/NN||cement-6/NN	prep_of||effects-3/NNS||monomer-7/NN	appos||effects-3/NNS||fat-9/JJ	appos||effects-3/NNS||marrowembolism-11/NN	conj_and||fat-9/JJ||marrowembolism-11/NN	appos||effects-3/NNS||activation-13/NN	conj_and||fat-9/JJ||activation-13/NN	det||cascade-17/NN||the-15/DT	amod||cascade-17/NN||clotting-16/VBG	prep_of||fat-9/JJ||cascade-17/NN	det||lungs-20/NNS||the-19/DT	prep_in||cascade-17/NN||lungs-20/NNS	nsubj||contribute-23/VBP||all-22/DT	nsubj||cement-25/VB||all-22/DT	dep||effects-3/NNS||contribute-23/VBP	aux||cement-25/VB||to-24/TO	xcomp||contribute-23/VBP||cement-25/VB	dobj||cement-25/VB||reaction-26/NN	marrowembolism-11||fat-9||no||peripheral vasodilatory effects of the cement monomer, fat and marrowembolism and activation of the clotting cascade in the lungs, all contribute to cement reaction.
det||bisphosphonate-3/NN||the-1/DT	amod||bisphosphonate-3/NN||oral-2/JJ	nsubj||appears-24/VBZ||bisphosphonate-3/NN	nsubj||mitigate-26/VB||bisphosphonate-3/NN	appos||bisphosphonate-3/NN||risedronate-5/NN	vmod||bisphosphonate-3/NN||dosed-7/VBN	det||food-11/NN||the-9/DT	nn||food-11/NN||us-10/PRP	prep_as||dosed-7/VBN||food-11/NN	nn||administration-14/NN||drug-13/NN	prep_as||dosed-7/VBN||administration-14/NN	conj_and||food-11/NN||administration-14/NN	vmod||administration-14/NN||approved-15/VBN	det||treatment-18/NN||the-17/DT	prep_for||approved-15/VBN||treatment-18/NN	prep_for||approved-15/VBN||prevention-20/NN	conj_or||treatment-18/NN||prevention-20/NN	prep_of||treatment-18/NN||postmenopausalosteoporosis-22/NNS	root||ROOT-0/null||appears-24/VBZ	aux||mitigate-26/VB||to-25/TO	xcomp||appears-24/VBZ||mitigate-26/VB	nn||loss-28/NN||bone-27/NN	dobj||mitigate-26/VB||loss-28/NN	vmod||loss-28/NN||associated-29/VBN	num||years-32/NNS||2-31/CD	prep_with||associated-29/VBN||years-32/NNS	amod||anastrozole-35/NN||adjuvant-34/JJ	prep_of||years-32/NNS||anastrozole-35/NN	prep_in||associated-29/VBN||women-37/NNS	amod||cancer-41/NN||early-stage-39/JJ	nn||cancer-41/NN||breast-40/NN	prep_with||women-37/NNS||cancer-41/NN	postmenopausalosteoporosis-22||risedronate-5||yes||the oral bisphosphonate, risedronate - dosed as the us food and drug administration approved for the treatment or prevention of postmenopausalosteoporosis - appears to mitigate bone loss associated with 2 years of adjuvant anastrozole in women with early-stage breast cancer.
advmod||produced-2/VBN||endogenously-1/RB	amod||interferons-3/NNS||produced-2/VBN	nsubj||regulate-5/VB||interferons-3/NNS	nsubjpass||administered-13/VBN||interferons-3/NNS	aux||regulate-5/VB||can-4/MD	root||ROOT-0/null||regulate-5/VB	det||growth-7/NN||the-6/DT	dobj||regulate-5/VB||growth-7/NN	nn||cells-10/NNS||melanoma-9/NN	prep_of||growth-7/NN||cells-10/NNS	auxpass||administered-13/VBN||are-12/VBP	conj_and||regulate-5/VB||administered-13/VBN	advmod||administered-13/VBN||exogenously-14/RB	amod||agents-17/NNS||therapeutic-16/JJ	prep_as||administered-13/VBN||agents-17/NNS	prep_to||administered-13/VBN||patients-19/NNS	amod||cancer-22/NN||advanced-21/JJ	prep_with||patients-19/NNS||cancer-22/NN	interferons-3||cancer-22||no_rel||endogenously produced interferons can regulate the growth of melanoma cells and are administered exogenously as therapeutic agents to patients with advanced cancer.
amod||rates-2/NNS||relapse-1/JJ	nsubj||high-9/JJ||rates-2/NNS	amod||treatments-6/NNS||current-4/JJ	nn||treatments-6/NNS||methamphetamineabuse-5/NN	prep_following||rates-2/NNS||treatments-6/NNS	cop||high-9/JJ||are-7/VBP	advmod||high-9/JJ||very-8/RB	dep||-lrb--10/VBD||high-9/JJ	root||ROOT-0/null||-lrb--10/VBD	number||1/4-12/CD||â-11/CD	num||40â-13/NNS||1/4-12/CD	dobj||-lrb--10/VBD||40â-13/NNS	nsubj||-lrb--10/VBD||$-14/$	num||%-17/NN||60-16/CD	npadvmod||-rrb--18/JJ||%-17/NN	amod||-rrb--32/NNS||-rrb--18/JJ	conj_and||-rrb--32/NNS||-rrb--18/JJ	npadvmod||arise-34/JJR||-rrb--18/JJ	det||impairments-23/NNS||the-21/DT	amod||impairments-23/NNS||neuropsychiatric-22/JJ	conj_and||-rrb--32/NNS||impairments-23/NNS	nn||-rrb--32/NNS||impairments-23/NNS	npadvmod||arise-34/JJR||impairments-23/NNS	nn||e.g.-25/NNP||-lrb--24/NNP	dep||impairments-23/NNS||e.g.-25/NNP	amod||-rrb--32/NNS||cognitive-27/JJ	conj_and||-rrb--32/NNS||cognitive-27/JJ	npadvmod||arise-34/JJR||cognitive-27/JJ	dep||cognitive-27/JJ||deficits-28/NNS	nn||disorders-31/NNS||mood-30/NN	appos||deficits-28/NNS||disorders-31/NNS	npadvmod||arise-34/JJR||-rrb--32/NNS	prep||-rrb--32/NNS||that-33/IN	amod||addiction-41/NNS||arise-34/JJR	conj_and||arise-34/JJR||persist-36/JJ	amod||addiction-41/NNS||persist-36/JJ	prep_during||persist-36/JJ||remission-38/NN	prep_from||remission-38/NN||methamphetamine-40/NN	npadvmod||likely-42/RB||addiction-41/NNS	dep||contribute-43/CD||likely-42/RB	num||$-14/$||contribute-43/CD	det||rates-48/NNS||these-45/DT	amod||rates-48/NNS||high-46/JJ	amod||rates-48/NNS||relapse-47/JJ	prep_to||$-14/$||rates-48/NNS	methamphetamineabuse-5||methamphetamine-40||no||relapse rates following current methamphetamineabuse treatments are very high -lrb- â 1/4 40â $ `` 60 % -rrb- , and the neuropsychiatric impairments -lrb- e.g. , cognitive deficits , mood disorders -rrb- that arise and persist during remission from methamphetamine addiction likely contribute to these high relapse rates .
det||varicellazostervirus-2/NNS||the-1/DT	nsubj||alpha-herpesvirus-10/NNS||varicellazostervirus-2/NNS	appos||varicellazostervirus-2/NNS||vzv-4/NN	cop||alpha-herpesvirus-10/NNS||is-6/VBZ	det||alpha-herpesvirus-10/NNS||a-7/DT	amod||alpha-herpesvirus-10/NNS||ubiquitous-8/JJ	amod||alpha-herpesvirus-10/NNS||human-9/JJ	root||ROOT-0/null||alpha-herpesvirus-10/NNS	nsubj||agent-15/NN||alpha-herpesvirus-10/NNS	cop||agent-15/NN||is-12/VBZ	det||agent-15/NN||the-13/DT	amod||agent-15/NN||causative-14/JJ	rcmod||alpha-herpesvirus-10/NNS||agent-15/NN	prep_of||agent-15/NN||chickenpox-17/NN	prep_of||agent-15/NN||shingles-19/NNS	conj_and||chickenpox-17/NN||shingles-19/NNS	chickenpox-17||vzv-4||yes||the varicellazostervirus (vzv) is a ubiquitous human alpha-herpesvirus that is the causative agent of chickenpox and shingles.
advmod||associated-19/VBN||interestingly-1/RB	amod||status-4/NN||vitamind-3/JJ	nsubjpass||associated-19/VBN||status-4/NN	det||start-7/NN||the-6/DT	prep_before||status-4/NN||start-7/NN	advmod||active-10/JJ||highly-9/RB	amod||therapy-12/NN||active-10/JJ	amod||therapy-12/NN||antiretroviral-11/JJ	prep_of||start-7/NN||therapy-12/NN	appos||therapy-12/NN||haart-14/NN	aux||associated-19/VBN||has-16/VBZ	auxpass||associated-19/VBN||been-17/VBN	advmod||associated-19/VBN||recently-18/RB	root||ROOT-0/null||associated-19/VBN	amod||progression-22/NN||hivdisease-21/JJ	prep_with||associated-19/VBN||progression-22/NN	amod||mortality-25/NN||overall-24/JJ	prep_with||associated-19/VBN||mortality-25/NN	conj_and||progression-22/NN||mortality-25/NN	amod||women-29/NNS||hiv-positive-27/JJ	amod||women-29/NNS||pregnant-28/JJ	prep_in||progression-22/NN||women-29/NNS	hivdisease-21||hiv--1||no||interestingly, vitamind status before the start of highly active antiretroviral therapy (haart) has been recently associated with hivdisease progression and overall mortality in hiv-positive pregnant women.
num||groups-4/NNS||two-1/CD	amod||groups-4/NNS||delocalized-2/JJ	nn||groups-4/NNS||carboxylâate-3/NN	nsubj||connected-7/JJ||groups-4/NNS	cop||connected-7/JJ||are-5/VBP	det||connected-7/JJ||each-6/DT	root||ROOT-0/null||connected-7/JJ	det||fashion-11/NN||a-9/DT	amod||fashion-11/NN||monodentate-10/JJ	prep_in||connected-7/JJ||fashion-11/NN	num||units-16/NNS||two-13/CD	amod||units-16/NNS||similar-14/JJ	nn||units-16/NNS||pentaâaquaâmanganese-15/NN	prep_to||connected-7/JJ||units-16/NNS	mark||uncoordinated-26/VBN||whereas-18/IN	det||groups-24/NNS||the-19/DT	amod||groups-24/NNS||other-20/JJ	num||groups-24/NNS||two-21/CD	amod||groups-24/NNS||localized-22/VBN	nn||groups-24/NNS||carboxylâate-23/NN	nsubjpass||uncoordinated-26/VBN||groups-24/NNS	auxpass||uncoordinated-26/VBN||are-25/VBP	advcl||connected-7/JJ||uncoordinated-26/VBN	uncoordinated-26||manganese--1||no_rel||two delocalized carboxylâ­ate groups are each connected in a monodentate fashion to two similar pentaâ­aquaâ­manganese units, whereas the other two localized carboxylâ­ate groups are uncoordinated.
num||expression-4/NN||decreased-1/CD	amod||expression-4/NN||cav-1-2/JJ	nn||expression-4/NN||gene-3/NN	nsubjpass||linked-7/VBN||expression-4/NN	auxpass||linked-7/VBN||was-5/VBD	advmod||linked-7/VBN||simultaneously-6/RB	root||ROOT-0/null||linked-7/VBN	amod||triglycerides-10/NNPS||increased-9/VBN	prep_to||linked-7/VBN||triglycerides-10/NNPS	amod||expression-15/NN||decreased-12/VBN	amod||expression-15/NN||lipogenic-13/JJ	nn||expression-15/NN||gene-14/NN	prep_to||linked-7/VBN||expression-15/NN	conj_and||triglycerides-10/NNPS||expression-15/NN	amod||subjects-18/NNS||obese-17/JJ	prep_among||linked-7/VBN||subjects-18/NNS	xcomp||linked-7/VBN||paralleling-20/VBG	det||observations-22/NNS||the-21/DT	dobj||paralleling-20/VBG||observations-22/NNS	prep_of||observations-22/NNS||hypertriglyceridemia-24/NN	amod||mice-28/NNS||cav-1-26/JJ	nn||mice-28/NNS||knockout-27/NN	prep_in||paralleling-20/VBG||mice-28/NNS	obese-17||triglycerides-10||no_rel||decreased cav-1 gene expression was simultaneously linked to increased triglycerides and decreased lipogenic gene expression among obese subjects, paralleling the observations of hypertriglyceridemia in cav-1 knockout mice.
nsubj||azole-5/NN||posaconazole-1/NN	cop||azole-5/NN||is-2/VBZ	det||azole-5/NN||the-3/DT	amod||azole-5/NN||only-4/JJ	root||ROOT-0/null||azole-5/NN	prep_with||azole-5/NN||activity-7/NN	prep_against||activity-7/NN||zygomycetes-9/NNS	amod||fungi-13/NNS||other-11/JJ	amod||fungi-13/NNS||difficult-to-treat-12/JJ	prep_against||activity-7/NN||fungi-13/NNS	conj_and||zygomycetes-9/NNS||fungi-13/NNS	vmod||azole-5/NN||representing-15/VBG	det||option-19/NN||a-16/DT	amod||option-19/NN||potential-17/JJ	nn||option-19/NN||treatment-18/NN	dobj||representing-15/VBG||option-19/NN	amod||mycosis-23/NNS||refractory-21/JJ	nn||mycosis-23/NNS||invasive-22/NN	prep_for||representing-15/VBG||mycosis-23/NNS	mycosis-23||fungi-13||no||posaconazole is the only azole with activity against zygomycetes and other difficult-to-treat fungi, representing a potential treatment option for refractory invasive mycosis.
det||use-2/NN||the-1/DT	nsubjpass||implicated-26/VBN||use-2/NN	amod||markers-5/NNS||selectable-4/JJ	prep_of||use-2/NN||markers-5/NNS	appos||markers-5/NNS||ecogpt-7/NN	nn||pressures-11/NNS||selection-10/NN	prep_of||use-2/NN||pressures-11/NNS	conj_and||markers-5/NNS||pressures-11/NNS	aux||aid-13/VB||to-12/TO	vmod||pressures-11/NNS||aid-13/VB	prep_in||aid-13/VB||detection-15/NN	amod||recombinants-23/NNS||poxvirus-17/JJ	dep||recombinants-23/NNS||vaccinia-19/NN	appos||vaccinia-19/NN||vv-21/NN	prep_of||detection-15/NN||recombinants-23/NNS	aux||implicated-26/VBN||has-24/VBZ	auxpass||implicated-26/VBN||been-25/VBN	root||ROOT-0/null||implicated-26/VBN	det||introduction-30/NN||the-28/DT	amod||introduction-30/NN||unintended-29/JJ	prep_in||implicated-26/VBN||introduction-30/NN	amod||mutations-34/NNS||second-32/JJ	nn||mutations-34/NNS||site-33/NN	prep_of||introduction-30/NN||mutations-34/NNS	vaccinia-19||vv-21||no||the use of selectable markers ( ecogpt ) and selection pressures to aid in detection of poxvirus (vaccinia, vv) recombinants has been implicated in the unintended introduction of second site mutations.
nsubj||allows-2/VBZ||it-1/PRP	root||ROOT-0/null||allows-2/VBZ	dobj||allows-2/VBZ||us-3/PRP	nsubj||show-5/VB||us-3/PRP	aux||show-5/VB||to-4/TO	xcomp||allows-2/VBZ||show-5/VB	mark||related-12/VBN||that-6/IN	det||sars-cov-8/NN||the-7/DT	nsubj||related-12/VBN||sars-cov-8/NN	cop||related-12/VBN||is-9/VBZ	advmod||closely-11/RB||most-10/RBS	advmod||related-12/VBN||closely-11/RB	ccomp||show-5/VB||related-12/VBN	det||coronavirus-15/NNS||a-14/DT	prep_to||related-12/VBN||coronavirus-15/NNS	det||civet-19/NN||the-17/DT	nn||civet-19/NN||palm-18/NN	prep_from||coronavirus-15/NNS||civet-19/NN	neg||related-12/VBN||not-20/RB	det||bird-23/NN||a-22/DT	prep_from||related-12/VBN||bird-23/NN	mark||suspected-26/VBD||as-24/IN	advmod||suspected-26/VBD||initially-25/RB	dep||related-12/VBN||suspected-26/VBD	det||hcov-hku1-34/NN||the-29/DT	advmod||discovered-31/VBN||newly-30/RB	amod||hcov-hku1-34/NN||discovered-31/VBN	amod||hcov-hku1-34/NN||human-32/JJ	nn||hcov-hku1-34/NN||coronavirus-33/NNS	nsubj||related-38/VBN||hcov-hku1-34/NN	cop||related-38/VBN||is-35/VBZ	advmod||related-38/VBN||more-36/RBR	advmod||related-38/VBN||closely-37/RB	conj_and||allows-2/VBZ||related-38/VBN	prep_to||related-38/VBN||sars-40/NNS	advmod||related-38/VBN||than-41/IN	det||member-46/NN||any-43/DT	amod||member-46/NN||other-44/JJ	amod||member-46/NN||known-45/VBN	prep_to||than-41/IN||member-46/NN	nn||coronavirus-50/NNS||group-48/NN	num||coronavirus-50/NNS||2-49/CD	prep_of||member-46/NN||coronavirus-50/NNS	sars-40||coronavirus-50||no||it allows us to show that the sars-cov is most closely related to a coronavirus from the palm civet not from a bird as initially suspected, and the newly discovered human coronavirus hcov-hku1 is more closely related to sars than to any other known member of group 2 coronavirus.
advmod||dissatisfied-10/VBN||however-1/RB	quantmod||10-4/CD||approximately-3/RB	num||%-5/NN||10-4/CD	nsubjpass||dissatisfied-10/VBN||%-5/NN	amod||patients-8/NNS||hypothyroid-7/JJ	prep_of||%-5/NN||patients-8/NNS	auxpass||dissatisfied-10/VBN||are-9/VBP	root||ROOT-0/null||dissatisfied-10/VBN	det||outcome-13/NN||the-12/DT	prep_with||dissatisfied-10/VBN||outcome-13/NN	amod||monotherapy-16/NN||levothyroxine-15/JJ	prep_of||outcome-13/NN||monotherapy-16/NN	nsubj||continue-20/VBP||physicians-19/NNS	nsubj||report-22/VB||physicians-19/NNS	conj_and||dissatisfied-10/VBN||continue-20/VBP	aux||report-22/VB||to-21/TO	xcomp||continue-20/VBP||report-22/VB	dobj||report-22/VB||benefits-23/NNS	amod||therapy-27/NN||combined-25/VBN	amod||therapy-27/NN||levothyroxine-triidothyronine-26/JJ	prep_from||report-22/VB||therapy-27/NN	det||patients-31/NNS||some-29/DT	amod||patients-31/NNS||hypothyroid-30/JJ	prep_for||therapy-27/NN||patients-31/NNS	hypothyroid-30||levothyroxine-15||yes||however, approximately 10% of hypothyroid patients are dissatisfied with the outcome of levothyroxine monotherapy, and physicians continue to report benefits from combined levothyroxine-triidothyronine therapy for some hypothyroid patients.
amod||atrophy-3/NN||multiple-1/JJ	nn||atrophy-3/NN||system-2/NN	nsubj||disease-11/NN||atrophy-3/NN	appos||atrophy-3/NN||msa-5/NN	cop||disease-11/NN||is-7/VBZ	det||disease-11/NN||a-8/DT	amod||disease-11/NN||rare-9/JJ	nn||disease-11/NN||neurodegenerative-10/NN	root||ROOT-0/null||disease-11/NN	amod||cause-14/NN||undetermined-13/JJ	prep_of||disease-11/NN||cause-14/NN	vmod||cause-14/NN||manifesting-15/VBG	amod||failure-19/NN||progressive-17/JJ	amod||failure-19/NN||autonomic-18/JJ	prep_with||manifesting-15/VBG||failure-19/NN	appos||failure-19/NN||af-21/NN	nn||ataxia-25/NN||cerebellar-24/NN	prep_with||manifesting-15/VBG||ataxia-25/NN	conj_and||failure-19/NN||ataxia-25/NN	num||±-44/NNS||parkinsonism-27/CD	amod||loss-31/NN||neuronal-30/JJ	prep_due_to||±-44/NNS||loss-31/NN	amod||areas-35/NNS||multiple-33/JJ	nn||areas-35/NNS||brain-34/NN	prep_in||loss-31/NN||areas-35/NNS	vmod||areas-35/NNS||associated-36/VBN	prep||associated-36/VBN||with-37/IN	dep||with-37/IN||oligodendro-39/NNP	amod||±-44/NNS||glial-41/JJ	amod||±-44/NNS||cytoplasmic-42/JJ	nn||±-44/NNS||î-43/NN	prep_with||manifesting-15/VBG||±-44/NNS	conj_and||failure-19/NN||±-44/NNS	nsubj||inclusions-52/VBZ||synuclein-46/NN	amod||syn-50/NN||î-48/JJ	amod||syn-50/NN||±-49/JJ	appos||synuclein-46/NN||syn-50/NN	parataxis||disease-11/NN||inclusions-52/VBZ	dobj||inclusions-52/VBZ||gcis-54/NNS	msa-5||parkinsonism-27||no_rel||multiple system atrophy (msa) is a rare neurodegenerative disease of undetermined cause manifesting with progressive autonomic failure (af), cerebellar ataxia and parkinsonism due to neuronal loss in multiple brain areas associated with (oligodendro)glial cytoplasmic î±-synuclein (î±syn) inclusions (gcis).
mark||be-4/VB||while-1/IN	nsubj||be-4/VB||clopidogrel-2/NN	aux||be-4/VB||may-3/MD	advcl||result-36/VB||be-4/VB	amod||effect-8/NN||little-6/JJ	amod||effect-8/NN||beneficial-7/JJ	prep_of||be-4/VB||effect-8/NN	mark||administered-10/VBN||if-9/IN	advcl||be-4/VB||administered-10/VBN	advmod||administered-10/VBN||immediately-11/RB	prep_prior_to||administered-10/VBN||pci-14/NN	aux||increase-18/VB||may-16/MD	advmod||increase-18/VB||even-17/RB	advcl||be-4/VB||increase-18/VB	conj_and||administered-10/VBN||increase-18/VB	amod||risk-21/NN||major-19/JJ	amod||risk-21/NN||bleeding-20/VBG	dobj||increase-18/VB||risk-21/NN	mark||anticipated-28/VBN||if-22/IN	amod||grafting-26/NN||coronary-23/JJ	nn||grafting-26/NN||artery-24/NN	nn||grafting-26/NN||bypass-25/NN	nsubjpass||anticipated-28/VBN||grafting-26/NN	auxpass||anticipated-28/VBN||is-27/VBZ	advcl||increase-18/VB||anticipated-28/VBN	amod||discontinuation-31/NN||early-30/JJ	nsubj||result-36/VB||discontinuation-31/NN	det||drug-34/NN||the-33/DT	prep_of||discontinuation-31/NN||drug-34/NN	aux||result-36/VB||may-35/MD	root||ROOT-0/null||result-36/VB	amod||coverage-40/NN||insufficient-38/JJ	nn||coverage-40/NN||antiplatelet-39/NN	prep_in||result-36/VB||coverage-40/NN	amod||complications-43/NNS||thrombotic-42/JJ	prep_with||coverage-40/NN||complications-43/NNS	bleeding-20||clopidogrel-2||no||while clopidogrel may be of little beneficial effect if administered immediately prior to pci and may even increase major bleeding risk if coronary artery bypass grafting is anticipated, early discontinuation of the drug may result in insufficient antiplatelet coverage with thrombotic complications.
advmod||present-4/VBP||here-1/RB	nsubj||present-4/VBP||we-3/PRP	root||ROOT-0/null||present-4/VBP	det||analysis-7/NN||a-5/DT	amod||analysis-7/NN||bioinformatic-6/JJ	dobj||present-4/VBP||analysis-7/NN	amod||populations-10/NNS||hcv-1a-9/JJ	prep_of||analysis-7/NN||populations-10/NNS	vmod||populations-10/NNS||isolated-11/VBN	num||children-14/NNS||23-13/CD	prep_from||isolated-11/VBN||children-14/NNS	prep_with||isolated-11/VBN||chronichepatitisc-16/NN	discourse||chronichepatitisc-16/NN||chc-18/UH	vmod||chronichepatitisc-16/NN||subjected-20/VBN	aux||interferonâ-22/VB||to-21/TO	xcomp||subjected-20/VBN||interferonâ-22/VB	num||therapy-26/NN||$-23/$	num||$-23/$||ribavirin-25/CD	dobj||interferonâ-22/VB||therapy-26/NN	chronichepatitisc-16||hcv--1||no||here, we present a bioinformatic analysis of hcv-1a populations isolated from 23 children with chronichepatitisc (chc) subjected to interferonâribavirin therapy.
amod||dye-3/NNS||evans-1/JJ	amod||dye-3/NNS||blue-2/JJ	nsubj||elicits-7/VBZ||dye-3/NNS	appos||dye-3/NNS||eb-5/NN	root||ROOT-0/null||elicits-7/VBZ	det||fluorescence-10/NN||a-8/DT	nn||fluorescence-10/NN||violet-9/NN	dobj||elicits-7/VBZ||fluorescence-10/NN	prep_by||elicits-7/VBZ||excitation-12/NN	prep_at||excitation-12/NN||345-nm-14/NN	prep_at||excitation-12/NN||emission-16/NN	conj_and||345-nm-14/NN||emission-16/NN	prep_at||elicits-7/VBZ||420-nm-18/JJ	det||reddish-brown-22/NN||a-21/DT	nsubj||fluorescence-23/VBP||reddish-brown-22/NN	conj_and||elicits-7/VBZ||fluorescence-23/VBP	prep_by||fluorescence-23/VBP||excitation-25/NN	prep_at||excitation-25/NN||470-nm-27/NN	prep_at||excitation-25/NN||emission-29/NN	conj_and||470-nm-27/NN||emission-29/NN	amod||characteristic-32/NN||515-nm-31/JJ	prep_at||fluorescence-23/VBP||characteristic-32/NN	prep_of||characteristic-32/NN||oxldl-34/NN	advmod||oxldl-34/NN||only-35/RB	evans-1||nm--1||no_rel||evans blue dye (eb) elicits a violet fluorescence by excitation at 345-nm and emission at 420-nm, and a reddish-brown fluorescence by excitation at 470-nm and emission at 515-nm characteristic of oxldl only.
amod||analysis-3/NN||pearson-1/JJ	nn||analysis-3/NN||correlation-2/NN	nsubj||demonstrated-4/VBD||analysis-3/NN	root||ROOT-0/null||demonstrated-4/VBD	det||correlation-7/NN||a-5/DT	amod||correlation-7/NN||positive-6/JJ	dobj||demonstrated-4/VBD||correlation-7/NN	prep_of||correlation-7/NN||mgi-9/NN	nn||duration-12/NN||transplant-11/NN	prep_with||demonstrated-4/VBD||duration-12/NN	amod||angiography-15/NN||coronary-14/JJ	prep_before||demonstrated-4/VBD||angiography-15/NN	amod||nephropathy-19/NN||chronic-17/JJ	nn||nephropathy-19/NN||allograft-18/NN	prep_before||demonstrated-4/VBD||nephropathy-19/NN	conj_and||angiography-15/NN||nephropathy-19/NN	mark||demonstrated-26/VBN||whereas-21/IN	det||correlation-24/NN||an-22/DT	amod||correlation-24/NN||inverse-23/JJ	nsubjpass||demonstrated-26/VBN||correlation-24/NN	auxpass||demonstrated-26/VBN||was-25/VBD	advcl||demonstrated-4/VBD||demonstrated-26/VBN	amod||fraction-29/NN||ejection-28/JJ	prep_with||demonstrated-26/VBN||fraction-29/NN	nn||use-32/NN||statin-31/NN	prep_with||demonstrated-26/VBN||use-32/NN	conj_and||fraction-29/NN||use-32/NN	nephropathy-19||statin-31||no_rel||pearson correlation analysis demonstrated a positive correlation of mgi with transplant duration before coronary angiography and chronic allograft nephropathy, whereas an inverse correlation was demonstrated with ejection fraction and statin use.
det||study-2/NN||this-1/DT	nsubj||compared-3/VBD||study-2/NN	root||ROOT-0/null||compared-3/VBD	det||response-7/NN||the-4/DT	amod||response-7/NN||niacin-5/JJ	amod||response-7/NN||flush-6/JJ	dobj||compared-3/VBD||response-7/NN	prep_in||compared-3/VBD||subjects-9/NNS	prep_from||subjects-9/NNS||families-11/NNS	advmod||member-15/NN||only-13/RB	num||member-15/NN||one-14/CD	prep_with||compared-3/VBD||member-15/NN	vmod||member-15/NN||affected-16/VBN	prep_with||affected-16/VBN||schizophrenia-18/NN	nn||families-21/NNS||simplex-20/NN	appos||schizophrenia-18/NN||families-21/NNS	prep_with||schizophrenia-18/NN||those-24/DT	prep_from||those-24/DT||families-26/NNS	vmod||families-26/NNS||having-27/VBG	det||sib-pair-29/NN||a-28/DT	dobj||having-27/VBG||sib-pair-29/NN	prep_with||sib-pair-29/NN||schizophrenia-31/NN	nn||families-34/NNS||multiplex-33/NN	appos||schizophrenia-18/NN||families-34/NNS	flush-6||niacin-5||no||this study compared the niacin flush response in subjects from families with only one member affected with schizophrenia (simplex families) with those from families having a sib-pair with schizophrenia (multiplex families).
mark||used-12/VBN||although-1/IN	det||vaccine-5/NN||an-2/DT	amod||vaccine-5/NN||attenuated-3/JJ	nn||vaccine-5/NN||vzv-4/NN	nsubjpass||used-12/VBN||vaccine-5/NN	appos||vaccine-5/NN||v-oka-7/NNP	aux||used-12/VBN||has-9/VBZ	auxpass||used-12/VBN||been-10/VBN	advmod||used-12/VBN||widely-11/RB	advcl||seen-24/VBN||used-12/VBN	prep_in||used-12/VBN||children-14/NNS	det||states-18/NNS||the-16/DT	amod||states-18/NNS||united-17/VBN	prep_in||children-14/NNS||states-18/NNS	nn||outbreaks-21/NNS||chickenpox-20/NN	nsubjpass||seen-24/VBN||outbreaks-21/NNS	auxpass||seen-24/VBN||are-22/VBP	advmod||seen-24/VBN||still-23/RB	root||ROOT-0/null||seen-24/VBN	det||vaccine-29/NN||the-27/DT	nn||vaccine-29/NN||shingles-28/NNS	nsubj||reduces-31/VBZ||vaccine-29/NN	advmod||reduces-31/VBZ||only-30/RB	conj_and||seen-24/VBN||reduces-31/VBZ	det||risk-33/NN||the-32/DT	dobj||reduces-31/VBZ||risk-33/NN	prep_of||risk-33/NN||shingles-35/NNS	num||%-38/NN||50-37/CD	prep_by||reduces-31/VBZ||%-38/NN	shingles-35||vzv-4||no||although an attenuated vzv vaccine (v-oka) has been widely used in children in the united states, chickenpox outbreaks are still seen, and the shingles vaccine only reduces the risk of shingles by 50%.
nsubj||î-10/VBP||treatment-1/NN	amod||chc-5/NN||chronichepatitisc-3/JJ	prep_of||treatment-1/NN||chc-5/NN	amod||interferon-9/NN||pegylated-8/JJ	prep_with||chc-5/NN||interferon-9/NN	root||ROOT-0/null||î-10/VBP	dobj||î-10/VBP||±-11/NNP	nn||±-14/NNP||pegifnî-13/NNP	appos||±-11/NNP||±-14/NNP	amod||results-18/NNS||ribavirin-17/JJ	dobj||î-10/VBP||results-18/NNS	conj_and||±-11/NNP||results-18/NNS	det||response-22/NN||a-20/DT	amod||response-22/NN||sustained-21/JJ	prep_in||results-18/NNS||response-22/NN	quantmod||half-25/PDT||approximately-24/RB	prep_in||response-22/NN||half-25/PDT	prep_of||half-25/PDT||patients-27/NNS	chronichepatitisc-3||interferon-9||yes||treatment of chronichepatitisc (chc) with pegylated interferon î± (pegifnî±) and ribavirin results in a sustained response in approximately half of patients.
nsubjpass||evidenced-9/VBN||lymeneuroborreliosis-1/NNS	nn||$-7/NN||â-3/NN	amod||$-7/NN||$-4/$	dep||$-4/$||neurological-5/JJ	nn||$-7/NN||lymediseaseâ-6/NNP	conj_or||lymeneuroborreliosis-1/NNS||$-7/NN	nsubjpass||evidenced-9/VBN||$-7/NN	auxpass||evidenced-9/VBN||was-8/VBD	root||ROOT-0/null||evidenced-9/VBN	prep_in||evidenced-9/VBN||2-11/CD	num||patients-14/NNS||23-13/CD	prep_of||2-11/CD||patients-14/NNS	vmod||patients-14/NNS||submitted-15/VBN	amod||criteria-18/NNS||strict-17/JJ	prep_to||submitted-15/VBN||criteria-18/NNS	nn||selection-21/NN||case-20/NN	prep_for||criteria-18/NNS||selection-21/NN	det||centers-24/NNS||the-23/DT	prep_of||selection-21/NN||centers-24/NNS	nn||control-27/NN||disease-26/NN	prep_for||centers-24/NNS||control-27/NN	prep_for||centers-24/NNS||prevention-29/NN	conj_and||control-27/NN||prevention-29/NN	xcomp||submitted-15/VBN||employing-30/VBG	det||test-33/NN||a-31/DT	amod||test-33/NN||two-tier-32/JJ	dobj||employing-30/VBG||test-33/NN	aux||detect-35/VB||to-34/TO	vmod||employing-30/VBG||detect-35/VB	dobj||detect-35/VB||antibodies-36/NNS	prep_to||detect-35/VB||borreliaburgdorferi-38/NNS	det||institution-42/NN||a-40/DT	amod||institution-42/NN||single-41/JJ	prep_at||borreliaburgdorferi-38/NNS||institution-42/NN	lymeneuroborreliosis-1||borreliaburgdorferi-38||no||lymeneuroborreliosis or âneurological lymediseaseâ? was evidenced in 2 of 23 patients submitted to strict criteria for case selection of the centers for disease control and prevention employing a two-tier test to detect antibodies to borreliaburgdorferi at a single institution.
nsubj||analogue-5/NN||adefovir-1/NN	cop||analogue-5/NN||is-2/VBZ	det||analogue-5/NN||an-3/DT	amod||analogue-5/NN||adenosine-4/JJ	dep||shown-34/VBN||analogue-5/NN	vmod||analogue-5/NN||approved-6/VBN	det||administration-12/NN||the-8/DT	nn||administration-12/NN||food-9/NN	conj_and||food-9/NN||drug-11/NN	nn||administration-12/NN||drug-11/NN	agent||approved-6/VBN||administration-12/NN	det||treatment-15/NN||the-14/DT	prep_for||administration-12/NN||treatment-15/NN	nn||mutations-19/NNS||chronichepatitisb-17/NNP	prep_of||treatment-15/NN||mutations-19/NNS	vmod||mutations-19/NNS||occurring-20/VBG	det||transcriptase-28/NN||the-22/DT	amod||transcriptase-28/NN||hepatitisbvirus-23/JJ	nn||transcriptase-28/NN||-lrb--24/NNP	nn||transcriptase-28/NN||hbv-25/NNP	nn||transcriptase-28/NN||-rrb--26/NNP	amod||transcriptase-28/NN||reverse-27/JJ	prep_in||occurring-20/VBG||transcriptase-28/NN	amod||domains-32/NNS||-lrb--29/JJ	nn||domains-32/NNS||rt-30/NN	nn||domains-32/NNS||-rrb--31/NN	nsubjpass||shown-34/VBN||domains-32/NNS	nsubj||confer-36/VB||domains-32/NNS	auxpass||shown-34/VBN||are-33/VBP	root||ROOT-0/null||shown-34/VBN	aux||confer-36/VB||to-35/TO	xcomp||shown-34/VBN||confer-36/VB	dobj||confer-36/VB||resistance-37/NN	prep_to||confer-36/VB||antiviraldrugs-39/NNS	chronichepatitisb-17||hepatitisbvirus-23||no||adefovir is an adenosine analogue approved by the food and drug administration for the treatment of chronichepatitisb. mutations occurring in the hepatitisbvirus -lrb- hbv -rrb- reverse transcriptase -lrb- rt -rrb- domains are shown to confer resistance to antiviraldrugs .
amod||oxymorphone-2/NN||oral-1/JJ	nsubj||formulation-6/NN||oxymorphone-2/NN	cop||formulation-6/NN||is-3/VBZ	det||formulation-6/NN||a-4/DT	amod||formulation-6/NN||new-5/JJ	root||ROOT-0/null||formulation-6/NN	det||opioid-11/NN||an-8/DT	amod||opioid-11/NN||existing-9/VBG	amod||opioid-11/NN||parenteral-10/JJ	prep_of||formulation-6/NN||opioid-11/NN	nsubj||become-14/VBN||opioid-11/NN	aux||become-14/VBN||has-13/VBZ	rcmod||opioid-11/NN||become-14/VBN	acomp||become-14/VBN||available-15/JJ	det||treatment-18/NN||the-17/DT	prep_for||become-14/VBN||treatment-18/NN	amod||postoperative-23/NN||significant-20/JJ	nn||postoperative-23/NN||pain-21/NN	amod||postoperative-23/NN||acute-22/JJ	prep_of||treatment-18/NN||postoperative-23/NN	amod||arthritis-26/NN||chronic-25/JJ	prep_of||treatment-18/NN||arthritis-26/NN	conj_and||postoperative-23/NN||arthritis-26/NN	amod||back-30/NN||chronic-28/JJ	amod||back-30/NN||low-29/JJ	prep_of||treatment-18/NN||back-30/NN	conj_and||postoperative-23/NN||back-30/NN	amod||pain-35/NN||chronic-33/JJ	nn||pain-35/NN||cancer-34/NN	prep_of||treatment-18/NN||pain-35/NN	conj_and||postoperative-23/NN||pain-35/NN	pain-35||oxymorphone-2||yes||oral oxymorphone is a new formulation of an existing parenteral opioid that has become available for the treatment of significant pain acute postoperative, chronic arthritis, chronic low back, and chronic cancer pain.
det||aims-3/NNS||the-1/DT	amod||aims-3/NNS||primary-2/JJ	nsubj||are-4/VBP||aims-3/NNS	nsubj||examine-6/VB||aims-3/NNS	root||ROOT-0/null||are-4/VBP	aux||examine-6/VB||to-5/TO	xcomp||are-4/VBP||examine-6/VB	det||efficacy-8/NN||the-7/DT	dobj||examine-6/VB||efficacy-8/NN	prep_of||efficacy-8/NN||atomoxetine-10/NN	prepc_for||examine-6/VB||improving-12/VBG	amod||function-16/NN||cognition-13/JJ	conj_and||cognition-13/JJ||emotional-15/JJ	amod||function-16/NN||emotional-15/JJ	dep||improving-12/VBG||function-16/NN	prep_in||function-16/NN||adhd-18/NN	mark||pronounced-28/JJ||whether-20/IN	det||improvements-22/NNS||any-21/DT	nsubj||pronounced-28/JJ||improvements-22/NNS	det||outcomes-25/NNS||these-24/DT	prep_in||improvements-22/NNS||outcomes-25/NNS	cop||pronounced-28/JJ||are-26/VBP	advmod||pronounced-28/JJ||more-27/RBR	dep||improving-12/VBG||pronounced-28/JJ	conj_and||function-16/NN||pronounced-28/JJ	prep_in||pronounced-28/JJ||participants-30/NNS	amod||anxiety-33/NN||comorbid-32/JJ	prep_with||participants-30/NNS||anxiety-33/NN	aux||determine-37/VB||to-36/TO	dep||improving-12/VBG||determine-37/VB	conj_and||function-16/NN||determine-37/VB	mark||reliable-47/JJ||if-38/IN	nsubj||reliable-47/JJ||changes-39/NNS	det||outcomes-42/NNS||these-41/DT	prep_in||changes-39/NNS||outcomes-42/NNS	prep_after||outcomes-42/NNS||atomoxetine-44/NN	cop||reliable-47/JJ||are-45/VBP	advmod||reliable-47/JJ||more-46/RBR	advcl||determine-37/VB||reliable-47/JJ	prep_than||reliable-47/JJ||changes-49/NNS	amod||symptoms-52/NNS||diagnostic-51/JJ	prep_in||changes-49/NNS||symptoms-52/NNS	prep_of||symptoms-52/NNS||adhd-54/NN	adhd-54||atomoxetine-44||yes||the primary aims are to examine the efficacy of atomoxetine for improving cognition and emotional function in adhd and whether any improvements in these outcomes are more pronounced in participants with comorbid anxiety; and to determine if changes in these outcomes after atomoxetine are more reliable than changes in diagnostic symptoms of adhd.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||effectiveness-10/NN||the-9/DT	dobj||evaluate-8/VB||effectiveness-10/NN	prep_of||effectiveness-10/NN||monotherapy-12/NN	amod||therapy-17/NN||interferonalpha-2b-14/JJ	conj_and||interferonalpha-2b-14/JJ||combination-16/NN	amod||therapy-17/NN||combination-16/NN	prep_with||evaluate-8/VB||therapy-17/NN	prep_with||therapy-17/NN||interferonalpha-2b-19/NNP	prep_with||therapy-17/NN||ribavirin-21/NNP	conj_plus||interferonalpha-2b-19/NNP||ribavirin-21/NNP	prep_on||evaluate-8/VB||chronichepatitiscinfection-23/NN	amod||patients-26/NNS||thalassaemic-25/JJ	prep_in||chronichepatitiscinfection-23/NN||patients-26/NNS	chronichepatitiscinfection-23||interferonalpha-2b-19||yes||the aim of this study was to evaluate the effectiveness of monotherapy with interferonalpha-2b and combination therapy with interferonalpha-2b plus ribavirin on chronichepatitiscinfection in thalassaemic patients.
nn||viruses-2/NNS||hiv-1/NN	nsubj||encode-3/VBP||viruses-2/NNS	root||ROOT-0/null||encode-3/VBP	det||set-5/NN||a-4/DT	nsubj||due-16/JJ||set-5/NN	amod||proteins-8/NNS||accessory-7/JJ	prep_of||set-5/NN||proteins-8/NNS	nsubj||determinants-13/NNS||proteins-8/NNS	cop||determinants-13/NNS||are-11/VBP	amod||determinants-13/NNS||important-12/JJ	rcmod||proteins-8/NNS||determinants-13/NNS	prep_of||determinants-13/NNS||virulence-15/NN	xcomp||encode-3/VBP||due-16/JJ	poss||ability-19/NN||their-18/PRP$	prep_to||due-16/JJ||ability-19/NN	aux||manipulate-21/VB||to-20/TO	vmod||ability-19/NN||manipulate-21/VB	det||cell-24/NN||the-22/DT	nn||cell-24/NN||host-23/NN	dobj||manipulate-21/VB||cell-24/NN	advmod||manipulate-21/VB||physiology-25/RB	det||benefit-28/NN||the-27/DT	prep_for||manipulate-21/VB||benefit-28/NN	det||virus-31/NN||the-30/DT	prep_of||benefit-28/NN||virus-31/NN	virus-31||viruses-2||no||hiv viruses encode a set of accessory proteins, which are important determinants of virulence due to their ability to manipulate the host cell physiology for the benefit of the virus.
det||study-3/NN||this-2/DT	prep_in||show-5/VBP||study-3/NN	nsubj||show-5/VBP||we-4/PRP	root||ROOT-0/null||show-5/VBP	mark||useful-23/JJ||that-6/IN	det||response-9/NN||the-7/DT	amod||response-9/NN||t-cell-8/JJ	nsubj||useful-23/JJ||response-9/NN	nsubj||discriminate-25/VB||response-9/NN	det||hbha-15/NN||a-11/DT	amod||hbha-15/NN||recombinant-12/JJ	conj_and||recombinant-12/JJ||methylated-14/JJ	amod||hbha-15/NN||methylated-14/JJ	prep_to||response-9/NN||hbha-15/NN	prep_of||hbha-15/NN||mtb-17/NN	vmod||mtb-17/NN||produced-18/VBN	nn||smegmatis-21/NNS||m.-20/NN	prep_in||produced-18/VBN||smegmatis-21/NNS	cop||useful-23/JJ||is-22/VBZ	ccomp||show-5/VBP||useful-23/JJ	aux||discriminate-25/VB||to-24/TO	xcomp||useful-23/JJ||discriminate-25/VB	amod||disease-31/NN||active-27/JJ	conj_and||active-27/JJ||non-active-29/JJ	amod||disease-31/NN||non-active-29/JJ	nn||disease-31/NN||tb-30/NN	prep_between||discriminate-25/VB||disease-31/NN	det||system-41/NN||those-33/DT	amod||system-41/NN||responsive-34/JJ	prep_to||responsive-34/JJ||qft-it-36/NN	det||blood-40/NN||a-38/DT	amod||blood-40/NN||whole-39/JJ	prep_in||qft-it-36/NN||blood-40/NN	prep_among||disease-31/NN||system-41/NN	tb-30||mtb-17||no||in this study we show that the t-cell response to a recombinant and methylated hbha of mtb produced in m. smegmatis is useful to discriminate between active and non-active tb disease among those responsive to qft-it in a whole blood system .
mark||intractable-5/JJ||while-1/IN	nsubj||intractable-5/JJ||seizures-2/NNS	cop||intractable-5/JJ||are-3/VBP	advmod||intractable-5/JJ||usually-4/RB	advcl||appears-24/VBZ||intractable-5/JJ	prep_to||intractable-5/JJ||medication-7/NN	amod||complex-11/NN||tuberous-9/JJ	nn||complex-11/NN||sclerosis-10/NN	prep_in||intractable-5/JJ||complex-11/NN	appos||complex-11/NN||tsc-13/NN	det||cause-19/NN||a-16/DT	amod||cause-19/NN||common-17/JJ	amod||cause-19/NN||genetic-18/JJ	dep||intractable-5/JJ||cause-19/NN	prep_of||cause-19/NN||epilepsy-21/NN	nsubj||appears-24/VBZ||vigabatrin-23/NN	nsubj||have-26/VB||vigabatrin-23/NN	root||ROOT-0/null||appears-24/VBZ	aux||have-26/VB||to-25/TO	xcomp||appears-24/VBZ||have-26/VB	amod||efficacy-28/NN||unique-27/JJ	dobj||have-26/VB||efficacy-28/NN	prep_for||efficacy-28/NN||epilepsy-30/NN	prep_in||epilepsy-30/NN||tsc-32/NN	epilepsy-30||vigabatrin-23||yes||while seizures are usually intractable to medication in tuberous sclerosis complex (tsc), a common genetic cause of epilepsy, vigabatrin appears to have unique efficacy for epilepsy in tsc.
amod||studies-3/NNS||future-1/JJ	amod||studies-3/NNS||randomised-2/JJ	nsubjpass||needed-5/VBN||studies-3/NNS	nsubj||assess-7/VB||studies-3/NNS	auxpass||needed-5/VBN||are-4/VBP	root||ROOT-0/null||needed-5/VBN	aux||assess-7/VB||to-6/TO	xcomp||needed-5/VBN||assess-7/VB	det||impact-9/NN||the-8/DT	dobj||assess-7/VB||impact-9/NN	amod||polypharmacy-12/NN||antipsychotic-11/JJ	prep_of||impact-9/NN||polypharmacy-12/NN	prep_in||assess-7/VB||schizophrenia-14/NN	schizophrenia-14||antipsychotic-11||no_rel||future randomised studies are needed to assess the impact of antipsychotic polypharmacy in schizophrenia.
amod||models-4/NNS||multiple-1/JJ	amod||models-4/NNS||logistic-2/JJ	nn||models-4/NNS||regression-3/NN	nsubjpass||used-6/VBN||models-4/NNS	nsubj||determine-8/VB||models-4/NNS	auxpass||used-6/VBN||were-5/VBD	root||ROOT-0/null||used-6/VBN	aux||determine-8/VB||to-7/TO	xcomp||used-6/VBN||determine-8/VB	nn||factors-10/NNS||risk-9/NN	dobj||determine-8/VB||factors-10/NNS	amod||stress-13/NN||psychosocial-12/JJ	prep_for||determine-8/VB||stress-13/NN	appos||stress-13/NN||demoralization-15/NN	nn||consumption-18/NN||tobacco-17/NN	appos||demoralization-15/NN||consumption-18/NN	nn||¹-22/NNP||â-20/NNP	nn||¹-22/NNP||-21/NNP	dep||consumption-18/NN||¹-22/NNP	num||items/day-24/NN||10-23/CD	dep||¹-22/NNP||items/day-24/NN	amod||consumption-29/NN||high-risk-27/JJ	nn||consumption-29/NN||alcohol-28/NN	appos||consumption-18/NN||consumption-29/NN	dep||consumption-29/NN||men-31/NNS	number||20-33/CD||>-32/CD	dep||men-31/NNS||20-33/CD	nn||alcohol/day-36/NN||g-34/NN	amod||alcohol/day-36/NN||pure-35/JJ	dep||20-33/CD||alcohol/day-36/NN	dep||men-31/NNS||women-38/NNS	number||10-40/CD||>-39/CD	dep||women-38/NNS||10-40/CD	nn||alcohol/day-43/NN||g-41/NN	amod||alcohol/day-43/NN||pure-42/JJ	dep||10-40/CD||alcohol/day-43/NN	appos||consumption-18/NN||binge-46/NN	vmod||binge-46/NN||drinking-47/VBG	vmod||consumption-18/NN||problemdrinking-49/VBG	prepc_according_to||problemdrinking-49/VBG||to-51/TO	pobj||problemdrinking-49/VBG||cage-52/NN	amod||intake-57/NN||regular-54/JJ	amod||intake-57/NN||medical-55/JJ	nn||intake-57/NN||drug-56/NN	pobj||problemdrinking-49/VBG||intake-57/NN	conj_and||cage-52/NN||intake-57/NN	quantmod||weekly-61/CD||at-59/IN	mwe||at-59/IN||least-60/JJS	pobj||at-59/IN||least-60/JJS	dep||consumption-18/NN||weekly-61/CD	problemdrinking-49||alcohol-28||no||multiple logistic regression models were used to determine risk factors for psychosocial stress, demoralization, tobacco consumption (â¹ 10 items/day), high-risk alcohol consumption (men > 20 g pure alcohol/day, women > 10 g pure alcohol/day), binge drinking, problemdrinking according to cage and regular medical drug intake (at least weekly).
amod||dehydrogenase-2/NN||glucose-6-phosphate-1/JJ	nsubj||enzyme-9/NN||dehydrogenase-2/NN	appos||dehydrogenase-2/NN||g6pd-4/NNP	cop||enzyme-9/NN||is-6/VBZ	det||enzyme-9/NN||a-7/DT	amod||enzyme-9/NN||key-8/JJ	root||ROOT-0/null||enzyme-9/NN	det||pathway-14/NN||the-11/DT	amod||pathway-14/NN||pentose-12/JJ	nn||pathway-14/NN||monophosphate-13/NN	prep_of||enzyme-9/NN||pathway-14/NN	poss||deficiency-18/NN||its-17/PRP$	nsubj||worldwide-25/NN||deficiency-18/NN	cop||worldwide-25/NN||is-19/VBZ	det||worldwide-25/NN||the-20/DT	advmod||common-22/JJ||most-21/RBS	amod||worldwide-25/NN||common-22/JJ	amod||worldwide-25/NN||inherited-23/VBN	nn||worldwide-25/NN||enzymopathy-24/NN	conj_and||enzyme-9/NN||worldwide-25/NN	enzymopathy-24||enzyme-9||no_rel||glucose-6-phosphate dehydrogenase (g6pd) is a key enzyme of the pentose monophosphate pathway, and its deficiency is the most common inherited enzymopathy worldwide.
det||approval-4/NN||the-2/DT	amod||approval-4/NN||recent-3/JJ	prep_with||available-38/JJ||approval-4/NN	prep_of||approval-4/NN||pazopanib-6/NN	det||inhibitor-13/NN||an-8/DT	amod||inhibitor-13/NN||oral-9/JJ	amod||inhibitor-13/NN||multitargeted-10/JJ	nn||inhibitor-13/NN||tyrosine-11/NN	nn||inhibitor-13/NN||kinase-12/NN	nsubj||targets-16/VBZ||inhibitor-13/NN	nsubj||available-38/JJ||inhibitor-13/NN	advmod||targets-16/VBZ||potently-15/RB	rcmod||inhibitor-13/NN||targets-16/VBZ	amod||factor-20/NN||vascular-17/JJR	amod||factor-20/NN||endothelial-18/JJ	nn||factor-20/NN||growth-19/NN	nsubj||receptors-21/VBZ||factor-20/NN	ccomp||targets-16/VBZ||receptors-21/VBZ	amod||$-23/$||1â-22/VBD	dobj||receptors-21/VBZ||$-23/$	num||$-23/$||3-25/CD	amod||factor-29/NN||platelet-derived-27/JJ	nn||factor-29/NN||growth-28/NN	conj_and||inhibitor-13/NN||factor-29/NN	nsubj||targets-16/VBZ||factor-29/NN	nsubj||available-38/JJ||factor-29/NN	conj_and||inhibitor-13/NN||c-kit-32/NN	nsubj||targets-16/VBZ||c-kit-32/NN	nsubj||available-38/JJ||c-kit-32/NN	num||agents-35/NNS||six-34/CD	appos||c-kit-32/NN||agents-35/NNS	cop||available-38/JJ||are-36/VBP	advmod||available-38/JJ||now-37/RB	root||ROOT-0/null||available-38/JJ	prep_for||available-38/JJ||use-40/NN	det||management-43/NN||the-42/DT	prep_in||use-40/NN||management-43/NN	amod||renalcellcarcinoma-46/NN||metastatic-45/JJ	prep_of||management-43/NN||renalcellcarcinoma-46/NN	discourse||renalcellcarcinoma-46/NN||rcc-48/UH	renalcellcarcinoma-46||tyrosine-11||no_rel||with the recent approval of pazopanib, an oral multitargeted tyrosine kinase inhibitor which potently targets vascular endothelial growth factor receptors 1â3, platelet-derived growth factor, and c-kit, six agents are now available for use in the management of metastatic renalcellcarcinoma (rcc).
nsubj||agent-6/NN||mycobacteriumtuberculosis-1/NNS	cop||agent-6/NN||is-2/VBZ	det||agent-6/NN||the-3/DT	amod||agent-6/NN||principal-4/JJ	amod||agent-6/NN||etiologic-5/JJ	root||ROOT-0/null||agent-6/NN	amod||-rrb--12/NNP||human-8/JJ	nn||-rrb--12/NNP||tuberculosis-9/NNP	nn||-rrb--12/NNP||-lrb--10/NNP	nn||-rrb--12/NNP||tb-11/NNP	prep_of||agent-6/NN||-rrb--12/NNP	det||member-15/NN||a-14/DT	conj_and||agent-6/NN||member-15/NN	det||-rrb--22/NNS||the-17/DT	amod||complex-19/JJ||m.tuberculosis-18/JJ	amod||-rrb--22/NNS||complex-19/JJ	amod||-rrb--22/NNS||-lrb--20/JJ	nn||-rrb--22/NNS||mtc-21/NN	prep_of||member-15/NN||-rrb--22/NNS	tb-11||m.tuberculosis-18||no||mycobacteriumtuberculosis is the principal etiologic agent of human tuberculosis -lrb- tb -rrb- and a member of the m.tuberculosis complex -lrb- mtc -rrb- .
num||cadets-3/NNS||201-2/CD	prep_of||manifested-14/VBN||cadets-3/NNS	vmod||cadets-3/NNS||infected-4/VBN	prep_with||infected-4/VBN||ebv-6/NN	num||yr-9/NN||4-8/CD	prep_over||ebv-6/NN||yr-9/NN	quantmod||26.4-11/CD||only-10/RB	num||%-12/NN||26.4-11/CD	nsubjpass||manifested-14/VBN||%-12/NN	auxpass||manifested-14/VBN||were-13/VBD	root||ROOT-0/null||manifested-14/VBN	amod||infectiousmononucleosis-19/NNS||heterophile-16/JJ	amod||infectiousmononucleosis-19/NNS||positive-17/JJ	amod||infectiousmononucleosis-19/NNS||clinical-18/JJ	agent||manifested-14/VBN||infectiousmononucleosis-19/NNS	infectiousmononucleosis-19||ebv-6||no||of 201 cadets infected with ebv over 4 yr only 26.4% were manifested by heterophile positive clinical infectiousmononucleosis.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||determined-6/VBD||study-4/NN	nsubj||determined-6/VBD||we-5/PRP	nsubj||assessed-33/VBD||we-5/PRP	root||ROOT-0/null||determined-6/VBD	det||levels-9/NNS||the-7/DT	nn||levels-9/NNS||serum-8/NN	dobj||determined-6/VBD||levels-9/NNS	amod||marker-12/NN||apoptotic-11/JJ	prep_of||levels-9/NNS||marker-12/NN	nn||a5-15/NNS||annexin-14/NN	appos||marker-12/NN||a5-15/NNS	nn||patients-19/NNS||familialmediterraneanfever-18/NN	prep_in||determined-6/VBD||patients-19/NNS	det||attack-23/NN||an-22/DT	prep_within||determined-6/VBD||attack-23/NN	prep_within||determined-6/VBD||attack-free-25/NN	conj_and||attack-23/NN||attack-free-25/NN	prep_in||determined-6/VBD||comparison-28/NN	amod||subjects-31/NNS||healthy-30/JJ	prep_to||determined-6/VBD||subjects-31/NNS	conj_and||determined-6/VBD||assessed-33/VBD	det||influence-35/NN||the-34/DT	dobj||assessed-33/VBD||influence-35/NN	amod||treatment-38/NN||colchicine-37/JJ	prep_of||influence-35/NN||treatment-38/NN	det||parameter-41/NN||this-40/DT	prep_on||assessed-33/VBD||parameter-41/NN	familialmediterraneanfever-18||colchicine-37||yes||in the present study we determined the serum levels of apoptotic marker, annexin a5, in familialmediterraneanfever patients, within an attack and attack-free, in comparison to healthy subjects and assessed the influence of colchicine treatment on this parameter.
prepc_based_on||used-14/VBN||on-2/IN	det||study-4/NN||this-3/DT	pobj||used-14/VBN||study-4/NN	nsubjpass||used-14/VBN||ceftriaxone-6/NN	conj_and||ceftriaxone-6/NN||cefixime-8/NN	nsubjpass||used-14/VBN||cefixime-8/NN	conj_and||ceftriaxone-6/NN||spectinomycin-11/NN	nsubjpass||used-14/VBN||spectinomycin-11/NN	aux||used-14/VBN||can-12/MD	auxpass||used-14/VBN||be-13/VB	root||ROOT-0/null||used-14/VBN	det||therapy-19/NN||an-16/DT	amod||therapy-19/NN||empirical-17/JJ	amod||therapy-19/NN||first-line-18/JJ	prep_as||used-14/VBN||therapy-19/NN	prep_for||therapy-19/NN||gonorrhoea-21/NN	nn||pakistan-25/NN||india-23/NN	prep_in||used-14/VBN||pakistan-25/NN	prep_in||used-14/VBN||bhutan-28/NN	conj_and||pakistan-25/NN||bhutan-28/NN	mark||be-43/VB||whereas-30/IN	nsubj||be-43/VB||ciprofloxacin-31/NN	appos||ciprofloxacin-31/NN||penicilling-33/NN	appos||ciprofloxacin-31/NN||tetracycline-35/NN	conj_and||penicilling-33/NN||tetracycline-35/NN	appos||ciprofloxacin-31/NN||erythromycin-37/NN	conj_and||penicilling-33/NN||erythromycin-37/NN	appos||ciprofloxacin-31/NN||azithromycin-40/NN	conj_and||penicilling-33/NN||azithromycin-40/NN	aux||be-43/VB||should-41/MD	neg||be-43/VB||not-42/RB	rcmod||pakistan-25/NN||be-43/VB	gonorrhoea-21||ceftriaxone-6||yes||based on this study, ceftriaxone, cefixime, and spectinomycin can be used as an empirical first-line therapy for gonorrhoea in india, pakistan, and bhutan, whereas ciprofloxacin, penicilling, tetracycline, erythromycin, and azithromycin should not be.
amod||iron-2/NN||internalized-1/JJ	nsubjpass||transported-4/VBN||iron-2/NN	nsubjpass||ironâ-13/VBN||iron-2/NN	auxpass||transported-4/VBN||is-3/VBZ	root||ROOT-0/null||transported-4/VBN	prep_to||transported-4/VBN||mitochondria-6/NN	det||synthesis-9/NN||the-8/DT	prep_for||transported-4/VBN||synthesis-9/NN	prep_of||synthesis-9/NN||haem-11/NN	conj_or||transported-4/VBN||ironâ-13/VBN	num||clusters-17/NNS||$-14/$	num||$-14/$||sulfur-16/CD	dobj||ironâ-13/VBN||clusters-17/NNS	nsubj||parts-22/NNS||clusters-17/NNS	cop||parts-22/NNS||are-20/VBP	amod||parts-22/NNS||integral-21/JJ	rcmod||clusters-17/NNS||parts-22/NNS	amod||metalloproteins-25/NNS||several-24/JJ	prep_of||parts-22/NNS||metalloproteins-25/NNS	nsubjpass||stored-30/VBN||excessiron-28/NN	nsubjpass||detoxified-32/VBN||excessiron-28/NN	auxpass||stored-30/VBN||is-29/VBZ	conj_and||transported-4/VBN||stored-30/VBN	conj_and||transported-4/VBN||detoxified-32/VBN	conj_and||stored-30/VBN||detoxified-32/VBN	amod||ferritin-35/NN||cytosolic-34/JJ	prep_in||stored-30/VBN||ferritin-35/NN	excessiron-28||iron-2||no||internalized iron is transported to mitochondria for the synthesis of haem or ironâsulfur clusters, which are integral parts of several metalloproteins, and excessiron is stored and detoxified in cytosolic ferritin.
root||ROOT-0/null||delayed-1/VBN	nn||results-4/NNS||insulin-2/NN	nn||results-4/NNS||secretion-3/NN	dobj||delayed-1/VBN||results-4/NNS	amod||concentrations-9/NNS||higher-6/JJR	nn||concentrations-9/NNS||peak-7/NN	nn||concentrations-9/NNS||glucose-8/NN	prep_in||results-4/NNS||concentrations-9/NNS	advmod||delayed-1/VBN||particularly-10/RB	advmod||impaired-16/JJ||when-11/WRB	nsubj||impaired-16/JJ||suppression-12/NN	prep_of||suppression-12/NN||glucagon-14/NN	cop||impaired-16/JJ||is-15/VBZ	advcl||delayed-1/VBN||impaired-16/JJ	mark||insulinresistance-19/JJ||whereas-18/IN	advcl||impaired-16/JJ||insulinresistance-19/JJ	dep||delayed-1/VBN||prolongs-20/VBZ	det||duration-22/NN||the-21/DT	nsubj||delayed-1/VBN||duration-22/NN	nsubjpass||marked-29/VBN||duration-22/NN	prep_of||duration-22/NN||hyperglycemia-24/NN	aux||marked-29/VBN||can-27/MD	auxpass||marked-29/VBN||be-28/VB	rcmod||duration-22/NN||marked-29/VBN	advmod||present-37/JJ||when-30/WRB	det||insulinresistance-35/NN||both-31/DT	amod||insulinresistance-35/NN||hepatic-32/JJ	conj_and||hepatic-32/JJ||extra-hepatic-34/JJ	amod||insulinresistance-35/NN||extra-hepatic-34/JJ	nsubj||present-37/JJ||insulinresistance-35/NN	cop||present-37/JJ||are-36/VBP	advcl||marked-29/VBN||present-37/JJ	insulin-2||insulinresistance-35||no_rel||delayed insulin secretion results in higher peak glucose concentrations particularly when suppression of glucagon is impaired, whereas insulinresistance prolongs the duration of hyperglycemia, which can be marked when both hepatic and extra-hepatic insulinresistance are present.
mark||identified-15/VBN||although-1/IN	nsubj||identified-15/VBN||sampling-2/NN	amod||birds-6/NNS||healthy-4/JJ	amod||birds-6/NNS||wild-5/JJ	prep_of||sampling-2/NN||birds-6/NNS	vmod||birds-6/NNS||representing-7/VBG	det||number-10/NN||a-8/DT	amod||number-10/NN||large-9/JJ	dobj||representing-7/VBG||number-10/NN	prep_of||number-10/NN||species-12/NNS	aux||identified-15/VBN||has-13/VBZ	neg||identified-15/VBN||not-14/RB	advcl||demonstrated-33/VBN||identified-15/VBN	amod||carriers-17/NNS||possible-16/JJ	dobj||identified-15/VBN||carriers-17/NNS	amod||-rrb--22/NNS||influenzavirus-19/JJ	amod||-rrb--22/NNS||-lrb--20/JJ	amod||-rrb--22/NNS||h5n1-21/JJ	prep_of||carriers-17/NNS||-rrb--22/NNS	prep_into||identified-15/VBN||europe-24/NN	nsubj||demonstrated-33/VBN||surveillance-26/NN	amod||birds-31/NNS||dead-28/JJ	conj_and||dead-28/JJ||sick-30/JJ	amod||birds-31/NNS||sick-30/JJ	prep_of||surveillance-26/NN||birds-31/NNS	aux||demonstrated-33/VBN||has-32/VBZ	root||ROOT-0/null||demonstrated-33/VBN	amod||-rrb--38/NNS||mute-34/JJ	num||cygnus-36/NNS||-lrb--35/CD	dep||mute-34/JJ||cygnus-36/NNS	nn||-rrb--38/NNS||olor-37/NN	dobj||demonstrated-33/VBN||-rrb--38/NNS	nn||cygnus-43/NNS||whooper-40/NN	amod||cygnus-43/NNS||-lrb--41/JJ	nn||cygnus-43/NNS||c.-42/NN	dobj||demonstrated-33/VBN||cygnus-43/NNS	conj_and||-rrb--38/NNS||cygnus-43/NNS	advmod||swans-45/JJ||-rrb--44/RB	amod||-rrb--38/NNS||swans-45/JJ	amod||sentinels-48/NNS||potential-47/JJ	prep_as||demonstrated-33/VBN||sentinels-48/NNS	h5n1-21||influenzavirus-19||no||although sampling of healthy wild birds representing a large number of species has not identified possible carriers of influenzavirus -lrb- h5n1 -rrb- into europe , surveillance of dead and sick birds has demonstrated mute -lrb- cygnus olor -rrb- and whooper -lrb- c. cygnus -rrb- swans as potential sentinels .
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubjpass||recommended-12/VBN||treatment-3/NN	prep_of||treatment-3/NN||malaria-5/NN	prep_with||malaria-5/NN||sulphadoxine-pyrimethamine-7/NN	appos||treatment-3/NN||sp-9/NN	auxpass||recommended-12/VBN||is-11/VBZ	root||ROOT-0/null||recommended-12/VBN	det||prevention-15/NN||the-14/DT	prep_for||recommended-12/VBN||prevention-15/NN	prep_of||prevention-15/NN||malaria-17/NN	prep_in||recommended-12/VBN||pregnancy-19/NN	amod||africa-22/NN||sub-saharan-21/JJ	prep_in||pregnancy-19/NN||africa-22/NN	malaria-17||pyrimethamine--1||yes||intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine (sp) is recommended for the prevention of malaria in pregnancy in sub-saharan africa.
nsubj||relaxed-30/VBD||persistence-1/NN	prep_of||persistence-1/NN||hepatitisbvirus-3/NNS	appos||hepatitisbvirus-3/NNS||hbv-5/NN	nsubj||requires-8/VBZ||infection-7/NN	rcmod||hepatitisbvirus-3/NNS||requires-8/VBZ	advmod||closed-10/JJ||covalently-9/RB	amod||formation-16/NNS||closed-10/JJ	amod||formation-16/NNS||circular-11/JJ	appos||formation-16/NNS||ccc-13/NN	dobj||requires-8/VBZ||dna-15/NN	conj_and||formation-16/NNS||dna-15/NN	nn||formation-16/NNS||dna-15/NN	nsubj||occur-22/VB||dna-15/NN	dobj||requires-8/VBZ||formation-16/NNS	nsubj||occur-22/VB||formation-16/NNS	dobj||requires-8/VBZ||amplification-18/NNS	conj_and||formation-16/NNS||amplification-18/NNS	nsubj||occur-22/VB||amplification-18/NNS	aux||occur-22/VB||can-21/MD	rcmod||formation-16/NNS||occur-22/VB	nn||recycling-25/NN||intracellular-24/NN	prep_via||occur-22/VB||recycling-25/NN	det||polymerase-linked-29/NN||the-27/DT	amod||polymerase-linked-29/NN||viral-28/JJ	prep_of||recycling-25/NN||polymerase-linked-29/NN	root||ROOT-0/null||relaxed-30/VBD	amod||genomes-36/NNS||circular-31/JJ	appos||genomes-36/NNS||rc-33/NN	amod||genomes-36/NNS||dna-35/JJ	nsubj||present-37/JJ||genomes-36/NNS	xcomp||relaxed-30/VBD||present-37/JJ	prep_in||present-37/JJ||virions-39/NNS	hbv-5||hepatitisbvirus-3||no||persistence of hepatitisbvirus (hbv) infection requires covalently closed circular (ccc)dna formation and amplification, which can occur via intracellular recycling of the viral polymerase-linked relaxed circular (rc) dna genomes present in virions.
aux||compare-2/VB||to-1/TO	root||ROOT-0/null||compare-2/VB	det||effectiveness-4/NN||the-3/DT	dobj||compare-2/VB||effectiveness-4/NN	prep_of||effectiveness-4/NN||ondansetron-6/NN	conj_and||compare-2/VB||prochlorperazine-8/VB	aux||treat-10/VB||to-9/TO	xcomp||prochlorperazine-8/VB||treat-10/VB	dobj||treat-10/VB||vomiting-11/NN	vomiting-11||ondansetron-6||yes||to compare the effectiveness of ondansetron and prochlorperazine to treat vomiting.
nsubj||achieved-2/VBD||she-1/PRP	root||ROOT-0/null||achieved-2/VBD	det||improvement-6/NN||a-3/DT	advmod||dramatic-5/JJ||rather-4/RB	amod||improvement-6/NN||dramatic-5/JJ	dobj||achieved-2/VBD||improvement-6/NN	nn||control-9/NN||pain-8/NN	prep_of||improvement-6/NN||control-9/NN	det||response-14/NN||a-11/DT	amod||response-14/NN||significant-12/JJ	amod||response-14/NN||biochemical-13/JJ	dobj||achieved-2/VBD||response-14/NN	conj_but||improvement-6/NN||response-14/NN	number||%-17/NN||75-16/CD	amod||reduction-18/NN||%-17/NN	prep_with||response-14/NN||reduction-18/NN	det||level-23/NN||the-20/DT	amod||level-23/NN||ca-125-21/JJ	nn||level-23/NN||antigen-22/NN	prep_of||reduction-18/NN||level-23/NN	amod||regression-30/NN||limited-27/JJ	amod||regression-30/NN||radiographic-28/JJ	nn||regression-30/NN||tumor-29/NN	dobj||achieved-2/VBD||regression-30/NN	conj_but||improvement-6/NN||regression-30/NN	tumor-29||ca--1||no_rel||she achieved a rather dramatic improvement of pain control, a significant biochemical response with 75% reduction of the ca-125 antigen level, but only limited radiographic tumor regression.
det||mechanism-4/NN||the-1/DT	amod||mechanism-4/NN||possible-2/JJ	amod||mechanism-4/NN||molecular-3/JJ	nsubjpass||explored-12/VBN||mechanism-4/NN	nsubj||indoleamine-18/VB||mechanism-4/NN	vmod||mechanism-4/NN||mediating-5/VBG	det||effect-8/NN||this-6/DT	amod||effect-8/NN||immunosuppressive-7/JJ	dobj||mediating-5/VBG||effect-8/NN	prep_of||effect-8/NN||uc-mscs-10/NNS	auxpass||explored-12/VBN||was-11/VBD	root||ROOT-0/null||explored-12/VBN	agent||explored-12/VBN||addition-14/NN	prep_of||addition-14/NN||inhibitors-16/NNS	aux||indoleamine-18/VB||to-17/TO	xcomp||explored-12/VBN||indoleamine-18/VB	amod||ido-21/NN||2,3-dioxygenase-19/JJ	dobj||indoleamine-18/VB||ido-21/NN	appos||ido-21/NN||nitricoxide-24/NN	discourse||nitricoxide-24/NN||no-26/UH	appos||ido-21/NN||prostaglandine2-29/NNS	conj_and||nitricoxide-24/NN||prostaglandine2-29/NNS	appos||prostaglandine2-29/NNS||pge2-31/NNP	amod||î-37/NN||transforming-34/JJ	nn||î-37/NN||growth-35/NN	nn||î-37/NN||factor-36/NN	appos||ido-21/NN||î-37/NN	conj_and||nitricoxide-24/NN||î-37/NN	number||1-39/CD||²-38/CD	amod||î-37/NN||1-39/CD	dep||1-39/CD||tgf-î-41/NNP	number||1-43/CD||²-42/CD	num||tgf-î-41/NNP||1-43/CD	appos||ido-21/NN||interleukin-46/NN	conj_and||nitricoxide-24/NN||interleukin-46/NN	num||interleukin-46/NN||10-47/CD	dep||interleukin-46/NN||il-10-49/JJ	pge2-31||uc--1||no_rel||the possible molecular mechanism mediating this immunosuppressive effect of uc-mscs was explored by addition of inhibitors to indoleamine 2,3-dioxygenase (ido), nitricoxide (no), prostaglandine2 (pge2), transforming growth factor î²1 (tgf-î²1) and interleukin 10 (il-10).
csubj||allows-10/VBZ||using-1/VBG	nn||viruses-3/NNS||plant-2/NN	dobj||using-1/VBG||viruses-3/NNS	aux||produce-5/VB||to-4/TO	vmod||using-1/VBG||produce-5/VB	amod||proteins-7/NNS||desirable-6/JJ	dobj||produce-5/VB||proteins-7/NNS	prep_in||produce-5/VB||plants-9/NNS	root||ROOT-0/null||allows-10/VBZ	prepc_for||allows-10/VBZ||using-12/VBG	amod||hosts-15/NNS||non-transgenic-13/JJ	nn||hosts-15/NNS||plant-14/NN	dobj||using-12/VBG||hosts-15/NNS	mark||necessary-18/JJ||if-17/IN	advcl||construct-29/VBZ||necessary-18/JJ	det||ability-21/NN||the-20/DT	nsubj||construct-29/VBZ||ability-21/NN	aux||make-23/VB||to-22/TO	vmod||ability-21/NN||make-23/VB	amod||changes-25/NNS||rapid-24/JJ	dobj||make-23/VB||changes-25/NNS	det||virus-28/NN||the-27/DT	prep_in||make-23/VB||virus-28/NN	conj_and||allows-10/VBZ||construct-29/VBZ	prep_for||construct-29/VBZ||increased-31/VBN	amod||yields-36/NNS||modified-33/VBN	nn||yields-36/NNS||protein-34/NN	nn||yields-36/NNS||product-35/NN	prep_for||construct-29/VBZ||yields-36/NNS	conj_or||increased-31/VBN||yields-36/NNS	virus-28||viruses-3||no||using plant viruses to produce desirable proteins in plants allows for using non-transgenic plant hosts and if necessary, the ability to make rapid changes in the virus construct for increased or modified protein product yields.
nn||properties-3/NNS||fluoride-1/NN	nn||properties-3/NNS||release/recharge-2/NN	nsubj||important-8/JJ||properties-3/NNS	amod||sealants-6/NNS||fissure-5/JJ	prep_of||properties-3/NNS||sealants-6/NNS	cop||important-8/JJ||are-7/VBP	root||ROOT-0/null||important-8/JJ	poss||inhibition-12/NN||their-10/PRP$	amod||inhibition-12/NN||long-term-11/JJ	prep_for||important-8/JJ||inhibition-12/NN	prep_of||inhibition-12/NN||caries-14/NNS	caries-14||fluoride-1||yes||fluoride release/recharge properties of fissure sealants are important for their long-term inhibition of caries.
num||patients-4/NNS||20-2/CD	nn||patients-4/NNS||sle-3/NN	prep_in||serum-8/VBP||patients-4/NNS	prep_with||patients-4/NNS||hypovitaminosisd-6/NN	root||ROOT-0/null||serum-8/VBP	num||levels-14/NNS||25-9/CD	amod||levels-14/NNS||-lrb--10/JJ	nn||levels-14/NNS||oh-11/NNP	nn||levels-14/NNS||-rrb--12/NNP	nn||levels-14/NNS||d-13/NNP	dobj||serum-8/VBP||levels-14/NNS	advmod||increased-16/VBN||dramatically-15/RB	vmod||levels-14/NNS||increased-16/VBN	amod||supplementation-19/NN||vitamind-18/JJ	prep_under||increased-16/VBN||supplementation-19/NN	number||â-22/CD||18.7-21/CD	num||6.7-24/CD||â-22/CD	number||6.7-24/CD||±-23/CD	prep_from||serum-8/VBP||6.7-24/CD	prep_at||serum-8/VBP||day-26/NN	num||day-26/NN||0-27/CD	num||±-31/NNS||51.4-29/CD	nn||±-31/NNS||â-30/NN	prep_to||serum-8/VBP||±-31/NNS	num||-rrb--37/NN||14.1-32/CD	amod||-rrb--37/NN||-lrb--33/JJ	amod||-rrb--37/NN||p-34/JJ	nn||-rrb--37/NN||<-35/NN	num||-rrb--37/NN||0.001-36/CD	nsubj||serum-8/VBP||-rrb--37/NN	num||months-40/NNS||2-39/CD	nsubj||±-44/VBG||months-40/NNS	num||â-43/NN||41.5-42/CD	conj_and||months-40/NNS||â-43/NN	nsubj||±-44/VBG||â-43/NN	prepc_at||serum-8/VBP||±-44/VBG	num||p-48/NN||10.1-45/CD	amod||p-48/NN||ng/ml-46/JJ	nn||p-48/NN||-lrb--47/NN	nsubj||<-49/JJ||p-48/NN	xcomp||±-44/VBG||<-49/JJ	num||-rrb--51/NNS||0.001-50/CD	npadvmod||at-52/IN||-rrb--51/NNS	advmod||months-54/NNS||at-52/IN	num||months-54/NNS||6-53/CD	tmod||±-44/VBG||months-54/NNS	hypovitaminosisd-6||vitamind-18||yes||in 20 sle patients with hypovitaminosisd. serum 25 -lrb- oh -rrb- d levels dramatically increased under vitamind supplementation from 18.7 â ± 6.7 at day 0 to 51.4 â ± 14.1 -lrb- p < 0.001 -rrb- at 2 months and 41.5 â ± 10.1 ng/ml -lrb- p < 0.001 -rrb- at 6 months .
amod||confounders-2/NNS||potential-1/JJ	nsubj||included-4/VBD||confounders-2/NNS	vmod||confounders-2/NNS||controlled-3/VBN	root||ROOT-0/null||included-4/VBD	nn||history-10/NN||age-5/NN	dep||history-10/NN||gender-7/NN	dep||history-10/NN||family-9/NN	dobj||included-4/VBD||history-10/NN	prep_of||included-4/VBD||osteoporosis-12/NNS	amod||activity-15/NN||physical-14/JJ	prep_of||included-4/VBD||activity-15/NN	conj_and||osteoporosis-12/NNS||activity-15/NN	prep_of||included-4/VBD||smoking-17/NN	conj_and||osteoporosis-12/NNS||smoking-17/NN	nn||intake-20/NN||calcium-19/NN	prep_of||included-4/VBD||intake-20/NN	conj_and||osteoporosis-12/NNS||intake-20/NN	amod||status-23/NN||vitamind-22/JJ	prep_of||included-4/VBD||status-23/NN	conj_and||osteoporosis-12/NNS||status-23/NN	nn||status-26/NN||estrogen-25/NN	prep_of||included-4/VBD||status-26/NN	conj_and||osteoporosis-12/NNS||status-26/NN	prep_of||included-4/VBD||medications-28/NNS	conj_and||osteoporosis-12/NNS||medications-28/NNS	amod||function-31/NN||renal-30/JJ	prep_of||included-4/VBD||function-31/NN	conj_and||osteoporosis-12/NNS||function-31/NN	nn||creatinine-34/NN||urine-33/NN	prep_of||included-4/VBD||creatinine-34/NN	conj_and||osteoporosis-12/NNS||creatinine-34/NN	nn||index-38/NN||body-36/NN	nn||index-38/NN||mass-37/NN	prep_of||included-4/VBD||index-38/NN	conj_and||osteoporosis-12/NNS||index-38/NN	prep_of||included-4/VBD||change-41/NN	conj_and||osteoporosis-12/NNS||change-41/NN	nn||index-45/NN||body-43/NN	nn||index-45/NN||mass-44/NN	prep_of||change-41/NN||index-45/NN	osteoporosis-12||vitamind-22||yes||potential confounders controlled included age, gender, family history of osteoporosis, physical activity, smoking, calcium intake, vitamind status, estrogen status, medications, renal function, urine creatinine, body mass index, and change of body mass index.
det||result-3/NN||a-2/DT	prep_as||decreased-16/VBD||result-3/NN	det||treatment-6/NN||the-5/DT	prep_of||result-3/NN||treatment-6/NN	amod||prednisolone-9/NN||30mg-8/JJ	prep_with||treatment-6/NN||prednisolone-9/NN	nsubj||decreased-16/VBD||the-11/DT	amod||the-11/DT||swelling-12/VBG	det||lns-15/NN||the-14/DT	prep_of||the-11/DT||lns-15/NN	root||ROOT-0/null||decreased-16/VBD	det||patient-20/NN||the-19/DT	nsubj||continued-21/VBD||patient-20/NN	nsubj||have-23/VB||patient-20/NN	conj_but||decreased-16/VBD||continued-21/VBD	aux||have-23/VB||to-22/TO	xcomp||continued-21/VBD||have-23/VB	amod||hematoproteinuria-25/NN||persistent-24/JJ	dobj||have-23/VB||hematoproteinuria-25/NN	swelling-12||prednisolone-9||yes||as a result of the treatment with 30mg prednisolone, the swelling of the lns decreased, but the patient continued to have persistent hematoproteinuria.
advmod||recently-2/RB||more-1/RBR	advmod||discovered-10/VBN||recently-2/RB	det||channels-7/NNS||the-4/DT	amod||channels-7/NNS||ttx-resistant-5/JJ	nn||channels-7/NNS||sodium-6/NN	nsubjpass||discovered-10/VBN||channels-7/NNS	nsubjpass||received-16/VBN||channels-7/NNS	aux||discovered-10/VBN||have-8/VBP	auxpass||discovered-10/VBN||been-9/VBN	root||ROOT-0/null||discovered-10/VBN	det||system-14/NN||the-12/DT	amod||system-14/NN||nervous-13/JJ	prep_in||discovered-10/VBN||system-14/NN	conj_and||discovered-10/VBN||received-16/VBN	amod||attention-18/NN||much-17/JJ	dobj||received-16/VBN||attention-18/NN	poss||role-22/NN||their-21/PRP$	prep_because_of||attention-18/NN||role-22/NN	nn||sensation-25/NN||pain-24/NN	prep_in||received-16/VBN||sensation-25/NN	ttx--1||pain-24||no_rel||more recently, the ttx-resistant sodium channels have been discovered in the nervous system and received much attention because of their role in pain sensation.
amod||dye-3/NNS||evans-1/JJ	amod||dye-3/NNS||blue-2/JJ	nsubj||elicits-7/VBZ||dye-3/NNS	appos||dye-3/NNS||eb-5/NN	root||ROOT-0/null||elicits-7/VBZ	det||fluorescence-10/NN||a-8/DT	nn||fluorescence-10/NN||violet-9/NN	dobj||elicits-7/VBZ||fluorescence-10/NN	prep_by||elicits-7/VBZ||excitation-12/NN	prep_at||excitation-12/NN||345-nm-14/NN	prep_at||excitation-12/NN||emission-16/NN	conj_and||345-nm-14/NN||emission-16/NN	prep_at||elicits-7/VBZ||420-nm-18/JJ	det||reddish-brown-22/NN||a-21/DT	nsubj||fluorescence-23/VBP||reddish-brown-22/NN	conj_and||elicits-7/VBZ||fluorescence-23/VBP	prep_by||fluorescence-23/VBP||excitation-25/NN	prep_at||excitation-25/NN||470-nm-27/NN	prep_at||excitation-25/NN||emission-29/NN	conj_and||470-nm-27/NN||emission-29/NN	amod||characteristic-32/NN||515-nm-31/JJ	prep_at||fluorescence-23/VBP||characteristic-32/NN	prep_of||characteristic-32/NN||oxldl-34/NN	advmod||oxldl-34/NN||only-35/RB	evans-1||nm--1||no_rel||evans blue dye (eb) elicits a violet fluorescence by excitation at 345-nm and emission at 420-nm, and a reddish-brown fluorescence by excitation at 470-nm and emission at 515-nm characteristic of oxldl only.
amod||-rrb--10/NNPS||vaccination-1/JJ	amod||calmette-guã-5/NNS||mycobacteriumbovis-3/JJ	nn||calmette-guã-5/NNS||bacille-4/NN	prep_with||vaccination-1/JJ||calmette-guã-5/NNS	amod||-rrb--10/NNPS||©-6/JJ	nn||-rrb--10/NNPS||rin-7/NN	nn||-rrb--10/NNPS||-lrb--8/NNP	nn||-rrb--10/NNPS||bcg-9/NNPS	nsubjpass||used-13/VBN||-rrb--10/NNPS	nsubj||reduce-15/VB||-rrb--10/NNPS	nsubjpass||reported-24/VBN||-rrb--10/NNPS	nsubj||have-26/VB||-rrb--10/NNPS	auxpass||used-13/VBN||is-11/VBZ	advmod||used-13/VBN||widely-12/RB	root||ROOT-0/null||used-13/VBN	aux||reduce-15/VB||to-14/TO	xcomp||used-13/VBN||reduce-15/VB	det||risk-17/NN||the-16/DT	dobj||reduce-15/VB||risk-17/NN	nn||tuberculosis-20/NNP||childhood-19/NNP	prep_of||risk-17/NN||tuberculosis-20/NNP	aux||reported-24/VBN||has-22/VBZ	auxpass||reported-24/VBN||been-23/VBN	conj_and||used-13/VBN||reported-24/VBN	aux||have-26/VB||to-25/TO	xcomp||reported-24/VBN||have-26/VB	amod||-rrb--42/NNP||efficacy-27/JJ	num||mycobacterialdiseases-31/NNS||two-29/CD	amod||mycobacterialdiseases-31/NNS||other-30/JJ	prep_against||efficacy-27/JJ||mycobacterialdiseases-31/NNS	prep_against||efficacy-27/JJ||leprosy-33/NNP	conj_and||mycobacterialdiseases-31/NNS||leprosy-33/NNP	prep_against||efficacy-27/JJ||buruliulcer-35/NN	conj_and||mycobacterialdiseases-31/NNS||buruliulcer-35/NN	vmod||buruliulcer-35/NN||caused-36/VBN	nn||ulcerans-39/NNS||m.-38/NN	agent||caused-36/VBN||ulcerans-39/NNS	nn||-rrb--42/NNP||-lrb--40/NNP	nn||-rrb--42/NNP||mu-41/NNP	dobj||have-26/VB||-rrb--42/NNP	tuberculosis-20||bcg-9||no||vaccination with mycobacteriumbovis bacille calmette-guã © rin -lrb- bcg -rrb- is widely used to reduce the risk of childhood tuberculosis and has been reported to have efficacy against two other mycobacterialdiseases , leprosy and buruliulcer caused by m. ulcerans -lrb- mu -rrb- .
det||understanding-3/NN||a-1/DT	amod||understanding-3/NN||better-2/JJR	nsubj||pave-11/VBD||understanding-3/NN	nsubj||essential-26/JJ||understanding-3/NN	amod||effects-6/NNS||immunomodulatory-5/JJ	prep_of||understanding-3/NN||effects-6/NNS	prep_of||effects-6/NNS||pregnancy-8/NN	prep_on||pregnancy-8/NN||diabeticretinopathy-10/NN	root||ROOT-0/null||pave-11/VBD	det||way-13/NN||the-12/DT	dobj||pave-11/VBD||way-13/NN	amod||investigations-16/NNS||further-15/JJ	prep_for||pave-11/VBD||investigations-16/NNS	det||mechanism-19/NN||the-18/DT	prep_of||investigations-16/NNS||mechanism-19/NN	poss||pathogenesis-22/NNS||its-21/PRP$	prep_of||mechanism-19/NN||pathogenesis-22/NNS	aux||essential-26/JJ||could-24/MD	cop||essential-26/JJ||be-25/VB	conj_and||pave-11/VBD||essential-26/JJ	nn||approaches-29/NNS||novel-28/NN	prep_for||essential-26/JJ||approaches-29/NNS	det||treatment-32/NN||the-31/DT	prep_to||essential-26/JJ||treatment-32/NN	det||sight-36/NN||this-34/DT	amod||sight-36/NN||serious-35/JJ	prep_of||treatment-32/NN||sight-36/NN	vmod||sight-36/NN||threatening-37/VBG	dobj||threatening-37/VBG||complication-38/NN	prep_of||complication-38/NN||diabetesmellitus-40/NNS	diabeticretinopathy-10||diabetesmellitus-40||no||a better understanding of immunomodulatory effects of pregnancy on diabeticretinopathy pave the way for further investigations of the mechanism of its pathogenesis and could be essential for novel approaches to the treatment of this serious sight threatening complication of diabetesmellitus.
det||study-2/NN||this-1/DT	nsubj||aimed-3/VBD||study-2/NN	nsubj||examine-5/VB||study-2/NN	root||ROOT-0/null||aimed-3/VBD	aux||examine-5/VB||to-4/TO	xcomp||aimed-3/VBD||examine-5/VB	det||hypothesis-7/NNS||the-6/DT	dobj||examine-5/VB||hypothesis-7/NNS	mark||relate-19/VBP||that-8/IN	det||factors-10/NNS||some-9/DT	nsubj||relate-19/VBP||factors-10/NNS	prep_of||factors-10/NNS||ptg-12/NN	amod||strength-17/NN||personal-16/JJ	prep_such_as||factors-10/NNS||strength-17/NN	ccomp||examine-5/VB||relate-19/VBP	prep_to||relate-19/VBP||resilience-21/NN	mark||relate-33/VBP||whereas-23/IN	amod||factors-25/NNS||other-24/JJ	nsubj||relate-33/VBP||factors-25/NNS	nsubj||ptsd-35/VB||factors-25/NNS	prep_such_as||factors-25/NNS||appreciation-29/NN	prep_of||appreciation-29/NN||life-31/NN	advcl||relate-19/VBP||relate-33/VBP	aux||ptsd-35/VB||to-34/TO	xcomp||relate-33/VBP||ptsd-35/VB	dobj||ptsd-35/VB||symptoms-36/NNS	amod||survivors-45/NNS||japanese-38/JJ	nn||survivors-45/NNS||motor-39/NN	nn||survivors-45/NNS||vehicle-40/NN	nn||survivors-45/NNS||accident-41/NN	nn||survivors-45/NNS||mva-43/NN	prep_among||ptsd-35/VB||survivors-45/NNS	vehicle-40||ptsd-35||no_rel||this study aimed to examine the hypothesis that some factors of ptg, such as personal strength, relate to resilience, whereas other factors, such as appreciation of life, relate to ptsd symptoms among japanese motor vehicle accident (mva) survivors.
amod||data-2/NNS||compelling-1/JJ	nsubj||demonstrate-3/VBP||data-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	mark||results-8/VBZ||that-4/IN	amod||anorexia-6/NN||inflammation-associated-5/JJ	nsubj||results-8/VBZ||anorexia-6/NN	advmod||results-8/VBZ||directly-7/RB	ccomp||demonstrate-3/VBP||results-8/VBZ	det||action-11/NN||the-10/DT	prep_from||results-8/VBZ||action-11/NN	amod||factors-14/NNS||pro-inflammatory-13/JJ	prep_of||action-11/NN||factors-14/NNS	advmod||e2-20/NNS||primarily-16/RB	amod||e2-20/NNS||cytokines-17/JJ	conj_and||cytokines-17/JJ||prostaglandins-19/JJ	amod||e2-20/NNS||prostaglandins-19/JJ	appos||factors-14/NNS||e2-20/NNS	det||system-25/NN||the-23/DT	amod||system-25/NN||nervous-24/JJ	prep_on||results-8/VBZ||system-25/NN	prostaglandins-19||inflammation--1||no_rel||compelling data demonstrate that inflammation-associated anorexia directly results from the action of pro-inflammatory factors, primarily cytokines and prostaglandins e2, on the nervous system.
det||database-8/NN||the-1/DT	nn||network-4/NN||health-2/NN	nn||network-4/NN||improvement-3/NN	nn||database-8/NN||network-4/NN	dep||network-4/NN||thin-6/JJ	nsubjpass||used-10/VBN||database-8/NN	nsubj||identify-12/VB||database-8/NN	auxpass||used-10/VBN||was-9/VBD	root||ROOT-0/null||used-10/VBN	aux||identify-12/VB||to-11/TO	xcomp||used-10/VBN||identify-12/VB	dobj||identify-12/VB||patients-13/NNS	prep_with||identify-12/VB||adhd-15/NN	nsubj||received-17/VBD||adhd-15/NN	rcmod||adhd-15/NN||received-17/VBD	poss||prescription-20/NN||their-18/PRP$	amod||prescription-20/NN||first-19/JJ	dobj||received-17/VBD||prescription-20/NN	prepc_for||received-17/VBD||methylphenidate-22/NN	punct||dexamfetamine/atomoxetine-24/NN||/-23/:	dep||methylphenidate-22/NN||dexamfetamine/atomoxetine-24/NN	amod||6â-27/NNS||aged-26/JJ	appos||dexamfetamine/atomoxetine-24/NN||6â-27/NNS	num||years-31/NNS||$-28/$	num||$-28/$||17-30/CD	tmod||methylphenidate-22/NN||years-31/NNS	adhd-15||methylphenidate-22||yes||the health improvement network (thin) database was used to identify patients with adhd who received their first prescription for methylphenidate/ dexamfetamine/atomoxetine, aged 6â17 years.
num||outpatients-2/NNS||seventeen-1/CD	nsubj||underwent-18/VBD||outpatients-2/NNS	prep_with||outpatients-2/NNS||schizophrenia-4/NN	num||aripiprazole-8/NN||9-6/CD	nn||aripiprazole-8/NN||taking-7/NN	dep||schizophrenia-4/NN||aripiprazole-8/NN	num||risperidone-12/NN||8-10/CD	nn||risperidone-12/NN||taking-11/NN	dep||schizophrenia-4/NN||risperidone-12/NN	conj_and||aripiprazole-8/NN||risperidone-12/NN	num||controls-17/NNS||18-15/CD	amod||controls-17/NNS||healthy-16/JJ	prep_with||outpatients-2/NNS||controls-17/NNS	conj_and||schizophrenia-4/NN||controls-17/NNS	root||ROOT-0/null||underwent-18/VBD	amod||pet-20/NN||18f-fluoroflumazenil-19/JJ	dobj||underwent-18/VBD||pet-20/NN	nn||receptor-24/NN||gabaa-23/NN	nsubjpass||compared-28/VBN||receptor-24/NN	amod||potential-26/JJ||binding-25/JJ	amod||receptor-24/NN||potential-26/JJ	auxpass||compared-28/VBN||was-27/VBD	conj_and||underwent-18/VBD||compared-28/VBN	det||groups-32/NNS||the-30/DT	num||groups-32/NNS||three-31/CD	prep_between||compared-28/VBN||groups-32/NNS	schizophrenia-4||risperidone-12||yes||seventeen outpatients with schizophrenia (9 taking aripiprazole and 8 taking risperidone) and 18 healthy controls underwent 18f-fluoroflumazenil pet, and gabaa receptor binding potential was compared between the three groups.
nsubj||remained-9/VBD||changes-1/NNS	nn||control-6/NN||adiposity-3/NN	conj_and||adiposity-3/NN||glucose-5/NN	nn||control-6/NN||glucose-5/NN	prep_in||changes-1/NNS||control-6/NN	prep_with||control-6/NN||ili-8/NN	root||ROOT-0/null||remained-9/VBD	amod||predictors-11/NNS||independent-10/JJ	xcomp||remained-9/VBD||predictors-11/NNS	amod||change-14/NN||hs-crp-13/JJ	prep_of||predictors-11/NNS||change-14/NN	num||year-17/NN||1-16/CD	prep_at||change-14/NN||year-17/NN	dep||year-17/NN||p-19/VBN	number||0.0001-21/CD||<-20/CD	dobj||p-19/VBN||0.0001-21/CD	prep_for||0.0001-21/CD||each-23/DT	prep_after||remained-9/VBD||adjustment-26/NN	prep_for||adjustment-26/NN||demographics-28/NNS	prep_for||adjustment-26/NN||smoking-30/NN	conj_and||demographics-28/NNS||smoking-30/NN	amod||use-38/NN||cardiovascular-32/JJ	nn||use-38/NN||history-33/NN	conj_and||history-33/NN||statin-35/NN	nn||use-38/NN||statin-35/NN	conj_and||history-33/NN||thiazolidinedione-37/NN	nn||use-38/NN||thiazolidinedione-37/NN	prep_for||adjustment-26/NN||use-38/NN	conj_and||demographics-28/NNS||use-38/NN	prep_for||adjustment-26/NN||changes-41/NNS	conj_and||demographics-28/NNS||changes-41/NNS	nn||control-46/NN||fitness-43/NN	conj_and||fitness-43/NN||lipid-45/NN	nn||control-46/NN||lipid-45/NN	prep_in||remained-9/VBD||control-46/NN	adiposity-3||statin-35||no_rel||changes in adiposity and glucose control with ili remained independent predictors of hs-crp change at 1 year ( p < 0.0001 for each) after adjustment for demographics, smoking, cardiovascular history, statin and thiazolidinedione use, and changes in fitness and lipid control.
det||formulation-3/NN||the-1/DT	amod||formulation-3/NN||immediate-release-2/JJ	nsubjpass||approved-11/VBN||formulation-3/NN	prep_of||formulation-3/NN||lamotrigine-5/NN	appos||formulation-3/NN||ltg-ir-7/NN	aux||approved-11/VBN||has-9/VBZ	auxpass||approved-11/VBN||been-10/VBN	root||ROOT-0/null||approved-11/VBN	amod||seizures-16/NNS||primary-13/JJ	amod||seizures-16/NNS||generalized-14/JJ	amod||seizures-16/NNS||tonic-clonic-15/JJ	prep_for||approved-11/VBN||seizures-16/NNS	prep_since||seizures-16/NNS||2006-18/CD	seizures-16||lamotrigine-5||yes||the immediate-release formulation of lamotrigine (ltg-ir) has been approved for primary generalized tonic-clonic seizures since 2006.
advmod||lowest-112/JJS||nationally-1/RB	num||%-4/NN||32.0-3/CD	nsubj||lowest-112/JJS||%-4/NN	num||-RSB--12/NNS||95-6/CD	nn||-RSB--12/NNS||%-7/NN	nn||-RSB--12/NNS||confidence-8/NN	amod||-RSB--12/NNS||interval-9/JJ	amod||-RSB--12/NNS||-LSB--10/JJ	nn||-RSB--12/NNS||ci-11/NN	dep||%-4/NN||-RSB--12/NNS	amod||-RSB--12/NNS||=-13/VBN	number||%-18/NN||30.3-14/CD	dep||%-18/NN||%-15/NN	dep||%-18/NN||to-16/TO	number||%-18/NN||33.6-17/CD	dep||=-13/VBN||%-18/NN	prep_of||%-4/NN||girls-21/NNS	vmod||girls-21/NNS||aged-22/VBN	number||17-25/CD||13-23/CD	dep||17-25/CD||to-24/TO	num||years-26/NNS||17-25/CD	nsubj||received-30/VBN||years-26/NNS	prep_in||years-26/NNS||2010-28/CD	aux||received-30/VBN||had-29/VBD	dep||aged-22/VBN||received-30/VBN	num||doses-32/NNS||three-31/CD	dobj||received-30/VBN||doses-32/NNS	det||vaccine-36/NN||the-34/DT	nn||vaccine-36/NN||hpv-35/NN	prep_of||doses-32/NNS||vaccine-36/NN	nsubj||lower-43/JJR||coverage-39/NN	nsubj||lower-43/JJR||coverage-39/NN	cop||lower-43/JJR||was-40/VBD	advmod||lower-43/JJR||statistically-41/RB	advmod||lower-43/JJR||significantly-42/RB	dep||aged-22/VBN||lower-43/JJR	conj_and||received-30/VBN||lower-43/JJR	conj_and||received-30/VBN||lower-43/JJR	conj_and||lower-43/JJR||lower-43/JJR	det||uninsured-46/JJ||the-45/DT	prep_among||lower-43/JJR||uninsured-46/JJ	num||%-49/NN||14.1-48/CD	dep||uninsured-46/JJ||%-49/NN	num||%-52/NN||95-51/CD	appos||%-49/NN||%-52/NN	vmod||%-52/NN||ci-53/VBN	dep||%-56/NN||=-54/SYM	num||%-56/NN||9.4-55/CD	ccomp||ci-53/VBN||%-56/NN	num||%-59/NN||20.6-58/CD	prep_to||ci-53/VBN||%-59/NN	det||states-65/NNS||some-63/DT	amod||states-65/NNS||southern-64/JJ	prep_in||lower-43/JJR||states-65/NNS	dep||states-65/NNS||eg-67/NN	num||%-70/NN||20.0-69/CD	appos||eg-67/NN||%-70/NN	nn||-RSB--83/NNS||alabama-72/NNP	nn||-RSB--83/NNS||-LSB--73/NNP	number||%-75/NN||95-74/CD	amod||-RSB--83/NNS||%-75/NN	amod||-RSB--83/NNS||ci-76/JJ	amod||-RSB--83/NNS||=-77/VBN	number||%-82/NN||13.9-78/CD	dep||%-82/NN||%-79/NN	dep||%-82/NN||to-80/TO	number||%-82/NN||27.9-81/CD	num||-RSB--83/NNS||%-82/NN	prep_in||%-70/NN||-RSB--83/NNS	nn||-RSB--96/NNS||mississippi-85/NNP	nn||-RSB--96/NNS||-LSB--86/NNP	number||%-88/NN||95-87/CD	amod||-RSB--96/NNS||%-88/NN	amod||-RSB--96/NNS||ci-89/JJ	amod||-RSB--96/NNS||=-90/VBN	number||%-95/NN||13.8-91/CD	dep||%-95/NN||%-92/NN	dep||%-95/NN||to-93/TO	number||%-95/NN||28.2-94/CD	num||-RSB--96/NNS||%-95/NN	prep_in||%-70/NN||-RSB--96/NNS	conj_and||-RSB--83/NNS||-RSB--96/NNS	advmod||highest-104/JJS||where-99/WRB	amod||rates-102/NNS||cervical-100/JJ	nn||rates-102/NNS||cancer-101/NN	nsubj||highest-104/JJS||rates-102/NNS	cop||highest-104/JJS||were-103/VBD	advcl||lower-43/JJR||highest-104/JJS	amod||prevalence-109/NN||recent-106/JJ	nn||prevalence-109/NN||pap-107/NN	amod||prevalence-109/NN||testing-108/VBG	advcl||lower-43/JJR||prevalence-109/NN	conj_and||highest-104/JJS||prevalence-109/NN	cop||lowest-112/JJS||was-110/VBD	det||lowest-112/JJS||the-111/DT	root||ROOT-0/null||lowest-112/JJS	cancer-101||pap-107||no_rel||nationally, 32.0% (95% confidence interval [ci] = 30.3% to 33.6%) of girls aged 13 to 17 years in 2010 had received three doses of the hpv vaccine, and coverage was statistically significantly lower among the uninsured (14.1%, 95% ci = 9.4% to 20.6%) and in some southern states (eg, 20.0% in alabama [95% ci = 13.9% to 27.9%] and mississippi [95% ci = 13.8% to 28.2%]), where cervical cancer rates were highest and recent pap testing prevalence was the lowest.
amod||forms-4/NNS||attractive-1/JJ	conj_and||attractive-1/JJ||novel-3/JJ	amod||forms-4/NNS||novel-3/JJ	nsubj||include-7/VBP||forms-4/NNS	prep_of||forms-4/NNS||therapy-6/NN	root||ROOT-0/null||include-7/VBP	dobj||include-7/VBP||strategies-8/NNS	aux||eliminate-10/VB||to-9/TO	vmod||strategies-8/NNS||eliminate-10/VB	amod||peptides-13/NNS||detrimental-11/JJ	nn||peptides-13/NNS||gluten-12/NN	dobj||eliminate-10/VB||peptides-13/NNS	det||diet-17/NN||the-15/DT	amod||diet-17/NN||celiac-16/JJ	prep_from||eliminate-10/VB||diet-17/NN	advmod||neutralized-29/VBN||so-18/RB	mark||neutralized-29/VBN||that-19/IN	det||effect-22/NN||the-20/DT	amod||effect-22/NN||immunogenic-21/JJ	nsubjpass||neutralized-29/VBN||effect-22/NN	det||epitopes-26/NNS||the-24/DT	nn||epitopes-26/NNS||gluten-25/NN	prep_of||effect-22/NN||epitopes-26/NNS	aux||neutralized-29/VBN||can-27/MD	auxpass||neutralized-29/VBN||be-28/VB	advcl||eliminate-10/VB||neutralized-29/VBN	dobj||include-7/VBP||strategies-34/NNS	conj_and||strategies-8/NNS||strategies-34/NNS	aux||block-36/VB||to-35/TO	vmod||strategies-34/NNS||block-36/VB	det||response-40/NN||the-37/DT	amod||response-40/NN||gluten-induced-38/JJ	amod||response-40/NN||inflammatory-39/JJ	dobj||block-36/VB||response-40/NN	celiac-16||gluten-25||no||attractive and novel forms of therapy include strategies to eliminate detrimental gluten peptides from the celiac diet so that the immunogenic effect of the gluten epitopes can be neutralized, as well as strategies to block the gluten-induced inflammatory response.
prep_in||contribute-6/VB||owat-2/NN	nsubj||contribute-6/VB||fibrosis-4/NN	nsubj||limit-8/VB||fibrosis-4/NN	nsubjpass||associated-13/VBN||fibrosis-4/NN	aux||contribute-6/VB||could-5/MD	root||ROOT-0/null||contribute-6/VB	aux||limit-8/VB||to-7/TO	xcomp||contribute-6/VB||limit-8/VB	amod||hypertrophy-10/NN||adipocyte-9/JJ	dobj||limit-8/VB||hypertrophy-10/NN	auxpass||associated-13/VBN||is-12/VBZ	conj_and||contribute-6/VB||associated-13/VBN	det||profile-18/NN||a-15/DT	amod||profile-18/NN||better-16/JJR	nn||profile-18/NN||lipid-17/NN	prep_with||associated-13/VBN||profile-18/NN	mark||hamper-24/VB||whereas-20/IN	nn||fibrosis-22/NN||scwat-21/NN	nsubj||hamper-24/VB||fibrosis-22/NN	aux||hamper-24/VB||may-23/MD	dep||profile-18/NN||hamper-24/VB	amod||loss-27/NN||fat-25/JJ	amod||loss-27/NN||mass-26/JJ	dobj||hamper-24/VB||loss-27/NN	vmod||loss-27/NN||induced-28/VBN	agent||induced-28/VBN||surgery-30/NN	fat-25||fibrosis-22||no_rel||in owat, fibrosis could contribute to limit adipocyte hypertrophy and is associated with a better lipid profile, whereas scwat fibrosis may hamper fat mass loss induced by surgery.
det||authors-2/NNS||the-1/DT	nsubj||assessed-3/VBD||authors-2/NNS	root||ROOT-0/null||assessed-3/VBD	det||resistance-8/NN||the-4/DT	amod||resistance-8/NN||efficacy-5/JJ	conj_and||efficacy-5/JJ||antiviral-7/JJ	amod||resistance-8/NN||antiviral-7/JJ	dobj||assessed-3/VBD||resistance-8/NN	amod||therapy-12/NN||48-week-10/JJ	nn||therapy-12/NN||clevudine-11/NN	prep_of||resistance-8/NN||therapy-12/NN	amod||patients-21/NNS||lamivudine-14/JJ	prep_in||lamivudine-14/JJ||treatment-16/NN	nn||¯-19/NNS||naã-18/NN	prep_of||treatment-16/NN||¯-19/NNS	nn||patients-21/NNS||ve-20/NN	prep_versus||therapy-12/NN||patients-21/NNS	prepc_with||assessed-3/VBD||hbeag-23/VBG	amod||chronichepatitisb-25/NN||positive-24/JJ	dobj||hbeag-23/VBG||chronichepatitisb-25/NN	antiviral-7||chronichepatitisb-25||no_rel||the authors assessed the efficacy and antiviral resistance of 48-week clevudine therapy versus lamivudine in treatment of naã¯ve patients with hbeag positive chronichepatitisb.
nn||discussions-2/NNS||group-1/NN	nsubjpass||conducted-7/VBN||discussions-2/NNS	amod||interviews-5/NNS||semistructured-4/JJ	conj_and||discussions-2/NNS||interviews-5/NNS	nsubjpass||conducted-7/VBN||interviews-5/NNS	auxpass||conducted-7/VBN||were-6/VBD	root||ROOT-0/null||conducted-7/VBN	prep_with||conducted-7/VBN||40-9/CD	ccomp||conducted-7/VBN||lay-10/VB	dobj||lay-10/VB||counselors-11/NNS	appos||counselors-11/NNS||57-13/CD	advmod||observed-15/JJ||directly-14/RB	amod||supporters-20/NNS||observed-15/JJ	nn||supporters-20/NNS||therapy-16/NN	appos||supporters-20/NNS||dot-18/NNP	dep||57-13/CD||supporters-20/NNS	num||syndrome-28/NN||13-23/CD	amod||syndrome-28/NN||tb-24/JJ	conj_and||tb-24/JJ||hiv/acquired-26/JJ	amod||syndrome-28/NN||hiv/acquired-26/JJ	amod||syndrome-28/NN||immunedeficiency-27/JJ	dobj||lay-10/VB||syndrome-28/NN	conj_and||counselors-11/NNS||syndrome-28/NN	appos||syndrome-28/NN||aids-30/NNS	nn||managers-33/NNS||program-32/NN	dep||counselors-11/NNS||managers-33/NNS	det||province-38/NN||the-35/DT	amod||province-38/NN||free-36/JJ	nn||province-38/NN||state-37/NN	prep_in||managers-33/NNS||province-38/NN	prep_between||province-38/NN||september-40/NNP	num||september-40/NNP||2007-41/CD	ccomp||conducted-7/VBN||march-43/VB	conj_and||lay-10/VB||march-43/VB	dobj||march-43/VB||2008-44/CD	aids-30||hiv--1||no||group discussions and semistructured interviews were conducted with 40 lay counselors, 57 directly observed therapy (dot) supporters, and 13 tb and hiv/acquired immunedeficiency syndrome (aids) program managers in the free state province between september 2007 and march 2008.
poss||science-3/NN||today-1/NN	nsubj||demonstrated-5/VBN||science-3/NN	aux||demonstrated-5/VBN||has-4/VBZ	root||ROOT-0/null||demonstrated-5/VBN	mark||caused-9/VBN||that-6/IN	nsubjpass||caused-9/VBN||caries-7/NNS	auxpass||caused-9/VBN||is-8/VBZ	ccomp||demonstrated-5/VBN||caused-9/VBN	amod||microorganisms-13/NNS||indigenous-11/JJ	amod||microorganisms-13/NNS||oral-12/JJ	agent||caused-9/VBN||microorganisms-13/NNS	vmod||microorganisms-13/NNS||becoming-14/VBG	det||biofilm-17/NN||a-15/DT	amod||biofilm-17/NN||dynamic-16/JJ	xcomp||becoming-14/VBG||biofilm-17/NN	nsubj||produce-26/VBP||biofilm-17/NN	det||presence-22/NN||the-21/DT	prep_in||produce-26/VBP||presence-22/NN	amod||sugars-25/NNS||fermentable-24/JJ	prep_of||presence-22/NN||sugars-25/NNS	rcmod||biofilm-17/NN||produce-26/VBP	amod||acids-28/NNS||organic-27/JJ	nsubj||capable-29/JJ||acids-28/NNS	xcomp||produce-26/VBP||capable-29/JJ	prepc_of||capable-29/JJ||dissolving-31/VBG	amod||enamel-33/NN||inorganic-32/JJ	dobj||dissolving-31/VBG||enamel-33/NN	dobj||dissolving-31/VBG||dentin-35/NN	conj_and||enamel-33/NN||dentin-35/NN	prepc_followed_by||dissolving-31/VBG||by-37/IN	det||destruction-40/NN||the-38/DT	amod||destruction-40/NN||proteolytic-39/JJ	nsubj||leaving-43/VBG||destruction-40/NN	prep_of||destruction-40/NN||collagen-42/NN	pcomp||dissolving-31/VBG||leaving-43/VBG	amod||dentin-46/NN||soft-44/JJ	amod||dentin-46/NN||infected-45/JJ	dobj||leaving-43/VBG||dentin-46/NN	sugars-25||caries-7||no_rel||today's science has demonstrated that caries is caused by indigenous oral microorganisms becoming a dynamic biofilm, that in the presence of fermentable sugars produce organic acids capable of dissolving inorganic enamel and dentin followed by the proteolytic destruction of collagen leaving soft infected dentin.
nn||design-2/NN||research-1/NN	nsubjpass||analyzed-22/VBN||design-2/NN	amod||atms-7/NNS||methodsâ-4/JJ	amod||atms-7/NNS||$-5/VBN	conj_and||design-2/NN||atms-7/NNS	nsubjpass||analyzed-22/VBN||atms-7/NNS	amod||mice-20/NNS||lean-9/JJ	conj_and||lean-9/JJ||obese-11/JJ	amod||mice-20/NNS||obese-11/JJ	amod||dietâ-14/NNS||high-fat-13/JJ	nsubj||$-15/VBZ||dietâ-14/NNS	dep||lean-9/JJ||$-15/VBZ	acomp||$-15/VBZ||fed-17/VBN	amod||mice-20/NNS||c57bl/6-19/JJ	prep_from||design-2/NN||mice-20/NNS	auxpass||analyzed-22/VBN||were-21/VBD	root||ROOT-0/null||analyzed-22/VBN	det||combination-25/NN||a-24/DT	agent||analyzed-22/VBN||combination-25/NN	nn||cytometry-28/NN||flow-27/NN	prep_of||combination-25/NN||cytometry-28/NN	prep_of||combination-25/NN||immunofluorescence-30/NN	conj_and||cytometry-28/NN||immunofluorescence-30/NN	nn||analysis-34/NN||expression-33/NN	prep_of||combination-25/NN||analysis-34/NN	conj_and||cytometry-28/NN||analysis-34/NN	amod||genes-39/NNS||m2a-36/JJ	conj_and||m2a-36/JJ||m1-38/JJ	amod||genes-39/NNS||m1-38/JJ	prep_for||analysis-34/NN||genes-39/NNS	fat--1||obese-11||no_rel||research design and methodsâ atms from lean and obese (high-fat dietâfed) c57bl/6 mice were analyzed by a combination of flow cytometry, immunofluorescence, and expression analysis for m2a and m1 genes.
mark||enhance-4/VB||whether-1/IN	nsubj||enhance-4/VB||glutamine-2/NN	aux||enhance-4/VB||may-3/MD	csubj||requires-8/VBZ||enhance-4/VB	nn||postexercise-7/NN||insulin-5/NN	nn||postexercise-7/NN||sensitivity-6/NN	dobj||enhance-4/VB||postexercise-7/NN	root||ROOT-0/null||requires-8/VBZ	amod||study-10/NN||further-9/JJ	dobj||requires-8/VBZ||study-10/NN	prep_in||study-10/NN||type1diabetes-12/CD	type1diabetes-12||insulin-5||yes||whether glutamine may enhance insulin sensitivity postexercise requires further study in type1diabetes.
nsubj||inhibited-3/VBD||gla-1/NN	nsubj||reversed-9/VBD||gla-1/NN	advmod||inhibited-3/VBD||significantly-2/RB	root||ROOT-0/null||inhibited-3/VBD	amod||production-5/NN||lps-induced-4/JJ	dobj||inhibited-3/VBD||production-5/NN	prep_of||production-5/NN||nitricoxide-7/NN	conj_and||inhibited-3/VBD||reversed-9/VBD	det||changes-12/NNS||the-10/DT	amod||changes-12/NNS||morphological-11/JJ	dobj||reversed-9/VBD||changes-12/NNS	amod||microglia-15/NN||primary-14/JJ	prep_in||reversed-9/VBD||microglia-15/NN	nitricoxide-7||gla-1||no_rel||gla significantly inhibited lps-induced production of nitricoxide and reversed the morphological changes in primary microglia.
nn||control-2/NN||vector-1/NN	nsubj||relies-3/VBZ||control-2/NN	nsubj||reduce-12/VB||control-2/NN	root||ROOT-0/null||relies-3/VBZ	det||use-6/NN||the-5/DT	prep_on||relies-3/VBZ||use-6/NN	amod||chemicals-9/NNS||insecticide-8/JJ	prep_of||use-6/NN||chemicals-9/NNS	aux||reduce-12/VB||to-10/TO	advmod||reduce-12/VB||significantly-11/RB	xcomp||relies-3/VBZ||reduce-12/VB	det||number-14/NN||the-13/DT	dobj||reduce-12/VB||number-14/NN	nn||vectors-17/NNS||malaria-16/NN	prep_of||number-14/NN||vectors-17/NNS	prepc_by||reduce-12/VB||targeting-19/VBG	det||portion-21/NN||that-20/DT	dobj||targeting-19/VBG||portion-21/NN	det||population-25/NN||the-23/DT	amod||population-25/NN||female-24/JJ	prep_of||portion-21/NN||population-25/NN	nsubj||takes-27/VBZ||population-25/NN	nsubj||rests-32/VBZ||population-25/NN	rcmod||population-25/NN||takes-27/VBZ	nn||meals-29/NNS||blood-28/NN	dobj||takes-27/VBZ||meals-29/NNS	advmod||rests-32/VBZ||subsequently-31/RB	rcmod||population-25/NN||rests-32/VBZ	conj_and||takes-27/VBZ||rests-32/VBZ	advmod||rests-32/VBZ||indoors-33/RB	insecticide-8||malaria-16||no_rel||vector control relies on the use of insecticide chemicals to significantly reduce the number of malaria vectors by targeting that portion of the female population that takes blood meals and subsequently rests indoors.
det||study-2/NN||this-1/DT	nsubjpass||undertaken-4/VBN||study-2/NN	nsubj||investigate-6/VB||study-2/NN	auxpass||undertaken-4/VBN||was-3/VBD	root||ROOT-0/null||undertaken-4/VBN	aux||investigate-6/VB||to-5/TO	xcomp||undertaken-4/VBN||investigate-6/VB	det||characteristics-11/NNS||the-7/DT	amod||characteristics-11/NNS||biochemical-8/JJ	conj_and||biochemical-8/JJ||physiological-10/JJ	amod||characteristics-11/NNS||physiological-10/JJ	dobj||investigate-6/VB||characteristics-11/NNS	prep_of||characteristics-11/NNS||obg-13/NN	prep_in||investigate-6/VB||mycobacteriumtuberculosis-15/NNS	nsubj||causes-18/VBZ||mycobacteriumtuberculosis-15/NNS	rcmod||mycobacteriumtuberculosis-15/NNS||causes-18/VBZ	dobj||causes-18/VBZ||tuberculosis-19/NNP	prep_in||tuberculosis-19/NNP||humans-21/NNS	tuberculosis-19||mycobacteriumtuberculosis-15||no||this study was undertaken to investigate the biochemical and physiological characteristics of obg in mycobacteriumtuberculosis , which causes tuberculosis in humans.
nsubj||drug-6/NN||atovaquone-proguanil-1/NN	cop||drug-6/NN||is-2/VBZ	num||drug-6/NN||one-3/CD	amod||drug-6/NN||such-4/JJ	nn||drug-6/NN||combination-5/NN	root||ROOT-0/null||drug-6/NN	vmod||drug-6/NN||used-7/VBN	dep||used-7/VBN||both-8/DT	prep_for||used-7/VBN||prophylaxis-10/NNS	prep_for||used-7/VBN||prophylaxis-10/NNS	conj_and||prophylaxis-10/NNS||prophylaxis-10/NNS	prep_in||prophylaxis-10/NNS||travellers-12/NNS	prep_for||prophylaxis-10/NNS||treatment-16/NN	amod||cases-20/NNS||acute-18/JJ	nn||cases-20/NNS||malaria-19/NN	prep_of||treatment-16/NN||cases-20/NNS	nn||hospitals-23/NNS||european-22/NN	prep_in||used-7/VBN||hospitals-23/NNS	prep_in||used-7/VBN||clinics-25/NNS	conj_and||hospitals-23/NNS||clinics-25/NNS	malaria-19||proguanil--1||yes||atovaquone-proguanil is one such combination drug used both for prophylaxis in travellers, and for treatment of acute malaria cases in european hospitals and clinics.
nn||±-2/NNP||pparî-1/NNP	nsubj||serves-3/VBZ||±-2/NNP	nsubj||regulate-11/VB||±-2/NNP	root||ROOT-0/null||serves-3/VBZ	det||sensor-9/NN||a-5/DT	nn||sensor-9/NN||xenobiotic-6/NN	conj_and||xenobiotic-6/NN||lipid-8/NN	nn||sensor-9/NN||lipid-8/NN	prep_as||serves-3/VBZ||sensor-9/NN	aux||regulate-11/VB||to-10/TO	xcomp||serves-3/VBZ||regulate-11/VB	nn||combustion-13/NN||energy-12/NN	dobj||regulate-11/VB||combustion-13/NN	amod||steatosis-16/NNS||hepatic-15/JJ	dobj||regulate-11/VB||steatosis-16/NNS	conj_and||combustion-13/NN||steatosis-16/NNS	nn||synthesis-19/NN||lipoprotein-18/NN	dobj||regulate-11/VB||synthesis-19/NN	conj_and||combustion-13/NN||synthesis-19/NN	dobj||regulate-11/VB||inflammation-21/NN	conj_and||combustion-13/NN||inflammation-21/NN	nn||cancer-24/NN||liver-23/NN	dobj||regulate-11/VB||cancer-24/NN	conj_and||combustion-13/NN||cancer-24/NN	lipid-8||cancer-24||no_rel||pparî± serves as a xenobiotic and lipid sensor to regulate energy combustion, hepatic steatosis, lipoprotein synthesis, inflammation and liver cancer.
nn||design-2/NN||research-1/NN	nsubj||â-5/VBP||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||â-5/VBP||methods-4/NNS	root||ROOT-0/null||â-5/VBP	dobj||â-5/VBP||$-6/$	nsubj||sample-12/NN||this-8/DT	cop||sample-12/NN||was-9/VBD	det||sample-12/NN||a-10/DT	amod||sample-12/NN||cross-sectional-11/JJ	rcmod||$-6/$||sample-12/NN	amod||individuals-15/NNS||281-14/JJ	prep_of||sample-12/NN||individuals-15/NNS	amod||metabolism-19/NN||normal-17/JJ	nn||metabolism-19/NN||glucose-18/NN	prep_with||individuals-15/NNS||metabolism-19/NN	discourse||metabolism-19/NN||ngm-21/UH	num||individuals-25/NNS||181-24/CD	dobj||â-5/VBP||individuals-25/NNS	conj_and||$-6/$||individuals-25/NNS	amod||metabolism-29/NN||impaired-27/VBN	nn||metabolism-29/NN||glucose-28/NN	prep_with||individuals-25/NNS||metabolism-29/NN	discourse||metabolism-29/NN||igm-31/UH	num||subjects-36/NNS||107-35/CD	dobj||â-5/VBP||subjects-36/NNS	conj_and||$-6/$||subjects-36/NNS	prep_with||subjects-36/NNS||type2diabetes-38/CD	cross--1||glucose-28||no_rel||research design and methods âthis was a cross-sectional sample of 281 individuals with normal glucose metabolism (ngm), 181 individuals with impaired glucose metabolism (igm), and 107 subjects with type2diabetes.
advmod||outline-3/VBZ||here-1/RB	nsubj||outline-3/VBZ||we-2/PRP	nsubj||discuss-47/VB||we-2/PRP	root||ROOT-0/null||outline-3/VBZ	det||ecology-6/NN||the-4/DT	amod||ecology-6/NN||known-5/JJ	dobj||outline-3/VBZ||ecology-6/NN	det||viruses-12/NNS||the-8/DT	amod||viruses-12/NNS||mosquito-borne-9/JJ	amod||viruses-12/NNS||equine-10/JJ	nn||viruses-12/NNS||encephalitis-11/NN	prep_of||ecology-6/NN||viruses-12/NNS	dep||viruses-12/NNS||weev-14/NNP	dep||viruses-12/NNS||eeev-16/NNP	conj_and||weev-14/NNP||eeev-16/NNP	dep||viruses-12/NNS||veev-19/NNP	conj_and||weev-14/NNP||veev-19/NNP	dobj||outline-3/VBZ||wnv-22/NN	conj_and||ecology-6/NN||wnv-22/NN	conj_and||ecology-6/NN||usuv-24/NNP	conj_and||wnv-22/NN||usuv-24/NNP	conj_and||ecology-6/NN||rvfv-26/NNP	conj_and||wnv-22/NN||rvfv-26/NNP	amod||virus-30/NN||japaneseencephalitis-29/JJ	conj_and||ecology-6/NN||virus-30/NN	conj_and||wnv-22/NN||virus-30/NN	amod||virus-36/NN||tick-borneencephalitis-35/JJ	dobj||outline-3/VBZ||virus-36/NN	conj_and||ecology-6/NN||virus-36/NN	poss||virus-43/NN||its-38/PRP$	nn||virus-43/NN||north-39/NN	num||virus-43/NN||american-40/CD	nn||virus-43/NN||counterpart-41/NN	nn||virus-43/NN||powassan-42/NN	conj_and||ecology-6/NN||virus-43/NN	conj_and||virus-36/NN||virus-43/NN	aux||discuss-47/VB||will-46/MD	conj_and||outline-3/VBZ||discuss-47/VB	det||mode-51/NN||the-48/DT	advmod||likely-50/JJ||most-49/RBS	amod||mode-51/NN||likely-50/JJ	dobj||discuss-47/VB||mode-51/NN	mark||expand-56/VB||that-52/IN	det||viruses-54/NNS||these-53/DT	nsubj||expand-56/VB||viruses-54/NNS	aux||expand-56/VB||could-55/MD	ccomp||discuss-47/VB||expand-56/VB	poss||range-60/NN||their-57/PRP$	amod||range-60/NN||respective-58/JJ	amod||range-60/NN||geographical-59/JJ	dobj||expand-56/VB||range-60/NN	virus-43||viruses-54||no||here we outline the known ecology of the mosquito-borne equine encephalitis viruses (weev, eeev, and veev), wnv, usuv, rvfv, and japaneseencephalitis virus, as well as tick-borneencephalitis virus and its north american counterpart powassan virus, and will discuss the most likely mode that these viruses could expand their respective geographical range.
det||antimalarialdrugs-4/NNS||the-2/DT	amod||antimalarialdrugs-4/NNS||various-3/JJ	prep_among||proven-24/VBN||antimalarialdrugs-4/NNS	amod||antimalarialdrugs-4/NNS||available-5/JJ	det||combination-9/NN||the-7/DT	amod||combination-9/NN||synergistic-8/JJ	nsubj||proven-24/VBN||combination-9/NN	prep_of||combination-9/NN||atovaquone-11/NN	prep_of||combination-9/NN||proguanil-13/NN	conj_and||atovaquone-11/NN||proguanil-13/NN	appos||atovaquone-11/NN||a/p-15/NN	nn||®-19/NNP||malaroneâ-18/NNP	dep||atovaquone-11/NN||®-19/NNP	dep||®-19/NNP||glaxo-smithkline-21/NN	aux||proven-24/VBN||has-23/VBZ	root||ROOT-0/null||proven-24/VBN	det||option-27/NN||a-25/DT	amod||option-27/NN||valuable-26/JJ	dobj||proven-24/VBN||option-27/NN	prep_in||proven-24/VBN||terms-29/NNS	amod||protection-32/NN||effective-31/JJ	prep_of||terms-29/NNS||protection-32/NN	prep_against||proven-24/VBN||chloroquine-34/NN	prep_against||proven-24/VBN||multi-drug-36/NN	conj_and||chloroquine-34/NN||multi-drug-36/NN	xcomp||proven-24/VBN||resistant-37/VBG	dobj||resistant-37/VBG||falciparummalaria-38/NN	dobj||resistant-37/VBG||safety-40/NN	conj_and||falciparummalaria-38/NN||safety-40/NN	dobj||resistant-37/VBG||tolerability-42/NN	conj_and||falciparummalaria-38/NN||tolerability-42/NN	dobj||resistant-37/VBG||ease-45/NN	conj_and||falciparummalaria-38/NN||ease-45/NN	prep_of||falciparummalaria-38/NN||use-47/NN	advmod||favoring-50/VBG||thus-49/RB	xcomp||proven-24/VBN||favoring-50/VBG	dobj||favoring-50/VBG||compliance-51/NN	falciparummalaria-38||proguanil-13||yes||among the various antimalarialdrugs available, the synergistic combination of atovaquone and proguanil (a/p) (malaroneâ®; glaxo-smithkline) has proven a valuable option in terms of effective protection against chloroquine and multi-drug resistant falciparummalaria, safety, tolerability, and ease of use, thus favoring compliance.
nsubj||examined-2/VBD||we-1/PRP	nsubj||compared-27/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	det||abundance-4/NN||the-3/DT	dobj||examined-2/VBD||abundance-4/NN	dobj||examined-2/VBD||diversity-6/NN	conj_and||abundance-4/NN||diversity-6/NN	nn||group-10/NN||clostridium-8/NN	nn||group-10/NN||leptum-9/NN	prep_of||abundance-4/NN||group-10/NN	det||group-14/NN||an-12/DT	amod||group-14/NN||important-13/JJ	appos||group-10/NN||group-14/NN	amod||bacteria-17/NNS||carbohydrate-fermenting-16/JJ	prep_of||group-14/NN||bacteria-17/NNS	det||feces-21/NNS||the-20/DT	prep_in||examined-2/VBD||feces-21/NNS	prep_of||feces-21/NNS||patients-23/NNS	prep_with||patients-23/NNS||ibd-25/NN	conj_and||examined-2/VBD||compared-27/VBD	dobj||compared-27/VBD||them-28/PRP	amod||controls-31/NNS||healthy-30/JJ	prep_with||compared-27/VBD||controls-31/NNS	carbohydrate--1||ibd-25||no_rel||we examined the abundance and diversity of clostridium leptum group, an important group of carbohydrate-fermenting bacteria, in the feces of patients with ibd and compared them with healthy controls.
mark||knew-4/VBD||although-1/IN	num||%-3/NN||91.4-2/CD	nsubj||knew-4/VBD||%-3/NN	advcl||know-15/VB||knew-4/VBD	nsubjpass||transmitted-7/VBN||tb-5/NN	auxpass||transmitted-7/VBN||was-6/VBD	ccomp||knew-4/VBD||transmitted-7/VBN	prep_via||transmitted-7/VBN||aerosols-9/NNS	quantmod||one-third-12/NN||about-11/RB	nsubj||know-15/VB||one-third-12/NN	aux||know-15/VB||did-13/VBD	neg||know-15/VB||not-14/RB	root||ROOT-0/null||know-15/VB	det||method-17/NN||the-16/DT	dobj||know-15/VB||method-17/NN	prepc_for||know-15/VB||administering-19/VBG	dobj||administering-19/VBG||tuberculin-20/NN	det||vaccine-28/NN||that-23/DT	amod||vaccine-28/NN||bacilluscalmette-guerin-24/JJ	nn||vaccine-28/NN||bcg-26/NN	nsubj||contraindication-32/NN||vaccine-28/NN	cop||contraindication-32/NN||was-29/VBD	neg||contraindication-32/NN||not-30/RB	det||contraindication-32/NN||a-31/DT	conj_or||know-15/VB||contraindication-32/NN	aux||tb-34/VB||to-33/TO	vmod||contraindication-32/NN||tb-34/VB	nn||testing-36/NN||skin-35/NN	dobj||tb-34/VB||testing-36/NN	tb-34||bcg-26||no||although 91.4% knew tb was transmitted via aerosols, about one-third did not know the method for administering tuberculin, or that bacilluscalmette-guerin (bcg) vaccine was not a contraindication to tb skin testing.
det||paper-2/NN||this-1/DT	nsubj||explores-3/VBZ||paper-2/NN	root||ROOT-0/null||explores-3/VBZ	det||association-6/NN||the-4/DT	amod||association-6/NN||possible-5/JJ	dobj||explores-3/VBZ||association-6/NN	prep_between||association-6/NN||antibiotics-8/NNS	vmod||antibiotics-8/NNS||prescribed-9/VBN	prep_in||prescribed-9/VBN||infancy-11/NN	prep_in||prescribed-9/VBN||allergicdisorders-13/NNS	conj_and||infancy-11/NN||allergicdisorders-13/NNS	advmod||eczema-16/NN||mainly-15/RB	appos||infancy-11/NN||eczema-16/NN	appos||infancy-11/NN||asthma-18/NN	conj_and||eczema-16/NN||asthma-18/NN	prep_in||prescribed-9/VBN||childhood-21/NN	eczema-16||antibiotics-8||no_rel||this paper explores the possible association between antibiotics prescribed in infancy and allergicdisorders, mainly eczema and asthma, in childhood.
det||routinely-2/NN||the-1/DT	nsubj||accepted-3/VBD||routinely-2/NN	root||ROOT-0/null||accepted-3/VBD	dobj||accepted-3/VBD||practice-4/NN	aux||start-6/VB||to-5/TO	vmod||accepted-3/VBD||start-6/VB	prep_with||start-6/VB||sulphasalazine-8/NN	appos||sulphasalazine-8/NN||ss-10/NN	mark||proves-24/VBZ||as-12/IN	det||treatment-16/NN||the-13/DT	amod||treatment-16/NN||first-14/JJ	nn||treatment-16/NN||line-15/NN	nsubj||proves-24/VBZ||treatment-16/NN	nsubj||ineffective-27/JJ||treatment-16/NN	prep_in||treatment-16/NN||patients-18/NNS	nn||jia-23/NN||hla-20/NN	amod||jia-23/NN||b27-21/JJ	amod||jia-23/NN||positive-22/JJ	prep_with||patients-18/NNS||jia-23/NN	advcl||start-6/VB||proves-24/VBZ	aux||ineffective-27/JJ||to-25/TO	cop||ineffective-27/JJ||be-26/VB	xcomp||proves-24/VBZ||ineffective-27/JJ	det||proportion-31/NN||a-29/DT	amod||proportion-31/NN||large-30/JJ	prep_in||ineffective-27/JJ||proportion-31/NN	prep_of||proportion-31/NN||children-33/NNS	sulphasalazine-8||jia-23||no_rel||the routinely accepted practice to start with sulphasalazine (ss) as the first line treatment in patients with hla b27 positive jia proves to be ineffective in a large proportion of children.
amod||therapy-3/NN||mefloquine-artesunate-1/JJ	nn||therapy-3/NN||combination-2/NN	nsubj||one-8/CD||therapy-3/NN	amod||falciparummalaria-6/NN||uncomplicated-5/JJ	prep_for||therapy-3/NN||falciparummalaria-6/NN	cop||one-8/CD||is-7/VBZ	root||ROOT-0/null||one-8/CD	det||treatments-11/NNS||the-10/DT	prep_of||one-8/CD||treatments-11/NNS	vmod||treatments-11/NNS||used-12/VBN	nn||children-15/NNS||african-14/NN	prep_in||used-12/VBN||children-15/NNS	falciparummalaria-6||mefloquine--1||yes||mefloquine-artesunate combination therapy for uncomplicated falciparummalaria is one of the treatments used in african children.
nsubj||drug-4/NN||disulfiram-1/NN	cop||drug-4/NN||is-2/VBZ	det||drug-4/NN||the-3/DT	root||ROOT-0/null||drug-4/NN	nsubjpass||prescribed-8/VBN||drug-4/NN	auxpass||prescribed-8/VBN||is-6/VBZ	advmod||prescribed-8/VBN||commonly-7/RB	rcmod||drug-4/NN||prescribed-8/VBN	det||treatment-11/NN||the-10/DT	prep_for||prescribed-8/VBN||treatment-11/NN	prep_of||treatment-11/NN||alcoholdependencesyndrome-13/NN	amod||psychosis-18/NNS||transient-16/JJ	nn||psychosis-18/NNS||functional-17/NN	nsubjpass||reported-21/VBN||psychosis-18/NNS	aux||reported-21/VBN||has-19/VBZ	auxpass||reported-21/VBN||been-20/VBN	conj_and||drug-4/NN||reported-21/VBN	nsubjpass||prescribed-8/VBN||reported-21/VBN	prep_as||reported-21/VBN||one-23/CD	poss||side-effects-26/NNS||its-25/PRP$	prep_of||one-23/CD||side-effects-26/NNS	alcoholdependencesyndrome-13||disulfiram-1||yes||disulfiram is the drug that is commonly prescribed for the treatment of alcoholdependencesyndrome, and transient functional psychosis has been reported as one of its side-effects.
det||concentrations-2/NNS||the-1/DT	nsubj||compounds-5/VBZ||concentrations-2/NNS	prep_of||concentrations-2/NNS||antioxidant-4/NN	root||ROOT-0/null||compounds-5/VBZ	advmod||phenolics-7/NNS||namely-6/RB	dobj||compounds-5/VBZ||phenolics-7/NNS	nsubjpass||correlated-31/VBN||phenolics-7/NNS	dobj||compounds-5/VBZ||carotenoids-9/NNS	conj_and||phenolics-7/NNS||carotenoids-9/NNS	nsubjpass||correlated-31/VBN||carotenoids-9/NNS	dobj||compounds-5/VBZ||flavonoids-11/NNS	conj_and||phenolics-7/NNS||flavonoids-11/NNS	nsubjpass||correlated-31/VBN||flavonoids-11/NNS	dobj||compounds-5/VBZ||tocopherols-13/NNS	conj_and||phenolics-7/NNS||tocopherols-13/NNS	nsubjpass||correlated-31/VBN||tocopherols-13/NNS	vmod||phenolics-7/NNS||estimated-14/VBN	det||oil-18/NN||the-16/DT	nn||oil-18/NN||seed-17/NN	prep_in||estimated-14/VBN||oil-18/NN	vmod||oil-18/NN||increased-19/VBN	acomp||increased-19/VBN||due-20/JJ	amod||proline-23/NN||foliar-applied-22/JJ	prep_to||due-20/JJ||proline-23/NN	nn||conditions-27/NNS||water-25/NN	nn||conditions-27/NNS||deficit-26/NN	prep_under||increased-19/VBN||conditions-27/NNS	auxpass||correlated-31/VBN||was-29/VBD	advmod||correlated-31/VBN||positively-30/RB	rcmod||phenolics-7/NNS||correlated-31/VBN	det||dpph-36/NN||the-33/DT	amod||dpph-36/NN||enhanced-34/JJ	nn||dpph-36/NN||oil-35/NN	nn||activity-40/NN||dpph-36/NN	amod||radical-38/JJ||free-37/JJ	amod||activity-40/NN||radical-38/JJ	nn||activity-40/NN||scavenging-39/NN	prep_with||correlated-31/VBN||activity-40/NN	deficit-26||tocopherols-13||no_rel||the concentrations of antioxidant compounds namely phenolics, carotenoids, flavonoids and tocopherols estimated in the seed oil increased due to foliar-applied proline under water deficit conditions that was positively correlated with the enhanced oil dpph free radical scavenging activity.
det||review-3/NN||this-2/DT	prep_in||focus-6/VBP||review-3/NN	nsubj||focus-6/VBP||we-5/PRP	root||ROOT-0/null||focus-6/VBP	prep_on||focus-6/VBP||processes-8/NNS	prep_on||focus-6/VBP||organs-10/NNS	conj_and||processes-8/NNS||organs-10/NNS	prep_on||focus-6/VBP||systems-12/NNS	conj_and||processes-8/NNS||systems-12/NNS	vmod||processes-8/NNS||targeted-13/VBN	det||yessotoxin-17/NN||the-15/DT	amod||yessotoxin-17/NN||marinetoxins-16/JJ	agent||targeted-13/VBN||yessotoxin-17/NN	appos||yessotoxin-17/NN||ytx-19/NN	agent||targeted-13/VBN||okadaicacid-22/NN	conj_and||yessotoxin-17/NN||okadaicacid-22/NN	appos||okadaicacid-22/NN||oa-24/NN	agent||targeted-13/VBN||palytoxin-27/NN	conj_and||yessotoxin-17/NN||palytoxin-27/NN	appos||palytoxin-27/NN||ptx-29/NN	oa-24||marinetoxins-16||no_rel||in this review, we focus on processes, organs and systems targeted by the marinetoxins yessotoxin (ytx), okadaicacid (oa) and palytoxin (ptx).
amod||predisposition-2/NN||genetic-1/JJ	nsubjpass||associated-12/VBN||predisposition-2/NN	prep_for||predisposition-2/NN||type2diabetes-4/CD	neg||predisposition-2/NN||not-7/RB	prep_for||predisposition-2/NN||overweight/obesity-9/NN	conj_but||type2diabetes-4/CD||overweight/obesity-9/NN	auxpass||associated-12/VBN||was-11/VBD	root||ROOT-0/null||associated-12/VBN	amod||expansion-15/NN||inappropriate-14/JJ	prep_with||associated-12/VBN||expansion-15/NN	det||cells-19/NNS||the-17/DT	amod||cells-19/NNS||adipose-18/JJ	prep_of||expansion-15/NN||cells-19/NNS	amod||sensitivity-23/NN||reduced-21/VBN	nn||sensitivity-23/NN||insulin-22/NN	prep_of||expansion-15/NN||sensitivity-23/NN	conj_and||cells-19/NNS||sensitivity-23/NN	det||profile-29/NN||a-25/DT	advmod||proatherogenic-27/JJ||more-26/RBR	amod||profile-29/NN||proatherogenic-27/JJ	nn||profile-29/NN||lipid-28/NN	prep_of||expansion-15/NN||profile-29/NN	conj_and||cells-19/NNS||profile-29/NN	amod||individuals-32/NNS||non-obese-31/JJ	prep_in||profile-29/NN||individuals-32/NNS	type2diabetes-4||insulin-22||yes||genetic predisposition for type2diabetes, but not for overweight/obesity, was associated with inappropriate expansion of the adipose cells, reduced insulin sensitivity and a more proatherogenic lipid profile in non-obese individuals.
nn||design-2/NN||research-1/NN	nsubj||â-5/VBP||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||â-5/VBP||methods-4/NNS	ccomp||compared-36/VBN||â-5/VBP	dobj||â-5/VBP||$-6/$	amod||hospital-10/NN||saint-louis-9/JJ	prep_at||$-6/$||hospital-10/NN	nsubjpass||compared-36/VBN||paris-12/NNS	dep||compared-36/VBN||france-14/JJ	num||patients-18/NNS||15-16/CD	nn||patients-18/NNS||african-17/NN	nsubjpass||compared-36/VBN||patients-18/NNS	prep_with||patients-18/NNS||kpd-20/NN	det||period-28/NN||an-22/DT	amod||period-28/NN||average-23/JJ	amod||period-28/NN||10.5-month-24/JJ	amod||period-28/NN||insulin-free-25/JJ	amod||period-28/NN||near-normoglycemic-26/JJ	nn||period-28/NN||remission-27/NN	prep_with||kpd-20/NN||period-28/NN	dep||period-28/NN||mean-30/VB	dobj||mean-30/VB||a1c-31/NNS	number||%-33/NN||6.2-32/CD	amod||a1c-31/NNS||%-33/NN	auxpass||compared-36/VBN||were-35/VBD	root||ROOT-0/null||compared-36/VBN	num||subjects-40/NNS||17-38/CD	nn||subjects-40/NNS||control-39/NN	prep_with||compared-36/VBN||subjects-40/NNS	vmod||subjects-40/NNS||matched-41/VBN	nn||bmi-47/NN||age-43/NN	dep||bmi-47/NN||sex-45/NN	prep_for||matched-41/VBN||bmi-47/NN	nn||origin-51/NN||geographical-50/NN	prep_for||matched-41/VBN||origin-51/NN	conj_and||bmi-47/NN||origin-51/NN	insulin--1||kpd-20||no_rel||research design and methods âat saint-louis hospital, paris, france, 15 african patients with kpd with an average 10.5-month insulin-free near-normoglycemic remission period (mean a1c 6.2%) were compared with 17 control subjects matched for age, sex, bmi, and geographical origin.
nsubj||allopurinol-10/NN||options-1/NNS	prep_for||options-1/NNS||treatment-3/NN	amod||gout-6/NN||chronic-5/JJ	prep_of||treatment-3/NN||gout-6/NN	prep_until||gout-6/NN||2008-8/CD	cop||allopurinol-10/NN||were-9/VBD	root||ROOT-0/null||allopurinol-10/NN	det||inhibitor-15/NN||a-12/DT	amod||inhibitor-15/NN||xanthine-13/JJ	nn||inhibitor-15/NN||oxidase-14/NN	conj_and||allopurinol-10/NN||inhibitor-15/NN	det||group-19/NN||the-18/DT	conj_and||allopurinol-10/NN||group-19/NN	prep_of||group-19/NN||drugs-21/NNS	vmod||drugs-21/NNS||known-22/VBN	prep_as||known-22/VBN||uricosurics-24/NNS	nsubj||stimulate-26/VB||uricosurics-24/NNS	rcmod||uricosurics-24/NNS||stimulate-26/VB	det||excretion-29/NN||the-27/DT	amod||excretion-29/NN||renal-28/JJ	dobj||stimulate-26/VB||excretion-29/NN	amod||acid-32/NN||uric-31/JJ	prep_of||excretion-29/NN||acid-32/NN	gout-6||allopurinol-10||yes||options for treatment of chronic gout until 2008 were allopurinol, a xanthine oxidase inhibitor, and the group of drugs known as uricosurics that stimulate the renal excretion of uric acid.
prep_at||produced-7/VBD||week-2/NN	num||week-2/NN||48-3/CD	amod||therapy-6/NN||clevudine-5/JJ	nsubj||produced-7/VBD||therapy-6/NN	root||ROOT-0/null||produced-7/VBD	det||reductions-12/NNS||a-8/DT	advmod||greater-10/JJR||significantly-9/RB	amod||reductions-12/NNS||greater-10/JJR	amod||reductions-12/NNS||mean-11/JJ	dobj||produced-7/VBD||reductions-12/NNS	nn||levels-17/NNS||serum-14/NN	nn||levels-17/NNS||hbv-15/NN	nn||levels-17/NNS||dna-16/NN	prep_in||reductions-12/NNS||levels-17/NNS	prep_from||produced-7/VBD||baseline-19/NN	amod||log10iu/ml-27/NNS||lamivudine-21/JJ	nn||log10iu/ml-27/NNS||therapy-22/NN	nn||log10iu/ml-27/NNS||-lrb--23/NNP	num||log10iu/ml-27/NNS||-5.2-24/CD	amod||log10iu/ml-27/NNS||vs.-25/IN	num||log10iu/ml-27/NNS||-4.2-26/CD	prep_than||baseline-19/NN||log10iu/ml-27/NNS	dep||baseline-19/NN||p-29/NN	dep||-rrb--32/NNS||=-30/SYM	num||-rrb--32/NNS||0.005-31/CD	rcmod||p-29/NN||-rrb--32/NNS	hbv-15||lamivudine-21||yes||at week 48 , clevudine therapy produced a significantly greater mean reductions in serum hbv dna levels from baseline than lamivudine therapy -lrb- -5.2 vs. -4.2 log10iu/ml ; p = 0.005 -rrb- .
nsubj||cause-14/NN||melioidosis-1/NNS	det||infection-4/NN||an-3/DT	appos||melioidosis-1/NNS||infection-4/NN	prep_due_to||burkholderiapseudomallei-9/NNS||gram-7/NN	amod||burkholderiapseudomallei-9/NNS||negative-8/JJ	dep||infection-4/NN||burkholderiapseudomallei-9/NNS	cop||cause-14/NN||is-11/VBZ	det||cause-14/NN||an-12/DT	amod||cause-14/NN||important-13/JJ	root||ROOT-0/null||cause-14/NN	prep_of||cause-14/NN||sepsis-16/NN	amod||asia-19/NN||east-18/JJ	prep_in||sepsis-16/NN||asia-19/NN	advmod||thailand-21/JJ||especially-20/RB	amod||sepsis-16/NN||thailand-21/JJ	amod||australia-24/NN||northern-23/JJ	amod||sepsis-16/NN||australia-24/NN	conj_and||thailand-21/JJ||australia-24/NN	melioidosis-1||burkholderiapseudomallei-9||no||melioidosis, an infection due to gram negative burkholderiapseudomallei , is an important cause of sepsis in east asia especially thailand and northern australia.
det||pandemic-4/NN||the-1/DT	num||pandemic-4/NN||2009-2/CD	nn||pandemic-4/NN||flu-3/NN	nsubj||outbreak-8/NN||pandemic-4/NN	cop||outbreak-8/NN||is-5/VBZ	det||outbreak-8/NN||a-6/DT	amod||outbreak-8/NN||global-7/JJ	root||ROOT-0/null||outbreak-8/NN	det||strain-12/NN||a-10/DT	amod||strain-12/NN||new-11/JJ	prep_of||outbreak-8/NN||strain-12/NN	prep_of||strain-12/NN||h1n1influenzavirus-14/CD	flu-3||influenzavirus--1||no||the 2009 flu pandemic is a global outbreak of a new strain of h1n1influenzavirus.
nsubjpass||demonstrated-3/VBN||it-1/PRP	auxpass||demonstrated-3/VBN||was-2/VBD	ccomp||methicillin-26/VBP||demonstrated-3/VBN	mark||effective-10/JJ||that-4/IN	amod||extract-8/NNS||persian-5/JJ	amod||extract-8/NNS||shallot-6/JJ	amod||extract-8/NNS||hydromethanolic-7/JJ	nsubj||effective-10/JJ||extract-8/NNS	cop||effective-10/JJ||was-9/VBD	ccomp||demonstrated-3/VBN||effective-10/JJ	num||species-14/NNS||10-12/CD	amod||species-14/NNS||different-13/JJ	prep_against||effective-10/JJ||species-14/NNS	amod||bacteria-17/NNS||pathogenic-16/JJ	prep_of||species-14/NNS||bacteria-17/NNS	amod||resistant-20/JJ||methicillin-19/JJ	amod||staphylococcusaureus-21/NNS||resistant-20/JJ	prep_including||bacteria-17/NNS||staphylococcusaureus-21/NNS	appos||staphylococcusaureus-21/NNS||mrsa-23/NNP	root||ROOT-0/null||methicillin-26/VBP	acomp||methicillin-26/VBP||sensitive-27/JJ	nsubj||methicillin-26/VBP||staphylococcusaureus-28/NNS	appos||staphylococcusaureus-28/NNS||mssa-30/NNP	appos||staphylococcusaureus-28/NNS||staphylococcusaureus-33/NNS	nn||epidermidis-36/NNS||staphylococcus-35/NN	appos||staphylococcusaureus-28/NNS||epidermidis-36/NNS	conj_and||staphylococcusaureus-33/NNS||epidermidis-36/NNS	appos||staphylococcusaureus-28/NNS||streptococcuspneumoniae-38/NN	conj_and||staphylococcusaureus-33/NNS||streptococcuspneumoniae-38/NN	appos||staphylococcusaureus-28/NNS||escherichiacoli-40/NNS	conj_and||staphylococcusaureus-33/NNS||escherichiacoli-40/NNS	amod||o157h7-43/NNS||escherichiacoli-42/JJ	appos||staphylococcusaureus-28/NNS||o157h7-43/NNS	conj_and||staphylococcusaureus-33/NNS||o157h7-43/NNS	appos||staphylococcusaureus-28/NNS||salmonellatyphimurium-45/NN	conj_and||staphylococcusaureus-33/NNS||salmonellatyphimurium-45/NN	amod||mirabilis-48/NNS||proteus-47/JJ	appos||staphylococcusaureus-28/NNS||mirabilis-48/NNS	conj_and||staphylococcusaureus-33/NNS||mirabilis-48/NNS	nn||pneumoniae-52/NN||klebsiella-51/NN	appos||staphylococcusaureus-28/NNS||pneumoniae-52/NN	conj_and||staphylococcusaureus-33/NNS||pneumoniae-52/NN	mrsa-23||staphylococcusaureus-33||no||it was demonstrated that persian shallot hydromethanolic extract was effective against 10 different species of pathogenic bacteria including methicillin resistant staphylococcusaureus (mrsa), methicillin sensitive staphylococcusaureus (mssa), staphylococcusaureus , staphylococcus epidermidis , streptococcuspneumoniae , escherichiacoli, escherichiacoli o157h7, salmonellatyphimurium, proteus mirabilis , and klebsiella pneumoniae .
det||results-2/NNS||these-1/DT	nsubj||demonstrate-3/VBP||results-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	mark||provide-17/VB||that-4/IN	nsubj||provide-17/VB||immunization-5/NN	prep_with||immunization-5/NN||ctb-7/NN	prep_by||ctb-7/NN||any-9/DT	amod||routes-12/NNS||several-11/JJ	prep_of||any-9/DT||routes-12/NNS	nn||regimens-15/NNS||dosing-14/NN	prep_of||any-9/DT||regimens-15/NNS	conj_and||routes-12/NNS||regimens-15/NNS	aux||provide-17/VB||can-16/MD	ccomp||demonstrate-3/VBP||provide-17/VB	dobj||provide-17/VB||protection-18/NN	amod||challenge-22/NN||live-20/JJ	nn||challenge-22/NN||v.cholerae-21/NN	prep_against||protection-18/NN||challenge-22/NN	det||model-27/NN||the-24/DT	amod||model-27/NN||suckling-25/VBG	nn||model-27/NN||mouse-26/NN	prep_in||provide-17/VB||model-27/NN	prep_of||model-27/NN||cholera-29/NN	cholera-29||v.cholerae-21||no||these results demonstrate that immunization with ctb by any of several routes and dosing regimens can provide protection against live v.cholerae challenge in the suckling mouse model of cholera .
det||polymorphisms-2/NNS||these-1/DT	nsubj||contribute-5/VB||polymorphisms-2/NNS	aux||contribute-5/VB||might-3/MD	advmod||contribute-5/VB||ultimately-4/RB	root||ROOT-0/null||contribute-5/VB	nn||risk-9/NN||lung-7/NN	nn||risk-9/NN||cancer-8/NN	prep_to||contribute-5/VB||risk-9/NN	poss||effect-12/NN||their-11/PRP$	prep_via||risk-9/NN||effect-12/NN	det||response-18/NN||the-14/DT	amod||response-18/NN||airway-15/JJ	nn||response-18/NN||gene-16/NN	nn||response-18/NN||expression-17/NN	prep_on||effect-12/NN||response-18/NN	amod||exposure-21/NN||tobacco-smoke-20/JJ	prep_to||contribute-5/VB||exposure-21/NN	cancer-8||smoke--1||no_rel||these polymorphisms might ultimately contribute to lung cancer risk via their effect on the airway gene expression response to tobacco-smoke exposure.
ccomp||were-15/VBD||results-1/VBZ	det||end-4/NN||the-3/DT	prep_at||results-1/VBZ||end-4/NN	prep_of||end-4/NN||2003-6/CD	dobj||results-1/VBZ||2005-8/CD	num||2005-8/CD||2007-10/CD	dobj||results-1/VBZ||2009-12/CD	conj_and||2005-8/CD||2009-12/CD	expl||were-15/VBD||there-14/EX	root||ROOT-0/null||were-15/VBD	det||people-26/NNS||an-16/DT	amod||people-26/NNS||estimated-17/JJ	num||0.65-20/NNS||0.84-18/CD	nn||people-26/NNS||0.65-20/NNS	num||0.65-20/NNS||0.70-22/CD	conj_and||0.65-20/NNS||0.74-24/CD	nn||people-26/NNS||0.74-24/CD	num||people-26/NNS||million-25/CD	nsubj||were-15/VBD||people-26/NNS	vmod||people-26/NNS||living-27/VBG	prep_with||living-27/VBG||hiv/aids-29/NNS	prep_in||hiv/aids-29/NNS||china-31/NN	advmod||living-27/VBG||respectively-33/RB	det||prevalence-39/NN||an-36/DT	amod||prevalence-39/NN||overall-37/JJ	nn||prevalence-39/NN||hiv-38/NN	prep_with||living-27/VBG||prevalence-39/NN	num||â-42/NN||0.05-41/CD	prep_of||prevalence-39/NN||â-42/NN	dep||%-46/NN||$-43/$	num||$-43/$||0.06-45/CD	amod||â-42/NN||%-46/NN	aids--1||hiv-38||no||results at the end of 2003, 2005, 2007 and 2009, there were an estimated 0.84, 0.65, 0.70 and 0.74 million people living with hiv/aids in china, respectively, with an overall hiv prevalence of 0.05â0.06%.
amod||patients-3/NNS||antiretroviral-naive-1/JJ	amod||patients-3/NNS||hiv-infected-2/JJ	nsubjpass||recruited-7/VBN||patients-3/NNS	prep_with||patients-3/NNS||tb-5/NN	auxpass||recruited-7/VBN||were-6/VBD	root||ROOT-0/null||recruited-7/VBN	det||trial-10/NN||a-9/DT	prep_to||recruited-7/VBN||trial-10/NN	amod||inhibitor-15/NN||once-daily-12/JJ	amod||inhibitor-15/NN||nonnucleoside-13/JJ	amod||inhibitor-15/NN||reverse-transcriptase-14/JJ	prep_of||trial-10/NN||inhibitor-15/NN	appos||inhibitor-15/NN||nnrti-17/NNP	advmod||based-22/VBN||â-19/RB	pobj||â-19/RB||$-20/$	dep||inhibitor-15/NN||based-22/VBN	dobj||based-22/VBN||art-23/NN	dep||inhibitor-15/NN||treated-25/VBN	conj_and||based-22/VBN||treated-25/VBN	amod||treatment-30/NN||rifampicin-based-27/JJ	amod||treatment-30/NN||thrice-weekly-28/JJ	nn||treatment-30/NN||antituberculosis-29/NNS	prep_with||treated-25/VBN||treatment-30/NN	discourse||treatment-30/NN||att-32/UH	nsubjpass||randomized-37/VBN||participants-35/NNS	nsubj||receive-39/VB||participants-35/NNS	auxpass||randomized-37/VBN||were-36/VBD	parataxis||recruited-7/VBN||randomized-37/VBN	aux||receive-39/VB||to-38/TO	xcomp||randomized-37/VBN||receive-39/VB	dobj||receive-39/VB||didanosine-40/NN	number||mg-43/CD||250/400-42/CD	dep||didanosine-40/NN||mg-43/CD	dobj||receive-39/VB||lamivudine-46/NN	conj_and||didanosine-40/NN||lamivudine-46/NN	number||mg-49/CD||300-48/CD	dep||lamivudine-46/NN||mg-49/CD	det||efavirenz-53/NN||either-52/DT	prep_with||receive-39/VB||efavirenz-53/NN	number||mg-56/CD||600-55/CD	dep||efavirenz-53/NN||mg-56/CD	amod||once-daily-64/NN||nevirapine-59/JJ	number||mg-62/CD||400-61/CD	dep||once-daily-64/NN||mg-62/CD	prep_with||receive-39/VB||once-daily-64/NN	conj_or||efavirenz-53/NN||once-daily-64/NN	det||phase-68/NN||an-66/DT	amod||phase-68/NN||intensive-67/JJ	prep_after||receive-39/VB||phase-68/NN	prep_of||phase-68/NN||att-70/NN	tb-5||antituberculosis-29||yes||antiretroviral-naive hiv-infected patients with tb were recruited to a trial of once-daily nonnucleoside reverse-transcriptase inhibitor (nnrti)âbased art and treated with rifampicin-based thrice-weekly antituberculosis treatment (att); participants were randomized to receive didanosine (250/400 mg) and lamivudine (300 mg) with either efavirenz (600 mg) or nevirapine (400 mg) once-daily after an intensive phase of att.
amod||ã-4/NN||average-2/JJ	num||ã-4/NN||15-3/CD	prep_on||found-11/VBN||ã-4/NN	nsubjpass||found-11/VBN||3-6/CD	nsubj||accommodate-13/VB||3-6/CD	amod||volume-9/NN||cavity-8/JJ	prep_of||3-6/CD||volume-9/NN	auxpass||found-11/VBN||is-10/VBZ	root||ROOT-0/null||found-11/VBN	aux||accommodate-13/VB||to-12/TO	xcomp||found-11/VBN||accommodate-13/VB	amod||water-15/NN||single-14/JJ	dobj||accommodate-13/VB||water-15/NN	det||ã-23/NN||another-18/DT	amod||ã-23/NN||40â-19/JJ	amod||ã-23/NN||$-20/$	num||$-20/$||45-22/CD	prep_with||found-11/VBN||ã-23/NN	dep||ã-23/NN||3-25/CD	vmod||3-25/CD||needed-26/VBN	det||molecule-31/NN||each-28/DT	amod||molecule-31/NN||additional-29/JJ	amod||molecule-31/NN||solvent-30/JJ	prep_for||needed-26/VBN||molecule-31/NN	cavity-8||solvent-30||no_rel||on average 15 ã3 of cavity volume is found to accommodate single water, with another 40â45 ã3 needed for each additional solvent molecule.
det||combination-2/NN||the-1/DT	nsubj||premixed-6/VBD||combination-2/NN	nn||propofol-5/NN||microemulsion-4/NN	prep_of||combination-2/NN||propofol-5/NN	root||ROOT-0/null||premixed-6/VBD	prep_with||premixed-6/VBD||lidocaine-8/NN	mark||effective-16/JJ||after-9/IN	det||pretreatment-11/NN||a-10/DT	nsubj||effective-16/JJ||pretreatment-11/NN	prep_with||pretreatment-11/NN||remifentanil-13/NN	cop||effective-16/JJ||was-14/VBD	advmod||effective-16/JJ||more-15/RBR	advcl||premixed-6/VBD||effective-16/JJ	prepc_in||effective-16/JJ||reducing-18/VBG	det||incidence-20/NN||the-19/DT	dobj||reducing-18/VBG||incidence-20/NN	prep_of||incidence-20/NN||pain-22/NN	det||injection-25/NN||the-24/DT	prep_upon||reducing-18/VBG||injection-25/NN	nn||propofol-28/NN||microemulsion-27/NN	prep_of||injection-25/NN||propofol-28/NN	det||treatment-31/NN||either-30/DT	prep_than||reducing-18/VBG||treatment-31/NN	advmod||effective-16/JJ||alone-32/RB	pain-22||lidocaine-8||yes||the combination of microemulsion propofol premixed with lidocaine after a pretreatment with remifentanil was more effective in reducing the incidence of pain upon the injection of microemulsion propofol than either treatment alone.
amod||rhinitis-2/NNS||allergic-1/JJ	nsubj||prevalent-10/JJ||rhinitis-2/NNS	conj_and||rhinitis-2/NNS||atopic/non-atopicasthma-4/NN	nsubj||prevalent-10/JJ||atopic/non-atopicasthma-4/NN	conj_and||rhinitis-2/NNS||atopicdermatitis-7/NNS	nsubj||prevalent-10/JJ||atopicdermatitis-7/NNS	cop||prevalent-10/JJ||were-8/VBD	advmod||prevalent-10/JJ||equally-9/RB	root||ROOT-0/null||prevalent-10/JJ	det||groups-14/NNS||the-12/DT	nn||groups-14/NNS||study-13/NN	prep_among||prevalent-10/JJ||groups-14/NNS	det||group-19/NN||the-17/DT	nn||group-19/NN||crs/rom-18/NN	prep_except_for||prevalent-10/JJ||group-19/NN	prep_in||prevalent-25/JJ||group-19/NN	nsubj||prevalent-25/JJ||non-atopicasthma-22/NN	cop||prevalent-25/JJ||was-23/VBD	advmod||prevalent-25/JJ||more-24/RBR	rcmod||group-19/NN||prevalent-25/JJ	num||%-28/NN||52.6-27/CD	appos||group-19/NN||%-28/NN	atopicdermatitis-7||atopic--1||no||allergic rhinitis, atopic/non-atopicasthma, and atopicdermatitis were equally prevalent among the study groups except for the crs/rom group in which non-atopicasthma was more prevalent (52.6%).
amod||changes-2/NNS||monthly-1/JJ	nsubjpass||analyzed-12/VBN||changes-2/NNS	det||volume-5/NN||the-4/DT	prep_in||changes-2/NNS||volume-5/NN	amod||services-10/NNS||hiv-7/JJ	conj_and||hiv-7/JJ||non-hiv-9/JJ	amod||services-10/NNS||non-hiv-9/JJ	prep_of||volume-5/NN||services-10/NNS	auxpass||analyzed-12/VBN||were-11/VBD	root||ROOT-0/null||analyzed-12/VBN	agent||analyzed-12/VBN||using-14/VBG	amod||models-16/NNS||multilevel-15/JJ	dobj||using-14/VBG||models-16/NNS	aux||examine-18/VB||to-17/TO	vmod||using-14/VBG||examine-18/VB	det||effect-20/NN||the-19/DT	dobj||examine-18/VB||effect-20/NN	det||program-24/NN||an-22/DT	amod||program-24/NN||hiv/aids-23/JJ	prep_of||effect-20/NN||program-24/NN	nn||delivery-28/NN||health-26/NN	nn||delivery-28/NN||service-27/NN	prep_on||examine-18/VB||delivery-28/NN	aids--1||hiv-7||no||monthly changes in the volume of hiv and non-hiv services were analyzed by using multilevel models to examine the effect of an hiv/aids program on health service delivery.
det||findings-2/NNS||these-1/DT	nsubj||include-5/VB||findings-2/NNS	aux||include-5/VB||do-3/VBP	neg||include-5/VB||not-4/RB	root||ROOT-0/null||include-5/VB	amod||arc-8/NN||aids-relatedcomplex-6/JJ	dobj||include-5/VB||arc-8/NN	amod||manifestations-12/NNS||other-11/JJ	dobj||include-5/VB||manifestations-12/NNS	conj_or||arc-8/NN||manifestations-12/NNS	nn||infection-18/NN||humanimmunodeficiencyvirus-14/NNP	appos||infection-18/NN||hiv-16/NN	prep_of||manifestations-12/NNS||infection-18/NN	aids-relatedcomplex-6||hiv-16||no||these findings do not include aids-relatedcomplex (arc) or other manifestations of humanimmunodeficiencyvirus (hiv) infection.
amod||challenges-2/NNS||new-1/JJ	nsubj||arisen-4/VBN||challenges-2/NNS	aux||arisen-4/VBN||have-3/VBP	root||ROOT-0/null||arisen-4/VBN	det||management-7/NN||the-6/DT	prep_for||arisen-4/VBN||management-7/NN	advmod||ill-10/JJ||critically-9/RB	amod||patients-12/NNS||ill-10/JJ	nn||patients-12/NNS||hiv/aids-11/NN	prep_of||management-7/NN||patients-12/NNS	aids--1||hiv--1||no||new challenges have arisen for the management of critically ill hiv/aids patients.
nsubjpass||shown-4/VBN||clozapine-1/NN	nsubj||superior-7/JJ||clozapine-1/NN	nsubj||chlorpromazine-9/VB||clozapine-1/NN	aux||shown-4/VBN||has-2/VBZ	auxpass||shown-4/VBN||been-3/VBN	root||ROOT-0/null||shown-4/VBN	aux||superior-7/JJ||to-5/TO	cop||superior-7/JJ||be-6/VB	xcomp||shown-4/VBN||superior-7/JJ	aux||chlorpromazine-9/VB||to-8/TO	xcomp||superior-7/JJ||chlorpromazine-9/VB	prepc_in||chlorpromazine-9/VB||improving-11/VBG	det||symptoms-16/NNS||the-12/DT	amod||symptoms-16/NNS||positive-13/JJ	conj_and||positive-13/JJ||negative-15/JJ	amod||symptoms-16/NNS||negative-15/JJ	dobj||improving-11/VBG||symptoms-16/NNS	prep_of||symptoms-16/NNS||schizophrenia-18/NN	schizophrenia-18||chlorpromazine-9||yes||clozapine has been shown to be superior to chlorpromazine in improving the positive and negative symptoms of schizophrenia.
vmod||analyzed-9/VBD||using-1/VBG	det||framework-5/NN||a-2/DT	amod||framework-5/NN||social-3/JJ	nn||framework-5/NN||exclusion-4/NN	dobj||using-1/VBG||framework-5/NN	det||paper-8/NN||this-7/DT	nsubj||analyzed-9/VBD||paper-8/NN	root||ROOT-0/null||analyzed-9/VBD	amod||literature-11/NN||existing-10/JJ	dobj||analyzed-9/VBD||literature-11/NN	prep_on||analyzed-9/VBD||hiv-13/NN	prep_in||hiv-13/NN||bangladesh-15/NN	aux||identify-17/VB||to-16/TO	vmod||analyzed-9/VBD||identify-17/VB	amod||forces-23/NNS||social-18/JJ	conj_and||social-18/JJ||economic-20/JJ	amod||forces-23/NNS||economic-20/JJ	conj_and||social-18/JJ||legal-22/JJ	amod||forces-23/NNS||legal-22/JJ	dobj||identify-17/VB||forces-23/NNS	nsubj||heighten-25/VB||forces-23/NNS	rcmod||forces-23/NNS||heighten-25/VB	det||vulnerability-27/NN||the-26/DT	dobj||heighten-25/VB||vulnerability-27/NN	amod||groups-31/NNS||such-29/JJ	amod||groups-31/NNS||excluded-30/VBN	prep_of||vulnerability-27/NN||groups-31/NNS	prep_to||identify-17/VB||hiv/aids-33/NNS	aids--1||hiv-13||no||using a social exclusion framework, this paper analyzed existing literature on hiv in bangladesh to identify social, economic and legal forces that heighten the vulnerability of such excluded groups to hiv/aids.
det||guideline-3/NN||the-1/DT	amod||guideline-3/NN||national-2/JJ	nsubj||recommends-4/VBZ||guideline-3/NN	root||ROOT-0/null||recommends-4/VBZ	num||diagnosis-7/NN||three-5/CD	amod||diagnosis-7/NN||different-6/JJ	dep||recommends-4/VBZ||diagnosis-7/NN	nn||strategies-10/NNS||treatment-9/NN	dep||recommends-4/VBZ||strategies-10/NNS	conj_and||diagnosis-7/NN||strategies-10/NNS	nn||i-15/NNS||health-12/NN	nn||i-15/NNS||post-13/NN	nn||i-15/NNS||level-14/NN	prep_at||diagnosis-7/NN||i-15/NNS	det||use-18/NN||the-17/DT	dobj||recommends-4/VBZ||use-18/NN	det||p.falciparum-21/NN||a-20/DT	prep_of||use-18/NN||p.falciparum-21/NN	punct||rdt-25/NN||/-22/:	amod||rdt-25/NN||vivax-23/JJ	amod||rdt-25/NN||specific-24/JJ	dep||use-18/NN||rdt-25/NN	nn||tool-28/NN||diagnosis-27/NN	prep_as||rdt-25/NN||tool-28/NN	aux||treat-31/VB||to-30/TO	prep_as||rdt-25/NN||treat-31/VB	conj_and||tool-28/NN||treat-31/VB	vmod||tool-28/NN||treat-31/VB	prep_with||treat-31/VB||artemether-lumefantrine-33/NN	appos||artemether-lumefantrine-33/NN||al-35/NNP	amod||cq-40/NN||chloroquine-38/JJ	prep_with||treat-31/VB||cq-40/NN	conj_or||artemether-lumefantrine-33/NN||cq-40/NN	prep_with||treat-31/VB||referral-43/NN	conj_or||artemether-lumefantrine-33/NN||referral-43/NN	mark||diagnosed-48/VBN||if-44/IN	det||patient-46/NN||the-45/DT	nsubjpass||diagnosed-48/VBN||patient-46/NN	auxpass||diagnosed-48/VBN||was-47/VBD	advcl||treat-31/VB||diagnosed-48/VBN	prep_with||diagnosed-48/VBN||p.falciparum-50/NN	prep_with||diagnosed-48/VBN||p.vivax-52/NN	conj_or||p.falciparum-50/NN||p.vivax-52/NN	neg||malaria-55/NN||no-54/DT	prep_with||diagnosed-48/VBN||malaria-55/NN	conj_or||p.falciparum-50/NN||malaria-55/NN	dep||rdt-25/NN||respectively-57/RB	nn||pan/pf-60/NN||parascreen-59/NN	dep||use-18/NN||pan/pf-60/NN	vmod||pan/pf-60/NN||based-61/VBN	dobj||based-61/VBN||strategy-62/NN	csubj||diagnosed-101/VBD||ii-65/VB	det||use-68/NN||the-67/DT	dobj||ii-65/VB||use-68/NN	det||rdt-73/NN||a-70/DT	amod||rdt-73/NN||p.falciparum-71/JJ	amod||rdt-73/NN||specific-72/JJ	prep_of||ii-65/VB||rdt-73/NN	prep_of||ii-65/VB||al-75/NNP	conj_and||rdt-73/NN||al-75/NNP	nn||cases-78/NNS||p.falciparum-77/NN	prep_for||al-75/NNP||cases-78/NNS	prep_for||al-75/NNP||cq-80/NN	conj_and||cases-78/NNS||cq-80/NN	det||rest-83/NN||the-82/DT	prep_for||cases-78/NNS||rest-83/NN	nn||pf-86/NN||paracheck-85/NN	dep||cases-78/NNS||pf-86/NN	vmod||pf-86/NN||based-87/VBN	dobj||based-87/VBN||strategy-88/NN	conj_and||ii-65/VB||iii-92/VB	csubj||diagnosed-101/VBD||iii-92/VB	det||use-95/NN||the-94/DT	dobj||iii-92/VB||use-95/NN	prep_of||iii-92/VB||al-97/NNP	det||cases-100/NNS||all-99/DT	prep_for||al-97/NNP||cases-100/NNS	parataxis||recommends-4/VBZ||diagnosed-101/VBD	advmod||diagnosed-101/VBD||presumptively-102/RB	prep_as||diagnosed-101/VBD||malaria-104/NN	dep||malaria-104/NN||presumptive-106/NN	vmod||presumptive-106/NN||based-107/VBN	dobj||based-107/VBN||strategy-108/NN	malaria-104||lumefantrine--1||yes||the national guideline recommends three different diagnosis and treatment strategies at health post level i) the use of a p.falciparum / vivax specific rdt as diagnosis tool and to treat with artemether-lumefantrine (al), chloroquine (cq) or referral if the patient was diagnosed with p.falciparum , p.vivax or no malaria, respectively (parascreen pan/pf based strategy); ii) the use of a p.falciparum specific rdt and al for p.falciparum cases and cq for the rest (paracheck pf based strategy); and iii) the use of al for all cases diagnosed presumptively as malaria (presumptive based strategy).
nsubj||influence-12/VBP||genotypes-1/NNS	dep||genotypes-1/NNS||a-3/DT	aux||h-5/VB||to-4/TO	dep||a-3/DT||h-5/VB	prep_of||genotypes-1/NNS||hepatitisbvirus-8/NNS	appos||hepatitisbvirus-8/NNS||hbv-10/NN	root||ROOT-0/null||influence-12/VBP	amod||progression-14/NN||liverdisease-13/JJ	dobj||influence-12/VBP||progression-14/NN	dobj||influence-12/VBP||response-16/NN	conj_and||progression-14/NN||response-16/NN	amod||therapy-19/NN||antiviral-18/JJ	prep_to||influence-12/VBP||therapy-19/NN	amod||patients-22/NNS||hbv-infected-21/JJ	prep_in||therapy-19/NN||patients-22/NNS	hbv-10||hepatitisbvirus-8||no||genotypes (a to h) of hepatitisbvirus (hbv) influence liverdisease progression and response to antiviral therapy in hbv-infected patients.
nn||analysis-2/NN||meta-1/NN	nsubj||showed-3/VBD||analysis-2/NN	root||ROOT-0/null||showed-3/VBD	mark||higher-59/JJR||that-4/IN	det||rate-6/NN||the-5/DT	nsubj||higher-59/JJR||rate-6/NN	amod||dna-11/NN||undetected-8/JJ	nn||dna-11/NN||serum-9/NN	nn||dna-11/NN||hbv-10/NN	prep_of||rate-6/NN||dna-11/NN	amod||risk-14/NN||relative-13/JJ	dep||dna-11/NN||risk-14/NN	amod||risk-14/NN||1.73-16/CD	number||%-19/NN||95-18/CD	amod||interval-21/NN||%-19/NN	nn||interval-21/NN||confidence-20/NN	dep||risk-14/NN||interval-21/NN	num||.17-24/CD||1.38-2-23/CD	dep||risk-14/NN||.17-24/CD	conj_and||interval-21/NN||.17-24/CD	dep||0.00001-28/CD||p-26/RB	number||0.00001-28/CD||<-27/CD	dep||.17-24/CD||0.00001-28/CD	dep||risk-14/NN||that-31/DT	conj_and||interval-21/NN||that-31/DT	nn||normalization-35/NN||serum-33/NN	nn||normalization-35/NN||alt-34/NN	prep_of||that-31/DT||normalization-35/NN	amod||risk-38/NN||relative-37/JJ	dep||normalization-35/NN||risk-38/NN	dep||risk-38/NN||1.25-40/CD	number||%-43/NN||95-42/CD	amod||interval-45/NN||%-43/NN	nn||interval-45/NN||confidence-44/NN	dep||risk-14/NN||interval-45/NN	num||.49-48/CD||1.06-1-47/CD	appos||interval-45/NN||.49-48/CD	dep||risk-14/NN||p-50/NN	dep||0.009-52/CD||=-51/SYM	rcmod||p-50/NN||0.009-52/CD	det||group-57/NN||the-55/DT	nn||group-57/NN||entecavir-56/NN	prep_in||dna-11/NN||group-57/NN	cop||higher-59/JJR||were-58/VBD	ccomp||showed-3/VBD||higher-59/JJR	prep_than||higher-59/JJR||those-61/DT	det||group-65/NN||the-63/DT	nn||group-65/NN||adefovir-64/NN	prep_in||those-61/DT||group-65/NN	hbv-10||entecavir-56||yes||meta analysis showed that the rate of undetected serum hbv dna (relative risk, 1.73; 95% confidence interval, 1.38-2.17; p < 0.00001) and that of serum alt normalization (relative risk, 1.25; 95% confidence interval, 1.06-1.49; p = 0.009) in the entecavir group were higher than those in the adefovir group.
amod||domain-3/NN||bcr-abl-1/JJ	nn||domain-3/NN||kinase-2/NN	root||ROOT-0/null||domain-3/NN	appos||domain-3/NN||kd-5/NN	nsubj||mechanism-11/NN||mutation-7/NN	cop||mechanism-11/NN||is-8/VBZ	det||mechanism-11/NN||the-9/DT	amod||mechanism-11/NN||major-10/JJ	rcmod||domain-3/NN||mechanism-11/NN	vmod||mechanism-11/NN||contributing-12/VBG	aux||suboptimal-14/VB||to-13/TO	xcomp||contributing-12/VBG||suboptimal-14/VB	dobj||suboptimal-14/VB||response-15/NN	aux||tyrosine-17/VB||to-16/TO	vmod||suboptimal-14/VB||tyrosine-17/VB	amod||inhibitors-19/NNS||kinase-18/JJ	dobj||tyrosine-17/VB||inhibitors-19/NNS	appos||inhibitors-19/NNS||tki-21/NN	prep_in||inhibitors-19/NNS||bcr-abl-24/NN	amod||chronicmyeloidleukemia-27/NN||positive-26/JJ	dep||domain-3/NN||chronicmyeloidleukemia-27/NN	appos||chronicmyeloidleukemia-27/NN||cml-29/NN	dep||chronicmyeloidleukemia-27/NN||patients-31/NNS	chronicmyeloidleukemia-27||tyrosine-17||no_rel||bcr-abl kinase domain (kd) mutation is the major mechanism contributing to suboptimal response to tyrosine kinase inhibitors (tki) in bcr-abl -positive chronicmyeloidleukemia (cml) patients.
advmod||greater-2/JJR||significantly-1/RB	amod||reductions-3/NNS||greater-2/JJR	nsubjpass||observed-9/VBN||reductions-3/NNS	nsubjpass||observed-9/VBN||reductions-3/NNS	amod||bp-7/NN||seated-5/JJ	amod||bp-7/NN||diastolic-6/JJ	prep_in||reductions-3/NNS||bp-7/NN	auxpass||observed-9/VBN||were-8/VBD	root||ROOT-0/null||observed-9/VBN	conj_and||observed-9/VBN||observed-9/VBN	prep_between||observed-9/VBN||baseline-11/NN	num||weeks-15/NNS||eight-14/CD	prep_after||observed-9/VBN||weeks-15/NNS	prep_of||weeks-15/NNS||treatment-17/NN	prep_with||observed-9/VBN||olmesartan/amlodipine-19/NN	prepc_compared_with||observed-9/VBN||with-22/IN	nn||doses-24/NNS||equivalent-23/NN	pobj||observed-9/VBN||doses-24/NNS	amod||monotherapy-29/NN||olmesartan-26/JJ	conj_or||olmesartan-26/JJ||amolodipine-28/JJ	amod||monotherapy-29/NN||amolodipine-28/JJ	prep_of||doses-24/NNS||monotherapy-29/NN	appos||monotherapy-29/NN||p-31/NNP	number||0.001-33/CD||<-32/CD	num||p-31/NNP||0.001-33/CD	det||combination-39/NN||the-37/DT	amod||combination-39/NN||factorial-38/JJ	prep_in||observed-9/VBN||combination-39/NN	nn||trial-50/NN||olmesartanmedoxomil-41/NN	conj_and||olmesartanmedoxomil-41/NN||amlodipinebesylate-43/JJ	nn||trial-50/NN||amlodipinebesylate-43/JJ	amod||highbloodpressure-46/NN||controlling-45/VBG	prep_in||amlodipinebesylate-43/JJ||highbloodpressure-46/NN	appos||highbloodpressure-46/NN||coach-48/NN	prep_of||combination-39/NN||trial-50/NN	highbloodpressure-46||olmesartan-26||yes||significantly greater reductions in seated diastolic bp were observed between baseline and after eight weeks of treatment with olmesartan/amlodipine, compared with equivalent doses of olmesartan or amolodipine monotherapy ( p < 0.001), in the factorial combination of olmesartanmedoxomil and amlodipinebesylate in controlling highbloodpressure (coach) trial.
det||treatments-3/NNS||both-2/DT	prep_under||experienced-9/VBD||treatments-3/NNS	quantmod||many-7/JJ||twice-5/RB	quantmod||many-7/JJ||as-6/RB	num||patients-8/NNS||many-7/JJ	nsubj||experienced-9/VBD||patients-8/NNS	root||ROOT-0/null||experienced-9/VBD	neg||pain-11/NN||no-10/DT	dobj||experienced-9/VBD||pain-11/NN	parataxis||experienced-9/VBD||score-13/VBP	dep||0-15/CD||=-14/SYM	ccomp||score-13/VBP||0-15/CD	det||day-21/NN||the-18/DT	amod||day-21/NN||first-19/JJ	nn||day-21/NN||postoperative-20/NN	prep_on||experienced-9/VBD||day-21/NN	prepc_compared_to||day-21/NN||to-23/TO	det||day-25/NN||the-24/DT	pobj||day-21/NN||day-25/NN	prep_of||day-25/NN||surgery-27/NN	num||%-30/NN||35.9-29/CD	dep||day-25/NN||%-30/NN	number||16.4-32/CD||vs-31/CD	num||%-33/NN||16.4-32/CD	nsubj||vs-39/VBP||%-33/NN	prep_for||%-33/NN||tramadol/paracetamol-35/NN	num||%-38/NN||36.7-37/CD	prep_for||%-33/NN||%-38/NN	conj_and||tramadol/paracetamol-35/NN||%-38/NN	rcmod||%-30/NN||vs-39/VBP	num||%-41/NN||18-40/CD	dobj||vs-39/VBP||%-41/NN	amod||treatment-44/NN||tramadol-43/JJ	prep_for||vs-39/VBP||treatment-44/NN	pain-11||tramadol-43||yes||under both treatments, twice as many patients experienced no pain (score = 0) on the first postoperative day compared to the day of surgery (35.9% vs 16.4% for tramadol/paracetamol and 36.7% vs 18% for tramadol treatment).
det||treatment-2/NN||the-1/DT	nsubj||evolved-9/VBN||treatment-2/NN	prep_of||treatment-2/NN||chronichepatitisc-4/NN	appos||chronichepatitisc-4/NN||chc-6/NN	aux||evolved-9/VBN||has-8/VBZ	root||ROOT-0/null||evolved-9/VBN	det||years-14/NNS||the-11/DT	amod||years-14/NNS||past-12/JJ	num||years-14/NNS||15-13/CD	prep_in||evolved-9/VBN||years-14/NNS	nsubj||therapy-26/NN||combination-16/NN	amod||interferon-19/NN||pegylated-18/JJ	prep_of||combination-16/NN||interferon-19/NN	prep||interferon-19/NN||plus-20/CC	pobj||plus-20/CC||ribavirin-21/NNP	cop||therapy-26/NN||is-22/VBZ	poss||therapy-26/NN||its-23/PRP$	amod||therapy-26/NN||current-24/JJ	amod||therapy-26/NN||standard-25/JJ	conj_and||evolved-9/VBN||therapy-26/NN	chronichepatitisc-4||ribavirin-21||yes||the treatment of chronichepatitisc (chc) has evolved in the past 15 years and combination of pegylated interferon plus ribavirin is its current standard therapy.
amod||approaches-3/NNS||new-1/JJ	amod||approaches-3/NNS||therapeutic-2/JJ	nsubj||are-4/VBP||approaches-3/NNS	root||ROOT-0/null||are-4/VBP	prep_under||are-4/VBP||study-6/NN	amod||systems-10/NNS||interferon-8/JJ	amod||systems-10/NNS||related-9/JJ	prep_like||study-6/NN||systems-10/NNS	amod||forms-13/NNS||modified-12/VBN	appos||systems-10/NNS||forms-13/NNS	prep_of||forms-13/NNS||ribavirin-15/NNP	amod||inhibitors-25/NNS||internal-17/JJ	amod||inhibitors-25/NNS||ribosome-18/JJ	nn||inhibitors-25/NNS||entry-19/NN	nn||inhibitors-25/NNS||site-20/NN	nn||ires-23/NNS||hcv-22/NN	appos||inhibitors-25/NNS||ires-23/NNS	prep_under||are-4/VBP||inhibitors-25/NNS	conj_and||study-6/NN||inhibitors-25/NNS	amod||inhibitors-30/NNS||ns3-27/JJ	conj_and||ns3-27/JJ||ns5a-29/JJ	amod||inhibitors-30/NNS||ns5a-29/JJ	prep_under||are-4/VBP||inhibitors-30/NNS	conj_and||study-6/NN||inhibitors-30/NNS	nn||immunomodulators-33/NNS||novel-32/NN	prep_under||are-4/VBP||immunomodulators-33/NNS	conj_and||study-6/NN||immunomodulators-33/NNS	advmod||targeted-36/VBN||specifically-35/RB	amod||therapy-38/NN||targeted-36/VBN	amod||therapy-38/NN||anti-viral-37/JJ	prep_under||are-4/VBP||therapy-38/NN	conj_and||study-6/NN||therapy-38/NN	amod||compounds-41/NNS||hepatitisc-40/JJ	prep_for||therapy-38/NN||compounds-41/NNS	hepatitisc-40||hcv-22||no||new therapeutic approaches are under study like interferon related systems, modified forms of ribavirin, internal ribosome entry site (hcv ires) inhibitors, ns3 and ns5a inhibitors, novel immunomodulators and specifically targeted anti-viral therapy for hepatitisc compounds.
det||result-2/NN||this-1/DT	nsubj||suggested-3/VBD||result-2/NN	root||ROOT-0/null||suggested-3/VBD	det||regimen-8/NN||the-4/DT	amod||regimen-8/NN||general-5/JJ	nn||regimen-8/NN||tb-6/NN	nn||regimen-8/NN||treatment-7/NN	dobj||suggested-3/VBD||regimen-8/NN	prep_including||regimen-8/NN||pyrazinamide-10/NN	aux||choice-15/NN||to-11/TO	cop||choice-15/NN||be-12/VB	det||choice-15/NN||the-13/DT	amod||choice-15/NN||first-14/JJ	vmod||pyrazinamide-10/NN||choice-15/NN	prep_in||choice-15/NN||bangladesh-17/NN	tb-6||pyrazinamide-10||yes||this result suggested the general tb treatment regimen including pyrazinamide to be the first choice in bangladesh.
nsubj||effective-4/JJ||montelukast-1/NN	aux||effective-4/JJ||might-2/MD	cop||effective-4/JJ||be-3/VB	root||ROOT-0/null||effective-4/JJ	amod||urticaria-7/NN||chronic-6/JJ	prep_in||effective-4/JJ||urticaria-7/NN	vmod||urticaria-7/NN||associated-8/VBN	prep_with||associated-8/VBN||aspirin-10/NN	appos||urticaria-7/NN||asa-12/NN	nn||-RSB--64/NN||food-15/NN	amod||-RSB--64/NN||additive-16/JJ	advmod||additive-16/JJ||hypersensitivity-17/RB	conj_or||additive-16/JJ||with-19/IN	amod||-RSB--64/NN||with-19/IN	pobj||with-19/IN||autoreactivity-20/NN	pobj||with-19/IN||autoreactivity-20/NN	conj_negcc||autoreactivity-20/NN||autoreactivity-20/NN	amod||injection-24/NN||intradermal-22/JJ	nn||injection-24/NN||serum-23/NN	prep_to||autoreactivity-20/NN||injection-24/NN	appos||injection-24/NN||asst-26/NN	advmod||taken-29/VBN||when-28/WRB	rcmod||injection-24/NN||taken-29/VBN	det||antihistamine-32/NN||an-31/DT	prep_with||taken-29/VBN||antihistamine-32/NN	amod||urticaria-43/NN||mild-36/JJ	conj_or||mild-36/JJ||moderate-38/JJ	amod||urticaria-43/NN||moderate-38/JJ	amod||urticaria-43/NN||chronic-39/JJ	amod||urticaria-43/NN||idiopathic-40/JJ	nn||urticaria-43/NN||urticaria-41/NN	amod||urticaria-43/NN||-LSB--42/VBG	prep_in||autoreactivity-20/NN||urticaria-43/NN	det||causes-48/NNS||any-45/DT	amod||causes-48/NNS||possible-46/JJ	amod||causes-48/NNS||secondary-47/JJ	prep_without||urticaria-43/NN||causes-48/NNS	dep||autoreactivity-20/NN||ie-50/NN	nn||additive-53/NN||food-52/NN	dep||autoreactivity-20/NN||additive-53/NN	conj_or||ie-50/NN||additive-53/NN	conj_or||ie-50/NN||asa-55/NN	conj_or||additive-53/NN||asa-55/NN	amod||hypersensitivity-59/NN||other-57/JJ	amod||hypersensitivity-59/NN||nsaid-58/JJ	conj_or||ie-50/NN||hypersensitivity-59/NN	conj_and||additive-53/NN||hypersensitivity-59/NN	dep||autoreactivity-20/NN||asst-62/NN	conj_or||ie-50/NN||asst-62/NN	prep_in||effective-4/JJ||-RSB--64/NN	conj_or||urticaria-7/NN||-RSB--64/NN	hypersensitivity-59||hypersensitivity-59||no||montelukast might be effective in chronic urticaria associated with aspirin (asa) or food additive hypersensitivity or with autoreactivity to intradermal serum injection (asst) when taken with an antihistamine but not in mild or moderate chronic idiopathic urticaria [urticaria without any possible secondary causes (ie, food additive or asa and other nsaid hypersensitivity, or asst)].
nsubj||showed-3/VBD||we-1/PRP	advmod||showed-3/VBD||previously-2/RB	root||ROOT-0/null||showed-3/VBD	mark||forms-14/VBZ||that-4/IN	advmod||neutralizing-6/JJ||broadly-5/RB	amod||2g12-8/NNS||neutralizing-6/JJ	amod||2g12-8/NNS||anti-hiv-1antibody-7/JJ	nsubj||forms-14/VBZ||2g12-8/NNS	amod||igg1-11/NNS||human-10/JJ	appos||2g12-8/NNS||igg1-11/NNS	advmod||forms-14/VBZ||naturally-13/RB	ccomp||showed-3/VBD||forms-14/VBZ	dobj||forms-14/VBZ||dimers-15/NNS	nsubj||potent-19/JJ||dimers-15/NNS	cop||potent-19/JJ||are-17/VBP	advmod||potent-19/JJ||more-18/RBR	rcmod||dimers-15/NNS||potent-19/JJ	amod||2g12-22/NNS||monomeric-21/JJ	prep_than||potent-19/JJ||2g12-22/NNS	dep||vitro-25/NN||in-24/IN	amod||neutralization-26/NN||vitro-25/NN	prep_in||2g12-22/NNS||neutralization-26/NN	amod||strains-29/NNS||various-28/JJ	prep_of||neutralization-26/NN||strains-29/NNS	prep_of||strains-29/NNS||hiv-1-31/CD	hiv-1antibody--1||hiv-1-31||no||we previously showed that broadly neutralizing anti-hiv-1antibody 2g12 (human igg1) naturally forms dimers that are more potent than monomeric 2g12 in in vitro neutralization of various strains of hiv-1.
det||availability-3/NN||the-2/DT	prep_despite||continues-11/VBZ||availability-3/NN	amod||vaccines-6/NNS||specific-5/JJ	prep_of||availability-3/NN||vaccines-6/NNS	prep_of||availability-3/NN||antiviraldrugs-8/NNS	conj_and||vaccines-6/NNS||antiviraldrugs-8/NNS	nsubj||continues-11/VBZ||influenza-10/NN	nsubj||impose-13/VB||influenza-10/NN	root||ROOT-0/null||continues-11/VBZ	aux||impose-13/VB||to-12/TO	xcomp||continues-11/VBZ||impose-13/VB	det||toll-16/NN||a-14/DT	amod||toll-16/NN||heavy-15/JJ	dobj||impose-13/VB||toll-16/NN	amod||health-19/NN||human-18/JJ	prep_on||toll-16/NN||health-19/NN	advmod||impose-13/VB||worldwide-20/RB	influenza-10||vaccines-6||no_rel||despite the availability of specific vaccines and antiviraldrugs, influenza continues to impose a heavy toll on human health worldwide.
nsubj||been-3/VBN||he-1/PRP	aux||been-3/VBN||has-2/VBZ	root||ROOT-0/null||been-3/VBN	amod||drugs-6/NNS||anti-tuberculous-5/JJ	prep_on||been-3/VBN||drugs-6/NNS	dep||drugs-6/NNS||isoniazid-8/NN	appos||isoniazid-8/NN||rifampin-10/NN	num||year-14/NN||1-13/CD	prep_for||been-3/VBN||year-14/NN	poss||encephalitis-18/NN||his-16/PRP$	amod||encephalitis-18/NN||tuberculous-17/JJ	prep_for||year-14/NN||encephalitis-18/NN	tuberculous-17||isoniazid-8||yes||he has been on anti-tuberculous drugs (isoniazid, rifampin) for 1 year for his tuberculous encephalitis.
nsubj||were-2/VBD||data-1/NNS	root||ROOT-0/null||were-2/VBD	amod||men-6/NNS||hiv-infected-4/JJ	amod||men-6/NNS||homosexual-5/JJ	prep_from||were-2/VBD||men-6/NNS	amod||dates-9/NNS||well-estimated-8/JJ	prep_with||were-2/VBD||dates-9/NNS	prep_of||dates-9/NNS||hivseroconversion-11/NN	dep||dates-9/NNS||ie-13/VB	dep||ie-13/VB||change-15/VB	prep_in||ie-13/VB||status-17/NN	cop||negative-21/JJ||being-19/VBG	advmod||negative-21/JJ||hiv-20/RB	prepc_from||ie-13/VB||negative-21/JJ	aux||detected-26/VBN||having-23/VBG	nn||antibodies-25/NNS||hiv-24/NN	dobj||detected-26/VBN||antibodies-25/NNS	prepc_to||negative-21/JJ||detected-26/VBN	hivseroconversion-11||hiv-24||no||data were from hiv-infected homosexual men with well-estimated dates of hivseroconversion (ie, change in status from being hiv negative to having hiv antibodies detected).
det||regimen-4/NN||the-1/DT	amod||regimen-4/NN||lengthy-2/JJ	nn||regimen-4/NN||treatment-3/NN	nsubj||necessary-8/JJ||regimen-4/NN	nsubj||eradicate-10/VB||regimen-4/NN	prep_for||regimen-4/NN||tuberculosis-6/NNP	cop||necessary-8/JJ||is-7/VBZ	root||ROOT-0/null||necessary-8/JJ	aux||eradicate-10/VB||to-9/TO	xcomp||necessary-8/JJ||eradicate-10/VB	det||sub-population-13/NN||a-11/DT	amod||sub-population-13/NN||small-12/JJ	dobj||eradicate-10/VB||sub-population-13/NN	prep_of||sub-population-13/NN||m.tuberculosis-15/NNS	nsubj||persists-17/VBZ||m.tuberculosis-15/NNS	rcmod||m.tuberculosis-15/NNS||persists-17/VBZ	amod||locations-21/NNS||certain-19/JJ	nn||locations-21/NNS||host-20/NN	prep_in||persists-17/VBZ||locations-21/NNS	nn||pressure-24/NN||drug-23/NN	prep_under||persists-17/VBZ||pressure-24/NN	tuberculosis-6||m.tuberculosis-15||no||the lengthy treatment regimen for tuberculosis is necessary to eradicate a small sub-population of m.tuberculosis that persists in certain host locations under drug pressure .
nsubj||studied-2/VBD||we-1/PRP	root||ROOT-0/null||studied-2/VBD	nsubj||isolates-4/VBZ||c.neoformans-3/NNS	ccomp||studied-2/VBD||isolates-4/VBZ	num||patients-8/NNS||7-6/CD	nn||patients-8/NNS||cuban-7/NN	prep_from||isolates-4/VBZ||patients-8/NNS	amod||cryptococcalmeningitis-11/NNS||recurrent-10/JJ	prep_with||patients-8/NNS||cryptococcalmeningitis-11/NNS	cryptococcalmeningitis-11||c.neoformans-3||no||we studied c.neoformans isolates from 7 cuban patients with recurrent cryptococcalmeningitis .
nsubj||show-2/VBP||we-1/PRP	root||ROOT-0/null||show-2/VBP	mark||observed-39/VBN||that-3/IN	mark||correlated-23/JJ||because-4/IN	det||rigidity-7/NN||the-6/DT	prep_of||correlated-23/JJ||rigidity-7/NN	det||bonds-11/NNS||the-9/DT	amod||bonds-11/NNS||covalent-10/JJ	prep_of||rigidity-7/NN||bonds-11/NNS	det||backbones-15/NNS||the-13/DT	amod||backbones-15/NNS||sugar-phosphate-14/JJ	prep_in||bonds-11/NNS||backbones-15/NNS	det||parameters-20/NNS||the-17/DT	nn||parameters-20/NNS||base-18/NN	nn||parameters-20/NNS||pair-19/NN	nsubj||correlated-23/JJ||parameters-20/NNS	cop||correlated-23/JJ||are-21/VBP	advmod||correlated-23/JJ||highly-22/RB	advcl||observed-39/VBN||correlated-23/JJ	advmod||correlated-23/JJ||especially-25/RB	amod||correlation-29/NN||strong-27/JJ	amod||correlation-29/NN||twist-roll-slide-28/JJ	nsubjpass||observed-39/VBN||correlation-29/NN	det||conformation-32/NN||the-31/DT	prep_in||correlation-29/NN||conformation-32/NN	det||dna-36/NN||the-34/DT	amod||dna-36/NN||nucleosomal-35/JJ	prep_of||conformation-32/NN||dna-36/NN	auxpass||observed-39/VBN||is-37/VBZ	advmod||observed-39/VBN||vividly-38/RB	ccomp||show-2/VBP||observed-39/VBN	det||results-43/NNS||the-41/DT	amod||results-43/NNS||calculated-42/JJ	prep_in||observed-39/VBN||results-43/NNS	sugar--1||rigidity-7||no_rel||we show that because of the rigidity of the covalent bonds in the sugar-phosphate backbones, the base pair parameters are highly correlated, especially, strong twist-roll-slide correlation in the conformation of the nucleosomal dna is vividly observed in the calculated results.
nsubj||caused-6/VBN||avianinfluenzavirus-1/NNS	appos||avianinfluenzavirus-1/NNS||h5n1-3/NNP	aux||caused-6/VBN||has-5/VBZ	root||ROOT-0/null||caused-6/VBN	amod||infections-8/NNS||serious-7/JJ	dobj||caused-6/VBN||infections-8/NNS	amod||beings-11/NNS||human-10/JJ	prep_in||caused-6/VBN||beings-11/NNS	h5n1-3||avianinfluenzavirus-1||no||avianinfluenzavirus (h5n1) has caused serious infections in human beings.
amod||users-3/NNS||most-1/JJS	nn||users-3/NNS||drug-2/NN	nsubj||answered-9/VBD||users-3/NNS	number||80.6-5/CD||-lrb--4/CD	num||%-6/NN||80.6-5/CD	npadvmod||-rrb--7/JJ||%-6/NN	amod||users-3/NNS||-rrb--7/JJ	advmod||answered-9/VBD||correctly-8/RB	root||ROOT-0/null||answered-9/VBD	mark||make-12/VBP||that-10/IN	nsubj||make-12/VBP||condoms-11/NNS	ccomp||answered-9/VBD||make-12/VBP	nsubj||safer-14/JJR||sex-13/NN	xcomp||make-12/VBP||safer-14/JJR	amod||beliefs-18/NNS||incorrect-17/JJ	nsubj||common-21/JJ||beliefs-18/NNS	cop||common-21/JJ||are-19/VBP	advmod||common-21/JJ||still-20/RB	conj_but||answered-9/VBD||common-21/JJ	nn||e.g.-23/NNP||-lrb--22/NNP	nsubj||reported-37/VBD||e.g.-23/NNP	quantmod||44-25/CD||nearly-24/RB	num||%-26/NN||44-25/CD	nsubj||believed-27/VBD||%-26/NN	rcmod||e.g.-23/NNP||believed-27/VBD	nsubjpass||transmitted-31/VBN||hiv-28/NN	aux||transmitted-31/VBN||can-29/MD	auxpass||transmitted-31/VBN||be-30/VB	ccomp||believed-27/VBD||transmitted-31/VBN	prep_through||transmitted-31/VBN||saliva-33/NN	num||%-36/NN||55-35/CD	prep_through||transmitted-31/VBN||%-36/NN	conj_and||saliva-33/NN||%-36/NN	ccomp||common-21/JJ||reported-37/VBD	mark||transmitted-42/VBN||that-38/IN	nsubjpass||transmitted-42/VBN||hivinfection-39/NN	aux||transmitted-42/VBN||can-40/MD	auxpass||transmitted-42/VBN||be-41/VB	ccomp||reported-37/VBD||transmitted-42/VBN	agent||transmitted-42/VBN||sharing-44/VBG	dobj||sharing-44/VBG||toothbrushes-45/NNS	advmod||sharing-44/VBG||-rrb--46/RB	amod||differences-50/NNS||significant-49/JJ	prep_with||sharing-44/VBG||differences-50/NNS	nsubj||had-55/VBD||differences-50/NNS	nn||users-53/NNS||drug-52/NN	prep_between||differences-50/NNS||users-53/NNS	rcmod||differences-50/NNS||had-55/VBD	nsubjpass||tested-61/VBN||who-57/WP	aux||tested-61/VBN||had-58/VBD	neg||tested-61/VBN||not-59/RB	auxpass||tested-61/VBN||been-60/VBN	ccomp||reported-37/VBD||tested-61/VBN	conj_and||transmitted-42/VBN||tested-61/VBN	prep_for||tested-61/VBN||hiv-63/NN	hivinfection-39||hiv-63||no||most drug users -lrb- 80.6 % -rrb- correctly answered that condoms make sex safer , but incorrect beliefs are still common -lrb- e.g. nearly 44 % believed hiv can be transmitted through saliva and 55 % reported that hivinfection can be transmitted by sharing toothbrushes -rrb- , with significant differences between drug users who had and who had not been tested for hiv .
det||review-2/NN||this-1/DT	nsubj||concludes-3/VBZ||review-2/NN	root||ROOT-0/null||concludes-3/VBZ	mark||factors-15/NNS||that-4/IN	amod||ors-7/NN||low-5/JJ	nn||ors-7/NN||osmolarilty-6/NN	nsubj||factors-15/NNS||ors-7/NN	nn||supplementation-10/NN||zinc-9/NN	conj_and||ors-7/NN||supplementation-10/NN	nsubj||factors-15/NNS||supplementation-10/NN	conj_and||ors-7/NN||rotavirusvaccine-12/NN	nsubj||factors-15/NNS||rotavirusvaccine-12/NN	cop||factors-15/NNS||are-13/VBP	amod||factors-15/NNS||major-14/JJ	ccomp||concludes-3/VBZ||factors-15/NNS	prepc_in||factors-15/NNS||reducing-17/VBG	det||morbidity-19/NN||the-18/DT	dobj||reducing-17/VBG||morbidity-19/NN	dobj||reducing-17/VBG||mortality-21/NN	conj_and||morbidity-19/NN||mortality-21/NN	dobj||reducing-17/VBG||hospitalization-23/NN	conj_and||morbidity-19/NN||hospitalization-23/NN	vmod||reducing-17/VBG||resulting-24/VBG	prep||resulting-24/VBG||from-25/IN	pcomp||from-25/IN||to-26/TO	amod||gastroenteritis-28/NNS||acute-27/JJ	pobj||to-26/TO||gastroenteritis-28/NNS	prep_in||gastroenteritis-28/NNS||childhood-30/NN	rotavirusvaccine-12||gastroenteritis-28||no_rel||this review concludes that low osmolarilty ors, zinc supplementation and rotavirusvaccine are major factors in reducing the morbidity, mortality and hospitalization resulting from to acute gastroenteritis in childhood.
det||patient-4/NN||a-1/DT	amod||patient-4/NN||73-year-old-2/JJ	amod||patient-4/NN||female-3/JJ	nsubjpass||treated-9/VBN||patient-4/NN	amod||cytomegalovirusretinitis-7/NNS||unilateral-6/JJ	prep_with||patient-4/NN||cytomegalovirusretinitis-7/NNS	auxpass||treated-9/VBN||was-8/VBD	root||ROOT-0/null||treated-9/VBN	amod||ganciclovir-12/NN||intravitreous-11/JJ	prep_with||treated-9/VBN||ganciclovir-12/NN	num||mg/0-15/NNS||4-14/CD	dep||ganciclovir-12/NN||mg/0-15/NNS	num||ml-17/NN||.04-16/CD	dep||mg/0-15/NNS||ml-17/NN	cytomegalovirusretinitis-7||ganciclovir-12||yes||a 73-year-old female patient with unilateral cytomegalovirusretinitis was treated with intravitreous ganciclovir (4 mg/0.04 ml).
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	det||case-6/NN||the-3/DT	amod||case-6/NN||first-4/JJ	amod||case-6/NN||known-5/JJ	dobj||present-2/VBP||case-6/NN	det||patient-9/NN||a-8/DT	prep_of||case-6/NN||patient-9/NN	amod||squamouscellcarcinoma-12/NN||cervical-11/JJ	prep_with||present-2/VBP||squamouscellcarcinoma-12/NN	vmod||squamouscellcarcinoma-12/NN||complicated-13/VBN	agent||complicated-13/VBN||paraneoplasticsyndromes-15/NNS	det||secretion-21/NN||both-17/DT	amod||secretion-21/NN||dermatomyositis-18/JJ	conj_and||dermatomyositis-18/JJ||inappropriate-20/JJ	amod||secretion-21/NN||inappropriate-20/JJ	prep_of||paraneoplasticsyndromes-15/NNS||secretion-21/NN	amod||hormone-24/NN||antidiuretic-23/JJ	prep_of||secretion-21/NN||hormone-24/NN	appos||hormone-24/NN||siadh-26/NN	squamouscellcarcinoma-12||hormone-24||no_rel||we present the first known case of a patient with cervical squamouscellcarcinoma complicated by paraneoplasticsyndromes of both dermatomyositis and inappropriate secretion of antidiuretic hormone (siadh).
amod||anesthesia-3/NN||ketamine/xylazine-1/JJ	nn||anesthesia-3/NN||cocktail-2/NN	nsubj||caused-4/VBD||anesthesia-3/NN	root||ROOT-0/null||caused-4/VBD	det||hypertension-7/NN||a-5/DT	amod||hypertension-7/NN||transient-6/JJ	dobj||caused-4/VBD||hypertension-7/NN	det||cats-10/NNS||the-9/DT	prep_in||caused-4/VBD||cats-10/NNS	nsubj||inhibited-13/VBD||ea-12/NN	nsubj||shortened-18/VBN||ea-12/NN	parataxis||caused-4/VBD||inhibited-13/VBD	det||hypertension-16/NN||this-14/DT	amod||hypertension-16/NN||anesthetic-induced-15/JJ	dobj||inhibited-13/VBD||hypertension-16/NN	parataxis||caused-4/VBD||shortened-18/VBN	conj_and||inhibited-13/VBD||shortened-18/VBN	det||time-22/NN||the-19/DT	amod||time-22/NN||post-anesthesia-20/JJ	nn||time-22/NN||recovery-21/NN	dobj||shortened-18/VBN||time-22/NN	hypertension-16||ketamine--1||no||ketamine/xylazine cocktail anesthesia caused a transient hypertension in the cats; ea inhibited this anesthetic-induced hypertension and shortened the post-anesthesia recovery time.
vmod||tested-16/VBN||using-1/VBG	det||design-4/NN||a-2/DT	amod||design-4/NN||cross-sectional-3/JJ	dobj||using-1/VBG||design-4/NN	det||total-7/NN||a-6/DT	nsubjpass||tested-16/VBN||total-7/NN	nsubjpass||compared-21/VBN||total-7/NN	nsubj||microscopy-23/VB||total-7/NN	num||patients-11/NNS||357-9/CD	amod||patients-11/NNS||febrile-10/JJ	prep_of||total-7/NN||patients-11/NNS	det||ages-14/NNS||all-13/DT	prep_of||patients-11/NNS||ages-14/NNS	auxpass||tested-16/VBN||were-15/VBD	root||ROOT-0/null||tested-16/VBN	xcomp||tested-16/VBN||using-17/VBG	dobj||using-17/VBG||ict-18/NN	conj_and||tested-16/VBN||compared-21/VBN	aux||microscopy-23/VB||to-22/TO	xcomp||compared-21/VBN||microscopy-23/VB	det||reference-28/NN||the-25/DT	amod||reference-28/NN||gold-26/JJ	amod||reference-28/NN||standard-27/JJ	prep_as||microscopy-23/VB||reference-28/NN	cross--1||gold-26||no_rel||using a cross-sectional design, a total of 357 febrile patients of all ages were tested using ict, and compared to microscopy as the gold standard reference.
nsubj||emphasized-2/VBD||points-1/NNS	root||ROOT-0/null||emphasized-2/VBD	cop||need-8/NN||are-3/VBP	dep||need-8/NN||1-5/LS	det||need-8/NN||the-7/DT	ccomp||emphasized-2/VBD||need-8/NN	prepc_for||need-8/NN||considering-10/VBG	det||viruses-15/JJ||these-11/DT	cc||viruses-15/JJ||and-13/CC	amod||viruses-15/JJ||other-14/JJ	dobj||considering-10/VBG||viruses-15/JJ	det||perspective-20/NN||an-18/DT	amod||perspective-20/NN||evolutionary-19/JJ	prep_from||considering-10/VBG||perspective-20/NN	dep||necessity-26/NN||2-23/LS	det||necessity-26/NN||the-25/DT	ccomp||emphasized-2/VBD||necessity-26/NN	conj_and||need-8/NN||necessity-26/NN	prepc_of||necessity-26/NN||disseminating-28/VBG	amod||methods-30/NNS||current-29/JJ	dobj||disseminating-28/VBG||methods-30/NNS	nn||identification-33/NN||virus-32/NN	prep_for||disseminating-28/VBG||identification-33/NN	dep||progress-40/NN||3-36/LS	det||progress-40/NN||the-38/DT	amod||progress-40/NN||great-39/JJ	ccomp||emphasized-2/VBD||progress-40/NN	conj_and||need-8/NN||progress-40/NN	amod||aspects-43/NNS||molecular-virological-42/JJ	prep_in||progress-40/NN||aspects-43/NNS	det||genetics-47/NNS||the-46/DT	prep_in||progress-40/NN||genetics-47/NNS	conj_and||aspects-43/NNS||genetics-47/NNS	det||virus-50/NN||the-49/DT	prep_of||genetics-47/NNS||virus-50/NN	nsubj||provide-52/VB||virus-50/NN	nsubj||define-61/VB||virus-50/NN	rcmod||virus-50/NN||provide-52/VB	amod||tools-54/NNS||new-53/JJ	dobj||provide-52/VB||tools-54/NNS	amod||studies-59/NNS||epidemiological-56/JJ	conj_and||epidemiological-56/JJ||immunological-58/JJ	amod||studies-59/NNS||immunological-58/JJ	prep_for||provide-52/VB||studies-59/NNS	rcmod||virus-50/NN||define-61/VB	conj_and||provide-52/VB||define-61/VB	advmod||convincingly-63/JJ||more-62/RBR	acomp||define-61/VB||convincingly-63/JJ	det||role-67/NN||the-64/DT	amod||role-67/NN||possible-65/JJ	amod||role-67/NN||causal-66/JJ	dep||convincingly-63/JJ||role-67/NN	prep_of||role-67/NN||hsv-2-69/JJ	amod||carcinogenesis-72/NNS||cervical-71/JJ	prep_in||hsv-2-69/JJ||carcinogenesis-72/NNS	dep||problems-78/NNS||4-75/LS	det||problems-78/NNS||the-77/DT	ccomp||emphasized-2/VBD||problems-78/NNS	conj_and||need-8/NN||problems-78/NNS	prep_with||problems-78/NNS||vaccines-80/NNS	det||advances-84/NNS||the-82/DT	amod||advances-84/NNS||therapeutic-83/JJ	prep_with||problems-78/NNS||advances-84/NNS	conj_and||vaccines-80/NNS||advances-84/NNS	conj_and||vaccines-80/NNS||failures-86/NNS	conj_and||advances-84/NNS||failures-86/NNS	appos||advances-84/NNS||5-89/CD	det||aspect-94/NN||the-91/DT	amod||aspect-94/NN||great-92/JJ	amod||aspect-94/NN||psychosocial-93/JJ	dep||advances-84/NNS||aspect-94/NN	det||infections-98/NNS||some-96/DT	amod||infections-98/NNS||herpetic-97/JJ	prep_of||aspect-94/NN||infections-98/NNS	det||need-101/NN||the-100/DT	prep_of||aspect-94/NN||need-101/NN	conj_and||infections-98/NNS||need-101/NN	aux||sympathetic-104/JJ||to-102/TO	cop||sympathetic-104/JJ||be-103/VB	vmod||need-101/NN||sympathetic-104/JJ	vmod||need-101/NN||supportive-106/JJ	conj_and||sympathetic-104/JJ||supportive-106/JJ	aux||afflicted-108/VB||to-107/TO	xcomp||sympathetic-104/JJ||afflicted-108/VB	dobj||afflicted-108/VB||patients-109/NNS	poss||families-112/NNS||their-111/PRP$	ccomp||emphasized-2/VBD||families-112/NNS	conj_and||need-8/NN||families-112/NNS	appos||families-112/NNS||6-115/CD	det||overreaction-118/NN||the-117/DT	dep||families-112/NNS||overreaction-118/NN	prep_regarding||overreaction-118/NN||hsv-120/NN	nsubj||exists-123/VBZ||hsv-120/NN	advmod||exists-123/VBZ||currently-122/RB	rcmod||hsv-120/NN||exists-123/VBZ	prep_among||exists-123/VBZ||physicians-125/NNS	prep_among||exists-123/VBZ||nurses-127/NNS	conj_and||physicians-125/NNS||nurses-127/NNS	det||public-130/NN||the-129/DT	prep_among||exists-123/VBZ||public-130/NN	conj_and||physicians-125/NNS||public-130/NN	det||press-134/NN||the-133/DT	prep_among||exists-123/VBZ||press-134/NN	conj_and||physicians-125/NNS||press-134/NN	xcomp||exists-123/VBZ||resulting-135/VBG	amod||misery-138/NN||increased-137/VBN	prep_in||resulting-135/VBG||misery-138/NN	prep_for||misery-138/NN||those-140/DT	vmod||those-140/DT||afflicted-141/VBN	vmod||those-140/DT||misdiagnosed-143/VBN	conj_or||afflicted-141/VBN||misdiagnosed-143/VBN	amod||advice-148/NN||poor-147/JJ	prep_in||resulting-135/VBG||advice-148/NN	conj_or||misery-138/NN||advice-148/NN	conj_or||misery-138/NN||management-150/NN	conj_or||advice-148/NN||management-150/NN	prep||advice-148/NN||given-151/VBN	pcomp||given-151/VBN||by-152/IN	det||physicians-154/NNS||some-153/DT	pobj||by-152/IN||physicians-154/NNS	vmod||physicians-154/NNS||pressured-155/VBN	prep_in||pressured-155/VBN||part-157/NN	det||fear-160/NN||the-159/DT	agent||pressured-155/VBN||fear-160/NN	nn||suits-163/NNS||malpractice-162/NN	prep_of||fear-160/NN||suits-163/NNS	virus-50||viruses-15||no||points emphasized are (1) the need for considering these (and other viruses) from an evolutionary perspective; (2) the necessity of disseminating current methods for virus identification; (3) the great progress in molecular-virological aspects and in the genetics of the virus which provide new tools for epidemiological and immunological studies and define more convincingly the possible causal role of hsv-2 in cervical carcinogenesis; (4) the problems with vaccines and the therapeutic advances and failures; (5) the great psychosocial aspect of some herpetic infections and the need to be sympathetic and supportive to afflicted patients and their families; (6) the overreaction regarding hsv that currently exists among physicians, nurses, the public, and the press resulting in increased misery for those afflicted or misdiagnosed, or in poor advice or management given by some physicians pressured in part by the fear of malpractice suits.
aux||estimate-2/VB||to-1/TO	advcl||took-10/VBD||estimate-2/VB	amod||risks-7/NNS||subtype-specific-3/JJ	nn||risks-7/NNS||lifetime-4/NN	nn||risks-7/NNS||breast-5/NN	nn||risks-7/NNS||cancer-6/NN	dobj||estimate-2/VB||risks-7/NNS	nsubj||took-10/VBD||we-9/PRP	root||ROOT-0/null||took-10/VBD	dobj||took-10/VBD||advantage-11/NN	prep_for||available-40/JJ||advantage-11/NN	amod||data-14/NNS||population-based-13/JJ	prep_of||advantage-11/NN||data-14/NNS	nsubj||available-40/JJ||information-17/NN	nn||expression-20/NN||tumor-19/NN	prep_regarding||information-17/NN||expression-20/NN	nn||receptor-23/NN||estrogen-22/NN	prep_of||expression-20/NN||receptor-23/NN	appos||receptor-23/NN||er-25/NN	amod||receptor-29/NN||progesterone-28/JJ	prep_of||expression-20/NN||receptor-29/NN	conj_and||receptor-23/NN||receptor-29/NN	appos||receptor-29/NN||pr-31/NN	prep_of||expression-20/NN||her2/neu-34/NNS	conj_and||receptor-23/NN||her2/neu-34/NNS	appos||her2/neu-34/NNS||her2-36/NNP	cop||available-40/JJ||was-38/VBD	advmod||available-40/JJ||newly-39/RB	rcmod||advantage-11/NN||available-40/JJ	estrogen-22||tumor-19||no_rel||to estimate subtype-specific lifetime breast cancer risks, we took advantage of population-based data for which information regarding tumor expression of estrogen receptor (er), progesterone receptor (pr) and her2/neu (her2) was newly available.
num||third-2/NN||one-1/CD	nsubjpass||estimated-9/VBN||third-2/NN	nsubjpass||infected-12/VBN||third-2/NN	det||world-5/NN||the-4/DT	poss||population-7/NN||world-5/NN	prep_of||third-2/NN||population-7/NN	auxpass||estimated-9/VBN||is-8/VBZ	root||ROOT-0/null||estimated-9/VBN	aux||infected-12/VBN||to-10/TO	auxpass||infected-12/VBN||be-11/VB	xcomp||estimated-9/VBN||infected-12/VBN	prep_with||infected-12/VBN||mycobacteriumtuberculosis-14/NNS	xcomp||estimated-9/VBN||representing-16/VBG	det||reservoir-19/NN||a-17/DT	amod||reservoir-19/NN||huge-18/JJ	dobj||representing-16/VBG||reservoir-19/NN	amod||disease-26/NNP||potential-21/JJ	nn||disease-26/NNP||tuberculosis-22/NNP	appos||disease-26/NNP||tb-24/NN	prep_of||reservoir-19/NN||disease-26/NNP	tuberculosis-22||mycobacteriumtuberculosis-14||no||one third of the world's population is estimated to be infected with mycobacteriumtuberculosis , representing a huge reservoir of potential tuberculosis (tb) disease.
nn||estimates-2/NNS||hiv-1/NN	nsubj||tool-6/NN||estimates-2/NNS	cop||tool-6/NN||are-3/VBP	det||tool-6/NN||a-4/DT	amod||tool-6/NN||valuable-5/JJ	root||ROOT-0/null||tool-6/NN	nn||policies-11/NNS||guiding-8/NNP	amod||policies-11/NNS||national-9/JJ	nn||policies-11/NNS||aids-10/NNS	prep_for||tool-6/NN||policies-11/NNS	vmod||policies-11/NNS||evaluating-12/VBG	nn||prevention-14/NN||hiv-13/NN	dobj||evaluating-12/VBG||prevention-14/NN	nn||programmes-17/NNS||control-16/NN	dobj||evaluating-12/VBG||programmes-17/NNS	conj_and||prevention-14/NN||programmes-17/NNS	aids-10||hiv-13||no||hiv estimates are a valuable tool for guiding national aids policies evaluating hiv prevention and control programmes.
root||ROOT-0/null||addition-1/NN	prep_of||addition-1/NN||imeglimin-3/NN	aux||metformin-5/VB||to-4/TO	vmod||addition-1/NN||metformin-5/VB	amod||control-8/NN||improved-6/VBN	amod||control-8/NN||glycemic-7/JJ	dobj||metformin-5/VB||control-8/NN	nn||potential-11/NN||offers-10/NNS	dobj||metformin-5/VB||potential-11/NN	conj_and||control-8/NN||potential-11/NN	det||treatment-15/NN||a-13/DT	amod||treatment-15/NN||new-14/JJ	prep_as||metformin-5/VB||treatment-15/NN	prep_for||treatment-15/NN||type2diabetes-17/CD	type2diabetes-17||metformin-5||yes||addition of imeglimin to metformin improved glycemic control and offers potential as a new treatment for type2diabetes.
nn||concentrations-2/NNS||serum-1/NN	nsubjpass||measured-50/VBN||concentrations-2/NNS	amod||cytokines-5/NNS||proinflammatory-4/JJ	prep_of||concentrations-2/NNS||cytokines-5/NNS	amod||interleukin-6-8/JJ||interleukin-1alpha-6/JJ	amod||cytokines-5/NNS||interleukin-6-8/JJ	nn||necrosis-11/NNS||tumor-10/NN	prep_of||concentrations-2/NNS||necrosis-11/NNS	conj_and||cytokines-5/NNS||necrosis-11/NNS	amod||colonystimulatingfactor-15/NN||factor-alpha-12/JJ	amod||colonystimulatingfactor-15/NN||granulocyte-macrophage-14/JJ	dep||necrosis-11/NNS||colonystimulatingfactor-15/NN	dep||colonystimulatingfactor-15/NN||gm-csf-17/JJ	det||markers-22/NNS||some-20/DT	amod||markers-22/NNS||biochemical-21/JJ	prep_of||concentrations-2/NNS||markers-22/NNS	conj_and||cytokines-5/NNS||markers-22/NNS	prep_of||markers-22/NNS||osteoporosis-24/NN	nn||alkaline-31/NN||osteocalcin-26/NN	conj_and||osteocalcin-26/NN||total-28/NN	nn||alkaline-31/NN||total-28/NN	conj_and||osteocalcin-26/NN||bone-30/NN	nn||alkaline-31/NN||bone-30/NN	dep||concentrations-2/NNS||alkaline-31/NN	amod||telopeptides-41/NNS||phosphatase-32/JJ	amod||telopeptides-41/NNS||procollagen-34/JJ	nn||telopeptides-41/NNS||type-35/NN	amod||telopeptides-41/NNS||i-36/JJ	amod||telopeptides-41/NNS||carboxyterminal-37/JJ	amod||telopeptides-41/NNS||propeptide-38/JJ	amod||telopeptides-41/NNS||carboxyterminal-40/JJ	dep||alkaline-31/NN||telopeptides-41/NNS	nn||collagen-45/NN||type-43/FW	nn||collagen-45/NN||i-44/FW	prep_of||telopeptides-41/NNS||collagen-45/NN	dep||collagen-45/NN||ctx-47/NN	auxpass||measured-50/VBN||were-49/VBD	root||ROOT-0/null||measured-50/VBN	collagen-45||tumor-10||no_rel||serum concentrations of proinflammatory cytokines interleukin-1alpha, interleukin-6, tumor necrosis factor-alpha, granulocyte-macrophage colonystimulatingfactor (gm-csf) and some biochemical markers of osteoporosis (osteocalcin, total and bone alkaline phosphatase, procollagen type i carboxyterminal propeptide, carboxyterminal telopeptides of type i collagen--ctx) were measured.
det||effects-2/NNS||the-1/DT	nsubj||range-15/VBP||effects-2/NNS	prep_of||effects-2/NNS||alcohol-4/NN	prep_on||alcohol-4/NN||hiv/aids-6/NNS	det||burden-11/NN||the-8/DT	amod||burden-11/NN||african-9/JJ	amod||burden-11/NN||global-10/JJ	prep_in||hiv/aids-6/NNS||burden-11/NN	nn||regions-14/NNS||disease-13/NN	prep_of||burden-11/NN||regions-14/NNS	root||ROOT-0/null||range-15/VBP	num||%-18/NN||0.03-17/CD	prep_from||range-15/VBP||%-18/NN	prep_from||range-15/VBP||%-18/NN	conj_and||%-18/NN||%-18/NN	num||%-21/NN||0.34-20/CD	prep_to||%-18/NN||%-21/NN	prep_for||%-21/NN||men-23/NNS	num||%-27/NN||0-26/CD	prep_from||%-18/NN||%-27/NN	num||%-30/NN||0.17-29/CD	prep_to||range-15/VBP||%-30/NN	prep_for||%-30/NN||women-32/NNS	prepc_depending_on||range-15/VBP||on-35/IN	nn||category-39/NN||region-36/NN	conj_and||region-36/NN||age-38/NN	nn||category-39/NN||age-38/NN	pobj||range-15/VBP||category-39/NN	aids--1||hiv--1||no||the effects of alcohol on hiv/aids in the african global burden of disease regions range from 0.03% to 0.34% for men and from 0% to 0.17% for women, depending on region and age category.
det||event-3/NN||the-1/DT	nn||event-3/NN||hallmark-2/NN	nsubj||accumulation-8/NN||event-3/NN	prep_in||event-3/NN||priondiseases-5/NNS	cop||accumulation-8/NN||is-6/VBZ	det||accumulation-8/NN||the-7/DT	root||ROOT-0/null||accumulation-8/NN	det||form-14/NN||a-10/DT	amod||form-14/NN||misfolded-11/JJ	conj_and||misfolded-11/JJ||infectious-13/JJ	amod||form-14/NN||infectious-13/JJ	prep_of||accumulation-8/NN||form-14/NN	det||prionprotein-17/NN||the-16/DT	prep_of||form-14/NN||prionprotein-17/NN	dep||prionprotein-17/NN||prpsc-19/JJ	priondiseases-5||prionprotein-17||no||the hallmark event in priondiseases is the accumulation of a misfolded and infectious form of the prionprotein (prpsc).
nsubj||found-2/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	quantmod||6-4/CD||only-3/RB	num||prescriptions-5/NNS||6-4/CD	dobj||found-2/VBD||prescriptions-5/NNS	vmod||prescriptions-5/NNS||having-6/VBG	det||treatment-9/NN||the-7/DT	amod||treatment-9/NN||recommended-8/VBN	dobj||having-6/VBG||treatment-9/NN	nsubjpass||ors-12/VBN||treatment-9/NN	auxpass||ors-12/VBN||is-11/VBZ	rcmod||treatment-9/NN||ors-12/VBN	prep_along_with||ors-12/VBN||zinc-15/NN	neg||probiotics-20/NNS||no-18/DT	amod||probiotics-20/NNS||additional-19/JJ	prep_with||ors-12/VBN||probiotics-20/NNS	prep_with||ors-12/VBN||antibiotics-22/NN	conj_or||probiotics-20/NNS||antibiotics-22/NN	prep_with||ors-12/VBN||racecadotril-24/NN	conj_or||probiotics-20/NNS||racecadotril-24/NN	prep_with||ors-12/VBN||antiemetics-26/NNS	conj_or||probiotics-20/NNS||antiemetics-26/NNS	prep_except||prescriptions-5/NNS||domperidone-29/NN	prep_for||domperidone-29/NN||vomiting-31/NN	vomiting-31||antibiotics-22||no_rel||we found only 6 prescriptions having the recommended treatment that is ors along with zinc, with no additional probiotics, antibiotics, racecadotril or antiemetics (except domperidone for vomiting).
nsubj||displays-10/VBZ||capsaicin-1/NN	nsubj||epidermoid-16/VBD||capsaicin-1/NN	det||ingredient-5/NN||the-3/DT	amod||ingredient-5/NN||active-4/JJ	appos||capsaicin-1/NN||ingredient-5/NN	amod||peppers-8/NNS||chilli-7/JJ	prep_of||ingredient-5/NN||peppers-8/NNS	root||ROOT-0/null||displays-10/VBZ	amod||activity-12/NN||anti-proliferative-11/JJ	dobj||displays-10/VBZ||activity-12/NN	prep_in||displays-10/VBZ||prostate-14/NN	conj_and||displays-10/VBZ||epidermoid-16/VBD	dobj||epidermoid-16/VBD||cancer-17/NN	prep_in||epidermoid-16/VBD||vitro-19/NN	cancer-17||capsaicin-1||no_rel||capsaicin, the active ingredient of chilli peppers, displays anti-proliferative activity in prostate and epidermoid cancer in vitro .
prepc_based_on||used-14/VBN||on-2/IN	det||study-4/NN||this-3/DT	pobj||used-14/VBN||study-4/NN	nsubjpass||used-14/VBN||ceftriaxone-6/NN	conj_and||ceftriaxone-6/NN||cefixime-8/NN	nsubjpass||used-14/VBN||cefixime-8/NN	conj_and||ceftriaxone-6/NN||spectinomycin-11/NN	nsubjpass||used-14/VBN||spectinomycin-11/NN	aux||used-14/VBN||can-12/MD	auxpass||used-14/VBN||be-13/VB	root||ROOT-0/null||used-14/VBN	det||therapy-19/NN||an-16/DT	amod||therapy-19/NN||empirical-17/JJ	amod||therapy-19/NN||first-line-18/JJ	prep_as||used-14/VBN||therapy-19/NN	prep_for||therapy-19/NN||gonorrhoea-21/NN	nn||pakistan-25/NN||india-23/NN	prep_in||used-14/VBN||pakistan-25/NN	prep_in||used-14/VBN||bhutan-28/NN	conj_and||pakistan-25/NN||bhutan-28/NN	mark||be-43/VB||whereas-30/IN	nsubj||be-43/VB||ciprofloxacin-31/NN	appos||ciprofloxacin-31/NN||penicilling-33/NN	appos||ciprofloxacin-31/NN||tetracycline-35/NN	conj_and||penicilling-33/NN||tetracycline-35/NN	appos||ciprofloxacin-31/NN||erythromycin-37/NN	conj_and||penicilling-33/NN||erythromycin-37/NN	appos||ciprofloxacin-31/NN||azithromycin-40/NN	conj_and||penicilling-33/NN||azithromycin-40/NN	aux||be-43/VB||should-41/MD	neg||be-43/VB||not-42/RB	rcmod||pakistan-25/NN||be-43/VB	gonorrhoea-21||ciprofloxacin-31||yes||based on this study, ceftriaxone, cefixime, and spectinomycin can be used as an empirical first-line therapy for gonorrhoea in india, pakistan, and bhutan, whereas ciprofloxacin, penicilling, tetracycline, erythromycin, and azithromycin should not be.
amod||animals-5/NNS||stz-treated-4/JJ	prep_with_respect_to||characterized-14/VBN||animals-5/NNS	nsubjpass||characterized-14/VBN||mice-7/NNS	vmod||mice-7/NNS||co-injected-8/VBN	nn||trail-12/NN||stz-10/NN	nn||trail-12/NN||+-11/NN	prep_with||co-injected-8/VBN||trail-12/NN	auxpass||characterized-14/VBN||were-13/VBD	root||ROOT-0/null||characterized-14/VBN	dep||levels-19/NNS||1-16/LS	amod||levels-19/NNS||lower-18/JJR	agent||characterized-14/VBN||levels-19/NNS	prep_of||levels-19/NNS||hyperglycemia-21/NN	dep||levels-26/NNS||2-23/LS	amod||levels-26/NNS||higher-25/JJR	agent||characterized-14/VBN||levels-26/NNS	conj_and||levels-19/NNS||levels-26/NNS	nn||weight-29/NN||body-28/NN	prep_of||levels-26/NNS||weight-29/NN	prep_of||levels-26/NNS||insulinemia-31/NN	conj_and||weight-29/NN||insulinemia-31/NN	dep||preservation-37/NN||3-33/LS	det||preservation-37/NN||a-35/DT	amod||preservation-37/NN||partial-36/JJ	agent||characterized-14/VBN||preservation-37/NN	conj_and||levels-19/NNS||preservation-37/NN	amod||islets-40/NNS||pancreatic-39/JJ	prep_of||preservation-37/NN||islets-40/NNS	amod||morphology-43/NN||normal-42/JJ	prep_with||islets-40/NNS||morphology-43/NN	dep||expression-50/NN||4-46/LS	det||expression-50/NN||a-48/DT	amod||expression-50/NN||lower-49/JJR	agent||characterized-14/VBN||expression-50/NN	conj_and||levels-19/NNS||expression-50/NN	det||systemic-53/NN||both-52/DT	prep_of||expression-50/NN||systemic-53/NN	amod||±-56/NNS||tnf-î-55/JJ	appos||systemic-53/NN||±-56/NNS	appos||systemic-53/NN||opg-58/NN	conj_and||±-56/NNS||opg-58/NN	amod||markers-73/NNS||pancreatic-61/JJ	nn||molecule-66/NN||vascular-63/NN	nn||molecule-66/NN||cell-64/NN	nn||molecule-66/NN||adhesion-65/NN	dep||pancreatic-61/JJ||molecule-66/NN	nn||-1-70/NNP||-LSB--67/NNP	nn||-1-70/NNP||vcam-68/NNP	nn||-1-70/NNP||-RSB--69/NNP	dep||molecule-66/NN||-1-70/NNP	amod||markers-73/NNS||inflammatory-72/JJ	prep_of||expression-50/NN||markers-73/NNS	conj_and||systemic-53/NN||markers-73/NNS	stz-10||adhesion-65||no_rel||with respect to stz-treated animals, mice co-injected with stz+trail were characterized by 1 ) lower levels of hyperglycemia, 2 ) higher levels of body weight and insulinemia, 3 ) a partial preservation of pancreatic islets with normal morphology, and 4 ) a lower expression of both systemic (tnf-î± and opg) and pancreatic (vascular cell adhesion molecule [vcam]-1) inflammatory markers.
nn||equivalence-2/NNS||conclusion-1/NN	nsubjpass||found-4/VBN||equivalence-2/NNS	auxpass||found-4/VBN||was-3/VBD	root||ROOT-0/null||found-4/VBN	amod||bcgvaccine-7/NN||intradermal-6/JJ	prep_between||found-4/VBN||bcgvaccine-7/NN	nn||bcg-10/NN||percutaneous-9/NNS	prep_between||found-4/VBN||bcg-10/NN	conj_and||bcgvaccine-7/NN||bcg-10/NN	det||incidence-13/NN||the-12/DT	prep_in||bcgvaccine-7/NN||incidence-13/NN	prep_of||incidence-13/NN||tuberculosis-15/NNP	amod||infants-19/NNS||south-17/JJ	nn||infants-19/NNS||african-18/NN	prep_in||found-4/VBN||infants-19/NNS	dep||infants-19/NNS||vaccinated-20/VBN	prep_at||vaccinated-20/VBN||birth-22/NN	dep||infants-19/NNS||followed-24/VBN	conj_and||vaccinated-20/VBN||followed-24/VBN	prt||followed-24/VBN||up-25/RP	num||years-28/NNS||two-27/CD	prep_for||followed-24/VBN||years-28/NNS	tuberculosis-15||bcg-10||no||conclusion equivalence was found between intradermal bcgvaccine and percutaneous bcg in the incidence of tuberculosis in south african infants vaccinated at birth and followed up for two years.
nsubj||served-7/VBN||hepatitisbsurfaceantigen-1/NN	nsubjpass||detected-16/VBN||hepatitisbsurfaceantigen-1/NN	appos||hepatitisbsurfaceantigen-1/NN||hbsag-3/NN	rcmod||hepatitisbsurfaceantigen-1/NN||served-7/VBN	det||marker-10/NN||the-9/DT	prep_as||served-7/VBN||marker-10/NN	nn||infection-13/NN||hbv-12/NN	prep_of||marker-10/NN||infection-13/NN	auxpass||detected-16/VBN||was-15/VBD	root||ROOT-0/null||detected-16/VBN	det||sandwich-21/NN||a-18/DT	amod||sandwich-21/NN||double-19/JJ	nn||sandwich-21/NN||antibody-20/NN	prep_in||detected-16/VBN||sandwich-21/NN	vmod||sandwich-21/NN||using-22/VBG	num||antibodies-25/NNS||two-23/CD	amod||antibodies-25/NNS||monoclonal-24/JJ	dobj||using-22/VBG||antibodies-25/NNS	appos||antibodies-25/NNS||mabs-27/NNS	nsubj||biotinylated-32/VBD||one-30/PRP	nsubj||capture-34/VB||one-30/PRP	advmod||biotinylated-32/VBD||chemically-31/RB	ccomp||detected-16/VBN||biotinylated-32/VBD	conj_and||detected-16/VBN||biotinylated-32/VBD	aux||capture-34/VB||to-33/TO	xcomp||biotinylated-32/VBD||capture-34/VB	det||other-38/JJ||the-37/DT	nsubj||labeled-39/VBD||other-38/JJ	nsubj||reveal-46/VB||other-38/JJ	conj_and||detected-16/VBN||labeled-39/VBD	amod||nanoparticles-43/NNS||eu3-41/JJ	amod||nanoparticles-43/NNS||+-42/JJ	prep_with||labeled-39/VBD||nanoparticles-43/NNS	aux||reveal-46/VB||to-45/TO	xcomp||labeled-39/VBD||reveal-46/VB	hbv-12||hepatitisbsurfaceantigen-1||yes||hepatitisbsurfaceantigen (hbsag), which served as the marker of hbv infection, was detected in a double antibody sandwich using two monoclonal antibodies (mabs), one chemically biotinylated to capture, and the other labeled with eu3+ nanoparticles, to reveal.
amod||therapies-2/NNS||hormonal-1/JJ	nsubj||agents-15/NNS||therapies-2/NNS	prep_including||therapies-2/NNS||estrogens-5/NNS	prep_including||therapies-2/NNS||progestogens-7/NNS	conj_and||estrogens-5/NNS||progestogens-7/NNS	cop||agents-15/NNS||are-9/VBP	det||agents-15/NNS||the-10/DT	advmod||known-13/VBN||most-11/RBS	advmod||known-13/VBN||well-12/RB	amod||agents-15/NNS||known-13/VBN	amod||agents-15/NNS||effective-14/JJ	root||ROOT-0/null||agents-15/NNS	amod||hotflashes-18/NNS||relieving-17/VBG	prep_in||agents-15/NNS||hotflashes-18/NNS	advmod||controversial-28/JJ||however-20/RB	det||safety-23/NN||the-22/DT	nsubj||controversial-28/JJ||safety-23/NN	det||agents-26/NNS||these-25/DT	prep_of||safety-23/NN||agents-26/NNS	cop||controversial-28/JJ||is-27/VBZ	parataxis||agents-15/NNS||controversial-28/JJ	hotflashes-18||estrogens-5||yes||hormonal therapies, including estrogens and progestogens, are the most well known effective agents in relieving hotflashes; however, the safety of these agents is controversial.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||assess-8/VB||aim-2/NN	nsubj||dexamethasone-19/VBP||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||assess-8/VB||to-7/TO	xcomp||was-6/VBD||assess-8/VB	det||efficacy-10/NN||the-9/DT	dobj||assess-8/VB||efficacy-10/NN	det||dose-15/NN||a-12/DT	amod||dose-15/NN||single-13/JJ	amod||dose-15/NN||prophylactic-14/JJ	prep_of||efficacy-10/NN||dose-15/NN	prep_of||dose-15/NN||amoxicillin-17/NNP	xcomp||was-6/VBD||dexamethasone-19/VBP	conj_and/or||assess-8/VB||dexamethasone-19/VBP	prepc_in||dexamethasone-19/VBP||preventing-21/VBG	dobj||preventing-21/VBG||postoperativecomplications-22/NNS	appos||postoperativecomplications-22/NNS||pc-24/NN	det||removal-29/NN||a-27/DT	amod||removal-29/NN||surgical-28/JJ	prep_after||preventing-21/VBG||removal-29/NN	det||molar-35/NN||a-31/DT	amod||molar-35/NN||single-32/JJ	amod||molar-35/NN||mandibular-33/JJ	amod||molar-35/NN||third-34/JJ	prep_of||removal-29/NN||molar-35/NN	appos||molar-35/NN||m3-37/NNP	amoxicillin-17||postoperativecomplications-22||no_rel||the aim of this study was to assess the efficacy of a single prophylactic dose of amoxicillin and/or dexamethasone in preventing postoperativecomplications (pc) after a surgical removal of a single mandibular third molar (m3).
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubj||suggests-4/VBZ||study-3/NN	root||ROOT-0/null||suggests-4/VBZ	mark||treatments-17/NNS||that-5/IN	amod||medications-8/NNS||atypical-6/JJ	amod||medications-8/NNS||antipsychotic-7/JJ	nsubj||treatments-17/NNS||medications-8/NNS	advmod||clozapine-11/JJ||especially-10/RB	amod||medications-8/NNS||clozapine-11/JJ	cop||treatments-17/NNS||are-13/VBP	det||treatments-17/NNS||the-14/DT	amod||treatments-17/NNS||primary-15/JJ	amod||treatments-17/NNS||psychiatric-16/JJ	ccomp||suggests-4/VBZ||treatments-17/NNS	prep_of||treatments-17/NNS||choice-19/NN	det||management-22/NN||the-21/DT	prep_in||choice-19/NN||management-22/NN	prep_of||management-22/NN||schizophrenia-24/NN	prep_in||schizophrenia-24/NN||china-26/NN	schizophrenia-24||clozapine-11||yes||the present study suggests that atypical antipsychotic medications, especially clozapine, are the primary psychiatric treatments of choice in the management of schizophrenia in china.
advmod||develop-8/VB||yet-1/RB	amod||users-5/NNS||heavy-3/JJ	nn||users-5/NNS||cannabis-4/NN	nsubj||develop-8/VB||users-5/NNS	aux||develop-8/VB||did-6/VBD	neg||develop-8/VB||not-7/RB	root||ROOT-0/null||develop-8/VB	acomp||develop-8/VB||cross-tolerance-9/JJ	det||effects-13/NNS||the-11/DT	amod||effects-13/NNS||impairing-12/VBG	prep_to||cross-tolerance-9/JJ||effects-13/NNS	prep_of||effects-13/NNS||alcohol-15/NN	det||presence-19/NN||the-18/DT	prep_to||cross-tolerance-9/JJ||presence-19/NN	conj_and||effects-13/NNS||presence-19/NN	det||latter-22/NN||the-21/DT	prep_of||presence-19/NN||latter-22/NN	advmod||potentiated-25/VBD||even-23/RB	advmod||potentiated-25/VBD||selectively-24/RB	dep||latter-22/NN||potentiated-25/VBD	nn||effects-27/NNS||thc-26/NN	dobj||potentiated-25/VBD||effects-27/NNS	prep_on||potentiated-25/VBD||measures-29/NNS	amod||attention-32/NN||divided-31/VBN	prep_of||measures-29/NNS||attention-32/NN	cross--1||alcohol-15||no_rel||yet, heavy cannabis users did not develop cross-tolerance to the impairing effects of alcohol, and the presence of the latter even selectively potentiated thc effects on measures of divided attention.
nsubjpass||caused-5/VBN||duckviralenteritis-1/NNS	nsubj||causes-12/VBZ||duckviralenteritis-1/NNS	auxpass||caused-5/VBN||is-4/VBZ	rcmod||duckviralenteritis-1/NNS||caused-5/VBN	agent||caused-5/VBN||duckenteritisvirus-7/NNS	appos||duckenteritisvirus-7/NNS||dev-9/NN	root||ROOT-0/null||causes-12/VBZ	amod||losses-15/NNS||significant-13/JJ	amod||losses-15/NNS||economic-14/JJ	dobj||causes-12/VBZ||losses-15/NNS	amod||waterfowls-20/NNS||domestic-17/JJ	conj_and||domestic-17/JJ||wild-19/JJ	amod||waterfowls-20/NNS||wild-19/JJ	prep_in||losses-15/NNS||waterfowls-20/NNS	det||mortality-25/NN||the-23/DT	amod||mortality-25/NN||high-24/JJ	prep_because_of||losses-15/NNS||mortality-25/NN	amod||rates-30/NNS||low-27/JJ	nn||rates-30/NNS||egg-28/NN	nn||rates-30/NNS||production-29/NN	prep_because_of||losses-15/NNS||rates-30/NNS	conj_and||mortality-25/NN||rates-30/NNS	duckviralenteritis-1||duckenteritisvirus-7||no||duckviralenteritis, which is caused by duckenteritisvirus (dev), causes significant economic losses in domestic and wild waterfowls because of the high mortality and low egg production rates.
nsubj||describe-2/VB||we-1/PRP	nsubj||assess-28/VB||we-1/PRP	root||ROOT-0/null||describe-2/VB	det||series-4/NN||a-3/DT	dobj||describe-2/VB||series-4/NN	prep_of||series-4/NN||exercises-6/NNS	vmod||exercises-6/NNS||involved-7/VBN	prepc_in||involved-7/VBN||adapting-9/VBG	det||model-13/NN||a-10/DT	amod||model-13/NN||computer-based-11/JJ	nn||model-13/NN||simulation-12/NN	dobj||adapting-9/VBG||model-13/NN	amod||cohort-26/NN||hivdisease-15/JJ	det||women-18/NNS||the-17/DT	poss||study-22/NN||women-18/NNS	nn||study-22/NN||interagency-20/NN	nn||study-22/NN||hiv-21/NN	prep_to||hivdisease-15/JJ||study-22/NN	num||wihs-24/NNS||-lrb--23/CD	npadvmod||-rrb--25/JJ||wihs-24/NNS	amod||cohort-26/NN||-rrb--25/JJ	prep_of||model-13/NN||cohort-26/NN	conj_and||describe-2/VB||assess-28/VB	nn||performance-30/NN||model-29/NN	dobj||assess-28/VB||performance-30/NN	mark||re-parameterized-33/VBD||as-31/IN	nsubj||re-parameterized-33/VBD||we-32/PRP	advcl||assess-28/VB||re-parameterized-33/VBD	det||model-35/NN||the-34/DT	dobj||re-parameterized-33/VBD||model-35/NN	aux||address-37/VB||to-36/TO	vmod||model-35/NN||address-37/VB	nn||questions-39/NNS||policy-38/NN	dobj||address-37/VB||questions-39/NNS	det||u.s.-42/NN||the-41/DT	prep_in||address-37/VB||u.s.-42/NN	amod||u.s.-42/NN||relevant-43/JJ	amod||women-46/NNS||hiv-infected-45/JJ	prep_to||relevant-43/JJ||women-46/NNS	vmod||women-46/NNS||using-47/VBG	dobj||using-47/VBG||data-48/NNS	det||wihs-51/NNS||the-50/DT	prep_from||using-47/VBG||wihs-51/NNS	hivdisease-15||hiv-21||no||we describe a series of exercises involved in adapting a computer-based simulation model of hivdisease to the women 's interagency hiv study -lrb- wihs -rrb- cohort and assess model performance as we re-parameterized the model to address policy questions in the u.s. relevant to hiv-infected women using data from the wihs .
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	ccomp||was-6/VBD||evaluate-8/VB	det||effect-10/NN||the-9/DT	dobj||evaluate-8/VB||effect-10/NN	amod||patients-26/NNS||tegaserod-12/JJ	prep_on||tegaserod-12/JJ||symptoms-14/NNS	prep_on||tegaserod-12/JJ||quality-16/NN	conj_and||symptoms-14/NNS||quality-16/NN	prep_of||symptoms-14/NNS||life-18/NN	appos||life-18/NN||qol-20/NN	prep_in||life-18/NN||korean-23/NN	amod||patients-26/NNS||female-24/JJ	nn||patients-26/NNS||ibs-25/NN	prep_of||effect-10/NN||patients-26/NNS	prep_with||evaluate-8/VB||constipation-28/NN	aux||evaluate-31/VB||to-30/TO	ccomp||was-6/VBD||evaluate-31/VB	conj_and||evaluate-8/VB||evaluate-31/VB	det||usefulness-33/NN||the-32/DT	dobj||evaluate-31/VB||usefulness-33/NN	det||ibs-qol-36/NN||the-35/DT	prep_of||usefulness-33/NN||ibs-qol-36/NN	amod||study-39/NN||clinical-38/JJ	prep_in||ibs-qol-36/NN||study-39/NN	ibs-25||tegaserod-12||yes||the aim of this study was to evaluate the effect of tegaserod on symptoms and quality of life (qol) in korean female ibs patients with constipation and to evaluate the usefulness of the ibs-qol in clinical study.
nsubj||agent-8/NN||humant-celllymphotropicvirustype1-1/JJ	dep||humant-celllymphotropicvirustype1-1/JJ||htlv-1-3/JJ	cop||agent-8/NN||is-5/VBZ	det||agent-8/NN||the-6/DT	amod||agent-8/NN||etiological-7/JJ	root||ROOT-0/null||agent-8/NN	amod||leukemia-12/NN||adult-10/JJ	amod||leukemia-12/NN||t-cell-11/JJ	prep_of||agent-8/NN||leukemia-12/NN	appos||leukemia-12/NN||atl-14/NN	amod||tropicalspasticparaparesis-19/NNS||htlv-1-associatedmyelopathy-17/JJ	amod||tropicalspasticparaparesis-19/NNS||/-18/JJ	prep_of||agent-8/NN||tropicalspasticparaparesis-19/NNS	conj_and||leukemia-12/NN||tropicalspasticparaparesis-19/NNS	appos||leukemia-12/NN||ham/tsp-21/NN	htlv-1-associatedmyelopathy-17||humant-celllymphotropicvirustype1-1||no||humant-celllymphotropicvirustype1 (htlv-1) is the etiological agent of adult t-cell leukemia (atl) and htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp).
nsubj||limit-4/VB||nutritional-1/NNP	nsubj||impair-16/VB||nutritional-1/NNP	advmod||limit-4/VB||irondeficiency-2/RB	aux||limit-4/VB||may-3/MD	root||ROOT-0/null||limit-4/VB	nn||availability-6/NN||iron-5/NN	dobj||limit-4/VB||availability-6/NN	det||parasite-10/NN||the-8/DT	nn||parasite-10/NN||malaria-9/NN	prep_to||limit-4/VB||parasite-10/NN	vmod||parasite-10/NN||reducing-11/VBG	nn||risk-13/NN||infection-12/NN	dobj||reducing-11/VBG||risk-13/NN	conj_and/or||limit-4/VB||impair-16/VB	nn||immunity-18/NN||host-17/NN	dobj||impair-16/VB||immunity-18/NN	advmod||increasing-20/VBG||thereby-19/RB	vmod||immunity-18/NN||increasing-20/VBG	det||risk-22/NN||this-21/DT	dobj||increasing-20/VBG||risk-22/NN	irondeficiency-2||iron-5||yes||nutritional irondeficiency may limit iron availability to the malaria parasite reducing infection risk, and/or impair host immunity thereby increasing this risk.
nsubj||study-5/NN||this-1/DT	cop||study-5/NN||was-2/VBD	det||study-5/NN||a-3/DT	amod||study-5/NN||prospective-4/JJ	root||ROOT-0/null||study-5/NN	prep_of||study-5/NN||patients-7/NNS	nn||iiib-13/NN||type2diabetes-9/NN	conj_and||type2diabetes-9/NN||ckd-11/NN	nn||iiib-13/NN||ckd-11/NN	nn||iiib-13/NN||stage-12/NN	prep_with||patients-7/NNS||iiib-13/NN	prep_of||study-5/NN||iv-15/NN	conj_or||patients-7/NNS||iv-15/NN	vmod||iv-15/NN||undergoing-16/VBG	amod||iron-18/NN||intravenous-17/JJ	dobj||undergoing-16/VBG||iron-18/NN	dep||iron-18/NN||group-20/NN	dep||group-20/NN||a-21/DT	vmod||iron-18/NN||and/or-23/VBG	dobj||and/or-23/VBG||esa-24/NN	appos||iron-18/NN||groupb-26/NN	groupb-26||iron-18||no_rel||this was a prospective study of patients with type2diabetes and ckd stage iiib or iv undergoing intravenous iron (group a) and/or esa (groupb).
mark||prevalent-5/JJ||while-1/IN	nsubj||prevalent-5/JJ||jcvirus-2/NNS	cop||prevalent-5/JJ||is-3/VBZ	advmod||prevalent-5/JJ||highly-4/RB	advcl||disease-15/NN||prevalent-5/JJ	det||population-9/NN||the-7/DT	amod||population-9/NN||human-8/JJ	prep_in||prevalent-5/JJ||population-9/NN	nsubj||disease-15/NN||pml-11/NN	cop||disease-15/NN||is-12/VBZ	det||disease-15/NN||a-13/DT	amod||disease-15/NN||rare-14/JJ	root||ROOT-0/null||disease-15/NN	nsubj||afflicts-18/VBZ||disease-15/NN	advmod||afflicts-18/VBZ||exclusively-17/RB	rcmod||disease-15/NN||afflicts-18/VBZ	advmod||percentage-22/NN||only-19/RB	det||percentage-22/NN||a-20/DT	amod||percentage-22/NN||small-21/JJ	dobj||afflicts-18/VBZ||percentage-22/NN	amod||individuals-25/NNS||immunocompromised-24/JJ	prep_of||percentage-22/NN||individuals-25/NNS	prep_including||individuals-25/NNS||those-27/DT	vmod||those-27/DT||affected-28/VBN	amod||aids-32/NNS||hiv-30/JJ	agent||affected-28/VBN||aids-32/NNS	amod||drugs-36/NNS||immunosuppressive-35/JJ	agent||affected-28/VBN||drugs-36/NNS	conj_or||aids-32/NNS||drugs-36/NNS	aids-32||hiv-30||no||while jcvirus is highly prevalent in the human population, pml is a rare disease that exclusively afflicts only a small percentage of immunocompromised individuals including those affected by hiv (aids) or immunosuppressive drugs.
det||study-9/NN||this-1/DT	amod||study-9/NN||prospective-2/JJ	amod||study-9/NN||6-week-4/JJ	amod||study-9/NN||multicenter-6/JJ	amod||study-9/NN||double-blind-8/JJ	nsubj||compared-22/VBD||study-9/NN	vmod||study-9/NN||examined-10/VBN	det||benefits-12/NNS||the-11/DT	dobj||examined-10/VBN||benefits-12/NNS	prepc_of||benefits-12/NNS||initiating-14/VBG	dobj||initiating-14/VBG||treatment-15/NN	nn||valsartan/hydrochlorothiazide-18/NN||combination-17/NN	prep_with||initiating-14/VBG||valsartan/hydrochlorothiazide-18/NN	appos||study-9/NN||hctz-20/NNP	root||ROOT-0/null||compared-22/VBD	amod||monotherapy-26/NN||initial-24/JJ	nn||monotherapy-26/NN||valsartan-25/NN	prep_with||compared-22/VBD||monotherapy-26/NN	num||patients-29/NNS||648-28/CD	prep_for||monotherapy-26/NN||patients-29/NNS	amod||hypertension-34/NN||stage-1-31/JJ	conj_or||stage-1-31/JJ||stage-2-33/JJ	amod||hypertension-34/NN||stage-2-33/JJ	prep_with||compared-22/VBD||hypertension-34/NN	dep||hypertension-34/NN||age-36/NN	dep||years-42/NNS||=-37/SYM	num||years-42/NNS||52.6-38/CD	nn||years-42/NNS||â-39/NNP	nn||years-42/NNS||±-40/NNP	num||years-42/NNS||10-41/CD	rcmod||age-36/NN||years-42/NNS	num||%-45/NN||54-44/CD	dep||age-36/NN||%-45/NN	dep||%-45/NN||male-46/NN	nn||blood-49/NN||baseline-48/NN	dep||age-36/NN||blood-49/NN	rcmod||blood-49/NN||pressure-50/NN	dep||pressure-50/NN||bp-52/NN	amod||stage-66/NN||=-54/JJ	dep||=-54/JJ||161/98-55/CD	amod||stage-66/NN||â-56/JJ	amod||stage-66/NN||$-57/$	dep||$-57/$||-58/JJ	amod||stage-66/NN||mmâ-59/JJ	amod||stage-66/NN||$-60/$	number||hg-62/CD||-61/CD	num||$-60/$||hg-62/CD	number||%-65/NN||32-64/CD	amod||stage-66/NN||%-65/NN	dobj||pressure-50/NN||stage-66/NN	dep||age-36/NN||1-67/CD	hypertension-34||hctz-20||yes||this prospective, 6-week, multicenter, double-blind study examined the benefits of initiating treatment with combination valsartan/hydrochlorothiazide (hctz) compared with initial valsartan monotherapy for 648 patients with stage-1 or stage-2 hypertension (age=52.6â±10 years; 54% male; baseline blood pressure (bp)=161/98âmmâhg, 32% stage 1).
advmod||occurs-6/VBZ||however-1/RB	amod||pancreatitis-4/NNS||severe-3/JJ	nsubj||occurs-6/VBZ||pancreatitis-4/NNS	advmod||occurs-6/VBZ||sometimes-5/RB	root||ROOT-0/null||occurs-6/VBZ	prep_in||occurs-6/VBZ||patients-8/NNS	vmod||patients-8/NNS||receiving-9/VBG	dobj||receiving-9/VBG||asnase-10/NN	det||mechanism-16/NN||an-14/DT	amod||mechanism-16/NN||unknown-15/JJ	prep_because_of||asnase-10/NN||mechanism-16/NN	pancreatitis-4||asnase-10||no||however, severe pancreatitis sometimes occurs in patients receiving asnase, because of an unknown mechanism.
amod||studies-2/NNS||previous-1/JJ	nsubj||shown-4/VBN||studies-2/NNS	aux||shown-4/VBN||have-3/VBP	root||ROOT-0/null||shown-4/VBN	mark||exhibit-10/VB||that-5/IN	nsubj||exhibit-10/VB||geminiviruses-6/NNS	nn||viruses-9/NNS||rna-8/NN	conj_and||geminiviruses-6/NNS||viruses-9/NNS	nsubj||exhibit-10/VB||viruses-9/NNS	ccomp||shown-4/VBN||exhibit-10/VB	amod||frequencies-13/NNS||similar-11/JJ	nn||frequencies-13/NNS||mutation-12/NN	dobj||exhibit-10/VB||frequencies-13/NNS	mark||replicated-18/VBN||although-15/IN	nsubjpass||replicated-18/VBN||geminiviruses-16/NNS	auxpass||replicated-18/VBN||are-17/VBP	advcl||shown-4/VBN||replicated-18/VBN	nn||polymerases-22/NNS||host-20/NN	nn||polymerases-22/NNS||dna-21/NN	agent||replicated-18/VBN||polymerases-22/NNS	nn||viruses-25/NNS||rna-24/NN	agent||replicated-18/VBN||viruses-25/NNS	conj_and||polymerases-22/NNS||viruses-25/NNS	poss||rna-polymerase-32/NN||their-27/PRP$	amod||rna-polymerase-32/NN||own-28/JJ	amod||rna-polymerase-32/NN||virus-encoded-29/JJ	amod||rna-polymerase-32/NN||error-prone-30/JJ	amod||rna-polymerase-32/NN||rna-dependent-31/JJ	agent||replicated-18/VBN||rna-polymerase-32/NN	virus--1||viruses-25||no||previous studies have shown that geminiviruses and rna viruses exhibit similar mutation frequencies, although geminiviruses are replicated by host dna polymerases and rna viruses by their own virus-encoded error-prone rna-dependent rna-polymerase.
nsubj||recruited-2/VBD||we-1/PRP	root||ROOT-0/null||recruited-2/VBD	num||patients-4/NNS||25-3/CD	dobj||recruited-2/VBD||patients-4/NNS	prep_with||recruited-2/VBD||type1diabetes-6/NNS	dep||type1diabetes-6/NNS||mean-8/VB	nn||â-11/NN||age-9/NN	num||â-11/NN||51-10/CD	dobj||mean-8/VB||â-11/NN	number||10-13/CD||±-12/CD	num||years-14/NNS||10-13/CD	tmod||mean-8/VB||years-14/NNS	dep||mean-8/VB||mean-16/VB	nn||duration-18/NN||disease-17/NN	dobj||mean-16/VB||duration-18/NN	num||years-23/NNS||26-19/CD	nn||years-23/NNS||â-20/NNP	nn||years-23/NNS||±-21/NNP	num||years-23/NNS||13-22/CD	tmod||mean-8/VB||years-23/NNS	num||type-28/NN||31-26/CD	amod||type-28/NN||insulin-treated-27/JJ	prep_with||recruited-2/VBD||type-28/NN	conj_and||type1diabetes-6/NNS||type-28/NN	num||patients-31/NNS||2-29/CD	amod||patients-31/NNS||diabetic-30/JJ	dep||type-28/NN||patients-31/NNS	dep||type-28/NN||mean-33/VB	nn||â-36/NN||age-34/NN	num||â-36/NN||66-35/CD	dobj||mean-33/VB||â-36/NN	number||8-38/CD||±-37/CD	num||years-39/NNS||8-38/CD	tmod||mean-33/VB||years-39/NNS	dep||mean-33/VB||mean-41/VB	nn||duration-43/NN||disease-42/NN	dobj||mean-41/VB||duration-43/NN	num||years-48/NNS||19-44/CD	nn||years-48/NNS||â-45/NNP	nn||years-48/NNS||±-46/NNP	num||years-48/NNS||9-47/CD	tmod||mean-33/VB||years-48/NNS	nsubj||received-52/VBD||who-51/WP	nsubj||sitagliptin-69/VBN||who-51/WP	prep_with||recruited-2/VBD||received-52/VBD	conj_and||type1diabetes-6/NNS||received-52/VBD	dobj||received-52/VBD||sitagliptin-53/NN	prep_with||received-52/VBD||metformin-55/NN	det||combination-59/NN||a-57/DT	amod||combination-59/NN||fixed-dose-58/JJ	prep_as||metformin-55/NN||combination-59/NN	num||mg-62/NN||50/1000-61/CD	npadvmod||once-63/RB||mg-62/NN	dep||received-52/VBD||once-63/RB	advmod||daily-66/JJ||twice-65/RB	dep||received-52/VBD||daily-66/JJ	conj_or||once-63/RB||daily-66/JJ	conj_and||type1diabetes-6/NNS||sitagliptin-69/VBN	conj_or||received-52/VBD||sitagliptin-69/VBN	nsubj||mg-72/VBP||100-71/CD	parataxis||sitagliptin-69/VBN||mg-72/VBP	advmod||mg-72/VBP||once-73/RB	advmod||mg-72/VBP||daily-74/RB	mark||metformin-79/VB||if-76/IN	nsubj||metformin-79/VB||intolerant-77/NN	aux||metformin-79/VB||to-78/TO	advcl||mg-72/VBP||metformin-79/VB	xcomp||mg-72/VBP||metformin-79/VB	amod||therapy-86/NN||ongoing-84/JJ	nn||therapy-86/NN||insulin-85/NN	prep_in_addition_to||sitagliptin-69/VBN||therapy-86/NN	num||â-89/NN||46-88/CD	prep_for||therapy-86/NN||â-89/NN	number||19-91/CD||±-90/CD	num||weeks-92/NNS||19-91/CD	dobj||sitagliptin-69/VBN||weeks-92/NNS	num||±-96/NNS||56-94/CD	nn||±-96/NNS||â-95/NN	dobj||sitagliptin-69/VBN||±-96/NNS	conj_and||weeks-92/NNS||±-96/NNS	num||weeks-98/NNS||14-97/CD	dep||±-96/NNS||weeks-98/NNS	advmod||±-96/NNS||respectively-100/RB	type1diabetes-6||sitagliptin-69||no||we recruited 25 patients with type1diabetes (mean age 51 â± 10 years, mean disease duration 26 â± 13 years) and 31 insulin-treated type 2 diabetic patients (mean age 66 â± 8 years, mean disease duration 19 â± 9 years), who received sitagliptin with metformin as a fixed-dose combination (50/1000 mg once or twice daily) or sitagliptin (100 mg once daily, if intolerant to metformin) in addition to ongoing insulin therapy for 46 â± 19 weeks and 56 â± 14 weeks, respectively.
det||purpose-2/NN||the-1/DT	nsubj||was-8/VBD||purpose-2/NN	nsubj||evaluate-10/VB||purpose-2/NN	det||study-7/NN||this-4/DT	nn||study-7/NN||multicenter-5/NN	nn||study-7/NN||spanish-6/NN	prep_of||purpose-2/NN||study-7/NN	root||ROOT-0/null||was-8/VBD	aux||evaluate-10/VB||to-9/TO	xcomp||was-8/VBD||evaluate-10/VB	det||response-12/NN||the-11/DT	dobj||evaluate-10/VB||response-12/NN	amod||methylphenidate-15/NN||immediate-release-14/JJ	prep_to||evaluate-10/VB||methylphenidate-15/NN	prep_by||evaluate-10/VB||children-17/NNS	prep_by||evaluate-10/VB||adults-19/NNS	conj_and||children-17/NNS||adults-19/NNS	vmod||children-17/NNS||diagnosed-20/VBN	prep_with||diagnosed-20/VBN||attention-deficit/hyperactivitydisorder-22/NN	dep||attention-deficit/hyperactivitydisorder-22/NN||adhd-24/VBN	aux||obtain-31/VB||to-30/TO	prep_by||evaluate-10/VB||obtain-31/VB	conj_and||children-17/NNS||obtain-31/VB	vmod||children-17/NNS||obtain-31/VB	dobj||obtain-31/VB||information-32/NN	amod||patterns-36/NNS||current-34/JJ	nn||patterns-36/NNS||therapy-35/NN	prep_on||obtain-31/VB||patterns-36/NNS	nn||characteristics-39/NNS||safety-38/NN	prep_on||obtain-31/VB||characteristics-39/NNS	conj_and||patterns-36/NNS||characteristics-39/NNS	hyperactivitydisorder--1||methylphenidate-15||yes||the purpose of this multicenter spanish study was to evaluate the response to immediate-release methylphenidate by children and adults diagnosed with attention-deficit/hyperactivitydisorder (adhd), as well as to obtain information on current therapy patterns and safety characteristics.
nsubj||reported-3/VBD||we-1/PRP	advmod||reported-3/VBD||earlier-2/RB	root||ROOT-0/null||reported-3/VBD	mark||resulted-20/VBD||that-4/IN	nsubj||resulted-20/VBD||treatment-5/NN	amod||cultures-8/NNS||astrocyte-7/JJ	prep_of||treatment-5/NN||cultures-8/NNS	det||concentration-12/NN||a-10/DT	amod||concentration-12/NN||pathophysiological-11/JJ	prep_with||cultures-8/NNS||concentration-12/NN	prep_of||concentration-12/NN||ammonia-14/NN	num||nh4cl-18/NNS||5-16/CD	nn||nh4cl-18/NNS||mm-17/NNP	appos||ammonia-14/NN||nh4cl-18/NNS	ccomp||reported-3/VBD||resulted-20/VBD	det||activation-23/NN||the-22/DT	prep_in||resulted-20/VBD||activation-23/NN	amod||factor-kappab-26/NN||nuclear-25/JJ	prep_of||activation-23/NN||factor-kappab-26/NN	appos||factor-kappab-26/NN||nf-îºb-28/NNP	mark||diminished-36/VBN||that-31/IN	nsubj||diminished-36/VBN||inhibition-32/NN	amod||activation-35/NN||such-34/JJ	prep_of||inhibition-32/NN||activation-35/NN	ccomp||reported-3/VBD||diminished-36/VBN	conj_and||resulted-20/VBD||diminished-36/VBN	dobj||diminished-36/VBN||astrocyte-37/NN	amod||astrocyte-37/NN||swelling-38/VBG	vmod||diminished-36/VBN||suggesting-40/VBG	det||role-43/NN||a-41/DT	amod||role-43/NN||key-42/JJ	dobj||suggesting-40/VBG||role-43/NN	prep_of||role-43/NN||nf-îºb-45/NN	det||mechanism-48/NN||the-47/DT	prep_in||suggesting-40/VBG||mechanism-48/NN	amod||astrocyte-51/NN||ammonia-induced-50/JJ	prep_of||mechanism-48/NN||astrocyte-51/NN	amod||astrocyte-51/NN||swelling-52/VBG	ammonia-14||swelling-52||no_rel||we earlier reported that treatment of astrocyte cultures with a pathophysiological concentration of ammonia (5 mm nh4cl) resulted in the activation of nuclear factor-kappab (nf-îºb) and that inhibition of such activation diminished astrocyte swelling, suggesting a key role of nf-îºb in the mechanism of ammonia-induced astrocyte swelling.
amod||events-2/NNS||clinical-1/JJ	nsubjpass||recorded-20/VBN||events-2/NNS	advmod||preceding-4/VBG||immediately-3/RB	amod||events-2/NNS||preceding-4/VBG	amod||events-2/NNS||concurrent-6/JJ	conj_or||preceding-4/VBG||concurrent-6/JJ	det||episode-9/NN||each-8/DT	prep_with||concurrent-6/JJ||episode-9/NN	prep_of||episode-9/NN||hypoglycaemia-11/NN	dep||episode-9/NN||glucose-13/NN	vmod||glucose-13/NN||<-14/VBN	dep||mmol/l-17/NN||=-15/SYM	num||mmol/l-17/NN||3.0-16/CD	ccomp||<-14/VBN||mmol/l-17/NN	auxpass||recorded-20/VBN||were-19/VBD	root||ROOT-0/null||recorded-20/VBN	hypoglycaemia-11||glucose-13||yes||clinical events immediately preceding or concurrent with each episode of hypoglycaemia (glucose < = 3.0 mmol/l) were recorded.
det||dacarbazine-4/NN||the-1/DT	amod||dacarbazine-4/NN||alkylating-2/JJ	nn||dacarbazine-4/NN||agent-3/NN	nsubjpass||used-10/VBN||dacarbazine-4/NN	dep||dacarbazine-4/NN||dtic-6/JJ	aux||used-10/VBN||has-8/VBZ	auxpass||used-10/VBN||been-9/VBN	root||ROOT-0/null||used-10/VBN	det||treatment-13/NN||the-12/DT	prep_in||used-10/VBN||treatment-13/NN	prep_of||treatment-13/NN||melanoma-15/NN	prep_for||melanoma-15/NN||decades-17/NNS	advmod||used-21/VBN||when-20/WRB	advcl||achieved-32/VBN||used-21/VBN	det||monotherapy-24/NN||a-23/DT	prep_as||used-21/VBN||monotherapy-24/NN	prep_for||monotherapy-24/NN||cancer-26/NN	advmod||achieved-32/VBN||only-27/RB	amod||rates-30/NNS||moderate-28/JJ	nn||rates-30/NNS||response-29/NN	nsubjpass||achieved-32/VBN||rates-30/NNS	auxpass||achieved-32/VBN||are-31/VBP	conj_but||used-10/VBN||achieved-32/VBN	melanoma-15||dtic-6||yes||the alkylating agent dacarbazine (dtic) has been used in the treatment of melanoma for decades, but when used as a monotherapy for cancer only moderate response rates are achieved.
nsubj||one-11/CD||tb-1/NN	vmod||tb-1/NN||caused-3/VBN	agent||caused-3/VBN||mycobacteriumtuberculosis-5/NNS	appos||mycobacteriumtuberculosis-5/NNS||mtb-7/NN	cop||one-11/CD||is-10/VBZ	root||ROOT-0/null||one-11/CD	det||diseases-17/NNS||the-13/DT	amod||diseases-17/NNS||major-14/JJ	amod||diseases-17/NNS||global-15/JJ	amod||diseases-17/NNS||infectious-16/JJ	prep_of||one-11/CD||diseases-17/NNS	tb-1||mtb-7||no||tb, caused by mycobacteriumtuberculosis (mtb), is one of the major global infectious diseases.
det||extract-4/NN||the-1/DT	amod||extract-4/NN||crude-2/JJ	amod||extract-4/NN||aqueous-methanolic-3/JJ	nsubjpass||studied-13/VBN||extract-4/NN	nn||rhizome-8/NN||valeriana-6/NN	nn||rhizome-8/NN||hardwickii-7/NN	prep_of||extract-4/NN||rhizome-8/NN	appos||rhizome-8/NN||vh.cr-10/NN	auxpass||studied-13/VBN||was-12/VBD	root||ROOT-0/null||studied-13/VBN	amod||jejunum-17/NN||isolated-15/JJ	nn||jejunum-17/NN||rabbit-16/NN	prep_on||studied-13/VBN||jejunum-17/NN	amod||diarrhea-20/NN||castoroil-induced-19/JJ	prep_on||studied-13/VBN||diarrhea-20/NN	conj_and||jejunum-17/NN||diarrhea-20/NN	prep_in||jejunum-17/NN||mice-22/NNS	amod||properties-27/NNS||spasmolytic-24/JJ	conj_and||spasmolytic-24/JJ||antidiarrheal-26/JJ	amod||properties-27/NNS||antidiarrheal-26/JJ	prep_for||mice-22/NNS||properties-27/NNS	advmod||studied-13/VBN||respectively-29/RB	diarrhea-20||castoroil--1||no||the crude aqueous-methanolic extract of valeriana hardwickii rhizome (vh.cr) was studied on isolated rabbit jejunum and castoroil-induced diarrhea in mice for spasmolytic and antidiarrheal properties, respectively.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubj||suggests-4/VBZ||study-3/NN	root||ROOT-0/null||suggests-4/VBZ	expl||are-6/VBP||there-5/EX	ccomp||suggests-4/VBZ||are-6/VBP	neg||differences-8/NNS||no-7/DT	nsubj||are-6/VBP||differences-8/NNS	prep_in||differences-8/NNS||terms-10/NNS	amod||performance-13/NN||cardiopulmonary-12/JJ	prep_of||terms-10/NNS||performance-13/NN	amod||transport-17/NN||global-15/JJ	nn||transport-17/NN||oxygen-16/NN	nsubj||are-6/VBP||transport-17/NN	conj_and||differences-8/NNS||transport-17/NN	amod||hemodynamics-21/NNS||regional-20/JJ	nsubj||are-6/VBP||hemodynamics-21/NNS	conj_and||differences-8/NNS||hemodynamics-21/NNS	tmod||administered-25/VBN||hemodynamics-21/NNS	advmod||administered-25/VBN||when-22/WRB	nsubjpass||administered-25/VBN||phenylephrine-23/NN	auxpass||administered-25/VBN||was-24/VBD	rcmod||hemodynamics-21/NNS||administered-25/VBN	prep_instead_of||administered-25/VBN||norepinephrine-28/NN	det||support-33/NN||the-30/DT	amod||support-33/NN||initial-31/JJ	amod||support-33/NN||hemodynamic-32/JJ	prep_in||norepinephrine-28/NN||support-33/NN	prep_of||support-33/NN||septicshock-35/NN	septicshock-35||phenylephrine-23||yes||the present study suggests there are no differences in terms of cardiopulmonary performance, global oxygen transport, and regional hemodynamics when phenylephrine was administered instead of norepinephrine in the initial hemodynamic support of septicshock.
root||ROOT-0/null||delayed-1/VBN	nn||results-4/NNS||insulin-2/NN	nn||results-4/NNS||secretion-3/NN	dobj||delayed-1/VBN||results-4/NNS	amod||concentrations-9/NNS||higher-6/JJR	nn||concentrations-9/NNS||peak-7/NN	nn||concentrations-9/NNS||glucose-8/NN	prep_in||results-4/NNS||concentrations-9/NNS	advmod||delayed-1/VBN||particularly-10/RB	advmod||impaired-16/JJ||when-11/WRB	nsubj||impaired-16/JJ||suppression-12/NN	prep_of||suppression-12/NN||glucagon-14/NN	cop||impaired-16/JJ||is-15/VBZ	advcl||delayed-1/VBN||impaired-16/JJ	mark||insulinresistance-19/JJ||whereas-18/IN	advcl||impaired-16/JJ||insulinresistance-19/JJ	dep||delayed-1/VBN||prolongs-20/VBZ	det||duration-22/NN||the-21/DT	nsubj||delayed-1/VBN||duration-22/NN	nsubjpass||marked-29/VBN||duration-22/NN	prep_of||duration-22/NN||hyperglycemia-24/NN	aux||marked-29/VBN||can-27/MD	auxpass||marked-29/VBN||be-28/VB	rcmod||duration-22/NN||marked-29/VBN	advmod||present-37/JJ||when-30/WRB	det||insulinresistance-35/NN||both-31/DT	amod||insulinresistance-35/NN||hepatic-32/JJ	conj_and||hepatic-32/JJ||extra-hepatic-34/JJ	amod||insulinresistance-35/NN||extra-hepatic-34/JJ	nsubj||present-37/JJ||insulinresistance-35/NN	cop||present-37/JJ||are-36/VBP	advcl||marked-29/VBN||present-37/JJ	glucagon-14||hyperglycemia-24||no_rel||delayed insulin secretion results in higher peak glucose concentrations particularly when suppression of glucagon is impaired, whereas insulinresistance prolongs the duration of hyperglycemia, which can be marked when both hepatic and extra-hepatic insulinresistance are present.
nsubj||inducer-15/NN||rifampicin-1/NN	det||component-5/NN||a-3/DT	amod||component-5/NN||critical-4/JJ	appos||rifampicin-1/NN||component-5/NN	nn||therapy-11/NN||tuberculosis-7/NNP	appos||therapy-11/NN||tb-9/NN	prep_of||component-5/NN||therapy-11/NN	cop||inducer-15/NN||is-12/VBZ	det||inducer-15/NN||a-13/DT	amod||inducer-15/NN||potent-14/JJ	root||ROOT-0/null||inducer-15/NN	nn||activity-19/NN||cyp-17/NN	nn||activity-19/NN||enzyme-18/NN	prep_of||inducer-15/NN||activity-19/NN	tb-9||rifampicin-1||yes||rifampicin, a critical component of tuberculosis (tb) therapy is a potent inducer of cyp enzyme activity.
nsubjpass||obtained-3/VBN||serum-1/NN	auxpass||obtained-3/VBN||was-2/VBD	root||ROOT-0/null||obtained-3/VBN	amod||intervals-6/NNS||weekly-5/JJ	prep_at||obtained-3/VBN||intervals-6/NNS	nn||samples-9/NNS||tissue-8/NN	nsubjpass||obtained-11/VBN||samples-9/NNS	auxpass||obtained-11/VBN||were-10/VBD	conj_and||obtained-3/VBN||obtained-11/VBN	det||end-14/NN||the-13/DT	prep_at||obtained-11/VBN||end-14/NN	prep_of||end-14/NN||supplementation-16/NN	aux||evaluate-20/VB||to-17/TO	dep||evaluate-20/VB||1-18/LS	vmod||end-14/NN||evaluate-20/VB	dobj||evaluate-20/VB||tocopherol-21/NN	xcomp||evaluate-20/VB||concentrations-22/VBG	prep_in||concentrations-22/VBG||serum-24/NN	prep_in||concentrations-22/VBG||uterus-26/NN	conj_and||serum-24/NN||uterus-26/NN	prep_in||concentrations-22/VBG||placentome-28/NN	conj_and||serum-24/NN||placentome-28/NN	dep||expressions-35/NNS||2-30/LS	amod||expressions-35/NNS||evaluate-32/JJ	amod||expressions-35/NNS||relative-33/JJ	nn||expressions-35/NNS||mrna-34/NN	dep||end-14/NN||expressions-35/NNS	amod||factor-40/NN||vascular-37/JJ	amod||factor-40/NN||endothelial-38/JJ	nn||factor-40/NN||growth-39/NN	prep_of||expressions-35/NNS||factor-40/NN	appos||factor-40/NN||vegf-42/NN	amod||factor-47/NN||placental-45/JJ	nn||factor-47/NN||growth-46/NN	appos||factor-40/NN||factor-47/NN	appos||factor-47/NN||plgf-49/NN	amod||synthase-54/NN||endothelial-52/JJ	nn||synthase-54/NN||nitricoxide-53/NN	appos||factor-40/NN||synthase-54/NN	dep||synthase-54/NN||enos-56/VBZ	nn||factors-61/NNS||hypoxia-59/NN	nn||factors-61/NNS||inducible-60/NN	prep_of||expressions-35/NNS||factors-61/NNS	conj_and||factor-40/NN||factors-61/NNS	appos||factors-61/NNS||hif-63/NN	prep_in||factors-61/NNS||uterus-66/NN	prep_in||factors-61/NNS||caruncle-68/NN	conj_and||uterus-66/NN||caruncle-68/NN	prep_in||factors-61/NNS||cotyledon-70/NN	conj_and||uterus-66/NN||cotyledon-70/NN	dep||morphometry-76/NN||3-72/LS	advmod||morphometry-76/NN||analyze-74/RB	det||morphometry-76/NN||the-75/DT	dep||end-14/NN||morphometry-76/NN	det||network-81/NN||the-78/DT	amod||network-81/NN||placental-79/JJ	nn||network-81/NN||vascular-80/NN	prep_of||morphometry-76/NN||network-81/NN	hypoxia-59||tocopherol-21||no_rel||serum was obtained at weekly intervals and tissue samples were obtained at the end of supplementation to 1) evaluate tocopherol concentrations in serum, uterus and placentome; 2) evaluate relative mrna expressions of vascular endothelial growth factor (vegf), placental growth factor (plgf), endothelial nitricoxide synthase (enos) and hypoxia inducible factors (hif) in uterus, caruncle and cotyledon; 3) analyze the morphometry of the placental vascular network.
nsubj||tool-5/NN||it-1/PRP	nsubj||serve-25/VB||it-1/PRP	cop||tool-5/NN||is-2/VBZ	det||tool-5/NN||a-3/DT	amod||tool-5/NN||powerful-4/JJ	root||ROOT-0/null||tool-5/NN	aux||support-7/VB||to-6/TO	vmod||tool-5/NN||support-7/VB	nn||making-9/NN||policy-8/NN	dobj||support-7/VB||making-9/NN	nn||evaluation-12/NN||program-11/NN	dobj||support-7/VB||evaluation-12/NN	conj_and||making-9/NN||evaluation-12/NN	dobj||support-7/VB||implementation-14/NN	conj_and||making-9/NN||implementation-14/NN	det||program-19/NN||the-16/DT	amod||program-19/NN||national-17/JJ	nn||program-19/NN||hiv/aids-18/NNS	prep_of||implementation-14/NN||program-19/NN	advmod||serve-25/VB||thus-22/RB	aux||serve-25/VB||may-24/MD	conj_and||tool-5/NN||serve-25/VB	det||model-27/NN||a-26/DT	dobj||serve-25/VB||model-27/NN	amod||countries-30/NNS||other-29/JJ	prep_for||model-27/NN||countries-30/NNS	aids--1||hiv--1||no||it is a powerful tool to support policy making, program evaluation and implementation of the national hiv/aids program and, thus, may serve a model for other countries.
vmod||found-12/VBD||using-1/VBG	amod||mice-4/NNS||athymic-2/JJ	amod||mice-4/NNS||nude-3/JJ	dobj||using-1/VBG||mice-4/NNS	det||model-9/NN||an-6/DT	advmod||model-9/NN||in-7/RB	amod||model-9/NN||vivo-8/JJ	prep_as||using-1/VBG||model-9/NN	nsubj||found-12/VBD||we-11/PRP	root||ROOT-0/null||found-12/VBD	mark||reduces-25/VBZ||that-13/IN	csubj||reduces-25/VBZ||feeding-14/VBG	iobj||feeding-14/VBG||animals-15/NNS	det||diet-20/NN||the-16/DT	number||%-18/NN||5-17/CD	amod||diet-20/NN||%-18/NN	amod||diet-20/NN||fishoil-supplemented-19/JJ	dobj||feeding-14/VBG||diet-20/NN	num||weeks-23/NNS||6-22/CD	prep_for||diet-20/NN||weeks-23/NNS	advmod||reduces-25/VBZ||significantly-24/RB	ccomp||found-12/VBD||reduces-25/VBZ	det||growth-27/NN||the-26/DT	dobj||reduces-25/VBZ||growth-27/NN	amod||cells-33/NNS||mcf-7-29/JJ	amod||cells-33/NNS||human-30/JJ	nn||cells-33/NNS||breast-31/NN	nn||cells-33/NNS||cancer-32/NN	prep_of||growth-27/NN||cells-33/NNS	prep_in||growth-27/NN||vivo-35/NN	prep_through||reduces-25/VBZ||inhibition-37/NN	nn||proliferation-41/NN||cancer-39/NN	nn||proliferation-41/NN||cell-40/NN	prep_of||inhibition-37/NN||proliferation-41/NN	prep_through||reduces-25/VBZ||promotion-45/NN	conj_and||inhibition-37/NN||promotion-45/NN	nn||death-48/NN||cell-47/NN	prep_of||promotion-45/NN||death-48/NN	fishoil--1||cancer-39||no_rel||using athymic nude mice as an in vivo model, we found that feeding animals the 5% fishoil-supplemented diet for 6 weeks significantly reduces the growth of mcf-7 human breast cancer cells in vivo through inhibition of cancer cell proliferation as well as promotion of cell death.
nsubj||taking-3/VBG||he-1/PRP	aux||taking-3/VBG||was-2/VBD	root||ROOT-0/null||taking-3/VBG	amod||mg-6/NN||atenolol-4/JJ	dep||atenolol-4/JJ||100-5/CD	dobj||taking-3/VBG||mg-6/NN	punct||day-8/NN||/-7/:	dep||mg-6/NN||day-8/NN	appos||day-8/NN||amlodipine-10/NN	num||amlodipine-10/NN||10-11/CD	advmod||taking-3/VBG||mg/day-12/RB	det||combination-16/NN||a-15/DT	nsubj||mg/hydrochlorothiazide-20/VBP||combination-16/NN	nsubj||experienced-25/VBD||combination-16/NN	amod||20-19/CD||lisinopril-18/JJ	prep_of||combination-16/NN||20-19/CD	conj_and||taking-3/VBG||mg/hydrochlorothiazide-20/VBP	num||mg-22/NN||12.5-21/CD	dobj||mg/hydrochlorothiazide-20/VBP||mg-22/NN	advmod||mg/hydrochlorothiazide-20/VBP||daily-23/RB	conj_and||taking-3/VBG||experienced-25/VBD	conj_but||mg/hydrochlorothiazide-20/VBP||experienced-25/VBD	amod||peaks-28/NNS||several-26/JJ	nn||peaks-28/NNS||hypertension-27/NN	dobj||experienced-25/VBD||peaks-28/NNS	dobj||experienced-25/VBD||hypotension-30/NN	conj_and||peaks-28/NNS||hypotension-30/NN	hypertension-27||amlodipine-10||yes||he was taking atenolol 100 mg /day, amlodipine 10 mg/day, and a combination of lisinopril 20 mg/hydrochlorothiazide 12.5 mg daily but experienced several hypertension peaks and hypotension.
nsubj||appears-3/VBZ||hypersensitivity-1/NN	advmod||appears-3/VBZ||usually-2/RB	root||ROOT-0/null||appears-3/VBZ	amod||infusions-6/NNS||multiple-5/JJ	prep_after||appears-3/VBZ||infusions-6/NNS	xcomp||appears-3/VBZ||suggesting-8/VBG	nn||allergicreactions-11/NNS||type-9/NN	nn||allergicreactions-11/NNS||i-10/NN	dobj||suggesting-8/VBG||allergicreactions-11/NNS	advmod||seem-20/VBP||however-13/RB	amod||types-16/NNS||other-15/JJ	nsubj||seem-20/VBP||types-16/NNS	nsubjpass||implicated-23/VBN||types-16/NNS	prep_of||types-16/NNS||hypersensitivity-18/NN	advmod||seem-20/VBP||also-19/RB	parataxis||appears-3/VBZ||seem-20/VBP	aux||implicated-23/VBN||to-21/TO	auxpass||implicated-23/VBN||be-22/VB	xcomp||seem-20/VBP||implicated-23/VBN	allergicreactions-11||hypersensitivity-18||no||hypersensitivity usually appears after multiple infusions, suggesting type i allergicreactions; however, other types of hypersensitivity also seem to be implicated.
amod||-rrb--6/NN||methicillin-1/JJ	amod||s.aureus-3/JJ||resistant-2/JJ	amod||-rrb--6/NN||s.aureus-3/JJ	nn||-rrb--6/NN||-lrb--4/NN	nn||-rrb--6/NN||mrsa-5/NN	nsubj||multi-resistant-11/JJ||-rrb--6/NN	nsubj||challenge-19/NN||-rrb--6/NN	cop||multi-resistant-11/JJ||is-9/VBZ	advmod||multi-resistant-11/JJ||usually-10/RB	rcmod||-rrb--6/NN||multi-resistant-11/JJ	prep_in||multi-resistant-11/JJ||hospitals-13/NNS	aux||challenge-19/NN||has-15/VBZ	cop||challenge-19/NN||been-16/VBN	det||challenge-19/NN||a-17/DT	amod||challenge-19/NN||daunting-18/JJ	root||ROOT-0/null||challenge-19/NN	prep_for||challenge-19/NN||clinicians-21/NNS	quantmod||half-25/PDT||more-23/JJR	quantmod||half-25/PDT||than-24/IN	prep_for||clinicians-21/NNS||half-25/PDT	det||century-27/NN||a-26/DT	dep||challenge-19/NN||century-27/NN	mrsa-5||s.aureus-3||no||methicillin resistant s.aureus -lrb- mrsa -rrb- , which is usually multi-resistant in hospitals , has been a daunting challenge for clinicians for more than half a century .
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	det||case-4/NN||a-3/DT	dobj||present-2/VBP||case-4/NN	amod||colitis-7/NNS||mycophenolatemofetil-6/JJ	prep_of||case-4/NN||colitis-7/NNS	vmod||colitis-7/NNS||mimicking-8/VBG	nn||gvhd-11/NN||grade-9/FW	nn||gvhd-11/NN||i-10/FW	dobj||mimicking-8/VBG||gvhd-11/NN	det||gut-14/NN||the-13/DT	prep_of||gvhd-11/NN||gut-14/NN	gvhd-11||mycophenolatemofetil-6||yes||we present a case of mycophenolatemofetil colitis mimicking grade i gvhd of the gut.
nsubjpass||optimized-32/VBN||proportions-1/NNS	num||enzymes-6/NNS||six-3/CD	amod||enzymes-6/NNS||core-4/JJ	amod||enzymes-6/NNS||fungal-5/JJ	prep_of||proportions-1/NNS||enzymes-6/NNS	nn||²-15/NNPS||cbh1-8/NNPS	dep||²-15/NNPS||cbh2-10/NNPS	dep||²-15/NNPS||eg1-12/NNPS	dep||²-15/NNPS||î-14/NNP	dep||enzymes-6/NNS||²-15/NNPS	dep||²-15/NNPS||glucosidase-17/NN	det||xylosidase-29/NN||a-19/DT	amod||xylosidase-29/NN||gh10-20/JJ	advmod||1,4-xylanase-23/JJ||endo-î-21/RB	advmod||1,4-xylanase-23/JJ||²-22/RB	amod||xylosidase-29/NN||1,4-xylanase-23/JJ	advmod||²-27/JJ||î-26/RB	conj_and||1,4-xylanase-23/JJ||²-27/JJ	amod||xylosidase-29/NN||²-27/JJ	appos||glucosidase-17/NN||xylosidase-29/NN	auxpass||optimized-32/VBN||were-31/VBD	root||ROOT-0/null||optimized-32/VBN	det||loading-37/NN||a-34/DT	amod||loading-37/NN||fixed-35/VBN	nn||loading-37/NN||enzyme-36/NN	prep_at||optimized-32/VBN||loading-37/NN	num||glucan-41/NN||15-39/CD	amod||glucan-41/NN||mg/g-40/VBG	prep_of||loading-37/NN||glucan-41/NN	prep_for||glucan-41/NN||release-43/NN	prep_of||release-43/NN||glc-45/NN	prep_of||release-43/NN||xyl-47/NN	conj_and||glc-45/NN||xyl-47/NN	det||combinations-50/NNS||all-49/DT	prep_from||glucan-41/NN||combinations-50/NNS	num||feedstocks-54/NNS||five-52/CD	amod||feedstocks-54/NNS||biomass-53/JJ	prep_of||combinations-50/NNS||feedstocks-54/NNS	nn||stover-57/NN||corn-56/NN	nsubj||dried-63/VBD||stover-57/NN	appos||stover-57/NN||switchgrass-59/NNS	appos||switchgrass-59/NNS||miscanthus-61/NNS	dep||glucan-41/NN||dried-63/VBD	poss||grains-66/NNS||distillers-64/NNS	dobj||dried-63/VBD||grains-66/NNS	prep||grains-66/NNS||plus-67/CC	amod||-RSB--71/NNP||solubles-68/JJ	amod||-RSB--71/NNP||-LSB--69/VBG	nn||-RSB--71/NNP||ddgs-70/NNS	pobj||plus-67/CC||-RSB--71/NNP	pobj||plus-67/CC||poplar-73/NNP	conj_and||-RSB--71/NNP||poplar-73/NNP	vmod||glucan-41/NN||subjected-75/VBN	num||pretreatments-79/NNS||three-77/CD	amod||pretreatments-79/NNS||alkaline-78/JJ	prep_to||subjected-75/VBN||pretreatments-79/NNS	dep||pretreatments-79/NNS||afex-81/VB	dep||pretreatments-79/NNS||dilute-83/VB	conj_and||afex-81/VB||dilute-83/VB	amod||-RSB--89/NN||base-84/JJ	amod||-RSB--89/NN||-LSB--85/JJ	number||%-87/NN||0.25-86/CD	amod||-RSB--89/NN||%-87/NN	nn||-RSB--89/NN||naoh-88/NN	dobj||dilute-83/VB||-RSB--89/NN	dep||pretreatments-79/NNS||alkaline-91/VB	conj_and||afex-81/VB||alkaline-91/VB	amod||-RSB--95/NNS||peroxide-92/JJ	amod||-RSB--95/NNS||-LSB--93/JJ	nn||-RSB--95/NNS||ap-94/NN	dobj||alkaline-91/VB||-RSB--95/NNS	base-84||endo--1||no_rel||proportions of six core fungal enzymes (cbh1, cbh2, eg1, î²-glucosidase, a gh10 endo-î²1,4-xylanase, and î²-xylosidase) were optimized at a fixed enzyme loading of 15 mg/g glucan for release of glc and xyl from all combinations of five biomass feedstocks (corn stover, switchgrass, miscanthus , dried distillers' grains plus solubles [ddgs] and poplar) subjected to three alkaline pretreatments (afex, dilute base [0.25% naoh] and alkaline peroxide [ap]).
advmod||brought-13/VBD||moreover-1/RB	nsubj||brought-13/VBD||data-3/NNS	det||interaction-6/NN||the-5/DT	prep_on||data-3/NNS||interaction-6/NN	prep_of||interaction-6/NN||microbiota-8/NN	prep_with||microbiota-8/NN||food-10/NN	prep_with||microbiota-8/NN||obesity-12/NN	conj_and||food-10/NN||obesity-12/NN	root||ROOT-0/null||brought-13/VBD	amod||hypothesis-15/NNS||new-14/JJ	dobj||brought-13/VBD||hypothesis-15/NNS	det||relationship-20/NN||the-17/DT	amod||relationship-20/NN||obesity/fat-18/JJ	nn||relationship-20/NN||diet-19/NN	prep_for||brought-13/VBD||relationship-20/NN	prep_with||brought-13/VBD||inflammation-22/NN	obesity-12||fat--1||no_rel||moreover, data on the interaction of microbiota with food and obesity brought new hypothesis for the obesity/fat diet relationship with inflammation.
amod||rats-4/NNS||forty-two-1/JJ	amod||rats-4/NNS||male-2/JJ	amod||rats-4/NNS||sprague-dawley-3/JJ	nsubjpass||divided-7/VBN||rats-4/NNS	auxpass||divided-7/VBN||were-5/VBD	advmod||divided-7/VBN||equally-6/RB	root||ROOT-0/null||divided-7/VBN	num||groups-10/NNS||six-9/CD	prep_into||divided-7/VBN||groups-10/NNS	nn||i-12/NNS||group-11/NN	dep||groups-10/NNS||i-12/NNS	appos||i-12/NNS||control-14/NN	amod||chow-19/NN||normal-17/JJ	nn||chow-19/NN||rat-18/NN	dep||groups-10/NNS||chow-19/NN	nn||ii-22/NN||group-21/NN	appos||chow-19/NN||ii-22/NN	amod||oil-26/NN||fresh-24/JJ	nn||oil-26/NN||soy-25/NN	dep||groups-10/NNS||oil-26/NN	nn||iii-29/NN||group-28/NN	appos||oil-26/NN||iii-29/NN	nn||oil-32/NN||soy-31/NN	dep||groups-10/NNS||oil-32/NN	amod||oil-32/NN||heated-33/JJ	dep||heated-33/JJ||once-34/RB	nn||iv-37/NN||group-36/NN	appos||once-34/RB||iv-37/NN	nn||oil-40/NN||soy-39/NN	dep||groups-10/NNS||oil-40/NN	amod||twice-42/JJ||heated-41/JJ	amod||oil-40/NN||twice-42/JJ	nn||v-45/NN||group-44/NN	appos||oil-40/NN||v-45/NN	nn||oil-48/NN||soy-47/NN	dep||groups-10/NNS||oil-48/NN	amod||oil-48/NN||heated-49/JJ	num||times-51/NNS||five-50/CD	dep||heated-49/JJ||times-51/NNS	nn||vi-54/NN||group-53/NN	appos||times-51/NNS||vi-54/NN	nn||oil-57/NN||soy-56/NN	dep||groups-10/NNS||oil-57/NN	amod||oil-57/NN||heated-58/JJ	num||times-60/NNS||ten-59/CD	dep||groups-10/NNS||times-60/NNS	oil-57||ten-59||no_rel||forty-two male sprague-dawley rats were equally divided into six groups group i (control) - normal rat chow, group ii - fresh soy oil, group iii - soy oil heated once, group iv - soy oil heated twice, group v - soy oil heated five times, group vi - soy oil heated ten times.
mark||understand-4/VB||in-1/IN	dep||understand-4/VB||order-2/NN	aux||understand-4/VB||to-3/TO	advcl||analysed-27/VBD||understand-4/VB	mark||serve-9/VB||whether-5/IN	det||snp-7/NN||this-6/DT	nsubj||serve-9/VB||snp-7/NN	nsubj||evaluate-11/VB||snp-7/NN	aux||serve-9/VB||may-8/MD	ccomp||understand-4/VB||serve-9/VB	aux||evaluate-11/VB||to-10/TO	xcomp||serve-9/VB||evaluate-11/VB	det||contribution-13/NN||the-12/DT	dobj||evaluate-11/VB||contribution-13/NN	det||gene-17/NN||the-15/DT	amod||gene-17/NN||ccl2-16/JJ	prep_of||contribution-13/NN||gene-17/NN	det||expression-20/NN||the-19/DT	prep_to||evaluate-11/VB||expression-20/NN	nn||disease-23/NN||tb-22/NN	prep_of||expression-20/NN||disease-23/NN	nsubj||analysed-27/VBD||we-25/PRP	advmod||analysed-27/VBD||further-26/RB	root||ROOT-0/null||analysed-27/VBD	dobj||analysed-27/VBD||distribution-28/NN	poss||alleles-31/NNS||its-30/PRP$	prep_of||distribution-28/NN||alleles-31/NNS	prep_of||distribution-28/NN||genotypes-33/NNS	conj_and||alleles-31/NNS||genotypes-33/NNS	num||cases-37/NNS||301-35/CD	nn||cases-37/NNS||tb-36/NN	prep_in||analysed-27/VBD||cases-37/NNS	num||controls-41/NNS||338-39/CD	amod||controls-41/NNS||non-infected-40/JJ	prep_versus||cases-37/NNS||controls-41/NNS	det||bcg-44/NN||all-43/DT	dep||controls-41/NNS||bcg-44/NN	vmod||bcg-44/NN||vaccinated-45/VBN	vmod||controls-41/NNS||representing-47/VBG	det||population-51/NN||a-48/DT	amod||population-51/NN||high-risk-49/JJ	amod||population-51/NN||pediatric-50/JJ	dobj||representing-47/VBG||population-51/NN	nn||china-54/NN||north-53/NN	prep_of||population-51/NN||china-54/NN	tb-36||bcg-44||yes||in order to understand whether this snp may serve to evaluate the contribution of the ccl2 gene to the expression of tb disease, we further analysed distribution of its alleles and genotypes in 301 tb cases versus 338 non-infected controls (all bcg vaccinated) representing a high-risk pediatric population of north china.
amod||treatment-2/NN||adefovirdipivoxil-1/JJ	nsubj||improved-5/VBN||treatment-2/NN	aux||improved-5/VBN||has-3/VBZ	advmod||improved-5/VBN||significantly-4/RB	root||ROOT-0/null||improved-5/VBN	det||outcome-7/NN||the-6/DT	dobj||improved-5/VBN||outcome-7/NN	amod||infection-14/NN||chronichepatitisb-9/JJ	nn||infection-14/NN||virus-10/NN	appos||infection-14/NN||hbv-12/NN	prep_of||outcome-7/NN||infection-14/NN	hbv-12||adefovirdipivoxil-1||yes||adefovirdipivoxil treatment has significantly improved the outcome of chronichepatitisb virus (hbv) infection.
nn||necrosis-2/NNS||tumor-1/NN	nsubj||factor-î-3/VBD||necrosis-2/NNS	root||ROOT-0/null||factor-î-3/VBD	amod||treatment-5/NN||±-4/JJ	nsubj||decreased-9/VBD||treatment-5/NN	amod||adipocytes-8/NNS||3t3-l1-7/JJ	prep_of||treatment-5/NN||adipocytes-8/NNS	ccomp||factor-î-3/VBD||decreased-9/VBD	amod||expression-11/NN||gsta4-10/JJ	dobj||decreased-9/VBD||expression-11/NN	csubj||resulted-20/VBD||silencing-14/VBG	csubj||lipolysis-40/VBZ||silencing-14/VBG	amod||mrna-16/NN||gsta4-15/JJ	dobj||silencing-14/VBG||mrna-16/NN	amod||adipocytes-19/NNS||cultured-18/JJ	prep_in||silencing-14/VBG||adipocytes-19/NNS	conj_and||factor-î-3/VBD||resulted-20/VBD	amod||carbonylation-24/NN||increased-22/VBN	nn||carbonylation-24/NN||protein-23/NN	prep_in||resulted-20/VBD||carbonylation-24/NN	amod||ros-28/NN||increased-26/VBN	amod||ros-28/NN||mitochondrial-27/JJ	prep_in||resulted-20/VBD||ros-28/NN	conj_and||carbonylation-24/NN||ros-28/NN	amod||respiration-33/NNS||dysfunctional-30/JJ	nn||respiration-33/NNS||state-31/NN	num||respiration-33/NNS||3-32/CD	prep_in||resulted-20/VBD||respiration-33/NNS	conj_and||carbonylation-24/NN||respiration-33/NNS	amod||transport-38/NN||altered-36/VBN	nn||transport-38/NN||glucose-37/NN	prep_in||resulted-20/VBD||transport-38/NN	conj_and||carbonylation-24/NN||transport-38/NN	conj_and||factor-î-3/VBD||lipolysis-40/VBZ	conj_and||resulted-20/VBD||lipolysis-40/VBZ	tumor-1||glucose-37||no_rel||tumor necrosis factor-î± treatment of 3t3-l1 adipocytes decreased gsta4 expression, and silencing gsta4 mrna in cultured adipocytes resulted in increased protein carbonylation, increased mitochondrial ros, dysfunctional state 3 respiration, and altered glucose transport and lipolysis.
advmod||less-5/JJR||however-1/RB	nsubj||less-5/JJR||sodiumretention-3/NN	cop||less-5/JJR||is-4/VBZ	root||ROOT-0/null||less-5/JJR	advmod||restricted-15/VBN||when-6/WRB	csubjpass||restricted-15/VBN||given-7/VBN	amod||intake-12/NN||sodiumbicarbonate-9/JJ	conj_and||sodiumbicarbonate-9/JJ||sodiumchloride-11/JJ	amod||intake-12/NN||sodiumchloride-11/JJ	prep_as||given-7/VBN||intake-12/NN	auxpass||restricted-15/VBN||is-13/VBZ	advmod||restricted-15/VBN||concomitantly-14/RB	advcl||less-5/JJR||restricted-15/VBN	sodiumretention-3||sodiumchloride-11||no||however, sodiumretention is less when given as sodiumbicarbonate and sodiumchloride intake is concomitantly restricted.
advmod||added-2/VBD||when-1/WRB	advcl||demonstrates-15/VBZ||added-2/VBD	amod||agents-6/NNS||oral-4/JJ	amod||agents-6/NNS||anti-diabetes-5/JJ	prep_to||added-2/VBD||agents-6/NNS	appos||agents-6/NNS||oads-8/NNS	prep_in||added-2/VBD||type2diabetes-11/CD	nn||detemir-14/NN||insulin-13/NN	nsubj||demonstrates-15/VBZ||detemir-14/NN	root||ROOT-0/null||demonstrates-15/VBZ	dobj||demonstrates-15/VBZ||superiority-16/NN	amod||options-21/NNS||other-18/JJ	amod||options-21/NNS||basal-19/JJ	nn||options-21/NNS||insulin-20/NN	prep_to||demonstrates-15/VBZ||options-21/NNS	type2diabetes-11||insulin-20||yes||when added to oral anti-diabetes agents (oads) in type2diabetes, insulin detemir demonstrates superiority to other basal insulin options.
amod||analysis-2/NN||phylogenetic-1/JJ	nsubj||contributed-9/VBN||analysis-2/NN	nsubj||played-15/VBD||analysis-2/NN	amod||sequences-5/NNS||partial-4/JJ	prep_of||analysis-2/NN||sequences-5/NNS	prep_of||sequences-5/NNS||rubellaviruses-7/NNS	aux||contributed-9/VBN||has-8/VBZ	root||ROOT-0/null||contributed-9/VBN	nn||efforts-13/NNS||virus-11/NN	nn||efforts-13/NNS||surveillance-12/NN	prep_to||contributed-9/VBN||efforts-13/NNS	conj_and||contributed-9/VBN||played-15/VBD	det||role-18/NN||an-16/DT	amod||role-18/NN||important-17/JJ	dobj||played-15/VBD||role-18/NN	prepc_in||played-15/VBD||demonstrating-20/VBG	mark||eliminated-26/VBN||that-21/IN	nn||rubellaviruses-23/NNS||indigenous-22/NNS	nsubjpass||eliminated-26/VBN||rubellaviruses-23/NNS	aux||eliminated-26/VBN||have-24/VBP	auxpass||eliminated-26/VBN||been-25/VBN	ccomp||demonstrating-20/VBG||eliminated-26/VBN	det||states-30/NNS||the-28/DT	amod||states-30/NNS||united-29/VBN	prep_in||eliminated-26/VBN||states-30/NNS	virus-11||viruses--1||no||phylogenetic analysis of partial sequences of rubellaviruses has contributed to virus surveillance efforts and played an important role in demonstrating that indigenous rubellaviruses have been eliminated in the united states.
det||findings-2/NNS||the-1/DT	nsubj||show-3/VBP||findings-2/NNS	root||ROOT-0/null||show-3/VBP	dep||exposed-13/VBN||1-4/LS	neg||facility-8/NN||no-6/DT	nn||facility-8/NN||health-7/NN	nsubjpass||exposed-13/VBN||facility-8/NN	nn||worker-11/NN||health-10/NN	conj_or||facility-8/NN||worker-11/NN	nsubjpass||exposed-13/VBN||worker-11/NN	auxpass||exposed-13/VBN||was-12/VBD	dep||show-3/VBP||exposed-13/VBN	det||components-16/NNS||all-15/DT	prep_to||exposed-13/VBN||components-16/NNS	det||intervention-19/NN||the-18/DT	prep_of||components-16/NNS||intervention-19/NN	dep||proportion-24/NN||2-21/LS	det||proportion-24/NN||the-23/DT	dep||intervention-19/NN||proportion-24/NN	nn||workers-27/NNS||health-26/NN	prep_of||proportion-24/NN||workers-27/NNS	nsubj||received-29/VBD||workers-27/NNS	rcmod||workers-27/NNS||received-29/VBD	det||training-33/NN||the-30/DT	amod||training-33/NN||enhanced-31/JJ	amod||training-33/NN||in-service-32/JJ	nsubj||%-36/NN||training-33/NN	cop||%-36/NN||was-34/VBD	num||%-36/NN||67-35/CD	ccomp||received-29/VBD||%-36/NN	dep||proportion-41/NN||3-38/LS	det||proportion-41/NN||the-40/DT	prep_of||proportion-24/NN||proportion-41/NN	conj_and||workers-27/NNS||proportion-41/NN	nsubj||received-29/VBD||proportion-41/NN	amod||children-44/NNS||febrile-43/JJ	prep_of||proportion-41/NN||children-44/NNS	amod||malaria-47/NN||uncomplicated-46/JJ	prep_with||children-44/NNS||malaria-47/NN	vmod||malaria-47/NN||treated-48/VBN	det||drug-53/NN||the-50/DT	amod||drug-53/NN||first-line-51/JJ	amod||drug-53/NN||anti-malarial-52/JJ	prep_with||treated-48/VBN||drug-53/NN	appos||drug-53/NN||artemether-lumefantrine-55/NN	appos||artemether-lumefantrine-55/NN||al-57/NNP	nn||facilities-62/NNS||health-61/NN	prep_at||treated-48/VBN||facilities-62/NNS	advmod||was-65/VBD||where-63/WRB	nsubj||was-65/VBD||al-64/NNP	advcl||treated-48/VBN||was-65/VBD	prep_in||was-65/VBD||stock-67/NN	vmod||stock-67/NN||increased-68/VBN	num||%-71/NN||76.9-70/CD	prep_from||increased-68/VBN||%-71/NN	num||%-74/NN||95-73/CD	dep||%-71/NN||%-74/NN	dep||%-74/NN||ci-75/NNP	num||ci-75/NNP||69.4-76/CD	num||ci-75/NNP||83.1-78/CD	num||%-82/NN||87.6-81/CD	prep_to||increased-68/VBN||%-82/NN	num||%-85/NN||95-84/CD	dep||%-82/NN||%-85/NN	number||82.5-87/CD||ci-86/CD	num||%-85/NN||82.5-87/CD	amod||%-85/NN||91.5-89/CD	dep||were-95/VBD||4-92/LS	expl||were-95/VBD||there-94/EX	parataxis||was-65/VBD||were-95/VBD	amod||improvements-99/NNS||modest-96/JJ	conj_but||modest-96/JJ||non-significant-98/JJ	amod||improvements-99/NNS||non-significant-98/JJ	nsubj||were-95/VBD||improvements-99/NNS	prepc_in||were-95/VBD||dispensing-101/VBG	prepc_in||were-95/VBD||counseling-103/VBG	conj_and||dispensing-101/VBG||counseling-103/VBG	dobj||dispensing-101/VBG||practices-104/NNS	prep_of||proportion-24/NN||5-107/CD	conj_and||workers-27/NNS||5-107/CD	nsubj||received-29/VBD||5-107/CD	advmod||restricted-113/VBN||when-109/WRB	det||analyses-111/NNS||the-110/DT	nsubjpass||restricted-113/VBN||analyses-111/NNS	auxpass||restricted-113/VBN||were-112/VBD	advcl||exposed-13/VBN||restricted-113/VBN	nn||workers-116/NNS||health-115/NN	prep_to||restricted-113/VBN||workers-116/NNS	nsubj||received-118/VBD||workers-116/NNS	nsubj||received-125/VBN||workers-116/NNS	rcmod||workers-116/NNS||received-118/VBD	det||training-122/NN||the-119/DT	amod||training-122/NN||enhanced-120/JJ	amod||training-122/NN||in-service-121/JJ	dobj||received-118/VBD||training-122/NN	aux||received-125/VBN||had-124/VBD	rcmod||workers-116/NNS||received-125/VBN	conj_and/or||received-118/VBD||received-125/VBN	amod||guidelines-127/NNS||new-126/JJ	dobj||received-125/VBN||guidelines-127/NNS	nn||aids-130/NNS||job-129/NN	nsubjpass||observed-140/VBN||aids-130/NNS	neg||improvements-134/NNS||no-132/DT	amod||improvements-134/NNS||significant-133/JJ	appos||aids-130/NNS||improvements-134/NNS	amod||tasks-138/NNS||reported-136/JJ	amod||tasks-138/NNS||case-management-137/JJ	prep_in||improvements-134/NNS||tasks-138/NNS	auxpass||observed-140/VBN||were-139/VBD	dep||show-3/VBP||observed-140/VBN	conj_and||exposed-13/VBN||observed-140/VBN	prepc_compared_to||observed-140/VBN||to-142/TO	pobj||observed-140/VBN||baseline-143/NN	malaria-47||lumefantrine--1||yes||the findings show 1) no health facility or health worker was exposed to all components of the intervention; 2) the proportion of health workers who received the enhanced in-service training was 67%; 3) the proportion of febrile children with uncomplicated malaria treated with the first-line anti-malarial drug, artemether-lumefantrine (al), at health facilities where al was in stock increased from 76.9% (95%ci 69.4, 83.1) to 87.6% (95% ci 82.5, 91.5); 4) there were modest but non-significant improvements in dispensing and counseling practices; and 5) when the analyses were restricted to health workers who received the enhanced in-service training and/or had received new guidelines and job aids, no significant improvements in reported case-management tasks were observed compared to baseline.
amod||analysis-3/NN||phylogenetic-2/JJ	nsubj||showed-4/VBD||analysis-3/NN	root||ROOT-0/null||showed-4/VBD	mark||was-12/VBD||that-5/IN	det||hbv-7/NN||the-6/DT	nsubj||was-12/VBD||hbv-7/NN	det||donors-11/NNS||all-9/DT	num||donors-11/NNS||five-10/CD	prep_in||hbv-7/NN||donors-11/NNS	ccomp||showed-4/VBD||was-12/VBD	advmod||was-12/VBD||genotype-13/RB	dep||was-12/VBD||b-14/SYM	det||deletion-19/NN||a-16/DT	amod||deletion-19/NN||single-17/JJ	nn||deletion-19/NN||base-18/NN	nsubjpass||detected-21/VBN||deletion-19/NN	auxpass||detected-21/VBN||was-20/VBD	ccomp||showed-4/VBD||detected-21/VBN	conj_and||was-12/VBD||detected-21/VBN	det||region-25/NN||the-23/DT	amod||region-25/NN||s-24/JJ	prep_in||detected-21/VBN||region-25/NN	nn||dna-28/NN||hbv-27/NN	prep_of||region-25/NN||dna-28/NN	num||donor-31/NN||one-30/CD	prep_from||detected-21/VBN||donor-31/NN	neg||mutation-35/NN||no-34/DT	nsubjpass||observed-37/VBN||mutation-35/NN	auxpass||observed-37/VBN||was-36/VBD	ccomp||showed-4/VBD||observed-37/VBN	conj_and||was-12/VBD||observed-37/VBN	prep_in||observed-37/VBN||the-39/NN	dep||the-39/NN||a-42/SYM	dep||observed-37/VBN||determinant-45/JJ	prepc_of||determinant-45/JJ||hbsag-47/VBG	num||donors-51/NNS||four-49/CD	amod||donors-51/NNS||other-50/JJ	prep_from||hbsag-47/VBG||donors-51/NNS	hbv-27||hbsag-47||yes||" phylogenetic analysis showed that the hbv in all five donors was genotype b; a single base deletion was detected in the s region of hbv dna from one donor, and no mutation was observed in the ""a"" determinant of hbsag from four other donors."
det||objectives-2/NNS||the-1/DT	nsubj||were-6/VBD||objectives-2/NNS	det||study-5/NN||this-4/DT	prep_of||objectives-2/NNS||study-5/NN	root||ROOT-0/null||were-6/VBD	aux||investigate-8/VB||to-7/TO	ccomp||were-6/VBD||investigate-8/VB	det||expression-10/NN||the-9/DT	nsubj||genes-20/NNS||expression-10/NN	amod||receptor-15/NN||et-1-12/JJ	conj_and||et-1-12/JJ||et-14/JJ	amod||receptor-15/NN||et-14/JJ	prep_of||expression-10/NN||receptor-15/NN	det||genes-20/NNS||a-16/DT	nn||genes-20/NNS||era-18/NN	xcomp||investigate-8/VB||genes-20/NNS	aux||evaluate-23/VB||to-22/TO	ccomp||were-6/VBD||evaluate-23/VB	conj_and||investigate-8/VB||evaluate-23/VB	det||effect-25/NN||the-24/DT	dobj||evaluate-23/VB||effect-25/NN	prep_of||effect-25/NN||bosentan-27/NN	prep_in||evaluate-23/VB||monocrotaline-29/NN	appos||monocrotaline-29/NN||mct-31/NN	amod||pulmonaryhypertension-35/NN||induced-34/JJ	dep||monocrotaline-29/NN||pulmonaryhypertension-35/NN	pulmonaryhypertension-35||bosentan-27||yes||the objectives of this study were to investigate the expression of et-1 and et receptor a (era) genes and to evaluate the effect of bosentan in monocrotaline (mct)-induced pulmonaryhypertension.
prep_in||demonstrated-11/VBD||contrast-2/NN	det||nucleus-7/NN||the-4/DT	nn||nucleus-7/NN||hpg-5/NN	nn||nucleus-7/NN||arcuate-6/NN	nsubj||demonstrated-11/VBD||nucleus-7/NN	appos||nucleus-7/NN||arc-9/NN	root||ROOT-0/null||demonstrated-11/VBD	det||increase-14/NN||a-12/DT	amod||increase-14/NN||10-fold-13/JJ	dobj||demonstrated-11/VBD||increase-14/NN	amod||mrna-17/NN||kiss1-16/JJ	prep_in||demonstrated-11/VBD||mrna-17/NN	nn||days-22/NNS||10-19/CD	conj_and||10-19/CD||30-21/CD	nn||days-22/NNS||30-21/CD	prep_between||mrna-17/NN||days-22/NNS	preconj||females-25/NNS||both-24/DT	prep_in||days-22/NNS||females-25/NNS	prep_in||days-22/NNS||males-27/NNS	conj_and||females-25/NNS||males-27/NNS	vmod||demonstrated-11/VBD||suggesting-29/VBG	mark||center-36/NN||that-30/IN	det||arc-32/NN||the-31/DT	nsubj||center-36/NN||arc-32/NN	cop||center-36/NN||is-33/VBZ	det||center-36/NN||a-34/DT	amod||center-36/NN||significant-35/JJ	ccomp||suggesting-29/VBG||center-36/NN	nn||expression-42/NN||sex-38/NN	amod||expression-42/NN||steroid-independent-39/JJ	amod||expression-42/NN||pubertal-40/JJ	nn||expression-42/NN||kisspeptin-41/NN	prep_for||center-36/NN||expression-42/NN	steroid--1||arc-32||no_rel||in contrast, the hpg arcuate nucleus (arc) demonstrated a 10-fold increase in kiss1 mrna between 10 and 30 days in both females and males, suggesting that the arc is a significant center for sex steroid-independent pubertal kisspeptin expression.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-4/NN||a-3/DT	nsubj||commenced-12/VBD||case-4/NN	det||lady-10/NN||a-6/DT	num||year-8/NN||53-7/CD	npadvmod||old-9/JJ||year-8/NN	amod||lady-10/NN||old-9/JJ	prep_of||case-4/NN||lady-10/NN	advmod||commenced-12/VBD||recently-11/RB	ccomp||report-2/VBP||commenced-12/VBD	prep_on||commenced-12/VBD||etanercept-14/NN	det||therapy-23/NN||an-16/DT	amod||therapy-23/NN||anti-tnf-17/JJ	nn||necrosis-20/NNS||tumour-19/NN	dep||anti-tnf-17/JJ||necrosis-20/NNS	dep||necrosis-20/NNS||factor-21/NN	appos||etanercept-14/NN||therapy-23/NN	prep_for||commenced-12/VBD||rheumatoidarthritis-25/NNS	vmod||rheumatoidarthritis-25/NNS||presenting-26/VBG	prep_with||presenting-26/VBG||confusion-28/NN	prep_with||presenting-26/VBG||pyrexia-30/NN	conj_and||confusion-28/NN||pyrexia-30/NN	det||rash-34/NN||an-32/DT	amod||rash-34/NN||erythematous-33/JJ	prep_with||presenting-26/VBG||rash-34/NN	conj_and||confusion-28/NN||rash-34/NN	rheumatoidarthritis-25||etanercept-14||yes||we report a case of a 53 year old lady recently commenced on etanercept, an anti-tnf (tumour necrosis factor) therapy for rheumatoidarthritis presenting with confusion, pyrexia and an erythematous rash.
nsubj||antiemeticdrug-6/NN||ondansetronhydrochloride-1/NN	cop||antiemeticdrug-6/NN||is-2/VBZ	det||antiemeticdrug-6/NN||an-3/DT	advmod||bitter-5/JJ||intensely-4/RB	amod||antiemeticdrug-6/NN||bitter-5/JJ	root||ROOT-0/null||antiemeticdrug-6/NN	vmod||antiemeticdrug-6/NN||used-7/VBN	aux||treat-9/VB||to-8/TO	xcomp||used-7/VBN||treat-9/VB	dobj||treat-9/VB||nausea-10/NN	dobj||treat-9/VB||vomiting-12/NN	conj_and||nausea-10/NN||vomiting-12/NN	prep_following||nausea-10/NN||chemotherapy-14/NN	antiemeticdrug-6||vomiting-12||no_rel||ondansetronhydrochloride is an intensely bitter antiemeticdrug used to treat nausea and vomiting following chemotherapy.
nsubj||lidocaine-4/VBP||pretreatment-1/NN	prep_with||pretreatment-1/NN||iv-3/NN	root||ROOT-0/null||lidocaine-4/VBP	num||mg-6/NNP||40-5/CD	dobj||lidocaine-4/VBP||mg-6/NNP	nn||mg-10/NNS||ketamine-8/NNP	num||mg-10/NNS||25-9/CD	dobj||lidocaine-4/VBP||mg-10/NNS	conj_plus||mg-6/NNP||mg-10/NNS	det||tourniquet-14/NN||a-12/DT	nn||tourniquet-14/NN||rubber-13/NN	prep_with||lidocaine-4/VBP||tourniquet-14/NN	det||min-19/NN||the-16/DT	nn||min-19/NN||forearm-17/NNP	num||min-19/NN||1-18/CD	prep_on||tourniquet-14/NN||min-19/NN	mark||effective-28/JJ||before-20/IN	det||injection-22/NN||the-21/DT	nsubj||effective-28/JJ||injection-22/NN	nn||propofol-25/NN||microemulsion-24/NN	prep_of||injection-22/NN||propofol-25/NN	cop||effective-28/JJ||is-26/VBZ	advmod||effective-28/JJ||more-27/RBR	advcl||lidocaine-4/VBP||effective-28/JJ	nn||mg-32/NN||lidocaine-30/NN	num||mg-32/NN||40-31/CD	prep_than||effective-28/JJ||mg-32/NN	nn||mg-36/NN||ketamine-34/NN	num||mg-36/NN||25-35/CD	prep_than||effective-28/JJ||mg-36/NN	conj_or||mg-32/NN||mg-36/NN	advmod||effective-28/JJ||alone-37/RB	prepc_in||effective-28/JJ||preventing-39/VBG	dobj||preventing-39/VBG||pain-40/NN	det||injection-43/NN||the-42/DT	prep_from||preventing-39/VBG||injection-43/NN	nn||propofol-46/NN||microemulsion-45/NN	prep_of||injection-43/NN||propofol-46/NN	pain-40||ketamine-34||yes||pretreatment with iv lidocaine 40 mg plus ketamine 25 mg with a rubber tourniquet on the forearm 1 min before the injection of microemulsion propofol is more effective than lidocaine 40 mg or ketamine 25 mg alone in preventing pain from the injection of microemulsion propofol.
csubjpass||associated-8/VBN||switching-1/VBG	prep_from||switching-1/VBG||bhi-3/NN	aux||biasp-5/VB||to-4/TO	xcomp||switching-1/VBG||biasp-5/VB	dobj||biasp-5/VB||30-6/CD	auxpass||associated-8/VBN||is-7/VBZ	root||ROOT-0/null||associated-8/VBN	amod||glucose-12/NN||improved-10/VBN	amod||glucose-12/NN||postprandial-11/JJ	prep_with||associated-8/VBN||glucose-12/NN	appos||glucose-12/NN||ppg-14/NN	amod||nocturnal-18/NN||reduced-17/VBN	prep_with||associated-8/VBN||nocturnal-18/NN	conj_and||glucose-12/NN||nocturnal-18/NN	amod||hypoglycaemia-21/NN||major-20/JJ	conj_and||glucose-12/NN||hypoglycaemia-21/NN	conj_and||nocturnal-18/NN||hypoglycaemia-21/NN	mark||higher-27/JJR||although-23/IN	amod||hypoglycaemia-25/NN||daytime-24/JJ	nsubj||higher-27/JJR||hypoglycaemia-25/NN	cop||higher-27/JJR||is-26/VBZ	advcl||associated-8/VBN||higher-27/JJR	prep_with||higher-27/JJR||biasp-29/NN	num||biasp-29/NN||30-30/CD	hypoglycaemia-25||glucose-12||yes||switching from bhi to biasp 30 is associated with improved postprandial glucose (ppg) and reduced nocturnal and major hypoglycaemia, although daytime hypoglycaemia is higher with biasp 30.
aux||evaluate-2/VB||to-1/TO	advcl||evaluated-27/VBN||evaluate-2/VB	det||effects-4/NNS||the-3/DT	dobj||evaluate-2/VB||effects-4/NNS	prep_of||effects-4/NNS||cyclosporina-6/NN	appos||cyclosporina-6/NN||cya-8/NN	amod||outcome-12/NN||clinical-11/JJ	prep_on||evaluate-2/VB||outcome-12/NN	amod||changes-15/NNS||pathologic-14/JJ	prep_on||evaluate-2/VB||changes-15/NNS	conj_and||outcome-12/NN||changes-15/NNS	prep_in||outcome-12/NN||children-17/NNS	nn||nephropathy-20/NN||iga-19/NN	prep_with||children-17/NNS||nephropathy-20/NN	appos||nephropathy-20/NN||igan-22/NN	nsubj||evaluated-27/VBN||we-25/PRP	advmod||evaluated-27/VBN||retrospectively-26/RB	root||ROOT-0/null||evaluated-27/VBN	num||children-29/NNS||14-28/CD	dobj||evaluated-27/VBN||children-29/NNS	nsubjpass||treated-47/VBN||children-29/NNS	dep||children-29/NNS||mean-31/VB	nn||±-35/NN||age-32/NN	num||±-35/NN||8.9-33/CD	nn||±-35/NN||â-34/NN	dobj||mean-31/VB||±-35/NN	num||yr-37/NN||2.9-36/CD	dep||±-35/NN||yr-37/NN	num||males-40/NNS||eight-39/CD	dep||±-35/NN||males-40/NNS	num||females-43/NNS||six-42/CD	appos||males-40/NNS||females-43/NNS	auxpass||treated-47/VBN||were-46/VBD	rcmod||children-29/NNS||treated-47/VBN	prep_with||treated-47/VBN||cya-49/NN	prep_with||treated-47/VBN||steroids-51/NNS	conj_and||cya-49/NN||steroids-51/NNS	nephropathy-20||steroids-51||no_rel||to evaluate the effects of cyclosporina (cya) on clinical outcome and pathologic changes in children with iga nephropathy (igan), we retrospectively evaluated 14 children (mean age 8.9â±2.9 yr; eight males, six females) who were treated with cya and steroids.
nsubjpass||redetermined-36/VBN||acta-1/NNP	num||acta-1/NNP||74-2/CD	num||acta-1/NNP||103â-4/CD	dep||acta-1/NNP||$-5/$	advmod||-RSB--8/RB||120-7/RB	dep||c16h20n4o3s-22/CD||-RSB--8/RB	det||tâ-11/NN||the-10/DT	prep_of||-RSB--8/RB||tâ-11/NN	dep||tâ-11/NN||$-12/$	nn||non-solvated-16/NN||n-14/NN	npadvmod||of-19/RB||non-solvated-16/NN	advmod||non-solvated-16/NN||polymorph-18/RB	dep||torasemide-20/CD||of-19/RB	num||$-12/$||torasemide-20/CD	num||$-5/$||c16h20n4o3s-22/CD	det||drug-26/NN||a-24/DT	amod||drug-26/NN||diuretic-25/JJ	appos||acta-1/NNP||drug-26/NN	vmod||drug-26/NN||used-27/VBN	det||treatment-30/NN||the-29/DT	prep_in||used-27/VBN||treatment-30/NN	prep_of||treatment-30/NN||hypertension-32/NN	aux||redetermined-36/VBN||has-34/VBZ	auxpass||redetermined-36/VBN||been-35/VBN	root||ROOT-0/null||redetermined-36/VBN	amod||temperature-39/NN||low-38/JJ	prep_at||redetermined-36/VBN||temperature-39/NN	hypertension-32||torasemide-20||yes||acta 74 , 103â120] of the tân (non-solvated) polymorph of torasemide, c16h20n4o3s, a diuretic drug used in the treatment of hypertension, has been redetermined at low temperature.
det||seconds-4/NNS||the-2/DT	num||seconds-4/NNS||10-3/CD	prep_during||measured-12/VBN||seconds-4/NNS	amod||injection-7/NN||propofol-6/JJ	prep_after||seconds-4/NNS||injection-7/NN	nn||intensity-10/NN||pain-9/NN	nsubjpass||measured-12/VBN||intensity-10/NN	auxpass||measured-12/VBN||was-11/VBD	root||ROOT-0/null||measured-12/VBN	det||scale-18/NN||an-14/DT	amod||scale-18/NN||11-point-15/JJ	amod||scale-18/NN||numerical-16/JJ	nn||scale-18/NN||rating-17/NN	prep_on||measured-12/VBN||scale-18/NN	dep||scale-18/NN||0-20/CD	dep||pain-23/NN||=-21/SYM	neg||pain-23/NN||no-22/DT	rcmod||0-20/CD||pain-23/NN	num||=-26/NNS||10-25/CD	dep||scale-18/NN||=-26/NNS	conj_and||0-20/CD||=-26/NNS	dep||possible-28/JJ||worst-27/JJS	amod||pain-29/NN||possible-28/JJ	dep||=-26/NNS||pain-29/NN	pain-29||propofol-6||yes||during the 10 seconds after propofol injection, pain intensity was measured on an 11-point numerical rating scale (0 = no pain and 10 = worst possible pain).
prep_in||fails-15/VBZ||areas-2/NNS	amod||resistance-6/NN||widespread-4/JJ	amod||resistance-6/NN||sulfadoxine-pyrimethamine-5/JJ	prep_of||areas-2/NNS||resistance-6/NN	amod||treatment-9/NN||intermittent-8/JJ	nsubj||fails-15/VBZ||treatment-9/NN	nsubj||prevent-17/VB||treatment-9/NN	nsubj||exacerbate-25/VB||treatment-9/NN	prep_in||treatment-9/NN||pregnancy-11/NN	appos||treatment-9/NN||iptp-13/NN	root||ROOT-0/null||fails-15/VBZ	aux||prevent-17/VB||to-16/TO	xcomp||fails-15/VBZ||prevent-17/VB	amod||malaria-19/NN||placental-18/JJ	dobj||prevent-17/VB||malaria-19/NN	appos||malaria-19/NN||pm-21/NN	aux||exacerbate-25/VB||may-24/MD	conj_and||fails-15/VBZ||exacerbate-25/VB	nn||infections-28/NNS||drug-26/NN	nn||infections-28/NNS||resistant-27/NN	dobj||exacerbate-25/VB||infections-28/NNS	malaria-19||pyrimethamine--1||no||in areas of widespread sulfadoxine-pyrimethamine resistance, intermittent treatment in pregnancy (iptp) fails to prevent placental malaria (pm) and may exacerbate drug resistant infections.
det||subclinical-3/NN||a-1/DT	amod||subclinical-3/NN||higher-2/JJR	nsubjpass||associated-6/VBN||subclinical-3/NN	advmod||associated-6/VBN||vitaminadeficiency-4/RB	auxpass||associated-6/VBN||was-5/VBD	root||ROOT-0/null||associated-6/VBN	neg||receiving-9/VBG||not-8/RB	prepc_with||associated-6/VBN||receiving-9/VBG	nn||supplement-11/NN||vitamina-10/NN	dobj||receiving-9/VBG||supplement-11/NN	det||year-14/NN||the-13/DT	prep_over||receiving-9/VBG||year-14/NN	aux||ill-18/JJ||having-16/VBG	cop||ill-18/JJ||been-17/VBN	vmod||receiving-9/VBG||ill-18/JJ	det||weeks-22/NNS||the-20/DT	num||weeks-22/NNS||two-21/CD	prep_during||ill-18/JJ||weeks-22/NNS	xcomp||ill-18/JJ||preceding-23/VBG	det||survey-25/NN||the-24/DT	nsubj||belonging-32/VBG||survey-25/NN	amod||vaccination-30/NN||no-27/DT	conj_or||no-27/DT||incomplete-29/JJ	amod||vaccination-30/NN||incomplete-29/JJ	appos||survey-25/NN||vaccination-30/NN	vmod||preceding-23/VBG||belonging-32/VBG	det||mother-35/NN||a-34/DT	prep_to||belonging-32/VBG||mother-35/NN	amod||parity-38/NN||high-37/JJ	prep_with||ill-18/JJ||parity-38/NN	amod||levels-42/NNS||low-41/JJ	nsubjpass||associated-56/VBN||levels-42/NNS	nsubj||being-50/VBG||awareness-44/NN	prep_of||awareness-44/NN||vitamina-46/NNP	advmod||vitamina-46/NNP||moreover-48/RB	prepc_of||levels-42/NNS||being-50/VBG	nn||household-53/NN||muslim-52/NN	prep_from||being-50/VBG||household-53/NN	auxpass||associated-56/VBN||was-54/VBD	advmod||associated-56/VBN||strongly-55/RB	conj_and||associated-6/VBN||associated-56/VBN	amod||levels-59/NNS||higher-58/JJR	prep_with||associated-56/VBN||levels-59/NNS	amod||vitaminadeficiency-62/NN||subclinical-61/JJ	prep_of||levels-59/NNS||vitaminadeficiency-62/NN	vitaminadeficiency-62||vitamina-46||yes||a higher subclinical vitaminadeficiency was associated with not receiving vitamina supplement over the year , having been ill during the two weeks preceding the survey , no or incomplete vaccination , belonging to a mother with high parity , and low levels of awareness of vitamina. moreover , being from muslim household was strongly associated with higher levels of subclinical vitaminadeficiency .
nsubj||cause-5/NN||staphylococcusaureus-1/NNS	cop||cause-5/NN||is-2/VBZ	det||cause-5/NN||a-3/DT	amod||cause-5/NN||common-4/JJ	ccomp||-lrb--25/VBD||cause-5/NN	amod||infection-8/NN||human-7/JJ	prep_of||cause-5/NN||infection-8/NN	nsubj||concern-18/NN||emergence-11/NN	amod||s.aureus-14/NNS||vancomycin-resistance-13/JJ	prep_of||emergence-11/NN||s.aureus-14/NNS	cop||concern-18/NN||is-15/VBZ	det||concern-18/NN||a-16/DT	amod||concern-18/NN||great-17/JJ	conj_and||cause-5/NN||concern-18/NN	ccomp||-lrb--25/VBD||concern-18/NN	prep_for||concern-18/NN||treatment-20/NN	amod||s.aureus-23/NNS||methicillin-resistant-22/JJ	prep_of||treatment-20/NN||s.aureus-23/NNS	root||ROOT-0/null||-lrb--25/VBD	nn||-rrb--27/NNS||mrsa-26/NN	dobj||-lrb--25/VBD||-rrb--27/NNS	amod||years-30/NNS||recent-29/JJ	prep_in||-lrb--25/VBD||years-30/NNS	num||-rrb--33/NN||-lrb--31/CD	nn||-rrb--33/NN||mrsa-32/NN	nsubj||-lrb--25/VBD||-rrb--33/NN	mrsa-32||s.aureus-23||no||staphylococcusaureus is a common cause of human infection , and emergence of vancomycin-resistance s.aureus is a great concern for treatment of methicillin-resistant s.aureus , -lrb- mrsa -rrb- in recent years -lrb- mrsa -rrb- .
nsubj||agent-5/NN||htlv-i-1/NNP	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causal-4/JJ	root||ROOT-0/null||agent-5/NN	amod||leukemia-10/NN||adult-7/JJ	nn||leukemia-10/NN||t-8/NN	nn||leukemia-10/NN||cell-9/NN	prep_of||agent-5/NN||leukemia-10/NN	dep||leukemia-10/NN||atll-12/JJ	prep_of||agent-5/NN||htlv-i-associatedmyelopathy/tropicalspasticparaparesis-15/NNS	conj_and||leukemia-10/NN||htlv-i-associatedmyelopathy/tropicalspasticparaparesis-15/NNS	appos||leukemia-10/NN||ham/tsp-17/NN	htlv-i-associatedmyelopathy--1||htlv-i-1||no||htlv-i is the causal agent of adult t cell leukemia (atll) and htlv-i-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp).
advmod||reached-4/VBD||influenza-1/RB	det||viralinfections-3/NNS||a-2/DT	nsubj||reached-4/VBD||viralinfections-3/NNS	root||ROOT-0/null||reached-4/VBD	amod||levels-6/NNS||pandemic-5/JJ	dobj||reached-4/VBD||levels-6/NNS	prep_in||reached-4/VBD||1918-8/NNP	num||1918-8/NNP||1957-10/CD	num||1918-8/NNP||1968-12/CD	advmod||recently-17/RB||most-16/RBS	dep||reached-4/VBD||recently-17/RB	prep_in||reached-4/VBD||2009-20/CD	conj_and||1918-8/NNP||2009-20/CD	det||emergence-23/NN||the-22/DT	prep_with||reached-4/VBD||emergence-23/NN	det||h1n1influenzavirus-27/NN||the-25/DT	amod||h1n1influenzavirus-27/NN||swine-origin-26/JJ	prep_of||emergence-23/NN||h1n1influenzavirus-27/NN	influenza-1||influenzavirus--1||no||influenza a viralinfections reached pandemic levels in 1918, 1957, 1968, and, most recently, in 2009 with the emergence of the swine-origin h1n1influenzavirus.
nsubj||africaâ-2/VBZ||conclusions-1/NNS	root||ROOT-0/null||africaâ-2/VBZ	dobj||africaâ-2/VBZ||$-3/$	num||$-3/$||-4/CD	nsubj||hiv/aids-6/VBZ||s-5/PRP	rcmod||$-3/$||hiv/aids-6/VBZ	nsubj||responsible-10/JJ||epidemic-7/NN	aux||responsible-10/JJ||might-8/MD	cop||responsible-10/JJ||be-9/VB	ccomp||hiv/aids-6/VBZ||responsible-10/JJ	det||number-14/NN||a-12/DT	amod||number-14/NN||large-13/JJ	prep_for||responsible-10/JJ||number-14/NN	amod||people-17/NNS||older-16/JJR	prep_of||number-14/NN||people-17/NNS	dep||people-17/NNS||losing-18/VBG	poss||support-20/NN||their-19/PRP$	dobj||losing-18/VBG||support-20/NN	dep||people-17/NNS||having-22/VBG	conj_and||losing-18/VBG||having-22/VBG	aux||care-24/VB||to-23/TO	xcomp||having-22/VBG||care-24/VB	amod||children-27/NNS||young-26/JJ	prep_for||care-24/VB||children-27/NNS	aids--1||hiv--1||no||conclusions africaâs hiv/aids epidemic might be responsible for a large number of older people losing their support and having to care for young children.
nsubj||analyzed-2/VBD||we-1/PRP	nsubj||evaluated-16/VBN||we-1/PRP	root||ROOT-0/null||analyzed-2/VBD	nn||flora-4/NNS||gut-3/NN	dobj||analyzed-2/VBD||flora-4/NNS	prep_in||analyzed-2/VBD||patients-6/NNS	amod||syndrome-11/NN||systemic-8/JJ	amod||syndrome-11/NN||inflammatory-9/JJ	nn||syndrome-11/NN||response-10/NN	prep_with||patients-6/NNS||syndrome-11/NN	appos||syndrome-11/NN||sirs-13/NNS	conj_and||analyzed-2/VBD||evaluated-16/VBN	amod||bacteria-18/NNS||key-17/JJ	dobj||evaluated-16/VBN||bacteria-18/NNS	poss||values-22/NNS||their-20/PRP$	nn||values-22/NNS||cutoff-21/NN	dobj||evaluated-16/VBN||values-22/NNS	conj_and||bacteria-18/NNS||values-22/NNS	amod||complications-25/NNS||infectious-24/JJ	prep_for||evaluated-16/VBN||complications-25/NNS	prep_for||evaluated-16/VBN||mortality-27/NN	conj_and||complications-25/NNS||mortality-27/NN	prepc_by||evaluated-16/VBN||using-29/VBG	nn||trees-33/NNS||classification-30/NN	conj_and||classification-30/NN||regression-32/NN	nn||trees-33/NNS||regression-32/NN	dobj||using-29/VBG||trees-33/NNS	appos||trees-33/NNS||cart-35/NN	sirs-13||bacteria-18||no||we analyzed gut flora in patients with systemic inflammatory response syndrome (sirs) and evaluated key bacteria and their cutoff values for infectious complications and mortality by using classification and regression trees (cart).
amod||drugs-2/NNS||current-1/JJ	nsubj||effective-24/JJ||drugs-2/NNS	vmod||drugs-2/NNS||used-3/VBN	det||treatment-6/NN||the-5/DT	prep_in||used-3/VBN||treatment-6/NN	nn||sdisease-10/NN||parkinson-8/NN	prep_of||treatment-6/NN||sdisease-10/NN	appos||drugs-2/NNS||pd-12/NN	prep_for||drugs-2/NNS||example-16/NN	prep_for||drugs-2/NNS||l-dopa-18/NN	conj_and||example-16/NN||l-dopa-18/NN	prep_for||drugs-2/NNS||dopamineagonists-20/NNS	conj_and||example-16/NN||dopamineagonists-20/NNS	cop||effective-24/JJ||are-22/VBP	advmod||effective-24/JJ||very-23/RB	root||ROOT-0/null||effective-24/JJ	prepc_at||effective-24/JJ||reversing-26/VBG	det||symptoms-29/NNS||the-27/DT	nn||symptoms-29/NNS||motor-28/NN	dobj||reversing-26/VBG||symptoms-29/NNS	det||disease-32/NN||the-31/DT	prep_of||symptoms-29/NNS||disease-32/NN	parkinson'sdisease--1||l-dopa-18||yes||current drugs used in the treatment of parkinson'sdisease (pd), for example, l-dopa and dopamineagonists, are very effective at reversing the motor symptoms of the disease.
det||subjects-5/NNS||the-3/DT	num||subjects-5/NNS||513-4/CD	prep_among||associated-20/VBN||subjects-5/NNS	nn||pain-8/NN||knee-7/NN	prep_with||subjects-5/NNS||pain-8/NN	det||presence-12/NN||the-10/DT	amod||presence-12/NN||additional-11/JJ	nsubjpass||associated-20/VBN||presence-12/NN	nsubjpass||associated-20/VBN||presence-12/NN	amod||evidence-15/NN||radiographic-14/JJ	prep_of||presence-12/NN||evidence-15/NN	prep_of||evidence-15/NN||oa-17/NN	auxpass||associated-20/VBN||was-18/VBD	advmod||associated-20/VBN||significantly-19/RB	root||ROOT-0/null||associated-20/VBN	conj_and||associated-20/VBN||associated-20/VBN	amod||occasions-23/NNS||more-22/JJR	prep_with||associated-20/VBN||occasions-23/NNS	prep_of||occasions-23/NNS||unbearable-27/NN	dep||occasions-23/NNS||pain-30/NN	num||%-33/NN||59-32/CD	dep||pain-30/NN||%-33/NN	num||%-36/NN||36-35/CD	dep||pain-30/NN||%-36/NN	conj_versus||%-33/NN||%-36/NN	amod||activity-40/NN||restricted-39/VBN	dep||occasions-23/NNS||activity-40/NN	conj_and||pain-30/NN||activity-40/NN	num||%-43/NN||64-42/CD	dep||activity-40/NN||%-43/NN	num||%-46/NN||39-45/CD	dep||activity-40/NN||%-46/NN	conj_versus||%-43/NN||%-46/NN	amod||use-53/NN||increased-52/VBN	npadvmod||associated-20/VBN||use-53/NN	prep_of||use-53/NN||nonsteroidalantiinflammatorydrugs-55/NNS	appos||nonsteroidalantiinflammatorydrugs-55/NNS||nsaids-57/NNS	num||%-61/NN||88-60/CD	dep||nonsteroidalantiinflammatorydrugs-55/NNS||%-61/NN	num||%-64/NN||78-63/CD	dep||nonsteroidalantiinflammatorydrugs-55/NNS||%-64/NN	conj_versus||%-61/NN||%-64/NN	det||number-69/NN||the-67/DT	amod||number-69/NN||reported-68/VBN	npadvmod||associated-20/VBN||number-69/NN	conj_and||use-53/NN||number-69/NN	nn||visits-72/NNS||doctor-71/NN	prep_of||number-69/NN||visits-72/NNS	num||%-75/NN||59-74/CD	dep||visits-72/NNS||%-75/NN	num||%-78/NN||33-77/CD	dep||visits-72/NNS||%-78/NN	conj_versus||%-75/NN||%-78/NN	det||year-83/NN||the-81/DT	amod||year-83/NN||past-82/JJ	prep_in||associated-20/VBN||year-83/NN	pain-30||nsaids-57||no_rel||" among the 513 subjects with knee pain, the additional presence of radiographic evidence of oa was significantly associated with more occasions of ""unbearable"" pain (59% versus 36%) and restricted activity (64% versus 39%), as well as increased use of nonsteroidalantiinflammatorydrugs (nsaids) (88% versus 78%) and the reported number of doctor visits (59% versus 33%) in the past year."
amod||features-2/NNS||clinical-1/JJ	nsubj||alert-24/VB||features-2/NNS	prep_of||features-2/NNS||headache-4/NN	amod||consciousness-7/NN||altered-6/JJ	prep_of||features-2/NNS||consciousness-7/NN	conj_and||headache-4/NN||consciousness-7/NN	amod||deficit-11/NN||focal-9/JJ	amod||deficit-11/NN||neurological-10/JJ	prep_of||features-2/NNS||deficit-11/NN	conj_and||headache-4/NN||deficit-11/NN	prep_of||features-2/NNS||seizures-14/NNS	conj_and||headache-4/NN||seizures-14/NNS	dep||features-2/NNS||developing-15/VBG	prep||developing-15/VBG||during-16/IN	dep||features-2/NNS||immediately-18/RB	conj_or||developing-15/VBG||immediately-18/RB	prep_after||immediately-18/RB||treatment-20/NN	prep_with||immediately-18/RB||l-asparaginase-22/NN	aux||alert-24/VB||should-23/MD	root||ROOT-0/null||alert-24/VB	det||physician-27/NN||the-25/DT	amod||physician-27/NN||treating-26/JJ	dobj||alert-24/VB||physician-27/NN	det||possibility-30/NN||the-29/DT	prep_to||alert-24/VB||possibility-30/NN	prep_of||possibility-30/NN||csvt-32/NN	l-asparaginase-22||seizures-14||no_rel||clinical features of headache, altered consciousness, focal neurological deficit, and seizures developing during or immediately after treatment with l-asparaginase should alert the treating physician to the possibility of csvt.
advmod||observed-34/VBN||importantly-1/RB	det||correlation-11/NN||a-3/DT	advmod||significant-5/JJ||highly-4/RB	amod||correlation-11/NN||significant-5/JJ	dep||significant-5/JJ||p-7/VBN	dep||0.000009-9/CD||=-8/SYM	ccomp||p-7/VBN||0.000009-9/CD	nsubjpass||observed-34/VBN||correlation-11/NN	amod||antigen-15/NN||hepatitisb-13/JJ	nn||antigen-15/NN||surface-14/NN	prep_between||correlation-11/NN||antigen-15/NN	appos||antigen-15/NN||hbsag-17/NN	vmod||correlation-11/NN||stimulated-19/VBN	amod||expression-22/NN||il-2-20/JJ	nn||expression-22/NN||gene-21/NN	dobj||stimulated-19/VBN||expression-22/NN	advmod||detectable-25/JJ||as-24/RB	dobj||stimulated-19/VBN||detectable-25/JJ	amod||expression-22/NN||detectable-25/JJ	conj_and||expression-22/NN||detectable-25/JJ	prep_in||detectable-25/JJ||wb-27/NN	amod||titers-32/NNS||specific-30/JJ	nn||titers-32/NNS||antibody-31/NN	dobj||stimulated-19/VBN||titers-32/NNS	conj_and||expression-22/NN||titers-32/NNS	auxpass||observed-34/VBN||was-33/VBD	root||ROOT-0/null||observed-34/VBN	prep_in||observed-34/VBN||donors-36/NNS	vmod||donors-36/NNS||vaccinated-37/VBN	amod||virus-40/NN||hepatitisb-39/JJ	prep_against||vaccinated-37/VBN||virus-40/NN	appos||virus-40/NN||hbv-42/NN	num||months-46/NNS||six-45/CD	prep_between||virus-40/NN||months-46/NNS	num||years-49/NNS||twenty-48/CD	prep_between||virus-40/NN||years-49/NNS	conj_and||months-46/NNS||years-49/NNS	det||tests-52/NNS||the-51/DT	prep_before||vaccinated-37/VBN||tests-52/NNS	hbsag-17||hbv-42||no_rel||importantly, a highly significant (p = 0.000009) correlation between hepatitisb surface antigen (hbsag) stimulated il-2 gene expression, as detectable in wb, and specific antibody titers was observed in donors vaccinated against hepatitisb virus (hbv) between six months and twenty years before the tests.
amod||therapy-4/NN||high-dose-1/JJ	amod||therapy-4/NN||potent-2/JJ	nn||therapy-4/NN||statin-3/NN	nsubj||practice-12/NN||therapy-4/NN	prep_in||therapy-4/NN||combination-6/NN	prep_with||combination-6/NN||ezetimibe-8/NN	cop||practice-12/NN||is-9/VBZ	advmod||practice-12/NN||now-10/RB	amod||practice-12/NN||standard-11/JJ	root||ROOT-0/null||practice-12/NN	det||treatment-15/NN||the-14/DT	prep_for||practice-12/NN||treatment-15/NN	amod||patients-18/NNS||adult-17/JJ	prep_of||treatment-15/NN||patients-18/NNS	amod||familialhypercholesterolemia-21/NN||heterozygous-20/JJ	prep_with||patients-18/NNS||familialhypercholesterolemia-21/NN	appos||familialhypercholesterolemia-21/NN||hefh-23/NN	det||result-28/NN||the-27/DT	prep_as||practice-12/NN||result-28/NN	amod||studies-31/NNS||numerous-30/JJ	prep_of||result-28/NN||studies-31/NNS	prep_in||practice-12/NN||patients-33/NNS	amod||hypercholesterolemia-36/NN||primary-35/JJ	prep_with||patients-33/NNS||hypercholesterolemia-36/NN	prep_with||patients-33/NNS||hefh-38/NN	conj_or||hypercholesterolemia-36/NN||hefh-38/NN	hypercholesterolemia-36||ezetimibe-8||yes||high-dose potent statin therapy in combination with ezetimibe is now standard practice for the treatment of adult patients with heterozygous familialhypercholesterolemia (hefh), as the result of numerous studies in patients with primary hypercholesterolemia or hefh.
det||1-year-3/NN||the-2/DT	prep_within||reported-10/VBD||1-year-3/NN	nn||diagnosis-7/NN||disease-6/NN	prep_prior_to||1-year-3/NN||diagnosis-7/NN	nsubj||reported-10/VBD||controls-9/NNS	root||ROOT-0/null||reported-10/VBD	advmod||more-12/JJR||slightly-11/RB	amod||infections-14/NNS||more-12/JJR	amod||infections-14/NNS||strep-tococcal-13/JJ	dobj||reported-10/VBD||infections-14/NNS	appos||infections-14/NNS||p-16/NNP	number||0.2-18/CD||<-17/CD	num||p-16/NNP||0.2-18/CD	dobj||reported-10/VBD||infections-21/NNS	conj_and||infections-14/NNS||infections-21/NNS	prep_with||infections-21/NNS||diarrhea-23/NN	prep_with||infections-21/NNS||vomiting-25/NN	conj_and||diarrhea-23/NN||vomiting-25/NN	dep||infections-14/NNS||p-27/VBN	num||0.3-29/CD||<-28/CD	dobj||p-27/VBN||0.3-29/CD	amod||use-34/NN||antibiotic-33/JJ	dobj||reported-10/VBD||use-34/NN	conj_and||infections-14/NNS||use-34/NN	appos||use-34/NN||p-36/NNP	number||0.09-38/CD||<-37/CD	num||p-36/NNP||0.09-38/CD	mark||significant-48/JJ||although-41/IN	nsubj||significant-48/JJ||none-42/NN	det||results-45/NNS||these-44/DT	prep_of||none-42/NN||results-45/NNS	cop||significant-48/JJ||were-46/VBD	advmod||significant-48/JJ||statistically-47/RB	dep||use-34/NN||significant-48/JJ	diarrhea-23||antibiotic-33||no_rel||within the 1-year prior to disease diagnosis, controls reported slightly more strep-tococcal infections (p<0.2), infections with diarrhea and vomiting (p<0.3), and antibiotic use (p<0.09), although none of these results were statistically significant.
det||objective-2/NN||the-1/DT	nsubj||was-6/VBD||objective-2/NN	nsubj||evaluate-8/VB||objective-2/NN	det||study-5/NN||this-4/DT	prep_of||objective-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||efficacy-10/NN||the-9/DT	dobj||evaluate-8/VB||efficacy-10/NN	dobj||evaluate-8/VB||safety-12/NN	conj_and||efficacy-10/NN||safety-12/NN	amod||extended-release-16/NN||methylphenidatehcl-14/JJ	nn||extended-release-16/NN||oros-15/NNS	prep_of||efficacy-10/NN||extended-release-16/NN	appos||extended-release-16/NN||oros-mph-18/NN	prep_among||extended-release-16/NN||children-21/NNS	prep_with||children-21/NNS||attentiondeficithyperactivitydisorder-23/NN	nsubjpass||treated-31/VBN||attentiondeficithyperactivitydisorder-23/NN	dep||attentiondeficithyperactivitydisorder-23/NN||adhd-25/VBN	aux||treated-31/VBN||had-28/VBD	auxpass||treated-31/VBN||been-29/VBN	advmod||treated-31/VBN||previously-30/RB	rcmod||attentiondeficithyperactivitydisorder-23/NN||treated-31/VBN	amod||immediate-release-34/NN||methylphenidatehcl-33/JJ	prep_with||treated-31/VBN||immediate-release-34/NN	appos||extended-release-16/NN||mph-ir-36/NN	attentiondeficithyperactivitydisorder-23||methylphenidatehcl-33||yes||the objective of this study was to evaluate the efficacy and safety of methylphenidatehcl oros extended-release (oros-mph) among children with attentiondeficithyperactivitydisorder (adhd) who had been previously treated with methylphenidatehcl immediate-release (mph-ir).
num||patients-2/NNS||nine-1/CD	npadvmod||seropositive-3/JJ||patients-2/NNS	root||ROOT-0/null||seropositive-3/JJ	prep_for||seropositive-3/JJ||hepatitisb-5/NN	dep||received-8/VBD||e-6/SYM	nsubj||received-8/VBD||antigen-7/NN	dep||seropositive-3/JJ||received-8/VBD	nn||monotherapy-10/NN||entecavir-9/NN	nsubjpass||analyzed-34/VBN||monotherapy-10/NN	num||months-13/NNS||12-12/CD	prep_for||monotherapy-10/NN||months-13/NNS	det||percentages-16/NNS||the-15/DT	prep_for||monotherapy-10/NN||percentages-16/NNS	conj_and||months-13/NNS||percentages-16/NNS	prep_of||percentages-16/NNS||tregs-18/NNS	amod||cells-21/NNS||th17-20/JJ	prep_of||percentages-16/NNS||cells-21/NNS	conj_and||tregs-18/NNS||cells-21/NNS	det||productions-28/NNS||the-25/DT	amod||productions-28/NNS||hbv-specific-26/JJ	amod||productions-28/NNS||il-17-27/JJ	prep_of||percentages-16/NNS||productions-28/NNS	conj_and||tregs-18/NNS||productions-28/NNS	det||patients-31/NNS||these-30/DT	prep_in||productions-28/NNS||patients-31/NNS	auxpass||analyzed-34/VBN||were-32/VBD	advmod||analyzed-34/VBN||longitudinally-33/RB	ccomp||received-8/VBD||analyzed-34/VBN	hbv--1||entecavir-9||yes||nine patients seropositive for hepatitisb e antigen received entecavir monotherapy for 12 months and the percentages of tregs and th17 cells as well as the hbv-specific il-17 productions in these patients were longitudinally analyzed.
nsubjpass||found-6/VBN||parasites-1/NNS	vmod||parasites-1/NNS||carrying-2/VBG	amod||mutations-4/NNS||pfcyt-b-3/JJ	dobj||carrying-2/VBG||mutations-4/NNS	auxpass||found-6/VBN||were-5/VBD	root||ROOT-0/null||found-6/VBN	num||patients-10/NNS||five-8/CD	nn||patients-10/NNS||falciparummalaria-9/NN	prep_in||found-6/VBN||patients-10/NNS	amod||parasitaemia-13/NN||recrudescent-12/JJ	prep_with||patients-10/NNS||parasitaemia-13/NN	xcomp||found-6/VBN||occurring-14/VBG	tmod||occurring-14/VBG||weeks-15/NNS	advmod||successful-18/JJ||apparently-17/RB	amod||treatment-19/NN||successful-18/JJ	prep_after||occurring-14/VBG||treatment-19/NN	det||infection-23/NN||a-21/DT	amod||infection-23/NN||primary-22/JJ	prep_of||treatment-19/NN||infection-23/NN	prep_with||infection-23/NN||atovaquone-proguanil-25/NN	falciparummalaria-9||proguanil--1||yes||parasites carrying pfcyt-b mutations were found in five falciparummalaria patients with recrudescent parasitaemia occurring weeks after apparently successful treatment of a primary infection with atovaquone-proguanil.
nsubj||compared-2/VBD||we-1/PRP	dep||-lrb--10/VBZ||compared-2/VBD	dobj||compared-2/VBD||colony-3/NN	vmod||colony-3/NN||spreading-4/VBG	advmod||isolated-7/VBN||clinically-6/RB	amod||s.aureus-9/NNS||isolated-7/VBN	amod||s.aureus-9/NNS||methicillin-sensitive-8/JJ	prep_of||spreading-4/VBG||s.aureus-9/NNS	root||ROOT-0/null||-lrb--10/VBZ	npadvmod||-rrb--12/JJ||mssa-11/NN	dobj||-lrb--10/VBZ||-rrb--12/JJ	amod||s.aureus-15/NNS||methicillin-resistant-14/JJ	dobj||-lrb--10/VBZ||s.aureus-15/NNS	conj_and||-rrb--12/JJ||s.aureus-15/NNS	num||-rrb--18/NN||-lrb--16/CD	nn||-rrb--18/NN||mrsa-17/NN	nsubj||-lrb--10/VBZ||-rrb--18/NN	mrsa-17||s.aureus-15||no||we compared colony spreading of clinically isolated methicillin-sensitive s.aureus -lrb- mssa -rrb- and methicillin-resistant s.aureus -lrb- mrsa -rrb- .
amod||dependent-2/JJ||vitamind-1/JJ	amod||i-5/NNS||dependent-2/JJ	amod||i-5/NNS||rickets-3/JJ	nn||i-5/NNS||type-4/NN	nsubj||disorder-29/NN||i-5/NNS	appos||i-5/NNS||vddr-i-7/NNP	advmod||referred-11/VBN||also-10/RB	vmod||i-5/NNS||referred-11/VBN	advmod||vitamind-14/JJ||as-13/RB	amod||±-16/NNS||vitamind-14/JJ	amod||±-16/NNS||1î-15/JJ	prep_to||referred-11/VBN||±-16/NNS	amod||deficiency-19/NN||hydroxylase-18/JJ	dep||±-16/NNS||deficiency-19/NN	amod||rickets-23/NNS||pseudovitamind-21/JJ	nn||rickets-23/NNS||deficiency-22/NN	dep||±-16/NNS||rickets-23/NNS	conj_or||deficiency-19/NN||rickets-23/NNS	cop||disorder-29/NN||is-25/VBZ	det||disorder-29/NN||an-26/DT	amod||disorder-29/NN||autosomal-27/JJ	nn||disorder-29/NN||recessive-28/NN	root||ROOT-0/null||disorder-29/NN	vmod||disorder-29/NN||characterized-30/VBN	dep||characterized-30/VBN||clinically-31/RB	prep_by||clinically-31/RB||hypotonia-33/NN	nn||weakness-36/NN||muscle-35/NN	conj_and||disorder-29/NN||weakness-36/NN	nn||failure-39/NN||growth-38/NN	appos||weakness-36/NN||failure-39/NN	amod||seizures-42/NNS||hypocalcemic-41/JJ	conj_and||disorder-29/NN||seizures-42/NNS	amod||infancy-45/NN||early-44/JJ	prep_in||seizures-42/NNS||infancy-45/NN	amod||findings-49/NNS||radiographic-48/JJ	conj_and||disorder-29/NN||findings-49/NNS	prep_of||findings-49/NNS||rickets-51/NNS	rickets-51||vitamind-14||yes||vitamind dependent rickets type i (vddr-i), also referred to as vitamind 1î±-hydroxylase deficiency or pseudovitamind deficiency rickets, is an autosomal recessive disorder characterized clinically by hypotonia, muscle weakness, growth failure, hypocalcemic seizures in early infancy, and radiographic findings of rickets.
det||result-2/NN||this-1/DT	nsubj||suggested-3/VBD||result-2/NN	root||ROOT-0/null||suggested-3/VBD	mark||useful-12/JJ||that-4/IN	amod||chemotherapy-6/NN||preoperative-5/JJ	nsubj||useful-12/JJ||chemotherapy-6/NN	vmod||chemotherapy-6/NN||chosen-7/VBN	agent||chosen-7/VBN||atp-cra-9/NN	aux||useful-12/JJ||may-10/MD	cop||useful-12/JJ||be-11/VB	ccomp||suggested-3/VBD||useful-12/JJ	prepc_for||useful-12/JJ||treating-14/VBG	amod||cancer-17/NN||advanced-15/JJ	nn||cancer-17/NN||colon-16/NN	dobj||treating-14/VBG||cancer-17/NN	amod||liver-20/NN||unresectable-19/JJ	prep_with||treating-14/VBG||liver-20/NN	amod||metastases-23/NNS||peritoneal-22/JJ	prep_with||treating-14/VBG||metastases-23/NNS	conj_and||liver-20/NN||metastases-23/NNS	cancer-17||atp--1||no_rel||this result suggested that preoperative chemotherapy chosen by atp-cra may be useful for treating advanced colon cancer with unresectable liver and peritoneal metastases.
amod||hyperglycemia-3/NN||intermittent-2/JJ	prep_for||exchanged-12/VBN||hyperglycemia-3/NN	det||medium-6/NN||the-5/DT	nsubjpass||exchanged-12/VBN||medium-6/NN	vmod||medium-6/NN||containing-7/VBG	num||glucose-10/NN||11-8/CD	nn||glucose-10/NN||mm-9/NN	dobj||containing-7/VBG||glucose-10/NN	auxpass||exchanged-12/VBN||was-11/VBD	root||ROOT-0/null||exchanged-12/VBN	det||medium-15/NN||the-14/DT	prep_with||exchanged-12/VBN||medium-15/NN	vmod||medium-15/NN||containing-16/VBG	num||glucose-19/NN||33-17/CD	nn||glucose-19/NN||mm-18/NN	iobj||containing-16/VBG||glucose-19/NN	det||hours-22/NNS||every-20/DT	num||hours-22/NNS||12-21/CD	dobj||containing-16/VBG||hours-22/NNS	hyperglycemia-3||glucose-19||no||for intermittent hyperglycemia, the medium containing 11 mm glucose was exchanged with the medium containing 33 mm glucose every 12 hours.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||level-4/NN||the-3/DT	dobj||evaluate-2/VB||level-4/NN	prep_of||level-4/NN||pain-6/NN	prep_during||evaluate-2/VB||phacoemulsification-8/NN	amod||implantation-13/NN||foldable-10/JJ	amod||implantation-13/NN||intraocular-11/JJ	nn||implantation-13/NN||lens-12/NN	prep_during||evaluate-2/VB||implantation-13/NN	conj_and||phacoemulsification-8/NN||implantation-13/NN	prep_under||evaluate-2/VB||instillation-15/NN	amod||eyedrops-20/NNS||tetracaine-17/JJ	number||%-19/NN||0.5-18/CD	amod||eyedrops-20/NNS||%-19/NN	prep_of||instillation-15/NN||eyedrops-20/NNS	det||combination-23/NN||a-22/DT	prep_versus||eyedrops-20/NNS||combination-23/NN	dep||%-27/NN||lidocaine-25/JJ	number||%-27/NN||2-26/CD	amod||gel-28/NN||%-27/NN	prep_of||combination-23/NN||gel-28/NN	prep_of||combination-23/NN||instillation-30/NN	conj_and||gel-28/NN||instillation-30/NN	amod||eyedrops-33/NNS||tetracaine-32/JJ	prep_of||eyedrops-20/NNS||eyedrops-33/NNS	pain-6||tetracaine-32||yes||to evaluate the level of pain during phacoemulsification and foldable intraocular lens implantation under instillation of tetracaine 0.5% eyedrops versus a combination of lidocaine 2% gel and instillation of tetracaine eyedrops.
amod||levels-3/NNS||total-1/JJ	nn||levels-3/NNS||cholesterol-2/NN	nsubjpass||correlated-10/VBN||levels-3/NNS	num||mg/dl-6/NN||200-5/CD	prep_above||levels-3/NNS||mg/dl-6/NN	aux||correlated-10/VBN||have-7/VBP	advmod||correlated-10/VBN||repeatedly-8/RB	auxpass||correlated-10/VBN||been-9/VBN	root||ROOT-0/null||correlated-10/VBN	det||factor-15/NN||an-12/DT	amod||factor-15/NN||independent-13/JJ	nn||factor-15/NN||risk-14/NN	prep_as||correlated-10/VBN||factor-15/NN	prep_for||factor-15/NN||development-17/NN	amod||vascular-20/NN||peripheral-19/JJ	prep_of||development-17/NN||vascular-20/NN	appos||vascular-20/NN||pvd-22/NN	prep_of||development-17/NN||coronaryarterydisease-25/NN	conj_and||vascular-20/NN||coronaryarterydisease-25/NN	appos||vascular-20/NN||cad-27/NN	amod||attention-32/NN||considerable-31/JJ	nsubjpass||directed-35/VBN||attention-32/NN	aux||directed-35/VBN||has-33/VBZ	auxpass||directed-35/VBN||been-34/VBN	conj_and||correlated-10/VBN||directed-35/VBN	prepc_toward||directed-35/VBN||evaluating-37/VBG	dobj||evaluating-37/VBG||mechanisms-38/NNS	dobj||impact-43/VB||which-40/WDT	nsubj||impact-43/VB||hypercholesterolemia-41/NN	aux||impact-43/VB||may-42/MD	prepc_by||evaluating-37/VBG||impact-43/VB	nn||outcomes-45/NNS||vascular-44/NN	dobj||impact-43/VB||outcomes-45/NNS	nsubj||include-48/VBP||these-47/DT	parataxis||correlated-10/VBN||include-48/VBP	det||results-50/NNS||both-49/DT	dobj||include-48/VBP||results-50/NNS	amod||cholesterol-53/NN||direct-52/JJ	prep_of||results-50/NNS||cholesterol-53/NN	vmod||cholesterol-53/NN||lowering-54/VBG	dobj||lowering-54/VBG||therapies-55/NNS	nn||interventions-58/NNS||alternative-57/NN	dobj||lowering-54/VBG||interventions-58/NNS	conj_and||therapies-55/NNS||interventions-58/NNS	prepc_for||lowering-54/VBG||improving-60/VBG	nn||function-62/NN||vascular-61/NN	dobj||improving-60/VBG||function-62/NN	hypercholesterolemia-41||cholesterol-53||no||total cholesterol levels above 200 mg/dl have repeatedly been correlated as an independent risk factor for development of peripheral vascular (pvd) and coronaryarterydisease (cad), and considerable attention has been directed toward evaluating mechanisms by which hypercholesterolemia may impact vascular outcomes; these include both results of direct cholesterol lowering therapies and alternative interventions for improving vascular function.
nsubjpass||defined-5/VBN||uncontrolled-2/NNP	auxpass||defined-5/VBN||was-4/VBD	ccomp||¥-18/VBZ||defined-5/VBN	nn||¥-11/NNP||hemoglobin-7/NN	nn||¥-11/NNP||a1c-8/NNS	nn||¥-11/NNP||â-9/NN	nn||¥-11/NNP||-10/NNP	prep_as||defined-5/VBN||¥-11/NNP	prep_for||¥-11/NNP||diabetes-13/NN	nn||-17/NNS||bp-15/NN	nn||-17/NNS||â-16/NN	nsubj||¥-18/VBZ||-17/NNS	root||ROOT-0/null||¥-18/VBZ	num||mmhg-20/NN||140/90-19/CD	dobj||¥-18/VBZ||mmhg-20/NN	dep||mmhg-20/NN||â-22/NN	vmod||â-22/NN||-23/VBN	number||130/80-25/CD||¥-24/CD	dobj||-23/VBN||130/80-25/CD	xcomp||-23/VBN||mmhg-26/VBG	mark||present-29/VBP||if-27/IN	nsubj||present-29/VBP||diabetes-28/NNP	advcl||mmhg-26/VBG||present-29/VBP	prep_for||¥-18/VBZ||hypertension-32/NN	amod||cholesterol-38/NN||low-35/JJ	nn||cholesterol-38/NN||density-36/NN	nn||cholesterol-38/NN||lipoprotein-37/NN	prep_for||¥-18/VBZ||cholesterol-38/NN	conj_and||hypertension-32/NN||cholesterol-38/NN	dep||hypertension-32/NN||ldl-c-40/JJ	nn||¥-44/NNP||â-42/NNP	nn||¥-44/NNP||-43/NNP	dobj||¥-18/VBZ||¥-44/NNP	iobj||¥-18/VBZ||¥-44/NNP	num||mg/dl-46/NN||130-45/CD	dep||¥-44/NNP||mg/dl-46/NN	parataxis||¥-18/VBZ||â-48/VB	nn||¥-50/NNP||-49/NNP	nsubj||present-55/VBP||¥-50/NNP	number||mg/dl-52/JJ||100-51/CD	dep||present-55/VBP||mg/dl-52/JJ	mark||present-55/VBP||if-53/IN	nsubj||present-55/VBP||diabetes-54/NNP	xcomp||â-48/VB||present-55/VBP	prep_for||¥-18/VBZ||hyperlipidemia-58/NN	cholesterol-38||hyperlipidemia-58||no_rel||'uncontrolled' was defined as hemoglobin a1c â¥ for diabetes, bp â¥ 140/90 mmhg (â¥ 130/80 mmhg if diabetes present) for hypertension, and low density lipoprotein cholesterol (ldl-c) â¥ 130 mg/dl (â¥ 100 mg/dl if diabetes present) for hyperlipidemia.
det||positivehiv-3/NN||a-2/DT	nsubj||serostatus-4/VBZ||positivehiv-3/NN	root||ROOT-0/null||serostatus-4/VBZ	prep_of||serostatus-4/VBZ||one-6/CD	det||partners-9/NNS||the-8/DT	prep_of||one-6/CD||partners-9/NNS	cop||predictor-13/NN||was-10/VBD	det||predictor-13/NN||a-11/DT	amod||predictor-13/NN||strong-12/JJ	rcmod||partners-9/NNS||predictor-13/NN	prep_of||predictor-13/NN||infection-15/NN	det||partner-19/NN||the-17/DT	amod||partner-19/NN||other-18/JJ	prep_in||infection-15/NN||partner-19/NN	num||%-22/NN||48-21/CD	prep_as||partner-19/NN||%-22/NN	prep_of||%-22/NN||individuals-24/NNS	nsubj||resolved-26/VBN||individuals-24/NNS	rcmod||individuals-24/NNS||resolved-26/VBN	prep_as||resolved-26/VBN||infected-30/NNS	rcmod||infected-30/NNS||had-33/VBD	det||spouse-36/NN||an-34/DT	amod||spouse-36/NN||hiv-infected-35/JJ	dobj||had-33/VBD||spouse-36/NN	positivehiv-3||hiv--1||no||" a positivehiv serostatus of one of the partners was a strong predictor of infection in the other partner as 48% of individuals who resolved as ""infected"" had an hiv-infected spouse."
aux||characterize-3/VB||to-1/TO	advmod||characterize-3/VB||better-2/RBR	advcl||examined-10/VBD||characterize-3/VB	det||substrates-5/NNS||the-4/DT	dobj||characterize-3/VB||substrates-5/NNS	prep_of||substrates-5/NNS||dicer-2-7/CD	nsubj||examined-10/VBD||we-9/PRP	root||ROOT-0/null||examined-10/VBD	det||sirnas-13/NNS||the-11/DT	amod||sirnas-13/NNS||virus-derived-12/JJ	nsubj||produced-14/VBD||sirnas-13/NNS	ccomp||examined-10/VBD||produced-14/VBD	det||response-20/NN||the-16/DT	amod||response-20/NN||drosophila-17/JJ	amod||response-20/NN||antiviral-18/JJ	nn||response-20/NN||rnai-19/NN	prep_during||produced-14/VBD||response-20/NN	num||viruses-24/NNS||four-22/CD	amod||viruses-24/NNS||different-23/JJ	prep_to||produced-14/VBD||viruses-24/NNS	vmod||viruses-24/NNS||using-25/VBG	amod||sequencing-27/NN||high-throughput-26/JJ	dobj||using-25/VBG||sequencing-27/NN	virus--1||viruses-24||no||to better characterize the substrates of dicer-2, we examined the virus-derived sirnas produced during the drosophila antiviral rnai response to four different viruses using high-throughput sequencing.
nsubj||employs-9/VBZ||borreliaburgdorferi-1/NNS	det||agent-5/NN||the-3/DT	amod||agent-5/NN||etiologic-4/JJ	appos||borreliaburgdorferi-1/NNS||agent-5/NN	prep_of||agent-5/NN||lymedisease-7/NN	root||ROOT-0/null||employs-9/VBZ	amod||means-11/NNS||sophisticated-10/JJ	dobj||employs-9/VBZ||means-11/NNS	nsubj||evade-13/VB||means-11/NNS	aux||evade-13/VB||to-12/TO	xcomp||employs-9/VBZ||evade-13/VB	xcomp||evade-13/VB||killing-14/VBG	poss||hosts-18/NNS||its-16/PRP$	amod||hosts-18/NNS||mammalian-17/JJ	prep_by||killing-14/VBG||hosts-18/NNS	lymedisease-7||borreliaburgdorferi-1||no||borreliaburgdorferi , the etiologic agent of lymedisease, employs sophisticated means to evade killing by its mammalian hosts.
amod||survival-2/NN||cumulative-1/JJ	nsubjpass||analyzed-12/VBN||survival-2/NN	nsubjpass||analyzed-12/VBN||survival-2/NN	amod||rates-10/NNS||hepatocellular-4/JJ	amod||rates-10/NNS||carcinoma-5/JJ	appos||rates-10/NNS||hcc-7/NN	nn||rates-10/NNS||development-9/NN	conj_and||survival-2/NN||rates-10/NNS	nsubjpass||analyzed-12/VBN||rates-10/NNS	auxpass||analyzed-12/VBN||were-11/VBD	root||ROOT-0/null||analyzed-12/VBN	conj_or||analyzed-12/VBN||analyzed-12/VBN	nn||abusive-15/NNS||alcohol-14/NN	prep_in||analyzed-12/VBN||abusive-15/NNS	amod||patients-18/NNS||cirrhotic-17/JJ	appos||abusive-15/NNS||patients-18/NNS	nn||virusinfection-23/NN||hepatitis-22/NN	prep_with||analyzed-12/VBN||virusinfection-23/NN	prep_without||analyzed-12/VBN||virusinfection-23/NN	alcohol-14||virusinfection-23||no_rel||cumulative survival and hepatocellular carcinoma (hcc) development rates were analyzed in alcohol abusive, cirrhotic patients with or without hepatitis virusinfection.
prep_during||believed-15/VBN||inhalationalanthrax-2/NN	nsubjpass||believed-15/VBN||internalization-4/NN	nsubj||step-20/NN||internalization-4/NN	amod||spores-7/NNS||bacillusanthracis-6/JJ	prep_of||internalization-4/NN||spores-7/NNS	nn||cells-10/NNS||host-9/NN	prep_by||spores-7/NNS||cells-10/NNS	det||lung-13/NN||the-12/DT	prep_within||cells-10/NNS||lung-13/NN	auxpass||believed-15/VBN||is-14/VBZ	root||ROOT-0/null||believed-15/VBN	aux||step-20/NN||to-16/TO	cop||step-20/NN||be-17/VB	det||step-20/NN||a-18/DT	amod||step-20/NN||key-19/JJ	xcomp||believed-15/VBN||step-20/NN	prepc_for||step-20/NN||initiating-22/VBG	det||transition-24/NN||the-23/DT	dobj||initiating-22/VBG||transition-24/NN	det||stages-30/NNS||the-26/DT	amod||disseminated-29/JJ||localized-27/JJ	dep||disseminated-29/JJ||to-28/TO	amod||stages-30/NNS||disseminated-29/JJ	prep_from||initiating-22/VBG||stages-30/NNS	prep_of||stages-30/NNS||infection-32/NN	inhalationalanthrax-2||bacillusanthracis-6||no||during inhalationalanthrax, internalization of bacillusanthracis spores by host cells within the lung is believed to be a key step for initiating the transition from the localized to disseminated stages of infection.
det||amount-2/NN||the-1/DT	nsubj||less-10/JJR||amount-2/NN	prep_of||amount-2/NN||fentanyl-4/NN	vmod||fentanyl-4/NN||required-5/VBN	amod||pain-8/NN||tourniquet-7/JJ	prep_for||required-5/VBN||pain-8/NN	cop||less-10/JJR||was-9/VBD	root||ROOT-0/null||less-10/JJR	amod||groups-13/NNS||adjuvant-12/JJ	prep_in||less-10/JJR||groups-13/NNS	advmod||compared-15/VBN||when-14/WRB	advcl||less-10/JJR||compared-15/VBN	nn||group-18/NN||control-17/NN	prep_with||compared-15/VBN||group-18/NN	pain-8||fentanyl-4||yes||the amount of fentanyl required for tourniquet pain was less in adjuvant groups when compared with control group.
det||guideline-3/NN||the-1/DT	amod||guideline-3/NN||national-2/JJ	nsubj||recommends-4/VBZ||guideline-3/NN	root||ROOT-0/null||recommends-4/VBZ	num||diagnosis-7/NN||three-5/CD	amod||diagnosis-7/NN||different-6/JJ	dep||recommends-4/VBZ||diagnosis-7/NN	nn||strategies-10/NNS||treatment-9/NN	dep||recommends-4/VBZ||strategies-10/NNS	conj_and||diagnosis-7/NN||strategies-10/NNS	nn||i-15/NNS||health-12/NN	nn||i-15/NNS||post-13/NN	nn||i-15/NNS||level-14/NN	prep_at||diagnosis-7/NN||i-15/NNS	det||use-18/NN||the-17/DT	dobj||recommends-4/VBZ||use-18/NN	det||p.falciparum-21/NN||a-20/DT	prep_of||use-18/NN||p.falciparum-21/NN	punct||rdt-25/NN||/-22/:	amod||rdt-25/NN||vivax-23/JJ	amod||rdt-25/NN||specific-24/JJ	dep||use-18/NN||rdt-25/NN	nn||tool-28/NN||diagnosis-27/NN	prep_as||rdt-25/NN||tool-28/NN	aux||treat-31/VB||to-30/TO	prep_as||rdt-25/NN||treat-31/VB	conj_and||tool-28/NN||treat-31/VB	vmod||tool-28/NN||treat-31/VB	prep_with||treat-31/VB||artemether-lumefantrine-33/NN	appos||artemether-lumefantrine-33/NN||al-35/NNP	amod||cq-40/NN||chloroquine-38/JJ	prep_with||treat-31/VB||cq-40/NN	conj_or||artemether-lumefantrine-33/NN||cq-40/NN	prep_with||treat-31/VB||referral-43/NN	conj_or||artemether-lumefantrine-33/NN||referral-43/NN	mark||diagnosed-48/VBN||if-44/IN	det||patient-46/NN||the-45/DT	nsubjpass||diagnosed-48/VBN||patient-46/NN	auxpass||diagnosed-48/VBN||was-47/VBD	advcl||treat-31/VB||diagnosed-48/VBN	prep_with||diagnosed-48/VBN||p.falciparum-50/NN	prep_with||diagnosed-48/VBN||p.vivax-52/NN	conj_or||p.falciparum-50/NN||p.vivax-52/NN	neg||malaria-55/NN||no-54/DT	prep_with||diagnosed-48/VBN||malaria-55/NN	conj_or||p.falciparum-50/NN||malaria-55/NN	dep||rdt-25/NN||respectively-57/RB	nn||pan/pf-60/NN||parascreen-59/NN	dep||use-18/NN||pan/pf-60/NN	vmod||pan/pf-60/NN||based-61/VBN	dobj||based-61/VBN||strategy-62/NN	csubj||diagnosed-101/VBD||ii-65/VB	det||use-68/NN||the-67/DT	dobj||ii-65/VB||use-68/NN	det||rdt-73/NN||a-70/DT	amod||rdt-73/NN||p.falciparum-71/JJ	amod||rdt-73/NN||specific-72/JJ	prep_of||ii-65/VB||rdt-73/NN	prep_of||ii-65/VB||al-75/NNP	conj_and||rdt-73/NN||al-75/NNP	nn||cases-78/NNS||p.falciparum-77/NN	prep_for||al-75/NNP||cases-78/NNS	prep_for||al-75/NNP||cq-80/NN	conj_and||cases-78/NNS||cq-80/NN	det||rest-83/NN||the-82/DT	prep_for||cases-78/NNS||rest-83/NN	nn||pf-86/NN||paracheck-85/NN	dep||cases-78/NNS||pf-86/NN	vmod||pf-86/NN||based-87/VBN	dobj||based-87/VBN||strategy-88/NN	conj_and||ii-65/VB||iii-92/VB	csubj||diagnosed-101/VBD||iii-92/VB	det||use-95/NN||the-94/DT	dobj||iii-92/VB||use-95/NN	prep_of||iii-92/VB||al-97/NNP	det||cases-100/NNS||all-99/DT	prep_for||al-97/NNP||cases-100/NNS	parataxis||recommends-4/VBZ||diagnosed-101/VBD	advmod||diagnosed-101/VBD||presumptively-102/RB	prep_as||diagnosed-101/VBD||malaria-104/NN	dep||malaria-104/NN||presumptive-106/NN	vmod||presumptive-106/NN||based-107/VBN	dobj||based-107/VBN||strategy-108/NN	malaria-104||lumefantrine--1||yes||the national guideline recommends three different diagnosis and treatment strategies at health post level i) the use of a p.falciparum / vivax specific rdt as diagnosis tool and to treat with artemether-lumefantrine (al), chloroquine (cq) or referral if the patient was diagnosed with p.falciparum , p.vivax or no malaria, respectively (parascreen pan/pf based strategy); ii) the use of a p.falciparum specific rdt and al for p.falciparum cases and cq for the rest (paracheck pf based strategy); and iii) the use of al for all cases diagnosed presumptively as malaria (presumptive based strategy).
det||line-3/NN||an-1/DT	amod||line-3/NN||independent-2/JJ	nsubjpass||provided-7/VBN||line-3/NN	prep_of||line-3/NN||evidence-5/NN	auxpass||provided-7/VBN||was-6/VBD	root||ROOT-0/null||provided-7/VBN	det||efficacy-10/NN||the-9/DT	prep_for||provided-7/VBN||efficacy-10/NN	amod||therapy-13/NN||antiviral-12/JJ	prep_of||efficacy-10/NN||therapy-13/NN	prepc_in||provided-7/VBN||preventing-15/VBG	dobj||preventing-15/VBG||phn-16/NN	prepc_in||provided-7/VBN||reducing-18/VBG	conj_and||preventing-15/VBG||reducing-18/VBG	amod||burden-21/NN||total-19/JJ	nn||burden-21/NN||pain-20/NN	dobj||reducing-18/VBG||burden-21/NN	antiviral-12||pain-20||no_rel||an independent line of evidence was provided for the efficacy of antiviral therapy in preventing phn and reducing total pain burden.
num||strategy-4/NN||one-1/CD	amod||strategy-4/NN||potential-2/JJ	nn||strategy-4/NN||vaccine-3/NN	nsubj||involves-10/VBZ||strategy-4/NN	det||fight-7/NN||the-6/DT	prep_in||strategy-4/NN||fight-7/NN	prep_against||fight-7/NN||meningococcaldisease-9/NN	root||ROOT-0/null||involves-10/VBZ	det||exploitation-12/NN||the-11/DT	dobj||involves-10/VBZ||exploitation-12/NN	amod||components-15/NNS||outer-membrane-14/JJ	prep_of||exploitation-12/NN||components-15/NNS	nn||lactamica-18/NN||neisseria-17/NN	prep_of||components-15/NNS||lactamica-18/NN	det||bacterium-22/NN||a-20/DT	amod||bacterium-22/NN||commensal-21/JJ	appos||lactamica-18/NN||bacterium-22/NN	advmod||related-24/VBN||closely-23/RB	amod||bacterium-22/NN||related-24/VBN	det||meningococcus-27/NNS||the-26/DT	prep_to||involves-10/VBZ||meningococcus-27/NNS	appos||meningococcus-27/NNS||neisseriameningitidis-29/NNS	meningococcaldisease-9||neisseriameningitidis-29||no||one potential vaccine strategy in the fight against meningococcaldisease involves the exploitation of outer-membrane components of neisseria lactamica , a commensal bacterium closely related to the meningococcus, neisseriameningitidis .
det||atom-4/NN||the-1/DT	amod||atom-4/NN||deprotonated-2/JJ	nn||atom-4/NN||oxygen-3/NN	nsubj||uncoordinated-11/VBD||atom-4/NN	nsubj||participates-13/VBZ||atom-4/NN	det||paoâ-7/NN||the-6/DT	poss||remains-10/NNS||paoâ-7/NN	amod||remains-10/NNS||ligand-9/JJ	prep_of||atom-4/NN||remains-10/NNS	root||ROOT-0/null||uncoordinated-11/VBD	conj_and||uncoordinated-11/VBD||participates-13/VBZ	nn||bonding-16/NN||hydrogen-15/NN	prep_in||participates-13/VBZ||bonding-16/NN	det||molecules-20/NNS||the-18/DT	amod||molecules-20/NNS||solvate-19/JJ	prep_with||participates-13/VBZ||molecules-20/NNS	oxygen-3||uncoordinated-11||no_rel||the deprotonated oxygen atom of the paoâ ligand remains uncoordinated and participates in hydrogen bonding with the solvate molecules.
det||study-3/NN||a-1/DT	amod||study-3/NN||cross-sectional-2/JJ	nsubj||conducted-4/VBD||study-3/NN	root||ROOT-0/null||conducted-4/VBD	prep_in||conducted-4/VBD||2006/7-6/CD	det||sample-10/NN||a-8/DT	nn||sample-10/NN||convenience-9/NN	prep_with||conducted-4/VBD||sample-10/NN	amod||users-15/NNS||295-12/JJ	amod||users-15/NNS||illicit-13/JJ	nn||users-15/NNS||drug-14/NN	prep_of||sample-10/NN||users-15/NNS	nn||janeiro-19/NNP||rio-17/NNP	nn||janeiro-19/NNP||de-18/FW	prep_in||users-15/NNS||janeiro-19/NNP	xcomp||conducted-4/VBD||assessing-21/VBG	dobj||assessing-21/VBG||knowledge-22/NN	amod||transmission-25/NN||aids/hiv-24/JJ	prep_on||assessing-21/VBG||transmission-25/NN	poss||relationship-28/NN||its-27/PRP$	prep_on||assessing-21/VBG||relationship-28/NN	conj_and||transmission-25/NN||relationship-28/NN	nn||testing-31/NN||hiv-30/NN	prep_with||assessing-21/VBG||testing-31/NN	aids--1||hiv-30||no||a cross-sectional study conducted in 2006/7 with a convenience sample of 295 illicit drug users in rio de janeiro, assessing knowledge on aids/hiv transmission and its relationship with hiv testing.
poss||data-2/NNS||our-1/PRP$	nsubj||demonstrate-3/VBP||data-2/NNS	root||ROOT-0/null||demonstrate-3/VBP	mark||arise-11/VB||that-4/IN	amod||cells-9/NNS||il-10-secreting-5/JJ	amod||cells-9/NNS||cd8-6/JJ	amod||cells-9/NNS||+-7/JJ	nn||cells-9/NNS||t-8/NN	nsubj||arise-11/VB||cells-9/NNS	aux||arise-11/VB||can-10/MD	ccomp||demonstrate-3/VBP||arise-11/VB	amod||infection-15/NN||chronic-13/JJ	nn||infection-15/NN||mtb-14/NN	prep_during||arise-11/VB||infection-15/NN	mark||remains-28/VBZ||although-17/IN	det||significance-19/NN||the-18/DT	nsubj||remains-28/VBZ||significance-19/NN	det||population-24/NN||this-21/DT	nn||population-24/NN||t-22/NN	nn||population-24/NN||cell-23/NN	prep_of||significance-19/NN||population-24/NN	nn||pathogenesis-27/NNS||tuberculosis-26/NNP	prep_in||population-24/NN||pathogenesis-27/NNS	advcl||arise-11/VB||remains-28/VBZ	acomp||remains-28/VBZ||unclear-29/JJ	tuberculosis-26||mtb-14||no||our data demonstrate that il-10-secreting cd8+ t cells can arise during chronic mtb infection, although the significance of this t cell population in tuberculosis pathogenesis remains unclear.
amod||studies-2/NNS||clinical-1/JJ	nsubj||indicate-3/VBP||studies-2/NNS	root||ROOT-0/null||indicate-3/VBP	mark||option-13/NN||that-4/IN	det||implant-7/NN||this-5/DT	amod||implant-7/NN||dexamethasone-6/JJ	nsubj||option-13/NN||implant-7/NN	cop||option-13/NN||is-8/VBZ	det||option-13/NN||a-9/DT	amod||option-13/NN||promising-10/JJ	amod||option-13/NN||new-11/JJ	nn||option-13/NN||treatment-12/NN	ccomp||indicate-3/VBP||option-13/NN	prep_for||option-13/NN||patients-15/NNS	amod||macularedema-18/NN||persistent-17/JJ	prep_with||patients-15/NNS||macularedema-18/NN	vmod||macularedema-18/NN||resulting-19/VBG	amod||occlusion-23/NN||retinal-21/JJ	nn||occlusion-23/NN||vein-22/NN	prep_from||resulting-19/VBG||occlusion-23/NN	advmod||resulting-19/VBG||diabeticretinopathy-25/RB	ccomp||indicate-3/VBP||uveitis-28/NNS	conj_and||option-13/NN||uveitis-28/NNS	amod||syndrome-31/NN||irvine-gass-30/JJ	conj_and||option-13/NN||syndrome-31/NN	conj_or||uveitis-28/NNS||syndrome-31/NN	macularedema-18||dexamethasone-6||no_rel||clinical studies indicate that this dexamethasone implant is a promising new treatment option for patients with persistent macularedema resulting from retinal vein occlusion, diabeticretinopathy, and uveitis or irvine-gass syndrome.
advmod||diagnosed-3/JJ||newly-2/RB	amod||patients-4/NNS||diagnosed-3/JJ	prep_in||documented-31/VBN||patients-4/NNS	prep_with||patients-4/NNS||hodgkinlymphoma-6/NN	dep||documented-31/VBN||hl-8/VB	det||effect-11/NN||the-10/DT	nsubjpass||documented-31/VBN||effect-11/NN	prep_of||effect-11/NN||doxorubicin-13/NN	prep_of||effect-11/NN||bleomycin-15/NN	conj_and||doxorubicin-13/NN||bleomycin-15/NN	prep_of||effect-11/NN||vinblastine-17/NN	conj_and||doxorubicin-13/NN||vinblastine-17/NN	prep_of||effect-11/NN||dacarbazine-19/NN	conj_and||doxorubicin-13/NN||dacarbazine-19/NN	dep||doxorubicin-13/NN||abvd-21/VBN	amod||neutropenia-25/NN||related-24/VBN	dep||doxorubicin-13/NN||neutropenia-25/NN	amod||delivery-28/NN||chemotherapy-27/JJ	prep_on||neutropenia-25/NN||delivery-28/NN	auxpass||documented-31/VBN||is-29/VBZ	advmod||documented-31/VBN||poorly-30/RB	root||ROOT-0/null||documented-31/VBN	hl-8||dacarbazine-19||yes||in newly diagnosed patients with hodgkinlymphoma (hl) the effect of doxorubicin, bleomycin, vinblastine and dacarbazine (abvd)-related neutropenia on chemotherapy delivery is poorly documented.
num||persons-4/NNS||1345-2/CD	amod||persons-4/NNS||hiv/aids-3/JJ	prep_among||exposed-16/VBN||persons-4/NNS	amod||care-7/NN||active-6/JJ	prep_in||persons-4/NNS||care-7/NN	prep_between||care-7/NN||2001-9/CD	prep_between||care-7/NN||2007-11/CD	conj_and||2001-9/CD||2007-11/CD	amod||individuals-14/NNS||169-13/JJ	nsubjpass||exposed-16/VBN||individuals-14/NNS	auxpass||exposed-16/VBN||were-15/VBD	root||ROOT-0/null||exposed-16/VBN	prep_to||exposed-16/VBN||aeds-18/NNS	det||peripheralneuropathy/neuropathicpain-23/NN||the-20/DT	amod||peripheralneuropathy/neuropathicpain-23/NN||following-21/JJ	nn||peripheralneuropathy/neuropathicpain-23/NN||indications-22/NNS	prep_for||aeds-18/NNS||peripheralneuropathy/neuropathicpain-23/NN	num||%-26/NN||60-25/CD	appos||peripheralneuropathy/neuropathicpain-23/NN||%-26/NN	prep_for||aeds-18/NNS||seizure/epilepsy-29/NN	conj_and||peripheralneuropathy/neuropathicpain-23/NN||seizure/epilepsy-29/NN	num||%-32/NN||24-31/CD	appos||seizure/epilepsy-29/NN||%-32/NN	nn||disorder-36/NN||mood-35/NN	prep_for||aeds-18/NNS||disorder-36/NN	conj_and||peripheralneuropathy/neuropathicpain-23/NN||disorder-36/NN	num||%-39/NN||13-38/CD	appos||disorder-36/NN||%-39/NN	nn||disorder-43/NN||movement-42/NN	prep_for||aeds-18/NNS||disorder-43/NN	conj_and||peripheralneuropathy/neuropathicpain-23/NN||disorder-43/NN	num||%-46/NN||2-45/CD	appos||disorder-43/NN||%-46/NN	aids--1||hiv--1||no||among 1345 hiv/aids persons in active care between 2001 and 2007, 169 individuals were exposed to aeds for the following indications peripheralneuropathy/neuropathicpain (60%), seizure/epilepsy (24%), mood disorder (13%) and movement disorder (2%).
dep||contains-41/VBZ||figure-1/VB	det||representation-4/NN||a-2/DT	amod||representation-4/NN||schematic-3/JJ	dobj||figure-1/VB||representation-4/NN	prepc_of||representation-4/NN||concentrating-6/VBG	dobj||concentrating-6/VBG||viruses-7/NNS	det||system-13/NN||an-9/DT	amod||system-13/NN||aqueous-10/JJ	amod||system-13/NN||two-phase-11/JJ	nn||system-13/NN||micellar-12/NN	prep_with||concentrating-6/VBG||system-13/NN	vmod||system-13/NN||containing-14/VBG	amod||surfactant-17/NN||triton-15/JJ	amod||surfactant-17/NN||x-114-16/JJ	dobj||containing-14/VBG||surfactant-17/NN	det||detection-21/NN||the-20/DT	prep_prior_to||containing-14/VBG||detection-21/NN	det||virus-24/NN||the-23/DT	prep_of||detection-21/NN||virus-24/NN	det||immunoassay-28/NN||the-26/DT	amod||immunoassay-28/NN||lateral-flow-27/JJ	prep_through||containing-14/VBG||immunoassay-28/NN	det||version-31/NN||the-29/DT	amod||version-31/NN||online-30/JJ	dep||immunoassay-28/NN||version-31/NN	det||article-34/NN||this-33/DT	prep_of||version-31/NN||article-34/NN	dep||s00216-010-4213-7-39/JJ||doi10-36/RB	num||/-38/NNS||.1007-37/CD	npadvmod||s00216-010-4213-7-39/JJ||/-38/NNS	dep||containing-14/VBG||s00216-010-4213-7-39/JJ	root||ROOT-0/null||contains-41/VBZ	amod||material-43/NN||supplementary-42/JJ	nsubj||contains-41/VBZ||material-43/NN	nsubj||available-47/JJ||material-43/NN	cop||available-47/JJ||is-46/VBZ	rcmod||material-43/NN||available-47/JJ	amod||users-50/NNS||authorized-49/JJ	prep_to||available-47/JJ||users-50/NNS	virus-24||viruses-7||no||figure a schematic representation of concentrating viruses with an aqueous two-phase micellar system containing triton x-114 surfactant prior to the detection of the virus through the lateral-flow immunoassay  the online version of this article (doi10.1007/s00216-010-4213-7) contains supplementary material, which is available to authorized users.
det||total-2/NN||a-1/DT	nsubj||referred-6/VBD||total-2/NN	nsubjpass||challenged-25/VBN||total-2/NN	number||consecutively-5/CD||580-4/CD	prep_of||total-2/NN||consecutively-5/CD	root||ROOT-0/null||referred-6/VBD	amod||patients-8/NNS||adult-7/JJ	dobj||referred-6/VBD||patients-8/NNS	det||history-11/NN||a-10/DT	prep_with||referred-6/VBD||history-11/NN	amod||allergicreactions-15/NNS||non-serious-13/JJ	nn||allergicreactions-15/NNS||cutaneous-14/NNS	prep_of||history-11/NN||allergicreactions-15/NNS	prep_to||referred-6/VBD||penicillin-17/NN	neg||ige-22/NN||no-21/DT	prep_with||challenged-25/VBN||ige-22/NN	auxpass||challenged-25/VBN||were-24/VBD	conj_but||referred-6/VBD||challenged-25/VBN	amod||doses-28/NNS||therapeutic-27/JJ	prep_with||challenged-25/VBN||doses-28/NNS	nn||v-31/NN||penicillin-30/NN	prep_of||doses-28/NNS||v-31/NN	appos||v-31/NN||phenoxymethylpenicillin-33/NN	prep_of||doses-28/NNS||penicilling-36/NN	conj_or||v-31/NN||penicilling-36/NN	appos||penicilling-36/NN||benzylpenicillin-38/NN	prep_of||doses-28/NNS||both-42/DT	conj_or||v-31/NN||both-42/DT	allergicreactions-15||penicilling-36||no||a total of 580 consecutively referred adult patients with a history of non-serious cutaneous allergicreactions to penicillin, but with no ige, were challenged with therapeutic doses of penicillin v (phenoxymethylpenicillin), penicilling (benzylpenicillin), or both.
nsubj||reduced-8/VBD||pretreatment-1/NN	nn||kg-7/NN||sufentanil-3/NN	num||kg-7/NN||0.3-4/CD	nn||kg-7/NN||âµg-5/NN	nn||kg-7/NN||/-6/NN	prep_with||pretreatment-1/NN||kg-7/NN	root||ROOT-0/null||reduced-8/VBD	det||severity-10/NN||the-9/DT	dobj||reduced-8/VBD||severity-10/NN	amod||pain-15/NN||microemulsion-12/JJ	amod||pain-15/NN||propofol-13/JJ	nn||pain-15/NN||injection-14/NN	prep_of||severity-10/NN||pain-15/NN	prepc_without||reduced-8/VBD||increasing-17/VBG	amod||pressure-20/NN||arterial-18/JJ	nn||pressure-20/NN||blood-19/NN	dobj||increasing-17/VBG||pressure-20/NN	nn||rate-23/NN||heart-22/NN	dobj||increasing-17/VBG||rate-23/NN	conj_and||pressure-20/NN||rate-23/NN	amod||intubation-26/NN||endotracheal-25/JJ	prep_after||increasing-17/VBG||intubation-26/NN	pain-15||sufentanil-3||yes||pretreatment with sufentanil 0.3 âµg/kg reduced the severity of microemulsion propofol injection pain without increasing arterial blood pressure and heart rate after endotracheal intubation.
amod||titers-3/NNS||anti-env-1/JJ	nn||titers-3/NNS||antibody-2/NN	nsubj||had-7/VBD||titers-3/NNS	num||lu-6/NN||100,000-5/CD	prep_above||titers-3/NNS||lu-6/NN	root||ROOT-0/null||had-7/VBD	number||%-9/NN||75-8/CD	amod||value-12/NN||%-9/NN	amod||value-12/NN||positive-10/JJ	amod||value-12/NN||predictive-11/JJ	dobj||had-7/VBD||value-12/NN	number||%-15/NN||79-14/CD	amod||value-18/NN||%-15/NN	amod||value-18/NN||negative-16/JJ	amod||value-18/NN||predictive-17/JJ	dobj||had-7/VBD||value-18/NN	conj_and||value-12/NN||value-18/NN	prepc_for||had-7/VBD||identifying-20/VBG	det||sub-type-23/NN||the-21/DT	nn||sub-type-23/NN||ham/tsp-22/NN	dobj||identifying-20/VBG||sub-type-23/NN	antibody-2||ham--1||no_rel||anti-env antibody titers above 100,000 lu had 75% positive predictive value and 79% negative predictive value for identifying the ham/tsp sub-type.
prep_among||used-6/VBN||them-2/PRP	nsubjpass||used-6/VBN||doxycycline-4/NN	nsubjpass||used-6/VBN||doxycycline-4/NN	auxpass||used-6/VBN||is-5/VBZ	root||ROOT-0/null||used-6/VBN	conj_or||used-6/VBN||used-6/VBN	advmod||used-6/VBN||alone-7/RB	nn||chemoprophylaxis-10/NNS||malaria-9/NN	prep_for||used-6/VBN||chemoprophylaxis-10/NNS	prep_in||used-6/VBN||combination-13/NN	nn||derivatives-18/NNS||quinine-15/NN	conj_or||quinine-15/NN||artemisinin-17/NN	nn||derivatives-18/NNS||artemisinin-17/NN	prep_with||used-6/VBN||derivatives-18/NNS	nn||treatment-21/NN||malaria-20/NN	prep_for||derivatives-18/NNS||treatment-21/NN	malaria-20||quinine-15||yes||among them, doxycycline is used alone for malaria chemoprophylaxis or in combination with quinine or artemisinin derivatives for malaria treatment.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	amod||parameters-4/NNS||anthropometric-3/JJ	dobj||evaluated-2/VBN||parameters-4/NNS	nn||index-12/NN||height-6/NN	dep||index-12/NN||weight-8/NN	dep||index-12/NN||body-10/NN	nn||index-12/NN||mass-11/NN	dep||parameters-4/NNS||index-12/NN	appos||index-12/NN||bmi-14/NN	appos||index-12/NN||waist-17/NN	nn||circumference-20/NN||hip-19/NN	appos||index-12/NN||circumference-20/NN	conj_and||waist-17/NN||circumference-20/NN	appos||index-12/NN||waist-22/NN	nn||ratio-25/NN||height-24/NN	prep_to||waist-22/NN||ratio-25/NN	dobj||evaluated-2/VBN||additionally-29/RB	advmod||parameters-4/NNS||additionally-29/RB	conj_and||parameters-4/NNS||additionally-29/RB	amod||biomarkers-33/NNS||cardiovascular-31/JJ	nn||biomarkers-33/NNS||risk-32/NN	dobj||evaluated-2/VBN||biomarkers-33/NNS	conj_and||parameters-4/NNS||biomarkers-33/NNS	amod||glucose-37/NN||fasting-35/JJ	nn||glucose-37/NN||plasma-36/NN	dep||biomarkers-33/NNS||glucose-37/NN	dep||biomarkers-33/NNS||hba1c-39/NNS	conj_and||glucose-37/NN||hba1c-39/NNS	dep||biomarkers-33/NNS||triglycerides-41/NNPS	conj_and||glucose-37/NN||triglycerides-41/NNPS	amod||cholesterol-44/NN||total-43/JJ	dep||biomarkers-33/NNS||cholesterol-44/NN	conj_and||glucose-37/NN||cholesterol-44/NN	dep||biomarkers-33/NNS||hdl-46/NN	conj_and||glucose-37/NN||hdl-46/NN	dep||biomarkers-33/NNS||ldl-48/NN	conj_and||glucose-37/NN||ldl-48/NN	dep||biomarkers-33/NNS||lipoprotein-51/NN	conj_and||glucose-37/NN||lipoprotein-51/NN	dep||lipoprotein-51/NN||a-53/SYM	num||patients-59/NNS||81-57/CD	amod||patients-59/NNS||acromegalic-58/JJ	prep_in||evaluated-2/VBN||patients-59/NNS	num||%-62/NN||58-61/CD	dep||patients-59/NNS||%-62/NN	vmod||%-62/NN||cured-63/VBN	prepc_compared_to||evaluated-2/VBN||to-66/TO	num||age-68/NN||320-67/CD	pobj||evaluated-2/VBN||age-68/NN	amod||controls-72/NNS||gender-matched-71/JJ	pobj||evaluated-2/VBN||controls-72/NNS	conj_and||age-68/NN||controls-72/NNS	appos||age-68/NN||ratio-74/NN	num||ratio-74/NN||14-75/CD	dep||evaluated-2/VBN||sampled-78/VBN	det||cohort-84/NN||the-80/DT	amod||cohort-84/NN||primary-81/JJ	nn||cohort-84/NN||care-82/NN	nn||cohort-84/NN||patient-83/NN	prep_from||sampled-78/VBN||cohort-84/NN	ccomp||evaluated-2/VBN||detect-85/VB	acromegalic-58||glucose-37||no_rel||we evaluated anthropometric parameters (height, weight, body mass index (bmi), waist and hip circumference, waist to height ratio) and, additionally, cardiovascular risk biomarkers (fasting plasma glucose, hba1c, triglycerides, total cholesterol, hdl, ldl, and lipoprotein (a), in 81 acromegalic patients (58% cured) compared to 320 age- and gender-matched controls (ratio 14), sampled from the primary care patient cohort detect.
nsubj||recruited-2/VBD||we-1/PRP	root||ROOT-0/null||recruited-2/VBD	num||patients-4/NNS||25-3/CD	dobj||recruited-2/VBD||patients-4/NNS	prep_with||recruited-2/VBD||type1diabetes-6/NNS	dep||type1diabetes-6/NNS||mean-8/VB	nn||â-11/NN||age-9/NN	num||â-11/NN||51-10/CD	dobj||mean-8/VB||â-11/NN	number||10-13/CD||±-12/CD	num||years-14/NNS||10-13/CD	tmod||mean-8/VB||years-14/NNS	dep||mean-8/VB||mean-16/VB	nn||duration-18/NN||disease-17/NN	dobj||mean-16/VB||duration-18/NN	num||years-23/NNS||26-19/CD	nn||years-23/NNS||â-20/NNP	nn||years-23/NNS||±-21/NNP	num||years-23/NNS||13-22/CD	tmod||mean-8/VB||years-23/NNS	num||type-28/NN||31-26/CD	amod||type-28/NN||insulin-treated-27/JJ	prep_with||recruited-2/VBD||type-28/NN	conj_and||type1diabetes-6/NNS||type-28/NN	num||patients-31/NNS||2-29/CD	amod||patients-31/NNS||diabetic-30/JJ	dep||type-28/NN||patients-31/NNS	dep||type-28/NN||mean-33/VB	nn||â-36/NN||age-34/NN	num||â-36/NN||66-35/CD	dobj||mean-33/VB||â-36/NN	number||8-38/CD||±-37/CD	num||years-39/NNS||8-38/CD	tmod||mean-33/VB||years-39/NNS	dep||mean-33/VB||mean-41/VB	nn||duration-43/NN||disease-42/NN	dobj||mean-41/VB||duration-43/NN	num||years-48/NNS||19-44/CD	nn||years-48/NNS||â-45/NNP	nn||years-48/NNS||±-46/NNP	num||years-48/NNS||9-47/CD	tmod||mean-33/VB||years-48/NNS	nsubj||received-52/VBD||who-51/WP	nsubj||sitagliptin-69/VBN||who-51/WP	prep_with||recruited-2/VBD||received-52/VBD	conj_and||type1diabetes-6/NNS||received-52/VBD	dobj||received-52/VBD||sitagliptin-53/NN	prep_with||received-52/VBD||metformin-55/NN	det||combination-59/NN||a-57/DT	amod||combination-59/NN||fixed-dose-58/JJ	prep_as||metformin-55/NN||combination-59/NN	num||mg-62/NN||50/1000-61/CD	npadvmod||once-63/RB||mg-62/NN	dep||received-52/VBD||once-63/RB	advmod||daily-66/JJ||twice-65/RB	dep||received-52/VBD||daily-66/JJ	conj_or||once-63/RB||daily-66/JJ	conj_and||type1diabetes-6/NNS||sitagliptin-69/VBN	conj_or||received-52/VBD||sitagliptin-69/VBN	nsubj||mg-72/VBP||100-71/CD	parataxis||sitagliptin-69/VBN||mg-72/VBP	advmod||mg-72/VBP||once-73/RB	advmod||mg-72/VBP||daily-74/RB	mark||metformin-79/VB||if-76/IN	nsubj||metformin-79/VB||intolerant-77/NN	aux||metformin-79/VB||to-78/TO	advcl||mg-72/VBP||metformin-79/VB	xcomp||mg-72/VBP||metformin-79/VB	amod||therapy-86/NN||ongoing-84/JJ	nn||therapy-86/NN||insulin-85/NN	prep_in_addition_to||sitagliptin-69/VBN||therapy-86/NN	num||â-89/NN||46-88/CD	prep_for||therapy-86/NN||â-89/NN	number||19-91/CD||±-90/CD	num||weeks-92/NNS||19-91/CD	dobj||sitagliptin-69/VBN||weeks-92/NNS	num||±-96/NNS||56-94/CD	nn||±-96/NNS||â-95/NN	dobj||sitagliptin-69/VBN||±-96/NNS	conj_and||weeks-92/NNS||±-96/NNS	num||weeks-98/NNS||14-97/CD	dep||±-96/NNS||weeks-98/NNS	advmod||±-96/NNS||respectively-100/RB	type1diabetes-6||sitagliptin-69||no||we recruited 25 patients with type1diabetes (mean age 51 â± 10 years, mean disease duration 26 â± 13 years) and 31 insulin-treated type 2 diabetic patients (mean age 66 â± 8 years, mean disease duration 19 â± 9 years), who received sitagliptin with metformin as a fixed-dose combination (50/1000 mg once or twice daily) or sitagliptin (100 mg once daily, if intolerant to metformin) in addition to ongoing insulin therapy for 46 â± 19 weeks and 56 â± 14 weeks, respectively.
nsubj||blocked-10/VBD||bay-1/NN	num||bay-1/NN||11-7082-2/CD	det||inhibitor-5/NN||an-4/DT	appos||bay-1/NN||inhibitor-5/NN	prep_of||inhibitor-5/NN||nf-îºb-7/NN	advmod||blocked-10/VBD||completely-9/RB	root||ROOT-0/null||blocked-10/VBD	det||astrocyte-12/JJ||the-11/DT	dobj||blocked-10/VBD||astrocyte-12/JJ	amod||astrocyte-12/JJ||swelling-13/VBG	prep_in||astrocyte-12/JJ||cultures-15/NNS	dep||cultures-15/NNS||pre-treated-16/VBN	prep_with||pre-treated-16/VBN||ammonia-18/NN	dep||cultures-15/NNS||followed-20/VBN	conj_and||pre-treated-16/VBN||followed-20/VBN	det||addition-23/NN||the-22/DT	prep_by||followed-20/VBN||addition-23/NN	det||mixture-26/NN||a-25/DT	prep_of||addition-23/NN||mixture-26/NN	prep_of||mixture-26/NN||cytokines-28/NNS	ammonia-18||swelling-13||no_rel||bay 11-7082, an inhibitor of nf-îºb, completely blocked the astrocyte swelling in cultures pre-treated with ammonia and followed by the addition of a mixture of cytokines.
det||strategies-4/NNS||the-2/DT	nn||strategies-4/NNS||prevention-3/NN	prep_of||involve-7/VBP||strategies-4/NNS	nsubj||involve-7/VBP||primordial-6/JJ	root||ROOT-0/null||involve-7/VBP	dobj||involve-7/VBP||improvement-8/NN	amod||status-11/NN||socioeconomic-10/JJ	prep_in||improvement-8/NN||status-11/NN	prep_in||improvement-8/NN||literacy-13/NN	conj_and||status-11/NN||literacy-13/NN	amod||financing-17/NN||adequate-15/JJ	nn||financing-17/NN||healthcare-16/NN	dobj||involve-7/VBP||financing-17/NN	conj_and||improvement-8/NN||financing-17/NN	amod||insurance-21/NN||public-19/JJ	nn||insurance-21/NN||health-20/NN	conj_and||improvement-8/NN||insurance-21/NN	conj_and||financing-17/NN||insurance-21/NN	amod||programme-27/NN||effective-23/JJ	amod||programme-27/NN||national-24/JJ	amod||programme-27/NN||cvd-25/JJ	nn||programme-27/NN||control-26/NN	appos||financing-17/NN||programme-27/NN	nn||policies-31/NNS||smoking-29/NN	nn||policies-31/NNS||control-30/NN	appos||financing-17/NN||policies-31/NNS	amod||control-34/NN||legislative-33/JJ	appos||financing-17/NN||control-34/NN	amod||fats-37/NNS||saturated-36/JJ	prep_of||control-34/NN||fats-37/NNS	amod||fats-40/NNS||trans-39/JJ	appos||financing-17/NN||fats-40/NNS	appos||financing-17/NN||salt-42/NN	conj_and||fats-40/NNS||salt-42/NN	appos||financing-17/NN||alcohol-44/NN	conj_and||fats-40/NNS||alcohol-44/NN	dobj||involve-7/VBP||development-47/NN	conj_and||improvement-8/NN||development-47/NN	prep_of||development-47/NN||facilities-49/NNS	prepc_for||involve-7/VBP||increasing-51/VBG	amod||activity-53/NN||physical-52/JJ	dobj||increasing-51/VBG||activity-53/NN	amod||planning-57/NN||better-55/JJR	amod||planning-57/NN||urban-56/JJ	prep_through||increasing-51/VBG||planning-57/NN	prep_through||increasing-51/VBG||school-based-59/NN	conj_and||planning-57/NN||school-based-59/NN	nn||interventions-62/NNS||worksite-61/NN	prep_through||increasing-51/VBG||interventions-62/NNS	conj_and||planning-57/NN||interventions-62/NNS	fats-40||cvd-25||no_rel||of the prevention strategies, primordial involve improvement in socioeconomic status and literacy, adequate healthcare financing and public health insurance, effective national cvd control programme, smoking control policies, legislative control of saturated fats, trans fats, salt and alcohol, and development of facilities for increasing physical activity through better urban planning and school-based and worksite interventions.
nsubj||demonstrated-3/VBN||fluoxetine-1/NN	nsubj||effective-7/JJ||fluoxetine-1/NN	aux||demonstrated-3/VBN||has-2/VBZ	root||ROOT-0/null||demonstrated-3/VBN	aux||effective-7/JJ||to-4/TO	cop||effective-7/JJ||be-5/VB	advmod||effective-7/JJ||as-6/RB	xcomp||demonstrated-3/VBN||effective-7/JJ	prep_as||effective-7/JJ||chlomipramine-9/NN	det||treatment-12/NN||the-11/DT	prep_in||effective-7/JJ||treatment-12/NN	prep_of||treatment-12/NN||obsessive-compulsive-disorder-14/NN	appos||obsessive-compulsive-disorder-14/NN||ocd-16/NN	ocd-16||chlomipramine-9||yes||fluoxetine has demonstrated to be as effective as chlomipramine in the treatment of obsessive-compulsive-disorder (ocd).
nsubj||found-2/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	mark||suggesting-25/VBG||that-3/IN	amod||cells-5/NNS||phototrophic-4/JJ	nsubj||suggesting-25/VBG||cells-5/NNS	cop||suggesting-25/VBG||are-6/VBP	advmod||impacted-8/JJ||less-7/RBR	acomp||suggesting-25/VBG||impacted-8/JJ	prep_by||impacted-8/JJ||irondeficiency-10/NN	det||correlates-13/NNS||this-12/DT	prep_by||impacted-8/JJ||correlates-13/NNS	conj_and||irondeficiency-10/NN||correlates-13/NNS	poss||content-18/NN||their-15/PRP$	amod||content-18/NN||higher-16/JJR	nn||content-18/NN||iron-17/NN	prep_with||suggesting-25/VBG||content-18/NN	det||basis-23/NN||a-20/DT	amod||basis-23/NN||per-21/IN	nn||basis-23/NN||cell-22/NN	prep_on||content-18/NN||basis-23/NN	ccomp||found-2/VBD||suggesting-25/VBG	det||capacity/ability-28/NN||a-26/DT	amod||capacity/ability-28/NN||greater-27/JJR	dobj||suggesting-25/VBG||capacity/ability-28/NN	nn||assimilation-31/NN||iron-30/NN	prep_for||suggesting-25/VBG||assimilation-31/NN	det||state-35/NN||this-33/DT	amod||state-35/NN||metabolic-34/JJ	prep_in||assimilation-31/NN||state-35/NN	irondeficiency-10||iron-30||yes||we found that phototrophic cells are less impacted by irondeficiency and this correlates with their higher iron content on a per cell basis, suggesting a greater capacity/ability for iron assimilation in this metabolic state.
det||subjects-5/NNS||the-2/DT	amod||subjects-5/NNS||first-3/JJ	num||subjects-5/NNS||14-4/CD	prep_for||induced-14/VBN||subjects-5/NNS	nsubjpass||induced-14/VBN||hypoglycemia-7/NN	dep||mg/dl-11/JJ||<-9/NNP	num||<-9/NNP||60-10/CD	dep||hypoglycemia-7/NN||mg/dl-11/JJ	auxpass||induced-14/VBN||was-13/VBD	root||ROOT-0/null||induced-14/VBN	advmod||increasing-17/VBG||gradually-16/RB	agent||induced-14/VBN||increasing-17/VBG	det||rate-22/NN||the-18/DT	amod||rate-22/NN||basal-19/JJ	nn||rate-22/NN||insulin-20/NN	nn||rate-22/NN||infusion-21/NN	dobj||increasing-17/VBG||rate-22/NN	det||use-26/NN||the-25/DT	prep_without||rate-22/NN||use-26/NN	nn||algorithms-30/NNS||pump-28/NN	nn||algorithms-30/NNS||shutoff-29/NN	prep_of||use-26/NN||algorithms-30/NNS	insulin-20||hypoglycemia-7||no_rel||for the first 14 subjects, hypoglycemia (<60 mg/dl) was induced by gradually increasing the basal insulin infusion rate (without the use of pump shutoff algorithms).
nsubj||is-5/VBZ||detection-1/NN	nsubj||is-5/VBZ||detection-1/NN	det||proteins-4/NNS||these-3/DT	prep_of||detection-1/NN||proteins-4/NNS	root||ROOT-0/null||is-5/VBZ	conj_but||is-5/VBZ||is-5/VBZ	amod||value-8/NN||great-7/JJ	prep_of||is-5/VBZ||value-8/NN	neg||only-10/JJ||not-9/RB	preconj||is-5/VBZ||only-10/JJ	amod||biology-14/NN||basic-12/JJ	nn||biology-14/NN||cell-13/NN	prep_in||is-5/VBZ||biology-14/NN	advmod||is-5/VBZ||also-16/RB	nn||monitoring-21/NN||diagnosis-18/NN	conj_and||diagnosis-18/NN||therapeutic-20/JJ	nn||monitoring-21/NN||therapeutic-20/JJ	prep_for||is-5/VBZ||monitoring-21/NN	amod||diseases-24/NNS||human-23/JJ	prep_of||monitoring-21/NN||diseases-24/NNS	prep_such_as||diseases-24/NNS||cancer-27/NN	cancer-27||basic-12||no_rel||detection of these proteins is of great value not only in basic cell biology but also for diagnosis and therapeutic monitoring of human diseases such as cancer.
det||types-2/NNS||all-1/DT	nsubjpass||included-8/VBN||types-2/NNS	amod||studies-6/NNS||prospective-4/JJ	amod||studies-6/NNS||clinical-5/JJ	prep_of||types-2/NNS||studies-6/NNS	auxpass||included-8/VBN||were-7/VBD	root||ROOT-0/null||included-8/VBN	mark||used-12/VBN||if-9/IN	nsubjpass||used-12/VBN||magnesiumsulfate-10/NN	nsubj||manage-14/VB||magnesiumsulfate-10/NN	auxpass||used-12/VBN||was-11/VBD	advcl||included-8/VBN||used-12/VBN	aux||manage-14/VB||to-13/TO	xcomp||used-12/VBN||manage-14/VB	dobj||manage-14/VB||pre-eclampsia-15/NN	dobj||manage-14/VB||eclampsia-17/NN	conj_or||pre-eclampsia-15/NN||eclampsia-17/NN	det||study-20/NN||the-19/DT	nsubjpass||conducted-22/VBN||study-20/NN	auxpass||conducted-22/VBN||was-21/VBD	dep||included-8/VBN||conducted-22/VBN	det||country-29/NN||a-24/DT	amod||country-29/NN||low-25/JJ	conj_or||low-25/JJ||middle-income-28/JJ	amod||country-29/NN||middle-income-28/JJ	prep_in||conducted-22/VBN||country-29/NN	det||study-33/NN||the-32/DT	nsubj||included-34/VBD||study-33/NN	conj_and||included-8/VBN||included-34/VBD	det||recording-36/NN||the-35/DT	dobj||included-34/VBD||recording-36/NN	det||incidence-39/NN||the-38/DT	prep_of||recording-36/NN||incidence-39/NN	det||effect-44/NN||any-41/DT	amod||effect-44/NN||adverse-42/JJ	nn||effect-44/NN||side-43/NN	prep_of||incidence-39/NN||effect-44/NN	vmod||effect-44/NN||resulting-45/VBG	amod||use-48/NN||magnesiumsulfate-47/JJ	prep_from||resulting-45/VBG||use-48/NN	eclampsia-17||magnesiumsulfate-47||yes||all types of prospective clinical studies were included if magnesiumsulfate was used to manage pre-eclampsia or eclampsia, the study was conducted in a low- or middle-income country, and the study included the recording of the incidence of any adverse side effect resulting from magnesiumsulfate use.
neg||differences-3/NNS||no-1/DT	amod||differences-3/NNS||significant-2/JJ	nsubjpass||found-5/VBN||differences-3/NNS	auxpass||found-5/VBN||were-4/VBD	root||ROOT-0/null||found-5/VBN	nn||subjects-10/NNS||smoking-7/NN	conj_and||smoking-7/NN||non-smoking-9/NN	nn||subjects-10/NNS||non-smoking-9/NN	prep_between||found-5/VBN||subjects-10/NNS	amod||asthma-13/NN||mild-12/JJ	prep_with||subjects-10/NNS||asthma-13/NN	prep_in||asthma-13/NN||regard-15/NN	amod||changes-18/NNS||clinical-17/JJ	prep_to||found-5/VBN||changes-18/NNS	nn||control-21/NN||asthma-20/NN	prep_in||changes-18/NNS||control-21/NN	amod||function-24/NN||pulmonary-23/JJ	appos||control-21/NN||function-24/NN	nn||inflammation-27/NN||airway-26/NN	appos||control-21/NN||inflammation-27/NN	conj_and||function-24/NN||inflammation-27/NN	det||period-32/NN||a-29/DT	amod||period-32/NN||2-month-30/JJ	nn||period-32/NN||treatment-31/NN	prep_following||function-24/NN||period-32/NN	prep_with||period-32/NN||budesonide-34/NN	det||association-37/NN||the-36/DT	prep_following||function-24/NN||association-37/NN	conj_or||period-32/NN||association-37/NN	prep_of||association-37/NN||budesonide-39/NN	prep_of||association-37/NN||formoterol-41/NN	conj_and||budesonide-39/NN||formoterol-41/NN	det||period-44/NN||a-43/DT	prep_for||association-37/NN||period-44/NN	num||months-47/NNS||2-46/CD	prep_of||period-44/NN||months-47/NNS	asthma-20||budesonide-39||no||no significant differences were found between smoking and non-smoking subjects with mild asthma in regard to clinical changes in asthma control, pulmonary function and airway inflammation following a 2-month treatment period with budesonide or the association of budesonide and formoterol for a period of 2 months.
nsubj||faces-17/VBZ||zambia-1/NN	prep_like||zambia-1/NN||many-4/JJ	det||countries-7/NNS||the-6/DT	prep_of||many-4/JJ||countries-7/NNS	advmod||affected-9/VBN||heavily-8/RB	vmod||countries-7/NNS||affected-9/VBN	agent||affected-9/VBN||hiv/aids-11/NNS	amod||africa-14/NN||southern-13/JJ	prep_in||hiv/aids-11/NNS||africa-14/NN	advmod||faces-17/VBZ||also-16/RB	root||ROOT-0/null||faces-17/VBZ	det||shortage-19/NN||a-18/DT	dobj||faces-17/VBZ||shortage-19/NN	amod||resources-22/NNS||human-21/JJ	prep_of||shortage-19/NN||resources-22/NNS	prep_for||resources-22/NNS||health-24/NN	aids--1||hiv--1||no||zambia, like many of the countries heavily affected by hiv/aids in southern africa, also faces a shortage of human resources for health.
nn||injection-2/NN||lps-1/NN	root||ROOT-0/null||injection-2/NN	vmod||injection-2/NN||induced-3/VBN	det||increase-6/NN||a-4/DT	amod||increase-6/NN||rapid-5/JJ	dobj||induced-3/VBN||increase-6/NN	nn||concentrations-9/NNS||plasma-8/NN	prep_in||increase-6/NN||concentrations-9/NNS	amod||metabolites-12/NNS||nitricoxide-11/JJ	prep_of||concentrations-9/NNS||metabolites-12/NNS	amod||concentrations-9/NNS||nitrite-14/JJ	amod||concentrations-9/NNS||nitrate-16/JJ	conj_and||nitrite-14/JJ||nitrate-16/JJ	appos||concentrations-9/NNS||nom-18/NN	amod||acidâ-23/NNS||thiobarbituric-22/JJ	dobj||induced-3/VBN||acidâ-23/NNS	conj_and||increase-6/NN||acidâ-23/NNS	dep||acidâ-23/NNS||$-24/$	advmod||substances-27/RB||reacting-26/RB	dep||generation-41/CD||substances-27/RB	pobj||substances-27/RB||tbars-29/NN	det||increase-33/NN||an-32/DT	appos||tbars-29/NN||increase-33/NN	amod||species-37/NNS||reactive-35/JJ	nn||species-37/NNS||oxygen-36/NN	prep_in||increase-33/NN||species-37/NNS	appos||species-37/NNS||ros-39/NN	num||$-24/$||generation-41/CD	nn||leukocytes-44/NNS||polymorphonuclear-43/NN	agent||induced-3/VBN||leukocytes-44/NNS	dep||injection-2/NN||pmnls-46/NNS	amod||increases-51/NNS||marked-50/VBN	conj_and||injection-2/NN||increases-51/NNS	amod||fattyacids-55/NNS||plasma-53/JJ	amod||fattyacids-55/NNS||free-54/JJ	prep_in||increases-51/NNS||fattyacids-55/NNS	nn||necrosis-58/NNS||tumor-57/NN	appos||fattyacids-55/NNS||necrosis-58/NNS	nn||±-60/NNP||factor-î-59/NNP	dep||injection-2/NN||±-60/NNP	nn||±-63/NNP||tnf-î-62/NNP	appos||±-60/NNP||±-63/NNP	dep||injection-2/NN||interleukin-6-66/JJ	conj_and||±-60/NNP||interleukin-6-66/JJ	dep||interleukin-6-66/JJ||il-6-68/JJ	amod||protein-1-73/NN||monocyte-71/JJ	nn||protein-1-73/NN||chemoattractant-72/NN	dep||injection-2/NN||protein-1-73/NN	conj_and||±-60/NNP||protein-1-73/NN	dep||protein-1-73/NN||mcp-1-75/JJ	amod||factor-81/NN||macrophage-78/JJ	nn||factor-81/NN||migration-79/NN	nn||factor-81/NN||inhibition-80/NN	appos||protein-1-73/NN||factor-81/NN	appos||factor-81/NN||mif-83/NN	amod||protein-87/NN||c-reactive-86/JJ	appos||protein-1-73/NN||protein-87/NN	appos||protein-87/NN||resistin-89/NN	vmod||protein-1-73/NN||visfatin-91/VBN	nn||protein-95/NN||lipopolysaccharide-93/NN	amod||protein-95/NN||binding-94/VBG	appos||protein-1-73/NN||protein-95/NN	appos||protein-95/NN||lbp-97/NN	advmod||group-b1-102/JJ||high-100/RB	advmod||group-b1-102/JJ||mobility-101/RB	dep||injection-2/NN||group-b1-102/JJ	amod||±-60/NNP||group-b1-102/JJ	conj_and||±-60/NNP||group-b1-102/JJ	dep||group-b1-102/JJ||hmg-b1-104/JJ	nn||concentrations-109/NNS||myoglobin-108/NN	dep||injection-2/NN||concentrations-109/NNS	conj_and||±-60/NNP||concentrations-109/NNS	tumor-57||nitrate-16||no_rel||lps injection induced a rapid increase in plasma concentrations of nitricoxide metabolites, nitrite and nitrate (nom), and thiobarbituric acidâreacting substances (tbars), an increase in reactive oxygen species (ros) generation by polymorphonuclear leukocytes (pmnls), and marked increases in plasma free fattyacids, tumor necrosis factor-î± (tnf-î±), interleukin-6 (il-6), monocyte chemoattractant protein-1 (mcp-1), macrophage migration inhibition factor (mif), c-reactive protein, resistin, visfatin, lipopolysaccharide binding protein (lbp), high mobility group-b1 (hmg-b1), and myoglobin concentrations.
det||aim-2/NN||the-1/DT	nsubj||is-6/VBZ||aim-2/NN	nsubj||examine-8/VB||aim-2/NN	nsubj||summarize-19/VB||aim-2/NN	det||review-5/NN||this-4/DT	prep_of||aim-2/NN||review-5/NN	root||ROOT-0/null||is-6/VBZ	aux||examine-8/VB||to-7/TO	xcomp||is-6/VBZ||examine-8/VB	amod||mechanisms-10/NNS||potential-9/JJ	dobj||examine-8/VB||mechanisms-10/NNS	amod||bacteria-13/NNS||probiotic-12/JJ	prep_of||mechanisms-10/NNS||bacteria-13/NNS	det||cavity-17/NN||the-15/DT	amod||cavity-17/NN||oral-16/JJ	prep_in||examine-8/VB||cavity-17/NN	xcomp||is-6/VBZ||summarize-19/VB	conj_and||examine-8/VB||summarize-19/VB	amod||effects-21/NNS||observed-20/JJ	dobj||summarize-19/VB||effects-21/NNS	prep_of||effects-21/NNS||probiotics-23/NNS	prep_with||probiotics-23/NNS||respect-25/NN	amod||health-28/NN||oral-27/JJ	prep_to||summarize-19/VB||health-28/NN	cavity-17||bacteria-13||no||the aim of this review is to examine potential mechanisms of probiotic bacteria in the oral cavity and summarize observed effects of probiotics with respect to oral health.
det||driver-3/NN||a-1/DT	amod||driver-3/NN||key-2/JJ	nsubj||impairment-10/NN||driver-3/NN	det||pathogenesis-6/NNS||the-5/DT	prep_in||driver-3/NN||pathogenesis-6/NNS	prep_of||pathogenesis-6/NNS||t2d-8/CD	cop||impairment-10/NN||is-9/VBZ	root||ROOT-0/null||impairment-10/NN	amod||²-14/NNS||pancreatic-12/JJ	nn||²-14/NNS||î-13/NN	prep_of||impairment-10/NN||²-14/NNS	nn||function-17/NN||cell-16/NN	dep||function-27/VBP||function-17/NN	det||hallmark-21/NN||the-20/DT	prep_with||function-17/NN||hallmark-21/NN	nn||²-24/NNS||î-23/NN	prep_of||hallmark-21/NN||²-24/NNS	nsubj||function-27/VBP||cell-26/NN	parataxis||impairment-10/NN||function-27/VBP	cop||secretion-31/NN||being-28/VBG	amod||secretion-31/NN||glucose-stimulated-29/JJ	nn||secretion-31/NN||insulin-30/NN	xcomp||function-27/VBP||secretion-31/NN	dep||secretion-31/NN||gsis-33/VBZ	t2d-8||insulin-30||yes||a key driver in the pathogenesis of t2d is impairment of pancreatic î²-cell function, with the hallmark of î²-cell function being glucose-stimulated insulin secretion (gsis).
advmod||randomized-51/VBN||overall-1/RB	num||subjects-6/NNS||28-3/CD	amod||subjects-6/NNS||insulin-naive-4/JJ	amod||subjects-6/NNS||type2diabetes-5/JJ	nsubjpass||randomized-51/VBN||subjects-6/NNS	nsubj||add-53/VB||subjects-6/NNS	amod||age-12/NN||mean-8/JJ	nn||age-12/NN||â-9/NN	nn||age-12/NN||±-10/NN	nn||age-12/NN||sd-11/NN	dep||subjects-6/NNS||age-12/NN	num||â-15/NN||61.5-14/CD	appos||age-12/NN||â-15/NN	number||6.7-17/CD||±-16/CD	num||years-18/NNS||6.7-17/CD	dep||â-15/NN||years-18/NNS	nn||duration-21/NN||diabetes-20/NN	dep||â-15/NN||duration-21/NN	num||â-24/NN||9.8-23/CD	appos||duration-21/NN||â-24/NN	number||6.5-26/CD||±-25/CD	num||years-27/NNS||6.5-26/CD	dep||â-24/NN||years-27/NNS	dep||â-15/NN||hba1c-29/NNS	num||±-33/NNS||7.1-31/CD	nn||±-33/NNS||â-32/NN	appos||hba1c-29/NNS||±-33/NNS	number||%-35/NN||0.5-34/CD	amod||±-33/NNS||%-35/NN	dep||â-15/NN||bmi-37/NN	number||â-40/CD||30.7-39/CD	num||kg/m2-43/NNS||â-40/CD	amod||kg/m2-43/NNS||±-41/JJ	num||kg/m2-43/NNS||4.3-42/CD	appos||bmi-37/NN||kg/m2-43/NNS	vmod||subjects-6/NNS||treated-45/VBN	prep_with||treated-45/VBN||metformin-47/NN	prep_with||treated-45/VBN||sulfonylurea-49/NN	conj_and||metformin-47/NN||sulfonylurea-49/NN	auxpass||randomized-51/VBN||were-50/VBD	root||ROOT-0/null||randomized-51/VBN	aux||add-53/VB||to-52/TO	xcomp||randomized-51/VBN||add-53/VB	amod||gla-55/NN||once-daily-54/JJ	dobj||add-53/VB||gla-55/NN	dobj||add-53/VB||nph-57/NN	conj_or||gla-55/NN||nph-57/NN	prep_at||add-53/VB||bedtime-59/NN	type2diabetes-5||metformin-47||yes||overall, 28 insulin-naive type2diabetes subjects (mean â± sd age, 61.5 â± 6.7 years; diabetes duration, 9.8 â± 6.5 years; hba1c, 7.1 â± 0.5%; bmi, 30.7 â± 4.3 kg/m2) treated with metformin and sulfonylurea were randomized to add once-daily gla or nph at bedtime.
det||study-2/NN||this-1/DT	nsubjpass||conducted-4/VBN||study-2/NN	nsubj||compare-6/VB||study-2/NN	auxpass||conducted-4/VBN||was-3/VBD	root||ROOT-0/null||conducted-4/VBN	aux||compare-6/VB||to-5/TO	xcomp||conducted-4/VBN||compare-6/VB	det||efficacy-8/NN||the-7/DT	dobj||compare-6/VB||efficacy-8/NN	det||combination-11/NN||a-10/DT	prep_of||efficacy-8/NN||combination-11/NN	prep_of||combination-11/NN||ondansetron-13/NN	prep_of||combination-11/NN||dexamethasone-15/NN	conj_and||ondansetron-13/NN||dexamethasone-15/NN	prep_with||compare-6/VB||that-17/DT	nn||analgesia-36/NN||metoclopramide-19/NN	conj_and||metoclopramide-19/NN||dexamethasone-21/JJ	nn||analgesia-36/NN||dexamethasone-21/JJ	prep_for||dexamethasone-21/JJ||prevention-23/NN	prepc_of||prevention-23/NN||postoperativenauseaandvomiting-25/VBG	dobj||postoperativenauseaandvomiting-25/VBG||ponv-27/NNP	amod||patients-31/NNS||gynecologic-30/JJ	prep_in||ponv-27/NNP||patients-31/NNS	vmod||patients-31/NNS||receiving-32/VBG	amod||analgesia-36/NN||fentanyl-33/JJ	amod||analgesia-36/NN||iv-patient-34/JJ	amod||analgesia-36/NN||controlled-35/VBN	prep_of||that-17/DT||analgesia-36/NN	ponv-27||metoclopramide-19||yes||this study was conducted to compare the efficacy of a combination of ondansetron and dexamethasone with that of metoclopramide and dexamethasone for prevention of postoperativenauseaandvomiting (ponv) in gynecologic patients receiving fentanyl iv-patient controlled analgesia.
poss||study-2/NN||our-1/PRP$	nsubj||demonstrated-3/VBD||study-2/NN	nsubj||find-17/VB||study-2/NN	root||ROOT-0/null||demonstrated-3/VBD	amod||incidence-5/NN||increased-4/VBN	dobj||demonstrated-3/VBD||incidence-5/NN	amod||pancreatitis-8/NNS||acute-7/JJ	prep_of||incidence-5/NN||pancreatitis-8/NNS	prep_in||pancreatitis-8/NNS||diabetic-10/NN	amod||patients-13/NNS||nondiabetic-12/JJ	prep_versus||diabetic-10/NN||patients-13/NNS	aux||find-17/VB||did-15/VBD	neg||find-17/VB||not-16/RB	conj_but||demonstrated-3/VBD||find-17/VB	det||association-19/NN||an-18/DT	dobj||find-17/VB||association-19/NN	det||use-22/NN||the-21/DT	prep_between||association-19/NN||use-22/NN	dep||sitagliptin-26/JJ||exenatide-24/JJ	amod||pancreatitis-29/NNS||sitagliptin-26/JJ	conj_and||sitagliptin-26/JJ||acute-28/JJ	amod||pancreatitis-29/NNS||acute-28/JJ	prep_of||use-22/NN||pancreatitis-29/NNS	pancreatitis-29||sitagliptin-26||no_rel||our study demonstrated increased incidence of acute pancreatitis in diabetic versus nondiabetic patients but did not find an association between the use of exenatide or sitagliptin and acute pancreatitis.
nsubj||hold-49/VBP||comparison-1/NN	det||sequence-8/NN||the-3/DT	amod||sequence-8/NN||fcov-4/JJ	amod||sequence-8/NN||c1je-5/JJ	amod||sequence-8/NN||genomic-6/JJ	nn||sequence-8/NN||rna-7/NN	prep_of||comparison-1/NN||sequence-8/NN	mark||have-26/VBP||sequence-8/NN	prep_with||sequence-8/NN||that-10/DT	det||virus-17/NN||the-12/DT	nn||virus-17/NN||laboratory-13/NN	nn||virus-17/NN||strain-14/NN	amod||virus-17/NN||fcov-15/JJ	nn||virus-17/NN||fip-16/NN	prep_of||that-10/DT||virus-17/NN	appos||virus-17/NN||fipv-19/NNP	nsubj||showed-22/VBD||79-1146-21/CD	rcmod||sequence-8/NN||showed-22/VBD	det||viruses-25/NNS||both-24/DT	nsubj||have-26/VBP||viruses-25/NNS	ccomp||showed-22/VBD||have-26/VBP	det||organisation-30/NN||a-27/DT	amod||organisation-30/NN||similar-28/JJ	nn||organisation-30/NN||genome-29/NN	dobj||have-26/VBP||organisation-30/NN	prep_of||comparison-1/NN||predictions-32/NNS	conj_and||sequence-8/NN||predictions-32/NNS	mark||have-26/VBP||predictions-32/NNS	vmod||predictions-32/NNS||made-33/VBN	det||frames-38/NNS||the-35/DT	amod||frames-38/NNS||open-36/JJ	nn||frames-38/NNS||reading-37/NN	prep_for||made-33/VBN||frames-38/NNS	prep_for||made-33/VBN||cis-40/NN	conj_and||frames-38/NNS||cis-40/NN	amod||elements-43/NNS||acting-42/VBG	prep_of||comparison-1/NN||elements-43/NNS	conj_and||sequence-8/NN||elements-43/NNS	mark||have-26/VBP||elements-43/NNS	det||genome-48/NN||the-45/DT	nn||genome-48/NN||fipv-46/NNP	num||genome-48/NN||79-1146-47/CD	prep_of||elements-43/NNS||genome-48/NN	root||ROOT-0/null||hold-49/VBP	acomp||hold-49/VBP||true-50/JJ	amod||c1je-53/NNS||fcov-52/JJ	prep_for||hold-49/VBP||c1je-53/NNS	virus-17||viruses-25||no||comparison of the fcov c1je genomic rna sequence with that of the laboratory strain fcov fip virus (fipv) 79-1146 showed that both viruses have a similar genome organisation and predictions made for the open reading frames and cis -acting elements of the fipv 79-1146 genome hold true for fcov c1je.
nsubj||review-2/VBP||we-1/PRP	root||ROOT-0/null||review-2/VBP	dep||review-2/VBP||chinaâ-3/VB	dobj||chinaâ-3/VB||$-4/$	num||$-4/$||-5/CD	cop||policies-10/NNS||s-6/VBZ	amod||policies-10/NNS||key-7/JJ	amod||policies-10/NNS||national-level-8/JJ	nn||policies-10/NNS||hiv/aids-9/NN	rcmod||$-4/$||policies-10/NNS	dep||review-2/VBP||discuss-12/VB	conj_and||chinaâ-3/VB||discuss-12/VB	nn||gaps-14/NNS||policy-13/NN	dobj||discuss-12/VB||gaps-14/NNS	dobj||discuss-12/VB||challenges-16/NNS	conj_and||gaps-14/NNS||challenges-16/NNS	advmod||discuss-12/VB||ahead-17/RB	aids--1||hiv--1||no||we review chinaâs key national-level hiv/aids policies and discuss policy gaps and challenges ahead.
amod||regimens-3/NNS||heterologous-1/JJ	amod||regimens-3/NNS||prime-boost-2/JJ	nsubj||represent-11/VBP||regimens-3/NNS	vmod||regimens-3/NNS||utilizing-4/VBG	dobj||utilizing-4/VBG||bcg-5/NN	det||vaccine-9/NN||a-7/DT	amod||vaccine-9/NN||prime-8/JJ	prep_as||utilizing-4/VBG||vaccine-9/NN	advmod||represent-11/VBP||probably-10/RB	root||ROOT-0/null||represent-11/VBP	det||hope-14/NN||the-12/DT	amod||hope-14/NN||best-13/JJS	dobj||represent-11/VBP||hope-14/NN	det||development-17/NN||the-16/DT	prep_for||hope-14/NN||development-17/NN	amod||tuberculosis-20/JJ||novel-19/JJ	amod||vaccines-24/NNS||tuberculosis-20/JJ	appos||vaccines-24/NNS||tb-22/NN	prep_of||development-17/NN||vaccines-24/NNS	tb-22||bcg-5||no||heterologous prime-boost regimens utilizing bcg as a prime vaccine probably represent the best hope for the development of novel tuberculosis (tb) vaccines.
nsubj||bacillus-2/VBZ||mycobacteriumbovis-1/NNS	ccomp||matter-30/NN||bacillus-2/VBZ	amod||rin-6/NN||calmette-3/JJ	nn||rin-6/NN||guã-4/NN	nn||rin-6/NN||©-5/NN	nsubj||vaccine-13/NN||rin-6/NN	appos||rin-6/NN||bcg-8/NN	cop||vaccine-13/NN||is-10/VBZ	det||vaccine-13/NN||a-11/DT	amod||vaccine-13/NN||sole-12/JJ	ccomp||bacillus-2/VBZ||vaccine-13/NN	advmod||used-15/VBN||currently-14/RB	vmod||vaccine-13/NN||used-15/VBN	prep_for||used-15/VBN||tb-17/NN	advmod||used-15/VBN||however-19/RB	det||efficacy-22/NN||the-21/DT	nsubj||matter-30/NN||efficacy-22/NN	prep_of||efficacy-22/NN||bcg-24/NN	prep_in||bcg-24/NN||adults-26/NNS	cop||matter-30/NN||is-27/VBZ	advmod||matter-30/NN||still-28/RB	det||matter-30/NN||a-29/DT	root||ROOT-0/null||matter-30/NN	prep_of||matter-30/NN||debate-32/NN	tb-17||bcg-24||no||mycobacteriumbovis bacillus calmette guã©rin (bcg) is a sole vaccine currently used for tb, however, the efficacy of bcg in adults is still a matter of debate.
nsubj||lidocaine-4/VBP||pretreatment-1/NN	prep_with||pretreatment-1/NN||iv-3/NN	root||ROOT-0/null||lidocaine-4/VBP	num||mg-6/NNP||40-5/CD	dobj||lidocaine-4/VBP||mg-6/NNP	nn||mg-10/NNS||ketamine-8/NNP	num||mg-10/NNS||25-9/CD	dobj||lidocaine-4/VBP||mg-10/NNS	conj_plus||mg-6/NNP||mg-10/NNS	det||tourniquet-14/NN||a-12/DT	nn||tourniquet-14/NN||rubber-13/NN	prep_with||lidocaine-4/VBP||tourniquet-14/NN	det||min-19/NN||the-16/DT	nn||min-19/NN||forearm-17/NNP	num||min-19/NN||1-18/CD	prep_on||tourniquet-14/NN||min-19/NN	mark||effective-28/JJ||before-20/IN	det||injection-22/NN||the-21/DT	nsubj||effective-28/JJ||injection-22/NN	nn||propofol-25/NN||microemulsion-24/NN	prep_of||injection-22/NN||propofol-25/NN	cop||effective-28/JJ||is-26/VBZ	advmod||effective-28/JJ||more-27/RBR	advcl||lidocaine-4/VBP||effective-28/JJ	nn||mg-32/NN||lidocaine-30/NN	num||mg-32/NN||40-31/CD	prep_than||effective-28/JJ||mg-32/NN	nn||mg-36/NN||ketamine-34/NN	num||mg-36/NN||25-35/CD	prep_than||effective-28/JJ||mg-36/NN	conj_or||mg-32/NN||mg-36/NN	advmod||effective-28/JJ||alone-37/RB	prepc_in||effective-28/JJ||preventing-39/VBG	dobj||preventing-39/VBG||pain-40/NN	det||injection-43/NN||the-42/DT	prep_from||preventing-39/VBG||injection-43/NN	nn||propofol-46/NN||microemulsion-45/NN	prep_of||injection-43/NN||propofol-46/NN	pain-40||ketamine-34||yes||pretreatment with iv lidocaine 40 mg plus ketamine 25 mg with a rubber tourniquet on the forearm 1 min before the injection of microemulsion propofol is more effective than lidocaine 40 mg or ketamine 25 mg alone in preventing pain from the injection of microemulsion propofol.
det||regions-3/NNS||these-2/DT	prep_in||associated-17/VBN||regions-3/NNS	advmod||rabies-6/JJ||most-5/RBS	amod||deaths-7/NNS||rabies-6/JJ	nsubjpass||associated-17/VBN||deaths-7/NNS	vmod||deaths-7/NNS||associated-8/VBN	prep_with||associated-8/VBN||bats-10/NNS	amod||mammals-14/NNS||nonhuman-12/JJ	amod||mammals-14/NNS||terrestrial-13/JJ	prep_in||bats-10/NNS||mammals-14/NNS	auxpass||associated-17/VBN||are-15/VBP	advmod||associated-17/VBN||also-16/RB	root||ROOT-0/null||associated-17/VBN	nn||variants-20/NNS||virus-19/NN	prep_with||associated-17/VBN||variants-20/NNS	amod||variants-20/NNS||specific-21/JJ	det||species-26/NNS||these-23/DT	num||species-26/NNS||two-24/CD	nn||species-26/NNS||bat-25/NN	prep_to||specific-21/JJ||species-26/NNS	advmod||common-30/JJ||more-29/RBR	amod||variants-20/NNS||common-30/JJ	conj_negcc||specific-21/JJ||common-30/JJ	nn||species-32/NNS||bat-31/NN	dobj||associated-17/VBN||species-32/NNS	det||rabiesviruses-42/NNS||these-36/DT	nn||rabiesviruses-42/NNS||regions-37/NNS	amod||rabiesviruses-42/NNS||more-39/JJR	amod||rabiesviruses-42/NNS||common-40/JJ	nn||rabiesviruses-42/NNS||bat-41/NN	prep_outside_of||species-32/NNS||rabiesviruses-42/NNS	rcmod||rabiesviruses-42/NNS||contribute-43/VBP	amod||transmissions-46/NNS||most-45/JJS	prep_to||contribute-43/VBP||transmissions-46/NNS	rabies-6||rabiesviruses-42||no||in these regions, most rabies deaths associated with bats in nonhuman terrestrial mammals are also associated with virus variants specific to these two bat species rather than more common bat species; outside of these regions, more common bat rabiesviruses contribute to most transmissions.
nn||studies-2/NNS||outcome-1/NN	nsubjpass||needed-4/VBN||studies-2/NNS	nsubj||determine-6/VB||studies-2/NNS	auxpass||needed-4/VBN||are-3/VBP	root||ROOT-0/null||needed-4/VBN	aux||determine-6/VB||to-5/TO	xcomp||needed-4/VBN||determine-6/VB	mark||had-10/VBD||whether-7/IN	nsubj||had-10/VBD||sb-8/NN	num||sb-8/NN||1159-9/CD	ccomp||determine-6/VB||had-10/VBD	det||impact-13/NN||the-11/DT	amod||impact-13/NN||desired-12/VBN	dobj||had-10/VBD||impact-13/NN	prepc_on||impact-13/NN||increasing-15/VBG	nn||access-17/NN||syringe-16/NN	dobj||increasing-15/VBG||access-17/NN	prepc_on||impact-13/NN||reducing-19/VBG	conj_and||increasing-15/VBG||reducing-19/VBG	amod||risk-22/NN||blood-borne-20/JJ	nn||risk-22/NN||viralinfection-21/NN	dobj||reducing-19/VBG||risk-22/NN	nn||idus-25/NNS||california-24/NN	prep_among||reducing-19/VBG||idus-25/NNS	viralinfection-21||idus-25||yes||outcome studies are needed to determine whether sb 1159 had the desired impact on increasing syringe access and reducing blood-borne viralinfection risk among california idus.
det||study-4/NN||an-1/DT	amod||study-4/NN||observational-2/JJ	nn||study-4/NN||retrospective-3/NN	root||ROOT-0/null||study-4/NN	amod||follow-up-7/NN||1-year-6/JJ	appos||study-4/NN||follow-up-7/NN	num||patients-11/NNS||104-10/CD	prep_on||study-4/NN||patients-11/NNS	prep_with||patients-11/NNS||oa-13/NN	nsubjpass||treated-38/VBN||oa-13/NN	nn||osteoarthritis-16/NNS||nodular-15/NN	dep||oa-13/NN||osteoarthritis-16/NNS	det||hand-19/NN||the-18/DT	prep_of||osteoarthritis-16/NNS||hand-19/NN	amod||osteoarthritis-22/NNS||erosive-21/JJ	appos||osteoarthritis-16/NNS||osteoarthritis-22/NNS	det||hand-25/NN||the-24/DT	prep_of||osteoarthritis-22/NNS||hand-25/NN	appos||osteoarthritis-16/NNS||eoa-27/NN	appos||osteoarthritis-16/NNS||osteoarthritis-29/NNS	det||knee-32/NN||the-31/DT	prep_of||osteoarthritis-29/NNS||knee-32/NN	prep_of||osteoarthritis-29/NNS||hip-34/NN	conj_or||knee-32/NN||hip-34/NN	auxpass||treated-38/VBN||were-37/VBD	rcmod||oa-13/NN||treated-38/VBN	nn||chondroitinsulfate-44/NN||gc-40/NN	conj_or||gc-40/NN||glucosamine-42/NN	nn||chondroitinsulfate-44/NN||glucosamine-42/NN	prep_with||treated-38/VBN||chondroitinsulfate-44/NN	nn||ii-48/NNS||collagen-46/NN	nn||ii-48/NNS||type-47/NN	prep_with||treated-38/VBN||ii-48/NNS	conj_and||chondroitinsulfate-44/NN||ii-48/NNS	appos||patients-11/NNS||gcc-50/NN	osteoarthritis-29||chondroitinsulfate-44||yes||an observational retrospective study, 1-year follow-up, on 104 patients with oa (nodular osteoarthritis of the hand, erosive osteoarthritis of the hand, eoa, osteoarthritis of the knee or hip) who were treated with gc or glucosamine, chondroitinsulfate and collagen type ii (gcc).
det||history-3/NN||the-1/DT	amod||history-3/NN||natural-2/JJ	nsubjpass||characterised-15/VBN||history-3/NN	nsubj||prevent-30/VB||history-3/NN	nn||infections-7/NNS||ocular-5/NN	nn||infections-7/NNS||chlamydiatrachomatis-6/NNS	prep_of||history-3/NN||infections-7/NNS	amod||communities-10/NNS||endemic-9/JJ	prep_in||infections-7/NNS||communities-10/NNS	aux||characterised-15/VBN||has-11/VBZ	neg||characterised-15/VBN||not-12/RB	auxpass||characterised-15/VBN||been-13/VBN	advmod||characterised-15/VBN||well-14/RB	root||ROOT-0/null||characterised-15/VBN	cop||determinant-20/NN||is-17/VBZ	det||determinant-20/NN||an-18/DT	amod||determinant-20/NN||important-19/JJ	conj_and||characterised-15/VBN||determinant-20/NN	det||effectiveness-23/NN||the-22/DT	prep_of||determinant-20/NN||effectiveness-23/NN	amod||strategies-28/NNS||different-25/JJ	amod||strategies-28/NNS||mass-26/JJ	nn||strategies-28/NNS||treatment-27/NN	prep_of||effectiveness-23/NN||strategies-28/NNS	aux||prevent-30/VB||to-29/TO	xcomp||characterised-15/VBN||prevent-30/VB	nsubj||due-32/JJ||blindness-31/NN	xcomp||prevent-30/VB||due-32/JJ	prep_to||due-32/JJ||trachoma-34/NN	trachoma-34||chlamydiatrachomatis-6||no||the natural history of ocular chlamydiatrachomatis infections in endemic communities has not been well characterised and is an important determinant of the effectiveness of different mass treatment strategies to prevent blindness due to trachoma.
advmod||seen-16/VBN||irondeficiency-1/RB	nsubjpass||seen-16/VBN||anemia-3/NN	amod||anemia-6/NN||irondeficiency-5/JJ	conj_and||anemia-3/NN||anemia-6/NN	nsubjpass||seen-16/VBN||anemia-6/NN	nn||depletion-9/NN||iron-8/NN	conj_and||anemia-3/NN||depletion-9/NN	nsubjpass||seen-16/VBN||depletion-9/NN	conj_and||anemia-3/NN||lack-11/NN	nsubjpass||seen-16/VBN||lack-11/NN	nn||resources-14/NNS||iron-13/NN	prep_of||lack-11/NN||resources-14/NNS	auxpass||seen-16/VBN||were-15/VBD	root||ROOT-0/null||seen-16/VBN	prep_in||seen-16/VBN||2.3-18/CD	prep_in||seen-16/VBN||4.08-20/CD	conj_and||2.3-18/CD||4.08-20/CD	prep_in||seen-16/VBN||2.14-22/CD	conj_and||2.3-18/CD||2.14-22/CD	prep_in||seen-16/VBN||22.76-24/NNP	conj_and||2.3-18/CD||22.76-24/NNP	amod||percent-27/NN||4.66-26/JJ	prep_in||seen-16/VBN||percent-27/NN	conj_and||2.3-18/CD||percent-27/NN	advmod||seen-16/VBN||respectively-28/RB	irondeficiency-5||iron-13||yes||irondeficiency, anemia, irondeficiency anemia, iron depletion and lack of iron resources were seen in 2.3, 4.08, 2.14, 22.76 and 4.66 percent respectively.
nsubj||revealed-2/VBD||they-1/PRP	root||ROOT-0/null||revealed-2/VBD	mark||proportional-33/JJ||that-3/IN	amod||times-6/NNS||relative-4/JJ	nn||times-6/NNS||divergence-5/NN	nsubj||proportional-33/JJ||times-6/NNS	det||wdv-10/NN||the-8/DT	amod||wdv-10/NN||viruses-9/JJ	prep_for||times-6/NNS||wdv-10/NN	nn||virus-14/NN||barley-12/NN	nn||virus-14/NN||dwarf-13/NN	appos||wdv-10/NN||virus-14/NN	appos||virus-14/NN||bdv-16/NN	nn||virus-21/NN||oat-19/NN	nn||virus-21/NN||dwarf-20/NN	appos||wdv-10/NN||virus-21/NN	conj_and||virus-14/NN||virus-21/NN	appos||virus-21/NN||odv-23/NN	amod||virus-28/NN||maize-26/JJ	nn||virus-28/NN||streak-27/NN	appos||wdv-10/NN||virus-28/NN	conj_and||virus-14/NN||virus-28/NN	appos||virus-28/NN||msv-30/NN	cop||proportional-33/JJ||are-32/VBP	ccomp||revealed-2/VBD||proportional-33/JJ	nn||times-36/NNS||divergence-35/NN	prep_to||proportional-33/JJ||times-36/NNS	poss||hosts-39/NNS||their-38/PRP$	prep_of||times-36/NNS||hosts-39/NNS	xcomp||proportional-33/JJ||suggesting-41/VBG	dobj||suggesting-41/VBG||codivergence-42/NN	virus-28||viruses-9||no||they revealed that relative divergence times for the viruses wdv, barley dwarf virus (bdv), oat dwarf virus (odv) and maize streak virus (msv) are proportional to divergence times of their hosts, suggesting codivergence.
det||control-3/NN||the-1/DT	amod||control-3/NN||bistable-2/JJ	nsubj||points-8/VBZ||control-3/NN	nn||expression-7/NN||virulence-5/NN	nn||expression-7/NN||gene-6/NN	prep_of||control-3/NN||expression-7/NN	root||ROOT-0/null||points-8/VBZ	det||mechanism-11/NN||a-10/DT	prep_to||points-8/VBZ||mechanism-11/NN	nsubj||generate-14/VB||mechanism-11/NN	aux||generate-14/VB||could-13/MD	rcmod||mechanism-11/NN||generate-14/VB	det||subpopulation-16/NN||a-15/DT	dobj||generate-14/VB||subpopulation-16/NN	nsubj||continues-20/VBZ||subpopulation-16/NN	nsubj||produce-22/VB||subpopulation-16/NN	prep_of||subpopulation-16/NN||v.cholerae-18/NN	rcmod||subpopulation-16/NN||continues-20/VBZ	aux||produce-22/VB||to-21/TO	xcomp||continues-20/VBZ||produce-22/VB	dobj||produce-22/VB||tcp-23/NN	dobj||produce-22/VB||ct-25/NN	conj_and||tcp-23/NN||ct-25/NN	det||stools-30/NNS||the-27/DT	nn||stools-30/NNS||rice-28/NN	nn||stools-30/NNS||water-29/NN	prep_in||produce-22/VB||stools-30/NNS	nn||patients-33/NNS||cholera-32/NN	prep_of||stools-30/NNS||patients-33/NNS	cholera-32||v.cholerae-18||no||the bistable control of virulence gene expression points to a mechanism that could generate a subpopulation of v.cholerae that continues to produce tcp and ct in the rice water stools of cholera patients .
num||hundred-2/CD||five-1/CD	nsubjpass||isolated-8/VBN||hundred-2/CD	amod||measlesviruses-6/NNS||sixty-five-4/JJ	amod||measlesviruses-6/NNS||wild-type-5/JJ	conj_and||hundred-2/CD||measlesviruses-6/NNS	nsubjpass||isolated-8/VBN||measlesviruses-6/NNS	auxpass||isolated-8/VBN||were-7/VBD	root||ROOT-0/null||isolated-8/VBN	prep_from||isolated-8/VBN||24-10/CD	num||provinces-13/NNS||31-12/CD	prep_of||24-10/CD||provinces-13/NNS	amod||china-16/NN||mainland-15/JJ	prep_in||provinces-13/NNS||china-16/NN	prep_during||isolated-8/VBN||2006-18/CD	prep_during||isolated-8/VBN||2007-20/CD	conj_and||2006-18/CD||2007-20/CD	nsubj||isolates-29/VBZ||all-23/DT	det||virus-28/NN||the-25/DT	amod||virus-28/NN||wild-26/JJ	nn||virus-28/NN||type-27/NN	prep_of||all-23/DT||virus-28/NN	conj_and||isolated-8/VBN||isolates-29/VBZ	dep||isolates-29/VBZ||belonged-30/VBN	prep_to||belonged-30/VBN||cluster-32/NN	num||cluster-32/NN||1-33/CD	amod||h1-36/NNS||genotype-35/JJ	prep_of||cluster-32/NN||h1-36/NNS	virus-28||viruses--1||no||five hundred and sixty-five wild-type measlesviruses were isolated from 24 of 31 provinces in mainland china during 2006 and 2007, and all of the wild type virus isolates belonged to cluster 1 of genotype h1.
advmod||available-17/JJ||however-1/RB	amod||evidence-4/NN||direct-3/JJ	nsubj||available-17/JJ||evidence-4/NN	det||presence-7/NN||the-6/DT	prep_of||evidence-4/NN||presence-7/NN	prep_of||presence-7/NN||viruses-9/NNS	poss||components-12/NNS||their-11/PRP$	prep_of||evidence-4/NN||components-12/NNS	conj_or||presence-7/NN||components-12/NNS	det||organ-15/NN||the-14/DT	prep_in||components-12/NNS||organ-15/NN	cop||available-17/JJ||are-16/VBP	root||ROOT-0/null||available-17/JJ	prep_for||available-17/JJ||retroviruses-19/NNS	appos||retroviruses-19/NNS||hfv-21/NN	prep_for||available-17/JJ||mumps-24/NNS	conj_and||retroviruses-19/NNS||mumps-24/NNS	amod||thyroiditis-27/NNS||subacute-26/JJ	prep_in||mumps-24/NNS||thyroiditis-27/NNS	prep_for||available-17/JJ||retroviruses-30/NNS	conj_and||retroviruses-19/NNS||retroviruses-30/NNS	dep||retroviruses-30/NNS||htlv-1-32/JJ	dep||retroviruses-30/NNS||hfv-34/NN	conj_and||htlv-1-32/JJ||hfv-34/NN	dep||retroviruses-30/NNS||hiv-36/NN	conj_and||htlv-1-32/JJ||hiv-36/NN	dep||retroviruses-30/NNS||sv40-38/NNS	conj_and||htlv-1-32/JJ||sv40-38/NNS	poss||disease-43/NN||graves-41/NNS	prep_in||retroviruses-30/NNS||disease-43/NN	prep_for||available-17/JJ||htlv-1-46/JJ	conj_and||retroviruses-19/NNS||htlv-1-46/JJ	conj_and||retroviruses-19/NNS||enterovirus-48/NNS	conj_and||htlv-1-46/JJ||enterovirus-48/NNS	conj_and||retroviruses-19/NNS||rubella-50/NN	conj_and||htlv-1-46/JJ||rubella-50/NN	conj_and||retroviruses-19/NNS||mumpsvirus-52/NNS	conj_and||htlv-1-46/JJ||mumpsvirus-52/NNS	conj_and||retroviruses-19/NNS||hsv-54/NN	conj_and||htlv-1-46/JJ||hsv-54/NN	conj_and||retroviruses-19/NNS||ebv-56/NN	conj_and||htlv-1-46/JJ||ebv-56/NN	conj_and||retroviruses-19/NNS||parvovirus-58/NNS	conj_and||htlv-1-46/JJ||parvovirus-58/NNS	poss||thyroiditis-62/NNS||hashimoto-60/NNP	prep_in||available-17/JJ||thyroiditis-62/NNS	mumps-24||mumpsvirus-52||yes||however, direct evidence of the presence of viruses or their components in the organ are available for retroviruses (hfv) and mumps in subacute thyroiditis, for retroviruses (htlv-1, hfv, hiv and sv40) in graves's disease and for htlv-1, enterovirus, rubella, mumpsvirus, hsv, ebv and parvovirus in hashimoto's thyroiditis.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||significance-5/NN||the-3/DT	amod||significance-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||significance-5/NN	amod||immunoglobulin-9/NN||serum-7/JJ	amod||immunoglobulin-9/NN||specific-8/JJ	prep_of||significance-5/NN||immunoglobulin-9/NN	dep||significance-5/NN||e-10/SYM	appos||significance-5/NN||lge-12/NN	det||enterotoxin-19/NN||the-15/DT	amod||enterotoxin-19/NN||staphylococcal-16/JJ	nn||enterotoxin-19/NN||superantigens-17/NNS	nn||enterotoxin-19/NN||staphylococcal-18/NN	prep_to||investigated-2/VBD||enterotoxin-19/NN	det||sea-22/NN||a-20/DT	dep||enterotoxin-19/NN||sea-22/NN	amod||enterotoxin-26/NN||staphylococcal-25/JJ	prep_to||investigated-2/VBD||enterotoxin-26/NN	conj_and||enterotoxin-19/NN||enterotoxin-26/NN	dep||enterotoxin-26/NN||b-27/SYM	appos||b-27/SYM||seb-29/NN	amod||toxin-34/NN||toxicshocksyndrome-33/JJ	prep_to||investigated-2/VBD||toxin-34/NN	conj_and||enterotoxin-19/NN||toxin-34/NN	appos||toxin-34/NN||tsst-36/NN	dep||toxin-34/NN||-1-38/CD	prep_in||investigated-2/VBD||patients-40/NNS	amod||urticaria-43/NN||chronic-42/JJ	prep_with||patients-40/NNS||urticaria-43/NN	appos||urticaria-43/NN||cu-45/NN	vmod||investigated-2/VBD||focusing-48/VBG	det||differences-51/NNS||the-50/DT	prep_on||focusing-48/VBG||differences-51/NNS	det||prevalences-54/NNS||these-53/DT	prep_in||differences-51/NNS||prevalences-54/NNS	amod||cu-57/NN||aspirin-intolerant-56/JJ	prep_between||prevalences-54/NNS||cu-57/NN	appos||cu-57/NN||aicu-59/NNP	amod||patients-67/NNS||aspirin-tolerant-62/JJ	nn||patients-67/NNS||cu-63/NN	appos||patients-67/NNS||atcu-65/NNP	prep_between||prevalences-54/NNS||patients-67/NNS	conj_and||cu-57/NN||patients-67/NNS	enterotoxin-26||urticaria-43||no_rel||we investigated the clinical significance of serum specific immunoglobulin e (lge) to the staphylococcal superantigens staphylococcal enterotoxin a (sea), staphylococcal enterotoxin b (seb), and toxicshocksyndrome toxin (tsst)-1 in patients with chronic urticaria (cu), focusing on the differences in these prevalences between aspirin-intolerant cu (aicu) and aspirin-tolerant cu (atcu) patients.
det||study-2/NN||this-1/DT	nsubj||tests-3/VBZ||study-2/NN	root||ROOT-0/null||tests-3/VBZ	det||hypothesis-5/NNS||the-4/DT	dobj||tests-3/VBZ||hypothesis-5/NNS	mark||acts-8/VBZ||that-6/IN	nsubj||acts-8/VBZ||insulin-7/NN	ccomp||tests-3/VBZ||acts-8/VBZ	advmod||acts-8/VBZ||directly-9/RB	det||brain-12/NN||the-11/DT	prep_in||acts-8/VBZ||brain-12/NN	aux||regulate-14/VB||to-13/TO	vmod||brain-12/NN||regulate-14/VB	amod||neurons-17/NNS||critical-15/JJ	amod||neurons-17/NNS||glucose-sensing-16/JJ	dobj||regulate-14/VB||neurons-17/NNS	det||hypothalamus-20/NNS||the-19/DT	prep_in||neurons-17/NNS||hypothalamus-20/NNS	aux||mediate-22/VB||to-21/TO	vmod||regulate-14/VB||mediate-22/VB	det||response-25/NN||the-23/DT	amod||response-25/NN||counterregulatory-24/JJ	dobj||mediate-22/VB||response-25/NN	prep_to||mediate-22/VB||hypoglycemia-27/NN	hypoglycemia-27||glucose--1||yes||this study tests the hypothesis that insulin acts directly in the brain to regulate critical glucose-sensing neurons in the hypothalamus to mediate the counterregulatory response to hypoglycemia.
nn||markers-6/NNS||hbvdna-1/NN	conj_and||hbvdna-1/NN||other-3/JJ	nn||markers-6/NNS||other-3/JJ	amod||markers-6/NNS||serum-4/JJ	nn||markers-6/NNS||hbv-5/NN	nsubjpass||tested-29/VBN||markers-6/NNS	amod||antigen-10/NN||hepatitisb-8/JJ	amod||antigen-10/NN||e-9/JJ	prep_including||markers-6/NNS||antigen-10/NN	appos||antigen-10/NN||hbeag-12/NN	amod||antibody-17/NN||hepatitisb-15/JJ	nn||antibody-17/NN||core-16/NN	prep_including||markers-6/NNS||antibody-17/NN	conj_and||antigen-10/NN||antibody-17/NN	dep||antibody-17/NN||anti-hbc-19/JJ	amod||antibody-24/NN||hepatitisb-22/JJ	nn||antibody-24/NN||surface-23/NN	prep_including||markers-6/NNS||antibody-24/NN	conj_and||antigen-10/NN||antibody-24/NN	appos||antibody-24/NN||anti-hbs-26/NNS	auxpass||tested-29/VBN||were-28/VBD	root||ROOT-0/null||tested-29/VBN	prepc_among||tested-29/VBN||hbsag-31/VBG	amod||women-34/NNS||positive-32/JJ	amod||women-34/NNS||pregnant-33/JJ	dobj||hbsag-31/VBG||women-34/NNS	hepatitisb-22||hbsag-31||yes||hbvdna and other serum hbv markers including hepatitisb e antigen (hbeag), hepatitisb core antibody (anti-hbc) and hepatitisb surface antibody (anti-hbs) were tested among hbsag positive pregnant women.
advmod||eradicate-8/VB||currently-1/RB	neg||therapy-5/NN||no-3/DT	amod||therapy-5/NN||licensed-4/JJ	nsubj||eradicate-8/VB||therapy-5/NN	aux||eradicate-8/VB||can-6/MD	advmod||eradicate-8/VB||thoroughly-7/RB	root||ROOT-0/null||eradicate-8/VB	dobj||eradicate-8/VB||hepatitisbvirus-9/NNS	appos||hepatitisbvirus-9/NNS||hbv-11/NN	det||body-15/NN||the-14/DT	prep_from||eradicate-8/VB||body-15/NN	amod||±-20/NNS||interferon-18/JJ	nn||±-20/NNS||î-19/NN	prep_including||eradicate-8/VB||±-20/NNS	prep_including||eradicate-8/VB||inhibitors-22/NNS	conj_and||±-20/NNS||inhibitors-22/NNS	nn||reverse-transcription-25/NN||hbv-24/NN	prep_of||±-20/NNS||reverse-transcription-25/NN	hbv-24||hepatitisbvirus-9||no||currently, no licensed therapy can thoroughly eradicate hepatitisbvirus (hbv) from the body, including interferon î± and inhibitors of hbv reverse-transcription.
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	amod||³-5/JJ||fluorophore-labelled-3/JJ	amod||³-5/JJ||anti-ifn-î-4/NNP	dobj||used-2/VBD||³-5/JJ	amod||antibodies-8/NNS||anti-il-2-7/JJ	dobj||used-2/VBD||antibodies-8/NNS	conj_and||³-5/JJ||antibodies-8/NNS	amod||overlay-11/NN||digital-10/JJ	prep_with||used-2/VBD||overlay-11/NN	amod||images-15/NNS||spatially-mapped-13/JJ	amod||images-15/NNS||colour-filtered-14/JJ	prep_of||overlay-11/NN||images-15/NNS	aux||enumerate-17/VB||to-16/TO	vmod||used-2/VBD||enumerate-17/VB	amod||t-cells-24/NNS||dual-18/JJ	conj_and||dual-18/JJ||single-20/JJ	amod||t-cells-24/NNS||single-20/JJ	amod||t-cells-24/NNS||cytokine-secreting-21/JJ	amod||t-cells-24/NNS||m.tuberculosis-22/JJ	amod||t-cells-24/NNS||antigen-specific-23/JJ	dobj||enumerate-17/VB||t-cells-24/NNS	nn||patients-27/NNS||tuberculosis-26/NNP	prep_in||t-cells-24/NNS||patients-27/NNS	nn||-rrb--34/NNP||latent-30/NN	nn||-rrb--34/NNP||tuberculosisinfection-31/NN	nn||-rrb--34/NNP||-lrb--32/NNP	nn||-rrb--34/NNP||ltbi-33/NNP	prep_in||t-cells-24/NNS||-rrb--34/NNP	conj_and||patients-27/NNS||-rrb--34/NNP	tuberculosisinfection-31||m.tuberculosis-22||no||we used fluorophore-labelled anti-ifn-î ³ and anti-il-2 antibodies with digital overlay of spatially-mapped colour-filtered images to enumerate dual and single cytokine-secreting m.tuberculosis antigen-specific t-cells in tuberculosis patients and in latent tuberculosisinfection -lrb- ltbi -rrb- .
amod||differences-2/NNS||regional-1/JJ	nsubj||depots-5/VBZ||differences-2/NNS	prep_among||differences-2/NNS||adipose-4/NN	root||ROOT-0/null||depots-5/VBZ	prep_in||depots-5/VBZ||capacities-7/NNS	amod||storage-10/NN||fattyacid-9/JJ	prep_for||capacities-7/NNS||storage-10/NN	advmod||depots-5/VBZ||susceptibility-12/RB	prep_to||depots-5/VBZ||hypoxia-14/NN	nsubj||contribute-19/VBP||inflammation-17/NN	advmod||contribute-19/VBP||likely-18/RB	conj_and||depots-5/VBZ||contribute-19/VBP	prep_to||contribute-19/VBP||complications-21/NNS	prep_of||complications-21/NNS||obesity-23/NN	fattyacid-9||hypoxia-14||no_rel||regional differences among adipose depots in capacities for fattyacid storage, susceptibility to hypoxia, and inflammation likely contribute to complications of obesity.
aux||compare-2/VB||to-1/TO	root||ROOT-0/null||compare-2/VB	det||effects-4/NNS||the-3/DT	dobj||compare-2/VB||effects-4/NNS	prepc_of||effects-4/NNS||combining-6/VBG	ccomp||combining-6/VBG||liraglutide-7/VB	dep||liraglutide-7/VB||0.6-9/CD	dep||liraglutide-7/VB||1.2-11/CD	conj_or||0.6-9/CD||1.2-11/CD	num||mg/day-14/NN||1.8-13/CD	dep||liraglutide-7/VB||mg/day-14/NN	conj_or||0.6-9/CD||mg/day-14/NN	ccomp||combining-6/VBG||rosiglitazone-17/VB	conj_or||liraglutide-7/VB||rosiglitazone-17/VB	num||mg/day-19/NN||4-18/CD	dobj||liraglutide-7/VB||mg/day-19/NN	det||228-26/FW||all-21/DT	nn||228-26/FW||n-22/FW	nn||228-26/FW||â-23/FW	nn||228-26/FW||-24/FW	nn||228-26/FW||¥-25/FW	dep||effects-4/NNS||228-26/FW	dobj||compare-2/VB||placebo-29/NN	conj_or||effects-4/NNS||placebo-29/NN	quantmod||114-33/CD||n-31/RB	number||114-33/CD||=-32/CD	dep||placebo-29/NN||114-33/CD	prep_with||placebo-29/NN||glimepiride-36/NN	dep||placebo-29/NN||2â-38/VBG	dobj||2â-38/VBG||$-39/$	num||$-39/$||4-41/CD	advmod||2â-38/VBG||mg/day-42/RB	amod||control-46/NN||glycaemic-45/JJ	prep_on||compare-2/VB||control-46/NN	nn||weight-49/NN||body-48/NN	prep_on||compare-2/VB||weight-49/NN	conj_and||control-46/NN||weight-49/NN	prep_on||compare-2/VB||safety-51/NN	conj_and||control-46/NN||safety-51/NN	prep_in||compare-2/VB||type2diabetes-53/CD	type2diabetes-53||rosiglitazone-17||yes||to compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n â¥ 228) or placebo ( n = 114) with glimepiride (2â4 mg/day) on glycaemic control, body weight and safety in type2diabetes.
det||objective-2/NN||the-1/DT	nsubj||was-6/VBD||objective-2/NN	nsubj||develop-8/VB||objective-2/NN	det||study-5/NN||this-4/DT	prep_in||objective-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||develop-8/VB||to-7/TO	xcomp||was-6/VBD||develop-8/VB	det||bone-16/NN||an-9/DT	amod||bone-16/NN||osteoconductive-10/JJ	conj_and||osteoconductive-10/JJ||biodegradable-12/JJ	amod||bone-16/NN||biodegradable-12/JJ	conj_and||osteoconductive-10/JJ||rifampicin-14/JJ	amod||bone-16/NN||rifampicin-14/JJ	amod||bone-16/NN||releasing-15/JJ	dobj||develop-8/VB||bone-16/NN	vmod||bone-16/NN||filling-17/VBG	amod||material-19/NN||composite-18/JJ	dobj||filling-17/VBG||material-19/NN	det||treatment-22/NN||the-21/DT	prep_for||filling-17/VBG||treatment-22/NN	prep_of||treatment-22/NN||osteomyelitis-24/NNS	det||bacterialinfection-27/NN||a-26/DT	appos||osteomyelitis-24/NNS||bacterialinfection-27/NN	nsubj||difficult-33/JJ||bacterialinfection-27/NN	nsubj||expensive-35/JJ||bacterialinfection-27/NN	nsubj||treat-37/VB||bacterialinfection-27/NN	prep_of||bacterialinfection-27/NN||bone-29/NN	cop||difficult-33/JJ||is-31/VBZ	advmod||difficult-33/JJ||very-32/RB	rcmod||bacterialinfection-27/NN||difficult-33/JJ	rcmod||bacterialinfection-27/NN||expensive-35/JJ	conj_and||difficult-33/JJ||expensive-35/JJ	aux||treat-37/VB||to-36/TO	xcomp||difficult-33/JJ||treat-37/VB	bacterialinfection-27||rifampicin-14||yes||the objective in this study was to develop an osteoconductive, biodegradable and rifampicin releasing bone filling composite material for the treatment of osteomyelitis, a bacterialinfection of bone that is very difficult and expensive to treat.
amod||women-2/NNS||pregnant-1/JJ	nsubjpass||assigned-7/VBN||women-2/NNS	vmod||women-2/NNS||attending-3/VBG	amod||clinics-5/NNS||antenatal-4/JJ	dobj||attending-3/VBG||clinics-5/NNS	auxpass||assigned-7/VBN||were-6/VBD	root||ROOT-0/null||assigned-7/VBN	prep_to||assigned-7/VBN||groups-9/NNS	vmod||groups-9/NNS||based-10/VBN	det||drug-13/NN||the-12/DT	prep_on||based-10/VBN||drug-13/NN	vmod||drug-13/NN||used-14/VBN	aux||treat-16/VB||to-15/TO	xcomp||used-14/VBN||treat-16/VB	poss||malaria-20/NN||their-17/PRP$	advmod||recent-19/JJ||most-18/RBS	amod||malaria-20/NN||recent-19/JJ	nn||al-23/NNP||malaria-20/NN	nn||al-23/NNP||episode-21/NN	nn||al-23/NNP||-lrb--22/NNP	dobj||treat-16/VB||al-23/NNP	amod||-rrb--28/NNS||sulphadoxine-pyrimethamine-25/JJ	amod||-rrb--28/NNS||sp-27/JJ	prep_vs.||al-23/NNP||-rrb--28/NNS	malaria-20||pyrimethamine--1||yes||pregnant women attending antenatal clinics were assigned to groups based on the drug used to treat their most recent malaria episode -lrb- al vs. sulphadoxine-pyrimethamine , sp -rrb- .
nn||organization-2/NN||gene-1/NN	nsubj||similar-16/JJ||organization-2/NN	nsubj||different-25/JJ||organization-2/NN	det||spacer-6/NN||the-4/DT	amod||spacer-6/NN||intergenic-5/JJ	prep_of||organization-2/NN||spacer-6/NN	det||rrna-10/NN||the-8/DT	amod||rrna-10/NN||16s-9/JJ	prep_between||spacer-6/NN||rrna-10/NN	det||rrna-14/NN||the-12/DT	amod||rrna-14/NN||23s-13/JJ	prep_between||spacer-6/NN||rrna-14/NN	conj_and||rrna-10/NN||rrna-14/NN	cop||similar-16/JJ||was-15/VBD	root||ROOT-0/null||similar-16/JJ	prep_to||similar-16/JJ||that-18/DT	amod||species-23/NNS||other-20/JJ	nn||species-23/NNS||tbrf-21/NN	nn||species-23/NNS||borrelia-22/NN	prep_of||that-18/DT||species-23/NNS	conj_and||similar-16/JJ||different-25/JJ	det||species-30/NN||the-27/DT	amod||species-30/NN||lymedisease-28/JJ	nn||species-30/NN||borrelia-29/NN	prep_from||different-25/JJ||species-30/NN	lymedisease-28||borrelia-29||no||gene organization of the intergenic spacer between the 16s rrna and the 23s rrna was similar to that of other tbrf borrelia species and different from the lymedisease borrelia species.
nsubjpass||excluded-9/VBN||subjects-1/NNS	vmod||subjects-1/NNS||receiving-2/VBG	dobj||receiving-2/VBG||thyroxine-3/NN	num||%-6/NN||10.6-5/CD	appos||thyroxine-3/NN||%-6/NN	auxpass||excluded-9/VBN||were-8/VBD	root||ROOT-0/null||excluded-9/VBN	num||%-12/NN||19.3-11/CD	nsubj||had-18/VBD||%-12/NN	vmod||%-12/NN||had-13/VBN	dobj||had-13/VBN||hypertension-14/NN	number||%-17/NN||43-16/CD	amod||hypertension-14/NN||%-17/NN	parataxis||excluded-9/VBN||had-18/VBD	det||history-21/NN||a-19/DT	nn||history-21/NN||family-20/NN	dobj||had-18/VBD||history-21/NN	prep_for||history-21/NN||hypertension-23/NN	thyroxine-3||hypertension-23||no_rel||subjects receiving thyroxine (10.6%) were excluded; 19.3% had hypertension, 43% had a family history for hypertension.
det||review-3/NN||this-2/DT	prep_in||present-5/VBP||review-3/NN	nsubj||present-5/VBP||we-4/PRP	root||ROOT-0/null||present-5/VBP	num||cases-7/NNS||two-6/CD	dobj||present-5/VBP||cases-7/NNS	num||patient-9/NN||one-8/CD	poss||presentation-12/NN||patient-9/NN	nsubjpass||found-42/VBN||patient-9/NN	nsubj||have-44/VB||patient-9/NN	amod||presentation-12/NN||first-11/JJ	nsubj||renaldisease-17/NN||presentation-12/NN	prep_of||presentation-12/NN||aids-14/NNS	cop||renaldisease-17/NN||was-15/VBD	amod||renaldisease-17/NN||end-stage-16/JJ	rcmod||patient-9/NN||renaldisease-17/NN	nsubjpass||found-23/VBN||renaldisease-17/NN	nsubj||hivan-26/VBN||renaldisease-17/NN	prep_on||found-23/VBN||biopsy-21/NN	auxpass||found-23/VBN||was-22/VBD	rcmod||renaldisease-17/NN||found-23/VBN	aux||hivan-26/VBN||to-24/TO	aux||hivan-26/VBN||have-25/VB	xcomp||found-23/VBN||hivan-26/VBN	det||second-30/NN||the-29/DT	rcmod||patient-9/NN||second-30/NN	conj_and||renaldisease-17/NN||second-30/NN	nsubjpass||found-23/VBN||second-30/NN	nsubjpass||infected-34/VBN||second-30/NN	nsubjpass||infected-34/VBN||second-30/NN	auxpass||infected-34/VBN||was-33/VBD	rcmod||second-30/NN||infected-34/VBN	rcmod||second-30/NN||infected-34/VBN	conj_and||infected-34/VBN||infected-34/VBN	prep_with||infected-34/VBN||hiv-36/NN	prep_on||infected-34/VBN||biopsy-40/NN	auxpass||found-42/VBN||was-41/VBD	rcmod||cases-7/NNS||found-42/VBN	aux||have-44/VB||to-43/TO	xcomp||found-42/VBN||have-44/VB	amod||glomerulonephritis-49/NNS||hepatitisc-related-45/JJ	amod||glomerulonephritis-49/NNS||hepatitisc-46/JJ	amod||glomerulonephritis-49/NNS||related-47/JJ	nn||glomerulonephritis-49/NNS||membranoproliferative-48/NN	dobj||have-44/VB||glomerulonephritis-49/NNS	hivan-26||hiv-36||no||in this review we present two cases one patient whose first presentation of aids was end-stage renaldisease, who on biopsy was found to have hivan, and the second, who was infected with hiv, and on biopsy was found to have hepatitisc-related hepatitisc related membranoproliferative glomerulonephritis.
aux||compare-2/VB||to-1/TO	csubj||adjuncts-16/VBZ||compare-2/VB	conj_and||compare-2/VB||evaluate-4/VB	csubj||adjuncts-16/VBZ||evaluate-4/VB	det||effect-6/NN||the-5/DT	dobj||compare-2/VB||effect-6/NN	prepc_of||effect-6/NN||adding-8/VBG	npadvmod||as-15/RB||ketamine-9/NN	conj_or||ketamine-9/NN||nitroglycerin-11/NN	npadvmod||as-15/RB||nitroglycerin-11/NN	appos||ketamine-9/NN||ntg-13/NN	advmod||adding-8/VBG||as-15/RB	root||ROOT-0/null||adjuncts-16/VBZ	aux||lidocaine-18/VB||to-17/TO	xcomp||adjuncts-16/VBZ||lidocaine-18/VB	amod||anesthesia-22/NN||intravenous-20/JJ	amod||anesthesia-22/NN||regional-21/JJ	prep_for||lidocaine-18/VB||anesthesia-22/NN	appos||anesthesia-22/NN||ivra-24/NNP	prep_on||anesthesia-22/NN||intraoperative-27/NN	xcomp||adjuncts-16/VBZ||postoperative-29/VB	conj_and||lidocaine-18/VB||postoperative-29/VB	nn||times-37/NNS||analgesia-30/NN	conj_and||analgesia-30/NN||sensorial-32/NN	nn||times-37/NNS||sensorial-32/NN	conj_and||analgesia-30/NN||motor-34/NN	nn||times-37/NNS||motor-34/NN	nn||times-37/NNS||block-35/NN	nn||times-37/NNS||onset-36/NN	dobj||postoperative-29/VB||times-37/NNS	xcomp||adjuncts-16/VBZ||tourniquet-40/VB	conj_and||lidocaine-18/VB||tourniquet-40/VB	dobj||tourniquet-40/VB||pain-41/NN	pain-41||ketamine-9||yes||to compare and evaluate the effect of adding ketamine or nitroglycerin (ntg) as adjuncts to lidocaine for intravenous regional anesthesia (ivra) on intraoperative and postoperative analgesia, sensorial and motor block onset times, and tourniquet pain.
det||effect-4/NN||the-1/DT	amod||effect-4/NN||main-2/JJ	amod||effect-4/NN||biological-3/JJ	nsubj||is-8/VBZ||effect-4/NN	det||substitutions-7/NNS||these-6/DT	prep_of||effect-4/NN||substitutions-7/NNS	root||ROOT-0/null||is-8/VBZ	aux||attenuate-10/VB||to-9/TO	ccomp||is-8/VBZ||attenuate-10/VB	det||consequences-12/NNS||the-11/DT	dobj||attenuate-10/VB||consequences-12/NNS	det||activity-16/NN||the-14/DT	amod||activity-16/NN||mutagenic-15/JJ	prep_of||consequences-12/NNS||activity-16/NN	nn||$-20/NNP||ribavirin-18/NNP	nn||$-20/NNP||â-19/FW	prep_of||activity-16/NN||$-20/NNP	prepc_by||attenuate-10/VB||avoiding-23/VBG	det||repertoire-26/NN||the-24/DT	amod||repertoire-26/NN||biased-25/JJ	dobj||avoiding-23/VBG||repertoire-26/NN	nn||mutations-29/NNS||transition-28/NN	prep_of||repertoire-26/NN||mutations-29/NNS	vmod||mutations-29/NNS||produced-30/VBN	det||$-35/NN||this-32/DT	amod||$-35/NN||purine-33/JJ	amod||$-35/NN||analogueâ-34/JJ	agent||produced-30/VBN||$-35/NN	aux||maintain-39/VB||to-38/TO	ccomp||is-8/VBZ||maintain-39/VB	conj_and||attenuate-10/VB||maintain-39/VB	det||fitness-42/NN||the-40/DT	amod||fitness-42/NN||replicative-41/JJ	dobj||maintain-39/VB||fitness-42/NN	det||virus-45/NN||the-44/DT	prep_of||fitness-42/NN||virus-45/NN	nsubj||able-48/JJ||virus-45/NN	nsubj||escape-50/VB||virus-45/NN	cop||able-48/JJ||is-47/VBZ	rcmod||virus-45/NN||able-48/JJ	aux||escape-50/VB||to-49/TO	xcomp||able-48/JJ||escape-50/VB	dobj||escape-50/VB||extinction-51/NN	prep_by||escape-50/VB||ribavirin-53/NNP	virus-45||ribavirin-53||yes||the main biological effect of these substitutions is to attenuate the consequences of the mutagenic activity of ribavirin âby avoiding the biased repertoire of transition mutations produced by this purine analogueâand to maintain the replicative fitness of the virus which is able to escape extinction by ribavirin.
mark||higher-6/JJR||although-1/IN	amod||prevalence-3/NN||hbsag-2/VBG	nsubj||higher-6/JJR||prevalence-3/NN	cop||higher-6/JJR||is-4/VBZ	advmod||higher-6/JJR||much-5/RB	advcl||high-29/JJ||higher-6/JJR	prep_among||higher-6/JJR||subjects-8/NNS	nsubj||hivpositive-11/JJ||subjects-8/NNS	cop||hivpositive-11/JJ||are-10/VBP	rcmod||subjects-8/NNS||hivpositive-11/JJ	num||%-14/NN||14.0-13/CD	dep||subjects-8/NNS||%-14/NN	num||%-17/NN||4.3-16/CD	dep||subjects-8/NNS||%-17/NN	conj_versus||%-14/NN||%-17/NN	det||prevalence-21/NN||the-20/DT	nsubj||high-29/JJ||prevalence-21/NN	nsubj||warrant-32/VB||prevalence-21/NN	prepc_of||prevalence-21/NN||hbsag-23/VBG	amod||subjects-27/NNS||hiv-25/JJ	amod||subjects-27/NNS||negative-26/JJ	prep_in||hbsag-23/VBG||subjects-27/NNS	cop||high-29/JJ||is-28/VBZ	root||ROOT-0/null||high-29/JJ	advmod||high-29/JJ||enough-30/RB	aux||warrant-32/VB||to-31/TO	xcomp||high-29/JJ||warrant-32/VB	det||recommendation-34/NN||a-33/DT	dobj||warrant-32/VB||recommendation-34/NN	aux||screen-36/VB||to-35/TO	vmod||recommendation-34/NN||screen-36/VB	det||clients-38/NNS||all-37/DT	dobj||screen-36/VB||clients-38/NNS	nn||centers-41/NNS||vct-40/NN	prep_at||screen-36/VB||centers-41/NNS	nn||status-45/NN||hiv-44/NN	prep_irrespective_of||screen-36/VB||status-45/NN	hivpositive-11||hiv-44||no||although hbsag prevalence is much higher among subjects who are hivpositive (14.0% versus 4.3%), the prevalence of hbsag in hiv negative subjects is high enough to warrant a recommendation to screen all clients at vct centers irrespective of hiv status.
advmod||demonstrate-4/VBP||further-1/RB	nsubj||demonstrate-4/VBP||we-3/PRP	root||ROOT-0/null||demonstrate-4/VBP	mark||recognized-8/VBN||that-5/IN	nsubjpass||recognized-8/VBN||ompl37-6/NNS	auxpass||recognized-8/VBN||is-7/VBZ	ccomp||demonstrate-4/VBP||recognized-8/VBN	amod||leptospirosis-13/NNS||acute-10/JJ	conj_and||acute-10/JJ||convalescent-12/JJ	amod||leptospirosis-13/NNS||convalescent-12/JJ	agent||recognized-8/VBN||leptospirosis-13/NNS	amod||sera-15/JJ||patient-14/JJ	amod||sera-23/NN||sera-15/JJ	advmod||sera-15/JJ||also-17/RB	conj_and||sera-15/JJ||also-17/RB	amod||sera-23/NN||also-17/RB	conj_and||sera-15/JJ||by-18/IN	amod||sera-23/NN||by-18/IN	prep_by||sera-15/JJ||leptospira-19/NN	amod||sera-23/NN||infected-21/JJ	nn||sera-23/NN||hamster-22/NN	dep||leptospirosis-13/NNS||sera-23/NN	leptospirosis-13||leptospira-19||no||further, we demonstrate that ompl37 is recognized by acute and convalescent leptospirosis patient sera and also by leptospira -infected hamster sera.
det||study-3/NN||this-2/DT	prep_in||shown-7/VBN||study-3/NN	nsubj||shown-7/VBN||we-5/PRP	aux||shown-7/VBN||have-6/VBP	root||ROOT-0/null||shown-7/VBN	det||vaccination-11/NN||that-8/DT	amod||vaccination-11/NN||heterologous-9/JJ	amod||vaccination-11/NN||prime-boost-10/JJ	dobj||shown-7/VBN||vaccination-11/NN	nn||tb-15/NN||tuberculosis-13/NNP	prep_against||shown-7/VBN||tb-15/NN	vmod||tb-15/NN||using-17/VBG	amod||priming/dna-hsp-20/NN||intranasal-18/JJ	nn||priming/dna-hsp-20/NN||bcg-19/NN	dobj||using-17/VBG||priming/dna-hsp-20/NN	prep_than||provided-26/VBD||priming/dna-hsp-20/NN	num||boosting-22/NNS||65-21/CD	nsubj||provided-26/VBD||boosting-22/NNS	appos||boosting-22/NNS||bcgin/dna-24/NNP	rcmod||priming/dna-hsp-20/NN||provided-26/VBD	advmod||greater-28/JJR||significantly-27/RB	amod||protection-29/NN||greater-28/JJR	dobj||provided-26/VBD||protection-29/NN	vmod||that-31/DT||afforded-32/VBN	det||subcutaneous-36/NNS||a-34/DT	amod||subcutaneous-36/NNS||single-35/JJ	agent||afforded-32/VBN||subcutaneous-36/NNS	nn||dose-39/NN||intranasal-38/NN	agent||afforded-32/VBN||dose-39/NN	conj_or||subcutaneous-36/NNS||dose-39/NN	prep_of||subcutaneous-36/NNS||bcg-41/NN	tb-15||bcg-41||no||in this study, we have shown that heterologous prime-boost vaccination against tuberculosis (tb) using intranasal bcg priming/dna-hsp65 boosting (bcgin/dna) provided significantly greater protection than that afforded by a single subcutaneous or intranasal dose of bcg.
preconj||loss-3/NN||both-1/DT	nn||loss-3/NN||weight-2/NN	nsubj||vldlâ-31/VBD||loss-3/NN	conj_and||loss-3/NN||ezetimibe-5/NN	nsubj||vldlâ-31/VBD||ezetimibe-5/NN	nn||loss-8/NN||weight-7/NN	conj_plus||loss-3/NN||loss-8/NN	nsubj||vldlâ-31/VBD||loss-8/NN	advmod||loss-3/NN||significantly-9/RB	det||p-12/NN||all-11/DT	nsubj||<-13/VBZ||p-12/NN	parataxis||vldlâ-31/VBD||<-13/VBZ	dobj||<-13/VBZ||0.05-14/CD	amod||tissues-24/NNS||reduced-16/JJ	nn||tissues-24/NNS||body-17/NN	nn||visceral-20/NN||weight-18/NN	nn||tissues-24/NNS||visceral-20/NN	conj_and||visceral-20/NN||subcutaneous-22/JJ	nn||tissues-24/NNS||subcutaneous-22/JJ	nn||tissues-24/NNS||adipose-23/NN	nsubj||vldlâ-31/VBD||tissues-24/NNS	nn||triglycerides-29/NNS||insulinresistance-26/NN	conj_and||insulinresistance-26/NN||plasma-28/NN	nn||triglycerides-29/NNS||plasma-28/NN	appos||tissues-24/NNS||triglycerides-29/NNS	root||ROOT-0/null||vldlâ-31/VBD	dobj||vldlâ-31/VBD||$-32/$	nn||fetuin-a-38/NN||apob-100-34/NNP	appos||fetuin-a-38/NN||apoc-iii-36/NNP	npadvmod||plasma-45/RB||fetuin-a-38/NN	dep||protein-4-42/JJ||retinol-binding-41/RB	dep||fetuin-a-38/NN||protein-4-42/JJ	dep||fetuin-a-38/NN||increased-44/JJ	conj_and||protein-4-42/JJ||increased-44/JJ	dep||adiponectin-46/CD||plasma-45/RB	num||$-32/$||adiponectin-46/CD	advmod||vldlâ-31/VBD||concentrations-47/RB	triglycerides-29||insulinresistance-26||no_rel||both weight loss and ezetimibe plus weight loss significantly (all p < 0.05) reduced body weight, visceral and subcutaneous adipose tissues, insulinresistance and plasma triglycerides, vldlâapob-100, apoc-iii, fetuin-a, and retinol-binding protein-4 and increased plasma adiponectin concentrations.
nsubjpass||concluded-3/VBN||it-1/PRP	auxpass||concluded-3/VBN||was-2/VBD	root||ROOT-0/null||concluded-3/VBN	mark||favor-7/VBP||that-4/IN	amod||nitrates-6/NNS||organic-5/JJ	nsubj||favor-7/VBP||nitrates-6/NNS	ccomp||concluded-3/VBN||favor-7/VBP	dobj||favor-7/VBP||regression-8/NN	prep_of||regression-8/NN||lvh-10/NN	amod||patients-13/NNS||hypertensive-12/JJ	prep_in||favor-7/VBP||patients-13/NNS	amod||dialysis-17/NN||chronic-15/JJ	amod||dialysis-17/NN||peritoneal-16/JJ	prep_on||patients-13/NNS||dialysis-17/NN	nsubjpass||considered-23/VBN||nitrates-20/NNS	aux||considered-23/VBN||may-21/MD	auxpass||considered-23/VBN||be-22/VB	conj_and||concluded-3/VBN||considered-23/VBN	prep_for||considered-23/VBN||use-25/NN	prepc_before||considered-23/VBN||employing-27/VBG	det||antihypertensiveagents-31/NNS||the-28/DT	num||antihypertensiveagents-31/NNS||five-29/CD	amod||antihypertensiveagents-31/NNS||other-30/JJ	dobj||employing-27/VBG||antihypertensiveagents-31/NNS	amod||antihypertensiveagents-31/NNS||other-32/JJ	prep_than||employing-27/VBG||nitrates-34/NNS	lvh-10||antihypertensiveagents-31||no_rel||it was concluded that organic nitrates favor regression of lvh in hypertensive patients on chronic peritoneal dialysis, and nitrates may be considered for use before employing the five other antihypertensiveagents other than nitrates.
prep||remain-13/VB||given-1/VBN	poss||cost-4/NN||its-2/PRP$	amod||cost-4/NN||low-3/JJ	pobj||given-1/VBN||cost-4/NN	amod||experience-8/NN||extensive-6/JJ	amod||experience-8/NN||clinical-7/JJ	pobj||given-1/VBN||experience-8/NN	conj_and||cost-4/NN||experience-8/NN	nsubj||remain-13/VB||allopurinol-10/NN	aux||remain-13/VB||will-11/MD	advmod||remain-13/VB||likely-12/RB	root||ROOT-0/null||remain-13/VB	det||drug-16/NN||the-14/DT	amod||drug-16/NN||first-line-15/JJ	xcomp||remain-13/VB||drug-16/NN	prep_for||remain-13/VB||management-18/NN	prep_of||management-18/NN||hyperuricemia-20/NN	prep_of||management-18/NN||gout-22/NN	conj_and||hyperuricemia-20/NN||gout-22/NN	gout-22||allopurinol-10||yes||given its low cost and extensive clinical experience, allopurinol will likely remain the first-line drug for management of hyperuricemia and gout.
nsubj||sought-2/VBD||we-1/PRP	nsubj||determine-4/VB||we-1/PRP	root||ROOT-0/null||sought-2/VBD	aux||determine-4/VB||to-3/TO	xcomp||sought-2/VBD||determine-4/VB	mark||altered-36/VBN||if-5/IN	nsubjpass||altered-36/VBN||upa-6/NN	nn||inhibitor-9/NN||pa-8/NN	appos||upa-6/NN||inhibitor-9/NN	appos||inhibitor-9/NN||pai-11/NN	dep||inhibitor-9/NN||-1-13/CD	num||expression-20/NN||prostaglandin-15/CD	nn||expression-20/NN||pg-17/NN	amod||expression-20/NN||e2-19/JJ	appos||upa-6/NN||expression-20/NN	conj_and||inhibitor-9/NN||expression-20/NN	amod||fluid-24/NN||nipple-22/JJ	nn||fluid-24/NN||aspirate-23/NN	prep_in||expression-20/NN||fluid-24/NN	appos||fluid-24/NN||naf-26/NN	nn||expression-32/NN||upa-29/NN	conj_and||upa-29/NN||pge2-31/JJ	nn||expression-32/NN||pge2-31/JJ	prep_in||expression-20/NN||expression-32/NN	conj_and||fluid-24/NN||expression-32/NN	prep_in||expression-32/NN||plasma-34/NN	auxpass||altered-36/VBN||were-35/VBD	advcl||determine-4/VB||altered-36/VBN	nn||dose-39/NN||celecoxib-38/NN	agent||altered-36/VBN||dose-39/NN	agent||altered-36/VBN||concentration-41/NN	conj_and||dose-39/NN||concentration-41/NN	prep_in||altered-36/VBN||women-43/NNS	amod||risk-48/NN||increased-45/VBN	nn||risk-48/NN||breast-46/NN	nn||risk-48/NN||cancer-47/NN	prep_at||women-43/NNS||risk-48/NN	cancer-47||upa-29||no_rel||we sought to determine if upa, pa inhibitor (pai)-1 and prostaglandin (pg)e2 expression in nipple aspirate fluid (naf) and upa and pge2 expression in plasma were altered by celecoxib dose and concentration in women at increased breast cancer risk.
det||kits-5/NNS||an-1/DT	amod||kits-5/NNS||additional-2/JJ	num||kits-5/NNS||six-3/CD	nn||kits-5/NNS||test-4/NN	nsubj||had-6/VBD||kits-5/NNS	nsubj||missed-17/VBN||kits-5/NNS	root||ROOT-0/null||had-6/VBD	amod||sensitivity-8/NN||high-7/JJ	dobj||had-6/VBD||sensitivity-8/NN	dep||had-6/VBD||<-10/VBG	amod||iu/ml-14/NN||0â-11/JJ	amod||iu/ml-14/NN||·-12/JJ	num||iu/ml-14/NN||13-13/CD	dobj||<-10/VBG||iu/ml-14/NN	conj_but||had-6/VBD||missed-17/VBN	xcomp||missed-17/VBN||hbsag-18/VBG	dobj||hbsag-18/VBG||mutants-19/NNS	conj_but||had-6/VBD||showed-21/VBD	conj_and/or||missed-17/VBN||showed-21/VBD	amod||sensitivity-23/NN||reduced-22/VBN	dobj||showed-21/VBD||sensitivity-23/NN	amod||genotypes-27/NNS||certain-25/JJ	nn||genotypes-27/NNS||hbv-26/NN	prep_to||showed-21/VBD||genotypes-27/NNS	hbv-26||hbsag-18||yes||an additional six test kits had high sensitivity (<0â·13 iu/ml) but missed hbsag mutants and/or showed reduced sensitivity to certain hbv genotypes.
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||previously-3/RB	root||ROOT-0/null||shown-4/VBN	mark||improves-10/VBZ||that-5/IN	amod||supplementation-8/NN||dietary-6/JJ	nn||supplementation-8/NN||leucine-7/NN	nsubj||improves-10/VBZ||supplementation-8/NN	advmod||improves-10/VBZ||significantly-9/RB	ccomp||shown-4/VBN||improves-10/VBZ	nn||metabolism-14/NN||glucose-11/NN	conj_and||glucose-11/NN||energy-13/NN	nn||metabolism-14/NN||energy-13/NN	dobj||improves-10/VBZ||metabolism-14/NN	amod||mice-18/NNS||diet-induced-16/JJ	nn||mice-18/NNS||obese-17/NN	prep_in||improves-10/VBZ||mice-18/NNS	vmod||improves-10/VBZ||suggesting-20/VBG	mark||therapy-30/NN||that-21/IN	amod||supplementation-23/NN||leucine-22/JJ	nsubj||therapy-30/NN||supplementation-23/NN	aux||therapy-30/NN||could-24/MD	advmod||therapy-30/NN||potentially-25/RB	cop||therapy-30/NN||be-26/VB	det||therapy-30/NN||a-27/DT	amod||adjuvant-29/JJ||useful-28/JJ	amod||therapy-30/NN||adjuvant-29/JJ	ccomp||suggesting-20/VBG||therapy-30/NN	prep_for||therapy-30/NN||obesity-32/NN	prep_for||therapy-30/NN||type2diabetes-34/NNS	conj_and||obesity-32/NN||type2diabetes-34/NNS	leucine-22||obesity-32||no_rel||we have previously shown that dietary leucine supplementation significantly improves glucose and energy metabolism in diet-induced obese mice, suggesting that leucine supplementation could potentially be a useful adjuvant therapy for obesity and type2diabetes.
aux||limit-2/VB||to-1/TO	advcl||proposed-20/VBN||limit-2/VB	predet||need-5/NN||both-3/PDT	det||need-5/NN||the-4/DT	dobj||limit-2/VB||need-5/NN	prep_for||limit-2/VB||transfusions-7/NNS	prep_for||limit-2/VB||co-morbidities-9/NNS	conj_and||transfusions-7/NNS||co-morbidities-9/NNS	vmod||transfusions-7/NNS||associated-10/VBN	prep_with||associated-10/VBN||bloodloss-12/NNS	det||use-15/NN||the-14/DT	nsubjpass||proposed-20/VBN||use-15/NN	prep_of||use-15/NN||anti-fibrinolyticagents-17/NNS	aux||proposed-20/VBN||has-18/VBZ	auxpass||proposed-20/VBN||been-19/VBN	root||ROOT-0/null||proposed-20/VBN	fibrinolyticagents--1||bloodloss-12||no_rel||to limit both the need for transfusions and co-morbidities associated with bloodloss, the use of anti-fibrinolyticagents has been proposed.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||studied-8/VBN||study-4/NN	nsubj||studied-8/VBN||we-6/PRP	aux||studied-8/VBN||have-7/VBP	root||ROOT-0/null||studied-8/VBN	ccomp||studied-8/VBN||total-9/VB	num||patients-12/NNS||177-10/CD	amod||patients-12/NNS||eligible-11/JJ	dobj||total-9/VB||patients-12/NNS	dobj||total-9/VB||subjects-14/NNS	conj_and||patients-12/NNS||subjects-14/NNS	num||epstein-barr-virus-19/NNS||128-16/CD	amod||epstein-barr-virus-19/NNS||healthy-17/JJ	nn||epstein-barr-virus-19/NNS||latent-18/NN	prep_including||patients-12/NNS||epstein-barr-virus-19/NNS	appos||epstein-barr-virus-19/NNS||ebv-21/NN	amod||subjects-25/NNS||infected-24/JJ	dep||epstein-barr-virus-19/NNS||subjects-25/NNS	num||patients-31/NNS||17-27/CD	amod||patients-31/NNS||newly-onset-28/JJ	amod||patients-31/NNS||acute-29/JJ	nn||patients-31/NNS||infectiousmononucleosis-30/NN	dep||epstein-barr-virus-19/NNS||patients-31/NNS	conj_and||subjects-25/NNS||patients-31/NNS	num||patients-37/NNS||16-33/CD	amod||patients-37/NNS||newly-diagnosed-34/JJ	amod||patients-37/NNS||ebv-associated-35/JJ	nn||patients-37/NNS||hodgkinlymphoma-36/NN	dep||epstein-barr-virus-19/NNS||patients-37/NNS	conj_and||subjects-25/NNS||patients-37/NNS	num||subjects-44/NNS||16-40/CD	amod||subjects-44/NNS||ebv-negative-41/JJ	amod||subjects-44/NNS||normal-42/JJ	nn||subjects-44/NNS||control-43/NN	dep||epstein-barr-virus-19/NNS||subjects-44/NNS	conj_and||subjects-25/NNS||subjects-44/NNS	infectiousmononucleosis-30||ebv-21||no||in the present study, we have studied total 177 eligible patients and subjects including 128 healthy latent epstein-barr-virus(ebv)-infected subjects, 17 newly-onset acute infectiousmononucleosis patients, 16 newly-diagnosed ebv-associated hodgkinlymphoma patients, and 16 ebv-negative normal control subjects.
poss||work-2/NN||our-1/PRP$	nsubj||demonstrated-4/VBD||work-2/NN	advmod||demonstrated-4/VBD||recently-3/RB	root||ROOT-0/null||demonstrated-4/VBD	amod||differences-6/NNS||fundamental-5/JJ	dobj||demonstrated-4/VBD||differences-6/NNS	det||composition-9/NN||the-8/DT	prep_in||demonstrated-4/VBD||composition-9/NN	det||carbohydrate-12/NN||the-11/DT	prep_of||composition-9/NN||carbohydrate-12/NN	nn||type-15/NN||hiv-14/NN	prep_on||carbohydrate-12/NN||type-15/NN	num||type-15/NN||1-16/CD	det||cause-19/NN||the-18/DT	appos||carbohydrate-12/NN||cause-19/NN	det||pandemic-23/NN||the-21/DT	nn||pandemic-23/NN||aids-22/NNS	prep_of||cause-19/NN||pandemic-23/NN	det||siv-27/NN||the-26/DT	prep_versus||carbohydrate-12/NN||siv-27/NN	det||monkey-32/NN||the-29/DT	advmod||mangabey-31/JJ||sooty-30/RB	amod||monkey-32/NN||mangabey-31/JJ	prep_in||demonstrated-4/VBD||monkey-32/NN	det||host-36/NN||a-34/DT	amod||host-36/NN||natural-35/JJ	appos||monkey-32/NN||host-36/NN	nsubj||develop-40/VB||host-36/NN	aux||develop-40/VB||does-38/VBZ	neg||develop-40/VB||not-39/RB	rcmod||host-36/NN||develop-40/VB	dobj||develop-40/VB||disease-41/NN	poss||infection-44/NN||its-43/PRP$	prep_from||develop-40/VB||infection-44/NN	aids-22||hiv-14||no||our work recently demonstrated fundamental differences in the composition of the carbohydrate on hiv type 1, the cause of the aids pandemic, versus the siv in the sooty mangabey monkey, a natural host that does not develop disease from its infection.
aux||investigate-2/VB||to-1/TO	dep||studied-11/VBD||investigate-2/VB	amod||differences-4/NNS||global-3/JJ	dobj||investigate-2/VB||differences-4/NNS	det||epidemiology-7/NN||the-6/DT	prep_in||investigate-2/VB||epidemiology-7/NN	prep_of||epidemiology-7/NN||chickenpox-9/NN	nsubj||studied-11/VBD||we-10/PRP	root||ROOT-0/null||studied-11/VBD	det||population-13/NN||a-12/DT	dobj||studied-11/VBD||population-13/NN	nn||bissau-16/NN||guinea-15/NN	prep_in||population-13/NN||bissau-16/NN	nsubj||has-25/VBZ||bissau-16/NN	prep_in||has-25/VBZ||contrast-20/NN	amod||countries-24/NNS||other-22/JJ	amod||countries-24/NNS||tropical-23/JJ	prep_to||contrast-20/NN||countries-24/NNS	rcmod||bissau-16/NN||has-25/VBZ	det||age-29/NN||an-26/DT	advmod||early-28/JJ||unexpectedly-27/RB	amod||age-29/NN||early-28/JJ	dobj||has-25/VBZ||age-29/NN	prep_of||age-29/NN||infection-31/NN	prep_with||infection-31/NN||vzv-33/NN	amod||age-29/NN||comparable-35/JJ	aux||temperate-37/VB||to-36/TO	xcomp||comparable-35/JJ||temperate-37/VB	dobj||temperate-37/VB||latitudes-38/NNS	chickenpox-9||vzv-33||no||to investigate global differences in the epidemiology of chickenpox we studied a population in guinea bissau, which in contrast to other tropical countries has an unexpectedly early age of infection with vzv, comparable to temperate latitudes.
amod||africa-3/NN||southern-2/JJ	prep_in||underway-10/JJ||africa-3/NN	det||transition-8/NN||a-5/DT	amod||transition-8/NN||substantial-6/JJ	nn||transition-8/NN||health-7/NN	nsubj||underway-10/JJ||transition-8/NN	cop||underway-10/JJ||is-9/VBZ	root||ROOT-0/null||underway-10/JJ	det||burden-15/NN||the-13/DT	amod||burden-15/NN||heavy-14/JJ	prep_with||underway-10/JJ||burden-15/NN	amod||illness-19/NN||chronic-17/JJ	amod||illness-19/NN||infectious-18/JJ	prep_of||burden-15/NN||illness-19/NN	dep||illness-19/NN||hiv/aids-21/NNS	dep||illness-19/NN||tuberculosis-23/NNP	conj_and||hiv/aids-21/NNS||tuberculosis-23/NNP	vmod||illness-19/NN||paralleled-25/VBN	det||threat-29/NN||the-27/DT	amod||threat-29/NN||growing-28/VBG	agent||paralleled-25/VBN||threat-29/NN	amod||diseases-32/NNS||non-communicable-31/JJ	prep_of||threat-29/NN||diseases-32/NNS	aids--1||hiv--1||no||in southern africa, a substantial health transition is underway, with the heavy burden of chronic infectious illness (hiv/aids and tuberculosis) paralleled by the growing threat of non-communicable diseases.
det||review-2/NN||this-1/DT	nsubj||exposes-3/VBZ||review-2/NN	root||ROOT-0/null||exposes-3/VBZ	det||gap-6/NN||a-4/DT	amod||gap-6/NN||broad-5/JJ	dobj||exposes-3/VBZ||gap-6/NN	det||use-10/NN||the-8/DT	amod||use-10/NN||widespread-9/JJ	prep_between||gap-6/NN||use-10/NN	amod||therapies-13/NNS||timh-12/JJ	prep_of||use-10/NN||therapies-13/NNS	prep_for||therapies-13/NNS||hiv/aids-15/NNS	det||dearth-19/NN||the-18/DT	nsubj||supporting-23/VBG||dearth-19/NN	amod||data-22/NNS||high-quality-21/JJ	prep_of||dearth-19/NN||data-22/NNS	conj_and||exposes-3/VBZ||supporting-23/VBG	poss||effectiveness-25/NN||their-24/PRP$	dobj||supporting-23/VBG||effectiveness-25/NN	dobj||supporting-23/VBG||safety-27/NN	conj_and||effectiveness-25/NN||safety-27/NN	aids--1||hiv--1||no||this review exposes a broad gap between the widespread use of timh therapies for hiv/aids, and the dearth of high-quality data supporting their effectiveness and safety.
det||patients-3/NNS||all-1/DT	amod||patients-3/NNS||hiv-positive-2/JJ	nsubj||met-4/VBD||patients-3/NNS	root||ROOT-0/null||met-4/VBD	det||criteria-6/NNS||the-5/DT	dobj||met-4/VBD||criteria-6/NNS	prep_for||met-4/VBD||aids-8/NNS	appos||aids-8/NNS||cdc/2008-10/NNP	aids-8||hiv--1||no||all hiv-positive patients met the criteria for aids (cdc/2008).
nn||injection-2/NN||intramuscular-1/NN	nsubj||route-7/NN||injection-2/NN	cop||route-7/NN||is-3/VBZ	det||route-7/NN||a-4/DT	advmod||efficient-6/JJ||relatively-5/RB	amod||route-7/NN||efficient-6/JJ	root||ROOT-0/null||route-7/NN	prep_of||route-7/NN||transmission-9/NN	amod||priondisease-12/NN||human-11/JJ	prep_of||transmission-9/NN||priondisease-12/NN	amod||women-16/NNS||young-15/JJ	nsubjpass||expected-22/VBN||women-16/NNS	nsubj||survive-24/VB||women-16/NNS	vmod||women-16/NNS||exposed-17/VBN	prep_to||exposed-17/VBN||prions-19/NNS	aux||expected-22/VBN||can-20/MD	auxpass||expected-22/VBN||be-21/VB	conj_and||route-7/NN||expected-22/VBN	aux||survive-24/VB||to-23/TO	xcomp||expected-22/VBN||survive-24/VB	det||period-27/NN||an-25/DT	nn||period-27/NN||incubation-26/NN	dobj||survive-24/VB||period-27/NN	vmod||period-27/NN||associated-28/VBN	det||inoculum-32/NN||a-30/DT	amod||inoculum-32/NN||minimal-31/JJ	prep_with||associated-28/VBN||inoculum-32/NN	priondisease-12||prions-19||no||intramuscular injection is a relatively efficient route of transmission of human priondisease, and young women exposed to prions can be expected to survive an incubation period associated with a minimal inoculum.
nn||treatment-3/NN||gancyclovir-2/NN	prep_following||went-11/VBD||treatment-3/NN	amod||viremia-7/NN||subsequent-5/JJ	nn||viremia-7/NN||cytomegalovirus-6/NNS	prep_of||treatment-3/NN||viremia-7/NN	det||patient-10/NN||the-9/DT	nsubj||went-11/VBD||patient-10/NN	nsubj||receive-14/VB||patient-10/NN	root||ROOT-0/null||went-11/VBD	prt||went-11/VBD||on-12/RP	aux||receive-14/VB||to-13/TO	xcomp||went-11/VBD||receive-14/VB	det||course-16/NN||a-15/DT	dobj||receive-14/VB||course-16/NN	prep_of||course-16/NN||epoch-18/NN	advmod||mg/m2/day-52/NN||etoposide-20/RB	num||mg/m2/day-22/NNS||50-21/CD	pobj||etoposide-20/RB||mg/m2/day-22/NNS	prep_on||etoposide-20/RB||days-24/NNS	amod||mg/m2/day-52/NN||1â-25/JJ	amod||mg/m2/day-52/NN||$-26/$	num||$-26/$||4-28/CD	amod||mg/m2/day-52/NN||vincristine-30/JJ	num||mg/m2/day-32/NNS||0.4-31/CD	dep||vincristine-30/JJ||mg/m2/day-32/NNS	prep_on||mg/m2/day-32/NNS||days-34/NNS	amod||mg/m2/day-52/NN||1â-35/JJ	amod||mg/m2/day-52/NN||$-36/$	num||$-36/$||4-38/CD	amod||mg/m2/day-52/NN||doxorubicin-40/JJ	num||mg/m2/day-42/NNS||10-41/CD	dep||doxorubicin-40/JJ||mg/m2/day-42/NNS	prep_on||mg/m2/day-42/NNS||days-44/NNS	amod||mg/m2/day-52/NN||1â-45/JJ	amod||mg/m2/day-52/NN||$-46/$	num||$-46/$||4-48/CD	amod||mg/m2/day-52/NN||cyclophosphamide-50/JJ	number||cyclophosphamide-50/JJ||750-51/CD	dep||epoch-18/NN||mg/m2/day-52/NN	prep_on||mg/m2/day-52/NN||day-54/NN	num||day-54/NN||6-55/CD	advmod||1â-63/JJ||prednisolone-58/RB	num||mg/m2/day-60/NNS||60-59/CD	pobj||prednisolone-58/RB||mg/m2/day-60/NNS	prep_on||prednisolone-58/RB||days-62/NNS	prep_on||mg/m2/day-52/NN||1â-63/JJ	conj_and||day-54/NN||1â-63/JJ	dep||1â-63/JJ||$-64/$	num||$-64/$||6-66/CD	gancyclovir-2||cytomegalovirus-6||no_rel||following gancyclovir treatment of subsequent cytomegalovirus viremia, the patient went on to receive a course of epoch (etoposide 50 mg/m2/day on days 1â4, vincristine 0.4 mg/m2/day on days 1â4, doxorubicin 10 mg/m2/day on days 1â4, cyclophosphamide 750 mg/m2/day on day 6, and prednisolone 60 mg/m2/day on days 1â6).
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubj||consists-11/VBZ||treatment-3/NN	prep_of||treatment-3/NN||malaria-5/NN	prep_in||malaria-5/NN||infants-7/NNS	appos||infants-7/NNS||ipti-9/NNP	root||ROOT-0/null||consists-11/VBZ	det||administration-14/NN||the-13/DT	prep_of||consists-11/VBZ||administration-14/NN	det||dose-18/NN||a-16/DT	nn||dose-18/NN||treatment-17/NN	prep_of||administration-14/NN||dose-18/NN	amod||sp-22/NN||sulphadoxine-pyrimethamine-20/JJ	prep_of||dose-18/NN||sp-22/NN	det||time-26/NN||the-25/DT	prep_at||sp-22/NN||time-26/NN	amod||vaccinations-29/NNS||routine-28/JJ	prep_of||time-26/NN||vaccinations-29/NNS	malaria-5||pyrimethamine--1||yes||intermittent preventive treatment of malaria in infants (ipti) consists of the administration of a treatment dose of sulphadoxine-pyrimethamine (sp) at the time of routine vaccinations.
det||purpose-2/NN||the-1/DT	nsubj||was-7/VBD||purpose-2/NN	nsubj||determine-9/VB||purpose-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||present-5/JJ	prep_of||purpose-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||determine-9/VB||to-8/TO	xcomp||was-7/VBD||determine-9/VB	dobj||determine-9/VB||relationship-10/NN	nn||activity-13/NN||disease-12/NN	prep_between||relationship-10/NN||activity-13/NN	amod||markers-16/NNS||systemic-15/JJ	dobj||determine-9/VB||markers-16/NNS	conj_and||relationship-10/NN||markers-16/NNS	nn||degradation-19/NN||cartilage-18/NN	prep_of||markers-16/NNS||degradation-19/NN	amod||telopeptides-24/NNS||urinary-21/JJ	amod||telopeptides-24/NNS||c-terminal-22/JJ	amod||telopeptides-24/NNS||cross-linking-23/JJ	dobj||determine-9/VB||telopeptides-24/NNS	conj_and||relationship-10/NN||telopeptides-24/NNS	nn||collagen-28/NN||type-26/NN	nn||collagen-28/NN||ii-27/NN	prep_of||telopeptides-24/NNS||collagen-28/NN	appos||collagen-28/NN||uctx-ii-30/NNP	nn||degradation-35/NN||bone-34/NN	dobj||determine-9/VB||degradation-35/NN	conj_and||relationship-10/NN||degradation-35/NN	advmod||telopeptides-40/NNS||urinary-37/RB	amod||telopeptides-40/NNS||c-terminal-38/JJ	amod||telopeptides-40/NNS||cross-linking-39/JJ	dobj||determine-9/VB||telopeptides-40/NNS	conj_and||relationship-10/NN||telopeptides-40/NNS	nn||collagen-44/NN||type-42/FW	nn||collagen-44/NN||i-43/FW	prep_of||telopeptides-40/NNS||collagen-44/NN	appos||collagen-44/NN||uctx-i-46/NNP	amod||progression-50/NN||structural-49/JJ	dobj||determine-9/VB||progression-50/NN	conj_and||relationship-10/NN||progression-50/NN	prep_of||progression-50/NN||osteoarthritis-52/NNS	appos||osteoarthritis-52/NNS||oa-54/NN	amod||efficacy-59/NN||potential-57/JJ	amod||efficacy-59/NN||therapeutic-58/JJ	dobj||determine-9/VB||efficacy-59/NN	conj_and||relationship-10/NN||efficacy-59/NN	nn||collagen-63/NN||type-61/NN	nn||collagen-63/NN||ii-62/NN	prep_of||efficacy-59/NN||collagen-63/NN	appos||collagen-63/NN||collii-65/NNP	prep_in||determine-9/VB||combination-68/NN	prep_with||determine-9/VB||glucosamine-70/NN	prep_with||determine-9/VB||chondroitinsulfate-72/NN	conj_and||glucosamine-70/NN||chondroitinsulfate-72/NN	appos||glucosamine-70/NN||gc-74/NN	oa-54||glucosamine-70||yes||the purpose of the present study was to determine relationship between disease activity, systemic markers of cartilage degradation, urinary c-terminal cross-linking telopeptides of type ii collagen (uctx-ii), and bone degradation, urinary c-terminal cross-linking telopeptides of type i collagen (uctx-i), structural progression of osteoarthritis (oa) and potential therapeutic efficacy of type ii collagen (collii) in combination with glucosamine and chondroitinsulfate (gc).
nn||equivalence-2/NNS||conclusion-1/NN	nsubjpass||found-4/VBN||equivalence-2/NNS	auxpass||found-4/VBN||was-3/VBD	root||ROOT-0/null||found-4/VBN	amod||bcgvaccine-7/NN||intradermal-6/JJ	prep_between||found-4/VBN||bcgvaccine-7/NN	nn||bcg-10/NN||percutaneous-9/NNS	prep_between||found-4/VBN||bcg-10/NN	conj_and||bcgvaccine-7/NN||bcg-10/NN	det||incidence-13/NN||the-12/DT	prep_in||bcgvaccine-7/NN||incidence-13/NN	prep_of||incidence-13/NN||tuberculosis-15/NNP	amod||infants-19/NNS||south-17/JJ	nn||infants-19/NNS||african-18/NN	prep_in||found-4/VBN||infants-19/NNS	dep||infants-19/NNS||vaccinated-20/VBN	prep_at||vaccinated-20/VBN||birth-22/NN	dep||infants-19/NNS||followed-24/VBN	conj_and||vaccinated-20/VBN||followed-24/VBN	prt||followed-24/VBN||up-25/RP	num||years-28/NNS||two-27/CD	prep_for||followed-24/VBN||years-28/NNS	tuberculosis-15||bcg-10||yes||conclusion equivalence was found between intradermal bcgvaccine and percutaneous bcg in the incidence of tuberculosis in south african infants vaccinated at birth and followed up for two years.
num||rats-5/NNS||resultsâ-1/CD	amod||rats-5/NNS||$-2/JJ	nn||rats-5/NNS||zdf-4/NN	nsubj||have-10/VBP||rats-5/NNS	prepc_compared_with||rats-5/NNS||with-7/IN	nn||rats-9/NNS||zcl-8/NN	pobj||rats-5/NNS||rats-9/NNS	root||ROOT-0/null||have-10/VBP	amod||gk-13/NN||lower-11/JJR	amod||gk-13/NN||hepatic-12/JJ	dobj||have-10/VBP||gk-13/NN	nsubj||increased-73/VBD||activity-14/NN	nn||activity-14/NN||-lrb--15/FW	nn||activity-14/NN||11.6-16/FW	nn||activity-14/NN||â-17/FW	nn||activity-14/NN||±-18/FW	nn||activity-14/NN||1.9-19/FW	nn||activity-14/NN||vs.-20/FW	nn||activity-14/NN||32.5-21/FW	nn||activity-14/NN||â-22/FW	nn||activity-14/NN||±-23/FW	nn||activity-14/NN||3.2-24/FW	nn||activity-14/NN||mu/mg-25/FW	nn||activity-14/NN||protein-26/FW	nn||activity-14/NN||-rrb--27/FW	nn||activity-14/NN||marked-29/FW	nn||activity-14/NN||hyperglycemia-30/FW	nn||activity-14/NN||-lrb--31/FW	nn||activity-14/NN||23.9-32/FW	nn||activity-14/NN||â-33/FW	nn||activity-14/NN||±-34/FW	nn||activity-14/NN||1.2-35/FW	nn||activity-14/NN||vs.-36/FW	nn||activity-14/NN||7.4-37/FW	nn||activity-14/NN||â-38/FW	dep||activity-14/NN||±-39/FW	number||-rrb--42/NN||0.3-40/CD	dep||-rrb--42/NN||mmol/l-41/JJ	amod||activity-14/NN||-rrb--42/NN	amod||endogenous-45/NNS||higher-44/JJR	appos||activity-14/NN||endogenous-45/NNS	advmod||activity-14/NN||glucose-46/RB	dep||activity-14/NN||production-47/NN	nn||production-47/NN||-lrb--48/FW	nn||production-47/NN||80-49/FW	nn||production-47/NN||â-50/FW	nn||production-47/NN||±-51/FW	nn||production-47/NN||3-52/FW	nn||production-47/NN||vs.-53/FW	nn||production-47/NN||38-54/FW	nn||production-47/NN||â-55/FW	nn||production-47/NN||±-56/FW	nn||production-47/NN||3-57/FW	nn||production-47/NN||î-58/FW	nn||production-47/NN||1/4-59/FW	nn||production-47/NN||mol-60/FW	nn||production-47/NN||â-61/FW	dep||production-47/NN||·-62/FW	poss||-rrb--71/NN||kgâ-63/NNP	number||â-66/NN||1-65/CD	amod||-rrb--71/NN||â-66/NN	punct||-rrb--71/NN||·-67/``	nn||-rrb--71/NN||minâ-68/NN	num||-rrb--71/NN||1-70/CD	dep||production-47/NN||-rrb--71/NN	rcmod||gk-13/NN||increased-73/VBD	amod||â-78/NN||glucose-6-phosphatase-74/JJ	nn||â-78/NN||flux-75/NN	nn||â-78/NN||-lrb--76/NN	num||â-78/NN||150-77/CD	iobj||increased-73/VBD||â-78/NN	punct||â-78/NN||±-79/``	nn||â-78/NN||11-80/FW	nn||â-78/NN||vs.-81/FW	nn||â-78/NN||58-82/FW	nn||â-78/NN||â-83/FW	nn||â-78/NN||±-84/FW	nn||â-78/NN||8-85/FW	nn||â-78/NN||î-86/FW	nn||â-78/NN||1/4-87/FW	nn||â-78/NN||mol-88/FW	dep||â-78/NN||â-89/FW	punct||â-78/NN||·-90/''	poss||â-94/NN||kgâ-91/NNP	num||â-94/NN||1-93/CD	iobj||increased-73/VBD||â-94/NN	dep||â-94/NN||·-95/SYM	poss||production-113/NN||minâ-96/NNP	number||-rrb--99/NN||1-98/CD	amod||production-113/NN||-rrb--99/NN	cc||during-102/IN||and-101/CC	dep||-rrb--99/NN||during-102/IN	det||clamp-105/NN||a-103/DT	amod||clamp-105/NN||hyperglycemic-104/JJ	pobj||during-102/IN||clamp-105/NN	det||failure-108/NN||a-107/DT	appos||clamp-105/NN||failure-108/NN	amod||endogenous-111/NNS||suppress-110/JJ	prep_to||failure-108/NN||endogenous-111/NNS	nn||production-113/NN||glucose-112/NN	iobj||increased-73/VBD||production-113/NN	amod||production-113/NN||-lrb--114/NN	number||-lrb--114/NN||80-115/CD	iobj||increased-73/VBD||â-116/NN	punct||â-116/NN||±-117/``	nn||â-116/NN||7-118/FW	nn||â-116/NN||vs.-119/FW	nn||â-116/NN||â-120/FW	nn||â-116/NN||7-122/FW	nn||â-116/NN||â-123/FW	nn||â-116/NN||±-124/FW	nn||â-116/NN||4-125/FW	nn||â-116/NN||î-126/FW	nn||â-116/NN||1/4-127/FW	nn||â-116/NN||mol-128/FW	dep||â-116/NN||â-129/FW	punct||â-116/NN||·-130/``	poss||â-134/NN||kgâ-131/NNP	num||â-134/NN||1-133/CD	dep||â-116/NN||â-134/NN	punct||â-116/NN||·-135/''	poss||incorporation-143/NN||minâ-136/NNP	number||-rrb--139/NN||1-138/CD	amod||incorporation-143/NN||-rrb--139/NN	conj_and||-rrb--139/NN||promote-141/JJ	amod||incorporation-143/NN||promote-141/JJ	nn||incorporation-143/NN||glucose-142/NN	dobj||increased-73/VBD||incorporation-143/NN	prep_into||increased-73/VBD||glycogen-145/NN	nn||glycogen-145/NN||-lrb--146/FW	nn||glycogen-145/NN||15-147/FW	nn||glycogen-145/NN||â-148/FW	nn||glycogen-145/NN||±-149/FW	nn||glycogen-145/NN||5-150/FW	nn||glycogen-145/NN||vs.-151/FW	nn||glycogen-145/NN||43-152/FW	nn||glycogen-145/NN||â-153/FW	nn||glycogen-145/NN||±-154/FW	nn||glycogen-145/NN||3-155/FW	dep||glycogen-145/NN||î-156/FW	dep||glycogen-145/NN||1/4-157/CD	xcomp||increased-73/VBD||mol/g-158/VBG	nn||-rrb--160/NNS||liver-159/NN	dobj||mol/g-158/VBG||-rrb--160/NNS	hyperglycemia-30||glucose-142||no||resultsâ $ '' zdf rats compared with zcl rats have lower hepatic gk activity -lrb- 11.6 â ± 1.9 vs. 32.5 â ± 3.2 mu/mg protein -rrb- , marked hyperglycemia -lrb- 23.9 â ± 1.2 vs. 7.4 â ± 0.3 mmol/l -rrb- , higher endogenous glucose production -lrb- 80 â ± 3 vs. 38 â ± 3 î 1/4 mol â · kgâ ' 1 â · minâ ' 1 -rrb- , increased glucose-6-phosphatase flux -lrb- 150 â ± 11 vs. 58 â ± 8 î 1/4 mol â · kgâ ' 1 â · minâ ' 1 -rrb- , and during a hyperglycemic clamp , a failure to suppress endogenous glucose production -lrb- 80 â ± 7 vs. â ' 7 â ± 4 î 1/4 mol â · kgâ ' 1 â · minâ ' 1 -rrb- and promote glucose incorporation into glycogen -lrb- 15 â ± 5 vs. 43 â ± 3 î 1/4 mol/g liver -rrb- .
nn||film-5/NN||background-1/NN	amod||film-5/NN||fentanyl-2/JJ	amod||film-5/NN||buccal-3/JJ	amod||film-5/NN||soluble-4/JJ	nsubjpass||developed-11/VBN||film-5/NN	appos||film-5/NN||fbsf-7/NN	aux||developed-11/VBN||has-9/VBZ	auxpass||developed-11/VBN||been-10/VBN	root||ROOT-0/null||developed-11/VBN	det||treatment-14/NN||a-13/DT	prep_as||developed-11/VBN||treatment-14/NN	nn||pain-17/NN||breakthrough-16/NN	prep_of||treatment-14/NN||pain-17/NN	amod||patients-20/NNS||opioid-tolerant-19/JJ	prep_in||pain-17/NN||patients-20/NNS	prep_with||developed-11/VBN||cancer-22/NN	pain-17||fentanyl-2||yes||background fentanyl buccal soluble film (fbsf) has been developed as a treatment of breakthrough pain in opioid-tolerant patients with cancer.
det||use-2/NN||the-1/DT	nsubj||growing-23/VBG||use-2/NN	prep_of||use-2/NN||viscosupplementation-4/NN	num||-rrb--10/NNS||i.e.-6/CD	amod||-rrb--10/NNS||intra-articular-7/JJ	nn||-rrb--10/NNS||-lrb--8/NNP	nn||-rrb--10/NNS||ia-9/NN	nsubj||hyaluronicacid-11/VBD||-rrb--10/NNS	parataxis||growing-23/VBG||hyaluronicacid-11/VBD	amod||therapy-16/NN||-lrb--12/JJ	nn||therapy-16/NN||ha-13/NN	nn||therapy-16/NN||-rrb--14/NN	nn||therapy-16/NN||drug-15/NN	dobj||hyaluronicacid-11/VBD||therapy-16/NN	aux||treat-19/VB||to-18/TO	vmod||hyaluronicacid-11/VBD||treat-19/VB	dobj||treat-19/VB||oa-20/NN	aux||growing-23/VBG||is-22/VBZ	root||ROOT-0/null||growing-23/VBG	advmod||growing-23/VBG||worldwide-24/RB	amod||results-29/NNS||important-28/JJ	prep_due_to||growing-23/VBG||results-29/NNS	vmod||results-29/NNS||obtained-30/VBN	amod||trials-34/NNS||several-32/JJ	amod||trials-34/NNS||clinical-33/JJ	prep_from||obtained-30/VBN||trials-34/NNS	nsubj||reported-37/VBD||trials-34/NNS	rcmod||trials-34/NNS||reported-37/VBD	amod||improvements-40/NNS||ia-38/JJ	amod||improvements-40/NNS||ha-related-39/JJ	dobj||reported-37/VBD||improvements-40/NNS	amod||activity-43/NN||functional-42/JJ	prep_in||reported-37/VBD||activity-43/NN	nn||management-46/NN||pain-45/NN	prep_in||reported-37/VBD||management-46/NN	conj_and||activity-43/NN||management-46/NN	pain-45||hyaluronicacid-11||yes||the use of viscosupplementation , i.e. intra-articular -lrb- ia -rrb- hyaluronicacid -lrb- ha -rrb- drug therapy , to treat oa , is growing worldwide , due to important results obtained from several clinical trials , which reported ia ha-related improvements in functional activity and pain management .
amod||surveys-2/NNS||epidemiological-1/JJ	nsubj||demonstrated-7/VBN||surveys-2/NNS	nn||experiments-5/NNS||laboratory-4/NN	conj_and||surveys-2/NNS||experiments-5/NNS	nsubj||demonstrated-7/VBN||experiments-5/NNS	aux||demonstrated-7/VBN||have-6/VBP	root||ROOT-0/null||demonstrated-7/VBN	mark||-lrb--21/VBZ||that-8/IN	det||virulence-12/NN||the-9/DT	advmod||acquired-11/VBN||newly-10/RB	amod||virulence-12/NN||acquired-11/VBN	nsubj||-lrb--21/VBZ||virulence-12/NN	amod||viruses-15/NNS||several-14/JJ	prep_of||virulence-12/NN||viruses-15/NNS	vmod||viruses-15/NNS||belonging-16/VBG	det||dicistroviridae-20/NN||the-18/DT	nn||dicistroviridae-20/NN||family-19/NN	prep_to||belonging-16/VBG||dicistroviridae-20/NN	ccomp||demonstrated-7/VBN||-lrb--21/VBZ	amod||virus-29/NN||acute-22/JJ	nn||virus-29/NN||bee-23/NN	nn||virus-29/NN||paralysis-24/NN	nn||virus-29/NN||virus-25/NN	dep||virus-29/NN||kashmir-27/NN	nn||virus-29/NN||bee-28/NN	dobj||-lrb--21/VBZ||virus-29/NN	amod||-rrb--35/NNS||israeli-31/JJ	amod||-rrb--35/NNS||acute-32/JJ	nn||-rrb--35/NNS||paralysis-33/NN	nn||-rrb--35/NNS||virus-34/NN	dobj||-lrb--21/VBZ||-rrb--35/NNS	conj_and||virus-29/NN||-rrb--35/NNS	prep_in||virus-29/NN||europe-37/NN	det||usa-40/NN||the-39/DT	nsubjpass||observed-43/VBN||usa-40/NN	nsubjpass||observed-43/VBN||usa-40/NN	aux||observed-43/VBN||had-41/VBD	auxpass||observed-43/VBN||been-42/VBN	conj_and||demonstrated-7/VBN||observed-43/VBN	conj_and||demonstrated-7/VBN||observed-43/VBN	conj_and||observed-43/VBN||observed-43/VBN	prep_in||observed-43/VBN||relation-45/NN	conj_and||demonstrated-7/VBN||destructor-48/NN	conj_v.||observed-43/VBN||destructor-48/NN	prep_with||observed-43/VBN||destructor-48/NN	vmod||destructor-48/NN||acting-49/VBG	vmod||destructor-48/NN||acting-49/VBG	conj_and||acting-49/VBG||acting-49/VBG	det||disseminator-52/NN||a-51/DT	prep_as||acting-49/VBG||disseminator-52/NN	det||viruses-55/NNS||these-54/DT	prep_of||disseminator-52/NN||viruses-55/NNS	nn||colonies-60/NNS||bee-59/NN	prep_between||acting-49/VBG||colonies-60/NNS	prep_within||acting-49/VBG||colonies-60/NNS	det||activator-64/NN||an-63/DT	prep_as||observed-43/VBN||activator-64/NN	prep_of||activator-64/NN||virus-66/NN	vmod||virus-66/NN||multiplication-67/VBN	det||larvae-73/NN||the-69/DT	amod||larvae-73/NN||infected-70/JJ	nn||larvae-73/NN||individuals-71/NNS	nn||larvae-73/NN||bee-72/NN	prep_in||multiplication-67/VBN||larvae-73/NN	prep_in||multiplication-67/VBN||adults-75/NNS	conj_and||larvae-73/NN||adults-75/NNS	virus-66||viruses-55||no||epidemiological surveys and laboratory experiments have demonstrated that the newly acquired virulence of several viruses belonging to the family dicistroviridae -lrb- acute bee paralysis virus , kashmir bee virus and israeli acute paralysis virus -rrb- in europe and the usa had been observed in relation with v. destructor acting as a disseminator of these viruses between and within bee colonies and as an activator of virus multiplication in the infected individuals bee larvae and adults .
poss||role-5/NN||its-3/PRP$	amod||role-5/NN||principal-4/JJ	prep_apart_from||attributed-16/VBN||role-5/NN	nn||metabolism-8/NN||bone-7/NN	prep_in||role-5/NN||metabolism-8/NN	nn||homeostasis-11/NNS||calcium-10/NN	prep_in||role-5/NN||homeostasis-11/NNS	conj_and||metabolism-8/NN||homeostasis-11/NNS	nsubjpass||attributed-16/VBN||vitamind-13/NN	aux||attributed-16/VBN||has-14/VBZ	auxpass||attributed-16/VBN||been-15/VBN	root||ROOT-0/null||attributed-16/VBN	amod||effects-18/NNS||additional-17/JJ	dobj||attributed-16/VBN||effects-18/NNS	det||capacity-29/NN||an-20/DT	amod||capacity-29/NN||immunomodulatory-21/JJ	amod||capacity-29/NN||anti-inflammatory-23/JJ	advmod||neuroprotective-28/JJ||possibly-26/RB	advmod||neuroprotective-28/JJ||even-27/RB	conj_and||anti-inflammatory-23/JJ||neuroprotective-28/JJ	amod||capacity-29/NN||neuroprotective-28/JJ	prep_including||effects-18/NNS||capacity-29/NN	nsubj||implicates-31/VBZ||which-30/WDT	ccomp||capacity-29/NN||implicates-31/VBZ	det||role-34/NN||a-32/DT	amod||role-34/NN||possible-33/JJ	dobj||implicates-31/VBZ||role-34/NN	prep_of||role-34/NN||vitamind-36/NN	prep_in||implicates-31/VBZ||autoimmunediseases-38/NNS	prep_like||autoimmunediseases-38/NNS||multiplesclerosis-40/NNS	appos||multiplesclerosis-40/NNS||ms-42/NN	autoimmunediseases-38||anti-inflammatory-23||no_rel||apart from its principal role in bone metabolism and calcium homeostasis, vitamind has been attributed additional effects including an immunomodulatory, anti-inflammatory, and possibly even neuroprotective capacity which implicates a possible role of vitamind in autoimmunediseases like multiplesclerosis (ms).
nsubj||weigh-6/VB||physicians-1/NNS	vmod||physicians-1/NNS||treating-2/VBG	nn||arthritis-4/NN||childhood-3/NN	dobj||treating-2/VBG||arthritis-4/NN	aux||weigh-6/VB||should-5/MD	root||ROOT-0/null||weigh-6/VB	det||risks-9/NNS||these-7/DT	amod||risks-9/NNS||potential-8/JJ	dobj||weigh-6/VB||risks-9/NNS	dobj||weigh-6/VB||benefits-11/NNS	conj_and||risks-9/NNS||benefits-11/NNS	nsubj||discussing-17/VBG||patients-13/NNS	poss||families-16/NNS||their-15/PRP$	conj_and||patients-13/NNS||families-16/NNS	nsubj||discussing-17/VBG||families-16/NNS	prepc_with||weigh-6/VB||discussing-17/VBG	det||limitations-20/NNS||the-18/DT	amod||limitations-20/NNS||current-19/JJ	dobj||discussing-17/VBG||limitations-20/NNS	amod||data-23/NNS||available-22/JJ	prep_in||limitations-20/NNS||data-23/NNS	det||risk-26/NN||the-25/DT	prep_regarding||data-23/NNS||risk-26/NN	prep_of||risk-26/NN||cancer-28/NN	prep_in||cancer-28/NN||children-30/NNS	vmod||children-30/NNS||treated-31/VBN	prep_with||treated-31/VBN||etanercept-33/NN	prep_for||etanercept-33/NN||juvenileidiopathicarthritis-35/NNS	juvenileidiopathicarthritis-35||etanercept-33||yes||physicians treating childhood arthritis should weigh these potential risks and benefits with patients and their families discussing the current limitations in available data regarding the risk of cancer in children treated with etanercept for juvenileidiopathicarthritis.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||effects-4/NNS||the-3/DT	dobj||evaluated-2/VBN||effects-4/NNS	prep_of||effects-4/NNS||bosentan-6/NN	det||antagonist-12/NN||a-8/DT	amod||antagonist-12/NN||dual-9/JJ	nn||antagonist-12/NN||endothelin-10/NN	nn||antagonist-12/NN||receptor-11/NN	dep||effects-4/NNS||antagonist-12/NN	prep_in||effects-4/NNS||patients-15/NNS	vmod||effects-4/NNS||receiving-16/VBG	amod||therapy-19/NN||first-line-17/JJ	nn||therapy-19/NN||dacarbazine-18/NN	dobj||receiving-16/VBG||therapy-19/NN	nn||cutaneousmelanoma-24/NN||stage-21/NN	nn||cutaneousmelanoma-24/NN||iv-22/NN	amod||cutaneousmelanoma-24/NN||metastatic-23/JJ	prep_for||therapy-19/NN||cutaneousmelanoma-24/NN	det||phase-27/NN||a-26/DT	prep_in||evaluated-2/VBN||phase-27/NN	num||phase-27/NN||2-28/CD	amod||study-31/NN||proof-of-concept-30/JJ	dobj||evaluated-2/VBN||study-31/NN	cutaneousmelanoma-24||dacarbazine-18||yes||we evaluated the effects of bosentan - a dual endothelin receptor antagonist - in patients receiving first-line dacarbazine therapy for stage iv metastatic cutaneousmelanoma in a phase 2, proof-of-concept study.
neg||differences-4/NNS||no-1/DT	amod||differences-4/NNS||significant-2/JJ	amod||differences-4/NNS||ethnic-3/JJ	nsubjpass||detected-6/VBN||differences-4/NNS	auxpass||detected-6/VBN||were-5/VBD	root||ROOT-0/null||detected-6/VBN	amod||status-9/NN||node-8/JJ	prep_for||detected-6/VBN||status-9/NN	nn||type-12/NN||tumour-11/NN	prep_for||detected-6/VBN||type-12/NN	conj_or||status-9/NN||type-12/NN	nn||size-15/NN||tumour-14/NN	prep_for||detected-6/VBN||size-15/NN	conj_or||status-9/NN||size-15/NN	amod||receptor-21/NN||human-17/JJ	nn||receptor-21/NN||epidermal-18/NN	nn||receptor-21/NN||growth-19/NN	nn||receptor-21/NN||factor-20/NN	prep_for||detected-6/VBN||receptor-21/NN	conj_or||status-9/NN||receptor-21/NN	nn||receptor-26/NN||oestrogen-23/NN	conj_and||oestrogen-23/NN||progesterone-25/NN	nn||receptor-26/NN||progesterone-25/NN	prep_for||detected-6/VBN||receptor-26/NN	conj_or||status-9/NN||receptor-26/NN	appos||receptor-26/NN||er/pr-28/NN	dep||receptor-26/NN||status-30/NN	prep_for||detected-6/VBN||survival-33/NN	conj_or||status-9/NN||survival-33/NN	progesterone-25||tumour-14||no_rel||no significant ethnic differences were detected for node status, tumour type, tumour size, human epidermal growth factor receptor, oestrogen and progesterone receptor (er/pr) status, or survival.
det||china-2/NN||each-1/DT	nsubj||cares-3/VBZ||china-2/NN	root||ROOT-0/null||cares-3/VBZ	nsubjpass||required-6/VBN||site-4/NN	nsubj||carry-8/VB||site-4/NN	auxpass||required-6/VBN||was-5/VBD	ccomp||cares-3/VBZ||required-6/VBN	aux||carry-8/VB||to-7/TO	xcomp||required-6/VBN||carry-8/VB	prt||carry-8/VB||out-9/RP	dobj||carry-8/VB||surveillance-10/NN	dobj||carry-8/VB||surveys-12/NNS	conj_and||surveillance-10/NN||surveys-12/NNS	aux||understand-14/VB||to-13/TO	vmod||carry-8/VB||understand-14/VB	det||epidemic-18/NN||the-15/DT	amod||epidemic-18/NN||local-16/JJ	nn||epidemic-18/NN||hiv/aids-17/NN	dobj||understand-14/VB||epidemic-18/NN	aux||deliver-21/VB||to-20/TO	vmod||carry-8/VB||deliver-21/VB	amod||interventions-23/NNS||primary-22/JJ	dobj||deliver-21/VB||interventions-23/NNS	aux||reduce-25/VB||to-24/TO	vmod||deliver-21/VB||reduce-25/VB	vmod||deliver-21/VB||reduce-25/VB	conj_and||reduce-25/VB||reduce-25/VB	amod||hivinfections-27/NNS||new-26/JJ	dobj||reduce-25/VB||hivinfections-27/NNS	amod||groups-32/NNS||high-risk-31/JJ	prep_among||reduce-25/VB||groups-32/NNS	prep_from||reduce-25/VB||groups-32/NNS	aux||prevent-35/VB||to-34/TO	dep||reduce-25/VB||prevent-35/VB	amod||transmission-37/NN||mother-to-child-36/JJ	dobj||prevent-35/VB||transmission-37/NN	aux||treat-40/VB||to-39/TO	dep||reduce-25/VB||treat-40/VB	conj_and||prevent-35/VB||treat-40/VB	nn||patients-42/NNS||aids-41/NNS	dobj||treat-40/VB||patients-42/NNS	amod||medicines-45/NNS||antiretroviral-44/JJ	prep_with||treat-40/VB||medicines-45/NNS	aux||provide-48/VB||to-47/TO	dep||reduce-25/VB||provide-48/VB	conj_and||prevent-35/VB||provide-48/VB	nn||services-50/NNS||support-49/NN	dobj||provide-48/VB||services-50/NNS	prep_to||provide-48/VB||families-52/NNS	vmod||families-52/NNS||affected-53/VBN	agent||affected-53/VBN||hiv/aids-55/NNS	hivinfections-27||hiv--1||no||each china cares site was required to carry out surveillance and surveys to understand the local hiv/aids epidemic, to deliver primary interventions to reduce new hivinfections among and from high-risk groups, to prevent mother-to-child transmission, to treat aids patients with antiretroviral medicines and to provide support services to families affected by hiv/aids.
vmod||detected-28/VBN||using-1/VBG	amod||chromatography-3/JJ||liquid-2/JJ	amod||techniques-7/NNS||chromatography-3/JJ	amod||techniques-7/NNS||mass-4/JJ	advmod||lipidomics-6/JJ||spectrometry-5/RB	amod||techniques-7/NNS||lipidomics-6/JJ	dobj||using-1/VBG||techniques-7/NNS	det||screen-11/NN||an-9/DT	amod||screen-11/NN||initial-10/JJ	prep_for||using-1/VBG||screen-11/NN	num||species-15/NNS||200-13/CD	nn||species-15/NNS||lipid-14/NN	prep_of||screen-11/NN||species-15/NNS	amod||changes-18/NNS||significant-17/JJ	nsubjpass||detected-28/VBN||changes-18/NNS	num||species-26/NNS||79-20/CD	amod||species-26/NNS||sphingolipid-21/JJ	conj_and||sphingolipid-21/JJ||glycerophospholipid-23/JJ	amod||species-26/NNS||glycerophospholipid-23/JJ	conj_and||sphingolipid-21/JJ||cholesterol-25/NN	amod||species-26/NNS||cholesterol-25/NN	prep_in||changes-18/NNS||species-26/NNS	auxpass||detected-28/VBN||were-27/VBD	root||ROOT-0/null||detected-28/VBN	det||cortex-32/NN||the-30/DT	amod||cortex-32/NN||visual-31/JJ	prep_in||detected-28/VBN||cortex-32/NN	amod||patients-37/NNS||parkinson-34/JJ	nn||patients-37/NNS||sdisease-36/NN	prep_of||cortex-32/NN||patients-37/NNS	parataxis||detected-28/VBN||nâ-39/VB	num||â-43/NN||$-40/$	number||=-42/CD||-41/CD	num||$-40/$||=-42/CD	dobj||nâ-39/VB||â-43/NN	amod||â-43/NN||$-44/$	dep||$-44/$||10-45/JJ	prepc_compared_to||detected-28/VBN||to-48/TO	pobj||detected-28/VBN||controls-49/NNS	dep||controls-49/NNS||nâ-51/NN	num||â-55/NN||$-52/$	number||=-54/CD||-53/CD	num||$-52/$||=-54/CD	dep||nâ-51/NN||â-55/NN	dep||â-55/NN||$-56/$	num||$-56/$||10-57/CD	dep||test-66/NN||assessed-60/NNP	amod||t-64/NN||two-sided-62/JJ	amod||t-64/NN||unpaired-63/JJ	prep_by||assessed-60/NNP||t-64/NN	prep_as||controls-49/NNS||test-66/NN	dep||test-66/NN||p-68/NN	nn||0.05-72/NNP||value-70/NN	nn||0.05-72/NNP||<-71/NNP	dep||p-68/NN||0.05-72/NNP	cholesterol-25||parkinson'sdisease--1||no_rel||using liquid chromatography mass spectrometry lipidomics techniques for an initial screen of 200 lipid species, significant changes in 79 sphingolipid, glycerophospholipid and cholesterol species were detected in the visual cortex of parkinson'sdisease patients (nâ=â10) compared to controls (nâ=â10) as assessed by two-sided unpaired t -test ( p- value <0.05).
nn||toxin-2/NN||cholera-1/NN	nsubj||factors-16/NNS||toxin-2/NN	appos||toxin-2/NN||ct-4/NN	amod||pili-8/NNS||toxin-co-regulated-7/JJ	conj_and||toxin-2/NN||pili-8/NNS	nsubj||factors-16/NNS||pili-8/NNS	appos||pili-8/NNS||tcp-10/NN	cop||factors-16/NNS||are-12/VBP	det||factors-16/NNS||the-13/DT	amod||factors-16/NNS||major-14/JJ	nn||factors-16/NNS||virulence-15/NN	root||ROOT-0/null||factors-16/NNS	nsubj||contribute-23/VBP||factors-16/NNS	amod||strains-21/NNS||vibriocholeraeo1-18/JJ	conj_and||vibriocholeraeo1-18/JJ||o139-20/JJ	amod||strains-21/NNS||o139-20/JJ	prep_of||factors-16/NNS||strains-21/NNS	rcmod||factors-16/NNS||contribute-23/VBP	det||pathogenesis-26/NNS||the-25/DT	prep_to||contribute-23/VBP||pathogenesis-26/NNS	prep_of||pathogenesis-26/NNS||disease-28/NN	amod||pandemics-32/NNS||devastating-30/JJ	nn||pandemics-32/NNS||cholera-31/NN	prep_during||contribute-23/VBP||pandemics-32/NNS	cholera-31||vibriocholeraeo1-18||no||cholera toxin (ct) and toxin-co-regulated pili (tcp) are the major virulence factors of vibriocholeraeo1 and o139 strains that contribute to the pathogenesis of disease during devastating cholera pandemics.
nn||predictors-2/NNS||baseline-1/NN	nsubjpass||identified-56/VBN||predictors-2/NNS	prep_of||predictors-2/NNS||level-4/NN	amod||acuity-7/NN||visual-6/JJ	prep_of||level-4/NN||acuity-7/NN	dep||acuity-7/NN||age-9/NN	amod||amd-13/NN||age-relatedmaculardegeneration-11/JJ	dep||acuity-7/NN||amd-13/NN	conj_and||age-9/NN||amd-13/NN	dep||acuity-7/NN||cataract-16/NN	conj_and||age-9/NN||cataract-16/NN	dep||acuity-7/NN||living-18/NN	conj_and||age-9/NN||living-18/NN	advmod||living-18/NN||alone-19/RB	amod||health-23/NN||low-21/JJ	amod||health-23/NN||self-rated-22/JJ	dep||acuity-7/NN||health-23/NN	conj_and||age-9/NN||health-23/NN	amod||life-style-27/NN||sedentary-26/JJ	dep||acuity-7/NN||life-style-27/NN	conj_and||age-9/NN||life-style-27/NN	prep_of||predictors-2/NNS||speed-30/NN	conj_and||level-4/NN||speed-30/NN	amod||loss-34/NN||continued-32/VBN	amod||loss-34/NN||visual-33/JJ	prep_of||speed-30/NN||loss-34/NN	nn||dr-42/NN||age-36/NN	dep||dr-42/NN||amd-38/NN	dep||dr-42/NN||diabeticretinopathy-40/NN	dep||loss-34/NN||dr-42/NN	appos||dr-42/NN||cataract-45/NN	appos||dr-42/NN||living-47/NN	conj_and||cataract-45/NN||living-47/NN	advmod||living-47/NN||alone-48/RB	amod||triglycerides-53/NNPS||high-51/JJ	amod||triglycerides-53/NNPS||fasting-52/VBG	appos||dr-42/NN||triglycerides-53/NNPS	conj_and||cataract-45/NN||triglycerides-53/NNPS	auxpass||identified-56/VBN||were-55/VBD	root||ROOT-0/null||identified-56/VBN	dr-42||triglycerides-53||no_rel||baseline predictors of level of visual acuity (age, age-relatedmaculardegeneration (amd), cataract, living alone, low self-rated health, and sedentary life-style) and speed of continued visual loss (age, amd, diabeticretinopathy (dr), cataract, living alone, and high fasting triglycerides) were identified.
preconj||insufficiency-3/NN||both-1/DT	nn||insufficiency-3/NN||food-2/NN	nsubj||problems-10/NNS||insufficiency-3/NN	conj_and||insufficiency-3/NN||hivinfection-5/NN	nsubj||problems-10/NNS||hivinfection-5/NN	cop||problems-10/NNS||are-6/VBP	amod||problems-10/NNS||major-7/JJ	amod||problems-10/NNS||public-8/JJ	nn||problems-10/NNS||health-9/NN	root||ROOT-0/null||problems-10/NNS	amod||africa-13/NN||sub-saharan-12/JJ	prep_in||problems-10/NNS||africa-13/NN	det||impact-17/NN||the-16/DT	nsubjpass||investigated-29/VBN||impact-17/NN	nn||insufficiency-20/NN||food-19/NN	prep_of||impact-17/NN||insufficiency-20/NN	nn||behavior-24/NN||hiv-22/NN	nn||behavior-24/NN||risk-23/NN	prep_on||insufficiency-20/NN||behavior-24/NN	aux||investigated-29/VBN||has-25/VBZ	neg||investigated-29/VBN||not-26/RB	auxpass||investigated-29/VBN||been-27/VBN	advmod||investigated-29/VBN||systematically-28/RB	conj_yet||problems-10/NNS||investigated-29/VBN	hivinfection-5||hiv-22||no||both food insufficiency and hivinfection are major public health problems in sub-saharan africa, yet the impact of food insufficiency on hiv risk behavior has not been systematically investigated.
advmod||report-15/VBP||here-1/RB	det||coexistence-6/NN||a-4/DT	amod||coexistence-6/NN||unique-5/JJ	prep_as||report-15/VBP||coexistence-6/NN	det||entities-12/NNS||these-8/DT	num||entities-12/NNS||two-9/CD	amod||entities-12/NNS||seperated-10/JJ	amod||entities-12/NNS||clinical-11/JJ	prep_of||coexistence-6/NN||entities-12/NNS	nsubj||report-15/VBP||we-14/PRP	root||ROOT-0/null||report-15/VBP	det||woman-18/NN||a-16/DT	amod||woman-18/NN||30-yr-old-17/JJ	dobj||report-15/VBP||woman-18/NN	vmod||woman-18/NN||presenting-19/VBG	amod||spasm-22/NN||carpal-21/JJ	prep_with||presenting-19/VBG||spasm-22/NN	vmod||spasm-22/NN||related-23/VBN	amod||preparation-42/NN||hypocalcemia-25/JJ	amod||calcium-28/NN||ionized-27/JJ	dep||preparation-42/NN||calcium-28/NN	num||mm/l-31/NN||1.90-30/CD	prep_of||calcium-28/NN||mm/l-31/NN	amod||preparation-42/NN||due-33/JJ	aux||acute-35/VB||to-34/TO	xcomp||due-33/JJ||acute-35/VB	amod||poisoning-37/NN||phosphate-36/JJ	dobj||acute-35/VB||poisoning-37/NN	amod||bowel-41/NN||oral-39/JJ	nn||bowel-41/NN||sodiumphosphate-40/NN	prep_after||acute-35/VB||bowel-41/NN	prep_to||related-23/VBN||preparation-42/NN	nsubj||resolved-45/VBN||preparation-42/NN	rcmod||preparation-42/NN||resolved-45/VBN	advmod||resolved-45/VBN||rapidly-46/RB	nn||gluconate-49/NN||calcium-48/NN	prep_after||resolved-45/VBN||gluconate-49/NN	advmod||resolved-45/VBN||intravenously-50/RB	sodiumphosphate-40||spasm-22||no_rel||here, as a unique coexistence of these two seperated clinical entities, we report a 30-yr-old woman presenting with carpal spasm related to hypocalcemia (ionized calcium of 1.90 mm/l) due to acute phosphate poisoning after oral sodiumphosphate bowel preparation, which resolved rapidly after calcium gluconate intravenously.
poss||properties-6/NNS||its-3/PRP$	amod||properties-6/NNS||unique-4/JJ	amod||properties-6/NNS||pharmacodynamic-5/JJ	prep_due_to||aripiprazole-23/NN||properties-6/NNS	amod||activity-11/NN||dopamine-8/JJ	amod||activity-11/NN||partial-9/JJ	nn||activity-11/NN||agonist-10/NN	prep_of||properties-6/NNS||activity-11/NN	poss||association-15/NN||its-14/PRP$	prep_of||properties-6/NNS||association-15/NN	conj_and||activity-11/NN||association-15/NN	amod||effects-21/NNS||few-17/JJ	conj_and||few-17/JJ||mild-19/JJ	amod||effects-21/NNS||mild-19/JJ	nn||effects-21/NNS||side-20/NN	prep_with||association-15/NN||effects-21/NNS	nsubj||antipsychotic-28/NN||aripiprazole-23/NN	cop||antipsychotic-28/NN||is-24/VBZ	det||antipsychotic-28/NN||a-25/DT	nn||antipsychotic-28/NN||candidate-26/NN	nn||antipsychotic-28/NN||atypical-27/NN	root||ROOT-0/null||antipsychotic-28/NN	prep_for||antipsychotic-28/NN||patients-30/NNS	prep_with||patients-30/NNS||ticdisorders-32/NNS	ticdisorders-32||antipsychotic-28||no_rel||due to its unique pharmacodynamic properties of dopamine partial agonist activity, and its association with few and mild side effects, aripiprazole is a candidate atypical antipsychotic for patients with ticdisorders.
det||study-4/NN||a-1/DT	amod||study-4/NN||prospective-2/JJ	amod||study-4/NN||comparative-3/JJ	nsubjpass||undertaken-6/VBN||study-4/NN	nsubj||compare-8/VB||study-4/NN	nsubj||surgeonâ-19/VB||study-4/NN	auxpass||undertaken-6/VBN||was-5/VBD	root||ROOT-0/null||undertaken-6/VBN	aux||compare-8/VB||to-7/TO	xcomp||undertaken-6/VBN||compare-8/VB	det||outcome-17/NN||the-9/DT	amod||outcome-17/NN||patientsâ-10/JJ	amod||outcome-17/NN||$-11/$	number||pain-13/CD||-12/CD	num||$-11/$||pain-13/CD	nn||outcome-17/NN||experience-14/NN	amod||outcome-17/NN||surgical-16/JJ	dobj||compare-8/VB||outcome-17/NN	xcomp||undertaken-6/VBN||surgeonâ-19/VB	conj_and||compare-8/VB||surgeonâ-19/VB	num||experience-23/NN||$-20/$	number||s-22/CD||-21/CD	num||$-20/$||s-22/CD	dobj||surgeonâ-19/VB||experience-23/NN	prep_in||experience-23/NN||phacoemulsification-25/NN	conj_and||compare-8/VB||manual-27/VB	conj_and||surgeonâ-19/VB||manual-27/VB	amod||surgery-31/NN||small-28/JJ	nn||surgery-31/NN||incision-29/NN	nn||surgery-31/NN||cataract-30/NN	dobj||manual-27/VB||surgery-31/NN	appos||surgery-31/NN||msics-33/NNS	amod||anesthesia-37/NN||topical-36/JJ	prep_under||manual-27/VB||anesthesia-37/NN	vmod||anesthesia-37/NN||supplemented-38/VBN	amod||lignocaine-41/NN||intracameral-40/JJ	prep_with||supplemented-38/VBN||lignocaine-41/NN	dep||lignocaine-41/NN||tasil-43/JJ	pain-13||lignocaine-41||yes||a prospective comparative study was undertaken to compare the patientsâ pain experience, surgical outcome and surgeonâs experience in phacoemulsification and manual small incision cataract surgery (msics) under topical anesthesia supplemented with intracameral lignocaine (tasil).
mark||involve-13/VBP||although-1/IN	det||manifestations-6/NNS||the-2/DT	advmod||frequent-4/JJ||most-3/RBS	amod||manifestations-6/NNS||frequent-4/JJ	amod||manifestations-6/NNS||extra-pulmonary-5/JJ	nsubj||involve-13/VBP||manifestations-6/NNS	nn||infection-12/NN||respiratorysyncytialvirus-8/NNP	appos||infection-12/NN||rsv-10/NN	prep_of||manifestations-6/NNS||infection-12/NN	advcl||collected-34/VBN||involve-13/VBP	det||system-16/NN||the-14/DT	amod||system-16/NN||cardiovascular-15/JJ	dobj||involve-13/VBP||system-16/NN	neg||data-19/NNS||no-18/DT	nsubjpass||collected-34/VBN||data-19/NNS	nn||function-22/NN||heart-21/NN	prep_regarding||data-19/NNS||function-22/NN	prep_in||function-22/NN||infants-24/NNS	prep_with||infants-24/NNS||bronchiolitis-26/NNS	vmod||bronchiolitis-26/NNS||associated-27/VBN	prep_with||associated-27/VBN||rsvinfection-29/NN	aux||collected-34/VBN||have-30/VBP	advmod||collected-34/VBN||yet-31/RB	auxpass||collected-34/VBN||been-32/VBN	advmod||collected-34/VBN||systematically-33/RB	root||ROOT-0/null||collected-34/VBN	rsvinfection-29||rsv-10||no||although the most frequent extra-pulmonary manifestations of respiratorysyncytialvirus (rsv) infection involve the cardiovascular system, no data regarding heart function in infants with bronchiolitis associated with rsvinfection have yet been systematically collected.
nsubj||suggested-2/VBD||this-1/DT	root||ROOT-0/null||suggested-2/VBD	mark||activates-11/VBZ||that-3/IN	amod||therapy-7/NN||current-4/JJ	nn||therapy-7/NN||androgen-5/NN	nn||therapy-7/NN||ablation-6/NN	nsubj||activates-11/VBZ||therapy-7/NN	nsubj||contribute-16/VB||therapy-7/NN	nn||cancer-10/NN||prostate-9/NN	prep_for||therapy-7/NN||cancer-10/NN	ccomp||suggested-2/VBD||activates-11/VBZ	amod||expression-13/NN||c-met-12/JJ	dobj||activates-11/VBZ||expression-13/NN	aux||contribute-16/VB||may-15/MD	ccomp||suggested-2/VBD||contribute-16/VB	conj_and||activates-11/VBZ||contribute-16/VB	prep_to||contribute-16/VB||development-18/NN	advmod||aggressive-21/JJ||more-20/RBR	amod||cancer-26/NN||aggressive-21/JJ	amod||resistant-24/JJ||castration-23/JJ	amod||cancer-26/NN||resistant-24/JJ	nn||cancer-26/NN||prostate-25/NN	prep_of||development-18/NN||cancer-26/NN	dep||development-18/NN||crpc-28/JJ	androgen-5||cancer-26||no_rel||this suggested that current androgen ablation therapy for prostate cancer activates c-met expression and may contribute to development of more aggressive, castration resistant prostate cancer (crpc).
amod||patients-3/NNS||eligible-1/JJ	nn||patients-3/NNS||adult-2/NN	nsubjpass||controlled-11/VBN||patients-3/NNS	nsubj||latanoprost-14/VBD||patients-3/NNS	nsubj||had-28/VBD||patients-3/NNS	prep_with||patients-3/NNS||ocularhypertension-5/NN	prep_with||patients-3/NNS||open-angleglaucoma-7/NN	conj_or||ocularhypertension-5/NN||open-angleglaucoma-7/NN	aux||controlled-11/VBN||had-9/VBD	auxpass||controlled-11/VBN||been-10/VBN	rcmod||patients-3/NNS||controlled-11/VBN	prep_with||controlled-11/VBN||bak-preserved-13/JJ	root||ROOT-0/null||latanoprost-14/VBD	num||%-16/NN||0.005-15/CD	dobj||latanoprost-14/VBD||%-16/NN	advmod||latanoprost-14/VBD||monotherapy-17/RB	number||®-20/CD||xalatanâ-19/CD	dep||latanoprost-14/VBD||®-20/CD	quantmod||one-25/CD||at-23/IN	mwe||at-23/IN||least-24/JJS	pobj||at-23/IN||least-24/JJS	prep_for||latanoprost-14/VBD||one-25/CD	tmod||latanoprost-14/VBD||month-26/NN	conj_and||latanoprost-14/VBD||had-28/VBD	det||score-30/NN||a-29/DT	dobj||had-28/VBD||score-30/NN	nn||-33/NNS||â-32/NN	prep_of||score-30/NN||-33/NNS	number||13-35/CD||¥-34/CD	dobj||latanoprost-14/VBD||13-35/CD	num||none-39/NN||0-37/CD	amod||none-39/NN||=-38/JJ	dep||13-35/CD||none-39/NN	num||=-42/NNS||100-41/CD	appos||none-39/NN||=-42/NNS	advmod||severe-44/JJ||most-43/RBS	amod||=-42/NNS||severe-44/JJ	det||index-51/NN||the-47/DT	nn||index-51/NN||ocular-48/NN	nn||index-51/NN||surface-49/NN	nn||index-51/NN||disease-50/NN	prep_on||latanoprost-14/VBD||index-51/NN	appos||index-51/NN||osdi-53/NNP	nsubjpass||entered-57/VBN||questionnaire-55/NN	auxpass||entered-57/VBN||were-56/VBD	rcmod||index-51/NN||entered-57/VBN	det||trial-69/NN||this-59/DT	amod||trial-69/NN||prospective-60/JJ	amod||trial-69/NN||double-masked-62/JJ	amod||trial-69/NN||randomized-64/JJ	amod||trial-69/NN||active-controlled-66/JJ	amod||trial-69/NN||multicenter-68/JJ	prep_into||entered-57/VBN||trial-69/NN	open-angleglaucoma-7||latanoprost-14||yes||eligible adult patients with ocularhypertension or open-angleglaucoma that had been controlled with bak-preserved latanoprost 0.005% monotherapy (xalatanâ®) for at least one month and had a score of â¥ 13 (0 = none, 100 = most severe) on the ocular surface disease index (osdi) questionnaire were entered into this prospective, double-masked, randomized, active-controlled, multicenter trial.
nsubj||induced-6/VBN||statusepilepticus-1/NNS	appos||statusepilepticus-1/NNS||se-3/NNP	aux||induced-6/VBN||was-5/VBD	root||ROOT-0/null||induced-6/VBN	amod||adenosine5-38/NNS||pilocarpine-8/JJ	prep_in||pilocarpine-8/JJ||rats-10/NNS	nsubjpass||infused-14/VBN||rats-10/NNS	auxpass||infused-14/VBN||were-12/VBD	advmod||infused-14/VBN||intracerebroventricularly-13/RB	rcmod||rats-10/NNS||infused-14/VBN	det||saline-17/NN||either-16/DT	prep_with||infused-14/VBN||saline-17/NN	appos||saline-17/NN||2-19/CD	poss||adenosine5-30/NN||,3-21/CD	dep||adenosine5-30/NN||o-24/NN	appos||o-24/NN||4-benzoylbenzoyl-27/NN	dep||2-19/CD||adenosine5-30/NN	dep||adenosine5-30/NN||triphosphate-33/NN	appos||triphosphate-33/NN||bzatp-35/NN	prep_by||induced-6/VBN||adenosine5-38/NNS	dep||induced-6/VBN||triphosphate-2-41/VBN	dobj||triphosphate-2-41/VBN||,3-43/CD	dep||induced-6/VBN||dialdehyde-46/JJ	dep||dialdehyde-46/JJ||oxatp-48/VB	dep||induced-6/VBN||il-1ra-52/JJ	conj_or||dialdehyde-46/JJ||il-1ra-52/JJ	dep||dialdehyde-46/JJ||interleukin-54/VB	num||antagonist-57/NN||1-55/CD	nn||antagonist-57/NN||receptor-56/NN	dobj||interleukin-54/VB||antagonist-57/NN	amod||induction-62/NN||se-61/JJ	prep_prior_to||dialdehyde-46/JJ||induction-62/NN	statusepilepticus-1||adenosine5'-triphosphate--1||no_rel||statusepilepticus (se) was induced by pilocarpine in rats that were intracerebroventricularly infused with either saline, 2',3'-o-(4-benzoylbenzoyl)-adenosine5'-triphosphate (bzatp), adenosine5'-triphosphate-2',3'-dialdehyde (oxatp), or il-1ra (interleukin 1 receptor antagonist) prior to se induction.
prep_in||able-7/JJ||addition-2/NN	det||kit-5/NN||the-4/DT	nsubj||able-7/JJ||kit-5/NN	nsubj||detect-9/VB||kit-5/NN	cop||able-7/JJ||was-6/VBD	root||ROOT-0/null||able-7/JJ	aux||detect-9/VB||to-8/TO	xcomp||able-7/JJ||detect-9/VB	num||strains-11/NNS||two-10/CD	dobj||detect-9/VB||strains-11/NNS	nn||influenzaviruses-14/NNS||novel-13/NN	prep_of||strains-11/NNS||influenzaviruses-14/NNS	nn||a/california/12-17/NNS||influenza-16/NN	appos||influenzaviruses-14/NNS||a/california/12-17/NNS	pobj||of-32/IN||a/california/12-17/NNS	punct||a/h1n1-29/NNS||/-18/:	dep||a/h1n1-29/NNS||2009-19/CD	appos||2009-19/CD||h1n1-21/NNP	advmod||isolated-25/JJ||clinically-24/RB	amod||novel-27/NN||isolated-25/JJ	amod||novel-27/NN||wild-type-26/JJ	conj_and||2009-19/CD||novel-27/NN	dep||a/h1n1-29/NNS||novel-27/NN	nn||a/h1n1-29/NNS||influenza-28/NN	dep||a/california/12-17/NNS||a/h1n1-29/NNS	dep||of-32/IN||both-31/DT	nsubj||spreading-35/VBG||of-32/IN	aux||spreading-35/VBG||are-34/VBP	rcmod||a/california/12-17/NNS||spreading-35/VBG	advmod||spreading-35/VBG||epidemically-36/RB	det||world-39/NN||the-38/DT	prep_throughout||spreading-35/VBG||world-39/NN	influenza-28||influenzaviruses-14||no||in addition, the kit was able to detect two strains of novel influenzaviruses, influenza a/california/12/2009(h1n1) and clinically isolated wild-type novel influenza a/h1n1, both of which are spreading epidemically throughout the world.
prepc_based_on||used-14/VBN||on-2/IN	det||study-4/NN||this-3/DT	pobj||used-14/VBN||study-4/NN	nsubjpass||used-14/VBN||ceftriaxone-6/NN	conj_and||ceftriaxone-6/NN||cefixime-8/NN	nsubjpass||used-14/VBN||cefixime-8/NN	conj_and||ceftriaxone-6/NN||spectinomycin-11/NN	nsubjpass||used-14/VBN||spectinomycin-11/NN	aux||used-14/VBN||can-12/MD	auxpass||used-14/VBN||be-13/VB	root||ROOT-0/null||used-14/VBN	det||therapy-19/NN||an-16/DT	amod||therapy-19/NN||empirical-17/JJ	amod||therapy-19/NN||first-line-18/JJ	prep_as||used-14/VBN||therapy-19/NN	prep_for||therapy-19/NN||gonorrhoea-21/NN	nn||pakistan-25/NN||india-23/NN	prep_in||used-14/VBN||pakistan-25/NN	prep_in||used-14/VBN||bhutan-28/NN	conj_and||pakistan-25/NN||bhutan-28/NN	mark||be-43/VB||whereas-30/IN	nsubj||be-43/VB||ciprofloxacin-31/NN	appos||ciprofloxacin-31/NN||penicilling-33/NN	appos||ciprofloxacin-31/NN||tetracycline-35/NN	conj_and||penicilling-33/NN||tetracycline-35/NN	appos||ciprofloxacin-31/NN||erythromycin-37/NN	conj_and||penicilling-33/NN||erythromycin-37/NN	appos||ciprofloxacin-31/NN||azithromycin-40/NN	conj_and||penicilling-33/NN||azithromycin-40/NN	aux||be-43/VB||should-41/MD	neg||be-43/VB||not-42/RB	rcmod||pakistan-25/NN||be-43/VB	gonorrhoea-21||tetracycline-35||yes||based on this study, ceftriaxone, cefixime, and spectinomycin can be used as an empirical first-line therapy for gonorrhoea in india, pakistan, and bhutan, whereas ciprofloxacin, penicilling, tetracycline, erythromycin, and azithromycin should not be.
nn||snps-2/NNS||ifnk-1/NN	nsubjpass||associated-4/VBN||snps-2/NNS	auxpass||associated-4/VBN||were-3/VBD	root||ROOT-0/null||associated-4/VBN	amod||ifn-10/NN||increased-6/VBN	nn||ifn-10/NN||serum-7/NN	nn||ifn-10/NN||type-8/NN	nn||ifn-10/NN||i-9/NN	prep_with||associated-4/VBN||ifn-10/NN	nn||patients-16/NNS||ea-12/NN	conj_and||ea-12/NN||aa-14/NN	nn||patients-16/NNS||aa-14/NN	nn||patients-16/NNS||sle-15/NN	prep_in||ifn-10/NN||patients-16/NNS	ifn-10||sle-15||no_rel||ifnk snps were associated with increased serum type i ifn in ea and aa sle patients.
prep_in||examined-55/VBN||total-2/NN	nn||lines-5/NNS||cell-4/NN	nsubjpass||examined-55/VBN||lines-5/NNS	num||carcinomas-9/NNS||three-7/CD	nn||carcinomas-9/NNS||endometrium-8/NN	prep_from||lines-5/NNS||carcinomas-9/NNS	nn||an3-15/NNS||ishikawa-11/NN	amod||an3-15/NNS||hec-1-a-13/JJ	nsubj||ca-16/MD||an3-15/NNS	dep||carcinomas-9/NNS||ca-16/MD	num||carcinomas-21/NNS||three-19/CD	amod||carcinomas-21/NNS||cervical-20/JJ	appos||carcinomas-9/NNS||carcinomas-21/NNS	nn||siha-27/NN||hela-23/NN	dep||siha-27/NN||caski-25/NN	appos||carcinomas-21/NNS||siha-27/NN	num||chorioncarcinomas-31/NNS||three-30/CD	appos||carcinomas-9/NNS||chorioncarcinomas-31/NNS	conj_and||carcinomas-21/NNS||chorioncarcinomas-31/NNS	nn||bewo-37/NN||jeg-33/NN	dep||bewo-37/NN||jar-35/NN	appos||chorioncarcinomas-31/NNS||bewo-37/NN	num||cancers-42/NNS||two-40/CD	nn||cancers-42/NNS||ovarian-41/NN	appos||carcinomas-9/NNS||cancers-42/NNS	conj_and||carcinomas-21/NNS||cancers-42/NNS	amod||oaw-42-46/JJ||bg-1-44/JJ	dep||cancers-42/NNS||oaw-42-46/JJ	num||teratocarcinoma-50/NN||one-49/CD	appos||carcinomas-9/NNS||teratocarcinoma-50/NN	conj_and||carcinomas-21/NNS||teratocarcinoma-50/NN	dep||teratocarcinoma-50/NN||pa-1-52/JJ	auxpass||examined-55/VBN||were-54/VBD	root||ROOT-0/null||examined-55/VBN	cancers-42||ca-16||no_rel||in total, cell lines from three endometrium carcinomas (ishikawa, hec-1-a, an3 ca), three cervical carcinomas (hela, caski, siha), three chorioncarcinomas (jeg, jar, bewo), two ovarian cancers (bg-1, oaw-42) and one teratocarcinoma (pa-1) were examined.
prep_in||correlated-8/VBN||addition-2/NN	amod||concentration-5/NN||formate-4/JJ	nsubjpass||correlated-8/VBN||concentration-5/NN	nsubjpass||correlated-38/VBN||concentration-5/NN	auxpass||correlated-8/VBN||was-6/VBD	advmod||correlated-8/VBN||negatively-7/RB	root||ROOT-0/null||correlated-8/VBN	amod||pc20-11/NNS||methacholine-10/JJ	prep_with||correlated-8/VBN||pc20-11/NNS	num||0.39-21/NNS||râ-13/CD	amod||0.39-21/NNS||$-14/$	number||=-16/CD||-15/CD	num||$-14/$||=-16/CD	amod||0.39-21/NNS||â-17/JJ	amod||0.39-21/NNS||$-18/$	dep||$-18/$||â-19/JJ	nsubj||asthmatics-32/VBZ||0.39-21/NNS	nn||â-27/NN||pâ-23/NN	amod||â-27/NN||$-24/$	dep||$-24/$||-25/JJ	nn||â-27/NN||=-26/NNP	appos||0.39-21/NNS||â-27/NN	dep||â-27/NN||$-28/$	num||$-28/$||0-29/CD	num||$-28/$||.002-30/CD	dep||pc20-11/NNS||asthmatics-32/VBZ	advmod||asthmatics-32/VBZ||only-33/RB	advmod||correlated-38/VBN||positively-37/RB	conj_and||correlated-8/VBN||correlated-38/VBN	det||nitrite-43/NN||the-40/DT	amod||nitrite-43/NN||no-derived-41/JJ	nn||nitrite-43/NN||ion-42/NN	prep_with||correlated-38/VBN||nitrite-43/NN	dep||nitrite-43/NN||râ-45/VBN	dobj||râ-45/VBN||$-46/$	number||=-48/CD||-47/CD	num||$-46/$||=-48/CD	dep||râ-45/VBN||â-49/VB	dobj||â-49/VB||$-50/$	number||.46-52/CD||0-51/CD	num||$-50/$||.46-52/CD	appos||$-50/$||p-54/NN	number||0.0001-56/CD||<-55/CD	dep||p-54/NN||0.0001-56/CD	amod||ige-64/NN||total-62/JJ	nn||ige-64/NN||serum-63/NN	prep_with||correlated-38/VBN||ige-64/NN	conj_and||nitrite-43/NN||ige-64/NN	dep||ige-64/NN||râ-66/VBN	num||â-70/NN||$-67/$	number||=-69/CD||-68/CD	num||$-67/$||=-69/CD	dobj||râ-66/VBN||â-70/NN	nsubj||asthmatics-84/VBZ||$-71/$	num||$-71/$||0-72/CD	num||$-71/$||.28-73/CD	nn||â-79/NN||pâ-75/NN	amod||â-79/NN||$-76/$	dep||$-76/$||-77/JJ	nn||â-79/NN||=-78/NNP	appos||$-71/$||â-79/NN	dep||â-79/NN||$-80/$	num||$-80/$||0-81/CD	num||$-80/$||.016-82/CD	rcmod||â-70/NN||asthmatics-84/VBZ	advmod||asthmatics-84/VBZ||only-85/RB	ion-42||asthmatics-84||no_rel||in addition, formate concentration was negatively correlated with methacholine pc20 (râ=ââ0.39, pâ=â0.002, asthmatics only), and positively correlated with the no-derived ion nitrite (râ=â0.46, p<0.0001) as well as with total serum ige (râ=â0.28, pâ=â0.016, asthmatics only).
nsubj||has-12/VBZ||chloroquine-1/NN	appos||chloroquine-1/NN||cq-3/NN	det||drug-10/NN||the-6/DT	amod||drug-10/NN||worldwide-7/JJ	amod||drug-10/NN||used-8/JJ	amod||drug-10/NN||anti-malarial-9/JJ	appos||chloroquine-1/NN||drug-10/NN	root||ROOT-0/null||has-12/VBZ	advmod||has-12/VBZ||recently-13/RB	auxpass||focused-15/VBN||being-14/VBG	xcomp||has-12/VBZ||focused-15/VBN	det||agent-20/NN||a-17/DT	amod||agent-20/NN||potential-18/JJ	amod||agent-20/NN||anti-cancer-19/JJ	prep_as||focused-15/VBN||agent-20/NN	det||chemosensitizer-25/NN||a-24/DT	prep_as||focused-15/VBN||chemosensitizer-25/NN	conj_and||agent-20/NN||chemosensitizer-25/NN	advmod||used-27/VBN||when-26/WRB	advcl||focused-15/VBN||used-27/VBN	prep_in||used-27/VBN||combination-29/NN	prep_with||used-27/VBN||anti-cancerdrugs-31/NNS	cancer--1||chloroquine-1||no_rel||chloroquine (cq), the worldwide used anti-malarial drug, has recently being focused as a potential anti-cancer agent as well as a chemosensitizer when used in combination with anti-cancerdrugs.
det||w-4/NN||both-1/DT	number||%-3/NN||10-2/CD	amod||w-4/NN||%-3/NN	nsubj||able-17/JJ||w-4/NN	nsubj||eradicate-19/VB||w-4/NN	nsubj||prevent-23/VB||w-4/NN	nsubj||tolerated-30/JJ||w-4/NN	punct||solutions-9/NNS||/-5/:	dep||solutions-9/NNS||v-6/RB	amod||solutions-9/NNS||fipronil-based-7/JJ	amod||solutions-9/NNS||spot-on-8/JJ	dep||w-4/NN||solutions-9/NNS	amod||vehicles-13/NNS||different-12/JJ	prep_despite||able-17/JJ||vehicles-13/NNS	cop||able-17/JJ||were-15/VBD	advmod||able-17/JJ||equally-16/RB	root||ROOT-0/null||able-17/JJ	aux||eradicate-19/VB||to-18/TO	xcomp||able-17/JJ||eradicate-19/VB	dobj||eradicate-19/VB||tickinfestation-20/NN	aux||prevent-23/VB||to-22/TO	xcomp||able-17/JJ||prevent-23/VB	amod||infestations-25/NNS||new-24/JJ	dobj||prevent-23/VB||infestations-25/NNS	cop||tolerated-30/JJ||were-27/VBD	advmod||tolerated-30/JJ||equally-28/RB	advmod||tolerated-30/JJ||well-29/RB	conj_and||able-17/JJ||tolerated-30/JJ	vehicles-13||infestations-25||no_rel||both 10% w / v fipronil-based spot-on solutions, despite different vehicles, were equally able to eradicate tickinfestation, to prevent new infestations and were equally well tolerated.
det||study-2/NN||this-1/DT	nsubjpass||conducted-4/VBN||study-2/NN	nsubj||identify-16/VB||study-2/NN	auxpass||conducted-4/VBN||was-3/VBD	root||ROOT-0/null||conducted-4/VBN	det||consortium-8/NN||the-6/DT	amod||consortium-8/NN||international-7/JJ	agent||conducted-4/VBN||consortium-8/NN	nn||safety-11/NN||blood-10/NN	prep_for||consortium-8/NN||safety-11/NN	appos||safety-11/NN||icbs-13/NNS	aux||identify-16/VB||to-15/TO	xcomp||conducted-4/VBN||identify-16/VB	amod||kits-19/NNS||high-quality-17/JJ	nn||kits-19/NNS||test-18/NN	dobj||identify-16/VB||kits-19/NNS	iobj||identify-16/VB||kits-19/NNS	prep_for||kits-19/NNS||detection-21/NN	amod||virus-24/NN||hepatitisb-23/JJ	prep_of||detection-21/NN||virus-24/NN	appos||kits-19/NNS||hbv-26/NN	nn||antigen-29/NN||surface-28/NN	dep||kits-19/NNS||antigen-29/NN	appos||antigen-29/NN||hbsag-31/NN	det||benefit-35/NN||the-34/DT	prep_for||antigen-29/NN||benefit-35/NN	amod||countries-38/NNS||developing-37/VBG	prep_of||benefit-35/NN||countries-38/NNS	hbv-26||hbsag-31||yes||this study was conducted by the international consortium for blood safety (icbs) to identify high-quality test kits for detection of hepatitisb virus (hbv) surface antigen (hbsag) for the benefit of developing countries.
nsubj||applied-2/VBD||we-1/PRP	root||ROOT-0/null||applied-2/VBD	amod||models-7/NNS||several-3/JJ	amod||models-7/NNS||semi-parametric-4/JJ	amod||models-7/NNS||proportional-5/JJ	nn||models-7/NNS||hazards-6/NNS	dobj||applied-2/VBD||models-7/NNS	aux||analyze-9/VB||to-8/TO	vmod||applied-2/VBD||analyze-9/VB	det||risk-11/NN||the-10/DT	dobj||analyze-9/VB||risk-11/NN	amod||events-18/NNS||recurrent-13/JJ	nn||events-18/NNS||myocardialinfarction-14/NN	nn||events-18/NNS||mi-16/NN	prep_of||risk-11/NN||events-18/NNS	prepc_based_on||analyze-9/VB||on-20/IN	pobj||analyze-9/VB||data-21/NNS	det||trial-28/NN||a-23/DT	advmod||large-25/JJ||very-24/RB	amod||trial-28/NN||large-25/JJ	amod||trial-28/NN||randomized-26/JJ	amod||trial-28/NN||placebo-controlled-27/JJ	prep_from||data-21/NNS||trial-28/NN	amod||drug-31/NN||cholesterol-lowering-30/JJ	prep_of||trial-28/NN||drug-31/NN	cholesterol--1||myocardialinfarction-14||no_rel||we applied several semi-parametric proportional hazards models to analyze the risk of recurrent myocardialinfarction (mi) events based on data from a very large randomized placebo-controlled trial of cholesterol-lowering drug.
nsubj||experience-3/VBP||individuals-1/NNS	nsubj||benefit-11/VBP||individuals-1/NNS	rcmod||individuals-1/NNS||experience-3/VBP	dobj||experience-3/VBP||flares-4/NNS	nn||while-7/NN||pain-6/NN	prep_of||flares-4/NNS||while-7/NN	amod||opioids-10/NNS||spinal-9/JJ	prep_on||while-7/NN||opioids-10/NNS	root||ROOT-0/null||benefit-11/VBP	amod||boluses-14/NNS||intrathecal-13/JJ	prep_from||benefit-11/VBP||boluses-14/NNS	amod||ketamine-19/NN||levobupivicaine-16/JJ	conj_or||levobupivicaine-16/JJ||sublingual-18/JJ	amod||ketamine-19/NN||sublingual-18/JJ	prep_of||boluses-14/NNS||ketamine-19/NN	pain-6||ketamine-19||yes||individuals who experience flares of pain while on spinal opioids benefit from intrathecal boluses of levobupivicaine or sublingual ketamine.
amod||feâ-2/NN||defective-1/JJ	poss||synthesis-5/NN||feâ-2/NN	nn||synthesis-5/NN||cluster-4/NN	nsubj||affects-8/VBZ||synthesis-5/NN	nsubj||alters-26/VBZ||synthesis-5/NN	neg||only-7/JJ||not-6/RB	preconj||affects-8/VBZ||only-7/JJ	root||ROOT-0/null||affects-8/VBZ	dobj||affects-8/VBZ||activities-9/NNS	amod||ironâ-12/NN||many-11/JJ	poss||enzymes-15/NNS||ironâ-12/NN	nn||enzymes-15/NNS||ulfur-14/NN	prep_of||activities-9/NNS||enzymes-15/NNS	amod||dehydrogenase-22/NN||aconitase-19/JJ	conj_and||aconitase-19/JJ||succinate-21/JJ	amod||dehydrogenase-22/NN||succinate-21/JJ	prep_such_as||activities-9/NNS||dehydrogenase-22/NN	advmod||alters-26/VBZ||also-25/RB	conj_but||affects-8/VBZ||alters-26/VBZ	det||regulation-28/NN||the-27/DT	dobj||alters-26/VBZ||regulation-28/NN	amod||homeostasis-32/NNS||cellular-30/JJ	nn||homeostasis-32/NNS||iron-31/NN	prep_of||regulation-28/NN||homeostasis-32/NNS	vmod||regulation-28/NN||causing-34/VBG	det||irondeficiency-40/NN||both-35/DT	amod||irondeficiency-40/NN||mitochondrial-36/JJ	amod||irondeficiency-40/NN||ironoverload-37/JJ	conj_and||ironoverload-37/JJ||cytosolic-39/JJ	amod||irondeficiency-40/NN||cytosolic-39/JJ	dobj||causing-34/VBG||irondeficiency-40/NN	ironoverload-37||iron-31||no||defective feâs cluster synthesis not only affects activities of many ironâsulfur enzymes, such as aconitase and succinate dehydrogenase, but also alters the regulation of cellular iron homeostasis, causing both mitochondrial ironoverload and cytosolic irondeficiency.
nsubj||show-2/VBP||we-1/PRP	root||ROOT-0/null||show-2/VBP	amod||levels-5/NNS||elevated-3/JJ	amod||levels-5/NNS||il-1ra-4/JJ	dobj||show-2/VBP||levels-5/NNS	num||years-8/NNS||13-7/CD	prep_for||levels-5/NNS||years-8/NNS	det||increase-12/NN||an-10/DT	amod||increase-12/NN||accelerated-11/JJ	prep_for||levels-5/NNS||increase-12/NN	conj_and||years-8/NNS||increase-12/NN	det||years-17/NNS||the-14/DT	amod||years-17/NNS||last-15/JJ	num||years-17/NNS||6-16/CD	prep_during||show-2/VBP||years-17/NNS	amod||diagnosis-20/NN||type2diabetes-19/JJ	prep_before||show-2/VBP||diagnosis-20/NN	vmod||show-2/VBP||indicating-22/VBG	det||presence-24/NN||the-23/DT	dobj||indicating-22/VBG||presence-24/NN	det||response-28/NN||an-26/DT	amod||response-28/NN||anti-inflammatory-27/JJ	prep_of||presence-24/NN||response-28/NN	nsubj||act-31/VB||response-28/NN	nsubj||counterbalance-33/VB||response-28/NN	aux||act-31/VB||may-30/MD	rcmod||response-28/NN||act-31/VB	aux||counterbalance-33/VB||to-32/TO	xcomp||act-31/VB||counterbalance-33/VB	det||disturbances-38/NNS||the-34/DT	amod||disturbances-38/NNS||metabolic-35/JJ	conj_and||metabolic-35/JJ||immunologic-37/JJ	amod||disturbances-38/NNS||immunologic-37/JJ	dobj||counterbalance-33/VB||disturbances-38/NNS	nsubj||precede-40/VB||disturbances-38/NNS	rcmod||disturbances-38/NNS||precede-40/VB	dobj||precede-40/VB||type2diabetes-41/NNS	anti-inflammatory-27||type2diabetes-41||no_rel||we show elevated il-1ra levels for 13 years and an accelerated increase during the last 6 years before type2diabetes diagnosis, indicating the presence of an anti-inflammatory response that may act to counterbalance the metabolic and immunologic disturbances that precede type2diabetes.
det||proposal-2/NN||this-1/DT	nsubjpass||supported-4/VBN||proposal-2/NN	auxpass||supported-4/VBN||is-3/VBZ	root||ROOT-0/null||supported-4/VBN	det||observation-7/NN||the-6/DT	agent||supported-4/VBN||observation-7/NN	mark||have-12/VBP||that-8/IN	amod||indians-11/NNS||south-9/JJ	nn||indians-11/NNS||asian-10/NN	nsubj||have-12/VBP||indians-11/NNS	ccomp||supported-4/VBN||have-12/VBP	amod||plasma-14/NN||lower-13/JJR	dobj||have-12/VBP||plasma-14/NN	nn||concentrations-17/NNS||tissue-16/NN	dobj||have-12/VBP||concentrations-17/NNS	conj_and||plasma-14/NN||concentrations-17/NNS	prep_of||plasma-14/NN||gla-19/NN	prep_of||plasma-14/NN||dgla-21/NN	conj_and||gla-19/NN||dgla-21/NN	prep_of||plasma-14/NN||aa-23/NN	conj_and||gla-19/NN||aa-23/NN	prep_of||plasma-14/NN||epa-25/NN	conj_and||gla-19/NN||epa-25/NN	prep_of||plasma-14/NN||dha-27/NN	conj_and||gla-19/NN||dha-27/NN	det||precursors-30/NNS||the-29/DT	appos||plasma-14/NN||precursors-30/NNS	prep_of||precursors-30/NNS||pge1-32/NNS	prep_of||precursors-30/NNS||pgi2-34/NNS	conj_and||pge1-32/NNS||pgi2-34/NNS	prep_of||precursors-30/NNS||pgi3-36/NNS	conj_and||pge1-32/NNS||pgi3-36/NNS	prep_of||precursors-30/NNS||lipoxins-38/NNS	conj_and||pge1-32/NNS||lipoxins-38/NNS	prep_of||precursors-30/NNS||resolvins-40/NNS	conj_and||pge1-32/NNS||resolvins-40/NNS	prep_of||precursors-30/NNS||protectins-42/NNS	conj_and||pge1-32/NNS||protectins-42/NNS	prep_of||precursors-30/NNS||nitrolipids-45/NNS	conj_and||pge1-32/NNS||nitrolipids-45/NNS	det||molecules-49/NNS||the-47/DT	amod||molecules-49/NNS||endogenous-48/JJ	appos||plasma-14/NN||molecules-49/NNS	mark||prevent-51/VB||that-50/IN	dep||molecules-49/NNS||prevent-51/VB	amod||aggregation-53/NN||platelet-52/JJ	dobj||prevent-51/VB||aggregation-53/NN	dobj||prevent-51/VB||vasoconstriction-55/NN	conj_and||aggregation-53/NN||vasoconstriction-55/NN	amod||formation-58/NN||thrombus-57/JJ	dobj||prevent-51/VB||formation-58/NN	conj_and||aggregation-53/NN||formation-58/NN	amod||activation-61/NN||leukocyte-60/JJ	dobj||prevent-51/VB||activation-61/NN	conj_and||aggregation-53/NN||activation-61/NN	amod||action-65/NN||possess-63/JJ	amod||action-65/NN||anti-inflammatory-64/JJ	dobj||prevent-51/VB||action-65/NN	conj_and||aggregation-53/NN||action-65/NN	advmod||capable-70/JJ||thus-67/RB	cop||capable-70/JJ||are-69/VBP	dep||molecules-49/NNS||capable-70/JJ	conj_and||prevent-51/VB||capable-70/JJ	prepc_of||capable-70/JJ||preventing-72/VBG	det||development-74/NN||the-73/DT	dobj||preventing-72/VBG||development-74/NN	amod||disease-87/NN||insulinresistance-76/JJ	conj_and||insulinresistance-76/JJ||atherosclerosis-78/JJ	amod||disease-87/NN||atherosclerosis-78/JJ	conj_and||insulinresistance-76/JJ||hypertension-80/JJ	amod||disease-87/NN||hypertension-80/JJ	conj_and||insulinresistance-76/JJ||type2diabetesmellitus-82/JJ	amod||disease-87/NN||type2diabetesmellitus-82/JJ	conj_and||insulinresistance-76/JJ||premature-84/JJ	amod||disease-87/NN||premature-84/JJ	amod||disease-87/NN||ischemic-85/JJ	nn||disease-87/NN||heart-86/NN	prep_of||development-74/NN||disease-87/NN	atherosclerosis-78||pgi2-34||yes||this proposal is supported by the observation that south asian indians have lower plasma and tissue concentrations of gla, dgla, aa, epa and dha, the precursors of pge1, pgi2, pgi3, lipoxins, resolvins, protectins, and nitrolipids, the endogenous molecules that prevent platelet aggregation, vasoconstriction, thrombus formation, leukocyte activation and possess anti-inflammatory action and thus, are capable of preventing the development of insulinresistance, atherosclerosis, hypertension, type2diabetesmellitus and premature ischemic heart disease.
det||male-3/NN||a-1/DT	amod||male-3/NN||56-year-old-2/JJ	nsubj||undergone-6/VBN||male-3/NN	nsubj||received-17/VBN||male-3/NN	aux||undergone-6/VBN||had-5/VBD	rcmod||male-3/NN||undergone-6/VBN	det||lobectomy-9/NN||a-7/DT	amod||lobectomy-9/NN||pulmonary-8/JJ	dobj||undergone-6/VBN||lobectomy-9/NN	nn||cancer-12/NN||lung-11/NN	prep_for||lobectomy-9/NN||cancer-12/NN	num||years-14/NNS||2-13/CD	npadvmod||before-15/RB||years-14/NNS	advmod||received-17/VBN||before-15/RB	aux||received-17/VBN||had-16/VBD	root||ROOT-0/null||received-17/VBN	dobj||received-17/VBN||warfarin-18/NN	quantmod||5-21/CD||about-20/RB	num||months-22/NNS||5-21/CD	prep_for||warfarin-18/NN||months-22/NNS	amod||veinthrombosis-26/NNS||pulmonary-25/JJ	prep_due_to||months-22/NNS||veinthrombosis-26/NNS	veinthrombosis-26||warfarin-18||yes||a 56-year-old male who had undergone a pulmonary lobectomy for lung cancer 2 years before had received warfarin for about 5 months due to pulmonary veinthrombosis.
det||rate-3/NN||the-1/DT	amod||rate-3/NN||relapse-2/JJ	nsubj||observed-4/VBD||rate-3/NN	root||ROOT-0/null||observed-4/VBD	num||months-7/NNS||12-6/CD	prep_after||observed-4/VBD||months-7/NNS	dobj||observed-4/VBD||treatment-8/NN	prep_with||treatment-8/NN||the-10/DT	nsubj||recommended-12/VBD||the-10/DT	rcmod||the-10/DT||recommended-12/VBD	nn||regimen-15/NN||mdr-13/NN	nn||regimen-15/NN||tb-14/NN	nsubj||equivalent-26/JJ||regimen-15/NN	dep||regimen-15/NN||amikacin-17/NN	appos||amikacin-17/NN||ethionamide-19/NN	appos||amikacin-17/NN||pyrazinamide-21/NN	conj_and||ethionamide-19/NN||pyrazinamide-21/NN	appos||amikacin-17/NN||moxifloxacin-23/NN	conj_and||ethionamide-19/NN||moxifloxacin-23/NN	cop||equivalent-26/JJ||was-25/VBD	ccomp||recommended-12/VBD||equivalent-26/JJ	det||treatment-35/NN||the-28/DT	dep||rate-30/NN||relapse-29/JJ	amod||treatment-35/NN||rate-30/NN	amod||treatment-35/NN||observed-31/JJ	num||months-34/NNS||6-33/CD	prep_after||observed-31/JJ||months-34/NNS	prep_to||equivalent-26/JJ||treatment-35/NN	det||regimen-42/NN||the-37/DT	amod||regimen-42/NN||recommended-38/VBN	nn||regimen-42/NN||drug-39/NN	amod||regimen-42/NN||susceptible-40/VBG	nn||regimen-42/NN||tb-41/NN	prep_with||treatment-35/NN||regimen-42/NN	dep||treatment-35/NN||rifampin-44/NN	dep||rifampin-44/NN||isoniazid-46/JJ	dep||rifampin-44/NN||pyrazinamide-48/JJ	conj_and||isoniazid-46/JJ||pyrazinamide-48/JJ	tb-41||isoniazid-46||yes||the relapse rate observed after 12 months treatment with the who recommended mdr tb regimen (amikacin, ethionamide, pyrazinamide and moxifloxacin) was equivalent to the relapse rate observed after 6 months treatment with the recommended drug susceptible tb regimen (rifampin, isoniazid and pyrazinamide).
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||outcomes-5/NNS||the-4/DT	prep_on||report-2/VBP||outcomes-5/NNS	num||patients-11/NNS||21-7/CD	amod||patients-11/NNS||consecutive-8/JJ	amod||patients-11/NNS||gastric-9/JJ	nn||patients-11/NNS||cancer-10/NN	prep_of||outcomes-5/NNS||patients-11/NNS	vmod||patients-11/NNS||treated-12/VBN	prep_off||treated-12/VBN||protocol-14/NN	amod||carboplatin-17/NNS||adjuvant-16/JJ	prep_with||treated-12/VBN||carboplatin-17/NNS	dep||carboplatin-17/NNS||area-19/NN	det||ã-25/NN||the-21/DT	nn||ã-25/NN||curve-22/NN	num||ã-25/NN||5-23/CD	nn||ã-25/NN||mg/ml-24/NN	prep_under||area-19/NN||ã-25/NN	dep||ã-25/NN||min-27/NN	prep_with||treated-12/VBN||paclitaxel-30/NN	conj_and||carboplatin-17/NNS||paclitaxel-30/NN	quantmod||$-33/$||175â-32/RB	num||mg/m2-36/NNS||$-33/$	num||$-33/$||200-35/CD	dep||paclitaxel-30/NN||mg/m2-36/NNS	det||weeks-40/NNS||every-38/DT	num||weeks-40/NNS||3-39/CD	tmod||treated-12/VBN||weeks-40/NNS	prepc_followed_by||treated-12/VBN||by-43/IN	amod||analogs-46/NNS||concurrent-44/JJ	nn||analogs-46/NNS||pyrimidine-45/NN	pobj||treated-12/VBN||analogs-46/NNS	dep||â-51/FW||either-48/DT	nn||â-51/FW||capecitabine-49/FW	nn||â-51/FW||1,600-50/FW	dep||analogs-46/NNS||â-51/FW	num||mg/m2/day-55/NNS||$-52/$	num||$-52/$||2,000-54/CD	dep||â-51/FW||mg/m2/day-55/NNS	num||patients-58/NNS||17-57/CD	prep_in||mg/m2/day-55/NNS||patients-58/NNS	number||200-62/CD||5fu-61/CD	num||mg/m2/day-63/NNS||200-62/CD	dep||â-51/FW||mg/m2/day-63/NNS	conj_or||mg/m2/day-55/NNS||mg/m2/day-63/NNS	num||patients-66/NNS||4-65/CD	prep_in||mg/m2/day-63/NNS||patients-66/NNS	pobj||treated-12/VBN||radiation-69/NN	conj_and||analogs-46/NNS||radiation-69/NN	dep||analogs-46/NNS||45â-71/NNS	dep||45â-71/NNS||$-72/$	num||$-72/$||50.4-74/CD	dep||$-72/$||gy-75/NN	cancer-10||capecitabine-49||no_rel||we report on the outcomes of 21 consecutive gastric cancer patients treated off protocol with adjuvant carboplatin (area under the curve 5 mg/ml ã min) and paclitaxel (175â200 mg/m2) every 3 weeks, followed by concurrent pyrimidine analogs (either capecitabine 1,600â2,000 mg/m2/day in 17 patients, or 5fu 200 mg/m2/day in 4 patients) and radiation (45â50.4 gy).
nsubj||showed-24/VBD||antisera-1/NN	vmod||antisera-1/NN||raised-2/VBN	det||virus-6/NN||the-4/DT	amod||virus-6/NN||parental-5/JJ	prep_against||raised-2/VBN||virus-6/NN	vmod||virus-6/NN||reacted-7/VBN	advmod||reacted-7/VBN||equally-8/RB	preconj||homologous-11/JJ||both-10/DT	amod||viruses-14/NNS||homologous-11/JJ	conj_and||homologous-11/JJ||heterlogous-13/JJ	amod||viruses-14/NNS||heterlogous-13/JJ	prep_to||reacted-7/VBN||viruses-14/NNS	advmod||showed-24/VBD||however-16/RB	nsubj||showed-24/VBD||antisera-18/NN	vmod||antisera-18/NN||raised-19/VBN	det||virus-23/NN||the-21/DT	amod||virus-23/NN||mutant-22/JJ	prep_against||raised-19/VBN||virus-23/NN	root||ROOT-0/null||showed-24/VBD	num||folds-26/NNS||4-8-25/CD	npadvmod||lower-27/JJR||folds-26/NNS	amod||reactivity-28/NN||lower-27/JJR	dobj||showed-24/VBD||reactivity-28/NN	det||virus-32/NN||the-30/DT	amod||virus-32/NN||parental-31/JJ	prep_to||showed-24/VBD||virus-32/NN	virus-32||viruses-14||no||antisera raised against the parental virus reacted equally to both homologous and heterlogous viruses, however, antisera raised against the mutant virus showed 4-8 folds lower reactivity to the parental virus.
amod||trials-3/NNS||published-1/VBN	amod||trials-3/NNS||double-blind-2/JJ	nsubj||show-4/VBP||trials-3/NNS	root||ROOT-0/null||show-4/VBP	mark||achieves-12/VBZ||that-5/IN	amod||therapy-7/NN||budesonide/formoterol-6/JJ	nsubj||achieves-12/VBZ||therapy-7/NN	vmod||therapy-7/NN||delivered-8/VBN	amod||fashion-11/NN||smart-10/JJ	prep_in||delivered-8/VBN||fashion-11/NN	ccomp||show-4/VBP||achieves-12/VBZ	amod||outcomes-15/NNS||better-13/JJR	nn||outcomes-15/NNS||asthma-14/NN	dobj||achieves-12/VBZ||outcomes-15/NNS	amod||monotherapy-18/NN||budesonide-17/JJ	prep_than||achieves-12/VBZ||monotherapy-18/NN	amod||doses-21/NNS||lower-20/JJR	prep_than||achieves-12/VBZ||doses-21/NNS	conj_or||monotherapy-18/NN||doses-21/NNS	amod||therapy-24/NN||budesonide/formoterol-23/JJ	prep_of||doses-21/NNS||therapy-24/NN	vmod||therapy-24/NN||delivered-25/VBN	amod||dosage-28/NN||constant-27/JJ	prep_in||delivered-25/VBN||dosage-28/NN	asthma-14||budesonide-17||no||published double-blind trials show that budesonide/formoterol therapy delivered in smart fashion achieves better asthma outcomes than budesonide monotherapy or lower doses of budesonide/formoterol therapy delivered in constant dosage.
det||association-3/NN||a-1/DT	amod||association-3/NN||significant-2/JJ	nsubjpass||observed-5/VBN||association-3/NN	auxpass||observed-5/VBN||was-4/VBD	root||ROOT-0/null||observed-5/VBN	det||sle-10/NN||the-7/DT	amod||sle-10/NN||lupus-8/JJ	nn||sle-10/NN||cohort-9/NN	prep_in||observed-5/VBN||sle-10/NN	amod||health-13/NN||gullah-12/JJ	prep_in||sle-10/NN||health-13/NN	appos||health-13/NN||sleigh-15/NN	det||allele-22/NN||the-18/DT	amod||allele-22/NN||ga26-19/JJ	nn||allele-22/NN||base-20/NN	nn||allele-22/NN||pair-21/NN	prep_between||health-13/NN||allele-22/NN	prep_in||sle-10/NN||absence-24/NN	conj_and||health-13/NN||absence-24/NN	prep_of||absence-24/NN||nephritis-26/NNS	base-20||lupus-8||no_rel||a significant association was observed in the lupus cohort sle in gullah health (sleigh) between the ga26 base pair allele and absence of nephritis.
det||study-6/NN||the-1/DT	amod||study-6/NN||alpha-tocopherol-2/JJ	amod||study-6/NN||beta-carotene-3/JJ	nn||study-6/NN||cancer-4/NN	nn||study-6/NN||prevention-5/NN	nsubj||examined-7/VBD||study-6/NN	root||ROOT-0/null||examined-7/VBD	det||effects-9/NNS||the-8/DT	dobj||examined-7/VBD||effects-9/NNS	amod||carotene-22/NN||vitamine-11/JJ	num||mg-14/NN||50-13/CD	dep||vitamine-11/JJ||mg-14/NN	prep_per||mg-14/NN||day-16/NN	npadvmod||²-20/JJ||î-19/NN	conj_and||vitamine-11/JJ||²-20/JJ	amod||carotene-22/NN||²-20/JJ	prep_of||effects-9/NNS||carotene-22/NN	num||mg-25/NN||20-24/CD	dep||carotene-22/NN||mg-25/NN	prep_per||mg-25/NN||day-27/NN	nn||cancer-31/NN||lung-30/NN	prep_on||examined-7/VBD||cancer-31/NN	num||smokers-35/NNS||29,133-33/CD	amod||smokers-35/NNS||male-34/JJ	prep_in||cancer-31/NN||smokers-35/NNS	vmod||smokers-35/NNS||aged-36/VBN	xcomp||aged-36/VBN||50â-37/VBG	num||years-41/NNS||$-38/$	num||$-38/$||69-40/CD	tmod||50â-37/VBG||years-41/NNS	vmod||50â-37/VBG||using-42/VBG	det||ã-45/NN||a-43/DT	num||ã-45/NN||2-44/CD	dobj||using-42/VBG||ã-45/NN	num||design-49/NN||2-47/CD	amod||design-49/NN||factorial-48/JJ	dep||ã-45/NN||design-49/NN	cancer-31||beta-carotene-3||no_rel||the alpha-tocopherol beta-carotene cancer prevention study examined the effects of vitamine (50 mg per day) and î²-carotene (20 mg per day) on lung cancer in 29,133 male smokers aged 50â69 years using a 2 ã 2 factorial design.
nn||reviews-2/NNS||retrospective-1/NN	nsubj||suggest-3/VBP||reviews-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||differ-30/VB||that-4/IN	det||receptor-7/NN||the-5/DT	nn||receptor-7/NN||estrogen-6/NN	nsubj||differ-30/VB||receptor-7/NN	appos||receptor-7/NN||er-9/NN	amod||receptor-13/NN||progesterone-12/JJ	appos||receptor-7/NN||receptor-13/NN	appos||receptor-13/NN||pr-15/NN	amod||receptor-28/NN||human-18/JJ	nn||receptor-28/NN||epidermal-19/NN	nn||receptor-28/NN||growth-20/NN	nn||receptor-28/NN||factor-21/NN	nn||receptor-28/NN||receptor-22/NN	nn||receptor-28/NN||type-23/NN	num||receptor-28/NN||2-24/CD	nn||receptor-28/NN||her2-26/NN	conj_and||receptor-7/NN||receptor-28/NN	nsubj||differ-30/VB||receptor-28/NN	aux||differ-30/VB||may-29/MD	ccomp||suggest-3/VBP||differ-30/VB	det||recurrence-36/NN||the-32/DT	amod||recurrence-36/NN||primary-33/JJ	conj_and||primary-33/JJ||loco-regional-35/JJ	amod||recurrence-36/NN||loco-regional-35/JJ	prep_between||differ-30/VB||recurrence-36/NN	amod||metastases-39/NNS||distant-38/JJ	prep_between||differ-30/VB||metastases-39/NNS	conj_or||recurrence-36/NN||metastases-39/NNS	estrogen-6||metastases-39||no_rel||retrospective reviews suggest that the estrogen receptor (er), progesterone receptor (pr) and human epidermal growth factor receptor type 2 (her2) receptor may differ between the primary and loco-regional recurrence or distant metastases.
aux||compare-2/VB||to-1/TO	root||ROOT-0/null||compare-2/VB	det||efficacy-4/NN||the-3/DT	dobj||compare-2/VB||efficacy-4/NN	dobj||compare-2/VB||tolerability-6/NN	conj_and||efficacy-4/NN||tolerability-6/NN	prep_of||efficacy-4/NN||telmisartan-8/NN	prep_with||compare-2/VB||enalapril-10/NN	prep_in||compare-2/VB||patients-12/NNS	amod||hypertension-15/NN||essential-14/JJ	prep_of||patients-12/NNS||hypertension-15/NN	hypertension-15||telmisartan-8||yes||to compare the efficacy and tolerability of telmisartan with enalapril in patients of essential hypertension.
num||controls-3/NNS||seventeen-1/CD	amod||controls-3/NNS||healthy-2/JJ	nsubj||participated-27/VBD||controls-3/NNS	appos||controls-3/NNS||hc-5/NN	num||patients-9/NNS||20-8/CD	conj_and||controls-3/NNS||patients-9/NNS	nsubj||participated-27/VBD||patients-9/NNS	amod||disease-15/NN||crohnâ-11/JJ	amod||disease-15/NN||$-12/$	number||s-14/CD||-13/CD	num||$-12/$||s-14/CD	prep_with||patients-9/NNS||disease-15/NN	appos||patients-9/NNS||cd-17/NN	num||patients-21/NNS||22-20/CD	conj_and||controls-3/NNS||patients-21/NNS	nsubj||participated-27/VBD||patients-21/NNS	prep_with||patients-21/NNS||ulcerativecolitis-23/NNS	appos||controls-3/NNS||uc-25/NN	root||ROOT-0/null||participated-27/VBD	det||study-30/NN||the-29/DT	prep_in||participated-27/VBD||study-30/NN	crohn--1||hc-5||no_rel||seventeen healthy controls (hc), 20 patients with crohnâs disease (cd) and 22 patients with ulcerativecolitis (uc) participated in the study.
aux||evaluate-3/VB||to-1/TO	advmod||evaluate-3/VB||further-2/RBR	advcl||analyzed-13/VBD||evaluate-3/VB	det||strategy-6/NN||the-4/DT	nn||strategy-6/NN||sga-5/NN	dobj||evaluate-3/VB||strategy-6/NN	prepc_for||strategy-6/NN||identifying-8/VBG	nn||viruses-10/NNS||transmitted/founder-9/NN	dobj||identifying-8/VBG||viruses-10/NNS	nsubj||analyzed-13/VBD||we-12/PRP	root||ROOT-0/null||analyzed-13/VBD	num||5â-16/NNS||239-14/CD	amod||5â-16/NNS||overlapping-15/VBG	dobj||analyzed-13/VBD||5â-16/NNS	amod||5â-16/NNS||$-17/$	number||$-17/$||²-18/CD	amod||genome-24/NNS||3â-20/VBD	amod||genome-24/NNS||$-21/$	number||$-21/$||²-22/CD	nn||genome-24/NNS||half-23/NN	dobj||analyzed-13/VBD||genome-24/NNS	conj_and||5â-16/NNS||genome-24/NNS	dobj||analyzed-13/VBD||env-26/NN	conj_or||5â-16/NNS||env-26/NN	amod||sequences-29/NNS||only-28/JJ	dep||env-26/NN||sequences-29/NNS	nn||rna-33/NN||plasma-31/NN	amod||rna-33/NN||viral-32/JJ	prep_from||sequences-29/NNS||rna-33/NN	appos||rna-33/NN||vrna-35/NNP	nn||dna-41/NN||blood-38/NN	nn||dna-41/NN||mononuclear-39/NN	nn||dna-41/NN||cell-40/NN	prep_from||sequences-29/NNS||dna-41/NN	conj_and||rna-33/NN||dna-41/NN	det||subject-45/NN||an-43/DT	nn||subject-45/NN||msm-44/NN	prep_in||dna-41/NN||subject-45/NN	nsubj||had-47/VBD||who-46/WP	dep||rna-33/NN||had-47/VBD	det||days-58/NNS||a-48/DT	advmod||well-documented-50/JJ||particularly-49/RB	amod||days-58/NNS||well-documented-50/JJ	nn||days-58/NNS||virus-51/NN	nn||days-58/NNS||exposure-52/NN	nn||days-58/NNS||history-53/NN	amod||days-58/NNS||3â-54/JJ	num||days-58/NNS||$-55/$	num||$-55/$||6-57/CD	dobj||had-47/VBD||days-58/NNS	nn||onset-61/NN||symptom-60/NN	prep_before||days-58/NNS||onset-61/NN	dobj||had-47/VBD||14â-63/NNS	conj_and||days-58/NNS||14â-63/NNS	num||days-67/NNS||$-64/$	num||$-64/$||17-66/CD	dep||14â-63/NNS||days-67/NNS	amod||viremia-71/NN||peak-69/JJ	nn||viremia-71/NN||plasma-70/NN	prep_before||had-47/VBD||viremia-71/NN	num||molecules/ml-75/NN||47,600,000-73/CD	nn||molecules/ml-75/NN||vrna-74/NN	appos||viremia-71/NN||molecules/ml-75/NN	viremia-71||viruses-10||no||to further evaluate the sga strategy for identifying transmitted/founder viruses, we analyzed 239 overlapping 5â² and 3â² half genome or env -only sequences from plasma viral rna (vrna) and blood mononuclear cell dna in an msm subject who had a particularly well-documented virus exposure history 3â6 days before symptom onset and 14â17 days before peak plasma viremia (47,600,000 vrna molecules/ml).
prepc_based_on||tested-28/VBD||on-2/IN	det||premise-4/NN||the-3/DT	pobj||tested-28/VBD||premise-4/NN	mark||receiving-21/VBG||that-5/IN	amod||patients-7/NNS||postabsorptive-6/JJ	nsubj||receiving-21/VBG||patients-7/NNS	prep_with||patients-7/NNS||type1diabetes-9/NNS	vmod||type1diabetes-9/NNS||receiving-10/VBG	amod||insulin-12/NN||intravenous-11/JJ	dobj||receiving-10/VBG||insulin-12/NN	det||dose-15/NN||a-14/DT	prep_in||receiving-10/VBG||dose-15/NN	nsubj||maintains-17/VBZ||dose-15/NN	rcmod||dose-15/NN||maintains-17/VBZ	amod||euglycemia-19/NN||stable-18/JJ	dobj||maintains-17/VBZ||euglycemia-19/NN	aux||receiving-21/VBG||are-20/VBP	dep||premise-4/NN||receiving-21/VBG	advmod||optimal-23/JJ||biologically-22/RB	amod||replacement-25/NN||optimal-23/JJ	nn||replacement-25/NN||insulin-24/NN	dobj||receiving-21/VBG||replacement-25/NN	nsubj||tested-28/VBD||we-27/PRP	root||ROOT-0/null||tested-28/VBD	det||hypothesis-30/NNS||the-29/DT	dobj||tested-28/VBD||hypothesis-30/NNS	mark||supports-33/VBZ||that-31/IN	nsubj||supports-33/VBZ||glucagon-32/NN	ccomp||tested-28/VBD||supports-33/VBZ	amod||concentrations-37/NNS||postabsorptive-34/JJ	nn||concentrations-37/NNS||plasma-35/NN	nn||concentrations-37/NNS||glucose-36/NN	dobj||supports-33/VBZ||concentrations-37/NNS	prep_in||concentrations-37/NNS||humans-39/NNS	insulin-24||type1diabetes-9||no_rel||based on the premise that postabsorptive patients with type1diabetes receiving intravenous insulin in a dose that maintains stable euglycemia are receiving biologically optimal insulin replacement, we tested the hypothesis that glucagon supports postabsorptive plasma glucose concentrations in humans.
nsubj||anticipate-2/VBP||we-1/PRP	root||ROOT-0/null||anticipate-2/VBP	mark||contribute-9/VB||that-3/IN	det||study-5/NN||this-4/DT	nsubj||contribute-9/VB||study-5/NN	nsubj||stimulate-23/VB||study-5/NN	aux||contribute-9/VB||will-6/MD	neg||contribute-9/VB||not-7/RB	advmod||contribute-9/VB||only-8/RB	ccomp||anticipate-2/VBP||contribute-9/VB	det||development-12/NN||the-11/DT	prep_toward||contribute-9/VB||development-12/NN	det||alternative-16/NN||a-14/DT	amod||alternative-16/NN||superior-15/JJ	prep_of||development-12/NN||alternative-16/NN	prep_to||contribute-9/VB||bcg-18/NN	aux||stimulate-23/VB||will-21/MD	advmod||stimulate-23/VB||also-22/RB	ccomp||anticipate-2/VBP||stimulate-23/VB	conj_but||contribute-9/VB||stimulate-23/VB	xcomp||stimulate-23/VB||designing-24/VBG	nn||vaccines-27/NNS||tb-26/NN	prep_of||designing-24/VBG||vaccines-27/NNS	prepc_based_on||designing-24/VBG||on-29/IN	amod||antigens-31/NNS||latency-30/JJ	pobj||designing-24/VBG||antigens-31/NNS	tb-26||bcg-18||yes||we anticipate that this study will not only contribute toward the development of a superior alternative to bcg, but will also stimulate designing of tb vaccines based on latency antigens.
nn||lusitaniae-2/NN||borrelia-1/NN	nsubj||species-7/NN||lusitaniae-2/NN	nsubj||prevails-19/VBZ||lusitaniae-2/NN	cop||species-7/NN||is-3/VBZ	det||species-7/NN||an-4/DT	amod||species-7/NN||old-5/JJ	nn||species-7/NN||world-6/NN	root||ROOT-0/null||species-7/NN	det||group-14/NN||the-9/DT	amod||group-14/NN||lymeborreliosis-10/JJ	appos||group-14/NN||lb-12/NN	prep_of||species-7/NN||group-14/NN	amod||spirochetes-17/NNS||tick-borne-16/JJ	prep_of||species-7/NN||spirochetes-17/NNS	conj_and||species-7/NN||prevails-19/VBZ	advmod||prevails-19/VBZ||mainly-20/RB	prep_in||prevails-19/VBZ||countries-22/NNS	det||basin-26/NN||the-24/DT	nn||basin-26/NN||mediterranean-25/NN	prep_around||countries-22/NNS||basin-26/NN	lymeborreliosis-10||borrelia-1||no||borrelia lusitaniae is an old world species of the lymeborreliosis (lb) group of tick-borne spirochetes and prevails mainly in countries around the mediterranean basin.
dep||help-60/VB||the-2/NN	dep||the-2/NN||gloom-5/NN	amod||results-11/NNS||disappointing-9/JJ	nn||results-11/NNS||research-10/NN	prep_over||help-60/VB||results-11/NNS	prep_on||help-60/VB||vaccine-13/NN	nsubj||threatens-19/VBZ||development-14/NN	nsubj||overshadow-21/VB||development-14/NN	conj_and||development-14/NN||virucides-16/NNS	nsubj||threatens-19/VBZ||virucides-16/NNS	nsubj||overshadow-21/VB||virucides-16/NNS	rcmod||vaccine-13/NN||threatens-19/VBZ	aux||overshadow-21/VB||to-20/TO	xcomp||threatens-19/VBZ||overshadow-21/VB	advmod||positive-23/JJ||more-22/RBR	acomp||overshadow-21/VB||positive-23/JJ	amod||vaccine-13/NN||hiv/aids-related-26/JJ	dep||hiv/aids-related-26/JJ||news-27/NN	prep_such_as||news-27/NN||findings-31/NNS	det||circumcision-34/NN||that-32/DT	amod||circumcision-34/NN||male-33/JJ	nsubj||reduce-36/VB||circumcision-34/NN	aux||reduce-36/VB||might-35/MD	parataxis||help-60/VB||reduce-36/VB	det||likelihood-38/NN||the-37/DT	dobj||reduce-36/VB||likelihood-38/NN	nn||transmission-41/NN||hiv-40/NN	prep_of||likelihood-38/NN||transmission-41/NN	nsubj||giving-44/VBG||that-43/WDT	dobj||reduce-36/VB||giving-44/VBG	conj_and||likelihood-38/NN||giving-44/VBG	amod||drugs-46/NNS||antiretroviral-45/JJ	dobj||giving-44/VBG||drugs-46/NNS	prep||reduce-36/VB||to-47/TO	nsubj||help-60/VB||high-risk-50/JJ	amod||people-54/NNS||hiv-negative-53/JJ	nsubj||help-60/VB||people-54/NNS	amod||prophylaxis-57/NNS||pre-exposure-56/JJ	appos||people-54/NNS||prophylaxis-57/NNS	aux||help-60/VB||could-59/MD	root||ROOT-0/null||help-60/VB	xcomp||help-60/VB||protect-61/VB	dobj||protect-61/VB||them-62/PRP	prep_from||protect-61/VB||infection-64/NN	aids--1||hiv-40||no||" the ""gloom"" over disappointing research results on vaccine development and virucides ""threatens to overshadow more positive"" hiv/aids-related news, such as findings that male circumcision might reduce the likelihood of hiv transmission and that giving antiretroviral drugs to ""high-risk"" hiv-negative people (pre-exposure prophylaxis) could help protect them from infection."
det||protein-17/NN||the-1/DT	amod||gp160-7/NNS||humanimmunodeficiencyvirus-2/JJ	amod||gp160-7/NNS||type-1-3/JJ	amod||gp160-7/NNS||hiv-1-5/JJ	nn||protein-17/NN||gp160-7/NNS	amod||complex-10/NN||gp120-gp41-9/JJ	appos||gp160-7/NNS||complex-10/NN	amod||protein-17/NN||trimer-12/JJ	nn||protein-17/NN||envelope-13/FW	appos||protein-17/NN||env-15/NN	nsubj||candidate-22/NN||protein-17/NN	cop||candidate-22/NN||is-18/VBZ	det||candidate-22/NN||a-19/DT	amod||candidate-22/NN||potential-20/JJ	nn||candidate-22/NN||vaccine-21/NN	root||ROOT-0/null||candidate-22/NN	prep_for||candidate-22/NN||hiv/aids-24/NNS	aids--1||hiv--1||no||the humanimmunodeficiencyvirus type-1 (hiv-1) gp160 (gp120-gp41 complex) trimer envelope (env) protein is a potential vaccine candidate for hiv/aids.
det||clones-5/NNS||the-1/DT	num||clones-5/NNS||a-2/SYM	conj_and||a-2/SYM||b-4/SYM	num||clones-5/NNS||b-4/SYM	nsubjpass||associated-23/VBN||clones-5/NNS	prep_of||clones-5/NNS||borreliaburgdorferisensustricto-7/NN	amod||sequences-19/NNS||distinguished-9/JJ	amod||protein-13/NN||outer-11/JJ	nn||protein-13/NN||surface-12/NN	prep_by||distinguished-9/JJ||protein-13/NN	dep||protein-13/NN||c-14/SYM	dep||distinguished-9/JJ||ospc-16/JJ	nn||sequences-19/NNS||gene-18/NN	appos||clones-5/NNS||sequences-19/NNS	auxpass||associated-23/VBN||are-21/VBP	advmod||associated-23/VBN||commonly-22/RB	root||ROOT-0/null||associated-23/VBN	amod||lymedisease-26/NN||disseminated-25/JJ	prep_with||associated-23/VBN||lymedisease-26/NN	lymedisease-26||borreliaburgdorferisensustricto-7||no||the a and b clones of borreliaburgdorferisensustricto, distinguished by outer surface protein c ( ospc ) gene sequences, are commonly associated with disseminated lymedisease.
det||overview-2/NN||an-1/DT	nsubjpass||provided-4/VBN||overview-2/NN	auxpass||provided-4/VBN||is-3/VBZ	root||ROOT-0/null||provided-4/VBN	det||benefits-8/NNS||the-6/DT	amod||benefits-8/NNS||clinical-7/JJ	prep_of||provided-4/VBN||benefits-8/NNS	amod||detection-11/NN||early-10/JJ	prep_of||benefits-8/NNS||detection-11/NN	amod||intervention-14/NN||prompt-13/JJ	prep_of||provided-4/VBN||intervention-14/NN	conj_and||benefits-8/NNS||intervention-14/NN	amod||levels-17/NNS||highbloodpressure-16/JJ	prep_of||intervention-14/NN||levels-17/NNS	det||analysis-22/NN||a-20/DT	amod||analysis-22/NN||closer-21/JJR	prep_with||provided-4/VBN||analysis-22/NN	amod||trials-26/NNS||recent-24/JJ	amod||trials-26/NNS||clinical-25/JJ	prep_of||analysis-22/NN||trials-26/NNS	vmod||analysis-22/NN||performed-28/VBN	prep_with||performed-28/VBN||olmesartanmedoxomil-30/NN	amod||subjects-33/NNS||young-32/JJ	prep_in||olmesartanmedoxomil-30/NN||subjects-33/NNS	prep_with||performed-28/VBN||hypertension-35/NN	hypertension-35||olmesartanmedoxomil-30||yes||an overview is provided of the clinical benefits of early detection and prompt intervention of highbloodpressure levels, with a closer analysis of recent clinical trials, performed with olmesartanmedoxomil in young subjects with hypertension.
det||values-3/NNS||the-1/DT	amod||values-3/NNS||median-2/JJ	nsubj||68.2-9/NN||values-3/NNS	amod||levels-7/NNS||serum-5/JJ	amod||levels-7/NNS||s100a12-6/JJ	prep_of||values-3/NNS||levels-7/NNS	aux||68.2-9/NN||were-8/VBD	root||ROOT-0/null||68.2-9/NN	dobj||68.2-9/NN||ng/ml-10/NN	parataxis||68.2-9/NN||range-12/VB	num||.4-14/CD||43.4-147-13/CD	dobj||range-12/VB||.4-14/CD	prep_in||68.2-9/NN||uc-17/NN	num||ng/ml-20/NN||70-19/CD	prep_in||68.2-9/NN||ng/ml-20/NN	conj_and||uc-17/NN||ng/ml-20/NN	number||.8-23/CD||41.4-169-22/CD	dep||ng/ml-20/NN||.8-23/CD	prep_in||ng/ml-20/NN||cd-26/NN	num||ng/ml-29/NN||43.4-28/CD	prep_in||68.2-9/NN||ng/ml-29/NN	conj_and||uc-17/NN||ng/ml-29/NN	number||.4-32/CD||34.4-74-31/CD	dep||ng/ml-29/NN||.4-32/CD	nn||patients-36/NNS||ibs-35/NN	prep_in||ng/ml-29/NN||patients-36/NNS	uc-17||cd-26||no_rel||the median values of serum s100a12 levels were 68.2 ng/ml (range 43.4-147.4) in uc, 70 ng/ml (41.4-169.8) in cd and 43.4 ng/ml (34.4-74.4) in ibs patients.
nsubjpass||evaluated-10/VBN||herein-1/NN	det||response-6/NN||the-3/DT	amod||response-6/NN||immune-mediated-4/JJ	nn||response-6/NN||cell-5/NN	appos||herein-1/NN||response-6/NN	prep_to||response-6/NN||hepatitiscantigens-8/NNS	auxpass||evaluated-10/VBN||was-9/VBD	root||ROOT-0/null||evaluated-10/VBN	amod||transfers-13/NNS||adoptive-12/JJ	agent||evaluated-10/VBN||transfers-13/NNS	amod||ester-17/NN||carboxyfluorescein-15/JJ	amod||ester-17/NN||succinimidyl-16/JJ	prep_of||transfers-13/NNS||ester-17/NN	appos||ester-17/NN||cfse-19/NN	vmod||ester-17/NN||labelled-21/VBN	dobj||labelled-21/VBN||splenocytes-22/NNS	amod||mice-26/NNS||hcv-24/JJ	amod||mice-26/NNS||immunized-25/JJ	prep_from||labelled-21/VBN||mice-26/NNS	amod||mice-30/NNS||hcv-28/JJ	amod||mice-30/NNS||transgenic-29/JJ	prep_into||labelled-21/VBN||mice-30/NNS	hepatitiscantigens-8||hcv-28||no||herein, the immune-mediated cell response to hepatitiscantigens was evaluated by adoptive transfers of carboxyfluorescein succinimidyl ester (cfse) labelled splenocytes from hcv immunized mice into hcv transgenic mice.
amod||type-6/NN||human-1/JJ	nn||type-6/NN||t-2/NN	nn||type-6/NN||cell-3/NN	nn||type-6/NN||leukemia-4/NN	nn||type-6/NN||virus-5/NN	nsubj||agent-14/NN||type-6/NN	dep||type-6/NN||1-7/CD	dep||type-6/NN||htlv-1-9/JJ	cop||agent-14/NN||is-11/VBZ	det||agent-14/NN||the-12/DT	amod||agent-14/NN||etiologic-13/JJ	root||ROOT-0/null||agent-14/NN	amod||leukemia-19/NN||adult-16/JJ	nn||leukemia-19/NN||t-17/NN	nn||leukemia-19/NN||cell-18/NN	prep_of||agent-14/NN||leukemia-19/NN	appos||leukemia-19/NN||atl-21/NN	det||disorder-26/NN||the-24/DT	amod||disorder-26/NN||neurological-25/JJ	conj_and||agent-14/NN||disorder-26/NN	amod||tropicalspasticparaparesis-29/NNS||htlv-1-associatedmyelopathy-27/JJ	amod||tropicalspasticparaparesis-29/NNS||/-28/JJ	dep||disorder-26/NN||tropicalspasticparaparesis-29/NNS	appos||tropicalspasticparaparesis-29/NNS||ham/tsp-31/NN	ham--1||htlv-1-9||no||human t cell leukemia virus type 1 (htlv-1) is the etiologic agent of adult t cell leukemia (atl) and the neurological disorder htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp).
det||findings-2/NNS||these-1/DT	nsubj||include-5/VB||findings-2/NNS	aux||include-5/VB||do-3/VBP	neg||include-5/VB||not-4/RB	root||ROOT-0/null||include-5/VB	amod||arc-8/NN||aids-relatedcomplex-6/JJ	dobj||include-5/VB||arc-8/NN	amod||manifestations-12/NNS||other-11/JJ	dobj||include-5/VB||manifestations-12/NNS	conj_or||arc-8/NN||manifestations-12/NNS	nn||infection-18/NN||humanimmunodeficiencyvirus-14/NNP	appos||infection-18/NN||hiv-16/NN	prep_of||manifestations-12/NNS||infection-18/NN	arc-8||hiv-16||no||these findings do not include aids-relatedcomplex (arc) or other manifestations of humanimmunodeficiencyvirus (hiv) infection.
advmod||demonstrated-5/VBN||previously-1/RB	nsubj||demonstrated-5/VBN||we-3/PRP	aux||demonstrated-5/VBN||have-4/VBP	root||ROOT-0/null||demonstrated-5/VBN	mark||sufficient-14/JJ||that-6/IN	nsubj||sufficient-14/JJ||treatment-7/NN	nsubj||tilt-16/VB||treatment-7/NN	advmod||modified-10/JJ||genetically-9/RB	amod||acidophilus-12/NNS||modified-10/JJ	nn||acidophilus-12/NNS||lactobacillus-11/NN	prep_with||treatment-7/NN||acidophilus-12/NNS	cop||sufficient-14/JJ||is-13/VBZ	ccomp||demonstrated-5/VBN||sufficient-14/JJ	aux||tilt-16/VB||to-15/TO	xcomp||sufficient-14/JJ||tilt-16/VB	det||balance-19/NN||the-17/DT	amod||balance-19/NN||immune-18/JJ	dobj||tilt-16/VB||balance-19/NN	prep_from||tilt-16/VB||proinflammatory-21/NN	prep_to||tilt-16/VB||regulatory-23/JJ	amod||models-26/NNS||experimental-25/JJ	prep_in||regulatory-23/JJ||models-26/NNS	prep_of||models-26/NNS||colitis-28/NNS	nn||cancer-31/NN||colon-30/NN	prep_of||models-26/NNS||cancer-31/NN	conj_and||colitis-28/NNS||cancer-31/NN	acidophilus-12||colitis-28||no_rel||previously, we have demonstrated that treatment with genetically modified lactobacillus acidophilus is sufficient to tilt the immune balance from proinflammatory to regulatory in experimental models of colitis and colon cancer.
amod||characteristics-2/NNS||patient-related-1/JJ	nsubjpass||evaluated-56/VBN||characteristics-2/NNS	dep||characteristics-2/NNS||age-4/NN	amod||status-7/NN||menopausal-6/JJ	dep||characteristics-2/NNS||status-7/NN	conj_and||age-4/NN||status-7/NN	amod||size-11/NN||pathological-9/JJ	nn||size-11/NN||stage/tumor-10/NN	dep||characteristics-2/NNS||size-11/NN	conj_and||age-4/NN||size-11/NN	nn||location-14/NN||tumor-13/NN	dep||characteristics-2/NNS||location-14/NN	conj_and||age-4/NN||location-14/NN	dep||characteristics-2/NNS||histology-16/NN	conj_and||age-4/NN||histology-16/NN	amod||status-20/NN||estrogen/progesterone-18/JJ	nn||status-20/NN||receptor-19/NN	dep||characteristics-2/NNS||status-20/NN	conj_and||age-4/NN||status-20/NN	amod||grade-23/NN||histological-22/JJ	dep||characteristics-2/NNS||grade-23/NN	conj_and||age-4/NN||grade-23/NN	amod||grade-26/NN||nuclear-25/JJ	dep||characteristics-2/NNS||grade-26/NN	conj_and||age-4/NN||grade-26/NN	nn||extension-29/NN||extracapsular-28/NN	dep||characteristics-2/NNS||extension-29/NN	conj_and||age-4/NN||extension-29/NN	nn||invasion-36/NN||lymphatic-31/JJ	conj_and||lymphatic-31/JJ||vascular-33/NN	nn||invasion-36/NN||vascular-33/NN	conj_and||lymphatic-31/JJ||perineural-35/NN	nn||invasion-36/NN||perineural-35/NN	dep||characteristics-2/NNS||invasion-36/NN	conj_and||age-4/NN||invasion-36/NN	dep||characteristics-2/NNS||ratio-38/NN	conj_and||age-4/NN||ratio-38/NN	amod||nodes/dissected-41/JJ||involved-40/JJ	amod||nodes-42/NNS||nodes/dissected-41/JJ	prep_of||ratio-38/NN||nodes-42/NNS	amod||factors-46/NNS||treatment-related-45/JJ	conj_and||characteristics-2/NNS||factors-46/NNS	nsubjpass||evaluated-56/VBN||factors-46/NNS	nn||therapy-53/NN||pmrt-48/NN	conj_and||pmrt-48/NN||chemotherapy-50/NN	nn||therapy-53/NN||chemotherapy-50/NN	conj_and||pmrt-48/NN||hormonal-52/NN	nn||therapy-53/NN||hormonal-52/NN	appos||factors-46/NNS||therapy-53/NN	auxpass||evaluated-56/VBN||were-55/VBD	root||ROOT-0/null||evaluated-56/VBN	prep_in||evaluated-56/VBN||terms-58/NNS	nn||rate-63/NN||lrr-60/NN	conj_and||lrr-60/NN||dm-62/NN	nn||rate-63/NN||dm-62/NN	prep_of||terms-58/NNS||rate-63/NN	tumor-13||dm-62||yes||patient-related characteristics (age, menopausal status, pathological stage/tumor size, tumor location, histology, estrogen/progesterone receptor status, histological grade, nuclear grade, extracapsular extension, lymphatic, vascular and perineural invasion and ratio of involved nodes/dissected nodes) and treatment-related factors (pmrt, chemotherapy and hormonal therapy) were evaluated in terms of lrr and dm rate.
det||virus-3/NN||the-1/DT	amod||virus-3/NN||cef-adapted-2/JJ	nsubj||contained-7/VBD||virus-3/NN	dep||virus-3/NN||d-cef-5/JJ	root||ROOT-0/null||contained-7/VBD	amod||changes-10/NNS||single-8/JJ	amod||changes-10/NNS||aminoacid-9/JJ	dobj||contained-7/VBD||changes-10/NNS	det||c-13/NN||the-12/DT	prep_in||changes-10/NNS||c-13/NN	nn||proteins-19/NNS||matrix-15/NN	nn||proteins-19/NNS||m-17/NN	prep_in||changes-10/NNS||proteins-19/NNS	conj_and||c-13/NN||proteins-19/NNS	num||substitutions-22/NNS||two-21/CD	dobj||contained-7/VBD||substitutions-22/NNS	conj_and||changes-10/NNS||substitutions-22/NNS	det||domain-28/NN||the-24/DT	amod||domain-28/NN||shared-25/VBN	amod||domain-28/NN||amino-26/JJ	nn||domain-28/NN||terminal-27/NN	prep_in||substitutions-22/NNS||domain-28/NN	det||phosphoprotein-31/NN||the-30/DT	prep_of||domain-28/NN||phosphoprotein-31/NN	appos||phosphoprotein-31/NN||p-33/NN	nn||protein-37/NN||v-36/NN	prep_of||domain-28/NN||protein-37/NN	conj_and||phosphoprotein-31/NN||protein-37/NN	aminoacid-9||virus-3||no_rel||the cef-adapted virus (d-cef) contained single aminoacid changes in the c and matrix (m) proteins and two substitutions in the shared amino terminal domain of the phosphoprotein (p) and v protein.
nn||women-2/NNS||participants-1/NNS	nsubj||aged-3/VBN||women-2/NNS	root||ROOT-0/null||aged-3/VBN	num||years-5/NNS||15-44-4/CD	tmod||aged-3/VBN||years-5/NNS	amod||factors-9/NNS||major-7/JJ	nn||factors-9/NNS||risk-8/NN	prep_without||aged-3/VBN||factors-9/NNS	nsubj||started-14/VBD||factors-9/NNS	amod||thromboembolism-12/NN||venous-11/JJ	prep_for||factors-9/NNS||thromboembolism-12/NN	rcmod||factors-9/NNS||started-14/VBD	det||episode-17/NN||a-15/DT	amod||episode-17/NN||new-16/JJ	dobj||started-14/VBD||episode-17/NN	prep_of||episode-17/NN||use-19/NN	det||oralcontraceptive-22/NN||an-21/DT	prep_of||use-19/NN||oralcontraceptive-22/NN	vmod||oralcontraceptive-22/NN||containing-23/VBG	num||oestrogen-26/NN||30-24/CD	nn||oestrogen-26/NN||âµg-25/NN	dobj||containing-23/VBG||oestrogen-26/NN	prep_in||oestrogen-26/NN||combination-28/NN	preconj||drospirenone-31/NN||either-30/DT	prep_with||containing-23/VBG||drospirenone-31/NN	prep_with||containing-23/VBG||levonorgestrel-33/NN	conj_or||drospirenone-31/NN||levonorgestrel-33/NN	aux||2002-36/VB||may-35/MD	prep_between||drospirenone-31/NN||2002-36/VB	prep_between||drospirenone-31/NN||september-38/NNP	conj_and||2002-36/VB||september-38/NNP	num||september-38/NNP||2009-39/CD	thromboembolism-12||oestrogen-26||no||participants women aged 15-44 years without major risk factors for venous thromboembolism who started a new episode of use of an oralcontraceptive containing 30 âµg oestrogen in combination with either drospirenone or levonorgestrel between may 2002 and september 2009.
nsubj||eliminated-12/VBD||suppression-1/NN	amod||expression-4/NN||her4/4icd-3/JJ	prep_of||suppression-1/NN||expression-4/NN	det||line-10/NN||the-6/DT	amod||line-10/NN||mcf-7-7/JJ	nn||line-10/NN||breasttumor-8/NN	nn||line-10/NN||cell-9/NN	prep_in||expression-4/NN||line-10/NN	advmod||eliminated-12/VBD||completely-11/RB	root||ROOT-0/null||eliminated-12/VBD	dobj||eliminated-12/VBD||estrogen-13/NN	vmod||estrogen-13/NN||stimulated-14/VBN	dobj||stimulated-14/VBN||expression-15/NN	prep_of||expression-15/NN||pgr-17/NN	breasttumor-8||estrogen-13||yes||suppression of her4/4icd expression in the mcf-7 breasttumor cell line completely eliminated estrogen stimulated expression of pgr.
nsubj||remains-2/VBZ||staphylococcusaureus-1/NNS	dep||complicates-20/VBZ||remains-2/VBZ	det||pathogen-5/NN||the-3/DT	amod||pathogen-5/NN||predominant-4/JJ	xcomp||remains-2/VBZ||pathogen-5/NN	amod||infections-8/NNS||diabeticfoot-7/JJ	prep_in||pathogen-5/NN||infections-8/NNS	xcomp||remains-2/VBZ||prevalence-10/NN	conj_and||pathogen-5/NN||prevalence-10/NN	amod||resistant-13/JJ||methicillin-12/JJ	amod||s.aureus-14/NNS||resistant-13/JJ	prep_of||prevalence-10/NN||s.aureus-14/NNS	appos||s.aureus-14/NNS||mrsa-16/NNP	nsubj||complicates-20/VBZ||strains-18/NNS	advmod||complicates-20/VBZ||further-19/RBR	root||ROOT-0/null||complicates-20/VBZ	det||situation-22/NN||the-21/DT	dobj||complicates-20/VBZ||situation-22/NN	mrsa-16||staphylococcusaureus-1||no||staphylococcusaureus remains the predominant pathogen in diabeticfoot infections and prevalence of methicillin resistant s.aureus (mrsa) strains further complicates the situation.
det||cohort-2/NN||a-1/DT	nsubjpass||characterized-14/VBN||cohort-2/NN	nsubjpass||genotyped-26/VBN||cohort-2/NN	num||individuals-7/NNS||1364-4/CD	amod||individuals-7/NNS||white-5/JJ	nn||individuals-7/NNS||european-6/NN	prep_of||cohort-2/NN||individuals-7/NNS	amod||risk-10/NN||increased-9/VBN	prep_at||individuals-7/NNS||risk-10/NN	prep_for||risk-10/NN||type2diabetes-12/CD	auxpass||characterized-14/VBN||was-13/VBD	root||ROOT-0/null||characterized-14/VBN	agent||characterized-14/VBN||ogtt-16/NN	prep_with||characterized-14/VBN||glucose-18/NN	prep_with||characterized-14/VBN||insulin-20/NN	conj_and||glucose-18/NN||insulin-20/NN	amod||measurements-24/NNS||c-peptide-23/JJ	prep_with||characterized-14/VBN||measurements-24/NNS	conj_and||glucose-18/NN||measurements-24/NNS	conj_and||characterized-14/VBN||genotyped-26/VBN	amod||polymorphisms-30/NNS||single-28/JJ	nn||polymorphisms-30/NNS||nucleotide-29/NN	prep_for||genotyped-26/VBN||polymorphisms-30/NNS	appos||polymorphisms-30/NNS||snps-32/NNS	vmod||polymorphisms-30/NNS||known-34/VBN	aux||affect-36/VB||to-35/TO	xcomp||known-34/VBN||affect-36/VB	amod||secretion-42/NN||glucose-37/JJ	conj_and||glucose-37/JJ||incretin-stimulated-40/JJ	amod||secretion-42/NN||incretin-stimulated-40/JJ	nn||secretion-42/NN||insulin-41/NN	dobj||affect-36/VB||secretion-42/NN	type2diabetes-12||insulin-41||yes||a cohort of 1364 white european individuals at increased risk for type2diabetes was characterized by ogtt with glucose, insulin, and c-peptide measurements and genotyped for single nucleotide polymorphisms (snps) known to affect glucose- and incretin-stimulated insulin secretion.
nsubj||efficacious-13/JJ||febuxostat-1/NN	prep_at||febuxostat-1/NN||doses-4/NNS	vmod||doses-4/NNS||ranging-5/VBG	number||240-9/CD||40-7/CD	dep||240-9/CD||to-8/TO	prep_from||ranging-5/VBG||240-9/CD	advmod||ranging-5/VBG||mg/day-10/RB	cop||efficacious-13/JJ||is-12/VBZ	root||ROOT-0/null||efficacious-13/JJ	prepc_in||efficacious-13/JJ||reducing-15/VBG	nn||urate-17/NN||serum-16/NN	dobj||reducing-15/VBG||urate-17/NN	prep_in||reducing-15/VBG||patients-19/NNS	prep_with||patients-19/NNS||hyperuricemia-21/NN	prep_with||patients-19/NNS||gout-23/NN	conj_and||hyperuricemia-21/NN||gout-23/NN	dep||reducing-15/VBG||comparing-25/VBG	advmod||comparing-25/VBG||favorably-26/RB	amod||doses-29/NNS||fixed-28/VBN	prep_with||comparing-25/VBG||doses-29/NNS	prep_of||doses-29/NNS||allopurinol-31/NN	det||respect-34/NN||that-33/DT	prep_in||allopurinol-31/NN||respect-34/NN	gout-23||allopurinol-31||yes||febuxostat, at doses ranging from 40 to 240 mg/day, is efficacious in reducing serum urate in patients with hyperuricemia and gout, comparing favorably with fixed doses of allopurinol in that respect.
amod||patients-2/NNS||eighty-1/JJ	nsubjpass||included-16/VBN||patients-2/NNS	nsubj||evaluate-21/VB||patients-2/NNS	vmod||patients-2/NNS||fulfilling-3/VBG	det||criteria-6/NNS||the-4/DT	amod||criteria-6/NNS||icd-10-5/JJ	dobj||fulfilling-3/VBG||criteria-6/NNS	prep_for||criteria-6/NNS||schizophrenia-8/NN	dep||with-11/IN||predominantly-10/RB	dep||included-16/VBN||with-11/IN	amod||symptoms-13/NNS||negative-12/JJ	pobj||with-11/IN||symptoms-13/NNS	auxpass||included-16/VBN||were-15/VBD	root||ROOT-0/null||included-16/VBN	det||study-19/NN||this-18/DT	prep_in||included-16/VBN||study-19/NN	aux||evaluate-21/VB||to-20/TO	xcomp||included-16/VBN||evaluate-21/VB	nn||gain-23/NN||weight-22/NN	dobj||evaluate-21/VB||gain-23/NN	det||effect-27/NN||an-25/DT	amod||effect-27/NN||adverse-26/JJ	prep_as||evaluate-21/VB||effect-27/NN	prep_of||effect-27/NN||treatment-29/NN	amod||index-43/NN||olanzapine-31/JJ	prep_in||olanzapine-31/JJ||relation-33/NN	prep_to||olanzapine-31/JJ||age-35/NN	prep_to||olanzapine-31/JJ||gender-37/NN	conj_and||age-35/NN||gender-37/NN	prep_to||olanzapine-31/JJ||dose-39/NN	conj_and||age-35/NN||dose-39/NN	prep_to||olanzapine-31/JJ||body-41/NN	conj_and||age-35/NN||body-41/NN	amod||index-43/NN||mass-42/JJ	prep_with||evaluate-21/VB||index-43/NN	appos||index-43/NN||bmi-45/NN	olanzapine-31||schizophrenia-8||no_rel||eighty patients fulfilling the icd-10 criteria for schizophrenia, predominantly with negative symptoms, were included in this study to evaluate weight gain as an adverse effect of treatment with olanzapine in relation to age, gender, dose and body mass index (bmi).
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	nsubj||compare-10/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	xcomp||was-6/VBD||compare-10/VB	conj_and||evaluate-8/VB||compare-10/VB	det||effects-12/NNS||the-11/DT	dobj||evaluate-8/VB||effects-12/NNS	det||combination-18/NN||a-14/DT	amod||combination-18/NN||long-term-15/JJ	amod||combination-18/NN||fixed-dose-17/JJ	prep_of||effects-12/NNS||combination-18/NN	prep_of||combination-18/NN||sitagliptin-20/NN	prep_of||combination-18/NN||metformin-22/NN	conj_and||sitagliptin-20/NN||metformin-22/NN	prep_as||evaluate-8/VB||add-on-24/JJ	prep_to||add-on-24/JJ||insulin-26/NN	nn||index-30/NN||body-28/NN	nn||index-30/NN||mass-29/NN	prep_on||insulin-26/NN||index-30/NN	amod||glucose-34/NN||fasting-32/JJ	nn||glucose-34/NN||plasma-33/NN	prep_on||insulin-26/NN||glucose-34/NN	conj_and||index-30/NN||glucose-34/NN	prep_on||insulin-26/NN||fructosamine-36/NN	conj_and||index-30/NN||fructosamine-36/NN	prep_on||insulin-26/NN||hba1c-38/NNS	conj_and||index-30/NN||hba1c-38/NNS	prep_on||insulin-26/NN||lipids-40/NNS	conj_and||index-30/NN||lipids-40/NNS	amod||dose-44/NN||daily-43/JJ	prep_on||insulin-26/NN||dose-44/NN	conj_and||index-30/NN||dose-44/NN	prep_of||dose-44/NN||insulin-46/NN	det||type2diabetes-52/NNS||both-48/DT	amod||type2diabetes-52/NNS||type1diabetes-49/JJ	conj_and||type1diabetes-49/JJ||insulin-treated-51/JJ	amod||type2diabetes-52/NNS||insulin-treated-51/JJ	prep_in||insulin-46/NN||type2diabetes-52/NNS	type1diabetes-49||insulin-46||yes||the aim of this study was to evaluate and compare the effects of a long-term, fixed-dose combination of sitagliptin and metformin as add-on to insulin on body mass index, fasting plasma glucose, fructosamine, hba1c, lipids, and daily dose of insulin in both type1diabetes and insulin-treated type2diabetes.
det||compound-3/NN||the-1/DT	nn||compound-3/NN||title-2/NN	nsubj||contains-12/VBZ||compound-3/NN	nn||-RSB--10/NNP||-LSB--5/NNP	nn||-RSB--10/NNP||zni2-6/NNP	appos||-RSB--10/NNP||c10h8n2s-8/NNP	appos||compound-3/NN||-RSB--10/NNP	root||ROOT-0/null||contains-12/VBZ	det||ring-16/NN||a-13/DT	amod||ring-16/NN||six-membered-14/JJ	nn||ring-16/NN||chelate-15/NN	dobj||contains-12/VBZ||ring-16/NN	vmod||ring-16/NN||adopting-17/VBG	vmod||ring-16/NN||adopting-17/VBG	conj_and||adopting-17/VBG||adopting-17/VBG	det||conformation-20/NN||a-18/DT	nn||conformation-20/NN||boat-19/NN	dobj||adopting-17/VBG||conformation-20/NN	dobj||coordinated-27/VBN||which-22/WDT	det||atom-25/NN||the-23/DT	nn||atom-25/NN||zn-24/NN	nsubjpass||coordinated-27/VBN||atom-25/NN	auxpass||coordinated-27/VBN||is-26/VBZ	prepc_in||adopting-17/VBG||coordinated-27/VBN	num||ions-31/NNS||two-29/CD	amod||ions-31/NNS||iodide-30/JJ	agent||coordinated-27/VBN||ions-31/NNS	det||atoms-38/NNS||the-34/DT	num||atoms-38/NNS||two-35/CD	amod||atoms-38/NNS||pyridyl-36/JJ	nn||atoms-38/NNS||n-37/NN	agent||adopting-17/VBG||atoms-38/NNS	det||sulfide-43/NN||a-40/DT	amod||sulfide-43/NN||single-41/JJ	amod||sulfide-43/NN||di-2-pyridyl-42/JJ	prep_of||atoms-38/NNS||sulfide-43/NN	vmod||sulfide-43/NN||ligand-44/VBN	det||tetraâhedron-49/NN||a-46/DT	advmod||distorted-48/JJ||slightly-47/RB	amod||tetraâhedron-49/NN||distorted-48/JJ	prep_within||ligand-44/VBN||tetraâhedron-49/NN	zn-24||di--1||no_rel||the title compound, [zni2(c10h8n2s)], contains a six-membered chelate ring adopting a boat conformation in which the zn atom is coordinated by two iodide ions and by the two pyridyl n atoms of a single di-2-pyridyl sulfide ligand within a slightly distorted tetraâ­hedron.
det||stroke-4/NN||some-2/DT	nn||stroke-4/NN||countries-3/NNS	prep_in||cause-11/VBP||stroke-4/NN	nsubj||cause-11/VBP||hypertension-6/NN	conj_and||hypertension-6/NN||diabetes-8/NN	nsubj||cause-11/VBP||diabetes-8/NN	conj_and||hypertension-6/NN||cancers-10/NNS	nsubj||cause-11/VBP||cancers-10/NNS	root||ROOT-0/null||cause-11/VBP	det||number-14/NN||a-12/DT	amod||number-14/NN||greater-13/JJR	dobj||cause-11/VBP||number-14/NN	amod||admissions-18/NNS||adult-16/JJ	amod||admissions-18/NNS||medical-17/JJ	prep_of||number-14/NN||admissions-18/NNS	prep_of||number-14/NN||deaths-20/NNS	conj_and||admissions-18/NNS||deaths-20/NNS	prepc_compared_to||admissions-18/NNS||to-22/TO	amod||diseases-24/NNS||communicable-23/JJ	pobj||admissions-18/NNS||diseases-24/NNS	prep_such_as||diseases-24/NNS||hiv/aids-27/NNS	prep_such_as||diseases-24/NNS||tuberculosis-29/NNP	conj_or||hiv/aids-27/NNS||tuberculosis-29/NNP	aids--1||hiv--1||no||in some countries stroke, hypertension, diabetes and cancers cause a greater number of adult medical admissions and deaths compared to communicable diseases such as hiv/aids or tuberculosis.
amod||rats-4/NNS||forty-two-1/JJ	amod||rats-4/NNS||male-2/JJ	amod||rats-4/NNS||sprague-dawley-3/JJ	nsubjpass||divided-7/VBN||rats-4/NNS	auxpass||divided-7/VBN||were-5/VBD	advmod||divided-7/VBN||equally-6/RB	root||ROOT-0/null||divided-7/VBN	num||groups-10/NNS||six-9/CD	prep_into||divided-7/VBN||groups-10/NNS	nn||i-12/NNS||group-11/NN	dep||groups-10/NNS||i-12/NNS	appos||i-12/NNS||control-14/NN	amod||chow-19/NN||normal-17/JJ	nn||chow-19/NN||rat-18/NN	dep||groups-10/NNS||chow-19/NN	nn||ii-22/NN||group-21/NN	appos||chow-19/NN||ii-22/NN	amod||oil-26/NN||fresh-24/JJ	nn||oil-26/NN||soy-25/NN	dep||groups-10/NNS||oil-26/NN	nn||iii-29/NN||group-28/NN	appos||oil-26/NN||iii-29/NN	nn||oil-32/NN||soy-31/NN	dep||groups-10/NNS||oil-32/NN	amod||oil-32/NN||heated-33/JJ	dep||heated-33/JJ||once-34/RB	nn||iv-37/NN||group-36/NN	appos||once-34/RB||iv-37/NN	nn||oil-40/NN||soy-39/NN	dep||groups-10/NNS||oil-40/NN	amod||twice-42/JJ||heated-41/JJ	amod||oil-40/NN||twice-42/JJ	nn||v-45/NN||group-44/NN	appos||oil-40/NN||v-45/NN	nn||oil-48/NN||soy-47/NN	dep||groups-10/NNS||oil-48/NN	amod||oil-48/NN||heated-49/JJ	num||times-51/NNS||five-50/CD	dep||heated-49/JJ||times-51/NNS	nn||vi-54/NN||group-53/NN	appos||times-51/NNS||vi-54/NN	nn||oil-57/NN||soy-56/NN	dep||groups-10/NNS||oil-57/NN	amod||oil-57/NN||heated-58/JJ	num||times-60/NNS||ten-59/CD	dep||groups-10/NNS||times-60/NNS	oil-57||ten-59||no_rel||forty-two male sprague-dawley rats were equally divided into six groups group i (control) - normal rat chow, group ii - fresh soy oil, group iii - soy oil heated once, group iv - soy oil heated twice, group v - soy oil heated five times, group vi - soy oil heated ten times.
nsubj||antiemeticdrug-6/NN||ondansetronhydrochloride-1/NN	cop||antiemeticdrug-6/NN||is-2/VBZ	det||antiemeticdrug-6/NN||an-3/DT	advmod||bitter-5/JJ||intensely-4/RB	amod||antiemeticdrug-6/NN||bitter-5/JJ	root||ROOT-0/null||antiemeticdrug-6/NN	vmod||antiemeticdrug-6/NN||used-7/VBN	aux||treat-9/VB||to-8/TO	xcomp||used-7/VBN||treat-9/VB	dobj||treat-9/VB||nausea-10/NN	dobj||treat-9/VB||vomiting-12/NN	conj_and||nausea-10/NN||vomiting-12/NN	prep_following||nausea-10/NN||chemotherapy-14/NN	vomiting-12||ondansetronhydrochloride-1||yes||ondansetronhydrochloride is an intensely bitter antiemeticdrug used to treat nausea and vomiting following chemotherapy.
det||study-2/NN||the-1/DT	nsubjpass||undertaken-4/VBN||study-2/NN	nsubj||investigate-6/VB||study-2/NN	auxpass||undertaken-4/VBN||was-3/VBD	root||ROOT-0/null||undertaken-4/VBN	aux||investigate-6/VB||to-5/TO	xcomp||undertaken-4/VBN||investigate-6/VB	det||features-8/NNS||the-7/DT	dobj||investigate-6/VB||features-8/NNS	amod||implications-11/NNS||clinical-10/JJ	dobj||investigate-6/VB||implications-11/NNS	conj_and||features-8/NNS||implications-11/NNS	amod||genotypes-18/NNS||hepatitisb-13/JJ	nn||genotypes-18/NNS||virus-14/NN	appos||genotypes-18/NNS||hbv-16/NN	prep_of||implications-11/NNS||genotypes-18/NNS	amod||promoter-22/NN||basal-20/JJ	nn||promoter-22/NN||core-21/NN	prep_of||implications-11/NNS||promoter-22/NN	conj_and||genotypes-18/NNS||promoter-22/NN	appos||promoter-22/NN||bcp-24/NN	amod||mutations-31/NNS||precore-27/JJ	dep||precore-27/JJ||pc-29/NN	prep_of||implications-11/NNS||mutations-31/NNS	conj_and||genotypes-18/NNS||mutations-31/NNS	amod||liverfailure-35/NN||hepatitisb-related-33/JJ	amod||liverfailure-35/NN||acute-on-chronic-34/JJ	prep_in||investigate-6/VB||liverfailure-35/NN	dep||liverfailure-35/NN||hb-aclf-37/JJ	hepatitisb-13||hepatitisbvirus--1||no||the study was undertaken to investigate the features and clinical implications of hepatitisb virus (hbv) genotypes, basal core promoter (bcp) and precore (pc) mutations in hepatitisb-related acute-on-chronic liverfailure (hb-aclf).
amod||vaccines-3/NNS||replicon-1/JJ	nn||vaccines-3/NNS||particle-2/NN	nsubj||induce-14/VB||vaccines-3/NNS	nsubj||reduce-18/VB||vaccines-3/NNS	nsubj||mitigate-24/VB||vaccines-3/NNS	vmod||vaccines-3/NNS||administered-4/VBN	det||regimen-8/NN||a-6/DT	amod||regimen-8/NN||prime/boost-7/JJ	prep_in||administered-4/VBN||regimen-8/NN	vmod||regimen-8/NN||expressing-9/VBG	amod||glycoprotein-12/NN||bvdv-10/JJ	amod||glycoprotein-12/NN||e2-11/JJ	dobj||expressing-9/VBG||glycoprotein-12/NN	aux||induce-14/VB||can-13/MD	root||ROOT-0/null||induce-14/VB	amod||titers-16/NNS||cross-neutralizing-15/JJ	dobj||induce-14/VB||titers-16/NNS	conj_and||induce-14/VB||reduce-18/VB	amod||challenge-21/NN||leukopenia-19/JJ	nn||challenge-21/NN||post-20/NN	dobj||reduce-18/VB||challenge-21/NN	conj_and||induce-14/VB||mitigate-24/VB	amod||disease-26/NN||clinical-25/JJ	dobj||mitigate-24/VB||disease-26/NN	prep_in||mitigate-24/VB||calves-28/NNS	cross--1||vaccines-3||no_rel||replicon particle vaccines administered in a prime/boost regimen expressing bvdv e2 glycoprotein can induce cross-neutralizing titers, reduce leukopenia post challenge, and mitigate clinical disease in calves.
amod||anti-inflammatorydrugs-2/NNS||non-steroidal-1/JJ	nsubj||drugs-8/NNS||anti-inflammatorydrugs-2/NNS	cop||drugs-8/NNS||are-3/VBP	det||drugs-8/NNS||the-4/DT	advmod||prescribed-7/JJ||most-5/RBS	advmod||prescribed-7/JJ||commonly-6/RB	amod||drugs-8/NNS||prescribed-7/JJ	root||ROOT-0/null||drugs-8/NNS	prep_for||drugs-8/NNS||arthritis-10/NN	prep_for||drugs-8/NNS||inflammation-12/NN	conj_and||arthritis-10/NN||inflammation-12/NN	amod||protection-16/NN||cardiovascular-15/JJ	prep_for||drugs-8/NNS||protection-16/NN	conj_and||arthritis-10/NN||protection-16/NN	anti-inflammatorydrugs-2||inflammation-12||no_rel||non-steroidal anti-inflammatorydrugs are the most commonly prescribed drugs for arthritis, inflammation, and cardiovascular protection.
nn||guidelines-3/NNS||osteoporosis-1/NN	nn||guidelines-3/NNS||treatment-2/NN	nsubj||recommend-4/VBP||guidelines-3/NNS	ccomp||unsatisfactory-25/JJ||recommend-4/VBP	nn||supplementation-8/NN||calcium-5/NN	conj_and||calcium-5/NN||vitamind-7/NN	nn||supplementation-8/NN||vitamind-7/NN	dobj||recommend-4/VBP||supplementation-8/NN	det||prevention-11/NN||both-10/DT	prep_for||recommend-4/VBP||prevention-11/NN	prep_for||recommend-4/VBP||treatment-15/NN	conj_and||prevention-11/NN||treatment-15/NN	advmod||recommend-4/VBP||however-17/RB	nsubj||unsatisfactory-25/JJ||compliance-19/NN	det||guidelines-22/NNS||these-21/DT	prep_with||compliance-19/NN||guidelines-22/NNS	cop||unsatisfactory-25/JJ||is-23/VBZ	advmod||unsatisfactory-25/JJ||often-24/RB	root||ROOT-0/null||unsatisfactory-25/JJ	osteoporosis-1||vitamind-7||yes||osteoporosis treatment guidelines recommend calcium and vitamind supplementation for both prevention as well as treatment, however, compliance with these guidelines is often unsatisfactory.
advmod||observed-18/VBN||when-1/WRB	amod||renalfailure-3/NN||rapid-2/JJ	nsubjpass||observed-18/VBN||renalfailure-3/NN	conj_or||renalfailure-3/NN||rpgn-5/NN	nsubjpass||observed-18/VBN||rpgn-5/NN	amod||sediments-9/NNS||active-7/JJ	nn||sediments-9/NNS||urine-8/NN	prep_with||renalfailure-3/NN||sediments-9/NNS	amod||manifestations-16/NNS||pulmonary-11/JJ	amod||manifestations-16/NNS||hemorrhage-12/JJ	amod||manifestations-16/NNS||and/or-13/JJ	amod||manifestations-16/NNS||systemic-14/JJ	amod||manifestations-16/NNS||inflammatory-15/JJ	appos||sediments-9/NNS||manifestations-16/NNS	auxpass||observed-18/VBN||are-17/VBP	advcl||considered-34/VBN||observed-18/VBN	prep_in||observed-18/VBN||patients-20/NNS	prep_with||patients-20/NNS||ssc-22/NN	xcomp||observed-18/VBN||having-23/VBG	amod||anca-25/NN||positive-24/JJ	dobj||having-23/VBG||anca-25/NN	det||possibility-28/NN||the-27/DT	nsubjpass||considered-34/VBN||possibility-28/NN	prep_of||possibility-28/NN||mpa-30/NN	aux||considered-34/VBN||should-31/MD	advmod||considered-34/VBN||always-32/RB	auxpass||considered-34/VBN||be-33/VB	root||ROOT-0/null||considered-34/VBN	hemorrhage-12||mpa-30||no||when rapid renalfailure or rpgn with active urine sediments, pulmonary hemorrhage and/or systemic inflammatory manifestations are observed in patients with ssc having positive anca, the possibility of mpa should always be considered.
amod||outcome-2/NN||main-1/JJ	nsubj||measures-3/VBZ||outcome-2/NN	root||ROOT-0/null||measures-3/VBZ	dobj||measures-3/VBZ||risk-4/NN	amod||variable-36/NN||coronaryheartdisease-6/JJ	prep||coronaryheartdisease-6/JJ||in-7/IN	dep||in-7/IN||treated-8/VBN	dep||in-7/IN||â-10/VBN	conj_and||treated-8/VBN||â-10/VBN	amod||patients-21/NNS||$-11/$	number||$-13/CD||untreatedâ-12/CD	num||$-11/$||$-13/CD	dep||$-11/$||delay-15/NN	amod||treatment-19/NN||starting-17/JJ	nn||treatment-19/NN||statin-18/NN	prep_in||delay-15/NN||treatment-19/NN	dobj||treated-8/VBN||patients-21/NNS	prepc_compared_with||treated-8/VBN||with-23/IN	det||model-27/NN||a-24/DT	nn||model-27/NN||cox-25/NN	nn||model-27/NN||regression-26/NN	pobj||treated-8/VBN||model-27/NN	prep_in||time-34/NN||model-27/NN	nn||use-31/NN||statin-30/NN	nsubj||time-34/NN||use-31/NN	cop||time-34/NN||was-32/VBD	det||time-34/NN||a-33/DT	rcmod||model-27/NN||time-34/NN	amod||variable-36/NN||dependent-35/JJ	prep_of||risk-4/NN||variable-36/NN	coronaryheartdisease-6||statin-30||no_rel||main outcome measures risk of coronaryheartdisease in treated and âuntreatedâ? (delay in starting statin treatment) patients compared with a cox regression model in which statin use was a time dependent variable.
nsubj||agent-10/NN||denguevirus-1/NNS	det||flavivirus-5/NNS||a-3/DT	amod||flavivirus-5/NNS||mosquito-borne-4/JJ	appos||denguevirus-1/NNS||flavivirus-5/NNS	cop||agent-10/NN||is-7/VBZ	det||agent-10/NN||the-8/DT	amod||agent-10/NN||etiological-9/JJ	root||ROOT-0/null||agent-10/NN	prep_of||agent-10/NN||denguefever-12/NN	prep_of||agent-10/NN||denguehemorrhagicfever-14/NN	conj_and||denguefever-12/NN||denguehemorrhagicfever-14/NN	prep_of||agent-10/NN||dengueshocksyndrome-17/NN	conj_and||denguefever-12/NN||dengueshocksyndrome-17/NN	denguehemorrhagicfever-14||denguevirus-1||no||denguevirus, a mosquito-borne flavivirus, is the etiological agent of denguefever, denguehemorrhagicfever, and dengueshocksyndrome.
nn||sizes-2/NNS||effect-1/NN	nsubjpass||analyzed-29/VBN||sizes-2/NNS	nn||thresholds-5/NNS||pain-4/NN	prep_on||sizes-2/NNS||thresholds-5/NNS	prep_to||thresholds-5/NNS||stimuli-7/NNS	vmod||stimuli-7/NNS||consisting-8/VBG	prep_of||consisting-8/VBG||heat-10/NN	amod||pressure-15/NN||cold-12/JJ	amod||pressure-15/NN||blunt-14/JJ	prep_of||consisting-8/VBG||pressure-15/NN	conj_and||heat-10/NN||pressure-15/NN	amod||pressure-18/NN||punctuate-17/JJ	prep_of||consisting-8/VBG||pressure-18/NN	conj_and||heat-10/NN||pressure-18/NN	amod||current-21/NN||electrical-20/JJ	prep_of||consisting-8/VBG||current-21/NN	conj_and||heat-10/NN||current-21/NN	vmod||sizes-2/NNS||administered-23/VBN	num||subjects-26/NNS||125-25/CD	prep_to||administered-23/VBN||subjects-26/NNS	auxpass||analyzed-29/VBN||were-28/VBD	root||ROOT-0/null||analyzed-29/VBN	num||variants-33/NNS||29-31/CD	amod||variants-33/NNS||common-32/JJ	nsubj||modulating-39/VBG||variants-33/NNS	num||genes-37/NNS||eight-35/CD	amod||genes-37/NNS||human-36/JJ	prep_in||variants-33/NNS||genes-37/NNS	advmod||modulating-39/VBG||reportedly-38/RB	prepc_for||analyzed-29/VBN||modulating-39/VBG	nn||procedures-45/NNS||pain-40/NN	conj_and||pain-40/NN||gender-42/NN	nn||procedures-45/NNS||gender-42/NN	conj_and||pain-40/NN||sensitization-44/NN	nn||procedures-45/NNS||sensitization-44/NN	dobj||modulating-39/VBG||procedures-45/NNS	vmod||modulating-39/VBG||using-46/VBG	dobj||using-46/VBG||capsaicin-47/NN	dobj||using-46/VBG||menthol-49/NN	conj_or||capsaicin-47/NN||menthol-49/NN	pain-40||menthol-49||yes||effect sizes on pain thresholds to stimuli consisting of heat, cold, blunt pressure, punctuate pressure and electrical current, administered to 125 subjects, were analyzed for 29 common variants in eight human genes reportedly modulating pain, gender and sensitization procedures using capsaicin or menthol.
det||effect-3/NN||the-1/DT	amod||effect-3/NN||adverse-2/JJ	nsubjpass||considered-19/VBN||effect-3/NN	amod||stress-8/NN||thermal-5/JJ	conj_and||thermal-5/JJ||oxidative-7/JJ	amod||stress-8/NN||oxidative-7/JJ	prep_of||effect-3/NN||stress-8/NN	vmod||considered-19/VBN||enhancing-10/VBG	det||release-12/NN||the-11/DT	dobj||enhancing-10/VBG||release-12/NN	amod||exosomes-15/NNS||immunosuppressive-14/JJ	prep_of||release-12/NN||exosomes-15/NNS	aux||considered-19/VBN||should-17/MD	auxpass||considered-19/VBN||be-18/VB	root||ROOT-0/null||considered-19/VBN	advmod||designed-27/VBN||when-20/WRB	amod||therapies-25/NNS||cytostatic-21/JJ	conj_and||cytostatic-21/JJ||hyperthermal-23/JJ	amod||therapies-25/NNS||hyperthermal-23/JJ	amod||therapies-25/NNS||anti-cancer-24/JJ	nsubjpass||designed-27/VBN||therapies-25/NNS	auxpass||designed-27/VBN||are-26/VBP	advcl||considered-19/VBN||designed-27/VBN	immunosuppressive-14||cancer--1||no_rel||the adverse effect of thermal and oxidative stress, enhancing the release of immunosuppressive exosomes, should be considered when cytostatic and hyperthermal anti-cancer therapies are designed.
nsubjpass||measured-19/VBN||markers-1/NNS	nn||control-4/NN||glucose-3/NN	prep_of||markers-1/NNS||control-4/NN	amod||test-10/NN||oral-7/JJ	nn||test-10/NN||glucose-8/NN	nn||test-10/NN||tolerance-9/NN	prep_including||markers-1/NNS||test-10/NN	amod||hemoglobin-13/NN||glycated-12/JJ	prep_including||markers-1/NNS||hemoglobin-13/NN	conj_and||test-10/NN||hemoglobin-13/NN	amod||glucose-16/NN||urinary-15/JJ	prep_including||markers-1/NNS||glucose-16/NN	conj_and||test-10/NN||glucose-16/NN	auxpass||measured-19/VBN||were-18/VBD	root||ROOT-0/null||measured-19/VBN	dobj||measured-19/VBN||adiposity-23/NN	det||accumulation-26/NN||the-25/DT	dobj||measured-19/VBN||accumulation-26/NN	conj_and||adiposity-23/NN||accumulation-26/NN	nn||lipids-29/NNS||liver-28/NN	prep_of||accumulation-26/NN||lipids-29/NNS	adiposity-23||glucose-16||no_rel||markers of glucose control, including oral glucose tolerance test, glycated hemoglobin and urinary glucose, were measured as well as adiposity and the accumulation of liver lipids.
mark||indicated-8/VBN||while-1/IN	nn||studies-6/NNS||human-2/NN	conj_and||human-2/NN||animal-4/NN	nn||studies-6/NNS||animal-4/NN	nn||studies-6/NNS||model-5/NN	nsubj||indicated-8/VBN||studies-6/NNS	aux||indicated-8/VBN||have-7/VBP	advcl||shown-29/VBN||indicated-8/VBN	det||role-11/NN||a-9/DT	amod||role-11/NN||protective-10/JJ	dobj||indicated-8/VBN||role-11/NN	prep_for||role-11/NN||estrogen-13/NN	prep_against||indicated-8/VBN||cardiovasculardisease-15/NN	prep_against||indicated-8/VBN||glomerulosclerosis-17/NNS	conj_and||cardiovasculardisease-15/NN||glomerulosclerosis-17/NNS	amod||studies-20/NNS||clinical-19/JJ	nsubj||shown-29/VBN||studies-20/NNS	nn||therapy-24/NN||hormone-22/NN	nn||therapy-24/NN||replacement-23/NN	prep_of||studies-20/NNS||therapy-24/NN	amod||women-27/NNS||postmenopausal-26/JJ	prep_in||therapy-24/NN||women-27/NNS	aux||shown-29/VBN||have-28/VBP	root||ROOT-0/null||shown-29/VBN	amod||results-31/NNS||polar-30/JJ	dobj||shown-29/VBN||results-31/NNS	det||improvement-34/NN||some-33/DT	prep_with||shown-29/VBN||improvement-34/NN	prep_in||improvement-34/NN||hypertension-36/NN	prep_with||shown-29/VBN||worsening-38/VBG	conj_but||improvement-34/NN||worsening-38/VBG	amod||kidneydisease-41/NN||hypertensive-40/JJ	prep_of||worsening-38/VBG||kidneydisease-41/NN	neg||effect-45/NN||no-44/DT	prep_with||shown-29/VBN||effect-45/NN	conj_or||improvement-34/NN||effect-45/NN	prep_at||effect-45/NN||all-47/DT	cardiovasculardisease-15||hormone-22||no_rel||while human and animal model studies have indicated a protective role for estrogen against cardiovasculardisease and glomerulosclerosis, clinical studies of hormone replacement therapy in postmenopausal women have shown polar results with some improvement in hypertension but worsening of hypertensive kidneydisease, or no effect at all.
mark||binding-3/JJ||upon-1/IN	dep||binding-3/JJ||hormone-2/NN	advcl||associates-7/VBZ||binding-3/JJ	det||ar-6/NN||the-5/DT	nsubj||associates-7/VBZ||ar-6/NN	root||ROOT-0/null||associates-7/VBZ	amod||proteins-11/NNS||numerous-9/JJ	amod||proteins-11/NNS||co-regulator-10/JJ	prep_with||associates-7/VBZ||proteins-11/NNS	nsubj||regulate-13/VB||proteins-11/NNS	rcmod||proteins-11/NNS||regulate-13/VB	det||status-16/NN||the-14/DT	nn||status-16/NN||activation-15/NN	dobj||regulate-13/VB||status-16/NN	nn||genes-19/NNS||target-18/NN	prep_of||status-16/NN||genes-19/NNS	prep_via||genes-19/NNS||flux-21/NN	det||status-26/NN||the-23/DT	amod||status-26/NN||post-translational-24/JJ	nn||status-26/NN||modification-25/NN	prep_to||regulate-13/VB||status-26/NN	prep_of||status-26/NN||histones-28/NNS	det||receptor-31/NN||the-30/DT	prep_of||status-26/NN||receptor-31/NN	conj_and||histones-28/NNS||receptor-31/NN	ar-6||hormone-2||no_rel||upon hormone binding, the ar associates with numerous co-regulator proteins that regulate the activation status of target genes via flux to the post-translational modification status of histones and the receptor.
amod||rate-2/NN||goitre-1/JJ	nsubjpass||measured-37/VBN||rate-2/NN	nsubjpass||compared-39/VBN||rate-2/NN	nn||hormone-6/NN||serum-4/NN	amod||hormone-6/NN||thyroid-stimulating-5/JJ	appos||rate-2/NN||hormone-6/NN	appos||hormone-6/NN||tsh-8/NN	appos||rate-2/NN||thyroxine-11/NN	conj_and||hormone-6/NN||thyroxine-11/NN	appos||thyroxine-11/NN||t4-13/NNP	nn||antibody-18/NN||thyroid-16/NN	nn||antibody-18/NN||peroxidase-17/NN	appos||rate-2/NN||antibody-18/NN	conj_and||hormone-6/NN||antibody-18/NN	appos||antibody-18/NN||tpoab-20/NN	nn||antibody-24/NN||thyroglobulin-23/NN	appos||rate-2/NN||antibody-24/NN	conj_and||hormone-6/NN||antibody-24/NN	appos||antibody-24/NN||tgab-26/NN	advmod||iodine-31/JJ||urinary-30/RB	amod||concentration-32/NN||iodine-31/JJ	appos||rate-2/NN||concentration-32/NN	conj_and||hormone-6/NN||concentration-32/NN	appos||concentration-32/NN||uic-34/NN	auxpass||measured-37/VBN||were-36/VBD	root||ROOT-0/null||measured-37/VBN	conj_and||measured-37/VBN||compared-39/VBN	det||goitrous-42/NNS||the-41/DT	prep_between||measured-37/VBN||goitrous-42/NNS	dep||goitrous-42/NNS||n-44/VBN	dep||478-46/CD||=-45/SYM	ccomp||n-44/VBN||478-46/CD	det||participants-56/NNS||the-49/DT	amod||participants-56/NNS||non-goitrous-50/JJ	dep||non-goitrous-50/JJ||n-52/VBN	dep||2,045-54/CD||=-53/SYM	ccomp||n-52/VBN||2,045-54/CD	prep_between||measured-37/VBN||participants-56/NNS	conj_and||goitrous-42/NNS||participants-56/NNS	goitre-1||thyroxine-11||yes||goitre rate, serum thyroid-stimulating hormone (tsh), thyroxine (t4), thyroid peroxidase antibody (tpoab), thyroglobulin antibody (tgab), and urinary iodine concentration (uic) were measured and compared between the goitrous (n=478) and the non-goitrous (n=2,045) participants.
det||epidemic-2/NN||the-1/DT	nsubjpass||caused-9/VBN||epidemic-2/NN	prep_of||epidemic-2/NN||severeacuterespiratorysyndrome-4/NN	appos||epidemic-2/NN||sars-6/NNS	auxpass||caused-9/VBN||was-8/VBD	root||ROOT-0/null||caused-9/VBN	det||coronavirus-14/NNS||a-11/DT	advmod||emerged-13/JJ||newly-12/RB	amod||coronavirus-14/NNS||emerged-13/JJ	agent||caused-9/VBN||coronavirus-14/NNS	appos||coronavirus-14/NNS||sars-cov-16/NNP	severeacuterespiratorysyndrome-4||sars-cov-16||no||the epidemic of severeacuterespiratorysyndrome (sars) was caused by a newly emerged coronavirus (sars-cov).
nsubj||way-21/NN||treatment-1/NN	det||combination-4/NN||a-3/DT	prep_with||treatment-1/NN||combination-4/NN	num||metoclopramide-8/NN||20-6/CD	nn||metoclopramide-8/NN||mg-7/NN	prep_of||combination-4/NN||metoclopramide-8/NN	num||dexamethasone-12/NN||5-10/CD	nn||dexamethasone-12/NN||mg-11/NN	prep_of||combination-4/NN||dexamethasone-12/NN	conj_and||metoclopramide-8/NN||dexamethasone-12/NN	cop||way-21/NN||is-13/VBZ	det||way-21/NN||an-14/DT	amod||way-21/NN||effective-15/JJ	conj_and||effective-15/JJ||safe-17/JJ	amod||way-21/NN||safe-17/JJ	conj_and||effective-15/JJ||inexpensive-20/JJ	amod||way-21/NN||inexpensive-20/JJ	root||ROOT-0/null||way-21/NN	aux||prevent-23/VB||to-22/TO	vmod||way-21/NN||prevent-23/VB	dobj||prevent-23/VB||ponv-24/NNP	dep||ponv-24/NNP||when-25/WRB	prepc_compared_to||prevent-23/VB||to-27/TO	pobj||prevent-23/VB||treatment-28/NN	num||ondansetron-32/NN||4-30/CD	nn||ondansetron-32/NN||mg-31/NN	prep_with||treatment-28/NN||ondansetron-32/NN	num||dexamethasone-36/NN||5-34/CD	nn||dexamethasone-36/NN||mg-35/NN	prep_with||treatment-28/NN||dexamethasone-36/NN	conj_and||ondansetron-32/NN||dexamethasone-36/NN	ponv-24||metoclopramide-8||yes||treatment with a combination of 20 mg metoclopramide and 5 mg dexamethasone is an effective, safe, and inexpensive way to prevent ponv when compared to treatment with 4 mg ondansetron and 5 mg dexamethasone.
mark||drug-7/NN||since-1/IN	nsubj||drug-7/NN||pyrazinamide-2/NN	cop||drug-7/NN||is-3/VBZ	det||drug-7/NN||a-4/DT	advmod||used-6/VBN||commonly-5/RB	amod||drug-7/NN||used-6/VBN	advcl||predict-28/VB||drug-7/NN	prep_in||drug-7/NN||tuberculosis-9/NNP	nsubj||disease-16/NN||which-11/WDT	cop||disease-16/NN||is-12/VBZ	det||disease-16/NN||a-13/DT	amod||disease-16/NN||common-14/JJ	amod||disease-16/NN||infectious-15/JJ	conj_and||drug-7/NN||disease-16/NN	advcl||predict-28/VB||disease-16/NN	amod||countries-19/NNS||developing-18/VBG	prep_in||disease-16/NN||countries-19/NNS	det||reports-24/NNS||the-22/DT	amod||reports-24/NNS||similar-23/JJ	prep_with||predict-28/VB||reports-24/NNS	nsubj||predict-28/VB||we-26/PRP	nsubj||prevent-34/VB||we-26/PRP	aux||predict-28/VB||can-27/MD	root||ROOT-0/null||predict-28/VB	amod||detection-31/NN||early-29/JJ	nn||detection-31/NN||case-30/NN	dobj||predict-28/VB||detection-31/NN	aux||prevent-34/VB||can-33/MD	conj_and||predict-28/VB||prevent-34/VB	det||occurrence-36/NN||the-35/DT	dobj||prevent-34/VB||occurrence-36/NN	amod||reactions-39/NNS||similar-38/JJ	prep_of||occurrence-36/NN||reactions-39/NNS	prep_in||prevent-34/VB||future-41/NN	tuberculosis-9||pyrazinamide-2||yes||since pyrazinamide is a commonly used drug in tuberculosis and which is a common infectious disease in developing countries, with the similar reports, we can predict early case detection and can prevent the occurrence of similar reactions in future.
nsubj||showed-5/VBD||smokers-1/NNS	vmod||smokers-1/NNS||treated-2/VBN	prep_with||treated-2/VBN||budesonide/formoterol-4/NN	root||ROOT-0/null||showed-5/VBD	det||increase-7/NN||an-6/DT	dobj||showed-5/VBD||increase-7/NN	det||number-10/NN||the-9/DT	prep_in||showed-5/VBD||number-10/NN	nn||episodes-13/NNS||asthma-12/NN	prep_of||number-10/NN||episodes-13/NNS	parataxis||showed-5/VBD||intercurrent-15/VB	nn||symptoms-17/NNS||asthma-16/NN	dobj||intercurrent-15/VB||symptoms-17/NNS	vmod||symptoms-17/NNS||p-19/VBN	dep||0.016-21/CD||=-20/SYM	ccomp||p-19/VBN||0.016-21/CD	mark||had-26/VBD||while-23/IN	amod||subjects-25/NNS||non-smoking-24/JJ	nsubj||had-26/VBD||subjects-25/NNS	advcl||showed-5/VBD||had-26/VBD	det||decrease-29/NN||a-27/DT	amod||decrease-29/NN||significant-28/JJ	dobj||had-26/VBD||decrease-29/NN	det||episodes-32/NNS||these-31/DT	prep_in||decrease-29/NN||episodes-32/NNS	dep||episodes-32/NNS||p-34/VBN	dep||0.009-36/CD||=-35/SYM	ccomp||p-34/VBN||0.009-36/CD	asthma-16||formoterol--1||yes||smokers treated with budesonide/formoterol showed an increase in the number of asthma episodes (intercurrent asthma symptoms, p=0.016) while non-smoking subjects had a significant decrease in these episodes (p=0.009).
det||data-3/NNS||these-2/DT	prep_from||derived-19/VBN||data-3/NNS	amod||indices-6/NNS||common-5/JJ	nsubjpass||derived-19/VBN||indices-6/NNS	amod||glycaemia-9/NN||postprandial-8/JJ	prep_of||indices-6/NNS||glycaemia-9/NN	amod||hyperglycaemia-12/NN||overall-11/JJ	prep_of||indices-6/NNS||hyperglycaemia-12/NN	conj_and||glycaemia-9/NN||hyperglycaemia-12/NN	nn||variability-15/NN||glucose-14/NN	prep_of||indices-6/NNS||variability-15/NN	conj_and||glycaemia-9/NN||variability-15/NN	prep_of||indices-6/NNS||hba1c-17/NNS	conj_and||glycaemia-9/NN||hba1c-17/NNS	auxpass||derived-19/VBN||were-18/VBD	root||ROOT-0/null||derived-19/VBN	hyperglycaemia-12||glucose-14||no||from these data, common indices of postprandial glycaemia, overall hyperglycaemia, glucose variability and hba1c were derived.
amod||abnormalities-2/NNS||g1/s-1/JJ	nsubj||crucial-4/JJ||abnormalities-2/NNS	cop||crucial-4/JJ||are-3/VBP	root||ROOT-0/null||crucial-4/JJ	det||progression-7/NN||the-6/DT	prep_for||crucial-4/JJ||progression-7/NN	prep_of||progression-7/NN||malignantmelanoma-9/NN	amod||d1-14/NNS||enhanced-12/JJ	nn||d1-14/NNS||cyclin-13/NN	nsubjpass||observed-24/VBN||d1-14/NNS	amod||expression-17/NN||d3-16/JJ	conj_and||d1-14/NNS||expression-17/NN	nsubjpass||observed-24/VBN||expression-17/NN	amod||expression-17/NN||leading-18/VBG	amod||proliferation-22/NN||increased-20/VBN	nn||proliferation-22/NN||melanocyte-21/NN	prep_to||d1-14/NNS||proliferation-22/NN	auxpass||observed-24/VBN||is-23/VBZ	conj_and||crucial-4/JJ||observed-24/VBN	det||melanoma-27/NN||both-26/DT	prep_in||observed-24/VBN||melanoma-27/NN	amod||nevi-30/NNS||dysplastic-29/JJ	prep_in||observed-24/VBN||nevi-30/NNS	conj_and||melanoma-27/NN||nevi-30/NNS	melanoma-27||d3-16||no_rel||g1/s abnormalities are crucial for the progression of malignantmelanoma, and enhanced cyclin d1 and d3 expression leading to increased melanocyte proliferation is observed in both melanoma and dysplastic nevi.
amod||tuberculosis-2/NNS||multidrug-resistant-1/JJ	nsubj||problem-18/NN||tuberculosis-2/NNS	appos||tuberculosis-2/NNS||mdr-tb-4/NNP	appos||tuberculosis-2/NNS||resistance-7/NN	aux||isoniazid-11/VB||to-8/TO	advmod||isoniazid-11/VB||at-9/IN	pobj||at-9/IN||least-10/JJS	vmod||resistance-7/NN||isoniazid-11/VB	vmod||resistance-7/NN||rifampin-13/VB	conj_and||isoniazid-11/VB||rifampin-13/VB	cop||problem-18/NN||is-15/VBZ	det||problem-18/NN||a-16/DT	amod||problem-18/NN||worldwide-17/JJ	root||ROOT-0/null||problem-18/NN	tb--1||isoniazid-11||yes||multidrug-resistant tuberculosis (mdr-tb), resistance to at least isoniazid and rifampin, is a worldwide problem.
det||sample-6/NN||any-1/DT	amod||sample-6/NN||patient-2/JJ	prep_with||patient-2/JJ||one-4/CD	nn||sample-6/NN||blood-5/NN	nsubj||received-15/VBD||sample-6/NN	vmod||sample-6/NN||containing-7/VBG	quantmod||than-9/IN||more-8/JJR	num||genomes-12/NNS||than-9/IN	num||cytomegalovirus-11/NNS||3000-10/CD	dep||than-9/IN||cytomegalovirus-11/NNS	dobj||containing-7/VBG||genomes-12/NNS	prep_per||genomes-12/NNS||ml-14/NN	root||ROOT-0/null||received-15/VBD	dobj||received-15/VBD||ganciclovir-16/NN	num||measurements-23/NNS||two-18/CD	amod||measurements-23/NNS||consecutive-19/JJ	amod||measurements-23/NNS||undetectable-20/JJ	nn||measurements-23/NNS||cytomegalovirus-21/NN	nn||measurements-23/NNS||dna-22/NN	prep_until||received-15/VBD||measurements-23/NNS	cytomegalovirus-21||ganciclovir-16||yes||any patient with one blood sample containing more than 3000 cytomegalovirus genomes per ml received ganciclovir until two consecutive undetectable cytomegalovirus dna measurements.
nsubj||determined-2/VBD||we-1/PRP	root||ROOT-0/null||determined-2/VBD	det||lineages-5/NNS||the-3/DT	amod||lineages-5/NNS||phylogenetic-4/JJ	nsubj||isolates-8/VBZ||lineages-5/NNS	prep_of||lineages-5/NNS||m.tuberculosis-7/NNS	ccomp||determined-2/VBD||isolates-8/VBZ	prep_from||isolates-8/VBZ||participants-10/NNS	dep||participants-10/NNS||enrolled-11/VBN	det||study-17/NN||the-13/DT	nn||study-17/NN||tuberculosis-14/NNP	nn||study-17/NN||trials-15/NNS	nn||study-17/NN||consortium-16/NN	prep_in||enrolled-11/VBN||study-17/NN	dobj||enrolled-11/VBN||28-18/CD	dep||participants-10/NNS||conducted-20/VBN	conj_and||enrolled-11/VBN||conducted-20/VBN	amod||africa-27/NN||brazil-22/JJ	dep||africa-27/NN||canada-24/NN	amod||africa-27/NN||south-26/JJ	prep_in||conducted-20/VBN||africa-27/NN	prep_in||conducted-20/VBN||spain-29/NN	conj_and||africa-27/NN||spain-29/NN	prep_in||conducted-20/VBN||uganda-31/NN	conj_and||africa-27/NN||uganda-31/NN	det||states-35/NNS||the-33/DT	amod||states-35/NNS||united-34/VBN	prep_in||conducted-20/VBN||states-35/NNS	conj_and||africa-27/NN||states-35/NNS	advmod||explored-39/VBD||secondarily-38/RB	dep||participants-10/NNS||explored-39/VBD	conj_and||enrolled-11/VBN||explored-39/VBD	det||relationship-41/NN||the-40/DT	dobj||explored-39/VBD||relationship-41/NN	amod||presentation-46/NN||lineage-43/JJ	prep_between||relationship-41/NN||clinical-45/JJ	amod||presentation-46/NN||clinical-45/JJ	conj_and||presentation-46/NN||clinical-45/JJ	prep_between||relationship-41/NN||presentation-46/NN	prep_between||relationship-41/NN||response-48/NN	conj_and||presentation-46/NN||response-48/NN	prep_to||explored-39/VBD||treatment-50/NN	tuberculosis-14||m.tuberculosis-7||no||we determined the phylogenetic lineages of m.tuberculosis isolates from participants enrolled in the tuberculosis trials consortium study 28 , conducted in brazil , canada , south africa , spain , uganda and the united states , and secondarily explored the relationship between lineage , clinical presentation and response to treatment .
amod||nd-3/NN||newcastledisease-1/JJ	nsubj||disease-18/NN||nd-3/NN	vmod||nd-3/NN||caused-5/VBN	amod||virus-9/NN||virulent-7/JJ	nn||virus-9/NN||newcastledisease-8/NN	agent||caused-5/VBN||virus-9/NN	appos||nd-3/NN||ndv-11/NN	cop||disease-18/NN||is-13/VBZ	det||disease-18/NN||a-14/DT	advmod||contagious-16/JJ||highly-15/RB	amod||disease-18/NN||contagious-16/JJ	amod||disease-18/NN||viral-17/JJ	root||ROOT-0/null||disease-18/NN	prep_of||disease-18/NN||poultry-20/NN	newcastledisease-8||newcastlediseasevirus--1||no||newcastledisease (nd) caused by virulent newcastledisease virus (ndv) is a highly contagious viral disease of poultry.
det||study-3/NN||this-2/DT	prep_in||used-5/VBD||study-3/NN	nsubj||used-5/VBD||we-4/PRP	root||ROOT-0/null||used-5/VBD	dobj||used-5/VBD||fludarabine-6/NN	prep||used-5/VBD||combined-7/VBN	pcomp||combined-7/VBN||with-8/IN	det||dose-11/NN||a-9/DT	amod||dose-11/NN||middle-10/JJ	pobj||with-8/IN||dose-11/NN	amod||arabinoside-14/NN||cytosine-13/JJ	prep_of||dose-11/NN||arabinoside-14/NN	dep||arabinoside-14/NN||ara-c-16/JJ	amod||arabinoside-14/NN||mitoxantrone-19/JJ	amod||arabinoside-14/NN||granulocyte-colonystimulatingfactor-21/JJ	conj_and||mitoxantrone-19/JJ||granulocyte-colonystimulatingfactor-21/JJ	dep||mitoxantrone-19/JJ||g-csf-23/JJ	det||therapy-28/NN||a-26/DT	nn||therapy-28/NN||salvage-27/NN	prep_as||arabinoside-14/NN||therapy-28/NN	prep_for||therapy-28/NN||patients-30/NNS	amod||aml-33/NN||relapsed-32/JJ	prep_with||patients-30/NNS||aml-33/NN	prep_in||aml-33/NN||china-35/NN	aml-33||mitoxantrone-19||yes||in this study we used fludarabine combined with a middle dose of cytosine arabinoside (ara-c), mitoxantrone and granulocyte-colonystimulatingfactor (g-csf) as a salvage therapy for patients with relapsed aml in china.
det||male-4/NN||a-1/DT	num||male-4/NN||27-2/CD	nn||male-4/NN||yo-3/NN	nsubj||received-8/VBD||male-4/NN	nn||origin-7/NN||african-6/NN	prep_of||male-4/NN||origin-7/NN	root||ROOT-0/null||received-8/VBD	dobj||received-8/VBD||telbivudine-9/NN	prep_for||received-8/VBD||hepatitisb-11/NN	num||months-14/NNS||3-13/CD	prep_during||received-8/VBD||months-14/NNS	hepatitisb-11||telbivudine-9||yes||a 27 yo male of african origin received telbivudine for hepatitisb during 3 months.
det||prionprotein-3/NN||a-1/DT	amod||prionprotein-3/NN||normal-2/JJ	nsubjpass||converted-8/VBN||prionprotein-3/NN	dep||prionprotein-3/NN||prpc-5/JJ	auxpass||converted-8/VBN||is-7/VBZ	root||ROOT-0/null||converted-8/VBN	det||isoform-12/NN||a-10/DT	amod||isoform-12/NN||protease-resistant-11/JJ	prep_to||converted-8/VBN||isoform-12/NN	det||activity-17/NN||an-14/DT	amod||activity-17/NN||apparent-15/JJ	amod||activity-17/NN||self-propagating-16/JJ	agent||converted-8/VBN||activity-17/NN	prep_in||activity-17/NN||transmissiblespongiformencephalopathy-19/NN	det||disease-23/NN||a-21/DT	amod||disease-23/NN||neurodegenerative-22/JJ	appos||transmissiblespongiformencephalopathy-19/NN||disease-23/NN	transmissiblespongiformencephalopathy-19||prionprotein-3||no||a normal prionprotein (prpc) is converted to a protease-resistant isoform by an apparent self-propagating activity in transmissiblespongiformencephalopathy, a neurodegenerative disease.
nn||scores-2/NNS||nausea-1/NN	nsubj||severe-12/JJ||scores-2/NNS	nsubj||similar-14/JJ||scores-2/NNS	prep_at||scores-2/NNS||baseline-4/NN	conj_and||scores-2/NNS||0â-6/NNS	nsubj||severe-12/JJ||0â-6/NNS	num||minutes-10/NNS||$-7/$	num||$-7/$||30-9/CD	dep||0â-6/NNS||minutes-10/NNS	cop||severe-12/JJ||were-11/VBD	root||ROOT-0/null||severe-12/JJ	conj_and||severe-12/JJ||similar-14/JJ	prep_between||severe-12/JJ||groups-16/NNS	advmod||had-35/VBD||however-18/RB	amod||$-22/$||31â-21/JJ	prep_at||had-35/VBD||$-22/$	num||$-22/$||60-24/CD	conj_and||$-22/$||61â-26/NNS	prep_at||had-35/VBD||61â-26/NNS	num||minutes-30/NNS||$-27/$	num||$-27/$||120-29/CD	dep||61â-26/NNS||minutes-30/NNS	nsubj||had-35/VBD||patients-32/NNS	vmod||patients-32/NNS||receiving-33/VBG	dobj||receiving-33/VBG||prochlorperazine-34/NN	parataxis||severe-12/JJ||had-35/VBD	amod||control-37/NN||better-36/JJR	dobj||had-35/VBD||control-37/NN	nn||=-47/FW||nausea-39/FW	nn||=-47/FW||-lrb--40/FW	nn||=-47/FW||24.9-41/FW	nn||=-47/FW||vs.-42/FW	nn||=-47/FW||43.7-43/FW	nn||=-47/FW||mm-44/FW	dep||=-47/FW||p-46/FW	prep_of||control-37/NN||=-47/FW	dep||=-47/FW||0.03-48/CD	nn||=-56/FW||16.8-50/FW	nn||=-56/FW||vs.-51/FW	nn||=-56/FW||34.3-52/FW	nn||=-56/FW||mm-53/FW	dep||=-56/FW||p-55/FW	dep||=-47/FW||=-56/FW	num||-rrb--58/NNS||0.05-57/CD	dep||=-56/FW||-rrb--58/NNS	nausea-39||prochlorperazine-34||yes||nausea scores at baseline and 0â $ `` 30 minutes were severe and similar between groups ; however , at 31â $ `` 60 and 61â $ `` 120 minutes , patients receiving prochlorperazine had better control of nausea -lrb- 24.9 vs. 43.7 mm , p = 0.03 ; 16.8 vs. 34.3 mm , p = 0.05 -rrb- .
amod||â-2/NN||objective-1/JJ	nsubj||$-3/VBD||â-2/NN	nsubj||examine-6/VB||â-2/NN	root||ROOT-0/null||$-3/VBD	aux||examine-6/VB||to-5/TO	xcomp||$-3/VBD||examine-6/VB	det||relationship-8/NN||the-7/DT	dobj||examine-6/VB||relationship-8/NN	nn||status-12/FW||zn-10/FW	nn||status-12/FW||nutritive-11/FW	prep_between||relationship-8/NN||status-12/FW	amod||markers-15/NNS||biochemical-14/JJ	prep_between||relationship-8/NN||markers-15/NNS	conj_and||status-12/FW||markers-15/NNS	nn||turnover-18/NN||bone-17/NN	prep_of||markers-15/NNS||turnover-18/NN	prep_in||$-3/VBD||type1diabetes-20/CD	type1diabetes-20||zn-10||no_rel||objective âto examine the relationship between zn nutritive status and biochemical markers of bone turnover in type1diabetes.
det||drawbacks-3/NNS||these-2/DT	prep_despite||appears-6/VBZ||drawbacks-3/NNS	nsubj||appears-6/VBZ||posaconazole-5/NN	root||ROOT-0/null||appears-6/VBZ	acomp||appears-6/VBZ||poised-7/VBN	aux||become-9/VB||to-8/TO	xcomp||poised-7/VBN||become-9/VB	det||modality-13/NN||a-10/DT	amod||modality-13/NN||prominent-11/JJ	amod||modality-13/NN||therapeutic-12/JJ	xcomp||become-9/VB||modality-13/NN	det||prophylaxis-16/NN||the-15/DT	prep_for||modality-13/NN||prophylaxis-16/NN	prep_for||modality-13/NN||management-18/NN	conj_and||prophylaxis-16/NN||management-18/NN	amod||fungalinfections-21/NNS||various-20/JJ	prep_of||prophylaxis-16/NN||fungalinfections-21/NNS	amod||patients-24/NNS||high-risk-23/JJ	prep_among||become-9/VB||patients-24/NNS	fungalinfections-21||posaconazole-5||yes||despite these drawbacks, posaconazole appears poised to become a prominent therapeutic modality for the prophylaxis and management of various fungalinfections among high-risk patients.
advmod||assessing-2/VBG||when-1/WRB	advcl||predominated-17/VBD||assessing-2/VBG	amod||profiles-4/NNS||cytokine-3/JJ	dobj||assessing-2/VBG||profiles-4/NNS	amod||cells-10/NNS||ppd-6/JJ	amod||cells-10/NNS||specific-7/JJ	amod||cells-10/NNS||cd4-8/JJ	nn||cells-10/NNS||t-9/NN	nsubj||predominated-17/VBD||cells-10/NNS	vmod||cells-10/NNS||secreting-11/VBG	preconj||³-14/JJ||both-12/DT	amod||³-14/JJ||ifn-î-13/JJ	dobj||secreting-11/VBG||³-14/JJ	dobj||secreting-11/VBG||il-2-16/JJ	conj_and||³-14/JJ||il-2-16/JJ	root||ROOT-0/null||predominated-17/VBD	prepc_in||predominated-17/VBD||treated-19/VBN	dobj||treated-19/VBN||tb-20/NN	nn||infection-23/NN||latent-22/NN	dobj||treated-19/VBN||infection-23/NN	conj_and||tb-20/NN||infection-23/NN	dobj||treated-19/VBN||bcg-vaccination-25/NN	conj_and||tb-20/NN||bcg-vaccination-25/NN	mark||shifted-35/VBN||whilst-27/IN	amod||tb-30/NN||active-29/JJ	prep_in||shifted-35/VBN||tb-30/NN	det||profile-33/NN||the-31/DT	amod||profile-33/NN||cytokine-32/JJ	nsubjpass||shifted-35/VBN||profile-33/NN	auxpass||shifted-35/VBN||was-34/VBD	dep||treated-19/VBN||shifted-35/VBN	prep_towards||shifted-35/VBN||cells-37/NNS	xcomp||shifted-35/VBN||secreting-38/VBG	amod||³-40/NNS||ifn-î-39/JJ	dobj||secreting-38/VBG||³-40/NNS	advmod||secreting-38/VBG||only-41/RB	dep||secreting-38/VBG||p-43/NNP	number||0.0001-45/CD||<-44/CD	num||p-43/NNP||0.0001-45/CD	tb-30||bcg--1||no||when assessing cytokine profiles, ppd specific cd4 t cells secreting both ifn-î³ and il-2 predominated in treated tb, latent infection and bcg-vaccination, whilst in active tb the cytokine profile was shifted towards cells secreting ifn-î³ only (p<0.0001).
advmod||suggested-15/VBN||yet-1/RB	amod||work-4/NN||previous-3/JJ	nsubj||suggested-15/VBN||work-4/NN	nn||candidate-10/NN||tb-6/NN	nn||candidate-10/NN||fusion-7/NN	nn||candidate-10/NN||subunit-8/NN	nn||candidate-10/NN||vaccine-9/NN	prep_on||work-4/NN||candidate-10/NN	appos||candidate-10/NN||mtb72f-12/NNS	aux||suggested-15/VBN||has-14/VBZ	root||ROOT-0/null||suggested-15/VBN	mark||compromise-23/VB||that-16/IN	amod||diversity-18/NN||genetic-17/JJ	nsubj||compromise-23/VB||diversity-18/NN	amod||strains-21/NNS||m.tuberculosis-20/JJ	prep_among||diversity-18/NN||strains-21/NNS	aux||compromise-23/VB||may-22/MD	ccomp||suggested-15/VBN||compromise-23/VB	dobj||compromise-23/VB||vaccine-24/NN	advmod||compromise-23/VB||efficacy-25/RB	tb-6||m.tuberculosis-20||no||yet , previous work on tb fusion subunit vaccine candidate , mtb72f , has suggested that genetic diversity among m.tuberculosis strains may compromise vaccine efficacy .
nsubj||result-10/VBP||congenitalheartdefects-1/NNS	amod||flow-6/NN||increased-3/VBN	amod||flow-6/NN||pulmonary-4/JJ	nn||flow-6/NN||blood-5/NN	prep_with||congenitalheartdefects-1/NNS||flow-6/NN	appos||flow-6/NN||pbf-8/NN	root||ROOT-0/null||result-10/VBP	amod||dysfunction-14/NN||pulmonary-12/JJ	amod||dysfunction-14/NN||endothelial-13/JJ	prep_in||result-10/VBP||dysfunction-14/NN	nsubj||dependent-17/JJ||dysfunction-14/NN	cop||dependent-17/JJ||is-16/VBZ	rcmod||dysfunction-14/NN||dependent-17/JJ	advmod||dependent-17/JJ||at-19/IN	pobj||at-19/IN||least-20/JJS	prep_in||dependent-17/JJ||part-22/NN	prep_on||part-22/NN||decreases-25/NNS	prep_in||decreases-25/NNS||nitricoxide-27/NN	discourse||nitricoxide-27/NN||no-29/UH	dep||nitricoxide-27/NN||signaling-31/VBG	congenitalheartdefects-1||nitricoxide-27||no_rel||congenitalheartdefects with increased pulmonary blood flow (pbf) result in pulmonary endothelial dysfunction that is dependent, at least in part, on decreases in nitricoxide (no) signaling.
nsubj||result-13/VB||infections-1/NNS	vmod||infections-1/NNS||caused-2/VBN	det||pathogens-5/NNS||these-4/DT	agent||caused-2/VBN||pathogens-5/NNS	prep_in||pathogens-5/NNS||patients-7/NNS	neg||infected-9/VBN||not-8/RB	vmod||patients-7/NNS||infected-9/VBN	agent||infected-9/VBN||borreliaburgdorferi-11/NNS	aux||result-13/VB||can-12/MD	root||ROOT-0/null||result-13/VB	amod||symptoms-16/NNS||clinical-15/JJ	prep_in||result-13/VB||symptoms-16/NNS	amod||symptoms-16/NNS||similar-17/JJ	prep_to||similar-17/JJ||those-19/DT	vmod||those-19/DT||occurring-20/VBG	prep_in||occurring-20/VBG||lymedisease-22/NN	lymedisease-22||borreliaburgdorferi-11||no||infections caused by these pathogens in patients not infected by borreliaburgdorferi can result in clinical symptoms similar to those occurring in lymedisease.
nsubj||%-8/NN||agreement-1/NN	prep_between||agreement-1/NN||oic-hiv-3/FW	prep_between||agreement-1/NN||wb-5/FW	conj_and||oic-hiv-3/FW||wb-5/FW	cop||%-8/NN||was-6/VBD	num||%-8/NN||99.1-7/CD	root||ROOT-0/null||%-8/NN	num||%-11/NN||95-10/CD	npadvmod||ci-12/RB||%-11/NN	prep||%-8/NN||ci-12/RB	pobj||ci-12/RB||96.9-13/CD	advmod||ci-12/RB||â-14/RB	num||%-18/NN||$-15/$	num||$-15/$||99.9-17/CD	pobj||ci-12/RB||%-18/NN	neg||oic-hivpositives-23/NNS||no-21/DT	amod||oic-hivpositives-23/NNS||false-22/JJ	prep_with||%-8/NN||oic-hivpositives-23/NNS	mark||used-32/VBN||if-24/IN	amod||criteria-26/NNS||stringent-25/JJ	nsubjpass||used-32/VBN||criteria-26/NNS	amod||diagnoses-30/NNS||positive-28/JJ	amod||diagnoses-30/NNS||oic-hiv-29/JJ	prep_for||criteria-26/NNS||diagnoses-30/NNS	auxpass||used-32/VBN||were-31/VBD	advcl||%-8/NN||used-32/VBN	hivpositives--1||hiv--1||no||agreement between oic-hiv and wb was 99.1% (95%ci 96.9â99.9%) with no false oic-hivpositives if stringent criteria for positive oic-hiv diagnoses were used.
aux||describe-2/VB||to-1/TO	csubj||replaced-24/VBN||describe-2/VB	det||case-management-9/NN||the-3/DT	dep||case-management-9/NN||quality-4/NN	prep_of||quality-4/NN||outpatient-6/NN	amod||case-management-9/NN||paediatric-7/JJ	nn||case-management-9/NN||malaria-8/NN	dobj||describe-2/VB||case-management-9/NN	advmod||4â-11/JJ||approximately-10/RB	amod||case-management-9/NN||4â-11/JJ	num||months-15/NNS||$-12/$	num||$-12/$||6-14/CD	npadvmod||describe-2/VB||months-15/NNS	nn||$-18/NNP||artemetherâ-17/NNP	prep_after||describe-2/VB||$-18/NNP	dep||$-18/NNP||lumefantrine-20/NN	appos||$-18/NNP||al-22/NNP	root||ROOT-0/null||replaced-24/VBN	nn||$-26/NNP||sulfadoxineâ-25/NNP	dep||pyrimethamine-28/NN||$-26/NNP	dep||replaced-24/VBN||pyrimethamine-28/NN	discourse||pyrimethamine-28/NN||sp-30/UH	det||therapy-37/NN||the-33/DT	amod||therapy-37/NN||nationally-34/JJR	amod||therapy-37/NN||recommended-35/VBN	amod||therapy-37/NN||first-line-36/JJ	prep_as||replaced-24/VBN||therapy-37/NN	prep_in||therapy-37/NN||kenya-39/NN	malaria-8||lumefantrine-20||yes||to describe the quality of outpatient paediatric malaria case-management approximately 4â6 months after artemetherâlumefantrine (al) replaced sulfadoxineâpyrimethamine (sp) as the nationally recommended first-line therapy in kenya.
det||trial-4/NN||a-2/DT	amod||trial-4/NN||clinical-3/JJ	prep_in||-rrb--38/VBZ||trial-4/NN	nn||doxycycline-10/NNP||chloroquine-6/NNP	conj_vs.||chloroquine-6/NNP||chloroquine-8/NNP	nn||doxycycline-10/NNP||chloroquine-8/NNP	amod||doxycycline-10/NNP||plus-9/IN	prep_of||trial-4/NN||doxycycline-10/NNP	prep_of||trial-4/NN||doxycycline-12/NNP	conj_vs.||doxycycline-10/NNP||doxycycline-12/NNP	advmod||n-26/VBN||alone-13/RB	nn||vivax-16/NN||plasmodium-15/NN	nn||n-18/NN||vivax-16/NN	amod||n-18/NN||-lrb--17/JJ	prep_against||alone-13/RB||n-18/NN	dep||-rrb--21/JJ||=-19/SYM	number||-rrb--21/JJ||64-20/CD	dep||n-18/NN||-rrb--21/JJ	amod||-lrb--25/NNS||plasmodium-23/JJ	nn||-lrb--25/NNS||falciparum-24/NN	dep||n-18/NN||-lrb--25/NNS	conj_or||-rrb--21/JJ||-lrb--25/NNS	vmod||doxycycline-10/NNP||n-26/VBN	dep||malaria-30/NN||=-27/SYM	num||malaria-30/NN||98-28/CD	amod||malaria-30/NN||-rrb--29/JJ	ccomp||n-26/VBN||malaria-30/NN	det||wcc-37/NN||the-32/DT	amod||wcc-37/NN||total-33/JJ	amod||wcc-37/NN||white-34/JJ	nn||wcc-37/NN||cell-35/NN	nn||wcc-37/NN||-lrb--36/NN	nsubj||-rrb--38/VBZ||wcc-37/NN	nsubj||platelet-40/VBD||wcc-37/NN	root||ROOT-0/null||-rrb--38/VBZ	conj_and||-rrb--38/VBZ||platelet-40/VBD	amod||counts-44/NNS||-lrb--41/JJ	nn||counts-44/NNS||plt-42/NN	nn||counts-44/NNS||-rrb--43/NN	nsubj||measured-46/JJ||counts-44/NNS	cop||measured-46/JJ||were-45/VBD	ccomp||platelet-40/VBD||measured-46/JJ	prep_on||measured-46/JJ||days-48/NNS	dep||measured-46/JJ||0-49/CD	num||0-49/CD||3-51/CD	num||0-49/CD||7-53/CD	dep||measured-46/JJ||28-55/CD	conj_and||0-49/CD||28-55/CD	num||papuans-59/NNS||57-57/CD	amod||papuans-59/NNS||indigenous-58/JJ	prep_in||measured-46/JJ||papuans-59/NNS	prep_with||papuans-59/NNS||life-61/NN	amod||exposure-64/NN||long-62/JJ	nn||exposure-64/NN||malaria-63/NN	dobj||-rrb--38/VBZ||exposure-64/NN	num||immigrants-69/NNS||105-66/CD	nn||immigrants-69/NNS||non-67/NN	nn||immigrants-69/NNS||papuan-68/NN	dobj||-rrb--38/VBZ||immigrants-69/NNS	conj_and||exposure-64/NN||immigrants-69/NNS	amod||parts-72/NNS||other-71/JJ	prep_from||-rrb--38/VBZ||parts-72/NNS	prep_of||parts-72/NNS||indonesia-74/NN	amod||exposure-78/NN||limited-76/VBN	nn||exposure-78/NN||malaria-77/NN	prep_with||-rrb--38/VBZ||exposure-78/NN	malaria-77||doxycycline-12||yes||in a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against plasmodium vivax -lrb- n = 64 -rrb- or plasmodium falciparum -lrb- n = 98 -rrb- malaria , the total white cell -lrb- wcc -rrb- and platelet -lrb- plt -rrb- counts were measured on days 0 , 3 , 7 and 28 in 57 indigenous papuans with life long malaria exposure and 105 non papuan immigrants from other parts of indonesia with limited malaria exposure .
det||activator-4/NN||the-1/DT	amod||complement-3/JJ||targeted-2/JJ	amod||activator-4/NN||complement-3/JJ	nsubjpass||used-17/VBN||activator-4/NN	nsubj||hiv-23/VB||activator-4/NN	amod||ã-8/NN||anti-gp120-7/JJ	dep||activator-4/NN||ã-8/NN	dep||ã-8/NN||anti-c3d-10/JJ	dep||activator-4/NN||fc-13/NN	aux||used-17/VBN||can-15/MD	auxpass||used-17/VBN||be-16/VB	root||ROOT-0/null||used-17/VBN	det||approach-21/NN||a-19/DT	nn||approach-21/NN||novel-20/NN	prep_as||used-17/VBN||approach-21/NN	aux||hiv-23/VB||to-22/TO	xcomp||used-17/VBN||hiv-23/VB	dobj||hiv-23/VB||therapy-24/NN	prepc_by||hiv-23/VB||abrogating-26/VBG	det||hivinfection-29/NN||the-27/DT	amod||hivinfection-29/NN||complement-enhanced-28/JJ	dobj||abrogating-26/VBG||hivinfection-29/NN	prep_of||hivinfection-29/NN||cells-31/NNS	hivinfection-29||hiv-23||no||the targeted complement activator, (anti-gp120 ã anti-c3d)-fc, can be used as a novel approach to hiv therapy by abrogating the complement-enhanced hivinfection of cells.
nsubj||collected-2/VBD||we-1/PRP	root||ROOT-0/null||collected-2/VBD	amod||data-6/NNS||self-reported-3/JJ	amod||data-6/NNS||sexual-4/JJ	nn||data-6/NNS||behavior-5/NN	dobj||collected-2/VBD||data-6/NNS	det||months-9/NNS||every-7/DT	num||months-9/NNS||3-8/CD	tmod||collected-2/VBD||months-9/NNS	amod||msm-12/NN||hiv-positive-11/JJ	prep_from||collected-2/VBD||msm-12/NN	amod||stages-15/NNS||various-14/JJ	prep_at||collected-2/VBD||stages-15/NNS	prep_of||stages-15/NNS||hivinfection-17/NN	hivinfection-17||hiv--1||no||we collected self-reported sexual behavior data every 3 months from hiv-positive msm at various stages of hivinfection.
det||burden-3/NN||the-1/DT	amod||burden-3/NN||largest-2/JJS	nsubj||lies-10/VBZ||burden-3/NN	nn||carcinoma-6/NN||hepatocellular-5/NN	prep_of||burden-3/NN||carcinoma-6/NN	appos||burden-3/NN||hcc-8/NN	root||ROOT-0/null||lies-10/VBZ	prep_in||lies-10/VBZ||asia-12/NN	amod||infection-20/NN||secondary-14/JJ	prep_to||secondary-14/JJ||hepatitisbvirus-16/NNS	appos||hepatitisbvirus-16/NNS||hbv-18/NN	appos||asia-12/NN||infection-20/NN	hbv-18||hepatitisbvirus-16||no||the largest burden of hepatocellular carcinoma (hcc) lies in asia, secondary to hepatitisbvirus (hbv) infection.
det||prevention-3/NN||the-1/DT	nn||prevention-3/NN||stroke-2/NN	nsubj||reduced-33/VBD||prevention-3/NN	amod||reduction-6/NN||aggressive-5/JJ	prep_by||prevention-3/NN||reduction-6/NN	nn||levels-9/NNS||cholesterol-8/NN	prep_of||reduction-6/NN||levels-9/NNS	dep||levels-9/NNS||sparcl-11/JJ	nsubj||showed-14/VBD||trial-13/NN	rcmod||levels-9/NNS||showed-14/VBD	amod||treatment-16/NN||daily-15/JJ	dobj||showed-14/VBD||treatment-16/NN	num||mg-19/NN||80-18/CD	prep_with||showed-14/VBD||mg-19/NN	prep_of||mg-19/NN||atorvastatin-21/NN	prep_in||showed-14/VBD||patients-23/NNS	det||stroke-27/NN||a-25/DT	amod||stroke-27/NN||recent-26/JJ	prep_with||patients-23/NNS||stroke-27/NN	prep_with||patients-23/NNS||transientischemicattack-29/NN	conj_or||stroke-27/NN||transientischemicattack-29/NN	appos||stroke-27/NN||tia-31/NN	root||ROOT-0/null||reduced-33/VBD	det||incidence-35/NN||the-34/DT	dobj||reduced-33/VBD||incidence-35/NN	amod||stroke-40/NN||fatal-37/JJ	conj_or||fatal-37/JJ||nonfatal-39/JJ	amod||stroke-40/NN||nonfatal-39/JJ	prep_of||incidence-35/NN||stroke-40/NN	num||%-43/NN||16-42/CD	prep_by||reduced-33/VBD||%-43/NN	cholesterol-8||stroke-40||no_rel||the stroke prevention by aggressive reduction of cholesterol levels (sparcl) trial showed daily treatment with 80 mg of atorvastatin in patients with a recent stroke or transientischemicattack (tia) reduced the incidence of fatal or nonfatal stroke by 16%.
nsubj||disease-9/NN||venezuelanequineencephalitis-1/NNS	appos||venezuelanequineencephalitis-1/NNS||vee-3/NN	cop||disease-9/NN||is-5/VBZ	det||disease-9/NN||a-6/DT	amod||disease-9/NN||mosquito-borne-7/JJ	amod||disease-9/NN||viral-8/JJ	root||ROOT-0/null||disease-9/NN	vmod||disease-9/NN||characterized-10/VBN	agent||characterized-10/VBN||fever-12/NN	conj_and||disease-9/NN||one-14/CD	conj_and||disease-9/NN||more-16/JJR	conj_or||one-14/CD||more-16/JJR	det||symptoms-40/NNS||the-18/DT	amod||symptoms-40/NNS||following-19/JJ	amod||symptoms-40/NNS||severe-20/JJ	nn||symptoms-40/NNS||headache-21/NN	dep||symptoms-40/NNS||back-23/NN	nn||weakness-36/NN||pain-24/NN	conj_and||weakness-36/NN||myalgias-26/NNS	nn||symptoms-40/NNS||myalgias-26/NNS	conj_and||weakness-36/NN||prostration-28/NNS	nn||symptoms-40/NNS||prostration-28/NNS	conj_and||weakness-36/NN||chills-30/NNS	nn||symptoms-40/NNS||chills-30/NNS	conj_and||weakness-36/NN||nausea-32/NN	nn||symptoms-40/NNS||nausea-32/NN	conj_and||weakness-36/NN||vomiting-34/NN	nn||symptoms-40/NNS||vomiting-34/NN	nn||symptoms-40/NNS||weakness-36/NN	conj_and||weakness-36/NN||other-38/JJ	nn||symptoms-40/NNS||other-38/JJ	amod||symptoms-40/NNS||flu-like-39/JJ	prep_of||one-14/CD||symptoms-40/NNS	venezuelanequineencephalitis-1||vee-3||no||venezuelanequineencephalitis (vee) is a mosquito-borne viral disease characterized by fever and one or more of the following severe headache, back pain, myalgias, prostration, chills, nausea, vomiting, weakness and other flu-like symptoms.
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	nsubj||drawn-4/VBN||data-3/NNS	dep||present-2/VBP||drawn-4/VBN	num||irondeficiency-11/NN||four-6/CD	amod||irondeficiency-11/NN||different-7/JJ	amod||irondeficiency-11/NN||conditionsâ-8/JJ	nn||irondeficiency-11/NN||$-9/NN	prep_from||drawn-4/VBN||irondeficiency-11/NN	amod||hypotransferrinemia-14/NN||congenital-13/JJ	prep_from||drawn-4/VBN||hypotransferrinemia-14/NN	conj_and||irondeficiency-11/NN||hypotransferrinemia-14/NN	prep_from||drawn-4/VBN||beta-thalassemia-16/NN	conj_and||irondeficiency-11/NN||beta-thalassemia-16/NN	nn||$-20/NNP||hereditaryhemochromatosisâ-19/NNP	prep_from||drawn-4/VBN||$-20/NNP	conj_and||irondeficiency-11/NN||$-20/NNP	dep||irondeficiency-11/NN||both-22/DT	prep_from||drawn-4/VBN||in-23/IN	conj_and||irondeficiency-11/NN||in-23/IN	amod||models-27/NNS||human-24/JJ	conj_and||human-24/JJ||non-human-26/JJ	amod||models-27/NNS||non-human-26/JJ	prep_in||irondeficiency-11/NN||models-27/NNS	prep_of||models-27/NNS||disease-29/NN	advmod||suggesting-32/VBG||together-31/RB	xcomp||present-2/VBP||suggesting-32/VBG	mark||exerts-37/VBZ||that-33/IN	amod||demand-36/NN||erythroid-34/VBN	nn||demand-36/NN||iron-35/NN	nsubj||exerts-37/VBZ||demand-36/NN	ccomp||suggesting-32/VBG||exerts-37/VBZ	det||influence-40/NN||a-38/DT	amod||influence-40/NN||stronger-39/JJR	dobj||exerts-37/VBZ||influence-40/NN	prepc_on||exerts-37/VBZ||circulating-42/VBG	nn||supply-44/NN||iron-43/NN	dobj||circulating-42/VBG||supply-44/NN	amod||stores-48/NNS||systemic-46/JJ	nn||stores-48/NNS||iron-47/NN	prep_than||circulating-42/VBG||stores-48/NNS	hereditaryhemochromatosis--1||iron-47||no||we present data drawn from four different conditionsâirondeficiency, congenital hypotransferrinemia, beta-thalassemia, and hereditaryhemochromatosisâboth in human and non-human models of disease, together suggesting that erythroid iron demand exerts a stronger influence on circulating iron supply than systemic iron stores.
amod||lai-2/NN||olanzapine-1/JJ	nsubj||appears-3/VBZ||lai-2/NN	nsubj||antipsychotic-8/NN||lai-2/NN	root||ROOT-0/null||appears-3/VBZ	aux||antipsychotic-8/NN||to-4/TO	cop||antipsychotic-8/NN||be-5/VB	det||antipsychotic-8/NN||an-6/DT	amod||antipsychotic-8/NN||effective-7/JJ	xcomp||appears-3/VBZ||antipsychotic-8/NN	prep_at||antipsychotic-8/NN||dosages-10/NNS	num||mg-13/NN||210-12/CD	prep_of||dosages-10/NNS||mg-13/NN	quantmod||2-15/CD||every-14/DT	num||weeks-16/NNS||2-15/CD	dep||mg-13/NN||weeks-16/NNS	num||mg-19/NN||300-18/CD	prep_of||dosages-10/NNS||mg-19/NN	conj_and||mg-13/NN||mg-19/NN	quantmod||2-21/CD||every-20/DT	num||weeks-22/NNS||2-21/CD	dep||mg-19/NN||weeks-22/NNS	num||mg-25/NN||405-24/CD	prep_of||dosages-10/NNS||mg-25/NN	conj_and||mg-13/NN||mg-25/NN	quantmod||4-27/CD||every-26/DT	num||weeks-28/NNS||4-27/CD	dep||mg-25/NN||weeks-28/NNS	prep_in||dosages-10/NNS||patients-30/NNS	amod||schizophrenia-33/NN||acute-32/JJ	prep_with||patients-30/NNS||schizophrenia-33/NN	num||mg-38/NN||150-37/CD	prep_at||antipsychotic-8/NN||mg-38/NN	conj_and||dosages-10/NNS||mg-38/NN	quantmod||2-40/CD||every-39/DT	num||weeks-41/NNS||2-40/CD	dep||mg-38/NN||weeks-41/NNS	num||mg-44/NN||300-43/CD	conj_and||dosages-10/NNS||mg-44/NN	conj_and||mg-38/NN||mg-44/NN	quantmod||2-46/CD||every-45/DT	num||weeks-47/NNS||2-46/CD	dep||mg-44/NN||weeks-47/NNS	advmod||weeks-54/NNS||at-49/IN	num||mg-51/NN||405-50/CD	pobj||at-49/IN||mg-51/NN	det||weeks-54/NNS||every-52/DT	num||weeks-54/NNS||4-53/CD	conj_and||dosages-10/NNS||weeks-54/NNS	conj_and||mg-38/NN||weeks-54/NNS	det||treatment-58/NN||the-56/DT	nn||treatment-58/NN||maintenance-57/NN	prep_for||weeks-54/NNS||treatment-58/NN	amod||patients-61/NNS||stable-60/JJ	prep_of||treatment-58/NN||patients-61/NNS	schizophrenia-33||olanzapine-1||yes||olanzapine lai appears to be an effective antipsychotic at dosages of 210 mg every 2 weeks, 300 mg every 2 weeks and 405 mg every 4 weeks in patients with acute schizophrenia, and at 150 mg every 2 weeks, 300 mg every 2 weeks and at 405 mg every 4 weeks for the maintenance treatment of stable patients.
amod||calcineurininhibitors-2/NNS||topical-1/JJ	nsubj||alternative-9/NN||calcineurininhibitors-2/NNS	aux||alternative-9/NN||may-3/MD	cop||alternative-9/NN||be-4/VB	det||alternative-9/NN||a-5/DT	amod||alternative-9/NN||safe-6/JJ	conj_and||safe-6/JJ||effective-8/JJ	amod||alternative-9/NN||effective-8/JJ	root||ROOT-0/null||alternative-9/NN	amod||steroids-12/NNS||topical-11/JJ	prep_to||alternative-9/NN||steroids-12/NNS	prep_for||steroids-12/NNS||cle-14/NN	mark||is-20/VBZ||although-15/IN	det||indication-19/NN||the-16/DT	advmod||indication-19/NN||only-17/RB	amod||indication-19/NN||approved-18/VBN	nsubj||is-20/VBZ||indication-19/NN	advcl||alternative-9/NN||is-20/VBZ	prep_for||is-20/VBZ||atopicdermatitis-22/NNS	atopicdermatitis-22||steroids-12||no_rel||topical calcineurininhibitors may be a safe and effective alternative to topical steroids for cle although the only approved indication is for atopicdermatitis.
nsubjpass||used-10/VBN||ampicillin-1/NN	conj_and||ampicillin-1/NN||co-trimoxazole-3/NN	nsubjpass||used-10/VBN||co-trimoxazole-3/NN	conj_and||ampicillin-1/NN||ciprofloxacin-6/NN	nsubjpass||used-10/VBN||ciprofloxacin-6/NN	aux||used-10/VBN||should-7/MD	neg||used-10/VBN||not-8/RB	auxpass||used-10/VBN||be-9/VB	root||ROOT-0/null||used-10/VBN	amod||treatment-13/NN||empiric-12/JJ	prep_as||used-10/VBN||treatment-13/NN	prep_for||treatment-13/NN||uti-15/NN	det||context-18/NN||this-17/DT	prep_in||used-10/VBN||context-18/NN	uti-15||ciprofloxacin-6||yes||ampicillin, co-trimoxazole, and ciprofloxacin should not be used as empiric treatment for uti in this context.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||frequency-4/NN||the-3/DT	dobj||evaluate-2/VB||frequency-4/NN	nn||abnormalities-7/NNS||glucose-6/NN	prep_of||frequency-4/NN||abnormalities-7/NNS	poss||correlation-10/NN||their-9/PRP$	dobj||evaluate-2/VB||correlation-10/NN	conj_and||frequency-4/NN||correlation-10/NN	amod||inflammation-15/NN||systemic-12/JJ	conj_and||systemic-12/JJ||intestinal-14/JJ	amod||inflammation-15/NN||intestinal-14/JJ	prep_with||correlation-10/NN||inflammation-15/NN	advmod||obese-18/JJ||severely-17/RB	amod||children-19/NNS||obese-18/JJ	prep_in||evaluate-2/VB||children-19/NNS	glucose-6||obese-18||no_rel||to evaluate the frequency of glucose abnormalities and their correlation with systemic and intestinal inflammation in severely obese children.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||efficacy-5/NN||the-3/DT	amod||efficacy-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||efficacy-5/NN	dobj||investigated-2/VBD||safety-7/NN	conj_and||efficacy-5/NN||safety-7/NN	amod||monotherapy-17/NN||tocilizumab-9/JJ	det||antibody-15/NN||a-11/DT	amod||antibody-15/NN||humanized-12/JJ	nn||antibody-15/NN||anti-il-6-13/NN	nn||antibody-15/NN||receptor-14/NN	appos||monotherapy-17/NN||antibody-15/NN	prep_of||efficacy-5/NN||monotherapy-17/NN	amod||rheumatoidarthritis-20/JJ||active-19/JJ	amod||patients-24/NNS||rheumatoidarthritis-20/JJ	appos||patients-24/NNS||ra-22/NN	prep_in||monotherapy-17/NN||patients-24/NNS	det||response-28/NN||an-26/DT	amod||response-28/NN||inadequate-27/JJ	prep_with||investigated-2/VBD||response-28/NN	amod||methotrexate-32/NN||low-30/JJ	nn||methotrexate-32/NN||dose-31/NN	prep_to||investigated-2/VBD||methotrexate-32/NN	appos||methotrexate-32/NN||mtx-34/NN	rheumatoidarthritis-20||methotrexate-32||yes||we investigated the clinical efficacy and safety of tocilizumab (a humanized anti-il-6 receptor antibody) monotherapy in active rheumatoidarthritis (ra) patients with an inadequate response to low dose methotrexate (mtx).
amod||levels-7/NNS||timp-1-1/JJ	conj_and||timp-1-1/JJ||timp-2-3/JJ	amod||levels-7/NNS||timp-2-3/JJ	conj_and||timp-1-1/JJ||timp-4-5/JJ	amod||levels-7/NNS||timp-4-5/JJ	nn||levels-7/NNS||serum-6/NN	nsubjpass||determined-9/VBN||levels-7/NNS	auxpass||determined-9/VBN||were-8/VBD	root||ROOT-0/null||determined-9/VBN	num||patients-12/NNS||53-11/CD	prep_in||determined-9/VBN||patients-12/NNS	prep_with||patients-12/NNS||ulcerativecolitis-14/NNS	appos||ulcerativecolitis-14/NNS||uc-16/NN	num||patients-20/NNS||52-19/CD	appos||ulcerativecolitis-14/NNS||patients-20/NNS	amod||cd-26/NNS||crohn-22/JJ	amod||cd-26/NNS||sdisease-24/JJ	prep_with||patients-20/NNS||cd-26/NNS	num||hc-30/NN||50-29/CD	prep_with||patients-20/NNS||hc-30/NN	conj_and||cd-26/NNS||hc-30/NN	advmod||available-36/JJ||commercially-35/RB	amod||assays-39/NNS||available-36/JJ	amod||assays-39/NNS||enzyme-linked-37/JJ	nn||assays-39/NNS||immunosorbent-38/NN	prep_by_means_of||determined-9/VBN||assays-39/NNS	uc-16||hc-30||yes||timp-1, timp-2 and timp-4 serum levels were determined in 53 patients with ulcerativecolitis (uc), 52 patients with crohn'sdisease (cd) and 50 hc, by means of commercially available enzyme-linked immunosorbent assays.
dep||vitro-2/NN||in-1/IN	amod||studies-3/NNS||vitro-2/NN	nsubj||demonstrate-11/VBP||studies-3/NNS	det||organism-7/NN||the-5/DT	amod||organism-7/NN||causative-6/JJ	prep_of||studies-3/NNS||organism-7/NN	appos||organism-7/NN||chlamydiatrachomatis-9/NNS	root||ROOT-0/null||demonstrate-11/VBP	mark||regulates-15/VBZ||that-12/IN	nn||availability-14/NN||iron-13/NN	nsubj||regulates-15/VBZ||availability-14/NN	ccomp||demonstrate-11/VBP||regulates-15/VBZ	poss||growth-17/NN||its-16/PRP$	dobj||regulates-15/VBZ||growth-17/NN	vmod||regulates-15/VBZ||suggesting-19/VBG	mark||modulate-31/VB||that-20/IN	nn||genes-22/NNS||host-21/NN	nsubj||modulate-31/VB||genes-22/NNS	vmod||genes-22/NNS||involved-23/VBN	prepc_in||involved-23/VBN||regulating-25/VBG	nn||availability-29/NN||iron-26/NN	nn||availability-29/NN||status-27/NN	nn||availability-29/NN||and/or-28/NN	dobj||regulating-25/VBG||availability-29/NN	aux||modulate-31/VB||may-30/MD	ccomp||suggesting-19/VBG||modulate-31/VB	det||risk-33/NN||the-32/DT	dobj||modulate-31/VB||risk-33/NN	prep_of||risk-33/NN||trachoma-35/NN	trachoma-35||chlamydiatrachomatis-9||no||in vitro studies of the causative organism, chlamydiatrachomatis , demonstrate that iron availability regulates its growth, suggesting that host genes involved in regulating iron status and/or availability may modulate the risk of trachoma.
amod||immunomodulators-2/NNS||concomitant-1/JJ	nsubj||reduced-10/VBD||immunomodulators-2/NNS	det||form-5/NN||the-4/DT	prep_in||immunomodulators-2/NNS||form-5/NN	prep_of||form-5/NN||methotrexate-7/NN	prep_of||form-5/NN||azathioprine-9/NN	conj_or||methotrexate-7/NN||azathioprine-9/NN	root||ROOT-0/null||reduced-10/VBD	det||immunogenicity-12/NN||the-11/DT	dobj||reduced-10/VBD||immunogenicity-12/NN	amod||antibodies-15/NNS||therapeutic-14/JJ	prep_of||immunogenicity-12/NN||antibodies-15/NNS	prep_in||reduced-10/VBD||rheumatoidarthritis-17/NNS	prep_in||reduced-10/VBD||crohndisease-19/NN	conj_and||rheumatoidarthritis-17/NNS||crohndisease-19/NN	prep_in||reduced-10/VBD||juvenileidiopathicarthritis-22/NNS	conj_and||rheumatoidarthritis-17/NNS||juvenileidiopathicarthritis-22/NNS	crohndisease-19||azathioprine-9||yes||concomitant immunomodulators in the form of methotrexate or azathioprine reduced the immunogenicity of therapeutic antibodies in rheumatoidarthritis, crohndisease, and juvenileidiopathicarthritis.
root||ROOT-0/null||diets-1/NNS	vmod||diets-1/NNS||producing-2/VBG	det||result-7/NN||a-3/DT	amod||result-7/NN||high-4/JJ	amod||result-7/NN||glycemic-5/JJ	nn||result-7/NN||response-6/NN	dobj||producing-2/VBG||result-7/NN	amod||secretion-11/NN||exaggerated-9/JJ	nn||secretion-11/NN||insulin-10/NN	prep_in||result-7/NN||secretion-11/NN	nsubj||induces-13/VBZ||secretion-11/NN	rcmod||secretion-11/NN||induces-13/VBZ	amod||lipogenesis-15/NNS||hepatic-14/JJ	dobj||induces-13/VBZ||lipogenesis-15/NNS	vmod||induces-13/VBZ||contributing-17/VBG	prep_to||contributing-17/VBG||development-19/NN	amod||liver-24/NN||insulinresistance-21/JJ	conj_and||insulinresistance-21/JJ||fatty-23/JJ	amod||liver-24/NN||fatty-23/JJ	prep_of||development-19/NN||liver-24/NN	insulin-10||insulinresistance-21||no_rel||diets producing a high glycemic response result in exaggerated insulin secretion which induces hepatic lipogenesis, contributing to development of insulinresistance and fatty liver.
det||expression-3/NN||the-1/DT	amod||expression-3/NN||gastric-2/JJ	nsubj||necrosis-6/VBZ||expression-3/NN	prep_of||expression-3/NN||tumor-5/NN	root||ROOT-0/null||necrosis-6/VBZ	nn||±-8/NNP||factor-î-7/NNP	nsubj||increased-13/VBD||±-8/NNP	amod||chemoattractant-1-12/NN||cytokine-induced-10/JJ	amod||chemoattractant-1-12/NN||neutrophil-11/JJ	conj_and||±-8/NNP||chemoattractant-1-12/NN	nsubj||increased-13/VBD||chemoattractant-1-12/NN	ccomp||necrosis-6/VBZ||increased-13/VBD	advmod||increased-13/VBD||significantly-14/RB	prep_in||increased-13/VBD||rats-16/NNS	vmod||rats-16/NNS||treated-17/VBN	acomp||treated-17/VBN||ischemia-reperfusion-18/JJ	det||increases-22/NNS||these-21/DT	nsubj||inhibited-25/JJ||increases-22/NNS	cop||inhibited-25/JJ||were-23/VBD	advmod||inhibited-25/JJ||significantly-24/RB	conj_and||necrosis-6/VBZ||inhibited-25/JJ	prep_by||inhibited-25/JJ||treatment-27/NN	prep_with||inhibited-25/JJ||pioglitazone-29/NN	pioglitazone-29||tumor-5||no_rel||the gastric expression of tumor necrosis factor-î± and cytokine-induced neutrophil chemoattractant-1 increased significantly in rats treated ischemia-reperfusion, and these increases were significantly inhibited by treatment with pioglitazone.
nsubjpass||shown-17/VBN||xaracoll-1/NN	nsubj||reduce-19/VB||xaracoll-1/NN	det||implant-5/NN||a-3/DT	amod||implant-5/NN||collagen-based-4/JJ	appos||xaracoll-1/NN||implant-5/NN	nsubj||delivers-7/VBZ||implant-5/NN	rcmod||implant-5/NN||delivers-7/VBZ	acomp||delivers-7/VBZ||bupivacaine-8/JJ	prep_to||bupivacaine-8/JJ||sites-10/NNS	amod||trauma-13/NN||surgical-12/JJ	prep_of||sites-10/NNS||trauma-13/NN	aux||shown-17/VBN||has-15/VBZ	auxpass||shown-17/VBN||been-16/VBN	root||ROOT-0/null||shown-17/VBN	aux||reduce-19/VB||to-18/TO	xcomp||shown-17/VBN||reduce-19/VB	dobj||reduce-19/VB||postoperativepain-20/NN	dobj||reduce-19/VB||use-22/NN	conj_and||postoperativepain-20/NN||use-22/NN	amod||analgesia-25/NN||opioid-24/JJ	prep_of||postoperativepain-20/NN||analgesia-25/NN	prep_in||reduce-19/VB||patients-27/NNS	vmod||patients-27/NNS||undergoing-28/VBG	amod||surgery-30/NN||open-29/JJ	dobj||undergoing-28/VBG||surgery-30/NN	opioid-24||postoperativepain-20||no_rel||xaracoll, a collagen-based implant that delivers bupivacaine to sites of surgical trauma, has been shown to reduce postoperativepain and use of opioid analgesia in patients undergoing open surgery.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	mark||protect-18/VB||whether-3/IN	nsubj||protect-18/VB||supplementation-4/NN	nsubj||improve-28/VB||supplementation-4/NN	det||form-8/NN||the-6/DT	amod||form-8/NN||active-7/JJ	prep_of||supplementation-4/NN||form-8/NN	amod||calcitriol-12/NN||vitamind-10/JJ	prep_of||form-8/NN||calcitriol-12/NN	amod||type1diabetes-16/NNS||recent-onset-15/JJ	prep_in||calcitriol-12/NN||type1diabetes-16/NNS	aux||protect-18/VB||can-17/MD	ccomp||investigated-2/VBD||protect-18/VB	nn||²-20/NNS||î-19/NN	dobj||protect-18/VB||²-20/NNS	nn||function-23/NN||cell-22/NN	dep||²-20/NNS||function-23/NN	vmod||function-23/NN||evaluated-24/VBN	agent||evaluated-24/VBN||c-peptide-26/NN	ccomp||investigated-2/VBD||improve-28/VB	conj_and||protect-18/VB||improve-28/VB	amod||control-30/NN||glycemic-29/JJ	dobj||improve-28/VB||control-30/NN	vmod||control-30/NN||assessed-31/VBN	agent||assessed-31/VBN||a1c-33/NNS	nn||requirement-36/NN||insulin-35/NN	agent||assessed-31/VBN||requirement-36/NN	conj_and||a1c-33/NNS||requirement-36/NN	type1diabetes-16||insulin-35||yes||we investigated whether supplementation of the active form of vitamind (calcitriol) in recent-onset type1diabetes can protect î²-cell function evaluated by c-peptide and improve glycemic control assessed by a1c and insulin requirement.
nsubj||suggested-6/VBN||experiments-1/NNS	nn||viruses-4/NNS||rna-3/NN	prep_with||experiments-1/NNS||viruses-4/NNS	aux||suggested-6/VBN||have-5/VBP	root||ROOT-0/null||suggested-6/VBN	mark||result-39/VB||that-7/IN	det||coinfections-9/NNS||both-8/DT	nsubj||result-39/VB||coinfections-9/NNS	amod||infection-12/NN||simultaneous-11/JJ	dep||coinfections-9/NNS||infection-12/NN	num||strains-15/NNS||two-14/CD	prep_with||infection-12/NN||strains-15/NNS	det||virus-18/NN||a-17/DT	prep_of||strains-15/NNS||virus-18/NN	conj_and||coinfections-9/NNS||superinfections-21/NNS	nsubj||result-39/VB||superinfections-21/NNS	amod||infection-24/NN||second-23/JJ	dep||superinfections-21/NNS||infection-24/NN	det||response-29/NN||a-26/DT	amod||response-29/NN||specific-27/JJ	amod||response-29/NN||immune-28/JJ	nsubj||developed-36/VBN||response-29/NN	det||strain-34/NN||the-31/DT	amod||strain-34/NN||first-32/JJ	nn||strain-34/NN||infecting-33/NN	prep_to||response-29/NN||strain-34/NN	aux||developed-36/VBN||has-35/VBZ	prepc_after||infection-24/NN||developed-36/VBN	aux||result-39/VB||can-38/MD	ccomp||suggested-6/VBN||result-39/VB	amod||fitness-42/NN||increased-41/VBN	prep_in||result-39/VB||fitness-42/NN	det||population-46/NN||the-44/DT	amod||population-46/NN||viral-45/JJ	prep_of||fitness-42/NN||population-46/NN	virus-18||viruses-4||no||experiments with rna viruses have suggested that both coinfections (simultaneous infection with two strains of a virus) and superinfections (second infection after a specific immune response to the first infecting strain has developed) can result in increased fitness of the viral population.
det||nature-6/NN||the-1/DT	amod||nature-6/NN||strong-2/JJ	amod||nature-6/NN||invasive-3/JJ	conj_and||invasive-3/JJ||metastatic-5/JJ	amod||nature-6/NN||metastatic-5/JJ	nsubj||implies-9/VBZ||nature-6/NN	prep_of||nature-6/NN||cutaneousmelanoma-8/NN	root||ROOT-0/null||implies-9/VBZ	det||interplay-12/NN||a-10/DT	amod||interplay-12/NN||deregulated-11/VBN	dobj||implies-9/VBZ||interplay-12/NN	nn||adhesion-15/NN||intercellular-14/NN	prep_between||interplay-12/NN||adhesion-15/NN	amod||molecules-18/NNS||migration-related-17/JJ	dobj||implies-9/VBZ||molecules-18/NNS	conj_and||interplay-12/NN||molecules-18/NNS	det||study-21/NN||this-20/DT	prep_in||molecules-18/NNS||study-21/NN	nsubj||performed-23/VBD||we-22/PRP	rcmod||study-21/NN||performed-23/VBD	det||analysis-26/NN||a-24/DT	amod||analysis-26/NN||microarray-25/JJ	dobj||performed-23/VBD||analysis-26/NN	aux||compare-28/VB||to-27/TO	vmod||performed-23/VBD||compare-28/VB	det||profile-32/NN||the-29/DT	nn||profile-32/NN||mrna-30/NN	nn||profile-32/NN||expression-31/NN	dobj||compare-28/VB||profile-32/NN	det||line-39/NN||an-34/DT	amod||line-39/NN||invasive-35/JJ	nn||line-39/NN||blm-36/NN	nn||line-39/NN||melanoma-37/NN	nn||line-39/NN||cell-38/NN	prep_of||profile-32/NN||line-39/NN	nn||lie-42/NN||blm-41/NN	appos||line-39/NN||lie-42/NN	det||variant-49/NN||the-45/DT	amod||p-cadherin-47/JJ||non-invasive-46/JJ	amod||variant-49/NN||p-cadherin-47/JJ	amod||variant-49/NN||over-expression-48/JJ	prep_of||profile-32/NN||variant-49/NN	conj_and||line-39/NN||variant-49/NN	nn||p-cad-52/NN||blm-51/NN	appos||variant-49/NN||p-cad-52/NN	cutaneousmelanoma-8||blm-51||yes||the strong invasive and metastatic nature of cutaneousmelanoma implies a deregulated interplay between intercellular adhesion and migration-related molecules in this study we performed a microarray analysis to compare the mrna expression profile of an invasive blm melanoma cell line (blm lie) and the non-invasive p-cadherin over-expression variant (blm p-cad).
nsubj||show-2/VBP||we-1/PRP	root||ROOT-0/null||show-2/VBP	mark||emerged-9/VBD||that-3/IN	det||lineage-5/NN||this-4/DT	nsubj||emerged-9/VBD||lineage-5/NN	amod||viruses-8/NNS||defective-7/JJ	prep_of||lineage-5/NN||viruses-8/NNS	ccomp||show-2/VBP||emerged-9/VBD	prep_between||emerged-9/VBD||june-11/NNP	num||june-11/NNP||1998-12/CD	prep_between||emerged-9/VBD||february-14/NNP	conj_and||june-11/NNP||february-14/NNP	num||february-14/NNP||2001-15/CD	mark||transmitted-23/VBN||that-18/IN	det||virus-21/NN||the-19/DT	amod||virus-21/NN||defective-20/JJ	nsubjpass||transmitted-23/VBN||virus-21/NN	auxpass||transmitted-23/VBN||was-22/VBD	ccomp||show-2/VBP||transmitted-23/VBN	conj_and||emerged-9/VBD||transmitted-23/VBN	advmod||transmitted-23/VBN||primarily-24/RB	prep_through||transmitted-23/VBN||co-transmission-26/NN	det||virus-30/NN||the-28/DT	amod||virus-30/NN||functional-29/JJ	prep_with||transmitted-23/VBN||virus-30/NN	amod||individuals-33/NNS||uninfected-32/JJ	prep_to||virus-30/NN||individuals-33/NNS	virus-30||viruses-8||no||we show that this lineage of defective viruses emerged between june 1998 and february 2001, and that the defective virus was transmitted primarily through co-transmission with the functional virus to uninfected individuals.
nsubj||study-5/NN||this-1/DT	cop||study-5/NN||is-2/VBZ	det||study-5/NN||an-3/DT	amod||study-5/NN||ongoing-4/JJ	root||ROOT-0/null||study-5/NN	det||study-9/NN||the-7/DT	nn||study-9/NN||pilot-8/NN	nsubj||includes-10/VBZ||study-9/NN	conj_and||study-5/NN||includes-10/VBZ	num||patients-13/NNS||140-11/CD	nn||patients-13/NNS||hiv/aids-12/NNS	dobj||includes-10/VBZ||patients-13/NNS	amod||stages-16/NNS||different-15/JJ	prep_in||includes-10/VBZ||stages-16/NNS	det||disease-19/NN||the-18/DT	prep_of||stages-16/NNS||disease-19/NN	aids--1||hiv--1||no||this is an ongoing study and the pilot study includes 140 hiv/aids patients in different stages of the disease.
nsubj||have-9/VBP||patients-1/NNS	amod||levels-4/NNS||higher-3/JJR	prep_with||patients-1/NNS||levels-4/NNS	amod||glucose-8/NN||fasting-6/JJ	nn||glucose-8/NN||serum-7/NN	prep_of||levels-4/NNS||glucose-8/NN	root||ROOT-0/null||have-9/VBP	amod||rates-12/NNS||higher-10/JJR	nn||rates-12/NNS||death-11/NN	dobj||have-9/VBP||rates-12/NNS	amod||cancer-15/NN||pancreatic-14/JJ	prep_from||rates-12/NNS||cancer-15/NN	prepc_compared_to||have-9/VBP||to-17/TO	pobj||have-9/VBP||patients-18/NNS	amod||levels-21/NNS||lower-20/JJR	prep_with||patients-18/NNS||levels-21/NNS	amod||glucose-25/NN||fasting-23/VBG	nn||glucose-25/NN||serum-24/NN	prep_of||levels-21/NNS||glucose-25/NN	glucose-25||cancer-15||no_rel||patients with higher levels of fasting serum glucose have higher death rates from pancreatic cancer compared to patients with lower levels of fasting serum glucose.
det||effects-3/NNS||the-1/DT	amod||effects-3/NNS||inhibitory-2/JJ	nsubj||similar-9/JJ||effects-3/NNS	det||antibodies-7/NNS||these-5/DT	num||antibodies-7/NNS||five-6/CD	prep_of||effects-3/NNS||antibodies-7/NNS	cop||similar-9/JJ||were-8/VBD	root||ROOT-0/null||similar-9/JJ	det||specific-19/NN||those-11/DT	amod||specific-19/NN||observed-12/JJ	det||antibody-18/NN||a-14/DT	advmod||described-16/JJ||previously-15/RB	amod||antibody-18/NN||described-16/JJ	nn||antibody-18/NN||neutralizing-17/NN	prep_with||observed-12/JJ||antibody-18/NN	prep_to||similar-9/JJ||specific-19/NN	det||loop-24/NN||the-21/DT	amod||loop-24/NN||140s-22/JJ	amod||loop-24/NN||antigenic-23/JJ	prep_for||specific-19/NN||loop-24/NN	ccomp||similar-9/JJ||present-25/VB	prep_within||present-25/VB||ha1-27/CD	ccomp||similar-9/JJ||highlight-29/VB	conj_and||present-25/VB||highlight-29/VB	det||possibility-32/NN||the-30/DT	amod||possibility-32/NN||exciting-31/JJ	dobj||highlight-29/VB||possibility-32/NN	mark||efficacious-38/NNS||that-33/IN	det||antibodies-35/NNS||these-34/DT	nsubj||efficacious-38/NNS||antibodies-35/NNS	aux||efficacious-38/NNS||may-36/MD	cop||efficacious-38/NNS||be-37/VB	ccomp||similar-9/JJ||efficacious-38/NNS	amod||strains-42/NNS||multiple-40/JJ	amod||strains-42/NNS||h5n1-41/JJ	prep_against||efficacious-38/NNS||strains-42/NNS	h5n1-41||antibodies-35||no_rel||the inhibitory effects of these five antibodies were similar to those observed with a previously described neutralizing antibody specific for the 140s antigenic loop present within ha1 and highlight the exciting possibility that these antibodies may be efficacious against multiple h5n1 strains.
ccomp||causes-10/VBZ||similar-1/JJ	nn||propofol-5/NN||lipid-3/NN	nn||propofol-5/NN||emulsion-4/NN	prep_to||similar-1/JJ||propofol-5/NN	nn||propofol-8/NN||microemulsion-7/NN	nsubj||causes-10/VBZ||propofol-8/NN	advmod||causes-10/VBZ||also-9/RB	root||ROOT-0/null||causes-10/VBZ	det||incidence-13/NN||a-11/DT	amod||incidence-13/NN||high-12/JJ	dobj||causes-10/VBZ||incidence-13/NN	prep_of||incidence-13/NN||pain-15/NN	amod||injection-18/NN||intravenous-17/JJ	prep_during||causes-10/VBZ||injection-18/NN	pain-15||propofol-8||yes||similar to lipid emulsion propofol, microemulsion propofol also causes a high incidence of pain during intravenous injection.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubjpass||recommended-12/VBN||treatment-3/NN	prep_of||treatment-3/NN||malaria-5/NN	prep_with||malaria-5/NN||sulphadoxine-pyrimethamine-7/NN	appos||treatment-3/NN||sp-9/NN	auxpass||recommended-12/VBN||is-11/VBZ	root||ROOT-0/null||recommended-12/VBN	det||prevention-15/NN||the-14/DT	prep_for||recommended-12/VBN||prevention-15/NN	prep_of||prevention-15/NN||malaria-17/NN	prep_in||recommended-12/VBN||pregnancy-19/NN	amod||africa-22/NN||sub-saharan-21/JJ	prep_in||pregnancy-19/NN||africa-22/NN	malaria-17||pyrimethamine--1||yes||intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine (sp) is recommended for the prevention of malaria in pregnancy in sub-saharan africa.
det||ulcer-2/NN||the-1/DT	nsubj||improved-3/VBD||ulcer-2/NN	root||ROOT-0/null||improved-3/VBD	advmod||slightly-5/RB||only-4/RB	dobj||improved-3/VBD||slightly-5/RB	num||months-8/NNS||2-7/CD	prep_after||improved-3/VBD||months-8/NNS	amod||ointment-12/NN||povidone-iodine-10/JJ	nn||ointment-12/NN||sugar-11/NN	prep_with||improved-3/VBD||ointment-12/NN	amod||nausea-16/NN||severe-15/JJ	prep_because_of||ointment-12/NN||nausea-16/NN	prep_because_of||ointment-12/NN||anorexia-18/NN	conj_and||nausea-16/NN||anorexia-18/NN	sugar-11||anorexia-18||no_rel||the ulcer improved only slightly after 2 months with povidone-iodine sugar ointment because of severe nausea and anorexia.
mark||assess-4/VB||in-1/IN	dep||assess-4/VB||order-2/NN	aux||assess-4/VB||to-3/TO	advcl||study-13/VBP||assess-4/VB	amod||value-7/NN||combined-5/VBN	amod||value-7/NN||diagnostic-6/JJ	dobj||assess-4/VB||value-7/NN	det||tests-10/NNS||these-9/DT	prep_of||value-7/NN||tests-10/NNS	nsubj||study-13/VBP||we-12/PRP	root||ROOT-0/null||study-13/VBP	det||profiles-16/NNS||the-14/DT	amod||profiles-16/NNS||kinetic-15/JJ	dobj||study-13/VBP||profiles-16/NNS	prepc_of||profiles-16/NNS||circulating-18/VBG	amod||igm-22/NN||ns1-19/JJ	amod||igm-22/NN||dengue-21/JJ	dobj||circulating-18/VBG||igm-22/NN	nn||antibodies-25/NNS||igg-24/NN	dobj||circulating-18/VBG||antibodies-25/NNS	conj_and||igm-22/NN||antibodies-25/NNS	det||course-28/NN||the-27/DT	prep_over||igm-22/NN||course-28/NN	det||disease-31/NN||the-30/DT	prep_of||course-28/NN||disease-31/NN	prepc_by||circulating-18/VBG||using-33/VBG	det||denv1-40/NN||an-34/DT	amod||denv1-40/NN||in-house-35/JJ	amod||denv1-40/NN||dengue-36/JJ	nn||denv1-40/NN||type-37/NN	num||denv1-40/NN||1-38/CD	dobj||using-33/VBG||denv1-40/NN	amod||elisa-45/NN||specific-42/JJ	amod||elisa-45/NN||ns1-43/JJ	nn||elisa-45/NN||capture-44/NN	dep||denv1-40/NN||elisa-45/NN	det||igm-51/NN||the-47/DT	amod||igm-51/NN||commercial-48/JJ	nn||igm-51/NN||panbio-49/NN	nn||igm-51/NN||dengue-50/NN	dobj||using-33/VBG||igm-51/NN	conj_and||denv1-40/NN||igm-51/NN	nn||elisas-55/NNS||igg-53/NN	nn||elisas-55/NNS||capture-54/NN	conj_and||denv1-40/NN||elisas-55/NNS	conj_and||igm-51/NN||elisas-55/NNS	antibodies-25||dengue-50||no_rel||in order to assess combined diagnostic value of these tests, we study the kinetic profiles of circulating ns1, dengue igm and igg antibodies over the course of the disease by using an in-house dengue type 1 (denv1) specific ns1 capture elisa and the commercial panbio dengue igm and igg capture elisas.
det||phenolic-3/NN||the-1/DT	amod||phenolic-3/NN||species-specific-2/JJ	nsubj||glycolipid-4/VBD||phenolic-3/NN	root||ROOT-0/null||glycolipid-4/VBD	nsubjpass||suspected-10/VBN||1-5/CD	nsubj||play-12/VB||1-5/CD	dep||1-5/CD||pgl-1-7/JJ	auxpass||suspected-10/VBN||is-9/VBZ	ccomp||glycolipid-4/VBD||suspected-10/VBN	aux||play-12/VB||to-11/TO	xcomp||suspected-10/VBN||play-12/VB	det||role-15/NN||a-13/DT	amod||role-15/NN||critical-14/JJ	dobj||play-12/VB||role-15/NN	det||pathogenesis-18/NNS||the-17/DT	prep_in||play-12/VB||pathogenesis-18/NNS	prep_of||pathogenesis-18/NNS||leprosy-20/NNP	det||disease-24/NN||a-22/DT	amod||disease-24/NN||chronic-23/JJ	prep_in||play-12/VB||disease-24/NN	conj_and||pathogenesis-18/NNS||disease-24/NN	det||skin-27/NN||the-26/DT	prep_of||disease-24/NN||skin-27/NN	amod||nerves-30/NNS||peripheral-29/JJ	prep_in||play-12/VB||nerves-30/NNS	conj_and||pathogenesis-18/NNS||nerves-30/NNS	vmod||nerves-30/NNS||caused-31/VBN	agent||caused-31/VBN||mycobacteriumleprae-33/NN	leprosy-20||mycobacteriumleprae-33||no||the species-specific phenolic glycolipid 1 (pgl-1) is suspected to play a critical role in the pathogenesis of leprosy, a chronic disease of the skin and peripheral nerves caused by mycobacteriumleprae .
det||receptor-8/NN||the-1/DT	amod||receptor-8/NN||insulin-like-2/JJ	nn||receptor-8/NN||growth-3/NN	nn||receptor-8/NN||factor-4/NN	num||receptor-8/NN||1-5/CD	nn||receptor-8/NN||tyrosine-6/NN	nn||receptor-8/NN||kinase-7/NN	nsubjpass||shown-22/VBN||receptor-8/NN	nsubj||play-24/VB||receptor-8/NN	dep||receptor-8/NN||igf-1r-10/JJ	det||receptor-17/NN||the-13/DT	amod||receptor-17/NN||chemokine-14/JJ	amod||receptor-17/NN||g-protein-15/JJ	nn||receptor-17/NN||coupled-16/NN	conj_and||receptor-8/NN||receptor-17/NN	nsubjpass||shown-22/VBN||receptor-17/NN	nsubj||play-24/VB||receptor-17/NN	appos||receptor-17/NN||cxcr4-19/NNS	aux||shown-22/VBN||have-20/VBP	auxpass||shown-22/VBN||been-21/VBN	root||ROOT-0/null||shown-22/VBN	aux||play-24/VB||to-23/TO	xcomp||shown-22/VBN||play-24/VB	det||role-27/NN||an-25/DT	amod||role-27/NN||important-26/JJ	dobj||play-24/VB||role-27/NN	nn||metastasis-31/NNS||breast-29/NN	nn||metastasis-31/NNS||cancer-30/NN	prep_in||play-24/VB||metastasis-31/NNS	insulin--1||cancer-30||no_rel||the insulin-like growth factor 1 tyrosine kinase receptor (igf-1r) and the chemokine g-protein coupled receptor, cxcr4 have been shown to play an important role in breast cancer metastasis.
expl||were-2/VBD||there-1/EX	root||ROOT-0/null||were-2/VBD	amod||cases-4/NNS||295-3/JJ	nsubj||were-2/VBD||cases-4/NNS	prep_of||diagnosed-31/VBN||cases-4/NNS	prep_of||cases-4/NNS||ibd-6/NN	dep||cases-4/NNS||uc-8/VBN	dep||240-10/CD||=-9/SYM	ccomp||uc-8/VBN||240-10/CD	ccomp||uc-8/VBN||cd-12/VB	dep||55-14/CD||=-13/SYM	ccomp||cd-12/VB||55-14/CD	nsubjpass||diagnosed-31/VBN||34-19/CD	dep||34-19/CD||uc-21/VBN	dep||30-23/CD||=-22/SYM	ccomp||uc-21/VBN||30-23/CD	ccomp||uc-21/VBN||cd-25/VB	dep||4-27/CD||=-26/SYM	ccomp||cd-25/VB||4-27/CD	auxpass||diagnosed-31/VBN||were-29/VBD	advmod||diagnosed-31/VBN||newly-30/RB	rcmod||cases-4/NNS||diagnosed-31/VBN	det||year-35/NN||the-33/DT	nn||year-35/NN||study-34/NN	prep_during||diagnosed-31/VBN||year-35/NN	cd-25||ibd-6||no_rel||there were 295 cases of ibd (uc = 240, cd = 55), of which 34 (uc = 30, cd = 4) were newly diagnosed during the study year.
det||epidemic-2/NN||the-1/DT	nsubjpass||caused-9/VBN||epidemic-2/NN	prep_of||epidemic-2/NN||severeacuterespiratorysyndrome-4/NN	appos||epidemic-2/NN||sars-6/NNS	auxpass||caused-9/VBN||was-8/VBD	root||ROOT-0/null||caused-9/VBN	det||coronavirus-14/NNS||a-11/DT	advmod||emerged-13/JJ||newly-12/RB	amod||coronavirus-14/NNS||emerged-13/JJ	agent||caused-9/VBN||coronavirus-14/NNS	appos||coronavirus-14/NNS||sars-cov-16/NNP	sars-6||sars-cov-16||no||the epidemic of severeacuterespiratorysyndrome (sars) was caused by a newly emerged coronavirus (sars-cov).
advmod||bolster-4/VB||additionally-1/RB	nsubj||bolster-4/VB||we-3/PRP	root||ROOT-0/null||bolster-4/VB	poss||reclassification-7/NN||our-5/PRP$	amod||reclassification-7/NN||recent-6/JJ	dobj||bolster-4/VB||reclassification-7/NN	prep_of||reclassification-7/NN||rickettsia-9/NN	prepc_by||bolster-4/VB||identifying-11/VBG	dobj||identifying-11/VBG||ogs-12/NN	nsubj||define-14/VB||ogs-12/NN	rcmod||ogs-12/NN||define-14/VB	det||ag-16/NN||the-15/DT	nsubj||rickettsiae-40/JJ||ag-16/NN	amod||group-19/NN||ancestral-18/JJ	appos||ag-16/NN||group-19/NN	conj_and||ag-16/NN||tg-22/NN	nsubj||rickettsiae-40/JJ||tg-22/NN	amod||group-25/NN||typhus-24/JJ	appos||tg-22/NN||group-25/NN	conj_and||ag-16/NN||trg-28/NN	nsubj||rickettsiae-40/JJ||trg-28/NN	amod||group-31/NN||transitional-30/JJ	appos||trg-28/NN||group-31/NN	conj_and||ag-16/NN||sfg-35/NN	nsubj||rickettsiae-40/JJ||sfg-35/NN	nn||group-38/NN||spottedfever-37/NN	appos||ag-16/NN||group-38/NN	xcomp||define-14/VB||rickettsiae-40/JJ	typhus-24||rickettsiae-40||no||additionally, we bolster our recent reclassification of rickettsia by identifying ogs that define the ag (ancestral group), tg (typhus group), trg (transitional group), and sfg (spottedfever group) rickettsiae.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||investigate-8/VB||aim-2/NN	nsubj||explore-21/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||level-12/NN||the-9/DT	amod||level-12/NN||cd127-10/JJ	nn||level-12/NN||expression-11/NN	dobj||investigate-8/VB||level-12/NN	amod||subsets-15/NNS||different-14/JJ	prep_on||investigate-8/VB||subsets-15/NNS	amod||cell-19/NN||cd8-17/JJ	nn||cell-19/NN||t-18/NN	prep_of||subsets-15/NNS||cell-19/NN	xcomp||was-6/VBD||explore-21/VB	conj_and||investigate-8/VB||explore-21/VB	det||relationship-23/NN||the-22/DT	dobj||explore-21/VB||relationship-23/NN	amod||expression-26/NN||cd127-25/JJ	prep_between||relationship-23/NN||expression-26/NN	amod||cells-31/NNS||cd8-28/JJ	nn||cells-31/NNS||memory-29/NN	nn||cells-31/NNS||t-30/NN	prep_on||expression-26/NN||cells-31/NNS	amod||dna-38/NN||serumhepatitisb-33/JJ	amod||dna-38/NN||virus-34/JJ	appos||dna-38/NN||hbv-36/NN	prep_between||relationship-23/NN||dna-38/NN	conj_and||expression-26/NN||dna-38/NN	nn||levels-46/NNS||hepatitisb-40/NN	nn||levels-46/NNS||e-41/NNS	nn||levels-46/NNS||antigen-42/NN	appos||levels-46/NNS||hbeag-44/NN	conj_and||expression-26/NN||levels-46/NNS	conj_and||dna-38/NN||levels-46/NNS	prep_in||dna-38/NN||patients-48/NNS	prep_with||patients-48/NNS||chronichepatitisb-50/NN	appos||chronichepatitisb-50/NN||chb-52/NN	hepatitisb-40||hepatitisbvirus--1||no||the aim of this study was to investigate the cd127 expression level on different subsets of cd8 t cell and explore the relationship between cd127 expression on cd8 memory t cells and serumhepatitisb virus (hbv) dna and hepatitisb e antigen (hbeag) levels in patients with chronichepatitisb (chb).
nsubj||cause-5/NN||staphylococcusaureus-1/NNS	cop||cause-5/NN||is-2/VBZ	det||cause-5/NN||a-3/DT	amod||cause-5/NN||common-4/JJ	ccomp||-lrb--25/VBD||cause-5/NN	amod||infection-8/NN||human-7/JJ	prep_of||cause-5/NN||infection-8/NN	nsubj||concern-18/NN||emergence-11/NN	amod||s.aureus-14/NNS||vancomycin-resistance-13/JJ	prep_of||emergence-11/NN||s.aureus-14/NNS	cop||concern-18/NN||is-15/VBZ	det||concern-18/NN||a-16/DT	amod||concern-18/NN||great-17/JJ	conj_and||cause-5/NN||concern-18/NN	ccomp||-lrb--25/VBD||concern-18/NN	prep_for||concern-18/NN||treatment-20/NN	amod||s.aureus-23/NNS||methicillin-resistant-22/JJ	prep_of||treatment-20/NN||s.aureus-23/NNS	root||ROOT-0/null||-lrb--25/VBD	nn||-rrb--27/NNS||mrsa-26/NN	dobj||-lrb--25/VBD||-rrb--27/NNS	amod||years-30/NNS||recent-29/JJ	prep_in||-lrb--25/VBD||years-30/NNS	num||-rrb--33/NN||-lrb--31/CD	nn||-rrb--33/NN||mrsa-32/NN	nsubj||-lrb--25/VBD||-rrb--33/NN	mrsa-32||staphylococcusaureus-1||no||staphylococcusaureus is a common cause of human infection , and emergence of vancomycin-resistance s.aureus is a great concern for treatment of methicillin-resistant s.aureus , -lrb- mrsa -rrb- in recent years -lrb- mrsa -rrb- .
amod||outcome-2/NN||main-1/JJ	nsubj||measures-3/VBZ||outcome-2/NN	root||ROOT-0/null||measures-3/VBZ	nsubj||investigated-5/VBD||we-4/PRP	ccomp||measures-3/VBZ||investigated-5/VBD	advmod||affected-18/VBN||how-6/WRB	num||measures-8/NNS||three-7/CD	nsubjpass||affected-18/VBN||measures-8/NNS	det||arrangements-12/NNS||the-10/DT	amod||arrangements-12/NNS||living-11/VBG	prep_of||measures-8/NNS||arrangements-12/NNS	amod||people-15/NNS||older-14/JJR	prep_of||arrangements-12/NNS||people-15/NNS	aux||affected-18/VBN||have-16/VBP	auxpass||affected-18/VBN||been-17/VBN	ccomp||investigated-5/VBD||affected-18/VBN	det||epidemic-22/NN||the-20/DT	amod||epidemic-22/NN||hiv/aids-21/JJ	agent||affected-18/VBN||epidemic-22/NN	det||number-24/NN||the-23/DT	dobj||affected-18/VBN||number-24/NN	amod||individuals-27/NNS||older-26/JJR	prep_of||number-24/NN||individuals-27/NNS	vmod||individuals-27/NNS||living-28/VBG	advmod||living-28/VBG||alone-29/RB	nsubj||number-35/NN||that-31/WDT	cop||number-35/NN||is-32/VBZ	det||number-35/NN||the-34/DT	parataxis||living-28/VBG||number-35/NN	amod||people-39/NNS||unattended-37/JJ	amod||people-39/NNS||elderly-38/JJ	prep_of||number-35/NN||people-39/NNS	det||number-43/NN||the-42/DT	dobj||affected-18/VBN||number-43/NN	conj_and||number-24/NN||number-43/NN	amod||individuals-46/NNS||older-45/JJR	prep_of||number-43/NN||individuals-46/NNS	vmod||individuals-46/NNS||living-47/VBG	advmod||dependent-50/JJ||only-49/RB	amod||children-51/NNS||dependent-50/JJ	prep_with||living-47/VBG||children-51/NNS	det||age-54/NN||the-53/DT	prep_under||living-47/VBG||age-54/NN	prep_of||age-54/NN||10-56/CD	nsubj||is-59/VBZ||that-58/WDT	parataxis||living-47/VBG||is-59/VBZ	dep||is-59/VBZ||in-61/IN	amod||households-64/NNS||missing-62/VBG	nn||households-64/NNS||generation-63/NN	pobj||in-61/IN||households-64/NNS	det||number-69/NN||the-68/DT	dobj||affected-18/VBN||number-69/NN	conj_and||number-24/NN||number-69/NN	prep_of||number-69/NN||adults-71/NNS	dep||adults-71/NNS||age-72/NN	num||age-72/NN||18-59-73/CD	nsubj||adults-80/NNS||that-75/WDT	cop||adults-80/NNS||is-76/VBZ	amod||adults-80/NNS||prime-78/JJ	nn||adults-80/NNS||age-79/NN	dep||adults-71/NNS||adults-80/NNS	prep_per||adults-71/NNS||household-83/NN	advmod||lives-88/VBZ||where-84/WRB	det||person-87/NN||an-85/DT	amod||person-87/NN||older-86/JJR	nsubj||lives-88/VBZ||person-87/NN	advcl||affected-18/VBN||lives-88/VBZ	aids--1||hiv--1||no||main outcome measures we investigated how three measures of the living arrangements of older people have been affected by the hiv/aids epidemic the number of older individuals living alone (that is, the number of unattended elderly people); the number of older individuals living with only dependent children under the age of 10 (that is, in missing generation households); and the number of adults age 18-59 (that is, prime age adults) per household where an older person lives.
nsubj||suspect-2/VBP||all-1/DT	root||ROOT-0/null||suspect-2/VBP	amod||cases-4/NNS||h5n1-3/JJ	nsubjpass||tested-6/VBN||cases-4/NNS	auxpass||tested-6/VBN||were-5/VBD	ccomp||suspect-2/VBP||tested-6/VBN	nn||assays-14/NNS||polymerase-8/NN	nn||assays-14/NNS||chain-9/NN	nn||assays-14/NNS||reaction-10/NN	nn||assays-14/NNS||pcr-12/NN	prep_with||tested-6/VBN||assays-14/NNS	prepc_for||tested-6/VBN||influenza-16/VBG	det||h5n1-19/NNS||a-17/DT	dobj||influenza-16/VBG||h5n1-19/NNS	dobj||influenza-16/VBG||humaninfluenzaviruses-22/NNS	conj_and||h5n1-19/NNS||humaninfluenzaviruses-22/NNS	h5n1-19||influenzaviruses--1||no||all suspect h5n1 cases were tested with polymerase chain reaction (pcr) assays for influenza a(h5n1) and humaninfluenzaviruses.
nsubj||were-2/VBD||data-1/NNS	root||ROOT-0/null||were-2/VBD	amod||men-6/NNS||hiv-infected-4/JJ	amod||men-6/NNS||homosexual-5/JJ	prep_from||were-2/VBD||men-6/NNS	amod||dates-9/NNS||well-estimated-8/JJ	prep_with||were-2/VBD||dates-9/NNS	prep_of||dates-9/NNS||hivseroconversion-11/NN	dep||dates-9/NNS||ie-13/VB	dep||ie-13/VB||change-15/VB	prep_in||ie-13/VB||status-17/NN	cop||negative-21/JJ||being-19/VBG	advmod||negative-21/JJ||hiv-20/RB	prepc_from||ie-13/VB||negative-21/JJ	aux||detected-26/VBN||having-23/VBG	nn||antibodies-25/NNS||hiv-24/NN	dobj||detected-26/VBN||antibodies-25/NNS	prepc_to||negative-21/JJ||detected-26/VBN	hivseroconversion-11||hiv-24||no||data were from hiv-infected homosexual men with well-estimated dates of hivseroconversion (ie, change in status from being hiv negative to having hiv antibodies detected).
poss||insulinglargine-5/NN||conclusions-1/NNS	amod||insulinglargine-5/NN||$-3/JJ	nsubjpass||associated-7/VBN||insulinglargine-5/NN	auxpass||associated-7/VBN||is-6/VBZ	root||ROOT-0/null||associated-7/VBN	amod||reductions-10/NNS||greater-9/JJR	prep_with||associated-7/VBN||reductions-10/NNS	nn||variability-13/NN||glucose-12/NN	prep_in||reductions-10/NNS||variability-13/NN	amod||insulin-16/NN||nph/lente-15/JJ	prep_than||associated-7/VBN||insulin-16/NN	amod||patients-19/NNS||pediatric-18/JJ	prep_in||insulin-16/NN||patients-19/NNS	prep_with||associated-7/VBN||type1diabetes-21/CD	type1diabetes-21||insulinglargine-5||yes||conclusions âinsulinglargine is associated with greater reductions in glucose variability than nph/lente insulin in pediatric patients with type1diabetes.
det||outbreak-3/NN||an-2/DT	prep_during||revealed-17/VBD||outbreak-3/NN	amod||sars-7/NNS||severeacuterespiratorysyndrome-5/JJ	prep_of||outbreak-3/NN||sars-7/NNS	prep_in||sars-7/NNS||march-10/NN	num||march-10/NN||2003-11/CD	nsubj||revealed-17/VBD||hybridization-13/NN	det||microarray-16/NN||this-15/DT	prep_to||hybridization-13/NN||microarray-16/NN	root||ROOT-0/null||revealed-17/VBD	det||presence-19/NN||the-18/DT	dobj||revealed-17/VBD||presence-19/NN	det||coronavirus-24/NNS||a-21/DT	advmod||uncharacterized-23/JJ||previously-22/RB	amod||coronavirus-24/NNS||uncharacterized-23/JJ	prep_of||presence-19/NN||coronavirus-24/NNS	det||cultivated-29/NNS||a-26/DT	amod||cultivated-29/NNS||viral-27/JJ	num||cultivated-29/NNS||isolate-28/CD	prep_in||coronavirus-24/NNS||cultivated-29/NNS	det||patient-33/NN||a-31/DT	amod||patient-33/NN||sars-32/JJ	prep_from||revealed-17/VBD||patient-33/NN	sars-32||coronavirus-24||no||during an outbreak of severeacuterespiratorysyndrome (sars) in march 2003, hybridization to this microarray revealed the presence of a previously uncharacterized coronavirus in a viral isolate cultivated from a sars patient.
nn||glucose-2/NN||plasma-1/NN	nsubjpass||measured-12/VBN||glucose-2/NN	nsubjpass||measured-12/VBN||glucose-2/NN	nsubjpass||measured-12/VBN||glucose-2/NN	conj_and||glucose-2/NN||insulin-4/NN	nsubjpass||measured-12/VBN||insulin-4/NN	conj_and||glucose-2/NN||c-peptide-6/NN	nsubjpass||measured-12/VBN||c-peptide-6/NN	nn||concentrations-10/NNS||glucagon-9/NN	conj_and||glucose-2/NN||concentrations-10/NNS	nsubjpass||measured-12/VBN||concentrations-10/NNS	auxpass||measured-12/VBN||were-11/VBD	root||ROOT-0/null||measured-12/VBN	conj_and||measured-12/VBN||measured-12/VBN	conj_and||measured-12/VBN||measured-12/VBN	det||min-15/NN||every-13/DT	num||min-15/NN||30-14/CD	dobj||measured-12/VBN||min-15/NN	amod||ingestion-42/NN||â-17/JJ	dep||â-17/JJ||60-18/CD	num||min-21/NN||180-20/CD	prep_through||â-17/JJ||min-21/NN	amod||administration-26/NN||random-sequence-23/JJ	amod||administration-26/NN||double-blind-25/JJ	prep_with||min-21/NN||administration-26/NN	prep_of||administration-26/NN||diazoxide-28/NN	num||mg/kg-31/NN||6.0-30/CD	appos||diazoxide-28/NN||mg/kg-31/NN	prep_of||administration-26/NN||placebo-34/NN	conj_or||diazoxide-28/NN||placebo-34/NN	amod||min-40/NN||â-36/JJ	dep||â-36/JJ||30-37/CD	dep||â-36/JJ||1-39/CD	conj_and||30-37/CD||1-39/CD	prep_at||placebo-34/NN||min-40/NN	prep_from||measured-12/VBN||ingestion-42/NN	det||meal-47/NN||a-44/DT	nn||meal-47/NN||formula-45/NN	amod||meal-47/NN||mixed-46/JJ	prep_of||ingestion-42/NN||meal-47/NN	parataxis||measured-12/VBN||ensure-49/VB	advmod||ensure-49/VB||plus-50/CC	prep_at||measured-12/VBN||0-53/CD	vmod||0-53/CD||min-54/VBN	prep_after||min-54/VBN||diazoxide-56/NN	prep_after||min-54/VBN||placebo-59/NN	conj_and||diazoxide-56/NN||placebo-59/NN	cc||measured-12/VBN||and-60/CC	det||occasion-65/NN||a-63/DT	amod||occasion-65/NN||separate-64/JJ	prep_on||measured-12/VBN||occasion-65/NN	npadvmod||measured-12/VBN||ingestion-67/NN	prep_of||ingestion-67/NN||glimepiride-69/NN	number||mg-72/CD||4.0-71/CD	dep||glimepiride-69/NN||mg-72/CD	num||min-76/NN||0-75/CD	prep_at||glimepiride-69/NN||min-76/NN	prep_with||glimepiride-69/NN||glucose-79/NN	vmod||glucose-79/NN||infused-80/VBN	aux||prevent-82/VB||to-81/TO	xcomp||infused-80/VBN||prevent-82/VB	dobj||prevent-82/VB||hypoglycemia-83/NN	prep_after||measured-12/VBN||diazoxide-86/NN	prep_after||measured-12/VBN||placebo-89/NN	num||adults-94/NNS||11-91/CD	amod||adults-94/NNS||healthy-92/JJ	amod||adults-94/NNS||young-93/JJ	prep_in||placebo-89/NN||adults-94/NNS	hypoglycemia-83||diazoxide-86||yes||plasma glucose, insulin, c-peptide, and glucagon concentrations were measured every 30 min from â60 through 180 min with random-sequence, double-blind administration of diazoxide (6.0 mg/kg) or placebo at â30 and 1 min, ingestion of a formula mixed meal (ensure plus) at 0 min after diazoxide and after placebo and, on a separate occasion, ingestion of glimepiride (4.0 mg) at 0 min (with glucose infused to prevent hypoglycemia) after diazoxide and after placebo in 11 healthy young adults.
aux||estimate-2/VB||to-1/TO	advcl||conducted-13/VBD||estimate-2/VB	det||dynamics-5/NNS||the-3/DT	nn||dynamics-5/NNS||transmission-4/NN	dobj||estimate-2/VB||dynamics-5/NNS	nn||tb-10/NN||mdr-7/NN	conj_and||mdr-7/NN||xdr-9/NN	nn||tb-10/NN||xdr-9/NN	prep_of||dynamics-5/NNS||tb-10/NN	nsubj||conducted-13/VBD||we-12/PRP	root||ROOT-0/null||conducted-13/VBD	det||analysis-17/NN||a-14/DT	nn||analysis-17/NN||dna-15/NN	amod||analysis-17/NN||fingerprinting-16/VBG	dobj||conducted-13/VBD||analysis-17/NN	num||strains-22/NNS||55-19/CD	nn||strains-22/NNS||mdr/xdr-20/NN	nn||strains-22/NNS||mycobacteriumtuberculosis-21/NN	prep_of||analysis-17/NN||strains-22/NNS	vmod||strains-22/NNS||isolated-23/VBN	nn||patients-26/NNS||tb-25/NN	prep_from||isolated-23/VBN||patients-26/NNS	prep_throughout||isolated-23/VBN||japan-28/NN	prep_in||japan-28/NN||2002-30/CD	tb-25||mycobacteriumtuberculosis-21||no||to estimate the transmission dynamics of mdr and xdr tb, we conducted a dna fingerprinting analysis of 55 mdr/xdr mycobacteriumtuberculosis strains isolated from tb patients throughout japan in 2002.
amod||chemotherapeutics-2/NNS||first-line-1/JJ	nsubj||dacarbazine-11/NN||chemotherapeutics-2/NNS	vmod||chemotherapeutics-2/NNS||used-3/VBN	nn||therapy-6/NN||melanoma-5/NN	prep_in||used-3/VBN||therapy-6/NN	cop||dacarbazine-11/NN||are-7/VBP	det||dacarbazine-11/NN||the-8/DT	amod||dacarbazine-11/NN||methylating-9/VBG	nn||dacarbazine-11/NN||agents-10/NNS	root||ROOT-0/null||dacarbazine-11/NN	dep||dacarbazine-11/NN||dtic-13/JJ	conj_and||dacarbazine-11/NN||temozolomide-16/NN	appos||temozolomide-16/NN||tmz-18/NN	det||agents-23/NNS||the-21/DT	amod||agents-23/NNS||chloroethylating-22/VBG	conj_and||dacarbazine-11/NN||agents-23/NNS	conj_and||temozolomide-16/NN||agents-23/NNS	amod||agents-23/NNS||bcnu-24/JJ	amod||agents-23/NNS||fotemustine-26/JJ	conj_and||bcnu-24/JJ||fotemustine-26/JJ	melanoma-5||dacarbazine-11||yes||first-line chemotherapeutics used in melanoma therapy are the methylating agents dacarbazine (dtic) and temozolomide (tmz) and the chloroethylating agents bcnu and fotemustine.
advmod||2006-11/VB||consecutively-1/RB	csubj||2006-11/VB||admitted-2/VBN	dobj||admitted-2/VBN||patients-3/NNS	det||period-6/NN||the-5/DT	prep_during||admitted-2/VBN||period-6/NN	tmod||admitted-2/VBN||august-7/NNP	num||august-7/NNP||2005-8/CD	prep||admitted-2/VBN||to-9/TO	aux||2006-11/VB||may-10/MD	root||ROOT-0/null||2006-11/VB	det||center-15/NN||the-14/DT	prep_in||recruited-41/VBN||center-15/NN	nn||psychiatry-18/NN||addiction-17/NN	prep_for||center-15/NN||psychiatry-18/NN	amod||institute-21/NN||central-20/JJ	nsubjpass||recruited-41/VBN||institute-21/NN	nsubjpass||administered-46/VBN||institute-21/NN	nn||india-27/NN||psychiatry-23/NN	dep||india-27/NN||ranchi-25/NN	prep_of||institute-21/NN||india-27/NN	amod||diagnosis-34/NN||icd-10-30/JJ	appos||diagnosis-34/NN||dcr-32/NN	prep_with||india-27/NN||diagnosis-34/NN	amod||syndrome-39/NN||alcoholdependencesyndrome-36/JJ	conj_or||alcoholdependencesyndrome-36/JJ||opioiddependence-38/JJ	amod||syndrome-39/NN||opioiddependence-38/JJ	prep_of||diagnosis-34/NN||syndrome-39/NN	auxpass||recruited-41/VBN||were-40/VBD	ccomp||2006-11/VB||recruited-41/VBN	conj_and||2006-11/VB||recruited-41/VBN	det||study-44/NN||the-43/DT	prep_for||recruited-41/VBN||study-44/NN	ccomp||2006-11/VB||administered-46/VBN	conj_and||2006-11/VB||administered-46/VBN	conj_and||recruited-41/VBN||administered-46/VBN	det||drug-51/NN||the-47/DT	nn||drug-51/NN||alcohol-48/NN	conj_or||alcohol-48/NN||other-50/JJ	nn||drug-51/NN||other-50/JJ	dobj||administered-46/VBN||drug-51/NN	dep||drug-51/NN||opioid-53/JJ	punct||drug-51/NN||section-55/,	prep_of||drug-51/NN||ssaga-ii-57/NN	advmod||ssaga-ii-57/NN||respectively-59/RB	det||data-63/NNS||the-62/DT	nsubjpass||entered-65/VBN||data-63/NNS	auxpass||entered-65/VBN||was-64/VBD	conj_and||2006-11/VB||entered-65/VBN	det||sheet-70/NN||the-67/DT	amod||sheet-70/NN||corresponding-68/JJ	nn||sheet-70/NN||tally-69/NN	prep_in||entered-65/VBN||sheet-70/NN	alcoholdependencesyndrome-36||alcohol-48||no||consecutively admitted patients during the period august 2005 to may 2006, in the center for addiction psychiatry, central institute of psychiatry, ranchi, india, with icd-10 (dcr) diagnosis of alcoholdependencesyndrome or opioiddependence syndrome were recruited for the study and administered the alcohol or other drug (opioid) section of ssaga-ii, respectively, and the data was entered in the corresponding tally sheet.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	ccomp||was-6/VBD||evaluate-8/VB	det||effect-10/NN||the-9/DT	dobj||evaluate-8/VB||effect-10/NN	amod||patients-26/NNS||tegaserod-12/JJ	prep_on||tegaserod-12/JJ||symptoms-14/NNS	prep_on||tegaserod-12/JJ||quality-16/NN	conj_and||symptoms-14/NNS||quality-16/NN	prep_of||symptoms-14/NNS||life-18/NN	appos||life-18/NN||qol-20/NN	prep_in||life-18/NN||korean-23/NN	amod||patients-26/NNS||female-24/JJ	nn||patients-26/NNS||ibs-25/NN	prep_of||effect-10/NN||patients-26/NNS	prep_with||evaluate-8/VB||constipation-28/NN	aux||evaluate-31/VB||to-30/TO	ccomp||was-6/VBD||evaluate-31/VB	conj_and||evaluate-8/VB||evaluate-31/VB	det||usefulness-33/NN||the-32/DT	dobj||evaluate-31/VB||usefulness-33/NN	det||ibs-qol-36/NN||the-35/DT	prep_of||usefulness-33/NN||ibs-qol-36/NN	amod||study-39/NN||clinical-38/JJ	prep_in||ibs-qol-36/NN||study-39/NN	ibs-25||tegaserod-12||yes||the aim of this study was to evaluate the effect of tegaserod on symptoms and quality of life (qol) in korean female ibs patients with constipation and to evaluate the usefulness of the ibs-qol in clinical study.
det||objective-2/NN||the-1/DT	nsubj||was-7/VBD||objective-2/NN	nsubj||assess-9/VB||objective-2/NN	nsubj||associated-16/JJ||objective-2/NN	det||study-6/NN||this-4/DT	amod||study-6/NN||observational-5/JJ	prep_of||objective-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||assess-9/VB||to-8/TO	xcomp||was-7/VBD||assess-9/VB	det||status-11/NN||the-10/DT	dobj||assess-9/VB||status-11/NN	amod||control-14/NN||glycemic-13/JJ	prep_of||status-11/NN||control-14/NN	xcomp||was-7/VBD||associated-16/JJ	conj_and||assess-9/VB||associated-16/JJ	amod||outcomes-18/NNS||patient-reported-17/JJ	dobj||associated-16/JJ||outcomes-18/NNS	amod||patients-22/NNS||ambulatory-20/JJ	nn||patients-22/NNS||hungarian-21/NN	prep_in||associated-16/JJ||patients-22/NNS	prep_with||was-7/VBD||type2diabetesmellitus-24/NNS	nsubjpass||prescribed-30/VBN||type2diabetesmellitus-24/NNS	appos||type2diabetesmellitus-24/NNS||t2dm-26/NNP	auxpass||prescribed-30/VBN||were-29/VBD	rcmod||type2diabetesmellitus-24/NNS||prescribed-30/VBN	preconj||sulfonylurea-33/NN||either-31/CC	det||sulfonylurea-33/NN||a-32/DT	dobj||prescribed-30/VBN||sulfonylurea-33/NN	appos||sulfonylurea-33/NN||su-35/NN	det||thiazolidinedione-39/NN||a-38/DT	dobj||prescribed-30/VBN||thiazolidinedione-39/NN	conj_or||sulfonylurea-33/NN||thiazolidinedione-39/NN	appos||thiazolidinedione-39/NN||tzd-41/NN	prep_in||thiazolidinedione-39/NN||addition-44/NN	det||metformin-48/NN||the-46/DT	amod||metformin-48/NN||prior-47/JJ	prep_to||prescribed-30/VBN||metformin-48/NN	appos||metformin-48/NN||mf-50/NN	advmod||metformin-48/NN||monotherapy-52/RB	type2diabetesmellitus-24||metformin-48||yes||the objective of this observational study was to assess the status of glycemic control and associated patient-reported outcomes in ambulatory hungarian patients with type2diabetesmellitus (t2dm) who were prescribed either a sulfonylurea (su) or a thiazolidinedione (tzd) in addition to the prior metformin (mf) monotherapy.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubjpass||recommended-11/VBN||treatment-3/NN	amod||ulphadoxine-pyrimethamine-6/NN||s-5/JJ	prep_with||treatment-3/NN||ulphadoxine-pyrimethamine-6/NN	appos||treatment-3/NN||sp-8/NN	auxpass||recommended-11/VBN||is-10/VBZ	root||ROOT-0/null||recommended-11/VBN	prepc_for||recommended-11/VBN||reducing-13/VBG	det||risk-15/NN||the-14/DT	dobj||reducing-13/VBG||risk-15/NN	prep_of||risk-15/NN||malaria-17/NN	prep_in||malaria-17/NN||pregnancy-19/NN	poss||consequences-22/NNS||its-21/PRP$	prep_of||risk-15/NN||consequences-22/NNS	conj_and||malaria-17/NN||consequences-22/NNS	prep_on||consequences-22/NNS||mothers-24/NNS	prep_on||consequences-22/NNS||babies-26/NNS	conj_and||mothers-24/NNS||babies-26/NNS	appos||mothers-24/NNS||iptp-sp-28/NN	malaria-17||pyrimethamine--1||no||intermittent preventive treatment with s ulphadoxine-pyrimethamine (sp) is recommended for reducing the risk of malaria in pregnancy and its consequences on mothers and babies (iptp-sp).
nsubj||tread-9/VBN||advances-1/NNS	det||field-4/NN||the-3/DT	prep_in||advances-1/NNS||field-4/NN	nn||analgesia-7/NN||labour-6/NN	prep_of||field-4/NN||analgesia-7/NN	aux||tread-9/VBN||have-8/VBP	root||ROOT-0/null||tread-9/VBN	det||journey-12/NN||a-10/DT	amod||journey-12/NN||long-11/JJ	dobj||tread-9/VBN||journey-12/NN	det||days-15/NNS||the-14/DT	prep_from||tread-9/VBN||days-15/NNS	prep_of||days-15/NNS||ether-17/NN	prep_of||days-15/NNS||chloroform-19/NN	conj_and||ether-17/NN||chloroform-19/NN	prep_in||tread-9/VBN||1847-21/CD	det||practice-26/NN||the-23/DT	amod||practice-26/NN||present-24/JJ	nn||practice-26/NN||day-25/NN	prep_to||tread-9/VBN||practice-26/NN	amod||programme-29/NN||comprehensive-28/JJ	prep_of||practice-26/NN||programme-29/NN	nn||management-33/NN||labour-31/NN	nn||management-33/NN||pain-32/NN	prep_of||programme-29/NN||management-33/NN	vmod||management-33/NN||using-34/VBG	amod||medicine-36/NN||evidence-based-35/JJ	dobj||using-34/VBG||medicine-36/NN	pain-32||ether-17||yes||advances in the field of labour analgesia have tread a long journey from the days of ether and chloroform in 1847 to the present day practice of comprehensive programme of labour pain management using evidence-based medicine.
amod||efforts-4/NNS||considerable-2/JJ	nn||efforts-4/NNS||research-3/NN	prep_despite||known-9/VBN||efforts-4/NNS	nsubjpass||known-9/VBN||little-6/RB	auxpass||known-9/VBN||is-7/VBZ	advmod||known-9/VBN||yet-8/RB	root||ROOT-0/null||known-9/VBN	amod||parameters-13/NNS||key-11/JJ	amod||parameters-13/NNS||epidemiological-12/JJ	prep_about||known-9/VBN||parameters-13/NNS	amod||influenzaviruses-18/NNS||h5n1-15/JJ	advmod||pathogenic-17/JJ||highly-16/RB	amod||influenzaviruses-18/NNS||pathogenic-17/JJ	prep_of||parameters-13/NNS||influenzaviruses-18/NNS	poss||hosts-22/NNS||their-20/PRP$	nn||hosts-22/NNS||avian-21/NN	prep_in||known-9/VBN||hosts-22/NNS	h5n1-15||influenzaviruses-18||no||despite considerable research efforts, little is yet known about key epidemiological parameters of h5n1 highly pathogenic influenzaviruses in their avian hosts.
mark||described-15/VBN||although-1/IN	det||outcomes-4/NNS||the-2/DT	amod||outcomes-4/NNS||medical-3/JJ	nsubjpass||described-15/VBN||outcomes-4/NNS	amod||therapy-7/NN||antiretroviral-6/JJ	prep_of||outcomes-4/NNS||therapy-7/NN	appos||therapy-7/NN||art-9/NN	prep_for||therapy-7/NN||hiv/aids-12/NNS	auxpass||described-15/VBN||are-13/VBP	advmod||described-15/VBN||well-14/RB	advcl||known-19/VBN||described-15/VBN	nsubjpass||known-19/VBN||less-17/JJR	auxpass||known-19/VBN||is-18/VBZ	root||ROOT-0/null||known-19/VBN	advmod||affects-23/VBZ||how-21/WRB	nsubj||affects-23/VBZ||art-22/NN	prepc_about||known-19/VBN||affects-23/VBZ	poss||activities-27/NNS||patients-24/NNS	amod||activities-27/NNS||economic-26/JJ	dobj||affects-23/VBZ||activities-27/NNS	dobj||affects-23/VBZ||quality-29/NN	conj_and||activities-27/NNS||quality-29/NN	prep_of||activities-27/NNS||life-31/NN	advmod||activities-27/NNS||especially-33/RB	amod||activities-27/NNS||after-34/IN	det||year-37/NN||the-35/DT	amod||year-37/NN||first-36/JJ	dep||activities-27/NNS||year-37/NN	prep_on||year-37/NN||art-39/NN	aids--1||hiv--1||no||although the medical outcomes of antiretroviral therapy (art) for hiv/aids are well described, less is known about how art affects patients' economic activities and quality of life, especially after the first year on art.
det||country-3/NN||a-2/DT	prep_in||vital-17/JJ||country-3/NN	advmod||infected-12/JJ||where-4/WRB	det||third-6/JJ||a-5/DT	nsubj||infected-12/JJ||third-6/JJ	amod||women-9/NNS||pregnant-8/JJ	prep_of||third-6/JJ||women-9/NNS	cop||infected-12/JJ||are-10/VBP	advmod||infected-12/JJ||hiv-11/RB	rcmod||country-3/NN||infected-12/JJ	amod||anc-15/NN||early-14/JJ	nsubj||vital-17/JJ||anc-15/NN	cop||vital-17/JJ||is-16/VBZ	root||ROOT-0/null||vital-17/JJ	mark||optimise-21/VB||in-18/IN	dep||optimise-21/VB||order-19/NN	aux||optimise-21/VB||to-20/TO	advcl||vital-17/JJ||optimise-21/VB	nn||initiation-23/NN||art-22/NN	dobj||optimise-21/VB||initiation-23/NN	advmod||reduce-26/VB||thereby-25/RB	advcl||vital-17/JJ||reduce-26/VB	conj_and||optimise-21/VB||reduce-26/VB	amod||mortality-28/NN||maternal-27/JJ	dobj||reduce-26/VB||mortality-28/NN	amod||hivinfection-31/NN||paediatric-30/JJ	dobj||reduce-26/VB||hivinfection-31/NN	conj_and||mortality-28/NN||hivinfection-31/NN	hivinfection-31||hiv-11||no||in a country where a third of pregnant women are hiv infected, early anc is vital in order to optimise art initiation and thereby reduce maternal mortality and paediatric hivinfection.
amod||virus-7/NN||incurable-2/JJ	conj_but||incurable-2/JJ||treatable-4/JJ	amod||virus-7/NN||treatable-4/JJ	amod||virus-7/NN||herpes-5/JJ	amod||virus-7/NN||simplex-6/JJ	prep_including||halve-18/VB||virus-7/NN	appos||virus-7/NN||hsv-9/NN	num||ulcers-12/NNS||-2-11/CD	nsubj||halve-18/VB||ulcers-12/NNS	det||calculation-16/NN||the-14/DT	nn||calculation-16/NN||effectiveness-15/NN	prep_in||ulcers-12/NNS||calculation-16/NN	aux||halve-18/VB||would-17/MD	root||ROOT-0/null||halve-18/VB	det||proportion-20/NN||the-19/DT	dobj||halve-18/VB||proportion-20/NN	prep_of||proportion-20/NN||ulcers-22/NNS	dep||ulcers-22/NNS||cured-23/VBN	advmod||treated-26/VBN||correctly-25/RB	dep||ulcers-22/NNS||treated-26/VBN	conj_or||cured-23/VBN||treated-26/VBN	det||reduction-30/NN||this-29/DT	nsubjpass||countered-34/VBN||reduction-30/NN	aux||countered-34/VBN||could-31/MD	auxpass||countered-34/VBN||be-32/VB	advmod||countered-34/VBN||entirely-33/RB	conj_but||halve-18/VB||countered-34/VBN	agent||countered-34/VBN||including-36/VBG	amod||treatment-39/NN||episodic-37/JJ	amod||treatment-39/NN||antiviral-38/JJ	dobj||including-36/VBG||treatment-39/NN	det||guidelines-43/NNS||the-41/DT	amod||guidelines-43/NNS||national-42/JJ	prep_in||including-36/VBG||guidelines-43/NNS	antiviral-38||ulcers-22||no_rel||including incurable but treatable herpes simplex virus (hsv)-2 ulcers in the effectiveness calculation would halve the proportion of ulcers cured or correctly treated, but this reduction could be entirely countered by including episodic antiviral treatment in the national guidelines.
nsubjpass||enrolled-3/VBN||participants-1/NNS	auxpass||enrolled-3/VBN||were-2/VBD	root||ROOT-0/null||enrolled-3/VBN	prep_into||enrolled-3/VBN||one-5/CD	num||groups-8/NNS||four-7/CD	prep_of||one-5/CD||groups-8/NNS	det||basis-11/NN||the-10/DT	prep_on||groups-8/NNS||basis-11/NN	nn||status-16/NN||hiv-13/NN	conj_and||hiv-13/NN||ks-15/NN	nn||status-16/NN||ks-15/NN	prep_of||basis-11/NN||status-16/NN	nsubj||negative/ks-19/VBZ||hiv-18/NN	dep||groups-8/NNS||negative/ks-19/VBZ	acomp||negative/ks-19/VBZ||negative-20/JJ	amod||negative-23/JJ||hivpositive/ks-22/JJ	acomp||negative/ks-19/VBZ||negative-23/JJ	conj_and||negative-20/JJ||negative-23/JJ	num||negative/ks-26/NNS||hiv-25/CD	npadvmod||positive-27/JJ||negative/ks-26/NNS	acomp||negative/ks-19/VBZ||positive-27/JJ	conj_and||negative-20/JJ||positive-27/JJ	amod||positive-31/JJ||hivpositive/ks-30/JJ	acomp||negative/ks-19/VBZ||positive-31/JJ	conj_and||negative-20/JJ||positive-31/JJ	hivpositive--1||hiv-25||no||participants were enrolled into one of four groups on the basis of hiv and ks status (hiv negative/ks negative, hivpositive/ks negative, hiv negative/ks positive, and hivpositive/ks positive).
amod||administration-6/NN||objective-1/JJ	nn||administration-6/NN||â-2/NN	nn||administration-6/NN||$-3/NN	nn||administration-6/NN||bedtime-5/NN	nsubj||prevents-17/VBZ||administration-6/NN	nsubj||causes-21/VBZ||administration-6/NN	num||mg-9/NN||5.0-8/CD	prep_of||administration-6/NN||mg-9/NN	det||terbutaline-16/NN||the-11/DT	nn||terbutaline-16/NN||î-12/NN	punct||terbutaline-16/NN||²-13/``	amod||terbutaline-16/NN||2-adrenergic-14/JJ	nn||terbutaline-16/NN||agonist-15/NN	prep_of||mg-9/NN||terbutaline-16/NN	root||ROOT-0/null||prevents-17/VBZ	amod||hypoglycemia-19/NN||nocturnal-18/JJ	dobj||prevents-17/VBZ||hypoglycemia-19/NN	conj_but||prevents-17/VBZ||causes-21/VBZ	nn||hyperglycemia-23/NN||morning-22/NN	dobj||causes-21/VBZ||hyperglycemia-23/NN	prep_in||causes-21/VBZ||type1diabetes-25/CD	terbutaline-16||hyperglycemia-23||no_rel||objective âbedtime administration of 5.0 mg of the î²2-adrenergic agonist terbutaline prevents nocturnal hypoglycemia but causes morning hyperglycemia in type1diabetes.
amod||tissue-2/NN||lymphoid-1/JJ	nsubj||feature-7/NN||tissue-2/NN	nsubj||absent-18/JJ||tissue-2/NN	advmod||feature-7/NN||immunopathology-3/RB	cop||feature-7/NN||is-4/VBZ	det||feature-7/NN||a-5/DT	amod||feature-7/NN||characteristic-6/JJ	root||ROOT-0/null||feature-7/NN	amod||infection-11/NN||chronic-9/JJ	amod||infection-11/NN||hiv/siv-10/JJ	prep_of||feature-7/NN||infection-11/NN	amod||species-14/NNS||aids-susceptible-13/JJ	prep_in||infection-11/NN||species-14/NNS	cop||absent-18/JJ||is-17/VBZ	conj_but||feature-7/NN||absent-18/JJ	amod||hosts-22/NNS||siv-infected-20/JJ	amod||hosts-22/NNS||natural-21/JJ	prep_in||absent-18/JJ||hosts-22/NNS	aids--1||hiv--1||no||lymphoid tissue immunopathology is a characteristic feature of chronic hiv/siv infection in aids-susceptible species, but is absent in siv-infected natural hosts.
amod||characterization-2/NN||analytical-1/JJ	nsubjpass||carried-4/VBN||characterization-2/NN	auxpass||carried-4/VBN||was-3/VBD	dep||isolated-12/VBD||carried-4/VBN	prepc_out||carried-4/VBN||using-6/VBG	num||strains-11/NNS||50-7/CD	amod||strains-11/NNS||egyptian-8/JJ	amod||strains-11/NNS||hpaiv-9/JJ	amod||strains-11/NNS||h5n1-10/JJ	dobj||using-6/VBG||strains-11/NNS	root||ROOT-0/null||isolated-12/VBD	prep_since||isolated-12/VBD||2006-14/CD	prep_since||isolated-12/VBD||45-16/CD	conj_and||2006-14/CD||45-16/CD	amod||avianinfluenzaviruses-18/NNS||other-17/JJ	nsubj||isolated-12/VBD||avianinfluenzaviruses-18/NNS	appos||avianinfluenzaviruses-18/NNS||aiv-20/NN	h5n1-10||influenzaviruses--1||no||analytical characterization was carried out using 50 egyptian hpaiv h5n1 strains isolated since 2006 and 45 other avianinfluenzaviruses (aiv).
amod||causes-2/NNS||flavobacteriumcolumnare-1/JJ	nsubj||columnarisdisease-3/VBP||causes-2/NNS	root||ROOT-0/null||columnarisdisease-3/VBP	amod||populations-9/NNS||cultured-5/JJ	conj_and||cultured-5/JJ||wild-7/JJ	amod||populations-9/NNS||wild-7/JJ	nn||populations-9/NNS||fish-8/NN	prep_in||columnarisdisease-3/VBP||populations-9/NNS	advmod||columnarisdisease-3/VBP||worldwide-10/RB	columnarisdisease-3||flavobacteriumcolumnare-1||no||flavobacteriumcolumnare causes columnarisdisease in cultured and wild fish populations worldwide.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	dobj||investigated-2/VBD||differences-3/NNS	nn||sensitivity-6/NN||insulin-5/NN	prep_in||investigated-2/VBD||sensitivity-6/NN	prep_in||investigated-2/VBD||secretion-8/NN	conj_and||sensitivity-6/NN||secretion-8/NN	prep_among||investigated-2/VBD||youth-10/NN	nn||igt-14/NN||ifg-12/NN	prep_with||youth-10/NN||igt-14/NN	nn||ifg/igt-18/NN||coexistent-17/NN	prep_with||youth-10/NN||ifg/igt-18/NN	conj_and||igt-14/NN||ifg/igt-18/NN	prepc_compared_with||investigated-2/VBD||with-20/IN	pobj||investigated-2/VBD||those-21/DT	amod||tolerance-25/NN||normal-23/JJ	nn||tolerance-25/NN||glucose-24/NN	prep_with||those-21/DT||tolerance-25/NN	appos||tolerance-25/NN||ngt-27/NN	prep_with||those-21/DT||type2diabetes-30/NNS	conj_and||tolerance-25/NN||type2diabetes-30/NNS	type2diabetes-30||insulin-5||yes||we investigated differences in insulin sensitivity and secretion among youth with ifg, igt, and coexistent ifg/igt compared with those with normal glucose tolerance (ngt) and type2diabetes.
det||associations-2/NNS||the-1/DT	nsubjpass||associated-43/VBN||associations-2/NNS	prep_with||associations-2/NNS||age-4/NN	prep_at||age-4/NN||menarche-6/NN	dep||menarche-6/NN||p-8/NN	amod||het-12/NN||heterogeneity-10/JJ	dep||p-8/NN||het-12/NN	dep||0.03-15/CD||=-14/SYM	rcmod||het-12/NN||0.03-15/CD	prep_at||age-4/NN||age-18/NN	conj_and||menarche-6/NN||age-18/NN	amod||birth-21/NN||first-20/JJ	prep_at||age-18/NN||birth-21/NN	dep||age-18/NN||p-23/NN	dep||p-23/NN||het-25/NN	number||0.001-27/CD||<-26/CD	dep||het-25/NN||0.001-27/CD	amod||use-32/NN||postmenopausal-30/JJ	nn||use-32/NN||hormone-31/NN	prep_at||age-4/NN||use-32/NN	conj_and||menarche-6/NN||use-32/NN	dep||use-32/NN||p-34/NN	dep||p-34/NN||het-36/NN	number||0.001-38/CD||<-37/CD	dep||het-36/NN||0.001-38/CD	auxpass||associated-43/VBN||were-40/VBD	advmod||strongly-42/RB||more-41/RBR	advmod||associated-43/VBN||strongly-42/RB	root||ROOT-0/null||associated-43/VBN	nn||cancers-46/NNS||lobular-45/NN	prep_with||associated-43/VBN||cancers-46/NNS	cancers-46||hormone-31||no_rel||the associations with age at menarche ( p -heterogeneity (het) = 0.03), age at first birth ( p -het < 0.001) and postmenopausal hormone use ( p -het < 0.001) were more strongly associated with lobular cancers.
prep_despite||failed-15/VBD||africa-2/NN	auxpass||affected-5/VBN||being-3/VBG	advmod||affected-5/VBN||greatly-4/RB	vmod||africa-2/NN||affected-5/VBN	det||pandemic-9/NN||the-7/DT	amod||pandemic-9/NN||hiv/aids-8/JJ	agent||affected-5/VBN||pandemic-9/NN	det||search-14/NN||an-11/DT	amod||search-14/NN||extensive-12/JJ	amod||search-14/NN||medline/pubmed-13/JJ	nsubj||failed-15/VBD||search-14/NN	nsubj||find-17/VB||search-14/NN	root||ROOT-0/null||failed-15/VBD	aux||find-17/VB||to-16/TO	xcomp||failed-15/VBD||find-17/VB	det||report-19/NN||any-18/DT	dobj||find-17/VB||report-19/NN	amod||lymphoma-23/NN||primary-21/JJ	nn||lymphoma-23/NN||effusion-22/NN	prep_of||report-19/NN||lymphoma-23/NN	amod||africa-26/NN||sub-saharan-25/JJ	prep_in||lymphoma-23/NN||africa-26/NN	aids--1||hiv--1||no||despite africa being greatly affected by the hiv/aids pandemic, an extensive medline/pubmed search failed to find any report of primary effusion lymphoma in sub-saharan africa.
nsubjpass||used-7/VBN||ivermectin-1/NN	appos||ivermectin-1/NN||ivm-3/NN	aux||used-7/VBN||has-5/VBZ	auxpass||used-7/VBN||been-6/VBN	root||ROOT-0/null||used-7/VBN	prep_in||used-7/VBN||ghana-9/NN	dep||used-7/VBN||for-10/IN	num||decades-13/NNS||two-12/CD	prep_over||used-7/VBN||decades-13/NNS	amod||control-16/NN||onchocerciasis-15/JJ	prep_for||decades-13/NNS||control-16/NN	onchocerciasis-15||ivermectin-1||yes||ivermectin (ivm) has been used in ghana for over two decades for onchocerciasis control.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	det||study-5/NN||the-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	det||efficacy-10/NN||the-9/DT	dobj||evaluate-8/VB||efficacy-10/NN	dobj||evaluate-8/VB||safety-12/NN	conj_and||efficacy-10/NN||safety-12/NN	prep_of||efficacy-10/NN||ziprasidone-14/NN	prep_versus||ziprasidone-14/NN||risperidone-16/NN	amod||subjects-19/NNS||chinese-18/JJ	prep_in||evaluate-8/VB||subjects-19/NNS	amod||exacerbation-22/NN||acute-21/JJ	prep_with||evaluate-8/VB||exacerbation-22/NN	prep_of||exacerbation-22/NN||schizophrenia-24/NN	schizophrenia-24||risperidone-16||yes||the aim of the study was to evaluate the efficacy and safety of ziprasidone versus risperidone in chinese subjects with acute exacerbation of schizophrenia.
advmod||seen-16/VBN||irondeficiency-1/RB	nsubjpass||seen-16/VBN||anemia-3/NN	amod||anemia-6/NN||irondeficiency-5/JJ	conj_and||anemia-3/NN||anemia-6/NN	nsubjpass||seen-16/VBN||anemia-6/NN	nn||depletion-9/NN||iron-8/NN	conj_and||anemia-3/NN||depletion-9/NN	nsubjpass||seen-16/VBN||depletion-9/NN	conj_and||anemia-3/NN||lack-11/NN	nsubjpass||seen-16/VBN||lack-11/NN	nn||resources-14/NNS||iron-13/NN	prep_of||lack-11/NN||resources-14/NNS	auxpass||seen-16/VBN||were-15/VBD	root||ROOT-0/null||seen-16/VBN	prep_in||seen-16/VBN||2.3-18/CD	prep_in||seen-16/VBN||4.08-20/CD	conj_and||2.3-18/CD||4.08-20/CD	prep_in||seen-16/VBN||2.14-22/CD	conj_and||2.3-18/CD||2.14-22/CD	prep_in||seen-16/VBN||22.76-24/NNP	conj_and||2.3-18/CD||22.76-24/NNP	amod||percent-27/NN||4.66-26/JJ	prep_in||seen-16/VBN||percent-27/NN	conj_and||2.3-18/CD||percent-27/NN	advmod||seen-16/VBN||respectively-28/RB	irondeficiency-5||iron-13||yes||irondeficiency, anemia, irondeficiency anemia, iron depletion and lack of iron resources were seen in 2.3, 4.08, 2.14, 22.76 and 4.66 percent respectively.
det||tissues-2/NNS||the-1/DT	nsubj||had-10/VBD||tissues-2/NNS	prep_from||tissues-2/NNS||patients-4/NNS	vmod||patients-4/NNS||revised-5/VBN	amod||wear-9/NN||suspected-7/VBN	amod||wear-9/NN||high-8/JJ	prep_for||revised-5/VBN||wear-9/NN	root||ROOT-0/null||had-10/VBD	det||score-14/NN||a-11/DT	amod||score-14/NN||lower-12/JJR	nn||score-14/NN||alval-13/NN	dobj||had-10/VBD||score-14/NN	amod||lymphocytes-17/NNS||fewer-16/JJR	appos||score-14/NN||lymphocytes-17/NNS	amod||macrophages-21/NN||more-20/JJR	dobj||had-10/VBD||macrophages-21/NN	conj_but||score-14/NN||macrophages-21/NN	nn||particles-24/NNS||metal-23/NN	conj_but||score-14/NN||particles-24/NNS	conj_and||macrophages-21/NN||particles-24/NNS	det||tissues-27/NNS||those-26/DT	prep_than||macrophages-21/NN||tissues-27/NNS	prep_from||had-10/VBD||hips-29/NNS	vmod||hips-29/NNS||revised-30/VBN	prep_for||revised-30/VBN||pain-32/NN	amod||hypersensitivity-36/NN||suspected-34/VBN	nn||hypersensitivity-36/NN||metal-35/NN	prep_for||revised-30/VBN||hypersensitivity-36/NN	conj_and||pain-32/NN||hypersensitivity-36/NN	metal-35||hypersensitivity-36||no_rel||the tissues from patients revised for suspected high wear had a lower alval score, fewer lymphocytes, but more macrophages and metal particles than those tissues from hips revised for pain and suspected metal hypersensitivity.
advmod||bolster-4/VB||additionally-1/RB	nsubj||bolster-4/VB||we-3/PRP	root||ROOT-0/null||bolster-4/VB	poss||reclassification-7/NN||our-5/PRP$	amod||reclassification-7/NN||recent-6/JJ	dobj||bolster-4/VB||reclassification-7/NN	prep_of||reclassification-7/NN||rickettsia-9/NN	prepc_by||bolster-4/VB||identifying-11/VBG	dobj||identifying-11/VBG||ogs-12/NN	nsubj||define-14/VB||ogs-12/NN	rcmod||ogs-12/NN||define-14/VB	det||ag-16/NN||the-15/DT	nsubj||rickettsiae-40/JJ||ag-16/NN	amod||group-19/NN||ancestral-18/JJ	appos||ag-16/NN||group-19/NN	conj_and||ag-16/NN||tg-22/NN	nsubj||rickettsiae-40/JJ||tg-22/NN	amod||group-25/NN||typhus-24/JJ	appos||tg-22/NN||group-25/NN	conj_and||ag-16/NN||trg-28/NN	nsubj||rickettsiae-40/JJ||trg-28/NN	amod||group-31/NN||transitional-30/JJ	appos||trg-28/NN||group-31/NN	conj_and||ag-16/NN||sfg-35/NN	nsubj||rickettsiae-40/JJ||sfg-35/NN	nn||group-38/NN||spottedfever-37/NN	appos||ag-16/NN||group-38/NN	xcomp||define-14/VB||rickettsiae-40/JJ	spottedfever-37||rickettsia-9||no||additionally, we bolster our recent reclassification of rickettsia by identifying ogs that define the ag (ancestral group), tg (typhus group), trg (transitional group), and sfg (spottedfever group) rickettsiae.
num||controls-3/NNS||seventeen-1/CD	amod||controls-3/NNS||healthy-2/JJ	nsubj||participated-27/VBD||controls-3/NNS	appos||controls-3/NNS||hc-5/NN	num||patients-9/NNS||20-8/CD	conj_and||controls-3/NNS||patients-9/NNS	nsubj||participated-27/VBD||patients-9/NNS	amod||disease-15/NN||crohnâ-11/JJ	amod||disease-15/NN||$-12/$	number||s-14/CD||-13/CD	num||$-12/$||s-14/CD	prep_with||patients-9/NNS||disease-15/NN	appos||patients-9/NNS||cd-17/NN	num||patients-21/NNS||22-20/CD	conj_and||controls-3/NNS||patients-21/NNS	nsubj||participated-27/VBD||patients-21/NNS	prep_with||patients-21/NNS||ulcerativecolitis-23/NNS	appos||controls-3/NNS||uc-25/NN	root||ROOT-0/null||participated-27/VBD	det||study-30/NN||the-29/DT	prep_in||participated-27/VBD||study-30/NN	uc-25||cd-17||no_rel||seventeen healthy controls (hc), 20 patients with crohnâs disease (cd) and 22 patients with ulcerativecolitis (uc) participated in the study.
nsubj||endocrinedisease-5/NN||endogenous-1/NNS	advmod||endocrinedisease-5/NN||cushingsyndrome-2/RB	cop||endocrinedisease-5/NN||is-3/VBZ	det||endocrinedisease-5/NN||an-4/DT	root||ROOT-0/null||endocrinedisease-5/NN	vmod||endocrinedisease-5/NN||caused-6/VBN	amod||secretion-9/NN||excessive-8/JJ	agent||caused-6/VBN||secretion-9/NN	nn||hormone-12/NN||adrenocorticotropin-11/NN	prep_of||secretion-9/NN||hormone-12/NN	quantmod||80-15/CD||approximately-14/RB	num||%-16/NN||80-15/CD	prep_in||caused-6/VBN||%-16/NN	prep_of||%-16/NN||cases-18/NNS	advmod||caused-6/VBN||usually-20/RB	det||adenoma-25/NN||a-22/DT	advmod||corticotroph-24/JJ||pituitary-23/RB	amod||adenoma-25/NN||corticotroph-24/JJ	agent||caused-6/VBN||adenoma-25/NN	amod||-RSB--30/NNP||cushingdisease-27/JJ	nn||-RSB--30/NNP||-LSB--28/NNP	nn||-RSB--30/NNP||cd-29/NN	appos||adenoma-25/NN||-RSB--30/NNP	endocrinedisease-5||hormone-12||no_rel||endogenous cushingsyndrome is an endocrinedisease caused by excessive secretion of adrenocorticotropin hormone in approximately 80% of cases, usually by a pituitary corticotroph adenoma (cushingdisease [cd]).
nsubj||±-12/NN||marek-1/NN	amod||virus-4/NN||sdisease-3/JJ	dep||marek-1/NN||virus-4/NN	appos||marek-1/NN||mdv-6/NN	cop||±-12/NN||is-8/VBZ	det||±-12/NN||a-9/DT	amod||±-12/NN||prevalent-10/JJ	nn||±-12/NN||î-11/NN	root||ROOT-0/null||±-12/NN	dep||±-12/NN||herpesvirus-14/NNS	prep_of||herpesvirus-14/NNS||poultry-16/NN	vmod||herpesvirus-14/NNS||inducing-18/VBG	num||tumors-28/NNS||cd4-19/CD	number||tcrî-21/CD||+-20/CD	num||tumors-28/NNS||tcrî-21/CD	nn||tumors-28/NNS||±-22/NNP	nn||tumors-28/NNS||î-23/NNP	nn||tumors-28/NNS||²-24/NNP	nn||tumors-28/NNS||+-25/NNP	nn||tumors-28/NNS||t-26/NNP	nn||tumors-28/NNS||cell-27/NN	dobj||inducing-18/VBG||tumors-28/NNS	amod||hosts-31/NNS||susceptible-30/JJ	prep_in||tumors-28/NNS||hosts-31/NNS	marek'sdisease--1||herpesvirus-14||no||marek'sdisease virus (mdv) is a prevalent î±-herpesvirus of poultry, inducing cd4+ tcrî±î²+ t cell tumors in susceptible hosts.
det||review-3/NN||this-2/DT	prep_in||describe-5/VBP||review-3/NN	nsubj||describe-5/VBP||we-4/PRP	root||ROOT-0/null||describe-5/VBP	poss||experience-7/NN||our-6/PRP$	dobj||describe-5/VBP||experience-7/NN	nn||measurements-11/NNS||csf-9/NN	nn||measurements-11/NNS||neopterin-10/NN	prep_with||describe-5/VBP||measurements-11/NNS	advmod||untreated-14/VBG||382-13/CD	prepc_in||measurements-11/NNS||untreated-14/VBG	amod||patients-16/NNS||hiv-infected-15/JJ	dobj||untreated-14/VBG||patients-16/NNS	det||spectrum-19/NN||the-18/DT	prep_across||untreated-14/VBG||spectrum-19/NN	nn||diseases-25/NNS||immunosuppression-21/NN	conj_and||immunosuppression-21/NN||hiv-related-23/JJ	nn||diseases-25/NNS||hiv-related-23/JJ	amod||diseases-25/NNS||neurological-24/JJ	prep_of||spectrum-19/NN||diseases-25/NNS	num||patients-31/NNS||73-28/CD	amod||patients-31/NNS||untreated-29/JJ	nn||patients-31/NNS||aids-30/NNS	prep_in||untreated-14/VBG||patients-31/NNS	amod||infections-35/NNS||opportunistic-33/JJ	nn||infections-35/NNS||cns-34/NN	prep_with||untreated-14/VBG||infections-35/NNS	number||treated-40/CD||233-39/CD	num||patients-41/NNS||treated-40/CD	prepc_in||measurements-11/NNS||patients-41/NNS	conj_and||untreated-14/VBG||patients-41/NNS	aids-30||hiv--1||no||in this review we describe our experience with csf neopterin measurements in 382 untreated hiv-infected patients across the spectrum of immunosuppression and hiv-related neurological diseases, in 73 untreated aids patients with opportunistic cns infections, and in 233 treated patients.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||develop-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||develop-8/VB||to-7/TO	xcomp||was-6/VBD||develop-8/VB	det||system-12/NN||a-9/DT	amod||system-12/NN||partial-10/JJ	amod||system-12/NN||closed-loop-11/JJ	dobj||develop-8/VB||system-12/NN	aux||prevent-15/VB||to-13/TO	advmod||prevent-15/VB||safely-14/RB	vmod||develop-8/VB||prevent-15/VB	amod||hypoglycemia-17/NN||nocturnal-16/JJ	dobj||prevent-15/VB||hypoglycemia-17/NN	prepc_by||prevent-15/VB||suspending-19/VBG	nn||delivery-21/NN||insulin-20/NN	dobj||suspending-19/VBG||delivery-21/NN	tmod||predicted-25/VBN||delivery-21/NN	advmod||predicted-25/VBN||when-22/WRB	nsubjpass||predicted-25/VBN||hypoglycemia-23/NN	auxpass||predicted-25/VBN||is-24/VBZ	rcmod||delivery-21/NN||predicted-25/VBN	prep_in||predicted-25/VBN||type1diabetes-27/CD	insulin-20||hypoglycemia-23||no_rel||the aim of this study was to develop a partial closed-loop system to safely prevent nocturnal hypoglycemia by suspending insulin delivery when hypoglycemia is predicted in type1diabetes.
det||increase-2/NN||an-1/DT	nsubjpass||associated-12/VBN||increase-2/NN	nsubjpass||associated-12/VBN||increase-2/NN	amod||adiposity-9/NN||total-4/JJ	conj_and||total-4/JJ||visceral-8/JJ	amod||adiposity-9/NN||visceral-8/JJ	prep_in||increase-2/NN||adiposity-9/NN	auxpass||associated-12/VBN||is-10/VBZ	advmod||associated-12/VBN||probably-11/RB	root||ROOT-0/null||associated-12/VBN	conj_negcc||associated-12/VBN||associated-12/VBN	det||decrease-15/NN||a-14/DT	prep_with||associated-12/VBN||decrease-15/NN	nn||distensibility-18/NN||vascular-17/NN	prep_in||decrease-15/NN||distensibility-18/NN	det||boys-24/NNS||the-20/DT	nn||boys-24/NNS||gujarati-21/NN	nn||boys-24/NNS||indian-22/NN	amod||boys-24/NNS||adolescent-23/JJ	prep_in||distensibility-18/NN||boys-24/NNS	prep_in||associated-12/VBN||girls-28/NNS	advmod||indicating-31/VBG||thus-30/RB	xcomp||associated-12/VBN||indicating-31/VBG	det||role-34/NN||a-32/DT	amod||role-34/NN||protective-33/JJ	dobj||indicating-31/VBG||role-34/NN	amod||estrogen-38/NN||female-36/JJ	nn||estrogen-38/NN||sexhormone-37/NN	prep_of||role-34/NN||estrogen-38/NN	nsubjpass||shown-42/VBN||estrogen-38/NN	nsubj||protect-45/VB||estrogen-38/NN	aux||shown-42/VBN||has-40/VBZ	auxpass||shown-42/VBN||been-41/VBN	rcmod||estrogen-38/NN||shown-42/VBN	advmod||shown-42/VBN||earlier-43/RBR	aux||protect-45/VB||to-44/TO	xcomp||shown-42/VBN||protect-45/VB	det||vasculature-47/NN||the-46/DT	dobj||protect-45/VB||vasculature-47/NN	prep_from||protect-45/VB||atherosclerosis-49/NNS	amod||dysfunction-52/NN||endothelial-51/JJ	appos||atherosclerosis-49/NNS||dysfunction-52/NN	nsubj||occurs-54/VBZ||dysfunction-52/NN	rcmod||dysfunction-52/NN||occurs-54/VBZ	prep_with||occurs-54/VBZ||increase-56/NN	prep_in||increase-56/NN||adiposity-58/NN	sexhormone-37||atherosclerosis-49||no_rel||an increase in total as well as visceral adiposity is probably associated with a decrease in vascular distensibility in the gujarati indian adolescent boys but not in girls, thus indicating a protective role of female sexhormone estrogen which has been shown earlier to protect the vasculature from atherosclerosis, endothelial dysfunction which occurs with increase in adiposity.
nsubj||searched-2/VBD||we-1/PRP	root||ROOT-0/null||searched-2/VBD	ccomp||searched-2/VBD||medline-3/VB	ccomp||searched-2/VBD||pubmed-5/VB	conj_and||medline-3/VB||pubmed-5/VB	dobj||medline-3/VB||terms-6/NNS	nn||stage-9/NN||labour-8/NN	dep||terms-6/NNS||stage-9/NN	dep||stage-9/NN||third-11/JJ	dep||ergonovine-17/NN||ergonovine-15/JJ	dep||medline-3/VB||ergonovine-17/NN	amod||ergonovine-17/NN||tartrate-18/JJ	amod||ergonovine-17/NN||methylergonovine-20/JJ	conj_or||tartrate-18/JJ||methylergonovine-20/JJ	amod||ergonovine-17/NN||oxytocin-22/JJ	conj_or||tartrate-18/JJ||oxytocin-22/JJ	amod||ergonovine-17/NN||oxytocics-24/JJ	conj_or||tartrate-18/JJ||oxytocics-24/JJ	amod||ergonovine-17/NN||misoprostol-26/JJ	conj_or||tartrate-18/JJ||misoprostol-26/JJ	ccomp||searched-2/VBD||and-28/VB	conj_and||medline-3/VB||and-28/VB	parataxis||and-28/VB||postpartumhaemorrhage-30/VB	parataxis||and-28/VB||haemorrhage-32/VB	conj_or||postpartumhaemorrhage-30/VB||haemorrhage-32/VB	conj_and||medline-3/VB||cochrane-35/VB	conj_and||and-28/VB||cochrane-35/VB	dobj||and-28/VB||reviews-36/NNS	det||restriction-40/NN||any-38/DT	nn||restriction-40/NN||language-39/NN	prep_without||and-28/VB||restriction-40/NN	postpartumhaemorrhage-30||methylergonovine-20||yes||we searched medline and pubmed terms (labour stage, third) and (ergonovine, ergonovine tartrate, methylergonovine, oxytocin, oxytocics or misoprostol) and (postpartumhaemorrhage or haemorrhage) and cochrane reviews without any language restriction.
advmod||screened-19/NN||finally-1/RB	vmod||screened-19/NN||using-3/VBG	det||method-5/NN||this-4/DT	dobj||using-3/VBG||method-5/NN	det||sites-10/NNS||the-7/DT	amod||sites-10/NNS||conservative-8/JJ	nn||sites-10/NNS||target-9/NN	nsubj||screened-19/NN||sites-10/NNS	prep_for||sites-10/NNS||hepatitisbvirus-12/NNS	dep||screened-19/NN||hbv-14/NN	nsubj||screened-19/NN||knockdown-16/NN	cop||screened-19/NN||were-17/VBD	amod||screened-19/NN||systemically-18/JJ	root||ROOT-0/null||screened-19/NN	nn||expression-23/NN||hbv-21/NN	nn||expression-23/NN||antigen-22/NN	conj_and||screened-19/NN||expression-23/NN	vmod||screened-19/NN||shown-24/VBN	aux||suppressed-28/VBN||to-25/TO	auxpass||suppressed-28/VBN||be-26/VB	advmod||suppressed-28/VBN||successfully-27/RB	xcomp||shown-24/VBN||suppressed-28/VBN	det||presence-31/NN||the-30/DT	prep_in||suppressed-28/VBN||presence-31/NN	amod||shrnas-35/NNS||connected-33/JJ	amod||shrnas-35/NNS||multiple-34/JJ	prep_of||presence-31/NN||shrnas-35/NNS	preconj||suppressed-28/VBN||both-36/DT	prep_in||suppressed-28/VBN||vitro-38/NNP	prep_in||suppressed-28/VBN||vivo-41/NN	conj_and||vitro-38/NNP||vivo-41/NN	hbv-21||hepatitisbvirus-12||no||finally, using this method, the conservative target sites for hepatitisbvirus (hbv) knockdown were systemically screened and hbv antigen expression shown to be successfully suppressed in the presence of connected multiple shrnas both in vitro and in vivo .
amod||anesthesia-3/NN||ketamine/xylazine-1/JJ	nn||anesthesia-3/NN||cocktail-2/NN	nsubj||caused-4/VBD||anesthesia-3/NN	root||ROOT-0/null||caused-4/VBD	det||hypertension-7/NN||a-5/DT	amod||hypertension-7/NN||transient-6/JJ	dobj||caused-4/VBD||hypertension-7/NN	det||cats-10/NNS||the-9/DT	prep_in||caused-4/VBD||cats-10/NNS	nsubj||inhibited-13/VBD||ea-12/NN	nsubj||shortened-18/VBN||ea-12/NN	parataxis||caused-4/VBD||inhibited-13/VBD	det||hypertension-16/NN||this-14/DT	amod||hypertension-16/NN||anesthetic-induced-15/JJ	dobj||inhibited-13/VBD||hypertension-16/NN	parataxis||caused-4/VBD||shortened-18/VBN	conj_and||inhibited-13/VBD||shortened-18/VBN	det||time-22/NN||the-19/DT	amod||time-22/NN||post-anesthesia-20/JJ	nn||time-22/NN||recovery-21/NN	dobj||shortened-18/VBN||time-22/NN	hypertension-16||ea-12||yes||ketamine/xylazine cocktail anesthesia caused a transient hypertension in the cats; ea inhibited this anesthetic-induced hypertension and shortened the post-anesthesia recovery time.
det||us-3/PRP||the-2/DT	prep_in||system-20/NN||us-3/PRP	det||system-8/NN||the-5/DT	amod||system-8/NN||selegiline-6/JJ	amod||system-8/NN||transdermal-7/JJ	nsubj||system-20/NN||system-8/NN	dep||system-8/NN||sts-10/NN	dep||sts-10/NN||emsam-12/NN	cop||system-20/NN||is-14/VBZ	det||system-20/NN||the-15/DT	amod||system-20/NN||first-16/JJ	amod||system-20/NN||antidepressant-17/JJ	amod||system-20/NN||transdermal-18/JJ	nn||system-20/NN||delivery-19/NN	root||ROOT-0/null||system-20/NN	aux||receive-22/VB||to-21/TO	vmod||system-20/NN||receive-22/VB	nn||administration-26/NN||food-23/NN	conj_and||food-23/NN||drug-25/NN	nn||administration-26/NN||drug-25/NN	dobj||receive-22/VB||administration-26/NN	appos||system-20/NN||fda-28/NN	vmod||system-20/NN||approved-30/VBN	xcomp||approved-30/VBN||labeling-31/VBG	det||treatment-34/NN||the-33/DT	prep_for||labeling-31/VBG||treatment-34/NN	amod||depressivedisorder-37/NN||major-36/JJ	prep_of||treatment-34/NN||depressivedisorder-37/NN	appos||depressivedisorder-37/NN||mdd-39/NN	depressivedisorder-37||selegiline-6||yes||in the us, the selegiline transdermal system (sts; emsam) is the first antidepressant transdermal delivery system to receive food and drug administration (fda) approved labeling for the treatment of major depressivedisorder (mdd).
vmod||limited-14/VBN||albeit-1/VBG	poss||benefits-4/NNS||its-2/PRP$	amod||benefits-4/NNS||great-3/JJ	dobj||albeit-1/VBG||benefits-4/NNS	prep_as||albeit-1/VBG||immunosuppressant-6/NN	det||use-9/NN||the-8/DT	nsubjpass||limited-14/VBN||use-9/NN	prep_of||use-9/NN||csa-11/NN	aux||limited-14/VBN||has-12/VBZ	auxpass||limited-14/VBN||been-13/VBN	root||ROOT-0/null||limited-14/VBN	amod||effects-18/NNS||undesirable-16/JJ	amod||effects-18/NNS||nephrotoxic-17/JJ	agent||limited-14/VBN||effects-18/NNS	nn||fibrosis-28/NN||sodiumretention-21/NN	dep||fibrosis-28/NN||hypertension-23/NN	dep||fibrosis-28/NN||hyperkalemia-25/NN	amod||fibrosis-28/NN||interstial-27/JJ	prep_including||limited-14/VBN||fibrosis-28/NN	amod||renalfailure-31/NN||progressive-30/JJ	prep_including||limited-14/VBN||renalfailure-31/NN	conj_and||fibrosis-28/NN||renalfailure-31/NN	nn||recipients-34/NNS||transplant-33/NN	prep_in||renalfailure-31/NN||recipients-34/NNS	renalfailure-31||csa-11||no||albeit its great benefits as immunosuppressant, the use of csa has been limited by undesirable nephrotoxic effects, including sodiumretention, hypertension, hyperkalemia, interstial fibrosis and progressive renalfailure in transplant recipients.
nsubj||sought-3/VBD||we-1/PRP	nsubj||evaluate-6/VB||we-1/PRP	advmod||sought-3/VBD||therefore-2/RB	root||ROOT-0/null||sought-3/VBD	aux||evaluate-6/VB||to-4/TO	advmod||evaluate-6/VB||retrospectively-5/RB	xcomp||sought-3/VBD||evaluate-6/VB	poss||influence-8/NN||their-7/PRP$	dobj||evaluate-6/VB||influence-8/NN	prep_on||evaluate-6/VB||outcomes-10/NNS	amod||patients-16/NNS||relapsed-12/JJ	amod||patients-16/NNS||and/or-13/JJ	amod||patients-16/NNS||refractory-14/JJ	nn||patients-16/NNS||myeloma-15/NN	prep_in||evaluate-6/VB||patients-16/NNS	vmod||patients-16/NNS||treated-17/VBN	prep_with||treated-17/VBN||bortezomib-19/NN	prep_with||treated-17/VBN||bortezomib-21/NN	conj_or||bortezomib-19/NN||bortezomib-21/NN	amod||doxorubicin-25/NN||pegylated-23/JJ	amod||doxorubicin-25/NN||liposomal-24/JJ	prep_with||treated-17/VBN||doxorubicin-25/NN	appos||doxorubicin-25/NN||pld-27/NN	myeloma-15||bortezomib-21||yes||we therefore sought to retrospectively evaluate their influence on outcomes in relapsed and/or refractory myeloma patients treated with bortezomib or bortezomib with pegylated liposomal doxorubicin (pld).
prepc_compared_to||had-24/VBD||to-2/TO	det||study-5/NN||an-3/DT	amod||study-5/NN||earlier-4/JJR	pobj||had-24/VBD||study-5/NN	nn||mg-9/NN||gabapentin-7/NN	num||mg-9/NN||900-8/CD	prep_of||study-5/NN||mg-9/NN	amod||pain-13/NN||acute-11/JJ	nn||pain-13/NN||zoster-12/NN	prep_for||mg-9/NN||pain-13/NN	conj_and||study-5/NN||allodynia-15/NN	nsubj||followed-17/VBD||allodynia-15/NN	pobj||had-24/VBD||allodynia-15/NN	rcmod||allodynia-15/NN||followed-17/VBD	det||protocol-21/NN||a-18/DT	advmod||identical-20/JJ||nearly-19/RB	amod||protocol-21/NN||identical-20/JJ	dobj||followed-17/VBD||protocol-21/NN	nsubj||had-24/VBD||pregabalin-23/NN	nsubjpass||tolerated-33/VBN||pregabalin-23/NN	root||ROOT-0/null||had-24/VBD	det||effect-27/NN||a-25/DT	amod||effect-27/NN||similar-26/JJ	dobj||had-24/VBD||effect-27/NN	prep_on||effect-27/NN||pain-29/NN	auxpass||tolerated-33/VBN||was-31/VBD	advmod||tolerated-33/VBN||well-32/RB	conj_and||had-24/VBD||tolerated-33/VBN	neg||difference-37/NN||no-36/DT	prep_with||tolerated-33/VBN||difference-37/NN	prep_from||difference-37/NN||placebo-39/NN	prep_on||placebo-39/NN||sleepiness-41/NNS	pain-29||gabapentin-7||yes||compared to an earlier study of gabapentin 900 mg for acute zoster pain and allodynia that followed a nearly identical protocol, pregabalin had a similar effect on pain and was well tolerated, with no difference from placebo on sleepiness.
nn||design-2/NN||research-1/NN	nsubjpass||studied-25/VBN||design-2/NN	poss||consequences-8/NNS||methods-4/NNS	amod||consequences-8/NNS||$-6/JJ	conj_and||design-2/NN||consequences-8/NNS	nsubjpass||studied-25/VBN||consequences-8/NNS	amod||changes-14/NNS||euglycemia-10/NN	conj_and||euglycemia-10/NN||hyperglycemia-induced-13/JJ	amod||changes-14/NNS||hyperglycemia-induced-13/JJ	prep_of||consequences-8/NNS||changes-14/NNS	amod||emptying-17/NN||gastric-16/JJ	prep_in||changes-14/NNS||emptying-17/NN	amod||fluxes-21/NNS||postprandial-19/JJ	nn||fluxes-21/NNS||glucose-20/NN	prep_on||emptying-17/NN||fluxes-21/NNS	prep_on||emptying-17/NN||excursions-23/NNS	conj_and||fluxes-21/NNS||excursions-23/NNS	auxpass||studied-25/VBN||were-24/VBD	root||ROOT-0/null||studied-25/VBN	num||subjects-29/NNS||10-27/CD	amod||subjects-29/NNS||healthy-28/JJ	prep_in||studied-25/VBN||subjects-29/NNS	num||type-32/NN||15-31/CD	prep_in||studied-25/VBN||type-32/NN	conj_and||subjects-29/NNS||type-32/NN	num||subjects-35/NNS||1-33/CD	amod||subjects-35/NNS||diabetic-34/JJ	dep||type-32/NN||subjects-35/NNS	prep_after||studied-25/VBN||ingestion-37/NN	det||meal-41/NN||a-39/DT	amod||meal-41/NN||mixed-40/JJ	prep_of||ingestion-37/NN||meal-41/NN	vmod||meal-41/NN||using-42/VBG	det||approach-46/NN||the-43/DT	amod||approach-46/NN||double-44/JJ	nn||approach-46/NN||isotope-45/NN	dobj||using-42/VBG||approach-46/NN	amod||-RSB--50/NNS||-LSB--48/JJ	amod||-RSB--50/NNS||6,6-2h2-49/JJ	dep||approach-46/NN||-RSB--50/NNS	amod||glucose-55/NN||-LSB--52/JJ	amod||glucose-55/NN||1-13c-53/JJ	nn||glucose-55/NN||-RSB--54/NN	dep||approach-46/NN||glucose-55/NN	conj_and||-RSB--50/NNS||glucose-55/NN	amod||measurements-59/NNS||scintigraphic-58/JJ	dobj||using-42/VBG||measurements-59/NNS	conj_and||approach-46/NN||measurements-59/NNS	amod||emptying-62/NN||gastric-61/JJ	prep_of||measurements-59/NNS||emptying-62/NN	hyperglycemia--1||glucose-55||no||research design and methods âconsequences of euglycemia- and hyperglycemia-induced changes in gastric emptying on postprandial glucose fluxes and excursions were studied in 10 healthy subjects and 15 type 1 diabetic subjects after ingestion of a mixed meal using the double isotope approach ([6,6-2h2] and [1-13c]glucose) and scintigraphic measurements of gastric emptying.
det||effects-4/NNS||the-1/DT	amod||effects-4/NNS||additive-2/JJ	amod||effects-4/NNS||neurotoxic-3/JJ	nsubj||highlight-11/VB||effects-4/NNS	prep_of||effects-4/NNS||hcv-6/NN	amod||proteins-10/NNS||hiv-encoded-9/JJ	prep_of||effects-4/NNS||proteins-10/NNS	conj_and||hcv-6/NN||proteins-10/NNS	root||ROOT-0/null||highlight-11/VB	amod||mechanisms-13/NNS||extrahepatic-12/JJ	dobj||highlight-11/VB||mechanisms-13/NNS	dobj||worsens-18/VBZ||which-15/WDT	nn||infection-17/NN||hcv-16/NN	nsubj||worsens-18/VBZ||infection-17/NN	prepc_by||highlight-11/VB||worsens-18/VBZ	det||course-21/NN||the-19/DT	nn||course-21/NN||disease-20/NN	dobj||worsens-18/VBZ||course-21/NN	prep_of||course-21/NN||hivinfection-23/NN	hivinfection-23||hiv--1||no||the additive neurotoxic effects of hcv- and hiv-encoded proteins highlight extrahepatic mechanisms by which hcv infection worsens the disease course of hivinfection.
det||trial-4/NN||a-2/DT	amod||trial-4/NN||clinical-3/JJ	prep_in||-rrb--38/VBZ||trial-4/NN	nn||doxycycline-10/NNP||chloroquine-6/NNP	conj_vs.||chloroquine-6/NNP||chloroquine-8/NNP	nn||doxycycline-10/NNP||chloroquine-8/NNP	amod||doxycycline-10/NNP||plus-9/IN	prep_of||trial-4/NN||doxycycline-10/NNP	prep_of||trial-4/NN||doxycycline-12/NNP	conj_vs.||doxycycline-10/NNP||doxycycline-12/NNP	advmod||n-26/VBN||alone-13/RB	nn||vivax-16/NN||plasmodium-15/NN	nn||n-18/NN||vivax-16/NN	amod||n-18/NN||-lrb--17/JJ	prep_against||alone-13/RB||n-18/NN	dep||-rrb--21/JJ||=-19/SYM	number||-rrb--21/JJ||64-20/CD	dep||n-18/NN||-rrb--21/JJ	amod||-lrb--25/NNS||plasmodium-23/JJ	nn||-lrb--25/NNS||falciparum-24/NN	dep||n-18/NN||-lrb--25/NNS	conj_or||-rrb--21/JJ||-lrb--25/NNS	vmod||doxycycline-10/NNP||n-26/VBN	dep||malaria-30/NN||=-27/SYM	num||malaria-30/NN||98-28/CD	amod||malaria-30/NN||-rrb--29/JJ	ccomp||n-26/VBN||malaria-30/NN	det||wcc-37/NN||the-32/DT	amod||wcc-37/NN||total-33/JJ	amod||wcc-37/NN||white-34/JJ	nn||wcc-37/NN||cell-35/NN	nn||wcc-37/NN||-lrb--36/NN	nsubj||-rrb--38/VBZ||wcc-37/NN	nsubj||platelet-40/VBD||wcc-37/NN	root||ROOT-0/null||-rrb--38/VBZ	conj_and||-rrb--38/VBZ||platelet-40/VBD	amod||counts-44/NNS||-lrb--41/JJ	nn||counts-44/NNS||plt-42/NN	nn||counts-44/NNS||-rrb--43/NN	nsubj||measured-46/JJ||counts-44/NNS	cop||measured-46/JJ||were-45/VBD	ccomp||platelet-40/VBD||measured-46/JJ	prep_on||measured-46/JJ||days-48/NNS	dep||measured-46/JJ||0-49/CD	num||0-49/CD||3-51/CD	num||0-49/CD||7-53/CD	dep||measured-46/JJ||28-55/CD	conj_and||0-49/CD||28-55/CD	num||papuans-59/NNS||57-57/CD	amod||papuans-59/NNS||indigenous-58/JJ	prep_in||measured-46/JJ||papuans-59/NNS	prep_with||papuans-59/NNS||life-61/NN	amod||exposure-64/NN||long-62/JJ	nn||exposure-64/NN||malaria-63/NN	dobj||-rrb--38/VBZ||exposure-64/NN	num||immigrants-69/NNS||105-66/CD	nn||immigrants-69/NNS||non-67/NN	nn||immigrants-69/NNS||papuan-68/NN	dobj||-rrb--38/VBZ||immigrants-69/NNS	conj_and||exposure-64/NN||immigrants-69/NNS	amod||parts-72/NNS||other-71/JJ	prep_from||-rrb--38/VBZ||parts-72/NNS	prep_of||parts-72/NNS||indonesia-74/NN	amod||exposure-78/NN||limited-76/VBN	nn||exposure-78/NN||malaria-77/NN	prep_with||-rrb--38/VBZ||exposure-78/NN	malaria-77||doxycycline-12||yes||in a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against plasmodium vivax -lrb- n = 64 -rrb- or plasmodium falciparum -lrb- n = 98 -rrb- malaria , the total white cell -lrb- wcc -rrb- and platelet -lrb- plt -rrb- counts were measured on days 0 , 3 , 7 and 28 in 57 indigenous papuans with life long malaria exposure and 105 non papuan immigrants from other parts of indonesia with limited malaria exposure .
det||pain-2/NN||the-1/DT	nsubjpass||refractory-4/VBN||pain-2/NN	auxpass||refractory-4/VBN||was-3/VBD	root||ROOT-0/null||refractory-4/VBN	amod||treatment-7/NN||medical-6/JJ	prep_to||refractory-4/VBN||treatment-7/NN	det||block-13/NN||a-10/DT	amod||block-13/NN||bilateral-11/JJ	amod||block-13/NN||sympathetic-12/JJ	nsubj||resulted-18/VBD||block-13/NN	prep_with||block-13/NN||lidocaine-15/NN	prep_with||block-13/NN||triamcinolone-17/NN	conj_and||lidocaine-15/NN||triamcinolone-17/NN	conj_but||refractory-4/VBN||resulted-18/VBD	prep_in||resulted-18/VBD||relief-20/NN	det||pain-23/NN||the-22/DT	prep_from||resulted-18/VBD||pain-23/NN	pain-23||lidocaine-15||yes||the pain was refractory to medical treatment, but a bilateral sympathetic block with lidocaine and triamcinolone resulted in relief from the pain.
amod||outcomes-2/NNS||secondary-1/JJ	nsubj||include-3/VBP||outcomes-2/NNS	root||ROOT-0/null||include-3/VBP	amod||measures-5/NNS||anthropometric-4/JJ	dobj||include-3/VBP||measures-5/NNS	nn||pressure-8/NN||blood-7/NN	dobj||include-3/VBP||pressure-8/NN	conj_and||measures-5/NNS||pressure-8/NN	nn||profile-12/NN||blood-10/NN	nn||profile-12/NN||lipid-11/NN	dobj||include-3/VBP||profile-12/NN	conj_and||measures-5/NNS||profile-12/NN	amod||measures-15/NNS||psychosocial-14/JJ	dobj||include-3/VBP||measures-15/NNS	conj_and||measures-5/NNS||measures-15/NNS	dobj||include-3/VBP||measures-19/NNS	conj_and||measures-5/NNS||measures-19/NNS	prep_of||measures-19/NNS||diet-21/NN	amod||activity-24/NN||physical-23/JJ	prep_of||measures-19/NNS||activity-24/NN	conj_and||diet-21/NN||activity-24/NN	amod||monitoring-27/NN||bloodglucose-26/JJ	prep_of||measures-19/NNS||monitoring-27/NN	conj_and||diet-21/NN||monitoring-27/NN	nn||care-30/NN||foot-29/NN	prep_of||measures-19/NNS||care-30/NN	conj_and||diet-21/NN||care-30/NN	nn||taking-33/NN||medication-32/NN	prep_of||measures-19/NNS||taking-33/NN	conj_and||diet-21/NN||taking-33/NN	lipid-11||secondary-1||no_rel||secondary outcomes include anthropometric measures, blood pressure, blood lipid profile, psychosocial measures as well as measures of diet, physical activity, bloodglucose monitoring, foot care and medication taking.
det||data-2/NNS||these-1/DT	nsubj||suggest-3/VBP||data-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||play-23/VB||that-4/IN	amod||clusterin-6/NN||secretory-5/JJ	nsubjpass||up-regulated-11/VBN||clusterin-6/NN	nsubj||play-23/VB||clusterin-6/NN	auxpass||up-regulated-11/VBN||is-9/VBZ	advmod||up-regulated-11/VBN||frequently-10/RB	rcmod||clusterin-6/NN||up-regulated-11/VBN	nn||cancers-14/NNS||breast-13/NN	prep_in||up-regulated-11/VBN||cancers-14/NNS	amod||therapies-17/NNS||common-16/JJ	agent||up-regulated-11/VBN||therapies-17/NNS	prep_including||up-regulated-11/VBN||anti-estrogens-20/NNS	aux||play-23/VB||may-22/MD	ccomp||suggest-3/VBP||play-23/VB	det||role-26/NN||a-24/DT	amod||role-26/NN||significant-25/JJ	dobj||play-23/VB||role-26/NN	nn||growth-29/NN||tumor-28/NN	prep_in||role-26/NN||growth-29/NN	amod||progression-32/NN||metastatic-31/JJ	prep_in||role-26/NN||progression-32/NN	conj_and||growth-29/NN||progression-32/NN	amod||resistance-36/NN||subsequent-34/JJ	nn||resistance-36/NN||drug-35/NN	prep_in||role-26/NN||resistance-36/NN	conj_and||growth-29/NN||resistance-36/NN	amod||cells-39/NNS||surviving-38/VBG	prep_in||play-23/VB||cells-39/NNS	cancers-14||anti-estrogens-20||no_rel||these data suggest that secretory clusterin, which is frequently up-regulated in breast cancers by common therapies, including anti-estrogens, may play a significant role in tumor growth, metastatic progression and subsequent drug resistance in surviving cells.
aux||compare-2/VB||to-1/TO	root||ROOT-0/null||compare-2/VB	det||effectiveness-4/NN||the-3/DT	dobj||compare-2/VB||effectiveness-4/NN	prep_of||effectiveness-4/NN||ondansetron-6/NN	conj_and||compare-2/VB||prochlorperazine-8/VB	aux||treat-10/VB||to-9/TO	xcomp||prochlorperazine-8/VB||treat-10/VB	dobj||treat-10/VB||vomiting-11/NN	vomiting-11||prochlorperazine-8||yes||to compare the effectiveness of ondansetron and prochlorperazine to treat vomiting.
prep_objectiveâ||demonstrated-7/VBN||$-2/$	amod||work-5/NN||previous-4/JJ	nsubj||demonstrated-7/VBN||work-5/NN	aux||demonstrated-7/VBN||has-6/VBZ	root||ROOT-0/null||demonstrated-7/VBN	mark||augments-20/VBZ||that-8/IN	amod||administration-10/NN||chronic-9/JJ	nsubj||augments-20/VBZ||administration-10/NN	det||fluoxetine-19/NN||the-12/DT	amod||reuptake-14/JJ||serotonin-13/JJ	amod||fluoxetine-19/NN||reuptake-14/JJ	nn||fluoxetine-19/NN||inhibitor-15/NN	appos||fluoxetine-19/NN||ssri-17/NNP	prep_of||administration-10/NN||fluoxetine-19/NN	ccomp||demonstrated-7/VBN||augments-20/VBZ	amod||responses-22/NNS||counterregulatory-21/JJ	dobj||augments-20/VBZ||responses-22/NNS	prep_to||augments-20/VBZ||hypoglycemia-24/NN	amod||humans-27/NNS||healthy-26/JJ	prep_in||hypoglycemia-24/NN||humans-27/NNS	hypoglycemia-24||ssri-17||no_rel||objectiveâ previous work has demonstrated that chronic administration of the serotonin reuptake inhibitor (ssri) fluoxetine augments counterregulatory responses to hypoglycemia in healthy humans.
det||trial-4/NN||a-2/DT	amod||trial-4/NN||clinical-3/JJ	prep_in||-rrb--38/VBZ||trial-4/NN	nn||doxycycline-10/NNP||chloroquine-6/NNP	conj_vs.||chloroquine-6/NNP||chloroquine-8/NNP	nn||doxycycline-10/NNP||chloroquine-8/NNP	amod||doxycycline-10/NNP||plus-9/IN	prep_of||trial-4/NN||doxycycline-10/NNP	prep_of||trial-4/NN||doxycycline-12/NNP	conj_vs.||doxycycline-10/NNP||doxycycline-12/NNP	advmod||n-26/VBN||alone-13/RB	nn||vivax-16/NN||plasmodium-15/NN	nn||n-18/NN||vivax-16/NN	amod||n-18/NN||-lrb--17/JJ	prep_against||alone-13/RB||n-18/NN	dep||-rrb--21/JJ||=-19/SYM	number||-rrb--21/JJ||64-20/CD	dep||n-18/NN||-rrb--21/JJ	amod||-lrb--25/NNS||plasmodium-23/JJ	nn||-lrb--25/NNS||falciparum-24/NN	dep||n-18/NN||-lrb--25/NNS	conj_or||-rrb--21/JJ||-lrb--25/NNS	vmod||doxycycline-10/NNP||n-26/VBN	dep||malaria-30/NN||=-27/SYM	num||malaria-30/NN||98-28/CD	amod||malaria-30/NN||-rrb--29/JJ	ccomp||n-26/VBN||malaria-30/NN	det||wcc-37/NN||the-32/DT	amod||wcc-37/NN||total-33/JJ	amod||wcc-37/NN||white-34/JJ	nn||wcc-37/NN||cell-35/NN	nn||wcc-37/NN||-lrb--36/NN	nsubj||-rrb--38/VBZ||wcc-37/NN	nsubj||platelet-40/VBD||wcc-37/NN	root||ROOT-0/null||-rrb--38/VBZ	conj_and||-rrb--38/VBZ||platelet-40/VBD	amod||counts-44/NNS||-lrb--41/JJ	nn||counts-44/NNS||plt-42/NN	nn||counts-44/NNS||-rrb--43/NN	nsubj||measured-46/JJ||counts-44/NNS	cop||measured-46/JJ||were-45/VBD	ccomp||platelet-40/VBD||measured-46/JJ	prep_on||measured-46/JJ||days-48/NNS	dep||measured-46/JJ||0-49/CD	num||0-49/CD||3-51/CD	num||0-49/CD||7-53/CD	dep||measured-46/JJ||28-55/CD	conj_and||0-49/CD||28-55/CD	num||papuans-59/NNS||57-57/CD	amod||papuans-59/NNS||indigenous-58/JJ	prep_in||measured-46/JJ||papuans-59/NNS	prep_with||papuans-59/NNS||life-61/NN	amod||exposure-64/NN||long-62/JJ	nn||exposure-64/NN||malaria-63/NN	dobj||-rrb--38/VBZ||exposure-64/NN	num||immigrants-69/NNS||105-66/CD	nn||immigrants-69/NNS||non-67/NN	nn||immigrants-69/NNS||papuan-68/NN	dobj||-rrb--38/VBZ||immigrants-69/NNS	conj_and||exposure-64/NN||immigrants-69/NNS	amod||parts-72/NNS||other-71/JJ	prep_from||-rrb--38/VBZ||parts-72/NNS	prep_of||parts-72/NNS||indonesia-74/NN	amod||exposure-78/NN||limited-76/VBN	nn||exposure-78/NN||malaria-77/NN	prep_with||-rrb--38/VBZ||exposure-78/NN	malaria-77||chloroquine-8||yes||in a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against plasmodium vivax -lrb- n = 64 -rrb- or plasmodium falciparum -lrb- n = 98 -rrb- malaria , the total white cell -lrb- wcc -rrb- and platelet -lrb- plt -rrb- counts were measured on days 0 , 3 , 7 and 28 in 57 indigenous papuans with life long malaria exposure and 105 non papuan immigrants from other parts of indonesia with limited malaria exposure .
dep||estimate-8/VBP||given-1/VBN	mark||occurs-5/VBZ||that-2/IN	amod||transmission-4/NN||human-to-human-3/JJ	nsubj||occurs-5/VBZ||transmission-4/NN	pcomp||given-1/VBN||occurs-5/VBZ	nsubj||estimate-8/VBP||we-7/PRP	root||ROOT-0/null||estimate-8/VBP	det||infection-10/NN||the-9/DT	dobj||estimate-8/VBP||infection-10/NN	amod||rates-13/NNS||secondary-11/JJ	nn||rates-13/NNS||attack-12/NN	dep||infection-10/NN||rates-13/NNS	appos||rates-13/NNS||sars-15/NNS	det||number-22/NN||the-18/DT	amod||number-22/NN||local-19/JJ	amod||number-22/NN||basic-20/JJ	amod||number-22/NN||reproductive-21/JJ	dobj||estimate-8/VBP||number-22/NN	conj_and||infection-10/NN||number-22/NN	appos||number-22/NN||r-24/NN	num||r-24/NN||0-25/CD	basic-20||sars-15||no_rel||given that human-to-human transmission occurs, we estimate the infection secondary attack rates (sars) and the local basic reproductive number, r 0 .
prep_in||granted-6/VBN||japan-2/NN	nsubjpass||granted-6/VBN||mtx-4/NN	auxpass||granted-6/VBN||was-5/VBD	root||ROOT-0/null||granted-6/VBN	dobj||granted-6/VBN||approval-7/NN	prep_in||approval-7/NN||1999-9/CD	det||ministry-13/NN||the-11/DT	amod||ministry-13/NN||then-12/JJ	agent||granted-6/VBN||ministry-13/NN	prep_of||ministry-13/NN||health-15/NN	prep_of||ministry-13/NN||welfare-17/NN	conj_and||health-15/NN||welfare-17/NN	advmod||granted-6/VBN||specifically-18/RB	prepc_for||granted-6/VBN||treating-20/VBG	dobj||treating-20/VBG||rheumatoidarthritis-21/NNS	amod||patients-24/NNS||adult-23/JJ	prep_in||treating-20/VBG||patients-24/NNS	vmod||treating-20/VBG||allowing-26/VBG	nsubjpass||used-30/VBN||it-27/PRP	auxpass||used-30/VBN||be-28/VB	advmod||used-30/VBN||generally-29/RB	ccomp||allowing-26/VBG||used-30/VBN	amod||institutions-33/NNS||medical-32/JJ	prep_in||used-30/VBN||institutions-33/NNS	prep_for||used-30/VBN||patients-35/NNS	vmod||patients-35/NNS||having-36/VBG	amod||insurance-39/NN||national-37/JJ	nn||insurance-39/NN||health-38/NN	dobj||having-36/VBG||insurance-39/NN	rheumatoidarthritis-21||mtx-4||yes||in japan, mtx was granted approval in 1999 by the then ministry of health and welfare specifically for treating rheumatoidarthritis in adult patients, allowing it be generally used in medical institutions for patients having national health insurance.
nsubj||plays-11/VBZ||recognition-1/NN	amod||antigens-6/NNS||pancreatic-3/JJ	amod||antigens-6/NNS||beta-4/JJ	nn||antigens-6/NNS||cell-5/NN	prep_of||recognition-1/NN||antigens-6/NNS	amod||lymphocytes-10/NNS||autoreactive-8/JJ	nn||lymphocytes-10/NNS||t-9/NN	prep_by||antigens-6/NNS||lymphocytes-10/NNS	root||ROOT-0/null||plays-11/VBZ	det||role-14/NN||a-12/DT	amod||role-14/NN||central-13/JJ	dobj||plays-11/VBZ||role-14/NN	det||pathogenesis-17/NNS||the-16/DT	prep_in||role-14/NN||pathogenesis-17/NNS	amod||type1diabetes-20/NNS||insulin-dependent-19/JJ	prep_of||pathogenesis-17/NNS||type1diabetes-20/NNS	type1diabetes-20||insulin--1||yes||recognition of pancreatic beta cell antigens by autoreactive t lymphocytes plays a central role in the pathogenesis of insulin-dependent type1diabetes.
advmod||accepted-20/VBD||conversely-1/RB	mark||found-10/VBN||after-3/IN	det||recurrence-8/NN||a-4/DT	amod||recurrence-8/NN||new-5/JJ	nn||recurrence-8/NN||alveolar-6/NN	nn||recurrence-8/NN||echinococcosis-7/NNS	nsubjpass||found-10/VBN||recurrence-8/NN	auxpass||found-10/VBN||was-9/VBD	advcl||accepted-20/VBD||found-10/VBN	det||lung-14/NN||the-12/DT	amod||lung-14/NN||right-13/JJ	prep_in||found-10/VBN||lung-14/NN	prep_in||lung-14/NN||1994-16/CD	det||patient-19/NN||the-18/DT	nsubj||accepted-20/VBD||patient-19/NN	nsubj||take-22/VB||patient-19/NN	root||ROOT-0/null||accepted-20/VBD	aux||take-22/VB||to-21/TO	xcomp||accepted-20/VBD||take-22/VB	dobj||take-22/VB||albendazole-23/NN	advmod||take-22/VB||continuously-24/RB	det||dosage-28/NN||the-26/DT	amod||dosage-28/NN||right-27/JJ	prep_at||take-22/VB||dosage-28/NN	echinococcosis-7||albendazole-23||yes||conversely, after a new alveolar echinococcosis recurrence was found in the right lung in 1994, the patient accepted to take albendazole continuously at the right dosage.
aux||gain-2/VB||to-1/TO	advcl||compiled-15/VBN||gain-2/VB	dobj||gain-2/VB||understanding-3/NN	prep_of||understanding-3/NN||surveillance-5/NN	prep_of||understanding-3/NN||epidemiology-7/NN	conj_and||surveillance-5/NN||epidemiology-7/NN	amod||outbreaks-10/NNS||viralgastroenteritis-9/JJ	prep_of||understanding-3/NN||outbreaks-10/NNS	prep_in||gain-2/VB||europe-12/NN	nsubj||compiled-15/VBN||we-14/PRP	root||ROOT-0/null||compiled-15/VBN	dobj||compiled-15/VBN||data-16/NNS	num||systems-20/NNS||10-18/CD	nn||systems-20/NNS||surveillance-19/NN	prep_from||compiled-15/VBN||systems-20/NNS	det||viruses-24/NNS||the-22/DT	amod||viruses-24/NNS||foodborne-23/JJ	prep_in||compiled-15/VBN||viruses-24/NNS	amod||network-27/NN||europe-26/JJ	prep_in||viruses-24/NNS||network-27/NN	viralgastroenteritis-9||viruses-24||no||to gain understanding of surveillance and epidemiology of viralgastroenteritis outbreaks in europe, we compiled data from 10 surveillance systems in the foodborne viruses in europe network.
amod||status-2/NN||hiv/aids-1/JJ	nsubjpass||known-4/VBN||status-2/NN	auxpass||known-4/VBN||was-3/VBD	ccomp||reported-19/VBD||known-4/VBN	amod||children-11/NNS||68-6/CD	num||%-9/NN||17.4-8/CD	appos||children-11/NNS||%-9/NN	agent||known-4/VBN||children-11/NNS	nn||caretakers-18/NNS||93-13/CD	num||%-16/NN||29-15/CD	appos||caretakers-18/NNS||%-16/NN	nsubj||reported-19/VBD||caretakers-18/NNS	root||ROOT-0/null||reported-19/VBD	xcomp||reported-19/VBD||knowing-20/VBG	det||child-22/NN||the-21/DT	poss||status-48/NN||child-22/NN	amod||status-48/NN||serostatus-24/JJ	num||years-26/NNS||two-25/CD	npadvmod||serostatus-24/JJ||years-26/NNS	poss||survey-30/NN||our-29/PRP$	prep_prior_to||serostatus-24/JJ||survey-30/NN	appos||survey-30/NN||180-32/CD	mark||told-44/VBN||180-32/CD	num||%-35/NN||46.2-34/CD	appos||180-32/CD||%-35/NN	nsubj||said-38/VBD||respondents-37/NNS	rcmod||180-32/CD||said-38/VBD	det||child-41/NN||the-40/DT	nsubjpass||told-44/VBN||child-41/NN	aux||told-44/VBN||should-42/MD	auxpass||told-44/VBN||be-43/VB	ccomp||said-38/VBD||told-44/VBN	nn||hiv/aids-47/NNS||his/her-46/NN	prep_about||told-44/VBN||hiv/aids-47/NNS	dobj||knowing-20/VBG||status-48/NN	advmod||older-52/JJR||when-49/WRB	nsubj||older-52/JJR||he/she-50/NN	cop||older-52/JJR||is-51/VBZ	rcmod||child-22/NN||older-52/JJR	ccomp||status-48/NN||older-52/JJR	num||years-55/NNS||14-54/CD	prep_than||older-52/JJR||years-55/NNS	prep_of||years-55/NNS||age-57/NN	aids--1||hiv--1||no||hiv/aids status was known by 68 (17.4%) children, 93 (29%) caretakers reported knowing the child's serostatus two years prior to our survey, 180 (46.2%) respondents said that the child should be told about his/her hiv/aids status when he/she is older than 14 years of age.
nn||knowledge-2/NN||mtx-1/NN	nsubjpass||expected-7/VBN||knowledge-2/NN	aux||expected-7/VBN||may-3/MD	auxpass||expected-7/VBN||be-4/VB	advmod||than-6/IN||less-5/RBR	advmod||expected-7/VBN||than-6/IN	root||ROOT-0/null||expected-7/VBN	det||parents-10/NNS||the-9/DT	prep_in||expected-7/VBN||parents-10/NNS	prep_of||parents-10/NNS||children-12/NNS	prep_with||children-12/NNS||jia-14/NN	jia-14||mtx-1||yes||mtx knowledge may be less than expected in the parents of children with jia.
nsubj||resulted-13/VBD||phagocytosis-1/NNS	prep_of||phagocytosis-1/NNS||cvb3-infected-3/JJ	amod||islets-12/NNS||mock-infected-7/JJ	conj_and||mock-infected-7/JJ||human-9/JJ	amod||islets-12/NNS||human-9/JJ	conj_and||mock-infected-7/JJ||porcine-11/JJ	amod||islets-12/NNS||porcine-11/JJ	prep_of||phagocytosis-1/NNS||islets-12/NNS	conj_negcc||cvb3-infected-3/JJ||islets-12/NNS	root||ROOT-0/null||resulted-13/VBD	prep_in||resulted-13/VBD||induction-15/NN	prep_of||induction-15/NN||isgs-17/NNS	prep_in||resulted-13/VBD||dcs-19/NN	det||rig-29/NN||the-22/DT	nn||rig-29/NN||retinoicacidâ-23/NNP	nn||rig-29/NN||$-24/NNP	nn||rig-29/NN||inducible-26/NN	nn||rig-29/NN||gene-27/NN	prep_including||resulted-13/VBD||rig-29/NN	prep_including||resulted-13/VBD||iâ-32/RB	advmod||rig-29/NN||iâ-32/RB	conj_and||rig-29/NN||iâ-32/RB	pobj||iâ-32/RB||$-33/$	prep_like||iâ-32/RB||helicases-36/NNS	dep||helicases-36/NNS||rlhs-38/NNS	prep_including||resulted-13/VBD||rig-i-41/NN	conj_and||rig-29/NN||rig-i-41/NN	nn||mda5-52/NN||melanoma-44/NNP	nn||mda5-52/NN||differentiationâ-45/NNP	nn||mda5-52/NN||$-46/NNP	amod||mda5-52/NN||associated-48/JJ	nn||mda5-52/NN||gene-49/NN	num||mda5-52/NN||5-50/CD	prep_including||resulted-13/VBD||mda5-52/NN	conj_and||rig-29/NN||mda5-52/NN	melanoma-44||retinoicacid--1||no_rel||phagocytosis of cvb3-infected, but not mock-infected, human and porcine islets resulted in induction of isgs in dcs, including the retinoicacidâinducible gene (rig)-iâlike helicases (rlhs), rig-i, and melanoma differentiationâassociated gene 5 (mda5).
advmod||poses-26/VBZ||yet-1/RB	det||persistence-4/NN||the-3/DT	nsubj||poses-26/VBZ||persistence-4/NN	amod||poliovirus-7/NNS||wild-6/JJ	prep_of||persistence-4/NN||poliovirus-7/NNS	det||countriesâ-13/NNS||the-9/DT	num||countriesâ-13/NNS||4-10/CD	amod||countriesâ-13/NNS||remaining-11/VBG	amod||countriesâ-13/NNS||polio-endemic-12/JJ	nsubj||$-14/VBG||countriesâ-13/NNS	prepc_in||poliovirus-7/NNS||$-14/VBG	dobj||$-14/VBG||afghanistan-16/NN	dobj||$-14/VBG||india-18/NN	conj_and||afghanistan-16/NN||india-18/NN	dobj||$-14/VBG||nigeria-20/NN	conj_and||afghanistan-16/NN||nigeria-20/NN	nn||$-24/NNP||pakistanâ-23/NNP	dobj||$-14/VBG||$-24/NNP	conj_and||afghanistan-16/NN||$-24/NNP	root||ROOT-0/null||poses-26/VBZ	det||risk-28/NN||a-27/DT	dobj||poses-26/VBZ||risk-28/NN	poss||importation-31/NN||its-30/PRP$	prep_for||risk-28/NN||importation-31/NN	det||countries-34/NNS||all-33/DT	prep_into||poses-26/VBZ||countries-34/NNS	vmod||countries-34/NNS||declared-35/VBN	nsubj||free-37/JJ||polio-36/NNP	xcomp||declared-35/VBN||free-37/JJ	polio-36||poliovirus-7||no||yet, the persistence of wild poliovirus in the 4 remaining polio-endemic countriesâafghanistan, india, nigeria, and pakistanâposes a risk for its importation into all countries declared polio free.
det||varicellazostervirus-2/NNS||the-1/DT	nsubj||alpha-herpesvirus-10/NNS||varicellazostervirus-2/NNS	appos||varicellazostervirus-2/NNS||vzv-4/NN	cop||alpha-herpesvirus-10/NNS||is-6/VBZ	det||alpha-herpesvirus-10/NNS||a-7/DT	amod||alpha-herpesvirus-10/NNS||ubiquitous-8/JJ	amod||alpha-herpesvirus-10/NNS||human-9/JJ	root||ROOT-0/null||alpha-herpesvirus-10/NNS	nsubj||agent-15/NN||alpha-herpesvirus-10/NNS	cop||agent-15/NN||is-12/VBZ	det||agent-15/NN||the-13/DT	amod||agent-15/NN||causative-14/JJ	rcmod||alpha-herpesvirus-10/NNS||agent-15/NN	prep_of||agent-15/NN||chickenpox-17/NN	prep_of||agent-15/NN||shingles-19/NNS	conj_and||chickenpox-17/NN||shingles-19/NNS	shingles-19||varicellazostervirus-2||no||the varicellazostervirus (vzv) is a ubiquitous human alpha-herpesvirus that is the causative agent of chickenpox and shingles.
det||study-2/NN||this-1/DT	nsubj||type/subtype-11/VBP||study-2/NN	vmod||study-2/NN||evaluated-3/VBN	det||effect-5/NN||the-4/DT	dobj||evaluated-3/VBN||effect-5/NN	amod||strains-9/NNS||matching/mismatching-7/VBG	nn||strains-9/NNS||vaccine-8/NN	prep_of||effect-5/NN||strains-9/NNS	root||ROOT-0/null||type/subtype-11/VBP	nn||changes-13/NNS||pattern-12/NN	dobj||type/subtype-11/VBP||changes-13/NNS	poss||influenzaviruses-17/NNS||taiwan-15/NN	prep_in||changes-13/NNS||influenzaviruses-17/NNS	det||impact-21/NN||the-20/DT	dobj||type/subtype-11/VBP||impact-21/NN	conj_and||changes-13/NNS||impact-21/NN	prep_of||impact-21/NN||post-sars-23/NNS	appos||post-sars-23/NNS||severeacuterespiratorysyndrome-25/NN	amod||efforts-29/NNS||public-27/JJ	nn||efforts-29/NNS||health-28/NN	dep||type/subtype-11/VBP||efforts-29/NNS	amod||mortalities-33/NNS||excess-31/JJ	amod||mortalities-33/NNS||influenza-associated-32/JJ	prep_on||efforts-29/NNS||mortalities-33/NNS	det||elderly-36/JJ||the-35/DT	prep_among||mortalities-33/NNS||elderly-36/JJ	influenza--1||influenzaviruses-17||no||this study evaluated the effect of matching/mismatching vaccine strains, type/subtype pattern changes in taiwan's influenzaviruses, and the impact of post-sars (severeacuterespiratorysyndrome) public health efforts on excess influenza-associated mortalities among the elderly.
det||effect-3/NN||a-1/DT	amod||effect-3/NN||dual-2/JJ	nsubjpass||observed-8/VBN||effect-3/NN	nn||action-6/NN||insulin-5/NN	prep_on||effect-3/NN||action-6/NN	auxpass||observed-8/VBN||was-7/VBD	root||ROOT-0/null||observed-8/VBN	advmod||exposed-14/VBN||when-9/WRB	nsubjpass||exposed-14/VBN||myotubes-10/NNS	conj_and||myotubes-10/NNS||mice-12/NNS	nsubjpass||exposed-14/VBN||mice-12/NNS	auxpass||exposed-14/VBN||were-13/VBD	advcl||observed-8/VBN||exposed-14/VBN	det||additive-18/NN||this-16/DT	amod||additive-18/NN||cytokine-17/JJ	prep_to||exposed-14/VBN||additive-18/NN	amod||insulin-21/NN||short-term-20/JJ	prep_with||additive-18/NN||insulin-21/NN	amod||uptake-25/NN||increased-23/JJ	nn||uptake-25/NN||glucose-24/NN	dep||insulin-21/NN||uptake-25/NN	amod||sensitivity-29/NN||systemic-27/JJ	nn||sensitivity-29/NN||insulin-28/NN	dep||insulin-21/NN||sensitivity-29/NN	conj_and||uptake-25/NN||sensitivity-29/NN	amod||exposure-33/NN||chronic-32/JJ	nsubj||produced-34/VBD||exposure-33/NN	conj_but||observed-8/VBN||produced-34/VBD	dobj||produced-34/VBD||insulinresistance-35/NN	dep||insulinresistance-35/NN||impaired-37/VBN	amod||translocation-39/NN||glut4-38/JJ	dobj||impaired-37/VBN||translocation-39/NN	nn||membrane-42/NNS||plasma-41/NN	prep_to||impaired-37/VBN||membrane-42/NNS	prep_to||impaired-37/VBN||defects-44/NNS	conj_and||membrane-42/NNS||defects-44/NNS	prep_in||impaired-37/VBN||insulin-46/NN	xcomp||impaired-37/VBN||signaling-47/VBG	det||substrate-52/NN||the-49/DT	nn||substrate-52/NN||insulin-50/NN	nn||substrate-52/NN||receptor-51/NN	nn||level-57/NN||substrate-52/NN	num||-LSB--54/NNS||1-53/CD	npadvmod||irs-1-55/JJ||-LSB--54/NNS	amod||level-57/NN||irs-1-55/JJ	nn||level-57/NN||-RSB--56/NN	prep_at||signaling-47/VBG||level-57/NN	insulin-50||insulinresistance-35||no_rel||a dual effect on insulin action was observed when myotubes and mice were exposed to this cytokine additive with short-term insulin (increased glucose uptake and systemic insulin sensitivity) but chronic exposure produced insulinresistance (impaired glut4 translocation to plasma membrane and defects in insulin signaling at the insulin receptor substrate 1 [irs-1] level).
det||inhalation-2/NN||the-1/DT	nsubj||induces-6/VBZ||inhalation-2/NN	nn||particles-5/NNS||silica-4/NN	prep_of||inhalation-2/NN||particles-5/NNS	root||ROOT-0/null||induces-6/VBZ	dobj||induces-6/VBZ||silicosis-7/NNS	det||lungdisease-13/NN||an-9/DT	amod||lungdisease-13/NN||inflammatory-10/JJ	conj_and||inflammatory-10/JJ||fibrotic-12/JJ	amod||lungdisease-13/NN||fibrotic-12/JJ	appos||silicosis-7/NNS||lungdisease-13/NN	vmod||lungdisease-13/NN||characterized-14/VBN	det||accumulation-18/NN||the-16/DT	amod||accumulation-18/NN||early-17/JJ	agent||characterized-14/VBN||accumulation-18/NN	prep_of||accumulation-18/NN||macrophages-20/NNS	prep_of||accumulation-18/NN||neutrophils-22/NNS	conj_and||macrophages-20/NNS||neutrophils-22/NNS	det||appearance-28/NN||the-24/DT	amod||appearance-28/NN||airspace-25/JJ	conj_and||airspace-25/JJ||subsequent-27/JJ	amod||appearance-28/NN||subsequent-27/JJ	prep_in||characterized-14/VBN||appearance-28/NN	amod||nodules-31/NNS||silicotic-30/JJ	prep_of||appearance-28/NN||nodules-31/NNS	det||result-34/NN||a-33/DT	prep_as||characterized-14/VBN||result-34/NN	amod||fibrosis-37/NN||progressive-36/JJ	prep_of||result-34/NN||fibrosis-37/NN	silicosis-7||silica-4||no||the inhalation of silica particles induces silicosis, an inflammatory and fibrotic lungdisease characterized by the early accumulation of macrophages and neutrophils in the airspace and subsequent appearance of silicotic nodules as a result of progressive fibrosis.
aux||counter-2/VB||to-1/TO	csubj||adopted-16/VBD||counter-2/VB	det||challenge-5/NN||the-3/DT	amod||challenge-5/NN||increasing-4/VBG	dobj||counter-2/VB||challenge-5/NN	amod||resistance-9/NN||anti-malarial-7/JJ	nn||resistance-9/NN||drug-8/NN	prep_of||challenge-5/NN||resistance-9/NN	conj_and||counter-2/VB||improve-11/VB	csubj||adopted-16/VBD||improve-11/VB	advmod||effective-13/JJ||highly-12/RB	amod||burundi-15/NNS||effective-13/JJ	nn||burundi-15/NNS||treatment-14/NN	dobj||improve-11/VB||burundi-15/NNS	root||ROOT-0/null||adopted-16/VBD	dobj||adopted-16/VBD||artesunate-amodiaquine-17/NN	appos||artesunate-amodiaquine-17/NN||as-aq-19/NNP	amod||treatment-23/NN||first-line-22/JJ	prep_as||adopted-16/VBD||treatment-23/NN	amod||plasmodiumfalciparummalaria-26/NN||uncomplicated-25/JJ	prep_for||treatment-23/NN||plasmodiumfalciparummalaria-26/NN	amod||quinine-29/NN||oral-28/JJ	prep_as||adopted-16/VBD||quinine-29/NN	conj_and||treatment-23/NN||quinine-29/NN	amod||treatment-32/NN||second-line-31/JJ	prep_as||quinine-29/NN||treatment-32/NN	poss||policy-37/NN||its-34/PRP$	amod||policy-37/NN||national-35/JJ	nn||policy-37/NN||treatment-36/NN	prep_in||adopted-16/VBD||policy-37/NN	prep_in||policy-37/NN||2003-39/CD	plasmodiumfalciparummalaria-26||quinine-29||yes||to counter the increasing challenge of anti-malarial drug resistance and improve highly effective treatment burundi adopted artesunate-amodiaquine (as-aq) as first-line treatment for uncomplicated plasmodiumfalciparummalaria and oral quinine as second-line treatment in its national treatment policy in 2003.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-4/NN||a-3/DT	dobj||report-2/VBP||case-4/NN	det||woman-8/NN||a-6/DT	nn||woman-8/NN||moroccan-7/NN	prep_about||case-4/NN||woman-8/NN	amod||lymphoma-14/NN||non-hodgkin-11/JJ	amod||lymphoma-14/NN||null-12/JJ	nn||lymphoma-14/NN||phenotype-13/NN	prep_with||report-2/VBP||lymphoma-14/NN	det||chest-17/NN||the-16/DT	prep_of||lymphoma-14/NN||chest-17/NN	vmod||chest-17/NN||treated-19/VBN	advmod||treated-19/VBN||successfully-20/RB	prep_with||treated-19/VBN||chop-22/NNP	dep||chop-22/NNP||cyclophosphamide-24/NN	appos||cyclophosphamide-24/NN||doxorubicin-26/NN	appos||cyclophosphamide-24/NN||vincristin-28/NN	conj_and||doxorubicin-26/NN||vincristin-28/NN	appos||cyclophosphamide-24/NN||prednisone-30/NN	conj_and||doxorubicin-26/NN||prednisone-30/NN	vmod||chop-22/NNP||followed-32/VBN	amod||radiotherapy-35/NN||local-34/JJ	agent||followed-32/VBN||radiotherapy-35/NN	hodgkin--1||cyclophosphamide-24||yes||we report a case about a moroccan woman, with non-hodgkin null phenotype lymphoma of the chest, treated successfully with chop (cyclophosphamide, doxorubicin, vincristin and prednisone) followed by local radiotherapy.
advmod||show-5/VBP||additionally-1/RB	amod||tests-4/NNS||existing-3/VBG	nsubj||show-5/VBP||tests-4/NNS	root||ROOT-0/null||show-5/VBP	amod||performance-7/NN||poor-6/JJ	dobj||show-5/VBP||performance-7/NN	prepc_in||performance-7/NN||diagnosing-9/VBG	dobj||diagnosing-9/VBG||tb-10/NN	prep_in||diagnosing-9/VBG||children-12/NNS	dobj||show-5/VBP||people-14/NNS	conj_and||performance-7/NN||people-14/NNS	vmod||people-14/NNS||living-15/VBG	prep_with||living-15/VBG||hiv/aids-17/NNS	amod||forms-21/NNS||extrapulmonary-20/JJ	dobj||show-5/VBP||forms-21/NNS	conj_and||performance-7/NN||forms-21/NNS	det||disease-24/NN||the-23/DT	prep_of||forms-21/NNS||disease-24/NN	aids--1||hiv--1||no||additionally, existing tests show poor performance in diagnosing tb in children, people living with hiv/aids, and extrapulmonary forms of the disease.
nsubj||introduced-2/VBD||we-1/PRP	root||ROOT-0/null||introduced-2/VBD	amod||opioids-4/NNS||strong-3/JJ	nsubj||tolerable-26/JJ||opioids-4/NNS	amod||patches-8/NNS||transdermal-6/JJ	amod||patches-8/NNS||fentanyl-7/JJ	dep||opioids-4/NNS||patches-8/NNS	det||pain-12/NN||the-10/DT	nn||pain-12/NN||background-11/NN	prep_for||patches-8/NNS||pain-12/NN	det||opioid-16/NN||a-14/DT	amod||opioid-16/NN||short-acting-15/JJ	dep||opioids-4/NNS||opioid-16/NN	conj_and||patches-8/NNS||opioid-16/NN	det||pain-20/NN||the-18/DT	nn||pain-20/NN||breakthrough-19/NN	prep_for||opioid-16/NN||pain-20/NN	poss||pain-24/NN||his-23/PRP$	conj_and||opioids-4/NNS||pain-24/NN	nsubj||tolerable-26/JJ||pain-24/NN	cop||tolerable-26/JJ||was-25/VBD	ccomp||introduced-2/VBD||tolerable-26/JJ	num||hr-31/NN||250-28/CD	nn||hr-31/NN||âµg-29/NN	nn||hr-31/NN||/-30/NN	prep_on||tolerable-26/JJ||hr-31/NN	amod||patches-34/NNS||fentanyl-33/JJ	prep_of||hr-31/NN||patches-34/NNS	num||months-37/NNS||3-36/CD	prep_for||tolerable-26/JJ||months-37/NNS	pain-24||fentanyl-33||yes||we introduced strong opioids (transdermal fentanyl patches for the background pain and a short-acting opioid for the breakthrough pain) and his pain was tolerable on 250 âµg/hr of fentanyl patches for 3 months.
advmod||investigated-25/VBN||sulphadoxine-pyrimethamine-1/RB	dep||investigated-25/VBN||sp-3/VB	det||treatment-8/NN||a-5/DT	advmod||used-7/VBN||widely-6/RB	amod||treatment-8/NN||used-7/VBN	nsubjpass||investigated-25/VBN||treatment-8/NN	amod||malaria-11/NN||uncomplicated-10/JJ	prep_for||treatment-8/NN||malaria-11/NN	prep_for||treatment-8/NN||recommended-13/VBN	conj_and||malaria-11/NN||recommended-13/VBN	amod||treatment-17/NN||intermittent-15/JJ	nn||treatment-17/NN||preventive-16/NN	prep_for||recommended-13/VBN||treatment-17/NN	prep_of||recommended-13/VBN||malaria-19/NN	prep_in||recommended-13/VBN||pregnancy-21/NN	aux||investigated-25/VBN||is-23/VBZ	auxpass||investigated-25/VBN||being-24/VBG	root||ROOT-0/null||investigated-25/VBN	amod||treatment-29/NN||intermittent-27/JJ	nn||treatment-29/NN||preventive-28/NN	prep_for||investigated-25/VBN||treatment-29/NN	prep_of||treatment-29/NN||malaria-31/NN	prep_in||malaria-31/NN||infants-33/NNS	appos||infants-33/NNS||ipti-35/NNP	malaria-31||pyrimethamine--1||yes||sulphadoxine-pyrimethamine (sp) a widely used treatment for uncomplicated malaria and recommended for intermittent preventive treatment of malaria in pregnancy, is being investigated for intermittent preventive treatment of malaria in infants (ipti).
amod||adjuvant-2/NN||current-1/JJ	nsubj||pharmacological-3/VBP||adjuvant-2/NN	root||ROOT-0/null||pharmacological-3/VBP	dobj||pharmacological-3/VBP||therapy-4/NN	amod||unfractionatedheparin-12/NN||ami-6/JJ	prep_with||ami-6/JJ||aspirin-8/NN	appos||aspirin-8/NN||clopidogrel-10/NN	prep_of||therapy-4/NN||unfractionatedheparin-12/NN	discourse||unfractionatedheparin-12/NN||uh-14/UH	amod||inhibitors-21/NNS||platelet-18/JJ	nn||inhibitors-21/NNS||gp-19/NN	nn||inhibitors-21/NNS||iib/iiia-20/NN	nsubj||provides-22/VBZ||inhibitors-21/NNS	conj_and||pharmacological-3/VBP||provides-22/VBZ	amod||benefits-25/NNS||useful-23/JJ	amod||benefits-25/NNS||therapeutic-24/JJ	dobj||provides-22/VBZ||benefits-25/NNS	ami-6||aspirin-8||yes||current adjuvant pharmacological therapy of ami with aspirin, clopidogrel, unfractionatedheparin (uh), and platelet gp iib/iiia inhibitors provides useful therapeutic benefits.
poss||findings-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||plays-8/VBZ||that-4/IN	amod||signaling-7/NNS||striatal-5/JJ	amod||signaling-7/NNS||mir-212-6/JJ	nsubj||plays-8/VBZ||signaling-7/NNS	ccomp||suggest-3/VBP||plays-8/VBZ	det||role-11/NN||a-9/DT	amod||role-11/NN||key-10/JJ	dobj||plays-8/VBZ||role-11/NN	prepc_in||plays-8/VBZ||determining-13/VBG	dobj||determining-13/VBG||vulnerability-14/NN	aux||cocaineaddiction-16/VB||to-15/TO	vmod||determining-13/VBG||cocaineaddiction-16/VB	vmod||determining-13/VBG||reveal-18/VB	conj_and||cocaineaddiction-16/VB||reveal-18/VB	amod||regulators-21/NNS||novel-19/JJ	amod||regulators-21/NNS||molecular-20/JJ	dobj||reveal-18/VB||regulators-21/NNS	nsubj||control-23/VBP||regulators-21/NNS	rcmod||regulators-21/NNS||control-23/VBP	det||actions-26/NNS||the-24/DT	amod||actions-26/NNS||complex-25/JJ	dobj||control-23/VBP||actions-26/NNS	prep_of||actions-26/NNS||cocaine-28/NN	nn||circuitries-32/NNS||brain-30/NN	nn||circuitries-32/NNS||reward-31/NN	prep_in||cocaine-28/NN||circuitries-32/NNS	vmod||determining-13/VBG||provide-35/VB	conj_and||cocaineaddiction-16/VB||provide-35/VB	det||direction-39/NN||an-36/DT	advmod||new-38/JJ||entirely-37/RB	amod||direction-39/NN||new-38/JJ	dobj||provide-35/VB||direction-39/NN	det||development-42/NN||the-41/DT	prep_for||direction-39/NN||development-42/NN	amod||therapeutics-45/NNS||anti-addiction-44/JJ	prep_of||development-42/NN||therapeutics-45/NNS	prepc_based_on||provide-35/VB||on-47/IN	pobj||provide-35/VB||modulation-48/NN	amod||rnas-51/NNS||noncoding-50/VBG	prep_of||modulation-48/NN||rnas-51/NNS	cocaineaddiction-16||cocaine-28||no||our findings suggest that striatal mir-212 signaling plays a key role in determining vulnerability to cocaineaddiction, reveal novel molecular regulators that control the complex actions of cocaine in brain reward circuitries, and provide an entirely new direction for the development of anti-addiction therapeutics based on modulation of noncoding rnas.
det||effects-2/NNS||the-1/DT	nsubjpass||maintained-16/VBN||effects-2/NNS	prep_of||effects-2/NNS||l-amphetamine-4/NN	aux||reduce-6/VB||to-5/TO	vmod||l-amphetamine-4/NN||reduce-6/VB	det||symptoms-9/NNS||the-7/DT	amod||symptoms-9/NNS||behavioral-8/JJ	dobj||reduce-6/VB||symptoms-9/NNS	prep_of||symptoms-9/NNS||adhd-11/NN	det||shr-14/NN||the-13/DT	prep_in||reduce-6/VB||shr-14/NN	auxpass||maintained-16/VBN||were-15/VBD	root||ROOT-0/null||maintained-16/VBN	det||days-20/NNS||the-18/DT	num||days-20/NNS||14-19/CD	prep_over||maintained-16/VBN||days-20/NNS	amod||dosing-23/NN||daily-22/JJ	prep_of||days-20/NNS||dosing-23/NN	neg||evidence-26/NN||no-25/DT	prep_with||maintained-16/VBN||evidence-26/NN	prep_of||evidence-26/NN||tolerance-28/NN	amod||tolerance-28/NN||developing-29/VBG	adhd-11||amphetamine--1||yes||the effects of l-amphetamine to reduce the behavioral symptoms of adhd in the shr were maintained over the 14 days of daily dosing with no evidence of tolerance developing.
det||gas-19/NN||the-1/DT	nn||gas-19/NN||impacts-2/NNS	amod||treatments-5/NNS||post-metallisation-4/JJ	prep_of||impacts-2/NNS||treatments-5/NNS	amod||acid-9/NN||phosphoric-8/JJ	prep_such_as||treatments-5/NNS||acid-9/NN	appos||impacts-2/NNS||h3po4-11/NNP	amod||gas-19/NN||etching-13/JJ	dep||gas-19/NN||nitrogen-15/NN	appos||gas-19/NN||n2-17/NNP	nsubj||anneal-20/VBP||gas-19/NN	root||ROOT-0/null||anneal-20/VBP	dep||investigated-39/VBN||forming-22/VBG	dobj||forming-22/VBG||gas-23/NN	appos||gas-23/NN||ar-25/NN	num||ar-25/NN||h2-26/CD	amod||gas-23/NN||anneal-28/JJ	det||$-32/$||the-30/DT	amod||$-32/$||cellsâ-31/JJ	prep_on||anneal-28/JJ||$-32/$	num||$-32/$||-33/CD	amod||properties-37/NNS||electrical-34/JJ	conj_and||electrical-34/JJ||photovoltaic-36/JJ	amod||properties-37/NNS||photovoltaic-36/JJ	nsubjpass||investigated-39/VBN||properties-37/NNS	auxpass||investigated-39/VBN||are-38/VBP	conj_and||anneal-20/VBP||investigated-39/VBN	ar-25||gas-23||no_rel||the impacts of post-metallisation treatments such as phosphoric acid (h3po4) etching, nitrogen (n2) gas anneal and forming gas (ar h2) anneal on the cellsâ electrical and photovoltaic properties are investigated.
advmod||remain-11/VBP||however-1/RB	det||manifestations-5/NNS||the-3/DT	amod||manifestations-5/NNS||pulmonary-4/JJ	nsubj||remain-11/VBP||manifestations-5/NNS	prep_of||manifestations-5/NNS||hiv/acquiredimmunodeficiencysyndrome-7/NN	appos||hiv/acquiredimmunodeficiencysyndrome-7/NN||aids-9/NNS	root||ROOT-0/null||remain-11/VBP	det||cause-14/NN||a-12/DT	amod||cause-14/NN||major-13/JJ	xcomp||remain-11/VBP||cause-14/NN	prep_of||cause-14/NN||morbidity-16/NN	prep_of||cause-14/NN||mortality-18/NN	conj_and||morbidity-16/NN||mortality-18/NN	acquiredimmunodeficiencysyndrome--1||hiv--1||no||however, the pulmonary manifestations of hiv/acquiredimmunodeficiencysyndrome (aids) remain a major cause of morbidity and mortality.
det||aprepitant-6/NN||the-1/DT	amod||aprepitant-6/NN||selective-2/JJ	amod||aprepitant-6/NN||neurokinin-1-3/JJ	nn||aprepitant-6/NN||receptor-4/NN	nn||aprepitant-6/NN||antagonist-5/NN	nsubj||effective-8/JJ||aprepitant-6/NN	cop||effective-8/JJ||is-7/VBZ	root||ROOT-0/null||effective-8/JJ	det||treatment-11/NN||the-10/DT	prep_in||effective-8/JJ||treatment-11/NN	amod||chemotherapy-inducednauseaandvomiting-16/NN||acute-13/JJ	conj_and||acute-13/JJ||delayed-15/JJ	amod||chemotherapy-inducednauseaandvomiting-16/NN||delayed-15/JJ	prep_of||treatment-11/NN||chemotherapy-inducednauseaandvomiting-16/NN	appos||chemotherapy-inducednauseaandvomiting-16/NN||cinv-18/NNP	vmod||chemotherapy-inducednauseaandvomiting-16/NN||associated-20/VBN	det||chemotherapy-27/NN||both-22/DT	advmod||chemotherapy-27/NN||moderately-23/RB	advmod||emetogenic-26/JJ||highly-25/RB	conj_and||moderately-23/RB||emetogenic-26/JJ	advmod||chemotherapy-27/NN||emetogenic-26/JJ	prep_with||associated-20/VBN||chemotherapy-27/NN	chemotherapy-inducednauseaandvomiting-16||aprepitant-6||no_rel||the selective neurokinin-1 receptor antagonist aprepitant is effective in the treatment of acute and delayed chemotherapy-inducednauseaandvomiting (cinv) associated with both moderately and highly emetogenic chemotherapy.
prep_from||treated-14/VBN||december-2/NNP	num||december-2/NNP||2007-3/CD	prep_to||treated-14/VBN||march-5/NN	num||march-5/NN||2009-6/CD	num||children-9/NNS||220-8/CD	nsubjpass||treated-14/VBN||children-9/NNS	amod||plasmodiumfalciparummalaria-12/NN||uncomplicated-11/JJ	prep_with||children-9/NNS||plasmodiumfalciparummalaria-12/NN	auxpass||treated-14/VBN||were-13/VBD	root||ROOT-0/null||treated-14/VBN	prep_with||treated-14/VBN||artesunate-16/NN	prep_with||treated-14/VBN||mefloquine-18/NN	conj_and||artesunate-16/NN||mefloquine-18/NN	plasmodiumfalciparummalaria-12||mefloquine-18||yes||from december 2007 to march 2009, 220 children with uncomplicated plasmodiumfalciparummalaria were treated with artesunate and mefloquine.
nsubj||showing-11/VBG||this-1/DT	aux||showing-11/VBG||was-2/VBD	prep_at||showing-11/VBG||variance-4/NN	amod||reports-7/NNS||several-6/JJ	prep_with||variance-4/NN||reports-7/NNS	amod||populations-10/NNS||other-9/JJ	prep_in||reports-7/NNS||populations-10/NNS	root||ROOT-0/null||showing-11/VBG	det||association-14/NN||an-12/DT	amod||association-14/NN||inverse-13/JJ	dobj||showing-11/VBG||association-14/NN	prep_of||association-14/NN||adiponectin-16/NN	nn||proinsulin-20/NN||insulinresistance-18/NN	prep_with||showing-11/VBG||proinsulin-20/NN	prep_with||showing-11/VBG||bmi-23/NN	conj_and||proinsulin-20/NN||bmi-23/NN	vmod||proinsulin-20/NN||suggesting-25/VBG	amod||differences-27/NNS||ethnic-26/JJ	dobj||suggesting-25/VBG||differences-27/NNS	det||relationship-30/NN||the-29/DT	prep_in||differences-27/NNS||relationship-30/NN	prep_of||relationship-30/NN||adiponectin-32/NN	nn||sensitivity-35/NN||insulin-34/NN	prep_with||suggesting-25/VBG||sensitivity-35/NN	insulin-34||insulinresistance-18||no_rel||this was at variance with several reports in other populations showing an inverse association of adiponectin with insulinresistance, proinsulin, and bmi, suggesting ethnic differences in the relationship of adiponectin with insulin sensitivity.
det||study-3/NN||this-2/DT	prep_in||investigated-6/VBD||study-3/NN	nsubj||investigated-6/VBD||we-5/PRP	nsubj||tested-21/VBD||we-5/PRP	root||ROOT-0/null||investigated-6/VBD	det||effects-8/NNS||the-7/DT	dobj||investigated-6/VBD||effects-8/NNS	prep_of||effects-8/NNS||vigabatrin-10/NN	prep_on||investigated-6/VBD||epilepsy-12/NN	det||model-17/NN||a-14/DT	amod||model-17/NN||knock-out-15/JJ	nn||model-17/NN||mouse-16/NN	prep_in||investigated-6/VBD||model-17/NN	prep_of||model-17/NN||tsc-19/NN	conj_and||investigated-6/VBD||tested-21/VBD	det||novel-23/NN||the-22/DT	nsubj||hypothesis-24/VBZ||novel-23/NN	ccomp||tested-21/VBD||hypothesis-24/VBZ	mark||inhibits-27/VBZ||that-25/IN	nsubj||inhibits-27/VBZ||vigabatrin-26/NN	ccomp||hypothesis-24/VBZ||inhibits-27/VBZ	det||target-30/NN||the-28/DT	amod||target-30/NN||mammalian-29/JJ	dobj||inhibits-27/VBZ||target-30/NN	amod||pathway-36/NN||rapamycin-32/JJ	appos||pathway-36/NN||mtor-34/NN	prep_of||target-30/NN||pathway-36/NN	det||pathway-41/NN||a-38/DT	amod||pathway-41/NN||key-39/JJ	amod||pathway-41/NN||signaling-40/JJ	appos||pathway-36/NN||pathway-41/NN	nsubjpass||dysregulated-44/VBN||pathway-41/NN	auxpass||dysregulated-44/VBN||is-43/VBZ	rcmod||pathway-41/NN||dysregulated-44/VBN	prep_in||dysregulated-44/VBN||tsc-46/NN	epilepsy-12||vigabatrin-26||yes||in this study, we investigated the effects of vigabatrin on epilepsy in a knock-out mouse model of tsc and tested the novel hypothesis that vigabatrin inhibits the mammalian target of rapamycin (mtor) pathway, a key signaling pathway that is dysregulated in tsc.
nn||criteria-2/NNS||eligibility-1/NN	nsubj||randomised-8/VBD||criteria-2/NNS	num||studies-5/NNS||selecting-4/CD	npadvmod||large-6/JJ||studies-5/NNS	amod||scale-7/NN||large-6/JJ	prep_for||criteria-2/NNS||scale-7/NN	root||ROOT-0/null||randomised-8/VBD	amod||trials-10/NNS||controlled-9/JJ	dobj||randomised-8/VBD||trials-10/NNS	mwe||than-13/IN||more-12/JJR	quantmod||200-14/CD||than-13/IN	num||patients-15/NNS||200-14/CD	prep_in||randomised-8/VBD||patients-15/NNS	prep_with||randomised-8/VBD||osteoarthritis-17/NNS	det||knee-20/NN||the-19/DT	prep_of||osteoarthritis-17/NNS||knee-20/NN	nsubj||compared-24/VBD||knee-20/NN	prep_of||osteoarthritis-17/NNS||hip-22/NN	conj_or||knee-20/NN||hip-22/NN	nsubj||compared-24/VBD||hip-22/NN	rcmod||knee-20/NN||compared-24/VBD	dobj||compared-24/VBD||glucosamine-25/NN	dobj||compared-24/VBD||chondroitin-27/NN	conj_or||glucosamine-25/NN||chondroitin-27/NN	poss||combination-31/NN||their-30/PRP$	dobj||compared-24/VBD||combination-31/NN	conj_or||glucosamine-25/NN||combination-31/NN	prep_with||compared-24/VBD||placebo-33/NN	prep_with||compared-24/VBD||head-35/NN	conj_or||placebo-33/NN||head-35/NN	prep_to||compared-24/VBD||head-37/NN	osteoarthritis-17||chondroitin-27||yes||eligibility criteria for selecting studies large scale randomised controlled trials in more than 200 patients with osteoarthritis of the knee or hip that compared glucosamine, chondroitin, or their combination with placebo or head to head.
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	nsubj||drawn-4/VBN||data-3/NNS	dep||present-2/VBP||drawn-4/VBN	num||irondeficiency-11/NN||four-6/CD	amod||irondeficiency-11/NN||different-7/JJ	amod||irondeficiency-11/NN||conditionsâ-8/JJ	nn||irondeficiency-11/NN||$-9/NN	prep_from||drawn-4/VBN||irondeficiency-11/NN	amod||hypotransferrinemia-14/NN||congenital-13/JJ	prep_from||drawn-4/VBN||hypotransferrinemia-14/NN	conj_and||irondeficiency-11/NN||hypotransferrinemia-14/NN	prep_from||drawn-4/VBN||beta-thalassemia-16/NN	conj_and||irondeficiency-11/NN||beta-thalassemia-16/NN	nn||$-20/NNP||hereditaryhemochromatosisâ-19/NNP	prep_from||drawn-4/VBN||$-20/NNP	conj_and||irondeficiency-11/NN||$-20/NNP	dep||irondeficiency-11/NN||both-22/DT	prep_from||drawn-4/VBN||in-23/IN	conj_and||irondeficiency-11/NN||in-23/IN	amod||models-27/NNS||human-24/JJ	conj_and||human-24/JJ||non-human-26/JJ	amod||models-27/NNS||non-human-26/JJ	prep_in||irondeficiency-11/NN||models-27/NNS	prep_of||models-27/NNS||disease-29/NN	advmod||suggesting-32/VBG||together-31/RB	xcomp||present-2/VBP||suggesting-32/VBG	mark||exerts-37/VBZ||that-33/IN	amod||demand-36/NN||erythroid-34/VBN	nn||demand-36/NN||iron-35/NN	nsubj||exerts-37/VBZ||demand-36/NN	ccomp||suggesting-32/VBG||exerts-37/VBZ	det||influence-40/NN||a-38/DT	amod||influence-40/NN||stronger-39/JJR	dobj||exerts-37/VBZ||influence-40/NN	prepc_on||exerts-37/VBZ||circulating-42/VBG	nn||supply-44/NN||iron-43/NN	dobj||circulating-42/VBG||supply-44/NN	amod||stores-48/NNS||systemic-46/JJ	nn||stores-48/NNS||iron-47/NN	prep_than||circulating-42/VBG||stores-48/NNS	hereditaryhemochromatosis--1||iron-47||no||we present data drawn from four different conditionsâirondeficiency, congenital hypotransferrinemia, beta-thalassemia, and hereditaryhemochromatosisâboth in human and non-human models of disease, together suggesting that erythroid iron demand exerts a stronger influence on circulating iron supply than systemic iron stores.
vmod||assessed-10/VBN||using-1/VBG	num||samples-3/NNS||128-2/CD	dobj||using-1/VBG||samples-3/NNS	det||methods-8/NNS||the-5/DT	num||methods-8/NNS||five-6/CD	nn||methods-8/NNS||pcr-7/NN	nsubjpass||assessed-10/VBN||methods-8/NNS	auxpass||assessed-10/VBN||were-9/VBD	root||ROOT-0/null||assessed-10/VBN	det||protocol-16/NN||an-13/DT	amod||protocol-16/NN||in-house-14/JJ	nn||protocol-16/NN||pcr-15/NN	prep_including||assessed-10/VBN||protocol-16/NN	det||mtb-21/NN||the-18/DT	amod||mtb-21/NN||cobas-19/JJ	nn||mtb-21/NN||amplicor-20/NN	prep_including||assessed-10/VBN||mtb-21/NN	conj_and||protocol-16/NN||mtb-21/NN	det||mtb-26/NN||the-23/DT	amod||mtb-26/NN||cobas-24/JJ	nn||mtb-26/NN||taqman-25/NN	prep_including||assessed-10/VBN||mtb-26/NN	conj_and||protocol-16/NN||mtb-26/NN	det||pcr-32/NN||the-28/DT	amod||pcr-32/NN||advansure-29/JJ	amod||pcr-32/NN||tb/ntm-30/JJ	amod||pcr-32/NN||real-time-31/JJ	prep_including||assessed-10/VBN||pcr-32/NN	conj_and||protocol-16/NN||pcr-32/NN	det||kit-38/NN||the-35/DT	amod||kit-38/NN||real-q-36/JJ	nn||kit-38/NN||m.tuberculosis-37/NNS	prep_including||assessed-10/VBN||kit-38/NN	conj_and||protocol-16/NN||kit-38/NN	tb--1||m.tuberculosis-37||no||using 128 samples , the five pcr methods were assessed , including an in-house pcr protocol , the cobas amplicor mtb , the cobas taqman mtb , the advansure tb/ntm real-time pcr , and the real-q m.tuberculosis kit .
nn||penicillin-2/NN||intramuscular-1/NN	nsubj||cures-20/VBZ||penicillin-2/NN	nsubj||prevents-23/VBZ||penicillin-2/NN	det||antibiotic-6/NN||an-4/DT	amod||antibiotic-6/NN||inexpensive-5/JJ	appos||penicillin-2/NN||antibiotic-6/NN	det||list-11/NN||the-8/DT	amod||list-11/NN||essential-9/JJ	nn||list-11/NN||medicine-10/NN	prep_on||antibiotic-6/NN||list-11/NN	prep_of||list-11/NN||nations-13/NNS	advmod||nations-13/NNS||all-14/DT	det||world-17/NN||the-16/DT	prep_over||nations-13/NNS||world-17/NN	advmod||cures-20/VBZ||effectively-19/RB	root||ROOT-0/null||cures-20/VBZ	dobj||cures-20/VBZ||infection-21/NN	conj_and||cures-20/VBZ||prevents-23/VBZ	dobj||prevents-23/VBZ||congenitalsyphilis-24/NNS	penicillin-2||congenitalsyphilis-24||no_rel||intramuscular penicillin, an inexpensive antibiotic on the essential medicine list of nations all over the world, effectively cures infection and prevents congenitalsyphilis.
det||organizations-2/NNS||these-1/DT	nsubj||include-3/VBP||organizations-2/NNS	root||ROOT-0/null||include-3/VBP	det||center-5/NN||the-4/DT	dobj||include-3/VBP||center-5/NN	amod||-rrb--12/NNP||hiv/aids-7/JJ	nn||-rrb--12/NNP||vaccine-8/NN	nn||-rrb--12/NNP||immunology-9/NN	nn||-rrb--12/NNP||-lrb--10/NNP	nn||-rrb--12/NNP||chavi-11/NNP	prep_for||center-5/NN||-rrb--12/NNP	det||network-17/NN||the-14/DT	amod||network-17/NN||immune-15/JJ	nn||network-17/NN||tolerance-16/NN	dobj||include-3/VBP||network-17/NN	conj_and||center-5/NN||network-17/NN	nn||-rrb--20/NNP||-lrb--18/NNP	nn||-rrb--20/NNP||itn-19/NNP	dep||network-17/NN||-rrb--20/NNP	det||hiv-23/NN||the-22/DT	dobj||include-3/VBP||hiv-23/NN	conj_and||center-5/NN||hiv-23/NN	nn||-rrb--29/NNP||vaccine-24/NN	nn||-rrb--29/NNP||trials-25/NNS	nn||-rrb--29/NNP||network-26/NN	nn||-rrb--29/NNP||-lrb--27/NNP	nn||-rrb--29/NNP||hvtn-28/NNP	dep||hiv-23/NN||-rrb--29/NNP	det||program-36/NN||the-31/DT	amod||program-36/NN||u.s.-32/JJ	amod||program-36/NN||military-33/JJ	nn||program-36/NN||hiv-34/NN	nn||program-36/NN||research-35/NN	dobj||include-3/VBP||program-36/NN	conj_and||center-5/NN||program-36/NN	amod||-rrb--39/NNS||-lrb--37/JJ	nn||-rrb--39/NNS||mhrp-38/NN	dep||program-36/NN||-rrb--39/NNS	det||network-43/NN||the-42/DT	dobj||include-3/VBP||network-43/NN	conj_and||center-5/NN||network-43/NN	amod||donors-47/NNS||pancreatic-45/JJ	nn||donors-47/NNS||organ-46/NN	prep_for||network-43/NN||donors-47/NNS	nn||-rrb--52/NN||diabetes-49/NN	nn||-rrb--52/NN||-lrb--50/NNP	amod||-rrb--52/NN||npod-51/JJ	prep_with||include-3/VBP||-rrb--52/NN	aids--1||hiv-34||no||these organizations include the center for hiv/aids vaccine immunology -lrb- chavi -rrb- , the immune tolerance network -lrb- itn -rrb- , the hiv vaccine trials network -lrb- hvtn -rrb- , the u.s. military hiv research program -lrb- mhrp -rrb- , and the network for pancreatic organ donors with diabetes -lrb- npod -rrb- .
nsubj||disease-8/NN||diabetesmellitus-1/NNS	appos||diabetesmellitus-1/NNS||dm-3/NN	cop||disease-8/NN||is-5/VBZ	det||disease-8/NN||a-6/DT	amod||disease-8/NN||complex-7/JJ	root||ROOT-0/null||disease-8/NN	vmod||disease-8/NN||characterized-9/VBN	amod||hyperglycemia-12/NN||chronic-11/JJ	agent||characterized-9/VBN||hyperglycemia-12/NN	det||factor-17/NN||a-14/DT	amod||factor-17/NN||known-15/VBN	nn||factor-17/NN||risk-16/NN	appos||hyperglycemia-12/NN||factor-17/NN	amod||atherosclerosis-20/NNS||accelerated-19/JJ	prep_for||factor-17/NN||atherosclerosis-20/NNS	prep_for||factor-17/NN||vasculardisease-22/NN	conj_and||atherosclerosis-20/NNS||vasculardisease-22/NN	dm-3||diabetesmellitus-1||no_rel||diabetesmellitus (dm) is a complex disease characterized by chronic hyperglycemia, a known risk factor for accelerated atherosclerosis and vasculardisease.
amod||therapy-4/NN||high-dose-1/JJ	amod||therapy-4/NN||potent-2/JJ	nn||therapy-4/NN||statin-3/NN	nsubj||practice-12/NN||therapy-4/NN	prep_in||therapy-4/NN||combination-6/NN	prep_with||combination-6/NN||ezetimibe-8/NN	cop||practice-12/NN||is-9/VBZ	advmod||practice-12/NN||now-10/RB	amod||practice-12/NN||standard-11/JJ	root||ROOT-0/null||practice-12/NN	det||treatment-15/NN||the-14/DT	prep_for||practice-12/NN||treatment-15/NN	amod||patients-18/NNS||adult-17/JJ	prep_of||treatment-15/NN||patients-18/NNS	amod||familialhypercholesterolemia-21/NN||heterozygous-20/JJ	prep_with||patients-18/NNS||familialhypercholesterolemia-21/NN	appos||familialhypercholesterolemia-21/NN||hefh-23/NN	det||result-28/NN||the-27/DT	prep_as||practice-12/NN||result-28/NN	amod||studies-31/NNS||numerous-30/JJ	prep_of||result-28/NN||studies-31/NNS	prep_in||practice-12/NN||patients-33/NNS	amod||hypercholesterolemia-36/NN||primary-35/JJ	prep_with||patients-33/NNS||hypercholesterolemia-36/NN	prep_with||patients-33/NNS||hefh-38/NN	conj_or||hypercholesterolemia-36/NN||hefh-38/NN	familialhypercholesterolemia-21||ezetimibe-8||yes||high-dose potent statin therapy in combination with ezetimibe is now standard practice for the treatment of adult patients with heterozygous familialhypercholesterolemia (hefh), as the result of numerous studies in patients with primary hypercholesterolemia or hefh.
amod||infection-2/NN||symptomatic-1/JJ	nsubj||range-9/VB||infection-2/NN	prep_by||infection-2/NN||denguevirus-4/NNS	appos||denguevirus-4/NNS||denv-6/NNP	aux||range-9/VB||can-8/MD	ccomp||understood-33/VBN||range-9/VB	prep_from||range-9/VB||denguefever-11/NN	appos||denguefever-11/NN||df-13/NN	prep_to||range-9/VB||denguehaemorrhagicfever-16/NN	appos||denguehaemorrhagicfever-16/NN||dhf-18/NN	advmod||range-9/VB||however-21/RB	det||determinants-24/NNS||the-23/DT	nsubjpass||understood-33/VBN||determinants-24/NNS	nn||progression-29/NN||df-26/NN	conj_or||df-26/NN||dhf-28/NN	nn||progression-29/NN||dhf-28/NN	prep_of||determinants-24/NNS||progression-29/NN	auxpass||understood-33/VBN||are-30/VBP	neg||understood-33/VBN||not-31/RB	advmod||understood-33/VBN||completely-32/RB	root||ROOT-0/null||understood-33/VBN	denguehaemorrhagicfever-16||denguevirus-4||no||symptomatic infection by denguevirus (denv) can range from denguefever (df) to denguehaemorrhagicfever (dhf), however, the determinants of df or dhf progression are not completely understood.
nn||titres-2/NNS||antibody-1/NN	nsubj||lower-5/JJR||titres-2/NNS	cop||lower-5/JJR||were-3/VBD	neg||lower-5/JJR||not-4/RB	root||ROOT-0/null||lower-5/JJR	prep_in||lower-5/JJR||subjects-7/NNS	nsubj||received-9/VBD||subjects-7/NNS	rcmod||subjects-7/NNS||received-9/VBD	det||doses-12/NNS||either-10/DT	num||doses-12/NNS||four-11/CD	dobj||received-9/VBD||doses-12/NNS	prep_of||doses-12/NNS||inactivatedpoliovaccine-14/NN	appos||subjects-7/NNS||ipv-16/NN	det||schedule-21/NN||a-19/DT	amod||schedule-21/NN||sequential-20/JJ	prep_in||lower-5/JJR||schedule-21/NN	conj_or||subjects-7/NNS||schedule-21/NN	nsubj||received-9/VBD||schedule-21/NN	vmod||schedule-21/NN||consisting-22/VBG	num||doses-25/NNS||two-24/CD	prep_of||consisting-22/VBG||doses-25/NNS	prep_of||doses-25/NNS||ipv-27/NN	prep_of||consisting-22/VBG||two-29/CD	conj_and||doses-25/NNS||two-29/CD	amod||vaccine-33/NN||oral-31/JJ	nn||vaccine-33/NN||polio-32/NNP	prep_of||two-29/CD||vaccine-33/NN	advmod||lower-5/JJR||than-34/IN	prep_in||than-34/IN||subjects-36/NNS	nsubj||received-38/VBD||subjects-36/NNS	rcmod||subjects-36/NNS||received-38/VBD	num||doses-40/NNS||four-39/CD	dobj||received-38/VBD||doses-40/NNS	prep_of||doses-40/NNS||opv-42/NN	polio-32||inactivatedpoliovaccine-14||yes||antibody titres were not lower in subjects who received either four doses of inactivatedpoliovaccine (ipv) or a sequential schedule consisting of two doses of ipv and two of oral polio vaccine than in subjects who received four doses of opv.
nsubj||produced-3/VBD||lp-1/NN	advmod||produced-3/VBD||also-2/RB	root||ROOT-0/null||produced-3/VBD	det||pattern-8/NN||a-4/DT	amod||pattern-8/NN||distinct-5/JJ	amod||pattern-8/NN||evoked-6/JJ	amod||pattern-8/NN||potential-7/JJ	dobj||produced-3/VBD||pattern-8/NN	prep_of||amplitude-10/NN||pattern-8/NN	det||amplitude-10/NN||the-9/DT	nsubjpass||correlated-15/VBN||amplitude-10/NN	auxpass||correlated-15/VBN||was-13/VBD	advmod||correlated-15/VBN||also-14/RB	rcmod||pattern-8/NN||correlated-15/VBN	nn||intensity-18/NN||pain-17/NN	prep_with||correlated-15/VBN||intensity-18/NN	nsubjpass||enhanced-22/VBN||intensity-18/NN	auxpass||enhanced-22/VBN||was-21/VBD	rcmod||intensity-18/NN||enhanced-22/VBN	amod||capsaicin-25/NN||topical-24/JJ	agent||enhanced-22/VBN||capsaicin-25/NN	det||latency-29/NN||the-28/DT	dobj||produced-3/VBD||latency-29/NN	conj_and||pattern-8/NN||latency-29/NN	prep_of||amplitude-10/NN||latency-29/NN	nsubjpass||used-34/VBN||which-31/WDT	nsubj||estimate-36/VB||which-31/WDT	aux||used-34/VBN||could-32/MD	auxpass||used-34/VBN||be-33/VB	prepc_of||latency-29/NN||used-34/VBN	aux||estimate-36/VB||to-35/TO	xcomp||used-34/VBN||estimate-36/VB	det||velocity-39/NN||the-37/DT	nn||velocity-39/NN||conduction-38/NN	dobj||estimate-36/VB||velocity-39/NN	det||fibers-44/NNS||the-41/DT	amod||fibers-44/NNS||mediating-42/JJ	amod||fibers-44/NNS||nociceptive-43/JJ	prep_of||velocity-39/NN||fibers-44/NNS	pain-17||capsaicin-25||yes||lp also produced a distinct evoked potential pattern the amplitude of which was also correlated with pain intensity, which was enhanced by topical capsaicin, and the latency of which could be used to estimate the conduction velocity of the mediating nociceptive fibers.
det||group-4/NN||the-2/DT	amod||group-4/NN||overweight/obese-3/JJ	prep_in||times-14/NNS||group-4/NN	nsubj||times-14/NNS||those-6/DT	amod||obesity-9/NN||central-8/JJ	prep_without||those-6/DT||obesity-9/NN	cop||times-14/NNS||were-10/VBD	nn||times-14/NNS||0.53-11/CD	conj_and||0.53-11/CD||0.27-13/CD	nn||times-14/NNS||0.27-13/CD	root||ROOT-0/null||times-14/NNS	advmod||likely-16/JJ||less-15/RBR	amod||times-14/NNS||likely-16/JJ	aux||have-18/VB||to-17/TO	dep||times-14/NNS||have-18/VB	amod||levels-21/NNS||significant-19/JJ	amod||levels-21/NNS||adverse-20/JJ	dobj||have-18/VB||levels-21/NNS	nn||cholesterol-24/NN||hdl-23/NN	prep_of||levels-21/NNS||cholesterol-24/NN	prep_of||levels-21/NNS||homa-ir-26/NN	conj_and||cholesterol-24/NN||homa-ir-26/NN	advmod||have-18/VB||respectively-28/RB	parataxis||have-18/VB||p-30/VB	num||0.05-32/CD||<-31/CD	dobj||p-30/VB||0.05-32/CD	prepc_as||times-14/NNS||compared-36/VBN	pcomp||compared-36/VBN||to-37/TO	pobj||to-37/TO||those-38/DT	amod||obesity-41/NN||central-40/JJ	prep_with||those-38/DT||obesity-41/NN	obesity-41||cholesterol-24||no_rel||in the overweight/obese group, those without central obesity were 0.53 and 0.27 times less likely to have significant adverse levels of hdl cholesterol and homa-ir, respectively (p < 0.05), as compared to those with central obesity.
det||study-3/NN||this-2/DT	prep_in||used-6/VBD||study-3/NN	nsubj||used-6/VBD||we-5/PRP	root||ROOT-0/null||used-6/VBD	det||model-9/NN||a-7/DT	nn||model-9/NN||mouse-8/NN	dobj||used-6/VBD||model-9/NN	acomp||used-6/VBD||pre-exposed-10/JJ	det||h1n1influenzavirus-13/NNS||an-12/DT	prep_to||pre-exposed-10/JJ||h1n1influenzavirus-13/NNS	acomp||used-6/VBD||evaluated-15/VBN	conj_and||pre-exposed-10/JJ||evaluated-15/VBN	det||ability-18/NN||the-16/DT	amod||ability-18/NN||protective-17/JJ	dobj||evaluated-15/VBN||ability-18/NN	prep||evaluated-15/VBN||provided-19/VBN	pcomp||provided-19/VBN||by-20/IN	det||dose-23/NN||a-21/DT	amod||dose-23/NN||single-22/JJ	nsubj||encoding-27/VBG||dose-23/NN	nn||vaccines-26/NNS||dna-25/NN	prep_of||dose-23/NN||vaccines-26/NNS	pcomp||by-20/IN||encoding-27/VBG	amod||proteins-30/NNS||conserved-28/JJ	amod||proteins-30/NNS||h5n1-29/JJ	dobj||encoding-27/VBG||proteins-30/NNS	h5n1-29||influenzavirus--1||no||in this study, we used a mouse model pre-exposed to an h1n1influenzavirus and evaluated the protective ability provided by a single dose of dna vaccines encoding conserved h5n1 proteins.
amod||response-2/NN||t-cell-1/JJ	nsubjpass||evaluated-6/VBN||response-2/NN	prep_to||response-2/NN||rv1985c-4/CD	auxpass||evaluated-6/VBN||was-5/VBD	root||ROOT-0/null||evaluated-6/VBN	amod||elispot-10/NN||ifn-î-8/JJ	amod||elispot-10/NN||³-9/JJ	agent||evaluated-6/VBN||elispot-10/NN	number||tb-13/CD||56-12/CD	num||patients-14/NNS||tb-13/CD	prep_in||elispot-10/NN||patients-14/NNS	num||infection-19/NN||20-16/CD	nn||infection-19/NN||latent-17/NN	nn||infection-19/NN||tb-18/NN	prep_in||elispot-10/NN||infection-19/NN	conj_and||patients-14/NNS||infection-19/NN	appos||infection-19/NN||ltbi-21/NNP	num||controls-26/NNS||30-24/CD	amod||controls-26/NNS||bcg-vaccinated-25/JJ	prep_in||elispot-10/NN||controls-26/NNS	conj_and||patients-14/NNS||controls-26/NNS	prep_in||controls-26/NNS||comparison-28/NN	det||t-spot-32/NN||the-30/DT	amod||t-spot-32/NN||commercial-31/JJ	prep_with||evaluated-6/VBN||t-spot-32/NN	tb-18||bcg--1||no||t-cell response to rv1985c was evaluated by ifn-î³ elispot in 56 tb patients, 20 latent tb infection (ltbi) and 30 bcg-vaccinated controls in comparison with the commercial t-spot.
det||administration-5/NN||both-1/DT	amod||administration-5/NN||oral-2/JJ	conj_and||oral-2/JJ||intraperitoneal-4/JJ	amod||administration-5/NN||intraperitoneal-4/JJ	nsubj||effective-9/JJ||administration-5/NN	prep_of||administration-5/NN||bne-7/NN	cop||effective-9/JJ||were-8/VBD	root||ROOT-0/null||effective-9/JJ	prepc_at||effective-9/JJ||inhibiting-11/VBG	det||production-13/NN||the-12/DT	dobj||inhibiting-11/VBG||production-13/NN	nn||dna-18/NN||hbsag-15/NN	conj_and||hbsag-15/NN||hbv-17/NN	nn||dna-18/NN||hbv-17/NN	prep_of||production-13/NN||dna-18/NN	mark||affected-25/VBN||whereas-20/IN	nn||growth-22/NN||tumor-21/NN	nsubjpass||affected-25/VBN||growth-22/NN	auxpass||affected-25/VBN||was-23/VBD	neg||affected-25/VBN||not-24/RB	advcl||effective-9/JJ||affected-25/VBN	det||articles-29/NNS||all-27/DT	nn||articles-29/NNS||test-28/NN	agent||affected-25/VBN||articles-29/NNS	hbv-17||hbsag-15||yes||both oral and intraperitoneal administration of bne were effective at inhibiting the production of hbsag and hbv dna, whereas tumor growth was not affected by all test articles.
det||article-2/NN||this-1/DT	nsubj||reviews-3/VBZ||article-2/NN	root||ROOT-0/null||reviews-3/VBZ	det||trials-6/NNS||the-4/DT	amod||trials-6/NNS||clinical-5/JJ	dobj||reviews-3/VBZ||trials-6/NNS	amod||therapies-10/NNS||ai-8/JJ	nn||therapies-10/NNS||adjuvant-9/NN	prep_of||trials-6/NNS||therapies-10/NNS	amod||cancer-14/NN||hormone-sensitive-12/JJ	nn||cancer-14/NN||breast-13/NN	prep_for||reviews-3/VBZ||cancer-14/NN	dep||reviews-3/VBZ||particularly-16/RB	det||context-19/NN||the-18/DT	prep_in||reviews-3/VBZ||context-19/NN	advmod||compare-23/VBP||how-21/WRB	nsubj||compare-23/VBP||they-22/PRP	prepc_of||context-19/NN||compare-23/VBP	amod||deaths-40/NNS||tamoxifen-25/JJ	prepc_in||tamoxifen-25/JJ||minimizing-27/VBG	det||risk-29/NN||the-28/DT	dobj||minimizing-27/VBG||risk-29/NN	prep_of||risk-29/NN||relapse-31/NN	dobj||minimizing-27/VBG||occurrence-33/NN	conj_and||risk-29/NN||occurrence-33/NN	prep_of||occurrence-33/NN||dm-35/NN	dobj||minimizing-27/VBG||breast-38/NN	conj_and||risk-29/NN||breast-38/NN	amod||deaths-40/NNS||cancer-related-39/JJ	prep_with||compare-23/VBP||deaths-40/NNS	adjuvant-9||cancer-14||no_rel||this article reviews the clinical trials of ai adjuvant therapies for hormone-sensitive breast cancer, particularly in the context of how they compare with tamoxifen in minimizing the risk of relapse, occurrence of dm, and breast cancer-related deaths.
det||themes-2/NNS||the-1/DT	nsubj||included-11/VBD||themes-2/NNS	vmod||themes-2/NNS||emerging-3/VBG	det||discussions-8/NNS||the-5/DT	nn||discussions-8/NNS||focus-6/NN	nn||discussions-8/NNS||group-7/NN	prep_from||emerging-3/VBG||discussions-8/NNS	prep_from||emerging-3/VBG||interviews-10/NNS	conj_and||discussions-8/NNS||interviews-10/NNS	root||ROOT-0/null||included-11/VBD	num||factors-16/NNS||four-12/CD	amod||factors-16/NNS||main-13/JJ	amod||factors-16/NNS||suggested-14/JJ	nn||factors-16/NNS||barrier-15/NN	dobj||included-11/VBD||factors-16/NNS	dep||fears-20/NNS||1-18/LS	dep||factors-16/NNS||fears-20/NNS	prep_of||fears-20/NNS||hiv/aids-22/NNS	amod||coinfection-25/NN||tb-hiv-24/JJ	prep_of||fears-20/NNS||coinfection-25/NN	conj_and||hiv/aids-22/NNS||coinfection-25/NN	prep_of||fears-20/NNS||death-27/NN	conj_and||hiv/aids-22/NNS||death-27/NN	prep_of||fears-20/NNS||stigma-30/NN	conj_and||hiv/aids-22/NNS||stigma-30/NN	dep||lack-36/NN||2-33/LS	amod||lack-36/NN||perceived-35/VBN	dobj||included-11/VBD||lack-36/NN	conj_and||factors-16/NNS||lack-36/NN	prep_of||lack-36/NN||confidentiality-38/NN	nn||results-42/NNS||hiv-40/NN	nn||results-42/NNS||test-41/NN	prep_of||confidentiality-38/NN||results-42/NNS	dep||shortages-48/NNS||3-45/LS	nn||shortages-48/NNS||staff-47/NN	dobj||included-11/VBD||shortages-48/NNS	conj_and||factors-16/NNS||shortages-48/NNS	prep||shortages-48/NNS||and-49/CC	amod||workload-51/NN||high-50/JJ	pobj||and-49/CC||workload-51/NN	dep||infrastructure-58/NN||4-55/LS	amod||infrastructure-58/NN||poor-57/VBN	dobj||included-11/VBD||infrastructure-58/NN	conj_and||factors-16/NNS||infrastructure-58/NN	aux||encourage-60/VB||to-59/TO	vmod||included-11/VBD||encourage-60/VB	vmod||included-11/VBD||monitor-62/VB	conj_and||encourage-60/VB||monitor-62/VB	vmod||included-11/VBD||deliver-65/VB	conj_and||encourage-60/VB||deliver-65/VB	dobj||encourage-60/VB||hct-66/NN	aids--1||hiv-40||no||the themes emerging from the focus group discussions and interviews included four main suggested barrier factors (1) fears of hiv/aids, tb-hiv coinfection, death, and stigma; (2) perceived lack of confidentiality of hiv test results; (3) staff shortages and high workload; and (4) poor infrastructure to encourage, monitor, and deliver hct.
det||paper-4/NN||the-2/DT	amod||paper-4/NN||present-3/JJ	prep_in||review-7/VBP||paper-4/NN	nsubj||review-7/VBP||we-6/PRP	nsubj||review-7/VBP||we-6/PRP	root||ROOT-0/null||review-7/VBP	conj_or||review-7/VBP||review-7/VBP	amod||developments-9/NNS||recent-8/JJ	dobj||review-7/VBP||developments-9/NNS	det||use-12/NN||the-11/DT	prep_in||review-7/VBP||use-12/NN	prep_of||use-12/NN||enzymes-14/NNS	prep_as||enzymes-14/NNS||additives-16/NNS	amod||aids-20/NNS||processing-19/VBG	prep_as||review-7/VBP||aids-20/NNS	det||industry-25/NN||the-22/DT	nn||industry-25/NN||food-23/NN	nn||industry-25/NN||biotechnology-24/NN	prep_in||aids-20/NNS||industry-25/NN	amod||gluten-28/NN||detoxify-27/JJ	prep_to||industry-25/NN||gluten-28/NN	aids-20||gluten-28||no_rel||in the present paper, we review recent developments in the use of enzymes as additives or as processing aids in the food biotechnology industry to detoxify gluten.
prep_in||proved-9/VBN||patients-2/NNS	amod||hypertension-5/NN||mild-to-moderate-4/JJ	prep_with||patients-2/NNS||hypertension-5/NN	nsubj||proved-9/VBN||telmisartan-7/NN	aux||proved-9/VBN||has-8/VBZ	root||ROOT-0/null||proved-9/VBN	acomp||proved-9/VBN||superior-10/JJ	amod||antihypertensiveagents-13/NNS||other-12/JJ	prep_to||superior-10/JJ||antihypertensiveagents-13/NNS	dep||antihypertensiveagents-13/NNS||valsartan-15/NN	dep||antihypertensiveagents-13/NNS||losartan-17/NN	conj_and||valsartan-15/NN||losartan-17/NN	dep||antihypertensiveagents-13/NNS||ramipril-19/NN	conj_and||valsartan-15/NN||ramipril-19/NN	dep||antihypertensiveagents-13/NNS||perindopril-21/NN	conj_and||valsartan-15/NN||perindopril-21/NN	dep||antihypertensiveagents-13/NNS||atenolol-24/NN	conj_and||valsartan-15/NN||atenolol-24/NN	amod||pressure-29/NN||controlling-27/JJ	nn||pressure-29/NN||blood-28/NN	prep_in||antihypertensiveagents-13/NNS||pressure-29/NN	advmod||proved-9/VBN||particularly-30/RB	det||end-33/NN||the-32/DT	prep_towards||proved-9/VBN||end-33/NN	det||interval-37/NN||the-35/DT	amod||interval-37/NN||dosing-36/JJ	prep_of||end-33/NN||interval-37/NN	hypertension-5||losartan-17||yes||in patients with mild-to-moderate hypertension, telmisartan has proved superior to other antihypertensiveagents (valsartan, losartan, ramipril, perindopril, and atenolol) in controlling blood pressure particularly towards the end of the dosing interval.
prepc_according_to||+-11/VBD||to-2/TO	det||sensitivity-5/NN||the-3/DT	amod||sensitivity-5/NN||different-4/JJ	pobj||+-11/VBD||sensitivity-5/NN	poss||bone-8/NN||their-7/PRP$	prep_of||sensitivity-5/NN||bone-8/NN	nn||cd34-10/NNS||marrow-9/NN	nsubj||+-11/VBD||cd34-10/NNS	root||ROOT-0/null||+-11/VBD	dobj||+-11/VBD||cells-12/NNS	dep||vitro-15/NN||in-14/IN	amod||treatment-16/NN||vitro-15/NN	prep_to||+-11/VBD||treatment-16/NN	nn||patients-26/NNS||etoposide-18/NN	conj_or||etoposide-18/NN||mafosfamide-20/NN	nn||patients-26/NNS||mafosfamide-20/NN	dep||patients-26/NNS||acutemyeloidleukaemia-22/NN	nn||patients-26/NNS||aml-24/NN	prep_with||+-11/VBD||patients-26/NNS	amod||remission-30/NN||apparent-28/JJ	amod||remission-30/NN||complete-29/JJ	prep_in||+-11/VBD||remission-30/NN	appos||remission-30/NN||cr-32/NN	amod||induction-36/NN||chemotherapy-35/JJ	nsubjpass||classified-39/VBN||induction-36/NN	aux||classified-39/VBN||may-37/MD	auxpass||classified-39/VBN||be-38/VB	prepc_after||remission-30/NN||classified-39/VBN	num||groups-42/NNS||three-41/CD	prep_into||classified-39/VBN||groups-42/NNS	appos||groups-42/NNS||i-44/NNP	advmod||responsive-47/JJ||normally-46/RB	amod||groups-42/NNS||responsive-47/JJ	appos||chemoresistant-52/NNS||ii-50/NN	dep||groups-42/NNS||chemoresistant-52/NNS	appos||remission-30/NN||iii-55/NN	advmod||chemosensitive-58/JJ||highly-57/RB	amod||remission-30/NN||chemosensitive-58/JJ	etoposide-18||acutemyeloidleukaemia-22||no_rel||according to the different sensitivity of their bone marrow cd34+ cells to in vitro treatment with etoposide or mafosfamide, acutemyeloidleukaemia (aml) patients in apparent complete remission (cr) after chemotherapy induction may be classified into three groups (i) normally responsive; (ii) chemoresistant; (iii) highly chemosensitive.
det||results-2/NNS||the-1/DT	nsubj||indicated-3/VBD||results-2/NNS	root||ROOT-0/null||indicated-3/VBD	mark||showed-27/VBD||that-4/IN	mark||had-10/VBD||although-5/IN	amod||children-9/NNS||adhd-6/JJ	advmod||adhd-6/JJ||as-8/RB	conj_and||adhd-6/JJ||as-8/RB	amod||children-9/NNS||as-8/RB	nsubj||had-10/VBD||children-9/NNS	nsubj||took-19/VBD||children-9/NNS	nsubj||complete-22/VB||children-9/NNS	advcl||showed-27/VBD||had-10/VBD	det||tendency-12/NN||a-11/DT	dobj||had-10/VBD||tendency-12/NN	prepc_of||tendency-12/NN||repeating-14/VBG	det||errors-17/NNS||the-15/DT	amod||errors-17/NNS||same-16/JJ	dobj||repeating-14/VBG||errors-17/NNS	conj_and||had-10/VBD||took-19/VBD	advcl||showed-27/VBD||took-19/VBD	advmod||took-19/VBD||longer-20/RBR	aux||complete-22/VB||to-21/TO	xcomp||took-19/VBD||complete-22/VB	det||sequence-24/NN||a-23/DT	dobj||complete-22/VB||sequence-24/NN	nsubj||showed-27/VBD||both-26/DT	ccomp||indicated-3/VBD||showed-27/VBD	det||degree-29/NN||a-28/DT	nsubj||similar-38/JJ||degree-29/NN	conj_and||degree-29/NN||pattern-31/NN	nsubj||similar-38/JJ||pattern-31/NN	prep_of||degree-29/NN||improvement-33/NN	prep_in||improvement-33/NN||accuracy-35/NN	prep_in||improvement-33/NN||speed-37/NN	conj_and||accuracy-35/NN||speed-37/NN	xcomp||showed-27/VBD||similar-38/JJ	prep_to||similar-38/JJ||that-40/DT	advmod||developing-43/VBG||typically-42/RB	prepc_of||that-40/DT||developing-43/VBG	dobj||developing-43/VBG||children-44/NNS	adhd-6||speed-37||no||the results indicated that although adhd and as children had a tendency of repeating the same errors and took longer to complete a sequence, both showed a degree and pattern of improvement in accuracy and speed similar to that of typically developing children.
dep||induced-2/VBD||ht-29-1/JJ	root||ROOT-0/null||induced-2/VBD	advmod||induced-2/VBD||autophagy-3/RB	prep_in||induced-2/VBD||response-5/NN	prep_to||induced-2/VBD||5-fu-7/JJ	nn||inhibited-11/NNS||cq-10/NN	prep_to||induced-2/VBD||inhibited-11/NNS	conj_and||5-fu-7/JJ||inhibited-11/NNS	det||induction-13/NN||this-12/DT	nsubj||induced-2/VBD||induction-13/NN	det||mechanism-17/NN||a-15/DT	amod||mechanism-17/NN||possible-16/JJ	appos||induction-13/NN||mechanism-17/NN	det||potentiation-20/NN||the-19/DT	prep_of||mechanism-17/NN||potentiation-20/NN	det||effect-24/NN||the-22/DT	amod||effect-24/NN||anti-cancer-23/JJ	prep_of||potentiation-20/NN||effect-24/NN	prep_of||effect-24/NN||5-fu-26/CD	5-fu-26||cancer--1||no_rel||ht-29 induced autophagy in response to 5-fu, and cq inhibited this induction, a possible mechanism of the potentiation of the anti-cancer effect of 5-fu.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||evaluate-8/VB||aim-2/NN	nsubj||compare-10/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||was-6/VBD||evaluate-8/VB	xcomp||was-6/VBD||compare-10/VB	conj_and||evaluate-8/VB||compare-10/VB	det||effects-12/NNS||the-11/DT	dobj||evaluate-8/VB||effects-12/NNS	det||combination-18/NN||a-14/DT	amod||combination-18/NN||long-term-15/JJ	amod||combination-18/NN||fixed-dose-17/JJ	prep_of||effects-12/NNS||combination-18/NN	prep_of||combination-18/NN||sitagliptin-20/NN	prep_of||combination-18/NN||metformin-22/NN	conj_and||sitagliptin-20/NN||metformin-22/NN	prep_as||evaluate-8/VB||add-on-24/JJ	prep_to||add-on-24/JJ||insulin-26/NN	nn||index-30/NN||body-28/NN	nn||index-30/NN||mass-29/NN	prep_on||insulin-26/NN||index-30/NN	amod||glucose-34/NN||fasting-32/JJ	nn||glucose-34/NN||plasma-33/NN	prep_on||insulin-26/NN||glucose-34/NN	conj_and||index-30/NN||glucose-34/NN	prep_on||insulin-26/NN||fructosamine-36/NN	conj_and||index-30/NN||fructosamine-36/NN	prep_on||insulin-26/NN||hba1c-38/NNS	conj_and||index-30/NN||hba1c-38/NNS	prep_on||insulin-26/NN||lipids-40/NNS	conj_and||index-30/NN||lipids-40/NNS	amod||dose-44/NN||daily-43/JJ	prep_on||insulin-26/NN||dose-44/NN	conj_and||index-30/NN||dose-44/NN	prep_of||dose-44/NN||insulin-46/NN	det||type2diabetes-52/NNS||both-48/DT	amod||type2diabetes-52/NNS||type1diabetes-49/JJ	conj_and||type1diabetes-49/JJ||insulin-treated-51/JJ	amod||type2diabetes-52/NNS||insulin-treated-51/JJ	prep_in||insulin-46/NN||type2diabetes-52/NNS	type2diabetes-52||sitagliptin-20||yes||the aim of this study was to evaluate and compare the effects of a long-term, fixed-dose combination of sitagliptin and metformin as add-on to insulin on body mass index, fasting plasma glucose, fructosamine, hba1c, lipids, and daily dose of insulin in both type1diabetes and insulin-treated type2diabetes.
nsubjpass||divided-3/VBN||patients-1/NNS	auxpass||divided-3/VBN||were-2/VBD	root||ROOT-0/null||divided-3/VBN	num||groups-6/NNS||two-5/CD	prep_into||divided-3/VBN||groups-6/NNS	amod||content-10/NN||hepatic-8/JJ	nn||content-10/NN||triglyceride-9/NN	prep_with||groups-6/NNS||content-10/NN	prep||divided-3/VBN||below-11/IN	dep||below-11/IN||type2diabetes-low-13/JJ	conj_or||divided-3/VBN||above-16/IN	dep||above-16/IN||type2diabetes-high-18/JJ	det||median-21/NN||the-20/DT	pobj||above-16/IN||median-21/NN	num||%-24/NN||8.6-23/CD	prep_of||median-21/NN||%-24/NN	type2diabetes--1||triglyceride-9||no_rel||patients were divided into two groups with hepatic triglyceride content below (type2diabetes-low) or above (type2diabetes-high) the median of 8.6%.
num||hundred-2/CD||one-1/CD	nsubj||isolates-6/VBZ||hundred-2/CD	amod||s.aureus-5/NNS||seventy-4/JJ	conj_and||hundred-2/CD||s.aureus-5/NNS	nsubj||isolates-6/VBZ||s.aureus-5/NNS	root||ROOT-0/null||isolates-6/VBZ	advmod||identified-8/VBN||previously-7/RB	acomp||isolates-6/VBZ||identified-8/VBN	mark||obtained-12/VBN||as-9/IN	nsubjpass||obtained-12/VBN||mrsa-10/NN	auxpass||obtained-12/VBN||were-11/VBD	dep||identified-8/VBN||obtained-12/VBN	num||hospitals-15/NNS||three-14/CD	prep_from||obtained-12/VBN||hospitals-15/NNS	prep_in||hospitals-15/NNS||tripoli-17/NNS	mrsa-10||s.aureus-5||no||one hundred and seventy s.aureus isolates previously identified as mrsa were obtained from three hospitals in tripoli .
det||proof-3/NN||this-2/DT	prep_for||compared-9/VBD||proof-3/NN	amod||study-6/NN||principal-5/JJ	prep_of||proof-3/NN||study-6/NN	nsubj||compared-9/VBD||we-8/PRP	root||ROOT-0/null||compared-9/VBD	amod||clearance-11/NN||bacillary-10/JJ	dobj||compared-9/VBD||clearance-11/NN	det||lungs-14/NNS||the-13/DT	prep_from||compared-9/VBD||lungs-14/NNS	prep_of||lungs-14/NNS||mtb-16/NN	amod||mice-19/NNS||infected-18/JJ	nsubj||treated-20/VBN||mice-19/NNS	parataxis||compared-9/VBD||treated-20/VBN	det||isoniazid-25/NN||the-22/DT	amod||isoniazid-25/NN||anti-tb-23/JJ	nn||isoniazid-25/NN||drug-24/NN	prep_with||treated-20/VBN||isoniazid-25/NN	appos||isoniazid-25/NN||inh-27/NN	det||presence-31/NN||the-30/DT	prep_in||treated-20/VBN||presence-31/NN	prep_in||treated-20/VBN||absence-33/NN	conj_and||presence-31/NN||absence-33/NN	det||inhibitor-39/NN||an-35/DT	amod||inhibitor-39/NN||immunomodulatory-36/JJ	amod||inhibitor-39/NN||phosphodiesterase-37/JJ	dep||phosphodiesterase-37/JJ||4-38/CD	prep_of||presence-31/NN||inhibitor-39/NN	appos||inhibitor-39/NN||pde4i-41/NNP	dep||treated-20/VBN||cc-3052-44/JJ	inh-27||tb--1||no_rel||for this proof of principal study, we compared bacillary clearance from the lungs of mtb -infected mice treated with the anti-tb drug isoniazid (inh) in the presence and absence of an immunomodulatory phosphodiesterase 4 inhibitor (pde4i), cc-3052.
det||effect-4/NN||the-1/DT	amod||effect-4/NN||acute-2/JJ	amod||effect-4/NN||protective-3/JJ	nsubjpass||tested-9/VBN||effect-4/NN	amod||budesonide-7/NN||inhaled-6/JJ	prep_of||effect-4/NN||budesonide-7/NN	auxpass||tested-9/VBN||was-8/VBD	root||ROOT-0/null||tested-9/VBN	det||model-12/NN||a-11/DT	prep_in||tested-9/VBN||model-12/NN	advmod||increased-15/JJ||temporarily-14/RB	amod||inflammation-17/NN||increased-15/JJ	nn||inflammation-17/NN||airway-16/NN	prep_of||model-12/NN||inflammation-17/NN	amod||challenges-22/NNS||repeated-19/VBN	amod||challenges-22/NNS||indirect-20/JJ	nn||challenges-22/NNS||airway-21/NN	prep_with||tested-9/VBN||challenges-22/NNS	vmod||challenges-22/NNS||mimicking-24/VBG	det||exacerbation-28/NN||an-25/DT	amod||exacerbation-28/NN||acute-26/JJ	nn||exacerbation-28/NN||asthma-27/NN	dobj||mimicking-24/VBG||exacerbation-28/NN	asthma-27||budesonide-7||no||the acute protective effect of inhaled budesonide was tested in a model of temporarily increased airway inflammation with repeated indirect airway challenges, mimicking an acute asthma exacerbation.
det||sample-4/NN||a-1/DT	nn||sample-4/NN||midstream-2/NN	nn||sample-4/NN||urine-3/NN	nsubj||detected-5/VBD||sample-4/NN	root||ROOT-0/null||detected-5/VBD	nn||cells-8/NNS||glomerular-6/NN	nn||cells-8/NNS||blood-7/NN	dobj||detected-5/VBD||cells-8/NNS	det||setting-11/NN||the-10/DT	prep_in||detected-5/VBD||setting-11/NN	amod||vasculitis-17/NNS||anti-neutrophil-13/JJ	amod||vasculitis-17/NNS||cytoplasmic-14/JJ	amod||vasculitis-17/NNS||antibody-positive-15/JJ	amod||vasculitis-17/NNS||renal-16/JJ	prep_of||setting-11/NN||vasculitis-17/NNS	amod||bacteremia-20/NN||streptococcuspyogenes-19/JJ	prep_of||setting-11/NN||bacteremia-20/NN	conj_and||vasculitis-17/NNS||bacteremia-20/NN	antibody--1||bacteremia-20||no_rel||a midstream urine sample detected glomerular blood cells in the setting of anti-neutrophil cytoplasmic antibody-positive renal vasculitis and streptococcuspyogenes bacteremia.
nsubjpass||associated-6/VBN||diabetesmellitus-1/NNS	appos||diabetesmellitus-1/NNS||dm-3/NN	auxpass||associated-6/VBN||is-5/VBZ	root||ROOT-0/null||associated-6/VBN	nn||complications-9/NNS||microvascular-8/NN	prep_with||associated-6/VBN||complications-9/NNS	prep_such_as||complications-9/NNS||diabeticretinopathy-13/NN	appos||diabeticretinopathy-13/NN||dr-15/NN	diabeticretinopathy-13||diabetesmellitus-1||no||diabetesmellitus (dm) is associated with microvascular complications, such as diabeticretinopathy (dr).
amod||trials-2/NNS||randomized-1/JJ	nsubj||shown-7/VBN||trials-2/NNS	nsubj||associated-15/VBN||trials-2/NNS	amod||patients-5/NNS||elective-4/JJ	prep_in||trials-2/NNS||patients-5/NNS	aux||shown-7/VBN||have-6/VBP	root||ROOT-0/null||shown-7/VBN	mark||safe-13/JJ||that-8/IN	amod||administration-11/NN||postprocedural-9/JJ	nn||administration-11/NN||protamine-10/NN	nsubj||safe-13/JJ||administration-11/NN	cop||safe-13/JJ||is-12/VBZ	ccomp||shown-7/VBN||safe-13/JJ	conj_and||shown-7/VBN||associated-15/VBN	det||reduction-19/NN||a-17/DT	amod||reduction-19/NN||significant-18/JJ	prep_with||associated-15/VBN||reduction-19/NN	amod||complications-22/NNS||bleeding-21/VBG	prep_in||reduction-19/NN||complications-22/NNS	bleeding-21||protamine-10||no_rel||randomized trials in elective patients have shown that postprocedural protamine administration is safe and associated with a significant reduction in bleeding complications.
nsubj||follow-6/VB||infectiousmononucleosis-1/NNS	nsubjpass||shown-19/VBN||infectiousmononucleosis-1/NNS	nsubj||increase-21/VB||infectiousmononucleosis-1/NNS	appos||infectiousmononucleosis-1/NNS||im-3/NN	aux||follow-6/VB||can-5/MD	root||ROOT-0/null||follow-6/VB	amod||infection-9/NN||late-7/JJ	amod||infection-9/NN||primary-8/JJ	dobj||follow-6/VB||infection-9/NN	prep_with||follow-6/VB||epstein-barrvirus-11/NNS	appos||epstein-barrvirus-11/NNS||ebv-13/NN	aux||shown-19/VBN||has-17/VBZ	auxpass||shown-19/VBN||been-18/VBN	conj_and||follow-6/VB||shown-19/VBN	aux||increase-21/VB||to-20/TO	xcomp||shown-19/VBN||increase-21/VB	det||risk-23/NN||the-22/DT	dobj||increase-21/VB||risk-23/NN	prep_of||risk-23/NN||multiplesclerosis-25/NNS	poss||disease-29/NN||hodgkin-27/NN	prep_of||risk-23/NN||disease-29/NN	conj_and||multiplesclerosis-25/NNS||disease-29/NN	infectiousmononucleosis-1||ebv-13||no||infectiousmononucleosis (im) can follow late primary infection with epstein-barrvirus (ebv), and has been shown to increase the risk of multiplesclerosis and hodgkin's disease.
det||study-2/NN||this-1/DT	nsubj||gives-3/VBZ||study-2/NN	root||ROOT-0/null||gives-3/VBZ	iobj||gives-3/VBZ||us-4/PRP	det||knowledge-9/NN||an-5/DT	amod||knowledge-9/NN||overview-6/JJ	prep_about||overview-6/JJ||hiv/aids-8/NNS	dobj||gives-3/VBZ||knowledge-9/NN	prep_in||knowledge-9/NN||detention-11/NN	nn||province-14/NN||hunan-13/NN	prep_in||detention-11/NN||province-14/NN	det||sites-19/NNS||all-17/DT	nn||sites-19/NNS||detention-18/NN	nsubj||provided-23/VBD||sites-19/NNS	det||study-22/NN||the-21/DT	prep_in||sites-19/NNS||study-22/NN	conj_and||gives-3/VBZ||provided-23/VBD	amod||services-26/NNS||hiv/aids-24/JJ	nn||services-26/NNS||intervention-25/NN	dobj||provided-23/VBD||services-26/NNS	prep_among||provided-23/VBD||detainees-28/NNS	nsubj||focused-30/VBN||detainees-28/NNS	rcmod||detainees-28/NNS||focused-30/VBN	amod||attitude-35/NN||hiv/aids-32/JJ	nn||attitude-35/NN||knowledge-33/NN	prep_on||focused-30/VBN||attitude-35/NN	nn||behaviors-39/NNS||health-38/NN	prep_on||focused-30/VBN||behaviors-39/NNS	conj_and||attitude-35/NN||behaviors-39/NNS	aids--1||hiv--1||no||this study gives us an overview about hiv/aids knowledge in detention in hunan province, and all detention sites in the study provided hiv/aids intervention services among detainees that focused on hiv/aids knowledge, attitude, and health behaviors.
amod||youth-2/NN||obese-1/JJ	nsubj||have-10/VB||youth-2/NN	det||diagnosis-6/NN||a-4/DT	amod||diagnosis-6/NN||clinical-5/JJ	prep_with||youth-2/NN||diagnosis-6/NN	prep_of||diagnosis-6/NN||type2diabetes-8/CD	aux||have-10/VB||may-9/MD	root||ROOT-0/null||have-10/VB	dobj||have-10/VB||evidence-11/NN	amod||autoimmunity-14/NN||islet-13/JJ	prep_of||evidence-11/NN||autoimmunity-14/NN	vmod||autoimmunity-14/NN||contributing-15/VBG	nn||deficiency-18/NN||insulin-17/NN	prep_to||contributing-15/VBG||deficiency-18/NN	type2diabetes-8||insulin-17||yes||obese youth with a clinical diagnosis of type2diabetes may have evidence of islet autoimmunity contributing to insulin deficiency.
amod||options-2/NNS||several-1/JJ	nsubjpass||licensed-10/VBN||options-2/NNS	det||treatment-5/NN||the-4/DT	prep_for||options-2/NNS||treatment-5/NN	prep_of||treatment-5/NN||hepatitisb-7/NN	aux||licensed-10/VBN||have-8/VBP	auxpass||licensed-10/VBN||been-9/VBN	root||ROOT-0/null||licensed-10/VBN	det||interferon-15/NN||the-12/DT	amod||interferon-15/NN||last-13/JJ	nn||interferon-15/NN||years-14/NNS	prep_in||licensed-10/VBN||interferon-15/NN	amod||interferon-18/NN||pegylated-17/JJ	prep_in||licensed-10/VBN||interferon-18/NN	conj_and||interferon-15/NN||interferon-18/NN	prep_in||licensed-10/VBN||lamivudine-20/NN	conj_and||interferon-15/NN||lamivudine-20/NN	prep_in||licensed-10/VBN||adefovir-22/NN	conj_and||interferon-15/NN||adefovir-22/NN	prep_in||licensed-10/VBN||entecavir-24/NN	conj_and||interferon-15/NN||entecavir-24/NN	prep_in||licensed-10/VBN||telbivudine-27/NN	conj_and||interferon-15/NN||telbivudine-27/NN	hepatitisb-7||entecavir-24||yes||several options for the treatment of hepatitisb have been licensed in the last years interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine.
nsubj||one-6/CD||isoniazid-1/NN	appos||isoniazid-1/NN||inh-3/NN	cop||one-6/CD||is-5/VBZ	root||ROOT-0/null||one-6/CD	det||drugs-12/NNS||the-8/DT	amod||drugs-12/NNS||main-9/JJ	amod||drugs-12/NNS||first-10/JJ	nn||drugs-12/NNS||line-11/NN	prep_of||one-6/CD||drugs-12/NNS	vmod||drugs-12/NNS||used-13/VBN	prep_in||used-13/VBN||treatment-15/NN	prep_of||treatment-15/NN||tuberculosis-17/NNP	nsubj||result-26/VB||development-19/NN	prep_of||development-19/NN||resistance-21/NN	det||compound-24/NN||this-23/DT	prep_against||resistance-21/NN||compound-24/NN	aux||result-26/VB||can-25/MD	conj_and||one-6/CD||result-26/VB	amod||problems-29/NNS||serious-28/JJ	prep_in||result-26/VB||problems-29/NNS	nn||procedures-32/NNS||treatment-31/NN	prep_in||problems-29/NNS||procedures-32/NNS	tuberculosis-17||isoniazid-1||yes||isoniazid (inh) is one of the main first line drugs used in treatment of tuberculosis and development of resistance against this compound can result in serious problems in treatment procedures.
advmod||administrated-13/VBN||even-1/RB	mark||administrated-13/VBN||though-2/IN	nsubjpass||administrated-13/VBN||immunoprophylaxis-3/NNS	prep_with||immunoprophylaxis-3/NNS||hepatitisbimmunoglobulin-5/NN	appos||hepatitisbimmunoglobulin-5/NN||hbig-7/NN	amod||vaccine-11/NN||hepatitisb-10/JJ	prep_with||immunoprophylaxis-3/NNS||vaccine-11/NN	conj_and||hepatitisbimmunoglobulin-5/NN||vaccine-11/NN	auxpass||administrated-13/VBN||is-12/VBZ	advcl||suffer-33/VBP||administrated-13/VBN	prep_to||administrated-13/VBN||neonates-15/NNS	poss||mothers-17/NNS||neonates-15/NNS	nsubj||antigen-21/NN||mothers-17/NNS	cop||antigen-21/NN||are-18/VBP	amod||antigen-21/NN||hepatitisb-19/JJ	nn||antigen-21/NN||surface-20/NN	rcmod||neonates-15/NNS||antigen-21/NN	appos||antigen-21/NN||hbsag-23/NN	amod||antigen-21/NN||positive-25/JJ	quantmod||10-28/CD||about-27/RB	num||%-29/NN||10-28/CD	nsubj||suffer-33/VBP||%-29/NN	det||neonates-32/NNS||the-31/DT	prep_of||%-29/NN||neonates-32/NNS	root||ROOT-0/null||suffer-33/VBP	nn||infection-36/NN||hbv-35/NN	prep_from||suffer-33/VBP||infection-36/NN	poss||life-40/NN||their-38/PRP$	amod||life-40/NN||early-39/JJ	prep_in||infection-36/NN||life-40/NN	hbv-35||hepatitisbimmunoglobulin-5||yes||even though immunoprophylaxis with hepatitisbimmunoglobulin (hbig) and hepatitisb vaccine is administrated to neonates whose mothers are hepatitisb surface antigen (hbsag) positive, about 10% of the neonates suffer from hbv infection in their early life.
nsubj||suggest-2/VBP||results-1/NNS	root||ROOT-0/null||suggest-2/VBP	mark||are-11/VBP||that-3/IN	amod||women-5/NNS||premenopausal-4/JJ	nsubj||are-11/VBP||women-5/NNS	amod||levels-10/NNS||elevated-7/JJ	nn||levels-10/NNS||serum-8/NN	nn||levels-10/NNS||testosterone-9/NN	prep_with||women-5/NNS||levels-10/NNS	ccomp||suggest-2/VBP||are-11/VBP	det||risk-15/NN||an-13/DT	amod||risk-15/NN||increased-14/VBN	prep_at||are-11/VBP||risk-15/NN	nn||cancer-18/NN||breast-17/NN	prep_of||risk-15/NN||cancer-18/NN	cancer-18||testosterone-9||no_rel||results suggest that premenopausal women with elevated serum testosterone levels are at an increased risk of breast cancer.
amod||titres-3/NNS||bcg-specific-1/JJ	nn||titres-3/NNS||igg-2/NN	nsubj||high-6/JJ||titres-3/NNS	cop||high-6/JJ||were-4/VBD	advmod||high-6/JJ||particularly-5/RB	root||ROOT-0/null||high-6/JJ	prep_among||high-6/JJ||patients-8/NNS	vmod||patients-8/NNS||coinfected-9/VBN	prep_with||coinfected-9/VBN||tb-11/FW	prep_with||coinfected-9/VBN||hiv-13/FW	conj_and||tb-11/FW||hiv-13/FW	amod||$-16/NNS||cd4â-15/JJ	prep_with||coinfected-9/VBN||$-16/NNS	amod||counts-19/NNS||t-cell-18/JJ	nsubj||<-20/VBP||counts-19/NNS	parataxis||high-6/JJ||<-20/VBP	amod||cells/ml-24/NN||200â-21/JJ	amod||cells/ml-24/NN||$-22/$	dobj||<-20/VBP||cells/ml-24/NN	nsubj||produced-26/VBD||cells/ml-24/NN	rcmod||cells/ml-24/NN||produced-26/VBD	amod||levels-28/NNS||low-27/JJ	dobj||produced-26/VBD||levels-28/NNS	prep_of||levels-28/NNS||mycobacteriumtuberculosis-30/NNS	amod||ifnî-33/NNS||specific-32/JJ	dep||mycobacteriumtuberculosis-30/NNS||ifnî-33/NNS	punct||mycobacteriumtuberculosis-30/NNS||³-34/''	prep_in||produced-26/VBD||vitro-36/NN	tb-11||bcg--1||no||bcg-specific igg titres were particularly high among patients coinfected with tb and hiv with cd4ât-cell counts <200âcells/ml who produced low levels of mycobacteriumtuberculosis -specific ifnî³ in vitro.
nsubj||found-2/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	quantmod||6-4/CD||only-3/RB	num||prescriptions-5/NNS||6-4/CD	dobj||found-2/VBD||prescriptions-5/NNS	vmod||prescriptions-5/NNS||having-6/VBG	det||treatment-9/NN||the-7/DT	amod||treatment-9/NN||recommended-8/VBN	dobj||having-6/VBG||treatment-9/NN	nsubjpass||ors-12/VBN||treatment-9/NN	auxpass||ors-12/VBN||is-11/VBZ	rcmod||treatment-9/NN||ors-12/VBN	prep_along_with||ors-12/VBN||zinc-15/NN	neg||probiotics-20/NNS||no-18/DT	amod||probiotics-20/NNS||additional-19/JJ	prep_with||ors-12/VBN||probiotics-20/NNS	prep_with||ors-12/VBN||antibiotics-22/NN	conj_or||probiotics-20/NNS||antibiotics-22/NN	prep_with||ors-12/VBN||racecadotril-24/NN	conj_or||probiotics-20/NNS||racecadotril-24/NN	prep_with||ors-12/VBN||antiemetics-26/NNS	conj_or||probiotics-20/NNS||antiemetics-26/NNS	prep_except||prescriptions-5/NNS||domperidone-29/NN	prep_for||domperidone-29/NN||vomiting-31/NN	antiemetics-26||vomiting-31||no_rel||we found only 6 prescriptions having the recommended treatment that is ors along with zinc, with no additional probiotics, antibiotics, racecadotril or antiemetics (except domperidone for vomiting).
det||patient-4/NN||a-1/DT	amod||patient-4/NN||confirmed-2/JJ	nn||patient-4/NN||case-3/NN	nsubjpass||defined-6/VBN||patient-4/NN	auxpass||defined-6/VBN||was-5/VBD	root||ROOT-0/null||defined-6/VBN	det||fever-13/NN||a-8/DT	amod||fever-13/NN||clinical-9/JJ	nn||fever-13/NN||case-10/NN	nn||fever-13/NN||-lrb--11/NNP	nn||fever-13/NN||i.e.-12/NNP	prep_as||defined-6/VBN||fever-13/NN	quantmod||one-17/CD||at-15/IN	mwe||at-15/IN||least-16/JJS	pobj||at-15/IN||least-16/JJS	num||suggestive-20/NN||one-17/CD	amod||suggestive-20/NN||additional-18/JJ	nn||suggestive-20/NN||symptom-19/NN	prep_as||defined-6/VBN||suggestive-20/NN	conj_and||fever-13/NN||suggestive-20/NN	prep_for||suggestive-20/NN||leptospirosis-22/NNS	vmod||leptospirosis-22/NNS||-rrb--23/VBN	quantmod||two-27/CD||at-25/IN	mwe||at-25/IN||least-26/JJS	pobj||at-25/IN||least-26/JJS	prep_with||-rrb--23/VBN||two-27/CD	det||tests-31/NNS||the-29/DT	amod||tests-31/NNS||following-30/JJ	prep_of||two-27/CD||tests-31/NNS	amod||suggestive-20/NN||positive-32/JJ	nn||igm-34/NN||elisa-33/NN	dep||positive-32/JJ||igm-34/NN	nn||testing-38/NN||latex-36/NN	nn||testing-38/NN||agglutination-37/NN	appos||igm-34/NN||testing-38/NN	amod||testing-43/NN||microscopic-41/JJ	nn||testing-43/NN||agglutination-42/NN	conj_and||fever-13/NN||testing-43/NN	conj_or||suggestive-20/NN||testing-43/NN	leptospirosis-22||latex-36||no_rel||a confirmed case patient was defined as a clinical case -lrb- i.e. fever and at least one additional symptom suggestive for leptospirosis -rrb- with at least two of the following tests positive elisa igm , latex agglutination testing , or microscopic agglutination testing .
nsubj||observed-3/VBD||we-1/PRP	advmod||observed-3/VBD||serendipitous-2/RB	root||ROOT-0/null||observed-3/VBD	det||tolerability-6/NN||an-4/DT	nn||tolerability-6/NN||increase-5/NN	dobj||observed-3/VBD||tolerability-6/NN	det||response-10/NN||a-8/DT	amod||response-10/NN||rapid-9/JJ	dobj||observed-3/VBD||response-10/NN	conj_and||tolerability-6/NN||response-10/NN	prep_to||response-10/NN||therapy-12/NN	det||onset-16/NN||an-14/DT	amod||onset-16/NN||early-15/JJ	dobj||observed-3/VBD||onset-16/NN	conj_and||tolerability-6/NN||onset-16/NN	amod||activity-20/NN||antidepressant-18/JJ	nn||activity-20/NN||fluvoxamine-19/NN	prep_of||onset-16/NN||activity-20/NN	advmod||associated-22/VBN||when-21/WRB	advcl||observed-3/VBD||associated-22/VBN	prep_with||associated-22/VBN||amisulpride-24/NN	prep_in||associated-22/VBN||patients-26/NNS	amod||depressivedisorder-29/NN||major-28/JJ	prep_with||associated-22/VBN||depressivedisorder-29/NN	depressivedisorder-29||fluvoxamine-19||yes||we serendipitous observed an increase tolerability, a rapid response to therapy and an early onset of antidepressant fluvoxamine activity when associated with amisulpride in patients with major depressivedisorder.
nn||methods-2/NNS||review-1/NN	nsubj||randomised-3/VBD||methods-2/NNS	root||ROOT-0/null||randomised-3/VBD	amod||trials-5/NNS||controlled-4/JJ	nsubj||eligible-23/JJ||trials-5/NNS	vmod||trials-5/NNS||comparing-6/VBG	dobj||comparing-6/VBG||fibre-7/NN	dobj||comparing-6/VBG||antispasmodics-9/NN	conj_and||fibre-7/NN||antispasmodics-9/NN	dobj||comparing-6/VBG||peppermintoil-12/NN	conj_and||fibre-7/NN||peppermintoil-12/NN	prep_with||comparing-6/VBG||placebo-14/NN	neg||treatment-17/NN||no-16/DT	prep_with||comparing-6/VBG||treatment-17/NN	conj_or||placebo-14/NN||treatment-17/NN	prep_in||comparing-6/VBG||adults-19/NNS	prep_with||adults-19/NNS||irritablebowelsyndrome-21/NN	cop||eligible-23/JJ||were-22/VBD	ccomp||randomised-3/VBD||eligible-23/JJ	prep_for||eligible-23/JJ||inclusion-25/NN	fibre-7||irritablebowelsyndrome-21||no_rel||review methods randomised controlled trials comparing fibre, antispasmodics, and peppermintoil with placebo or no treatment in adults with irritablebowelsyndrome were eligible for inclusion.
advmod||infecting-2/JJ||latently-1/RB	amod||viruses-3/NNS||infecting-2/JJ	nsubj||class-7/NN||viruses-3/NNS	cop||class-7/NN||are-4/VBP	det||class-7/NN||an-5/DT	amod||class-7/NN||important-6/JJ	root||ROOT-0/null||class-7/NN	nsubj||plays-11/VBZ||class-7/NN	prep_of||class-7/NN||virus-9/NN	rcmod||class-7/NN||plays-11/VBZ	det||role-14/NN||a-12/DT	amod||role-14/NN||key-13/JJ	dobj||plays-11/VBZ||role-14/NN	amod||evolution-17/NN||viral-16/JJ	prep_in||role-14/NN||evolution-17/NN	amod||health-20/NN||human-19/JJ	prep_in||role-14/NN||health-20/NN	conj_and||evolution-17/NN||health-20/NN	virus-9||viruses-3||no||latently infecting viruses are an important class of virus that plays a key role in viral evolution and human health.
det||antimalarialdrugs-4/NNS||the-2/DT	amod||antimalarialdrugs-4/NNS||various-3/JJ	prep_among||proven-24/VBN||antimalarialdrugs-4/NNS	amod||antimalarialdrugs-4/NNS||available-5/JJ	det||combination-9/NN||the-7/DT	amod||combination-9/NN||synergistic-8/JJ	nsubj||proven-24/VBN||combination-9/NN	prep_of||combination-9/NN||atovaquone-11/NN	prep_of||combination-9/NN||proguanil-13/NN	conj_and||atovaquone-11/NN||proguanil-13/NN	appos||atovaquone-11/NN||a/p-15/NN	nn||®-19/NNP||malaroneâ-18/NNP	dep||atovaquone-11/NN||®-19/NNP	dep||®-19/NNP||glaxo-smithkline-21/NN	aux||proven-24/VBN||has-23/VBZ	root||ROOT-0/null||proven-24/VBN	det||option-27/NN||a-25/DT	amod||option-27/NN||valuable-26/JJ	dobj||proven-24/VBN||option-27/NN	prep_in||proven-24/VBN||terms-29/NNS	amod||protection-32/NN||effective-31/JJ	prep_of||terms-29/NNS||protection-32/NN	prep_against||proven-24/VBN||chloroquine-34/NN	prep_against||proven-24/VBN||multi-drug-36/NN	conj_and||chloroquine-34/NN||multi-drug-36/NN	xcomp||proven-24/VBN||resistant-37/VBG	dobj||resistant-37/VBG||falciparummalaria-38/NN	dobj||resistant-37/VBG||safety-40/NN	conj_and||falciparummalaria-38/NN||safety-40/NN	dobj||resistant-37/VBG||tolerability-42/NN	conj_and||falciparummalaria-38/NN||tolerability-42/NN	dobj||resistant-37/VBG||ease-45/NN	conj_and||falciparummalaria-38/NN||ease-45/NN	prep_of||falciparummalaria-38/NN||use-47/NN	advmod||favoring-50/VBG||thus-49/RB	xcomp||proven-24/VBN||favoring-50/VBG	dobj||favoring-50/VBG||compliance-51/NN	falciparummalaria-38||proguanil-13||yes||among the various antimalarialdrugs available, the synergistic combination of atovaquone and proguanil (a/p) (malaroneâ®; glaxo-smithkline) has proven a valuable option in terms of effective protection against chloroquine and multi-drug resistant falciparummalaria, safety, tolerability, and ease of use, thus favoring compliance.
nn||levels-2/NNS||glucagon-1/NN	nsubj||remained-3/VBD||levels-2/NNS	root||ROOT-0/null||remained-3/VBD	acomp||remained-3/VBD||suppressed-4/VBN	det||decrease-7/NN||a-6/DT	prep_following||suppressed-4/VBN||decrease-7/NN	amod||insulin-10/NN||zinc-free-9/JJ	prep_in||decrease-7/NN||insulin-10/NN	prep_in||decrease-7/NN||insulin-10/NN	conj_and||insulin-10/NN||insulin-10/NN	prep_with||insulin-10/NN||euglycemia-12/NN	dep||insulin-10/NN||â-14/VB	num||±-17/NN||14-15/CD	nn||±-17/NN||â-16/NN	nsubj||-LSB--20/VBG||±-17/NN	number||pg/ml-19/JJ||3-18/CD	dep||-LSB--20/VBG||pg/ml-19/JJ	xcomp||â-14/VB||-LSB--20/VBG	poss||-RSB--28/NN||â-21/NNP	number||â-24/CD||4.0-23/CD	num||-RSB--28/NN||â-24/CD	nn||-RSB--28/NN||±-25/NN	num||-RSB--28/NN||0.9-26/CD	nn||-RSB--28/NN||pmol/l-27/NN	dobj||-LSB--20/VBG||-RSB--28/NN	amod||hyperinsulinemia-33/NN||sustained-32/VBN	prep_during||insulin-10/NN||hyperinsulinemia-33/NN	prep_with||hyperinsulinemia-33/NN||hypoglycemia-35/NN	nn||±-40/NN||â-37/NN	num||±-40/NN||14-38/CD	nn||±-40/NN||â-39/NN	dep||hypoglycemia-35/NN||±-40/NN	num||-LSB--43/NNS||2-41/CD	amod||-LSB--43/NNS||pg/ml-42/JJ	dep||±-40/NN||-LSB--43/NNS	poss||-RSB--51/NN||â-44/NNP	amod||-RSB--51/NN||4.0-46/JJ	nn||-RSB--51/NN||â-47/NN	nn||-RSB--51/NN||±-48/NN	num||-RSB--51/NN||0.6-49/CD	amod||-RSB--51/NN||pmol/l-50/JJ	dep||-LSB--43/NNS||-RSB--51/NN	acomp||remained-3/VBD||increased-54/VBN	conj_but||suppressed-4/VBN||increased-54/VBN	poss||pg/ml-62/NN||â-56/NNP	number||â-59/CD||3-58/CD	num||pg/ml-62/NN||â-59/CD	amod||pg/ml-62/NN||±-60/JJ	num||pg/ml-62/NN||3-61/CD	prep_to||increased-54/VBN||pg/ml-62/NN	poss||â-67/NN||â-64/NNP	num||â-67/NN||0.9-66/CD	npadvmod||pmol/l-70/JJ||â-67/NN	number||0.9-69/CD||±-68/CD	num||â-67/NN||0.9-69/CD	dep||pg/ml-62/NN||pmol/l-70/JJ	parataxis||increased-54/VBN||p-73/VB	num||0.01-75/CD||<-74/CD	dobj||p-73/VB||0.01-75/CD	det||decrease-79/NN||a-78/DT	prep_following||increased-54/VBN||decrease-79/NN	amod||insulin-82/NN||zinc-free-81/JJ	prep_in||decrease-79/NN||insulin-82/NN	prep_with||insulin-82/NN||hypoglycemia-84/NN	det||min-89/NNS||the-86/DT	amod||min-89/NNS||next-87/JJ	num||min-89/NNS||120-88/CD	prep_over||hypoglycemia-84/NN||min-89/NNS	zinc--1||hypoglycemia-84||no_rel||glucagon levels remained suppressed following a decrease in zinc-free insulin with euglycemia (â14 â± 3 pg/ml [â4.0 â± 0.9 pmol/l]) and during sustained hyperinsulinemia with hypoglycemia (â14 â± 2 pg/ml [â4.0 â± 0.6 pmol/l]) but increased to â3 â± 3 pg/ml (â0.9 â± 0.9 pmol/l) ( p < 0.01) following a decrease in zinc-free insulin with hypoglycemia over the next 120 min.
nsubj||important-10/JJ||distribution-1/NN	nn||infectivity-4/NN||prion-3/NN	prep_of||distribution-1/NN||infectivity-4/NN	prep_in||infectivity-4/NN||organs-6/NNS	prep_in||infectivity-4/NN||tissues-8/NNS	conj_and||organs-6/NNS||tissues-8/NNS	cop||important-10/JJ||is-9/VBZ	root||ROOT-0/null||important-10/JJ	prepc_in||important-10/JJ||understanding-12/VBG	amod||pathogenesis-14/NNS||priondisease-13/JJ	dobj||understanding-12/VBG||pathogenesis-14/NNS	prepc_in||important-10/JJ||designing-16/VBG	conj_and||understanding-12/VBG||designing-16/VBG	dobj||designing-16/VBG||strategies-17/NNS	aux||prevent-19/VB||to-18/TO	vmod||designing-16/VBG||prevent-19/VB	nn||infection-21/NN||prion-20/NN	dobj||prevent-19/VB||infection-21/NN	prep_in||prevent-19/VB||animals-23/NNS	prep_in||prevent-19/VB||humans-25/NNS	conj_and||animals-23/NNS||humans-25/NNS	priondisease-13||prion-20||no||distribution of prion infectivity in organs and tissues is important in understanding priondisease pathogenesis and designing strategies to prevent prion infection in animals and humans.
nn||samples-2/NNS||tumor-1/NN	nsubjpass||obtained-10/VBN||samples-2/NNS	num||patients-5/NNS||249-4/CD	prep_from||samples-2/NNS||patients-5/NNS	amod||sts-8/NN||non-gist-7/JJ	prep_with||patients-5/NNS||sts-8/NN	auxpass||obtained-10/VBN||were-9/VBD	root||ROOT-0/null||obtained-10/VBN	nn||microarrays-13/NNS||tissue-12/NN	nsubjpass||constructed-15/VBN||microarrays-13/NNS	auxpass||constructed-15/VBN||were-14/VBD	conj_and||obtained-10/VBN||constructed-15/VBN	det||specimen-18/NN||each-17/DT	prep_for||constructed-15/VBN||specimen-18/NN	tumor-1||sts-8||no||tumor samples from 249 patients with non-gist sts were obtained and tissue microarrays were constructed for each specimen.
nsubj||disease-5/NN||lymeborreliosis-1/NNS	cop||disease-5/NN||is-2/VBZ	det||disease-5/NN||a-3/DT	amod||disease-5/NN||zoonotic-4/JJ	root||ROOT-0/null||disease-5/NN	vmod||disease-5/NN||caused-6/VBN	amod||bacteria-11/NNS||borreliaburgdorferi-8/JJ	amod||bacteria-11/NNS||sensu-9/JJ	nn||bacteria-11/NNS||lato-10/NN	agent||caused-6/VBN||bacteria-11/NNS	vmod||bacteria-11/NNS||transmitted-12/VBN	prep_to||transmitted-12/VBN||humans-14/NNS	amod||animals-17/NNS||domestic-16/JJ	prep_to||transmitted-12/VBN||animals-17/NNS	conj_and||humans-14/NNS||animals-17/NNS	det||bite-20/NN||the-19/DT	agent||transmitted-12/VBN||bite-20/NN	det||spp-24/NN||an-22/DT	amod||spp-24/NN||ixodes-23/JJ	prep_of||bite-20/NN||spp-24/NN	lymeborreliosis-1||bacteria-11||no||lymeborreliosis is a zoonotic disease caused by borreliaburgdorferi sensu lato bacteria transmitted to humans and domestic animals by the bite of an ixodes spp.
mark||clear-4/JJ||although-1/IN	nsubj||clear-4/JJ||it-2/PRP	cop||clear-4/JJ||is-3/VBZ	advcl||cause-47/VB||clear-4/JJ	mark||have-16/VBP||that-5/IN	det||patients-7/NNS||some-6/DT	nsubj||have-16/VBP||patients-7/NNS	prep_with||patients-7/NNS||acetylsalicylicacid-9/NN	appos||acetylsalicylicacid-9/NN||asa-11/NN	amod||asthma-15/NN||sensitive-14/JJ	dep||acetylsalicylicacid-9/NN||asthma-15/NN	ccomp||clear-4/JJ||have-16/VBP	poss||onset-19/NN||their-17/PRP$	amod||onset-19/NN||clinical-18/JJ	dobj||have-16/VBP||onset-19/NN	prep_of||onset-19/NN||disease-21/NN	prep_in||disease-21/NN||childhood-23/NN	prep_in||disease-21/NN||bronchoconstriction-25/NN	conj_and||childhood-23/NN||bronchoconstriction-25/NN	mark||seen-30/VBN||after-26/IN	nn||challenge-28/NN||asa-27/NN	nsubjpass||seen-30/VBN||challenge-28/NN	auxpass||seen-30/VBN||is-29/VBZ	advcl||have-16/VBP||seen-30/VBN	prep_in||seen-30/VBN||0-32/CD	num||%-35/NN||22-34/CD	prep_to||seen-30/VBN||%-35/NN	amod||children-38/NNS||asthmatic-37/JJ	prep_of||%-35/NN||children-38/NNS	advmod||challenged-40/VBN||so-39/RB	vmod||children-38/NNS||challenged-40/VBN	nsubj||cause-47/VB||ibuprofen-42/NN	amod||doses-45/NNS||antipyretic-44/JJ	prep_at||ibuprofen-42/NN||doses-45/NNS	aux||cause-47/VB||may-46/MD	root||ROOT-0/null||cause-47/VB	amod||problems-50/NNS||acute-48/JJ	nn||problems-50/NNS||respiratory-49/NN	dobj||cause-47/VB||problems-50/NNS	advmod||cause-47/VB||only-51/RB	det||number-56/NN||a-53/DT	advmod||small-55/JJ||very-54/RB	amod||number-56/NN||small-55/JJ	prep_in||cause-47/VB||number-56/NN	amod||moderate-60/JJ||mild-58/JJ	dep||moderate-60/JJ||to-59/TO	amod||asthmatics-61/NNS||moderate-60/JJ	prep_of||number-56/NN||asthmatics-61/NNS	asthmatics-61||asa-27||no||although it is clear that some patients with acetylsalicylicacid (asa)-sensitive asthma have their clinical onset of disease in childhood and bronchoconstriction after asa challenge is seen in 0 to 22% of asthmatic children so challenged, ibuprofen at antipyretic doses may cause acute respiratory problems only in a very small number of mild to moderate asthmatics.
advmod||report-15/VBP||here-1/RB	det||coexistence-6/NN||a-4/DT	amod||coexistence-6/NN||unique-5/JJ	prep_as||report-15/VBP||coexistence-6/NN	det||entities-12/NNS||these-8/DT	num||entities-12/NNS||two-9/CD	amod||entities-12/NNS||seperated-10/JJ	amod||entities-12/NNS||clinical-11/JJ	prep_of||coexistence-6/NN||entities-12/NNS	nsubj||report-15/VBP||we-14/PRP	root||ROOT-0/null||report-15/VBP	det||woman-18/NN||a-16/DT	amod||woman-18/NN||30-yr-old-17/JJ	dobj||report-15/VBP||woman-18/NN	vmod||woman-18/NN||presenting-19/VBG	amod||spasm-22/NN||carpal-21/JJ	prep_with||presenting-19/VBG||spasm-22/NN	vmod||spasm-22/NN||related-23/VBN	amod||preparation-42/NN||hypocalcemia-25/JJ	amod||calcium-28/NN||ionized-27/JJ	dep||preparation-42/NN||calcium-28/NN	num||mm/l-31/NN||1.90-30/CD	prep_of||calcium-28/NN||mm/l-31/NN	amod||preparation-42/NN||due-33/JJ	aux||acute-35/VB||to-34/TO	xcomp||due-33/JJ||acute-35/VB	amod||poisoning-37/NN||phosphate-36/JJ	dobj||acute-35/VB||poisoning-37/NN	amod||bowel-41/NN||oral-39/JJ	nn||bowel-41/NN||sodiumphosphate-40/NN	prep_after||acute-35/VB||bowel-41/NN	prep_to||related-23/VBN||preparation-42/NN	nsubj||resolved-45/VBN||preparation-42/NN	rcmod||preparation-42/NN||resolved-45/VBN	advmod||resolved-45/VBN||rapidly-46/RB	nn||gluconate-49/NN||calcium-48/NN	prep_after||resolved-45/VBN||gluconate-49/NN	advmod||resolved-45/VBN||intravenously-50/RB	calcium-48||spasm-22||no_rel||here, as a unique coexistence of these two seperated clinical entities, we report a 30-yr-old woman presenting with carpal spasm related to hypocalcemia (ionized calcium of 1.90 mm/l) due to acute phosphate poisoning after oral sodiumphosphate bowel preparation, which resolved rapidly after calcium gluconate intravenously.
dep||assess-4/VB||a-1/LS	aux||assess-4/VB||to-3/TO	root||ROOT-0/null||assess-4/VB	det||suitability-6/NN||the-5/DT	dobj||assess-4/VB||suitability-6/NN	det||content-10/NN||the-8/DT	nn||content-10/NN||curriculum-9/NN	prep_of||suitability-6/NN||content-10/NN	amod||quality-13/NN||didactical-12/JJ	nsubj||delivered-16/VBD||quality-13/NN	nsubj||educate-18/VB||quality-13/NN	prep_of||quality-13/NN||information-15/NN	conj_and||assess-4/VB||delivered-16/VBD	aux||educate-18/VB||to-17/TO	xcomp||delivered-16/VBD||educate-18/VB	dobj||educate-18/VB||journalists-19/NNS	det||program-23/NN||the-21/DT	amod||program-23/NN||j2j-22/JJ	prep_in||journalists-19/NNS||program-23/NN	prep_in||journalists-19/NNS||hiv/aids-25/NNS	nn||evaluation-28/NN||process-27/NN	appos||hiv/aids-25/NNS||evaluation-28/NN	prep_in||journalists-19/NNS||b-31/SYM	conj_and||hiv/aids-25/NNS||b-31/SYM	aux||explore-34/VB||to-33/TO	vmod||educate-18/VB||explore-34/VB	det||effects-36/NNS||the-35/DT	dobj||explore-34/VB||effects-36/NNS	amod||programs-39/NNS||such-38/JJ	prep_of||effects-36/NNS||programs-39/NNS	poss||reporting-43/NN||journalists-41/NNS	prep_on||explore-34/VB||reporting-43/NN	amod||related-46/JJ||hiv/aids-45/JJ	amod||information-47/NN||related-46/JJ	prep_of||reporting-43/NN||information-47/NN	nn||evaluation-50/NN||outcome-49/NN	appos||information-47/NN||evaluation-50/NN	aids--1||hiv--1||no||a) to assess the suitability of the curriculum content and didactical quality of information delivered to educate journalists in the j2j program in hiv/aids (process evaluation) and b) to explore the effects of such programs on journalists' reporting of hiv/aids related information (outcome evaluation).
prepc_depending_on||include-10/VB||on-2/IN	det||populations-4/NNS||the-3/DT	pobj||include-10/VB||populations-4/NNS	vmod||populations-4/NNS||targeted-5/VBN	det||interventions-8/NNS||these-7/DT	nsubj||include-10/VB||interventions-8/NNS	aux||include-10/VB||may-9/MD	root||ROOT-0/null||include-10/VB	dobj||include-10/VB||education-11/NN	amod||distribution-15/NN||free-13/JJ	nn||distribution-15/NN||condom-14/NN	dobj||include-10/VB||distribution-15/NN	conj_and||education-11/NN||distribution-15/NN	dobj||include-10/VB||syringe-17/NN	conj_and||education-11/NN||syringe-17/NN	nn||programs-21/NNS||needle-19/NN	nn||programs-21/NNS||prescription-20/NN	dobj||include-10/VB||programs-21/NNS	conj_and||education-11/NN||programs-21/NNS	nn||screening-25/NN||chest-23/NN	nn||screening-25/NN||radiography-24/NN	dobj||include-10/VB||screening-25/NN	conj_and||education-11/NN||screening-25/NN	prep_for||screening-25/NN||tuberculosis-27/NNP	advmod||observed-30/JJ||directly-29/RB	amod||therapy-31/NN||observed-30/JJ	dobj||include-10/VB||therapy-31/NN	conj_and||education-11/NN||therapy-31/NN	nn||treatment-34/NN||tuberculosis-33/NNP	prep_for||therapy-31/NN||treatment-34/NN	dobj||include-10/VB||improvement-36/NN	conj_and||education-11/NN||improvement-36/NN	amod||clothing-39/NN||personal-38/JJ	prep_of||improvement-36/NN||clothing-39/NN	nn||hygiene-42/NN||bedding-41/NN	prep_of||improvement-36/NN||hygiene-42/NN	conj_and||clothing-39/NN||hygiene-42/NN	amod||use-46/NN||widespread-45/JJ	dobj||include-10/VB||use-46/NN	conj_and||education-11/NN||use-46/NN	prep_of||use-46/NN||ivermectin-48/NN	prep_for||include-10/VB||scabies-50/NNS	nn||infestation-54/NN||body-52/NN	nn||infestation-54/NN||louse-53/NN	prep_for||include-10/VB||infestation-54/NN	conj_and||scabies-50/NNS||infestation-54/NN	scabies-50||ivermectin-48||yes||depending on the populations targeted, these interventions may include education, free condom distribution, syringe and needle prescription programs, chest radiography screening for tuberculosis, directly observed therapy for tuberculosis treatment, improvement of personal clothing and bedding hygiene, and widespread use of ivermectin for scabies and body louse infestation.
det||purpose-2/NN||the-1/DT	nsubj||is-6/VBZ||purpose-2/NN	det||review-5/NN||this-4/DT	prep_of||purpose-2/NN||review-5/NN	root||ROOT-0/null||is-6/VBZ	aux||analyze-8/VB||to-7/TO	ccomp||is-6/VBZ||analyze-8/VB	dobj||analyze-8/VB||some-9/DT	det||data-13/NNS||the-11/DT	amod||data-13/NNS||current-12/JJ	prep_of||some-9/DT||data-13/NNS	prep_of||data-13/NNS||hdaci-15/NNS	amod||targets-18/NNS||possible-17/JJ	prep_as||analyze-8/VB||targets-18/NNS	nn||development-21/NN||drug-20/NN	prep_of||targets-18/NNS||development-21/NN	aux||provide-24/VB||to-23/TO	ccomp||is-6/VBZ||provide-24/VB	conj_and||analyze-8/VB||provide-24/VB	det||insight-26/NN||some-25/DT	dobj||provide-24/VB||insight-26/NN	det||problems-30/NNS||the-28/DT	amod||problems-30/NNS||current-29/JJ	prep_into||provide-24/VB||problems-30/NNS	amod||cancer-33/NN||pancreatic-32/JJ	prep_with||problems-30/NNS||cancer-33/NN	prep_into||provide-24/VB||points-35/NNS	conj_and||problems-30/NNS||points-35/NNS	prep_of||points-35/NNS||interest-37/NN	amod||study-40/NN||further-39/JJ	prep_for||provide-24/VB||study-40/NN	prep_of||study-40/NN||hdaci-42/NNS	amod||molecules-45/NNS||potential-44/JJ	prep_as||hdaci-42/NNS||molecules-45/NNS	amod||therapy-50/NN||pancreatic-47/JJ	nn||therapy-50/NN||cancer-48/NN	nn||therapy-50/NN||adjuvant-49/NN	prep_for||molecules-45/NNS||therapy-50/NN	cancer-48||adjuvant-49||no_rel||the purpose of this review is to analyze some of the current data of hdaci as possible targets of drug development and to provide some insight into the current problems with pancreatic cancer and points of interest for further study of hdaci as potential molecules for pancreatic cancer adjuvant therapy.
det||spread-2/NN||the-1/DT	nsubj||suggests-23/VBZ||spread-2/NN	det||h1n1influenzavirus-6/NNS||the-4/DT	num||h1n1influenzavirus-6/NNS||2009-5/CD	prep_of||spread-2/NN||h1n1influenzavirus-6/NNS	det||population-9/NN||the-8/DT	prep_in||h1n1influenzavirus-6/NNS||population-9/NN	advmod||population-9/NN||worldwide-10/RB	det||number-17/NN||the-15/DT	amod||number-17/NN||large-16/JJ	prep_in_addition_to||spread-2/NN||number-17/NN	prep_of||number-17/NN||individuals-19/NNS	advmod||vaccinated-21/VBN||already-20/RB	vmod||individuals-19/NNS||vaccinated-21/VBN	root||ROOT-0/null||suggests-23/VBZ	mark||have-32/VBP||that-24/IN	det||proportion-27/NN||a-25/DT	amod||proportion-27/NN||large-26/JJ	nsubj||have-32/VBP||proportion-27/NN	det||population-30/NN||the-29/DT	prep_of||proportion-27/NN||population-30/NN	advmod||have-32/VBP||now-31/RB	ccomp||suggests-23/VBZ||have-32/VBP	amod||antibodies-34/NNS||cross-protective-33/JJ	dobj||have-32/VBP||antibodies-34/NNS	det||virus-38/NN||the-36/DT	num||virus-38/NN||1918-37/CD	prep_against||antibodies-34/NNS||virus-38/NN	advmod||alleviating-41/VBG||greatly-40/RB	vmod||antibodies-34/NNS||alleviating-41/VBG	dobj||alleviating-41/VBG||concerns-42/NNS	dobj||alleviating-41/VBG||fears-44/NNS	conj_and||concerns-42/NNS||fears-44/NNS	det||exposure/release-48/NN||the-46/DT	amod||exposure/release-48/NN||accidental-47/JJ	prep_regarding||concerns-42/NNS||exposure/release-48/NN	det||virus-52/NN||the-50/DT	num||virus-52/NN||1918-51/CD	prep_of||exposure/release-48/NN||virus-52/NN	det||laboratory-55/NN||the-54/DT	prep_from||virus-52/NN||laboratory-55/NN	det||use-58/NN||the-57/DT	prep_of||exposure/release-48/NN||use-58/NN	conj_and||virus-52/NN||use-58/NN	det||virus-61/NN||the-60/DT	prep_of||use-58/NN||virus-61/NN	det||agent-65/NN||a-63/DT	amod||agent-65/NN||bioterrorist-64/JJ	prep_as||virus-61/NN||agent-65/NN	virus-61||antibodies-34||no_rel||the spread of the 2009 h1n1influenzavirus in the population worldwide, in addition to the large number of individuals already vaccinated, suggests that a large proportion of the population now have cross-protective antibodies against the 1918 virus, greatly alleviating concerns and fears regarding the accidental exposure/release of the 1918 virus from the laboratory and the use of the virus as a bioterrorist agent.
nsubj||prevented-9/VBD||loperamide-1/NN	det||drug-6/NN||a-3/DT	amod||drug-6/NN||standard-4/JJ	amod||drug-6/NN||antidiarrheal-5/JJ	appos||loperamide-1/NN||drug-6/NN	advmod||prevented-9/VBD||similarly-8/RB	root||ROOT-0/null||prevented-9/VBD	det||diarrhea-11/NN||the-10/DT	dobj||prevented-9/VBD||diarrhea-11/NN	diarrhea-11||loperamide-1||yes||loperamide, a standard antidiarrheal drug, similarly prevented the diarrhea.
det||challenge-2/NN||a-1/DT	nsubj||is-9/VBZ||challenge-2/NN	nsubj||develop-11/VB||challenge-2/NN	nn||research-8/NN||tuberculosis-4/NNP	appos||research-8/NN||tb-6/NN	prep_in||challenge-2/NN||research-8/NN	root||ROOT-0/null||is-9/VBZ	aux||develop-11/VB||to-10/TO	xcomp||is-9/VBZ||develop-11/VB	det||test-15/NN||a-12/DT	amod||test-15/NN||new-13/JJ	amod||test-15/NN||immunological-14/JJ	dobj||develop-11/VB||test-15/NN	nsubj||help-18/VB||test-15/NN	aux||help-18/VB||can-17/MD	rcmod||test-15/NN||help-18/VB	ccomp||help-18/VB||distinguish-19/VB	prep_among||distinguish-19/VB||subjects-22/NNS	amod||subjects-22/NNS||responsive-23/JJ	nn||gold-27/NN||quantiferon-25/NN	nn||gold-27/NN||tb-26/NN	prep_to||responsive-23/JJ||gold-27/NN	prep_in||gold-27/NN||tube-29/NN	appos||subjects-22/NNS||qft-it-31/NN	dobj||distinguish-19/VB||those-34/DT	nsubj||able-37/JJ||those-34/DT	nsubj||control-39/VB||those-34/DT	cop||able-37/JJ||are-36/VBP	rcmod||those-34/DT||able-37/JJ	aux||control-39/VB||to-38/TO	xcomp||able-37/JJ||control-39/VB	nn||replication-41/NN||mtb-40/NN	dobj||control-39/VB||replication-41/NN	amod||ltbi-44/NNS||remote-43/JJ	dep||replication-41/NN||ltbi-44/NNS	amod||infection-47/NN||recent-46/JJ	dep||replication-41/NN||infection-47/NN	conj_and||ltbi-44/NNS||infection-47/NN	amod||tb-50/NN||past-49/JJ	dep||replication-41/NN||tb-50/NN	conj_and||ltbi-44/NNS||tb-50/NN	prep_from||control-39/VB||those-53/DT	nsubj||can-55/MD||those-53/DT	rcmod||those-53/DT||can-55/MD	neg||can-55/MD||not-56/RB	amod||disease-60/NN||active-58/JJ	nn||disease-60/NN||tb-59/NN	appos||those-53/DT||disease-60/NN	tuberculosis-4||mtb-40||no||a challenge in tuberculosis (tb) research is to develop a new immunological test that can help distinguish, among subjects responsive to quantiferon tb gold in tube (qft-it), those who are able to control mtb replication (remote ltbi, recent infection and past tb) from those who cannot (active tb disease).
det||prevalence-4/NN||the-2/DT	amod||prevalence-4/NN||global-3/JJ	prep_with||pose-22/VB||prevalence-4/NN	prep_of||prevalence-4/NN||diabetes-6/NN	auxpass||projected-9/VBN||being-7/VBG	advmod||projected-9/VBN||relentlessly-8/RB	vmod||diabetes-6/NN||projected-9/VBN	aux||rise-11/VB||to-10/TO	xcomp||projected-9/VBN||rise-11/VB	number||million-14/CD||438-13/CD	num||subjects-15/NNS||million-14/CD	prep_to||rise-11/VB||subjects-15/NNS	prep_by||rise-11/VB||2030-17/CD	nsubj||pose-22/VB||dr-19/NN	aux||pose-22/VB||will-20/MD	advmod||pose-22/VB||undoubtedly-21/RB	root||ROOT-0/null||pose-22/VB	det||concern-27/NN||a-23/DT	amod||concern-27/NN||major-24/JJ	amod||concern-27/NN||public-25/JJ	nn||concern-27/NN||health-26/NN	dobj||pose-22/VB||concern-27/NN	dr-19||rise-11||no_rel||with the global prevalence of diabetes being relentlessly projected to rise to 438 million subjects by 2030, dr will undoubtedly pose a major public health concern.
nsubj||observed-3/VBD||we-1/PRP	advmod||observed-3/VBD||serendipitous-2/RB	root||ROOT-0/null||observed-3/VBD	det||tolerability-6/NN||an-4/DT	nn||tolerability-6/NN||increase-5/NN	dobj||observed-3/VBD||tolerability-6/NN	det||response-10/NN||a-8/DT	amod||response-10/NN||rapid-9/JJ	dobj||observed-3/VBD||response-10/NN	conj_and||tolerability-6/NN||response-10/NN	prep_to||response-10/NN||therapy-12/NN	det||onset-16/NN||an-14/DT	amod||onset-16/NN||early-15/JJ	dobj||observed-3/VBD||onset-16/NN	conj_and||tolerability-6/NN||onset-16/NN	amod||activity-20/NN||antidepressant-18/JJ	nn||activity-20/NN||fluvoxamine-19/NN	prep_of||onset-16/NN||activity-20/NN	advmod||associated-22/VBN||when-21/WRB	advcl||observed-3/VBD||associated-22/VBN	prep_with||associated-22/VBN||amisulpride-24/NN	prep_in||associated-22/VBN||patients-26/NNS	amod||depressivedisorder-29/NN||major-28/JJ	prep_with||associated-22/VBN||depressivedisorder-29/NN	antidepressant-18||depressivedisorder-29||no_rel||we serendipitous observed an increase tolerability, a rapid response to therapy and an early onset of antidepressant fluvoxamine activity when associated with amisulpride in patients with major depressivedisorder.
det||patient-3/NN||a-1/DT	amod||patient-3/NN||43-year-old-2/JJ	nsubj||developed-4/VBD||patient-3/NN	root||ROOT-0/null||developed-4/VBD	amod||symptoms-7/NNS||severe-5/JJ	nn||symptoms-7/NNS||anaphylaxis-6/NN	dobj||developed-4/VBD||symptoms-7/NNS	prepc_within||developed-4/VBD||5â-9/VBG	dobj||5â-9/VBG||$-10/$	num||minutes-13/NN||10-12/CD	npadvmod||of-17/RB||minutes-13/NN	amod||s.c.-15/NN||after-14/IN	npadvmod||injection-16/RB||s.c.-15/NN	advmod||minutes-13/NN||injection-16/RB	dep||enoxaparin-18/CD||of-17/RB	num||$-10/$||enoxaparin-18/CD	anaphylaxis-6||enoxaparin-18||no_rel||a 43-year-old patient developed severe anaphylaxis symptoms within 5â $ `` 10 minutes after s.c. injection of enoxaparin .
nsubj||inoculated-5/VBD||chickens-1/NNS	conj_and||chickens-1/NNS||blackbirds-3/NNS	nsubj||inoculated-5/VBD||blackbirds-3/NNS	advmod||inoculated-5/VBD||directly-4/RB	root||ROOT-0/null||inoculated-5/VBD	mark||shed-9/VBD||with-6/IN	det||viruses-8/NNS||these-7/DT	nsubj||shed-9/VBD||viruses-8/NNS	nsubj||seroconverted-15/VBD||viruses-8/NNS	advcl||inoculated-5/VBD||shed-9/VBD	amod||amounts-11/NNS||significant-10/JJ	dobj||shed-9/VBD||amounts-11/NNS	prep_of||amounts-11/NNS||virus-13/NN	advcl||inoculated-5/VBD||seroconverted-15/VBD	conj_and||shed-9/VBD||seroconverted-15/VBD	nsubj||developed-20/VBD||rats-17/NNS	conj_and||rats-17/NNS||pigeons-19/NNS	nsubj||developed-20/VBD||pigeons-19/NNS	parataxis||inoculated-5/VBD||developed-20/VBD	amod||antibodies-22/NNS||antiviral-21/JJ	dobj||developed-20/VBD||antibodies-22/NNS	cc||failed-31/VBD||but-24/CC	prepc_except_for||failed-31/VBD||for-27/IN	num||pigeon-29/NN||one-28/CD	pobj||failed-31/VBD||pigeon-29/NN	parataxis||inoculated-5/VBD||failed-31/VBD	aux||shed-33/VB||to-32/TO	xcomp||failed-31/VBD||shed-33/VB	dobj||shed-33/VB||virus-34/NN	virus-34||viruses-8||no||chickens and blackbirds directly inoculated with these viruses shed significant amounts of virus and seroconverted; rats and pigeons developed antiviral antibodies, but, except for one pigeon, failed to shed virus.
det||study-3/NN||this-1/DT	amod||study-3/NN||prospective-2/JJ	nsubj||assessed-4/VBD||study-3/NN	root||ROOT-0/null||assessed-4/VBD	det||effects-6/NNS||the-5/DT	dobj||assessed-4/VBD||effects-6/NNS	amod||function-9/NN||auditory-8/JJ	prep_on||assessed-4/VBD||function-9/NN	det||dose-15/NN||a-11/DT	amod||dose-15/NN||standard-12/JJ	amod||dose-15/NN||3-day-13/JJ	amod||dose-15/NN||oral-14/JJ	prep_of||function-9/NN||dose-15/NN	prep_of||dose-15/NN||artesunate-17/NN	num||mg/kg/day-20/NN||4-19/CD	appos||artesunate-17/NN||mg/kg/day-20/NN	prep||assessed-4/VBD||combined-22/VBN	pcomp||combined-22/VBN||with-23/IN	pobj||with-23/IN||mefloquine-24/NN	num||mg/kg-27/NN||25-26/CD	appos||mefloquine-24/NN||mg/kg-27/NN	prep_in||mefloquine-24/NN||patients-30/NNS	amod||falciparummalaria-34/NN||acute-32/JJ	amod||falciparummalaria-34/NN||uncomplicated-33/JJ	prep_with||patients-30/NNS||falciparummalaria-34/NN	vmod||falciparummalaria-34/NN||treated-35/VBN	det||unit-41/NN||the-37/DT	amod||unit-41/NN||shoklo-38/JJ	nn||unit-41/NN||malaria-39/NN	nn||unit-41/NN||research-40/NN	prep_at||treated-35/VBN||unit-41/NN	det||border-46/NN||the-44/DT	amod||border-46/NN||thai-burmese-45/JJ	prep_on||treated-35/VBN||border-46/NN	malaria-39||mefloquine-24||yes||this prospective study assessed the effects on auditory function of a standard 3-day oral dose of artesunate (4 mg/kg/day) combined with mefloquine (25 mg/kg) in patients with acute uncomplicated falciparummalaria treated at the shoklo malaria research unit, on the thai-burmese border.
nsubjpass||documented-3/VBN||hbv-seropositivity-1/NN	auxpass||documented-3/VBN||was-2/VBD	dep||positive-17/JJ||documented-3/VBN	amod||participants-10/NNS||582-5/JJ	num||%-8/NN||29-7/CD	appos||participants-10/NNS||%-8/NN	prep_in||documented-3/VBN||participants-10/NNS	nsubj||positive-17/JJ||14-11/CD	num||%-14/NN||0.7-13/CD	appos||14-11/CD||%-14/NN	cop||positive-17/JJ||were-16/VBD	root||ROOT-0/null||positive-17/JJ	prep_for||positive-17/JJ||hbsag-19/NN	appos||hbsag-19/NN||452-21/NNP	num||%-24/NN||22.6-23/CD	appos||452-21/NNP||%-24/NN	prep_for||452-21/NNP||anti-hbc-27/CD	prep_for||452-21/NNP||116-29/CD	conj_and||anti-hbc-27/CD||116-29/CD	num||%-32/NN||5.8-31/CD	appos||anti-hbc-27/CD||%-32/NN	dep||hbsag-36/JJ||both-35/DT	prep_for||positive-17/JJ||hbsag-36/JJ	prep_for||positive-17/JJ||anti-hbc-38/JJ	conj_and||hbsag-36/JJ||anti-hbc-38/JJ	hbv--1||hbsag-36||yes||hbv-seropositivity was documented in 582 (29%) participants 14 (0.7%) were positive for hbsag, 452 (22.6%) for anti-hbc and 116 (5.8%) for both hbsag and anti-hbc.
amod||trials-4/NNS||controlled-2/JJ	amod||trials-4/NNS||clinical-3/JJ	prep_in||effective-8/JJ||trials-4/NNS	nsubj||effective-8/JJ||sertindole-5/NN	cop||effective-8/JJ||was-6/VBD	advmod||effective-8/JJ||more-7/RBR	root||ROOT-0/null||effective-8/JJ	prep_than||effective-8/JJ||placebo-10/NN	prepc_in||effective-8/JJ||reducing-12/VBG	amod||symptoms-16/NNS||positive-13/JJ	conj_and||positive-13/JJ||negative-15/JJ	amod||symptoms-16/NNS||negative-15/JJ	dobj||reducing-12/VBG||symptoms-16/NNS	mark||effective-22/JJ||whereas-18/IN	nsubj||effective-22/JJ||it-19/PRP	cop||effective-22/JJ||was-20/VBD	advmod||effective-22/JJ||as-21/RB	advcl||effective-8/JJ||effective-22/JJ	prep_as||effective-22/JJ||haloperidol-24/NN	prep_as||effective-22/JJ||risperidone-26/NN	conj_and||haloperidol-24/NN||risperidone-26/NN	det||symptoms-30/NNS||the-28/DT	amod||symptoms-30/NNS||positive-29/JJ	prep_against||effective-22/JJ||symptoms-30/NNS	prep_of||symptoms-30/NNS||schizophrenia-32/NN	schizophrenia-32||risperidone-26||yes||in controlled clinical trials sertindole was more effective than placebo in reducing positive and negative symptoms, whereas it was as effective as haloperidol and risperidone against the positive symptoms of schizophrenia.
amod||determinants-2/NNS||relevant-1/JJ	nsubjpass||discussed-12/VBN||determinants-2/NNS	det||spread-6/NN||the-4/DT	amod||spread-6/NN||future-5/JJ	prep_of||determinants-2/NNS||spread-6/NN	prep_of||spread-6/NN||hiv-8/NN	prep_among||hiv-8/NN||ivdu-10/NN	auxpass||discussed-12/VBN||are-11/VBP	root||ROOT-0/null||discussed-12/VBN	det||factors-18/NNS||the-15/DT	amod||factors-18/NNS||major-16/JJ	nn||factors-18/NNS||risk-17/NN	prep_including||discussed-12/VBN||factors-18/NNS	prep_for||factors-18/NNS||hivseropositivity-20/NN	det||modes-23/NNS||the-22/DT	prep_including||discussed-12/VBN||modes-23/NNS	conj_and||factors-18/NNS||modes-23/NNS	nn||transmission-26/NN||hiv-25/NN	prep_of||modes-23/NNS||transmission-26/NN	prep_including||discussed-12/VBN||aspects-29/NNS	conj_and||factors-18/NNS||aspects-29/NNS	det||history-33/NN||the-31/DT	amod||history-33/NN||natural-32/JJ	prep_of||aspects-29/NNS||history-33/NN	prep_of||history-33/NN||hivinfection-35/NN	prep_in||hivinfection-35/NN||ivdu-37/NN	hivinfection-35||hiv-25||no||relevant determinants of the future spread of hiv among ivdu are discussed, including the major risk factors for hivseropositivity, the modes of hiv transmission, and aspects of the natural history of hivinfection in ivdu.
dep||important-27/JJ||given-1/VBN	mark||suffer-9/VBP||that-2/IN	mwe||than-4/IN||more-3/JJR	quantmod||billion-6/CD||than-4/IN	number||billion-6/CD||2-5/CD	num||people-7/NNS||billion-6/CD	nsubj||suffer-9/VBP||people-7/NNS	advmod||suffer-9/VBP||worldwide-8/RB	pcomp||given-1/VBN||suffer-9/VBP	prep_from||suffer-9/VBP||irondeficiency-11/NN	mark||one-16/CD||that-13/IN	nsubj||one-16/CD||ironoverload-14/NN	cop||one-16/CD||is-15/VBZ	pcomp||given-1/VBN||one-16/CD	conj_and||suffer-9/VBP||one-16/CD	det||diseases-23/NNS||the-18/DT	advmod||common-20/JJ||most-19/RBS	amod||diseases-23/NNS||common-20/JJ	amod||diseases-23/NNS||single-gene-21/JJ	amod||diseases-23/NNS||inherited-22/VBN	prep_of||one-16/CD||diseases-23/NNS	nsubj||important-27/JJ||it-25/PRP	nsubj||understand-29/VB||it-25/PRP	cop||important-27/JJ||is-26/VBZ	root||ROOT-0/null||important-27/JJ	aux||understand-29/VB||to-28/TO	xcomp||important-27/JJ||understand-29/VB	mark||influence-35/VB||whether-30/IN	nn||status-33/NN||host-31/NN	nn||status-33/NN||iron-32/NN	nsubj||influence-35/VB||status-33/NN	aux||influence-35/VB||may-34/MD	ccomp||understand-29/VB||influence-35/VB	advmod||glabrata-37/JJ||c.-36/RB	amod||progression-40/NN||glabrata-37/JJ	amod||progression-40/NN||infectious-38/JJ	nn||progression-40/NN||disease-39/NN	dobj||influence-35/VB||progression-40/NN	irondeficiency-11||iron-32||yes||given that more than 2 billion people worldwide suffer from irondeficiency and that ironoverload is one of the most common single-gene inherited diseases , it is important to understand whether host iron status may influence c. glabrata infectious disease progression .
prep_in||revealed-10/VBD||contrast-2/NN	det||dlst-5/NN||the-4/DT	prep_to||contrast-2/NN||dlst-5/NN	det||test-9/NN||a-7/DT	nn||test-9/NN||provocation-8/NN	nsubj||revealed-10/VBD||test-9/NN	root||ROOT-0/null||revealed-10/VBD	mark||induced-13/VBN||that-11/IN	nsubj||induced-13/VBN||amoxicillin-12/NNP	ccomp||revealed-10/VBD||induced-13/VBN	det||drugallergy-15/NN||the-14/DT	dobj||induced-13/VBN||drugallergy-15/NN	drugallergy-15||amoxicillin-12||no||in contrast to the dlst, a provocation test revealed that amoxicillin induced the drugallergy.
advmod||assessed-3/VBN||adiposity-1/RB	auxpass||assessed-3/VBN||was-2/VBD	root||ROOT-0/null||assessed-3/VBN	prep_in||assessed-3/VBN||terms-5/NNS	prep_of||terms-5/NNS||bmi-7/NN	appos||bmi-7/NN||body-9/NN	num||%-11/NN||fat-10/CD	nsubjpass||assessed-3/VBN||%-11/NN	amod||mass-14/NN||fat-13/JJ	appos||%-11/NN||mass-14/NN	amod||index-18/NN||fat-16/JJ	amod||index-18/NN||mass-17/JJ	appos||%-11/NN||index-18/NN	conj_and||mass-14/NN||index-18/NN	amod||circumference-21/NN||waist-20/JJ	appos||%-11/NN||circumference-21/NN	conj_and||mass-14/NN||circumference-21/NN	adiposity-1||fat-16||no_rel||adiposity was assessed in terms of bmi, body fat %, fat mass, fat mass index and waist circumference.
det||majority-3/NN||the-2/DT	prep_in||detectable-21/JJ||majority-3/NN	det||segments-8/NNS||the-5/DT	amod||segments-8/NNS||evaluated-6/JJ	amod||segments-8/NNS||coronary-7/JJ	prep_of||majority-3/NN||segments-8/NNS	nn||patients-11/NNS||cad-10/NN	prep_in||segments-8/NNS||patients-11/NNS	nsubj||detectable-21/JJ||lge-13/NN	det||wall-18/NN||the-15/DT	amod||wall-18/NN||coronary-16/JJ	nn||wall-18/NN||vessel-17/NN	prep_of||lge-13/NN||wall-18/NN	cop||detectable-21/JJ||was-19/VBD	advmod||detectable-21/JJ||already-20/RB	root||ROOT-0/null||detectable-21/JJ	xcomp||detectable-21/JJ||30â-22/VBG	dobj||30â-22/VBG||$-23/$	advmod||minutes-26/NNS||45-25/RB	dep||contrastagent-31/CD||minutes-26/NNS	prep_after||minutes-26/NNS||administration-28/NN	prep_of||administration-28/NN||the-30/DT	num||$-23/$||contrastagent-31/CD	contrastagent-31||cad-10||no_rel||in the majority of the evaluated coronary segments in cad patients, lge of the coronary vessel wall was already detectable 30â45 minutes after administration of the contrastagent.
amod||responses-2/NNS||cytokine-1/JJ	nsubj||comparable-10/JJ||responses-2/NNS	vmod||responses-2/NNS||induced-3/VBN	amod||viruses-6/NNS||pdmh1n1-5/JJ	agent||induced-3/VBN||viruses-6/NNS	prep_in||viruses-6/NNS||vitro-8/NNP	cop||comparable-10/JJ||are-9/VBP	root||ROOT-0/null||comparable-10/JJ	amod||influenzaviruses-14/NNS||other-12/JJ	amod||influenzaviruses-14/NNS||seasonal-13/JJ	prep_to||comparable-10/JJ||influenzaviruses-14/NNS	vmod||influenzaviruses-14/NNS||suggesting-15/VBG	det||dysregulation-18/NN||the-16/DT	amod||dysregulation-18/NN||cytokine-17/JJ	dobj||suggesting-15/VBG||dysregulation-18/NN	mark||feature-27/NN||as-19/IN	csubj||feature-27/NN||seen-20/VBN	amod||infection-23/NN||h5n1-22/JJ	prep_in||seen-20/VBN||infection-23/NN	cop||feature-27/NN||is-24/VBZ	neg||feature-27/NN||not-25/RB	det||feature-27/NN||a-26/DT	advcl||suggesting-15/VBG||feature-27/NN	det||virus-31/NN||the-29/DT	amod||virus-31/NN||pdmh1n1-30/JJ	prep_of||feature-27/NN||virus-31/NN	virus-31||viruses-6||no||cytokine responses induced by pdmh1n1 viruses in vitro are comparable to other seasonal influenzaviruses suggesting the cytokine dysregulation as seen in h5n1 infection is not a feature of the pdmh1n1 virus.
amod||effects-2/NNS||direct-1/JJ	nsubjpass||evaluated-9/VBN||effects-2/NNS	prep_of||effects-2/NNS||calcitonin-4/NN	nn||cartilage-7/NN||articular-6/NN	prep_on||calcitonin-4/NN||cartilage-7/NN	auxpass||evaluated-9/VBN||were-8/VBD	root||ROOT-0/null||evaluated-9/VBN	dep||measurement-13/NN||1-11/LS	agent||evaluated-9/VBN||measurement-13/NN	nn||synthesis-16/NN||proteoglycan-15/NN	prep_of||measurement-13/NN||synthesis-16/NN	prep_by||synthesis-16/NN||incorporation-18/NN	prep_of||incorporation-18/NN||radioactive-20/NN	vmod||radioactive-20/NN||labeled-21/VBN	amod||ci-27/NN||35so4-22/JJ	amod||ci-27/NN||-LSB--23/JJ	num||ci-27/NN||5-24/CD	nn||ci-27/NN||î-25/NN	num||ci-27/NN||1/4-26/CD	dobj||labeled-21/VBN||ci-27/NN	xcomp||labeled-21/VBN||-RSB--28/VBG	dep||quantification-31/NN||2-29/LS	dobj||-RSB--28/VBG||quantification-31/NN	nn||formation-34/NN||collagen-type-ii-33/NN	prep_of||quantification-31/NN||formation-34/NN	prep_by||formation-34/NN||pro-peptides-36/NNS	nn||elisa-44/NN||collagen-38/NN	nn||elisa-44/NN||type-39/NN	nn||elisa-44/NN||ii-40/NN	nn||elisa-44/NN||piinp-42/NN	prep_of||pro-peptides-36/NNS||elisa-44/NN	dep||expression-49/NN||3-46/LS	nn||expression-49/NN||qpcr-48/NN	appos||elisa-44/NN||expression-49/NN	det||receptor-53/NN||the-51/DT	nn||receptor-53/NN||calcitonin-52/NN	prep_of||expression-49/NN||receptor-53/NN	nn||chondrocytes-56/NNS||oa-55/NN	prep_in||receptor-53/NN||chondrocytes-56/NNS	vmod||chondrocytes-56/NNS||using-57/VBG	num||pairs-61/NNS||four-58/CD	amod||pairs-61/NNS||individual-59/JJ	nn||pairs-61/NNS||primer-60/NN	dobj||using-57/VBG||pairs-61/NNS	dep||activation-65/NN||4-63/LS	appos||quantification-31/NN||activation-65/NN	det||camp-68/NN||the-67/DT	prep_of||activation-65/NN||camp-68/NN	vmod||camp-68/NN||signaling-69/VBG	advmod||signaling-69/VBG||pathway-70/RB	agent||signaling-69/VBG||eia-72/NN	dep||investigations-77/NNS||5-75/CD	agent||evaluated-9/VBN||investigations-77/NNS	conj_and||measurement-13/NN||investigations-77/NNS	amod||activity-80/NN||metabolic-79/JJ	prep_of||investigations-77/NNS||activity-80/NN	prep_by||activity-80/NN||alamarblue-82/NN	calcitonin-52||eia-72||no_rel||direct effects of calcitonin on articular cartilage were evaluated by 1) measurement of proteoglycan synthesis by incorporation of radioactive labeled 35so4 [5 î¼ci] 2) quantification of collagen-type-ii formation by pro-peptides of collagen type ii (piinp) elisa, 3) qpcr expression of the calcitonin receptor in oa chondrocytes using four individual primer pairs, 4) activation of the camp signaling pathway by eia and, 5) investigations of metabolic activity by alamarblue.
mark||cause-6/VBP||although-1/IN	quantmod||1400-3/CD||over-2/IN	num||serovars-5/NNS||1400-3/CD	nn||serovars-5/NNS||salmonella-4/NN	nsubj||cause-6/VBP||serovars-5/NNS	advcl||cause-24/VB||cause-6/VBP	advmod||self-limited-8/JJ||usually-7/RB	amod||gastroenteritis-9/NNS||self-limited-8/JJ	dobj||cause-6/VBP||gastroenteritis-9/NNS	prep_in||gastroenteritis-9/NNS||humans-11/NNS	det||salmonellatyphi-18/NNS||a-13/DT	amod||salmonellatyphi-18/NNS||few-14/JJ	dep||salmonellatyphi-18/NNS||e.g.-16/NNP	appos||humans-11/NNS||salmonellatyphi-18/NNS	nn||paratyphi-21/NN||s.-20/NN	appos||humans-11/NNS||paratyphi-21/NN	conj_and||salmonellatyphi-18/NNS||paratyphi-21/NN	dep||gastroenteritis-9/NNS||c-22/SYM	root||ROOT-0/null||cause-24/VB	acomp||cause-24/VB||typhoid-25/JJ	det||infection-31/NN||a-27/DT	advmod||fatal-29/JJ||potentially-28/RB	amod||infection-31/NN||fatal-29/JJ	amod||infection-31/NN||systemic-30/JJ	dobj||cause-24/VB||infection-31/NN	typhoid-25||salmonellatyphi-18||no||although over 1400 salmonella serovars cause usually self-limited gastroenteritis in humans , a few , e.g. , salmonellatyphi and s. paratyphi c , cause typhoid , a potentially fatal systemic infection .
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||determine-8/VB||aim-2/NN	nsubj||prednisone-22/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||determine-8/VB||to-7/TO	xcomp||was-6/VBD||determine-8/VB	mark||pharmacokinetics-14/VBZ||whether-9/IN	nsubj||pharmacokinetics-14/VBZ||mycophenolatemofetil-10/NN	appos||mycophenolatemofetil-10/NN||mmf-12/NN	ccomp||determine-8/VB||pharmacokinetics-14/VBZ	dep||pharmacokinetics-14/VBZ||pk-16/NN	amod||mmf-20/NN||combined-19/VBN	prep_under||pharmacokinetics-14/VBZ||mmf-20/NN	xcomp||was-6/VBD||prednisone-22/VB	conj_and||determine-8/VB||prednisone-22/VB	amod||therapy-24/NN||remission-maintenance-23/JJ	nsubj||predict-26/VB||therapy-24/NN	aux||predict-26/VB||can-25/MD	ccomp||prednisone-22/VB||predict-26/VB	dobj||predict-26/VB||systemiclupuserythematosus-27/NNS	appos||systemiclupuserythematosus-27/NNS||sle-29/NN	amod||flares-32/NNS||clinical-31/JJ	dobj||determine-8/VB||flares-32/NNS	prednisone-22||systemiclupuserythematosus-27||no_rel||the aim of this study was to determine whether mycophenolatemofetil (mmf) pharmacokinetics (pk) under combined mmf and prednisone remission-maintenance therapy can predict systemiclupuserythematosus (sle) clinical flares.
nn||design-2/NN||research-1/NN	nsubj||â-5/VBP||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||â-5/VBP||methods-4/NNS	root||ROOT-0/null||â-5/VBP	dobj||â-5/VBP||$-6/$	nsubj||sample-12/NN||this-8/DT	cop||sample-12/NN||was-9/VBD	det||sample-12/NN||a-10/DT	amod||sample-12/NN||cross-sectional-11/JJ	rcmod||$-6/$||sample-12/NN	amod||individuals-15/NNS||281-14/JJ	prep_of||sample-12/NN||individuals-15/NNS	amod||metabolism-19/NN||normal-17/JJ	nn||metabolism-19/NN||glucose-18/NN	prep_with||individuals-15/NNS||metabolism-19/NN	discourse||metabolism-19/NN||ngm-21/UH	num||individuals-25/NNS||181-24/CD	dobj||â-5/VBP||individuals-25/NNS	conj_and||$-6/$||individuals-25/NNS	amod||metabolism-29/NN||impaired-27/VBN	nn||metabolism-29/NN||glucose-28/NN	prep_with||individuals-25/NNS||metabolism-29/NN	discourse||metabolism-29/NN||igm-31/UH	num||subjects-36/NNS||107-35/CD	dobj||â-5/VBP||subjects-36/NNS	conj_and||$-6/$||subjects-36/NNS	prep_with||subjects-36/NNS||type2diabetes-38/CD	glucose-28||cross--1||no_rel||research design and methods âthis was a cross-sectional sample of 281 individuals with normal glucose metabolism (ngm), 181 individuals with impaired glucose metabolism (igm), and 107 subjects with type2diabetes.
advmod||considered-5/VBN||however-1/RB	nsubjpass||considered-5/VBN||nsaids-3/NNS	nsubj||effective-9/JJ||nsaids-3/NNS	auxpass||considered-5/VBN||are-4/VBP	root||ROOT-0/null||considered-5/VBN	aux||effective-9/JJ||to-6/TO	cop||effective-9/JJ||be-7/VB	advmod||effective-9/JJ||more-8/RBR	xcomp||considered-5/VBN||effective-9/JJ	prep_than||effective-9/JJ||acetaminophen-11/NN	prep_for||effective-9/JJ||relief-13/NN	prep_of||relief-13/NN||pain-15/NN	acetaminophen-11||pain-15||no_rel||however, nsaids are considered to be more effective than acetaminophen for relief of pain.
nsubj||erythroid-5/VBD||activation-1/NN	amod||factor-4/NN||nuclear-3/JJ	prep_of||activation-1/NN||factor-4/NN	root||ROOT-0/null||erythroid-5/VBD	amod||factor-7/NN||2-related-6/JJ	nsubj||belongs-13/VBZ||factor-7/NN	nsubj||strategy-25/NN||factor-7/NN	appos||factor-7/NN||nrf2-9/NNP	rcmod||factor-7/NN||belongs-13/VBZ	det||family-21/NN||the-15/DT	amod||family-21/NN||basic-16/JJ	amod||family-21/NN||leucine-17/JJ	nn||family-21/NN||zipper-18/NN	nn||family-21/NN||transcription-19/NN	nn||family-21/NN||factor-20/NN	prep_to||belongs-13/VBZ||family-21/NN	cop||strategy-25/NN||is-23/VBZ	det||strategy-25/NN||a-24/DT	ccomp||erythroid-5/VBD||strategy-25/NN	nn||phytochemicals-29/NNS||cancer-27/NN	nn||phytochemicals-29/NNS||chemopreventive-28/NN	prep_for||strategy-25/NN||phytochemicals-29/NNS	cancer-27||leucine-17||no_rel||activation of nuclear factor erythroid 2-related factor (nrf2), which belongs to the basic leucine zipper transcription factor family, is a strategy for cancer chemopreventive phytochemicals.
amod||dysfunction-2/NN||endothelial-1/JJ	nsubj||present-5/JJ||dysfunction-2/NN	nsubjpass||induced-15/VBN||dysfunction-2/NN	cop||present-5/JJ||is-3/VBZ	advmod||present-5/JJ||frequently-4/RB	root||ROOT-0/null||present-5/JJ	prep_in||present-5/JJ||individuals-7/NNS	prep_with||individuals-7/NNS||insulinresistance-9/NN	prep_with||individuals-7/NNS||type2diabetes-11/NNS	conj_or||insulinresistance-9/NN||type2diabetes-11/NNS	aux||induced-15/VBN||can-13/MD	auxpass||induced-15/VBN||be-14/VB	conj_and||present-5/JJ||induced-15/VBN	amod||meals-20/NNS||high-fat-17/JJ	conj_or||high-fat-17/JJ||high-carbohydrate-19/JJ	amod||meals-20/NNS||high-carbohydrate-19/JJ	agent||induced-15/VBN||meals-20/NNS	type2diabetes-11||fat--1||no_rel||endothelial dysfunction is frequently present in individuals with insulinresistance or type2diabetes and can be induced by high-fat or high-carbohydrate meals.
nn||mycobacteriumtuberculosis-2/NNS||understanding-1/NN	nsubj||essential-8/JJ||mycobacteriumtuberculosis-2/NNS	nsubj||guide-10/VB||mycobacteriumtuberculosis-2/NNS	appos||mycobacteriumtuberculosis-2/NNS||mtb-4/NN	advmod||essential-8/JJ||transmission-6/RB	cop||essential-8/JJ||is-7/VBZ	root||ROOT-0/null||essential-8/JJ	aux||guide-10/VB||to-9/TO	xcomp||essential-8/JJ||guide-10/VB	amod||strategies-14/NNS||efficient-11/JJ	nn||strategies-14/NNS||tuberculosis-12/NNP	nn||strategies-14/NNS||control-13/NN	dobj||guide-10/VB||strategies-14/NNS	tuberculosis-12||mtb-4||no||understanding mycobacteriumtuberculosis (mtb) transmission is essential to guide efficient tuberculosis control strategies.
nsubj||aimed-2/VBD||we-1/PRP	nsubj||investigate-4/VB||we-1/PRP	root||ROOT-0/null||aimed-2/VBD	aux||investigate-4/VB||to-3/TO	xcomp||aimed-2/VBD||investigate-4/VB	det||effect-7/NN||the-5/DT	amod||effect-7/NN||long-term-6/JJ	dobj||investigate-4/VB||effect-7/NN	prep_of||effect-7/NN||metformin-9/NN	det||control-13/NN||the-11/DT	amod||control-13/NN||bloodglucose-12/JJ	prep_on||investigate-4/VB||control-13/NN	amod||patients-16/NNS||non-obese-15/JJ	prep_in||control-13/NN||patients-16/NNS	prep_with||investigate-4/VB||type2diabetesmellitus-18/CD	type2diabetesmellitus-18||metformin-9||yes||we aimed to investigate the long-term effect of metformin on the bloodglucose control in non-obese patients with type2diabetesmellitus.
advmod||investigated-4/VBD||here-1/RB	nsubj||investigated-4/VBD||we-3/PRP	root||ROOT-0/null||investigated-4/VBD	det||expression-6/NN||the-5/DT	dobj||investigated-4/VBD||expression-6/NN	prep_of||expression-6/NN||cd39-8/NNS	amod||cells-13/NNS||cd4-10/JJ	amod||cells-13/NNS||+-11/JJ	nn||cells-13/NNS||t-12/NN	prep_on||cd39-8/NNS||cells-13/NNS	det||cohort-16/NN||a-15/DT	prep_from||investigated-4/VBD||cohort-16/NN	nn||patients-19/NNS||ham/tsp-18/NN	prep_of||cohort-16/NN||patients-19/NNS	amod||carriers-23/NNS||htlv-1-21/JJ	amod||carriers-23/NNS||asymptomatic-22/JJ	prep_from||investigated-4/VBD||carriers-23/NNS	conj_and||cohort-16/NN||carriers-23/NNS	appos||carriers-23/NNS||ac-25/NN	amod||controls-31/NNS||matched-29/VBN	amod||controls-31/NNS||uninfected-30/JJ	prep_from||investigated-4/VBD||controls-31/NNS	conj_and||cohort-16/NN||controls-31/NNS	ham--1||htlv-1-21||no||here, we investigated the expression of cd39 on cd4+ t cells from a cohort of ham/tsp patients, htlv-1 asymptomatic carriers (ac), and matched uninfected controls.
det||pandemic-11/NN||the-1/DT	nn||pandemic-11/NN||humanimmunodeficiencyvirus-2/NNS	appos||humanimmunodeficiencyvirus-2/NNS||hiv-4/NN	amod||pandemic-11/NN||/-6/JJ	nn||pandemic-11/NN||acquiredimmunedeficiencysyndrome-7/NN	appos||pandemic-11/NN||aids-9/NNS	nsubj||has-12/VBZ||pandemic-11/NN	root||ROOT-0/null||has-12/VBZ	amod||effects-14/NNS||pervasive-13/JJ	dobj||has-12/VBZ||effects-14/NNS	prep_on||effects-14/NNS||culture-16/NN	prep_on||effects-14/NNS||economics-18/NNS	conj_and||culture-16/NN||economics-18/NNS	prep_on||effects-14/NNS||policy-20/NN	conj_and||culture-16/NN||policy-20/NN	amod||development-24/NN||human-23/JJ	prep_on||effects-14/NNS||development-24/NN	conj_and||culture-16/NN||development-24/NN	acquiredimmunedeficiencysyndrome-7||humanimmunodeficiencyvirus-2||no||the humanimmunodeficiencyvirus (hiv)/ acquiredimmunedeficiencysyndrome (aids) pandemic has pervasive effects on culture, economics, policy, and human development.
det||surveillance-3/NN||this-1/DT	amod||surveillance-3/NN||post-marketing-2/JJ	nsubj||confirms-12/VBZ||surveillance-3/NN	nsubj||highlights-24/VBZ||surveillance-3/NN	prep_of||surveillance-3/NN||levofloxacin-5/NN	vmod||surveillance-3/NN||conducted-7/VBN	num||years-10/NNS||4-9/CD	prep_over||conducted-7/VBN||years-10/NNS	root||ROOT-0/null||confirms-12/VBZ	det||safety-14/NN||the-13/DT	dobj||confirms-12/VBZ||safety-14/NN	dobj||confirms-12/VBZ||efficacy-16/NN	conj_and||safety-14/NN||efficacy-16/NN	prep_of||safety-14/NN||levofloxacin-18/NN	amod||use-22/NN||regular-20/JJ	amod||use-22/NN||clinical-21/JJ	prep_in||confirms-12/VBZ||use-22/NN	conj_and||confirms-12/VBZ||highlights-24/VBZ	mark||treatment-30/NN||that-25/IN	nsubj||treatment-30/NN||levofloxacin-26/NN	cop||treatment-30/NN||is-27/VBZ	det||treatment-30/NN||a-28/DT	amod||treatment-30/NN||promising-29/JJ	ccomp||highlights-24/VBZ||treatment-30/NN	det||variety-33/NN||a-32/DT	prep_for||treatment-30/NN||variety-33/NN	amod||ocularbacterialinfections-36/NNS||external-35/JJ	prep_of||variety-33/NN||ocularbacterialinfections-36/NNS	ocularbacterialinfections-36||levofloxacin-26||yes||this post-marketing surveillance of levofloxacin, conducted over 4 years, confirms the safety and efficacy of levofloxacin in regular clinical use and highlights that levofloxacin is a promising treatment for a variety of external ocularbacterialinfections.
prep_in||found-14/VBD||addition-2/NN	vmod||found-14/VBD||using-4/VBG	det||cox-6/NN||a-5/DT	poss||model-11/NN||cox-6/NN	amod||model-11/NN||proportional-8/JJ	nn||model-11/NN||hazards-9/NNS	nn||model-11/NN||regression-10/NN	dobj||using-4/VBG||model-11/NN	nsubj||found-14/VBD||we-13/PRP	root||ROOT-0/null||found-14/VBD	mark||factor-33/NN||that-15/IN	det||level-20/NN||an-16/DT	amod||level-20/NN||elevated-17/JJ	nn||level-20/NN||opn-18/NN	nn||level-20/NN||protein-19/NN	nsubj||factor-33/NN||level-20/NN	det||serum-23/NN||the-22/DT	prep_in||level-20/NN||serum-23/NN	nn||extracts-27/NNS||tumor-25/NN	nn||extracts-27/NNS||tissue-26/NN	prep_in||level-20/NN||extracts-27/NNS	conj_and||serum-23/NN||extracts-27/NNS	cop||factor-33/NN||is-28/VBZ	det||factor-33/NN||a-29/DT	amod||factor-33/NN||significant-30/JJ	amod||factor-33/NN||negative-31/JJ	amod||factor-33/NN||prognostic-32/JJ	ccomp||found-14/VBD||factor-33/NN	prep_for||factor-33/NN||patients-35/NNS	prep_with||patients-35/NNS||sts-37/NN	tumor-25||sts-37||no||in addition, using a cox's proportional hazards regression model, we found that an elevated opn protein level in the serum and tumor tissue extracts is a significant negative prognostic factor for patients with sts.
num||specimens-3/NNS||33-2/CD	prep_of||%-27/NN||specimens-3/NNS	amod||results-7/NNS||concurrent-5/JJ	nn||results-7/NNS||dst-6/NN	prep_with||specimens-3/NNS||results-7/NNS	nsubj||%-27/NN||sensitivity-9/NN	det||assay-13/NN||the-11/DT	amod||assay-13/NN||mods-12/JJ	prep_of||sensitivity-9/NN||assay-13/NN	prep_for||assay-13/NN||detection-15/NN	prep_of||detection-15/NN||resistance-17/NN	prep_to||resistance-17/NN||isoniazid-19/NN	prep_to||resistance-17/NN||rifampin-21/NN	conj_and||isoniazid-19/NN||rifampin-21/NN	prep_to||resistance-17/NN||mdr-tb-24/NN	conj_and||isoniazid-19/NN||mdr-tb-24/NN	cop||%-27/NN||was-25/VBD	num||%-27/NN||88-26/CD	root||ROOT-0/null||%-27/NN	num||%-30/NN||95-29/CD	npadvmod||ci-31/JJ||%-30/NN	dep||68â-33/NNS||ci-31/JJ	dep||%-27/NN||68â-33/NNS	dep||%-37/NN||$-34/$	num||$-34/$||97-36/CD	amod||68â-33/NNS||%-37/NN	num||%-41/NN||96-40/CD	conj_and||%-27/NN||%-41/NN	num||%-44/NN||95-43/CD	npadvmod||ci-45/JJ||%-44/NN	dep||79â-47/NNS||ci-45/JJ	dep||%-41/NN||79â-47/NNS	dep||%-51/NN||$-48/$	num||$-48/$||100-50/CD	amod||79â-47/NNS||%-51/NN	num||%-56/NN||91-55/CD	conj_and||%-27/NN||%-56/NN	num||%-59/NN||95-58/CD	npadvmod||ci-60/JJ||%-59/NN	dep||72â-62/NNS||ci-60/JJ	dep||%-56/NN||72â-62/NNS	dep||%-66/NN||$-63/$	num||$-63/$||99-65/CD	amod||72â-62/NNS||%-66/NN	advmod||%-27/NN||respectively-69/RB	nsubj||%-74/NN||specificity-71/NN	cop||%-74/NN||was-72/VBD	num||%-74/NN||89-73/CD	parataxis||%-27/NN||%-74/NN	num||%-77/NN||95-76/CD	npadvmod||ci-78/JJ||%-77/NN	dep||52â-80/NNS||ci-78/JJ	dep||%-74/NN||52â-80/NNS	dep||%-84/NN||$-81/$	num||$-81/$||100-83/CD	amod||52â-80/NNS||%-84/NN	num||%-88/NN||89-87/CD	parataxis||%-27/NN||%-88/NN	conj_and||%-74/NN||%-88/NN	num||%-91/NN||95-90/CD	npadvmod||ci-92/JJ||%-91/NN	dep||52â-94/NNS||ci-92/JJ	dep||%-88/NN||52â-94/NNS	dep||%-98/NN||$-95/$	num||$-95/$||100-97/CD	amod||52â-94/NNS||%-98/NN	num||%-103/NN||90-102/CD	parataxis||%-27/NN||%-103/NN	conj_and||%-74/NN||%-103/NN	num||%-106/NN||95-105/CD	npadvmod||ci-107/JJ||%-106/NN	dep||56â-109/NNS||ci-107/JJ	dep||%-103/NN||56â-109/NNS	dep||%-113/NN||$-110/$	num||$-110/$||100-112/CD	amod||56â-109/NNS||%-113/NN	advmod||%-74/NN||respectively-116/RB	tb--1||isoniazid-19||yes||of 33 specimens with concurrent dst results, sensitivity of the mods assay for detection of resistance to isoniazid, rifampin, and mdr-tb was 88% (95% ci, 68â97%), 96% (95% ci, 79â100%), and 91% (95% ci, 72â99%), respectively; specificity was 89% (95% ci, 52â100%), 89% (95% ci, 52â100%), and 90% (95% ci, 56â100%), respectively.
amod||analysis-3/NN||multivariate-2/JJ	prep_in||factor-11/NN||analysis-3/NN	amod||resistance-6/NN||clopidogrel-5/JJ	nsubj||factor-11/NN||resistance-6/NN	cop||factor-11/NN||was-7/VBD	det||factor-11/NN||a-8/DT	amod||factor-11/NN||significant-9/JJ	nn||factor-11/NN||risk-10/NN	root||ROOT-0/null||factor-11/NN	amod||cerebralischemia-14/NN||post-procedural-13/JJ	prep_for||factor-11/NN||cerebralischemia-14/NN	cerebralischemia-14||clopidogrel-5||yes||in multivariate analysis, clopidogrel resistance was a significant risk factor for post-procedural cerebralischemia.
nsubj||proved-13/VBN||drugs-1/NNS	amod||analogues-4/NNS||thalidomide-3/JJ	prep_like||drugs-1/NNS||analogues-4/NNS	amod||drugs-11/NNS||pentoxifylline-6/JJ	amod||drugs-11/NNS||selective-8/JJ	nn||drugs-11/NNS||cytokine-9/NN	nn||drugs-11/NNS||inhibitory-10/NN	appos||analogues-4/NNS||drugs-11/NNS	aux||proved-13/VBN||have-12/VBP	root||ROOT-0/null||proved-13/VBN	acomp||proved-13/VBN||effective-14/JJ	prepc_in||effective-14/JJ||controlling-16/VBG	amod||reaction-18/NN||type-2-17/JJ	dobj||controlling-16/VBG||reaction-18/NN	nn||patients-21/NNS||leprosy-20/NNP	prep_in||controlling-16/VBG||patients-21/NNS	leprosy-20||thalidomide-3||yes||drugs like thalidomide analogues, pentoxifylline, selective cytokine inhibitory drugs have proved effective in controlling type-2 reaction in leprosy patients.
det||risk-2/NN||the-1/DT	nsubjpass||thought-16/VBN||risk-2/NN	nsubjpass||increased-19/VBN||risk-2/NN	nn||tb-6/NN||tuberculosis-4/NNP	prep_of||risk-2/NN||tb-6/NN	prep_in||tb-6/NN||patients-9/NNS	prep_with||patients-9/NNS||rheumatoidarthritis-11/NNS	appos||rheumatoidarthritis-11/NNS||ra-13/NN	auxpass||thought-16/VBN||is-15/VBZ	root||ROOT-0/null||thought-16/VBN	aux||increased-19/VBN||to-17/TO	auxpass||increased-19/VBN||be-18/VB	xcomp||thought-16/VBN||increased-19/VBN	amod||therapy-27/NN||anti-tumour-21/JJ	nn||therapy-27/NN||necrosis-22/NNS	nn||therapy-27/NN||factor-23/NN	dep||therapy-27/NN||anti-tnf-25/JJ	prep_following||increased-19/VBN||therapy-27/NN	det||risk-33/NN||a-30/DT	amod||risk-33/NN||proposed-31/VBN	nn||risk-33/NN||differential-32/NN	prep_with||thought-16/VBN||risk-33/NN	det||etanercept-38/NN||the-35/DT	amod||etanercept-38/NN||anti-tnf-36/JJ	nn||etanercept-38/NN||drugs-37/NNS	prep_between||risk-33/NN||etanercept-38/NN	appos||etanercept-38/NN||eta-40/NN	prep_between||risk-33/NN||infliximab-43/NN	conj_and||etanercept-38/NN||infliximab-43/NN	appos||infliximab-43/NN||inf-45/NN	prep_between||risk-33/NN||adalimumab-48/NN	conj_and||etanercept-38/NN||adalimumab-48/NN	appos||adalimumab-48/NN||ada-50/NN	rheumatoidarthritis-11||adalimumab-48||yes||the risk of tuberculosis (tb) in patients with rheumatoidarthritis (ra) is thought to be increased following anti-tumour necrosis factor (anti-tnf) therapy, with a proposed differential risk between the anti-tnf drugs etanercept (eta), infliximab (inf) and adalimumab (ada).
advmod||suppressed-5/VBD||additionally-1/RB	amod||nac-5-htr4-4/NNS||inactivating-3/VBG	nsubj||suppressed-5/VBD||nac-5-htr4-4/NNS	root||ROOT-0/null||suppressed-5/VBD	poss||preference-8/NN||ecstasy-6/NN	dobj||suppressed-5/VBD||preference-8/NN	vmod||suppressed-5/VBD||strengthening-10/VBG	det||facet-13/NN||the-11/DT	amod||facet-13/NN||rewarding-12/JJ	dobj||strengthening-10/VBG||facet-13/NN	prep_of||facet-13/NN||anorexia-15/NNP	ecstasy-6||anorexia-15||no_rel||additionally, inactivating nac-5-htr4 suppressed ecstasy's preference, strengthening the rewarding facet of anorexia.
nsubj||describe-2/VBP||we-1/PRP	root||ROOT-0/null||describe-2/VBP	det||estimation-4/NN||these-3/DT	nsubj||processes-5/VBZ||estimation-4/NN	nsubj||present-7/VB||estimation-4/NN	ccomp||describe-2/VBP||processes-5/VBZ	ccomp||describe-2/VBP||present-7/VB	conj_and||processes-5/VBZ||present-7/VB	det||results-9/NNS||the-8/DT	dobj||present-7/VB||results-9/NNS	prepc_of||results-9/NNS||chinaâ-11/VBG	dobj||chinaâ-11/VBG||$-12/$	num||$-12/$||-13/CD	nsubj||hiv/aids-15/VBZ||s-14/PRP	rcmod||$-12/$||hiv/aids-15/VBZ	nn||exercises-17/NNS||estimation-16/NN	dobj||hiv/aids-15/VBZ||exercises-17/NNS	num||2009-21/CD||2003-19/CD	dep||2009-21/CD||to-20/TO	prep_from||hiv/aids-15/VBZ||2009-21/CD	aids--1||hiv--1||no||we describe these estimation processes and present the results of chinaâs hiv/aids estimation exercises from 2003 to 2009.
det||protein-4/NN||the-1/DT	amod||protein-4/NN||interferon-induced-2/JJ	amod||protein-4/NN||bst-2-3/JJ	nsubj||has-5/VBZ||protein-4/NN	ccomp||ssarcomaâ-18/VBZ||has-5/VBZ	det||ability-8/NN||the-6/DT	amod||ability-8/NN||unique-7/JJ	dobj||has-5/VBZ||ability-8/NN	aux||restrict-10/VB||to-9/TO	vmod||ability-8/NN||restrict-10/VB	det||egress-12/NNS||the-11/DT	dobj||restrict-10/VB||egress-12/NNS	prep_of||egress-12/NNS||hiv-1-14/CD	nsubj||ssarcomaâ-18/VBZ||kaposi-16/NNS	root||ROOT-0/null||ssarcomaâ-18/VBZ	dobj||ssarcomaâ-18/VBZ||$-19/$	advmod||herpesvirus-22/RB||associated-21/RB	dep||viruses-33/CD||herpesvirus-22/RB	nn||ebola-27/NNP||kshv-24/NNP	dep||virus-28/IN||ebola-27/NNP	prep||herpesvirus-22/RB||virus-28/IN	prep||herpesvirus-22/RB||other-31/JJ	conj_and||virus-28/IN||other-31/JJ	dep||other-31/JJ||enveloped-32/JJ	num||$-19/$||viruses-33/CD	kaposi'ssarcoma--1||interferon--1||no||the interferon-induced bst-2 protein has the unique ability to restrict the egress of hiv-1, kaposi'ssarcomaâassociated herpesvirus (kshv), ebola virus, and other enveloped viruses.
dep||murine-8/VB||vaccination-1/JJ	prep_by||vaccination-1/JJ||bcg-3/NN	amod||bcg-3/NN||prime-4/JJ	amod||+-7/NNS||ighsp65-6/JJ	prep_with||bcg-3/NN||+-7/NNS	dep||boost-12/NN||murine-8/VB	acomp||murine-8/VB||il-12-9/JJ	punct||boost-12/NN||/-10/:	amod||boost-12/NN||hvj-envelope-11/JJ	root||ROOT-0/null||boost-12/NN	vmod||boost-12/NN||resulted-13/VBN	amod||efficacy-17/NN||significant-15/JJ	amod||efficacy-17/NN||protective-16/JJ	prep_in||resulted-13/VBN||efficacy-17/NN	dep||efficacy-17/NN||>-19/NNP	num||>-19/NNP||10-20/CD	num||>-19/NNP||â-22/CD	npadvmod||000-fold-25/JJ||$-23/$	num||$-23/$||-24/CD	amod||>-19/NNP||000-fold-25/JJ	prep_versus||>-19/NNP||bcg-27/NN	advmod||bcg-27/NN||alone-28/RB	nn||infection-32/NN||tb-31/NN	prep_against||efficacy-17/NN||infection-32/NN	det||lungs-35/NNS||the-34/DT	prep_in||resulted-13/VBN||lungs-35/NNS	prep_of||lungs-35/NNS||mice-37/NNS	tb-31||bcg-27||no||vaccination by bcg prime with ighsp65+murine il-12/hvj-envelope boost resulted in significant protective efficacy (>10,â000-fold versus bcg alone) against tb infection in the lungs of mice.
det||cat-3/NN||the-1/DT	amod||cat-3/NN||domestic-2/JJ	nsubj||offered-5/VBN||cat-3/NN	aux||offered-5/VBN||has-4/VBZ	root||ROOT-0/null||offered-5/VBN	amod||potential-8/NN||enormous-6/JJ	amod||potential-8/NN||genomic-7/JJ	dobj||offered-5/VBN||potential-8/NN	det||description-12/NN||the-10/DT	amod||description-12/NN||veterinary-11/JJ	prep_in||offered-5/VBN||description-12/NN	quantmod||250-15/CD||over-14/IN	num||models-17/NNS||250-15/CD	amod||models-17/NNS||hereditarydisease-16/JJ	prep_of||description-12/NN||models-17/NNS	det||occurrence-22/NN||the-21/DT	prep_in||offered-5/VBN||occurrence-22/NN	conj_and||description-12/NN||occurrence-22/NN	amod||viruses-27/NNS||several-24/JJ	amod||viruses-27/NNS||deadly-25/JJ	amod||viruses-27/NNS||feline-26/JJ	prep_of||occurrence-22/NN||viruses-27/NNS	amod||virus-31/NN||feline-29/JJ	nn||virus-31/NN||leukemia-30/NN	dep||offered-5/VBN||virus-31/NN	dep||virus-31/NN||felv-33/NNP	amod||coronavirus-36/NNS||feline-35/JJ	appos||felv-33/NNP||coronavirus-36/NNS	amod||virus-42/NN||fecv-38/JJ	amod||virus-42/NN||feline-40/JJ	amod||virus-42/NN||immunodeficiency-41/JJ	dep||felv-33/NNP||virus-42/NN	dep||virus-31/NN||fiv-44/VBN	mark||homologues-48/JJ||that-46/IN	cop||homologues-48/JJ||are-47/VBP	ccomp||offered-5/VBN||homologues-48/JJ	amod||scourges-51/NNS||human-50/JJ	prep_to||homologues-48/JJ||scourges-51/NNS	dep||homologues-48/JJ||cancer-53/NN	dep||homologues-48/JJ||sars-55/NNS	conj_and||cancer-53/NN||sars-55/NNS	dep||homologues-48/JJ||aids-58/NNS	conj_and||cancer-53/NN||aids-58/NNS	advmod||aids-58/NNS||respectively-59/RB	sars-55||coronavirus-36||no||the domestic cat has offered enormous genomic potential in the veterinary description of over 250 hereditarydisease models as well as the occurrence of several deadly feline viruses (feline leukemia virus -- felv, feline coronavirus -- fecv, feline immunodeficiency virus - fiv) that are homologues to human scourges (cancer, sars, and aids respectively).
det||test-4/NN||the-1/DT	amod||test-4/NN||xpert-2/JJ	nn||test-4/NN||mtb/rif-3/NN	nsubj||detect-15/VB||test-4/NN	dep||test-4/NN||cepheid-6/VBN	dobj||cepheid-6/VBN||sunnyvale-8/NN	dep||sunnyvale-8/NN||ca-10/MD	appos||sunnyvale-8/NN||usa-12/NN	aux||detect-15/VB||can-14/MD	root||ROOT-0/null||detect-15/VB	dobj||detect-15/VB||tuberculosis-16/NNP	poss||form-20/NN||its-18/PRP$	amod||form-20/NN||multidrug-resistant-19/JJ	dobj||detect-15/VB||form-20/NN	conj_and||tuberculosis-16/NNP||form-20/NN	advmod||high-23/JJ||very-22/RB	amod||sensitivity-24/NN||high-23/JJ	prep_with||detect-15/VB||sensitivity-24/NN	prep_with||detect-15/VB||specificity-26/NN	conj_and||sensitivity-24/NN||specificity-26/NN	amod||studies-29/NNS||controlled-28/JJ	prep_in||detect-15/VB||studies-29/NNS	neg||data-34/NNS||no-32/DT	nn||data-34/NNS||performance-33/NN	nsubj||exist-35/VBP||data-34/NNS	conj_but||detect-15/VB||exist-35/VBP	nn||facilities-41/NNS||district-37/NN	conj_and||district-37/NN||subdistrict-39/NN	nn||facilities-41/NNS||subdistrict-39/NN	nn||facilities-41/NNS||health-40/NN	prep_from||exist-35/VBP||facilities-41/NNS	amod||countries-44/NNS||tuberculosis-endemic-43/JJ	prep_in||exist-35/VBP||countries-44/NNS	tuberculosis-16||rif--1||yes||the xpert mtb/rif test (cepheid, sunnyvale, ca, usa) can detect tuberculosis and its multidrug-resistant form with very high sensitivity and specificity in controlled studies, but no performance data exist from district and subdistrict health facilities in tuberculosis-endemic countries.
nsubj||shown-3/VBN||studies-1/NNS	aux||shown-3/VBN||have-2/VBP	root||ROOT-0/null||shown-3/VBN	mark||is-6/VBZ||that-4/IN	expl||is-6/VBZ||there-5/EX	ccomp||shown-3/VBN||is-6/VBZ	neg||level-9/NN||no-7/DT	amod||level-9/NN||safe-8/JJ	nsubj||is-6/VBZ||level-9/NN	amod||exposure-16/NN||secondhand-11/JJ	nn||exposure-16/NN||smoke-12/NN	appos||exposure-16/NN||shs-14/NN	prep_of||level-9/NN||exposure-16/NN	expl||is-19/VBZ||there-18/EX	conj_and||shown-3/VBN||is-19/VBZ	det||link-22/NN||a-20/DT	amod||link-22/NN||close-21/JJ	nsubj||is-19/VBZ||link-22/NN	prep_between||link-22/NN||shs-24/NN	det||risk-27/NN||the-26/DT	nsubj||is-19/VBZ||risk-27/NN	conj_and||link-22/NN||risk-27/NN	prep_of||risk-27/NN||coronaryheartdisease-29/NN	prep_of||risk-27/NN||stroke-31/NN	conj_and||coronaryheartdisease-29/NN||stroke-31/NN	stroke-31||smoke-12||no_rel||studies have shown that there is no safe level of secondhand smoke (shs) exposure and there is a close link between shs and the risk of coronaryheartdisease and stroke.
det||study-4/NN||a-1/DT	amod||study-4/NN||prospective-2/JJ	amod||study-4/NN||comparative-3/JJ	nsubjpass||undertaken-6/VBN||study-4/NN	nsubj||compare-8/VB||study-4/NN	nsubj||surgeonâ-19/VB||study-4/NN	auxpass||undertaken-6/VBN||was-5/VBD	root||ROOT-0/null||undertaken-6/VBN	aux||compare-8/VB||to-7/TO	xcomp||undertaken-6/VBN||compare-8/VB	det||outcome-17/NN||the-9/DT	amod||outcome-17/NN||patientsâ-10/JJ	amod||outcome-17/NN||$-11/$	number||pain-13/CD||-12/CD	num||$-11/$||pain-13/CD	nn||outcome-17/NN||experience-14/NN	amod||outcome-17/NN||surgical-16/JJ	dobj||compare-8/VB||outcome-17/NN	xcomp||undertaken-6/VBN||surgeonâ-19/VB	conj_and||compare-8/VB||surgeonâ-19/VB	num||experience-23/NN||$-20/$	number||s-22/CD||-21/CD	num||$-20/$||s-22/CD	dobj||surgeonâ-19/VB||experience-23/NN	prep_in||experience-23/NN||phacoemulsification-25/NN	conj_and||compare-8/VB||manual-27/VB	conj_and||surgeonâ-19/VB||manual-27/VB	amod||surgery-31/NN||small-28/JJ	nn||surgery-31/NN||incision-29/NN	nn||surgery-31/NN||cataract-30/NN	dobj||manual-27/VB||surgery-31/NN	appos||surgery-31/NN||msics-33/NNS	amod||anesthesia-37/NN||topical-36/JJ	prep_under||manual-27/VB||anesthesia-37/NN	vmod||anesthesia-37/NN||supplemented-38/VBN	amod||lignocaine-41/NN||intracameral-40/JJ	prep_with||supplemented-38/VBN||lignocaine-41/NN	dep||lignocaine-41/NN||tasil-43/JJ	pain-13||lignocaine-41||yes||a prospective comparative study was undertaken to compare the patientsâ pain experience, surgical outcome and surgeonâs experience in phacoemulsification and manual small incision cataract surgery (msics) under topical anesthesia supplemented with intracameral lignocaine (tasil).
det||sample-2/NN||the-1/DT	nsubj||consisted-3/VBD||sample-2/NN	root||ROOT-0/null||consisted-3/VBD	num||patients-6/NNS||131-5/CD	prep_of||consisted-3/VBD||patients-6/NNS	nsubj||received-24/VBD||patients-6/NNS	vmod||patients-6/NNS||suffering-7/VBG	amod||affectivedisorders-10/NNS||different-9/JJ	prep_from||suffering-7/VBG||affectivedisorders-10/NNS	amod||depressivedisorder-14/NN||major-13/JJ	prep_including||patients-6/NNS||depressivedisorder-14/NN	prep_including||patients-6/NNS||bipolardisorder-16/NN	conj_and||depressivedisorder-14/NN||bipolardisorder-16/NN	amod||disorder-21/NN||generalized-19/JJ	nn||disorder-21/NN||anxiety-20/NN	prep_including||patients-6/NNS||disorder-21/NN	conj_and||depressivedisorder-14/NN||disorder-21/NN	rcmod||patients-6/NNS||received-24/VBD	dobj||received-24/VBD||escitalopram-25/NN	quantmod||4-29/CD||at-27/IN	mwe||at-27/IN||least-28/JJS	pobj||at-27/IN||least-28/JJS	num||weeks-30/NNS||4-29/CD	prep_for||received-24/VBD||weeks-30/NNS	depressivedisorder-14||escitalopram-25||yes||the sample consisted of 131 patients suffering from different affectivedisorders, including major depressivedisorder, bipolardisorder, and generalized anxiety disorder, who received escitalopram for at least 4 weeks.
det||study-2/NN||this-1/DT	nsubj||shows-3/VBZ||study-2/NN	root||ROOT-0/null||shows-3/VBZ	mark||are-36/VBP||that-4/IN	advmod||established-9/VBN||when-5/WRB	det||collaboration-7/NN||a-6/DT	nsubjpass||established-9/VBN||collaboration-7/NN	nsubj||strengthen-11/VB||collaboration-7/NN	auxpass||established-9/VBN||is-8/VBZ	advcl||are-36/VBP||established-9/VBN	aux||strengthen-11/VB||to-10/TO	xcomp||established-9/VBN||strengthen-11/VB	amod||systems-14/NNS||existing-12/JJ	nn||systems-14/NNS||health-13/NN	dobj||strengthen-11/VB||systems-14/NNS	prepc_in_addition_to||established-9/VBN||providing-19/VBG	amod||services-21/NNS||hiv/aids-20/JJ	dobj||providing-19/VBG||services-21/NNS	det||setting-24/NN||a-23/DT	prep_in||providing-19/VBG||setting-24/NN	prep_in||delivered-33/VBN||setting-24/NN	amod||care-30/NN||other-27/JJ	amod||care-30/NN||primary-28/JJ	nn||care-30/NN||health-29/NN	nsubjpass||delivered-33/VBN||care-30/NN	aux||delivered-33/VBN||is-31/VBZ	auxpass||delivered-33/VBN||being-32/VBG	rcmod||setting-24/NN||delivered-33/VBN	expl||are-36/VBP||there-35/EX	ccomp||shows-3/VBZ||are-36/VBP	amod||effects-38/NNS||positive-37/JJ	nsubj||are-36/VBP||effects-38/NNS	neg||only-40/JJ||not-39/RB	preconj||are-36/VBP||only-40/JJ	amod||services-43/NNS||hiv/aids-42/JJ	prep_on||are-36/VBP||services-43/NNS	amod||services-51/NNS||many-48/JJ	amod||services-51/NNS||other-49/JJ	amod||services-51/NNS||essential-50/JJ	prep_on||are-36/VBP||services-51/NNS	conj_and||services-43/NNS||services-51/NNS	aids--1||hiv--1||no||this study shows that when a collaboration is established to strengthen existing health systems, in addition to providing hiv/aids services in a setting in which other primary health care is being delivered, there are positive effects not only on hiv/aids services, but also on many other essential services.
det||practice-2/NN||the-1/DT	nsubj||explanation-14/NN||practice-2/NN	prepc_of||practice-2/NN||combining-4/VBG	dobj||combining-4/VBG||agents-5/NNS	nsubj||counteract-7/VB||agents-5/NNS	rcmod||agents-5/NNS||counteract-7/VB	amod||mechanisms-9/NNS||different-8/JJ	dobj||counteract-7/VB||mechanisms-9/NNS	cop||explanation-14/NN||is-10/VBZ	det||explanation-14/NN||the-11/DT	advmod||likely-13/JJ||most-12/RBS	amod||explanation-14/NN||likely-13/JJ	root||ROOT-0/null||explanation-14/NN	det||fact-17/NN||the-16/DT	prep_for||explanation-14/NN||fact-17/NN	mark||have-23/VBP||that-18/IN	advmod||available-20/JJ||most-19/RBS	amod||combinations-22/NNS||available-20/JJ	amod||combinations-22/NNS||two-drug-21/JJ	nsubj||have-23/VBP||combinations-22/NNS	ccomp||explanation-14/NN||have-23/VBP	det||agent-25/NN||an-24/DT	dobj||have-23/VBP||agent-25/NN	nsubj||addresses-27/VBZ||agent-25/NN	rcmod||agent-25/NN||addresses-27/VBZ	nn||secretion-29/NN||renin-28/NN	dobj||addresses-27/VBZ||secretion-29/NN	dep||agent-25/NN||beta-blocker-31/NN	appos||beta-blocker-31/NN||angiotensinconvertingenzymeinhibitor-33/NN	nn||blocker-38/NN||angiotensin-35/NN	nn||blocker-38/NN||ii-36/NN	nn||blocker-38/NN||receptor-37/NN	appos||beta-blocker-31/NN||blocker-38/NN	amod||inhibitor-42/NN||direct-40/JJ	nn||inhibitor-42/NN||renin-41/NN	appos||beta-blocker-31/NN||inhibitor-42/NN	conj_or||blocker-38/NN||inhibitor-42/NN	det||one-46/NN||another-45/DT	conj_and||agent-25/NN||one-46/NN	nsubj||effective-50/JJ||one-46/NN	cop||effective-50/JJ||is-48/VBZ	advmod||effective-50/JJ||more-49/RBR	rcmod||one-46/NN||effective-50/JJ	amod||hypertension-53/NN||renin-independent-52/JJ	prep_in||effective-50/JJ||hypertension-53/NN	nn||calciumchannelblocker-60/NN||diuretic-55/NN	conj_or||diuretic-55/NN||dihydropyridine-57/NN	nn||calciumchannelblocker-60/NN||dihydropyridine-57/NN	conj_or||diuretic-55/NN||non-dihydropyridine-59/NN	nn||calciumchannelblocker-60/NN||non-dihydropyridine-59/NN	appos||one-46/NN||calciumchannelblocker-60/NN	hypertension-53||calciumchannelblocker-60||no_rel||the practice of combining agents that counteract different mechanisms is the most likely explanation for the fact that most available two-drug combinations have an agent that addresses renin secretion (beta-blocker, angiotensinconvertingenzymeinhibitor, angiotensin ii receptor blocker or direct renin inhibitor) and another one that is more effective in renin-independent hypertension (diuretic, dihydropyridine or non-dihydropyridine calciumchannelblocker).
det||study-2/NN||the-1/DT	nsubjpass||performed-5/VBN||study-2/NN	aux||performed-5/VBN||will-3/MD	auxpass||performed-5/VBN||be-4/VB	root||ROOT-0/null||performed-5/VBN	det||study-9/NN||a-7/DT	amod||study-9/NN||dose-escalation-8/JJ	prep_as||performed-5/VBN||study-9/NN	vmod||study-9/NN||evaluating-10/VBG	det||dose-15/NN||the-11/DT	amod||dose-15/NN||optimal-12/JJ	nn||dose-15/NN||carbon-13/NN	nn||dose-15/NN||ion-14/NN	dobj||evaluating-10/VBG||dose-15/NN	prep_with||dose-15/NN||respect-17/NN	nn||control-22/NN||toxicity-19/NN	conj_and||toxicity-19/NN||tumor-21/NN	nn||control-22/NN||tumor-21/NN	prep_to||evaluating-10/VBG||control-22/NN	carbon-13||tumor-21||no_rel||the study will be performed as a dose-escalation study evaluating the optimal carbon ion dose with respect to toxicity and tumor control.
num||assays-6/NNS||two-1/CD	amod||assays-6/NNS||commercial-2/JJ	nn||assays-6/NNS||interferon-3/NN	nn||assays-6/NNS||gamma-4/NN	nn||assays-6/NNS||release-5/NN	nsubj||become-33/VBN||assays-6/NNS	amod||®-12/NNP||-lrb--7/JJ	nn||®-12/NNP||igras-8/NNS	nn||®-12/NNP||-rrb--9/NNP	nn||®-12/NNP||-lrb--10/NNP	nn||®-12/NNP||quantiferonâ-11/NNP	nsubj||tb-23/VBP||®-12/NNP	nn||gold-15/NN||tb-14/NN	dep||®-12/NNP||gold-15/NN	nn||®-21/NNS||tube-17/NN	conj_and||tube-17/NN||t-19/NN	nn||®-21/NNS||t-19/NN	nn||®-21/NNS||spotâ-20/NN	prep_in||gold-15/NN||®-21/NNS	rcmod||assays-6/NNS||tb-23/VBP	acomp||tb-23/VBP||-rrb--24/JJ	aux||detect-26/VB||to-25/TO	xcomp||-rrb--24/JJ||detect-26/VB	det||contact-28/NN||a-27/DT	dobj||detect-26/VB||contact-28/NN	prep_with||detect-26/VB||m.tuberculosis-30/NNS	aux||become-33/VBN||have-31/VBP	advmod||become-33/VBN||recently-32/RB	root||ROOT-0/null||become-33/VBN	acomp||become-33/VBN||available-34/JJ	tb-23||m.tuberculosis-30||no||two commercial interferon gamma release assays -lrb- igras -rrb- -lrb- quantiferonâ ® - tb gold in tube and t spotâ ® - tb -rrb- to detect a contact with m.tuberculosis have recently become available .
advmod||had-21/VBD||however-1/RB	nsubj||had-21/VBD||children-3/NNS	prep_with||children-3/NNS||heredity-5/NN	prep_for||heredity-5/NN||allergies-7/NNS	prep_with||children-3/NNS||presence-10/NN	conj_and||heredity-5/NN||presence-10/NN	amod||smoke-14/NN||secondhand-12/JJ	nn||smoke-14/NN||tobacco-13/NN	prep_of||presence-10/NN||smoke-14/NN	poss||year-18/NN||their-16/PRP$	amod||year-18/NN||first-17/JJ	prep_during||smoke-14/NN||year-18/NN	prep_in||year-18/NN||life-20/NN	root||ROOT-0/null||had-21/VBD	advmod||odds-24/NNS||highly-22/RB	amod||odds-24/NNS||increased-23/VBN	dobj||had-21/VBD||odds-24/NNS	prepc_of||odds-24/NNS||developing-26/VBG	det||allergy-28/NN||an-27/DT	dobj||developing-26/VBG||allergy-28/NN	aux||sought-31/VBN||having-30/VBG	prepc_of||odds-24/NNS||sought-31/VBN	conj_and||developing-26/VBG||sought-31/VBN	amod||care-33/NN||medical-32/JJ	dobj||sought-31/VBN||care-33/NN	amod||symptoms-37/NNS||allergic-36/JJ	prep_due_to||sought-31/VBN||symptoms-37/NNS	num||years-40/NNS||4-39/CD	prep_at||symptoms-37/NNS||years-40/NNS	prep_of||years-40/NNS||age-42/NN	allergy-28||allergies-7||no||however, children with heredity for allergies and with presence of secondhand tobacco smoke during their first year in life had highly increased odds of developing an allergy and having sought medical care due to allergic symptoms at 4 years of age.
mark||determined-7/VBN||once-1/IN	amod||infection-4/NN||acute-2/JJ	nn||infection-4/NN||dengue-3/NN	nsubjpass||determined-7/VBN||infection-4/NN	aux||determined-7/VBN||has-5/VBZ	auxpass||determined-7/VBN||been-6/VBN	advcl||distinguish-20/VB||determined-7/VBN	det||classifier-11/NN||a-9/DT	amod||classifier-11/NN||2-d-10/JJ	nsubj||distinguish-20/VB||classifier-11/NN	prepc_based_on||classifier-11/NN||on-13/IN	amod||kits-17/NNS||common-14/JJ	amod||kits-17/NNS||denguevirus-15/JJ	nn||kits-17/NNS||igg-16/NN	pobj||classifier-11/NN||kits-17/NNS	aux||distinguish-20/VB||can-18/MD	advmod||distinguish-20/VB||reliably-19/RB	root||ROOT-0/null||distinguish-20/VB	nn||infections-25/NNS||primary-21/NN	conj_and||primary-21/NN||secondary-23/JJ	nn||infections-25/NNS||secondary-23/JJ	nn||infections-25/NNS||dengue-24/NN	dobj||distinguish-20/VB||infections-25/NNS	dengue-24||denguevirus-15||no||once acute dengue infection has been determined, a 2-d classifier based on common denguevirus igg kits can reliably distinguish primary and secondary dengue infections.
det||cohort-3/NN||the-1/DT	amod||cohort-3/NN||medalist-2/JJ	nsubj||has-29/VBZ||cohort-3/NN	det||±-9/NN||a-6/DT	amod||±-9/NN||mean-7/JJ	nn||±-9/NN||â-8/NN	prep_with||cohort-3/NN||±-9/NN	vmod||±-9/NN||sd-10/VBN	nn||duration-12/NN||disease-11/NN	nn||â-22/NN||duration-12/NN	conj_and||duration-12/NN||age-14/NN	nn||â-22/NN||age-14/NN	num||â-17/NN||56.2-16/CD	prep_of||duration-12/NN||â-17/NN	amod||â-22/NN||±-18/JJ	dep||±-18/JJ||5.8-19/CD	dep||±-18/JJ||67.2-21/CD	conj_and||5.8-19/CD||67.2-21/CD	dobj||sd-10/VBN||â-22/NN	number||7.5-24/CD||±-23/CD	num||years-25/NNS||7.5-24/CD	tmod||sd-10/VBN||years-25/NNS	advmod||sd-10/VBN||respectively-27/RB	dep||mean-39/VBP||has-29/VBZ	det||phenotype-32/NN||a-30/DT	amod||phenotype-32/NN||clinical-31/JJ	dobj||has-29/VBZ||phenotype-32/NN	amod||type1diabetes-35/JJ||similar-33/JJ	dep||type1diabetes-35/JJ||to-34/TO	amod||phenotype-32/NN||type1diabetes-35/JJ	appos||phenotype-32/NN||type1diabetes-37/NNP	root||ROOT-0/null||mean-39/VBP	nn||onset-43/NN||â-40/NN	num||onset-43/NN||±-41/CD	nn||onset-43/NN||sd-42/NN	dobj||mean-39/VBP||onset-43/NN	num||±-47/NNS||11.0-45/CD	nn||±-47/NNS||â-46/NN	prep_at||onset-43/NN||±-47/NNS	num||years-49/NNS||6.4-48/CD	nsubj||mean-39/VBP||years-49/NNS	appos||years-49/NNS||bmi-51/NN	num||â-54/NN||26.0-53/CD	prep_at||bmi-51/NN||â-54/NN	number||5.1-56/CD||±-55/CD	num||kg/m2-57/NNS||5.1-56/CD	dep||â-54/NN||kg/m2-57/NNS	nn||dose-60/NN||insulin-59/NN	prep_at||bmi-51/NN||dose-60/NN	conj_and||â-54/NN||dose-60/NN	num||±-64/NNS||0.46-62/CD	nn||±-64/NNS||â-63/NN	prep_of||dose-60/NN||±-64/NNS	number||u/kg-66/JJ||0.2-65/CD	amod||±-64/NNS||u/kg-66/JJ	number||1/4-69/CD||â-68/CD	prep_at||bmi-51/NN||1/4-69/CD	conj_and||â-54/NN||1/4-69/CD	num||%-71/NN||94-70/CD	npadvmod||positive-72/JJ||%-71/NN	amod||1/4-69/CD||positive-72/JJ	amod||dr4-76/NNS||dr3-74/JJ	amod||dr4-76/NNS||and/or-75/JJ	prep_for||1/4-69/CD||dr4-76/NNS	num||%-80/NN||29.5-79/CD	prep_at||bmi-51/NN||%-80/NN	conj_and||â-54/NN||%-80/NN	amod||autoantibodies-91/NNS||positive-81/JJ	det||decarboxylase-87/NN||either-83/DT	amod||decarboxylase-87/NN||ia2-84/JJ	conj_or||ia2-84/JJ||glutamicacid-86/JJ	amod||decarboxylase-87/NN||glutamicacid-86/JJ	prep_for||positive-81/JJ||decarboxylase-87/NN	appos||decarboxylase-87/NN||gad-89/NN	dep||%-80/NN||autoantibodies-91/NNS	type1diabetes-37||glutamicacid-86||no_rel||the medalist cohort, with a mean â± sd disease duration and age of 56.2 â± 5.8 and 67.2 â± 7.5 years, respectively, has a clinical phenotype similar to type1diabetes (type1diabetes) mean â± sd onset at 11.0 â± 6.4 years, bmi at 26.0 â± 5.1 kg/m2, insulin dose of 0.46 â± 0.2 u/kg, â¼94% positive for dr3 and/or dr4, and 29.5% positive for either ia2 or glutamicacid decarboxylase (gad) autoantibodies.
nsubjpass||induced-3/VBN||constipation-1/NN	auxpass||induced-3/VBN||was-2/VBD	root||ROOT-0/null||induced-3/VBN	amod||administration-6/NN||oral-5/JJ	agent||induced-3/VBN||administration-6/NN	prep_of||administration-6/NN||loperamide-8/NN	number||mg/kg-11/CD||3-10/CD	num||weight-13/NN||mg/kg-11/CD	nn||weight-13/NN||body-12/NN	appos||loperamide-8/NN||weight-13/NN	mark||received-19/VBD||while-15/IN	det||rats-18/NNS||the-16/DT	nn||rats-18/NNS||control-17/NN	nsubj||received-19/VBD||rats-18/NNS	advcl||induced-3/VBN||received-19/VBD	amod||saline-21/NN||normal-20/JJ	dobj||received-19/VBD||saline-21/NN	constipation-1||loperamide-8||no||constipation was induced by oral administration of loperamide (3 mg/kg body weight) while the control rats received normal saline.
amod||responses-2/NNS||inappropriate-1/JJ	nsubjpass||involved-9/VBN||responses-2/NNS	amod||bacteria-6/NNS||normal-4/JJ	amod||bacteria-6/NNS||intestinal-5/JJ	prep_to||responses-2/NNS||bacteria-6/NNS	aux||involved-9/VBN||may-7/MD	auxpass||involved-9/VBN||be-8/VB	ccomp||-lrb--30/VBD||involved-9/VBN	det||development-12/NN||the-11/DT	prep_in||involved-9/VBN||development-12/NN	amod||ibd-18/NN||inflammatory-14/JJ	nn||ibd-18/NN||bowel-15/NN	nn||ibd-18/NN||diseases-16/NNS	nn||ibd-18/NN||-lrb--17/NN	prep_of||development-12/NN||ibd-18/NN	nn||crohn-21/NNP||e.g.-20/NNP	poss||-rrb--26/NN||crohn-21/NNP	nn||-rrb--26/NN||disease-23/NN	amod||-rrb--26/NN||-lrb--24/JJ	nn||-rrb--26/NN||cd-25/NN	appos||ibd-18/NN||-rrb--26/NN	amod||colitis-29/NNS||ulcerative-28/JJ	nsubj||-lrb--30/VBD||colitis-29/NNS	root||ROOT-0/null||-lrb--30/VBD	nn||-rrb--33/NNS||uc-31/NN	amod||-rrb--33/NNS||-rrb--32/JJ	nsubj||mediate-41/VB||-rrb--33/NNS	conj_and||-rrb--33/NNS||variations-35/NNS	nsubj||mediate-41/VB||variations-35/NNS	det||genome-39/NN||the-37/DT	nn||genome-39/NN||host-38/NN	prep_in||-rrb--33/NNS||genome-39/NN	aux||mediate-41/VB||may-40/MD	ccomp||-lrb--30/VBD||mediate-41/VB	det||process-43/NN||this-42/DT	dobj||mediate-41/VB||process-43/NN	cd-25||crohn's disease--1||no_rel||inappropriate responses to normal intestinal bacteria may be involved in the development of inflammatory bowel diseases -lrb- ibd , e.g. crohn 's disease -lrb- cd -rrb- , ulcerative colitis -lrb- uc -rrb- -rrb- and variations in the host genome may mediate this process .
poss||parents-2/NNS||her-1/PRP$	nsubj||had-3/VBD||parents-2/NNS	nsubj||reported-9/VBD||parents-2/NNS	root||ROOT-0/null||had-3/VBD	amod||levels-7/NNS||normal-4/JJ	nn||levels-7/NNS||plasma-5/NN	nn||levels-7/NNS||cholesterol-6/NN	dobj||had-3/VBD||levels-7/NNS	conj_and||had-3/VBD||reported-9/VBD	neg||history-12/NN||no-10/DT	nn||history-12/NN||family-11/NN	dobj||reported-9/VBD||history-12/NN	prep_of||history-12/NN||hypercholesterolemia-14/NN	vmod||had-3/VBD||suggesting-16/VBG	preconj||disorder-21/NN||either-17/CC	det||disorder-21/NN||an-18/DT	amod||disorder-21/NN||autosomal-19/JJ	nn||disorder-21/NN||recessive-20/NN	dobj||suggesting-16/VBG||disorder-21/NN	det||mutation-26/NN||a-23/DT	nn||mutation-26/NN||de-24/FW	nn||mutation-26/NN||novo-25/NN	dobj||suggesting-16/VBG||mutation-26/NN	conj_or||disorder-21/NN||mutation-26/NN	hypercholesterolemia-14||cholesterol-6||no||her parents had normal plasma cholesterol levels and reported no family history of hypercholesterolemia, suggesting either an autosomal recessive disorder or a de novo mutation.
advmod||extends-27/VBZ||thus-1/RB	advmod||demonstrating-7/VBG||clearly-6/RB	prepc_in_addition_to||extends-27/VBZ||demonstrating-7/VBG	det||role-10/NN||the-8/DT	amod||role-10/NN||critical-9/JJ	dobj||demonstrating-7/VBG||role-10/NN	amod||viruses-23/NNS||lsd1-12/JJ	prep||viruses-23/NNS||in-13/IN	pobj||in-13/IN||regulation-14/NN	prep_of||regulation-14/NN||hsvinfection-16/NN	amod||dna-22/NN||other-21/JJ	conj_and||in-13/IN||dna-22/NN	prep||viruses-23/NNS||dna-22/NN	prep_of||role-10/NN||viruses-23/NNS	det||data-26/NNS||the-25/DT	nsubj||extends-27/VBZ||data-26/NNS	root||ROOT-0/null||extends-27/VBZ	det||potential-30/NN||the-28/DT	amod||potential-30/NN||therapeutic-29/JJ	dobj||extends-27/VBZ||potential-30/NN	amod||inhibitors-34/NNS||chromatin-32/JJ	nn||inhibitors-34/NNS||modulation-33/NN	prep_of||potential-30/NN||inhibitors-34/NNS	det||field-38/NN||the-36/DT	amod||field-38/NN||focused-37/JJ	prep_from||inhibitors-34/NNS||field-38/NN	prep_of||field-38/NN||oncology-40/NN	det||arena-43/NN||the-42/DT	prep_to||extends-27/VBZ||arena-43/NN	prep_of||arena-43/NN||antiviralagents-45/NNS	hsvinfection-16||antiviralagents-45||no_rel||thus, in addition to clearly demonstrating the critical role of lsd1 in regulation of hsvinfection, as well as other dna viruses, the data extends the therapeutic potential of chromatin modulation inhibitors from the focused field of oncology to the arena of antiviralagents.
det||beginning-3/NN||the-2/DT	prep_since||provided-16/VBN||beginning-3/NN	det||century-7/NN||the-5/DT	amod||century-7/NN||21st-6/JJ	prep_of||beginning-3/NN||century-7/NN	nn||assistance-10/NN||development-9/NN	nsubjpass||provided-16/VBN||assistance-10/NN	prep_for||assistance-10/NN||hiv/aids-12/NNS	aux||provided-16/VBN||has-13/VBZ	advmod||provided-16/VBN||increasingly-14/RB	auxpass||provided-16/VBN||been-15/VBN	root||ROOT-0/null||provided-16/VBN	amod||initiatives-20/NNS||global-18/JJ	nn||initiatives-20/NNS||health-19/NN	prep_through||provided-16/VBN||initiatives-20/NNS	advmod||plan-28/VBP||specifically-22/RB	det||emergency-27/NN||the-23/DT	amod||emergency-27/NN||united-24/VBN	nn||emergency-27/NN||states-25/NNS	amod||emergency-27/NN||presidential-26/JJ	nsubj||plan-28/VBP||emergency-27/NN	nsubj||fight-37/VB||emergency-27/NN	parataxis||provided-16/VBN||plan-28/VBP	nn||relief-31/NN||aids-30/NNS	prep_for||plan-28/VBP||relief-31/NN	det||fund-35/NN||the-33/DT	amod||fund-35/NN||global-34/JJ	appos||relief-31/NN||fund-35/NN	aux||fight-37/VB||to-36/TO	xcomp||plan-28/VBP||fight-37/VB	dobj||fight-37/VB||hiv-38/NN	dobj||fight-37/VB||tb-40/NN	conj_and||hiv-38/NN||tb-40/NN	dobj||fight-37/VB||malaria-42/NN	conj_and||hiv-38/NN||malaria-42/NN	det||multi-country-47/NN||the-44/DT	nn||multi-country-47/NN||world-45/NN	nn||multi-country-47/NN||bank-46/NN	nsubj||aids-48/VBZ||multi-country-47/NN	conj_and||provided-16/VBN||aids-48/VBZ	dobj||aids-48/VBZ||programme-49/NN	aids-48||hiv-38||no||since the beginning of the 21st century, development assistance for hiv/aids has increasingly been provided through global health initiatives, specifically the united states presidential emergency plan for aids relief, the global fund to fight hiv, tb and malaria and the world bank multi-country aids programme.
nsubj||likely-16/JJ||patients-1/NNS	nsubj||have-18/VB||patients-1/NNS	amod||obstructivepulmonarydisease-4/NN||chronic-3/JJ	prep_with||patients-1/NNS||obstructivepulmonarydisease-4/NN	nsubj||received-6/VBD||obstructivepulmonarydisease-4/NN	rcmod||obstructivepulmonarydisease-4/NN||received-6/VBD	amod||oxygen-8/NN||titrated-7/JJ	dobj||received-6/VBD||oxygen-8/NN	prepc_according_to||received-6/VBD||to-10/TO	det||protocol-12/NN||the-11/DT	pobj||received-6/VBD||protocol-12/NN	cop||likely-16/JJ||were-13/VBD	advmod||likely-16/JJ||significantly-14/RB	advmod||likely-16/JJ||less-15/RBR	root||ROOT-0/null||likely-16/JJ	aux||have-18/VB||to-17/TO	xcomp||likely-16/JJ||have-18/VB	dobj||have-18/VB||respiratoryacidosis-19/NNS	dep||respiratoryacidosis-19/NNS||mean-21/VB	nsubj||n-35/VBP||difference-22/NN	number||0.12-25/CD||ph-24/CD	prep_in||difference-22/NN||0.12-25/CD	appos||0.12-25/CD||se-27/NNP	num||se-27/NNP||0.05-28/CD	vmod||difference-22/NN||p-31/VBN	dep||0.01-33/CD||=-32/SYM	ccomp||p-31/VBN||0.01-33/CD	ccomp||mean-21/VB||n-35/VBP	dep||28-37/CD||=-36/SYM	ccomp||n-35/VBP||28-37/CD	dobj||have-18/VB||hypercapnia-40/NN	conj_or||respiratoryacidosis-19/NNS||hypercapnia-40/NN	amod||difference-43/NN||mean-42/JJ	dep||hypercapnia-40/NN||difference-43/NN	amod||pressure-47/NN||arterial-45/JJ	nn||pressure-47/NN||carbondioxide-46/NN	prep_in||difference-43/NN||pressure-47/NN	poss||hg-55/NN||â-48/NNP	nn||hg-55/NN||33.6-50/NNP	appos||hg-55/NN||16.3-52/CD	nn||hg-55/NN||mm-54/NN	dep||pressure-47/NN||hg-55/NN	dep||pressure-47/NN||p-57/NN	dep||0.02-59/CD||=-58/SYM	rcmod||p-57/NN||0.02-59/CD	vmod||difference-43/NN||n-61/VBN	dep||29-63/CD||=-62/SYM	ccomp||n-61/VBN||29-63/CD	mark||patients-67/NNS||than-65/IN	cop||patients-67/NNS||were-66/VBD	advcl||likely-16/JJ||patients-67/NNS	nsubj||received-69/VBD||patients-67/NNS	rcmod||patients-67/NNS||received-69/VBD	amod||oxygen-72/NN||high-70/JJ	nn||oxygen-72/NN||flow-71/NN	dobj||received-69/VBD||oxygen-72/NN	obstructivepulmonarydisease-4||oxygen-72||yes||patients with chronic obstructivepulmonarydisease who received titrated oxygen according to the protocol were significantly less likely to have respiratoryacidosis (mean difference in ph 0.12 (se 0.05); p=0.01; n=28) or hypercapnia (mean difference in arterial carbondioxide pressure â33.6 (16.3) mm hg; p=0.02; n=29) than were patients who received high flow oxygen.
amod||adjustment-3/NN||further-2/JJ	prep_after||associated-23/VBN||adjustment-3/NN	det||covariates-7/NNS||all-5/DT	amod||covariates-7/NNS||other-6/JJ	prep_for||adjustment-3/NN||covariates-7/NNS	prep_for||adjustment-3/NN||covariates-7/NNS	conj_less||covariates-7/NNS||covariates-7/NNS	det||value-11/NN||a-9/DT	nn||value-11/NN||p-10/NN	prep_with||covariates-7/NNS||value-11/NN	amod||associations-17/NNS||0.3-14/CD	conj_and||0.3-14/CD||nonlinear-16/JJR	amod||associations-17/NNS||nonlinear-16/JJR	prep_than||covariates-7/NNS||associations-17/NNS	prep_with||associations-17/NNS||cancer-19/NN	nsubjpass||associated-23/VBN||a1c-21/NNS	auxpass||associated-23/VBN||was-22/VBD	root||ROOT-0/null||associated-23/VBN	det||risk-28/NN||an-25/DT	amod||risk-28/NN||increased-26/VBN	nn||risk-28/NN||cancer-27/NN	prep_with||associated-23/VBN||risk-28/NN	dep||hr-30/NN||-lrb--29/NN	amod||risk-28/NN||hr-30/NN	prep_per||risk-28/NN||percentage-32/NN	num||percentage-32/NN||1.26-33/CD	num||%-36/NN||95-35/CD	npadvmod||ci-37/RB||%-36/NN	advmod||â-39/NN||ci-37/RB	num||â-39/NN||1.03-38/CD	appos||percentage-32/NN||â-39/NN	dep||-rrb--43/NN||$-40/$	num||$-40/$||1.55-42/CD	amod||â-39/NN||-rrb--43/NN	mark||associated-50/VBN||whereas-45/IN	nsubjpass||associated-50/VBN||use-46/NN	prep_of||use-46/NN||insulin-48/NN	auxpass||associated-50/VBN||was-49/VBD	dep||percentage-32/NN||associated-50/VBN	det||risk-55/NN||a-52/DT	amod||risk-55/NN||decreased-53/VBN	nn||risk-55/NN||cancer-54/NN	prep_with||associated-50/VBN||risk-55/NN	dep||hr-57/NN||-lrb--56/NN	amod||risk-55/NN||hr-57/NN	nn||users-60/NNS||insulin-59/NN	prep_of||risk-55/NN||users-60/NNS	prep_vs.||users-60/NNS||nonusers-62/NNP	num||nonusers-62/NNP||0.17-63/CD	num||nonusers-62/NNP||0.09-65/CD	quantmod||$-67/$||â-66/RB	dep||-rrb--70/NN||$-67/$	num||$-67/$||0.32-69/CD	amod||risk-55/NN||-rrb--70/NN	insulin-59||cancer-54||no_rel||after further adjustment for all other covariates with a p value less than 0.3 and nonlinear associations with cancer , a1c was associated with an increased cancer risk -lrb- hr per percentage 1.26 , 95 % ci 1.03 â $ `` 1.55 -rrb- , whereas use of insulin was associated with a decreased cancer risk -lrb- hr of insulin users vs. nonusers 0.17 , 0.09 â $ `` 0.32 -rrb- .
advmod||treatment-9/NN||moreover-1/RB	prep_in||treatment-9/NN||japan-4/NN	nsubj||treatment-9/NN||s-1-5/JJ	cop||treatment-9/NN||is-6/VBZ	det||treatment-9/NN||a-7/DT	amod||treatment-9/NN||standard-8/JJ	root||ROOT-0/null||treatment-9/NN	prep_for||treatment-9/NN||patients-11/NNS	nn||ii/iii-14/NNS||stage-13/NN	prep_with||patients-11/NNS||ii/iii-14/NNS	amod||cancer-16/NN||gastric-15/JJ	dep||patients-11/NNS||cancer-16/NN	amod||resection-19/NN||curative-18/JJ	prep_after||cancer-16/NN||resection-19/NN	det||option-23/NN||a-21/DT	amod||option-23/NN||promising-22/JJ	prep_for||treatment-9/NN||option-23/NN	conj_and||patients-11/NNS||option-23/NN	prep_for||option-23/NN||patients-25/NNS	amod||metastases-29/NNS||colorectal-27/JJ	nn||metastases-29/NNS||liver-28/NN	prep_with||patients-25/NNS||metastases-29/NNS	det||setting-33/NN||an-31/DT	amod||setting-33/NN||adjuvant-32/JJ	prep_in||metastases-29/NNS||setting-33/NN	metastases-29||adjuvant-32||no_rel||moreover, in japan s-1 is a standard treatment for patients with stage ii/iii gastric cancer after curative resection and a promising option for patients with colorectal liver metastases in an adjuvant setting.
det||nature-6/NN||the-1/DT	amod||nature-6/NN||strong-2/JJ	amod||nature-6/NN||invasive-3/JJ	conj_and||invasive-3/JJ||metastatic-5/JJ	amod||nature-6/NN||metastatic-5/JJ	nsubj||implies-9/VBZ||nature-6/NN	prep_of||nature-6/NN||cutaneousmelanoma-8/NN	root||ROOT-0/null||implies-9/VBZ	det||interplay-12/NN||a-10/DT	amod||interplay-12/NN||deregulated-11/VBN	dobj||implies-9/VBZ||interplay-12/NN	nn||adhesion-15/NN||intercellular-14/NN	prep_between||interplay-12/NN||adhesion-15/NN	amod||molecules-18/NNS||migration-related-17/JJ	dobj||implies-9/VBZ||molecules-18/NNS	conj_and||interplay-12/NN||molecules-18/NNS	det||study-21/NN||this-20/DT	prep_in||molecules-18/NNS||study-21/NN	nsubj||performed-23/VBD||we-22/PRP	rcmod||study-21/NN||performed-23/VBD	det||analysis-26/NN||a-24/DT	amod||analysis-26/NN||microarray-25/JJ	dobj||performed-23/VBD||analysis-26/NN	aux||compare-28/VB||to-27/TO	vmod||performed-23/VBD||compare-28/VB	det||profile-32/NN||the-29/DT	nn||profile-32/NN||mrna-30/NN	nn||profile-32/NN||expression-31/NN	dobj||compare-28/VB||profile-32/NN	det||line-39/NN||an-34/DT	amod||line-39/NN||invasive-35/JJ	nn||line-39/NN||blm-36/NN	nn||line-39/NN||melanoma-37/NN	nn||line-39/NN||cell-38/NN	prep_of||profile-32/NN||line-39/NN	nn||lie-42/NN||blm-41/NN	appos||line-39/NN||lie-42/NN	det||variant-49/NN||the-45/DT	amod||p-cadherin-47/JJ||non-invasive-46/JJ	amod||variant-49/NN||p-cadherin-47/JJ	amod||variant-49/NN||over-expression-48/JJ	prep_of||profile-32/NN||variant-49/NN	conj_and||line-39/NN||variant-49/NN	nn||p-cad-52/NN||blm-51/NN	appos||variant-49/NN||p-cad-52/NN	melanoma-37||blm-51||yes||the strong invasive and metastatic nature of cutaneousmelanoma implies a deregulated interplay between intercellular adhesion and migration-related molecules in this study we performed a microarray analysis to compare the mrna expression profile of an invasive blm melanoma cell line (blm lie) and the non-invasive p-cadherin over-expression variant (blm p-cad).
nn||expression-2/NN||gene-1/NN	nsubjpass||upregulated-16/VBN||expression-2/NN	prep_of||expression-2/NN||hepcidin-4/NN	amod||protein-1-9/NN||ferritin-h-6/JJ	amod||protein-1-9/NN||iron-regulatory-8/JJ	prep_of||expression-2/NN||protein-1-9/NN	conj_and||hepcidin-4/NN||protein-1-9/NN	amod||oxygenase-1-13/NN||heme-12/JJ	prep_of||expression-2/NN||oxygenase-1-13/NN	conj_and||hepcidin-4/NN||oxygenase-1-13/NN	auxpass||upregulated-16/VBN||was-14/VBD	advmod||upregulated-16/VBN||also-15/RB	root||ROOT-0/null||upregulated-16/VBN	mark||downregulated-31/VBN||whereas-18/IN	nsubjpass||downregulated-31/VBN||that-19/DT	prep_of||that-19/DT||hemojuvelin-21/NN	prep_of||that-19/DT||ferroportin-1-23/JJ	conj_and||hemojuvelin-21/NN||ferroportin-1-23/JJ	det||gene-28/NN||the-26/DT	amod||gene-28/NN||hemochromatosis-27/JJ	prep_of||that-19/DT||gene-28/NN	conj_and||hemojuvelin-21/NN||gene-28/NN	auxpass||downregulated-31/VBN||was-29/VBD	advmod||downregulated-31/VBN||significantly-30/RB	advcl||upregulated-16/VBN||downregulated-31/VBN	det||points-36/NNS||the-33/DT	amod||points-36/NNS||same-34/JJ	nn||points-36/NNS||time-35/NN	prep_at||downregulated-31/VBN||points-36/NNS	predet||brain-40/NN||both-38/PDT	det||brain-40/NN||the-39/DT	prep_in||points-36/NNS||brain-40/NN	det||liver-43/NN||the-42/DT	prep_in||points-36/NNS||liver-43/NN	conj_and||brain-40/NN||liver-43/NN	det||level-47/NN||the-45/DT	nn||level-47/NN||rna-46/NN	prep_at||downregulated-31/VBN||level-47/NN	hemochromatosis-27||iron--1||no||gene expression of hepcidin, ferritin-h, iron-regulatory protein-1, and heme oxygenase-1 was also upregulated, whereas that of hemojuvelin, ferroportin-1, and the hemochromatosis gene was significantly downregulated at the same time points in both the brain and the liver at the rna level.
det||data-2/NNS||these-1/DT	nsubj||provide-3/VBP||data-2/NNS	root||ROOT-0/null||provide-3/VBP	amod||evidence-5/NN||further-4/JJ	dobj||provide-3/VBP||evidence-5/NN	amod||rsvinfection-8/NN||serious-7/JJ	prep_of||evidence-5/NN||rsvinfection-8/NN	prep_in||provide-3/VBP||children-10/NNS	det||federation-14/NN||the-12/DT	nn||federation-14/NN||russian-13/NN	prep_in||children-10/NNS||federation-14/NN	prep_in||provide-3/VBP||guidance-19/NN	conj_and||children-10/NNS||guidance-19/NN	prep_for||guidance-19/NN||timing-21/NN	amod||prophylaxis-25/NNS||seasonal-23/JJ	nn||prophylaxis-25/NNS||rsv-24/NN	prep_of||timing-21/NN||prophylaxis-25/NNS	dep||provide-3/VBP||especially-27/RB	prep_among||provide-3/VBP||individuals-29/NNS	amod||risk-32/NN||high-31/JJ	prep_at||individuals-29/NNS||risk-32/NN	amod||rsvinfection-35/NN||serious-34/JJ	prep_for||risk-32/NN||rsvinfection-35/NN	rsvinfection-35||rsv-24||no||these data provide further evidence of serious rsvinfection in children in the russian federation, as well as guidance for timing of seasonal rsv prophylaxis, especially among individuals at high risk for serious rsvinfection.
advmod||hepatitisbvirus-8/VBZ||recently-1/RB	det||-rrb--7/NN||a-3/DT	amod||-rrb--7/NN||complex-4/JJ	amod||-rrb--7/NN||-lrb--5/JJ	nn||-rrb--7/NN||x/c-6/NN	nsubj||hepatitisbvirus-8/VBZ||-rrb--7/NN	root||ROOT-0/null||hepatitisbvirus-8/VBZ	nn||recombinant-12/NNP||-lrb--9/NNP	nn||recombinant-12/NNP||hbv-10/NNP	nn||recombinant-12/NNP||-rrb--11/NNP	nsubjpass||proposed-20/VBN||recombinant-12/NNP	advmod||reported-15/VBN||first-14/RB	vmod||recombinant-12/NNP||reported-15/VBN	prep_in||reported-15/VBN||2000-17/CD	auxpass||proposed-20/VBN||was-19/VBD	ccomp||hepatitisbvirus-8/VBZ||proposed-20/VBN	det||genotype-24/NN||a-22/DT	amod||genotype-24/NN||new-23/JJ	prep_as||proposed-20/VBN||genotype-24/NN	mark||refuted-29/VBN||although-26/IN	nsubjpass||refuted-29/VBN||this-27/DT	auxpass||refuted-29/VBN||was-28/VBD	advcl||isolates-59/VBZ||refuted-29/VBN	advmod||refuted-29/VBN||immediately-30/RB	mark||differ-34/VBP||because-31/IN	det||strains-33/NNS||the-32/DT	nsubj||differ-34/VBP||strains-33/NNS	advcl||refuted-29/VBN||differ-34/VBP	mwe||than-37/IN||less-36/JJR	quantmod||8â-38/CD||than-37/IN	prep_by||differ-34/VBP||8â-38/CD	num||%-41/NN||$-39/$	num||$-39/$||-40/CD	dobj||differ-34/VBP||%-41/NN	amod||distance-44/NN||nucleotide-43/JJ	prep_in||%-41/NN||distance-44/NN	amod||c.-47/NN||genotype-46/JJ	prep_from||differ-34/VBP||c.-47/NN	number||â-50/CD||13.5-49/CD	num||-lrb--54/NNS||â-50/CD	dep||%-53/NN||$-51/$	num||$-51/$||-52/CD	amod||-lrb--54/NNS||%-53/NN	prep_over||c.-47/NN||-lrb--54/NNS	num||-rrb--56/NNS||38/281-55/CD	nsubj||isolates-59/VBZ||-rrb--56/NNS	prep_of||-rrb--56/NNS||hbv-58/NN	parataxis||hepatitisbvirus-8/VBZ||isolates-59/VBZ	det||long-62/JJ||the-61/DT	prep_from||isolates-59/VBZ||long-62/JJ	det||cohort-64/NN||an-63/DT	nsubjpass||assigned-69/VBN||cohort-64/NN	prep_in||cohort-64/NN||china-66/NN	auxpass||assigned-69/VBN||were-67/VBD	neg||assigned-69/VBN||not-68/RB	rcmod||long-62/JJ||assigned-69/VBN	det||genotype-73/NN||a-71/DT	amod||genotype-73/NN||specific-72/JJ	prep_to||assigned-69/VBN||genotype-73/NN	xcomp||assigned-69/VBN||using-75/VBG	amod||tools-78/NNS||current-76/JJ	nn||tools-78/NNS||genotyping-77/NN	dobj||using-75/VBG||tools-78/NNS	aux||analyse-80/VB||to-79/TO	vmod||using-75/VBG||analyse-80/VB	nn||sequences-83/NNS||surface-81/NN	nn||sequences-83/NNS||orf-82/NN	dobj||analyse-80/VB||sequences-83/NNS	nsubj||have-87/VBP||these-86/DT	parataxis||hepatitisbvirus-8/VBZ||have-87/VBP	conj_and||isolates-59/VBZ||have-87/VBP	amod||similarity-93/NN||98â-89/JJ	dep||%-92/NN||$-90/$	num||$-90/$||-91/CD	amod||similarity-93/NN||%-92/NN	prep_about||have-87/VBP||similarity-93/NN	det||recombinants-97/NNS||the-95/DT	nn||recombinants-97/NNS||x/c-96/NN	prep_to||have-87/VBP||recombinants-97/NNS	hbv-58||hepatitisbvirus-8||no||recently , a complex -lrb- x/c -rrb- hepatitisbvirus -lrb- hbv -rrb- recombinant , first reported in 2000 , was proposed as a new genotype ; although this was refuted immediately because the strains differ by less than 8â $  % in nucleotide distance from genotype c. over 13.5 â $  % -lrb- 38/281 -rrb- of hbv isolates from the long an cohort in china were not assigned to a specific genotype , using current genotyping tools to analyse surface orf sequences , and these have about 98â $  % similarity to the x/c recombinants .
nsubj||superior-15/JJ||zotarolimus-1/NNS	vmod||zotarolimus-1/NNS||eluting-2/VBG	dobj||eluting-2/VBG||stents-3/NNS	det||stent-9/NN||the-5/DT	amod||stent-9/NN||2nd-6/JJ	nn||stent-9/NN||generation-7/NN	nn||stent-9/NN||drug-eluting-8/NN	prep_as||eluting-2/VBG||stent-9/NN	appos||stent-9/NN||des-11/NNP	cop||superior-15/JJ||was-13/VBD	neg||superior-15/JJ||not-14/RB	root||ROOT-0/null||superior-15/JJ	det||des-20/NNP||the-17/DT	num||des-20/NNP||1st-18/CD	nn||des-20/NNP||generation-19/NN	prep_to||superior-15/JJ||des-20/NNP	prep_in||superior-15/JJ||contrast-23/NN	det||studies-28/NNS||the-25/DT	amod||studies-28/NNS||western-26/JJ	nn||studies-28/NNS||ami-27/NN	prep_to||superior-15/JJ||studies-28/NNS	ami-27||des-20||no_rel||zotarolimus eluting stents as the 2nd generation drug-eluting stent (des) was not superior to the 1st generation des, in contrast to the western ami studies.
nsubjpass||treated-3/VBN||osteomyelitis-1/NNS	auxpass||treated-3/VBN||was-2/VBD	root||ROOT-0/null||treated-3/VBN	amod||teicoplanin-6/NN||parenteral-5/JJ	prep_with||treated-3/VBN||teicoplanin-6/NN	amod||rifampicin-9/NN||oral-8/JJ	prep_with||treated-3/VBN||rifampicin-9/NN	conj_and||teicoplanin-6/NN||rifampicin-9/NN	prep_with||treated-3/VBN||azithromycin-11/NN	conj_and||teicoplanin-6/NN||azithromycin-11/NN	rifampicin-9||osteomyelitis-1||no_rel||osteomyelitis was treated with parenteral teicoplanin, oral rifampicin and azithromycin.
amod||hepatitisbvirus-4/NNS||occult-1/JJ	conj_or||occult-1/JJ||latent-3/JJ	amod||hepatitisbvirus-4/NNS||latent-3/JJ	nsubjpass||defined-10/VBN||hepatitisbvirus-4/NNS	appos||hepatitisbvirus-4/NNS||hbv-6/NN	advmod||defined-10/VBN||infection-8/RB	auxpass||defined-10/VBN||is-9/VBZ	root||ROOT-0/null||defined-10/VBN	prep_as||defined-10/VBN||infection-12/NN	amod||dna-16/NN||detectable-14/JJ	nn||dna-16/NN||hbv-15/NN	prep_with||defined-10/VBN||dna-16/NN	amod||antigen-20/NN||undetectable-18/JJ	nn||antigen-20/NN||surface-19/NN	prep_with||defined-10/VBN||antigen-20/NN	conj_and||dna-16/NN||antigen-20/NN	appos||dna-16/NN||hbsag-22/NN	poss||blood-27/NN||patients-25/NNS	prep_in||dna-16/NN||blood-27/NN	hbv-15||hepatitisbvirus-4||no||occult or latent hepatitisbvirus (hbv) infection is defined as infection with detectable hbv dna and undetectable surface antigen (hbsag) in patients' blood.
amod||receptors-3/NNS||adenosine-1/JJ	amod||receptors-3/NNS||a2a-2/JJ	nsubjpass||thought-8/VBN||receptors-3/NNS	nsubj||interact-10/VB||receptors-3/NNS	appos||receptors-3/NNS||a2ars-5/NNP	auxpass||thought-8/VBN||are-7/VBP	root||ROOT-0/null||thought-8/VBN	aux||interact-10/VB||to-9/TO	xcomp||thought-8/VBN||interact-10/VB	advmod||interact-10/VB||negatively-11/RB	det||receptor-16/NN||the-13/DT	amod||receptor-16/NN||dopamine-14/JJ	amod||receptor-16/NN||d2-15/JJ	prep_with||interact-10/VB||receptor-16/NN	appos||receptor-16/NN||d2r-18/NNP	dep||thought-8/VBN||so-21/IN	amod||antagonists-24/NNS||selective-22/JJ	amod||antagonists-24/NNS||a2ar-23/JJ	nsubj||attracted-26/VBN||antagonists-24/NNS	aux||attracted-26/VBN||have-25/VBP	parataxis||thought-8/VBN||attracted-26/VBN	dobj||attracted-26/VBN||attention-27/NN	nn||treatments-30/NNS||novel-29/NN	prep_as||attracted-26/VBN||treatments-30/NNS	prep_for||treatments-30/NNS||parkinson-32/NN	dep||parkinson-32/NN||sdisease-34/NN	appos||parkinson-32/NN||pd-36/NN	adenosine-1||parkinson'sdisease--1||no_rel||adenosine a2a receptors (a2ars) are thought to interact negatively with the dopamine d2 receptor (d2r), so selective a2ar antagonists have attracted attention as novel treatments for parkinson'sdisease (pd).
mark||low-8/JJ||while-1/IN	amod||hiv-3/NN||comprehensive-2/JJ	nsubj||low-8/JJ||hiv-3/NN	nn||knowledge-6/NN||aids-5/NNS	conj_and||hiv-3/NN||knowledge-6/NN	nsubj||low-8/JJ||knowledge-6/NN	cop||low-8/JJ||is-7/VBZ	advcl||show-18/VBP||low-8/JJ	amod||women-12/NNS||urban-10/JJ	amod||women-12/NNS||young-11/JJ	prep_among||low-8/JJ||women-12/NNS	prep_in||women-12/NNS||kenya-14/NN	det||results-17/NNS||the-16/DT	nsubj||show-18/VBP||results-17/NNS	root||ROOT-0/null||show-18/VBP	det||increase-21/NN||a-19/DT	amod||increase-21/NN||significant-20/JJ	dobj||show-18/VBP||increase-21/NN	amod||knowledge-24/NN||comprehensive-23/JJ	prep_in||increase-21/NN||knowledge-24/NN	num||%-27/NN||9-26/CD	prep_from||knowledge-24/NN||%-27/NN	prep_in||%-27/NN||1993-29/CD	num||%-32/NN||54-31/CD	prep_to||show-18/VBP||%-32/NN	prep_in||%-32/NN||2008/09-34/CD	aids-5||hiv-3||no||while comprehensive hiv and aids knowledge is low among urban young women in kenya, the results show a significant increase in comprehensive knowledge from 9% in 1993 to 54% in 2008/09.
det||paper-2/NN||this-1/DT	nsubj||describes-3/VBZ||paper-2/NN	root||ROOT-0/null||describes-3/VBZ	det||features-6/NNS||the-4/DT	amod||features-6/NNS||clinical-5/JJ	nsubj||2008â-41/VB||features-6/NNS	det||series-9/NN||a-8/DT	prep_of||features-6/NNS||series-9/NN	prep_of||series-9/NN||patients-11/NNS	vmod||patients-11/NNS||admitted-12/VBN	det||jagori-19/NN||the-14/DT	amod||jagori-19/NN||specialist-15/JJ	amod||jagori-19/NN||hiv/aids-16/JJ	nn||jagori-19/NN||unit-17/NN	prep_to||admitted-12/VBN||jagori-19/NN	det||hospital-24/NN||the-22/DT	nn||hospital-24/NN||dhaka-23/NN	prep_of||jagori-19/NN||hospital-24/NN	appos||hospital-24/NN||icddr-26/NN	dep||jagori-19/NN||b-28/SYM	amod||centre-31/NN||international-30/JJ	dep||jagori-19/NN||centre-31/NN	amod||research-35/NN||diarrhoeal-33/JJ	nn||research-35/NN||disease-34/NN	prep_for||centre-31/NN||research-35/NN	advmod||centre-31/NN||bangladesh-37/RB	prep||admitted-12/VBN||during-39/IN	aux||2008â-41/VB||may-40/MD	ccomp||describes-3/VBZ||2008â-41/VB	dobj||2008â-41/VB||$-42/$	tmod||2008â-41/VB||february-44/NNP	num||february-44/NNP||2010-45/CD	aids--1||hiv--1||no||this paper describes the clinical features of a series of patients admitted to the specialist hiv/aids unit (jagori) of the dhaka hospital, icddr, b (international centre for diarrhoeal disease research, bangladesh) during may 2008âfebruary 2010.
nsubjpass||expressed-4/VBN||myb-1/NN	auxpass||expressed-4/VBN||is-2/VBZ	advmod||expressed-4/VBN||highly-3/RB	root||ROOT-0/null||expressed-4/VBN	amod||breasttumours-14/NNS||estrogen-6/JJ	nn||breasttumours-14/NNS||receptor-7/NN	nn||breasttumours-14/NNS||positive-8/NN	amod||ve-12/NN||er-10/JJ	amod||ve-12/NN||+-11/JJ	appos||breasttumours-14/NNS||ve-12/NN	prep_in||expressed-4/VBN||breasttumours-14/NNS	nn||lines-18/NNS||tumour-16/NN	nn||lines-18/NNS||cell-17/NN	prep_in||expressed-4/VBN||lines-18/NNS	conj_and||breasttumours-14/NNS||lines-18/NNS	breasttumours-14||estrogen-6||no||myb is highly expressed in estrogen receptor positive (er + ve) breasttumours and tumour cell lines.
det||era-3/NN||an-2/DT	prep_in||becoming-15/VBG||era-3/NN	amod||immunity-6/NN||reduced-5/VBN	prep_of||era-3/NN||immunity-6/NN	prep_from||immunity-6/NN||humanimmunodeficiencyvirus-8/NNS	prep_from||immunity-6/NN||acquiredimmunodeficiencysyndrome-10/NN	conj_and||humanimmunodeficiencyvirus-8/NNS||acquiredimmunodeficiencysyndrome-10/NN	det||disease-13/NN||the-12/DT	nsubj||becoming-15/VBG||disease-13/NN	aux||becoming-15/VBG||is-14/VBZ	root||ROOT-0/null||becoming-15/VBG	advmod||prevalent-17/JJ||more-16/RBR	acomp||becoming-15/VBG||prevalent-17/JJ	acquiredimmunodeficiencysyndrome-10||humanimmunodeficiencyvirus-8||no||in an era of reduced immunity from humanimmunodeficiencyvirus and acquiredimmunodeficiencysyndrome, the disease is becoming more prevalent.
det||evidence-3/NN||the-1/DT	amod||evidence-3/NN||current-2/JJ	nsubj||shows-4/VBZ||evidence-3/NN	root||ROOT-0/null||shows-4/VBZ	mark||option-10/NN||that-5/IN	nsubj||option-10/NN||pioglitazone-6/NN	cop||option-10/NN||is-7/VBZ	det||option-10/NN||an-8/DT	amod||option-10/NN||effective-9/JJ	ccomp||shows-4/VBZ||option-10/NN	det||treatment-13/NN||the-12/DT	prep_in||option-10/NN||treatment-13/NN	prep_of||treatment-13/NN||type2diabetes-15/CD	type2diabetes-15||pioglitazone-6||yes||the current evidence shows that pioglitazone is an effective option in the treatment of type2diabetes.
nsubj||result-6/VBP||mutations-1/NNS	nsubj||produce-11/VB||mutations-1/NNS	det||gene-5/NN||the-3/DT	nn||gene-5/NN||hfe-4/NN	prep_in||mutations-1/NNS||gene-5/NN	ccomp||characterized-22/VBD||result-6/VBP	prep_in||result-6/VBP||ironoverload-8/NN	aux||produce-11/VB||can-10/MD	conj_and||result-6/VBP||produce-11/VB	ccomp||characterized-22/VBD||produce-11/VB	dobj||produce-11/VB||hereditaryhemochromatosis-12/NNS	appos||hereditaryhemochromatosis-12/NNS||hh-14/NN	det||disorder-18/NN||a-17/DT	nsubj||characterized-22/VBD||disorder-18/NN	nn||metabolism-21/NN||iron-20/NN	prep_of||disorder-18/NN||metabolism-21/NN	root||ROOT-0/null||characterized-22/VBD	amod||absorption-27/NN||increased-24/VBN	amod||absorption-27/NN||intestinal-25/JJ	nn||absorption-27/NN||iron-26/NN	prep_by||characterized-22/VBD||absorption-27/NN	ironoverload-8||iron-26||no||mutations in the hfe gene result in ironoverload and can produce hereditaryhemochromatosis (hh), a disorder of iron metabolism characterized by increased intestinal iron absorption.
det||study-2/NN||this-1/DT	nsubjpass||done-4/VBN||study-2/NN	nsubj||evaluate-6/VB||study-2/NN	auxpass||done-4/VBN||was-3/VBD	root||ROOT-0/null||done-4/VBN	aux||evaluate-6/VB||to-5/TO	xcomp||done-4/VBN||evaluate-6/VB	det||effect-8/NN||the-7/DT	dobj||evaluate-6/VB||effect-8/NN	nn||relief-11/NN||pain-10/NN	prep_on||evaluate-6/VB||relief-11/NN	advmod||added-15/VBN||when-12/WRB	nsubjpass||added-15/VBN||acetaminophen-13/NN	nsubj||lidocaine-17/VB||acetaminophen-13/NN	auxpass||added-15/VBN||was-14/VBD	advcl||evaluate-6/VB||added-15/VBN	aux||lidocaine-17/VB||to-16/TO	xcomp||added-15/VBN||lidocaine-17/VB	amod||anesthesia-21/NN||intravenous-19/JJ	amod||anesthesia-21/NN||regional-20/JJ	prep_for||lidocaine-17/VB||anesthesia-21/NN	appos||anesthesia-21/NN||ivra-23/NNP	pain-10||lidocaine-17||yes||this study was done to evaluate the effect on pain relief when acetaminophen was added to lidocaine for intravenous regional anesthesia (ivra).
advmod||demonstrated-8/VBD||recently-1/RB	det||article-4/NN||an-3/DT	nsubj||demonstrated-8/VBD||article-4/NN	amod||rheumatology-7/NN||pediatric-6/JJ	prep_in||article-4/NN||rheumatology-7/NN	root||ROOT-0/null||demonstrated-8/VBD	mark||risk-16/NN||that-9/IN	expl||risk-16/NN||there-10/EX	aux||risk-16/NN||may-11/MD	neg||risk-16/NN||not-12/RB	cop||risk-16/NN||be-13/VB	det||risk-16/NN||an-14/DT	amod||risk-16/NN||increased-15/VBN	ccomp||demonstrated-8/VBD||risk-16/NN	prep_of||risk-16/NN||cancer-18/NN	prep_in||risk-16/NN||children-20/NNS	prep_with||children-20/NNS||juvenileidiopathicarthritis-22/NNS	vmod||juvenileidiopathicarthritis-22/NNS||treated-23/VBN	advmod||treated-23/VBN||specifically-24/RB	det||protein-32/NN||the-26/DT	nn||protein-32/NN||tumor-27/NN	nn||protein-32/NN||necrosis-28/NN	nn||protein-32/NN||factor-29/NN	nn||protein-32/NN||receptor-30/NN	nn||protein-32/NN||fusion-31/NN	prep_with||treated-23/VBN||protein-32/NN	appos||protein-32/NN||etanercept-34/NN	juvenileidiopathicarthritis-22||etanercept-34||yes||recently, an article in pediatric rheumatology demonstrated that there may not be an increased risk of cancer in children with juvenileidiopathicarthritis treated specifically with the tumor necrosis factor receptor fusion protein, etanercept.
nsubj||receiving-3/VBG||patients-2/NNS	prepc_in||had-17/VBD||receiving-3/VBG	dobj||receiving-3/VBG||dacarbazine-4/NN	amod||chemotherapy-7/NN||first-line-6/JJ	prep_as||receiving-3/VBG||chemotherapy-7/NN	amod||melanoma-10/NN||metastatic-9/JJ	prep_for||chemotherapy-7/NN||melanoma-10/NN	det||addition-13/NN||the-12/DT	nsubj||had-17/VBD||addition-13/NN	amod||bosentan-16/NN||high-dose-15/JJ	prep_of||addition-13/NN||bosentan-16/NN	root||ROOT-0/null||had-17/VBD	neg||effect-19/NN||no-18/DT	dobj||had-17/VBD||effect-19/NN	prep_on||effect-19/NN||time-21/NN	nn||progression-24/NN||tumor-23/NN	prep_to||had-17/VBD||progression-24/NN	amod||parameters-28/NNS||other-26/JJ	nn||parameters-28/NNS||efficacy-27/NN	prep_to||had-17/VBD||parameters-28/NNS	conj_or||progression-24/NN||parameters-28/NNS	bosentan-16||tumor-23||no_rel||in patients receiving dacarbazine as first-line chemotherapy for metastatic melanoma, the addition of high-dose bosentan had no effect on time to tumor progression or other efficacy parameters.
root||ROOT-0/null||basal-1/NN	conj_and||basal-1/NN||interferon-alpha-3/NN	nn||±-6/NNP||ifn-î-5/NNP	appos||basal-1/NN||±-6/NNP	conj_or||basal-1/NN||interferon-gamma-9/NN	nn||³-12/NNP||ifn-î-11/NNP	appos||interferon-gamma-9/NN||³-12/NNP	amod||expression-16/NN||induced-15/JJ	nsubjpass||evaluated-23/VBN||expression-16/NN	amod||proteins-21/NNS||socs1-18/JJ	conj_and||socs1-18/JJ||socs3-20/JJ	amod||proteins-21/NNS||socs3-20/JJ	prep_of||expression-16/NN||proteins-21/NNS	auxpass||evaluated-23/VBN||was-22/VBD	dep||basal-1/NN||evaluated-23/VBN	amod||analysis-26/NN||immunoblot-25/JJ	agent||evaluated-23/VBN||analysis-26/NN	det||panel-29/NN||a-28/DT	prep_in||analysis-26/NN||panel-29/NN	prep_of||panel-29/NN||n-31/NN	dep||lines-38/NNS||=-32/SYM	num||lines-38/NNS||10-33/CD	amod||lines-38/NNS||metastatic-34/JJ	amod||lines-38/NNS||human-35/JJ	nn||lines-38/NNS||melanoma-36/NNP	nn||lines-38/NNS||cell-37/NN	ccomp||evaluated-23/VBN||lines-38/NNS	amod||melanocytes-43/NNS||human-41/JJ	amod||melanocytes-43/NNS||embryonic-42/JJ	prep_in||basal-1/NN||melanocytes-43/NNS	appos||melanocytes-43/NNS||hem-45/NN	prep_in||basal-1/NN||radial-49/NN	conj_and||melanocytes-43/NNS||radial-49/NN	amod||cells-55/NNS||vertical-51/JJ	nn||cells-55/NNS||growth-52/NN	nn||cells-55/NNS||phase-53/NN	nn||cells-55/NNS||melanoma-54/NN	conj_and||melanocytes-43/NNS||cells-55/NNS	conj_or||radial-49/NN||cells-55/NNS	melanoma-54||ifn--1||yes||basal and interferon-alpha (ifn-î±) or interferon-gamma (ifn-î³)-induced expression of socs1 and socs3 proteins was evaluated by immunoblot analysis in a panel of n = 10 metastatic human melanoma cell lines, in human embryonic melanocytes (hem), and radial or vertical growth phase melanoma cells.
num||hundred-2/CD||one-1/CD	nsubjpass||randomized-10/VBN||hundred-2/CD	num||patients-5/NNS||twenty-4/CD	conj_and||hundred-2/CD||patients-5/NNS	nsubjpass||randomized-10/VBN||patients-5/NNS	amod||hypertension-8/NN||essential-7/JJ	prep_with||hundred-2/CD||hypertension-8/NN	auxpass||randomized-10/VBN||were-9/VBD	root||ROOT-0/null||randomized-10/VBN	num||groups-13/NNS||four-12/CD	prep_into||randomized-10/VBN||groups-13/NNS	vmod||groups-13/NNS||receiving-14/VBG	acomp||receiving-14/VBG||enalapril-15/JJ	acomp||receiving-14/VBG||lisinopril-17/JJ	conj_and||enalapril-15/JJ||lisinopril-17/JJ	acomp||receiving-14/VBG||ramipril-19/JJ	conj_and||enalapril-15/JJ||ramipril-19/JJ	acomp||receiving-14/VBG||fosinopril-22/JJ	conj_and||enalapril-15/JJ||fosinopril-22/JJ	hypertension-8||fosinopril-22||yes||one hundred and twenty patients with essential hypertension were randomized into four groups receiving enalapril, lisinopril, ramipril, and fosinopril.
nsubjpass||transmitted-7/VBN||avianinfluenzavirus-1/NNS	appos||avianinfluenzavirus-1/NNS||h5n1-3/NNP	aux||transmitted-7/VBN||can-5/MD	auxpass||transmitted-7/VBN||be-6/VB	root||ROOT-0/null||transmitted-7/VBN	prep_to||transmitted-7/VBN||humans-9/NNS	xcomp||transmitted-7/VBN||resulting-11/VBG	det||disease-17/NN||a-13/DT	amod||disease-17/NN||severe-14/JJ	conj_or||severe-14/JJ||fatal-16/JJ	amod||disease-17/NN||fatal-16/JJ	prep_in||resulting-11/VBG||disease-17/NN	h5n1-3||avianinfluenzavirus-1||no||avianinfluenzavirus (h5n1) can be transmitted to humans, resulting in a severe or fatal disease.
nsubj||accounted-23/VBD||questions-1/NNS	vmod||questions-1/NNS||related-2/VBN	prep_to||related-2/VBN||co-morbidities-4/NNS	prep_in||co-morbidities-4/NNS||hiv/aids-6/NNS	amod||cancers-10/NNS||non-aids-8/JJ	amod||cancers-10/NNS||related-9/JJ	dep||hiv/aids-6/NNS||cancers-10/NNS	amod||diseases-13/NNS||systemic-12/JJ	dep||hiv/aids-6/NNS||diseases-13/NNS	conj_and||cancers-10/NNS||diseases-13/NNS	amod||toxicities-19/NNS||chronic-16/JJ	amod||toxicities-19/NNS||antiretroviral-17/JJ	nn||toxicities-19/NNS||treatment-18/NN	prep_in||co-morbidities-4/NNS||toxicities-19/NNS	conj_and||hiv/aids-6/NNS||toxicities-19/NNS	dep||hiv/aids-6/NNS||metabolicdisorders-21/NNS	root||ROOT-0/null||accounted-23/VBD	advmod||lower-26/JJR||significantly-25/RB	amod||scores-27/NNS||lower-26/JJR	prep_for||accounted-23/VBD||scores-27/NNS	dep||scores-27/NNS||mean-29/NN	num||%-32/NN||41.7-31/CD	appos||mean-29/NN||%-32/NN	num||%-35/NN||95-34/CD	npadvmod||ci-36/RB||%-35/NN	advmod||mean-29/NN||ci-36/RB	num||%-38/NN||39.3-37/CD	dep||mean-29/NN||%-38/NN	quantmod||$-40/$||â-39/RB	num||%-43/NN||$-40/$	num||$-40/$||44-42/CD	dep||%-38/NN||%-43/NN	prepc_compared_to||accounted-23/VBD||to-46/TO	nn||epidemiology-48/NN||hiv/aids-47/NNS	pobj||accounted-23/VBD||epidemiology-48/NN	pobj||accounted-23/VBD||prevention-50/NN	conj_and||epidemiology-48/NN||prevention-50/NN	dep||epidemiology-48/NN||mean-52/VB	num||%-55/NN||65.7-54/CD	nsubj||$-63/VBG||%-55/NN	number||%-58/NN||95-57/CD	amod||ci-59/NN||%-58/NN	appos||%-55/NN||ci-59/NN	num||%-61/NN||63.7-60/CD	npadvmod||â-62/RB||%-61/NN	advmod||$-63/VBG||â-62/RB	ccomp||mean-52/VB||$-63/VBG	num||%-66/NN||67.7-65/CD	dobj||$-63/VBG||%-66/NN	aids--1||hiv--1||no||questions related to co-morbidities in hiv/aids (non-aids related cancers and systemic diseases) and chronic antiretroviral treatment toxicities (metabolicdisorders) accounted for significantly lower scores (mean, 41.7%, 95% ci 39.3%â44%) compared to hiv/aids epidemiology and prevention (mean, 65.7%, 95% ci 63.7%â67.7%).
det||parents-2/NNS||the-1/DT	nsubjpass||surveyed-16/VBN||parents-2/NNS	num||children-5/NNS||100-4/CD	prep_of||parents-2/NNS||children-5/NNS	prep_with||children-5/NNS||jia-7/NN	vmod||jia-7/NN||taking-8/VBG	dobj||taking-8/VBG||mtx-9/NN	quantmod||2-13/CD||at-11/IN	mwe||at-11/IN||least-12/JJS	pobj||at-11/IN||least-12/JJS	num||months-14/NNS||2-13/CD	prep_for||mtx-9/NN||months-14/NNS	auxpass||surveyed-16/VBN||were-15/VBD	root||ROOT-0/null||surveyed-16/VBN	det||visit-21/NN||a-18/DT	amod||visit-21/NN||routine-19/JJ	nn||visit-21/NN||office-20/NN	prep_during||surveyed-16/VBN||visit-21/NN	jia-7||mtx-9||yes||the parents of 100 children with jia taking mtx for at least 2 months were surveyed during a routine office visit.
nsubjpass||associated-3/VBN||rs12553951c-1/NNS	auxpass||associated-3/VBN||was-2/VBD	root||ROOT-0/null||associated-3/VBN	prep_with||associated-3/VBN||sle-5/NN	nn||males-8/NNS||ea-7/NN	prep_in||sle-5/NN||males-8/NNS	nn||ratio-11/NN||odds-10/NNS	dep||males-8/NNS||ratio-11/NN	dep||1.93-13/CD||=-12/SYM	rcmod||ratio-11/NN||1.93-13/CD	advmod||10â-20/NNS||p-15/RB	number||2.5-17/CD||=-16/CD	num||10â-20/NNS||2.5-17/CD	amod||10â-20/NNS||ã-18/JJ	appos||ratio-11/NN||10â-20/NNS	dep||10â-20/NNS||4-22/CD	prep_with||associated-3/VBN||females-27/NNS	conj_negcc||sle-5/NN||females-27/NNS	ea-7||sle-5||no_rel||rs12553951c was associated with sle in ea males (odds ratio = 1.93, p = 2.5 ã 10â4), but not females.
nn||identification-2/NN||species-1/NN	nsubj||seems-13/VBZ||identification-2/NN	nsubj||important-16/JJ||identification-2/NN	prep_of||identification-2/NN||isolates-4/NNP	vmod||isolates-4/NNP||belonging-5/VBG	det||-rrb--12/NNS||the-7/DT	amod||complex-9/JJ||mycobacteriumtuberculosis-8/JJ	amod||-rrb--12/NNS||complex-9/JJ	amod||-rrb--12/NNS||-lrb--10/JJ	nn||-rrb--12/NNS||mtc-11/NN	prep_to||belonging-5/VBG||-rrb--12/NNS	root||ROOT-0/null||seems-13/VBZ	aux||important-16/JJ||to-14/TO	cop||important-16/JJ||be-15/VB	xcomp||seems-13/VBZ||important-16/JJ	det||treatment-20/NN||the-18/DT	amod||treatment-20/NN||appropriate-19/JJ	prep_for||important-16/JJ||treatment-20/NN	prep_of||treatment-20/NN||patients-22/NNS	mark||resistant-29/JJ||since-24/IN	nn||bovis-26/NNS||m.-25/NN	nsubj||resistant-29/JJ||bovis-26/NNS	cop||resistant-29/JJ||is-27/VBZ	advmod||resistant-29/JJ||naturally-28/RB	advcl||important-16/JJ||resistant-29/JJ	det||drug-38/NN||a-31/DT	amod||drug-38/NN||first-32/JJ	nn||drug-38/NN||line-33/NN	amod||drug-38/NN||anti-tuberculosis-34/JJ	nn||drug-38/NN||-lrb--35/NNP	nn||drug-38/NN||tb-36/NN	nn||drug-38/NN||-rrb--37/NN	prep_to||resistant-29/JJ||drug-38/NN	appos||drug-38/NN||pyrazinamide-40/NN	mark||susceptible-50/JJ||while-42/IN	nsubj||susceptible-50/JJ||most-43/JJS	det||members-48/NNS||the-45/DT	amod||members-48/NNS||other-46/JJ	nn||members-48/NNS||mtc-47/NN	prep_of||most-43/JJS||members-48/NNS	cop||susceptible-50/JJ||are-49/VBP	advcl||resistant-29/JJ||susceptible-50/JJ	det||agent-54/NN||this-52/DT	amod||agent-54/NN||antimicrobial-53/JJ	prep_to||susceptible-50/JJ||agent-54/NN	tuberculosis--1||pyrazinamide-40||yes||species identification of isolates belonging to the mycobacteriumtuberculosis complex -lrb- mtc -rrb- seems to be important for the appropriate treatment of patients , since m. bovis is naturally resistant to a first line anti-tuberculosis -lrb- tb -rrb- drug , pyrazinamide , while most of the other mtc members are susceptible to this antimicrobial agent .
prep_in||shown-6/VBN||humans-2/NNS	nsubjpass||shown-6/VBN||chemerin-4/NN	nsubjpass||associated-9/VBN||chemerin-4/NN	auxpass||shown-6/VBN||was-5/VBD	root||ROOT-0/null||shown-6/VBN	aux||associated-9/VBN||to-7/TO	auxpass||associated-9/VBN||be-8/VB	xcomp||shown-6/VBN||associated-9/VBN	amod||components-12/NNS||multiple-11/JJ	prep_with||associated-9/VBN||components-12/NNS	det||syndrome-16/NN||the-14/DT	amod||syndrome-16/NN||metabolic-15/JJ	prep_of||components-12/NNS||syndrome-16/NN	prep_including||syndrome-16/NN||bmi-18/NN	prep_including||syndrome-16/NN||triglycerides-20/NNPS	conj_and||bmi-18/NN||triglycerides-20/NNPS	nn||cholesterol-23/NN||hdl-22/NN	prep_including||syndrome-16/NN||cholesterol-23/NN	conj_and||bmi-18/NN||cholesterol-23/NN	prep_including||syndrome-16/NN||hypertension-26/NN	conj_and||bmi-18/NN||hypertension-26/NN	hypertension-26||triglycerides-20||no_rel||in humans, chemerin was shown to be associated with multiple components of the metabolic syndrome including bmi, triglycerides, hdl cholesterol, and hypertension.
prep_on||provided-6/VBD||average-2/NN	amod||peers-5/NNS||experienced-4/JJ	nsubj||provided-6/VBD||peers-5/NNS	root||ROOT-0/null||provided-6/VBD	amod||responses-8/NNS||correct-7/JJ	dobj||provided-6/VBD||responses-8/NNS	num||%-11/NN||73-10/CD	prep_to||provided-6/VBD||%-11/NN	prep_of||%-11/NN||questions-13/NNS	prep_about||questions-13/NNS||hiv-15/NN	prep_about||questions-13/NNS||aids-17/NNS	conj_and||hiv-15/NN||aids-17/NNS	num||%-21/NN||65-20/CD	prep_of||%-11/NN||%-21/NN	conj_and||questions-13/NNS||%-21/NN	prep_of||%-21/NN||questions-23/NNS	det||role-27/NN||the-25/DT	amod||role-27/NN||appropriate-26/JJ	prep_about||provided-6/VBD||role-27/NN	det||peer-30/NN||a-29/DT	prep_of||role-27/NN||peer-30/NN	aids-17||hiv-15||no||on average, experienced peers provided correct responses to 73% of questions about hiv and aids, and 65% of questions about the appropriate role of a peer.
amod||ironoverload-3/NN||dietary-2/JJ	prep_in||promotes-8/VBZ||ironoverload-3/NN	amod||iron-7/NN||excess-5/JJ	amod||iron-7/NN||hepatic-6/JJ	nsubj||promotes-8/VBZ||iron-7/NN	root||ROOT-0/null||promotes-8/VBZ	nn||damage-10/NN||liver-9/NN	dobj||promotes-8/VBZ||damage-10/NN	ironoverload-3||iron-7||no||in dietary ironoverload, excess hepatic iron promotes liver damage.
amod||mortality-2/NN||overall-1/JJ	nsubj||%-5/NN||mortality-2/NN	cop||%-5/NN||was-3/VBD	num||%-5/NN||9-4/CD	root||ROOT-0/null||%-5/NN	num||deaths-8/NNS||21-7/CD	appos||%-5/NN||deaths-8/NNS	det||arm-15/NN||the-11/DT	amod||arm-15/NN||high-12/JJ	nn||arm-15/NN||flow-13/NN	nn||arm-15/NN||oxygen-14/NN	prep_in||%-5/NN||arm-15/NN	prep||arm-15/NN||compared-16/VBN	pcomp||compared-16/VBN||with-17/IN	num||%-19/NN||4-18/CD	pobj||with-17/IN||%-19/NN	num||deaths-22/NNS||7-21/CD	appos||%-19/NN||deaths-22/NNS	det||arm-28/NN||the-25/DT	amod||arm-28/NN||titrated-26/JJ	nn||arm-28/NN||oxygen-27/NN	prep_in||%-19/NN||arm-28/NN	nsubj||%-40/NN||mortality-30/NN	det||subgroup-33/NN||the-32/DT	prep_in||mortality-30/NN||subgroup-33/NN	amod||obstructivepulmonarydisease-37/NN||confirmed-35/JJ	amod||obstructivepulmonarydisease-37/NN||chronic-36/JJ	prep_with||subgroup-33/NN||obstructivepulmonarydisease-37/NN	cop||%-40/NN||was-38/VBD	num||%-40/NN||9-39/CD	parataxis||%-5/NN||%-40/NN	num||deaths-43/NNS||11-42/CD	appos||%-40/NN||deaths-43/NNS	det||arm-49/NN||the-46/DT	amod||arm-49/NN||high-47/JJ	nn||arm-49/NN||flow-48/NN	prep_in||%-40/NN||arm-49/NN	prepc_compared_with||arm-49/NN||with-51/IN	num||%-53/NN||2-52/CD	pobj||arm-49/NN||%-53/NN	num||deaths-56/NNS||2-55/CD	appos||%-53/NN||deaths-56/NNS	det||arm-62/NN||the-59/DT	amod||arm-62/NN||titrated-60/JJ	nn||arm-62/NN||oxygen-61/NN	prep_in||%-53/NN||arm-62/NN	obstructivepulmonarydisease-37||oxygen-61||yes||overall mortality was 9% (21 deaths) in the high flow oxygen arm compared with 4% (7 deaths) in the titrated oxygen arm; mortality in the subgroup with confirmed chronic obstructivepulmonarydisease was 9% (11 deaths) in the high flow arm compared with 2% (2 deaths) in the titrated oxygen arm.
det||lack-2/NN||the-1/DT	nsubj||hindered-12/VBN||lack-2/NN	amod||trials-7/NNS||adequate-4/JJ	amod||trials-7/NNS||randomized-5/JJ	amod||trials-7/NNS||clinical-6/JJ	prep_of||lack-2/NN||trials-7/NNS	appos||trials-7/NNS||rct-9/NN	aux||hindered-12/VBN||has-11/VBZ	root||ROOT-0/null||hindered-12/VBN	dobj||hindered-12/VBN||identification-13/NN	nsubj||safe-19/JJ||identification-13/NN	nsubj||effective-21/JJ||identification-13/NN	amod||therapies-16/NNS||new-15/JJ	prep_of||identification-13/NN||therapies-16/NNS	cop||safe-19/JJ||are-18/VBP	rcmod||identification-13/NN||safe-19/JJ	rcmod||identification-13/NN||effective-21/JJ	conj_and||safe-19/JJ||effective-21/JJ	prep_for||safe-19/JJ||patients-23/NNS	amod||focalsegmentalglomerulosclerosis-26/NNS||primary-25/JJ	prep_with||patients-23/NNS||focalsegmentalglomerulosclerosis-26/NNS	appos||focalsegmentalglomerulosclerosis-26/NNS||fsgs-28/NNS	dep||safe-19/JJ||especially-31/RB	prep_in||safe-19/JJ||patients-33/NNS	nsubj||fail-35/VBP||patients-33/NNS	nsubj||respond-37/VB||patients-33/NNS	rcmod||patients-33/NNS||fail-35/VBP	aux||respond-37/VB||to-36/TO	xcomp||fail-35/VBP||respond-37/VB	prep_to||respond-37/VB||corticosteroids-39/NNS	nn||therapies-42/NNS||immunosuppressive-41/NN	prep_to||respond-37/VB||therapies-42/NNS	conj_and||corticosteroids-39/NNS||therapies-42/NNS	corticosteroids-39||focalsegmentalglomerulosclerosis-26||no_rel||the lack of adequate randomized clinical trials (rct) has hindered identification of new therapies that are safe and effective for patients with primary focalsegmentalglomerulosclerosis (fsgs), especially in patients who fail to respond to corticosteroids and immunosuppressive therapies.
nn||ebv-3/NN||type-1/NN	num||ebv-3/NN||1-2/CD	nsubj||genotypes-12/NNS||ebv-3/NN	amod||zp-p-6/NN||bzlf1-5/JJ	conj_and||ebv-3/NN||zp-p-6/NN	nsubj||genotypes-12/NNS||zp-p-6/NN	prep_of||zp-p-6/NN||ebv-8/NN	cop||genotypes-12/NNS||were-9/VBD	det||genotypes-12/NNS||the-10/DT	amod||genotypes-12/NNS||predominant-11/JJ	root||ROOT-0/null||genotypes-12/NNS	amod||ebv-15/NN||nonmalignant-14/JJ	prep_in||genotypes-12/NNS||ebv-15/NN	vmod||ebv-15/NN||associated-16/VBN	dobj||associated-16/VBN||diseases-17/NNS	amod||children-20/NNS||chinese-19/JJ	prep_in||diseases-17/NNS||children-20/NNS	amod||variant-23/NN||zp-v3-22/JJ	nsubj||correlates-25/VB||variant-23/NN	aux||correlates-25/VB||may-24/MD	conj_and||genotypes-12/NNS||correlates-25/VB	prep_with||correlates-25/VB||the-27/DT	amod||the-27/DT||developing-28/VBG	amod||diseases-32/NNS||severe-30/JJ	nn||diseases-32/NNS||ebvinfection-31/NN	prep_of||the-27/DT||diseases-32/NNS	prep_such_as||the-27/DT||caebv-36/NN	prep_such_as||the-27/DT||ebv-hlh-38/NN	conj_and||caebv-36/NN||ebv-hlh-38/NN	ebvinfection-31||ebv-15||no||type 1 ebv and bzlf1 zp-p of ebv were the predominant genotypes in nonmalignant ebv associated diseases in chinese children and zp-v3 variant may correlates with the developing of severe ebvinfection diseases, such as caebv and ebv-hlh.
advmod||investigated-25/VBN||sulphadoxine-pyrimethamine-1/RB	dep||investigated-25/VBN||sp-3/VB	det||treatment-8/NN||a-5/DT	advmod||used-7/VBN||widely-6/RB	amod||treatment-8/NN||used-7/VBN	nsubjpass||investigated-25/VBN||treatment-8/NN	amod||malaria-11/NN||uncomplicated-10/JJ	prep_for||treatment-8/NN||malaria-11/NN	prep_for||treatment-8/NN||recommended-13/VBN	conj_and||malaria-11/NN||recommended-13/VBN	amod||treatment-17/NN||intermittent-15/JJ	nn||treatment-17/NN||preventive-16/NN	prep_for||recommended-13/VBN||treatment-17/NN	prep_of||recommended-13/VBN||malaria-19/NN	prep_in||recommended-13/VBN||pregnancy-21/NN	aux||investigated-25/VBN||is-23/VBZ	auxpass||investigated-25/VBN||being-24/VBG	root||ROOT-0/null||investigated-25/VBN	amod||treatment-29/NN||intermittent-27/JJ	nn||treatment-29/NN||preventive-28/NN	prep_for||investigated-25/VBN||treatment-29/NN	prep_of||treatment-29/NN||malaria-31/NN	prep_in||malaria-31/NN||infants-33/NNS	appos||infants-33/NNS||ipti-35/NNP	malaria-31||pyrimethamine--1||yes||sulphadoxine-pyrimethamine (sp) a widely used treatment for uncomplicated malaria and recommended for intermittent preventive treatment of malaria in pregnancy, is being investigated for intermittent preventive treatment of malaria in infants (ipti).
amod||animals-5/NNS||stz-treated-4/JJ	prep_with_respect_to||characterized-14/VBN||animals-5/NNS	nsubjpass||characterized-14/VBN||mice-7/NNS	vmod||mice-7/NNS||co-injected-8/VBN	nn||trail-12/NN||stz-10/NN	nn||trail-12/NN||+-11/NN	prep_with||co-injected-8/VBN||trail-12/NN	auxpass||characterized-14/VBN||were-13/VBD	root||ROOT-0/null||characterized-14/VBN	dep||levels-19/NNS||1-16/LS	amod||levels-19/NNS||lower-18/JJR	agent||characterized-14/VBN||levels-19/NNS	prep_of||levels-19/NNS||hyperglycemia-21/NN	dep||levels-26/NNS||2-23/LS	amod||levels-26/NNS||higher-25/JJR	agent||characterized-14/VBN||levels-26/NNS	conj_and||levels-19/NNS||levels-26/NNS	nn||weight-29/NN||body-28/NN	prep_of||levels-26/NNS||weight-29/NN	prep_of||levels-26/NNS||insulinemia-31/NN	conj_and||weight-29/NN||insulinemia-31/NN	dep||preservation-37/NN||3-33/LS	det||preservation-37/NN||a-35/DT	amod||preservation-37/NN||partial-36/JJ	agent||characterized-14/VBN||preservation-37/NN	conj_and||levels-19/NNS||preservation-37/NN	amod||islets-40/NNS||pancreatic-39/JJ	prep_of||preservation-37/NN||islets-40/NNS	amod||morphology-43/NN||normal-42/JJ	prep_with||islets-40/NNS||morphology-43/NN	dep||expression-50/NN||4-46/LS	det||expression-50/NN||a-48/DT	amod||expression-50/NN||lower-49/JJR	agent||characterized-14/VBN||expression-50/NN	conj_and||levels-19/NNS||expression-50/NN	det||systemic-53/NN||both-52/DT	prep_of||expression-50/NN||systemic-53/NN	amod||±-56/NNS||tnf-î-55/JJ	appos||systemic-53/NN||±-56/NNS	appos||systemic-53/NN||opg-58/NN	conj_and||±-56/NNS||opg-58/NN	amod||markers-73/NNS||pancreatic-61/JJ	nn||molecule-66/NN||vascular-63/NN	nn||molecule-66/NN||cell-64/NN	nn||molecule-66/NN||adhesion-65/NN	dep||pancreatic-61/JJ||molecule-66/NN	nn||-1-70/NNP||-LSB--67/NNP	nn||-1-70/NNP||vcam-68/NNP	nn||-1-70/NNP||-RSB--69/NNP	dep||molecule-66/NN||-1-70/NNP	amod||markers-73/NNS||inflammatory-72/JJ	prep_of||expression-50/NN||markers-73/NNS	conj_and||systemic-53/NN||markers-73/NNS	stz-10||hyperglycemia-21||no_rel||with respect to stz-treated animals, mice co-injected with stz+trail were characterized by 1 ) lower levels of hyperglycemia, 2 ) higher levels of body weight and insulinemia, 3 ) a partial preservation of pancreatic islets with normal morphology, and 4 ) a lower expression of both systemic (tnf-î± and opg) and pancreatic (vascular cell adhesion molecule [vcam]-1) inflammatory markers.
det||calcineurininhibitors-3/NNS||the-1/DT	amod||calcineurininhibitors-3/NNS||topical-2/JJ	nsubjpass||used-11/VBN||calcineurininhibitors-3/NNS	nsubj||treat-13/VB||calcineurininhibitors-3/NNS	nsubj||inhibit-20/VB||calcineurininhibitors-3/NNS	appos||calcineurininhibitors-3/NNS||tacrolimus-5/NNS	appos||calcineurininhibitors-3/NNS||pimecrolimus-7/NNS	conj_and||tacrolimus-5/NNS||pimecrolimus-7/NNS	aux||used-11/VBN||have-9/VBP	auxpass||used-11/VBN||been-10/VBN	root||ROOT-0/null||used-11/VBN	aux||treat-13/VB||to-12/TO	xcomp||used-11/VBN||treat-13/VB	amod||cutaneous-15/JJ||resistant-14/JJ	amod||lupus-16/NNS||cutaneous-15/JJ	dobj||treat-13/VB||lupus-16/NNS	prep_since||treat-13/VB||2002-18/CD	xcomp||used-11/VBN||inhibit-20/VB	conj_and||treat-13/VB||inhibit-20/VB	det||proliferation-22/NN||the-21/DT	dobj||inhibit-20/VB||proliferation-22/NN	dobj||inhibit-20/VB||activation-24/NN	conj_and||proliferation-22/NN||activation-24/NN	prep_of||proliferation-22/NN||t-cells-26/NNS	conj_and||treat-13/VB||suppress-28/VB	conj_and||inhibit-20/VB||suppress-28/VB	amod||cutaneousinflammation-30/NN||immune-mediated-29/JJ	dobj||suppress-28/VB||cutaneousinflammation-30/NN	cutaneousinflammation-30||tacrolimus-5||no_rel||the topical calcineurininhibitors, tacrolimus and pimecrolimus, have been used to treat resistant cutaneous lupus since 2002 and inhibit the proliferation and activation of t-cells and suppress immune-mediated cutaneousinflammation.
det||ibs-qol-2/NN||the-1/DT	nsubjpass||improved-11/VBN||ibs-qol-2/NN	prep_of||ibs-qol-2/NN||responders-4/NNS	amod||treatment-7/NN||tegaserod-6/JJ	prep_to||responders-4/NNS||treatment-7/NN	auxpass||improved-11/VBN||was-8/VBD	advmod||improved-11/VBN||also-9/RB	advmod||improved-11/VBN||significantly-10/RB	root||ROOT-0/null||improved-11/VBN	num||weeks-14/NNS||4-13/CD	prep_after||improved-11/VBN||weeks-14/NNS	nn||0.01-18/NNP||p-16/NNP	nn||0.01-18/NNP||<-17/NNP	appos||weeks-14/NNS||0.01-18/NNP	ibs--1||tegaserod-6||yes||the ibs-qol of responders to tegaserod treatment was also significantly improved after 4 weeks (p <0.01).
det||exception-2/NN||an-1/DT	nsubj||infection-15/NN||exception-2/NN	cop||infection-15/NN||is-3/VBZ	det||treatment-6/NN||the-5/DT	prep_in||infection-15/NN||treatment-6/NN	amod||virus-9/NN||chronichepatitisc-8/JJ	prep_for||treatment-6/NN||virus-9/NN	appos||virus-9/NN||hcv-11/NN	amod||infection-15/NN||genotype-13/JJ	dep||genotype-13/JJ||1-14/CD	root||ROOT-0/null||infection-15/NN	amod||±-20/NNS||pegylated-17/JJ	nn||±-20/NNS||interferon-18/NN	nn||±-20/NNS||î-19/NN	prep_with||infection-15/NN||±-20/NNS	prep_with||infection-15/NN||ribavirin-22/NNP	conj_and||±-20/NNS||ribavirin-22/NNP	chronichepatitisc-8||ribavirin-22||yes||an exception is in the treatment for chronichepatitisc virus (hcv) genotype 1 infection with pegylated interferon î± and ribavirin.
vmod||shown-12/VBN||using-1/VBG	nn||preparations-5/NNS||bloc-3/NN	nn||preparations-5/NNS||medullary-4/NN	prep_en||using-1/VBG||preparations-5/NNS	amod||mice-8/NNS||neonatal-7/JJ	prep_from||using-1/VBG||mice-8/NNS	nsubj||shown-12/VBN||we-10/PRP	aux||shown-12/VBN||have-11/VBP	root||ROOT-0/null||shown-12/VBN	det||time-16/NN||the-14/DT	amod||time-16/NN||first-15/JJ	prep_for||shown-12/VBN||time-16/NN	mark||abolished-24/VBN||that-17/IN	det||response-20/NN||the-18/DT	amod||response-20/NN||respiratory-19/JJ	nsubjpass||abolished-24/VBN||response-20/NN	prep_to||response-20/NN||acidosis-22/NNS	auxpass||abolished-24/VBN||is-23/VBZ	dep||time-16/NN||abolished-24/VBN	prep_after||abolished-24/VBN||pre-treatment-26/NN	det||fluoxetine-31/NN||the-28/DT	amod||fluoxetine-31/NN||serotonin-transporter-29/JJ	nn||fluoxetine-31/NN||blocker-30/NN	prep_with||abolished-24/VBN||fluoxetine-31/NN	dep||âµm-37/NN||25â-33/NNS	dep||âµm-37/NN||$-34/$	num||$-34/$||50-36/CD	dep||time-16/NN||âµm-37/NN	number||min-40/NN||20-39/CD	dep||âµm-37/NN||min-40/NN	det||antidepressant-46/NN||a-43/DT	advmod||used-45/VBN||commonly-44/RB	amod||antidepressant-46/NN||used-45/VBN	appos||time-16/NN||antidepressant-46/NN	serotonin--1||acidosis-22||no_rel||using en bloc medullary preparations from neonatal mice, we have shown for the first time that the respiratory response to acidosis is abolished after pre-treatment with the serotonin-transporter blocker fluoxetine (25â50 âµm, 20 min), a commonly used antidepressant.
advmod||active-2/JJ||highly-1/RB	amod||therapy-4/NN||active-2/JJ	amod||therapy-4/NN||antiretroviral-3/JJ	nsubj||changed-9/VBN||therapy-4/NN	appos||therapy-4/NN||haart-6/NN	aux||changed-9/VBN||has-8/VBZ	root||ROOT-0/null||changed-9/VBN	det||face-11/NN||the-10/DT	dobj||changed-9/VBN||face-11/NN	prep_of||face-11/NN||humanimmunodeficiencyvirus-13/NNS	appos||humanimmunodeficiencyvirus-13/NNS||hiv-15/NN	vmod||humanimmunodeficiencyvirus-13/NNS||acquired-17/VBN	amod||syndrome-19/NN||immunedeficiency-18/JJ	dobj||acquired-17/VBN||syndrome-19/NN	appos||syndrome-19/NN||aids-21/NNS	agent||acquired-17/VBN||leading-24/VBG	amod||decreases-27/NNS||dramatic-26/JJ	prep_to||leading-24/VBG||decreases-27/NNS	amod||morbidity-30/NN||hiv-related-29/JJ	prep_in||decreases-27/NNS||morbidity-30/NN	prep_in||decreases-27/NNS||mortality-32/NN	conj_and||morbidity-30/NN||mortality-32/NN	det||developed-35/JJ||the-34/DT	prep_in||leading-24/VBG||developed-35/JJ	agent||acquired-17/VBN||developing-39/VBG	conj_and||leading-24/VBG||developing-39/VBG	dobj||developing-39/VBG||world-40/NN	aids-21||humanimmunodeficiencyvirus-13||no||highly active antiretroviral therapy (haart) has changed the face of humanimmunodeficiencyvirus (hiv) acquired immunedeficiency syndrome (aids) by leading to dramatic decreases in hiv-related morbidity and mortality in the developed as well as developing world.
det||orfvirus-2/NNS||the-1/DT	nsubj||prototype-8/NN||orfvirus-2/NNS	appos||orfvirus-2/NNS||orfv-4/NNP	cop||prototype-8/NN||is-6/VBZ	det||prototype-8/NN||the-7/DT	root||ROOT-0/null||prototype-8/NN	det||genus-12/NNS||the-10/DT	amod||genus-12/NNS||parapoxvirus-11/JJ	prep_of||prototype-8/NN||genus-12/NNS	nsubj||causes-16/VBZ||it-14/PRP	advmod||causes-16/VBZ||primarily-15/RB	conj_and||prototype-8/NN||causes-16/VBZ	dobj||causes-16/VBZ||contagiousecthyma-17/NN	prep_in||contagiousecthyma-17/NN||goats-19/NNS	prep_in||contagiousecthyma-17/NN||sheep-21/NN	conj_and||goats-19/NNS||sheep-21/NN	amod||ruminants-25/NNS||other-24/JJ	prep_in||contagiousecthyma-17/NN||ruminants-25/NNS	conj_and||goats-19/NNS||ruminants-25/NNS	advmod||causes-16/VBZ||worldwide-26/RB	contagiousecthyma-17||orfvirus-2||no||the orfvirus (orfv) is the prototype of the parapoxvirus genus and it primarily causes contagiousecthyma in goats, sheep, and other ruminants worldwide.
amod||ifn-gamma-responses-2/NNS||increased-1/VBN	nsubj||represents-15/VBZ||ifn-gamma-responses-2/NNS	amod||proliferation-7/NN||antigen-specific-4/JJ	nn||proliferation-7/NN||t-5/NN	nn||proliferation-7/NN||cell-6/NN	conj_and||ifn-gamma-responses-2/NNS||proliferation-7/NN	nsubj||represents-15/VBZ||proliferation-7/NN	det||subset-14/NN||the-9/DT	amod||subset-14/NN||cd8alpha/alpha-10/JJ	amod||subset-14/NN||+-11/JJ	nn||subset-14/NN||t-12/NN	nn||subset-14/NN||cell-13/NN	prep_in||proliferation-7/NN||subset-14/NN	root||ROOT-0/null||represents-15/VBZ	det||marker-18/NN||a-16/DT	amod||marker-18/NN||valuable-17/JJ	dobj||represents-15/VBZ||marker-18/NN	prep_for||marker-18/NN||vaccine-take-20/NN	amod||trials-25/NNS||bcg-based-22/JJ	nn||trials-25/NNS||tb-23/NN	nn||trials-25/NNS||vaccine-24/NN	prep_in||vaccine-take-20/NN||trials-25/NNS	ifn--1||tb-23||no_rel||increased ifn-gamma-responses and antigen-specific t cell proliferation in the cd8alpha/alpha+ t cell subset represents a valuable marker for vaccine-take in bcg-based tb vaccine trials
amod||fat-2/NN||visceral-1/JJ	nsubjpass||reported-5/VBN||fat-2/NN	nsubjpass||associated-8/VBN||fat-2/NN	aux||reported-5/VBN||has-3/VBZ	auxpass||reported-5/VBN||been-4/VBN	root||ROOT-0/null||reported-5/VBN	aux||associated-8/VBN||to-6/TO	auxpass||associated-8/VBN||be-7/VB	xcomp||reported-5/VBN||associated-8/VBN	prep_with||associated-8/VBN||nonalcoholicfattyliverdisease-10/NN	dep||nonalcoholicfattyliverdisease-10/NN||nafld-12/JJ	det||syndrome-17/NN||the-15/DT	amod||syndrome-17/NN||metabolic-16/JJ	prep_with||associated-8/VBN||syndrome-17/NN	conj_and||nonalcoholicfattyliverdisease-10/NN||syndrome-17/NN	appos||nonalcoholicfattyliverdisease-10/NN||mets-19/NNS	fat-2||liverdisease--1||no_rel||visceral fat has been reported to be associated with nonalcoholicfattyliverdisease (nafld) and the metabolic syndrome (mets).
det||intensity-4/NN||the-1/DT	amod||intensity-4/NN||summed-2/JJ	nn||intensity-4/NN||pain-3/NN	nsubj||similar-17/JJ||intensity-4/NN	nsubj||lower-35/JJR||intensity-4/NN	nn||use-7/NN||total-6/NN	conj_and||intensity-4/NN||use-7/NN	nsubj||similar-17/JJ||use-7/NN	amod||analgesia-10/NN||opioid-9/JJ	prep_of||intensity-4/NN||analgesia-10/NN	det||hours-15/NNS||the-12/DT	amod||hours-15/NNS||first-13/JJ	num||hours-15/NNS||24-14/CD	prep_through||analgesia-10/NN||hours-15/NNS	cop||similar-17/JJ||were-16/VBD	root||ROOT-0/null||similar-17/JJ	det||values-20/NNS||the-19/DT	prep_to||similar-17/JJ||values-20/NNS	vmod||values-20/NNS||observed-21/VBN	advmod||reported-24/VBN||previously-23/RB	amod||studies-25/NNS||reported-24/VBN	prep_in||observed-21/VBN||studies-25/NNS	amod||patients-28/NNS||xaracoll-treated-27/JJ	prep_for||studies-25/NNS||patients-28/NNS	amod||surgery-31/NN||open-30/JJ	prep_after||similar-17/JJ||surgery-31/NN	cop||lower-35/JJR||were-34/VBD	conj_but||similar-17/JJ||lower-35/JJR	nn||hours-40/NNS||48-37/CD	conj_and||48-37/CD||72-39/CD	nn||hours-40/NNS||72-39/CD	prep_through||lower-35/JJR||hours-40/NNS	opioid-9||pain-3||no_rel||the summed pain intensity and total use of opioid analgesia through the first 24 hours were similar to the values observed in previously reported studies for xaracoll-treated patients after open surgery, but were lower through 48 and 72 hours.
csubj||increases-22/VBZ||adding-1/VBG	dobj||adding-1/VBG||snps-2/NNS	advmod||associated-4/VBN||previously-3/RB	vmod||snps-2/NNS||associated-4/VBN	prepc_with||associated-4/VBN||fasting-6/VBG	dobj||fasting-6/VBG||glucose-7/NN	dobj||fasting-6/VBG||insulin-9/NN	conj_or||glucose-7/NN||insulin-9/NN	dobj||fasting-6/VBG||lipids-11/NN	conj_or||glucose-7/NN||lipids-11/NN	dobj||fasting-6/VBG||obesity-13/NN	conj_or||glucose-7/NN||obesity-13/NN	det||score-18/NN||a-15/DT	amod||score-18/NN||genetic-16/JJ	nn||score-18/NN||risk-17/NN	prep_to||fasting-6/VBG||score-18/NN	prep_for||score-18/NN||type2diabetes-20/CD	advmod||increases-22/VBZ||significantly-21/RB	root||ROOT-0/null||increases-22/VBZ	det||power-24/NN||the-23/DT	dobj||increases-22/VBZ||power-24/NN	aux||discriminate-26/VB||to-25/TO	vmod||power-24/NN||discriminate-26/VB	vmod||power-24/NN||discriminate-26/VB	conj_and||discriminate-26/VB||discriminate-26/VB	prep_between||discriminate-26/VB||people-28/NNS	advmod||manifest-33/JJ||clinically-32/RB	amod||type2diabetes-34/NNS||manifest-33/JJ	prep_with||discriminate-26/VB||type2diabetes-34/NNS	prep_without||discriminate-26/VB||type2diabetes-34/NNS	prepc_compared_with||discriminate-26/VB||with-36/IN	det||model-38/NN||a-37/DT	pobj||discriminate-26/VB||model-38/NN	amod||loci-43/NNS||only-40/JJ	amod||loci-43/NNS||conventional-41/JJ	amod||loci-43/NNS||type2diabetes-42/JJ	prep_including||model-38/NN||loci-43/NNS	type2diabetes-42||insulin-9||yes||adding snps previously associated with fasting glucose, insulin, lipids or obesity to a genetic risk score for type2diabetes significantly increases the power to discriminate between people with and without clinically manifest type2diabetes compared with a model including only conventional type2diabetes loci.
nn||patients-4/NNS||case-1/NN	conj_and||case-1/NN||control-3/NN	nn||patients-4/NNS||control-3/NN	nsubjpass||matched-12/VBN||patients-4/NNS	det||diagnosis-8/NN||a-6/DT	amod||diagnosis-8/NN||recorded-7/JJ	prep_with||patients-4/NNS||diagnosis-8/NN	prep_of||diagnosis-8/NN||type2diabetes-10/CD	auxpass||matched-12/VBN||were-11/VBD	root||ROOT-0/null||matched-12/VBN	prep_on||matched-12/VBN||age-14/NN	nn||time-17/NN||calendar-16/NN	prep_on||matched-12/VBN||time-17/NN	conj_and||age-14/NN||time-17/NN	amod||practice-21/NN||general-20/JJ	prep_on||matched-12/VBN||practice-21/NN	conj_and||age-14/NN||practice-21/NN	det||analyses-29/NNS||the-24/DT	amod||analyses-29/NNS||multivariate-25/JJ	amod||logistic-27/JJ||conditional-26/JJ	amod||analyses-29/NNS||logistic-27/JJ	nn||analyses-29/NNS||regression-28/NN	nsubjpass||adjusted-32/VBN||analyses-29/NNS	auxpass||adjusted-32/VBN||were-30/VBD	advmod||adjusted-32/VBN||further-31/RBR	conj_and||matched-12/VBN||adjusted-32/VBN	prep_for||adjusted-32/VBN||use-34/NN	amod||drugs-38/NNS||oral-36/JJ	nn||drugs-38/NNS||antidiabetes-37/NNS	prep_of||use-34/NN||drugs-38/NNS	prep_of||use-34/NN||insulin-40/NN	conj_and||drugs-38/NNS||insulin-40/NN	prep_of||use-34/NN||estrogens-42/NNS	conj_and||drugs-38/NNS||estrogens-42/NNS	nn||bmi-45/NN||smoking-44/NN	prep_of||use-34/NN||bmi-45/NN	conj_and||drugs-38/NNS||bmi-45/NN	nn||duration-48/NN||diabetes-47/NN	prep_of||use-34/NN||duration-48/NN	conj_and||drugs-38/NNS||duration-48/NN	amod||a1c-53/NNS||hba1c-51/JJ	prep_of||use-34/NN||a1c-53/NNS	conj_and||drugs-38/NNS||a1c-53/NNS	type2diabetes-10||insulin-40||yes||case and control patients with a recorded diagnosis of type2diabetes were matched on age, calendar time, and general practice, and the multivariate conditional logistic regression analyses were further adjusted for use of oral antidiabetes drugs, insulin, estrogens, smoking bmi, diabetes duration, and hba1c (a1c).
amod||mice-4/NNS||conclusionsâ-1/JJ	amod||mice-4/NNS||$-2/$	nsubj||resistant-9/JJ||mice-4/NNS	nsubj||provide-18/VB||mice-4/NNS	amod||pref-1-6/JJ||overexpressing-5/JJ	amod||mice-4/NNS||pref-1-6/JJ	cop||resistant-9/JJ||are-7/VBP	advmod||resistant-9/JJ||insulin-8/RB	root||ROOT-0/null||resistant-9/JJ	auxpass||protected-12/VBN||being-11/VBG	prepc_despite||resistant-9/JJ||protected-12/VBN	amod||obesity-15/NN||diet-induced-14/JJ	prep_from||protected-12/VBN||obesity-15/NN	aux||provide-18/VB||may-17/MD	conj_and||resistant-9/JJ||provide-18/VB	det||model-22/NN||a-19/DT	amod||model-22/NN||new-20/JJ	nn||model-22/NN||rodent-21/NN	dobj||provide-18/VB||model-22/NN	det||study-25/NN||the-24/DT	prep_for||provide-18/VB||study-25/NN	amod||disorders-28/NNS||lipodystrophic-27/JJ	prep_of||study-25/NN||disorders-28/NNS	insulin-8||obesity-15||no_rel||conclusionsâ mice overexpressing pref-1 are insulin resistant despite being protected from diet-induced obesity and may provide a new rodent model for the study of lipodystrophic disorders.
nn||design-2/NN||research-1/NN	nsubjpass||defined-11/VBN||design-2/NN	poss||syndrome-9/NN||methods-4/NNS	npadvmod||metabolic-8/JJ||$-6/$	amod||syndrome-9/NN||metabolic-8/JJ	conj_and||design-2/NN||syndrome-9/NN	nsubjpass||defined-11/VBN||syndrome-9/NN	auxpass||defined-11/VBN||was-10/VBD	root||ROOT-0/null||defined-11/VBN	amod||criteria-21/NNS||national-13/JJ	nn||criteria-21/NNS||cholesterol-14/NN	nn||criteria-21/NNS||education-15/NN	nn||criteria-21/NNS||program-16/NN	nn||criteria-21/NNS||adult-17/NN	nn||criteria-21/NNS||treatment-18/NN	nn||criteria-21/NNS||panel-19/NN	nn||criteria-21/NNS||iii-20/NN	agent||defined-11/VBN||criteria-21/NNS	det||definition-25/NN||the-23/DT	nn||definition-25/NN||asian-24/NN	prep_with||criteria-21/NNS||definition-25/NN	prep_of||definition-25/NN||obesity-27/NN	cholesterol-14||obesity-27||no_rel||research design and methods âmetabolic syndrome was defined by national cholesterol education program adult treatment panel iii criteria with the asian definition of obesity.
det||papers-2/NNS||the-1/DT	nsubj||offer-3/VBP||papers-2/NNS	root||ROOT-0/null||offer-3/VBP	amod||evidence-6/NN||new-4/JJ	amod||evidence-6/NN||empirical-5/JJ	dobj||offer-3/VBP||evidence-6/NN	amod||reviews-9/NNS||comprehensive-8/JJ	dobj||offer-3/VBP||reviews-9/NNS	conj_and||evidence-6/NN||reviews-9/NNS	prep_on||reviews-9/NNS||diabetes-11/NN	prep_in||diabetes-11/NN||tanzania-13/NN	amod||disease-17/NN||sickle-15/JJ	nn||disease-17/NN||cell-16/NN	dobj||offer-3/VBP||disease-17/NN	conj_and||evidence-6/NN||disease-17/NN	prep_in||disease-17/NN||nigeria-19/NN	amod||illness-23/NN||chronic-21/JJ	amod||illness-23/NN||mental-22/JJ	dobj||offer-3/VBP||illness-23/NN	conj_and||evidence-6/NN||illness-23/NN	amod||ghana-26/NN||rural-25/JJ	prep_in||illness-23/NN||ghana-26/NN	amod||care-giving-29/NN||hiv/aids-28/JJ	dobj||offer-3/VBP||care-giving-29/NN	conj_and||evidence-6/NN||care-giving-29/NN	prep_among||care-giving-29/NN||children-31/NNS	prep_in||children-31/NNS||kenya-33/NN	amod||interventions-37/NNS||chronic-35/JJ	nn||interventions-37/NNS||disease-36/NN	dobj||offer-3/VBP||interventions-37/NNS	conj_and||evidence-6/NN||interventions-37/NNS	prep_in||interventions-37/NNS||ghana-39/NN	prep_in||interventions-37/NNS||cameroon-41/NN	conj_and||ghana-39/NN||cameroon-41/NN	aids--1||hiv--1||no||the papers offer new empirical evidence and comprehensive reviews on diabetes in tanzania, sickle cell disease in nigeria, chronic mental illness in rural ghana, hiv/aids care-giving among children in kenya and chronic disease interventions in ghana and cameroon.
amod||evaluation-2/NN||intraoperative-1/JJ	nsubj||included-3/VBD||evaluation-2/NN	root||ROOT-0/null||included-3/VBD	dobj||included-3/VBD||time-4/NN	vmod||time-4/NN||weighted-5/VBN	ccomp||weighted-5/VBN||mean-6/VB	amod||dose-8/NN||remifentanil-7/JJ	dobj||mean-6/VB||dose-8/NN	amod||evaluations-12/NNS||postoperative-11/JJ	nsubj||included-13/VBD||evaluations-12/NNS	conj_and||included-3/VBD||included-13/VBD	dobj||included-13/VBD||degree-14/NN	nn||severity-17/NN||pain-16/NN	prep_of||degree-14/NN||severity-17/NN	prep_at||severity-17/NN||1-19/CD	dobj||included-13/VBD||6-21/CD	conj_and||degree-14/NN||6-21/CD	num||6-21/CD||12-23/CD	conj_and||degree-14/NN||24-26/CD	conj_and||6-21/CD||24-26/CD	dep||6-21/CD||hours-27/NNS	advmod||6-21/CD||time-29/NN	amod||requirement-33/NN||first-31/JJ	nn||requirement-33/NN||postoperative-32/NN	prep_to||time-29/NN||requirement-33/NN	amod||dose-37/NN||analgesic-36/JJ	dobj||included-13/VBD||dose-37/NN	conj_and||degree-14/NN||dose-37/NN	vmod||dose-37/NN||required-38/VBN	num||hours-41/NNS||24-40/CD	prep_during||required-38/VBN||hours-41/NNS	prep_after||required-38/VBN||operation-43/NN	pain-16||remifentanil-7||yes||intraoperative evaluation included time weighted mean remifentanil dose, and postoperative evaluations included degree of pain severity at 1, 6, 12, and 24 hours, time to first postoperative requirement, and analgesic dose required during 24 hours after operation.
nn||analysis-3/NN||glycan-1/NN	nn||analysis-3/NN||microarray-2/NN	nsubj||reassortantâ-11/VBD||analysis-3/NN	det||â-8/NN||a-5/DT	amod||â-8/NN||high-6/JJ	nn||â-8/NN||infectivity-7/NN	prep_with||analysis-3/NN||â-8/NN	amod||â-8/NN||$-9/$	dep||$-9/$||triple-10/JJ	root||ROOT-0/null||reassortantâ-11/VBD	nsubj||spread-24/VBN||$-12/$	nsubj||showed-51/VBD||$-12/$	num||$-12/$||virus-13/CD	amod||/-17/NN||a/swine/mn-16/JJ	dep||$-12/$||/-17/NN	num||/-17/NN||593/99-18/CD	appos||$-12/$||h3n2-20/NNP	rcmod||$-12/$||spread-24/VBN	advmod||spread-24/VBN||widely-25/RB	det||population-31/NN||the-27/DT	nn||population-31/NN||north-28/NN	nn||population-31/NN||american-29/NN	nn||population-31/NN||swine-30/NNS	prep_throughout||spread-24/VBN||population-31/NN	det||virus-37/NN||a-33/DT	dep||human-36/JJ||lower-34/JJR	advmod||human-36/JJ||infectivity-35/RB	amod||virus-37/NN||human-36/JJ	conj_and||$-12/$||virus-37/NN	nsubj||spread-24/VBN||virus-37/NN	nsubj||showed-51/VBD||virus-37/NN	vmod||virus-37/NN||isolated-38/VBN	det||pig-42/NN||a-40/DT	amod||pig-42/NN||single-41/JJ	prep_from||isolated-38/VBN||pig-42/NN	dep||virus-37/NN||a/swine/ont-44/VB	number||00130/97-46/CD||/-45/CD	dobj||a/swine/ont-44/VB||00130/97-46/CD	appos||00130/97-46/CD||h3n2-48/NNP	ccomp||reassortantâ-11/VBD||showed-51/VBD	mark||viruses-54/VBZ||that-52/IN	nsubj||viruses-54/VBZ||both-53/DT	ccomp||showed-51/VBD||viruses-54/VBZ	acomp||viruses-54/VBZ||bound-55/VBN	advmod||bound-55/VBN||exclusively-56/RB	prep_to||bound-55/VBN||glycans-58/NNS	vmod||glycans-58/NNS||containing-59/VBG	nn||±-61/NNP||neuacî-60/NNP	dobj||containing-59/VBG||±-61/NNP	vmod||±-61/NNP||2â-62/VBG	dobj||2â-62/VBG||$-63/$	npadvmod||polylactosamine-72/JJ||6-65/CD	prep_with||6-65/CD||strong-68/JJ	amod||6-65/CD||binding-69/JJ	dep||sialylated-71/CD||to-70/TO	num||6-65/CD||sialylated-71/CD	amod||n-75/NNS||polylactosamine-72/JJ	conj_and||polylactosamine-72/JJ||sialylated-74/JJ	amod||n-75/NNS||sialylated-74/JJ	npadvmod||--76/RB||n-75/NNS	num||$-63/$||glycans-77/CD	virus-37||viruses-54||no||glycan microarray analysis with a high infectivity âtriple reassortantâ? virus ((a/swine/mn/593/99 (h3n2)) that spread widely throughout the north american swine population and a lower infectivity human virus isolated from a single pig (a/swine/ont/00130/97 (h3n2)) showed that both viruses bound exclusively to glycans containing neuacî±2â6, with strong binding to sialylated polylactosamine and sialylated n -glycans.
advmod||named-5/VBD||recently-1/RB	det||polerovirus-4/NNS||a-3/DT	nsubj||named-5/VBD||polerovirus-4/NNS	root||ROOT-0/null||named-5/VBD	nn||leafroll-7/NN||cotton-6/NN	nsubj||dwarf-8/VBP||leafroll-7/NN	ccomp||named-5/VBD||dwarf-8/VBP	nsubjpass||shown-14/VBN||virus-9/NN	nsubjpass||associated-17/VBN||virus-9/NN	appos||virus-9/NN||clrdv-11/NNP	auxpass||shown-14/VBN||was-13/VBD	ccomp||dwarf-8/VBP||shown-14/VBN	aux||associated-17/VBN||to-15/TO	auxpass||associated-17/VBN||be-16/VB	xcomp||shown-14/VBN||associated-17/VBN	prep_with||associated-17/VBN||cbd-19/NN	dwarf-8||cbd-19||no_rel||recently, a polerovirus named cotton leafroll dwarf virus (clrdv) was shown to be associated with cbd.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubjpass||recommended-12/VBN||treatment-3/NN	prep_of||treatment-3/NN||malaria-5/NN	prep_with||malaria-5/NN||sulphadoxine-pyrimethamine-7/NN	appos||treatment-3/NN||sp-9/NN	auxpass||recommended-12/VBN||is-11/VBZ	root||ROOT-0/null||recommended-12/VBN	det||prevention-15/NN||the-14/DT	prep_for||recommended-12/VBN||prevention-15/NN	prep_of||prevention-15/NN||malaria-17/NN	prep_in||recommended-12/VBN||pregnancy-19/NN	amod||africa-22/NN||sub-saharan-21/JJ	prep_in||pregnancy-19/NN||africa-22/NN	malaria-17||pyrimethamine--1||no||intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine (sp) is recommended for the prevention of malaria in pregnancy in sub-saharan africa.
det||proportion-2/NN||the-1/DT	nsubj||decreased-14/VBD||proportion-2/NN	prep_of||proportion-2/NN||msm-4/NN	vmod||decreased-14/VBD||presenting-6/VBG	preconj||aids-9/NNS||either-8/DT	prep_with||presenting-6/VBG||aids-9/NNS	nn||illness-12/NN||hiv-11/NN	prep_with||presenting-6/VBG||illness-12/NN	conj_or||aids-9/NNS||illness-12/NN	root||ROOT-0/null||decreased-14/VBD	prep_over||decreased-14/VBD||time-16/NN	mark||increased-24/VBD||while-18/IN	amod||illness-23/NN||asymptomatic-19/JJ	conj_and||asymptomatic-19/JJ||acute-21/JJ	amod||illness-23/NN||acute-21/JJ	amod||illness-23/NN||hiv-22/JJ	nsubj||increased-24/VBD||illness-23/NN	advcl||decreased-14/VBD||increased-24/VBD	dep||increased-24/VBD||p-26/NN	prep_for||p-26/NN||trend-28/NN	amod||p-26/NN||=-29/JJ	dep||=-29/JJ||0.034-30/CD	dep||=-29/JJ||less-32/JJR	conj_or||0.034-30/CD||less-32/JJR	aids-9||hiv-22||no||the proportion of msm, presenting with either aids or hiv illness, decreased over time, while asymptomatic and acute hiv illness increased (p for trend=0.034 or less).
det||results-2/NNS||these-1/DT	nsubj||indicated-3/VBD||results-2/NNS	root||ROOT-0/null||indicated-3/VBD	mark||offers-6/VBZ||that-4/IN	nsubj||offers-6/VBZ||ea-5/NN	ccomp||indicated-3/VBD||offers-6/VBZ	det||effect-9/NN||a-7/DT	amod||effect-9/NN||beneficial-8/JJ	dobj||offers-6/VBZ||effect-9/NN	prep_on||offers-6/VBZ||insulinresistance-11/NN	amod||mice-17/NNS||obese-13/JJ	conj_and||obese-13/JJ||diabetic-15/JJ	amod||mice-17/NNS||diabetic-15/JJ	nn||mice-17/NNS||db/db-16/NN	prep_in||insulinresistance-11/NN||mice-17/NNS	dep||mice-17/NNS||at-19/IN	pobj||at-19/IN||least-20/JJS	dep||at-19/IN||partly-21/RB	prep_via||insulinresistance-11/NN||stimulation-24/NN	amod||±-29/NNS||sirt1/pgc-26/JJ	amod||±-29/NNS||-1-27/JJ	nn||±-29/NNS||î-28/NN	prep_of||stimulation-24/NN||±-29/NNS	advmod||resulting-32/VBG||thus-31/RB	vmod||offers-6/VBZ||resulting-32/VBG	amod||signal-36/NN||improved-34/VBN	nn||signal-36/NN||insulin-35/NN	prep_in||resulting-32/VBG||signal-36/NN	ea-5||insulinresistance-11||no_rel||these results indicated that ea offers a beneficial effect on insulinresistance in obese and diabetic db/db mice, at least partly, via stimulation of sirt1/pgc-1 î± , thus resulting in improved insulin signal.
advmod||review-4/VBP||here-1/RB	nsubj||review-4/VBP||we-2/PRP	nsubj||discuss-6/VB||we-2/PRP	advmod||review-4/VBP||first-3/RB	root||ROOT-0/null||review-4/VBP	conj_and||review-4/VBP||discuss-6/VB	det||infection-13/NN||the-7/DT	nn||infection-13/NN||rabbitpox-8/NN	nn||infection-13/NN||virus-9/NN	appos||infection-13/NN||rpv-11/NN	dobj||discuss-6/VB||infection-13/NN	amod||rabbits-18/NNS||new-15/JJ	amod||rabbits-18/NNS||zealand-16/JJ	amod||rabbits-18/NNS||white-17/JJ	prep_of||infection-13/NN||rabbits-18/NNS	det||model-21/NN||a-20/DT	prep_as||rabbits-18/NNS||model-21/NN	prep_for||model-21/NN||smallpox-23/NN	aux||test-25/VB||to-24/TO	vmod||discuss-6/VB||test-25/VB	det||efficacy-27/NN||the-26/DT	dobj||test-25/VB||efficacy-27/NN	prep_of||efficacy-27/NN||cmx001-29/CD	det||prophylactic-32/JJ||a-31/DT	prep_as||test-25/VB||prophylactic-32/JJ	amod||antiviral-36/NNS||early-34/JJ	nn||antiviral-36/NNS||disease-35/NN	prep_as||test-25/VB||antiviral-36/NNS	conj_and||prophylactic-32/JJ||antiviral-36/NNS	smallpox-23||antiviral-36||no_rel||here we first review and discuss the rabbitpox virus (rpv) infection of new zealand white rabbits as a model for smallpox to test the efficacy of cmx001 as a prophylactic and early disease antiviral.
nn||authorities-2/NNS||programme-1/NN	nsubj||acknowledge-3/VBP||authorities-2/NNS	root||ROOT-0/null||acknowledge-3/VBP	dobj||acknowledge-3/VBP||problems-4/NNS	prep_in||problems-4/NNS||scale-up-6/NN	nsubjpass||restricted-12/VBN||discussions-9/NNS	aux||restricted-12/VBN||have-10/VBP	auxpass||restricted-12/VBN||been-11/VBN	conj_yet||acknowledge-3/VBP||restricted-12/VBN	amod||constraints-15/NNS||operational-14/JJ	prep_to||restricted-12/VBN||constraints-15/NNS	amod||consideration-19/NN||little-18/JJ	prep_with||restricted-12/VBN||consideration-19/NN	advmod||influence-28/VBP||how-21/WRB	amod||responses-25/NNS||local-22/JJ	nn||responses-25/NNS||health-23/NN	nn||responses-25/NNS||system-24/NN	nsubj||influence-28/VBP||responses-25/NNS	prep_to||responses-25/NNS||hiv/aids-27/NNS	prepc_for||consideration-19/NN||influence-28/VBP	det||delivery-30/NN||the-29/DT	dobj||influence-28/VBP||delivery-30/NN	prep_of||delivery-30/NN||art-32/NN	aids--1||hiv--1||no||programme authorities acknowledge problems in scale-up, yet discussions have been restricted to operational constraints, with little consideration for how local health system responses to hiv/aids influence the delivery of art.
quantmod||49-2/CD||about-1/RB	num||%-3/NN||49-2/CD	nsubj||isolates-7/VBZ||%-3/NN	nn||negatives-6/NNS||gram-5/NN	prep_of||%-3/NN||negatives-6/NNS	root||ROOT-0/null||isolates-7/VBZ	cop||resistant-9/JJ||were-8/VBD	ccomp||isolates-7/VBZ||resistant-9/JJ	prep_to||resistant-9/JJ||thirdgenerationcephalosporins-11/NNS	num||%-14/NN||28-13/CD	nsubjpass||found-18/VBN||%-14/NN	nsubj||methicillinresistantstaphylococcusaureus-21/JJ||%-14/NN	prep_of||%-14/NN||staphylococcusaureus-16/NNS	auxpass||found-18/VBN||were-17/VBD	conj_and||isolates-7/VBZ||found-18/VBN	aux||methicillinresistantstaphylococcusaureus-21/JJ||to-19/TO	cop||methicillinresistantstaphylococcusaureus-21/JJ||be-20/VB	xcomp||found-18/VBN||methicillinresistantstaphylococcusaureus-21/JJ	dep||methicillinresistantstaphylococcusaureus-21/JJ||mrsa-23/NNP	methicillinresistantstaphylococcusaureus-21||staphylococcusaureus-16||no||about 49% of gram negatives isolates were resistant to thirdgenerationcephalosporins and 28% of staphylococcusaureus were found to be methicillinresistantstaphylococcusaureus (mrsa).
prep_objectiveâ||suggested-7/VBN||$-2/$	nsubjpass||suggested-7/VBN||it-4/PRP	aux||suggested-7/VBN||has-5/VBZ	auxpass||suggested-7/VBN||been-6/VBN	root||ROOT-0/null||suggested-7/VBN	mark||links-15/VBZ||that-8/IN	amod||protein-10/NN||retinol-binding-9/JJ	nsubj||links-15/VBZ||protein-10/NN	num||protein-10/NN||4-11/CD	appos||protein-10/NN||rbp4-13/NNP	ccomp||suggested-7/VBN||links-15/VBZ	dobj||links-15/VBZ||adiposity-16/NN	dobj||links-15/VBZ||insulinresistance-18/NN	conj_and||adiposity-16/NN||insulinresistance-18/NN	dobj||links-15/VBZ||type2diabetes-21/NN	conj_and||adiposity-16/NN||type2diabetes-21/NN	retinol--1||insulinresistance-18||no_rel||objectiveâ it has been suggested that retinol-binding protein 4 (rbp4) links adiposity, insulinresistance, and type2diabetes.
aux||begin-2/VB||to-1/TO	advcl||utilized-23/VBD||begin-2/VB	aux||understand-4/VB||to-3/TO	xcomp||begin-2/VB||understand-4/VB	det||contributions-6/NNS||the-5/DT	dobj||understand-4/VB||contributions-6/NNS	amod||obesity-9/NN||maternal-8/JJ	prep_of||contributions-6/NNS||obesity-9/NN	prep_of||contributions-6/NNS||over-nutrition-11/NN	conj_and||obesity-9/NN||over-nutrition-11/NN	amod||development-14/NN||human-13/JJ	prep_to||understand-4/VB||development-14/NN	det||origins-18/NNS||the-16/DT	amod||origins-18/NNS||early-17/JJ	prep_to||understand-4/VB||origins-18/NNS	conj_and||development-14/NN||origins-18/NNS	prep_of||origins-18/NNS||obesity-20/NN	nsubj||utilized-23/VBD||we-22/PRP	root||ROOT-0/null||utilized-23/VBD	det||model-27/NN||a-24/DT	amod||model-27/NN||non-human-25/JJ	nn||model-27/NN||primate-26/NN	dobj||utilized-23/VBD||model-27/NN	aux||investigate-29/VB||to-28/TO	vmod||utilized-23/VBD||investigate-29/VB	det||effects-31/NNS||the-30/DT	dobj||investigate-29/VB||effects-31/NNS	amod||feeding-35/NN||maternal-33/JJ	amod||feeding-35/NN||high-fat-34/JJ	prep_of||effects-31/NNS||feeding-35/NN	vmod||utilized-23/VBD||obesity-37/VB	conj_and||investigate-29/VB||obesity-37/VB	nn||milk-40/NN||breast-39/NN	prep_on||obesity-37/VB||milk-40/NN	prep_on||obesity-37/VB||maternal-42/NN	conj_and||milk-40/NN||maternal-42/NN	amod||composition-47/NN||fetal-44/JJ	nn||composition-47/NN||plasma-45/NN	nn||composition-47/NN||fattyacid-46/NN	prep_on||obesity-37/VB||composition-47/NN	conj_and||milk-40/NN||composition-47/NN	amod||development-51/NN||fetal-49/JJ	amod||development-51/NN||hepatic-50/JJ	conj_and||milk-40/NN||development-51/NN	conj_and||composition-47/NN||development-51/NN	obesity-37||fattyacid-46||no_rel||to begin to understand the contributions of maternal obesity and over-nutrition to human development and the early origins of obesity, we utilized a non-human primate model to investigate the effects of maternal high-fat feeding and obesity on breast milk, maternal and fetal plasma fattyacid composition and fetal hepatic development.
nsubj||jcvirusinfection-9/NN||progressivemultifocalleukoencephalopathy-1/NN	appos||progressivemultifocalleukoencephalopathy-1/NN||pml-3/NN	cop||jcvirusinfection-9/NN||is-5/VBZ	det||jcvirusinfection-9/NN||an-6/DT	amod||jcvirusinfection-9/NN||opportunistic-7/JJ	nn||jcvirusinfection-9/NN||brain-8/NN	root||ROOT-0/null||jcvirusinfection-9/NN	nsubjpass||shown-13/VBN||jcvirusinfection-9/NN	nsubjpass||associated-16/VBN||jcvirusinfection-9/NN	aux||shown-13/VBN||has-11/VBZ	auxpass||shown-13/VBN||been-12/VBN	rcmod||jcvirusinfection-9/NN||shown-13/VBN	aux||associated-16/VBN||to-14/TO	auxpass||associated-16/VBN||be-15/VB	xcomp||shown-13/VBN||associated-16/VBN	amod||treatment-19/NN||natalizumab-18/JJ	prep_with||associated-16/VBN||treatment-19/NN	pml-3||jcvirus--1||no||progressivemultifocalleukoencephalopathy (pml) is an opportunistic brain jcvirusinfection that has been shown to be associated with natalizumab treatment.
det||purpose-2/NN||the-1/DT	nsubj||was-6/VBD||purpose-2/NN	nsubj||investigate-8/VB||purpose-2/NN	det||study-5/NN||this-4/DT	prep_of||purpose-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||prevalence-10/NN||the-9/DT	dobj||investigate-8/VB||prevalence-10/NN	dobj||investigate-8/VB||persistence-12/NN	conj_and||prevalence-10/NN||persistence-12/NN	amod||significance-15/NN||clinical-14/JJ	dobj||investigate-8/VB||significance-15/NN	conj_and||prevalence-10/NN||significance-15/NN	dobj||investigate-8/VB||characteristics-18/NNS	conj_and||prevalence-10/NN||characteristics-18/NNS	prep_of||characteristics-18/NNS||apls-20/NNS	prep_in||investigate-8/VB||hepatitisbvirus-22/NNS	appos||hepatitisbvirus-22/NNS||hbv-24/NN	amod||patients-28/NNS||infected-27/JJ	dep||hepatitisbvirus-22/NNS||patients-28/NNS	hbv-24||hepatitisbvirus-22||no||the purpose of this study was to investigate the prevalence, persistence, clinical significance, and characteristics of apls in hepatitisbvirus (hbv)-infected patients.
det||strategy-5/NN||a-1/DT	amod||strategy-5/NN||pubmed-2/JJ	nn||strategy-5/NN||literature-3/NN	nn||strategy-5/NN||search-4/NN	nsubjpass||used-12/VBN||strategy-5/NN	det||terms-10/NNS||the-7/DT	amod||terms-10/NNS||following-8/JJ	nn||terms-10/NNS||mesh-9/NN	prep_including||strategy-5/NN||terms-10/NNS	auxpass||used-12/VBN||were-11/VBD	root||ROOT-0/null||used-12/VBN	mark||follows-14/VBZ||as-13/IN	advcl||used-12/VBN||follows-14/VBZ	dep||follows-14/VBZ||â-15/VB	dobj||â-15/VB||$-16/$	num||$-16/$||dentin-17/CD	vmod||$-16/$||sensitivityâ-18/VBG	dobj||sensitivityâ-18/VBG||$-19/$	num||$-19/$||-LSB--20/CD	vmod||$-19/$||mesh-21/VBN	iobj||mesh-21/VBN||terms-22/NNS	iobj||mesh-21/VBN||-RSB--23/NN	iobj||mesh-21/VBN||â-25/NN	conj_or||-RSB--23/NN||â-25/NN	dep||mesh-21/VBN||$-26/$	num||$-26/$||dentinâ-27/CD	dep||mesh-21/VBN||$-28/$	num||$-28/$||-LSB--29/CD	det||fields-31/NNS||all-30/DT	iobj||mesh-21/VBN||fields-31/NNS	iobj||mesh-21/VBN||-RSB--32/NN	iobj||mesh-21/VBN||â-34/NN	conj_and||-RSB--32/NN||â-34/NN	dep||mesh-21/VBN||$-35/$	num||$-35/$||sensitivityâ-36/CD	dep||mesh-21/VBN||$-37/$	num||$-37/$||-LSB--38/CD	det||fields-40/NNS||all-39/DT	iobj||mesh-21/VBN||fields-40/NNS	iobj||mesh-21/VBN||-RSB--41/NN	iobj||mesh-21/VBN||â-43/NN	conj_or||-RSB--41/NN||â-43/NN	dep||mesh-21/VBN||$-44/$	num||$-44/$||dentin-45/CD	num||$-44/$||sensitivityâ-46/CD	dep||mesh-21/VBN||$-47/$	num||$-47/$||-LSB--48/CD	det||fields-50/NNS||all-49/DT	iobj||mesh-21/VBN||fields-50/NNS	iobj||mesh-21/VBN||-RSB--51/NN	iobj||mesh-21/VBN||â-53/NN	conj_or||-RSB--51/NN||â-53/NN	dep||mesh-21/VBN||$-54/$	num||$-54/$||dentinâ-55/CD	dep||mesh-21/VBN||$-56/$	num||$-56/$||-LSB--57/CD	det||fields-59/NNS||all-58/DT	iobj||mesh-21/VBN||fields-59/NNS	iobj||mesh-21/VBN||-RSB--60/NN	iobj||mesh-21/VBN||â-62/NN	conj_and||-RSB--60/NN||â-62/NN	dep||mesh-21/VBN||$-63/$	num||$-63/$||hypersensitivityâ-64/CD	dep||mesh-21/VBN||$-65/$	num||$-65/$||-LSB--66/CD	det||fields-68/NNS||all-67/DT	iobj||mesh-21/VBN||fields-68/NNS	iobj||mesh-21/VBN||-RSB--69/NN	iobj||mesh-21/VBN||â-71/NN	conj_or||-RSB--69/NN||â-71/NN	dep||mesh-21/VBN||$-72/$	num||$-72/$||dentin-73/CD	num||$-72/$||hypersensitivityâ-74/CD	dep||mesh-21/VBN||$-75/$	num||$-75/$||-LSB--76/CD	det||fields-78/NNS||all-77/DT	iobj||mesh-21/VBN||fields-78/NNS	iobj||mesh-21/VBN||-RSB--79/NN	iobj||mesh-21/VBN||â-81/NN	conj_and||-RSB--79/NN||â-81/NN	dep||mesh-21/VBN||$-82/$	num||$-82/$||diagnosisâ-83/CD	dep||mesh-21/VBN||$-84/$	num||$-84/$||-LSB--85/CD	amod||-RSB--87/NN||subheading-86/JJ	iobj||mesh-21/VBN||-RSB--87/NN	iobj||mesh-21/VBN||â-89/NN	conj_or||-RSB--87/NN||â-89/NN	dep||mesh-21/VBN||$-90/$	num||$-90/$||diagnosisâ-91/CD	dep||mesh-21/VBN||$-92/$	num||$-92/$||-LSB--93/CD	det||fields-95/NNS||all-94/DT	iobj||mesh-21/VBN||fields-95/NNS	iobj||mesh-21/VBN||-RSB--96/NN	iobj||mesh-21/VBN||â-98/NN	conj_or||-RSB--96/NN||â-98/NN	dep||mesh-21/VBN||$-99/$	num||$-99/$||diagnosisâ-100/CD	dep||mesh-21/VBN||$-101/$	num||$-101/$||-LSB--102/CD	nn||terms-104/NNS||mesh-103/NN	iobj||mesh-21/VBN||terms-104/NNS	iobj||mesh-21/VBN||-RSB--105/NN	iobj||mesh-21/VBN||â-107/NN	conj_and||-RSB--105/NN||â-107/NN	dobj||mesh-21/VBN||$-108/$	num||$-108/$||assessmentâ-109/CD	prep||mesh-21/VBN||$-110/$	num||$-110/$||-LSB--111/CD	det||-RSB--114/NN||all-112/DT	nn||-RSB--114/NN||fields-113/NNS	dep||$-110/$||-RSB--114/NN	dep||-RSB--114/NN||â-117/NN	dep||â-117/NN||$-118/$	num||$-118/$||methodsâ-119/CD	num||-RSB--123/NNS||$-120/$	number||subheading-122/CD||-LSB--121/CD	num||$-120/$||subheading-122/CD	dep||$-118/$||-RSB--123/NNS	advmod||$-126/$||â-125/RB	dep||-RSB--114/NN||$-126/$	conj_or||â-117/NN||$-126/$	rcmod||â-117/NN||$-126/$	num||$-126/$||methodsâ-127/CD	dep||$-126/$||$-128/$	num||$-128/$||-LSB--129/CD	det||-RSB--132/NN||all-130/DT	nn||-RSB--132/NN||fields-131/NNS	dep||$-110/$||-RSB--132/NN	conj_and||-RSB--114/NN||-RSB--132/NN	dep||follows-14/VBZ||â-134/VB	conj_or||â-15/VB||â-134/VB	dobj||â-134/VB||$-135/$	num||$-135/$||methodsâ-136/CD	num||terms-140/NNS||$-137/$	number||mesh-139/CD||-LSB--138/CD	num||$-137/$||mesh-139/CD	npadvmod||-RSB--141/JJ||terms-140/NNS	amod||$-135/$||-RSB--141/JJ	hypersensitivity--1||hypersensitivity--1||no||a pubmed literature search strategy including the following mesh terms were used as follows âdentin sensitivityâ?[mesh terms] or âdentinâ?[all fields] and âsensitivityâ?[all fields] or âdentin sensitivityâ?[all fields] or âdentinâ?[all fields] and âhypersensitivityâ?[all fields] or âdentin hypersensitivityâ?[all fields] and âdiagnosisâ?[subheading] or âdiagnosisâ?[all fields] or âdiagnosisâ?[mesh terms] and âassessmentâ?[all fields] and (âmethodsâ?[subheading] or âmethodsâ?[all fields] or âmethodsâ?[mesh terms].
nsubj||combined-25/VBD||objective-1/NN	aux||compare-3/VB||to-2/TO	vmod||objective-1/NN||compare-3/VB	det||costs-6/NNS||the-4/DT	nn||costs-6/NNS||treatment-5/NN	dobj||compare-3/VB||costs-6/NNS	prep_of||costs-6/NNS||insulinglargine-8/NN	dep||insulinglargine-8/NN||ig-10/NN	nn||®-13/NNP||lantusâ-12/NNP	dep||ig-10/NN||®-13/NNP	aux||detemir-16/VB||to-15/TO	vmod||insulinglargine-8/NN||detemir-16/VB	dep||combined-25/VBD||id-18/NN	nn||®-21/NNP||levemirâ-20/NNP	dep||id-18/NN||®-21/NNP	nsubj||combined-25/VBD||both-24/DT	root||ROOT-0/null||combined-25/VBD	amod||insulinaspart-28/NN||bolus-27/JJ	prep_with||combined-25/VBD||insulinaspart-28/NN	nn||®-31/NNP||novorapidâ-30/NNP	appos||insulinaspart-28/NN||®-31/NNP	amod||t2d-36/NNS||type2diabetes-34/JJ	prep_in||combined-25/VBD||t2d-36/NNS	prep_in||t2d-36/NNS||germany-39/NN	t2d-36||insulinglargine-8||yes||objective to compare the treatment costs of insulinglargine (ig; lantusâ®) to detemir (id; levemirâ®), both combined with bolus insulinaspart (novorapidâ®) in type2diabetes (t2d) in germany.
det||children-2/NNS||all-1/DT	nsubjpass||treated-4/VBN||children-2/NNS	auxpass||treated-4/VBN||were-3/VBD	root||ROOT-0/null||treated-4/VBN	prep_for||treated-4/VBN||malaria-6/NN	nn||artemether-9/NN||intramuscular-8/NN	prep_with||treated-4/VBN||artemether-9/NN	malaria-6||artemether-9||yes||all children were treated for malaria with intramuscular artemether.
det||combination-2/NN||the-1/DT	nsubj||provide-17/VBP||combination-2/NN	nn||recruitment-5/NN||community-4/NN	prep_of||combination-2/NN||recruitment-5/NN	prep_of||combination-2/NN||acasi-7/NNS	conj_and||recruitment-5/NN||acasi-7/NNS	amod||testing-10/NN||rapid-9/JJ	prep_of||combination-2/NN||testing-10/NN	conj_and||recruitment-5/NN||testing-10/NN	det||study-16/NN||a-12/DT	amod||study-16/NN||linked-13/VBN	amod||study-16/NN||diagnostic-14/JJ	nn||study-16/NN||accuracy-15/NN	prep_of||combination-2/NN||study-16/NN	conj_and||recruitment-5/NN||study-16/NN	root||ROOT-0/null||provide-17/VBP	amod||methods-19/NNS||enhanced-18/VBN	dobj||provide-17/VBP||methods-19/NNS	prepc_for||provide-17/VBP||conducting-21/VBG	dobj||conducting-21/VBG||blood-22/NN	vmod||blood-22/NN||borne-23/VBN	nn||studies-26/NNS||virus-24/NN	amod||studies-26/NNS||sero-prevalence-25/JJ	dobj||borne-23/VBN||studies-26/NNS	prep_in||borne-23/VBN||idus-28/NNS	virus-24||idus-28||yes||the combination of community recruitment, acasi, rapid testing and a linked diagnostic accuracy study provide enhanced methods for conducting blood borne virus sero-prevalence studies in idus.
advmod||hivpositive-16/JJ||also-1/RB	num||weeks-4/NNS||two-3/CD	prep_after||hivpositive-16/JJ||weeks-4/NNS	prep_of||weeks-4/NNS||treatment-6/NN	det||rate-9/NN||the-7/DT	nn||rate-9/NN||conversion-8/NN	nsubj||hivpositive-16/JJ||rate-9/NN	amod||microscopy-12/NN||fluorescence-11/JJ	prep_by||rate-9/NN||microscopy-12/NN	cop||hivpositive-16/JJ||was-13/VBD	dep||in-15/IN||higher-14/JJR	advmod||hivpositive-16/JJ||in-15/IN	root||ROOT-0/null||hivpositive-16/JJ	num||%-19/NN||72.8-18/CD	dep||hivpositive-16/JJ||%-19/NN	advmod||in-22/IN||than-21/RBR	prep||hivpositive-16/JJ||in-22/IN	dep||in-22/IN||hiv-23/VB	dep||in-22/IN||hiv-23/VB	conj_negcc||hiv-23/VB||hiv-23/VB	amod||patients-29/NNS||negative-24/JJ	num||%-27/NN||63.2-26/CD	appos||patients-29/NNS||%-27/NN	dobj||hiv-23/VB||patients-29/NNS	amod||analysis-32/NN||univariate-31/JJ	prep_by||hiv-23/VB||analysis-32/NN	dep||analysis-32/NN||p-34/VBN	dep||0.043-36/CD||=-35/SYM	ccomp||p-34/VBN||0.043-36/CD	det||analysis-43/NN||the-41/DT	amod||analysis-43/NN||multivariate-42/JJ	prep_in||hiv-23/VB||analysis-43/NN	hivpositive-16||hiv-23||no||also after two weeks of treatment the conversion rate by fluorescence microscopy was higher in hivpositive (72.8%) than in hiv negative(63.2%) patients by univariate analysis (p = 0.043) but not in the multivariate analysis.
poss||setting-3/NN||our-2/PRP$	prep_in||defining-7/VBG||setting-3/NN	amod||aids-6/NNS||new-5/JJ	nsubj||defining-7/VBG||aids-6/NNS	nsubj||m.tb-12/JJ||aids-6/NNS	root||ROOT-0/null||defining-7/VBG	dobj||defining-7/VBG||illnesses-8/NNS	dep||m.tb-12/JJ||drug-10/NN	npadvmod||m.tb-12/JJ||resistant-11/NN	conj_and||defining-7/VBG||m.tb-12/JJ	amod||bacteria-17/NNS||other-14/JJ	nn||bacteria-17/NNS||drug-15/NN	nn||bacteria-17/NNS||resistant-16/NN	nsubj||reasons-20/NNS||bacteria-17/NNS	cop||reasons-20/NNS||are-18/VBP	amod||reasons-20/NNS||important-19/JJ	conj_and||defining-7/VBG||reasons-20/NNS	amod||deterioration-23/NN||clinical-22/JJ	prep_for||reasons-20/NNS||deterioration-23/NN	amod||patients-27/NNS||hiv-1-25/JJ	amod||patients-27/NNS||co-infected-26/JJ	prep_in||deterioration-23/NN||patients-27/NNS	vmod||patients-27/NNS||receiving-28/VBG	nn||treatment-30/NN||antitubercular-29/NN	dobj||receiving-28/VBG||treatment-30/NN	tb--1||antitubercular-29||yes||in our setting, new aids defining illnesses, drug resistant m.tb and other drug resistant bacteria are important reasons for clinical deterioration in hiv-1 co-infected patients receiving antitubercular treatment.
nsubj||effect-8/NN||bisphosphonate-associatedosteonecrosisofthejaws-1/NNS	appos||bisphosphonate-associatedosteonecrosisofthejaws-1/NNS||bp-onj-3/NNP	cop||effect-8/NN||is-5/VBZ	det||effect-8/NN||an-6/DT	amod||effect-8/NN||adverse-7/JJ	root||ROOT-0/null||effect-8/NN	amod||treatment-11/NN||bisphosphonate-10/JJ	prep_of||effect-8/NN||treatment-11/NN	amod||rates-16/NNS||varying-13/VBG	amod||rates-16/NNS||reported-14/JJ	nn||rates-16/NNS||incidence-15/NN	prep_with||treatment-11/NN||rates-16/NNS	bisphosphonate-associatedosteonecrosisofthejaws-1||bisphosphonate-10||no||bisphosphonate-associatedosteonecrosisofthejaws (bp-onj) is an adverse effect of bisphosphonate treatment with varying reported incidence rates.
amod||knowledge-3/NN||whereas-1/JJ	amod||knowledge-3/NN||much-2/JJ	nsubj||exists-4/VBZ||knowledge-3/NN	ccomp||appreciated-19/VBN||exists-4/VBZ	det||role-7/NN||the-6/DT	prep_on||exists-4/VBZ||role-7/NN	amod||immunity-10/NN||adaptive-9/JJ	prep_of||role-7/NN||immunity-10/NN	prep_during||exists-4/VBZ||hivinfection-12/NN	nsubjpass||appreciated-19/VBN||it-14/PRP	aux||appreciated-19/VBN||has-15/VBZ	advmod||recently-17/RB||only-16/RB	advmod||appreciated-19/VBN||recently-17/RB	auxpass||appreciated-19/VBN||been-18/VBN	root||ROOT-0/null||appreciated-19/VBN	mark||plays-26/VBZ||that-20/IN	det||response-24/NN||the-21/DT	amod||response-24/NN||innate-22/JJ	amod||response-24/NN||immune-23/JJ	nsubj||plays-26/VBZ||response-24/NN	advmod||plays-26/VBZ||also-25/RB	ccomp||appreciated-19/VBN||plays-26/VBZ	det||part-29/NN||an-27/DT	amod||part-29/NN||important-28/JJ	dobj||plays-26/VBZ||part-29/NN	nn||pathogenesis-32/NNS||hiv-31/NN	prep_in||part-29/NN||pathogenesis-32/NNS	hivinfection-12||hiv-31||no||whereas much knowledge exists on the role of adaptive immunity during hivinfection, it has only recently been appreciated that the innate immune response also plays an important part in hiv pathogenesis.
advmod||expressed-7/VBN||interestingly-1/RB	amod||oatps-4/NNS||certain-3/JJ	nsubjpass||expressed-7/VBN||oatps-4/NNS	auxpass||expressed-7/VBN||are-5/VBP	advmod||expressed-7/VBN||prominently-6/RB	root||ROOT-0/null||expressed-7/VBN	prep_in||expressed-7/VBN||cancers-9/NNS	mark||mc-17/VBP||as-10/IN	prepc_compared_to||mc-17/VBP||to-12/TO	amod||tissues-14/NNS||normal-13/JJ	pobj||mc-17/VBP||tissues-14/NNS	nsubj||mc-17/VBP||qualifying-16/NNP	advcl||expressed-7/VBN||mc-17/VBP	amod||candidates-20/NNS||potential-19/JJ	prep_as||mc-17/VBP||candidates-20/NNS	amod||development-23/NN||cancerdrug-22/JJ	prep_for||candidates-20/NNS||development-23/NN	cancerdrug-22||cancers-9||no_rel||interestingly, certain oatps are prominently expressed in cancers as compared to normal tissues, qualifying mc as potential candidates for cancerdrug development.
nsubj||include-12/VBP||recommendations-1/NNS	aux||reduce-3/VB||to-2/TO	vmod||recommendations-1/NNS||reduce-3/VB	nn||incidence-5/NN||hiv-4/NN	dobj||reduce-3/VB||incidence-5/NN	amod||rates-9/NNS||aids-7/JJ	nn||rates-9/NNS||mortality-8/NN	dobj||reduce-3/VB||rates-9/NNS	conj_and||incidence-5/NN||rates-9/NNS	prep_in||reduce-3/VB||mozambique-11/NN	root||ROOT-0/null||include-12/VBP	nn||strengthening-15/NN||health-13/NN	nn||strengthening-15/NN||system-14/NN	dobj||include-12/VBP||strengthening-15/NN	amod||outreach-18/NN||rural-17/JJ	appos||strengthening-15/NN||outreach-18/NN	aux||increase-20/VB||to-19/TO	vmod||outreach-18/NN||increase-20/VB	dobj||increase-20/VB||testing-21/NN	dobj||increase-20/VB||linkage-23/NN	conj_and||testing-21/NN||linkage-23/NN	prep_to||testing-21/NN||care-25/NN	dobj||increase-20/VB||education-27/NN	conj_and||testing-21/NN||education-27/NN	nn||reduction-30/NN||risk-29/NN	prep_about||education-27/NN||reduction-30/NN	nn||adherence-33/NNS||drug-32/NN	prep_about||education-27/NN||adherence-33/NNS	conj_and||reduction-30/NN||adherence-33/NNS	dobj||increase-20/VB||partnerships-36/NNS	conj_and||testing-21/NN||partnerships-36/NNS	amod||healers-39/NNS||traditional-38/JJ	prep_with||partnerships-36/NNS||healers-39/NNS	prep_with||partnerships-36/NNS||midwives-41/NNS	conj_and||healers-39/NNS||midwives-41/NNS	aux||effect-43/VB||to-42/TO	vmod||increase-20/VB||effect-43/VB	det||lessening-45/NN||a-44/DT	dobj||effect-43/VB||lessening-45/NN	prep_of||lessening-45/NN||stigma-47/NN	aids-7||hiv-4||no||recommendations to reduce hiv incidence and aids mortality rates in mozambique include health system strengthening, rural outreach to increase testing and linkage to care, education about risk reduction and drug adherence, and partnerships with traditional healers and midwives to effect a lessening of stigma.
det||range-4/NN||this-2/DT	nn||range-4/NN||dose-3/NN	prep_within||reduced-15/VBD||range-4/NN	det||population-9/NN||this-7/DT	nn||population-9/NN||patients-8/NNS	prep_in||reduced-15/VBD||population-9/NN	amod||dosage-13/NN||increasing-11/JJ	nn||dosage-13/NN||lidocaine-12/NN	nsubj||reduced-15/VBD||dosage-13/NN	nsubj||reduced-15/VBD||dosage-13/NN	advmod||reduced-15/VBD||significantly-14/RB	root||ROOT-0/null||reduced-15/VBD	conj_and||reduced-15/VBD||reduced-15/VBD	dobj||reduced-15/VBD||pain-16/NN	prep_during||reduced-15/VBD||injection-18/NN	nn||propofol-21/NN||microemulsion-20/NN	prep_of||injection-18/NN||propofol-21/NN	pain-16||lidocaine-12||yes||within this dose range and in this patients population, increasing lidocaine dosage significantly reduced pain during injection of microemulsion propofol.
nsubj||discovered-3/VBD||we-1/PRP	advmod||discovered-3/VBD||previously-2/RB	root||ROOT-0/null||discovered-3/VBD	det||facet-7/NN||an-4/DT	amod||facet-7/NN||addictive-5/JJ	amod||facet-7/NN||molecular-6/JJ	dobj||discovered-3/VBD||facet-7/NN	prep_of||facet-7/NN||anorexia-9/NNP	vmod||discovered-3/VBD||involving-11/VBG	dobj||involving-11/VBG||production-12/NN	det||accumbens-17/NNS||the-15/DT	nn||accumbens-17/NNS||nucleus-16/NN	prep_in||discovered-3/VBD||accumbens-17/NNS	appos||accumbens-17/NNS||nac-19/NN	det||transcripts-25/NNS||the-23/DT	amod||transcripts-25/NNS||same-24/JJ	prep_of||accumbens-17/NNS||transcripts-25/NNS	vmod||transcripts-25/NNS||stimulated-26/VBN	prep_in||stimulated-26/VBN||response-28/NN	prep_to||stimulated-26/VBN||cocaine-30/NN	prep_to||stimulated-26/VBN||amphetamine-32/NN	conj_and||cocaine-30/NN||amphetamine-32/NN	appos||cocaine-30/NN||cart-34/NN	prep_upon||stimulated-26/VBN||stimulation-37/NN	det||receptors-41/NNS||the-39/DT	amod||receptors-41/NNS||5-ht4-40/JJ	prep_of||stimulation-37/NN||receptors-41/NNS	dep||receptors-41/NNS||5-htr4-43/JJ	prep_of||stimulation-37/NN||mdma-46/NN	conj_or||receptors-41/NNS||mdma-46/NN	appos||receptors-41/NNS||ecstasy-48/NN	ecstasy-48||anorexia-9||no_rel||we previously discovered an addictive molecular facet of anorexia, involving production, in the nucleus accumbens (nac), of the same transcripts stimulated in response to cocaine and amphetamine (cart) upon stimulation of the 5-ht4 receptors (5-htr4) or mdma (ecstasy).
amod||combinations-4/NNS||docetaxel-1/JJ	conj_and||docetaxel-1/JJ||gemcitabine-3/JJ	amod||combinations-4/NNS||gemcitabine-3/JJ	nsubj||proven-6/VBN||combinations-4/NNS	aux||proven-6/VBN||have-5/VBP	root||ROOT-0/null||proven-6/VBN	acomp||proven-6/VBN||active-7/JJ	det||treatment-10/NN||the-9/DT	prep_for||proven-6/VBN||treatment-10/NN	prep_of||treatment-10/NN||non-smallcelllungcancer-12/NN	dep||non-smallcelllungcancer-12/NN||nsclc-14/JJ	non-smallcelllungcancer-12||docetaxel-1||yes||docetaxel and gemcitabine combinations have proven active for the treatment of non-smallcelllungcancer (nsclc).
vmod||show-15/VBP||using-1/VBG	amod||assays-4/NNS||checkerboard-2/JJ	nn||assays-4/NNS||microdilution-3/NN	dobj||using-1/VBG||assays-4/NNS	amod||experiments-8/NNS||time-kill-6/JJ	nn||experiments-8/NNS||curve-7/NN	dobj||using-1/VBG||experiments-8/NNS	conj_and||assays-4/NNS||experiments-8/NNS	nn||assays-12/NNS||agar-10/NN	nn||assays-12/NNS||diffusion-11/NN	dobj||using-1/VBG||assays-12/NNS	conj_and||assays-4/NNS||assays-12/NNS	nsubj||show-15/VBP||we-14/PRP	root||ROOT-0/null||show-15/VBP	det||synergism-17/NN||a-16/DT	dobj||show-15/VBP||synergism-17/NN	prep_between||synergism-17/NN||medihoney-19/NN	prep_between||synergism-17/NN||rifampicin-21/NN	conj_and||medihoney-19/NN||rifampicin-21/NN	nn||isolates-26/NNS||mrsa-23/NN	conj_and||mrsa-23/NN||clinical-25/JJ	nn||isolates-26/NNS||clinical-25/JJ	prep_against||show-15/VBP||isolates-26/NNS	prep_of||isolates-26/NNS||s.aureus-28/NNS	mrsa-23||s.aureus-28||no||using checkerboard microdilution assays , time-kill curve experiments and agar diffusion assays , we show a synergism between medihoney and rifampicin against mrsa and clinical isolates of s.aureus .
det||study-2/NN||the-1/DT	nsubj||included-3/VBD||study-2/NN	root||ROOT-0/null||included-3/VBD	num||patients-7/NNS||one-4/CD	num||patients-7/NNS||hundred-5/CD	amod||patients-7/NNS||eighty-6/JJ	dobj||included-3/VBD||patients-7/NNS	dep||patients-7/NNS||divided-8/VBN	det||diabetic-13/NN||the-10/DT	amod||diabetic-13/NN||following-11/JJ	nn||diabetic-13/NN||groups-12/NNS	prep_in||divided-8/VBN||diabetic-13/NN	amod||disorders-17/NNS||ischemic-15/JJ	amod||disorders-17/NNS||cardiopathy-related-16/JJ	prep_without||diabetic-13/NN||disorders-17/NNS	appos||diabetic-13/NN||dm-19/NN	amod||disorders-35/NNS||diabetic-22/JJ	prep_with||diabetic-22/JJ||clinical-24/JJ	prep_with||diabetic-22/JJ||off-clinical-26/JJ	conj_or||clinical-24/JJ||off-clinical-26/JJ	dep||diabetic-22/JJ||electrocardiogram-28/NN	amod||ultrasound-31/NN||cardiac-30/JJ	appos||electrocardiogram-28/NN||ultrasound-31/NN	amod||disorders-35/NNS||ischemic-33/JJ	amod||disorders-35/NNS||cardiopathy-related-34/JJ	appos||diabetic-13/NN||disorders-35/NNS	amod||ic-39/NN||dm-37/JJ	amod||ic-39/NN||+-38/JJ	appos||disorders-35/NNS||ic-39/NN	dep||patients-7/NNS||nondiabetic-43/JJ	conj_and||divided-8/VBN||nondiabetic-43/JJ	amod||disorders-47/NNS||ischemic-45/JJ	amod||disorders-47/NNS||cardiopathy-related-46/JJ	prep_with||nondiabetic-43/JJ||disorders-47/NNS	appos||disorders-47/NNS||ic-49/NN	cardiopathy--1||dm-37||no_rel||the study included one hundred eighty patients divided in the following groups diabetic without ischemic cardiopathy-related disorders (dm), diabetic with clinical or off-clinical (electrocardiogram, cardiac ultrasound) ischemic cardiopathy-related disorders (dm + ic), and nondiabetic with ischemic cardiopathy-related disorders (ic).
amod||t2d-3/NNS||type2diabetesmellitus-1/JJ	nsubj||disease-20/NN||t2d-3/NNS	det||disorder-8/NN||a-6/DT	amod||disorder-8/NN||metabolic-7/JJ	appos||t2d-3/NNS||disorder-8/NN	vmod||disorder-8/NN||characterized-9/VBN	amod||deficiency-15/NN||insulinresistance-11/JJ	conj_and||insulinresistance-11/JJ||relative-13/JJ	amod||deficiency-15/NN||relative-13/JJ	nn||deficiency-15/NN||insulin-14/NN	agent||characterized-9/VBN||deficiency-15/NN	cop||disease-20/NN||is-17/VBZ	det||disease-20/NN||a-18/DT	amod||disease-20/NN||complex-19/JJ	root||ROOT-0/null||disease-20/NN	amod||importance-25/NN||major-22/JJ	amod||importance-25/NN||public-23/JJ	nn||importance-25/NN||health-24/NN	prep_of||disease-20/NN||importance-25/NN	type2diabetesmellitus-1||insulin-14||yes||type2diabetesmellitus (t2d), a metabolic disorder characterized by insulinresistance and relative insulin deficiency, is a complex disease of major public health importance.
advmod||recommended-13/VBN||currently-1/RB	amod||drugs-4/NNS||several-3/JJ	nsubjpass||recommended-13/VBN||drugs-4/NNS	nsubjpass||shown-34/VBN||drugs-4/NNS	nsubj||potent-38/JJ||drugs-4/NNS	prep_such_as||drugs-4/NNS||tenofovir-8/NN	prep_such_as||drugs-4/NNS||adefovir-10/NN	conj_and||tenofovir-8/NN||adefovir-10/NN	auxpass||recommended-13/VBN||are-12/VBP	root||ROOT-0/null||recommended-13/VBN	prep_for||recommended-13/VBN||treatment-15/NN	prep_of||treatment-15/NN||patients-17/NNS	mark||analog-25/NN||with-18/IN	nn||tenofovir-21/NNP||chronichepatitisb-19/NN	nsubj||analog-25/NN||tenofovir-21/NNP	cop||analog-25/NN||is-22/VBZ	det||analog-25/NN||a-23/DT	amod||analog-25/NN||nucleoside-24/JJ	advcl||recommended-13/VBN||analog-25/NN	amod||activity-28/NN||selective-27/JJ	prep_with||analog-25/NN||activity-28/NN	prep_against||activity-28/NN||hepatitisbvirus-30/NNS	aux||shown-34/VBN||has-32/VBZ	auxpass||shown-34/VBN||been-33/VBN	conj_and||recommended-13/VBN||shown-34/VBN	aux||potent-38/JJ||to-35/TO	cop||potent-38/JJ||be-36/VB	advmod||potent-38/JJ||more-37/RBR	xcomp||shown-34/VBN||potent-38/JJ	prep_in||potent-38/JJ||vitro-40/NN	prep_than||vitro-40/NN||adefovir-42/NN	chronichepatitisb-19||hepatitisbvirus-30||no||currently , several drugs , such as tenofovir and adefovir , are recommended for treatment of patients with chronichepatitisb. tenofovir is a nucleoside analog with selective activity against hepatitisbvirus and has been shown to be more potent in vitro than adefovir .
nsubj||demonstrated-2/VBD||we-1/PRP	root||ROOT-0/null||demonstrated-2/VBD	mark||employed-7/VBN||that-3/IN	nsubjpass||employed-7/VBN||bmscs-4/NNS	aux||employed-7/VBN||might-5/MD	auxpass||employed-7/VBN||be-6/VB	ccomp||demonstrated-2/VBD||employed-7/VBN	det||vehicle-11/NN||a-9/DT	amod||vehicle-11/NN||promising-10/JJ	prep_as||employed-7/VBN||vehicle-11/NN	nn||therapy-15/NN||tumor-13/NN	nn||therapy-15/NN||gene-14/NN	prep_for||vehicle-11/NN||therapy-15/NN	nsubj||improve-21/VB||therapy-15/NN	nsubj||modify-32/VB||therapy-15/NN	aux||improve-21/VB||can-17/MD	advmod||improve-21/VB||effectively-18/RB	neg||improve-21/VB||not-19/RB	advmod||improve-21/VB||only-20/RB	rcmod||therapy-15/NN||improve-21/VB	det||concentration-23/NN||the-22/DT	dobj||improve-21/VB||concentration-23/NN	amod||therapeutics-26/NNS||anticancer-25/JJ	prep_of||concentration-23/NN||therapeutics-26/NNS	prep_in||therapeutics-26/NNS||tumors-28/NNS	advmod||modify-32/VB||also-31/RB	rcmod||therapy-15/NN||modify-32/VB	conj_but||improve-21/VB||modify-32/VB	det||microenvironment-35/NN||the-33/DT	nn||microenvironment-35/NN||tumor-34/NN	dobj||modify-32/VB||microenvironment-35/NN	vehicle-11||tumor-34||no_rel||we demonstrated that bmscs might be employed as a promising vehicle for tumor gene therapy which can effectively not only improve the concentration of anticancer therapeutics in tumors, but also modify the tumor microenvironment.
nsubjpass||made-4/VBN||consideration-1/NN	nsubj||avoid-6/VB||consideration-1/NN	nsubj||change-10/VB||consideration-1/NN	nsubj||premedicate-15/VB||consideration-1/NN	aux||made-4/VBN||should-2/MD	auxpass||made-4/VBN||be-3/VB	root||ROOT-0/null||made-4/VBN	aux||avoid-6/VB||to-5/TO	xcomp||made-4/VBN||avoid-6/VB	dobj||avoid-6/VB||fluorescein-7/NN	advmod||avoid-6/VB||angiography-8/RB	xcomp||made-4/VBN||change-10/VB	conj_or||avoid-6/VB||change-10/VB	nn||route-12/NN||administration-11/NN	dobj||change-10/VB||route-12/NN	xcomp||made-4/VBN||premedicate-15/VB	conj_or||avoid-6/VB||premedicate-15/VB	prep_with||premedicate-15/VB||antihistamines-17/NNS	prep_in||antihistamines-17/NNS||patients-19/NNS	amod||albuminsolutionallergy-23/NN||known-21/JJ	amod||albuminsolutionallergy-23/NN||human-22/JJ	prep_with||patients-19/NNS||albuminsolutionallergy-23/NN	albuminsolutionallergy-23||antihistamines-17||no_rel||consideration should be made to avoid fluorescein angiography, change administration route, or premedicate with antihistamines in patients with known human albuminsolutionallergy.
det||expression-2/NN||the-1/DT	nsubj||makes-11/VBZ||expression-2/NN	prep_of||expression-2/NN||cta-4/NN	nn||cells-10/NNS||mhc-6/NN	nn||cells-10/NNS||class-7/NN	nn||cells-10/NNS||i-deficient-8/NN	amod||cells-10/NNS||germline-9/JJ	prep_in||cta-4/NN||cells-10/NNS	root||ROOT-0/null||makes-11/VBZ	det||proteins-13/NNS||these-12/DT	nsubj||attractive-15/JJ||proteins-13/NNS	advmod||attractive-15/JJ||particularly-14/RB	xcomp||makes-11/VBZ||attractive-15/JJ	amod||targets-18/NNS||immunotherapeutic-17/JJ	prep_as||attractive-15/JJ||targets-18/NNS	mark||serve-21/VBP||because-19/IN	nsubj||serve-21/VBP||they-20/PRP	advcl||makes-11/VBZ||serve-21/VBP	mark||i-restricted-29/VBD||as-22/IN	advmod||tumor-specific-24/JJ||essentially-23/RB	amod||antigens-25/NNS||tumor-specific-24/JJ	nsubj||i-restricted-29/VBD||antigens-25/NNS	nn||class-28/NN||mhc-27/NN	prep_for||antigens-25/NNS||class-28/NN	advcl||serve-21/VBP||i-restricted-29/VBD	amod||cells-33/NNS||cd8-30/JJ	amod||cells-33/NNS||+-31/JJ	nn||cells-33/NNS||t-32/NN	dobj||i-restricted-29/VBD||cells-33/NNS	i---1||tumor--1||no_rel||the expression of cta in mhc class i-deficient germline cells makes these proteins particularly attractive as immunotherapeutic targets because they serve as essentially tumor-specific antigens for mhc class i-restricted cd8+ t cells.
nsubjpass||reported-7/VBN||cases-1/NNS	amod||pancreatitis-4/NNS||acute-3/JJ	prep_of||cases-1/NNS||pancreatitis-4/NNS	aux||reported-7/VBN||have-5/VBP	auxpass||reported-7/VBN||been-6/VBN	root||ROOT-0/null||reported-7/VBN	prep_in||reported-7/VBN||association-9/NN	prep_with||reported-7/VBN||exenatide-11/NN	prep_with||reported-7/VBN||sitagliptin-13/NN	conj_and||exenatide-11/NN||sitagliptin-13/NN	prep_with||reported-7/VBN||type2diabetes-16/NNS	conj_and||exenatide-11/NN||type2diabetes-16/NNS	prep_without||reported-7/VBN||use-18/NN	det||medications-21/NNS||these-20/DT	prep_of||use-18/NN||medications-21/NNS	type2diabetes-16||exenatide-11||yes||cases of acute pancreatitis have been reported in association with exenatide, sitagliptin, and type2diabetes without use of these medications.
nsubj||report-2/VBP||authors-1/NNS	root||ROOT-0/null||report-2/VBP	det||case-5/NN||a-3/DT	amod||case-5/NN||rare-4/JJ	dobj||report-2/VBP||case-5/NN	amod||subdural-9/NN||acute-7/JJ	nn||subdural-9/NN||intracranial-8/NN	prep_of||case-5/NN||subdural-9/NN	nsubjpass||caused-15/VBN||subdural-9/NN	nn||hemorrhage-12/NN||intraventricular-11/NN	prep_of||case-5/NN||hemorrhage-12/NN	conj_and||subdural-9/NN||hemorrhage-12/NN	nsubjpass||caused-15/VBN||hemorrhage-12/NN	auxpass||caused-15/VBN||were-14/VBD	rcmod||subdural-9/NN||caused-15/VBN	agent||caused-15/VBN||intracranialhypotension-17/NN	vmod||intracranialhypotension-17/NN||resulted-18/VBN	prep_from||resulted-18/VBN||cerebrospinalfluidleakage-20/NN	det||site-26/NN||an-22/DT	amod||site-26/NN||unidentified-23/JJ	amod||site-26/NN||dural-24/JJ	nn||site-26/NN||tear-25/NN	prep_through||resulted-18/VBN||site-26/NN	amod||surgery-29/NN||spinal-28/JJ	prep_during||site-26/NN||surgery-29/NN	intracranialhypotension-17||cerebrospinalfluidleakage-20||no||authors report a rare case of acute intracranial subdural and intraventricular hemorrhage that were caused by intracranialhypotension resulted from cerebrospinalfluidleakage through an unidentified dural tear site during spinal surgery.
expl||were-2/VBD||there-1/EX	root||ROOT-0/null||were-2/VBD	neg||differences-4/NNS||no-3/DT	nsubj||were-2/VBD||differences-4/NNS	prep_in||differences-4/NNS||duration-6/NN	amod||therapy-11/NN||candidemia-8/JJ	amod||therapy-11/NN||antifungal-10/JJ	prep_of||duration-6/NN||therapy-11/NN	nn||species-14/NNS||candida-13/NN	prep_of||duration-6/NN||species-14/NNS	conj_or||therapy-11/NN||species-14/NNS	det||groups-17/NNS||the-16/DT	prep_between||therapy-11/NN||groups-17/NNS	candidemia-8||candida-13||no||there were no differences in duration of candidemia, antifungal therapy or candida species between the groups.
nsubj||found-2/VBD||we-1/PRP	dep||â-48/VBP||found-2/VBD	mark||associated-13/VBN||that-3/IN	amod||tg/gg-6/NN||il-23r-4/JJ	amod||tg/gg-6/NN||rs1884444-5/JJ	nsubjpass||associated-13/VBN||tg/gg-6/NN	amod||genotypes-11/NNS||rs6682925-8/JJ	amod||genotypes-11/NNS||tc/cc-9/JJ	nn||genotypes-11/NNS||variant-10/NN	conj_and||tg/gg-6/NN||genotypes-11/NNS	nsubjpass||associated-13/VBN||genotypes-11/NNS	auxpass||associated-13/VBN||were-12/VBD	ccomp||found-2/VBD||associated-13/VBN	advmod||increased-16/JJ||significantly-15/RB	amod||risk-17/NN||increased-16/JJ	prep_with||associated-13/VBN||risk-17/NN	poss||ratio-24/NN||aml-19/PRP$	num||rs1884444-21/NNS||-LSB--20/CD	npadvmod||adjusted-22/JJ||rs1884444-21/NNS	amod||ratio-24/NN||adjusted-22/JJ	nn||ratio-24/NN||odds-23/NNS	prep_of||risk-17/NN||ratio-24/NN	det||interval-40/NN||â-28/DT	amod||interval-40/NN||$-29/$	number||=-31/CD||-30/CD	num||$-29/$||=-31/CD	amod||interval-40/NN||â-32/JJ	amod||interval-40/NN||$-33/$	number||.28-35/CD||1-34/CD	num||$-33/$||.28-35/CD	number||%-38/NN||95-37/CD	amod||interval-40/NN||%-38/NN	nn||interval-40/NN||confidence-39/NN	nsubj||â-44/VBP||interval-40/NN	discourse||interval-40/NN||ci-42/UH	conj_or||found-2/VBD||â-44/VBP	dep||â-48/VBP||â-44/VBP	dobj||â-44/VBP||$-45/$	number||=-47/CD||-46/CD	num||$-45/$||=-47/CD	root||ROOT-0/null||â-48/VBP	dobj||â-48/VBP||$-49/$	num||$-49/$||1-50/CD	num||â-52/NNS||.01-51/CD	amod||$-49/$||â-52/NNS	dep||â-52/NNS||$-53/$	num||$-53/$||1.62-55/CD	dep||$-53/$||rs6682925-57/NNS	vmod||rs6682925-57/NNS||adjusted-58/VBN	quantmod||$-60/$||orâ-59/RB	nsubj||â-63/NN||$-60/$	num||$-60/$||-61/CD	dep||â-63/NN||=-62/SYM	ccomp||adjusted-58/VBN||â-63/NN	nsubj||â-48/VBP||$-64/$	num||$-64/$||1-65/CD	num||$-64/$||.30-66/CD	num||%-69/NN||95-68/CD	appos||$-64/$||%-69/NN	vmod||%-69/NN||ciâ-70/VBN	num||-RSB--82/NNS||$-71/$	number||=-73/CD||-72/CD	num||$-71/$||=-73/CD	amod||-RSB--82/NNS||â-74/JJ	dep||â-78/NN||$-75/$	number||.01-77/CD||1-76/CD	num||$-75/$||.01-77/CD	amod||-RSB--82/NNS||â-78/NN	num||-RSB--82/NNS||$-79/$	num||$-79/$||1.67-81/CD	dobj||ciâ-70/VBN||-RSB--82/NNS	prepc_compared_to||ciâ-70/VBN||to-85/TO	poss||homozygotes-89/NNS||their-86/PRP$	amod||homozygotes-89/NNS||corresponding-87/JJ	amod||homozygotes-89/NNS||wild-type-88/JJ	pobj||ciâ-70/VBN||homozygotes-89/NNS	dep||ciâ-70/VBN||respectively-91/RB	tg--1||aml-19||no_rel||we found that il-23r rs1884444 tg/gg and rs6682925 tc/cc variant genotypes were associated with significantly increased risk of aml [rs1884444 adjusted odds ratio (or)â=â1.28, 95% confidence interval (ci)â=â1.01â1.62; rs6682925 adjusted orâ=â1.30, 95%ciâ=â1.01â1.67], compared to their corresponding wild-type homozygotes, respectively.
advmod||hbsag-24/VBG||furthermore-1/RB	mark||expressed-12/VBD||while-3/IN	nsubj||expressed-12/VBD||most-4/JJS	det||controls-7/NNS||the-6/DT	prep_of||most-4/JJS||controls-7/NNS	amod||infection-11/NN||ongoing-9/JJ	nn||infection-11/NN||hbv-10/NN	prep_with||controls-7/NNS||infection-11/NN	advcl||hbsag-24/VBG||expressed-12/VBD	xcomp||expressed-12/VBD||hbsag-13/VBG	det||majority-16/NN||the-15/DT	nsubj||hbsag-24/VBG||majority-16/NN	nn||patients-22/NNS||hcv-18/NN	conj_and||hcv-18/NN||hbv-20/JJ	nn||patients-22/NNS||hbv-20/JJ	amod||patients-22/NNS||positive-21/JJ	prep_of||majority-16/NN||patients-22/NNS	aux||hbsag-24/VBG||were-23/VBD	root||ROOT-0/null||hbsag-24/VBG	amod||positive-29/NN||negative-25/JJ	conj_and||negative-25/JJ||hbv-27/NN	amod||positive-29/NN||hbv-27/NN	nn||positive-29/NN||dna-28/NN	dobj||hbsag-24/VBG||positive-29/NN	hbv-27||hbsag-24||yes||furthermore, while most of the controls with ongoing hbv infection expressed hbsag, the majority of hcv and hbv positive patients were hbsag negative and hbv dna positive.
amod||expenditure-5/NN||pre-haart-1/JJ	dep||capita-3/NN||per-2/IN	amod||expenditure-5/NN||capita-3/NN	nn||expenditure-5/NN||health-4/NN	nsubjpass||associated-27/VBN||expenditure-5/NN	nn||treatment-9/NN||drug-7/NN	nn||treatment-9/NN||abuse-8/NN	conj_and||expenditure-5/NN||treatment-9/NN	nsubjpass||associated-27/VBN||treatment-9/NN	dep||expenditure-5/NN||rates-10/NNS	amod||rates-23/NNS||pre-13/JJ	amod||increases-17/NNS||haart-era-16/JJ	prep_to||pre-13/JJ||increases-17/NNS	nn||counseling-20/NN||hiv-19/NN	prep_in||pre-13/JJ||counseling-20/NN	prep_in||pre-13/JJ||testing-22/NN	conj_and||counseling-20/NN||testing-22/NN	conj_and||expenditure-5/NN||rates-23/NNS	nsubjpass||associated-27/VBN||rates-23/NNS	auxpass||associated-27/VBN||were-25/VBD	advmod||associated-27/VBN||weakly-26/RB	root||ROOT-0/null||associated-27/VBN	amod||decline-30/NN||greater-29/JJR	prep_with||associated-27/VBN||decline-30/NN	nn||mortality-33/NN||aids-32/NNS	prep_in||decline-30/NN||mortality-33/NN	aids-32||hiv-19||no||pre-haart per capita health expenditure and drug abuse treatment rates, and pre- to haart-era increases in hiv counseling and testing rates, were weakly associated with greater decline in aids mortality.
det||article-2/NN||this-1/DT	nsubj||reviews-3/VBZ||article-2/NN	root||ROOT-0/null||reviews-3/VBZ	acomp||reviews-3/VBZ||available-4/JJ	amod||data-8/NNS||preclinical-5/JJ	conj_and||preclinical-5/JJ||clinical-7/JJ	amod||data-8/NNS||clinical-7/JJ	dep||available-4/JJ||data-8/NNS	prep_of||data-8/NNS||posaconazole-10/NN	xcomp||reviews-3/VBZ||focusing-12/VBG	poss||role-15/NN||its-14/PRP$	prep_on||focusing-12/VBG||role-15/NN	det||teatment-18/NN||the-17/DT	prep_in||role-15/NN||teatment-18/NN	amod||fungalinfections-22/NNS||refractory-20/JJ	nn||fungalinfections-22/NNS||invasive-21/NN	prep_of||teatment-18/NN||fungalinfections-22/NNS	fungalinfections-22||posaconazole-10||yes||this article reviews available preclinical and clinical data of posaconazole, focusing on its role in the teatment of refractory invasive fungalinfections.
det||survey-2/NN||this-1/DT	nsubj||inh-4/VBP||survey-2/NN	vmod||survey-2/NN||evaluated-3/VBN	root||ROOT-0/null||inh-4/VBP	amod||mutations-6/NNS||resistant-associated-5/JJ	dobj||inh-4/VBP||mutations-6/NNS	mark||determine-10/VB||in-7/IN	dep||determine-10/VB||order-8/NN	aux||determine-10/VB||to-9/TO	advcl||inh-4/VBP||determine-10/VB	amod||detection-12/NN||rapid-11/JJ	dobj||determine-10/VB||detection-12/NN	nn||resistance-15/NN||tb-14/NN	prep_of||detection-12/NN||resistance-15/NN	tb-14||inh-4||yes||this survey evaluated inh resistant-associated mutations in order to determine rapid detection of tb resistance.
advmod||was-9/VBD||therefore-1/RB	det||aim-5/NN||the-3/DT	amod||aim-5/NN||specific-4/JJ	nsubj||was-9/VBD||aim-5/NN	nsubj||test-11/VB||aim-5/NN	det||study-8/NN||this-7/DT	prep_of||aim-5/NN||study-8/NN	root||ROOT-0/null||was-9/VBD	aux||test-11/VB||to-10/TO	xcomp||was-9/VBD||test-11/VB	det||hypothesis-13/NNS||the-12/DT	dobj||test-11/VB||hypothesis-13/NNS	mark||amplify-22/VB||that-14/IN	amod||use-16/NN||6-week-15/JJ	nsubj||amplify-22/VB||use-16/NN	det||fluoxetine-20/NN||the-18/DT	amod||fluoxetine-20/NN||ssri-19/JJ	prep_of||use-16/NN||fluoxetine-20/NN	aux||amplify-22/VB||would-21/MD	ccomp||test-11/VB||amplify-22/VB	amod||system-25/NN||autonomic-23/JJ	amod||system-25/NN||nervous-24/JJ	dobj||amplify-22/VB||system-25/NN	dep||amplify-22/VB||ans-27/NN	amod||responses-30/NNS||counterregulatory-29/JJ	dobj||amplify-22/VB||responses-30/NNS	prep_to||responses-30/NNS||hypoglycemia-32/NN	prep_in||amplify-22/VB||individuals-34/NNS	prep_with||amplify-22/VB||type1diabetes-36/CD	type1diabetes-36||ssri-19||no_rel||therefore, the specific aim of this study was to test the hypothesis that 6-week use of the ssri fluoxetine would amplify autonomic nervous system (ans) counterregulatory responses to hypoglycemia in individuals with type1diabetes.
det||study-8/NN||a-2/DT	amod||study-8/NN||multicenter-3/JJ	amod||study-8/NN||double-blind-5/JJ	amod||study-8/NN||randomized-7/JJ	prep_in||assigned-16/VBN||study-8/NN	num||patients-11/NNS||131-10/CD	nsubjpass||assigned-16/VBN||patients-11/NNS	amod||uc-14/NN||quiescent-13/JJ	prep_with||patients-11/NNS||uc-14/NN	auxpass||assigned-16/VBN||were-15/VBD	root||ROOT-0/null||assigned-16/VBN	num||groups-19/NNS||two-18/CD	prep_to||assigned-16/VBN||groups-19/NNS	dobj||assigned-16/VBN||65-20/CD	aux||receive-22/VB||to-21/TO	vmod||65-20/CD||receive-22/VB	det||formulation-26/NN||a-23/DT	amod||formulation-26/NN||ph-dependent-24/JJ	nn||formulation-26/NN||release-25/NN	dobj||receive-22/VB||formulation-26/NN	prep_of||formulation-26/NN||mesalamine-28/NN	num||g/day-31/NN||2.4-30/CD	prep_at||receive-22/VB||g/day-31/NN	dep||65-20/CD||ph-2-33/JJ	number||g-35/CD||.4-34/CD	dep||ph-2-33/JJ||g-35/CD	dobj||assigned-16/VBN||66-38/CD	conj_and||65-20/CD||66-38/CD	aux||receive-40/VB||to-39/TO	vmod||66-38/CD||receive-40/VB	det||formulation-44/NN||a-41/DT	amod||formulation-44/NN||time-dependent-42/JJ	nn||formulation-44/NN||release-43/NN	dobj||receive-40/VB||formulation-44/NN	prep_of||formulation-44/NN||mesalamine-46/NN	num||g/day-49/NN||2.25-48/CD	prep_at||receive-40/VB||g/day-49/NN	dep||66-38/CD||time-2-51/JJ	number||g-53/CD||.25-52/CD	dep||time-2-51/JJ||g-53/CD	uc-14||mesalamine-46||yes||in a multicenter, double-blind, randomized study, 131 patients with quiescent uc were assigned to two groups 65 to receive a ph-dependent release formulation of mesalamine at 2.4 g/day (ph-2.4 g) and 66 to receive a time-dependent release formulation of mesalamine at 2.25 g/day (time-2.25 g).
num||participants-3/NNS||17,377-2/CD	prep_among||%-11/NN||participants-3/NNS	det||rate-8/NN||the-5/DT	nn||rate-8/NN||hiv/aids-6/NNS	nn||rate-8/NN||knowledge-7/NN	nsubj||%-11/NN||rate-8/NN	cop||%-11/NN||was-9/VBD	num||%-11/NN||66.2-10/CD	root||ROOT-0/null||%-11/NN	aids--1||hiv--1||no||among 17,377 participants, the hiv/aids knowledge rate was 66.2%.
det||study-2/NN||this-1/DT	nsubj||kept-31/VBD||study-2/NN	vmod||study-2/NN||aimed-3/VBN	aux||analyze-5/VB||to-4/TO	xcomp||aimed-3/VBN||analyze-5/VB	det||effects-7/NNS||the-6/DT	dobj||analyze-5/VB||effects-7/NNS	prep_of||effects-7/NNS||exercise-9/NN	det||transition-13/NN||the-11/DT	amod||transition-13/NN||aerobic/anaerobic-12/JJ	prep_at||analyze-5/VB||transition-13/NN	det||markers-16/NNS||the-15/DT	prep_on||transition-13/NN||markers-16/NNS	amod||nafld-20/NN||non-alcoholicfattyliverdisease-18/JJ	prep_of||markers-16/NNS||nafld-20/NN	nn||sensitivity-24/NN||insulin-23/NN	prep_of||markers-16/NNS||sensitivity-24/NN	conj_and||nafld-20/NN||sensitivity-24/NN	det||chemistry-28/NN||the-26/DT	nn||chemistry-28/NN||blood-27/NN	prep_of||markers-16/NNS||chemistry-28/NN	conj_and||nafld-20/NN||chemistry-28/NN	prep_of||chemistry-28/NN||rats-30/NNS	root||ROOT-0/null||kept-31/VBD	det||diet-35/NN||a-33/DT	amod||diet-35/NN||fructose-rich-34/JJ	prep_on||kept-31/VBD||diet-35/NN	insulin-23||alcoholicfattyliver--1||no_rel||this study aimed to analyze the effects of exercise at the aerobic/anaerobic transition on the markers of non-alcoholicfattyliverdisease (nafld), insulin sensitivity and the blood chemistry of rats kept on a fructose-rich diet.
poss||role-5/NN||its-3/PRP$	amod||role-5/NN||principal-4/JJ	prep_apart_from||attributed-16/VBN||role-5/NN	nn||metabolism-8/NN||bone-7/NN	prep_in||role-5/NN||metabolism-8/NN	nn||homeostasis-11/NNS||calcium-10/NN	prep_in||role-5/NN||homeostasis-11/NNS	conj_and||metabolism-8/NN||homeostasis-11/NNS	nsubjpass||attributed-16/VBN||vitamind-13/NN	aux||attributed-16/VBN||has-14/VBZ	auxpass||attributed-16/VBN||been-15/VBN	root||ROOT-0/null||attributed-16/VBN	amod||effects-18/NNS||additional-17/JJ	dobj||attributed-16/VBN||effects-18/NNS	det||capacity-29/NN||an-20/DT	amod||capacity-29/NN||immunomodulatory-21/JJ	amod||capacity-29/NN||anti-inflammatory-23/JJ	advmod||neuroprotective-28/JJ||possibly-26/RB	advmod||neuroprotective-28/JJ||even-27/RB	conj_and||anti-inflammatory-23/JJ||neuroprotective-28/JJ	amod||capacity-29/NN||neuroprotective-28/JJ	prep_including||effects-18/NNS||capacity-29/NN	nsubj||implicates-31/VBZ||which-30/WDT	ccomp||capacity-29/NN||implicates-31/VBZ	det||role-34/NN||a-32/DT	amod||role-34/NN||possible-33/JJ	dobj||implicates-31/VBZ||role-34/NN	prep_of||role-34/NN||vitamind-36/NN	prep_in||implicates-31/VBZ||autoimmunediseases-38/NNS	prep_like||autoimmunediseases-38/NNS||multiplesclerosis-40/NNS	appos||multiplesclerosis-40/NNS||ms-42/NN	anti-inflammatory-23||multiplesclerosis-40||no_rel||apart from its principal role in bone metabolism and calcium homeostasis, vitamind has been attributed additional effects including an immunomodulatory, anti-inflammatory, and possibly even neuroprotective capacity which implicates a possible role of vitamind in autoimmunediseases like multiplesclerosis (ms).
nsubj||severity-20/NN||some-1/DT	nsubj||sensitivity-22/JJ||some-1/DT	nsubj||dysregulated-29/VBN||some-1/DT	det||areas-5/NNS||the-3/DT	amod||areas-5/NNS||key-4/JJ	prep_of||some-1/DT||areas-5/NNS	nn||research-8/NN||alcoholism-7/NN	prep_of||areas-5/NNS||research-8/NN	advmod||possible-17/JJ||where-9/WRB	nsubj||possible-17/JJ||consilience-10/NN	nn||studies-15/NNS||human-12/NN	conj_and||human-12/NN||animal-14/NN	nn||studies-15/NNS||animal-14/NN	prep_between||consilience-10/NN||studies-15/NNS	cop||possible-17/JJ||is-16/VBZ	rcmod||areas-5/NNS||possible-17/JJ	cop||severity-20/NN||are-18/VBP	amod||severity-20/NN||alcoholwithdrawal-19/JJ	root||ROOT-0/null||severity-20/NN	amod||severity-20/NN||sensitivity-22/JJ	conj_and||severity-20/NN||sensitivity-22/JJ	prep_to||sensitivity-22/JJ||rewards-24/NNS	dep||severity-20/NN||impulsivity-26/RB	conj_and||severity-20/NN||dysregulated-29/VBN	vmod||severity-20/NN||dysregulated-29/VBN	nn||consumption-31/NN||alcohol-30/NN	dobj||dysregulated-29/VBN||consumption-31/NN	alcoholism-7||alcohol-30||no||some of the key areas of alcoholism research where consilience between human and animal studies is possible are alcoholwithdrawal severity, sensitivity to rewards, impulsivity, and dysregulated alcohol consumption.
neg||difference-2/NN||no-1/DT	nsubj||emerged-7/VBD||difference-2/NN	nsubj||aids-13/VBZ||difference-2/NN	prep_in||difference-2/NN||history-4/NN	prep_of||history-4/NN||pap-smear-6/NN	root||ROOT-0/null||emerged-7/VBD	prep_by||emerged-7/VBD||mode-9/NN	prep_of||mode-9/NN||hiv-acquisition-11/NN	conj_or||emerged-7/VBD||aids-13/VBZ	dobj||aids-13/VBZ||status-14/NN	aids-13||hiv--1||no||no difference in history of pap-smear emerged by mode of hiv-acquisition or aids status.
det||tt-5/NN||the-1/DT	amod||tt-5/NN||kcnb1-2/JJ	amod||tt-5/NN||rs1051295-3/JJ	nn||tt-5/NN||genotype-4/NN	nsubjpass||associated-12/VBN||tt-5/NN	det||population-10/NN||the-7/DT	amod||population-10/NN||chinese-8/JJ	nn||population-10/NN||han-9/NN	prep_in||tt-5/NN||population-10/NN	auxpass||associated-12/VBN||is-11/VBZ	root||ROOT-0/null||associated-12/VBN	amod||sensitivity-16/NN||decreased-14/VBN	nn||sensitivity-16/NN||insulin-15/NN	prep_with||associated-12/VBN||sensitivity-16/NN	amod||tg-20/NN||increased-18/VBN	nn||tg-20/NN||plasma-19/NN	prep_with||associated-12/VBN||tg-20/NN	conj_and||sensitivity-16/NN||tg-20/NN	nn||ratio-23/NN||w/h-22/NN	prep_with||associated-12/VBN||ratio-23/NN	conj_and||sensitivity-16/NN||ratio-23/NN	nsubj||contribute-27/VBP||ratio-23/NN	advmod||contribute-27/VBP||together-26/RB	rcmod||ratio-23/NN||contribute-27/VBP	det||risk-31/NN||an-29/DT	amod||risk-31/NN||increased-30/VBN	prep_to||contribute-27/VBP||risk-31/NN	prep_for||risk-31/NN||t2d-33/CD	t2d-33||insulin-15||yes||the kcnb1 rs1051295 genotype tt in the chinese han population is associated with decreased insulin sensitivity and increased plasma tg and w/h ratio, which together contribute to an increased risk for t2d.
det||proportion-2/NN||the-1/DT	nsubj||increased-14/VBD||proportion-2/NN	prep_of||proportion-2/NN||spouses-4/NNS	advmod||reported-7/VBN||newly-6/RB	amod||cases-9/NNS||reported-7/VBN	amod||cases-9/NNS||hiv/aids-8/JJ	prep_of||spouses-4/NNS||cases-9/NNS	auxpass||tested-11/VBN||being-10/VBG	vmod||cases-9/NNS||tested-11/VBN	prep_for||tested-11/VBN||hiv-13/NN	root||ROOT-0/null||increased-14/VBD	number||63.4-18/CD||24.7-16/CD	dep||63.4-18/CD||to-17/TO	num||%-19/NN||63.4-18/CD	prep_from||increased-14/VBD||%-19/NN	appos||%-19/NN||p-21/NNP	number||0.001-23/CD||<-22/CD	num||p-21/NNP||0.001-23/CD	aids--1||hiv-13||no||the proportion of spouses of newly reported hiv/aids cases being tested for hiv increased from 24.7 to 63.4% ( p < 0.001).
nsubj||quantified-2/VBN||we-1/PRP	root||ROOT-0/null||quantified-2/VBN	det||hbz-4/NN||the-3/DT	dobj||quantified-2/VBN||hbz-4/NN	nn||levels-9/NNS||tax-6/NN	nn||levels-9/NNS||mrna-7/NN	nn||levels-9/NNS||expression-8/NN	dobj||quantified-2/VBN||levels-9/NNS	conj_and||hbz-4/NN||levels-9/NNS	amod||blood-12/NN||peripheral-11/JJ	prep_in||quantified-2/VBN||blood-12/NN	number||/-16/NN||56-14/CD	dep||/-16/NN||htlv-1-associatedmyelopathy-15/JJ	amod||patients-21/NNS||/-16/NN	nn||patients-21/NNS||tropicalspasticparaparesis-17/NN	appos||patients-21/NNS||ham/tsp-19/NN	prep_from||quantified-2/VBN||patients-21/NNS	number||atl-24/CD||10-23/CD	num||patients-25/NNS||atl-24/CD	prep_from||quantified-2/VBN||patients-25/NNS	conj_and||patients-21/NNS||patients-25/NNS	num||carriers-30/NNS||38-27/CD	amod||carriers-30/NNS||healthy-28/JJ	amod||carriers-30/NNS||asymptomatic-29/JJ	prep_from||quantified-2/VBN||carriers-30/NNS	conj_and||patients-21/NNS||carriers-30/NNS	appos||carriers-30/NNS||hcs-32/NN	num||controls-38/NNS||20-35/CD	amod||controls-38/NNS||normal-36/JJ	amod||controls-38/NNS||uninfected-37/JJ	prep_from||quantified-2/VBN||controls-38/NNS	conj_and||patients-21/NNS||controls-38/NNS	amod||lines-46/NNS||human-43/JJ	amod||lines-46/NNS||leukemic-44/JJ	amod||lines-46/NNS||t-cell-45/JJ	prep_from||quantified-2/VBN||lines-46/NNS	conj_and||patients-21/NNS||lines-46/NNS	amod||lines-50/NNS||htlv-1-infected-48/JJ	amod||lines-50/NNS||t-cell-49/JJ	conj_and||patients-21/NNS||lines-50/NNS	conj_and||lines-46/NNS||lines-50/NNS	det||data-54/NNS||the-53/DT	nsubjpass||correlated-56/VBN||data-54/NNS	auxpass||correlated-56/VBN||were-55/VBD	conj_and||quantified-2/VBN||correlated-56/VBN	amod||parameters-59/NNS||clinical-58/JJ	prep_with||correlated-56/VBN||parameters-59/NNS	ham--1||htlv-1--1||no||we quantified the hbz and tax mrna expression levels in peripheral blood from 56 htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp) patients, 10 atl patients, 38 healthy asymptomatic carriers (hcs) and 20 normal uninfected controls, as well as human leukemic t-cell lines and htlv-1-infected t-cell lines, and the data were correlated with clinical parameters.
poss||case-2/NN||our-1/PRP$	nsubj||report-7/NN||case-2/NN	cop||report-7/NN||is-3/VBZ	advmod||report-7/NN||also-4/RB	det||report-7/NN||a-5/DT	amod||report-7/NN||first-6/JJ	root||ROOT-0/null||report-7/NN	nn||complex-11/NN||mycobacteria-9/NN	nn||complex-11/NN||avium-10/NN	prep_of||report-7/NN||complex-11/NN	nn||gordonae-14/NN||mycobacteria-13/NN	prep_of||report-7/NN||gordonae-14/NN	conj_and||complex-11/NN||gordonae-14/NN	vmod||complex-11/NN||isolated-15/VBN	advmod||isolated-15/VBN||simultaneously-16/RB	amod||patient-19/NN||individual-18/JJ	prep_from||isolated-15/VBN||patient-19/NN	amod||mycobacterialdisease-22/NN||nontuberculous-21/JJ	prep_with||isolated-15/VBN||mycobacterialdisease-22/NN	mycobacterialdisease-22||mycobacteria-13||no||our case is also a first report of mycobacteria avium complex and mycobacteria gordonae isolated simultaneously from individual patient with nontuberculous mycobacterialdisease.
nsubjpass||prompted-35/VBN||reports-1/NNS	mark||abundant-17/JJ||that-2/IN	nsubj||abundant-17/JJ||bacteria-3/NNS	det||phylum-7/NN||the-5/DT	amod||phylum-7/NN||firmicutes-6/JJ	prep_within||bacteria-3/NNS||phylum-7/NN	advmod||phylum-7/NN||especially-9/RB	det||prausnitzii-13/NN||the-10/DT	nn||prausnitzii-13/NN||species-11/NN	nn||prausnitzii-13/NN||faecalibacterium-12/NN	dep||phylum-7/NN||prausnitzii-13/NN	cop||abundant-17/JJ||are-15/VBP	advmod||abundant-17/JJ||less-16/RBR	dep||reports-1/NNS||abundant-17/JJ	poss||patients-25/NNS||crohn-19/NN	nn||patients-25/NNS||disease-21/NN	nn||patients-25/NNS||-lrb--22/NN	nn||patients-25/NNS||cd-23/NN	nn||patients-25/NNS||-rrb--24/NN	prep_in||abundant-17/JJ||patients-25/NNS	prep_in||abundant-17/JJ||supernatants-27/NNS	conj_and||patients-25/NNS||supernatants-27/NNS	prep_from||abundant-17/JJ||cultures-29/NNS	det||bacterium-32/NN||this-31/DT	prep_of||cultures-29/NNS||bacterium-32/NN	auxpass||prompted-35/VBN||are-33/VBP	advmod||prompted-35/VBN||anti-inflammatory-34/RB	root||ROOT-0/null||prompted-35/VBN	det||investigation-37/NN||the-36/DT	dobj||prompted-35/VBN||investigation-37/NN	det||correlations-41/NNS||the-39/DT	amod||correlations-41/NNS||possible-40/JJ	prep_of||investigation-37/NN||correlations-41/NNS	det||abundance-44/NN||the-43/DT	prep_between||correlations-41/NNS||abundance-44/NN	nn||prausnitzii-47/NNS||f.-46/NN	prep_of||abundance-44/NN||prausnitzii-47/NNS	det||response-50/NN||the-49/DT	prep_of||abundance-44/NN||response-50/NN	conj_and||prausnitzii-47/NNS||response-50/NN	prep_to||prompted-35/VBN||treatment-52/NN	prep_in||prompted-35/VBN||patients-54/NNS	nn||diseases-57/NNS||gut-56/NN	prep_with||patients-54/NNS||diseases-57/NNS	amod||controls-60/NNS||healthy-59/JJ	prep_with||patients-54/NNS||controls-60/NNS	conj_and||diseases-57/NNS||controls-60/NNS	cd-23||crohn's disease--1||no_rel||reports that bacteria within the firmicutes phylum , especially the species faecalibacterium prausnitzii , are less abundant in crohn 's disease -lrb- cd -rrb- patients and supernatants from cultures of this bacterium are anti-inflammatory prompted the investigation of the possible correlations between the abundance of f. prausnitzii and the response to treatment in patients with gut diseases and healthy controls .
det||motifs-2/NNS||the-1/DT	nsubj||2-unit-4/JJ||motifs-2/NNS	cop||2-unit-4/JJ||are-3/VBP	root||ROOT-0/null||2-unit-4/JJ	ccomp||2-unit-4/JJ||rgd-5/VBP	amod||prg-8/NN||binding-6/VBG	nn||prg-8/NN||sequence-7/NN	dobj||rgd-5/VBP||prg-8/NN	appos||prg-8/NN||prgdsgyrgds-10/NNS	nn||pds-17/NN||laminin-13/NN	nn||pds-17/NN||cell-14/NN	nn||pds-17/NN||adhesion-15/NN	nn||pds-17/NN||motif-16/NN	dobj||rgd-5/VBP||pds-17/NN	conj_and||prg-8/NN||pds-17/NN	appos||pds-17/NN||pdsgr-19/NN	adhesion-15||prg-8||no_rel||the motifs are 2-unit rgd binding sequence prg (prgdsgyrgds) and laminin cell adhesion motif pds (pdsgr).
nsubj||problem-22/NN||tuberculosis-1/NNP	vmod||tuberculosis-1/NNP||caused-2/VBN	agent||caused-2/VBN||multidrug-resistant-4/NN	appos||multidrug-resistant-4/NN||mdr-6/NN	amod||strains-18/NNS||extensively-9/JJ	amod||strains-18/NNS||drug-resistant-10/JJ	appos||strains-18/NNS||xdr-12/NN	nn||strains-18/NNS||mycobacteriumtuberculosis-14/NN	appos||strains-18/NNS||mtb-16/NN	agent||caused-2/VBN||strains-18/NNS	conj_and||multidrug-resistant-4/NN||strains-18/NNS	cop||problem-22/NN||is-19/VBZ	det||problem-22/NN||a-20/DT	amod||problem-22/NN||growing-21/VBG	root||ROOT-0/null||problem-22/NN	amod||countries-25/NNS||many-24/JJ	prep_in||problem-22/NN||countries-25/NNS	tuberculosis-1||mtb-16||no||tuberculosis caused by multidrug-resistant (mdr) and extensively drug-resistant (xdr) mycobacteriumtuberculosis (mtb) strains is a growing problem in many countries.
det||end-3/NN||the-2/DT	prep_by||comparable-25/JJ||end-3/NN	det||day-8/NN||the-5/DT	amod||day-8/NN||first-6/JJ	nn||day-8/NN||postoperative-7/NN	prep_of||end-3/NN||day-8/NN	det||proportion-11/NN||the-10/DT	nsubj||comparable-25/JJ||proportion-11/NN	nn||responders-14/NNS||treatment-13/NN	prep_of||proportion-11/NN||responders-14/NNS	vmod||responders-14/NNS||based-15/VBN	nn||satisfaction-18/NN||treatment-17/NN	prep_on||based-15/VBN||satisfaction-18/NN	amod||variable-22/NN||primary-20/JJ	amod||variable-22/NN||efficacy-21/JJ	appos||satisfaction-18/NN||variable-22/NN	cop||comparable-25/JJ||was-24/VBD	root||ROOT-0/null||comparable-25/JJ	det||groups-28/NNS||the-27/DT	prep_between||comparable-25/JJ||groups-28/NNS	num||%-31/NN||78.1-30/CD	dep||groups-28/NNS||%-31/NN	dep||%-31/NN||combination-32/NN	dep||%-35/NN||71.9-34/CD	advmod||%-31/NN||%-35/NN	dep||%-31/NN||tramadol-36/NN	dep||tramadol-36/NN||p-38/NN	dep||0.24-40/CD||=-39/SYM	rcmod||p-38/NN||0.24-40/CD	amod||intensity-45/NN||mean-43/JJ	nn||intensity-45/NN||pain-44/NN	nsubjpass||reduced-66/VBN||intensity-45/NN	dep||intensity-45/NN||rated-47/VBN	det||scale-51/NN||a-49/DT	amod||scale-51/NN||numerical-50/JJ	prep_on||rated-47/VBN||scale-51/NN	prep_from||scale-51/NN||0-53/CD	dep||pain-56/NN||=-54/SYM	neg||pain-56/NN||no-55/DT	rcmod||0-53/CD||pain-56/NN	number||=-59/NN||10-58/CD	amod||pain-62/NN||=-59/NN	dep||imaginable-61/JJ||worst-60/JJS	amod||pain-62/NN||imaginable-61/JJ	prep_to||rated-47/VBN||pain-62/NN	aux||reduced-66/VBN||had-64/VBD	auxpass||reduced-66/VBN||been-65/VBN	conj_and||comparable-25/JJ||reduced-66/VBN	number||â-69/CD||1.7-68/CD	num||2.0-71/CD||â-69/CD	number||2.0-71/CD||±-70/CD	prep_to||reduced-66/VBN||2.0-71/CD	det||groups-74/NNS||both-73/DT	prep_for||reduced-66/VBN||groups-74/NNS	pain-62||tramadol-36||yes||by the end of the first postoperative day, the proportion of treatment responders based on treatment satisfaction (primary efficacy variable) was comparable between the groups (78.1% combination, 71.9% tramadol; p = 0.24) and mean pain intensity (rated on a numerical scale from 0 = no pain to 10 = worst imaginable pain) had been reduced to 1.7 â± 2.0 for both groups.
nsubj||posed-5/VBN||hiv-1/NN	conj_and||hiv-1/NN||aids-3/NNS	nsubj||posed-5/VBN||aids-3/NNS	aux||posed-5/VBN||have-4/VBP	root||ROOT-0/null||posed-5/VBN	amod||problems-14/NNS||various-6/JJ	amod||problems-14/NNS||medical-7/JJ	conj_and||medical-7/JJ||nutritional-9/JJ	amod||problems-14/NNS||nutritional-9/JJ	conj_and||medical-7/JJ||social-11/JJ	amod||problems-14/NNS||social-11/JJ	conj_and||medical-7/JJ||economic-13/JJ	amod||problems-14/NNS||economic-13/JJ	dobj||posed-5/VBN||problems-14/NNS	amod||households-17/NNS||female-headed-16/JJ	appos||problems-14/NNS||households-17/NNS	auxpass||affected-21/VBN||being-18/VBG	det||most-20/JJS||the-19/DT	dobj||affected-21/VBN||most-20/JJS	vmod||households-17/NNS||affected-21/VBN	aids-3||hiv-1||no||hiv and aids have posed various medical, nutritional, social and economic problems, female-headed households being the most affected.
nsubj||respiratorydisease-8/NN||tuberculosis-1/NNP	cop||respiratorydisease-8/NN||is-2/VBZ	det||respiratorydisease-8/NN||a-3/DT	advmod||communicable-5/JJ||highly-4/RB	amod||respiratorydisease-8/NN||communicable-5/JJ	conj_and||communicable-5/JJ||chronic-7/JJ	amod||respiratorydisease-8/NN||chronic-7/JJ	root||ROOT-0/null||respiratorydisease-8/NN	vmod||respiratorydisease-8/NN||caused-9/VBN	amod||mycobacteriumtuberculosis-13/NNS||pathogenic-11/JJ	nn||mycobacteriumtuberculosis-13/NNS||bacterium-12/NN	agent||caused-9/VBN||mycobacteriumtuberculosis-13/NNS	tuberculosis-1||mycobacteriumtuberculosis-13||no||tuberculosis is a highly communicable and chronic respiratorydisease caused by pathogenic bacterium mycobacteriumtuberculosis .
det||evidence-3/NN||the-1/DT	amod||evidence-3/NN||first-2/JJ	nsubj||observation-16/NN||evidence-3/NN	det||link-7/NN||a-5/DT	amod||link-7/NN||genetic-6/JJ	prep_of||evidence-3/NN||link-7/NN	nn||interferons-11/NNS||type-9/FW	nn||interferons-11/NNS||i-10/FW	prep_between||link-7/NN||interferons-11/NNS	prep_between||link-7/NN||autoimmunediseases-13/NNS	conj_and||interferons-11/NNS||autoimmunediseases-13/NNS	cop||observation-16/NN||was-14/VBD	det||observation-16/NN||the-15/DT	root||ROOT-0/null||observation-16/NN	nsubj||elevated-18/VBD||observation-16/NN	rcmod||observation-16/NN||elevated-18/VBD	amod||activity-21/NN||ifnî-19/JJ	amod||activity-21/NN||±-20/JJ	nsubjpass||detected-24/VBN||activity-21/NN	auxpass||detected-24/VBN||is-22/VBZ	advmod||detected-24/VBN||frequently-23/RB	ccomp||elevated-18/VBD||detected-24/VBN	det||sera-27/NN||the-26/DT	prep_in||detected-24/VBN||sera-27/NN	prep_of||sera-27/NN||patients-29/NNS	amod||lupuserythematosus-32/NNS||systemic-31/JJ	prep_with||patients-29/NNS||lupuserythematosus-32/NNS	mark||shows-38/VBZ||that-35/IN	det||trait-37/NN||this-36/DT	nsubj||shows-38/VBZ||trait-37/NN	ccomp||elevated-18/VBD||shows-38/VBZ	conj_and||detected-24/VBN||shows-38/VBZ	amod||heritability-40/NN||high-39/JJ	dobj||shows-38/VBZ||heritability-40/NN	nn||aggregation-43/NN||familial-42/NN	dobj||shows-38/VBZ||aggregation-43/NN	conj_and||heritability-40/NN||aggregation-43/NN	poss||relatives-48/NNS||their-45/PRP$	amod||relatives-48/NNS||first-degree-46/JJ	amod||relatives-48/NNS||healthy-47/JJ	prep_in||heritability-40/NN||relatives-48/NNS	autoimmunediseases-13||interferons-11||no||the first evidence of a genetic link between type i interferons and autoimmunediseases was the observation that elevated ifnî± activity is frequently detected in the sera of patients with systemic lupuserythematosus, and that this trait shows high heritability and familial aggregation in their first-degree healthy relatives.
nsubj||showed-5/VBD||mice-1/NNS	vmod||mice-1/NNS||bearing-2/VBG	amod||tumors-4/NNS||subcutaneous-3/JJ	dobj||bearing-2/VBG||tumors-4/NNS	root||ROOT-0/null||showed-5/VBD	det||growth-9/NN||a-6/DT	amod||growth-9/NN||reduced-7/JJ	nn||growth-9/NN||tumor-8/NN	dobj||showed-5/VBD||growth-9/NN	prep_upon||showed-5/VBD||treatment-11/NN	prep_with||showed-5/VBD||dox-13/NN	nsubj||induced-17/VBN||dox-13/NN	nsubj||revealed-22/VBD||dox-13/NN	advmod||induced-17/VBN||effectively-16/RB	rcmod||dox-13/NN||induced-17/VBN	dobj||induced-17/VBN||shrna-18/NN	prep_against||induced-17/VBN||psca-20/NN	mark||revealed-22/VBD||as-21/IN	advcl||induced-17/VBN||revealed-22/VBD	nn||expression-25/NN||gfp-24/NN	prep_by||revealed-22/VBD||expression-25/NN	tumor-8||dox-13||no_rel||mice bearing subcutaneous tumors showed a reduced tumor growth upon treatment with dox, which effectively induced shrna against psca as revealed by gfp expression.
det||case-2/NN||this-1/DT	nsubj||documents-3/VBZ||case-2/NN	root||ROOT-0/null||documents-3/VBZ	det||woman-6/NN||a-4/DT	amod||woman-6/NN||62-year-old-5/JJ	dobj||documents-3/VBZ||woman-6/NN	nsubj||presented-8/VBN||woman-6/NN	rcmod||woman-6/NN||presented-8/VBN	amod||vasculitis-15/NNS||hydralazine-induced-10/JJ	amod||vasculitis-15/NNS||anti-neutrophil-11/JJ	amod||vasculitis-15/NNS||cytoplasmic-12/JJ	amod||vasculitis-15/NNS||antibody-positive-13/JJ	amod||vasculitis-15/NNS||renal-14/JJ	prep_with||presented-8/VBN||vasculitis-15/NNS	det||rash-20/NN||a-17/DT	amod||cutaneous-19/JJ||puzzling-18/JJ	amod||rash-20/NN||cutaneous-19/JJ	prep_with||vasculitis-15/NNS||rash-20/NN	vasculitis-15||hydralazine--1||no_rel||this case documents a 62-year-old woman who presented with hydralazine-induced anti-neutrophil cytoplasmic antibody-positive renal vasculitis with a puzzling cutaneous rash.
amod||samples-4/NNS||overall-2/JJ	amod||samples-4/NNS||positive-3/JJ	prep_from||positive-9/JJ||samples-4/NNS	nsubj||positive-9/JJ||2939-6/CD	cop||positive-9/JJ||were-7/VBD	advmod||positive-9/JJ||hbv-8/RB	root||ROOT-0/null||positive-9/JJ	advmod||positive-9/JJ||192-11/RB	advmod||positive-13/JJ||hcv-12/RB	dep||positive-9/JJ||positive-13/JJ	mark||positive-18/JJ||while-14/IN	num||samples-16/NNS||14-15/CD	nsubj||positive-18/JJ||samples-16/NNS	cop||positive-18/JJ||were-17/VBD	advcl||positive-9/JJ||positive-18/JJ	det||viruses-21/NNS||both-20/DT	prep_for||positive-18/JJ||viruses-21/NNS	hbv-8||viruses-21||no||from overall positive samples, 2939 were hbv positive, 192 hcv positive while 14 samples were positive for both viruses.
det||objectives-2/NNS||the-1/DT	nsubj||were-6/VBD||objectives-2/NNS	nsubj||evaluate-8/VB||objectives-2/NNS	det||study-5/NN||this-4/DT	prep_of||objectives-2/NNS||study-5/NN	root||ROOT-0/null||were-6/VBD	aux||evaluate-8/VB||to-7/TO	xcomp||were-6/VBD||evaluate-8/VB	mark||correlated-12/VBD||whether-9/IN	amod||differences-11/NNS||morphologic-10/JJ	nsubj||correlated-12/VBD||differences-11/NNS	ccomp||evaluate-8/VB||correlated-12/VBD	amod||characteristics-17/NNS||urodynamic-14/JJ	conj_and||urodynamic-14/JJ||clinical-16/JJ	amod||characteristics-17/NNS||clinical-16/JJ	prep_with||correlated-12/VBD||characteristics-17/NNS	prep_in||correlated-12/VBD||patients-19/NNS	amod||prostatic-22/JJ||benign-21/JJ	amod||hyperplasia-23/NN||prostatic-22/JJ	prep_with||patients-19/NNS||hyperplasia-23/NN	appos||hyperplasia-23/NN||bph-25/NN	amod||protrusion-30/NN||intravesical-28/JJ	amod||protrusion-30/NN||prostatic-29/JJ	prep_with||correlated-12/VBD||protrusion-30/NN	appos||protrusion-30/NN||ipp-32/NN	nn||adenoma-38/NN||trilobar-35/NN	conj_or||trilobar-35/NN||bilobar-37/NN	nn||adenoma-38/NN||bilobar-37/NN	prep_of||protrusion-30/NN||adenoma-38/NN	ipp-32||adenoma-38||no_rel||the objectives of this study were to evaluate whether morphologic differences correlated with urodynamic and clinical characteristics in patients with benign prostatic hyperplasia (bph) with intravesical prostatic protrusion (ipp) of trilobar or bilobar adenoma.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||outcomes-5/NNS||the-4/DT	prep_on||report-2/VBP||outcomes-5/NNS	num||patients-11/NNS||21-7/CD	amod||patients-11/NNS||consecutive-8/JJ	amod||patients-11/NNS||gastric-9/JJ	nn||patients-11/NNS||cancer-10/NN	prep_of||outcomes-5/NNS||patients-11/NNS	vmod||patients-11/NNS||treated-12/VBN	prep_off||treated-12/VBN||protocol-14/NN	amod||carboplatin-17/NNS||adjuvant-16/JJ	prep_with||treated-12/VBN||carboplatin-17/NNS	dep||carboplatin-17/NNS||area-19/NN	det||ã-25/NN||the-21/DT	nn||ã-25/NN||curve-22/NN	num||ã-25/NN||5-23/CD	nn||ã-25/NN||mg/ml-24/NN	prep_under||area-19/NN||ã-25/NN	dep||ã-25/NN||min-27/NN	prep_with||treated-12/VBN||paclitaxel-30/NN	conj_and||carboplatin-17/NNS||paclitaxel-30/NN	quantmod||$-33/$||175â-32/RB	num||mg/m2-36/NNS||$-33/$	num||$-33/$||200-35/CD	dep||paclitaxel-30/NN||mg/m2-36/NNS	det||weeks-40/NNS||every-38/DT	num||weeks-40/NNS||3-39/CD	tmod||treated-12/VBN||weeks-40/NNS	prepc_followed_by||treated-12/VBN||by-43/IN	amod||analogs-46/NNS||concurrent-44/JJ	nn||analogs-46/NNS||pyrimidine-45/NN	pobj||treated-12/VBN||analogs-46/NNS	dep||â-51/FW||either-48/DT	nn||â-51/FW||capecitabine-49/FW	nn||â-51/FW||1,600-50/FW	dep||analogs-46/NNS||â-51/FW	num||mg/m2/day-55/NNS||$-52/$	num||$-52/$||2,000-54/CD	dep||â-51/FW||mg/m2/day-55/NNS	num||patients-58/NNS||17-57/CD	prep_in||mg/m2/day-55/NNS||patients-58/NNS	number||200-62/CD||5fu-61/CD	num||mg/m2/day-63/NNS||200-62/CD	dep||â-51/FW||mg/m2/day-63/NNS	conj_or||mg/m2/day-55/NNS||mg/m2/day-63/NNS	num||patients-66/NNS||4-65/CD	prep_in||mg/m2/day-63/NNS||patients-66/NNS	pobj||treated-12/VBN||radiation-69/NN	conj_and||analogs-46/NNS||radiation-69/NN	dep||analogs-46/NNS||45â-71/NNS	dep||45â-71/NNS||$-72/$	num||$-72/$||50.4-74/CD	dep||$-72/$||gy-75/NN	cancer-10||5fu-61||no_rel||we report on the outcomes of 21 consecutive gastric cancer patients treated off protocol with adjuvant carboplatin (area under the curve 5 mg/ml ã min) and paclitaxel (175â200 mg/m2) every 3 weeks, followed by concurrent pyrimidine analogs (either capecitabine 1,600â2,000 mg/m2/day in 17 patients, or 5fu 200 mg/m2/day in 4 patients) and radiation (45â50.4 gy).
det||nervosa-14/NN||the-1/DT	amod||nervosa-14/NN||meta-analysis-2/JJ	amod||nervosa-14/NN||available-3/JJ	det||use-6/NN||the-5/DT	prep_on||available-3/JJ||use-6/NN	prep_of||use-6/NN||fluoxetine-8/NN	det||treatment-11/NN||the-10/DT	prep_in||fluoxetine-8/NN||treatment-11/NN	prep_of||treatment-11/NN||bulimia-13/NN	nsubj||shows-15/VBZ||nervosa-14/NN	root||ROOT-0/null||shows-15/VBZ	mark||effective-21/JJ||that-16/IN	det||drug-18/NN||the-17/DT	nsubj||effective-21/JJ||drug-18/NN	cop||effective-21/JJ||is-19/VBZ	advmod||effective-21/JJ||as-20/RB	ccomp||shows-15/VBZ||effective-21/JJ	amod||agents-24/NNS||other-23/JJ	prep_as||effective-21/JJ||agents-24/NNS	amod||patients-27/NNS||fewer-26/JJR	prep_with||agents-24/NNS||patients-27/NNS	xcomp||effective-21/JJ||dropping-28/VBG	prep_out_of||dropping-28/VBG||treatment-31/NN	bulimia-13||fluoxetine-8||yes||the meta-analysis available on the use of fluoxetine in the treatment of bulimia nervosa shows that the drug is as effective as other agents with fewer patients dropping out of treatment.
det||study-5/NN||a-2/DT	amod||study-5/NN||one-year-3/JJ	nn||study-5/NN||follow-up-4/NN	prep_in||tb-70/VBP||study-5/NN	nsubj||tb-70/VBP||11-7/CD	num||%-10/NN||19.3-9/CD	appos||11-7/CD||%-10/NN	num||test-16/NN||57-13/CD	nn||test-16/NN||tuberculin-14/NN	nn||test-16/NN||skin-15/NN	prep_of||11-7/CD||test-16/NN	appos||test-16/NN||tst-18/NN	amod||inmates-23/NNS||hiv-negative-22/JJ	conj_and||11-7/CD||inmates-23/NNS	nsubj||tb-70/VBP||inmates-23/NNS	vmod||inmates-23/NNS||became-24/VBD	nsubj||hiv-positive-32/JJ||tst-positive-25/NN	conj_and||tst-positive-25/NN||one-27/NN	nsubj||hiv-positive-32/JJ||one-27/NN	num||%-30/NN||1.8-29/CD	appos||tst-positive-25/NN||%-30/NN	xcomp||became-24/VBD||hiv-positive-32/JJ	conj_and||11-7/CD||eight-34/CD	conj_and||inmates-23/NNS||eight-34/CD	num||%-37/NN||13.8-36/CD	appos||eight-34/CD||%-37/NN	det||inmates-45/NNS||the-40/DT	num||inmates-45/NNS||58-41/CD	amod||inmates-45/NNS||tst-positive-42/JJ	conj_but||tst-positive-42/JJ||hiv-negative-44/JJ	amod||inmates-45/NNS||hiv-negative-44/JJ	prep_of||eight-34/CD||inmates-45/NNS	vmod||inmates-45/NNS||developed-46/VBN	dobj||developed-46/VBN||tb-47/NN	conj_and||11-7/CD||one-50/CD	conj_and||inmates-23/NNS||one-50/CD	num||%-53/NN||1.7-52/CD	appos||one-50/CD||%-53/NN	rcmod||one-50/CD||became-55/VBD	amod||six-57/CD||hiv-infected-56/JJ	xcomp||became-55/VBD||six-57/CD	num||%-60/NN||24.0-59/CD	appos||six-57/CD||%-60/NN	num||tst-64/NN||25-63/CD	prep_of||six-57/CD||tst-64/NN	amod||inmates-68/NNS||hiv-positive-67/JJ	conj_and||inmates-23/NNS||inmates-68/NNS	conj_and||one-50/CD||inmates-68/NNS	vmod||inmates-68/NNS||developed-69/VBN	root||ROOT-0/null||tb-70/VBP	mark||became-83/VBD||while-71/IN	nsubj||became-83/VBD||five-72/CD	num||%-75/NN||33.3-74/CD	appos||five-72/CD||%-75/NN	num||inmates-82/NNS||15-78/CD	amod||inmates-82/NNS||tst-negative-79/JJ	conj_but||tst-negative-79/JJ||hiv-positive-81/JJ	amod||inmates-82/NNS||hiv-positive-81/JJ	prep_of||five-72/CD||inmates-82/NNS	advcl||tb-70/VBP||became-83/VBD	acomp||became-83/VBD||tst-positive-84/JJ	nsubj||progressed-92/VBD||one-87/CD	num||%-90/NN||6.7-89/CD	appos||one-87/CD||%-90/NN	conj_and||tb-70/VBP||progressed-92/VBD	prep_to||progressed-92/VBD||aids-94/NNS	aids-94||hiv--1||no||in a one-year follow-up study, 11 (19.3%) of 57 tuberculin skin test (tst)- and hiv-negative inmates became tst-positive and one (1.8%) hiv-positive, eight (13.8%) of the 58 tst-positive but hiv-negative inmates developed tb, and one (1.7%) became hiv-infected six (24.0%) of 25 tst- and hiv-positive inmates developed tb while five (33.3%) of 15 tst-negative but hiv-positive inmates became tst-positive, and one (6.7%) progressed to aids.
nsubj||cause-10/VB||feeding-1/NN	amod||oil-7/NN||fresh-3/JJ	conj_and||fresh-3/JJ||once-heated-5/JJ	amod||oil-7/NN||once-heated-5/JJ	nn||oil-7/NN||palm-6/NN	prep_with||feeding-1/NN||oil-7/NN	aux||cause-10/VB||does-8/VBZ	neg||cause-10/VB||not-9/RB	root||ROOT-0/null||cause-10/VB	det||effect-13/NN||any-11/DT	amod||effect-13/NN||deleterious-12/JJ	dobj||cause-10/VB||effect-13/NN	advmod||harmful-20/JJ||repeatedly-15/RB	amod||oil-17/NN||heated-16/VBN	nsubj||harmful-20/JJ||oil-17/NN	aux||harmful-20/JJ||may-18/MD	cop||harmful-20/JJ||be-19/VB	conj_but||cause-10/VB||harmful-20/JJ	mark||causes-23/VBZ||because-21/IN	nsubj||causes-23/VBZ||it-22/PRP	advcl||harmful-20/JJ||causes-23/VBZ	amod||damage-25/NN||oxidative-24/JJ	dobj||causes-23/VBZ||damage-25/NN	advmod||predisposing-27/VBG||thereby-26/RB	vmod||damage-25/NN||predisposing-27/VBG	prep_to||predisposing-27/VBG||atherosclerosis-29/NNS	atherosclerosis-29||oil-17||no_rel||feeding with fresh and once-heated palm oil does not cause any deleterious effect but repeatedly heated oil may be harmful because it causes oxidative damage thereby predisposing to atherosclerosis.
number||hundred-2/CD||two-1/CD	num||s.aureus-4/NNS||hundred-2/CD	amod||s.aureus-4/NNS||thirty-nine-3/JJ	nsubj||isolates-5/VBZ||s.aureus-4/NNS	root||ROOT-0/null||isolates-5/VBZ	number||121-7/CD||-lrb--6/CD	num||s.aureus-9/NNS||121-7/CD	amod||s.aureus-9/NNS||methicillin-resistant-8/JJ	dobj||isolates-5/VBZ||s.aureus-9/NNS	nn||-rsb--12/NNP||-lsb--10/NNP	nn||-rsb--12/NNP||mrsa-11/NNP	dep||s.aureus-9/NNS||-rsb--12/NNP	num||s.aureus-16/NNS||118-14/CD	amod||s.aureus-16/NNS||methicillin-susceptible-15/JJ	dobj||isolates-5/VBZ||s.aureus-16/NNS	conj_and||s.aureus-9/NNS||s.aureus-16/NNS	nn||-rrb--20/NNP||-lsb--17/NNP	nn||-rrb--20/NNP||mssa-18/NNP	nn||-rrb--20/NNP||-rsb--19/NNP	nsubjpass||screened-22/VBN||-rrb--20/NNP	auxpass||screened-22/VBN||were-21/VBD	rcmod||s.aureus-16/NNS||screened-22/VBN	nn||acgh-29/NN||array-24/NN	amod||acgh-29/NN||comparative-25/JJ	amod||acgh-29/NN||genomic-26/JJ	nn||acgh-29/NN||hybridization-27/NN	nn||acgh-29/NN||-lrb--28/NN	agent||screened-22/VBN||acgh-29/NN	vmod||acgh-29/NN||-rrb--30/VBN	aux||identify-32/VB||to-31/TO	xcomp||-rrb--30/VBN||identify-32/VB	dobj||identify-32/VB||genes-33/NNS	vmod||genes-33/NNS||implicated-34/VBN	amod||infections-37/NNS||complicated-36/JJ	prep_in||implicated-34/VBN||infections-37/NNS	mrsa-11||s.aureus-16||no||two hundred thirty-nine s.aureus isolates -lrb- 121 methicillin-resistant s.aureus -lsb- mrsa -rsb- and 118 methicillin-susceptible s.aureus -lsb- mssa -rsb- -rrb- were screened by array comparative genomic hybridization -lrb- acgh -rrb- to identify genes implicated in complicated infections .
csubj||complicated-11/JJ||becoming-1/VBG	acomp||becoming-1/VBG||pregnant-2/JJ	det||woman-6/NN||an-4/DT	amod||woman-6/NN||hiv-infected-5/JJ	prep_as||becoming-1/VBG||woman-6/NN	cop||complicated-11/JJ||was-7/VBD	dep||complicated-11/JJ||however-9/RB	root||ROOT-0/null||complicated-11/JJ	det||dilemmas-14/NNS||the-13/DT	prep_by||complicated-11/JJ||dilemmas-14/NNS	vmod||dilemmas-14/NNS||related-15/VBN	prepc_to||related-15/VBN||disclosing-17/VBG	dobj||disclosing-17/VBG||hivinfection-18/NN	prepc_to||related-15/VBN||discussing-20/VBG	conj_and||disclosing-17/VBG||discussing-20/VBG	nn||intentions-22/NNS||pregnancy-21/NN	dobj||discussing-20/VBG||intentions-22/NNS	poss||partners-25/NNS||their-24/PRP$	prep_with||discussing-20/VBG||partners-25/NNS	hivinfection-18||hiv--1||no||becoming pregnant as an hiv-infected woman was, however, complicated by the dilemmas related to disclosing hivinfection and discussing pregnancy intentions with their partners.
aux||compare-2/VB||to-1/TO	root||ROOT-0/null||compare-2/VB	det||effects-4/NNS||the-3/DT	dobj||compare-2/VB||effects-4/NNS	prepc_of||effects-4/NNS||combining-6/VBG	ccomp||combining-6/VBG||liraglutide-7/VB	dep||liraglutide-7/VB||0.6-9/CD	dep||liraglutide-7/VB||1.2-11/CD	conj_or||0.6-9/CD||1.2-11/CD	num||mg/day-14/NN||1.8-13/CD	dep||liraglutide-7/VB||mg/day-14/NN	conj_or||0.6-9/CD||mg/day-14/NN	ccomp||combining-6/VBG||rosiglitazone-17/VB	conj_or||liraglutide-7/VB||rosiglitazone-17/VB	num||mg/day-19/NN||4-18/CD	dobj||liraglutide-7/VB||mg/day-19/NN	det||228-26/FW||all-21/DT	nn||228-26/FW||n-22/FW	nn||228-26/FW||â-23/FW	nn||228-26/FW||-24/FW	nn||228-26/FW||¥-25/FW	dep||effects-4/NNS||228-26/FW	dobj||compare-2/VB||placebo-29/NN	conj_or||effects-4/NNS||placebo-29/NN	quantmod||114-33/CD||n-31/RB	number||114-33/CD||=-32/CD	dep||placebo-29/NN||114-33/CD	prep_with||placebo-29/NN||glimepiride-36/NN	dep||placebo-29/NN||2â-38/VBG	dobj||2â-38/VBG||$-39/$	num||$-39/$||4-41/CD	advmod||2â-38/VBG||mg/day-42/RB	amod||control-46/NN||glycaemic-45/JJ	prep_on||compare-2/VB||control-46/NN	nn||weight-49/NN||body-48/NN	prep_on||compare-2/VB||weight-49/NN	conj_and||control-46/NN||weight-49/NN	prep_on||compare-2/VB||safety-51/NN	conj_and||control-46/NN||safety-51/NN	prep_in||compare-2/VB||type2diabetes-53/CD	type2diabetes-53||glimepiride-36||yes||to compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n â¥ 228) or placebo ( n = 114) with glimepiride (2â4 mg/day) on glycaemic control, body weight and safety in type2diabetes.
amod||concentrations-2/NNS||low-1/JJ	nsubjpass||enhanced-25/VBN||concentrations-2/NNS	dep||concentrations-2/NNS||1â-4/NNS	number||5-6/CD||1/4-5/CD	dep||1â-4/NNS||5-6/CD	dep||5-6/CD||mm-7/NN	prep_of||concentrations-2/NNS||formaldehyde-10/NN	vmod||formaldehyde-10/NN||induced-11/VBN	nn||responses-13/NNS||pain-12/NN	dobj||induced-11/VBN||responses-13/NNS	prep_in||induced-11/VBN||rat-15/NN	prep_via||rat-15/NN||trpv1-17/NNS	det||response-21/NN||this-19/DT	nn||response-21/NN||pain-20/NN	prep_via||rat-15/NN||response-21/NN	conj_and||trpv1-17/NNS||response-21/NN	aux||enhanced-25/VBN||could-22/MD	auxpass||enhanced-25/VBN||be-23/VB	advmod||enhanced-25/VBN||significantly-24/RB	root||ROOT-0/null||enhanced-25/VBN	agent||enhanced-25/VBN||ph-27/NN	num||ph-27/NN||6.0-28/CD	dep||ph-27/NN||mimicking-30/VBG	det||microenvironment-34/NN||the-31/DT	amod||microenvironment-34/NN||acidic-32/JJ	nn||microenvironment-34/NN||tumor-33/NN	dobj||mimicking-30/VBG||microenvironment-34/NN	formaldehyde-10||tumor-33||no_rel||low concentrations (1â¼5 mm) of formaldehyde induced pain responses in rat via trpv1 and this pain response could be significantly enhanced by ph 6.0 (mimicking the acidic tumor microenvironment).
det||combination-2/NN||a-1/DT	nsubj||treatment-14/NN||combination-2/NN	prep_of||combination-2/NN||levodopa-4/NN	appos||levodopa-4/NN||l-dopa-6/NNP	prep_of||combination-2/NN||carbidopa-9/NN	conj_and||levodopa-4/NN||carbidopa-9/NN	cop||treatment-14/NN||is-10/VBZ	det||treatment-14/NN||the-11/DT	advmod||commonly-used-13/JJ||most-12/RBS	amod||treatment-14/NN||commonly-used-13/JJ	root||ROOT-0/null||treatment-14/NN	nn||management-17/NN||symptom-16/NN	prep_for||treatment-14/NN||management-17/NN	nn||sdisease-21/NN||parkinson-19/NN	prep_in||management-17/NN||sdisease-21/NN	parkinson'sdisease--1||l-dopa-6||yes||a combination of levodopa (l-dopa) and carbidopa is the most commonly-used treatment for symptom management in parkinson'sdisease.
nsubj||used-3/VBD||we-1/PRP	advmod||used-3/VBD||then-2/RB	root||ROOT-0/null||used-3/VBD	det||technique-5/NN||this-4/DT	dobj||used-3/VBD||technique-5/NN	aux||measure-7/VB||to-6/TO	dep||used-3/VBD||measure-7/VB	dobj||measure-7/VB||concentrations-8/NNS	det||viruses-11/NNS||these-10/DT	prep_of||concentrations-8/NNS||viruses-11/NNS	nn||days-14/NNS||ads-13/NNS	prep_on||measure-7/VB||days-14/NNS	nn||days-17/NNS||background-16/NN	prep_on||measure-7/VB||days-17/NNS	conj_and||days-14/NNS||days-17/NNS	aux||assess-21/VB||to-20/TO	dep||used-3/VBD||assess-21/VB	conj_and||measure-7/VB||assess-21/VB	det||relationships-23/NNS||the-22/DT	dobj||assess-21/VB||relationships-23/NNS	amod||influenza-26/NN||ambient-25/JJ	prep_between||relationships-23/NNS||influenza-26/NN	prep_between||relationships-23/NNS||avianinfluenzaviruses-28/NNS	conj_and||influenza-26/NN||avianinfluenzaviruses-28/NNS	conj_and||used-3/VBD||air-31/NN	dobj||air-31/NN||pollutants-32/NNS	influenza-26||influenzaviruses--1||no||we then used this technique to measure concentrations of these viruses on ads days and background days, and to assess the relationships between ambient influenza and avianinfluenzaviruses, and air pollutants.
amod||viruses-3/NNS||finnish-1/JJ	nn||viruses-3/NNS||epidemic-2/NN	root||ROOT-0/null||viruses-3/NNS	conj_and||viruses-3/NNS||a/california/07-5/NNS	punct||viruses-3/NNS||/-6/:	num||strain-10/NN||2009-7/CD	nn||strain-10/NN||vaccine-8/NN	nn||strain-10/NN||virus-9/NN	nsubj||varied-11/VBN||strain-10/NN	dep||viruses-3/NNS||varied-11/VBN	prepc_from||varied-11/VBN||2â-13/VBG	dobj||2â-13/VBG||$-14/$	npadvmod||respective-33/JJ||8-16/CD	conj_and||8-16/CD||0â-18/NNS	npadvmod||respective-33/JJ||0â-18/NNS	dep||8-16/CD||$-19/$	num||aminoacids-22/NN||5-21/CD	npadvmod||na-26/RB||aminoacids-22/NN	dep||and-25/NNP||in-23/RB	advmod||and-25/NNP||ha-24/RB	dep||aminoacids-22/NN||and-25/NNP	dep||molecules-27/CD||na-26/RB	num||$-19/$||molecules-27/CD	dep||8-16/CD||respectively-29/RB	quantmod||a-32/DT||giving-31/RB	num||8-16/CD||a-32/DT	amod||maximal-34/NNS||respective-33/JJ	npadvmod||evolution-35/RB||maximal-34/NNS	dep||speed-36/CD||evolution-35/RB	num||$-14/$||speed-36/CD	num||%-39/NN||1.4-38/CD	prep_of||$-14/$||%-39/NN	num||%-42/NN||1.1-41/CD	prep_of||$-14/$||%-42/NN	conj_and||%-39/NN||%-42/NN	virus-9||viruses-3||no||finnish epidemic viruses and a/california/07/2009 vaccine virus strain varied from 2â8 and 0â5 aminoacids in ha and na molecules, respectively, giving a respective maximal evolution speed of 1.4% and 1.1%.
nsubj||emphasized-2/VBD||points-1/NNS	root||ROOT-0/null||emphasized-2/VBD	cop||need-8/NN||are-3/VBP	dep||need-8/NN||1-5/LS	det||need-8/NN||the-7/DT	ccomp||emphasized-2/VBD||need-8/NN	prepc_for||need-8/NN||considering-10/VBG	det||viruses-15/JJ||these-11/DT	cc||viruses-15/JJ||and-13/CC	amod||viruses-15/JJ||other-14/JJ	dobj||considering-10/VBG||viruses-15/JJ	det||perspective-20/NN||an-18/DT	amod||perspective-20/NN||evolutionary-19/JJ	prep_from||considering-10/VBG||perspective-20/NN	dep||necessity-26/NN||2-23/LS	det||necessity-26/NN||the-25/DT	ccomp||emphasized-2/VBD||necessity-26/NN	conj_and||need-8/NN||necessity-26/NN	prepc_of||necessity-26/NN||disseminating-28/VBG	amod||methods-30/NNS||current-29/JJ	dobj||disseminating-28/VBG||methods-30/NNS	nn||identification-33/NN||virus-32/NN	prep_for||disseminating-28/VBG||identification-33/NN	dep||progress-40/NN||3-36/LS	det||progress-40/NN||the-38/DT	amod||progress-40/NN||great-39/JJ	ccomp||emphasized-2/VBD||progress-40/NN	conj_and||need-8/NN||progress-40/NN	amod||aspects-43/NNS||molecular-virological-42/JJ	prep_in||progress-40/NN||aspects-43/NNS	det||genetics-47/NNS||the-46/DT	prep_in||progress-40/NN||genetics-47/NNS	conj_and||aspects-43/NNS||genetics-47/NNS	det||virus-50/NN||the-49/DT	prep_of||genetics-47/NNS||virus-50/NN	nsubj||provide-52/VB||virus-50/NN	nsubj||define-61/VB||virus-50/NN	rcmod||virus-50/NN||provide-52/VB	amod||tools-54/NNS||new-53/JJ	dobj||provide-52/VB||tools-54/NNS	amod||studies-59/NNS||epidemiological-56/JJ	conj_and||epidemiological-56/JJ||immunological-58/JJ	amod||studies-59/NNS||immunological-58/JJ	prep_for||provide-52/VB||studies-59/NNS	rcmod||virus-50/NN||define-61/VB	conj_and||provide-52/VB||define-61/VB	advmod||convincingly-63/JJ||more-62/RBR	acomp||define-61/VB||convincingly-63/JJ	det||role-67/NN||the-64/DT	amod||role-67/NN||possible-65/JJ	amod||role-67/NN||causal-66/JJ	dep||convincingly-63/JJ||role-67/NN	prep_of||role-67/NN||hsv-2-69/JJ	amod||carcinogenesis-72/NNS||cervical-71/JJ	prep_in||hsv-2-69/JJ||carcinogenesis-72/NNS	dep||problems-78/NNS||4-75/LS	det||problems-78/NNS||the-77/DT	ccomp||emphasized-2/VBD||problems-78/NNS	conj_and||need-8/NN||problems-78/NNS	prep_with||problems-78/NNS||vaccines-80/NNS	det||advances-84/NNS||the-82/DT	amod||advances-84/NNS||therapeutic-83/JJ	prep_with||problems-78/NNS||advances-84/NNS	conj_and||vaccines-80/NNS||advances-84/NNS	conj_and||vaccines-80/NNS||failures-86/NNS	conj_and||advances-84/NNS||failures-86/NNS	appos||advances-84/NNS||5-89/CD	det||aspect-94/NN||the-91/DT	amod||aspect-94/NN||great-92/JJ	amod||aspect-94/NN||psychosocial-93/JJ	dep||advances-84/NNS||aspect-94/NN	det||infections-98/NNS||some-96/DT	amod||infections-98/NNS||herpetic-97/JJ	prep_of||aspect-94/NN||infections-98/NNS	det||need-101/NN||the-100/DT	prep_of||aspect-94/NN||need-101/NN	conj_and||infections-98/NNS||need-101/NN	aux||sympathetic-104/JJ||to-102/TO	cop||sympathetic-104/JJ||be-103/VB	vmod||need-101/NN||sympathetic-104/JJ	vmod||need-101/NN||supportive-106/JJ	conj_and||sympathetic-104/JJ||supportive-106/JJ	aux||afflicted-108/VB||to-107/TO	xcomp||sympathetic-104/JJ||afflicted-108/VB	dobj||afflicted-108/VB||patients-109/NNS	poss||families-112/NNS||their-111/PRP$	ccomp||emphasized-2/VBD||families-112/NNS	conj_and||need-8/NN||families-112/NNS	appos||families-112/NNS||6-115/CD	det||overreaction-118/NN||the-117/DT	dep||families-112/NNS||overreaction-118/NN	prep_regarding||overreaction-118/NN||hsv-120/NN	nsubj||exists-123/VBZ||hsv-120/NN	advmod||exists-123/VBZ||currently-122/RB	rcmod||hsv-120/NN||exists-123/VBZ	prep_among||exists-123/VBZ||physicians-125/NNS	prep_among||exists-123/VBZ||nurses-127/NNS	conj_and||physicians-125/NNS||nurses-127/NNS	det||public-130/NN||the-129/DT	prep_among||exists-123/VBZ||public-130/NN	conj_and||physicians-125/NNS||public-130/NN	det||press-134/NN||the-133/DT	prep_among||exists-123/VBZ||press-134/NN	conj_and||physicians-125/NNS||press-134/NN	xcomp||exists-123/VBZ||resulting-135/VBG	amod||misery-138/NN||increased-137/VBN	prep_in||resulting-135/VBG||misery-138/NN	prep_for||misery-138/NN||those-140/DT	vmod||those-140/DT||afflicted-141/VBN	vmod||those-140/DT||misdiagnosed-143/VBN	conj_or||afflicted-141/VBN||misdiagnosed-143/VBN	amod||advice-148/NN||poor-147/JJ	prep_in||resulting-135/VBG||advice-148/NN	conj_or||misery-138/NN||advice-148/NN	conj_or||misery-138/NN||management-150/NN	conj_or||advice-148/NN||management-150/NN	prep||advice-148/NN||given-151/VBN	pcomp||given-151/VBN||by-152/IN	det||physicians-154/NNS||some-153/DT	pobj||by-152/IN||physicians-154/NNS	vmod||physicians-154/NNS||pressured-155/VBN	prep_in||pressured-155/VBN||part-157/NN	det||fear-160/NN||the-159/DT	agent||pressured-155/VBN||fear-160/NN	nn||suits-163/NNS||malpractice-162/NN	prep_of||fear-160/NN||suits-163/NNS	virus-50||viruses-15||no||points emphasized are (1) the need for considering these (and other viruses) from an evolutionary perspective; (2) the necessity of disseminating current methods for virus identification; (3) the great progress in molecular-virological aspects and in the genetics of the virus which provide new tools for epidemiological and immunological studies and define more convincingly the possible causal role of hsv-2 in cervical carcinogenesis; (4) the problems with vaccines and the therapeutic advances and failures; (5) the great psychosocial aspect of some herpetic infections and the need to be sympathetic and supportive to afflicted patients and their families; (6) the overreaction regarding hsv that currently exists among physicians, nurses, the public, and the press resulting in increased misery for those afflicted or misdiagnosed, or in poor advice or management given by some physicians pressured in part by the fear of malpractice suits.
nsubj||emerged-8/VBN||variants-1/NNS	nsubjpass||known-13/VBN||variants-1/NNS	amod||biotype-6/NN||vibriocholeraeo1-3/JJ	nn||biotype-6/NN||el-4/NN	nn||biotype-6/NN||tor-5/NN	prep_of||variants-1/NNS||biotype-6/NN	aux||emerged-8/VBN||have-7/VBP	root||ROOT-0/null||emerged-8/VBN	advmod||little-11/RB||very-10/RB	advmod||emerged-8/VBN||little-11/RB	conj_but||emerged-8/VBN||little-11/RB	auxpass||known-13/VBN||is-12/VBZ	conj_but||emerged-8/VBN||known-13/VBN	prep_about||known-13/VBN||strains-15/NNS	vmod||strains-15/NNS||causing-16/VBG	nn||outbreaks-18/NNS||cholera-17/NN	dobj||causing-16/VBG||outbreaks-18/NNS	amod||africa-21/NN||west-20/JJ	prep_in||causing-16/VBG||africa-21/NN	nsubj||crucial-25/JJ||africa-21/NN	nsubj||control-32/VB||africa-21/NN	cop||crucial-25/JJ||is-24/VBZ	rcmod||africa-21/NN||crucial-25/JJ	det||implementation-28/NN||the-27/DT	prep_for||crucial-25/JJ||implementation-28/NN	prep_of||implementation-28/NN||interventions-30/NNS	aux||control-32/VB||to-31/TO	xcomp||crucial-25/JJ||control-32/VB	dobj||control-32/VB||epidemiccholera-33/NN	epidemiccholera-33||vibriocholeraeo1-3||no||variants of vibriocholeraeo1 el tor biotype have emerged but very little is known about strains causing cholera outbreaks in west africa, which is crucial for the implementation of interventions to control epidemiccholera.
nsubj||some-10/DT||smoking-1/NN	nn||carcinogens-4/NNS||chemical-3/NN	appos||smoking-1/NN||carcinogens-4/NNS	prep_like||carcinogens-4/NNS||asbestos-6/NN	prep_like||carcinogens-4/NNS||organicsolvents-8/NNS	conj_or||asbestos-6/NN||organicsolvents-8/NNS	cop||some-10/DT||are-9/VBP	root||ROOT-0/null||some-10/DT	det||factors-13/NNS||these-12/DT	prep_of||some-10/DT||factors-13/NNS	nsubj||increase-15/VBP||factors-13/NNS	rcmod||factors-13/NNS||increase-15/VBP	det||risk-17/NN||the-16/DT	dobj||increase-15/VBP||risk-17/NN	det||rcc-20/NN||the-19/DT	prep_of||risk-17/NN||rcc-20/NN	rcc-20||organicsolvents-8||no_rel||smoking, chemical carcinogens like asbestos or organicsolvents are some of these factors that increase the risk of the rcc.
nsubj||sized-35/VBD||participants-1/NNS	num||adults-3/NNS||24-2/CD	nsubjpass||tested-30/VBN||adults-3/NNS	num||men-6/NNS||10-5/CD	appos||adults-3/NNS||men-6/NNS	num||women-9/NNS||14-8/CD	dep||men-6/NNS||women-9/NNS	prep_with||adults-3/NNS||type1diabetes-12/NNS	nsubj||used-19/VBN||type1diabetes-12/NNS	vmod||type1diabetes-12/NNS||aged-14/VBN	dobj||aged-14/VBN||18-65-15/CD	aux||used-19/VBN||had-18/VBD	rcmod||type1diabetes-12/NNS||used-19/VBN	nn||therapy-22/NN||insulin-20/NN	nn||therapy-22/NN||pump-21/NN	dobj||used-19/VBN||therapy-22/NN	quantmod||three-26/CD||at-24/IN	mwe||at-24/IN||least-25/JJS	pobj||at-24/IN||least-25/JJS	num||months-27/NNS||three-26/CD	prep_for||therapy-22/NN||months-27/NNS	dep||months-27/NNS||12-28/CD	auxpass||tested-30/VBN||were-29/VBD	rcmod||participants-1/NNS||tested-30/VBN	prepc_after||tested-30/VBN||consuming-32/VBG	det||medium-34/NN||a-33/DT	dobj||consuming-32/VBG||medium-34/NN	root||ROOT-0/null||sized-35/VBD	dobj||sized-35/VBD||meal-36/NN	det||12-40/CD||the-38/DT	amod||12-40/CD||other-39/JJ	dobj||sized-35/VBD||12-40/CD	conj_and||meal-36/NN||12-40/CD	prepc_after||sized-35/VBD||consuming-42/VBG	det||meal-45/NN||a-43/DT	amod||meal-45/NN||larger-44/JJR	dobj||consuming-42/VBG||meal-45/NN	vmod||meal-45/NN||accompanied-46/VBN	agent||accompanied-46/VBN||alcohol-48/NN	type1diabetes-12||insulin-20||yes||participants 24 adults (10 men, 14 women) with type1diabetes, aged 18-65, who had used insulin pump therapy for at least three months 12 were tested after consuming a medium sized meal and the other 12 after consuming a larger meal accompanied by alcohol.
nn||necrosis-9/NNS||etanercept-1/NN	amod||necrosis-9/NNS||infliximab-3/JJ	conj_and||infliximab-3/JJ||adalimumab-6/JJ	amod||necrosis-9/NNS||adalimumab-6/JJ	nn||necrosis-9/NNS||target-7/NN	nn||necrosis-9/NNS||tumor-8/NN	nsubj||factor-alpha-10/VBZ||necrosis-9/NNS	nsubj||demonstrated-13/VBN||necrosis-9/NNS	root||ROOT-0/null||factor-alpha-10/VBZ	aux||demonstrated-13/VBN||have-12/VBP	conj_and||factor-alpha-10/VBZ||demonstrated-13/VBN	advmod||demonstrated-13/VBN||efficacy-14/RB	det||treatment-17/NN||the-16/DT	prep_in||demonstrated-13/VBN||treatment-17/NN	prep_of||treatment-17/NN||psoriasis-19/NNS	prep_of||treatment-17/NN||psoriaticarthritis-21/NNS	conj_and||psoriasis-19/NNS||psoriaticarthritis-21/NNS	psoriaticarthritis-21||etanercept-1||yes||etanercept, infliximab, and adalimumab target tumor necrosis factor-alpha and have demonstrated efficacy in the treatment of psoriasis and psoriaticarthritis.
det||man-3/NN||a-1/DT	amod||man-3/NN||64-year-old-2/JJ	nsubj||duration-11/VBD||man-3/NN	nsubj||achieved-27/VBD||man-3/NN	amod||granulomaannulare-7/NN||generalized-5/JJ	nn||granulomaannulare-7/NN||papular-6/NN	prep_with||man-3/NN||granulomaannulare-7/NN	num||years-10/NNS||four-9/CD	prep_of||granulomaannulare-7/NN||years-10/NNS	root||ROOT-0/null||duration-11/VBD	amod||relapses-14/NNS||frequent-13/JJ	prep_with||duration-11/VBD||relapses-14/NNS	prep_with||duration-11/VBD||remissions-16/NNS	conj_and||relapses-14/NNS||remissions-16/NNS	vmod||relapses-14/NNS||presented-17/VBN	amod||lesions-20/NNS||persistent-19/JJ	prep_with||presented-17/VBN||lesions-20/NNS	dobj||duration-11/VBD||while-21/NN	num||prednisolone-25/NN||15-23/CD	nn||prednisolone-25/NN||mg-24/NN	prep_on||duration-11/VBD||prednisolone-25/NN	conj_and||duration-11/VBD||achieved-27/VBD	amod||remission-29/NN||complete-28/JJ	dobj||achieved-27/VBD||remission-29/NN	amod||therapy-32/NN||puvasol-31/JJ	prep_with||achieved-27/VBD||therapy-32/NN	vmod||therapy-32/NN||using-33/VBG	dobj||using-33/VBG||solarium-34/NN	granulomaannulare-7||prednisolone-25||no_rel||a 64-year-old man with generalized papular granulomaannulare of four years duration with frequent relapses and remissions presented with persistent lesions while on 15 mg prednisolone and achieved complete remission with puvasol therapy using solarium.
det||gradation-2/NN||the-1/DT	nsubjpass||correlated-38/VBN||gradation-2/NN	nsubj||document-44/VB||gradation-2/NN	conj_and||gradation-2/NN||localization-4/NN	nsubjpass||correlated-38/VBN||localization-4/NN	nsubj||document-44/VB||localization-4/NN	det||expression-7/NN||the-6/DT	prep_of||gradation-2/NN||expression-7/NN	prep_of||expression-7/NN||antibodies-9/NNS	nn||±-13/NNP||tnfî-12/NNP	prep_such_as||antibodies-9/NNS||±-13/NNP	amod||²-16/NNS||il-1î-15/JJ	appos||gradation-2/NN||²-16/NNS	appos||gradation-2/NN||il-6-18/JJ	appos||gradation-2/NN||hsps-20/NNS	nn||²-23/NNP||î-22/NNP	appos||gradation-2/NN||²-23/NNP	num||²-23/NNP||app-24/CD	num||²-23/NNP||anti-tryph-26/CD	num||²-23/NNP||gap43-28/CD	num||²-23/NNP||gfap-30/CD	num||²-23/NNP||cox2-32/CD	num||²-23/NNP||orp-150-34/CD	aux||correlated-38/VBN||could-36/MD	auxpass||correlated-38/VBN||be-37/VB	root||ROOT-0/null||correlated-38/VBN	det||damage-42/NN||an-40/DT	amod||damage-42/NN||hypoxic-ischemic-41/JJ	prep_with||correlated-38/VBN||damage-42/NN	aux||document-44/VB||to-43/TO	xcomp||correlated-38/VBN||document-44/VB	det||correlation-47/NN||a-45/DT	amod||correlation-47/NN||significant-46/JJ	dobj||document-44/VB||correlation-47/NN	prep_between||correlation-47/NN||response-49/NN	det||time-52/NN||the-51/DT	dobj||document-44/VB||time-52/NN	conj_and||correlation-47/NN||time-52/NN	prep_of||time-52/NN||onset-54/NN	amod||onset-54/NN||acute-55/JJ	dep||-58/JJ||â-57/RB	dep||acute-55/JJ||-58/JJ	dep||-58/JJ||$-59/$	number||hs-61/CD||8-60/CD	num||$-59/$||hs-61/CD	amod||onset-54/NN||non-acute-64/JJ	conj_or||acute-55/JJ||non-acute-64/JJ	nn||¥-68/NNP||â-66/NNP	nn||¥-68/NNP||-67/NNP	dep||onset-54/NN||¥-68/NNP	num||-72/NNS||8-69/CD	nn||-72/NNS||hs-70/NN	nn||-72/NNS||â-71/NN	dep||¥-68/NNP||-72/NNS	dep||-72/NNS||$-73/$	number||hs-75/CD||48-74/CD	num||$-73/$||hs-75/CD	hypoxic--1||antibodies-9||no_rel||the gradation and localization of the expression of antibodies such as tnfî±, il-1î², il-6, hsps, î² app, anti-tryph, gap43, gfap, cox2, orp-150, could be correlated with an hypoxic-ischemic damage to document a significant correlation between response and the time of onset acute (â¤8 hs) or non-acute (â¥8 hs â¤48 hs).
nsubj||agent-5/NN||mycobacteriumtuberculosis-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	ccomp||strain-18/NN||agent-5/NN	det||disease-8/NN||the-7/DT	prep_of||agent-5/NN||disease-8/NN	nsubj||strain-18/NN||tuberculosis-10/NNP	conj_and||tuberculosis-10/NNP||h37rv-12/NNP	nsubj||strain-18/NN||h37rv-12/NNP	cop||strain-18/NN||is-13/VBZ	det||strain-18/NN||the-14/DT	advmod||studied-16/JJ||most-15/RBS	amod||strain-18/NN||studied-16/JJ	amod||strain-18/NN||clinical-17/JJ	root||ROOT-0/null||strain-18/NN	tuberculosis-10||mycobacteriumtuberculosis-1||no||mycobacteriumtuberculosis is the causative agent of the disease, tuberculosis and h37rv is the most studied clinical strain.
det||mechanism-2/NN||this-1/DT	nsubj||has-9/VBZ||mechanism-2/NN	mark||finds-6/VBZ||if-4/IN	nsubj||finds-6/VBZ||it-5/PRP	dep||mechanism-2/NN||finds-6/VBZ	dobj||finds-6/VBZ||support-7/NN	root||ROOT-0/null||has-9/VBZ	amod||implications-11/NNS||important-10/JJ	dobj||has-9/VBZ||implications-11/NNS	amod||research-14/NN||future-13/JJ	prep_for||implications-11/NNS||research-14/NN	det||hazard-18/NN||the-16/DT	nn||hazard-18/NN||mesothelioma-17/NN	prep_into||has-9/VBZ||hazard-18/NN	prep_into||has-9/VBZ||hazard-18/NN	conj_and||hazard-18/NN||hazard-18/NN	prep_from||hazard-18/NN||harn-20/NN	advmod||hazard-18/NN||also-22/RB	poss||view-26/NN||our-24/PRP$	amod||view-26/NN||current-25/JJ	prep_for||hazard-18/NN||view-26/NN	det||origins-29/NNS||the-28/DT	prep_of||view-26/NN||origins-29/NNS	amod||mesothelioma-33/NN||asbestos-initiated-31/JJ	amod||mesothelioma-33/NN||pleural-32/JJ	prep_of||origins-29/NNS||mesothelioma-33/NN	det||use-37/NN||the-35/DT	amod||use-37/NN||common-36/JJ	prep_of||view-26/NN||use-37/NN	conj_and||origins-29/NNS||use-37/NN	prep_of||use-37/NN||lung-39/NN	amod||burden-43/NN||parenchymal-40/JJ	nn||burden-43/NN||asbestos-41/NN	nn||burden-43/NN||fibre-42/NN	pobj||hazard-18/NN||burden-43/NN	det||correlate-46/NN||a-45/DT	prep_as||has-9/VBZ||correlate-46/NN	det||tumour-49/NN||this-48/DT	prep_of||correlate-46/NN||tumour-49/NN	nsubj||arises-53/VBZ||tumour-49/NN	advmod||arises-53/VBZ||actually-52/RB	rcmod||tumour-49/NN||arises-53/VBZ	det||pleura-57/NN||the-55/DT	amod||pleura-57/NN||parietal-56/JJ	prep_in||arises-53/VBZ||pleura-57/NN	asbestos-41||tumour-49||no_rel||this mechanism, if it finds support, has important implications for future research into the mesothelioma hazard from harn and also for our current view of the origins of asbestos-initiated pleural mesothelioma and the common use of lung parenchymal asbestos fibre burden as a correlate of this tumour, which actually arises in the parietal pleura.
poss||results-3/NNS||our-1/PRP$	amod||results-3/NNS||previous-2/JJ	nsubj||shown-5/VBN||results-3/NNS	aux||shown-5/VBN||have-4/VBP	root||ROOT-0/null||shown-5/VBN	mark||enhanced-15/VBN||that-6/IN	nsubjpass||enhanced-15/VBN||adhesion-7/NN	nsubjpass||blocked-25/VBN||adhesion-7/NN	prep_of||adhesion-7/NN||thymocytes-9/NNS	amod||line-13/NN||cultured-11/JJ	nn||line-13/NN||tec-12/NN	prep_to||thymocytes-9/NNS||line-13/NN	auxpass||enhanced-15/VBN||is-14/VBZ	ccomp||shown-5/VBN||enhanced-15/VBN	det||presence-18/NN||the-17/DT	prep_in||enhanced-15/VBN||presence-18/NN	prep_of||presence-18/NN||fibronectin-20/NN	aux||blocked-25/VBN||can-23/MD	auxpass||blocked-25/VBN||be-24/VB	ccomp||shown-5/VBN||blocked-25/VBN	conj_and||enhanced-15/VBN||blocked-25/VBN	amod||antibody-28/NN||anti-vla-5-27/JJ	prep_with||blocked-25/VBN||antibody-28/NN	antibody-28||adhesion-7||no_rel||our previous results have shown that adhesion of thymocytes to cultured tec line is enhanced in the presence of fibronectin, and can be blocked with anti-vla-5 antibody.
nn||estimates-3/NNS||hiv-1/NN	nn||estimates-3/NNS||incidence-2/NN	nsubjpass||used-8/VBN||estimates-3/NNS	nsubj||target-10/VB||estimates-3/NNS	aux||used-8/VBN||can-4/MD	aux||used-8/VBN||should-6/MD	conj_and||used-8/VBN||should-6/MD	auxpass||used-8/VBN||be-7/VB	root||ROOT-0/null||used-8/VBN	aux||target-10/VB||to-9/TO	xcomp||used-8/VBN||target-10/VB	nn||efforts-12/NNS||prevention-11/NN	dobj||target-10/VB||efforts-12/NNS	prep_towards||target-10/VB||populations-14/NNS	amod||risk-17/NN||highest-16/JJS	prep_at||populations-14/NNS||risk-17/NN	prepc_of||populations-14/NNS||acquiring-19/VBG	amod||hivinfections-21/NNS||new-20/JJ	dobj||acquiring-19/VBG||hivinfections-21/NNS	xcomp||used-8/VBN||focusing-23/VBG	prt||focusing-23/VBG||on-24/RP	amod||disparities-31/NNS||geographic-25/JJ	conj_and||geographic-25/JJ||racial-27/JJ	amod||disparities-31/NNS||racial-27/JJ	conj_and||geographic-25/JJ||risk-29/NN	amod||disparities-31/NNS||risk-29/NN	nn||disparities-31/NNS||group-30/NN	dobj||focusing-23/VBG||disparities-31/NNS	hivinfections-21||hiv-1||no||hiv incidence estimates can and should be used to target prevention efforts towards populations at highest risk of acquiring new hivinfections, focusing on geographic, racial and risk group disparities.
nn||transfection-3/NN||vivo-2/NN	prep_in||gave-29/VBD||transfection-3/NN	det||lipid-8/NN||the-5/DT	amod||lipid-8/NN||folate-modified-6/JJ	amod||lipid-8/NN||mm18-7/JJ	prep_with||transfection-3/NN||lipid-8/NN	dep||gave-29/VBD||containing-10/VBG	det||amount-13/NN||the-11/DT	amod||amount-13/NN||highest-12/JJS	dobj||containing-10/VBG||amount-13/NN	amod||co-lipid-16/NN||fa-peg570-diether-15/JJ	prep_of||amount-13/NN||co-lipid-16/NN	dep||co-lipid-16/NN||ww-18/NN	dep||ww-18/NN||9010-20/CD	det||ratio-27/NN||a-24/DT	amod||ratio-27/NN||neutral-25/JJ	nn||ratio-27/NN||charge-26/NN	prep_at||co-lipid-16/NN||ratio-27/NN	root||ROOT-0/null||gave-29/VBD	amod||expression-32/NN||luciferase-30/JJ	nn||expression-32/NN||transgene-31/NN	dobj||gave-29/VBD||expression-32/NN	lipid-8||fa--1||no_rel||in vivo transfection with the folate-modified mm18 lipid, containing the highest amount of fa-peg570-diether co-lipid ( ww ; 9010), at a neutral charge ratio, gave luciferase transgene expression.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||compare-9/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-9/VB||to-7/TO	advmod||compare-9/VB||directly-8/RB	xcomp||was-6/VBD||compare-9/VB	det||effects-11/NNS||the-10/DT	dobj||compare-9/VB||effects-11/NNS	prep_of||effects-11/NNS||cr-13/NN	amod||exercise-16/NN||endurance-15/JJ	dobj||compare-9/VB||exercise-16/NN	conj_and||effects-11/NNS||exercise-16/NN	det||model-20/NN||a-18/DT	nn||model-20/NN||mouse-19/NN	prep_in||exercise-16/NN||model-20/NN	amod||obesity-23/NN||diet-induced-22/JJ	prep_of||model-20/NN||obesity-23/NN	prep_of||model-20/NN||insulinresistance-25/NN	conj_and||obesity-23/NN||insulinresistance-25/NN	cr-13||insulinresistance-25||no_rel||the aim of this study was to directly compare the effects of cr and endurance exercise in a mouse model of diet-induced obesity and insulinresistance.
nsubj||recorded-2/VBD||we-1/PRP	nsubj||examined-22/VBD||we-1/PRP	root||ROOT-0/null||recorded-2/VBD	amod||data-4/NNS||demographic-3/JJ	dobj||recorded-2/VBD||data-4/NNS	amod||prescription-7/NN||antenatal-6/JJ	appos||data-4/NNS||prescription-7/NN	amod||therapy-11/NN||intermittent-9/JJ	nn||therapy-11/NN||preventive-10/NN	prep_of||prescription-7/NN||therapy-11/NN	prep_during||recorded-2/VBD||pregnancy-13/NN	nn||use-19/NN||sulfadoxine-pyrimethamine-15/NN	conj_and||sulfadoxine-pyrimethamine-15/NN||bed-17/NN	nn||use-19/NN||bed-17/NN	amod||use-19/NN||net-18/JJ	prep_with||recorded-2/VBD||use-19/NN	conj_and||recorded-2/VBD||examined-22/VBD	amod||blood-24/NN||finger-prick-23/JJ	dobj||examined-22/VBD||blood-24/NN	nn||parasites-27/NNS||malaria-26/NN	prep_for||examined-22/VBD||parasites-27/NNS	nn||concentration-30/NN||hemoglobin-29/NN	prep_for||examined-22/VBD||concentration-30/NN	conj_and||parasites-27/NNS||concentration-30/NN	malaria-26||pyrimethamine--1||yes||we recorded demographic data, antenatal prescription of intermittent preventive therapy during pregnancy with sulfadoxine-pyrimethamine and bed net use, and examined finger-prick blood for malaria parasites and hemoglobin concentration.
nn||patients-2/NNS||results-1/NNS	nsubj||referred-3/VBD||patients-2/NNS	root||ROOT-0/null||referred-3/VBD	det||programme-7/NN||the-5/DT	amod||programme-7/NN||hiv/aids-6/JJ	prep_to||referred-3/VBD||programme-7/NN	amod||care-11/NN||general-9/JJ	amod||care-11/NN||primary-10/JJ	prep_through||referred-3/VBD||care-11/NN	nn||clinics-14/NNS||intervention-13/NN	prep_at||referred-3/VBD||clinics-14/NNS	cop||likely-17/JJ||were-15/VBD	advmod||likely-17/JJ||more-16/RBR	rcmod||clinics-14/NNS||likely-17/JJ	prep_than||likely-17/JJ||those-19/DT	nn||clinics-22/NNS||control-21/NN	prep_at||those-19/DT||clinics-22/NNS	aux||receive-24/VB||to-23/TO	xcomp||likely-17/JJ||receive-24/VB	amod||prophylaxis-26/NNS||co-trimoxazole-25/JJ	dobj||receive-24/VB||prophylaxis-26/NNS	num||%-29/NN||41-28/CD	nsubj||v-34/VBP||%-29/NN	appos||%-29/NN||2253/5523-32/CD	dep||clinics-14/NNS||v-34/VBP	num||%-36/NN||32-35/CD	dobj||v-34/VBP||%-36/NN	appos||%-36/NN||1340/4210-38/CD	dep||%-36/NN||odds-41/NNS	nsubj||interval-48/VBP||ratio-42/NN	num||ratio-42/NN||1.95-43/CD	number||%-46/NN||95-45/CD	amod||confidence-47/NN||%-46/NN	appos||ratio-42/NN||confidence-47/NN	rcmod||odds-41/NNS||interval-48/VBP	number||3.40-51/CD||1.11-49/CD	dep||3.40-51/CD||to-50/TO	dobj||interval-48/VBP||3.40-51/CD	nsubj||likely-58/JJ||tuberculosis-55/NNP	nsubjpass||diagnosed-61/VBN||tuberculosis-55/NNP	cop||likely-58/JJ||was-56/VBD	advmod||likely-58/JJ||more-57/RBR	conj_and||referred-3/VBD||likely-58/JJ	aux||diagnosed-61/VBN||to-59/TO	auxpass||diagnosed-61/VBN||be-60/VB	xcomp||likely-58/JJ||diagnosed-61/VBN	prep_among||diagnosed-61/VBN||patients-63/NNS	prep_with||patients-63/NNS||hiv/aids/art-65/NN	num||%-68/NN||7-67/CD	nsubj||v-72/VBP||%-68/NN	appos||%-68/NN||417/5793-70/CD	dep||patients-63/NNS||v-72/VBP	num||%-74/NN||6-73/CD	dobj||v-72/VBP||%-74/NN	appos||%-74/NN||245/4343-76/CD	dep||%-74/NN||1.25-79/CD	number||1.55-83/CD||1.01-81/CD	dep||1.55-83/CD||to-82/TO	appos||1.25-79/CD||1.55-83/CD	aids--1||hiv--1||no||results patients referred to the hiv/aids programme through general primary care at intervention clinics were more likely than those at control clinics to receive co-trimoxazole prophylaxis (41%, (2253/5523) v 32% (1340/4210); odds ratio 1.95, 95% confidence interval 1.11 to 3.40), and tuberculosis was more likely to be diagnosed among patients with hiv/aids/art (7% (417/5793) v 6% (245/4343); 1.25, 1.01 to 1.55).
amod||men-2/NNS||fifty-nine-1/JJ	nsubjpass||studied-14/VBN||men-2/NNS	advmod||controlled-5/VBN||well-4/RB	amod||type2diabetes-6/NNS||controlled-5/VBN	prep_with||men-2/NNS||type2diabetes-6/NNS	num||men-12/NNS||18-8/CD	amod||men-12/NNS||age-matched-9/JJ	amod||men-12/NNS||healthy-10/JJ	amod||men-12/NNS||normoglycemic-11/JJ	prep_with||men-2/NNS||men-12/NNS	conj_and||type2diabetes-6/NNS||men-12/NNS	auxpass||studied-14/VBN||were-13/VBD	root||ROOT-0/null||studied-14/VBN	xcomp||studied-14/VBN||using-15/VBG	amod||tomography-18/NN||positron-16/JJ	nn||tomography-18/NN||emission-17/NN	dobj||using-15/VBG||tomography-18/NN	aux||assess-20/VB||to-19/TO	vmod||using-15/VBG||assess-20/VB	amod||perfusion-23/NN||hepatic-21/JJ	nn||perfusion-23/NN||tissue-22/NN	dobj||assess-20/VB||perfusion-23/NN	amod||glucose-26/NN||insulin-stimulated-25/JJ	dobj||assess-20/VB||glucose-26/NN	amod||metabolism-31/NN||fasting-29/JJ	amod||metabolism-31/NN||fattyacid-30/JJ	dobj||assess-20/VB||metabolism-31/NN	conj_and||glucose-26/NN||metabolism-31/NN	dobj||assess-20/VB||respectively-33/RB	advmod||glucose-26/NN||respectively-33/RB	conj_and||glucose-26/NN||respectively-33/RB	prep_in||assess-20/VB||relation-36/NN	amod||content-40/NN||hepatic-38/JJ	nn||content-40/NN||triglyceride-39/NN	prep_to||relation-36/NN||content-40/NN	vmod||content-40/NN||quantified-42/VBN	amod||spectroscopy-47/NN||proton-44/JJ	amod||spectroscopy-47/NN||magnetic-45/JJ	nn||spectroscopy-47/NN||resonance-46/NN	agent||quantified-42/VBN||spectroscopy-47/NN	triglyceride-39||type2diabetes-6||no_rel||fifty-nine men with well controlled type2diabetes and 18 age-matched healthy normoglycemic men were studied using positron emission tomography to assess hepatic tissue perfusion, insulin-stimulated glucose, and fasting fattyacid metabolism, respectively, in relation to hepatic triglyceride content, quantified by proton magnetic resonance spectroscopy.
amod||couples-2/NNS||heterosexual-1/JJ	nsubj||visited-3/VBD||couples-2/NNS	root||ROOT-0/null||visited-3/VBD	det||centres-11/NNS||the-4/DT	nn||centres-11/NNS||rwanda-5/NN	nn||centres-11/NNS||zambia-6/NN	nn||centres-11/NNS||hiv-7/NN	nn||centres-11/NNS||research-8/NN	nn||centres-11/NNS||group-9/NN	nn||centres-11/NNS||testing-10/NN	dobj||visited-3/VBD||centres-11/NNS	prep_in||centres-11/NNS||kigali-13/NN	prep_in||centres-11/NNS||rwanda-15/NN	conj_and||kigali-13/NN||rwanda-15/NN	prep_in||centres-11/NNS||lusaka-18/NN	conj_and||kigali-13/NN||lusaka-18/NN	appos||kigali-13/NN||zambia-20/NN	aux||assess-23/VB||to-22/TO	vmod||visited-3/VBD||assess-23/VB	nn||status-25/NN||hivinfection-24/NN	dobj||assess-23/VB||status-25/NN	hivinfection-24||hiv-7||no||heterosexual couples visited the rwanda zambia hiv research group testing centres in kigali, rwanda, and lusaka, zambia, to assess hivinfection status.
det||period-5/NN||the-2/DT	amod||period-5/NN||6-month-3/JJ	nn||period-5/NN||study-4/NN	prep_following||decreased-20/VBN||period-5/NN	det||glucose-13/NN||the-7/DT	nn||glucose-13/NN||plasma-8/NN	nn||glucose-13/NN||tbars-9/NNS	nn||glucose-13/NN||levels-10/NNS	conj_and||glucose-13/NN||fasting-12/NN	nsubjpass||decreased-20/VBN||fasting-12/NN	nsubjpass||decreased-20/VBN||glucose-13/NN	nsubjpass||decreased-20/VBN||glucose-13/NN	conj_and||glucose-13/NN||hba1c-15/NN	nsubjpass||decreased-20/VBN||hba1c-15/NN	conj_and||glucose-13/NN||insulinresistance-17/NN	nsubjpass||decreased-20/VBN||insulinresistance-17/NN	auxpass||decreased-20/VBN||were-18/VBD	advmod||decreased-20/VBN||significantly-19/RB	root||ROOT-0/null||decreased-20/VBN	conj_but||decreased-20/VBN||decreased-20/VBN	det||cr-23/NN||the-22/DT	prep_in||decreased-20/VBN||cr-23/NN	nn||groups-32/NNS||crâ-25/NN	nn||groups-32/NNS||+-26/NNP	nn||groups-32/NNS||â-27/NN	nn||groups-32/NNS||câ-28/NN	nn||groups-32/NNS||+-29/NN	nn||groups-32/NNS||â-30/NN	amod||groups-32/NNS||e-31/JJ	prep_in||decreased-20/VBN||groups-32/NNS	conj_and||cr-23/NN||groups-32/NNS	neg||decreased-20/VBN||not-35/RB	det||group-39/NN||the-37/DT	nn||group-39/NN||placebo-38/NN	prep_for||decreased-20/VBN||group-39/NN	glucose-13||insulinresistance-17||no_rel||following the 6-month study period, the plasma tbars levels, fasting glucose, hba1c and insulinresistance were significantly decreased in the cr and crâ +â câ +â e groups, but not for the placebo group.
nsubj||completed-9/VBD||methods-1/NNS	number||hundred-3/CD||seven-2/CD	dep||methods-1/NNS||hundred-3/CD	amod||patients-6/NNS||thirty-two-5/JJ	conj_and||methods-1/NNS||patients-6/NNS	nsubj||completed-9/VBD||patients-6/NNS	prep_with||patients-6/NNS||type2diabetes-8/CD	root||ROOT-0/null||completed-9/VBD	det||questionnaire-12/NN||a-10/DT	amod||questionnaire-12/NN||77-item-11/JJ	dobj||completed-9/VBD||questionnaire-12/NN	det||study-20/NN||a-14/DT	amod||study-20/NN||randomized-15/JJ	amod||study-20/NN||52-week-17/JJ	amod||study-20/NN||double-blind-19/JJ	prep_during||completed-9/VBD||study-20/NN	amod||mg-24/NN||liraglutide-22/JJ	dep||liraglutide-22/JJ||1.2-23/CD	prep_with||study-20/NN||mg-24/NN	dep||study-20/NN||n-26/VBN	dep||245-28/CD||=-27/SYM	ccomp||n-26/VBN||245-28/CD	number||mg-32/CD||1.8-31/CD	prep_during||completed-9/VBD||mg-32/CD	conj_or||study-20/NN||mg-32/CD	appos||mg-32/CD||n-34/NNP	number||242-36/CD||=-35/CD	num||n-34/NNP||242-36/CD	prepc_compared_with||mg-32/CD||with-39/IN	amod||mg-42/NN||glimepiride-40/JJ	dep||glimepiride-40/JJ||8-41/CD	pobj||mg-32/CD||mg-42/NN	dep||mg-42/NN||n-44/VBN	dep||245-46/CD||=-45/SYM	ccomp||n-44/VBN||245-46/CD	type2diabetes-8||glimepiride-40||yes||methods seven hundred and thirty-two patients with type2diabetes completed a 77-item questionnaire during a randomized, 52-week, double-blind study with liraglutide 1.2 mg ( n = 245) or 1.8 mg ( n = 242) compared with glimepiride 8 mg ( n = 245).
nsubj||studied-2/VBD||we-1/PRP	root||ROOT-0/null||studied-2/VBD	amod||polymorphisms-6/NNS||ifnk-3/JJ	amod||polymorphisms-6/NNS||single-4/JJ	nn||polymorphisms-6/NNS||nucleotide-5/NN	dobj||studied-2/VBD||polymorphisms-6/NNS	appos||polymorphisms-6/NNS||snps-8/NNS	num||cases-13/NNS||3982-11/CD	nn||cases-13/NNS||sle-12/NN	prep_in||polymorphisms-6/NNS||cases-13/NNS	num||controls-16/NNS||4275-15/CD	prep_in||polymorphisms-6/NNS||controls-16/NNS	conj_and||cases-13/NNS||controls-16/NNS	vmod||polymorphisms-6/NNS||composed-18/VBN	prep_of||composed-18/VBN||european-20/NN	appos||european-20/NN||ea-22/NN	amod||aa-27/NN||african-american-25/JJ	prep_of||composed-18/VBN||aa-27/NN	conj_and||european-20/NN||aa-27/NN	nn||ancestry-32/NN||asian-31/NN	prep_of||composed-18/VBN||ancestry-32/NN	conj_and||european-20/NN||ancestry-32/NN	ea-22||sle-12||no_rel||we studied ifnk single nucleotide polymorphisms (snps) in 3982 sle cases and 4275 controls, composed of european (ea), african-american (aa), and asian ancestry.
det||dacarbazine-4/NN||the-1/DT	amod||dacarbazine-4/NN||alkylating-2/JJ	nn||dacarbazine-4/NN||agent-3/NN	nsubjpass||used-10/VBN||dacarbazine-4/NN	dep||dacarbazine-4/NN||dtic-6/JJ	aux||used-10/VBN||has-8/VBZ	auxpass||used-10/VBN||been-9/VBN	root||ROOT-0/null||used-10/VBN	det||treatment-13/NN||the-12/DT	prep_in||used-10/VBN||treatment-13/NN	prep_of||treatment-13/NN||melanoma-15/NN	prep_for||melanoma-15/NN||decades-17/NNS	advmod||used-21/VBN||when-20/WRB	advcl||achieved-32/VBN||used-21/VBN	det||monotherapy-24/NN||a-23/DT	prep_as||used-21/VBN||monotherapy-24/NN	prep_for||monotherapy-24/NN||cancer-26/NN	advmod||achieved-32/VBN||only-27/RB	amod||rates-30/NNS||moderate-28/JJ	nn||rates-30/NNS||response-29/NN	nsubjpass||achieved-32/VBN||rates-30/NNS	auxpass||achieved-32/VBN||are-31/VBP	conj_but||used-10/VBN||achieved-32/VBN	melanoma-15||dacarbazine-4||yes||the alkylating agent dacarbazine (dtic) has been used in the treatment of melanoma for decades, but when used as a monotherapy for cancer only moderate response rates are achieved.
nsubj||unclear-26/JJ||factor-1/NN	vmod||factor-1/NN||causing-2/VBG	det||elimination-4/NN||the-3/DT	dobj||causing-2/VBG||elimination-4/NN	det||biotype-8/NN||the-6/DT	amod||biotype-8/NN||classical-7/JJ	prep_of||elimination-4/NN||biotype-8/NN	prep_of||biotype-8/NN||vibriocholeraeo1-10/CD	poss||replacement-14/NN||its-13/PRP$	dobj||causing-2/VBG||replacement-14/NN	conj_and||elimination-4/NN||replacement-14/NN	det||biotype-19/NN||the-16/DT	nn||biotype-19/NN||el-17/NN	nn||biotype-19/NN||tor-18/NN	prep_by||replacement-14/NN||biotype-19/NN	vmod||causing-2/VBG||causing-20/VBG	det||pandemic-24/NN||the-21/DT	amod||pandemic-24/NN||7th-22/JJ	nn||pandemic-24/NN||cholera-23/NN	dobj||causing-20/VBG||pandemic-24/NN	cop||unclear-26/JJ||are-25/VBP	root||ROOT-0/null||unclear-26/JJ	cholera-23||vibriocholeraeo1-10||no||factor causing the elimination of the classical biotype of vibriocholeraeo1, and its replacement by the el tor biotype causing the 7th cholera pandemic are unclear.
nsubjpass||used-8/VBN||supplementation-1/NN	nsubj||treat-10/VB||supplementation-1/NN	prep_of||supplementation-1/NN||l-3/NN	dep||l-3/NN||arginine-5/NN	aux||used-8/VBN||has-6/VBZ	auxpass||used-8/VBN||been-7/VBN	ccomp||caused-27/VBD||used-8/VBN	aux||treat-10/VB||to-9/TO	xcomp||used-8/VBN||treat-10/VB	dobj||treat-10/VB||melas-11/NNS	amod||encephalopathy-14/NN||mitochondrial-13/JJ	dep||melas-11/NNS||encephalopathy-14/NN	amod||acidosis-17/NNS||lactic-16/JJ	prep_with||encephalopathy-14/NN||acidosis-17/NNS	dep||melas-11/NNS||stroke-19/NN	conj_and||encephalopathy-14/NN||stroke-19/NN	prep_like||stroke-19/NN||syndrome-21/NN	det||disease-26/NN||a-24/DT	amod||disease-26/NN||mitochondrial-25/JJ	nsubj||caused-27/VBD||disease-26/NN	root||ROOT-0/null||caused-27/VBD	det||mutation-34/NN||the-29/DT	amod||mutation-34/NN||m.-30/JJ	amod||mutation-34/NN||3243a-31/JJ	nn||mutation-34/NN||>-32/NN	nn||mutation-34/NN||g-33/NN	prep_by||caused-27/VBD||mutation-34/NN	arginine-5||stroke-19||no_rel||supplementation of l -arginine has been used to treat melas (mitochondrial encephalopathy with lactic acidosis and stroke like syndrome), a mitochondrial disease caused by the m.3243a>g mutation.
det||approval-4/NN||the-2/DT	amod||approval-4/NN||recent-3/JJ	prep_with||available-38/JJ||approval-4/NN	prep_of||approval-4/NN||pazopanib-6/NN	det||inhibitor-13/NN||an-8/DT	amod||inhibitor-13/NN||oral-9/JJ	amod||inhibitor-13/NN||multitargeted-10/JJ	nn||inhibitor-13/NN||tyrosine-11/NN	nn||inhibitor-13/NN||kinase-12/NN	nsubj||targets-16/VBZ||inhibitor-13/NN	nsubj||available-38/JJ||inhibitor-13/NN	advmod||targets-16/VBZ||potently-15/RB	rcmod||inhibitor-13/NN||targets-16/VBZ	amod||factor-20/NN||vascular-17/JJR	amod||factor-20/NN||endothelial-18/JJ	nn||factor-20/NN||growth-19/NN	nsubj||receptors-21/VBZ||factor-20/NN	ccomp||targets-16/VBZ||receptors-21/VBZ	amod||$-23/$||1â-22/VBD	dobj||receptors-21/VBZ||$-23/$	num||$-23/$||3-25/CD	amod||factor-29/NN||platelet-derived-27/JJ	nn||factor-29/NN||growth-28/NN	conj_and||inhibitor-13/NN||factor-29/NN	nsubj||targets-16/VBZ||factor-29/NN	nsubj||available-38/JJ||factor-29/NN	conj_and||inhibitor-13/NN||c-kit-32/NN	nsubj||targets-16/VBZ||c-kit-32/NN	nsubj||available-38/JJ||c-kit-32/NN	num||agents-35/NNS||six-34/CD	appos||c-kit-32/NN||agents-35/NNS	cop||available-38/JJ||are-36/VBP	advmod||available-38/JJ||now-37/RB	root||ROOT-0/null||available-38/JJ	prep_for||available-38/JJ||use-40/NN	det||management-43/NN||the-42/DT	prep_in||use-40/NN||management-43/NN	amod||renalcellcarcinoma-46/NN||metastatic-45/JJ	prep_of||management-43/NN||renalcellcarcinoma-46/NN	discourse||renalcellcarcinoma-46/NN||rcc-48/UH	rcc-48||tyrosine-11||no_rel||with the recent approval of pazopanib, an oral multitargeted tyrosine kinase inhibitor which potently targets vascular endothelial growth factor receptors 1â3, platelet-derived growth factor, and c-kit, six agents are now available for use in the management of metastatic renalcellcarcinoma (rcc).
amod||viruses-3/NNS||classically-1/JJ	amod||viruses-3/NNS||attenuated-2/JJ	nsubj||proven-16/VBN||viruses-3/NNS	nsubj||means-21/NN||viruses-3/NNS	appos||viruses-3/NNS||those-5/DT	vmod||those-5/DT||created-6/VBN	agent||created-6/VBN||passaging-8/VBG	det||virus-10/NN||a-9/DT	dobj||passaging-8/VBG||virus-10/NN	amod||cells-13/NNS||cultured-12/JJ	prep_in||passaging-8/VBG||cells-13/NNS	aux||proven-16/VBN||have-15/VBP	root||ROOT-0/null||proven-16/VBN	aux||means-21/NN||to-17/TO	cop||means-21/NN||be-18/VB	det||means-21/NN||an-19/DT	amod||means-21/NN||effective-20/JJ	xcomp||proven-16/VBN||means-21/NN	prepc_for||means-21/NN||preventing-23/VBG	amod||viraldiseases-25/NNS||many-24/JJ	dobj||preventing-23/VBG||viraldiseases-25/NNS	prep_including||proven-16/VBN||smallpox-28/NN	prep_including||proven-16/VBN||polio-30/NNP	conj_and||smallpox-28/NN||polio-30/NNP	prep_including||proven-16/VBN||measles-32/NNS	conj_and||smallpox-28/NN||measles-32/NNS	prep_including||proven-16/VBN||mumps-34/NNS	conj_and||smallpox-28/NN||mumps-34/NNS	amod||fever-38/NN||yellow-37/JJ	prep_including||proven-16/VBN||fever-38/NN	conj_and||smallpox-28/NN||fever-38/NN	virus-10||viruses-3||no||classically attenuated viruses, those created by passaging a virus in cultured cells, have proven to be an effective means for preventing many viraldiseases, including smallpox, polio, measles, mumps, and yellow fever.
det||framework-3/NN||the-2/DT	prep_within||isolated-15/VBD||framework-3/NN	det||-rrb--11/NNP||a-5/DT	amod||-rrb--11/NNP||dutch-german-6/JJ	nn||-rrb--11/NNP||network-7/NN	nn||-rrb--11/NNP||project-8/NN	nn||-rrb--11/NNP||-lrb--9/NNP	nn||-rrb--11/NNP||euregio-10/NNP	prep_of||framework-3/NN||-rrb--11/NNP	num||mrsa-14/NN||14,036-13/CD	nsubj||isolated-15/VBD||mrsa-14/NN	ccomp||subjected-55/VBN||isolated-15/VBD	amod||-lrb--21/NNS||clinical-17/JJ	conj_and||clinical-17/JJ||screening-19/NN	amod||-lrb--21/NNS||screening-19/NN	nn||-lrb--21/NNS||specimens-20/NNS	prep_from||isolated-15/VBD||-lrb--21/NNS	tmod||isolated-15/VBD||january-22/NNP	num||january-22/NNP||2008-23/CD	nn||-rrb--27/NNP||june-25/NNP	nn||-rrb--27/NNP||2012-26/NNP	parataxis||isolated-15/VBD||-rrb--27/NNP	vmod||-rrb--27/NNP||derived-28/VBN	amod||patients-31/NNS||human-30/JJ	prep_from||derived-28/VBN||patients-31/NNS	prep_in||patients-31/NNS||hospitals-33/NNS	amod||practices-40/NNS||general-37/JJ	conj_or||general-37/JJ||specialized-39/JJ	amod||practices-40/NNS||specialized-39/JJ	parataxis||isolated-15/VBD||practices-40/NNS	conj_and||-rrb--27/NNP||practices-40/NNS	det||region-44/NN||a-42/DT	nn||region-44/NN||german-43/NN	prep_in||practices-40/NNS||region-44/NN	vmod||region-44/NN||characterized-45/VBN	det||density-49/NN||a-47/DT	amod||density-49/NN||high-48/JJ	agent||characterized-45/VBN||density-49/NN	nn||production-52/NN||livestock-51/NN	prep_of||density-49/NN||production-52/NN	auxpass||subjected-55/VBN||were-54/VBD	root||ROOT-0/null||subjected-55/VBN	amod||protein-58/NN||s.aureus-57/JJ	prep_to||subjected-55/VBN||protein-58/NN	det||sequence-63/NN||a-59/DT	amod||sequence-63/NN||-lrb--60/JJ	nn||sequence-63/NN||spa-61/NN	nn||sequence-63/NN||-rrb--62/NN	nsubjpass||subjected-55/VBN||sequence-63/NN	dep||sequence-63/NN||typing-64/VBG	mrsa-14||s.aureus-57||no||within the framework of a dutch-german network project -lrb- euregio -rrb- , 14,036 mrsa isolated from clinical and screening specimens -lrb- january 2008 - june 2012 -rrb- derived from human patients in hospitals as well as general or specialized practices in a german region characterized by a high density of livestock production , were subjected to s.aureus protein a -lrb- spa -rrb- sequence typing .
nsubj||received-9/VBD||patients-1/NNS	amod||hypertension-4/NN||uncontrolled-3/JJ	prep_with||patients-1/NNS||hypertension-4/NN	amod||risk-8/NN||added-6/VBN	amod||risk-8/NN||cardiovascular-7/JJ	prep_with||patients-1/NNS||risk-8/NN	conj_and||hypertension-4/NN||risk-8/NN	root||ROOT-0/null||received-9/VBD	det||combination-12/NN||a-10/DT	amod||combination-12/NN||fixed-dose-11/JJ	dobj||received-9/VBD||combination-12/NN	amod||mg-16/NN||candesartancilexetil-14/JJ	dep||candesartancilexetil-14/JJ||16-15/CD	prep_of||combination-12/NN||mg-16/NN	nn||mg-20/NN||hctz-18/NN	num||mg-20/NN||12.5-19/CD	prep_of||combination-12/NN||mg-20/NN	conj_and||mg-16/NN||mg-20/NN	nn||group-24/NN||combination-22/NN	nn||group-24/NN||therapy-23/NN	dep||mg-20/NN||group-24/NN	amod||monotherapy-28/NN||high-dose-27/JJ	dobj||received-9/VBD||monotherapy-28/NN	conj_or||combination-12/NN||monotherapy-28/NN	amod||mg-32/NN||candesartancilexetil-30/JJ	dep||candesartancilexetil-30/JJ||32-31/CD	prep_with||monotherapy-28/NN||mg-32/NN	amod||group-36/NN||high-dose-34/JJ	amod||group-36/NN||monotherapy-35/JJ	appos||mg-32/NN||group-36/NN	hypertension-4||candesartancilexetil-30||yes||patients with uncontrolled hypertension and added cardiovascular risk received a fixed-dose combination of candesartancilexetil 16 mg and hctz 12.5 mg (combination therapy group) or high-dose monotherapy with candesartancilexetil 32 mg (high-dose monotherapy group).
amod||reduction-2/NN||comparable-1/JJ	nsubjpass||observed-7/VBN||reduction-2/NN	amod||lesions-5/NNS||acne-4/JJ	prep_of||reduction-2/NN||lesions-5/NNS	auxpass||observed-7/VBN||was-6/VBD	root||ROOT-0/null||observed-7/VBN	det||groups-13/NNS||the-9/DT	nn||groups-13/NNS||taubr-10/NN	conj_and||taubr-10/NN||clindamycin-12/NN	nn||groups-13/NNS||clindamycin-12/NN	prep_in||observed-7/VBN||groups-13/NNS	prep_of||groups-13/NNS||patients-15/NNS	amod||acnevulgaris-22/NNS||mild-17/JJ	conj_and||mild-17/JJ||moderate-19/JJ	amod||acnevulgaris-22/NNS||moderate-19/JJ	amod||acnevulgaris-22/NNS||inflammatory-20/JJ	amod||acnevulgaris-22/NNS||facial-21/JJ	prep_with||patients-15/NNS||acnevulgaris-22/NNS	acnevulgaris-22||clindamycin-12||yes||comparable reduction of acne lesions was observed in the taubr and clindamycin groups of patients with mild and moderate inflammatory facial acnevulgaris.
amod||levels-5/NNS||optimize-2/JJ	nn||levels-5/NNS||tta-3/NN	nn||levels-5/NNS||expression-4/NN	prep_to||tested-14/VBN||levels-5/NNS	amod||promoters-8/NNS||several-7/JJ	nsubjpass||tested-14/VBN||promoters-8/NNS	amod||expression-12/NN||driving-10/VBG	nn||expression-12/NN||tta-11/NN	prep_for||promoters-8/NNS||expression-12/NN	auxpass||tested-14/VBN||were-13/VBD	root||ROOT-0/null||tested-14/VBN	det||promoter-23/NN||the-17/DT	amod||humancytomegalovirus-19/NNS||weakest-18/JJS	nn||promoter-23/NN||humancytomegalovirus-19/NNS	appos||humancytomegalovirus-19/NNS||cmv-21/NN	nsubj||showed-24/VBD||promoter-23/NN	conj_and||tested-14/VBN||showed-24/VBD	det||ratio-28/NN||the-25/DT	dep||induction/background-27/JJ||best-26/JJS	amod||ratio-28/NN||induction/background-27/JJ	dobj||showed-24/VBD||ratio-28/NN	cmv-21||humancytomegalovirus-19||no||to optimize tta expression levels, several promoters for driving tta expression were tested, and the weakest humancytomegalovirus (cmv) promoter showed the best induction/background ratio.
det||study-2/NN||this-1/DT	nsubjpass||done-4/VBN||study-2/NN	nsubj||evaluate-6/VB||study-2/NN	auxpass||done-4/VBN||was-3/VBD	root||ROOT-0/null||done-4/VBN	aux||evaluate-6/VB||to-5/TO	xcomp||done-4/VBN||evaluate-6/VB	det||effect-8/NN||the-7/DT	dobj||evaluate-6/VB||effect-8/NN	nn||relief-11/NN||pain-10/NN	prep_on||evaluate-6/VB||relief-11/NN	advmod||added-15/VBN||when-12/WRB	nsubjpass||added-15/VBN||acetaminophen-13/NN	nsubj||lidocaine-17/VB||acetaminophen-13/NN	auxpass||added-15/VBN||was-14/VBD	advcl||evaluate-6/VB||added-15/VBN	aux||lidocaine-17/VB||to-16/TO	xcomp||added-15/VBN||lidocaine-17/VB	amod||anesthesia-21/NN||intravenous-19/JJ	amod||anesthesia-21/NN||regional-20/JJ	prep_for||lidocaine-17/VB||anesthesia-21/NN	appos||anesthesia-21/NN||ivra-23/NNP	pain-10||acetaminophen-13||yes||this study was done to evaluate the effect on pain relief when acetaminophen was added to lidocaine for intravenous regional anesthesia (ivra).
nsubj||protein-6/NN||adiponectin-1/NN	cop||protein-6/NN||is-2/VBZ	det||protein-6/NN||an-3/DT	advmod||related-5/VBN||obesity-4/RB	amod||protein-6/NN||related-5/VBN	root||ROOT-0/null||protein-6/NN	nsubj||mediates-8/VBZ||that-7/WDT	ccomp||protein-6/NN||mediates-8/VBZ	det||risk-10/NN||the-9/DT	dobj||mediates-8/VBZ||risk-10/NN	prep_of||risk-10/NN||type2diabetes-12/NNS	amod||individuals-15/NNS||obese-14/JJ	prep_in||type2diabetes-12/NNS||individuals-15/NNS	poss||anti-inflammatory-18/NN||its-17/PRP$	prep_with||mediates-8/VBZ||anti-inflammatory-18/NN	nn||properties-21/NNS||insulin-sensitizing-20/NN	prep_with||mediates-8/VBZ||properties-21/NNS	conj_and||anti-inflammatory-18/NN||properties-21/NNS	anti-inflammatory-18||obesity-4||no_rel||adiponectin is an obesity related protein that mediates the risk of type2diabetes in obese individuals with its anti-inflammatory and insulin-sensitizing properties.
mark||highest-9/JJS||although-1/IN	det||amount-3/NN||the-2/DT	nsubj||highest-9/JJS||amount-3/NN	nsubj||lowest-18/JJS||amount-3/NN	nn||expression-7/NN||hbz-5/NN	nn||expression-7/NN||mrna-6/NN	prep_of||amount-3/NN||expression-7/NN	cop||highest-9/JJS||was-8/VBD	advcl||differed-36/VBD||highest-9/JJS	prep_in||highest-9/JJS||atl-11/NN	conj_and||highest-9/JJS||medium-13/NN	advcl||differed-36/VBD||medium-13/NN	prep_in||medium-13/NN||ham/tsp-15/NN	conj_and||highest-9/JJS||lowest-18/JJS	advcl||differed-36/VBD||lowest-18/JJS	prep_in||lowest-18/JJS||hcs-20/NN	amod||significance-24/NN||statistical-23/JJ	prep_with||highest-9/JJS||significance-24/NN	preconj||tax-27/NN||neither-26/CC	nsubj||differed-36/VBD||tax-27/NN	det||expression-32/NN||the-29/DT	nn||expression-32/NN||hbz-30/NN	nn||expression-32/NN||mrna-31/NN	conj_nor||tax-27/NN||expression-32/NN	nsubj||differed-36/VBD||expression-32/NN	amod||cell-35/NN||htlv-1-infected-34/JJ	prep_per||expression-32/NN||cell-35/NN	root||ROOT-0/null||differed-36/VBD	advmod||differed-36/VBD||significantly-37/RB	det||group-41/NN||each-39/DT	amod||group-41/NN||clinical-40/JJ	prep_between||differed-36/VBD||group-41/NN	ham--1||htlv-1--1||no||although the amount of hbz mrna expression was highest in atl, medium in ham/tsp, and lowest in hcs, with statistical significance, neither tax nor the hbz mrna expression per htlv-1-infected cell differed significantly between each clinical group.
det||objective-2/NN||the-1/DT	nsubj||was-6/VBD||objective-2/NN	nsubj||compare-8/VB||objective-2/NN	det||trial-5/NN||this-4/DT	prep_of||objective-2/NN||trial-5/NN	root||ROOT-0/null||was-6/VBD	aux||compare-8/VB||to-7/TO	xcomp||was-6/VBD||compare-8/VB	amod||regimen-10/NN||cisplatin-plus-vinorelbine-9/JJ	dobj||compare-8/VB||regimen-10/NN	amod||regimen-13/NN||cisplatin-plus-gemcitabine-12/JJ	prep_with||compare-8/VB||regimen-13/NN	prep_in||regimen-13/NN||patients-15/NNS	nn||non-smallcelllungcancer-19/NN||stage-17/NN	amod||non-smallcelllungcancer-19/NN||iiib-iv-18/JJ	prep_with||patients-15/NNS||non-smallcelllungcancer-19/NN	dep||non-smallcelllungcancer-19/NN||nsclc-21/JJ	nsclc-21||vinorelbine--1||yes||the objective of this trial was to compare cisplatin-plus-vinorelbine regimen with cisplatin-plus-gemcitabine regimen in patients with stage iiib-iv non-smallcelllungcancer (nsclc).
mark||identify-4/VB||in-1/IN	dep||identify-4/VB||order-2/NN	aux||identify-4/VB||to-3/TO	advcl||treated-15/VBD||identify-4/VB	dobj||identify-4/VB||genes-5/NNS	nsubjpass||regulated-9/VBN||genes-5/NNS	auxpass||regulated-9/VBN||are-7/VBP	advmod||regulated-9/VBN||epigenetically-8/RB	rcmod||genes-5/NNS||regulated-9/VBN	nn||tumors-12/NNS||neuroblastoma-11/NN	prep_in||regulated-9/VBN||tumors-12/NNS	nsubj||treated-15/VBD||we-14/PRP	root||ROOT-0/null||treated-15/VBD	num||lines-19/NNS||four-16/CD	nn||lines-19/NNS||neuroblastoma-17/NN	nn||lines-19/NNS||cell-18/NN	dobj||treated-15/VBD||lines-19/NNS	det||agent-23/NN||the-21/DT	amod||agent-23/NN||demethylating-22/JJ	prep_with||lines-19/NNS||agent-23/NN	amod||agent-23/NN||5-aza-2-24/JJ	dep||agent-23/NN||deoxycytidine-27/NN	dep||agent-23/NN||5-aza-dc-29/JJ	dep||lines-19/NNS||either-31/DT	dep||either-31/DT||separately-32/RB	dep||lines-19/NNS||in-34/IN	conj_or||either-31/DT||in-34/IN	pobj||in-34/IN||conjunction-35/NN	det||inhibitor-40/NN||the-37/DT	amod||inhibitor-40/NN||histone-38/JJ	nn||inhibitor-40/NN||deacetylase-39/NN	prep_with||conjunction-35/NN||inhibitor-40/NN	vmod||inhibitor-40/NN||trichostatin-41/VBN	det||tsa-44/NN||a-42/DT	dep||trichostatin-41/VBN||tsa-44/NN	neuroblastoma-17||aza--1||no_rel||in order to identify genes that are epigenetically regulated in neuroblastoma tumors, we treated four neuroblastoma cell lines with the demethylating agent 5-aza-2'-deoxycytidine (5-aza-dc) either separately or in conjunction with the histone deacetylase inhibitor trichostatin a (tsa).
det||development-2/NN||the-1/DT	nsubjpass||posited-6/VBN||development-2/NN	nsubj||involve-8/VB||development-2/NN	prep_of||development-2/NN||alcoholdependence-4/NN	auxpass||posited-6/VBN||is-5/VBZ	root||ROOT-0/null||posited-6/VBN	aux||involve-8/VB||to-7/TO	xcomp||posited-6/VBN||involve-8/VB	amod||changes-10/NNS||numerous-9/JJ	dobj||involve-8/VB||changes-10/NNS	nn||chemistry-13/NN||brain-12/NN	prep_in||involve-8/VB||chemistry-13/NN	nsubj||lead-20/VBP||chemistry-13/NN	nsubj||physiological-22/VB||chemistry-13/NN	nsubj||promote-33/VB||chemistry-13/NN	dep||neurotransmission-17/JJ||i.e.-15/FW	dep||chemistry-13/NN||neurotransmission-17/JJ	rcmod||chemistry-13/NN||lead-20/VBP	aux||physiological-22/VB||to-21/TO	xcomp||lead-20/VBP||physiological-22/VB	dobj||physiological-22/VB||signs-23/NNS	prep_of||signs-23/NNS||withdrawal-25/NN	prep_upon||physiological-22/VB||abstinence-27/NN	prep_from||physiological-22/VB||alcohol-29/NN	xcomp||lead-20/VBP||promote-33/VB	conj_and||physiological-22/VB||promote-33/VB	dobj||promote-33/VB||vulnerability-34/NN	aux||relapse-36/VB||to-35/TO	vmod||promote-33/VB||relapse-36/VB	amod||people-39/NNS||dependent-38/JJ	prep_in||relapse-36/VB||people-39/NNS	alcoholdependence-4||alcohol-29||no||the development of alcoholdependence is posited to involve numerous changes in brain chemistry (i.e., neurotransmission) that lead to physiological signs of withdrawal upon abstinence from alcohol as well as promote vulnerability to relapse in dependent people.
nsubj||likely-9/JJ||persons-1/NNS	nsubjpass||older-16/JJR||persons-1/NNS	nsubjpass||admitted-18/VBN||persons-1/NNS	prep_without||persons-1/NNS||hiv/aids-3/NNS	vmod||hiv/aids-3/NNS||hospitalized-4/VBN	prep_with||hospitalized-4/VBN||cryptococcosis-6/NNS	cop||likely-9/JJ||were-7/VBD	advmod||likely-9/JJ||more-8/RBR	root||ROOT-0/null||likely-9/JJ	prep_than||likely-9/JJ||those-11/DT	prep_with||those-11/DT||hiv/aids-13/NNS	aux||older-16/JJR||to-14/TO	auxpass||older-16/JJR||be-15/VB	cop||older-16/JJR||be-15/VB	xcomp||likely-9/JJ||older-16/JJR	xcomp||likely-9/JJ||admitted-18/VBN	conj_and||older-16/JJR||admitted-18/VBN	amod||cryptococcosis-21/NNS||pulmonary-20/JJ	prep_for||admitted-18/VBN||cryptococcosis-21/NNS	aids--1||hiv--1||no||persons without hiv/aids hospitalized with cryptococcosis were more likely than those with hiv/aids to be older and admitted for pulmonary cryptococcosis.
det||study-4/NN||the-2/DT	amod||study-4/NN||present-3/JJ	prep_in||surveyed-7/VBD||study-4/NN	nsubj||surveyed-7/VBD||we-6/PRP	root||ROOT-0/null||surveyed-7/VBD	nn||distribution-9/NN||tissue-8/NN	dobj||surveyed-7/VBD||distribution-9/NN	nn||infectivity-12/NN||prion-11/NN	prep_of||distribution-9/NN||infectivity-12/NN	prep_in||surveyed-7/VBD||mice-14/NNS	prep_with||mice-14/NNS||priondisease-16/NN	priondisease-16||prion-11||no||in the present study, we surveyed tissue distribution of prion infectivity in mice with priondisease.
nsubj||drives-2/VBZ||bcgvaccine-1/NN	root||ROOT-0/null||drives-2/VBZ	det||immunity-9/NN||a-3/DT	amod||immunity-9/NN||strong-4/JJ	nn||immunity-9/NN||t-5/NN	nn||immunity-9/NN||helper-6/NN	num||immunity-9/NN||1-7/CD	amod||immunity-9/NN||cellular-8/JJ	dobj||drives-2/VBZ||immunity-9/NN	nsubj||essential-12/JJ||immunity-9/NN	cop||essential-12/JJ||is-11/VBZ	rcmod||immunity-9/NN||essential-12/JJ	det||protection-15/NN||the-14/DT	prep_for||essential-12/JJ||protection-15/NN	prep_against||protection-15/NN||mycobacteria-17/NN	advmod||suggest-22/VBP||however-19/RB	amod||studies-21/NNS||recent-20/JJ	nsubj||suggest-22/VBP||studies-21/NNS	parataxis||drives-2/VBZ||suggest-22/VBP	mark||have-27/VB||that-23/IN	nn||vaccination-25/NN||bcg-24/NN	nsubj||have-27/VB||vaccination-25/NN	aux||have-27/VB||can-26/MD	ccomp||suggest-22/VBP||have-27/VB	amod||effects-30/NNS||non-specific-28/JJ	amod||effects-30/NNS||beneficial-29/JJ	nsubj||unrelated-31/JJ||effects-30/NNS	xcomp||have-27/VB||unrelated-31/JJ	prep_to||have-27/VB||tuberculosis-33/NNP	tuberculosis-33||bcgvaccine-1||yes||bcgvaccine drives a strong t helper 1 cellular immunity which is essential for the protection against mycobacteria, however recent studies suggest that bcg vaccination can have non-specific beneficial effects unrelated to tuberculosis.
mark||immunization-3/NN||upon-1/IN	nn||immunization-3/NN||rabbit-2/NN	advcl||elicited-8/VBD||immunization-3/NN	det||proteins-7/NNS||both-5/DT	nn||proteins-7/NNS||ha-6/NN	nsubj||elicited-8/VBD||proteins-7/NNS	root||ROOT-0/null||elicited-8/VBD	amod||antibodies-10/NNS||neutralizing-9/VBG	dobj||elicited-8/VBD||antibodies-10/NNS	det||virus-14/NN||the-12/DT	amod||virus-14/NN||homologous-13/JJ	prep_against||antibodies-10/NNS||virus-14/NN	dep||virus-14/NN||a/vietnam/1203-16/NNP	punct||a/vietnam/1203-16/NNP||/-17/:	dep||a/vietnam/1203-16/NNP||2004-18/CD	appos||2004-18/CD||clade-20/NN	num||clade-20/NN||1-21/CD	amod||antibodies-27/NNS||cross-neutralizing-26/JJ	dobj||elicited-8/VBD||antibodies-27/NNS	conj_and||antibodies-10/NNS||antibodies-27/NNS	amod||h5n1-30/NNS||heterologous-29/JJ	prep_against||antibodies-27/NNS||h5n1-30/NNS	amod||h5n1-30/NNS||clade-31/JJ	num||strains-33/NNS||2-32/CD	dep||clade-31/JJ||strains-33/NNS	amod||/-37/NNP||a/indonesia/5-36/JJ	prep_including||h5n1-30/NNS||/-37/NNP	num||/-37/NNP||2005-38/CD	virus-14||antibodies-27||no_rel||upon rabbit immunization, both ha proteins elicited neutralizing antibodies against the homologous virus (a/vietnam/1203/2004, clade 1) as well as cross-neutralizing antibodies against heterologous h5n1 clade 2 strains, including a/indonesia/5/2005.
nsubj||analogue-5/NN||adefovir-1/NN	cop||analogue-5/NN||is-2/VBZ	det||analogue-5/NN||an-3/DT	amod||analogue-5/NN||adenosine-4/JJ	root||ROOT-0/null||analogue-5/NN	vmod||analogue-5/NN||approved-6/VBN	det||administration-12/NN||the-8/DT	nn||administration-12/NN||food-9/NN	conj_and||food-9/NN||drug-11/NN	nn||administration-12/NN||drug-11/NN	agent||approved-6/VBN||administration-12/NN	det||treatment-15/NN||the-14/DT	prep_for||administration-12/NN||treatment-15/NN	nn||mutations-19/NNS||chronichepatitisb-17/NNP	prep_of||treatment-15/NN||mutations-19/NNS	vmod||mutations-19/NNS||occurring-20/VBG	det||virus-24/NN||the-22/DT	amod||virus-24/NN||hepatitisb-23/JJ	prep_in||occurring-20/VBG||virus-24/NN	amod||-rrb--27/NNS||-lrb--25/JJ	nn||-rrb--27/NNS||hbv-26/NN	nsubj||transcriptase-29/VBP||-rrb--27/NNS	advmod||transcriptase-29/VBP||reverse-28/RB	rcmod||virus-24/NN||transcriptase-29/VBP	amod||domains-33/NNS||-lrb--30/JJ	nn||domains-33/NNS||rt-31/NN	nn||domains-33/NNS||-rrb--32/NN	nsubjpass||shown-35/VBN||domains-33/NNS	nsubj||confer-37/VB||domains-33/NNS	auxpass||shown-35/VBN||are-34/VBP	ccomp||transcriptase-29/VBP||shown-35/VBN	aux||confer-37/VB||to-36/TO	xcomp||shown-35/VBN||confer-37/VB	dobj||confer-37/VB||resistance-38/NN	prep_to||confer-37/VB||antiviraldrugs-40/NNS	hbv-26||adefovir-1||yes||adefovir is an adenosine analogue approved by the food and drug administration for the treatment of chronichepatitisb. mutations occurring in the hepatitisb virus -lrb- hbv -rrb- reverse transcriptase -lrb- rt -rrb- domains are shown to confer resistance to antiviraldrugs .
amod||patients-2/NNS||many-1/JJ	nsubj||take-5/VBP||patients-2/NNS	prep_with||patients-2/NNS||osteoarthritis-4/NNS	root||ROOT-0/null||take-5/VBP	amod||anti-inflammatorydrugs-7/NNS||nonsteroidal-6/JJ	iobj||take-5/VBP||anti-inflammatorydrugs-7/NNS	appos||term-12/NN||nsaids-9/NNS	amod||term-12/NN||long-11/JJ	dobj||take-5/VBP||term-12/NN	nn||control-15/NN||pain-14/NN	prep_for||term-12/NN||control-15/NN	nsaids-9||osteoarthritis-4||no_rel||many patients with osteoarthritis take nonsteroidal anti-inflammatorydrugs (nsaids) long term for pain control.
det||complex-3/NN||the-1/DT	amod||complex-3/NN||enzyme-2/JJ	nsubj||contains-4/VBZ||complex-3/NN	root||ROOT-0/null||contains-4/VBZ	num||components-7/NNS||two-5/CD	amod||components-7/NNS||main-6/JJ	dobj||contains-4/VBZ||components-7/NNS	amod||-rrb--14/NNS||telomerase-9/JJ	amod||-rrb--14/NNS||reverse-10/JJ	amod||-rrb--14/NNS||transcriptase-11/JJ	amod||-rrb--14/NNS||-lrb--12/JJ	nn||-rrb--14/NNS||tert-13/NN	dobj||contains-4/VBZ||-rrb--14/NNS	conj_and||components-7/NNS||-rrb--14/NNS	det||subunit-18/NN||the-16/DT	amod||subunit-18/NN||catalytic-17/JJ	dobj||contains-4/VBZ||subunit-18/NN	conj_and||components-7/NNS||subunit-18/NN	amod||-rrb--25/NNS||telomerase-21/JJ	nn||-rrb--25/NNS||rna-22/NN	nn||-rrb--25/NNS||-lrb--23/NN	nn||-rrb--25/NNS||tr-24/NN	dobj||contains-4/VBZ||-rrb--25/NNS	conj_and||components-7/NNS||-rrb--25/NNS	nsubj||serves-28/VBZ||-rrb--25/NNS	rcmod||-rrb--25/NNS||serves-28/VBZ	mark||encodes-59/VBZ||as-29/IN	det||-rrb--48/NN||a-30/DT	amod||-rrb--48/NN||template-31/JJ	det||addition-34/NN||the-33/DT	prep_for||template-31/JJ||addition-34/NN	amod||marek-42/NN||telomeric-36/JJ	nn||marek-42/NN||repeats-37/NNP	nn||marek-42/NN||-lrb--38/NNP	nn||marek-42/NN||ttaggg-39/NN	num||marek-42/NN||-rrb--40/CD	nn||marek-42/NN||n.-41/NN	poss||virus-45/NN||marek-42/NN	nn||virus-45/NN||disease-44/NN	prep_of||addition-34/NN||virus-45/NN	amod||-rrb--48/NN||-lrb--46/JJ	nn||-rrb--48/NN||mdv-47/NN	nsubj||encodes-59/VBZ||-rrb--48/NN	det||herpesvirus-52/NNS||an-50/DT	amod||herpesvirus-52/NNS||oncogenic-51/JJ	appos||-rrb--48/NN||herpesvirus-52/NNS	vmod||herpesvirus-52/NNS||inducing-53/VBG	amod||lymphoma-55/NN||fatal-54/JJ	dobj||inducing-53/VBG||lymphoma-55/NN	prep_in||inducing-53/VBG||chickens-57/NNS	advcl||serves-28/VBZ||encodes-59/VBZ	det||homologue-62/NN||a-60/DT	nn||homologue-62/NN||tr-61/NN	dobj||encodes-59/VBZ||homologue-62/NN	nsubj||contributes-72/VBZ||homologue-62/NN	amod||-rrb--68/NNS||viral-64/JJ	nn||-rrb--68/NNS||tr-65/NN	nn||-rrb--68/NNS||-lrb--66/NN	nn||-rrb--68/NNS||vtr-67/NN	appos||homologue-62/NN||-rrb--68/NNS	advmod||contributes-72/VBZ||significantly-71/RB	rcmod||homologue-62/NN||contributes-72/VBZ	amod||lymphomagenesis-75/NNS||mdv-induced-74/JJ	prep_to||contributes-72/VBZ||lymphomagenesis-75/NNS	marek's disease--1||herpesvirus-52||no||the enzyme complex contains two main components , telomerase reverse transcriptase -lrb- tert -rrb- , the catalytic subunit , and telomerase rna -lrb- tr -rrb- , which serves as a template for the addition of telomeric repeats -lrb- ttaggg -rrb- n. marek 's disease virus -lrb- mdv -rrb- , an oncogenic herpesvirus inducing fatal lymphoma in chickens , encodes a tr homologue , viral tr -lrb- vtr -rrb- , which significantly contributes to mdv-induced lymphomagenesis .
mark||multifold-10/VBN||since-1/IN	det||cause-4/NN||the-2/DT	amod||cause-4/NN||underlying-3/VBG	nsubjpass||multifold-10/VBN||cause-4/NN	prep_for||cause-4/NN||obesity-6/NN	prep_for||cause-4/NN||type2diabetes-8/NNS	conj_and||obesity-6/NN||type2diabetes-8/NNS	auxpass||multifold-10/VBN||is-9/VBZ	advcl||investigated-14/VBD||multifold-10/VBN	nsubj||investigated-14/VBD||we-12/PRP	nsubj||explored-29/VBD||we-12/PRP	advmod||investigated-14/VBD||further-13/RBR	root||ROOT-0/null||investigated-14/VBD	amod||effects-16/NNS||metabolic-15/JJ	dobj||investigated-14/VBD||effects-16/NNS	amod||supplementation-19/NN||leucine-18/JJ	prep_of||effects-16/NNS||supplementation-19/NN	amod||models-23/NNS||obese/diabetes-21/JJ	nn||models-23/NNS||mouse-22/NN	prep_in||supplementation-19/NN||models-23/NNS	amod||etiologies-26/NNS||different-25/JJ	prep_with||investigated-14/VBD||etiologies-26/NNS	conj_and||investigated-14/VBD||explored-29/VBD	det||mechanisms-33/NNS||the-30/DT	amod||mechanisms-33/NNS||underlying-31/JJ	amod||mechanisms-33/NNS||molecular-32/JJ	dobj||explored-29/VBD||mechanisms-33/NNS	leucine-18||obese--1||no_rel||since the underlying cause for obesity and type2diabetes is multifold, we further investigated metabolic effects of leucine supplementation in obese/diabetes mouse models with different etiologies, and explored the underlying molecular mechanisms.
amod||resonance-4/NN||manganese-enhanced-1/JJ	amod||resonance-4/NN||cardiovascular-2/JJ	amod||resonance-4/NN||magnetic-3/JJ	nsubj||assess-10/VB||resonance-4/NN	appos||resonance-4/NN||mecmr-6/NN	aux||assess-10/VB||can-8/MD	advmod||assess-10/VB||non-invasively-9/RB	root||ROOT-0/null||assess-10/VB	amod||influx-13/NN||myocardial-11/JJ	nn||influx-13/NN||calcium-12/NN	dobj||assess-10/VB||influx-13/NN	nn||levels-17/NNS||calcium-16/NN	nsubjpass||known-19/VBN||levels-17/NNS	nsubjpass||elevated-22/VBN||levels-17/NNS	auxpass||known-19/VBN||are-18/VBP	conj_and||assess-10/VB||known-19/VBN	aux||elevated-22/VBN||to-20/TO	auxpass||elevated-22/VBN||be-21/VB	xcomp||known-19/VBN||elevated-22/VBN	amod||cardiomyopathy-25/NN||musculardystrophy-24/JJ	prep_in||elevated-22/VBN||cardiomyopathy-25/NN	prepc_based_on||elevated-22/VBN||on-27/IN	amod||studies-29/NNS||cellular-28/JJ	pobj||elevated-22/VBN||studies-29/NNS	calcium-16||cardiomyopathy-25||no_rel||manganese-enhanced cardiovascular magnetic resonance (mecmr) can non-invasively assess myocardial calcium influx, and calcium levels are known to be elevated in musculardystrophy cardiomyopathy based on cellular studies.
nsubjpass||measured-3/VBN||glucose-1/NN	auxpass||measured-3/VBN||was-2/VBD	root||ROOT-0/null||measured-3/VBN	quantmod||times-7/NNS||at-4/IN	mwe||at-4/IN||least-5/JJS	pobj||at-4/IN||least-5/JJS	number||times-7/NNS||two-6/CD	dobj||measured-3/VBN||times-7/NNS	det||day-9/NN||a-8/DT	dep||times-7/NNS||day-9/NN	nsubjpass||divided-14/VBN||patients-12/NNS	auxpass||divided-14/VBN||were-13/VBD	conj_and||measured-3/VBN||divided-14/VBN	det||group-18/NN||the-16/DT	nn||group-18/NN||hyperglycaemia-17/NN	prep_into||divided-14/VBN||group-18/NN	nn||¥-23/NNP||glucose-20/NN	nn||¥-23/NNP||â-21/NN	nn||¥-23/NNP||-22/NNP	dep||mmol/l-25/JJ||¥-23/NNP	number||mmol/l-25/JJ||7.8-24/CD	dep||group-18/NN||mmol/l-25/JJ	nn||group-29/NN||normoglycaemia-28/NN	prep_into||divided-14/VBN||group-29/NN	conj_and||group-18/NN||group-29/NN	hyperglycaemia-17||glucose-20||no||glucose was measured at least two times a day, and patients were divided into the hyperglycaemia group (glucose â¥7.8 mmol/l) and normoglycaemia group.
nsubj||pathogen-11/NN||groupastreptococcus-1/NNS	dep||groupastreptococcus-1/NNS||gas-3/NN	appos||gas-3/NN||streptococcuspyogenes-5/NNS	cop||pathogen-11/NN||is-7/VBZ	det||pathogen-11/NN||a-8/DT	amod||pathogen-11/NN||gram-positive-9/JJ	amod||pathogen-11/NN||human-10/JJ	root||ROOT-0/null||pathogen-11/NN	amod||pathogen-11/NN||responsible-12/JJ	det||variety-16/NN||a-14/DT	amod||variety-16/NN||diverse-15/JJ	prep_for||responsible-12/JJ||variety-16/NN	prep_of||pathogen-11/NN||diseases-18/NNS	prep_including||pathogen-11/NN||pharyngitis-21/NNS	nn||infections-24/NNS||skin-23/NN	prep_including||pathogen-11/NN||infections-24/NNS	conj_and||pharyngitis-21/NNS||infections-24/NNS	amod||necrotizingfasciitis-27/NNS||invasive-26/JJ	prep_including||pathogen-11/NN||necrotizingfasciitis-27/NNS	conj_and||pharyngitis-21/NNS||necrotizingfasciitis-27/NNS	amod||sequelae-30/NN||autoimmune-29/JJ	prep_including||pathogen-11/NN||sequelae-30/NN	conj_and||pharyngitis-21/NNS||sequelae-30/NN	necrotizingfasciitis-27||streptococcuspyogenes-5||no||groupastreptococcus (gas, streptococcuspyogenes ) is a gram-positive human pathogen responsible for a diverse variety of diseases, including pharyngitis, skin infections, invasive necrotizingfasciitis and autoimmune sequelae.
mark||recognized-3/VBN||although-1/IN	advmod||recognized-3/VBN||increasingly-2/RB	advcl||development-13/NN||recognized-3/VBN	amod||surgery-6/NN||bariatric-5/JJ	prep_following||recognized-3/VBN||surgery-6/NN	nsubj||development-13/NN||this-8/DT	cop||development-13/NN||is-9/VBZ	det||development-13/NN||the-10/DT	amod||development-13/NN||first-11/JJ	amod||development-13/NN||reported-12/VBN	root||ROOT-0/null||development-13/NN	prep_of||development-13/NN||niphs-15/NNS	amod||syndrome-20/NN||non-insulinoma-17/JJ	nn||syndrome-20/NN||pancreatogenous-18/NN	nn||syndrome-20/NN||hypoglycemia-19/NN	appos||niphs-15/NNS||syndrome-20/NN	nn||surgery-24/NN||fundoplication-23/NN	prep_following||niphs-15/NNS||surgery-24/NN	det||use-32/NN||the-29/DT	amod||use-32/NN||first-30/JJ	amod||use-32/NN||documented-31/VBN	conj_and||development-13/NN||use-32/NN	prep_of||use-32/NN||octreotide-34/NN	amod||niphs-37/NNS||post-operative-36/JJ	prep_in||use-32/NN||niphs-37/NNS	hypoglycemia-19||octreotide-34||no_rel||although increasingly recognized following bariatric surgery, this is the first reported development of niphs (non-insulinoma pancreatogenous hypoglycemia syndrome) following fundoplication surgery, as well as the first documented use of octreotide in post-operative niphs.
det||consumption-8/NN||the-1/DT	amod||consumption-8/NN||acute-2/JJ	advmod||acute-2/JJ||hypersensitivity-3/RB	prep||acute-2/JJ||to-4/TO	conj_and||acute-2/JJ||increased-6/JJ	amod||consumption-8/NN||increased-6/JJ	amod||consumption-8/NN||voluntary-7/JJ	nsubj||observed-11/VBD||consumption-8/NN	prep_of||consumption-8/NN||ethanol-10/NN	root||ROOT-0/null||observed-11/VBD	amod||mice-15/NNS||lightweight-13/JJ	nn||mice-15/NNS||heterozygous-14/NNS	prep_in||observed-11/VBD||mice-15/NNS	prep_in||observed-11/VBD||combination-17/NN	det||elegans-26/NNS||the-19/DT	amod||elegans-26/NNS||observed-20/JJ	advmod||observed-20/JJ||hypersensitivity-21/RB	aux||ethanol-23/VB||to-22/TO	xcomp||observed-20/JJ||ethanol-23/VB	prep_in||ethanol-23/VB||c.-25/NN	prep_with||observed-11/VBD||elegans-26/NNS	amod||elegans-26/NNS||unc-79-27/JJ	amod||elegans-26/NNS||unc-80-29/JJ	conj_and||unc-79-27/JJ||unc-80-29/JJ	amod||elegans-26/NNS||nca-1-32/JJ	conj_and||unc-79-27/JJ||nca-1-32/JJ	amod||mutants-36/NNS||nca-2-34/JJ	amod||mutants-36/NNS||double-35/JJ	nsubj||suggests-37/VBZ||mutants-36/NNS	parataxis||observed-11/VBD||suggests-37/VBZ	det||pathway-41/NN||a-38/DT	amod||pathway-41/NN||novel-39/JJ	amod||pathway-41/NN||conserved-40/JJ	dobj||suggests-37/VBZ||pathway-41/NN	nsubj||influence-44/VB||pathway-41/NN	aux||influence-44/VB||might-43/MD	rcmod||pathway-41/NN||influence-44/VB	amod||behaviors-46/NNS||alcohol-related-45/JJ	dobj||influence-44/VB||behaviors-46/NNS	prep_in||influence-44/VB||humans-48/NNS	hypersensitivity-21||hypersensitivity-21||no||the acute hypersensitivity to and increased voluntary consumption of ethanol observed in lightweight heterozygous mice in combination with the observed hypersensitivity to ethanol in c. elegans unc-79 , unc-80 , and nca-1 ; nca-2 double mutants suggests a novel conserved pathway that might influence alcohol-related behaviors in humans .
aux||explore-2/VB||to-1/TO	advcl||conducted-27/VBN||explore-2/VB	dobj||explore-2/VB||beliefs-3/NNS	vmod||beliefs-3/NNS||relating-4/VBG	prep_to||relating-4/VBG||diet-6/NN	prep_to||relating-4/VBG||work-8/NN	conj_and||diet-6/NN||work-8/NN	prep_to||relating-4/VBG||hiv/aids-11/NN	conj_and||diet-6/NN||hiv/aids-11/NN	det||busoga-14/NN||the-13/DT	prep_among||diet-6/NN||busoga-14/NN	amod||uganda-18/NN||rural-16/JJ	amod||uganda-18/NN||southeastern-17/JJ	prep_of||busoga-14/NN||uganda-18/NN	det||survey-22/NN||a-20/DT	amod||survey-22/NN||cross-sectional-21/JJ	nsubjpass||conducted-27/VBN||survey-22/NN	amod||adults-25/NNS||322-24/JJ	prep_of||survey-22/NN||adults-25/NNS	auxpass||conducted-27/VBN||was-26/VBD	root||ROOT-0/null||conducted-27/VBN	prep_in||conducted-27/VBN||2007-29/CD	amod||district-32/NN||mayuge-31/JJ	prep_in||conducted-27/VBN||district-32/NN	appos||district-32/NN||uganda-34/NN	aids--1||hiv--1||no||to explore beliefs relating to diet, work, and hiv/aids among the busoga of rural southeastern uganda, a cross-sectional survey of 322 adults was conducted in 2007 in mayuge district, uganda.
nsubj||bacillus-2/VBZ||mycobacteriumbovis-1/NNS	ccomp||matter-30/NN||bacillus-2/VBZ	amod||rin-6/NN||calmette-3/JJ	nn||rin-6/NN||guã-4/NN	nn||rin-6/NN||©-5/NN	nsubj||vaccine-13/NN||rin-6/NN	appos||rin-6/NN||bcg-8/NN	cop||vaccine-13/NN||is-10/VBZ	det||vaccine-13/NN||a-11/DT	amod||vaccine-13/NN||sole-12/JJ	ccomp||bacillus-2/VBZ||vaccine-13/NN	advmod||used-15/VBN||currently-14/RB	vmod||vaccine-13/NN||used-15/VBN	prep_for||used-15/VBN||tb-17/NN	advmod||used-15/VBN||however-19/RB	det||efficacy-22/NN||the-21/DT	nsubj||matter-30/NN||efficacy-22/NN	prep_of||efficacy-22/NN||bcg-24/NN	prep_in||bcg-24/NN||adults-26/NNS	cop||matter-30/NN||is-27/VBZ	advmod||matter-30/NN||still-28/RB	det||matter-30/NN||a-29/DT	root||ROOT-0/null||matter-30/NN	prep_of||matter-30/NN||debate-32/NN	tb-17||bcg-24||no||mycobacteriumbovis bacillus calmette guã©rin (bcg) is a sole vaccine currently used for tb, however, the efficacy of bcg in adults is still a matter of debate.
nn||lines-2/NNS||melanoma-1/NN	nsubj||resistant-8/JJ||lines-2/NNS	nsubj||tmz-10/VB||lines-2/NNS	nsubj||fotemustine-12/JJ||lines-2/NNS	vmod||lines-2/NNS||expressing-3/VBG	nn||wild-type-5/NN||p53-4/NN	dobj||expressing-3/VBG||wild-type-5/NN	cop||resistant-8/JJ||were-6/VBD	advmod||resistant-8/JJ||more-7/RBR	root||ROOT-0/null||resistant-8/JJ	aux||tmz-10/VB||to-9/TO	xcomp||resistant-8/JJ||tmz-10/VB	conj_and||resistant-8/JJ||fotemustine-12/JJ	num||lines-17/NNS||p53-14/CD	amod||lines-17/NNS||mutant-15/JJ	nn||lines-17/NNS||melanoma-16/NN	prep_than||fotemustine-12/JJ||lines-17/NNS	nsubj||is-20/VBZ||lines-17/NNS	rcmod||lines-17/NNS||is-20/VBZ	amod||contrast-23/NN||marked-22/JJ	prep_in||is-20/VBZ||contrast-23/NN	amod||data-26/NNS||previous-25/JJ	prep_to||is-20/VBZ||data-26/NNS	vmod||data-26/NNS||reported-27/VBN	nn||cells-30/NNS||glioma-29/NN	prep_for||reported-27/VBN||cells-30/NNS	vmod||cells-30/NNS||treated-31/VBN	prep_with||treated-31/VBN||tmz-33/NN	melanoma-16||tmz-33||yes||melanoma lines expressing p53 wild-type were more resistant to tmz and fotemustine than p53 mutant melanoma lines, which is in marked contrast to previous data reported for glioma cells treated with tmz.
nsubjpass||shown-4/VBN||clozapine-1/NN	nsubj||superior-7/JJ||clozapine-1/NN	nsubj||chlorpromazine-9/VB||clozapine-1/NN	aux||shown-4/VBN||has-2/VBZ	auxpass||shown-4/VBN||been-3/VBN	root||ROOT-0/null||shown-4/VBN	aux||superior-7/JJ||to-5/TO	cop||superior-7/JJ||be-6/VB	xcomp||shown-4/VBN||superior-7/JJ	aux||chlorpromazine-9/VB||to-8/TO	xcomp||superior-7/JJ||chlorpromazine-9/VB	prepc_in||chlorpromazine-9/VB||improving-11/VBG	det||symptoms-16/NNS||the-12/DT	amod||symptoms-16/NNS||positive-13/JJ	conj_and||positive-13/JJ||negative-15/JJ	amod||symptoms-16/NNS||negative-15/JJ	dobj||improving-11/VBG||symptoms-16/NNS	prep_of||symptoms-16/NNS||schizophrenia-18/NN	schizophrenia-18||clozapine-1||yes||clozapine has been shown to be superior to chlorpromazine in improving the positive and negative symptoms of schizophrenia.
advmod||determined-29/VBN||here-1/RB	det||sequences-6/NNS||the-3/DT	amod||sequences-6/NNS||whole-4/JJ	amod||sequences-6/NNS||genome-5/JJ	nsubjpass||determined-29/VBN||sequences-6/NNS	nsubjpass||characterized-31/VBN||sequences-6/NNS	num||viruses-10/NNS||two-8/CD	amod||viruses-10/NNS||newcastledisease-9/JJ	prep_of||sequences-6/NNS||viruses-10/NNS	appos||sequences-6/NNS||ndv-12/NN	amod||viii-16/NNS||genotype-15/JJ	prep_of||sequences-6/NNS||viii-16/NNS	nsubjpass||isolated-20/VBN||viii-16/NNS	auxpass||isolated-20/VBN||were-19/VBD	rcmod||viii-16/NNS||isolated-20/VBN	amod||china-23/NN||west-22/JJ	prep_from||isolated-20/VBN||china-23/NN	det||1980s-26/NNS||the-25/DT	prep_in||china-23/NN||1980s-26/NNS	auxpass||determined-29/VBN||were-28/VBD	root||ROOT-0/null||determined-29/VBN	conj_and||determined-29/VBN||characterized-31/VBN	advmod||determined-29/VBN||phylogenetically-32/RB	newcastledisease-9||ndv-12||no||here, the whole genome sequences of two newcastledisease viruses (ndv) of genotype viii, which were isolated from west china in the 1980s, were determined and characterized phylogenetically.
amod||differences-2/NNS||regional-1/JJ	nsubj||depots-5/VBZ||differences-2/NNS	prep_among||differences-2/NNS||adipose-4/NN	root||ROOT-0/null||depots-5/VBZ	prep_in||depots-5/VBZ||capacities-7/NNS	amod||storage-10/NN||fattyacid-9/JJ	prep_for||capacities-7/NNS||storage-10/NN	advmod||depots-5/VBZ||susceptibility-12/RB	prep_to||depots-5/VBZ||hypoxia-14/NN	nsubj||contribute-19/VBP||inflammation-17/NN	advmod||contribute-19/VBP||likely-18/RB	conj_and||depots-5/VBZ||contribute-19/VBP	prep_to||contribute-19/VBP||complications-21/NNS	prep_of||complications-21/NNS||obesity-23/NN	inflammation-17||fattyacid-9||no_rel||regional differences among adipose depots in capacities for fattyacid storage, susceptibility to hypoxia, and inflammation likely contribute to complications of obesity.
amod||members-7/NNS||ninety-six/246-1/JJ	num||%-4/NN||39-3/CD	dep||ninety-six/246-1/JJ||%-4/NN	nn||members-7/NNS||family-6/NN	nsubj||hbv-seropositive-18/JJ||members-7/NNS	vmod||members-7/NNS||residing-8/VBG	amod||households-11/NNS||same-10/JJ	prep_at||residing-8/VBG||households-11/NNS	prepc_with||residing-8/VBG||hbsag-13/VBG	amod||participants-15/NNS||positive-14/JJ	dobj||hbsag-13/VBG||participants-15/NNS	cop||hbv-seropositive-18/JJ||were-16/VBD	advmod||hbv-seropositive-18/JJ||also-17/RB	root||ROOT-0/null||hbv-seropositive-18/JJ	number||74-20/CD||-LSB--19/CD	dep||hbv-seropositive-18/JJ||74-20/CD	num||%-23/NN||30.1-22/CD	appos||74-20/CD||%-23/NN	prep_for||74-20/CD||anti-hbc-26/CD	prep_for||74-20/CD||22-28/CD	conj_and||anti-hbc-26/CD||22-28/CD	num||%-31/NN||8.9-30/CD	appos||anti-hbc-26/CD||%-31/NN	det||-RSB--38/NN||both-34/DT	amod||-RSB--38/NN||hbsag-35/JJ	conj_and||hbsag-35/JJ||anti-hbc-37/JJ	amod||-RSB--38/NN||anti-hbc-37/JJ	prep_for||hbv-seropositive-18/JJ||-RSB--38/NN	nsubj||higher-43/JJR||-RSB--38/NN	cop||higher-43/JJR||was-41/VBD	advmod||higher-43/JJR||significantly-42/RB	rcmod||-RSB--38/NN||higher-43/JJR	nn||members-46/NNS||family-45/NN	prep_among||higher-43/JJR||members-46/NNS	num||%-49/NN||39-48/CD	appos||members-46/NNS||%-49/NN	prep_than||higher-43/JJR||that-52/DT	nn||participants-55/NNS||study-54/NN	prep_of||that-52/DT||participants-55/NNS	num||%-58/NN||29-57/CD	appos||participants-55/NNS||%-58/NN	cc||1.56-62/CD||or-61/CC	dep||participants-55/NNS||1.56-62/CD	dep||1.56-62/CD||p-64/NN	number||0.001-66/CD||<-65/CD	dep||p-64/NN||0.001-66/CD	hbv--1||hbsag-35||yes||ninety-six/246 (39%) family members residing at same households with hbsag positive participants were also hbv-seropositive [74 (30.1%) for anti-hbc and 22 (8.9%) for both hbsag and anti-hbc], which was significantly higher among family members (39%) than that of study participants (29%) (or 1.56; p < 0.001).
advmod||emphasized-7/VBD||recently-1/RB	det||organization-6/NN||the-3/DT	nn||organization-6/NN||world-4/NN	nn||organization-6/NN||health-5/NN	nsubj||emphasized-7/VBD||organization-6/NN	nsubj||recommended-25/VBD||organization-6/NN	root||ROOT-0/null||emphasized-7/VBD	det||benefit-10/NN||the-8/DT	amod||benefit-10/NN||potential-9/JJ	dobj||emphasized-7/VBD||benefit-10/NN	amod||treatment-14/NN||intermittent-12/JJ	nn||treatment-14/NN||preventive-13/NN	prep_of||benefit-10/NN||treatment-14/NN	prep_in||treatment-14/NN||infants-16/NNS	appos||infants-16/NNS||ipti-18/NNP	nn||malaria-22/NN||control-21/NN	prep_to||emphasized-7/VBD||malaria-22/NN	advmod||recommended-25/VBD||officially-24/RB	conj_and||emphasized-7/VBD||recommended-25/VBD	dobj||recommended-25/VBD||implementation-26/NN	prep_of||implementation-26/NN||ipti-28/NNS	amod||sp-32/NN||sulfadoxine-pyrimethamine-30/JJ	prep_with||ipti-28/NNS||sp-32/NN	prep_in||sp-32/NN||areas-35/NNS	amod||transmission-40/NN||moderate-37/JJ	conj_and||moderate-37/JJ||high-39/JJ	amod||transmission-40/NN||high-39/JJ	prep_with||areas-35/NNS||transmission-40/NN	advmod||high-47/JJ||where-42/WRB	nn||resistance-44/NN||sp-43/NN	nsubj||high-47/JJ||resistance-44/NN	cop||high-47/JJ||is-45/VBZ	neg||high-47/JJ||not-46/RB	rcmod||transmission-40/NN||high-47/JJ	malaria-22||pyrimethamine--1||no||recently, the world health organization emphasized the potential benefit of intermittent preventive treatment in infants (ipti) to control malaria and officially recommended implementation of ipti with sulfadoxine-pyrimethamine (sp) in areas with moderate and high transmission, where sp resistance is not high.
nsubj||occurs-5/VBZ||magnesiumdeficiency-1/NN	prep_in||magnesiumdeficiency-1/NN||pregnancy-3/NN	advmod||occurs-5/VBZ||frequently-4/RB	root||ROOT-0/null||occurs-5/VBZ	amod||intake-11/NN||inadequate-8/JJ	conj_or||inadequate-8/JJ||low-10/JJ	amod||intake-11/NN||low-10/JJ	prep_because_of||occurs-5/VBZ||intake-11/NN	prep_of||intake-11/NN||magnesium-13/NN	magnesiumdeficiency-1||magnesium-13||yes||magnesiumdeficiency in pregnancy frequently occurs because of inadequate or low intake of magnesium.
nsubj||shown-14/VBN||bevacizumab-1/NN	det||antibody-5/NN||a-3/DT	amod||antibody-5/NN||monoclonal-4/JJ	appos||bevacizumab-1/NN||antibody-5/NN	vmod||antibody-5/NN||directed-6/VBN	det||ligand-9/NN||the-8/DT	prep_against||directed-6/VBN||ligand-9/NN	appos||ligand-9/NN||vegf-11/NN	aux||shown-14/VBN||has-13/VBZ	root||ROOT-0/null||shown-14/VBN	dobj||shown-14/VBN||activity-15/NN	prep_against||activity-15/NN||rcc-17/NN	det||agent-21/NN||a-19/DT	amod||agent-21/NN||single-20/JJ	prep_as||shown-14/VBN||agent-21/NN	prep_in||agent-21/NN||patients-23/NNS	nsubj||failed-26/VBN||patients-23/NNS	aux||failed-26/VBN||had-25/VBD	rcmod||patients-23/NNS||failed-26/VBN	amod||therapy-29/NN||prior-27/JJ	nn||therapy-29/NN||cytokine-28/NN	dobj||failed-26/VBN||therapy-29/NN	dobj||failed-26/VBN||as-31/RB	advmod||therapy-29/NN||as-31/RB	conj_and||therapy-29/NN||as-31/RB	amod||therapy-34/NN||first-32/JJ	nn||therapy-34/NN||line-33/NN	dep||therapy-29/NN||therapy-34/NN	prep_in||therapy-34/NN||combination-36/NN	prep_with||failed-26/VBN||interferon-38/NN	rcc-17||interferon-38||yes||bevacizumab, a monoclonal antibody directed against the ligand, vegf, has shown activity against rcc as a single agent in patients who had failed prior cytokine therapy and as first line therapy in combination with interferon.
det||history-3/NN||the-1/DT	amod||history-3/NN||natural-2/JJ	nsubjpass||complex-10/JJ||history-3/NN	nsubjpass||influenced-12/VBN||history-3/NN	prep_of||history-3/NN||hepatitisbvirus-5/NNS	appos||hepatitisbvirus-5/NNS||hbv-7/NN	auxpass||complex-10/JJ||is-9/VBZ	cop||complex-10/JJ||is-9/VBZ	root||ROOT-0/null||complex-10/JJ	conj_and||complex-10/JJ||influenced-12/VBN	det||level-15/NN||the-14/DT	prep_by||influenced-12/VBN||level-15/NN	amod||replication-18/NN||viral-17/JJ	prep_of||level-15/NN||replication-18/NN	nn||factors-21/NNS||host-20/NN	prep_of||level-15/NN||factors-21/NNS	conj_and||replication-18/NN||factors-21/NNS	hbv-7||hepatitisbvirus-5||no||the natural history of hepatitisbvirus (hbv) is complex and influenced by the level of viral replication and host factors.
amod||mice-4/NNS||liver-1/JJ	amod||mice-4/NNS||ct26-2/JJ	amod||mice-4/NNS||tumor-bearing-3/JJ	nsubjpass||injected-7/VBN||mice-4/NNS	auxpass||injected-7/VBN||were-5/VBD	advmod||injected-7/VBN||hydrodynamically-6/RB	root||ROOT-0/null||injected-7/VBN	amod||doses-10/NNS||different-9/JJ	prep_with||injected-7/VBN||doses-10/NNS	det||plasmid-13/NN||a-12/DT	prep_of||doses-10/NNS||plasmid-13/NN	xcomp||injected-7/VBN||containing-14/VBG	det||transposon-16/NN||a-15/DT	dobj||containing-14/VBG||transposon-16/NN	vmod||transposon-16/NN||encoding-17/VBG	det||gene-21/NN||an-18/DT	amod||gene-21/NN||angiostatin-endostatin-19/JJ	nn||gene-21/NN||fusion-20/NN	dobj||encoding-17/VBG||gene-21/NN	nn||ae-24/NN||statin-23/NN	appos||gene-21/NN||ae-24/NN	amod||amounts-29/NNS||varying-28/VBG	prep_along_with||gene-21/NN||amounts-29/NNS	amod||plasmid-33/NN||sb-31/JJ	amod||plasmid-33/NN||transposase-encoding-32/JJ	prep_of||amounts-29/NNS||plasmid-33/NN	statin-23||tumor--1||no_rel||liver ct26 tumor-bearing mice were hydrodynamically injected with different doses of a plasmid containing a transposon encoding an angiostatin-endostatin fusion gene (statin ae) along with varying amounts of sb transposase-encoding plasmid.
det||programme-5/NN||a-1/DT	amod||programme-5/NN||comprehensive-2/JJ	amod||programme-5/NN||home-based-3/JJ	nn||programme-5/NN||care-4/NN	nsubjpass||needed-7/VBN||programme-5/NN	nsubj||lessen-9/VB||programme-5/NN	auxpass||needed-7/VBN||is-6/VBZ	root||ROOT-0/null||needed-7/VBN	aux||lessen-9/VB||to-8/TO	xcomp||needed-7/VBN||lessen-9/VB	det||burden-11/NN||the-10/DT	dobj||lessen-9/VB||burden-11/NN	vmod||burden-11/NN||placed-12/VBN	det||caregivers-15/NNS||the-14/DT	prep_on||placed-12/VBN||caregivers-15/NNS	det||suffering-18/NN||those-17/DT	prep_of||caregivers-15/NNS||suffering-18/NN	prep_from||placed-12/VBN||hiv/aids-20/NNS	aids--1||hiv--1||no||a comprehensive home-based care programme is needed to lessen the burden placed on the caregivers of those suffering from hiv/aids.
amod||overexpression-2/NN||nac-5-htr4-1/JJ	nsubj||upregulated-3/VBD||overexpression-2/NN	root||ROOT-0/null||upregulated-3/VBD	dobj||upregulated-3/VBD||nac-cart-4/NN	vmod||nac-cart-4/NN||provoked-6/VBN	dobj||provoked-6/VBN||anorexia-7/NN	dobj||provoked-6/VBN||hyperactivity-9/NN	conj_and||anorexia-7/NN||hyperactivity-9/NN	nac--1||anorexia-7||no_rel||nac-5-htr4 overexpression upregulated nac-cart, provoked anorexia and hyperactivity.
det||discovery-2/NN||the-1/DT	nsubj||highlights-6/VBZ||discovery-2/NN	nn||virus-5/NN||kampar-4/NN	prep_of||discovery-2/NN||virus-5/NN	root||ROOT-0/null||highlights-6/VBZ	det||trend-9/NN||the-7/DT	amod||trend-9/NN||increasing-8/VBG	dobj||highlights-6/VBZ||trend-9/NN	prep_of||trend-9/NN||emergence-11/NN	nn||viruses-15/NNS||bat-13/NN	nn||viruses-15/NNS||zoonotic-14/NN	prep_of||trend-9/NN||viruses-15/NNS	det||need-18/NN||the-17/DT	dobj||highlights-6/VBZ||need-18/NN	conj_and||trend-9/NN||need-18/NN	aux||expand-20/VB||to-19/TO	vmod||need-18/NN||expand-20/VB	poss||understanding-22/NN||our-21/PRP$	dobj||expand-20/VB||understanding-22/NN	prep_of||understanding-22/NN||bats-24/NNS	det||source-27/NN||a-26/DT	prep_as||expand-20/VB||source-27/NN	amod||viruses-31/NNS||many-29/JJ	amod||viruses-31/NNS||unknown-30/JJ	prep_of||source-27/NN||viruses-31/NNS	virus-5||viruses-31||no||the discovery of kampar virus highlights the increasing trend of emergence of bat zoonotic viruses and the need to expand our understanding of bats as a source of many unknown viruses.
root||ROOT-0/null||switching-1/VBG	prep_from||switching-1/VBG||exenatide-3/NN	aux||liraglutide-5/VB||to-4/TO	xcomp||switching-1/VBG||liraglutide-5/VB	advmod||liraglutide-5/VB||further-6/RB	advmod||liraglutide-5/VB||significantly-8/RB	conj_and||further-6/RB||significantly-8/RB	dep||switching-1/VBG||reduced-9/VBD	nsubj||switching-1/VBG||a1c-10/NNS	nsubj||liraglutide-5/VB||a1c-10/NNS	num||%-13/NN||0.32-12/CD	appos||a1c-10/NNS||%-13/NN	amod||glucose-18/NN||fasting-16/VBG	nn||glucose-18/NN||plasma-17/NN	appos||a1c-10/NNS||glucose-18/NN	num||mmol/l-21/NN||0.9-20/CD	appos||glucose-18/NN||mmol/l-21/NN	nn||weight-25/NN||body-24/NN	appos||a1c-10/NNS||weight-25/NN	conj_and||glucose-18/NN||weight-25/NN	num||kg-28/NNS||0.9-27/CD	appos||weight-25/NN||kg-28/NNS	amod||pressure-34/NN||systolic-32/JJ	nn||pressure-34/NN||blood-33/NN	appos||a1c-10/NNS||pressure-34/NN	conj_and||glucose-18/NN||pressure-34/NN	num||mmhg-37/NN||3.8-36/CD	appos||pressure-34/NN||mmhg-37/NN	amod||hypoglycemia-42/NN||minimal-40/JJ	amod||hypoglycemia-42/NN||minor-41/JJ	prep_with||pressure-34/NN||hypoglycemia-42/NN	num||episodes/patient-year-45/NN||1.30-44/CD	appos||hypoglycemia-42/NN||episodes/patient-year-45/NN	prep_with||pressure-34/NN||nausea-48/NN	conj_or||hypoglycemia-42/NN||nausea-48/NN	num||%-51/NN||3.2-50/CD	appos||hypoglycemia-42/NN||%-51/NN	hypoglycemia-42||glucose-18||yes||switching from exenatide to liraglutide further and significantly reduced a1c (0.32%), fasting plasma glucose (0.9 mmol/l), body weight (0.9 kg), and systolic blood pressure (3.8 mmhg) with minimal minor hypoglycemia (1.30 episodes/patient-year) or nausea (3.2%).
poss||use-3/NN||their-1/PRP$	amod||use-3/NN||tramadol-2/JJ	nsubj||begun-5/VBN||use-3/NN	nsubj||begun-5/VBN||use-3/NN	aux||begun-5/VBN||had-4/VBD	root||ROOT-0/null||begun-5/VBN	conj_and||begun-5/VBN||begun-5/VBN	det||prescription-8/NN||a-7/DT	prep_with||begun-5/VBN||prescription-8/NN	prep_of||prescription-8/NN||tramadol-10/NN	amod||detoxification-13/NN||opioid-12/JJ	prep_for||begun-5/VBN||detoxification-13/NN	nn||pains-19/NNS||headache-16/NN	conj_and||headache-16/NN||body-18/NN	nn||pains-19/NNS||body-18/NN	prep_for||begun-5/VBN||pains-19/NNS	det||alternative-24/NN||an-23/DT	prep_as||begun-5/VBN||alternative-24/NN	aux||injectable-26/VB||to-25/TO	vmod||alternative-24/NN||injectable-26/VB	dobj||injectable-26/VB||opioids-27/NNS	pains-19||tramadol-10||yes||their tramadol use had begun with a prescription of tramadol for opioid detoxification, for headache and body pains, and as an alternative to injectable opioids.
det||topic-2/NN||the-1/DT	nsubjpass||studied-12/VBN||topic-2/NN	amod||response-5/NN||early-4/JJ	prep_of||topic-2/NN||response-5/NN	amod||treatment-8/NN||antidepressant-7/JJ	prep_to||response-5/NN||treatment-8/NN	aux||studied-12/VBN||has-9/VBZ	auxpass||studied-12/VBN||been-10/VBN	advmod||studied-12/VBN||extensively-11/RB	root||ROOT-0/null||studied-12/VBN	amod||depressivedisorder-15/NN||major-14/JJ	prep_in||studied-12/VBN||depressivedisorder-15/NN	appos||depressivedisorder-15/NN||mdd-17/NN	antidepressant-7||depressivedisorder-15||no_rel||the topic of early response to antidepressant treatment has been extensively studied in major depressivedisorder (mdd).
det||potency-2/NN||the-1/DT	nsubj||comparable-18/JJ||potency-2/NN	prepc_of||potency-2/NN||pgg-ptx-4/VBG	advmod||tested-6/VBN||when-5/WRB	advcl||pgg-ptx-4/VBG||tested-6/VBN	amod||line-16/NN||vitro-8/NN	det||cancer-13/NN||the-10/DT	amod||cancer-13/NN||human-11/JJ	nn||cancer-13/NN||lung-12/NN	prep_against||vitro-8/NN||cancer-13/NN	amod||line-16/NN||h460-14/JJ	nn||line-16/NN||cell-15/NN	prep_in||tested-6/VBN||line-16/NN	cop||comparable-18/JJ||was-17/VBD	root||ROOT-0/null||comparable-18/JJ	amod||conjugates-23/NNS||other-20/JJ	amod||conjugates-23/NNS||known-21/VBN	amod||conjugates-23/NNS||polymer-ptx-22/JJ	prep_to||comparable-18/JJ||conjugates-23/NNS	ptx--1||cancer-13||no_rel||the potency of pgg-ptx when tested in vitro against the human lung cancer h460 cell line was comparable to other known polymer-ptx conjugates.
det||scores-4/NNS||the-1/DT	amod||scores-4/NNS||highest-2/JJS	amod||scores-4/NNS||alval-3/JJ	nsubj||occurred-5/VBD||scores-4/NNS	root||ROOT-0/null||occurred-5/VBD	prep_in||occurred-5/VBD||patients-7/NNS	nsubjpass||revised-10/VBN||patients-7/NNS	auxpass||revised-10/VBN||were-9/VBD	rcmod||patients-7/NNS||revised-10/VBN	prep_for||revised-10/VBN||pain-12/NN	amod||hypersensitivity-16/NN||suspected-14/VBN	nn||hypersensitivity-16/NN||metal-15/NN	prep_for||revised-10/VBN||hypersensitivity-16/NN	conj_and||pain-12/NN||hypersensitivity-16/NN	metal-15||hypersensitivity-16||no_rel||the highest alval scores occurred in patients who were revised for pain and suspected metal hypersensitivity.
nsubj||suggests-2/VBZ||this-1/DT	root||ROOT-0/null||suggests-2/VBZ	mark||imminent-9/JJ||that-3/IN	det||epidemic-6/NN||an-4/DT	nn||epidemic-6/NN||hiv/aids-5/NNS	nsubj||imminent-9/JJ||epidemic-6/NN	aux||imminent-9/JJ||could-7/MD	cop||imminent-9/JJ||be-8/VB	ccomp||suggests-2/VBZ||imminent-9/JJ	prep_in||imminent-9/JJ||bangladesh-11/NN	aids--1||hiv--1||no||this suggests that an hiv/aids epidemic could be imminent in bangladesh.
neg||effect-3/NN||no-1/DT	amod||effect-3/NN||significant-2/JJ	nsubj||derived-9/VBD||effect-3/NN	nn||length-6/NN||gene-5/NN	prep_in||effect-3/NN||length-6/NN	prep_in||effect-3/NN||vaccine-8/NN	conj_or||length-6/NN||vaccine-8/NN	root||ROOT-0/null||derived-9/VBD	amod||dvpvs-12/NNS||polioviruses-10/JJ	nsubjpass||observed-22/VBN||dvpvs-12/NNS	amod||viruses-16/NNS||wild-15/JJ	conj_and||dvpvs-12/NNS||viruses-16/NNS	nsubjpass||observed-22/VBN||viruses-16/NNS	amod||virus-20/NN||live-18/JJ	amod||virus-20/NN||attenuated-19/JJ	conj_and||dvpvs-12/NNS||virus-20/NN	nsubjpass||observed-22/VBN||virus-20/NN	auxpass||observed-22/VBN||was-21/VBD	ccomp||derived-9/VBD||observed-22/VBN	det||variations-25/NNS||the-24/DT	prep_on||observed-22/VBN||variations-25/NNS	amod||codon-28/JJ||synonymous-27/JJ	amod||usage-29/NN||codon-28/JJ	prep_of||variations-25/NNS||usage-29/NN	det||genes-33/NNS||the-31/DT	nn||genes-33/NNS||virus-32/NN	prep_in||usage-29/NN||genes-33/NNS	virus-32||viruses-16||no||no significant effect in gene length or vaccine derived polioviruses (dvpvs), wild viruses and live attenuated virus was observed on the variations of synonymous codon usage in the virus genes.
amod||mice-2/NNS||newborn-1/JJ	nsubj||immunized-3/VBD||mice-2/NNS	nsubjpass||protected-17/VBN||mice-2/NNS	root||ROOT-0/null||immunized-3/VBD	advmod||immunized-3/VBD||intranasally-4/RB	amod||antibodies-9/NNS||gem-lcrv-6/JJ	amod||antibodies-9/NNS||developed-7/JJ	amod||antibodies-9/NNS||lcrv-specific-8/JJ	prep_with||immunized-3/VBD||antibodies-9/NNS	amod||immunity-13/NN||th1-type-11/JJ	amod||immunity-13/NN||cell-mediated-12/JJ	appos||antibodies-9/NNS||immunity-13/NN	auxpass||protected-17/VBN||were-16/VBD	conj_and||immunized-3/VBD||protected-17/VBN	amod||y.pestis-20/NNS||lethal-19/JJ	nn||infection-24/NN||y.pestis-20/NNS	nn||infection-24/NN||-lrb--21/NNP	nn||infection-24/NN||plague-22/NNP	nn||infection-24/NN||-rrb--23/NNP	prep_against||protected-17/VBN||infection-24/NN	plague-22||y.pestis-20||no||newborn mice immunized intranasally with gem-lcrv developed lcrv-specific antibodies , th1-type cell-mediated immunity , and were protected against lethal y.pestis -lrb- plague -rrb- infection .
prepc_based_on||high-30/JJ||on-2/IN	det||test-5/NN||the-3/DT	nn||test-5/NN||fragestrom-4/NN	pobj||high-30/JJ||test-5/NN	prep_of||test-5/NN||nicotinedependence-7/NN	prep_of||nicotinedependence-7/NN||cigarette-9/NN	nsubj||high-30/JJ||35-11/CD	nsubj||high-32/JJ||35-11/CD	nsubj||dependent-35/JJ||35-11/CD	number||%-14/NN||9.1-13/CD	dep||35-11/CD||%-14/NN	conj_and||35-11/CD||69-17/CD	nsubj||high-30/JJ||69-17/CD	num||%-20/NN||18-19/CD	appos||69-17/CD||%-20/NN	conj_and||35-11/CD||48-23/CD	nsubj||high-30/JJ||48-23/CD	num||%-26/NN||12.5-25/CD	appos||35-11/CD||%-26/NN	cop||high-30/JJ||were-28/VBD	advmod||high-30/JJ||very-29/RB	root||ROOT-0/null||high-30/JJ	conj_and||high-30/JJ||high-32/JJ	npadvmod||dependent-35/JJ||medium-34/NN	conj_and||high-30/JJ||dependent-35/JJ	prep_on||high-30/JJ||nicotine-37/NN	advmod||high-30/JJ||respectively-38/RB	nicotinedependence-7||nicotine-37||no||based on the fragestrom test of nicotinedependence of cigarette, 35 (9.1%), 69 (18%) and 48(12.5%) were very high, high and medium dependent on nicotine respectively.
nsubj||focused-2/VBD||assessment-1/NN	root||ROOT-0/null||focused-2/VBD	num||aspects-5/NNS||five-4/CD	prep_on||focused-2/VBD||aspects-5/NNS	appos||aspects-5/NNS||i-7/NNP	det||environment-11/NN||the-9/DT	amod||environment-11/NN||political-10/JJ	dep||aspects-5/NNS||environment-11/NN	amod||access-16/NN||ii-14/JJ	dep||aspects-5/NNS||access-16/NN	amod||resources-19/NNS||financial-18/JJ	prep_to||access-16/NN||resources-19/NNS	dep||aspects-5/NNS||iii-22/NN	det||number-25/NN||the-24/DT	dep||iii-22/NN||number-25/NN	prep_of||aspects-5/NNS||csos-27/NNS	xcomp||focused-2/VBD||working-28/VBG	prep_on||working-28/VBG||hiv/aids-30/NNS	prep_on||working-28/VBG||iv-33/NN	conj_and||hiv/aids-30/NNS||iv-33/NN	det||scope-36/NN||the-35/DT	dep||iv-33/NN||scope-36/NN	prep_of||scope-36/NN||work-38/NN	appos||hiv/aids-30/NNS||v-42/NN	det||impact-45/NN||the-44/DT	prep_on||working-28/VBG||impact-45/NN	conj_and||hiv/aids-30/NNS||impact-45/NN	nn||involvement-48/NN||cso-47/NN	prep_of||impact-45/NN||involvement-48/NN	prep_on||working-28/VBG||programmes-50/NNS	aids--1||hiv--1||no||assessment focused on five aspects (i) the political environment; (ii) access to financial resources; (iii) the number of csos working on hiv/aids; (iv) the scope of work; and (v) the impact of cso involvement on programmes.
det||advantages-3/NNS||the-1/DT	amod||advantages-3/NNS||pharmacological-2/JJ	nsubj||contributed-14/VBN||advantages-3/NNS	det||analog-7/NN||the-5/DT	amod||analog-7/NN||rapid-acting-6/JJ	prep_of||advantages-3/NNS||analog-7/NN	appos||analog-7/NN||insulinaspart-9/NN	prep_over||analog-7/NN||humaninsulin-12/NN	aux||contributed-14/VBN||have-13/VBP	root||ROOT-0/null||contributed-14/VBN	det||prescription-18/NN||the-16/DT	amod||prescription-18/NN||widespread-17/JJ	prep_to||contributed-14/VBN||prescription-18/NN	det||premix-21/NN||the-20/DT	prep_of||prescription-18/NN||premix-21/NN	amod||insulinaspart-24/NN||biphasic-23/JJ	appos||premix-21/NN||insulinaspart-24/NN	num||insulinaspart-24/NN||30/70-25/CD	appos||insulinaspart-24/NN||biasp-27/NN	num||biasp-27/NN||30-28/CD	prep_in||contributed-14/VBN||type-32/NN	num||type-32/NN||1-33/CD	appos||type-32/NN||t1dm-35/NNP	prep_in||contributed-14/VBN||type2diabetes-38/NNS	conj_and||type-32/NN||type2diabetes-38/NNS	appos||type-32/NN||t2dm-40/NNP	type2diabetes-38||insulinaspart-24||yes||the pharmacological advantages of the rapid-acting analog, insulinaspart, over humaninsulin have contributed to the widespread prescription of the premix, biphasic insulinaspart 30/70 (biasp 30), in type 1 (t1dm) and type2diabetes (t2dm).
mark||cause-7/NN||although-1/IN	nsubj||cause-7/NN||alcoholabuse-2/NN	cop||cause-7/NN||is-3/VBZ	det||cause-7/NN||the-4/DT	advmod||common-6/JJ||most-5/RBS	amod||cause-7/NN||common-6/JJ	advcl||related-30/VBD||cause-7/NN	prep_of||cause-7/NN||livercirrhosis-9/NNS	det||states-13/NNS||the-11/DT	amod||states-13/NNS||united-12/VBN	prep_in||livercirrhosis-9/NNS||states-13/NNS	det||effects-17/NNS||the-15/DT	amod||effects-17/NNS||enhancing-16/JJ	nsubj||related-30/VBD||effects-17/NNS	prep_of||effects-17/NNS||alcohol-19/NN	det||prognosis-23/NN||the-21/DT	amod||prognosis-23/NN||long-term-22/JJ	prep_on||alcohol-19/NN||prognosis-23/NN	amod||virus-26/NN||hepatitisc-25/JJ	prep_of||prognosis-23/NN||virus-26/NN	appos||virus-26/NN||hcv-28/NN	root||ROOT-0/null||related-30/VBD	nsubjpass||clarified-35/VBN||livercirrhosis-31/NNS	aux||clarified-35/VBN||has-32/VBZ	neg||clarified-35/VBN||not-33/RB	auxpass||clarified-35/VBN||been-34/VBN	ccomp||related-30/VBD||clarified-35/VBN	alcohol-19||livercirrhosis-31||no_rel||although alcoholabuse is the most common cause of livercirrhosis in the united states, the enhancing effects of alcohol on the long-term prognosis of hepatitisc virus (hcv) related livercirrhosis has not been clarified.
nn||fabric-2/NN||cotton-1/NN	nsubj||ca-5/MD||fabric-2/NN	nsubj||showed-8/VBD||fabric-2/NN	vmod||fabric-2/NN||treated-3/VBN	prep||treated-3/VBN||with-4/IN	root||ROOT-0/null||ca-5/MD	advmod||showed-8/VBD||shp-7/RB	conj_and||ca-5/MD||showed-8/VBD	amod||activity-11/NN||significant-9/JJ	amod||activity-11/NN||antibacterial-10/JJ	dobj||showed-8/VBD||activity-11/NN	prep_against||activity-11/NN||mrsa-13/NN	num||log10-16/NNS||6.38-15/CD	dep||mrsa-13/NN||log10-16/NNS	vmod||log10-16/NNS||treated-17/VBN	amod||drying-20/NNS||conventional-19/JJ	agent||treated-17/VBN||drying-20/NNS	num||log10-23/NNS||6.46-22/CD	agent||treated-17/VBN||log10-23/NNS	conj_and||drying-20/NNS||log10-23/NNS	vmod||log10-23/NNS||treated-24/VBN	agent||treated-24/VBN||microwave-26/NN	vmod||microwave-26/NN||drying-27/VBG	prepc_before||drying-27/VBG||washing-29/VBG	num||log10-33/NNS||6.90-32/CD	conj_and||drying-20/NNS||log10-33/NNS	conj_and||log10-23/NNS||log10-33/NNS	num||log10-36/NNS||7.86-35/CD	conj_and||log10-23/NNS||log10-36/NNS	conj_and||log10-33/NNS||log10-36/NNS	advmod||treated-17/VBN||respectively-38/RB	num||cycle-42/NN||1-41/CD	prep_after||treated-17/VBN||cycle-42/NN	nn||laundering-46/NN||home-44/NN	amod||laundering-46/NN||domestic-45/JJ	prep_of||cycle-42/NN||laundering-46/NN	vmod||laundering-46/NN||washing-47/VBG	amod||-RSB--50/NNS||-LSB--48/JJ	nn||-RSB--50/NNS||hdlw-49/NN	dobj||washing-47/VBG||-RSB--50/NNS	mrsa-13||antibacterial-10||no_rel||cotton fabric treated with ca and shp showed significant antibacterial activity against mrsa (6.38 log10 treated by conventional drying and 6.46 log10 treated by microwave drying before washing, and 6.90 log10 and 7.86 log10, respectively, after 1 cycle of home domestic laundering washing [hdlw]).
det||agent-3/NN||the-1/DT	amod||agent-3/NN||causative-2/JJ	nsubj||one-10/CD||agent-3/NN	prep_of||agent-3/NN||tb-5/NN	appos||agent-3/NN||mycobacteriumtuberculosis-7/NNS	cop||one-10/CD||is-9/VBZ	root||ROOT-0/null||one-10/CD	det||$-14/$||the-12/DT	amod||$-14/$||worldâ-13/JJ	prep_of||one-10/CD||$-14/$	num||$-14/$||-15/CD	cop||pathogens-21/NNS||s-16/VBZ	advmod||ancient-18/JJ||most-17/RBS	amod||pathogens-21/NNS||ancient-18/JJ	conj_and||ancient-18/JJ||successful-20/JJ	amod||pathogens-21/NNS||successful-20/JJ	rcmod||one-10/CD||pathogens-21/NNS	tb-5||mycobacteriumtuberculosis-7||no||the causative agent of tb, mycobacteriumtuberculosis , is one of the worldâs most ancient and successful pathogens.
det||plus-5/NN||the-1/DT	nn||plus-5/NN||genotypeâ-2/NNP	nn||plus-5/NN||®-3/NNP	nn||plus-5/NN||mtbdr-4/NN	nsubjpass||validated-9/VBN||plus-5/NN	nsubj||mdr-tb-32/JJ||plus-5/NN	advmod||validated-9/VBN||assay-6/RB	aux||validated-9/VBN||has-7/VBZ	auxpass||validated-9/VBN||been-8/VBN	root||ROOT-0/null||validated-9/VBN	mark||isolates-23/VBZ||as-10/IN	det||test-17/NN||a-11/DT	amod||test-17/NN||rapid-12/JJ	conj_and||rapid-12/JJ||reliable-14/JJ	amod||test-17/NN||reliable-14/JJ	amod||test-17/NN||first-line-15/JJ	amod||test-17/NN||diagnostic-16/JJ	nsubj||isolates-23/VBZ||test-17/NN	amod||sputum-20/NN||afb-positive-19/JJ	prep_on||test-17/NN||sputum-20/NN	prep_on||test-17/NN||mtb-22/NN	conj_or||sputum-20/NN||mtb-22/NN	advcl||validated-9/VBN||isolates-23/VBZ	nn||resistance-26/NN||inh-25/NN	prep_for||isolates-23/VBZ||resistance-26/NN	nn||resistance-29/NN||rif-28/NN	appos||resistance-26/NN||resistance-29/NN	conj_and||validated-9/VBN||mdr-tb-32/JJ	prep_in||mdr-tb-32/JJ||bangkok-34/NN	dep||validated-9/VBN||thailand-36/VBN	tb--1||rif-28||yes||the genotypeâ® mtbdr plus assay has been validated as a rapid and reliable first-line diagnostic test on afb-positive sputum or mtb isolates for inh resistance, rif resistance, and mdr-tb in bangkok, thailand.
nsubjpass||described-4/VBN||visfatin-1/NN	auxpass||described-4/VBN||was-2/VBD	advmod||described-4/VBN||recently-3/RB	root||ROOT-0/null||described-4/VBN	det||adipocytokine-7/NN||an-6/DT	prep_as||described-4/VBN||adipocytokine-7/NN	advmod||important-10/JJ||potentially-9/RB	amod||effects-11/NNS||important-10/JJ	prep_with||adipocytokine-7/NN||effects-11/NNS	nn||metabolism-14/NN||glucose-13/NN	prep_on||described-4/VBN||metabolism-14/NN	prep_on||described-4/VBN||atherosclerosis-16/NNS	conj_and||metabolism-14/NN||atherosclerosis-16/NNS	glucose-13||atherosclerosis-16||no_rel||visfatin was recently described as an adipocytokine with potentially important effects on glucose metabolism and atherosclerosis.
advmod||propose-4/VBP||thus-1/RB	nsubj||propose-4/VBP||we-3/PRP	root||ROOT-0/null||propose-4/VBP	mark||avenue-14/NN||that-5/IN	nsubj||avenue-14/NN||secretion-6/NN	prep_of||secretion-6/NN||ages-8/NNS	prep_by||ages-8/NNS||bacteria-10/NNS	cop||avenue-14/NN||is-11/VBZ	det||avenue-14/NN||a-12/DT	nn||avenue-14/NN||novel-13/NN	ccomp||propose-4/VBP||avenue-14/NN	nsubj||important-21/JJ||avenue-14/NN	amod||inflammation-17/NN||bacterial-induced-16/JJ	prep_of||avenue-14/NN||inflammation-17/NN	cop||important-21/JJ||is-19/VBZ	advmod||important-21/JJ||potentially-20/RB	rcmod||avenue-14/NN||important-21/JJ	det||pathophysiology-24/NN||the-23/DT	prep_in||important-21/JJ||pathophysiology-24/NN	prep_of||pathophysiology-24/NN||bacterialinfections-26/NNS	bacterialinfections-26||bacterial--1||no||thus, we propose that secretion of ages by bacteria is a novel avenue of bacterial-induced inflammation which is potentially important in the pathophysiology of bacterialinfections.
prep_due_to||protected-30/VBN||variation-3/NN	det||sequences-8/NNS||both-5/DT	amod||sequences-8/NNS||m.tuberculosis-6/JJ	nn||sequences-8/NNS||protein-7/NN	prep_in||variation-3/NN||sequences-8/NNS	amod||capabilities-11/NNS||epitope-binding-10/JJ	conj_and||variation-3/NN||capabilities-11/NNS	prep_due_to||protected-30/VBN||capabilities-11/NNS	amod||alleles-15/NNS||different-13/JJ	nn||alleles-15/NNS||hla-14/NN	prep_of||capabilities-11/NNS||alleles-15/NNS	amod||populations-19/NNS||certain-17/JJ	amod||populations-19/NNS||human-18/JJ	nsubjpass||protected-30/VBN||populations-19/NNS	det||burden-23/NN||a-21/DT	amod||burden-23/NN||high-22/JJ	prep_with||populations-19/NNS||burden-23/NN	prep_of||burden-23/NN||tuberculosis-25/NNP	aux||protected-30/VBN||may-26/MD	neg||protected-30/VBN||not-27/RB	auxpass||protected-30/VBN||be-28/VB	advmod||protected-30/VBN||optimally-29/RB	root||ROOT-0/null||protected-30/VBN	det||vaccine-34/NN||the-32/DT	amod||vaccine-34/NN||mtb72f-33/JJ	agent||protected-30/VBN||vaccine-34/NN	tuberculosis-25||m.tuberculosis-6||no||due to variation in both m.tuberculosis protein sequences and epitope-binding capabilities of different hla alleles , certain human populations with a high burden of tuberculosis may not be optimally protected by the mtb72f vaccine .
nsubj||phagocytosed-12/JJ||studies-1/NNS	nsubj||revealed-14/VBD||studies-1/NNS	amod||cells-6/NNS||murine-3/JJ	amod||cells-6/NNS||min6-4/JJ	nn||cells-6/NNS||insuloma-5/NN	prep_with||studies-1/NNS||cells-6/NNS	cop||phagocytosed-12/JJ||were-9/VBD	advmod||phagocytosed-12/JJ||also-10/RB	advmod||also-10/RB||efficiently-11/RB	rcmod||studies-1/NNS||phagocytosed-12/JJ	root||ROOT-0/null||revealed-14/VBD	det||expression-18/NN||that-15/DT	amod||expression-18/NN||increased-16/JJ	nn||expression-18/NN||isg-17/NN	dobj||revealed-14/VBD||expression-18/NN	prep_in||revealed-14/VBD||dcs-20/NN	prepc_upon||revealed-14/VBD||encountering-22/VBG	amod||cells-24/NNS||cvb-infected-23/JJ	dobj||encountering-22/VBG||cells-24/NNS	vmod||cells-24/NNS||resulted-25/VBN	det||state-29/NN||an-27/DT	amod||state-29/NN||antiviral-28/JJ	prep_in||resulted-25/VBN||state-29/NN	nsubj||protected-31/VBD||state-29/NN	rcmod||state-29/NN||protected-31/VBD	dobj||protected-31/VBD||dcs-32/NN	amod||enterovirusinfection-35/NN||subsequent-34/JJ	prep_from||protected-31/VBD||enterovirusinfection-35/NN	antiviral-28||enterovirusinfection-35||no_rel||studies with murine min6 insuloma cells, which were also efficiently phagocytosed, revealed that increased isg expression in dcs upon encountering cvb-infected cells resulted in an antiviral state that protected dcs from subsequent enterovirusinfection.
nsubj||propose-3/VBP||we-1/PRP	advmod||propose-3/VBP||also-2/RB	root||ROOT-0/null||propose-3/VBP	mark||performed-25/VBN||that-4/IN	nsubjpass||performed-25/VBN||surveillance-5/NN	nsubj||detect-36/VB||surveillance-5/NN	nn||scans-8/NNS||mri-7/NN	prep_with||surveillance-5/NN||scans-8/NNS	det||months-14/NNS||every-10/DT	amod||months-14/NNS||3â-11/JJ	amod||months-14/NNS||$-12/$	dep||$-12/$||-13/JJ	appos||surveillance-5/NN||months-14/NNS	amod||months-19/NNS||24â-16/JJ	amod||months-19/NNS||$-17/$	dep||$-17/$||-18/JJ	prep_after||months-14/NNS||months-19/NNS	prep_of||months-19/NNS||treatment-21/NN	aux||performed-25/VBN||should-23/MD	auxpass||performed-25/VBN||be-24/VB	ccomp||propose-3/VBP||performed-25/VBN	amod||patients-32/NNS||jcvirus-27/JJ	nn||patients-32/NNS||antibody-28/NN	amod||patients-32/NNS||positive-29/JJ	amod||patients-32/NNS||natalizumab-treated-30/JJ	nn||patients-32/NNS||ms-31/NN	prep_in||performed-25/VBN||patients-32/NNS	prep_in||patients-32/NNS||order-34/NN	aux||detect-36/VB||to-35/TO	xcomp||performed-25/VBN||detect-36/VB	dobj||detect-36/VB||pml-37/NN	det||phase-41/NN||an-39/DT	amod||phase-41/NN||early-40/JJ	prep_in||detect-36/VB||phase-41/NN	pml-37||jcvirus-27||no||we also propose that surveillance with mri scans, every 3âmonths after 24âmonths of treatment, should be performed in jcvirus antibody positive natalizumab-treated ms patients in order to detect pml in an early phase.
num||nef-2/NN||one-1/CD	dep||deleted-4/VBN||nef-2/NN	root||ROOT-0/null||deleted-4/VBN	dobj||deleted-4/VBN||virus-5/NN	nsubjpass||isolated-8/VBN||virus-5/NN	auxpass||isolated-8/VBN||was-7/VBD	rcmod||virus-5/NN||isolated-8/VBN	det||development-11/NN||the-10/DT	prep_on||isolated-8/VBN||development-11/NN	prep_of||development-11/NN||aids-13/NNS	vmod||aids-13/NNS||caused-14/VBN	amod||levels-16/NNS||high-15/JJ	dobj||caused-14/VBN||levels-16/NNS	prep_of||levels-16/NNS||syncytia-18/NN	prep_in||caused-14/VBN||mdm-20/NN	amod||mdm-20/NN||similar-21/JJ	nn||viruses-24/NNS||control-23/NN	prep_to||similar-21/JJ||viruses-24/NNS	num||viruses-28/NNS||five-27/CD	npadvmod||isolated-29/JJ||viruses-28/NNS	amod||mdm-20/NN||isolated-29/JJ	conj_but||similar-21/JJ||isolated-29/JJ	amod||times-32/NNS||earlier-31/JJR	prep_from||mdm-20/NN||times-32/NNS	nn||onset-36/NN||aids-35/NNS	prep_prior_to||mdm-20/NN||onset-36/NN	vmod||onset-36/NN||caused-37/VBN	advmod||minimal-39/JJ||only-38/RB	acomp||caused-37/VBN||minimal-39/JJ	advmod||caused-37/VBN||cytopathicity-40/RB	virus-5||viruses-28||no||one nef -deleted virus that was isolated on the development of aids caused high levels of syncytia in mdm similar to control viruses, but five viruses isolated from earlier times prior to aids onset caused only minimal cytopathicity.
nsubj||compared-2/VBD||we-1/PRP	nsubj||isolates-47/VBZ||we-1/PRP	root||ROOT-0/null||compared-2/VBD	det||performance-4/NN||the-3/DT	dobj||compared-2/VBD||performance-4/NN	det||mtbdr-9/NN||the-6/DT	nn||mtbdr-9/NN||genotypeâ-7/NNP	nn||mtbdr-9/NN||®-8/NNP	prep_of||performance-4/NN||mtbdr-9/NN	amod||specimens-45/NNS||assay-11/JJ	amod||tube-16/NN||mycobacterial-13/JJ	nn||tube-16/NN||growth-14/NN	nn||tube-16/NN||indicator-15/NN	prep_to||assay-11/JJ||tube-16/NN	amod||testing-20/NN||antimycobacterial-18/JJ	nn||testing-20/NN||susceptibility-19/NN	prep_for||tube-16/NN||testing-20/NN	amod||ast-23/NN||mgit-22/JJ	appos||testing-20/NN||ast-23/NN	nn||resistance-28/NN||detection-26/NN	nn||resistance-28/NN||inh-27/NN	prep_for||testing-20/NN||resistance-28/NN	nn||resistance-31/NN||rif-30/NN	appos||resistance-28/NN||resistance-31/NN	conj_and||assay-11/JJ||mdr-tb-34/JJ	amod||specimens-45/NNS||mdr-tb-34/JJ	amod||bacilli-38/NNS||stored-36/JJ	amod||bacilli-38/NNS||acid-fast-37/JJ	prep_in||mdr-tb-34/JJ||bacilli-38/NNS	appos||bacilli-38/NNS||afb-40/NN	amod||specimens-45/NNS||positive-43/JJ	nn||specimens-45/NNS||sputum-44/NN	dobj||compared-2/VBD||specimens-45/NNS	conj_plus||performance-4/NN||specimens-45/NNS	conj_and||compared-2/VBD||isolates-47/VBZ	det||laboratory-52/NN||a-49/DT	amod||laboratory-52/NN||public-50/JJ	nn||laboratory-52/NN||tb-51/NN	prep_at||isolates-47/VBZ||laboratory-52/NN	prep_in||laboratory-52/NN||bangkok-54/NN	dep||compared-2/VBD||thailand-56/VBD	tb-51||inh-27||yes||we compared the performance of the genotypeâ® mtbdr plus assay to mycobacterial growth indicator tube for antimycobacterial susceptibility testing (mgit ast) for detection inh resistance, rif resistance, and mdr-tb in stored acid-fast bacilli (afb)-positive sputum specimens and isolates at a public tb laboratory in bangkok, thailand.
csubj||exacerbated-13/VBD||challenging-1/VBG	dobj||challenging-1/VBG||mice-2/NNS	det||diet-6/NN||an-4/DT	nn||diet-6/NN||hf-5/NN	prep_with||challenging-1/VBG||diet-6/NN	prep_following||diet-6/NN||pre-treatment-8/NN	det||agonist-12/NN||the-10/DT	nn||agonist-12/NN||cb-11/NN	prep_with||pre-treatment-8/NN||agonist-12/NN	root||ROOT-0/null||exacerbated-13/VBD	det||glucoseintolerance-17/NN||the-14/DT	amod||glucoseintolerance-17/NN||hf-15/JJ	amod||glucoseintolerance-17/NN||diet-induced-16/JJ	dobj||exacerbated-13/VBD||glucoseintolerance-17/NN	det||infiltration-22/NN||the-19/DT	nn||infiltration-22/NN||muscle-20/NN	nn||infiltration-22/NN||macrophage-21/NN	dobj||exacerbated-13/VBD||infiltration-22/NN	conj_and||glucoseintolerance-17/NN||infiltration-22/NN	det||muscle-25/NN||the-24/DT	poss||content-28/NN||muscle-25/NN	nn||content-28/NN||lipid-27/NN	dobj||exacerbated-13/VBD||content-28/NN	conj_and||glucoseintolerance-17/NN||content-28/NN	prepc_without||exacerbated-13/VBD||affecting-30/VBG	det||weight-33/NN||the-31/DT	nn||weight-33/NN||body-32/NN	dobj||affecting-30/VBG||weight-33/NN	det||mass-37/NN||the-35/DT	amod||mass-37/NN||fat-36/JJ	dobj||affecting-30/VBG||mass-37/NN	conj_or||weight-33/NN||mass-37/NN	lipid-27||glucoseintolerance-17||no_rel||challenging mice with an hf diet following pre-treatment with the cb agonist exacerbated the hf diet-induced glucoseintolerance, the muscle macrophage infiltration and the muscle's lipid content without affecting the body weight or the fat mass.
det||response-4/NN||the-1/DT	amod||response-4/NN||encouraging-2/JJ	amod||response-4/NN||clinical-3/JJ	nsubj||reported-5/VBD||response-4/NN	root||ROOT-0/null||reported-5/VBD	nsubj||suggests-7/VBZ||here-6/RB	ccomp||reported-5/VBD||suggests-7/VBZ	mark||have-12/VB||that-8/IN	amod||temozolomide-10/NN||dose-intensified-9/JJ	nsubj||have-12/VB||temozolomide-10/NN	aux||have-12/VB||might-11/MD	ccomp||suggests-7/VBZ||have-12/VB	amod||activity-14/NN||significant-13/JJ	dobj||have-12/VB||activity-14/NN	det||treatment-17/NN||the-16/DT	prep_in||activity-14/NN||treatment-17/NN	amod||dissemination-20/NN||leptomeningeal-19/JJ	prep_of||treatment-17/NN||dissemination-20/NN	prep_of||dissemination-20/NN||melanoma-22/NN	aux||option-29/NN||may-24/MD	cop||option-29/NN||be-25/VB	det||option-29/NN||a-26/DT	amod||option-29/NN||valid-27/JJ	nn||option-29/NN||treatment-28/NN	conj_and||reported-5/VBD||option-29/NN	prep_for||option-29/NN||patients-31/NNS	nsubjpass||exposed-37/VBN||patients-31/NNS	aux||exposed-37/VBN||have-33/VBP	neg||exposed-37/VBN||not-34/RB	auxpass||exposed-37/VBN||been-35/VBN	advmod||exposed-37/VBN||previously-36/RB	rcmod||patients-31/NNS||exposed-37/VBN	det||agent-40/NN||this-39/DT	prep_to||exposed-37/VBN||agent-40/NN	melanoma-22||temozolomide-10||yes||the encouraging clinical response reported here suggests that dose-intensified temozolomide might have significant activity in the treatment of leptomeningeal dissemination of melanoma and may be a valid treatment option for patients who have not been previously exposed to this agent.
det||1,25-dihydroxyvitamind3-5/NN||the-1/DT	amod||1,25-dihydroxyvitamind3-5/NN||active-2/JJ	amod||1,25-dihydroxyvitamind3-5/NN||vitamind-3/JJ	nn||1,25-dihydroxyvitamind3-5/NN||metabolite-4/NN	nsubj||inhibits-13/VBZ||1,25-dihydroxyvitamind3-5/NN	nsubj||promotes-16/VBZ||1,25-dihydroxyvitamind3-5/NN	dep||1,25-dihydroxyvitamind3-5/NN||1,25-7/CD	discourse||1,25-7/CD||oh-9/UH	dep||1,25-7/CD||2d3-11/NNS	root||ROOT-0/null||inhibits-13/VBZ	dobj||inhibits-13/VBZ||proliferation-14/NN	conj_and||inhibits-13/VBZ||promotes-16/VBZ	dobj||promotes-16/VBZ||differentiation-17/NN	nn||cells-21/NNS||colon-19/NN	nn||cells-21/NNS||cancer-20/NN	prep_of||differentiation-17/NN||cells-21/NNS	det||activation-24/NN||the-23/DT	prep_through||promotes-16/VBZ||activation-24/NN	amod||receptor-27/NN||vitamind-26/JJ	prep_of||activation-24/NN||receptor-27/NN	appos||receptor-27/NN||vdr-29/NN	det||factor-34/NN||a-32/DT	nn||factor-34/NN||transcription-33/NN	appos||receptor-27/NN||factor-34/NN	det||superfamily-39/NN||the-36/DT	amod||superfamily-39/NN||nuclear-37/JJ	nn||superfamily-39/NN||receptor-38/NN	prep_of||factor-34/NN||superfamily-39/NN	1--1||25-dihydroxyvitamind3--1||no_rel||the active vitamind metabolite 1,25-dihydroxyvitamind3 (1,25(oh)2d3) inhibits proliferation and promotes differentiation of colon cancer cells through the activation of vitamind receptor (vdr), a transcription factor of the nuclear receptor superfamily.
det||study-4/NN||an-1/DT	amod||study-4/NN||observational-2/JJ	nn||study-4/NN||retrospective-3/NN	root||ROOT-0/null||study-4/NN	amod||follow-up-7/NN||1-year-6/JJ	appos||study-4/NN||follow-up-7/NN	num||patients-11/NNS||104-10/CD	prep_on||study-4/NN||patients-11/NNS	prep_with||patients-11/NNS||oa-13/NN	nsubjpass||treated-38/VBN||oa-13/NN	nn||osteoarthritis-16/NNS||nodular-15/NN	dep||oa-13/NN||osteoarthritis-16/NNS	det||hand-19/NN||the-18/DT	prep_of||osteoarthritis-16/NNS||hand-19/NN	amod||osteoarthritis-22/NNS||erosive-21/JJ	appos||osteoarthritis-16/NNS||osteoarthritis-22/NNS	det||hand-25/NN||the-24/DT	prep_of||osteoarthritis-22/NNS||hand-25/NN	appos||osteoarthritis-16/NNS||eoa-27/NN	appos||osteoarthritis-16/NNS||osteoarthritis-29/NNS	det||knee-32/NN||the-31/DT	prep_of||osteoarthritis-29/NNS||knee-32/NN	prep_of||osteoarthritis-29/NNS||hip-34/NN	conj_or||knee-32/NN||hip-34/NN	auxpass||treated-38/VBN||were-37/VBD	rcmod||oa-13/NN||treated-38/VBN	nn||chondroitinsulfate-44/NN||gc-40/NN	conj_or||gc-40/NN||glucosamine-42/NN	nn||chondroitinsulfate-44/NN||glucosamine-42/NN	prep_with||treated-38/VBN||chondroitinsulfate-44/NN	nn||ii-48/NNS||collagen-46/NN	nn||ii-48/NNS||type-47/NN	prep_with||treated-38/VBN||ii-48/NNS	conj_and||chondroitinsulfate-44/NN||ii-48/NNS	appos||patients-11/NNS||gcc-50/NN	osteoarthritis-29||glucosamine-42||yes||an observational retrospective study, 1-year follow-up, on 104 patients with oa (nodular osteoarthritis of the hand, erosive osteoarthritis of the hand, eoa, osteoarthritis of the knee or hip) who were treated with gc or glucosamine, chondroitinsulfate and collagen type ii (gcc).
amod||stenosis-2/NNS||mitral-1/JJ	nsubj||abnormality-9/NN||stenosis-2/NNS	appos||stenosis-2/NNS||ms-4/NN	cop||abnormality-9/NN||is-6/VBZ	det||abnormality-9/NN||a-7/DT	amod||abnormality-9/NN||structural-8/JJ	root||ROOT-0/null||abnormality-9/NN	det||apparatus-14/NN||the-11/DT	amod||apparatus-14/NN||mitral-12/JJ	nn||apparatus-14/NN||valve-13/NN	prep_of||abnormality-9/NN||apparatus-14/NN	nsubjpass||resulted-18/VBN||apparatus-14/NN	aux||resulted-18/VBN||can-16/MD	auxpass||resulted-18/VBN||be-17/VB	rcmod||apparatus-14/NN||resulted-18/VBN	amod||rheumaticfever-21/NN||previous-20/JJ	prep_from||resulted-18/VBN||rheumaticfever-21/NN	prep_from||resulted-18/VBN||non-rheumaticfever-23/NN	conj_or||rheumaticfever-21/NN||non-rheumaticfever-23/NN	amod||stenosis-28/NNS||congenital-26/JJ	amod||stenosis-28/NNS||mitral-27/JJ	prep_such_as||rheumaticfever-21/NN||stenosis-28/NNS	amod||etc.-33/NNS||malignant-30/JJ	amod||etc.-33/NNS||carcinoid-31/JJ	nn||etc.-33/NNS||disease-32/NN	appos||stenosis-28/NNS||etc.-33/NNS	rheumaticfever-21||rheumaticfever-21||no||mitral stenosis (ms) is a structural abnormality of the mitral valve apparatus that can be resulted from previous rheumaticfever or non-rheumaticfever such as congenital mitral stenosis, malignant carcinoid disease etc.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||effects-4/NNS||the-3/DT	iobj||evaluated-2/VBN||effects-4/NNS	det||therapy-8/NN||a-6/DT	amod||therapy-8/NN||combined-7/JJ	prep_of||effects-4/NNS||therapy-8/NN	amod||âµg-18/NN||budesonide-10/JJ	dep||budesonide-10/JJ||200-11/CD	nn||âµg-18/NN||âµg-12/NN	advmod||daily-14/RB||twice-13/RB	advmod||âµg-18/NN||daily-14/RB	conj_and||daily-14/RB||formoterol-16/JJ	advmod||âµg-18/NN||formoterol-16/JJ	dep||formoterol-16/JJ||6-17/CD	prep_of||therapy-8/NN||âµg-18/NN	advmod||daily-20/RB||twice-19/RB	dobj||evaluated-2/VBN||daily-20/RB	prepc_compared_with||evaluated-2/VBN||with-22/IN	amod||âµg-25/NN||budesonide-23/JJ	dep||budesonide-23/JJ||200-24/CD	pobj||evaluated-2/VBN||âµg-25/NN	advmod||âµg-25/NN||twice-26/RB	advmod||alone-28/RB||daily-27/RB	pobj||twice-26/RB||alone-28/RB	nn||questionnaire-32/NN||asthma-30/NN	nn||questionnaire-32/NN||control-31/NN	prep_on||twice-26/RB||questionnaire-32/NN	appos||questionnaire-32/NN||acq-34/NN	nn||quality-38/NN||asthma-37/NN	appos||questionnaire-32/NN||quality-38/NN	nn||questionnaire-41/NN||life-40/NN	prep_of||quality-38/NN||questionnaire-41/NN	appos||quality-38/NN||aqlq-43/NNP	dep||aqlq-43/NNP||juniper-45/NN	amod||function-49/NN||pulmonary-48/JJ	appos||questionnaire-32/NN||function-49/NN	conj_and||quality-38/NN||function-49/NN	amod||inflammation-52/NN||airway-51/JJ	appos||questionnaire-32/NN||inflammation-52/NN	conj_and||quality-38/NN||inflammation-52/NN	det||study-59/NN||a-55/DT	amod||study-59/NN||cross-over-56/JJ	amod||study-59/NN||randomized-57/JJ	amod||study-59/NN||double-blind-58/JJ	prep_in||evaluated-2/VBN||study-59/NN	nn||periods-62/NNS||treatment-61/NN	prep_with||study-59/NN||periods-62/NNS	num||months-65/NNS||two-64/CD	prep_of||periods-62/NNS||months-65/NNS	vmod||months-65/NNS||separated-66/VBN	det||period-71/NN||a-68/DT	amod||period-71/NN||one-month-69/JJ	amod||period-71/NN||wash-out-70/JJ	agent||separated-66/VBN||period-71/NN	asthma-37||budesonide-23||yes||we evaluated the effects of a combined therapy of budesonide 200 âµg twice daily and formoterol 6 âµg twice daily compared with budesonide 200 âµg twice daily alone on asthma control questionnaire (acq), asthma quality of life questionnaire (aqlq- juniper), pulmonary function and airway inflammation, in a cross-over randomized double-blind study with treatment periods of two months separated by a one-month wash-out period.
amod||studies-2/NNS||more-1/JJR	nsubj||large-7/JJ||studies-2/NNS	cop||large-7/JJ||are-3/VBP	amod||large-7/JJ||necessary-4/JJ	advmod||large-7/JJ||preferentially-6/RB	root||ROOT-0/null||large-7/JJ	amod||trials-11/NNS||prospective-8/JJ	amod||trials-11/NNS||randomized-9/JJ	amod||trials-11/NNS||clinical-10/JJ	nsubj||obtain-13/VB||trials-11/NNS	aux||obtain-13/VB||to-12/TO	ccomp||large-7/JJ||obtain-13/VB	amod||information-15/NN||more-14/JJR	dobj||obtain-13/VB||information-15/NN	det||impact-18/NN||the-17/DT	prep_on||obtain-13/VB||impact-18/NN	det||rituximab-21/NN||the-20/DT	prep_of||impact-18/NN||rituximab-21/NN	det||b-celllymphoma-26/NN||the-23/DT	amod||b-celllymphoma-26/NN||primary-24/JJ	amod||b-celllymphoma-26/NN||gastric-25/JJ	prep_in||rituximab-21/NN||b-celllymphoma-26/NN	rituximab-21||b-celllymphoma-26||no_rel||more studies are necessary, preferentially large prospective randomized clinical trials to obtain more information on the impact of the rituximab in the primary gastric b-celllymphoma.
nsubj||drug-7/NN||lansoprazole-1/NN	cop||drug-7/NN||is-2/VBZ	det||drug-7/NN||an-3/DT	amod||drug-7/NN||acid-4/JJ	amod||drug-7/NN||proton-pump-5/JJ	nn||drug-7/NN||inhibiting-6/NN	root||ROOT-0/null||drug-7/NN	nsubjpass||used-10/VBN||drug-7/NN	auxpass||used-10/VBN||is-9/VBZ	rcmod||drug-7/NN||used-10/VBN	det||treatment-13/NN||the-12/DT	prep_for||used-10/VBN||treatment-13/NN	prep_of||treatment-13/NN||duodenal-15/NNS	prep_of||treatment-13/NN||gastriculcers-17/NNS	conj_or||duodenal-15/NNS||gastriculcers-17/NNS	nn||infection-21/NN||h.-19/NN	nn||infection-21/NN||pylori-20/NN	prep_of||treatment-13/NN||infection-21/NN	conj_or||duodenal-15/NNS||infection-21/NN	prep_of||treatment-13/NN||gastroesophagealrefluxdisease-23/NN	conj_or||duodenal-15/NNS||gastroesophagealrefluxdisease-23/NN	amod||syndrome-26/NN||zollinger-ellison-25/JJ	prep_of||treatment-13/NN||syndrome-26/NN	conj_or||duodenal-15/NNS||syndrome-26/NN	gastriculcers-17||lansoprazole-1||yes||lansoprazole is an acid proton-pump inhibiting drug that is used for the treatment of duodenal or gastriculcers , h. pylori infection , gastroesophagealrefluxdisease or zollinger-ellison syndrome .
det||group-4/NN||the-2/DT	amod||group-4/NN||overweight/obese-3/JJ	prep_in||times-14/NNS||group-4/NN	nsubj||times-14/NNS||those-6/DT	amod||obesity-9/NN||central-8/JJ	prep_without||those-6/DT||obesity-9/NN	cop||times-14/NNS||were-10/VBD	nn||times-14/NNS||0.53-11/CD	conj_and||0.53-11/CD||0.27-13/CD	nn||times-14/NNS||0.27-13/CD	root||ROOT-0/null||times-14/NNS	advmod||likely-16/JJ||less-15/RBR	amod||times-14/NNS||likely-16/JJ	aux||have-18/VB||to-17/TO	dep||times-14/NNS||have-18/VB	amod||levels-21/NNS||significant-19/JJ	amod||levels-21/NNS||adverse-20/JJ	dobj||have-18/VB||levels-21/NNS	nn||cholesterol-24/NN||hdl-23/NN	prep_of||levels-21/NNS||cholesterol-24/NN	prep_of||levels-21/NNS||homa-ir-26/NN	conj_and||cholesterol-24/NN||homa-ir-26/NN	advmod||have-18/VB||respectively-28/RB	parataxis||have-18/VB||p-30/VB	num||0.05-32/CD||<-31/CD	dobj||p-30/VB||0.05-32/CD	prepc_as||times-14/NNS||compared-36/VBN	pcomp||compared-36/VBN||to-37/TO	pobj||to-37/TO||those-38/DT	amod||obesity-41/NN||central-40/JJ	prep_with||those-38/DT||obesity-41/NN	cholesterol-24||obesity-41||no_rel||in the overweight/obese group, those without central obesity were 0.53 and 0.27 times less likely to have significant adverse levels of hdl cholesterol and homa-ir, respectively (p < 0.05), as compared to those with central obesity.
det||stoichiometries-3/NNS||the-2/DT	nsubj||produce-8/VBP||stoichiometries-3/NNS	nsubj||consume-10/VBP||stoichiometries-3/NNS	prep_from||support-31/VBP||stoichiometries-3/NNS	amod||pathways-6/NNS||metabolic-5/JJ	prep_of||stoichiometries-3/NNS||pathways-6/NNS	rcmod||stoichiometries-3/NNS||produce-8/VBP	rcmod||stoichiometries-3/NNS||consume-10/VBP	conj_or||produce-8/VBP||consume-10/VBP	number||+-12/CD||h-11/CD	dobj||produce-8/VBP||+-12/CD	det||availability-17/NN||the-15/DT	amod||availability-17/NN||greater-16/JJR	dobj||produce-8/VBP||availability-17/NN	conj_and||+-12/CD||availability-17/NN	prep_of||availability-17/NN||glucose-19/NN	prepc_compared_to||produce-8/VBP||to-21/TO	pobj||produce-8/VBP||oxygen-22/NN	amod||parts-25/NNS||most-24/JJS	prep_in||oxygen-22/NN||parts-25/NNS	det||tumor-28/NN||a-27/DT	prep_of||parts-25/NNS||tumor-28/NN	nsubj||support-31/VBP||we-30/PRP	root||ROOT-0/null||support-31/VBP	det||view-34/NN||the-32/DT	amod||view-34/NN||classic-33/JJ	dobj||support-31/VBP||view-34/NN	mark||originates-45/VBZ||that-35/IN	nsubj||originates-45/VBZ||most-36/JJS	nsubj||add-59/VBP||most-36/JJS	det||efflux-41/NN||the-38/DT	amod||efflux-41/NN||net-39/JJ	nn||efflux-41/NN||proton-40/NN	prep_of||most-36/JJS||efflux-41/NN	amod||gliomas-44/NNS||c6-43/JJ	prep_from||efflux-41/NN||gliomas-44/NNS	ccomp||support-31/VBP||originates-45/VBZ	amod||formation-48/NN||glycolytic-47/JJ	prep_in||originates-45/VBZ||formation-48/NN	nn||+-53/NNS||lactate-50/NN	conj_and||lactate-50/NN||h-52/NN	nn||+-53/NNS||h-52/NN	prep_of||formation-48/NN||+-53/NNS	det||tumor-56/NN||the-55/DT	prep_inside||originates-45/VBZ||tumor-56/NN	ccomp||support-31/VBP||add-59/VBP	conj_but||originates-45/VBZ||add-59/VBP	mark||taken-64/VBN||that-60/IN	det||lactate-62/NN||some-61/DT	nsubjpass||taken-64/VBN||lactate-62/NN	auxpass||taken-64/VBN||is-63/VBZ	ccomp||add-59/VBP||taken-64/VBN	prt||taken-64/VBN||up-65/RP	prep_into||taken-64/VBN||cells-67/NNS	det||rim-70/NN||the-69/DT	prep_in||cells-67/NNS||rim-70/NN	prep_on||rim-70/NN||mct1-72/CD	det||lactate-76/NN||some-75/DT	nsubj||diffuses-77/VBZ||lactate-76/NN	ccomp||add-59/VBP||diffuses-77/VBZ	conj_and||taken-64/VBN||diffuses-77/VBZ	prt||diffuses-77/VBZ||away-78/RP	xcomp||diffuses-77/VBZ||leaving-80/VBG	poss||protons-83/NNS||its-81/PRP$	amod||protons-83/NNS||associated-82/JJ	dobj||leaving-80/VBG||protons-83/NNS	acomp||originates-45/VBZ||available-84/JJ	aux||re-enter-86/VB||to-85/TO	xcomp||available-84/JJ||re-enter-86/VB	dobj||re-enter-86/VB||cells-87/NNS	prep_for||cells-87/NNS||extrusion-89/NN	prep_on||re-enter-86/VB||nhe1-91/CD	tumor-56||glucose-19||no_rel||from the stoichiometries of metabolic pathways that produce or consume h+, and the greater availability of glucose compared to oxygen in most parts of a tumor, we support the classic view that most of the net proton efflux from c6 gliomas originates in glycolytic formation of lactate and h+ inside the tumor, but add that some lactate is taken up into cells in the rim on mct1, and some lactate diffuses away, leaving its associated protons available to re-enter cells for extrusion on nhe1.
nsubj||causes-2/VBZ||varicella-zostervirus-1/NNS	nsubj||shingles-8/VBZ||varicella-zostervirus-1/NNS	root||ROOT-0/null||causes-2/VBZ	dobj||causes-2/VBZ||chickenpox-3/NN	amod||infection-6/NN||primary-5/JJ	prep_upon||causes-2/VBZ||infection-6/NN	conj_and||causes-2/VBZ||shingles-8/VBZ	prep_after||shingles-8/VBZ||reactivation-10/NN	chickenpox-3||varicella-zostervirus-1||no||varicella-zostervirus causes chickenpox upon primary infection and shingles after reactivation.
advmod||suggest-15/VBP||indeed-1/RB	amod||lines-4/NNS||several-3/JJ	nsubj||suggest-15/VBP||lines-4/NNS	prep_of||lines-4/NNS||evidence-6/NN	prep_including||evidence-6/NN||epidemiologic-8/NN	prep_including||evidence-6/NN||preclinical-10/JJ	conj_and||epidemiologic-8/NN||preclinical-10/JJ	amod||data-14/NNS||clinical-13/JJ	prep_including||evidence-6/NN||data-14/NNS	conj_and||epidemiologic-8/NN||data-14/NNS	root||ROOT-0/null||suggest-15/VBP	mark||and/or-20/VBD||that-16/IN	amod||levels-19/NNS||reduced-17/VBN	amod||levels-19/NNS||vitamind-18/JJ	nsubj||and/or-20/VBD||levels-19/NNS	ccomp||suggest-15/VBP||and/or-20/VBD	nsubj||factor-28/NN||dysregulation-21/NN	amod||homeostasis-24/NNS||vitamind-23/JJ	prep_of||dysregulation-21/NN||homeostasis-24/NNS	cop||factor-28/NN||is-25/VBZ	det||factor-28/NN||a-26/DT	nn||factor-28/NN||risk-27/NN	ccomp||and/or-20/VBD||factor-28/NN	det||development-31/NN||the-30/DT	prep_for||factor-28/NN||development-31/NN	prep_of||development-31/NN||multiplesclerosis-33/NNS	det||hand-37/NN||the-35/DT	num||hand-37/NN||one-36/CD	prep_on||multiplesclerosis-33/NNS||hand-37/NN	mark||associated-46/VBN||that-40/IN	amod||levels-43/NNS||vitamind-41/JJ	nn||levels-43/NNS||serum-42/NN	nsubjpass||associated-46/VBN||levels-43/NNS	auxpass||associated-46/VBN||are-44/VBP	advmod||associated-46/VBN||inversely-45/RB	ccomp||suggest-15/VBP||associated-46/VBN	conj_and||and/or-20/VBD||associated-46/VBN	nn||activity-49/NN||disease-48/NN	prep_with||associated-46/VBN||activity-49/NN	prep_with||associated-46/VBN||progression-51/NN	conj_and||activity-49/NN||progression-51/NN	det||hand-55/NN||the-53/DT	amod||hand-55/NN||other-54/JJ	prep_on||associated-46/VBN||hand-55/NN	multiplesclerosis-33||vitamind-41||no_rel||indeed, several lines of evidence including epidemiologic, preclinical, and clinical data suggest that reduced vitamind levels and/or dysregulation of vitamind homeostasis is a risk factor for the development of multiplesclerosis on the one hand, and that vitamind serum levels are inversely associated with disease activity and progression on the other hand.
det||study-3/NN||this-2/DT	prep_in||emerged-8/VBD||study-3/NN	nsubj||emerged-8/VBD||treatment-5/NN	prep_with||treatment-5/NN||sulphadoxine-pyrimethamine-7/NN	root||ROOT-0/null||emerged-8/VBD	mark||followed-16/VBD||as-9/IN	det||efficacious-12/NNS||the-10/DT	amod||efficacious-12/NNS||most-11/JJS	nsubj||followed-16/VBD||efficacious-12/NNS	amod||falciparummalaria-15/NN||uncomplicated-14/JJ	prep_on||efficacious-12/NNS||falciparummalaria-15/NN	advcl||emerged-8/VBD||followed-16/VBD	prep_by||followed-16/VBD||amodiaquine-18/NN	falciparummalaria-15||pyrimethamine--1||yes||in this study, treatment with sulphadoxine-pyrimethamine emerged as the most efficacious on uncomplicated falciparummalaria followed by amodiaquine.
amod||devices-5/NNS||patient-friendly-3/JJ	nn||devices-5/NNS||injection-4/NN	prep_together_with||provides-11/VBZ||devices-5/NNS	nn||adjustments-8/NNS||dose-7/NN	conj_and||devices-5/NNS||adjustments-8/NNS	prep_together_with||provides-11/VBZ||adjustments-8/NNS	nsubj||provides-11/VBZ||it-10/PRP	root||ROOT-0/null||provides-11/VBZ	det||option-14/NN||a-12/DT	nn||option-14/NN||treatment-13/NN	dobj||provides-11/VBZ||option-14/NN	det||potential-17/NN||the-16/DT	prep_with||provides-11/VBZ||potential-17/NN	aux||lower-19/VB||to-18/TO	vmod||potential-17/NN||lower-19/VB	det||barriers-22/NNS||the-20/DT	amod||barriers-22/NNS||key-21/JJ	dobj||lower-19/VB||barriers-22/NNS	prep_of||barriers-22/NNS||adherence-24/NN	nn||therapy-27/NN||insulin-26/NN	prep_to||lower-19/VB||therapy-27/NN	prep_in||therapy-27/NN||type2diabetes-29/CD	type2diabetes-29||insulin-26||yes||together with patient-friendly injection devices and dose adjustments, it provides a treatment option with the potential to lower the key barriers of adherence to insulin therapy in type2diabetes.
det||changes-3/NNS||the-1/DT	amod||changes-3/NNS||dynamic-2/JJ	nsubj||suggest-13/VBP||changes-3/NNS	nsubj||offers-24/VBZ||changes-3/NNS	amod||currents-6/NNS||electric-5/JJ	prep_of||changes-3/NNS||currents-6/NNS	amod||fluxes-10/NNS||specific-8/JJ	nn||fluxes-10/NNS||ion-9/NN	conj_and||changes-3/NNS||fluxes-10/NNS	nsubj||suggest-13/VBP||fluxes-10/NNS	prep_after||fluxes-10/NNS||wounding-12/NN	root||ROOT-0/null||suggest-13/VBP	mark||response-20/NN||that-14/IN	amod||signaling-16/NNS||electrical-15/JJ	nsubj||response-20/NN||signaling-16/NNS	cop||response-20/NN||is-17/VBZ	det||response-20/NN||an-18/DT	amod||response-20/NN||active-19/JJ	ccomp||suggest-13/VBP||response-20/NN	prep_to||response-20/NN||injury-22/NN	conj_and||suggest-13/VBP||offers-24/VBZ	amod||approaches-27/NNS||potential-25/JJ	nn||approaches-27/NNS||novel-26/NN	dobj||offers-24/VBZ||approaches-27/NNS	amod||healing-31/NN||modulate-29/JJ	nn||healing-31/NN||wound-30/NN	prep_to||offers-24/VBZ||healing-31/NN	nn||eye-drops-35/NNS||example-34/NN	prep_for||suggest-13/VBP||eye-drops-35/NNS	vmod||eye-drops-35/NNS||targeting-36/VBG	nn||transport-38/NN||ion-37/NN	dobj||targeting-36/VBG||transport-38/NN	aux||aid-40/VB||to-39/TO	vmod||targeting-36/VBG||aid-40/VB	det||management-44/NN||the-42/DT	amod||management-44/NN||challenging-43/JJ	prep_in||aid-40/VB||management-44/NN	amod||cornealulcers-47/NNS||non-healing-46/JJ	prep_of||management-44/NN||cornealulcers-47/NNS	ion-37||cornealulcers-47||no_rel||the dynamic changes of electric currents and specific ion fluxes after wounding suggest that electrical signaling is an active response to injury and offers potential novel approaches to modulate wound healing, for example eye-drops targeting ion transport to aid in the challenging management of non-healing cornealulcers.
nn||autoantibodies-2/NNS||insulin-1/NN	nsubjpass||reduced-4/VBN||autoantibodies-2/NNS	auxpass||reduced-4/VBN||were-3/VBD	root||ROOT-0/null||reduced-4/VBN	prepc_in||reduced-4/VBN||glp-1â-6/VBG	dobj||glp-1â-6/VBG||$-7/$	npadvmod||nod-11/RB||and-9/NNP	advmod||and-9/NNP||gastrin-treated-10/RB	dep||mice-12/CD||nod-11/RB	num||$-7/$||mice-12/CD	nsubj||delayed-19/VBD||splenocytes-15/NNS	det||mice-18/NNS||these-17/DT	prep_from||splenocytes-15/NNS||mice-18/NNS	conj_and||reduced-4/VBN||delayed-19/VBD	amod||transfer-21/NN||adoptive-20/JJ	dobj||delayed-19/VBD||transfer-21/NN	prep_of||transfer-21/NN||diabetes-23/NN	amod||mice-26/NNS||nod-scid-25/JJ	prep_in||delayed-19/VBD||mice-26/NNS	insulin-1||scid--1||no_rel||insulin autoantibodies were reduced in glp-1âand gastrin-treated nod mice, and splenocytes from these mice delayed adoptive transfer of diabetes in nod-scid mice.
det||data-2/NNS||these-1/DT	nsubj||able-9/JJ||data-2/NNS	nsubj||explain-11/VB||data-2/NNS	aux||able-9/JJ||may-3/MD	prep_in||able-9/JJ||part-6/NN	cop||able-9/JJ||be-8/VB	root||ROOT-0/null||able-9/JJ	aux||explain-11/VB||to-10/TO	xcomp||able-9/JJ||explain-11/VB	det||use-14/NN||the-12/DT	amod||use-14/NN||traditional-13/JJ	dobj||explain-11/VB||use-14/NN	amod||plants-18/NNS||tannin-containing-16/JJ	amod||plants-18/NNS||medicinal-17/JJ	prep_of||use-14/NN||plants-18/NNS	det||treatment-21/NN||the-20/DT	prep_for||explain-11/VB||treatment-21/NN	det||variety-24/NN||a-23/DT	prep_of||treatment-21/NN||variety-24/NN	prep_of||variety-24/NN||inflammatorydiseases-26/NNS	prep_including||explain-11/VB||inflammatoryboweldisease-29/NN	prep_including||explain-11/VB||celiacdisease-31/NN	conj_and||inflammatoryboweldisease-29/NN||celiacdisease-31/NN	prep_including||explain-11/VB||rheumatoidarthritis-34/NNS	conj_and||inflammatoryboweldisease-29/NN||rheumatoidarthritis-34/NNS	tannin--1||disease--1||no_rel||these data may, in part, be able to explain the traditional use of tannin-containing medicinal plants for the treatment of a variety of inflammatorydiseases, including inflammatoryboweldisease, celiacdisease, and rheumatoidarthritis.
amod||cells-2/NNS||epithelial-1/JJ	nsubjpass||grown-29/VBN||cells-2/NNS	nsubjpass||treated-36/VBN||cells-2/NNS	amod||brushings-5/NNS||bronchial-4/JJ	prep_from||cells-2/NNS||brushings-5/NNS	prep_of||brushings-5/NNS||normal-7/JJ	dep||normal-7/JJ||n-9/VBN	dep||8-11/CD||=-10/SYM	ccomp||n-9/VBN||8-11/CD	prep_of||brushings-5/NNS||asthma-14/NN	conj_and||normal-7/JJ||asthma-14/NN	dep||asthma-14/NN||n-16/VBN	dep||8-18/CD||=-17/SYM	ccomp||n-16/VBN||8-18/CD	amod||subjects-27/NNS||copd-21/JJ	dep||copd-21/JJ||n-23/VBN	dep||8-25/CD||=-24/SYM	ccomp||n-23/VBN||8-25/CD	prep_of||brushings-5/NNS||subjects-27/NNS	conj_and||normal-7/JJ||subjects-27/NNS	auxpass||grown-29/VBN||were-28/VBD	root||ROOT-0/null||grown-29/VBN	amod||cultures-33/NNS||air-liquid-31/JJ	nn||cultures-33/NNS||interface-32/NN	prep_in||grown-29/VBN||cultures-33/NNS	conj_and||grown-29/VBN||treated-36/VBN	nn||smoke-39/NN||cigarette-38/NN	prep_with||treated-36/VBN||smoke-39/NN	ccomp||treated-36/VBN||extract-40/VB	appos||th2-45/NN||cse-42/NN	amod||th2-45/NN||and/or-44/JJ	dobj||extract-40/VB||th2-45/NN	amod||il-13-47/JJ||cytokine-46/JJ	amod||th2-45/NN||il-13-47/JJ	conj_and||grown-29/VBN||followed-49/VBN	conj_and||treated-36/VBN||followed-49/VBN	nn||infection-52/NN||mp-51/NN	prep_by||followed-49/VBN||infection-52/NN	prep_by||followed-49/VBN||treatment-54/NN	conj_and||infection-52/NN||treatment-54/NN	nn||albuterol-59/NN||î-56/NN	nn||albuterol-59/NN||²-57/NNP	amod||albuterol-59/NN||2-agonists-58/JJ	prep_with||followed-49/VBN||albuterol-59/NN	conj_and||grown-29/VBN||formoterol-61/JJ	conj_and||treated-36/VBN||formoterol-61/JJ	quantmod||seven-65/CD||up-63/IN	dep||seven-65/CD||to-64/TO	num||days-66/NNS||seven-65/CD	prep_for||formoterol-61/JJ||days-66/NNS	asthma-14||formoterol-61||no||epithelial cells from bronchial brushings of normal (n = 8), asthma (n = 8) and copd (n = 8) subjects were grown in air-liquid interface cultures, and treated with cigarette smoke extract (cse) and/or th2 cytokine il-13, followed by mp infection and treatment with î²2-agonists albuterol and formoterol for up to seven days.
nsubj||discuss-2/VB||we-1/PRP	root||ROOT-0/null||discuss-2/VB	det||implications-4/NNS||the-3/DT	dobj||discuss-2/VB||implications-4/NNS	det||control-7/NN||the-6/DT	prep_for||implications-4/NNS||control-7/NN	amod||avianinfluenzavirus-10/NNS||h5n1-9/JJ	prep_of||control-7/NN||avianinfluenzavirus-10/NNS	prep_in||discuss-2/VB||areas-12/NNS	advmod||endemic-16/JJ||where-13/WRB	nsubj||endemic-16/JJ||it-14/PRP	cop||endemic-16/JJ||is-15/VBZ	rcmod||areas-12/NNS||endemic-16/JJ	h5n1-9||avianinfluenzavirus-10||no||we discuss the implications for the control of h5n1 avianinfluenzavirus in areas where it is endemic.
nsubj||decreased-2/VBD||melatonin-1/NN	root||ROOT-0/null||decreased-2/VBD	det||hyperglycemia-5/NN||the-3/DT	amod||hyperglycemia-5/NN||abnormal-4/JJ	dobj||decreased-2/VBD||hyperglycemia-5/NN	vmod||hyperglycemia-5/NN||seen-6/VBN	det||load-10/NN||a-8/DT	nn||load-10/NN||glucose-9/NN	prep_after||seen-6/VBN||load-10/NN	number||%-13/NN||10-12/CD	amod||rats-15/NNS||%-13/NN	amod||rats-15/NNS||fructose-treated-14/JJ	prep_in||load-10/NN||rats-15/NNS	nsubj||modify-20/VB||it-17/PRP	aux||modify-20/VB||did-18/VBD	neg||modify-20/VB||not-19/RB	conj_but||decreased-2/VBD||modify-20/VB	det||tolerance-23/NN||the-21/DT	amod||tolerance-23/NN||greater-22/JJR	dobj||modify-20/VB||tolerance-23/NN	prep_to||modify-20/VB||glucose-25/NN	vmod||glucose-25/NN||observed-26/VBN	prep_in||observed-26/VBN||animals-28/NNS	vmod||animals-28/NNS||drinking-29/VBG	number||%-31/NN||5-30/CD	amod||fructose-32/NN||%-31/NN	dobj||drinking-29/VBG||fructose-32/NN	hyperglycemia-5||glucose-25||no||melatonin decreased the abnormal hyperglycemia seen after a glucose load in 10% fructose-treated rats but it did not modify the greater tolerance to glucose observed in animals drinking 5% fructose.
amod||effects-2/NNS||direct-1/JJ	nsubjpass||evaluated-9/VBN||effects-2/NNS	prep_of||effects-2/NNS||calcitonin-4/NN	nn||cartilage-7/NN||articular-6/NN	prep_on||calcitonin-4/NN||cartilage-7/NN	auxpass||evaluated-9/VBN||were-8/VBD	root||ROOT-0/null||evaluated-9/VBN	dep||measurement-13/NN||1-11/LS	agent||evaluated-9/VBN||measurement-13/NN	nn||synthesis-16/NN||proteoglycan-15/NN	prep_of||measurement-13/NN||synthesis-16/NN	prep_by||synthesis-16/NN||incorporation-18/NN	prep_of||incorporation-18/NN||radioactive-20/NN	vmod||radioactive-20/NN||labeled-21/VBN	amod||ci-27/NN||35so4-22/JJ	amod||ci-27/NN||-LSB--23/JJ	num||ci-27/NN||5-24/CD	nn||ci-27/NN||î-25/NN	num||ci-27/NN||1/4-26/CD	dobj||labeled-21/VBN||ci-27/NN	xcomp||labeled-21/VBN||-RSB--28/VBG	dep||quantification-31/NN||2-29/LS	dobj||-RSB--28/VBG||quantification-31/NN	nn||formation-34/NN||collagen-type-ii-33/NN	prep_of||quantification-31/NN||formation-34/NN	prep_by||formation-34/NN||pro-peptides-36/NNS	nn||elisa-44/NN||collagen-38/NN	nn||elisa-44/NN||type-39/NN	nn||elisa-44/NN||ii-40/NN	nn||elisa-44/NN||piinp-42/NN	prep_of||pro-peptides-36/NNS||elisa-44/NN	dep||expression-49/NN||3-46/LS	nn||expression-49/NN||qpcr-48/NN	appos||elisa-44/NN||expression-49/NN	det||receptor-53/NN||the-51/DT	nn||receptor-53/NN||calcitonin-52/NN	prep_of||expression-49/NN||receptor-53/NN	nn||chondrocytes-56/NNS||oa-55/NN	prep_in||receptor-53/NN||chondrocytes-56/NNS	vmod||chondrocytes-56/NNS||using-57/VBG	num||pairs-61/NNS||four-58/CD	amod||pairs-61/NNS||individual-59/JJ	nn||pairs-61/NNS||primer-60/NN	dobj||using-57/VBG||pairs-61/NNS	dep||activation-65/NN||4-63/LS	appos||quantification-31/NN||activation-65/NN	det||camp-68/NN||the-67/DT	prep_of||activation-65/NN||camp-68/NN	vmod||camp-68/NN||signaling-69/VBG	advmod||signaling-69/VBG||pathway-70/RB	agent||signaling-69/VBG||eia-72/NN	dep||investigations-77/NNS||5-75/CD	agent||evaluated-9/VBN||investigations-77/NNS	conj_and||measurement-13/NN||investigations-77/NNS	amod||activity-80/NN||metabolic-79/JJ	prep_of||investigations-77/NNS||activity-80/NN	prep_by||activity-80/NN||alamarblue-82/NN	collagen-38||oa-55||no_rel||direct effects of calcitonin on articular cartilage were evaluated by 1) measurement of proteoglycan synthesis by incorporation of radioactive labeled 35so4 [5 î¼ci] 2) quantification of collagen-type-ii formation by pro-peptides of collagen type ii (piinp) elisa, 3) qpcr expression of the calcitonin receptor in oa chondrocytes using four individual primer pairs, 4) activation of the camp signaling pathway by eia and, 5) investigations of metabolic activity by alamarblue.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	amod||outcomes-4/NNS||various-3/JJ	dobj||evaluate-2/VB||outcomes-4/NNS	amod||treatment-8/NN||short-course-6/JJ	nn||treatment-8/NN||cyclosporine-7/NN	prep_of||outcomes-4/NNS||treatment-8/NN	amod||psoriasis-11/NNS||severe-10/JJ	prep_for||treatment-8/NN||psoriasis-11/NNS	aux||describe-15/VB||to-14/TO	conj_and||evaluate-2/VB||describe-15/VB	poss||use-18/NN||dermatologists-16/NNS	dobj||describe-15/VB||use-18/NN	det||rule-21/NN||the-20/DT	prep_of||use-18/NN||rule-21/NN	prep_of||rule-21/NN||tens-23/NNS	psoriasis-11||cyclosporine-7||no||to evaluate various outcomes of short-course cyclosporine treatment for severe psoriasis; and to describe dermatologists' use of the rule of tens.
nsubj||recorded-2/VBD||we-1/PRP	root||ROOT-0/null||recorded-2/VBD	nn||time-4/NN||onset-3/NN	iobj||recorded-2/VBD||time-4/NN	det||block-8/NN||the-6/DT	amod||block-8/NN||sensory-7/JJ	prep_of||time-4/NN||block-8/NN	nn||time-11/NN||end-10/NN	appos||block-8/NN||time-11/NN	det||block-15/NN||the-13/DT	amod||block-15/NN||sensory-14/JJ	prep_of||time-11/NN||block-15/NN	appos||block-15/NN||presence-17/NN	det||block-21/NN||the-19/DT	nn||block-21/NN||motor-20/NN	prep_of||presence-17/NN||block-21/NN	det||time-24/NN||the-23/DT	dobj||recorded-2/VBD||time-24/NN	advmod||reported-29/VBD||when-25/WRB	det||patient-27/NN||the-26/DT	nsubj||reported-29/VBD||patient-27/NN	advmod||reported-29/VBD||verbally-28/RB	advcl||recorded-2/VBD||reported-29/VBD	amod||pain-31/NN||tourniquet-30/JJ	dobj||reported-29/VBD||pain-31/NN	amod||pain-34/NN||surgical-33/JJ	dobj||reported-29/VBD||pain-34/NN	conj_and||pain-31/NN||pain-34/NN	appos||pain-31/NN||duration-36/NN	amod||tolerance-39/NN||tourniquet-38/JJ	prep_of||duration-36/NN||tolerance-39/NN	amod||consumption-42/NN||fentanyl-41/JJ	appos||pain-31/NN||consumption-42/NN	det||operation-45/NN||the-44/DT	prep_during||consumption-42/NN||operation-45/NN	appos||pain-31/NN||time-47/NN	amod||requirement-51/NN||first-49/JJ	amod||requirement-51/NN||analgesic-50/JJ	prep_to||time-47/NN||requirement-51/NN	nn||values-54/NNS||methemoglobin-53/NN	appos||pain-31/NN||values-54/NNS	amod||minutes-57/NNS||60â-56/JJ	prep_at||values-54/NNS||minutes-57/NNS	amod||conditions-60/NNS||operative-59/JJ	prep_at||values-54/NNS||conditions-60/NNS	conj_and||minutes-57/NNS||conditions-60/NNS	amod||consumption-64/NN||24-hour-62/JJ	amod||consumption-64/NN||analgesic-63/JJ	prep_at||values-54/NNS||consumption-64/NN	conj_and||minutes-57/NNS||consumption-64/NN	nn||time-67/NN||discharge-66/NN	prep_at||values-54/NNS||time-67/NN	conj_and||minutes-57/NNS||time-67/NN	amod||parameters-71/NNS||hemodynamic-70/JJ	prep_at||values-54/NNS||parameters-71/NNS	conj_and||minutes-57/NNS||parameters-71/NNS	pain-34||fentanyl-41||yes||we recorded onset time of the sensory block, end time of the sensory block, presence of the motor block, the time when the patient verbally reported tourniquet pain and surgical pain, duration of tourniquet tolerance, fentanyl consumption during the operation, time to first analgesic requirement, methemoglobin values at 60â minutes, operative conditions, 24-hour analgesic consumption, discharge time, and hemodynamic parameters.
root||ROOT-0/null||asbestos-1/NN	conj_or||asbestos-1/NN||asbestos-1/NN	amod||diseases-3/NNS||related-2/JJ	nsubj||include-4/VBP||diseases-3/NNS	rcmod||asbestos-1/NN||include-4/VBP	det||number-6/NN||a-5/DT	dobj||include-4/VBP||number-6/NN	prep_of||number-6/NN||conditions-8/NNS	prep_due_to||asbestos-1/NN||inhalation-11/NN	nn||fibres-14/NNS||asbestos-13/NN	prep_of||inhalation-11/NN||fibres-14/NNS	prep_at||fibres-14/NNS||work-16/NN	prep_at||asbestos-1/NN||home-19/NN	det||environment-23/NN||the-22/DT	prep_in||asbestos-1/NN||environment-23/NN	amod||mesothelioma-28/NN||pleural-27/JJ	prep_such_as||asbestos-1/NN||mesothelioma-28/NN	prep_such_as||asbestos-1/NN||asbestosis-30/NNS	conj_and||mesothelioma-28/NN||asbestosis-30/NNS	amod||plaques-34/NNS||calcified-32/JJ	amod||plaques-34/NNS||pleural-33/JJ	prep_such_as||asbestos-1/NN||plaques-34/NNS	conj_and||mesothelioma-28/NN||plaques-34/NNS	asbestosis-30||asbestos-13||no||asbestos related diseases include a number of conditions due to inhalation of asbestos fibres at work, at home or in the environment, such as pleural mesothelioma, asbestosis and calcified pleural plaques.
aux||compare-2/VB||to-1/TO	csubj||ort-22/VBP||compare-2/VB	det||efficacy-4/NN||the-3/DT	dobj||compare-2/VB||efficacy-4/NN	prep_of||efficacy-4/NN||ondansetron-6/NN	prep_of||efficacy-4/NN||domperidone-8/NN	conj_and||ondansetron-6/NN||domperidone-8/NN	det||treatment-12/NN||the-10/DT	amod||treatment-12/NN||symptomatic-11/JJ	prep_for||compare-2/VB||treatment-12/NN	nsubj||failed-21/VBN||treatment-12/NN	prep_of||treatment-12/NN||vomiting-14/NN	prep_in||vomiting-14/NN||children-16/NNS	prep_with||children-16/NNS||ag-18/NN	aux||failed-21/VBN||have-20/VBP	rcmod||treatment-12/NN||failed-21/VBN	root||ROOT-0/null||ort-22/VBP	domperidone-8||vomiting-14||no_rel||to compare the efficacy of ondansetron and domperidone for the symptomatic treatment of vomiting in children with ag who have failed ort.
nsubj||reporting-3/VBG||we-1/PRP	aux||reporting-3/VBG||are-2/VBP	root||ROOT-0/null||reporting-3/VBG	det||female-6/NN||a-4/DT	amod||female-6/NN||37-year-old-5/JJ	dobj||reporting-3/VBG||female-6/NN	neg||factors-10/NNS||no-8/DT	nn||factors-10/NNS||risk-9/NN	prep_with||reporting-3/VBG||factors-10/NNS	nsubj||developed-16/VBN||factors-10/NNS	amod||cancer-13/NN||cervical-12/JJ	prep_for||factors-10/NNS||cancer-13/NN	aux||developed-16/VBN||had-15/VBD	rcmod||factors-10/NNS||developed-16/VBN	dobj||developed-16/VBN||cin-i-17/NN	dobj||developed-16/VBN||vin-i-19/NN	conj_and||cin-i-17/NN||vin-i-19/NN	det||period-24/NN||a-21/DT	amod||period-24/NN||6-month-22/JJ	nn||period-24/NN||treatment-23/NN	prep_during||developed-16/VBN||period-24/NN	amod||isotretinoin-27/NN||oral-26/JJ	prep_of||period-24/NN||isotretinoin-27/NN	poss||acnevulgaris-31/NNS||her-29/PRP$	amod||acnevulgaris-31/NNS||severe-30/JJ	prep_for||isotretinoin-27/NN||acnevulgaris-31/NNS	acnevulgaris-31||isotretinoin-27||yes||we are reporting a 37-year-old female with no risk factors for cervical cancer who had developed cin-i and vin-i during a 6-month treatment period of oral isotretinoin for her severe acnevulgaris.
aux||investigate-3/VB||to-1/TO	advmod||investigate-3/VB||further-2/RBR	advcl||analyzed-13/VBD||investigate-3/VB	det||diversity-5/NN||the-4/DT	dobj||investigate-3/VB||diversity-5/NN	dobj||investigate-3/VB||origins-7/NNS	conj_and||diversity-5/NN||origins-7/NNS	det||viruses-10/NNS||these-9/DT	prep_of||diversity-5/NN||viruses-10/NNS	nsubj||analyzed-13/VBD||we-12/PRP	root||ROOT-0/null||analyzed-13/VBD	amod||data-15/NNS||molecular-14/JJ	nsubj||isolates-20/VBZ||data-15/NNS	nsubj||compared-22/VBD||data-15/NNS	num||vacv-19/NNS||8-17/CD	nn||vacv-19/NNS||brazilian-18/NN	prep_from||data-15/NNS||vacv-19/NNS	ccomp||analyzed-13/VBD||isolates-20/VBZ	ccomp||analyzed-13/VBD||compared-22/VBD	conj_and||isolates-20/VBZ||compared-22/VBD	amod||genes-24/NNS||several-23/JJ	dobj||compared-22/VBD||genes-24/NNS	vmod||genes-24/NNS||involved-25/VBN	nn||structure-28/NN||virus-27/NN	prep_in||involved-25/VBN||structure-28/NN	prep_in||involved-25/VBN||pathogenicity-30/NN	conj_and||structure-28/NN||pathogenicity-30/NN	virus-27||viruses-10||no||to further investigate the diversity and origins of these viruses, we analyzed molecular data from 8 brazilian vacv isolates and compared several genes involved in virus structure and pathogenicity.
amod||lupuserythematosus-2/NNS||systemic-1/JJ	nsubj||autoimmunedisease-9/NN||lupuserythematosus-2/NNS	appos||lupuserythematosus-2/NNS||sle-4/NN	cop||autoimmunedisease-9/NN||is-6/VBZ	det||autoimmunedisease-9/NN||a-7/DT	amod||autoimmunedisease-9/NN||systemic-8/JJ	root||ROOT-0/null||autoimmunedisease-9/NN	vmod||autoimmunedisease-9/NN||characterized-10/VBN	amod||interferons-15/NNS||increased-12/VBN	nn||interferons-15/NNS||type-13/NN	amod||interferons-15/NNS||i-14/VBG	agent||characterized-10/VBN||interferons-15/NNS	dep||autoimmunedisease-9/NN||ifns-17/NNS	nn||inflammation-21/NN||multiorgan-20/NN	conj_and||autoimmunedisease-9/NN||inflammation-21/NN	advmod||targeting-23/VBG||frequently-22/RB	vmod||inflammation-21/NN||targeting-23/VBG	det||skin-25/NN||the-24/DT	dobj||targeting-23/VBG||skin-25/NN	autoimmunedisease-9||interferons-15||no||systemic lupuserythematosus (sle) is a systemic autoimmunedisease characterized by increased type i interferons (ifns) and multiorgan inflammation frequently targeting the skin.
nsubj||remain-2/VBP||uncertainties-1/NNS	root||ROOT-0/null||remain-2/VBP	prepc_as_to||remain-2/VBP||to-4/TO	det||knowledge-6/NN||the-5/DT	pobj||remain-2/VBP||knowledge-6/NN	prep_of||knowledge-6/NN||predictors-8/NNS	amod||pain-11/NN||hz-related-10/JJ	prep_of||predictors-8/NNS||pain-11/NN	det||role-15/NN||the-14/DT	prep_including||knowledge-6/NN||role-15/NN	amod||therapy-18/NN||antiviral-17/JJ	prep_of||role-15/NN||therapy-18/NN	prepc_in||remain-2/VBP||preventing-20/VBG	dobj||preventing-20/VBG||phn-21/NN	amod||practice-25/NN||ordinary-23/JJ	amod||practice-25/NN||clinical-24/JJ	prep_in||preventing-20/VBG||practice-25/NN	antiviral-17||pain-11||no_rel||uncertainties remain as to the knowledge of predictors of hz-related pain, including the role of antiviral therapy in preventing phn in ordinary clinical practice.
det||attempt-3/NN||a-1/DT	amod||attempt-3/NN||vigorous-2/JJ	nsubj||improve-20/VB||attempt-3/NN	vmod||attempt-3/NN||aiming-4/VBG	nn||clearance-7/NN||tumor-6/NN	prep_at||aiming-4/VBG||clearance-7/NN	vmod||clearance-7/NN||followed-8/VBN	amod||therapy-12/NN||adjuvant-10/JJ	amod||therapy-12/NN||multimodality-11/JJ	agent||followed-8/VBN||therapy-12/NN	det||program-18/NN||a-15/DT	nn||program-18/NN||tumor-16/NN	nn||program-18/NN||surveillance-17/NN	prep_along_with||improve-20/VB||program-18/NN	aux||improve-20/VB||may-19/MD	root||ROOT-0/null||improve-20/VB	dobj||improve-20/VB||survival-21/NN	tumor-16||adjuvant-10||no_rel||a vigorous attempt aiming at tumor clearance followed by adjuvant multimodality therapy along with a tumor surveillance program may improve survival.
det||review-3/NN||this-2/DT	prep_in||discuss-6/VB||review-3/NN	nsubj||discuss-6/VB||we-5/PRP	nsubj||summarize-17/VB||we-5/PRP	root||ROOT-0/null||discuss-6/VB	amod||aspects-8/NNS||basic-7/JJ	dobj||discuss-6/VB||aspects-8/NNS	amod||biology-13/NN||b-cell-10/JJ	conj_and||b-cell-10/JJ||blys-12/JJ	amod||biology-13/NN||blys-12/JJ	prep_of||aspects-8/NNS||biology-13/NN	prep_in||discuss-6/VB||sle-15/NN	conj_and||discuss-6/VB||summarize-17/VB	det||evidence-19/NN||the-18/DT	dobj||summarize-17/VB||evidence-19/NN	vmod||evidence-19/NN||supporting-20/VBG	det||role-22/NN||a-21/DT	dobj||supporting-20/VBG||role-22/NN	prep_of||role-22/NN||belimumab-24/NN	prep_in||belimumab-24/NN||sle-26/NN	nn||studies-30/NNS||animal-29/NN	prep_from||supporting-20/VBG||studies-30/NNS	aux||phase-32/VB||to-31/TO	vmod||supporting-20/VBG||phase-32/VB	amod||trials-35/NNS||iii-33/JJ	amod||trials-35/NNS||clinical-34/JJ	dobj||phase-32/VB||trials-35/NNS	sle-26||basic-7||no_rel||in this review, we discuss basic aspects of b-cell and blys biology in sle and summarize the evidence supporting a role of belimumab in sle, from animal studies to phase iii clinical trials.
nsubj||analogs-5/VBZ||administration-1/NN	amod||insulin-4/NN||rapid-acting-3/JJ	prep_of||administration-1/NN||insulin-4/NN	root||ROOT-0/null||analogs-5/VBZ	num||min-7/NN||15-6/CD	nsubj||spent-19/VBN||min-7/NN	amod||results-10/NNS||mealtime-9/JJ	prep_before||min-7/NN||results-10/NNS	amod||excursions-15/NNS||lower-12/JJR	amod||excursions-15/NNS||postprandial-13/JJ	nn||excursions-15/NNS||glucose-14/NN	prep_in||results-10/NNS||excursions-15/NNS	amod||time-18/NN||more-17/JJR	prep_in||results-10/NNS||time-18/NN	conj_and||excursions-15/NNS||time-18/NN	dep||analogs-5/VBZ||spent-19/VBN	det||â-23/NN||the-21/DT	num||â-23/NN||3.5-22/CD	prep_in||spent-19/VBN||â-23/NN	dobj||spent-19/VBN||$-24/$	num||range-28/NN||10.0-26/CD	nn||range-28/NN||mmol/l-27/NNP	npadvmod||of-33/RB||range-28/NN	amod||risk-32/NN||increased-31/JJ	prep_without||range-28/NN||risk-32/NN	dep||hypoglycemia-34/CD||of-33/RB	num||$-24/$||hypoglycemia-34/CD	hypoglycemia-34||glucose-14||yes||administration of rapid-acting insulin analogs 15 min before mealtime results in lower postprandial glucose excursions and more time spent in the 3.5â10.0 mmol/l range, without increased risk of hypoglycemia.
det||cases-5/NNS||the-2/DT	amod||cases-5/NNS||human-3/JJ	nn||cases-5/NNS||anthrax-4/NN	prep_after||received-17/VBD||cases-5/NNS	conj_and||cases-5/NNS||exposures-7/NNS	prep_after||received-17/VBD||exposures-7/NNS	prep_in||cases-5/NNS||2001-9/CD	det||department-13/NN||the-11/DT	amod||department-13/NN||illinois-12/JJ	nsubj||received-17/VBD||department-13/NN	amod||health-16/NN||public-15/JJ	prep_of||department-13/NN||health-16/NN	root||ROOT-0/null||received-17/VBD	det||number-20/NN||an-18/DT	amod||number-20/NN||increasing-19/VBG	dobj||received-17/VBD||number-20/NN	amod||samples-25/NNS||environmental-22/JJ	conj_and||environmental-22/JJ||human-24/NN	amod||samples-25/NNS||human-24/NN	prep_of||number-20/NN||samples-25/NNS	num||submissions-29/NNS||1,496-27/CD	amod||submissions-29/NNS||environmental-28/JJ	dep||samples-25/NNS||submissions-29/NNS	det||negative-32/JJ||all-31/DT	appos||submissions-29/NNS||negative-32/JJ	prep_for||negative-32/JJ||bacillusanthracis-34/NNS	anthrax-4||bacillusanthracis-34||no||after the human anthrax cases and exposures in 2001, the illinois department of public health received an increasing number of environmental and human samples (1,496 environmental submissions, all negative for bacillusanthracis ).
aux||study-2/VB||to-1/TO	csubj||refractory-14/VBD||study-2/VB	det||efficacy-4/NN||the-3/DT	dobj||study-2/VB||efficacy-4/NN	amod||patients-13/NNS||rituximab-6/JJ	amod||rheumatoidarthritis-9/NNS||active-8/JJ	prep_in||rituximab-6/JJ||rheumatoidarthritis-9/NNS	appos||patients-13/NNS||ra-11/NN	prep_of||efficacy-4/NN||patients-13/NNS	root||ROOT-0/null||refractory-14/VBD	prep_to||refractory-14/VBD||disease-16/NN	xcomp||refractory-14/VBD||modifying-17/VBG	amod||dmards-20/NNS||anti-rheumaticdrugs-18/JJ	dobj||modifying-17/VBG||dmards-20/NNS	det||factor-26/NN||the-23/DT	nn||factor-26/NN||tumor-24/NN	nn||factor-26/NN||necrosis-25/NNS	prep_including||dmards-20/NNS||factor-26/NN	appos||factor-26/NN||tnf-28/NN	nn||antagonists-33/NNS||î-31/NN	nn||antagonists-33/NNS||±-32/NN	dep||factor-26/NN||antagonists-33/NNS	tumor-24||rituximab-6||no_rel||to study the efficacy of rituximab in active rheumatoidarthritis (ra) patients refractory to disease modifying anti-rheumaticdrugs (dmards) including the tumor necrosis factor (tnf)-î± antagonists.
nsubj||common-6/JJ||variants-1/NNS	nsubjpass||associated-15/VBN||variants-1/NNS	nsubj||promote-21/VB||variants-1/NNS	prep_of||variants-1/NNS||hfe-3/NN	cop||common-6/JJ||are-4/VBP	advmod||common-6/JJ||relatively-5/RB	root||ROOT-0/null||common-6/JJ	det||population-10/NN||the-8/DT	amod||population-10/NN||general-9/JJ	prep_in||common-6/JJ||population-10/NN	auxpass||associated-15/VBN||are-12/VBP	advmod||commonly-14/RB||most-13/RBS	advmod||associated-15/VBN||commonly-14/RB	conj_and||common-6/JJ||associated-15/VBN	prep_with||associated-15/VBN||ironoverload-17/NN	aux||promote-21/VB||can-20/MD	conj_but||common-6/JJ||promote-21/VB	amod||iron-24/NN||subclinical-22/JJ	amod||iron-24/NN||cellular-23/JJ	dobj||promote-21/VB||iron-24/NN	vmod||iron-24/NN||loading-25/VBG	advmod||loading-25/VBG||even-26/RB	det||absence-29/NN||the-28/DT	prep_in||loading-25/VBG||absence-29/NN	advmod||identified-32/VBN||clinically-31/RB	amod||disease-33/NN||identified-32/VBN	prep_of||absence-29/NN||disease-33/NN	ironoverload-17||iron-24||no||variants of hfe are relatively common in the general population and are most commonly associated with ironoverload, but can promote subclinical cellular iron loading even in the absence of clinically identified disease.
nsubj||drug-9/NN||levetiracetam-1/NN	appos||levetiracetam-1/NN||lev-3/NN	cop||drug-9/NN||is-5/VBZ	det||drug-9/NN||a-6/DT	amod||drug-9/NN||novel-7/JJ	amod||drug-9/NN||antiepileptic-8/JJ	root||ROOT-0/null||drug-9/NN	nsubjpass||approved-17/VBN||drug-9/NN	appos||drug-9/NN||aed-11/NN	aux||approved-17/VBN||has-14/VBZ	advmod||approved-17/VBN||recently-15/RB	auxpass||approved-17/VBN||been-16/VBN	rcmod||drug-9/NN||approved-17/VBN	amod||treatment-20/NN||add-on-19/JJ	prep_as||approved-17/VBN||treatment-20/NN	amod||types-24/NNS||various-22/JJ	nn||types-24/NNS||seizure-23/NN	prep_for||treatment-20/NN||types-24/NNS	nn||populations-27/NNS||epilepsy-26/NN	prep_in||approved-17/VBN||populations-27/NNS	nsubj||include-29/VBP||populations-27/NNS	rcmod||populations-27/NNS||include-29/VBP	dobj||include-29/VBP||children-30/NNS	amod||seizures-34/NNS||refractory-32/JJ	amod||seizures-34/NNS||partial-33/JJ	prep_for||children-30/NNS||seizures-34/NNS	nn||¥-40/NNP||epilepsy-36/NN	nn||¥-40/NNP||patients-37/NNS	nn||¥-40/NNP||â-38/NN	nn||¥-40/NNP||-39/NNP	prep_in||include-29/VBP||¥-40/NNP	num||years-42/NNS||4-41/CD	npadvmod||old-43/JJ||years-42/NNS	amod||¥-40/NNP||old-43/JJ	amod||seizures-47/NNS||myoclonic-46/JJ	prep_for||¥-40/NNP||seizures-47/NNS	amod||myoclonic-50/JJ||juvenile-49/JJ	amod||patients-70/NNS||myoclonic-50/JJ	nn||patients-70/NNS||epilepsy-51/NN	nn||patients-70/NNS||patients-52/NNS	nn||patients-70/NNS||â-53/NN	amod||patients-70/NNS||-54/JJ	number||12-56/CD||¥-55/CD	num||years-57/NNS||12-56/CD	npadvmod||old-58/JJ||years-57/NNS	amod||patients-70/NNS||old-58/JJ	conj_and||old-58/JJ||for-61/IN	amod||patients-70/NNS||for-61/IN	amod||seizures-65/NNS||primary-62/JJ	amod||seizures-65/NNS||generalized-63/JJ	amod||seizures-65/NNS||tonic-clonic-64/JJ	pobj||for-61/IN||seizures-65/NNS	prep_in||seizures-65/NNS||idiopathic-67/NN	amod||patients-70/NNS||generalized-68/JJ	nn||patients-70/NNS||epilepsy-69/NN	prep_in||seizures-47/NNS||patients-70/NNS	dep||patients-70/NNS||â-72/VBN	nn||¥-74/NNP||-73/NNP	dobj||â-72/VBN||¥-74/NNP	num||years-76/NNS||6-75/CD	npadvmod||old-77/JJ||years-76/NNS	amod||¥-74/NNP||old-77/JJ	nn||approval-80/NN||fda-79/NN	prep_with||â-72/VBN||approval-80/NN	nn||¥-84/NNP||â-82/NNP	nn||¥-84/NNP||-83/NNP	dep||approval-80/NN||¥-84/NNP	num||years-86/NNS||12-85/CD	npadvmod||old-87/JJ||years-86/NNS	amod||¥-84/NNP||old-87/JJ	nn||approval-90/NN||emea-89/NN	prep_with||â-72/VBN||approval-90/NN	epilepsy-69||levetiracetam-1||yes||levetiracetam (lev) is a novel antiepileptic drug (aed) that has recently been approved as add-on treatment for various seizure types in epilepsy populations that include children for refractory partial seizures in epilepsy patients â¥4 years old, for myoclonic seizures in juvenile myoclonic epilepsy patients â¥12 years old, and for primary generalized tonic-clonic seizures in idiopathic generalized epilepsy patients (â¥6 years old with fda approval; â¥12 years old with emea approval).
dep||vitro-2/NN||in-1/IN	amod||exposure-3/NN||vitro-2/NN	nsubj||revealed-15/VBD||exposure-3/NN	amod||samples-6/NNS||patient-5/JJ	prep_of||exposure-3/NN||samples-6/NNS	aux||etoposide-8/VB||to-7/TO	vmod||exposure-3/NN||etoposide-8/VB	det||agent-13/NN||a-10/DT	advmod||damaging-12/VBG||dna-11/RB	amod||agent-13/NN||damaging-12/VBG	appos||exposure-3/NN||agent-13/NN	root||ROOT-0/null||revealed-15/VBD	num||â-18/NN||three-16/CD	amod||â-18/NN||distinct-17/JJ	dobj||revealed-15/VBD||â-18/NN	amod||response-22/NN||$-19/$	dep||$-19/$||dna-20/JJ	nn||response-22/NN||damage-21/NN	prep||â-18/NN||response-22/NN	appos||response-22/NN||ddr-24/NN	punct||$-28/$||/-26/:	dep||$-28/$||apoptosisâ-27/RB	dep||response-22/NN||$-28/$	number||1-30/CD||profiles-29/CD	num||$-28/$||1-30/CD	nn||blasts-33/NNS||aml-32/NN	dep||response-22/NN||blasts-33/NNS	det||ddr-37/NN||a-35/DT	amod||ddr-37/NN||defective-36/JJ	prep_with||blasts-33/NNS||ddr-37/NN	prep_with||blasts-33/NNS||failure-39/NN	conj_and||ddr-37/NN||failure-39/NN	aux||undergo-41/VB||to-40/TO	vmod||blasts-33/NNS||undergo-41/VB	dobj||undergo-41/VB||apoptosis-42/NNS	dep||blasts-47/NNS||2-44/LS	nn||blasts-47/NNS||aml-46/NN	dep||response-22/NN||blasts-47/NNS	conj_and||blasts-33/NNS||blasts-47/NNS	amod||ddr-50/NN||proficient-49/JJ	prep_with||blasts-47/NNS||ddr-50/NN	prep_with||blasts-47/NNS||failure-52/NN	conj_and||ddr-50/NN||failure-52/NN	aux||undergo-54/VB||to-53/TO	vmod||failure-52/NN||undergo-54/VB	dobj||undergo-54/VB||apoptosis-55/NNS	dep||blasts-60/NNS||3-57/LS	nn||blasts-60/NNS||aml-59/NN	dep||response-22/NN||blasts-60/NNS	conj_and||blasts-33/NNS||blasts-60/NNS	prep_with||blasts-60/NNS||proficiency-62/NN	det||ddr-65/NN||both-64/DT	prep_in||proficiency-62/NN||ddr-65/NN	amod||pathways-68/NNS||apoptosis-67/JJ	dep||response-22/NN||pathways-68/NNS	conj_and||blasts-33/NNS||pathways-68/NNS	aml-59||etoposide-8||yes||in vitro exposure of patient samples to etoposide, a dna damaging agent, revealed three distinct âdna damage response (ddr)/apoptosisâ? profiles 1) aml blasts with a defective ddr and failure to undergo apoptosis; 2) aml blasts with proficient ddr and failure to undergo apoptosis; 3) aml blasts with proficiency in both ddr and apoptosis pathways.
nsubj||problem-9/NN||hepatitisbvirus-1/NNS	appos||hepatitisbvirus-1/NNS||hbv-3/NN	advmod||problem-9/NN||infection-5/RB	cop||problem-9/NN||is-6/VBZ	amod||problem-9/NN||significant-7/JJ	nn||problem-9/NN||health-8/NN	root||ROOT-0/null||problem-9/NN	mark||lead-14/VB||as-11/IN	nsubj||lead-14/VB||it-12/PRP	aux||lead-14/VB||can-13/MD	advcl||problem-9/NN||lead-14/VB	prep_to||lead-14/VB||chronichepatitis-16/NNS	prep_to||lead-14/VB||livercirrhosis-18/NNS	conj_and||chronichepatitis-16/NNS||livercirrhosis-18/NNS	amod||carcinoma-22/NN||hepatic-21/JJ	prep_to||lead-14/VB||carcinoma-22/NN	conj_and||chronichepatitis-16/NNS||carcinoma-22/NN	hbv-3||hepatitisbvirus-1||no||hepatitisbvirus (hbv) infection is significant health problem, as it can lead to chronichepatitis, livercirrhosis, and hepatic carcinoma.
det||results-2/NNS||these-1/DT	nsubj||exceeded-3/VBD||results-2/NNS	root||ROOT-0/null||exceeded-3/VBD	det||responses-7/NNS||the-4/DT	amod||responses-7/NNS||human-5/JJ	nn||responses-7/NNS||antibody-6/NN	dobj||exceeded-3/VBD||responses-7/NNS	det||vaccine-13/NN||the-9/DT	amod||vaccine-13/NN||inactivated-10/JJ	amod||vaccine-13/NN||sub-virion-11/JJ	amod||vaccine-13/NN||h5n1-12/JJ	prep_against||exceeded-3/VBD||vaccine-13/NN	h5n1-12||antibody-6||no_rel||these results exceeded the human antibody responses against the inactivated sub-virion h5n1 vaccine.
amod||sepsis-2/NN||severe-1/JJ	nsubj||emerged-4/VBN||sepsis-2/NN	aux||emerged-4/VBN||has-3/VBZ	root||ROOT-0/null||emerged-4/VBN	det||cause-8/NN||a-6/DT	amod||cause-8/NN||major-7/JJ	prep_as||emerged-4/VBN||cause-8/NN	prep_of||cause-8/NN||admission-10/NN	prep_of||cause-8/NN||mortality-12/NN	conj_and||admission-10/NN||mortality-12/NN	amod||patients-16/NNS||hospitalized-14/JJ	nn||patients-16/NNS||hiv/aids-15/NNS	prep_for||admission-10/NN||patients-16/NNS	advmod||affecting-19/VBG||significantly-18/RB	xcomp||emerged-4/VBN||affecting-19/VBG	amod||survival-24/NN||short-20/JJ	conj_and||short-20/JJ||longer-term-23/JJ	amod||survival-24/NN||longer-term-23/JJ	dobj||affecting-19/VBG||survival-24/NN	advmod||ill-27/JJ||critically-26/RB	amod||patients-29/NNS||ill-27/JJ	nn||patients-29/NNS||hiv/aids-28/NN	prep_of||survival-24/NN||patients-29/NNS	aids--1||hiv--1||no||severe sepsis has emerged as a major cause of admission and mortality for hospitalized hiv/aids patients, significantly affecting short- and longer-term survival of critically ill hiv/aids patients.
nsubj||considerations-4/NNS||these-1/DT	cop||considerations-4/NNS||are-2/VBP	amod||considerations-4/NNS||important-3/JJ	root||ROOT-0/null||considerations-4/NNS	prep_for||considerations-4/NNS||communities-6/NNS	vmod||communities-6/NNS||hard-hit-7/VBN	agent||hard-hit-7/VBN||hiv-9/NN	agent||hard-hit-7/VBN||aids-11/NNS	conj_and||hiv-9/NN||aids-11/NNS	prep||hard-hit-7/VBN||given-13/VBN	det||extent-15/NN||the-14/DT	pobj||given-13/VBN||extent-15/NN	pobj||given-13/VBN||nature-17/NN	conj_and||extent-15/NN||nature-17/NN	prep_of||extent-15/NN||deprivation-19/NN	det||risk-23/NN||the-21/DT	amod||risk-23/NN||long-term-22/JJ	pobj||given-13/VBN||risk-23/NN	conj_and||extent-15/NN||risk-23/NN	amod||capital-26/NN||human-25/JJ	prep_to||risk-23/NN||capital-26/NN	det||willingness-31/NN||the-28/DT	amod||willingness-31/NN||current-29/JJ	amod||willingness-31/NN||political-30/JJ	pobj||given-13/VBN||willingness-31/NN	conj_and||extent-15/NN||willingness-31/NN	prep_to||willingness-31/NN||act-33/NN	aids-11||hiv-9||no||these are important considerations for communities hard-hit by hiv and aids, given the extent and nature of deprivation, the long-term risk to human capital and the current political willingness to act.
det||study-4/NN||a-1/DT	amod||study-4/NN||recent-2/JJ	nn||study-4/NN||retrospective-3/NN	nsubj||showed-18/VBD||study-4/NN	num||patients-8/NNS||174-6/CD	nn||patients-8/NNS||gbs-7/NN	prep_in||study-4/NN||patients-8/NNS	vmod||patients-8/NNS||enrolled-9/VBN	prep_in||enrolled-9/VBN||one-11/CD	poss||trials-17/NNS||our-13/PRP$	amod||trials-17/NNS||randomized-14/JJ	amod||trials-17/NNS||controlled-15/JJ	amod||trials-17/NNS||clinical-16/JJ	prep_of||one-11/CD||trials-17/NNS	root||ROOT-0/null||showed-18/VBD	mark||recovered-34/VBD||that-19/IN	nsubj||recovered-34/VBD||patients-20/NNS	det||increase-24/NN||a-22/DT	amod||increase-24/NN||minor-23/JJ	prep_with||patients-20/NNS||increase-24/NN	nn||level-28/NN||serum-26/NN	nn||level-28/NN||igg-27/NN	prep_of||increase-24/NN||level-28/NN	amod||dose-33/NN||standard-30/JJ	amod||dose-33/NN||single-31/JJ	nn||dose-33/NN||ivig-32/NN	prep_after||level-28/NN||dose-33/NN	ccomp||showed-18/VBD||recovered-34/VBD	advmod||slower-36/JJR||significantly-35/RB	acomp||recovered-34/VBD||slower-36/JJR	gbs-7||ivig-32||yes||a recent retrospective study in 174 gbs patients enrolled in one of our randomized controlled clinical trials showed that patients with a minor increase of serum igg level after standard single ivig dose recovered significantly slower.
prep_in||changed-11/VBN||2002-2/CD	det||treatment-6/NN||the-4/DT	amod||treatment-6/NN||first-line-5/JJ	nsubjpass||changed-11/VBN||treatment-6/NN	amod||malaria-9/NN||uncomplicated-8/JJ	prep_for||treatment-6/NN||malaria-9/NN	auxpass||changed-11/VBN||was-10/VBD	root||ROOT-0/null||changed-11/VBN	prep_to||changed-11/VBN||artemether-lumefantrine-13/NN	nsubj||proved-19/VBN||artemether-lumefantrine-13/NN	nsubj||efficacious-23/JJ||artemether-lumefantrine-13/NN	appos||artemether-lumefantrine-13/NN||al-15/NNP	aux||proved-19/VBN||has-18/VBZ	rcmod||artemether-lumefantrine-13/NN||proved-19/VBN	aux||efficacious-23/JJ||to-20/TO	cop||efficacious-23/JJ||be-21/VB	advmod||efficacious-23/JJ||highly-22/RB	xcomp||proved-19/VBN||efficacious-23/JJ	prepc_against||efficacious-23/JJ||multidrug-25/VBG	amod||falciparum-28/NN||resistant-26/JJ	nn||falciparum-28/NN||plasmodium-27/NN	dobj||multidrug-25/VBG||falciparum-28/NN	malaria-9||lumefantrine--1||yes||in 2002, the first-line treatment for uncomplicated malaria was changed to artemether-lumefantrine (al) that has proved to be highly efficacious against multidrug resistant plasmodium falciparum .
det||strength-2/NN||the-1/DT	nsubj||led-17/VBD||strength-2/NN	det||evidence-5/NN||the-4/DT	prep_of||strength-2/NN||evidence-5/NN	vmod||evidence-5/NN||linking-6/VBG	advmod||linking-6/VBG||concurrency-7/RB	aux||hiv-9/VB||to-8/TO	xcomp||linking-6/VBG||hiv-9/VB	nn||severity-11/NN||epidemic-10/NN	dobj||hiv-9/VB||severity-11/NN	amod||africa-16/NN||southern-13/JJ	conj_and||southern-13/JJ||eastern-15/JJ	amod||africa-16/NN||eastern-15/JJ	prep_in||hiv-9/VB||africa-16/NN	root||ROOT-0/null||led-17/VBD	det||programme-22/NN||the-18/DT	amod||programme-22/NN||joint-19/JJ	amod||programme-22/NN||united-20/JJ	nn||programme-22/NN||nations-21/NNS	dobj||led-17/VBD||programme-22/NN	prep_on||programme-22/NN||hiv/aids-24/NNS	det||community-30/NN||the-26/DT	amod||community-30/NN||southern-27/JJ	nn||community-30/NN||african-28/NN	nn||community-30/NN||development-29/NN	prep_on||programme-22/NN||community-30/NN	conj_and||hiv/aids-24/NNS||community-30/NN	prep_in||led-17/VBD||2006-32/CD	aux||conclude-34/VB||to-33/TO	vmod||led-17/VBD||conclude-34/VB	mark||drivers-57/NNS||that-35/IN	amod||rates-37/NNS||high-36/JJ	nsubj||drivers-57/NNS||rates-37/NNS	amod||partnerships-41/NNS||concurrent-39/JJ	amod||partnerships-41/NNS||sexual-40/JJ	prep_of||rates-37/NNS||partnerships-41/NNS	vmod||rates-37/NNS||combined-43/VBN	amod||rates-46/NNS||low-45/JJ	prep_with||combined-43/VBN||rates-46/NNS	amod||circumcision-49/NN||male-48/JJ	nn||use-53/NN||circumcision-49/NN	conj_and||circumcision-49/NN||infrequent-51/JJ	nn||use-53/NN||infrequent-51/JJ	nn||use-53/NN||condom-52/NN	prep_of||rates-46/NNS||use-53/NN	cop||drivers-57/NNS||are-55/VBP	amod||drivers-57/NNS||major-56/JJ	ccomp||conclude-34/VB||drivers-57/NNS	det||epidemic-61/NN||the-59/DT	nn||epidemic-61/NN||aids-60/NNS	prep_of||drivers-57/NNS||epidemic-61/NN	amod||africa-64/NN||southern-63/JJ	prep_in||epidemic-61/NN||africa-64/NN	aids-60||hiv-9||no||the strength of the evidence linking concurrency to hiv epidemic severity in southern and eastern africa led the joint united nations programme on hiv/aids and the southern african development community in 2006 to conclude that high rates of concurrent sexual partnerships, combined with low rates of male circumcision and infrequent condom use, are major drivers of the aids epidemic in southern africa.
det||group-3/NN||the-1/DT	amod||group-3/NN||whole-2/JJ	nsubj||presented-8/VBD||group-3/NN	num||patients-7/NNS||81-5/CD	amod||patients-7/NNS||acromegalic-6/JJ	prep_of||group-3/NN||patients-7/NNS	root||ROOT-0/null||presented-8/VBD	advmod||higher-11/JJR||significantly-10/RB	amod||biomarkers-32/NNS||higher-11/JJR	amod||biomarkers-32/NNS||anthropometric-12/JJ	nn||biomarkers-32/NNS||parameters-13/NNS	nn||circumference-24/NNS||weight-17/NN	conj_and||weight-17/NN||bmi-19/NN	nn||circumference-24/NNS||bmi-19/NN	conj_and||weight-17/NN||waist-21/NN	nn||circumference-24/NNS||waist-21/NN	conj_and||weight-17/NN||hip-23/NN	nn||circumference-24/NNS||hip-23/NN	prep_such_as||parameters-13/NNS||circumference-24/NNS	conj_but||parameters-13/NNS||with-27/IN	nn||biomarkers-32/NNS||with-27/IN	advmod||favourable-29/JJ||more-28/RBR	pobj||with-27/IN||favourable-29/JJ	amod||biomarkers-32/NNS||cardiovascular-30/JJ	nn||biomarkers-32/NNS||risk-31/NN	prep_with||presented-8/VBD||biomarkers-32/NNS	amod||glucose-38/NN||fasting-36/JJ	nn||glucose-38/NN||plasma-37/NN	prep_such_as||biomarkers-32/NNS||glucose-38/NN	amod||cholesterol-41/NN||total-40/JJ	prep_such_as||biomarkers-32/NNS||cholesterol-41/NN	conj_and||glucose-38/NN||cholesterol-41/NN	prep_such_as||biomarkers-32/NNS||triglycerides-43/NNPS	conj_and||glucose-38/NN||triglycerides-43/NNPS	nn||levels-46/NNS||hdl-45/NN	prep_such_as||biomarkers-32/NNS||levels-46/NNS	conj_and||glucose-38/NN||levels-46/NNS	prep_in||presented-8/VBD||comparison-49/NN	poss||controls-53/NNS||their-51/PRP$	amod||controls-53/NNS||respective-52/JJ	prep_to||presented-8/VBD||controls-53/NNS	glucose-38||acromegalic-6||no_rel||the whole group of 81 acromegalic patients presented with significantly higher anthropometric parameters, such as weight, bmi, waist and hip circumference, but with more favourable cardiovascular risk biomarkers, such as fasting plasma glucose, total cholesterol, triglycerides and hdl levels, in comparison to their respective controls.
advmod||assessed-17/VBN||here-1/RB	det||significance-5/NN||the-3/DT	amod||significance-5/NN||prognostic-4/JJ	nsubjpass||assessed-17/VBN||significance-5/NN	det||marker-9/NN||this-7/DT	amod||marker-9/NN||epigenetic-8/JJ	prep_of||significance-5/NN||marker-9/NN	amod||toxicity-15/NN||severe-13/JJ	amod||toxicity-15/NN||5-fu-14/JJ	prep_with_respect_to||marker-9/NN||toxicity-15/NN	auxpass||assessed-17/VBN||was-16/VBD	root||ROOT-0/null||assessed-17/VBN	num||patients-21/NNS||27-19/CD	nn||patients-21/NNS||cancer-20/NN	prep_in||assessed-17/VBN||patients-21/NNS	vmod||patients-21/NNS||receiving-22/VBG	dobj||receiving-22/VBG||5-fu-23/JJ	vmod||5-fu-23/JJ||based-24/VBN	advmod||based-24/VBN||chemotherapy-25/RB	num||patients-29/NNS||17-28/CD	prep_including||based-24/VBN||patients-29/NNS	vmod||patients-29/NNS||experiencing-30/VBG	amod||effects-34/NNS||severe-31/JJ	amod||effects-34/NNS||toxic-32/JJ	nn||effects-34/NNS||side-33/NN	dobj||experiencing-30/VBG||effects-34/NNS	nn||administration-37/NN||drug-36/NN	prep_following||effects-34/NNS||administration-37/NN	prep_of||none-39/NN||administration-37/NN	nsubj||carriers-43/NNS||none-39/NN	cop||carriers-43/NNS||were-42/VBD	rcmod||administration-37/NN||carriers-43/NNS	det||mutation-49/NN||a-45/DT	amod||mutation-49/NN||known-46/JJ	amod||mutation-49/NN||deleterious-47/JJ	amod||mutation-49/NN||dpyd-48/JJ	prep_of||carriers-43/NNS||mutation-49/NN	num||patients-54/NNS||ten-52/CD	nn||patients-54/NNS||control-53/NN	dobj||receiving-22/VBG||patients-54/NNS	conj_and||5-fu-23/JJ||patients-54/NNS	5-fu-23||ten-52||no_rel||here, the prognostic significance of this epigenetic marker with respect to severe 5-fu toxicity was assessed in 27 cancer patients receiving 5-fu based chemotherapy, including 17 patients experiencing severe toxic side effects following drug administration, none of which were carriers of a known deleterious dpyd mutation, and ten control patients.
amod||inhibitor-3/NN||urinary-1/JJ	nn||inhibitor-3/NN||trypsin-2/NN	nsubjpass||used-16/VBN||inhibitor-3/NN	appos||inhibitor-3/NN||uti-5/NN	det||inhibitor-11/NN||a-8/DT	amod||inhibitor-11/NN||serine-9/JJ	nn||inhibitor-11/NN||protease-10/NN	appos||inhibitor-3/NN||inhibitor-11/NN	aux||used-16/VBN||has-13/VBZ	auxpass||used-16/VBN||been-14/VBN	advmod||used-16/VBN||widely-15/RB	root||ROOT-0/null||used-16/VBN	prep_in||used-16/VBN||japan-18/NN	det||drug-21/NN||a-20/DT	prep_as||used-16/VBN||drug-21/NN	prep_for||drug-21/NN||patients-23/NNS	amod||inflammatory-26/JJ||acute-25/JJ	amod||disorders-27/NNS||inflammatory-26/JJ	prep_with||patients-23/NNS||disorders-27/NNS	prep_such_as||disorders-27/NNS||disseminatedintravascularcoagulation-30/NN	appos||disseminatedintravascularcoagulation-30/NN||dic-32/NN	prep_such_as||disorders-27/NNS||shock-35/NN	conj_and||disseminatedintravascularcoagulation-30/NN||shock-35/NN	prep_such_as||disorders-27/NNS||pancreatitis-38/NNS	conj_and||disseminatedintravascularcoagulation-30/NN||pancreatitis-38/NNS	disseminatedintravascularcoagulation-30||dic-32||no_rel||urinary trypsin inhibitor (uti), a serine protease inhibitor, has been widely used in japan as a drug for patients with acute inflammatory disorders such as disseminatedintravascularcoagulation (dic), shock, and pancreatitis.
det||consumption-8/NN||the-1/DT	amod||consumption-8/NN||acute-2/JJ	advmod||acute-2/JJ||hypersensitivity-3/RB	prep||acute-2/JJ||to-4/TO	conj_and||acute-2/JJ||increased-6/JJ	amod||consumption-8/NN||increased-6/JJ	amod||consumption-8/NN||voluntary-7/JJ	nsubj||observed-11/VBD||consumption-8/NN	prep_of||consumption-8/NN||ethanol-10/NN	root||ROOT-0/null||observed-11/VBD	amod||mice-15/NNS||lightweight-13/JJ	nn||mice-15/NNS||heterozygous-14/NNS	prep_in||observed-11/VBD||mice-15/NNS	prep_in||observed-11/VBD||combination-17/NN	det||elegans-26/NNS||the-19/DT	amod||elegans-26/NNS||observed-20/JJ	advmod||observed-20/JJ||hypersensitivity-21/RB	aux||ethanol-23/VB||to-22/TO	xcomp||observed-20/JJ||ethanol-23/VB	prep_in||ethanol-23/VB||c.-25/NN	prep_with||observed-11/VBD||elegans-26/NNS	amod||elegans-26/NNS||unc-79-27/JJ	amod||elegans-26/NNS||unc-80-29/JJ	conj_and||unc-79-27/JJ||unc-80-29/JJ	amod||elegans-26/NNS||nca-1-32/JJ	conj_and||unc-79-27/JJ||nca-1-32/JJ	amod||mutants-36/NNS||nca-2-34/JJ	amod||mutants-36/NNS||double-35/JJ	nsubj||suggests-37/VBZ||mutants-36/NNS	parataxis||observed-11/VBD||suggests-37/VBZ	det||pathway-41/NN||a-38/DT	amod||pathway-41/NN||novel-39/JJ	amod||pathway-41/NN||conserved-40/JJ	dobj||suggests-37/VBZ||pathway-41/NN	nsubj||influence-44/VB||pathway-41/NN	aux||influence-44/VB||might-43/MD	rcmod||pathway-41/NN||influence-44/VB	amod||behaviors-46/NNS||alcohol-related-45/JJ	dobj||influence-44/VB||behaviors-46/NNS	prep_in||influence-44/VB||humans-48/NNS	hypersensitivity-21||hypersensitivity-21||no||the acute hypersensitivity to and increased voluntary consumption of ethanol observed in lightweight heterozygous mice in combination with the observed hypersensitivity to ethanol in c. elegans unc-79 , unc-80 , and nca-1 ; nca-2 double mutants suggests a novel conserved pathway that might influence alcohol-related behaviors in humans .
det||proof-3/NN||this-2/DT	prep_for||compared-9/VBD||proof-3/NN	amod||study-6/NN||principal-5/JJ	prep_of||proof-3/NN||study-6/NN	nsubj||compared-9/VBD||we-8/PRP	root||ROOT-0/null||compared-9/VBD	amod||clearance-11/NN||bacillary-10/JJ	dobj||compared-9/VBD||clearance-11/NN	det||lungs-14/NNS||the-13/DT	prep_from||compared-9/VBD||lungs-14/NNS	prep_of||lungs-14/NNS||mtb-16/NN	amod||mice-19/NNS||infected-18/JJ	nsubj||treated-20/VBN||mice-19/NNS	parataxis||compared-9/VBD||treated-20/VBN	det||isoniazid-25/NN||the-22/DT	amod||isoniazid-25/NN||anti-tb-23/JJ	nn||isoniazid-25/NN||drug-24/NN	prep_with||treated-20/VBN||isoniazid-25/NN	appos||isoniazid-25/NN||inh-27/NN	det||presence-31/NN||the-30/DT	prep_in||treated-20/VBN||presence-31/NN	prep_in||treated-20/VBN||absence-33/NN	conj_and||presence-31/NN||absence-33/NN	det||inhibitor-39/NN||an-35/DT	amod||inhibitor-39/NN||immunomodulatory-36/JJ	amod||inhibitor-39/NN||phosphodiesterase-37/JJ	dep||phosphodiesterase-37/JJ||4-38/CD	prep_of||presence-31/NN||inhibitor-39/NN	appos||inhibitor-39/NN||pde4i-41/NNP	dep||treated-20/VBN||cc-3052-44/JJ	isoniazid-25||tb--1||no_rel||for this proof of principal study, we compared bacillary clearance from the lungs of mtb -infected mice treated with the anti-tb drug isoniazid (inh) in the presence and absence of an immunomodulatory phosphodiesterase 4 inhibitor (pde4i), cc-3052.
nsubjpass||employed-3/VBN||autodock-1/NN	nsubj||dock-5/VB||autodock-1/NN	auxpass||employed-3/VBN||was-2/VBD	root||ROOT-0/null||employed-3/VBN	aux||dock-5/VB||to-4/TO	xcomp||employed-3/VBN||dock-5/VB	det||polymerase/rt-8/NN||the-6/DT	nn||polymerase/rt-8/NN||hbv-7/NN	dobj||dock-5/VB||polymerase/rt-8/NN	dobj||dock-5/VB||adefovir-10/NN	conj_and||polymerase/rt-8/NN||adefovir-10/NN	hbv-7||adefovir-10||yes||autodock was employed to dock the hbv polymerase/rt and adefovir.
advmod||cultured-4/VBN||when-1/WRB	nsubjpass||cultured-4/VBN||viruses-2/NNS	auxpass||cultured-4/VBN||are-3/VBP	advcl||cause-20/VB||cultured-4/VBN	amod||passage-7/NN||serial-6/JJ	agent||cultured-4/VBN||passage-7/NN	amod||cells-11/NNS||susceptible-9/JJ	nn||cells-11/NNS||host-10/NN	prep_on||passage-7/NN||cells-11/NNS	det||presence-14/NN||the-13/DT	nsubj||cause-20/VB||presence-14/NN	amod||particles-18/NNS||virus-like-16/JJ	nn||particles-18/NNS||di-17/NNP	prep_of||presence-14/NN||particles-18/NNS	aux||cause-20/VB||can-19/MD	root||ROOT-0/null||cause-20/VB	nn||populations-22/NNS||virus-21/NN	dobj||cause-20/VB||populations-22/NNS	aux||rise-24/VB||to-23/TO	vmod||cause-20/VB||rise-24/VB	vmod||cause-20/VB||fall-26/VB	conj_and||rise-24/VB||fall-26/VB	xcomp||cause-20/VB||reflecting-28/VBG	amod||interactions-30/NNS||predator-prey-29/JJ	dobj||reflecting-28/VBG||interactions-30/NNS	prep_between||interactions-30/NNS||di-32/FW	nn||particles-35/NNS||virus-34/NN	prep_between||interactions-30/NNS||particles-35/NNS	conj_and||di-32/FW||particles-35/NNS	virus-34||viruses-2||no||when viruses are cultured by serial passage on susceptible host cells, the presence of virus-like di particles can cause virus populations to rise and fall, reflecting predator-prey interactions between di and virus particles.
aux||identify-2/VB||to-1/TO	dep||meet-8/VBP||identify-2/VB	conj_and||identify-2/VB||implement-4/VB	dep||meet-8/VBP||implement-4/VB	dobj||identify-2/VB||strategies-5/NNS	det||help-7/NN||that-6/DT	nsubj||meet-8/VBP||help-7/NN	root||ROOT-0/null||meet-8/VBP	nn||requirements-11/NNS||safety-9/NN	nn||requirements-11/NNS||monitoring-10/NN	dobj||meet-8/VBP||requirements-11/NNS	det||context-14/NN||the-13/DT	prep_in||requirements-11/NNS||context-14/NN	det||study-18/NN||an-16/DT	amod||study-18/NN||observational-17/JJ	prep_of||context-14/NN||study-18/NN	amod||treatment-27/NN||artemether-lumefantrine-20/JJ	appos||treatment-27/NN||al-22/NNP	amod||treatment-27/NN||administered-24/VBN	prep_as||administered-24/VBN||first-line-26/NN	prep_for||meet-8/VBP||treatment-27/NN	amod||malaria-30/NN||uncomplicated-29/JJ	prep_for||treatment-27/NN||malaria-30/NN	amod||tanzania-33/NN||rural-32/JJ	prep_in||malaria-30/NN||tanzania-33/NN	malaria-30||lumefantrine--1||yes||to identify and implement strategies that help meet safety monitoring requirements in the context of an observational study for artemether-lumefantrine (al) administered as first-line treatment for uncomplicated malaria in rural tanzania.
dep||voclosporin-5/NN||e-1/SYM	amod||voclosporin-5/NN||isa247-3/JJ	root||ROOT-0/null||voclosporin-5/NN	nsubj||is-12/VBZ||voclosporin-5/NN	cop||analogue-10/NN||is-7/VBZ	det||analogue-10/NN||a-8/DT	nn||analogue-10/NN||cyclosporina-9/NN	rcmod||voclosporin-5/NN||analogue-10/NN	rcmod||analogue-10/NN||is-12/VBZ	amod||development-16/NN||late-stage-14/JJ	amod||development-16/NN||clinical-15/JJ	prep_in||is-12/VBZ||development-16/NN	det||treatment-19/NN||the-18/DT	prep_for||development-16/NN||treatment-19/NN	prep_of||treatment-19/NN||autoimmunediseases-21/NNS	det||prevention-24/NN||the-23/DT	prep_for||development-16/NN||prevention-24/NN	conj_and||treatment-19/NN||prevention-24/NN	nn||rejection-28/NN||organ-26/NN	nn||rejection-28/NN||graft-27/NN	prep_of||prevention-24/NN||rejection-28/NN	cyclosporina-9||autoimmunediseases-21||no_rel||e -isa247 (voclosporin) is a cyclosporina analogue that is in late-stage clinical development for the treatment of autoimmunediseases and the prevention of organ graft rejection.
aux||investigate-2/VB||to-1/TO	advcl||tested-41/VBD||investigate-2/VB	det||occurrence-5/NN||the-3/DT	amod||occurrence-5/NN||possible-4/JJ	dobj||investigate-2/VB||occurrence-5/NN	iobj||investigate-2/VB||occurrence-5/NN	prep_of||occurrence-5/NN||humanimmunodeficiencyvirus-7/NNS	appos||humanimmunodeficiencyvirus-7/NNS||hiv-9/NN	amod||virus-15/NN||human-12/JJ	amod||virus-15/NN||t-cell-13/JJ	amod||virus-15/NN||lymphotropic-14/JJ	prep_of||occurrence-5/NN||virus-15/NN	conj_or||humanimmunodeficiencyvirus-7/NNS||virus-15/NN	nn||i-18/NNS||type-17/NN	appos||virus-15/NN||i-18/NNS	appos||occurrence-5/NN||htlv-i-20/NNP	dep||occurrence-5/NN||infections-22/NNS	det||states-26/NNS||the-24/DT	amod||states-26/NNS||united-25/VBN	prep_in||infections-22/NNS||states-26/NNS	prep_prior_to||investigate-2/VB||1979-1981-29/CD	advmod||recognized-38/VBN||when-31/WRB	nsubjpass||recognized-38/VBN||acquiredimmunedeficiencysyndrome-32/NN	appos||acquiredimmunedeficiencysyndrome-32/NN||aids-34/NNS	auxpass||recognized-38/VBN||was-36/VBD	advmod||recognized-38/VBN||first-37/RB	advcl||investigate-2/VB||recognized-38/VBN	nsubj||tested-41/VBD||we-40/PRP	root||ROOT-0/null||tested-41/VBD	dobj||tested-41/VBD||sera-42/NN	amod||women-46/NNS||310-44/JJ	amod||women-46/NNS||pregnant-45/JJ	prep_from||tested-41/VBD||women-46/NNS	nsubj||participated-48/VBD||women-46/NNS	rcmod||women-46/NNS||participated-48/VBD	det||project-53/NN||the-50/DT	amod||project-53/NN||collaborative-51/JJ	amod||project-53/NN||perinatal-52/JJ	prep_in||participated-48/VBD||project-53/NN	det||1959-1964-57/NN||the-55/DT	nn||1959-1964-57/NN||period-56/NN	prep_during||participated-48/VBD||1959-1964-57/NN	prep_for||1959-1964-57/NN||hiv-59/NN	prep_for||1959-1964-57/NN||htlv-iantibody-61/NN	conj_and||hiv-59/NN||htlv-iantibody-61/NN	acquiredimmunedeficiencysyndrome-32||humanimmunodeficiencyvirus-7||no||to investigate the possible occurrence of humanimmunodeficiencyvirus (hiv) or human t-cell lymphotropic virus, type i (htlv-i) infections in the united states prior to 1979-1981, when acquiredimmunedeficiencysyndrome (aids) was first recognized, we tested sera from 310 pregnant women who participated in the collaborative perinatal project during the period 1959-1964 for hiv and htlv-iantibody.
nsubj||endocrinedisease-5/NN||endogenous-1/NNS	advmod||endocrinedisease-5/NN||cushingsyndrome-2/RB	cop||endocrinedisease-5/NN||is-3/VBZ	det||endocrinedisease-5/NN||an-4/DT	root||ROOT-0/null||endocrinedisease-5/NN	vmod||endocrinedisease-5/NN||caused-6/VBN	amod||secretion-9/NN||excessive-8/JJ	agent||caused-6/VBN||secretion-9/NN	nn||hormone-12/NN||adrenocorticotropin-11/NN	prep_of||secretion-9/NN||hormone-12/NN	quantmod||80-15/CD||approximately-14/RB	num||%-16/NN||80-15/CD	prep_in||caused-6/VBN||%-16/NN	prep_of||%-16/NN||cases-18/NNS	advmod||caused-6/VBN||usually-20/RB	det||adenoma-25/NN||a-22/DT	advmod||corticotroph-24/JJ||pituitary-23/RB	amod||adenoma-25/NN||corticotroph-24/JJ	agent||caused-6/VBN||adenoma-25/NN	amod||-RSB--30/NNP||cushingdisease-27/JJ	nn||-RSB--30/NNP||-LSB--28/NNP	nn||-RSB--30/NNP||cd-29/NN	appos||adenoma-25/NN||-RSB--30/NNP	adrenocorticotropin-11||endocrinedisease-5||no_rel||endogenous cushingsyndrome is an endocrinedisease caused by excessive secretion of adrenocorticotropin hormone in approximately 80% of cases, usually by a pituitary corticotroph adenoma (cushingdisease [cd]).
det||emergence-4/NN||the-3/DT	prep_because_of||recommended-23/VBN||emergence-4/NN	amod||resistance-7/NN||chloroquine-6/JJ	prep_of||emergence-4/NN||resistance-7/NN	prep_in||resistance-7/NN||mali-9/NNS	nsubjpass||recommended-23/VBN||artemether-lumefantrine-11/NN	nsubj||available-35/JJ||artemether-lumefantrine-11/NN	appos||artemether-lumefantrine-11/NN||al-13/NNP	conj_or||artemether-lumefantrine-11/NN||artesunate-amodiaquine-16/NN	nsubjpass||recommended-23/VBN||artesunate-amodiaquine-16/NN	quantmod||aq-20/CD||as-18/RB	number||aq-20/CD||+-19/CD	dep||artesunate-amodiaquine-16/NN||aq-20/CD	auxpass||recommended-23/VBN||are-22/VBP	root||ROOT-0/null||recommended-23/VBN	amod||therapy-26/NN||first-line-25/JJ	prep_as||recommended-23/VBN||therapy-26/NN	amod||malaria-29/NN||uncomplicated-28/JJ	prep_for||therapy-26/NN||malaria-29/NN	aux||available-35/JJ||have-32/VBP	neg||available-35/JJ||not-33/RB	cop||available-35/JJ||been-34/VBN	conj_but||recommended-23/VBN||available-35/JJ	prep_in||available-35/JJ||mali-37/NNS	prep||available-35/JJ||until-38/IN	pobj||until-38/IN||recently-39/RB	amod||costs-43/NNS||high-42/JJ	prep_because_of||recently-39/RB||costs-43/NNS	malaria-29||chloroquine-6||yes||because of the emergence of chloroquine resistance in mali, artemether-lumefantrine (al) or artesunate-amodiaquine (as+aq) are recommended as first-line therapy for uncomplicated malaria, but have not been available in mali until recently because of high costs.
aux||examine-2/VB||to-1/TO	root||ROOT-0/null||examine-2/VB	det||efficacy-4/NN||the-3/DT	dobj||examine-2/VB||efficacy-4/NN	dobj||examine-2/VB||safety-6/NN	conj_and||efficacy-4/NN||safety-6/NN	dobj||examine-2/VB||tolerability-9/NN	conj_and||efficacy-4/NN||tolerability-9/NN	amod||chloride-15/NN||travoprost-11/JJ	num||%-13/NN||0.004-12/CD	dep||travoprost-11/JJ||%-13/NN	nn||chloride-15/NN||benzalkonium-14/NN	prep_of||efficacy-4/NN||chloride-15/NN	appos||chloride-15/NN||bak-17/NN	amod||living-32/NN||free-20/JJ	prepc_compared_with||free-20/JJ||with-22/IN	amod||use-24/NN||previous-23/JJ	pobj||free-20/JJ||use-24/NN	number||0.005-27/CD||latanoprost-26/CD	num||%-28/NN||0.005-27/CD	prep_of||use-24/NN||%-28/NN	amod||patients-31/NNS||japanese-30/JJ	prep_in||%-28/NN||patients-31/NNS	dep||examine-2/VB||living-32/NN	det||us-35/PRP||the-34/DT	prep_in||living-32/NN||us-35/PRP	nsubj||had-37/VBD||us-35/PRP	rcmod||us-35/PRP||had-37/VBD	amod||open-angleglaucoma-39/NN||primary-38/JJ	dobj||had-37/VBD||open-angleglaucoma-39/NN	dobj||had-37/VBD||ocularhypertension-41/NN	conj_or||open-angleglaucoma-39/NN||ocularhypertension-41/NN	open-angleglaucoma-39||travoprost-11||yes||to examine the efficacy, safety, and tolerability of travoprost 0.004% benzalkonium chloride (bak)-free compared with previous use of latanoprost 0.005% in japanese patients living in the us who had primary open-angleglaucoma or ocularhypertension.
det||combination-3/NN||the-1/DT	amod||combination-3/NN||budesonide/formoterol-2/JJ	nsubjpass||used-6/VBN||combination-3/NN	auxpass||used-6/VBN||is-4/VBZ	advmod||used-6/VBN||successfully-5/RB	root||ROOT-0/null||used-6/VBN	amod||relief-9/NN||fast-8/JJ	prep_for||used-6/VBN||relief-9/NN	nn||symptoms-12/NNS||asthma-11/NN	prep_of||relief-9/NN||symptoms-12/NNS	prep_in||symptoms-12/NNS||addition-14/NN	poss||use-17/NN||its-16/PRP$	prep_to||used-6/VBN||use-17/NN	nn||therapy-20/NN||maintenance-19/NN	prep_as||used-6/VBN||therapy-20/NN	asthma-11||budesonide--1||no||the budesonide/formoterol combination is successfully used for fast relief of asthma symptoms in addition to its use as maintenance therapy.
poss||data-2/NNS||our-1/PRP$	nsubj||suggests-3/VBZ||data-2/NNS	root||ROOT-0/null||suggests-3/VBZ	mark||provide-14/VB||that-4/IN	amod||screening-6/NN||genetic-5/JJ	nsubj||provide-14/VB||screening-6/NN	nsubj||provide-14/VB||screening-6/NN	det||mutation-12/NN||the-8/DT	amod||mutation-12/NN||s315t-9/JJ	nn||mutation-12/NN||kat-10/NN	nn||mutation-12/NN||g-11/NN	prep_for||screening-6/NN||mutation-12/NN	aux||provide-14/VB||may-13/MD	ccomp||suggests-3/VBZ||provide-14/VB	ccomp||suggests-3/VBZ||provide-14/VB	conj_and||provide-14/VB||provide-14/VB	amod||information-16/NN||rapid-15/JJ	dobj||provide-14/VB||information-16/NN	amod||selection-20/NN||anti-tb-18/JJ	nn||selection-20/NN||regimen-19/NN	prep_for||provide-14/VB||selection-20/NN	amod||monitoring-23/NN||epidemiological-22/JJ	appos||selection-20/NN||monitoring-23/NN	nn||resistance-26/NN||inh-25/NN	prep_of||monitoring-23/NN||resistance-26/NN	dep||provide-14/VB||possibly-29/RB	nn||transmission-33/NN||track-32/NN	prep_to||provide-14/VB||transmission-33/NN	advmod||resistant-36/JJ||inh-35/RB	amod||strains-37/NNS||resistant-36/JJ	prep_of||transmission-33/NN||strains-37/NNS	tb--1||inh-35||yes||our data suggests that genetic screening for the s315t kat g mutation may provide rapid information for anti-tb regimen selection, epidemiological monitoring of inh resistance and, possibly, to track transmission of inh resistant strains.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-4/NN||a-3/DT	dobj||report-2/VBP||case-4/NN	amod||loss-7/NN||sudden-6/JJ	prep_of||case-4/NN||loss-7/NN	prep_of||loss-7/NN||vision-9/NN	det||development-13/NN||the-12/DT	prep_due_to||case-4/NN||development-13/NN	amod||myopia-16/NN||acute-15/JJ	prep_of||development-13/NN||myopia-16/NN	det||intake-19/NN||the-18/DT	prep_after||case-4/NN||intake-19/NN	prep_of||intake-19/NN||chlorthalidone-21/NN	vmod||case-4/NN||used-22/VBN	prepc_for||used-22/VBN||treating-24/VBG	dobj||treating-24/VBG||systemichypertension-25/NN	systemichypertension-25||chlorthalidone-21||yes||we report a case of sudden loss of vision due to the development of acute myopia after the intake of chlorthalidone used for treating systemichypertension.
prep_as||showed-12/VBD||part-2/NN	det||investigation-9/NN||a-4/DT	amod||investigation-9/NN||fatal-5/JJ	amod||investigation-9/NN||human-6/JJ	nn||investigation-9/NN||plague-7/NN	nn||investigation-9/NN||case-8/NN	prep_of||part-2/NN||investigation-9/NN	nsubj||showed-12/VBD||we-11/PRP	root||ROOT-0/null||showed-12/VBD	mark||survive-21/VB||that-13/IN	det||bacterium-16/NN||the-14/DT	amod||bacterium-16/NN||plague-15/JJ	nsubj||survive-21/VB||bacterium-16/NN	appos||bacterium-16/NN||yersiniapestis-18/NNS	aux||survive-21/VB||can-20/MD	ccomp||showed-12/VBD||survive-21/VB	quantmod||24-25/CD||at-23/IN	mwe||at-23/IN||least-24/JJS	pobj||at-23/IN||least-24/JJS	num||days-26/NNS||24-25/CD	prep_for||survive-21/VB||days-26/NNS	amod||soil-29/NN||contaminated-28/JJ	prep_in||days-26/NNS||soil-29/NN	amod||conditions-32/NNS||natural-31/JJ	prep_under||survive-21/VB||conditions-32/NNS	plague-15||yersiniapestis-18||no||as part of a fatal human plague case investigation, we showed that the plague bacterium, yersiniapestis, can survive for at least 24 days in contaminated soil under natural conditions.
nsubj||inducer-15/NN||rifampicin-1/NN	det||component-5/NN||a-3/DT	amod||component-5/NN||critical-4/JJ	appos||rifampicin-1/NN||component-5/NN	nn||therapy-11/NN||tuberculosis-7/NNP	appos||therapy-11/NN||tb-9/NN	prep_of||component-5/NN||therapy-11/NN	cop||inducer-15/NN||is-12/VBZ	det||inducer-15/NN||a-13/DT	amod||inducer-15/NN||potent-14/JJ	root||ROOT-0/null||inducer-15/NN	nn||activity-19/NN||cyp-17/NN	nn||activity-19/NN||enzyme-18/NN	prep_of||inducer-15/NN||activity-19/NN	tuberculosis-7||rifampicin-1||yes||rifampicin, a critical component of tuberculosis (tb) therapy is a potent inducer of cyp enzyme activity.
det||protection-3/NN||the-1/DT	amod||protection-3/NN||acute-2/JJ	nsubj||supports-19/VBZ||protection-3/NN	amod||stimuli-7/NNS||subsequent-5/JJ	nn||stimuli-7/NNS||bronchoconstrictor-6/NN	prep_against||protection-3/NN||stimuli-7/NNS	amod||amp-11/NN||inhaled-10/JJ	prep_such_as||stimuli-7/NNS||amp-11/NN	det||reversal-15/NN||the-13/DT	amod||reversal-15/NN||rapid-14/JJ	prep_such_as||stimuli-7/NNS||reversal-15/NN	conj_and||amp-11/NN||reversal-15/NN	amod||obstruction-18/NN||airway-17/JJ	prep_of||reversal-15/NN||obstruction-18/NN	root||ROOT-0/null||supports-19/VBZ	det||use-21/NN||the-20/DT	dobj||supports-19/VBZ||use-21/NN	prep_of||use-21/NN||budesonide/formoterol-23/NN	preconj||relief-26/NN||both-25/DT	prep_for||supports-19/VBZ||relief-26/NN	prep_for||supports-19/VBZ||prevention-28/NN	conj_and||relief-26/NN||prevention-28/NN	det||treatment-31/NN||the-30/DT	prep_in||relief-26/NN||treatment-31/NN	prep_of||treatment-31/NN||asthma-33/NN	asthma-33||budesonide--1||yes||the acute protection against subsequent bronchoconstrictor stimuli such as inhaled amp and the rapid reversal of airway obstruction supports the use of budesonide/formoterol for both relief and prevention in the treatment of asthma.
det||evolution-2/NN||the-1/DT	nsubjpass||slow-6/JJ||evolution-2/NN	nsubjpass||characterized-8/VBN||evolution-2/NN	prep_of||evolution-2/NN||lupuspanniculitis-4/NNS	auxpass||slow-6/JJ||is-5/VBZ	cop||slow-6/JJ||is-5/VBZ	root||ROOT-0/null||slow-6/JJ	conj_and||slow-6/JJ||characterized-8/VBN	prep_by||characterized-8/VBN||regression-10/NN	det||lesions-14/NNS||the-12/DT	amod||lesions-14/NNS||inflammatory-13/JJ	prep_of||regression-10/NN||lesions-14/NNS	advmod||treated-16/VBN||when-15/WRB	advcl||characterized-8/VBN||treated-16/VBN	prep_with||treated-16/VBN||antimalarialdrugs-18/NNS	lupuspanniculitis-4||antimalarialdrugs-18||no_rel||the evolution of lupuspanniculitis is slow and characterized by regression of the inflammatory lesions when treated with antimalarialdrugs.
neg||differences-3/NNS||no-1/DT	amod||differences-3/NNS||significant-2/JJ	nsubjpass||found-5/VBN||differences-3/NNS	auxpass||found-5/VBN||were-4/VBD	root||ROOT-0/null||found-5/VBN	nn||subjects-10/NNS||smoking-7/NN	conj_and||smoking-7/NN||non-smoking-9/NN	nn||subjects-10/NNS||non-smoking-9/NN	prep_between||found-5/VBN||subjects-10/NNS	amod||asthma-13/NN||mild-12/JJ	prep_with||subjects-10/NNS||asthma-13/NN	prep_in||asthma-13/NN||regard-15/NN	amod||changes-18/NNS||clinical-17/JJ	prep_to||found-5/VBN||changes-18/NNS	nn||control-21/NN||asthma-20/NN	prep_in||changes-18/NNS||control-21/NN	amod||function-24/NN||pulmonary-23/JJ	appos||control-21/NN||function-24/NN	nn||inflammation-27/NN||airway-26/NN	appos||control-21/NN||inflammation-27/NN	conj_and||function-24/NN||inflammation-27/NN	det||period-32/NN||a-29/DT	amod||period-32/NN||2-month-30/JJ	nn||period-32/NN||treatment-31/NN	prep_following||function-24/NN||period-32/NN	prep_with||period-32/NN||budesonide-34/NN	det||association-37/NN||the-36/DT	prep_following||function-24/NN||association-37/NN	conj_or||period-32/NN||association-37/NN	prep_of||association-37/NN||budesonide-39/NN	prep_of||association-37/NN||formoterol-41/NN	conj_and||budesonide-39/NN||formoterol-41/NN	det||period-44/NN||a-43/DT	prep_for||association-37/NN||period-44/NN	num||months-47/NNS||2-46/CD	prep_of||period-44/NN||months-47/NNS	asthma-20||budesonide-39||no||no significant differences were found between smoking and non-smoking subjects with mild asthma in regard to clinical changes in asthma control, pulmonary function and airway inflammation following a 2-month treatment period with budesonide or the association of budesonide and formoterol for a period of 2 months.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||contribution-4/NN||the-3/DT	dobj||investigated-2/VBD||contribution-4/NN	amod||s-transferase-7/JJ||glutathione-6/JJ	amod||enzymes-11/NNS||s-transferase-7/JJ	appos||enzymes-11/NNS||gst-9/NN	prep_of||contribution-4/NN||enzymes-11/NNS	nn||tolerance-16/NN||permethrin-13/NN	conj_and||permethrin-13/NN||ivermectin-15/NN	nn||tolerance-16/NN||ivermectin-15/NN	prep_to||investigated-2/VBD||tolerance-16/NN	amod||mites-19/NNS||scabies-18/JJ	prep_in||tolerance-16/NN||mites-19/NNS	vmod||mites-19/NNS||using-20/VBG	amod||approaches-24/NNS||biochemical-21/JJ	conj_and||biochemical-21/JJ||molecular-23/JJ	amod||approaches-24/NNS||molecular-23/JJ	dobj||using-20/VBG||approaches-24/NNS	scabies-18||ivermectin-15||yes||we investigated the contribution of glutathione s-transferase (gst) enzymes to permethrin and ivermectin tolerance in scabies mites using biochemical and molecular approaches.
mark||unexplained-10/JJ||as-1/IN	det||link-3/NN||the-2/DT	nsubj||unexplained-10/JJ||link-3/NN	prep_between||link-3/NN||contactallergy-5/NN	prep_between||link-3/NN||diabetes-7/NN	conj_and||contactallergy-5/NN||diabetes-7/NN	cop||unexplained-10/JJ||is-8/VBZ	advmod||unexplained-10/JJ||yet-9/RB	advcl||examined-13/VBD||unexplained-10/JJ	nsubj||examined-13/VBD||we-11/PRP	advmod||examined-13/VBD||also-12/RB	root||ROOT-0/null||examined-13/VBD	det||effect-15/NN||the-14/DT	dobj||examined-13/VBD||effect-15/NN	prep_of||effect-15/NN||provocation-17/NN	amod||cells-27/NNS||allergens-19/JJ	amod||t-23/NN||natural-21/JJ	nn||t-23/NN||killer-22/NN	prep_on||allergens-19/JJ||t-23/NN	appos||cells-27/NNS||nkt-25/NN	prep_with||examined-13/VBD||cells-27/NNS	mark||suggest-35/VB||since-29/IN	nsubj||suggest-35/VB||involvement-30/NN	nn||cells-33/NNS||nkt-32/NN	prep_of||involvement-30/NN||cells-33/NNS	aux||suggest-35/VB||could-34/MD	advcl||examined-13/VBD||suggest-35/VB	det||connection-38/NN||an-36/DT	amod||connection-38/NN||innate-37/JJ	dobj||suggest-35/VB||connection-38/NN	det||diseases-42/NNS||the-40/DT	num||diseases-42/NNS||two-41/CD	prep_between||connection-38/NN||diseases-42/NNS	contactallergy-5||allergens-19||no||as the link between contactallergy and diabetes is yet unexplained we also examined the effect of provocation with allergens on natural killer t (nkt) cells, since involvement of nkt cells could suggest an innate connection between the two diseases.
nsubj||conclude-2/VBP||we-1/PRP	root||ROOT-0/null||conclude-2/VBP	mark||precedes-15/VBZ||that-3/IN	amod||activation-6/NN||altered-4/JJ	nn||activation-6/NN||insulin-5/NN	nsubj||precedes-15/VBZ||activation-6/NN	nsubj||contribute-18/VB||activation-6/NN	det||pi3k/akt-9/NN||the-8/DT	prep_of||activation-6/NN||pi3k/akt-9/NN	det||pathway-14/NN||the-12/DT	nn||pathway-14/NN||mapk-13/NN	prep_of||activation-6/NN||pathway-14/NN	conj_negcc||pi3k/akt-9/NN||pathway-14/NN	ccomp||conclude-2/VBP||precedes-15/VBZ	aux||contribute-18/VB||may-17/MD	ccomp||conclude-2/VBP||contribute-18/VB	conj_and||precedes-15/VBZ||contribute-18/VB	prep_to||contribute-18/VB||development-20/NN	amod||insulinresistance-23/NN||whole-body-22/JJ	prep_of||development-20/NN||insulinresistance-23/NN	prep_of||development-20/NN||type2diabetes-25/NNS	conj_and||insulinresistance-23/NN||type2diabetes-25/NNS	prep_in||contribute-18/VB||men-27/NNS	prep_with||men-27/NNS||lbw-29/NN	insulin-5||type2diabetes-25||no_rel||we conclude that altered insulin activation of the pi3k/akt but not the mapk pathway precedes and may contribute to development of whole-body insulinresistance and type2diabetes in men with lbw.
det||signal-5/NN||the-1/DT	amod||signal-5/NN||therapeutic-2/JJ	nn||signal-5/NN||class-3/NN	amod||signal-5/NN||specific-4/JJ	nsubjpass||found-13/VBN||signal-5/NN	prep_of||signal-5/NN||bradycardia-7/NN	vmod||bradycardia-7/NN||associated-8/VBN	prep_with||associated-8/VBN||propranololhydrochloride-10/NN	auxpass||found-13/VBN||was-11/VBD	neg||found-13/VBN||not-12/RB	root||ROOT-0/null||found-13/VBN	acomp||found-13/VBN||potent-14/JJ	advmod||potent-14/JJ||enough-15/RB	aux||cause-17/VB||to-16/TO	xcomp||potent-14/JJ||cause-17/VB	dobj||cause-17/VB||bradycardia-18/NN	bradycardia-18||propranololhydrochloride-10||no||the therapeutic class specific signal of bradycardia associated with propranololhydrochloride was not found potent enough to cause bradycardia.
nsubjpass||advised-4/VBN||patients-1/NNS	nsubj||use-6/VB||patients-1/NNS	auxpass||advised-4/VBN||are-2/VBP	advmod||advised-4/VBN||often-3/RB	root||ROOT-0/null||advised-4/VBN	aux||use-6/VB||to-5/TO	xcomp||advised-4/VBN||use-6/VB	nn||medications-12/NNS||acetaminophen-7/NN	conj_or||acetaminophen-7/NN||other-9/JJ	nn||medications-12/NNS||other-9/JJ	amod||medications-12/NNS||over-the-counter-10/JJ	nn||medications-12/NNS||pain-11/NN	dobj||use-6/VB||medications-12/NNS	advmod||needed-14/VBN||as-13/RB	amod||medications-12/NNS||needed-14/VBN	pain-11||acetaminophen-7||yes||patients are often advised to use acetaminophen or other over-the-counter pain medications as needed.
nsubj||likely-14/JJ||women-1/NNS	nsubj||have-16/VB||women-1/NNS	det||malaria-11/NN||either-3/DT	dep||acute-7/JJ||acute-4/JJ	amod||malaria-11/NN||acute-7/JJ	conj_and||acute-7/JJ||chronic-9/JJ	amod||malaria-11/NN||chronic-9/JJ	amod||malaria-11/NN||placental-10/JJ	prep_with||women-1/NNS||malaria-11/NN	cop||likely-14/JJ||were-12/VBD	advmod||likely-14/JJ||less-13/RBR	dep||is-25/VBZ||likely-14/JJ	aux||have-16/VB||to-15/TO	xcomp||likely-14/JJ||have-16/VB	dobj||have-16/VB||irondeficiency-17/NN	prep_than||irondeficiency-17/NN||women-19/NNS	amod||infection-23/NN||placental-21/JJ	nn||infection-23/NN||malaria-22/NN	prep_without||have-16/VB||infection-23/NN	expl||is-25/VBZ||there-24/EX	root||ROOT-0/null||is-25/VBZ	det||priority-27/NN||a-26/DT	nsubj||is-25/VBZ||priority-27/NN	aux||establish-29/VB||to-28/TO	vmod||priority-27/NN||establish-29/VB	mark||enhances-43/VBZ||if-30/IN	csubj||enhances-43/VBZ||reversing-31/VBG	advmod||reversing-31/VBG||irondeficiency-32/RB	nn||programs-36/NNS||iron-34/NN	nn||programs-36/NNS||supplementation-35/NN	prep_through||reversing-31/VBG||programs-36/NNS	dep||programs-36/NNS||either-37/DT	dep||either-37/DT||prior-38/RB	prep||prior-38/RB||to-39/TO	dep||programs-36/NNS||during-41/IN	conj_or||either-37/DT||during-41/IN	pobj||during-41/IN||pregnancy-42/NN	advcl||establish-29/VB||enhances-43/VBZ	nn||risk-45/NN||malaria-44/NN	dobj||enhances-43/VBZ||risk-45/NN	irondeficiency-32||iron-34||yes||women with either acute, or acute and chronic placental malaria were less likely to have irondeficiency than women without placental malaria infection there is a priority to establish if reversing irondeficiency through iron supplementation programs either prior to or during pregnancy enhances malaria risk.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubj||demonstrates-4/VBZ||study-3/NN	root||ROOT-0/null||demonstrates-4/VBZ	det||efficacy-6/NN||the-5/DT	dobj||demonstrates-4/VBZ||efficacy-6/NN	advmod||synthesized-9/JJ||biologically-8/RB	amod||nanoparticles-11/NNS||synthesized-9/JJ	nn||nanoparticles-11/NNS||silver-10/NN	prep_of||efficacy-6/NN||nanoparticles-11/NNS	appos||nanoparticles-11/NNS||agnps-13/NNS	det||agent-18/NN||an-16/DT	nn||agent-18/NN||antitumor-17/NN	prep_as||demonstrates-4/VBZ||agent-18/NN	vmod||agent-18/NN||using-19/VBG	num||lines-30/NNS||daltonâ-20/CD	amod||lines-30/NNS||$-21/$	number||s-23/CD||-22/CD	num||$-21/$||s-23/CD	amod||lines-30/NNS||lymphoma-24/JJ	amod||lines-30/NNS||ascites-25/JJ	appos||lines-30/NNS||dla-27/NN	nn||lines-30/NNS||cell-29/NN	dobj||using-19/VBG||lines-30/NNS	prep_in||lines-30/NNS||vitro-32/NN	prep_in||lines-30/NNS||in-34/IN	conj_and||vitro-32/NN||in-34/IN	pobj||in-34/IN||vivo-35/NN	lymphoma-24||silver-10||no_rel||the present study demonstrates the efficacy of biologically synthesized silver nanoparticles (agnps) as an antitumor agent using daltonâs lymphoma ascites (dla) cell lines in vitro and in vivo.
num||proteins-3/NNS||six-1/CD	amod||proteins-3/NNS||unique-2/JJ	nsubjpass||found-5/VBN||proteins-3/NNS	auxpass||found-5/VBN||were-4/VBD	root||ROOT-0/null||found-5/VBN	dobj||found-5/VBN||differentially-6/NN	vmod||differentially-6/NN||expressed-7/VBN	number||.1-10/CD||pcdna3-9/CD	prep_in||expressed-7/VBN||.1-10/CD	appos||.1-10/CD||igfbp7-12/NNP	amod||cells-17/NNS||transfected-15/JJ	nn||cells-17/NNS||rko-16/NN	dobj||found-5/VBN||cells-17/NNS	conj_and||differentially-6/NN||cells-17/NNS	prep_including||cells-17/NNS||albumin-20/NN	appos||albumin-20/NN||alb-22/NN	num||kda-26/NN||60-25/CD	dobj||found-5/VBN||kda-26/NN	conj_and||differentially-6/NN||kda-26/NN	nn||protein-29/NN||heat-27/NN	nn||protein-29/NN||shock-28/NN	dep||kda-26/NN||protein-29/NN	appos||protein-29/NN||hsp60-31/NNP	dobj||found-5/VBN||actin-34/NN	conj_and||differentially-6/NN||actin-34/NN	amod||actin-34/NN||cytoplasmic-35/JJ	dep||cytoplasmic-35/JJ||1-36/CD	dep||cytoplasmic-35/JJ||2-38/CD	conj_or||1-36/CD||2-38/CD	amod||muscle-42/NN||pyruvate-40/JJ	nn||muscle-42/NN||kinase-41/NN	dobj||found-5/VBN||muscle-42/NN	conj_and||differentially-6/NN||muscle-42/NN	dep||muscle-42/NN||2-43/CD	appos||2-43/CD||pkm2-45/NNP	amod||subunit-49/NN||beta-48/JJ	dobj||found-5/VBN||subunit-49/NN	conj_and||differentially-6/NN||subunit-49/NN	amod||synthetase-52/NN||phenylalanyl-trna-51/JJ	prep_of||subunit-49/NN||synthetase-52/NN	appos||synthetase-52/NN||farsb-54/NN	amod||protein-58/NN||hypothetical-57/JJ	dobj||found-5/VBN||protein-58/NN	conj_and||differentially-6/NN||protein-58/NN	shock-28||albumin-20||yes||six unique proteins were found differentially expressed in pcdna3.1( igfbp7 )-transfected rko cells, including albumin (alb), 60 kda heat shock protein(hsp60), actin cytoplasmic 1 or 2, pyruvate kinase muscle 2(pkm2), beta subunit of phenylalanyl-trna synthetase(farsb) and hypothetical protein.
amod||cells-4/NNS||cd8-1/JJ	amod||cells-4/NNS||+-2/JJ	nn||cells-4/NNS||t-3/NN	nsubj||contribute-5/VBP||cells-4/NNS	root||ROOT-0/null||contribute-5/VBP	det||clearance-8/NN||the-7/DT	prep_to||contribute-5/VBP||clearance-8/NN	nn||infection-14/NN||hepatitisbvirus-10/NNP	appos||infection-14/NN||hbv-12/NN	prep_of||clearance-8/NN||infection-14/NN	det||response-22/NN||an-16/DT	amod||response-22/NN||insufficient-17/JJ	amod||response-22/NN||cd8-18/JJ	amod||response-22/NN||+-19/JJ	nn||response-22/NN||t-20/NN	nn||response-22/NN||cell-21/NN	nsubj||one-25/CD||response-22/NN	aux||one-25/CD||may-23/MD	cop||one-25/CD||be-24/VB	conj_and||contribute-5/VBP||one-25/CD	det||factors-29/NNS||the-27/DT	amod||factors-29/NNS||major-28/JJ	prep_of||one-25/CD||factors-29/NNS	vmod||factors-29/NNS||leading-30/VBG	amod||infection-34/NN||chronic-32/JJ	nn||infection-34/NN||hbv-33/NN	prep_to||leading-30/VBG||infection-34/NN	hbv-33||hepatitisbvirus-10||no||cd8+ t cells contribute to the clearance of hepatitisbvirus (hbv) infection and an insufficient cd8+ t cell response may be one of the major factors leading to chronic hbv infection.
det||majority-2/NN||the-1/DT	nsubj||experience-6/VBP||majority-2/NN	nn||patients-5/NNS||cancer-4/NN	prep_of||majority-2/NN||patients-5/NNS	root||ROOT-0/null||experience-6/VBP	amod||loss-9/NN||dramatic-7/JJ	nn||loss-9/NN||weight-8/NN	dobj||experience-6/VBP||loss-9/NN	prep_due_to||loss-9/NN||cachexia-13/NN	dobj||experience-6/VBP||consisting-15/VBG	conj_and||loss-9/NN||consisting-15/VBG	amod||muscle-18/NN||skeletal-17/JJ	prep_of||consisting-15/VBG||muscle-18/NN	amod||wasting-22/NN||fat-20/JJ	nn||wasting-22/NN||tissue-21/NN	prep_of||consisting-15/VBG||wasting-22/NN	conj_and||muscle-18/NN||wasting-22/NN	cancer-4||fat-20||no_rel||the majority of cancer patients experience dramatic weight loss, due to cachexia and consisting of skeletal muscle and fat tissue wasting.
det||incidence-3/NN||the-1/DT	amod||incidence-3/NN||higher-2/JJR	nsubj||was-7/VBD||incidence-3/NN	amod||patients-6/NNS||diabeticfoot-5/JJ	prep_of||incidence-3/NN||patients-6/NNS	root||ROOT-0/null||was-7/VBD	det||age-11/NN||the-9/DT	amod||age-11/NN||mean-10/JJ	prep_in||was-7/VBD||age-11/NN	nsubjpass||controlled-19/VBN||age-11/NN	amod||±-14/NNS||57â-13/JJ	prep_of||age-11/NN||±-14/NNS	num||years-16/NNS||3.4-15/CD	dep||age-11/NN||years-16/NNS	auxpass||controlled-19/VBN||was-18/VBD	rcmod||age-11/NN||controlled-19/VBN	nn||therapy-22/NN||combination-21/NN	prep_with||controlled-19/VBN||therapy-22/NN	nn||antidiabetics-27/NNS||insulin-24/NN	conj_and||insulin-24/NN||oral-26/JJ	nn||antidiabetics-27/NNS||oral-26/JJ	prep_of||therapy-22/NN||antidiabetics-27/NNS	num||%-30/NN||63.0-29/CD	dep||antidiabetics-27/NNS||%-30/NN	nn||516-34/NNP||n-32/NNP	nn||516-34/NNP||=-33/NNP	appos||%-30/NN||516-34/NNP	antidiabetics-27||diabeticfoot-5||no_rel||the higher incidence of diabeticfoot patients was in the mean age of 57â±3.4 years that was controlled with combination therapy of insulin and oral antidiabetics (63.0%, n=516).
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||efficacy-4/NN||the-3/DT	dobj||evaluated-2/VBN||efficacy-4/NN	prep_of||efficacy-4/NN||glimepiride-6/NN	prep_of||efficacy-4/NN||metformin-8/NN	conj_and||glimepiride-6/NN||metformin-8/NN	prep_of||efficacy-4/NN||rosiglitazone-11/NN	conj_and||glimepiride-6/NN||rosiglitazone-11/NN	amod||treatment-14/NN||initial-13/JJ	prep_as||glimepiride-6/NN||treatment-14/NN	amod||patients-20/NNS||drug-naã-16/JJ	nn||patients-20/NNS||¯-17/NN	nn||patients-20/NNS||ve-18/NN	amod||patients-20/NNS||type2diabetesmellitus-19/JJ	prep_for||treatment-14/NN||patients-20/NNS	det||study-29/NN||a-22/DT	amod||study-29/NN||48-week-23/JJ	amod||study-29/NN||double-blind-25/JJ	amod||study-29/NN||randomized-27/JJ	amod||study-29/NN||controlled-28/JJ	prep_in||evaluated-2/VBN||study-29/NN	nsubj||included-31/VBD||study-29/NN	rcmod||study-29/NN||included-31/VBD	num||patients-34/NNS||349-32/CD	nn||patients-34/NNS||korean-33/NN	dobj||included-31/VBD||patients-34/NNS	type2diabetesmellitus-19||metformin-8||yes||we evaluated the efficacy of glimepiride, metformin, and rosiglitazone as initial treatment for drug-naã¯ve type2diabetesmellitus patients in a 48-week, double-blind, randomized controlled study that included 349 korean patients.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubj||reduces-16/VBZ||treatment-3/NN	prep_of||treatment-3/NN||malaria-5/NN	prep_in||malaria-5/NN||pregnancy-7/NN	appos||pregnancy-7/NN||iptp-9/NN	prep_with||pregnancy-7/NN||sulphadoxine-pyrimethamine-12/NN	appos||treatment-3/NN||sp-14/NN	root||ROOT-0/null||reduces-16/VBZ	det||incidence-18/NN||the-17/DT	dobj||reduces-16/VBZ||incidence-18/NN	amod||birth-weight-21/NN||low-20/JJ	prep_of||incidence-18/NN||birth-weight-21/NN	amod||delivery-24/NN||pre-term-23/JJ	prep_of||incidence-18/NN||delivery-24/NN	conj_and||birth-weight-21/NN||delivery-24/NN	amod||growth-retardation-27/NN||intrauterine-26/JJ	prep_of||incidence-18/NN||growth-retardation-27/NN	conj_and||birth-weight-21/NN||growth-retardation-27/NN	amod||anaemia-30/NN||maternal-29/JJ	prep_of||incidence-18/NN||anaemia-30/NN	conj_and||birth-weight-21/NN||anaemia-30/NN	malaria-5||pyrimethamine--1||no||intermittent preventive treatment of malaria in pregnancy (iptp) with sulphadoxine-pyrimethamine (sp) reduces the incidence of low birth-weight, pre-term delivery, intrauterine growth-retardation and maternal anaemia.
det||aim-2/NN||the-1/DT	nsubj||was-6/VBD||aim-2/NN	nsubj||investigate-8/VB||aim-2/NN	det||study-5/NN||this-4/DT	prep_of||aim-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	xcomp||was-6/VBD||investigate-8/VB	det||possibility-10/NN||the-9/DT	dobj||investigate-8/VB||possibility-10/NN	mark||causes-17/VBZ||that-11/IN	det||synthesis-16/NN||a-12/DT	amod||synthesis-16/NN||decreased-13/VBN	amod||synthesis-16/NN||mitochondrial-14/JJ	nn||synthesis-16/NN||atp-15/NN	nsubj||causes-17/VBZ||synthesis-16/NN	nsubj||plays-23/VBZ||synthesis-16/NN	ccomp||investigate-8/VB||causes-17/VBZ	amod||fatigue-21/NN||muscular-18/JJ	conj_and||muscular-18/JJ||mental-20/JJ	amod||fatigue-21/NN||mental-20/JJ	dobj||causes-17/VBZ||fatigue-21/NN	ccomp||investigate-8/VB||plays-23/VBZ	conj_and||causes-17/VBZ||plays-23/VBZ	det||role-25/NN||a-24/DT	dobj||plays-23/VBZ||role-25/NN	det||pathophysiology-28/NN||the-27/DT	prep_in||plays-23/VBZ||pathophysiology-28/NN	det||syndrome-33/NN||the-30/DT	amod||syndrome-33/NN||chronic-31/JJ	nn||syndrome-33/NN||fatigue-32/NN	prep_of||pathophysiology-28/NN||syndrome-33/NN	appos||syndrome-33/NN||cfs/me-35/NN	atp-15||fatigue-32||no_rel||the aim of this study was to investigate the possibility that a decreased mitochondrial atp synthesis causes muscular and mental fatigue and plays a role in the pathophysiology of the chronic fatigue syndrome (cfs/me).
prep_in||estimated-31/VBN||india-2/NN	amod||prevalence-5/NN||hbsag-4/VBG	nsubjpass||estimated-31/VBN||prevalence-5/NN	nsubj||million-35/CD||prevalence-5/NN	amod||ranges-9/NNS||general-7/JJ	nn||ranges-9/NNS||population-8/NN	prep_among||prevalence-5/NN||ranges-9/NNS	number||%-15/NN||2-11/CD	dep||%-15/NN||%-12/NN	dep||%-15/NN||to-13/TO	number||%-15/NN||8-14/CD	prep_from||ranges-9/NNS||%-15/NN	nn||india-18/NN||placing-17/NN	prep_among||prevalence-5/NN||india-18/NN	conj_and||ranges-9/NNS||india-18/NN	amod||zone-23/NN||intermediate-20/JJ	nn||zone-23/NN||hbv-21/NN	nn||zone-23/NN||endemicity-22/NN	prep_in||india-18/NN||zone-23/NN	det||number-26/NN||the-25/DT	prep_among||prevalence-5/NN||number-26/NN	conj_and||ranges-9/NNS||number-26/NN	nn||carriers-29/NNS||hbv-28/NN	prep_of||number-26/NN||carriers-29/NNS	auxpass||estimated-31/VBN||is-30/VBZ	root||ROOT-0/null||estimated-31/VBN	aux||million-35/CD||to-32/TO	cop||million-35/CD||be-33/VB	number||million-35/CD||50-34/CD	xcomp||estimated-31/VBN||million-35/CD	vmod||million-35/CD||forming-37/VBG	det||pool-42/NN||the-38/DT	amod||pool-42/NN||second-39/JJ	amod||pool-42/NN||largest-40/JJS	amod||pool-42/NN||global-41/JJ	dobj||forming-37/VBG||pool-42/NN	amod||infections-46/NNS||chronic-44/JJ	nn||infections-46/NNS||hbv-45/NN	prep_of||pool-42/NN||infections-46/NNS	hbv-45||hbsag-4||yes||in india, hbsag prevalence among general population ranges from 2% to 8%, placing india in intermediate hbv endemicity zone and the number of hbv carriers is estimated to be 50 million, forming the second largest global pool of chronic hbv infections.
amod||artesunate-2/NN||monthly-1/JJ	nsubj||reduced-5/VBD||artesunate-2/NN	prep||artesunate-2/NN||plus-3/CC	pobj||plus-3/CC||amodiaquine-4/NN	root||ROOT-0/null||reduced-5/VBD	det||incidence-7/NN||the-6/DT	dobj||reduced-5/VBD||incidence-7/NN	prep_of||incidence-7/NN||malaria-9/NN	num||%-12/NN||69-11/CD	prep_by||reduced-5/VBD||%-12/NN	number||%-15/NN||95-14/CD	amod||ci-16/NN||%-15/NN	dep||%-12/NN||ci-16/NN	number||%-18/NN||63-17/CD	amod||ci-16/NN||%-18/NN	num||%-21/NN||74-20/CD	appos||ci-16/NN||%-21/NN	prep_by||reduced-5/VBD||anaemia-24/NN	conj_and||%-12/NN||anaemia-24/NN	num||%-27/NN||45-26/CD	prep_by||reduced-5/VBD||%-27/NN	number||%-30/NN||95-29/CD	amod||ci-31/NN||%-30/NN	dep||%-27/NN||ci-31/NN	number||%-33/NN||25-32/CD	amod||ci-31/NN||%-33/NN	num||%-35/NN||,60-34/CD	dep||ci-31/NN||%-35/NN	amod||sulphadoxine-pyrimethamine-39/NN||bimonthly-38/JJ	nsubj||reduced-40/VBD||sulphadoxine-pyrimethamine-39/NN	conj_and||reduced-5/VBD||reduced-40/VBD	det||incidence-42/NN||the-41/DT	dobj||reduced-40/VBD||incidence-42/NN	prep_of||incidence-42/NN||malaria-44/NN	num||%-47/NN||24-46/CD	prep_by||reduced-40/VBD||%-47/NN	number||%-50/NN||95-49/CD	amod||ci-51/NN||%-50/NN	dep||%-47/NN||ci-51/NN	number||%-53/NN||14-52/CD	amod||ci-51/NN||%-53/NN	num||%-55/NN||,33-54/CD	dep||ci-51/NN||%-55/NN	prep_by||reduced-40/VBD||anaemia-58/NN	conj_and||%-47/NN||anaemia-58/NN	num||%-61/NN||30-60/CD	prep_by||reduced-40/VBD||%-61/NN	number||%-64/NN||95-63/CD	amod||ci-65/NN||%-64/NN	dep||%-61/NN||ci-65/NN	number||%-67/NN||6-66/CD	amod||ci-65/NN||%-67/NN	num||%-70/NN||49-69/CD	appos||ci-65/NN||%-70/NN	amod||artesunate-74/NN||bimonthly-73/JJ	nsubj||reduced-77/VBD||artesunate-74/NN	prep||artesunate-74/NN||plus-75/CC	pobj||plus-75/CC||amodiaquine-76/NN	conj_and||reduced-5/VBD||reduced-77/VBD	det||incidence-79/NN||the-78/DT	dobj||reduced-77/VBD||incidence-79/NN	prep_of||incidence-79/NN||malaria-81/NN	num||%-84/NN||17-83/CD	prep_by||reduced-77/VBD||%-84/NN	number||%-87/NN||95-86/CD	amod||ci-88/NN||%-87/NN	dep||%-84/NN||ci-88/NN	number||%-90/NN||6-89/CD	amod||ci-88/NN||%-90/NN	num||%-93/NN||27-92/CD	appos||ci-88/NN||%-93/NN	prep_by||reduced-77/VBD||anaemia-96/NN	conj_and||%-84/NN||anaemia-96/NN	num||%-99/NN||32-98/CD	prep_by||reduced-77/VBD||%-99/NN	number||%-102/NN||95-101/CD	amod||ci-103/NN||%-102/NN	dep||%-99/NN||ci-103/NN	number||%-105/NN||7-104/CD	amod||ci-103/NN||%-105/NN	num||%-108/NN||50-107/CD	appos||ci-103/NN||%-108/NN	prepc_compared_to||reduced-77/VBD||to-111/TO	pobj||reduced-77/VBD||placebo-112/NN	malaria-81||pyrimethamine--1||no||monthly artesunate plus amodiaquine reduced the incidence of malaria by 69% (95% ci 63%, 74%) and anaemia by 45% (95% ci 25%,60%), bimonthly sulphadoxine-pyrimethamine reduced the incidence of malaria by 24% (95% ci 14%,33%) and anaemia by 30% (95% ci 6%, 49%) and bimonthly artesunate plus amodiaquine reduced the incidence of malaria by 17% (95% ci 6%, 27%) and anaemia by 32% (95% ci 7%, 50%) compared to placebo.
num||lines-5/NNS||seventeen-1/CD	amod||lines-5/NNS||breast-2/JJ	nn||lines-5/NNS||cancer-3/NN	nn||lines-5/NNS||cell-4/NN	nsubjpass||harvested-7/VBN||lines-5/NNS	nsubjpass||fixed-9/VBN||lines-5/NNS	nsubjpass||made-13/VBN||lines-5/NNS	auxpass||harvested-7/VBN||were-6/VBD	root||ROOT-0/null||harvested-7/VBN	conj_and||harvested-7/VBN||fixed-9/VBN	prep_in||fixed-9/VBN||formalin-11/NN	conj_and||harvested-7/VBN||made-13/VBN	nn||blocks-16/NNS||cell-15/NN	prep_into||made-13/VBN||blocks-16/NNS	formalin-11||cancer-3||no_rel||seventeen breast cancer cell lines were harvested, fixed in formalin and made into cell blocks.
root||ROOT-0/null||basal-1/NN	conj_and||basal-1/NN||interferon-alpha-3/NN	nn||±-6/NNP||ifn-î-5/NNP	appos||basal-1/NN||±-6/NNP	conj_or||basal-1/NN||interferon-gamma-9/NN	nn||³-12/NNP||ifn-î-11/NNP	appos||interferon-gamma-9/NN||³-12/NNP	amod||expression-16/NN||induced-15/JJ	nsubjpass||evaluated-23/VBN||expression-16/NN	amod||proteins-21/NNS||socs1-18/JJ	conj_and||socs1-18/JJ||socs3-20/JJ	amod||proteins-21/NNS||socs3-20/JJ	prep_of||expression-16/NN||proteins-21/NNS	auxpass||evaluated-23/VBN||was-22/VBD	dep||basal-1/NN||evaluated-23/VBN	amod||analysis-26/NN||immunoblot-25/JJ	agent||evaluated-23/VBN||analysis-26/NN	det||panel-29/NN||a-28/DT	prep_in||analysis-26/NN||panel-29/NN	prep_of||panel-29/NN||n-31/NN	dep||lines-38/NNS||=-32/SYM	num||lines-38/NNS||10-33/CD	amod||lines-38/NNS||metastatic-34/JJ	amod||lines-38/NNS||human-35/JJ	nn||lines-38/NNS||melanoma-36/NNP	nn||lines-38/NNS||cell-37/NN	ccomp||evaluated-23/VBN||lines-38/NNS	amod||melanocytes-43/NNS||human-41/JJ	amod||melanocytes-43/NNS||embryonic-42/JJ	prep_in||basal-1/NN||melanocytes-43/NNS	appos||melanocytes-43/NNS||hem-45/NN	prep_in||basal-1/NN||radial-49/NN	conj_and||melanocytes-43/NNS||radial-49/NN	amod||cells-55/NNS||vertical-51/JJ	nn||cells-55/NNS||growth-52/NN	nn||cells-55/NNS||phase-53/NN	nn||cells-55/NNS||melanoma-54/NN	conj_and||melanocytes-43/NNS||cells-55/NNS	conj_or||radial-49/NN||cells-55/NNS	melanoma-54||ifn--1||yes||basal and interferon-alpha (ifn-î±) or interferon-gamma (ifn-î³)-induced expression of socs1 and socs3 proteins was evaluated by immunoblot analysis in a panel of n = 10 metastatic human melanoma cell lines, in human embryonic melanocytes (hem), and radial or vertical growth phase melanoma cells.
det||total-2/NN||a-1/DT	nsubjpass||enrolled-20/VBN||total-2/NN	num||patients-5/NNS||40-4/CD	prep_of||total-2/NN||patients-5/NNS	amod||schizophrenia-8/NN||chronic-7/JJ	prep_with||patients-5/NNS||schizophrenia-8/NN	nsubj||taken-11/VBN||schizophrenia-8/NN	aux||taken-11/VBN||had-10/VBD	rcmod||schizophrenia-8/NN||taken-11/VBN	acomp||taken-11/VBN||risperidone-12/JJ	number||6-16/CD||2-14/CD	dep||6-16/CD||to-15/TO	num||mg/day-17/NNS||6-16/CD	appos||schizophrenia-8/NN||mg/day-17/NNS	auxpass||enrolled-20/VBN||were-19/VBD	root||ROOT-0/null||enrolled-20/VBN	schizophrenia-8||risperidone-12||yes||a total of 40 patients with chronic schizophrenia who had taken risperidone (2 to 6 mg/day) were enrolled.
nsubjpass||diagnosed-3/VBN||tb-1/NN	auxpass||diagnosed-3/VBN||was-2/VBD	root||ROOT-0/null||diagnosed-3/VBN	det||presence-6/NN||the-5/DT	agent||diagnosed-3/VBN||presence-6/NN	amod||bacilli-9/NNS||acid-fast-8/JJ	prep_of||presence-6/NN||bacilli-9/NNS	prep_on||diagnosed-3/VBN||smears-11/NNS	prep_from||smears-11/NNS||sputum-13/NN	det||isolation-17/NN||the-16/DT	prep_on||diagnosed-3/VBN||isolation-17/NN	conj_and||smears-11/NNS||isolation-17/NN	prep_of||isolation-17/NN||m.tuberculosis-19/NNS	tb-1||m.tuberculosis-19||no||tb was diagnosed by the presence of acid-fast bacilli on smears from sputum , and the isolation of m.tuberculosis .
amod||patients-3/NNS||diabetic-2/JJ	prep_in||remain-12/VBP||patients-3/NNS	nn||hyperglycaemia-8/NN||insulin-5/NN	nn||hyperglycaemia-8/NN||administration-6/NN	nn||hyperglycaemia-8/NN||controls-7/NNS	nsubj||remain-12/VBP||hyperglycaemia-8/NN	prep||hyperglycaemia-8/NN||but-9/CC	amod||complications-11/NNS||cardiovascular-10/JJ	pobj||but-9/CC||complications-11/NNS	root||ROOT-0/null||remain-12/VBP	hyperglycaemia-8||insulin-5||yes||in diabetic patients, insulin administration controls hyperglycaemia but cardiovascular complications remain.
amod||formulations-3/NNS||commercial-1/JJ	nn||formulations-3/NNS||methotrexate-2/NN	nsubj||have-7/VBP||formulations-3/NNS	appos||formulations-3/NNS||mtx-5/NN	root||ROOT-0/null||have-7/VBP	amod||action-10/NN||poor-8/JJ	amod||action-10/NN||anti-inflammatory-9/JJ	dobj||have-7/VBP||action-10/NN	amod||treatment-13/NN||intra-articular-12/JJ	prep_for||action-10/NN||treatment-13/NN	prep_of||treatment-13/NN||rheumatoidarthritis-15/NNS	rheumatoidarthritis-15||mtx-5||yes||commercial methotrexate formulations (mtx) have poor anti-inflammatory action for intra-articular treatment of rheumatoidarthritis.
mark||immunosuppressed-5/VBN||since-1/IN	nsubjpass||immunosuppressed-5/VBN||rats-2/NNS	nsubj||develop-9/VB||rats-2/NNS	aux||immunosuppressed-5/VBN||must-3/MD	auxpass||immunosuppressed-5/VBN||be-4/VB	advcl||examined-39/VBN||immunosuppressed-5/VBN	prep_in||immunosuppressed-5/VBN||order-7/NN	aux||develop-9/VB||to-8/TO	xcomp||immunosuppressed-5/VBN||develop-9/VB	dobj||develop-9/VB||pneumocystisinfection-10/NN	nn||macrophages-13/NNS||alveolar-12/NN	nsubjpass||examined-39/VBN||macrophages-13/NNS	num||rats-16/NNS||four-15/CD	prep_from||macrophages-13/NNS||rats-16/NNS	det||sex-20/NN||the-18/DT	amod||sex-20/NN||same-19/JJ	prep_of||rats-16/NNS||sex-20/NN	nsubjpass||treated-25/VBN||sex-20/NN	prep_of||rats-16/NNS||age-22/NN	conj_and||sex-20/NN||age-22/NN	nsubjpass||treated-25/VBN||age-22/NN	auxpass||treated-25/VBN||were-24/VBD	rcmod||sex-20/NN||treated-25/VBN	prep_with||treated-25/VBN||dexamethasone-27/NN	det||weeks-32/NNS||the-29/DT	amod||weeks-32/NNS||entire-30/JJ	num||weeks-32/NNS||eight-31/CD	prep_for||dexamethasone-27/NN||weeks-32/NNS	det||period-36/NN||the-34/DT	nn||period-36/NN||study-35/NN	prep_of||dexamethasone-27/NN||period-36/NN	auxpass||examined-39/VBN||were-37/VBD	advmod||examined-39/VBN||also-38/RB	root||ROOT-0/null||examined-39/VBN	dexamethasone-27||pneumocystisinfection-10||no_rel||since rats must be immunosuppressed in order to develop pneumocystisinfection, alveolar macrophages from four rats of the same sex and age that were treated with dexamethasone for the entire eight weeks of the study period were also examined.
det||mutations-2/NNS||the-1/DT	nsubjpass||detected-14/VBN||mutations-2/NNS	vmod||mutations-2/NNS||known-3/VBN	prepc_as||known-3/VBN||causing-5/VBG	nn||resistance-7/NN||adefovir-6/NN	dobj||causing-5/VBG||resistance-7/NN	amod||resistance-7/NN||rtn236t-9/JJ	amod||resistance-7/NN||rta181v/t-11/JJ	conj_and||rtn236t-9/JJ||rta181v/t-11/JJ	auxpass||detected-14/VBN||are-13/VBP	root||ROOT-0/null||detected-14/VBN	det||domain-21/NN||the-16/DT	dep||functional-20/JJ||d-17/SYM	conj_and||d-17/SYM||b-19/SYM	dep||functional-20/JJ||b-19/SYM	amod||domain-21/NN||functional-20/JJ	prep_within||detected-14/VBN||domain-21/NN	det||polymerase-25/NN||the-23/DT	nn||polymerase-25/NN||hbv-24/NN	prep_of||domain-21/NN||polymerase-25/NN	advmod||detected-14/VBN||respectively-27/RB	hbv-24||adefovir-6||yes||the mutations known as causing adefovir resistance, rtn236t and rta181v/t, are detected within the d and b functional domain of the hbv polymerase, respectively.
nsubj||constituent-18/NN||prpsc-1/NN	det||form-7/NN||a-3/DT	amod||form-7/NN||misfolded-4/JJ	conj_and||misfolded-4/JJ||aggregated-6/JJ	amod||form-7/NN||aggregated-6/JJ	appos||prpsc-1/NN||form-7/NN	det||prpc-12/NN||the-9/DT	amod||prpc-12/NN||cellular-10/JJ	nn||prpc-12/NN||prionprotein-11/NN	prep_of||form-7/NN||prpc-12/NN	cop||constituent-18/NN||is-14/VBZ	det||constituent-18/NN||the-15/DT	advmod||constituent-18/NN||only-16/RB	amod||constituent-18/NN||defined-17/JJ	root||ROOT-0/null||constituent-18/NN	det||agent-22/NN||the-20/DT	amod||agent-22/NN||transmissible-21/JJ	prep_of||constituent-18/NN||agent-22/NN	vmod||agent-22/NN||causing-23/VBG	dobj||causing-23/VBG||priondiseases-24/NNS	priondiseases-24||prionprotein-11||no||prpsc, a misfolded and aggregated form of the cellular prionprotein prpc, is the only defined constituent of the transmissible agent causing priondiseases.
nsubj||increased-7/VBD||bortezomib-1/NN	vmod||bortezomib-1/NN||used-2/VBN	amod||treatment-5/NN||first-line-4/JJ	prep_as||used-2/VBN||treatment-5/NN	advmod||increased-7/VBD||significantly-6/RB	root||ROOT-0/null||increased-7/VBD	nn||deposition-9/NN||collagen-8/NN	dobj||increased-7/VBD||deposition-9/NN	prep_in||increased-7/VBD||patients-11/NNS	nn||lesions-16/NNS||multiplemyeloma-13/NN	conj_and||multiplemyeloma-13/NN||osteolytic-15/NN	nn||lesions-16/NNS||osteolytic-15/NN	prep_with||increased-7/VBD||lesions-16/NNS	det||addition-20/NN||the-19/DT	nsubj||inhibited-28/VBD||addition-20/NN	det||transiently-27/NN||a-22/DT	amod||transiently-27/NN||glucocorticoid-23/JJ	det||treatment-26/NN||the-25/DT	prep_to||glucocorticoid-23/JJ||treatment-26/NN	prep_of||addition-20/NN||transiently-27/NN	conj_but||increased-7/VBD||inhibited-28/VBD	det||effect-31/NN||the-29/DT	amod||effect-31/NN||positive-30/JJ	dobj||inhibited-28/VBD||effect-31/NN	prep_of||effect-31/NN||bortezomib-33/NN	vmod||inhibited-28/VBD||suggesting-35/VBG	mark||result-39/VB||that-36/IN	nsubj||result-39/VB||bortezomib-37/NN	aux||result-39/VB||may-38/MD	ccomp||suggesting-35/VBG||result-39/VB	amod||healing-42/NN||better-41/JJR	prep_in||result-39/VB||healing-42/NN	amod||lesions-45/NNS||osteolytic-44/JJ	prep_of||healing-42/NN||lesions-45/NNS	advmod||used-47/VBN||when-46/WRB	advcl||result-39/VB||used-47/VBN	prep_without||used-47/VBN||glucocorticoids-49/NNS	prep_in||glucocorticoids-49/NNS||patients-51/NNS	nsubj||obtained-54/VBN||patients-51/NNS	aux||obtained-54/VBN||have-53/VBP	rcmod||patients-51/NNS||obtained-54/VBN	dobj||obtained-54/VBN||remission-55/NN	det||therapy-59/NN||a-57/DT	amod||therapy-59/NN||previous-58/JJ	prep_with||obtained-54/VBN||therapy-59/NN	multiplemyeloma-13||bortezomib-37||yes||bortezomib used as first-line treatment significantly increased collagen deposition in patients with multiplemyeloma and osteolytic lesions, but the addition of a glucocorticoid to the treatment transiently inhibited the positive effect of bortezomib, suggesting that bortezomib may result in better healing of osteolytic lesions when used without glucocorticoids in patients that have obtained remission with a previous therapy.
det||objective-2/NN||the-1/DT	nsubj||reported-6/VBD||objective-2/NN	det||study-5/NN||the-4/DT	prep_of||objective-2/NN||study-5/NN	root||ROOT-0/null||reported-6/VBD	nsubj||was-8/VBD||here-7/RB	nsubj||determine-10/VB||here-7/RB	ccomp||reported-6/VBD||was-8/VBD	aux||determine-10/VB||to-9/TO	xcomp||was-8/VBD||determine-10/VB	det||prevalence-12/NN||the-11/DT	dobj||determine-10/VB||prevalence-12/NN	amod||viruses-18/NNS||human-14/JJ	amod||viruses-18/NNS||immunodeficiency-15/JJ	conj_and||immunodeficiency-15/JJ||hepatitisc-17/JJ	amod||viruses-18/NNS||hepatitisc-17/JJ	prep_of||prevalence-12/NN||viruses-18/NNS	dep||hiv-22/NN||respectively-20/RB	appos||viruses-18/NNS||hiv-22/NN	appos||viruses-18/NNS||hcv-24/NNS	conj_and||hiv-22/NN||hcv-24/NNS	det||communities-29/NNS||the-27/DT	amod||communities-29/NNS||earthquake-affected-28/JJ	prep_in||determine-10/VB||communities-29/NNS	prep_of||communities-29/NNS||pakistan-31/NN	hepatitisc-17||viruses-18||no||the objective of the study reported here was to determine the prevalence of human immunodeficiency and hepatitisc viruses (respectively, hiv and hcv) in the earthquake-affected communities of pakistan.
det||number-2/NN||the-1/DT	nsubj||%-18/NN||number-2/NN	amod||persons-6/NNS||hiv-4/JJ	amod||persons-6/NNS||infected-5/JJ	prep_of||number-2/NN||persons-6/NNS	vmod||persons-6/NNS||reported-7/VBN	aux||screened-11/VBN||to-8/TO	aux||screened-11/VBN||have-9/VB	auxpass||screened-11/VBN||been-10/VBN	xcomp||reported-7/VBN||screened-11/VBN	prep_for||screened-11/VBN||tb-13/NN	cop||%-18/NN||was-14/VBD	mwe||than-16/IN||less-15/JJR	quantmod||1-17/CD||than-16/IN	num||%-18/NN||1-17/CD	root||ROOT-0/null||%-18/NN	mark||reported-24/VBN||while-19/IN	amod||therapy-22/NN||isoniazid-20/JJ	nn||therapy-22/NN||preventive-21/NN	nsubjpass||reported-24/VBN||therapy-22/NN	nsubjpass||provided-28/VBN||therapy-22/NN	auxpass||reported-24/VBN||was-23/VBD	dep||%-18/NN||reported-24/VBN	aux||provided-28/VBN||to-25/TO	aux||provided-28/VBN||have-26/VB	auxpass||provided-28/VBN||been-27/VBN	xcomp||reported-24/VBN||provided-28/VBN	mwe||than-31/IN||less-30/JJR	quantmod||0.1-32/CD||than-31/IN	num||%-33/NN||0.1-32/CD	prep_to||provided-28/VBN||%-33/NN	amod||persons-36/NNS||eligible-35/JJ	prep_of||%-33/NN||persons-36/NNS	prep_in||persons-36/NNS||2006-38/CD	tb-13||isoniazid-20||yes||the number of hiv infected persons reported to have been screened for tb was less than 1% while isoniazid preventive therapy was reported to have been provided to less than 0.1% of eligible persons in 2006.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||efficacy-5/NN||the-3/DT	amod||efficacy-5/NN||clinical-4/JJ	dobj||investigated-2/VBD||efficacy-5/NN	dobj||investigated-2/VBD||safety-7/NN	conj_and||efficacy-5/NN||safety-7/NN	amod||monotherapy-17/NN||tocilizumab-9/JJ	det||antibody-15/NN||a-11/DT	amod||antibody-15/NN||humanized-12/JJ	nn||antibody-15/NN||anti-il-6-13/NN	nn||antibody-15/NN||receptor-14/NN	appos||monotherapy-17/NN||antibody-15/NN	prep_of||efficacy-5/NN||monotherapy-17/NN	amod||rheumatoidarthritis-20/JJ||active-19/JJ	amod||patients-24/NNS||rheumatoidarthritis-20/JJ	appos||patients-24/NNS||ra-22/NN	prep_in||monotherapy-17/NN||patients-24/NNS	det||response-28/NN||an-26/DT	amod||response-28/NN||inadequate-27/JJ	prep_with||investigated-2/VBD||response-28/NN	amod||methotrexate-32/NN||low-30/JJ	nn||methotrexate-32/NN||dose-31/NN	prep_to||investigated-2/VBD||methotrexate-32/NN	appos||methotrexate-32/NN||mtx-34/NN	rheumatoidarthritis-20||mtx-34||yes||we investigated the clinical efficacy and safety of tocilizumab (a humanized anti-il-6 receptor antibody) monotherapy in active rheumatoidarthritis (ra) patients with an inadequate response to low dose methotrexate (mtx).
det||duration-2/NN||the-1/DT	nsubj||influence-7/VB||duration-2/NN	prep_of||duration-2/NN||imprisonment-4/NN	aux||influence-7/VB||did-5/VBD	neg||influence-7/VB||not-6/RB	root||ROOT-0/null||influence-7/VB	det||rates-9/NNS||the-8/DT	dobj||influence-7/VB||rates-9/NNS	prep_of||rates-9/NNS||infection-11/NN	det||transmission-15/NN||the-14/DT	nsubj||require-21/VB||transmission-15/NN	prep_of||transmission-15/NN||mycobacteriumtuberculosis-17/NNS	aux||require-21/VB||did-18/VBD	neg||require-21/VB||not-19/RB	advmod||require-21/VB||necessarily-20/RB	conj_and||influence-7/VB||require-21/VB	xcomp||require-21/VB||sharing-22/VBG	det||cell-24/NN||a-23/DT	dobj||sharing-22/VBG||cell-24/NN	det||case-28/NN||a-26/DT	nn||case-28/NN||tb-27/NN	prep_with||sharing-22/VBG||case-28/NN	tb-27||mycobacteriumtuberculosis-17||no||the duration of imprisonment did not influence the rates of infection, and the transmission of mycobacteriumtuberculosis did not necessarily require sharing a cell with a tb case.
nsubj||forms-24/VBZ||proliferation-1/NN	nn||receptors-4/NNS||nmda-3/NN	prep_of||proliferation-1/NN||receptors-4/NNS	prep_of||proliferation-1/NN||role-6/NN	conj_and||receptors-4/NNS||role-6/NN	amod||phenomena-18/NNS||glutamate-8/JJ	prepc_in||glutamate-8/JJ||producing-10/VBG	amod||sensitization-12/NN||central-11/JJ	dobj||producing-10/VBG||sensitization-12/NN	prepc_in||glutamate-8/JJ||wind-15/VBP	conj_and||producing-10/VBG||wind-15/VBP	prt||wind-15/VBP||up-16/RP	prep_of||receptors-4/NNS||phenomena-18/NNS	amod||-RSB--23/NNS||crps-20/JJ	amod||-RSB--23/NNS||-LSB--21/JJ	nn||-RSB--23/NNS||complexregionalpainsyndrome-22/NN	prep_in||phenomena-18/NNS||-RSB--23/NNS	root||ROOT-0/null||forms-24/VBZ	det||basis-27/NN||a-25/DT	amod||basis-27/NN||strong-26/JJ	dobj||forms-24/VBZ||basis-27/NN	det||use-30/NN||the-29/DT	prep_for||forms-24/VBZ||use-30/NN	prep_of||use-30/NN||ketamine-32/NN	aux||block-34/VB||to-33/TO	vmod||forms-24/VBZ||block-34/VB	det||mechanisms-37/NNS||the-35/DT	amod||mechanisms-37/NNS||cellular-36/JJ	dobj||block-34/VB||mechanisms-37/NNS	nsubj||initiate-39/VBP||mechanisms-37/NNS	nsubj||maintain-41/VBP||mechanisms-37/NNS	rcmod||mechanisms-37/NNS||initiate-39/VBP	rcmod||mechanisms-37/NNS||maintain-41/VBP	conj_and||initiate-39/VBP||maintain-41/VBP	det||changes-43/NNS||these-42/DT	dobj||initiate-39/VBP||changes-43/NNS	complexregionalpainsyndrome-22||ketamine-32||no_rel||proliferation of nmda receptors and role of glutamate in producing central sensitization and 'wind up' phenomena in crps [complexregionalpainsyndrome] forms a strong basis for the use of ketamine to block the cellular mechanisms that initiate and maintain these changes.
num||statements-2/NNS||three-1/CD	nsubj||addressed-3/VBD||statements-2/NNS	root||ROOT-0/null||addressed-3/VBD	det||validity-5/NN||the-4/DT	dobj||addressed-3/VBD||validity-5/NN	nn||growthhormone-8/NN||serum-7/NN	prep_of||validity-5/NN||growthhormone-8/NN	appos||growthhormone-8/NN||gh-10/NN	amod||concentrations-19/NNS||insulin-like-13/JJ	nn||concentrations-19/NNS||growth-14/NN	nn||concentrations-19/NNS||factor-i-15/NN	appos||concentrations-19/NNS||igf-i-17/NNP	prep_of||validity-5/NN||concentrations-19/NNS	conj_and||growthhormone-8/NN||concentrations-19/NNS	prep_as||addressed-3/VBD||indicators-21/NNS	prep_as||addressed-3/VBD||predictors-23/NNS	conj_or||indicators-21/NNS||predictors-23/NNS	prep_of||indicators-21/NNS||disease-25/NN	prep_in||addressed-3/VBD||acromegaly-27/NN	insulin--1||acromegaly-27||no_rel||three statements addressed the validity of serum growthhormone (gh) and insulin-like growth factor-i (igf-i) concentrations as indicators or predictors of disease in acromegaly.
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	det||case-4/NN||the-3/DT	dobj||present-2/VBP||case-4/NN	det||man-9/NN||a-6/DT	amod||man-9/NN||51-year-old-7/JJ	nn||man-9/NN||african-8/NN	prep_of||case-4/NN||man-9/NN	nn||tuberculosis-12/NNP||testicular-11/NNP	prep_with||present-2/VBP||tuberculosis-12/NNP	amod||intracranialtuberculomas-15/NNS||multiple-14/JJ	prep_with||present-2/VBP||intracranialtuberculomas-15/NNS	conj_and||tuberculosis-12/NNP||intracranialtuberculomas-15/NNS	nsubjpass||managed-19/VBN||intracranialtuberculomas-15/NNS	auxpass||managed-19/VBN||was-17/VBD	advmod||managed-19/VBN||initially-18/RB	rcmod||intracranialtuberculomas-15/NNS||managed-19/VBN	nn||cancer-22/NN||testicular-21/NN	prep_for||managed-19/VBN||cancer-22/NN	amod||metastasis-25/NNS||intracranial-24/JJ	prep_with||managed-19/VBN||metastasis-25/NNS	intracranialtuberculomas-15||tuberculosis-12||no||we present the case of a 51-year-old african man with testicular tuberculosis and multiple intracranialtuberculomas who was initially managed for testicular cancer with intracranial metastasis.
amod||glomerulosclerosis-7/NNS||5/6-nx-1/JJ	nn||glomerulosclerosis-7/NNS||induced-2/NN	nn||glomerulosclerosis-7/NNS||hypertension-3/NN	dep||glomerulosclerosis-7/NNS||albuminuria-5/NN	nsubjpass||attenuated-15/VBN||glomerulosclerosis-7/NNS	amod||damage-10/NN||tubulo-interstitial-9/JJ	conj_and||glomerulosclerosis-7/NNS||damage-10/NN	nsubjpass||attenuated-15/VBN||damage-10/NN	det||effects-13/NNS||these-12/DT	conj_and||glomerulosclerosis-7/NNS||effects-13/NNS	nsubjpass||attenuated-15/VBN||effects-13/NNS	auxpass||attenuated-15/VBN||were-14/VBD	root||ROOT-0/null||attenuated-15/VBN	agent||attenuated-15/VBN||ramipril-17/NN	hypertension-3||ramipril-17||yes||5/6-nx induced hypertension, albuminuria, glomerulosclerosis and tubulo-interstitial damage and these effects were attenuated by ramipril.
nsubj||studied-2/VBD||we-1/PRP	root||ROOT-0/null||studied-2/VBD	num||patients-4/NNS||27-3/CD	dobj||studied-2/VBD||patients-4/NNS	prep_with||studied-2/VBD||type2diabetes-6/NNS	num||women-9/NNS||11-8/CD	dep||type2diabetes-6/NNS||women-9/NNS	number||â-12/CD||60.3-11/CD	num||years-13/NNS||â-12/CD	dep||type2diabetes-6/NNS||years-13/NNS	conj_and||women-9/NNS||years-13/NNS	amod||years-13/NNS||â-14/JJ	amod||years-17/NNS||±-15/JJ	amod||years-17/NNS||6â-16/JJ	dep||â-14/JJ||years-17/NNS	amod||<-21/NNS||hba1c-20/JJ	prep_with||years-17/NNS||<-21/NNS	number||%-23/NN||7-22/CD	amod||<-21/NNS||%-23/NN	neg||nephropathy-26/NN||no-25/DT	dep||type2diabetes-6/NNS||nephropathy-26/NN	conj_and||women-9/NNS||nephropathy-26/NN	num||patients-31/NNS||16-30/CD	prep_including||studied-2/VBD||patients-31/NNS	vmod||patients-31/NNS||treated-32/VBN	amod||agents-35/NNS||anti-diabetic-34/JJ	prep_with||treated-32/VBN||agents-35/NNS	dep||agents-35/NNS||no-ins-37/NNS	num||women-40/NNS||8-39/CD	appos||no-ins-37/NNS||women-40/NNS	num||patients-44/NNS||11-43/CD	prep_with||treated-32/VBN||patients-44/NNS	conj_and||agents-35/NNS||patients-44/NNS	vmod||patients-44/NNS||treated-45/VBN	vmod||patients-44/NNS||treated-45/VBN	conj_or||treated-45/VBN||treated-45/VBN	prep_with||treated-45/VBN||insulin-47/NN	advmod||treated-45/VBN||alone-48/RB	prep_in||treated-45/VBN||combination-51/NN	amod||agents-54/NNS||anti-diabetic-53/JJ	prep_with||treated-45/VBN||agents-54/NNS	appos||agents-54/NNS||ins-56/NN	num||women-59/NNS||3-58/CD	dep||ins-56/NN||women-59/NNS	type2diabetes-6||insulin-47||yes||we studied 27 patients with type2diabetes (11 women, 60.3â years â± 6â years, with hba1c < 7% and no nephropathy), including 16 patients treated with anti-diabetic agents (no-ins, 8 women) and 11 patients treated with insulin alone or in combination with anti-diabetic agents (ins, 3 women).
aux||inform-2/VB||to-1/TO	advcl||characterized-13/VBD||inform-2/VB	dobj||inform-2/VB||development-3/NN	prep_of||development-3/NN||tuberculosis-5/NNP	parataxis||inform-2/VB||tb-7/VB	nn||strategies-10/NNS||control-9/NN	dobj||inform-2/VB||strategies-10/NNS	nsubj||characterized-13/VBD||we-12/PRP	root||ROOT-0/null||characterized-13/VBD	det||total-15/NN||a-14/DT	nsubj||isolates-19/VBZ||total-15/NN	num||mycobacteriumtuberculosiscomplex-18/NN||2,261-17/CD	prep_of||total-15/NN||mycobacteriumtuberculosiscomplex-18/NN	ccomp||characterized-13/VBD||isolates-19/VBZ	prepc_by||isolates-19/VBZ||using-21/VBG	amod||phenotypic-23/JJ||multiple-22/JJ	dobj||using-21/VBG||phenotypic-23/JJ	amod||markers-26/NNS||molecular-25/JJ	dobj||using-21/VBG||markers-26/NNS	conj_and||phenotypic-23/JJ||markers-26/NNS	prep_including||isolates-19/VBZ||polymorphisms-29/NNS	amod||sequences-32/NNS||repetitive-31/JJ	prep_in||polymorphisms-29/NNS||sequences-32/NNS	nn||repeats-38/NNS||spoligotyping-34/NN	conj_and||spoligotyping-34/NN||variable-number-36/JJ	nn||repeats-38/NNS||variable-number-36/JJ	nn||repeats-38/NNS||tandem-37/NN	dep||-RSB--41/JJ||repeats-38/NNS	num||vntrs-40/NNS||-LSB--39/CD	npadvmod||-RSB--41/JJ||vntrs-40/NNS	dep||sequences-32/NNS||-RSB--41/JJ	amod||sequence-45/NN||large-44/JJ	prep_including||isolates-19/VBZ||sequence-45/NN	conj_and||polymorphisms-29/NNS||sequence-45/NN	amod||polymorphisms-48/NNS||single-nucleotide-47/JJ	conj_and||polymorphisms-29/NNS||polymorphisms-48/NNS	conj_and||sequence-45/NN||polymorphisms-48/NNS	tuberculosis-5||mycobacteriumtuberculosiscomplex-18||no||to inform development of tuberculosis (tb) control strategies, we characterized a total of 2,261 mycobacteriumtuberculosiscomplex isolates by using multiple phenotypic and molecular markers, including polymorphisms in repetitive sequences (spoligotyping and variable-number tandem repeats [vntrs]) and large sequence and single-nucleotide polymorphisms.
det||genes-4/NNS||both-1/DT	amod||genes-4/NNS||early/transient/proliferation-2/JJ	nn||genes-4/NNS||response-3/NN	nsubj||able-9/JJ||genes-4/NNS	nsubj||predict-11/VB||genes-4/NNS	amod||genes-7/NNS||continuous/late/estrogen-response-6/JJ	conj_and||genes-4/NNS||genes-7/NNS	nsubj||able-9/JJ||genes-7/NNS	nsubj||predict-11/VB||genes-7/NNS	cop||able-9/JJ||are-8/VBP	root||ROOT-0/null||able-9/JJ	aux||predict-11/VB||to-10/TO	xcomp||able-9/JJ||predict-11/VB	dobj||predict-11/VB||prognosis-12/NN	amod||breasttumours-15/NNS||primary-14/JJ	prep_of||prognosis-12/NN||breasttumours-15/NNS	det||manner-19/NN||a-17/DT	amod||manner-19/NN||dynamic-18/JJ	prep_in||predict-11/VB||manner-19/NN	breasttumours-15||estrogen--1||no||both early/transient/proliferation response genes and continuous/late/estrogen-response genes are able to predict prognosis of primary breasttumours in a dynamic manner.
det||study-3/NN||this-2/DT	prep_in||demonstrate-6/VBP||study-3/NN	nsubj||demonstrate-6/VBP||we-5/PRP	root||ROOT-0/null||demonstrate-6/VBP	mark||elicits-15/VBZ||that-7/IN	nsubj||elicits-15/VBZ||vaccination-8/NN	det||vaccine-14/NN||the-10/DT	num||vaccine-14/NN||2009-11/CD	amod||vaccine-14/NN||pandemic-12/JJ	nn||vaccine-14/NN||h1n1-13/NN	prep_with||vaccination-8/NN||vaccine-14/NN	ccomp||demonstrate-6/VBP||elicits-15/VBZ	num||antibodies-19/NNS||1918-16/CD	nn||antibodies-19/NNS||virus-17/NN	nn||antibodies-19/NNS||cross-protective-18/NN	dobj||elicits-15/VBZ||antibodies-19/NNS	prep_in||antibodies-19/NNS||mice-21/NNS	prep_in||antibodies-19/NNS||humans-23/NNS	conj_and||mice-21/NNS||humans-23/NNS	mark||reduced-34/VBD||that-26/IN	nn||transfer-30/NN||vaccination-27/NN	conj_or||vaccination-27/NN||passive-29/JJ	nn||transfer-30/NN||passive-29/JJ	nsubj||reduced-34/VBD||transfer-30/NN	nsubj||conferred-37/VBD||transfer-30/NN	amod||sera-33/NN||human-positive-32/JJ	prep_of||transfer-30/NN||sera-33/NN	ccomp||demonstrate-6/VBP||reduced-34/VBD	conj_and||elicits-15/VBZ||reduced-34/VBD	dobj||reduced-34/VBD||morbidity-35/NN	conj_and||elicits-15/VBZ||conferred-37/VBD	conj_and||reduced-34/VBD||conferred-37/VBD	amod||protection-39/NN||full-38/JJ	dobj||conferred-37/VBD||protection-39/NN	amod||challenge-42/NN||lethal-41/JJ	prep_from||conferred-37/VBD||challenge-42/NN	det||virus-46/NN||the-44/DT	num||virus-46/NN||1918-45/CD	prep_with||challenge-42/NN||virus-46/NN	prep_in||conferred-37/VBD||mice-48/NNS	virus-46||antibodies-19||no_rel||in this study, we demonstrate that vaccination with the 2009 pandemic h1n1 vaccine elicits 1918 virus cross-protective antibodies in mice and humans, and that vaccination or passive transfer of human-positive sera reduced morbidity and conferred full protection from lethal challenge with the 1918 virus in mice.
nn||caregivers-2/NNS||volunteer-1/NN	nsubj||source-6/NN||caregivers-2/NNS	cop||source-6/NN||are-3/VBP	det||source-6/NN||a-4/DT	amod||source-6/NN||critical-5/JJ	root||ROOT-0/null||source-6/NN	prep_of||source-6/NN||support-8/NN	det||majority-11/NN||the-10/DT	prep_for||support-8/NN||majority-11/NN	prep_of||majority-11/NN||people-13/NNS	vmod||people-13/NNS||living-14/VBG	prep_with||living-14/VBG||hiv-16/NN	prep_with||living-14/VBG||aids-18/NNS	conj_and||hiv-16/NN||aids-18/NNS	amod||africa-21/NN||southern-20/JJ	prep_in||living-14/VBG||africa-21/NN	nsubj||has-24/VBZ||africa-21/NN	rcmod||africa-21/NN||has-24/VBZ	advmod||high-26/JJ||extremely-25/RB	amod||rates-29/NNS||high-26/JJ	amod||rates-29/NNS||hiv/aids-27/JJ	nn||rates-29/NNS||prevalence-28/NN	dobj||has-24/VBZ||rates-29/NNS	aids-18||hiv-16||no||volunteer caregivers are a critical source of support for the majority of people living with hiv and aids in southern africa, which has extremely high hiv/aids prevalence rates.
nn||factors-2/NNS||risk-1/NN	nsubj||significant-42/JJ||factors-2/NNS	prep_such_as||factors-2/NNS||age-5/NN	nn||status-8/NN||smoking-7/NN	prep_such_as||factors-2/NNS||status-8/NN	conj_and||age-5/NN||status-8/NN	amod||cholesterol-11/NN||total-10/JJ	prep_such_as||factors-2/NNS||cholesterol-11/NN	conj_and||age-5/NN||cholesterol-11/NN	amod||levels-17/NNS||high-13/JJ	nn||levels-17/NNS||density-14/NN	nn||levels-17/NNS||lipoprotein-15/NN	nn||levels-17/NNS||cholesterol-16/NN	prep_such_as||factors-2/NNS||levels-17/NNS	conj_and||age-5/NN||levels-17/NNS	vmod||significant-42/JJ||qualifying-19/VBG	dobj||qualifying-19/VBG||event-20/NN	det||syndrome-25/NN||the-22/DT	amod||syndrome-25/NN||acute-23/JJ	amod||syndrome-25/NN||coronary-24/JJ	prep_for||qualifying-19/VBG||syndrome-25/NN	appos||syndrome-25/NN||revascularization-27/NN	appos||revascularization-27/NN||history-29/NN	prep_of||history-29/NN||stroke-31/NN	prep_of||history-29/NN||diabetes-33/NN	conj_or||stroke-31/NN||diabetes-33/NN	nn||grade-36/NN||angina-35/NN	nsubj||significant-42/JJ||grade-36/NN	conj_and||grade-36/NN||treatment-38/NN	nsubj||significant-42/JJ||treatment-38/NN	prep_with||grade-36/NN||pravastatin-40/NN	cop||significant-42/JJ||were-41/VBD	root||ROOT-0/null||significant-42/JJ	prep_for||significant-42/JJ||development-44/NN	preconj||first-47/JJ||both-46/DT	prep_of||development-44/NN||first-47/JJ	amod||events-51/NNS||subsequent-49/JJ	nn||events-51/NNS||mi-50/NN	prep_of||development-44/NN||events-51/NNS	conj_and||first-47/JJ||events-51/NNS	pravastatin-40||stroke-31||no_rel||risk factors such as age, smoking status, total cholesterol and high density lipoprotein cholesterol levels, qualifying event for the acute coronary syndrome, revascularization, history of stroke or diabetes, angina grade and treatment with pravastatin were significant for development of both first and subsequent mi events.
amod||studies-2/NNS||several-1/JJ	nsubj||reported-4/VBN||studies-2/NNS	aux||reported-4/VBN||have-3/VBP	root||ROOT-0/null||reported-4/VBN	mark||contribute-21/VBP||that-5/IN	nn||group-8/NN||abo-6/NN	nn||group-8/NN||blood-7/NN	nsubj||contribute-21/VBP||group-8/NN	appos||group-8/NN||hepatitisbvirus-10/NNS	appos||hepatitisbvirus-10/NNS||hbv-12/NN	amod||virus-16/NN||hepatitisc-15/JJ	appos||group-8/NN||virus-16/NN	conj_and||hepatitisbvirus-10/NNS||virus-16/NN	appos||virus-16/NN||hcv-18/NN	dep||virus-16/NN||infection-20/NN	ccomp||reported-4/VBN||contribute-21/VBP	det||development-24/NN||the-23/DT	prep_to||contribute-21/VBP||development-24/NN	amod||cancer-27/NN||pancreatic-26/JJ	prep_of||development-24/NN||cancer-27/NN	hbv-12||hepatitisbvirus-10||no||several studies have reported that abo blood group, hepatitisbvirus (hbv) and hepatitisc virus (hcv) infection contribute to the development of pancreatic cancer.
nsubj||group-7/NN||transmissiblespongiformencephalopathies-1/NNS	appos||transmissiblespongiformencephalopathies-1/NNS||tses-3/NNS	cop||group-7/NN||are-5/VBP	det||group-7/NN||a-6/DT	root||ROOT-0/null||group-7/NN	amod||disorders-12/NNS||progressive-9/JJ	amod||disorders-12/NNS||fatal-10/JJ	nn||disorders-12/NNS||neurodegenerative-11/NN	prep_of||group-7/NN||disorders-12/NNS	vmod||disorders-12/NNS||triggered-14/VBN	amod||folding-17/NN||abnormal-16/JJ	agent||triggered-14/VBN||folding-17/NN	det||molecule-22/NN||the-19/DT	amod||molecule-22/NN||endogenous-20/JJ	nn||molecule-22/NN||prionprotein-21/NN	prep_of||folding-17/NN||molecule-22/NN	transmissiblespongiformencephalopathies-1||prionprotein-21||no||transmissiblespongiformencephalopathies (tses) are a group of progressive fatal neurodegenerative disorders, triggered by abnormal folding of the endogenous prionprotein molecule.
nsubjpass||assumed-12/VBN||sorption-1/NN	nsubj||negligible-15/JJ||sorption-1/NN	nsubj||higher-26/JJR||sorption-1/NN	prep_of||sorption-1/NN||venlafaxine-3/NN	prep_of||sorption-1/NN||desmethylvenlafaxine-5/NN	conj_and||venlafaxine-3/NN||desmethylvenlafaxine-5/NN	prep_of||sorption-1/NN||carbamazepine-8/NN	conj_and||venlafaxine-3/NN||carbamazepine-8/NN	prep_on||venlafaxine-3/NN||sludge-10/NN	auxpass||assumed-12/VBN||was-11/VBD	root||ROOT-0/null||assumed-12/VBN	aux||negligible-15/JJ||to-13/TO	cop||negligible-15/JJ||be-14/VB	xcomp||assumed-12/VBN||negligible-15/JJ	dep||negligible-15/JJ||log-17/VB	nn||-20/NNS||kd-18/NN	nn||-20/NNS||â-19/NN	dobj||log-17/VB||-20/NNS	amod||-20/NNS||$-21/$	number||$-21/$||2-22/CD	xcomp||assumed-12/VBN||higher-26/JJR	conj_but||negligible-15/JJ||higher-26/JJR	nn||behavior-28/NN||sorption-27/NN	nsubjpass||expected-31/VBN||behavior-28/NN	aux||expected-31/VBN||can-29/MD	auxpass||expected-31/VBN||be-30/VB	ccomp||higher-26/JJR||expected-31/VBN	prep_for||expected-31/VBN||sertraline-33/NN	dep||negligible-15/JJ||log-35/VB	nn||â-37/NN||kd-36/NN	dobj||log-35/VB||â-37/NN	vmod||â-37/NN||-38/VBG	number||4-40/CD||¥-39/CD	dobj||-38/VBG||4-40/CD	kd-36||carbamazepine-8||no_rel||sorption of venlafaxine, desmethylvenlafaxine, and carbamazepine on sludge was assumed to be negligible (log kd â¤ 2), but higher sorption behavior can be expected for sertraline (log kd â¥ 4).
det||incidence-2/NN||the-1/DT	nsubjpass||reduced-7/VBN||incidence-2/NN	prep_of||incidence-2/NN||pain-4/NN	auxpass||reduced-7/VBN||was-5/VBD	advmod||reduced-7/VBN||significantly-6/RB	root||ROOT-0/null||reduced-7/VBN	prep_in||reduced-7/VBN||groups-9/NNS	nsubj||received-11/VBD||groups-9/NNS	rcmod||groups-9/NNS||received-11/VBD	acomp||received-11/VBD||remifentanil-12/JJ	det||groups-18/NNS||the-14/DT	amod||groups-18/NNS||cold-15/JJ	conj_and||cold-15/JJ||combination-17/NN	amod||groups-18/NNS||combination-17/NN	prep_in||remifentanil-12/JJ||groups-18/NNS	advmod||-rrb--40/VBZ||when-19/WRB	prepc_compared_with||-rrb--40/VBZ||with-21/IN	det||group-24/NN||the-22/DT	nn||group-24/NN||control-23/NN	pobj||-rrb--40/VBZ||group-24/NN	number||27.5-26/CD||-lrb--25/CD	num||%-27/NN||27.5-26/CD	nsubj||-rrb--40/VBZ||%-27/NN	num||%-30/NN||30-29/CD	appos||%-27/NN||%-30/NN	num||%-34/NN||2.5-33/CD	conj_and||%-27/NN||%-34/NN	nsubj||-rrb--40/VBZ||%-34/NN	num||%-37/NN||70-36/CD	prep_vs.||%-34/NN||%-37/NN	advmod||-rrb--40/VBZ||respectively-39/RB	advcl||received-11/VBD||-rrb--40/VBZ	pain-4||remifentanil-12||yes||the incidence of pain was significantly reduced in groups that received remifentanil in the cold and combination groups when compared with the control group -lrb- 27.5 % , 30 % , and 2.5 % vs. 70 % , respectively -rrb- .
advmod||used-27/VBN||however-1/RB	mark||susceptible-7/JJ||because-3/IN	nsubj||susceptible-7/JJ||ferrets-4/NNS	cop||susceptible-7/JJ||are-5/VBP	advmod||susceptible-7/JJ||naturally-6/RB	advcl||used-27/VBN||susceptible-7/JJ	prep_to||susceptible-7/JJ||infection-9/NN	prep_with||infection-9/NN||humaninfluenzaviruses-11/NNS	mark||resembles-17/VBZ||because-13/IN	det||state-16/NN||the-14/DT	nn||state-16/NN||disease-15/NN	nsubj||resembles-17/VBZ||state-16/NN	conj_and||susceptible-7/JJ||resembles-17/VBZ	advcl||used-27/VBN||resembles-17/VBZ	xcomp||resembles-17/VBZ||that-18/DT	prep_of||that-18/DT||humaninfluenza-20/NN	det||animals-23/NNS||these-22/DT	nsubjpass||used-27/VBN||animals-23/NNS	nsubj||study-32/VB||animals-23/NNS	aux||used-27/VBN||have-24/VBP	auxpass||used-27/VBN||been-25/VBN	advmod||used-27/VBN||widely-26/RB	root||ROOT-0/null||used-27/VBN	det||model-30/NN||a-29/DT	prep_as||used-27/VBN||model-30/NN	aux||study-32/VB||to-31/TO	xcomp||used-27/VBN||study-32/VB	amod||pathogenesis-34/NNS||influenzavirus-33/JJ	dobj||study-32/VB||pathogenesis-34/NNS	humaninfluenza-20||influenzavirus-33||no||however, because ferrets are naturally susceptible to infection with humaninfluenzaviruses and because the disease state resembles that of humaninfluenza, these animals have been widely used as a model to study influenzavirus pathogenesis.
num||patient-2/NN||one-1/CD	nsubj||developed-3/VBD||patient-2/NN	root||ROOT-0/null||developed-3/VBD	nn||reactivation-5/NN||hbv-4/NN	dobj||developed-3/VBD||reactivation-5/NN	amod||withdrawal-8/NN||lamivudine-7/JJ	prep_after||developed-3/VBD||withdrawal-8/NN	num||patients-12/NNS||4-11/CD	nsubj||developed-13/VBD||patients-12/NNS	conj_and||developed-3/VBD||developed-13/VBD	det||mutation-19/NN||the-14/DT	amod||mutation-19/NN||ymdd-15/JJ	dep||ymdd-15/JJ||tyrosine-methionine-aspartate-aspartate-17/JJ	dobj||developed-13/VBD||mutation-19/NN	amod||therapy-22/NN||lamivudine-21/JJ	prep_during||developed-13/VBD||therapy-22/NN	hbv-4||lamivudine-21||yes||one patient developed hbv reactivation after lamivudine withdrawal, and 4 patients developed the ymdd (tyrosine-methionine-aspartate-aspartate) mutation during lamivudine therapy.
amod||standard-2/NN||gold-1/JJ	nsubj||number-8/NN||standard-2/NN	amod||fever-5/NN||malaria-attributable-4/JJ	prep_for||standard-2/NN||fever-5/NN	cop||number-8/NN||was-6/VBD	det||number-8/NN||the-7/DT	root||ROOT-0/null||number-8/NN	prep_of||number-8/NN||fevers-10/NNS	amod||fevers-10/NNS||attributable-11/JJ	prep_to||attributable-11/JJ||malaria-13/NN	vmod||fevers-10/NNS||estimated-15/VBN	agent||estimated-15/VBN||comparing-17/VBG	nn||densities-19/NNS||parasite-18/NN	dobj||comparing-17/VBG||densities-19/NNS	prep_of||densities-19/NNS||febrile-21/NN	amod||subjects-24/NNS||non-febrile-23/JJ	prep_versus||febrile-21/NN||subjects-24/NNS	malaria-13||gold-1||no_rel||gold standard for malaria-attributable fever was the number of fevers attributable to malaria, estimated by comparing parasite densities of febrile versus non-febrile subjects.
nsubj||cause-8/NN||hepatitisbvirus-1/NNS	appos||hepatitisbvirus-1/NNS||hbv-3/NN	cop||cause-8/NN||is-5/VBZ	det||cause-8/NN||the-6/DT	amod||cause-8/NN||major-7/JJ	root||ROOT-0/null||cause-8/NN	nn||cirrhosis-12/NNS||chronichepatitis-10/NNS	prep_of||cause-8/NN||cirrhosis-12/NNS	nn||carcinoma-16/NNS||hepatocellular-15/NN	prep_of||cause-8/NN||carcinoma-16/NNS	conj_and||cirrhosis-12/NNS||carcinoma-16/NNS	hbv-3||hepatitisbvirus-1||no||hepatitisbvirus (hbv) is the major cause of chronichepatitis, cirrhosis, and hepatocellular carcinoma.
prep_in||retained-6/VBD||vitro-2/NN	det||conjugates-5/NNS||all-4/DT	nsubj||retained-6/VBD||conjugates-5/NNS	root||ROOT-0/null||retained-6/VBD	det||phototoxicity-8/NN||the-7/DT	dobj||retained-6/VBD||phototoxicity-8/NN	det||porphyrin-11/NN||the-10/DT	prep_of||phototoxicity-8/NN||porphyrin-11/NN	det||immunoreactivity-14/NN||the-13/DT	dobj||retained-6/VBD||immunoreactivity-14/NN	conj_and||phototoxicity-8/NN||immunoreactivity-14/NN	det||antibody-17/NN||the-16/DT	prep_of||immunoreactivity-14/NN||antibody-17/NN	phototoxicity-8||antibody-17||no_rel||in vitro , all conjugates retained the phototoxicity of the porphyrin and the immunoreactivity of the antibody.
prep_despite||continues-16/VBZ||this-2/DT	det||role-6/NN||the-4/DT	amod||role-6/NN||exact-5/JJ	nsubj||continues-16/VBZ||role-6/NN	nsubj||emerge-18/VB||role-6/NN	prep_of||role-6/NN||dronedarone-8/NN	det||management-11/NN||the-10/DT	prep_in||dronedarone-8/NN||management-11/NN	prep_of||management-11/NN||patients-13/NNS	prep_with||patients-13/NNS||atrialfibrillation-15/NN	root||ROOT-0/null||continues-16/VBZ	aux||emerge-18/VB||to-17/TO	xcomp||continues-16/VBZ||emerge-18/VB	atrialfibrillation-15||dronedarone-8||no_rel||despite this, the exact role of dronedarone in the management of patients with atrialfibrillation continues to emerge.
nsubjpass||associated-8/VBN||antibodies-1/NNS	prep_against||antibodies-1/NNS||adalimumab-3/NN	appos||antibodies-1/NNS||aaa-5/NN	auxpass||associated-8/VBN||are-7/VBP	root||ROOT-0/null||associated-8/VBN	prep_with||associated-8/VBN||non-response-10/NN	prep_to||associated-8/VBN||treatment-12/NN	aaa-5||antibodies-1||no_rel||antibodies against adalimumab (aaa) are associated with non-response to treatment.
prep_for||plasmid-28/VBN||animals-2/NNS	vmod||animals-2/NNS||injected-3/VBN	num||transposon-11/NNS||10-5/CD	number||1/4-7/CD||î-6/CD	num||transposon-11/NNS||1/4-7/CD	amod||transposon-11/NNS||g-8/JJ	amod||transposon-11/NNS||statin-9/JJ	nn||transposon-11/NNS||ae-10/NN	prep_with||injected-3/VBN||transposon-11/NNS	vmod||transposon-11/NNS||plasmid-12/VBN	det||number-15/NN||the-14/DT	nsubjpass||plasmid-28/VBN||number-15/NN	nn||nodules-18/NNS||tumor-17/NN	prep_of||number-15/NN||nodules-18/NNS	auxpass||plasmid-28/VBN||was-19/VBD	advmod||plasmid-28/VBN||inversely-20/RB	pobj||inversely-20/RB||proportional-21/CD	det||amount-24/NN||the-23/DT	prep_to||inversely-20/RB||amount-24/NN	amod||sb-27/NN||co-injected-26/JJ	prep_of||amount-24/NN||sb-27/NN	root||ROOT-0/null||plasmid-28/VBN	tumor-17||statin-9||no_rel||for animals injected with 10 î¼g statin ae transposon plasmid, the number of tumor nodules was inversely proportional to the amount of co-injected sb plasmid.
det||people-5/NNS||an-1/DT	amod||people-5/NNS||estimated-2/VBN	number||million-4/CD||150-200-3/CD	num||people-5/NNS||million-4/CD	nsubjpass||infected-8/VBN||people-5/NNS	advmod||infected-8/VBN||worldwide-6/RB	auxpass||infected-8/VBN||are-7/VBP	root||ROOT-0/null||infected-8/VBN	prep_with||infected-8/VBN||hepatitisc-10/NNP	advmod||information-14/NN||only-12/RB	amod||information-14/NN||limited-13/JJ	nsubj||hcv-22/VBP||information-14/NN	det||epidemiology-17/NN||the-16/DT	prep_about||information-14/NN||epidemiology-17/NN	amod||-lrb--21/NNS||hepatitisc-19/JJ	nn||-lrb--21/NNS||virus-20/NN	prep_of||epidemiology-17/NN||-lrb--21/NNS	rcmod||hepatitisc-10/NNP||hcv-22/VBP	amod||infection-24/NN||-rrb--23/JJ	nsubj||available-26/JJ||infection-24/NN	cop||available-26/JJ||is-25/VBZ	ccomp||hcv-22/VBP||available-26/JJ	hepatitisc-19||hcv-22||no||an estimated 150-200 million people worldwide are infected with hepatitisc. only limited information about the epidemiology of hepatitisc virus -lrb- hcv -rrb- infection is available .
nsubj||reduced-8/VBD||pretreatment-1/NN	nn||kg-7/NN||sufentanil-3/NN	num||kg-7/NN||0.3-4/CD	nn||kg-7/NN||âµg-5/NN	nn||kg-7/NN||/-6/NN	prep_with||pretreatment-1/NN||kg-7/NN	root||ROOT-0/null||reduced-8/VBD	det||severity-10/NN||the-9/DT	dobj||reduced-8/VBD||severity-10/NN	amod||pain-15/NN||microemulsion-12/JJ	amod||pain-15/NN||propofol-13/JJ	nn||pain-15/NN||injection-14/NN	prep_of||severity-10/NN||pain-15/NN	prepc_without||reduced-8/VBD||increasing-17/VBG	amod||pressure-20/NN||arterial-18/JJ	nn||pressure-20/NN||blood-19/NN	dobj||increasing-17/VBG||pressure-20/NN	nn||rate-23/NN||heart-22/NN	dobj||increasing-17/VBG||rate-23/NN	conj_and||pressure-20/NN||rate-23/NN	amod||intubation-26/NN||endotracheal-25/JJ	prep_after||increasing-17/VBG||intubation-26/NN	pain-15||propofol-13||yes||pretreatment with sufentanil 0.3 âµg/kg reduced the severity of microemulsion propofol injection pain without increasing arterial blood pressure and heart rate after endotracheal intubation.
det||objectives-3/NNS||the-1/DT	amod||objectives-3/NNS||overall-2/JJ	nsubj||are-7/VBP||objectives-3/NNS	det||paper-6/NN||this-5/DT	prep_of||objectives-3/NNS||paper-6/NN	root||ROOT-0/null||are-7/VBP	dobj||are-7/VBP||1-9/CD	nsubj||provide-12/VB||1-9/CD	aux||provide-12/VB||to-11/TO	xcomp||are-7/VBP||provide-12/VB	det||overview-14/NN||an-13/DT	dobj||provide-12/VB||overview-14/NN	amod||studies-17/NNS||recent-16/JJ	prep_on||provide-12/VB||studies-17/NNS	nsubj||highlight-19/VB||studies-17/NNS	rcmod||studies-17/NNS||highlight-19/VB	det||risk-22/NN||the-20/DT	amod||risk-22/NN||increased-21/VBN	dobj||highlight-19/VB||risk-22/NN	amod||complications-25/NNS||respiratory-24/JJ	prep_for||risk-22/NN||complications-25/NNS	prep_following||complications-25/NNS||sedation-27/NN	prep_following||complications-25/NNS||analgesia-29/NN	conj_and||sedation-27/NN||analgesia-29/NN	prep_in||sedation-27/NN||children-31/NNS	amod||disabilities-34/NNS||developmental-33/JJ	prep_with||children-31/NNS||disabilities-34/NNS	prep_with||children-31/NNS||neurologicdisorders-36/NNS	conj_and||disabilities-34/NNS||neurologicdisorders-36/NNS	appos||disabilities-34/NNS||2-39/CD	aux||provide-42/VB||to-41/TO	vmod||risk-22/NN||provide-42/VB	det||understanding-45/NN||a-43/DT	amod||understanding-45/NN||better-44/JJR	dobj||provide-42/VB||understanding-45/NN	nsubjpass||used-54/VBN||understanding-45/NN	prep_of||understanding-45/NN||sedatives-47/NNS	amod||medications-50/NNS||analgesic-49/JJ	prep_of||understanding-45/NN||medications-50/NNS	conj_and||sedatives-47/NNS||medications-50/NNS	auxpass||used-54/VBN||are-52/VBP	advmod||used-54/VBN||commonly-53/RB	rcmod||understanding-45/NN||used-54/VBN	prep_in||used-54/VBN||children-56/NNS	amod||disabilities-59/NNS||developmental-58/JJ	prep_with||children-56/NNS||disabilities-59/NNS	prep_with||children-56/NNS||neurologicdisorders-61/NNS	conj_and||disabilities-59/NNS||neurologicdisorders-61/NNS	det||system-66/NN||the-63/DT	amod||system-66/NN||central-64/JJ	amod||system-66/NN||nervous-65/JJ	prep_on||used-54/VBN||system-66/NN	neurologicdisorders-61||sedatives-47||no_rel||the overall objectives of this paper are (1) to provide an overview on recent studies that highlight the increased risk for respiratory complications following sedation and analgesia in children with developmental disabilities and neurologicdisorders, (2) to provide a better understanding of sedatives and analgesic medications which are commonly used in children with developmental disabilities and neurologicdisorders on the central nervous system.
nn||measures-2/NNS||outcome-1/NN	nsubj||included-3/VBD||measures-2/NNS	root||ROOT-0/null||included-3/VBD	dobj||included-3/VBD||change-4/NN	amod||haemoglobin-7/NN||glycosylated-6/JJ	prep_in||included-3/VBD||haemoglobin-7/NN	appos||haemoglobin-7/NN||hba1c-9/NNP	vmod||included-3/VBD||fasting-12/VBG	nn||glucose-14/NN||plasma-13/NN	dobj||fasting-12/VBG||glucose-14/NN	appos||glucose-14/NN||fpg-16/NN	nn||weight-20/NN||body-19/NN	appos||glucose-14/NN||weight-20/NN	appos||glucose-14/NN||frequency-22/NN	conj_and||weight-20/NN||frequency-22/NN	prep_of||weight-20/NN||nausea-24/NN	prep_of||weight-20/NN||hypoglycaemia-26/NN	conj_and||nausea-24/NN||hypoglycaemia-26/NN	hypoglycaemia-26||glucose-14||yes||outcome measures included change in glycosylated haemoglobin (hba1c), fasting plasma glucose (fpg), body weight and frequency of nausea and hypoglycaemia.
det||vaccine-3/NN||the-1/DT	nn||vaccine-3/NN||quadrivalent-2/NN	nsubj||protects-5/VBZ||vaccine-3/NN	advmod||protects-5/VBZ||additionally-4/RB	root||ROOT-0/null||protects-5/VBZ	amod||type-9/NN||low-risk-7/JJ	nn||type-9/NN||hpv-8/NN	prep_against||protects-5/VBZ||type-9/NN	dep||type-9/NN||6-10/CD	dep||type-9/NN||11-12/CD	conj_and||6-10/CD||11-12/CD	amod||type-9/NN||responsible-14/JJ	amod||cases-17/NNS||most-16/JJS	prep_for||responsible-14/JJ||cases-17/NNS	prep_of||type-9/NN||genitalwarts-19/NNS	genitalwarts-19||hpv-8||no||the quadrivalent vaccine additionally protects against low-risk hpv type 6 and 11, responsible for most cases of genitalwarts.
det||incidence-3/NN||the-1/DT	nn||incidence-3/NN||cancer-2/NN	nsubj||higher-9/JJR||incidence-3/NN	nn||nonusers-6/NNS||insulin-5/NN	prep_in||incidence-3/NN||nonusers-6/NNS	cop||higher-9/JJR||was-7/VBD	advmod||higher-9/JJR||much-8/RB	root||ROOT-0/null||higher-9/JJR	prep_than||higher-9/JJR||that-11/DT	nn||users-14/NNS||insulin-13/NN	prep_in||-lrb--15/NN||users-14/NNS	rcmod||that-11/DT||-lrb--15/NN	num||-lrb--15/NN||49.2-16/CD	prep||-lrb--15/NN||vs.-17/FW	pobj||vs.-17/FW||10.2-18/CD	num||person-years-22/NNS||1,000-21/CD	prep_per||-lrb--15/NN||person-years-22/NNS	advmod||<-25/JJ||p-24/RB	dep||higher-9/JJR||<-25/JJ	num||-rrb--27/NNS||0.0001-26/CD	dep||higher-9/JJR||-rrb--27/NNS	cancer-2||insulin-13||no_rel||the cancer incidence in insulin nonusers was much higher than that in insulin users -lrb- 49.2 vs. 10.2 , per 1,000 person-years , p < 0.0001 -rrb- .
prep_conclusionsâ||demonstrated-7/VBN||$-2/$	det||study-5/NN||this-4/DT	nsubj||demonstrated-7/VBN||study-5/NN	aux||demonstrated-7/VBN||has-6/VBZ	root||ROOT-0/null||demonstrated-7/VBN	mark||amplify-16/VB||that-8/IN	amod||administration-10/NN||6-week-9/JJ	nsubj||amplify-16/VB||administration-10/NN	det||fluoxetine-14/NN||the-12/DT	amod||fluoxetine-14/NN||ssri-13/JJ	prep_of||administration-10/NN||fluoxetine-14/NN	aux||amplify-16/VB||can-15/MD	ccomp||demonstrated-7/VBN||amplify-16/VB	nn||mechanisms-21/NNS||ans-17/NN	conj_and||ans-17/NN||metabolic-19/JJ	nn||mechanisms-21/NNS||metabolic-19/JJ	nn||mechanisms-21/NNS||counterregulatory-20/NN	dobj||amplify-16/VB||mechanisms-21/NNS	amod||hypoglycemia-24/NN||moderate-23/JJ	prep_during||amplify-16/VB||hypoglycemia-24/NN	prep_in||hypoglycemia-24/NN||patients-26/NNS	prep_with||patients-26/NNS||type1diabetes-28/CD	fluoxetine-14||type1diabetes-28||no_rel||conclusionsâ this study has demonstrated that 6-week administration of the ssri fluoxetine can amplify ans and metabolic counterregulatory mechanisms during moderate hypoglycemia in patients with type1diabetes.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||association-4/NN||the-3/DT	dobj||investigated-2/VBD||association-4/NN	det||variant-8/NN||the-6/DT	amod||variant-8/NN||c1858t-7/JJ	prep_of||association-4/NN||variant-8/NN	amod||function-12/NN||residual-10/JJ	amod||function-12/NN||beta-cell-11/JJ	prep_with||investigated-2/VBD||function-12/NN	advmod||assessed-15/JJ||as-14/RB	dep||function-12/NN||assessed-15/JJ	amod||hba1c-24/NNS||stimulated-17/JJ	nn||hba1c-24/NNS||c-peptide-18/NN	conj_and||c-peptide-18/NN||proinsulin-20/NN	nn||hba1c-24/NNS||proinsulin-20/NN	conj_and||c-peptide-18/NN||insulin-22/NN	nn||hba1c-24/NNS||insulin-22/NN	nn||hba1c-24/NNS||dose-adjusted-23/NN	prep_by||assessed-15/JJ||hba1c-24/NNS	amod||control-28/NN||glycemic-27/JJ	prep_with||investigated-2/VBD||control-28/NN	conj_and||function-12/NN||control-28/NN	amod||requirements-32/NNS||daily-30/JJ	nn||requirements-32/NNS||insulin-31/NN	prep_with||investigated-2/VBD||requirements-32/NNS	conj_and||function-12/NN||requirements-32/NNS	prep_with||investigated-2/VBD||diabeticketoacidosis-34/NNS	conj_and||function-12/NN||diabeticketoacidosis-34/NNS	appos||diabeticketoacidosis-34/NNS||dka-36/NN	amod||autoantibodies-40/NNS||diabetes-related-39/JJ	prep_with||investigated-2/VBD||autoantibodies-40/NNS	conj_and||function-12/NN||autoantibodies-40/NNS	nn||ica-46/NN||ia-2a-42/NN	dep||ica-46/NN||gada-44/NN	appos||autoantibodies-40/NNS||ica-46/NN	dep||ica-46/NN||znt8ab-48/NNP	prep_in||investigated-2/VBD||children-51/NNS	det||year-55/NN||the-53/DT	amod||year-55/NN||first-54/JJ	prep_during||children-51/NNS||year-55/NN	prep_after||investigated-2/VBD||diagnosis-57/NN	prep_of||diagnosis-57/NN||type1diabetes-59/CD	type1diabetes-59||insulin-31||yes||we investigated the association of the c1858t variant with residual beta-cell function (as assessed by stimulated c-peptide, proinsulin and insulin dose-adjusted hba1c), glycemic control, daily insulin requirements, diabeticketoacidosis (dka) and diabetes-related autoantibodies (ia-2a, gada, ica, znt8ab) in children during the first year after diagnosis of type1diabetes.
nn||detemir-2/NN||insulin-1/NN	nsubj||has-3/VBZ||detemir-2/NN	root||ROOT-0/null||has-3/VBZ	amod||variability-6/NN||lower-4/JJR	amod||variability-6/NN||glycemic-5/JJ	dobj||has-3/VBZ||variability-6/NN	amod||variability-11/NN||less-9/JJR	amod||variability-11/NN||intra-subject-10/JJ	prep_with||variability-6/NN||variability-11/NN	amod||levels-14/NNS||bloodglucose-13/JJ	prep_in||variability-11/NN||levels-14/NNS	prep_in||has-3/VBZ||patients-16/NNS	prep_with||patients-16/NNS||type-18/NN	num||type-18/NN||1-19/CD	prep_with||patients-16/NNS||type2diabetes-21/NNS	conj_and||type-18/NN||type2diabetes-21/NNS	prepc_without||has-3/VBZ||increasing-24/VBG	det||risk-26/NN||the-25/DT	dobj||increasing-24/VBG||risk-26/NN	prep_of||risk-26/NN||hypoglycemia-28/NN	hypoglycemia-28||glucose--1||yes||insulin detemir has lower glycemic variability, with less intra-subject variability in bloodglucose levels in patients with type 1 and type2diabetes, without increasing the risk of hypoglycemia.
nsubj||conducted-3/VBN||we-1/PRP	aux||conducted-3/VBN||have-2/VBP	root||ROOT-0/null||conducted-3/VBN	det||screening-6/NN||a-4/DT	amod||screening-6/NN||phenotypic-5/JJ	dobj||conducted-3/VBN||screening-6/NN	amod||cells-9/NNS||endothelial-8/JJ	prep_in||conducted-3/VBN||cells-9/NNS	vmod||cells-9/NNS||exposed-10/VBN	amod||glucose-14/NN||elevated-12/JJ	nn||glucose-14/NN||extracellular-13/NN	prep_to||exposed-10/VBN||glucose-14/NN	det||model-19/NN||an-16/DT	dep||vitro-18/NN||in-17/IN	amod||model-19/NN||vitro-18/NN	dep||glucose-14/NN||model-19/NN	prep_of||model-19/NN||hyperglycemia-21/NN	aux||identify-24/VB||to-23/TO	xcomp||exposed-10/VBN||identify-24/VB	dobj||identify-24/VB||compounds-25/NNS	dep||identify-24/VB||that-26/IN	dep||identify-24/VB||prevent-27/VB	amod||species-31/NNS||hyperglycemia-induced-28/JJ	amod||species-31/NNS||reactive-29/JJ	nn||species-31/NNS||oxygen-30/NN	dobj||prevent-27/VB||species-31/NNS	appos||species-31/NNS||ros-33/NN	dobj||identify-24/VB||formation-35/NN	advmod||affecting-38/VBG||adversely-37/RB	prepc_without||identify-24/VB||affecting-38/VBG	nn||viability-40/NN||cell-39/NN	dobj||affecting-38/VBG||viability-40/NN	hyperglycemia-21||glucose-14||no||we have conducted a phenotypic screening in endothelial cells exposed to elevated extracellular glucose (an in vitro model of hyperglycemia) to identify compounds that prevent hyperglycemia-induced reactive oxygen species (ros) formation without adversely affecting cell viability.
amod||deaths-2/NNS||registered-1/JJ	nsubj||showed-14/VBD||deaths-2/NNS	amod||authorities-5/NNS||traditional-4/JJ	prep_at||deaths-2/NNS||authorities-5/NNS	det||sale-8/NN||the-7/DT	appos||authorities-5/NNS||sale-8/NN	prep_of||sale-8/NN||coffins-10/NNS	nn||funerals-13/NNS||church-12/NN	prep_of||sale-8/NN||funerals-13/NNS	conj_and||coffins-10/NNS||funerals-13/NNS	root||ROOT-0/null||showed-14/VBD	det||trend-18/NN||a-15/DT	amod||trend-18/NN||significant-16/JJ	amod||trend-18/NN||downward-17/JJ	nsubjpass||associated-27/VBN||trend-18/NN	det||period-22/NN||a-20/DT	amod||period-22/NN||8-year-21/JJ	prep_over||trend-18/NN||period-22/NN	dobj||believe-25/VBP||period-22/NN	nsubj||believe-25/VBP||we-24/PRP	rcmod||period-22/NN||believe-25/VBP	auxpass||associated-27/VBN||was-26/VBD	ccomp||showed-14/VBD||associated-27/VBN	det||scaling-30/NN||the-29/DT	prep_with||associated-27/VBN||scaling-30/NN	amod||care-33/NN||hiv/aids-32/JJ	prep_up||associated-27/VBN||care-33/NN	prep_up||associated-27/VBN||art-35/NN	conj_and||care-33/NN||art-35/NN	aids--1||hiv--1||no||registered deaths at traditional authorities, the sale of coffins and church funerals showed a significant downward trend over a 8-year period which we believe was associated with the scaling up hiv/aids care and art.
mark||related-8/VBN||although-1/IN	det||presence-3/NN||the-2/DT	nsubjpass||related-8/VBN||presence-3/NN	prep_of||presence-3/NN||viremia-5/NN	auxpass||related-8/VBN||was-6/VBD	neg||related-8/VBN||not-7/RB	advcl||play-16/VB||related-8/VBN	amod||responses-12/NNS||hbv-specific-10/JJ	amod||responses-12/NNS||t-cell-11/JJ	prep_to||related-8/VBN||responses-12/NNS	nsubj||play-16/VB||ctls-14/NNS	aux||play-16/VB||might-15/MD	root||ROOT-0/null||play-16/VB	det||role-18/NN||a-17/DT	dobj||play-16/VB||role-18/NN	det||control-21/NN||the-20/DT	prep_in||role-18/NN||control-21/NN	nn||infection-24/NN||hbv-23/NN	prep_of||control-21/NN||infection-24/NN	prep_in||play-16/VB||children-26/NNS	vmod||children-26/NNS||born-27/VBN	amod||mothers-30/NNS||hbsag-positive-29/JJ	prep_to||born-27/VBN||mothers-30/NNS	amod||treatment-33/NN||immunoprophylactic-32/JJ	prep_after||born-27/VBN||treatment-33/NN	hbv-23||hbsag--1||yes||although the presence of viremia was not related to hbv-specific t-cell responses, ctls might play a role in the control of hbv infection in children born to hbsag-positive mothers after immunoprophylactic treatment.
advmod||active-2/JJ||highly-1/RB	amod||therapy-4/NN||active-2/JJ	amod||therapy-4/NN||antiretroviral-3/JJ	nsubj||changed-9/VBN||therapy-4/NN	appos||therapy-4/NN||haart-6/NN	aux||changed-9/VBN||has-8/VBZ	root||ROOT-0/null||changed-9/VBN	det||face-11/NN||the-10/DT	dobj||changed-9/VBN||face-11/NN	prep_of||face-11/NN||humanimmunodeficiencyvirus-13/NNS	appos||humanimmunodeficiencyvirus-13/NNS||hiv-15/NN	vmod||humanimmunodeficiencyvirus-13/NNS||acquired-17/VBN	amod||syndrome-19/NN||immunedeficiency-18/JJ	dobj||acquired-17/VBN||syndrome-19/NN	appos||syndrome-19/NN||aids-21/NNS	agent||acquired-17/VBN||leading-24/VBG	amod||decreases-27/NNS||dramatic-26/JJ	prep_to||leading-24/VBG||decreases-27/NNS	amod||morbidity-30/NN||hiv-related-29/JJ	prep_in||decreases-27/NNS||morbidity-30/NN	prep_in||decreases-27/NNS||mortality-32/NN	conj_and||morbidity-30/NN||mortality-32/NN	det||developed-35/JJ||the-34/DT	prep_in||leading-24/VBG||developed-35/JJ	agent||acquired-17/VBN||developing-39/VBG	conj_and||leading-24/VBG||developing-39/VBG	dobj||developing-39/VBG||world-40/NN	aids-21||hiv-15||no||highly active antiretroviral therapy (haart) has changed the face of humanimmunodeficiencyvirus (hiv) acquired immunedeficiency syndrome (aids) by leading to dramatic decreases in hiv-related morbidity and mortality in the developed as well as developing world.
det||plus-5/NN||the-1/DT	nn||plus-5/NN||genotypeâ-2/NNP	nn||plus-5/NN||®-3/NNP	nn||plus-5/NN||mtbdr-4/NN	nsubjpass||validated-9/VBN||plus-5/NN	nsubj||mdr-tb-32/JJ||plus-5/NN	advmod||validated-9/VBN||assay-6/RB	aux||validated-9/VBN||has-7/VBZ	auxpass||validated-9/VBN||been-8/VBN	root||ROOT-0/null||validated-9/VBN	mark||isolates-23/VBZ||as-10/IN	det||test-17/NN||a-11/DT	amod||test-17/NN||rapid-12/JJ	conj_and||rapid-12/JJ||reliable-14/JJ	amod||test-17/NN||reliable-14/JJ	amod||test-17/NN||first-line-15/JJ	amod||test-17/NN||diagnostic-16/JJ	nsubj||isolates-23/VBZ||test-17/NN	amod||sputum-20/NN||afb-positive-19/JJ	prep_on||test-17/NN||sputum-20/NN	prep_on||test-17/NN||mtb-22/NN	conj_or||sputum-20/NN||mtb-22/NN	advcl||validated-9/VBN||isolates-23/VBZ	nn||resistance-26/NN||inh-25/NN	prep_for||isolates-23/VBZ||resistance-26/NN	nn||resistance-29/NN||rif-28/NN	appos||resistance-26/NN||resistance-29/NN	conj_and||validated-9/VBN||mdr-tb-32/JJ	prep_in||mdr-tb-32/JJ||bangkok-34/NN	dep||validated-9/VBN||thailand-36/VBN	tb--1||inh-25||yes||the genotypeâ® mtbdr plus assay has been validated as a rapid and reliable first-line diagnostic test on afb-positive sputum or mtb isolates for inh resistance, rif resistance, and mdr-tb in bangkok, thailand.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	neg||change-4/NN||no-3/DT	nsubj||was-2/VBD||change-4/NN	amod||bloodglucose-7/NN||mean-6/JJ	prep_in||change-4/NN||bloodglucose-7/NN	prep_in||bloodglucose-7/NN||group-9/NN	det||-lsb--14/NNS||a-10/DT	amod||-lsb--14/NNS||-lrb--11/JJ	num||-lsb--14/NNS||9.55-12/CD	amod||-lsb--14/NNS||mmol/l-13/JJ	nsubj||8.20-15/VBD||-lsb--14/NNS	rcmod||change-4/NN||8.20-15/VBD	iobj||8.20-15/VBD||â-16/NN	dep||8.20-15/VBD||$-17/$	num||-rsb--20/NN||10.90-19/CD	npadvmod||8.29-25/RB||-rsb--20/NN	advmod||-rsb--20/NN||vs.-21/RB	num||-lsb--24/NNS||9.71-22/CD	amod||-lsb--24/NNS||mmol/l-23/JJ	pobj||vs.-21/RB||-lsb--24/NNS	dep||â-26/CD||8.29-25/RB	num||$-17/$||â-26/CD	dep||8.20-15/VBD||$-27/$	advmod||-rsb--30/JJ||11.13-29/RB	amod||p-32/NNS||-rsb--30/JJ	npadvmod||=-33/RB||p-32/NNS	dep||0.07-34/CD||=-33/RB	num||$-27/$||0.07-34/CD	advmod||-lrb--39/NNS||-rrb--35/RB	conj_and||-rrb--35/RB||in-37/IN	advmod||-lrb--39/NNS||in-37/IN	pobj||in-37/IN||groupb-38/NN	iobj||8.20-15/VBD||-lrb--39/NNS	num||â-44/NNS||8.72-40/CD	amod||â-44/NNS||mmol/l-41/JJ	amod||â-44/NNS||-lsb--42/JJ	dep||-lsb--42/JJ||7.31-43/CD	iobj||8.20-15/VBD||â-44/NNS	dep||8.20-15/VBD||$-45/$	num||-rsb--48/NN||10.12-47/CD	npadvmod||7.47-53/RB||-rsb--48/NN	advmod||-rsb--48/NN||vs.-49/RB	num||-lsb--52/NNS||8.78-50/CD	amod||-lsb--52/NNS||mmol/l-51/JJ	pobj||vs.-49/RB||-lsb--52/NNS	dep||â-54/CD||7.47-53/RB	num||$-45/$||â-54/CD	dobj||8.20-15/VBD||$-55/$	advmod||-rsb--58/JJ||9.99-57/RB	amod||p-60/NNS||-rsb--58/JJ	npadvmod||=-61/RB||p-60/NNS	dep||0.61-62/CD||=-61/RB	num||$-55/$||0.61-62/CD	xcomp||8.20-15/VBD||-rrb--63/VBG	det||period-67/NN||the-65/DT	nn||period-67/NN||study-66/NN	prep_over||-rrb--63/VBG||period-67/NN	groupb-38||glucose--1||no_rel||there was no change in mean bloodglucose in group a -lrb- 9.55 mmol/l -lsb- 8.20 â $ `` 10.90 -rsb- vs. 9.71 mmol/l -lsb- 8.29 â $ `` 11.13 -rsb- , p = 0.07 -rrb- and in groupb -lrb- 8.72 mmol/l -lsb- 7.31 â $ `` 10.12 -rsb- vs. 8.78 mmol/l -lsb- 7.47 â $ `` 9.99 -rsb- , p = 0.61 -rrb- over the study period .
nn||replacement-2/NN||iapp-1/NN	nsubj||slowed-14/VBD||replacement-2/NN	vmod||replacement-2/NN||using-4/VBG	det||pramlintide-7/NN||the-5/DT	amod||pramlintide-7/NN||analog-6/JJ	dobj||using-4/VBG||pramlintide-7/NN	nn||subjects-13/NNS||type-10/NN	num||subjects-13/NNS||1-11/CD	nn||subjects-13/NNS||diabetic-12/NN	prep_in||slowed-14/VBD||subjects-13/NNS	root||ROOT-0/null||slowed-14/VBD	amod||emptying-16/NN||gastric-15/JJ	dobj||slowed-14/VBD||emptying-16/NN	det||extent-20/NN||a-18/DT	amod||extent-20/NN||comparable-19/JJ	prep_to||slowed-14/VBD||extent-20/NN	mark||did-23/VBD||as-22/IN	advcl||slowed-14/VBD||did-23/VBD	dobj||did-23/VBD||hyperglycemia-24/NN	amod||subjects-27/NNS||healthy-26/JJ	prep_in||did-23/VBD||subjects-27/NNS	dep||<-30/JJ||p-29/RB	dep||did-23/VBD||<-30/JJ	dep||<-30/JJ||0.14-31/CD	advmod||reduced-36/VBD||greatly-35/RB	advcl||slowed-14/VBD||reduced-36/VBD	conj_and||did-23/VBD||reduced-36/VBD	amod||hyperglycemia-38/NN||postprandial-37/JJ	dobj||reduced-36/VBD||hyperglycemia-38/NN	appos||hyperglycemia-38/NN||p-40/NNP	number||00.1-42/CD||<-41/CD	num||p-40/NNP||00.1-42/CD	pramlintide-7||hyperglycemia-38||no_rel||iapp replacement, using the analog pramlintide, in type 1 diabetic subjects slowed gastric emptying to a comparable extent, as did hyperglycemia in healthy subjects ( p < 0.14), and greatly reduced postprandial hyperglycemia ( p < 00.1).
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	amod||parameters-4/NNS||anthropometric-3/JJ	dobj||evaluated-2/VBN||parameters-4/NNS	nn||index-12/NN||height-6/NN	dep||index-12/NN||weight-8/NN	dep||index-12/NN||body-10/NN	nn||index-12/NN||mass-11/NN	dep||parameters-4/NNS||index-12/NN	appos||index-12/NN||bmi-14/NN	appos||index-12/NN||waist-17/NN	nn||circumference-20/NN||hip-19/NN	appos||index-12/NN||circumference-20/NN	conj_and||waist-17/NN||circumference-20/NN	appos||index-12/NN||waist-22/NN	nn||ratio-25/NN||height-24/NN	prep_to||waist-22/NN||ratio-25/NN	dobj||evaluated-2/VBN||additionally-29/RB	advmod||parameters-4/NNS||additionally-29/RB	conj_and||parameters-4/NNS||additionally-29/RB	amod||biomarkers-33/NNS||cardiovascular-31/JJ	nn||biomarkers-33/NNS||risk-32/NN	dobj||evaluated-2/VBN||biomarkers-33/NNS	conj_and||parameters-4/NNS||biomarkers-33/NNS	amod||glucose-37/NN||fasting-35/JJ	nn||glucose-37/NN||plasma-36/NN	dep||biomarkers-33/NNS||glucose-37/NN	dep||biomarkers-33/NNS||hba1c-39/NNS	conj_and||glucose-37/NN||hba1c-39/NNS	dep||biomarkers-33/NNS||triglycerides-41/NNPS	conj_and||glucose-37/NN||triglycerides-41/NNPS	amod||cholesterol-44/NN||total-43/JJ	dep||biomarkers-33/NNS||cholesterol-44/NN	conj_and||glucose-37/NN||cholesterol-44/NN	dep||biomarkers-33/NNS||hdl-46/NN	conj_and||glucose-37/NN||hdl-46/NN	dep||biomarkers-33/NNS||ldl-48/NN	conj_and||glucose-37/NN||ldl-48/NN	dep||biomarkers-33/NNS||lipoprotein-51/NN	conj_and||glucose-37/NN||lipoprotein-51/NN	dep||lipoprotein-51/NN||a-53/SYM	num||patients-59/NNS||81-57/CD	amod||patients-59/NNS||acromegalic-58/JJ	prep_in||evaluated-2/VBN||patients-59/NNS	num||%-62/NN||58-61/CD	dep||patients-59/NNS||%-62/NN	vmod||%-62/NN||cured-63/VBN	prepc_compared_to||evaluated-2/VBN||to-66/TO	num||age-68/NN||320-67/CD	pobj||evaluated-2/VBN||age-68/NN	amod||controls-72/NNS||gender-matched-71/JJ	pobj||evaluated-2/VBN||controls-72/NNS	conj_and||age-68/NN||controls-72/NNS	appos||age-68/NN||ratio-74/NN	num||ratio-74/NN||14-75/CD	dep||evaluated-2/VBN||sampled-78/VBN	det||cohort-84/NN||the-80/DT	amod||cohort-84/NN||primary-81/JJ	nn||cohort-84/NN||care-82/NN	nn||cohort-84/NN||patient-83/NN	prep_from||sampled-78/VBN||cohort-84/NN	ccomp||evaluated-2/VBN||detect-85/VB	triglycerides-41||acromegalic-58||no_rel||we evaluated anthropometric parameters (height, weight, body mass index (bmi), waist and hip circumference, waist to height ratio) and, additionally, cardiovascular risk biomarkers (fasting plasma glucose, hba1c, triglycerides, total cholesterol, hdl, ldl, and lipoprotein (a), in 81 acromegalic patients (58% cured) compared to 320 age- and gender-matched controls (ratio 14), sampled from the primary care patient cohort detect.
nsubj||demonstrated-3/VBD||we-1/PRP	advmod||demonstrated-3/VBD||recently-2/RB	root||ROOT-0/null||demonstrated-3/VBD	mark||have-7/VBP||that-4/IN	amod||strains-6/NNS||s-5/JJ	nsubj||have-7/VBP||strains-6/NNS	ccomp||demonstrated-3/VBD||have-7/VBP	amod||systems-11/NNS||defective-8/JJ	nn||systems-11/NNS||iron-9/NN	nn||systems-11/NNS||storage-10/NN	dobj||have-7/VBP||systems-11/NNS	vmod||have-7/VBP||leading-13/VBG	dobj||leading-13/VBG||us-14/PRP	nsubj||propose-16/VB||us-14/PRP	aux||propose-16/VB||to-15/TO	xcomp||leading-13/VBG||propose-16/VB	mark||experience-21/VB||that-17/IN	det||strains-19/NNS||these-18/DT	nsubj||experience-21/VB||strains-19/NNS	aux||experience-21/VB||might-20/MD	ccomp||propose-16/VB||experience-21/VB	nn||toxicity-23/NN||iron-22/NN	dobj||experience-21/VB||toxicity-23/NN	advmod||provided-27/VBN||when-24/WRB	nsubjpass||provided-27/VBN||excessiron-25/NN	auxpass||provided-27/VBN||is-26/VBZ	advcl||experience-21/VB||provided-27/VBN	det||medium-30/NN||the-29/DT	prep_in||provided-27/VBN||medium-30/NN	excessiron-25||iron-22||no||we recently demonstrated that s strains have defective iron storage systems, leading us to propose that these strains might experience iron toxicity when excessiron is provided in the medium.
det||lack-4/NN||this-1/DT	nn||lack-4/NN||study-2/NN	nn||lack-4/NN||shows-3/NNS	nsubj||ca-44/MD||lack-4/NN	amod||activity-8/NN||co2-6/JJ	nn||activity-8/NN||hydration-7/NN	prep_of||lack-4/NN||activity-8/NN	det||protein-12/NN||a-10/DT	amod||protein-12/NN||recombinant-11/JJ	prep_in||activity-8/NN||protein-12/NN	vmod||protein-12/NN||expressed-13/VBN	det||gene-16/NN||a-15/DT	prep_from||expressed-13/VBN||gene-16/NN	vmod||gene-16/NN||predicted-17/VBN	aux||encode-19/VB||to-18/TO	xcomp||predicted-17/VBN||encode-19/VB	det||³-22/NN||a-20/DT	nn||³-22/NN||î-21/NN	dobj||encode-19/VB||³-22/NN	amod||anhydrase-25/NN||carbonic-24/JJ	dep||cross-31/VBP||anhydrase-25/NN	nn||brasilense-28/NN||a.-27/NN	prep_in||anhydrase-25/NN||brasilense-28/NN	mark||cross-31/VBP||although-29/IN	nsubj||cross-31/VBP||it-30/PRP	dep||lack-4/NN||cross-31/VBP	ccomp||cross-31/VBP||reacts-32/VBZ	amod||antibody-35/NN||anti-cam-34/JJ	prep_with||reacts-32/VBZ||antibody-35/NN	vmod||antibody-35/NN||raised-36/VBN	det||³-42/NN||a-38/DT	advmod||characterized-40/JJ||well-39/RB	amod||³-42/NN||characterized-40/JJ	nn||³-42/NN||î-41/NN	prep_against||raised-36/VBN||³-42/NN	root||ROOT-0/null||ca-44/MD	cross-31||co2-6||no_rel||this study shows lack of co2 hydration activity in a recombinant protein expressed from a gene predicted to encode a î ³ - carbonic anhydrase in a. brasilense although it cross reacts with anti-cam antibody raised against a well characterized î ³ - ca .
poss||results-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||results-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||remain-19/VB||that-4/IN	mark||vary-9/VB||while-5/IN	amod||interactions-7/NNS||prion-soil-6/JJ	nsubj||vary-9/VB||interactions-7/NNS	aux||vary-9/VB||can-8/MD	advcl||remain-19/VB||vary-9/VB	nn||chemistry-12/NN||solution-11/NN	prep_with||vary-9/VB||chemistry-12/NN	nsubj||remain-19/VB||prions-14/NNS	vmod||prions-14/NNS||bound-15/VBN	prep_to||bound-15/VBN||soil-17/NN	aux||remain-19/VB||could-18/MD	ccomp||suggest-3/VBP||remain-19/VB	det||risk-21/NN||a-20/DT	xcomp||remain-19/VB||risk-21/NN	prepc_for||remain-19/VB||transmitting-23/VBG	dobj||transmitting-23/VBG||priondiseases-24/NNS	prep_after||transmitting-23/VBG||months-26/NNS	det||environment-29/NN||the-28/DT	prep_in||months-26/NNS||environment-29/NN	priondiseases-24||prions-14||no||our results suggest that while prion-soil interactions can vary with solution chemistry, prions bound to soil could remain a risk for transmitting priondiseases after months in the environment.
amod||identification-2/NN||accurate-1/JJ	nsubj||necessary-4/JJ||identification-2/NN	nsubj||necessary-4/JJ||identification-2/NN	cop||necessary-4/JJ||is-3/VBZ	root||ROOT-0/null||necessary-4/JJ	conj_and||necessary-4/JJ||necessary-4/JJ	amod||species-10/NNS||discriminate-6/JJ	amod||species-10/NNS||harmless-7/JJ	amod||species-10/NNS||environmental-8/JJ	nn||species-10/NNS||yersinia-9/NN	prep_to||necessary-4/JJ||species-10/NNS	det||enterocolitica-16/NN||the-12/DT	amod||enterocolitica-16/NN||food-borne-13/JJ	nn||enterocolitica-16/NN||pathogens-14/NNS	nn||enterocolitica-16/NN||yersinia-15/NN	prep_from||species-10/NNS||enterocolitica-16/NN	nn||pseudotuberculosis-19/NNS||yersinia-18/NN	prep_from||species-10/NNS||pseudotuberculosis-19/NNS	conj_and||enterocolitica-16/NN||pseudotuberculosis-19/NNS	det||group-23/NN||the-22/DT	prep_from||necessary-4/JJ||group-23/NN	det||bioterrorism-25/NN||a-24/DT	nsubj||plague-26/VB||bioterrorism-25/NN	rcmod||group-23/NN||plague-26/VB	nn||yersiniapestis-28/NNS||agent-27/NN	dobj||plague-26/VB||yersiniapestis-28/NNS	plague-26||yersiniapestis-28||no||accurate identification is necessary to discriminate harmless environmental yersinia species from the food-borne pathogens yersinia enterocolitica and yersinia pseudotuberculosis and from the group a bioterrorism plague agent yersiniapestis .
nsubjpass||treated-7/VBN||pmvec-1/NN	vmod||pmvec-1/NN||isolated-2/VBN	amod||lung-5/NN||human-4/JJ	prep_from||isolated-2/VBN||lung-5/NN	auxpass||treated-7/VBN||were-6/VBD	root||ROOT-0/null||treated-7/VBN	amod||albumin-45/NN||vitro-9/NN	amod||stimulation-12/NN||septic-11/JJ	prep_with||vitro-9/NN||stimulation-12/NN	amod||-RSB--17/NNS||lipopolysaccharide-14/JJ	amod||-RSB--17/NNS||-LSB--15/JJ	nn||-RSB--17/NNS||lps-16/NN	dep||stimulation-12/NN||-RSB--17/NNS	det||mixture-20/NN||a-19/DT	dep||stimulation-12/NN||mixture-20/NN	conj_or||-RSB--17/NNS||mixture-20/NN	amod||-RSB--26/NNS||clinically-relevant-22/JJ	nn||-RSB--26/NNS||cytokines-23/NNS	nn||-RSB--26/NNS||-LSB--24/NN	nn||-RSB--26/NNS||cytomix-25/NN	prep_of||mixture-20/NN||-RSB--26/NNS	dep||stimulation-12/NN||plasma-29/NN	conj_or||-RSB--17/NNS||plasma-29/NN	prep_from||plasma-29/NN||patients-31/NNS	amod||sepsis-34/NN||severe-33/JJ	prep_with||patients-31/NNS||sepsis-34/NN	det||leak-40/NN||the-38/DT	amod||leak-40/NN||trans-pmvec-39/JJ	prep_with||vitro-9/NN||leak-40/NN	conj_and||stimulation-12/NN||leak-40/NN	prep_of||leak-40/NN||evans-42/NNS	amod||albumin-45/NN||blue-43/JJ	amod||albumin-45/NN||dye-labeled-44/JJ	prep_in||treated-7/VBN||albumin-45/NN	vmod||albumin-45/NN||assessed-46/VBN	sepsis-34||albumin-45||no_rel||pmvec isolated from human lung were treated in vitro with septic stimulation (lipopolysaccharide [lps], a mixture of clinically-relevant cytokines [cytomix], or plasma from patients with severe sepsis), and the trans-pmvec leak of evans blue dye-labeled albumin assessed.
nsubj||resulted-2/VBD||anakinra-1/NN	root||ROOT-0/null||resulted-2/VBD	amod||vessels-6/NNS||decreased-4/VBN	nn||vessels-6/NNS||blood-5/NN	prep_in||resulted-2/VBD||vessels-6/NNS	det||pannus-9/NNS||the-8/DT	prep_in||vessels-6/NNS||pannus-9/NNS	amod||joints-12/NNS||affected-11/JJ	prep_of||pannus-9/NNS||joints-12/NNS	prep_in||joints-12/NNS||patients-14/NNS	prep_with||patients-14/NNS||rheumatoidarthritis-16/NNS	rheumatoidarthritis-16||anakinra-1||yes||anakinra resulted in decreased blood vessels in the pannus of affected joints in patients with rheumatoidarthritis.
nsubj||were-9/VBD||patients-1/NNS	vmod||patients-1/NNS||enrolled-2/VBN	det||trial-8/NN||the-4/DT	nn||trial-8/NN||asthma-5/NN	nn||trial-8/NN||intervention-6/NN	nn||trial-8/NN||research-7/NN	prep_in||enrolled-2/VBN||trial-8/NN	root||ROOT-0/null||were-9/VBD	amod||corticosteroids-12/NNS||inhaled-11/JJ	prep_on||were-9/VBD||corticosteroids-12/NNS	dep||corticosteroids-12/NNS||â-13/VBN	xcomp||â-13/VBN||-14/VBG	number||200-16/CD||¥-15/CD	num||+-23/NNS||200-16/CD	nn||+-23/NNS||î-17/NNP	num||+-23/NNS||1/4-18/CD	amod||+-23/NNS||g-19/JJ	amod||+-23/NNS||beclomethasone-20/JJ	conj_or||beclomethasone-20/JJ||equivalent-22/JJ	amod||+-23/NNS||equivalent-22/JJ	nsubj||long-acting-beta2-agonists-24/JJ||+-23/NNS	xcomp||-14/VBG||long-acting-beta2-agonists-24/JJ	dep||corticosteroids-12/NNS||demonstrated-26/VBN	conj_and||â-13/VBN||demonstrated-26/VBN	dobj||demonstrated-26/VBN||worsening-27/VBG	prep_of||worsening-27/VBG||asthma-29/NN	nn||withdrawal-34/NN||long-acting-î-31/NNP	nn||withdrawal-34/NN||²-32/NNP	amod||withdrawal-34/NN||2-agonist-33/JJ	prep_on||asthma-29/NN||withdrawal-34/NN	corticosteroids-12||asthma-29||no_rel||patients enrolled in the asthma intervention research trial were on inhaled corticosteroids â¥200 î¼g beclomethasone or equivalent + long-acting-beta2-agonists and demonstrated worsening of asthma on long-acting-î²2-agonist withdrawal.
det||goal-2/NN||the-1/DT	nsubj||was-6/VBD||goal-2/NN	det||study-5/NN||the-4/DT	prep_of||goal-2/NN||study-5/NN	root||ROOT-0/null||was-6/VBD	aux||investigate-8/VB||to-7/TO	ccomp||was-6/VBD||investigate-8/VB	det||ä-13/NN||the-9/DT	nn||ä-13/NN||regä-10/NNP	nn||ä-13/NN||±-11/NNP	amod||ä-13/NN||onal-12/JJ	nsubj||±-17/VBG||ä-13/NN	num||ntravenous-15/NNS||±-14/CD	npadvmod||anesthesä-16/JJ||ntravenous-15/NNS	dep||±-17/VBG||anesthesä-16/JJ	xcomp||investigate-8/VB||±-17/VBG	det||procedure-19/NN||a-18/DT	dobj||±-17/VBG||procedure-19/NN	nn||arthroscopy-22/NN||knee-21/NN	prep_in||±-17/VBG||arthroscopy-22/NN	aux||evaluate-25/VB||to-24/TO	ccomp||was-6/VBD||evaluate-25/VB	conj_and||investigate-8/VB||evaluate-25/VB	det||effects-27/NNS||the-26/DT	dobj||evaluate-25/VB||effects-27/NNS	prepc_of||effects-27/NNS||adding-29/VBG	dobj||adding-29/VBG||ketamine-30/NN	det||charactery-35/NN||the-32/DT	nn||charactery-35/NN||anesthesia-33/NN	nn||charactery-35/NN||block-34/NN	prep_over||adding-29/VBG||charactery-35/NN	nn||pain-38/NN||tourniquet-37/NN	prep_over||adding-29/VBG||pain-38/NN	conj_and||charactery-35/NN||pain-38/NN	pain-38||ketamine-30||yes||the goal of the study was to investigate the regä±onal ä±ntravenous anesthesä±a procedure in knee arthroscopy and to evaluate the effects of adding ketamine over the anesthesia block charactery and tourniquet pain.
amod||scabies-2/NNS||ordinary-1/JJ	nsubjpass||treated-5/VBN||scabies-2/NNS	auxpass||treated-5/VBN||is-3/VBZ	advmod||treated-5/VBN||commonly-4/RB	root||ROOT-0/null||treated-5/VBN	amod||creams-8/NNS||topical-7/JJ	prep_with||treated-5/VBN||creams-8/NNS	prep_such_as||creams-8/NNS||permethrin-11/NN	mark||treated-17/VBN||while-13/IN	amod||scabies-15/NNS||crusted-14/JJ	nsubjpass||treated-17/VBN||scabies-15/NNS	auxpass||treated-17/VBN||is-16/VBZ	advcl||treated-5/VBN||treated-17/VBN	amod||creams-20/NNS||topical-19/JJ	prep_with||treated-17/VBN||creams-20/NNS	prep_in||creams-20/NNS||combination-22/NN	amod||ivermectin-25/NN||oral-24/JJ	prep_with||treated-17/VBN||ivermectin-25/NN	scabies-15||permethrin-11||yes||ordinary scabies is commonly treated with topical creams such as permethrin, while crusted scabies is treated with topical creams in combination with oral ivermectin.
neg||differences-3/NNS||no-1/DT	amod||differences-3/NNS||significant-2/JJ	nsubjpass||found-5/VBN||differences-3/NNS	auxpass||found-5/VBN||were-4/VBD	root||ROOT-0/null||found-5/VBN	nn||subjects-10/NNS||smoking-7/NN	conj_and||smoking-7/NN||non-smoking-9/NN	nn||subjects-10/NNS||non-smoking-9/NN	prep_between||found-5/VBN||subjects-10/NNS	amod||asthma-13/NN||mild-12/JJ	prep_with||subjects-10/NNS||asthma-13/NN	prep_in||asthma-13/NN||regard-15/NN	amod||changes-18/NNS||clinical-17/JJ	prep_to||found-5/VBN||changes-18/NNS	nn||control-21/NN||asthma-20/NN	prep_in||changes-18/NNS||control-21/NN	amod||function-24/NN||pulmonary-23/JJ	appos||control-21/NN||function-24/NN	nn||inflammation-27/NN||airway-26/NN	appos||control-21/NN||inflammation-27/NN	conj_and||function-24/NN||inflammation-27/NN	det||period-32/NN||a-29/DT	amod||period-32/NN||2-month-30/JJ	nn||period-32/NN||treatment-31/NN	prep_following||function-24/NN||period-32/NN	prep_with||period-32/NN||budesonide-34/NN	det||association-37/NN||the-36/DT	prep_following||function-24/NN||association-37/NN	conj_or||period-32/NN||association-37/NN	prep_of||association-37/NN||budesonide-39/NN	prep_of||association-37/NN||formoterol-41/NN	conj_and||budesonide-39/NN||formoterol-41/NN	det||period-44/NN||a-43/DT	prep_for||association-37/NN||period-44/NN	num||months-47/NNS||2-46/CD	prep_of||period-44/NN||months-47/NNS	asthma-20||budesonide-39||no||no significant differences were found between smoking and non-smoking subjects with mild asthma in regard to clinical changes in asthma control, pulmonary function and airway inflammation following a 2-month treatment period with budesonide or the association of budesonide and formoterol for a period of 2 months.
det||study-2/NN||this-1/DT	nsubj||attempts-3/VBZ||study-2/NN	nsubj||determine-5/VB||study-2/NN	nsubj||provides-20/VBZ||study-2/NN	root||ROOT-0/null||attempts-3/VBZ	aux||determine-5/VB||to-4/TO	xcomp||attempts-3/VBZ||determine-5/VB	dobj||determine-5/VB||factors-6/NNS	vmod||factors-6/NNS||associated-7/VBN	prep_with||associated-7/VBN||compliance-9/NN	prep_to||associated-7/VBN||community-11/NN	vmod||community-11/NN||directed-12/VBN	dobj||directed-12/VBN||treatment-13/NN	prep_with||directed-12/VBN||ivermectin-15/NN	appos||ivermectin-15/NN||cdti-17/NNP	conj_and||attempts-3/VBZ||provides-20/VBZ	det||basis-22/NN||a-21/DT	dobj||provides-20/VBZ||basis-22/NN	prepc_for||provides-20/VBZ||trying-24/VBG	aux||understand-26/VB||to-25/TO	xcomp||trying-24/VBG||understand-26/VB	advmod||sustain-30/VB||how-27/WRB	nsubj||sustain-30/VB||best-28/JJS	aux||sustain-30/VB||to-29/TO	ccomp||understand-26/VB||sustain-30/VB	xcomp||understand-26/VB||sustain-30/VB	amod||compliance-32/NN||long-term-31/JJ	dobj||sustain-30/VB||compliance-32/NN	mark||achieve-36/VB||in-33/IN	dep||achieve-36/VB||order-34/NN	aux||achieve-36/VB||to-35/TO	advcl||sustain-30/VB||achieve-36/VB	dobj||achieve-36/VB||success-37/NN	det||control-40/NN||the-39/DT	prep_in||achieve-36/VB||control-40/NN	prep_of||control-40/NN||onchocerciasis-42/NNS	onchocerciasis-42||ivermectin-15||yes||this study attempts to determine factors associated with compliance to community directed treatment with ivermectin (cdti) and provides a basis for trying to understand how best to sustain long-term compliance in order to achieve success in the control of onchocerciasis.
nsubj||assessed-2/VBD||we-1/PRP	root||ROOT-0/null||assessed-2/VBD	dobj||assessed-2/VBD||effects-3/NNS	amod||therapy-7/NN||high-dose-5/JJ	nn||therapy-7/NN||simvastatin-6/NN	prep_of||effects-3/NNS||therapy-7/NN	amod||sensitivity-13/NNS||peripheral-9/JJ	conj_and||peripheral-9/JJ||hepatic-11/JJ	amod||sensitivity-13/NNS||hepatic-11/JJ	nn||sensitivity-13/NNS||insulin-12/NN	prep_on||assessed-2/VBD||sensitivity-13/NNS	amod||deposition-21/NN||ectopic-19/JJ	nn||deposition-21/NN||lipid-20/NN	prep_on||assessed-2/VBD||deposition-21/NN	conj_and||sensitivity-13/NNS||deposition-21/NN	prep_in||deposition-21/NN||patients-23/NNS	prep_with||assessed-2/VBD||hypercholesterolemia-25/NN	prep_with||assessed-2/VBD||type2diabetes-27/NNS	conj_and||hypercholesterolemia-25/NN||type2diabetes-27/NNS	hypercholesterolemia-25||simvastatin-6||yes||we assessed effects of high-dose simvastatin therapy on peripheral and hepatic insulin sensitivity, as well as on ectopic lipid deposition in patients with hypercholesterolemia and type2diabetes.
advmod||based-2/VBN||physiologically-1/RB	root||ROOT-0/null||based-2/VBN	xcomp||based-2/VBN||modelling-3/VBG	vmod||modelling-3/VBG||using-4/VBG	dobj||using-4/VBG||debtox-5/NN	amod||budget-9/NN||dynamic-7/JJ	nn||budget-9/NN||energy-8/NN	dep||debtox-5/NN||budget-9/NN	prep_in||budget-9/NN||toxicology-11/NN	amod||profiling-15/NN||transcriptional-14/JJ	dobj||using-4/VBG||profiling-15/NN	conj_and||debtox-5/NN||profiling-15/NN	auxpass||used-17/VBN||were-16/VBD	auxpass||based-2/VBN||used-17/VBN	amod||elegans-20/NNS||caenorhabditis-19/JJ	prep_in||used-17/VBN||elegans-20/NNS	aux||identify-22/VB||to-21/TO	xcomp||used-17/VBN||identify-22/VB	advmod||associated-39/VBN||how-23/WRB	amod||modes-25/NNS||physiological-24/JJ	nsubjpass||associated-39/VBN||modes-25/NNS	prep_of||modes-25/NNS||action-27/NN	mark||indicated-30/VBD||as-29/IN	dep||action-27/NN||indicated-30/VBD	prep_by||indicated-30/VBD||effects-32/NNS	nn||allocation-37/NN||system-34/NN	nn||allocation-37/NN||level-35/NN	nn||allocation-37/NN||resource-36/NN	prep_on||indicated-30/VBD||allocation-37/NN	auxpass||associated-39/VBN||were-38/VBD	ccomp||identify-22/VB||associated-39/VBN	prep_with||associated-39/VBN||changes-41/NNS	nn||expression-44/NN||gene-43/NN	prep_in||changes-41/NNS||expression-44/NN	prep_following||expression-44/NN||exposure-46/NN	num||chemicals-50/NNS||three-48/CD	amod||chemicals-50/NNS||toxic-49/JJ	prep_to||exposure-46/NN||chemicals-50/NNS	nsubjpass||based-2/VBN||cadmium-51/NN	appos||cadmium-51/NN||fluoranthene-53/NN	appos||fluoranthene-53/NN||fa-55/NN	appos||cadmium-51/NN||atrazine-58/NN	conj_and||fluoranthene-53/NN||atrazine-58/NN	appos||atrazine-58/NN||az-60/NN	fa-55||cadmium-51||no_rel||physiologically based modelling using debtox (dynamic energy budget in toxicology) and transcriptional profiling were used in caenorhabditis elegans to identify how physiological modes of action, as indicated by effects on system level resource allocation were associated with changes in gene expression following exposure to three toxic chemicals cadmium, fluoranthene (fa) and atrazine (az).
root||ROOT-0/null||saturated-1/VBN	acomp||saturated-1/VBN||fat-2/JJ	nsubj||induce-21/VB||carbohydrates-4/NNS	appos||carbohydrates-4/NNS||components-6/NNS	det||meal-10/NN||the-8/DT	amod||meal-10/NN||hfhc-9/JJ	prep_of||components-6/NNS||meal-10/NN	vmod||meal-10/NN||known-12/VBN	aux||induce-14/VB||to-13/TO	xcomp||known-12/VBN||induce-14/VB	amod||stress-16/NN||oxidative-15/JJ	dobj||induce-14/VB||stress-16/NN	dobj||induce-14/VB||inflammation-18/NN	conj_and||stress-16/NN||inflammation-18/NN	advmod||induce-21/VB||also-20/RB	conj_and||saturated-1/VBN||induce-21/VB	det||increase-23/NN||an-22/DT	dobj||induce-21/VB||increase-23/NN	prep_in||induce-21/VB||lps-25/NN	prep_in||induce-21/VB||tlr-4-27/JJ	conj_and||lps-25/NN||tlr-4-27/JJ	prep_in||induce-21/VB||socs3-30/NNS	conj_and||lps-25/NN||socs3-30/NNS	carbohydrates-4||inflammation-18||no_rel||saturated fat and carbohydrates, components of the hfhc meal, known to induce oxidative stress and inflammation, also induce an increase in lps, tlr-4, and socs3.
advmod||explants-16/VBZ||accordingly-1/RB	det||avianinfluenzaviruses-5/NNS||both-3/DT	amod||avianinfluenzaviruses-5/NNS||h5n1-4/JJ	nsubj||explants-16/VBZ||avianinfluenzaviruses-5/NNS	amod||influenzaviruses-8/NNS||seasonal-7/JJ	conj_and||avianinfluenzaviruses-5/NNS||influenzaviruses-8/NNS	nsubj||explants-16/VBZ||influenzaviruses-8/NNS	vmod||influenzaviruses-8/NNS||replicated-9/VBN	advmod||efficiently-11/RB||more-10/RBR	advmod||replicated-9/VBN||efficiently-11/RB	amod||tissues-15/NNS||nasal-13/JJ	nn||tissues-15/NNS||polyp-14/NN	prep_in||replicated-9/VBN||tissues-15/NNS	root||ROOT-0/null||explants-16/VBZ	h5n1-4||influenzaviruses-8||no||accordingly, both h5n1 avianinfluenzaviruses and seasonal influenzaviruses replicated more efficiently in nasal polyp tissues explants.
aux||understand-2/VB||to-1/TO	ccomp||studied-30/VBD||understand-2/VB	det||mechanism-5/NN||the-3/DT	amod||mechanism-5/NN||molecular-4/JJ	dobj||understand-2/VB||mechanism-5/NN	nn||responses-8/NNS||host-7/NN	prep_of||mechanism-5/NN||responses-8/NNS	advmod||pathogenic-11/JJ||highly-10/RB	amod||avianinfluenzavirusinfection-12/NN||pathogenic-11/JJ	prep_to||understand-2/VB||avianinfluenzavirusinfection-12/NN	aux||get-15/VB||to-14/TO	conj_and||understand-2/VB||get-15/VB	ccomp||studied-30/VBD||get-15/VB	det||insight-17/NN||an-16/DT	dobj||get-15/VB||insight-17/NN	det||means-20/NN||the-19/DT	prep_into||get-15/VB||means-20/NN	prep_through||overcomes-24/VBZ||means-20/NN	nsubj||overcomes-24/VBZ||virus-23/NN	rcmod||means-20/NN||overcomes-24/VBZ	nn||mechanism-27/NN||host-25/NN	nn||mechanism-27/NN||defense-26/NN	dobj||overcomes-24/VBZ||mechanism-27/NN	nsubj||studied-30/VBD||we-29/PRP	nsubj||compared-60/VBD||we-29/PRP	root||ROOT-0/null||studied-30/VBD	amod||response-34/NN||global-31/JJ	nn||response-34/NN||gene-32/NN	nn||response-34/NN||expression-33/NN	nsubj||virus-58/NN||response-34/NN	amod||cells-39/NNS||human-36/JJ	nn||cells-39/NNS||lung-37/NN	nn||cells-39/NNS||carcinoma-38/NN	prep_of||response-34/NN||cells-39/NNS	appos||cells-39/NNS||a549-41/NNP	amod||stages-47/NNS||early-44/JJ	conj_and||early-44/JJ||late-46/JJ	amod||stages-47/NNS||late-46/JJ	prep_at||cells-39/NNS||stages-47/NNS	prep_of||cells-39/NNS||infection-49/NN	advmod||pathogenic-52/JJ||highly-51/RB	amod||avianinfluenza-53/NN||pathogenic-52/JJ	prep_with||infection-49/NN||avianinfluenza-53/NN	det||virus-58/NN||a-54/DT	nn||virus-58/NN||h5n1-56/NN	xcomp||studied-30/VBD||virus-58/NN	conj_and||studied-30/VBD||compared-60/VBD	dobj||compared-60/VBD||it-61/PRP	det||genetics-65/NNS||a-63/DT	amod||genetics-65/NNS||reverse-64/JJ	prep_with||compared-60/VBD||genetics-65/NNS	vmod||genetics-65/NNS||modified-66/VBN	xcomp||modified-66/VBN||recombinant-67/VBG	det||virus-73/NN||a-68/DT	appos||virus-73/NN||h5n1-70/NNP	nn||virus-73/NN||vaccine-72/NN	dobj||recombinant-67/VBG||virus-73/NN	vmod||virus-73/NN||using-74/VBG	amod||platform-76/NN||microarray-75/JJ	dobj||using-74/VBG||platform-76/NN	h5n1-70||avianinfluenzavirus--1||no||to understand the molecular mechanism of host responses to highly pathogenic avianinfluenzavirusinfection and to get an insight into the means through which virus overcomes host defense mechanism, we studied global gene expression response of human lung carcinoma cells (a549) at early and late stages of infection with highly pathogenic avianinfluenza a (h5n1) virus and compared it with a reverse genetics modified recombinant a (h5n1) vaccine virus using microarray platform.
advmod||seen-16/VBN||irondeficiency-1/RB	nsubjpass||seen-16/VBN||anemia-3/NN	amod||anemia-6/NN||irondeficiency-5/JJ	conj_and||anemia-3/NN||anemia-6/NN	nsubjpass||seen-16/VBN||anemia-6/NN	nn||depletion-9/NN||iron-8/NN	conj_and||anemia-3/NN||depletion-9/NN	nsubjpass||seen-16/VBN||depletion-9/NN	conj_and||anemia-3/NN||lack-11/NN	nsubjpass||seen-16/VBN||lack-11/NN	nn||resources-14/NNS||iron-13/NN	prep_of||lack-11/NN||resources-14/NNS	auxpass||seen-16/VBN||were-15/VBD	root||ROOT-0/null||seen-16/VBN	prep_in||seen-16/VBN||2.3-18/CD	prep_in||seen-16/VBN||4.08-20/CD	conj_and||2.3-18/CD||4.08-20/CD	prep_in||seen-16/VBN||2.14-22/CD	conj_and||2.3-18/CD||2.14-22/CD	prep_in||seen-16/VBN||22.76-24/NNP	conj_and||2.3-18/CD||22.76-24/NNP	amod||percent-27/NN||4.66-26/JJ	prep_in||seen-16/VBN||percent-27/NN	conj_and||2.3-18/CD||percent-27/NN	advmod||seen-16/VBN||respectively-28/RB	anemia-6||irondeficiency-5||yes||irondeficiency, anemia, irondeficiency anemia, iron depletion and lack of iron resources were seen in 2.3, 4.08, 2.14, 22.76 and 4.66 percent respectively.
nsubj||disorder-10/NN||coeliacdisease-1/NN	appos||coeliacdisease-1/NN||cd-3/NN	cop||disorder-10/NN||is-5/VBZ	det||disorder-10/NN||a-6/DT	amod||disorder-10/NN||common-7/JJ	conj_and||common-7/JJ||complex-9/JJ	amod||disorder-10/NN||complex-9/JJ	root||ROOT-0/null||disorder-10/NN	det||intestine-14/NN||the-12/DT	amod||intestine-14/NN||small-13/JJ	prep_of||disorder-10/NN||intestine-14/NN	dep||intestine-14/NN||caused-15/VBN	prep_by||caused-15/VBN||intolerance-17/NN	nn||gluten-20/NN||wheat-19/NN	prep_to||caused-15/VBN||gluten-20/NN	dep||intestine-14/NN||related-22/VBN	conj_and||caused-15/VBN||related-22/VBN	amod||cereals-24/NNS||edible-23/JJ	dobj||related-22/VBN||cereals-24/NNS	prep_like||related-22/VBN||barley-26/NN	prep_like||related-22/VBN||rye-28/NN	conj_and||barley-26/NN||rye-28/NN	coeliacdisease-1||gluten-20||no||coeliacdisease (cd) is a common and complex disorder of the small intestine caused by intolerance to wheat gluten and related edible cereals like barley and rye.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||effects-4/NNS||the-3/DT	iobj||evaluated-2/VBN||effects-4/NNS	det||therapy-8/NN||a-6/DT	amod||therapy-8/NN||combined-7/JJ	prep_of||effects-4/NNS||therapy-8/NN	amod||âµg-18/NN||budesonide-10/JJ	dep||budesonide-10/JJ||200-11/CD	nn||âµg-18/NN||âµg-12/NN	advmod||daily-14/RB||twice-13/RB	advmod||âµg-18/NN||daily-14/RB	conj_and||daily-14/RB||formoterol-16/JJ	advmod||âµg-18/NN||formoterol-16/JJ	dep||formoterol-16/JJ||6-17/CD	prep_of||therapy-8/NN||âµg-18/NN	advmod||daily-20/RB||twice-19/RB	dobj||evaluated-2/VBN||daily-20/RB	prepc_compared_with||evaluated-2/VBN||with-22/IN	amod||âµg-25/NN||budesonide-23/JJ	dep||budesonide-23/JJ||200-24/CD	pobj||evaluated-2/VBN||âµg-25/NN	advmod||âµg-25/NN||twice-26/RB	advmod||alone-28/RB||daily-27/RB	pobj||twice-26/RB||alone-28/RB	nn||questionnaire-32/NN||asthma-30/NN	nn||questionnaire-32/NN||control-31/NN	prep_on||twice-26/RB||questionnaire-32/NN	appos||questionnaire-32/NN||acq-34/NN	nn||quality-38/NN||asthma-37/NN	appos||questionnaire-32/NN||quality-38/NN	nn||questionnaire-41/NN||life-40/NN	prep_of||quality-38/NN||questionnaire-41/NN	appos||quality-38/NN||aqlq-43/NNP	dep||aqlq-43/NNP||juniper-45/NN	amod||function-49/NN||pulmonary-48/JJ	appos||questionnaire-32/NN||function-49/NN	conj_and||quality-38/NN||function-49/NN	amod||inflammation-52/NN||airway-51/JJ	appos||questionnaire-32/NN||inflammation-52/NN	conj_and||quality-38/NN||inflammation-52/NN	det||study-59/NN||a-55/DT	amod||study-59/NN||cross-over-56/JJ	amod||study-59/NN||randomized-57/JJ	amod||study-59/NN||double-blind-58/JJ	prep_in||evaluated-2/VBN||study-59/NN	nn||periods-62/NNS||treatment-61/NN	prep_with||study-59/NN||periods-62/NNS	num||months-65/NNS||two-64/CD	prep_of||periods-62/NNS||months-65/NNS	vmod||months-65/NNS||separated-66/VBN	det||period-71/NN||a-68/DT	amod||period-71/NN||one-month-69/JJ	amod||period-71/NN||wash-out-70/JJ	agent||separated-66/VBN||period-71/NN	asthma-37||formoterol-16||yes||we evaluated the effects of a combined therapy of budesonide 200 âµg twice daily and formoterol 6 âµg twice daily compared with budesonide 200 âµg twice daily alone on asthma control questionnaire (acq), asthma quality of life questionnaire (aqlq- juniper), pulmonary function and airway inflammation, in a cross-over randomized double-blind study with treatment periods of two months separated by a one-month wash-out period.
amod||studies-3/NNS||islet-1/JJ	amod||studies-3/NNS||morphometric-2/JJ	nsubj||demonstrated-4/VBD||studies-3/NNS	root||ROOT-0/null||demonstrated-4/VBD	amod||²-7/NNS||decreased-5/VBN	nn||²-7/NNS||î-6/NN	dobj||demonstrated-4/VBD||²-7/NNS	nn||mass-10/NN||cell-9/NN	dep||²-7/NNS||mass-10/NN	vmod||mass-10/NN||suggesting-11/VBG	mark||component-17/NN||that-12/IN	nsubj||component-17/NN||this-13/DT	cop||component-17/NN||was-14/VBD	det||component-17/NN||a-15/DT	amod||component-17/NN||major-16/JJ	ccomp||suggesting-11/VBG||component-17/NN	amod||component-17/NN||responsible-18/JJ	amod||secretion-22/NN||altered-20/JJ	nn||secretion-22/NN||insulin-21/NN	prep_for||responsible-18/JJ||secretion-22/NN	amod||component-17/NN||glucoseintolerance-24/JJ	conj_and||responsible-18/JJ||glucoseintolerance-24/JJ	amod||mice-28/NNS||cacn-26/JJ	nn||mice-28/NNS||rip-27/NN	prep_in||glucoseintolerance-24/JJ||mice-28/NNS	insulin-21||glucoseintolerance-24||no_rel||islet morphometric studies demonstrated decreased î²-cell mass suggesting that this was a major component responsible for altered insulin secretion and glucoseintolerance in cacn rip mice.
amod||strains-3/NNS||thirteen-1/JJ	nn||strains-3/NNS||poliovirus-2/NNS	nsubjpass||isolated-5/VBN||strains-3/NNS	auxpass||isolated-5/VBN||were-4/VBD	root||ROOT-0/null||isolated-5/VBN	num||children-8/NNS||11-7/CD	prep_from||isolated-5/VBN||children-8/NNS	number||humanimmunodeficiencyviruspositive-10/JJ||5-9/CD	amod||children-8/NNS||humanimmunodeficiencyviruspositive-10/JJ	num||humanimmunodeficiencyvirus-13/NNS||6-12/CD	npadvmod||negative-14/JJ||humanimmunodeficiencyvirus-13/NNS	amod||children-8/NNS||negative-14/JJ	conj_and||humanimmunodeficiencyviruspositive-10/JJ||negative-14/JJ	humanimmunodeficiencyviruspositive-10||humanimmunodeficiencyvirus-13||no||thirteen poliovirus strains were isolated from 11 children 5 humanimmunodeficiencyviruspositive and 6 humanimmunodeficiencyvirus negative.
nsubjpass||adopted-7/VBN||artemether/lumefantrine-1/NN	appos||artemether/lumefantrine-1/NN||al-3/NNP	aux||adopted-7/VBN||has-5/VBZ	auxpass||adopted-7/VBN||been-6/VBN	root||ROOT-0/null||adopted-7/VBN	det||treatment-10/NN||the-9/DT	prep_as||adopted-7/VBN||treatment-10/NN	prep_of||treatment-10/NN||choice-12/NN	amod||malaria-15/NN||uncomplicated-14/JJ	prep_for||adopted-7/VBN||malaria-15/NN	prep_in||malaria-15/NN||kenya-17/NN	amod||countries-20/NNS||other-19/JJ	prep_for||adopted-7/VBN||countries-20/NNS	conj_and||malaria-15/NN||countries-20/NNS	det||region-23/NN||the-22/DT	prep_in||countries-20/NNS||region-23/NN	malaria-15||artemether--1||yes||artemether/lumefantrine (al) has been adopted as the treatment of choice for uncomplicated malaria in kenya and other countries in the region.
nn||patients-4/NNS||uc-1/NN	conj_and||uc-1/NN||cd-3/NN	nn||patients-4/NNS||cd-3/NN	nsubj||had-5/VBD||patients-4/NNS	root||ROOT-0/null||had-5/VBD	advmod||higher-7/JJR||significantly-6/RB	amod||levels-10/NNS||higher-7/JJR	amod||levels-10/NNS||serum-8/JJ	amod||levels-10/NNS||timp-1-9/JJ	dobj||had-5/VBD||levels-10/NNS	advmod||compared-12/VBN||when-11/WRB	rcmod||levels-10/NNS||compared-12/VBN	prep_to||compared-12/VBN||hc-14/NN	dep||had-5/VBD||p-17/VB	number||0.0001-19/CD||<-18/CD	dobj||p-17/VB||0.0001-19/CD	det||groups-22/NNS||both-21/DT	prep_in||0.0001-19/CD||groups-22/NNS	uc-1||hc-14||yes||uc and cd patients had significantly higher serum timp-1 levels when compared to hc, (p < 0.0001 in both groups).
nsubj||disease-18/NN||newcastledisease-1/NN	appos||newcastledisease-1/NN||nd-3/NN	vmod||newcastledisease-1/NN||caused-6/VBN	amod||virus-9/NN||newcastledisease-8/JJ	agent||caused-6/VBN||virus-9/NN	appos||virus-9/NN||ndv-11/NN	cop||disease-18/NN||is-14/VBZ	det||disease-18/NN||a-15/DT	advmod||contagious-17/JJ||highly-16/RB	amod||disease-18/NN||contagious-17/JJ	root||ROOT-0/null||disease-18/NN	prep_of||disease-18/NN||birds-20/NNS	aux||one-24/CD||has-22/VBZ	cop||one-24/CD||been-23/VBN	conj_and||disease-18/NN||one-24/CD	det||causes-28/NNS||the-26/DT	amod||causes-28/NNS||major-27/JJ	prep_of||one-24/CD||causes-28/NNS	amod||losses-31/NNS||economic-30/JJ	prep_of||causes-28/NNS||losses-31/NNS	det||industry-35/NN||the-33/DT	nn||industry-35/NN||poultry-34/NN	prep_in||one-24/CD||industry-35/NN	newcastledisease-8||newcastlediseasevirus--1||no||newcastledisease (nd), caused by newcastledisease virus (ndv), is a highly contagious disease of birds and has been one of the major causes of economic losses in the poultry industry.
amod||hepatitisbvirus-4/NNS||occult-1/JJ	conj_or||occult-1/JJ||latent-3/JJ	amod||hepatitisbvirus-4/NNS||latent-3/JJ	nsubjpass||defined-10/VBN||hepatitisbvirus-4/NNS	appos||hepatitisbvirus-4/NNS||hbv-6/NN	advmod||defined-10/VBN||infection-8/RB	auxpass||defined-10/VBN||is-9/VBZ	root||ROOT-0/null||defined-10/VBN	prep_as||defined-10/VBN||infection-12/NN	amod||dna-16/NN||detectable-14/JJ	nn||dna-16/NN||hbv-15/NN	prep_with||defined-10/VBN||dna-16/NN	amod||antigen-20/NN||undetectable-18/JJ	nn||antigen-20/NN||surface-19/NN	prep_with||defined-10/VBN||antigen-20/NN	conj_and||dna-16/NN||antigen-20/NN	appos||dna-16/NN||hbsag-22/NN	poss||blood-27/NN||patients-25/NNS	prep_in||dna-16/NN||blood-27/NN	hbv-15||hepatitisbvirus-4||no||occult or latent hepatitisbvirus (hbv) infection is defined as infection with detectable hbv dna and undetectable surface antigen (hbsag) in patients' blood.
amod||sensitivity-3/NN||mtb/rif-1/JJ	nn||sensitivity-3/NN||test-2/NN	nsubj||·-6/NNS||sensitivity-3/NN	cop||·-6/NNS||was-4/VBD	amod||·-6/NNS||76â-5/JJ	root||ROOT-0/null||·-6/NNS	number||%-8/NN||9-7/CD	amod||·-6/NNS||%-8/NN	amod||patients-13/NNS||smear-negative-10/JJ	amod||patients-13/NNS||culture-positive-12/JJ	prep_in||·-6/NNS||patients-13/NNS	number||385-17/CD||296-15/CD	quantmod||385-17/CD||of-16/IN	num||samples-18/NNS||385-17/CD	appos||patients-13/NNS||samples-18/NNS	amod||·-23/NNS||99â-22/JJ	prep_in||·-6/NNS||·-23/NNS	conj_and||patients-13/NNS||·-23/NNS	num||%-25/NN||0-24/CD	npadvmod||specific-26/JJ||%-25/NN	amod||·-23/NNS||specific-26/JJ	dep||specific-26/JJ||2846-28/CD	num||samples-32/NNS||2876-30/CD	amod||samples-32/NNS||non-tuberculosis-31/JJ	prep_of||2846-28/CD||samples-32/NNS	tuberculosis--1||rif--1||yes||mtb/rif test sensitivity was 76â·9% in smear-negative, culture-positive patients (296 of 385 samples), and 99â·0% specific (2846 of 2876 non-tuberculosis samples).
det||analysis-3/NN||a-1/DT	nn||analysis-3/NN||cost-2/NN	nsubj||evaluated-4/VBN||analysis-3/NN	nsubj||dehydration-17/VBN||analysis-3/NN	root||ROOT-0/null||evaluated-4/VBN	amod||administration-7/NN||oral-5/JJ	nn||administration-7/NN||ondansetron-6/NN	dobj||evaluated-4/VBN||administration-7/NN	prep_to||evaluated-4/VBN||children-9/NNS	vmod||children-9/NNS||presenting-10/VBG	nn||departments-13/NNS||emergency-12/NN	prep_to||presenting-10/VBG||departments-13/NNS	prep_with||presenting-10/VBG||vomiting-15/VBG	conj_and||evaluated-4/VBN||dehydration-17/VBN	acomp||dehydration-17/VBN||secondary-18/JJ	prep_to||secondary-18/JJ||gastroenteritis-20/NNS	det||societal-23/JJ||a-22/DT	poss||perspective-29/NN||societal-23/JJ	nn||payer-27/NN||health-25/NN	nn||payer-27/NN||care-26/NN	conj_and||societal-23/JJ||payer-27/NN	poss||perspective-29/NN||payer-27/NN	prep_from||gastroenteritis-20/NNS||perspective-29/NN	preconj||us-33/PRP||both-31/PDT	det||us-33/PRP||the-32/DT	prep_in||dehydration-17/VBN||us-33/PRP	prep_in||dehydration-17/VBN||canada-35/NN	conj_and||us-33/PRP||canada-35/NN	vomiting-15||ondansetron-6||yes||a cost analysis evaluated oral ondansetron administration to children presenting to emergency departments with vomiting and dehydration secondary to gastroenteritis from a societal and health care payer's perspective in both the us and canada.
amod||m.tb-2/NN||rifampin-resistant-1/JJ	nsubjpass||found-37/VBN||m.tb-2/NN	dep||m.tb-2/NN||nâ-4/NN	num||â-8/NN||$-5/$	number||=-7/CD||-6/CD	num||$-5/$||=-7/CD	dep||nâ-4/NN||â-8/NN	dep||â-8/NN||$-9/$	num||$-9/$||41-10/CD	conj_and||m.tb-2/NN||tb-iris-13/NNS	nsubjpass||found-37/VBN||tb-iris-13/NNS	dep||tb-iris-13/NNS||nâ-15/NN	num||â-19/NN||$-16/$	number||=-18/CD||-17/CD	num||$-16/$||=-18/CD	dep||nâ-15/NN||â-19/NN	dep||â-19/NN||$-20/$	num||$-20/$||51-21/CD	npadvmod||resistant-25/JJ||drug-24/NN	amod||bacterialinfections-26/NNS||resistant-25/JJ	conj_and||m.tb-2/NN||bacterialinfections-26/NNS	nsubjpass||found-37/VBN||bacterialinfections-26/NNS	dep||m.tb-2/NN||nâ-28/NN	num||â-32/NN||$-29/$	number||=-31/CD||-30/CD	num||$-29/$||=-31/CD	dep||nâ-28/NN||â-32/NN	dep||â-32/NN||$-33/$	num||$-33/$||12-34/CD	auxpass||found-37/VBN||were-36/VBD	root||ROOT-0/null||found-37/VBN	num||%-40/NN||12-39/CD	prep_in||found-37/VBN||%-40/NN	num||%-43/NN||14-42/CD	prep_in||found-37/VBN||%-43/NN	conj_and||%-40/NN||%-43/NN	num||%-46/NN||3.4-45/CD	prep_in||found-37/VBN||%-46/NN	conj_and||%-40/NN||%-46/NN	det||cases-50/NNS||the-48/DT	amod||cases-50/NNS||352-49/JJ	prep_of||%-46/NN||cases-50/NNS	advmod||found-37/VBN||respectively-52/RB	tb--1||rifampin--1||yes||rifampin-resistant m.tb (nâ=â41), tb-iris (nâ=â51) and drug resistant bacterialinfections (nâ=â12) were found in 12%, 14% and 3.4% of the 352 cases, respectively.
amod||subjects-3/NNS||male-2/JJ	prep_in||persisted-32/VBD||subjects-3/NNS	det||associations-6/NNS||the-5/DT	nsubj||persisted-32/VBD||associations-6/NNS	prep_of||associations-6/NNS||retinopathy-8/NN	prep_with||retinopathy-8/NN||g-10/NN	prep_with||speed-24/NN||tests-14/NNS	amod||fluency-17/NN||verbal-16/JJ	prep_of||tests-14/NNS||fluency-17/NN	amod||flexibility-20/NN||mental-19/JJ	prep_of||tests-14/NNS||flexibility-20/NN	conj_and||fluency-17/NN||flexibility-20/NN	prep_of||tests-14/NNS||processing-23/NN	conj_and||fluency-17/NN||processing-23/NN	dep||associations-6/NNS||speed-24/NN	nn||reasoning-30/NN||memory-27/NN	conj_and||memory-27/NN||nonverbal-29/NN	nn||reasoning-30/NN||nonverbal-29/NN	dep||associations-6/NNS||reasoning-30/NN	conj_negcc||speed-24/NN||reasoning-30/NN	root||ROOT-0/null||persisted-32/VBD	dep||<-35/JJ||p-34/RB	dep||persisted-32/VBD||<-35/JJ	dep||<-35/JJ||0.05-36/CD	advmod||adjusted-40/VBN||when-38/WRB	advmod||adjusted-40/VBN||further-39/RB	advcl||persisted-32/VBD||adjusted-40/VBN	prep_for||adjusted-40/VBN||vocabulary-42/NN	nn||cognitivedecline-47/NN||estimate-45/NN	nn||cognitivedecline-47/NN||lifetime-46/NN	prep_to||vocabulary-42/NN||cognitivedecline-47/NN	prep_for||adjusted-40/VBN||depression-50/NN	conj_and||vocabulary-42/NN||depression-50/NN	amod||characteristics-53/NNS||sociodemographic-52/JJ	prep_for||adjusted-40/VBN||characteristics-53/NNS	conj_and||vocabulary-42/NN||characteristics-53/NNS	amod||factors-57/NNS||cardiovascular-55/JJ	nn||factors-57/NNS||risk-56/NN	prep_for||adjusted-40/VBN||factors-57/NNS	conj_and||vocabulary-42/NN||factors-57/NNS	prep_for||adjusted-40/VBN||macrovasculardisease-60/NN	conj_and||vocabulary-42/NN||macrovasculardisease-60/NN	cognitivedecline-47||speed-24||no_rel||in male subjects, the associations of retinopathy with g (and with tests of verbal fluency, mental flexibility, and processing speed but not memory and nonverbal reasoning) persisted ( p < 0.05) when further adjusted for vocabulary (to estimate lifetime cognitivedecline), depression, sociodemographic characteristics, cardiovascular risk factors, and macrovasculardisease.
nsubj||effective-18/JJ||methotrexate-1/NN	nsubj||brings-20/VBZ||methotrexate-1/NN	appos||methotrexate-1/NN||mtx-3/NN	det||treatment-8/NN||the-6/DT	amod||treatment-8/NN||primary-7/JJ	appos||methotrexate-1/NN||treatment-8/NN	det||juvenileidiopathicarthritis-12/NNS||the-10/DT	amod||juvenileidiopathicarthritis-12/NNS||articular-type-11/JJ	prep_for||treatment-8/NN||juvenileidiopathicarthritis-12/NNS	appos||juvenileidiopathicarthritis-12/NNS||jia-14/NN	cop||effective-18/JJ||is-17/VBZ	root||ROOT-0/null||effective-18/JJ	conj_and||effective-18/JJ||brings-20/VBZ	amod||improvement-23/NN||radiological-22/JJ	prep_about||brings-20/VBZ||improvement-23/NN	jia-14||mtx-3||yes||methotrexate (mtx), the primary treatment for the articular-type juvenileidiopathicarthritis (jia), is effective and brings about radiological improvement.
nn||control-2/NN||quality-1/NN	nsubj||become-7/VBP||control-2/NN	amod||measures-6/NNS||strict-4/JJ	amod||measures-6/NNS||cross-contamination-5/JJ	conj_and||control-2/NN||measures-6/NNS	nsubj||become-7/VBP||measures-6/NNS	root||ROOT-0/null||become-7/VBP	advmod||critical-9/JJ||increasingly-8/RB	acomp||become-7/VBP||critical-9/JJ	det||burden-12/NN||the-11/DT	prep_as||critical-9/JJ||burden-12/NN	nn||infection-15/NN||mtb-14/NN	prep_of||burden-12/NN||infection-15/NN	nn||increases-19/NNS||tb-17/NN	nn||increases-19/NNS||suspects-18/NNS	prep_among||become-7/VBP||increases-19/NNS	tb-17||mtb-14||no||quality control and strict cross-contamination measures become increasingly critical as the burden of mtb infection among tb suspects increases.
det||number-2/NN||the-1/DT	nsubj||similar-26/JJ||number-2/NN	prep_of||number-2/NN||patients-4/NNS	vmod||patients-4/NNS||experiencing-5/VBG	nn||vomiting-7/NN||breakthrough-6/NN	dobj||experiencing-5/VBG||vomiting-7/NN	amod||$-10/$||0â-9/JJ	prep_at||experiencing-5/VBG||$-10/$	num||$-10/$||30-12/CD	amod||$-15/$||31â-14/JJ	prep_at||experiencing-5/VBG||$-15/$	conj_and||$-10/$||$-15/$	num||$-15/$||60-17/CD	prep_at||experiencing-5/VBG||61â-20/NNS	conj_and||$-10/$||61â-20/NNS	num||minutes-24/NNS||$-21/$	num||$-21/$||120-23/CD	dep||61â-20/NNS||minutes-24/NNS	cop||similar-26/JJ||was-25/VBD	root||ROOT-0/null||similar-26/JJ	prep_between||similar-26/JJ||groups-28/NNS	det||periods-32/NNS||these-30/DT	nn||periods-32/NNS||time-31/NN	prep_for||groups-28/NNS||periods-32/NNS	advmod||experienced-40/VBD||however-34/RB	amod||patients-37/NNS||more-36/JJR	nsubj||experienced-40/VBD||patients-37/NNS	vmod||patients-37/NNS||receiving-38/VBG	dobj||receiving-38/VBG||ondansetron-39/NN	parataxis||similar-26/JJ||experienced-40/VBD	nn||-lrb--43/NN||vomiting-41/NN	amod||-lrb--43/NN||overall-42/JJ	dobj||experienced-40/VBD||-lrb--43/NN	number||-lsb--45/NN||7-44/CD	amod||-lrb--43/NN||-lsb--45/NN	number||-rsb--48/NN||22-46/CD	dep||-rsb--48/NN||%-47/NN	amod||-lrb--43/NN||-rsb--48/NN	prep||experienced-40/VBD||vs.-49/CC	number||-lsb--51/NN||2-50/CD	amod||patients-55/NNS||-lsb--51/NN	num||%-53/NN||3.2-52/CD	dep||-lsb--51/NN||%-53/NN	amod||patients-55/NNS||-rsb--54/JJ	pobj||vs.-49/CC||patients-55/NNS	vmod||patients-55/NNS||p-57/VBN	dep||-rrb--61/NN||=-58/SYM	neg||-rrb--61/NN||not-59/RB	amod||-rrb--61/NN||significant-60/JJ	ccomp||p-57/VBN||-rrb--61/NN	vomiting-41||ondansetron-39||yes||the number of patients experiencing breakthrough vomiting at 0â $ `` 30 , 31â $ `` 60 , and 61â $ `` 120 minutes was similar between groups for these time periods ; however , more patients receiving ondansetron experienced vomiting overall -lrb- 7 -lsb- 22 % -rsb- vs. 2 -lsb- 3.2 % -rsb- patients , p = not significant -rrb- .
mark||understand-5/VB||in-1/IN	dep||understand-5/VB||order-2/NN	aux||understand-5/VB||to-3/TO	advmod||understand-5/VB||well-4/RB	advcl||conducted-15/VBN||understand-5/VB	det||knowledge-8/NN||the-6/DT	amod||knowledge-8/NN||hiv/aids-7/JJ	dobj||understand-5/VB||knowledge-8/NN	prep_among||knowledge-8/NN||detainees-10/NNS	det||survey-13/NN||a-12/DT	nsubjpass||conducted-15/VBN||survey-13/NN	auxpass||conducted-15/VBN||was-14/VBD	root||ROOT-0/null||conducted-15/VBN	amod||settings-19/NNS||different-17/JJ	nn||settings-19/NNS||detention-18/NN	prep_in||conducted-15/VBN||settings-19/NNS	nn||province-22/NN||hunan-21/NN	prep_in||settings-19/NNS||province-22/NN	prep_in||province-22/NN||2008-24/CD	aux||assess-26/VB||to-25/TO	ccomp||conducted-15/VBN||assess-26/VB	dobj||assess-26/VB||knowledge-27/NN	dobj||assess-26/VB||attitudes-29/NNS	conj_and||knowledge-27/NN||attitudes-29/NNS	prep_about||assess-26/VB||hiv-31/NN	prep_among||hiv-31/NN||detainees-33/NNS	aux||provide-36/VB||to-35/TO	ccomp||conducted-15/VBN||provide-36/VB	conj_and||assess-26/VB||provide-36/VB	amod||information-38/NN||useful-37/JJ	dobj||provide-36/VB||information-38/NN	nn||prevention-41/NN||hiv-40/NN	prep_for||information-38/NN||prevention-41/NN	nn||strategies-44/NNS||intervention-43/NN	prep_for||information-38/NN||strategies-44/NNS	conj_and||prevention-41/NN||strategies-44/NNS	nn||centers-47/NNS||detention-46/NN	prep_in||provide-36/VB||centers-47/NNS	aids--1||hiv-40||no||in order to well understand the hiv/aids knowledge among detainees, a survey was conducted in different detention settings in hunan province in 2008 to assess knowledge and attitudes about hiv among detainees and to provide useful information for hiv prevention and intervention strategies in detention centers.
amod||spirochetes-2/NNS||lymedisease-1/JJ	nsubj||similar-5/JJ||spirochetes-2/NNS	cop||similar-5/JJ||are-3/VBP	advmod||similar-5/JJ||also-4/RB	root||ROOT-0/null||similar-5/JJ	prep_to||similar-5/JJ||borrelia-7/NN	cop||bacteria-13/NNS||being-9/VBG	amod||bacteria-13/NNS||microaerophilic-10/JJ	amod||bacteria-13/NNS||catalase-negative-12/JJ	prepc_in||borrelia-7/NN||bacteria-13/NNS	lymedisease-1||borrelia-7||no||lymedisease spirochetes are also similar to borrelia in being microaerophilic, catalase-negative bacteria.
det||prevalence-3/NN||the-1/DT	amod||prevalence-3/NN||high-2/JJ	nsubj||indicates-17/VBZ||prevalence-3/NN	amod||deficits-6/NNS||nutritional-5/JJ	prep_of||prevalence-3/NN||deficits-6/NNS	prep_among||deficits-6/NNS||infants-8/NNS	nn||suggestive-11/NN||symptoms-10/NNS	prep_with||infants-8/NNS||suggestive-11/NN	poss||allergy-16/NN||cow-13/NN	nn||allergy-16/NN||milk-15/NN	prep_of||suggestive-11/NN||allergy-16/NN	root||ROOT-0/null||indicates-17/VBZ	mark||prescribed-24/VBN||that-18/IN	amod||diets-21/NNS||effective-19/JJ	nn||diets-21/NNS||elimination-20/NN	nsubjpass||prescribed-24/VBN||diets-21/NNS	aux||prescribed-24/VBN||should-22/MD	auxpass||prescribed-24/VBN||be-23/VB	ccomp||indicates-17/VBZ||prescribed-24/VBN	aux||control-26/VB||to-25/TO	ccomp||prescribed-24/VBN||control-26/VB	nn||symptoms-28/NNS||allergy-27/NN	dobj||control-26/VB||symptoms-28/NNS	aux||prevent-31/VB||to-30/TO	ccomp||prescribed-24/VBN||prevent-31/VB	conj_and||control-26/VB||prevent-31/VB	conj_and||control-26/VB||treat-33/VB	conj_or||prevent-31/VB||treat-33/VB	dobj||prevent-31/VB||malnutrition-34/NN	allergy-27||allergy-27||no||the high prevalence of nutritional deficits among infants with symptoms suggestive of cow's milk allergy indicates that effective elimination diets should be prescribed to control allergy symptoms and to prevent or treat malnutrition.
amod||expression-3/NN||increased-1/VBN	amod||expression-3/NN||cd23-2/JJ	nsubjpass||found-5/VBN||expression-3/NN	auxpass||found-5/VBN||is-4/VBZ	root||ROOT-0/null||found-5/VBN	prep_in||found-5/VBN||patients-7/NNS	prep_during||found-5/VBN||allergicreactions-9/NNS	prep_during||found-5/VBN||rheumatoidarthritis-11/NNS	conj_and||allergicreactions-9/NNS||rheumatoidarthritis-11/NNS	mark||remains-19/VBZ||while-12/IN	poss||role-15/NN||its-13/PRP$	amod||role-15/NN||physiopathologic-14/JJ	nsubj||remains-19/VBZ||role-15/NN	nsubjpass||clarified-22/VBN||role-15/NN	det||diseases-18/NNS||these-17/DT	prep_in||role-15/NN||diseases-18/NNS	advcl||found-5/VBN||remains-19/VBZ	aux||clarified-22/VBN||to-20/TO	auxpass||clarified-22/VBN||be-21/VB	xcomp||remains-19/VBZ||clarified-22/VBN	rheumatoidarthritis-11||allergicreactions-9||no||increased cd23 expression is found in patients during allergicreactions and rheumatoidarthritis while its physiopathologic role in these diseases remains to be clarified.
nsubj||growing-25/VBG||evidence-1/NN	det||utility-4/NN||the-3/DT	prep_for||evidence-1/NN||utility-4/NN	det||mycobacteriumtuberculosis-8/NNS||the-6/DT	amod||mycobacteriumtuberculosis-8/NNS||new-7/JJ	prep_of||utility-4/NN||mycobacteriumtuberculosis-8/NNS	dep||mycobacteriumtuberculosis-8/NNS||mtb-10/VBN	amod||assays-16/NNS||specific-12/JJ	amod||assays-16/NNS||ifn-î-13/JJ	amod||assays-16/NNS||³-14/JJ	nn||assays-16/NNS||release-15/NN	dep||mycobacteriumtuberculosis-8/NNS||assays-16/NNS	prepc_in||assays-16/NNS||diagnosing-18/VBG	nn||tuberculosisinfection-20/NN||latent-19/NN	dobj||diagnosing-18/VBG||tuberculosisinfection-20/NN	appos||tuberculosisinfection-20/NN||ltbi-22/NNP	cop||growing-25/VBG||is-24/VBZ	root||ROOT-0/null||growing-25/VBG	tuberculosisinfection-20||mycobacteriumtuberculosis-8||no||evidence for the utility of the new mycobacteriumtuberculosis (mtb) specific ifn-î³ release assays in diagnosing latent tuberculosisinfection (ltbi) is growing.
nn||sizes-2/NNS||effect-1/NN	nsubjpass||analyzed-29/VBN||sizes-2/NNS	nn||thresholds-5/NNS||pain-4/NN	prep_on||sizes-2/NNS||thresholds-5/NNS	prep_to||thresholds-5/NNS||stimuli-7/NNS	vmod||stimuli-7/NNS||consisting-8/VBG	prep_of||consisting-8/VBG||heat-10/NN	amod||pressure-15/NN||cold-12/JJ	amod||pressure-15/NN||blunt-14/JJ	prep_of||consisting-8/VBG||pressure-15/NN	conj_and||heat-10/NN||pressure-15/NN	amod||pressure-18/NN||punctuate-17/JJ	prep_of||consisting-8/VBG||pressure-18/NN	conj_and||heat-10/NN||pressure-18/NN	amod||current-21/NN||electrical-20/JJ	prep_of||consisting-8/VBG||current-21/NN	conj_and||heat-10/NN||current-21/NN	vmod||sizes-2/NNS||administered-23/VBN	num||subjects-26/NNS||125-25/CD	prep_to||administered-23/VBN||subjects-26/NNS	auxpass||analyzed-29/VBN||were-28/VBD	root||ROOT-0/null||analyzed-29/VBN	num||variants-33/NNS||29-31/CD	amod||variants-33/NNS||common-32/JJ	nsubj||modulating-39/VBG||variants-33/NNS	num||genes-37/NNS||eight-35/CD	amod||genes-37/NNS||human-36/JJ	prep_in||variants-33/NNS||genes-37/NNS	advmod||modulating-39/VBG||reportedly-38/RB	prepc_for||analyzed-29/VBN||modulating-39/VBG	nn||procedures-45/NNS||pain-40/NN	conj_and||pain-40/NN||gender-42/NN	nn||procedures-45/NNS||gender-42/NN	conj_and||pain-40/NN||sensitization-44/NN	nn||procedures-45/NNS||sensitization-44/NN	dobj||modulating-39/VBG||procedures-45/NNS	vmod||modulating-39/VBG||using-46/VBG	dobj||using-46/VBG||capsaicin-47/NN	dobj||using-46/VBG||menthol-49/NN	conj_or||capsaicin-47/NN||menthol-49/NN	pain-40||capsaicin-47||yes||effect sizes on pain thresholds to stimuli consisting of heat, cold, blunt pressure, punctuate pressure and electrical current, administered to 125 subjects, were analyzed for 29 common variants in eight human genes reportedly modulating pain, gender and sensitization procedures using capsaicin or menthol.
nsubj||was-5/VBD||hepatitisbvirus-1/NNS	appos||hepatitisbvirus-1/NNS||hbv-3/NN	root||ROOT-0/null||was-5/VBD	det||virus-9/NN||the-7/DT	amod||virus-9/NN||first-8/JJ	prep_among||was-5/VBD||virus-9/NN	vmod||virus-9/NN||known-10/VBN	aux||transmitted-13/VBN||to-11/TO	auxpass||transmitted-13/VBN||be-12/VB	xcomp||known-10/VBN||transmitted-13/VBN	nn||productions-18/NNS||blood-15/NN	conj_and||blood-15/NN||blood-17/NN	nn||productions-18/NNS||blood-17/NN	agent||transmitted-13/VBN||productions-18/NNS	hbv-3||hepatitisbvirus-1||no||hepatitisbvirus (hbv) was among the first virus known to be transmitted by blood and blood productions.
nsubjpass||treated-4/VBN||diarrhea-1/NN	aux||treated-4/VBN||can-2/MD	auxpass||treated-4/VBN||be-3/VB	root||ROOT-0/null||treated-4/VBN	prep_with||treated-4/VBN||loperamide-6/NN	prep_with||treated-4/VBN||diphenoxylate-8/NN	conj_or||loperamide-6/NN||diphenoxylate-8/NN	diarrhea-1||diphenoxylate-8||yes||diarrhea can be treated with loperamide or diphenoxylate.
det||review-3/NN||this-2/DT	prep_in||summarise-6/VBP||review-3/NN	nsubj||summarise-6/VBP||we-5/PRP	root||ROOT-0/null||summarise-6/VBP	cc||critically-8/RB||and-7/CC	dep||summarise-6/VBP||critically-8/RB	ccomp||critically-8/RB||evaluate-9/VB	det||data-12/NNS||the-10/DT	amod||data-12/NNS||existing-11/VBG	dobj||evaluate-9/VB||data-12/NNS	det||link-16/NN||the-14/DT	amod||link-16/NN||possible-15/JJ	prep_on||data-12/NNS||link-16/NN	prep_between||link-16/NN||vitamind-18/NN	prep_between||link-16/NN||multiplesclerosis-20/NNS	conj_and||vitamind-18/NN||multiplesclerosis-20/NNS	prep_in||data-12/NNS||light-22/NN	det||question-26/NN||the-24/DT	amod||question-26/NN||crucial-25/JJ	prep_of||light-22/NN||question-26/NN	mark||impact-33/VB||whether-27/IN	nsubj||impact-33/VB||optimization-28/NN	amod||status-31/NN||vitamind-30/JJ	prep_of||optimization-28/NN||status-31/NN	aux||impact-33/VB||may-32/MD	ccomp||summarise-6/VBP||impact-33/VB	det||risk-35/NN||the-34/DT	dobj||impact-33/VB||risk-35/NN	vmod||risk-35/NN||and/or-36/VBG	det||course-38/NN||the-37/DT	dobj||and/or-36/VBG||course-38/NN	prep_of||course-38/NN||multiplesclerosis-40/NNS	vitamind-30||multiplesclerosis-40||no_rel||in this review, we summarise and critically evaluate the existing data on the possible link between vitamind and multiplesclerosis in light of the crucial question whether optimization of vitamind status may impact the risk and/or the course of multiplesclerosis.
prep_during||spread-10/VBD||spring-2/NN	prep_of||spring-2/NN||2009-4/CD	det||ah1n1-9/NNS||a-6/DT	amod||ah1n1-9/NNS||new-7/JJ	nn||ah1n1-9/NNS||influenzavirus-8/NNS	nsubj||spread-10/VBD||ah1n1-9/NNS	root||ROOT-0/null||spread-10/VBD	det||world-13/NN||the-12/DT	prep_in||spread-10/VBD||world-13/NN	vmod||world-13/NN||causing-14/VBG	amod||respiratory-16/JJ||acute-15/JJ	amod||illness-17/NN||respiratory-16/JJ	dobj||causing-14/VBG||illness-17/NN	dobj||causing-14/VBG||death-19/NN	conj_and||illness-17/NN||death-19/NN	xcomp||spread-10/VBD||resulting-21/VBG	det||pandemic-26/NN||the-23/DT	amod||pandemic-26/NN||first-24/JJ	nn||pandemic-26/NN||influenza-25/NN	prep_in||resulting-21/VBG||pandemic-26/NN	prep_since||pandemic-26/NN||1968-28/CD	influenza-25||influenzavirus-8||no||during spring of 2009, a new influenzavirus ah1n1 spread in the world causing acute respiratory illness and death, resulting in the first influenza pandemic since 1968.
nsubj||described-3/VBD||we-1/PRP	advmod||described-3/VBD||previously-2/RB	root||ROOT-0/null||described-3/VBD	det||pseudoknot-7/NN||an-4/DT	amod||pseudoknot-7/NN||unusual-5/JJ	amod||pseudoknot-7/NN||three-stemmed-6/JJ	dobj||described-3/VBD||pseudoknot-7/NN	nsubj||stimulated-19/VBN||pseudoknot-7/NN	det||coronavirus-14/NNS||the-9/DT	amod||coronavirus-14/NNS||severeacuterespiratorysyndrome-10/JJ	appos||coronavirus-14/NNS||sars-12/NNS	prep_from||pseudoknot-7/NN||coronavirus-14/NNS	appos||pseudoknot-7/NN||cov-16/NN	rcmod||pseudoknot-7/NN||stimulated-19/VBN	num||prf-21/NN||-1-20/CD	dobj||stimulated-19/VBN||prf-21/NN	severeacuterespiratorysyndrome-10||coronavirus-14||no||we previously described an unusual three-stemmed pseudoknot from the severeacuterespiratorysyndrome (sars) coronavirus (cov) that stimulated -1 prf.
nsubj||$-2/VBD||objectiveâ-1/NNP	nsubj||examine-5/VB||objectiveâ-1/NNP	root||ROOT-0/null||$-2/VBD	aux||examine-5/VB||to-4/TO	xcomp||$-2/VBD||examine-5/VB	dobj||examine-5/VB||associations-6/NNS	amod||adiposity-9/NN||neonatal-8/JJ	prep_of||associations-6/NNS||adiposity-9/NN	amod||levels-13/NNS||maternal-11/JJ	nn||levels-13/NNS||glucose-12/NN	prep_with||examine-5/VB||levels-13/NNS	nn||c-peptide-17/NN||cord-15/NN	nn||c-peptide-17/NN||serum-16/NN	prep_with||examine-5/VB||c-peptide-17/NN	conj_and||levels-13/NNS||c-peptide-17/NN	det||study-22/NN||a-19/DT	amod||study-22/NN||multicenter-20/JJ	amod||study-22/NN||multinational-21/JJ	prep_in||examine-5/VB||study-22/NN	det||study-33/NN||the-24/DT	amod||study-33/NN||hyperglycemia-25/NN	conj_and||hyperglycemia-25/NN||adverse-27/JJ	amod||study-33/NN||adverse-27/JJ	nn||study-33/NN||pregnancy-28/NN	nn||study-33/NN||outcome-29/NN	discourse||study-33/NN||hapo-31/UH	appos||study-22/NN||study-33/NN	advmod||assessing-36/VBG||thereby-35/RB	xcomp||$-2/VBD||assessing-36/VBG	det||hypothesis-39/NNS||the-37/DT	nn||hypothesis-39/NNS||pederson-38/NN	dobj||assessing-36/VBG||hypothesis-39/NNS	vmod||assessing-36/VBG||linking-40/VBG	amod||glycemia-42/NN||maternal-41/JJ	dobj||linking-40/VBG||glycemia-42/NN	nsubj||neonatal-47/VB||glycemia-42/NN	amod||hyperinsulinemia-45/NN||fetal-44/JJ	dobj||linking-40/VBG||hyperinsulinemia-45/NN	conj_and||glycemia-42/NN||hyperinsulinemia-45/NN	nsubj||neonatal-47/VB||hyperinsulinemia-45/NN	aux||neonatal-47/VB||to-46/TO	xcomp||linking-40/VBG||neonatal-47/VB	advmod||neonatal-47/VB||adiposity-48/RB	hyperglycemia-25||glucose-12||no||objectiveâ to examine associations of neonatal adiposity with maternal glucose levels and cord serum c-peptide in a multicenter multinational study, the hyperglycemia and adverse pregnancy outcome (hapo) study, thereby assessing the pederson hypothesis linking maternal glycemia and fetal hyperinsulinemia to neonatal adiposity.
det||prevalence-2/NN||the-1/DT	nsubj||%-10/NN||prevalence-2/NN	prep_of||prevalence-2/NN||tb-4/NN	amod||population-7/NN||hiv/aids-6/JJ	prep_among||tb-4/NN||population-7/NN	cop||%-10/NN||was-8/VBD	number||%-10/NN||7.2-9/CD	root||ROOT-0/null||%-10/NN	num||%-13/NN||4.2-12/CD	npadvmod||â-14/RB||%-13/NN	dep||%-18/NN||â-14/RB	dep||%-18/NN||$-15/$	num||$-15/$||12.3-17/CD	dep||%-10/NN||%-18/NN	nsubj||higher-25/JJR||this-22/DT	cop||higher-25/JJR||was-23/VBD	advmod||higher-25/JJR||much-24/RB	conj_but||%-10/NN||higher-25/JJR	advmod||restricted-30/VBN||when-26/WRB	det||analyses-28/NNS||the-27/DT	nsubjpass||restricted-30/VBN||analyses-28/NNS	auxpass||restricted-30/VBN||were-29/VBD	ccomp||higher-25/JJR||restricted-30/VBN	nn||patients-33/NNS||aids-32/NNS	prep_to||restricted-30/VBN||patients-33/NNS	num||%-36/NN||22.8-35/CD	appos||patients-33/NNS||%-36/NN	aids-32||hiv--1||no||the prevalence of tb among hiv/aids population was 7.2% (4.2%â12.3%), but this was much higher when the analyses were restricted to aids patients (22.8%).
nsubj||autoimmunedisease-4/NN||type1diabetesmellitus-1/NNS	cop||autoimmunedisease-4/NN||is-2/VBZ	det||autoimmunedisease-4/NN||an-3/DT	root||ROOT-0/null||autoimmunedisease-4/NN	dep||autoimmunedisease-4/NN||caused-5/VBN	prep_by||caused-5/VBN||destruction-7/NN	amod||cells-11/NNS||pancreatic-9/JJ	nn||cells-11/NNS||beta-10/NN	prep_of||destruction-7/NN||cells-11/NNS	dep||autoimmunedisease-4/NN||characterized-13/VBN	conj_and||caused-5/VBN||characterized-13/VBN	prep_by||characterized-13/VBN||defect-15/NN	nn||secretion-18/NN||insulin-17/NN	prep_in||defect-15/NN||secretion-18/NN	mark||and/or-27/VBZ||while-19/IN	amod||results-21/NNS||type2diabetesmellitus-20/JJ	nsubj||and/or-27/VBZ||results-21/NNS	prep_from||results-21/NNS||abnormalities-23/NNS	nn||secretion-26/NN||insulin-25/NN	prep_in||abnormalities-23/NNS||secretion-26/NN	advcl||characterized-13/VBN||and/or-27/VBZ	nn||action-29/NN||insulin-28/NN	dobj||and/or-27/VBZ||action-29/NN	dobj||and/or-27/VBZ||both-31/DT	conj_or||action-29/NN||both-31/DT	type2diabetesmellitus-20||insulin-28||yes||type1diabetesmellitus is an autoimmunedisease caused by destruction of pancreatic beta cells and characterized by defect in insulin secretion while type2diabetesmellitus results from abnormalities in insulin secretion and/or insulin action or both.
nsubjpass||identified-3/VBN||irs-1/NN	nsubjpass||hospitalization-20/VBN||irs-1/NN	auxpass||identified-3/VBN||were-2/VBD	root||ROOT-0/null||identified-3/VBN	prepc_based_on||identified-3/VBN||on-5/IN	det||occurrence-7/NN||the-6/DT	pobj||identified-3/VBN||occurrence-7/NN	nn||treatment-10/NN||outpatient-9/NN	prep_of||occurrence-7/NN||treatment-10/NN	nn||room-13/NN||emergency-12/NN	appos||treatment-10/NN||room-13/NN	appos||treatment-10/NN||er-15/NN	dep||treatment-10/NN||visit-17/NN	conj_and/or||identified-3/VBN||hospitalization-20/VBN	prep_for||hospitalization-20/VBN||hypersensitivity-22/NN	prep_for||hospitalization-20/VBN||allergicreactions-24/NNS	conj_and||hypersensitivity-22/NN||allergicreactions-24/NNS	hypersensitivity-22||allergicreactions-24||no||irs were identified based on the occurrence of outpatient treatment, emergency room (er) visit, and/or hospitalization for hypersensitivity and allergicreactions.
amod||time-4/NN||sensory-1/JJ	nn||time-4/NN||block-2/NN	nn||time-4/NN||onset-3/NN	nsubjpass||defined-13/VBN||time-4/NN	nsubj||fentanyl-21/VB||time-4/NN	nsubjpass||recorded-35/VBN||time-4/NN	amod||time-9/NN||tourniquet-6/JJ	nn||time-9/NN||pain-7/NN	nn||time-9/NN||onset-8/NN	appos||time-4/NN||time-9/NN	auxpass||defined-13/VBN||was-12/VBD	rcmod||time-4/NN||defined-13/VBN	det||time-16/NN||the-15/DT	prep_as||defined-13/VBN||time-16/NN	amod||application-19/NN||tourniquet-18/JJ	prep_from||time-16/NN||application-19/NN	aux||fentanyl-21/VB||to-20/TO	xcomp||defined-13/VBN||fentanyl-21/VB	dobj||fentanyl-21/VB||administration-22/NN	prepc_for||fentanyl-21/VB||relieving-24/VBG	nn||pain-26/NN||tourniquet-25/NN	dobj||relieving-24/VBG||pain-26/NN	dobj||relieving-24/VBG||amount-28/NN	conj_and||pain-26/NN||amount-28/NN	amod||consumption-31/NN||analgesic-30/JJ	prep_of||pain-26/NN||consumption-31/NN	prep_during||relieving-24/VBG||surgery-33/NN	auxpass||recorded-35/VBN||were-34/VBD	root||ROOT-0/null||recorded-35/VBN	pain-26||fentanyl-21||yes||sensory block onset time, tourniquet pain onset time, which was defined as the time from tourniquet application to fentanyl administration for relieving tourniquet pain and amount of analgesic consumption during surgery were recorded.
amod||regimen-3/NN||current-1/JJ	nn||regimen-3/NN||treatment-2/NN	nsubj||succeed-13/VB||regimen-3/NN	nsubj||eliminate-15/VB||regimen-3/NN	vmod||regimen-3/NN||consisting-4/VBG	prep_of||consisting-4/VBG||interferon-6/NN	amod||interferon-6/NN||alpha-7/NN	amod||interferon-6/NN||ribavirin-9/NN	conj_and||alpha-7/NN||ribavirin-9/NN	aux||succeed-13/VB||does-10/VBZ	neg||succeed-13/VB||not-11/RB	advmod||succeed-13/VB||always-12/RB	root||ROOT-0/null||succeed-13/VB	aux||eliminate-15/VB||to-14/TO	xcomp||succeed-13/VB||eliminate-15/VB	dobj||eliminate-15/VB||virus-16/NN	advmod||eliminate-15/VB||completely-17/RB	det||patient-20/NN||the-19/DT	poss||body-22/NN||patient-20/NN	prep_from||eliminate-15/VB||body-22/NN	virus-16||ribavirin-9||yes||current treatment regimen consisting of interferon alpha and ribavirin does not always succeed to eliminate virus completely from the patient's body.
nsubj||pathogen-5/NN||cryptococcusneoformans-1/NNS	cop||pathogen-5/NN||is-2/VBZ	det||pathogen-5/NN||an-3/DT	amod||pathogen-5/NN||opportunistic-4/JJ	root||ROOT-0/null||pathogen-5/NN	nsubj||infects-8/VBZ||pathogen-5/NN	advmod||infects-8/VBZ||primarily-7/RB	rcmod||pathogen-5/NN||infects-8/VBZ	det||system-12/NN||the-9/DT	amod||system-12/NN||central-10/JJ	amod||system-12/NN||nervous-11/JJ	dobj||infects-8/VBZ||system-12/NN	det||region-15/NN||a-14/DT	appos||system-12/NN||region-15/NN	amod||concentration-19/NN||high-17/JJ	amod||concentration-19/NN||inositol-18/JJ	prep_of||region-15/NN||concentration-19/NN	amod||individuals-23/NNS||immunocompromised-22/JJ	prep_of||system-12/NN||individuals-23/NNS	inositol-18||cryptococcusneoformans-1||no_rel||cryptococcusneoformans is an opportunistic pathogen which primarily infects the central nervous system, a region of high inositol concentration, of immunocompromised individuals.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	amod||effects-5/NNS||possible-3/JJ	amod||effects-5/NNS||direct-4/JJ	dobj||investigated-2/VBD||effects-5/NNS	prep_of||effects-5/NNS||salmoncalcitonin-7/NN	prep_on||investigated-2/VBD||proteoglycans-9/NNS	nn||synthesis-12/NN||collagen-type-ii-11/NN	prep_on||investigated-2/VBD||synthesis-12/NN	conj_and||proteoglycans-9/NNS||synthesis-12/NN	amod||cartilage-18/NNS||osteoarthritic-14/JJ	appos||cartilage-18/NNS||oa-16/NN	prep_in||investigated-2/VBD||cartilage-18/NNS	oa-16||collagen--1||no_rel||we investigated possible direct effects of salmoncalcitonin on proteoglycans and collagen-type-ii synthesis in osteoarthritic (oa) cartilage.
det||period-3/NN||the-1/DT	amod||period-3/NN||latency-2/JJ	nsubjpass||diagnosed-23/VBN||period-3/NN	det||time-6/NN||the-5/DT	dep||period-3/NN||time-6/NN	amod||exposure-9/NN||initial-8/JJ	prep_between||time-6/NN||exposure-9/NN	nn||imaging-12/NN||radiological-11/NN	prep_between||time-6/NN||imaging-12/NN	conj_and||exposure-9/NN||imaging-12/NN	conj_and||period-3/NN||duration-15/NN	nsubjpass||diagnosed-23/VBN||duration-15/NN	nn||exposure-18/NN||silica-17/NN	prep_of||duration-15/NN||exposure-18/NN	auxpass||diagnosed-23/VBN||was-19/VBD	advmod||diagnosed-23/VBN||longer-20/RB	prep_in||longer-20/RB||patients-22/NNS	root||ROOT-0/null||diagnosed-23/VBN	prep_with||diagnosed-23/VBN||silicosis-25/NNS	dep||diagnosed-23/VBN||than-26/IN	prep_in||diagnosed-23/VBN||those-28/DT	prep_without||those-28/DT||silicosis-30/NNS	dep||silicosis-30/NNS||p-32/VBN	num||0.05-34/CD||<-33/CD	dobj||p-32/VBN||0.05-34/CD	silicosis-30||silica-17||no||the latency period (the time between initial exposure and radiological imaging) and duration of silica exposure was longer in patients diagnosed with silicosis than in those without silicosis (p < 0.05).
amod||subjects-2/NNS||eighty-three-1/JJ	nsubjpass||enrolled-15/VBN||subjects-2/NNS	nsubjpass||received-17/VBN||subjects-2/NNS	dep||subjects-2/NNS||mean-4/VB	nsubj||10.78-10/NNS||age-5/NN	dep||10.78-10/NNS||=-6/SYM	num||10.78-10/NNS||57.87-7/CD	nn||10.78-10/NNS||â-8/NN	nn||10.78-10/NNS||±-9/NN	ccomp||mean-4/VB||10.78-10/NNS	prep_with||subjects-2/NNS||type2diabetesmellitus-13/CD	auxpass||enrolled-15/VBN||were-14/VBD	root||ROOT-0/null||enrolled-15/VBN	conj_and||enrolled-15/VBN||received-17/VBN	advmod||dose-20/NN||daily-18/RB	num||dose-20/NN||one-19/CD	dobj||enrolled-15/VBN||dose-20/NN	prep_of||dose-20/NN||rosiglitazone-22/NN	number||mg-25/CD||4-24/CD	dep||rosiglitazone-22/NN||mg-25/CD	prep_of||dose-20/NN||pioglitazone-28/NN	conj_or||rosiglitazone-22/NN||pioglitazone-28/NN	number||mg-31/CD||15-30/CD	dep||rosiglitazone-22/NN||mg-31/CD	type2diabetesmellitus-13||pioglitazone-28||yes||eighty-three subjects (mean age = 57.87 â± 10.78) with type2diabetesmellitus were enrolled and received daily one dose of rosiglitazone (4 mg) or pioglitazone (15 mg).
prepc_after||3.077-57/CD||adjusting-2/VBG	prep_for||adjusting-2/VBG||covariates-4/NNS	nn||type-16/NN||gender-7/NN	dep||type-16/NN||age-9/NN	dep||type-16/NN||hypertension-11/NN	dep||type-16/NN||diabetes-13/NN	amod||type-16/NN||va-15/JJ	prep_such_as||covariates-4/NNS||type-16/NN	nn||levels-19/NNS||hemoglobin-18/NN	prep_such_as||covariates-4/NNS||levels-19/NNS	conj_and||type-16/NN||levels-19/NNS	nn||index-23/NN||body-21/NN	nn||index-23/NN||mass-22/NN	prep_such_as||covariates-4/NNS||index-23/NN	conj_and||type-16/NN||index-23/NN	amod||hormone-26/NN||parathyroid-25/JJ	prep_such_as||covariates-4/NNS||hormone-26/NN	conj_and||type-16/NN||hormone-26/NN	amod||levels-31/NNS||calcium-phosphorus-29/JJ	nn||levels-31/NNS||product-30/NN	prep_such_as||covariates-4/NNS||levels-31/NNS	conj_and||type-16/NN||levels-31/NNS	det||ratio-35/NN||the-33/DT	nn||ratio-35/NN||hazard-34/NN	nsubj||3.077-57/CD||ratio-35/NN	prep_of||ratio-35/NN||vabf-37/NN	dep||ratio-35/NN||defined-39/VBN	prepc_as||defined-39/VBN||<-41/VBG	num||ml/min-43/NN||853-42/CD	dobj||<-41/VBG||ml/min-43/NN	prep_in||ml/min-43/NN||avf-45/NN	prepc_as||defined-39/VBN||<-47/VBG	conj_or||<-41/VBG||<-47/VBG	num||ml/min-49/NN||830-48/CD	dobj||<-47/VBG||ml/min-49/NN	prep_in||ml/min-49/NN||avg-51/NN	nn||va-55/NN||incident-54/NN	prep_to||ratio-35/NN||va-55/NN	cop||3.077-57/CD||was-56/VBD	root||ROOT-0/null||3.077-57/CD	num||%-60/NN||95-59/CD	dep||3.077-57/CD||%-60/NN	nn||interval-62/NN||confidence-61/NN	dep||%-60/NN||interval-62/NN	num||.395-65/CD||1.127-8-64/CD	appos||interval-62/NN||.395-65/CD	dep||interval-62/NN||p-67/NN	dep||0.028-69/CD||=-68/SYM	rcmod||p-67/NN||0.028-69/CD	calcium--1||hypertension-11||no_rel||after adjusting for covariates such as gender, age, hypertension, diabetes, va type, hemoglobin levels, body mass index, parathyroid hormone, and calcium-phosphorus product levels, the hazard ratio of vabf (defined as <853 ml/min in avf or <830 ml/min in avg) to incident va was 3.077 (95% confidence interval, 1.127-8.395; p =0.028).
nn||depletion-2/NN||iron-1/NN	nsubjpass||evaluated-16/VBN||depletion-2/NN	appos||depletion-2/NN||lack-4/NN	nn||stores-7/NNS||iron-6/NN	prep_of||lack-4/NN||stores-7/NNS	advmod||evaluated-16/VBN||irondeficiency-9/RB	amod||anemia-12/NN||irondeficiency-11/JJ	nsubjpass||evaluated-16/VBN||anemia-12/NN	conj_and||anemia-12/NN||anemia-14/NN	nsubjpass||evaluated-16/VBN||anemia-14/NN	auxpass||evaluated-16/VBN||were-15/VBD	root||ROOT-0/null||evaluated-16/VBN	prep_among||evaluated-16/VBN||them-18/PRP	irondeficiency-11||iron-6||yes||iron depletion, lack of iron stores, irondeficiency, irondeficiency anemia and anemia were evaluated among them.
nsubjpass||evaluated-5/VBN||severity-1/NN	prep_of||severity-1/NN||aws-3/NN	auxpass||evaluated-5/VBN||was-4/VBD	root||ROOT-0/null||evaluated-5/VBN	det||assessment-11/NN||the-7/DT	amod||assessment-11/NN||clinical-8/JJ	nn||assessment-11/NN||institute-9/NN	nn||assessment-11/NN||withdrawal-10/NN	agent||evaluated-5/VBN||assessment-11/NN	nn||scale-14/NN||alcohol-13/NN	prep_of||assessment-11/NN||scale-14/NN	appos||scale-14/NN||ciwa-ar-16/NN	agent||evaluated-5/VBN||that-19/DT	conj_and||assessment-11/NN||that-19/DT	prep_of||that-19/DT||alcoholdependence-21/NN	prep_of||that-19/DT||craving-23/NN	conj_and||alcoholdependence-21/NN||craving-23/NN	det||questionnaire-42/NN||the-25/DT	amod||compulsive-27/JJ||obsessive-26/JJ	amod||questionnaire-42/NN||compulsive-27/JJ	nn||questionnaire-42/NN||drinking-28/NN	nn||questionnaire-42/NN||scale-29/NN	num||ocds-31/NNS||-LSB--30/CD	npadvmod||-RSB--32/JJ||ocds-31/NNS	amod||questionnaire-42/NN||-RSB--32/JJ	det||severity-35/NN||the-34/DT	conj_and||-RSB--32/JJ||severity-35/NN	amod||questionnaire-42/NN||severity-35/NN	amod||data-38/NNS||alcoholdependence-37/JJ	prep_of||severity-35/NN||data-38/NNS	dep||data-38/NNS||sadd-40/JJ	agent||evaluated-5/VBN||questionnaire-42/NN	alcoholdependence-37||alcohol-13||no||severity of aws was evaluated by the clinical institute withdrawal assessment of alcohol scale (ciwa-ar) and that of alcoholdependence and craving by the obsessive compulsive drinking scale [ocds] and the severity of alcoholdependence data (sadd) questionnaire.
det||palivizumab-9/NN||the-1/DT	amod||palivizumab-9/NN||f-2/JJ	amod||palivizumab-9/NN||protein-directed-3/JJ	amod||palivizumab-9/NN||monoclonal-4/JJ	nn||palivizumab-9/NN||antibody-5/NN	appos||palivizumab-9/NN||mab-7/NN	nsubjpass||shown-12/VBN||palivizumab-9/NN	nsubj||prevent-14/VB||palivizumab-9/NN	aux||shown-12/VBN||has-10/VBZ	auxpass||shown-12/VBN||been-11/VBN	root||ROOT-0/null||shown-12/VBN	aux||prevent-14/VB||to-13/TO	xcomp||shown-12/VBN||prevent-14/VB	amod||rsvinfection-19/NN||severe-15/JJ	dep||severe-15/JJ||lower-16/JJR	amod||rsvinfection-19/NN||respiratory-17/JJ	nn||rsvinfection-19/NN||tract-18/NN	dobj||prevent-14/VB||rsvinfection-19/NN	prep_in||prevent-14/VB||animals-21/NNS	prep_in||prevent-14/VB||humans-23/NNS	conj_and||animals-21/NNS||humans-23/NNS	rsvinfection-19||palivizumab-9||yes||the f protein-directed monoclonal antibody (mab) palivizumab has been shown to prevent severe lower respiratory tract rsvinfection in animals and humans.
amod||studies-4/NNS||recent-1/JJ	dep||vitro-3/NN||in-2/IN	amod||studies-4/NNS||vitro-3/NN	nsubj||demonstrated-6/VBN||studies-4/NNS	aux||demonstrated-6/VBN||have-5/VBP	root||ROOT-0/null||demonstrated-6/VBN	mark||have-12/VB||that-7/IN	amod||inhibitors-10/NNS||serine-8/JJ	nn||inhibitors-10/NNS||protease-9/NN	nsubj||have-12/VB||inhibitors-10/NNS	aux||have-12/VB||may-11/MD	ccomp||demonstrated-6/VBN||have-12/VB	amod||properties-14/NNS||anti-inflammatory-13/JJ	dobj||have-12/VB||properties-14/NNS	poss||inhibition-17/NN||their-16/PRP$	prep_beyond||have-12/VB||inhibition-17/NN	amod||elastase-20/NN||neutrophil-19/JJ	prep_of||inhibition-17/NN||elastase-20/NN	det||site-23/NN||the-22/DT	prep_at||elastase-20/NN||site-23/NN	prep_of||site-23/NN||inflammation-25/NN	inflammation-25||anti-inflammatory-13||no_rel||recent in vitro studies have demonstrated that serine protease inhibitors may have anti-inflammatory properties beyond their inhibition of neutrophil elastase at the site of inflammation.
amod||activity-2/NN||epileptic-1/JJ	nsubjpass||induced-5/VBN||activity-2/NN	auxpass||induced-5/VBN||is-3/VBZ	advmod||induced-5/VBN||generally-4/RB	root||ROOT-0/null||induced-5/VBN	amod||models-8/NNS||experimental-7/JJ	prep_in||induced-5/VBN||models-8/NNS	amod||application-11/NN||local-10/JJ	agent||induced-5/VBN||application-11/NN	amod||drugs-14/NNS||epileptogenic-13/JJ	prep_of||application-11/NN||drugs-14/NNS	prep_including||induced-5/VBN||pentylenetetrazol-17/NN	appos||pentylenetetrazol-17/NN||ptz-19/NN	advmod||used-23/VBN||widely-22/RB	vmod||pentylenetetrazol-17/NN||used-23/VBN	preconj||vertebrate-26/JJ||both-25/DT	amod||neurons-29/NNS||vertebrate-26/JJ	conj_and||vertebrate-26/JJ||invertebrate-28/JJ	amod||neurons-29/NNS||invertebrate-28/JJ	prep_on||used-23/VBN||neurons-29/NNS	epileptic-1||ptz-19||no||epileptic activity is generally induced in experimental models by local application of epileptogenic drugs, including pentylenetetrazol (ptz), widely used on both vertebrate and invertebrate neurons.
amod||delivery-2/NN||premature-1/JJ	nsubj||common-6/JJ||delivery-2/NN	cop||common-6/JJ||was-3/VBD	advmod||common-6/JJ||significantly-4/RB	advmod||common-6/JJ||more-5/RBR	root||ROOT-0/null||common-6/JJ	det||group-9/NN||the-8/DT	nsubj||-lrb--13/VBG||group-9/NN	amod||addicts-12/NNS||pregnant-11/JJ	prep_of||group-9/NN||addicts-12/NNS	prepc_in||common-6/JJ||-lrb--13/VBG	num||%-15/NN||21-14/CD	dobj||-lrb--13/VBG||%-15/NN	number||%-18/NN||6-17/CD	amod||-rrb--19/NNS||%-18/NN	prep_vs.||%-15/NN||-rrb--19/NNS	num||%-22/NN||49-21/CD	nsubj||carriers-27/NNS||%-22/NN	amod||addicts-25/NNS||pregnant-24/JJ	prep_of||%-22/NN||addicts-25/NNS	cop||carriers-27/NNS||were-26/VBD	parataxis||common-6/JJ||carriers-27/NNS	amod||-rrb--33/NNP||hepatitisc-29/JJ	nn||-rrb--33/NNP||virus-30/NN	nn||-rrb--33/NNP||-lrb--31/NNP	nn||-rrb--33/NNP||hcv-32/NNP	prep_of||carriers-27/NNS||-rrb--33/NNP	num||%-36/NN||14-35/CD	parataxis||common-6/JJ||%-36/NN	conj_and||carriers-27/NNS||%-36/NN	amod||-rrb--41/NNS||hepatitisbvirus-38/JJ	amod||-rrb--41/NNS||-lrb--39/JJ	nn||-rrb--41/NNS||hbv-40/NN	prep_of||%-36/NN||-rrb--41/NNS	hbv-40||hepatitisbvirus-38||no||premature delivery was significantly more common in the group of pregnant addicts -lrb- 21 % vs. 6 % -rrb- ; 49 % of pregnant addicts were carriers of hepatitisc virus -lrb- hcv -rrb- and 14 % of hepatitisbvirus -lrb- hbv -rrb- .
amod||bortezomib-3/NN||single-1/JJ	nn||bortezomib-3/NN||agent-2/NN	nsubj||results-4/VBZ||bortezomib-3/NN	nsubjpass||touted-22/VBN||bortezomib-3/NN	nsubj||effective-26/JJ||bortezomib-3/NN	root||ROOT-0/null||results-4/VBZ	nn||rates-7/NNS||response-6/NN	prep_in||results-4/VBZ||rates-7/NNS	num||%-10/NN||51-9/CD	prep_of||rates-7/NNS||%-10/NN	prep_in||%-10/NN||patients-12/NNS	advmod||diagnosed-15/JJ||newly-14/RB	amod||multiplemyeloma-16/NN||diagnosed-15/JJ	prep_with||patients-12/NNS||multiplemyeloma-16/NN	appos||multiplemyeloma-16/NN||mm-18/NN	auxpass||touted-22/VBN||is-21/VBZ	conj_and||results-4/VBZ||touted-22/VBN	aux||effective-26/JJ||to-23/TO	cop||effective-26/JJ||be-24/VB	advmod||effective-26/JJ||especially-25/RB	xcomp||touted-22/VBN||effective-26/JJ	amod||disease-29/NN||high-risk-28/JJ	prep_in||effective-26/JJ||disease-29/NN	multiplemyeloma-16||bortezomib-3||yes||single agent bortezomib results in response rates of 51% in patients with newly diagnosed multiplemyeloma (mm) and is touted to be especially effective in high-risk disease.
det||part-4/NN||this-1/DT	nn||part-4/NN||paper-2/NN	nn||part-4/NN||forms-3/NNS	nsubj||â-21/VBP||part-4/NN	nsubj||changing-38/VBG||part-4/NN	det||review-7/NN||a-6/DT	prep_of||part-4/NN||review-7/NN	advmod||commissioned-11/VBN||â-8/RB	pobj||â-8/RB||$-9/$	vmod||review-7/NN||commissioned-11/VBN	det||initiative-16/NN||the-13/DT	amod||initiative-16/NN||joint-14/JJ	nn||initiative-16/NN||learning-15/NN	agent||commissioned-11/VBN||initiative-16/NN	prep_on||initiative-16/NN||children-18/NNS	prep_on||initiative-16/NN||hiv/aids-20/NNS	conj_and||children-18/NNS||hiv/aids-20/NNS	root||ROOT-0/null||â-21/VBP	dobj||â-21/VBP||$-22/$	amod||studies-26/NNS||qualitative-25/JJ	prep_of||$-22/$||studies-26/NNS	advmod||changed-34/VBN||how-28/WRB	nsubj||changed-34/VBN||families-29/NNS	amod||africa-32/NN||southern-31/JJ	prep_in||families-29/NNS||africa-32/NN	aux||changed-34/VBN||have-33/VBP	prepc_of||studies-26/NNS||changed-34/VBN	aux||changing-38/VBG||are-37/VBP	conj_and||â-21/VBP||changing-38/VBG	det||result-42/NN||a-41/DT	prep_as||changing-38/VBG||result-42/NN	det||impact-45/NN||the-44/DT	prep_of||result-42/NN||impact-45/NN	prep_of||impact-45/NN||hiv-47/NN	prep_of||impact-45/NN||aids-49/NNS	conj_and||hiv-47/NN||aids-49/NNS	aids-49||hiv-47||no||this paper forms part of a review â commissioned by the joint learning initiative on children and hiv/aids â of qualitative studies of how families in southern africa have changed, and are changing, as a result of the impact of hiv and aids.
det||standard-3/NN||the-1/DT	amod||standard-3/NN||current-2/JJ	nsubj||eradicates-14/VBZ||standard-3/NN	prep_of||standard-3/NN||care-5/NN	nn||treatment-8/NN||combination-7/NN	appos||standard-3/NN||treatment-8/NN	prep_with||treatment-8/NN||interferon-10/NN	prep_with||treatment-8/NN||ribavirin-12/NN	conj_and||interferon-10/NN||ribavirin-12/NN	root||ROOT-0/null||eradicates-14/VBZ	det||virus-16/NN||the-15/DT	dobj||eradicates-14/VBZ||virus-16/NN	quantmod||50-20/CD||only-18/RB	quantmod||50-20/CD||about-19/RB	num||%-21/NN||50-20/CD	prep_in||virus-16/NN||%-21/NN	advmod||patients-25/NNS||chronically-23/RB	amod||patients-25/NNS||infected-24/JJ	prep_of||%-21/NN||patients-25/NNS	virus-16||ribavirin-12||yes||the current standard of care, combination treatment with interferon and ribavirin, eradicates the virus in only about 50% of chronically infected patients.
nn||recruitment-2/NN||subject-1/NN	nsubj||proved-3/VBD||recruitment-2/NN	root||ROOT-0/null||proved-3/VBD	acomp||proved-3/VBD||difficult-4/JJ	prep_in||difficult-4/JJ||part-6/NN	det||use-12/NN||the-9/DT	amod||use-12/NN||widespread-10/JJ	amod||use-12/NN||off-label-11/JJ	prep_due_to||proved-3/VBD||use-12/NN	prep_of||use-12/NN||gabapentin-14/NN	prep_of||use-12/NN||pregabalin-16/NN	conj_and||gabapentin-14/NN||pregabalin-16/NN	amod||pain-20/NN||acute-18/JJ	nn||pain-20/NN||zoster-19/NN	prep_for||proved-3/VBD||pain-20/NN	poss||region-23/NN||our-22/PRP$	prep_in||pain-20/NN||region-23/NN	det||usa-26/NN||the-25/DT	prep_of||region-23/NN||usa-26/NN	pain-20||gabapentin-14||yes||subject recruitment proved difficult in part due to the widespread off-label use of gabapentin and pregabalin for acute zoster pain in our region of the usa.
mark||well-known-4/JJ||while-1/IN	nsubj||well-known-4/JJ||type2diabetes-2/NNS	nsubjpass||associated-7/VBN||type2diabetes-2/NNS	cop||well-known-4/JJ||is-3/VBZ	advcl||reported-16/VBN||well-known-4/JJ	aux||associated-7/VBN||to-5/TO	auxpass||associated-7/VBN||be-6/VB	xcomp||well-known-4/JJ||associated-7/VBN	amod||performance-11/NN||poorer-9/JJR	nn||performance-11/NN||cognitive-10/NN	prep_with||associated-7/VBN||performance-11/NN	amod||studies-14/NNS||few-13/JJ	nsubj||reported-16/VBN||studies-14/NNS	aux||reported-16/VBN||have-15/VBP	root||ROOT-0/null||reported-16/VBN	det||association-19/NN||the-18/DT	prep_on||reported-16/VBN||association-19/NN	amod||syndrome-22/NN||metabolic-21/JJ	prep_of||association-19/NN||syndrome-22/NN	appos||syndrome-22/NN||mets-24/NNS	amod||factors-28/NNS||contributing-27/JJ	prep_of||association-19/NN||factors-28/NNS	conj_and||syndrome-22/NN||factors-28/NNS	amod||homa-ir-34/NN||insulin-resistance-32/JJ	prep_such_as||factors-28/NNS||homa-ir-34/NN	amod||adiponectin-38/NN||low-37/JJ	appos||homa-ir-34/NN||adiponectin-38/NN	amod||protein-44/NN||high-42/JJ	amod||protein-44/NN||c-reactive-43/JJ	prep_of||association-19/NN||protein-44/NN	conj_and||syndrome-22/NN||protein-44/NN	appos||protein-44/NN||crp-46/NN	dep||association-19/NN||levels-49/NNS	type2diabetes-2||insulin--1||yes||while type2diabetes is well-known to be associated with poorer cognitive performance, few studies have reported on the association of metabolic syndrome (mets) and contributing factors, such as insulin-resistance (homa-ir), low adiponectin-, and high c-reactive protein (crp)- levels.
aux||update-2/VB||to-1/TO	root||ROOT-0/null||update-2/VB	det||programme-7/NN||the-3/DT	amod||programme-7/NN||national-4/JJ	nn||programme-7/NN||malaria-5/NN	nn||programme-7/NN||control-6/NN	dobj||update-2/VB||programme-7/NN	prep_of||programme-7/NN||mali-9/NNS	det||efficacy-12/NN||the-11/DT	prep_on||mali-9/NNS||efficacy-12/NN	prep_of||efficacy-12/NN||chloroquine-14/NN	prep_of||efficacy-12/NN||amodiaquine-16/NN	conj_and||chloroquine-14/NN||amodiaquine-16/NN	prep_of||efficacy-12/NN||sulphadoxine-pyrimethamine-18/NN	conj_and||chloroquine-14/NN||sulphadoxine-pyrimethamine-18/NN	det||treatment-21/NN||the-20/DT	prep_in||update-2/VB||treatment-21/NN	amod||falciparummalaria-24/NN||uncomplicated-23/JJ	prep_of||treatment-21/NN||falciparummalaria-24/NN	malaria-5||pyrimethamine--1||yes||to update the national malaria control programme of mali on the efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine in the treatment of uncomplicated falciparummalaria.
mark||used-30/VBN||although-1/IN	amod||strategies-4/NNS||established-2/JJ	amod||strategies-4/NNS||therapeutic-3/JJ	nsubjpass||used-30/VBN||strategies-4/NNS	nsubj||treat-32/VB||strategies-4/NNS	amod||control-10/NN||appropriate-8/JJ	nn||control-10/NN||bloodglucose-9/NN	prep_such_as||strategies-4/NNS||control-10/NN	nn||control-14/NN||blood-12/NN	nn||control-14/NN||pressure-13/NN	appos||control-10/NN||control-14/NN	prepc_with||control-14/NN||reninâ-16/VBG	dobj||reninâ-16/VBG||$-17/$	advmod||with-26/IN||angiotensin-19/RB	nn||blockade-21/NN||system-20/NN	npadvmod||with-26/IN||blockade-21/NN	cc||lowering-25/NNP||and-23/CC	dep||lowering-25/NNP||lipid-24/RB	dep||blockade-21/NN||lowering-25/NNP	dep||statins-27/CD||with-26/IN	num||$-17/$||statins-27/CD	auxpass||used-30/VBN||are-29/VBP	advcl||increased-49/VBN||used-30/VBN	aux||treat-32/VB||to-31/TO	xcomp||used-30/VBN||treat-32/VB	dobj||treat-32/VB||diabetes-33/NN	det||contribution-36/NN||the-35/DT	nsubj||increased-49/VBN||contribution-36/NN	amod||end-stagekidneydisease-39/NN||diabetic-38/JJ	prep_of||contribution-36/NN||end-stagekidneydisease-39/NN	det||number-43/NN||the-41/DT	amod||number-43/NN||total-42/JJ	prep_to||end-stagekidneydisease-39/NN||number-43/NN	prep_of||number-43/NN||cases-45/NNS	vmod||cases-45/NNS||requiring-46/VBG	dobj||requiring-46/VBG||hemodialysis-47/NNS	aux||increased-49/VBN||has-48/VBZ	root||ROOT-0/null||increased-49/VBN	advmod||increased-49/VBN||tremendously-50/RB	det||decades-55/NNS||the-52/DT	amod||decades-55/NNS||past-53/JJ	num||decades-55/NNS||two-54/CD	prep_in||increased-49/VBN||decades-55/NNS	end-stagekidneydisease-39||statins-27||no_rel||although established therapeutic strategies, such as appropriate bloodglucose control, blood pressure control with reninâangiotensin system blockade, and lipid lowering with statins, are used to treat diabetes, the contribution of diabetic end-stagekidneydisease to the total number of cases requiring hemodialysis has increased tremendously in the past two decades.
nsubjpass||used-5/VBN||adalimumab-1/NN	aux||used-5/VBN||has-2/VBZ	auxpass||used-5/VBN||been-3/VBN	advmod||used-5/VBN||successfully-4/RB	root||ROOT-0/null||used-5/VBN	det||treatment-8/NN||the-7/DT	prep_for||used-5/VBN||treatment-8/NN	prep_of||treatment-8/NN||rheumatoidarthritis-10/NNS	amod||spondylitis-13/NNS||ankylosing-12/JJ	prep_of||treatment-8/NN||spondylitis-13/NNS	conj_and||rheumatoidarthritis-10/NNS||spondylitis-13/NNS	amod||arthritis-17/NN||psoriasis-16/JJ	prep_of||treatment-8/NN||arthritis-17/NN	conj_and||rheumatoidarthritis-10/NNS||arthritis-17/NN	rheumatoidarthritis-10||adalimumab-1||yes||adalimumab has been successfully used for the treatment of rheumatoidarthritis, ankylosing spondylitis, and psoriasis arthritis.
nsubj||preserved-9/VBD||attachment-1/NN	amod||chains-5/NNS||neutral-3/JJ	amod||chains-5/NNS||amide-linked-4/JJ	prep_of||attachment-1/NN||chains-5/NNS	amod||chains-8/NNS||thiourea-containing-7/JJ	prep_of||attachment-1/NN||chains-8/NNS	conj_or||chains-5/NNS||chains-8/NNS	root||ROOT-0/null||preserved-9/VBD	det||affinity-12/NN||the-10/DT	amod||affinity-12/NN||moderate-11/JJ	dobj||preserved-9/VBD||affinity-12/NN	dobj||preserved-9/VBD||efficacy-14/NN	conj_and||affinity-12/NN||efficacy-14/NN	det||subtype-19/NN||the-16/DT	amod||subtype-19/NN||a1-17/JJ	nn||subtype-19/NN||ar-18/NN	prep_at||preserved-9/VBD||subtype-19/NN	expl||was-23/VBD||there-22/EX	conj_but||preserved-9/VBD||was-23/VBD	neg||selectivity-25/NN||no-24/DT	nsubj||was-23/VBD||selectivity-25/NN	det||ar-29/NN||the-27/DT	amod||ar-29/NN||a3-28/JJ	prep_for||selectivity-25/NN||ar-29/NN	ar-29||thiourea--1||no_rel||attachment of neutral amide-linked chains or thiourea-containing chains preserved the moderate affinity and efficacy at the a1 ar subtype, but there was no selectivity for the a3 ar.
prep_for||bâ-10/VBP||example-2/NN	amod||patients-6/NNS||gerd-5/JJ	prep_in||bâ-10/VBP||patients-6/NNS	prep_with||patients-6/NNS||los-8/NN	nsubj||bâ-10/VBP||angeles-9/NNS	root||ROOT-0/null||bâ-10/VBP	dobj||bâ-10/VBP||$-11/$	npadvmod||more-21/JJR||d-13/NNS	det||cents-18/NNS||the-15/DT	amod||cents-18/NNS||requestâ-16/JJ	num||cents-18/NNS||-17/CD	appos||d-13/NNS||cents-18/NNS	nn||falls-20/NNS||score-19/NN	dep||cents-18/NNS||falls-20/NNS	dep||40-24/CD||more-21/JJR	prep_with||more-21/JJR||pantoprazole-23/NN	num||$-11/$||40-24/CD	vmod||$-11/$||mg-25/VBN	advmod||with-27/IN||than-26/RBR	prep||mg-25/VBN||with-27/IN	dep||with-27/IN||esomoprazole-28/VB	num||mg-30/NN||40-29/CD	dobj||esomoprazole-28/VB||mg-30/NN	num||weeks-33/NNS||12-32/CD	prep_after||esomoprazole-28/VB||weeks-33/NNS	prep_of||weeks-33/NNS||therapy-35/NN	gerd-5||pantoprazole-23||yes||for example, in gerd patients with los angeles bâd, the requestâ¢ score falls more with pantoprazole 40 mg than with esomoprazole 40 mg after 12 weeks of therapy.
nsubj||trial-7/NN||e1684-1/NNS	cop||trial-7/NN||was-2/VBD	det||trial-7/NN||the-3/DT	amod||trial-7/NN||pivotal-4/JJ	amod||trial-7/NN||adjuvant-5/JJ	nn||trial-7/NN||melanoma-6/NN	root||ROOT-0/null||trial-7/NN	prep_for||trial-7/NN||establishment-9/NN	amod||interferon-12/NN||high-dose-11/JJ	prep_of||establishment-9/NN||interferon-12/NN	appos||trial-7/NN||ifn-14/NN	amod||therapy-18/NN||effective-17/JJ	prep_as||trial-7/NN||therapy-18/NN	amod||patients-22/NNS||high-risk-20/JJ	nn||patients-22/NNS||melanoma-21/NN	prep_of||therapy-18/NN||patients-22/NNS	melanoma-21||interferon-12||yes||e1684 was the pivotal adjuvant melanoma trial for establishment of high-dose interferon (ifn) as effective therapy of high-risk melanoma patients.
amod||type-6/NN||human-1/JJ	nn||type-6/NN||t-2/NN	nn||type-6/NN||cell-3/NN	nn||type-6/NN||leukemia-4/NN	nn||type-6/NN||virus-5/NN	nsubj||agent-14/NN||type-6/NN	dep||type-6/NN||1-7/CD	dep||type-6/NN||htlv-1-9/JJ	cop||agent-14/NN||is-11/VBZ	det||agent-14/NN||the-12/DT	amod||agent-14/NN||etiologic-13/JJ	root||ROOT-0/null||agent-14/NN	amod||leukemia-19/NN||adult-16/JJ	nn||leukemia-19/NN||t-17/NN	nn||leukemia-19/NN||cell-18/NN	prep_of||agent-14/NN||leukemia-19/NN	appos||leukemia-19/NN||atl-21/NN	det||disorder-26/NN||the-24/DT	amod||disorder-26/NN||neurological-25/JJ	conj_and||agent-14/NN||disorder-26/NN	amod||tropicalspasticparaparesis-29/NNS||htlv-1-associatedmyelopathy-27/JJ	amod||tropicalspasticparaparesis-29/NNS||/-28/JJ	dep||disorder-26/NN||tropicalspasticparaparesis-29/NNS	appos||tropicalspasticparaparesis-29/NNS||ham/tsp-31/NN	tropicalspasticparaparesis-29||htlv-1-9||no||human t cell leukemia virus type 1 (htlv-1) is the etiologic agent of adult t cell leukemia (atl) and the neurological disorder htlv-1-associatedmyelopathy/tropicalspasticparaparesis (ham/tsp).
nsubj||important-3/JJ||they-1/PRP	cop||important-3/JJ||are-2/VBP	root||ROOT-0/null||important-3/JJ	prepc_because_of||important-3/JJ||of-5/IN	poss||magnitude-7/NN||their-6/PRP$	pobj||important-3/JJ||magnitude-7/NN	amod||complications-10/NNS||potential-9/JJ	pobj||important-3/JJ||complications-10/NNS	conj_and||magnitude-7/NN||complications-10/NNS	pobj||important-3/JJ||interactions-12/NNS	conj_and||magnitude-7/NN||interactions-12/NNS	prep_with||important-3/JJ||hiv/aids-14/NNS	aids--1||hiv--1||no||they are important because of their magnitude, potential complications and interactions with hiv/aids.
det||study-3/NN||the-1/DT	amod||study-3/NN||current-2/JJ	nsubjpass||conducted-5/VBN||study-3/NN	nsubj||assess-7/VB||study-3/NN	auxpass||conducted-5/VBN||was-4/VBD	root||ROOT-0/null||conducted-5/VBN	aux||assess-7/VB||to-6/TO	xcomp||conducted-5/VBN||assess-7/VB	mark||protect-18/VB||whether-8/IN	nsubj||protect-18/VB||colostrum-9/NN	vmod||colostrum-9/NN||containing-10/VBG	amod||antibodies-12/NNS||rotavirus-specific-11/JJ	dobj||containing-10/VBG||antibodies-12/NNS	nn||®-15/NNP||gastrogard-râ-14/NNP	appos||antibodies-12/NNS||®-15/NNP	aux||protect-18/VB||could-17/MD	ccomp||assess-7/VB||protect-18/VB	prep_against||protect-18/VB||rotavirusinfection-20/NN	rotavirusinfection-20||rotavirus--1||no||the current study was conducted to assess whether colostrum containing rotavirus-specific antibodies (gastrogard-râ®) could protect against rotavirusinfection.
det||purpose-2/NN||the-1/DT	nsubj||was-7/VBD||purpose-2/NN	nsubj||assess-9/VB||purpose-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||current-5/JJ	prep_of||purpose-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||assess-9/VB||to-8/TO	xcomp||was-7/VBD||assess-9/VB	det||efficacy-11/NN||the-10/DT	dobj||assess-9/VB||efficacy-11/NN	amod||lamivudine-14/NN||prophylactic-13/JJ	prep_of||efficacy-11/NN||lamivudine-14/NN	prepc_in||assess-9/VB||reducing-16/VBG	det||incidence-18/NN||the-17/DT	dobj||reducing-16/VBG||incidence-18/NN	dobj||reducing-16/VBG||severity-20/NN	conj_and||incidence-18/NN||severity-20/NN	nn||reactivation-23/NN||hbv-22/NN	prep_of||incidence-18/NN||reactivation-23/NN	amod||patients-28/NNS||post-operative-25/JJ	nn||patients-28/NNS||breast-26/NN	nn||patients-28/NNS||cancer-27/NN	prep_in||reducing-16/VBG||patients-28/NNS	vmod||patients-28/NNS||undergoing-29/VBG	amod||chemotherapy-32/NN||adjuvant-30/JJ	amod||chemotherapy-32/NN||doxorubicin-containing-31/JJ	dobj||undergoing-29/VBG||chemotherapy-32/NN	hbv-22||lamivudine-14||yes||the purpose of the current study was to assess the efficacy of prophylactic lamivudine in reducing the incidence and severity of hbv reactivation in post-operative breast cancer patients undergoing adjuvant doxorubicin-containing chemotherapy.
poss||study-2/NN||our-1/PRP$	nsubj||focuses-3/VBZ||study-2/NN	root||ROOT-0/null||focuses-3/VBZ	det||level-9/NN||the-5/DT	amod||level-9/NN||cellular-6/JJ	conj_and||cellular-6/JJ||molecular-8/JJ	amod||level-9/NN||molecular-8/JJ	prep_at||focuses-3/VBZ||level-9/NN	nsubjpass||mediated-15/VBN||level-9/NN	nsubjpass||mediated-15/VBN||level-9/NN	amod||effects-12/NNS||ethanol-induced-11/JJ	prep_on||level-9/NN||effects-12/NNS	auxpass||mediated-15/VBN||are-14/VBP	rcmod||level-9/NN||mediated-15/VBN	rcmod||level-9/NN||mediated-15/VBN	conj_and||mediated-15/VBN||mediated-15/VBN	det||receptor-19/NN||the-17/DT	amod||receptor-19/NN||mu-opioid-18/JJ	prep_through||mediated-15/VBN||receptor-19/NN	dep||mediated-15/VBN||mop-21/VB	det||effects-26/NNS||the-25/DT	prep_on||mediated-15/VBN||effects-26/NNS	prep_of||effects-26/NNS||naltrexone-28/NN	det||antagonist-32/NN||a-30/DT	amod||antagonist-32/NN||well-known-31/JJ	appos||naltrexone-28/NN||antagonist-32/NN	nsubj||used-37/JJ||antagonist-32/NN	nsubj||prevent-40/VB||antagonist-32/NN	prep_at||antagonist-32/NN||mop-34/NNP	cop||used-37/JJ||is-36/VBZ	rcmod||antagonist-32/NN||used-37/JJ	advmod||used-37/JJ||clinically-38/RB	aux||prevent-40/VB||to-39/TO	xcomp||used-37/JJ||prevent-40/VB	dobj||prevent-40/VB||relapse-41/NN	prep_in||prevent-40/VB||alcoholism-43/NN	alcoholism-43||naltrexone-28||yes||our study focuses at the cellular and molecular level on ethanol-induced effects that are mediated through the mu-opioid receptor (mop) and on the effects of naltrexone, a well-known antagonist at mop that is used clinically to prevent relapse in alcoholism.
mark||applied-7/VBN||after-1/IN	number||%-3/NN||5-2/CD	amod||patches-5/NNS||%-3/NN	nn||patches-5/NNS||lidocaine-4/NN	nsubjpass||applied-7/VBN||patches-5/NNS	auxpass||applied-7/VBN||were-6/VBD	advcl||exhibited-19/VBD||applied-7/VBN	det||part-12/NN||the-9/DT	amod||part-12/NN||painful-10/JJ	nn||part-12/NN||body-11/NN	prep_to||applied-7/VBN||part-12/NN	num||weeks-15/NNS||two-14/CD	prep_for||part-12/NN||weeks-15/NNS	nn||patients-18/NNS||cbp-17/NN	nsubj||exhibited-19/VBD||patients-18/NNS	root||ROOT-0/null||exhibited-19/VBD	det||decrease-22/NN||a-20/DT	amod||decrease-22/NN||significant-21/JJ	dobj||exhibited-19/VBD||decrease-22/NN	amod||measures-26/NNS||clinical-24/JJ	nn||measures-26/NNS||pain-25/NN	prep_in||exhibited-19/VBD||measures-26/NNS	mark||showed-35/VBD||while-28/IN	nn||questionnaire-32/NN||oa-30/NN	amod||questionnaire-32/NN||clinical-31/JJ	prep_in||showed-35/VBD||questionnaire-32/NN	vmod||questionnaire-32/NN||based-33/VBN	nsubj||showed-35/VBD||outcomes-34/NNS	advcl||exhibited-19/VBD||showed-35/VBD	neg||effect-38/NN||no-36/DT	nn||effect-38/NN||treatment-37/NN	nsubj||evoked-41/VBD||effect-38/NN	prep||effect-38/NN||but-39/CC	pobj||but-39/CC||stimulus-40/NN	ccomp||showed-35/VBD||evoked-41/VBD	nsubj||showed-43/VBD||pain-42/NN	ccomp||evoked-41/VBD||showed-43/VBD	det||decrease-46/NN||a-44/DT	amod||decrease-46/NN||borderline-45/JJ	dobj||showed-43/VBD||decrease-46/NN	pain-42||lidocaine-4||yes||after 5% lidocaine patches were applied to the painful body part for two weeks, cbp patients exhibited a significant decrease in clinical pain measures, while in oa clinical questionnaire based outcomes showed no treatment effect but stimulus evoked pain showed a borderline decrease.
nn||identification-2/NN||species-1/NN	nsubj||seems-13/VBZ||identification-2/NN	nsubj||important-16/JJ||identification-2/NN	prep_of||identification-2/NN||isolates-4/NNP	vmod||isolates-4/NNP||belonging-5/VBG	det||-rrb--12/NNS||the-7/DT	amod||complex-9/JJ||mycobacteriumtuberculosis-8/JJ	amod||-rrb--12/NNS||complex-9/JJ	amod||-rrb--12/NNS||-lrb--10/JJ	nn||-rrb--12/NNS||mtc-11/NN	prep_to||belonging-5/VBG||-rrb--12/NNS	root||ROOT-0/null||seems-13/VBZ	aux||important-16/JJ||to-14/TO	cop||important-16/JJ||be-15/VB	xcomp||seems-13/VBZ||important-16/JJ	det||treatment-20/NN||the-18/DT	amod||treatment-20/NN||appropriate-19/JJ	prep_for||important-16/JJ||treatment-20/NN	prep_of||treatment-20/NN||patients-22/NNS	mark||resistant-29/JJ||since-24/IN	nn||bovis-26/NNS||m.-25/NN	nsubj||resistant-29/JJ||bovis-26/NNS	cop||resistant-29/JJ||is-27/VBZ	advmod||resistant-29/JJ||naturally-28/RB	advcl||important-16/JJ||resistant-29/JJ	det||drug-38/NN||a-31/DT	amod||drug-38/NN||first-32/JJ	nn||drug-38/NN||line-33/NN	amod||drug-38/NN||anti-tuberculosis-34/JJ	nn||drug-38/NN||-lrb--35/NNP	nn||drug-38/NN||tb-36/NN	nn||drug-38/NN||-rrb--37/NN	prep_to||resistant-29/JJ||drug-38/NN	appos||drug-38/NN||pyrazinamide-40/NN	mark||susceptible-50/JJ||while-42/IN	nsubj||susceptible-50/JJ||most-43/JJS	det||members-48/NNS||the-45/DT	amod||members-48/NNS||other-46/JJ	nn||members-48/NNS||mtc-47/NN	prep_of||most-43/JJS||members-48/NNS	cop||susceptible-50/JJ||are-49/VBP	advcl||resistant-29/JJ||susceptible-50/JJ	det||agent-54/NN||this-52/DT	amod||agent-54/NN||antimicrobial-53/JJ	prep_to||susceptible-50/JJ||agent-54/NN	tb-36||pyrazinamide-40||yes||species identification of isolates belonging to the mycobacteriumtuberculosis complex -lrb- mtc -rrb- seems to be important for the appropriate treatment of patients , since m. bovis is naturally resistant to a first line anti-tuberculosis -lrb- tb -rrb- drug , pyrazinamide , while most of the other mtc members are susceptible to this antimicrobial agent .
nn||design-2/NN||research-1/NN	nsubj||â-5/VBP||design-2/NN	conj_and||design-2/NN||methods-4/NNS	nsubj||â-5/VBP||methods-4/NNS	root||ROOT-0/null||â-5/VBP	dobj||â-5/VBP||$-6/$	nsubj||measured-9/VBD||we-8/PRP	rcmod||$-6/$||measured-9/VBD	amod||circumference-11/NN||waist-10/JJ	dobj||measured-9/VBD||circumference-11/NN	nn||pressure-14/NN||blood-13/NN	dobj||measured-9/VBD||pressure-14/NN	conj_and||circumference-11/NN||pressure-14/NN	nn||concentrations-21/NNS||glucose-16/NN	conj_and||glucose-16/NN||insulin-18/NN	nn||concentrations-21/NNS||insulin-18/NN	conj_and||glucose-16/NN||lipid-20/NN	nn||concentrations-21/NNS||lipid-20/NN	dobj||measured-9/VBD||concentrations-21/NNS	conj_and||circumference-11/NN||concentrations-21/NNS	det||prevalence-25/NN||the-24/DT	dobj||measured-9/VBD||prevalence-25/NN	conj_and||circumference-11/NN||prevalence-25/NN	amod||syndrome-28/NN||metabolic-27/JJ	prep_of||prevalence-25/NN||syndrome-28/NN	amod||panel-36/NN||national-30/JJ	nn||panel-36/NN||cholesterol-31/NN	nn||panel-36/NN||education-32/NN	nn||panel-36/NN||program-33/NN	nn||panel-36/NN||adult-34/NN	nn||panel-36/NN||treatment-35/NN	dep||syndrome-28/NN||panel-36/NN	dep||syndrome-28/NN||definition-38/NN	conj_iii||panel-36/NN||definition-38/NN	num||men-42/NNS||1,492-41/CD	prep_in||measured-9/VBD||men-42/NNS	prep_in||measured-9/VBD||women-44/NNS	conj_and||men-42/NNS||women-44/NNS	vmod||men-42/NNS||aged-45/VBN	dobj||aged-45/VBN||26â-46/NNS	num||years-50/NNS||$-47/$	num||$-47/$||32-49/CD	npadvmod||aged-45/VBN||years-50/NNS	prep_in||aged-45/VBN||delhi-52/NNS	poss||weight-57/NN||delhi-52/NNS	appos||delhi-52/NNS||india-54/NN	nsubjpass||recorded-61/VBN||weight-57/NN	conj_and||weight-57/NN||height-59/NN	nsubjpass||recorded-61/VBN||height-59/NN	auxpass||recorded-61/VBN||were-60/VBD	rcmod||delhi-52/NNS||recorded-61/VBN	det||months-64/NNS||every-62/DT	num||months-64/NNS||6-63/CD	tmod||recorded-61/VBN||months-64/NNS	prep_throughout||recorded-61/VBN||infancy-66/NN	dep||infancy-66/NN||0â-68/NNS	num||years-72/NNS||$-69/$	num||$-69/$||2-71/CD	dep||0â-68/NNS||years-72/NNS	prep_throughout||recorded-61/VBN||childhood-75/NN	conj_and||infancy-66/NN||childhood-75/NN	dep||childhood-75/NN||2â-77/NNS	num||years-81/NNS||$-78/$	num||$-78/$||11-80/CD	dep||2â-77/NNS||years-81/NNS	prep_throughout||recorded-61/VBN||adolescence-85/NN	conj_and||infancy-66/NN||adolescence-85/NN	num||yearsâ-88/NNS||11-87/CD	dep||adolescence-85/NN||yearsâ-88/NNS	dep||yearsâ-88/NNS||$-89/$	dep||$-89/$||adult-91/NN	insulin-18||delhi-52||no_rel||research design and methods âwe measured waist circumference, blood pressure, glucose, insulin and lipid concentrations, and the prevalence of metabolic syndrome (national cholesterol education program adult treatment panel iii definition) in 1,492 men and women aged 26â32 years in delhi, india, whose weight and height were recorded every 6 months throughout infancy (0â2 years), childhood (2â11 years), and adolescence (11 yearsâadult).
amod||titres-3/NNS||bcg-specific-1/JJ	nn||titres-3/NNS||igg-2/NN	nsubj||high-6/JJ||titres-3/NNS	cop||high-6/JJ||were-4/VBD	advmod||high-6/JJ||particularly-5/RB	root||ROOT-0/null||high-6/JJ	prep_among||high-6/JJ||patients-8/NNS	vmod||patients-8/NNS||coinfected-9/VBN	prep_with||coinfected-9/VBN||tb-11/FW	prep_with||coinfected-9/VBN||hiv-13/FW	conj_and||tb-11/FW||hiv-13/FW	amod||$-16/NNS||cd4â-15/JJ	prep_with||coinfected-9/VBN||$-16/NNS	amod||counts-19/NNS||t-cell-18/JJ	nsubj||<-20/VBP||counts-19/NNS	parataxis||high-6/JJ||<-20/VBP	amod||cells/ml-24/NN||200â-21/JJ	amod||cells/ml-24/NN||$-22/$	dobj||<-20/VBP||cells/ml-24/NN	nsubj||produced-26/VBD||cells/ml-24/NN	rcmod||cells/ml-24/NN||produced-26/VBD	amod||levels-28/NNS||low-27/JJ	dobj||produced-26/VBD||levels-28/NNS	prep_of||levels-28/NNS||mycobacteriumtuberculosis-30/NNS	amod||ifnî-33/NNS||specific-32/JJ	dep||mycobacteriumtuberculosis-30/NNS||ifnî-33/NNS	punct||mycobacteriumtuberculosis-30/NNS||³-34/''	prep_in||produced-26/VBD||vitro-36/NN	tb-11||bcg--1||yes||bcg-specific igg titres were particularly high among patients coinfected with tb and hiv with cd4ât-cell counts <200âcells/ml who produced low levels of mycobacteriumtuberculosis -specific ifnî³ in vitro.
prep_in||desirable-29/JJ||view-2/NN	det||incidence-6/NN||the-4/DT	amod||incidence-6/NN||high-5/JJ	prep_of||view-2/NN||incidence-6/NN	prep_of||incidence-6/NN||hyperglycemia-8/NN	prep_of||incidence-6/NN||need-10/NN	conj_and||hyperglycemia-8/NN||need-10/NN	nn||treatment-13/NN||insulin-12/NN	prep_for||hyperglycemia-8/NN||treatment-13/NN	amod||studies-16/NNS||future-15/JJ	nsubj||desirable-29/JJ||studies-16/NNS	det||effect-19/NN||the-18/DT	prep_on||studies-16/NNS||effect-19/NN	prep_of||effect-19/NN||insulin-21/NN	amod||metabolism-24/NN||cerebral-23/JJ	prep_on||insulin-21/NN||metabolism-24/NN	nn||patients-27/NNS||sah-26/NN	prep_in||metabolism-24/NN||patients-27/NNS	cop||desirable-29/JJ||are-28/VBP	root||ROOT-0/null||desirable-29/JJ	hyperglycemia-8||insulin-21||yes||in view of the high incidence of hyperglycemia and need for insulin treatment, future studies on the effect of insulin on cerebral metabolism in sah patients are desirable.
det||assay-5/NN||the-1/DT	amod||assay-5/NN||adenosinetriphosphate-based-2/JJ	amod||assay-5/NN||chemotherapy-3/JJ	nn||assay-5/NN||response-4/NN	nsubj||test-12/NN||assay-5/NN	appos||assay-5/NN||atp-cra-7/NNP	cop||test-12/NN||is-9/VBZ	det||test-12/NN||a-10/DT	amod||test-12/NN||chemosensitivity-11/JJ	root||ROOT-0/null||test-12/NN	nsubj||offers-14/VBZ||test-12/NN	rcmod||test-12/NN||offers-14/VBZ	det||potential-16/NN||the-15/DT	dobj||offers-14/VBZ||potential-16/NN	prepc_of||potential-16/NN||selecting-18/VBG	nn||treatments-20/NNS||cancer-19/NN	dobj||selecting-18/VBG||treatments-20/NNS	prepc_based_on||selecting-18/VBG||on-22/IN	det||responsiveness-24/NNS||the-23/DT	pobj||selecting-18/VBG||responsiveness-24/NNS	amod||tumors-27/NNS||individual-26/JJ	prep_of||responsiveness-24/NNS||tumors-27/NNS	cancer-19||adenosinetriphosphate--1||no_rel||the adenosinetriphosphate-based chemotherapy response assay (atp-cra) is a chemosensitivity test that offers the potential of selecting cancer treatments based on the responsiveness of individual tumors.
nsubjpass||used-6/VBN||analogues-1/NNS	prep_of||analogues-1/NNS||vitamind3-3/CD	auxpass||used-6/VBN||are-4/VBP	advmod||used-6/VBN||extensively-5/RB	root||ROOT-0/null||used-6/VBN	det||treatment-9/NN||the-8/DT	prep_in||used-6/VBN||treatment-9/NN	amod||illnesses-12/NNS||various-11/JJ	prep_of||treatment-9/NN||illnesses-12/NNS	prep_such_as||treatment-9/NN||osteoporosis-16/NNS	amod||diseases-20/NNS||inflammatory-18/JJ	nn||diseases-20/NNS||skin-19/NN	prep_such_as||treatment-9/NN||diseases-20/NNS	conj_and||osteoporosis-16/NNS||diseases-20/NNS	prep_such_as||treatment-9/NN||cancer-23/NN	conj_and||osteoporosis-16/NNS||cancer-23/NN	osteoporosis-16||vitamind3-3||yes||analogues of vitamind3 are extensively used in the treatment of various illnesses, such as osteoporosis, inflammatory skin diseases, and cancer.
amod||patients-2/NNS||asymptomatic-1/JJ	nsubjpass||enrolled-64/VBN||patients-2/NNS	appos||patients-2/NNS||n-4/NNP	number||485-6/CD||=-5/CD	num||n-4/NNP||485-6/CD	vmod||patients-2/NNS||aged-8/VBN	nn||-10/NNS||â-9/NN	dobj||aged-8/VBN||-10/NNS	number||50-12/CD||¥-11/CD	num||years-13/NNS||50-12/CD	npadvmod||aged-8/VBN||years-13/NNS	advmod||thickness-21/NN||either-15/RB	det||thickness-21/NN||a-16/DT	amod||carotid-18/JJ||maximal-17/JJ	amod||thickness-21/NN||carotid-18/JJ	nn||thickness-21/NN||artery-19/NN	nn||thickness-21/NN||intima-media-20/NN	prep_with||aged-8/VBN||thickness-21/NN	nn||-24/NNS||â-23/NN	prep_of||thickness-21/NN||-24/NNS	amod||thickness-21/NN||¥-25/JJ	num||mm-27/NNS||1.1-26/CD	dep||¥-25/JJ||mm-27/NNS	det||creatinine-38/NN||a-30/DT	advmod||albumin-32/JJ||urinary-31/RB	amod||creatinine-38/NN||albumin-32/JJ	nn||creatinine-38/NN||â-33/NNP	nn||creatinine-38/NN||-34/NNP	nn||creatinine-38/NN||¥-35/NNP	num||creatinine-38/NN||30-36/CD	nn||creatinine-38/NN||mg/g-37/NN	prep_with||aged-8/VBN||creatinine-38/NN	conj_or||thickness-21/NN||creatinine-38/NN	nsubj||had-41/VBD||who-40/WP	prep_with||aged-8/VBN||had-41/VBD	conj_or||thickness-21/NN||had-41/VBD	quantmod||two-44/CD||at-42/IN	mwe||at-42/IN||least-43/JJS	pobj||at-42/IN||least-43/JJS	dobj||had-41/VBD||two-44/CD	det||obesity-50/NN||the-46/DT	amod||obesity-50/NN||following-47/JJ	amod||obesity-50/NN||abdominal-49/JJ	prep_of||two-44/CD||obesity-50/NN	amod||cholesterol-54/NN||low-52/JJ	nn||cholesterol-54/NN||hdl-53/NN	prep_of||two-44/CD||cholesterol-54/NN	conj_and||obesity-50/NN||cholesterol-54/NN	amod||levels-58/NNS||high-56/JJ	nn||levels-58/NNS||triglyceride-57/NN	prep_of||two-44/CD||levels-58/NNS	conj_and||obesity-50/NN||levels-58/NNS	prep_of||two-44/CD||hypertension-61/NN	conj_and||obesity-50/NN||hypertension-61/NN	auxpass||enrolled-64/VBN||were-63/VBD	root||ROOT-0/null||enrolled-64/VBN	num||institutions-67/NNS||50-66/CD	prep_at||enrolled-64/VBN||institutions-67/NNS	triglyceride-57||obesity-50||no_rel||asymptomatic patients ( n = 485) aged â¥50 years with either a maximal carotid artery intima-media thickness of â¥1.1 mm, or a urinary albumin â¥30 mg/g creatinine or who had at least two of the following, abdominal obesity, low hdl cholesterol, high triglyceride levels, and hypertension, were enrolled at 50 institutions.
nsubj||intraindividual-10/NN||this-1/DT	cop||intraindividual-10/NN||was-2/VBD	det||intraindividual-10/NN||an-3/DT	amod||intraindividual-10/NN||open-label-4/JJ	amod||intraindividual-10/NN||multicenter-6/JJ	amod||intraindividual-10/NN||bilateral-8/JJ	root||ROOT-0/null||intraindividual-10/NN	amod||study-14/NN||active-controlled-13/JJ	conj_and||intraindividual-10/NN||study-14/NN	prep_in||changed-35/VBN||study-14/NN	num||patients-20/NNS||20-17/CD	amod||patients-20/NNS||japanese-18/JJ	nn||patients-20/NNS||american-19/NN	nsubj||%-32/NN||patients-20/NNS	nsubjpass||changed-35/VBN||patients-20/NNS	nsubj||monotherapy-37/VB||patients-20/NNS	amod||open-angleglaucoma-23/NN||primary-22/JJ	prep_with||patients-20/NNS||open-angleglaucoma-23/NN	prep_with||patients-20/NNS||ocularhypertension-25/NN	conj_or||open-angleglaucoma-23/NN||ocularhypertension-25/NN	aux||%-32/NN||had-27/VBD	cop||%-32/NN||been-28/VBN	prep_on||%-32/NN||latanoprost-30/NN	num||%-32/NN||0.005-31/CD	rcmod||patients-20/NNS||%-32/NN	advmod||%-32/NN||monotherapy-33/RB	auxpass||changed-35/VBN||were-34/VBD	rcmod||study-14/NN||changed-35/VBN	aux||monotherapy-37/VB||to-36/TO	xcomp||changed-35/VBN||monotherapy-37/VB	amod||daily-43/NN||travoprost-39/JJ	num||%-41/NN||0.004-40/CD	dep||travoprost-39/JJ||%-41/NN	amod||daily-43/NN||bak-free-42/JJ	prep_with||monotherapy-37/VB||daily-43/NN	num||weeks-46/NNS||12-45/CD	prep_for||daily-43/NN||weeks-46/NNS	open-angleglaucoma-23||travoprost-39||yes||this was an open-label, multicenter, bilateral, intraindividual, and active-controlled study in which 20 japanese american patients with primary open-angleglaucoma or ocularhypertension who had been on latanoprost 0.005% monotherapy were changed to monotherapy with travoprost 0.004% bak-free daily for 12 weeks.
amod||aim-3/NN||objective-1/JJ	det||aim-3/NN||the-2/DT	nsubj||was-7/VBD||aim-3/NN	nsubj||assess-9/VB||aim-3/NN	det||analysis-6/NN||this-5/DT	prep_of||aim-3/NN||analysis-6/NN	root||ROOT-0/null||was-7/VBD	aux||assess-9/VB||to-8/TO	xcomp||was-7/VBD||assess-9/VB	det||effect-11/NN||the-10/DT	dobj||assess-9/VB||effect-11/NN	amod||pressurized-14/JJ||budesonide/formoterol-13/JJ	amod||inhaler-16/NN||pressurized-14/JJ	amod||inhaler-16/NN||metered-dose-15/JJ	prep_of||effect-11/NN||inhaler-16/NN	nn||pmdi-19/NNS||bud/fm-18/NN	appos||inhaler-16/NN||pmdi-19/NNS	dobj||assess-9/VB||bud-22/NN	conj_and||effect-11/NN||bud-22/NN	amod||criteria-25/NNS||predefined-24/JJ	prep_on||bud-22/NN||criteria-25/NNS	prep_for||criteria-25/NNS||asthma-27/NN	amod||asthma-27/NN||worsening-28/VBG	det||metric-33/NN||an-30/DT	nn||metric-33/NN||asthma-31/NN	nn||metric-33/NN||control-32/NN	appos||bud-22/NN||metric-33/NN	advmod||aligned-35/VBN||generally-34/RB	vmod||metric-33/NN||aligned-35/VBN	prep_with||aligned-35/VBN||definitions-37/NNS	amod||exacerbations-41/NNS||moderate-39/JJ	nn||exacerbations-41/NNS||asthma-40/NN	prep_of||definitions-37/NNS||exacerbations-41/NNS	num||populations-46/NNS||four-44/CD	amod||populations-46/NNS||different-45/JJ	prep_across||bud-22/NN||populations-46/NNS	asthma-40||formoterol--1||yes||objective the aim of this analysis was to assess the effect of budesonide/formoterol pressurized metered-dose inhaler (bud/fm pmdi) and bud on predefined criteria for asthma worsening, an asthma control metric generally aligned with definitions of moderate asthma exacerbations, across four different populations.
nsubj||indicate-5/VBP||results-1/NNS	det||study-4/NN||this-3/DT	prep_of||results-1/NNS||study-4/NN	root||ROOT-0/null||indicate-5/VBP	mark||improves-9/VBZ||that-6/IN	nsubj||improves-9/VBZ||miglitol-7/NN	advmod||improves-9/VBZ||significantly-8/RB	ccomp||indicate-5/VBP||improves-9/VBZ	amod||control-11/NN||metabolic-10/JJ	dobj||improves-9/VBZ||control-11/NN	amod||patients-14/NNS||chinese-13/JJ	prep_in||improves-9/VBZ||patients-14/NNS	prep_with||patients-14/NNS||type2diabetesmellitus-16/CD	type2diabetesmellitus-16||miglitol-7||yes||results of this study indicate that miglitol significantly improves metabolic control in chinese patients with type2diabetesmellitus.
det||raloxifene-2/NN||both-1/DT	nsubjpass||indicated-6/VBN||raloxifene-2/NN	conj_and||raloxifene-2/NN||bisphosphonates-4/NNS	nsubjpass||indicated-6/VBN||bisphosphonates-4/NNS	auxpass||indicated-6/VBN||are-5/VBP	root||ROOT-0/null||indicated-6/VBN	det||prevention-9/NN||the-8/DT	prep_for||indicated-6/VBN||prevention-9/NN	prep_for||indicated-6/VBN||treatment-11/NN	conj_and||prevention-9/NN||treatment-11/NN	prep_of||prevention-9/NN||postmenopausalosteoporosis-13/NNS	advmod||have-18/VBP||however-15/RB	det||medications-17/NNS||these-16/DT	nsubj||have-18/VBP||medications-17/NNS	parataxis||indicated-6/VBN||have-18/VBP	amod||efficacy-20/NN||different-19/JJ	dobj||have-18/VBP||efficacy-20/NN	nn||profiles-23/NNS||safety-22/NN	dobj||have-18/VBP||profiles-23/NNS	conj_and||efficacy-20/NN||profiles-23/NNS	postmenopausalosteoporosis-13||raloxifene-2||yes||both raloxifene and bisphosphonates are indicated for the prevention and treatment of postmenopausalosteoporosis, however these medications have different efficacy and safety profiles.
amod||patients-3/NNS||thirty-three-1/JJ	amod||patients-3/NNS||consecutive-2/JJ	nsubj||received-7/VBD||patients-3/NNS	amod||lupusnephritis-6/NNS||proliferative-5/JJ	prep_with||patients-3/NNS||lupusnephritis-6/NNS	root||ROOT-0/null||received-7/VBD	nn||therapy-9/NN||induction-8/NN	dobj||received-7/VBD||therapy-9/NN	iobj||received-7/VBD||therapy-9/NN	number||seven-13/CD||five-11/CD	dep||seven-13/CD||to-12/TO	num||pulses-19/NNS||seven-13/CD	amod||pulses-19/NNS||monthly-14/JJ	amod||pulses-19/NNS||intravenous-15/JJ	appos||pulses-19/NNS||iv-17/NN	prep_with||therapy-9/NN||pulses-19/NNS	prep_of||therapy-9/NN||cyclophosphamide-21/NN	appos||cyclophosphamide-21/NN||cyc-23/NN	amod||therapy-9/NN||plus-25/IN	nn||steroids-27/NNS||iv-26/NN	dep||therapy-9/NN||steroids-27/NNS	vmod||steroids-27/NNS||followed-28/VBN	amod||g/day-33/NN||oral-30/JJ	nn||g/day-33/NN||mmf-31/NN	num||g/day-33/NN||2-32/CD	agent||followed-28/VBN||g/day-33/NN	nn||therapy-36/NN||maintenance-35/NN	prep_as||received-7/VBD||therapy-36/NN	det||time-40/NN||a-38/DT	amod||time-40/NN||median-39/JJ	prep_for||received-7/VBD||time-40/NN	num||months-43/NNS||29-42/CD	prep_of||time-40/NN||months-43/NNS	parataxis||received-7/VBD||range-45/VB	number||71-48/CD||9-46/CD	dep||71-48/CD||to-47/TO	num||months-49/NNS||71-48/CD	tmod||range-45/VB||months-49/NNS	lupusnephritis-6||cyclophosphamide-21||yes||thirty-three consecutive patients with proliferative lupusnephritis received induction therapy with five to seven monthly intravenous (iv) pulses of cyclophosphamide (cyc) plus iv steroids followed by oral mmf 2 g/day as maintenance therapy for a median time of 29 months (range 9 to 71 months).
det||guideline-3/NN||the-1/DT	amod||guideline-3/NN||national-2/JJ	nsubj||recommends-4/VBZ||guideline-3/NN	root||ROOT-0/null||recommends-4/VBZ	num||diagnosis-7/NN||three-5/CD	amod||diagnosis-7/NN||different-6/JJ	dep||recommends-4/VBZ||diagnosis-7/NN	nn||strategies-10/NNS||treatment-9/NN	dep||recommends-4/VBZ||strategies-10/NNS	conj_and||diagnosis-7/NN||strategies-10/NNS	nn||i-15/NNS||health-12/NN	nn||i-15/NNS||post-13/NN	nn||i-15/NNS||level-14/NN	prep_at||diagnosis-7/NN||i-15/NNS	det||use-18/NN||the-17/DT	dobj||recommends-4/VBZ||use-18/NN	det||p.falciparum-21/NN||a-20/DT	prep_of||use-18/NN||p.falciparum-21/NN	punct||rdt-25/NN||/-22/:	amod||rdt-25/NN||vivax-23/JJ	amod||rdt-25/NN||specific-24/JJ	dep||use-18/NN||rdt-25/NN	nn||tool-28/NN||diagnosis-27/NN	prep_as||rdt-25/NN||tool-28/NN	aux||treat-31/VB||to-30/TO	prep_as||rdt-25/NN||treat-31/VB	conj_and||tool-28/NN||treat-31/VB	vmod||tool-28/NN||treat-31/VB	prep_with||treat-31/VB||artemether-lumefantrine-33/NN	appos||artemether-lumefantrine-33/NN||al-35/NNP	amod||cq-40/NN||chloroquine-38/JJ	prep_with||treat-31/VB||cq-40/NN	conj_or||artemether-lumefantrine-33/NN||cq-40/NN	prep_with||treat-31/VB||referral-43/NN	conj_or||artemether-lumefantrine-33/NN||referral-43/NN	mark||diagnosed-48/VBN||if-44/IN	det||patient-46/NN||the-45/DT	nsubjpass||diagnosed-48/VBN||patient-46/NN	auxpass||diagnosed-48/VBN||was-47/VBD	advcl||treat-31/VB||diagnosed-48/VBN	prep_with||diagnosed-48/VBN||p.falciparum-50/NN	prep_with||diagnosed-48/VBN||p.vivax-52/NN	conj_or||p.falciparum-50/NN||p.vivax-52/NN	neg||malaria-55/NN||no-54/DT	prep_with||diagnosed-48/VBN||malaria-55/NN	conj_or||p.falciparum-50/NN||malaria-55/NN	dep||rdt-25/NN||respectively-57/RB	nn||pan/pf-60/NN||parascreen-59/NN	dep||use-18/NN||pan/pf-60/NN	vmod||pan/pf-60/NN||based-61/VBN	dobj||based-61/VBN||strategy-62/NN	csubj||diagnosed-101/VBD||ii-65/VB	det||use-68/NN||the-67/DT	dobj||ii-65/VB||use-68/NN	det||rdt-73/NN||a-70/DT	amod||rdt-73/NN||p.falciparum-71/JJ	amod||rdt-73/NN||specific-72/JJ	prep_of||ii-65/VB||rdt-73/NN	prep_of||ii-65/VB||al-75/NNP	conj_and||rdt-73/NN||al-75/NNP	nn||cases-78/NNS||p.falciparum-77/NN	prep_for||al-75/NNP||cases-78/NNS	prep_for||al-75/NNP||cq-80/NN	conj_and||cases-78/NNS||cq-80/NN	det||rest-83/NN||the-82/DT	prep_for||cases-78/NNS||rest-83/NN	nn||pf-86/NN||paracheck-85/NN	dep||cases-78/NNS||pf-86/NN	vmod||pf-86/NN||based-87/VBN	dobj||based-87/VBN||strategy-88/NN	conj_and||ii-65/VB||iii-92/VB	csubj||diagnosed-101/VBD||iii-92/VB	det||use-95/NN||the-94/DT	dobj||iii-92/VB||use-95/NN	prep_of||iii-92/VB||al-97/NNP	det||cases-100/NNS||all-99/DT	prep_for||al-97/NNP||cases-100/NNS	parataxis||recommends-4/VBZ||diagnosed-101/VBD	advmod||diagnosed-101/VBD||presumptively-102/RB	prep_as||diagnosed-101/VBD||malaria-104/NN	dep||malaria-104/NN||presumptive-106/NN	vmod||presumptive-106/NN||based-107/VBN	dobj||based-107/VBN||strategy-108/NN	malaria-104||chloroquine-38||yes||the national guideline recommends three different diagnosis and treatment strategies at health post level i) the use of a p.falciparum / vivax specific rdt as diagnosis tool and to treat with artemether-lumefantrine (al), chloroquine (cq) or referral if the patient was diagnosed with p.falciparum , p.vivax or no malaria, respectively (parascreen pan/pf based strategy); ii) the use of a p.falciparum specific rdt and al for p.falciparum cases and cq for the rest (paracheck pf based strategy); and iii) the use of al for all cases diagnosed presumptively as malaria (presumptive based strategy).
amod||evidence-2/NN||epidemiological-1/JJ	nsubj||indicated-5/VBN||evidence-2/NN	aux||indicated-5/VBN||has-3/VBZ	advmod||indicated-5/VBN||clearly-4/RB	root||ROOT-0/null||indicated-5/VBN	mark||factor-19/NN||that-6/IN	amod||infection-8/NN||chronic-7/JJ	nsubj||factor-19/NN||infection-8/NN	det||hepatitisbvirus-11/NNS||the-10/DT	prep_with||infection-8/NN||hepatitisbvirus-11/NNS	appos||hepatitisbvirus-11/NNS||hbv-13/NN	cop||factor-19/NN||is-15/VBZ	det||factor-19/NN||the-16/DT	amod||factor-19/NN||major-17/JJ	nn||factor-19/NN||risk-18/NN	ccomp||indicated-5/VBN||factor-19/NN	amod||carcinoma-23/NN||developing-21/VBG	nn||carcinoma-23/NN||hepatocellular-22/NN	prep_for||factor-19/NN||carcinoma-23/NN	appos||carcinoma-23/NN||hcc-25/NN	hbv-13||hepatitisbvirus-11||no||epidemiological evidence has clearly indicated that chronic infection with the hepatitisbvirus (hbv) is the major risk factor for developing hepatocellular carcinoma (hcc).
nsubj||same-10/JJ||threats-1/NNS	amod||biodiversity-4/NN||marine-3/JJ	prep_to||threats-1/NNS||biodiversity-4/NN	det||u.s.-7/NN||the-6/DT	prep_in||biodiversity-4/NN||u.s.-7/NN	cop||same-10/JJ||are-8/VBP	det||same-10/JJ||the-9/DT	root||ROOT-0/null||same-10/JJ	prep_as||same-10/JJ||those-12/DT	prep_for||those-12/DT||most-14/JJS	det||overexploitation-18/NN||the-16/DT	nn||overexploitation-18/NN||world-17/NN	prep_of||most-14/JJS||overexploitation-18/NN	nn||resources-21/NNS||living-20/NN	prep_of||same-10/JJ||resources-21/NNS	amod||quality-25/NN||reduced-23/JJ	nn||quality-25/NN||water-24/NN	conj_and||same-10/JJ||quality-25/NN	amod||development-28/NN||coastal-27/JJ	conj_and||same-10/JJ||development-28/NN	conj_and||same-10/JJ||shipping-30/NN	amod||species-33/NNS||invasive-32/JJ	conj_and||same-10/JJ||species-33/NNS	amod||temperature-36/NN||rising-35/JJ	conj_and||same-10/JJ||temperature-36/NN	conj_and||same-10/JJ||concentrations-38/NNS	prep_of||same-10/JJ||carbondioxide-40/NN	det||ocean-44/NN||the-42/DT	nn||ocean-44/NN||surface-43/NN	prep_in||carbondioxide-40/NN||ocean-44/NN	amod||changes-48/NNS||other-47/JJ	conj_and||same-10/JJ||changes-48/NNS	nsubj||consequences-52/NNS||changes-48/NNS	aux||consequences-52/NNS||may-50/MD	cop||consequences-52/NNS||be-51/VB	rcmod||changes-48/NNS||consequences-52/NNS	amod||change-55/NN||global-54/JJ	prep_of||consequences-52/NNS||change-55/NN	amod||currents-59/NNS||shifting-58/VBG	prep_including||consequences-52/NNS||currents-59/NNS	amod||number-62/NN||increased-61/VBN	rcmod||changes-48/NNS||number-62/NN	conj_and||consequences-52/NNS||number-62/NN	conj_and||consequences-52/NNS||size-64/NN	conj_and||number-62/NN||size-64/NN	amod||areas-69/NNS||hypoxic-66/JJ	conj_or||hypoxic-66/JJ||anoxic-68/JJ	amod||areas-69/NNS||anoxic-68/JJ	prep_of||number-62/NN||areas-69/NNS	amod||number-73/NN||increased-72/VBN	rcmod||changes-48/NNS||number-73/NN	conj_and||consequences-52/NNS||number-73/NN	conj_and||consequences-52/NNS||duration-75/NN	conj_and||number-73/NN||duration-75/NN	amod||blooms-79/NNS||harmful-77/JJ	amod||blooms-79/NNS||algal-78/JJ	prep_of||number-73/NN||blooms-79/NNS	hypoxic-66||carbondioxide-40||no_rel||threats to marine biodiversity in the u.s. are the same as those for most of the world overexploitation of living resources ; reduced water quality ; coastal development ; shipping ; invasive species ; rising temperature and concentrations of carbondioxide in the surface ocean , and other changes that may be consequences of global change , including shifting currents ; increased number and size of hypoxic or anoxic areas ; and increased number and duration of harmful algal blooms .
amod||cancer-2/NN||endometrial-1/JJ	nsubj||cancer-9/NN||cancer-2/NN	appos||cancer-2/NN||ec-4/NN	cop||cancer-9/NN||is-6/VBZ	det||cancer-9/NN||a-7/DT	amod||cancer-9/NN||hormone-dependent-8/JJ	root||ROOT-0/null||cancer-9/NN	nsubj||represents-12/VBZ||cancer-9/NN	advmod||represents-12/VBZ||currently-11/RB	rcmod||cancer-9/NN||represents-12/VBZ	det||malignancy-16/NN||the-13/DT	advmod||frequent-15/JJ||most-14/RBS	amod||malignancy-16/NN||frequent-15/JJ	dobj||represents-12/VBZ||malignancy-16/NN	det||tract-21/NN||the-18/DT	amod||tract-21/NN||female-19/JJ	amod||tract-21/NN||reproductive-20/JJ	prep_of||malignancy-16/NN||tract-21/NN	malignancy-16||hormone--1||no_rel||endometrial cancer (ec) is a hormone-dependent cancer that currently represents the most frequent malignancy of the female reproductive tract.
det||review-3/NN||this-2/DT	prep_in||discuss-6/VB||review-3/NN	nsubj||discuss-6/VB||we-5/PRP	nsubj||summarize-17/VB||we-5/PRP	root||ROOT-0/null||discuss-6/VB	amod||aspects-8/NNS||basic-7/JJ	dobj||discuss-6/VB||aspects-8/NNS	amod||biology-13/NN||b-cell-10/JJ	conj_and||b-cell-10/JJ||blys-12/JJ	amod||biology-13/NN||blys-12/JJ	prep_of||aspects-8/NNS||biology-13/NN	prep_in||discuss-6/VB||sle-15/NN	conj_and||discuss-6/VB||summarize-17/VB	det||evidence-19/NN||the-18/DT	dobj||summarize-17/VB||evidence-19/NN	vmod||evidence-19/NN||supporting-20/VBG	det||role-22/NN||a-21/DT	dobj||supporting-20/VBG||role-22/NN	prep_of||role-22/NN||belimumab-24/NN	prep_in||belimumab-24/NN||sle-26/NN	nn||studies-30/NNS||animal-29/NN	prep_from||supporting-20/VBG||studies-30/NNS	aux||phase-32/VB||to-31/TO	vmod||supporting-20/VBG||phase-32/VB	amod||trials-35/NNS||iii-33/JJ	amod||trials-35/NNS||clinical-34/JJ	dobj||phase-32/VB||trials-35/NNS	sle-26||basic-7||no_rel||in this review, we discuss basic aspects of b-cell and blys biology in sle and summarize the evidence supporting a role of belimumab in sle, from animal studies to phase iii clinical trials.
prep_in||improved-18/VBD||conclusion-2/NN	dep||improved-18/VBD||initiating-4/VBG	dobj||initiating-4/VBG||therapy-5/NN	det||combination-8/NN||a-7/DT	prep_with||initiating-4/VBG||combination-8/NN	nn||results-14/NNS||valsartan-10/NN	conj_and||valsartan-10/NN||low-dose-12/JJ	nn||results-14/NNS||low-dose-12/JJ	nn||results-14/NNS||hctz-13/NN	prep_of||combination-8/NN||results-14/NNS	prep_in||initiating-4/VBG||early-16/JJ	root||ROOT-0/null||improved-18/VBD	nn||efficacy-20/NN||bp-19/NN	dobj||improved-18/VBD||efficacy-20/NN	amod||tolerability-23/NN||similar-22/JJ	prep_with||improved-18/VBD||tolerability-23/NN	prep||improved-18/VBD||as-24/IN	prepc_compared_with||improved-18/VBD||with-26/IN	pcomp||improved-18/VBD||starting-27/VBG	dobj||starting-27/VBG||treatment-28/NN	det||dose-34/NN||a-30/DT	amod||dose-34/NN||low-31/JJ	conj_or||low-31/JJ||higher-33/JJR	amod||dose-34/NN||higher-33/JJR	prep_with||starting-27/VBG||dose-34/NN	prep_of||dose-34/NN||valsartan-36/NN	prep_for||valsartan-36/NN||patients-38/NNS	amod||hypertension-43/NN||stage-1-40/JJ	conj_and||stage-1-40/JJ||stage-2-42/JJ	amod||hypertension-43/NN||stage-2-42/JJ	prep_with||patients-38/NNS||hypertension-43/NN	hypertension-43||valsartan-36||yes||in conclusion, initiating therapy with a combination of valsartan and low-dose hctz results in early, improved bp efficacy with similar tolerability as compared with starting treatment with a low or higher dose of valsartan for patients with stage-1 and stage-2 hypertension.
det||possibility-2/NN||the-1/DT	nsubj||allow-14/VB||possibility-2/NN	nsubj||help-27/VB||possibility-2/NN	prepc_of||possibility-2/NN||extracting-4/VBG	dobj||extracting-4/VBG||rna-5/NN	prepc_of||possibility-2/NN||measuring-7/VBG	conj_and||extracting-4/VBG||measuring-7/VBG	nn||expression-9/NN||rna-8/NN	dobj||measuring-7/VBG||expression-9/NN	nn||sections-12/NNS||paraffin-11/NN	prep_from||measuring-7/VBG||sections-12/NNS	aux||allow-14/VB||can-13/MD	root||ROOT-0/null||allow-14/VB	amod||investigations-16/NNS||extensive-15/JJ	dobj||allow-14/VB||investigations-16/NNS	amod||samples-20/NNS||stored-18/JJ	nn||samples-20/NNS||paraffin-19/NN	prep_on||allow-14/VB||samples-20/NNS	vmod||samples-20/NNS||obtained-21/VBN	amod||livers-24/NNS||diseased-23/JJ	prep_from||obtained-21/VBN||livers-24/NNS	aux||help-27/VB||could-26/MD	conj_and||allow-14/VB||help-27/VB	conj_and||allow-14/VB||help-27/VB	conj_and||help-27/VB||help-27/VB	prep_with||help-27/VB||studies-29/NNS	det||history-33/NN||the-31/DT	amod||history-33/NN||natural-32/JJ	prep_of||studies-29/NNS||history-33/NN	nn||fibrosis-36/NN||liver-35/NN	prep_of||history-33/NN||fibrosis-36/NN	prep_of||history-33/NN||inflammation-38/NN	conj_and||fibrosis-36/NN||inflammation-38/NN	amod||mechanisms-46/NNS||particular-42/JJ	amod||mechanisms-46/NNS||correlate-44/JJ	amod||mechanisms-46/NNS||basic-45/JJ	prep_in||help-27/VB||mechanisms-46/NNS	amod||outcomes-49/NNS||clinical-48/JJ	prep_to||help-27/VB||outcomes-49/NNS	paraffin-19||fibrosis-36||no_rel||the possibility of extracting rna and measuring rna expression from paraffin sections can allow extensive investigations on stored paraffin samples obtained from diseased livers and could help with studies of the natural history of liver fibrosis and inflammation, and in particular, correlate basic mechanisms to clinical outcomes.
det||epidemic-2/NN||the-1/DT	nsubj||emerged-9/VBN||epidemic-2/NN	nsubj||alleviate-11/VB||epidemic-2/NN	nsubj||brought-14/VBN||epidemic-2/NN	prep_of||epidemic-2/NN||hiv/aids-4/NNS	prep_of||epidemic-2/NN||treatments-6/NNS	conj_and||hiv/aids-4/NNS||treatments-6/NNS	aux||emerged-9/VBN||have-8/VBP	rcmod||epidemic-2/NN||emerged-9/VBN	aux||alleviate-11/VB||to-10/TO	xcomp||emerged-9/VBN||alleviate-11/VB	aux||brought-14/VBN||have-13/VBP	root||ROOT-0/null||brought-14/VBN	det||shift-17/NN||a-16/DT	prep_about||brought-14/VBN||shift-17/NN	det||burden-20/NN||the-19/DT	prep_in||shift-17/NN||burden-20/NN	prep_of||burden-20/NN||disease-22/NN	prep_from||brought-14/VBN||death-24/NN	prep_to||brought-14/VBN||quality-26/NN	prep_of||quality-26/NN||life/disability-28/NN	aids--1||hiv--1||no||the epidemic of hiv/aids and treatments that have emerged to alleviate, have brought about a shift in the burden of disease from death to quality of life/disability.
det||evolution-3/NN||the-1/DT	amod||evolution-3/NN||continuous-2/JJ	nsubjpass||defined-30/VBN||evolution-3/NN	det||results-10/NNS||the-5/DT	advmod||pathogenic-7/JJ||highly-6/RB	amod||results-10/NNS||pathogenic-7/JJ	amod||results-10/NNS||h5n1-8/JJ	amod||results-10/NNS||influenzaviruses-9/JJ	prep_of||evolution-3/NN||results-10/NNS	det||emergence-13/NN||the-12/DT	prep_in||results-10/NNS||emergence-13/NN	amod||variations-18/NNS||natural-15/JJ	amod||variations-18/NNS||na-16/JJ	nn||variations-18/NNS||gene-17/NN	prep_of||emergence-13/NN||variations-18/NNS	poss||impact-20/NN||variations-18/NNS	dep||on-21/IN||impact-20/NN	rcmod||variations-18/NNS||on-21/IN	amod||fitness-23/NN||viral-22/JJ	pobj||on-21/IN||fitness-23/NN	aux||inhibitor-26/VB||na-25/TO	rcmod||variations-18/NNS||inhibitor-26/VB	conj_and||on-21/IN||inhibitor-26/VB	advmod||inhibitor-26/VB||susceptibility-27/RB	auxpass||defined-30/VBN||are-28/VBP	advmod||defined-30/VBN||poorly-29/RB	root||ROOT-0/null||defined-30/VBN	h5n1-8||influenzaviruses-9||no||the continuous evolution of the highly pathogenic h5n1 influenzaviruses results in the emergence of natural na gene variations whose impact on viral fitness and na inhibitor susceptibility are poorly defined.
amod||lamivudine-2/NN||prophylactic-1/JJ	nsubj||reduced-4/VBD||lamivudine-2/NN	advmod||reduced-4/VBD||significantly-3/RB	root||ROOT-0/null||reduced-4/VBD	det||incidence-6/NN||the-5/DT	dobj||reduced-4/VBD||incidence-6/NN	dobj||reduced-4/VBD||severity-8/NN	conj_and||incidence-6/NN||severity-8/NN	nn||reactivation-11/NN||hbv-10/NN	prep_of||incidence-6/NN||reactivation-11/NN	nn||patients-15/NNS||breast-13/NN	nn||patients-15/NNS||cancer-14/NN	prep_in||reduced-4/VBD||patients-15/NNS	vmod||patients-15/NNS||undergoing-16/VBG	amod||adjuvant-18/NN||anthracycline-based-17/JJ	dobj||undergoing-16/VBG||adjuvant-18/NN	advmod||undergoing-16/VBG||chemotherapy-19/RB	hbv-10||lamivudine-2||yes||prophylactic lamivudine significantly reduced the incidence and severity of hbv reactivation in breast cancer patients undergoing anthracycline-based adjuvant chemotherapy.
aux||assess-2/VB||to-1/TO	root||ROOT-0/null||assess-2/VB	nn||discomfort-4/NN||ocular-3/NN	dobj||assess-2/VB||discomfort-4/NN	prep_upon||assess-2/VB||instillation-6/NN	amod||preference-9/NN||patient-8/JJ	prep_upon||assess-2/VB||preference-9/NN	conj_and||instillation-6/NN||preference-9/NN	prep_for||preference-9/NN||brinzolamide/timolol-11/NN	amod||dorzolamide/timolol-14/JJ||relative-12/JJ	dep||dorzolamide/timolol-14/JJ||to-13/TO	amod||preference-9/NN||dorzolamide/timolol-14/JJ	prep_in||preference-9/NN||patients-17/NNS	prep_with||patients-17/NNS||open-angleglaucoma-19/NN	prep_with||patients-17/NNS||ocularhypertension-21/NN	conj_or||open-angleglaucoma-19/NN||ocularhypertension-21/NN	open-angleglaucoma-19||dorzolamide--1||yes||to assess ocular discomfort upon instillation and patient preference for brinzolamide/timolol relative to dorzolamide/timolol, in patients with open-angleglaucoma or ocularhypertension.
nsubj||control-57/VBP||aims-1/NNS	aux||compare-3/VB||to-2/TO	vmod||aims-1/NNS||compare-3/VB	num||approaches-6/NNS||two-4/CD	amod||approaches-6/NNS||progressive-5/JJ	dobj||compare-3/VB||approaches-6/NNS	iobj||compare-3/VB||approaches-6/NNS	amod||insulinglargine-9/NN||-lsb--7/JJ	amod||insulinglargine-9/NN||once-daily-8/JJ	dep||approaches-6/NNS||insulinglargine-9/NN	amod||approaches-6/NNS||plus-10/IN	nn||+-19/NNS||â-11/NNP	nn||+-19/NNS||-12/NNP	amod||+-19/NNS||$-13/$	number||$-13/$||3-14/CD	dep||$-13/$||mealtime-15/JJ	amod||+-19/NNS||lispro-16/JJ	amod||+-19/NNS||-lrb--17/JJ	nn||+-19/NNS||g-18/NN	dep||approaches-6/NNS||+-19/NNS	nn||-rrb--21/NNP||l-20/NNP	dep||+-19/NNS||-rrb--21/NNP	nn||-rrb--28/NNP||insulinlispro-23/NN	nn||-rrb--28/NNP||mix-24/NN	nn||-rrb--28/NNP||50/50-25/NNP	nn||-rrb--28/NNP||-lrb--26/NNP	nn||-rrb--28/NNP||lm50/50-27/NNPS	prep_vs.||-rrb--21/NNP||-rrb--28/NNP	dep||-rrb--21/NNP||progression-29/VBN	advmod||up-31/RB||once-30/RB	advmod||progression-29/VBN||up-31/RB	aux||thrice-33/VB||to-32/TO	xcomp||progression-29/VBN||thrice-33/VB	amod||progression-37/NN||daily-34/JJ	amod||progression-37/NN||-lrb--35/JJ	nn||progression-37/NN||premix-36/NN	dobj||thrice-33/VB||progression-37/NN	nn||-rsb--41/NNP||pp-39/NNP	nn||-rsb--41/NNP||-rrb--40/NNP	appos||progression-37/NN||-rsb--41/NNP	prepc_of||-rsb--41/NNP||beginning-43/VBG	prepc_of||-rsb--41/NNP||advancing-45/VBG	conj_and||beginning-43/VBG||advancing-45/VBG	dobj||beginning-43/VBG||insulin-46/NN	prep_in||beginning-43/VBG||patients-48/NNS	amod||-rrb--53/NNS||type2diabetes-50/JJ	amod||-rrb--53/NNS||-lrb--51/JJ	amod||-rrb--53/NNS||t2d-52/JJ	prep_with||patients-48/NNS||-rrb--53/NNS	amod||glycaemic-56/JJ||inadequate-55/JJ	dep||-rrb--21/NNP||glycaemic-56/JJ	conj_and||progression-29/VBN||glycaemic-56/JJ	root||ROOT-0/null||control-57/VBP	amod||therapy-60/NN||oral-59/JJ	prep_on||control-57/VBP||therapy-60/NN	det||aim-64/NN||the-63/DT	prep_with||control-57/VBP||aim-64/NN	prepc_of||aim-64/NN||showing-66/VBG	dobj||showing-66/VBG||non-inferiority-67/NN	prep_of||non-inferiority-67/NN||pp-69/NN	prep_to||showing-66/VBG||g-71/NN	amod||l-73/NN||+-72/JJ	dobj||control-57/VBP||l-73/NN	t2d-52||insulinlispro-23||yes||aims to compare two progressive approaches -lsb- once-daily insulinglargine plus â  $ 3 mealtime lispro -lrb- g+l -rrb- vs. insulinlispro mix 50/50 -lrb- lm50/50 -rrb- progression once up to thrice daily -lrb- premix progression , pp -rrb- -rsb- of beginning and advancing insulin in patients with type2diabetes -lrb- t2d -rrb- and inadequate glycaemic control on oral therapy , with the aim of showing non-inferiority of pp to g+l .
amod||exposure-2/NN||fetal-infant-1/JJ	nsubjpass||associated-6/VBN||exposure-2/NN	prep_to||exposure-2/NN||famine-4/NN	auxpass||associated-6/VBN||was-5/VBD	root||ROOT-0/null||associated-6/VBN	amod||systolic-9/NN||elevated-8/JJ	prep_with||associated-6/VBN||systolic-9/NN	num||mmhg-12/NN||+7-11/CD	dep||systolic-9/NN||mmhg-12/NN	dep||mmhg-12/NN||p-14/NN	dep||0.001-16/CD||<-15/SYM	rcmod||p-14/NN||0.001-16/CD	amod||bp-28/NN||diastolic-19/JJ	num||mmhg-22/NN||+5-21/CD	dep||bp-28/NN||mmhg-22/NN	dep||mmhg-22/NN||p-24/NN	dep||0.001-26/CD||<-25/SYM	rcmod||p-24/NN||0.001-26/CD	prep_with||associated-6/VBN||bp-28/NN	conj_and||systolic-9/NN||bp-28/NN	amod||p-glucose-31/JJ||increased-30/JJ	appos||bp-28/NN||p-glucose-31/JJ	num||mmol/l-34/NN||+0.3-33/CD	dep||p-glucose-31/JJ||mmol/l-34/NN	dep||mmol/l-34/NN||p-36/NN	dep||0.05-38/CD||<-37/SYM	rcmod||p-36/NN||0.05-38/CD	amod||circumference-42/NN||waist-41/JJ	appos||bp-28/NN||circumference-42/NN	conj_and||p-glucose-31/JJ||circumference-42/NN	num||cm-45/NN||+3-44/CD	dep||circumference-42/NN||cm-45/NN	advmod||cm-45/NN||p-47/RB	num||0.001-49/CD||<-48/CD	pobj||p-47/RB||0.001-49/CD	amod||risk-53/NN||increased-52/VBN	appos||bp-28/NN||risk-53/NN	amod||hypertension-56/NN||systolic-55/JJ	prep_of||risk-53/NN||hypertension-56/NN	dep||risk-53/NN||adjusted-58/VBN	cc||2.87-60/CD||or-59/CC	dobj||adjusted-58/VBN||2.87-60/CD	number||%-63/NN||95-62/CD	amod||â-66/NNS||%-63/NN	amod||â-66/NNS||ci-64/JJ	num||â-66/NNS||1.90-65/CD	dep||2.87-60/CD||â-66/NNS	num||â-66/NNS||$-67/$	num||$-67/$||4.34-69/CD	appos||bp-28/NN||igt-72/NN	cc||ci-79/VBP||or-74/CC	nsubj||ci-79/VBP||1.65-75/CD	num||%-78/NN||95-77/CD	dep||1.65-75/CD||%-78/NN	dep||igt-72/NN||ci-79/VBP	num||â-81/NNS||1.02-80/CD	dobj||ci-79/VBP||â-81/NNS	num||â-81/NNS||$-82/$	num||$-82/$||2.69-84/CD	npadvmod||as-101/RB||overweight-87/NN	cc||1.41-90/CD||or-89/CC	dep||overweight-87/NN||1.41-90/CD	num||%-93/NN||95-92/CD	dep||1.41-90/CD||%-93/NN	nn||â-96/FW||ci-94/FW	nn||â-96/FW||1.03-95/FW	dep||%-93/NN||â-96/FW	dep||â-96/FW||$-97/$	num||$-97/$||1.93-99/CD	conj_and||associated-6/VBN||as-101/RB	prepc_compared_to||as-101/RB||to-103/TO	pobj||as-101/RB||people-104/NNS	vmod||people-104/NNS||born-105/VBN	det||famine-108/NN||the-107/DT	prep_after||born-105/VBN||famine-108/NN	hypertension-56||glucose--1||no_rel||fetal-infant exposure to famine was associated with elevated systolic (+7 mmhg; p<0.001) and diastolic (+5 mmhg; p<0.001) bp, increased p-glucose (+0.3 mmol/l; p<0.05) and waist circumference (+3cm, p<0.001), increased risk of systolic hypertension (adjusted or 2.87; 95% ci 1.90â4.34), igt (or 1.65; 95% ci 1.02â2.69) and overweight (or 1.41; 95% ci 1.03â1.93) as compared to people born after the famine.
advmod||become-23/VBN||recently-1/RB	det||association-4/NN||the-3/DT	nsubj||become-23/VBN||association-4/NN	amod||therapy-7/NN||antineoplastic-6/JJ	prep_between||association-4/NN||therapy-7/NN	nn||difficile-10/NN||c.-9/NN	prep_between||association-4/NN||difficile-10/NN	conj_and||therapy-7/NN||difficile-10/NN	amod||diarrhea-13/NN||associated-12/VBN	dep||therapy-7/NN||diarrhea-13/NN	det||absence-16/NN||the-15/DT	prep_in||diarrhea-13/NN||absence-16/NN	det||therapy-21/NN||a-18/DT	amod||therapy-21/NN||prior-19/JJ	amod||therapy-21/NN||antibiotic-20/JJ	prep_of||absence-16/NN||therapy-21/NN	aux||become-23/VBN||has-22/VBZ	root||ROOT-0/null||become-23/VBN	advmod||apparent-25/JJ||more-24/RBR	acomp||become-23/VBN||apparent-25/JJ	diarrhea-13||antibiotic-20||no_rel||recently , the association between antineoplastic therapy and c. difficile - associated diarrhea in the absence of a prior antibiotic therapy has become more apparent .
nn||patients-2/NNS||patients-1/NNS	nsubj||carvedilol-naive-4/JJ||patients-2/NNS	nsubj||had-6/VBD||patients-2/NNS	cop||carvedilol-naive-4/JJ||were-3/VBD	root||ROOT-0/null||carvedilol-naive-4/JJ	conj_and||carvedilol-naive-4/JJ||had-6/VBD	amod||hypertension-8/NN||essential-7/JJ	dobj||had-6/VBD||hypertension-8/NN	amod||hypertension-12/NN||renal-10/JJ	amod||hypertension-12/NN||parenchymal-11/JJ	dobj||had-6/VBD||hypertension-12/NN	conj_or||hypertension-8/NN||hypertension-12/NN	hypertension-12||carvedilol--1||yes||patients patients were carvedilol-naive and had essential hypertension or renal parenchymal hypertension.
det||immunofluorometric-8/NN||a-1/DT	advmod||specific-3/JJ||highly-2/RB	amod||immunofluorometric-8/NN||specific-3/JJ	conj_and||specific-3/JJ||novel-5/JJ	amod||immunofluorometric-8/NN||novel-5/JJ	amod||immunofluorometric-8/NN||dual-label-6/JJ	amod||immunofluorometric-8/NN||time-resolved-7/JJ	nsubjpass||developed-11/VBN||immunofluorometric-8/NN	advmod||developed-11/VBN||assay-9/RB	auxpass||developed-11/VBN||was-10/VBD	root||ROOT-0/null||developed-11/VBN	xcomp||developed-11/VBN||exploiting-12/VBG	det||wavelengths-16/NNS||the-13/DT	amod||wavelengths-16/NNS||unique-14/JJ	nn||wavelengths-16/NNS||emission-15/NN	dobj||exploiting-12/VBG||wavelengths-16/NNS	det||terbium-21/NN||the-18/DT	amod||terbium-21/NN||intrinsically-19/JJ	amod||terbium-21/NN||fluorescent-20/JJ	prep_of||wavelengths-16/NNS||terbium-21/NN	num||+-24/NNS||tb3-23/CD	appos||terbium-21/NN||+-24/NNS	amod||tracers-32/NNS||europium-27/JJ	num||+-30/NNS||eu3-29/CD	appos||tracers-32/NNS||+-30/NNS	conj_and||developed-11/VBN||tracers-32/NNS	dep||tracers-32/NNS||for-33/IN	det||detection-36/NN||the-34/DT	amod||detection-36/NN||simultaneous-35/JJ	pobj||for-33/IN||detection-36/NN	prep_of||detection-36/NN||humanimmunodeficiencyvirus-38/NNS	num||humanimmunodeficiencyvirus-38/NNS||1-39/CD	dep||humanimmunodeficiencyvirus-38/NNS||hiv-1-41/JJ	pobj||for-33/IN||hepatitisbvirus-44/NNS	conj_and||detection-36/NN||hepatitisbvirus-44/NNS	appos||hepatitisbvirus-44/NNS||hbv-46/NN	dep||hepatitisbvirus-44/NNS||infections-48/NNS	advmod||tracers-32/NNS||respectively-50/RB	hbv-46||hepatitisbvirus-44||no||a highly specific and novel dual-label time-resolved immunofluorometric assay was developed exploiting the unique emission wavelengths of the intrinsically fluorescent terbium (tb3+) and europium (eu3+) tracers for the simultaneous detection of humanimmunodeficiencyvirus 1 (hiv-1) and hepatitisbvirus (hbv) infections, respectively.
nsubj||demonstrated-2/VBD||we-1/PRP	root||ROOT-0/null||demonstrated-2/VBD	mark||inhibited-7/VBN||that-3/IN	nsubjpass||inhibited-7/VBN||hivinfection-4/NN	aux||inhibited-7/VBN||could-5/MD	auxpass||inhibited-7/VBN||be-6/VB	ccomp||demonstrated-2/VBD||inhibited-7/VBN	xcomp||inhibited-7/VBN||using-8/VBG	det||strategy-10/NN||a-9/DT	dobj||using-8/VBG||strategy-10/NN	vmod||strategy-10/NN||aimed-11/VBN	amod||interactions-15/NNS||hiv-specific-13/JJ	amod||interactions-15/NNS||molecular-14/JJ	prep_at||aimed-11/VBN||interactions-15/NNS	nn||display-20/NN||caulobacter-17/NN	nn||display-20/NN||surface-18/NN	nn||display-20/NN||protein-19/NN	prep_with||interactions-15/NNS||display-20/NN	mark||mimicked-31/VBN||that-23/IN	amod||folding-26/NN||sufficient-24/JJ	nn||folding-26/NN||protein-25/NN	nsubjpass||mimicked-31/VBN||folding-26/NN	conj_and||folding-26/NN||conformation-28/NN	nsubjpass||mimicked-31/VBN||conformation-28/NN	aux||mimicked-31/VBN||could-29/MD	auxpass||mimicked-31/VBN||be-30/VB	ccomp||demonstrated-2/VBD||mimicked-31/VBN	conj_and||inhibited-7/VBN||mimicked-31/VBN	nn||entry-36/NN||bind-33/NN	conj_and||bind-33/NN||block-35/NN	nn||entry-36/NN||block-35/NN	prep_to||mimicked-31/VBN||entry-36/NN	hivinfection-4||hiv--1||no||we demonstrated that hivinfection could be inhibited using a strategy aimed at hiv-specific molecular interactions with caulobacter surface protein display, and that sufficient protein folding and conformation could be mimicked to bind and block entry.
nsubjpass||complicated-14/VBN||treatment-1/NN	nn||patients-4/NNS||cancer-3/NN	prep_of||treatment-1/NN||patients-4/NNS	amod||doxorubicin-8/NN||anthracycline-6/JJ	amod||doxorubicin-8/NN||antibiotic-7/JJ	prep_with||patients-4/NNS||doxorubicin-8/NN	appos||treatment-1/NN||dox-10/NN	aux||complicated-14/VBN||may-12/MD	auxpass||complicated-14/VBN||be-13/VB	root||ROOT-0/null||complicated-14/VBN	agent||complicated-14/VBN||development-16/NN	amod||congestiveheartfailure-21/NN||acute-18/JJ	conj_and||acute-18/JJ||chronic-20/JJ	amod||congestiveheartfailure-21/NN||chronic-20/JJ	prep_of||development-16/NN||congestiveheartfailure-21/NN	appos||congestiveheartfailure-21/NN||chf-23/NN	amod||arrhythmias-27/NNS||malignant-26/JJ	prep_of||development-16/NN||arrhythmias-27/NNS	conj_and||congestiveheartfailure-21/NN||arrhythmias-27/NNS	prep_of||development-16/NN||death-29/NN	conj_and||congestiveheartfailure-21/NN||death-29/NN	chf-23||dox-10||no||treatment of cancer patients with anthracycline antibiotic doxorubicin (dox) may be complicated by development of acute and chronic congestiveheartfailure (chf), malignant arrhythmias and death.
mark||detect-4/VB||in-1/IN	dep||detect-4/VB||order-2/NN	aux||detect-4/VB||to-3/TO	advcl||developed-17/VBD||detect-4/VB	amod||igm-6/NN||anti-hav-5/JJ	dobj||detect-4/VB||igm-6/NN	det||serum-9/NN||the-8/DT	prep_in||detect-4/VB||serum-9/NN	prep_of||serum-9/NN||patients-11/NNS	vmod||patients-11/NNS||infected-12/VBN	prep_with||infected-12/VBN||hav-14/NN	nsubj||developed-17/VBD||we-16/PRP	root||ROOT-0/null||developed-17/VBD	det||assay-20/NN||a-18/DT	amod||assay-20/NN||rapid-19/JJ	dobj||developed-17/VBD||assay-20/NN	prep_based_on||assay-20/NN||immunochromatography-23/NN	appos||immunochromatography-23/NN||ica-25/NN	dobj||developed-17/VBD||evaluated-28/VBN	conj_and||assay-20/NN||evaluated-28/VBN	det||sensitivity-30/NN||the-29/DT	dobj||evaluated-28/VBN||sensitivity-30/NN	det||immunoassay-42/NN||this-32/DT	amod||immunoassay-42/NN||assay-33/JJ	prepc_by||assay-33/JJ||comparing-35/VBG	dobj||comparing-35/VBG||it-36/PRP	det||microparticle-40/NN||a-38/DT	amod||microparticle-40/NN||commercial-39/JJ	prep_with||comparing-35/VBG||microparticle-40/NN	amod||immunoassay-42/NN||enzyme-41/JJ	prep_of||sensitivity-30/NN||immunoassay-42/NN	appos||immunoassay-42/NN||meia-44/NNP	nsubjpass||used-49/VBN||that-46/WDT	auxpass||used-49/VBN||is-47/VBZ	advmod||used-49/VBN||widely-48/RB	ccomp||immunoassay-42/NN||used-49/VBN	amod||diagnosis-52/NN||serological-51/JJ	prep_for||used-49/VBN||diagnosis-52/NN	enzyme-41||hav-14||no_rel||in order to detect anti-hav igm in the serum of patients infected with hav, we developed a rapid assay based on immunochromatography (ica) and evaluated the sensitivity of this assay by comparing it with a commercial microparticle enzyme immunoassay (meia) that is widely used for serological diagnosis.
mark||cause-7/NN||although-1/IN	nsubj||cause-7/NN||alcoholabuse-2/NN	cop||cause-7/NN||is-3/VBZ	det||cause-7/NN||the-4/DT	advmod||common-6/JJ||most-5/RBS	amod||cause-7/NN||common-6/JJ	advcl||related-30/VBD||cause-7/NN	prep_of||cause-7/NN||livercirrhosis-9/NNS	det||states-13/NNS||the-11/DT	amod||states-13/NNS||united-12/VBN	prep_in||livercirrhosis-9/NNS||states-13/NNS	det||effects-17/NNS||the-15/DT	amod||effects-17/NNS||enhancing-16/JJ	nsubj||related-30/VBD||effects-17/NNS	prep_of||effects-17/NNS||alcohol-19/NN	det||prognosis-23/NN||the-21/DT	amod||prognosis-23/NN||long-term-22/JJ	prep_on||alcohol-19/NN||prognosis-23/NN	amod||virus-26/NN||hepatitisc-25/JJ	prep_of||prognosis-23/NN||virus-26/NN	appos||virus-26/NN||hcv-28/NN	root||ROOT-0/null||related-30/VBD	nsubjpass||clarified-35/VBN||livercirrhosis-31/NNS	aux||clarified-35/VBN||has-32/VBZ	neg||clarified-35/VBN||not-33/RB	auxpass||clarified-35/VBN||been-34/VBN	ccomp||related-30/VBD||clarified-35/VBN	alcohol-19||alcoholabuse-2||no_rel||although alcoholabuse is the most common cause of livercirrhosis in the united states, the enhancing effects of alcohol on the long-term prognosis of hepatitisc virus (hcv) related livercirrhosis has not been clarified.
det||activity-5/NN||the-1/DT	dep||vitro-3/NN||in-2/IN	amod||activity-5/NN||vitro-3/NN	amod||activity-5/NN||anticandidal-4/JJ	nsubj||racemosus-8/VBZ||activity-5/NN	prep_of||activity-5/NN||asparagus-7/NNS	dep||investigated-14/VBN||racemosus-8/VBZ	nsubj||extract-12/VB||roots-9/NNS	conj_and||roots-9/NNS||tubers-11/NNS	nsubj||extract-12/VB||tubers-11/NNS	ccomp||racemosus-8/VBZ||extract-12/VB	auxpass||investigated-14/VBN||was-13/VBD	root||ROOT-0/null||investigated-14/VBN	prep_against||investigated-14/VBN||candidaalbicans-16/NNS	nn||tropicalis-19/NNS||candida-18/NN	prep_against||investigated-14/VBN||tropicalis-19/NNS	conj_and||candidaalbicans-16/NNS||tropicalis-19/NNS	nn||krusei-22/NNS||candida-21/NN	prep_against||investigated-14/VBN||krusei-22/NNS	conj_and||candidaalbicans-16/NNS||krusei-22/NNS	nn||guillermondii-25/NNS||candida-24/NN	prep_against||investigated-14/VBN||guillermondii-25/NNS	conj_and||candidaalbicans-16/NNS||guillermondii-25/NNS	nn||parapsilosis-28/NNS||candida-27/NN	prep_against||investigated-14/VBN||parapsilosis-28/NNS	conj_and||candidaalbicans-16/NNS||parapsilosis-28/NNS	prep_against||investigated-14/VBN||candida-30/NN	conj_and||candidaalbicans-16/NNS||candida-30/NN	nsubjpass||investigated-14/VBN||stellatoida-31/NN	nsubjpass||isolated-35/VBN||stellatoida-31/NN	auxpass||isolated-35/VBN||are-34/VBP	rcmod||stellatoida-31/NN||isolated-35/VBN	amod||patients-38/NNS||vaginalthrush-37/JJ	prep_from||isolated-35/VBN||patients-38/NNS	vaginalthrush-37||candida-30||no||the in vitro anticandidal activity of asparagus racemosus roots and tubers extract was investigated against candidaalbicans, candida tropicalis, candida krusei, candida guillermondii, candida parapsilosis and candida stellatoida, which are isolated from vaginalthrush patients.
nn||c75-4/NNP||resultsâ-1/NNP	nn||c75-4/NNP||$-2/NNP	nsubj||increased-7/VBD||c75-4/NNP	conj_and||c75-4/NNP||cerulenin-6/NN	nsubj||increased-7/VBD||cerulenin-6/NN	root||ROOT-0/null||increased-7/VBD	dobj||increased-7/VBD||phosphorylation-8/NN	prep_of||phosphorylation-8/NN||s6k1-10/NNS	prep_of||phosphorylation-8/NN||s6-12/NNS	conj_and||s6k1-10/NNS||s6-12/NNS	poss||action-17/NN||their-15/PRP$	amod||action-17/NN||anorexic-16/JJ	nsubjpass||reduced-19/VBN||action-17/NN	auxpass||reduced-19/VBN||was-18/VBD	conj_and||increased-7/VBD||reduced-19/VBN	amod||rats-22/NNS||rapamycin-treated-21/JJ	prep_in||reduced-19/VBN||rats-22/NNS	amod||â-26/NN||s6k1-25/JJ	poss||mice-31/NNS||â-26/NN	num||mice-31/NNS||/-28/CD	nn||mice-31/NNS||â-29/NN	prep_in||reduced-19/VBN||mice-31/NNS	conj_and||rats-22/NNS||mice-31/NNS	anorexic-16||rapamycin--1||no_rel||resultsâ c75 and cerulenin increased phosphorylation of s6k1 and s6, and their anorexic action was reduced in rapamycin-treated rats and in s6k1 â/â mice.
nsubj||antiemeticdrug-6/NN||ondansetronhydrochloride-1/NN	cop||antiemeticdrug-6/NN||is-2/VBZ	det||antiemeticdrug-6/NN||an-3/DT	advmod||bitter-5/JJ||intensely-4/RB	amod||antiemeticdrug-6/NN||bitter-5/JJ	root||ROOT-0/null||antiemeticdrug-6/NN	vmod||antiemeticdrug-6/NN||used-7/VBN	aux||treat-9/VB||to-8/TO	xcomp||used-7/VBN||treat-9/VB	dobj||treat-9/VB||nausea-10/NN	dobj||treat-9/VB||vomiting-12/NN	conj_and||nausea-10/NN||vomiting-12/NN	prep_following||nausea-10/NN||chemotherapy-14/NN	antiemeticdrug-6||nausea-10||no_rel||ondansetronhydrochloride is an intensely bitter antiemeticdrug used to treat nausea and vomiting following chemotherapy.
amod||studies-2/NNS||recent-1/JJ	nsubj||suggest-3/VBP||studies-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||plays-10/VBZ||that-4/IN	det||induction-6/NN||the-5/DT	nsubj||plays-10/VBZ||induction-6/NN	amod||expression-9/NN||ho-1-8/JJ	prep_of||induction-6/NN||expression-9/NN	ccomp||suggest-3/VBP||plays-10/VBZ	det||role-14/NN||a-11/DT	amod||role-14/NN||critical-12/JJ	amod||role-14/NN||protective-13/JJ	dobj||plays-10/VBZ||role-14/NN	amod||models-18/NNS||intestinal-16/JJ	nn||models-18/NNS||damage-17/NN	prep_in||plays-10/VBZ||models-18/NNS	vmod||models-18/NNS||induced-19/VBN	agent||induced-19/VBN||ischemia-reperfusion-21/NN	agent||induced-19/VBN||indomethacin-23/NN	conj_and||ischemia-reperfusion-21/NN||indomethacin-23/NN	amod||sepsis-26/NN||lipopolysaccharide-associated-25/JJ	agent||induced-19/VBN||sepsis-26/NN	conj_and||ischemia-reperfusion-21/NN||sepsis-26/NN	amod||acid-30/NN||trinitrobenzene-28/JJ	amod||acid-30/NN||sulfonic-29/JJ	agent||induced-19/VBN||acid-30/NN	conj_and||ischemia-reperfusion-21/NN||acid-30/NN	nn||sodium-35/NN||dextran-33/NN	nn||sodium-35/NN||sulfate-34/NN	agent||induced-19/VBN||sodium-35/NN	conj_and||ischemia-reperfusion-21/NN||sodium-35/NN	vmod||plays-10/VBZ||indicating-37/VBG	mark||act-43/VB||that-38/IN	nsubj||act-43/VB||activation-39/NN	nsubj||reduce-50/VB||activation-39/NN	prep_of||activation-39/NN||ho-1-41/CD	aux||act-43/VB||may-42/MD	ccomp||indicating-37/VBG||act-43/VB	det||mechanism-48/NN||an-45/DT	amod||mechanism-48/NN||endogenous-46/JJ	amod||mechanism-48/NN||defensive-47/JJ	prep_as||act-43/VB||mechanism-48/NN	aux||reduce-50/VB||to-49/TO	xcomp||act-43/VB||reduce-50/VB	nn||injury-54/NN||inflammation-51/NN	conj_and||inflammation-51/NN||tissue-53/NN	nn||injury-54/NN||tissue-53/NN	dobj||reduce-50/VB||injury-54/NN	det||tract-58/NN||the-56/DT	amod||tract-58/NN||gastrointestinal-57/JJ	prep_in||reduce-50/VB||tract-58/NN	indomethacin-23||inflammation-51||no_rel||recent studies suggest that the induction of ho-1 expression plays a critical protective role in intestinal damage models induced by ischemia-reperfusion, indomethacin, lipopolysaccharide-associated sepsis, trinitrobenzene sulfonic acid, and dextran sulfate sodium, indicating that activation of ho-1 may act as an endogenous defensive mechanism to reduce inflammation and tissue injury in the gastrointestinal tract.
mark||understand-5/VB||in-1/IN	dep||understand-5/VB||order-2/NN	aux||understand-5/VB||to-3/TO	advmod||understand-5/VB||better-4/RBR	advcl||examined-21/VBD||understand-5/VB	det||situation-8/NN||the-6/DT	amod||situation-8/NN||current-7/JJ	dobj||understand-5/VB||situation-8/NN	aux||explore-11/VB||to-10/TO	conj_and||understand-5/VB||explore-11/VB	advcl||examined-21/VBD||explore-11/VB	amod||strategies-13/NNS||possible-12/JJ	dobj||explore-11/VB||strategies-13/NNS	aux||support-15/VB||to-14/TO	vmod||explore-11/VB||support-15/VB	amod||children-17/NNS||hiv-affected-16/JJ	dobj||support-15/VB||children-17/NNS	det||study-20/NN||this-19/DT	nsubj||examined-21/VBD||study-20/NN	nsubj||aids-28/VBZ||study-20/NN	root||ROOT-0/null||examined-21/VBD	poss||attitudes-24/NNS||children-22/NNS	dobj||examined-21/VBD||attitudes-24/NNS	prep_towards||examined-21/VBD||hiv-26/NN	conj_and||examined-21/VBD||aids-28/VBZ	xcomp||aids-28/VBZ||using-29/VBG	dobj||using-29/VBG||questionnaires-30/NNS	nn||discussions-34/NNS||focus-32/NN	nn||discussions-34/NNS||group-33/NN	dobj||using-29/VBG||discussions-34/NNS	conj_and||questionnaires-30/NNS||discussions-34/NNS	prep_with||using-29/VBG||children-36/NNS	prep_in||children-36/NNS||grades-38/NNS	vmod||grades-38/NNS||three-six-39/VBN	num||schools-43/NNS||five-41/CD	amod||schools-43/NNS||primary-42/JJ	prep_in||three-six-39/VBN||schools-43/NNS	det||province-47/NN||a-45/DT	amod||province-47/NN||northern-46/JJ	prep_in||schools-43/NNS||province-47/NN	prep_in||province-47/NN||thailand-49/NN	aids-28||hiv-26||no||in order to better understand the current situation and to explore possible strategies to support hiv-affected children, this study examined children's attitudes towards hiv and aids using questionnaires and focus group discussions with children in grades three-six in five primary schools in a northern province in thailand.
det||propagation-2/NN||the-1/DT	nsubj||requires-17/VBZ||propagation-2/NN	prep_of||propagation-2/NN||prions-4/NNS	det||agents-8/NNS||the-6/DT	amod||agents-8/NNS||causative-7/JJ	appos||propagation-2/NN||agents-8/NNS	amod||disease-11/NN||creutzfeldt-jakob-10/JJ	prep_of||agents-8/NNS||disease-11/NN	amod||priondiseases-15/NNS||other-13/JJ	amod||priondiseases-15/NNS||human-14/JJ	prep_of||agents-8/NNS||priondiseases-15/NNS	conj_and||disease-11/NN||priondiseases-15/NNS	root||ROOT-0/null||requires-17/VBZ	amod||conversion-19/NN||post-translational-18/JJ	dobj||requires-17/VBZ||conversion-19/NN	amod||prionprotein-23/NN||normal-21/JJ	amod||prionprotein-23/NN||cellular-22/JJ	prep_of||conversion-19/NN||prionprotein-23/NN	amod||forms-26/NNS||disease-associated-25/JJ	prep_to||requires-17/VBZ||forms-26/NNS	priondiseases-15||prionprotein-23||no||the propagation of prions, the causative agents of creutzfeldt-jakob disease and other human priondiseases, requires post-translational conversion of normal cellular prionprotein to disease-associated forms.
det||comparison-3/NN||the-2/DT	prep_in||received-16/VBD||comparison-3/NN	amod||individuals-6/NNS||insulin-treated-5/JJ	prep_of||comparison-3/NN||individuals-6/NNS	prep_with||individuals-6/NNS||lada-8/NN	prep_with||individuals-6/NNS||type2diabetes-10/NNS	conj_and||lada-8/NN||type2diabetes-10/NNS	amod||patients-13/NNS||more-12/JJR	nsubj||received-16/VBD||patients-13/NNS	prep_with||patients-13/NNS||lada-15/NN	ccomp||p-34/NN||received-16/VBD	iobj||received-16/VBD||insulin-17/NN	number||40-19/CD||-lrb--18/CD	dobj||received-16/VBD||40-19/CD	num||%-22/NN||22-21/CD	prep_vs.||40-19/CD||%-22/NN	nn||-rrb--27/NNP||p-24/NN	nn||-rrb--27/NNP||<-25/NN	num||-rrb--27/NNP||0.001-26/CD	nsubj||p-34/NN||-rrb--27/NNP	amod||levels-30/NNS||c-peptide-29/JJ	conj_and||-rrb--27/NNP||levels-30/NNS	nsubj||p-34/NN||levels-30/NNS	cop||p-34/NN||were-31/VBD	amod||p-34/NN||lower-32/JJR	amod||p-34/NN||-lrb--33/JJ	root||ROOT-0/null||p-34/NN	vmod||p-34/NN||<-35/VBG	num||-rrb--37/NNS||0.001-36/CD	dobj||<-35/VBG||-rrb--37/NNS	type2diabetes-10||insulin-17||yes||in the comparison of insulin-treated individuals with lada and type2diabetes , more patients with lada received insulin -lrb- 40 vs. 22 % , p < 0.001 -rrb- and c-peptide levels were lower -lrb- p < 0.001 -rrb- .
advmod||was-9/VBD||therefore-1/RB	det||aim-5/NN||the-3/DT	amod||aim-5/NN||specific-4/JJ	nsubj||was-9/VBD||aim-5/NN	nsubj||test-11/VB||aim-5/NN	det||study-8/NN||this-7/DT	prep_of||aim-5/NN||study-8/NN	root||ROOT-0/null||was-9/VBD	aux||test-11/VB||to-10/TO	xcomp||was-9/VBD||test-11/VB	det||hypothesis-13/NNS||the-12/DT	dobj||test-11/VB||hypothesis-13/NNS	mark||amplify-22/VB||that-14/IN	amod||use-16/NN||6-week-15/JJ	nsubj||amplify-22/VB||use-16/NN	det||fluoxetine-20/NN||the-18/DT	amod||fluoxetine-20/NN||ssri-19/JJ	prep_of||use-16/NN||fluoxetine-20/NN	aux||amplify-22/VB||would-21/MD	ccomp||test-11/VB||amplify-22/VB	amod||system-25/NN||autonomic-23/JJ	amod||system-25/NN||nervous-24/JJ	dobj||amplify-22/VB||system-25/NN	dep||amplify-22/VB||ans-27/NN	amod||responses-30/NNS||counterregulatory-29/JJ	dobj||amplify-22/VB||responses-30/NNS	prep_to||responses-30/NNS||hypoglycemia-32/NN	prep_in||amplify-22/VB||individuals-34/NNS	prep_with||amplify-22/VB||type1diabetes-36/CD	hypoglycemia-32||ssri-19||no_rel||therefore, the specific aim of this study was to test the hypothesis that 6-week use of the ssri fluoxetine would amplify autonomic nervous system (ans) counterregulatory responses to hypoglycemia in individuals with type1diabetes.
amod||patients-2/NNS||many-1/JJ	nsubj||take-5/VBP||patients-2/NNS	prep_with||patients-2/NNS||osteoarthritis-4/NNS	root||ROOT-0/null||take-5/VBP	amod||term-11/NN||nonsteroidalanti-inflammatorydrugs-6/JJ	nn||term-11/NN||nsaids-8/NN	amod||term-11/NN||long-10/JJ	dobj||take-5/VBP||term-11/NN	nn||control-14/NN||pain-13/NN	prep_for||term-11/NN||control-14/NN	nonsteroidalanti-inflammatorydrugs-6||pain-13||no_rel||many patients with osteoarthritis take nonsteroidalanti-inflammatorydrugs (nsaids) long term for pain control.
advmod||associated-6/VBN||however-1/RB	det||maneuver-4/NN||this-3/DT	nsubjpass||associated-6/VBN||maneuver-4/NN	auxpass||associated-6/VBN||is-5/VBZ	root||ROOT-0/null||associated-6/VBN	amod||injury-12/NN||ischemia/reperfusion-8/JJ	appos||injury-12/NN||i/r-10/NN	prep_with||associated-6/VBN||injury-12/NN	advmod||related-14/VBN||strongly-13/RB	vmod||injury-12/NN||related-14/VBN	aux||oxidative-16/VB||to-15/TO	xcomp||related-14/VBN||oxidative-16/VB	dobj||oxidative-16/VB||stress-17/NN	dobj||oxidative-16/VB||reduction-19/NN	conj_and||stress-17/NN||reduction-19/NN	amod||bioavailability-22/NN||nitricoxide-21/JJ	prep_of||stress-17/NN||bioavailability-22/NN	nitricoxide-21||ischemia--1||no_rel||however, this maneuver is associated with ischemia/reperfusion (i/r) injury strongly related to oxidative stress and reduction of nitricoxide bioavailability.
nsubj||intolerance-5/NN||celiacdisease-1/NN	cop||intolerance-5/NN||is-2/VBZ	det||intolerance-5/NN||a-3/DT	amod||intolerance-5/NN||permanent-4/JJ	root||ROOT-0/null||intolerance-5/NN	det||fraction-9/NN||the-7/DT	nn||fraction-9/NN||gliadin-8/NN	prep_to||intolerance-5/NN||fraction-9/NN	nn||gluten-12/NN||wheat-11/NN	prep_of||fraction-9/NN||gluten-12/NN	amod||barley-16/NN||similar-15/JJ	prep_to||intolerance-5/NN||barley-16/NN	conj_and||fraction-9/NN||barley-16/NN	nsubj||occurs-21/VBZ||barley-16/NN	nn||proteins-19/NNS||rye-18/NN	conj_and||fraction-9/NN||proteins-19/NNS	conj_and||barley-16/NN||proteins-19/NNS	nsubj||occurs-21/VBZ||proteins-19/NNS	rcmod||barley-16/NN||occurs-21/VBZ	advmod||susceptible-24/JJ||genetically-23/RB	amod||subjects-25/NNS||susceptible-24/JJ	prep_in||occurs-21/VBZ||subjects-25/NNS	celiacdisease-1||gluten-12||no||celiacdisease is a permanent intolerance to the gliadin fraction of wheat gluten and to similar barley and rye proteins that occurs in genetically susceptible subjects.
nsubj||received-4/VBD||patients-1/NNS	prep_with||patients-1/NNS||melanoma-3/NN	root||ROOT-0/null||received-4/VBD	amod||2b-7/NNS||ifn-î-5/JJ	amod||2b-7/NNS||±-6/JJ	dobj||received-4/VBD||2b-7/NNS	vmod||2b-7/NNS||administered-8/VBN	advmod||administered-8/VBN||intravenously-9/RB	num||mu/m2-12/NNS||20-11/CD	dep||day-14/NN||mu/m2-12/NNS	det||day-14/NN||each-13/DT	advmod||for-21/IN||day-14/NN	prep_from||day-14/NN||day-16/NN	num||day-16/NN||1-17/CD	prep_to||day-14/NN||day-19/NN	num||day-19/NN||5-20/CD	dep||administered-8/VBN||for-21/IN	num||weeks-24/NNS||4-22/CD	amod||weeks-24/NNS||consecutive-23/JJ	pobj||for-21/IN||weeks-24/NNS	melanoma-3||ifn--1||yes||patients with melanoma received ifn-î± 2b administered intravenously (20 mu/m2 each day from day 1 to day 5 for 4 consecutive weeks).
mark||trigger-9/NN||since-1/IN	nsubj||trigger-9/NN||inflammation-2/NN	amod||fat-5/NN||visceral-4/JJ	prep_of||inflammation-2/NN||fat-5/NN	cop||trigger-9/NN||is-6/VBZ	det||trigger-9/NN||a-7/DT	amod||trigger-9/NN||crucial-8/JJ	advcl||explain-23/VB||trigger-9/NN	prep_of||trigger-9/NN||atherogenesis-11/NNS	amod||fat-15/NN||decreased-13/VBN	amod||fat-15/NN||visceral-14/JJ	appos||atherogenesis-11/NNS||fat-15/NN	amod||±-18/NNS||pgc-1î-17/JJ	prep_in||fat-15/NN||±-18/NNS	nn||mice-21/NNS||deficient-20/NN	nsubj||explain-23/VB||mice-21/NNS	aux||explain-23/VB||may-22/MD	root||ROOT-0/null||explain-23/VB	advmod||develop-29/VB||why-24/WRB	det||mice-26/NNS||these-25/DT	nsubj||develop-29/VB||mice-26/NNS	aux||develop-29/VB||do-27/VBP	neg||develop-29/VB||not-28/RB	advcl||explain-23/VB||develop-29/VB	amod||atherosclerosis-31/NNS||enhanced-30/JJ	dobj||develop-29/VB||atherosclerosis-31/NNS	atherosclerosis-31||fat-15||no_rel||since inflammation of visceral fat is a crucial trigger of atherogenesis, decreased visceral fat in pgc-1î± -deficient mice may explain why these mice do not develop enhanced atherosclerosis.
nsubj||lidocaine-4/VBP||pretreatment-1/NN	prep_with||pretreatment-1/NN||iv-3/NN	root||ROOT-0/null||lidocaine-4/VBP	num||mg-6/NNP||40-5/CD	dobj||lidocaine-4/VBP||mg-6/NNP	nn||mg-10/NNS||ketamine-8/NNP	num||mg-10/NNS||25-9/CD	dobj||lidocaine-4/VBP||mg-10/NNS	conj_plus||mg-6/NNP||mg-10/NNS	det||tourniquet-14/NN||a-12/DT	nn||tourniquet-14/NN||rubber-13/NN	prep_with||lidocaine-4/VBP||tourniquet-14/NN	det||min-19/NN||the-16/DT	nn||min-19/NN||forearm-17/NNP	num||min-19/NN||1-18/CD	prep_on||tourniquet-14/NN||min-19/NN	mark||effective-28/JJ||before-20/IN	det||injection-22/NN||the-21/DT	nsubj||effective-28/JJ||injection-22/NN	nn||propofol-25/NN||microemulsion-24/NN	prep_of||injection-22/NN||propofol-25/NN	cop||effective-28/JJ||is-26/VBZ	advmod||effective-28/JJ||more-27/RBR	advcl||lidocaine-4/VBP||effective-28/JJ	nn||mg-32/NN||lidocaine-30/NN	num||mg-32/NN||40-31/CD	prep_than||effective-28/JJ||mg-32/NN	nn||mg-36/NN||ketamine-34/NN	num||mg-36/NN||25-35/CD	prep_than||effective-28/JJ||mg-36/NN	conj_or||mg-32/NN||mg-36/NN	advmod||effective-28/JJ||alone-37/RB	prepc_in||effective-28/JJ||preventing-39/VBG	dobj||preventing-39/VBG||pain-40/NN	det||injection-43/NN||the-42/DT	prep_from||preventing-39/VBG||injection-43/NN	nn||propofol-46/NN||microemulsion-45/NN	prep_of||injection-43/NN||propofol-46/NN	pain-40||lidocaine-30||yes||pretreatment with iv lidocaine 40 mg plus ketamine 25 mg with a rubber tourniquet on the forearm 1 min before the injection of microemulsion propofol is more effective than lidocaine 40 mg or ketamine 25 mg alone in preventing pain from the injection of microemulsion propofol.
advmod||investigated-4/VBD||therefore-1/RB	nsubj||investigated-4/VBD||we-3/PRP	root||ROOT-0/null||investigated-4/VBD	xcomp||investigated-4/VBD||using-5/VBG	amod||technology-8/NN||luciferase-6/JJ	nn||technology-8/NN||immunoprecipitation-7/NN	dobj||using-5/VBG||technology-8/NN	dep||investigated-4/VBD||lips-10/VB	nn||responses-13/NNS||antibody-12/NN	dobj||investigated-4/VBD||responses-13/NNS	num||proteins-17/NNS||seven-15/CD	amod||proteins-17/NNS||htlv-i-16/JJ	prep_to||responses-13/NNS||proteins-17/NNS	amod||controls-20/NNS||non-infected-19/JJ	prep_in||proteins-17/NNS||controls-20/NNS	amod||htlv-i-carriers-23/NNS||asymptomatic-22/JJ	prep_in||proteins-17/NNS||htlv-i-carriers-23/NNS	conj_and||controls-20/NNS||htlv-i-carriers-23/NNS	prep_in||proteins-17/NNS||atll-25/NN	conj_and||controls-20/NNS||atll-25/NN	nn||samples-29/NNS||ham/tsp-27/NN	nn||samples-29/NNS||sera-28/NN	prep_in||proteins-17/NNS||samples-29/NNS	conj_and||controls-20/NNS||samples-29/NNS	ham--1||i---1||no_rel||therefore, we investigated using luciferase immunoprecipitation technology (lips) antibody responses to seven htlv-i proteins in non-infected controls, asymptomatic htlv-i-carriers, atll and ham/tsp sera samples.
amod||³-2/NNS||ifn-î-1/JJ	nsubj||play-6/VB||³-2/NNS	conj_and||³-2/NNS||monocytes-4/NNS	nsubj||play-6/VB||monocytes-4/NNS	aux||play-6/VB||might-5/MD	root||ROOT-0/null||play-6/VB	det||role-8/NN||a-7/DT	dobj||play-6/VB||role-8/NN	prep_in||role-8/NN||immunopathology-10/NN	prep_of||immunopathology-10/NN||non-atopicasthma-12/NN	amod||children-16/NNS||latin-14/JJ	nn||children-16/NNS||american-15/NN	prep_in||play-6/VB||children-16/NNS	atopicasthma--1||ifn--1||no_rel||ifn-î³ and monocytes might play a role in immunopathology of non-atopicasthma in latin american children.
advmod||limited-19/JJ||currently-1/RB	det||use-4/NN||the-3/DT	nsubj||limited-19/JJ||use-4/NN	advmod||administered-7/VBN||orally-6/RB	amod||antidepressants-10/NNS||administered-7/VBN	nn||antidepressants-10/NNS||mao-8/NN	nn||antidepressants-10/NNS||inhibitor-9/NN	prep_of||use-4/NN||antidepressants-10/NNS	nn||tranylcypromine-16/NN||eg-12/NN	dep||tranylcypromine-16/NN||phenelzine-14/NN	appos||antidepressants-10/NNS||tranylcypromine-16/NN	cop||limited-19/JJ||is-18/VBZ	root||ROOT-0/null||limited-19/JJ	det||risk-22/NN||the-21/DT	prep_by||limited-19/JJ||risk-22/NN	amod||events-25/NNS||tyramine-provoked-24/JJ	prep_of||risk-22/NN||events-25/NNS	dep||limited-19/JJ||eg-27/NN	amod||hypertension-30/NN||acute-29/JJ	appos||eg-27/NN||hypertension-30/NN	appos||eg-27/NN||headache-32/NN	conj_and||hypertension-30/NN||headache-32/NN	advmod||known-35/VBN||also-34/RB	vmod||hypertension-30/NN||known-35/VBN	det||$-42/NN||the-37/DT	amod||$-42/NN||â-38/JJ	amod||$-42/NN||$-39/$	dep||$-39/$||cheese-40/JJ	amod||$-42/NN||reactionâ-41/JJ	prep_as||known-35/VBN||$-42/NN	advmod||combined-45/VBN||when-44/WRB	advcl||limited-19/JJ||combined-45/VBN	amod||tyramine-48/NN||dietary-47/JJ	prep_with||combined-45/VBN||tyramine-48/NN	hypertension-30||tranylcypromine-16||no||currently, the use of orally administered mao inhibitor antidepressants (eg, phenelzine, tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the âcheese reactionâ?) when combined with dietary tyramine.
nsubj||prevented-3/VBD||caregiving-1/NN	advmod||prevented-3/VBD||often-2/RB	root||ROOT-0/null||prevented-3/VBD	dobj||prevented-3/VBD||adults-4/NNS	prepc_from||prevented-3/VBD||working-6/VBG	amod||time-8/NN||full-7/JJ	dobj||working-6/VBG||time-8/NN	prepc_from||prevented-3/VBD||earning-10/VBG	conj_or||working-6/VBG||earning-10/VBG	poss||level-13/NN||their-11/PRP$	amod||level-13/NN||previous-12/JJ	dobj||earning-10/VBG||level-13/NN	prep_of||level-13/NN||income-15/NN	num||%-18/NN||47-17/CD	nsubj||reported-28/VBD||%-18/NN	amod||caregivers-21/NNS||orphan-20/JJ	prep_of||%-18/NN||caregivers-21/NNS	num||%-24/NN||64-23/CD	conj_and||%-18/NN||%-24/NN	nsubj||reported-28/VBD||%-24/NN	amod||caregivers-27/NNS||hiv/aids-26/JJ	prep_of||%-24/NN||caregivers-27/NNS	parataxis||prevented-3/VBD||reported-28/VBD	amod||difficulties-30/NNS||financial-29/JJ	nsubj||due-31/JJ||difficulties-30/NNS	xcomp||reported-28/VBD||due-31/JJ	prepc_to||due-31/JJ||caregiving-33/VBG	aids--1||hiv--1||no||caregiving often prevented adults from working full time or earning their previous level of income; 47% of orphan caregivers and 64% of hiv/aids caregivers reported financial difficulties due to caregiving.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||effects-4/NNS||the-3/DT	iobj||evaluated-2/VBN||effects-4/NNS	det||therapy-8/NN||a-6/DT	amod||therapy-8/NN||combined-7/JJ	prep_of||effects-4/NNS||therapy-8/NN	amod||âµg-18/NN||budesonide-10/JJ	dep||budesonide-10/JJ||200-11/CD	nn||âµg-18/NN||âµg-12/NN	advmod||daily-14/RB||twice-13/RB	advmod||âµg-18/NN||daily-14/RB	conj_and||daily-14/RB||formoterol-16/JJ	advmod||âµg-18/NN||formoterol-16/JJ	dep||formoterol-16/JJ||6-17/CD	prep_of||therapy-8/NN||âµg-18/NN	advmod||daily-20/RB||twice-19/RB	dobj||evaluated-2/VBN||daily-20/RB	prepc_compared_with||evaluated-2/VBN||with-22/IN	amod||âµg-25/NN||budesonide-23/JJ	dep||budesonide-23/JJ||200-24/CD	pobj||evaluated-2/VBN||âµg-25/NN	advmod||âµg-25/NN||twice-26/RB	advmod||alone-28/RB||daily-27/RB	pobj||twice-26/RB||alone-28/RB	nn||questionnaire-32/NN||asthma-30/NN	nn||questionnaire-32/NN||control-31/NN	prep_on||twice-26/RB||questionnaire-32/NN	appos||questionnaire-32/NN||acq-34/NN	nn||quality-38/NN||asthma-37/NN	appos||questionnaire-32/NN||quality-38/NN	nn||questionnaire-41/NN||life-40/NN	prep_of||quality-38/NN||questionnaire-41/NN	appos||quality-38/NN||aqlq-43/NNP	dep||aqlq-43/NNP||juniper-45/NN	amod||function-49/NN||pulmonary-48/JJ	appos||questionnaire-32/NN||function-49/NN	conj_and||quality-38/NN||function-49/NN	amod||inflammation-52/NN||airway-51/JJ	appos||questionnaire-32/NN||inflammation-52/NN	conj_and||quality-38/NN||inflammation-52/NN	det||study-59/NN||a-55/DT	amod||study-59/NN||cross-over-56/JJ	amod||study-59/NN||randomized-57/JJ	amod||study-59/NN||double-blind-58/JJ	prep_in||evaluated-2/VBN||study-59/NN	nn||periods-62/NNS||treatment-61/NN	prep_with||study-59/NN||periods-62/NNS	num||months-65/NNS||two-64/CD	prep_of||periods-62/NNS||months-65/NNS	vmod||months-65/NNS||separated-66/VBN	det||period-71/NN||a-68/DT	amod||period-71/NN||one-month-69/JJ	amod||period-71/NN||wash-out-70/JJ	agent||separated-66/VBN||period-71/NN	asthma-37||formoterol-16||no||we evaluated the effects of a combined therapy of budesonide 200 âµg twice daily and formoterol 6 âµg twice daily compared with budesonide 200 âµg twice daily alone on asthma control questionnaire (acq), asthma quality of life questionnaire (aqlq- juniper), pulmonary function and airway inflammation, in a cross-over randomized double-blind study with treatment periods of two months separated by a one-month wash-out period.
prep_in||improved-8/VBD||type2diabetes-2/CD	det||therapy-6/NN||the-4/DT	nn||therapy-6/NN||combination-5/NN	nsubj||improved-8/VBD||therapy-6/NN	nsubj||decreased-17/VBD||therapy-6/NN	advmod||improved-8/VBD||significantly-7/RB	root||ROOT-0/null||improved-8/VBD	amod||control-10/NN||metabolic-9/JJ	dobj||improved-8/VBD||control-10/NN	det||profile-14/NN||the-12/DT	nn||profile-14/NN||lipid-13/NN	dobj||improved-8/VBD||profile-14/NN	conj_and||control-10/NN||profile-14/NN	conj_and||improved-8/VBD||decreased-17/VBD	nn||requirements-19/NNS||insulin-18/NN	dobj||decreased-17/VBD||requirements-19/NNS	advmod||decreased-17/VBD||even-21/RB	det||absence-24/NN||the-23/DT	prep_in||decreased-17/VBD||absence-24/NN	advmod||significant-27/JJ||clinically-26/RB	amod||loss-29/NN||significant-27/JJ	nn||loss-29/NN||weight-28/NN	prep_of||absence-24/NN||loss-29/NN	type2diabetes-2||insulin-18||yes||in type2diabetes, the combination therapy significantly improved metabolic control and the lipid profile, and decreased insulin requirements, even in the absence of clinically significant weight loss.
det||use-3/NN||the-2/DT	prep_through||compared-15/VBD||use-3/NN	amod||gold-6/NN||quantiferon-tb-5/JJ	prep_of||use-3/NN||gold-6/NN	det||assay-12/NN||a-8/DT	amod||assay-12/NN||commercial-9/JJ	nn||assay-12/NN||ifn-î-10/NNP	nn||assay-12/NN||³-11/NNP	appos||gold-6/NN||assay-12/NN	nsubj||compared-15/VBD||we-14/PRP	root||ROOT-0/null||compared-15/VBD	dobj||compared-15/VBD||differences-16/NNS	amod||responses-20/NNS||quantitative-18/JJ	amod||responses-20/NNS||t-cell-19/JJ	prep_in||compared-15/VBD||responses-20/NNS	prep_to||compared-15/VBD||mycobacteriumtuberculosis-22/NNS	appos||mycobacteriumtuberculosis-22/NNS||mtb-24/NN	amod||antigens-28/NNS||specific-27/JJ	nsubj||quantiferon-30/VB||antigens-28/NNS	advmod||quantiferon-30/VB||-LSB--29/RB	parataxis||compared-15/VBD||quantiferon-30/VB	amod||disease-44/NN||tb-2g-31/JJ	dep||disease-44/NN||qft-2g-33/JJ	amod||disease-44/NN||-RSB--35/JJ	prep_between||-RSB--35/JJ||patients-37/NNS	amod||tuberculosis-40/NNP||active-39/JJ	prep_with||patients-37/NNS||tuberculosis-40/NNP	dep||patients-37/NNS||tb-42/VBN	dobj||quantiferon-30/VB||disease-44/NN	dobj||quantiferon-30/VB||those-46/DT	conj_and||disease-44/NN||those-46/DT	nn||infection-50/NN||latent-48/NN	nn||infection-50/NN||tb-49/NN	prep_with||those-46/DT||infection-50/NN	appos||infection-50/NN||ltbi-52/NNP	tb-49||mycobacteriumtuberculosis-22||no||through the use of quantiferon-tb gold, a commercial ifn-î³ assay, we compared differences in quantitative t-cell responses to mycobacteriumtuberculosis (mtb)-specific antigens [quantiferon tb-2g (qft-2g)] between patients with active tuberculosis (tb) disease and those with latent tb infection (ltbi).
det||findings-2/NNS||these-1/DT	nsubj||show-3/VBP||findings-2/NNS	root||ROOT-0/null||show-3/VBP	det||prevalence-6/NN||an-4/DT	amod||prevalence-6/NN||high-5/JJ	dobj||show-3/VBP||prevalence-6/NN	prep_of||prevalence-6/NN||rotavirusinfections-8/NNS	prep_among||show-3/VBP||children-10/NNS	vmod||children-10/NNS||admitted-11/VBN	prep_to||admitted-11/VBN||hospital-13/NN	amod||gastroenteritis-16/NNS||acute-15/JJ	prep_for||admitted-11/VBN||gastroenteritis-16/NNS	vmod||gastroenteritis-16/NNS||caused-17/VBN	amod||strains-21/NNS||different-19/JJ	nn||strains-21/NNS||rotavirus-20/NNS	agent||caused-17/VBN||strains-21/NNS	vmod||strains-21/NNS||circulating-22/VBG	det||area-25/NN||the-24/DT	prep_in||circulating-22/VBG||area-25/NN	vmod||area-25/NN||studied-26/VBN	rotavirusinfections-8||rotavirus-20||no||these findings show an high prevalence of rotavirusinfections among children admitted to hospital for acute gastroenteritis caused by different rotavirus strains circulating in the area studied.
advmod||associated-2/VBN||dyskinesias-1/RB	root||ROOT-0/null||associated-2/VBN	amod||movements-5/NNS||involuntary-4/JJ	prep_with||associated-2/VBN||movements-5/NNS	amod||contractions-9/NNS||painful-7/JJ	nn||contractions-9/NNS||muscle-8/NN	prep_with||associated-2/VBN||contractions-9/NNS	conj_and||movements-5/NNS||contractions-9/NNS	cop||complication-15/NN||are-10/VBP	det||complication-15/NN||a-11/DT	amod||complication-15/NN||common-12/JJ	conj_and||common-12/JJ||severe-14/JJ	amod||complication-15/NN||severe-14/JJ	auxpass||associated-2/VBN||complication-15/NN	amod||levodopa-18/NN||standard-17/JJ	prep_of||complication-15/NN||levodopa-18/NN	appos||levodopa-18/NN||l-dopa-20/NNP	dep||l-dopa-20/NNP||l-3-22/NN	num||l-3-22/NN||,4-23/CD	dep||l-dopa-20/NNP||dihydroxyphenylalanine-25/NN	nsubjpass||associated-2/VBN||therapy-27/NN	nn||sdisease-31/NN||parkinson-29/NN	prep_for||therapy-27/NN||sdisease-31/NN	parkinson'sdisease--1||l-3-22||yes||dyskinesias associated with involuntary movements and painful muscle contractions are a common and severe complication of standard levodopa (l-dopa, l-3,4-dihydroxyphenylalanine) therapy for parkinson'sdisease.
prep_in||contribute-6/VB||owat-2/NN	nsubj||contribute-6/VB||fibrosis-4/NN	nsubj||limit-8/VB||fibrosis-4/NN	nsubjpass||associated-13/VBN||fibrosis-4/NN	aux||contribute-6/VB||could-5/MD	root||ROOT-0/null||contribute-6/VB	aux||limit-8/VB||to-7/TO	xcomp||contribute-6/VB||limit-8/VB	amod||hypertrophy-10/NN||adipocyte-9/JJ	dobj||limit-8/VB||hypertrophy-10/NN	auxpass||associated-13/VBN||is-12/VBZ	conj_and||contribute-6/VB||associated-13/VBN	det||profile-18/NN||a-15/DT	amod||profile-18/NN||better-16/JJR	nn||profile-18/NN||lipid-17/NN	prep_with||associated-13/VBN||profile-18/NN	mark||hamper-24/VB||whereas-20/IN	nn||fibrosis-22/NN||scwat-21/NN	nsubj||hamper-24/VB||fibrosis-22/NN	aux||hamper-24/VB||may-23/MD	dep||profile-18/NN||hamper-24/VB	amod||loss-27/NN||fat-25/JJ	amod||loss-27/NN||mass-26/JJ	dobj||hamper-24/VB||loss-27/NN	vmod||loss-27/NN||induced-28/VBN	agent||induced-28/VBN||surgery-30/NN	lipid-17||fibrosis-22||no_rel||in owat, fibrosis could contribute to limit adipocyte hypertrophy and is associated with a better lipid profile, whereas scwat fibrosis may hamper fat mass loss induced by surgery.
det||individuals-2/NNS||the-1/DT	nsubj||have-16/VBP||individuals-2/NNS	nsubj||identified-4/VBD||we-3/PRP	rcmod||individuals-2/NNS||identified-4/VBD	prepc_as||identified-4/VBD||having-6/VBG	amod||influence-10/NN||regional-7/JJ	conj_or||regional-7/JJ||international-9/JJ	amod||influence-10/NN||international-9/JJ	dobj||having-6/VBG||influence-10/NN	det||field-13/NN||the-12/DT	prep_in||influence-10/NN||field-13/NN	prep_of||field-13/NN||hiv/aids-15/NNS	root||ROOT-0/null||have-16/VBP	det||ability-18/NN||the-17/DT	dobj||have-16/VBP||ability-18/NN	prep_to||ability-18/NN||leverage-20/NN	det||environment-25/NN||an-21/DT	advmod||conducive-23/JJ||increasingly-22/RB	amod||environment-25/NN||conducive-23/JJ	nn||environment-25/NN||funding-24/NN	dep||leverage-20/NN||environment-25/NN	det||base-30/NN||a-27/DT	amod||base-30/NN||growing-28/VBG	nn||base-30/NN||evidence-29/NN	prep_to||ability-18/NN||base-30/NN	conj_and||leverage-20/NN||base-30/NN	aux||address-32/VB||to-31/TO	vmod||have-16/VBP||address-32/VB	det||challenges-39/NNS||the-33/DT	amod||challenges-39/NNS||policy-34/NN	conj_and||policy-34/NN||programmatic-36/JJ	amod||challenges-39/NNS||programmatic-36/JJ	conj_and||policy-34/NN||operational-38/JJ	amod||challenges-39/NNS||operational-38/JJ	dobj||address-32/VB||challenges-39/NNS	prepc_to||address-32/VB||integrating-41/VBG	nn||planning-43/NN||family-42/NN	dobj||integrating-41/VBG||planning-43/NN	prep_with||integrating-41/VBG||hiv/aids-45/NNS	aids--1||hiv--1||no||the individuals we identified as having regional or international influence in the field of hiv/aids have the ability to leverage an increasingly conducive funding environment and a growing evidence base to address the policy, programmatic and operational challenges to integrating family planning with hiv/aids.
amod||adults-2/NNS||overweight-1/JJ	nsubj||±-10/VBD||adults-2/NNS	advmod||controlled-5/VBN||inadequately-4/RB	amod||type2diabetes-6/NNS||controlled-5/VBN	prep_with||adults-2/NNS||type2diabetes-6/NNS	nn||â-9/NN||metformin-8/NN	prep_on||type2diabetes-6/NNS||â-9/NN	root||ROOT-0/null||±-10/VBD	det||thiazolidinedione-12/NN||a-11/DT	nsubjpass||randomized-14/VBN||thiazolidinedione-12/NN	nsubj||subcutaneous-16/VB||thiazolidinedione-12/NN	nsubj||taspoglutide-27/VB||thiazolidinedione-12/NN	nsubj||exenatide-38/VB||thiazolidinedione-12/NN	auxpass||randomized-14/VBN||were-13/VBD	ccomp||±-10/VBD||randomized-14/VBN	aux||subcutaneous-16/VB||to-15/TO	xcomp||randomized-14/VBN||subcutaneous-16/VB	nn||weekly-20/NN||taspoglutide-17/NN	num||weekly-20/NN||10-18/CD	nn||weekly-20/NN||mg-19/NN	dobj||subcutaneous-16/VB||weekly-20/NN	dep||weekly-20/NN||n-22/VBN	dep||399-24/CD||=-23/SYM	ccomp||n-22/VBN||399-24/CD	xcomp||randomized-14/VBN||taspoglutide-27/VB	conj_or||subcutaneous-16/VB||taspoglutide-27/VB	num||weekly-30/NN||20-28/CD	nn||weekly-30/NN||mg-29/NN	dobj||taspoglutide-27/VB||weekly-30/NN	dep||weekly-30/NN||n-32/VBN	dep||398-34/CD||=-33/SYM	ccomp||n-32/VBN||398-34/CD	xcomp||randomized-14/VBN||exenatide-38/VB	conj_or||subcutaneous-16/VB||exenatide-38/VB	number||âµg-40/CD||10-39/CD	num||daily-42/RB||âµg-40/CD	advmod||daily-42/RB||twice-41/RB	dobj||exenatide-38/VB||daily-42/RB	dep||daily-42/RB||n-44/VBN	dep||392-46/CD||=-45/SYM	ccomp||n-44/VBN||392-46/CD	det||trial-53/NN||an-49/DT	amod||trial-53/NN||open-label-50/JJ	amod||trial-53/NN||multicenter-52/JJ	prep_in||exenatide-38/VB||trial-53/NN	type2diabetes-6||metformin-8||yes||overweight adults with inadequately controlled type2diabetes on metformin â± a thiazolidinedione were randomized to subcutaneous taspoglutide 10 mg weekly ( n = 399), taspoglutide 20 mg weekly ( n = 398), or exenatide 10 âµg twice daily ( n = 392) in an open-label, multicenter trial.
vmod||examined-14/VBD||using-1/VBG	det||model-4/NN||a-2/DT	amod||model-4/NN||murine-3/JJ	dobj||using-1/VBG||model-4/NN	amod||ischemia-8/NN||partial-6/JJ	amod||ischemia-8/NN||hepatic-7/JJ	prep_of||model-4/NN||ischemia-8/NN	amod||min-11/NN||90â-10/JJ	prep_for||ischemia-8/NN||min-11/NN	nsubj||examined-14/VBD||we-13/PRP	root||ROOT-0/null||examined-14/VBD	det||levels-16/NNS||the-15/DT	nn||h-38/NN||levels-16/NNS	conj_and||levels-16/NNS||pathway-18/NN	nn||h-38/NN||pathway-18/NN	prep_of||levels-16/NNS||apoptosis-20/NNS	det||expression-25/NN||the-23/DT	amod||expression-25/NN||peroxynitrite-24/JJ	prep_of||levels-16/NNS||expression-25/NN	conj_and||apoptosis-20/NNS||expression-25/NN	amod||levels-30/NNS||serum-27/JJ	amod||levels-30/NNS||alanine-28/JJ	nn||levels-30/NNS||aminotransferase-29/NN	prep_of||levels-16/NNS||levels-30/NNS	conj_and||apoptosis-20/NNS||levels-30/NNS	prep_of||levels-16/NNS||liver-33/NN	conj_and||apoptosis-20/NNS||liver-33/NN	amod||h-38/NN||histology-34/JJ	dep||histology-34/JJ||1-35/CD	dep||histology-34/JJ||4â-37/CD	conj_and||1-35/CD||4â-37/CD	dobj||examined-14/VBD||h-38/NN	prep_after||examined-14/VBD||reperfusion-40/NN	ischemia-8||alanine-28||no_rel||using a murine model of partial hepatic ischemia for 90â min, we examined the levels and pathway of apoptosis, and the peroxynitrite expression, serum alanine aminotransferase levels, and liver histology 1 and 4â h after reperfusion.
mark||seen-8/VBN||since-1/IN	det||neurotropism-5/NN||a-2/DT	nn||neurotropism-5/NN||latent-3/NN	amod||neurotropism-5/NN||viral-4/JJ	nsubjpass||seen-8/VBN||neurotropism-5/NN	aux||seen-8/VBN||can-6/MD	auxpass||seen-8/VBN||be-7/VB	advcl||difficult-26/JJ||seen-8/VBN	det||variety-11/NN||a-10/DT	prep_with||seen-8/VBN||variety-11/NN	prep_of||variety-11/NN||viruses-13/NNS	det||seropositivity-17/NN||a-15/DT	amod||seropositivity-17/NN||widespread-16/JJ	nsubj||exists-18/VBZ||seropositivity-17/NN	conj_and||seen-8/VBN||exists-18/VBZ	advcl||difficult-26/JJ||exists-18/VBZ	det||population-21/NN||the-20/DT	prep_among||exists-18/VBZ||population-21/NN	nsubj||difficult-26/JJ||it-23/PRP	nsubj||establish-28/VB||it-23/PRP	aux||difficult-26/JJ||has-24/VBZ	cop||difficult-26/JJ||been-25/VBN	root||ROOT-0/null||difficult-26/JJ	aux||establish-28/VB||to-27/TO	xcomp||difficult-26/JJ||establish-28/VB	det||association-30/NN||an-29/DT	dobj||establish-28/VB||association-30/NN	nn||malignancy-35/NN||viralinfection-32/NN	conj_and||viralinfection-32/NN||cns-34/NN	nn||malignancy-35/NN||cns-34/NN	prep_between||association-30/NN||malignancy-35/NN	prepc_based_on||establish-28/VB||on-37/IN	pobj||establish-28/VB||epidemiology-38/NN	advmod||establish-28/VB||alone-39/RB	viralinfection-32||viruses-13||no||since a latent viral neurotropism can be seen with a variety of viruses and a widespread seropositivity exists among the population, it has been difficult to establish an association between viralinfection and cns malignancy based on epidemiology alone.
aux||estimate-2/VB||to-1/TO	root||ROOT-0/null||estimate-2/VB	det||rates-4/NNS||the-3/DT	dobj||estimate-2/VB||rates-4/NNS	prep_of||rates-4/NNS||prevalence-6/NN	prep_of||rates-4/NNS||diagnosis-8/NN	conj_and||prevalence-6/NN||diagnosis-8/NN	prep_of||rates-4/NNS||treatment-11/NN	conj_and||prevalence-6/NN||treatment-11/NN	amod||glucose-15/NN||impaired-13/VBN	amod||glucose-15/NN||fasting-14/JJ	prep_of||prevalence-6/NN||glucose-15/NN	appos||glucose-15/NN||ifg-17/NN	prep_of||prevalence-6/NN||impairedglucosetolerance-20/NN	conj_and||glucose-15/NN||impairedglucosetolerance-20/NN	dep||impairedglucosetolerance-20/NN||igt-22/VBN	glucose-15||impairedglucosetolerance-20||no_rel||to estimate the rates of prevalence, diagnosis, and treatment of impaired fasting glucose (ifg) and impairedglucosetolerance (igt).
aux||evaluate-2/VB||to-1/TO	advcl||generated-15/VBD||evaluate-2/VB	det||implication-4/NN||the-3/DT	dobj||evaluate-2/VB||implication-4/NN	amod||cells-7/NNS||treg-6/VBG	prep_of||implication-4/NN||cells-7/NNS	det||development-10/NN||the-9/DT	prep_in||cells-7/NNS||development-10/NN	prep_of||development-10/NN||silicosis-12/NNS	nsubj||generated-15/VBD||we-14/PRP	root||ROOT-0/null||generated-15/VBD	det||model-19/NN||the-16/DT	amod||model-19/NN||treg-depleted-17/JJ	nn||model-19/NN||mice-18/NNS	nsubjpass||exposed-28/VBN||model-19/NN	nsubj||establish-35/VB||model-19/NN	prep_by||model-19/NN||administration-21/NN	amod||mabs-24/NNS||anti-cd25-23/JJ	prep_of||administration-21/NN||mabs-24/NNS	prep_of||administration-21/NN||mice-26/NNS	conj_and||mabs-24/NNS||mice-26/NNS	auxpass||exposed-28/VBN||were-27/VBD	ccomp||generated-15/VBD||exposed-28/VBN	prep_to||exposed-28/VBN||silica-30/NN	amod||instillation-33/NN||intratracheal-32/JJ	agent||exposed-28/VBN||instillation-33/NN	aux||establish-35/VB||to-34/TO	xcomp||exposed-28/VBN||establish-35/VB	amod||model-37/NN||experimental-36/JJ	dobj||establish-35/VB||model-37/NN	amod||fibrosis-41/NN||silica-induced-39/JJ	nn||fibrosis-41/NN||lung-40/NN	prep_of||model-37/NN||fibrosis-41/NN	silicosis-12||silica-30||no||to evaluate the implication of treg cells in the development of silicosis, we generated the treg-depleted mice model by administration of anti-cd25 mabs and mice were exposed to silica by intratracheal instillation to establish experimental model of silica-induced lung fibrosis.
mwe||than-2/IN||more-1/JJR	quantmod||74.2-3/CD||than-2/IN	num||%-4/NN||74.2-3/CD	nsubj||knew-8/VBD||%-4/NN	det||adults-7/NNS||the-6/DT	prep_of||%-4/NN||adults-7/NNS	root||ROOT-0/null||knew-8/VBD	dobj||knew-8/VBD||someone-9/NN	prep_with||knew-8/VBD||hiv/aids-11/NNS	mwe||than-15/IN||more-14/JJR	quantmod||90-16/CD||than-15/IN	num||%-17/NN||90-16/CD	nsubj||identified-19/VBD||%-17/NN	advmod||identified-19/VBD||correctly-18/RB	conj_and||knew-8/VBD||identified-19/VBD	nn||modes-21/NNS||transmission-20/NN	dobj||identified-19/VBD||modes-21/NNS	nn||methods-24/NNS||prevention-23/NN	dobj||identified-19/VBD||methods-24/NNS	conj_and||modes-21/NNS||methods-24/NNS	prep_of||modes-21/NNS||hiv-26/NN	aids--1||hiv-26||no||more than 74.2% of the adults knew someone with hiv/aids, and more than 90% correctly identified transmission modes and prevention methods of hiv.
nsubj||showed-5/VBD||smokers-1/NNS	vmod||smokers-1/NNS||treated-2/VBN	prep_with||treated-2/VBN||budesonide/formoterol-4/NN	root||ROOT-0/null||showed-5/VBD	det||increase-7/NN||an-6/DT	dobj||showed-5/VBD||increase-7/NN	det||number-10/NN||the-9/DT	prep_in||showed-5/VBD||number-10/NN	nn||episodes-13/NNS||asthma-12/NN	prep_of||number-10/NN||episodes-13/NNS	parataxis||showed-5/VBD||intercurrent-15/VB	nn||symptoms-17/NNS||asthma-16/NN	dobj||intercurrent-15/VB||symptoms-17/NNS	vmod||symptoms-17/NNS||p-19/VBN	dep||0.016-21/CD||=-20/SYM	ccomp||p-19/VBN||0.016-21/CD	mark||had-26/VBD||while-23/IN	amod||subjects-25/NNS||non-smoking-24/JJ	nsubj||had-26/VBD||subjects-25/NNS	advcl||showed-5/VBD||had-26/VBD	det||decrease-29/NN||a-27/DT	amod||decrease-29/NN||significant-28/JJ	dobj||had-26/VBD||decrease-29/NN	det||episodes-32/NNS||these-31/DT	prep_in||decrease-29/NN||episodes-32/NNS	dep||episodes-32/NNS||p-34/VBN	dep||0.009-36/CD||=-35/SYM	ccomp||p-34/VBN||0.009-36/CD	asthma-16||formoterol--1||no||smokers treated with budesonide/formoterol showed an increase in the number of asthma episodes (intercurrent asthma symptoms, p=0.016) while non-smoking subjects had a significant decrease in these episodes (p=0.009).
csubjpass||associated-8/VBN||switching-1/VBG	prep_from||switching-1/VBG||bhi-3/NN	aux||biasp-5/VB||to-4/TO	xcomp||switching-1/VBG||biasp-5/VB	dobj||biasp-5/VB||30-6/CD	auxpass||associated-8/VBN||is-7/VBZ	root||ROOT-0/null||associated-8/VBN	amod||glucose-12/NN||improved-10/VBN	amod||glucose-12/NN||postprandial-11/JJ	prep_with||associated-8/VBN||glucose-12/NN	appos||glucose-12/NN||ppg-14/NN	amod||nocturnal-18/NN||reduced-17/VBN	prep_with||associated-8/VBN||nocturnal-18/NN	conj_and||glucose-12/NN||nocturnal-18/NN	amod||hypoglycaemia-21/NN||major-20/JJ	conj_and||glucose-12/NN||hypoglycaemia-21/NN	conj_and||nocturnal-18/NN||hypoglycaemia-21/NN	mark||higher-27/JJR||although-23/IN	amod||hypoglycaemia-25/NN||daytime-24/JJ	nsubj||higher-27/JJR||hypoglycaemia-25/NN	cop||higher-27/JJR||is-26/VBZ	advcl||associated-8/VBN||higher-27/JJR	prep_with||higher-27/JJR||biasp-29/NN	num||biasp-29/NN||30-30/CD	hypoglycaemia-25||glucose-12||yes||switching from bhi to biasp 30 is associated with improved postprandial glucose (ppg) and reduced nocturnal and major hypoglycaemia, although daytime hypoglycaemia is higher with biasp 30.
nsubjpass||believed-14/VBN||melioidosis-1/NNS	det||disease-8/NN||a-3/DT	amod||disease-8/NN||severe-4/JJ	conj_and||severe-4/JJ||fatal-6/JJ	amod||disease-8/NN||fatal-6/JJ	amod||disease-8/NN||infectious-7/JJ	appos||melioidosis-1/NNS||disease-8/NN	vmod||disease-8/NN||caused-9/VBN	agent||caused-9/VBN||burkholderiapseudomallei-11/NNS	auxpass||believed-14/VBN||is-13/VBZ	root||ROOT-0/null||believed-14/VBN	det||threat-19/NN||an-16/DT	amod||threat-19/NN||emerging-17/VBG	amod||threat-19/NN||global-18/JJ	prep_to||believed-14/VBN||threat-19/NN	melioidosis-1||burkholderiapseudomallei-11||no||melioidosis, a severe and fatal infectious disease caused by burkholderiapseudomallei , is believed to an emerging global threat.
nn||glucose-2/NN||plasma-1/NN	nsubjpass||measured-12/VBN||glucose-2/NN	nsubjpass||measured-12/VBN||glucose-2/NN	nsubjpass||measured-12/VBN||glucose-2/NN	conj_and||glucose-2/NN||insulin-4/NN	nsubjpass||measured-12/VBN||insulin-4/NN	conj_and||glucose-2/NN||c-peptide-6/NN	nsubjpass||measured-12/VBN||c-peptide-6/NN	nn||concentrations-10/NNS||glucagon-9/NN	conj_and||glucose-2/NN||concentrations-10/NNS	nsubjpass||measured-12/VBN||concentrations-10/NNS	auxpass||measured-12/VBN||were-11/VBD	root||ROOT-0/null||measured-12/VBN	conj_and||measured-12/VBN||measured-12/VBN	conj_and||measured-12/VBN||measured-12/VBN	det||min-15/NN||every-13/DT	num||min-15/NN||30-14/CD	dobj||measured-12/VBN||min-15/NN	amod||ingestion-42/NN||â-17/JJ	dep||â-17/JJ||60-18/CD	num||min-21/NN||180-20/CD	prep_through||â-17/JJ||min-21/NN	amod||administration-26/NN||random-sequence-23/JJ	amod||administration-26/NN||double-blind-25/JJ	prep_with||min-21/NN||administration-26/NN	prep_of||administration-26/NN||diazoxide-28/NN	num||mg/kg-31/NN||6.0-30/CD	appos||diazoxide-28/NN||mg/kg-31/NN	prep_of||administration-26/NN||placebo-34/NN	conj_or||diazoxide-28/NN||placebo-34/NN	amod||min-40/NN||â-36/JJ	dep||â-36/JJ||30-37/CD	dep||â-36/JJ||1-39/CD	conj_and||30-37/CD||1-39/CD	prep_at||placebo-34/NN||min-40/NN	prep_from||measured-12/VBN||ingestion-42/NN	det||meal-47/NN||a-44/DT	nn||meal-47/NN||formula-45/NN	amod||meal-47/NN||mixed-46/JJ	prep_of||ingestion-42/NN||meal-47/NN	parataxis||measured-12/VBN||ensure-49/VB	advmod||ensure-49/VB||plus-50/CC	prep_at||measured-12/VBN||0-53/CD	vmod||0-53/CD||min-54/VBN	prep_after||min-54/VBN||diazoxide-56/NN	prep_after||min-54/VBN||placebo-59/NN	conj_and||diazoxide-56/NN||placebo-59/NN	cc||measured-12/VBN||and-60/CC	det||occasion-65/NN||a-63/DT	amod||occasion-65/NN||separate-64/JJ	prep_on||measured-12/VBN||occasion-65/NN	npadvmod||measured-12/VBN||ingestion-67/NN	prep_of||ingestion-67/NN||glimepiride-69/NN	number||mg-72/CD||4.0-71/CD	dep||glimepiride-69/NN||mg-72/CD	num||min-76/NN||0-75/CD	prep_at||glimepiride-69/NN||min-76/NN	prep_with||glimepiride-69/NN||glucose-79/NN	vmod||glucose-79/NN||infused-80/VBN	aux||prevent-82/VB||to-81/TO	xcomp||infused-80/VBN||prevent-82/VB	dobj||prevent-82/VB||hypoglycemia-83/NN	prep_after||measured-12/VBN||diazoxide-86/NN	prep_after||measured-12/VBN||placebo-89/NN	num||adults-94/NNS||11-91/CD	amod||adults-94/NNS||healthy-92/JJ	amod||adults-94/NNS||young-93/JJ	prep_in||placebo-89/NN||adults-94/NNS	hypoglycemia-83||diazoxide-86||yes||plasma glucose, insulin, c-peptide, and glucagon concentrations were measured every 30 min from â60 through 180 min with random-sequence, double-blind administration of diazoxide (6.0 mg/kg) or placebo at â30 and 1 min, ingestion of a formula mixed meal (ensure plus) at 0 min after diazoxide and after placebo and, on a separate occasion, ingestion of glimepiride (4.0 mg) at 0 min (with glucose infused to prevent hypoglycemia) after diazoxide and after placebo in 11 healthy young adults.
det||1,25-dihydroxyvitamind3-5/NN||the-1/DT	amod||1,25-dihydroxyvitamind3-5/NN||active-2/JJ	amod||1,25-dihydroxyvitamind3-5/NN||vitamind-3/JJ	nn||1,25-dihydroxyvitamind3-5/NN||metabolite-4/NN	nsubj||inhibits-13/VBZ||1,25-dihydroxyvitamind3-5/NN	nsubj||promotes-16/VBZ||1,25-dihydroxyvitamind3-5/NN	dep||1,25-dihydroxyvitamind3-5/NN||1,25-7/CD	discourse||1,25-7/CD||oh-9/UH	dep||1,25-7/CD||2d3-11/NNS	root||ROOT-0/null||inhibits-13/VBZ	dobj||inhibits-13/VBZ||proliferation-14/NN	conj_and||inhibits-13/VBZ||promotes-16/VBZ	dobj||promotes-16/VBZ||differentiation-17/NN	nn||cells-21/NNS||colon-19/NN	nn||cells-21/NNS||cancer-20/NN	prep_of||differentiation-17/NN||cells-21/NNS	det||activation-24/NN||the-23/DT	prep_through||promotes-16/VBZ||activation-24/NN	amod||receptor-27/NN||vitamind-26/JJ	prep_of||activation-24/NN||receptor-27/NN	appos||receptor-27/NN||vdr-29/NN	det||factor-34/NN||a-32/DT	nn||factor-34/NN||transcription-33/NN	appos||receptor-27/NN||factor-34/NN	det||superfamily-39/NN||the-36/DT	amod||superfamily-39/NN||nuclear-37/JJ	nn||superfamily-39/NN||receptor-38/NN	prep_of||factor-34/NN||superfamily-39/NN	cancer-20||vitamind-26||no_rel||the active vitamind metabolite 1,25-dihydroxyvitamind3 (1,25(oh)2d3) inhibits proliferation and promotes differentiation of colon cancer cells through the activation of vitamind receptor (vdr), a transcription factor of the nuclear receptor superfamily.
nsubj||continues-12/VBZ||pertussis-1/NN	nsubj||threat-19/NN||pertussis-1/NN	appos||pertussis-1/NN||whoopingcough-3/NN	dep||continues-12/VBZ||caused-5/VBN	prep_by||caused-5/VBN||bordetellapertussis-7/NNS	appos||bordetellapertussis-7/NNS||b.p-9/NN	root||ROOT-0/null||continues-12/VBZ	aux||threat-19/NN||to-13/TO	cop||threat-19/NN||be-14/VB	det||threat-19/NN||a-15/DT	amod||threat-19/NN||serious-16/JJ	amod||threat-19/NN||public-17/JJ	nn||threat-19/NN||health-18/NN	xcomp||continues-12/VBZ||threat-19/NN	whoopingcough-3||bordetellapertussis-7||no||pertussis (whoopingcough) caused by bordetellapertussis ( b.p ), continues to be a serious public health threat.
nn||testing-2/NN||hiv-1/NN	nsubj||component-8/NN||testing-2/NN	prep_with||testing-2/NN||counseling-4/NN	cop||component-8/NN||is-5/VBZ	det||component-8/NN||an-6/DT	amod||component-8/NN||integral-7/JJ	root||ROOT-0/null||component-8/NN	advmod||hiv-12/NN||most-10/RBS	amod||hiv-12/NN||national-11/JJ	prep_of||component-8/NN||hiv-12/NN	nn||strategies-16/NNS||aids-14/NNS	nn||strategies-16/NNS||prevention-15/NN	prep_of||component-8/NN||strategies-16/NNS	conj_and||hiv-12/NN||strategies-16/NNS	amod||africa-19/NN||southern-18/JJ	prep_in||component-8/NN||africa-19/NN	aids-14||hiv-12||no||hiv testing with counseling is an integral component of most national hiv and aids prevention strategies in southern africa.
nsubj||organisms-8/NNS||bacteria-1/NNS	det||genusbrucella-4/NN||the-3/DT	prep_of||bacteria-1/NNS||genusbrucella-4/NN	cop||organisms-8/NNS||are-5/VBP	det||organisms-8/NNS||the-6/DT	amod||organisms-8/NNS||causative-7/JJ	root||ROOT-0/null||organisms-8/NNS	prep_of||organisms-8/NNS||brucellosis-10/NNS	prep_in||brucellosis-10/NNS||animals-12/NNS	prep_in||brucellosis-10/NNS||man-14/NN	conj_and||animals-12/NNS||man-14/NN	brucellosis-10||genusbrucella-4||no||bacteria of the genusbrucella are the causative organisms of brucellosis in animals and man.
nsubj||disease-13/NN||scrubtyphus-1/NNS	nsubj||fatal-20/JJ||scrubtyphus-1/NNS	det||zoonosis-5/NNS||a-3/DT	amod||zoonosis-5/NNS||mite-transmitted-4/JJ	appos||scrubtyphus-1/NNS||zoonosis-5/NNS	vmod||zoonosis-5/NNS||caused-6/VBN	agent||caused-6/VBN||orientiatsutsugamushi-8/NNS	cop||disease-13/NN||is-10/VBZ	det||disease-13/NN||an-11/DT	amod||disease-13/NN||endemic-12/JJ	root||ROOT-0/null||disease-13/NN	prep_in||disease-13/NN||taiwan-15/NN	aux||fatal-20/JJ||may-17/MD	cop||fatal-20/JJ||be-18/VB	advmod||fatal-20/JJ||potentially-19/RB	conj_and||disease-13/NN||fatal-20/JJ	mark||delayed-24/VBN||if-21/IN	nsubjpass||delayed-24/VBN||diagnosis-22/NN	auxpass||delayed-24/VBN||is-23/VBZ	advcl||fatal-20/JJ||delayed-24/VBN	scrubtyphus-1||orientiatsutsugamushi-8||no||scrubtyphus, a mite-transmitted zoonosis caused by orientiatsutsugamushi , is an endemic disease in taiwan and may be potentially fatal if diagnosis is delayed.
nsubj||involved-5/VBN||subtypes-1/NNS	amod||receptors-4/NNS||purinergic-3/JJ	prep_of||subtypes-1/NNS||receptors-4/NNS	root||ROOT-0/null||involved-5/VBN	prep_in||involved-5/VBN||modulation-7/NN	amod||concentration-12/NN||cytoplasmic-9/JJ	nn||concentration-12/NN||calcium-10/NN	nn||concentration-12/NN||ion-11/NN	prep_of||modulation-7/NN||concentration-12/NN	nn||i-18/NNP||-LSB--14/NNP	nn||i-18/NNP||ca2-15/NNP	nn||i-18/NNP||+-16/NNP	nn||i-18/NNP||-RSB--17/NNP	appos||concentration-12/NN||i-18/NNP	nn||release-22/NN||insulin-21/NN	prep_in||involved-5/VBN||release-22/NN	conj_and||modulation-7/NN||release-22/NN	nn||²-27/NNS||mouse-24/NN	amod||²-27/NNS||pancreatic-25/JJ	nn||²-27/NNS||î-26/NN	prep_in||release-22/NN||²-27/NNS	nsubjpass||examined-31/VBN||cells-29/NNS	auxpass||examined-31/VBN||were-30/VBD	parataxis||involved-5/VBN||examined-31/VBN	num||systems-34/NNS||two-33/CD	prep_in||examined-31/VBN||systems-34/NNS	amod||islets-37/NNS||pancreatic-36/JJ	appos||systems-34/NNS||islets-37/NNS	amod||culture-40/NN||primary-39/JJ	prep_in||islets-37/NNS||culture-40/NN	amod||cells-44/NNS||beta-tc6-42/JJ	nn||cells-44/NNS||insulinoma-43/NN	prep_in||islets-37/NNS||cells-44/NNS	conj_and||culture-40/NN||cells-44/NNS	calcium-10||insulinoma-43||no_rel||subtypes of purinergic receptors involved in modulation of cytoplasmic calcium ion concentration ([ca2+]i) and insulin release in mouse pancreatic î²-cells were examined in two systems, pancreatic islets in primary culture and beta-tc6 insulinoma cells.
nsubjpass||considered-15/VBN||infections-1/NNS	nsubj||problems-20/NNS||infections-1/NNS	vmod||infections-1/NNS||caused-2/VBN	agent||caused-2/VBN||hepatitisbvirus-4/NNS	appos||hepatitisbvirus-4/NNS||hbv-6/NN	amod||virus-10/NN||hepatitisc-9/JJ	agent||caused-2/VBN||virus-10/NN	conj_and||hepatitisbvirus-4/NNS||virus-10/NN	appos||hepatitisbvirus-4/NNS||hcv-12/NN	auxpass||considered-15/VBN||are-14/VBP	root||ROOT-0/null||considered-15/VBN	aux||problems-20/NNS||to-16/TO	cop||problems-20/NNS||be-17/VB	amod||problems-20/NNS||important-18/JJ	nn||problems-20/NNS||health-19/NN	xcomp||considered-15/VBN||problems-20/NNS	advmod||problems-20/NNS||worldwide-21/RB	hbv-6||hepatitisbvirus-4||no||infections caused by hepatitisbvirus (hbv) and hepatitisc virus (hcv) are considered to be important health problems worldwide.
nn||samples-4/NNS||naf-1/NN	conj_and||naf-1/NN||plasma-3/NN	nn||samples-4/NNS||plasma-3/NN	nsubjpass||collected-6/VBN||samples-4/NNS	nsubjpass||collected-6/VBN||samples-4/NNS	auxpass||collected-6/VBN||were-5/VBD	root||ROOT-0/null||collected-6/VBN	conj_and||collected-6/VBN||collected-6/VBN	prep_in||collected-6/VBN||women-8/NNS	amod||risk-13/NN||increased-10/VBN	nn||risk-13/NN||breast-11/NN	nn||risk-13/NN||cancer-12/NN	prep_at||collected-6/VBN||risk-13/NN	advmod||risk-13/NN||before-14/IN	num||weeks-17/NNS||2-16/CD	npadvmod||collected-6/VBN||weeks-17/NNS	prepc_after||collected-6/VBN||taking-19/VBG	num||200-21/CD||celecoxib-20/CD	num||daily-26/RB||200-21/CD	num||mg-24/CD||400-23/CD	conj_or||200-21/CD||mg-24/CD	num||daily-26/RB||mg-24/CD	advmod||daily-26/RB||twice-25/RB	dobj||taking-19/VBG||daily-26/RB	appos||daily-26/RB||bid-28/NN	cancer-12||naf-1||no_rel||naf and plasma samples were collected in women at increased breast cancer risk before and 2 weeks after taking celecoxib 200 or 400 mg twice daily (bid).
amod||patients-3/NNS||antiretroviral-naive-1/JJ	amod||patients-3/NNS||hiv-infected-2/JJ	nsubjpass||recruited-7/VBN||patients-3/NNS	prep_with||patients-3/NNS||tb-5/NN	auxpass||recruited-7/VBN||were-6/VBD	root||ROOT-0/null||recruited-7/VBN	det||trial-10/NN||a-9/DT	prep_to||recruited-7/VBN||trial-10/NN	amod||inhibitor-15/NN||once-daily-12/JJ	amod||inhibitor-15/NN||nonnucleoside-13/JJ	amod||inhibitor-15/NN||reverse-transcriptase-14/JJ	prep_of||trial-10/NN||inhibitor-15/NN	appos||inhibitor-15/NN||nnrti-17/NNP	advmod||based-22/VBN||â-19/RB	pobj||â-19/RB||$-20/$	dep||inhibitor-15/NN||based-22/VBN	dobj||based-22/VBN||art-23/NN	dep||inhibitor-15/NN||treated-25/VBN	conj_and||based-22/VBN||treated-25/VBN	amod||treatment-30/NN||rifampicin-based-27/JJ	amod||treatment-30/NN||thrice-weekly-28/JJ	nn||treatment-30/NN||antituberculosis-29/NNS	prep_with||treated-25/VBN||treatment-30/NN	discourse||treatment-30/NN||att-32/UH	nsubjpass||randomized-37/VBN||participants-35/NNS	nsubj||receive-39/VB||participants-35/NNS	auxpass||randomized-37/VBN||were-36/VBD	parataxis||recruited-7/VBN||randomized-37/VBN	aux||receive-39/VB||to-38/TO	xcomp||randomized-37/VBN||receive-39/VB	dobj||receive-39/VB||didanosine-40/NN	number||mg-43/CD||250/400-42/CD	dep||didanosine-40/NN||mg-43/CD	dobj||receive-39/VB||lamivudine-46/NN	conj_and||didanosine-40/NN||lamivudine-46/NN	number||mg-49/CD||300-48/CD	dep||lamivudine-46/NN||mg-49/CD	det||efavirenz-53/NN||either-52/DT	prep_with||receive-39/VB||efavirenz-53/NN	number||mg-56/CD||600-55/CD	dep||efavirenz-53/NN||mg-56/CD	amod||once-daily-64/NN||nevirapine-59/JJ	number||mg-62/CD||400-61/CD	dep||once-daily-64/NN||mg-62/CD	prep_with||receive-39/VB||once-daily-64/NN	conj_or||efavirenz-53/NN||once-daily-64/NN	det||phase-68/NN||an-66/DT	amod||phase-68/NN||intensive-67/JJ	prep_after||receive-39/VB||phase-68/NN	prep_of||phase-68/NN||att-70/NN	tb-5||rifampicin--1||yes||antiretroviral-naive hiv-infected patients with tb were recruited to a trial of once-daily nonnucleoside reverse-transcriptase inhibitor (nnrti)âbased art and treated with rifampicin-based thrice-weekly antituberculosis treatment (att); participants were randomized to receive didanosine (250/400 mg) and lamivudine (300 mg) with either efavirenz (600 mg) or nevirapine (400 mg) once-daily after an intensive phase of att.
nsubj||reported-3/VBN||we-1/PRP	aux||reported-3/VBN||have-2/VBP	root||ROOT-0/null||reported-3/VBN	det||rate-11/NN||a-4/DT	amod||rate-11/NN||promising-5/JJ	amod||remission-7/JJ||complete-6/JJ	amod||rate-11/NN||remission-7/JJ	appos||rate-11/NN||cr-9/NN	dobj||reported-3/VBN||rate-11/NN	advmod||diagnosed-14/JJ||newly-13/RB	amod||patients-16/NNS||diagnosed-14/JJ	nn||patients-16/NNS||myeloma-15/NN	prep_for||rate-11/NN||patients-16/NNS	vmod||patients-16/NNS||treated-17/VBN	det||approach-21/NN||a-19/DT	amod||approach-21/NN||staged-20/JJ	agent||treated-17/VBN||approach-21/NN	prep_in||underwent-27/VBD||approach-21/NN	amod||patients-26/NNS||chemosensitive-25/JJ	nsubj||underwent-27/VBD||patients-26/NNS	rcmod||approach-21/NN||underwent-27/VBD	nsubj||stem-30/VB||autologous-28/NNS	dep||stem-30/VB||haematopoietic-29/JJ	xcomp||underwent-27/VBD||stem-30/VB	nn||transplantation-32/NN||cell-31/NN	dobj||stem-30/VB||transplantation-32/NN	appos||transplantation-32/NN||auto-hsct-34/NN	mark||received-40/VBD||while-36/IN	amod||patients-39/NNS||less-37/JJR	nn||patients-39/NNS||chemosensitive-38/NN	nsubj||received-40/VBD||patients-39/NNS	dep||transplantation-32/NN||received-40/VBD	nn||therapy-42/NN||salvage-41/NN	dobj||received-40/VBD||therapy-42/NN	prep_with||received-40/VBD||bortezomib/thalidomide/dexamethasone-44/NN	prep_prior_to||received-40/VBD||auto-hsct-47/NN	myeloma-15||thalidomide--1||yes||we have reported a promising complete remission (cr) rate for newly diagnosed myeloma patients treated by a staged approach, in which chemosensitive patients underwent autologous haematopoietic stem cell transplantation (auto-hsct) while less chemosensitive patients received salvage therapy with bortezomib/thalidomide/dexamethasone prior to auto-hsct.
nsubj||includes-13/VBZ||hypersensitivity-1/NN	nsubjpass||known-25/VBN||hypersensitivity-1/NN	nsubj||play-27/VB||hypersensitivity-1/NN	det||esophagus-4/NNS||the-3/DT	prep_of||hypersensitivity-1/NN||esophagus-4/NNS	prep_like||includes-13/VBZ||that-7/DT	amod||organs-11/NNS||other-9/JJ	amod||organs-11/NNS||visceral-10/JJ	prep_of||that-7/DT||organs-11/NNS	root||ROOT-0/null||includes-13/VBZ	dobj||includes-13/VBZ||peripheral-14/JJ	dobj||includes-13/VBZ||central-16/JJ	conj_and||peripheral-14/JJ||central-16/JJ	advmod||hypersensitivity-21/NN||probably-18/RB	amod||hypersensitivity-21/NN||psychosocial-19/JJ	amod||hypersensitivity-21/NN||factor-mediated-20/JJ	dobj||includes-13/VBZ||hypersensitivity-21/NN	conj_and||peripheral-14/JJ||hypersensitivity-21/NN	auxpass||known-25/VBN||is-24/VBZ	conj_and||includes-13/VBZ||known-25/VBN	aux||play-27/VB||to-26/TO	xcomp||known-25/VBN||play-27/VB	amod||roles-29/NNS||crucial-28/JJ	dobj||play-27/VB||roles-29/NNS	det||pathoegenesis-32/NNS||the-31/DT	prep_in||play-27/VB||pathoegenesis-32/NNS	amod||disease-36/NN||nonerosive-34/JJ	nn||disease-36/NN||reflux-35/NN	prep_of||pathoegenesis-32/NNS||disease-36/NN	amod||heartburn-39/NN||functional-38/JJ	prep_of||pathoegenesis-32/NNS||heartburn-39/NN	conj_and||disease-36/NN||heartburn-39/NN	amod||pain-43/NN||non-cardiac-41/JJ	nn||pain-43/NN||chest-42/NN	prep_of||pathoegenesis-32/NNS||pain-43/NN	conj_and||disease-36/NN||pain-43/NN	hypersensitivity-21||hypersensitivity-21||no||hypersensitivity of the esophagus, like that of other visceral organs, includes peripheral, central and probably psychosocial factor-mediated hypersensitivity, and is known to play crucial roles in the pathoegenesis of nonerosive reflux disease, functional heartburn and non-cardiac chest pain.
amod||³-3/NN||murine-1/JJ	nn||³-3/NN||î-2/NN	root||ROOT-0/null||³-3/NN	dep||³-3/NN||herpesvirus-5/NNS	num||herpesvirus-5/NNS||68-6/CD	dep||herpesvirus-5/NNS||mhv-68-8/JJ	dep||herpesvirus-5/NNS||infection-10/NN	nn||musculus-13/NNS||mus-12/NN	prep_of||herpesvirus-5/NNS||musculus-13/NNS	dep||³-3/NN||derived-15/VBN	nsubj||model-22/NN||strains-16/NNS	prep_of||strains-16/NNS||mice-18/NNS	cop||model-22/NN||is-19/VBZ	det||model-22/NN||an-20/DT	amod||model-22/NN||attractive-21/JJ	dep||derived-15/VBN||model-22/NN	nn||³-25/NNS||î-24/NN	prep_of||model-22/NN||³-25/NNS	dep||model-22/NN||herpesvirusinfection-27/NN	herpesvirusinfection-27||herpesvirus-5||no||murine î³-herpesvirus 68 (mhv-68) infection of mus musculus -derived strains of mice is an attractive model of î³-herpesvirusinfection.
expl||was-2/VBD||there-1/EX	root||ROOT-0/null||was-2/VBD	det||incidence-6/NN||a-3/DT	advmod||lower-5/JJR||significantly-4/RB	amod||incidence-6/NN||lower-5/JJR	nsubj||was-2/VBD||incidence-6/NN	prep_of||incidence-6/NN||microemulsion-8/NN	amod||pain-11/NN||propofol-9/JJ	nn||pain-11/NN||injection-10/NN	npadvmod||than-26/IN||pain-11/NN	dep||pain-11/NN||severity-13/$	num||severity-13/$||2-14/CD	dep||pain-11/NN||more-16/JJR	conj_or||severity-13/$||more-16/JJR	det||group-21/NN||the-19/DT	nn||group-21/NN||combination-20/NN	prep_in||severity-13/$||group-21/NN	num||%-24/NN||12.5-23/CD	appos||pain-11/NN||%-24/NN	advmod||was-2/VBD||than-26/IN	det||groups-32/NNS||the-28/DT	amod||groups-32/NNS||remifentanil-29/JJ	conj_and||remifentanil-29/JJ||lidocaine-31/JJ	amod||groups-32/NNS||lidocaine-31/JJ	prep_in||than-26/IN||groups-32/NNS	num||%-35/NN||90-34/CD	nsubj||p-42/VBP||%-35/NN	num||%-38/NN||65-37/CD	conj_and||%-35/NN||%-38/NN	nsubj||p-42/VBP||%-38/NN	advmod||%-38/NN||respectively-40/RB	dep||groups-32/NNS||p-42/VBP	num||0.05-44/CD||<-43/CD	dobj||p-42/VBP||0.05-44/CD	pain-11||lidocaine-31||yes||there was a significantly lower incidence of microemulsion propofol injection pain (severity 2 or more) in the combination group (12.5%) than in the remifentanil and lidocaine groups (90% and 65%, respectively, p < 0.05).
det||plurality-2/NN||a-1/DT	nsubjpass||treated-8/VBN||plurality-2/NN	prep_of||plurality-2/NN||patients-4/NNS	prep_with||patients-4/NNS||schizophrenia-6/NN	auxpass||treated-8/VBN||was-7/VBD	root||ROOT-0/null||treated-8/VBN	prep_with||treated-8/VBN||clozapine-10/NN	num||%-13/NN||39-12/CD	appos||clozapine-10/NN||%-13/NN	nsubjpass||followed-18/VBN||this-16/DT	auxpass||followed-18/VBN||was-17/VBD	parataxis||treated-8/VBN||followed-18/VBN	agent||followed-18/VBN||risperidone-20/JJ	agent||followed-18/VBN||sulpride-22/JJ	conj_and||risperidone-20/JJ||sulpride-22/JJ	agent||followed-18/VBN||chlorpromazine-24/JJ	conj_and||risperidone-20/JJ||chlorpromazine-24/JJ	agent||followed-18/VBN||perphenazine-26/JJ	conj_and||risperidone-20/JJ||perphenazine-26/JJ	agent||followed-18/VBN||haloperidol-29/JJ	conj_and||risperidone-20/JJ||haloperidol-29/JJ	schizophrenia-6||haloperidol-29||yes||a plurality of patients with schizophrenia was treated with clozapine (39%); this was followed by risperidone, sulpride, chlorpromazine, perphenazine, and haloperidol.
nsubj||describe-2/VBP||we-1/PRP	root||ROOT-0/null||describe-2/VBP	det||case-5/NN||the-3/DT	amod||case-5/NN||second-4/JJ	nsubj||reported-6/VBD||case-5/NN	ccomp||describe-2/VBP||reported-6/VBD	det||patient-9/NN||a-8/DT	prep_of||reported-6/VBD||patient-9/NN	ccomp||reported-6/VBD||developing-10/VBG	det||c.-13/NN||a-11/DT	amod||c.-13/NN||severe-12/JJ	nsubj||difficile-14/VB||c.-13/NN	nsubj||review-24/VB||c.-13/NN	ccomp||developing-10/VBG||difficile-14/VB	dobj||difficile-14/VB||colitis-15/NNS	prep||difficile-14/VB||following-16/VBG	advmod||without-18/IN||chemotherapy-17/RB	pcomp||following-16/VBG||without-18/IN	det||use-22/NN||any-19/DT	amod||use-22/NN||recent-20/JJ	amod||use-22/NN||antibiotic-21/JJ	pobj||without-18/IN||use-22/NN	ccomp||developing-10/VBG||review-24/VB	conj_and||difficile-14/VB||review-24/VB	det||data-26/NNS||the-25/DT	dobj||review-24/VB||data-26/NNS	det||literature-29/NN||the-28/DT	prep_of||data-26/NNS||literature-29/NN	ccomp||reported-6/VBD||emphasizing-31/VBG	conj_and||developing-10/VBG||emphasizing-31/VBG	det||need-33/NN||the-32/DT	dobj||emphasizing-31/VBG||need-33/NN	det||diagnosis-37/NN||a-35/DT	amod||diagnosis-37/NN||prompt-36/JJ	prep_to||emphasizing-31/VBG||diagnosis-37/NN	nsubj||decrease-43/VB||diagnosis-37/NN	prep_to||emphasizing-31/VBG||management-39/NN	conj_and||diagnosis-37/NN||management-39/NN	nsubj||decrease-43/VB||management-39/NN	aux||decrease-43/VB||can-41/MD	advmod||decrease-43/VB||significantly-42/RB	rcmod||diagnosis-37/NN||decrease-43/VB	det||morbidity-45/NN||the-44/DT	dobj||decrease-43/VB||morbidity-45/NN	ccomp||reported-6/VBD||life-threatening-47/VBG	conj_and||developing-10/VBG||life-threatening-47/VBG	dobj||life-threatening-47/VBG||complications-48/NNS	vmod||complications-48/NNS||associated-49/VBN	det||infection-52/NN||this-51/DT	prep_with||associated-49/VBN||infection-52/NN	antibiotic-21||colitis-15||no_rel||we describe the second case reported of a patient developing a severe c. difficile colitis following chemotherapy without any recent antibiotic use and review the data of the literature , emphasizing the need to a prompt diagnosis and management that can significantly decrease the morbidity and life-threatening complications associated with this infection .
nn||sizes-2/NNS||effect-1/NN	nsubjpass||analyzed-29/VBN||sizes-2/NNS	nn||thresholds-5/NNS||pain-4/NN	prep_on||sizes-2/NNS||thresholds-5/NNS	prep_to||thresholds-5/NNS||stimuli-7/NNS	vmod||stimuli-7/NNS||consisting-8/VBG	prep_of||consisting-8/VBG||heat-10/NN	amod||pressure-15/NN||cold-12/JJ	amod||pressure-15/NN||blunt-14/JJ	prep_of||consisting-8/VBG||pressure-15/NN	conj_and||heat-10/NN||pressure-15/NN	amod||pressure-18/NN||punctuate-17/JJ	prep_of||consisting-8/VBG||pressure-18/NN	conj_and||heat-10/NN||pressure-18/NN	amod||current-21/NN||electrical-20/JJ	prep_of||consisting-8/VBG||current-21/NN	conj_and||heat-10/NN||current-21/NN	vmod||sizes-2/NNS||administered-23/VBN	num||subjects-26/NNS||125-25/CD	prep_to||administered-23/VBN||subjects-26/NNS	auxpass||analyzed-29/VBN||were-28/VBD	root||ROOT-0/null||analyzed-29/VBN	num||variants-33/NNS||29-31/CD	amod||variants-33/NNS||common-32/JJ	nsubj||modulating-39/VBG||variants-33/NNS	num||genes-37/NNS||eight-35/CD	amod||genes-37/NNS||human-36/JJ	prep_in||variants-33/NNS||genes-37/NNS	advmod||modulating-39/VBG||reportedly-38/RB	prepc_for||analyzed-29/VBN||modulating-39/VBG	nn||procedures-45/NNS||pain-40/NN	conj_and||pain-40/NN||gender-42/NN	nn||procedures-45/NNS||gender-42/NN	conj_and||pain-40/NN||sensitization-44/NN	nn||procedures-45/NNS||sensitization-44/NN	dobj||modulating-39/VBG||procedures-45/NNS	vmod||modulating-39/VBG||using-46/VBG	dobj||using-46/VBG||capsaicin-47/NN	dobj||using-46/VBG||menthol-49/NN	conj_or||capsaicin-47/NN||menthol-49/NN	pain-40||capsaicin-47||yes||effect sizes on pain thresholds to stimuli consisting of heat, cold, blunt pressure, punctuate pressure and electrical current, administered to 125 subjects, were analyzed for 29 common variants in eight human genes reportedly modulating pain, gender and sensitization procedures using capsaicin or menthol.
nsubj||remains-2/VBZ||it-1/PRP	root||ROOT-0/null||remains-2/VBZ	acomp||remains-2/VBZ||uncertain-3/JJ	mark||considered-8/VBN||if-4/IN	nsubjpass||considered-8/VBN||dronedarone-5/NN	aux||considered-8/VBN||should-6/MD	auxpass||considered-8/VBN||be-7/VB	advcl||remains-2/VBZ||considered-8/VBN	det||strategy-12/NN||a-9/DT	amod||strategy-12/NN||primary-10/JJ	nn||strategy-12/NN||treatment-11/NN	dobj||considered-8/VBN||strategy-12/NN	prep_for||strategy-12/NN||atrialfibrillation-14/NN	dronedarone-5||atrialfibrillation-14||no_rel||it remains uncertain if dronedarone should be considered a primary treatment strategy for atrialfibrillation.
det||matrices-3/NNS||these-1/DT	amod||matrices-3/NNS||synthetic-2/JJ	nsubjpass||validated-6/VBN||matrices-3/NNS	auxpass||validated-6/VBN||are-4/VBP	advmod||validated-6/VBN||then-5/RB	root||ROOT-0/null||validated-6/VBN	prep||validated-6/VBN||against-7/IN	pobj||against-7/IN||recently-8/RB	vmod||recently-8/RB||collected-9/VBN	amod||data-12/NNS||italian-10/JJ	amod||data-12/NNS||serological-11/JJ	dobj||collected-9/VBN||data-12/NNS	prep_for||data-12/NNS||varicella-14/NN	appos||varicella-14/NN||vzv-16/NN	prep_for||data-12/NNS||parvovirus-19/NNS	conj_and||varicella-14/NN||parvovirus-19/NNS	appos||varicella-14/NN||b19-21/NNP	varicella-14||vzv-16||yes||these synthetic matrices are then validated against recently collected italian serological data for varicella (vzv) and parvovirus (b19).
num||kinds-2/NNS||two-1/CD	nsubj||viruses-7/NNS||kinds-2/NNS	prep_of||kinds-2/NNS||them-4/PRP	cop||viruses-7/NNS||are-5/VBP	amod||viruses-7/NNS||mosquito-borne-6/JJ	root||ROOT-0/null||viruses-7/NNS	nsubj||lead-16/VBP||viruses-7/NNS	nsubj||denguefever/denguehemorrhagicfever-21/VBP||viruses-7/NNS	advmod||virus-11/NN||namely-9/RB	amod||virus-11/NN||japaneseencephalitis-10/JJ	appos||viruses-7/NNS||virus-11/NN	appos||viruses-7/NNS||denguevirus-13/NNS	conj_and||virus-11/NN||denguevirus-13/NNS	rcmod||viruses-7/NNS||lead-16/VBP	prep_to||lead-16/VBP||japaneseencephalitis-18/NNS	rcmod||viruses-7/NNS||denguefever/denguehemorrhagicfever-21/VBP	conj_and||lead-16/VBP||denguefever/denguehemorrhagicfever-21/VBP	advmod||denguefever/denguehemorrhagicfever-21/VBP||respectively-22/RB	det||two-26/CD||the-24/DT	amod||two-26/CD||other-25/JJ	nsubj||viruses-29/NNS||two-26/CD	cop||viruses-29/NNS||are-27/VBP	amod||viruses-29/NNS||tick-borne-28/JJ	parataxis||viruses-7/NNS||viruses-29/NNS	nsubj||contribute-48/VBP||viruses-29/NNS	advmod||virus-33/NN||namely-31/RB	amod||virus-33/NN||tick-borneencephalitis-32/JJ	parataxis||viruses-7/NNS||virus-33/NN	conj_and||viruses-29/NNS||virus-33/NN	nsubj||contribute-48/VBP||virus-33/NN	amod||virus-37/NN||crimean-congo-35/JJ	nn||virus-37/NN||hemorrhagicfever-36/NN	parataxis||viruses-7/NNS||virus-37/NN	conj_and||viruses-29/NNS||virus-37/NN	nsubj||contribute-48/VBP||virus-37/NN	advmod||known-40/VBN||also-39/RB	dep||viruses-29/NNS||known-40/VBN	prepc_as||known-40/VBN||xinjiang-42/VBG	nn||virus-44/NN||hemorrhagicfever-43/NN	dobj||xinjiang-42/VBG||virus-44/NN	rcmod||viruses-29/NNS||contribute-48/VBP	prep_to||contribute-48/VBP||tick-borneencephalitis-50/NNS	nn||hemorrhagicfever-53/NN||xinjiang-52/NN	prep_to||contribute-48/VBP||hemorrhagicfever-53/NN	conj_and||tick-borneencephalitis-50/NNS||hemorrhagicfever-53/NN	advmod||contribute-48/VBP||respectively-54/RB	denguehemorrhagicfever--1||denguevirus-13||no||two kinds of them are mosquito-borne viruses, namely japaneseencephalitis virus and denguevirus, which lead to japaneseencephalitis, and denguefever/denguehemorrhagicfever respectively; the other two are tick-borne viruses, namely tick-borneencephalitis virus and crimean-congo hemorrhagicfever virus (also known as xinjiang hemorrhagicfever virus), which contribute to tick-borneencephalitis and xinjiang hemorrhagicfever respectively.
mark||clear-4/JJ||although-1/IN	nsubj||clear-4/JJ||it-2/PRP	cop||clear-4/JJ||is-3/VBZ	advcl||cause-47/VB||clear-4/JJ	mark||have-16/VBP||that-5/IN	det||patients-7/NNS||some-6/DT	nsubj||have-16/VBP||patients-7/NNS	prep_with||patients-7/NNS||acetylsalicylicacid-9/NN	appos||acetylsalicylicacid-9/NN||asa-11/NN	amod||asthma-15/NN||sensitive-14/JJ	dep||acetylsalicylicacid-9/NN||asthma-15/NN	ccomp||clear-4/JJ||have-16/VBP	poss||onset-19/NN||their-17/PRP$	amod||onset-19/NN||clinical-18/JJ	dobj||have-16/VBP||onset-19/NN	prep_of||onset-19/NN||disease-21/NN	prep_in||disease-21/NN||childhood-23/NN	prep_in||disease-21/NN||bronchoconstriction-25/NN	conj_and||childhood-23/NN||bronchoconstriction-25/NN	mark||seen-30/VBN||after-26/IN	nn||challenge-28/NN||asa-27/NN	nsubjpass||seen-30/VBN||challenge-28/NN	auxpass||seen-30/VBN||is-29/VBZ	advcl||have-16/VBP||seen-30/VBN	prep_in||seen-30/VBN||0-32/CD	num||%-35/NN||22-34/CD	prep_to||seen-30/VBN||%-35/NN	amod||children-38/NNS||asthmatic-37/JJ	prep_of||%-35/NN||children-38/NNS	advmod||challenged-40/VBN||so-39/RB	vmod||children-38/NNS||challenged-40/VBN	nsubj||cause-47/VB||ibuprofen-42/NN	amod||doses-45/NNS||antipyretic-44/JJ	prep_at||ibuprofen-42/NN||doses-45/NNS	aux||cause-47/VB||may-46/MD	root||ROOT-0/null||cause-47/VB	amod||problems-50/NNS||acute-48/JJ	nn||problems-50/NNS||respiratory-49/NN	dobj||cause-47/VB||problems-50/NNS	advmod||cause-47/VB||only-51/RB	det||number-56/NN||a-53/DT	advmod||small-55/JJ||very-54/RB	amod||number-56/NN||small-55/JJ	prep_in||cause-47/VB||number-56/NN	amod||moderate-60/JJ||mild-58/JJ	dep||moderate-60/JJ||to-59/TO	amod||asthmatics-61/NNS||moderate-60/JJ	prep_of||number-56/NN||asthmatics-61/NNS	asthmatics-61||ibuprofen-42||no||although it is clear that some patients with acetylsalicylicacid (asa)-sensitive asthma have their clinical onset of disease in childhood and bronchoconstriction after asa challenge is seen in 0 to 22% of asthmatic children so challenged, ibuprofen at antipyretic doses may cause acute respiratory problems only in a very small number of mild to moderate asthmatics.
nsubj||control-57/VBP||aims-1/NNS	aux||compare-3/VB||to-2/TO	vmod||aims-1/NNS||compare-3/VB	num||approaches-6/NNS||two-4/CD	amod||approaches-6/NNS||progressive-5/JJ	dobj||compare-3/VB||approaches-6/NNS	iobj||compare-3/VB||approaches-6/NNS	amod||insulinglargine-9/NN||-lsb--7/JJ	amod||insulinglargine-9/NN||once-daily-8/JJ	dep||approaches-6/NNS||insulinglargine-9/NN	amod||approaches-6/NNS||plus-10/IN	nn||+-19/NNS||â-11/NNP	nn||+-19/NNS||-12/NNP	amod||+-19/NNS||$-13/$	number||$-13/$||3-14/CD	dep||$-13/$||mealtime-15/JJ	amod||+-19/NNS||lispro-16/JJ	amod||+-19/NNS||-lrb--17/JJ	nn||+-19/NNS||g-18/NN	dep||approaches-6/NNS||+-19/NNS	nn||-rrb--21/NNP||l-20/NNP	dep||+-19/NNS||-rrb--21/NNP	nn||-rrb--28/NNP||insulinlispro-23/NN	nn||-rrb--28/NNP||mix-24/NN	nn||-rrb--28/NNP||50/50-25/NNP	nn||-rrb--28/NNP||-lrb--26/NNP	nn||-rrb--28/NNP||lm50/50-27/NNPS	prep_vs.||-rrb--21/NNP||-rrb--28/NNP	dep||-rrb--21/NNP||progression-29/VBN	advmod||up-31/RB||once-30/RB	advmod||progression-29/VBN||up-31/RB	aux||thrice-33/VB||to-32/TO	xcomp||progression-29/VBN||thrice-33/VB	amod||progression-37/NN||daily-34/JJ	amod||progression-37/NN||-lrb--35/JJ	nn||progression-37/NN||premix-36/NN	dobj||thrice-33/VB||progression-37/NN	nn||-rsb--41/NNP||pp-39/NNP	nn||-rsb--41/NNP||-rrb--40/NNP	appos||progression-37/NN||-rsb--41/NNP	prepc_of||-rsb--41/NNP||beginning-43/VBG	prepc_of||-rsb--41/NNP||advancing-45/VBG	conj_and||beginning-43/VBG||advancing-45/VBG	dobj||beginning-43/VBG||insulin-46/NN	prep_in||beginning-43/VBG||patients-48/NNS	amod||-rrb--53/NNS||type2diabetes-50/JJ	amod||-rrb--53/NNS||-lrb--51/JJ	amod||-rrb--53/NNS||t2d-52/JJ	prep_with||patients-48/NNS||-rrb--53/NNS	amod||glycaemic-56/JJ||inadequate-55/JJ	dep||-rrb--21/NNP||glycaemic-56/JJ	conj_and||progression-29/VBN||glycaemic-56/JJ	root||ROOT-0/null||control-57/VBP	amod||therapy-60/NN||oral-59/JJ	prep_on||control-57/VBP||therapy-60/NN	det||aim-64/NN||the-63/DT	prep_with||control-57/VBP||aim-64/NN	prepc_of||aim-64/NN||showing-66/VBG	dobj||showing-66/VBG||non-inferiority-67/NN	prep_of||non-inferiority-67/NN||pp-69/NN	prep_to||showing-66/VBG||g-71/NN	amod||l-73/NN||+-72/JJ	dobj||control-57/VBP||l-73/NN	t2d-52||lispro-16||yes||aims to compare two progressive approaches -lsb- once-daily insulinglargine plus â  $ 3 mealtime lispro -lrb- g+l -rrb- vs. insulinlispro mix 50/50 -lrb- lm50/50 -rrb- progression once up to thrice daily -lrb- premix progression , pp -rrb- -rsb- of beginning and advancing insulin in patients with type2diabetes -lrb- t2d -rrb- and inadequate glycaemic control on oral therapy , with the aim of showing non-inferiority of pp to g+l .
nsubj||reported-6/VBD||none-1/NN	det||other-4/JJ||the-3/DT	prep_of||none-1/NN||other-4/JJ	advmod||reported-6/VBD||previously-5/RB	root||ROOT-0/null||reported-6/VBD	nsubjpass||associated-9/VBN||snps-7/NNS	auxpass||associated-9/VBN||were-8/VBD	ccomp||reported-6/VBD||associated-9/VBN	prep_with||associated-9/VBN||type2diabetes-11/CD	advmod||found-17/VBN||however-13/RB	nsubjpass||found-17/VBN||associations-15/NNS	auxpass||found-17/VBN||were-16/VBD	parataxis||reported-6/VBD||found-17/VBN	amod||variants-22/NNS||cdkal1-19/JJ	conj_and||cdkal1-19/JJ||hhex-21/JJ	amod||variants-22/NNS||hhex-21/JJ	prep_between||found-17/VBN||variants-22/NNS	amod||response-26/NN||acute-24/JJ	nn||response-26/NN||insulin-25/NN	prep_between||found-17/VBN||response-26/NN	conj_and||variants-22/NNS||response-26/NN	appos||response-26/NN||air-28/NN	advmod||associated-39/VBN||where-31/WRB	det||alleles-35/NNS||the-32/DT	amod||alleles-35/NNS||caucasian-33/JJ	nn||alleles-35/NNS||risk-34/NN	nsubjpass||associated-39/VBN||alleles-35/NNS	prep_for||alleles-35/NNS||type2diabetes-37/CD	auxpass||associated-39/VBN||were-38/VBD	rcmod||response-26/NN||associated-39/VBN	amod||secretion-43/NN||reduced-41/VBN	nn||secretion-43/NN||insulin-42/NN	prep_with||associated-39/VBN||secretion-43/NN	amod||indians-47/NNS||normoglycemic-45/JJ	nn||indians-47/NNS||pima-46/NN	prep_in||secretion-43/NN||indians-47/NNS	type2diabetes-37||insulin-42||yes||none of the other previously reported snps were associated with type2diabetes; however, associations were found between cdkal1 and hhex variants and acute insulin response (air), where the caucasian risk alleles for type2diabetes were associated with reduced insulin secretion in normoglycemic pima indians.
det||possibility-2/NN||the-1/DT	nsubj||allow-14/VB||possibility-2/NN	nsubj||help-27/VB||possibility-2/NN	prepc_of||possibility-2/NN||extracting-4/VBG	dobj||extracting-4/VBG||rna-5/NN	prepc_of||possibility-2/NN||measuring-7/VBG	conj_and||extracting-4/VBG||measuring-7/VBG	nn||expression-9/NN||rna-8/NN	dobj||measuring-7/VBG||expression-9/NN	nn||sections-12/NNS||paraffin-11/NN	prep_from||measuring-7/VBG||sections-12/NNS	aux||allow-14/VB||can-13/MD	root||ROOT-0/null||allow-14/VB	amod||investigations-16/NNS||extensive-15/JJ	dobj||allow-14/VB||investigations-16/NNS	amod||samples-20/NNS||stored-18/JJ	nn||samples-20/NNS||paraffin-19/NN	prep_on||allow-14/VB||samples-20/NNS	vmod||samples-20/NNS||obtained-21/VBN	amod||livers-24/NNS||diseased-23/JJ	prep_from||obtained-21/VBN||livers-24/NNS	aux||help-27/VB||could-26/MD	conj_and||allow-14/VB||help-27/VB	conj_and||allow-14/VB||help-27/VB	conj_and||help-27/VB||help-27/VB	prep_with||help-27/VB||studies-29/NNS	det||history-33/NN||the-31/DT	amod||history-33/NN||natural-32/JJ	prep_of||studies-29/NNS||history-33/NN	nn||fibrosis-36/NN||liver-35/NN	prep_of||history-33/NN||fibrosis-36/NN	prep_of||history-33/NN||inflammation-38/NN	conj_and||fibrosis-36/NN||inflammation-38/NN	amod||mechanisms-46/NNS||particular-42/JJ	amod||mechanisms-46/NNS||correlate-44/JJ	amod||mechanisms-46/NNS||basic-45/JJ	prep_in||help-27/VB||mechanisms-46/NNS	amod||outcomes-49/NNS||clinical-48/JJ	prep_to||help-27/VB||outcomes-49/NNS	paraffin-19||fibrosis-36||no_rel||the possibility of extracting rna and measuring rna expression from paraffin sections can allow extensive investigations on stored paraffin samples obtained from diseased livers and could help with studies of the natural history of liver fibrosis and inflammation, and in particular, correlate basic mechanisms to clinical outcomes.
num||weeks-3/NNS||16-2/CD	prep_at||â-9/NN||weeks-3/NNS	nn||hbp-6/NN||morning-5/NN	nsubj||â-9/NN||hbp-6/NN	cop||â-9/NN||was-7/VBD	num||â-9/NN||135.0-8/CD	root||ROOT-0/null||â-9/NN	num||13.7-11/CD||±-10/CD	dep||â-9/NN||13.7-11/CD	punct||13.7-11/CD||/-12/:	number||â-14/CD||78.8-13/CD	num||hg-23/NN||â-14/CD	nn||hg-23/NN||±-15/NNP	num||hg-23/NN||9.9-16/CD	amod||hg-23/NN||â-17/JJ	prep||â-17/JJ||$-18/$	number||mmâ-20/CD||-19/CD	num||$-18/$||mmâ-20/CD	dep||$-18/$||$-21/$	num||$-21/$||-22/CD	nsubj||â-29/NN||hg-23/NN	amod||hbp-26/NN||bedtime-25/JJ	conj_and||hg-23/NN||hbp-26/NN	nsubj||â-29/NN||hbp-26/NN	cop||â-29/NN||was-27/VBD	num||â-29/NN||129.7-28/CD	dep||13.7-11/CD||â-29/NN	number||13.8-31/CD||±-30/CD	dep||â-29/NN||13.8-31/CD	punct||â-34/NN||/-32/:	num||â-34/NN||74.7-33/CD	dep||â-29/NN||â-34/NN	vmod||â-34/NN||±-35/VBN	num||â-37/NNS||10.1-36/CD	iobj||±-35/VBN||â-37/NNS	num||â-37/NNS||$-38/$	number||mmâ-40/CD||-39/CD	num||$-38/$||mmâ-40/CD	dobj||±-35/VBN||$-41/$	num||$-41/$||-42/CD	advmod||$-41/$||hg-43/RB	mark||±-50/NNP||whereas-45/IN	nsubj||±-50/NNP||cbp-46/NN	cop||±-50/NNP||was-47/VBD	number||â-49/CD||135.6-48/CD	num||±-50/NNP||â-49/CD	advcl||±-35/VBN||±-50/NNP	num||±-50/NNP||15.4-51/CD	punct||â-34/NN||/-52/:	number||â-54/CD||77.6-53/CD	num||â-57/NN||â-54/CD	nn||â-57/NN||±-55/NNP	num||â-57/NN||10.9-56/CD	dep||â-29/NN||â-57/NN	num||$-61/$||$-58/$	number||mmâ-60/CD||-59/CD	num||$-58/$||mmâ-60/CD	dep||â-57/NN||$-61/$	number||hg-63/CD||-62/CD	num||$-61/$||hg-63/CD	hg-63||hbp-26||no_rel||at 16 weeks, morning hbp was 135.0â±13.7/78.8â±9.9âmmâhg and bedtime hbp was 129.7â±13.8/74.7â±10.1âmmâhg, whereas cbp was 135.6â±15.4/77.6â±10.9âmmâhg.
nsubj||drugs-14/NNS||chondroitinsulfate-1/NN	appos||chondroitinsulfate-1/NN||cs-3/NN	amod||sulfate-7/NN||glucosamine-6/JJ	conj_and||chondroitinsulfate-1/NN||sulfate-7/NN	nsubj||drugs-14/NNS||sulfate-7/NN	appos||sulfate-7/NN||gs-9/NN	cop||drugs-14/NNS||are-11/VBP	amod||drugs-14/NNS||symptomatic-12/JJ	amod||drugs-14/NNS||slow-acting-13/JJ	root||ROOT-0/null||drugs-14/NNS	prep_for||drugs-14/NNS||osteoarthritis-16/NNS	appos||osteoarthritis-16/NNS||oa-18/NN	advmod||used-21/VBN||widely-20/RB	vmod||osteoarthritis-16/NNS||used-21/VBN	prep_in||used-21/VBN||clinic-23/NN	osteoarthritis-16||chondroitinsulfate-1||yes||chondroitinsulfate (cs) and glucosamine sulfate (gs) are symptomatic slow-acting drugs for osteoarthritis (oa) widely used in clinic.
nsubj||involved-5/VBN||subtypes-1/NNS	amod||receptors-4/NNS||purinergic-3/JJ	prep_of||subtypes-1/NNS||receptors-4/NNS	root||ROOT-0/null||involved-5/VBN	prep_in||involved-5/VBN||modulation-7/NN	amod||concentration-12/NN||cytoplasmic-9/JJ	nn||concentration-12/NN||calcium-10/NN	nn||concentration-12/NN||ion-11/NN	prep_of||modulation-7/NN||concentration-12/NN	nn||i-18/NNP||-LSB--14/NNP	nn||i-18/NNP||ca2-15/NNP	nn||i-18/NNP||+-16/NNP	nn||i-18/NNP||-RSB--17/NNP	appos||concentration-12/NN||i-18/NNP	nn||release-22/NN||insulin-21/NN	prep_in||involved-5/VBN||release-22/NN	conj_and||modulation-7/NN||release-22/NN	nn||²-27/NNS||mouse-24/NN	amod||²-27/NNS||pancreatic-25/JJ	nn||²-27/NNS||î-26/NN	prep_in||release-22/NN||²-27/NNS	nsubjpass||examined-31/VBN||cells-29/NNS	auxpass||examined-31/VBN||were-30/VBD	parataxis||involved-5/VBN||examined-31/VBN	num||systems-34/NNS||two-33/CD	prep_in||examined-31/VBN||systems-34/NNS	amod||islets-37/NNS||pancreatic-36/JJ	appos||systems-34/NNS||islets-37/NNS	amod||culture-40/NN||primary-39/JJ	prep_in||islets-37/NNS||culture-40/NN	amod||cells-44/NNS||beta-tc6-42/JJ	nn||cells-44/NNS||insulinoma-43/NN	prep_in||islets-37/NNS||cells-44/NNS	conj_and||culture-40/NN||cells-44/NNS	insulin-21||insulinoma-43||no_rel||subtypes of purinergic receptors involved in modulation of cytoplasmic calcium ion concentration ([ca2+]i) and insulin release in mouse pancreatic î²-cells were examined in two systems, pancreatic islets in primary culture and beta-tc6 insulinoma cells.
amod||aes-2/NN||placebo-adjusted-1/JJ	nsubj||insomnia-9/JJ||aes-2/NN	advmod||common-4/JJ||more-3/RBR	amod||aes-2/NN||common-4/JJ	amod||er-7/NN||paliperidone-6/JJ	prep_with||common-4/JJ||er-7/NN	cop||insomnia-9/JJ||were-8/VBD	ccomp||congestion-36/NN||insomnia-9/JJ	nn||tachycardia-12/NN||sinus-11/NNS	nsubj||congestion-36/NN||tachycardia-12/NN	conj_and||tachycardia-12/NN||tachycardia-14/NN	nsubj||congestion-36/NN||tachycardia-14/NN	advmod||common-17/JJ||more-16/RBR	amod||tachycardia-12/NN||common-17/JJ	prep_with||tachycardia-12/NN||risperidone-19/NN	cop||congestion-36/NN||were-20/VBD	nn||congestion-36/NN||somnolence-21/NN	conj_and||somnolence-21/NN||restlessness-23/NNS	nn||congestion-36/NN||restlessness-23/NNS	conj_and||somnolence-21/NN||nausea-25/NN	nn||congestion-36/NN||nausea-25/NN	conj_and||somnolence-21/NN||anxiety-27/NN	nn||congestion-36/NN||anxiety-27/NN	conj_and||somnolence-21/NN||salivaryhypersecretion-29/NN	nn||congestion-36/NN||salivaryhypersecretion-29/NN	conj_and||somnolence-21/NN||akathisia-31/NN	nn||congestion-36/NN||akathisia-31/NN	conj_and||somnolence-21/NN||dizziness-33/NN	nn||congestion-36/NN||dizziness-33/NN	conj_and||somnolence-21/NN||nasal-35/NN	nn||congestion-36/NN||nasal-35/NN	root||ROOT-0/null||congestion-36/NN	nausea-25||risperidone-19||no_rel||placebo-adjusted aes more common with paliperidone er were insomnia, sinus tachycardia and tachycardia; more common with risperidone were somnolence, restlessness, nausea, anxiety, salivaryhypersecretion, akathisia, dizziness and nasal congestion.
amod||methods-2/NNS||various-1/JJ	nsubjpass||used-5/VBN||methods-2/NNS	nsubj||minimize-7/VB||methods-2/NNS	aux||used-5/VBN||have-3/VBP	auxpass||used-5/VBN||been-4/VBN	root||ROOT-0/null||used-5/VBN	aux||minimize-7/VB||to-6/TO	xcomp||used-5/VBN||minimize-7/VB	det||incidence-9/NN||the-8/DT	dobj||minimize-7/VB||incidence-9/NN	dobj||minimize-7/VB||severity-11/NN	conj_and||incidence-9/NN||severity-11/NN	prep_of||incidence-9/NN||pain-13/NN	prep_on||minimize-7/VB||injection-15/NN	nn||propofol-19/NN||lipid-17/NN	nn||propofol-19/NN||emulsion-18/NN	prep_of||injection-15/NN||propofol-19/NN	pain-13||propofol-19||yes||various methods have been used to minimize the incidence and severity of pain on injection of lipid emulsion propofol.
aux||investigate-2/VB||to-1/TO	advcl||tested-43/VBD||investigate-2/VB	det||occurrence-5/NN||the-3/DT	amod||occurrence-5/NN||possible-4/JJ	dobj||investigate-2/VB||occurrence-5/NN	iobj||investigate-2/VB||occurrence-5/NN	prep_of||occurrence-5/NN||humanimmunodeficiencyvirus-7/NNS	appos||humanimmunodeficiencyvirus-7/NNS||hiv-9/NN	amod||virus-15/NN||human-12/JJ	amod||virus-15/NN||t-cell-13/JJ	amod||virus-15/NN||lymphotropic-14/JJ	prep_of||occurrence-5/NN||virus-15/NN	conj_or||humanimmunodeficiencyvirus-7/NNS||virus-15/NN	nn||i-18/NNS||type-17/NN	appos||virus-15/NN||i-18/NNS	appos||occurrence-5/NN||htlv-i-20/NNP	dep||occurrence-5/NN||infections-22/NNS	det||states-26/NNS||the-24/DT	amod||states-26/NNS||united-25/VBN	prep_in||infections-22/NNS||states-26/NNS	prep_prior_to||investigate-2/VB||1979-1981-29/CD	advmod||recognized-40/VBN||when-31/WRB	amod||syndrome-34/NN||acquired-32/VBN	amod||syndrome-34/NN||immunedeficiency-33/JJ	nsubjpass||recognized-40/VBN||syndrome-34/NN	appos||syndrome-34/NN||aids-36/NNS	auxpass||recognized-40/VBN||was-38/VBD	advmod||recognized-40/VBN||first-39/RB	advcl||investigate-2/VB||recognized-40/VBN	nsubj||tested-43/VBD||we-42/PRP	root||ROOT-0/null||tested-43/VBD	dobj||tested-43/VBD||sera-44/NN	amod||women-48/NNS||310-46/JJ	amod||women-48/NNS||pregnant-47/JJ	prep_from||tested-43/VBD||women-48/NNS	nsubj||participated-50/VBD||women-48/NNS	rcmod||women-48/NNS||participated-50/VBD	det||project-55/NN||the-52/DT	amod||project-55/NN||collaborative-53/JJ	amod||project-55/NN||perinatal-54/JJ	prep_in||participated-50/VBD||project-55/NN	det||1959-1964-59/NN||the-57/DT	nn||1959-1964-59/NN||period-58/NN	prep_during||participated-50/VBD||1959-1964-59/NN	prep_for||1959-1964-59/NN||hiv-61/NN	prep_for||1959-1964-59/NN||htlv-iantibody-63/NN	conj_and||hiv-61/NN||htlv-iantibody-63/NN	htlv-iantibody-63||htlv-i-20||no||to investigate the possible occurrence of humanimmunodeficiencyvirus (hiv) or human t-cell lymphotropic virus, type i (htlv-i) infections in the united states prior to 1979-1981, when acquired immunedeficiency syndrome (aids) was first recognized, we tested sera from 310 pregnant women who participated in the collaborative perinatal project during the period 1959-1964 for hiv and htlv-iantibody.
det||practice-2/NN||the-1/DT	nsubj||explanation-14/NN||practice-2/NN	prepc_of||practice-2/NN||combining-4/VBG	dobj||combining-4/VBG||agents-5/NNS	nsubj||counteract-7/VB||agents-5/NNS	rcmod||agents-5/NNS||counteract-7/VB	amod||mechanisms-9/NNS||different-8/JJ	dobj||counteract-7/VB||mechanisms-9/NNS	cop||explanation-14/NN||is-10/VBZ	det||explanation-14/NN||the-11/DT	advmod||likely-13/JJ||most-12/RBS	amod||explanation-14/NN||likely-13/JJ	root||ROOT-0/null||explanation-14/NN	det||fact-17/NN||the-16/DT	prep_for||explanation-14/NN||fact-17/NN	mark||have-23/VBP||that-18/IN	advmod||available-20/JJ||most-19/RBS	amod||combinations-22/NNS||available-20/JJ	amod||combinations-22/NNS||two-drug-21/JJ	nsubj||have-23/VBP||combinations-22/NNS	ccomp||explanation-14/NN||have-23/VBP	det||agent-25/NN||an-24/DT	dobj||have-23/VBP||agent-25/NN	nsubj||addresses-27/VBZ||agent-25/NN	rcmod||agent-25/NN||addresses-27/VBZ	nn||secretion-29/NN||renin-28/NN	dobj||addresses-27/VBZ||secretion-29/NN	dep||agent-25/NN||beta-blocker-31/NN	appos||beta-blocker-31/NN||angiotensinconvertingenzymeinhibitor-33/NN	nn||blocker-38/NN||angiotensin-35/NN	nn||blocker-38/NN||ii-36/NN	nn||blocker-38/NN||receptor-37/NN	appos||beta-blocker-31/NN||blocker-38/NN	amod||inhibitor-42/NN||direct-40/JJ	nn||inhibitor-42/NN||renin-41/NN	appos||beta-blocker-31/NN||inhibitor-42/NN	conj_or||blocker-38/NN||inhibitor-42/NN	det||one-46/NN||another-45/DT	conj_and||agent-25/NN||one-46/NN	nsubj||effective-50/JJ||one-46/NN	cop||effective-50/JJ||is-48/VBZ	advmod||effective-50/JJ||more-49/RBR	rcmod||one-46/NN||effective-50/JJ	amod||hypertension-53/NN||renin-independent-52/JJ	prep_in||effective-50/JJ||hypertension-53/NN	nn||calciumchannelblocker-60/NN||diuretic-55/NN	conj_or||diuretic-55/NN||dihydropyridine-57/NN	nn||calciumchannelblocker-60/NN||dihydropyridine-57/NN	conj_or||diuretic-55/NN||non-dihydropyridine-59/NN	nn||calciumchannelblocker-60/NN||non-dihydropyridine-59/NN	appos||one-46/NN||calciumchannelblocker-60/NN	hypertension-53||angiotensinconvertingenzymeinhibitor-33||no_rel||the practice of combining agents that counteract different mechanisms is the most likely explanation for the fact that most available two-drug combinations have an agent that addresses renin secretion (beta-blocker, angiotensinconvertingenzymeinhibitor, angiotensin ii receptor blocker or direct renin inhibitor) and another one that is more effective in renin-independent hypertension (diuretic, dihydropyridine or non-dihydropyridine calciumchannelblocker).
nn||glucose-2/NN||plasma-1/NN	nsubjpass||measured-12/VBN||glucose-2/NN	nsubjpass||measured-12/VBN||glucose-2/NN	nsubjpass||measured-12/VBN||glucose-2/NN	conj_and||glucose-2/NN||insulin-4/NN	nsubjpass||measured-12/VBN||insulin-4/NN	conj_and||glucose-2/NN||c-peptide-6/NN	nsubjpass||measured-12/VBN||c-peptide-6/NN	nn||concentrations-10/NNS||glucagon-9/NN	conj_and||glucose-2/NN||concentrations-10/NNS	nsubjpass||measured-12/VBN||concentrations-10/NNS	auxpass||measured-12/VBN||were-11/VBD	root||ROOT-0/null||measured-12/VBN	conj_and||measured-12/VBN||measured-12/VBN	conj_and||measured-12/VBN||measured-12/VBN	det||min-15/NN||every-13/DT	num||min-15/NN||30-14/CD	dobj||measured-12/VBN||min-15/NN	amod||ingestion-42/NN||â-17/JJ	dep||â-17/JJ||60-18/CD	num||min-21/NN||180-20/CD	prep_through||â-17/JJ||min-21/NN	amod||administration-26/NN||random-sequence-23/JJ	amod||administration-26/NN||double-blind-25/JJ	prep_with||min-21/NN||administration-26/NN	prep_of||administration-26/NN||diazoxide-28/NN	num||mg/kg-31/NN||6.0-30/CD	appos||diazoxide-28/NN||mg/kg-31/NN	prep_of||administration-26/NN||placebo-34/NN	conj_or||diazoxide-28/NN||placebo-34/NN	amod||min-40/NN||â-36/JJ	dep||â-36/JJ||30-37/CD	dep||â-36/JJ||1-39/CD	conj_and||30-37/CD||1-39/CD	prep_at||placebo-34/NN||min-40/NN	prep_from||measured-12/VBN||ingestion-42/NN	det||meal-47/NN||a-44/DT	nn||meal-47/NN||formula-45/NN	amod||meal-47/NN||mixed-46/JJ	prep_of||ingestion-42/NN||meal-47/NN	parataxis||measured-12/VBN||ensure-49/VB	advmod||ensure-49/VB||plus-50/CC	prep_at||measured-12/VBN||0-53/CD	vmod||0-53/CD||min-54/VBN	prep_after||min-54/VBN||diazoxide-56/NN	prep_after||min-54/VBN||placebo-59/NN	conj_and||diazoxide-56/NN||placebo-59/NN	cc||measured-12/VBN||and-60/CC	det||occasion-65/NN||a-63/DT	amod||occasion-65/NN||separate-64/JJ	prep_on||measured-12/VBN||occasion-65/NN	npadvmod||measured-12/VBN||ingestion-67/NN	prep_of||ingestion-67/NN||glimepiride-69/NN	number||mg-72/CD||4.0-71/CD	dep||glimepiride-69/NN||mg-72/CD	num||min-76/NN||0-75/CD	prep_at||glimepiride-69/NN||min-76/NN	prep_with||glimepiride-69/NN||glucose-79/NN	vmod||glucose-79/NN||infused-80/VBN	aux||prevent-82/VB||to-81/TO	xcomp||infused-80/VBN||prevent-82/VB	dobj||prevent-82/VB||hypoglycemia-83/NN	prep_after||measured-12/VBN||diazoxide-86/NN	prep_after||measured-12/VBN||placebo-89/NN	num||adults-94/NNS||11-91/CD	amod||adults-94/NNS||healthy-92/JJ	amod||adults-94/NNS||young-93/JJ	prep_in||placebo-89/NN||adults-94/NNS	hypoglycemia-83||diazoxide-86||no||plasma glucose, insulin, c-peptide, and glucagon concentrations were measured every 30 min from â60 through 180 min with random-sequence, double-blind administration of diazoxide (6.0 mg/kg) or placebo at â30 and 1 min, ingestion of a formula mixed meal (ensure plus) at 0 min after diazoxide and after placebo and, on a separate occasion, ingestion of glimepiride (4.0 mg) at 0 min (with glucose infused to prevent hypoglycemia) after diazoxide and after placebo in 11 healthy young adults.
poss||analyses-2/NNS||our-1/PRP$	nsubj||indicated-3/VBD||analyses-2/NNS	ccomp||attached-24/VBN||indicated-3/VBD	mark||deserves-12/VBZ||that-4/IN	det||prevalence-6/NN||the-5/DT	nsubj||deserves-12/VBZ||prevalence-6/NN	amod||co-infection-9/NN||hiv/tb-8/JJ	prep_of||prevalence-6/NN||co-infection-9/NN	prep_in||co-infection-9/NN||china-11/NN	ccomp||indicated-3/VBD||deserves-12/VBZ	amod||attention-14/NN||special-13/JJ	dobj||deserves-12/VBZ||attention-14/NN	nsubjpass||attached-24/VBN||screening-16/NN	prep_of||screening-16/NN||tb-18/NN	amod||populations-21/NNS||hiv/aids-20/JJ	prep_among||tb-18/NN||populations-21/NNS	aux||attached-24/VBN||should-22/MD	auxpass||attached-24/VBN||be-23/VB	root||ROOT-0/null||attached-24/VBN	amod||importance-26/NN||more-25/JJR	dobj||attached-24/VBN||importance-26/NN	nsubj||helpful-33/JJ||importance-26/NN	aux||helpful-33/JJ||would-29/MD	cop||helpful-33/JJ||be-30/VB	advmod||helpful-33/JJ||much-31/RB	advmod||helpful-33/JJ||more-32/RBR	rcmod||importance-26/NN||helpful-33/JJ	prep_for||helpful-33/JJ||treatment-35/NN	det||diseases-38/NNS||both-37/DT	prep_of||treatment-35/NN||diseases-38/NNS	aids--1||hiv--1||no||our analyses indicated that the prevalence of hiv/tb co-infection in china deserves special attention, screening of tb among hiv/aids populations should be attached more importance, which would be much more helpful for treatment of both diseases.
nsubj||superior-3/JJ||entecavir-1/NN	nsubj||adefovir-5/VB||entecavir-1/NN	cop||superior-3/JJ||is-2/VBZ	root||ROOT-0/null||superior-3/JJ	aux||adefovir-5/VB||to-4/TO	xcomp||superior-3/JJ||adefovir-5/VB	amod||dna-10/NN||decreasing-7/VBG	nn||dna-10/NN||serum-8/NN	nn||dna-10/NN||hbv-9/NN	prep_in||adefovir-5/VB||dna-10/NN	amod||alt-13/NN||normalizing-12/VBG	prep_in||adefovir-5/VB||alt-13/NN	conj_and||dna-10/NN||alt-13/NN	amod||adefovir-38/NN||similar-15/JJ	prep_with||similar-15/JJ||adefovir-17/NN	prepc_in||adefovir-17/NN||clearing-19/VBG	vmod||clearing-19/VBG||hbeag-20/VBG	prepc_in||adefovir-17/NN||encouraging-22/VBG	conj_and||clearing-19/VBG||encouraging-22/VBG	amod||seroconversion-24/NN||hbeag-23/VBG	dobj||encouraging-22/VBG||seroconversion-24/NN	det||nucleos-28/NNS||the-26/DT	amod||nucleos-28/NNS||hbeag-positive-27/JJ	prep_for||seroconversion-24/NN||nucleos-28/NNS	amod||t-30/NN||-lrb--29/JJ	dep||encouraging-22/VBG||t-30/NN	dep||t-30/NN||-rrb--31/VBG	amod||patients-34/NNS||ide-naive-32/JJ	nn||patients-34/NNS||asian-33/NN	dobj||-rrb--31/VBG||patients-34/NNS	prep_with||-rrb--31/VBG||chronichepatitisb-36/NN	nsubjpass||used-42/VBN||adefovir-38/NN	aux||used-42/VBN||can-39/MD	auxpass||used-42/VBN||be-40/VB	advmod||used-42/VBN||still-41/RB	conj_but||superior-3/JJ||used-42/VBN	amod||therapy-45/NN||first-line-44/JJ	prep_for||used-42/VBN||therapy-45/NN	det||patients-48/NNS||these-47/DT	prep_in||therapy-45/NN||patients-48/NNS	hbv-9||entecavir-1||yes||entecavir is superior to adefovir in decreasing serum hbv dna and normalizing alt but similar with adefovir in clearing hbeag and encouraging hbeag seroconversion for the hbeag-positive nucleos -lrb- t -rrb- ide-naive asian patients with chronichepatitisb. adefovir can be still used for first-line therapy in these patients .
aux||describe-2/VB||to-1/TO	csubj||replaced-24/VBN||describe-2/VB	det||case-management-9/NN||the-3/DT	dep||case-management-9/NN||quality-4/NN	prep_of||quality-4/NN||outpatient-6/NN	amod||case-management-9/NN||paediatric-7/JJ	nn||case-management-9/NN||malaria-8/NN	dobj||describe-2/VB||case-management-9/NN	advmod||4â-11/JJ||approximately-10/RB	amod||case-management-9/NN||4â-11/JJ	num||months-15/NNS||$-12/$	num||$-12/$||6-14/CD	npadvmod||describe-2/VB||months-15/NNS	nn||$-18/NNP||artemetherâ-17/NNP	prep_after||describe-2/VB||$-18/NNP	dep||$-18/NNP||lumefantrine-20/NN	appos||$-18/NNP||al-22/NNP	root||ROOT-0/null||replaced-24/VBN	nn||$-26/NNP||sulfadoxineâ-25/NNP	dep||pyrimethamine-28/NN||$-26/NNP	dep||replaced-24/VBN||pyrimethamine-28/NN	discourse||pyrimethamine-28/NN||sp-30/UH	det||therapy-37/NN||the-33/DT	amod||therapy-37/NN||nationally-34/JJR	amod||therapy-37/NN||recommended-35/VBN	amod||therapy-37/NN||first-line-36/JJ	prep_as||replaced-24/VBN||therapy-37/NN	prep_in||therapy-37/NN||kenya-39/NN	malaria-8||pyrimethamine-28||no||to describe the quality of outpatient paediatric malaria case-management approximately 4â6 months after artemetherâlumefantrine (al) replaced sulfadoxineâpyrimethamine (sp) as the nationally recommended first-line therapy in kenya.
nsubj||sought-2/VBD||we-1/PRP	nsubj||determine-4/VB||we-1/PRP	root||ROOT-0/null||sought-2/VBD	aux||determine-4/VB||to-3/TO	xcomp||sought-2/VBD||determine-4/VB	mark||altered-36/VBN||if-5/IN	nsubjpass||altered-36/VBN||upa-6/NN	nn||inhibitor-9/NN||pa-8/NN	appos||upa-6/NN||inhibitor-9/NN	appos||inhibitor-9/NN||pai-11/NN	dep||inhibitor-9/NN||-1-13/CD	num||expression-20/NN||prostaglandin-15/CD	nn||expression-20/NN||pg-17/NN	amod||expression-20/NN||e2-19/JJ	appos||upa-6/NN||expression-20/NN	conj_and||inhibitor-9/NN||expression-20/NN	amod||fluid-24/NN||nipple-22/JJ	nn||fluid-24/NN||aspirate-23/NN	prep_in||expression-20/NN||fluid-24/NN	appos||fluid-24/NN||naf-26/NN	nn||expression-32/NN||upa-29/NN	conj_and||upa-29/NN||pge2-31/JJ	nn||expression-32/NN||pge2-31/JJ	prep_in||expression-20/NN||expression-32/NN	conj_and||fluid-24/NN||expression-32/NN	prep_in||expression-32/NN||plasma-34/NN	auxpass||altered-36/VBN||were-35/VBD	advcl||determine-4/VB||altered-36/VBN	nn||dose-39/NN||celecoxib-38/NN	agent||altered-36/VBN||dose-39/NN	agent||altered-36/VBN||concentration-41/NN	conj_and||dose-39/NN||concentration-41/NN	prep_in||altered-36/VBN||women-43/NNS	amod||risk-48/NN||increased-45/VBN	nn||risk-48/NN||breast-46/NN	nn||risk-48/NN||cancer-47/NN	prep_at||women-43/NNS||risk-48/NN	cancer-47||pge2-31||no_rel||we sought to determine if upa, pa inhibitor (pai)-1 and prostaglandin (pg)e2 expression in nipple aspirate fluid (naf) and upa and pge2 expression in plasma were altered by celecoxib dose and concentration in women at increased breast cancer risk.
amod||sinovenousthrombosis-2/NNS||cerebral-1/JJ	nsubj||complication-9/NN||sinovenousthrombosis-2/NNS	appos||sinovenousthrombosis-2/NNS||csvt-4/NN	cop||complication-9/NN||is-6/VBZ	det||complication-9/NN||a-7/DT	amod||complication-9/NN||serious-8/JJ	root||ROOT-0/null||complication-9/NN	amod||chemotherapy-12/NN||l-asparaginase-11/JJ	prep_of||complication-9/NN||chemotherapy-12/NN	prep_for||chemotherapy-12/NN||leukemia-14/NN	prep_in||leukemia-14/NN||children-16/NNS	l-asparaginase-11||leukemia-14||no_rel||cerebral sinovenousthrombosis (csvt) is a serious complication of l-asparaginase chemotherapy for leukemia in children.
prep_in||resistant-7/JJ||contrast-2/NN	amod||mice-5/NNS||angptl4-null-4/JJ	nsubj||resistant-7/JJ||mice-5/NNS	cop||resistant-7/JJ||were-6/VBD	root||ROOT-0/null||resistant-7/JJ	amod||obesity-10/NN||diet-induced-9/JJ	prep_to||resistant-7/JJ||obesity-10/NN	xcomp||resistant-7/JJ||indicating-12/VBG	amod||effects-14/NNS||obesity-promoting-13/JJ	dobj||indicating-12/VBG||effects-14/NNS	prep_of||effects-14/NNS||angptl4-16/CD	det||condition-19/NN||the-18/DT	prep_under||indicating-12/VBG||condition-19/NN	amod||diet-22/NN||fat-enriched-21/JJ	prep_of||condition-19/NN||diet-22/NN	obesity-10||fat--1||no_rel||in contrast, angptl4-null mice were resistant to diet-induced obesity, indicating obesity-promoting effects of angptl4 under the condition of fat-enriched diet.
nsubj||revealed-2/VBD||msp-1/NN	nsubj||identified-21/VBD||msp-1/NN	root||ROOT-0/null||revealed-2/VBD	num||viruses-6/NNS||two-3/CD	amod||viruses-6/NNS||unreported-4/JJ	nn||viruses-6/NNS||rna-5/NN	dobj||revealed-2/VBD||viruses-6/NNS	nn||bees-11/NNS||north-8/NN	nn||bees-11/NNS||american-9/NN	nn||bees-11/NNS||honey-10/NN	prep_in||revealed-2/VBD||bees-11/NNS	amod||virus-15/NN||varroa-13/JJ	amod||virus-15/NN||destructor-1-14/JJ	prep_in||revealed-2/VBD||virus-15/NN	conj_and||bees-11/NNS||virus-15/NN	nn||virus-18/NN||kakugo-17/NN	prep_in||revealed-2/VBD||virus-18/NN	conj_and||bees-11/NNS||virus-18/NN	conj_and||revealed-2/VBD||identified-21/VBD	det||virus-25/NN||an-22/DT	amod||virus-25/NN||invertebrate-23/JJ	nn||virus-25/NN||iridescent-24/NN	dobj||identified-21/VBD||virus-25/NN	dep||virus-25/NN||iiv-27/NN	amod||virus-25/NN||iridoviridae-30/JJ	vmod||virus-25/NN||associated-32/VBN	nn||colonies-35/NNS||ccd-34/NN	prep_with||associated-32/VBN||colonies-35/NNS	virus-25||viruses-6||no||msp revealed two unreported rna viruses in north american honey bees, varroa destructor-1 virus and kakugo virus, and identified an invertebrate iridescent virus (iiv) ( iridoviridae ) associated with ccd colonies.
nn||types-7/NNS||fibrosis-1/NN	nn||types-7/NNS||amount-2/NN	conj_and||amount-2/NN||distribution-4/NN	nn||types-7/NNS||distribution-4/NN	conj_and||amount-2/NN||collagen-6/NN	nn||types-7/NNS||collagen-6/NN	nsubj||present-16/VBP||types-7/NNS	nsubj||present-16/VBP||types-7/NNS	dep||types-7/NNS||i-9/FW	dep||types-7/NNS||iii-11/NN	conj_and||i-9/FW||iii-11/NN	dep||types-7/NNS||vi-14/NN	conj_and||i-9/FW||vi-14/NN	root||ROOT-0/null||present-16/VBP	conj_and||present-16/VBP||present-16/VBP	amod||characteristics-18/NNS||distinct-17/JJ	dobj||present-16/VBP||characteristics-18/NNS	amod||subjects-23/NNS||lean-20/JJ	conj_and||lean-20/JJ||obese-22/JJ	amod||subjects-23/NNS||obese-22/JJ	prep_in||present-16/VBP||subjects-23/NNS	nn||localization-28/NN||wat-26/NN	nn||localization-28/NN||depots-27/NN	prep_with||present-16/VBP||localization-28/NN	dep||localization-28/NN||subcutaneous-30/JJ	dep||localization-28/NN||omental-32/JJ	conj_or||subcutaneous-30/JJ||omental-32/JJ	obese-22||collagen-6||no_rel||fibrosis amount, distribution and collagen types (i, iii, and vi) present distinct characteristics in lean and obese subjects and with wat depots localization (subcutaneous or omental).
det||aims-3/NNS||the-1/DT	amod||aims-3/NNS||primary-2/JJ	nsubj||are-4/VBP||aims-3/NNS	nsubj||examine-6/VB||aims-3/NNS	root||ROOT-0/null||are-4/VBP	aux||examine-6/VB||to-5/TO	xcomp||are-4/VBP||examine-6/VB	det||efficacy-8/NN||the-7/DT	dobj||examine-6/VB||efficacy-8/NN	prep_of||efficacy-8/NN||atomoxetine-10/NN	prepc_for||examine-6/VB||improving-12/VBG	amod||function-16/NN||cognition-13/JJ	conj_and||cognition-13/JJ||emotional-15/JJ	amod||function-16/NN||emotional-15/JJ	dep||improving-12/VBG||function-16/NN	prep_in||function-16/NN||adhd-18/NN	mark||pronounced-28/JJ||whether-20/IN	det||improvements-22/NNS||any-21/DT	nsubj||pronounced-28/JJ||improvements-22/NNS	det||outcomes-25/NNS||these-24/DT	prep_in||improvements-22/NNS||outcomes-25/NNS	cop||pronounced-28/JJ||are-26/VBP	advmod||pronounced-28/JJ||more-27/RBR	dep||improving-12/VBG||pronounced-28/JJ	conj_and||function-16/NN||pronounced-28/JJ	prep_in||pronounced-28/JJ||participants-30/NNS	amod||anxiety-33/NN||comorbid-32/JJ	prep_with||participants-30/NNS||anxiety-33/NN	aux||determine-37/VB||to-36/TO	dep||improving-12/VBG||determine-37/VB	conj_and||function-16/NN||determine-37/VB	mark||reliable-47/JJ||if-38/IN	nsubj||reliable-47/JJ||changes-39/NNS	det||outcomes-42/NNS||these-41/DT	prep_in||changes-39/NNS||outcomes-42/NNS	prep_after||outcomes-42/NNS||atomoxetine-44/NN	cop||reliable-47/JJ||are-45/VBP	advmod||reliable-47/JJ||more-46/RBR	advcl||determine-37/VB||reliable-47/JJ	prep_than||reliable-47/JJ||changes-49/NNS	amod||symptoms-52/NNS||diagnostic-51/JJ	prep_in||changes-49/NNS||symptoms-52/NNS	prep_of||symptoms-52/NNS||adhd-54/NN	adhd-54||atomoxetine-44||yes||the primary aims are to examine the efficacy of atomoxetine for improving cognition and emotional function in adhd and whether any improvements in these outcomes are more pronounced in participants with comorbid anxiety; and to determine if changes in these outcomes after atomoxetine are more reliable than changes in diagnostic symptoms of adhd.
nsubj||recommend-2/VBP||we-1/PRP	root||ROOT-0/null||recommend-2/VBP	amod||monitoring-4/NN||vigilant-3/JJ	dobj||recommend-2/VBP||monitoring-4/NN	amod||count-8/NN||complete-6/JJ	nn||count-8/NN||blood-7/NN	prep_of||monitoring-4/NN||count-8/NN	dobj||recommend-2/VBP||signs-10/NNS	conj_and||monitoring-4/NN||signs-10/NNS	conj_and||monitoring-4/NN||symptoms-12/NNS	conj_and||signs-10/NNS||symptoms-12/NNS	prepc_of||signs-10/NNS||bleeding-14/VBG	det||occurrence-17/NN||the-16/DT	prep_after||bleeding-14/VBG||occurrence-17/NN	amod||hypersensitivity-20/NN||oxaliplatin-induced-19/JJ	prep_of||occurrence-17/NN||hypersensitivity-20/NN	aux||avoid-22/VB||to-21/TO	xcomp||bleeding-14/VBG||avoid-22/VB	amod||complications-24/NNS||serious-23/JJ	dobj||avoid-22/VB||complications-24/NNS	prep_of||complications-24/NNS||immune-mediatedthrombocytopenia-26/NN	immune-mediatedthrombocytopenia-26||hypersensitivity-20||no||we recommend vigilant monitoring of complete blood count and signs and symptoms of bleeding after the occurrence of oxaliplatin-induced hypersensitivity to avoid serious complications of immune-mediatedthrombocytopenia.
prep_in||assigned-32/VBN||patients-2/NNS	vmod||patients-2/NNS||meeting-3/VBG	det||classification-6/NN||the-4/DT	amod||classification-6/NN||chinese-5/JJ	dobj||meeting-3/VBG||classification-6/NN	amod||criteria-10/NNS||mental-8/JJ	nn||criteria-10/NNS||disorders-9/NNS	prep_of||classification-6/NN||criteria-10/NNS	prep_of||classification-6/NN||criteria-10/NNS	conj_and||criteria-10/NNS||criteria-10/NNS	prep_for||criteria-10/NNS||schizophrenia-12/NN	det||score-25/NN||a-15/DT	amod||score-25/NN||positive-16/JJ	conj_and||positive-16/JJ||negative-18/JJ	amod||score-25/NN||negative-18/JJ	nn||score-25/NN||syndrome-19/NN	nn||score-25/NN||scale-20/NN	dep||score-25/NN||panss-22/NNS	amod||score-25/NN||total-24/JJ	prep_with||criteria-10/NNS||score-25/NN	advmod||meeting-3/VBG||â-26/RB	dep||60-29/CD||-27/SYM	punct||60-29/CD||¥-28/:	dep||meeting-3/VBG||60-29/CD	auxpass||assigned-32/VBN||were-30/VBD	advmod||assigned-32/VBN||randomly-31/RB	root||ROOT-0/null||assigned-32/VBN	num||weeks-35/NNS||six-34/CD	prep_to||assigned-32/VBN||weeks-35/NNS	amod||treatment-38/NN||double-blind-37/JJ	prep_of||weeks-35/NNS||treatment-38/NN	amod||40â-41/NNS||ziprasidone-40/JJ	prep_with||assigned-32/VBN||40â-41/NNS	dep||mg-45/NN||$-42/$	num||$-42/$||80-44/CD	amod||40â-41/NNS||mg-45/NN	advmod||daily-47/JJ||twice-46/RB	nsubjpass||assigned-32/VBN||daily-47/JJ	amod||1â-50/NNS||risperidone-49/JJ	nsubjpass||assigned-32/VBN||1â-50/NNS	conj_or||daily-47/JJ||1â-50/NNS	amod||bid-55/NN||$-51/$	num||$-51/$||3-53/CD	nn||bid-55/NN||mg-54/NN	dep||daily-47/JJ||bid-55/NN	advmod||dosed-58/VBN||flexibly-57/RB	amod||daily-47/JJ||dosed-58/VBN	schizophrenia-12||ziprasidone-40||yes||in patients meeting the chinese classification of mental disorders criteria for schizophrenia and with a positive and negative syndrome scale (panss) total score â¥60 were randomly assigned to six weeks of double-blind treatment with ziprasidone 40â80 mg twice daily or risperidone 1â3 mg bid, flexibly dosed.
det||progression-2/NN||the-1/DT	nsubjpass||influenced-15/VBN||progression-2/NN	amod||infection-13/NN||liverdisease-4/JJ	prep_in||liverdisease-4/JJ||patients-6/NNS	amod||virus-9/NN||chronichepatitisc-8/JJ	prep_with||patients-6/NNS||virus-9/NN	appos||virus-9/NN||hcv-11/NN	prep_of||progression-2/NN||infection-13/NN	auxpass||influenced-15/VBN||is-14/VBZ	root||ROOT-0/null||influenced-15/VBN	nn||factors-20/NNS||host-17/NN	conj_and||host-17/NN||viral-19/JJ	nn||factors-20/NNS||viral-19/JJ	agent||influenced-15/VBN||factors-20/NNS	chronichepatitisc-8||hcv-11||no||the progression of liverdisease in patients with chronichepatitisc virus (hcv) infection is influenced by host and viral factors.
det||model-4/NN||a-2/DT	nn||model-4/NN||rabbit-3/NN	prep_in||evaluated-26/VBN||model-4/NN	amod||osteoarthritis-7/NNS||collagenase-induced-6/JJ	prep_of||model-4/NN||osteoarthritis-7/NNS	det||effects-11/NNS||the-9/DT	amod||effects-11/NNS||additive-10/JJ	nsubjpass||evaluated-26/VBN||effects-11/NNS	amod||humangrowthhormone-15/NN||intra-articular-13/JJ	amod||humangrowthhormone-15/NN||recombinant-14/JJ	prep_of||effects-11/NNS||humangrowthhormone-15/NN	dep||evaluated-26/VBN||gh-17/NN	nn||hyaluronicacid-21/NN||administration-19/NN	dep||hyaluronicacid-21/NN||to-20/TO	nsubjpass||evaluated-26/VBN||hyaluronicacid-21/NN	appos||hyaluronicacid-21/NN||ha-23/NN	auxpass||evaluated-26/VBN||were-25/VBD	root||ROOT-0/null||evaluated-26/VBN	humangrowthhormone-15||osteoarthritis-7||no_rel||in a rabbit model of collagenase-induced osteoarthritis, the additive effects of intra-articular recombinant humangrowthhormone (gh) administration to hyaluronicacid (ha) were evaluated.
det||study-2/NN||this-1/DT	nsubj||shows-3/VBZ||study-2/NN	root||ROOT-0/null||shows-3/VBZ	mark||preserved-9/VBN||that-4/IN	nn||sensitivity-7/NN||vascular-5/NN	nn||sensitivity-7/NN||insulin-6/NN	nsubjpass||preserved-9/VBN||sensitivity-7/NN	auxpass||preserved-9/VBN||was-8/VBD	ccomp||shows-3/VBZ||preserved-9/VBN	prep_during||preserved-9/VBN||treatment-11/NN	amod||while-14/NN||carvedilol-13/JJ	prep_with||preserved-9/VBN||while-14/NN	vmod||while-14/NN||blunted-15/VBN	prep_during||blunted-15/VBN||treatment-17/NN	prep_with||blunted-15/VBN||metoprolol-19/NN	prep_in||metoprolol-19/NN||patients-21/NNS	prep_with||patients-21/NNS||type2diabetes-23/CD	type2diabetes-23||insulin-6||yes||this study shows that vascular insulin sensitivity was preserved during treatment with carvedilol while blunted during treatment with metoprolol in patients with type2diabetes.
nsubjpass||documented-34/VBN||viruses-1/NNS	nsubj||develop-36/VB||viruses-1/NNS	dep||viruses-1/NNS||other-2/JJ	det||viruses-6/NNS||the-4/DT	nn||viruses-6/NNS||hepatitis-5/NN	prep_than||viruses-1/NNS||viruses-6/NNS	amod||virus-15/NN||parvovirusb19-9/JJ	amod||epstein-13/JJ||cytomegalovirus-11/JJ	amod||virus-15/NN||epstein-13/JJ	nn||virus-15/NN||bar-14/NN	prep_such_as||viruses-6/NNS||virus-15/NN	nn||virus-19/NN||transfusion-17/NN	amod||virus-19/NN||transmitted-18/JJ	prep_such_as||viruses-6/NNS||virus-19/NN	conj_and||virus-15/NN||virus-19/NN	appos||virus-19/NN||ttv-21/NN	amod||virus-26/NN||non-a-e-24/JJ	nn||virus-26/NN||hepatitis-25/NN	prep_such_as||viruses-6/NNS||virus-26/NN	conj_and||virus-15/NN||virus-26/NN	amod||viruses-29/NNS||unknown-28/JJ	appos||virus-26/NN||viruses-29/NNS	aux||documented-34/VBN||has-31/VBZ	advmod||documented-34/VBN||also-32/RB	auxpass||documented-34/VBN||been-33/VBN	root||ROOT-0/null||documented-34/VBN	aux||develop-36/VB||to-35/TO	xcomp||documented-34/VBN||develop-36/VB	det||syndrome-38/NN||the-37/DT	dobj||develop-36/VB||syndrome-38/NN	virus-26||viruses-29||no||viruses other than the hepatitis viruses such as parvovirusb19, cytomegalovirus, epstein bar virus, transfusion transmitted virus (ttv) and non-a-e hepatitis virus (unknown viruses) has also been documented to develop the syndrome.
aux||examine-2/VB||to-1/TO	advcl||performed-10/VBN||examine-2/VB	det||question-4/NN||this-3/DT	dobj||examine-2/VB||question-4/NN	amod||clamps-8/NNS||euglycemic-6/JJ	nn||clamps-8/NNS||glucose-7/NN	nsubjpass||performed-10/VBN||clamps-8/NNS	auxpass||performed-10/VBN||were-9/VBD	root||ROOT-0/null||performed-10/VBN	advmod||performed-10/VBN||twice-11/RB	amod||order-15/NN||random-14/JJ	prep_in||performed-10/VBN||order-15/NN	num||youth-19/NN||11-18/CD	prep_in||performed-10/VBN||youth-19/NN	prep_with||youth-19/NN||type1diabetes-21/CD	nn||15.1-24/NNS||age-23/NN	nsubj||â-25/VBP||15.1-24/NNS	dep||youth-19/NN||â-25/VBP	number||3-27/CD||±-26/CD	num||years-28/NNS||3-27/CD	tmod||â-25/VBP||years-28/NNS	amod||â-32/NN||a1c-30/JJ	num||â-32/NN||7.6-31/CD	nsubj||±-33/VBG||â-32/NN	vmod||â-25/VBP||±-33/VBG	num||%-35/NN||0.6-34/CD	dobj||±-33/VBG||%-35/NN	num||lispro-40/NN||0.2-38/CD	amod||lispro-40/NN||units/kg-39/VBG	prep_with||youth-19/NN||lispro-40/NN	num||glargine-44/NN||0.4-42/CD	amod||glargine-44/NN||units/kg-43/VBG	prep_with||youth-19/NN||glargine-44/NN	conj_and||lispro-40/NN||glargine-44/NN	vmod||lispro-40/NN||given-46/VBN	preconj||given-46/VBN||either-47/CC	prep_as||given-46/VBN||separate-49/JJ	det||injection-55/NN||a-52/DT	amod||injection-55/NN||single-53/JJ	amod||injection-55/NN||mixed-54/JJ	prep_as||given-46/VBN||injection-55/NN	conj_or||separate-49/JJ||injection-55/NN	type1diabetes-21||glargine-44||yes||to examine this question, euglycemic glucose clamps were performed twice, in random order, in 11 youth with type1diabetes (age 15.1 â± 3 years, a1c 7.6 â± 0.6%) with 0.2 units/kg lispro and 0.4 units/kg glargine, given either as separate or as a single mixed injection.
mark||covered-7/VBN||although-1/IN	det||expenses-3/NNS||the-2/DT	nsubjpass||covered-7/VBN||expenses-3/NNS	prep_of||expenses-3/NNS||livercirrhosis-5/NNS	auxpass||covered-7/VBN||are-6/VBP	advcl||related-31/VBD||covered-7/VBN	det||fund-12/NN||a-9/DT	amod||fund-12/NN||critical-10/JJ	nn||fund-12/NN||illness-11/NN	agent||covered-7/VBN||fund-12/NN	det||program-18/NN||the-14/DT	amod||program-18/NN||current-15/JJ	nn||program-18/NN||health-16/NN	nn||program-18/NN||insurance-17/NN	prep_under||covered-7/VBN||program-18/NN	prep_in||program-18/NN||china-20/NN	det||burden-24/NN||the-22/DT	amod||burden-24/NN||economic-23/JJ	nsubj||related-31/VBD||burden-24/NN	vmod||burden-24/NN||associated-25/VBN	prep_with||associated-25/VBN||hepatitisbvirus-27/NNS	appos||burden-24/NN||hbv-29/NN	root||ROOT-0/null||related-31/VBD	nsubjpass||addressed-36/VBN||diseases-32/NNS	auxpass||addressed-36/VBN||is-33/VBZ	neg||addressed-36/VBN||not-34/RB	advmod||addressed-36/VBN||well-35/RB	ccomp||related-31/VBD||addressed-36/VBN	hbv-29||hepatitisbvirus-27||no||although the expenses of livercirrhosis are covered by a critical illness fund under the current health insurance program in china, the economic burden associated with hepatitisbvirus (hbv) related diseases is not well addressed.
amod||transmission-2/NN||vertical-1/JJ	nsubj||accounts-3/VBZ||transmission-2/NN	root||ROOT-0/null||accounts-3/VBZ	det||majority-6/NN||the-5/DT	prep_for||accounts-3/VBZ||majority-6/NN	amod||cases-9/NNS||pediatric-8/JJ	prep_of||majority-6/NN||cases-9/NNS	nn||infection-15/NN||hepatitiscviral-11/NNP	appos||infection-15/NN||hcv-13/NN	prep_of||cases-9/NNS||infection-15/NN	hepatitiscviral-11||hcv-13||no||vertical transmission accounts for the majority of pediatric cases of hepatitiscviral (hcv) infection.
nsubjpass||recommended-3/VBN||it-1/PRP	auxpass||recommended-3/VBN||is-2/VBZ	root||ROOT-0/null||recommended-3/VBN	mark||-lrb--7/VBD||that-4/IN	amod||s.aureus-6/NNS||methicillin-susceptible-5/JJ	nsubj||-lrb--7/VBD||s.aureus-6/NNS	ccomp||recommended-3/VBN||-lrb--7/VBD	nn||-rrb--9/NNS||mssa-8/NN	nsubjpass||tested-15/VBN||-rrb--9/NNS	conj_and||-rrb--9/NNS||mrsa-11/NN	nsubjpass||tested-15/VBN||mrsa-11/NN	aux||tested-15/VBN||should-12/MD	auxpass||tested-15/VBN||be-13/VB	advmod||tested-15/VBN||routinely-14/RB	ccomp||-lrb--7/VBD||tested-15/VBN	nn||resistance-18/NN||mupirocin-17/NN	prep_for||tested-15/VBN||resistance-18/NN	advmod||tested-15/VBN||even-19/RB	prep_in||tested-15/VBN||facilities-21/NNS	advmod||administered-27/VBN||where-22/WRB	det||agent-24/NN||the-23/DT	nsubjpass||administered-27/VBN||agent-24/NN	auxpass||administered-27/VBN||is-25/VBZ	neg||administered-27/VBN||not-26/RB	rcmod||facilities-21/NNS||administered-27/VBN	mrsa-11||s.aureus-6||no||it is recommended that methicillin-susceptible s.aureus -lrb- mssa -rrb- and mrsa should be routinely tested for mupirocin resistance even in facilities where the agent is not administered .
aux||elucidate-2/VB||to-1/TO	advcl||investigated-25/VBD||elucidate-2/VB	nn||mechanisms-4/NNS||novel-3/NN	dobj||elucidate-2/VB||mechanisms-4/NNS	vmod||mechanisms-4/NNS||contributing-5/VBG	det||complex-10/NN||the-7/DT	amod||complex-10/NN||htlv-1-8/JJ	amod||complex-10/NN||neurological-9/JJ	prep_to||contributing-5/VBG||complex-10/NN	poss||presentation-15/NN||its-12/PRP$	amod||presentation-15/NN||classic-13/JJ	amod||presentation-15/NN||neurological-14/JJ	prep_to||contributing-5/VBG||presentation-15/NN	conj_and||complex-10/NN||presentation-15/NN	vmod||presentation-15/NN||called-16/VBN	dobj||called-16/VBN||ham/tsp-17/NN	amod||myelopathy/tropicalspasticparaparesis-21/NNS||htlv-1-19/JJ	amod||myelopathy/tropicalspasticparaparesis-21/NNS||associated-20/JJ	appos||ham/tsp-17/NN||myelopathy/tropicalspasticparaparesis-21/NNS	nsubj||investigated-25/VBD||we-24/PRP	root||ROOT-0/null||investigated-25/VBD	det||expression-27/NN||the-26/DT	dobj||investigated-25/VBD||expression-27/NN	det||receptor-31/NN||the-29/DT	amod||receptor-31/NN||tim-3-30/JJ	prep_of||expression-27/NN||receptor-31/NN	amod||cells-36/NNS||cd8-33/JJ	amod||cells-36/NNS||+-34/JJ	nn||cells-36/NNS||t-35/NN	prep_on||receptor-31/NN||cells-36/NNS	det||cohort-39/NN||a-38/DT	prep_from||investigated-25/VBD||cohort-39/NN	amod||patients-46/NNS||htlv-1-41/JJ	amod||patients-46/NNS||seropositive-42/JJ	amod||patients-46/NNS||asymptomatic-43/JJ	conj_and||asymptomatic-43/JJ||symptomatic-45/JJ	amod||patients-46/NNS||symptomatic-45/JJ	prep_of||cohort-39/NN||patients-46/NNS	tropicalspasticparaparesis--1||htlv-1-41||no||to elucidate novel mechanisms contributing to the htlv-1 neurological complex and its classic neurological presentation called ham/tsp (htlv-1 associated myelopathy/tropicalspasticparaparesis), we investigated the expression of the tim-3 receptor on cd8+ t cells from a cohort of htlv-1 seropositive asymptomatic and symptomatic patients.
nsubj||conclude-2/VBP||we-1/PRP	root||ROOT-0/null||conclude-2/VBP	mark||accurate-7/JJ||that-3/IN	det||tests-5/NNS||both-4/DT	nsubj||accurate-7/JJ||tests-5/NNS	nsubj||detect-9/VB||tests-5/NNS	cop||accurate-7/JJ||are-6/VBP	ccomp||conclude-2/VBP||accurate-7/JJ	aux||detect-9/VB||to-8/TO	xcomp||accurate-7/JJ||detect-9/VB	nn||tuberculosis-11/NNP||latent-10/NNP	dobj||detect-9/VB||tuberculosis-11/NNP	mark||have-17/VBP||although-13/IN	amod||assays-16/NNS||interferon-gamma-14/JJ	nn||assays-16/NNS||release-15/NN	nsubj||have-17/VBP||assays-16/NNS	dep||tuberculosis-11/NNP||have-17/VBP	amod||specificity-19/NN||higher-18/JJR	dobj||have-17/VBP||specificity-19/NN	nn||testing-23/NN||tuberculin-21/NN	nn||testing-23/NN||skin-22/NN	prep_than||have-17/VBP||testing-23/NN	amod||populations-26/NNS||bcg-vaccinated-25/JJ	prep_in||testing-23/NN||populations-26/NNS	advmod||received-32/VBN||particularly-28/RB	mark||received-32/VBN||if-29/IN	nsubjpass||received-32/VBN||bcg-30/NN	auxpass||received-32/VBN||is-31/VBZ	advcl||have-17/VBP||received-32/VBN	prep_after||received-32/VBN||infancy-34/NN	tuberculosis-11||bcg-30||yes||we conclude that both tests are accurate to detect latent tuberculosis, although interferon-gamma release assays have higher specificity than tuberculin skin testing in bcg-vaccinated populations, particularly if bcg is received after infancy.
nsubj||speculate-2/VBP||we-1/PRP	root||ROOT-0/null||speculate-2/VBP	mark||plays-10/VBZ||that-3/IN	nsubj||plays-10/VBZ||hijacking-4/NN	prep_of||hijacking-4/NN||pals1-6/NNS	amod||e-9/NNS||sars-cov-8/JJ	prep_by||pals1-6/NNS||e-9/NNS	ccomp||speculate-2/VBP||plays-10/VBZ	det||role-13/NN||a-11/DT	amod||role-13/NN||determinant-12/JJ	dobj||plays-10/VBZ||role-13/NN	det||disruption-16/NN||the-15/DT	prep_in||role-13/NN||disruption-16/NN	det||epithelium-20/NN||the-18/DT	nn||epithelium-20/NN||lung-19/NN	prep_of||disruption-16/NN||epithelium-20/NN	amod||patients-23/NNS||sars-22/JJ	prep_in||epithelium-20/NN||patients-23/NNS	sars-22||sars-cov-8||no||we speculate that hijacking of pals1 by sars-cov e plays a determinant role in the disruption of the lung epithelium in sars patients.
det||causes-3/NNS||the-1/DT	amod||causes-3/NNS||molecular-2/JJ	nsubj||responsible-27/JJ||causes-3/NNS	nsubj||contribute-36/VBP||causes-3/NNS	prep_of||causes-3/NNS||insulinresistance-5/NN	vmod||responsible-27/JJ||i.e.-7/VBG	amod||insulin-9/NN||impaired-8/VBN	dobj||i.e.-7/VBG||insulin-9/NN	vmod||insulin-9/NN||signalling-10/VBG	det||pathway-15/NN||the-12/DT	amod||pathway-15/NN||phosphoinositol-3-13/JJ	nn||pathway-15/NN||kinase-14/NN	prep_through||signalling-10/VBG||pathway-15/NN	amod||signalling-18/NN||intact-17/JJ	prep_with||pathway-15/NN||signalling-18/NN	det||kinase-23/NN||the-20/DT	amod||kinase-23/NN||mitogen-activated-21/JJ	nn||kinase-23/NN||protein-22/NN	prep_through||signalling-10/VBG||kinase-23/NN	advmod||signalling-10/VBG||pathway-24/RB	cop||responsible-27/JJ||are-26/VBP	root||ROOT-0/null||responsible-27/JJ	det||impairment-30/NN||the-29/DT	prep_for||responsible-27/JJ||impairment-30/NN	amod||metabolism-34/NN||insulin-stimulated-32/JJ	nn||metabolism-34/NN||glucose-33/NN	prep_in||impairment-30/NN||metabolism-34/NN	conj_and||responsible-27/JJ||contribute-36/VBP	det||rate-40/NN||the-38/DT	amod||rate-40/NN||accelerated-39/VBN	prep_to||contribute-36/VBP||rate-40/NN	prep_of||rate-40/NN||cvd-42/NN	amod||patients-45/NNS||type2diabetes-44/JJ	prep_in||cvd-42/NN||patients-45/NNS	type2diabetes-44||insulin-9||yes||the molecular causes of insulinresistance , i.e. impaired insulin signalling through the phosphoinositol-3 kinase pathway with intact signalling through the mitogen-activated protein kinase pathway , are responsible for the impairment in insulin-stimulated glucose metabolism and contribute to the accelerated rate of cvd in type2diabetes patients .
mark||develop-4/VB||in-1/IN	dep||develop-4/VB||order-2/NN	aux||develop-4/VB||to-3/TO	advcl||necessary-30/JJ||develop-4/VB	amod||strategies-6/NNS||new-5/JJ	dobj||develop-4/VB||strategies-6/NNS	aux||prevent-8/VB||to-7/TO	vmod||develop-4/VB||prevent-8/VB	dobj||prevent-8/VB||escherichiacoli-9/NNS	amod||mastitis-12/NNS||induced-11/JJ	dep||escherichiacoli-9/NNS||mastitis-12/NNS	det||understanding-16/NN||a-14/DT	amod||understanding-16/NN||detailed-15/JJ	nsubj||necessary-30/JJ||understanding-16/NN	det||mechanisms-20/NNS||the-18/DT	amod||mechanisms-20/NNS||molecular-19/JJ	prep_of||understanding-16/NN||mechanisms-20/NNS	vmod||mechanisms-20/NNS||underlying-21/VBG	det||response-25/NN||the-22/DT	nn||response-25/NN||host-23/NN	amod||response-25/NN||immune-24/JJ	dobj||underlying-21/VBG||response-25/NN	det||e.coliinfection-28/NN||an-27/DT	prep_to||underlying-21/VBG||e.coliinfection-28/NN	cop||necessary-30/JJ||is-29/VBZ	root||ROOT-0/null||necessary-30/JJ	e.coliinfection-28||escherichiacoli-9||no||in order to develop new strategies to prevent escherichiacoli - induced mastitis , a detailed understanding of the molecular mechanisms underlying the host immune response to an e.coliinfection is necessary .
nn||t3-2/NNS||serum-1/NN	nsubjpass||decreased-6/VBN||t3-2/NNS	conj_and||t3-2/NNS||t4-4/NNS	nsubjpass||decreased-6/VBN||t4-4/NNS	auxpass||decreased-6/VBN||were-5/VBD	root||ROOT-0/null||decreased-6/VBN	num||children-9/NNS||34/78-8/CD	prep_in||decreased-6/VBN||children-9/NNS	nn||infections-12/NNS||cns-11/NN	prep_with||children-9/NNS||infections-12/NNS	nsubj||lower-19/JJR||t3-14/NNS	nsubj||higher-33/JJR||t3-14/NNS	conj_and||t3-14/NNS||t4-16/NNS	nsubj||lower-19/JJR||t4-16/NNS	cop||lower-19/JJR||were-17/VBD	advmod||lower-19/JJR||much-18/RB	dep||decreased-6/VBN||lower-19/JJR	prep_than||lower-19/JJR||those-21/DT	amod||adult-24/NN||healthy-23/JJ	prep_of||those-21/DT||adult-24/NN	dep||<-27/JJ||p-26/RB	dep||lower-19/JJR||<-27/JJ	dep||<-27/JJ||0.05-28/CD	advmod||higher-33/JJR||still-32/RB	dep||decreased-6/VBN||higher-33/JJR	conj_but||lower-19/JJR||higher-33/JJR	prep_than||higher-33/JJR||that-35/DT	det||hypothyroidism-39/NN||the-37/DT	amod||hypothyroidism-39/NN||primary-38/JJ	prep_of||that-35/DT||hypothyroidism-39/NN	dep||<-42/JJ||p-41/RB	dep||higher-33/JJR||<-42/JJ	dep||<-42/JJ||0.05-43/CD	nn||levels-48/NNS||tsh-47/NN	nsubj||differences-52/NNS||levels-48/NNS	cop||differences-52/NNS||were-49/VBD	neg||differences-52/NNS||not-50/RB	amod||differences-52/NNS||significant-51/JJ	conj_and||decreased-6/VBN||differences-52/NNS	prep_among||differences-52/NNS||children-54/NNS	nn||infections-57/NNS||cns-56/NN	prep_with||children-54/NNS||infections-57/NNS	prep_with||children-54/NNS||children-59/NNS	conj_and||infections-57/NNS||children-59/NNS	amod||infections-62/NNS||non-cns-61/JJ	prep_with||children-54/NNS||infections-62/NNS	dep||children-54/NNS||p-64/VBN	num||0.05-66/CD||>-65/CD	dobj||p-64/VBN||0.05-66/CD	hypothyroidism-39||t3-14||yes||serum t3 and t4 were decreased in 34/78 children with cns infections, t3 and t4 were much lower than those of healthy adult (p < 0.05), but still higher than that of the primary hypothyroidism (p < 0.05), and tsh levels were not significant differences among children with cns infections and children with non-cns infections (p > 0.05).
nn||severity-2/NN||sah-1/NN	nsubj||affect-5/VB||severity-2/NN	aux||affect-5/VB||did-3/VBD	neg||affect-5/VB||not-4/RB	root||ROOT-0/null||affect-5/VB	amod||concentrations-7/NNS||cortisol-6/JJ	dobj||affect-5/VB||concentrations-7/NNS	advmod||indicating-10/VBG||possibly-9/RB	vmod||affect-5/VB||indicating-10/VBG	amod||pituitary-adrenalinsufficiency-12/NN||relative-11/JJ	dobj||indicating-10/VBG||pituitary-adrenalinsufficiency-12/NN	prep_in||indicating-10/VBG||patients-14/NNS	advmod||severe-17/JJ||more-16/RBR	amod||bleeding-18/NN||severe-17/JJ	prep_with||patients-14/NNS||bleeding-18/NN	adrenalinsufficiency--1||cortisol-6||yes||sah severity did not affect cortisol concentrations, possibly indicating relative pituitary-adrenalinsufficiency in patients with more severe bleeding.
nsubj||represents-10/VBZ||osteoporosis-1/NNS	det||reduction-4/NN||a-3/DT	appos||osteoporosis-1/NNS||reduction-4/NN	nn||density-8/NN||bone-6/NN	nn||density-8/NN||mineral-7/NN	prep_in||reduction-4/NN||density-8/NN	root||ROOT-0/null||represents-10/VBZ	det||bonedisease-15/NN||the-11/DT	advmod||common-13/JJ||most-12/RBS	amod||bonedisease-15/NN||common-13/JJ	amod||bonedisease-15/NN||metabolic-14/JJ	dobj||represents-10/VBZ||bonedisease-15/NN	mineral-7||osteoporosis-1||no_rel||osteoporosis, a reduction in bone mineral density, represents the most common metabolic bonedisease.
amod||correlations-2/NNS||significant-1/JJ	nsubjpass||detected-4/VBN||correlations-2/NNS	auxpass||detected-4/VBN||were-3/VBD	root||ROOT-0/null||detected-4/VBN	amod||grade-7/NN||increased-6/VBN	prep_between||detected-4/VBN||grade-7/NN	amod||levels-10/NNS||increased-9/VBN	prep_between||detected-4/VBN||levels-10/NNS	conj_and||grade-7/NN||levels-10/NNS	prep_of||grade-7/NN||hypoxia-12/NN	amod||factor-1-14/JJ||inducible-13/JJ	amod||hypoxia-12/NN||factor-1-14/JJ	amod||±-17/NN||hif-1î-16/JJ	appos||grade-7/NN||±-17/NN	advmod||transporter-1-21/JJ||glucose-20/RB	prep_between||detected-4/VBN||transporter-1-21/JJ	amod||grade-7/NN||transporter-1-21/JJ	conj_and||grade-7/NN||transporter-1-21/JJ	dep||transporter-1-21/JJ||glut-1-23/JJ	amod||density-27/NN||microvessel-26/JJ	prep_between||detected-4/VBN||density-27/NN	conj_and||grade-7/NN||density-27/NN	appos||density-27/NN||mvd-29/NN	prep_between||detected-4/VBN||cytokeratins-32/NNS	conj_and||grade-7/NN||cytokeratins-32/NNS	amod||cytokeratins-32/NNS||ck5/6-33/JJ	dep||<-36/JJ||p-35/RB	dep||ck5/6-33/JJ||<-36/JJ	dep||<-36/JJ||0.05-37/CD	hypoxia-12||glucose-20||no_rel||significant correlations were detected between increased grade and increased levels of hypoxia inducible factor-1 (hif-1î±), glucose transporter-1 (glut-1), microvessel density (mvd) and cytokeratins ck5/6 (p < 0.05).
nsubj||adopt-9/VB||subjects-1/NNS	vmod||subjects-1/NNS||suffering-2/VBG	amod||allergy/intolerance-7/NN||coeliacdisease-4/JJ	amod||allergy/intolerance-7/NN||gluten-6/JJ	prep_from||suffering-2/VBG||allergy/intolerance-7/NN	aux||adopt-9/VB||must-8/MD	root||ROOT-0/null||adopt-9/VB	det||avoidance-12/NN||a-10/DT	amod||avoidance-12/NN||lifelong-11/JJ	dobj||adopt-9/VB||avoidance-12/NN	prep_of||avoidance-12/NN||gluten-14/NN	coeliacdisease-4||gluten-14||no||subjects suffering from coeliacdisease, gluten allergy/intolerance must adopt a lifelong avoidance of gluten.
amod||adjustment-3/NN||further-2/JJ	prep_after||associated-23/VBN||adjustment-3/NN	det||covariates-7/NNS||all-5/DT	amod||covariates-7/NNS||other-6/JJ	prep_for||adjustment-3/NN||covariates-7/NNS	prep_for||adjustment-3/NN||covariates-7/NNS	conj_less||covariates-7/NNS||covariates-7/NNS	det||value-11/NN||a-9/DT	nn||value-11/NN||p-10/NN	prep_with||covariates-7/NNS||value-11/NN	amod||associations-17/NNS||0.3-14/CD	conj_and||0.3-14/CD||nonlinear-16/JJR	amod||associations-17/NNS||nonlinear-16/JJR	prep_than||covariates-7/NNS||associations-17/NNS	prep_with||associations-17/NNS||cancer-19/NN	nsubjpass||associated-23/VBN||a1c-21/NNS	auxpass||associated-23/VBN||was-22/VBD	root||ROOT-0/null||associated-23/VBN	det||risk-28/NN||an-25/DT	amod||risk-28/NN||increased-26/VBN	nn||risk-28/NN||cancer-27/NN	prep_with||associated-23/VBN||risk-28/NN	dep||hr-30/NN||-lrb--29/NN	amod||risk-28/NN||hr-30/NN	prep_per||risk-28/NN||percentage-32/NN	num||percentage-32/NN||1.26-33/CD	num||%-36/NN||95-35/CD	npadvmod||ci-37/RB||%-36/NN	advmod||â-39/NN||ci-37/RB	num||â-39/NN||1.03-38/CD	appos||percentage-32/NN||â-39/NN	dep||-rrb--43/NN||$-40/$	num||$-40/$||1.55-42/CD	amod||â-39/NN||-rrb--43/NN	mark||associated-50/VBN||whereas-45/IN	nsubjpass||associated-50/VBN||use-46/NN	prep_of||use-46/NN||insulin-48/NN	auxpass||associated-50/VBN||was-49/VBD	dep||percentage-32/NN||associated-50/VBN	det||risk-55/NN||a-52/DT	amod||risk-55/NN||decreased-53/VBN	nn||risk-55/NN||cancer-54/NN	prep_with||associated-50/VBN||risk-55/NN	dep||hr-57/NN||-lrb--56/NN	amod||risk-55/NN||hr-57/NN	nn||users-60/NNS||insulin-59/NN	prep_of||risk-55/NN||users-60/NNS	prep_vs.||users-60/NNS||nonusers-62/NNP	num||nonusers-62/NNP||0.17-63/CD	num||nonusers-62/NNP||0.09-65/CD	quantmod||$-67/$||â-66/RB	dep||-rrb--70/NN||$-67/$	num||$-67/$||0.32-69/CD	amod||risk-55/NN||-rrb--70/NN	cancer-54||insulin-59||no_rel||after further adjustment for all other covariates with a p value less than 0.3 and nonlinear associations with cancer , a1c was associated with an increased cancer risk -lrb- hr per percentage 1.26 , 95 % ci 1.03 â $ `` 1.55 -rrb- , whereas use of insulin was associated with a decreased cancer risk -lrb- hr of insulin users vs. nonusers 0.17 , 0.09 â $ `` 0.32 -rrb- .
nsubjpass||associated-13/VBN||s100a12-1/NNS	det||protein-6/NN||a-3/DT	amod||protein-6/NN||calcium-binding-4/JJ	nn||protein-6/NN||proinflammatory-5/NN	appos||s100a12-1/NNS||protein-6/NN	vmod||protein-6/NN||secreted-7/VBN	agent||secreted-7/VBN||granulocytes-9/NNS	aux||associated-13/VBN||has-11/VBZ	auxpass||associated-13/VBN||been-12/VBN	root||ROOT-0/null||associated-13/VBN	amod||diseases-16/NNS||different-15/JJ	prep_with||associated-13/VBN||diseases-16/NNS	amod||origin-19/NN||inflammatory-18/JJ	prep_of||diseases-16/NNS||origin-19/NN	prep_including||diseases-16/NNS||inflammatoryboweldisease-22/NN	appos||inflammatoryboweldisease-22/NN||ibd-24/NN	calcium--1||inflammatoryboweldisease-22||no_rel||s100a12, a calcium-binding proinflammatory protein secreted by granulocytes, has been associated with different diseases of inflammatory origin, including inflammatoryboweldisease (ibd).
det||scale-7/NN||a-2/DT	number||cm-4/CD||10-3/CD	num||scale-7/NN||cm-4/CD	amod||scale-7/NN||visual-5/JJ	amod||scale-7/NN||analogue-6/JJ	prep_on||cm-21/NN||scale-7/NN	det||difference-10/NN||the-8/DT	amod||difference-10/NN||overall-9/JJ	nsubj||cm-21/NN||difference-10/NN	nn||intensity-13/NN||pain-12/NN	prep_in||difference-10/NN||intensity-13/NN	prepc_compared_with||intensity-13/NN||with-15/IN	pobj||intensity-13/NN||placebo-16/NN	cop||cm-21/NN||was-17/VBD	poss||cm-21/NN||â-18/NNP	num||cm-21/NN||0.4-20/CD	root||ROOT-0/null||cm-21/NN	number||%-24/NN||95-23/CD	amod||0.7-29/NNS||%-24/NN	amod||interval-26/JJ||credible-25/JJ	amod||0.7-29/NNS||interval-26/JJ	nn||0.7-29/NNS||â-27/NN	dep||cm-21/NN||0.7-29/NNS	poss||cm-34/NN||â-31/NNP	num||cm-34/NN||0.1-33/CD	prep_to||0.7-29/NNS||cm-34/NN	prep_for||cm-21/NN||glucosamine-37/NN	poss||cm-42/NN||â-39/NNP	num||cm-42/NN||0.3-41/CD	conj_and||cm-21/NN||cm-42/NN	poss||0.7-46/NN||â-44/NNP	dep||cm-42/NN||0.7-46/NN	num||cm-49/NN||0.0-48/CD	prep_to||0.7-46/NN||cm-49/NN	prep_for||cm-42/NN||chondroitin-52/NN	poss||cm-58/NN||â-55/NNP	num||cm-58/NN||0.5-57/CD	conj_and||cm-21/NN||cm-58/NN	poss||0.9-62/NN||â-60/NNP	dep||cm-58/NN||0.9-62/NN	num||cm-65/NN||0.0-64/CD	prep_to||0.9-62/NN||cm-65/NN	det||combination-69/NN||the-68/DT	prep_for||cm-58/NN||combination-69/NN	pain-12||chondroitin-52||yes||on a 10 cm visual analogue scale the overall difference in pain intensity compared with placebo was â0.4 cm (95% credible interval â0.7 to â0.1 cm) for glucosamine, â0.3 cm (â0.7 to 0.0 cm) for chondroitin, and â0.5 cm (â0.9 to 0.0 cm) for the combination.
advmod||pathogenic-2/JJ||highly-1/RB	amod||avianinfluenzavirus-3/NNS||pathogenic-2/JJ	nsubj||subtype-4/VBP||avianinfluenzavirus-3/NNS	nsubj||has-14/VBZ||avianinfluenzavirus-3/NNS	root||ROOT-0/null||subtype-4/VBP	amod||humans-7/NNS||h5n1-5/JJ	nn||humans-7/NNS||infects-6/NN	dobj||subtype-4/VBP||humans-7/NNS	det||rate-12/NN||a-9/DT	amod||rate-12/NN||high-10/JJ	nn||rate-12/NN||fatality-11/NN	prep_with||subtype-4/VBP||rate-12/NN	conj_and||subtype-4/VBP||has-14/VBZ	amod||potential-16/NN||pandemic-15/JJ	dobj||has-14/VBZ||potential-16/NN	h5n1-5||avianinfluenzavirus-3||no||highly pathogenic avianinfluenzavirus subtype h5n1 infects humans with a high fatality rate and has pandemic potential.
amod||testing-2/NN||bloodglucose-1/JJ	nsubj||routine-5/JJ||testing-2/NN	aux||routine-5/JJ||should-3/MD	cop||routine-5/JJ||be-4/VB	root||ROOT-0/null||routine-5/JJ	det||patients-8/NNS||all-7/DT	prep_in||routine-5/JJ||patients-8/NNS	amod||impairment-12/NN||acute-10/JJ	amod||impairment-12/NN||neurological-11/JJ	prep_with||routine-5/JJ||impairment-12/NN	nsubjpass||included-17/VBN||hypoglycaemia-14/NN	aux||included-17/VBN||should-15/MD	auxpass||included-17/VBN||be-16/VB	conj_and||routine-5/JJ||included-17/VBN	det||diagnosis-21/NN||the-19/DT	nn||diagnosis-21/NN||differential-20/NN	prep_in||included-17/VBN||diagnosis-21/NN	nn||appearances-24/NNS||imaging-23/NN	prep_of||diagnosis-21/NN||appearances-24/NNS	prep_in||included-17/VBN||patients-26/NNS	vmod||patients-26/NNS||presenting-27/VBG	amod||stroke-30/NN||acute-29/JJ	prep_with||presenting-27/VBG||stroke-30/NN	hypoglycaemia-14||glucose--1||yes||bloodglucose testing should be routine in all patients with acute neurological impairment and hypoglycaemia should be included in the differential diagnosis of imaging appearances in patients presenting with acute stroke.
amod||calcineurininhibitors-2/NNS||topical-1/JJ	nsubj||alternative-9/NN||calcineurininhibitors-2/NNS	aux||alternative-9/NN||may-3/MD	cop||alternative-9/NN||be-4/VB	det||alternative-9/NN||a-5/DT	amod||alternative-9/NN||safe-6/JJ	conj_and||safe-6/JJ||effective-8/JJ	amod||alternative-9/NN||effective-8/JJ	root||ROOT-0/null||alternative-9/NN	amod||steroids-12/NNS||topical-11/JJ	prep_to||alternative-9/NN||steroids-12/NNS	prep_for||steroids-12/NNS||cle-14/NN	mark||is-20/VBZ||although-15/IN	det||indication-19/NN||the-16/DT	advmod||indication-19/NN||only-17/RB	amod||indication-19/NN||approved-18/VBN	nsubj||is-20/VBZ||indication-19/NN	advcl||alternative-9/NN||is-20/VBZ	prep_for||is-20/VBZ||atopicdermatitis-22/NNS	atopicdermatitis-22||calcineurininhibitors-2||no_rel||topical calcineurininhibitors may be a safe and effective alternative to topical steroids for cle although the only approved indication is for atopicdermatitis.
amod||analysis-3/NN||bayesian-1/JJ	amod||analysis-3/NN||phylogenetic-2/JJ	nsubj||demonstrated-13/VBD||analysis-3/NN	vmod||analysis-3/NN||using-4/VBG	amod||sequences-8/NNS||partial-5/JJ	nn||sequences-8/NNS||nucleoprotein-6/NN	nn||sequences-8/NNS||gene-7/NN	dobj||using-4/VBG||sequences-8/NNS	vmod||sequences-8/NNS||derived-9/VBN	det||samples-12/NNS||the-11/DT	prep_from||derived-9/VBN||samples-12/NNS	root||ROOT-0/null||demonstrated-13/VBD	det||viruses-15/NNS||the-14/DT	nsubj||belong-16/VB||viruses-15/NNS	nsubj||share-23/VB||viruses-15/NNS	ccomp||demonstrated-13/VBD||belong-16/VB	det||variant-21/NN||a-18/DT	amod||variant-21/NN||single-19/JJ	nn||variant-21/NN||virus-20/NN	prep_to||belong-16/VB||variant-21/NN	ccomp||demonstrated-13/VBD||share-23/VB	conj_and||belong-16/VB||share-23/VB	det||ancestor-26/NN||a-24/DT	amod||ancestor-26/NN||common-25/JJ	dobj||share-23/VB||ancestor-26/NN	prep_with||share-23/VB||viruses-28/NNS	amod||countries-31/NNS||neighbouring-30/JJ	prep_from||share-23/VB||countries-31/NNS	amod||countries-31/NNS||22-33/CD	num||%-36/NN||95-35/CD	dep||countries-31/NNS||%-36/NN	vmod||%-36/NN||hpd-37/VBN	amod||$-39/$||14â-38/VBD	dobj||hpd-37/VBN||$-39/$	num||$-39/$||32-41/CD	npadvmod||ago-44/RB||years-43/NNS	advmod||countries-31/NNS||ago-44/RB	virus-20||viruses-28||no||bayesian phylogenetic analysis using partial nucleoprotein gene sequences derived from the samples demonstrated the viruses belong to a single virus variant and share a common ancestor with viruses from neighbouring countries, 22 (95% hpd 14â32) years ago.
prep_in||are-5/VBP||contrast-2/NN	expl||are-5/VBP||there-4/EX	root||ROOT-0/null||are-5/VBP	amod||factors-7/NNS||numerous-6/JJ	nsubj||are-5/VBP||factors-7/NNS	dep||factors-7/NNS||suggesting-8/VBG	mark||increasing-12/VBG||that-9/IN	nsubj||increasing-12/VBG||hiv-10/NN	aux||increasing-12/VBG||is-11/VBZ	ccomp||suggesting-8/VBG||increasing-12/VBG	dep||factors-7/NNS||ready-14/JJ	conj_and||suggesting-8/VBG||ready-14/JJ	aux||emerge-16/VB||to-15/TO	xcomp||ready-14/JJ||emerge-16/VB	amod||rates-19/NNS||high-18/JJ	prep_at||emerge-16/VB||rates-19/NNS	det||rates-25/NNS||the-22/DT	amod||rates-25/NNS||lowest-23/JJS	amod||rates-25/NNS||documented-24/VBN	prep_including||emerge-16/VB||rates-25/NNS	nn||use-28/NN||condom-27/NN	prep_of||rates-25/NNS||use-28/NN	prep_in||use-28/NN||asia-30/NN	dep||factors-7/NNS||increasing-32/VBG	amod||activity-35/NN||casual-33/JJ	amod||activity-35/NN||sexual-34/JJ	dobj||increasing-32/VBG||activity-35/NN	parataxis||increasing-32/VBG||returning-37/VBG	amod||workers-40/NNS||overseas-38/JJ	nn||workers-40/NNS||filipino-39/NN	dobj||returning-37/VBG||workers-40/NNS	amod||settings-43/NNS||high-prevalence-42/JJ	prep_from||returning-37/VBG||settings-43/NNS	amod||misconceptions-46/NNS||widespread-45/JJ	nsubj||are-5/VBP||misconceptions-46/NNS	conj_and||factors-7/NNS||misconceptions-46/NNS	prep_about||misconceptions-46/NNS||hiv/aids-48/NNS	amod||rates-53/NNS||high-51/JJ	amod||rates-53/NNS||needle-sharing-52/JJ	nsubj||are-5/VBP||rates-53/NNS	conj_and||factors-7/NNS||rates-53/NNS	amod||users-57/NNS||injecting-55/VBG	nn||users-57/NNS||drug-56/NN	prep_among||rates-53/NNS||users-57/NNS	aids--1||hiv-10||no||in contrast, there are numerous factors suggesting that hiv is increasing and ready to emerge at high rates, including the lowest documented rates of condom use in asia; increasing casual sexual activity; returning overseas filipino workers from high-prevalence settings; widespread misconceptions about hiv/aids; and high needle-sharing rates among injecting drug users.
advmod||evaluate-4/VB||here-1/RB	nsubj||evaluate-4/VB||we-3/PRP	root||ROOT-0/null||evaluate-4/VB	dobj||evaluate-4/VB||detection-5/NN	amod||markers-9/NNS||ibd-7/JJ	amod||markers-9/NNS||serological-8/JJ	prep_of||detection-5/NN||markers-9/NNS	amod||patients-12/NNS||hiv-infected-11/JJ	prep_in||markers-9/NNS||patients-12/NNS	amod||disease-15/NN||advanced-14/JJ	prep_with||patients-12/NNS||disease-15/NN	poss||relationship-18/NN||their-17/PRP$	prep_of||detection-5/NN||relationship-18/NN	conj_and||markers-9/NNS||relationship-18/NN	aux||hivdisease-20/VB||to-19/TO	vmod||relationship-18/NN||hivdisease-20/VB	dobj||hivdisease-20/VB||markers-21/NNS	hivdisease-20||hiv--1||no||here, we evaluate detection of ibd serological markers in hiv-infected patients with advanced disease and their relationship to hivdisease markers.
mark||performed-6/VBN||although-1/IN	amod||studies-3/NNS||many-2/JJ	nsubjpass||performed-6/VBN||studies-3/NNS	aux||performed-6/VBN||have-4/VBP	auxpass||performed-6/VBN||been-5/VBN	advcl||known-26/VBN||performed-6/VBN	prep_on||performed-6/VBN||efficacy-8/NN	prep_on||performed-6/VBN||tolerability-10/NN	conj_and||efficacy-8/NN||tolerability-10/NN	det||arthemeter-lumefantrine-14/NN||the-12/DT	nn||arthemeter-lumefantrine-14/NN||combination-13/NN	prep_of||efficacy-8/NN||arthemeter-lumefantrine-14/NN	appos||arthemeter-lumefantrine-14/NN||al-16/NNP	prep_of||efficacy-8/NN||dihydroartemisinin-piperaquine-19/NN	conj_or||arthemeter-lumefantrine-14/NN||dihydroartemisinin-piperaquine-19/NN	appos||arthemeter-lumefantrine-14/NN||dp-21/NN	nsubjpass||known-26/VBN||less-24/JJR	auxpass||known-26/VBN||is-25/VBZ	root||ROOT-0/null||known-26/VBN	det||effect-29/NN||the-28/DT	prep_of||known-26/VBN||effect-29/NN	det||drugs-32/NNS||these-31/DT	prep_of||effect-29/NN||drugs-32/NNS	amod||development-35/NN||gametocyte-34/JJ	prep_on||known-26/VBN||development-35/NN	nsubj||issue-41/NN||development-35/NN	cop||issue-41/NN||is-38/VBZ	det||issue-41/NN||an-39/DT	amod||issue-41/NN||important-40/JJ	rcmod||development-35/NN||issue-41/NN	nn||control-44/NN||malaria-43/NN	prep_in||issue-41/NN||control-44/NN	malaria-43||lumefantrine--1||yes||although many studies have been performed on efficacy and tolerability of the combination arthemeter-lumefantrine (al) or dihydroartemisinin-piperaquine (dp), less is known of the effect of these drugs on gametocyte development, which is an important issue in malaria control.
vmod||showed-9/VBD||using-1/VBG	det||model-4/NN||an-2/DT	amod||model-4/NN||orthotopic-3/JJ	dobj||using-1/VBG||model-4/NN	prep_of||model-4/NN||renalcellcarcinoma-6/NN	nsubj||showed-9/VBD||we-8/PRP	root||ROOT-0/null||showed-9/VBD	advmod||showed-9/VBD||previously-10/RB	mark||resulted-16/VBD||that-11/IN	amod||immunotherapy-15/NN||il-2-12/JJ	amod||immunotherapy-15/NN||/-13/JJ	amod||immunotherapy-15/NN||anti-cd40-14/JJ	nsubj||resulted-16/VBD||immunotherapy-15/NN	ccomp||showed-9/VBD||resulted-16/VBD	amod||responses-20/NNS||synergistic-18/JJ	amod||responses-20/NNS||anti-tumor-19/JJ	prep_in||resulted-16/VBD||responses-20/NNS	mark||mediated-30/VBD||whereas-22/IN	amod||cd40-28/NNS||il-2-23/JJ	advmod||±-26/JJ||î-25/RB	conj_or||il-2-23/JJ||±-26/JJ	amod||cd40-28/NNS||±-26/JJ	nsubj||mediated-30/VBD||cd40-28/NNS	advmod||mediated-30/VBD||alone-29/RB	advcl||resulted-16/VBD||mediated-30/VBD	amod||effects-34/NNS||partial-31/JJ	amod||effects-34/NNS||transient-32/JJ	nn||effects-34/NNS||anti-tumor-33/NN	dobj||mediated-30/VBD||effects-34/NNS	il-2-23||tumor--1||no_rel||using an orthotopic model of renalcellcarcinoma, we showed previously that il-2/anti-cd40 immunotherapy resulted in synergistic anti-tumor responses, whereas il-2 or î±-cd40 alone mediated partial transient anti-tumor effects.
root||ROOT-0/null||hereditary-1/VBG	amod||deficiency-5/NN||combined-2/VBN	amod||deficiency-5/NN||vitamink-dependent-3/JJ	nn||deficiency-5/NN||clottingfactors-4/NN	dobj||hereditary-1/VBG||deficiency-5/NN	dep||deficiency-5/NN||vkcfd-7/VBN	cop||bleedingdisorder-13/NN||is-9/VBZ	det||bleedingdisorder-13/NN||a-10/DT	amod||bleedingdisorder-13/NN||rare-11/JJ	amod||bleedingdisorder-13/NN||congenital-12/JJ	aux||hereditary-1/VBG||bleedingdisorder-13/NN	vmod||bleedingdisorder-13/NN||resulting-14/VBG	amod||levels-18/NNS||variably-16/JJ	amod||levels-18/NNS||decreased-17/VBN	prep_from||resulting-14/VBG||levels-18/NNS	amod||ii-21/NN||coagulationfactors-20/JJ	prep_of||levels-18/NNS||ii-21/NN	prep_of||levels-18/NNS||vii-23/NN	conj_and||ii-21/NN||vii-23/NN	prep_of||levels-18/NNS||ix-25/NN	conj_and||ii-21/NN||ix-25/NN	prep_of||levels-18/NNS||x-27/SYM	conj_and||ii-21/NN||x-27/SYM	amod||anticoagulants-32/NNS||natural-31/JJ	aux||hereditary-1/VBG||anticoagulants-32/NNS	conj_and||bleedingdisorder-13/NN||anticoagulants-32/NNS	dep||anticoagulants-32/NNS||protein-33/NN	nsubj||hereditary-1/VBG||c-34/SYM	nn||s-37/NNS||protein-36/NN	appos||c-34/SYM||s-37/NNS	nn||z.-40/NN||protein-39/NN	appos||c-34/SYM||z.-40/NN	conj_and||s-37/NNS||z.-40/NN	bleedingdisorder-13||clottingfactors-4||no_rel||hereditary combined vitamink-dependent clottingfactors deficiency (vkcfd) is a rare congenital bleedingdisorder resulting from variably decreased levels of coagulationfactors ii, vii, ix and x as well as natural anticoagulants protein c, protein s and protein z.
prep_at||determined-26/VBN||inclusion-2/NN	amod||parameters-6/NNS||steady-state-4/JJ	nn||parameters-6/NNS||pk-5/NN	nsubjpass||determined-26/VBN||parameters-6/NNS	det||form-11/NN||the-8/DT	advmod||active-10/JJ||mmf-9/RB	amod||form-11/NN||active-10/JJ	prep_of||parameters-6/NNS||form-11/NN	prep_of||parameters-6/NNS||mycophenolicacid-13/NN	conj_and||form-11/NN||mycophenolicacid-13/NN	appos||mycophenolicacid-13/NN||mpa-15/NN	poss||metabolite-21/NN||its-19/PRP$	amod||metabolite-21/NN||glucuronide-20/JJ	prep_of||parameters-6/NNS||metabolite-21/NN	conj_and||form-11/NN||metabolite-21/NN	appos||metabolite-21/NN||mpag-23/NN	auxpass||determined-26/VBN||were-25/VBD	root||ROOT-0/null||determined-26/VBN	num||patients-31/NNS||25-28/CD	amod||patients-31/NNS||stable-29/JJ	nn||patients-31/NNS||sle-30/NN	prep_for||determined-26/VBN||patients-31/NNS	amod||manifestations-34/NNS||renal-33/JJ	prep_without||determined-26/VBN||manifestations-34/NNS	mpa-15||sle-30||no_rel||at inclusion, steady-state pk parameters of the mmf active form, mycophenolicacid (mpa), and its glucuronide metabolite (mpag) were determined for 25 stable sle patients without renal manifestations.
nsubj||have-11/VBP||adults-1/NNS	amod||origin-5/NN||south-3/JJ	nn||origin-5/NN||asian-4/NN	prep_of||adults-1/NNS||origin-5/NN	vmod||origin-5/NN||living-6/VBG	det||kingdom-10/NN||the-8/DT	amod||kingdom-10/NN||united-9/VBN	prep_in||living-6/VBG||kingdom-10/NN	root||ROOT-0/null||have-11/VBP	amod||risks-13/NNS||high-12/JJ	nsubj||raised-20/VBD||risks-13/NNS	amod||obesity-18/NN||type2diabetes-15/JJ	conj_and||type2diabetes-15/JJ||central-17/JJ	amod||obesity-18/NN||central-17/JJ	prep_of||risks-13/NNS||obesity-18/NN	ccomp||have-11/VBP||raised-20/VBD	xcomp||raised-20/VBD||circulating-21/VBG	dobj||circulating-21/VBG||insulin-22/NN	dobj||circulating-21/VBG||triglyceride-24/NN	conj_and||insulin-22/NN||triglyceride-24/NN	amod||concentrations-29/NNS||c-reactive-27/JJ	nn||concentrations-29/NNS||protein-28/NN	dobj||circulating-21/VBG||concentrations-29/NNS	conj_and||insulin-22/NN||concentrations-29/NNS	amod||hdl-cholesterol-33/NN||low-32/JJ	dobj||circulating-21/VBG||hdl-cholesterol-33/NN	conj_and||insulin-22/NN||hdl-cholesterol-33/NN	dep||circulating-21/VBG||when-34/WRB	prepc_compared_with||raised-20/VBD||with-36/IN	amod||europeans-38/NNS||white-37/JJ	pobj||raised-20/VBD||europeans-38/NNS	type2diabetes-15||triglyceride-24||no_rel||adults of south asian origin living in the united kingdom have high risks of type2diabetes and central obesity; raised circulating insulin, triglyceride, and c-reactive protein concentrations; and low hdl-cholesterol when compared with white europeans.
mark||begun-7/VBN||although-1/IN	amod||interventions-3/NNS||many-2/JJ	nsubj||begun-7/VBN||interventions-3/NNS	nsubjpass||integrated-10/VBN||interventions-3/NNS	conj_and||interventions-3/NNS||procedures-5/NNS	nsubj||begun-7/VBN||procedures-5/NNS	nsubjpass||integrated-10/VBN||procedures-5/NNS	aux||begun-7/VBN||have-6/VBP	advcl||need-34/VBP||begun-7/VBN	aux||integrated-10/VBN||to-8/TO	auxpass||integrated-10/VBN||be-9/VB	xcomp||begun-7/VBN||integrated-10/VBN	advmod||integrated-10/VBN||routinely-11/RB	nn||practice-17/NN||heroin-13/NN	nn||practice-17/NN||use-14/NN	nn||practice-17/NN||disorder-15/NN	amod||practice-17/NN||clinical-16/JJ	prep_into||integrated-10/VBN||practice-17/NN	det||context-22/NN||the-19/DT	amod||context-22/NN||south-20/JJ	nn||context-22/NN||african-21/NN	prep_within||practice-17/NN||context-22/NN	amod||factors-25/NNS||comorbidity-24/JJ	nsubj||need-34/VBP||factors-25/NNS	nsubjpass||addressed-39/VBN||factors-25/NNS	amod||illness-30/NN||psychiatric-29/JJ	prep_such_as||factors-25/NNS||illness-30/NN	prep_such_as||factors-25/NNS||hiv/aids-32/NNS	conj_and||illness-30/NN||hiv/aids-32/NNS	root||ROOT-0/null||need-34/VBP	aux||addressed-39/VBN||to-35/TO	auxpass||addressed-39/VBN||be-36/VB	advmod||addressed-39/VBN||more-37/RBR	advmod||addressed-39/VBN||cogently-38/RB	xcomp||need-34/VBP||addressed-39/VBN	aids--1||hiv--1||no||although many interventions and procedures have begun to be integrated routinely into heroin use disorder clinical practice within the south african context, comorbidity factors, such as psychiatric illness and hiv/aids, need to be more cogently addressed.
amod||treatment-3/NN||intermittent-1/JJ	nn||treatment-3/NN||preventive-2/NN	nsubjpass||recommended-11/VBN||treatment-3/NN	amod||ulphadoxine-pyrimethamine-6/NN||s-5/JJ	prep_with||treatment-3/NN||ulphadoxine-pyrimethamine-6/NN	appos||treatment-3/NN||sp-8/NN	auxpass||recommended-11/VBN||is-10/VBZ	root||ROOT-0/null||recommended-11/VBN	prepc_for||recommended-11/VBN||reducing-13/VBG	det||risk-15/NN||the-14/DT	dobj||reducing-13/VBG||risk-15/NN	prep_of||risk-15/NN||malaria-17/NN	prep_in||malaria-17/NN||pregnancy-19/NN	poss||consequences-22/NNS||its-21/PRP$	prep_of||risk-15/NN||consequences-22/NNS	conj_and||malaria-17/NN||consequences-22/NNS	prep_on||consequences-22/NNS||mothers-24/NNS	prep_on||consequences-22/NNS||babies-26/NNS	conj_and||mothers-24/NNS||babies-26/NNS	appos||mothers-24/NNS||iptp-sp-28/NN	malaria-17||pyrimethamine--1||yes||intermittent preventive treatment with s ulphadoxine-pyrimethamine (sp) is recommended for reducing the risk of malaria in pregnancy and its consequences on mothers and babies (iptp-sp).
advmod||demonstrated-5/VBN||previously-1/RB	nsubj||demonstrated-5/VBN||we-3/PRP	aux||demonstrated-5/VBN||have-4/VBP	root||ROOT-0/null||demonstrated-5/VBN	mark||sufficient-14/JJ||that-6/IN	nsubj||sufficient-14/JJ||treatment-7/NN	nsubj||tilt-16/VB||treatment-7/NN	advmod||modified-10/JJ||genetically-9/RB	amod||acidophilus-12/NNS||modified-10/JJ	nn||acidophilus-12/NNS||lactobacillus-11/NN	prep_with||treatment-7/NN||acidophilus-12/NNS	cop||sufficient-14/JJ||is-13/VBZ	ccomp||demonstrated-5/VBN||sufficient-14/JJ	aux||tilt-16/VB||to-15/TO	xcomp||sufficient-14/JJ||tilt-16/VB	det||balance-19/NN||the-17/DT	amod||balance-19/NN||immune-18/JJ	dobj||tilt-16/VB||balance-19/NN	prep_from||tilt-16/VB||proinflammatory-21/NN	prep_to||tilt-16/VB||regulatory-23/JJ	amod||models-26/NNS||experimental-25/JJ	prep_in||regulatory-23/JJ||models-26/NNS	prep_of||models-26/NNS||colitis-28/NNS	nn||cancer-31/NN||colon-30/NN	prep_of||models-26/NNS||cancer-31/NN	conj_and||colitis-28/NNS||cancer-31/NN	acidophilus-12||cancer-31||no_rel||previously, we have demonstrated that treatment with genetically modified lactobacillus acidophilus is sufficient to tilt the immune balance from proinflammatory to regulatory in experimental models of colitis and colon cancer.
amod||antigen-3/NN||hepatitisb-1/JJ	nn||antigen-3/NN||surface-2/NN	nsubjpass||done-23/VBN||antigen-3/NN	appos||antigen-3/NN||hbsag-5/NN	amod||antigen-10/NN||hepatitisb-8/JJ	nn||antigen-10/NN||envelope-9/NN	appos||antigen-3/NN||antigen-10/NN	appos||antigen-10/NN||hbeag-12/NN	conj_and||antigen-3/NN||hbv-dna-15/NN	nsubjpass||done-23/VBN||hbv-dna-15/NN	nn||biopsy-19/NN||liver-18/NN	conj_and||antigen-3/NN||biopsy-19/NN	nsubjpass||done-23/VBN||biopsy-19/NN	prep_before||biopsy-19/NN||rt-21/NN	auxpass||done-23/VBN||were-22/VBD	root||ROOT-0/null||done-23/VBN	det||patients-26/NNS||all-25/DT	prep_in||done-23/VBN||patients-26/NNS	hepatitisb-8||hbsag-5||yes||hepatitisb surface antigen (hbsag), hepatitisb envelope antigen (hbeag), hbv-dna, and liver biopsy before rt were done in all patients.
nsubj||had-5/VBD||none-1/NN	det||patients-4/NNS||the-3/DT	prep_of||none-1/NN||patients-4/NNS	root||ROOT-0/null||had-5/VBD	amod||pain-7/NN||severe-6/JJ	dobj||had-5/VBD||pain-7/NN	det||procedure-10/NN||the-9/DT	prep_during||pain-7/NN||procedure-10/NN	quantmod||2-13/CD||only-12/RB	num||%-14/NN||2-13/CD	nsubj||required-20/VBD||%-14/NN	number||300-18/CD||six-16/CD	quantmod||300-18/CD||of-17/IN	dep||%-14/NN||300-18/CD	parataxis||had-5/VBD||required-20/VBD	nsubj||high-42/JJ||use-21/NN	amod||sedation-24/NN||intravenous-23/JJ	prep_of||use-21/NN||sedation-24/NN	dep||sedation-24/NN||propofol-26/JJ	preconj||sedation-24/NN||both-29/CC	det||$-32/$||the-30/DT	amod||$-32/$||surgeonâ-31/JJ	prep_of||use-21/NN||$-32/$	conj_and||sedation-24/NN||$-32/$	number||s-34/CD||-33/CD	num||$-32/$||s-34/CD	det||satisfaction-40/NN||the-36/DT	amod||satisfaction-40/NN||patientsâ-37/JJ	amod||satisfaction-40/NN||$-38/$	dep||$-38/$||-39/JJ	prep_of||use-21/NN||satisfaction-40/NN	conj_and||sedation-24/NN||satisfaction-40/NN	cop||high-42/JJ||were-41/VBD	ccomp||required-20/VBD||high-42/JJ	pain-7||propofol-26||yes||none of the patients had severe pain during the procedure; only 2% (six of 300) required use of intravenous sedation (propofol), both the surgeonâs and the patientsâ satisfaction were high.
nsubj||used-17/VBD||celecoxib-1/NN	conj_and||celecoxib-1/NN||diclofenac-3/NN	nsubj||used-17/VBD||diclofenac-3/NN	conj_and||celecoxib-1/NN||ibuprofen-5/NN	nsubj||used-17/VBD||ibuprofen-5/NN	conj_and||celecoxib-1/NN||nimesulide-8/NN	nsubj||used-17/VBD||nimesulide-8/NN	cop||anti-inflammatorydrugs-11/NNS||are-9/VBP	amod||anti-inflammatorydrugs-11/NNS||nonsteroidal-10/JJ	rcmod||celecoxib-1/NN||anti-inflammatorydrugs-11/NNS	appos||celecoxib-1/NN||nsaids-13/NNS	advmod||commonly-16/RB||very-15/RB	advmod||used-17/VBD||commonly-16/RB	root||ROOT-0/null||used-17/VBD	det||treatment-20/NN||the-19/DT	prep_for||used-17/VBD||treatment-20/NN	amod||mild-24/JJ||moderate-22/JJ	dep||mild-24/JJ||to-23/TO	amod||pain-25/NN||mild-24/JJ	prep_of||treatment-20/NN||pain-25/NN	nn||acetaminophen-31/NN||paracetamol-29/NNP	prep_together_with||used-17/VBD||acetaminophen-31/NN	det||analgesic-38/NN||a-34/DT	advmod||used-37/JJ||very-35/RB	advmod||used-37/JJ||widely-36/RB	amod||analgesic-38/NN||used-37/JJ	appos||acetaminophen-31/NN||analgesic-38/NN	det||effect-43/NN||a-40/DT	amod||effect-43/NN||lesser-41/JJR	amod||effect-43/NN||anti-inflammatory-42/JJ	prep_with||analgesic-38/NN||effect-43/NN	pain-25||paracetamol-29||yes||celecoxib, diclofenac, ibuprofen, and nimesulide are nonsteroidal anti-inflammatorydrugs (nsaids) very commonly used for the treatment of moderate to mild pain, together with paracetamol (acetaminophen), a very widely used analgesic with a lesser anti-inflammatory effect.
aux||update-2/VB||to-1/TO	root||ROOT-0/null||update-2/VB	det||programme-7/NN||the-3/DT	amod||programme-7/NN||national-4/JJ	nn||programme-7/NN||malaria-5/NN	nn||programme-7/NN||control-6/NN	dobj||update-2/VB||programme-7/NN	prep_of||programme-7/NN||mali-9/NNS	det||efficacy-12/NN||the-11/DT	prep_on||mali-9/NNS||efficacy-12/NN	prep_of||efficacy-12/NN||chloroquine-14/NN	prep_of||efficacy-12/NN||amodiaquine-16/NN	conj_and||chloroquine-14/NN||amodiaquine-16/NN	prep_of||efficacy-12/NN||sulphadoxine-pyrimethamine-18/NN	conj_and||chloroquine-14/NN||sulphadoxine-pyrimethamine-18/NN	det||treatment-21/NN||the-20/DT	prep_in||update-2/VB||treatment-21/NN	amod||falciparummalaria-24/NN||uncomplicated-23/JJ	prep_of||treatment-21/NN||falciparummalaria-24/NN	falciparummalaria-24||sulphadoxine--1||yes||to update the national malaria control programme of mali on the efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine in the treatment of uncomplicated falciparummalaria.
nsubj||had-5/VBD||most-1/JJS	det||gps-4/NN||the-3/DT	prep_of||most-1/JJS||gps-4/NN	root||ROOT-0/null||had-5/VBD	amod||knowledge-7/NN||adequate-6/JJ	dobj||had-5/VBD||knowledge-7/NN	prep_about||knowledge-7/NN||transmission-9/NN	prep_of||transmission-9/NN||hbv-11/NN	prep_of||transmission-9/NN||hcv-13/NN	conj_and||hbv-11/NN||hcv-13/NN	advmod||knowledge-7/NN||also-15/RB	nn||factors-18/NNS||risk-17/NN	prep_about||knowledge-7/NN||factors-18/NNS	conj_and||transmission-9/NN||factors-18/NNS	prep_for||had-5/VBD||transmission-20/NN	prep_of||transmission-20/NN||viruses-22/NNS	hbv-11||viruses-22||no||most of the gps had adequate knowledge about transmission of hbv and hcv and also about risk factors for transmission of viruses.
nsubj||inflammatorydisease-5/NN||celiacdisease-1/NN	cop||inflammatorydisease-5/NN||is-2/VBZ	det||inflammatorydisease-5/NN||an-3/DT	amod||inflammatorydisease-5/NN||autoimmune-4/JJ	root||ROOT-0/null||inflammatorydisease-5/NN	det||intestine-9/NN||the-7/DT	amod||intestine-9/NN||small-8/JJ	prep_of||inflammatorydisease-5/NN||intestine-9/NN	vmod||intestine-9/NN||precipitated-10/VBD	det||ingestion-13/NN||the-12/DT	agent||precipitated-10/VBD||ingestion-13/NN	prep_of||ingestion-13/NN||gluten-15/NN	det||component-18/NN||a-17/DT	appos||gluten-15/NN||component-18/NN	nn||protein-21/NN||wheat-20/NN	prep_of||component-18/NN||protein-21/NN	advmod||susceptible-25/JJ||genetically-24/RB	amod||persons-26/NNS||susceptible-25/JJ	prep_in||precipitated-10/VBD||persons-26/NNS	celiacdisease-1||gluten-15||no||celiacdisease is an autoimmune inflammatorydisease of the small intestine precipitated by the ingestion of gluten, a component of wheat protein, in genetically susceptible persons.
nsubj||allows-2/VBZ||it-1/PRP	root||ROOT-0/null||allows-2/VBZ	dobj||allows-2/VBZ||us-3/PRP	nsubj||show-5/VB||us-3/PRP	aux||show-5/VB||to-4/TO	xcomp||allows-2/VBZ||show-5/VB	mark||related-12/VBN||that-6/IN	det||sars-cov-8/NN||the-7/DT	nsubj||related-12/VBN||sars-cov-8/NN	cop||related-12/VBN||is-9/VBZ	advmod||closely-11/RB||most-10/RBS	advmod||related-12/VBN||closely-11/RB	ccomp||show-5/VB||related-12/VBN	det||coronavirus-15/NNS||a-14/DT	prep_to||related-12/VBN||coronavirus-15/NNS	det||civet-19/NN||the-17/DT	nn||civet-19/NN||palm-18/NN	prep_from||coronavirus-15/NNS||civet-19/NN	neg||related-12/VBN||not-20/RB	det||bird-23/NN||a-22/DT	prep_from||related-12/VBN||bird-23/NN	mark||suspected-26/VBD||as-24/IN	advmod||suspected-26/VBD||initially-25/RB	dep||related-12/VBN||suspected-26/VBD	det||hcov-hku1-34/NN||the-29/DT	advmod||discovered-31/VBN||newly-30/RB	amod||hcov-hku1-34/NN||discovered-31/VBN	amod||hcov-hku1-34/NN||human-32/JJ	nn||hcov-hku1-34/NN||coronavirus-33/NNS	nsubj||related-38/VBN||hcov-hku1-34/NN	cop||related-38/VBN||is-35/VBZ	advmod||related-38/VBN||more-36/RBR	advmod||related-38/VBN||closely-37/RB	conj_and||allows-2/VBZ||related-38/VBN	prep_to||related-38/VBN||sars-40/NNS	advmod||related-38/VBN||than-41/IN	det||member-46/NN||any-43/DT	amod||member-46/NN||other-44/JJ	amod||member-46/NN||known-45/VBN	prep_to||than-41/IN||member-46/NN	nn||coronavirus-50/NNS||group-48/NN	num||coronavirus-50/NNS||2-49/CD	prep_of||member-46/NN||coronavirus-50/NNS	sars-40||coronavirus-50||no||it allows us to show that the sars-cov is most closely related to a coronavirus from the palm civet not from a bird as initially suspected, and the newly discovered human coronavirus hcov-hku1 is more closely related to sars than to any other known member of group 2 coronavirus.
det||study-2/NN||this-1/DT	nsubj||gives-3/VBZ||study-2/NN	root||ROOT-0/null||gives-3/VBZ	iobj||gives-3/VBZ||us-4/PRP	det||knowledge-9/NN||an-5/DT	amod||knowledge-9/NN||overview-6/JJ	prep_about||overview-6/JJ||hiv/aids-8/NNS	dobj||gives-3/VBZ||knowledge-9/NN	prep_in||knowledge-9/NN||detention-11/NN	nn||province-14/NN||hunan-13/NN	prep_in||detention-11/NN||province-14/NN	det||sites-19/NNS||all-17/DT	nn||sites-19/NNS||detention-18/NN	nsubj||provided-23/VBD||sites-19/NNS	det||study-22/NN||the-21/DT	prep_in||sites-19/NNS||study-22/NN	conj_and||gives-3/VBZ||provided-23/VBD	amod||services-26/NNS||hiv/aids-24/JJ	nn||services-26/NNS||intervention-25/NN	dobj||provided-23/VBD||services-26/NNS	prep_among||provided-23/VBD||detainees-28/NNS	nsubj||focused-30/VBN||detainees-28/NNS	rcmod||detainees-28/NNS||focused-30/VBN	amod||attitude-35/NN||hiv/aids-32/JJ	nn||attitude-35/NN||knowledge-33/NN	prep_on||focused-30/VBN||attitude-35/NN	nn||behaviors-39/NNS||health-38/NN	prep_on||focused-30/VBN||behaviors-39/NNS	conj_and||attitude-35/NN||behaviors-39/NNS	aids--1||hiv--1||no||this study gives us an overview about hiv/aids knowledge in detention in hunan province, and all detention sites in the study provided hiv/aids intervention services among detainees that focused on hiv/aids knowledge, attitude, and health behaviors.
nsubj||reviewed-2/VBN||we-1/PRP	nsubj||conducted-6/VBN||we-1/PRP	root||ROOT-0/null||reviewed-2/VBN	det||literature-4/NN||the-3/DT	dobj||reviewed-2/VBN||literature-4/NN	conj_and||reviewed-2/VBN||conducted-6/VBN	det||study-8/NN||this-7/DT	dobj||conducted-6/VBN||study-8/NN	aux||assess-10/VB||to-9/TO	vmod||study-8/NN||assess-10/VB	det||impact-12/NN||the-11/DT	dobj||assess-10/VB||impact-12/NN	prepc_of||impact-12/NN||xqlg-14/VBG	det||therapy-18/NN||an-16/DT	amod||therapy-18/NN||add-on-17/JJ	prep_as||xqlg-14/VBG||therapy-18/NN	prep_to||xqlg-14/VBG||treatment-20/NN	amod||seretide-24/NN||fluticasone/salmeterol-22/JJ	prep_with||assess-10/VB||seretide-24/NN	amod||patients-28/NNS||adult-27/JJ	prep_in||seretide-24/NN||patients-28/NNS	amod||asthma-33/NN||mild-to-moderate-30/JJ	amod||asthma-33/NN||persistent-32/JJ	prep_with||assess-10/VB||asthma-33/NN	asthma-33||salmeterol--1||yes||we reviewed the literature and conducted this study to assess the impact of xqlg as an add-on therapy to treatment with fluticasone/salmeterol (seretide) in adult patients with mild-to-moderate, persistent asthma.
advmod||developed-14/VBN||thus-1/RB	prep_upon||developed-14/VBN||interaction-4/NN	amod||viruses-7/NNS||certain-6/JJ	prep_with||developed-14/VBN||viruses-7/NNS	amod||cells-12/NNS||cd8-9/JJ	amod||cells-12/NNS||lineage-specific-10/JJ	nn||cells-12/NNS||nkt-11/NN	nsubj||developed-14/VBN||cells-12/NNS	aux||developed-14/VBN||are-13/VBP	root||ROOT-0/null||developed-14/VBN	dep||developed-14/VBN||differentiated-16/VBN	dep||developed-14/VBN||matured-18/VBN	conj_and||differentiated-16/VBN||matured-18/VBN	advmod||differentiated-16/VBN||intrathymically-19/RB	det||finding-22/NN||a-21/DT	dobj||developed-14/VBN||finding-22/NN	amod||importance-26/NN||potential-24/JJ	amod||importance-26/NN||therapeutic-25/JJ	prep_with||finding-22/NN||importance-26/NN	prep_against||importance-26/NN||viralinfections-28/NNS	prep_against||importance-26/NN||tumors-30/NNS	conj_and||viralinfections-28/NNS||tumors-30/NNS	viralinfections-28||viruses-7||no||thus, upon interaction with certain viruses, cd8 lineage-specific nkt cells are developed, differentiated and matured intrathymically, a finding with potential therapeutic importance against viralinfections and tumors.
advmod||found-4/VBD||recently-1/RB	nsubj||found-4/VBD||we-3/PRP	root||ROOT-0/null||found-4/VBD	mark||retinoicacid-9/VBD||that-5/IN	nsubj||retinoicacid-9/VBD||all-6/DT	nsubj||retinoicacid-9/VBD||trans-8/NNS	ccomp||found-4/VBD||retinoicacid-9/VBD	amod||-rrb--12/NNS||-lrb--10/JJ	nn||-rrb--12/NNS||atra-11/NN	nsubj||triggers-13/VBZ||-rrb--12/NNS	ccomp||retinoicacid-9/VBD||triggers-13/VBZ	det||activation-15/NN||the-14/DT	dobj||triggers-13/VBZ||activation-15/NN	amod||-rrb--22/NNS||extracellular-signal-regulated-17/JJ	amod||-rrb--22/NNS||kinase-18/JJ	num||-lrb--20/NNS||2-19/CD	dep||kinase-18/JJ||-lrb--20/NNS	amod||-rrb--22/NNS||erk2-21/JJ	prep_of||activation-15/NN||-rrb--22/NNS	nsubj||phosphorylates-25/VBZ||-rrb--22/NNS	nsubj||stimulates-28/VBZ||-rrb--22/NNS	rcmod||-rrb--22/NNS||phosphorylates-25/VBZ	dobj||phosphorylates-25/VBZ||tr2-26/NNS	rcmod||-rrb--22/NNS||stimulates-28/VBZ	conj_and||phosphorylates-25/VBZ||stimulates-28/VBZ	poss||partitioning-30/NN||its-29/PRP$	dobj||stimulates-28/VBZ||partitioning-30/NN	amod||bodies-37/NNS||promyelocyticleukemia-32/JJ	nn||bodies-37/NNS||-lrb--33/NNP	nn||bodies-37/NNS||pml-34/NN	nn||bodies-37/NNS||-rrb--35/NN	amod||bodies-37/NNS||nuclear-36/JJ	prep_to||stimulates-28/VBZ||bodies-37/NNS	advmod||converting-40/VBG||thereby-39/RB	vmod||activation-15/NN||converting-40/VBG	det||function-43/NN||the-41/DT	nn||function-43/NN||activator-42/NN	dobj||converting-40/VBG||function-43/NN	prep_of||function-43/NN||tr2-45/CD	nn||gupta-49/NN||repression-47/NN	nn||gupta-49/NN||-lrb--48/NN	prep_into||converting-40/VBG||gupta-49/NN	prep_into||converting-40/VBG||al.-51/NN	conj_et||gupta-49/NN||al.-51/NN	num||al.-51/NN||2008-52/CD	nn||et-55/NNS||park-54/NN	nsubj||al.-56/VBP||et-55/NNS	parataxis||found-4/VBD||al.-56/VBP	num||-rrb--58/NNS||2007-57/CD	dobj||al.-56/VBP||-rrb--58/NNS	promyelocyticleukemia-32||atra-11||yes||recently , we found that all - trans retinoicacid -lrb- atra -rrb- triggers the activation of extracellular-signal-regulated kinase 2 -lrb- erk2 -rrb- , which phosphorylates tr2 and stimulates its partitioning to promyelocyticleukemia -lrb- pml -rrb- nuclear bodies , thereby converting the activator function of tr2 into repression -lrb- gupta et al. 2008 ; park et al. 2007 -rrb- .
amod||controversy-2/NN||much-1/JJ	nsubj||exists-3/VBZ||controversy-2/NN	root||ROOT-0/null||exists-3/VBZ	xcomp||exists-3/VBZ||concerning-4/VBG	det||efficacy-6/NN||the-5/DT	nsubj||due-21/JJ||efficacy-6/NN	amod||cardioverter-defibrillators-11/NNS||primary-8/JJ	amod||cardioverter-defibrillators-11/NNS||prophylactic-9/JJ	nn||cardioverter-defibrillators-11/NNS||implantable-10/NN	prep_of||efficacy-6/NN||cardioverter-defibrillators-11/NNS	appos||cardioverter-defibrillators-11/NNS||icds-13/NNS	prep_in||cardioverter-defibrillators-11/NNS||patients-16/NNS	amod||fraction-20/NN||low-18/JJ	nn||fraction-20/NN||ejection-19/NN	prep_with||patients-16/NNS||fraction-20/NN	xcomp||concerning-4/VBG||due-21/JJ	prep_to||due-21/JJ||coronaryarterydisease-23/NN	appos||coronaryarterydisease-23/NN||cad-25/NN	prep_to||due-21/JJ||dilatedcardiomyopathy-28/NN	conj_or||coronaryarterydisease-23/NN||dilatedcardiomyopathy-28/NN	appos||coronaryarterydisease-23/NN||dcm-30/NN	dcm-30||cad-25||no_rel||much controversy exists concerning the efficacy of primary prophylactic implantable cardioverter-defibrillators (icds) in patients with low ejection fraction due to coronaryarterydisease (cad) or dilatedcardiomyopathy (dcm).
amod||charges-3/NNS||inpatient-1/JJS	nn||charges-3/NNS||hiv/aids-2/NNS	nsubj||decreased-4/VBD||charges-3/NNS	root||ROOT-0/null||decreased-4/VBD	amod||$-7/NNS||1996â-6/JJ	prep_from||decreased-4/VBD||$-7/NNS	dep||$-7/NNS||2000-9/CD	aids--1||hiv--1||no||inpatient hiv/aids charges decreased from 1996â2000.
amod||analysis-2/NN||microarray-1/JJ	nsubj||shows-14/VBZ||analysis-2/NN	det||effects-5/NNS||the-4/DT	prep_of||analysis-2/NN||effects-5/NNS	amod||over-expression-8/NN||ets-1-7/JJ	prep_of||effects-5/NNS||over-expression-8/NN	det||cells-13/NNS||these-10/DT	amod||cells-13/NNS||ovarian-11/JJ	nn||cells-13/NNS||cancer-12/NN	prep_in||over-expression-8/NN||cells-13/NNS	root||ROOT-0/null||shows-14/VBZ	mark||involved-20/VBN||that-15/IN	amod||enzymes-19/NNS||ets-1-16/JJ	amod||enzymes-19/NNS||up-regulates-17/JJ	amod||enzymes-19/NNS||key-18/JJ	nsubj||involved-20/VBN||enzymes-19/NNS	nsubj||associated-24/JJ||enzymes-19/NNS	ccomp||shows-14/VBZ||involved-20/VBN	prep_in||involved-20/VBN||glycolysis-22/NNS	ccomp||shows-14/VBZ||associated-24/JJ	conj_and||involved-20/VBN||associated-24/JJ	nn||pathways-26/NNS||feeder-25/NN	dobj||associated-24/JJ||pathways-26/NNS	amod||metabolism-29/NN||fattyacid-28/JJ	dobj||associated-24/JJ||metabolism-29/NN	conj_and||pathways-26/NNS||metabolism-29/NN	amod||defense-33/NN||antioxidant-32/JJ	dobj||associated-24/JJ||defense-33/NN	conj_and||pathways-26/NNS||defense-33/NN	enzymes-19||cancer-12||no_rel||microarray analysis of the effects of ets-1 over-expression in these ovarian cancer cells shows that ets-1 up-regulates key enzymes involved in glycolysis and associated feeder pathways, fattyacid metabolism, and antioxidant defense.
vmod||demonstrate-9/VBP||using-1/VBG	amod||models-3/NNS||macrophage-2/JJ	dobj||using-1/VBG||models-3/NNS	amod||ironoverloaddisease-6/NN||human-5/JJ	prep_of||models-3/NNS||ironoverloaddisease-6/NN	nsubj||demonstrate-9/VBP||we-8/PRP	root||ROOT-0/null||demonstrate-9/VBP	mark||altered-14/VBD||that-10/IN	nn||senses-13/NNS||c.-11/NN	nn||senses-13/NNS||glabrata-12/NN	nsubj||altered-14/VBD||senses-13/NNS	ccomp||demonstrate-9/VBP||altered-14/VBD	nn||levels-16/NNS||iron-15/NN	dobj||altered-14/VBD||levels-16/NNS	det||compartment-20/NN||the-18/DT	amod||compartment-20/NN||phagosomal-19/JJ	prep_within||altered-14/VBD||compartment-20/NN	ironoverloaddisease-6||iron-15||no||using macrophage models of human ironoverloaddisease , we demonstrate that c. glabrata senses altered iron levels within the phagosomal compartment .
nsubj||recruited-2/VBD||we-1/PRP	root||ROOT-0/null||recruited-2/VBD	num||patients-4/NNS||25-3/CD	dobj||recruited-2/VBD||patients-4/NNS	prep_with||recruited-2/VBD||type1diabetes-6/NNS	dep||type1diabetes-6/NNS||mean-8/VB	nn||â-11/NN||age-9/NN	num||â-11/NN||51-10/CD	dobj||mean-8/VB||â-11/NN	number||10-13/CD||±-12/CD	num||years-14/NNS||10-13/CD	tmod||mean-8/VB||years-14/NNS	dep||mean-8/VB||mean-16/VB	nn||duration-18/NN||disease-17/NN	dobj||mean-16/VB||duration-18/NN	num||years-23/NNS||26-19/CD	nn||years-23/NNS||â-20/NNP	nn||years-23/NNS||±-21/NNP	num||years-23/NNS||13-22/CD	tmod||mean-8/VB||years-23/NNS	num||type-28/NN||31-26/CD	amod||type-28/NN||insulin-treated-27/JJ	prep_with||recruited-2/VBD||type-28/NN	conj_and||type1diabetes-6/NNS||type-28/NN	num||patients-31/NNS||2-29/CD	amod||patients-31/NNS||diabetic-30/JJ	dep||type-28/NN||patients-31/NNS	dep||type-28/NN||mean-33/VB	nn||â-36/NN||age-34/NN	num||â-36/NN||66-35/CD	dobj||mean-33/VB||â-36/NN	number||8-38/CD||±-37/CD	num||years-39/NNS||8-38/CD	tmod||mean-33/VB||years-39/NNS	dep||mean-33/VB||mean-41/VB	nn||duration-43/NN||disease-42/NN	dobj||mean-41/VB||duration-43/NN	num||years-48/NNS||19-44/CD	nn||years-48/NNS||â-45/NNP	nn||years-48/NNS||±-46/NNP	num||years-48/NNS||9-47/CD	tmod||mean-33/VB||years-48/NNS	nsubj||received-52/VBD||who-51/WP	nsubj||sitagliptin-69/VBN||who-51/WP	prep_with||recruited-2/VBD||received-52/VBD	conj_and||type1diabetes-6/NNS||received-52/VBD	dobj||received-52/VBD||sitagliptin-53/NN	prep_with||received-52/VBD||metformin-55/NN	det||combination-59/NN||a-57/DT	amod||combination-59/NN||fixed-dose-58/JJ	prep_as||metformin-55/NN||combination-59/NN	num||mg-62/NN||50/1000-61/CD	npadvmod||once-63/RB||mg-62/NN	dep||received-52/VBD||once-63/RB	advmod||daily-66/JJ||twice-65/RB	dep||received-52/VBD||daily-66/JJ	conj_or||once-63/RB||daily-66/JJ	conj_and||type1diabetes-6/NNS||sitagliptin-69/VBN	conj_or||received-52/VBD||sitagliptin-69/VBN	nsubj||mg-72/VBP||100-71/CD	parataxis||sitagliptin-69/VBN||mg-72/VBP	advmod||mg-72/VBP||once-73/RB	advmod||mg-72/VBP||daily-74/RB	mark||metformin-79/VB||if-76/IN	nsubj||metformin-79/VB||intolerant-77/NN	aux||metformin-79/VB||to-78/TO	advcl||mg-72/VBP||metformin-79/VB	xcomp||mg-72/VBP||metformin-79/VB	amod||therapy-86/NN||ongoing-84/JJ	nn||therapy-86/NN||insulin-85/NN	prep_in_addition_to||sitagliptin-69/VBN||therapy-86/NN	num||â-89/NN||46-88/CD	prep_for||therapy-86/NN||â-89/NN	number||19-91/CD||±-90/CD	num||weeks-92/NNS||19-91/CD	dobj||sitagliptin-69/VBN||weeks-92/NNS	num||±-96/NNS||56-94/CD	nn||±-96/NNS||â-95/NN	dobj||sitagliptin-69/VBN||±-96/NNS	conj_and||weeks-92/NNS||±-96/NNS	num||weeks-98/NNS||14-97/CD	dep||±-96/NNS||weeks-98/NNS	advmod||±-96/NNS||respectively-100/RB	type1diabetes-6||insulin-85||yes||we recruited 25 patients with type1diabetes (mean age 51 â± 10 years, mean disease duration 26 â± 13 years) and 31 insulin-treated type 2 diabetic patients (mean age 66 â± 8 years, mean disease duration 19 â± 9 years), who received sitagliptin with metformin as a fixed-dose combination (50/1000 mg once or twice daily) or sitagliptin (100 mg once daily, if intolerant to metformin) in addition to ongoing insulin therapy for 46 â± 19 weeks and 56 â± 14 weeks, respectively.
det||female-3/NN||a-1/DT	amod||female-3/NN||69-year-old-2/JJ	nsubj||presented-4/VBD||female-3/NN	root||ROOT-0/null||presented-4/VBD	det||emergency-7/NN||an-6/DT	prep_as||presented-4/VBD||emergency-7/NN	prep_with||presented-4/VBD||atrialfibrillation-9/NN	nsubjpass||treated-13/VBN||atrialfibrillation-9/NN	auxpass||treated-13/VBN||was-12/VBD	rcmod||atrialfibrillation-9/NN||treated-13/VBN	prep_with||treated-13/VBN||warfarin-15/NN	atrialfibrillation-9||warfarin-15||yes||a 69-year-old female presented as an emergency with atrialfibrillation, which was treated with warfarin.
amod||injection-3/NN||propofol-2/JJ	prep_before||injected-10/VBD||injection-3/NN	prep_for||injection-3/NN||induction-5/NN	prep_of||induction-5/NN||anesthesia-7/NN	nsubj||injected-10/VBD||we-9/PRP	root||ROOT-0/null||injected-10/VBD	number||%-12/NN||1-11/CD	amod||iv-16/NN||%-12/NN	amod||iv-16/NN||lidocaine-13/JJ	num||iv-16/NN||50-14/CD	nn||iv-16/NN||mg-15/NN	dobj||injected-10/VBD||iv-16/NN	nn||relief-19/NN||pain-18/NN	prep_for||iv-16/NN||relief-19/NN	pain-18||lidocaine-13||yes||before propofol injection for induction of anesthesia, we injected 1% lidocaine 50 mg iv for pain relief.
nsubj||reflect-12/VB||differences-1/NNS	det||level-4/NN||the-3/DT	prep_in||differences-1/NNS||level-4/NN	amod||diversity-7/NN||viral-6/JJ	prep_of||level-4/NN||diversity-7/NN	amod||infants-10/NNS||hiv-infected-9/JJ	prep_in||diversity-7/NN||infants-10/NNS	aux||reflect-12/VB||may-11/MD	root||ROOT-0/null||reflect-12/VB	dobj||reflect-12/VB||differences-13/NNS	amod||dynamics-16/NNS||viral-15/JJ	prep_in||differences-13/NNS||dynamics-16/NNS	amod||responses-19/NNS||immune-18/JJ	dobj||reflect-12/VB||responses-19/NNS	conj_or||differences-13/NNS||responses-19/NNS	amod||factors-23/NNS||other-22/JJ	dobj||reflect-12/VB||factors-23/NNS	conj_or||differences-13/NNS||factors-23/NNS	nsubj||influence-27/VB||factors-23/NNS	aux||influence-27/VB||may-25/MD	advmod||influence-27/VB||also-26/RB	rcmod||factors-23/NNS||influence-27/VB	amod||progression-29/NN||hivdisease-28/JJ	dobj||influence-27/VB||progression-29/NN	hivdisease-28||hiv--1||no||differences in the level of viral diversity in hiv-infected infants may reflect differences in viral dynamics, immune responses, or other factors that may also influence hivdisease progression.
det||study-3/NN||this-1/DT	nn||study-3/NN||retrospective-2/NN	nsubjpass||undertaken-5/VBN||study-3/NN	auxpass||undertaken-5/VBN||was-4/VBD	root||ROOT-0/null||undertaken-5/VBN	aux||determine-7/VB||to-6/TO	ccomp||undertaken-5/VBN||determine-7/VB	det||usefulness-9/NN||the-8/DT	dobj||determine-7/VB||usefulness-9/NN	amod||blocks-17/NNS||intravenous-11/JJ	amod||blocks-17/NNS||regional-12/JJ	nn||blocks-17/NNS||anesthetic-13/NN	appos||blocks-17/NNS||ivra-15/NNP	prep_of||usefulness-9/NN||blocks-17/NNS	vmod||blocks-17/NNS||containing-18/VBG	acomp||containing-18/VBG||ketorolac-19/JJ	acomp||containing-18/VBG||lidocaine-21/JJ	conj_and||ketorolac-19/JJ||lidocaine-21/JJ	det||management-24/NN||the-23/DT	prep_in||containing-18/VBG||management-24/NN	amod||pain-27/NN||sympathetically-mediated-26/JJ	prep_of||management-24/NN||pain-27/NN	aux||determine-31/VB||to-30/TO	ccomp||undertaken-5/VBN||determine-31/VB	conj_and||determine-7/VB||determine-31/VB	dobj||predicted-38/VBD||what-32/WP	nsubj||predicted-38/VBD||factors-33/NNS	dep||factors-33/NNS||if-35/IN	dep||if-35/IN||any-36/DT	ccomp||determine-31/VB||predicted-38/VBD	dobj||predicted-38/VBD||success-39/NN	det||technique-42/NN||this-41/DT	prep_with||predicted-38/VBD||technique-42/NN	pain-27||lidocaine-21||yes||this retrospective study was undertaken to determine the usefulness of intravenous regional anesthetic (ivra) blocks containing ketorolac and lidocaine in the management of sympathetically-mediated pain, and to determine what factors, if any, predicted success with this technique.
mark||identify-4/VB||in-1/IN	dep||identify-4/VB||order-2/NN	aux||identify-4/VB||to-3/TO	advcl||treated-15/VBD||identify-4/VB	dobj||identify-4/VB||genes-5/NNS	nsubjpass||regulated-9/VBN||genes-5/NNS	auxpass||regulated-9/VBN||are-7/VBP	advmod||regulated-9/VBN||epigenetically-8/RB	rcmod||genes-5/NNS||regulated-9/VBN	nn||tumors-12/NNS||neuroblastoma-11/NN	prep_in||regulated-9/VBN||tumors-12/NNS	nsubj||treated-15/VBD||we-14/PRP	root||ROOT-0/null||treated-15/VBD	num||lines-19/NNS||four-16/CD	nn||lines-19/NNS||neuroblastoma-17/NN	nn||lines-19/NNS||cell-18/NN	dobj||treated-15/VBD||lines-19/NNS	det||agent-23/NN||the-21/DT	amod||agent-23/NN||demethylating-22/JJ	prep_with||lines-19/NNS||agent-23/NN	amod||agent-23/NN||5-aza-2-24/JJ	dep||agent-23/NN||deoxycytidine-27/NN	dep||agent-23/NN||5-aza-dc-29/JJ	dep||lines-19/NNS||either-31/DT	dep||either-31/DT||separately-32/RB	dep||lines-19/NNS||in-34/IN	conj_or||either-31/DT||in-34/IN	pobj||in-34/IN||conjunction-35/NN	det||inhibitor-40/NN||the-37/DT	amod||inhibitor-40/NN||histone-38/JJ	nn||inhibitor-40/NN||deacetylase-39/NN	prep_with||conjunction-35/NN||inhibitor-40/NN	vmod||inhibitor-40/NN||trichostatin-41/VBN	det||tsa-44/NN||a-42/DT	dep||trichostatin-41/VBN||tsa-44/NN	neuroblastoma-17||aza--1||no_rel||in order to identify genes that are epigenetically regulated in neuroblastoma tumors, we treated four neuroblastoma cell lines with the demethylating agent 5-aza-2'-deoxycytidine (5-aza-dc) either separately or in conjunction with the histone deacetylase inhibitor trichostatin a (tsa).
amod||patients-2/NNS||asymptomatic-1/JJ	nsubjpass||enrolled-64/VBN||patients-2/NNS	appos||patients-2/NNS||n-4/NNP	number||485-6/CD||=-5/CD	num||n-4/NNP||485-6/CD	vmod||patients-2/NNS||aged-8/VBN	nn||-10/NNS||â-9/NN	dobj||aged-8/VBN||-10/NNS	number||50-12/CD||¥-11/CD	num||years-13/NNS||50-12/CD	npadvmod||aged-8/VBN||years-13/NNS	advmod||thickness-21/NN||either-15/RB	det||thickness-21/NN||a-16/DT	amod||carotid-18/JJ||maximal-17/JJ	amod||thickness-21/NN||carotid-18/JJ	nn||thickness-21/NN||artery-19/NN	nn||thickness-21/NN||intima-media-20/NN	prep_with||aged-8/VBN||thickness-21/NN	nn||-24/NNS||â-23/NN	prep_of||thickness-21/NN||-24/NNS	amod||thickness-21/NN||¥-25/JJ	num||mm-27/NNS||1.1-26/CD	dep||¥-25/JJ||mm-27/NNS	det||creatinine-38/NN||a-30/DT	advmod||albumin-32/JJ||urinary-31/RB	amod||creatinine-38/NN||albumin-32/JJ	nn||creatinine-38/NN||â-33/NNP	nn||creatinine-38/NN||-34/NNP	nn||creatinine-38/NN||¥-35/NNP	num||creatinine-38/NN||30-36/CD	nn||creatinine-38/NN||mg/g-37/NN	prep_with||aged-8/VBN||creatinine-38/NN	conj_or||thickness-21/NN||creatinine-38/NN	nsubj||had-41/VBD||who-40/WP	prep_with||aged-8/VBN||had-41/VBD	conj_or||thickness-21/NN||had-41/VBD	quantmod||two-44/CD||at-42/IN	mwe||at-42/IN||least-43/JJS	pobj||at-42/IN||least-43/JJS	dobj||had-41/VBD||two-44/CD	det||obesity-50/NN||the-46/DT	amod||obesity-50/NN||following-47/JJ	amod||obesity-50/NN||abdominal-49/JJ	prep_of||two-44/CD||obesity-50/NN	amod||cholesterol-54/NN||low-52/JJ	nn||cholesterol-54/NN||hdl-53/NN	prep_of||two-44/CD||cholesterol-54/NN	conj_and||obesity-50/NN||cholesterol-54/NN	amod||levels-58/NNS||high-56/JJ	nn||levels-58/NNS||triglyceride-57/NN	prep_of||two-44/CD||levels-58/NNS	conj_and||obesity-50/NN||levels-58/NNS	prep_of||two-44/CD||hypertension-61/NN	conj_and||obesity-50/NN||hypertension-61/NN	auxpass||enrolled-64/VBN||were-63/VBD	root||ROOT-0/null||enrolled-64/VBN	num||institutions-67/NNS||50-66/CD	prep_at||enrolled-64/VBN||institutions-67/NNS	cholesterol-54||obesity-50||no_rel||asymptomatic patients ( n = 485) aged â¥50 years with either a maximal carotid artery intima-media thickness of â¥1.1 mm, or a urinary albumin â¥30 mg/g creatinine or who had at least two of the following, abdominal obesity, low hdl cholesterol, high triglyceride levels, and hypertension, were enrolled at 50 institutions.
amod||î-4/NN||reovirus-1/JJ	amod||î-4/NN||outer-capsid-2/JJ	nn||î-4/NN||protein-3/NN	dobj||penetrate-11/VB||î-4/NN	nsubj||regulator-22/NN||î-4/NN	number||1-6/CD||1/4-5/CD	dep||î-4/NN||1-6/CD	nsubj||penetrate-11/VB||functions-9/NNS	aux||penetrate-11/VB||to-10/TO	rcmod||î-4/NN||penetrate-11/VB	vmod||î-4/NN||penetrate-11/VB	nn||membranes-14/NNS||host-12/NN	nn||membranes-14/NNS||cell-13/NN	dobj||penetrate-11/VB||membranes-14/NNS	amod||entry-17/NN||viral-16/JJ	prep_during||penetrate-11/VB||entry-17/NN	cop||regulator-22/NN||is-19/VBZ	det||regulator-22/NN||the-20/DT	amod||regulator-22/NN||primary-21/JJ	root||ROOT-0/null||regulator-22/NN	prep_of||regulator-22/NN||apoptosis-24/NNS	prep_following||apoptosis-24/NNS||reovirusinfection-26/NN	reovirusinfection-26||reovirus-1||no||reovirus outer-capsid protein î¼1, which functions to penetrate host cell membranes during viral entry, is the primary regulator of apoptosis following reovirusinfection.
det||success-2/NN||the-1/DT	nsubj||sent-11/VBN||success-2/NN	prep_of||success-2/NN||bortezomib-4/NN	det||treatment-7/NN||the-6/DT	prep_in||bortezomib-4/NN||treatment-7/NN	prep_of||treatment-7/NN||multiplemyeloma-9/NN	aux||sent-11/VBN||has-10/VBZ	root||ROOT-0/null||sent-11/VBN	xcomp||sent-11/VBN||encouraging-12/VBG	dobj||encouraging-12/VBG||signals-13/NNS	mark||used-19/VBN||that-14/IN	amod||inhibitors-16/NNS||proteasome-15/JJ	nsubjpass||used-19/VBN||inhibitors-16/NNS	nsubj||treat-21/VB||inhibitors-16/NNS	aux||used-19/VBN||could-17/MD	auxpass||used-19/VBN||be-18/VB	ccomp||encouraging-12/VBG||used-19/VBN	aux||treat-21/VB||to-20/TO	xcomp||used-19/VBN||treat-21/VB	amod||types-23/NNS||other-22/JJ	dobj||treat-21/VB||types-23/NNS	prep_of||types-23/NNS||cancers-25/NNS	cancers-25||bortezomib-4||no_rel||the success of bortezomib in the treatment of multiplemyeloma has sent encouraging signals that proteasome inhibitors could be used to treat other types of cancers.
amod||monitoring-3/NN||adequate-2/JJ	prep_with||reduces-10/VBZ||monitoring-3/NN	nn||adherence-6/NN||patient-5/NN	conj_and||monitoring-3/NN||adherence-6/NN	prep_with||reduces-10/VBZ||adherence-6/NN	amod||treatment-9/NN||cyclosporine-8/JJ	nsubj||reduces-10/VBZ||treatment-9/NN	nsubj||improves-17/VBZ||treatment-9/NN	nsubj||tolerated-23/JJ||treatment-9/NN	root||ROOT-0/null||reduces-10/VBZ	det||severity-12/NN||the-11/DT	dobj||reduces-10/VBZ||severity-12/NN	amod||psoriasis-15/NNS||severe-14/JJ	prep_of||severity-12/NN||psoriasis-15/NNS	conj_and||reduces-10/VBZ||improves-17/VBZ	dobj||improves-17/VBZ||qol-18/NN	cop||tolerated-23/JJ||is-21/VBZ	advmod||tolerated-23/JJ||appropriately-22/RB	conj_and||reduces-10/VBZ||tolerated-23/JJ	parataxis||reduces-10/VBZ||leading-25/VBG	amod||satisfaction-29/NN||high-27/JJ	nn||satisfaction-29/NN||patient-28/NN	prep_to||leading-25/VBG||satisfaction-29/NN	psoriasis-15||cyclosporine-8||no||with adequate monitoring and patient adherence, cyclosporine treatment reduces the severity of severe psoriasis, improves qol, and is appropriately tolerated; leading to high patient satisfaction.
nsubj||represents-10/VBZ||osteoporosis-1/NNS	det||reduction-4/NN||a-3/DT	appos||osteoporosis-1/NNS||reduction-4/NN	nn||density-8/NN||bone-6/NN	nn||density-8/NN||mineral-7/NN	prep_in||reduction-4/NN||density-8/NN	root||ROOT-0/null||represents-10/VBZ	det||metabolicbonedisease-14/NN||the-11/DT	advmod||common-13/JJ||most-12/RBS	amod||metabolicbonedisease-14/NN||common-13/JJ	dobj||represents-10/VBZ||metabolicbonedisease-14/NN	mineral-7||metabolicbonedisease-14||no_rel||osteoporosis, a reduction in bone mineral density, represents the most common metabolicbonedisease.
advmod||suggest-7/VBP||importantly-1/RB	det||analyses-6/NNS||the-3/DT	amod||analyses-6/NNS||warfarin-polymer-4/JJ	amod||analyses-6/NNS||rebinding-5/VBG	nsubj||suggest-7/VBP||analyses-6/NNS	root||ROOT-0/null||suggest-7/VBP	dobj||suggest-7/VBP||strategies-8/NNS	prepc_for||suggest-7/VBP||regulating-10/VBG	amod||binding-12/JJ||ligand-11/JJ	amod||capacity-13/NN||binding-12/JJ	dobj||regulating-10/VBG||capacity-13/NN	dobj||regulating-10/VBG||specificity-15/NN	conj_and||capacity-13/NN||specificity-15/NN	prep_through||regulating-10/VBG||variation-17/NN	det||degree-20/NN||the-19/DT	prep_of||variation-17/NN||degree-20/NN	prep_of||degree-20/NN||cross-linking-22/NN	advmod||afford-33/VB||where-24/WRB	nsubj||afford-33/VB||polymers-25/NNS	vmod||polymers-25/NNS||prepared-26/VBN	det||degree-30/NN||a-28/DT	amod||degree-30/NN||lower-29/JJR	prep_with||prepared-26/VBN||degree-30/NN	prep_of||degree-30/NN||cross-linking-32/NN	advcl||suggest-7/VBP||afford-33/VB	amod||capacity-35/NN||higher-34/JJR	dobj||afford-33/VB||capacity-35/NN	dep||non-specific-37/JJ||though-36/IN	acomp||afford-33/VB||non-specific-37/JJ	prep_in||non-specific-37/JJ||character-39/NN	cross--1||warfarin--1||no_rel||importantly, the warfarin-polymer rebinding analyses suggest strategies for regulating ligand binding capacity and specificity through variation of the degree of cross-linking, where polymers prepared with a lower degree of cross-linking afford higher capacity though non-specific in character.
nsubj||drug-6/NN||methotrexate-1/NN	cop||drug-6/NN||is-2/VBZ	det||drug-6/NN||a-3/DT	amod||drug-6/NN||disease-modifying-4/JJ	amod||drug-6/NN||antirheumatic-5/JJ	root||ROOT-0/null||drug-6/NN	advmod||used-8/VBN||commonly-7/RB	vmod||drug-6/NN||used-8/VBN	aux||treat-10/VB||to-9/TO	xcomp||used-8/VBN||treat-10/VB	amod||conditions-12/NNS||inflammatory-11/JJ	dobj||treat-10/VB||conditions-12/NNS	prep_such_as||conditions-12/NNS||rheumatoidarthritis-15/NNS	dobj||linked-19/VBN||rheumatoidarthritis-15/NNS	nsubjpass||linked-19/VBN||itself-17/PRP	auxpass||linked-19/VBN||is-18/VBZ	rcmod||rheumatoidarthritis-15/NNS||linked-19/VBN	amod||risk-23/NN||increased-21/VBN	amod||risk-23/NN||cardiovascular-22/JJ	prep_to||linked-19/VBN||risk-23/NN	rheumatoidarthritis-15||methotrexate-1||yes||methotrexate is a disease-modifying antirheumatic drug commonly used to treat inflammatory conditions such as rheumatoidarthritis which itself is linked to increased cardiovascular risk.
csubj||occurred-5/VBD||persisting-1/VBG	conj_or||persisting-1/VBG||relapsing-3/VBG	csubj||occurred-5/VBD||relapsing-3/VBG	dobj||persisting-1/VBG||bacteraemia-4/NN	root||ROOT-0/null||occurred-5/VBD	num||%-8/NN||27-7/CD	prep_in||occurred-5/VBD||%-8/NN	prep_of||%-8/NN||daptomycin-10/NN	num||%-13/NN||21-12/CD	prep_in||occurred-5/VBD||%-13/NN	conj_and||%-8/NN||%-13/NN	nn||patients-16/NNS||vancomycin/gentamicin-15/NN	prep_of||%-13/NN||patients-16/NNS	det||patients-20/NNS||these-19/DT	prep_among||occurred-29/VBD||patients-20/NNS	nsubj||occurred-29/VBD||mics-22/NNS	nn||¥-26/NNP||â-24/NNP	nn||¥-26/NNP||-25/NNP	prep_of||mics-22/NNS||¥-26/NNP	number||mg/l-28/JJ||2-27/CD	amod||¥-26/NNP||mg/l-28/JJ	parataxis||occurred-5/VBD||occurred-29/VBD	num||daptomycin-32/NN||five-31/CD	prep_in||occurred-29/VBD||daptomycin-32/NN	num||patients-36/NNS||four-34/CD	nn||patients-36/NNS||vancomycin/gentamicin-35/NN	prep_in||occurred-29/VBD||patients-36/NNS	conj_and||daptomycin-32/NN||patients-36/NNS	bacteraemia-4||daptomycin-32||no_rel||persisting or relapsing bacteraemia occurred in 27% of daptomycin and 21% of vancomycin/gentamicin patients; among these patients, mics of â¥2 mg/l occurred in five daptomycin and four vancomycin/gentamicin patients.
det||search-2/NN||the-1/DT	nsubj||focused-10/VBN||search-2/NN	amod||hepatitisc-5/JJ||effective-4/JJ	amod||therapies-7/NNS||hepatitisc-5/JJ	amod||therapies-7/NNS||antiviral-6/JJ	prep_for||search-2/NN||therapies-7/NNS	aux||focused-10/VBN||has-8/VBZ	advmod||focused-10/VBN||recently-9/RB	root||ROOT-0/null||focused-10/VBN	nn||metabolism-14/NN||host-12/NN	amod||metabolism-14/NN||sterol-13/JJ	prep_on||focused-10/VBN||metabolism-14/NN	nn||pathways-18/NNS||protein-16/NN	nn||pathways-18/NNS||prenylation-17/NN	prep_on||focused-10/VBN||pathways-18/NNS	conj_and||metabolism-14/NN||pathways-18/NNS	nsubj||affect-21/VBP||pathways-18/NNS	advmod||affect-21/VBP||indirectly-20/RB	rcmod||pathways-18/NNS||affect-21/VBP	amod||replication-23/NN||viral-22/JJ	dobj||affect-21/VBP||replication-23/NN	antiviral-6||hepatitisc-5||no_rel||the search for effective hepatitisc antiviral therapies has recently focused on host sterol metabolism and protein prenylation pathways that indirectly affect viral replication.
amod||nanotube-4/NN||single-1/JJ	nn||nanotube-4/NN||wall-2/NN	nn||nanotube-4/NN||carbon-3/NN	nn||constructs-8/NNS||nanotube-4/NN	appos||constructs-8/NNS||swcnt-6/NN	nsubjpass||appended-11/VBN||constructs-8/NNS	auxpass||appended-11/VBN||were-9/VBD	advmod||appended-11/VBN||covalently-10/RB	root||ROOT-0/null||appended-11/VBN	amod||chelates-14/NNS||radiometal-ion-13/JJ	prep_with||appended-11/VBN||chelates-14/NNS	amod||,4,7,10-17/CD||1,4,7,10-tetraazacyclododecane-1-16/JJ	dep||chelates-14/NNS||,4,7,10-17/CD	amod||-RSB--23/NNP||tetraacetic-19/JJ	amod||-RSB--23/NNP||acid-20/JJ	nn||-RSB--23/NNP||-LSB--21/NNP	nn||-RSB--23/NNP||dota-22/NNP	dep||,4,7,10-17/CD||-RSB--23/NNP	amod||-RSB--28/NNS||desferrioxamineb-25/JJ	amod||-RSB--28/NNS||-LSB--26/JJ	nn||-RSB--28/NNS||dfo-27/NN	dep||,4,7,10-17/CD||-RSB--28/NNS	conj_or||-RSB--23/NNP||-RSB--28/NNS	det||tumor-32/NN||the-31/DT	prep_with||appended-11/VBN||tumor-32/NN	conj_and||chelates-14/NNS||tumor-32/NN	amod||e4g10-35/NNS||neovascular-targeting-33/JJ	nn||e4g10-35/NNS||antibody-34/NN	dep||tumor-32/NN||e4g10-35/NNS	carbon-3||tumor-32||no_rel||single wall carbon nanotube (swcnt) constructs were covalently appended with radiometal-ion chelates (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [dota] or desferrioxamineb [dfo]) and the tumor neovascular-targeting antibody e4g10.
amod||speed-3/NN||faster-1/JJR	amod||speed-3/NN||walking-2/VBG	nsubjpass||associated-6/VBN||speed-3/NN	auxpass||associated-6/VBN||was-4/VBD	advmod||associated-6/VBN||also-5/RB	root||ROOT-0/null||associated-6/VBN	amod||adiposity-9/NN||lower-8/JJR	prep_with||associated-6/VBN||adiposity-9/NN	amod||protein-12/NN||c-reactive-11/JJ	prep_with||associated-6/VBN||protein-12/NN	conj_and||adiposity-9/NN||protein-12/NN	nn||cholesterol-16/NN||low-density-14/NN	nn||cholesterol-16/NN||lipoprotein-15/NN	prep_with||associated-6/VBN||cholesterol-16/NN	conj_and||adiposity-9/NN||cholesterol-16/NN	adiposity-9||speed-3||yes||faster walking speed was also associated with lower adiposity, c-reactive protein and low-density lipoprotein cholesterol.
nsubj||agent-5/NN||burkholderiapseudomallei-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||causative-4/JJ	root||ROOT-0/null||agent-5/NN	prep_of||agent-5/NN||melioidosis-7/NNS	det||disease-13/NN||an-9/DT	amod||disease-13/NN||emerging-10/VBG	amod||disease-13/NN||bacterial-11/JJ	amod||disease-13/NN||infectious-12/JJ	appos||melioidosis-7/NNS||disease-13/NN	amod||areas-18/NNS||tropical-15/JJ	conj_and||tropical-15/JJ||subtropical-17/JJ	amod||areas-18/NNS||subtropical-17/JJ	prep_in||disease-13/NN||areas-18/NNS	melioidosis-7||burkholderiapseudomallei-1||no||burkholderiapseudomallei is the causative agent of melioidosis, an emerging bacterial infectious disease in tropical and subtropical areas.
nsubj||belong-9/VBP||mutations-1/NNS	nsubj||lead-24/VB||mutations-1/NNS	amod||c-8/NN||mybpc3-3/JJ	nn||c-8/NN||encoding-4/NN	nn||c-8/NN||myosin-5/NN	amod||c-8/NN||binding-6/VBG	nn||c-8/NN||protein-7/NN	prep_in||mutations-1/NNS||c-8/NN	root||ROOT-0/null||belong-9/VBP	det||causes-14/NNS||the-11/DT	advmod||causes-14/NNS||most-12/RBS	amod||causes-14/NNS||frequent-13/JJ	prep_to||belong-9/VBP||causes-14/NNS	amod||cardiomyopathy-17/NN||hypertrophic-16/JJ	prep_of||causes-14/NNS||cardiomyopathy-17/NN	appos||cardiomyopathy-17/NN||hcm-19/NN	aux||lead-24/VB||may-22/MD	advmod||lead-24/VB||also-23/RB	conj_and||belong-9/VBP||lead-24/VB	prep_to||lead-24/VB||dilatedcardiomyopathy-26/NN	appos||dilatedcardiomyopathy-26/NN||dcm-28/NN	dcm-28||dilatedcardiomyopathy-26||no_rel||mutations in mybpc3 encoding myosin binding protein c belong to the most frequent causes of hypertrophic cardiomyopathy (hcm) and may also lead to dilatedcardiomyopathy (dcm).
nsubj||rare-32/JJ||diseases-1/NNS	vmod||diseases-1/NNS||associated-2/VBN	amod||infections-8/NNS||epstein-barrvirus-4/JJ	appos||infections-8/NNS||ebv-6/NN	prep_with||associated-2/VBN||infections-8/NNS	prep_such_as||associated-2/VBN||infectiousmononucleosis-12/NNS	appos||infectiousmononucleosis-12/NNS||im-14/NN	amod||lymphohistiocytosis-19/NNS||ebv-associated-17/JJ	amod||lymphohistiocytosis-19/NNS||hemophagocytic-18/JJ	prep_such_as||associated-2/VBN||lymphohistiocytosis-19/NNS	conj_and||infectiousmononucleosis-12/NNS||lymphohistiocytosis-19/NNS	appos||lymphohistiocytosis-19/NNS||ebv-hlh-21/NN	amod||ebvinfection-26/NN||chronic-24/JJ	amod||ebvinfection-26/NN||active-25/JJ	prep_such_as||associated-2/VBN||ebvinfection-26/NN	conj_and||infectiousmononucleosis-12/NNS||ebvinfection-26/NN	appos||ebvinfection-26/NN||caebv-28/NNP	cop||rare-32/JJ||are-30/VBP	neg||rare-32/JJ||not-31/RB	root||ROOT-0/null||rare-32/JJ	amod||children-35/NNS||chinese-34/JJ	prep_in||rare-32/JJ||children-35/NNS	ebvinfection-26||ebv-6||no||diseases associated with epstein-barrvirus (ebv) infections, such as infectiousmononucleosis (im), ebv-associated hemophagocytic lymphohistiocytosis (ebv-hlh) and chronic active ebvinfection (caebv) are not rare in chinese children.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||administration-4/NN||the-3/DT	dobj||evaluate-2/VB||administration-4/NN	prep_of||administration-4/NN||antipyretics-6/NNS	prep_to||evaluate-2/VB||children-8/NNS	prep_with||children-8/NNS||upperrespiratorytractinfections-10/NNS	appos||upperrespiratorytractinfections-10/NNS||urti-12/NNP	poss||parents-16/NNS||their-15/PRP$	prep_by||evaluate-2/VB||parents-16/NNS	prep_by||evaluate-2/VB||guardians-18/NNS	conj_or||parents-16/NNS||guardians-18/NNS	prep_without||evaluate-2/VB||consultation-20/NN	prep_with||consultation-20/NN||physicians-22/NNS	conj_and||evaluate-2/VB||compare-25/VB	amod||characteristics-29/NNS||epidemiological-26/JJ	conj_and||epidemiological-26/JJ||clinical-28/JJ	amod||characteristics-29/NNS||clinical-28/JJ	dobj||compare-25/VB||characteristics-29/NNS	prep_of||characteristics-29/NNS||patients-31/NNS	nsubj||received-33/VBD||patients-31/NNS	rcmod||patients-31/NNS||received-33/VBD	dobj||received-33/VBD||antipyretics-34/NNS	dep||evaluate-2/VB||of-36/IN	pcomp||of-36/IN||untreated-37/VBG	dobj||untreated-37/VBG||patients-38/NNS	antipyretics-34||urti-12||no_rel||to evaluate the administration of antipyretics to children with upperrespiratorytractinfections (urti) by their parents or guardians without consultation with physicians, and compare epidemiological and clinical characteristics of patients who received antipyretics and of untreated patients.
nn||hepatitisbvirus-2/NNS||posttransfusion-1/NN	nn||infection-6/NNS||hepatitisbvirus-2/NNS	appos||infection-6/NNS||hbv-4/NN	nsubj||occurs-8/VBZ||infection-6/NNS	advmod||occurs-8/VBZ||still-7/RB	root||ROOT-0/null||occurs-8/VBZ	mark||reduced-15/VBN||although-9/IN	poss||incidence-11/NN||its-10/PRP$	nsubjpass||reduced-15/VBN||incidence-11/NN	aux||reduced-15/VBN||has-12/VBZ	auxpass||reduced-15/VBN||been-13/VBN	advmod||reduced-15/VBN||substantially-14/RB	advcl||occurs-8/VBZ||reduced-15/VBN	det||introduction-18/NN||the-17/DT	prep_since||reduced-15/VBN||introduction-18/NN	prep_of||introduction-18/NN||screening-20/NN	amod||antigen-24/NN||hepatitisb-22/JJ	nn||antigen-24/NN||surface-23/NN	prep_of||screening-20/NN||antigen-24/NN	appos||antigen-24/NN||hbsag-26/NN	nn||donors-30/NNS||blood-29/NN	prep_in||antigen-24/NN||donors-30/NNS	hbv-4||hepatitisbvirus-2||no||posttransfusion hepatitisbvirus (hbv) infection still occurs although its incidence has been substantially reduced since the introduction of screening of hepatitisb surface antigen (hbsag) in blood donors.
nsubjpass||enrolled-3/VBN||participants-1/NNS	auxpass||enrolled-3/VBN||were-2/VBD	root||ROOT-0/null||enrolled-3/VBN	det||study-7/NN||a-5/DT	amod||study-7/NN||cross-sectional-6/JJ	prep_in||enrolled-3/VBN||study-7/NN	amod||assessment-10/NN||lipoatrophy-9/JJ	prep_with||enrolled-3/VBN||assessment-10/NN	amod||test-15/NN||oral-12/JJ	nn||test-15/NN||glucose-13/NN	nn||test-15/NN||tolerance-14/NN	prep_with||enrolled-3/VBN||test-15/NN	conj_and||assessment-10/NN||test-15/NN	amod||triglycerides-18/NNPS||fasting-17/JJ	prep_with||enrolled-3/VBN||triglycerides-18/NNPS	conj_and||assessment-10/NN||triglycerides-18/NNPS	nn||lactate-22/NN||finger-20/NN	nn||lactate-22/NN||prick-21/NN	prep_with||enrolled-3/VBN||lactate-22/NN	conj_and||assessment-10/NN||lactate-22/NN	amod||concentrations-26/NNS||stavudine-25/JJ	prep_with||enrolled-3/VBN||concentrations-26/NNS	conj_and||assessment-10/NN||concentrations-26/NNS	cross--1||glucose-13||no_rel||participants were enrolled in a cross-sectional study with lipoatrophy assessment, oral glucose tolerance test, fasting triglycerides, finger prick lactate, and stavudine concentrations.
nsubj||conducted-2/VBD||we-1/PRP	root||ROOT-0/null||conducted-2/VBD	det||analysis-6/NN||a-3/DT	amod||analysis-6/NN||molecular-4/JJ	amod||analysis-6/NN||epidemiologic-5/JJ	nsubj||isolates-13/VBZ||analysis-6/NN	num||mycobacteriumtuberculosis-9/NNS||356-8/CD	prep_of||analysis-6/NN||mycobacteriumtuberculosis-9/NNS	appos||mycobacteriumtuberculosis-9/NNS||mtb-11/NN	ccomp||conducted-2/VBD||isolates-13/VBZ	prep_from||isolates-13/VBZ||patients-15/NNS	vmod||patients-15/NNS||presenting-16/VBG	dobj||presenting-16/VBG||pulmonarytuberculosis-17/NNS	amod||taipei-20/NNS||metropolitan-19/JJ	prep_in||pulmonarytuberculosis-17/NNS||taipei-20/NNS	pulmonarytuberculosis-17||mycobacteriumtuberculosis-9||no||we conducted a molecular epidemiologic analysis of 356 mycobacteriumtuberculosis (mtb) isolates from patients presenting pulmonarytuberculosis in metropolitan taipei.
det||design-6/NN||a-2/DT	amod||design-6/NN||double-blinded-3/JJ	amod||design-6/NN||randomized-4/JJ	nn||design-6/NN||crossover-5/NN	prep_in||examined-12/VBN||design-6/NN	amod||function-10/NN||postprandial-8/JJ	amod||function-10/NN||endothelial-9/JJ	nsubjpass||examined-12/VBN||function-10/NN	auxpass||examined-12/VBN||was-11/VBD	root||ROOT-0/null||examined-12/VBN	num||individuals-15/NNS||28-14/CD	prep_in||examined-12/VBN||individuals-15/NNS	amod||type2diabetes-20/NNS||impairedglucosetolerance-17/JJ	conj_or||impairedglucosetolerance-17/JJ||recent-onset-19/JJ	amod||type2diabetes-20/NNS||recent-onset-19/JJ	prep_with||individuals-15/NNS||type2diabetes-20/NNS	det||injection-24/NN||a-22/DT	amod||injection-24/NN||single-23/JJ	prep_after||examined-12/VBN||injection-24/NN	prep_of||injection-24/NN||exenatide-26/NN	prep_of||injection-24/NN||placebo-28/NN	conj_or||exenatide-26/NN||placebo-28/NN	vmod||injection-24/NN||given-29/VBN	advmod||given-29/VBN||just-30/RB	det||meal-34/NN||a-32/DT	amod||meal-34/NN||high-fat-33/JJ	prep_before||given-29/VBN||meal-34/NN	exenatide-26||type2diabetes-20||no_rel||in a double-blinded randomized crossover design, postprandial endothelial function was examined in 28 individuals with impairedglucosetolerance or recent-onset type2diabetes after a single injection of exenatide or placebo given just before a high-fat meal.
amod||patients-3/NNS||chinese-2/JJ	prep_in||predicts-8/VBZ||patients-3/NNS	prep_with||patients-3/NNS||type2diabetes-5/CD	nsubj||predicts-8/VBZ||hyperglycemia-7/NN	root||ROOT-0/null||predicts-8/VBZ	dobj||predicts-8/VBZ||cancer-9/NN	mark||associated-15/VBN||whereas-11/IN	nn||usage-13/NN||insulin-12/NN	nsubjpass||associated-15/VBN||usage-13/NN	auxpass||associated-15/VBN||was-14/VBD	advcl||predicts-8/VBZ||associated-15/VBN	det||risk-20/NN||a-17/DT	amod||risk-20/NN||reduced-18/VBN	nn||risk-20/NN||cancer-19/NN	prep_with||associated-15/VBN||risk-20/NN	type2diabetes-5||insulin-12||yes||in chinese patients with type2diabetes, hyperglycemia predicts cancer, whereas insulin usage was associated with a reduced cancer risk.
amod||regimens-2/NNS||efavirenz-based-1/JJ	nsubjpass||associated-11/VBN||regimens-2/NNS	neg||aids-6/NNS||no-4/DT	amod||aids-6/NNS||clinical-5/JJ	conj_and||regimens-2/NNS||aids-6/NNS	nsubjpass||associated-11/VBN||aids-6/NNS	amod||initiation-9/NN||haart-8/JJ	prep_at||aids-6/NNS||initiation-9/NN	auxpass||associated-11/VBN||were-10/VBD	root||ROOT-0/null||associated-11/VBN	amod||risk-14/NN||lower-13/JJR	prep_with||associated-11/VBN||risk-14/NN	prep_of||risk-14/NN||change-16/NN	nn||ratio-19/NN||hazard-18/NN	dep||risk-14/NN||ratio-19/NN	discourse||ratio-19/NN||hr-21/UH	rcmod||ratio-19/NN||â-23/VBP	num||â-27/NN||$-24/$	number||=-26/CD||-25/CD	num||$-24/$||=-26/CD	dobj||â-23/VBP||â-27/NN	amod||â-27/NN||$-28/$	number||.7-30/CD||1-29/CD	num||$-28/$||.7-30/CD	num||%-33/NN||95-32/CD	dep||$-28/$||%-33/NN	nn||â-36/FW||ci-34/FW	nn||â-36/FW||1.1-35/FW	dep||%-33/NN||â-36/FW	dep||â-36/FW||$-37/$	num||$-37/$||2.6-39/CD	dobj||â-23/VBP||2.1-42/CD	conj_and||â-27/NN||2.1-42/CD	num||%-45/NN||95-44/CD	dep||2.1-42/CD||%-45/NN	vmod||%-45/NN||ci-46/VBN	num||â-48/NNS||1.7-47/CD	dobj||ci-46/VBN||â-48/NNS	num||â-48/NNS||$-49/$	num||$-49/$||2.5-51/CD	vmod||2.1-42/CD||comparing-53/VBG	amod||regimens-55/NNS||neverapine-based-54/JJ	dobj||comparing-53/VBG||regimens-55/NNS	amod||regimens-58/NNS||other-57/JJ	dobj||comparing-53/VBG||regimens-58/NNS	conj_and||regimens-55/NNS||regimens-58/NNS	prep_to||comparing-53/VBG||efavirenz-60/NN	advmod||comparing-53/VBG||respectively-62/RB	nn||â-68/FW||hrâ-64/FW	nn||â-68/FW||$-65/FW	nn||â-68/FW||-66/FW	nn||â-68/FW||=-67/FW	dobj||â-23/VBP||â-68/FW	conj_and||â-27/NN||â-68/FW	dep||â-68/FW||$-69/$	number||.3-71/CD||1-70/CD	num||$-69/$||.3-71/CD	num||%-74/NN||95-73/CD	dep||â-27/NN||%-74/NN	vmod||%-74/NN||ci-75/VBN	num||â-77/NNS||1.1-76/CD	dobj||ci-75/VBN||â-77/NNS	num||â-77/NNS||$-78/$	num||$-78/$||1.5-80/CD	amod||aids-84/NNS||clinical-83/JJ	prep_for||ratio-19/NN||aids-84/NNS	amod||initiation-87/NN||haart-86/JJ	prep_at||aids-84/NNS||initiation-87/NN	aids-84||efavirenz-60||yes||efavirenz-based regimens and no clinical aids at haart initiation were associated with lower risk of change (hazard ratio (hr)â=â1.7 (95% ci 1.1â2.6) and 2.1 (95% ci 1.7â2.5) comparing neverapine-based regimens and other regimens to efavirenz, respectively; hrâ=â1.3 (95% ci 1.1â1.5) for clinical aids at haart initiation).
det||microenvironment-3/NN||the-1/DT	nn||microenvironment-3/NN||tumor-2/NN	nsubj||caused-4/VBD||microenvironment-3/NN	root||ROOT-0/null||caused-4/VBD	amod||up-regulation-8/NN||rapid-5/JJ	conj_and||rapid-5/JJ||dramatic-7/JJ	amod||up-regulation-8/NN||dramatic-7/JJ	dobj||caused-4/VBD||up-regulation-8/NN	amod||i-11/FW||arginase-10/JJ	prep_of||up-regulation-8/NN||i-11/FW	amod||synthase-15/NN||inducible-13/JJ	nn||synthase-15/NN||nitricoxide-14/NN	dobj||caused-4/VBD||synthase-15/NN	conj_and||up-regulation-8/NN||synthase-15/NN	prep_in||synthase-15/NN||mdsc-17/NN	nsubjpass||accompanied-21/VBN||mdsc-17/NN	auxpass||accompanied-21/VBN||was-20/VBD	rcmod||mdsc-17/NN||accompanied-21/VBN	agent||accompanied-21/VBN||down-regulation-23/NN	amod||dinucleotide-27/NN||nicotinamide-25/JJ	nn||dinucleotide-27/NN||adenine-26/NN	prep_of||down-regulation-23/NN||dinucleotide-27/NN	vmod||dinucleotide-27/NN||phosphateâ-28/VBG	dobj||phosphateâ-28/VBG||$-29/$	nn||and-32/NNP||oxidase-31/NNP	npadvmod||oxygen-34/RB||and-32/NNP	advmod||and-32/NNP||reactive-33/RB	dep||species-35/CD||oxygen-34/RB	num||$-29/$||species-35/CD	det||cells-38/NNS||these-37/DT	prep_in||$-29/$||cells-38/NNS	nicotinamide-25||tumor-2||no_rel||the tumor microenvironment caused rapid and dramatic up-regulation of arginase i and inducible nitricoxide synthase in mdsc, which was accompanied by down-regulation of nicotinamide adenine dinucleotide phosphateâoxidase and reactive oxygen species in these cells.
det||requirement-2/NN||this-1/DT	nsubjpass||demonstrated-10/VBN||requirement-2/NN	nn||ii-5/NN||nm-4/NN	prep_for||requirement-2/NN||ii-5/NN	prep_in||ii-5/NN||karyokinesis-7/NNS	auxpass||demonstrated-10/VBN||is-8/VBZ	advmod||demonstrated-10/VBN||further-9/RBR	root||ROOT-0/null||demonstrated-10/VBN	det||line-15/NN||the-12/DT	amod||line-15/NN||hl-1-13/JJ	nn||line-15/NN||cell-14/NN	prep_in||demonstrated-10/VBN||line-15/NN	vmod||line-15/NN||derived-16/VBN	nn||myocytes-20/NNS||mouse-18/NN	nn||myocytes-20/NNS||atrial-19/NN	prep_from||derived-16/VBN||myocytes-20/NNS	agent||demonstrated-10/VBN||using-23/VBG	amod||knockdown-27/NN||small-24/JJ	amod||knockdown-27/NN||interfering-25/JJ	nn||knockdown-27/NN||rna-26/NN	dobj||using-23/VBG||knockdown-27/NN	nn||ii-30/NN||nm-29/NN	prep_of||knockdown-27/NN||ii-30/NN	prep_of||knockdown-27/NN||treatment-32/NN	conj_or||ii-30/NN||treatment-32/NN	det||blebbistatin-37/NN||the-34/DT	nn||blebbistatin-37/NN||myosin-35/NN	nn||blebbistatin-37/NN||inhibitor-36/NN	prep_with||using-23/VBG||blebbistatin-37/NN	hl--1||nm-29||yes||this requirement for nm ii in karyokinesis is further demonstrated in the hl-1 cell line derived from mouse atrial myocytes, by using small interfering rna knockdown of nm ii or treatment with the myosin inhibitor blebbistatin.
amod||women-2/NNS||pregnant-1/JJ	nsubjpass||asked-29/VBN||women-2/NNS	nsubj||participate-31/VB||women-2/NNS	vmod||women-2/NNS||aged-3/VBN	npadvmod||aged-3/VBN||18-4/CD	npadvmod||aged-3/VBN||over-6/IN	conj_and||18-4/CD||over-6/IN	preconj||diabetesmellitustype1-9/CD||either-8/CC	prep_with||aged-3/VBN||diabetesmellitustype1-9/CD	prep_with||aged-3/VBN||2-11/CD	conj_or||diabetesmellitustype1-9/CD||2-11/CD	nn||therapy-14/NN||insulin-13/NN	prep_on||diabetesmellitustype1-9/CD||therapy-14/NN	amod||diabetes-18/NN||gestational-17/JJ	prep_with||aged-3/VBN||diabetes-18/NN	conj_or||diabetesmellitustype1-9/CD||diabetes-18/NN	vmod||diabetes-18/NN||requiring-19/VBG	nn||therapy-21/NN||insulin-20/NN	dobj||requiring-19/VBG||therapy-21/NN	num||weeks-24/NNS||30-23/CD	prep_before||requiring-19/VBG||weeks-24/NNS	prep_of||weeks-24/NNS||gestation-26/NN	aux||asked-29/VBN||will-27/MD	auxpass||asked-29/VBN||be-28/VB	root||ROOT-0/null||asked-29/VBN	aux||participate-31/VB||to-30/TO	xcomp||asked-29/VBN||participate-31/VB	diabetesmellitustype1-9||insulin-20||yes||pregnant women aged 18 and over with either diabetesmellitustype1 or 2 on insulin therapy or with gestational diabetes requiring insulin therapy before 30 weeks of gestation will be asked to participate.
amod||concentrations-2/NNS||low-1/JJ	nsubjpass||enhanced-25/VBN||concentrations-2/NNS	dep||concentrations-2/NNS||1â-4/NNS	number||5-6/CD||1/4-5/CD	dep||1â-4/NNS||5-6/CD	dep||5-6/CD||mm-7/NN	prep_of||concentrations-2/NNS||formaldehyde-10/NN	vmod||formaldehyde-10/NN||induced-11/VBN	nn||responses-13/NNS||pain-12/NN	dobj||induced-11/VBN||responses-13/NNS	prep_in||induced-11/VBN||rat-15/NN	prep_via||rat-15/NN||trpv1-17/NNS	det||response-21/NN||this-19/DT	nn||response-21/NN||pain-20/NN	prep_via||rat-15/NN||response-21/NN	conj_and||trpv1-17/NNS||response-21/NN	aux||enhanced-25/VBN||could-22/MD	auxpass||enhanced-25/VBN||be-23/VB	advmod||enhanced-25/VBN||significantly-24/RB	root||ROOT-0/null||enhanced-25/VBN	agent||enhanced-25/VBN||ph-27/NN	num||ph-27/NN||6.0-28/CD	dep||ph-27/NN||mimicking-30/VBG	det||microenvironment-34/NN||the-31/DT	amod||microenvironment-34/NN||acidic-32/JJ	nn||microenvironment-34/NN||tumor-33/NN	dobj||mimicking-30/VBG||microenvironment-34/NN	pain-20||formaldehyde-10||no_rel||low concentrations (1â¼5 mm) of formaldehyde induced pain responses in rat via trpv1 and this pain response could be significantly enhanced by ph 6.0 (mimicking the acidic tumor microenvironment).
amod||aim-3/NN||objective-1/JJ	det||aim-3/NN||the-2/DT	nsubj||was-7/VBD||aim-3/NN	nsubj||assess-9/VB||aim-3/NN	det||analysis-6/NN||this-5/DT	prep_of||aim-3/NN||analysis-6/NN	root||ROOT-0/null||was-7/VBD	aux||assess-9/VB||to-8/TO	xcomp||was-7/VBD||assess-9/VB	det||effect-11/NN||the-10/DT	dobj||assess-9/VB||effect-11/NN	amod||pressurized-14/JJ||budesonide/formoterol-13/JJ	amod||inhaler-16/NN||pressurized-14/JJ	amod||inhaler-16/NN||metered-dose-15/JJ	prep_of||effect-11/NN||inhaler-16/NN	nn||pmdi-19/NNS||bud/fm-18/NN	appos||inhaler-16/NN||pmdi-19/NNS	dobj||assess-9/VB||bud-22/NN	conj_and||effect-11/NN||bud-22/NN	amod||criteria-25/NNS||predefined-24/JJ	prep_on||bud-22/NN||criteria-25/NNS	prep_for||criteria-25/NNS||asthma-27/NN	amod||asthma-27/NN||worsening-28/VBG	det||metric-33/NN||an-30/DT	nn||metric-33/NN||asthma-31/NN	nn||metric-33/NN||control-32/NN	appos||bud-22/NN||metric-33/NN	advmod||aligned-35/VBN||generally-34/RB	vmod||metric-33/NN||aligned-35/VBN	prep_with||aligned-35/VBN||definitions-37/NNS	amod||exacerbations-41/NNS||moderate-39/JJ	nn||exacerbations-41/NNS||asthma-40/NN	prep_of||definitions-37/NNS||exacerbations-41/NNS	num||populations-46/NNS||four-44/CD	amod||populations-46/NNS||different-45/JJ	prep_across||bud-22/NN||populations-46/NNS	asthma-40||formoterol--1||no||objective the aim of this analysis was to assess the effect of budesonide/formoterol pressurized metered-dose inhaler (bud/fm pmdi) and bud on predefined criteria for asthma worsening, an asthma control metric generally aligned with definitions of moderate asthma exacerbations, across four different populations.
poss||findings-2/NNS||our-1/PRP$	nsubj||support-3/VBP||findings-2/NNS	root||ROOT-0/null||support-3/VBP	det||benefit-5/NN||the-4/DT	dobj||support-3/VBP||benefit-5/NN	nsubj||ahei-9/VB||benefit-5/NN	prep_of||benefit-5/NN||adherence-7/NN	aux||ahei-9/VB||to-8/TO	xcomp||support-3/VBP||ahei-9/VB	amod||guidelines-11/NNS||dietary-10/JJ	dobj||ahei-9/VB||guidelines-11/NNS	prep_for||guidelines-11/NNS||individuals-13/NNS	prep_with||ahei-9/VB||mets-15/NNS	advmod||mets-15/NNS||especially-17/RB	dep||mets-15/NNS||those-18/DT	amod||obesity-21/NN||central-20/JJ	prep_with||ahei-9/VB||obesity-21/NN	amod||levels-25/NNS||high-23/JJ	nn||levels-25/NNS||triglyceride-24/NN	prep_with||ahei-9/VB||levels-25/NNS	conj_or||obesity-21/NN||levels-25/NNS	triglyceride-24||obesity-21||no_rel||our findings support the benefit of adherence to ahei dietary guidelines for individuals with mets, especially those with central obesity or high triglyceride levels.
advmod||greater-2/JJR||significantly-1/RB	amod||reductions-3/NNS||greater-2/JJR	nsubjpass||observed-9/VBN||reductions-3/NNS	nsubjpass||observed-9/VBN||reductions-3/NNS	amod||bp-7/NN||seated-5/JJ	amod||bp-7/NN||diastolic-6/JJ	prep_in||reductions-3/NNS||bp-7/NN	auxpass||observed-9/VBN||were-8/VBD	root||ROOT-0/null||observed-9/VBN	conj_and||observed-9/VBN||observed-9/VBN	prep_between||observed-9/VBN||baseline-11/NN	num||weeks-15/NNS||eight-14/CD	prep_after||observed-9/VBN||weeks-15/NNS	prep_of||weeks-15/NNS||treatment-17/NN	prep_with||observed-9/VBN||olmesartan/amlodipine-19/NN	prepc_compared_with||observed-9/VBN||with-22/IN	nn||doses-24/NNS||equivalent-23/NN	pobj||observed-9/VBN||doses-24/NNS	amod||monotherapy-29/NN||olmesartan-26/JJ	conj_or||olmesartan-26/JJ||amolodipine-28/JJ	amod||monotherapy-29/NN||amolodipine-28/JJ	prep_of||doses-24/NNS||monotherapy-29/NN	appos||monotherapy-29/NN||p-31/NNP	number||0.001-33/CD||<-32/CD	num||p-31/NNP||0.001-33/CD	det||combination-39/NN||the-37/DT	amod||combination-39/NN||factorial-38/JJ	prep_in||observed-9/VBN||combination-39/NN	nn||trial-50/NN||olmesartanmedoxomil-41/NN	conj_and||olmesartanmedoxomil-41/NN||amlodipinebesylate-43/JJ	nn||trial-50/NN||amlodipinebesylate-43/JJ	amod||highbloodpressure-46/NN||controlling-45/VBG	prep_in||amlodipinebesylate-43/JJ||highbloodpressure-46/NN	appos||highbloodpressure-46/NN||coach-48/NN	prep_of||combination-39/NN||trial-50/NN	highbloodpressure-46||amlodipine--1||yes||significantly greater reductions in seated diastolic bp were observed between baseline and after eight weeks of treatment with olmesartan/amlodipine, compared with equivalent doses of olmesartan or amolodipine monotherapy ( p < 0.001), in the factorial combination of olmesartanmedoxomil and amlodipinebesylate in controlling highbloodpressure (coach) trial.
det||study-3/NN||the-1/DT	amod||study-3/NN||present-2/JJ	nsubjpass||designed-5/VBN||study-3/NN	nsubj||assess-7/VB||study-3/NN	auxpass||designed-5/VBN||was-4/VBD	root||ROOT-0/null||designed-5/VBN	aux||assess-7/VB||to-6/TO	xcomp||designed-5/VBN||assess-7/VB	dobj||assess-7/VB||tolerance-8/NN	dobj||assess-7/VB||cross-tolerance-10/NN	conj_and||tolerance-8/NN||cross-tolerance-10/NN	det||effects-14/NNS||the-12/DT	amod||effects-14/NNS||neurocognitive-13/JJ	prep_to||assess-7/VB||effects-14/NNS	prep_of||effects-14/NNS||thc-16/NN	prep_of||effects-14/NNS||alcohol-18/NN	conj_and||thc-16/NN||alcohol-18/NN	amod||users-22/NNS||heavy-20/JJ	nn||users-22/NNS||cannabis-21/NN	prep_in||assess-7/VB||users-22/NNS	cross--1||thc-16||no_rel||the present study was designed to assess tolerance and cross-tolerance to the neurocognitive effects of thc and alcohol in heavy cannabis users.
nsubj||hold-49/VBP||comparison-1/NN	det||sequence-8/NN||the-3/DT	amod||sequence-8/NN||fcov-4/JJ	amod||sequence-8/NN||c1je-5/JJ	amod||sequence-8/NN||genomic-6/JJ	nn||sequence-8/NN||rna-7/NN	prep_of||comparison-1/NN||sequence-8/NN	mark||have-26/VBP||sequence-8/NN	prep_with||sequence-8/NN||that-10/DT	det||virus-17/NN||the-12/DT	nn||virus-17/NN||laboratory-13/NN	nn||virus-17/NN||strain-14/NN	amod||virus-17/NN||fcov-15/JJ	nn||virus-17/NN||fip-16/NN	prep_of||that-10/DT||virus-17/NN	appos||virus-17/NN||fipv-19/NNP	nsubj||showed-22/VBD||79-1146-21/CD	rcmod||sequence-8/NN||showed-22/VBD	det||viruses-25/NNS||both-24/DT	nsubj||have-26/VBP||viruses-25/NNS	ccomp||showed-22/VBD||have-26/VBP	det||organisation-30/NN||a-27/DT	amod||organisation-30/NN||similar-28/JJ	nn||organisation-30/NN||genome-29/NN	dobj||have-26/VBP||organisation-30/NN	prep_of||comparison-1/NN||predictions-32/NNS	conj_and||sequence-8/NN||predictions-32/NNS	mark||have-26/VBP||predictions-32/NNS	vmod||predictions-32/NNS||made-33/VBN	det||frames-38/NNS||the-35/DT	amod||frames-38/NNS||open-36/JJ	nn||frames-38/NNS||reading-37/NN	prep_for||made-33/VBN||frames-38/NNS	prep_for||made-33/VBN||cis-40/NN	conj_and||frames-38/NNS||cis-40/NN	amod||elements-43/NNS||acting-42/VBG	prep_of||comparison-1/NN||elements-43/NNS	conj_and||sequence-8/NN||elements-43/NNS	mark||have-26/VBP||elements-43/NNS	det||genome-48/NN||the-45/DT	nn||genome-48/NN||fipv-46/NNP	num||genome-48/NN||79-1146-47/CD	prep_of||elements-43/NNS||genome-48/NN	root||ROOT-0/null||hold-49/VBP	acomp||hold-49/VBP||true-50/JJ	amod||c1je-53/NNS||fcov-52/JJ	prep_for||hold-49/VBP||c1je-53/NNS	fip-16||fipv-46||no||comparison of the fcov c1je genomic rna sequence with that of the laboratory strain fcov fip virus (fipv) 79-1146 showed that both viruses have a similar genome organisation and predictions made for the open reading frames and cis -acting elements of the fipv 79-1146 genome hold true for fcov c1je.
amod||initiation-3/NN||early-1/JJ	amod||initiation-3/NN||sexual-2/JJ	nsubjpass||associated-7/VBN||initiation-3/NN	auxpass||associated-7/VBN||was-4/VBD	advmod||associated-7/VBN||also-5/RB	advmod||associated-7/VBN||positively-6/RB	dep||ci-82/VBP||associated-7/VBN	auxpass||employed-11/VBN||being-9/VBG	neg||employed-11/VBN||not-10/RB	prepc_with||associated-7/VBN||employed-11/VBN	nn||hr-13/NNP||adj.-12/NNP	dobj||employed-11/VBN||hr-13/NNP	dobj||employed-11/VBN||-lrb--15/NNP	conj_and||hr-13/NNP||-lrb--15/NNP	number||%-17/NN||95-16/CD	amod||ci-18/NN||%-17/NN	nsubj||-lrb--46/NNS||ci-18/NN	vmod||ci-18/NN||-rrb--19/VBN	dep||1.455-23/CD||=-20/SYM	num||1.455-23/CD||7.372-21/CD	amod||1.455-23/CD||-lrb--22/JJ	ccomp||-rrb--19/VBN||1.455-23/CD	num||-rrb--26/NNS||37.357-25/CD	npadvmod||-rsb--27/JJ||-rrb--26/NNS	dep||-rrb--19/VBN||-rsb--27/JJ	neg||having-30/VBG||not-29/RB	xcomp||-rrb--19/VBN||having-30/VBG	amod||knowledge-32/NN||comprehensive-31/JJ	dobj||having-30/VBG||knowledge-32/NN	nn||hr-37/NNP||hiv/aids-34/NNS	nn||hr-37/NNP||-lsb--35/NNP	nn||hr-37/NNP||adj.-36/NNP	prep_on||having-30/VBG||hr-37/NNP	nn||-rrb--43/NN||-lrb--39/NNP	number||%-41/NN||95-40/CD	amod||-rrb--43/NN||%-41/NN	nn||-rrb--43/NN||ci-42/NN	prep_on||having-30/VBG||-rrb--43/NN	conj_and||hr-37/NNP||-rrb--43/NN	dep||-lrb--46/NNS||=-44/SYM	num||-lrb--46/NNS||8.247-45/CD	rcmod||hr-13/NNP||-lrb--46/NNS	dep||hr-13/NNP||2.121-47/CD	num||-rsb--51/NNS||32.067-49/CD	amod||-rsb--51/NNS||-rrb--50/JJ	appos||2.121-47/CD||-rsb--51/NNS	nn||use-54/NN||alcohol-53/NN	dep||hr-13/NNP||use-54/NN	nn||hr-57/NNP||-lsb--55/NNP	nn||hr-57/NNP||adj.-56/NNP	nsubj||ci-62/VBP||hr-57/NNP	conj_and||hr-57/NNP||-lrb--59/NNP	nsubj||ci-62/VBP||-lrb--59/NNP	number||%-61/NN||95-60/CD	amod||hr-57/NNP||%-61/NN	rcmod||use-54/NN||ci-62/VBP	nsubj||1.315-67/CD||-rrb--63/NNP	dep||1.315-67/CD||=-64/SYM	num||1.315-67/CD||3.815-65/CD	amod||1.315-67/CD||-lrb--66/JJ	ccomp||ci-62/VBP||1.315-67/CD	num||-rrb--70/NNS||11.070-69/CD	npadvmod||-rsb--71/JJ||-rrb--70/NNS	amod||hr-13/NNP||-rsb--71/JJ	prepc_with||associated-7/VBN||khat-73/VBN	conj_and||employed-11/VBN||khat-73/VBN	ccomp||khat-73/VBN||use-74/VB	nn||hr-77/NNP||-lsb--75/NNP	nn||hr-77/NNP||adj.-76/NNP	dobj||use-74/VB||hr-77/NNP	dobj||use-74/VB||-lrb--79/NNP	conj_and||hr-77/NNP||-lrb--79/NNP	number||%-81/NN||95-80/CD	amod||hr-77/NNP||%-81/NN	root||ROOT-0/null||ci-82/VBP	nsubj||-lrb--86/NNS||-rrb--83/NNP	dep||-lrb--86/NNS||=-84/SYM	num||-lrb--86/NNS||7.241-85/CD	ccomp||ci-82/VBP||-lrb--86/NNS	nsubj||ci-82/VBP||1.871-87/CD	number||-rrb--90/CD||28.016-89/CD	num||-rsb--91/NNS||-rrb--90/CD	appos||1.871-87/CD||-rsb--91/NNS	aids--1||hiv--1||no||early sexual initiation was also positively associated with being not employed adj. hr & -lrb- 95 % ci -rrb- = 7.372 -lrb- 1.455 , 37.357 -rrb- -rsb- , not having comprehensive knowledge on hiv/aids -lsb- adj. hr & -lrb- 95 % ci -rrb- = 8.247 -lrb- 2.121 , 32.067 -rrb- -rsb- , alcohol use -lsb- adj. hr & -lrb- 95 % ci -rrb- = 3.815 -lrb- 1.315 , 11.070 -rrb- -rsb- and khat use -lsb- adj. hr & -lrb- 95 % ci -rrb- = 7.241 -lrb- 1.871 , 28.016 -rrb- -rsb- .
det||stoichiometries-3/NNS||the-2/DT	nsubj||produce-8/VBP||stoichiometries-3/NNS	nsubj||consume-10/VBP||stoichiometries-3/NNS	prep_from||support-31/VBP||stoichiometries-3/NNS	amod||pathways-6/NNS||metabolic-5/JJ	prep_of||stoichiometries-3/NNS||pathways-6/NNS	rcmod||stoichiometries-3/NNS||produce-8/VBP	rcmod||stoichiometries-3/NNS||consume-10/VBP	conj_or||produce-8/VBP||consume-10/VBP	number||+-12/CD||h-11/CD	dobj||produce-8/VBP||+-12/CD	det||availability-17/NN||the-15/DT	amod||availability-17/NN||greater-16/JJR	dobj||produce-8/VBP||availability-17/NN	conj_and||+-12/CD||availability-17/NN	prep_of||availability-17/NN||glucose-19/NN	prepc_compared_to||produce-8/VBP||to-21/TO	pobj||produce-8/VBP||oxygen-22/NN	amod||parts-25/NNS||most-24/JJS	prep_in||oxygen-22/NN||parts-25/NNS	det||tumor-28/NN||a-27/DT	prep_of||parts-25/NNS||tumor-28/NN	nsubj||support-31/VBP||we-30/PRP	root||ROOT-0/null||support-31/VBP	det||view-34/NN||the-32/DT	amod||view-34/NN||classic-33/JJ	dobj||support-31/VBP||view-34/NN	mark||originates-45/VBZ||that-35/IN	nsubj||originates-45/VBZ||most-36/JJS	nsubj||add-59/VBP||most-36/JJS	det||efflux-41/NN||the-38/DT	amod||efflux-41/NN||net-39/JJ	nn||efflux-41/NN||proton-40/NN	prep_of||most-36/JJS||efflux-41/NN	amod||gliomas-44/NNS||c6-43/JJ	prep_from||efflux-41/NN||gliomas-44/NNS	ccomp||support-31/VBP||originates-45/VBZ	amod||formation-48/NN||glycolytic-47/JJ	prep_in||originates-45/VBZ||formation-48/NN	nn||+-53/NNS||lactate-50/NN	conj_and||lactate-50/NN||h-52/NN	nn||+-53/NNS||h-52/NN	prep_of||formation-48/NN||+-53/NNS	det||tumor-56/NN||the-55/DT	prep_inside||originates-45/VBZ||tumor-56/NN	ccomp||support-31/VBP||add-59/VBP	conj_but||originates-45/VBZ||add-59/VBP	mark||taken-64/VBN||that-60/IN	det||lactate-62/NN||some-61/DT	nsubjpass||taken-64/VBN||lactate-62/NN	auxpass||taken-64/VBN||is-63/VBZ	ccomp||add-59/VBP||taken-64/VBN	prt||taken-64/VBN||up-65/RP	prep_into||taken-64/VBN||cells-67/NNS	det||rim-70/NN||the-69/DT	prep_in||cells-67/NNS||rim-70/NN	prep_on||rim-70/NN||mct1-72/CD	det||lactate-76/NN||some-75/DT	nsubj||diffuses-77/VBZ||lactate-76/NN	ccomp||add-59/VBP||diffuses-77/VBZ	conj_and||taken-64/VBN||diffuses-77/VBZ	prt||diffuses-77/VBZ||away-78/RP	xcomp||diffuses-77/VBZ||leaving-80/VBG	poss||protons-83/NNS||its-81/PRP$	amod||protons-83/NNS||associated-82/JJ	dobj||leaving-80/VBG||protons-83/NNS	acomp||originates-45/VBZ||available-84/JJ	aux||re-enter-86/VB||to-85/TO	xcomp||available-84/JJ||re-enter-86/VB	dobj||re-enter-86/VB||cells-87/NNS	prep_for||cells-87/NNS||extrusion-89/NN	prep_on||re-enter-86/VB||nhe1-91/CD	oxygen-22||tumor-56||no_rel||from the stoichiometries of metabolic pathways that produce or consume h+, and the greater availability of glucose compared to oxygen in most parts of a tumor, we support the classic view that most of the net proton efflux from c6 gliomas originates in glycolytic formation of lactate and h+ inside the tumor, but add that some lactate is taken up into cells in the rim on mct1, and some lactate diffuses away, leaving its associated protons available to re-enter cells for extrusion on nhe1.
det||total-2/NN||a-1/DT	nsubjpass||checked-25/VBN||total-2/NN	num||women-6/NNS||105-4/CD	amod||women-6/NNS||consecutive-5/JJ	prep_of||total-2/NN||women-6/NNS	amod||ra-9/NN||early-8/JJ	prep_with||women-6/NNS||ra-9/NN	nn||â-13/NN||disease-11/NN	nn||â-13/NN||duration-12/NN	dep||women-6/NNS||â-13/NN	vmod||â-13/NN||-14/VBN	amod||years-17/NNS||$-15/$	number||$-15/$||3-16/CD	tmod||-14/VBN||years-17/NNS	num||women-23/NNS||105-20/CD	amod||women-23/NNS||age-matched-21/JJ	amod||women-23/NNS||healthy-22/JJ	prep_of||total-2/NN||women-23/NNS	conj_and||women-6/NNS||women-23/NNS	auxpass||checked-25/VBN||were-24/VBD	root||ROOT-0/null||checked-25/VBN	prep_for||checked-25/VBN||mets-27/NNS	prepc_according_to||checked-25/VBN||to-29/TO	num||definitions-32/NNS||six-30/CD	amod||definitions-32/NNS||mets-31/JJ	pobj||checked-25/VBN||definitions-32/NNS	amod||consensus-35/NN||joint-34/JJ	dep||definitions-32/NNS||consensus-35/NN	amod||federation-39/NN||international-37/JJ	nn||federation-39/NN||diabetes-38/NN	appos||consensus-35/NN||federation-39/NN	amod||program-44/NN||national-41/JJ	nn||program-44/NN||cholesterol-42/NN	nn||program-44/NN||education-43/NN	dep||consensus-35/NN||program-44/NN	dep||program-44/NN||2004-45/CD	dep||program-44/NN||2001-47/CD	conj_and||2004-45/CD||2001-47/CD	nn||group-50/NN||european-49/NN	dep||consensus-35/NN||group-50/NN	conj_and||program-44/NN||group-50/NN	prep_for||group-50/NN||study-52/NN	prep_of||study-52/NN||insulinresistance-54/NN	nn||organization-59/NN||world-57/NN	nn||organization-59/NN||health-58/NN	dep||consensus-35/NN||organization-59/NN	conj_and||program-44/NN||organization-59/NN	cholesterol-42||insulinresistance-54||no_rel||a total of 105 consecutive women with early ra (disease duration â¤3 years) and 105 age-matched healthy women were checked for mets according to six mets definitions (joint consensus, international diabetes federation, national cholesterol education program 2004 and 2001, european group for study of insulinresistance, and world health organization).
vmod||amyloid-8/VBD||circulating-1/VBG	dobj||circulating-1/VBG||levels-2/NNS	amod||protein-5/NN||c-reactive-4/JJ	prep_of||levels-2/NNS||protein-5/NN	nsubj||amyloid-8/VBD||serum-7/NN	root||ROOT-0/null||amyloid-8/VBD	det||±-14/NNS||a-9/DT	nn||necrosis-12/NNS||tumor-11/NN	nn||±-14/NNS||necrosis-12/NNS	amod||±-14/NNS||factor-î-13/JJ	nsubjpass||measured-39/VBN||±-14/NNS	amod||-1-20/NN||interleukin-16/JJ	appos||-1-20/NN||il-18/NN	conj_and||±-14/NNS||-1-20/NN	nsubjpass||measured-39/VBN||-1-20/NN	amod||monocyte-26/JJ||il-6-22/JJ	amod||monocyte-26/JJ||il-8-24/JJ	amod||protein-1-28/NN||monocyte-26/JJ	amod||protein-1-28/NN||chemotactic-27/JJ	conj_and||±-14/NNS||protein-1-28/NN	nsubjpass||measured-39/VBN||protein-1-28/NN	nn||protein-33/NN||heat-31/NN	nn||protein-33/NN||shock-32/NN	conj_and||±-14/NNS||protein-33/NN	nsubjpass||measured-39/VBN||protein-33/NN	appos||protein-33/NN||hsp-35/NN	dep||protein-33/NN||70-37/CD	auxpass||measured-39/VBN||were-38/VBD	ccomp||amyloid-8/VBD||measured-39/VBN	amod||assays-43/NNS||enzyme-linked-41/JJ	nn||assays-43/NNS||immunosorbent-42/NN	prep_with||measured-39/VBN||assays-43/NNS	enzyme--1||tumor-11||no_rel||circulating levels of c-reactive protein, serum amyloid a, tumor necrosis factor-î±, interleukin (il)-1, il-6, il-8, monocyte chemotactic protein-1, and heat shock protein (hsp)70 were measured with enzyme-linked immunosorbent assays.
nsubj||have-4/VB||acarbose-1/NN	aux||have-4/VB||may-2/MD	advmod||have-4/VB||thus-3/RB	root||ROOT-0/null||have-4/VB	advmod||beneficial-6/JJ||more-5/RBR	amod||effects-7/NNS||beneficial-6/JJ	dobj||have-4/VB||effects-7/NNS	amod||function-11/NN||postprandial-9/JJ	amod||function-11/NN||endothelial-10/JJ	prep_on||have-4/VB||function-11/NN	prep_in||function-11/NN||patients-13/NNS	prep_with||patients-13/NNS||type2diabetes-15/CD	prep_than||have-4/VB||nateglinide-17/NN	type2diabetes-15||nateglinide-17||yes||acarbose may thus have more beneficial effects on postprandial endothelial function in patients with type2diabetes than nateglinide.
mark||likely-14/JJ||since-1/IN	det||part-4/NN||a-2/DT	amod||part-4/NN||significant-3/JJ	nsubj||likely-14/JJ||part-4/NN	nsubj||relate-16/VB||part-4/NN	det||diversity-8/NN||the-6/DT	amod||diversity-8/NN||clinicopathological-7/JJ	prep_of||part-4/NN||diversity-8/NN	vmod||diversity-8/NN||seen-9/VBN	amod||priondisease-12/NN||human-11/JJ	prep_in||seen-9/VBN||priondisease-12/NN	cop||likely-14/JJ||is-13/VBZ	advcl||compared-28/VBN||likely-14/JJ	aux||relate-16/VB||to-15/TO	xcomp||likely-14/JJ||relate-16/VB	det||propagation-19/NN||the-18/DT	prep_to||relate-16/VB||propagation-19/NN	amod||strains-24/NNS||distinct-21/JJ	amod||strains-24/NNS||human-22/JJ	nn||strains-24/NNS||prion-23/NN	prep_of||propagation-19/NN||strains-24/NNS	nsubj||compared-28/VBN||we-26/PRP	aux||compared-28/VBN||have-27/VBP	root||ROOT-0/null||compared-28/VBN	det||properties-31/NNS||the-29/DT	nn||properties-31/NNS||transmission-30/NN	dobj||compared-28/VBN||properties-31/NNS	amod||prions-34/NNS||kuru-33/JJ	prep_of||properties-31/NNS||prions-34/NNS	prep_with||compared-28/VBN||those-36/DT	vmod||those-36/DT||isolated-37/VBN	prep_from||isolated-37/VBN||patients-39/NNS	amod||cjd-46/NN||sporadic-41/JJ	conj_and||sporadic-41/JJ||iatrogenic-43/JJ	amod||cjd-46/NN||iatrogenic-43/JJ	conj_and||sporadic-41/JJ||variant-45/JJ	amod||cjd-46/NN||variant-45/JJ	prep_with||patients-39/NNS||cjd-46/NN	preconj||transgenic-49/JJ||both-48/DT	amod||mice-52/NNS||transgenic-49/JJ	conj_and||transgenic-49/JJ||wild-type-51/JJ	amod||mice-52/NNS||wild-type-51/JJ	prep_in||cjd-46/NN||mice-52/NNS	cjd-46||prion-23||no_rel||since a significant part of the clinicopathological diversity seen in human priondisease is likely to relate to the propagation of distinct human prion strains, we have compared the transmission properties of kuru prions with those isolated from patients with sporadic, iatrogenic and variant cjd in both transgenic and wild-type mice.
poss||objective-2/NN||our-1/PRP$	nsubj||was-3/VBD||objective-2/NN	nsubj||estimate-5/VB||objective-2/NN	nsubj||determine-26/VB||objective-2/NN	root||ROOT-0/null||was-3/VBD	aux||estimate-5/VB||to-4/TO	xcomp||was-3/VBD||estimate-5/VB	det||proportion-7/NN||the-6/DT	dobj||estimate-5/VB||proportion-7/NN	prep_of||proportion-7/NN||idus-9/NNS	det||diagnosis-14/NN||a-11/DT	amod||diagnosis-14/NN||late-12/JJ	nn||diagnosis-14/NN||hiv-13/NN	prep_with||idus-9/NNS||diagnosis-14/NN	dep||idus-9/NNS||aids-16/VBZ	dobj||aids-16/VBZ||diagnosis-17/NN	num||months-20/NNS||12-19/CD	prep_within||aids-16/VBZ||months-20/NNS	nn||diagnosis-23/NN||hiv-22/NN	prep_of||months-20/NNS||diagnosis-23/NN	xcomp||was-3/VBD||determine-26/VB	conj_and||estimate-5/VB||determine-26/VB	det||factors-28/NNS||the-27/DT	dobj||determine-26/VB||factors-28/NNS	vmod||factors-28/NNS||associated-29/VBN	nn||progression-32/NN||disease-31/NN	prep_with||associated-29/VBN||progression-32/NN	nn||diagnosis-35/NN||hiv-34/NN	prep_after||associated-29/VBN||diagnosis-35/NN	aids-16||hiv-34||no||our objective was to estimate the proportion of idus with a late hiv diagnosis (aids diagnosis within 12 months of hiv diagnosis) and determine the factors associated with disease progression after hiv diagnosis.
amod||evidence-2/NN||further-1/JJ	nsubjpass||observed-7/VBN||evidence-2/NN	amod||swineinfluenzavirusinfections-5/NNS||occupational-4/JJ	prep_of||evidence-2/NN||swineinfluenzavirusinfections-5/NNS	auxpass||observed-7/VBN||was-6/VBD	root||ROOT-0/null||observed-7/VBN	amod||data-12/NNS||self-reported-9/JJ	amod||data-12/NNS||influenza-like-10/JJ	nn||data-12/NNS||illness-11/NN	prep_through||observed-7/VBN||data-12/NNS	prep_through||observed-7/VBN||comparisons-14/NNS	conj_and||data-12/NNS||comparisons-14/NNS	nn||samples-20/NNS||enrollment-16/NN	conj_and||enrollment-16/NN||follow-up-18/NN	nn||samples-20/NNS||follow-up-18/NN	nn||samples-20/NNS||serum-19/NN	prep_of||comparisons-14/NNS||samples-20/NNS	det||isolation-24/NN||the-23/DT	prep_through||observed-7/VBN||isolation-24/NN	conj_and||data-12/NNS||isolation-24/NN	det||virus-32/NN||a-26/DT	amod||virus-32/NN||reassortant-27/JJ	nn||virus-32/NN||swineinfluenza-28/NN	appos||virus-32/NN||h1n1-30/NNP	prep_of||isolation-24/NN||virus-32/NN	det||farmer-37/NN||an-34/DT	amod||farmer-37/NN||ill-35/JJ	nn||farmer-37/NN||swine-36/NNS	prep_from||observed-7/VBN||farmer-37/NN	swineinfluenza-28||influenzavirus--1||no||further evidence of occupational swineinfluenzavirusinfections was observed through self-reported influenza-like illness data, comparisons of enrollment and follow-up serum samples, and the isolation of a reassortant swineinfluenza (h1n1) virus from an ill swine farmer.
prep_in||demonstrated-8/VBN||line-2/NN	prep_with||line-2/NN||this-4/DT	nsubjpass||demonstrated-8/VBN||bisphosphonates-6/NNS	nsubj||effective-12/JJ||bisphosphonates-6/NNS	auxpass||demonstrated-8/VBN||are-7/VBP	root||ROOT-0/null||demonstrated-8/VBN	aux||effective-12/JJ||to-9/TO	cop||effective-12/JJ||be-10/VB	advmod||effective-12/JJ||particularly-11/RB	xcomp||demonstrated-8/VBN||effective-12/JJ	prepc_at||effective-12/JJ||reducing-14/VBG	nn||growth-16/NN||breasttumour-15/NN	dobj||reducing-14/VBG||growth-16/NN	advmod||used-18/VBN||when-17/WRB	advcl||effective-12/JJ||used-18/VBN	prep_in||used-18/VBN||combination-20/NN	prep_with||used-18/VBN||agents-22/NNS	nsubj||target-25/VBP||agents-22/NNS	advmod||target-25/VBP||directly-24/RB	rcmod||agents-22/NNS||target-25/VBP	nn||cells-27/NNS||cancer-26/NN	dobj||target-25/VBP||cells-27/NNS	bisphosphonates-6||breasttumour-15||no_rel||in line with this, bisphosphonates are demonstrated to be particularly effective at reducing breasttumour growth when used in combination with agents that directly target cancer cells.
advmod||differed-11/VBD||however-1/RB	det||expression-7/NN||the-3/DT	amod||expression-7/NN||serological-4/JJ	conj_and||serological-4/JJ||molecular-6/JJ	amod||expression-7/NN||molecular-6/JJ	nsubj||differed-11/VBD||expression-7/NN	nn||infection-10/NN||hbv-9/NN	prep_of||expression-7/NN||infection-10/NN	root||ROOT-0/null||differed-11/VBD	det||groups-15/NNS||the-13/DT	num||groups-15/NNS||two-14/CD	prep_in||differed-11/VBD||groups-15/NNS	det||group-17/NN||the-16/DT	nsubj||included-20/VBD||group-17/NN	prep_of||group-17/NN||patients-19/NNS	rcmod||groups-15/NNS||included-20/VBD	amod||individuals-22/NNS||more-21/JJR	dobj||included-20/VBD||individuals-22/NNS	amod||infection-26/NN||ongoing-24/JJ	nn||infection-26/NN||hbv-25/NN	prep_with||included-20/VBD||infection-26/NN	mark||defined-29/VBN||as-28/IN	advcl||included-20/VBD||defined-29/VBN	det||presence-32/NN||the-31/DT	prep_by||defined-29/VBN||presence-32/NN	amod||hbsag-35/NN||detectable-34/JJ	prep_of||presence-32/NN||hbsag-35/NN	prep_in||differed-11/VBD||or-37/CC	conj_or||groups-15/NNS||or-37/CC	nn||dna-39/NN||hbv-38/NN	prep_in||differed-11/VBD||dna-39/NN	conj_or||groups-15/NNS||dna-39/NN	num||%-42/NN||17-41/CD	dep||dna-39/NN||%-42/NN	num||%-45/NN||12-44/CD	dep||dna-39/NN||%-45/NN	conj_and||%-42/NN||%-45/NN	advmod||%-42/NN||respectively-47/RB	hbv-38||hbsag-35||yes||however, the serological and molecular expression of hbv infection differed in the two groups the group of patients included more individuals with ongoing hbv infection, as defined by the presence of detectable hbsag and or hbv dna (17% and 12%, respectively).
nsubj||remains-6/VBZ||hepatitisbvirus-1/NNS	appos||hepatitisbvirus-1/NNS||hbv-3/NN	advmod||remains-6/VBZ||infection-5/RB	root||ROOT-0/null||remains-6/VBZ	det||burden-10/NN||a-7/DT	amod||burden-10/NN||significant-8/JJ	nn||burden-10/NN||health-9/NN	xcomp||remains-6/VBZ||burden-10/NN	advmod||remains-6/VBZ||world-wide-11/RB	mark||help-15/VBP||although-13/IN	nsubj||help-15/VBP||vaccines-14/NNS	advcl||remains-6/VBZ||help-15/VBP	xcomp||help-15/VBP||decrease-16/VB	det||problem-18/NN||this-17/DT	dobj||decrease-16/VB||problem-18/NN	hbv-3||hepatitisbvirus-1||no||hepatitisbvirus (hbv) infection remains a significant health burden world-wide, although vaccines help decrease this problem.
poss||profiling-3/NN||our-1/PRP$	amod||profiling-3/NN||systematic-2/JJ	nsubj||advanced-14/VBD||profiling-3/NN	nsubj||identified-29/VBD||profiling-3/NN	nn||changes-6/NNS||phosphorylation-5/NN	prep_of||profiling-3/NN||changes-6/NNS	prep_in||changes-6/NNS||response-8/NN	amod||treatment-11/NN||bortezomib-10/JJ	prep_to||response-8/NN||treatment-11/NN	neg||only-13/JJ||not-12/RB	preconj||advanced-14/VBD||only-13/JJ	root||ROOT-0/null||advanced-14/VBD	det||understanding-18/NN||the-15/DT	amod||understanding-18/NN||global-16/JJ	amod||understanding-18/NN||mechanistic-17/JJ	dobj||advanced-14/VBD||understanding-18/NN	det||action-21/NN||the-20/DT	prep_of||understanding-18/NN||action-21/NN	prep_of||action-21/NN||bortezomib-23/NN	nn||cells-26/NNS||myeloma-25/NN	prep_on||advanced-14/VBD||cells-26/NNS	advmod||identified-29/VBD||also-28/RB	conj_but||advanced-14/VBD||identified-29/VBD	advmod||uncharacterized-31/JJ||previously-30/RB	acomp||signaling-32/VBG||uncharacterized-31/JJ	ccomp||identified-29/VBD||signaling-32/VBG	xcomp||identified-29/VBD||signaling-32/VBG	dobj||signaling-32/VBG||proteins-33/NNS	nn||cells-36/NNS||myeloma-35/NN	prep_in||signaling-32/VBG||cells-36/NNS	myeloma-35||bortezomib-23||yes||our systematic profiling of phosphorylation changes in response to bortezomib treatment not only advanced the global mechanistic understanding of the action of bortezomib on myeloma cells but also identified previously uncharacterized signaling proteins in myeloma cells.
nsubj||assess-2/VBP||we-1/PRP	root||ROOT-0/null||assess-2/VBP	det||system-8/NN||the-3/DT	amod||system-8/NN||new-4/JJ	amod||system-8/NN||decentralized-5/JJ	nn||system-8/NN||service-6/NN	nn||system-8/NN||provision-7/NN	dobj||assess-2/VBP||system-8/NN	prep_for||system-8/NN||people-10/NNS	vmod||people-10/NNS||living-11/VBG	prep_with||living-11/VBG||hiv/aids-13/NNS	amod||populations-16/NNS||rural-15/JJ	prep_in||hiv/aids-13/NNS||populations-16/NNS	prep_in||populations-16/NNS||china-18/NN	aids--1||hiv--1||no||we assess the new decentralized service provision system for people living with hiv/aids in rural populations in china.
nn||estimates-2/NNS||hiv-1/NN	nsubj||tool-6/NN||estimates-2/NNS	cop||tool-6/NN||are-3/VBP	det||tool-6/NN||a-4/DT	amod||tool-6/NN||valuable-5/JJ	root||ROOT-0/null||tool-6/NN	nn||policies-11/NNS||guiding-8/NNP	amod||policies-11/NNS||national-9/JJ	nn||policies-11/NNS||aids-10/NNS	prep_for||tool-6/NN||policies-11/NNS	vmod||policies-11/NNS||evaluating-12/VBG	nn||prevention-14/NN||hiv-13/NN	dobj||evaluating-12/VBG||prevention-14/NN	nn||programmes-17/NNS||control-16/NN	dobj||evaluating-12/VBG||programmes-17/NNS	conj_and||prevention-14/NN||programmes-17/NNS	aids-10||hiv-13||no||hiv estimates are a valuable tool for guiding national aids policies evaluating hiv prevention and control programmes.
det||profiling-3/NN||the-1/DT	amod||profiling-3/NN||global-2/JJ	nsubj||gives-8/VBZ||profiling-3/NN	det||genome-7/NN||the-5/DT	nn||genome-7/NN||vzv-6/NN	prep_of||profiling-3/NN||genome-7/NN	root||ROOT-0/null||gives-8/VBZ	amod||insights-10/NNS||further-9/JJ	dobj||gives-8/VBZ||insights-10/NNS	det||replication-13/NN||the-12/DT	prep_into||gives-8/VBZ||replication-13/NN	prep_into||gives-8/VBZ||pathogenesis-15/NNS	conj_and||replication-13/NN||pathogenesis-15/NNS	det||virus-18/NN||this-17/DT	prep_of||replication-13/NN||virus-18/NN	nsubj||lead-22/VB||virus-18/NN	aux||lead-22/VB||can-21/MD	rcmod||virus-18/NN||lead-22/VB	amod||prevention-25/NN||improved-24/VBN	prep_to||lead-22/VB||prevention-25/NN	prep_to||lead-22/VB||therapy-27/NN	conj_and||prevention-25/NN||therapy-27/NN	prep_of||prevention-25/NN||chickenpox-29/NN	prep_of||prevention-25/NN||shingles-31/NNS	conj_and||chickenpox-29/NN||shingles-31/NNS	chickenpox-29||vzv-6||yes||the global profiling of the vzv genome gives further insights into the replication and pathogenesis of this virus, which can lead to improved prevention and therapy of chickenpox and shingles.
nsubj||tested-2/VBD||we-1/PRP	root||ROOT-0/null||tested-2/VBD	det||hypothesis-4/NNS||the-3/DT	dobj||tested-2/VBD||hypothesis-4/NNS	mark||suppresses-21/VBZ||that-5/IN	det||increase-7/NN||an-6/DT	nsubj||suppresses-21/VBZ||increase-7/NN	prep_in||increase-7/NN||insulin-9/NN	nn||se-11/FW||per-10/FW	advmod||insulin-9/NN||se-11/FW	dep||se-11/FW||i.e.-13/CD	det||absence-17/NN||the-16/DT	prep_in||se-11/FW||absence-17/NN	prep_of||absence-17/NN||zinc-19/NN	ccomp||tested-2/VBD||suppresses-21/VBZ	nn||secretion-23/NN||glucagon-22/NN	dobj||suppresses-21/VBZ||secretion-23/NN	prep_during||suppresses-21/VBZ||euglycemia-25/NN	mark||stimulates-34/VBZ||that-27/IN	det||decrease-29/NN||a-28/DT	nsubj||stimulates-34/VBZ||decrease-29/NN	prep_in||decrease-29/NN||insulin-31/NN	nn||se-33/FW||per-32/FW	advmod||stimulates-34/VBZ||se-33/FW	ccomp||tested-2/VBD||stimulates-34/VBZ	conj_and||suppresses-21/VBZ||stimulates-34/VBZ	nn||secretion-36/NN||glucagon-35/NN	dobj||stimulates-34/VBZ||secretion-36/NN	prep_during||stimulates-34/VBZ||hypoglycemia-38/NN	prep_in||hypoglycemia-38/NN||humans-40/NNS	hypoglycemia-38||glucagon-35||yes||we tested the hypothesis that an increase in insulin per se, i.e., in the absence of zinc, suppresses glucagon secretion during euglycemia and that a decrease in insulin per se stimulates glucagon secretion during hypoglycemia in humans.
det||model-3/NN||a-2/DT	prep_in||examined-9/VBD||model-3/NN	amod||emphysema-7/NN||elastase-induced-5/JJ	amod||emphysema-7/NN||pulmonary-6/JJ	prep_of||model-3/NN||emphysema-7/NN	nsubj||examined-9/VBD||we-8/PRP	root||ROOT-0/null||examined-9/VBD	det||response-11/NN||the-10/DT	nsubj||fluid-39/JJ||response-11/NN	amod||mice-14/NNS||il-17a-deficient-13/JJ	prep_of||response-11/NN||mice-14/NNS	nn||inflammation-18/NN||monitoring-16/NN	nn||inflammation-18/NN||airway-17/NN	prep_of||response-11/NN||inflammation-18/NN	conj_and||mice-14/NNS||inflammation-18/NN	amod||compliance-21/NN||static-20/JJ	prep_of||response-11/NN||compliance-21/NN	conj_and||mice-14/NNS||compliance-21/NN	nn||histology-24/NN||lung-23/NN	prep_of||response-11/NN||histology-24/NN	conj_and||mice-14/NNS||histology-24/NN	prep_of||response-11/NN||levels-26/NNS	conj_and||mice-14/NNS||levels-26/NNS	amod||chemokine-29/NN||neutrophil-related-28/JJ	prep_of||response-11/NN||chemokine-29/NN	nn||cytokines-32/NNS||pro-inflammatory-31/NN	prep_of||response-11/NN||cytokines-32/NNS	conj_and||chemokine-29/NN||cytokines-32/NNS	nn||lavage-35/NN||bronchoalveolar-34/NN	prep_in||chemokine-29/NN||lavage-35/NN	appos||response-11/NN||bal-37/NN	xcomp||examined-9/VBD||fluid-39/JJ	bal-37||inflammation-18||no_rel||in a model of elastase-induced pulmonary emphysema we examined the response of il-17a-deficient mice, monitoring airway inflammation, static compliance, lung histology and levels of neutrophil-related chemokine and pro-inflammatory cytokines in bronchoalveolar lavage (bal) fluid.
nsubj||syndrome-8/NN||allergicbronchopulmonarymycosis-1/NNS	appos||allergicbronchopulmonarymycosis-1/NNS||abpm-3/NNP	cop||syndrome-8/NN||is-5/VBZ	det||syndrome-8/NN||a-6/DT	amod||syndrome-8/NN||clinical-7/JJ	root||ROOT-0/null||syndrome-8/NN	vmod||syndrome-8/NN||associated-9/VBN	amod||sensitivity-12/NN||immune-11/JJ	prep_with||associated-9/VBN||sensitivity-12/NN	amod||fungi-15/NNS||various-14/JJ	prep_to||associated-9/VBN||fungi-15/NNS	advmod||aspergillus-17/VBZ||notably-16/RB	dep||fungi-15/NNS||aspergillus-17/VBZ	dobj||aspergillus-17/VBZ||spp-18/NN	allergicbronchopulmonarymycosis-1||fungi-15||no||allergicbronchopulmonarymycosis (abpm) is a clinical syndrome associated with immune sensitivity to various fungi notably aspergillus spp.
nsubj||syndrome-8/NN||allergicbronchopulmonarymycosis-1/NNS	appos||allergicbronchopulmonarymycosis-1/NNS||abpm-3/NNP	cop||syndrome-8/NN||is-5/VBZ	det||syndrome-8/NN||a-6/DT	amod||syndrome-8/NN||clinical-7/JJ	root||ROOT-0/null||syndrome-8/NN	vmod||syndrome-8/NN||associated-9/VBN	amod||sensitivity-12/NN||immune-11/JJ	prep_with||associated-9/VBN||sensitivity-12/NN	amod||fungi-15/NNS||various-14/JJ	prep_to||associated-9/VBN||fungi-15/NNS	advmod||aspergillus-17/VBZ||notably-16/RB	dep||fungi-15/NNS||aspergillus-17/VBZ	dobj||aspergillus-17/VBZ||spp-18/NN	--1||--1||no_rel||allergicbronchopulmonarymycosis (abpm) is a clinical syndrome associated with immune sensitivity to various fungi notably aspergillus spp.
nsubj||likely-14/JJ||women-1/NNS	nsubj||have-16/VB||women-1/NNS	det||malaria-11/NN||either-3/DT	dep||acute-7/JJ||acute-4/JJ	amod||malaria-11/NN||acute-7/JJ	conj_and||acute-7/JJ||chronic-9/JJ	amod||malaria-11/NN||chronic-9/JJ	amod||malaria-11/NN||placental-10/JJ	prep_with||women-1/NNS||malaria-11/NN	cop||likely-14/JJ||were-12/VBD	advmod||likely-14/JJ||less-13/RBR	dep||is-25/VBZ||likely-14/JJ	aux||have-16/VB||to-15/TO	xcomp||likely-14/JJ||have-16/VB	dobj||have-16/VB||irondeficiency-17/NN	prep_than||irondeficiency-17/NN||women-19/NNS	amod||infection-23/NN||placental-21/JJ	nn||infection-23/NN||malaria-22/NN	prep_without||have-16/VB||infection-23/NN	expl||is-25/VBZ||there-24/EX	root||ROOT-0/null||is-25/VBZ	det||priority-27/NN||a-26/DT	nsubj||is-25/VBZ||priority-27/NN	aux||establish-29/VB||to-28/TO	vmod||priority-27/NN||establish-29/VB	mark||enhances-43/VBZ||if-30/IN	csubj||enhances-43/VBZ||reversing-31/VBG	advmod||reversing-31/VBG||irondeficiency-32/RB	nn||programs-36/NNS||iron-34/NN	nn||programs-36/NNS||supplementation-35/NN	prep_through||reversing-31/VBG||programs-36/NNS	dep||programs-36/NNS||either-37/DT	dep||either-37/DT||prior-38/RB	prep||prior-38/RB||to-39/TO	dep||programs-36/NNS||during-41/IN	conj_or||either-37/DT||during-41/IN	pobj||during-41/IN||pregnancy-42/NN	advcl||establish-29/VB||enhances-43/VBZ	nn||risk-45/NN||malaria-44/NN	dobj||enhances-43/VBZ||risk-45/NN	irondeficiency-32||iron-34||yes||women with either acute, or acute and chronic placental malaria were less likely to have irondeficiency than women without placental malaria infection there is a priority to establish if reversing irondeficiency through iron supplementation programs either prior to or during pregnancy enhances malaria risk.
det||addition-2/NN||the-1/DT	nsubj||shortens-9/VBZ||addition-2/NN	nsubj||shortens-9/VBZ||addition-2/NN	prep_of||addition-2/NN||acetaminophen-4/NN	aux||lidocaine-6/VB||to-5/TO	vmod||acetaminophen-4/NN||lidocaine-6/VB	prep_for||lidocaine-6/VB||ivra-8/NN	root||ROOT-0/null||shortens-9/VBZ	conj_but||shortens-9/VBZ||shortens-9/VBZ	det||time-12/NN||the-10/DT	nn||time-12/NN||onset-11/NN	dobj||shortens-9/VBZ||time-12/NN	amod||block-15/NN||sensory-14/JJ	prep_of||shortens-9/VBZ||block-15/NN	nn||pain-19/NN||delays-17/NNS	nn||pain-19/NN||tourniquet-18/NN	prep_of||shortens-9/VBZ||pain-19/NN	conj_and||block-15/NN||pain-19/NN	amod||time-21/NN||onset-20/JJ	dep||block-15/NN||time-21/NN	neg||shortens-9/VBZ||not-24/RB	prep_with||shortens-9/VBZ||ketorolac-26/NN	pain-19||lidocaine-6||yes||the addition of acetaminophen to lidocaine for ivra shortens the onset time of sensory block and delays tourniquet pain onset time, but not with ketorolac.
nsubj||increased-10/VBD||results-1/NNS	det||number-3/NN||the-2/DT	dep||results-1/NNS||number-3/NN	prep_of||results-1/NNS||csos-5/NNS	advmod||results-1/NNS||specificly-6/RB	vmod||results-1/NNS||working-7/VBG	prep_on||working-7/VBG||hiv/aids-9/NNS	root||ROOT-0/null||increased-10/VBD	prep_from||increased-10/VBD||0-12/CD	prep_before||increased-10/VBD||1988-14/CD	quantmod||400-17/CD||over-16/IN	prep_to||increased-10/VBD||400-17/CD	prep_in||increased-10/VBD||2009-19/CD	aids--1||hiv--1||no||results the number of csos specificly working on hiv/aids increased from 0 before 1988 to over 400 in 2009.
det||vaccine-5/NN||the-1/DT	amod||vaccine-5/NN||only-2/JJ	advmod||available-4/JJ||currently-3/RB	amod||vaccine-5/NN||available-4/JJ	nsubj||calmette-guerin-14/NN||vaccine-5/NN	prep_against||vaccine-5/NN||tuberculosis-7/NNP	appos||vaccine-5/NN||tb-9/NN	cop||calmette-guerin-14/NN||is-11/VBZ	amod||bacille-13/JJ||mycobacteriumbovis-12/JJ	amod||calmette-guerin-14/NN||bacille-13/JJ	root||ROOT-0/null||calmette-guerin-14/NN	nsubj||inconsistent-21/JJ||calmette-guerin-14/NN	nsubj||protect-24/VB||calmette-guerin-14/NN	appos||calmette-guerin-14/NN||bcg-16/NN	aux||inconsistent-21/JJ||has-20/VBZ	rcmod||calmette-guerin-14/NN||inconsistent-21/JJ	advmod||inconsistent-21/JJ||efficacy-22/RB	aux||protect-24/VB||to-23/TO	xcomp||inconsistent-21/JJ||protect-24/VB	det||disease-27/NN||the-26/DT	prep_against||protect-24/VB||disease-27/NN	prep_in||inconsistent-21/JJ||adults-29/NNS	tb-9||bcg-16||no||the only currently available vaccine against tuberculosis (tb) is mycobacteriumbovis bacille calmette-guerin (bcg), which has inconsistent efficacy to protect against the disease in adults.
det||extent-3/NN||the-2/DT	prep_to||suggests-26/VBZ||extent-3/NN	mark||mimics-11/VBZ||that-4/IN	det||nicotine-7/NN||the-5/DT	amod||nicotine-7/NN||combined-6/VBN	nsubj||mimics-11/VBZ||nicotine-7/NN	nn||sensitization-10/NN||pcp-9/NN	conj_and||nicotine-7/NN||sensitization-10/NN	nsubj||mimics-11/VBZ||sensitization-10/NN	dep||extent-3/NN||mimics-11/VBZ	amod||nicotineaddiction-13/NN||comorbid-12/JJ	dobj||mimics-11/VBZ||nicotineaddiction-13/NN	prep_in||nicotineaddiction-13/NN||schizophrenia-15/NN	det||effect-20/NN||the-17/DT	amod||effect-20/NN||preferential-18/JJ	nn||effect-20/NN||inhibitory-19/NN	nsubj||suggests-26/VBZ||effect-20/NN	prep_of||effect-20/NN||iptakalim-22/NN	amod||hyperlocomotion-25/NN||nicotine-induced-24/JJ	prep_on||iptakalim-22/NN||hyperlocomotion-25/NN	root||ROOT-0/null||suggests-26/VBZ	mark||drug-34/NN||that-27/IN	nsubj||drug-34/NN||iptakalim-28/NN	aux||drug-34/NN||may-29/MD	cop||drug-34/NN||be-30/VB	det||drug-34/NN||a-31/DT	amod||drug-34/NN||potential-32/JJ	amod||drug-34/NN||useful-33/JJ	ccomp||suggests-26/VBZ||drug-34/NN	det||abuse-39/NN||the-36/DT	nn||abuse-39/NN||treatment-37/NN	nn||abuse-39/NN||nicotine-38/NN	prep_for||drug-34/NN||abuse-39/NN	prep_in||abuse-39/NN||schizophrenia-41/NN	nicotineaddiction-13||nicotine-38||no||to the extent that the combined nicotine and pcp sensitization mimics comorbid nicotineaddiction in schizophrenia, the preferential inhibitory effect of iptakalim on nicotine-induced hyperlocomotion suggests that iptakalim may be a potential useful drug for the treatment nicotine abuse in schizophrenia.
dep||abundant-19/JJ||transforming-1/VBG	nn||factor-î-3/NNS||growth-2/NN	dobj||transforming-1/VBG||factor-î-3/NNS	number||1-5/CD||²-4/CD	nsubj||abundant-19/JJ||1-5/CD	appos||1-5/CD||tgf-î-7/NNP	number||1-9/CD||²-8/CD	num||tgf-î-7/NNP||1-9/CD	det||cytokine-15/NN||a-12/DT	amod||cytokine-15/NN||potent-13/JJ	amod||cytokine-15/NN||fibrogenic-14/JJ	appos||1-5/CD||cytokine-15/NN	cop||abundant-19/JJ||is-17/VBZ	advmod||abundant-19/JJ||more-18/RBR	root||ROOT-0/null||abundant-19/JJ	prepc_in||abundant-19/JJ||rejecting-21/VBG	amod||allografts-23/NNS||renal-22/JJ	dobj||rejecting-21/VBG||allografts-23/NNS	nsubjpass||infected-26/VBN||allografts-23/NNS	auxpass||infected-26/VBN||are-25/VBP	rcmod||allografts-23/NNS||infected-26/VBN	preconj||cmv-32/NN||either-28/DT	nn||cmv-32/NN||hcmv-29/NN	conj_or||hcmv-29/NN||rat-31/NN	nn||cmv-32/NN||rat-31/NN	prep_with||infected-26/VBN||cmv-32/NN	prepc_as||infected-26/VBN||compared-34/VBN	pcomp||compared-34/VBN||to-35/TO	amod||grafts-39/NNS||uninfected-36/JJ	amod||grafts-39/NNS||rejecting-38/JJ	pobj||to-35/TO||grafts-39/NNS	cmv-32||hcmv-29||no||transforming growth factor-î²1 (tgf-î²1), a potent fibrogenic cytokine, is more abundant in rejecting renal allografts that are infected with either hcmv or rat cmv as compared to uninfected, rejecting grafts.
root||ROOT-0/null||basal-1/NN	conj_and||basal-1/NN||interferon-alpha-3/NN	nn||±-6/NNP||ifn-î-5/NNP	appos||basal-1/NN||±-6/NNP	conj_or||basal-1/NN||interferon-gamma-9/NN	nn||³-12/NNP||ifn-î-11/NNP	appos||interferon-gamma-9/NN||³-12/NNP	amod||expression-16/NN||induced-15/JJ	nsubjpass||evaluated-23/VBN||expression-16/NN	amod||proteins-21/NNS||socs1-18/JJ	conj_and||socs1-18/JJ||socs3-20/JJ	amod||proteins-21/NNS||socs3-20/JJ	prep_of||expression-16/NN||proteins-21/NNS	auxpass||evaluated-23/VBN||was-22/VBD	dep||basal-1/NN||evaluated-23/VBN	amod||analysis-26/NN||immunoblot-25/JJ	agent||evaluated-23/VBN||analysis-26/NN	det||panel-29/NN||a-28/DT	prep_in||analysis-26/NN||panel-29/NN	prep_of||panel-29/NN||n-31/NN	dep||lines-38/NNS||=-32/SYM	num||lines-38/NNS||10-33/CD	amod||lines-38/NNS||metastatic-34/JJ	amod||lines-38/NNS||human-35/JJ	nn||lines-38/NNS||melanoma-36/NNP	nn||lines-38/NNS||cell-37/NN	ccomp||evaluated-23/VBN||lines-38/NNS	amod||melanocytes-43/NNS||human-41/JJ	amod||melanocytes-43/NNS||embryonic-42/JJ	prep_in||basal-1/NN||melanocytes-43/NNS	appos||melanocytes-43/NNS||hem-45/NN	prep_in||basal-1/NN||radial-49/NN	conj_and||melanocytes-43/NNS||radial-49/NN	amod||cells-55/NNS||vertical-51/JJ	nn||cells-55/NNS||growth-52/NN	nn||cells-55/NNS||phase-53/NN	nn||cells-55/NNS||melanoma-54/NN	conj_and||melanocytes-43/NNS||cells-55/NNS	conj_or||radial-49/NN||cells-55/NNS	melanoma-54||ifn--1||yes||basal and interferon-alpha (ifn-î±) or interferon-gamma (ifn-î³)-induced expression of socs1 and socs3 proteins was evaluated by immunoblot analysis in a panel of n = 10 metastatic human melanoma cell lines, in human embryonic melanocytes (hem), and radial or vertical growth phase melanoma cells.
det||perturbations-3/NNS||some-1/DT	amod||perturbations-3/NNS||minor-2/JJ	nsubj||caused-14/VBD||perturbations-3/NNS	prepc_like||perturbations-3/NNS||increasing-5/VBG	det||concentration-8/NN||the-6/DT	nn||concentration-8/NN||glucose-7/NN	dobj||increasing-5/VBG||concentration-8/NN	number||1-12/CD||0.1-10/CD	dep||1-12/CD||to-11/TO	num||g/l-13/NN||1-12/CD	prep_from||increasing-5/VBG||g/l-13/NN	root||ROOT-0/null||caused-14/VBD	det||difference-19/NN||a-15/DT	number||million-17/CD||ten-16/CD	num||difference-19/NN||million-17/CD	nn||difference-19/NN||fold-18/NN	dobj||caused-14/VBD||difference-19/NN	amod||cells-22/NNS||culturable-21/JJ	prep_in||caused-14/VBD||cells-22/NNS	det||treatment-29/NN||a-24/DT	amod||treatment-29/NN||twenty-25/CD	num||hour-27/NN||four-26/CD	dep||twenty-25/CD||hour-27/NN	amod||treatment-29/NN||antibiotic-28/JJ	prep_over||caused-14/VBD||treatment-29/NN	ten-16||glucose-7||no_rel||some minor perturbations like increasing the glucose concentration from 0.1 to 1 g/l caused a ten million fold difference in culturable cells over a twenty four hour antibiotic treatment.
amod||explants-4/NNS||human-1/JJ	nn||explants-4/NNS||oa-2/NN	nn||explants-4/NNS||cartilage-3/NN	nsubjpass||cultured-6/VBN||explants-4/NNS	auxpass||cultured-6/VBN||were-5/VBD	root||ROOT-0/null||cultured-6/VBN	prep_with||cultured-6/VBN||salmoncalcitonin-8/NN	xcomp||cultured-6/VBN||-LSB--9/VBG	num||-RSB--13/NNS||100-10/CD	amod||-RSB--13/NNS||pm-100-11/JJ	nn||-RSB--13/NNS||nm-12/NN	dobj||-LSB--9/VBG||-RSB--13/NNS	nm-12||oa-2||no_rel||human oa cartilage explants were cultured with salmoncalcitonin [100 pm-100 nm].
det||introduction-3/NN||the-2/DT	prep_with||is-21/VBZ||introduction-3/NN	amod||therapy-7/NN||artemisinin-based-5/JJ	nn||therapy-7/NN||combination-6/NN	prep_of||introduction-3/NN||therapy-7/NN	appos||therapy-7/NN||act-9/NN	prep_for||therapy-7/NN||treatment-12/NN	prep_of||treatment-12/NN||malaria-14/NN	amod||settings-18/NNS||many-16/JJ	amod||settings-18/NNS||low-resource-17/JJ	prep_in||malaria-14/NN||settings-18/NNS	expl||is-21/VBZ||there-20/EX	root||ROOT-0/null||is-21/VBZ	nsubj||is-21/VBZ||need-22/NN	aux||target-24/VB||to-23/TO	vmod||need-22/NN||target-24/VB	dobj||target-24/VB||treatment-25/NN	prep_to||target-24/VB||patients-27/NNS	prep_with||target-24/VB||parasitologically-29/NN	vmod||parasitologically-29/NN||confirmed-30/VBN	dobj||confirmed-30/VBN||malaria-31/NN	prep_in||confirmed-30/VBN||order-33/NN	aux||improve-35/VB||to-34/TO	vmod||confirmed-30/VBN||improve-35/VB	dobj||improve-35/VB||quality-36/NN	prep_of||quality-36/NN||care-38/NN	vmod||confirmed-30/VBN||reduce-40/VB	conj_and||improve-35/VB||reduce-40/VB	prt||reduce-40/VB||over-41/RP	dobj||reduce-40/VB||consumption-42/NN	prep_of||consumption-42/NN||anti-malarials-44/NNS	vmod||confirmed-30/VBN||reduce-46/VB	conj_and||improve-35/VB||reduce-46/VB	nn||pressure-48/NN||drug-47/NN	dobj||reduce-46/VB||pressure-48/NN	advmod||turn-51/VB||in-50/RB	vmod||confirmed-30/VBN||turn-51/VB	conj_and||improve-35/VB||turn-51/VB	nn||development-53/NN||delay-52/NN	dobj||turn-51/VB||development-53/NN	dobj||turn-51/VB||spread-55/NN	conj_and||development-53/NN||spread-55/NN	nn||resistance-58/NN||drug-57/NN	prep_of||development-53/NN||resistance-58/NN	anti-malarials-44||malaria-31||no_rel||with the introduction of artemisinin-based combination therapy (act) for treatment of malaria in many low-resource settings, there is need to target treatment to patients with parasitologically confirmed malaria in order to improve quality of care, reduce over consumption of anti-malarials, reduce drug pressure and in turn delay development and spread of drug resistance.
advmod||grown-4/VBN||when-1/WRB	nsubjpass||grown-4/VBN||bacteria-2/NNS	auxpass||grown-4/VBN||were-3/VBD	advcl||reduced-21/VBN||grown-4/VBN	nn||infusion-10/NN||mb-6/NN	conj_and||mb-6/NN||brain-8/NN	nn||infusion-10/NN||brain-8/NN	nn||infusion-10/NN||heart-9/NN	prep_in||grown-4/VBN||infusion-10/NN	amod||bhin-14/NN||nahco3-12/JJ	prep_with||grown-4/VBN||bhin-14/NN	prep||bhin-14/NN||plus-16/CC	pobj||plus-16/CC||lactose-17/NN	nsubjpass||reduced-21/VBN||ph-19/PRP	auxpass||reduced-21/VBN||was-20/VBD	root||ROOT-0/null||reduced-21/VBN	num||â-24/NNS||5.5-23/CD	prep_to||reduced-21/VBN||â-24/NNS	num||â-24/NNS||$-25/$	num||$-25/$||5.9-27/CD	expl||was-30/VBD||there-29/EX	conj_and||reduced-21/VBN||was-30/VBD	det||decrease-33/NN||a-31/DT	amod||decrease-33/NN||significant-32/JJ	nsubj||was-30/VBD||decrease-33/NN	prep_in||decrease-33/NN||expression-35/NN	det||locus-38/NNS||the-37/DT	prep_of||expression-35/NN||locus-38/NNS	amod||effacement-41/JJ||enterocyte-40/JJ	amod||genes-45/NNS||effacement-41/JJ	discourse||genes-45/NNS||lee-43/UH	prep_of||locus-38/NNS||genes-45/NNS	discourse||espd-50/VB||eae-46/UH	dep||eae-46/UH||tir-48/UH	dep||was-30/VBD||espd-50/VB	amod||r-54/NN||grla-52/FW	dep||grla-52/FW||/-53/FW	dobj||espd-50/VB||r-54/NN	dobj||espd-50/VB||ler-56/NN	conj_and||r-54/NN||ler-56/NN	det||increase-60/NN||an-59/DT	nsubj||gade-75/VBP||increase-60/NN	nsubj||hfq-77/VBP||increase-60/NN	prep_in||increase-60/NN||cya-62/NN	appos||cya-62/NN||camp-64/NN	num||regulators-70/NNS||two-68/CD	amod||regulators-70/NNS||negative-69/JJ	prep_in||increase-60/NN||regulators-70/NNS	conj_and||cya-62/NN||regulators-70/NNS	det||lee-73/NN||the-72/DT	prep_of||regulators-70/NNS||lee-73/NN	conj_and||reduced-21/VBN||gade-75/VBP	conj_and||reduced-21/VBN||hfq-77/VBP	conj_and||gade-75/VBP||hfq-77/VBP	nahco3-12||eae-46||no_rel||when bacteria were grown in mb and brain heart infusion with nahco3 (bhin) plus lactose, ph was reduced to 5.5â5.9 and there was a significant decrease in expression of the locus of enterocyte effacement (lee) genes eae , tir , espd , grla /r and ler , and an increase in cya (camp), and two negative regulators of the lee, gade and hfq .
nsubj||shown-4/VBN||we-1/PRP	aux||shown-4/VBN||have-2/VBP	advmod||shown-4/VBN||previously-3/RB	root||ROOT-0/null||shown-4/VBN	mark||reveals-15/VBZ||that-5/IN	nsubj||reveals-15/VBZ||transient-6/JJ	prep_in||transient-6/JJ||vivo-8/NN	vmod||vivo-8/NN||treg-9/VBG	nn||depletion-11/NN||cell-10/NN	dobj||treg-9/VBG||depletion-11/NN	amod||fivinfection-14/NN||asymptomatic-13/JJ	prep_during||treg-9/VBG||fivinfection-14/NN	ccomp||shown-4/VBN||reveals-15/VBZ	amod||responses-18/NNS||fiv-specific-16/JJ	amod||responses-18/NNS||immune-17/JJ	dobj||reveals-15/VBZ||responses-18/NNS	vmod||responses-18/NNS||suppressed-19/VBN	amod||cells-22/NNS||treg-21/VBG	agent||suppressed-19/VBN||cells-22/NNS	fivinfection-14||fiv--1||no||we have previously shown that transient in vivo treg cell depletion during asymptomatic fivinfection reveals fiv-specific immune responses suppressed by treg cells.
nn||replacement-2/NN||iapp-1/NN	nsubj||slowed-14/VBD||replacement-2/NN	vmod||replacement-2/NN||using-4/VBG	det||pramlintide-7/NN||the-5/DT	amod||pramlintide-7/NN||analog-6/JJ	dobj||using-4/VBG||pramlintide-7/NN	nn||subjects-13/NNS||type-10/NN	num||subjects-13/NNS||1-11/CD	nn||subjects-13/NNS||diabetic-12/NN	prep_in||slowed-14/VBD||subjects-13/NNS	root||ROOT-0/null||slowed-14/VBD	amod||emptying-16/NN||gastric-15/JJ	dobj||slowed-14/VBD||emptying-16/NN	det||extent-20/NN||a-18/DT	amod||extent-20/NN||comparable-19/JJ	prep_to||slowed-14/VBD||extent-20/NN	mark||did-23/VBD||as-22/IN	advcl||slowed-14/VBD||did-23/VBD	dobj||did-23/VBD||hyperglycemia-24/NN	amod||subjects-27/NNS||healthy-26/JJ	prep_in||did-23/VBD||subjects-27/NNS	dep||<-30/JJ||p-29/RB	dep||did-23/VBD||<-30/JJ	dep||<-30/JJ||0.14-31/CD	advmod||reduced-36/VBD||greatly-35/RB	advcl||slowed-14/VBD||reduced-36/VBD	conj_and||did-23/VBD||reduced-36/VBD	amod||hyperglycemia-38/NN||postprandial-37/JJ	dobj||reduced-36/VBD||hyperglycemia-38/NN	appos||hyperglycemia-38/NN||p-40/NNP	number||00.1-42/CD||<-41/CD	num||p-40/NNP||00.1-42/CD	pramlintide-7||hyperglycemia-38||no_rel||iapp replacement, using the analog pramlintide, in type 1 diabetic subjects slowed gastric emptying to a comparable extent, as did hyperglycemia in healthy subjects ( p < 0.14), and greatly reduced postprandial hyperglycemia ( p < 00.1).
nn||cancer-2/NN||breast-1/NN	nsubj||cancer-8/NN||cancer-2/NN	cop||cancer-8/NN||is-3/VBZ	advmod||cancer-8/NN||frequently-4/RB	det||cancer-8/NN||a-5/DT	advmod||dependent-7/JJ||hormonally-6/RB	amod||cancer-8/NN||dependent-7/JJ	root||ROOT-0/null||cancer-8/NN	nsubjpass||established-24/VBN||associations-11/NNS	prepc_of||associations-11/NNS||circulating-13/VBG	dobj||circulating-13/VBG||estrogens-14/NNS	dobj||circulating-13/VBG||androgens-16/NNS	conj_and||estrogens-14/NNS||androgens-16/NNS	amod||risk-21/NN||subsequent-18/JJ	nn||risk-21/NN||breast-19/NN	nn||risk-21/NN||cancer-20/NN	prep_with||circulating-13/VBG||risk-21/NN	auxpass||established-24/VBN||are-22/VBP	advmod||established-24/VBN||well-23/RB	conj_and||cancer-8/NN||established-24/VBN	amod||women-27/NNS||postmenopausal-26/JJ	prep_in||established-24/VBN||women-27/NNS	androgens-16||cancer-20||no_rel||breast cancer is frequently a hormonally dependent cancer, and associations of circulating estrogens and androgens with subsequent breast cancer risk are well established in postmenopausal women.
amod||mutants-2/NNS||spontaneous-1/JJ	nsubjpass||isolated-16/VBN||mutants-2/NNS	nsubjpass||found-18/VBN||mutants-2/NNS	prep_of||mutants-2/NNS||mycobacteriumtuberculosis-4/NNS	nsubj||resistant-7/JJ||mycobacteriumtuberculosis-4/NNS	cop||resistant-7/JJ||were-6/VBD	rcmod||mycobacteriumtuberculosis-4/NNS||resistant-7/JJ	det||drugs-11/NNS||the-9/DT	amod||drugs-11/NNS||anti-tuberculosis-10/JJ	prep_to||resistant-7/JJ||drugs-11/NNS	amod||drugs-11/NNS||ethionamide-12/JJ	amod||drugs-11/NNS||isoniazid-14/JJ	conj_and||ethionamide-12/JJ||isoniazid-14/JJ	auxpass||isolated-16/VBN||were-15/VBD	root||ROOT-0/null||isolated-16/VBN	conj_and||isolated-16/VBN||found-18/VBN	prep_to||isolated-16/VBN||map-20/NN	prep_to||isolated-16/VBN||msha-22/NN	det||gene-25/NN||a-24/DT	appos||msha-22/NN||gene-25/NN	vmod||gene-25/NN||encoding-26/VBG	det||enzyme-29/NN||the-27/DT	amod||enzyme-29/NN||first-28/JJ	dobj||encoding-26/VBG||enzyme-29/NN	vmod||enzyme-29/NN||involved-30/VBN	det||biosynthesis-33/NNS||the-32/DT	prep_in||involved-30/VBN||biosynthesis-33/NNS	prep_of||biosynthesis-33/NNS||mycothiol-35/NN	det||thiol-40/NN||a-37/DT	amod||thiol-40/NN||major-38/JJ	amod||thiol-40/NN||low-molecular-weight-39/JJ	appos||mycothiol-35/NN||thiol-40/NN	prep_in||thiol-40/NN||m.tuberculosis-42/NNS	tuberculosis--1||m.tuberculosis-42||no||spontaneous mutants of mycobacteriumtuberculosis that were resistant to the anti-tuberculosis drugs ethionamide and isoniazid were isolated and found to map to msha , a gene encoding the first enzyme involved in the biosynthesis of mycothiol , a major low-molecular-weight thiol in m.tuberculosis .
aux||study-2/VB||to-1/TO	csubj||refractory-14/VBD||study-2/VB	det||efficacy-4/NN||the-3/DT	dobj||study-2/VB||efficacy-4/NN	amod||patients-13/NNS||rituximab-6/JJ	amod||rheumatoidarthritis-9/NNS||active-8/JJ	prep_in||rituximab-6/JJ||rheumatoidarthritis-9/NNS	appos||patients-13/NNS||ra-11/NN	prep_of||efficacy-4/NN||patients-13/NNS	root||ROOT-0/null||refractory-14/VBD	prep_to||refractory-14/VBD||disease-16/NN	xcomp||refractory-14/VBD||modifying-17/VBG	amod||dmards-20/NNS||anti-rheumaticdrugs-18/JJ	dobj||modifying-17/VBG||dmards-20/NNS	det||factor-26/NN||the-23/DT	nn||factor-26/NN||tumor-24/NN	nn||factor-26/NN||necrosis-25/NNS	prep_including||dmards-20/NNS||factor-26/NN	appos||factor-26/NN||tnf-28/NN	nn||antagonists-33/NNS||î-31/NN	nn||antagonists-33/NNS||±-32/NN	dep||factor-26/NN||antagonists-33/NNS	anti-rheumaticdrugs-18||tumor-24||no_rel||to study the efficacy of rituximab in active rheumatoidarthritis (ra) patients refractory to disease modifying anti-rheumaticdrugs (dmards) including the tumor necrosis factor (tnf)-î± antagonists.
advmod||show-3/VBP||here-1/RB	nsubj||show-3/VBP||we-2/PRP	root||ROOT-0/null||show-3/VBP	mark||plays-6/VBZ||that-4/IN	nsubj||plays-6/VBZ||cholesterol-5/NN	ccomp||show-3/VBP||plays-6/VBZ	det||role-9/NN||a-7/DT	amod||role-9/NN||major-8/JJ	dobj||plays-6/VBZ||role-9/NN	neg||only-11/JJ||not-10/RB	preconj||plays-6/VBZ||only-11/JJ	det||uptake-14/NN||the-13/DT	prep_in||plays-6/VBZ||uptake-14/NN	nn||integrin-21/NN||î-16/NN	amod||integrin-21/NN||±-17/JJ	amod||integrin-21/NN||2î-18/JJ	nn||integrin-21/NN||²-19/NNP	num||integrin-21/NN||1-20/CD	prep_of||uptake-14/NN||integrin-21/NN	poss||ligands-24/NNS||its-23/PRP$	prep_of||uptake-14/NN||ligands-24/NNS	conj_and||integrin-21/NN||ligands-24/NNS	advmod||plays-6/VBZ||also-26/RB	det||formation-29/NN||the-28/DT	prep_in||plays-6/VBZ||formation-29/NN	conj_but||uptake-14/NN||formation-29/NN	prep_of||formation-29/NN||î-31/NN	dep||plays-6/VBZ||±-32/VBG	num||bodies-36/NNS||2-33/CD	amod||bodies-36/NNS||integrin-specific-34/JJ	nn||bodies-36/NNS||multivesicular-35/NN	dobj||±-32/VBG||bodies-36/NNS	num||±-39/NNS||î-38/CD	npadvmod||2-mvbs-40/JJ||±-39/NNS	dep||bodies-36/NNS||2-mvbs-40/JJ	dobj||±-32/VBG||virusinfection-43/NN	conj_and||bodies-36/NNS||virusinfection-43/NN	virusinfection-43||cholesterol-5||no_rel||here we show that cholesterol plays a major role not only in the uptake of î±2î²1 integrin and its ligands but also in the formation of î±2 integrin-specific multivesicular bodies (î±2-mvbs) and virusinfection.
det||study-4/NN||a-1/DT	amod||cohort-3/JJ||retrospective-2/JJ	amod||study-4/NN||cohort-3/JJ	nsubjpass||conducted-6/VBN||study-4/NN	auxpass||conducted-6/VBN||was-5/VBD	root||ROOT-0/null||conducted-6/VBN	xcomp||conducted-6/VBN||using-7/VBG	det||center-11/NN||an-8/DT	amod||center-11/NN||academic-9/JJ	nn||center-11/NN||health-10/NN	dobj||using-7/VBG||center-11/NN	amod||record-15/NN||enterprise-wide-12/JJ	amod||record-15/NN||electronic-13/JJ	nn||record-15/NN||health-14/NN	prep||center-11/NN||record-15/NN	appos||record-15/NN||ehr-17/NN	dep||record-15/NN||system-19/NN	aux||identify-21/VB||to-20/TO	vmod||system-19/NN||identify-21/VB	num||patients-23/NNS||11,141-22/CD	dobj||identify-21/VB||patients-23/NNS	prep_with||identify-21/VB||type2diabetes-25/NNS	num||initiators-28/NNS||4,279-27/CD	dep||type2diabetes-25/NNS||initiators-28/NNS	prep_of||initiators-28/NNS||monotherapy-30/NN	prep_with||monotherapy-30/NN||glyburide-32/NN	num||initiators-35/NNS||4,325-34/CD	dep||type2diabetes-25/NNS||initiators-35/NNS	conj_and||initiators-28/NNS||initiators-35/NNS	prep_of||initiators-35/NNS||monotherapy-37/NN	prep_with||monotherapy-37/NN||glipizide-39/NN	num||initiators-43/NNS||2,537-42/CD	dep||type2diabetes-25/NNS||initiators-43/NNS	conj_and||initiators-28/NNS||initiators-43/NNS	prep_of||initiators-43/NNS||monotherapy-45/NN	prep_with||monotherapy-45/NN||glimepiride-47/NN	vmod||system-19/NN||â-50/VB	conj_and||identify-21/VB||â-50/VB	conj_and||identify-21/VB||â-50/VB	conj_and||â-50/VB||â-50/VB	nn||¥-52/NNP||-51/NNP	dobj||â-50/VB||¥-52/NNP	num||years-54/NNS||18-53/CD	npadvmod||¥-52/NNP||years-54/NNS	prep_of||¥-52/NNP||age-56/NN	det||history-61/NN||a-60/DT	prep_with||â-50/VB||history-61/NN	prep_without||â-50/VB||history-61/NN	prep_of||history-61/NN||coronaryarterydisease-63/NN	appos||history-61/NN||cad-65/NN	vmod||system-19/NN||not-68/RB	conj_and||identify-21/VB||not-68/RB	neg||identify-21/VB||not-68/RB	prep_on||not-68/RB||insulin-70/NN	det||noninsulin-73/NN||a-72/DT	prep_on||not-68/RB||noninsulin-73/NN	conj_or||insulin-70/NN||noninsulin-73/NN	vmod||system-19/NN||injectable-74/VB	conj_and||identify-21/VB||injectable-74/VB	prep_at||injectable-74/VB||baseline-76/NN	type2diabetes-25||glimepiride-47||yes||a retrospective cohort study was conducted using an academic health center enterprise-wide electronic health record (ehr) system to identify 11,141 patients with type2diabetes (4,279 initiators of monotherapy with glyburide, 4,325 initiators of monotherapy with glipizide, and 2,537 initiators of monotherapy with glimepiride), â¥18 years of age with and without a history of coronaryarterydisease (cad) and not on insulin or a noninsulin injectable at baseline.
num||weeks-3/NNS||16-2/CD	prep_at||â-9/NN||weeks-3/NNS	nn||hbp-6/NN||morning-5/NN	nsubj||â-9/NN||hbp-6/NN	cop||â-9/NN||was-7/VBD	num||â-9/NN||135.0-8/CD	root||ROOT-0/null||â-9/NN	num||13.7-11/CD||±-10/CD	dep||â-9/NN||13.7-11/CD	punct||13.7-11/CD||/-12/:	number||â-14/CD||78.8-13/CD	num||hg-23/NN||â-14/CD	nn||hg-23/NN||±-15/NNP	num||hg-23/NN||9.9-16/CD	amod||hg-23/NN||â-17/JJ	prep||â-17/JJ||$-18/$	number||mmâ-20/CD||-19/CD	num||$-18/$||mmâ-20/CD	dep||$-18/$||$-21/$	num||$-21/$||-22/CD	nsubj||â-29/NN||hg-23/NN	amod||hbp-26/NN||bedtime-25/JJ	conj_and||hg-23/NN||hbp-26/NN	nsubj||â-29/NN||hbp-26/NN	cop||â-29/NN||was-27/VBD	num||â-29/NN||129.7-28/CD	dep||13.7-11/CD||â-29/NN	number||13.8-31/CD||±-30/CD	dep||â-29/NN||13.8-31/CD	punct||â-34/NN||/-32/:	num||â-34/NN||74.7-33/CD	dep||â-29/NN||â-34/NN	vmod||â-34/NN||±-35/VBN	num||â-37/NNS||10.1-36/CD	iobj||±-35/VBN||â-37/NNS	num||â-37/NNS||$-38/$	number||mmâ-40/CD||-39/CD	num||$-38/$||mmâ-40/CD	dobj||±-35/VBN||$-41/$	num||$-41/$||-42/CD	advmod||$-41/$||hg-43/RB	mark||±-50/NNP||whereas-45/IN	nsubj||±-50/NNP||cbp-46/NN	cop||±-50/NNP||was-47/VBD	number||â-49/CD||135.6-48/CD	num||±-50/NNP||â-49/CD	advcl||±-35/VBN||±-50/NNP	num||±-50/NNP||15.4-51/CD	punct||â-34/NN||/-52/:	number||â-54/CD||77.6-53/CD	num||â-57/NN||â-54/CD	nn||â-57/NN||±-55/NNP	num||â-57/NN||10.9-56/CD	dep||â-29/NN||â-57/NN	num||$-61/$||$-58/$	number||mmâ-60/CD||-59/CD	num||$-58/$||mmâ-60/CD	dep||â-57/NN||$-61/$	number||hg-63/CD||-62/CD	num||$-61/$||hg-63/CD	hg-63||hbp-26||no_rel||at 16 weeks, morning hbp was 135.0â±13.7/78.8â±9.9âmmâhg and bedtime hbp was 129.7â±13.8/74.7â±10.1âmmâhg, whereas cbp was 135.6â±15.4/77.6â±10.9âmmâhg.
det||detections-3/NNS||the-1/DT	amod||detections-3/NNS||infrequent-2/JJ	nsubj||suggest-17/VBP||detections-3/NNS	det||viruses-6/NNS||these-5/DT	prep_of||detections-3/NNS||viruses-6/NNS	amod||samples-9/NNS||multiple-8/JJ	prep_in||viruses-6/NNS||samples-9/NNS	amod||individuals-12/NNS||immunosuppressed-11/JJ	prep_from||samples-9/NNS||individuals-12/NNS	prep_including||individuals-12/NNS||those-14/DT	prep_with||those-14/DT||pml-16/NN	root||ROOT-0/null||suggest-17/VBP	mark||different-24/JJ||that-18/IN	poss||mechanisms-21/NNS||their-19/PRP$	nn||mechanisms-21/NNS||reactivation-20/NN	nsubj||different-24/JJ||mechanisms-21/NNS	aux||different-24/JJ||may-22/MD	cop||different-24/JJ||be-23/VB	ccomp||suggest-17/VBP||different-24/JJ	prep_from||different-24/JJ||that-26/DT	prep_of||that-26/DT||jcpolyomavirus-28/NNS	appos||jcpolyomavirus-28/NNS||jcpyv-30/NNP	mark||play-37/VB||that-33/IN	nsubj||play-37/VB||they-34/PRP	aux||play-37/VB||do-35/VBP	neg||play-37/VB||not-36/RB	ccomp||suggest-17/VBP||play-37/VB	conj_and||different-24/JJ||play-37/VB	det||role-39/NN||a-38/DT	dobj||play-37/VB||role-39/NN	det||pathogenesis-42/NNS||the-41/DT	prep_in||play-37/VB||pathogenesis-42/NNS	prep_of||pathogenesis-42/NNS||pml-44/NN	pml-44||jcpolyomavirus-28||no||the infrequent detections of these viruses in multiple samples from immunosuppressed individuals including those with pml suggest that their reactivation mechanisms may be different from that of jcpolyomavirus (jcpyv) and that they do not play a role in the pathogenesis of pml.
det||infection-2/NN||the-1/DT	nsubjpass||associated-9/VBN||infection-2/NN	prep_of||infection-2/NN||cells-4/NNS	nn||viruses-7/NNS||rna-6/NN	prep_by||cells-4/NNS||viruses-7/NNS	auxpass||associated-9/VBN||is-8/VBZ	root||ROOT-0/null||associated-9/VBN	det||recognition-12/NN||the-11/DT	prep_with||associated-9/VBN||recognition-12/NN	nn||pamps-15/NNS||virus-14/NN	prep_of||recognition-12/NN||pamps-15/NNS	amod||patterns-19/NNS||pathogen-associated-17/JJ	amod||patterns-19/NNS||molecular-18/JJ	appos||pamps-15/NNS||patterns-19/NNS	det||production-23/NN||the-22/DT	prep_with||associated-9/VBN||production-23/NN	conj_and||recognition-12/NN||production-23/NN	nn||interferon-27/NN||type-25/FW	nn||interferon-27/NN||i-26/FW	prep_of||production-23/NN||interferon-27/NN	appos||interferon-27/NN||ifn-29/NN	virus-14||viruses-7||no||the infection of cells by rna viruses is associated with the recognition of virus pamps (pathogen-associated molecular patterns) and the production of type i interferon (ifn).
nsubj||conducted-5/VBD||we-1/PRP	advmod||conducted-5/VBD||therefore-3/RB	root||ROOT-0/null||conducted-5/VBD	det||evaluation-8/NN||a-6/DT	amod||evaluation-8/NN||comprehensive-7/JJ	dobj||conducted-5/VBD||evaluation-8/NN	advmod||resistant-11/JJ||inh-10/RB	amod||levels-54/NNS||resistant-11/JJ	amod||strains-13/NNS||m.tuberculosis-12/JJ	nn||n-15/NN||strains-13/NNS	amod||n-15/NN||-lrb--14/JJ	npadvmod||resistant-11/JJ||n-15/NN	dep||-rrb--18/NNS||=-16/SYM	num||-rrb--18/NNS||224-17/CD	dep||n-15/NN||-rrb--18/NNS	npadvmod||south-21/RB||three-20/CD	advmod||countries-23/NNS||south-21/RB	amod||countries-23/NNS||american-22/JJ	prep_from||resistant-11/JJ||countries-23/NNS	amod||burden-26/NN||high-25/JJ	prep_with||resistant-11/JJ||burden-26/NN	prep_of||burden-26/NN||drug-28/NN	amod||levels-54/NNS||resistant-29/JJ	advmod||resistant-29/JJ||tb-30/RB	aux||characterize-32/VB||to-31/TO	xcomp||resistant-29/JJ||characterize-32/VB	dobj||characterize-32/VB||mutations-33/NNS	nn||g-36/NN||kat-35/NN	prep_in||characterize-32/VB||g-36/NN	xcomp||resistant-29/JJ||ahp-38/VB	conj_and||characterize-32/VB||ahp-38/VB	dep||ahp-38/VB||c-39/SYM	xcomp||resistant-29/JJ||inh-41/VB	conj_and||characterize-32/VB||inh-41/VB	det||loci-44/NN||a-42/DT	nn||loci-44/NN||gene-43/NN	dobj||inh-41/VB||loci-44/NN	conj_and||characterize-32/VB||correlate-46/VB	conj_and||inh-41/VB||correlate-46/VB	amod||concentrations-50/NNS||minimal-48/JJ	nn||concentrations-50/NNS||inhibitory-49/NN	prep_with||correlate-46/VB||concentrations-50/NNS	amod||levels-54/NNS||-lrb--51/JJ	amod||levels-54/NNS||mic-52/JJ	nn||levels-54/NNS||-rrb--53/NN	prep_of||evaluation-8/NN||levels-54/NNS	amod||family-58/NN||spoligotype-56/JJ	nn||family-58/NN||strain-57/NN	prep_of||evaluation-8/NN||family-58/NN	conj_and||levels-54/NNS||family-58/NN	tb-30||inh-41||yes||we , therefore , conducted a comprehensive evaluation of inh resistant m.tuberculosis strains -lrb- n = 224 -rrb- from three south american countries with high burden of drug resistant tb to characterize mutations in kat g , ahp c and inh a gene loci and correlate with minimal inhibitory concentrations -lrb- mic -rrb- levels and spoligotype strain family .
nsubj||control-57/VBP||aims-1/NNS	aux||compare-3/VB||to-2/TO	vmod||aims-1/NNS||compare-3/VB	num||approaches-6/NNS||two-4/CD	amod||approaches-6/NNS||progressive-5/JJ	dobj||compare-3/VB||approaches-6/NNS	iobj||compare-3/VB||approaches-6/NNS	amod||insulinglargine-9/NN||-lsb--7/JJ	amod||insulinglargine-9/NN||once-daily-8/JJ	dep||approaches-6/NNS||insulinglargine-9/NN	amod||approaches-6/NNS||plus-10/IN	nn||+-19/NNS||â-11/NNP	nn||+-19/NNS||-12/NNP	amod||+-19/NNS||$-13/$	number||$-13/$||3-14/CD	dep||$-13/$||mealtime-15/JJ	amod||+-19/NNS||lispro-16/JJ	amod||+-19/NNS||-lrb--17/JJ	nn||+-19/NNS||g-18/NN	dep||approaches-6/NNS||+-19/NNS	nn||-rrb--21/NNP||l-20/NNP	dep||+-19/NNS||-rrb--21/NNP	nn||-rrb--28/NNP||insulinlispro-23/NN	nn||-rrb--28/NNP||mix-24/NN	nn||-rrb--28/NNP||50/50-25/NNP	nn||-rrb--28/NNP||-lrb--26/NNP	nn||-rrb--28/NNP||lm50/50-27/NNPS	prep_vs.||-rrb--21/NNP||-rrb--28/NNP	dep||-rrb--21/NNP||progression-29/VBN	advmod||up-31/RB||once-30/RB	advmod||progression-29/VBN||up-31/RB	aux||thrice-33/VB||to-32/TO	xcomp||progression-29/VBN||thrice-33/VB	amod||progression-37/NN||daily-34/JJ	amod||progression-37/NN||-lrb--35/JJ	nn||progression-37/NN||premix-36/NN	dobj||thrice-33/VB||progression-37/NN	nn||-rsb--41/NNP||pp-39/NNP	nn||-rsb--41/NNP||-rrb--40/NNP	appos||progression-37/NN||-rsb--41/NNP	prepc_of||-rsb--41/NNP||beginning-43/VBG	prepc_of||-rsb--41/NNP||advancing-45/VBG	conj_and||beginning-43/VBG||advancing-45/VBG	dobj||beginning-43/VBG||insulin-46/NN	prep_in||beginning-43/VBG||patients-48/NNS	amod||-rrb--53/NNS||type2diabetes-50/JJ	amod||-rrb--53/NNS||-lrb--51/JJ	amod||-rrb--53/NNS||t2d-52/JJ	prep_with||patients-48/NNS||-rrb--53/NNS	amod||glycaemic-56/JJ||inadequate-55/JJ	dep||-rrb--21/NNP||glycaemic-56/JJ	conj_and||progression-29/VBN||glycaemic-56/JJ	root||ROOT-0/null||control-57/VBP	amod||therapy-60/NN||oral-59/JJ	prep_on||control-57/VBP||therapy-60/NN	det||aim-64/NN||the-63/DT	prep_with||control-57/VBP||aim-64/NN	prepc_of||aim-64/NN||showing-66/VBG	dobj||showing-66/VBG||non-inferiority-67/NN	prep_of||non-inferiority-67/NN||pp-69/NN	prep_to||showing-66/VBG||g-71/NN	amod||l-73/NN||+-72/JJ	dobj||control-57/VBP||l-73/NN	type2diabetes-50||insulin-46||yes||aims to compare two progressive approaches -lsb- once-daily insulinglargine plus â  $ 3 mealtime lispro -lrb- g+l -rrb- vs. insulinlispro mix 50/50 -lrb- lm50/50 -rrb- progression once up to thrice daily -lrb- premix progression , pp -rrb- -rsb- of beginning and advancing insulin in patients with type2diabetes -lrb- t2d -rrb- and inadequate glycaemic control on oral therapy , with the aim of showing non-inferiority of pp to g+l .
nsubj||assessed-2/VBD||we-1/PRP	root||ROOT-0/null||assessed-2/VBD	nsubj||enrolled-7/VBD||nvp-resistance-3/NN	nn||infants-6/NNS||indian-5/NN	prep_in||nvp-resistance-3/NN||infants-6/NNS	dep||assessed-2/VBD||enrolled-7/VBD	det||transmission-34/NN||the-9/DT	amod||transmission-34/NN||â-10/JJ	amod||transmission-34/NN||$-11/$	dep||$-11/$||six-week-12/JJ	nn||transmission-34/NN||extended-dose-13/NN	dep||$-15/$||nevirapineâ-14/RB	dep||transmission-34/NN||$-15/$	amod||trial-19/NN||swen-17/JJ	npadvmod||of-31/RB||trial-19/NN	npadvmod||nvp-23/JJ||who-20/WP	npadvmod||single-dose-22/JJ||received-21/JJ	amod||who-20/WP||single-dose-22/JJ	advmod||trial-19/NN||nvp-23/JJ	dep||nvp-23/JJ||sd-nvp-25/NN	advmod||trial-19/NN||swen-28/JJ	conj_or||nvp-23/JJ||swen-28/JJ	prep_for||nvp-23/JJ||prevention-30/NN	dep||breast-milk-32/CD||of-31/RB	num||$-15/$||breast-milk-32/CD	amod||transmission-34/NN||hiv-33/JJ	prep_in||enrolled-7/VBD||transmission-34/NN	nsubj||acquired-38/VBD||who-36/WP	advmod||acquired-38/VBD||also-37/RB	dep||assessed-2/VBD||acquired-38/VBD	conj_but||enrolled-7/VBD||acquired-38/VBD	amod||hivinfection-41/NN||subtype-39/JJ	nn||hivinfection-41/NN||c-40/NN	dobj||acquired-38/VBD||hivinfection-41/NN	det||year-45/NN||the-43/DT	amod||year-45/NN||first-44/JJ	prep_during||acquired-38/VBD||year-45/NN	prep_of||year-45/NN||life-47/NN	hivinfection-41||nvp-23||yes||we assessed nvp-resistance in indian infants enrolled in the âsix-week extended-dose nevirapineâ? (swen) trial who received single-dose nvp (sd-nvp) or swen for prevention of breast-milk hiv transmission but who also acquired subtype c hivinfection during the first year of life.
nn||samples-2/NNS||dna-1/NN	nsubjpass||analyzed-9/VBN||samples-2/NNS	amod||samples-2/NNS||positive-3/JJ	amod||complex-6/NN||m.tuberculosis-5/JJ	prep_for||positive-3/JJ||complex-6/NN	auxpass||analyzed-9/VBN||were-7/VBD	advmod||analyzed-9/VBN||further-8/RBR	ccomp||innogenetics-20/VBZ||analyzed-9/VBN	nn||probe-14/NN||pcr-11/NN	conj_and||pcr-11/NN||line-13/NN	nn||probe-14/NN||line-13/NN	agent||analyzed-9/VBN||probe-14/NN	advmod||-lrb--16/VBG||assay-15/RB	vmod||probe-14/NN||-lrb--16/VBG	amod||rif.tb-18/NN||inno-lipa-17/JJ	dobj||-lrb--16/VBG||rif.tb-18/NN	root||ROOT-0/null||innogenetics-20/VBZ	nn||-rrb--26/NN||nv-21/NN	dep||-rrb--26/NN||gent-23/NN	dep||-rrb--26/NN||belgium-25/NN	dobj||innogenetics-20/VBZ||-rrb--26/NN	aux||detect-28/VB||to-27/TO	vmod||innogenetics-20/VBZ||detect-28/VB	dobj||detect-28/VB||mutations-29/NNS	det||rpo-32/NN||the-31/DT	prep_in||mutations-29/NNS||rpo-32/NN	dep||mutations-29/NNS||b-33/SYM	nsubj||innogenetics-20/VBZ||gene-34/NN	vmod||gene-34/NN||associated-35/VBN	nn||resistance-38/NN||rifampicin-37/NN	prep_with||associated-35/VBN||resistance-38/NN	tb--1||m.tuberculosis-5||no||dna samples positive for m.tuberculosis complex were further analyzed by pcr and line probe assay -lrb- inno-lipa rif.tb , innogenetics nv , gent , belgium -rrb- to detect mutations in the rpo b gene associated with rifampicin resistance .
amod||transition-2/NN||sustained-1/JJ	nsubjpass||achieved-16/VBN||transition-2/NN	det||antigen-8/NN||the-4/DT	amod||antigen-8/NN||inactive-5/JJ	nn||antigen-8/NN||hepatitisb-6/NN	nn||antigen-8/NN||surface-7/NN	prep_to||transition-2/NN||antigen-8/NN	dep||transition-2/NN||hbsag-10/VBG	nn||state-13/NN||carrier-12/NN	dep||transition-2/NN||state-13/NN	aux||achieved-16/VBN||can-14/MD	auxpass||achieved-16/VBN||be-15/VB	root||ROOT-0/null||achieved-16/VBN	quantmod||30-19/CD||about-18/RB	num||%-20/NN||30-19/CD	prep_in||achieved-16/VBN||%-20/NN	amod||patients-38/NNS||hepatitisb-22/JJ	dep||â-28/VBP||e-23/SYM	nsubj||â-28/VBP||antigen-24/NN	appos||antigen-24/NN||hbeag-26/NN	ccomp||hepatitisb-22/JJ||â-28/VBP	dobj||â-28/VBP||$-29/$	advmod||of-36/IN||positive-31/RB	num||%-35/NN||patients-32/CD	conj_and||patients-32/CD||20-34/CD	num||%-35/NN||20-34/CD	npadvmod||of-36/IN||%-35/NN	dep||hbeag-negative-37/CD||of-36/IN	num||$-29/$||hbeag-negative-37/CD	prep_of||%-20/NN||patients-38/NNS	hepatitisb-22||hepatitisbsurfaceantigen--1||yes||sustained transition to the inactive hepatitisb surface antigen (hbsag) carrier state can be achieved in about 30% of hepatitisb e antigen (hbeag)âpositive patients and 20% of hbeag-negative patients.
nsubj||applied-2/VBD||we-1/PRP	root||ROOT-0/null||applied-2/VBD	amod||principles-5/NNS||fuzzy-3/JJ	nn||principles-5/NNS||logic-4/NN	dobj||applied-2/VBD||principles-5/NNS	aux||modify-7/VB||to-6/TO	vmod||applied-2/VBD||modify-7/VB	amod||rates-14/NNS||intravenous-8/JJ	amod||rates-14/NNS||norepinephrine-9/JJ	appos||rates-14/NNS||noradrenaline-11/NN	nn||rates-14/NNS||infusion-13/NN	dobj||modify-7/VB||rates-14/NNS	amod||infusion-17/NN||norepinephrine-16/JJ	prep_during||rates-14/NNS||infusion-17/NN	amod||patients-20/NNS||septic-19/JJ	prep_in||modify-7/VB||patients-20/NNS	mark||reduce-24/VB||in-21/IN	dep||reduce-24/VB||order-22/NN	aux||reduce-24/VB||to-23/TO	advcl||modify-7/VB||reduce-24/VB	det||duration-26/NN||the-25/DT	dobj||reduce-24/VB||duration-26/NN	prep_of||duration-26/NN||shock-28/NN	shock-28||noradrenaline-11||yes||we applied fuzzy logic principles to modify intravenous norepinephrine (noradrenaline) infusion rates during norepinephrine infusion in septic patients in order to reduce the duration of shock.
nsubj||â-2/VBP||conclusions-1/NNS	root||ROOT-0/null||â-2/VBP	dobj||â-2/VBP||$-3/$	nsubj||found-6/VBD||we-5/PRP	rcmod||$-3/$||found-6/VBD	det||association-9/NN||a-7/DT	amod||association-9/NN||close-8/JJ	dobj||found-6/VBD||association-9/NN	nsubjpass||reduced-21/VBN||association-9/NN	amod||metabolism-12/NN||carbohydrate-11/JJ	prep_between||association-9/NN||metabolism-12/NN	nn||antibodies-16/NNS||igm-14/NN	nn||antibodies-16/NNS||anti-oxldl-15/NN	prep_between||association-9/NN||antibodies-16/NNS	conj_and||metabolism-12/NN||antibodies-16/NNS	auxpass||reduced-21/VBN||were-19/VBD	advmod||reduced-21/VBN||significantly-20/RB	rcmod||association-9/NN||reduced-21/VBN	det||patients-26/NNS||the-23/DT	advmod||obese-25/JJ||morbidly-24/RB	amod||patients-26/NNS||obese-25/JJ	prep_in||reduced-21/VBN||patients-26/NNS	prep_with||patients-26/NNS||diabetes-28/NN	obese-25||antibodies-16||no_rel||conclusions âwe found a close association between carbohydrate metabolism and igm anti-oxldl antibodies, which were significantly reduced in the morbidly obese patients with diabetes.
nn||ifn-2/NNP||alpha-1/NNP	nsubj||studied-6/NN||ifn-2/NNP	cop||studied-6/NN||is-3/VBZ	det||studied-6/NN||the-4/DT	amod||studied-6/NN||best-5/JJS	root||ROOT-0/null||studied-6/NN	nn||activity-9/NN||displays-8/NNS	conj_and||studied-6/NN||activity-9/NN	amod||diseases-13/NNS||many-11/JJ	amod||diseases-13/NNS||neoplastic-12/JJ	prep_in||studied-6/NN||diseases-13/NNS	nsubj||shown-17/VBN||it-15/PRP	aux||shown-17/VBN||has-16/VBZ	parataxis||studied-6/NN||shown-17/VBN	det||promise-20/NN||the-18/DT	amod||promise-20/NN||most-19/JJS	dobj||shown-17/VBN||promise-20/NN	det||cancers-24/NNS||the-22/DT	amod||cancers-24/NNS||hematological-23/JJ	prep_in||promise-20/NN||cancers-24/NNS	mark||respond-41/VB||although-25/IN	amod||tumors-28/NNS||several-26/JJ	amod||tumors-28/NNS||solid-27/JJ	nsubj||respond-41/VB||tumors-28/NNS	nn||kaposi-32/NNS||epidemic-31/NN	prep_including||tumors-28/NNS||kaposi-32/NNS	dep||kaposi-32/NNS||ssarcoma-34/NN	dep||kaposi-32/NNS||renalcellcarcinoma-36/NN	conj_and||ssarcoma-34/NN||renalcellcarcinoma-36/NN	dep||kaposi-32/NNS||melanoma-39/NN	conj_and||ssarcoma-34/NN||melanoma-39/NN	advcl||shown-17/VBN||respond-41/VB	renalcellcarcinoma-36||ifn-2||yes||alpha ifn is the best studied and displays activity in many neoplastic diseases; it has shown the most promise in the hematological cancers although several solid tumors, including epidemic kaposi'ssarcoma, renalcellcarcinoma, and melanoma, respond.
amod||receptors-2/NNS||nuclear-1/JJ	nsubj||proteins-15/NNS||receptors-2/NNS	appos||receptors-2/NNS||nrs-4/NN	nn||kinases-9/NNS||receptor-7/NN	nn||kinases-9/NNS||tyrosine-8/NN	conj_and||receptors-2/NNS||kinases-9/NNS	nsubj||proteins-15/NNS||kinases-9/NNS	appos||kinases-9/NNS||rtks-11/NNS	cop||proteins-15/NNS||are-13/VBP	amod||proteins-15/NNS||essential-14/JJ	root||ROOT-0/null||proteins-15/NNS	amod||processes-19/NNS||many-17/JJ	amod||processes-19/NNS||cellular-18/JJ	prep_in||proteins-15/NNS||processes-19/NNS	nn||variations-22/NNS||sequence-21/NN	nsubjpass||reported-28/VBN||variations-22/NNS	nsubjpass||involved-31/VBN||variations-22/NNS	poss||genes-25/NNS||their-24/PRP$	prep_in||variations-22/NNS||genes-25/NNS	aux||reported-28/VBN||have-26/VBP	auxpass||reported-28/VBN||been-27/VBN	conj_and||proteins-15/NNS||reported-28/VBN	aux||involved-31/VBN||to-29/TO	auxpass||involved-31/VBN||be-30/VB	xcomp||reported-28/VBN||involved-31/VBN	amod||diseases-34/NNS||many-33/JJ	prep_in||involved-31/VBN||diseases-34/NNS	prep_including||diseases-34/NNS||cancer-36/NN	cancer-36||tyrosine-8||no_rel||nuclear receptors (nrs) and receptor tyrosine kinases (rtks) are essential proteins in many cellular processes and sequence variations in their genes have been reported to be involved in many diseases including cancer.
det||proportion-2/NN||the-1/DT	nsubj||increased-14/VBD||proportion-2/NN	prep_of||proportion-2/NN||spouses-4/NNS	advmod||reported-7/VBN||newly-6/RB	amod||cases-9/NNS||reported-7/VBN	amod||cases-9/NNS||hiv/aids-8/JJ	prep_of||spouses-4/NNS||cases-9/NNS	auxpass||tested-11/VBN||being-10/VBG	vmod||cases-9/NNS||tested-11/VBN	prep_for||tested-11/VBN||hiv-13/NN	root||ROOT-0/null||increased-14/VBD	number||63.4-18/CD||24.7-16/CD	dep||63.4-18/CD||to-17/TO	num||%-19/NN||63.4-18/CD	prep_from||increased-14/VBD||%-19/NN	appos||%-19/NN||p-21/NNP	number||0.001-23/CD||<-22/CD	num||p-21/NNP||0.001-23/CD	aids--1||hiv-13||no||the proportion of spouses of newly reported hiv/aids cases being tested for hiv increased from 24.7 to 63.4% ( p < 0.001).
nsubj||problem-5/NN||hiv/aids-1/NNS	cop||problem-5/NN||is-2/VBZ	det||problem-5/NN||the-3/DT	amod||problem-5/NN||major-4/JJ	root||ROOT-0/null||problem-5/NN	det||obstacle-8/NN||an-7/DT	conj_and||problem-5/NN||obstacle-8/NN	preconj||health-12/NN||both-10/PDT	det||health-12/NN||the-11/DT	prep_to||obstacle-8/NN||health-12/NN	prep_to||obstacle-8/NN||development-14/NN	conj_and||health-12/NN||development-14/NN	prep_of||obstacle-8/NN||people-16/NNS	nn||today-19/NN||ethiopia-18/NN	prep_in||people-16/NNS||today-19/NN	aids--1||hiv--1||no||hiv/aids is the major problem and an obstacle to both the health and development of people in ethiopia today.
nsubj||oncogene-6/NN||lmp1-1/NNS	cop||oncogene-6/NN||is-2/VBZ	det||oncogene-6/NN||the-3/DT	nn||oncogene-6/NN||tumour-4/NN	amod||oncogene-6/NN||predisposing-5/VBG	root||ROOT-0/null||oncogene-6/NN	nsubj||give-16/VBP||oncogene-6/NN	num||series-10/NN||two-8/CD	amod||series-10/NN||different-9/JJ	prep_in||oncogene-6/NN||series-10/NN	amod||mice-13/NNS||transgenic-12/JJ	prep_of||series-10/NN||mice-13/NNS	advmod||give-16/VBP||separately-15/RB	rcmod||oncogene-6/NN||give-16/VBP	dobj||give-16/VBP||rise-17/NN	preconj||b-celllymphomas-20/NNS||either-19/CC	prep_to||give-16/VBP||b-celllymphomas-20/NNS	prep_to||give-16/VBP||carcinomas-22/NNS	conj_or||b-celllymphomas-20/NNS||carcinomas-22/NNS	rise-17||carcinomas-22||no_rel||lmp1 is the tumour predisposing oncogene in two different series of transgenic mice which separately give rise to either b-celllymphomas or carcinomas.
nsubj||bacterium-9/NN||orientiatsutsugamushi-1/NNS	nsubj||tsutsugamushidisease-24/VBD||orientiatsutsugamushi-1/NNS	appos||orientiatsutsugamushi-1/NNS||ot-3/NN	cop||bacterium-9/NN||is-5/VBZ	det||bacterium-9/NN||an-6/DT	amod||bacterium-9/NN||obligate-7/JJ	nn||bacterium-9/NN||intracellular-8/NN	root||ROOT-0/null||bacterium-9/NN	xcomp||bacterium-9/NN||belonging-10/VBG	det||rickettsiaceae-14/NN||the-12/DT	nn||rickettsiaceae-14/NN||family-13/NN	prep_to||belonging-10/VBG||rickettsiaceae-14/NN	cop||agent-19/NN||is-16/VBZ	det||agent-19/NN||the-17/DT	amod||agent-19/NN||causative-18/JJ	conj_and||bacterium-9/NN||agent-19/NN	prep_of||agent-19/NN||scrubtyphus-21/NNS	conj_or||bacterium-9/NN||tsutsugamushidisease-24/VBD	scrubtyphus-21||orientiatsutsugamushi-1||no||orientiatsutsugamushi (ot) is an obligate intracellular bacterium belonging to the family rickettsiaceae and is the causative agent of scrubtyphus, or tsutsugamushidisease.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||effects-4/NNS||the-3/DT	iobj||evaluated-2/VBN||effects-4/NNS	det||therapy-8/NN||a-6/DT	amod||therapy-8/NN||combined-7/JJ	prep_of||effects-4/NNS||therapy-8/NN	amod||âµg-18/NN||budesonide-10/JJ	dep||budesonide-10/JJ||200-11/CD	nn||âµg-18/NN||âµg-12/NN	advmod||daily-14/RB||twice-13/RB	advmod||âµg-18/NN||daily-14/RB	conj_and||daily-14/RB||formoterol-16/JJ	advmod||âµg-18/NN||formoterol-16/JJ	dep||formoterol-16/JJ||6-17/CD	prep_of||therapy-8/NN||âµg-18/NN	advmod||daily-20/RB||twice-19/RB	dobj||evaluated-2/VBN||daily-20/RB	prepc_compared_with||evaluated-2/VBN||with-22/IN	amod||âµg-25/NN||budesonide-23/JJ	dep||budesonide-23/JJ||200-24/CD	pobj||evaluated-2/VBN||âµg-25/NN	advmod||âµg-25/NN||twice-26/RB	advmod||alone-28/RB||daily-27/RB	pobj||twice-26/RB||alone-28/RB	nn||questionnaire-32/NN||asthma-30/NN	nn||questionnaire-32/NN||control-31/NN	prep_on||twice-26/RB||questionnaire-32/NN	appos||questionnaire-32/NN||acq-34/NN	nn||quality-38/NN||asthma-37/NN	appos||questionnaire-32/NN||quality-38/NN	nn||questionnaire-41/NN||life-40/NN	prep_of||quality-38/NN||questionnaire-41/NN	appos||quality-38/NN||aqlq-43/NNP	dep||aqlq-43/NNP||juniper-45/NN	amod||function-49/NN||pulmonary-48/JJ	appos||questionnaire-32/NN||function-49/NN	conj_and||quality-38/NN||function-49/NN	amod||inflammation-52/NN||airway-51/JJ	appos||questionnaire-32/NN||inflammation-52/NN	conj_and||quality-38/NN||inflammation-52/NN	det||study-59/NN||a-55/DT	amod||study-59/NN||cross-over-56/JJ	amod||study-59/NN||randomized-57/JJ	amod||study-59/NN||double-blind-58/JJ	prep_in||evaluated-2/VBN||study-59/NN	nn||periods-62/NNS||treatment-61/NN	prep_with||study-59/NN||periods-62/NNS	num||months-65/NNS||two-64/CD	prep_of||periods-62/NNS||months-65/NNS	vmod||months-65/NNS||separated-66/VBN	det||period-71/NN||a-68/DT	amod||period-71/NN||one-month-69/JJ	amod||period-71/NN||wash-out-70/JJ	agent||separated-66/VBN||period-71/NN	asthma-37||budesonide-23||no||we evaluated the effects of a combined therapy of budesonide 200 âµg twice daily and formoterol 6 âµg twice daily compared with budesonide 200 âµg twice daily alone on asthma control questionnaire (acq), asthma quality of life questionnaire (aqlq- juniper), pulmonary function and airway inflammation, in a cross-over randomized double-blind study with treatment periods of two months separated by a one-month wash-out period.
det||study-2/NN||this-1/DT	nsubj||shows-3/VBZ||study-2/NN	root||ROOT-0/null||shows-3/VBZ	mark||are-36/VBP||that-4/IN	advmod||established-9/VBN||when-5/WRB	det||collaboration-7/NN||a-6/DT	nsubjpass||established-9/VBN||collaboration-7/NN	nsubj||strengthen-11/VB||collaboration-7/NN	auxpass||established-9/VBN||is-8/VBZ	advcl||are-36/VBP||established-9/VBN	aux||strengthen-11/VB||to-10/TO	xcomp||established-9/VBN||strengthen-11/VB	amod||systems-14/NNS||existing-12/JJ	nn||systems-14/NNS||health-13/NN	dobj||strengthen-11/VB||systems-14/NNS	prepc_in_addition_to||established-9/VBN||providing-19/VBG	amod||services-21/NNS||hiv/aids-20/JJ	dobj||providing-19/VBG||services-21/NNS	det||setting-24/NN||a-23/DT	prep_in||providing-19/VBG||setting-24/NN	prep_in||delivered-33/VBN||setting-24/NN	amod||care-30/NN||other-27/JJ	amod||care-30/NN||primary-28/JJ	nn||care-30/NN||health-29/NN	nsubjpass||delivered-33/VBN||care-30/NN	aux||delivered-33/VBN||is-31/VBZ	auxpass||delivered-33/VBN||being-32/VBG	rcmod||setting-24/NN||delivered-33/VBN	expl||are-36/VBP||there-35/EX	ccomp||shows-3/VBZ||are-36/VBP	amod||effects-38/NNS||positive-37/JJ	nsubj||are-36/VBP||effects-38/NNS	neg||only-40/JJ||not-39/RB	preconj||are-36/VBP||only-40/JJ	amod||services-43/NNS||hiv/aids-42/JJ	prep_on||are-36/VBP||services-43/NNS	amod||services-51/NNS||many-48/JJ	amod||services-51/NNS||other-49/JJ	amod||services-51/NNS||essential-50/JJ	prep_on||are-36/VBP||services-51/NNS	conj_and||services-43/NNS||services-51/NNS	aids--1||hiv--1||no||this study shows that when a collaboration is established to strengthen existing health systems, in addition to providing hiv/aids services in a setting in which other primary health care is being delivered, there are positive effects not only on hiv/aids services, but also on many other essential services.
amod||changes-2/NNS||possible-1/JJ	nsubjpass||compared-11/VBN||changes-2/NNS	nsubjpass||compared-11/VBN||changes-2/NNS	nn||patterns-5/NNS||protein-4/NN	prep_of||changes-2/NNS||patterns-5/NNS	amod||tb-8/NN||active-7/JJ	prep_in||patterns-5/NNS||tb-8/NN	auxpass||compared-11/VBN||were-9/VBD	advmod||compared-11/VBN||also-10/RB	root||ROOT-0/null||compared-11/VBN	conj_and||compared-11/VBN||compared-11/VBN	amod||vivo-13/NN||ex-12/JJ	dobj||compared-11/VBN||vivo-13/NN	amod||samples-17/NNS||whole-15/JJ	nn||samples-17/NNS||blood-16/NN	prep_between||compared-11/VBN||samples-17/NNS	vmod||samples-17/NNS||incubated-18/VBN	prep_with||incubated-18/VBN||mycobacteriumtuberculosis-20/NNS	appos||samples-17/NNS||mtb-22/NN	amod||antigens-26/NNS||specific-25/JJ	dep||samples-17/NNS||antigens-26/NNS	dep||antigens-26/NNS||stimulated-28/VBN	dobj||stimulated-28/VBN||condition-29/NN	amod||conditions-34/NNS||unstimulated-33/JJ	prep_under||compared-11/VBN||conditions-34/NNS	tb-8||mtb-22||no||possible changes of protein patterns in active tb were also compared ex vivo between whole blood samples incubated with mycobacteriumtuberculosis ( mtb )-specific antigens (stimulated condition) and under unstimulated conditions.
det||group-4/NN||the-2/DT	amod||group-4/NN||met-anov-3/JJ	prep_in||observed-10/VBN||group-4/NN	neg||correlation-8/NN||no-6/DT	amod||correlation-8/NN||significant-7/JJ	nsubjpass||observed-10/VBN||correlation-8/NN	auxpass||observed-10/VBN||was-9/VBD	root||ROOT-0/null||observed-10/VBN	nn||concentrations-13/NNS||amh-12/NN	prep_between||observed-10/VBN||concentrations-13/NNS	det||fluid-17/NN||the-15/DT	nn||fluid-17/NN||follicular-16/NN	prep_in||concentrations-13/NNS||fluid-17/NN	prep_in||concentrations-13/NNS||variation-19/NN	conj_and||fluid-17/NN||variation-19/NN	nn||androgens-22/NNS||serum-21/NN	prep_in||fluid-17/NN||androgens-22/NNS	amod||indexes-27/NNS||amh-24/JJ	conj_and||amh-24/JJ||insulinresistance-26/JJ	amod||indexes-27/NNS||insulinresistance-26/JJ	appos||fluid-17/NN||indexes-27/NNS	mark||detected-36/VBN||whereas-29/IN	amod||group-32/NN||met-ov-31/JJ	prep_in||detected-36/VBN||group-32/NN	amod||correlations-34/NNS||significant-33/JJ	nsubjpass||detected-36/VBN||correlations-34/NNS	auxpass||detected-36/VBN||were-35/VBD	advcl||observed-10/VBN||detected-36/VBN	nn||levels-39/NNS||amh-38/NN	prep_between||detected-36/VBN||levels-39/NNS	det||fluid-43/NN||the-41/DT	nn||fluid-43/NN||follicular-42/NN	prep_in||levels-39/NNS||fluid-43/NN	prep_in||levels-39/NNS||variation-45/NN	conj_and||fluid-43/NN||variation-45/NN	amod||indexes-53/NNS||serum-47/JJ	nn||indexes-53/NNS||androgens-48/NNS	conj_and||androgens-48/NNS||amh-50/NN	nn||indexes-53/NNS||amh-50/NN	conj_and||androgens-48/NNS||insulinresistance-52/NN	nn||indexes-53/NNS||insulinresistance-52/NN	prep_in||fluid-43/NN||indexes-53/NNS	androgens-48||insulinresistance-52||no_rel||in the met-anov group, no significant correlation was observed between amh concentrations in the follicular fluid and variation in serum androgens, amh and insulinresistance indexes; whereas in met-ov group significant correlations were detected between amh levels in the follicular fluid and variation in serum androgens, amh and insulinresistance indexes.
nsubj||agent-5/NN||chlamydiapsittaci-1/NNS	cop||agent-5/NN||is-2/VBZ	det||agent-5/NN||the-3/DT	amod||agent-5/NN||etiological-4/JJ	root||ROOT-0/null||agent-5/NN	prep_of||agent-5/NN||psittacosis-7/NNS	cop||pathogen-12/NN||is-9/VBZ	det||pathogen-12/NN||a-10/DT	amod||pathogen-12/NN||zoonotic-11/JJ	conj_and||agent-5/NN||pathogen-12/NN	xcomp||pathogen-12/NN||infecting-13/VBG	dobj||infecting-13/VBG||birds-14/NNS	det||variety-17/NN||a-16/DT	dobj||infecting-13/VBG||variety-17/NN	conj_and||birds-14/NNS||variety-17/NN	amod||hosts-20/NNS||mammalian-19/JJ	prep_of||variety-17/NN||hosts-20/NNS	psittacosis-7||chlamydiapsittaci-1||no||chlamydiapsittaci is the etiological agent of psittacosis and is a zoonotic pathogen infecting birds and a variety of mammalian hosts.
nsubj||changed-5/VBD||duration-1/NN	nn||secretion-4/NN||melatonin-3/NN	prep_of||duration-1/NN||secretion-4/NN	root||ROOT-0/null||changed-5/VBD	prep_in||changed-5/VBD||response-7/NN	prep_to||changed-5/VBD||stroke-9/NN	det||change-13/NN||this-12/DT	nsubjpass||determined-16/VBN||change-13/NN	auxpass||determined-16/VBN||was-14/VBD	advmod||determined-16/VBN||strongly-15/RB	conj_and||changed-5/VBD||determined-16/VBN	det||shift-19/NN||the-18/DT	agent||determined-16/VBN||shift-19/NN	amod||time-23/NN||melatonin-21/JJ	nn||time-23/NN||onset-22/NN	prep_in||shift-19/NN||time-23/NN	melatonin-21||stroke-9||no_rel||duration of melatonin secretion changed in response to stroke, and this change was strongly determined by the shift in melatonin onset time.
det||ability-2/NN||the-1/DT	nsubj||important-10/JJ||ability-2/NN	aux||give-4/VB||to-3/TO	vmod||ability-2/NN||give-4/VB	amod||doses-6/NNS||high-5/JJ	dobj||give-4/VB||doses-6/NNS	prep_of||doses-6/NNS||iron-8/NN	cop||important-10/JJ||is-9/VBZ	root||ROOT-0/null||important-10/JJ	det||context-13/NN||the-12/DT	prep_in||important-10/JJ||context-13/NN	amod||irondeficiencyanemia-16/NN||managing-15/VBG	prep_of||context-13/NN||irondeficiencyanemia-16/NN	det||number-19/NN||a-18/DT	prep_in||irondeficiencyanemia-16/NN||number-19/NN	amod||conditions-22/NNS||clinical-21/JJ	prep_of||number-19/NN||conditions-22/NNS	advmod||high-28/JJ||where-23/WRB	nsubj||high-28/JJ||demands-24/NNS	prep_for||demands-24/NNS||iron-26/NN	cop||high-28/JJ||are-27/VBP	rcmod||irondeficiencyanemia-16/NN||high-28/JJ	dep||important-10/JJ||including-30/VBG	amod||bloodloss-32/NNS||chronic-31/JJ	pobj||including-30/VBG||bloodloss-32/NNS	vmod||bloodloss-32/NNS||associated-33/VBN	nn||menorrhagia-37/NN||inflammatoryboweldisease-35/NN	prep_with||associated-33/VBN||menorrhagia-37/NN	nn||kidneydisease-41/NN||chronic-40/NN	prep_with||associated-33/VBN||kidneydisease-41/NN	conj_and||menorrhagia-37/NN||kidneydisease-41/NN	irondeficiencyanemia-16||iron-26||yes||the ability to give high doses of iron is important in the context of managing irondeficiencyanemia in a number of clinical conditions where demands for iron are high (including chronic bloodloss associated with inflammatoryboweldisease, menorrhagia, and chronic kidneydisease).
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	det||efficacy-5/NN||the-3/DT	amod||efficacy-5/NN||long-term-4/JJ	dobj||evaluate-2/VB||efficacy-5/NN	dobj||evaluate-2/VB||safety-7/NN	conj_and||efficacy-5/NN||safety-7/NN	num||combinations-13/NNS||3-9/CD	advmod||available-11/JJ||commercially-10/RB	amod||combinations-13/NNS||available-11/JJ	amod||combinations-13/NNS||fixed-12/VBN	prep_of||efficacy-5/NN||combinations-13/NNS	nn||analogs-16/NNS||prostaglandin-15/NN	prep_of||evaluate-2/VB||analogs-16/NNS	det||prostamide-19/NN||a-18/DT	prep_of||evaluate-2/VB||prostamide-19/NN	conj_or||analogs-16/NNS||prostamide-19/NN	prep_with||evaluate-2/VB||timololmaleate-21/NN	prep_in||timololmaleate-21/NN||patients-23/NNS	amod||openangleglaucoma-26/NN||primary-25/JJ	prep_with||patients-23/NNS||openangleglaucoma-26/NN	prep_with||patients-23/NNS||ocularhypertension-28/NN	conj_or||openangleglaucoma-26/NN||ocularhypertension-28/NN	openangleglaucoma-26||timololmaleate-21||yes||to evaluate the long-term efficacy and safety of 3 commercially available fixed combinations of prostaglandin analogs or a prostamide with timololmaleate in patients with primary openangleglaucoma or ocularhypertension.
nsubj||antibiotic-4/JJ||minocycline-1/NN	cop||antibiotic-4/JJ||is-2/VBZ	det||antibiotic-4/JJ||an-3/DT	root||ROOT-0/null||antibiotic-4/JJ	nsubjpass||used-11/VBN||antibiotic-4/JJ	amod||derivatives-7/NNS||tetracycline-6/JJ	prep_of||antibiotic-4/JJ||derivatives-7/NNS	auxpass||used-11/VBN||is-9/VBZ	advmod||used-11/VBN||commonly-10/RB	rcmod||antibiotic-4/JJ||used-11/VBN	det||treatment-14/NN||the-13/DT	prep_in||used-11/VBN||treatment-14/NN	amod||severe-18/JJ||moderate-16/JJ	dep||severe-18/JJ||to-17/TO	amod||acnevulgaris-19/NNS||severe-18/JJ	prep_of||treatment-14/NN||acnevulgaris-19/NNS	acnevulgaris-19||tetracycline-6||yes||minocycline is an antibiotic of tetracycline derivatives that is commonly used in the treatment of moderate to severe acnevulgaris.
amod||vaccines-6/NNS||novel-1/JJ	nn||vaccines-6/NNS||tuberculosis-2/NNP	appos||vaccines-6/NNS||tb-4/NN	nsubjpass||designed-13/VBN||vaccines-6/NNS	nsubj||boost-15/VB||vaccines-6/NNS	advmod||tested-8/VBN||recently-7/RB	vmod||vaccines-6/NNS||tested-8/VBN	prep_in||tested-8/VBN||humans-10/NNS	aux||designed-13/VBN||have-11/VBP	auxpass||designed-13/VBN||been-12/VBN	ccomp||mycobacteriumbovis-23/VBZ||designed-13/VBN	aux||boost-15/VB||to-14/TO	xcomp||designed-13/VBN||boost-15/VB	dobj||boost-15/VB||immunity-16/NN	vmod||immunity-16/NN||induced-17/VBN	det||vaccine-21/NN||the-19/DT	amod||vaccine-21/NN||current-20/JJ	agent||induced-17/VBN||vaccine-21/NN	root||ROOT-0/null||mycobacteriumbovis-23/VBZ	amod||rin-27/NN||bacille-24/JJ	amod||rin-27/NN||calmette-guã-25/JJ	nn||rin-27/NN||©-26/NN	nsubj||mycobacteriumbovis-23/VBZ||rin-27/NN	appos||rin-27/NN||bcg-29/NN	tb-4||bcg-29||yes||novel tuberculosis (tb) vaccines recently tested in humans have been designed to boost immunity induced by the current vaccine, mycobacteriumbovis bacille calmette-guã©rin (bcg).
poss||results-2/NNS||our-1/PRP$	nsubj||show-3/VBP||results-2/NNS	nsubj||complement-33/VB||results-2/NNS	root||ROOT-0/null||show-3/VBP	mark||stably-20/VB||that-4/IN	det||tip-6/NN||a-5/DT	nsubj||stably-20/VB||tip-6/NN	vmod||tip-6/NN||engineered-8/VBN	prep_with||engineered-8/VBN||properties-10/NNS	vmod||properties-10/NNS||based-11/VBN	det||trial-17/NN||a-13/DT	amod||trial-17/NN||recent-14/JJ	nn||trial-17/NN||hiv-15/NN	nn||trial-17/NN||gene-therapy-16/NN	prep_on||based-11/VBN||trial-17/NN	aux||stably-20/VB||could-19/MD	ccomp||show-3/VBP||stably-20/VB	amod||prevalence-23/NN||lower-21/JJR	nn||prevalence-23/NN||hiv/aids-22/NN	dobj||stably-20/VB||prevalence-23/NN	prep_by||stably-20/VB||â-25/NN	num||â-25/NN||1/4-26/CD	amod||â-25/NN||30-fold-27/JJ	amod||â-25/NN||within-28/IN	num||years-30/NNS||50-29/CD	dep||â-25/NN||years-30/NNS	aux||complement-33/VB||could-32/MD	conj_and||show-3/VBP||complement-33/VB	amod||therapies-35/NNS||current-34/JJ	dobj||complement-33/VB||therapies-35/NNS	aids--1||hiv-15||no||our results show that a tip, engineered with properties based on a recent hiv gene-therapy trial, could stably lower hiv/aids prevalence by â¼30-fold within 50 years and could complement current therapies.
mark||clear-4/JJ||although-1/IN	nsubj||clear-4/JJ||it-2/PRP	cop||clear-4/JJ||is-3/VBZ	advcl||cause-47/VB||clear-4/JJ	mark||have-16/VBP||that-5/IN	det||patients-7/NNS||some-6/DT	nsubj||have-16/VBP||patients-7/NNS	prep_with||patients-7/NNS||acetylsalicylicacid-9/NN	appos||acetylsalicylicacid-9/NN||asa-11/NN	amod||asthma-15/NN||sensitive-14/JJ	dep||acetylsalicylicacid-9/NN||asthma-15/NN	ccomp||clear-4/JJ||have-16/VBP	poss||onset-19/NN||their-17/PRP$	amod||onset-19/NN||clinical-18/JJ	dobj||have-16/VBP||onset-19/NN	prep_of||onset-19/NN||disease-21/NN	prep_in||disease-21/NN||childhood-23/NN	prep_in||disease-21/NN||bronchoconstriction-25/NN	conj_and||childhood-23/NN||bronchoconstriction-25/NN	mark||seen-30/VBN||after-26/IN	nn||challenge-28/NN||asa-27/NN	nsubjpass||seen-30/VBN||challenge-28/NN	auxpass||seen-30/VBN||is-29/VBZ	advcl||have-16/VBP||seen-30/VBN	prep_in||seen-30/VBN||0-32/CD	num||%-35/NN||22-34/CD	prep_to||seen-30/VBN||%-35/NN	amod||children-38/NNS||asthmatic-37/JJ	prep_of||%-35/NN||children-38/NNS	advmod||challenged-40/VBN||so-39/RB	vmod||children-38/NNS||challenged-40/VBN	nsubj||cause-47/VB||ibuprofen-42/NN	amod||doses-45/NNS||antipyretic-44/JJ	prep_at||ibuprofen-42/NN||doses-45/NNS	aux||cause-47/VB||may-46/MD	root||ROOT-0/null||cause-47/VB	amod||problems-50/NNS||acute-48/JJ	nn||problems-50/NNS||respiratory-49/NN	dobj||cause-47/VB||problems-50/NNS	advmod||cause-47/VB||only-51/RB	det||number-56/NN||a-53/DT	advmod||small-55/JJ||very-54/RB	amod||number-56/NN||small-55/JJ	prep_in||cause-47/VB||number-56/NN	amod||moderate-60/JJ||mild-58/JJ	dep||moderate-60/JJ||to-59/TO	amod||asthmatics-61/NNS||moderate-60/JJ	prep_of||number-56/NN||asthmatics-61/NNS	asthmatic-37||ibuprofen-42||no||although it is clear that some patients with acetylsalicylicacid (asa)-sensitive asthma have their clinical onset of disease in childhood and bronchoconstriction after asa challenge is seen in 0 to 22% of asthmatic children so challenged, ibuprofen at antipyretic doses may cause acute respiratory problems only in a very small number of mild to moderate asthmatics.
nsubj||anticoagulant-7/NN||warfarin-1/NN	cop||anticoagulant-7/NN||is-2/VBZ	det||anticoagulant-7/NN||a-3/DT	advmod||prescribed-5/JJ||commonly-4/RB	amod||anticoagulant-7/NN||prescribed-5/JJ	amod||anticoagulant-7/NN||oral-6/JJ	root||ROOT-0/null||anticoagulant-7/NN	prep_in||anticoagulant-7/NN||patients-9/NNS	amod||thromboembolism-16/NN||prosthetic-11/JJ	nn||thromboembolism-16/NN||valve-12/NN	nn||thromboembolism-16/NN||disease-13/NN	prep_with||patients-9/NNS||venous-15/NNS	conj_and||thromboembolism-16/NN||venous-15/NNS	prep_with||patients-9/NNS||thromboembolism-16/NN	prep_with||patients-9/NNS||stroke-18/NN	conj_and||thromboembolism-16/NN||stroke-18/NN	stroke-18||warfarin-1||yes||warfarin is a commonly prescribed oral anticoagulant in patients with prosthetic valve disease, venous thromboembolism and stroke.
ccomp||shown-10/VBN||consistent-1/JJ	det||similarities-4/NNS||these-3/DT	prep_with||consistent-1/JJ||similarities-4/NNS	amod||studies-8/NNS||recent-6/JJ	amod||studies-8/NNS||epidemiological-7/JJ	nsubj||shown-10/VBN||studies-8/NNS	aux||shown-10/VBN||have-9/VBP	root||ROOT-0/null||shown-10/VBN	mark||likely-18/JJ||that-11/IN	amod||users-13/NNS||methamphetamine-12/JJ	nsubj||likely-18/JJ||users-13/NNS	cop||likely-18/JJ||are-14/VBP	advmod||twice-16/RB||almost-15/RB	advmod||likely-18/JJ||twice-16/RB	advmod||likely-18/JJ||as-17/RB	ccomp||shown-10/VBN||likely-18/JJ	prep_as||likely-18/JJ||non-users-20/NNS	aux||develop-22/VB||to-21/TO	vmod||non-users-20/NNS||develop-22/VB	dobj||develop-22/VB||pd-23/NN	det||fact-27/NN||the-26/DT	prep_despite||develop-22/VB||fact-27/NN	mark||have-32/VBP||that-28/IN	nsubj||have-32/VBP||methamphetamineabuse-29/NN	conj_and||methamphetamineabuse-29/NN||pd-31/NN	nsubj||have-32/VBP||pd-31/NN	ccomp||likely-18/JJ||have-32/VBP	amod||profiles-35/NNS||distinct-33/JJ	amod||profiles-35/NNS||symptomatic-34/JJ	dobj||have-32/VBP||profiles-35/NNS	methamphetamineabuse-29||methamphetamine-12||no||consistent with these similarities, recent epidemiological studies have shown that methamphetamine users are almost twice as likely as non-users to develop pd, despite the fact that methamphetamineabuse and pd have distinct symptomatic profiles.
nsubj||describe-2/VBP||we-1/PRP	root||ROOT-0/null||describe-2/VBP	det||case-4/NN||a-3/DT	dobj||describe-2/VBP||case-4/NN	amod||bleeding-7/NN||severe-6/JJ	prep_of||case-4/NN||bleeding-7/NN	det||tongue-10/NN||the-9/DT	prep_from||bleeding-7/NN||tongue-10/NN	amod||acquired-13/JJ||secondary-11/JJ	dep||acquired-13/JJ||to-12/TO	amod||case-4/NN||acquired-13/JJ	vmod||case-4/NN||hemophiliaand-14/VBN	ccomp||hemophiliaand-14/VBN||discuss-15/VB	nn||options-17/NNS||treatment-16/NN	dobj||discuss-15/VB||options-17/NNS	amod||factorviii-23/NNS||aminocaproicacid-20/JJ	conj_and||aminocaproicacid-20/JJ||recombinant-22/JJ	amod||factorviii-23/NNS||recombinant-22/JJ	prep_including||hemophiliaand-14/VBN||factorviii-23/NNS	nsubjpass||reported-30/VBN||factorviii-23/NNS	aux||reported-30/VBN||have-26/VBP	neg||reported-30/VBN||not-27/RB	auxpass||reported-30/VBN||been-28/VBN	advmod||reported-30/VBN||widely-29/RB	rcmod||factorviii-23/NNS||reported-30/VBN	det||literature-33/NN||the-32/DT	prep_in||reported-30/VBN||literature-33/NN	det||management-36/NN||the-35/DT	prep_for||literature-33/NN||management-36/NN	amod||patients-39/NNS||such-38/JJ	prep_of||management-36/NN||patients-39/NNS	hemophilia--1||factorviii-23||yes||we describe a case of severe bleeding from the tongue secondary to acquired hemophiliaand discuss treatment options, including aminocaproicacid and recombinant factorviii, which have not been widely reported in the literature for the management of such patients.
det||calcineurininhibitors-3/NNS||the-1/DT	amod||calcineurininhibitors-3/NNS||topical-2/JJ	nsubjpass||used-11/VBN||calcineurininhibitors-3/NNS	nsubj||treat-13/VB||calcineurininhibitors-3/NNS	nsubj||inhibit-20/VB||calcineurininhibitors-3/NNS	appos||calcineurininhibitors-3/NNS||tacrolimus-5/NNS	appos||calcineurininhibitors-3/NNS||pimecrolimus-7/NNS	conj_and||tacrolimus-5/NNS||pimecrolimus-7/NNS	aux||used-11/VBN||have-9/VBP	auxpass||used-11/VBN||been-10/VBN	root||ROOT-0/null||used-11/VBN	aux||treat-13/VB||to-12/TO	xcomp||used-11/VBN||treat-13/VB	amod||cutaneous-15/JJ||resistant-14/JJ	amod||lupus-16/NNS||cutaneous-15/JJ	dobj||treat-13/VB||lupus-16/NNS	prep_since||treat-13/VB||2002-18/CD	xcomp||used-11/VBN||inhibit-20/VB	conj_and||treat-13/VB||inhibit-20/VB	det||proliferation-22/NN||the-21/DT	dobj||inhibit-20/VB||proliferation-22/NN	dobj||inhibit-20/VB||activation-24/NN	conj_and||proliferation-22/NN||activation-24/NN	prep_of||proliferation-22/NN||t-cells-26/NNS	conj_and||treat-13/VB||suppress-28/VB	conj_and||inhibit-20/VB||suppress-28/VB	amod||cutaneousinflammation-30/NN||immune-mediated-29/JJ	dobj||suppress-28/VB||cutaneousinflammation-30/NN	tacrolimus-5||lupus-16||no_rel||the topical calcineurininhibitors, tacrolimus and pimecrolimus, have been used to treat resistant cutaneous lupus since 2002 and inhibit the proliferation and activation of t-cells and suppress immune-mediated cutaneousinflammation.
amod||damage-2/NN||intestinal-1/JJ	nsubjpass||induced-4/VBN||damage-2/NN	auxpass||induced-4/VBN||was-3/VBD	root||ROOT-0/null||induced-4/VBN	amod||administration-7/NN||subcutaneous-6/JJ	agent||induced-4/VBN||administration-7/NN	prep_of||administration-7/NN||indomethacin-9/NN	amod||mg/kg-12/NN||10â-11/JJ	appos||indomethacin-9/NN||mg/kg-12/NN	amod||rats-17/NNS||male-15/JJ	nn||rats-17/NNS||wistar-16/NN	prep_in||indomethacin-9/NN||rats-17/NNS	det||severity-21/NN||the-20/DT	nsubjpass||evaluated-26/VBN||severity-21/NN	det||injury-24/NN||the-23/DT	prep_of||severity-21/NN||injury-24/NN	auxpass||evaluated-26/VBN||was-25/VBD	conj_and||induced-4/VBN||evaluated-26/VBN	agent||evaluated-26/VBN||measuring-28/VBG	det||area-30/NN||the-29/DT	dobj||measuring-28/VBG||area-30/NN	amod||ulcerative-33/JJ||visible-32/JJ	amod||lesions-34/NNS||ulcerative-33/JJ	prep_of||area-30/NN||lesions-34/NNS	indomethacin-9||ulcerative-33||no_rel||intestinal damage was induced by subcutaneous administration of indomethacin (10â mg/kg) in male wistar rats, and the severity of the injury was evaluated by measuring the area of visible ulcerative lesions.
mark||done-7/VBN||though-1/IN	neg||work-3/NN||no-2/DT	nsubjpass||done-7/VBN||work-3/NN	nsubj||demonstrate-9/VB||work-3/NN	aux||done-7/VBN||has-4/VBZ	advmod||done-7/VBN||directly-5/RB	auxpass||done-7/VBN||been-6/VBN	advcl||mediated-30/VBD||done-7/VBN	aux||demonstrate-9/VB||to-8/TO	xcomp||done-7/VBN||demonstrate-9/VB	det||function-11/NN||the-10/DT	dobj||demonstrate-9/VB||function-11/NN	det||isoform-15/NN||this-13/DT	amod||isoform-15/NN||soluble-14/JJ	prep_of||function-11/NN||isoform-15/NN	prep_in||isoform-15/NN||arenaviralinfections-17/NNS	nn||points-20/NNS||evidence-19/NN	nsubj||mediated-30/VBD||points-20/NNS	amod||effects-23/NNS||immunomodulatory-22/JJ	prep_to||points-20/NNS||effects-23/NNS	det||host-26/NN||the-25/DT	poss||system-29/NN||host-26/NN	amod||system-29/NN||immune-28/JJ	prep_against||effects-23/NNS||system-29/NN	root||ROOT-0/null||mediated-30/VBD	det||component-35/NN||a-32/DT	amod||component-35/NN||secreted-33/JJ	nn||component-35/NN||glycoprotein-34/NN	prep_by||mediated-30/VBD||component-35/NN	prep_in||mediated-30/VBD||filoviruses-37/NNS	det||class-40/NN||another-39/DT	appos||filoviruses-37/NNS||class-40/NN	amod||viruses-43/NNS||hemorrhagicfever-causing-42/JJ	prep_of||class-40/NN||viruses-43/NNS	hemorrhagicfever--1||viruses-43||no||though no work has directly been done to demonstrate the function of this soluble isoform in arenaviralinfections, evidence points to immunomodulatory effects against the host's immune system mediated by a secreted glycoprotein component in filoviruses, another class of hemorrhagicfever-causing viruses.
amod||studies-2/NNS||forty-nine-1/JJ	nsubj||met-3/VBD||studies-2/NNS	root||ROOT-0/null||met-3/VBD	det||criteria-6/NNS||the-4/DT	nn||criteria-6/NNS||inclusion-5/NN	dobj||met-3/VBD||criteria-6/NNS	num||indicators-10/NNS||30-8/CD	amod||indicators-10/NNS||different-9/JJ	nsubjpass||extracted-12/VBN||indicators-10/NNS	nsubjpass||categorized-14/VBN||indicators-10/NNS	auxpass||extracted-12/VBN||were-11/VBD	parataxis||met-3/VBD||extracted-12/VBN	parataxis||met-3/VBD||categorized-14/VBN	conj_and||extracted-12/VBN||categorized-14/VBN	num||categories-18/NNS||four-16/CD	amod||categories-18/NNS||nonorthogonal-17/JJ	prep_into||extracted-12/VBN||categories-18/NNS	amod||zones-20/NNS||bloodglucose-19/JJ	dep||categories-18/NNS||zones-20/NNS	prep_for||zones-20/NNS||example-23/NN	dep||example-23/NN||hypoglycaemia-26/NN	amod||levels-31/NNS||bloodglucose-30/JJ	prep_into||extracted-12/VBN||levels-31/NNS	conj_and||categories-18/NNS||levels-31/NNS	prep_for||levels-31/NNS||example-34/NN	amod||level-39/NN||mean-37/JJ	nn||level-39/NN||bloodglucose-38/NN	dep||example-34/NN||level-39/NN	nn||intervals-44/NNS||time-43/NN	prep_into||extracted-12/VBN||intervals-44/NNS	conj_and||categories-18/NNS||intervals-44/NNS	prep_for||intervals-44/NNS||example-47/NN	dep||example-47/NN||time-50/NN	prep_to||time-50/NN||occurrence-52/NN	det||event-55/NN||an-54/DT	prep_of||occurrence-52/NN||event-55/NN	nn||characteristics-61/NNS||protocol-60/NN	prep_into||extracted-12/VBN||characteristics-61/NNS	conj_and||categories-18/NNS||characteristics-61/NNS	prep_for||categories-18/NNS||example-64/NN	nsubj||sampling-68/VBG||bloodglucose-67/NN	dep||example-64/NN||sampling-68/VBG	dobj||sampling-68/VBG||frequency-69/NN	hypoglycaemia-26||glucose--1||yes||forty-nine studies met the inclusion criteria; 30 different indicators were extracted and categorized into four nonorthogonal categories bloodglucose zones (for example, 'hypoglycaemia'); bloodglucose levels (for example, 'mean bloodglucose level'); time intervals (for example, 'time to occurrence of an event'); and protocol characteristics (for example, 'bloodglucose sampling frequency').
det||categories-5/NNS||the-2/DT	num||categories-5/NNS||3-3/CD	amod||categories-5/NNS||broad-4/JJ	prep_of||related-14/VBN||categories-5/NNS	prep_of||categories-5/NNS||themes-7/NNS	nsubjpass||identified-10/VBN||themes-7/NNS	auxpass||identified-10/VBN||were-9/VBD	rcmod||themes-7/NNS||identified-10/VBN	amod||barriers-13/NNS||major-12/JJ	nsubj||related-14/VBN||barriers-13/NNS	root||ROOT-0/null||related-14/VBN	det||accuracy-17/NN||the-16/DT	prep_to||related-14/VBN||accuracy-17/NN	prep_to||related-14/VBN||feasibility-19/NN	conj_and||accuracy-17/NN||feasibility-19/NN	prepc_of||accuracy-17/NN||extracting-21/VBG	nn||results-26/NNS||bone-22/NN	nn||results-26/NNS||mineral-23/NN	nn||results-26/NNS||density-24/NN	nn||results-26/NNS||test-25/NN	dobj||extracting-21/VBG||results-26/NNS	dobj||extracting-21/VBG||medications-28/NNS	conj_and||results-26/NNS||medications-28/NNS	det||questionnaire-33/NN||the-30/DT	nn||questionnaire-33/NN||risk-31/NN	nn||questionnaire-33/NN||assessment-32/NN	prep_from||extracting-21/VBG||questionnaire-33/NN	parataxis||related-14/VBN||using-35/VBG	det||device-39/NN||an-36/DT	amod||device-39/NN||electronic-37/JJ	nn||device-39/NN||input-38/NN	dobj||using-35/VBG||device-39/NN	det||pc-44/NN||a-42/DT	amod||pc-44/NN||tablet-43/JJ	prep_such_as||device-39/NN||pc-44/NN	det||room-48/NN||the-46/DT	amod||room-48/NN||waiting-47/VBG	prep_in||pc-44/NN||room-48/NN	det||importance-52/NN||the-51/DT	prep_such_as||device-39/NN||importance-52/NN	conj_and||pc-44/NN||importance-52/NN	prepc_of||importance-52/NN||including-54/VBG	amod||information-56/NN||well-balanced-55/JJ	dobj||including-54/VBG||information-56/NN	det||component-61/NN||the-58/DT	amod||component-61/NN||patient-59/JJ	nn||component-61/NN||education-60/NN	prep_in||including-54/VBG||component-61/NN	det||tool-65/NN||the-63/DT	nn||tool-65/NN||osteoporosis-64/NN	prep_of||component-61/NN||tool-65/NN	osteoporosis-64||mineral-23||no_rel||of the 3 broad categories of themes that were identified, major barriers related to the accuracy and feasibility of extracting bone mineral density test results and medications from the risk assessment questionnaire; using an electronic input device such as a tablet pc in the waiting room; and the importance of including well-balanced information in the patient education component of the osteoporosis tool.
nsubj||forms-24/VBZ||proliferation-1/NN	nn||receptors-4/NNS||nmda-3/NN	prep_of||proliferation-1/NN||receptors-4/NNS	prep_of||proliferation-1/NN||role-6/NN	conj_and||receptors-4/NNS||role-6/NN	amod||phenomena-18/NNS||glutamate-8/JJ	prepc_in||glutamate-8/JJ||producing-10/VBG	amod||sensitization-12/NN||central-11/JJ	dobj||producing-10/VBG||sensitization-12/NN	prepc_in||glutamate-8/JJ||wind-15/VBP	conj_and||producing-10/VBG||wind-15/VBP	prt||wind-15/VBP||up-16/RP	prep_of||receptors-4/NNS||phenomena-18/NNS	amod||-RSB--23/NNS||crps-20/JJ	amod||-RSB--23/NNS||-LSB--21/JJ	nn||-RSB--23/NNS||complexregionalpainsyndrome-22/NN	prep_in||phenomena-18/NNS||-RSB--23/NNS	root||ROOT-0/null||forms-24/VBZ	det||basis-27/NN||a-25/DT	amod||basis-27/NN||strong-26/JJ	dobj||forms-24/VBZ||basis-27/NN	det||use-30/NN||the-29/DT	prep_for||forms-24/VBZ||use-30/NN	prep_of||use-30/NN||ketamine-32/NN	aux||block-34/VB||to-33/TO	vmod||forms-24/VBZ||block-34/VB	det||mechanisms-37/NNS||the-35/DT	amod||mechanisms-37/NNS||cellular-36/JJ	dobj||block-34/VB||mechanisms-37/NNS	nsubj||initiate-39/VBP||mechanisms-37/NNS	nsubj||maintain-41/VBP||mechanisms-37/NNS	rcmod||mechanisms-37/NNS||initiate-39/VBP	rcmod||mechanisms-37/NNS||maintain-41/VBP	conj_and||initiate-39/VBP||maintain-41/VBP	det||changes-43/NNS||these-42/DT	dobj||initiate-39/VBP||changes-43/NNS	ketamine-32||crps-20||no_rel||proliferation of nmda receptors and role of glutamate in producing central sensitization and 'wind up' phenomena in crps [complexregionalpainsyndrome] forms a strong basis for the use of ketamine to block the cellular mechanisms that initiate and maintain these changes.
expl||were-2/VBD||there-1/EX	root||ROOT-0/null||were-2/VBD	amod||cases-4/NNS||295-3/JJ	nsubj||were-2/VBD||cases-4/NNS	prep_of||diagnosed-31/VBN||cases-4/NNS	prep_of||cases-4/NNS||ibd-6/NN	dep||cases-4/NNS||uc-8/VBN	dep||240-10/CD||=-9/SYM	ccomp||uc-8/VBN||240-10/CD	ccomp||uc-8/VBN||cd-12/VB	dep||55-14/CD||=-13/SYM	ccomp||cd-12/VB||55-14/CD	nsubjpass||diagnosed-31/VBN||34-19/CD	dep||34-19/CD||uc-21/VBN	dep||30-23/CD||=-22/SYM	ccomp||uc-21/VBN||30-23/CD	ccomp||uc-21/VBN||cd-25/VB	dep||4-27/CD||=-26/SYM	ccomp||cd-25/VB||4-27/CD	auxpass||diagnosed-31/VBN||were-29/VBD	advmod||diagnosed-31/VBN||newly-30/RB	rcmod||cases-4/NNS||diagnosed-31/VBN	det||year-35/NN||the-33/DT	nn||year-35/NN||study-34/NN	prep_during||diagnosed-31/VBN||year-35/NN	uc-21||cd-25||no_rel||there were 295 cases of ibd (uc = 240, cd = 55), of which 34 (uc = 30, cd = 4) were newly diagnosed during the study year.
nsubjpass||shown-3/VBN||fondaparinux-1/NN	nsubj||efficacious-6/JJ||fondaparinux-1/NN	auxpass||shown-3/VBN||was-2/VBD	root||ROOT-0/null||shown-3/VBN	aux||efficacious-6/JJ||to-4/TO	cop||efficacious-6/JJ||be-5/VB	xcomp||shown-3/VBN||efficacious-6/JJ	det||prevention-9/NN||the-8/DT	prep_in||efficacious-6/JJ||prevention-9/NN	amod||heparins-15/NNS||deep-11/JJ	nn||heparins-15/NNS||veinthrombosis-12/NN	nn||heparins-15/NNS||vs-13/NN	amod||heparins-15/NNS||low-molecular-weight-14/JJ	prep_of||prevention-9/NN||heparins-15/NNS	mark||shown-28/VBN||while-17/IN	det||setting-20/NN||the-19/DT	prep_in||shown-28/VBN||setting-20/NN	amod||disease-24/NN||venous-22/JJ	amod||disease-24/NN||thrombo-embolic-23/JJ	prep_of||setting-20/NN||disease-24/NN	nsubjpass||shown-28/VBN||it-26/PRP	nsubj||noninferior-31/JJ||it-26/PRP	auxpass||shown-28/VBN||was-27/VBD	advcl||efficacious-6/JJ||shown-28/VBN	aux||noninferior-31/JJ||to-29/TO	cop||noninferior-31/JJ||be-30/VB	xcomp||shown-28/VBN||noninferior-31/JJ	prep_to||noninferior-31/JJ||enoxaparin-33/NN	prep_to||noninferior-31/JJ||ufh-35/NN	conj_and||enoxaparin-33/NN||ufh-35/NN	veinthrombosis-12||fondaparinux-1||yes||fondaparinux was shown to be efficacious in the prevention of deep veinthrombosis vs low-molecular-weight heparins, while in the setting of venous thrombo-embolic disease, it was shown to be noninferior to enoxaparin and ufh.
det||study-5/NN||this-2/DT	nn||study-5/NN||retrospective-3/NN	amod||study-5/NN||cross-sectional-4/JJ	prep_in||evaluated-26/VBN||study-5/NN	det||value-8/NN||the-6/DT	amod||value-8/NN||prognostic-7/JJ	nsubjpass||evaluated-26/VBN||value-8/NN	amod||parameters-16/NNS||basic-10/JJ	amod||parameters-16/NNS||cerebrospinal-11/JJ	nn||parameters-16/NNS||fluid-12/NN	appos||parameters-16/NNS||csf-14/NN	prep_of||value-8/NN||parameters-16/NNS	prep_in||parameters-16/NNS||patients-18/NNS	prep_with||patients-18/NNS||bacterialmeningitis-20/NNS	prep_with||patients-18/NNS||viralmeningoencephalitis-22/NNS	conj_and||bacterialmeningitis-20/NNS||viralmeningoencephalitis-22/NNS	prep_with||patients-18/NNS||leptomeningealmetastases-24/NNS	conj_and||bacterialmeningitis-20/NNS||leptomeningealmetastases-24/NNS	auxpass||evaluated-26/VBN||were-25/VBD	root||ROOT-0/null||evaluated-26/VBN	cross--1||basic-10||no_rel||in this retrospective cross-sectional study the prognostic value of basic cerebrospinal fluid (csf) parameters in patients with bacterialmeningitis, viralmeningoencephalitis and leptomeningealmetastases were evaluated.
nsubj||report-2/VBP||we-1/PRP	root||ROOT-0/null||report-2/VBP	det||case-5/NN||a-3/DT	amod||case-5/NN||rare-4/JJ	dobj||report-2/VBP||case-5/NN	amod||vasculitis-11/NNS||hydralazine-induced-7/JJ	amod||vasculitis-11/NNS||anti-neutrophil-8/JJ	amod||vasculitis-11/NNS||cytoplasmic-9/JJ	amod||vasculitis-11/NNS||antibody-associated-10/JJ	prep_of||case-5/NN||vasculitis-11/NNS	det||woman-16/NN||a-13/DT	amod||woman-16/NN||62-year-old-14/JJ	amod||woman-16/NN||caucasian-15/JJ	prep_in||vasculitis-11/NNS||woman-16/NN	nsubj||presented-18/VBD||woman-16/NN	rcmod||woman-16/NN||presented-18/VBD	det||syndrome-22/NN||a-20/DT	amod||syndrome-22/NN||vasculitic-21/JJ	prep_with||presented-18/VBD||syndrome-22/NN	det||sorethroat-25/NN||a-24/DT	prep_with||syndrome-22/NN||sorethroat-25/NN	prep_with||syndrome-22/NN||mouthulcers-27/NNS	conj_and||sorethroat-25/NN||mouthulcers-27/NNS	prep_with||syndrome-22/NN||otalgia-29/NN	conj_and||sorethroat-25/NN||otalgia-29/NN	amod||months-32/NNS||several-31/JJ	prep_after||presented-18/VBD||months-32/NNS	amod||symptoms-35/NNS||constitutional-34/JJ	prep_of||months-32/NNS||symptoms-35/NNS	hydralazine--1||otalgia-29||no_rel||we report a rare case of hydralazine-induced anti-neutrophil cytoplasmic antibody-associated vasculitis in a 62-year-old caucasian woman who presented with a vasculitic syndrome with a sorethroat, mouthulcers and otalgia after several months of constitutional symptoms.
det||study-2/NN||this-1/DT	nsubj||demonstrates-3/VBZ||study-2/NN	root||ROOT-0/null||demonstrates-3/VBZ	mark||play-10/VB||that-4/IN	nsubj||play-10/VB||aba-5/NN	advmod||likely-7/JJ||most-6/RBS	amod||aba-5/NN||likely-7/JJ	aux||play-10/VB||does-8/VBZ	neg||play-10/VB||not-9/RB	ccomp||demonstrates-3/VBZ||play-10/VB	det||role-13/NN||any-11/DT	amod||role-13/NN||direct-12/JJ	dobj||play-10/VB||role-13/NN	nn||refilling-16/NN||embolism-15/NN	prep_in||play-10/VB||refilling-16/NN	det||modulation-21/NN||the-20/DT	prep_through||influence-28/VB||modulation-21/NN	amod||content-24/NN||carbohydrate-23/JJ	prep_of||modulation-21/NN||content-24/NN	nsubj||influence-28/VB||it-26/PRP	aux||influence-28/VB||could-27/MD	conj_but||demonstrates-3/VBZ||influence-28/VB	det||capacity-34/NN||the-29/DT	amod||capacity-34/NN||plantâ-30/JJ	amod||capacity-34/NN||$-31/$	number||s-33/CD||-32/CD	num||$-31/$||s-33/CD	dobj||influence-28/VB||capacity-34/NN	prep_for||capacity-34/NN||refilling-36/NN	carbohydrate-23||embolism-15||no_rel||this study demonstrates that aba most likely does not play any direct role in embolism refilling, but through the modulation of carbohydrate content, it could influence the plantâs capacity for refilling.
poss||findings-2/NNS||our-1/PRP$	nsubj||suggest-3/VBP||findings-2/NNS	root||ROOT-0/null||suggest-3/VBP	mark||effective-9/JJ||that-4/IN	num||terazosin-7/NN||5-5/CD	nn||terazosin-7/NN||mg-6/NN	nsubj||effective-9/JJ||terazosin-7/NN	cop||effective-9/JJ||is-8/VBZ	ccomp||suggest-3/VBP||effective-9/JJ	mark||has-13/VBZ||that-11/IN	nsubj||has-13/VBZ||it-12/PRP	ccomp||suggest-3/VBP||has-13/VBZ	conj_and||effective-9/JJ||has-13/VBZ	det||profile-17/NN||an-14/DT	amod||profile-17/NN||acceptable-15/JJ	nn||profile-17/NN||safety-16/NN	dobj||has-13/VBZ||profile-17/NN	det||therapy-21/NN||an-19/DT	amod||therapy-21/NN||add-on-20/JJ	prep_as||profile-17/NN||therapy-21/NN	prep_for||therapy-21/NN||patients-23/NNS	prep_with||patients-23/NNS||luts-25/NNS	nn||hypertension-28/NN||concomitant-27/NN	prep_with||patients-23/NNS||hypertension-28/NN	conj_and||luts-25/NNS||hypertension-28/NN	hypertension-28||terazosin-7||yes||our findings suggest that 5 mg terazosin is effective and that it has an acceptable safety profile as an add-on therapy for patients with luts and concomitant hypertension.
nn||manifestations-2/NNS||ocular-1/NN	root||ROOT-0/null||manifestations-2/NNS	aux||occur-4/VB||can-3/MD	rcmod||manifestations-2/NNS||occur-4/VB	quantmod||50-8/CD||up-6/IN	dep||50-8/CD||to-7/TO	num||%-9/NN||50-8/CD	prep_in||occur-4/VB||%-9/NN	prep_of||%-9/NN||humanimmunodeficiencyvirus-11/NNS	appos||humanimmunodeficiencyvirus-11/NNS||hiv-13/NN	punct||manifestations-2/NNS||/-15/:	dep||manifestations-2/NNS||acquired-16/VBD	amod||patients-22/NNS||immunedeficiency-17/JJ	nn||patients-22/NNS||syndrome-18/NN	appos||patients-22/NNS||aids-20/NNS	nsubj||presentation-31/NN||patients-22/NNS	nn||involvement-26/NN||posterior-24/NN	nn||involvement-26/NN||segment-25/NN	conj_and||patients-22/NNS||involvement-26/NN	nsubj||presentation-31/NN||involvement-26/NN	cop||presentation-31/NN||is-27/VBZ	det||presentation-31/NN||the-28/DT	advmod||common-30/JJ||most-29/RBS	amod||presentation-31/NN||common-30/JJ	ccomp||acquired-16/VBD||presentation-31/NN	aids-20||humanimmunodeficiencyvirus-11||no||ocular manifestations can occur in up to 50% of humanimmunodeficiencyvirus (hiv)/acquired immunedeficiency syndrome (aids) patients and posterior segment involvement is the most common presentation.
amod||sinovenousthrombosis-2/NNS||cerebral-1/JJ	nsubj||complication-9/NN||sinovenousthrombosis-2/NNS	appos||sinovenousthrombosis-2/NNS||csvt-4/NN	cop||complication-9/NN||is-6/VBZ	det||complication-9/NN||a-7/DT	amod||complication-9/NN||serious-8/JJ	root||ROOT-0/null||complication-9/NN	amod||chemotherapy-12/NN||l-asparaginase-11/JJ	prep_of||complication-9/NN||chemotherapy-12/NN	prep_for||chemotherapy-12/NN||leukemia-14/NN	prep_in||leukemia-14/NN||children-16/NNS	thrombosis--1||l-asparaginase-11||no_rel||cerebral sinovenousthrombosis (csvt) is a serious complication of l-asparaginase chemotherapy for leukemia in children.
nsubj||people-4/NNS||participants-1/NNS	cop||people-4/NNS||were-2/VBD	num||people-4/NNS||59-3/CD	root||ROOT-0/null||people-4/NNS	prep_with||people-4/NNS||type2diabetes-6/CD	neg||taking-8/VBG||not-7/RB	xcomp||people-4/NNS||taking-8/VBG	dobj||taking-8/VBG||insulin-9/NN	dep||insulin-9/NN||recruited-11/VBN	amod||lists-15/NNS||general-13/JJ	nn||lists-15/NNS||practice-14/NN	prep_from||recruited-11/VBN||lists-15/NNS	dep||insulin-9/NN||opportunistically-17/JJ	conj_or||recruited-11/VBN||opportunistically-17/JJ	amod||staff-21/NN||general-19/JJ	nn||staff-21/NN||practice-20/NN	prep_by||opportunistically-17/JJ||staff-21/NN	type2diabetes-6||insulin-9||yes||participants were 59 people with type2diabetes not taking insulin, recruited from general practice lists or opportunistically by general practice staff.
det||case-2/NN||this-1/DT	nsubj||documents-3/VBZ||case-2/NN	root||ROOT-0/null||documents-3/VBZ	det||woman-6/NN||a-4/DT	amod||woman-6/NN||62-year-old-5/JJ	dobj||documents-3/VBZ||woman-6/NN	nsubj||presented-8/VBN||woman-6/NN	rcmod||woman-6/NN||presented-8/VBN	amod||vasculitis-15/NNS||hydralazine-induced-10/JJ	amod||vasculitis-15/NNS||anti-neutrophil-11/JJ	amod||vasculitis-15/NNS||cytoplasmic-12/JJ	amod||vasculitis-15/NNS||antibody-positive-13/JJ	amod||vasculitis-15/NNS||renal-14/JJ	prep_with||presented-8/VBN||vasculitis-15/NNS	det||rash-20/NN||a-17/DT	amod||cutaneous-19/JJ||puzzling-18/JJ	amod||rash-20/NN||cutaneous-19/JJ	prep_with||vasculitis-15/NNS||rash-20/NN	vasculitis-15||antibody--1||no_rel||this case documents a 62-year-old woman who presented with hydralazine-induced anti-neutrophil cytoplasmic antibody-positive renal vasculitis with a puzzling cutaneous rash.
nsubj||profile-3/VB||we-1/PRP	nsubj||propose-18/VB||we-1/PRP	nsubj||enzyme-30/VB||we-1/PRP	advmod||profile-3/VB||first-2/RB	root||ROOT-0/null||profile-3/VB	det||reaction-5/NN||each-4/DT	dobj||profile-3/VB||reaction-5/NN	poss||states-9/NNS||its-7/PRP$	nn||states-9/NNS||flux-8/NN	prep_by||profile-3/VB||states-9/NNS	amod||lines-14/NNS||nci-60-11/JJ	nn||lines-14/NNS||cancer-12/NN	nn||lines-14/NNS||cell-13/NN	prep_in||profile-3/VB||lines-14/NNS	advmod||propose-18/VB||then-17/RB	conj_and||profile-3/VB||propose-18/VB	det||model-23/NN||a-19/DT	amod||model-23/NN||kernel-20/JJ	amod||model-23/NN||k-nearest-21/JJ	nn||model-23/NN||neighbor-22/NN	dobj||propose-18/VB||model-23/NN	aux||predict-25/VB||to-24/TO	vmod||propose-18/VB||predict-25/VB	amod||reactions-28/NNS||related-26/JJ	amod||reactions-28/NNS||metabolic-27/JJ	dobj||predict-25/VB||reactions-28/NNS	conj_and||profile-3/VB||enzyme-30/VB	dobj||enzyme-30/VB||targets-31/NNS	amod||cancerdrugs-34/NNS||approved-33/JJ	prep_for||targets-31/NNS||cancerdrugs-34/NNS	enzyme-30||cancer-12||no_rel||we first profile each reaction by its flux states in nci-60 cancer cell lines, and then propose a kernel k-nearest neighbor model to predict related metabolic reactions and enzyme targets for approved cancerdrugs.
nsubjpass||included-21/VBN||hundred-1/CD	amod||patients-4/NNS||thirty-six-3/JJ	conj_and||hundred-1/CD||patients-4/NNS	nsubjpass||included-21/VBN||patients-4/NNS	conj_and||hundred-1/CD||91-6/CD	nsubjpass||included-21/VBN||91-6/CD	prep_with||91-6/CD||bd-8/NN	conj_and||hundred-1/CD||45-10/CD	nsubjpass||included-21/VBN||45-10/CD	prep_with||45-10/CD||sz-12/NN	num||controls-16/NNS||73-14/CD	amod||controls-16/NNS||healthy-15/JJ	conj_and||hundred-1/CD||controls-16/NNS	nsubjpass||included-21/VBN||controls-16/NNS	appos||controls-16/NNS||hc-18/NN	auxpass||included-21/VBN||were-20/VBD	root||ROOT-0/null||included-21/VBN	hc-18||sz-12||no_rel||hundred and thirty-six patients, 91 with bd, 45 with sz and 73 healthy controls (hc) were included.
amod||options-2/NNS||several-1/JJ	nsubjpass||licensed-10/VBN||options-2/NNS	det||treatment-5/NN||the-4/DT	prep_for||options-2/NNS||treatment-5/NN	prep_of||treatment-5/NN||hepatitisb-7/NN	aux||licensed-10/VBN||have-8/VBP	auxpass||licensed-10/VBN||been-9/VBN	root||ROOT-0/null||licensed-10/VBN	det||interferon-15/NN||the-12/DT	amod||interferon-15/NN||last-13/JJ	nn||interferon-15/NN||years-14/NNS	prep_in||licensed-10/VBN||interferon-15/NN	amod||interferon-18/NN||pegylated-17/JJ	prep_in||licensed-10/VBN||interferon-18/NN	conj_and||interferon-15/NN||interferon-18/NN	prep_in||licensed-10/VBN||lamivudine-20/NN	conj_and||interferon-15/NN||lamivudine-20/NN	prep_in||licensed-10/VBN||adefovir-22/NN	conj_and||interferon-15/NN||adefovir-22/NN	prep_in||licensed-10/VBN||entecavir-24/NN	conj_and||interferon-15/NN||entecavir-24/NN	prep_in||licensed-10/VBN||telbivudine-27/NN	conj_and||interferon-15/NN||telbivudine-27/NN	hepatitisb-7||telbivudine-27||yes||several options for the treatment of hepatitisb have been licensed in the last years interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine.
det||activity-3/NN||an-1/DT	amod||activity-3/NN||antimicrobial-2/JJ	nsubj||demonstrated-7/VBD||activity-3/NN	amod||cultures-6/NNS||planktonic-5/JJ	prep_toward||activity-3/NN||cultures-6/NNS	root||ROOT-0/null||demonstrated-7/VBD	det||-14/NNP||a-8/DT	amod||-14/NNP||significant-9/JJ	amod||-14/NNP||bacteriocidal-10/JJ	nn||-14/NNP||activity-11/NN	nn||-14/NNP||-lrb--12/NNP	nn||-14/NNP||â-13/NNP	nsubj||¥-15/VBZ||-14/NNP	ccomp||demonstrated-7/VBD||¥-15/VBZ	num||-rrb--20/NNS||4-16/CD	nn||-rrb--20/NNS||log-17/NN	nn||-rrb--20/NNS||cycle-18/NN	nn||-rrb--20/NNS||reduction-19/NN	nsubj||extract-25/VB||-rrb--20/NNS	det||triloba-24/NN||the-22/DT	nn||triloba-24/NN||s.-23/NN	prep_for||-rrb--20/NNS||triloba-24/NN	ccomp||¥-15/VBZ||extract-25/VB	prep_against||extract-25/VB||s.aureus-27/NNS	prep_including||s.aureus-27/NNS||mrsa-29/NN	mrsa-29||s.aureus-27||no||an antimicrobial activity toward planktonic cultures demonstrated a significant bacteriocidal activity -lrb- â  ¥ 4 log cycle reduction -rrb- for the s. triloba extract against s.aureus including mrsa .
det||studies-6/NNS||the-2/DT	amod||studies-6/NNS||subsequent-3/JJ	num||studies-6/NNS||26-4/CD	amod||studies-6/NNS||patient-5/JJ	prep_during||occurred-10/VBD||studies-6/NNS	nn||shutoff-9/NN||pump-8/NN	nsubj||occurred-10/VBD||shutoff-9/NN	root||ROOT-0/null||occurred-10/VBD	advmod||predicted-31/VBD||when-11/WRB	advmod||three-13/CD||either-12/RB	nsubj||predicted-31/VBD||three-13/CD	prep_of||three-13/CD||five-15/CD	dep||three-13/CD||n-17/VBN	dep||10-19/CD||=-18/SYM	ccomp||n-17/VBN||10-19/CD	conj_or||three-13/CD||two-22/CD	nsubj||predicted-31/VBD||two-22/CD	prep_of||two-22/CD||five-24/CD	dep||two-22/CD||n-26/VBN	dep||16-28/CD||=-27/SYM	ccomp||n-26/VBN||16-28/CD	advmod||predicted-31/VBD||algorithms-30/RB	advcl||occurred-10/VBD||predicted-31/VBD	dobj||predicted-31/VBD||hypoglycemia-32/NN	prepc_based_on||predicted-31/VBD||on-34/IN	det||levels-37/NNS||the-35/DT	nn||levels-37/NNS||glucose-36/NN	pobj||predicted-31/VBD||levels-37/NNS	vmod||levels-37/NNS||measured-38/VBN	det||navigator-42/NN||the-40/DT	amod||navigator-42/NN||freestyle-41/JJ	prep_with||measured-38/VBN||navigator-42/NN	amod||care-46/NN||abbott-44/JJ	nn||care-46/NN||diabetes-45/NN	appos||navigator-42/NN||care-46/NN	hypoglycemia-32||glucose-36||yes||during the subsequent 26 patient studies, pump shutoff occurred when either three of five ( n = 10) or two of five ( n = 16) algorithms predicted hypoglycemia based on the glucose levels measured with the freestyle navigator (abbott diabetes care).
amod||tuberculosis-2/NNS||multidrug-resistant-1/JJ	nsubj||is-6/VBZ||tuberculosis-2/NNS	appos||tuberculosis-2/NNS||mdr-tb-4/NNP	root||ROOT-0/null||is-6/VBZ	dep||resistant-9/NN||vitro-8/NN	prep_in||is-6/VBZ||resistant-9/NN	prep_to||is-6/VBZ||isoniazid-11/NN	appos||isoniazid-11/NN||h-13/NN	prep_to||is-6/VBZ||rifampicin-16/NN	conj_and||isoniazid-11/NN||rifampicin-16/NN	appos||isoniazid-11/NN||r-18/NN	tb--1||rifampicin-16||yes||multidrug-resistant tuberculosis (mdr-tb) is in vitro resistant to isoniazid (h) and rifampicin (r).
nsubj||messenger-6/NN||c-di-gmp-1/NN	cop||messenger-6/NN||is-2/VBZ	det||messenger-6/NN||a-3/DT	amod||messenger-6/NN||bacterial-4/JJ	amod||messenger-6/NN||second-5/JJ	root||ROOT-0/null||messenger-6/NN	vmod||messenger-6/NN||regulating-7/VBG	amod||phenotypes-10/NNS||diverse-8/JJ	amod||phenotypes-10/NNS||bacterial-9/JJ	dobj||regulating-7/VBG||phenotypes-10/NNS	advmod||phenotypes-10/NNS||notably-12/RB	nn||formation-16/NN||motility-13/NN	conj_and||motility-13/NN||biofilm-15/NN	nn||formation-16/NN||biofilm-15/NN	dep||phenotypes-10/NNS||formation-16/NN	prep_in||regulating-7/VBG||proteobacteria-19/NN	prep_such_as||proteobacteria-19/NN||vibriocholerae-22/NN	prep_such_as||proteobacteria-19/NN||pseudomonasaeruginosa-24/NN	conj_and||vibriocholerae-22/NN||pseudomonasaeruginosa-24/NN	prep_such_as||proteobacteria-19/NN||salmonella-27/NN	conj_and||vibriocholerae-22/NN||salmonella-27/NN	vibriocholerae-22||bacterial-9||no||c-di-gmp is a bacterial second messenger regulating diverse bacterial phenotypes, notably motility and biofilm formation, in proteobacteria such as vibriocholerae, pseudomonasaeruginosa , and salmonella .
nsubj||compared-2/VBD||we-1/PRP	nsubj||isolates-47/VBZ||we-1/PRP	root||ROOT-0/null||compared-2/VBD	det||performance-4/NN||the-3/DT	dobj||compared-2/VBD||performance-4/NN	det||mtbdr-9/NN||the-6/DT	nn||mtbdr-9/NN||genotypeâ-7/NNP	nn||mtbdr-9/NN||®-8/NNP	prep_of||performance-4/NN||mtbdr-9/NN	amod||specimens-45/NNS||assay-11/JJ	amod||tube-16/NN||mycobacterial-13/JJ	nn||tube-16/NN||growth-14/NN	nn||tube-16/NN||indicator-15/NN	prep_to||assay-11/JJ||tube-16/NN	amod||testing-20/NN||antimycobacterial-18/JJ	nn||testing-20/NN||susceptibility-19/NN	prep_for||tube-16/NN||testing-20/NN	amod||ast-23/NN||mgit-22/JJ	appos||testing-20/NN||ast-23/NN	nn||resistance-28/NN||detection-26/NN	nn||resistance-28/NN||inh-27/NN	prep_for||testing-20/NN||resistance-28/NN	nn||resistance-31/NN||rif-30/NN	appos||resistance-28/NN||resistance-31/NN	conj_and||assay-11/JJ||mdr-tb-34/JJ	amod||specimens-45/NNS||mdr-tb-34/JJ	amod||bacilli-38/NNS||stored-36/JJ	amod||bacilli-38/NNS||acid-fast-37/JJ	prep_in||mdr-tb-34/JJ||bacilli-38/NNS	appos||bacilli-38/NNS||afb-40/NN	amod||specimens-45/NNS||positive-43/JJ	nn||specimens-45/NNS||sputum-44/NN	dobj||compared-2/VBD||specimens-45/NNS	conj_plus||performance-4/NN||specimens-45/NNS	conj_and||compared-2/VBD||isolates-47/VBZ	det||laboratory-52/NN||a-49/DT	amod||laboratory-52/NN||public-50/JJ	nn||laboratory-52/NN||tb-51/NN	prep_at||isolates-47/VBZ||laboratory-52/NN	prep_in||laboratory-52/NN||bangkok-54/NN	dep||compared-2/VBD||thailand-56/VBD	tb-51||rif-30||yes||we compared the performance of the genotypeâ® mtbdr plus assay to mycobacterial growth indicator tube for antimycobacterial susceptibility testing (mgit ast) for detection inh resistance, rif resistance, and mdr-tb in stored acid-fast bacilli (afb)-positive sputum specimens and isolates at a public tb laboratory in bangkok, thailand.
nsubj||examined-2/VBD||we-1/PRP	root||ROOT-0/null||examined-2/VBD	det||benefit-5/NN||the-3/DT	amod||benefit-5/NN||relative-4/JJ	iobj||examined-2/VBD||benefit-5/NN	prepc_of||benefit-5/NN||introducing-7/VBG	amod||maintenance-12/NN||budesonide/formoterol-8/JJ	appos||maintenance-12/NN||bud/form-10/NNP	dobj||introducing-7/VBG||maintenance-12/NN	nn||therapy-15/NN||reliever-14/NN	dobj||introducing-7/VBG||therapy-15/NN	conj_and||maintenance-12/NN||therapy-15/NN	amod||®-21/NNP||symbicort-17/JJ	nn||®-21/NNP||smartâ-18/NNP	nn||®-21/NNP||®-19/NNP	nn||®-21/NNP||turbuhalerâ-20/NNP	appos||therapy-15/NN||®-21/NNP	prep_in||introducing-7/VBG||patients-24/NNS	advmod||prescribed-26/VBN||previously-25/RB	vmod||patients-24/NNS||prescribed-26/VBN	dobj||prescribed-26/VBN||treatments-27/NNS	amod||initiative-30/NN||global-29/JJ	prep_from||prescribed-26/VBN||initiative-30/NN	amod||steps-36/NNS||asthma-32/JJ	appos||steps-36/NNS||gina-34/NNP	prep_for||prescribed-26/VBN||steps-36/NNS	dobj||examined-2/VBD||2-37/CD	num||2-37/CD||3-39/CD	dobj||examined-2/VBD||4-41/CD	conj_or||2-37/CD||4-41/CD	asthma-32||budesonide--1||no||we examined the relative benefit of introducing budesonide/formoterol (bud/form) maintenance and reliever therapy (symbicort smartâ® turbuhalerâ®) in patients previously prescribed treatments from global initiative for asthma (gina) steps 2, 3 or 4.
nn||cancer-2/NN||breast-1/NN	nsubj||disease-6/NN||cancer-2/NN	nsubjpass||characterized-10/VBN||cancer-2/NN	cop||disease-6/NN||is-3/VBZ	det||disease-6/NN||a-4/DT	amod||disease-6/NN||heterogeneous-5/JJ	root||ROOT-0/null||disease-6/NN	aux||characterized-10/VBN||may-8/MD	auxpass||characterized-10/VBN||be-9/VB	conj_and||disease-6/NN||characterized-10/VBN	det||basis-13/NN||the-12/DT	prep_on||characterized-10/VBN||basis-13/NN	mark||expressed-22/VBN||whether-15/IN	nn||receptors-17/NNS||estrogen-16/NN	nsubjpass||expressed-22/VBN||receptors-17/NNS	appos||receptors-17/NNS||er-19/NN	auxpass||expressed-22/VBN||are-21/VBP	prepc_of||basis-13/NN||expressed-22/VBN	det||cells-26/NNS||the-24/DT	nn||cells-26/NNS||tumour-25/NN	prep_in||expressed-22/VBN||cells-26/NNS	cancer-2||estrogen-16||no_rel||breast cancer is a heterogeneous disease and may be characterized on the basis of whether estrogen receptors (er) are expressed in the tumour cells.
nsubj||found-2/VBD||we-1/PRP	root||ROOT-0/null||found-2/VBD	mark||enhances-12/VBZ||that-3/IN	det||treatment-5/NN||the-4/DT	nsubj||enhances-12/VBZ||treatment-5/NN	amod||cells-9/NNS||a375-7/JJ	nn||cells-9/NNS||melanoma-8/NN	prep_of||treatment-5/NN||cells-9/NNS	prep_with||cells-9/NNS||vemurafenib-11/NN	ccomp||found-2/VBD||enhances-12/VBZ	det||induction-14/NN||the-13/DT	dobj||enhances-12/VBZ||induction-14/NN	nn||i-18/NN||mhc-16/NN	nn||i-18/NN||class-17/NN	prep_of||induction-14/NN||i-18/NN	nn||molecules-22/NNS||class-20/NN	nn||molecules-22/NNS||ii-21/NN	prep_of||induction-14/NN||molecules-22/NNS	conj_and||i-18/NN||molecules-22/NNS	amod||³-26/NNP||interferon-24/JJ	nn||³-26/NNP||î-25/NN	prep_by||enhances-12/VBZ||³-26/NNP	nn||2b-30/NNS||ifnî-28/NNP	nn||2b-30/NNS||±-29/NNP	prep_by||enhances-12/VBZ||2b-30/NNS	conj_and||³-26/NNP||2b-30/NNS	melanoma-8||interferon-24||yes||we found that the treatment of a375 melanoma cells with vemurafenib enhances the induction of mhc class i and class ii molecules by interferon î³ and ifnî±2b.
det||increase-3/NN||the-1/DT	amod||increase-3/NN||observed-2/JJ	nsubj||indicates-10/VBZ||increase-3/NN	amod||ratio-9/NN||serum-5/JJ	amod||ratio-9/NN||igf-1-6/JJ	conj_and||igf-1-6/JJ||insulin-to-glucose-8/JJ	amod||ratio-9/NN||insulin-to-glucose-8/JJ	prep_of||increase-3/NN||ratio-9/NN	root||ROOT-0/null||indicates-10/VBZ	mark||result-15/VB||that-11/IN	nn||restriction-13/NN||sleep-12/NN	nsubj||result-15/VB||restriction-13/NN	aux||result-15/VB||may-14/MD	ccomp||indicates-10/VBZ||result-15/VB	det||risk-19/NN||an-17/DT	amod||risk-19/NN||increased-18/VBN	prep_in||result-15/VB||risk-19/NN	aux||develop-21/VB||to-20/TO	vmod||risk-19/NN||develop-21/VB	dobj||develop-21/VB||type2diabetes-22/NNS	type2diabetes-22||glucose--1||no_rel||the observed increase of serum igf-1 and insulin-to-glucose ratio indicates that sleep restriction may result in an increased risk to develop type2diabetes.
vmod||established-18/VBD||based-1/VBN	amod||similarities-8/NNS||clinical-3/JJ	conj_and||clinical-3/JJ||histopathological-5/JJ	amod||similarities-8/NNS||histopathological-5/JJ	conj_and||clinical-3/JJ||serological-7/JJ	amod||similarities-8/NNS||serological-7/JJ	prep_on||based-1/VBN||similarities-8/NNS	amod||celiacdisease-11/NN||human-10/JJ	prep_to||based-1/VBN||celiacdisease-11/NN	appos||celiacdisease-11/NN||cd-13/NN	nsubj||established-18/VBD||we-16/PRP	advmod||established-18/VBD||recently-17/RB	root||ROOT-0/null||established-18/VBD	det||model-22/NN||the-19/DT	amod||model-22/NN||rhesus-20/JJ	nn||model-22/NN||macaque-21/NN	dobj||established-18/VBD||model-22/NN	prep_of||model-22/NN||glutensensitivity-24/NN	cd-13||glutensensitivity-24||no_rel||based on clinical, histopathological and serological similarities to human celiacdisease (cd), we recently established the rhesus macaque model of glutensensitivity.
aux||begin-2/VB||to-1/TO	advcl||utilized-23/VBD||begin-2/VB	aux||understand-4/VB||to-3/TO	xcomp||begin-2/VB||understand-4/VB	det||contributions-6/NNS||the-5/DT	dobj||understand-4/VB||contributions-6/NNS	amod||obesity-9/NN||maternal-8/JJ	prep_of||contributions-6/NNS||obesity-9/NN	prep_of||contributions-6/NNS||over-nutrition-11/NN	conj_and||obesity-9/NN||over-nutrition-11/NN	amod||development-14/NN||human-13/JJ	prep_to||understand-4/VB||development-14/NN	det||origins-18/NNS||the-16/DT	amod||origins-18/NNS||early-17/JJ	prep_to||understand-4/VB||origins-18/NNS	conj_and||development-14/NN||origins-18/NNS	prep_of||origins-18/NNS||obesity-20/NN	nsubj||utilized-23/VBD||we-22/PRP	root||ROOT-0/null||utilized-23/VBD	det||model-27/NN||a-24/DT	amod||model-27/NN||non-human-25/JJ	nn||model-27/NN||primate-26/NN	dobj||utilized-23/VBD||model-27/NN	aux||investigate-29/VB||to-28/TO	vmod||utilized-23/VBD||investigate-29/VB	det||effects-31/NNS||the-30/DT	dobj||investigate-29/VB||effects-31/NNS	amod||feeding-35/NN||maternal-33/JJ	amod||feeding-35/NN||high-fat-34/JJ	prep_of||effects-31/NNS||feeding-35/NN	vmod||utilized-23/VBD||obesity-37/VB	conj_and||investigate-29/VB||obesity-37/VB	nn||milk-40/NN||breast-39/NN	prep_on||obesity-37/VB||milk-40/NN	prep_on||obesity-37/VB||maternal-42/NN	conj_and||milk-40/NN||maternal-42/NN	amod||composition-47/NN||fetal-44/JJ	nn||composition-47/NN||plasma-45/NN	nn||composition-47/NN||fattyacid-46/NN	prep_on||obesity-37/VB||composition-47/NN	conj_and||milk-40/NN||composition-47/NN	amod||development-51/NN||fetal-49/JJ	amod||development-51/NN||hepatic-50/JJ	conj_and||milk-40/NN||development-51/NN	conj_and||composition-47/NN||development-51/NN	obesity-37||fat--1||no_rel||to begin to understand the contributions of maternal obesity and over-nutrition to human development and the early origins of obesity, we utilized a non-human primate model to investigate the effects of maternal high-fat feeding and obesity on breast milk, maternal and fetal plasma fattyacid composition and fetal hepatic development.
advmod||focused-4/VBD||here-1/RB	nsubj||focused-4/VBD||we-3/PRP	nsubj||potentiate-14/VB||we-3/PRP	root||ROOT-0/null||focused-4/VBD	det||combination-7/NN||the-6/DT	prep_on||focused-4/VBD||combination-7/NN	prep_of||combination-7/NN||cq-9/NN	det||mechanism-12/NN||a-11/DT	prep_as||focused-4/VBD||mechanism-12/NN	aux||potentiate-14/VB||to-13/TO	xcomp||focused-4/VBD||potentiate-14/VB	det||effect-17/NN||the-15/DT	amod||effect-17/NN||inhibitory-16/JJ	dobj||potentiate-14/VB||effect-17/NN	amod||cells-24/NNS||5-fu-19/JJ	amod||colon-22/NN||human-21/JJ	prep_on||5-fu-19/JJ||colon-22/NN	nn||cells-24/NNS||cancer-23/NN	prep_of||effect-17/NN||cells-24/NNS	5-fu-19||cancer-23||no_rel||here, we focused on the combination of cq as a mechanism to potentiate the inhibitory effect of 5-fu on human colon cancer cells.
nsubj||choice-8/NN||methotrexate-1/NN	appos||methotrexate-1/NN||mtx-3/NN	cop||choice-8/NN||is-5/VBZ	det||choice-8/NN||the-6/DT	amod||choice-8/NN||first-7/JJ	root||ROOT-0/null||choice-8/NN	amod||drug-12/NN||conventional-9/JJ	amod||drug-12/NN||disease-modifying-10/JJ	amod||drug-12/NN||antirheumatic-11/JJ	dep||choice-8/NN||drug-12/NN	dep||choice-8/NN||dmard-14/VBN	prep_for||choice-8/NN||rheumatoidarthritis-17/NNS	rheumatoidarthritis-17||methotrexate-1||yes||methotrexate (mtx) is the first choice conventional disease-modifying antirheumatic drug (dmard) for rheumatoidarthritis.
poss||data-2/NNS||our-1/PRP$	nsubj||suggested-3/VBD||data-2/NNS	root||ROOT-0/null||suggested-3/VBD	mark||have-9/VB||that-4/IN	amod||b-celllymphoma-7/NN||primary-5/JJ	amod||b-celllymphoma-7/NN||gastric-6/JJ	nsubj||have-9/VB||b-celllymphoma-7/NN	aux||have-9/VB||might-8/MD	ccomp||suggested-3/VBD||have-9/VB	det||outcome-12/NN||an-10/DT	amod||outcome-12/NN||improved-11/JJ	dobj||have-9/VB||outcome-12/NN	prep_with||have-9/VB||rituximab-14/NN	prep_in||rituximab-14/NN||addition-16/NN	aux||chemotherapy-18/VB||to-17/TO	vmod||have-9/VB||chemotherapy-18/VB	b-celllymphoma-7||rituximab-14||yes||our data suggested that primary gastric b-celllymphoma might have an improved outcome with rituximab in addition to chemotherapy.
prepc_based_on||tested-28/VBD||on-2/IN	det||premise-4/NN||the-3/DT	pobj||tested-28/VBD||premise-4/NN	mark||receiving-21/VBG||that-5/IN	amod||patients-7/NNS||postabsorptive-6/JJ	nsubj||receiving-21/VBG||patients-7/NNS	prep_with||patients-7/NNS||type1diabetes-9/NNS	vmod||type1diabetes-9/NNS||receiving-10/VBG	amod||insulin-12/NN||intravenous-11/JJ	dobj||receiving-10/VBG||insulin-12/NN	det||dose-15/NN||a-14/DT	prep_in||receiving-10/VBG||dose-15/NN	nsubj||maintains-17/VBZ||dose-15/NN	rcmod||dose-15/NN||maintains-17/VBZ	amod||euglycemia-19/NN||stable-18/JJ	dobj||maintains-17/VBZ||euglycemia-19/NN	aux||receiving-21/VBG||are-20/VBP	dep||premise-4/NN||receiving-21/VBG	advmod||optimal-23/JJ||biologically-22/RB	amod||replacement-25/NN||optimal-23/JJ	nn||replacement-25/NN||insulin-24/NN	dobj||receiving-21/VBG||replacement-25/NN	nsubj||tested-28/VBD||we-27/PRP	root||ROOT-0/null||tested-28/VBD	det||hypothesis-30/NNS||the-29/DT	dobj||tested-28/VBD||hypothesis-30/NNS	mark||supports-33/VBZ||that-31/IN	nsubj||supports-33/VBZ||glucagon-32/NN	ccomp||tested-28/VBD||supports-33/VBZ	amod||concentrations-37/NNS||postabsorptive-34/JJ	nn||concentrations-37/NNS||plasma-35/NN	nn||concentrations-37/NNS||glucose-36/NN	dobj||supports-33/VBZ||concentrations-37/NNS	prep_in||concentrations-37/NNS||humans-39/NNS	type1diabetes-9||insulin-24||yes||based on the premise that postabsorptive patients with type1diabetes receiving intravenous insulin in a dose that maintains stable euglycemia are receiving biologically optimal insulin replacement, we tested the hypothesis that glucagon supports postabsorptive plasma glucose concentrations in humans.
vmod||showed-9/VBD||using-1/VBG	det||model-4/NN||an-2/DT	amod||model-4/NN||orthotopic-3/JJ	dobj||using-1/VBG||model-4/NN	prep_of||model-4/NN||renalcellcarcinoma-6/NN	nsubj||showed-9/VBD||we-8/PRP	root||ROOT-0/null||showed-9/VBD	advmod||showed-9/VBD||previously-10/RB	mark||resulted-16/VBD||that-11/IN	amod||immunotherapy-15/NN||il-2-12/JJ	amod||immunotherapy-15/NN||/-13/JJ	amod||immunotherapy-15/NN||anti-cd40-14/JJ	nsubj||resulted-16/VBD||immunotherapy-15/NN	ccomp||showed-9/VBD||resulted-16/VBD	amod||responses-20/NNS||synergistic-18/JJ	amod||responses-20/NNS||anti-tumor-19/JJ	prep_in||resulted-16/VBD||responses-20/NNS	mark||mediated-30/VBD||whereas-22/IN	amod||cd40-28/NNS||il-2-23/JJ	advmod||±-26/JJ||î-25/RB	conj_or||il-2-23/JJ||±-26/JJ	amod||cd40-28/NNS||±-26/JJ	nsubj||mediated-30/VBD||cd40-28/NNS	advmod||mediated-30/VBD||alone-29/RB	advcl||resulted-16/VBD||mediated-30/VBD	amod||effects-34/NNS||partial-31/JJ	amod||effects-34/NNS||transient-32/JJ	nn||effects-34/NNS||anti-tumor-33/NN	dobj||mediated-30/VBD||effects-34/NNS	renalcellcarcinoma-6||il-2-23||no_rel||using an orthotopic model of renalcellcarcinoma, we showed previously that il-2/anti-cd40 immunotherapy resulted in synergistic anti-tumor responses, whereas il-2 or î±-cd40 alone mediated partial transient anti-tumor effects.
nsubj||piloting-3/VBG||zambia-1/NN	aux||piloting-3/VBG||is-2/VBZ	root||ROOT-0/null||piloting-3/VBG	det||use-5/NN||the-4/DT	dobj||piloting-3/VBG||use-5/NN	prep_of||use-5/NN||artemether-lumefantrine-7/NN	appos||artemether-lumefantrine-7/NN||al-9/NNP	nn||workers-14/NNS||community-12/NN	nn||workers-14/NNS||health-13/NN	prep_by||piloting-3/VBG||workers-14/NNS	appos||workers-14/NNS||chws-16/NNS	aux||treat-19/VB||to-18/TO	vmod||piloting-3/VBG||treat-19/VB	amod||malaria-21/NN||uncomplicated-20/JJ	dobj||treat-19/VB||malaria-21/NN	malaria-21||lumefantrine--1||yes||zambia is piloting the use of artemether-lumefantrine (al) by community health workers (chws) to treat uncomplicated malaria.
nsubj||used-2/VBD||we-1/PRP	root||ROOT-0/null||used-2/VBD	nn||rip-chip-4/NN||hur-3/NN	dobj||used-2/VBD||rip-chip-4/NN	det||method-10/NN||a-6/DT	amod||method-10/NN||comprehensive-7/JJ	conj_and||comprehensive-7/JJ||systematic-9/JJ	amod||method-10/NN||systematic-9/JJ	prep_as||used-2/VBD||method-10/NN	aux||survey-12/VB||to-11/TO	vmod||used-2/VBD||survey-12/VB	nn||genes-16/NNS||breast-13/NN	nn||genes-16/NNS||cancer-14/NN	nn||genes-16/NNS||target-15/NN	dobj||survey-12/VB||genes-16/NNS	det||lines-41/NNS||both-18/DT	amod||lines-41/NNS||mcf-7-19/JJ	nn||positive-23/NN||estrogen-21/NN	nn||positive-23/NN||receptor-22/NN	dep||mcf-7-19/JJ||positive-23/NN	nn||+-26/NNS||er-25/NN	appos||positive-23/NN||+-26/NNS	conj_and||mcf-7-19/JJ||mda-mb-231-29/JJ	amod||lines-41/NNS||mda-mb-231-29/JJ	num||receptor-32/NN||estrogen-31/CD	npadvmod||negative-33/JJ||receptor-32/NN	dep||er-35/NN||negative-33/JJ	dep||mda-mb-231-29/JJ||er-35/NN	nn||lines-41/NNS||breast-38/NN	nn||lines-41/NNS||cancer-39/NN	nn||lines-41/NNS||cell-40/NN	prep_in||genes-16/NNS||lines-41/NNS	cancer-39||estrogen-31||no_rel||we used hur rip-chip as a comprehensive and systematic method to survey breast cancer target genes in both mcf-7 (estrogen receptor positive, er+) and mda-mb-231 (estrogen receptor negative, er-) breast cancer cell lines.
advmod||found-4/VBD||therefore-1/RB	nsubj||found-4/VBD||we-3/PRP	root||ROOT-0/null||found-4/VBD	mark||has-24/VBZ||that-5/IN	nsubj||has-24/VBZ||ropivacaine-6/NN	advmod||ropivacaine-6/NN||alone-8/RB	advmod||ropivacaine-6/NN||with-10/IN	conj_or||alone-8/RB||with-10/IN	pobj||with-10/IN||morphine-11/NN	vmod||ropivacaine-6/NN||injected-13/VBN	det||tissue-17/NN||the-15/DT	amod||tissue-17/NN||synovial-16/JJ	prep_into||injected-13/VBN||tissue-17/NN	det||pca-23/NN||an-21/DT	amod||pca-23/NN||epidural-22/JJ	prep_along_with||has-24/VBZ||pca-23/NN	ccomp||found-4/VBD||has-24/VBZ	neg||benefits-27/NNS||no-25/DT	amod||benefits-27/NNS||additional-26/JJ	dobj||has-24/VBZ||benefits-27/NNS	nn||control-30/NN||pain-29/NN	prep_in||benefits-27/NNS||control-30/NN	det||arthroplasty-35/NN||a-32/DT	amod||arthroplasty-35/NN||total-33/JJ	nn||arthroplasty-35/NN||knee-34/NN	prep_after||has-24/VBZ||arthroplasty-35/NN	pain-29||ropivacaine-6||yes||therefore, we found that ropivacaine, alone or with morphine, injected into the synovial tissue, along with an epidural pca has no additional benefits in pain control after a total knee arthroplasty.
nsubj||studied-2/VBD||we-1/PRP	root||ROOT-0/null||studied-2/VBD	advmod||studied-2/VBD||prospectively-3/RB	num||groups-5/NNS||three-4/CD	dobj||studied-2/VBD||groups-5/NNS	iobj||studied-2/VBD||groups-5/NNS	prep_of||groups-5/NNS||patients-7/NNS	appos||groups-5/NNS||1-9/CD	num||group-12/NN||one-11/CD	dep||groups-5/NNS||group-12/NN	num||patients-15/NNS||35-14/CD	prep_of||group-12/NN||patients-15/NNS	prep_with||patients-15/NNS||fibroticdisorders-17/NNS	prep_of||group-12/NN||16-19/CD	conj_and||patients-15/NNS||16-19/CD	amod||pulmonaryfibrosis-22/NNS||idiopathic-21/JJ	prep_with||16-19/CD||pulmonaryfibrosis-22/NNS	appos||pulmonaryfibrosis-22/NNS||ipf-24/NN	prep_of||group-12/NN||19-27/CD	conj_and||patients-15/NNS||19-27/CD	amod||pneumonias-31/NNS||fibrotic-29/JJ	amod||pneumonias-31/NNS||interstitial-30/JJ	prep_with||19-27/CD||pneumonias-31/NNS	vmod||group-12/NN||associated-32/VBN	nn||disorders-36/NNS||collagen-34/NN	nn||disorders-36/NNS||tissue-35/NN	prep_with||associated-32/VBN||disorders-36/NNS	dep||group-12/NN||ctd-ips-38/NNS	dep||group-45/NN||2-42/LS	num||group-45/NN||one-44/CD	dep||group-12/NN||group-45/NN	num||patients-48/NNS||14-47/CD	prep_of||group-45/NN||patients-48/NNS	prep_with||patients-48/NNS||pulmonarysarcoidosis-50/NNS	appos||patients-48/NNS||3-54/CD	num||subjects-58/NNS||11-56/CD	amod||subjects-58/NNS||normal-57/JJ	prep_of||group-45/NN||subjects-58/NNS	conj_and||patients-48/NNS||subjects-58/NNS	pneumonias-31||collagen-34||no_rel||we studied prospectively three groups of patients (1) one group of 35 patients with fibroticdisorders, 16 with idiopathic pulmonaryfibrosis (ipf) and 19 with fibrotic interstitial pneumonias associated with collagen tissue disorders (ctd-ips); (2) one group of 14 patients with pulmonarysarcoidosis; and (3) 11 normal subjects.
det||populations-3/NNS||the-1/DT	nn||populations-3/NNS||study-2/NN	nsubj||parents/caretakers-5/NNS||populations-3/NNS	cop||parents/caretakers-5/NNS||were-4/VBD	root||ROOT-0/null||parents/caretakers-5/NNS	conj_and||parents/caretakers-5/NNS||children-7/NNS	vmod||parents/caretakers-5/NNS||living-8/VBG	prep_with||living-8/VBG||hiv/aids-10/NNS	nsubj||receiving-13/VBG||hiv/aids-10/NNS	aux||receiving-13/VBG||were-12/VBD	rcmod||hiv/aids-10/NNS||receiving-13/VBG	advmod||active-15/JJ||highly-14/RB	amod||therapy-17/NN||active-15/JJ	amod||therapy-17/NN||antiretroviral-16/JJ	dobj||receiving-13/VBG||therapy-17/NN	appos||therapy-17/NN||haart-19/NN	amod||hospitals-23/NNS||selected-22/VBN	prep_in||receiving-13/VBG||hospitals-23/NNS	amod||ababa-26/NN||addis-25/JJ	prep_in||hospitals-23/NNS||ababa-26/NN	aids--1||hiv--1||no||the study populations were parents/caretakers and children living with hiv/aids who were receiving highly active antiretroviral therapy (haart) in selected hospitals in addis ababa.
det||progress-4/NN||the-2/DT	amod||progress-4/NN||recent-3/JJ	prep_despite||remains-15/VBZ||progress-4/NN	amod||therapies-10/NNS||interferon-6/JJ	appos||therapies-10/NNS||ifn-8/NN	prep_in||progress-4/NN||therapies-10/NNS	prep_for||progress-4/NN||chronichepatitisc-12/NN	nsubj||remains-15/VBZ||livercirrhosis-14/NNS	root||ROOT-0/null||remains-15/VBZ	xcomp||remains-15/VBZ||refractory-16/JJ	chronichepatitisc-12||interferon-6||yes||despite the recent progress in interferon (ifn) therapies for chronichepatitisc, livercirrhosis remains refractory.
nsubj||reduced-9/VBD||conclusion-1/NN	amod||doses-4/NNS||lower-2/JJR	nn||doses-4/NNS||statin-3/NN	nsubj||advised-8/VBD||doses-4/NNS	prep_than||doses-4/NNS||those-6/DT	advmod||advised-8/VBD||currently-7/RB	rcmod||conclusion-1/NN||advised-8/VBD	root||ROOT-0/null||reduced-9/VBD	det||risk-11/NN||the-10/DT	dobj||reduced-9/VBD||risk-11/NN	prep_of||risk-11/NN||coronaryheartdisease-13/NN	det||extent-17/NN||a-15/DT	amod||extent-17/NN||greater-16/JJR	prep_to||reduced-9/VBD||extent-17/NN	advmod||anticipated-19/VBN||than-18/IN	vmod||extent-17/NN||anticipated-19/VBN	prep_in||anticipated-19/VBN||patients-21/NNS	prep_with||patients-21/NNS||familialhypercholesterolaemia-23/NN	statin-3||familialhypercholesterolaemia-23||no_rel||conclusion lower statin doses than those currently advised reduced the risk of coronaryheartdisease to a greater extent than anticipated in patients with familialhypercholesterolaemia.
prep||proven-13/VBN||given-1/VBN	advmod||daily-3/JJ||once-2/RB	advmod||at-4/IN||daily-3/JJ	pcomp||given-1/VBN||at-4/IN	num||mg-6/NN||150-5/CD	pobj||at-4/IN||mg-6/NN	num||mg-9/NN||220-8/CD	pobj||at-4/IN||mg-9/NN	conj_or||mg-6/NN||mg-9/NN	nsubj||proven-13/VBN||it-11/PRP	nsubj||competitive-16/JJ||it-11/PRP	aux||proven-13/VBN||has-12/VBZ	root||ROOT-0/null||proven-13/VBN	aux||competitive-16/JJ||to-14/TO	cop||competitive-16/JJ||be-15/VB	xcomp||proven-13/VBN||competitive-16/JJ	prep_with||competitive-16/JJ||enoxaparin-18/NN	det||prevention-21/NN||the-20/DT	prep_in||enoxaparin-18/NN||prevention-21/NN	amod||thromboembolism-24/NN||venous-23/JJ	prep_of||prevention-21/NN||thromboembolism-24/NN	amod||surgery-28/NN||major-26/JJ	amod||surgery-28/NN||orthopedic-27/JJ	prep_after||competitive-16/JJ||surgery-28/NN	det||profile-34/NN||a-31/DT	amod||profile-34/NN||comparable-32/JJ	nn||profile-34/NN||safety-33/NN	prep_with||competitive-16/JJ||profile-34/NN	thromboembolism-24||enoxaparin-18||yes||given once daily at 150 mg or 220 mg, it has proven to be competitive with enoxaparin in the prevention of venous thromboembolism after major orthopedic surgery, with a comparable safety profile.
det||rat-3/NN||the-1/DT	nn||rat-3/NN||wistar-2/NN	nsubj||model-7/NN||rat-3/NN	cop||model-7/NN||is-4/VBZ	det||model-7/NN||a-5/DT	amod||model-7/NN||valuable-6/JJ	root||ROOT-0/null||model-7/NN	nsubj||result-14/VBP||model-7/NN	amod||interactions-12/NNS||better-9/JJR	nn||interactions-12/NNS||understanding-10/NN	amod||interactions-12/NNS||host-pathogen-11/JJ	prep_for||model-7/NN||interactions-12/NNS	rcmod||model-7/NN||result-14/VBP	prep_in||result-14/VBP||control-16/NN	nn||infection-19/NN||mtb-18/NN	prep_of||control-16/NN||infection-19/NN	advmod||establishment-22/NN||potentially-21/RB	conj_and||model-7/NN||establishment-22/NN	nsubj||result-14/VBP||establishment-22/NN	nn||tb-25/NN||latent-24/NN	prep_of||establishment-22/NN||tb-25/NN	tb-25||mtb-18||no||the wistar rat is a valuable model for better understanding host-pathogen interactions that result in control of mtb infection and potentially establishment of latent tb.
det||analysis-2/NN||this-1/DT	nsubjpass||carried-4/VBN||analysis-2/NN	auxpass||carried-4/VBN||was-3/VBD	root||ROOT-0/null||carried-4/VBN	prt||carried-4/VBN||out-5/RP	det||context-8/NN||the-7/DT	prep_in||carried-4/VBN||context-8/NN	det||trial-11/NN||a-10/DT	prep_of||context-8/NN||trial-11/NN	amod||treatment-16/NN||malaria-13/JJ	amod||treatment-16/NN||intermittent-14/JJ	nn||treatment-16/NN||preventive-15/NN	prep_of||trial-11/NN||treatment-16/NN	prep_in||treatment-16/NN||pregnancy-18/NN	amod||iptp-sp-22/NN||sulphadoxine-pyrimethamine-20/JJ	prep_with||carried-4/VBN||iptp-sp-22/NN	advmod||received-29/VBD||where-25/WRB	det||groups-28/NNS||both-26/DT	nn||groups-28/NNS||intervention-27/NN	nsubj||received-29/VBD||groups-28/NNS	rcmod||iptp-sp-22/NN||received-29/VBD	det||insecticide-31/NN||an-30/DT	nsubj||treated-32/VBD||insecticide-31/NN	ccomp||received-29/VBD||treated-32/VBD	dobj||treated-32/VBD||net-33/NN	det||clinic-37/NN||the-35/DT	amod||clinic-37/NN||antenatal-36/JJ	prep_through||treated-32/VBD||clinic-37/NN	appos||clinic-37/NN||anc-39/NN	prep_in||treated-32/VBD||mozambique-42/NN	malaria-13||pyrimethamine--1||no||this analysis was carried out in the context of a trial of malaria intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine (iptp-sp), where both intervention groups received an insecticide treated net through the antenatal clinic (anc) in mozambique.
nsubj||mitigated-3/VBD||oliveoil-1/NN	advmod||mitigated-3/VBD||effectively-2/RB	root||ROOT-0/null||mitigated-3/VBD	amod||osteoporosis-5/NNS||ovariectomy-induced-4/JJ	dobj||mitigated-3/VBD||osteoporosis-5/NNS	prep_in||mitigated-3/VBD||rats-7/NNS	cop||candidate-13/NN||is-10/VBZ	det||candidate-13/NN||a-11/DT	amod||candidate-13/NN||promising-12/JJ	conj_and||mitigated-3/VBD||candidate-13/NN	det||treatment-16/NN||the-15/DT	prep_for||candidate-13/NN||treatment-16/NN	prep_of||treatment-16/NN||postmenopausalosteoporosis-18/NNS	postmenopausalosteoporosis-18||oliveoil-1||no_rel||oliveoil effectively mitigated ovariectomy-induced osteoporosis in rats, and is a promising candidate for the treatment of postmenopausalosteoporosis.
nsubjpass||associated-58/VBN||quartiles-1/NNS	nsubjpass||related-83/VBN||quartiles-1/NNS	prep_of||quartiles-1/NNS||acr-3/NN	amod||-RSB--8/NNS||median-5/JJ	amod||-RSB--8/NNS||-LSB--6/JJ	nn||-RSB--8/NNS||range-7/NN	dep||quartiles-1/NNS||-RSB--8/NNS	amod||1-11/CD||quartiles-10/JJ	prep_within||-RSB--8/NNS||1-11/CD	npadvmod||-LSB--14/RB||3.0-13/CD	advmod||-RSB--8/NNS||-LSB--14/RB	num||â-16/NN||0.7-15/CD	dep||-RSB--8/NNS||â-16/NN	num||-RSB--20/NNS||$-17/$	num||$-17/$||3.7-19/CD	dep||â-16/NN||-RSB--20/NNS	dep||-RSB--8/NNS||2-22/CD	conj_and||â-16/NN||2-22/CD	num||-RSB--31/NNS||4.6-24/CD	number||3.7-26/CD||-LSB--25/CD	num||-RSB--31/NNS||3.7-26/CD	amod||-RSB--31/NNS||â-27/JJ	num||-RSB--31/NNS||$-28/$	num||$-28/$||5.5-30/CD	appos||2-22/CD||-RSB--31/NNS	dep||-RSB--8/NNS||3-33/CD	conj_and||â-16/NN||3-33/CD	num||-RSB--42/NNS||7.1-35/CD	number||5.5-37/CD||-LSB--36/CD	num||-RSB--42/NNS||5.5-37/CD	amod||-RSB--42/NNS||â-38/JJ	num||-RSB--42/NNS||$-39/$	num||$-39/$||9.7-41/CD	appos||3-33/CD||-RSB--42/NNS	dep||-RSB--8/NNS||4-45/CD	conj_and||â-16/NN||4-45/CD	num||-RSB--54/NNS||16.5-47/CD	number||9.7-49/CD||-LSB--48/CD	num||-RSB--54/NNS||9.7-49/CD	amod||-RSB--54/NNS||â-50/JJ	num||-RSB--54/NNS||$-51/$	num||$-51/$||1,578-53/CD	appos||4-45/CD||-RSB--54/NNS	auxpass||associated-58/VBN||were-56/VBD	advmod||associated-58/VBN||positively-57/RB	root||ROOT-0/null||associated-58/VBN	prep_with||associated-58/VBN||age-60/NN	prep_with||associated-58/VBN||markers-62/NNS	conj_and||age-60/NN||markers-62/NNS	nn||secretion-67/NN||adiposity-64/NN	conj_and||adiposity-64/NN||insulin-66/NN	nn||secretion-67/NN||insulin-66/NN	prep_of||markers-62/NNS||secretion-67/NN	prep_of||markers-62/NNS||resistance-69/NN	conj_and||secretion-67/NN||resistance-69/NN	nn||pressure-72/NN||blood-71/NN	appos||secretion-67/NN||pressure-72/NN	prep_with||associated-58/VBN||use-75/NN	conj_and||age-60/NN||use-75/NN	prep_of||use-75/NN||antihypertensiveagents-77/NNS	amod||effects-80/NNS||antiproteinuric-79/JJ	prep_with||antihypertensiveagents-77/NNS||effects-80/NNS	advmod||related-83/VBN||inversely-82/RB	conj_and||associated-58/VBN||related-83/VBN	amod||sex-86/NN||male-85/JJ	prep_to||related-83/VBN||sex-86/NN	nn||creatinine-89/NN||serum-88/NN	prep_to||related-83/VBN||creatinine-89/NN	conj_and||sex-86/NN||creatinine-89/NN	adiposity-64||antihypertensiveagents-77||no_rel||quartiles of acr (median [range] within quartiles 1, 3.0 [0.7â3.7]; 2, 4.6 [3.7â5.5]; 3, 7.1 [5.5â9.7]; and 4, 16.5 [9.7â1,578]) were positively associated with age, markers of adiposity and insulin secretion and resistance, blood pressure, and use of antihypertensiveagents with antiproteinuric effects and inversely related to male sex and serum creatinine.
nsubj||active-9/JJ||combinations-1/NNS	prep_of||combinations-1/NNS||capecitabine-3/NN	det||taxane-6/NN||a-5/DT	prep_of||combinations-1/NNS||taxane-6/NN	conj_and||capecitabine-3/NN||taxane-6/NN	cop||active-9/JJ||are-7/VBP	advmod||active-9/JJ||highly-8/RB	root||ROOT-0/null||active-9/JJ	amod||cancer-13/NN||metastatic-11/JJ	nn||cancer-13/NN||breast-12/NN	prep_in||active-9/JJ||cancer-13/NN	nsubjpass||demonstrated-24/VBN||synergy-16/NN	prep_between||synergy-16/NN||capecitabine-18/NN	prep_between||synergy-16/NN||docetaxel-20/NN	conj_and||capecitabine-18/NN||docetaxel-20/NN	aux||demonstrated-24/VBN||has-21/VBZ	advmod||demonstrated-24/VBN||also-22/RB	auxpass||demonstrated-24/VBN||been-23/VBN	conj_and||active-9/JJ||demonstrated-24/VBN	cancer-13||capecitabine-18||no_rel||combinations of capecitabine and a taxane are highly active in metastatic breast cancer, and synergy between capecitabine and docetaxel has also been demonstrated.
advmod||appears-7/VBZ||furthermore-1/RB	det||effectiveness-4/NN||the-3/DT	nsubj||appears-7/VBZ||effectiveness-4/NN	nsubj||greater-10/JJR||effectiveness-4/NN	prep_of||effectiveness-4/NN||vildagliptin-6/NN	root||ROOT-0/null||appears-7/VBZ	aux||greater-10/JJR||to-8/TO	cop||greater-10/JJR||be-9/VB	xcomp||appears-7/VBZ||greater-10/JJR	advmod||used-14/VBN||when-11/WRB	nsubjpass||used-14/VBN||insulin-12/NN	auxpass||used-14/VBN||is-13/VBZ	ccomp||greater-10/JJR||used-14/VBN	det||regimen-18/NN||a-16/DT	amod||regimen-18/NN||basal-17/JJ	prep_as||used-14/VBN||regimen-18/NN	advmod||opposed-20/VBN||as-19/RB	amod||regimen-18/NN||opposed-20/VBN	auxpass||used-23/VBN||being-22/VBG	prepc_to||greater-10/JJR||used-23/VBN	aux||reduce-25/VB||to-24/TO	xcomp||used-23/VBN||reduce-25/VB	amod||hyperglycemia-27/NN||postprandial-26/JJ	dobj||reduce-25/VB||hyperglycemia-27/NN	mark||plays-35/VBZ||since-29/IN	nsubj||plays-35/VBZ||improvement-30/NN	nn||secretion-33/NN||insulin-32/NN	prep_in||improvement-30/NN||secretion-33/NN	advmod||plays-35/VBZ||likely-34/RB	advcl||appears-7/VBZ||plays-35/VBZ	det||role-38/NN||a-36/DT	amod||role-38/NN||minor-37/JJ	dobj||plays-35/VBZ||role-38/NN	tmod||administered-46/VBN||role-38/NN	advmod||administered-46/VBN||when-39/WRB	advmod||high-41/JJ||relatively-40/RB	amod||doses-42/NNS||high-41/JJ	nsubjpass||administered-46/VBN||doses-42/NNS	prep_of||doses-42/NNS||insulin-44/NN	auxpass||administered-46/VBN||are-45/VBP	rcmod||role-38/NN||administered-46/VBN	prep_before||administered-46/VBN||meals-48/NNS	hyperglycemia-27||insulin-44||yes||furthermore, the effectiveness of vildagliptin appears to be greater when insulin is used as a basal regimen as opposed to being used to reduce postprandial hyperglycemia, since improvement in insulin secretion likely plays a minor role when relatively high doses of insulin are administered before meals.
nsubj||vaccinated-13/VBD||objective-1/NN	aux||compare-3/VB||to-2/TO	vmod||objective-1/NN||compare-3/VB	det||incidence-5/NN||the-4/DT	dobj||compare-3/VB||incidence-5/NN	prep_of||incidence-5/NN||tuberculosis-7/NNP	num||years-10/NNS||two-9/CD	prep_over||compare-3/VB||years-10/NNS	prep_in||years-10/NNS||infants-12/NNS	root||ROOT-0/null||vaccinated-13/VBD	prep_at||vaccinated-13/VBD||birth-15/NN	amod||bcg-18/NN||intradermal-17/JJ	prep_with||vaccinated-13/VBD||bcg-18/NN	amod||bcg-22/NN||percutaneous-21/JJ	prep_with||vaccinated-13/VBD||bcg-22/NN	conj_or||bcg-18/NN||bcg-22/NN	tuberculosis-7||bcg-22||no||objective to compare the incidence of tuberculosis over two years in infants vaccinated at birth with intradermal bcg or with percutaneous bcg.
det||proof-3/NN||this-2/DT	prep_for||compared-9/VBD||proof-3/NN	amod||study-6/NN||principal-5/JJ	prep_of||proof-3/NN||study-6/NN	nsubj||compared-9/VBD||we-8/PRP	root||ROOT-0/null||compared-9/VBD	amod||clearance-11/NN||bacillary-10/JJ	dobj||compared-9/VBD||clearance-11/NN	det||lungs-14/NNS||the-13/DT	prep_from||compared-9/VBD||lungs-14/NNS	prep_of||lungs-14/NNS||mtb-16/NN	amod||mice-19/NNS||infected-18/JJ	nsubj||treated-20/VBN||mice-19/NNS	parataxis||compared-9/VBD||treated-20/VBN	det||isoniazid-25/NN||the-22/DT	amod||isoniazid-25/NN||anti-tb-23/JJ	nn||isoniazid-25/NN||drug-24/NN	prep_with||treated-20/VBN||isoniazid-25/NN	appos||isoniazid-25/NN||inh-27/NN	det||presence-31/NN||the-30/DT	prep_in||treated-20/VBN||presence-31/NN	prep_in||treated-20/VBN||absence-33/NN	conj_and||presence-31/NN||absence-33/NN	det||inhibitor-39/NN||an-35/DT	amod||inhibitor-39/NN||immunomodulatory-36/JJ	amod||inhibitor-39/NN||phosphodiesterase-37/JJ	dep||phosphodiesterase-37/JJ||4-38/CD	prep_of||presence-31/NN||inhibitor-39/NN	appos||inhibitor-39/NN||pde4i-41/NNP	dep||treated-20/VBN||cc-3052-44/JJ	tb--1||mtb-16||no||for this proof of principal study, we compared bacillary clearance from the lungs of mtb -infected mice treated with the anti-tb drug isoniazid (inh) in the presence and absence of an immunomodulatory phosphodiesterase 4 inhibitor (pde4i), cc-3052.
det||review-3/NN||this-2/DT	prep_in||present-5/VBP||review-3/NN	nsubj||present-5/VBP||we-4/PRP	root||ROOT-0/null||present-5/VBP	num||cases-7/NNS||two-6/CD	dobj||present-5/VBP||cases-7/NNS	num||patient-9/NN||one-8/CD	poss||presentation-12/NN||patient-9/NN	nsubjpass||found-42/VBN||patient-9/NN	nsubj||have-44/VB||patient-9/NN	amod||presentation-12/NN||first-11/JJ	nsubj||renaldisease-17/NN||presentation-12/NN	prep_of||presentation-12/NN||aids-14/NNS	cop||renaldisease-17/NN||was-15/VBD	amod||renaldisease-17/NN||end-stage-16/JJ	rcmod||patient-9/NN||renaldisease-17/NN	nsubjpass||found-23/VBN||renaldisease-17/NN	nsubj||hivan-26/VBN||renaldisease-17/NN	prep_on||found-23/VBN||biopsy-21/NN	auxpass||found-23/VBN||was-22/VBD	rcmod||renaldisease-17/NN||found-23/VBN	aux||hivan-26/VBN||to-24/TO	aux||hivan-26/VBN||have-25/VB	xcomp||found-23/VBN||hivan-26/VBN	det||second-30/NN||the-29/DT	rcmod||patient-9/NN||second-30/NN	conj_and||renaldisease-17/NN||second-30/NN	nsubjpass||found-23/VBN||second-30/NN	nsubjpass||infected-34/VBN||second-30/NN	nsubjpass||infected-34/VBN||second-30/NN	auxpass||infected-34/VBN||was-33/VBD	rcmod||second-30/NN||infected-34/VBN	rcmod||second-30/NN||infected-34/VBN	conj_and||infected-34/VBN||infected-34/VBN	prep_with||infected-34/VBN||hiv-36/NN	prep_on||infected-34/VBN||biopsy-40/NN	auxpass||found-42/VBN||was-41/VBD	rcmod||cases-7/NNS||found-42/VBN	aux||have-44/VB||to-43/TO	xcomp||found-42/VBN||have-44/VB	amod||glomerulonephritis-49/NNS||hepatitisc-related-45/JJ	amod||glomerulonephritis-49/NNS||hepatitisc-46/JJ	amod||glomerulonephritis-49/NNS||related-47/JJ	nn||glomerulonephritis-49/NNS||membranoproliferative-48/NN	dobj||have-44/VB||glomerulonephritis-49/NNS	aids-14||hiv-36||no||in this review we present two cases one patient whose first presentation of aids was end-stage renaldisease, who on biopsy was found to have hivan, and the second, who was infected with hiv, and on biopsy was found to have hepatitisc-related hepatitisc related membranoproliferative glomerulonephritis.
det||duration-3/NN||the-1/DT	amod||duration-3/NN||optimal-2/JJ	nsubj||remain-22/VBP||duration-3/NN	nn||therapy-6/NN||warfarin-5/NN	prep_of||duration-3/NN||therapy-6/NN	det||thromboembolicevent-11/NN||a-8/DT	amod||thromboembolicevent-11/NN||first-9/JJ	nn||thromboembolicevent-11/NN||venous-10/NNS	nsubj||matter-15/NN||thromboembolicevent-11/NN	cop||matter-15/NN||is-12/VBZ	advmod||matter-15/NN||however-13/RB	det||matter-15/NN||a-14/DT	prepc_after||therapy-6/NN||matter-15/NN	det||controversy-18/NN||some-17/DT	prep_of||matter-15/NN||controversy-18/NN	amod||questions-21/NNS||many-20/JJ	prep_of||matter-15/NN||questions-21/NNS	conj_and||controversy-18/NN||questions-21/NNS	root||ROOT-0/null||remain-22/VBP	acomp||remain-22/VBP||unanswered-23/JJ	thromboembolicevent-11||warfarin-5||yes||the optimal duration of warfarin therapy after a first venous thromboembolicevent is however a matter of some controversy and many questions remain unanswered.
amod||achievements-2/NNS||major-1/JJ	nsubjpass||reached-5/VBN||achievements-2/NNS	aux||reached-5/VBN||have-3/VBP	auxpass||reached-5/VBN||been-4/VBN	root||ROOT-0/null||reached-5/VBN	det||treatment-8/NN||the-7/DT	prep_in||reached-5/VBN||treatment-8/NN	prep_of||treatment-8/NN||rheumatoidarthritis-10/NNS	amod||decades-13/NNS||past-12/JJ	prep_during||rheumatoidarthritis-10/NNS||decades-13/NNS	det||recognition-17/NN||the-16/DT	prep_due_to||reached-5/VBN||recognition-17/NN	prep_of||recognition-17/NN||methotrexate-19/NN	det||drug-23/NN||an-21/DT	amod||drug-23/NN||anchor-22/JJ	prep_as||methotrexate-19/NN||drug-23/NN	prep_for||drug-23/NN||treatment-25/NN	prep_of||treatment-25/NN||rheumatoidarthritis-27/NNS	det||notion-32/NN||the-31/DT	prep_due_to||reached-5/VBN||notion-32/NN	det||window-36/NN||a-34/DT	nn||window-36/NN||treatment-35/NN	prep_of||notion-32/NN||window-36/NN	prep_of||window-36/NN||opportunity-38/NN	prep_in||opportunity-38/NN||patients-40/NNS	amod||rheumatoidarthritis-43/NNS||recent-onset-42/JJ	prep_with||patients-40/NNS||rheumatoidarthritis-43/NNS	vmod||rheumatoidarthritis-43/NNS||necessitating-44/VBG	amod||therapy-47/NN||early-45/JJ	amod||therapy-47/NN||aggressive-46/JJ	dobj||necessitating-44/VBG||therapy-47/NN	det||development-52/NN||the-51/DT	prep_due_to||therapy-47/NN||development-52/NN	prep_of||development-52/NN||biologics-54/NNS	dobj||necessitating-44/VBG||due-56/JJ	conj_and||therapy-47/NN||due-56/JJ	aux||remission-58/VB||to-57/TO	vmod||therapy-47/NN||remission-58/VB	det||target-62/NN||a-60/DT	nn||target-62/NN||treatment-61/NN	prep_as||remission-58/VB||target-62/NN	rheumatoidarthritis-43||methotrexate-19||yes||major achievements have been reached in the treatment of rheumatoidarthritis during past decades due to the recognition of methotrexate as an anchor drug for treatment of rheumatoidarthritis, due to the notion of a treatment window of opportunity in patients with recent-onset rheumatoidarthritis necessitating early aggressive therapy, due to the development of biologics and due to remission as a treatment target.
nsubj||investigated-2/VBD||we-1/PRP	root||ROOT-0/null||investigated-2/VBD	det||role-4/NN||the-3/DT	dobj||investigated-2/VBD||role-4/NN	amod||reductase-10/NN||polyol-6/JJ	nn||reductase-10/NN||pathway-7/NN	nn||reductase-10/NN||enzymes-8/NNS	nn||reductase-10/NN||aldose-9/NN	prep_of||role-4/NN||reductase-10/NN	appos||reductase-10/NN||ar-12/NN	amod||dehydrogenase-16/NN||sorbitol-15/JJ	prep_of||role-4/NN||dehydrogenase-16/NN	conj_and||reductase-10/NN||dehydrogenase-16/NN	appos||reductase-10/NN||sdh-18/NN	prepc_in||investigated-2/VBD||mediating-21/VBG	dobj||mediating-21/VBG||injury-22/NN	amod||ischemia-reperfusion-25/JJ||due-23/JJ	dep||ischemia-reperfusion-25/JJ||to-24/TO	amod||injury-22/NN||ischemia-reperfusion-25/JJ	appos||injury-22/NN||ir-27/NN	amod||hearts-35/NNS||type-30/NN	number||type-30/NN||2-31/CD	amod||hearts-35/NNS||diabetic-32/JJ	amod||hearts-35/NNS||bbz-33/JJ	nn||hearts-35/NNS||rat-34/NN	prep_in||mediating-21/VBG||hearts-35/NNS	enzymes-8||ar-12||no_rel||we investigated the role of polyol pathway enzymes aldose reductase (ar) and sorbitol dehydrogenase (sdh) in mediating injury due to ischemia-reperfusion (ir) in type 2 diabetic bbz rat hearts.
nsubjpass||enrolled-3/VBN||participants-1/NNS	auxpass||enrolled-3/VBN||were-2/VBD	root||ROOT-0/null||enrolled-3/VBN	prep_into||enrolled-3/VBN||one-5/CD	num||groups-8/NNS||four-7/CD	prep_of||one-5/CD||groups-8/NNS	det||basis-11/NN||the-10/DT	prep_on||groups-8/NNS||basis-11/NN	nn||status-16/NN||hiv-13/NN	conj_and||hiv-13/NN||ks-15/NN	nn||status-16/NN||ks-15/NN	prep_of||basis-11/NN||status-16/NN	nsubj||negative/ks-19/VBZ||hiv-18/NN	dep||groups-8/NNS||negative/ks-19/VBZ	acomp||negative/ks-19/VBZ||negative-20/JJ	amod||negative-23/JJ||hivpositive/ks-22/JJ	acomp||negative/ks-19/VBZ||negative-23/JJ	conj_and||negative-20/JJ||negative-23/JJ	num||negative/ks-26/NNS||hiv-25/CD	npadvmod||positive-27/JJ||negative/ks-26/NNS	acomp||negative/ks-19/VBZ||positive-27/JJ	conj_and||negative-20/JJ||positive-27/JJ	amod||positive-31/JJ||hivpositive/ks-30/JJ	acomp||negative/ks-19/VBZ||positive-31/JJ	conj_and||negative-20/JJ||positive-31/JJ	hivpositive--1||hiv-25||no||participants were enrolled into one of four groups on the basis of hiv and ks status (hiv negative/ks negative, hivpositive/ks negative, hiv negative/ks positive, and hivpositive/ks positive).
num||weeks-3/NNS||24-2/CD	prep_within||experienced-16/VBD||weeks-3/NNS	prepc_of||weeks-3/NNS||initiating-5/VBG	amod||treatment-7/NN||antituberculosis-6/JJ	dobj||initiating-5/VBG||treatment-7/NN	num||%-10/NN||40-9/CD	nsubj||experienced-16/VBD||%-10/NN	appos||%-10/NN||117/292-12/CD	prep_of||%-10/NN||patients-15/NNS	root||ROOT-0/null||experienced-16/VBD	amod||deterioration-18/NN||clinical-17/JJ	dobj||experienced-16/VBD||deterioration-18/NN	amod||illness-22/NN||co-morbid-21/JJ	prep_due_to||experienced-16/VBD||illness-22/NN	dep||illness-22/NN||n-24/VBN	dep||70-26/CD||=-25/SYM	ccomp||n-24/VBN||70-26/CD	amod||illness-31/NN||tuberculosis-29/JJ	amod||illness-31/NN||related-30/VBN	prep_due_to||experienced-16/VBD||illness-31/NN	conj_and||illness-22/NN||illness-31/NN	dep||illness-31/NN||n-33/VBN	dep||47-35/CD||=-34/SYM	ccomp||n-33/VBN||47-35/CD	nn||infection-42/NN||non-38/NN	amod||infection-42/NN||aids-defining-39/JJ	amod||infection-42/NN||hiv-1-40/JJ	amod||infection-42/NN||related-41/JJ	prep_due_to||experienced-16/VBD||infection-42/NN	conj_and||illness-22/NN||infection-42/NN	dep||infection-42/NN||n-44/VBN	dep||25-46/CD||=-45/SYM	ccomp||n-44/VBN||25-46/CD	amod||illness-50/NN||aids-defining-49/JJ	prep_due_to||experienced-16/VBD||illness-50/NN	conj_and||illness-22/NN||illness-50/NN	dep||illness-50/NN||n-52/VBN	dep||21-54/CD||=-53/SYM	ccomp||n-52/VBN||21-54/CD	aids--1||antituberculosis-6||no_rel||within 24 weeks of initiating antituberculosis treatment, 40% (117/292) of patients experienced clinical deterioration due to co-morbid illness (n = 70), tuberculosis related illness (n = 47), non aids-defining hiv-1 related infection (n = 25) and aids-defining illness (n = 21).
det||segregation-2/NN||the-1/DT	nsubj||cluster-11/VB||segregation-2/NN	nn||+-5/NNS||tb-4/NN	prep_between||segregation-2/NN||+-5/NNS	prep_between||segregation-2/NN||tbâ-7/NNS	conj_and||+-5/NNS||tbâ-7/NNS	aux||cluster-11/VB||does-9/VBZ	neg||cluster-11/VB||not-10/RB	root||ROOT-0/null||cluster-11/VB	amod||recognition-14/NN||specific-13/JJ	prep_into||cluster-11/VB||recognition-14/NN	amod||proteins-18/NNS||distinct-16/JJ	nn||proteins-18/NNS||mtb-17/NN	prep_of||recognition-14/NN||proteins-18/NNS	amod||peptide-23/NN||specific-22/JJ	nn||â-25/NN||peptide-23/NN	amod||â-25/NN||epitope-24/JJ	prep_into||cluster-11/VB||â-25/NN	conj_but||recognition-14/NN||â-25/NN	dep||â-25/NN||$-26/$	num||$-26/$||hotspotsâ-27/CD	dobj||$-26/$||$-28/$	num||$-28/$||-29/CD	amod||locations-32/NNS||different-31/JJ	prep_at||$-28/$||locations-32/NNS	det||protein-36/NN||the-34/DT	amod||protein-36/NN||same-35/JJ	prep_within||$-26/$||protein-36/NN	tb-4||mtb-17||no||the segregation between tb+ and tbâ does not cluster into specific recognition of distinct mtb proteins, but into specific peptide epitope âhotspotsâ at different locations within the same protein.
num||hundred-2/CD||one-1/CD	nsubjpass||studied-37/VBN||hundred-2/CD	nsubj||anti-hcc-72/JJ||hundred-2/CD	amod||addicts-7/NNS||seventy-seven-4/JJ	amod||addicts-7/NNS||former-5/JJ	nn||addicts-7/NNS||heroin-6/NN	conj_and||hundred-2/CD||addicts-7/NNS	nsubjpass||studied-37/VBN||addicts-7/NNS	vmod||studied-37/VBN||consisting-9/VBG	prep_of||consisting-9/VBG||85-11/CD	nsubjpass||admitted-15/VBN||85-11/CD	auxpass||admitted-15/VBN||were-13/VBD	advmod||admitted-15/VBN||newly-14/RB	rcmod||85-11/CD||admitted-15/VBN	det||program-20/NN||a-17/DT	amod||program-20/NN||methadone-18/JJ	nn||program-20/NN||maintenance-19/NN	prep_to||admitted-15/VBN||program-20/NN	prep_to||admitted-15/VBN||92-22/CD	conj_and||program-20/NN||92-22/CD	nsubj||received-25/VBN||92-22/CD	aux||received-25/VBN||had-24/VBD	rcmod||92-22/CD||received-25/VBN	acomp||received-25/VBN||methadone-26/JJ	det||period-30/NN||a-28/DT	amod||period-30/NN||mean-29/JJ	prep_for||received-25/VBN||period-30/NN	num||months-33/NNS||30-32/CD	prep_of||period-30/NN||months-33/NNS	auxpass||studied-37/VBN||were-35/VBD	advmod||studied-37/VBN||prospectively-36/RB	root||ROOT-0/null||studied-37/VBN	quantmod||2-41/CD||up-39/IN	dep||2-41/CD||to-40/TO	num||years-42/NNS||2-41/CD	prep_for||studied-37/VBN||years-42/NNS	mark||determine-46/VB||in-43/IN	dep||determine-46/VB||order-44/NN	aux||determine-46/VB||to-45/TO	advcl||studied-37/VBN||determine-46/VB	dep||effect-51/NN||1-48/LS	det||effect-51/NN||the-50/DT	dobj||determine-46/VB||effect-51/NN	nn||withdrawal-54/NN||heroin-53/NN	prep_of||effect-51/NN||withdrawal-54/NN	det||abnormalities-58/NNS||the-56/DT	amod||abnormalities-58/NNS||hepatic-57/JJ	prep_on||withdrawal-54/NN||abnormalities-58/NNS	dep||incidence-65/NN||2-62/LS	det||incidence-65/NN||the-64/DT	dobj||determine-46/VB||incidence-65/NN	conj_and||effect-51/NN||incidence-65/NN	prep_of||incidence-65/NN||hbsag-67/NN	appos||hbsag-67/NN||anti-hbs-69/NNS	conj_and||studied-37/VBN||anti-hcc-72/JJ	prep_as||anti-hcc-72/JJ||indices-74/NNS	det||frequency-77/NN||the-76/DT	prep_of||indices-74/NNS||frequency-77/NN	prep_of||frequency-77/NN||hepatitisbvirusinfection-79/NN	anti-hbs-69||hepatitisbvirus--1||no||one hundred and seventy-seven former heroin addicts, consisting of 85 who were newly admitted to a methadone maintenance program and 92 who had received methadone for a mean period of 30 months, were prospectively studied for up to 2 years in order to determine (1) the effect of heroin withdrawal on the hepatic abnormalities, and (2) the incidence of hbsag, anti-hbs, and anti-hcc as indices of the frequency of hepatitisbvirusinfection.
det||substitution-2/NN||the-1/DT	nsubjpass||made-8/VBN||substitution-2/NN	prep_of||substitution-2/NN||pis-4/NN	prep_with||pis-4/NN||nevirapine-6/NN	auxpass||made-8/VBN||was-7/VBD	root||ROOT-0/null||made-8/VBN	advmod||showed-12/VBD||when-9/WRB	det||patient-11/NN||the-10/DT	nsubj||showed-12/VBD||patient-11/NN	advcl||made-8/VBN||showed-12/VBD	nsubj||and/or-19/VBZ||hyperlipidemia-13/NN	conj_or||hyperlipidemia-13/NN||lipodystrophy-15/NN	nsubj||and/or-19/VBZ||lipodystrophy-15/NN	det||physician-18/NN||the-17/DT	conj_or||hyperlipidemia-13/NN||physician-18/NN	nsubj||and/or-19/VBZ||physician-18/NN	ccomp||showed-12/VBD||and/or-19/VBZ	det||patient-21/NN||the-20/DT	poss||willingness-23/NN||patient-21/NN	dobj||and/or-19/VBZ||willingness-23/NN	aux||simplify-25/VB||to-24/TO	vmod||willingness-23/NN||simplify-25/VB	nevirapine-6||hyperlipidemia-13||no_rel||the substitution of pis with nevirapine was made when the patient showed hyperlipidemia or lipodystrophy or the physician and/or the patient's willingness to simplify.
amod||disease-4/NN||bacterial-1/JJ	amod||disease-4/NN||cold-2/JJ	nn||disease-4/NN||water-3/NN	nsubj||bacterialdiseases-15/NNS||disease-4/NN	amod||disease-9/NN||enteric-6/JJ	amod||disease-9/NN||red-7/JJ	nn||disease-9/NN||mouth-8/NN	conj_and||disease-4/NN||disease-9/NN	nsubj||bacterialdiseases-15/NNS||disease-9/NN	conj_and||disease-4/NN||frunculosis-11/NNS	nsubj||bacterialdiseases-15/NNS||frunculosis-11/NNS	cop||bacterialdiseases-15/NNS||are-12/VBP	det||bacterialdiseases-15/NNS||the-13/DT	amod||bacterialdiseases-15/NNS||common-14/JJ	root||ROOT-0/null||bacterialdiseases-15/NNS	prep_of||bacterialdiseases-15/NNS||fish-17/NN	advmod||bacterialdiseases-15/NNS||worldwide-18/RB	bacterialdiseases-15||bacterial-1||no||bacterial cold water disease, enteric red mouth disease and frunculosis are the common bacterialdiseases of fish worldwide.
nsubj||evaluated-2/VBN||we-1/PRP	root||ROOT-0/null||evaluated-2/VBN	det||effects-4/NNS||the-3/DT	iobj||evaluated-2/VBN||effects-4/NNS	det||therapy-8/NN||a-6/DT	amod||therapy-8/NN||combined-7/JJ	prep_of||effects-4/NNS||therapy-8/NN	amod||âµg-18/NN||budesonide-10/JJ	dep||budesonide-10/JJ||200-11/CD	nn||âµg-18/NN||âµg-12/NN	advmod||daily-14/RB||twice-13/RB	advmod||âµg-18/NN||daily-14/RB	conj_and||daily-14/RB||formoterol-16/JJ	advmod||âµg-18/NN||formoterol-16/JJ	dep||formoterol-16/JJ||6-17/CD	prep_of||therapy-8/NN||âµg-18/NN	advmod||daily-20/RB||twice-19/RB	dobj||evaluated-2/VBN||daily-20/RB	prepc_compared_with||evaluated-2/VBN||with-22/IN	amod||âµg-25/NN||budesonide-23/JJ	dep||budesonide-23/JJ||200-24/CD	pobj||evaluated-2/VBN||âµg-25/NN	advmod||âµg-25/NN||twice-26/RB	advmod||alone-28/RB||daily-27/RB	pobj||twice-26/RB||alone-28/RB	nn||questionnaire-32/NN||asthma-30/NN	nn||questionnaire-32/NN||control-31/NN	prep_on||twice-26/RB||questionnaire-32/NN	appos||questionnaire-32/NN||acq-34/NN	nn||quality-38/NN||asthma-37/NN	appos||questionnaire-32/NN||quality-38/NN	nn||questionnaire-41/NN||life-40/NN	prep_of||quality-38/NN||questionnaire-41/NN	appos||quality-38/NN||aqlq-43/NNP	dep||aqlq-43/NNP||juniper-45/NN	amod||function-49/NN||pulmonary-48/JJ	appos||questionnaire-32/NN||function-49/NN	conj_and||quality-38/NN||function-49/NN	amod||inflammation-52/NN||airway-51/JJ	appos||questionnaire-32/NN||inflammation-52/NN	conj_and||quality-38/NN||inflammation-52/NN	det||study-59/NN||a-55/DT	amod||study-59/NN||cross-over-56/JJ	amod||study-59/NN||randomized-57/JJ	amod||study-59/NN||double-blind-58/JJ	prep_in||evaluated-2/VBN||study-59/NN	nn||periods-62/NNS||treatment-61/NN	prep_with||study-59/NN||periods-62/NNS	num||months-65/NNS||two-64/CD	prep_of||periods-62/NNS||months-65/NNS	vmod||months-65/NNS||separated-66/VBN	det||period-71/NN||a-68/DT	amod||period-71/NN||one-month-69/JJ	amod||period-71/NN||wash-out-70/JJ	agent||separated-66/VBN||period-71/NN	asthma-37||budesonide-23||yes||we evaluated the effects of a combined therapy of budesonide 200 âµg twice daily and formoterol 6 âµg twice daily compared with budesonide 200 âµg twice daily alone on asthma control questionnaire (acq), asthma quality of life questionnaire (aqlq- juniper), pulmonary function and airway inflammation, in a cross-over randomized double-blind study with treatment periods of two months separated by a one-month wash-out period.
amod||genes-2/NNS||reactivated-1/JJ	nsubj||remained-4/VBD||genes-2/NNS	nsubj||expressed-5/VBD||genes-2/NNS	rcmod||genes-2/NNS||remained-4/VBD	root||ROOT-0/null||expressed-5/VBD	num||days-7/NNS||10-6/CD	tmod||expressed-5/VBD||days-7/NNS	nn||treatment-10/NN||post-8/NN	amod||treatment-10/NN||5-aza-dc-9/JJ	nsubj||featured-11/VBD||treatment-10/NN	dep||expressed-5/VBD||featured-11/VBD	amod||sites-14/NNS||hypomethylated-12/JJ	nn||sites-14/NNS||cpg-13/NN	dobj||featured-11/VBD||sites-14/NNS	advmod||featured-11/VBD||adjacent-15/JJ	det||site-20/NN||the-17/DT	amod||site-20/NN||transcription-18/JJ	nn||site-20/NN||start-19/NN	prep_to||featured-11/VBD||site-20/NN	appos||site-20/NN||tss-22/NN	aza--1||tss-22||no_rel||reactivated genes which remained expressed 10 days post 5-aza-dc treatment featured hypomethylated cpg sites adjacent to the transcription start site (tss).
amod||insulinresistance-2/NN||peripheral-1/JJ	nsubjpass||linked-4/VBN||insulinresistance-2/NN	auxpass||linked-4/VBN||is-3/VBZ	root||ROOT-0/null||linked-4/VBN	det||increase-7/NN||an-6/DT	prep_to||linked-4/VBN||increase-7/NN	amod||species-11/NNS||reactive-9/JJ	nn||species-11/NNS||oxygen-10/NN	prep_in||increase-7/NN||species-11/NNS	appos||species-11/NNS||ros-13/NN	vmod||increase-7/NN||leading-16/VBG	prep_in||leading-16/VBG||part-18/NN	det||production-21/NN||the-20/DT	prep_to||part-18/NN||production-21/NN	amod||aldehydes-25/NNS||reactive-23/JJ	nn||aldehydes-25/NNS||lipid-24/NN	prep_of||production-21/NN||aldehydes-25/NNS	mark||termed-37/VBD||that-26/IN	csubj||termed-37/VBD||modify-27/VB	det||chains-30/NNS||the-28/DT	nn||chains-30/NNS||side-29/NN	dobj||modify-27/VB||chains-30/NNS	nn||aminoacids-33/NNS||protein-32/NN	prep_of||chains-30/NNS||aminoacids-33/NNS	det||reaction-36/NN||a-35/DT	prep_in||aminoacids-33/NNS||reaction-36/NN	ccomp||leading-16/VBG||termed-37/VBD	nn||carbonylation-39/NN||protein-38/NN	dobj||termed-37/VBD||carbonylation-39/NN	aminoacids-33||insulinresistance-2||no_rel||peripheral insulinresistance is linked to an increase in reactive oxygen species (ros), leading in part to the production of reactive lipid aldehydes that modify the side chains of protein aminoacids in a reaction termed protein carbonylation.
num||%-2/NN||18.1-1/CD	nsubj||performed-11/VBN||%-2/NN	appos||%-2/NN||799/4416-4/CD	det||respondents-8/NNS||the-7/DT	prep_of||%-2/NN||respondents-8/NNS	aux||performed-11/VBN||had-9/VBD	advmod||performed-11/VBN||ever-10/RB	root||ROOT-0/null||performed-11/VBN	det||self-test-13/NN||a-12/DT	dobj||performed-11/VBN||self-test-13/NN	det||tests-19/NNS||the-15/DT	advmod||frequently-17/RB||most-16/RBS	advmod||used-18/VBN||frequently-17/RB	amod||tests-19/NNS||used-18/VBN	appos||self-test-13/NN||tests-19/NNS	aux||those-21/DT||being-20/VBG	vmod||tests-19/NNS||those-21/DT	prep_for||those-21/DT||diabetes-23/NN	num||%-26/NN||5.3-25/CD	appos||diabetes-23/NN||%-26/NN	prep_for||those-21/DT||kidneydisease-29/NN	conj_and||diabetes-23/NN||kidneydisease-29/NN	num||%-32/NN||4.9-31/CD	appos||kidneydisease-29/NN||%-32/NN	prep_for||those-21/DT||cholesterol-35/NN	conj_and||diabetes-23/NN||cholesterol-35/NN	num||%-38/NN||4.5-37/CD	appos||cholesterol-35/NN||%-38/NN	prep_for||those-21/DT||urinarytractinfection-41/NN	conj_and||diabetes-23/NN||urinarytractinfection-41/NN	num||%-44/NN||1.9-43/CD	appos||urinarytractinfection-41/NN||%-44/NN	prep_for||those-21/DT||hiv/aids-47/NNS	conj_and||diabetes-23/NN||hiv/aids-47/NNS	conj_and||diabetes-23/NN||chlamydia-49/NNS	conj_and||hiv/aids-47/NNS||chlamydia-49/NNS	dep||%-53/NN||both-51/DT	number||%-53/NN||1.6-52/CD	dep||hiv/aids-47/NNS||%-53/NN	cholesterol-35||aids--1||no_rel||18.1% (799/4416) of the respondents had ever performed a self-test, the most frequently used tests being those for diabetes (5.3%), kidneydisease (4.9%), cholesterol (4.5%), urinarytractinfection (1.9%) and hiv/aids and chlamydia (both 1.6%).
det||article-2/NN||this-1/DT	nsubj||focuses-3/VBZ||article-2/NN	root||ROOT-0/null||focuses-3/VBZ	det||determination-6/NN||the-5/DT	prep_on||focuses-3/VBZ||determination-6/NN	nn||species-9/NNS||arsenic-8/NN	prep_of||determination-6/NN||species-9/NNS	nn||samples-12/NNS||saliva-11/NN	prep_in||species-9/NNS||samples-12/NNS	nn||patients-15/NNS||apl-14/NN	prep_from||focuses-3/VBZ||patients-15/NNS	vmod||patients-15/NNS||undergoing-16/VBG	nn||treatment-18/NN||arsenic-17/NN	dobj||undergoing-16/VBG||treatment-18/NN	apl-14||arsenic-17||yes||this article focuses on the determination of arsenic species in saliva samples from apl patients undergoing arsenic treatment.
nn||pressure-2/NN||blood-1/NN	nsubjpass||compared-63/VBN||pressure-2/NN	appos||pressure-2/NN||bp-4/NN	amod||glucose-9/NN||random-7/JJ	nn||glucose-9/NN||plasma-8/NN	conj_or||pressure-2/NN||glucose-9/NN	nsubjpass||compared-63/VBN||glucose-9/NN	dep||glucose-9/NN||p-glucose-11/JJ	conj_or||pressure-2/NN||anthropometrics-14/NNS	conj_and||glucose-9/NN||anthropometrics-14/NNS	conj_or||pressure-2/NN||prevalence-19/NN	conj_and||glucose-9/NN||prevalence-19/NN	prep_of||prevalence-19/NN||hypertension-21/NN	nn||>-24/NNS||bp-23/NN	dep||glucose-9/NN||>-24/NNS	num||mmhg-26/NN||140/90-25/CD	dep||>-24/NNS||mmhg-26/NN	conj_or||pressure-2/NN||impairedglucosetolerance-29/NN	nsubjpass||compared-63/VBN||impairedglucosetolerance-29/NN	dep||impairedglucosetolerance-29/NN||igt-31/NN	amod||â-35/NN||p-glucose-33/JJ	amod||â-35/NN||7.8-34/JJ	dep||igt-31/NN||â-35/NN	dep||â-35/NN||$-36/$	amod||mmol/l-39/NNS||11.0-38/JJ	npadvmod||11.1-50/RB||mmol/l-39/NNS	amod||¥-49/NNP||dm-44/JJ	amod||¥-49/NNP||p-glucose-46/JJ	nn||¥-49/NNP||â-47/NNP	nn||¥-49/NNP||-48/NNP	prep_diabetes||mmol/l-39/NNS||¥-49/NNP	dep||mmol/l-51/CD||11.1-50/RB	num||$-36/$||mmol/l-51/CD	conj_or||pressure-2/NN||overweight-55/NN	nsubjpass||compared-63/VBN||overweight-55/NN	dep||pressure-2/NN||bmi-57/VBN	xcomp||bmi-57/VBN||>-58/VBG	num||kg/m2-60/NNS||25-59/CD	dobj||>-58/VBG||kg/m2-60/NNS	auxpass||compared-63/VBN||were-62/VBD	root||ROOT-0/null||compared-63/VBN	det||groups-67/NNS||the-65/DT	num||groups-67/NNS||three-66/CD	prep_between||compared-63/VBN||groups-67/NNS	impairedglucosetolerance-29||glucose-9||no_rel||blood pressure (bp), random plasma glucose (p-glucose) and anthropometrics, as well as prevalence of hypertension (bp>140/90 mmhg), impairedglucosetolerance (igt; p-glucose 7.8â11.0 mmol/l), diabetes (dm; p-glucose â¥11.1 mmol/l), or overweight (bmi>25 kg/m2) were compared between the three groups.
aux||understand-3/VB||to-1/TO	advmod||understand-3/VB||better-2/RBR	advcl||examined-19/VBD||understand-3/VB	det||mechanism-6/NN||the-4/DT	amod||mechanism-6/NN||cellular-5/JJ	dobj||understand-3/VB||mechanism-6/NN	dep||mechanism-6/NN||s-8/PRP	vmod||mechanism-6/NN||linking-10/VBG	amod||stress-12/NN||oxidative-11/JJ	dobj||linking-10/VBG||stress-12/NN	dobj||linking-10/VBG||inflammation-14/NN	conj_and||stress-12/NN||inflammation-14/NN	prep_to||linking-10/VBG||amd-16/NN	nsubj||examined-19/VBD||we-18/PRP	root||ROOT-0/null||examined-19/VBD	det||expression-21/NN||the-20/DT	dobj||examined-19/VBD||expression-21/NN	amod||protein-1-26/NN||pro-inflammatory-23/JJ	amod||protein-1-26/NN||monocyte-24/JJ	nn||protein-1-26/NN||chemoattractant-25/NN	prep_of||expression-21/NN||protein-1-26/NN	dep||protein-1-26/NN||mcp-1-28/JJ	amod||factor-35/NN||pro-angiogenic-31/JJ	nn||factor-35/NN||vascular-32/NN	nn||factor-35/NN||endothelial-33/NN	nn||factor-35/NN||growth-34/NN	dobj||examined-19/VBD||factor-35/NN	conj_and||expression-21/NN||factor-35/NN	appos||factor-35/NN||vegf-37/NN	amod||epithelial-42/NN||anti-angiogenic-40/JJ	nn||epithelial-42/NN||pigment-41/NN	dobj||examined-19/VBD||epithelial-42/NN	conj_and||expression-21/NN||epithelial-42/NN	vmod||epithelial-42/NN||derived-43/VBN	dobj||derived-43/VBN||factor-44/NN	appos||factor-44/NN||pedf-46/NN	prep_in||factor-44/NN||rpe-49/NN	nn||patients-52/NNS||smoker-51/NN	prep_from||derived-43/VBN||patients-52/NNS	prep_with||derived-43/VBN||amd-54/NN	mcp--1||inflammation-14||no_rel||to better understand the cellular mechanism(s) linking oxidative stress and inflammation to amd, we examined the expression of pro-inflammatory monocyte chemoattractant protein-1 (mcp-1), pro-angiogenic vascular endothelial growth factor (vegf) and anti-angiogenic pigment epithelial derived factor (pedf) in rpe from smoker patients with amd.
nn||hemophiliaa-2/NN||background-1/NN	nsubj||results-3/VBZ||hemophiliaa-2/NN	root||ROOT-0/null||results-3/VBZ	det||deficiency-6/NN||a-5/DT	prep_from||results-3/VBZ||deficiency-6/NN	amod||activity-9/NN||factorviii-8/JJ	prep_in||deficiency-6/NN||activity-9/NN	hemophiliaa-2||factorviii-8||yes||background hemophiliaa results from a deficiency in factorviii activity.
nsubj||tried-6/VBN||youth-2/NN	nsubj||lose-8/VB||youth-2/NN	prep_among||common-35/JJ||youth-2/NN	aux||tried-6/VBN||had-4/VBD	advmod||tried-6/VBN||ever-5/RB	rcmod||youth-2/NN||tried-6/VBN	aux||lose-8/VB||to-7/TO	xcomp||tried-6/VBN||lose-8/VB	dobj||lose-8/VB||weight-9/NN	dep||youth-2/NN||n-11/VBN	dep||1,646-13/CD||=-12/SYM	ccomp||n-11/VBN||1,646-13/CD	amod||practices-18/NNS||healthy-16/JJ	amod||practices-18/NNS||weight-loss-17/JJ	nsubj||common-35/JJ||practices-18/NNS	dep||practices-18/NNS||diet-20/NN	number||76.5-22/CD||-LSB--21/CD	num||%-23/NN||76.5-22/CD	nsubj||-RSB--24/VBZ||%-23/NN	nsubj||exercise-26/VBP||%-23/NN	rcmod||diet-20/NN||-RSB--24/VBZ	rcmod||diet-20/NN||exercise-26/VBP	conj_and||-RSB--24/VBZ||exercise-26/VBP	number||94.8-28/CD||-LSB--27/CD	dep||%-29/NN||94.8-28/CD	dep||-RSB--30/NNS||%-29/NN	dobj||exercise-26/VBP||-RSB--30/NNS	cop||common-35/JJ||were-32/VBD	det||common-35/JJ||the-33/DT	advmod||common-35/JJ||most-34/RBS	root||ROOT-0/null||common-35/JJ	mark||common-75/JJ||whereas-37/IN	amod||practices-39/NNS||unhealthy-38/JJ	nsubj||common-75/JJ||practices-39/NNS	dep||practices-39/NNS||fasting-41/VBG	ccomp||fasting-41/VBG||-LSB--42/VBG	num||%-44/NN||8.6-43/CD	dobj||-LSB--42/VBG||%-44/NN	advmod||-LSB--42/VBG||-RSB--45/RB	ccomp||fasting-41/VBG||using-47/VBG	conj_and||-LSB--42/VBG||using-47/VBG	nn||aids-49/NNS||diet-48/NN	dobj||using-47/VBG||aids-49/NNS	vmod||aids-49/NNS||-LSB--50/VBN	number||%-52/NN||7.5-51/CD	amod||-RSB--62/NN||%-52/NN	nn||-RSB--62/NN||-RSB--53/JJ	conj_or||-RSB--53/JJ||vomiting-55/NN	nn||-RSB--62/NN||vomiting-55/NN	conj_or||-RSB--53/JJ||laxative-57/NN	nn||-RSB--62/NN||laxative-57/NN	nn||-RSB--62/NN||use-58/NN	num||-RSB--62/NN||-LSB--59/CD	number||%-61/NN||2.3-60/CD	amod||-RSB--62/NN||%-61/NN	dep||-LSB--50/VBN||-RSB--62/NN	ccomp||fasting-41/VBG||skipping-65/VBG	conj_and||-LSB--42/VBG||skipping-65/VBG	nn||doses-67/NNS||insulin-66/NN	dobj||skipping-65/VBG||doses-67/NNS	vmod||skipping-65/VBG||-LSB--68/VBG	number||%-70/NN||4.2-69/CD	amod||-RSB--71/NNS||%-70/NN	dobj||-LSB--68/VBG||-RSB--71/NNS	cop||common-75/JJ||were-73/VBD	advmod||common-75/JJ||less-74/RBR	advcl||common-35/JJ||common-75/JJ	laxative-57||vomiting-55||no_rel||among youth who had ever tried to lose weight ( n = 1,646), healthy weight-loss practices (diet [76.5%] and exercise [94.8%]) were the most common, whereas unhealthy practices (fasting [8.6%], using diet aids [7.5%], vomiting or laxative use [2.3%], and skipping insulin doses [4.2%]) were less common.
prep_in||undergoing-22/VBG||addition-2/NN	amod||inhibitors-7/NNS||promising-4/JJ	nn||inhibitors-7/NNS||novel-5/NN	nn||inhibitors-7/NNS||proteasome-6/NN	nsubj||distinct-11/JJ||inhibitors-7/NNS	nsubj||undergoing-22/VBG||inhibitors-7/NNS	cop||distinct-11/JJ||are-10/VBP	rcmod||inhibitors-7/NNS||distinct-11/JJ	prep_from||distinct-11/JJ||bortezomib-13/NN	nn||activities-19/NNS||exhibit-16/NN	nn||activities-19/NNS||equipotent-17/NN	amod||activities-19/NNS||anti-multiplemyeloma-18/JJ	rcmod||inhibitors-7/NNS||activities-19/NNS	conj_and||distinct-11/JJ||activities-19/NNS	aux||undergoing-22/VBG||are-21/VBP	root||ROOT-0/null||undergoing-22/VBG	amod||evaluation-24/NN||clinical-23/JJ	dobj||undergoing-22/VBG||evaluation-24/NN	mark||improve-28/VB||in-25/IN	dep||improve-28/VB||order-26/NN	aux||improve-28/VB||to-27/TO	advcl||undergoing-22/VBG||improve-28/VB	amod||outcome-30/NN||patient-29/JJ	dobj||improve-28/VB||outcome-30/NN	prep_in||improve-28/VB||multiplemyeloma-32/NN	multiplemyeloma-32||bortezomib-13||yes||in addition, promising novel proteasome inhibitors, which are distinct from bortezomib, and exhibit equipotent anti-multiplemyeloma activities, are undergoing clinical evaluation in order to improve patient outcome in multiplemyeloma.
mark||clear-4/JJ||although-1/IN	nsubj||clear-4/JJ||it-2/PRP	cop||clear-4/JJ||is-3/VBZ	advcl||cause-47/VB||clear-4/JJ	mark||have-16/VBP||that-5/IN	det||patients-7/NNS||some-6/DT	nsubj||have-16/VBP||patients-7/NNS	prep_with||patients-7/NNS||acetylsalicylicacid-9/NN	appos||acetylsalicylicacid-9/NN||asa-11/NN	amod||asthma-15/NN||sensitive-14/JJ	dep||acetylsalicylicacid-9/NN||asthma-15/NN	ccomp||clear-4/JJ||have-16/VBP	poss||onset-19/NN||their-17/PRP$	amod||onset-19/NN||clinical-18/JJ	dobj||have-16/VBP||onset-19/NN	prep_of||onset-19/NN||disease-21/NN	prep_in||disease-21/NN||childhood-23/NN	prep_in||disease-21/NN||bronchoconstriction-25/NN	conj_and||childhood-23/NN||bronchoconstriction-25/NN	mark||seen-30/VBN||after-26/IN	nn||challenge-28/NN||asa-27/NN	nsubjpass||seen-30/VBN||challenge-28/NN	auxpass||seen-30/VBN||is-29/VBZ	advcl||have-16/VBP||seen-30/VBN	prep_in||seen-30/VBN||0-32/CD	num||%-35/NN||22-34/CD	prep_to||seen-30/VBN||%-35/NN	amod||children-38/NNS||asthmatic-37/JJ	prep_of||%-35/NN||children-38/NNS	advmod||challenged-40/VBN||so-39/RB	vmod||children-38/NNS||challenged-40/VBN	nsubj||cause-47/VB||ibuprofen-42/NN	amod||doses-45/NNS||antipyretic-44/JJ	prep_at||ibuprofen-42/NN||doses-45/NNS	aux||cause-47/VB||may-46/MD	root||ROOT-0/null||cause-47/VB	amod||problems-50/NNS||acute-48/JJ	nn||problems-50/NNS||respiratory-49/NN	dobj||cause-47/VB||problems-50/NNS	advmod||cause-47/VB||only-51/RB	det||number-56/NN||a-53/DT	advmod||small-55/JJ||very-54/RB	amod||number-56/NN||small-55/JJ	prep_in||cause-47/VB||number-56/NN	amod||moderate-60/JJ||mild-58/JJ	dep||moderate-60/JJ||to-59/TO	amod||asthmatics-61/NNS||moderate-60/JJ	prep_of||number-56/NN||asthmatics-61/NNS	asthmatic-37||acetylsalicylicacid-9||no||although it is clear that some patients with acetylsalicylicacid (asa)-sensitive asthma have their clinical onset of disease in childhood and bronchoconstriction after asa challenge is seen in 0 to 22% of asthmatic children so challenged, ibuprofen at antipyretic doses may cause acute respiratory problems only in a very small number of mild to moderate asthmatics.
amod||naive-3/JJ||temozolomide-2/JJ	amod||gbm-4/NN||naive-3/JJ	prep_for||treatment-18/NN||gbm-4/NN	nn||patients-9/NNS||astrocytoma-6/NN	nn||patients-9/NNS||grade-7/NN	nn||patients-9/NNS||iii-8/NN	conj_and||gbm-4/NN||patients-9/NNS	prep_for||treatment-18/NN||patients-9/NNS	nn||progression-12/NN||disease-11/NN	prep_with||gbm-4/NN||progression-12/NN	nsubj||treatment-18/NN||temozolomide-14/NN	cop||treatment-18/NN||is-15/VBZ	advmod||treatment-18/NN||still-16/RB	det||treatment-18/NN||the-17/DT	root||ROOT-0/null||treatment-18/NN	nn||outside-21/NN||choice-20/NN	prep_of||treatment-18/NN||outside-21/NN	amod||studies-24/NNS||clinical-23/JJ	prep_of||outside-21/NN||studies-24/NNS	astrocytoma-6||temozolomide-14||yes||for temozolomide naive gbm and astrocytoma grade iii patients with disease progression, temozolomide is still the treatment of choice outside of clinical studies.
det||substudy-6/NN||this-2/DT	amod||substudy-6/NN||randomized-3/JJ	amod||substudy-6/NN||placebo-controlled-5/JJ	prep_in||received-12/VBD||substudy-6/NN	num||patients-9/NNS||122-8/CD	nsubj||received-12/VBD||patients-9/NNS	prep_with||patients-9/NNS||jia-11/NN	root||ROOT-0/null||received-12/VBD	number||3-14/CD||infliximab-13/CD	dobj||received-12/VBD||3-14/CD	xcomp||received-12/VBD||mg/kg-15/VBG	amod||methotrexate-17/NN||+-16/JJ	dobj||mg/kg-15/VBG||methotrexate-17/NN	appos||methotrexate-17/NN||mtx-19/NN	dep||methotrexate-17/NN||n-22/VBN	dep||60-24/CD||=-23/SYM	ccomp||n-22/VBN||60-24/CD	nn||mtx-29/NN||placebo-27/NN	amod||mtx-29/NN||+-28/VBG	dobj||mg/kg-15/VBG||mtx-29/NN	conj_or||methotrexate-17/NN||mtx-29/NN	dep||mtx-29/NN||n-31/VBN	dep||62-33/CD||=-32/SYM	ccomp||n-31/VBN||62-33/CD	prep_at||received-12/VBD||weeks-36/NNS	dep||weeks-36/NNS||0-37/CD	num||0-37/CD||2-39/CD	dep||weeks-36/NNS||6-42/CD	conj_and||0-37/CD||6-42/CD	jia-11||methotrexate-17||yes||in this randomized, placebo-controlled substudy, 122 patients with jia received infliximab 3 mg/kg + methotrexate (mtx)(n = 60) or placebo + mtx (n = 62) at weeks 0, 2, and 6.
amod||hbsag-2/NN||quantitative-1/JJ	nsubjpass||recognized-5/VBN||hbsag-2/NN	nsubj||assist-7/VB||hbsag-2/NN	aux||recognized-5/VBN||has-3/VBZ	auxpass||recognized-5/VBN||been-4/VBN	root||ROOT-0/null||recognized-5/VBN	aux||assist-7/VB||to-6/TO	xcomp||recognized-5/VBN||assist-7/VB	det||management-10/NN||the-9/DT	prep_in||assist-7/VB||management-10/NN	nn||infection-16/NN||chronichepatitisbvirus-12/NNP	appos||infection-16/NN||hbv-14/NN	prep_of||management-10/NN||infection-16/NN	hbv-14||hepatitisbvirus--1||no||quantitative hbsag has been recognized to assist in the management of chronichepatitisbvirus (hbv) infection.
advmod||burden-16/NN||yet-1/RB	nsubj||burden-16/NN||implementation-2/NN	det||intervention-8/NN||this-4/DT	amod||intervention-8/NN||basic-5/JJ	amod||intervention-8/NN||public-6/JJ	nn||intervention-8/NN||health-7/NN	prep_of||implementation-2/NN||intervention-8/NN	cop||burden-16/NN||is-9/VBZ	amod||burden-16/NN||sporadic-10/JJ	prep_in||sporadic-10/JJ||countries-12/NNS	amod||congenitalsyphilis-15/NNS||highest-14/JJS	prep_with||countries-12/NNS||congenitalsyphilis-15/NNS	root||ROOT-0/null||burden-16/NN	basic-5||congenitalsyphilis-15||no_rel||yet implementation of this basic public health intervention is sporadic in countries with highest congenitalsyphilis burden.
nsubj||seen-7/VBN||management-1/NN	prep_of||management-1/NN||children-3/NNS	prep_with||children-3/NNS||type1diabetes-5/CD	aux||seen-7/VBN||has-6/VBZ	root||ROOT-0/null||seen-7/VBN	det||shift-9/NN||a-8/DT	dobj||seen-7/VBN||shift-9/NN	prep_in||seen-7/VBN||favor-11/NN	prepc_of||favor-11/NN||mimicking-13/VBG	amod||responses-17/NNS||normal-14/JJ	amod||responses-17/NNS||physiological-15/JJ	nn||responses-17/NNS||insulin-16/NN	dobj||mimicking-13/VBG||responses-17/NNS	amod||infusions-26/NNS||multiple-19/JJ	amod||infusions-26/NNS||daily-20/JJ	nn||infusions-26/NNS||injections-21/NNS	conj_or||injections-21/NNS||continuous-23/JJ	nn||infusions-26/NNS||continuous-23/JJ	amod||infusions-26/NNS||subcutaneous-24/JJ	nn||infusions-26/NNS||insulin-25/NN	prep_with||mimicking-13/VBG||infusions-26/NNS	appos||infusions-26/NNS||csii-28/NNP	type1diabetes-5||insulin-25||yes||management of children with type1diabetes has seen a shift in favor of mimicking normal physiological insulin responses with multiple daily injections or continuous subcutaneous insulin infusions (csii).
nn||gamma-2/NN||interferon-1/NN	nsubj||cytokine-7/NN||gamma-2/NN	cop||cytokine-7/NN||is-3/VBZ	det||cytokine-7/NN||a-4/DT	amod||cytokine-7/NN||major-5/JJ	amod||cytokine-7/NN||macrophage-activating-6/JJ	root||ROOT-0/null||cytokine-7/NN	prep_during||cytokine-7/NN||infection-9/NN	prep_with||cytokine-7/NN||mycobacteriumtuberculosis-11/NNS	det||pathogen-15/NN||the-13/DT	amod||pathogen-15/NN||causative-14/JJ	dep||cytokine-7/NN||pathogen-15/NN	prep_of||pathogen-15/NN||tuberculosis-17/NNP	poss||role-21/NN||its-20/PRP$	nsubjpass||established-25/VBN||role-21/NN	aux||established-25/VBN||has-22/VBZ	auxpass||established-25/VBN||been-23/VBN	advmod||established-25/VBN||well-24/RB	conj_and||cytokine-7/NN||established-25/VBN	nn||models-28/NNS||animal-27/NN	prep_in||established-25/VBN||models-28/NNS	prep_in||established-25/VBN||humans-31/NNS	conj_and||models-28/NNS||humans-31/NNS	tuberculosis-17||mycobacteriumtuberculosis-11||no||interferon gamma is a major macrophage-activating cytokine during infection with mycobacteriumtuberculosis , the causative pathogen of tuberculosis, and its role has been well established in animal models and in humans.
aux||evaluate-2/VB||to-1/TO	root||ROOT-0/null||evaluate-2/VB	dobj||evaluate-2/VB||barriers-3/NNS	vmod||barriers-3/NNS||preventing-4/VBG	amod||women-6/NNS||pregnant-5/JJ	dobj||preventing-4/VBG||women-6/NNS	prepc_from||preventing-4/VBG||using-8/VBG	amod||nets-10/NNS||insecticide-treated-9/JJ	dobj||using-8/VBG||nets-10/NNS	appos||nets-10/NNS||itn-12/NN	amod||treatment-17/NN||intermittent-15/JJ	nn||treatment-17/NN||presumptive-16/NN	nsubj||promoting-36/VBG||treatment-17/NN	appos||treatment-17/NN||ipt-19/NN	amod||sp-24/NN||sulphadoxine-pyrimethamine-22/JJ	prep_with||treatment-17/NN||sp-24/NN	num||years-27/NNS||5-26/CD	dep||sp-24/NN||years-27/NNS	det||launch-30/NN||the-29/DT	prep_after||sp-24/NN||launch-30/NN	det||strategy-35/NN||the-32/DT	amod||strategy-35/NN||national-33/JJ	nn||strategy-35/NN||malaria-34/NN	prep_of||launch-30/NN||strategy-35/NN	conj_and||evaluate-2/VB||promoting-36/VBG	det||measures-38/NNS||these-37/DT	dobj||promoting-36/VBG||measures-38/NNS	prep_in||promoting-36/VBG||kenya-40/NN	malaria-34||pyrimethamine--1||no||to evaluate barriers preventing pregnant women from using insecticide-treated nets (itn) and intermittent presumptive treatment (ipt) with sulphadoxine-pyrimethamine (sp) 5 years after the launch of the national malaria strategy promoting these measures in kenya.
amod||strategies-3/NNS||newer-1/JJR	nn||strategies-3/NNS||pharmacological-2/NN	nsubj||include-13/VBP||strategies-3/NNS	det||treatment-6/NN||the-5/DT	prep_for||strategies-3/NNS||treatment-6/NN	nn||failure-9/NN||rv-8/NN	prep_of||treatment-6/NN||failure-9/NN	amod||pulmonaryhypertension-12/NN||associated-11/VBN	prep_of||treatment-6/NN||pulmonaryhypertension-12/NN	conj_and||failure-9/NN||pulmonaryhypertension-12/NN	root||ROOT-0/null||include-13/VBP	det||inhibitors-18/NNS||the-14/DT	amod||inhibitors-18/NNS||phosphodiesterase-15/JJ	nn||inhibitors-18/NNS||fraction-16/NN	nn||inhibitors-18/NNS||iii-17/NN	dobj||include-13/VBP||inhibitors-18/NNS	det||prostaglandins-21/NNS||the-20/DT	dobj||include-13/VBP||prostaglandins-21/NNS	conj_and||inhibitors-18/NNS||prostaglandins-21/NNS	advmod||pge1-24/JJ||specifically-23/RB	amod||inhibitors-18/NNS||pge1-24/JJ	pulmonaryhypertension-12||pge1-24||yes||newer pharmacological strategies for the treatment of rv failure and associated pulmonaryhypertension include the phosphodiesterase fraction iii inhibitors and the prostaglandins, specifically pge1.
det||samples-3/NNS||these-1/DT	nn||samples-3/NNS||test-2/NN	nsubjpass||assayed-24/VBN||samples-3/NNS	prep_at||mg/kg-11/VBG||100-6/CD	num||100-6/CD||200-8/CD	conj_and||100-6/CD||400-10/CD	prep_at||mg/kg-11/VBG||400-10/CD	dep||samples-3/NNS||mg/kg-11/VBG	det||extract-14/NNS||the-13/DT	prep_for||mg/kg-11/VBG||extract-14/NNS	prep_for||mg/kg-11/VBG||fractions-16/NNS	conj_and||extract-14/NNS||fractions-16/NNS	num||mg/kg-19/NN||2.5-18/CD	dep||samples-3/NNS||mg/kg-19/NN	conj_and||mg/kg-11/VBG||mg/kg-19/NN	prep_for||mg/kg-19/NN||compound-21/NN	auxpass||assayed-24/VBN||were-23/VBD	root||ROOT-0/null||assayed-24/VBN	det||periods-28/NNS||the-26/DT	nn||periods-28/NNS||latent-27/NN	prep_on||assayed-24/VBN||periods-28/NNS	amod||indices-31/NNS||purging-30/JJ	prep_on||assayed-24/VBN||indices-31/NNS	conj_and||periods-28/NNS||indices-31/NNS	amod||frequencies-34/NNS||fecal-33/JJ	prep_on||assayed-24/VBN||frequencies-34/NNS	conj_and||periods-28/NNS||frequencies-34/NNS	amod||diarrhea-37/NN||castoroil-induced-36/JJ	prep_in||assayed-24/VBN||diarrhea-37/NN	diarrhea-37||castoroil--1||no||these test samples (at 100, 200 and 400 mg/kg for the extract and fractions and 2.5 mg/kg for compound) were assayed on the latent periods, purging indices and fecal frequencies in castoroil-induced diarrhea.
poss||patients-4/NNS||our-2/PRP$	nn||patients-4/NNS||sle-3/NN	prep_for||associated-16/VBN||patients-4/NNS	amod||manifestations-7/NNS||renal-6/JJ	prep_without||patients-4/NNS||manifestations-7/NNS	amod||flares-10/NNS||clinical-9/JJ	nsubjpass||associated-16/VBN||flares-10/NNS	vmod||flares-10/NNS||developing-11/VBG	nn||therapy-14/NN||maintenance-13/NN	prep_under||developing-11/VBG||therapy-14/NN	auxpass||associated-16/VBN||were-15/VBD	root||ROOT-0/null||associated-16/VBN	amod||<-23/NNS||steady-state-18/JJ	nn||<-23/NNS||inclusion-19/NN	nn||<-23/NNS||mpa-20/NN	nn||<-23/NNS||c12-21/NN	nn||<-23/NNS||h-22/NN	prep_with||associated-16/VBN||<-23/NNS	number||mg/l-25/JJ||3-24/CD	amod||<-23/NNS||mg/l-25/JJ	mpa-20||sle-3||no_rel||for our sle patients without renal manifestations, clinical flares developing under maintenance therapy were associated with steady-state inclusion mpa c12 h < 3 mg/l.
nsubj||aimed-2/VBD||we-1/PRP	nsubj||compare-4/VB||we-1/PRP	root||ROOT-0/null||aimed-2/VBD	aux||compare-4/VB||to-3/TO	xcomp||aimed-2/VBD||compare-4/VB	det||effects-6/NNS||the-5/DT	dobj||compare-4/VB||effects-6/NNS	prep_of||effects-6/NNS||sufentanil-8/NN	amod||doses-11/NNS||analgesic-10/JJ	prep_in||sufentanil-8/NN||doses-11/NNS	prepc_for||compare-4/VB||reducing-13/VBG	det||pain-16/NN||the-14/DT	nn||pain-16/NN||injection-15/NN	dobj||reducing-13/VBG||pain-16/NN	nn||propofol-19/NN||microemulsion-18/NN	prep_of||pain-16/NN||propofol-19/NN	pain-16||propofol-19||yes||we aimed to compare the effects of sufentanil in analgesic doses for reducing the injection pain of microemulsion propofol.
det||campaign-5/NN||a-1/DT	advmod||implemented-3/JJ||fully-2/RB	amod||campaign-5/NN||implemented-3/JJ	amod||campaign-5/NN||rabies-control-4/JJ	nsubj||make-7/VB||campaign-5/NN	aux||make-7/VB||could-6/MD	root||ROOT-0/null||make-7/VB	nn||lanka-9/NN||sri-8/NN	iobj||make-7/VB||lanka-9/NN	det||country-13/NN||the-10/DT	amod||country-13/NN||first-11/JJ	nn||country-13/NN||asian-12/NN	dobj||make-7/VB||country-13/NN	prep_in||country-13/NN||>-15/NNP	num||years-17/NNS||30-16/CD	dep||country-13/NN||years-17/NNS	aux||become-19/VB||to-18/TO	vmod||country-13/NN||become-19/VB	xcomp||become-19/VB||free-20/JJ	prep_of||free-20/JJ||rabiesvirus-22/NNS	rabies--1||rabiesvirus-22||no||a fully implemented rabies-control campaign could make sri lanka the first asian country in >30 years to become free of rabiesvirus.
nsubjpass||documented-34/VBN||viruses-1/NNS	nsubj||develop-36/VB||viruses-1/NNS	dep||viruses-1/NNS||other-2/JJ	det||viruses-6/NNS||the-4/DT	nn||viruses-6/NNS||hepatitis-5/NN	prep_than||viruses-1/NNS||viruses-6/NNS	amod||virus-15/NN||parvovirusb19-9/JJ	amod||epstein-13/JJ||cytomegalovirus-11/JJ	amod||virus-15/NN||epstein-13/JJ	nn||virus-15/NN||bar-14/NN	prep_such_as||viruses-6/NNS||virus-15/NN	nn||virus-19/NN||transfusion-17/NN	amod||virus-19/NN||transmitted-18/JJ	prep_such_as||viruses-6/NNS||virus-19/NN	conj_and||virus-15/NN||virus-19/NN	appos||virus-19/NN||ttv-21/NN	amod||virus-26/NN||non-a-e-24/JJ	nn||virus-26/NN||hepatitis-25/NN	prep_such_as||viruses-6/NNS||virus-26/NN	conj_and||virus-15/NN||virus-26/NN	amod||viruses-29/NNS||unknown-28/JJ	appos||virus-26/NN||viruses-29/NNS	aux||documented-34/VBN||has-31/VBZ	advmod||documented-34/VBN||also-32/RB	auxpass||documented-34/VBN||been-33/VBN	root||ROOT-0/null||documented-34/VBN	aux||develop-36/VB||to-35/TO	xcomp||documented-34/VBN||develop-36/VB	det||syndrome-38/NN||the-37/DT	dobj||develop-36/VB||syndrome-38/NN	virus-26||viruses-29||no||viruses other than the hepatitis viruses such as parvovirusb19, cytomegalovirus, epstein bar virus, transfusion transmitted virus (ttv) and non-a-e hepatitis virus (unknown viruses) has also been documented to develop the syndrome.
det||proportion-2/NN||the-1/DT	nsubj||increased-13/VBD||proportion-2/NN	advmod||reported-5/VBN||newly-4/RB	amod||cases-7/NNS||reported-5/VBN	amod||cases-7/NNS||hiv/aids-6/JJ	prep_of||proportion-2/NN||cases-7/NNS	det||investigation-12/NN||a-9/DT	amod||investigation-12/NN||completed-10/VBN	nn||investigation-12/NN||epidemiological-11/NN	prep_with||cases-7/NNS||investigation-12/NN	root||ROOT-0/null||increased-13/VBD	num||%-16/NN||77.7-15/CD	prep_from||increased-13/VBD||%-16/NN	prep_in||%-16/NN||2007-18/CD	num||%-21/NN||91.1-20/CD	prep_to||increased-13/VBD||%-21/NN	prep_in||%-21/NN||2009-23/CD	dep||increased-13/VBD||p-25/NNP	number||0.0001-27/CD||<-26/CD	num||p-25/NNP||0.0001-27/CD	aids--1||hiv--1||no||the proportion of newly reported hiv/aids cases with a completed epidemiological investigation increased from 77.7% in 2007 to 91.1% in 2009 ( p < 0.0001).
nn||studies-3/NNS||lipid-1/NN	nn||studies-3/NNS||metabolism-2/NN	nsubjpass||started-8/VBN||studies-3/NNS	nsubjpass||concentrated-18/VBN||studies-3/NNS	prep_in||studies-3/NNS||psoriasis-5/NNS	aux||started-8/VBN||have-6/VBP	auxpass||started-8/VBN||been-7/VBN	root||ROOT-0/null||started-8/VBN	det||beginning-11/NN||the-10/DT	prep_at||started-8/VBN||beginning-11/NN	det||century-15/NN||the-13/DT	amod||century-15/NN||20th-14/JJ	prep_of||beginning-11/NN||century-15/NN	auxpass||concentrated-18/VBN||are-17/VBP	conj_and||started-8/VBN||concentrated-18/VBN	nn||lipids-22/NNS||skin-20/NN	nn||lipids-22/NNS||surface-21/NN	prep_on||concentrated-18/VBN||lipids-22/NNS	nn||lipids-26/NNS||stratum-24/NN	nn||lipids-26/NNS||corneum-25/NN	appos||lipids-22/NNS||lipids-26/NNS	nn||phospholipids-29/NNS||epidermal-28/NN	appos||lipids-22/NNS||phospholipids-29/NNS	conj_and||lipids-26/NNS||phospholipids-29/NNS	nn||lipids-32/NNS||serum-31/NN	appos||lipids-22/NNS||lipids-32/NNS	amod||lipoproteins-36/NNS||dermal-34/JJ	nn||lipoproteins-36/NNS||low-density-35/NN	appos||lipids-22/NNS||lipoproteins-36/NNS	det||skin-40/NN||the-38/DT	amod||skin-40/NN||psoriatic-39/JJ	prep_in||lipoproteins-36/NNS||skin-40/NN	nn||metabolism-43/NN||lipid-42/NN	prep_in||lipoproteins-36/NNS||metabolism-43/NN	conj_and||skin-40/NN||metabolism-43/NN	amod||stress-46/NN||oxidative-45/JJ	prep_in||lipoproteins-36/NNS||stress-46/NN	conj_and||skin-40/NN||stress-46/NN	prep_in||lipoproteins-36/NNS||correlations-48/NNS	conj_and||skin-40/NN||correlations-48/NNS	amod||parameters-51/NNS||inflammatory-50/JJ	prep_between||lipoproteins-36/NNS||parameters-51/NNS	nn||parameters-54/NNS||lipid-53/NN	appos||lipids-22/NNS||parameters-54/NNS	amod||symptoms-57/NNS||clinical-56/JJ	prep_on||concentrated-18/VBN||symptoms-57/NNS	conj_and||lipids-22/NNS||symptoms-57/NNS	det||disease-60/NN||the-59/DT	prep_of||symptoms-57/NNS||disease-60/NN	psoriasis-5||lipid-53||no_rel||lipid metabolism studies in psoriasis have been started at the beginning of the 20th century and are concentrated on skin surface lipids, stratum corneum lipids and epidermal phospholipids, serum lipids, dermal low-density lipoproteins in the psoriatic skin, lipid metabolism, oxidative stress and correlations between inflammatory parameters, lipid parameters and clinical symptoms of the disease.
nsubj||due-3/JJ||this-1/DT	cop||due-3/JJ||is-2/VBZ	root||ROOT-0/null||due-3/JJ	prep_in||due-3/JJ||part-5/NN	amod||suppression-9/NN||impaired-7/VBN	amod||suppression-9/NN||insulin-induced-8/JJ	prep_to||due-3/JJ||suppression-9/NN	amod||production-13/NN||endogenous-11/JJ	nn||production-13/NN||glucose-12/NN	prep_of||suppression-9/NN||production-13/NN	nsubjpass||observed-17/VBN||production-13/NN	auxpass||observed-17/VBN||is-16/VBZ	rcmod||production-13/NN||observed-17/VBN	advmod||observed-17/VBN||early-18/RB	det||evolution-21/NN||the-20/DT	prep_in||observed-17/VBN||evolution-21/NN	prep_of||evolution-21/NN||type2diabetes-23/CD	type2diabetes-23||glucose-12||no_rel||this is due in part to impaired insulin-induced suppression of endogenous glucose production, which is observed early in the evolution of type2diabetes.
det||aim-2/NN||the-1/DT	nsubj||was-7/VBD||aim-2/NN	nsubj||evaluate-9/VB||aim-2/NN	det||study-6/NN||the-4/DT	amod||study-6/NN||current-5/JJ	prep_of||aim-2/NN||study-6/NN	root||ROOT-0/null||was-7/VBD	aux||evaluate-9/VB||to-8/TO	xcomp||was-7/VBD||evaluate-9/VB	amod||patients-12/NNS||stemi-11/JJ	prep_in||evaluate-9/VB||patients-12/NNS	dep||patients-12/NNS||undergoing-13/VBG	amod||intervention-17/NN||primary-14/JJ	amod||intervention-17/NN||percutaneous-15/JJ	amod||intervention-17/NN||coronary-16/JJ	dobj||undergoing-13/VBG||intervention-17/NN	appos||intervention-17/NN||pci-19/NN	prep_with||intervention-17/NN||abciximab-22/NN	dep||patients-12/NNS||stenting-24/VBG	conj_and||undergoing-13/VBG||stenting-24/VBG	mark||safe-33/JJ||whether-25/IN	amod||reversal-27/NN||immediate-26/JJ	nsubj||safe-33/JJ||reversal-27/NN	prep_of||reversal-27/NN||anticoagulation-29/NN	prep_by||anticoagulation-29/NN||protamine-31/NN	cop||safe-33/JJ||is-32/VBZ	ccomp||stenting-24/VBG||safe-33/JJ	dep||patients-12/NNS||associated-35/JJ	conj_and||undergoing-13/VBG||associated-35/JJ	det||reduction-38/NN||a-37/DT	prep_with||associated-35/JJ||reduction-38/NN	det||occurrence-41/NN||the-40/DT	prep_in||reduction-38/NN||occurrence-41/NN	amod||complications-44/NNS||bleeding-43/VBG	prep_of||occurrence-41/NN||complications-44/NNS	abciximab-22||bleeding-43||no_rel||the aim of the current study was to evaluate in stemi patients undergoing primary percutaneous coronary intervention (pci) with abciximab and stenting whether immediate reversal of anticoagulation by protamine is safe and associated with a reduction in the occurrence of bleeding complications.
nsubj||present-2/VBP||we-1/PRP	root||ROOT-0/null||present-2/VBP	advmod||present-2/VBP||here-3/RB	det||case-5/NN||a-4/DT	dobj||present-2/VBP||case-5/NN	amod||degeneration-9/NN||dorsal-7/JJ	nn||degeneration-9/NN||column-8/NN	prep_of||case-5/NN||degeneration-9/NN	det||patient-13/NN||a-11/DT	amod||patient-13/NN||female-12/JJ	prep_in||degeneration-9/NN||patient-13/NN	nn||exposure-17/NN||multiplemyeloma-15/NN	amod||exposure-17/NN||following-16/VBG	prep_with||patient-13/NN||exposure-17/NN	prep_to||exposure-17/NN||bortezomib-19/NN	multiplemyeloma-15||bortezomib-19||yes||we present here a case of dorsal column degeneration in a female patient with multiplemyeloma following exposure to bortezomib.
nsubj||reduced-4/VBD||administration-1/NN	prep_of||administration-1/NN||bosentan-3/NN	root||ROOT-0/null||reduced-4/VBD	amod||expression-7/NN||et-1-5/JJ	nn||expression-7/NN||gene-6/NN	dobj||reduced-4/VBD||expression-7/NN	amod||pulmonaryhypertension-10/NN||mct-induced-9/JJ	prep_in||reduced-4/VBD||pulmonaryhypertension-10/NN	prep_in||reduced-4/VBD||rats-12/NNS	pulmonaryhypertension-10||bosentan-3||yes||administration of bosentan reduced et-1 gene expression in mct-induced pulmonaryhypertension in rats.
nsubj||aimed-2/VBD||we-1/PRP	nsubj||assess-4/VB||we-1/PRP	root||ROOT-0/null||aimed-2/VBD	aux||assess-4/VB||to-3/TO	xcomp||aimed-2/VBD||assess-4/VB	det||incidence-6/NN||the-5/DT	dobj||assess-4/VB||incidence-6/NN	amod||neutropenia-9/NN||febrile-8/JJ	prep_of||incidence-6/NN||neutropenia-9/NN	prep_in||assess-4/VB||patients-11/NNS	amod||cancer-17/NN||non-13/JJ	amod||cancer-17/NN||small-14/JJ	nn||cancer-17/NN||cell-15/NN	nn||cancer-17/NN||lung-16/NN	prep_with||patients-11/NNS||cancer-17/NN	vmod||patients-11/NNS||treated-18/VBN	prep_with||treated-18/VBN||docetaxel-20/NN	amod||chemotherapy-24/NN||second-22/JJ	nn||chemotherapy-24/NN||line-23/NN	prep_as||treated-18/VBN||chemotherapy-24/NN	amod||review-27/NN||systematic-26/JJ	agent||treated-18/VBN||review-27/NN	agent||treated-18/VBN||meta-analysis-29/NNS	conj_and||review-27/NN||meta-analysis-29/NNS	amod||studies-32/NNS||clinical-31/JJ	prep_of||review-27/NN||studies-32/NNS	neutropenia-9||docetaxel-20||no||we aimed to assess the incidence of febrile neutropenia in patients with non small cell lung cancer treated with docetaxel as second line chemotherapy by systematic review and meta-analysis of clinical studies.
poss||aims-2/NNS||our-1/PRP$	nsubj||were-3/VBD||aims-2/NNS	root||ROOT-0/null||were-3/VBD	aux||survey-5/VB||to-4/TO	ccomp||were-3/VBD||survey-5/VB	det||changes-7/NNS||the-6/DT	dobj||survey-5/VB||changes-7/NNS	nn||profile-11/NN||plasma-9/NN	nn||profile-11/NN||lipid-10/NN	prep_in||survey-5/VB||profile-11/NN	prep_in||profile-11/NN||patients-13/NNS	prep_with||patients-13/NNS||hypertension-15/NN	det||period-19/NN||a-17/DT	amod||period-19/NN||one-year-18/JJ	prep_over||hypertension-15/NN||period-19/NN	aux||examine-23/VB||to-22/TO	ccomp||were-3/VBD||examine-23/VB	conj_and||survey-5/VB||examine-23/VB	det||correlations-25/NNS||the-24/DT	dobj||examine-23/VB||correlations-25/NNS	det||values-28/NNS||these-27/DT	prep_between||correlations-25/NNS||values-28/NNS	det||time-31/NN||the-30/DT	prep_between||correlations-25/NNS||time-31/NN	conj_and||values-28/NNS||time-31/NN	det||start-34/NN||the-33/DT	prep_after||examine-23/VB||start-34/NN	nn||monotherapy-37/NN||arb-36/NN	prep_of||start-34/NN||monotherapy-37/NN	prep_with||examine-23/VB||candesartan-39/NN	hypertension-15||candesartan-39||yes||our aims were to survey the changes in plasma lipid profile in patients with hypertension over a one-year period, and to examine the correlations between these values and the time after the start of arb monotherapy with candesartan.
det||profile-5/NN||the-1/DT	nn||profile-5/NN||safety-2/NN	conj_and||safety-2/NN||efficacy-4/NN	nn||profile-5/NN||efficacy-4/NN	nsubj||were-15/VBD||profile-5/NN	prep_of||profile-5/NN||caspofungin-7/NN	prep_of||profile-5/NN||micafungin-9/NN	conj_and||caspofungin-7/NN||micafungin-9/NN	amod||patients-12/NNS||japanese-11/JJ	prep_in||caspofungin-7/NN||patients-12/NNS	prep_with||patients-12/NNS||fungalinfections-14/NNS	root||ROOT-0/null||were-15/VBD	advmod||were-15/VBD||directly-16/RB	prep||were-15/VBD||compared-17/VBN	pcomp||compared-17/VBN||in-18/IN	det||study-25/NN||this-19/DT	amod||study-25/NN||prospective-20/JJ	amod||study-25/NN||randomized-22/JJ	amod||study-25/NN||double-blind-24/JJ	pobj||in-18/IN||study-25/NN	fungalinfections-14||caspofungin-7||yes||the safety and efficacy profile of caspofungin and micafungin in japanese patients with fungalinfections were directly compared in this prospective, randomized, double-blind study.
num||kinds-2/NNS||two-1/CD	nsubj||viruses-7/NNS||kinds-2/NNS	prep_of||kinds-2/NNS||them-4/PRP	cop||viruses-7/NNS||are-5/VBP	amod||viruses-7/NNS||mosquito-borne-6/JJ	root||ROOT-0/null||viruses-7/NNS	nsubj||lead-16/VBP||viruses-7/NNS	nsubj||denguefever/denguehemorrhagicfever-21/VBP||viruses-7/NNS	advmod||virus-11/NN||namely-9/RB	amod||virus-11/NN||japaneseencephalitis-10/JJ	appos||viruses-7/NNS||virus-11/NN	appos||viruses-7/NNS||denguevirus-13/NNS	conj_and||virus-11/NN||denguevirus-13/NNS	rcmod||viruses-7/NNS||lead-16/VBP	prep_to||lead-16/VBP||japaneseencephalitis-18/NNS	rcmod||viruses-7/NNS||denguefever/denguehemorrhagicfever-21/VBP	conj_and||lead-16/VBP||denguefever/denguehemorrhagicfever-21/VBP	advmod||denguefever/denguehemorrhagicfever-21/VBP||respectively-22/RB	det||two-26/CD||the-24/DT	amod||two-26/CD||other-25/JJ	nsubj||viruses-29/NNS||two-26/CD	cop||viruses-29/NNS||are-27/VBP	amod||viruses-29/NNS||tick-borne-28/JJ	parataxis||viruses-7/NNS||viruses-29/NNS	nsubj||contribute-48/VBP||viruses-29/NNS	advmod||virus-33/NN||namely-31/RB	amod||virus-33/NN||tick-borneencephalitis-32/JJ	parataxis||viruses-7/NNS||virus-33/NN	conj_and||viruses-29/NNS||virus-33/NN	nsubj||contribute-48/VBP||virus-33/NN	amod||virus-37/NN||crimean-congo-35/JJ	nn||virus-37/NN||hemorrhagicfever-36/NN	parataxis||viruses-7/NNS||virus-37/NN	conj_and||viruses-29/NNS||virus-37/NN	nsubj||contribute-48/VBP||virus-37/NN	advmod||known-40/VBN||also-39/RB	dep||viruses-29/NNS||known-40/VBN	prepc_as||known-40/VBN||xinjiang-42/VBG	nn||virus-44/NN||hemorrhagicfever-43/NN	dobj||xinjiang-42/VBG||virus-44/NN	rcmod||viruses-29/NNS||contribute-48/VBP	prep_to||contribute-48/VBP||tick-borneencephalitis-50/NNS	nn||hemorrhagicfever-53/NN||xinjiang-52/NN	prep_to||contribute-48/VBP||hemorrhagicfever-53/NN	conj_and||tick-borneencephalitis-50/NNS||hemorrhagicfever-53/NN	advmod||contribute-48/VBP||respectively-54/RB	japaneseencephalitis-18||japaneseencephalitisvirus--1||no||two kinds of them are mosquito-borne viruses, namely japaneseencephalitis virus and denguevirus, which lead to japaneseencephalitis, and denguefever/denguehemorrhagicfever respectively; the other two are tick-borne viruses, namely tick-borneencephalitis virus and crimean-congo hemorrhagicfever virus (also known as xinjiang hemorrhagicfever virus), which contribute to tick-borneencephalitis and xinjiang hemorrhagicfever respectively.
amod||factors-3/NNS||numerous-1/JJ	nn||factors-3/NNS||risk-2/NN	nsubjpass||established-11/VBN||factors-3/NNS	det||development-6/NN||the-5/DT	prep_for||factors-3/NNS||development-6/NN	prep_of||development-6/NN||gout-8/NN	aux||established-11/VBN||have-9/VBP	auxpass||established-11/VBN||been-10/VBN	root||ROOT-0/null||established-11/VBN	prep_including||established-11/VBN||hyperuricaemia-14/NN	amod||factors-17/NNS||genetic-16/JJ	prep_including||established-11/VBN||factors-17/NNS	conj_and||hyperuricaemia-14/NN||factors-17/NNS	amod||factors-20/NNS||dietary-19/JJ	prep_including||established-11/VBN||factors-20/NNS	conj_and||hyperuricaemia-14/NN||factors-20/NNS	nn||consumption-23/NN||alcohol-22/NN	prep_including||established-11/VBN||consumption-23/NN	conj_and||hyperuricaemia-14/NN||consumption-23/NN	amod||syndrome-26/NN||metabolic-25/JJ	prep_including||established-11/VBN||syndrome-26/NN	conj_and||hyperuricaemia-14/NN||syndrome-26/NN	prep_including||established-11/VBN||hypertension-28/NN	conj_and||hyperuricaemia-14/NN||hypertension-28/NN	prep_including||established-11/VBN||obesity-30/NN	conj_and||hyperuricaemia-14/NN||obesity-30/NN	amod||use-33/NN||diuretic-32/JJ	prep_including||established-11/VBN||use-33/NN	conj_and||hyperuricaemia-14/NN||use-33/NN	prep_including||established-11/VBN||chronicrenaldisease-35/NN	conj_and||hyperuricaemia-14/NN||chronicrenaldisease-35/NN	chronicrenaldisease-35||diuretic-32||no_rel||numerous risk factors for the development of gout have been established, including hyperuricaemia, genetic factors, dietary factors, alcohol consumption, metabolic syndrome, hypertension, obesity, diuretic use and chronicrenaldisease.
